<SEC-DOCUMENT>0001628280-23-040219.txt : 20231129
<SEC-HEADER>0001628280-23-040219.hdr.sgml : 20231129
<ACCEPTANCE-DATETIME>20231129160907
ACCESSION NUMBER:		0001628280-23-040219
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		123
CONFORMED PERIOD OF REPORT:	20230930
FILED AS OF DATE:		20231129
DATE AS OF CHANGE:		20231129

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARROWHEAD PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0000879407
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				460408024
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38042
		FILM NUMBER:		231452268

	BUSINESS ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105
		BUSINESS PHONE:		626-696-4702

	MAIL ADDRESS:	
		STREET 1:		177 E COLORADO BLVD
		STREET 2:		SUITE 700
		CITY:			PASADENA
		STATE:			CA
		ZIP:			91105

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARROWHEAD RESEARCH CORP
		DATE OF NAME CHANGE:	20040112

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE GROUP INC
		DATE OF NAME CHANGE:	20020509

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	INTERACTIVE INC
		DATE OF NAME CHANGE:	19940224
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>arwr-20230930.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with the Workiva Platform--><!--Copyright 2023 Workiva--><!--r:d14395b2-bc79-4df5-8659-886540a562de,g:ab3d3e76-c740-4da0-ace7-13e457c841a4,d:2ac2b5b9b196490b92657e8462cd4206--><html xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:srt="http://fasb.org/srt/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:arwr="http://www.arrowheadresearch.com/20230930" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:ecd="http://xbrl.sec.gov/ecd/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>arwr-20230930</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-33">2023</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-34">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-35">0000879407</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-36">false</ix:nonNumeric><ix:nonNumeric contextRef="c-22" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-85">20</ix:nonNumeric><ix:nonNumeric contextRef="c-23" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-86">20</ix:nonNumeric><ix:nonNumeric contextRef="c-24" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-87">28</ix:nonNumeric><ix:nonNumeric contextRef="c-25" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-88">364</ix:nonNumeric><ix:nonNumeric contextRef="c-26" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-89">26</ix:nonNumeric><ix:nonNumeric contextRef="c-27" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-90">2</ix:nonNumeric><ix:nonNumeric contextRef="c-28" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-91">208</ix:nonNumeric><ix:nonNumeric contextRef="c-29" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-92">141</ix:nonNumeric><ix:nonNumeric contextRef="c-30" name="ecd:TrdArrDuration" format="ixt-sec:durday" id="f-93">20</ix:nonNumeric><ix:nonNumeric contextRef="c-75" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="f-426">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="c-154" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="f-669">P5Y0M0D</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="arwr-20230930.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-11-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:MauroFerrariMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:MauroFerrariMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:DouglassGivenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:DouglassGivenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:JamesHamiltonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:JamesHamiltonTerminatedPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:JamesHamiltonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:JamesHamiltonTerminatedPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:JamesHamiltonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:JamesHamiltonAugust2023PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:JamesHamiltonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:JamesHamiltonAugust2023PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:PatrickOBrienMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:PatrickOBrienMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:TracieOliverMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:TracieOliverMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:VictoriaVakienerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:VictoriaVakienerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:WilliamWaddillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-07-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:WilliamWaddillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:MauroFerrariMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:DouglassGivenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:JamesHamiltonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:JamesHamiltonTerminatedPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:JamesHamiltonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:JamesHamiltonAugust2023PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:PatrickOBrienMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:TracieOliverMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:VictoriaVakienerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:WilliamWaddillMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-09</xbrli:startDate><xbrli:endDate>2022-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-22</xbrli:startDate><xbrli:endDate>2021-11-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="obligation"><xbrli:measure>arwr:obligation</xbrli:measure></xbrli:unit><xbrli:unit id="bundle"><xbrli:measure>arwr:bundle</xbrli:measure></xbrli:unit><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:HorizonLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-18</xbrli:startDate><xbrli:endDate>2021-06-18</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:HorizonLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:HorizonLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:HorizonLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:HorizonLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-07</xbrli:startDate><xbrli:endDate>2020-10-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-07</xbrli:startDate><xbrli:endDate>2020-10-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-07</xbrli:startDate><xbrli:endDate>2020-10-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:JohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-03</xbrli:startDate><xbrli:endDate>2018-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:CommonStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:JohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-03</xbrli:startDate><xbrli:endDate>2018-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-10-03</xbrli:startDate><xbrli:endDate>2018-10-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-10-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="agreement"><xbrli:measure>arwr:agreement</xbrli:measure></xbrli:unit><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-28</xbrli:startDate><xbrli:endDate>2016-09-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-25</xbrli:startDate><xbrli:endDate>2022-04-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-02</xbrli:startDate><xbrli:endDate>2022-12-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:VeronaTechnologyParkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-20</xbrli:startDate><xbrli:endDate>2021-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="acre"><xbrli:measure>utr:acre</xbrli:measure></xbrli:unit><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:DrugManufacturingFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:LaboratoryAndOfficeFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-20</xbrli:startDate><xbrli:endDate>2021-12-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROENacAndAROHIF2CandidatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="option"><xbrli:measure>arwr:option</xbrli:measure></xbrli:unit><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SorrentoValleyOwnerDELLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-18</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:OutsideOfEquityCompensationPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:OutsideOfEquityCompensationPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arwr:RestrictedStockUnitsMarketBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arwr:RestrictedStockUnitsMarketBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-08</xbrli:startDate><xbrli:endDate>2022-07-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arwr:RestrictedStockUnitsPerformanceBasedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-07-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-235"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-236"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-237"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-238"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-239"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-240"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-243"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">arwr:EmployeeContributionsUpToThreePercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-244"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">arwr:EmployeeContributionNextTwoPercentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-245"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-11-09</xbrli:startDate><xbrli:endDate>2022-11-09</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-246"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-09</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-247"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000879407</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-01</xbrli:startDate><xbrli:endDate>2023-09-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i2ac2b5b9b196490b92657e8462cd4206_1"></div><div style="min-height:31.5pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:4pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, DC 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Mark One)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:3.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">September 30</ix:nonNumeric>, 2023</ix:nonNumeric>.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:3.300%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.500%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:114%">TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the transition period from &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-38042</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14.5pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">ARROWHEAD PHARMACEUTICALS, INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">46-0408024</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(I.R.S. Employer Identification No.)</span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-10">626</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-11">304-3400</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-12">177 E. Colorado Blvd</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-13">Suite 700</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-14">Pasadena</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-15">California</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-16">91105</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Address and telephone number of principal executive offices) </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:120%">__________________________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Exchange Act: </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:37.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.116%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.293%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:2pt;font-weight:400;line-height:115%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Title of each class</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:114%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common Stock, $0.001 par value</ix:nonNumeric></span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">ARWR</ix:nonNumeric></span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Global Select Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Exchange Act: None </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by a check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-20">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by a check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act. Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-21">No</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-22">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167; 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-23">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.657%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.079%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-24">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%">x</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-25">Smaller reporting company</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:100%">o</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-26">Emerging growth company</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-27">x</ix:nonNumeric></span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-28">o</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:7pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-29">&#9744;</ix:nonNumeric></span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:112%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:400;line-height:112%">&#9744;</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">The aggregate market value of issuer&#8217;s voting and non-voting outstanding common stock held by non-affiliates was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-8" name="dei:EntityPublicFloat" scale="9" id="f-30">2.3</ix:nonFraction> billion based upon the closing stock price of issuer&#8217;s common stock on March 31, 2023. Shares of common stock held by each officer and director and by each person who is known to own 10% or more of the outstanding common stock have been excluded in that such persons may be deemed to be affiliates of the Company. This determination of affiliate status is not necessarily a conclusive determination for other purposes. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">As of November&#160;20, 2023, <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-31">107,432,210</ix:nonFraction> shares of the issuer&#8217;s Common Stock were issued and outstanding.</span></div><div style="margin-top:6pt;text-align:center;text-indent:27.78pt"><span><br/></span></div><div style="margin-top:6pt;text-align:center;text-indent:27.78pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-32" escape="true"><div style="margin-top:6pt;text-indent:30.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Portions of the Definitive Proxy Statement to be filed for Arrowhead Pharmaceuticals Inc.&#8217;s 2024 Annual Meeting of Stockholders are incorporated by reference into Part III hereof.</span></div></ix:nonNumeric><div style="text-indent:30.6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.491%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"></td></tr></table></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i2ac2b5b9b196490b92657e8462cd4206_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.718%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.961%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_13">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_16">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_16">TEM 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_16">B</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_16">USINESS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_19">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_19">TEM 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_19">R</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_19">ISK </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_19">F</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_19">ACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_19">33</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_22">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_22">TEM 1B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_22">U</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_22">NRESOLVED </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_22">S</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_22">TAFF </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_22">C</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_22">OMMENTS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_22">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_25">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_25">TEM 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_25">P</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_25">ROPERTIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_25">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_28">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_28">TEM 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_28">L</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_28">EGAL </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_28">P</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_28">ROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_28">56</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_31">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_31">TEM 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_31">M</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_31">INE </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_31">S</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_31">AFETY </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_31">D</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_31">ISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_31">56</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_34">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_37">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_37">TEM 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_37">M</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_37">ARKET FOR THE </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_37">R</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_37">EGISTRANT&#8217;S </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_37">C</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_37">OMMON </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_37">E</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_37">QUITY, </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_37">R</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_37">ELATED </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_37">S</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_37">TOCKHOLDER </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_37">M</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_37">ATTERS AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_37">I</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_37">SSUER </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_37">P</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_37">URCHASES OF </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_37">E</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_37">QUITY </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_37">S</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_37">ECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_37">57</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_40">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_40">TEM 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_40">R</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_40">eserved</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_40">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_43">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_43">TEM 7.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_43">M</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_43">ANAGEMENT&#8217;S </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_43">D</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_43">ISCUSSION AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_43">A</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_43">NALYSIS OF </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_43">F</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_43">INANCIAL </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_43">C</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_43">ONDITION AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_43">R</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_43">ESULTS OF </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_43">O</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_43">PERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_43">58</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_64">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_64">TEM 7A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_64">Q</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_64">UANTITATIVE AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_64">Q</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_64">UALITATIVE </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_64">D</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_64">ISCLOSURES </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_64">A</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_64">BOUT </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_64">M</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_64">ARKET </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_64">R</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_64">ISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_64">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_67">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_67">TEM 8.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_67">F</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_67">INANCIAL </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_67">S</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_67">TATEMENTS AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_67">S</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_67">UPPLEMENTARY </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_67">D</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_67">ATA</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_67">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_70">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_70">TEM 9.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_70">C</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_70">HANGES IN AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_70">D</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_70">ISAGREEMENTS WITH </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_70">A</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_70">CCOUNTANTS ON </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_70">A</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_70">CCOUNTING AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_70">F</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_70">INANCIAL </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_70">D</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_70">ISCLOSURE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_70">69</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_73">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_73">TEM 9A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_73">C</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_73">ONTROLS AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_73">P</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_73">ROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_73">70</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_76">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_76">TEM 9B.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_76">O</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_76">THER </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_76">I</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_76">NFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_76">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_79">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_79">TEM 9C.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_79">D</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_79">ISCLOSURE </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_79">R</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_79">EGARDING </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_79">F</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_79">OREIGN </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_79">J</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_79">URISDICTIONS </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_79">T</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_79">HAT </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_79">P</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_79">REVENT </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_79">I</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_79">NSPECTIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_79">71</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_82">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_85">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_85">TEM 10.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_85">D</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_85">IRECTORS, </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_85">E</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_85">XECUTIVE </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_85">O</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_85">FFICERS, AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_85">C</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_85">ORPORATE </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_85">G</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_85">OVERNANCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_85">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_88">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_88">TEM 11.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_88">E</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_88">XECUTIVE </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_88">C</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_88">OMPENSATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_88">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_91">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_91">TEM 12.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_91">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_91">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_94">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_94">TEM 13.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_94">C</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_94">ERTAIN </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_94">R</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_94">ELATIONSHIPS, </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_94">R</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_94">ELATED </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_94">T</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_94">RANSACTIONS AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_94">D</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_94">IRECTORS </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_94">I</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_94">NDEPENDENCE</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_94">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_97">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_97">TEM 14.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_97">P</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_97">RINCIPAL </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_97">A</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_97">CCOUNTANT </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_97">F</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_97">EES AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_97">S</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_97">ERVICES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_97">72</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_100">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_103">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_103">TEM 15.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_103">E</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_103">XHIBITS AND </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_103">F</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_103">INANCIAL </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_103">S</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_103">TATEMENT </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_103">S</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_103">CHEDULES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_103">72</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_106">I</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_106">TEM 16.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_106">F</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_106">ORM 10-K </a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:107%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_106">S</a></span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_106">UMMARY</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_106">75</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_109">SIGNATURE</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_112">INDEX TO FINANCIAL STATEMENTS AND SCHEDULES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_112">1</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i2ac2b5b9b196490b92657e8462cd4206_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FORWARD-LOOKING STATEMENTS</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and we intend that such forward-looking statements be subject to the safe harbors created thereby. For this purpose, any statements contained in this Annual Report on Form 10-K except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221;  &#8220;goal,&#8221; &#8220;endeavor,&#8221; &#8220;strive,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;project,&#8221; &#8220;could,&#8221; &#8220;estimate,&#8221; &#8220;target,&#8221; &#8220;forecast,&#8221; or &#8220;continue&#8221; or the negative of these words or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, our research and development programs, and our &#8220;20 in 25&#8221; pipeline goal; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding the amount and timing of future milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The forward-looking statements included herein are based on current expectations of our management based on available information and involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately, and many of which are beyond our control. As such, our actual results and timing of certain events may differ materially from the results discussed, projected, anticipated or indicated in any forward-looking statements. Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and cash flows may differ materially. Factors that may cause or contribute to such differences include, but are not limited to, those discussed in more detail in &#8220;Item 1. Business&#8221; and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1A. Risk Factors&#8221; of Part I and &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of Part II of this Annual Report on Form 10-K. Readers should carefully review these risks, as well as the additional risks described in other documents we file from time to time with the Securities and Exchange Commission (the &#8220;SEC&#8221;). In light of the significant risks and uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to place undue reliance on such forward-looking information. Statements made herein are as of the date of the filing of this Annual Report on Form 10-K with the SEC and should not be relied upon as of any subsequent date. Except as may be required by law, we disclaim any intent to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-top:12pt;text-align:justify"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i2ac2b5b9b196490b92657e8462cd4206_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unless otherwise noted, (1) the term &#8220;Arrowhead&#8221; refers to Arrowhead Pharmaceuticals, Inc., a Delaware corporation and its Subsidiaries, (2) the terms &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; refer to the ongoing business operations of Arrowhead and its Subsidiaries, whether conducted through Arrowhead or a subsidiary of Arrowhead, (3) the term &#8220;Subsidiaries&#8221; refers to Arrowhead Madison Inc. (&#8220;Arrowhead Madison&#8221;), Arrowhead Australia Pty Ltd (&#8220;Arrowhead Australia&#8221;), and Visirna Therapeutics Inc. (&#8220;Visirna&#8221;) (4) the term &#8220;common stock&#8221; refers to Arrowhead&#8217;s common stock, (5) the term &#8220;preferred stock&#8221; refers to Arrowhead&#8217;s preferred stock and (6) the term &#8220;stockholder(s)&#8221; refers to the holders of Arrowhead common stock. </span></div><div id="i2ac2b5b9b196490b92657e8462cd4206_16"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">BUSINESS</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#8217;s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s pipeline of 14 clinical stage investigational medicines range in development stage from Phase 1 to Phase 3. In addition, the Company has a robust discovery stage pipeline which is capable of generating multiple new clinical candidates each year. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#8220;20 in 25&#8221; Pipeline Development Strategy</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes that there is no shortage of need that it can endeavor to serve and no shortage of lives that potentially can be touched by the versatility of RNAi technology. The Company endeavors to serve unmet needs and change lives leveraging the versatility of RNAi technology. The Company is acutely aware of the urgent need to develop solutions for the many diseases that have genetic targets that are otherwise undruggable by small molecules or biologics. To that end, the Company embraced its bold goal and strives to have 20 individual drugs, either partnered or wholly owned, in clinical trials or on the market in 2025. </span></div><div style="margin-top:6pt;text-align:justify"><img src="arwr-20230930_g1.gif" alt="Profile.gif" style="height:216px;margin-bottom:5pt;vertical-align:text-bottom;width:662px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RNA Interference and the Benefits of RNAi Therapeutics</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RNA interference (&#8220;RNAi&#8221;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Small molecule and antibody drugs have proven effective at inhibiting certain cell surface, intracellular, and extracellular targets. However, other drug targets have proven difficult to inhibit with traditional drug-based and biologic therapeutics. Developing effective drugs for these targets would have the potential to address large underserved markets for the treatment of many diseases. Using the ability to specifically silence any gene, RNAi therapeutics may be able to address previously &#8220;undruggable&#8221; targets, unlocking the market potential of such targets. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><img src="arwr-20230930_g2.jpg" alt="Benefits of RNAi Therapeutics.jpg" style="height:340px;margin-bottom:5pt;vertical-align:text-bottom;width:454px"/></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This figure depicts the mechanism by which gene silencing occurs. Double stranded RNAi triggers are introduced into a cell and are loaded into the RNA-induced silencing complex, (&#8220;RISC&#8221;). The strands are then separated, leaving an active RISC/RNAi trigger complex. This complex can then pair with and degrade the complementary messenger RNAs (&#8220;mRNA&#8221;) and stop the production of the target proteins. RNAi is a catalytic process, so each RNAi trigger can degrade mRNA hundreds of times, which results in a relatively long duration of effect for RNAi therapeutics.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Key Benefits of RNAi as a Therapeutic Modality</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Silences the expression of disease associated genes; </span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:23.5pt">Potential to address any target in the transcriptome including previously &#8220;undruggable&#8221; targets;</span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Rapid lead identification;</span></div><div style="padding-left:54pt;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">High specificity;</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Opportunity to use multiple RNA sequences in one drug product for synergistic silencing of related targets; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">RNAi therapeutics are uniquely suited for personalized medicine through target and cell specific delivery and gene knockdown.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Targeted RNAi Molecule (TRiM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-style:italic;font-weight:700;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">) Platform</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. Targeting has been core to the Company&#8217;s development philosophy and the TRiMTM platform builds on more than a decade of work on actively targeted drug delivery vehicles. The Company&#8217;s scientists have discovered ways to progressively &#8220;TRiM&#8221; away extraneous features and chemistries and retain optimal pharmacologic activity.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The TRiMTM platform is comprised of a highly potent RNA trigger identified using the Company&#8217;s proprietary trigger selection rules and algorithms with the following components optimized, as needed, for each drug candidate: a high affinity targeting ligand; various linker and chemistries; structures that enhance pharmacokinetics; and highly potent RNAi triggers with sequence specific stabilization chemistries. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Therapeutics developed with the TRiM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform offer several advantages: simplified manufacturing and reduced costs; multiple routes of administration; and potential for improved safety because there are less metabolites from smaller molecules, thereby reducing the risk of intracellular buildup. The Company also believes that for RNAi to reach its true potential, it must target organs outside the liver. The Company is leading this expansion with the TRiM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform, which has shown the potential to reach multiple tissues, including liver, lung, central nervous system (CNS), muscle, and adipose tissue.</span></div><div style="margin-top:12pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:center"><img src="arwr-20230930_g3.jpg" alt="TRiM.jpg" style="height:288px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RNA Chemistries</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The structure and chemistries of the oligonucleotide molecules used to trigger the RNAi mechanism can be tailored for optimal activity. The Company&#8217;s broad portfolio of RNA trigger structures and chemistries, including some proprietary structures, enable the Company to optimize each drug candidate on a target-by-target basis and utilize the combination of structure and chemical modifications that yield the most potent RNAi trigger.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a component of the TRiM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform, the Company&#8217;s design philosophy for RNA chemical modifications is to start with a structurally simple molecule and add only selective modification and stabilization chemistries as necessary to achieve the desired level of target knockdown and duration of effect. The conceptual framework for the stabilization strategy starts with a more sophisticated RNAi trigger screening and selection process that identifies potent sequences rapidly in locations that others may miss. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pipeline</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is focused on developing innovative drugs for diseases with a genetic basis, typically characterized by the overproduction of one or more proteins that are involved with disease. The depth and versatility of the Company&#8217;s RNAi technologies enables the Company to potentially address conditions in virtually any therapeutic area and pursue disease targets that are not otherwise addressable by small molecules and biologic. The Company is focused on bringing the promise of RNAi to address diseases outside of the liver, and its pipeline now includes disease targets in the liver, lung, muscle and CNS.</span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="margin-top:6pt;text-align:center"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:center"><img src="arwr-20230930_g4.gif" alt="Pipeline.gif" style="height:293px;margin-bottom:5pt;vertical-align:text-bottom;width:660px"/></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Plozasiran (ARO-APOC3)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plozasiran (formerly ARO-APOC3) is designed to reduce production of Apolipoprotein C-III (apoC-III), a component of triglyceride rich lipoproteins (TRLs) including Very Low Density Lipoprotein (VLDL) and chylomicrons and a key regulator of triglyceride metabolism. The Company believes that knocking down the hepatic production of apoC-III may result in reduced VLDL synthesis and assembly, enhanced breakdown of TRLs, and better clearance of VLDL and chylomicron remnants. The Company is currently investigating plozasiran in two Phase 2b clinical trials, one Phase 3 clinical trial, and additional Phase 3 clinical trials on schedule to begin in 2024.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hypertriglyceridemia: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Elevated triglyceride levels are an independent risk factor for cardiovascular disease. Severely elevated triglycerides (often over 2,000 mg/dL) in patients with familial chylomicronemia syndrome (FCS), a rare genetic disorder, can result in potentially fatal acute pancreatitis.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia (SHASTA-2)</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Severe Hypertriglyceridemia</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">ClinicalTrials.gov Identifier: NCT04720534</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: Study of ARO-APOC3 in Adults With Mixed Dyslipidemia (MUIR)</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Mixed Dyslipidemia</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">ClinicalTrials.gov Identifier: NCT04998201</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: Study of ARO-APOC3 in Adults With FCS (PALISADE)</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults With Familial Chylomicronemia Syndrome</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">ClinicalTrials.gov Identifier: NCT05089084</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Zodasiran (ARO-ANG3)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Zodasiran (formerly ARO-ANG3) is designed to reduce production of angiopoietin-like protein 3 (ANGPTL3), a liver synthesized inhibitor of lipoprotein lipase and endothelial lipase. ANGPTL3 inhibition has been shown to lower serum LDL, serum and liver triglyceride and has genetic validation as a novel target for cardiovascular disease. The Company is currently investigating zodasiran in two Phase 2b clinical trials.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dyslipidemia and Hypertriglyceridemia: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dyslipidemia and hypertriglyceridemia are risk factors for atherosclerotic coronary heart disease and cardiovascular events.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: Study of ARO-ANG3 in Adults With Mixed Dyslipidemia (ARCHES-2)</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">A Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of ARO-ANG3 in Adults With Mixed Dyslipidemia</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">ClinicalTrials.gov Identifier: NCT04832971</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HoFH) (GATEWAY) </span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Phase 2 Study to Evaluate the Safety and Efficacy of ARO-ANG3 in Subjects with Homozygous Familial Hypercholesterolemia (HoFH) </span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">ClinicalTrials.gov Identifier: NCT05217667</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARO-PNPLA3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARO-PNPLA3 (formerly JNJ-75220795) is an investigational RNAi therapeutic designed to reduce liver expression of patatin-like phospholipase domain containing 3 (PNPLA3) as a potential treatment for patients with non-alcoholic steatohepatitis (NASH). PNPLA3 has strong genetic and preclinical validation as a driver of fat accumulation and damage in the livers of patients who carry the common I148M mutation. Former licensee Janssen Pharmaceuticals, Inc. investigated ARO-PNPLA3 in two Phase 1 clinical trials and the Company is currently designing a Phase 2 clinical trial.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NASH:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> NASH is a subgroup of non-alcoholic fatty liver disease (NAFLD) in which hepatic cell injury and inflammation has developed over background steatosis. The I148M genetic variant in the PNPLA3 gene is involved with the underlying pathophysiology and is a known risk factor for hepatic steatosis, steatohepatitis, elevated plasma liver enzyme levels, hepatic fibrosis and cirrhosis. The rising prevalence of NASH presents a significant health burden in many developed countries.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARO-RAGE</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARO-RAGE is designed to reduce production of the Receptor for Advanced Glycation End products (RAGE) as a potential treatment for various inflammatory pulmonary diseases. The Company is currently investigating ARO-RAGE in a Phase 1/2a clinical trial. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%;text-decoration:underline">Study Name: Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease</span></div><div style="padding-left:27pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">A Phase 1/2a Study Evaluating the Effects of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease</span></div><div style="padding-left:27pt;text-align:justify"><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">ClinicalTrials.gov Identifier: NCT05276570</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARO-MUC5AC</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARO-MUC5AC is designed to reduce production of mucin 5AC (MUC5AC) as a potential treatment for various muco-obstructive pulmonary diseases. The Company is currently investigating ARO-MUC5AC in a phase 1/2a clinical trial.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: Study of ARO-MUC5AC in Healthy Subjects and  Patients With Muco-Obstructive Lung Disease</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">A Phase 1/2a Study to Evaluate the Effects of ARO-MUC5AC in Healthy Subjects and Patients with Muco-Obstructive Lung Disease</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">ClinicalTrials.gov Identifier: </span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">NCT05292950</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%"> </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARO-MMP7</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ARO-MMP7 is designed to reduce expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic Pulmonary Fibrosis (IPF). The Company is currently investigating ARO-MMP7 in a Phase 1/2a clinical trial.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%;text-decoration:underline">Study Name: </span><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:107%;text-decoration:underline">Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis</span></div><div style="padding-left:27pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">A Phase 1/2a Study Evaluating the Effects of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis</span></div><div style="padding-left:27pt"><span style="background-color:#ffffff;color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">ClinicalTrials.gov Identifier: NCT05537025</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARO-DUX4</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARO-DUX4 is designed to target the gene that encodes human double homeobox 4 (DUX4) protein as a potential treatment for patients with facioscapulohumeral muscular dystrophy. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Facioscapulohumeral Muscular Dystrophy: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facioscapulohumeral muscular dystrophy (FSHD) is an autosomal dominant disease associated with the failure to maintain complete epigenetic suppression of DUX4 expression in differentiated skeletal muscle, leading to overexpression of DUX4, which is myotoxic and can lead to muscle degeneration. As DUX4 expression is recognized as the cause of muscle pathology in FSHD patients, the Company believes that the selective targeting and knockdown of DUX4 using RNAi may prevent or reverse downstream myotoxicity and lead to muscle repair and improvement in muscle function in patients. There are currently no effective treatments specifically for FSHD.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">ClinicalTrials.gov Identifier: NCT06131983</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARO-SOD1</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARO-SOD1 is designed to target the gene that encodes human superoxide dismutase 1 (SOD1) protein as a potential treatment for patients with amyotrophic lateral sclerosis (ALS) harboring a SOD1 mutations.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amyotrophic Lateral Sclerosis (ALS): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ALS is a fatal motoneuronal disorder that causes progressive degeneration of upper and lower motor neurons in the primary motor cortex, brainstem, and spinal cord. Among the genetically defined ALS cases, about 15% are associated with dominantly inherited mutations in the SOD1 gene. Although the exact disease-causing mechanism of SOD1 mutations remains incompletely understood, there is a consensus that there is a toxic gain-of-function leading to toxicity induced by aggregation of mutant SOD1 in neurons.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">A Phase 1 Randomized Placebo-Controlled Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ARO-SOD1 in Adult Patients With Amyotrophic Lateral Sclerosis Harboring a Superoxide Dismutase-1 Mutation Considered to be Causative of Amyotrophic Lateral Sclerosis</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">ClinicalTrials.gov Identifier: NCT05949294</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARO-C3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARO-C3 is designed to reduce production of complement component 3 (C3) as a potential therapy for patients with various complement mediated or complement associated renal diseases. The Company is currently investigating ARO-C3 in a Phase 1/2a clinical trial.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:117%">Complement-Mediated Renal Disease:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:117%"> A number of rare renal diseases result from uncontrolled activation of the alternative pathway of complement, leading to progressive glomerular damage, proteinuria, hematuria, and impaired kidney function, and often resulting in end-stage renal disease (ESRD). In addition, dysregulation of the alternative complement pathway has been shown to play a role in the pathogenesis and progression of disease in some of the more common glomerulopathies. Silencing C3 may be a therapeutic approach for treatment of these conditions. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement-Mediated Renal Disease</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and/or Pharmacodynamics of ARO-C3 in Adult Healthy Volunteers and in Adult Patients With Complement-Mediated Renal Disease</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">ClinicalTrials.gov Identifier: NCT05083364</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Collaboration and License Agreements</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Glaxosmithkline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 22, 2021, GSK and the Company entered into an Exclusive License Agreement (the &#8220;GSK License Agreement&#8221;). Under the GSK License Agreement, GSK has received an exclusive license for GSK-4532990 (formerly ARO-HSD). The exclusive license is worldwide with the exception of greater China. GSK is wholly responsible for all clinical development and commercialization of GSK-4532990 in its territory. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, the Company received an upfront payment of $120.0 million, and an additional payment of $30.0 million was received at the start of a Phase 2 clinical trial. The Company is also eligible for an additional payment of $100.0 million upon achieving the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $190.0 million at first commercial sale, and up to $590.0 million in sales-related milestone payments. The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GSK-4532990</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GSK-4532990 (formerly ARO-HSD) is designed to reduce production of HSD17B13, a hydroxysteroid dehydrogenase involved in the metabolism of hormones, fatty acids and bile acids. Published human genetic data indicate that a loss of function mutation in HSD17B13 provides strong protection against nonalcoholic steatohepatitis (NASH) cirrhosis and alcoholic hepatitis and cirrhosis. GSK is conducting a Phase 2b clinical trial.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nonalcoholic Steatohepatitis: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NASH is liver inflammation and damage caused by a buildup of fat in the liver. This can cause scarring of the liver and in advanced cases can lead to cirrhosis.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: Phase 2b Study of GSK4532990 in Adults With NASH (HORIZON)</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">17 &#946;-Hydroxysteroid Dehydrogenase Type 13 Minimization for the Treatment of NASH (HORIZON): A Double-Blind, Placebo-Controlled Phase 2b Study to Evaluate the Efficacy and Safety of GSK4532990 in Adults With Pre-Cirrhotic Nonalcoholic Steatohepatitis</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">ClinicalTrials.gov Identifier: NCT05583344</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Horizon Therapeutics Ireland DAC (&#8220;Horizon&#8221;) </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021, Horizon and the Company entered into a collaboration and license agreement (the &#8220;Horizon License Agreement&#8221;). Under the terms of the Horizon License Agreement, Horizon received a worldwide exclusive license for HZN-457, a clinical-stage medicine being developed by Horizon as a potential treatment for people with uncontrolled gout. Horizon is wholly responsible for clinical development and commercialization of HZN-457. On October 6, 2023, Amgen completed its acquisition of Horizon.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, the Company received an upfront payment of $40.0 million, and an additional payment of $15.0 million was received at the start of a Phase 1 clinical trial. On November 21, 2023, the Company received notice from Horizon that it has elected to terminate the Horizon License Agreement. Horizon exercised its right to terminate the Horizon License Agreement for convenience. The termination will take effect on December 21, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">HZN-457</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HZN-457 is designed to reduce production of xanthine dehydrogenase (XDH) as a potential treatment for people with uncontrolled gout. Gout is a serious and painful form of arthritis that is caused by excess uric acid in the blood. In the United States, there are more than nine million gout patients and approximately one-third of those patients are treated with oral urate-lowering therapies. However, a meaningful portion of treated patients do not respond sufficiently to treatment and therefore continue to experience painful and debilitating gout symptoms. XDH represents a clinically validated target that is the primary source of serum uric acid (sUA). High levels of sUA, if left untreated or undertreated, can potentially lead to serious long-term or even permanent damage to the bones, joints and organs.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: Study to Evaluate HZN-457 in Healthy Volunteers</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 1 Randomized, Placebo-Controlled Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HZN-457 in Healthy Volunteers</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT05565768</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 7, 2020, Takeda and the Company entered into an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;). Under the Takeda License Agreement, Takeda and the Company co-develop the Company&#8217;s Fazirsiran program (formerly TAK-999 and ARO-AAT), the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, fazirsiran, if approved, will be co-commercialized under a 50/50 profit sharing structure. Outside the United States, Takeda received an exclusive license to commercialize fazirsiran and will lead the global commercialization strategy, while the Company will be eligible to receive tiered royalties of 20% to 25% on net sales. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, the Company received $300.0 million as an upfront payment and an additional payment of $40.0 million at the start of Phase 3. The Company is also eligible to receive up to $527.5 million in additional potential development, regulatory and commercial milestones.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Fazirsiran</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fazirsiran is a subcutaneously administered RNAi therapeutic being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency (AATD), which is a rare genetic disorder that severely damages the liver and lungs of affected individuals. Fazirsiran is designed to reduce production of the mutant Z-AAT protein by silencing the AAT gene in order to prevent accumulation of Z-AAT in the liver, allow clearance of the accumulated Z-AAT protein, prevent repeated cycles of cellular damage, and possibly prevent or even reverse the progression of liver fibrosis.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goal of Fazirsiran Treatment: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goal of Fazirsiran treatment is prevention and potential reversal of Z-AAT accumulation-related liver injury and fibrosis. Reduction of inflammatory Z-AAT protein, which has been clearly defined as the cause of progressive liver disease in AATD patients, is important as it is expected to halt the progression of liver disease and allow fibrotic tissue repair.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Alpha-1 Antitrypsin Deficiency (AATD): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">AATD is a genetic disorder associated with liver disease in children and adults, and pulmonary disease in adults. AAT is a circulating glycoprotein protease inhibitor that is primarily synthesized and secreted by liver hepatocytes. Its physiologic function is the inhibition of neutrophil protease to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protect healthy lung tissues during inflammation and prevent tissue damage. The most common disease variant, the Z mutant, has a single amino acid substitution that results in improper folding of the protein. The mutant protein cannot be effectively secreted and accumulates in globules in the hepatocytes. This triggers continuous hepatocyte injury, leading to fibrosis, cirrhosis, and increased risk of hepatocellular carcinoma.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Current Treatments: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individuals with the homozygous PiZZ genotype have severe deficiency of functional AAT leading to pulmonary disease and hepatocyte injury and liver disease. Lung disease in this patient population is frequently treated with AAT augmentation therapy. However, augmentation therapy does nothing to treat liver disease, and there is no specific therapy for hepatic manifestations. There is a significant unmet need as liver transplant, with its attendant morbidity and mortality, is currently the only available treatment.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trials:</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein (REDWOOD)</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">REDWOOD &#8211; A Randomized, Double-blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Stage F2 to F4 Fibrosis</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT05677971</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 3, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of fazirsiran in Participants With Alpha-1 Antitrypsin Deficiency-Associated Liver Disease</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ClinicalTrials.gov Identifier: NCT05899673</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 3, 2018, Janssen, part of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, and the Company entered into a License Agreement (the &#8220;Janssen License Agreement&#8221;). The Company also entered into a stock purchase agreement with JJDC, Inc. (&#8220;JJDC&#8221;), Johnson &amp; Johnson&#8217;s venture capital arm (the &#8220;JJDC Stock Purchase Agreement&#8221;). Under the Janssen License Agreement, Janssen received a worldwide, exclusive license to the Company&#8217;s JNJ-3989 (formerly ARO-HBV) program, the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#8217;s Phase 1/2 study of JNJ-3989, which the Company was responsible for completing, Janssen is wholly responsible for clinical development and commercialization of JNJ-3989.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Janssen License Agreement, the Company received $175.0 million as an upfront payment, $75.0 million in the form of an equity investment by JJDC in the Company&#8217;s common stock under the JJDC Stock Purchase Agreement, and milestone and option payments totaling $73.0 million. The Company may receive up to $825.0 million in development and sales milestone payments for the Janssen License Agreement. The Company is further eligible to receive tiered royalties on product sales up to mid-teens under the Janssen License Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 7, 2023, Janssen voluntarily terminated its collaboration agreement with the Company, dated October 3, 2018. Upon termination of the collaboration agreement, the Company regained full rights to ARO-PNPLA3, formerly called JNJ-75220795. ARO-PNPLA3 is in Phase 1 clinical trials that are now being developed by the Company.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">JNJ-3989 (also referred to as JNJ-73763989)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">JNJ-3989 is being developed by Janssen as a potential therapy for patients with chronic hepatitis B infection, when used in combination with other therapeutic modalities. JNJ-3989 is a subcutaneous RNAi therapy candidate which is designed to silence all HBV gene products and intervenes upstream of the reverse transcription process where current standard-of-care nucleotide and nucleoside analogues act. The Company believes this, especially the elimination of hepatitis B surface antigen (HBsAg), may allow the body&#8217;s natural immune defenses to clear the virus and potentially lead to a functional cure. JNJ-3989 is currently being investigated in multiple Phase 2 clinical trials being conducted by Janssen. The Phase 1/2a study and its preceding studies were conducted by the Company. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trials:</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus (REEF-D)</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled Study With Deferred Active Treatment to Investigate the Efficacy, Safety, and Pharmacokinetics of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT04535544</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: A Study of JNJ-73763989 Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-Naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 2, Randomized, Open-label, Multicenter Study to Evaluate Efficacy, Pharmacokinetics, Safety, and Tolerability of Treatment With JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog With or Without JNJ-56136379 in Treatment-naive Patients With HBeAg Positive Chronic Hepatitis B Virus Infection</span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT04439539</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: A Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Chronic Hepatitis B Virus Infection (INSIGHT)</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 2 Randomized, Open-label, Parallel-group, Multicenter Study to Assess Intrahepatic and Peripheral Changes of Immunologic and Virologic Markers in Response to Combination Regimens Containing JNJ-73763989 and Nucleos(t)Ide Analog With or Without JNJ-56136379 in Patients With Chronic Hepatitis B Virus Infection</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: NCT04585789</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: An Efficacy and Safety Study of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs (NA), and a Programmed Cell Death Protein Receptor-1 (PD-1) Inhibitor in Chronic Hepatitis B Participants (OCTOPUS-1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">)</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 2 Open-label Trial to Evaluate Safety, Efficacy, Tolerability, and Pharmacodynamics of a Combination of JNJ-73763989, Nucleos(t)Ide Analogs, and a PD-1 Inhibitor in Chronic Hepatitis B Patients</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NCT05275023</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Study Name: A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection (OSPREY)</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Phase 1b, Open-label, Single-arm, Multicenter Study to Assess Efficacy, Safety, and Tolerability of Treatment With JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, HBeAg-negative Participants With Chronic Hepatitis B Virus Infection</span></div><div style="padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NCT05123599</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amgen Inc. (&#8220;Amgen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2016, Amgen and the Company entered into two collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the &#8220;Olpasiran Agreement&#8221;), Amgen received a worldwide, exclusive license to the Company&#8217;s novel RNAi olpasiran (previously referred to as AMG 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the Olpasiran Agreement, Amgen is wholly responsible for clinical development and commercialization. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Olpasiran Agreement, the Company has received $35.0 million in upfront payments, $21.5 million in the form of an equity investment by Amgen in the Company&#8217;s common stock, and $55.0 million in milestone payments. The Company has substantially completed its performance obligations under the Olpasiran Agreement.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, Royalty Pharma Investments 2019 ICAV (&#8220;Royalty Pharma&#8221;) and the Company entered into a Royalty Purchase Agreement (the &#8220;Royalty Pharma Agreement&#8221;). In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive up to an additional $535.0 million in remaining development, regulatory and sales milestone payments payable from Amgen and Royalty Pharma. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Olpasiran</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Olpasiran is designed to reduce production of apolipoprotein A, a key component of lipoprotein(a), which has been genetically linked with increased risk of cardiovascular diseases, independent of cholesterol and LDL levels. Amgen completed a Phase 2 clinical study evaluating the efficacy, safety, and tolerability of olpasiran in subjects with elevated levels of lipoprotein(a). Amgen reported Phase 2 clinical results at the American Heart Association (AHA) Scientific Sessions in November 2022 and simultaneously published in the New England Journal of Medicine. Amgen began evaluating olpasiran in a Phase 3 study to assess the impact of olpasiran on major cardiovascular events in participants with atherosclerotic cardiovascular disease and elevated lipoprotein(a), in a double-blind, randomized, placebo-controlled, multi center study in December 2022, which triggered a $25 million milestone payment to the Company. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ClinicalTrials.gov Identifier: (NCT05581303)</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Joint Venture and License Agreement with Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2022, Visirna and the Company entered into a License Agreement (the &#8220;Visirna License Agreement&#8221;), pursuant to which Visirna received an exclusive license to develop, manufacture and commercialize four of the Company&#8217;s RNAi-based investigational cardiometabolic medicines in Greater China (including the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan). Pursuant to a Share Purchase Agreement entered into simultaneously with the Visirna License Agreement (the &#8220;Visirna SPA&#8221;), the Company acquired a majority stake in Visirna (after accounting for shares reserved for Visirna&#8217;s employee stock ownership plan) as partial consideration for the Visirna License Agreement. Under the Visirna SPA, entities affiliated with Vivo Capital also acquired a minority stake in Visirna in exchange for $60.0&#160;million in upfront capital to support the operations of Visirna. As further consideration under the Visirna License Agreement, the Company is also eligible to receive potential royalties on commercial sales.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property and Other Key Agreements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company controls approximately 534 issued patents (including 342 directed to RNAi trigger molecules; 89 directed to targeting groups or targeting compounds; and one for hydrodynamic gene delivery), including European validations, and approximately 793 currently pending patent applications worldwide from 79 different patent families. The Company&#8217;s patent applications have been filed throughout the world, including, in the United States, Argentina, ARIPO (Africa Regional Intellectual Property Organization), Australia, Brazil, Canada, Chile, China, Eurasian Patent Organization, Europe, GCC (Gulf Cooperation Council), Hong Kong, Israel, India, Indonesia, Iraq, Jordan, Japan, Lebanon, Mexico, New Zealand, OAPI (African Intellectual Property Organization), Peru, Philippines, Russian Federation, South Africa, Saudi Arabia, Singapore, South Korea, Thailand, Taiwan, Uruguay, Venezuela, and Vietnam.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">RNAi Triggers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company owns issued patents or has filed patent applications directed to RNAi trigger molecules, which serve as the foundation of the Company&#8217;s TRiM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform, and are targeted to reduce expression of various gene targets. However, the Company cannot be certain that issued patents will be enforceable or provide adequate protection or that pending patent applications will result in issued patents. These patents and patent applications include the following: </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Group</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Year(s) of Expiration*</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">AAT</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035, 2038</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APOC3</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2035, 2038</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ANGPTL3</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2038</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PNPLA3</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSD17B13</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MUC5AC</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2042</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RAGE (AGER)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2042</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MMP7</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2042</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DUX4</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XDH</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2042</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HBV </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032, 2036, 2037</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LPA</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COVID</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2043</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HIF2&#945;</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034, 2036, 2040</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Factor 12</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036, 2038</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RRM2</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#945;-ENaC </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028, 2038</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#946;-ENaC</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031, 2040</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#946;-Catenin</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cx43</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2029</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HIF1A</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HRH1</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HSF1</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2030, 2032</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">FRP-1</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">KRAS</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2033</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">P2X3</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mob-5</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PDtype4</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PI4Kinase</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SYK</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TNF-&#945;</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027, 2028</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Assuming issuance of any pending patent applications, and excluding any patent term adjustments or patent term extensions.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Delivery Technologies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The delivery technology-related patents and patent applications, which include components used in the Company&#8217;s TRiM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform, have been filed and/or issued in various jurisdictions worldwide including the United States, Argentina, Australia, Brazil, Canada, China, Eurasian Patent Organization, Europe (including validations in France, Germany, Italy, Spain, Switzerland, United Kingdom), GCC (Gulf Cooperation Council), Israel, India, Japan, Lebanon, Mexico, New Zealand, Philippines, Russia, South Africa, South Korea, Singapore, Taiwan, and Uruguay. The Company also controls a patent directed to hydrodynamic nucleic acid delivery that issued in the United States. The approximate year of expiration for each of these various groups of patents and applications are set forth below: </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Patent Group</span></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Estimated Year(s) of Expiration*</span></td></tr><tr><td colspan="3" style="background-color:#eeece1;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Targeting ligands and other RNAi delivery and platform technologies</span></td><td colspan="3" style="background-color:#eeece1;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Targeting groups (Galactose derivative trimer-PK)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2031</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Targeting groups (&#945;v&#946;3/&#945;v&#946;5 integrin)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2034, 2038, 2039</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Targeting groups (&#945;v&#946;6 integrin)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037, 2038, 2041</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Targeting groups (Galactose derivative ligands)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037, 2037</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RNAi agent design (5&#8242;-phosphate mimic)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2037</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Physiologically labile linkers</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Biologically cleavable linkers</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2036</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trialkyne linkers</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2039</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Muscle delivery platform</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041, 2041</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">PK/PD lipid modifiers</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2041</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Transferrin targeting</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LDLR targeting</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peptide targeting (CPP-Arg) </span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peptide targeting (YM3-10H)</span></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2032</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#eeece1;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Hydrodynamic delivery</span></td><td colspan="3" style="background-color:#eeece1;border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third iteration</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Assuming issuance of any pending patent applications, and excluding any patent term adjustments or patent term extensions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RNAi and drug delivery patent landscapes are complex and rapidly evolving. As such, the Company may need to obtain additional patent licenses prior to commercialization of its candidates. Please see &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Acquisition of Assets from Novartis</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 3, 2015, Novartis and the Company entered into an Asset Purchase and Exclusive License Agreement (the &#8220;RNAi Purchase Agreement&#8221;) pursuant to which the Company acquired Novartis&#8217;s RNAi assets and rights thereunder. Pursuant to the RNAi Purchase Agreement, the Company acquired or was granted a license to certain patents and patent applications owned or controlled by Novartis related to RNAi therapeutics, was assigned Novartis&#8217;s rights under a license from Alnylam Pharmaceuticals, Inc. (&#8220;Alnylam&#8221;) (the &#8220;Alnylam-Novartis License&#8221;) and acquired a license to certain additional Novartis assets (the &#8220;Licensed Novartis Assets&#8221;). The patents acquired from Novartis include multiple patent families covering delivery technologies and RNAi-trigger design rules and modifications. The Licensed Novartis Assets include an exclusive, worldwide right and license, solely in the RNAi field, with the right to grant sublicenses through multiple tiers under or with respect to certain patent rights and know how relating to delivery technologies and RNAi-trigger design rules and modifications. Under the assigned Alnylam-Novartis License, the Company acquired a worldwide, royalty-bearing, exclusive license with limited sublicensing rights to existing and future Alnylam intellectual property (including intellectual property that came under Alnylam&#8217;s control on or before March 31, 2016), excluding intellectual property concerning delivery technology, to research, develop and commercialize 30 undisclosed gene targets. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-Exclusively Licensed Patent Rights from Roche</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 21, 2011, the Company acquired the RNAi therapeutics business of Hoffmann-La Roche, Inc. and F. Hoffmann-La Roche Ltd. (collectively, &#8220;Roche&#8221;). The acquisition provided the Company with two primary sources of value:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Broad freedom to operate with respect to key patents directed to the primary RNAi-trigger formats: canonical, UNA, meroduplex, and dicer substrate structures; and</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">A large team of scientists experienced in RNAi and oligonucleotide delivery. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to this acquisition, Roche assigned to the Company its entire rights under certain licenses including: the License and Collaboration Agreement between Roche and Alnylam dated July 8, 2007 (the &#8220;Alnylam License&#8221;); the Non-Exclusive Patent License Agreement between Roche and MDRNA, Inc. dated February 12, 2009 (&#8220;MDRNA License&#8221;); </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the Non-Exclusive License Agreement between Roche and City of Hope dated September 19, 2011 (the &#8220;COH License&#8221;) (collectively the &#8220;RNAi Licenses&#8221;).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RNAi Licenses include licenses to patents related to modifications of double-stranded oligonucleotides, including modifications to the base, sugar, or internucleoside linkage, nucleotide mimetics, and end modifications, which do not abolish the RNAi activity of the double-stranded oligonucleotides. Also included are patents relating to modified double-stranded oligonucleotides, such as meroduplexes described in U.S. Patent No. 9,074,205 assigned to Marina Biotech (f/k/a MDRNA, Inc.), as well as U.S. Patent Nos. 8,314,227, 9,051,570, and 9,303,260 related to unlocked nucleotide analogs (&#8220;UNA&#8221;). The UNA patents were assigned by Marina Biotech to Arcturus Therapeutics, Inc., but remain part of the MDRNA License. The RNAi Licenses further include patents related to dicer substrates and uses of the double-stranded oligonucleotides that function through the mechanism of RNA interference, such as described in City of Hope&#8217;s U.S. Patent Nos. 8,084,599, 8,658,356, 8,691,786, 8,796,444, 8,809,515, and 9,518,262. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States, at the federal, state, and local levels, and in other countries and jurisdictions, including the European Union (&#8220;EU&#8221;), extensively regulate, among other things, the research, development, testing, product approval, manufacture, quality control, manufacturing changes, packaging, storage, recordkeeping, labeling, promotion, advertising, sales, distribution, marketing, and import and export of drugs and biologic products. All of the Company&#8217;s current product candidates are expected to be regulated as drugs. The processes for obtaining regulatory approval in the United States and in foreign countries and jurisdictions, along with compliance with applicable statutes and regulations and other regulatory authorities both pre- and post-commercialization, are a significant factor in the production and marketing of the Company&#8217;s products and its R&amp;D activities and require the expenditure of substantial time and financial resources.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Review and Approval of Drugs in the United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States Food and Drug Administration (the &#8220;FDA&#8221;) and other government entities regulate drugs under the Federal Food, Drug, and Cosmetic Act (the &#8220;FDCA&#8221;), the Public Health Service Act, and the regulations promulgated under those statutes, as well as other federal and state statutes and regulations. Failure to comply with applicable legal and regulatory requirements in the United States at any time during the product development process, approval process, or after approval, may subject us to a variety of administrative or judicial sanctions, such as a delay in approving or refusal by the FDA to approve pending applications, withdrawal of approvals, delay or suspension of clinical trials, issuance of warning letters and other types of regulatory letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil monetary penalties, refusals of or debarment from government contracts, exclusion from the federal healthcare programs, restitution, disgorgement of profits, civil or criminal investigations by the FDA, U.S. Department of Justice, State Attorneys General, and/or other agencies, False Claims Act suits and/or other litigation, and/or criminal prosecutions. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An applicant seeking approval to market and distribute a new drug in the United States must typically undertake the following: </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) completion of preclinical laboratory tests, which may include animal and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> studies, and formulation studies in compliance with the FDA&#8217;s good laboratory practice (&#8220;GLP&#8221;) regulations; </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) submission to the FDA of an Investigational New Drug (&#8220;IND&#8221;) for human clinical testing, which must become effective without FDA objection before human clinical trials may begin; </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) approval by an independent institutional review board (&#8220;IRB&#8221;), representing each clinical site before each clinical trial may be initiated; </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) performance of adequate and well-controlled human clinical trials in accordance with the FDA&#8217;s current good clinical practice (&#8220;cGCP&#8221;) regulations, to establish the safety and effectiveness of the proposed drug product for each indication for which approval is sought; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) preparation and submission to the FDA of a New Drug Application (&#8220;NDA&#8221;);</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) satisfactory review of the NDA by an FDA advisory committee, where appropriate or if applicable;</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7) satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the drug product, and the active pharmaceutical ingredient or ingredients thereof, are produced to assess compliance with current good manufacturing practice (&#8220;cGMP&#8221;) regulations and to assure that the facilities, methods, and controls are adequate to ensure the product&#8217;s identity, strength, quality, and purity; </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8) payment of user fees, as applicable, and securing FDA approval of the NDA; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9) compliance with any post-approval requirements, such as any Risk Evaluation and Mitigation Strategies (&#8220;REMS&#8221;) or post-approval studies required by the FDA. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Preclinical Studies and an IND </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preclinical studies can include </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and animal studies to assess the potential for adverse events and, in some cases, to establish a rationale for therapeutic use. The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations. Other studies include laboratory evaluation of the purity, stability and physical form of the manufactured drug substance or active pharmaceutical ingredient and the physical properties, stability and reproducibility of the formulated drug or drug product. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical studies, among other things, to the FDA as part of an IND. Some preclinical testing, such as longer-term toxicity testing, animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to a proposed clinical trial and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following commencement of a clinical trial under an IND, the FDA may place a clinical hold on that trial. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so. No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Human Clinical Studies in Support of an NDA </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with cGCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health for public dissemination on its ClinicalTrials.gov website. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined: </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 1: The product candidate is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 2: The product candidate is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Phase 3: The product candidate is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Phase 1, Phase 2, and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. The FDA will typically inspect one or more clinical sites in late-stage clinical trials to assure compliance with cGCP and the integrity of the clinical data submitted. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain FDA regulatory requirements in order to use the study as support for an IND or application for marketing approval or licensure, including that the study was conducted in accordance with GCP, including review and approval by an independent ethics committee and use of proper procedures for obtaining informed consent from subjects, and the FDA is able to validate the data from the study through an onsite inspection if the FDA deems such inspection necessary. The GCP requirements encompass both ethical and data integrity standards for clinical studies. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Submission of an NDA to the FDA </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assuming successful completion of required clinical testing and other requirements, the results of the preclinical and clinical studies, together with detailed information relating to the product&#8217;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the drug product for one or more indications. Under federal law, the submission of most NDAs is additionally subject to an application user fee, currently approximately $4.0 million for fiscal year 2024, for applications requiring clinical data, and the sponsor of an approved NDA is also subject to an annual program fee, currently approximately $0.4 million for fiscal year 2024. These fees are adjusted annually.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain circumstances, the FDA will waive the application fee for the first human drug application that a small business, defined as a company with less than 500 employees, including employees of affiliates, submits for review. An affiliate is defined as a business entity that has a relationship with a second business entity if one business entity controls, or has the power to control, the other business entity, or a third-party controls, or has the power to control, both entities. In addition, an application to market a prescription drug product that has received orphan designation is not subject to a prescription drug user fee unless the application includes an indication for other than the rare disease or condition for which the drug was designated.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA conducts a preliminary review of an NDA within 60 days of its receipt and informs the sponsor by the 74th day after the FDA&#8217;s receipt of the submission to determine whether the application is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review process of NDAs. Most such applications are meant to be reviewed within ten months from the date of filing, and most applications for &#8220;priority review&#8221; products are meant to be reviewed within six months of filing. The review process may be extended by the FDA for three additional months to consider new information or clarification provided by the applicant to address an outstanding deficiency identified by the FDA following the original submission. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with cGCP. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA also may require submission of a REMS plan to mitigate any identified or suspected serious risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is required to refer an application for a novel drug to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">The FDA&#8217;s Decision on an NDA </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On the basis of the FDA&#8217;s evaluation of the NDA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the product with specific prescribing information for specific indications. A </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA approves a product, it may limit the approved indications for use for the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies be conducted to further assess the drug&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution restrictions or other risk management mechanisms, including REMS, which can materially affect the potential market and profitability of the product. After approval, the FDA may seek to prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs. Some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The product may also be subject to official lot release, meaning that the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official lot release, the manufacturer must submit samples of each lot, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot, to the FDA. The FDA may in addition perform certain confirmatory tests on lots of some products before releasing the lots for distribution. Finally, the FDA will conduct laboratory research related to the safety and effectiveness of drug products. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug for this type of disease or condition will be recovered from sales in the United States for that drug. Orphan drug designation entitles the applicant to incentives such as grant funding towards clinical study costs, tax advantages, and waivers of FDA user fees. Orphan drug designation must be requested before submitting an NDA, and both the drug and the disease or condition must meet certain criteria specified in the Orphan Drug Act and FDA&#8217;s implementing regulations at 21 C.F.R. Part 316. The granting of an orphan drug designation does not alter the standard regulatory requirements and process for obtaining marketing approval. Safety and effectiveness of a drug must be established through adequate and well-controlled studies. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other application to market the same drug for the same indication, except in very limited circumstances, for seven years. Orphan drug exclusivity does not prevent the FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or condition.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA&#8217;s interpretation of the scope of orphan drug exclusivity may change. The FDA&#8217;s longstanding interpretation of the Orphan Drug Act is that exclusivity is specific to the orphan indication for which the drug was actually approved. As a result, the scope of exclusivity has been narrow and protected only against competition from the same &#8220;use or indication&#8221; rather than the broader &#8220;disease or condition.&#8221; In the September 2021 case Catalyst Pharmaceuticals, Inc. v. FDA, a federal circuit court set aside the FDA&#8217;s narrow interpretation and ruled that orphan drug exclusivity covers the full scope of the orphan-designated disease or condition regardless of whether the drug obtains approval only for a narrower use. The decision concerned amifampridine, a drug used to treat Lambert-Eaton myasthenic syndrome (LEMS). Depending on how the FDA applies the decision beyond this case, it may limit the drugs that can receive exclusivity. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Expedited Review and Accelerated Approval Programs</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor may seek approval of its product candidate under programs designed to accelerate the FDA&#8217;s review and approval of NDAs. For example, Fast Track Designation may be granted to a drug intended for treatment of a serious or life-threatening disease or condition and data demonstrate its potential to address unmet medical needs for the disease or condition. The key benefits of Fast Track Designation are the eligibility for priority review, rolling review (submission of portions of an application before the complete marketing application is submitted), and accelerated approval, if relevant criteria are met. The FDA may grant the NDA a priority review designation, which sets the target date for FDA action on the application at six months after the FDA accepts the application for filing. Priority review is granted where there is evidence that the proposed product would be a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may approve an NDA under the accelerated approval program if the drug treats a serious condition, provides a meaningful advantage over available therapies, and demonstrates an effect on either (1) a surrogate endpoint that is reasonably likely to predict clinical benefit, or (2) on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Post-marketing studies or completion of ongoing studies after marketing approval are generally required to verify the drug&#8217;s clinical benefit in relationship to the surrogate endpoint or ultimate outcome in relationship to the clinical benefit. Under the Food and Drug Omnibus Reform Act of 2022 (&#8220;FDORA&#8221;), the FDA may require, as appropriate, that such studies be underway prior to approval or within a specific time period after the date of approval for a product granted accelerated approval. The FDA also has increased authority for expedited procedures to withdraw approval of a product or indication approved under accelerated approval if the sponsor fails to conduct the required post-marketing studies or if such studies fail to verify the predicted clinical benefit. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials, which could adversely impact the timing of the commercial launch of the product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Food and Drug Administration Safety and Innovation Act of 2012 (&#8220;FDASIA&#8221;) established the Breakthrough Therapy designation. A sponsor may seek FDA designation of its product candidate as a breakthrough therapy if the drug is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. If a drug is designated as breakthrough therapy, FDA will provide more intensive guidance on the drug development program and expedite its review. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Post-Approval Requirements </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drugs manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to prior FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events or problems with manufacturing processes of unanticipated severity or frequency, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">fines, warning letters or holds on post-approval clinical trials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product license approvals; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">product seizure or detention, or refusal to permit the import or export of products; or </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">injunctions or the imposition of civil or criminal penalties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act (&#8220;PDMA&#8221;), which regulates the distribution of drugs and drug samples at the federal level and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Abbreviated New Drug Applications for Generic Drugs </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 1984, with passage of the Drug Price Competition and Patent Term Restoration Act of 1984 (commonly referred to as the &#8220;Hatch-Waxman Amendments&#8221;) amending the FDCA, Congress authorized the FDA to approve generic drugs that are the same as drugs previously approved by the FDA under the NDA provisions of the statute. To obtain approval of a generic drug, an applicant must submit an abbreviated new drug application (&#8220;ANDA&#8221;) to the agency. In support of such applications, a generic manufacturer may rely on the preclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference listed drug (&#8220;RLD&#8221;). To reference that information, however, the ANDA applicant must demonstrate, and the FDA must conclude, that the generic drug does, in fact, perform in the same way as the RLD it purports to copy. Specifically, in order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration, the dosage form, and the strength of the drug. However, an applicant may submit an ANDA suitability petition to request the FDA&#8217;s prior permission to submit an abbreviated application for a drug that differs from the RLD in route of administration, dosage form, or strength, or for a drug that has one different active ingredient in a fixed combination drug product (i.e., a drug product with multiple active ingredients).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the same time, the FDA must also determine that the generic drug is &#8220;bioequivalent&#8221; to the innovator drug. Under the statute, a generic drug is bioequivalent to a RLD if &#8220;the rate and extent of absorption of the generic drug do not show a significant difference from the rate and extent of absorption of the RLD.&#8221; Upon approval of an ANDA, the FDA indicates that the generic product is &#8220;therapeutically equivalent&#8221; to the RLD and it assigns a therapeutic equivalence rating to the approved generic drug in its publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; also referred to as the &#8220;Orange Book.&#8221; Physicians and pharmacists consider the therapeutic equivalence rating to mean that a generic drug is fully substitutable for the RLD. In addition, by operation of certain state laws and numerous health insurance programs, the FDA&#8217;s designation of a therapeutic equivalence rating often results in substitution of the generic drug without the knowledge or consent of either the prescribing physician or patient. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Hatch-Waxman Amendments, the FDA may not approve an ANDA until any applicable period of nonpatent exclusivity for the RLD has expired. The FDCA provides a period of five years of data exclusivity for NDAs containing a new chemical entity. In cases where such exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, in which case the applicant may submit its application four years following the original product approval. The FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Hatch-Waxman Patent Certification and the 30 Month Stay </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the applicant&#8217;s product or a method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. When an ANDA applicant files its application with the FDA, the applicant is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book, except for patents covering methods of use for which the ANDA applicant is not seeking approval. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, the applicant must certify with respect to each patent that: </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the required patent information has not been filed; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the listed patent has expired; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the listed patent is invalid, unenforceable or will not be infringed by the new product. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A certification that the new product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If the applicant does not challenge the listed patents or indicate that it is not seeking approval of a patented method of use, the ANDA application will not be approved until all the listed patents claiming the referenced product have expired. If the ANDA applicant has provided a Paragraph IV </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months, expiration of the patent, settlement of the lawsuit or a decision in the infringement case that is favorable to the ANDA applicant. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">505(b)(2) New Drug Applications</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an alternative path to FDA approval for modifications to formulations or uses of products previously approved by the FDA pursuant to an NDA, an applicant may submit an NDA under Section 505(b)(2) of the FDCA. Section 505(b)(2) was enacted as part of the Hatch-Waxman Amendments and permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by, or for, the applicant, and for which the applicant has not obtained a right of reference. If the 505(b)(2) applicant can establish that reliance on the FDA&#8217;s previous findings of safety and effectiveness is scientifically and legally appropriate, it may eliminate the need to conduct certain preclinical studies or clinical trials of the new product. The FDA may also require companies to perform additional bridging studies or measurements, including clinical trials, to support the change from the previously approved reference drug. The FDA may then approve the new drug candidate for all, or some, of the label indications for which the reference drug has been approved, as well as for any new indication sought by the 505(b)(2) applicant.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that a Section 505(b)(2) applicant is relying on studies conducted for an already approved product, the applicant is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA applicant would. As a result, approval of a 505(b)(2) NDA can be stalled until all the listed patents claiming the referenced product have expired, until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, listed in the Orange Book for the referenced product has expired, and, in the case of a Paragraph IV certification and subsequent patent infringement suit, until the earlier of 30 months, settlement of the lawsuit or a decision in the infringement case that is favorable to the Section 505(b)(2) applicant. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pediatric Studies and Exclusivity </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pediatric Research Equity Act of 2003, an NDA or supplement thereto must contain data that are adequate to assess the safety and effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. With the enactment of FDASIA, sponsors must also submit pediatric study plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric study or studies the applicant plans to conduct, including study objectives and design, any deferral or waiver requests, and other information required by regulation. The applicant, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in FDASIA. Unless otherwise required by regulation, the pediatric data requirements do not apply to products with orphan designation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing regulatory exclusivity, including the non-patent and orphan exclusivity. This six-month exclusivity may be granted if an NDA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. This is not a patent term extension, but it effectively extends the regulatory period during which the FDA cannot accept or approve another application. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Patent Term Restoration and Extension </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Amendments. Those Amendments permit a patent restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted is typically one-half the time between the effective date of an IND and the submission date of a NDA, plus the time between the submission date of a NDA and ultimate approval. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date. Only one patent applicable to an approved drug product is eligible for the extension, and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the application for the extension must be submitted prior to the expiration of the patent in question. The U.S. Patent and Trademark Office reviews and approves the application for any patent term extension or restoration in consultation with the FDA.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Review and Approval of Drugs in the European Union</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">and United Kingdom</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any pharmaceutical product outside of the United States, a company must also comply with numerous and varying regulatory requirements of other countries and jurisdictions governing, among other things, research and development, testing, manufacturing, quality control, safety, efficacy, labeling, clinical trials, marketing authorization, packaging, storage, record keeping, reporting, export and import, advertising, marketing and other promotional practices involving pharmaceutical products, as well as commercial sales, distribution, authorization, approval and post-approval monitoring and reporting of its products. Whether or not a company obtains FDA approval for a pharmaceutical product, the company would need to obtain the necessary approvals by the comparable foreign regulatory authorities before it can commence clinical trials or marketing of the pharmaceutical product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United Kingdom (&#8220;UK&#8221;) formally left the EU on January 31, 2020 (&#8220;Brexit&#8221;) and EU laws now only apply to the UK in respect of Northern Ireland as laid out in the Protocol on Ireland and Northern Ireland. The EU and the UK have agreed on a trade and cooperation agreement (&#8220;TCA&#8221;) which includes provisions affecting the life sciences sector (including on customs and tariffs). There are some specific provisions concerning pharmaceuticals, including the mutual recognition of Good Manufacturing Practice (&#8220;GMP&#8221;) and issued GMP documents. The TCA does not, however, contain wholesale mutual recognition of UK and EU pharmaceutical regulations and product standards.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK government has enacted the Medicines and Medical Devices Act 2021. The purpose of the act is to enable the existing regulatory frameworks in relation to human medicines and clinical trials of human medicines, among others, to be updated. The powers under the act may only be exercised in relation to specified matters and must safeguard public health.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Medicines and Medical Devices Act 2021 supplements the UK Medical Devices Regulations 2002 (&#8220;UK Regulations&#8221;), which are based on the EU Medical Devices Directive as amended to reflect the UK&#8217;s post-Brexit regulatory regime. Notably, the UK Regulations do not include any of the revisions that have been made by the EU Medical Devices Regulation (EU) 2017/745, which, since May 26, 2021, applies in all EU member states. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The UK&#8217;s Medicines and Healthcare products Regulatory Agency (&#8220;MHRA&#8221;) conducted a comprehensive consultation in 2021 on proposals to develop a new UK regime for medical devices in the UK. The proposals include more closely aligning definitions for medical devices and in vitro medical devices with internationally recognized definitions and changing the classification of medical devices according to levels or risk. The proposals are intended to improve patient and public safety and increase the appeal of the UK market. Core aspects of the new regime are planned to come into force on July 1, 2025, with strengthened post-market surveillance proposals to be introduced ahead of this in 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Medical Devices (Amendment) (Great Britain) Regulations 2023, CE marked European medical devices will continue to be accepted for sale in the UK until 2028 or 2030 (depending on the type of device).</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Drug and Biologic Development Process</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The conduct of clinical trials in the EU is governed by the EU Clinical Trials Regulation (EU) No. 536/2014 (&#8220;CTR&#8221;) which entered into force on January 31, 2022. The CTR replaced the Clinical Trials Directive 2001/20/EC, (Clinical Trials Directive) and introduced a complete overhaul of the existing regulation of clinical trials for medicinal products in the EU. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the former regime, which will expire after a transition period of one or three years, respectively, as outlined below in more detail, before a clinical trial can be initiated, it must be approved in each EU member state where there is a site at which the clinical trial is to be conducted. The approval must be obtained from two separate entities: the National Competent Authority (&#8220;NCA&#8221;), and one or more Ethics Committees. The NCA of the EU member states in which the clinical trial will be conducted must authorize the conduct of the trial, and the independent Ethics Committee must grant a positive opinion in relation to the conduct of the clinical trial in the relevant EU member state before the commencement of the trial. Any substantial changes to the trial protocol or other information submitted with the Clinical Trial Applications (&#8220;CTA&#8221;) must be submitted to or approved by the relevant NCA and Ethics Committees. Under the current regime all </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">suspected unexpected serious adverse reactions to the investigated drug that occur during the clinical trial must be reported to the NCA and to the Ethics Committees of the EU member state where they occur.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A more unified procedure will apply under the new CTR. A sponsor will be able to submit a single application for approval of a clinical trial through the a centralized EU clinical trials portal. One national regulatory authority (the reporting EU member state proposed by the applicant) will take the lead in validating and evaluating the application, and consult and coordinate with the other concerned EU member states. If an application is rejected, it may be amended and resubmitted through the EU clinical trials portal. If an approval is issued, the sponsor may start the clinical trial in all concerned EU member states. However, a concerned EU member state may in limited circumstances declare an &#8220;opt-out&#8221; from an approval and prevent the clinical trial from being conducted in such EU member state. The CTR also aims to streamline and simplify the rules on safety reporting and introduces enhanced transparency requirements such as mandatory submission of a summary of the clinical trial results to the EU Database (&#8220;CTIS&#8221;). The CTR includes a three-year transition period. Member states will work in CTIS immediately after the system has gone live. Since January 31, 2023, submission of initial CTA via CTIS is mandatory, and by January 31, 2025, all ongoing trials approved under the former Clinical Trials Directive will need to comply with the CTR and have to be transitioned to CTIS.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under both the former regime and the new CTR, national laws, regulations, and the applicable Good Clinical Practice (&#8220;GCP&#8221;) and Good Laboratory Practice standards must also be respected during the conduct of the trials, including the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (&#8220;ICH&#8221;) guidelines on GCP, and the ethical principles that have their origin in the Declaration of Helsinki.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the development of a medicinal product, the European Medicines Agency (&#8220;EMA&#8221;) and national regulators within the EU provide the opportunity for dialogue and guidance on the development program. At the EMA level, this is usually done in the form of scientific advice, which is given by the Committee for Medicinal Products for Human Use (&#8220;CHMP&#8221;) on the recommendation of the Scientific Advice Working Party (&#8220;SAWP&#8221;). A fee is incurred with each scientific advice procedure, but is significantly reduced for designated orphan medicines. Advice from the EMA is typically provided based on questions concerning, for example, quality (chemistry, manufacturing and controls testing), nonclinical testing and clinical studies, and pharmacovigilance plans and risk-management programs. Advice is not legally binding with regard to any future Marketing Authorization Application (&#8220;MAA&#8221;) of the product concerned.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Marketing Authorization Procedures </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU and in Iceland, Norway and Liechtenstein (together the European Economic Area or &#8220;EEA&#8221;), after completion of all required clinical testing, pharmaceutical products may only be placed on the market after obtaining a Marketing Authorization (&#8220;MA&#8221;). To obtain an MA of a drug under EU regulatory systems, an applicant can submit a MAA through, amongst others, a centralized or decentralized procedure. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The centralized procedure provides for the grant of a single MA by the European Commission (&#8220;EC&#8221;) that is valid for all EU member states and, after respective national implementing decisions, in the three additional member states of the EEA. The centralized procedure is compulsory for specific pharmaceutical products, including for medicines developed by means of certain biotechnological processes, products designated as orphan pharmaceutical products, advanced therapy pharmaceutical products and pharmaceutical products with a new active substance indicated for the treatment of certain diseases (AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases). For pharmaceutical products containing a new active substance not yet authorized in the European Economic Area before May 20, 2004 and indicated for the treatment of other diseases, pharmaceutical products that constitute significant therapeutic, scientific or technical innovations or for which the grant of a MA through the centralized procedure would be in the interest of public health at EU level, an applicant may voluntarily submit an application for a marketing authorization through the centralized procedure. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the centralized procedure, the CHMP established at the EMA is responsible for conducting the initial assessment of a drug. The CHMP is also responsible for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure, the timeframe for the evaluation of an MAA by the EMA&#8217;s CHMP is, in principle, 210 days from receipt of a valid MAA. However, this timeline excludes clock stops, when additional written or oral information is to be provided by the applicant in response to questions asked by the CHMP, so the overall process typically takes a year or more, unless the application is eligible for an accelerated assessment. Accelerated assessment might be granted by the CHMP in exceptional cases when a pharmaceutical product is expected to be of major public health interest, particularly from the point of therapeutic innovation. On request, the CHMP can reduce the time frame to 150 days if the applicant provides sufficient justification for an accelerated assessment. The CHMP will provide a positive opinion regarding the application only if it meets certain quality, safety and efficacy requirements. However, the EC has final authority for granting the MA within 67 days after receipt of the CHMP opinion.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decentralized procedure permits companies to file identical MA applications for a pharmaceutical product to the competent authorities in various EU member states simultaneously if such pharmaceutical product has not received marketing approval in any EU member state before. This procedure is available for pharmaceutical products not falling within the mandatory scope of the centralized procedure. The competent authority of a single EU member state, known as the reference EU member state, is appointed to review the application and provide an assessment report. Under this procedure, an applicant submits an application based on identical dossiers and related materials, including a draft summary of product characteristics, and draft labeling and package leaflet, to the reference EU member state and concerned EU member states. The reference EU member state prepares a draft assessment report and drafts of the related materials within 120 days after receipt of a valid application. Subsequently, each concerned EU member state must decide whether to approve the assessment report and related materials. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an EU member state cannot approve the assessment report and related materials on the grounds of potential serious risk to public health, the disputed points are subject to a dispute resolution mechanism and may eventually be referred to the EC, whose decision is binding for all EU member states. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All new MAAs must include a Risk Management Plan (&#8220;RMP&#8221;), describing the risk management system that the company will put in place and documenting measures to prevent or minimize the risks associated with the product. RMPs are continually modified and updated throughout the lifetime of the medicine as new information becomes available. New RMPs are required to be submitted (i) at the request of EMA or a national competent authority, or (ii) whenever the risk-management system is modified, especially as the result of new information being received that may lead to a significant change to the benefit-risk profile or as a result of an important pharmacovigilance or risk-minimization milestone being reached. The regulatory authorities may also impose specific obligations as a condition of the MA. Since October 20, 2023, all RMPs for centrally authorized products are published by the EMA subject to only limited redactions.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing Authorizations have an initial duration of five years. After these five years, the authorization may subsequently be renewed on the basis of a reevaluation of the risk-benefit balance. Once renewed, the MA is valid for an unlimited period unless the EC or the national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with only one additional five-year renewal. Applications for renewal must be made to the EMA at least nine months before the five-year period expires.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Data and Market Exclusivity in the European Union</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As in the United States, it may be possible to obtain a period of market and / or data exclusivity in the EU that would have the effect of postponing the entry into the marketplace of a competitor&#8217;s generic, hybrid or biosimilar product (even if the pharmaceutical product has already received an MA) and prohibiting another applicant from relying on the MA holder&#8217;s pharmacological, toxicological and clinical data in support of another MA for the purposes of submitting an application, obtaining MA or placing the product on the market. New Chemical Entities (&#8220;NCE&#8221;) approved in the EU qualify for eight years of data exclusivity and ten years of marketing exclusivity. The overall ten-year period can be extended to a maximum of eleven years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are deemed to bring a significant clinical benefit in comparison with existing therapies. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The data exclusivity period begins on the date of the product&#8217;s first MA in the EU. After eight years, a generic product application may be submitted and generic companies may rely on the MA holder&#8217;s data. However, a generic product cannot launch until two years later (or a total of 10 years after the first MA in the EU of the innovator product), or three years later (or a total of 11 years after the first MA in the EU of the innovator product) if the MA holder obtains MA for a new indication with significant clinical benefit within the eight-year data exclusivity period. Additionally, another noncumulative one-year period of data exclusivity can be added to the eight years of data exclusivity where an application is made for a new indication for a well-established substance, provided that significant preclinical or clinical studies were carried out in relation to the new indication. Another year of data exclusivity may be added to the eight years, where a change of classification of a pharmaceutical product has been authorized on the basis of significant pre-trial tests or clinical trials (when examining an application by another applicant for or holder of market authorization for a change of classification of the same substance the competent authority will not refer to the results of those tests or trials for one year after the initial change was authorized).</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products may not be granted data exclusivity since there is no guarantee that a product will be considered by the EU&#8217;s regulatory authorities to include a NCE. Even if a compound is considered to be a NCE and the MA applicant is able to gain the prescribed period of data exclusivity, another company nevertheless could also market another version of the pharmaceutical product if such company can complete a full MAA with their own complete database of pharmaceutical tests, preclinical studies and clinical trials and obtain MA of its pharmaceutical product. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 26, 2023, the EC submitted a proposal for the reform of the European pharmaceutical legislation. The current draft envisages e.g., a shortening of the periods of data exclusivity, however, there is currently neither a final version of this draft nor a date for its entry into force.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Orphan Designation and Exclusivity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The criteria for designating an orphan medicinal product in the EU are similar in principle to those in the United States. The EMA grants orphan drug designation if the medicinal product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the EU (prevalence criterion). In addition, Orphan Drug Designation can be granted if, for economic reasons, the medicinal product would be unlikely to be developed without incentives and if there is no other satisfactory method approved in the EU of diagnosing, preventing, or treating the condition, or if such a method exists, the proposed medicinal product is a significant benefit to patients affected by the condition. An application for orphan drug designation (which is not a marketing authorization, as not all orphan-designated medicines reach the authorization application stage) must be submitted first before an application for marketing authorization of the medicinal product is submitted. The applicant will receive a fee reduction for the marketing authorization application if the orphan drug designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted, and sponsors must submit an annual report to EMA summarizing the status of development of the medicine. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Designated orphan medicines are eligible for conditional marketing authorization.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EMA&#8217;s Committee for Orphan Medicinal Products reassesses the orphan drug designation of a product in parallel with the review for a marketing authorization; for a product to benefit from market exclusivity it must maintain its orphan drug designation at the time of marketing authorization review by the EMA and approval by the EC. Additionally, any marketing authorization granted for an orphan medicinal product must only cover the therapeutic indication(s) that are covered by the orphan drug designation. Upon the grant of a marketing authorization, orphan drug designation provides up to ten years of market exclusivity in the orphan indication.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the 10-year period of market exclusivity, with a limited number of exceptions, the regulatory authorities of the EU member states and the EMA may not accept applications for marketing authorization, accept an application to extend an existing marketing authorization or grant marketing authorization for other similar medicinal products for the same therapeutic indication. A similar medicinal product is defined as a medicinal product containing a similar active substance or substances as contained in a currently authorized orphan medicinal product, and which is intended for the same therapeutic indication. An orphan medicinal product can also obtain an additional two years of market exclusivity for an orphan-designated condition when the results of specific studies are reflected in the Summary of Product Characteristics (&#8220;SmPC&#8221;), addressing the pediatric population and completed in accordance with a fully compliant Pediatric Investigation Plan (&#8220;PIP&#8221;). No extension to any supplementary protection certificate can be granted on the basis of pediatric studies for orphan indications.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, i.e. the condition prevalence or financial returns criteria under Article 3 of Regulation (EC) No. 141/2000 on orphan medicinal products. When the period of orphan market exclusivity for an indication ends, the orphan drug designation for that indication expires as well. Orphan exclusivity runs in parallel with normal rules on data exclusivity and market protection. Additionally, a marketing authorization may be granted to a similar medicinal product (orphan or not) for the same or overlapping indication subject to certain requirements.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pediatric Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, companies developing a new pharmaceutical product are obligated to study their product in children and must therefore submit a PIP together with a request for agreement to the EMA. The EMA issues a decision on the PIP based on an opinion of the EMA&#8217;s Pediatric Committee (&#8220;PDCO&#8221;). Companies must conduct pediatric clinical trials in accordance with the PIP approved by the EMA, unless a deferral (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> until enough information to demonstrate its effectiveness and safety in adults is available) or waiver (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> because the relevant disease or condition occurs only in adults) has been granted by the EMA. The MAA for the pharmaceutical product must include the results of all pediatric clinical trials performed and details of all information collected in compliance with the approved PIP, unless a waiver or a deferral has been granted, in which case the pediatric clinical trials may be completed at a later date. Pharmaceutical products that are granted a marketing authorization on the basis of the pediatric clinical trials conducted in accordance with the approved PIP are eligible for a six month extension of the protection under a supplementary protection certificate (if any is in effect at the time of approval) or, in the case of orphan pharmaceutical products, a two year extension of the orphan market exclusivity. This pediatric reward is subject to specific conditions and is not automatically available when data in compliance with the approved PIP are developed and submitted. An approved PIP is also required when a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">marketing authorization holder wants to add a new indication, pharmaceutical form or route of administration for a medicine that is already authorized and covered by intellectual property rights.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Post-Approval Regulation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar to the United States, both MA holders and manufacturers of pharmaceutical products are subject to comprehensive regulatory oversight by the EMA, the EC and/or the competent regulatory authorities of the EU member states. This oversight applies both before and after grant of manufacturing licenses and marketing authorizations. It includes control of compliance with EU good manufacturing practices rules, manufacturing authorizations, pharmacovigilance rules and requirements governing advertising, promotion, sale, and distribution, recordkeeping, importing and exporting of pharmaceutical products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure by us or by any of our third-party partners, including suppliers, manufacturers and distributors to comply with EU laws and the related national laws of individual EU member states governing the conduct of clinical trials, manufacturing approval, MA of pharmaceutical products and marketing of such products, both before and after grant of MA, manufacturing of pharmaceutical products, statutory health insurance, bribery and anti-corruption or other applicable regulatory requirements may result in administrative, civil or criminal penalties. These penalties could include delays or refusal to authorize the conduct of clinical trials or to grant MA, product withdrawals and recalls, product seizures, suspension, withdrawal or variation of the MA, total or partial suspension of production, distribution, manufacturing or clinical trials, operating restrictions, injunctions, suspension of licenses, fines and criminal penalties.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The holder of an EU MA for a pharmaceutical product must also comply with EU pharmacovigilance legislation and its related regulations and guidelines, which entail many requirements for conducting pharmacovigilance, or the assessment and monitoring of the safety of pharmaceutical products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These pharmacovigilance rules can impose on holders of MAs the obligation to conduct a labor intensive collection of data regarding the risks and benefits of marketed pharmaceutical products and to engage in ongoing assessments of those risks and benefits, including the possible requirement to conduct additional clinical studies or post-authorization safety studies to obtain further information on a medicine&#8217;s safety, or to measure the effectiveness of risk-management measures, which may be time consuming and expensive and could impact our profitability. MA holders must establish and maintain a pharmacovigilance system and appoint an individual qualified person for pharmacovigilance who is responsible for oversight of that system. Key obligations include expedited reporting of suspected serious adverse reactions and submission of Periodic Safety Update Reports (&#8220;PSURs&#8221;) in relation to pharmaceutical products for which they hold MAs. The EMA reviews PSURs for pharmaceutical products authorized through the centralized procedure. If the EMA has concerns that the risk-benefit profile of a product has varied, it can adopt an opinion advising that the existing MA for the product be suspended, withdrawn or varied. The agency can advise that the MA holder be obliged to conduct post-authorization Phase 4 safety studies. If the EC agrees with the opinion, it can adopt a decision varying the existing MA. Failure by the MA holder to fulfill the obligations for which the European Commission&#8217;s decision provides can undermine the on-going validity of the MA.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More generally, non-compliance with pharmacovigilance obligations can lead to the variation, suspension or withdrawal of the marketing authorization for the pharmaceutical product or imposition of financial penalties or other enforcement measures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The manufacturing process for pharmaceutical products in the EU is highly regulated and regulators may shut down manufacturing facilities that they believe do not comply with regulations. Manufacturing requires a manufacturing authorization, and the manufacturing authorization holder must comply with various requirements set out in the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice (&#8220;GMP&#8221;). These requirements include compliance with EU GMP standards when manufacturing pharmaceutical products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import the active pharmaceutical ingredients into the EU.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#231f20;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, the distribution of pharmaceutical products into and within the EU is subject to compliance with the applicable EU laws, regulations and guidelines, including the requirement to hold appropriate authorizations for distribution granted by the competent authorities of the EU member states. The manufacturer or importer must have a qualified person who is responsible for certifying that each batch of product has been manufactured in accordance with GMP, before releasing the product for commercial distribution in the EU or for use in a clinical trial. Manufacturing facilities are subject to periodic inspections by the competent authorities for compliance with GMP.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Advertising and Promotion</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The advertising and promotion of our products is also subject to EU laws concerning promotion of pharmaceutical products, interactions with physicians, misleading and comparative advertising and unfair commercial practices. In addition, other national legislation of individual EU member states may apply to the advertising and promotion of pharmaceutical products and may differ from one country to another. These laws require that promotional materials and advertising in relation to pharmaceutical products comply with the product&#8217;s SmPC as approved by the competent regulatory authorities. The SmPC is the document that provides information to physicians concerning the safe and effective use of the pharmaceutical product. It forms an intrinsic and integral part of the marketing authorization granted for the pharmaceutical product. Promotion of a pharmaceutical product that does not comply with the SmPC is considered to constitute off-label promotion. All advertising and promotional activities for the product must be consistent with the approved SmPC and therefore all off-label promotion of pharmaceutical products is prohibited in the EU. Direct-to-consumer advertising of prescription-only pharmaceutical products is prohibited in the EU. Violations of the rules governing the promotion of pharmaceutical products in the EU could be penalized by administrative measures, fines and imprisonment. These laws may further limit or restrict the advertising and promotion of our products to the general public and may also impose limitations on its promotional activities with healthcare professionals.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pricing and Reimbursement Environment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a pharmaceutical product obtains a marketing authorization in the EU, there can be no assurance that reimbursement for such product will be secured on a timely basis or at all. The EU member states are free to restrict the range of pharmaceutical products for which their national health insurance systems provide reimbursement, and to control the prices and reimbursement levels of pharmaceutical products for human use. An EU member state may approve a specific price or level of reimbursement for the pharmaceutical product, or alternatively adopt a system of direct or indirect controls on the profitability of the company responsible for placing the pharmaceutical product on the market, including volume-based arrangements, caps and reference pricing mechanisms.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of our product candidates, if any, to other available therapies in order to obtain or maintain reimbursement or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, pharmaceutical products launched in the EU do not follow price structures of the United States and generally published and actual prices tend to be significantly lower. Publication of discounts by third-party payers or authorities and public tenders may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The so-called health technology assessment (&#8220;HTA&#8221;) of pharmaceutical products is becoming an increasingly common part of the pricing and reimbursement procedures in some EU member states, including France, Germany, Ireland, Italy and Sweden. The HTA process, which is governed by the national laws of these countries, is the procedure according to which the assessment of the public health impact, therapeutic impact, and the economic and societal impact of use of a given pharmaceutical product in the national healthcare systems of the individual country is conducted. HTA generally focuses on the clinical efficacy and effectiveness, safety, cost, and cost-effectiveness of individual pharmaceutical products as well as their potential implications for the healthcare system. Those elements of pharmaceutical products are compared with other treatment options available on the market. The outcome of HTA regarding specific pharmaceutical products will often influence the pricing and reimbursement status granted to pharmaceutical products by the regulatory authorities of individual EU member states. A negative HTA of one of our products by a leading and recognized HTA body could not only undermine our ability to obtain reimbursement for such product in the EU member state in which such negative assessment was issued, but also in other EU member states. For example, EU member states that have not yet developed HTA mechanisms could rely to some extent on the HTA performed in other countries with a developed HTA framework, when adopting decisions concerning the pricing and reimbursement of a specific pharmaceutical product.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2018, the European Commission adopted a proposal for a regulation on health technology assessment. This legislative proposal is intended to boost EU level cooperation among EU member states in assessing health technologies, including new pharmaceutical products, and providing the basis for cooperation at the EU level for joint clinical assessments in these areas. The proposal provides that EU member states will be able to use common HTA tools, methodologies and procedures across the EU, working together in four main areas, including joint clinical assessment of the innovative health technologies with the most potential impact for patients, joint scientific consultations whereby developers can seek advice from HTA authorities, identification of emerging health technologies to identify promising technologies early, and continuing voluntary cooperation in other areas. Individual EU member states will </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continue to be responsible for assessing non-clinical (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement. While EU member states could choose to delay participation in the joint work until three years after the rules enter into force, it will become mandatory after six years. The European Commission has stated that the role of the HTA regulation is not to influence pricing and reimbursement decisions in the individual EU member states, but there can be no assurance that the HTA regulation will not have effects on pricing and reimbursement decisions. The HTA entered into force on January 11, 2022 and applies as of January 2025 followed by a further three-year transitional period during which EU member states must fully adapt to the new system. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain reimbursement or pricing approval in some countries, including the EU member states, we may be required to conduct studies that compare the cost-effectiveness of our product candidates to other therapies that are considered the local standard of care. There can be no assurance that any country will allow favorable pricing, reimbursement and market access conditions for any of our products, or that we will be feasible to conduct additional cost-effectiveness studies, if required.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain of the EU member states, pharmaceutical products that are designated as orphan pharmaceutical products may be exempted or waived from having to provide certain clinical, cost-effectiveness and other economic data in connection with their filings for pricing/reimbursement approval. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Data Privacy and Security Laws</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous U.S. federal, state, and local laws and regulations, as well as foreign legislation, in particular in the EU and UK, which regulate personal information, including how that information may be used, processed, and disclosed. These regulations also cover sensitive and confidential personal information, including medical and health information, and impose requirements on entities that handle such information to implement certain privacy and security measures.  We and/or our partners may be subject to these laws.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, at the federal level, the regulations promulgated under the Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH Act&#8221;), impose data privacy, security and data breach reporting obligations with respect to protected health information (&#8220;PHI&#8221;) on covered entities&#8212;which include health plans, healthcare clearinghouses and certain healthcare providers&#8212;and business associates&#8212;which include persons or entities that perform certain functions or activities that involve the use or disclosure of PHI on behalf of, or in connection with providing a service for, a covered entity.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also a number of U.S. state privacy laws, such as the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;), as amended by the California Privacy Rights Act of 2020 (&#8220;CPRA&#8221;), that govern the privacy and security of personal information in certain circumstances. The CCPA/CPRA applies to personal data of consumers, business representatives, and employees, and imposes obligations on certain businesses that do business in California, including to provide specific disclosures in privacy notices, rights to California residents in relation to their personal information. Health information falls under the CCPA/CPRA&#8217;s definition of personal information where it identifies, relates to, describes, or is reasonably capable of being associated with or could reasonably be linked with a particular consumer or household&#8212;unless it is subject to HIPAA&#8212;and is included under a new category of personal information, &#8220;sensitive personal information,&#8221; which is offered greater protection. Some of these laws and regulations impose different, and in certain instances, more stringent requirements than HIPAA. Failing comply with these laws and regulations can result in significant civil and/or criminal penalties, as well as exposure to private litigation, all of which can result in financial and reputational risks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The collection and use of personal health data and other personal data in the EU is governed by the provisions of the European General Data Protection Regulation (EU) 2016/679 (&#8220;GDPR&#8221;), which came into force in May 2018 and related implementing laws in individual EU member states. The GDPR has a number of significant practical consequences, in particular for international data transfers, competent supervisory authorities and enforcement of the GDPR. The GDPR increased responsibility and liability in relation to personal data that we process.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR imposes a number of strict obligations and restrictions on the ability to process (processing includes collection, analysis and transfer of) personal data of individuals in the EEA, including health data from clinical trials and adverse event reporting. The GDPR also includes requirements relating to the consent of the individuals to whom the personal data relates, the information provided to the individuals prior to processing their personal data or personal health data, notification obligations to the national data protection authorities and the security and confidentiality of the personal data. EU member states may also impose additional requirements in relation to health, genetic and biometric data through their national implementing legislation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The GDPR also imposes specific restrictions on the transfer of personal data to countries outside of the EEA that are not considered by the European Commission to provide an adequate level of data protection. Appropriate safeguards are required to enable such transfers. Among the appropriate safeguards that can be used, the data exporter may use the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">standard contractual clauses (&#8220;SCCs&#8221;). In this respect, recent legal developments in Europe have created complexity and compliance uncertainty regarding certain transfers of personal data from the EEA. For example, following the Schrems II decision of the Court of Justice of the EU on July 16, 2020, in which the Court invalidated the Privacy Shield under which personal data could be transferred from the EEA to U.S. entities who had self-certified under the Privacy Shield scheme, there is uncertainty as to the general permissibility of international data transfers under the GDPR. The Court did not invalidate the then current SCCs, but ruled that data exporters relying on these SCCs are required to verify, on a case-by-case basis, if the law of the third country ensures an adequate level of data protection that is essentially equivalent to that guaranteed in the EEA. In light of the implications of this decision, we may face difficulties regarding the transfer of personal data from the EEA to third countries. On June 4, 2021, the EU Commission has issued a new set of SCCs which replace the old sets of SCCs that were adopted under the previous European Data Protection Directive 95/46. In addition, when relying on SCCs, the data exporters are required to conduct a transfer risk assessment to verify if anything in the law and/or practices of the third country may impinge on the effectiveness of the SCCs in the context of the transfer at stake and, if so, to identify and adopt supplementary measures that are necessary to bring the level of protection of the data transferred to the EU standard of essential equivalence. Where no supplementary measure is suitable, the data exporter should avoid, suspend or terminate the transfer. On June 18, 2021, the European Data Protection Board has adopted recommendations to assist data exporters with such assessment and their duty to identify and implement supplementary measures where they are needed to ensure compliance with the EU level of protection to the personal data they transfer to third countries. With regard to the transfer of data from the EEA to the US, on July 10, 2023, the European Commission adopted its adequacy decision for the EU-US Data Privacy Framework. On the basis of the new adequacy decision, personal data can flow from the EEA to US companies participating in the framework.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with the requirements of the GDPR and the related national data protection laws of the EU member states may result in significant monetary fines for noncompliance of up to &#8364;20 million or 4% of the annual global revenues of the noncompliant company, whichever is greater, other administrative penalties and a number of criminal offenses (punishable by uncapped fines) for organizations and in certain cases their directors and officers as well as civil liability claims from individuals whose personal data was processed. Data protection authorities from the different EU member states may still implement certain variations, enforce the GDPR and national data protection laws differently, and introduce additional national regulations and guidelines, which adds to the complexity of processing personal data in the EU. Guidance developed at both EU level and at the national level in individual EU member states concerning implementation and compliance practices are often updated or otherwise revised.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is, moreover, a growing trend towards required public disclosure of clinical trial data in the EU which adds to the complexity of obligations relating to processing health data from clinical trials. Such public disclosure obligations are provided in the new EU Clinical Trials Regulation, EMA disclosure initiatives and voluntary commitments by industry. Failing to comply with these obligations could lead to government enforcement actions and significant penalties against us, harm to our reputation, and adversely impact our business and operating results. The uncertainty regarding the interplay between different regulatory frameworks, such as the Clinical Trials Regulation and the GDPR, further adds to the complexity that we face with regard to data protection regulation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to the transfer of data from the EEA to the UK, on June 28, 2021 the European Commission adopted two adequacy decisions for the UK: one under the GDPR and the other for the Law Enforcement Directive. Personal data may now freely flow from the EU to the UK since the UK is deemed to have an adequate data protection level for the purposes of the EU regime. However, the adequacy of decisions are subject to a &#8216;sunset clause&#8217; which entails that the decisions will automatically expire four years after their entry into force, unless renewed. Additionally, following the UK&#8217;s withdrawal from the EEA, companies also have to comply with the UK&#8217;s data protection laws (including the GDPR as incorporated into UK national law), the latter regime having the ability to impose fines up to the greater of &#163;17.5 million or 4% of global turnover. Furthermore, transfers from the UK to other countries, including to the EEA, are subject to specific transfer rules under the UK regime; personal data may freely flow from the UK to the EEA, since the EEA is deemed to have an adequate data protection level for purposes of the UK regime. These UK international transfer rules broadly mirror the EU GDPR rules. On February 2, 2022, the UK Secretary of State laid before the UK Parliament the international data transfer agreement (IDTA) and the international data transfer addendum to the European Commission&#8217;s standard contractual clauses for international data transfers (Addendum) and a document setting out transitional provisions. The IDTA and Addendum came into force on March 21, 2022 and replaced the old EU SCCs for the purposes of the UK regime. However, the transitional provisions, adopted with the IDTA and the Addendum, provide that contracts concluded on or before September 21, 2022 on the basis of any old EU SCCs continue to provide appropriate safeguards for the purpose of the UK regime until March 21, 2024, provided that the processing operations that are the subject matter of the contract remain unchanged and reliance on those clauses ensures that the transfer of personal data is subject to appropriate safeguards.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With regard to the transfer of data from the UK to the US, the UK government has adopted an adequacy decision for the US, the UK-US Data Bridge, which came into force on October 12, 2023. The UK-US Data Bridge recognizes the US as offering an adequate level of data protection where the transfer is to a US company participating in the EU-US Data Privacy Framework and the UK Extension.</span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Promotional Activities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, interactions between pharmaceutical companies and physicians are also governed by strict laws, regulations, industry self-regulation codes of conduct and physicians&#8217; codes of professional conduct both at EU level and in the individual EU member states. The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of pharmaceutical products is prohibited in the EU. The provision of benefits or advantages to physicians is also governed by the national anti-bribery laws of the EU member states. Violation of these laws could result in substantial fines and imprisonment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payments made to physicians in certain EU member states must be publicly disclosed. Moreover, agreements with physicians must often be the subject of prior notification and approval by the physician&#8217;s employer, his/her regulatory professional organization, and/or the competent authorities of the individual EU member states. These requirements are provided in the national laws, industry codes, or professional codes of conduct, applicable in the individual EU member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the UK has left the EU, as mentioned above, it should be noted that the UK still has the strictest anti-bribery regime in Europe, the UK Bribery Act 2010. The Act is applicable English law and continues to apply to any company incorporated in or &#8220;carrying on business&#8221; in the UK, irrespective of where in the world the alleged bribery activity occurs. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Legislation Regarding Marketing, Authorization and Pricing of Pharmaceutical Products in the European Union</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Other core legislation relating to the marketing, authorization and pricing of pharmaceutical products in the EU exists as regulations and directives, while the implementing acts and guidelines based on these may vary in each EU member state. In addition, the respective national provisions of the member states, as well as self-committed codes of the pharmaceutical industry, must be observed. Such regulations and directives include the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directive 2001/83/EC, establishing the requirements and procedures governing the marketing authorization for medicinal products for human use, as well as the rules for the constant supervision of products following authorization. This Directive has been amended several times, most recently by Directive 2012/26/EU regarding pharmacovigilance, and the Falsified Medicines Directive 2011/62/EU. </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Regulation (EC) 726/2004, as amended, establishing procedures for the authorization, supervision and pharmacovigilance of medicinal products for human and veterinary use and establishing the EMA.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Regulation (EC) 469/2009, establishing the requirements necessary to obtain a Supplementary Protection Certificate, which extends the period of patent protection applicable to medicinal products at the EU-level. </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directive 89/105/EEC, ensuring the transparency of measures taken by the EU member states to set the prices and reimbursements of medicinal products. Specifically, while each member state has competence over the pricing and reimbursement of medicines for human use, they must also comply with this Directive, which establishes procedures to ensure that member state decisions and policies do not obstruct trade in medicinal products. The European Commission proposed to repeal and replace Directive 89/105/EEC, but this proposal was withdrawn in 2015. </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directive 2003/94/EC, laying down the principles of good manufacturing practice in respect of medicinal products and investigational medicinal products for human use (the &#8220;GMP Directive&#8221;); repealed by Directive 2017/1572 on January 31, 2022; this directive also lays out standards and principles for manufacturing practices of medicinal products for human use and investigational medicinal products for human use.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directive 2005/28/EC of April 8, 2005, laying down principles and detailed guidelines for good clinical practice as regards investigational medicinal products for human use, as well as the requirements for authorization of the manufacturing or importation of such products (the &#8220;GCP Directive&#8221;). </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directives 2004/9/EC and 2004/10/EC laying down principles of GLP including on the organizational process under which non-clinical health and safety studies are performed.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directive 2010/84/EU and Regulation (EU) 1235/2010 on pharmacovigilance laying down procedures for the authorization and supervision of medicinal products for human and veterinary use. </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directive 2006/114/EC concerning misleading and comparative advertising. </span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directive 2005/29/EC regulating unfair business-to-consumer commercial practices that occur before, during and after a business-to-consumer transaction.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Regulation (EC) 1223/2009 on Cosmetic Products, setting mandatory requirements for cosmetics which are available on the market within the EU.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Regulation (EC) 1901/2006 on Pediatric Use, laying down rules to ensure that medicines for use in children are researched, developed and authorized appropriately.</span></div><div style="padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Directive (2004/109/EC) on Transparency laying down rules to improves the harmonization of information duties of issuers, whose securities are listed at a regulated market at a stock exchange within the EU; amended by Directive (EU) 2022/2464 with effect from May 1, 2023 as regards corporate sustainability reporting.</span></div><div style="margin-top:9pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Pharmaceutical Coverage, Pricing and Reimbursemen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Sales of products will depend, in part, on the extent to which the costs of the products will be covered by third-party payors, including government health programs such as, in the United States, Medicare and Medicaid, commercial health insurers and managed care organizations. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include all of the approved products for a particular indication. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. A payor&#8217;s decision to provide coverage for a drug product does not necessarily imply that an adequate reimbursement rate will be approved. Third-party reimbursement may not be sufficient to maintain price levels high enough to realize an appropriate return on our investment in product development. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The containment of healthcare costs has become a priority of federal, state and foreign governments, and the prices of drugs have been a focus in this effort. Third-party payors are increasingly challenging the prices charged for medical products and services and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. If these third-party payors do not consider a product to be cost effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. The U.S. government, state legislatures and foreign governments have shown significant interest in implementing cost containment programs to limit the growth of government-paid health care costs, including price controls, risk sharing, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. Recently, the U.S. government passed the Inflation Reduction Act </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(&#8220;IRA&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which authorizes the U.S. Department of Health and Human Services to negotiate prices of certain drugs with participating manufacturers in federal healthcare programs. Adoption of such controls and measures and tightening of restrictive policies in jurisdictions with existing controls and measures, could limit payments for pharmaceuticals. As a result, the marketability of any product which receives regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, an increasing emphasis on managed care in the United States has increased and will continue to increase the pressure on drug pricing. Coverage policies, third-party reimbursement rates and drug pricing regulation may change at any time. In particular, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act, contains provisions that may reduce the profitability of drug products, including, for example, increased rebates for drugs sold to Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&#8217; share of sales to federal health care programs. Even if favorable coverage and reimbursement status is attained for one or more products that receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, pricing and reimbursement schemes vary widely between member states. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some member states may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies. For example, the EU provides options for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU member states may approve a specific price for a drug product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the drug product on the market. Other member states allow companies to fix their own prices for drug products but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">competitive pressure that may reduce pricing within a country. Any country that has price controls or reimbursement limitations for drug products may not allow favorable reimbursement and pricing arrangements for any of our products.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Healthcare Laws and Regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors play important roles in the recommendation and prescription of drug products that are granted marketing approval. Arrangements with healthcare providers, physicians, third-party payors and customers are subject to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which the Company markets, sells and distributes products for which it obtains marketing approval. Restrictions under applicable federal and state healthcare laws and regulations, include the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Anti-Kickback Statute prohibits, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing any remuneration (in cash or in kind), directly or indirectly, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any item, facility or service for which payment may be made in whole or in part under a federal healthcare program such as Medicare and Medicaid; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Foreign Corrupt Practices Act prohibits, among other things, U.S. corporations and persons acting on their behalf from offering, promising, authorizing or making payments to any foreign government official (including certain healthcare professionals in many countries), political party, or political candidate in an attempt to obtain or retain business or otherwise seek preferential treatment abroad;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal False Claims Act, which may be enforced by the U.S. Department of Justice or private whistleblowers who bring civil actions (qui tam actions) on behalf of the federal government, imposes civil penalties, as well as liability for treble damages and for attorneys&#8217; fees and costs, on individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent, making a false statement material to a false or fraudulent claim, or improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the U.S. Department of Health and Human Services&#8217; Civil Monetary Penalty authorities, which imposes administrative sanctions for, among other things, presenting or causing to be presented false claims for government payment and providing remuneration to government health program beneficiaries to influence them to order or receive healthcare items or services; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">HIPAA imposes criminal and civil liability for, among other conduct, executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">HIPAA, as amended by the HITECH Act and its implementing regulations, also imposes criminal and civil liability and penalties on those who violate requirements, including mandatory contractual terms, intended to safeguard the privacy, security, transmission and use of individually identifiable health information; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal false statements statute relating to healthcare matters imposes criminal liability for knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for healthcare benefits, items or services; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">the federal Physician Payment Sunshine Act requires manufacturers of drugs (among other products) to report to the Centers for Medicare and Medicaid Services within the U.S. Department of Health and Human Services information related to payments and other transfers of value to various healthcare professionals including physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists, certified nurse-midwives and teaching hospitals, as well as physician ownership and investment interests in the reporting manufacturers; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">similar state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply (e.g., in the EU, where the implementation of EU-wide regulations as well as independent national legislation may vary for each EU member state) to sales or marketing arrangements and claims involving healthcare items or services reimbursed by nongovernmental third-party payors, including private insurers; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">certain state laws require pharmaceutical companies to comply with voluntary compliance guidelines promulgated by a pharmaceutical industry association and relevant compliance guidance issues by the U.S. Department of Health and Human Services Office of Inspector General; bar drug manufacturers from offering or providing certain types of payments or gifts to physicians and other health care providers; and/or require disclosure of gifts or payments to physicians and other healthcare providers. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various state and foreign laws also govern the privacy and security of health information in some circumstances; many of these laws differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Facilities</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates lab facilities in San Diego, California and Madison, Wisconsin where its research and development activities, including the development of RNAi therapeutics, take place. The Company&#8217;s principal executive offices are located in Pasadena, California. A summary of research and development resources is provided below:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">432 R&amp;D personnel as of September&#160;30, 2023;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">State-of-the-art laboratories comprising more than 255,000 total square feet;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Cell culture laboratories;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Complete animal facilities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Primate colony housed at the Wisconsin National Primate Research Center, an affiliate of the University of Wisconsin, and at other contract research organizations;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Animal efficacy models for numerous diseases, including cardio metabolic, viral, liver, skeletal muscle, ocular, CNS and lung diseases;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Animal safety screening and assessment;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Clinical pathology laboratories and in-house histopathology capabilities; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Drug metabolism and pharmacokinetics (DMPK), bioanalytical, biodistribution, and clearance assessment and methodology capabilities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Pharmacodynamic method development and analysis and translational biomarker development capabilities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Conventional and confocal microscopy, flow cytometry, Luminex platform, qRT-PCR and clinical chemistry analytics;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Oligonucleotide, peptide, and small molecule discovery, synthesis, and analytics capabilities (for example, HPLC, NMR, LCMS);</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">In-house drug substance manufacturing capabilities to produce and release GMP material (API) and capabilities to release finished drug product.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Management</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, the Company employed 525 full time employees based at three facilities in the United States, including Pasadena and San Diego, California, and Madison, Wisconsin. The following table presents total number of employees as of September 30 by location.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Site</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pasadena, CA</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Madison, WI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">225&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">San Diego, CA</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">525&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">397&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continued to add additional employees in fiscal year 2023 with a focus on expanding its in-house manufacturing capacity, as well as increasing expertise and throughput in clinical and preclinical research and development. The Company continually evaluates the business need and opportunity and balances in-house expertise and capacity with outsourced expertise and capacity. Currently, the Company outsources substantial clinical trial work to clinical research organizations and certain drug manufacturing to contract manufacturers.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug development is a complex endeavor which requires deep expertise and experience across a broad array of disciplines. Pharmaceutical companies both large and small compete for a limited number of qualified applicants to fill specialized positions. To attract qualified applicants to the Company, it offers a total compensation package consisting of base salary and cash target bonus targeting the 50</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to 75</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">th</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> percentile of market, and offers a comprehensive benefit package and equity compensation to every employee. Bonus opportunity and equity compensation increase as a percentage of total compensation based on level of responsibility. Actual bonus payout is based on performance.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of the Company&#8217;s employees have obtained advanced degrees in their professions. The Company supports its employees&#8217; further development with individualized development plans, mentoring, coaching, group training, conference attendance and financial support including tuition reimbursement. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Diversity and Inclusion  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is committed to maintaining a welcome, healthy and equitable environment where all employees can excel and contribute to its mission of bringing safe and effective medicine to patients in need. The Company continues the formal training and processes initiated in 2021 to promote awareness of inclusion and diversity issues for management and employees, including anti-bias training and employee outreach and engagement. In fiscal year 2022, the Company formed a Diversity, Equity, and Inclusion (DEI) committee comprised of a diverse group of employees across each of its worksites. The Company&#8217;s DEI committee meets regularly, provides well-attended education and outreach opportunities to its employee base, and offers advice to its senior management concerning the Company&#8217;s efforts to build a more diverse, equitable, and inclusive workplace.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investor Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http://www.arrowheadpharma.com.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s website address is not intended to function as a hyperlink and the information contained on its website is not, and should not be considered part of, and is not incorporated by reference into, this Annual Report on Form 10-K. The Company&#8217;s reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), including its Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, Proxy Statements, and amendments to such periodic reports and Proxy Statements, are accessible through its website, free of charge, as soon as reasonably practicable after these reports are filed electronically with, or otherwise furnished to, the SEC. These SEC reports can be accessed through the &#8220;Investors&#8221; section of the Company&#8217;s website. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The SEC maintains an Internet website that contains reports, proxy and information statements, and other information regarding the Company and other issuers that file electronically with the SEC. The SEC&#8217;s Internet website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">http://www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32</span></div></div></div><div id="i2ac2b5b9b196490b92657e8462cd4206_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.14pt">RISK FACTORS</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Company&#8217;s business involves various risks and uncertainties in addition to the normal risks of business, some of which are discussed in this section. It should be noted that the Company&#8217;s business may be adversely affected by general economic conditions and other forces beyond the Company&#8217;s control. In addition, other risks and uncertainties not presently known or that the Company currently believes to be immaterial may also adversely affect the Company&#8217;s business. Any such risks or uncertainties, or any of the following risks or uncertainties, that develop into actual events could result in a material and adverse effect on the Company&#8217;s business, financial condition, results of operations, or liquidity.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The information discussed below should be considered carefully with the other information contained in this Annual Report on Form 10-K and the other documents and materials filed by the Company with the SEC, as well as news releases and other information publicly disseminated by the Company from time to time.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risk Factors Summary</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Discovery, Development, and Commercialization of Medicines</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our prospects substantially depend on the success of our clinical-stage product candidates. If we and our licensees are unable to obtain approval for and commercialize these product candidates, our business could be materially harmed.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">There are substantial risks inherent in attempting to commercialize our new drugs, and, as a result, we may not be able to successfully develop products for commercial use.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our product candidates are in clinical development, which is a lengthy and expensive process with uncertain outcomes and the potential for substantial delays. There can be no assurance that our product candidates will obtain regulatory approval, which is necessary before they can be commercialized.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical trials may not yield successful results for the product candidates that we may identify and pursue for their intended uses, which would prevent, delay or limit the scope of regulatory approval and commercialization.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our clinical trials may reveal significant adverse events, toxicities or other side effects and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Results of earlier studies or clinical trials may not be predictive of future clinical trial results, and initial studies or clinical trials may not establish an adequate safety or efficacy profile for our product candidates to justify proceeding to advanced clinical trials or an application for regulatory approval.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for a product candidate and may have to limit its commercialization.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The successful commercialization of our product candidates, if approved, will depend in part on the extent to which government authorities and health insurers establish adequate reimbursement levels and pricing policies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Regulatory Review and Approval of Our Candidates</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Fast Track product designation may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We and our licensees conduct clinical trials for product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">if</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we obtain FDA approval for products in the United States, we may never obtain approval to commercialize any product candidates outside of the United States, which would limit our ability to realize their full market potential.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if our product candidates are approved for commercialization, failure to comply with regulatory requirements or unanticipated problems with our products may result in various adverse actions such as the suspension or withdrawal of one or more of our products, closure of a facility or enforcement of substantial penalties or fines.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are party to technology license agreements with third parties that require us to satisfy obligations to keep them effective and, if these agreements are terminated, our technology and our business could be seriously and adversely affected.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may be subject to patent infringement claims, which could result in substantial costs and liability and prevent us from commercializing our potential products.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to effectively secure first-tier technologies when competing against other companies or investors.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Business Model</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business model assumes we will generate revenue by, among other activities, marketing or out-licensing the products we develop. Our drug candidates are in various stages of development and we have no approved products based on RNA interference and our delivery technologies. Accordingly, there is a limited amount of information about us upon which you can evaluate our business and prospects.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may need to establish additional relationships with strategic and development partners to fully develop our drug candidates and market any approved products.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to generate milestone and royalty payments under our current and potential future licensing and collaboration agreements is substantially controlled by our partners, and as such, we will likely need other sources of financing to continue to develop our internal drug candidates. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may lose a considerable amount of control over our intellectual property and may not receive anticipated revenues in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">strategic</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> transactions, particularly where the consideration is contingent on the achievement of development or sales milestones.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need to achieve commercial acceptance of our drug candidates to generate revenues and achieve </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">profitability</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have limited manufacturing capability and must rely on third-party manufacturers to manufacture our clinical supplies and commercial products, if and when approved, and if they fail to meet their obligations, the development and commercialization of our products could be adversely affected.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> third parties to conduct our clinical trials, and if they fail to fulfill their obligations, the development of our products may be adversely affected.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face competition from various entities including large pharmaceutical companies, small biotech companies, private companies, and research institutions. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may have difficulty expanding our operations successfully as we evolve our pipeline and move toward </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercializing drugs.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Because we use biological materials, hazardous materials, chemicals and radioactive compounds, if we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operations, including our relationships with healthcare providers, physicians and third-party payers, are subject to applicable anti-kickback, fraud and abuse, and other healthcare laws and regulations, which, in the event of a violation, exposes us to liability for criminal sanctions, civil penalties, and contractual damages, and reputational harm and diminished profits and future earnings.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Our Financial Condition</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will require substantial additional funds to complete our research and development activities.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If the estimates we make, or the assumptions on which we rely, in preparing our consolidated financial statements prove inaccurate, our actual results may vary from those reflected in our accruals.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The investment of our cash, cash equivalents and fixed income securities is subject to risks which may cause losses and affect the liquidity of these investments.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to utilize net operating loss carryforwards and other tax benefits may be limited. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risks Related to Investment and Securities</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If securities or industry analysts do not publish research reports about our business or if they make adverse recommendations regarding an investment in our stock, our stock price and trading volume may decline.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The market for purchases and sales of our common stock may be limited, and the sale of a limited number of shares could cause the price to fall sharply.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our common stock price has fluctuated significantly over the last several years and may continue to do so in the future, without regard to our results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Economic and Industry Risks</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Drug development is time consuming, expensive and risky.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The healthcare system is under significant financial pressure to reduce costs, which could reduce payment and reimbursement rates for drugs.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory standards are subject to change over time, making it difficult to accurately predict the likelihood of marketing approval even when clinical trials meet their endpoints.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Discovery, Development, and Commercialization of Medicines</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our prospects substantially depend on the success of our clinical-stage product candidates. If we and our licensees are unable to obtain approval for and commercialize these product candidates, our business could be materially harmed.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success is substantially dependent on the ability of our company and our licensees to timely complete clinical trials and obtain marketing approval for, and then successfully commercialize our clinical-stage product candidates. We are not permitted to market or promote our product candidates before we receive marketing approval from the FDA and comparable foreign regulatory authorities, and we may never receive such marketing approvals.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of developing and commercializing our product candidates will depend on several factors, including the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining positive data that supports demonstration of efficacy, safety and tolerability profiles and durability of effect for our product candidates that are satisfactory to the FDA or any comparable foreign regulatory authority for marketing approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successful and timely enrollment of appropriate patients for the indications included in our current and future clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential variability of patient outcomes;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent of any required post-marketing approval commitments to applicable regulatory authorities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the establishment of and maintenance of sufficient internal manufacturing capabilities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the maintenance of existing or the establishment of new supply arrangements with third-party drug product suppliers and manufacturers for clinical development and, if approved, commercialization of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the maintenance of existing or the establishment of new scaled production arrangements with third-party manufacturers to obtain finished products that are appropriately packaged for sale;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent protection, trade secret protection and regulatory exclusivity, both in the United States and internationally;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">protecting our rights in our intellectual property portfolio, including our licensed intellectual property;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing sales, marketing and distribution capabilities and the successful launch of commercial sales of our product candidates if and when approved for marketing, whether alone or in collaboration with others;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a continued acceptable safety profile following any marketing approval;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commercial acceptance by patients, the medical community and third-party payors; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to compete with other therapies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process, potential threats to our intellectual property rights and the manufacturing, marketing, distribution and sales efforts of any collaborator or licensee. For development programs that are licensed to third parties, we generally do not have control over the design or conduct of clinical trials and will not have discretion over marketing decisions. If we are not successful with respect to one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize any product candidates from our lead programs, which would materially harm our business. If we do not receive marketing approvals for such product candidates, we may not be able to continue our operations.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">There </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">are substantial risks inherent in attempting to commercialize our new drugs, and, as a result, we may not be able to successfully develop products for commercial use.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Scientific research and development requires significant amounts of capital and takes a long time to reach commercial viability if it can be achieved at all. To date, our research and development projects have not produced commercially viable drugs and may never do so. During the research and development process, we may experience technological barriers that we may be unable to overcome. Because we use platform technology to develop drug candidates, toxicology signals that may emerge in the course of testing of one particular candidate may apply broadly across our drug candidate platform. Further, certain underlying premises in our development programs are not proven and many of the drug targets that we are pursuing have not yet been validated clinically. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, ARO-RAGE has demonstrated the ability to reduce the expression of RAGE in the lung, however it has not been established that this will have an anti-inflammatory effect sufficient for a meaningful clinical benefit in patients with inflammatory lung disease. Further, it is also unknown at this time what may be required to gain favorable reimbursement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> With respect to fazirsiran, it is also unknown at this time what changes in the liver may be required to gain regulatory approval and/or favorable reimbursement for a drug that reduces the production of mutant alpha-1 antitrypsin in the liver. Similar uncertainties and risks exist that are specific to each of our development programs. Because of these and similar uncertainties, it is possible that no commercial products will be successfully developed. If we are unable to successfully develop commercial products, we will be unable to generate revenue or build a sustainable or profitable business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our product candidates are in clinical development, which is a lengthy and expensive process with uncertain outcomes and the potential for substantial delays. There can be no assurance that our product candidates will obtain regulatory approval, which is necessary before they can be commercialized.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of human therapeutic products in the United States and foreign jurisdictions is subject to extensive and time-consuming regulatory approval which requires, among other things:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">controlled research and human clinical testing;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishment of the safety and efficacy of the product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">government review and approval of a submission containing manufacturing, preclinical and clinical data; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adherence to cGMP regulations during production and storage.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since 2011, we have focused substantially all of our efforts and financial resources on identifying, acquiring and developing our product candidates, including conducting lead optimization, nonclinical studies, preclinical studies and clinical trials, and providing general administrative support for these operations. And, the clinical-stage product candidates we currently have under development will require significant development, preclinical and clinical testing and investment of significant funds to gain regulatory approval before they can be approved for commercialization. The results of our research and human clinical testing of our products may not meet regulatory requirements. Some of our product candidates, if approved, may require the completion of post-market studies. There can be no assurance that any of our products will be further developed and approved. The process of completing clinical testing and obtaining required approvals will take several years and require the use of substantial resources. For instance, we currently plan to study plozasiran in a cardiovascular outcomes trial, and cardiovascular outcomes trials are expensive clinical trials performed in a large number of subjects over several years. Further, there can be no assurance that product candidates employing a new technology will be shown to be safe and effective in clinical trials or receive applicable regulatory approvals. If we fail to obtain regulatory approvals for any or all of our products, we will not be able to market such product and our operations may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may not yield successful results for the product candidates that</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> we may</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">i</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">dentify and pursue for their intended uses, which would prevent, delay or limit the scope of regulatory approval and commercialization.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We must demonstrate our product candidates&#8217; safety and efficacy in humans for each target indication through extensive clinical testing. We may experience numerous unforeseen events during, or as a result of, the testing process that could delay or prevent commercialization of any products, including the following:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of preclinical studies may be inconclusive, or they may not be indicative of results that will be obtained in human clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">safety and efficacy results attained in early human clinical trials may not be indicative of results that are obtained in later clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">after reviewing test results, we may abandon projects that we might previously have believed to be promising;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we or our regulators may suspend or terminate clinical trials because the participating subjects or patients are being exposed to unacceptable health risks; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may not have the desired effects or may include undesirable side effects or other characteristics that preclude regulatory approval or limit their commercial use if approved.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot be certain that current clinical trials or any future clinical trials, whether conducted by us or our licensees, will be successful. Additionally, any safety concerns observed in any one of our clinical trials in our targeted indications could limit the prospects for regulatory approval of our product candidates in those and other indications, which could have a material adverse effect on our business, financial condition and results of operation. Success in clinical trials in a particular indication does not ensure that a product candidate will be successful in other indications. Similarly, approval of a product candidate in a particular indication does not ensure that the product candidate will be successful in other indications. For instance, even if plozasiran's Phase 3 trial for patients with FCS is successful in achieving its endpoints and a regulatory authority approves plozasiran for the treatment of FCS, plozasiran may not succeed in achieving its clinical trial endpoints or be approved for the treatment of larger indications such as sHTG or ASCVD because the endpoints and clinical data required for approval in a rare disease indication are different from what is required for a broader patient population. Moreover, results acceptable to support approval in one jurisdiction may be deemed inadequate by another regulatory authority to support regulatory approval in that other jurisdiction. To the extent that the results of the trials are not satisfactory to the FDA or comparable foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Even if regulatory approval is secured for a product candidate, the terms of such approval may limit the scope and use of the specific product candidate, which may also limit its commercial potential.  </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical trials may reveal significant adverse events, toxicities or other side effects and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to obtain marketing approval for any of our product candidates, we must demonstrate the safety and efficacy of the product candidate for the relevant clinical indication or indications through preclinical studies and clinical trials as well as additional supporting data. As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events (&#8220;AEs&#8221;) associated with the use of our products or product candidates. If our product candidates are associated with undesirable side effects in preclinical studies or clinical trials, or have unexpected characteristics, we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If further significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to the clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of that product candidate altogether. We, the FDA, the EMA, other applicable regulatory authorities or an institutional review board may suspend clinical trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology industry that initially showed therapeutic promise in early-stage studies have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the drug from obtaining or maintaining marketing approval, undesirable side effects may inhibit market acceptance of the approved product due to its tolerability relative to other therapies. Any of these developments could materially harm our business, financial condition and prospects.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical trials of our product candidates may not uncover all possible adverse events that patients may experience.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are conducted in representative samples of the potential patient population, which may have significant variability. By design, clinical trials are based on a limited number of subjects and are of limited duration of exposure to the product, to determine whether the product candidate demonstrates the substantial evidence of efficacy and safety necessary to obtain regulatory approval. As with the results of any statistical sampling, we cannot be sure that all side effects of our product candidates may be uncovered. It may be the case that only with a significantly larger number of patients exposed to the product candidate for a longer duration may a more complete safety profile be identified. Further, even larger clinical trials may not identify rare significant AEs, and the duration of such studies may not be sufficient to identify when those events may occur. Other products have been approved by the regulatory authorities for which safety concerns have been uncovered following approval. Such safety concerns have led to labeling changes, restrictions on distribution through use of a REMS, or withdrawal of products from the market, and any of our product candidates may be subject to similar risks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although to date our current drug candidates have generally evidenced an acceptable safety profile in clinical trials, patients treated with our products, if approved, may experience previously unreported adverse reactions or minor incidences of adverse reactions may manifest with greater frequency in subsequent larger trials, and it is possible that the FDA or other regulatory authorities may ask for additional safety data as a condition of, or in connection with, our efforts to obtain approval of our product candidates. If toxicities, adverse events or any other safety problems occur or are identified after our products, if any, reach the market, we may make the decision or be required by regulatory authorities to conduct additional clinical safety trials, amend the labeling of our products or add additional warnings to the labeling, recall our products, or even withdraw approval for our products.</span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Topline data may not accurately reflect the complete results of a particular study or trial.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may publicly disclose topline or interim data from time to time, which is based on a preliminary analysis of then-available efficacy and safety data which are based on preliminary analysis of key efficacy and safety data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimations, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular drug candidate or drug and our company in general. In addition, the information we may publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, drug candidate or our business. If the topline data that we report differ from a future analysis of results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our product candidates, our business, operating results, prospects or financial condition may be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of earlier studies or clinical trials </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">may not be predictive of future clinical trial results, and initial studies or clinical trials may not establish an adequate safety or efficacy profile for our product candidates to justify proceeding to advanced clinical trials or an application for regulatory approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of nonclinical and preclinical studies and clinical trials may not be predictive of the results of later-stage clinical trials, and interim results of clinical trials do not necessarily predict final results. The results of preclinical studies and clinical trials in one set of patients or disease indications, or from preclinical studies or clinical trials that we did not lead, may not be predictive of those obtained in another. In some instances, there can be significant variability in safety or efficacy results between different clinical trials of the same product candidate due to numerous factors, including changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the dosing regimen and other clinical trial protocols and the rate of dropout among clinical trial participants. In addition, preclinical and clinical data are often susceptible to various interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through nonclinical studies and initial clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, or after achieving positive results in pivotal trials, and we cannot be certain that we will not face similar setbacks. Even if early-stage clinical trials are successful, we may need to conduct additional clinical trials of our product candidates in additional patient populations or under different treatment conditions before we are able to seek approvals from the FDA and regulatory authorities outside the United States to market and sell these product candidates. Our failure to obtain marketing approval for our product candidates for commercially viable indications, or at all, would substantially harm our business, prospects, financial condition and results of operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">It may take us longer than we project to complete clinical trials, and we may not be able to complete them at all.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although for planning purposes we project the commencement, continuation and completion of our clinical trials, a number of factors, including scheduling conflicts with participating clinicians and clinical institutions, and difficulties in identifying or enrolling patients who meet trial eligibility criteria, may cause significant delays. Enrollment of clinical trials may be particularly difficult in orphan diseases or limited-sized patient populations. The FDA or other regulatory bodies may require additional, longer or broader clinical trials to establish safety and effectiveness, notwithstanding guidance the Company may have received from those bodies during clinical trial planning and execution. Further, the cost for conducting clinical trials is significant and if our cash resources become limited we may not be able to commence, continue and/or complete our clinical trials. We may not commence or complete clinical trials involving any of our product candidates as projected or may not conduct them successfully.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for a product candidate and may have to limit its commercialization.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The use of our product candidates in clinical trials and the sale of any products for which we obtain marketing approval expose us to the risk of product liability claims. Product liability claims might be brought against us by clinical trial participants, consumers, healthcare providers, pharmaceutical companies, or others selling our products. If we cannot successfully defend ourselves against these claims, we may incur substantial liabilities. Regardless of merit or eventual outcomes of such claims, product liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impairment of our business reputation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of clinical trial participants;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of litigation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to patients or other claimants; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenues.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our insurance coverage may not be sufficient to reimburse us for all expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The successful commercialization of our product candidates, if approved, will depend in part on the extent to which government authorities and health insurers establish adequate reimbursement levels and pricing policies.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of any approved drug candidate will depend in part on the availability of coverage and reimbursement from third-party payers such as government insurance programs, including Medicare and Medicaid, private health insurers, health maintenance organizations and other health care related organizations, who are increasingly challenging the price of medical products and services. Accordingly, coverage and reimbursement may be uncertain. Adoption of any drug by the medical community may be limited if third-party payers will not offer adequate coverage. Additionally, significant uncertainty exists as to the reimbursement status of newly-approved drugs. Cost control initiatives may decrease coverage and payment levels for any drug and, in turn, the price that we will be able to charge and/or the volume of our sales. We are unable to predict all changes to the coverage or reimbursement methodologies that will be applied by private or government payers. Any denial of private or government payer coverage or inadequate reimbursement could harm our business and reduce our revenue. With respect to our partnered product candidates, we will be reliant on that partner to obtain reimbursement from government and private payors for the drug, if approved, and any failure of that partner to establish adequate reimbursement could have a negative impact on our revenues and profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, both the federal and state governments in the United States and foreign governments continue to propose and pass new legislation, regulations, and policies affecting coverage and reimbursement rates, which are designed to contain or reduce the cost of health care. Further federal and state proposals and healthcare reforms are likely, which could limit the prices that can be charged for the product candidates that we develop and may further limit our commercial opportunity. For example, the IRA includes several measures intended to lower the cost of prescription drugs and related healthcare reforms, including limits on price increases and subjecting an escalating number of drugs to annual price negotiations with CMS (The Centers for Medicare &amp; Medicaid Services). We cannot be sure whether additional legislation or rulemaking related to the IRA will be issued or enacted, or what impact, if any, such changes will have on the profitability of any of our drug candidates, if approved for commercial use, in the future. There also may be future changes unrelated to the IRA that result in reductions in potential coverage and reimbursement levels for our product candidates, if approved and commercialized, and we cannot predict the scope of any future changes or the impact that those changes would have on our operations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If future reimbursement for approved product candidates, if any, is substantially less than we project, or rebate obligations associated with them are substantially greater than we expect, our future net revenue and profitability could be materially diminished.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not enjoy the market exclusivity benefits of our orphan drug designations.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we may obtain orphan designations in the treatment of certain diseases our products are intended to treat, the designation may not be applicable to any particular product we might get approved and that product may not be the first product to receive approval for that indication. Under the Orphan Drug Act, the first product with an orphan designation receives market exclusivity, which prohibits the FDA from approving the &#8220;same&#8221; drug for the same indication. The FDA has stated that drugs can be the &#8220;same&#8221; even when they are not identical but has not provided guidance with respect to how it will determine &#8220;sameness&#8221; for RNAi drugs. It is possible that another RNAi drug could be approved for the treatment of a disease that one of our orphan products is intended to treat before our product is approved, which means that we may not obtain orphan drug exclusivity and could also potentially be blocked from approval until the first product&#8217;s orphan drug exclusivity period expires or we demonstrate, if we can, that our product is superior. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved and granted orphan drug exclusivity, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is safer, more effective or makes a major contribution to patient care. Further, orphan drug exclusivity can be lost if the FDA later determines that the request for designation was materially defective or if the applicant is unable to assure the availability of sufficient quantities of the drug to meet the needs of patients with the disease or condition for which the drug was designated.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our success depends on the attraction and retention of senior management and scientists with relevant expertise.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success depends to a significant extent on the continued services of our key employees, including our senior scientific, technical and managerial personnel. We do not maintain key person life insurance for any of our executives and we do not maintain employment agreements with many senior employees. Competition for qualified employees in the pharmaceutical industry is high, and our ability to execute our strategy will depend in part on our ability to continue to attract and retain qualified scientists, management and other employees. This will depend in part on our ability to create and maintain a desirable workplace culture, which may be impacted by employee preferences for remote working. In addition, the market for qualified employees in the pharmaceutical industry is experiencing labor shortages and inflationary pressures are causing salaries and wages to increase, all of which exacerbates these competitive dynamics. If </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we are unable to find, hire and retain qualified individuals, we will have difficulty implementing our business plan in a timely manner, or at all.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Regulatory Review and Approval of Our Product Candidates</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Breakthrough Therapy designation for Fazirsiran (formerly ARO-AAT) may not lead to a faster development or review process.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been granted a Breakthrough Therapy designation for fazirsiran in the United States for the treatment of liver disease associated with AATD. Breakthrough Therapy designation is intended to facilitate the development and expedite the review of new therapies to treat serious conditions with unmet medical needs by providing sponsors with the opportunity for frequent interactions and additional drug development guidance with the FDA and its senior managers. Breakthrough Therapy designation applies to the combination of the drug candidate and the specific indication for which it is being studied. Product candidates that receive Breakthrough Therapy designation may receive more frequent interactions with the FDA regarding the product candidate&#8217;s development plan and clinical trials and may be eligible for the FDA&#8217;s Rolling Review.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Despite receiving Breakthrough Therapy designation, fazirsiran may not actually benefit from faster clinical development or regulatory review or approval any sooner than other product candidates that do not have such designation, or at all. Furthermore, such a designation does not increase the likelihood that fazirsiran will receive marketing approval in the United States. The FDA may also rescind Breakthrough Therapy designation if it determines that fazirsiran</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> no longer meets the relevant criteria.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A Fast Track product designation may not lead to faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received a Fast Track product designation for plozasiran in the United States for the treatment of FCS, and we may seek Fast Track designation for other of our current or future product candidates. The Fast Track designation is a program offered by the FDA designed to facilitate drug development and to expedite the review of new drugs that are intended to treat serious or life-threatening conditions. Compounds selected must demonstrate the potential to address unmet medical needs. The FDA&#8217;s Fast Track designation allows for close and frequent interaction with the FDA. A designated Fast Track drug may also be considered for priority review with a shortened review time, rolling submission, and accelerated approval if applicable. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Fast Track designation does not, however, guarantee FDA approval or expedited approval of any application for the product candidate. The receipt of such a designation for a product candidate may not result in a faster development process, review, or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate marketing approval by the FDA. In addition, the FDA may later decide that the products no longer meet the designation conditions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We intend to deliver some of our product candidates via drug delivery devices that will have their own regulatory, development, supply and other risks.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We intend to deliver some of our product candidates via drug delivery devices, such as an autoinjector or nebulizer. There may be unforeseen technical complications related to the development activities required to bring such a product to market, including container compatibility and/or dose volume requirements. Our product candidates may not be approved or may be substantially delayed in receiving approval if the devices do not gain and/or maintain their own regulatory approvals or clearances. Where approval of the drug product and device is sought under a single application, the increased complexity of the review process may delay approval. In addition, some drug delivery devices are provided by single-source unaffiliated third-party companies. We may be dependent on the sustained cooperation and effort of those third-party companies both to supply the devices and, in some cases, to conduct the studies required for approval or other regulatory clearance of the devices. Even if approval is obtained, we may also be dependent on those third-party companies continuing to maintain such approvals or clearances once they have been received. Failure of third-party companies to supply the devices, to successfully complete studies on the devices in a timely manner, or to obtain or maintain required approvals or clearances of the devices could result in increased development costs, delays in or failure to obtain regulatory approval and delays in product candidates reaching the market or in gaining approval or clearance for expanded labels for new indications.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and our licensees con</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">duct clinical trials for product candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our licensees currently conduct clinical trials outside the United States. The acceptance by the FDA or comparable foreign regulatory authority of study data from clinical trials conducted outside the United States or another </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">jurisdiction may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such as inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. Additionally, the FDA&#8217;s clinical trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any comparable foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. Most of our clinical trials involve study subjects outside of the United States</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including most of our phase 1 clinical trials (which often enroll study subjects in Australia and New Zealand), and our Phase 3 clinical trials of plozasiran, for which we have enrolled (with respect to FCS) and plan to enroll (with respect to sHTG and ASCVD) cohorts outside the United States. If</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the FDA or any comparable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in product candidates that we may develop not receiving approval or clearance for commercialization in the applicable jurisdiction. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain FDA approval for products in the United States, we may never obtain approval to commercialize any product candidates outside of the United States, which would limit our ability to realize their full market potential. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any products outside of the United States, we must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and effectiveness. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional or different administrative review periods from those in the United States, including additional preclinical studies or clinical trials. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval before a product can be marketed in that jurisdiction, even after establishing safety and efficacy in a clinical setting.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Seeking foreign regulatory approval could result in difficulties and costs and require additional nonclinical studies or clinical trials which could be costly and time-consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our product candidates in those countries. The foreign regulatory approval process may include all of the risks associated with obtaining FDA approval. We do not have any product candidates approved for sale in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approval in international markets is delayed, our target market will be reduced and our ability to realize the full market potential of our products will be harmed.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if our product candidates are approved for commercialization, failure to comply with regulatory requirements or unanticipated problems with our products may result in various adverse actions such as the suspension or withdrawal of one or more of our products, closure of a facility or enforcement of substantial penalties or fines.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If regulatory approval to sell any of our product candidates is received, regulatory agencies will subject any marketed product(s) and the facilities where they are manufactured to continual review and periodic inspection. If previously unknown problems with a product, manufacturing and laboratory facilities or regulatory requirements are discovered, such as adverse events of unanticipated severity or frequency, problems with a manufacturing process or laboratory facility, or failure to comply with applicable regulatory approval requirements, a regulatory agency may impose restrictions or penalties on that product or on us. Such restrictions or penalties may include, among other things:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, the withdrawal of the product from the market or product recalls;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">warning letters or holds on clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of approvals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of our product candidates; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">closure of the facility, enforcement of substantial fines, injunctions, or the imposition of civil or criminal penalties.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Intellectual Property</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to protect our patents and other proprietary rights is uncertain, exposing us to the possible loss of competitive advantage.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have licensed rights to patents and have filed and expect to continue to file patent applications. Researchers sponsored by us may also file patent applications that we may need to license. Such patent applications may not be available for licensing or may not be economically feasible to license. Certain of our patents may not be granted or may not contain claims of the necessary breadth because, for example, prior patents exist. If a particular patent is not granted, the value of the invention described in the patent would be diminished. Further, even if these patents are granted, they may be difficult to enforce. Even if ultimately successful, efforts to enforce our patent rights could be expensive, distracting for management, cause our patents to be invalidated or held unenforceable, and thus frustrate commercialization of products. Even if patents are issued and are enforceable, others may develop similar, superior or parallel technologies to any technology developed by us and not infringe on our patents. Our technology may prove to infringe upon patents or rights owned by others. Patent prosecution and maintenance is expensive, and we may be forced to curtail prosecution or maintenance if our cash resources are limited. Thus, the patents held by or licensed to us may not afford us any meaningful competitive advantage. In addition, the laws of some foreign countries in which we do business, including through our joint ventures, do not protect intellectual property rights to the same extent or in the same manner as the laws of the United States. Moreover, if we or our licensors fail to maintain the patents and patent applications covering our product candidates or technologies, including as a result of geopolitical events such as civil or political unrest (including the ongoing conflicts between Ukraine and Russia and Israel and Palestine), we may not be able to use such patents and patent applications or stop a competitor from marketing products that are the same as or similar to our product candidates. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to adequately protect our owned intellectual property or derive sufficient value from our licensed or owned intellectual property, the value of your investment may decline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, patent grant standards by the USPTO and its foreign counterparts are not always uniform or predictable, and subject to change. For example, the America Invents Act enacted a number of changes to U.S. patent laws, which may prevent us from adequately protecting our inventions and discoveries, including our ability to seek injunctive relief, pursue infringement claims, and obtain substantial damage awards. An example of a major provision of the America Invents Act is the change in the U.S. patent policy from a first-to-invent to a first-to-file practice. Foreign counterparts to this law are also not uniform, and there is no worldwide policy governing the subject matter and scope of claims granted in a pharmaceutical or biotechnology patent. Uncertainty, arising from changing laws, can impact our ability to protect our patents and other proprietary rights.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are party to technology license agreements with third parties that require us to satisfy obligations to keep them effective and, if these agreements are terminated, our technology and our business could be seriously and adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to license agreements to incorporate third-party proprietary technologies into our drug products under development. These license agreements require us to pay royalties and satisfy other conditions. If we fail to satisfy our obligations under these agreements, the terms of the licenses may be materially modified, such as by rendering currently exclusive licenses non-exclusive, or may give our licensors the right to terminate their respective agreement with us, which could limit our ability to implement our current business plan and harm our business and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to patent infringement claims, which could result in substantial costs and liability and prevent us from commercializing our potential products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because the intellectual property landscape in the fields in which we participate is rapidly evolving and interdisciplinary, it is difficult to conclusively assess our freedom to operate without infringing on third-party rights. However, if granted marketing approval, we are currently aware of certain patent rights held by third parties that, if found to be valid and enforceable, could be alleged to render one or more of our drug candidates infringing. If a claim should be brought and is successful, we may be required to pay substantial damages, be forced to abandon any affected drug candidates and/or seek a license from the patent holder. In addition, any patent infringement claims brought against us, whether or not successful, may cause us to incur significant expenses and divert the attention of our management and key personnel from other business concerns. These could negatively affect our results of operations and prospects. We cannot be certain that patents owned or licensed by us will not be challenged, potentially successfully, by others.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if our product candidates are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against our customers, licensees and other parties with whom we have business relationships, and we may be required to indemnify those parties for any damages they suffer as a result of these claims. The claims may require us to initiate or defend protracted and costly litigation on behalf of customers, licensees, and other </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">parties regardless of the merits of these claims. If any of these claims succeed, we may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products they use. If we cannot obtain all necessary licenses on commercially reasonable terms, we may be unable to continue selling such products.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We license patent rights from third-party owners and we rely on such owners to obtain, maintain and enforce the patents underlying such licenses.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a number of licenses that give us rights to third-party intellectual property that is necessary or useful for our business. We also expect to enter into additional licenses to third-party intellectual property in the future.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success may depend in part on the ability of our licensors to obtain, maintain and enforce patent protection for our licensed intellectual property, in particular, those patents to which we have secured exclusive rights. Our licensors may not successfully prosecute the patent applications to which we are licensed. Even if patents are issued in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue such litigation less aggressively than we would. Without protection for the intellectual property we license, other companies might be able to offer substantially identical products for sale, which could adversely affect our competitive business position and harm our business prospects.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our technology licensed from various third parties may be subject to retained rights.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our licensors often retain certain rights under their agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Confidentiality agreements with employees and others may not adequately prevent disclosure of trade secrets and other proprietary information.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to protect our proprietary technology and processes, we rely in part on confidentiality agreements with our collaborators, employees, consultants, outside scientific collaborators and sponsored researchers, and other advisors. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. As our organization grows, so does the risk of unauthorized disclosure of confidential information. In addition, while we undertake efforts to protect our trade secrets and other confidential information from disclosure, others may independently discover trade secrets and proprietary information, and in such cases, we may not be able to assert any trade secret rights against such party. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to effectively secure first-tier technologies when competing against other companies or investors.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future success may require that we acquire patent rights and know-how to new or complimentary technologies. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, we also compete with a substantial number of other companies that are working to develop novel drugs using technology that compete directly with us. We are aware of several other companies that are working to develop RNAi therapeutic products and any one of these companies may develop its RNAi technology more rapidly and more effectively than us] may also compete for technologies we desire.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In addition, many venture capital firms and other institutional investors, as well as other pharmaceutical and biotech companies, invest in companies seeking to commercialize various types of emerging technologies. Many of these companies have greater financial, scientific and commercial resources than us. Therefore, we may not be able to secure the technologies we desire or to otherwise effectively compete. Furthermore, should any commercial undertaking by us prove to be successful, there can be no assurance competitors with greater financial resources will not offer competitive products and/or technologies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents covering our current and any future product candidates in all countries throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we or our licensors have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection but where patent enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued or licensed patents, and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing. Issued patents may be challenged by third parties in the courts or patent offices in various countries throughout the world. Invalidation proceedings may result in patent claims being narrowed, invalidated or held </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unenforceable. Uncertainties regarding the outcome of such proceedings, as well as any resulting losses of patent protection, could harm our business.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. Some countries do not enforce patents related to medical treatments, or limit enforceability in the case of a public emergency. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intellectual property systems in other countries can be destabilized or unpredictable as a result of geopolitical events such as civil or political unrest (including the ongoing conflicts between Ukraine and Russia and Israel and Palestine). Therefore, during such geopolitical events, the ability to obtain, retain and enforce intellectual property protection in the affected countries may be uncertain and evolve during the course of such geopolitical event. The U.S. government&#8217;s response to geopolitical events may also negatively affect our ability to obtain, retain and enforce intellectual property protection in the affected countries. Uncertainties regarding geopolitical events, as well as any resulting losses of intellectual property protection, could harm our business.</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Business Model</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business model assumes we will generate revenue by, among other activities, marketing or out-licensing the products we deve</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">lop. Our drug candidates are in various stages of development and we have no approved products based on RNA interference  and our delivery technologies. Accordingly, there is a limited amount of information about us upon which you can evalua</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">te our business and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have no approved drugs and thus have not begun to market or generate revenues from the commercialization of any product candidates. Because no drug candidates generated with our product platform have been approved, we have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical area. For example, to execute our business plan, we will need to successfully:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Execute product development activities using technologies that have not yet generated an approved product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Build, maintain, and protect a strong intellectual property portfolio;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Demonstrate safety and efficacy of our drug candidates in multiple human clinical studies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Receive FDA approval and approval from similar foreign regulatory bodies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Gain market acceptance for the development and commercialization of any drugs we develop;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Ensure our products are reimbursed by commercial and/or government payors at a rate that permits commercial viability;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Develop and maintain successful strategic relationships with suppliers, distributors, and commercial licensing partners;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Manage our spending and cash requirements as our expenses will increase in the near term if we add programs and additional preclinical and clinical trials; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Effectively market any products for which we obtain marketing approval.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unsuccessful in accomplishing these objectives, we may not be able to develop products, raise capital, expand our business or continue our operations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to establish additional relationships with strategic and development partners to fully develop our drug candidates and market any approved products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Over the past several years we have entered into license and collaboration agreements with Takeda, Janssen, Amgen, Horizon, GSK and Visirna. Our business strategy includes securing additional collaborations with other pharmaceutical and biotech companies to support the development of our RNAi therapeutics and other drug candidates. We do not possess all of the financial and development resources necessary to develop and commercialize all of the products that may result from our technologies. Unless we expand our product development capacity and enhance our internal marketing capability, we may need to make appropriate arrangements with strategic partners to develop and commercialize any drug candidates that may be approved. We may not be able to attract such partners, and even if we are able to enter into such partnerships, the terms may be less favorable than anticipated. Further, entering into partnership agreements may limit our commercialization options and/or require us to share revenues and profits with our partners. If we do not find appropriate partners, or if our existing arrangements or future agreements are not successful, our ability to develop and commercialize products could be adversely affected. Even if we are able to find collaborative partners, the overall success </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the development and commercialization of product candidates in those programs will depend largely on the efforts of other parties and will be beyond our control, particularly as partnered programs progress and our licensees may elect to assume greater control over these programs. In addition, in the event we pursue our commercialization strategy through collaboration or licenses to third parties, there are a variety of technical, business and legal risks, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may not be able to control the amount and timing of resources that our collaborators may be willing or able to devote to the development or commercialization of our drug candidates or to their marketing and distribution; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Disputes may arise between us and our collaborators that result in the delay or termination of the research, development or commercialization of our drug candidates or that result in costly litigation or arbitration that diverts our management&#8217;s resources.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The occurrence of any of the above events or other related events could impair our ability to generate revenues and harm our business and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to generate milestone and royalty payments under our current and potential future licensing and collaboration agreements is substantially controlled by our partners, and as such, we will likely need other sources of financing to continue to develop our internal drug candidates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under our licensing and collaboration agreements with Amgen, Janssen, Takeda, Horizon, GSK and Visirna, our partners substantially control clinical development and commercialization for all of the candidates covered under those agreements in their relevant territories. To the extent that (i) our partners&#8217; interests in advancing these candidates or targets changes, (ii) unforeseen scientific issues with the candidates arise, or (iii) the pace at which our partners move the candidates through clinical trials toward commercialization slows, our ability to collect milestones and royalties may be significantly diminished. This would further cause us to rely upon other sources of financing to continue to develop our other internal drug candidates. </span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may lose a considerable amount of control over our intellectual property and may not receive anticipated revenues in strategic transactions, particularly where the consideration is contingent on the achievement of development or sales milestones.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business model has been to develop new technologies and to utilize the intellectual property created through the research and development process to develop commercially successful products. If the acquirers of our technologies fail to achieve performance milestones, we may not receive a significant portion of the total value of any sale, license or other strategic transaction.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need to achieve commercial acceptance of our drug candidates to generate revenues and achieve profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if our research and development efforts yield technologically feasible applications, we may not successfully develop commercial products. Drug development takes years of study in human clinical trials prior to regulatory approval, and, even if we are successful in getting regulatory approval of our drug candidates, it may not be on a timely basis. During our drug development period, superior competitive technologies may be introduced which could diminish or extinguish the potential commercial uses for our drug candidates. Additionally, the degree to which the medical community and consumers will adopt any product we develop is uncertain. The rate and degree of market acceptance of our products will depend on a number of factors, including the establishment and demonstration in the medical community of the clinical efficacy and safety of our products, their potential advantage over alternative treatments, and the costs to patients and third-party payors, including insurance companies and Medicare. Recent efforts in the United States and abroad to reduce overall healthcare spending has put significant pressure on the price of prescription drugs and certain companies have been publicly criticized for the relatively high cost of their therapies. These pressures may force us to sell any approved drugs at a lower price than we or analysts may anticipate or may result in lower levels of reimbursement and coverage from third parties. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict whether significant commercial market acceptance for our products, if approved, will ever develop, and we cannot reliably estimate the projected size of any such potential market. Our revenue growth and achievement of consistent profitability will depend substantially on our ability to introduce products that will be accepted by the medical community. If we are unable to cost-effectively achieve acceptance of our technology among the medical establishment and patients, or if the associated products do not achieve wide market acceptance, our business will be materially and adversely affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on outside sources for various components and processes for our products.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on third parties for various components and processes for our product candidates. We may not be able to achieve multiple sourcing because there may be no acceptable second source, other companies may choose not to work with us, or the component or process sought may be so new that a second source does not exist or does not exist on acceptable terms. For instance, many of our pulmonary drug candidates are administered using a proprietary delivery </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">device which can only be sourced from a single manufacturer. There may be a disruption or delay in the performance of our third-party contractors, suppliers or collaborators which is beyond our control. If such third parties are unable to satisfy their commitments to us, the development of our products would be adversely affected. Therefore, it is possible that our development plans will have to be slowed down or stopped completely at times due to our inability to obtain required raw materials, components, and outsourced processes at an acceptable cost, if at all, or to get a timely response from vendors, particularly as a result of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recent labor market and global supply chain constraints.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have limited manufacturing capability and must rely on third-party manufacturers to manufacture our clinical supplies and commercial products, if and when approved, and if they fail to meet their obligations, the development and commercialization of our products could be adversely affected. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we are currently in the process of further developing our own internal manufacturing capabilities, we hav</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e limited internal manufacturing capabilities and we rely, and expect to continue to rely, on third-party manufacturers for the production of some of our product candidates for clinical trials and potential future commercialization. If we were to experience an unexpected loss or interruption of supply for any of our product candidates, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. Further, our drug candidates are composed of multiple components and require specialized formulations for which scale-up and manufacturing could be difficult. We have limited experience in such scale-up and manufacturing requiring us to depend on a limited number of third parties, who may not be able to deliver in a timely manner, or at all. In order to develop products, apply for regulatory approvals, and commercialize our products, we will need to develop, contract for, or otherwise arrange for the necessary manufacturing capabilities. Our internal GMP manufacturing capabilities are currently limited to small-scale production of material, although we anticipate an increase in our GMP manufacturing capacity following the successful completion and integration of our manufacturing facility in Verona, Wisconsin. There are a limited number of manufacturers that supply synthetic oligonucleotides. There are risks inherent in pharmaceutical manufacturing that could affect the ability of our or our contract manufacturers to meet our delivery time requirements or provide adequate amounts of material to meet our needs. Included in these risks are synthesis and purification failures and contamination during the manufacturing process, which could result in unusable product and cause delays in our development process, as well as additional expense to us.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our product candidates have not yet been manufactured for commercial use. If any of our product candidates become approved for commercial sale, we will need to establish either internal or third-party manufacturing capacity. Manufacturing partner requirements may require us to fund capital improvements, perhaps on behalf of third parties, to support the scale-up of manufacturing and related activities. We may not be able to establish scaled manufacturing capacity for an approved product in a timely or economic manner, if at all. If we or our third-party manufacturers are unable to provide commercial quantities of such an approved product, we will have to successfully transfer manufacturing technology to a different manufacturer. Engaging a new manufacturer for such an approved product could require us to conduct comparative studies or utilize other means to determine bioequivalence of the new and prior manufacturers&#8217; products, which could delay or prevent our ability to commercialize such an approved product. If we or any of these manufacturers is unable or unwilling to increase its manufacturing capacity or if we are unable to establish alternative arrangements on a timely basis or on acceptable terms, the development and commercialization of such an approved product may be delayed or there may be a shortage in supply. Any inability to manufacture our product candidates or future approved drugs in sufficient quantities when needed would seriously harm our business. While we are exploring alternative suppliers for certain critical materials, there can be no assurance that our efforts will be successful.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our drug candidates is approved by a regulatory authority, manufacturers of our approved products (including us, if we chose to internally manufacture) must comply with cGMP requirements relating to methods, facilities and controls used in the manufacturing, processing and packaging of the product, which are intended to ensure that drug products are safe and that they consistently meet applicable requirements and specifications. These requirements include quality control, quality assurance, and the maintenance of records and documentation. These manufacturers (including us, if we chose to internally manufacture) may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. These requirements are enforced by the FDA and other health authorities through periodic announced and unannounced inspections of manufacturing facilities. A failure to comply with these requirements or to provide adequate and timely corrective actions in response to deficiencies identified in an inspection may result in enforcement action, including warning letters, fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall, plant shutdown, or the delay, withholding, or withdrawal of product approval. If the safety of any quantities supplied is compromised due to a manufacturer&#8217;s failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products, which would seriously harm our business.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct our clinical trials, and if they fail to fulfill their obligations, the development of our products may be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on independent clinical investigators, contract research organizations and other third-party service providers to assist us in managing, monitoring and otherwise carrying out our clinical trials. We contract with certain third-parties to provide certain services, including site selection, enrollment, monitoring and data management services. We rely on these parties to carry out our clinical trials in compliance with GCP and other relevant requirements. Although we depend heavily on these parties, we do not control them and therefore we cannot be assured that these third parties will adequately perform all of their contractual obligations to us. If our third-party service providers cannot adequately and timely fulfill their obligations to us, or if the quality and accuracy of our clinical trial data is compromised due to failure by such third parties to adhere to our protocols, GCP, or other regulatory requirements or if such third parties otherwise fail to meet deadlines or quality requirements, our development plans may be delayed or terminated. Further, if clinical study results are compromised, then we may need to repeat the affected studies, which could result in significant additional costs and delays to us.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face competition from various entities including large pharmaceutical companies, small biotech companies, private companies, and research institutions.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have greater financial resources and may have more experience in research and development, manufacturing, managing clinical trials and/or regulatory compliance than we do. Our competitors may compete with us for lead clinical trial investigators, clinical trial site locations and patient enrollment. These competitors may also compete with us on recruiting scientific and management personnel. Because our products are in vario</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">us stages </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of preclinical and clinical development, along with many of the competing products, and given unpredictability inherent in drug development, it is difficult to predict which third parties may provide the most competition, and on what specific basis that competition may be based.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may have difficulty expanding our operations successfully as we evolve our pipeline and move toward commercializing drugs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future financial performance and our ability to commercialize products and compete effectively will depend, in part, on our ability to effectively manage future growth. We expect that as we increase the number of product candidates we are developing we will also need to expand our operations. This expected growth may place a strain on our administrative and operational infrastructure and information technology systems. As product candidates we develop enter and advance through clinical trials, we will need to expand our development, regulatory, manufacturing, marketing, and sales capabilities or contract with other organizations to provide these capabilities for us. We are currently planning to establish a sales and marketing infrastructure, although we have no institutional experience in the sale, marketing, or distribution of pharmaceutical products. To achieve commercial success for any approved product for which we retain sales and marketing rights, we must continue to develop a sales and marketing organization or outsource these functions to third parties. If we or our collaborators are unable to establish sales, marketing and distribution capabilities or enter into or maintain agreements with third parties to market and sell our product candidates, we may not be successful in commercializing our product candidates if and when they are approved. Further, as our operations expand due to our development progress, we expect that we will need to manage additional relationships with various collaborators, suppliers, and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial, information technology and management controls, reporting systems and procedures. We may not be able to effectively manage the expansion of our operations or implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business and operations could suffer in the event of information technology system failures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal computer systems and those of our contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, ransomware and other cyber-attacks, human error, natural disasters, terrorism, war, and telecommunication and electrical failures. Such events could cause interruption of our operations and loss of intellectual property. For example, the loss of preclinical trial data or data from completed or ongoing clinical trials for our product candidates could result in delays in our regulatory filings and development efforts and significantly increase our costs. Further, cybersecurity breaches may allow hackers access to our preclinical compounds, strategies, discoveries, trade secrets, and/or other confidential information. Additionally, sensitive data could be leaked, disclosed, or revealed as a result of or in connection with our employees&#8217;, personnel&#8217;s, vendors&#8217; or partners&#8217; use of generative AI technologies. To the extent that any disruption or security breach were to result in a loss of or damage to our data, or inappropriate disclosure of confidential, proprietary or private information, we could incur liability or regulatory penalties, including under laws and regulations governing the protection of health and other personally identifiable information, we could lose valuable trade secret rights, the development of our product candidates could be delayed, and we could suffer reputational damage and damage to key business relationships. The risk of a cyber-security breach or other informational technology disruption, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">particularly through cyber-attacks, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. We have experienced cyber-security attacks in the past, which to date have not had a material impact on our operations or development programs; however; there is no assurance that such impacts will not be material in the future.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we use biological materials, hazardous materials, chemicals and radioactive compounds, if we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research, development and manufacturing activities involve the use of potentially harmful biological materials as well as materials, chemicals and various radioactive compounds that could be hazardous to human health and safety or the environment. We store most of these materials and various wastes resulting from their use at our facilities in Madison, Wisconsin and San Diego, California pending ultimate use and disposal. We cannot completely eliminate the risk of contamination, which could cause interruption to our research and development and manufacturing efforts, injury to our employees and others, environmental damage, and liabilities under federal, state and local law. In such an event, we may be held liable for any resulting damages, and any liability could exceed our resources. Although we carry insurance in amounts and types that we consider commercially reasonable, we do not have insurance coverage for losses relating to an interruption of our research, development or manufacturing efforts caused by contamination, and the coverage or coverage limits of our insurance policies may not be adequate. If our losses exceed our insurance coverage, our financial condition would be affected.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation claims may result in financial losses or harm our reputation and may divert management resources.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:31.51pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the market price of a stock is volatile, holders of that stock have often initiated securities class action litigation against the company that issued the stock. We cannot predict with certainty the eventual outcome of such litigation, arbitration or third-party inquiry. We may not be successful in defending ourselves or asserting our rights in current or future lawsuits, investigations, or claims that have been or may be brought against us and, as a result, our business could be materially harmed. These lawsuits, arbitrations, investigations or claims may result in large judgments or settlements against us, any of which could have a negative effect on our financial performance and business. Additionally, lawsuits, arbitrations and investigations can be expensive to defend, whether or not the lawsuit, arbitration or investigation has merit, and the defense of these actions may divert the attention of our management and other resources that would otherwise be engaged in running our business.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operations, including our relationships with healthcare providers, physicians and third-party payers, are subject to applicable anti-kickback, fraud and abuse, and other healthcare laws and regulations, which, in the event of a violation, exposes us to liability for criminal sanctions, civil penalties, and contractual damages, and reputational harm and diminished profits and future earnings.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations, including any arrangements that we enter into with healthcare providers, physicians, and third-party payers, are subject to broadly applicable fraud and abuse and other healthcare laws and regulations. Such laws and regulations, including applicable U.S. federal and state healthcare laws and regulations, as well as foreign laws, such as the federal Anti-Kickback Statute, the False Claims Act, the Health Insurance Portability and Accountability Act of 1996, or the Foreign Corrupt Practices Act, may constrain our operation and the business or financial arrangements through which we can market, sell and distribute any drug candidates for which we obtain marketing approval. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to confirm that our business arrangements with third parties comply with applicable healthcare laws and regulations involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we become subject to significant civil, criminal and administrative penalties, damages, fines, imprisonment, exclusion of products from government funded healthcare programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If any of the physicians or other healthcare providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Financial Condition</span></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have a history of net losses, and we expect to continue to incur net losses and may not achieve or maintain profitability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have incurred net losses since our inception and we expect that our operating losses will continue for the foreseeable future as we continue our drug development efforts and prepare for the potential commercialization of our product candidates. To achieve profitability, we must, either directly or through licensing and/or partnering relationships, meet certain milestones, successfully develop and obtain regulatory approval for one or more drug candidates and effectively manufacture, market and sell any drugs we successfully develop. Even if we successfully commercialize drug candidates that receive regulatory approval, we may not be able to realize revenues at a level that would allow us to achieve or sustain profitability. Accordingly, we may never generate significant revenue and, even if we do generate significant revenue, we may never achieve consistent profitability.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will require substantial additional funds to complete our research and development activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business currently does not generate the cash that is necessary to finance our operations. Subject to the success of the research and development programs of our Company and our partners, and potential licensing or partnering transactions, we may need to raise additional capital to:  </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fund research and development infrastructure and activities relating to the development of our drug candidates, including preclinical and clinical trials and manufacturing to support these efforts;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fund a commercialization infrastructure and activities related to the sale, marketing, customer support, and distribution of our drug products if and when they become approved;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Fund our general and administrative infrastructure and activities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pursue business development opportunities for our technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Add to and protect our intellectual property; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Retain our management and technical staff.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future capital needs depend on many factors, including:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The scope, duration, and expenditures associated with our research and development, including the progression of our clinical trials, with late-stage trials generally requiring greater capital than early-stage trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Regulatory requirements for our clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The extent to which our research and development and clinical efforts are successful;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Expenditures to build out or contract for sales, marketing and distribution capabilities as we prepare for the potential commercialization of our product candidates, if any;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The outcome of potential partnering or licensing transactions, if any, and the extent to which our business development efforts result in the acquisition of new programs or technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Competing technological developments;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our intellectual property positions, if any, in our products; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The regulatory approval process and regulatory standards for our drug candidates.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> will</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> need to raise additional funds through public or private equity offerings, debt financings or additional strategic alliances and licensing arrangements in the future to continue our operations. We may not be able to obtain additional financing on terms favorable to us, if at all. General market conditions may make it very difficult for us to seek financing from the capital markets, and the terms of any financing may adversely affect the holdings or the rights of our stockholders. For example, if we raise additional funds by issuing equity securities, further dilution to our stockholders will result, which may substantially dilute the value of investment. In addition, as a condition to providing additional funds to us, future investors may demand, and may be granted, rights superior to those of existing stockholders. Debt financing, if available, may involve restrictive covenants that could limit our flexibility in conducting future business activities and, in the event of insolvency, would be paid before holders of equity securities received any distribution of corporate assets. In order to raise additional funds through alliance, joint venture or licensing arrangements, we may be required to relinquish rights to our technologies or drug candidates or grant licenses on terms that are not favorable to us. If adequate funds are not available, we may have to further delay, reduce or eliminate one or more of our planned activities. These actions would likely reduce the market price of our common stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the estimates we make, or the assumptions on which we rely, in preparing our consolidated financial statements prove inaccurate, our actual results may vary from those reflected in our accruals.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of our assets, liabilities, revenues and expenses, the amounts of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">charges accrued by us and related disclosure of contingent assets and liabilities. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. We cannot assure you, however, that our estimates, or the assumptions underlying them, will be correct.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or our guidance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our quarterly and annual operating results have fluctuated and may continue to fluctuate significantly in the future, which makes it difficult for us to predict our future operating results. From time to time, we may enter into license or collaboration agreements or strategic partnerships with other companies that include development funding and significant upfront and milestone payments and/or royalties. These upfront and milestone payments may vary significantly from period to period and any such variance could cause a significant fluctuation in our operating results from one period to the next.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we measure compensation cost for stock-based awards made to employees at the grant date of the award, based on the fair value of the award, and recognize the cost as an expense over the employee&#8217;s requisite service period. As the variables that we use as a basis for valuing these awards change over time, including our underlying stock price and stock price volatility, the magnitude of the expense that we must recognize may vary significantly.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, our operating results may fluctuate due to a variety of other factors, may of which are outside of our control and may be difficult to predict, including the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and cost of, and level of investment in, research and development activities relating to our current and any future product candidates, which will change from time to time;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enroll patients in clinical trials and the timing of enrollment;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of manufacturing our current and any future product candidates, which may vary depending on FDA guidelines and requirements, the quantity of production and the terms of our agreements with manufacturers and other suppliers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenditures that we will or may incur to acquire or develop additional product candidates and technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and outcomes of clinical trials for  product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the need to conduct unanticipated clinical trials or trials that are larger or more complex than anticipated;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">competition from existing and potential future products that compete with any of our product candidates, and changes in the competitive landscape of our industry, including consolidation among our competitors or partners;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any delays in regulatory review or approval of any of our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of demand for any of our product candidates, if approved, which may fluctuate significantly and be difficult to predict;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the risk/benefit profile, cost and reimbursement policies with respect to our product candidates, if approved, and existing and potential future products that compete with our product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to commercialize any of our product candidates, if approved, inside and outside of the United States, either independently or working with third parties;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations, licensing or other arrangements;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to adequately support future growth;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential unforeseen business disruptions that increase our costs or expenses;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">future accounting pronouncements or changes in our accounting policies; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the changing and volatile global economic environment.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cumulative effect of these factors could result in large fluctuations and unpredictability in our quarterly and annual operating results. As a result, comparing our operating results on a period-to-period basis may not be meaningful. Investors should not rely on our past results as an indication of our future performance. This variability and unpredictability could also result in our failing to meet the expectations of industry or financial analysts or investors for any period. If our revenue or operating results fall below the expectations of analysts or investors or below any forecasts we may provide to the market, or if the forecasts we provide to the market are below the expectations of analysts or investors, the price of our common stock could decline substantially. Such a stock price decline could occur even when we have met any previously publicly stated guidance we may provide.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The investment of our cash, cash equivalents and fixed income securities is subject to risks which may cause losses and affect the liquidity of these investments.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2023, we h</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ad $403.6 million in cash, cash equivalents and restricted cash and fixed income securities. Ou</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">r investments may also include commercial paper, securities issued by the U.S. government obligations, and money market funds meeting the criteria of our investment policy, which is focused on the preservation of our capital. These investments are subject to general credit, liquidity, and market and interest rate risks, particularly in the current </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">economic environment. We may realize losses in the fair value of these investments or a complete loss of these investments, which would have a negative effect on our consolidated financial statements. In addition, should our investments cease paying or reduce the amount of interest paid to us, our interest income would suffer. The market risks associated with our investment portfolio may have an adverse effect on our results of operations, liquidity and financial condition.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to utilize net operating loss carryforwards and other tax benefits may be limited.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically incurred net losses. Under the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), a corporation is generally allowed a deduction for net operating losses (NOLs) carried forward from a prior taxable year. Under that provision, we can carryforward our NOLs to offset our future taxable income, if any, until such NOLs are used or expire. As o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">f </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we had federal and state NOL carryforwards of approximately $134.3 million and $491.5 million, resp</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ectively. As a result of the Coronavirus Aid, Relief, and Economic Security Act of 2020 (&#8220;CARES Act&#8221;) and legislation commonly referred to as the Tax Cuts and Jobs Act of 2017 (&#8220;2017 Tax Act&#8221;), NOLs arising before January 1, 2018, and NOLs arising after January 1, 2018, are subject to different rules. Under the CARES Act and 2017 Tax Act, federal NOLs incurred in 2018, 2019 and 2020 can generally be carried back five years, carried forward indefinitely and can offset 100% of future taxable income for tax years before January 1, 2021 and up to 80% of future taxable income for tax years after December 31, 2020. Any NOLs arising on or after January 1, 2021, cannot be carried back,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> but can generally be carried forward indefinitely and can offset up to 80% of future taxable income. It is uncertain if and to what extent various states will conform to the newly enacted federal tax law. These NOL carryforwards could expire unused before offsetting potential future income tax liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under Section 382 and 383 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Code and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50 percent change, by value, in its equity ownership over a three-year period, the corporation&#8217;s ability to use its pre-change NOL carryforwards and other pre-change tax attributes to offset its post-change income or taxes may be limited. It is possible that we have experienced an ownership change limitation. We may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an ownership change occurs and our ability to use our NOL carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We could be subject to additional tax liabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S. federal, state, and local taxes in the United States and other countries. Significant judgment is required in evaluating our tax positions. During the ordinary course of business, there are many activities and transactions for which the ultimate tax determination is uncertain. In addition, our tax obligations and effective tax rates could be adversely affected by changes in the relevant tax, accounting and other laws, regulations, principles and interpretations, including those relating to income tax nexus, by recognizing tax losses or lower than anticipated earnings in jurisdictions where we have lower statutory rates and higher than anticipated earnings in jurisdictions where we have higher statutory rates, by changes in foreign currency exchange rates, or by changes in the valuation of our deferred tax assets and liabilities.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, beginning in 2022, the 2017 Tax Act eliminated the option of expensing all research and development expenditures in the current year, instead requiring amortization over five years for expenditures in the U.S. and over fifteen years for foreign-based expenditures. There is no assurance that the requirement will be deferred, repealed, or otherwise modified. This change in law increased our tax liability for the fiscal year.We continue to monitor new tax legislation or other developments since significant changes in tax legislation, or in the interpretation of existing legislation, could materially and adversely affect our financial condition and operating results.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Additionally,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> we may be audited in various jurisdictions, and such jurisdictions may assess additional taxes, sales taxes and value-added taxes against us. Although we believe our tax estimates are reasonable, the final determination of any tax audits or litigation could be materially different from our historical tax provisions and accruals, which could have a material adverse effect on our operating results or cash flows in the period for which a determination is made.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to changing regulations for corporate governance and public disclosure that has increased both our costs and the risk of noncompliance.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each year we are required to evaluate our internal controls systems in order to allow management to report on and our Independent Registered Public Accounting Firm to attest to, our internal controls as required by Section 404 of the Sarbanes-Oxley Act. As a result, we continue to incur additional expenses and divert our management&#8217;s time to comply with these regulations. In addition, if we cannot continue to comply with the requirements of Section 404 in a timely manner, we might be subject to sanctions or investigation by regulatory authorities, such as the SEC, the Public Company Accounting Oversight Board or The Nasdaq Global Select Market. Any such action could adversely affect our financial results and the market price of our common stock. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Investment and Securities</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our Board of Directors has the authority to issue shares of &#8220;blank check&#8221; preferred stock, which may make an acquisition of the Company by another company more difficult.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted and may in the future adopt certain measures that may have the effect of delaying, deferring or preventing a takeover or other change in control of the Company that a holder of our common stock might consider in its best interest. For example, our Board of Directors, without further action by our stockholders, currently has the authority to issue up to 5,000,000 shares of preferred stock and to fix the rights (including voting rights), preferences and privileges of these shares (&#8220;blank check&#8221; preferred). Such preferred stock may have rights, including economic rights, senior to our common stock. These factors could also reduce the price that certain investors might be willing to pay for shares of our common stock and result in the market price being lower than it would be without these provisions.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not intend to declare cash dividends on our common stock.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will not distribute cash to our stockholders unless and until we can develop sufficient funds from operations to meet our ongoing needs and implement our business plan. The time frame for that is unpredictable and investors should not expect dividends in the near future, if at all.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research reports about our business or if they make adverse recommendations regarding an investment in our stock, our stock price and trading volume may decline.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock can be influenced by the research and reports that industry or securities analysts publish about our business. Currently, coverage of our Company by industry and securities analysts is limited. Investors have many investment opportunities and may limit their investments to companies that receive greater coverage from analysts. If additional industry or securities analysts do not commence coverage of the Company, the trading price of our stock could be negatively impacted. If one or more of the analysts downgrade our stock or comment negatively on our prospects, our stock price may decline. If one or more of these analysts cease to cover our industry or us or fail to publish reports about the Company regularly, our common stock could lose visibility in the financial markets, which could also cause our stock price or trading volume to decline. Further, incorrect judgments, estimates or assumptions made by research analysts may adversely affect our stock price, particularly if subsequent performance falls below the levels that were projected by the research analyst(s), even if we did not set or endorse such expectations. Any of these events could cause further volatility in our stock price and could result in substantial declines in the value of our stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The market for purchases and sales of our common stock may be limited, and the sale of a limited number of shares could cause the price to fall sharply.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although our common stock is listed for trading on the Nasdaq Global Select Market, at various times our securities are relatively thinly traded. Investor trading patterns could serve to exacerbate the volatility of the price of our stock. For example, mandatory sales of our common stock by institutional holders could be triggered if an investment in our common stock no longer satisfies their investment standards and guidelines. It may be difficult to sell shares of our common stock quickly without significantly depressing the value of the stock. Unless we are successful in developing continued investor interest in our stock, sales of our stock could result in major fluctuations in the price of the stock.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our common stock price has fluctuated significantly over the last several years and may continue to do so in the future, without regard to our results of operations and prospects.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Bec</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ause we are still a clinical-stage pharmaceutical company and have not yet commercialized a drug, t</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">here are few objective metrics by which our progress may be measured. Consequently, we expect that the market price of our common stock will continue to fluctuate significantly. We may not continue to generate substantial revenue from the license or sale of our technology for several years, if at all. In the absence of product revenue as a measure of our operating performance, we anticipate that investors and market analysts will assess our performance by considering factors such as:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announcements of developments related to our business;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our ability to enter into or extend investigation phase, development phase, commercialization phase and other agreements with new and/or existing partners;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announcements regarding the status of any or all of our collaborations or products, including clinical trial results;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market perception and/or investor sentiment regarding our technology;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announcements of actions taken by regulatory authorities, such as the U.S. Food and Drug Administration;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announcements regarding developments in the RNA interference, antisense technologies, gene editing technologies or biotechnology fields in general;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Announcements regarding clinical trial results with our products or competitors&#8217; products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market perception and/or announcements regarding other companies developing products in the field of biotechnology generally or specifically RNA interference;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The issuance of competitive patents or disallowance or loss of our patent rights;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The addition or departure of key executives; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Variations in our operating results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will not have control over many of these factors but expect that they may influence our stock price. As a result, our stock price may be volatile and such volatility could result in the loss of all or part of your investment.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stockholder equity interest may be substantially diluted in any additional equity issuances.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that significant additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; and other adverse business consequences.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of business, we collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect, secure, dispose of, transmit, and share confidential, proprietary, and sensitive information, including personal information, business data, trade secrets, intellectual property, information we collect about trial participants in connection with clinical trials, sensitive third-party data, business plans, transactions, and financial information.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our data processing activities may subject us to numerous data privacy and security obligations, such as various laws, regulations, guidance, industry standards, external and internal privacy and security policies, contractual requirements, and other obligations relating to data privacy and security. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, there are state data privacy and security laws, including data breach notification laws, personal data privacy laws, consumer protection laws (e.g., Section 5 of the Federal Trade Commission Act), HIPPA, and other similar laws (e.g., wiretapping laws). For example, the California Consumer Privacy Act of 2018 (&#8220;CCPA&#8221;) applies to personal data of consumers, business representatives, and employees, and requires businesses to provide specific disclosures in privacy notices and honor requests of California residents to exercise certain privacy rights. The CCPA provides for civil penalties of up to $7,500 per violation and allows private litigants affected by certain data breaches to recover significant statutory damages. In addition, the California Privacy Rights Act of 2020 expands the CCPA&#8217;s requirements, including by adding a new right for individuals to correct their personal data and establishing a new regulatory agency to implement and enforce the law. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the United States, laws, regulations, and industry standards govern data privacy and security. For example, the GDPR imposes strict requirements for processing personal data, including health-related information. Under the GDPR, companies may face fines of up to 20 million Euros or 4% of annual global revenue, whichever is greater; or private litigation related to processing of personal data. Although there are currently various mechanisms that may be used to transfer personal data from the EEA and UK to the United States in compliance with law, such as the EEA and UK&#8217;s standard contractual clauses, these mechanisms are subject to legal challenges. Additionally, companies that transfer personal data out of the EEA and UK to other jurisdictions are subject to scrutiny from regulators, individual litigants, and activities groups.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Preparing for and complying with these obligations requires us to devote resources and may necessitate changes to our services, information technologies, systems, and practices and to those of any third parties that process personal data on our behalf. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or the third parties on which we rely fail, or are perceived to have failed, to address or comply with applicable data privacy and security obligations, we could face significant consequences, including but not limited to: government enforcement actions (e.g., investigations, fines, penalties, audits, inspections, and similar); litigation (including class-action claims); additional reporting requirements and/or oversight; bans on processing personal data; and orders to destroy or not use personal data. Any of these events could have a material adverse effect on our reputation, business, or financial condition, including but not limited to: loss of customers; inability to process personal data or to operate in certain jurisdictions; limited ability to develop or commercialize our products; expenditure of time and resources to defend any claim or inquiry; adverse publicity; or substantial changes to our business model or operations.</span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Economic and Industry Risks</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unfavorable global economic conditions, whether brought about by material global crises, health epidemics, military conflicts or war, geopolitical and trade disputes or other factors, may adversely affect our business and financial results.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is sensitive to global economic conditions, which can be adversely affected by epidemics and other public health crises (such as the COVID-19 pandemic), political and military conflict, trade and other international disputes, significant natural disasters (including as a result of climate change) or other events that disrupt macroeconomic conditions. Adverse macroeconomic conditions, including inflation, slower growth or recession, new or increased tariffs and other barriers to trade, changes to fiscal and monetary policy or government budget dynamics (particularly in the pharmaceutical and biotech areas), tighter credit, higher interest rates, volatility in financial markets, high unemployment, labor availability constraints, currency fluctuations and other challenges in the global economy have in the past adversely affected, and may in the future adversely affect, us and our business partners and suppliers.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, trade policies and geopolitical disputes (including as a result of China-Taiwan relations) and other international conflicts can result in tariffs, sanctions and other measures that restrict international trade, and can materially adversely affect our business, particularly if these measures occur in regions where we source our components or raw materials. For example, tensions between the United States and China have led to a series of tariffs being imposed by the United States on imports from China mainland, as well as other business restrictions. Tariffs increase the costs of the components and raw materials we source. Countries may also adopt other measures, such as controls on imports or exports of goods, technology or data, that could adversely impact the Company&#8217;s operations and supply chain. These geopolitical risks could also adversely affect Visirna.   </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, military conflicts or wars (such as the ongoing conflicts between Russia and Ukraine </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Israel and Palestine</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) can cause exacerbated volatility and disruptions to various aspects of the global economy. The uncertain nature, magnitude, and duration of hostilities stemming from such conflicts, including the potential effects of sanctions and counter-sanctions, or retaliatory cyber-attacks on the world economy and markets, have contributed to increased market volatility and uncertainty, which could have an adverse impact on macroeconomic factors that affect our business and operations, such as worldwide supply chain issues. Additionally, the ongoing conflict between Russia and Ukraine has impacted our business decisions with respect to potential clinical trial sites in Europe. For example, a number of our clinical trial sites we had previously planned to use in Russia, Ukraine and Belarus were shut down and we had to seek alternatives in other geographies. We cannot be certain of the overall impact of the conflict between Russia and Ukraine on our ability to conduct and complete our clinical trials as planned, and any interruptions of our clinical trials can result in significant delays or termination of the research, development or commercialization of our drug candidates, which could impair our ability to generate revenues and harm our business and financial condition. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, the conflict between Israel and Palestine could impact future business decisions to locate potential clinical trials in Israel</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. It is not possible to predict the short and long-term implications of military conflicts or wars or geopolitical tensions which could include further sanctions, uncertainty about economic and political stability, increases in inflation rate and energy prices, cyber-attacks, supply chain challenges and adverse effects on currency exchange rates and financial markets. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our operations and facilities, as well as operations of our suppliers and manufacturers, may be located in areas that are prone to earthquakes, wildfires and other natural disasters. Such operations and facilities are also subject to the risk of interruption by drought, power shortages, nuclear power plant accidents and other industrial accidents, terrorist attacks and other hostile acts, ransomware and other cybersecurity attacks, labor disputes, public health crises (including the COVID-19 pandemic), and other events beyond the Company&#8217;s control. Global climate change is resulting in certain types of natural disasters occurring more frequently or with more intense effects. Such events can create delays or interruptions to the Company&#8217;s development efforts and inefficiencies in the Company&#8217;s supply and manufacturing chain. Significant delays in our development efforts could materially impact our ability to obtain regulatory approval and to commercialize our products. Any insurance we maintain against damage to our property and the disruption of our business due to disaster may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, or at all. Further, because the Company relies on single or limited sources for the supply and manufacture of many critical components, a business interruption affecting such sources would exacerbate any negative consequences to the Company. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any public health crises, including the COVID-19 pandemic, may affect our operations and those of third parties on which we rely, including our business partners and suppliers. In the past four years, the COVID-19 pandemic has had an adverse impact on the global economy, including as a result of impacts associated with protective health measures that we, other businesses and governments are taking or might have to take again in the future to manage the pandemic.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Without limiting the foregoing, we have experienced and/or may in the future experience: </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in receiving authorization from regulatory authorities to initiate any planned clinical trials, inspections, reviews and approvals of products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays or difficulties enrolling patients in our clinical trials; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in or disruptions to the conduct of preclinical programs and clinical trials; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">constraints  on the movement of products and supplies through the supply chain, which can disrupt our ability to conduct clinical trials and develop our products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">price increases in raw materials and capital equipment, as well as increasing price competition in our markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse impacts on our workforce and/or key employees; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">increased risk that counterparties to our contractual arrangements will become insolvent or otherwise unable to fulfill their contractual obligations.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug development is time consuming, expensive and risky.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focused on technology related to new and improved pharmaceutical candidates. Product candidates that appear promising in the early phases of development, such as in animal and early human clinical trials, often fail to reach the market for a number of reasons, such as:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Clinical trial results may be unacceptable, even though preclinical trial results were promising;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Inefficacy and/or harmful side effects in humans or animals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The necessary regulatory bodies, such as the FDA, may not approve our potential product for the intended use, or at all; and/or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Manufacturing and distribution may be uneconomical.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, any positive preclinical results in animals may not be replicated in human clinical studies. These programs may be also found to be unsafe in humans, particularly at higher doses needed to achieve the desired levels of efficacy. Also, the positive safety results from single dose human clinical studies may not be replicated in other human studies, including multiple dose studies. Clinical and preclinical study results are frequently susceptible to varying interpretations by scientists, medical personnel, regulatory personnel, statisticians and others, which often delays, limits, or prevents further clinical development or regulatory approvals of potential products. Clinical trials can take many years to complete, including the process of study design, clinical site selection and the recruitment of patients. As a result, we can experience significant delays in completing clinical studies, which can increase the cost of developing a drug candidate and shorten the time that an approved product may be protected by patents. If our drug candidates are not successful in human clinical trials, we may be forced to curtail or abandon certain development programs. If we experience significant delays in commencing or completing our clinical studies, we could suffer from significant cost overruns, which could negatively affect our capital resources and our ability to complete these studies.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The healthcare system is under significant financial pressure to reduce costs, which could reduce payment and reimbursement rates for drugs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout the world and particularly in the United States, the healthcare system is under significant financial pressure to reduce costs. The price of pharmaceuticals has been a topic of considerable public discussion that could lead to price controls or other price-limiting strategies by payors that have the effect of lowering payment and reimbursement rates for drugs or otherwise making the commercialization of pharmaceuticals less profitable. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. These effects could reduce or eliminate our ability to return value to our stockholders.</span></div><div style="margin-top:6pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Regulatory standards are subject to change over time, making it difficult to accurately predict the likelihood of marketing approval even when clinical trials meet their endpoints.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory standards are promulgated by various government entities and are subject to change based on factors such as scientific developments, public perceptions of risk, and political forces. Because clinical trials often take years to complete, it is sometimes possible for standards that exist during the conception and initiation of a clinical trial to change before the clinical trial is completed or reviewed by government regulators. For example, we may initiate clinical trials that are designed to show benefits on relatively short-term endpoints, but ultimately be required to show benefits in longer-term outcome studies. While some government entities have safeguards intended to ensure standards agreed upon by sponsors and regulators at the outset of a clinical trial are applied during regulatory review processes, those safeguards generally permit regulators to apply more rigorous standards where regulators believe doing so is necessary. As such, there can be no assurance that regulatory standards that are appropriate at the outset of a clinical trial program will not become more rigorous during the regulatory approval process and could potentially result in a delayed approval or denial of marketing authorization.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55</span></div></div></div><div id="i2ac2b5b9b196490b92657e8462cd4206_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.7pt">UNRESOLVED STAFF COMMENTS</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div id="i2ac2b5b9b196490b92657e8462cd4206_25"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">PROPERTIES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2021, the Company completed a purchase of 13 acres of land in the Verona Technology Park in Verona, Wisconsin, which is being developed into an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility which will support the Company&#8217;s process development and analytical activities. Additionally, the Company entered into a lease agreement for a new 144,000 square foot laboratory and office facility in San Diego, California to support discovery activities; the rent commencement date was April 19, 2023. The following table summarizes the Company&#8217;s leased facilities as of September&#160;30, 2023.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.869%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.466%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.207%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Approximate Square Footage</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Primary Use</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease<br/>Expiration</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Lease <br/>Term (year)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pasadena, California</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">49,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate Headquarters</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.6</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Madison, Wisconsin</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research Facility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">September 2031</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.9</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">San Diego, California</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">144,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and Office Facility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 2038</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.6</span></td></tr></table></div><div id="i2ac2b5b9b196490b92657e8462cd4206_28"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">LEGAL PROCEEDINGS</span></div><div style="text-indent:27pt"><span><br/></span></div><div style="text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Legal Proceedings are set forth in the Company&#8217;s financial statement schedules in Part IV, Item 15 of this Annual Report and are incorporated herein by reference. See Note 7 &#8212; Commitments and Contingencies of Notes to Consolidated Financial Statements of Part IV, &#8220;Item 15. Exhibits and Financial Statement Schedules.&#8221;</span></div><div id="i2ac2b5b9b196490b92657e8462cd4206_31"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">56</span></div></div></div><div id="i2ac2b5b9b196490b92657e8462cd4206_34"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i2ac2b5b9b196490b92657e8462cd4206_37"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Market Information</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares of the Company&#8217;s common stock are traded on The Nasdaq Global Select Market under the symbol &#8220;ARWR.&#8221; There were 97 holders of record of the Company&#8217;s common stock as of November&#160;20, 2023.  </span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Dividends </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has never paid dividends on its common stock and does not anticipate that it will do so in the foreseeable future. </span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Repurchases of Equity Securities </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="margin-top:18pt;padding-left:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Graph</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following performance graph shall not be deemed &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933 or Securities Exchange Act of 1934, each as amended, except to the extent that we specifically incorporate it by reference into such filing. The graph compares the cumulative 5-year total return to stockholders on the Company&#8217;s common stock relative to the cumulative total returns of the Nasdaq Composite Index and the Nasdaq Biotechnology Index. The Company selected the Nasdaq Biotechnology Index because it believes the index reflects the market conditions within the industry in which the Company primarily operates. The comparison of total return on investment, defined as the change in year-end stock price plus reinvested dividends, for each of the periods assumes that $100 was invested on September 30, 2018, in each of the Company&#8217;s common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index, with investment weighted on the basis of market capitalization.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The comparisons in the following graph are based on historical data and are not intended to forecast the possible future performance of the Company&#8217;s common stock.</span></div><div style="margin-top:12pt;text-align:center"><img src="arwr-20230930_g5.jpg" alt="1843" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:613px"/></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"></td><td style="width:18.498%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.856%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.864%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$100 investment in stock or index</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ticker</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2018</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2019</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Arrowhead Pharmaceuticals, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">ARWR</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">147.00&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">224.62&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">325.67&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">172.40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">140.17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NASDAQ Biotechnology Index</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#94;NBI</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">81.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">110.98&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">132.58&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">98.23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">103.08&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NASDAQ Composite Index</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#94;IXIC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">100.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">99.42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">138.79&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">179.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">131.43&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">164.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i2ac2b5b9b196490b92657e8462cd4206_40"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6.               RESERVED</span></div><div id="i2ac2b5b9b196490b92657e8462cd4206_43"></div><div style="margin-top:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div id="i2ac2b5b9b196490b92657e8462cd4206_46"></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">OVERVIEW</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#8217;s therapies trigger the RNAi interference mechanism to induce rapid, deep and durable knockdown of target genes. RNAi is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has focused its resources on therapeutics that exclusively utilize its high levels of pharmacologic activity in multiple animal models spanning several therapeutic areas. The Company believes that TRiM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> enabled therapeutics offer several potential advantages over prior generation and competing technologies, including: simplified manufacturing and reduced costs; multiple routes of administration including subcutaneous injection and inhaled administration; the ability to target multiple tissue types including liver, lung, CNS, muscle, and adipose tissue; and the potential for improved safety and reduced risk of intracellular buildup, because there are fewer metabolites from smaller, simpler molecules. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s pipeline includes:</span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Hypertriglyceridemia - Plozasiran (formerly ARO-APOC3)</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Dyslipidemia - Zodasiran (formerly ARO-ANG3)</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Cardiovascular disease - olpasiran (formerly AMG 890 or ARO-LPA, out-licensed to Amgen) </span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Muco-obstructive or inflammatory pulmonary conditions - ARO-MUC5AC and ARO-RAGE</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Idiopathic pulmonary fibrosis - ARO-MMP7</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Non-alcoholic steatohepatitis (NASH) - GSK-4532990 (formerly ARO-HSD, out-licensed to GSK)</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Alpha-1 antitrypsin deficiency (AATD) - fazirsiran (formerly ARO-AAT, a collaboration with Takeda)</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Chronic hepatitis B virus - JNJ-3989 (formerly ARO-HBV, out-licensed to Janssen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) </span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Uncontrolled gout - HZN-457 (formerly ARO-XDH, out-licensed to Horizon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">)</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Complement mediated diseases - ARO-C3</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Non-alcoholic steatohepatitis (NASH) - ARO-PNPLA3 (formerly JNJ-75220795 or ARO-JNJ1)</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Facioscapulohumeral muscular dystrophy - ARO-DUX4</span></div><div style="padding-left:36pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.5pt">Amyotrophic lateral sclerosis &#8220;ALS&#8221; (CNS) - ARO-SOD1 </span></div><div style="margin-top:3pt;padding-left:72pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(1) On October 30, 2023, the Company entered into an Assignment and Consent Agreement with Janssen, whereby, the Company consented to the assignment of the Janssen License Agreement to GSK, which assignment shall be effective upon the receipt of certain anti-trust approvals.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:36pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(2) On October 6, 2023, Amgen announced that it has completed its acquisition of Horizon.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates lab facilities in San Diego, California and Madison, Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company&#8217;s principal executive offices are located in Pasadena, California.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continues to develop other clinical candidates for future clinical trials. Clinical candidates are tested internally and through GLP toxicology studies at outside laboratories. Drug materials for such studies and clinical trials are either manufactured internally or contracted to third-party manufacturers. The Company engages third-party contract research organizations to manage clinical trials and works cooperatively with such organizations on all aspects of clinical trial management, including plan design, patient recruiting, and follow up. These outside costs, relating to the preparation for and administration of clinical trials, are referred to as &#8220;candidate costs.&#8221; As clinical candidates progress through clinical development, candidate costs will increase.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2023 Business Highlights</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During fiscal year 2023, the Company continued to develop and advance its pipeline and partnered candidates and expanded its facilities to support its growing programs. The bullets below highlight some of these key developments; however, this list is not all-inclusive and is meant to be read in conjunction with the entirety of management&#8217;s discussion and analysis, the Company&#8217;s Consolidated Financial Statements and notes thereto, and all other items contained within this Annual Report on Form 10-K.</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">presented data on Company&#8217;s pulmonary pipeline at the European Respiratory Society (ERS) International Congress 2023 in Milan, Italy in September 2023, which included:</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">in an ongoing Phase 1/2 clinical trial, ARO-RAGE achieved mean target gene knockdown of up to 90% with a maximum of 95% after a single inhaled administration;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">the TRiM&#8482; platform can achieve compelling results across multiple additional gene targets in the lung, including MUC5AC, MMP7, and the Company&#8217;s newest program against thymic stromal lymphopoietin (TSLP), a clinically well validated target;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">filed an application for clearance to initiate a Phase 1/2 clinical trial of ARO-DUX4 in July 2023, which is being developed as a potential treatment for patients with facioscapulohumeral muscular dystrophy (FSHD);</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">hosted a Research &amp; Development (&#8220;R&amp;D&#8221;) Day on June 1, 2023 to discuss progress of the Company&#8217;s pipeline of RNAi Therapeutics, at which the following updates were discussed: </span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">ARO-RAGE showed continued dose response with single inhaled dose of 184 mg achieving mean knockdown of 90% and max of 95%;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">adipose delivery platform achieved single dose target gene silencing of greater than 90% with six months of duration in non-human primates;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">improved hepatic dimer platform achieved equivalent or better knockdown of two target genes with longer duration than monomer mixture in non-human primates;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">TRiM&#8482; platform now has potential to address multiple cell types including liver, solid tumors, lung, central nervous system, skeletal muscle, and adipose;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">announced progress towards the Company's &#8220;20 in 25&#8221; goal to grow its pipeline of RNAi therapeutics that leverage the proprietary Targeted RNAi Molecule (TRiM&#8482;) platform to a total of 20 clinical stage or marketed products in the year 2025;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">presented updated data from the Phase 2 SEQUOIA study of investigational RNAi therapy fazirsiran in patients with alpha-1 antitrypsin deficiency liver disease which included:</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">fazirsiran reduced serum Z-AAT concentration in a dose-dependent manner;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">fazirsiran significantly reduced liver Z-AAT; median reductions of 94% of Z-AAT accumulation in the liver;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">fazirsiran consistently reduced hepatic globule burden; mean reductions of 68% in histologic globule burden were observed;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">fazirsiran treatment reduced histological signs of hepatic inflammation;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">50% of the pooled fazirsiran treated patients showed at least a one-point improvement in METAVIR liver fibrosis versus 38% in the placebo group;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">fazirsiran has been well tolerated to date; treatment emergent adverse events were generally well balanced between fazirsiran and placebo group;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">pulmonary function test results (FEV1 and DLCO) for both fazirsiran and placebo were stable over time with no apparent dose-dependent effects;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">updated Phase 2 clinical data were presented at the European Association for the Study of the Liver (EASL) Congress 2023 in an oral presentation titled, &#8220;Fazirsiran reduces liver Z-alpha-1 antitrypsin synthesis, decreases globule burden and improves histological measures of liver disease in adults with alpha-1 antitrypsin deficiency: a randomized placebo-controlled phase 2 study&#8221;;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">results were consistent with AROAAT-2002 open-label study previously published in The New England Journal of Medicine;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">presented interim data from the ongoing Phase 2 GATEWAY clinical study of ARO-ANG3 which included:</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">mean reduction in LDL-C of 48.1% (200mg) and 44.0% (300mg);</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">ANPTL3 inhibition with ARO-ANG3 also reduced HDL-C, non-HDL-C, and triglycerides, consistent with published human genetic data;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">safety and tolerability;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">completed enrollment of the Phase 3 PALISADE clinical trial evaluating ARO-APOC3 for treatment of familial chylomicronemia syndrome;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">announced interim results from ARO-RAGE administration in Part 1 of the ongoing Phase 1/2 study in normal healthy volunteers which included:</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">reductions in soluble RAGE (sRAGE) as measured in serum after two doses on Day 1 and Day 29;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">duration of pharmacologic effect persisted for at least 6 weeks after the second administration of the 92 mg does with further follow up ongoing;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">reduction in sRAGE as measured in bronchoalveolar lavage fluid (BALF) at Day 31 after a single dose;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">reduction in in serum sRAGE was observed after a single dose;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">the pooled placebo groups experienced a mean sRAGE increase of 8% in BALF and a mean decrease of 1% serum;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">safety and tolerability;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">expanded TRiM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform to include an optimized intrathecal administration for CNS delivery with distribution throughout the brain and in all relevant brain cell types. The first development candidate to utilize this new delivery platform is ARO-SOD1. In June 2023, the Company filed a CTA for approval to initiate a Phase 1 clinical study. In preclinical studies, ARO-SOD1 achieved 95% spinal cord tissue mRNA knockdown after a single intrathecal dose in human SOD1 transgenic rats and maintained greater than 80% spinal cord tissue mRNA knockdown three months after a single intrathecal dose in non-human primates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">dosed the first patient in Takeda&#8217;s Phase 3 REDWOOD clinical study of fazirsiran for the treatment of alpha-1 antitrypsin deficiency associated liver diseases, triggering a $40.0&#160;million milestone payment to the Company which was paid in the third quarter of fiscal 2023;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">dosed the first patient in GSK&#8217;s Phase 2b trial of GSK4532990, an investigational RNAi therapeutic for the treatment of patients with non-alcoholic steatohepatitis (NASH), triggering a $30.0&#160;million milestone payment to the Company which was paid in the third quarter of fiscal 2023;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">announced that the FDA has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome (FCS). ARO-APOC3 was previously granted Orphan Drug designation by the FDA and the European Union;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">announced interim results from Part 1 of AROC3-1001, an ongoing Phase 1/2 clinical study of ARO-C3, which included:</span></div><div style="margin-top:6pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">a dose-dependent reduction in serum C3, with 88% mean reduction at highest dose tested;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">a dose-dependent reduction in AH50, a marker of alternative complement pathway hemolytic activity, with 91% mean reduction at highest dose tested;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">duration of pharmacologic effect supportive of quarterly or less frequent subcutaneous dose administration;</span></div><div style="margin-top:3pt;padding-left:90pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">safety and tolerability;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">initiated dosing in ARO-MMP7-1001 (NCT05537025), a Phase 1/2a single ascending dose and multiple ascending dose clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-MMP7, an investigational RNAi therapeutic designed to reduce expression of matrix metalloproteinase 7 (MMP7) as a potential treatment for idiopathic pulmonary fibrosis (IPF), in up to 56 healthy volunteers and in up to 21 patients with IPF;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">enrolled the first subject in a Phase 1 randomized, placebo-controlled trial to assess the safety tolerability, pharmacokinetics and pharmacodynamics of a development-stage medicine, HZN-457, which is out-licensed to Horizon, triggering a $15.0 million milestone payment to the Company which was paid in the second quarter of fiscal 2023;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">enrolled the first subject in Amgen&#8217;s Phase 3 trial of olpasiran, which triggered a $25.0 million milestone payment to the Company, which was paid in the second quarter of fiscal 2023;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10pt">entered into the Royalty Pharma Agreement on November 9, 2022, pursuant to which Royalty Pharma paid $250.0 million upfront (See Note 11 &#8212; Liability Related to the Sale of Future Royalties of Notes to Consolidated Financial Statements of Part I, &#8220;Item 1. Financial Statements.&#8221;)</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2023 Financial Performance Summary</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net loss attributable to Arrowhead Pharmaceuticals, Inc. was $205.3 million for the year ended September&#160;30, 2023 as compared to $176.1 million for the year ended September&#160;30, 2022. Net loss per share &#8211; diluted was $1.92 for the year ended September&#160;30, 2023 as compared to $1.67 for the year ended September&#160;30, 2022. The change in net loss for the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">year ended September&#160;30, 2023 reflected an increase in research and development expenses, which have continued to increase as the Company&#8217;s pipeline of candidates has expanded and progressed through clinical trial phases.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $110.9 million of cash, cash equivalents and restricted cash, $292.7 million in available-for-sale securities and $765.6 million of total assets as of September&#160;30, 2023, as compared to $108.0 million of cash, cash equivalents and restricted cash, $374.3 million in held-to-maturities debt securities, and $691.9 million of total assets as of September&#160;30, 2022. Based upon the Company&#8217;s current cash and investment resources and operating plan, the Company expects to have sufficient liquidity to fund operations for at least the next twelve months. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Critical Accounting Estimates </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management makes certain judgments and uses certain estimates and assumptions when applying U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) in the preparation of the Company&#8217;s Consolidated Financial Statements. On an ongoing basis, the Company evaluates its estimates, judgments and assumptions. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results may vary from what the Company anticipates and different assumptions or estimates about the future could change its reported results. The Company believes the following accounting policies are the most critical to it, in that they require its most difficult, subjective or complex judgments in the preparation of the Company&#8217;s Consolidated Financial Statements. For further information, see Note 1, Organization and Significant Accounting Policies of the Notes to the Company&#8217;s Consolidated Financial Statements in Part IV, &#8220;Item 15. Exhibits and Financial Statement Schedules.&#8221; </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company has adopted Financial Accounting Standards Board (&#8220;FASB&#8221;) Topic 606 &#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue for Contracts from Customers. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has not yet achieved commercial sales of its drug candidates to date, however, this standard is applicable to its licensing and collaboration agreements. This is discussed further in Note 2, Collaboration and License Agreements of the Notes to the Company&#8217;s Consolidated Financial Statements in Part IV, &#8220;Item 15. Exhibits and Financial Statement Schedules.&#8221;</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that it determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing. If the license is not considered to be distinct from other performance obligations, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time. If the performance obligation is satisfied over time, the Company then determines the appropriate method of measuring progress for purposes of recognizing revenue from license payments. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, the Company&#8217;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a CTA or a NDA in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas. The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most-likely-amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in the Company&#8217;s consolidated statements of operations and comprehensive loss. Typically, milestone payments and royalties are achieved after the Company&#8217;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or preclinical program. Milestones or royalties achieved after the Company&#8217;s </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its licensing or collaboration agreements. Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment. Additionally, future royalty payments are not substantially within the control of the Company or the customer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whenever we determine that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using the input method. Labor hours, costs incurred or patient visits in clinical trials are typically used as the measure of performance. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations. If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on the Company&#8217;s consolidated balance sheets. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards, and therefore an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of FASB Topic 808&#8212;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative arrangement based on the nature of each activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to research and development expense or general and administrative expense, as appropriate. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;The Company classifies each of its leases as operating or financing considering factors such as the length of the lease term, the present value of the lease payments, the nature of the asset being leased, and the potential for ownership of the asset to transfer during the lease term. Leases with terms greater than one-year are recognized on the Company&#8217;s consolidated balance sheets as right-of-use assets that represent its right to use an underlying asset for the lease term, and lease liabilities that represent its obligation to make lease payments arising from the lease. Lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the expected lease term. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize fixed lease payments on a straight-line basis over the expected lease term. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">63</span></div></div></div><div id="i2ac2b5b9b196490b92657e8462cd4206_49"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RESULTS OF OPERATIONS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following data summarizes the Company&#8217;s results of operations for the following periods indicated: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.005%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240,735&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243,231&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,287&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(205,002)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(178,507)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(149,036)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(205,275)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(176,063)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(140,848)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share (diluted) attributable to Arrowhead Pharmaceuticals, Inc.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.92)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.67)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.36)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div id="i2ac2b5b9b196490b92657e8462cd4206_52"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended September 30, 2023 Compared to Year Ended September 30, 2022</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revenue</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenue for the year ended September&#160;30, 2023 decreased slightly to $240.7 million, 1.0% from the same period of 2022. The revenue is mainly associated with GSK, Horizon, Takeda and Amgen license agreements, as discussed below. The Company has evaluated each agreement in accordance with FASB Topic 808&#8211;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Topic 606-</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue for Contracts from Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. See Note 2 &#8212; Collaboration and License Agreements of the Notes to Consolidated Financial Statements of Part IV, &#8220;Item 15. Exhibits and Financial Statement Schedules.&#8221;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GSK</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the GSK License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibility to complete the Phase 1/2 study (the &#8220;GSK R&amp;D Services&#8221;). Due to the specialized and unique nature of the GSK R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $120.0 million, including the upfront payment, which was collected in January 2022. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company has allocated the total $120.0 million initial transaction price to its one distinct performance obligation for the GSK-4532990 license and the associated GSK R&amp;D Services. As the Company has completed its performance obligation related to this agreement, the upfront payment of $120.0 million was fully recognized in the year ended September&#160;30, 2022. Further, GSK dosed the first patient in a Phase 2b trial in March 2023, triggering a $30.0 million milestone payment to the Company which was paid in the third quarter of fiscal 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also performed certain development and manufacturing activities, including drug substance and drug product manufacture under GMP conditions, for GSK pursuant to the GSK License Agreement, for which the Company has been reimbursed for its costs. The Company recognized $0.3&#160;million and $4.8&#160;million in connection with these efforts for the years ended September&#160;30, 2023 and 2022, respectively. </span><span style="color:#3051f2;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Horizon </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibilities to conduct all activities through the preclinical stages of development of HZN-457 (the &#8220;Horizon R&amp;D Services&#8221;). Due to the specialized and unique nature of these Horizon R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $40.0 million, including the upfront payment, which was collected in July 2021. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company allocated the total $40.0 million initial transaction price to its one distinct performance obligation for the HZN-457 license and the associated Horizon R&amp;D Services. Further, Horizon enrolled the first subject in December 2022 in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pharmacodynamics of HZN-457, triggering a $15.0 million milestone payment to the Company which was paid in the second quarter of fiscal 2023.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has performed certain development and manufacturing activities, including drug substance and drug product manufacture under GMP conditions, for Horizon pursuant to the Horizon License Agreement. The Company recognized $1.5&#160;million and $2.5&#160;million in connection with these efforts for the years ended September&#160;30, 2023 and 2022, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Takeda License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of fazirsiran drug product is completed and delivered to Takeda (the &#8220;Takeda R&amp;D Services&#8221;). Due to the specialized and unique nature of these Takeda R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. Beyond the Takeda R&amp;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States. Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50/50 profit sharing</span><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> structure within the United States. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Takeda License Agreement, the Company received $300.0 million as an upfront payment in January 2021 and an additional $40.0 million upon Takeda&#8217;s initiation of a Phase 3 REDWOOD clinical study of fazirsiran in March 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has allocated the total $300.0 million initial transaction price to its one distinct performance obligation for the fazirsiran license and the associated Takeda R&amp;D Services. Revenue is recognized using the input method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). The Company previously expected these clinical trials to extend to September 2025 in order to demonstrate long term safety and efficacy in the open label extension (OLE) part of the studies; however, in August 2023, Takeda initiated a Phase 3 OLE study available to patients participating in these Phase 2 studies. Based on this new information, patients enrolled in the SEQUOIA and AROAAT2002 studies are expected to complete their Phase 2 study visits between June 2023 and December 2023, shortening the Company&#8217;s performance obligation. As a result, effective the second quarter of fiscal 2023, the Company changed its estimates of the revenue recognition to better reflect this newly estimated performance period. The effect of these changes in estimates resulted in accelerated revenue by $70.5&#160;million, or $0.66 per share (diluted) for the year ended September&#160;30, 2023.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#242424;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amgen</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Olpasiran Agreement, the Company has received $35.0&#160;million in upfront payments and $21.5&#160;million in the form of an equity investment by Amgen in the Company&#8217;s common stock. Further, the Company received an additional $55.0 million in milestone payments; $10.0 million upon Amgen&#8217;s initiation of a Phase 1 study in September 2018, $20.0 million upon its initiation of a Phase 2 clinical study in July 2020, and $25.0 million upon its first subject enrollment in a Phase 3 trial in December 2022. The Company has substantially completed its performance obligations under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, Royalty Pharma and the Company entered into the Royalty Pharma Agreement. In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive up to an additional $535.0 million in remaining development, regulatory and sales milestone payments payable from Amgen and Royalty Pharma. See Note 13 &#8212; Liability Related to the Sale of Future Royalties of Notes to Consolidated Financial Statements of Part IV, &#8220;Item 15. Exhibits and Financial Statement Schedules.&#8221;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">65</span></div></div></div><div id="i2ac2b5b9b196490b92657e8462cd4206_55"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The analysis below details the operating expenses and discusses the expenditures of the Company within the major expense categories. For purposes of comparison, the amounts for the years ended September&#160;30, 2023 and 2022 are shown in the tables below. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development (R&amp;D) Expenses</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses are related to the Company&#8217;s research and development discovery efforts and related candidate costs, which are comprised primarily of outsourced costs related to the manufacturing of clinical supplies, toxicity/efficacy studies and clinical trial expenses. Internal costs primarily relate to discovery operations at the Company&#8217;s research facilities in San Diego, California and Madison, Wisconsin, including facility costs and laboratory-related expenses. The Company does not separately track R&amp;D expenses by individual research and development projects, or by individual drug candidates. The Company operates in a cross-functional manner across projects and does not separately allocate facilities-related costs, candidate costs, discovery costs, compensation expenses, depreciation and amortization expenses, and other expenses related to research and development activities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details of research and development expenses:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.580%"></td><td style="width:0.1%"></td></tr><tr style="height:27pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Months</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September&#160;30, 2023</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of<br/>Expense<br/>Category </span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Months</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September&#160;30, 2022</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of<br/>Expense<br/>Category </span></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease) </span></td></tr><tr style="height:18pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Candidate costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">136,904&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,532&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">R&amp;D discovery costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">54,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,263&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salaries</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Facilities related</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,948&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development expense, excluding non-cash expense</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">307,980&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">256,129&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,851&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,332&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,371&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,961&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,876&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">353,188&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">297,307&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">55,881&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Candidate costs increased $4.5 million, or 3%, for the year ended September&#160;30, 2023 compared to the same period of 2022. This increase was primarily due to the additional progression of the Company&#8217;s pipeline of candidates into and through clinical trials, which resulted in higher outsourced clinical trial, toxicity study and manufacturing costs.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D discovery costs increased $22.3 million, or 41%, for the year ended September&#160;30, 2023 compared to the same period of 2022. This increase was due to the growth of the Company&#8217;s discovery efforts and continued advancement into novel therapeutic areas and tissue types. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salaries and stock compensation expense consist of salary, bonuses, payroll taxes, related benefits and stock compensation for the Company&#8217;s R&amp;D personnel. The increases in salaries and stock comp expenses for 2023 were primarily due to an increase in R&amp;D headcount that has occurred as the Company has expanded its pipeline of candidates, in addition to annual salary increases. Stock compensation expense was based upon the valuation of stock options and restricted stock units granted to employees. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities-related expense primarily includes lease costs for the Company&#8217;s research and development facilities in San Diego, California and Madison, Wisconsin. Facilities-related costs increased $3.3 million, or 26%, for the year ended September&#160;30, 2023 compared to the same period of 2022. This increase was mainly due to the additional lease expense as the Company expands discovery efforts to identify new drug candidates. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense, a non-cash expense, relates to depreciation on lab equipment and leasehold improvements at the facilities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company anticipates these R&amp;D expenses to continue to increase as its pipeline of candidates grows and progresses to later phase clinical trials, in addition to inflationary pressure on goods and services and the labor market. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General &amp; Administrative Expenses</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides details of general and administrative expenses: </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.580%"></td><td style="width:0.1%"></td></tr><tr style="height:32pt"><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(in thousands)</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Months</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September&#160;30, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of<br/>Expense<br/>Category </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Twelve</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Months</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ended</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September&#160;30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of<br/>Expense<br/>Category</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Increase (Decrease) </span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ </span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Salaries</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,999&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16,646&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,353&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Professional, outside services, and other</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Facilities related</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,415&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,912&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">503&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total general &amp; administrative expense, excluding non-cash expense</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47,134&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,296&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,838&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">43,798&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">88,521&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(44,723)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(51)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation/amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,617&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total general &amp; administrative expense</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">92,549&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,431&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,882)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Salaries expense increased $6.4 million, or 38%, for the year ended September&#160;30, 2023 compared to the same period of 2022. The increase was driven by the combination of annual salary increases and increased headcount required to support the Company&#8217;s growth.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Professional, outside services, and other expense includes legal, consulting, patent expenses, business insurance expenses, other outside services, travel, and communication and technology expenses. This expense increased $6.0 million, or 41%, for the year ended September&#160;30, 2023 compared to the same period of 2022. The increase was mainly due to the cost associated with consulting services focused on the preparation of commercialization activities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Facilities related expense primarily includes rental costs and other facilities-related costs for the Company&#8217;s corporate headquarters in Pasadena, California. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock compensation expense, a non-cash expense, decreased by $44.7 million, or 51%, for the year ended September&#160;30, 2023 compared to the same period of 2022. The decrease was mainly due to the lower amount of recognized compensation costs and the reversal of recognized compensation costs related to a performance award where the minimum performance goal was not met. The fair value of market condition-based awards was expensed ratably over the service period and was not adjusted for actual achievement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense, a noncash expense, was primarily related to amortization of leasehold improvements for the Company&#8217;s corporate headquarters. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than with respect to the stock compensation costs described above, the Company anticipates these general and administrative expenses to continue to increase as its pipeline of candidates grows and progresses to later phase clinical trials, in addition to inflationary pressure on goods and services and the labor market. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Income (Expense)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income (expense) is primarily related to interest income and expense. Other expense was $1.5 million for the year ended September&#160;30, 2023 compared to other income of $5.8 million for the year ended September&#160;30, 2022. The change was primarily due to the interest expense on the liability related to the sale of future royalties, partially offset by higher yields on investments due to increased interest rates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Year Ended September 30, 2022 Compared to Year Ended September 30, 2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of the Company&#8217;s Form 10-K for the year ended September&#160;30, 2022 for a discussion of changes in its results of operations from the year ended September&#160;30, 2022 to the year ended September&#160;30, 2021.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">67</span></div></div></div><div id="i2ac2b5b9b196490b92657e8462cd4206_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has historically financed its operations through the sale of its equity securities, revenue from its licensing and collaboration agreements, and the sale of certain future royalties. Research and development activities have required significant capital investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure as the Company&#8217;s pipeline continues to expand and matures into later stage clinical trials. Additionally, the Company expanded its facilities in Verona, Wisconsin and commenced the lease agreement for additional facilities in San Diego, California. These expansions are designed to increase the Company&#8217;s internal manufacturing and discovery capabilities, and the ongoing expansion in Verona, Wisconsin continues to require capital investment. For further information on our capital needs, see the section titled &#8220;Risks Related to Our Financial Condition&#8221; in &#8220;Item 1A. Risk Factors&#8221; of this Annual Report on Form 10-K.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash, cash equivalents and restricted cash slightly increased to $110.9 million at September&#160;30, 2023 compared to $108.0 million at September&#160;30, 2022. Cash invested in available-for-sale debt securities was $292.7 million at September&#160;30, 2023 compared to held-to-maturity debt securities of $374.3 million at September&#160;30, 2022. In April 2022, the Company sold all of its investments in mutual funds for $122.3 million.  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September&#160;30, 2023, the Company changed the classification of its investment securities from held-to-maturity to available-for-sale. This change enables the Company to sell securities to diversify its portfolio, reduce exposure to market risks, and provide flexibility to meet cash flow needs and new investment opportunities. </span></div><div style="margin-bottom:12pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 2, 2022, the Company entered into the Open Market Sale Agreement (See Note 6 &#8212; Stockholders&#8217; Equity to Consolidated Financial Statements of Part I, &#8220;Item 1. Financial Statements&#8221;), pursuant to which the Company may, from time to time, sell up to $250.0 million in shares of the Company&#8217;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering. As of September&#160;30, 2023, no shares have been issued under the Open Market Sale Agreement. The Company believes its current financial resources are sufficient to fund its operations through at least the next twelve months. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of cash flows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30, </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash Flow from:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(153,890)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(136,131)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,312&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96,155)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,417)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(141,678)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">253,053&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">65,186&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,305&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,008&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(76,362)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">108,005&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">184,434&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended September&#160;30, 2023, cash flow used by operating activities was $153.9 million, which was primarily due to the ongoing expenses related to the Company&#8217;s research and development programs and general and administrative expenses, partially offset by the receipt of the $110.0 million from collaboration and license agreements (See Note 2 &#8212; Collaboration and License Agreements of Notes to Consolidated Financial Statements of Part IV, &#8220;Item 15. Exhibits and Financial Statement Schedules.&#8221;). Cash used in investing activities was $96.2 million, which was primarily related to the purchase of property and equipment of $176.7 million, offset by net proceeds of $80.6 million from maturities of securities. Cash provided by financing activities of $253.1 million was primarily related to the $250.0 million payment from Royalty Pharma as well as cash received from stock option exercises (See Note 13 &#8212; Liability Related to the Sale of Future Royalties of Notes to Consolidated Financial Statements of Part IV, &#8220;Item 15. Exhibits and Financial Statement Schedules.&#8221;). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended September&#160;30, 2022, cash flow used by operating activities was $136.1 million, which was primarily due to the ongoing expenses related to the Company&#8217;s research and development programs and general and administrative expenses, partially offset by the receipt of the $120.0 million upfront payment from GSK. Cash used in investing activities was $5.4 million, which was primarily related to the purchase of property and equipment of $52.8 million, offset by net proceeds from maturities of investments of $47.4 million. Cash provided by financing activities of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$65.2 million was primarily related to the formation of the Company&#8217;s joint venture, Visirna, as well as cash received from stock option exercises. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2021, the Company completed a purchase of 13 acres of land in the Verona Technology Park in Verona, Wisconsin, which is being developed into an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility which will support the Company&#8217;s process development and analytical activities. The Company is now occupying the laboratory and office facility, but construction of the manufacturing facility is still ongoing. As of September&#160;30, 2023, the Company has incurred $166.2 million and intends to spend an additional $120.0 million to $130.0 million to complete the build out of the facilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of this land acquisition, the Company entered into a development agreement with the City of Verona to construct certain infrastructure improvements within the tax increment district and will be reimbursed up to $16.0&#160;million by the City of Verona by future tax increment revenue generated from the developed property. The total amount of funding that City of Verona will pay under the Tax Increment Financing program is not guaranteed and will depend on future tax revenues generated from the developed property</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also became eligible to receive up to $2.5&#160;million in refundable Wisconsin state income tax credits from the Wisconsin Economic Development Corporation (WEDC) as incentives for investing in the local community and creating new job opportunities. As of September&#160;30, 2023, the Company has collected $1.5 million of these credits. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; of the Company&#8217;s Form 10-K for the year ended September&#160;30, 2022 for a discussion of cash flows from the year ended September&#160;30, 2021.</span></div><div id="i2ac2b5b9b196490b92657e8462cd4206_61"></div><div style="margin-top:12pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Contractual Obligations</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information related to the Company&#8217;s future commitments for its facility-related obligations and collaboration and licensing agreements, see Notes 8 and 2, respectively, of Notes to the Company&#8217;s Consolidated Financial Statements of Part IV, &#8220;Item 15. Exhibits and Financial Statement Schedules.&#8221; Commitments related to the Company&#8217;s clinical, manufacturing and business operation related agreements are $579.7 million as of September&#160;30, 2023, but many of these agreements are cancellable. </span></div><div id="i2ac2b5b9b196490b92657e8462cd4206_64"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 7A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.14pt">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to market risk exposures primarily due to its investing activities. The primary market risk exposure is change in interest rates. Adverse changes to rates may occur due to changes in the liquidity of a market or to changes in market perceptions of creditworthiness and risk tolerance. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not hold any instruments for trading purposes and investment criteria are governed by its Investment Policy. As of September&#160;30, 2023 and 2022, the Company had cash, cash equivalents, and restricted cash of $110.9 million and $108.0 million, respectively, and investments of $292.7 million and $374.3 million, respectively. The Company has invested its cash reserves in corporate bonds typically with maturities of less than 3 years and historically classified these investments as held-to-maturity. On September&#160;30, 2023, the Company changed the classification of its investment securities from held-to-maturity to available-for-sale. This change enables the Company to sell securities to diversify its portfolio, reduce exposure to market risks, and provide flexibility to meet cash flow needs and new investment opportunities.  Due to the relatively short-term nature of the investments that the Company holds, it does not believe that the results of operations or cash flows would be affected to any significant degree by a sudden change in market interest rates relative to its investment portfolio.</span></div><div id="i2ac2b5b9b196490b92657e8462cd4206_67"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this item is included in Item 15 of this Annual Report on Form 10-K. </span></div><div id="i2ac2b5b9b196490b92657e8462cd4206_70"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:35.36pt">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">69</span></div></div></div><div id="i2ac2b5b9b196490b92657e8462cd4206_73"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.14pt">CONTROLS AND PROCEDURES</span></div><div style="margin-top:12pt;text-indent:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains disclosure controls and procedures designed to ensure that information required to be disclosed in its reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to its management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily was required to apply its judgment in evaluating the cost benefit relationship of possible controls and procedures.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by Rule 13a-15(b) of the Exchange Act, the Company carried out an evaluation, under the supervision and with the participation of its management, including its Chief Executive Officer and Chief Financial Officer, of the effectiveness of the design and operation of the Company&#8217;s disclosure controls and procedures as of the end of the period covered by this Annual Report on Form 10-K. Based on the foregoing, the Company&#8217;s Chief Executive Officer and Chief Financial Officer concluded that the Company&#8217;s disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act. The Company&#8217;s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of its Consolidated Financial Statements for external purposes in accordance with GAAP. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This process includes those policies and procedures that:</span></div><div style="margin-top:6pt;padding-left:40.5pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the Company&#8217;s assets; </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with GAAP, and that receipts and expenditures are being made only in accordance with authorizations of the Company&#8217;s management and directors; and </span></div><div style="margin-top:6pt;padding-left:40.5pt;text-align:justify;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s assets that could have a material effect on the Company&#8217;s financial statements.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of the internal control over financial reporting to future periods are subject to risk that controls may become inadequate because either conditions change or the degree of compliance with policies or procedures may deteriorate.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management has assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of September&#160;30, 2023. In making this assessment, the Company used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control-Integrated Framework (2013). Based on this assessment, management concluded that the Company&#8217;s internal control over financial reporting was effective as of September&#160;30, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rose, Snyder and Jacobs LLP, the independent registered public accounting firm that audited the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Financial Statements</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> included in this 2023 Annual Report on Form 10-K, has issued an audit report on the effectiveness of the Company&#8217;s internal control over financial reporting as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September&#160;30, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which is included herein.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been no change in the Company&#8217;s internal control over financial reporting during the Company&#8217;s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. The Company&#8217;s process for evaluating controls and procedures is continuous and encompasses consistent improvement of the design and effectiveness of established controls and procedures and the remediation of any deficiencies which may be identified during this process.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70</span></div></div></div><div id="i2ac2b5b9b196490b92657e8462cd4206_76"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.7pt">OTHER INFORMATION</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(b) <ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-37"><ix:nonNumeric contextRef="c-1" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-38">Trading Plans</ix:nonNumeric></ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="ecd:MtrlTermsOfTrdArrTextBlock" id="f-39" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended September&#160;30, 2023, the following directors and officers (as defined in Exchange Act Rule 16a-1(f)) adopted certain trading plans intended to satisfy Rule 10b5-1(c):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"></td><td style="width:14.014%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.373%"></td><td style="width:0.1%"></td></tr><tr style="height:28pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Adoption or Termination Date</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Plan Start Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Plan End Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares Vesting and Subject to Sell-To-Cover </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:114%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Other Shares Being Sold (Subject to Certain Conditions)</span></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-4" name="ecd:TrdArrIndName" id="f-40">Mauro Ferrari</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-4" name="ecd:TrdArrIndTitle" id="f-41">Board Member</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-4" name="ecd:TrdArrAdoptionDate" id="f-42"><ix:nonNumeric contextRef="c-4" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-43">09/28/2023</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/11/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/31/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-44">3,147</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-6" name="ecd:TrdArrIndName" id="f-45">Douglass Given</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-6" name="ecd:TrdArrIndTitle" id="f-46">Board Member</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-6" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-47"><ix:nonNumeric contextRef="c-6" name="ecd:TrdArrAdoptionDate" id="f-48">09/26/2023</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/11/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/31/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-49">2,911</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">James Hamilton </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:114%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-8" name="ecd:TrdArrIndTitle" id="f-50">Chief Discovery and Translational Medicine</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-8" name="ecd:TrdArrTerminationDate" id="f-51">08/15/2023</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/03/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/31/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-52">52,500</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-10" name="ecd:TrdArrIndName" id="f-53"><ix:nonNumeric contextRef="c-8" name="ecd:TrdArrIndName" id="f-54">James Hamilton</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-10" name="ecd:TrdArrIndTitle" id="f-55">Chief Discovery and Translational Medicine</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-10" name="ecd:TrdArrAdoptionDate" id="f-56"><ix:nonNumeric contextRef="c-10" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-57">08/22/2023</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">12/01/2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">11/29/2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-11" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-58">35,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-12" name="ecd:TrdArrIndName" id="f-59">Ken Myszkowski</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-12" name="ecd:TrdArrIndTitle" id="f-60">Chief Financial Officer</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-12" name="ecd:TrdArrAdoptionDate" id="f-61"><ix:nonNumeric contextRef="c-12" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-62">09/07/2023</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/05/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/31/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-13" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-63">30,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><ix:nonNumeric contextRef="c-14" name="ecd:TrdArrIndName" id="f-64"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Patrick O</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Brien</span></ix:nonNumeric></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-14" name="ecd:TrdArrIndTitle" id="f-65">Chief Operating Officer and General Counsel</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-14" name="ecd:TrdArrAdoptionDate" id="f-66"><ix:nonNumeric contextRef="c-14" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-67">09/03/2023</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/03/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/05/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-15" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-68">4,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-16" name="ecd:TrdArrIndName" id="f-69">Tracie Oliver</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-16" name="ecd:TrdArrIndTitle" id="f-70">Chief Commercial Officer</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-16" name="ecd:TrdArrAdoptionDate" id="f-71"><ix:nonNumeric contextRef="c-16" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-72">08/28/2023</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/05/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">07/31/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-73">17,625</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-18" name="ecd:TrdArrIndName" id="f-74">Victoria Vakiener</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-18" name="ecd:TrdArrIndTitle" id="f-75">Board Member</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-18" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-76"><ix:nonNumeric contextRef="c-18" name="ecd:TrdArrAdoptionDate" id="f-77">09/28/2023</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/11/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">05/31/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-78">6,519</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-20" name="ecd:TrdArrIndName" id="f-79">William Waddill</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-20" name="ecd:TrdArrIndTitle" id="f-80">Board Member</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-20" name="ecd:TrdArrAdoptionDate" id="f-81"><ix:nonNumeric contextRef="c-20" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-true" id="f-82">08/29/2023</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/11/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/31/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-21" decimals="INF" name="ecd:TrdArrSecuritiesAggAvailAmt" format="ixt:num-dot-decimal" scale="0" id="f-83">3,934</ix:nonFraction></span></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) This column indicates the total number of shares vesting, but the 10b5-1 Plan provides for the sale of only those shares necessary to satisfy payment of applicable withholding taxes.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(2) <ix:nonNumeric contextRef="c-8" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-true" id="f-84">Termination</ix:nonNumeric> of a trading plan that was intended to satisfy Rule 10b5-1(c).</span></div></ix:nonNumeric><div id="i2ac2b5b9b196490b92657e8462cd4206_79"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 9C.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.14pt">DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i2ac2b5b9b196490b92657e8462cd4206_82"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III</span></div><div id="i2ac2b5b9b196490b92657e8462cd4206_85"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this Item will be incorporated by reference from the Company&#8217;s Definitive Proxy Statement, under the headings Proposal One &#8212; Election of Directors, Equity Compensation Plan Information, Corporate Governance, Environmental and Social Commitment, and, if applicable, Delinquent Section 16(a) Reports, to be filed for the Company&#8217;s 2024 Annual Meeting of Stockholders, which proxy statement will be filed no later than January 26, 2024 (the &#8220;Definitive Proxy Statement&#8221;).</span></div><div id="i2ac2b5b9b196490b92657e8462cd4206_88"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">EXECUTIVE COMPENSATION</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this Item will be incorporated by reference from the Definitive Proxy Statement, under the heading Executive Compensation.</span></div><div id="i2ac2b5b9b196490b92657e8462cd4206_91"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this Item will be incorporated by reference from the Definitive Proxy Statement, under the heading Voting Securities of Principal Stockholders and Management.</span></div><div id="i2ac2b5b9b196490b92657e8462cd4206_94"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">CERTAIN RELATIONSHIPS, RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this Item will be incorporated by reference from the Definitive Proxy Statement, under the headings Review and Approval of Related-Party Transactions and Certain Relationships and Related Transactions, and Director Independence.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">71</span></div></div></div><div id="i2ac2b5b9b196490b92657e8462cd4206_97"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">PRINCIPAL ACCOUNTANT FEES AND SERVICES </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this Item will be incorporated by reference from the Definitive Proxy Statement, under the heading Audit Fees.</span></div><div id="i2ac2b5b9b196490b92657e8462cd4206_100"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i2ac2b5b9b196490b92657e8462cd4206_103"></div><div style="-sec-extract:summary;margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">EXHIBITS AND FINANCIAL STATEMENT SCHEDULES </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are filed as part of this Annual Report on Form 10-K: </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:33.34pt">Financial Statements.</span></div><div style="margin-top:6pt;padding-left:27pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Index to Financial Statements and Schedule on page F-1. </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:33.34pt">Financial Statement Schedules.</span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Index to Financial Statements and Schedule on page F-1. All other schedules are omitted as the required information is not present or is not present in amounts sufficient to require submission of the schedule, or because the information required is included in the Consolidated Financial Statements or notes thereto. </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:33.34pt">Exhibits. </span></div><div style="margin-top:6pt;padding-left:27pt;text-align:justify;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following exhibits are filed (or incorporated by reference herein) as part of this Annual Report on Form 10-K:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Herein</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828022031597/arrowhead-atmxsalesagreeme.htm">Open Market Sale Agreement, dated as of December 2, 2022, by and between Arrowhead Pharmaceuticals, Inc. and Jefferies LLC</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current Report on Form 8-K as Exhibit 1.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2, 2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.1&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312511347334/d265091dex21.htm">Stock and Asset Purchase Agreement between Arrowhead Research Corporation and Roche entities, dated October 21, 2011</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Annual Report on Form 10-K as Exhibit 2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 20, 2011</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000156459015003902/arwr-ex21_20150331298.htm">Asset Purchase and Exclusive License Agreement between Arrowhead Research Corporation and Novartis Institutes for BioMedical Research, Inc., dated March 3, 2015</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quarterly Report on Form 10-Q, as Exhibit 2.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 11, 2015</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312516532364/d175317dex33.htm">Amended and Restated Certificate of Incorporation</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312516532364/d175317dex33.htm"> </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312516532364/d175317dex33.htm">(incorporated by reference from Exhibit 3.3 of the Company&#8217;s Form 8-K filed on April 6, 2016)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current Report on Form 8-K as Exhibit 3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 6, 2016</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828023014856/arrowheadpharmaceuticals.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Arrowhead Pharmaceuticals, Inc. (incorporated by reference from Exhibit 3.2 of the Company&#8217;s Form 10-Q filed on May 2, 2023)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quarterly Report on Form 10-Q, as Exhibit 3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">May 2, 2023</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828023002413/exhibit32.htm">Second Amended and Restated Bylaws (incorporated by reference from Exhibit 3.1 of the Company&#8217;s Form 8-K filed on January 30, 2023)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current Report on Form 8-K as Exhibit 3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 30, 2023</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312516532364/d175317dex41.htm">Form of Common Stock Certificate of Arrowhead Pharmaceuticals, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current Report on Form 8-K, as Exhibit 4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">April 6, 2016</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000119312519304271/d807419ds3asr.htm">Form of Indenture</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Registration Statement on Form S-3, as Exhibit 4.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 2, 2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312517092797/d319463dex41.htm">Rights Agreement dated as of March 21, 2017, between the Company and Computershare Trust Company, N.A., as rights agent, which includes as Exhibit B the Form of Rights Certificate</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current Report on Form 8-K, as Exhibit 4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">March 23, 2017</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000156459019044376/arwr-ex44_92.htm">Description of Registrant&#8217;s Securities</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Annual Report on Form 10-K, as Exhibit 4.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 25, 2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.5</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000095012319000828/arwr-ex104_153.htm">Registration Rights Agreement by and between Arrowhead Pharmaceuticals, Inc. and Johnson &amp; Johnson Innovation-JJDC, Inc., dated October 3, 2018</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quarterly Report on Form 10-Q, as Exhibit 10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 7, 2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Herein</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.1**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312512009893/d275001ddef14a.htm">Arrowhead Research Corporation 2004 Equity Incentive Plan, as amended</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Schedule 14C, as Annex B</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 12, 2012</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.2**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312513481209/d647635ddef14a.htm">Arrowhead Research Corporation 2013 Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Schedule 14C, as Annex A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 20, 2013</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.3**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312514048097/d675317dex101.htm">Form of Stock Option Agreement for use with the 2013 Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current Report on Form 8-K, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 12, 2014</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.4**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312514048097/d675317dex102.htm">Form of Restricted Stock Unit Agreement for use with the 2013 Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current Report on Form 8-K, as Exhibit 10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">February 12, 2014</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.5**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000119312521019640/d76219ddef14a.htm">Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Schedule 14A, Exhibit A</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 28, 2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.6**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459021041593/arwr-ex101_33.htm">Form of RSU Agreement for Officers and Certain Other Employees (Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan- Inducement Award)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Registration Statement on Form S-8, Exhibit 99.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 22, 2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.7*, **</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="a107-2021formofrsuoffice.htm">Form of RSU Agreement for Officers and Certain Other Employees (Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.8**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000119312521365055/d278970dex992.htm">Form of RSU Agreement for Employees (Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan- Inducement Award)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Registration Statement on Form S-8, Exhibit 99.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 22, 2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.9*, **</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="a109-2021formrsuawardemp.htm">Form of RSU Agreement for Employees (Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.10**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000119312521365055/d278970dex993.htm">Form of Stock Option Grant (Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan- Inducement Award)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Registration Statement on Form S-8, Exhibit 99.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">December 22, 2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.11*, **</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1011-arrowhead_2021plan.htm">Form of Stock Option Grant (Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.12**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312506253375/dex1011.htm">Executive Incentive Plan, adopted December 12, 2006</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">December 14, 2006</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.13**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312508133616/dex101.htm">Employment Agreement between Arrowhead and Dr. Christopher Anzalone, dated June 11, 2008</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Current Report on Form 8-K, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">June 13, 2008</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.14**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312509258134/dex108.htm">Amendment to Employment Agreement between Arrowhead and Dr. Christopher Anzalone, effective May 12, 2009</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.8</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">December 22, 2009</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.15&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312511347334/d265091dex1036.htm">Collaboration Agreement by and among Alnylam Pharmaceuticals, Inc. and F. Hoffmann-La Roche Ltd and Hoffman-La Roche Inc., dated October 29, 2009 &#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.36</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">December 20, 2011</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.16&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312511347334/d265091dex1033.htm">Non-Exclusive License Agreement between Arrowhead Research Corporation and Roche entities, dated October 21, 2011&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">December 20, 2011</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.16&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000156459014003557/arwr-ex10_20140630353.htm">License Agreement by and between Alnylam Pharmaceuticals, Inc., Arrowhead Research Corporation and Arrowhead Madison, Inc.&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">August 12, 2014</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.17&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000156459016030217/arwr-ex1019_309.htm">Second Collaboration and Licensing Agreement between Arrowhead Pharmaceuticals, Inc. and Amgen Inc., dated September 28, 2016&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">December 14, 2016</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.18</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000119312516776646/d272157dex101.htm">Common Stock Purchase Agreement between the Company and Amgen Inc., dated September 28, 2016</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Amendment No. 1 to the Registration Statement on Form S-3, as Exhibit 10.1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">November 25, 2016</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.19&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000095012319000828/arwr-ex101_156.htm">License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated October 3, 2018&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">February 7, 2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Herein</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.20&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459019044376/arwr-ex1019_310.htm">Amendment No. 1 to License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated December 18, 2018&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.19</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">November 25, 2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.21&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000156459019044376/arwr-ex1020_311.htm">Amendment No. 2 to License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Janssen Pharmaceuticals, Inc., dated February 4, 2019&#8224;</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.20</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">November 25, 2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.22</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000095012319000828/arwr-ex103_154.htm">Stock Purchase Agreement by and between Johnson &amp; Johnson Innovation-JJDC, Inc. and Arrowhead Pharmaceuticals, Inc., dated October 3, 2018</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">February 7, 2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.23&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459021004319/arwr-ex101_863.htm">Exclusive License and Co-Funding Agreement by and between Arrowhead Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc., dated October 7, 2020</a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">February 4, 2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459022019275/arwr-ex101_473.htm">First Amendment to Exclusive License and Co-Funding Agreement by and between Arrowhead Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. dated March 15, 2022</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">May 10, 2022</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.25&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459021041593/arwr-ex104_195.htm">Collaboration and License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Horizon Therapeutics Ireland DAC, dated June 18, 2021</a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">&#8224;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">August 5, 2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459022003616/arwr-ex101_514.htm">Collaboration and License Agreement by and between Arrowhead Pharmaceuticals, Inc. and Glaxosmithkline Intellectual Property, dated November 22, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">February 2, 2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000162828023002413/exhibit101.htm">Royalty Purchase Agreement, dated as of November 9, 2022, by and between Arrowhead Pharmaceuticals, Inc. and Royalty Pharma Investments 2019 ICAV</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">February 6, 2023</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">10.28</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000156459016012515/arwr-ex101_83.htm">Lease Agreement between University Research Park, Incorporated and Arrowhead Madison, Inc., dated January 8, 2016</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">February 9. 2016</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.29</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459020054893/arwr-ex1023_125.htm">Amendment No. 1 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated October 22, 2018</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Annual Report on Form 10-K, as Exhibit 10.23</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">November 23, 2020</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.30</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459020054893/arwr-ex1024_124.htm">Amendment No. 2 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated January 10, 2019</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.24</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">November 23, 2020</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.31</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459020054893/arwr-ex1025_123.htm">Amendment No. 3 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated January 11, 2019</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Annual Report on Form 10-K, as Exhibit 10.25</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">November 23, 2020</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.32</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459020054893/arwr-ex1026_121.htm">Amendment No. 4 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated September 19, 2019 </a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Annual report on Form 10-K, as Exhibit 10.26</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">November 23, 2020</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.33</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459020054893/arwr-ex1027_122.htm">Amendment No. 5 to Lease Agreement between Arrowhead Pharmaceuticals, Inc. and University Research Park, Incorporated, dated May 14, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Annual report on Form 10-K, as Exhibit 10.27</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">November 23, 2020</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.34</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459021004319/arwr-ex103_51.htm">Amendment No. 6 to Lease Agreement by and between Arrowhead Pharmaceuticals, Inc. and University Research Park, dated November 23, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">February 4, 2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.35</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="background-color:#ffffff;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459021004319/arwr-ex104_52.htm">Amendment No. 7 to Lease Agreement by and between Arrowhead Pharmaceuticals, Inc. and University Research Park, dated December 9, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Quarterly Report on Form 10-Q, as Exhibit 10.4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">February 4, 2021</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.36</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/879407/000156459019028760/arwr-ex101_67.htm">Office Lease by and between 177 Colorado Owner LLC and Arrowhead Pharmaceuticals, Inc., dated April 17, 2019</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">August 5, 2019</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:9.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:51.172%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Incorporated by Reference Herein</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit<br/>Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Form</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.37</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline">First Amendment to Office Lease by<a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/0000879407/000156459021004319/arwr-ex102_50.htm"> and between Arrowhead Pharmaceuticals, Inc. and 177 Colorado Owner LLC., dated October 23, 2020</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Quarterly Report on Form 10-Q, as Exhibit 10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">February 4, 2021</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.38</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459022003616/arwr-ex102_515.htm">Lease Agreement by and between Arrowhead Pharmaceuticals, Inc. and ARE-SD Region No. 72, LLC, dated November 19, 2021</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Quarterly Report on Form 10-Q, as Exhibit 10.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">February 2, 2022</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">10.39*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline" href="a1039-firstamendmenttole.htm">First Amendment to Lease Agreement by and between Arrowhead Pharmaceuticals, Inc. and ARE-SD Region No. 72, LLC, dated September 26, 2023</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">21.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/879407/000156459021057888/arwr-ex211_11.htm">List of Subsidiaries</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">23.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="arwr-20230930xex231.htm">Consent of Independent Public Registered Accounting Firm</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">31.1*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="arwr-20230930xex311.htm">Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">31.2*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="arwr-20230930xex312.htm">Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">32.1***</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="arwr-20230930xex321.htm">Certification by Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">32.2***</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="arwr-20230930xex322.htm">Certification by Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">97*, **</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%;text-decoration:underline" href="a97-arwrxclawbackpolicyf.htm">Arrowhead Pharmaceuticals, Inc. Compensation Recoupment (Clawback) Policy, dated November 20, 2023</a></span><span style="color:#0000ee;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">     </span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">104*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:114%">The cover page from the Company&#8217;s Annual Report on Form 10-K for the year ended September 30, 2023, formatted in Inline XBRL (included as Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Indicates compensation plan, contract or arrangement.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">***&#160;&#160;&#160;&#160;Furnished herewith</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Certain portions of this exhibit were redacted by means of marking such portions with asterisks because the identified portions are (i) not material and (ii) treated as private or confidential by the Company.</span></div><div id="i2ac2b5b9b196490b92657e8462cd4206_106"></div><div style="margin-top:18pt;padding-left:72pt;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:30.36pt">FORM 10-K SUMMARY</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">75</span></div></div></div><div id="i2ac2b5b9b196490b92657e8462cd4206_109"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">SIGNATURE</span></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated: November&#160;29, 2023</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.295%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARROWHEAD PHARMACEUTICALS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christopher Anzalone</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Christopher Anzalone</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:29.203%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.204%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christopher Anzalone</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer, President and Director (Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 29, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Christopher Anzalone</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Kenneth A. Myszkowski</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer (Principal Financial and Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 29, 2023</span></td></tr><tr style="height:14pt"><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Kenneth A. Myszkowski</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Douglass Given</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director, Chairman of the Board of Directors</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 29, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Douglass Given</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Mauro Ferrari</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 29, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Mauro Ferrari</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Michael S. Perry</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 29, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Michael S. Perry</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ William Waddill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 29, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">William Waddill</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Adeoye Olukotun</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 29, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Adeoye Olukotun</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Victoria Vakiener</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 29, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Victoria Vakiener</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">76</span></div></div></div><div id="i2ac2b5b9b196490b92657e8462cd4206_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX TO FINANCIAL STATEMENTS AND SCHEDULE</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:91.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.022%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_118">Reports of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"> (PCAOB ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-94">468</ix:nonNumeric>)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_118">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_124">Consolidated Balance Sheets as of September 30, 202</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_124">3</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_124"> and 2022</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_124">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_127">Consolidated Statements of Operations and Comprehensive Loss for the years ended September 30, </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_127">2023, </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_127">2022</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_127"> and</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_127"> 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_127">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_130">Consolidated Statements of Stockholders&#8217; Equity for the years ended September 30, </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_130">2023, </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_130">2022</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_130"> </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_130">and</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_130"> 2021</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_130">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_133">Consolidated Statements of Cash Flows </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_133">for the years ended September 30, </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_133">2023, </a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_133">2022</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_133"> and</a><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_133"> 2021 </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_133">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt;text-indent:-12pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i2ac2b5b9b196490b92657e8462cd4206_136">Notes to Consolidated Financial Statements </a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">F-<a style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i2ac2b5b9b196490b92657e8462cd4206_136">9</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-1</span></div></div></div><div id="i2ac2b5b9b196490b92657e8462cd4206_118"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders of Arrowhead Pharmaceuticals, Inc.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Arrowhead Pharmaceuticals, Inc. and Subsidiaries (the Company) as of September 30, 2023 and 2022, and the related consolidated statements of operations and comprehensive income (loss), stockholders&#8217; equity, and cash flows for each of the years in the three-year period ended September 30, 2023, and the related notes (collectively referred to as the financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of September 30, 2023 and 2022, and the results of its operations and its cash flows for each of the years in the three-year period ended September 30, 2023, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of September 30, 2023, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#8212;Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO), and our report dated November&#160;29, 2023, expressed an unqualified opinion.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matters</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matters communicated below are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition &#8211; Revenue Recognized Over Time</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Description of the Matter</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As discussed in Note 1 and Note 2 to the Consolidated Financial Statements, the Company earns its revenue through license and collaboration agreements. For performance obligations related to services that are required to be recognized over time, the Company measures its progress to completion using various measures, including an input measure of total labor costs incurred divided by total labor costs expected to be incurred, time elapsed, and an output measure of total patient visits divided by total patient visits expected. The selection of measurement criteria is based on the nature and phase of trials being conducted.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Auditing revenue recognition is complex and highly judgmental due to the variability and uncertainty associated with the Company&#8217;s assessment of measure of progress. Changes in these estimates would have a significant effect on the amount of revenue recognized. </span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">How We Addressed the Matter in Our Audit</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We obtained an understanding, evaluated the design, and tested the operating effectiveness of controls that address the risk of material misstatement of license and collaboration agreement revenue including those associated with cost to complete estimates. We tested controls over management&#8217;s process to collect, review, and approve the data used in assessing revenue recognized over time. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To test the measures of progress used for performance obligations related to services that are required to be recognized over time, our audit procedures included, among others, evaluating the appropriateness of the Company&#8217;s accounting policy for each type of arrangement, testing the identified measure of performance by reading contracts with customers, including all amendments, and reviewing the contract analyses prepared by management. We evaluated whether the selected measures of progress towards satisfaction of performance obligations were applied consistently. We also tested the completeness and accuracy of the underlying data used for the measure of progress by testing and or analyzing the underlying data. </span></div><div style="margin-top:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-95">Rose, Snyder &amp; Jacobs LLP</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company&#8217;s auditor since 2004.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-96">Encino, California</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November&#160;29, 2023</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the Board of Directors and</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stockholders of Arrowhead Pharmaceuticals, Inc. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited Arrowhead Pharmaceuticals, Inc. and its Subsidiaries (the Company&#8217;s) internal control over financial reporting as of September 30, 2023, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#8212;Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of September 30, 2023, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control&#8212;Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by COSO.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets as of September 30, 2023 and 2022 and the related consolidated statements of operations and comprehensive income (loss), stockholders&#8217; equity, and cash flows for each of the three years in the period ended September 30, 2023 and related notes, and our report dated November&#160;29, 2023 expressed an unqualified opinion thereon.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rose, Snyder &amp; Jacobs LLP</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Encino, CA</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">November&#160;29, 2023</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-4</span></div></div></div><div id="i2ac2b5b9b196490b92657e8462cd4206_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:3pt"><span><br/></span></div><div id="i2ac2b5b9b196490b92657e8462cd4206_124"></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-97">110,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-98">108,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="3" id="f-99">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-100">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale securities, at fair value</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-101">292,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="f-102">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held-to-maturity securities, at amortized cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:fixed-zero" scale="3" id="f-103">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-104">268,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-105">8,813</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-106">7,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-107">7,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-108">20,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-109">419,521</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-110">405,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-111">290,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-112">110,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-113">10,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-114">11,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held-to-maturity securities, at amortized cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:fixed-zero" scale="3" id="f-115">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-116">105,872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-117">45,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-118">58,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-119">210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="f-120">218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-121">765,552</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-122">691,939</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-123">35,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-124">2,868</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-125">39,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-126">46,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued payroll and benefits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-127">17,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-128">12,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-129">10,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-130">2,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="f-131">866</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-132">74,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-133">435</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" format="ixt:fixed-zero" scale="3" id="f-134">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-135">105,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-136">138,850</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-137">104,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-138">78,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue, net of current portion</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-139">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-140">55,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="arwr:RoyaltiesLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-141">268,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="arwr:RoyaltiesLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="f-142">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-143">372,934</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:LiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-144">134,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 7)</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-31" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-145"></ix:nonFraction></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-32" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-146"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interest and stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-31" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-147"><ix:nonFraction unitRef="usdPerShare" contextRef="c-32" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-148">0.001</ix:nonFraction></ix:nonFraction> par value:</span></div><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Authorized <ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-149">290,000</ix:nonFraction> shares; issued and outstanding  <ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-150"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-151">107,312</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-32" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-152"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-153">105,960</ix:nonFraction></ix:nonFraction> shares  </span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-154">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-155">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-156">1,300,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-157">1,219,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-158">3,222</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="f-159">136</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-160">1,026,030</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-161">820,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Arrowhead Pharmaceuticals, Inc. stockholders' equity</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-162">271,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-163">398,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="f-164">15,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:MinorityInterest" format="ixt:num-dot-decimal" scale="3" id="f-165">19,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total noncontrolling interest and stockholders' equity</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-166">287,162</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-167">418,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Liabilities, Noncontrolling Interest and Stockholders' Equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-168">765,552</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-169">691,939</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-5</span></div></div></div><div id="i2ac2b5b9b196490b92657e8462cd4206_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-170">240,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-171">243,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-172">138,287</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-173">353,188</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-174">297,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="3" id="f-175">206,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-176">92,549</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-177">124,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-178">80,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-179">445,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-180">421,738</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-181">287,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-182">205,002</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-183">178,507</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-184">149,036</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" format="ixt:num-dot-decimal" scale="3" id="f-185">15,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" format="ixt:num-dot-decimal" scale="3" id="f-186">5,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:InvestmentIncomeInterestAndDividend" format="ixt:num-dot-decimal" scale="3" id="f-187">6,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpense" format="ixt:num-dot-decimal" scale="3" id="f-188">18,326</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="f-189">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:InterestExpense" format="ixt:fixed-zero" scale="3" id="f-190">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-191">1,538</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="f-192">765</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-193">2,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other (expense) income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-194">1,489</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-195">5,798</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="f-196">8,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income tax expense and noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-197">206,491</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-198">172,709</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-199">140,846</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-200">2,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-201">3,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-202">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss including noncontrolling interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-203">209,275</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-204">176,494</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-205">140,848</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to noncontrolling interest, net of tax</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-206">4,000</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="INF" sign="-" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" scale="3" id="f-207">431</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="INF" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-208">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-209">205,275</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-210">176,063</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-211">140,848</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share attributable to Arrowhead Pharmaceuticals, Inc.:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-212">1.92</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-33" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-213">1.67</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-34" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-214">1.36</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-215">1.92</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-33" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-216">1.67</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-34" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-217">1.36</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares used in calculating</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-218">106,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-219">105,426</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-220">103,745</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-221">106,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-222">105,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-223">103,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss, net of tax:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized losses on available-for-sale securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-224">2,964</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="f-225">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="f-226">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-227">122</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-228">67</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-229">87</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-230">212,361</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-231">176,561</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-232">140,935</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-6</span></div></div></div><div id="i2ac2b5b9b196490b92657e8462cd4206_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Stockholders&#8217; Equity </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.015%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Totals </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at September 30, 2020</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-233">102,376</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-234">195</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-235">965,410</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-236">18</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-237">503,844</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-238">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-239">461,779</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-240">76,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-241">76,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-242">1,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-243">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-244">11,304</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-245">11,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="f-246">899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-247">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-248">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="f-249">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-250">87</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-251">87</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-252">140,848</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-253">140,848</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-254">104,327</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-255">197</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-256">1,053,386</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-257">69</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-258">644,692</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-259">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-260">408,822</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.015%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Totals </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at September 30, 2021</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-45" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-261">104,327</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-262">197</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-263">1,053,386</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-264">69</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-265">644,692</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="3" id="f-266">&#8212;</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-267">408,822</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-268">120,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-269">120,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-270">606</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-271">5,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-272">5,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" format="ixt:num-dot-decimal" scale="3" id="f-273">1,027</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-274">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-275">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="f-276">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-277">67</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-278">67</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Interest in joint venture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="3" id="f-279">39,750</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="3" id="f-280">20,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" format="ixt:num-dot-decimal" scale="3" id="f-281">60,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-282">176,063</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" sign="-" name="us-gaap:ProfitLoss" scale="3" id="f-283">431</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-284">176,494</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-56" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-285">105,960</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-286">198</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-287">1,219,213</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-288">136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-289">820,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-290">19,819</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-291">418,339</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.455%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.244%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.015%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Common<br/>Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Amount ($)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Additional<br/>Paid-In<br/>Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Non-<br/>controlling<br/>Interest</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Totals</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at September 30, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-56" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-292">105,960</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-293">198</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-294">1,219,213</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-295">136</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-296">820,755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-297">19,819</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-298">418,339</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-299">78,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-300">78,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-62" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-301">439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-302">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-303">3,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-304">3,054</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Common stock - restricted stock units vesting</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-62" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="3" id="f-305">913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-306">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="3" id="f-307">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" format="ixt:fixed-zero" scale="3" id="f-308">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Unrealized losses on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-309">2,964</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-310">2,964</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Foreign currency translation adjustments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-311">122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="3" id="f-312">122</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-313">205,275</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-314">4,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-315">209,275</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">Balance at September 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-66" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-316">107,312</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="3" id="f-317">200</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-318">1,300,395</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-319">3,222</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-3" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-320">1,026,030</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-321">15,819</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-322">287,162</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-7</span></div></div></div><div id="i2ac2b5b9b196490b92657e8462cd4206_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.687%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.569%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CASH FLOWS FROM OPERATING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-323">209,275</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-324">176,494</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:ProfitLoss" format="ixt:num-dot-decimal" scale="3" id="f-325">140,848</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash flow from operating activities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-326">78,130</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-327">120,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-328">76,673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-329">12,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-330">10,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-331">8,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Accretion) amortization of note premiums/discounts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="3" id="f-332">2,017</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" format="ixt:num-dot-decimal" scale="3" id="f-333">2,910</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" scale="3" id="f-334">266</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-cash interest expense on liability related to the sale of future royalties</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-335">18,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="f-336">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="f-337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss (gain) from investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:fixed-zero" scale="3" id="f-338">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-339">4,432</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:GainLossOnInvestments" format="ixt:num-dot-decimal" scale="3" id="f-340">1,708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-341">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-342">8,845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-343">9,409</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-344">11,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-345">19,291</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-346">360</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-347">32,998</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-348">6,589</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-349">2,628</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-350">14,965</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-351">17,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-352">9,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-353">129,183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-354">112,501</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-355">223,258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease, net</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-356">46,590</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-357">13,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-358">3,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:fixed-zero" scale="3" id="f-359">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="f-360">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="3" id="f-361">169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) operating activities</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-362">153,890</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-363">136,131</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-364">171,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CASH FLOWS FROM INVESTING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-365">176,737</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-366">52,777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-367">23,567</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-368">246,141</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-369">223,391</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="3" id="f-370">240,703</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales and maturities of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="f-371">326,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="f-372">270,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="3" id="f-373">122,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in investing activities</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-374">96,155</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-375">5,417</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-376">141,678</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CASH FLOWS FROM FINANCING ACTIVITIES:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the exercises of stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-377">3,053</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-378">5,186</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-379">11,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the sale of future royalties</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="arwr:ProceedsFromSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="3" id="f-380">250,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="arwr:ProceedsFromSaleOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="f-381">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="arwr:ProceedsFromSaleOfFutureRoyalties" format="ixt:fixed-zero" scale="3" id="f-382">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from investment in joint venture</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromContributedCapital" format="ixt:fixed-zero" scale="3" id="f-383">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:ProceedsFromContributedCapital" format="ixt:num-dot-decimal" scale="3" id="f-384">60,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:ProceedsFromContributedCapital" format="ixt:fixed-zero" scale="3" id="f-385">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-386">253,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-387">65,186</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-388">11,305</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-389">3,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-390">76,362</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-391">40,939</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-392">122</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="INF" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-393">67</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="INF" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-394">88</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">CASH, CASH EQUIVALENTS AND RESTRICTED CASH:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BEGINNING OR PERIOD</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-395">108,005</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-396">184,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-397">143,583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">END OF PERIOD</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-398">110,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-399">108,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-400">184,434</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 13pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplementary disclosures:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="0" id="f-401">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="0" id="f-402">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:fixed-zero" scale="0" id="f-403">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income Taxes Paid</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="0" id="f-404">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-405">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:IncomeTaxesPaidNet" scale="3" id="f-406">2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accompanying notes are an integral part of these consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-8</span></div></div></div><div id="i2ac2b5b9b196490b92657e8462cd4206_136"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:24pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Arrowhead Pharmaceuticals, Inc.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div id="i2ac2b5b9b196490b92657e8462cd4206_139"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="c-1" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="f-407" continuedAt="f-407-1" escape="true">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="f-407-1" continuedAt="f-407-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the &#8220;Company&#8221;) are primarily engaged in developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#8217;s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#8220;RNAi&#8221;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. The Company&#8217;s RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </span></div><ix:nonNumeric contextRef="c-1" name="arwr:ScheduleOfCurrentProductsTableTextBlock" id="f-408" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s current pipeline:</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.962%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Therapeutic Area</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stage</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product Rights</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cardiometabolic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plozasiran (ARO-APOC3)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Two Phase 2b and one Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zodasiran (ARO-ANG3)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Two Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Olpasiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amgen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pulmonary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-RAGE</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-MUC5AC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-MMP7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liver</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GSK-4532990</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GSK</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fazirsiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Takeda and Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNJ-3989</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HZN-457</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Horizon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-C3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-PNPLA3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Muscle</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-DUX4</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-Clinical</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Central Nervous System (CNS)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-SOD1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-Clinical</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr></table></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(1) On October 30, 2023, the Company entered into an Assignment and Consent Agreement with Janssen. See Note 15.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(2) On October 6, 2023, Amgen announced that it has completed its acquisition of Horizon.</span></div></ix:nonNumeric><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates lab facilities in San Diego, California and Madison, Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company&#8217;s principal executive offices are located in Pasadena, California.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of Arrowhead Pharmaceuticals, Inc. and its subsidiaries (wholly-owned subsidiaries and a variable interest entity for which the Company is the primary beneficiary). Subsidiaries refer to Arrowhead Madison, Inc., Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;), and Arrowhead Australia Pty Ltd. For subsidiaries in which the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interests retained in such entity by the respective noncontrolling party.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform with the current period presentation. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s primary sources of financing have been through the sale of its securities, revenue from its licensing and collaboration agreements and the sale of certain future royalties. Research and development activities have required significant capital investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#8217;s pipeline of drug candidates and its headcount have both expanded </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-407-2" continuedAt="f-407-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significantly. Additionally, significant capital investment will be required as the Company&#8217;s pipeline matures into later stage clinical trials and as the Company plans to increase its internal manufacturing capabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2023, the Company had $<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="f-409">110.9</ix:nonFraction> million in cash, cash equivalents and restricted cash ($<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-410">7.9</ix:nonFraction> million in restricted cash) and $<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-411">292.7</ix:nonFraction> million in available-for-sale debt securities to fund operations. During the year ended September&#160;30, 2023, the Company&#8217;s cash, cash equivalents and restricted cash and investments balance decreased by $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="arwr:IncreaseDecreaseInCashAndInvestments" format="ixt:num-dot-decimal" scale="6" id="f-412">78.6</ix:nonFraction> million which was primarily due to cash used to fund its operations, offset by the $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="arwr:CashReceivedAsDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="f-413">250.0</ix:nonFraction> million upfront payment received from Royalty Pharma (Note 13) and $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="arwr:UpfrontMilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-414">110.0</ix:nonFraction>&#160;million in milestone payments from the Company&#8217;s collaboration and license agreements (Note 2). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-8" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="9" id="f-415">2.8</ix:nonFraction> billion in developmental, regulatory and sales milestones, and may receive various royalties on net sales from its licensing and collaboration agreements, subject to the terms and conditions of those agreements. The revenue recognition for these collaboration agreements is discussed further in Note 2.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Accounting Policies </span></div><ix:nonNumeric contextRef="c-1" name="arwr:BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" id="f-416" continuedAt="f-416-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-416-1">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, judgments and assumptions. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results could materially differ from those estimates.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationVariableInterestEntityPolicy" id="f-417" continuedAt="f-417-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Variable Interest Entity (&#8220;VIE&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A VIE is an entity that, by design, either (i) lacks sufficient equity to permit the entity to finance its activities without additional subordinated financial support from other parties; or (ii) has equity investors that do not have the ability to make significant decisions relating to the entity&#8217;s operations through voting rights, or do not have the obligation to absorb the expected losses, or do not have the right to receive the residual returns of the entity. The primary beneficiary of a VIE is required to consolidate the assets and liabilities of the VIE. The primary beneficiary is the party that has both (i) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance, and (ii) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE through its interest in the VIE.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2022, the Company entered into a license agreement with Visirna (Note 2) and consolidated Visirna&#8217;s financial statements in which the Company has a direct controlling financial interest based on the VIE model. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all the facts and circumstances, including its role in establishing Visirna and its ongoing rights and responsibilities to assess whether the Company has the power to direct the activities of Visirna. In general, the parties that make the most significant decisions affecting a VIE and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also considers all of its economic interests to assess whether the Company has the obligation to absorb losses of Visirna or the right to receive benefits from it that could potentially be significant to Visirna. This assessment requires the Company to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to Visirna. Factors considered in assessing the significance include: the design of the Visirna, including its capitalization structure, subordination of interests, payment priority, and the reasons why the interests are held by the Company. </span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-417-1">At Visirna&#8217;s inception, the Company determined whether it was the primary beneficiary and if Visirna should be consolidated based on the facts and circumstances. The Company performs ongoing reassessments of the VIE based on reconsideration events and reevaluates whether a change to the consolidation is required. As of September&#160;30, 2023, there were no events to be reconsidered in the consolidation.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="f-418" continuedAt="f-418-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly liquid interest-bearing investments are classified as cash equivalents. These investments mainly include commercial paper with maturities of three months or less when purchased. The carrying value of these cash equivalents approximate fair value. </span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-418-1">There was $<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-419">7.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="f-420">7.3</ix:nonFraction> million restricted cash at September&#160;30, 2023 and 2022, respectively, that is primarily held as collateral associated with letters of credit for the Company&#8217;s facility leases.</ix:continuation> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-407-3" continuedAt="f-407-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-421" continuedAt="f-421-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Concentration of Credit Risk</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-421-1">Financial instruments that potentially expose the Company to concentration of credit risk primarily consist of cash, cash equivalents and restricted cash and investments. As of September&#160;30, 2023 and 2022, the Company&#8217;s investments were primarily invested in money market funds, certificates of deposit, commercial paper, and corporate debt securities through highly rated financial institutions. The Company also maintains several bank accounts primarily at three financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="INF" name="us-gaap:CashFDICInsuredAmount" format="ixt:num-dot-decimal" scale="0" id="f-422">250,000</ix:nonFraction> per institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentPolicyTextBlock" id="f-423" continuedAt="f-423-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities are mainly held-to-maturity investments, available-for-sale, and marketable securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These held-to-maturity investments may consist of investment-grade interest bearing instruments, primarily money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper, which are stated at amortized cost. The Company does not intend to sell these investment securities and the contractual maturities are not greater than 36 months. Those with maturities less than twelve months are included in short-term investments on the Company&#8217;s consolidated balance sheets, while those with remaining maturities in excess of twelve months are included in long-term investments on its consolidated balance sheets. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security, and no gains or losses on held-to-maturity investment are realized until they are sold. The Company reassesses the classification of held-to-maturity at each reporting period.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The available-for-sale investments may consist of investment-grade interest bearing instruments, primarily money market</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">accounts,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">government-sponsored</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">enterprise</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">corporate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">bonds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">and/or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">commercial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">paper, which are accounted for at fair value.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Changes in fair values are reported as unrealized gains or losses and are recorded in the Company&#8217;s consolidated statement of operations and comprehensive loss.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">On September 30, 2023, the Company changed the classification of debt securities to available-for-sale from held-to-maturity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">As a result, these debt securities are carried at fair value.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketable debt securities consisted of mutual funds that primarily invest in U.S. government bonds, U.S. government agency bonds, and corporate bonds. Dividends from these funds were automatically re-invested. These securities were recorded at fair value, and all unrealized gains/losses were recorded in the Company&#8217;s consolidated statement of operations and comprehensive loss. In April 2022, the Company sold all of its investments in mutual funds for $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="6" id="f-424">122.3</ix:nonFraction> million. </span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-423-1">The Company monitors its investments closely. If an unrealized loss is determined to be other-than-temporary, it is written off as a realized loss through the consolidated statements of operations and comprehensive loss. The Company&#8217;s methodology of assessing other-than-temporary impairments is based on security-specific analysis as of the balance sheet date and considers various factors, including the length of time to maturity and the extent to which the fair value has been less than the cost, recoverability of future cash flows as compared to carrying value of the security, the financial condition and the near-term prospects of the issuer, and the Company&#8217;s ability and intent to hold the security. If a decline in fair value of investments is determined to be other-than-temporary, the securities are written down to fair value as the new cost basis and the amount of the write down is accounted for as realized losses. The Company did not recognize any other-than-temporary impairments of its investment for the years ended September&#160;30, 2023, 2022, and 2021.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-425" continuedAt="f-425-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property and Equipment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from <span style="-sec-ix-hidden:f-426">three</span> to <ix:nonNumeric contextRef="c-73" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-427">seven years</ix:nonNumeric>. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically assesses long-lived assets or asset groups, including property and equipment, for recoverability when events or changes in circumstances indicate that their carrying amounts may not be recoverable. If the Company identifies an indicator of impairment, the Company assesses recoverability by comparing the carrying amount of the asset to the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-407-4" continuedAt="f-407-5"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-425-1">An impairment loss is recognized when the carrying amount is not recoverable and is measured as the excess of carrying value over fair value. There were no impairment charges during the years ended September&#160;30, 2023, 2022, and 2021.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="f-428" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intangible Assets Subject to Amortization</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization include certain patents and license agreements. The Company qualitatively evaluates intangible assets for impairment annually or whenever events or changes in circumstances indicate that it is more likely than not that the carrying amount of intangible assets may exceed their implied fair values. As of September&#160;30, 2023 and 2022, intangible impairment assessments indicated that there was <ix:nonFraction unitRef="usd" contextRef="c-33" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-429"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfIntangibleAssetsFinitelived" format="ixt:fixed-zero" scale="0" id="f-430">no</ix:nonFraction></ix:nonFraction> impairment.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-431" continuedAt="f-431-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether a contract is, or contains, a lease at inception. All of the Company&#8217;s leases are classified as operating leases. Leases with terms greater than one-year are recognized on the Company&#8217;s consolidated balance sheets as right-of-use assets that represent the Company&#8217;s right to use an underlying asset for the lease term, and lease liabilities that represent its obligation to make lease payments arising from the lease. Lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the expected lease term.</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-431-1">The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize  lease payments on a straight-line basis over the expected lease term. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-432" continuedAt="f-432-1" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that it determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing. If the license is not considered to be distinct from other performance obligations, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time. If the performance obligation is satisfied over time, the Company then determines the appropriate method of measuring progress for purposes of recognizing revenue from license payments. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition. </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-407-5" continuedAt="f-407-6"><ix:continuation id="f-432-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, the Company&#8217;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a Clinical Trial Application (&#8220;CTA&#8221;) or a New Drug Application (&#8220;NDA&#8221;) in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas. The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in the Company&#8217;s consolidated statements of operation and comprehensive loss. Typically, milestone payments and royalties are achieved after the Company&#8217;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or preclinical program. Milestones or royalties achieved after the Company&#8217;s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its licensing or collaboration agreements. Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment. Additionally, future royalty payments are not substantially within the control of the Company or the customer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using the input method; Labor hours, costs incurred or patient visits in clinical trials are typically used as the measure of performance. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations.  If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain judgments affect the application of the Company&#8217;s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company&#8217;s current operating plan and, the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementAccountingPolicy" id="f-433" continuedAt="f-433-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope of Financial Accounting Standards Board (&#8220;FASB&#8221;) Topic 808 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For collaborative arrangements that contain multiple elements, the Company determines which units of account are deemed to be within the scope of Topic 808 and which units of account are more reflective of a vendor-customer relationship, and therefore are within the scope of Topic 606. For units of account that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of Topic 808, the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative arrangement based on the nature </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-407-6"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-433-1">of each activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to research and development expense or general and administrative expense, as appropriate.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-434" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#8217;s research and development operations, and costs to acquire technology licenses.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-435" continuedAt="f-435-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock-Based Compensation</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-435-1">Share-based compensation expenses for all stock grants are based on their estimated grant-date fair value. The fair value of stock option awards is estimated using the Black-Scholes option valuation model which requires the input of subjective assumptions to calculate the value of stock options. For restricted stock units, the value of the award is based on the Company&#8217;s stock price at the grant date. For performance-based restricted stock unit awards, the value of the award is based on the Company&#8217;s stock price at the grant date, with consideration given to the probability of the performance condition being achieved. The Company uses historical data and other information to estimate the expected price volatility and the expected forfeiture rate for stock option awards. Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#8217;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-436" escape="true"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting basis and the respective tax basis of the Company&#8217;s assets and liabilities, and expected benefits of utilizing net operating loss, capital loss, and tax-credit carryforwards. The Company assesses the likelihood that its deferred tax assets will be realized and, to the extent management does not believe these assets are more likely than not to be realized, a valuation allowance is established. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates or laws is recognized in earnings in the period that includes the enactment date.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-437" continuedAt="f-437-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Earnings per Share</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units outstanding. </span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-437-1">During the years ended September&#160;30, 2023, 2022 and 2021, the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units outstanding during the period due to their anti-dilutive effect.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="f-438" continuedAt="f-438-1" escape="true"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign currency translation adjustments</span></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-438-1">One of the Company&#8217;s wholly-owned subsidiaries&#8217; functional currencies are not the United States dollar, which is the Company&#8217;s reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Translation adjustments arising from the use of different exchange rates from period to period are included in the accumulated other comprehensive loss.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-439" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no recent accounting pronouncements that have significantly impacted this Annual Report on Form 10-K.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-14</span></div></div></div><div id="i2ac2b5b9b196490b92657e8462cd4206_142"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-440" continuedAt="f-440-1" escape="true">COLLABORATION AND LICENSE AGREEMENTS</ix:nonNumeric></span></div><ix:continuation id="f-440-1" continuedAt="f-440-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="f-441" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of revenue recognized:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GSK</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-442">29,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-443">124,764</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-444">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Horizon</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-445">23,206</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-446">29,181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-447">6,816</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-448">162,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-449">85,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-450">90,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="f-451">356</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-452">3,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-453">40,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amgen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-454">25,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-455">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-456">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-457">240,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-458">243,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-459">138,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="f-460" escape="true"><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance of receivables and contract liabilities related to the Company&#8217;s collaboration and license agreements:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables included in accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:AccountsReceivableNet" format="ixt:fixed-zero" scale="3" id="f-461">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:AccountsReceivableNet" format="ixt:num-dot-decimal" scale="3" id="f-462">1,410</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liabilities included in deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:ContractWithCustomerLiability" scale="3" id="f-463">866</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:ContractWithCustomerLiability" format="ixt:num-dot-decimal" scale="3" id="f-464">130,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Glaxosmithkline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;22, 2021, GSK and the Company entered into an Exclusive License Agreement (the &#8220;GSK License Agreement&#8221;). Under the GSK License Agreement, GSK has received an exclusive license for GSK-4532990 (formerly ARO-HSD). The exclusive license is worldwide with the exception of greater China. GSK is wholly responsible for all clinical development and commercialization of GSK-4532990 in its territory.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the GSK License Agreement, the Company identified <ix:nonFraction unitRef="obligation" contextRef="c-91" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-465">one</ix:nonFraction> distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibility to complete the Phase 1/2 study (the &#8220;GSK R&amp;D Services&#8221;). Due to the specialized and unique nature of the GSK R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented <ix:nonFraction unitRef="bundle" contextRef="c-91" decimals="INF" name="arwr:NumberOfDistinctBundle" format="ixt-sec:numwordsen" scale="0" id="f-466">one</ix:nonFraction> distinct bundle and, thus, <ix:nonFraction unitRef="obligation" contextRef="c-91" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-467">one</ix:nonFraction> performance obligation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-468">120.0</ix:nonFraction> million, including the upfront payment, which was collected in January 2022. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company has allocated the total $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-469">120.0</ix:nonFraction> million initial transaction price to its one distinct performance obligation for the GSK-4532990 license and the associated GSK R&amp;D Services. As the Company has completed its performance obligation related to this agreement, the upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-470">120.0</ix:nonFraction> million was fully recognized in the year ended September&#160;30, 2022. Further, GSK dosed the first patient in a Phase 2b trial in March 2023, triggering a $<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="arwr:MilestonePaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="f-471">30.0</ix:nonFraction>&#160;million milestone payment to the Company which was paid in the third quarter of fiscal 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also eligible for an additional payment of $<ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" format="ixt:num-dot-decimal" scale="6" id="f-472">100.0</ix:nonFraction> million upon achieving the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="arwr:CommercialMilestonePaymentsAtFirstCommercialSale" format="ixt:num-dot-decimal" scale="6" id="f-473">190.0</ix:nonFraction> million at first commercial sale, and up to $<ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="arwr:SalesRelatedMilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-474">590.0</ix:nonFraction> million in sales-related milestone payments. The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also performed certain development and manufacturing activities, including the manufacture of drug substance and drug product under GMP conditions, for GSK pursuant to the GSK License Agreement, for which the Company has been reimbursed for its costs. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-475">0.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-476">4.8</ix:nonFraction>&#160;million in connection with these efforts for the years ended September&#160;30, 2023 and 2022, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Horizon Therapeutics Ireland DAC (&#8220;Horizon&#8221;) </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;18, 2021, Horizon and the Company entered into a collaboration and license agreement (the &#8220;Horizon License Agreement&#8221;). Under the terms of the Horizon License Agreement, Horizon received a worldwide exclusive license for HZN-457, a clinical-stage medicine being developed by Horizon as a potential treatment for people with uncontrolled </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-440-2" continuedAt="f-440-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gout. Horizon is wholly responsible for clinical development and commercialization of HZN-457. On October 6, 2023, Amgen completed its acquisition of Horizon. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Horizon License Agreement, the Company identified <ix:nonFraction unitRef="obligation" contextRef="c-97" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-477">one</ix:nonFraction> distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibilities to conduct all activities through the preclinical stages of development of HZN-457 (the &#8220;Horizon R&amp;D Services&#8221;). Due to the specialized and unique nature of these Horizon R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented <ix:nonFraction unitRef="bundle" contextRef="c-97" decimals="INF" name="arwr:NumberOfDistinctBundle" format="ixt-sec:numwordsen" scale="0" id="f-478">one</ix:nonFraction> distinct bundle and, thus, <ix:nonFraction unitRef="obligation" contextRef="c-97" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-479">one</ix:nonFraction> performance obligation. Beyond the Horizon R&amp;D Services, which are the responsibility of the Company, Horizon will be responsible for managing future clinical development and commercialization of HZN-457. The Company conducted all activities through the preclinical stages of development of HZN-457. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, the Company received an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-480">40.0</ix:nonFraction>&#160;million in July 2021. The Company determined the initial transaction price totaled $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-481">40.0</ix:nonFraction>&#160;million and has excluded any future estimated milestones or royalties from this transaction price to date. The Company allocated the total $<ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-482">40.0</ix:nonFraction>&#160;million initial transaction price to its one distinct performance obligation for the HZN-457 license and the associated Horizon R&amp;D Services. Revenue was recognized on a straight-line basis over the timeframe for completing the Horizon R&amp;D Services. The Company determined that the straight-line basis was appropriate as its efforts were expended evenly over the course of completing its performance obligation. Further, Horizon enrolled the first subject in December 2022 in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HZN-457, triggering a $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" name="arwr:UpfrontMilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-483">15.0</ix:nonFraction>&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 21, 2023, the Company received notice from Horizon that it has elected to terminate the Horizon License Agreement. Horizon exercised its right to terminate the Horizon License Agreement for convenience. The termination will take effect on December 21, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has performed certain development and manufacturing activities, including drug substance and drug product manufacture under GMP conditions, for Horizon pursuant to the Horizon License Agreement. The Company recognized $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-484">1.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-485">2.5</ix:nonFraction>&#160;million in connection with these efforts for the years ended September&#160;30, 2023 and 2022, respectively. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;7, 2020, Takeda and the Company entered into an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;). Under the Takeda License Agreement, Takeda and the Company will co-develop the Company&#8217;s Fazirsiran program (formerly TAK-999 and ARO-AAT), the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, fazirsiran, if approved, will be co-commercialized under a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50/50 profit sharing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> structure. Outside the United States, Takeda received an exclusive license to commercialize fazirsiran and will lead the global commercialization strategy, while the Company will be eligible to receive tiered royalties of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-102" decimals="2" name="arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" scale="-2" id="f-486">20</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-103" decimals="2" name="arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" scale="-2" id="f-487">25</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on net sales. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Takeda License Agreement, the Company identified <ix:nonFraction unitRef="obligation" contextRef="c-104" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-488">one</ix:nonFraction> distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of fazirsiran drug product is completed and delivered to Takeda (the &#8220;Takeda R&amp;D Services&#8221;). Due to the specialized and unique nature of these Takeda R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent <ix:nonFraction unitRef="bundle" contextRef="c-104" decimals="INF" name="arwr:NumberOfDistinctBundle" format="ixt-sec:numwordsen" scale="0" id="f-489">one</ix:nonFraction> distinct bundle and, thus, <ix:nonFraction unitRef="obligation" contextRef="c-104" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-490">one</ix:nonFraction> performance obligation. Beyond the Takeda R&amp;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States. Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Takeda License Agreement, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-491">300.0</ix:nonFraction>&#160;million as an upfront payment in January 2021 and an additional $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="f-492">40.0</ix:nonFraction> million upon Takeda&#8217;s initiation of a Phase 3 REDWOOD clinical study of fazirsiran in March 2023, and is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="f-493">527.5</ix:nonFraction> million in additional potential development, regulatory and commercial milestones. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-440-3" continuedAt="f-440-4"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has allocated the total $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-494">300.0</ix:nonFraction> million initial transaction price to its <ix:nonFraction unitRef="obligation" contextRef="c-104" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-495">one</ix:nonFraction> distinct performance obligation for the fazirsiran license and the associated Takeda R&amp;D Services. Revenue is recognized using the input method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). The Company previously expected these clinical trials to extend to September 2025 in order to demonstrate long term safety and efficacy in the open label extension (OLE) part of the studies; however, in August 2023, Takeda initiated a Phase 3 OLE study available to patients participating in these Phase 2 studies. Based on this new information, patients enrolled in the SEQUOIA and AROAAT2002 studies are expected to complete their Phase 2 study visits between June 2023 and December 2023, shortening the Company&#8217;s performance obligation. As a result, effective the second quarter of fiscal 2023, the Company changed its estimates of the revenue recognition to better reflect this newly estimated performance period. The effect of these changes in estimates resulted in accelerated revenue by $<ix:nonFraction unitRef="usd" contextRef="c-107" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="f-496">70.5</ix:nonFraction>&#160;million, or $<ix:nonFraction unitRef="usdPerShare" contextRef="c-107" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-497">0.66</ix:nonFraction> per share (diluted) for the year ended September&#160;30, 2023. There were $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="f-498">0.9</ix:nonFraction>&#160;million of contract liabilities recorded as current deferred revenue as of September&#160;30, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also recorded $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="f-499">4.5</ix:nonFraction>&#160;million as accrued expenses as of September&#160;30, 2023 that was primarily driven by co-development and co-commercialization activities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 3, 2018, Janssen, part of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, and the Company entered into a License Agreement (the &#8220;Janssen License Agreement&#8221;). The Company also entered into a stock purchase agreement with JJDC, Inc. (&#8220;JJDC&#8221;), Johnson &amp; Johnson&#8217;s venture capital arm (the &#8220;JJDC Stock Purchase Agreement&#8221;). Under the Janssen License Agreement, Janssen received a worldwide, exclusive license to the Company&#8217;s JNJ-3989 (formerly ARO-HBV) program, the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#8217;s Phase 1/2 study of JNJ-3989, which the Company was responsible for completing, Janssen is wholly responsible for clinical development and commercialization of JNJ-3989. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Janssen License Agreement, the Company received $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-5" name="arwr:CashReceivedAsDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="f-500">175.0</ix:nonFraction> million as an upfront payment, $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-501">75.0</ix:nonFraction> million in the form of an equity investment by JJDC in the Company&#8217;s common stock under the JJDC Stock Purchase Agreement, and milestone and option payments totaling $<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="f-502">73.0</ix:nonFraction>&#160;million, and the Company may receive up to $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="arwr:DevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="f-503">825.0</ix:nonFraction> million in development and sales milestone payments for the Janssen License Agreement. The Company is further eligible to receive tiered royalties on product sales up to mid-teens under the Janssen License Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibility to complete the Phase 1/2 study of JNJ-3989 and the Company&#8217;s responsibility to ensure certain manufacturing of JNJ-3989 drug product is completed and delivered to Janssen (the &#8220;Janssen R&amp;D Services&#8221;). Due to the specialized and unique nature of these Janssen R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent <ix:nonFraction unitRef="bundle" contextRef="c-113" decimals="INF" name="arwr:NumberOfDistinctBundle" format="ixt-sec:numwordsen" scale="0" id="f-504">one</ix:nonFraction> distinct bundle and, thus, <ix:nonFraction unitRef="obligation" contextRef="c-113" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-505">one</ix:nonFraction> performance obligation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the transaction price totaled approximately $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-506">252.7</ix:nonFraction> million, which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, two $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="arwr:MilestonePaymentEarned" format="ixt:num-dot-decimal" scale="6" id="f-507">25.0</ix:nonFraction> million milestone payments related to JNJ-3989, and estimated payments for reimbursable Janssen R&amp;D Services to be performed. The Company has allocated the total $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-508">252.7</ix:nonFraction> million initial transaction price to its <ix:nonFraction unitRef="obligation" contextRef="c-113" decimals="INF" name="arwr:NumberOfDistinctPerformanceObligations" format="ixt-sec:numwordsen" scale="0" id="f-509">one</ix:nonFraction> distinct performance obligation for the JNJ-3989 license and the associated Janssen R&amp;D Services. The Company recognized this transaction price in its entirety as of September&#160;30, 2021, as its performance obligations were substantially completed. There were <ix:nonFraction unitRef="usd" contextRef="c-115" decimals="INF" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="0" id="f-510"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="f-511">no</ix:nonFraction></ix:nonFraction> contract assets and liabilities recorded as of September&#160;30, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 7, 2023, Janssen voluntarily terminated its collaboration agreement with the Company, dated October 3, 2018. Upon termination of the collaboration agreement, the Company regained full rights to ARO-PNPLA3, formerly called JNJ-75220795. ARO-PNPLA3 is in Phase 1 clinical trials that are now being developed by the Company.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amgen Inc. (&#8220;Amgen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2016, Amgen and the Company entered into <ix:nonFraction unitRef="agreement" contextRef="c-116" decimals="INF" name="arwr:NumberOfAgreements" format="ixt-sec:numwordsen" scale="0" id="f-512">two</ix:nonFraction> collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the &#8220;Olpasiran Agreement&#8221;), Amgen received a worldwide, exclusive license to the Company&#8217;s novel RNAi olpasiran (previously referred to as AMG- 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the Olpasiran Agreement, Amgen is wholly responsible for clinical development and commercialization. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Olpasiran Agreement, the Company has received $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="arwr:CashReceivedAsDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="f-513">35.0</ix:nonFraction>&#160;million in upfront payments and $<ix:nonFraction unitRef="usd" contextRef="c-117" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="f-514">21.5</ix:nonFraction>&#160;million in the form of an equity investment by Amgen in the Company&#8217;s common stock. Further, the Company received additional an </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-440-4"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-5" name="arwr:MilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-515">55.0</ix:nonFraction> million in milestone payments; $<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-5" name="arwr:MilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-516">10.0</ix:nonFraction> million upon Amgen&#8217;s initiation of a Phase 1 study in September 2018, $<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-5" name="arwr:MilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-517">20.0</ix:nonFraction> million upon its initiation of a Phase 2 clinical study in July 2020, and $<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-5" name="arwr:MilestonePaymentReceived" format="ixt:num-dot-decimal" scale="6" id="f-518">25.0</ix:nonFraction> million upon its first subject enrollment in a Phase 3 trial in December 2022. The Company has substantially completed its performance obligations under the Olpasiran Agreement. There were <ix:nonFraction unitRef="usd" contextRef="c-118" decimals="INF" name="us-gaap:ContractWithCustomerAssetNetCurrent" format="ixt:fixed-zero" scale="0" id="f-519"><ix:nonFraction unitRef="usd" contextRef="c-118" decimals="INF" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:fixed-zero" scale="0" id="f-520">no</ix:nonFraction></ix:nonFraction> contract assets and liabilities recorded as of September&#160;30, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, Royalty Pharma Investments 2019 ICAV (&#8220;Royalty Pharma&#8221;) and the Company entered into a Royalty Purchase Agreement (the &#8220;Royalty Pharma Agreement&#8221;). In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-5" name="arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" format="ixt:num-dot-decimal" scale="6" id="f-521">535.0</ix:nonFraction> million in remaining development, regulatory and sales milestone payments payable from Amgen and Royalty Pharma. See Note 13.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Joint Venture and License Agreement with Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2022, the Company entered into a License Agreement with Visirna (the &#8220;Visirna License Agreement&#8221;), pursuant to which Visirna received an exclusive license to develop, manufacture and commercialize four of the Company&#8217;s RNAi-based investigational cardiometabolic medicines in Greater China (including the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan). Pursuant to a Share Purchase Agreement entered into simultaneously with the Visirna License Agreement (the &#8220;Visirna SPA&#8221;), the Company acquired a majority stake in Visirna (after accounting for shares reserved for Visirna&#8217;s employee stock ownership plan) as partial consideration for the Visirna License Agreement. Under the Visirna SPA, entities affiliated with Vivo Capital also acquired a minority stake in Visirna in exchange for $<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-5" name="us-gaap:ProceedsFromContributedCapital" format="ixt:num-dot-decimal" scale="6" id="f-522">60.0</ix:nonFraction>&#160;million in upfront capital to support the operations of Visirna. As further consideration under the Visirna License Agreement, the Company is also eligible to receive potential royalties on commercial sales.</span></div></ix:continuation><div id="i2ac2b5b9b196490b92657e8462cd4206_145"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-523" continuedAt="f-523-1" escape="true">PROPERTY AND EQUIPMENT</ix:nonNumeric></span></div><ix:continuation id="f-523-1" continuedAt="f-523-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-524" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s major classes of property and equipment: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computers, software, office equipment and furniture </span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="INF" name="arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross" format="ixt:num-dot-decimal" scale="3" id="f-525">2,240</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="INF" name="arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross" format="ixt:num-dot-decimal" scale="3" id="f-526">2,182</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:Land" format="ixt:num-dot-decimal" scale="3" id="f-527">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:Land" format="ixt:num-dot-decimal" scale="3" id="f-528">2,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="arwr:ResearchEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-529">56,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="arwr:ResearchEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-530">38,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:LeaseholdImprovementsGross" format="ixt:num-dot-decimal" scale="3" id="f-531">103,813</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:LeaseholdImprovementsGross" format="ixt:num-dot-decimal" scale="3" id="f-532">42,017</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="f-533">166,655</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="3" id="f-534">56,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-535">332,213</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="f-536">141,851</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-537">41,951</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-538">31,554</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-539">290,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="f-540">110,297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for property and equipment for the years ended September&#160;30, 2023, 2022, and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-541">10.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-542">8.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="f-543">6.6</ix:nonFraction> million respectively. </span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-523-2">The increase in the construction in progress during 2023 was mainly due to the continuing developments of manufacturing, laboratory and office facilities in Verona, Wisconsin. In May 2023, the Company completed the development of the San Diego facility, which resulted in the reclassification of related construction in progress to leasehold improvements as of September&#160;30, 2023.</ix:continuation>  </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-18</span></div></div></div><div id="i2ac2b5b9b196490b92657e8462cd4206_148"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="f-544" continuedAt="f-544-1" escape="true">INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="f-544-1"><ix:nonNumeric contextRef="c-1" name="arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" id="f-545" continuedAt="f-545-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following:</span></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="f-546">295,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" format="ixt:fixed-zero" scale="3" id="f-547">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-548">2,964</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-549">292,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent" format="ixt:num-dot-decimal" scale="3" id="f-550">295,699</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" format="ixt:fixed-zero" scale="3" id="f-551">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-552">2,964</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-553">292,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2023, the Company changed the classification of its investment securities from held-to-maturity to available-for-sale. This change enables the Company&#8217;s need to be able to respond to market and liquidity risks in managing its portfolio. Such investments are carried at fair value with any unrealized gains and losses reported as a component of other accumulated comprehensive loss. At the date of the transfer, the carrying value of the Company&#8217;s held-to-maturity securities was $<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="f-554">295.7</ix:nonFraction>&#160;million, and net unrealized losses of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeReclassificationAdjustmentForHeldToMaturityTransferredToAvailableForSaleSecuritiesBeforeTax" format="ixt:num-dot-decimal" scale="6" id="f-555">3.0</ix:nonFraction>&#160;million were recognized in accumulated other comprehensive loss. <ix:continuation id="f-545-1" continuedAt="f-545-2">The Company does not believe that the available-for-sale debt securities that were in an unrealized loss position have any credit loss impairment as of September 30, 2023.</ix:continuation></span></div><ix:continuation id="f-545-2"><div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term investments (due within one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-556">218,391</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" format="ixt:fixed-zero" scale="3" id="f-557">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-558">3,661</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" format="ixt:num-dot-decimal" scale="3" id="f-559">214,730</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held-to-maturity certificate of deposit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-560">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" format="ixt:fixed-zero" scale="3" id="f-561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" format="ixt:fixed-zero" scale="3" id="f-562">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" format="ixt:num-dot-decimal" scale="3" id="f-563">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-564">268,391</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" format="ixt:fixed-zero" scale="3" id="f-565">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" format="ixt:num-dot-decimal" scale="3" id="f-566">3,661</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent" format="ixt:num-dot-decimal" scale="3" id="f-567">264,730</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term investments (Due within one through three years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-568">105,872</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" format="ixt:fixed-zero" scale="3" id="f-569">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-570">5,569</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-571">100,303</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total long-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-572">105,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" format="ixt:fixed-zero" scale="3" id="f-573">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-574">5,569</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-575">100,303</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div></ix:continuation></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-19</span></div></div></div><div id="i2ac2b5b9b196490b92657e8462cd4206_151"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="c-1" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="f-576" continuedAt="f-576-1" escape="true">INTANGIBLE ASSETS</ix:nonNumeric></span></div><ix:continuation id="f-576-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="f-577" continuedAt="f-577-1" escape="true">The following table presents the components of intangible assets: </ix:nonNumeric></span></div><ix:continuation id="f-577-1"><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"></td><td style="width:24.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful Lives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-578">21,728</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-579">13,321</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="f-580">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-127" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-581">8,407</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-127" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-582">14</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-583">3,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-584">1,274</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="f-585">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-128" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-586">1,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-128" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-587">21</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-588">24,857</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-589">14,595</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="f-590">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-591">10,262</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-592">21,728</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-593">11,770</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="f-594">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-130" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-595">9,958</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-130" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-596">14</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-597">3,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-598">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="f-599">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-131" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-600">2,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-131" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="f-601">21</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total intangible assets, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-602">24,857</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="3" id="f-603">12,895</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="INF" name="arwr:FiniteLivedIntangibleAssetsImpairment" format="ixt:fixed-zero" scale="3" id="f-604">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-132" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-605">11,962</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during 2023 and 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Intangible assets amortization expense in each of 2023, 2022, and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-606"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-607"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="f-608">1.7</ix:nonFraction></ix:nonFraction></ix:nonFraction> million. None of the intangible assets with definite useful lives are anticipated to have a residual value.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="f-609" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the estimated future amortization expense related to intangible assets as of September&#160;30, 2023:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.272%"><tr><td style="width:1.0%"></td><td style="width:60.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization Expense</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending September 30, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-610">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-611">1,700</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="3" id="f-612">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="3" id="f-613">1,700</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="3" id="f-614">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-615">1,762</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="INF" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="3" id="f-616">10,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i2ac2b5b9b196490b92657e8462cd4206_154"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <ix:nonNumeric contextRef="c-1" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="f-617" continuedAt="f-617-1" escape="true">STOCKHOLDERS&#8217; EQUITY</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfStockByClassTextBlock" id="f-618" continuedAt="f-618-1" escape="true"><ix:continuation id="f-617-1" continuedAt="f-617-2"><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s shares of common stock and preferred stock:</span></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-617-2"><ix:continuation id="f-618-1"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.818%"><tr><td style="width:1.0%"></td><td style="width:31.294%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-31" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-619">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-620">290,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-621">107,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-622">107,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-31" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-623">0.001</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-624">5,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="f-625">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-626">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-32" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-627">0.001</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-628">145,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-629">105,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-630">105,960</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-32" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-631">0.001</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-632">5,000</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="f-633">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-634">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;16, 2023, the Company&#8217;s stockholders approved an increase in authorized common shares, par value $<ix:nonFraction unitRef="usdPerShare" contextRef="c-133" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-635">0.001</ix:nonFraction> per share, from <ix:nonFraction unitRef="shares" contextRef="c-134" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-636">145,000,000</ix:nonFraction> to <ix:nonFraction unitRef="shares" contextRef="c-133" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-637">290,000,000</ix:nonFraction>. The amendment to the Amended and Restated Certificate of Incorporation was filed on April&#160;27, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023 and 2022, respectively, <ix:nonFraction unitRef="shares" contextRef="c-135" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-638">12,709,837</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-136" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-639">14,000,392</ix:nonFraction> shares of common stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Company&#8217;s 2004 Equity Incentive Plan, 2013 Incentive Plan, and 2021 Incentive Plan, as well as for inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 2, 2022, the Company entered into an open market sale agreement (the &#8220;Open Market Sale Agreement&#8221;), pursuant to which the Company may, from time to time, sell up to $<ix:nonFraction unitRef="usd" contextRef="c-137" decimals="INF" name="arwr:CommonStockCapitalSharesValueReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-640">250,000,000</ix:nonFraction> in shares of the Company&#8217;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#8220;ATM Offering&#8221;). The Company is not required to sell shares under the Open Market Sale Agreement. The Company will pay Jefferies LLC a commission of up to <ix:nonFraction unitRef="number" contextRef="c-138" decimals="3" name="arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" scale="-2" id="f-641">3.0</ix:nonFraction>% of the aggregate gross proceeds received from all sales of the common stock under the Open Market Sale Agreement. Unless otherwise terminated, the ATM Offering shall terminate upon the earlier of (i) the sale of all shares of common stock subject to the Sales Agreement and (ii) the termination of the Sales Agreement as permitted therein. The Company and Jefferies may each terminate the Open Market Sale Agreement at any time upon prior notice. As of September&#160;30, 2023, <ix:nonFraction unitRef="shares" contextRef="c-139" decimals="INF" name="us-gaap:SharesIssued" format="ixt:fixed-zero" scale="0" id="f-642">no</ix:nonFraction> shares have been issued under the Open Market Sale Agreement.</span></div></ix:continuation><div id="i2ac2b5b9b196490b92657e8462cd4206_157"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-643" continuedAt="f-643-1" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><ix:continuation id="f-643-1" continuedAt="f-643-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were <ix:nonFraction unitRef="usd" contextRef="c-31" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="f-644"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="INF" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="0" id="f-645">no</ix:nonFraction></ix:nonFraction> contingent liabilities recorded as of September&#160;30, 2023 and 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2021, the Company completed a purchase of <ix:nonFraction unitRef="acre" contextRef="c-140" decimals="INF" name="arwr:NumberOfAcresOfLandPurchased" scale="0" id="f-646">13</ix:nonFraction> acres of land in the Verona Technology Park in Verona, Wisconsin, which is being developed into an approximately <ix:nonFraction unitRef="sqft" contextRef="c-141" decimals="-3" name="us-gaap:AreaOfLand" format="ixt:num-dot-decimal" scale="0" id="f-647">160,000</ix:nonFraction> square foot drug manufacturing facility and an approximately <ix:nonFraction unitRef="sqft" contextRef="c-142" decimals="-3" name="us-gaap:AreaOfLand" format="ixt:num-dot-decimal" scale="0" id="f-648">140,000</ix:nonFraction> square foot laboratory and office facility which will support the Company&#8217;s process development and analytical activities. As of September&#160;30, 2023, the Company has incurred $<ix:nonFraction unitRef="usd" contextRef="c-143" decimals="-5" name="us-gaap:ConstructionInProgressGross" format="ixt:num-dot-decimal" scale="6" id="f-649">166.2</ix:nonFraction> million and intends to spend an additional $<ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-5" name="arwr:AmountIntendedToInvestForBuildoutOfFacilities" format="ixt:num-dot-decimal" scale="6" id="f-650">120.0</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-5" name="arwr:AmountIntendedToInvestForBuildoutOfFacilities" format="ixt:num-dot-decimal" scale="6" id="f-651">130.0</ix:nonFraction> million to complete the build out of the facilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of this land acquisition, the Company entered into a development agreement with the City of Verona to construct certain infrastructure improvements within the tax increment district and will be reimbursed up to $<ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-5" name="arwr:TaxIncrementFinancingAward" format="ixt:num-dot-decimal" scale="6" id="f-652">16.0</ix:nonFraction>&#160;million by the City of Verona by future tax increment revenue generated from the developed property. The total amount of funding that City of Verona will pay under the Tax Increment Financing program is not guaranteed and will depend on future tax revenues generated from the developed property</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also became eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-5" name="arwr:TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement" format="ixt:num-dot-decimal" scale="6" id="f-653">2.5</ix:nonFraction>&#160;million in refundable Wisconsin state income tax credits from the Wisconsin Economic Development Corporation (WEDC) as incentives for investing in the local community and creating new job opportunities. As of September&#160;30, 2023, the Company has collected $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCredits" format="ixt:num-dot-decimal" scale="6" id="f-654">1.5</ix:nonFraction> million of these credits. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Technology License Commitments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has licensed from third parties the rights to use certain technologies for its research and development activities, as well as in any products it may develop using these licensed technologies. These agreements and other similar agreements often require the Company to make milestone and royalty payments. Milestone payments, for example, may be </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-643-2">required as the research and development process progresses through various stages of development, such as when clinical candidates enter or progress through clinical trials, upon NDA and/or certain sales level milestones. The Company did not reach any milestones during the years of 2023 and 2022. During 2021, the Company triggered the milestone related to the progression of the ARO-ENaC and ARO-HIF2 candidates and made milestone payments of $<ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-5" name="arwr:MilestonePayments" format="ixt:num-dot-decimal" scale="6" id="f-655">2.4</ix:nonFraction> million.</ix:continuation> </span></div><div id="i2ac2b5b9b196490b92657e8462cd4206_160"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-656" continuedAt="f-656-1" escape="true">LEASES</ix:nonNumeric></span></div><ix:continuation id="f-656-1" continuedAt="f-656-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;19, 2021, the Company entered into a <ix:nonNumeric contextRef="c-149" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-657">15</ix:nonNumeric>-year lease for approximately <ix:nonFraction unitRef="sqft" contextRef="c-149" decimals="0" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="f-658">144,000</ix:nonFraction> square feet of office and research and development laboratory space in San Diego, California, for which the rent commencement date began on April&#160;19, 2023. This new facility accommodates increased personnel for its expanding pipeline of current and future drug candidates. Pursuant to the lease, within twelve months of the expiration of the initial <ix:nonNumeric contextRef="c-149" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:duryear" id="f-659">15</ix:nonNumeric>-year term, the Company has the option to extend the lease for up to <ix:nonFraction unitRef="option" contextRef="c-150" decimals="INF" name="arwr:NumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="f-660">one</ix:nonFraction> additional <ix:nonNumeric contextRef="c-149" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-661">ten-year</ix:nonNumeric> term, with certain annual increases in base rent. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease agreement grants the Company the right to receive an Additional Tenant Improvement Allowance (&#8220;ATIA&#8221;) funded by the lessor, with a maximum amount of $<ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="arwr:MaximumAdditionalTenantImprovementAllowance" format="ixt:num-dot-decimal" scale="6" id="f-662">7.2</ix:nonFraction> million, subject to a <ix:nonFraction unitRef="number" contextRef="c-149" decimals="2" name="arwr:AdditionalTenantImprovementAllowanceInterestPerAnnum" scale="-2" id="f-663">7</ix:nonFraction>% interest per annum over the base term. Further, on September&#160;25, 2023, the Company executed the first amendment to the lease, which grants a second ATIA with a maximum amount of $<ix:nonFraction unitRef="usd" contextRef="c-151" decimals="-5" name="arwr:MaximumAdditionalTenantImprovementAllowance" format="ixt:num-dot-decimal" scale="6" id="f-664">23.6</ix:nonFraction> million, bearing interest at a rate of <ix:nonFraction unitRef="number" contextRef="c-151" decimals="2" name="arwr:AdditionalTenantImprovementAllowanceInterestPerAnnum" scale="-2" id="f-665">9</ix:nonFraction>% per annum over the base term. The Company has received $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="arwr:AdditionalTenantImprovementAllowanceLiability" format="ixt:num-dot-decimal" scale="6" id="f-666">27.8</ix:nonFraction> million ATIA from the lessor as of September&#160;30, 2023. As a result, the Company remeasured its lease liability and right-of-use assets to reflect these additional allowances and the related increase lease payments. The Company has further concluded that these ATIAs have no effects on the classification of the lease.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Significant Leases</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pasadena, California</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases <ix:nonFraction unitRef="sqft" contextRef="c-153" decimals="-3" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="f-667">49,000</ix:nonFraction> square feet of office space located at 177 East Colorado Blvd. for its corporate headquarters from 177 Colorado Owner, LLC, which lease expires on April&#160;30, 2027. The lease contains an option to renew for <ix:nonFraction unitRef="option" contextRef="c-154" decimals="INF" name="arwr:NumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="f-668">one</ix:nonFraction> term of <span style="-sec-ix-hidden:f-669">five</span> years. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">San Diego, California</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company subleased space from Halozyme, Inc. for additional research and development space in San Diego, California. The term of this sublease commenced on April&#160;1, 2020 and ended on January&#160;14, 2023. On December&#160;23, 2022, the Company entered into a new <ix:nonNumeric contextRef="c-155" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-670">six-month</ix:nonNumeric> lease agreement with 11404 &amp; 11408 Sorrento Valley Owner (DE) LLC, effective January&#160;15, 2023. The lease ended on July&#160;15, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Madison, Wisconsin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases space for office and laboratory facilities, which expires on September&#160;30, 2031. The lease contains options to renew for <ix:nonFraction unitRef="option" contextRef="c-156" decimals="INF" name="arwr:NumberOfOptionsToRenew" format="ixt-sec:numwordsen" scale="0" id="f-671">two</ix:nonFraction> terms of <ix:nonNumeric contextRef="c-156" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="f-672">five years</ix:nonNumeric>. After accounting for additional rental square feet added pursuant to amendments to the lease agreement in 2019 and 2020, the Company currently leases a total of <ix:nonFraction unitRef="sqft" contextRef="c-156" decimals="-3" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="f-673">115,000</ix:nonFraction> square feet.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-674" continuedAt="f-674-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease assets and liabilities along with their classification on the Company&#8217;s consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"></td><td style="width:33.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.080%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-675">45,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-676">58,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-677">10,563</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-678">2,776</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-679">104,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-680">78,800</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost along with its classification on the Company&#8217;s consolidated statements of operations were as follows:</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-656-2"><ix:continuation id="f-674-1"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.388%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-681">10,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-682">7,278</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-683">3,649</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-684">1,730</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-685">1,757</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-686">1,498</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-687">1,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-688">728</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-159" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-689">814</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:fixed-zero" scale="3" id="f-690">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-3" name="us-gaap:VariableLeaseCost" format="ixt:fixed-zero" scale="3" id="f-691">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-162" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="f-692">1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-693">13,259</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-694">9,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-695">5,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Variable lease cost is primarily related to operating expenses associated with the Company&#8217;s operating leases.</span></div></ix:continuation><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-696">1.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="us-gaap:ShortTermLeaseCost" format="ixt:num-dot-decimal" scale="6" id="f-697">0.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" name="us-gaap:ShortTermLeaseCost" scale="6" id="f-698">0</ix:nonFraction> short-term lease cost during the years ended September&#160;30, 2023, 2022, and 2021, respectively. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-699" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents maturities of operating lease liabilities on an undiscounted basis as of September&#160;30, 2023:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"></td><td style="width:82.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="f-700">10,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="f-701">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="f-702">15,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="f-703">14,514</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" format="ixt:num-dot-decimal" scale="3" id="f-704">13,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" format="ixt:num-dot-decimal" scale="3" id="f-705">124,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-706">193,697</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="f-707">78,526</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-708">115,171</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"><tr><td style="width:1.0%"></td><td style="width:65.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash received for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-709">48,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="f-710">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" format="ixt:fixed-zero" scale="3" id="f-711">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for amended operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-712">17,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-713">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="3" id="f-714">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-715">5,204</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-716">4,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-717">3,100</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-31" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-718">13.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-32" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-719">7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-50" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-720">8</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-31" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-721">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-32" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-722">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-50" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-723">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-23</span></div></div></div><div id="i2ac2b5b9b196490b92657e8462cd4206_163"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-724" continuedAt="f-724-1" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="f-724-1" continuedAt="f-724-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan (the &#8220;2004 Plan&#8221;) and the 2013 Incentive Plan (the &#8220;2013 Plan&#8221;), <ix:nonFraction unitRef="shares" contextRef="c-163" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="f-725">0</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-164" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-726">3,408,707</ix:nonFraction> shares, respectively, of the Company&#8217;s common stock are reserved for the grant of stock options and restricted stock awards to employees and directors of the Company as of September&#160;30, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;18, 2021, the Company&#8217;s Board of Directors approved the Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan (the &#8220;2021 Plan&#8221;), which authorized <ix:nonFraction unitRef="shares" contextRef="c-165" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-727">8,000,000</ix:nonFraction> shares (subject to certain adjustments) available for grants of stock options, stock appreciation rights, restricted and unrestricted stock, performance awards, cash awards and other awards convertible into or otherwise based on shares of the Company&#8217;s common stock. The maximum number of shares authorized under the 2021 Plan will be (i) reduced by any shares subject to awards made under the 2013 Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. As of September&#160;30, 2023, the total number of shares reserved for issuance was <ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-728">6,204,720</ix:nonFraction> shares, which includes <ix:nonFraction unitRef="shares" contextRef="c-166" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-729">217,922</ix:nonFraction> shares that were forfeited under the 2013 Plan, and <ix:nonFraction unitRef="shares" contextRef="c-167" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-730">1,979,364</ix:nonFraction> shares have been granted under the 2021 Plan. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there were <ix:nonFraction unitRef="shares" contextRef="c-168" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-731">707,432</ix:nonFraction> shares reserved for options and <ix:nonFraction unitRef="shares" contextRef="c-169" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-732">683,825</ix:nonFraction> shares reserved for restricted stock units issued as inducement grants to new employees granted outside of the Company&#8217;s equity-based compensation plans under Rule 5635(c)(4) of the Nasdaq Listing Rules.   </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="f-733" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of awards outstanding:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2004 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2013 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inducement Awards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Granted and outstanding awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-163" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:fixed-zero" scale="0" id="f-734">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-164" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-735">1,522,207</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-170" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-736">33,838</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-171" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-737">707,432</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-738">2,263,477</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-172" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:fixed-zero" scale="0" id="f-739">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-173" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-740">1,886,500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-174" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-741">1,671,315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-175" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-742">683,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-176" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-743">4,241,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-163" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:fixed-zero" scale="0" id="f-744">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-164" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-745">3,408,707</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-170" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-746">1,705,153</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-171" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-747">1,391,257</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-748">6,505,117</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Awards</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-749" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the stock option activity for the year ended September&#160;30, 2023:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-750">2,721,384</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-32" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-751">20.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-752">32,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-753">33.03</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancelled or expired</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-754">50,708</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-755">60.72</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="f-756">439,350</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-757">6.94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at September 30, 2023</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-758">2,263,477</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-31" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-759">22.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-760">4.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="0" id="f-761">26,795,879</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at September 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-762">2,141,592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-31" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-763">21.45</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-764">4.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="0" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="0" id="f-765">26,786,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values represent the amount by which the market price of the underlying stock exceeds the exercise price of the option. The total intrinsic value of the options exercised during the years ended September&#160;30, 2023, 2022, and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-766">12.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-767">27.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="f-768">66.9</ix:nonFraction> million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to stock options outstanding for the years ended September&#160;30, 2023, 2022, and 2021 was $<ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-769">8.4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-770">10.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-771">12.4</ix:nonFraction> million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, the pre-tax compensation expense for all outstanding unvested stock options in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="f-772">2.9</ix:nonFraction> million will be recognized in the Company&#8217;s results of operations over a weighted average period of <ix:nonNumeric contextRef="c-177" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-773">0.4</ix:nonNumeric> years.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#8217;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-724-2" continuedAt="f-724-3"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subjective variables. Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-774" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the assumptions used in the calculation of grant-date fair values of these stock options based on the Black-Scholes option pricing model: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-775">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-33" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-776">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-34" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-777">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-778">3.69</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="c-1" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-779">4.57</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-34" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-780">0.40</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="c-34" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-781">1.1</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-782">86.4</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-34" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-783">86.2</ix:nonFraction> &#8211; <ix:nonFraction unitRef="number" contextRef="c-34" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-784">90.4</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-785">6.25</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-34" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-786">6.25</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-787">25.61</ix:nonFraction></span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-34" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-788">48.64</ix:nonFraction></span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) The dividend yield is <ix:nonFraction unitRef="number" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="f-789">zero</ix:nonFraction> as the Company currently does not pay a dividend. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(2) The risk-free interest rate is based on that of the U.S. Treasury yields with equivalent terms in effect at the time of the grant.. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(3) Volatility is estimated based on volatility average of the Company&#8217;s common stock price. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(4) The expected term represents the period of time that stock options granted are expected to be outstanding, by using historical exercise patterns and post-vesting termination behavior.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(5) No options were granted during the year ended September&#160;30, 2022.</span></div></ix:nonNumeric><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units (&#8220;RSUs&#8221;), including market-based, time-based and performance-based awards, have been granted under the Company&#8217;s 2013 and 2021 Plans and as inducements grants granted outside of the Company&#8217;s equity-based compensation plans. At vesting, each outstanding RSU will be exchanged for one share of the Company&#8217;s common stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="f-790" escape="true"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of the Company&#8217;s RSUs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2022</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-181" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-791">4,069,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-181" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-792">64.39</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-182" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-793">1,243,644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-182" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-794">34.32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-182" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-795">913,146</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-182" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-796">52.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-182" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-797">158,789</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-182" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-798">53.80</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2023</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-176" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-799">4,241,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-176" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-800">58.43</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs was determined based on the closing price of the Company&#8217;s common stock on the grant date, with consideration given to the probability of achieving service and/or performance conditions for awards.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 8, 2022, the Company revised the equity award made to its Chief Executive Officer on January 1, 2022 consisting of <ix:nonFraction unitRef="shares" contextRef="c-183" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-801">800,000</ix:nonFraction> shares, equal in value to $<ix:nonFraction unitRef="usd" contextRef="c-184" decimals="-5" name="arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" format="ixt:num-dot-decimal" scale="6" id="f-802">38.4</ix:nonFraction>&#160;million, that was a 100% market-based award. The revised awards consist of <ix:nonFraction unitRef="shares" contextRef="c-185" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-803">99,521</ix:nonFraction> RSUs and <ix:nonFraction unitRef="shares" contextRef="c-186" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-804">149,282</ix:nonFraction> performance-based RSUs. No incremental expense resulted from the modification. The fair values of these awards were estimated on the date of grant using a closed-form valuation model (Monte-Carlo).</span></div></ix:continuation><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-724-3">For the years ended September&#160;30, 2023, 2022 and 2021, the Company recorded stock-based compensation expense of $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-805">69.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-806">113.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="f-807">64.2</ix:nonFraction> million, respectively, related to shares of RSUs. As of September&#160;30, 2023, there was $<ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="f-808">94.4</ix:nonFraction> million of total unrecognized compensation cost related to RSUs that is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="c-182" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-809">1.6</ix:nonNumeric> years.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-25</span></div></div></div><div id="i2ac2b5b9b196490b92657e8462cd4206_166"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-810" continuedAt="f-810-1" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="f-810-1" continuedAt="f-810-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date using the exit price. Accordingly, when market observable data are not readily available, the Company&#8217;s own assumptions are used to reflect those that market participants would be presumed to use in pricing the asset or liability at the measurement date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on the consolidated balance sheets are categorized based on the level of judgment associated with inputs used to measure their fair values and the level of market price observability, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#160;&#160;&#160;&#160;Unadjusted quoted prices are available in active markets for identical assets or liabilities as of the  reporting date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#160;&#160;&#160;&#160;Pricing inputs are other than quoted prices in active markets, which are based on the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Quoted prices for similar assets or liabilities in active markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Quoted prices for identical or similar assets or liabilities in non-active markets; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Either directly or indirectly observable inputs as of the reporting date.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#160;&#160;&#160;&#160;Pricing inputs are unobservable and significant to the overall fair value measurement, and the determination of fair value requires significant management judgment or estimation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. Thus, a Level 3 fair value measurement may include inputs that are observable (Level 1 or Level 2) and unobservable (Level 3). The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and consideration of factors specific to the asset or liability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses prices and inputs that are current as of the measurement date, including during periods of market disruption. In periods of market disruption, the ability to observe prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2, or from Level 2 to Level 3. The Company recognizes transfers between levels at either the actual date of the event or a change in circumstances that caused the transfer. At September&#160;30, 2023 and 2022, the Company did not have any financial assets or financial liabilities based on Level 3 measurements</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-811" continuedAt="f-811-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis, and indicate the fair value hierarchy of the valuation techniques utilized by the Company: </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-810-2"><div style="margin-top:12pt;text-align:center"><ix:continuation id="f-811-1"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:33.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-812">31,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-813">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-814">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-815">31,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-816">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-817">7,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-818">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-819">7,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-820">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-821">22,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-822">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-823">22,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-824">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-825">231,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-826">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-827">231,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available-for-sale debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-828">31,553</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-829">261,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-830">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-831">292,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="f-832">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-833">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-834">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="f-835">347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-205" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-836">31,900</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-837">261,182</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-838">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-839">293,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:33.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Held-to-maturity debt securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="f-840">1,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="f-841">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="f-842">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="f-843">1,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="f-844">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="f-845">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="f-846">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="f-847">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="f-848">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="f-849">41,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="f-850">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="f-851">41,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="f-852">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="f-853">271,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="f-854">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="f-855">271,333</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="f-856">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="f-857">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="f-858">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="f-859">50,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total held-to-maturity debt securities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="f-860">51,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="f-861">313,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:fixed-zero" scale="3" id="f-862">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="3" id="f-863">365,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-237" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-864">39,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-238" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-865">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-239" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-866">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-240" decimals="-3" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-867">39,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial assets</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-868">91,235</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-869">313,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-235" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-870">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-236" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-871">404,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities were reclassified from held-to-maturity to available-for-sale recorded at fair value on a recurring basis. The fair value of debt securities are priced using model pricing based on the securities&#8217; relationship to other benchmark quoted prices as provided by an independent third party, and under GAAP are considered a Level 2 input.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Levels 1, 2, and 3 of the fair value hierarchy during the years ended September&#160;30, 2023 and 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses of the Company approximate fair value based on the short maturities of these instruments. At September&#160;30, 2023, the Company did not have any nonrecurring fair value measurements of nonfinancial assets or nonfinancial liabilities.</span></div></ix:continuation><div id="i2ac2b5b9b196490b92657e8462cd4206_169"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-872" continuedAt="f-872-1" escape="true">INCOME TAXES</ix:nonNumeric></span></div><ix:continuation id="f-872-1" continuedAt="f-872-2"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Provision</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="f-873" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the loss before income taxes are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-874">194,639</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-875">170,570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="3" id="f-876">140,846</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-877">7,852</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="3" id="f-878">1,708</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:fixed-zero" scale="3" id="f-879">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-880">202,491</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-881">172,278</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:IncomeLossAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-882">140,846</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-883" continuedAt="f-883-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes consisted of the following components:</span></div></ix:nonNumeric></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-872-2" continuedAt="f-872-3"><ix:continuation id="f-883-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:69.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.170%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.170%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.174%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-884">1,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-885">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="f-886">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-887">1,710</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-888">304</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-889">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-890">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-891">3,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-892">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current tax</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-893">2,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-894">3,785</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-895">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-896">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-897">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-898">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-899">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-900">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-901">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-902">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-903">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-904">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-905">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-906">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-907">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-908">2,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-909">3,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-910">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-911" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the tax expense based on the statutory rate to the Company&#8217;s actual tax expense in the consolidated statements of operations. A notional 21% tax rate was applied as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. federal statutory income tax</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-912">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-33" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-913">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-34" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-914">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-915">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-33" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-916">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-34" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-917">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" scale="-2" id="f-918">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-33" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" format="ixt:fixed-zero" scale="-2" id="f-919">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-34" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" format="ixt:fixed-zero" scale="-2" id="f-920">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Permanent and other items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-921">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-<ix:nonFraction unitRef="number" contextRef="c-33" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="f-922">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-34" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" format="ixt:fixed-zero" scale="-2" id="f-923">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-deductible compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="arwr:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent" scale="-2" id="f-924">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-33" decimals="3" name="arwr:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent" format="ixt:fixed-zero" scale="-2" id="f-925">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-34" decimals="3" name="arwr:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent" format="ixt:fixed-zero" scale="-2" id="f-926">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign-derived intangible income deduction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent" scale="-2" id="f-927">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-33" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent" format="ixt:fixed-zero" scale="-2" id="f-928">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-34" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent" format="ixt:fixed-zero" scale="-2" id="f-929">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-930">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-<ix:nonFraction unitRef="number" contextRef="c-33" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-931">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-34" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-932">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-933">20.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-<ix:nonFraction unitRef="number" contextRef="c-33" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-934">28.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-<ix:nonFraction unitRef="number" contextRef="c-34" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-935">29.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-936">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-<ix:nonFraction unitRef="number" contextRef="c-33" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-937">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-34" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" format="ixt:fixed-zero" scale="-2" id="f-938">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Income Taxes</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-939" continuedAt="f-939-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the significant components of the Company&#8217;s net deferred tax assets and liabilities: </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-872-3" continuedAt="f-872-4"><ix:continuation id="f-939-1"><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.404%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-940">60,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-941">171,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost" format="ixt:num-dot-decimal" scale="3" id="f-942">75,208</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost" scale="3" id="f-943">324</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-944">66,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" format="ixt:fixed-zero" scale="3" id="f-945">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-946">59,441</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="3" id="f-947">38,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-948">25,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-949">2,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-950">10,296</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-951">41,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" format="ixt:num-dot-decimal" scale="3" id="f-952">3,082</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" format="ixt:num-dot-decimal" scale="3" id="f-953">2,961</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-954">1,523</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-955">2,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-956">2,636</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-957">2,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-958">304,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-959">262,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Valuation allowance</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-960">284,626</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-961">242,394</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-962">9,878</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-963">1,088</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:num-dot-decimal" scale="3" id="f-964">9,966</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" format="ixt:fixed-zero" scale="3" id="f-965">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="arwr:DeferredTaxLiabilitiesStateTaxes" format="ixt:fixed-zero" scale="3" id="f-966">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="arwr:DeferredTaxLiabilitiesStateTaxes" format="ixt:num-dot-decimal" scale="3" id="f-967">19,390</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax liability</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-968">19,844</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-969">20,478</ix:nonFraction>)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="INF" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-970">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="INF" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-971">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded to reduce deferred tax assets to the amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended September&#160;30, 2023. Such objective evidence limits the ability to consider other subjective evidence such as its projections for future growth. On the basis of this evaluation at September&#160;30, 2023 and 2022, a valuation allowance of $<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-972">284.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="6" id="f-973">242.4</ix:nonFraction> million, respectively, has been recorded. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of September&#160;30, 2023, the Company had accumulated federal and state net operating loss (&#8220;NOL&#8221;) carry forwards of $<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-974">134.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-975">491.5</ix:nonFraction> million, respectively. Of the $<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-976">134.3</ix:nonFraction> million of federal NOL carryforwards, $<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-5" name="arwr:OperatingLossCarryforwardsSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-977">34.0</ix:nonFraction> million was generated before January 1, 2018 and is subject to the 20-year carryforward period (&#8220;pre-Tax Act losses&#8221;). The remaining $<ix:nonFraction unitRef="usd" contextRef="c-241" decimals="-5" name="arwr:OperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-978">100.3</ix:nonFraction> million (&#8220;post-Tax Act losses&#8221;) can be carried forward indefinitely but is subject to the 80% taxable income limitation. Of the $<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-5" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="6" id="f-979">491.5</ix:nonFraction> million of state NOL carryforwards $<ix:nonFraction unitRef="usd" contextRef="c-242" decimals="-5" name="arwr:OperatingLossCarryforwardsNotSubjectToExpiration" format="ixt:num-dot-decimal" scale="6" id="f-980">2.9</ix:nonFraction> million can be carried forward indefinitely. The pre-Tax Act U.S. federal and state net operating loss carryforwards will expire at various dates through 2041.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) Sections 382 and 383, annual use of an entity&#8217;s NOL and research and development credit carryforwards may be limited if there is a cumulative change in ownership of greater than 50% within a three-year period. The amount of the annual limitation is determined based on the value of the entity immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. If limited, the related tax asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. To date, the Company has not completed an analysis pursuant to Sections 382 and 383. Future changes in ownership may occur which could limit the Company&#8217;s ability to utilize attributes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uncertainty in Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted guidance issued by the FASB that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold of more-likely-than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more-likely-than not that a tax position will be sustained upon examination, based solely on the technical merits of the position and must assume that the tax position will be examined by taxing authorities. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-981" continuedAt="f-981-1" escape="true"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s gross unrecognized tax benefits:</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-872-4"><ix:continuation id="f-981-1"><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance of unrecognized tax benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-982">3,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="3" id="f-983">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="3" id="f-984">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross increase for prior period tax positions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-985">9,495</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-986">3,481</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-987">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross decrease for prior period tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-988">1,489</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-989">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-990">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross increase for current period tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:num-dot-decimal" scale="3" id="f-991">3,049</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-992">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="3" id="f-993">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance of unrecognized tax benefits</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-994">14,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-995">3,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:fixed-zero" scale="3" id="f-996">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended September&#160;30, 2023, 2022 and 2021, the Company has recorded income tax expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="f-997">0</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" format="ixt:num-dot-decimal" scale="6" id="f-998">3.5</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="f-999">0</ix:nonFraction> respectively, related to uncertain tax positions. The Company&#8217;s policy is to recognize potential interest and penalties related to unrecognized tax benefits associated with uncertain tax positions, if any, in the income tax provision. As of September&#160;30, 2023, the Company has accrued interest and penalties of $<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" format="ixt:num-dot-decimal" scale="6" id="f-1000">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" format="ixt:num-dot-decimal" scale="6" id="f-1001">0.9</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the unrecognized tax benefit at September&#160;30, 2023 are ultimately recognized, excluding the impact of U.S. Tax benefits netted against deferred taxes that are subject to a valuation allowance, approximately $<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="6" id="f-1002">3.5</ix:nonFraction> million would result in a reduction in the Company&#8217;s income tax expense and effective tax rate. The Company expects that $<ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" name="us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" format="ixt:num-dot-decimal" scale="6" id="f-1003">3.5</ix:nonFraction> million of its unrecognized tax benefits to change over the next 12 months.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to taxation in the U.S. and various states along with other foreign countries. Due to the presence of NOL carryforwards, all of the income tax years remain open for examination domestically. The Company has not been notified that it is under audit by the Internal Revenue Service or foreign taxing authorities; however, the Company has been notified of an income tax examination by the state of California. There are no other audits in any other jurisdictions.</span></div></ix:continuation><div id="i2ac2b5b9b196490b92657e8462cd4206_172"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12. <ix:nonNumeric contextRef="c-1" name="us-gaap:CompensationAndEmployeeBenefitPlansTextBlock" id="f-1004" continuedAt="f-1004-1" escape="true">EMPLOYEE BENEFIT PLANS</ix:nonNumeric></span></div><ix:continuation id="f-1004-1"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors a defined contribution retirement plan which is under Section 401(k) of the Internal Revenue Code and is designed to adhere to ERISA Fiduciary standards. Substantially all of the Company&#8217;s employees are eligible to participate this plan. Under the terms of the plan, an eligible employee may elect to contribute a portion of their salary on a pre-tax basis, subject to federal statutory limitations. The plan allows for a discretionary match in an amount up to <ix:nonFraction unitRef="number" contextRef="c-243" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="f-1005">100</ix:nonFraction>% of each participant&#8217;s first <ix:nonFraction unitRef="number" contextRef="c-243" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="f-1006">3</ix:nonFraction>% of compensation contributed plus <ix:nonFraction unitRef="number" contextRef="c-244" decimals="INF" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" scale="-2" id="f-1007">50</ix:nonFraction>% of each participant&#8217;s next <ix:nonFraction unitRef="number" contextRef="c-244" decimals="2" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" id="f-1008">2</ix:nonFraction>% of compensation contributed. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended September&#160;30, 2023, 2022, and 2021, the Company recorded expenses for the matching contributions under this plan of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-1009">2.2</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-1010">1.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="f-1011">1.3</ix:nonFraction> million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also provides certain employee benefit plans, including those which provide health and life insurance benefits to employees.</span></div></ix:continuation><div id="i2ac2b5b9b196490b92657e8462cd4206_425"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTE 13. <ix:nonNumeric contextRef="c-1" name="arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" id="f-1012" continuedAt="f-1012-1" escape="true">LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES</ix:nonNumeric></span></div><ix:continuation id="f-1012-1" continuedAt="f-1012-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2022, the Company and Royalty Pharma entered into the Royalty Pharma Agreement, pursuant to which Royalty Pharma agreed to pay up to $<ix:nonFraction unitRef="usd" contextRef="c-245" decimals="-5" name="arwr:InitialTransactionPrice" format="ixt:num-dot-decimal" scale="6" id="f-1013">410.0</ix:nonFraction> million in cash to the Company in consideration for the Company&#8217;s future royalty interest in olpasiran, a small interfering RNA (siRNA) originally developed by the Company and licensed to Amgen in 2016 under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="arwr:CashReceivedAsDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="f-1014">250.0</ix:nonFraction> million upfront and agreed to pay up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-5" name="arwr:MilestonePaymentReceivable" format="ixt:num-dot-decimal" scale="6" id="f-1015">160.0</ix:nonFraction> million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) $<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-5" name="arwr:MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" format="ixt:num-dot-decimal" scale="6" id="f-1016">50.0</ix:nonFraction> million on completion of enrollment in the OCEAN Phase 3 clinical trial for olpasiran, (ii) $<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-5" name="arwr:MilestonePaymentReceivableUponFDAApproval" format="ixt:num-dot-decimal" scale="6" id="f-1017">50.0</ix:nonFraction> million upon receipt of FDA approval of olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a)), and (iii) $<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-5" name="arwr:MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" format="ixt:num-dot-decimal" scale="6" id="f-1018">60.0</ix:nonFraction> million upon Royalty Pharma&#8217;s receipt of at least $<ix:nonFraction unitRef="usd" contextRef="c-246" decimals="-5" name="arwr:RoyaltyPaymentThreshold" format="ixt:num-dot-decimal" scale="6" id="f-1019">70.0</ix:nonFraction> million of royalty payments under the Royalty Pharma Agreement in any single calendar year. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="padding-left:27pt"><span><br/></span></div></div><ix:continuation id="f-1012-2"><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the terms of the Royalty Pharma Agreement and concluded in accordance with the relevant accounting guidance that the Company accounted for the transaction as debt and the funding of $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="arwr:CashReceivedAsDueUnderCollaborationAgreement" format="ixt:num-dot-decimal" scale="6" id="f-1020">250.0</ix:nonFraction> million from Royalty Pharma was recorded as a liability related to the sale of future royalties on its consolidated balance sheets. The Company is not obligated to repay this upfront funding received under the  Royalty Pharma Agreement. This liability is amortized over the expected repayment term using an effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate may vary during the term of the agreement depending on a number of factors, including the amount and timing of forecasted net revenues which affects the repayment timing and ultimate amount of repayment. The Company will evaluate the effective interest rate periodically based on its current revenue forecasts utilizing the prospective method. For 2023, the Company recognized non-cash interest expense of $<ix:nonFraction unitRef="usd" contextRef="c-247" decimals="-5" name="arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" format="ixt:num-dot-decimal" scale="6" id="f-1021">18.3</ix:nonFraction> million, on the consolidated statements of operations and comprehensive loss.</span></div></ix:continuation><div id="i2ac2b5b9b196490b92657e8462cd4206_431"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">NOTE 14. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-1022" continuedAt="f-1022-1" escape="true">EARNINGS PER SHARE</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-1023" escape="true"><ix:continuation id="f-1022-1" continuedAt="f-1022-2"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the computation of basic and diluted earnings per share for the years ended September&#160;30, 2023, 2022 and 2021. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1024">205,275</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1025">176,063</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-1026">140,848</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average basic shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1027">106,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1028">105,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-1029">103,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="3" id="f-1030">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="3" id="f-1031">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="3" id="f-1032">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average diluted shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1033">106,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-33" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1034">105,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-1035">103,745</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basic earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1036">1.92</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-33" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1037">1.67</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-34" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-1038">1.36</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1039">1.92</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-33" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1040">1.67</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-34" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-1041">1.36</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation></ix:nonNumeric><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1022-2">Potentially dilutive securities representing approximately <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1042">4,053,000</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-33" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1043">3,885,000</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-34" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="f-1044">2,063,000</ix:nonFraction> shares of common stock were excluded from the computation of diluted earnings per share for the years ended September&#160;30, 2023, 2022 and 2021, respectively, because their effect would have been anti-dilutive.</ix:continuation> </span></div><div id="i2ac2b5b9b196490b92657e8462cd4206_175"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 15. <ix:nonNumeric contextRef="c-1" name="us-gaap:SubsequentEventsTextBlock" id="f-1045" continuedAt="f-1045-1" escape="true">SUBSEQUENT EVENTS</ix:nonNumeric></span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-1045-1">On October 30, 2023, the Company entered into an Assignment and Consent Agreement with Janssen, whereby, the Company consented to the assignment of the Janssen License Agreement to GSK, which assignment shall be effective upon the receipt of certain anti-trust approvals.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">F-31</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>2
<FILENAME>a107-2021formofrsuoffice.htm
<DESCRIPTION>EX-10.7
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>a107-2021formofrsuoffice</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- a107-2021formofrsuoffice001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a107-2021formofrsuoffice001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">Name: Number of Restricted Stock Units subject to Award: Date of Grant: Vesting Schedule: Grant ID: ARROWHEAD PHARMACEUTICALS, INC. 2021 INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT (OFFICERS &amp; CERTAIN OTHER EMPLOYEES) This agreement (this &#8220;Agreement&#8221;) evidences an award (the &#8220;Award&#8221;) consisting of, in  aggregate, the number of restricted stock units set forth in the table above (the &#8220;Restricted Stock  Units&#8221; or &#8220;RSUs&#8221;) granted by Arrowhead Pharmaceuticals, Inc. (the &#8220;Company&#8221;) to the  individual named above (the &#8220;Grantee&#8221;) pursuant to and subject to the terms of the Arrowhead  Pharmaceuticals, Inc. 2021 Incentive Plan (as amended from time to time, the &#8220;Plan&#8221;), which is  incorporated herein by reference.  1. Grant of Restricted Stock Units.  The Company grants to the Grantee on the date set forth above (the &#8220;Date of Grant&#8221;) an award consisting of the right to receive on the terms  provided herein and in the Plan, one share of Stock with respect to each Restricted Stock Unit  forming part of the Award, in each case, subject to adjustment pursuant to Section 7 of the Plan  in respect of transactions occurring after the date hereof.   2. Meaning of Certain Terms.  Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.   3. Vesting.  Unless earlier terminated, forfeited, relinquished or expired, the Restricted Stock Units shall vest in accordance with the schedule set forth in the table above.   4. Delivery of Stock.  The Company shall deliver to the Grantee as soon as practicable upon the vesting of the Restricted Stock Units or any portion thereof, but in all events  no later than thirty (30) days following the date on which such Restricted Stock Units vest, one  share of Stock with respect to each such vested Restricted Stock Unit, subject to the terms of the  Plan and this Agreement. 5. Dividends; Other Rights.  The Award shall not be interpreted to bestow upon the Grantee any equity interest or ownership in the Company or any Affiliate prior to the date on  which the Company delivers shares of Stock to the Grantee (if any).  The Grantee is not entitled  to vote any shares of Stock by reason of the granting of this Award or to receive or be credited  with any dividends declared and payable on any share of Stock prior to the date on which any  such share is delivered to the Grantee hereunder.  The Grantee shall have the rights of a  shareholder only as to those shares of Stock, if any, that are actually delivered under this Award.   </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a107-2021formofrsuoffice002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a107-2021formofrsuoffice002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">- 2 - 6. Forfeiture; Recovery of Compensation. (a) To the extent that Grantee does not vest in any Restricted Stock Units, all interest in such Restricted Stock Units shall be forfeited.  Grantee has no right or interest in any  Restricted Stock Units that are forfeited. (b) The Administrator may cancel, rescind, withhold or otherwise limit or restrict the Award at any time if the Grantee is not in compliance with all applicable provisions of this  Agreement and the Plan. (c) By accepting the Award the Grantee expressly acknowledges and agrees that his or her rights (and those of any permitted transferee of the Award) under the Award to any Stock  acquired under the Award or any proceeds from the disposition thereof, are subject to Section  6(a)(6) of the Plan (including any successor provision).  Nothing in the preceding sentence shall  be construed as limiting the general application of Section 11 of this Agreement. 7. Nontransferability.  Neither the Award nor the Restricted Stock Units may be transferred except as expressly permitted under Section 6(a)(3) of the Plan. 8. Certain Tax Matters.  The Grantee expressly acknowledges and agrees that the Grantee&#8217;s rights hereunder, including the right to be issued shares of Stock upon the vesting of  the Restricted Stock Units (or any portion thereof), are subject to the Grantee&#8217;s promptly paying,  or in respect of any later requirement of withholding being liable promptly to pay at such time as  such withholdings are due, to the Company in cash (or by such other means as may be acceptable  to the Administrator in its discretion) all taxes required to be withheld, if any.  No shares of  Stock will be transferred pursuant to the vesting of the Restricted Stock Units (or any portion  thereof) unless and until the Grantee or the person then holding the Award has remitted to the  Company an amount in cash sufficient to satisfy any federal, state, or local requirements with  respect to tax withholdings then due and has committed (and by accepting this Award the  Grantee shall be deemed to have committed) to pay in cash all tax withholdings required at any  later time in respect of the transfer of such shares, or has made other arrangements satisfactory to  the Administrator with respect to such taxes.  The Grantee also authorizes the Company and its  subsidiaries to withhold any required tax withholdings amount from any amounts otherwise  owed to the Grantee, but nothing in this sentence shall be construed as relieving the Grantee of  any liability for satisfying his or her obligations under the preceding provisions of this Section.  9. Net Settlement.  With the written consent of the Company and approval by the Administrator, the payment of the Grantee&#8217;s tax withholding obligations may be made via &#8220;net  settlement&#8221;, whereby the Grantee elects to satisfy all applicable tax withholding requirements via  issuance from Company to the Grantee an amount of shares consisting of the number of shares  vested less shares withheld to cover the tax withholding obligations (&#8220;the withheld shares&#8221;).  In  this case, the Company will remit to the appropriate taxing authorities withheld taxes on behalf  of the Grantee in an amount equal to the value of the withheld shares.  The number of withheld  shares will be calculated by valuing the withheld shares based upon the closing price on the  applicable vesting date.  Net settlement resulting in partial shares will be rounded up.  Tax  withholding due related to federal and state income taxes will be made at minimum withholding  requirements. </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a107-2021formofrsuoffice003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a107-2021formofrsuoffice003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">- 3 - 10. Effect on Employment.  Neither the grant of the Award, nor the issuance of  Shares upon vesting of the Award, will give the Grantee any right to be retained in the employ or  service of the Company or any of its Affiliates, affect the right of the Company or any of its  Affiliates to discharge or discipline such Grantee at any time, or affect any right of such Grantee  to terminate his or her Employment at any time. 11. Provisions of the Plan.  A copy of the Plan as in effect on the Date of Grant has  been furnished to the Grantee.  By accepting the Award, the Grantee agrees to be bound by the  terms of the Plan and this Agreement.  In the event of any conflict between the terms of this  Agreement and the Plan, the terms of the Plan shall control.   12. Acknowledgments.  The Grantee acknowledges and agrees that (a) this Agreement may be executed in two or more counterparts, each of which shall be an original and  all of which together shall constitute one and the same instrument, (b) this agreement may be  executed and exchanged using facsimile, portable document format (PDF) or electronic  signature, which, in each case, shall constitute an original signature for all purposes hereunder  and (c) such signature by the Company will be binding against the Company and will create a  legally binding agreement when this Agreement is countersigned by the Grantee. 13. Electronic Delivery and Acceptance. The Company may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan or future  Awards that may be granted under the Plan by electronic means or to request the Grantee&#8217;s  consent to participate in the Plan by electronic means. The Grantee hereby consents to receive  such documents by electronic delivery and, if requested, agrees to accept this Award and  participate in the Plan through an online or electronic system established and maintained by the  Company or a third party designated by the Company. [The remainder of this page is intentionally left blank.] </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a107-2021formofrsuoffice004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a107-2021formofrsuoffice004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">[Signature Page to Restricted Stock Unit Agreement] IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its  duly authorized officer.   ARROWHEAD PHARMACEUTICALS, INC. By:            Name:   Title:  Date:   Accepted by: If the Company requests that the Grantee&#8217;s acceptance of this Agreement be evidenced other  than electronically, please complete and sign the following: Acknowledged and Agreed: _______________________        ParticipantNam Date:  ______________________ </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>3
<FILENAME>a109-2021formrsuawardemp.htm
<DESCRIPTION>EX-10.9
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>a109-2021formrsuawardemp</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- a109-2021formrsuawardemp001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a109-2021formrsuawardemp001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">Name: Number of Restricted Stock Units subject to Award: Date of Grant: Vesting Schedule: Grant ID: ARROWHEAD PHARMACEUTICALS, INC. 2021 INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT (EMPLOYEES) This agreement (this &#8220;Agreement&#8221;) evidences an award (the &#8220;Award&#8221;) consisting of, in  aggregate, the number of restricted stock units set forth in the table above (the &#8220;Restricted Stock  Units&#8221; or &#8220;RSUs&#8221;) granted by Arrowhead Pharmaceuticals, Inc. (the &#8220;Company&#8221;) to the  individual named above (the &#8220;Grantee&#8221;) pursuant to and subject to the terms of the Arrowhead  Pharmaceuticals, Inc. 2021 Incentive Plan (as amended from time to time, the &#8220;Plan&#8221;), which is  incorporated herein by reference.  1. Grant of Restricted Stock Units.  The Company grants to the Grantee on the date set forth above (the &#8220;Date of Grant&#8221;) an award consisting of the right to receive on the terms  provided herein and in the Plan, one share of Stock with respect to each Restricted Stock Unit  forming part of the Award, in each case, subject to adjustment pursuant to Section 7 of the Plan  in respect of transactions occurring after the date hereof.   2. Meaning of Certain Terms.  Except as otherwise defined herein, all capitalized terms used herein have the same meaning as in the Plan.   3. Vesting.  Unless earlier terminated, forfeited, relinquished or expired, the Restricted Stock Units shall vest in accordance with the schedule set forth in the table above.   4. Delivery of Stock.  The Company shall deliver to the Grantee as soon as practicable upon the vesting of the Restricted Stock Units or any portion thereof, but in all events  no later than thirty (30) days following the date on which such Restricted Stock Units vest, one  share of Stock with respect to each such vested Restricted Stock Unit, subject to the terms of the  Plan and this Agreement. 5. Dividends; Other Rights.  The Award shall not be interpreted to bestow upon the Grantee any equity interest or ownership in the Company or any Affiliate prior to the date on  which the Company delivers shares of Stock to the Grantee (if any).  The Grantee is not entitled  to vote any shares of Stock by reason of the granting of this Award or to receive or be credited  with any dividends declared and payable on any share of Stock prior to the date on which any  such share is delivered to the Grantee hereunder.  The Grantee shall have the rights of a  shareholder only as to those shares of Stock, if any, that are actually delivered under this Award.   </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a109-2021formrsuawardemp002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a109-2021formrsuawardemp002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">- 2 - 6. Forfeiture; Recovery of Compensation. (a) To the extent that Grantee does not vest in any Restricted Stock Units, all interest in such Restricted Stock Units shall be forfeited.  Grantee has no right or interest in any  Restricted Stock Units that are forfeited. (b) The Administrator may cancel, rescind, withhold or otherwise limit or restrict the Award at any time if the Grantee is not in compliance with all applicable provisions of this  Agreement and the Plan. (c) By accepting the Award the Grantee expressly acknowledges and agrees that his or her rights (and those of any permitted transferee of the Award) under the Award to any Stock  acquired under the Award or any proceeds from the disposition thereof, are subject to Section  6(a)(6) of the Plan (including any successor provision).  Nothing in the preceding sentence shall  be construed as limiting the general application of Section 11 of this Agreement. 7. Nontransferability.  Neither the Award nor the Restricted Stock Units may be transferred except as expressly permitted under Section 6(a)(3) of the Plan. 8. Certain Tax Matters.  The Grantee expressly acknowledges and agrees that the Grantee&#8217;s rights hereunder, including the right to be issued shares of Stock upon the vesting of  the Restricted Stock Units (or any portion thereof), are subject to the Grantee&#8217;s promptly paying,  or in respect of any later requirement of withholding being liable promptly to pay at such time as  such withholdings are due, to the Company in cash (or by such other means as may be acceptable  to the Administrator in its discretion) all taxes required to be withheld, if any.  No shares of  Stock will be transferred pursuant to the vesting of the Restricted Stock Units (or any portion  thereof) unless and until the Grantee or the person then holding the Award has remitted to the  Company an amount in cash sufficient to satisfy any federal, state, or local requirements with  respect to tax withholdings then due and has committed (and by accepting this Award the  Grantee shall be deemed to have committed) to pay in cash all tax withholdings required at any  later time in respect of the transfer of such shares, or has made other arrangements satisfactory to  the Administrator with respect to such taxes.  The Grantee also authorizes the Company and its  subsidiaries to withhold any required tax withholdings amount from any amounts otherwise  owed to the Grantee, but nothing in this sentence shall be construed as relieving the Grantee of  any liability for satisfying his or her obligations under the preceding provisions of this Section.  9. Net Settlement.  With the written consent of the Company and approval by the Administrator, the payment of the Grantee&#8217;s tax withholding obligations may be made via &#8220;net  settlement&#8221;, whereby the Grantee elects to satisfy all applicable tax withholding requirements via  issuance from Company to the Grantee an amount of shares consisting of the number of shares  vested less shares withheld to cover the tax withholding obligations (&#8220;the withheld shares&#8221;).  In  this case, the Company will remit to the appropriate taxing authorities withheld taxes on behalf  of the Grantee in an amount equal to the value of the withheld shares.  The number of withheld  shares will be calculated by valuing the withheld shares based upon the closing price on the  applicable vesting date.  Net settlement resulting in partial shares will be rounded up.  Tax  withholding due related to federal and state income taxes will be made at minimum withholding  requirements. </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a109-2021formrsuawardemp003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a109-2021formrsuawardemp003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">- 3 - 10. Effect on Employment.  Neither the grant of the Award, nor the issuance of  Shares upon vesting of the Award, will give the Grantee any right to be retained in the employ or  service of the Company or any of its Affiliates, affect the right of the Company or any of its  Affiliates to discharge or discipline such Grantee at any time, or affect any right of such Grantee  to terminate his or her Employment at any time. 11. Provisions of the Plan.  A copy of the Plan as in effect on the Date of Grant has  been furnished to the Grantee.  By accepting the Award, the Grantee agrees to be bound by the  terms of the Plan and this Agreement.  In the event of any conflict between the terms of this  Agreement and the Plan, the terms of the Plan shall control.   12. Acknowledgments.  The Grantee acknowledges and agrees that (a) this Agreement may be executed in two or more counterparts, each of which shall be an original and  all of which together shall constitute one and the same instrument, (b) this agreement may be  executed and exchanged using facsimile, portable document format (PDF) or electronic  signature, which, in each case, shall constitute an original signature for all purposes hereunder  and (c) such signature by the Company will be binding against the Company and will create a  legally binding agreement when this Agreement is countersigned by the Grantee. 13. Electronic Delivery and Acceptance. The Company may, in its sole discretion, decide to deliver any documents related to the Award and participation in the Plan or future  Awards that may be granted under the Plan by electronic means or to request the Grantee&#8217;s  consent to participate in the Plan by electronic means. The Grantee hereby consents to receive  such documents by electronic delivery and, if requested, agrees to accept this Award and  participate in the Plan through an online or electronic system established and maintained by the  Company or a third party designated by the Company. [The remainder of this page is intentionally left blank.] </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a109-2021formrsuawardemp004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a109-2021formrsuawardemp004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">[Signature Page to Restricted Stock Unit Agreement] IN WITNESS WHEREOF, the Company has caused this Agreement to be executed by its  duly authorized officer.   ARROWHEAD PHARMACEUTICALS, INC. By:        Name:   Title:  Date:   Accepted by: If the Company requests that the Grantee&#8217;s acceptance of this Agreement be evidenced other  than electronically, please complete and sign the following: Acknowledged and Agreed: _______________________         Participant Name Date:  ______________________ </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>4
<FILENAME>a1011-arrowhead_2021plan.htm
<DESCRIPTION>EX-10.11
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>a1011-arrowhead_2021plan</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- a1011-arrowhead_2021plan001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a1011-arrowhead_2021plan001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">    STOCK OPTION GRANT  2021 INCENTIVE PLAN  NOTICE OF GRANT  (PART I OF THE STOCK OPTION AWARD AGREEMENT)  To: _______________ (&#8220;Optionee&#8221;)  From: Arrowhead Pharmaceuticals, Inc.  We are pleased to inform you that you have been approved for a grant of an option (your &#8220;Option&#8221;) to  purchase shares of Arrowhead Pharmaceuticals, Inc.&#8217;s common stock.  Your Option has been granted pursuant to, and shall be governed by, the Company&#8217;s 2021 Incentive Plan (the  &#8220;Plan&#8221;), as currently in effect and as may be amended hereafter from time to time, the attached Stock Option Award  Agreement (the &#8220;Option Agreement&#8221;) and the following specific provisions (which are subject to adjustment under  the Plan and the Option Agreement):  The &#8220;Date of Grant&#8221; for your Option is:  The &#8220;Expiration Date&#8221; of your Option is:  The &#8220;Number of Shares&#8221; covered by your Option is:  The &#8220;Exercise Price&#8221; per share for your Option is:  The &#8220;Commencement Date&#8221; of your Option is:  Vesting: As long as you remain an employee or board member of the Company, your Option will vest and  become exercisable with respect to ____ of the Number of Shares one year from the Commencement Date and then  in ____ equal monthly installments thereafter. Your Option cannot be exercised except to the extent vested; if all  other terms and conditions are satisfied, your Option will be fully vested and exercisable as of the fourth anniversary  of the Commencement Date. Of course, you can never exercise the Option for more than the Number of Shares or  after the Expiration Date (in each case as adjusted under the terms of the Plan and the Option Agreement). This  Option is a non-statutory Stock Option under the U.S. Internal Revenue Code of 1986, as amended.    Electronic Acceptance: The Option is contingent upon your agreement to the provisions of this Notice of  Grant and the terms and conditions of the Plan and the Option Agreement, which are hereby delivered via the online  Document Library of the Company&#8217;s stock option administration portal (the &#8220;Portal&#8221;). Your electronic acceptance  of the grant in the Portal constitutes your agreement to these terms and conditions as binding as a manual signature.  Your electronic acceptance also signifies your consent to be governed by the terms and conditions of use of the  Portal, also made available in the Document Library. Provisions of the Plan, the Option Agreement and this Notice  of Grant and the terms of use of the Portal are subject to adjustment. Paper copies of any of these documents can be  requested from the Administrator (as defined in the Plan).  Grant Number:  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a1011-arrowhead_2021plan002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a1011-arrowhead_2021plan002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">    ARROWHEAD PHARMACEUTICALS, INC.  STOCK OPTION AWARD AGREEMENT  Unless otherwise defined herein, the terms defined in the Arrowhead Pharmaceuticals, Inc. 2021 Incentive  Plan (the &#8220;Plan&#8221;) shall have the same defined meanings in this Stock Option Award Agreement (the &#8220;Option  Agreement&#8221;).  AGREEMENT  A. Grant of Option.  (i) Arrowhead Pharmaceuticals, Inc. (the &#8220;Company&#8221;) hereby grants to the optionee named in the  Notice of Grant attached as Part I of this Option Agreement (the &#8220;Optionee&#8221;), on the date of grant set forth in the  Notice of Grant, an option (the &#8220;Option&#8221;) to purchase the number of shares of the Company&#8217;s common stock  (&#8220;Shares&#8221;), as set forth in the Notice of Grant, at the exercise price per Share set forth in the Notice of Grant (the  &#8220;Exercise Price&#8221;). The Option has been granted pursuant to, and shall be governed by, the Plan, as currently in  effect and as may be amended hereafter from time to time, the terms of which are incorporated herein by reference.  In the event of a conflict between the terms and conditions of the Plan and the terms and conditions of this Option  Agreement, the terms and conditions of the Plan shall prevail.  (ii) This Option shall be treated as a non-statutory Stock Option (&#8220;NSO&#8221;) under Section 422 of the  U.S. Internal Revenue Code of 1986, as amended.  B. Exercise of Option.  (i) Right to Exercise. This Option is exercisable during its term in accordance with the vesting  schedule set out in the Notice of Grant and the applicable provisions of the Plan and this Option Agreement.  (ii) Exercise Period. In no event shall this Option be exercised later than the Expiration Date set forth  in the Notice of Grant. Specifically, any vested portion of this Option may be exercised after a termination of  Employment in accordance with the provisions of Section 6(a)(4) of the Plan, but not later than the Expiration Date  set forth in the Notice of Grant.  (iii) Method of Exercise. This Option is exercisable by delivery of an exercise notice, in the form  attached as Exhibit A (the &#8220;Exercise Notice&#8221;), which shall state the election to exercise the Option, the number of  Shares in respect of which the Option is being exercised (the &#8220;Exercised Shares&#8221;), and such other representations  and agreements as may be required by the Company pursuant to the provisions of the Plan. The Exercise Notice  shall be completed by the Optionee and delivered to the Secretary of the Company. The Exercise Notice shall be  accompanied by payment of the aggregate Exercise Price as to all Exercised Shares. This Option shall be deemed to  be exercised with respect to the Exercised Shares upon receipt by the Company of such fully executed Exercise  Notice accompanied by such aggregate Exercise Price  (iv) Tax Withholding. The Optionee shall, not later than the date as of which the exercise of this  Option becomes a taxable event for federal income tax purposes, pay to the Company or make arrangements  satisfactory to the Administrator for payment of any federal, state, and local taxes required by law to be withheld on  account of such taxable event.  The Company shall have the authority to cause the required tax withholding  obligation to be satisfied, in whole or in part, by withholding from Shares to be issued to the Optionee a number of  Shares with an aggregate Fair Market Value that would satisfy the withholding amount due.  The Company shall not  be obligated to issue any Shares pursuant to the exercise of this Option unless and until the Optionee satisfies such  withholding obligations.   (v) Compliance with Applicable Laws. No Shares shall be issued pursuant to the exercise of this  Option unless such issuance and exercise complies with applicable laws. Assuming such compliance, for income tax  purposes the Exercised Shares shall be considered transferred to the Optionee on the date the Option is exercised  with respect to such Exercised Shares.  C. Method of Payment.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a1011-arrowhead_2021plan003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a1011-arrowhead_2021plan003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">    Payment of the aggregate Exercise Price shall be by any of the following, or a combination thereof, at  the election of the Optionee:    1. Cash; or  2. Check; or  3. Consideration received by the Company under a cashless exercise program implemented by the  Company in connection with the Plan; or  4. Surrender of other Shares which (i) in the case of Shares acquired upon exercise of an option, have  been owned by the Optionee for more than six (6) months on the date of surrender, and (ii) have a Fair Market  Value on the date of surrender equal to the aggregate Exercise Price of the Exercised Shares.  D. Non-Transferability of Option. This Option may not be transferred in any manner other than by will or by  the laws of descent or distribution and may be exercised during the lifetime of Optionee only by the Optionee. The  terms of the Plan and this Option Agreement shall be binding upon the executors, administrators, heirs, successors  and assigns of the Optionee.  E. Term of Option. This Option may be exercised only within the term set out in the Notice of Grant, and may  be exercised during such term only in accordance with the Plan and the terms of this Option Agreement.  F. Tax Consequences. Some of the federal tax consequences relating to this Option, as of the date of this  Option, are set forth below. THIS SUMMARY IS NECESSARILY INCOMPLETE, AND THE TAX LAWS AND  REGULATIONS ARE SUBJECT TO CHANGE. THE OPTIONEE SHOULD CONSULT A TAX ADVISER  BEFORE EXERCISING THIS OPTION OR DISPOSING OF THE SHARES.  (i) Exercise of Option. The Optionee may incur regular federal income tax liability upon exercise of an  NSO. The Optionee will be treated as having received compensation income (taxable at ordinary income tax rates)  equal to the excess, if any, of the Fair Market Value of the Exercised Shares on the date of exercise over their  aggregate Exercise Price. If the Optionee is an Employee or a former Employee, the Company will be required to  withhold from his or her compensation or collect from Optionee and pay to the applicable taxing authorities an  amount in cash equal to a percentage of this compensation income at the time of exercise, and may refuse to honor  the exercise and refuse to deliver Shares if such withholding amounts are not delivered at the time of exercise. This  Option does not qualify as an incentive stock option under Section 422 of the U.S. Internal Revenue Code of 1986,  as amended.  (ii) Disposition of Shares. If the Optionee holds NSO Shares for at least one year, any gain realized on  disposition of the Shares will be treated as long-term capital gain for federal income tax purposes.  G. Entire Agreement: Governing Law. The Plan is incorporated herein by reference. The Plan, this Option  Agreement and the Notice of Grant constitute the entire agreement of the parties with respect to the subject matter  hereof and supersede in their entirety all prior undertakings and agreements of the Company and Optionee with  respect to the subject matter hereof. This agreement is governed by the internal substantive laws but not the choice  of law rules of Delaware.  H. Forfeiture; Recovery of Compensation. By accepting this Option the Optionee expressly acknowledges and  agrees that his or her rights (and those of any permitted transferee) under this Option or to any Shares acquired  under this Option or any proceeds from the disposition thereof are subject to Section 6(a)(6) of the Plan (including  any successor provision).    I. NO GUARANTEE OF CONTINUED SERVICE. OPTIONEE ACKNOWLEDGES AND AGREES THAT  THE VESTING OF SHARES PURSUANT TO THE VESTING SCHEDULE HEREOF IS EARNED ONLY BY  CONTINUING AS A SERVICE PROVIDER AT THE WILL OF THE COMPANY (AND NOT THROUGH THE  ACT OF BEING HIRED, BEING GRANTED AN OPTION OR PURCHASING SHARES HEREUNDER).  OPTIONEE FURTHER ACKNOWLEDGES AND AGREES THAT THIS AGREEMENT, THE  TRANSACTIONS CONTEMPLATED HEREUNDER AND THE VESTING SCHEDULE SET FORTH HEREIN  DO NOT CONSTITUTE AN EXPRESS OR IMPLIED PROMISE OF CONTINUED ENGAGEMENT AS A  SERVICE PROVIDER FOR THE VESTING PERIOD, FOR ANY PERIOD, OR AT ALL, AND SHALL NOT  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a1011-arrowhead_2021plan004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a1011-arrowhead_2021plan004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">    INTERFERE WITH OPTIONEE&#8217;S RIGHT OR THE COMPANY&#8217;S RIGHT TO TERMINATE OPTIONEE&#8217;S  RELATIONSHIP AS A SERVICE PROVIDER AT ANY TIME, WITH OR WITHOUT CAUSE.  J. Electronic Delivery and Acceptance. The Company may, in its sole discretion, decide to deliver any  documents related to this Award or future Awards by electronic means or to request the Optionee&#8217;s consent to  participate in the Plan by electronic means. The Optionee hereby consents to receive such documents by electronic  delivery and, if requested, agrees to accept this Award and participate in the Plan through an online or electronic  system established and maintained by the Company or a third party designated by the Company.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a1011-arrowhead_2021plan005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a1011-arrowhead_2021plan005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">    Optionee has reviewed the Plan, this Option Agreement and the Notice of Grant in their entirety, has had an  opportunity to obtain the advice of counsel prior to executing this Option Agreement and fully understands all  provisions of the Plan, this Option Agreement and the Notice of Grant. Optionee hereby agrees to accept as binding,  conclusive and final all decisions or interpretations of the Administrator upon any questions relating to the Plan, this  Option Agreement and the Notice of Grant. Optionee further agrees to notify the Company upon any change in the  residence address indicated in this Option Agreement.     ARROWHEAD PHARMACEUTICALS,  INC.     By:      Name:     Title:      Date:  Accepted by:  Date:  If the Company requests that the Grantee&#8217;s acceptance of this Agreement be evidenced other than electronically,  please complete and sign the following:           Date:      </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a1011-arrowhead_2021plan006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a1011-arrowhead_2021plan006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">    EXHIBIT A  ARROWHEAD PHARMACEUTICALS, INC.  2021 INCENTIVE PLAN  EXERCISE NOTICE  Arrowhead Pharmaceuticals, Inc.  177 East Colorado Boulevard, Suite 700  Pasadena, California 91105  Attention: Secretary  1. Exercise of Option. Effective as of today, ________________, the undersigned (&#8220;Purchaser&#8221;), hereby elects  to purchase shares (the &#8220;Shares&#8221;) of the common stock of Arrowhead Pharmaceuticals, Inc. (the &#8220;Company&#8221;) under  the Stock Option Agreement dated _______________, (the &#8220;Option Agreement&#8221;). The purchase price for the Shares  shall be $_____________, as required by the Option Agreement. Capitalized terms not otherwise defined herein  shall have the meaning ascribed to such terms in the Option Agreement.  2. Delivery of Payment. Purchaser herewith delivers to the Company the full purchase price for the Shares.  3. Representations of Purchaser. Purchaser acknowledges that Purchaser has received and read and  understands the Plan and the Option Agreement and agrees to abide by and be bound by their terms and conditions.  4. Rights as Shareholder. Until the issuance (as evidenced by the appropriate entry on the books of the  Company or of a duly authorized transfer agent of the Company) of the Shares, no right to vote or receive dividends  or any other rights as a shareholder shall exist with respect to the optioned Stock, notwithstanding the exercise of the  Option. The Shares so acquired shall be issued to the Optionee as soon as practicable after exercise of the Option.  No adjustment will be made for a dividend or other right for which the record date is prior to the date of issuance,  except as provided in Section 7 of the Plan.  5. Tax Consultation. Purchaser understands that Purchaser may suffer adverse tax consequences as a result of  Purchaser&#8217;s purchase or disposition of the Shares. Purchaser represents that Purchaser has consulted with any tax  consultants Purchaser deems advisable in connection with the purchase or disposition of the Shares and that  Purchaser is not relying on the Company for any tax advice.  6. Entire Agreement: Governing Law. The Plan, the Option Agreement and the Notice of Grant are  incorporated herein by reference. This Exercise Notice, the Plan, the Option Agreement and the Notice of Grant  constitute the entire agreement of the parties with respect to the subject matter hereof and supersede in their entirety  all prior undertakings and agreements of the Company and Purchaser with respect to the subject matter hereof. This  agreement is governed by the internal substantive laws, but not the choice of law rules, of Delaware.  Submitted by:              Accepted by:  PURCHASER          ARROWHEAD PHARMACEUTICALS, INC.                    Signature          By                    Print Name          Title                    Date Received          Date Received      Address:          Address:                  177 East Colorado Blvd, Suite 700  Pasadena, CA 91105    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.39
<SEQUENCE>5
<FILENAME>a1039-firstamendmenttole.htm
<DESCRIPTION>EX-10.39
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>a1039-firstamendmenttole</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- a1039-firstamendmenttole001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a1039-firstamendmenttole001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">1  FIRST AMENDMENT TO LEASE THIS FIRST AMENDMENT TO LEASE (this First Amendment ) is dated as of September __,  2023 (the Effective Date , by and between ARE-SD REGION NO. 72, LLC, a Delaware limited liability  Landlord ARROWHEAD PHARMACEUTICALS, INC., a Delaware corporation  ( Tenant ).  RECITALS  A. Landlord and Tenant are parties to that certain Lease Agreement dated as of November 19, 2021 (as amended, the Lease ).  Pursuant to the Lease, Tenant leases that certain building having an  address of 10102 Hoyt Park Drive, San Diego, California, containing approximately 144,113 rentable  square feet (the Premises ).  The Premises are more particularly described in the Lease.  Capitalized  terms used herein without definition shall have the meanings defined for such terms in the Lease.  B. Landlord and Tenant desire to amend the Lease to, among other things, to increase the amount of the Allowance available to Tenant under the work letter attached to the Lease as Exhibit C (the  Work Letter .  NOW, THEREFORE, in consideration of the foregoing Recitals, which are incorporated herein by  this reference, the mutual promises and conditions contained herein, and for other good and valuable  consideration, the receipt and sufficiency of which are hereby acknowledged, Landlord and Tenant hereby  agree as follows:  1. Additional Tenant Improvement Allowance.  The parties acknowledge that, notwithstanding anything to the contrary contained in the Work Letter, Tenant has elected to use 100% of the Additional Tenant Improvement Allowance.  Commencing on the Effective Date, the term Allowance the Warm Shell Allowance, the Additional Tenant Improvement Allowance and the Second Additional Tenant Improvement Allowance (as defined in Section 2 below). 2. Second Additional Tenant Improvement Allowance.  In addition to the Tenant Improvement Allowance, the Warm Shell Allowance and the Additional Tenant Improvement Allowance, Landlord Second Additional Tenant Improvement Allowance maximum amount of $23,577,199.00.  The parties acknowledge that Tenant has elected to use 100% of the Second Additional Tenant Improvement Allowance.  Commencing on the first day of the calendar month immediately following date that Landlord first disburses all or a portion of the Second Additional Tenant Improvement Allowance and continuing thereafter on the first day of each calendar month during the Base Term, Tenant shall pay the amount necessary to fully amortize the Second Additional Tenant Improvement Allowance in equal monthly payments with annual interest at a rate of 9.0% per annum over the Base Term, which interest shall begin to accrue on the date that Landlord first disburses such Second Additional Tenant Improvement Allowance or any portion(s) thereof Additional TI Rent .  Tenant acknowledges and agrees that, if the Second Additional Tenant Improvement Allowance is disbursed in more than one disbursement, the amount of Additional TI Rent payable by Tenant pursuant to this Section 2 may be adjusted following Allowance.  Any Additional TI Rent remaining unpaid as of the expiration or earlier termination of the Lease shall be paid to Landlord in a lump sum on the expiration or earlier termination of the Lease.  Tenant shall have no right to prepay all or any portion of the Additional TI Rent at any time prior to the expiration or earlier termination of the Lease. 3. Allowance Outside Date.  For the avoidance of doubt, Tenant acknowledges and agrees that Tenant shall have no right to any portion of the Allowance (including, without limitation, the Second Additional Tenant Improvement Allowance) that is not properly requested pursuant to the terms of Section 6(e) of the Work Letter before October 31, 2023. </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a1039-firstamendmenttole002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a1039-firstamendmenttole002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> 2   4. California Accessibility Disclosure.  The provisions of Section 41(q) of the Lease are  incorporated by reference into this First Amendment.  5. OFAC.  Tenant and all beneficial owners of Tenant are currently (a) in compliance with and shall  at all times during the Term of the Lease remain in compliance with the regulations of the Office of  Foreign Assets Control ( OFAC ) of the U.S. Department of Treasury and any statute, executive  order, or regulation relating thereto (collectively, the OFAC Rules ), (b) not listed on, and shall not  during the Term of the Lease be listed on, the Specially Designated Nationals and Blocked Persons  List maintained by OFAC and/or on any other similar list maintained by OFAC or other  governmental authority pursuant to any authorizing statute, executive order, or regulation, and (c)  not a person or entity with whom a U.S. person is prohibited from conducting business under the  OFAC Rules.  6. Brokers.  Landlord and Tenant each represents and warrants that it has not dealt with any broker,  agent or other person (collectively, Broker ) in connection with the transaction reflected in this  First Amendment and that no Broker brought about this transaction.  Landlord and Tenant each  hereby agrees to indemnify and hold the other harmless from and against any claims by any Broker,  claiming a commission or other form of compensation by virtue of having dealt with Tenant or  Landlord, as applicable, with regard to this First Amendment.    7. Miscellaneous.  a. This First Amendment is the entire agreement between the parties with respect to the  subject matter hereof and supersedes all prior and contemporaneous oral and written agreements  and discussions.  This First Amendment may be amended only by an agreement in writing, signed  by the parties hereto.  b. This First Amendment is binding upon and shall inure to the benefit of the parties hereto  and their respective agents and assigns.  c. This First Amendment may be executed in 2 or more counterparts, each of which shall be  deemed an original, but all of which together shall constitute one and the same instrument.   Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic  signature process complying with the U.S. federal ESIGN Act of 2000) or other transmission  method and any counterpart so delivered shall be deemed to have been duly and validly delivered  and be valid and effective for all purposes.  Electronic signatures shall be deemed original  signatures for purposes of this First Amendment and all matters related thereto, with such electronic  signatures having the same legal effect as original signatures.  d. Except as amended and/or modified by this First Amendment, the Lease is hereby ratified  and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and  unchanged by this First Amendment.  In the event of any conflict between the provisions of this  First Amendment and the provisions of the Lease, the provisions of this First Amendment shall  prevail.  Whether or not specifically amended by this First Amendment, all of the terms and  provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose  and intent of this First Amendment.  [Signatures are on the next page.]  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a1039-firstamendmenttole003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a1039-firstamendmenttole003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">3  IN WITNESS WHEREOF, the parties hereto have executed this First Amendment as of the day  and year first above written.  TENANT:  ARROWHEAD PHARMACEUTICALS, INC.,  a Delaware corporation  By: /s/ Kenneth Myszkowski Name: Kenneth Myszkowski Its: CFO &#9633; I hereby certify that the signature, name, and title above are my signature, name and title. LANDLORD:  ARE-SD REGION NO. 72, LLC,  a Delaware Limited Liability Company  By: ALEXANDRIA REAL ESTATE EQUITIES, L.P.,  a Delaware Limited Partnership,   Managing Member  By:  ARE-QRS CORP.,  a Maryland corporation, General Partner  By: /s/ Gary Dean Name: Gary Dean Its: Executive Vice President - Real Estate Legal Affairs </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>arwr-20230930xex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="icb085fe1fb644a0eba1e7ffe797287bc_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">Exhibit 23.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We hereby consent to the incorporation by reference in the Registration Statements on Forms S-1 (Nos. 333-164039 and 333-161344), Forms S-3 (Nos. 333-268665, 333-228598, 333-214315, 333-214311, 333-213484, 333-202737, 333-191922, 333-188718, 333-178532, 333-178073, 333-178072, 333-144109, 333-137329, 333-132310, 333-124065, and 333-113065), and Forms S-8 (Nos. 333-270779, 333-261847, 333-256255, 333-238616, 333-230621, 333-223836, 333-210117, 333-202741, 333-198920, 333-194596, 333-190970, 333-180692, 333-170252, 333-136225, 333-124066, and 333-120072</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> of Arrowhead Pharmaceuticals, Inc. of our report dated November 29, 2023, with respect to the consolidated balance sheets of Arrowhead Pharmaceuticals, Inc. and Subsidiaries as of September 30, 2023 and September 30, 2022, and the related consolidated statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for each of the years in the three-year period ended September 30, 2023, and the effectiveness of internal control over financial reporting as of September 30, 2023, which reports appear in the September 30, 2023 annual report on Form 10-K of Arrowhead Pharmaceuticals, Inc.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Rose, Snyder &#38; Jacobs LLP</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Encino, California</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">November 29, 2023</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>arwr-20230930xex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>arwr-20230930xex311</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- arwr-20230930xex311001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="arwr-20230930xex311001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>arwr-20230930xex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>arwr-20230930xex312</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- arwr-20230930xex312001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="arwr-20230930xex312001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>arwr-20230930xex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>arwr-20230930xex321</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- arwr-20230930xex321001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="arwr-20230930xex321001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>arwr-20230930xex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>arwr-20230930xex322</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- arwr-20230930xex322001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="arwr-20230930xex322001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-97
<SEQUENCE>11
<FILENAME>a97-arwrxclawbackpolicyf.htm
<DESCRIPTION>EX-97
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>a97-arwrxclawbackpolicyf</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- a97-arwrxclawbackpolicyf001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a97-arwrxclawbackpolicyf001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">      ARROWHEAD PHARMACEUTICALS, INC  COMPENSATION RECOUPMENT (CLAWBACK) POLICY  Recoupment of Incentive-Based Compensation  It is the policy of Arrowhead Pharmaceuticals, Inc. (the &#8220;Company&#8221;) that, in the event the  Company is required to prepare an accounting restatement of the Company&#8217;s financial statements  due to material non-compliance with any financial reporting requirement under the federal  securities laws (including any such correction that is material to the previously issued financial  statements, or that would result in a material misstatement if the error were corrected in the current  period or left uncorrected in the current period), the Company will recover on a reasonably prompt  basis the amount of any Incentive-Based Compensation Received by a Covered Executive during  the Recovery Period that exceeds the amount that otherwise would have been Received had it been  determined based on the restated financial statements.   Policy Administration and Definitions   This Policy is administered by the Compensation Committee (the &#8220;Committee&#8221;) of the  Company&#8217;s Board of Directors, subject to ratification by the independent members of the Board  of Directors with respect to application of this Policy to the Company&#8217;s Chief Executive Officer,  and is intended to comply with, and as applicable to be administered and interpreted consistent  with, and subject to the exceptions set forth in, Listing Standard 5608 adopted by The Nasdaq  Stock Market to implement Rule 10D-1 under the Securities Exchange Act of 1934, as amended  (collectively, &#8220;Rule 10D-1&#8221;).   For purposes of this Policy:   &#8220;Incentive-Based Compensation&#8221; means any compensation granted, earned, or vested  based in whole or in part on the Company&#8217;s attainment of a financial reporting measure  that was Received by a person (i) on or after October 2, 2023 and after the person began  service as a Covered Executive, and (ii) who served as a Covered Executive at any time  during the performance period for the Incentive-Based Compensation. A financial  reporting measure is (i) any measure that is determined and presented in accordance with  the accounting principles used in preparing the Company&#8217;s financial statements and any  measure derived wholly or in part from such a measure, and (ii) any measure based in  whole or in part on the Company&#8217;s stock price or total shareholder return.     Incentive-Based Compensation is deemed to be &#8220;Received&#8221; in the fiscal period during  which the relevant financial reporting measure is attained, regardless of when the  compensation is actually paid or awarded.   &#8220;Covered Executive&#8221; means any &#8220;officer&#8221; of the Company as defined under Rule 16a-1(f)  under the Securities Exchange Act of 1934, as amended.     </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a97-arwrxclawbackpolicyf002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a97-arwrxclawbackpolicyf002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white"> 2   &#8220;Recovery Period&#8221; means the three completed fiscal years immediately preceding the date  that the Company is required to prepare the accounting restatement described in this Policy,  all as determined pursuant to Rule 10D-1, and any transition period of less than nine months  that is within or immediately following such three fiscal years.   If the Committee determines the amount of Incentive-Based Compensation Received by a  Covered Executive during a Recovery Period exceeds the amount that would have been Received  if determined or calculated based on the Company&#8217;s restated financial results, such excess amount  of Incentive-Based Compensation shall be subject to recoupment by the Company pursuant to this  Policy. For Incentive-Based Compensation based on stock price or total shareholder return, where  the amount of erroneously awarded compensation is not subject to mathematical recalculation  directly from the information in an accounting restatement, the Committee will determine the  amount based on a reasonable estimate of the effect of the accounting restatement on the relevant  stock price or total shareholder return. In all cases, the calculation of the excess amount of  Incentive-Based Compensation to be recovered will be determined without regard to any taxes  paid with respect to such compensation. The Company will maintain and will provide to The  Nasdaq Stock Market documentation of all determinations and actions taken in complying with  this Policy. Any determinations made by the Committee under this Policy shall be final and  binding on all affected individuals.    The Company may effect any recovery pursuant to this Policy by requiring payment of  such amount(s) to the Company, by set-off, by reducing future compensation, or by such other  means or combination of means as the Committee determines to be appropriate. The Company  need not recover the excess amount of Incentive-Based Compensation if and to the extent that the  Committee determines that such recovery is impracticable, subject to and in accordance with any  applicable exceptions under The NASDAQ Stock Market listing rules, and not required under Rule  10D-1, including if the Committee determines that the direct expense paid to a third party to assist  in enforcing this Policy would exceed the amount to be recovered after making a reasonable  attempt to recover such amounts. The Company is authorized to take appropriate steps to  implement this Policy with respect to Incentive-Based Compensation arrangements with Covered  Executives.  Any right of recoupment or recovery pursuant to this Policy is in addition to, and not in  lieu of, any other remedies or rights of recoupment that may be available to the Company pursuant  to the terms of any other policy, any employment agreement or plan or award terms, and any other  legal remedies available to the Company; provided that the Company shall not recoup amounts  pursuant to such other policy, terms or remedies to the extent it is recovered pursuant to this Policy.   The Company shall not indemnify any Covered Executive against the loss of any Incentive-Based  Compensation pursuant to this Policy.  Certification  All Covered Executives subject to this Policy will be required to certify their understanding  of and intent to comply with this Policy periodically. </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a97-arwrxclawbackpolicyf003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a97-arwrxclawbackpolicyf003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  [ACKNOWLEDGMENT AND CERTIFICATION]  ACKNOWLEDGMENT AND CERTIFICATION  By signing below, the undersigned covered executive (the &#8220;Covered Executive&#8221;)  acknowledges and confirms that the Covered Executive has received and reviewed a copy of the  Arrowhead Pharmaceuticals, Inc. (the &#8220;Company&#8221;) Incentive Compensation Clawback Policy  (the &#8220;Policy&#8221;), and in addition, the Covered Executive acknowledges and agrees that, for good and  valid consideration, including continuing participation in the Company&#8217;s incentive compensation  programs, the receipt and sufficiency of which the Covered Executive hereby acknowledges, the  Covered Executive will be bound by and abide by the Policy as follows:  (a) the Covered Executive is and will continue to be subject to the Policy and the Policy will  apply both during and after the Covered Executive&#8217;s employment with the Company;    (b) to the extent necessary to comply with the Policy, the Company hereby amends any  employment agreement, equity award agreement or similar agreement that the Covered  Executive is a party to with the Company;    (c) the Covered Executive shall abide by the terms of the Policy, including, without limitation,  by returning any compensation to the Company to the extent required by, and in a manner  permitted by, the Policy, and understands and agrees that the Company is not permitted to,  and will not, indemnify the Covered Executive for the loss of any compensation that is  subject to recovery by the Company;    (d) any amounts payable to the Covered Executive shall be subject to the Policy as may be in  effect and interpreted or modified from time to time in the sole discretion of the  Compensation Committee of the Company&#8217;s Board of Directors (the &#8220;Committee&#8221;) or as  required by applicable law or the requirements of any securities exchange on which the  Company&#8217;s securities are listed, and that such interpretation or modification will be  covered by this acknowledgment;    (e) the Company may recover compensation paid to the Covered Executive through any  method of recovery the Committee or its delegate deems appropriate, including without  limitation by reducing any amount that is or may become payable to the Covered Executive,  and the Covered Executive agrees to comply with any request or demand for repayment by  the Company in order to comply with the Policy; and    (f) the Company is not responsible for and shall not make the Covered Executive whole for  any effect under any tax law or regulation of the recovery of any compensation pursuant to  the Policy, or for any taxes paid by the Covered Executive on compensation that is subject  to recovery or is recovered pursuant to the Policy.     Signature     Print Name     Date  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>12
<FILENAME>arwr-20230930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:d14395b2-bc79-4df5-8659-886540a562de,g:ab3d3e76-c740-4da0-ace7-13e457c841a4-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:arwr="http://www.arrowheadresearch.com/20230930" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arrowheadresearch.com/20230930">
  <xs:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2023" schemaLocation="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2023" schemaLocation="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20230930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20230930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20230930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arwr-20230930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.arrowheadresearch.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.arrowheadresearch.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofStockholdersEquity" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity">
        <link:definition>0000006 - Statement - Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPolicies" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Organization and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreements" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements">
        <link:definition>0000009 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipment" roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipment">
        <link:definition>0000010 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Investments" roleURI="http://www.arrowheadresearch.com/role/Investments">
        <link:definition>0000011 - Disclosure - Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssets" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssets">
        <link:definition>0000012 - Disclosure - Intangible Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquity" roleURI="http://www.arrowheadresearch.com/role/StockholdersEquity">
        <link:definition>0000013 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingencies">
        <link:definition>0000014 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.arrowheadresearch.com/role/Leases">
        <link:definition>0000015 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensation">
        <link:definition>0000016 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurements">
        <link:definition>0000017 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.arrowheadresearch.com/role/IncomeTaxes">
        <link:definition>0000018 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlans" roleURI="http://www.arrowheadresearch.com/role/EmployeeBenefitPlans">
        <link:definition>0000019 - Disclosure - Employee Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheSaleofFutureRoyalties" roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties">
        <link:definition>0000020 - Disclosure - Liability Related to the Sale of Future Royalties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.arrowheadresearch.com/role/EarningsPerShare">
        <link:definition>0000021 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.arrowheadresearch.com/role/SubsequentEvents">
        <link:definition>0000022 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesPolicies" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies">
        <link:definition>9954471 - Disclosure - Organization and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesTables" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables">
        <link:definition>9954472 - Disclosure - Organization and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsTables" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables">
        <link:definition>9954473 - Disclosure - Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentTables" roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentTables">
        <link:definition>9954474 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsTables" roleURI="http://www.arrowheadresearch.com/role/InvestmentsTables">
        <link:definition>9954475 - Disclosure - Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsTables" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsTables">
        <link:definition>9954476 - Disclosure - Intangible Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityTables" roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityTables">
        <link:definition>9954477 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.arrowheadresearch.com/role/LeasesTables">
        <link:definition>9954478 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationTables">
        <link:definition>9954479 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsTables">
        <link:definition>9954480 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesTables">
        <link:definition>9954481 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.arrowheadresearch.com/role/EarningsPerShareTables">
        <link:definition>9954482 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSignificantAccountingPoliciesDetails" roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails">
        <link:definition>9954483 - Disclosure - Organization and Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsRevenueDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails">
        <link:definition>9954484 - Disclosure - Collaboration and License Agreements - Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails">
        <link:definition>9954485 - Disclosure - Collaboration and License Agreements - Receivables and Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails">
        <link:definition>9954486 - Disclosure - Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails">
        <link:definition>9954487 - Disclosure - Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails">
        <link:definition>9954488 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails">
        <link:definition>9954489 - Disclosure - Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsAmgenIncDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails">
        <link:definition>9954490 - Disclosure - Collaboration and License Agreements - Amgen, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails" roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails">
        <link:definition>9954491 - Disclosure - Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentSummaryofPropertyandEquipmentDetails" roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails">
        <link:definition>9954492 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentAdditionalInformationDetails" roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetails">
        <link:definition>9954493 - Disclosure - Property and Equipment - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails">
        <link:definition>9954494 - Disclosure - Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsScheduleofIntangibleAssetsDetails" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails">
        <link:definition>9954495 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsExpectedFutureAmortizationDetails" roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails">
        <link:definition>9954496 - Disclosure - Intangible Assets - Expected Future Amortization (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDetails" roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityDetails">
        <link:definition>9954497 - Disclosure - Stockholders' Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesAdditionalInformationDetails" roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails">
        <link:definition>9954498 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails">
        <link:definition>9954499 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseAssetsandLiabilitiesDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails">
        <link:definition>9954500 - Disclosure - Leases - Components of Lease Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails">
        <link:definition>9954501 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1">
        <link:definition>9954501 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails" roleURI="http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails">
        <link:definition>9954502 - Disclosure - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>9954503 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails">
        <link:definition>9954504 - Disclosure - Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails">
        <link:definition>9954505 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails">
        <link:definition>9954506 - Disclosure - Stock-Based Compensation - Assumptions Used to Value Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationSummaryofRSUsActivityDetails" roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails">
        <link:definition>9954507 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails">
        <link:definition>9954508 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails">
        <link:definition>9954509 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesProvisionsforIncomeTaxesDetails" roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails">
        <link:definition>9954510 - Disclosure - Income Taxes - Provisions for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails" roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails">
        <link:definition>9954511 - Disclosure - Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails" roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails">
        <link:definition>9954512 - Disclosure - Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>9954513 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesGrossUnrecognizedTaxBenefitsDetails" roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>9954514 - Disclosure - Income Taxes - Gross Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeBenefitPlansAdditionalInformationDetails" roleURI="http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails">
        <link:definition>9954515 - Disclosure - Employee Benefit Plans - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LiabilityRelatedtotheSaleofFutureRoyaltiesDetails" roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails">
        <link:definition>9954516 - Disclosure - Liability Related to the Sale of Future Royalties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareDetails" roleURI="http://www.arrowheadresearch.com/role/EarningsPerShareDetails">
        <link:definition>9954517 - Disclosure - Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="arwr_HorizonTherapeuticsIrelandDACMember" abstract="true" name="HorizonTherapeuticsIrelandDACMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_NumberOfAcresOfLandPurchased" abstract="false" name="NumberOfAcresOfLandPurchased" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:areaItemType"/>
  <xs:element id="arwr_SorrentoValleyOwnerDELLCMember" abstract="true" name="SorrentoValleyOwnerDELLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_ColoradoOwnerLLCMember" abstract="true" name="ColoradoOwnerLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_OutsideOfEquityCompensationPlansMember" abstract="true" name="OutsideOfEquityCompensationPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_TracieOliverMember" abstract="true" name="TracieOliverMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" abstract="true" name="LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_MilestonePayments" abstract="false" name="MilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DrugManufacturingFacilityMember" abstract="true" name="DrugManufacturingFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" abstract="false" name="MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_OrganizationAndSignificantAccountingPoliciesLineItems" abstract="true" name="OrganizationAndSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_RestrictedStockUnitsMarketBasedMember" abstract="true" name="RestrictedStockUnitsMarketBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_EmployeeContributionsUpToThreePercentMember" abstract="true" name="EmployeeContributionsUpToThreePercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_DouglassGivenMember" abstract="true" name="DouglassGivenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_JamesHamiltonAugust2023PlanMember" abstract="true" name="JamesHamiltonAugust2023PlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arwr_MilestonePaymentReceived" abstract="false" name="MilestonePaymentReceived" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_IncreaseDecreaseInCashAndInvestments" abstract="false" name="IncreaseDecreaseInCashAndInvestments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ScheduleOfCurrentProductsTableTextBlock" abstract="false" name="ScheduleOfCurrentProductsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="arwr_AmgenIncorporatedMember" abstract="true" name="AmgenIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_AmountIntendedToInvestForBuildoutOfFacilities" abstract="false" name="AmountIntendedToInvestForBuildoutOfFacilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_JanssenPharmaceuticalsIncorporationMember" abstract="true" name="JanssenPharmaceuticalsIncorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" abstract="false" name="OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" abstract="false" name="DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" abstract="false" name="DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_AROENacAndAROHIF2CandidatesMember" abstract="true" name="AROENacAndAROHIF2CandidatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_InitialTransactionPrice" abstract="false" name="InitialTransactionPrice" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_JamesHamiltonMember" abstract="true" name="JamesHamiltonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponFDAApproval" abstract="false" name="MilestonePaymentReceivableUponFDAApproval" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_OlpasiranAgreementMember" abstract="true" name="OlpasiranAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_WilliamWaddillMember" abstract="true" name="WilliamWaddillMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_NumberOfAgreements" abstract="false" name="NumberOfAgreements" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivable" abstract="false" name="MilestonePaymentReceivable" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_VictoriaVakienerMember" abstract="true" name="VictoriaVakienerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_FiniteLivedIntangibleAssetsImpairment" abstract="false" name="FiniteLivedIntangibleAssetsImpairment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" abstract="false" name="LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="arwr_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_LicenseAndCoFundingAgreementMember" abstract="true" name="LicenseAndCoFundingAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" abstract="false" name="DevelopmentRegulatoryAndSalesMilestonesPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" abstract="false" name="DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ResearchFacilityInMadisonMember" abstract="true" name="ResearchFacilityInMadisonMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_JamesHamiltonTerminatedPlanMember" abstract="true" name="JamesHamiltonTerminatedPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_RoyaltyPharmaAgreementMember" abstract="true" name="RoyaltyPharmaAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_HorizonLicenseAgreementMember" abstract="true" name="HorizonLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_TwoThousandTwentyOneIncentivePlanMember" abstract="true" name="TwoThousandTwentyOneIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_AdditionalTenantImprovementAllowanceLiability" abstract="false" name="AdditionalTenantImprovementAllowanceLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement" abstract="false" name="TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CorporateHeadquartersInPasadenaMember" abstract="true" name="CorporateHeadquartersInPasadenaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_AtTheMarketAgreementMember" abstract="true" name="AtTheMarketAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_RoyaltyPaymentThreshold" abstract="false" name="RoyaltyPaymentThreshold" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MauroFerrariMember" abstract="true" name="MauroFerrariMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" abstract="false" name="BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="arwr_NovartisMember" abstract="true" name="NovartisMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_OperatingLossCarryforwardsNotSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsNotSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_TwoThousandsThirteenIncentivePlanMember" abstract="true" name="TwoThousandsThirteenIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" abstract="false" name="DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_RestrictedStockUnitsPerformanceBasedMember" abstract="true" name="RestrictedStockUnitsPerformanceBasedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_KenMyszkowskiMember" abstract="true" name="KenMyszkowskiMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" abstract="true" name="ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arwr_InducementAwardsMember" abstract="true" name="InducementAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" abstract="true" name="JohnsonAndJohnsonInnovationJJDCIncorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_CommonStockPurchaseAgreementMember" abstract="true" name="CommonStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_NumberOfDistinctPerformanceObligations" abstract="false" name="NumberOfDistinctPerformanceObligations" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum" abstract="false" name="AdditionalTenantImprovementAllowanceInterestPerAnnum" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" abstract="false" name="NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" abstract="false" name="CommonStockCapitalSharesValueReservedForFutureIssuance" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_VisirnaTherapeuticsIncMember" abstract="true" name="VisirnaTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" abstract="true" name="CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" abstract="false" name="HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="arwr_OrganizationAndSignificantAccountingPoliciesTable" abstract="true" name="OrganizationAndSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" abstract="true" name="TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" abstract="false" name="MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_UpfrontMilestonePaymentReceived" abstract="false" name="UpfrontMilestonePaymentReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arwr_TaxIncrementFinancingAward" abstract="false" name="TaxIncrementFinancingAward" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" abstract="false" name="PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="arwr_MaximumAdditionalTenantImprovementAllowance" abstract="false" name="MaximumAdditionalTenantImprovementAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_LaboratoryAndOfficeFacilityMember" abstract="true" name="LaboratoryAndOfficeFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_DeferredTaxLiabilitiesStateTaxes" abstract="false" name="DeferredTaxLiabilitiesStateTaxes" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" abstract="false" name="DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ProceedsFromSaleOfFutureRoyalties" abstract="false" name="ProceedsFromSaleOfFutureRoyalties" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_JNJ3989AROHBVAgreementMember" abstract="true" name="JNJ3989AROHBVAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" abstract="false" name="AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" abstract="true" name="ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" abstract="false" name="DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CollaborationAndLicenseAgreementsMember" abstract="true" name="CollaborationAndLicenseAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_ResearchEquipmentGross" abstract="false" name="ResearchEquipmentGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CommercialNotesMember" abstract="true" name="CommercialNotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_OperatingLossCarryforwardsSubjectToExpiration" abstract="false" name="OperatingLossCarryforwardsSubjectToExpiration" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_CommercialMilestonePaymentsAtFirstCommercialSale" abstract="false" name="CommercialMilestonePaymentsAtFirstCommercialSale" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" abstract="false" name="MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" abstract="false" name="DeferredTaxAssetsInProcessResearchAndDevelopmentCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_VeronaTechnologyParkMember" abstract="true" name="VeronaTechnologyParkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" abstract="false" name="PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="arwr_SalesRelatedMilestonePayments" abstract="false" name="SalesRelatedMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_TwoThousandsFourEquityIncentivePlanMember" abstract="true" name="TwoThousandsFourEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_FacilitiesMember" abstract="true" name="FacilitiesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_RoyaltiesLiabilityNoncurrent" abstract="false" name="RoyaltiesLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" abstract="true" name="TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_CollaborationAndLicenseAgreementsAbstract" abstract="true" name="CollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arwr_PatrickOBrienMember" abstract="true" name="PatrickOBrienMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arwr_CashReceivedAsDueUnderCollaborationAgreement" abstract="false" name="CashReceivedAsDueUnderCollaborationAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_TechnologyLicenseCommitmentsMember" abstract="true" name="TechnologyLicenseCommitmentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_ResearchFacilityInSanDiegoMember" abstract="true" name="ResearchFacilityInSanDiegoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_NumberOfOptionsToRenew" abstract="false" name="NumberOfOptionsToRenew" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_NumberOfDistinctBundle" abstract="false" name="NumberOfDistinctBundle" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" abstract="false" name="ComputersSoftwareOfficeEquipmentAndFurnitureGross" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_MilestonePaymentEarned" abstract="false" name="MilestonePaymentEarned" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arwr_GlaxosmithklineIntellectualPropertyLimitedMember" abstract="true" name="GlaxosmithklineIntellectualPropertyLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="arwr_EmployeeContributionNextTwoPercentMember" abstract="true" name="EmployeeContributionNextTwoPercentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>13
<FILENAME>arwr-20230930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:d14395b2-bc79-4df5-8659-886540a562de,g:ab3d3e76-c740-4da0-ace7-13e457c841a4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="arwr-20230930.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_cff0d02e-a6f7-4ffd-9c57-12be2896cf0f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_32de8df8-1321-484d-b9b6-7218ffbeecc2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cff0d02e-a6f7-4ffd-9c57-12be2896cf0f" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_32de8df8-1321-484d-b9b6-7218ffbeecc2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_cc3a38dd-fa71-422d-b488-d40376d8de1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cff0d02e-a6f7-4ffd-9c57-12be2896cf0f" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_cc3a38dd-fa71-422d-b488-d40376d8de1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_7cec557c-d08e-40b3-8079-de9fbb3a817c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cff0d02e-a6f7-4ffd-9c57-12be2896cf0f" xlink:to="loc_us-gaap_OtherAssetsCurrent_7cec557c-d08e-40b3-8079-de9fbb3a817c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2da89229-09ea-4b11-8bfe-34496a2fe970" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cff0d02e-a6f7-4ffd-9c57-12be2896cf0f" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2da89229-09ea-4b11-8bfe-34496a2fe970" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_a2abb3d7-410a-41e2-a79a-0417e0d984cc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cff0d02e-a6f7-4ffd-9c57-12be2896cf0f" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_a2abb3d7-410a-41e2-a79a-0417e0d984cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_008cafb0-30f1-49d6-b18d-db7e704b8ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_cff0d02e-a6f7-4ffd-9c57-12be2896cf0f" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_008cafb0-30f1-49d6-b18d-db7e704b8ee4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_7d4ca463-7dee-4eee-ad69-e3393fb06443" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_46285ae8-871b-4d91-ba31-3f17838ee25a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7d4ca463-7dee-4eee-ad69-e3393fb06443" xlink:to="loc_us-gaap_AccountsPayableCurrent_46285ae8-871b-4d91-ba31-3f17838ee25a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_5bb99c82-d361-408f-a798-e4051dacedba" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7d4ca463-7dee-4eee-ad69-e3393fb06443" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_5bb99c82-d361-408f-a798-e4051dacedba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_bcf9015e-073c-48b0-8455-e69783f6339e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7d4ca463-7dee-4eee-ad69-e3393fb06443" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_bcf9015e-073c-48b0-8455-e69783f6339e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_d9cf6250-1e65-43a3-a988-66d53b0132d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7d4ca463-7dee-4eee-ad69-e3393fb06443" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_d9cf6250-1e65-43a3-a988-66d53b0132d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d3e1a034-553c-48c5-bac6-f2fe692dfd38" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7d4ca463-7dee-4eee-ad69-e3393fb06443" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_d3e1a034-553c-48c5-bac6-f2fe692dfd38" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_66613dc0-6d2f-4aa5-a261-89ece7297e20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_7d4ca463-7dee-4eee-ad69-e3393fb06443" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_66613dc0-6d2f-4aa5-a261-89ece7297e20" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_37ff36f1-3fb4-42db-8b56-ffe307ea2e36" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_856176a1-3c71-421c-bbba-3a1e93907884" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_37ff36f1-3fb4-42db-8b56-ffe307ea2e36" xlink:to="loc_us-gaap_StockholdersEquity_856176a1-3c71-421c-bbba-3a1e93907884" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_1dffa376-96d1-4339-b734-3504bb65d7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_37ff36f1-3fb4-42db-8b56-ffe307ea2e36" xlink:to="loc_us-gaap_MinorityInterest_1dffa376-96d1-4339-b734-3504bb65d7d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f1e17013-31b0-4393-a245-d45e58efe76e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_d8244c07-79c0-4c9c-9330-9dad2e549497" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f1e17013-31b0-4393-a245-d45e58efe76e" xlink:to="loc_us-gaap_CommonStockValue_d8244c07-79c0-4c9c-9330-9dad2e549497" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1bce642a-8d2a-4573-98d2-be94f91715d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f1e17013-31b0-4393-a245-d45e58efe76e" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_1bce642a-8d2a-4573-98d2-be94f91715d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_765d9044-1ad3-406d-b108-86c103d4d350" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f1e17013-31b0-4393-a245-d45e58efe76e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_765d9044-1ad3-406d-b108-86c103d4d350" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9a7a22bd-6538-4d22-b568-34f781ddf92d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f1e17013-31b0-4393-a245-d45e58efe76e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_9a7a22bd-6538-4d22-b568-34f781ddf92d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_47ae455d-24d2-4c17-9f0b-2fe518cf99ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_59e20349-0fd0-4272-9be2-ef0b68ea98f3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_47ae455d-24d2-4c17-9f0b-2fe518cf99ac" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_59e20349-0fd0-4272-9be2-ef0b68ea98f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_92afbcee-9867-4eba-8a8d-ab42674f1ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_47ae455d-24d2-4c17-9f0b-2fe518cf99ac" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_92afbcee-9867-4eba-8a8d-ab42674f1ffa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_e2e5e870-4f90-4d98-b3d2-1cf6a5853aed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_47ae455d-24d2-4c17-9f0b-2fe518cf99ac" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_e2e5e870-4f90-4d98-b3d2-1cf6a5853aed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ef85aa67-e514-4869-b753-06cb75373879" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_47ae455d-24d2-4c17-9f0b-2fe518cf99ac" xlink:to="loc_us-gaap_AssetsCurrent_ef85aa67-e514-4869-b753-06cb75373879" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f0bea85e-6f81-449a-8307-0099d5c4bca1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_47ae455d-24d2-4c17-9f0b-2fe518cf99ac" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f0bea85e-6f81-449a-8307-0099d5c4bca1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8567afdd-ad7f-4c4e-a1da-cb4b9cc6070d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_47ae455d-24d2-4c17-9f0b-2fe518cf99ac" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8567afdd-ad7f-4c4e-a1da-cb4b9cc6070d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_c160ddd5-8d96-46e4-a318-5453e7523e40" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltiesLiabilityNoncurrent_61dd5b72-72a5-4e7c-a6ea-1792d9cc0a91" xlink:href="arwr-20230930.xsd#arwr_RoyaltiesLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_c160ddd5-8d96-46e4-a318-5453e7523e40" xlink:to="loc_arwr_RoyaltiesLiabilityNoncurrent_61dd5b72-72a5-4e7c-a6ea-1792d9cc0a91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_418339c4-645b-4f4e-b3ad-6957b15200ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_c160ddd5-8d96-46e4-a318-5453e7523e40" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_418339c4-645b-4f4e-b3ad-6957b15200ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_08040ea2-27d6-404a-b8ab-456001853749" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesNoncurrent_c160ddd5-8d96-46e4-a318-5453e7523e40" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_08040ea2-27d6-404a-b8ab-456001853749" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_af597fa8-7320-4a52-8cc0-c462e9da0ac5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_d1af06f1-470f-4927-bbfe-010843f60cab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_af597fa8-7320-4a52-8cc0-c462e9da0ac5" xlink:to="loc_us-gaap_LiabilitiesCurrent_d1af06f1-470f-4927-bbfe-010843f60cab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_d0e986ab-e523-4c24-a220-80652fe2a1c0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_af597fa8-7320-4a52-8cc0-c462e9da0ac5" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_d0e986ab-e523-4c24-a220-80652fe2a1c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_702c8e73-9da5-48a9-aeb9-08f66b65ba93" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_af597fa8-7320-4a52-8cc0-c462e9da0ac5" xlink:to="loc_us-gaap_CommitmentsAndContingencies_702c8e73-9da5-48a9-aeb9-08f66b65ba93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_42fc6f40-00ec-4e74-9ecb-915102d4669e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_af597fa8-7320-4a52-8cc0-c462e9da0ac5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_42fc6f40-00ec-4e74-9ecb-915102d4669e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="arwr-20230930.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8b462397-790e-434f-a145-227b345c3cdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fee9b16d-7ecf-49ab-857e-de02c8748e68" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8b462397-790e-434f-a145-227b345c3cdb" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fee9b16d-7ecf-49ab-857e-de02c8748e68" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e6c42ad1-7be8-403c-84b9-bb333fb6bb96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8b462397-790e-434f-a145-227b345c3cdb" xlink:to="loc_us-gaap_OperatingExpenses_e6c42ad1-7be8-403c-84b9-bb333fb6bb96" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_c9b1b57a-2ea0-4f1e-9df6-5a000656fd46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_e54781d2-742c-4754-b437-9ab29b883693" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_c9b1b57a-2ea0-4f1e-9df6-5a000656fd46" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_e54781d2-742c-4754-b437-9ab29b883693" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_025fe560-9458-465d-89bf-d56ae4d8bafd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_c9b1b57a-2ea0-4f1e-9df6-5a000656fd46" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_025fe560-9458-465d-89bf-d56ae4d8bafd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_11b24611-8707-450c-a931-d2d2d9c60840" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_6fa61f22-23b0-4239-ba3d-6982fbc6438b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_11b24611-8707-450c-a931-d2d2d9c60840" xlink:to="loc_us-gaap_ProfitLoss_6fa61f22-23b0-4239-ba3d-6982fbc6438b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5762cab6-5126-42f0-af19-a9eef21714e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_11b24611-8707-450c-a931-d2d2d9c60840" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_5762cab6-5126-42f0-af19-a9eef21714e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_02bedeca-b8db-4ddb-b66e-fd98ee53fb65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ceb81d40-179d-4b65-ae6c-1f012a96639d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_02bedeca-b8db-4ddb-b66e-fd98ee53fb65" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ceb81d40-179d-4b65-ae6c-1f012a96639d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_cf9f0ef5-af3b-4ec8-ac58-17d49700ed7d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_02bedeca-b8db-4ddb-b66e-fd98ee53fb65" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_cf9f0ef5-af3b-4ec8-ac58-17d49700ed7d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_e156cb92-1a0f-4e0e-a3f0-1f120512aef4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_136a4135-ada0-460b-8f23-7ba2af300461" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_e156cb92-1a0f-4e0e-a3f0-1f120512aef4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_136a4135-ada0-460b-8f23-7ba2af300461" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_0aab8f16-59ec-4794-a436-84be44751a9e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_e156cb92-1a0f-4e0e-a3f0-1f120512aef4" xlink:to="loc_us-gaap_ProfitLoss_0aab8f16-59ec-4794-a436-84be44751a9e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_53b799af-fc3d-4314-bc9f-6ac8331c4f22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_e156cb92-1a0f-4e0e-a3f0-1f120512aef4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_53b799af-fc3d-4314-bc9f-6ac8331c4f22" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5379d090-2a45-41fd-93e2-8d346ea82980" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e1501893-c598-44cb-8397-63c04a57ced7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5379d090-2a45-41fd-93e2-8d346ea82980" xlink:to="loc_us-gaap_OperatingIncomeLoss_e1501893-c598-44cb-8397-63c04a57ced7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8d170bb0-54b9-4cb1-9628-bf43fbdfa219" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_5379d090-2a45-41fd-93e2-8d346ea82980" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8d170bb0-54b9-4cb1-9628-bf43fbdfa219" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e13caa0a-a404-4085-8f4b-f4d1b3383ca6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_0c140e86-d20a-446e-8953-666e5be4470b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_e13caa0a-a404-4085-8f4b-f4d1b3383ca6" xlink:to="loc_us-gaap_InterestExpense_0c140e86-d20a-446e-8953-666e5be4470b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_1bdd4846-7475-4659-9dfa-f6a84ad2d444" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_e13caa0a-a404-4085-8f4b-f4d1b3383ca6" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_1bdd4846-7475-4659-9dfa-f6a84ad2d444" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_6d8e74ea-feec-4a8f-adfd-5bc8cc6238e3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_e13caa0a-a404-4085-8f4b-f4d1b3383ca6" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_6d8e74ea-feec-4a8f-adfd-5bc8cc6238e3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="arwr-20230930.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_5b29addd-f9d8-4764-96c4-6e8980f5dd70" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_09ac4181-37b9-4c1c-a5e1-ab9ad30fd56e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_5b29addd-f9d8-4764-96c4-6e8980f5dd70" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_09ac4181-37b9-4c1c-a5e1-ab9ad30fd56e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c19cf60-b81e-44a5-9a37-bb4eee1ea89f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_5b29addd-f9d8-4764-96c4-6e8980f5dd70" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c19cf60-b81e-44a5-9a37-bb4eee1ea89f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1fb594f6-ed2f-4a7f-b1da-be2f538907f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_5b29addd-f9d8-4764-96c4-6e8980f5dd70" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1fb594f6-ed2f-4a7f-b1da-be2f538907f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5a080acb-9f47-4e77-b628-bff0ae114c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_30b3bdd2-c959-4d52-bcf9-01f28d50f7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5a080acb-9f47-4e77-b628-bff0ae114c9d" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_30b3bdd2-c959-4d52-bcf9-01f28d50f7e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital_223aa9e2-37ac-4cef-8820-cfca9fa7cfb4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5a080acb-9f47-4e77-b628-bff0ae114c9d" xlink:to="loc_us-gaap_ProceedsFromContributedCapital_223aa9e2-37ac-4cef-8820-cfca9fa7cfb4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromSaleOfFutureRoyalties_d1bb4b77-b962-4524-84ae-de20c5c334f8" xlink:href="arwr-20230930.xsd#arwr_ProceedsFromSaleOfFutureRoyalties"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_5a080acb-9f47-4e77-b628-bff0ae114c9d" xlink:to="loc_arwr_ProceedsFromSaleOfFutureRoyalties_d1bb4b77-b962-4524-84ae-de20c5c334f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0bfd6f09-0f8b-4b5b-a228-f726e0826877" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_df5f309f-ce47-4031-81b1-d134392985b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0bfd6f09-0f8b-4b5b-a228-f726e0826877" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_df5f309f-ce47-4031-81b1-d134392985b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_fe7206a3-e9c1-4fc6-a320-e54ec3f14703" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0bfd6f09-0f8b-4b5b-a228-f726e0826877" xlink:to="loc_us-gaap_GainLossOnInvestments_fe7206a3-e9c1-4fc6-a320-e54ec3f14703" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3f6b850a-1a76-4f66-84d0-b6216acce65d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0bfd6f09-0f8b-4b5b-a228-f726e0826877" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_3f6b850a-1a76-4f66-84d0-b6216acce65d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_47edfeea-8bf8-4e75-a7f0-2682b67f52ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0bfd6f09-0f8b-4b5b-a228-f726e0826877" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_47edfeea-8bf8-4e75-a7f0-2682b67f52ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_e70acbc9-4ff0-4efe-8eb7-feda24dd8479" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0bfd6f09-0f8b-4b5b-a228-f726e0826877" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_e70acbc9-4ff0-4efe-8eb7-feda24dd8479" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bbe40839-b2ec-493d-ba00-db18eacd626d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0bfd6f09-0f8b-4b5b-a228-f726e0826877" xlink:to="loc_us-gaap_ShareBasedCompensation_bbe40839-b2ec-493d-ba00-db18eacd626d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_13808c03-81d6-431e-a3a3-bb573a59a5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0bfd6f09-0f8b-4b5b-a228-f726e0826877" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_13808c03-81d6-431e-a3a3-bb573a59a5aa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_bcba2ff9-5f30-42cc-95b0-73862982b93a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0bfd6f09-0f8b-4b5b-a228-f726e0826877" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_bcba2ff9-5f30-42cc-95b0-73862982b93a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_26daad40-1390-44eb-8157-35f011291cca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0bfd6f09-0f8b-4b5b-a228-f726e0826877" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_26daad40-1390-44eb-8157-35f011291cca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_384b4988-80fe-452a-8ffb-f35862b1e67a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0bfd6f09-0f8b-4b5b-a228-f726e0826877" xlink:to="loc_us-gaap_DepreciationAndAmortization_384b4988-80fe-452a-8ffb-f35862b1e67a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ce07d847-1da6-466e-aaae-e7a193316615" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0bfd6f09-0f8b-4b5b-a228-f726e0826877" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_ce07d847-1da6-466e-aaae-e7a193316615" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_7400debb-b3f0-472a-9095-f1b84d48e6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0bfd6f09-0f8b-4b5b-a228-f726e0826877" xlink:to="loc_us-gaap_ProfitLoss_7400debb-b3f0-472a-9095-f1b84d48e6ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_9a141124-77c3-4612-8c04-c3c7fa4d8ea8" xlink:href="arwr-20230930.xsd#arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_0bfd6f09-0f8b-4b5b-a228-f726e0826877" xlink:to="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_9a141124-77c3-4612-8c04-c3c7fa4d8ea8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1390ad0-7d50-4d1d-8137-0d51e2c67f81" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0258ebf2-6fba-4881-8327-4ec9c71d065c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1390ad0-7d50-4d1d-8137-0d51e2c67f81" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0258ebf2-6fba-4881-8327-4ec9c71d065c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_86cfebc6-11da-47c3-902e-0d7b5a968f33" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1390ad0-7d50-4d1d-8137-0d51e2c67f81" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_86cfebc6-11da-47c3-902e-0d7b5a968f33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_d6c32f41-6d26-4d02-82c2-b5e6394434d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f1390ad0-7d50-4d1d-8137-0d51e2c67f81" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_d6c32f41-6d26-4d02-82c2-b5e6394434d3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#PropertyandEquipmentSummaryofPropertyandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_ef992889-369d-429a-b8cb-89c750920dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentGross_8465a884-1578-4102-b746-ebaaaca1b523" xlink:href="arwr-20230930.xsd#arwr_ResearchEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_ef992889-369d-429a-b8cb-89c750920dc3" xlink:to="loc_arwr_ResearchEquipmentGross_8465a884-1578-4102-b746-ebaaaca1b523" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_a906fb98-67ac-4e5c-a78a-135441922b85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_ef992889-369d-429a-b8cb-89c750920dc3" xlink:to="loc_us-gaap_ConstructionInProgressGross_a906fb98-67ac-4e5c-a78a-135441922b85" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_22a95a3e-66ef-4807-8b95-59d7ecef2c4f" xlink:href="arwr-20230930.xsd#arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_ef992889-369d-429a-b8cb-89c750920dc3" xlink:to="loc_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_22a95a3e-66ef-4807-8b95-59d7ecef2c4f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_9fd7d9e2-150c-4d5a-ac41-de69747dad19" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_ef992889-369d-429a-b8cb-89c750920dc3" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_9fd7d9e2-150c-4d5a-ac41-de69747dad19" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_9e920979-9bd5-4f3c-bece-be84d134cb13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Land"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_ef992889-369d-429a-b8cb-89c750920dc3" xlink:to="loc_us-gaap_Land_9e920979-9bd5-4f3c-bece-be84d134cb13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_59c362a4-ee26-4962-ba1b-d3e0d58ed7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_74ed83c5-1b4a-41d7-8251-631171c2d508" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_59c362a4-ee26-4962-ba1b-d3e0d58ed7b5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_74ed83c5-1b4a-41d7-8251-631171c2d508" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_883ab413-0f50-478c-850d-eb6dc3b97e2f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_59c362a4-ee26-4962-ba1b-d3e0d58ed7b5" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_883ab413-0f50-478c-850d-eb6dc3b97e2f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_fada5264-c419-487f-93ce-f68f007de546" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_735e4572-4989-4446-87f1-debe6399d050" xlink:href="arwr-20230930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent_fada5264-c419-487f-93ce-f68f007de546" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_735e4572-4989-4446-87f1-debe6399d050" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_cb416ec9-8df1-434b-a431-0bbcd8022304" xlink:href="arwr-20230930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent_fada5264-c419-487f-93ce-f68f007de546" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_cb416ec9-8df1-434b-a431-0bbcd8022304" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_a8f3a873-647f-476f-8163-ccd93c5df4a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent_fada5264-c419-487f-93ce-f68f007de546" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_a8f3a873-647f-476f-8163-ccd93c5df4a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_9da1f82e-b9ba-44af-9ec4-3a0d5ce040c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_baff0c0c-b8b0-48af-8368-83f3722420c8" xlink:href="arwr-20230930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_9da1f82e-b9ba-44af-9ec4-3a0d5ce040c6" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_baff0c0c-b8b0-48af-8368-83f3722420c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_f001dc65-7e84-4875-9856-ee728e68c8ae" xlink:href="arwr-20230930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_9da1f82e-b9ba-44af-9ec4-3a0d5ce040c6" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_f001dc65-7e84-4875-9856-ee728e68c8ae" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_d4cf0379-e420-4ead-82db-efa54262bf31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_9da1f82e-b9ba-44af-9ec4-3a0d5ce040c6" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_d4cf0379-e420-4ead-82db-efa54262bf31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_798f2692-454e-4c80-9c3b-0470731d47b2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_12298fc8-343d-4bc8-babe-ee3d49534662" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_798f2692-454e-4c80-9c3b-0470731d47b2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_12298fc8-343d-4bc8-babe-ee3d49534662" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_1bb2f9cc-4cff-49d7-b923-5998ad3fbbd6" xlink:href="arwr-20230930.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_798f2692-454e-4c80-9c3b-0470731d47b2" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_1bb2f9cc-4cff-49d7-b923-5998ad3fbbd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_057a073e-78f4-4c0a-b005-b2d9088553b8" xlink:href="arwr-20230930.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_798f2692-454e-4c80-9c3b-0470731d47b2" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_057a073e-78f4-4c0a-b005-b2d9088553b8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f2c65d8d-46ef-4f8d-a41d-8510a332414b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0f288a7c-252f-44c8-85ed-78c92cd4f99f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f2c65d8d-46ef-4f8d-a41d-8510a332414b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_0f288a7c-252f-44c8-85ed-78c92cd4f99f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1d4e2647-6d10-42da-bd6a-10a187acb3f4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f2c65d8d-46ef-4f8d-a41d-8510a332414b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_1d4e2647-6d10-42da-bd6a-10a187acb3f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment_d03a4b2e-42fc-4ae8-be74-8603dc18f84c" xlink:href="arwr-20230930.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_f2c65d8d-46ef-4f8d-a41d-8510a332414b" xlink:to="loc_arwr_FiniteLivedIntangibleAssetsImpairment_d03a4b2e-42fc-4ae8-be74-8603dc18f84c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#IntangibleAssetsExpectedFutureAmortizationDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a5c106f5-87df-4cd2-bbe2-9827595ad66e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4c91bf78-9369-4631-ae47-1599af26bc16" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a5c106f5-87df-4cd2-bbe2-9827595ad66e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_4c91bf78-9369-4631-ae47-1599af26bc16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_be43407c-2839-4d0b-b150-a1036a0d9d27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a5c106f5-87df-4cd2-bbe2-9827595ad66e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_be43407c-2839-4d0b-b150-a1036a0d9d27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_11a58f28-1701-4dbb-b215-fdc00b85175b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a5c106f5-87df-4cd2-bbe2-9827595ad66e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_11a58f28-1701-4dbb-b215-fdc00b85175b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6cffcc4e-17bb-4878-98f7-ec170ffd7df2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a5c106f5-87df-4cd2-bbe2-9827595ad66e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_6cffcc4e-17bb-4878-98f7-ec170ffd7df2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3d6a4d33-54d2-4f10-a86a-16da4194a12a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a5c106f5-87df-4cd2-bbe2-9827595ad66e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_3d6a4d33-54d2-4f10-a86a-16da4194a12a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_0fae7760-2663-4c77-9c2b-6e2d1721b857" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a5c106f5-87df-4cd2-bbe2-9827595ad66e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_0fae7760-2663-4c77-9c2b-6e2d1721b857" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#LeasesComponentsofLeaseAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_cdf028ea-6937-4b71-bd64-d0b5d11c5b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_03e94e33-ed33-4b10-8f37-b22aed59ce7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_cdf028ea-6937-4b71-bd64-d0b5d11c5b0b" xlink:to="loc_us-gaap_VariableLeaseCost_03e94e33-ed33-4b10-8f37-b22aed59ce7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_d0c1e3f5-2d53-44c6-8551-14852f07aba8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_cdf028ea-6937-4b71-bd64-d0b5d11c5b0b" xlink:to="loc_us-gaap_OperatingLeaseCost_d0c1e3f5-2d53-44c6-8551-14852f07aba8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_783df600-4bb6-4256-a69a-b9fdb680c965" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_bdc74aa4-1e23-420d-8ee2-6e9a11c55cfe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_783df600-4bb6-4256-a69a-b9fdb680c965" xlink:to="loc_us-gaap_OperatingLeaseLiability_bdc74aa4-1e23-420d-8ee2-6e9a11c55cfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_04e140fa-9fa3-4ba7-b98f-22fdec33b3aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_783df600-4bb6-4256-a69a-b9fdb680c965" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_04e140fa-9fa3-4ba7-b98f-22fdec33b3aa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" xlink:type="simple" xlink:href="arwr-20230930.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cc6233a6-7a58-40a5-8fc7-78b2b709f7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1acd3753-1e84-4851-b7ce-20986d6b39a9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cc6233a6-7a58-40a5-8fc7-78b2b709f7dd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1acd3753-1e84-4851-b7ce-20986d6b39a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fd5e00e3-589c-4360-8dc0-aa29a2e65475" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cc6233a6-7a58-40a5-8fc7-78b2b709f7dd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_fd5e00e3-589c-4360-8dc0-aa29a2e65475" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ce418a48-d71d-4a84-899a-29eb0a018e0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cc6233a6-7a58-40a5-8fc7-78b2b709f7dd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ce418a48-d71d-4a84-899a-29eb0a018e0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ca0ffadf-8555-48ce-86ae-6dd2d86160fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cc6233a6-7a58-40a5-8fc7-78b2b709f7dd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_ca0ffadf-8555-48ce-86ae-6dd2d86160fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3d3387e9-a1fd-4136-b455-3af18da9d8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cc6233a6-7a58-40a5-8fc7-78b2b709f7dd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_3d3387e9-a1fd-4136-b455-3af18da9d8fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c995f2a4-21ce-46d9-b65b-10fd49386737" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_cc6233a6-7a58-40a5-8fc7-78b2b709f7dd" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_c995f2a4-21ce-46d9-b65b-10fd49386737" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_9580dee2-201c-4217-81e7-eea366417451" xlink:href="arwr-20230930.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70c5117e-a074-4f51-941d-f196e9804305" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_9580dee2-201c-4217-81e7-eea366417451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_70c5117e-a074-4f51-941d-f196e9804305" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_592ee2ba-1d36-4955-bc9a-3617b495475b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_9580dee2-201c-4217-81e7-eea366417451" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_592ee2ba-1d36-4955-bc9a-3617b495475b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_ef79be32-b5db-4a87-bc81-941962c94822" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1c22192c-05da-423e-a13d-0c430a0a5d29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_ef79be32-b5db-4a87-bc81-941962c94822" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1c22192c-05da-423e-a13d-0c430a0a5d29" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4ab627b8-5a93-4adb-846c-c8ea8cd14939" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_ef79be32-b5db-4a87-bc81-941962c94822" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_4ab627b8-5a93-4adb-846c-c8ea8cd14939" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_021ccd93-e467-4cd6-be45-836e19fe191b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_ef79be32-b5db-4a87-bc81-941962c94822" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_021ccd93-e467-4cd6-be45-836e19fe191b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_b364fd4d-de54-446d-b4ef-5c24a32935a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_cc12d339-deb5-436a-98de-7d732f994995" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_b364fd4d-de54-446d-b4ef-5c24a32935a0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_cc12d339-deb5-436a-98de-7d732f994995" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_3bb84732-7810-4e44-b62d-6c080a8447c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossAttributableToParent_b364fd4d-de54-446d-b4ef-5c24a32935a0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_3bb84732-7810-4e44-b62d-6c080a8447c1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#IncomeTaxesProvisionsforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_90db0fbd-3857-448d-84ef-1ec90a691198" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_a3db682d-1299-405f-a268-ae6979de634c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_90db0fbd-3857-448d-84ef-1ec90a691198" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_a3db682d-1299-405f-a268-ae6979de634c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_165bd862-7323-4d1f-b2cb-9fe7d06221eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_90db0fbd-3857-448d-84ef-1ec90a691198" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_165bd862-7323-4d1f-b2cb-9fe7d06221eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f66ad655-3cac-4da7-9b4c-3d3384089e9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_90db0fbd-3857-448d-84ef-1ec90a691198" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_f66ad655-3cac-4da7-9b4c-3d3384089e9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1246826e-d9ce-46da-baec-e7ec54042f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_caa5cfc8-a8d0-45a2-9d5b-c7b1728a66ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1246826e-d9ce-46da-baec-e7ec54042f8b" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_caa5cfc8-a8d0-45a2-9d5b-c7b1728a66ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_608193b1-9944-4fad-9abb-e4fe859178c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1246826e-d9ce-46da-baec-e7ec54042f8b" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_608193b1-9944-4fad-9abb-e4fe859178c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a4f7ac57-f408-4f87-b400-0e630ebe0001" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_1246826e-d9ce-46da-baec-e7ec54042f8b" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_a4f7ac57-f408-4f87-b400-0e630ebe0001" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_98b7cd6c-6b1b-48a2-ba3d-ec52a1b2f06f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4500fd46-6a85-40d7-b1ea-3655bd257db3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_98b7cd6c-6b1b-48a2-ba3d-ec52a1b2f06f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_4500fd46-6a85-40d7-b1ea-3655bd257db3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c3fda769-8110-4077-8ab3-11ea666a0d86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_98b7cd6c-6b1b-48a2-ba3d-ec52a1b2f06f" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_c3fda769-8110-4077-8ab3-11ea666a0d86" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7c01df68-2f77-4551-962e-3713671847ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0f20d696-0612-4507-8487-e3ecd0f90115" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7c01df68-2f77-4551-962e-3713671847ef" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0f20d696-0612-4507-8487-e3ecd0f90115" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_a337be6e-db49-43fa-8743-275d8da7b837" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7c01df68-2f77-4551-962e-3713671847ef" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_a337be6e-db49-43fa-8743-275d8da7b837" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_224312c4-9f00-4569-a105-5cbae25efa88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7c01df68-2f77-4551-962e-3713671847ef" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_224312c4-9f00-4569-a105-5cbae25efa88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_100f236d-ec03-46a7-9a2c-1b49bcfc4bd8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7c01df68-2f77-4551-962e-3713671847ef" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_100f236d-ec03-46a7-9a2c-1b49bcfc4bd8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_c895d1a6-d905-48d9-b58e-ff7202f928fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7c01df68-2f77-4551-962e-3713671847ef" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_c895d1a6-d905-48d9-b58e-ff7202f928fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent_47796ecf-22b4-46ed-8867-672b5d8523b9" xlink:href="arwr-20230930.xsd#arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7c01df68-2f77-4551-962e-3713671847ef" xlink:to="loc_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent_47796ecf-22b4-46ed-8867-672b5d8523b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8bdce5d3-ca93-4b11-8b8c-e0a7034b7c49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7c01df68-2f77-4551-962e-3713671847ef" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8bdce5d3-ca93-4b11-8b8c-e0a7034b7c49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_98eac447-fd5c-456b-a619-c045f161c042" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7c01df68-2f77-4551-962e-3713671847ef" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_98eac447-fd5c-456b-a619-c045f161c042" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_346222ab-6c59-4e23-a802-9bb31424318e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_b1c76410-9a58-423f-99cc-16e413c0d4d9" xlink:href="arwr-20230930.xsd#arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_346222ab-6c59-4e23-a802-9bb31424318e" xlink:to="loc_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_b1c76410-9a58-423f-99cc-16e413c0d4d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_ba574e00-9b4b-40b0-8b97-6f93560f73bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_346222ab-6c59-4e23-a802-9bb31424318e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_ba574e00-9b4b-40b0-8b97-6f93560f73bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_3b935178-fa31-406a-82d2-4e2d312729a5" xlink:href="arwr-20230930.xsd#arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_346222ab-6c59-4e23-a802-9bb31424318e" xlink:to="loc_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_3b935178-fa31-406a-82d2-4e2d312729a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_23b7c40f-56d2-46d8-a260-34bdaaa0d03e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_346222ab-6c59-4e23-a802-9bb31424318e" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_23b7c40f-56d2-46d8-a260-34bdaaa0d03e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_602d25ab-1e54-41a6-87fe-0e0a2e73c3db" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_346222ab-6c59-4e23-a802-9bb31424318e" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_602d25ab-1e54-41a6-87fe-0e0a2e73c3db" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_de742f63-9b4d-4000-b3a6-89da59b68a49" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_346222ab-6c59-4e23-a802-9bb31424318e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_de742f63-9b4d-4000-b3a6-89da59b68a49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_51edfc26-487c-40b9-aae2-4cf2d8976b45" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_346222ab-6c59-4e23-a802-9bb31424318e" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_51edfc26-487c-40b9-aae2-4cf2d8976b45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_b30d5d99-4c44-4081-a5e6-4af0d4831f8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_346222ab-6c59-4e23-a802-9bb31424318e" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_b30d5d99-4c44-4081-a5e6-4af0d4831f8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_ba1571b7-c7d8-4ca0-9de4-927d0e922903" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_346222ab-6c59-4e23-a802-9bb31424318e" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_ba1571b7-c7d8-4ca0-9de4-927d0e922903" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_9019b3d8-d6b3-4c8f-9e65-25958fba0ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_efbd80a7-01a8-4728-9116-e1629baf82a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_9019b3d8-d6b3-4c8f-9e65-25958fba0ad4" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_efbd80a7-01a8-4728-9116-e1629baf82a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxLiabilitiesStateTaxes_0225f81d-f743-41f0-8a94-6d34fca46534" xlink:href="arwr-20230930.xsd#arwr_DeferredTaxLiabilitiesStateTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_9019b3d8-d6b3-4c8f-9e65-25958fba0ad4" xlink:to="loc_arwr_DeferredTaxLiabilitiesStateTaxes_0225f81d-f743-41f0-8a94-6d34fca46534" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_26fddae4-5930-462b-9f90-7fe23560b815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_9019b3d8-d6b3-4c8f-9e65-25958fba0ad4" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_26fddae4-5930-462b-9f90-7fe23560b815" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a13c119b-ad7d-4e92-b47a-2916b95e5020" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9ff173b0-29a0-4a2e-bcb7-63812c5a7740" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a13c119b-ad7d-4e92-b47a-2916b95e5020" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_9ff173b0-29a0-4a2e-bcb7-63812c5a7740" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_bedf8415-8ed6-4777-983c-ef5617dd80d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a13c119b-ad7d-4e92-b47a-2916b95e5020" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_bedf8415-8ed6-4777-983c-ef5617dd80d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_6f135128-06e0-405e-a379-78f4cbcdd8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_a13c119b-ad7d-4e92-b47a-2916b95e5020" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_6f135128-06e0-405e-a379-78f4cbcdd8d3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#EarningsPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.arrowheadresearch.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_380114dd-e704-48f8-9acb-94b5483925a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6136b501-5f96-415c-b320-6dade7d55392" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_380114dd-e704-48f8-9acb-94b5483925a4" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_6136b501-5f96-415c-b320-6dade7d55392" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7ed06634-7be9-43fb-b548-51fa3a8e54fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_380114dd-e704-48f8-9acb-94b5483925a4" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7ed06634-7be9-43fb-b548-51fa3a8e54fe" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>14
<FILENAME>arwr-20230930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:d14395b2-bc79-4df5-8659-886540a562de,g:ab3d3e76-c740-4da0-ace7-13e457c841a4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="arwr-20230930.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6f954bf4-1a35-4e20-b693-dba0166d691e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6f954bf4-1a35-4e20-b693-dba0166d691e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_510b61c5-73aa-4fde-8b8b-e116b8a2f53e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_510b61c5-73aa-4fde-8b8b-e116b8a2f53e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a3db19e2-a8c3-4f48-9a37-9ab32ed431b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:to="loc_us-gaap_SharesOutstanding_a3db19e2-a8c3-4f48-9a37-9ab32ed431b9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_faec25d5-deef-46fb-b7f8-3d9ae62d42ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_faec25d5-deef-46fb-b7f8-3d9ae62d42ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_72468b36-b7e2-4831-941b-fe937268c772" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_72468b36-b7e2-4831-941b-fe937268c772" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7b3f5552-71b0-4242-9f7f-64741bd9bae2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7b3f5552-71b0-4242-9f7f-64741bd9bae2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_16d70c18-9a00-411d-9db2-b7cef000e509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_16d70c18-9a00-411d-9db2-b7cef000e509" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_d5053adc-ebe0-47e9-bf32-1de353b564d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_d5053adc-ebe0-47e9-bf32-1de353b564d5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_abb94925-1522-4a2d-8fc0-44d0fa2c5398" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_abb94925-1522-4a2d-8fc0-44d0fa2c5398" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ae139115-2765-4990-9c83-057751dcd9da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ae139115-2765-4990-9c83-057751dcd9da" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_81fe479f-712d-4812-ab1f-59e1ccf8df5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_81fe479f-712d-4812-ab1f-59e1ccf8df5e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4b5c8c1e-0f5f-4d90-b4a0-de2e965c5f47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:to="loc_us-gaap_ProfitLoss_4b5c8c1e-0f5f-4d90-b4a0-de2e965c5f47" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c87ce50b-9f49-4645-b31a-ceae0b973fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_65f89256-a369-47a8-81c9-555f947bcf65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c2d23612-38cd-4695-bfbd-3fe64676fe43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6f954bf4-1a35-4e20-b693-dba0166d691e" xlink:to="loc_us-gaap_StatementTable_c2d23612-38cd-4695-bfbd-3fe64676fe43" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bc19caee-c203-4c94-aaf5-db58c84bbd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c2d23612-38cd-4695-bfbd-3fe64676fe43" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bc19caee-c203-4c94-aaf5-db58c84bbd7e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bc19caee-c203-4c94-aaf5-db58c84bbd7e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bc19caee-c203-4c94-aaf5-db58c84bbd7e" xlink:to="loc_us-gaap_EquityComponentDomain_bc19caee-c203-4c94-aaf5-db58c84bbd7e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_47acddab-92f1-4e20-a387-baf00a424d64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bc19caee-c203-4c94-aaf5-db58c84bbd7e" xlink:to="loc_us-gaap_EquityComponentDomain_47acddab-92f1-4e20-a387-baf00a424d64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3855e176-71e1-4ade-ba78-bf9a2d998722" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_47acddab-92f1-4e20-a387-baf00a424d64" xlink:to="loc_us-gaap_CommonStockMember_3855e176-71e1-4ade-ba78-bf9a2d998722" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7ceb2091-aa3c-476a-95a2-f92b99c1dc91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_47acddab-92f1-4e20-a387-baf00a424d64" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7ceb2091-aa3c-476a-95a2-f92b99c1dc91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_062a9907-2c6e-46dd-a604-2809e2492325" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_47acddab-92f1-4e20-a387-baf00a424d64" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_062a9907-2c6e-46dd-a604-2809e2492325" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_27ba09f8-d69d-43df-8ced-a5a26fd69547" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_47acddab-92f1-4e20-a387-baf00a424d64" xlink:to="loc_us-gaap_RetainedEarningsMember_27ba09f8-d69d-43df-8ced-a5a26fd69547" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_e9ff823d-442c-4402-9400-f0eb90683327" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_47acddab-92f1-4e20-a387-baf00a424d64" xlink:to="loc_us-gaap_NoncontrollingInterestMember_e9ff823d-442c-4402-9400-f0eb90683327" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#OrganizationandSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:href="arwr-20230930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9e1e84c2-fb9b-454c-b589-6ef3c90efcbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9e1e84c2-fb9b-454c-b589-6ef3c90efcbe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_adade941-4715-40b2-b620-59197e976822" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_adade941-4715-40b2-b620-59197e976822" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_79284377-620a-4268-8a8f-6603233e04b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_79284377-620a-4268-8a8f-6603233e04b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_IncreaseDecreaseInCashAndInvestments_f53f406a-dc82-436b-a297-38b349406a50" xlink:href="arwr-20230930.xsd#arwr_IncreaseDecreaseInCashAndInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:to="loc_arwr_IncreaseDecreaseInCashAndInvestments_f53f406a-dc82-436b-a297-38b349406a50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_d0e6507c-254f-415f-90fa-75161a7afef7" xlink:href="arwr-20230930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_d0e6507c-254f-415f-90fa-75161a7afef7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontMilestonePaymentReceived_59ae53ed-c123-48bd-bf57-2f87d5c82424" xlink:href="arwr-20230930.xsd#arwr_UpfrontMilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:to="loc_arwr_UpfrontMilestonePaymentReceived_59ae53ed-c123-48bd-bf57-2f87d5c82424" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_4d0dab85-9ed9-4826-a474-665039209e6a" xlink:href="arwr-20230930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_4d0dab85-9ed9-4826-a474-665039209e6a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFDICInsuredAmount_f38b3349-f14e-4ca9-b393-6a3218ac9836" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:to="loc_us-gaap_CashFDICInsuredAmount_f38b3349-f14e-4ca9-b393-6a3218ac9836" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_b6821435-1d97-45a8-8e73-4a23721870e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_b6821435-1d97-45a8-8e73-4a23721870e9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_05830acc-a277-41bb-b68b-14eff470189a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_05830acc-a277-41bb-b68b-14eff470189a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9b2a1970-2fcd-40a4-9dbf-051399856c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9b2a1970-2fcd-40a4-9dbf-051399856c9a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_c9d63843-204b-42ec-9dc3-31ba7ba01209" xlink:href="arwr-20230930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:to="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_c9d63843-204b-42ec-9dc3-31ba7ba01209" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_607915de-bd56-4c6e-93a8-7d75f773bc64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_c9d63843-204b-42ec-9dc3-31ba7ba01209" xlink:to="loc_us-gaap_TypeOfArrangementAxis_607915de-bd56-4c6e-93a8-7d75f773bc64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_607915de-bd56-4c6e-93a8-7d75f773bc64_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_607915de-bd56-4c6e-93a8-7d75f773bc64" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_607915de-bd56-4c6e-93a8-7d75f773bc64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d648dca0-9fe7-40f5-aa97-3564ccec47eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_607915de-bd56-4c6e-93a8-7d75f773bc64" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d648dca0-9fe7-40f5-aa97-3564ccec47eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaAgreementMember_0f43af0b-a5d0-4f3c-a90b-204006c3d78d" xlink:href="arwr-20230930.xsd#arwr_RoyaltyPharmaAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d648dca0-9fe7-40f5-aa97-3564ccec47eb" xlink:to="loc_arwr_RoyaltyPharmaAgreementMember_0f43af0b-a5d0-4f3c-a90b-204006c3d78d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsMember_2e56544c-721f-4b65-b0c6-9f395ce24496" xlink:href="arwr-20230930.xsd#arwr_CollaborationAndLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d648dca0-9fe7-40f5-aa97-3564ccec47eb" xlink:to="loc_arwr_CollaborationAndLicenseAgreementsMember_2e56544c-721f-4b65-b0c6-9f395ce24496" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f445efb7-bbcf-4842-a121-d2edad690923" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_c9d63843-204b-42ec-9dc3-31ba7ba01209" xlink:to="loc_srt_RangeAxis_f445efb7-bbcf-4842-a121-d2edad690923" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_f445efb7-bbcf-4842-a121-d2edad690923_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_f445efb7-bbcf-4842-a121-d2edad690923" xlink:to="loc_srt_RangeMember_f445efb7-bbcf-4842-a121-d2edad690923_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3bca016b-3992-4dbf-902e-1dc490ef0240" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_f445efb7-bbcf-4842-a121-d2edad690923" xlink:to="loc_srt_RangeMember_3bca016b-3992-4dbf-902e-1dc490ef0240" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bb740a07-201e-41d5-b595-4e0b7a1b6dc0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3bca016b-3992-4dbf-902e-1dc490ef0240" xlink:to="loc_srt_MinimumMember_bb740a07-201e-41d5-b595-4e0b7a1b6dc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1094f974-e5a5-497b-bf1a-f2641da8f8bd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_3bca016b-3992-4dbf-902e-1dc490ef0240" xlink:to="loc_srt_MaximumMember_1094f974-e5a5-497b-bf1a-f2641da8f8bd" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#CollaborationandLicenseAgreementsRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7a6fd717-7635-4a87-845f-20e78b9f1c91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_623addfd-444b-4b98-911c-9da5642daac3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7a6fd717-7635-4a87-845f-20e78b9f1c91" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_623addfd-444b-4b98-911c-9da5642daac3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_dc7c30f0-edd9-42dd-9415-f6c16c3d5f41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7a6fd717-7635-4a87-845f-20e78b9f1c91" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_dc7c30f0-edd9-42dd-9415-f6c16c3d5f41" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c36d10cf-5442-4e11-9874-30a3ce654de9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_dc7c30f0-edd9-42dd-9415-f6c16c3d5f41" xlink:to="loc_srt_MajorCustomersAxis_c36d10cf-5442-4e11-9874-30a3ce654de9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_c36d10cf-5442-4e11-9874-30a3ce654de9_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_c36d10cf-5442-4e11-9874-30a3ce654de9" xlink:to="loc_srt_NameOfMajorCustomerDomain_c36d10cf-5442-4e11-9874-30a3ce654de9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4f5506d2-31c2-43fb-a9bc-525e7f4f31be" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_c36d10cf-5442-4e11-9874-30a3ce654de9" xlink:to="loc_srt_NameOfMajorCustomerDomain_4f5506d2-31c2-43fb-a9bc-525e7f4f31be" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_7f00640a-56d7-45f7-a831-cec3c7be4f2c" xlink:href="arwr-20230930.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4f5506d2-31c2-43fb-a9bc-525e7f4f31be" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_7f00640a-56d7-45f7-a831-cec3c7be4f2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember_dbd2afd9-0c91-4618-9b8b-e364e3153596" xlink:href="arwr-20230930.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4f5506d2-31c2-43fb-a9bc-525e7f4f31be" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACMember_dbd2afd9-0c91-4618-9b8b-e364e3153596" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_311e0771-91e0-4807-b8d0-d3a3afd85ee2" xlink:href="arwr-20230930.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4f5506d2-31c2-43fb-a9bc-525e7f4f31be" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_311e0771-91e0-4807-b8d0-d3a3afd85ee2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember_33fa755e-8c76-4d96-a80b-a4ec66d98cfc" xlink:href="arwr-20230930.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4f5506d2-31c2-43fb-a9bc-525e7f4f31be" xlink:to="loc_arwr_JanssenPharmaceuticalsIncorporationMember_33fa755e-8c76-4d96-a80b-a4ec66d98cfc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_c9932437-cfd6-4f91-96ef-cbea2e24240d" xlink:href="arwr-20230930.xsd#arwr_AmgenIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_4f5506d2-31c2-43fb-a9bc-525e7f4f31be" xlink:to="loc_arwr_AmgenIncorporatedMember_c9932437-cfd6-4f91-96ef-cbea2e24240d" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84a52fa6-9720-42b8-b90e-c3e94238c608" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_9d179759-ff3d-464c-b5d1-b5240c961063" xlink:href="arwr-20230930.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84a52fa6-9720-42b8-b90e-c3e94238c608" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_9d179759-ff3d-464c-b5d1-b5240c961063" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_2c7c1c7c-4339-4418-a462-f2a6f56d069c" xlink:href="arwr-20230930.xsd#arwr_NumberOfDistinctBundle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84a52fa6-9720-42b8-b90e-c3e94238c608" xlink:to="loc_arwr_NumberOfDistinctBundle_2c7c1c7c-4339-4418-a462-f2a6f56d069c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_4dafed73-63c1-4ce0-a240-0be9d5edce28" xlink:href="arwr-20230930.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84a52fa6-9720-42b8-b90e-c3e94238c608" xlink:to="loc_arwr_InitialTransactionPrice_4dafed73-63c1-4ce0-a240-0be9d5edce28" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_453b35f6-522f-4db5-a234-74d263e29693" xlink:href="arwr-20230930.xsd#arwr_MilestonePaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84a52fa6-9720-42b8-b90e-c3e94238c608" xlink:to="loc_arwr_MilestonePaymentReceivable_453b35f6-522f-4db5-a234-74d263e29693" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_33d4a9d2-1859-4fb0-9e06-6054ad981324" xlink:href="arwr-20230930.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84a52fa6-9720-42b8-b90e-c3e94238c608" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_33d4a9d2-1859-4fb0-9e06-6054ad981324" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_c6565903-fb5c-41a9-b4ba-c4053d9b0bee" xlink:href="arwr-20230930.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84a52fa6-9720-42b8-b90e-c3e94238c608" xlink:to="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_c6565903-fb5c-41a9-b4ba-c4053d9b0bee" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments_b00d7df7-fea6-4fe2-8917-6a11ccdf3991" xlink:href="arwr-20230930.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84a52fa6-9720-42b8-b90e-c3e94238c608" xlink:to="loc_arwr_SalesRelatedMilestonePayments_b00d7df7-fea6-4fe2-8917-6a11ccdf3991" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7268fbf5-8830-48c0-be80-daff29d1ae73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84a52fa6-9720-42b8-b90e-c3e94238c608" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7268fbf5-8830-48c0-be80-daff29d1ae73" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4faa8f63-84af-4537-8074-efd8f6ab5a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84a52fa6-9720-42b8-b90e-c3e94238c608" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4faa8f63-84af-4537-8074-efd8f6ab5a2d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c30bc2a1-8641-4ce6-8016-64f8058b847d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4faa8f63-84af-4537-8074-efd8f6ab5a2d" xlink:to="loc_srt_CounterpartyNameAxis_c30bc2a1-8641-4ce6-8016-64f8058b847d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c30bc2a1-8641-4ce6-8016-64f8058b847d_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_c30bc2a1-8641-4ce6-8016-64f8058b847d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_c30bc2a1-8641-4ce6-8016-64f8058b847d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91fed46f-4231-4798-b6d5-604d18911c4c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_c30bc2a1-8641-4ce6-8016-64f8058b847d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91fed46f-4231-4798-b6d5-604d18911c4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_15487269-434e-4141-8d69-478c2f61b9d9" xlink:href="arwr-20230930.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91fed46f-4231-4798-b6d5-604d18911c4c" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_15487269-434e-4141-8d69-478c2f61b9d9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9fde3b82-e183-4385-9d63-05a5542baf85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4faa8f63-84af-4537-8074-efd8f6ab5a2d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9fde3b82-e183-4385-9d63-05a5542baf85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9fde3b82-e183-4385-9d63-05a5542baf85_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9fde3b82-e183-4385-9d63-05a5542baf85" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9fde3b82-e183-4385-9d63-05a5542baf85_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0341b19-968c-4c1c-9909-e0faee4076dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9fde3b82-e183-4385-9d63-05a5542baf85" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0341b19-968c-4c1c-9909-e0faee4076dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsMember_c42389b0-1256-4891-9114-3035f6b5b4ca" xlink:href="arwr-20230930.xsd#arwr_CollaborationAndLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0341b19-968c-4c1c-9909-e0faee4076dd" xlink:to="loc_arwr_CollaborationAndLicenseAgreementsMember_c42389b0-1256-4891-9114-3035f6b5b4ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aaeb0290-83df-4f9c-b18e-14100268b6ce" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4faa8f63-84af-4537-8074-efd8f6ab5a2d" xlink:to="loc_srt_RangeAxis_aaeb0290-83df-4f9c-b18e-14100268b6ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_aaeb0290-83df-4f9c-b18e-14100268b6ce_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_aaeb0290-83df-4f9c-b18e-14100268b6ce" xlink:to="loc_srt_RangeMember_aaeb0290-83df-4f9c-b18e-14100268b6ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d10998ca-d3cc-4226-a206-afde40758d3c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_aaeb0290-83df-4f9c-b18e-14100268b6ce" xlink:to="loc_srt_RangeMember_d10998ca-d3cc-4226-a206-afde40758d3c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_341eb999-7790-4698-b2aa-ef1612d4a27b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_d10998ca-d3cc-4226-a206-afde40758d3c" xlink:to="loc_srt_MaximumMember_341eb999-7790-4698-b2aa-ef1612d4a27b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6332d105-8c14-49a8-842d-c9e945093854" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_5431d5d3-3dd9-4127-933f-8144cf9306b2" xlink:href="arwr-20230930.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6332d105-8c14-49a8-842d-c9e945093854" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_5431d5d3-3dd9-4127-933f-8144cf9306b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_afdb6d34-0d95-4265-a229-7bd4a00ad986" xlink:href="arwr-20230930.xsd#arwr_NumberOfDistinctBundle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6332d105-8c14-49a8-842d-c9e945093854" xlink:to="loc_arwr_NumberOfDistinctBundle_afdb6d34-0d95-4265-a229-7bd4a00ad986" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_8f2ac1a7-c30f-405a-b588-b4d14be93f1d" xlink:href="arwr-20230930.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6332d105-8c14-49a8-842d-c9e945093854" xlink:to="loc_arwr_InitialTransactionPrice_8f2ac1a7-c30f-405a-b588-b4d14be93f1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontMilestonePaymentReceived_f213688f-8072-48c9-9c0c-02685de25491" xlink:href="arwr-20230930.xsd#arwr_UpfrontMilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6332d105-8c14-49a8-842d-c9e945093854" xlink:to="loc_arwr_UpfrontMilestonePaymentReceived_f213688f-8072-48c9-9c0c-02685de25491" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c891b3c8-5e33-4dcc-97c7-024a45422342" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6332d105-8c14-49a8-842d-c9e945093854" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c891b3c8-5e33-4dcc-97c7-024a45422342" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_723a59bd-facb-48bb-b64c-a7b697a40354" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6332d105-8c14-49a8-842d-c9e945093854" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_723a59bd-facb-48bb-b64c-a7b697a40354" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3f18059c-4598-48f8-b512-718a6de88d34" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_723a59bd-facb-48bb-b64c-a7b697a40354" xlink:to="loc_srt_CounterpartyNameAxis_3f18059c-4598-48f8-b512-718a6de88d34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f18059c-4598-48f8-b512-718a6de88d34_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3f18059c-4598-48f8-b512-718a6de88d34" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3f18059c-4598-48f8-b512-718a6de88d34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9162b83c-2626-4cfb-a2b8-5b33c083a866" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3f18059c-4598-48f8-b512-718a6de88d34" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9162b83c-2626-4cfb-a2b8-5b33c083a866" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember_60883199-17a8-4272-b967-cd739ef895a3" xlink:href="arwr-20230930.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9162b83c-2626-4cfb-a2b8-5b33c083a866" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACMember_60883199-17a8-4272-b967-cd739ef895a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_707bf7e5-8aa5-4b80-aaa2-e7ff65c4d87e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_723a59bd-facb-48bb-b64c-a7b697a40354" xlink:to="loc_us-gaap_TypeOfArrangementAxis_707bf7e5-8aa5-4b80-aaa2-e7ff65c4d87e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_707bf7e5-8aa5-4b80-aaa2-e7ff65c4d87e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_707bf7e5-8aa5-4b80-aaa2-e7ff65c4d87e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_707bf7e5-8aa5-4b80-aaa2-e7ff65c4d87e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b9735585-08b4-436e-87e1-5cd635e9991a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_707bf7e5-8aa5-4b80-aaa2-e7ff65c4d87e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b9735585-08b4-436e-87e1-5cd635e9991a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonLicenseAgreementMember_0c175662-c5d9-4f80-8e6f-c33f6297a331" xlink:href="arwr-20230930.xsd#arwr_HorizonLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b9735585-08b4-436e-87e1-5cd635e9991a" xlink:to="loc_arwr_HorizonLicenseAgreementMember_0c175662-c5d9-4f80-8e6f-c33f6297a331" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbd69c50-9589-4c01-8190-ec0d1851f949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_9f08be1d-a4a0-46c1-b189-c893032dc3c4" xlink:href="arwr-20230930.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbd69c50-9589-4c01-8190-ec0d1851f949" xlink:to="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_9f08be1d-a4a0-46c1-b189-c893032dc3c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_1f9660d7-aebd-4e7e-8302-855b8e70de9b" xlink:href="arwr-20230930.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbd69c50-9589-4c01-8190-ec0d1851f949" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_1f9660d7-aebd-4e7e-8302-855b8e70de9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_b85e36ad-1323-4952-adaf-c782c56a7535" xlink:href="arwr-20230930.xsd#arwr_NumberOfDistinctBundle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbd69c50-9589-4c01-8190-ec0d1851f949" xlink:to="loc_arwr_NumberOfDistinctBundle_b85e36ad-1323-4952-adaf-c782c56a7535" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_fef0be86-0c4d-42b6-acc4-f034cd0571c0" xlink:href="arwr-20230930.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbd69c50-9589-4c01-8190-ec0d1851f949" xlink:to="loc_arwr_InitialTransactionPrice_fef0be86-0c4d-42b6-acc4-f034cd0571c0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_f730ad11-4def-402b-af14-414819b58fa6" xlink:href="arwr-20230930.xsd#arwr_MilestonePaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbd69c50-9589-4c01-8190-ec0d1851f949" xlink:to="loc_arwr_MilestonePaymentEarned_f730ad11-4def-402b-af14-414819b58fa6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_4115d6c7-078c-4398-b0f6-008612a8b154" xlink:href="arwr-20230930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbd69c50-9589-4c01-8190-ec0d1851f949" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_4115d6c7-078c-4398-b0f6-008612a8b154" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bb33f7d7-a3db-477b-89ac-e2c0d15e4fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbd69c50-9589-4c01-8190-ec0d1851f949" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bb33f7d7-a3db-477b-89ac-e2c0d15e4fb5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_55186541-a303-45e7-84eb-e2ac01a02cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbd69c50-9589-4c01-8190-ec0d1851f949" xlink:to="loc_us-gaap_EarningsPerShareDiluted_55186541-a303-45e7-84eb-e2ac01a02cbe" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_75a40d71-3777-4cc4-a178-4f540d9e2866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbd69c50-9589-4c01-8190-ec0d1851f949" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_75a40d71-3777-4cc4-a178-4f540d9e2866" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_93a517a2-5ad5-4b13-9709-0342e5c2eefd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbd69c50-9589-4c01-8190-ec0d1851f949" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_93a517a2-5ad5-4b13-9709-0342e5c2eefd" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_63b11947-ee69-4ce6-b8cc-66fea22c942a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbd69c50-9589-4c01-8190-ec0d1851f949" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_63b11947-ee69-4ce6-b8cc-66fea22c942a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_98e1aade-bfb6-45ea-b6b9-365fc14ee502" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_63b11947-ee69-4ce6-b8cc-66fea22c942a" xlink:to="loc_srt_CounterpartyNameAxis_98e1aade-bfb6-45ea-b6b9-365fc14ee502" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98e1aade-bfb6-45ea-b6b9-365fc14ee502_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_98e1aade-bfb6-45ea-b6b9-365fc14ee502" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_98e1aade-bfb6-45ea-b6b9-365fc14ee502_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d25b2a8-8a9c-4da2-abd4-5f8c387e8699" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_98e1aade-bfb6-45ea-b6b9-365fc14ee502" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d25b2a8-8a9c-4da2-abd4-5f8c387e8699" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_4b6f7277-ffd3-4cbd-848e-6f24525b3a14" xlink:href="arwr-20230930.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d25b2a8-8a9c-4da2-abd4-5f8c387e8699" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_4b6f7277-ffd3-4cbd-848e-6f24525b3a14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d34b19a7-6507-4b58-b22e-4441f7605fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_63b11947-ee69-4ce6-b8cc-66fea22c942a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d34b19a7-6507-4b58-b22e-4441f7605fa5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d34b19a7-6507-4b58-b22e-4441f7605fa5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d34b19a7-6507-4b58-b22e-4441f7605fa5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d34b19a7-6507-4b58-b22e-4441f7605fa5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9ce2d6cd-1d42-4a66-823a-57d807db62dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d34b19a7-6507-4b58-b22e-4441f7605fa5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9ce2d6cd-1d42-4a66-823a-57d807db62dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember_e84b1796-c512-4948-8d24-c109e107d0e6" xlink:href="arwr-20230930.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9ce2d6cd-1d42-4a66-823a-57d807db62dc" xlink:to="loc_arwr_LicenseAndCoFundingAgreementMember_e84b1796-c512-4948-8d24-c109e107d0e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_03b3757c-7463-449e-ad2a-4dcd6f4190ae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_63b11947-ee69-4ce6-b8cc-66fea22c942a" xlink:to="loc_srt_RangeAxis_03b3757c-7463-449e-ad2a-4dcd6f4190ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_03b3757c-7463-449e-ad2a-4dcd6f4190ae_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_03b3757c-7463-449e-ad2a-4dcd6f4190ae" xlink:to="loc_srt_RangeMember_03b3757c-7463-449e-ad2a-4dcd6f4190ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_04d7a724-f5e8-4478-87ac-c31e0d5a7fcc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_03b3757c-7463-449e-ad2a-4dcd6f4190ae" xlink:to="loc_srt_RangeMember_04d7a724-f5e8-4478-87ac-c31e0d5a7fcc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7030af54-b921-407a-958d-7ec97fb62ab6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_04d7a724-f5e8-4478-87ac-c31e0d5a7fcc" xlink:to="loc_srt_MinimumMember_7030af54-b921-407a-958d-7ec97fb62ab6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4271e354-b7a1-45b9-98d5-1bdbd53a6f46" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_04d7a724-f5e8-4478-87ac-c31e0d5a7fcc" xlink:to="loc_srt_MaximumMember_4271e354-b7a1-45b9-98d5-1bdbd53a6f46" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_217429f1-2204-4591-a613-f0847044abc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_fa4146ae-563e-4b32-8782-0a4a2effdc82" xlink:href="arwr-20230930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_217429f1-2204-4591-a613-f0847044abc7" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_fa4146ae-563e-4b32-8782-0a4a2effdc82" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_94a18929-b155-4cee-b95f-0bfd519eb599" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_217429f1-2204-4591-a613-f0847044abc7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_94a18929-b155-4cee-b95f-0bfd519eb599" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_55e42e0f-7a49-4843-9b8d-33fa3b009b95" xlink:href="arwr-20230930.xsd#arwr_MilestonePaymentEarned"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_217429f1-2204-4591-a613-f0847044abc7" xlink:to="loc_arwr_MilestonePaymentEarned_55e42e0f-7a49-4843-9b8d-33fa3b009b95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_462e4278-6079-4552-8b1a-f9ec636be5f1" xlink:href="arwr-20230930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_217429f1-2204-4591-a613-f0847044abc7" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_462e4278-6079-4552-8b1a-f9ec636be5f1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_7742ed99-212f-4fe7-ac8f-b0d34ef346e9" xlink:href="arwr-20230930.xsd#arwr_NumberOfDistinctBundle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_217429f1-2204-4591-a613-f0847044abc7" xlink:to="loc_arwr_NumberOfDistinctBundle_7742ed99-212f-4fe7-ac8f-b0d34ef346e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_105dc928-fd7d-44be-858e-2396800a6681" xlink:href="arwr-20230930.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_217429f1-2204-4591-a613-f0847044abc7" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_105dc928-fd7d-44be-858e-2396800a6681" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_c77b616e-896e-42d8-962f-6b8b35c4d154" xlink:href="arwr-20230930.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_217429f1-2204-4591-a613-f0847044abc7" xlink:to="loc_arwr_InitialTransactionPrice_c77b616e-896e-42d8-962f-6b8b35c4d154" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5cec7912-1d29-4b66-b18c-75f094c265cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_217429f1-2204-4591-a613-f0847044abc7" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5cec7912-1d29-4b66-b18c-75f094c265cb" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_813f4025-ad16-4a5d-9b9b-59fd27a7368b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_217429f1-2204-4591-a613-f0847044abc7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_813f4025-ad16-4a5d-9b9b-59fd27a7368b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_520b73b0-67ef-4df2-8163-e2edc3f0d014" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_217429f1-2204-4591-a613-f0847044abc7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_520b73b0-67ef-4df2-8163-e2edc3f0d014" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_514dd499-b6f4-42c4-ba07-0154899656fb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_520b73b0-67ef-4df2-8163-e2edc3f0d014" xlink:to="loc_srt_CounterpartyNameAxis_514dd499-b6f4-42c4-ba07-0154899656fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_514dd499-b6f4-42c4-ba07-0154899656fb_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_514dd499-b6f4-42c4-ba07-0154899656fb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_514dd499-b6f4-42c4-ba07-0154899656fb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a824876-4458-47ba-ad7b-25f96632a065" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_514dd499-b6f4-42c4-ba07-0154899656fb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a824876-4458-47ba-ad7b-25f96632a065" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_0dd812e5-b171-4577-86eb-54797ee01f83" xlink:href="arwr-20230930.xsd#arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a824876-4458-47ba-ad7b-25f96632a065" xlink:to="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_0dd812e5-b171-4577-86eb-54797ee01f83" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember_11314a4e-83b1-465f-b1a4-6c45804475de" xlink:href="arwr-20230930.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a824876-4458-47ba-ad7b-25f96632a065" xlink:to="loc_arwr_JanssenPharmaceuticalsIncorporationMember_11314a4e-83b1-465f-b1a4-6c45804475de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e5191fa6-97c6-48af-a515-29cc9d973145" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_520b73b0-67ef-4df2-8163-e2edc3f0d014" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e5191fa6-97c6-48af-a515-29cc9d973145" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e5191fa6-97c6-48af-a515-29cc9d973145_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e5191fa6-97c6-48af-a515-29cc9d973145" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_e5191fa6-97c6-48af-a515-29cc9d973145_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4e4f646e-29e0-40b6-b362-dcfceec37aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e5191fa6-97c6-48af-a515-29cc9d973145" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4e4f646e-29e0-40b6-b362-dcfceec37aaf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockPurchaseAgreementMember_a914ef2f-ab3d-4117-ae0d-0bbbdb0fc6b5" xlink:href="arwr-20230930.xsd#arwr_CommonStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4e4f646e-29e0-40b6-b362-dcfceec37aaf" xlink:to="loc_arwr_CommonStockPurchaseAgreementMember_a914ef2f-ab3d-4117-ae0d-0bbbdb0fc6b5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_be2df002-4636-42f2-9c31-66c60a8d8db9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_520b73b0-67ef-4df2-8163-e2edc3f0d014" xlink:to="loc_us-gaap_TypeOfArrangementAxis_be2df002-4636-42f2-9c31-66c60a8d8db9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_be2df002-4636-42f2-9c31-66c60a8d8db9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_be2df002-4636-42f2-9c31-66c60a8d8db9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_be2df002-4636-42f2-9c31-66c60a8d8db9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fb6ca5f8-5a98-40dc-8119-84e96d6a4df1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_be2df002-4636-42f2-9c31-66c60a8d8db9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fb6ca5f8-5a98-40dc-8119-84e96d6a4df1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsMember_485e010d-b213-4988-84a0-61e54c8f3465" xlink:href="arwr-20230930.xsd#arwr_CollaborationAndLicenseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fb6ca5f8-5a98-40dc-8119-84e96d6a4df1" xlink:to="loc_arwr_CollaborationAndLicenseAgreementsMember_485e010d-b213-4988-84a0-61e54c8f3465" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ3989AROHBVAgreementMember_3fe33aa5-b4e7-4bdb-ae0d-8f08928862b8" xlink:href="arwr-20230930.xsd#arwr_JNJ3989AROHBVAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fb6ca5f8-5a98-40dc-8119-84e96d6a4df1" xlink:to="loc_arwr_JNJ3989AROHBVAgreementMember_3fe33aa5-b4e7-4bdb-ae0d-8f08928862b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_82ef4dd7-6782-4e7f-a55a-22c8fce63700" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_520b73b0-67ef-4df2-8163-e2edc3f0d014" xlink:to="loc_srt_RangeAxis_82ef4dd7-6782-4e7f-a55a-22c8fce63700" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_82ef4dd7-6782-4e7f-a55a-22c8fce63700_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_82ef4dd7-6782-4e7f-a55a-22c8fce63700" xlink:to="loc_srt_RangeMember_82ef4dd7-6782-4e7f-a55a-22c8fce63700_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1c9154f3-c39f-4dcd-8f97-45cea3288f87" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_82ef4dd7-6782-4e7f-a55a-22c8fce63700" xlink:to="loc_srt_RangeMember_1c9154f3-c39f-4dcd-8f97-45cea3288f87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1b7e2e2c-d610-43e4-8fbf-2a0846cb3700" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1c9154f3-c39f-4dcd-8f97-45cea3288f87" xlink:to="loc_srt_MaximumMember_1b7e2e2c-d610-43e4-8fbf-2a0846cb3700" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#CollaborationandLicenseAgreementsAmgenIncDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca8d059b-64e8-4949-830b-ea73855bf0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAgreements_131db3a9-9013-41c8-8015-fa63879b2342" xlink:href="arwr-20230930.xsd#arwr_NumberOfAgreements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca8d059b-64e8-4949-830b-ea73855bf0c4" xlink:to="loc_arwr_NumberOfAgreements_131db3a9-9013-41c8-8015-fa63879b2342" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_6f14df44-9ea1-488a-bf80-fe007b6a57c6" xlink:href="arwr-20230930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca8d059b-64e8-4949-830b-ea73855bf0c4" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_6f14df44-9ea1-488a-bf80-fe007b6a57c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bdb4a6f8-61d8-4efa-befa-18622084ec59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca8d059b-64e8-4949-830b-ea73855bf0c4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bdb4a6f8-61d8-4efa-befa-18622084ec59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceived_c0dddcb5-99e4-4f80-966b-068b9250454e" xlink:href="arwr-20230930.xsd#arwr_MilestonePaymentReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca8d059b-64e8-4949-830b-ea73855bf0c4" xlink:to="loc_arwr_MilestonePaymentReceived_c0dddcb5-99e4-4f80-966b-068b9250454e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_703f7ab4-c965-414b-915f-cd8239f90ede" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca8d059b-64e8-4949-830b-ea73855bf0c4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_703f7ab4-c965-414b-915f-cd8239f90ede" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_6e8bde3b-4a1f-493d-b1c3-e0f9c602b291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca8d059b-64e8-4949-830b-ea73855bf0c4" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_6e8bde3b-4a1f-493d-b1c3-e0f9c602b291" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_44cad62f-607d-4b97-844f-f206336317b7" xlink:href="arwr-20230930.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca8d059b-64e8-4949-830b-ea73855bf0c4" xlink:to="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_44cad62f-607d-4b97-844f-f206336317b7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9d601756-e315-4c2d-ae3a-02f0dce59544" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca8d059b-64e8-4949-830b-ea73855bf0c4" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9d601756-e315-4c2d-ae3a-02f0dce59544" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a36cdbc2-5c13-41dc-a91d-ee44a144b035" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9d601756-e315-4c2d-ae3a-02f0dce59544" xlink:to="loc_srt_CounterpartyNameAxis_a36cdbc2-5c13-41dc-a91d-ee44a144b035" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a36cdbc2-5c13-41dc-a91d-ee44a144b035_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_a36cdbc2-5c13-41dc-a91d-ee44a144b035" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a36cdbc2-5c13-41dc-a91d-ee44a144b035_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1125e344-55e2-406a-b739-7a8573da79ff" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_a36cdbc2-5c13-41dc-a91d-ee44a144b035" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1125e344-55e2-406a-b739-7a8573da79ff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_c0a8fd7e-0706-4798-a35b-1fb5acc4ca49" xlink:href="arwr-20230930.xsd#arwr_AmgenIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1125e344-55e2-406a-b739-7a8573da79ff" xlink:to="loc_arwr_AmgenIncorporatedMember_c0a8fd7e-0706-4798-a35b-1fb5acc4ca49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6a72c49f-76bc-486e-920b-2ee2988ac110" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9d601756-e315-4c2d-ae3a-02f0dce59544" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6a72c49f-76bc-486e-920b-2ee2988ac110" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a72c49f-76bc-486e-920b-2ee2988ac110_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6a72c49f-76bc-486e-920b-2ee2988ac110" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6a72c49f-76bc-486e-920b-2ee2988ac110_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e51870d-da5d-43c3-9cee-3c59b43a7c43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6a72c49f-76bc-486e-920b-2ee2988ac110" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e51870d-da5d-43c3-9cee-3c59b43a7c43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAgreementMember_6bea643a-de9e-44fa-94ca-2b26a16e1ca4" xlink:href="arwr-20230930.xsd#arwr_OlpasiranAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e51870d-da5d-43c3-9cee-3c59b43a7c43" xlink:to="loc_arwr_OlpasiranAgreementMember_6bea643a-de9e-44fa-94ca-2b26a16e1ca4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5293ffd1-4728-49c7-b434-613a5b2a3569" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9d601756-e315-4c2d-ae3a-02f0dce59544" xlink:to="loc_srt_RangeAxis_5293ffd1-4728-49c7-b434-613a5b2a3569" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5293ffd1-4728-49c7-b434-613a5b2a3569_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_5293ffd1-4728-49c7-b434-613a5b2a3569" xlink:to="loc_srt_RangeMember_5293ffd1-4728-49c7-b434-613a5b2a3569_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4edacc92-7b9f-46b1-bbae-d92ffc45fb78" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_5293ffd1-4728-49c7-b434-613a5b2a3569" xlink:to="loc_srt_RangeMember_4edacc92-7b9f-46b1-bbae-d92ffc45fb78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_38f6e1bc-0fca-4a7c-93d8-937179dd19cd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4edacc92-7b9f-46b1-bbae-d92ffc45fb78" xlink:to="loc_srt_MaximumMember_38f6e1bc-0fca-4a7c-93d8-937179dd19cd" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4d52fb55-3b2e-42d1-b1de-44c68bc9ddb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital_bea060b9-d2e5-4e50-b576-6171f3e9daa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4d52fb55-3b2e-42d1-b1de-44c68bc9ddb7" xlink:to="loc_us-gaap_ProceedsFromContributedCapital_bea060b9-d2e5-4e50-b576-6171f3e9daa2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d56e9502-7334-488b-8d34-dc21b218001a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4d52fb55-3b2e-42d1-b1de-44c68bc9ddb7" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d56e9502-7334-488b-8d34-dc21b218001a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_45cee61b-2327-4ff9-934a-673e01126503" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d56e9502-7334-488b-8d34-dc21b218001a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_45cee61b-2327-4ff9-934a-673e01126503" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_45cee61b-2327-4ff9-934a-673e01126503_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_45cee61b-2327-4ff9-934a-673e01126503" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_45cee61b-2327-4ff9-934a-673e01126503_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_569db29b-2709-4879-abc2-b13fa7c77ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_45cee61b-2327-4ff9-934a-673e01126503" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_569db29b-2709-4879-abc2-b13fa7c77ca9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaTherapeuticsIncMember_9142bf54-cf09-4397-8478-d4919bf2970f" xlink:href="arwr-20230930.xsd#arwr_VisirnaTherapeuticsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_569db29b-2709-4879-abc2-b13fa7c77ca9" xlink:to="loc_arwr_VisirnaTherapeuticsIncMember_9142bf54-cf09-4397-8478-d4919bf2970f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_1b0eea0a-f68f-4fc5-971a-b12f6a668e7b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d56e9502-7334-488b-8d34-dc21b218001a" xlink:to="loc_srt_ConsolidatedEntitiesAxis_1b0eea0a-f68f-4fc5-971a-b12f6a668e7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_1b0eea0a-f68f-4fc5-971a-b12f6a668e7b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1b0eea0a-f68f-4fc5-971a-b12f6a668e7b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_1b0eea0a-f68f-4fc5-971a-b12f6a668e7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_4957c87a-9dd2-44e4-a3d0-c65d071b69a4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1b0eea0a-f68f-4fc5-971a-b12f6a668e7b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_4957c87a-9dd2-44e4-a3d0-c65d071b69a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_0a59a058-bd5b-45bd-9ad7-45407c021224" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidatedEntitiesDomain_4957c87a-9dd2-44e4-a3d0-c65d071b69a4" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_0a59a058-bd5b-45bd-9ad7-45407c021224" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:href="arwr-20230930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_13ab8789-71b9-40d4-b9be-864f9a24a855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_13ab8789-71b9-40d4-b9be-864f9a24a855" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_d0bb415c-13c2-4bba-8e65-998cef4e30a3" xlink:href="arwr-20230930.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_d0bb415c-13c2-4bba-8e65-998cef4e30a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_ab4f85f2-d47f-4358-bd05-1d3aafbc5f7a" xlink:href="arwr-20230930.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_ab4f85f2-d47f-4358-bd05-1d3aafbc5f7a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_327911c2-6de4-4b46-8a73-e1d43bcb62ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_327911c2-6de4-4b46-8a73-e1d43bcb62ec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e4d9ee85-b8c9-49ac-9599-1af1c2069563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e4d9ee85-b8c9-49ac-9599-1af1c2069563" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeReclassificationAdjustmentForHeldToMaturityTransferredToAvailableForSaleSecuritiesBeforeTax_ceaf8047-0e05-4e6d-9b67-65ab66eec4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeReclassificationAdjustmentForHeldToMaturityTransferredToAvailableForSaleSecuritiesBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeReclassificationAdjustmentForHeldToMaturityTransferredToAvailableForSaleSecuritiesBeforeTax_ceaf8047-0e05-4e6d-9b67-65ab66eec4e7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_2e172d53-30e5-4dc3-be87-77bdb0f794e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_2e172d53-30e5-4dc3-be87-77bdb0f794e5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_cd117dc2-42ba-4877-952a-4bfdd0efbff1" xlink:href="arwr-20230930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_cd117dc2-42ba-4877-952a-4bfdd0efbff1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_8e8247b4-a74d-4e85-badb-b6175eacd6cb" xlink:href="arwr-20230930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_8e8247b4-a74d-4e85-badb-b6175eacd6cb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_b7836879-90ab-4988-84ba-177c5908cc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_b7836879-90ab-4988-84ba-177c5908cc8c" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_716c7c73-d947-489f-9f74-3669dbfb2cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_716c7c73-d947-489f-9f74-3669dbfb2cc4" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_16477c5f-cf19-4cea-8c2d-cbaba3b10fe2" xlink:href="arwr-20230930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_16477c5f-cf19-4cea-8c2d-cbaba3b10fe2" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_3ca8fec2-0c44-451b-a411-622d4751530c" xlink:href="arwr-20230930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_3ca8fec2-0c44-451b-a411-622d4751530c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_195b6b76-7dec-4728-a8b7-f2694f60beee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_195b6b76-7dec-4728-a8b7-f2694f60beee" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_c34b3571-506f-48c6-a9a6-48f22f50c6c4" xlink:href="arwr-20230930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_c34b3571-506f-48c6-a9a6-48f22f50c6c4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_238d049a-ea0e-4df2-85f3-442b0ff9684c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_c34b3571-506f-48c6-a9a6-48f22f50c6c4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_238d049a-ea0e-4df2-85f3-442b0ff9684c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_238d049a-ea0e-4df2-85f3-442b0ff9684c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_238d049a-ea0e-4df2-85f3-442b0ff9684c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_238d049a-ea0e-4df2-85f3-442b0ff9684c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_becc96d9-9fbf-4601-8e27-125fc07ec0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_238d049a-ea0e-4df2-85f3-442b0ff9684c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_becc96d9-9fbf-4601-8e27-125fc07ec0b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_afdc70be-2f0f-403a-88a8-1be815ca0968" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_becc96d9-9fbf-4601-8e27-125fc07ec0b6" xlink:to="loc_us-gaap_DebtSecuritiesMember_afdc70be-2f0f-403a-88a8-1be815ca0968" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_a46a20d6-e743-4edf-9618-09123816787e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_becc96d9-9fbf-4601-8e27-125fc07ec0b6" xlink:to="loc_us-gaap_CertificatesOfDepositMember_a46a20d6-e743-4edf-9618-09123816787e" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c00d6745-b7b0-42e1-882a-394d7cd26bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_79269e7f-a58b-465d-a937-abf27d0d7534" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c00d6745-b7b0-42e1-882a-394d7cd26bf6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_79269e7f-a58b-465d-a937-abf27d0d7534" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ca5be912-6efb-4e92-9f61-f31634a1699b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c00d6745-b7b0-42e1-882a-394d7cd26bf6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ca5be912-6efb-4e92-9f61-f31634a1699b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment_130ca673-618c-4e79-bd07-8ee198b49d11" xlink:href="arwr-20230930.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c00d6745-b7b0-42e1-882a-394d7cd26bf6" xlink:to="loc_arwr_FiniteLivedIntangibleAssetsImpairment_130ca673-618c-4e79-bd07-8ee198b49d11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c817c0e0-b899-4a22-9667-39f60d22b50d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c00d6745-b7b0-42e1-882a-394d7cd26bf6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c817c0e0-b899-4a22-9667-39f60d22b50d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8bb12877-20b3-4886-8bf6-3d5e029bb9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c00d6745-b7b0-42e1-882a-394d7cd26bf6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8bb12877-20b3-4886-8bf6-3d5e029bb9c4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8ccb6204-fc39-4b8c-a7f4-7b3527eff04f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c00d6745-b7b0-42e1-882a-394d7cd26bf6" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8ccb6204-fc39-4b8c-a7f4-7b3527eff04f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_3af2c7cd-1e35-42be-a343-07ba266dafa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8ccb6204-fc39-4b8c-a7f4-7b3527eff04f" xlink:to="loc_us-gaap_AssetAcquisitionAxis_3af2c7cd-1e35-42be-a343-07ba266dafa6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_3af2c7cd-1e35-42be-a343-07ba266dafa6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_3af2c7cd-1e35-42be-a343-07ba266dafa6" xlink:to="loc_us-gaap_AssetAcquisitionDomain_3af2c7cd-1e35-42be-a343-07ba266dafa6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_49ad35eb-71bd-48ec-b368-1fb93468663c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_3af2c7cd-1e35-42be-a343-07ba266dafa6" xlink:to="loc_us-gaap_AssetAcquisitionDomain_49ad35eb-71bd-48ec-b368-1fb93468663c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember_48bf4020-43d5-4c58-bc9c-1d6e05d77f4a" xlink:href="arwr-20230930.xsd#arwr_NovartisMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_49ad35eb-71bd-48ec-b368-1fb93468663c" xlink:to="loc_arwr_NovartisMember_48bf4020-43d5-4c58-bc9c-1d6e05d77f4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_37f34994-2cc8-41d5-b543-54b647095c77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8ccb6204-fc39-4b8c-a7f4-7b3527eff04f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_37f34994-2cc8-41d5-b543-54b647095c77" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_37f34994-2cc8-41d5-b543-54b647095c77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_37f34994-2cc8-41d5-b543-54b647095c77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_37f34994-2cc8-41d5-b543-54b647095c77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5c825666-31c3-42cd-8ada-191b55fb1c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_37f34994-2cc8-41d5-b543-54b647095c77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5c825666-31c3-42cd-8ada-191b55fb1c0c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_5dbe86f0-86e5-4f36-8d5f-713f6750fc96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5c825666-31c3-42cd-8ada-191b55fb1c0c" xlink:to="loc_us-gaap_PatentsMember_5dbe86f0-86e5-4f36-8d5f-713f6750fc96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_e74c897e-ffb9-4b22-b25b-553607270939" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5c825666-31c3-42cd-8ada-191b55fb1c0c" xlink:to="loc_us-gaap_LicensingAgreementsMember_e74c897e-ffb9-4b22-b25b-553607270939" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#StockholdersEquityDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c9f904a6-54ac-42ce-a0dc-4ae23a4718d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c9f904a6-54ac-42ce-a0dc-4ae23a4718d6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1eee02f9-8957-4b4e-99f2-8cfb8c5ea4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1eee02f9-8957-4b4e-99f2-8cfb8c5ea4ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8050c3b3-dc9e-4982-be93-c3559471c861" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:to="loc_us-gaap_CommonStockSharesIssued_8050c3b3-dc9e-4982-be93-c3559471c861" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_60f6a94e-4105-4e08-b3d7-fbbf5bceb3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_60f6a94e-4105-4e08-b3d7-fbbf5bceb3bc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f5abc63c-848e-4cbf-b277-ef6fcaf9c3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f5abc63c-848e-4cbf-b277-ef6fcaf9c3e4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_357817c6-dd9b-4887-a6d6-b2c81306f685" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_357817c6-dd9b-4887-a6d6-b2c81306f685" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1a9795a0-216f-4495-8b7b-09f2e4141db3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1a9795a0-216f-4495-8b7b-09f2e4141db3" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_195b5e38-d941-447f-92ee-a58b4befa5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_195b5e38-d941-447f-92ee-a58b4befa5d4" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ec158772-5333-4b2f-9192-6be97bfc3b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ec158772-5333-4b2f-9192-6be97bfc3b4f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_4fabc078-129c-4e98-9fdb-e8c2aa7c0f14" xlink:href="arwr-20230930.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:to="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_4fabc078-129c-4e98-9fdb-e8c2aa7c0f14" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_340fbe62-9702-48cc-ab8b-9580e02133a2" xlink:href="arwr-20230930.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:to="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_340fbe62-9702-48cc-ab8b-9580e02133a2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_452cc8e8-2fdb-44ec-9ac7-6c68e5a01321" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:to="loc_us-gaap_SharesIssued_452cc8e8-2fdb-44ec-9ac7-6c68e5a01321" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_43d4cbe1-3019-4e3d-b65b-c66346becf89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_43d4cbe1-3019-4e3d-b65b-c66346becf89" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_999fd6bc-da6c-46b0-93df-697c075c91b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_43d4cbe1-3019-4e3d-b65b-c66346becf89" xlink:to="loc_us-gaap_PlanNameAxis_999fd6bc-da6c-46b0-93df-697c075c91b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_999fd6bc-da6c-46b0-93df-697c075c91b6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_999fd6bc-da6c-46b0-93df-697c075c91b6" xlink:to="loc_us-gaap_PlanNameDomain_999fd6bc-da6c-46b0-93df-697c075c91b6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cfc252d3-87d2-44f7-9526-149f07551aab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_999fd6bc-da6c-46b0-93df-697c075c91b6" xlink:to="loc_us-gaap_PlanNameDomain_cfc252d3-87d2-44f7-9526-149f07551aab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_53b88c6f-24c7-47a3-b790-4acf16fe6e35" xlink:href="arwr-20230930.xsd#arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_cfc252d3-87d2-44f7-9526-149f07551aab" xlink:to="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_53b88c6f-24c7-47a3-b790-4acf16fe6e35" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6bbd010c-17f4-4dad-882f-d6ddbb9cde91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_43d4cbe1-3019-4e3d-b65b-c66346becf89" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6bbd010c-17f4-4dad-882f-d6ddbb9cde91" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6bbd010c-17f4-4dad-882f-d6ddbb9cde91_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6bbd010c-17f4-4dad-882f-d6ddbb9cde91" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6bbd010c-17f4-4dad-882f-d6ddbb9cde91_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6d674baf-0cb3-4ed7-a36f-cdf58537382f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6bbd010c-17f4-4dad-882f-d6ddbb9cde91" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6d674baf-0cb3-4ed7-a36f-cdf58537382f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AtTheMarketAgreementMember_66576cf7-12e2-45e1-b51c-f5b51c4be971" xlink:href="arwr-20230930.xsd#arwr_AtTheMarketAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6d674baf-0cb3-4ed7-a36f-cdf58537382f" xlink:to="loc_arwr_AtTheMarketAgreementMember_66576cf7-12e2-45e1-b51c-f5b51c4be971" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_041bc382-c7d0-41e0-b298-870422106674" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_43d4cbe1-3019-4e3d-b65b-c66346becf89" xlink:to="loc_srt_RangeAxis_041bc382-c7d0-41e0-b298-870422106674" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_041bc382-c7d0-41e0-b298-870422106674_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_041bc382-c7d0-41e0-b298-870422106674" xlink:to="loc_srt_RangeMember_041bc382-c7d0-41e0-b298-870422106674_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c7e50f05-a9ef-4958-ba82-b63e0eb6b865" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_041bc382-c7d0-41e0-b298-870422106674" xlink:to="loc_srt_RangeMember_c7e50f05-a9ef-4958-ba82-b63e0eb6b865" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f6cb86f5-88b1-4ebb-9d3a-031aec300bf3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_c7e50f05-a9ef-4958-ba82-b63e0eb6b865" xlink:to="loc_srt_MaximumMember_f6cb86f5-88b1-4ebb-9d3a-031aec300bf3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_f6907e63-269e-4e22-8cc7-a310b20b1626" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_501da8b5-9074-4f61-80d6-bcc3d8377f99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f6907e63-269e-4e22-8cc7-a310b20b1626" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_501da8b5-9074-4f61-80d6-bcc3d8377f99" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAcresOfLandPurchased_e492bdbf-c810-45a7-bf3b-0631409d4fdd" xlink:href="arwr-20230930.xsd#arwr_NumberOfAcresOfLandPurchased"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f6907e63-269e-4e22-8cc7-a310b20b1626" xlink:to="loc_arwr_NumberOfAcresOfLandPurchased_e492bdbf-c810-45a7-bf3b-0631409d4fdd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_b92e335c-1c59-4ce5-9910-72ef7bd1170c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f6907e63-269e-4e22-8cc7-a310b20b1626" xlink:to="loc_us-gaap_AreaOfLand_b92e335c-1c59-4ce5-9910-72ef7bd1170c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_c619160e-4418-4af4-9205-609c4bbbfe84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f6907e63-269e-4e22-8cc7-a310b20b1626" xlink:to="loc_us-gaap_ConstructionInProgressGross_c619160e-4418-4af4-9205-609c4bbbfe84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmountIntendedToInvestForBuildoutOfFacilities_a5b7bab1-00b2-4e6f-bfcb-3acc8b1a590f" xlink:href="arwr-20230930.xsd#arwr_AmountIntendedToInvestForBuildoutOfFacilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f6907e63-269e-4e22-8cc7-a310b20b1626" xlink:to="loc_arwr_AmountIntendedToInvestForBuildoutOfFacilities_a5b7bab1-00b2-4e6f-bfcb-3acc8b1a590f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TaxIncrementFinancingAward_4c38c8b8-9a15-4078-930f-b18db2f20f70" xlink:href="arwr-20230930.xsd#arwr_TaxIncrementFinancingAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f6907e63-269e-4e22-8cc7-a310b20b1626" xlink:to="loc_arwr_TaxIncrementFinancingAward_4c38c8b8-9a15-4078-930f-b18db2f20f70" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement_0d829e05-4a9c-4536-b15f-20c3e76d950b" xlink:href="arwr-20230930.xsd#arwr_TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f6907e63-269e-4e22-8cc7-a310b20b1626" xlink:to="loc_arwr_TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement_0d829e05-4a9c-4536-b15f-20c3e76d950b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_b3aa4b38-1474-408e-95a9-4ae96e5932f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f6907e63-269e-4e22-8cc7-a310b20b1626" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_b3aa4b38-1474-408e-95a9-4ae96e5932f8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePayments_fe45a067-fd00-409c-aa33-05840dedcd9b" xlink:href="arwr-20230930.xsd#arwr_MilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f6907e63-269e-4e22-8cc7-a310b20b1626" xlink:to="loc_arwr_MilestonePayments_fe45a067-fd00-409c-aa33-05840dedcd9b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_43fc2e5c-cab9-48c9-bbe5-e7fc5d8a6970" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f6907e63-269e-4e22-8cc7-a310b20b1626" xlink:to="loc_us-gaap_OtherCommitmentsTable_43fc2e5c-cab9-48c9-bbe5-e7fc5d8a6970" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e1e6a85e-2709-4c15-a9e1-8227c3743306" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_43fc2e5c-cab9-48c9-bbe5-e7fc5d8a6970" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e1e6a85e-2709-4c15-a9e1-8227c3743306" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e6a85e-2709-4c15-a9e1-8227c3743306_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e1e6a85e-2709-4c15-a9e1-8227c3743306" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e1e6a85e-2709-4c15-a9e1-8227c3743306_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b3b4ea5-c745-4f26-8b01-233e1b490ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e1e6a85e-2709-4c15-a9e1-8227c3743306" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b3b4ea5-c745-4f26-8b01-233e1b490ee7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VeronaTechnologyParkMember_955cc602-0f24-43c3-97d1-17396f7678ea" xlink:href="arwr-20230930.xsd#arwr_VeronaTechnologyParkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b3b4ea5-c745-4f26-8b01-233e1b490ee7" xlink:to="loc_arwr_VeronaTechnologyParkMember_955cc602-0f24-43c3-97d1-17396f7678ea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember_4890d56f-bd2e-48bc-a5c0-f5d1512aa11a" xlink:href="arwr-20230930.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_VeronaTechnologyParkMember_955cc602-0f24-43c3-97d1-17396f7678ea" xlink:to="loc_arwr_DrugManufacturingFacilityMember_4890d56f-bd2e-48bc-a5c0-f5d1512aa11a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember_f5c9cc5c-9b2c-4f34-a5d6-c78a2e464d2c" xlink:href="arwr-20230930.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_VeronaTechnologyParkMember_955cc602-0f24-43c3-97d1-17396f7678ea" xlink:to="loc_arwr_LaboratoryAndOfficeFacilityMember_f5c9cc5c-9b2c-4f34-a5d6-c78a2e464d2c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FacilitiesMember_67c2c420-ac33-4e0d-a313-c778b8ecfe4b" xlink:href="arwr-20230930.xsd#arwr_FacilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arwr_VeronaTechnologyParkMember_955cc602-0f24-43c3-97d1-17396f7678ea" xlink:to="loc_arwr_FacilitiesMember_67c2c420-ac33-4e0d-a313-c778b8ecfe4b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_82335894-a45f-484a-843d-76a681287332" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_43fc2e5c-cab9-48c9-bbe5-e7fc5d8a6970" xlink:to="loc_srt_RangeAxis_82335894-a45f-484a-843d-76a681287332" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_82335894-a45f-484a-843d-76a681287332_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_82335894-a45f-484a-843d-76a681287332" xlink:to="loc_srt_RangeMember_82335894-a45f-484a-843d-76a681287332_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8a8cea1c-9e53-4b4b-bfda-d845b0048d15" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_82335894-a45f-484a-843d-76a681287332" xlink:to="loc_srt_RangeMember_8a8cea1c-9e53-4b4b-bfda-d845b0048d15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1591c381-a2bc-4763-93bf-6d8d5921de85" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8a8cea1c-9e53-4b4b-bfda-d845b0048d15" xlink:to="loc_srt_MinimumMember_1591c381-a2bc-4763-93bf-6d8d5921de85" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4e4a13b5-e976-4de6-aedd-c777f0cdde59" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8a8cea1c-9e53-4b4b-bfda-d845b0048d15" xlink:to="loc_srt_MaximumMember_4e4a13b5-e976-4de6-aedd-c777f0cdde59" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4f6fbe3a-70e2-49d9-b7e9-1170de0544db" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_43fc2e5c-cab9-48c9-bbe5-e7fc5d8a6970" xlink:to="loc_srt_StatementGeographicalAxis_4f6fbe3a-70e2-49d9-b7e9-1170de0544db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_4f6fbe3a-70e2-49d9-b7e9-1170de0544db_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_4f6fbe3a-70e2-49d9-b7e9-1170de0544db" xlink:to="loc_srt_SegmentGeographicalDomain_4f6fbe3a-70e2-49d9-b7e9-1170de0544db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e7bf4742-c7f8-472d-88d1-55283ff1da32" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_4f6fbe3a-70e2-49d9-b7e9-1170de0544db" xlink:to="loc_srt_SegmentGeographicalDomain_e7bf4742-c7f8-472d-88d1-55283ff1da32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_9692f7f2-8757-401a-add5-67e99e3b1a44" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_WI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_e7bf4742-c7f8-472d-88d1-55283ff1da32" xlink:to="loc_stpr_WI_9692f7f2-8757-401a-add5-67e99e3b1a44" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_e541eaa0-a6ff-4ee7-a161-b3e0c43c8aae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_43fc2e5c-cab9-48c9-bbe5-e7fc5d8a6970" xlink:to="loc_us-gaap_OtherCommitmentsAxis_e541eaa0-a6ff-4ee7-a161-b3e0c43c8aae" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_e541eaa0-a6ff-4ee7-a161-b3e0c43c8aae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherCommitmentsAxis_e541eaa0-a6ff-4ee7-a161-b3e0c43c8aae" xlink:to="loc_us-gaap_OtherCommitmentsDomain_e541eaa0-a6ff-4ee7-a161-b3e0c43c8aae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_40e154c3-4fd0-4e57-8cd6-026b8b0ca773" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherCommitmentsAxis_e541eaa0-a6ff-4ee7-a161-b3e0c43c8aae" xlink:to="loc_us-gaap_OtherCommitmentsDomain_40e154c3-4fd0-4e57-8cd6-026b8b0ca773" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TechnologyLicenseCommitmentsMember_814a5789-c3ea-4b14-acff-286653b52d32" xlink:href="arwr-20230930.xsd#arwr_TechnologyLicenseCommitmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherCommitmentsDomain_40e154c3-4fd0-4e57-8cd6-026b8b0ca773" xlink:to="loc_arwr_TechnologyLicenseCommitmentsMember_814a5789-c3ea-4b14-acff-286653b52d32" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d5061ae9-d1c5-46b5-b0e6-74cc7415ffc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherCommitmentsTable_43fc2e5c-cab9-48c9-bbe5-e7fc5d8a6970" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d5061ae9-d1c5-46b5-b0e6-74cc7415ffc5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d5061ae9-d1c5-46b5-b0e6-74cc7415ffc5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d5061ae9-d1c5-46b5-b0e6-74cc7415ffc5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d5061ae9-d1c5-46b5-b0e6-74cc7415ffc5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1a169eed-1179-4d49-a569-bfc74b1373d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d5061ae9-d1c5-46b5-b0e6-74cc7415ffc5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1a169eed-1179-4d49-a569-bfc74b1373d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROENacAndAROHIF2CandidatesMember_8d4a7e8f-3d9c-449c-80f4-78e33045f910" xlink:href="arwr-20230930.xsd#arwr_AROENacAndAROHIF2CandidatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1a169eed-1179-4d49-a569-bfc74b1373d8" xlink:to="loc_arwr_AROENacAndAROHIF2CandidatesMember_8d4a7e8f-3d9c-449c-80f4-78e33045f910" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_bd2ddeb9-2f17-4027-81d4-763b367fff56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0ccf403a-fe7e-4b38-88f2-1eb59c4f73cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bd2ddeb9-2f17-4027-81d4-763b367fff56" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0ccf403a-fe7e-4b38-88f2-1eb59c4f73cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_c02b1dfc-4f35-4009-970e-08b8c9b7f960" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bd2ddeb9-2f17-4027-81d4-763b367fff56" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_c02b1dfc-4f35-4009-970e-08b8c9b7f960" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfOptionsToRenew_35b66d07-601e-44bb-b711-4d3117bece42" xlink:href="arwr-20230930.xsd#arwr_NumberOfOptionsToRenew"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bd2ddeb9-2f17-4027-81d4-763b367fff56" xlink:to="loc_arwr_NumberOfOptionsToRenew_35b66d07-601e-44bb-b711-4d3117bece42" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_f1937167-d497-4360-8820-e06372b5180f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bd2ddeb9-2f17-4027-81d4-763b367fff56" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_f1937167-d497-4360-8820-e06372b5180f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MaximumAdditionalTenantImprovementAllowance_c78698d3-7cfd-4a49-933c-65434deb2aa4" xlink:href="arwr-20230930.xsd#arwr_MaximumAdditionalTenantImprovementAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bd2ddeb9-2f17-4027-81d4-763b367fff56" xlink:to="loc_arwr_MaximumAdditionalTenantImprovementAllowance_c78698d3-7cfd-4a49-933c-65434deb2aa4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum_e5a2169c-4d24-4fbd-8deb-a67da03a1c3d" xlink:href="arwr-20230930.xsd#arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bd2ddeb9-2f17-4027-81d4-763b367fff56" xlink:to="loc_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum_e5a2169c-4d24-4fbd-8deb-a67da03a1c3d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalTenantImprovementAllowanceLiability_589d662e-9ba7-4326-a284-22d861561f45" xlink:href="arwr-20230930.xsd#arwr_AdditionalTenantImprovementAllowanceLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bd2ddeb9-2f17-4027-81d4-763b367fff56" xlink:to="loc_arwr_AdditionalTenantImprovementAllowanceLiability_589d662e-9ba7-4326-a284-22d861561f45" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_c67c612e-8dcd-40bd-9b0e-4c373c3220a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bd2ddeb9-2f17-4027-81d4-763b367fff56" xlink:to="loc_us-gaap_ShortTermLeaseCost_c67c612e-8dcd-40bd-9b0e-4c373c3220a8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_167c7c87-dc39-4245-9fd3-b58c37a052c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bd2ddeb9-2f17-4027-81d4-763b367fff56" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_167c7c87-dc39-4245-9fd3-b58c37a052c9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f37b3c7d-2458-4192-9bc8-4de2d7378568" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_167c7c87-dc39-4245-9fd3-b58c37a052c9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f37b3c7d-2458-4192-9bc8-4de2d7378568" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f37b3c7d-2458-4192-9bc8-4de2d7378568_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f37b3c7d-2458-4192-9bc8-4de2d7378568" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_f37b3c7d-2458-4192-9bc8-4de2d7378568_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a254951-57a6-466a-acb6-8cd08b4dcb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f37b3c7d-2458-4192-9bc8-4de2d7378568" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a254951-57a6-466a-acb6-8cd08b4dcb8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember_9cba635e-f2aa-482c-a45c-31a7e59bdada" xlink:href="arwr-20230930.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a254951-57a6-466a-acb6-8cd08b4dcb8b" xlink:to="loc_arwr_ResearchFacilityInSanDiegoMember_9cba635e-f2aa-482c-a45c-31a7e59bdada" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CorporateHeadquartersInPasadenaMember_6e7b20d0-6e04-45e5-9c80-6f852689f530" xlink:href="arwr-20230930.xsd#arwr_CorporateHeadquartersInPasadenaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a254951-57a6-466a-acb6-8cd08b4dcb8b" xlink:to="loc_arwr_CorporateHeadquartersInPasadenaMember_6e7b20d0-6e04-45e5-9c80-6f852689f530" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInMadisonMember_d6bf8d77-fc0a-4f1e-9447-db5a41fcc978" xlink:href="arwr-20230930.xsd#arwr_ResearchFacilityInMadisonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a254951-57a6-466a-acb6-8cd08b4dcb8b" xlink:to="loc_arwr_ResearchFacilityInMadisonMember_d6bf8d77-fc0a-4f1e-9447-db5a41fcc978" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_099d4afd-3c40-4443-9f9b-1e24c332624a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_167c7c87-dc39-4245-9fd3-b58c37a052c9" xlink:to="loc_srt_StatementGeographicalAxis_099d4afd-3c40-4443-9f9b-1e24c332624a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_099d4afd-3c40-4443-9f9b-1e24c332624a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_099d4afd-3c40-4443-9f9b-1e24c332624a" xlink:to="loc_srt_SegmentGeographicalDomain_099d4afd-3c40-4443-9f9b-1e24c332624a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2efa7947-d0b2-4886-a3de-7381a8b2d688" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_099d4afd-3c40-4443-9f9b-1e24c332624a" xlink:to="loc_srt_SegmentGeographicalDomain_2efa7947-d0b2-4886-a3de-7381a8b2d688" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_31fe4996-6a15-4bec-8c4c-5f0879fb00bd" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2efa7947-d0b2-4886-a3de-7381a8b2d688" xlink:to="loc_stpr_CA_31fe4996-6a15-4bec-8c4c-5f0879fb00bd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_1d8f66d5-e996-4a09-b8b1-6d64cd82597c" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_WI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_2efa7947-d0b2-4886-a3de-7381a8b2d688" xlink:to="loc_stpr_WI_1d8f66d5-e996-4a09-b8b1-6d64cd82597c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d21b2bdd-b739-4897-8ff8-2de35698613b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_167c7c87-dc39-4245-9fd3-b58c37a052c9" xlink:to="loc_srt_RangeAxis_d21b2bdd-b739-4897-8ff8-2de35698613b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d21b2bdd-b739-4897-8ff8-2de35698613b_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d21b2bdd-b739-4897-8ff8-2de35698613b" xlink:to="loc_srt_RangeMember_d21b2bdd-b739-4897-8ff8-2de35698613b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_74ba9c2f-2bb1-4f3e-8a0b-4707663d5aad" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d21b2bdd-b739-4897-8ff8-2de35698613b" xlink:to="loc_srt_RangeMember_74ba9c2f-2bb1-4f3e-8a0b-4707663d5aad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c4b88714-1089-410c-a358-54cddb7ac809" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_74ba9c2f-2bb1-4f3e-8a0b-4707663d5aad" xlink:to="loc_srt_MaximumMember_c4b88714-1089-410c-a358-54cddb7ac809" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_220a3aac-b1cc-4c22-8cc3-fbef05699b0a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_167c7c87-dc39-4245-9fd3-b58c37a052c9" xlink:to="loc_srt_CounterpartyNameAxis_220a3aac-b1cc-4c22-8cc3-fbef05699b0a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_220a3aac-b1cc-4c22-8cc3-fbef05699b0a_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_220a3aac-b1cc-4c22-8cc3-fbef05699b0a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_220a3aac-b1cc-4c22-8cc3-fbef05699b0a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1c72044c-adda-491c-a1a6-dbc33793d869" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_220a3aac-b1cc-4c22-8cc3-fbef05699b0a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1c72044c-adda-491c-a1a6-dbc33793d869" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ColoradoOwnerLLCMember_4bf07c2f-0638-43b4-a0cf-33b8922ee084" xlink:href="arwr-20230930.xsd#arwr_ColoradoOwnerLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1c72044c-adda-491c-a1a6-dbc33793d869" xlink:to="loc_arwr_ColoradoOwnerLLCMember_4bf07c2f-0638-43b4-a0cf-33b8922ee084" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SorrentoValleyOwnerDELLCMember_a4b6dbab-5717-4cec-bbc0-7d923fe6969b" xlink:href="arwr-20230930.xsd#arwr_SorrentoValleyOwnerDELLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1c72044c-adda-491c-a1a6-dbc33793d869" xlink:to="loc_arwr_SorrentoValleyOwnerDELLCMember_a4b6dbab-5717-4cec-bbc0-7d923fe6969b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#LeasesComponentsofLeaseAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_f29b73df-5a51-494a-ad00-40e5065b6b26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_76c21343-edd7-4260-823b-98517a4998a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_f29b73df-5a51-494a-ad00-40e5065b6b26" xlink:to="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_76c21343-edd7-4260-823b-98517a4998a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4c75f67c-2d05-4f38-8fe0-2d3a87a7f226" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_76c21343-edd7-4260-823b-98517a4998a5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4c75f67c-2d05-4f38-8fe0-2d3a87a7f226" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f4d30b94-648a-48de-b70e-08682255aad5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_76c21343-edd7-4260-823b-98517a4998a5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f4d30b94-648a-48de-b70e-08682255aad5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9688e73e-1ab9-4202-8eb2-8b3d7895d79a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_76c21343-edd7-4260-823b-98517a4998a5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9688e73e-1ab9-4202-8eb2-8b3d7895d79a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_74c38583-a3dc-42a8-81ea-a682499f4368" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_f29b73df-5a51-494a-ad00-40e5065b6b26" xlink:to="loc_us-gaap_LeaseCostAbstract_74c38583-a3dc-42a8-81ea-a682499f4368" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_b5a82fbf-c5b2-43b9-9cfa-4e6ede1a5b31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_74c38583-a3dc-42a8-81ea-a682499f4368" xlink:to="loc_us-gaap_OperatingLeaseCost_b5a82fbf-c5b2-43b9-9cfa-4e6ede1a5b31" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_85354564-579d-4dcf-ba8b-7df4614a477d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_74c38583-a3dc-42a8-81ea-a682499f4368" xlink:to="loc_us-gaap_VariableLeaseCost_85354564-579d-4dcf-ba8b-7df4614a477d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_7b8c55b8-ca62-4dca-99c0-aa027f04a310" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseCostAbstract_74c38583-a3dc-42a8-81ea-a682499f4368" xlink:to="loc_us-gaap_LeaseCost_7b8c55b8-ca62-4dca-99c0-aa027f04a310" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f451496c-ea61-4409-88bb-a58503b0f26c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_f29b73df-5a51-494a-ad00-40e5065b6b26" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f451496c-ea61-4409-88bb-a58503b0f26c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e8efa838-9ae8-4a12-a93c-b510f796f560" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f451496c-ea61-4409-88bb-a58503b0f26c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e8efa838-9ae8-4a12-a93c-b510f796f560" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e8efa838-9ae8-4a12-a93c-b510f796f560_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e8efa838-9ae8-4a12-a93c-b510f796f560" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e8efa838-9ae8-4a12-a93c-b510f796f560_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_41d0d4c6-9db9-425a-928f-f9bcefa3b295" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e8efa838-9ae8-4a12-a93c-b510f796f560" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_41d0d4c6-9db9-425a-928f-f9bcefa3b295" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5ba042cc-b156-402a-a2fb-68bd7a9f086c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_41d0d4c6-9db9-425a-928f-f9bcefa3b295" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5ba042cc-b156-402a-a2fb-68bd7a9f086c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5c2ea7ab-40dc-44cf-aefa-293a66d22efe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_41d0d4c6-9db9-425a-928f-f9bcefa3b295" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5c2ea7ab-40dc-44cf-aefa-293a66d22efe" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_065e1f19-d04f-4fa9-849b-b47e314ceeda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_065e1f19-d04f-4fa9-849b-b47e314ceeda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_251c63af-0f97-4130-93f0-16fa1761c8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_251c63af-0f97-4130-93f0-16fa1761c8b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ed07769f-e56a-4fbb-8f64-6f364e4c6f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ed07769f-e56a-4fbb-8f64-6f364e4c6f0b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_dc9c161a-61bc-4dd2-ba3c-620802fe8807" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_dc9c161a-61bc-4dd2-ba3c-620802fe8807" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e5a9a007-ef2c-47fc-ac52-e9d746899bda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e5a9a007-ef2c-47fc-ac52-e9d746899bda" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3546b9b4-13cd-46cf-837d-d9d367d22670" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3546b9b4-13cd-46cf-837d-d9d367d22670" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e89ca41d-8bf8-4d49-8c1e-b681cb9cddbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e89ca41d-8bf8-4d49-8c1e-b681cb9cddbc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c02f34f2-4723-4921-a802-ff024e713a95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c02f34f2-4723-4921-a802-ff024e713a95" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_68247de5-a6c1-4671-a985-e3e85a5b5154" xlink:href="arwr-20230930.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:to="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_68247de5-a6c1-4671-a985-e3e85a5b5154" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_68e25128-c338-4d65-9c09-b0b0e608fb88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_68e25128-c338-4d65-9c09-b0b0e608fb88" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1466518d-3fa4-445f-a934-8e0dc1ec7e86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1466518d-3fa4-445f-a934-8e0dc1ec7e86" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32f00b9f-0328-49d9-a5fa-ba07d6ed6940" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32f00b9f-0328-49d9-a5fa-ba07d6ed6940" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_16aff7d2-4695-419e-8e5a-9a904a52fa21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32f00b9f-0328-49d9-a5fa-ba07d6ed6940" xlink:to="loc_us-gaap_PlanNameAxis_16aff7d2-4695-419e-8e5a-9a904a52fa21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_16aff7d2-4695-419e-8e5a-9a904a52fa21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_16aff7d2-4695-419e-8e5a-9a904a52fa21" xlink:to="loc_us-gaap_PlanNameDomain_16aff7d2-4695-419e-8e5a-9a904a52fa21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f1d1c123-92e1-4d28-9e93-d830a22cdb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_16aff7d2-4695-419e-8e5a-9a904a52fa21" xlink:to="loc_us-gaap_PlanNameDomain_f1d1c123-92e1-4d28-9e93-d830a22cdb2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_a676aea6-d125-4c03-bbd0-f99ed85c973d" xlink:href="arwr-20230930.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f1d1c123-92e1-4d28-9e93-d830a22cdb2a" xlink:to="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_a676aea6-d125-4c03-bbd0-f99ed85c973d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_50af36d0-a7bb-44db-bc1a-f14685fb4573" xlink:href="arwr-20230930.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f1d1c123-92e1-4d28-9e93-d830a22cdb2a" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_50af36d0-a7bb-44db-bc1a-f14685fb4573" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_04cc5ed4-4984-45e7-ac8b-6446f70879a6" xlink:href="arwr-20230930.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f1d1c123-92e1-4d28-9e93-d830a22cdb2a" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_04cc5ed4-4984-45e7-ac8b-6446f70879a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OutsideOfEquityCompensationPlansMember_05ec430a-e9e7-4802-b1ae-584cbc1b039d" xlink:href="arwr-20230930.xsd#arwr_OutsideOfEquityCompensationPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_f1d1c123-92e1-4d28-9e93-d830a22cdb2a" xlink:to="loc_arwr_OutsideOfEquityCompensationPlansMember_05ec430a-e9e7-4802-b1ae-584cbc1b039d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_42a3898d-8e78-4bed-85d4-d6c29ec4283f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32f00b9f-0328-49d9-a5fa-ba07d6ed6940" xlink:to="loc_us-gaap_AwardTypeAxis_42a3898d-8e78-4bed-85d4-d6c29ec4283f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42a3898d-8e78-4bed-85d4-d6c29ec4283f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_42a3898d-8e78-4bed-85d4-d6c29ec4283f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_42a3898d-8e78-4bed-85d4-d6c29ec4283f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f81086d8-2a00-4c46-8731-6b45857009cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_42a3898d-8e78-4bed-85d4-d6c29ec4283f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f81086d8-2a00-4c46-8731-6b45857009cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4aec6d9b-c867-46fd-a8b4-5aa95995985a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f81086d8-2a00-4c46-8731-6b45857009cd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4aec6d9b-c867-46fd-a8b4-5aa95995985a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4ba4a709-16e8-46d2-92b0-5e1eced6f58c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f81086d8-2a00-4c46-8731-6b45857009cd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4ba4a709-16e8-46d2-92b0-5e1eced6f58c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RestrictedStockUnitsMarketBasedMember_3d3f0be1-df2f-4843-bc32-372b80e53022" xlink:href="arwr-20230930.xsd#arwr_RestrictedStockUnitsMarketBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f81086d8-2a00-4c46-8731-6b45857009cd" xlink:to="loc_arwr_RestrictedStockUnitsMarketBasedMember_3d3f0be1-df2f-4843-bc32-372b80e53022" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RestrictedStockUnitsPerformanceBasedMember_0c80c9c9-886f-4202-91ec-4f11884483e5" xlink:href="arwr-20230930.xsd#arwr_RestrictedStockUnitsPerformanceBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f81086d8-2a00-4c46-8731-6b45857009cd" xlink:to="loc_arwr_RestrictedStockUnitsPerformanceBasedMember_0c80c9c9-886f-4202-91ec-4f11884483e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_7f083428-523d-459a-827d-41a3ca389810" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32f00b9f-0328-49d9-a5fa-ba07d6ed6940" xlink:to="loc_srt_TitleOfIndividualAxis_7f083428-523d-459a-827d-41a3ca389810" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7f083428-523d-459a-827d-41a3ca389810_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_7f083428-523d-459a-827d-41a3ca389810" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_7f083428-523d-459a-827d-41a3ca389810_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3a3fc7c8-b8a4-4bf2-8bd0-16060bd1e96d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_7f083428-523d-459a-827d-41a3ca389810" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3a3fc7c8-b8a4-4bf2-8bd0-16060bd1e96d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_14b820b7-78f5-475c-86a6-3d31fb72c1f0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3a3fc7c8-b8a4-4bf2-8bd0-16060bd1e96d" xlink:to="loc_srt_ChiefExecutiveOfficerMember_14b820b7-78f5-475c-86a6-3d31fb72c1f0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb105c06-736f-4cea-ac18-87841cdab46a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cc4ea8c9-5d96-40e9-aca7-a853b78d5c79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb105c06-736f-4cea-ac18-87841cdab46a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cc4ea8c9-5d96-40e9-aca7-a853b78d5c79" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_eabec679-d78d-4c21-bf60-682bd820dc96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb105c06-736f-4cea-ac18-87841cdab46a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_eabec679-d78d-4c21-bf60-682bd820dc96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_77a17245-7259-42a0-835d-13c2c0856157" xlink:href="arwr-20230930.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb105c06-736f-4cea-ac18-87841cdab46a" xlink:to="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_77a17245-7259-42a0-835d-13c2c0856157" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06187f63-5b9e-4fc0-ae3f-e964f17825c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb105c06-736f-4cea-ac18-87841cdab46a" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06187f63-5b9e-4fc0-ae3f-e964f17825c6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_abc04403-493b-439b-9e9b-75de8cd27151" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06187f63-5b9e-4fc0-ae3f-e964f17825c6" xlink:to="loc_us-gaap_AwardTypeAxis_abc04403-493b-439b-9e9b-75de8cd27151" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abc04403-493b-439b-9e9b-75de8cd27151_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_abc04403-493b-439b-9e9b-75de8cd27151" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_abc04403-493b-439b-9e9b-75de8cd27151_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca6d09c6-748a-4e35-89cc-21082394752d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_abc04403-493b-439b-9e9b-75de8cd27151" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca6d09c6-748a-4e35-89cc-21082394752d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ce8adfc2-f861-4db4-b058-b9517976292a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca6d09c6-748a-4e35-89cc-21082394752d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ce8adfc2-f861-4db4-b058-b9517976292a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_faadd36c-48a6-432f-9281-99465a672aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06187f63-5b9e-4fc0-ae3f-e964f17825c6" xlink:to="loc_us-gaap_PlanNameAxis_faadd36c-48a6-432f-9281-99465a672aa7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_faadd36c-48a6-432f-9281-99465a672aa7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_faadd36c-48a6-432f-9281-99465a672aa7" xlink:to="loc_us-gaap_PlanNameDomain_faadd36c-48a6-432f-9281-99465a672aa7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e9573d81-3e4d-43f5-a5dc-60e13bd972b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_faadd36c-48a6-432f-9281-99465a672aa7" xlink:to="loc_us-gaap_PlanNameDomain_e9573d81-3e4d-43f5-a5dc-60e13bd972b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_cb9f6d76-5624-4a5f-8d81-946ab3f56699" xlink:href="arwr-20230930.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e9573d81-3e4d-43f5-a5dc-60e13bd972b5" xlink:to="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_cb9f6d76-5624-4a5f-8d81-946ab3f56699" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_6f6785e0-f38e-467c-bff4-d417d28c3855" xlink:href="arwr-20230930.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e9573d81-3e4d-43f5-a5dc-60e13bd972b5" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_6f6785e0-f38e-467c-bff4-d417d28c3855" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_6ef512e8-557b-4f3e-b618-72a12b6e504f" xlink:href="arwr-20230930.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e9573d81-3e4d-43f5-a5dc-60e13bd972b5" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_6ef512e8-557b-4f3e-b618-72a12b6e504f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementAwardsMember_7d755ba1-1558-47a3-9737-4de6080e09cd" xlink:href="arwr-20230930.xsd#arwr_InducementAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_e9573d81-3e4d-43f5-a5dc-60e13bd972b5" xlink:to="loc_arwr_InducementAwardsMember_7d755ba1-1558-47a3-9737-4de6080e09cd" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#StockBasedCompensationSummaryofRSUsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1102d450-e35b-4cc0-898a-86cce398c446" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0adc21ff-f83e-41f9-8299-c6d921bb34be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1102d450-e35b-4cc0-898a-86cce398c446" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0adc21ff-f83e-41f9-8299-c6d921bb34be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_42f0f725-e558-4f00-9019-a7e20b153e46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0adc21ff-f83e-41f9-8299-c6d921bb34be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_42f0f725-e558-4f00-9019-a7e20b153e46" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2b502653-7014-491b-86ea-2f2f021e9cde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0adc21ff-f83e-41f9-8299-c6d921bb34be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2b502653-7014-491b-86ea-2f2f021e9cde" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1522dfbd-c3af-40ca-a66d-07320886809e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0adc21ff-f83e-41f9-8299-c6d921bb34be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1522dfbd-c3af-40ca-a66d-07320886809e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c77d414c-7d99-4d10-9fca-7646069ced0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0adc21ff-f83e-41f9-8299-c6d921bb34be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c77d414c-7d99-4d10-9fca-7646069ced0c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b45c2069-6a27-40fe-a64c-197eeb02f43f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0aa405e7-f087-483c-9302-aca2a13cc41e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1102d450-e35b-4cc0-898a-86cce398c446" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0aa405e7-f087-483c-9302-aca2a13cc41e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e50a03f4-446f-4c29-8741-3e09b9700ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0aa405e7-f087-483c-9302-aca2a13cc41e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e50a03f4-446f-4c29-8741-3e09b9700ac6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f6e4b595-83d2-41e6-80ea-50156aa855ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0aa405e7-f087-483c-9302-aca2a13cc41e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f6e4b595-83d2-41e6-80ea-50156aa855ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_018edd95-31e9-43b7-a930-2e1783e48297" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0aa405e7-f087-483c-9302-aca2a13cc41e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_018edd95-31e9-43b7-a930-2e1783e48297" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_765bc57c-0f16-491b-9c64-dac91ebad3da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0aa405e7-f087-483c-9302-aca2a13cc41e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_765bc57c-0f16-491b-9c64-dac91ebad3da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d8f965b9-de1d-40f7-bea4-f50d85f5b707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c4a30665-6a91-4eaa-9dda-b819451a3340" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1102d450-e35b-4cc0-898a-86cce398c446" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c4a30665-6a91-4eaa-9dda-b819451a3340" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0a65b697-484d-4b4b-89ff-1571b43f3383" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c4a30665-6a91-4eaa-9dda-b819451a3340" xlink:to="loc_us-gaap_AwardTypeAxis_0a65b697-484d-4b4b-89ff-1571b43f3383" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0a65b697-484d-4b4b-89ff-1571b43f3383_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_0a65b697-484d-4b4b-89ff-1571b43f3383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_0a65b697-484d-4b4b-89ff-1571b43f3383_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_143e46f2-cdf2-4aab-8f20-b8e4b68453fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_0a65b697-484d-4b4b-89ff-1571b43f3383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_143e46f2-cdf2-4aab-8f20-b8e4b68453fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ad0a2272-bf96-4d6d-894b-00825c118f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_143e46f2-cdf2-4aab-8f20-b8e4b68453fe" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ad0a2272-bf96-4d6d-894b-00825c118f5a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e42e59e-0851-441f-ba38-7130dabc181e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8129e8f2-97ff-46e8-9d62-5b6db6733854" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e42e59e-0851-441f-ba38-7130dabc181e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8129e8f2-97ff-46e8-9d62-5b6db6733854" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_fb3ae3a5-b649-44a0-a2f0-ba8841ca4cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e42e59e-0851-441f-ba38-7130dabc181e" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_fb3ae3a5-b649-44a0-a2f0-ba8841ca4cf0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_866d6799-0342-4f58-966c-27ca1a792235" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e42e59e-0851-441f-ba38-7130dabc181e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_866d6799-0342-4f58-966c-27ca1a792235" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_47105dfb-4e1d-4134-bb34-f5eda62d2062" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e42e59e-0851-441f-ba38-7130dabc181e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_47105dfb-4e1d-4134-bb34-f5eda62d2062" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b3ff30b4-b417-4a7c-9be7-7450c7c75eae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e42e59e-0851-441f-ba38-7130dabc181e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b3ff30b4-b417-4a7c-9be7-7450c7c75eae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_21d9725c-c11c-43ce-8e33-d68c2143cb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b3ff30b4-b417-4a7c-9be7-7450c7c75eae" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_21d9725c-c11c-43ce-8e33-d68c2143cb6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_21d9725c-c11c-43ce-8e33-d68c2143cb6b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_21d9725c-c11c-43ce-8e33-d68c2143cb6b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_21d9725c-c11c-43ce-8e33-d68c2143cb6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d3c92bcb-93d2-48a8-8658-f26e2d6f0691" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_21d9725c-c11c-43ce-8e33-d68c2143cb6b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d3c92bcb-93d2-48a8-8658-f26e2d6f0691" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_66974d19-f1b7-48bc-a8bd-ada74160d74d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d3c92bcb-93d2-48a8-8658-f26e2d6f0691" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_66974d19-f1b7-48bc-a8bd-ada74160d74d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f541360a-ec88-455b-a0f5-e8a96a77f5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b3ff30b4-b417-4a7c-9be7-7450c7c75eae" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f541360a-ec88-455b-a0f5-e8a96a77f5bc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f541360a-ec88-455b-a0f5-e8a96a77f5bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f541360a-ec88-455b-a0f5-e8a96a77f5bc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_f541360a-ec88-455b-a0f5-e8a96a77f5bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84979e5b-7a79-493d-bf94-61926f5d09fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f541360a-ec88-455b-a0f5-e8a96a77f5bc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84979e5b-7a79-493d-bf94-61926f5d09fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9cb67c50-46af-4717-b44a-d90c3e05d318" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84979e5b-7a79-493d-bf94-61926f5d09fa" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9cb67c50-46af-4717-b44a-d90c3e05d318" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c8f9ff5c-6dd5-48cd-9cb2-f514401acdbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84979e5b-7a79-493d-bf94-61926f5d09fa" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c8f9ff5c-6dd5-48cd-9cb2-f514401acdbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_40e4762c-1c16-4d60-a8af-b4fef542e6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84979e5b-7a79-493d-bf94-61926f5d09fa" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_40e4762c-1c16-4d60-a8af-b4fef542e6fe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_fc0896a4-3430-421d-ab6a-0ff558924a56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b3ff30b4-b417-4a7c-9be7-7450c7c75eae" xlink:to="loc_us-gaap_FinancialInstrumentAxis_fc0896a4-3430-421d-ab6a-0ff558924a56" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc0896a4-3430-421d-ab6a-0ff558924a56_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fc0896a4-3430-421d-ab6a-0ff558924a56" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_fc0896a4-3430-421d-ab6a-0ff558924a56_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f1421b7-ad2c-4fda-beca-0c52eb159b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fc0896a4-3430-421d-ab6a-0ff558924a56" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f1421b7-ad2c-4fda-beca-0c52eb159b2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_dc4436d8-91cc-4ef3-8b3c-75a8b0c47abb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f1421b7-ad2c-4fda-beca-0c52eb159b2c" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_dc4436d8-91cc-4ef3-8b3c-75a8b0c47abb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_188c4937-f91a-4b15-aac8-607fd2cd06ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f1421b7-ad2c-4fda-beca-0c52eb159b2c" xlink:to="loc_us-gaap_MunicipalBondsMember_188c4937-f91a-4b15-aac8-607fd2cd06ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesMember_e8a5bb9d-d1b5-4f88-ae25-9bf4f274797c" xlink:href="arwr-20230930.xsd#arwr_CommercialNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f1421b7-ad2c-4fda-beca-0c52eb159b2c" xlink:to="loc_arwr_CommercialNotesMember_e8a5bb9d-d1b5-4f88-ae25-9bf4f274797c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c8b65631-c3fc-4916-a6a3-24fd56b3ea4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f1421b7-ad2c-4fda-beca-0c52eb159b2c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c8b65631-c3fc-4916-a6a3-24fd56b3ea4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_bbbdc727-d647-47d1-9858-3b8e5737bc13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f1421b7-ad2c-4fda-beca-0c52eb159b2c" xlink:to="loc_us-gaap_CertificatesOfDepositMember_bbbdc727-d647-47d1-9858-3b8e5737bc13" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_5cf3fe39-3649-4fd5-9582-e32948d15220" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b3ff30b4-b417-4a7c-9be7-7450c7c75eae" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_5cf3fe39-3649-4fd5-9582-e32948d15220" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5cf3fe39-3649-4fd5-9582-e32948d15220_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_5cf3fe39-3649-4fd5-9582-e32948d15220" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5cf3fe39-3649-4fd5-9582-e32948d15220_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5be51a26-0040-4082-b036-266a6cab9d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_5cf3fe39-3649-4fd5-9582-e32948d15220" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5be51a26-0040-4082-b036-266a6cab9d6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_57a057a9-041e-4a09-a2f8-e5813a72f923" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5be51a26-0040-4082-b036-266a6cab9d6a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_57a057a9-041e-4a09-a2f8-e5813a72f923" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_2090ed98-a132-4d95-9ec5-8ce4b0912f50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_484cf8bc-1423-48c3-983d-1f9d491a56c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2090ed98-a132-4d95-9ec5-8ce4b0912f50" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_484cf8bc-1423-48c3-983d-1f9d491a56c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_c814c2c3-3220-474f-b3fc-562b0b968e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2090ed98-a132-4d95-9ec5-8ce4b0912f50" xlink:to="loc_us-gaap_OperatingLossCarryforwards_c814c2c3-3220-474f-b3fc-562b0b968e8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OperatingLossCarryforwardsSubjectToExpiration_c1d9e687-b44a-472b-af77-ad13040a8ea4" xlink:href="arwr-20230930.xsd#arwr_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2090ed98-a132-4d95-9ec5-8ce4b0912f50" xlink:to="loc_arwr_OperatingLossCarryforwardsSubjectToExpiration_c1d9e687-b44a-472b-af77-ad13040a8ea4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OperatingLossCarryforwardsNotSubjectToExpiration_b60f46aa-163a-419f-8976-ba4a5bdf1010" xlink:href="arwr-20230930.xsd#arwr_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2090ed98-a132-4d95-9ec5-8ce4b0912f50" xlink:to="loc_arwr_OperatingLossCarryforwardsNotSubjectToExpiration_b60f46aa-163a-419f-8976-ba4a5bdf1010" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_1c9b4bc8-047b-48a0-98dc-5138cf48c1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2090ed98-a132-4d95-9ec5-8ce4b0912f50" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_1c9b4bc8-047b-48a0-98dc-5138cf48c1ea" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_1686ed3c-1509-4ce1-8ca2-6c478e1ba9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2090ed98-a132-4d95-9ec5-8ce4b0912f50" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_1686ed3c-1509-4ce1-8ca2-6c478e1ba9bb" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_a07b903a-71da-44d1-ae79-4bf28dd569b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2090ed98-a132-4d95-9ec5-8ce4b0912f50" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_a07b903a-71da-44d1-ae79-4bf28dd569b5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_8d4b1c9b-fe85-4595-829d-547f584d1166" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2090ed98-a132-4d95-9ec5-8ce4b0912f50" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_8d4b1c9b-fe85-4595-829d-547f584d1166" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_a799457f-83bd-4fa3-b991-a140963d7d22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2090ed98-a132-4d95-9ec5-8ce4b0912f50" xlink:to="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_a799457f-83bd-4fa3-b991-a140963d7d22" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_46fb8e3a-14a9-47d4-9ba7-4785d0f17550" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2090ed98-a132-4d95-9ec5-8ce4b0912f50" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_46fb8e3a-14a9-47d4-9ba7-4785d0f17550" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f99f8a2a-6218-4e80-8b87-98b619ca5e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_46fb8e3a-14a9-47d4-9ba7-4785d0f17550" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f99f8a2a-6218-4e80-8b87-98b619ca5e2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f99f8a2a-6218-4e80-8b87-98b619ca5e2e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f99f8a2a-6218-4e80-8b87-98b619ca5e2e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f99f8a2a-6218-4e80-8b87-98b619ca5e2e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_557dc704-0c67-4a6d-a08b-045361e68ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f99f8a2a-6218-4e80-8b87-98b619ca5e2e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_557dc704-0c67-4a6d-a08b-045361e68ca5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_44de37c3-2a41-4919-897c-19d3d258da48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_557dc704-0c67-4a6d-a08b-045361e68ca5" xlink:to="loc_us-gaap_DomesticCountryMember_44de37c3-2a41-4919-897c-19d3d258da48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_21c4b17b-5383-4290-844e-62726b645016" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_557dc704-0c67-4a6d-a08b-045361e68ca5" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_21c4b17b-5383-4290-844e-62726b645016" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#EmployeeBenefitPlansAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ac80fb48-51fa-4c17-b0af-15d9e7b98b52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_739e398b-d589-4149-b465-98f827f67e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ac80fb48-51fa-4c17-b0af-15d9e7b98b52" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_739e398b-d589-4149-b465-98f827f67e3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_5631e43b-48e8-4a8f-b662-e5ee0902d1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ac80fb48-51fa-4c17-b0af-15d9e7b98b52" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_5631e43b-48e8-4a8f-b662-e5ee0902d1f5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_afb1d4ed-8474-4bd5-b45f-6ce613442485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ac80fb48-51fa-4c17-b0af-15d9e7b98b52" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_afb1d4ed-8474-4bd5-b45f-6ce613442485" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c76515ad-705c-4c1d-9bee-b8568a41dc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ac80fb48-51fa-4c17-b0af-15d9e7b98b52" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c76515ad-705c-4c1d-9bee-b8568a41dc1c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_8dd25ff9-0fc3-40e3-8024-fa006e3e3a66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c76515ad-705c-4c1d-9bee-b8568a41dc1c" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_8dd25ff9-0fc3-40e3-8024-fa006e3e3a66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8dd25ff9-0fc3-40e3-8024-fa006e3e3a66_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8dd25ff9-0fc3-40e3-8024-fa006e3e3a66" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8dd25ff9-0fc3-40e3-8024-fa006e3e3a66_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_50bf1640-b200-4420-92f3-b0c56c7d62b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8dd25ff9-0fc3-40e3-8024-fa006e3e3a66" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_50bf1640-b200-4420-92f3-b0c56c7d62b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EmployeeContributionsUpToThreePercentMember_212091da-a979-4b50-8a10-6e2dab622dda" xlink:href="arwr-20230930.xsd#arwr_EmployeeContributionsUpToThreePercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_50bf1640-b200-4420-92f3-b0c56c7d62b8" xlink:to="loc_arwr_EmployeeContributionsUpToThreePercentMember_212091da-a979-4b50-8a10-6e2dab622dda" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EmployeeContributionNextTwoPercentMember_a2ae8631-c040-4917-8e7b-01dc748c4e9f" xlink:href="arwr-20230930.xsd#arwr_EmployeeContributionNextTwoPercentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_50bf1640-b200-4420-92f3-b0c56c7d62b8" xlink:to="loc_arwr_EmployeeContributionNextTwoPercentMember_a2ae8631-c040-4917-8e7b-01dc748c4e9f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"/>
  <link:definitionLink xlink:role="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0196c7d-0362-4abc-ac1e-694901f484f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_49b91a82-69b4-4bd1-bb1c-0d61d0da78df" xlink:href="arwr-20230930.xsd#arwr_InitialTransactionPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0196c7d-0362-4abc-ac1e-694901f484f5" xlink:to="loc_arwr_InitialTransactionPrice_49b91a82-69b4-4bd1-bb1c-0d61d0da78df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_0e9a855e-bf96-4022-83e3-e7e4c632e8ad" xlink:href="arwr-20230930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0196c7d-0362-4abc-ac1e-694901f484f5" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_0e9a855e-bf96-4022-83e3-e7e4c632e8ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_76182be5-9ffc-4cd2-82b2-5021574fc516" xlink:href="arwr-20230930.xsd#arwr_MilestonePaymentReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0196c7d-0362-4abc-ac1e-694901f484f5" xlink:to="loc_arwr_MilestonePaymentReceivable_76182be5-9ffc-4cd2-82b2-5021574fc516" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_9895bc23-0ea2-4c8d-afa9-4da890851395" xlink:href="arwr-20230930.xsd#arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0196c7d-0362-4abc-ac1e-694901f484f5" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_9895bc23-0ea2-4c8d-afa9-4da890851395" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponFDAApproval_9dd9d07b-cf32-449e-a924-07e1b9a3608f" xlink:href="arwr-20230930.xsd#arwr_MilestonePaymentReceivableUponFDAApproval"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0196c7d-0362-4abc-ac1e-694901f484f5" xlink:to="loc_arwr_MilestonePaymentReceivableUponFDAApproval_9dd9d07b-cf32-449e-a924-07e1b9a3608f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_dd351f96-4cc1-4d4f-8fe0-2ef8b48c402a" xlink:href="arwr-20230930.xsd#arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0196c7d-0362-4abc-ac1e-694901f484f5" xlink:to="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_dd351f96-4cc1-4d4f-8fe0-2ef8b48c402a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPaymentThreshold_1bbff291-ee01-41b1-894e-0d0c70b0033c" xlink:href="arwr-20230930.xsd#arwr_RoyaltyPaymentThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0196c7d-0362-4abc-ac1e-694901f484f5" xlink:to="loc_arwr_RoyaltyPaymentThreshold_1bbff291-ee01-41b1-894e-0d0c70b0033c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_e2416494-9007-4797-bc2e-77b31a99d3d0" xlink:href="arwr-20230930.xsd#arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0196c7d-0362-4abc-ac1e-694901f484f5" xlink:to="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_e2416494-9007-4797-bc2e-77b31a99d3d0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1f9821ff-4f8d-41ae-a03f-ae6fc2bb0d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0196c7d-0362-4abc-ac1e-694901f484f5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1f9821ff-4f8d-41ae-a03f-ae6fc2bb0d8f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_031fe450-98a0-440e-9deb-d2358fb1cf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1f9821ff-4f8d-41ae-a03f-ae6fc2bb0d8f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_031fe450-98a0-440e-9deb-d2358fb1cf8a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_031fe450-98a0-440e-9deb-d2358fb1cf8a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_031fe450-98a0-440e-9deb-d2358fb1cf8a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_031fe450-98a0-440e-9deb-d2358fb1cf8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c533a23-98e5-4f65-8e21-853eab9cc762" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_031fe450-98a0-440e-9deb-d2358fb1cf8a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c533a23-98e5-4f65-8e21-853eab9cc762" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaAgreementMember_af0a3a96-629e-427b-9ba7-d5d8a4bd4c7f" xlink:href="arwr-20230930.xsd#arwr_RoyaltyPharmaAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c533a23-98e5-4f65-8e21-853eab9cc762" xlink:to="loc_arwr_RoyaltyPharmaAgreementMember_af0a3a96-629e-427b-9ba7-d5d8a4bd4c7f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8736fb50-f7d0-4dee-9f1f-6fb38911db51" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1f9821ff-4f8d-41ae-a03f-ae6fc2bb0d8f" xlink:to="loc_srt_RangeAxis_8736fb50-f7d0-4dee-9f1f-6fb38911db51" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8736fb50-f7d0-4dee-9f1f-6fb38911db51_default" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8736fb50-f7d0-4dee-9f1f-6fb38911db51" xlink:to="loc_srt_RangeMember_8736fb50-f7d0-4dee-9f1f-6fb38911db51_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_df9f53c7-2ec1-462e-ab1b-71788e3a141c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8736fb50-f7d0-4dee-9f1f-6fb38911db51" xlink:to="loc_srt_RangeMember_df9f53c7-2ec1-462e-ab1b-71788e3a141c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_207f6fbe-a7ab-457f-aa91-ce66f6dca86b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_df9f53c7-2ec1-462e-ab1b-71788e3a141c" xlink:to="loc_srt_MaximumMember_207f6fbe-a7ab-457f-aa91-ce66f6dca86b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#TradingArrangmentsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/TradingArrangementsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JamesHamiltonTerminatedPlanMember_acd5564f-8413-4040-a7f7-5f4e568af34c" xlink:href="arwr-20230930.xsd#arwr_JamesHamiltonTerminatedPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_arwr_JamesHamiltonTerminatedPlanMember_acd5564f-8413-4040-a7f7-5f4e568af34c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JamesHamiltonAugust2023PlanMember_f96e9d45-9604-4f2d-8d3c-879d2ae16fb8" xlink:href="arwr-20230930.xsd#arwr_JamesHamiltonAugust2023PlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_arwr_JamesHamiltonAugust2023PlanMember_f96e9d45-9604-4f2d-8d3c-879d2ae16fb8" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTypeOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/AwardTypeOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RestrictedStockUnitsMarketBasedMember_2089173c-f757-438f-afcc-c1bc25a2d388" xlink:href="arwr-20230930.xsd#arwr_RestrictedStockUnitsMarketBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_arwr_RestrictedStockUnitsMarketBasedMember_2089173c-f757-438f-afcc-c1bc25a2d388" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RestrictedStockUnitsPerformanceBasedMember_4a833f8e-3191-41b4-b790-ce21c595687f" xlink:href="arwr-20230930.xsd#arwr_RestrictedStockUnitsPerformanceBasedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_arwr_RestrictedStockUnitsPerformanceBasedMember_4a833f8e-3191-41b4-b790-ce21c595687f" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#IndividualsOnly"/>
  <link:definitionLink xlink:role="http://xbrl.sec.gov/ecd/role/IndividualsOnly" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MauroFerrariMember_eade5c17-27e6-4ee2-b897-24ad7610de50" xlink:href="arwr-20230930.xsd#arwr_MauroFerrariMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_MauroFerrariMember_eade5c17-27e6-4ee2-b897-24ad7610de50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DouglassGivenMember_150395b7-0ddb-48f7-b088-603870e8220c" xlink:href="arwr-20230930.xsd#arwr_DouglassGivenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_DouglassGivenMember_150395b7-0ddb-48f7-b088-603870e8220c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JamesHamiltonMember_bf28ed3a-2d8b-4473-8111-1397a2736f69" xlink:href="arwr-20230930.xsd#arwr_JamesHamiltonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_JamesHamiltonMember_bf28ed3a-2d8b-4473-8111-1397a2736f69" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_KenMyszkowskiMember_0545749b-3419-4db1-8e6f-2a292ef5cc97" xlink:href="arwr-20230930.xsd#arwr_KenMyszkowskiMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_KenMyszkowskiMember_0545749b-3419-4db1-8e6f-2a292ef5cc97" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PatrickOBrienMember_8260560c-cbc9-4e1c-aee8-716092db3f2d" xlink:href="arwr-20230930.xsd#arwr_PatrickOBrienMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_PatrickOBrienMember_8260560c-cbc9-4e1c-aee8-716092db3f2d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TracieOliverMember_623a2336-1dae-42fe-9ca8-77c8bd4d15cd" xlink:href="arwr-20230930.xsd#arwr_TracieOliverMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_TracieOliverMember_623a2336-1dae-42fe-9ca8-77c8bd4d15cd" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VictoriaVakienerMember_f2f5c306-0be0-4ee5-8307-17be48aedcb5" xlink:href="arwr-20230930.xsd#arwr_VictoriaVakienerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_VictoriaVakienerMember_f2f5c306-0be0-4ee5-8307-17be48aedcb5" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_WilliamWaddillMember_faae1af8-bf66-4a39-9ab8-2b7eb5134b68" xlink:href="arwr-20230930.xsd#arwr_WilliamWaddillMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_WilliamWaddillMember_faae1af8-bf66-4a39-9ab8-2b7eb5134b68" xlink:type="arc" order="9"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>15
<FILENAME>arwr-20230930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:d14395b2-bc79-4df5-8659-886540a562de,g:ab3d3e76-c740-4da0-ace7-13e457c841a4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_f123898d-e8a0-4297-bc7d-54106daa70f1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leased Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems" xlink:to="lab_us-gaap_OperatingLeasedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_b2c9fbb8-c5d5-4f6f-9220-7928e4c7bfa8_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesAxis_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesAxis" xlink:to="lab_srt_ConsolidatedEntitiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RoyaltiesLiabilityNoncurrent_1f34a865-8751-46d3-b740-6b4ddeaf4d9f_terseLabel_en-US" xlink:label="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability related to the sale of future royalties</link:label>
    <link:label id="lab_arwr_RoyaltiesLiabilityNoncurrent_label_en-US" xlink:label="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties, Liability, Noncurrent</link:label>
    <link:label id="lab_arwr_RoyaltiesLiabilityNoncurrent_documentation_en-US" xlink:label="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalties, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltiesLiabilityNoncurrent" xlink:href="arwr-20230930.xsd#arwr_RoyaltiesLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RoyaltiesLiabilityNoncurrent" xlink:to="lab_arwr_RoyaltiesLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_591a52fd-dc7c-48ea-b0ae-338d3536fa3d_terseLabel_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Office space leases (in sq ft)</link:label>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_label_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land Subject to Ground Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandSubjectToGroundLeases" xlink:to="lab_us-gaap_LandSubjectToGroundLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_c6f1a99c-fb1b-4772-b60e-446c1bc4d484_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to noncontrolling interest, net of tax</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_ba997e41-b84b-4c5a-82ea-6aa68bd31070_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of marketable debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_9cc76e3a-f9a7-4382-a0da-bed22a49a0c3_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_0b652fa1-bd6b-49ef-b9b0-14d045249080_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_7f9c06bc-b310-4725-80a9-2a758ceed98e_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_WI_2fcdd7eb-648e-4b65-9b59-0a83926c5fe4_terseLabel_en-US" xlink:label="lab_stpr_WI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wisconsin</link:label>
    <link:label id="lab_stpr_WI_label_en-US" xlink:label="lab_stpr_WI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">WISCONSIN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_WI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_WI" xlink:to="lab_stpr_WI" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_28b24f17-8a91-4e44-8592-9abb650bb4ab_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_18a90285-a45b-46d4-aca4-469aec5bac68_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_aa3d8af1-5697-4178-9223-7113d80edb06_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based payment award (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_f52e76d4-793e-48a1-a1dc-bdaca07b4352_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4a2a8a24-c45f-42e1-b96a-c1252df95b5b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_49c1932d-3300-4e5b-a8c9-e32af565879e_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Accretion) amortization of note premiums/discounts</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Net, Amortization of Discount and Premium</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="lab_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TechnologyLicenseCommitmentsMember_8c279bf7-d9f8-48dc-a379-b80dc4b0ae36_terseLabel_en-US" xlink:label="lab_arwr_TechnologyLicenseCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology License Commitments</link:label>
    <link:label id="lab_arwr_TechnologyLicenseCommitmentsMember_label_en-US" xlink:label="lab_arwr_TechnologyLicenseCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology License Commitments [Member]</link:label>
    <link:label id="lab_arwr_TechnologyLicenseCommitmentsMember_documentation_en-US" xlink:label="lab_arwr_TechnologyLicenseCommitmentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Technology license commitments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TechnologyLicenseCommitmentsMember" xlink:href="arwr-20230930.xsd#arwr_TechnologyLicenseCommitmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TechnologyLicenseCommitmentsMember" xlink:to="lab_arwr_TechnologyLicenseCommitmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_9c998234-ad2b-46b3-ad94-5ae086060b24_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_3f462fbb-8d73-4fb2-b3fc-3e4767ac37f9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_9bae52ba-b46b-491a-bb42-3646bd498a35_terseLabel_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary</link:label>
    <link:label id="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_label_en-US" xlink:label="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity, Primary Beneficiary [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:to="lab_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fef9e1c4-8749-440a-b6b6-e324c2edaf51_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DouglassGivenMember_label_en-US" xlink:label="lab_arwr_DouglassGivenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Douglass Given [Member]</link:label>
    <link:label id="lab_arwr_DouglassGivenMember_documentation_en-US" xlink:label="lab_arwr_DouglassGivenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Douglass Given</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DouglassGivenMember" xlink:href="arwr-20230930.xsd#arwr_DouglassGivenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DouglassGivenMember" xlink:to="lab_arwr_DouglassGivenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_49d0e0e6-41c7-467b-9631-550afeedd8e6_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets subject to amortization, impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets, Finite-Lived</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsFinitelived" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_33891a1b-77d8-4490-a524-92b6b0d6cf31_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign-derived intangible income deduction</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, FDII, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_15baef33-4387-4f74-9bb4-eab269c9fc53_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_a539dc3a-522d-4b49-bce8-e7151d64a9c9_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_111e11b5-d2d6-453b-87c9-74dd6b769471_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_b39060eb-6f4b-4596-9a6d-af9256f8cf1d_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_ca067e00-3fb1-4f3c-9700-acc55b96c549_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_556caccb-a78d-4a79-bd06-f7938e30e92a_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other (expense) income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_686251a8-d870-4d18-9c74-11ea07c80243_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. federal statutory income tax</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_67a86460-f8d7-4a2a-8084-b04c7fe7d826_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 7)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4b6c36c2-e117-4fb8-8e26-778b0b580133_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options Outstanding, Exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TaxIncrementFinancingAward_6c10b5b0-b7e4-4095-b8ee-a17864141bcf_terseLabel_en-US" xlink:label="lab_arwr_TaxIncrementFinancingAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax increment financing award</link:label>
    <link:label id="lab_arwr_TaxIncrementFinancingAward_label_en-US" xlink:label="lab_arwr_TaxIncrementFinancingAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Increment Financing Award</link:label>
    <link:label id="lab_arwr_TaxIncrementFinancingAward_documentation_en-US" xlink:label="lab_arwr_TaxIncrementFinancingAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Increment Financing Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TaxIncrementFinancingAward" xlink:href="arwr-20230930.xsd#arwr_TaxIncrementFinancingAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TaxIncrementFinancingAward" xlink:to="lab_arwr_TaxIncrementFinancingAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_34aea2d4-094a-4f90-a74f-0134ff70c455_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressGross_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressGross" xlink:to="lab_us-gaap_ConstructionInProgressGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_b4ec16f9-c203-47a0-a755-7688f94a1da5_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_4c7207c8-ee5e-4e84-be55-93fd019e6b53_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_366cdadb-556b-4a9b-a1d5-9e58e0956baf_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_819b74e0-7b53-47f4-9de5-c0c532e53fd0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Operating Leased Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_4d7a11db-58de-4d57-9c99-72d882a87792_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of future royalties</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_2f10a07c-dcc6-42d1-9a95-6fad9ee78471_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_e74c9a71-201a-4d1d-9bdb-5963f4606c27_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_0c53219b-b79d-438d-9514-3808887f4a2a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_47f9f554-23dd-4ef5-bb65-68db2a111640_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_992637d5-3d80-41d9-b4a1-76c7a701ca67_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_bb014969-6163-4362-a592-b0ec2882311e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_c93ae01d-164d-472b-b1a1-9e375e6259b4_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_612a1f9a-fd3d-4ea4-ad8e-c83baa6e1d40_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_517d9658-8637-4733-b03a-40d9ed4d4dad_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_d9da61e5-fd63-437f-a396-8218b93f0429_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0391228a-b095-4c5d-ab71-710e562f326e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_611d3ddf-183f-463b-ae62-560574632091_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_ed2d0ffa-99d6-42f2-85f4-f0689a8dd75f_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_3d164956-3670-4b94-8804-987fc989a7ae_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Land_9c92266f-78d9-4ce2-9c68-a722f5557896_terseLabel_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:label id="lab_us-gaap_Land_label_en-US" xlink:label="lab_us-gaap_Land" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Land"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Land" xlink:to="lab_us-gaap_Land" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement_945d8726-7a5a-4ad6-873b-5a9e158da4c2_terseLabel_en-US" xlink:label="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement_label_en-US" xlink:label="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Received As Due Under Collaboration Agreement</link:label>
    <link:label id="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement_documentation_en-US" xlink:label="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received as due under collaboration agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:href="arwr-20230930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:to="lab_arwr_CashReceivedAsDueUnderCollaborationAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_2c7db856-c557-47a2-8fb9-b5f2eef5f3aa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b6c3d11f-b061-4241-989b-a295b6d9b5db_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_a736a1eb-ba73-458d-8380-bb99191d8f1e_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_c802b77e-5632-4824-820e-c80b78d1386b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_12239505-da2d-4897-ae4c-2d896e0ffe70_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_4c48a1a0-c417-4442-afe2-aa219afd99de_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RestrictedStockUnitsMarketBasedMember_ccc6df18-e78c-4770-a67b-42fa21a3b227_terseLabel_en-US" xlink:label="lab_arwr_RestrictedStockUnitsMarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units, Market-Based</link:label>
    <link:label id="lab_arwr_RestrictedStockUnitsMarketBasedMember_label_en-US" xlink:label="lab_arwr_RestrictedStockUnitsMarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units, Market-Based [Member]</link:label>
    <link:label id="lab_arwr_RestrictedStockUnitsMarketBasedMember_documentation_en-US" xlink:label="lab_arwr_RestrictedStockUnitsMarketBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units, Market-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RestrictedStockUnitsMarketBasedMember" xlink:href="arwr-20230930.xsd#arwr_RestrictedStockUnitsMarketBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RestrictedStockUnitsMarketBasedMember" xlink:to="lab_arwr_RestrictedStockUnitsMarketBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_fbe52b66-780b-4430-95fd-1df2c8f14895_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterestAndDividend_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest and Dividend</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterestAndDividend" xlink:to="lab_us-gaap_InvestmentIncomeInterestAndDividend" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7e973b7b-dcba-4964-a85d-59804c523ede_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_d0a28adb-4fab-4ad6-a5e3-bcb62c577eaf_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average grant date fair value per share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_3f444a28-4e41-41b1-a02d-7980b27624e0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_f2cdb6d6-2fa8-44b1-b259-1abfeaffe581_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_f468ecc2-d215-454b-a4f1-c60c19266124_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_1c1f7898-dd8d-4c4b-bd65-2d5ff3f9ab9f_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_9b3dc55d-e984-4960-8dae-bd174e51e6c0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_eb17f810-478a-484d-b543-fc21c0b45d1e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_8f8113c6-1984-4f81-be0e-50278d066941_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_b0f53565-3c3f-4c4d-abb1-bf5ed20a6c53_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_38d3eca2-92af-42f0-ae5a-f0a3048789c7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_e7fce324-375a-4453-940e-5c4685205353_terseLabel_en-US" xlink:label="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock shares value reserved for future issuance</link:label>
    <link:label id="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_label_en-US" xlink:label="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Capital Shares Value Reserved For Future Issuance</link:label>
    <link:label id="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_documentation_en-US" xlink:label="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, capital shares value reserved for future issuance.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:href="arwr-20230930.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:to="lab_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssued_3301201b-3227-439d-8e5c-ca7532733738_verboseLabel_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued</link:label>
    <link:label id="lab_us-gaap_SharesIssued_label_en-US" xlink:label="lab_us-gaap_SharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued" xlink:to="lab_us-gaap_SharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_69c9187a-f730-4a33-902c-3a7fd865a8b0_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_d43e1232-a83a-497f-973f-6d00de1805f4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_904a4c45-35ac-4556-9fec-de0e59badee0_totalLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Available-for-sale, Adjusted Basis</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_c8d04cb2-ffca-440a-94d3-3642e6370950_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_87c8fb58-c596-43e5-8b75-c10695131d18_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_c0cda030-e8f2-40c9-a6b9-dd5c5aacc3f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Gross Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_5326281d-1a9f-41b5-aab8-ec01f7c4316a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities included in deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7712a568-1d69-453b-8fcf-9f7fc6c56ddb_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_6cf02fc7-a9e5-48b4-8c2a-72b2015b8614_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_dab4beae-a47a-4ce9-859d-e06805567993_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_SorrentoValleyOwnerDELLCMember_bf340499-e451-491c-88ca-fd46ffdb122b_terseLabel_en-US" xlink:label="lab_arwr_SorrentoValleyOwnerDELLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sorrento Valley Owner (DE) LLC</link:label>
    <link:label id="lab_arwr_SorrentoValleyOwnerDELLCMember_label_en-US" xlink:label="lab_arwr_SorrentoValleyOwnerDELLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sorrento Valley Owner (DE) LLC [Member]</link:label>
    <link:label id="lab_arwr_SorrentoValleyOwnerDELLCMember_documentation_en-US" xlink:label="lab_arwr_SorrentoValleyOwnerDELLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sorrento Valley Owner (DE) LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SorrentoValleyOwnerDELLCMember" xlink:href="arwr-20230930.xsd#arwr_SorrentoValleyOwnerDELLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_SorrentoValleyOwnerDELLCMember" xlink:to="lab_arwr_SorrentoValleyOwnerDELLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1182f26b-e82e-4178-b2f8-2bc08deb97c7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandsThirteenIncentivePlanMember_5715ea5d-83e0-4ce9-ad56-1042ab60e67b_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2013 Plan</link:label>
    <link:label id="lab_arwr_TwoThousandsThirteenIncentivePlanMember_label_en-US" xlink:label="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousands Thirteen Incentive Plan [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandsThirteenIncentivePlanMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousands thirteen incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:href="arwr-20230930.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:to="lab_arwr_TwoThousandsThirteenIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_81d7869b-9784-4ac8-ba3a-92894be1f6bb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of RSUs</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent_e693c644-577a-4a6f-802d-c9cfd3e01dcc_terseLabel_en-US" xlink:label="lab_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-deductible compensation</link:label>
    <link:label id="lab_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent_label_en-US" xlink:label="lab_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Compensation, Percent</link:label>
    <link:label id="lab_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent_documentation_en-US" xlink:label="lab_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Compensation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent" xlink:href="arwr-20230930.xsd#arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent" xlink:to="lab_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_febb88b5-f22a-4d87-bfef-affa6ee2a691_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsTable_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsTable" xlink:to="lab_us-gaap_OtherCommitmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_72a7bfd0-a220-4035-b5cf-da7d8abe844e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_SalesRelatedMilestonePayments_cac73f7e-bd47-4c41-bbaf-53da22ccdad3_terseLabel_en-US" xlink:label="lab_arwr_SalesRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-related milestone payments</link:label>
    <link:label id="lab_arwr_SalesRelatedMilestonePayments_label_en-US" xlink:label="lab_arwr_SalesRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Related Milestone Payments</link:label>
    <link:label id="lab_arwr_SalesRelatedMilestonePayments_documentation_en-US" xlink:label="lab_arwr_SalesRelatedMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales-related milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments" xlink:href="arwr-20230930.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_SalesRelatedMilestonePayments" xlink:to="lab_arwr_SalesRelatedMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_f5aa2f41-5e3c-4f1b-9496-5b01bcf4333b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PatentsMember_21384d51-118c-4993-9f1f-39e715d4f294_terseLabel_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents</link:label>
    <link:label id="lab_us-gaap_PatentsMember_label_en-US" xlink:label="lab_us-gaap_PatentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PatentsMember" xlink:to="lab_us-gaap_PatentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_e585f3eb-958b-44ef-9c31-352a9f447032_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross increase for prior period tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_211351d2-da1f-46a5-ad50-c40f0cb5c469_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_59ef2437-5d0d-4889-9a29-27d1dd61661e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_3493605b-b612-4b91-94d1-50779a0833d6_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_45c10f7a-dc25-486b-b396-f2148f76921f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_e0e363b0-4fd2-4059-8ac3-6cb15476d735_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificate of deposits</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c338d202-d903-410d-9905-5028fa29bd5a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_f88ddf70-a3ad-47ac-b218-d55aeb960a0e_negatedTerseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Available-for-sale, Gross Unrealized Losses</link:label>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_label_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Current</link:label>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" xlink:href="arwr-20230930.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" xlink:to="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_dff0f219-e30f-46b2-a91c-321378f76a0d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Lease Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_9cc2b6da-237b-44fb-98a9-33c67bdb38b0_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0941c32c-3360-4a23-8a20-93eefcc81831_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementsMember_5d92af5e-9232-49b2-8a5a-7ddc7a426941_terseLabel_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License agreements</link:label>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementsMember_label_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements [Member]</link:label>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementsMember_documentation_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsMember" xlink:href="arwr-20230930.xsd#arwr_CollaborationAndLicenseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsMember" xlink:to="lab_arwr_CollaborationAndLicenseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_648f9c18-f149-41bd-8b38-866a64d5471e_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_50ecad29-b79c-4c67-b394-7a89ce9ddd82_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_0c2f8ff1-66fe-4c0f-8cf7-636f516b2f4f_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_bcb5349b-99a3-4092-8ef6-f71ba5fdf19c_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfDistinctPerformanceObligations_69cdddca-f999-4cea-82a4-15c07c07e0e6_terseLabel_en-US" xlink:label="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct performance obligations</link:label>
    <link:label id="lab_arwr_NumberOfDistinctPerformanceObligations_label_en-US" xlink:label="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Distinct Performance Obligations</link:label>
    <link:label id="lab_arwr_NumberOfDistinctPerformanceObligations_documentation_en-US" xlink:label="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct performance obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations" xlink:href="arwr-20230930.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfDistinctPerformanceObligations" xlink:to="lab_arwr_NumberOfDistinctPerformanceObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_5552cc6b-7039-4a08-b542-11ffeb422e77_terseLabel_en-US" xlink:label="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of commission to sales agent</link:label>
    <link:label id="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_label_en-US" xlink:label="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Commission On Aggregate Gross Proceeds From Sale Of Common Stock</link:label>
    <link:label id="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_documentation_en-US" xlink:label="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of commission on aggregate gross proceeds from sale of common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:href="arwr-20230930.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:to="lab_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum_a791fcf8-87ce-4bde-be75-9b09f904c84b_terseLabel_en-US" xlink:label="lab_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest per annum</link:label>
    <link:label id="lab_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum_label_en-US" xlink:label="lab_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Tenant Improvement Allowance, Interest Per Annum</link:label>
    <link:label id="lab_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum_documentation_en-US" xlink:label="lab_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Tenant Improvement Allowance, Interest Per Annum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum" xlink:href="arwr-20230930.xsd#arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum" xlink:to="lab_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommercialNotesMember_1a86beaa-d325-4e94-89e0-60284710ac34_terseLabel_en-US" xlink:label="lab_arwr_CommercialNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial notes</link:label>
    <link:label id="lab_arwr_CommercialNotesMember_label_en-US" xlink:label="lab_arwr_CommercialNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Notes [Member]</link:label>
    <link:label id="lab_arwr_CommercialNotesMember_documentation_en-US" xlink:label="lab_arwr_CommercialNotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesMember" xlink:href="arwr-20230930.xsd#arwr_CommercialNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommercialNotesMember" xlink:to="lab_arwr_CommercialNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_82ccd6ef-3fee-43ee-8d76-499a7a63839e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_1021c0c4-9963-4e32-8f5d-4e36c32456c0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_307afc64-dfd5-4a44-84d9-306bb8bbafb1_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_15cd17cc-dc68-4a64-89fd-a56a1ddb51ec_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash and Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_6a714c8b-737e-40d1-b00b-840634afdce7_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_1f5f7cda-68c2-4244-bcc5-c8ecff0e48c7_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ProceedsFromSaleOfFutureRoyalties_c09e9185-8506-4a22-9a72-dfc34c19ade4_terseLabel_en-US" xlink:label="lab_arwr_ProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the sale of future royalties</link:label>
    <link:label id="lab_arwr_ProceedsFromSaleOfFutureRoyalties_label_en-US" xlink:label="lab_arwr_ProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Future Royalties</link:label>
    <link:label id="lab_arwr_ProceedsFromSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_arwr_ProceedsFromSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromSaleOfFutureRoyalties" xlink:href="arwr-20230930.xsd#arwr_ProceedsFromSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ProceedsFromSaleOfFutureRoyalties" xlink:to="lab_arwr_ProceedsFromSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RestrictedStockUnitsPerformanceBasedMember_0fab91df-5182-441c-820d-fc743614fc44_terseLabel_en-US" xlink:label="lab_arwr_RestrictedStockUnitsPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance-Based Restricted Stock Units</link:label>
    <link:label id="lab_arwr_RestrictedStockUnitsPerformanceBasedMember_label_en-US" xlink:label="lab_arwr_RestrictedStockUnitsPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units, Performance-Based [Member]</link:label>
    <link:label id="lab_arwr_RestrictedStockUnitsPerformanceBasedMember_documentation_en-US" xlink:label="lab_arwr_RestrictedStockUnitsPerformanceBasedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units, Performance-Based</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RestrictedStockUnitsPerformanceBasedMember" xlink:href="arwr-20230930.xsd#arwr_RestrictedStockUnitsPerformanceBasedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RestrictedStockUnitsPerformanceBasedMember" xlink:to="lab_arwr_RestrictedStockUnitsPerformanceBasedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_d0ae4472-f878-4b91-a0c4-56687db61368_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_dca8535a-e437-4ed0-a0ef-feca1db8721f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_174bc917-ae7e-44ea-9ccb-c5427a72a744_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c9c53504-075c-41b2-8f37-9a2a87a531d6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchFacilityInSanDiegoMember_86b981c5-c3b3-4d63-bb29-21b90c05e79d_terseLabel_en-US" xlink:label="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Facility in San Diego</link:label>
    <link:label id="lab_arwr_ResearchFacilityInSanDiegoMember_label_en-US" xlink:label="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Facility In San Diego [Member]</link:label>
    <link:label id="lab_arwr_ResearchFacilityInSanDiegoMember_documentation_en-US" xlink:label="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Facility in San Diego.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember" xlink:href="arwr-20230930.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchFacilityInSanDiegoMember" xlink:to="lab_arwr_ResearchFacilityInSanDiegoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_d441d20a-93c0-4743-84bc-816d1d82b1dd_terseLabel_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development regulatory and sales milestones payments</link:label>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_7aedc09f-9079-466b-a3de-a196fe87b902_verboseLabel_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development, regulatory and sales milestones payments</link:label>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_label_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development Regulatory And Sales Milestones Payments</link:label>
    <link:label id="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_documentation_en-US" xlink:label="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Development regulatory and sales milestones payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:href="arwr-20230930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:to="lab_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_1d787061-4c0b-408b-9351-bbf49bc1fb93_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_f87f9e28-d405-4a01-967e-b6dc18cc5e65_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_23afd980-c061-4967-a63e-29f114ef825e_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Interest Entity</link:label>
    <link:label id="lab_us-gaap_ConsolidationVariableInterestEntityPolicy_label_en-US" xlink:label="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Variable Interest Entity, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:to="lab_us-gaap_ConsolidationVariableInterestEntityPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_VictoriaVakienerMember_label_en-US" xlink:label="lab_arwr_VictoriaVakienerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Victoria Vakiener [Member]</link:label>
    <link:label id="lab_arwr_VictoriaVakienerMember_documentation_en-US" xlink:label="lab_arwr_VictoriaVakienerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Victoria Vakiener</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VictoriaVakienerMember" xlink:href="arwr-20230930.xsd#arwr_VictoriaVakienerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_VictoriaVakienerMember" xlink:to="lab_arwr_VictoriaVakienerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_fe14ddaf-f274-4d90-ab0d-e3de4e09da89_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Lease Assets and Liabilities and Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_160c1273-c0c7-432b-9620-9a2fc6d3f284_terseLabel_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Short-term, Long-term Investments and Marketable Securities</link:label>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_label_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held To Maturity Securities And Marketable Securities Table [Table Text Block]</link:label>
    <link:label id="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_documentation_en-US" xlink:label="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held to maturity securities and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:href="arwr-20230930.xsd#arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:to="lab_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_91398571-1e04-427b-a298-5374db11e48e_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments, Held to maturity, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" xlink:to="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_16bde5dc-2305-41cc-88c9-9dbf36280dbe_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_088dd694-b841-44b4-8d4b-c4d399e88d11_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AdditionalTenantImprovementAllowanceLiability_5877faa5-02e2-4754-81fe-e073fc301934_terseLabel_en-US" xlink:label="lab_arwr_AdditionalTenantImprovementAllowanceLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional tenant improvement allowance liability</link:label>
    <link:label id="lab_arwr_AdditionalTenantImprovementAllowanceLiability_label_en-US" xlink:label="lab_arwr_AdditionalTenantImprovementAllowanceLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Tenant Improvement Allowance Liability</link:label>
    <link:label id="lab_arwr_AdditionalTenantImprovementAllowanceLiability_documentation_en-US" xlink:label="lab_arwr_AdditionalTenantImprovementAllowanceLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Tenant Improvement Allowance Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalTenantImprovementAllowanceLiability" xlink:href="arwr-20230930.xsd#arwr_AdditionalTenantImprovementAllowanceLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AdditionalTenantImprovementAllowanceLiability" xlink:to="lab_arwr_AdditionalTenantImprovementAllowanceLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_2e178570-636a-4e5c-bfea-7eec9cecffcb_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_eb6a79a0-c603-4740-8f62-553daf2e6510_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potentially dilutive securities excluded from computation of diluted earnings per share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_9ba3044c-6a21-4a8a-b3bf-7ee3237e71c2_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9ab4efcf-50ae-4783-b974-1ee93a111937_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_252de522-cc22-4b69-a65f-17630c1e144d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_2c55c1e6-ffaa-408a-ac0c-92b58df40349_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_a50fcfbc-fd6b-42fb-b32d-1e6afb38de6d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_124fcc4f-8722-4b80-9cfe-8064be520793_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized pre-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9426e996-e391-4f87-82b0-1b296d2632ca_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_19577534-95a9-4380-b217-072e9a112b73_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_80950895-0e61-492c-bbee-324fe3e05402_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_c8765d15-8cf5-415f-a3e6-27a7befe6628_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_d3aff3c6-2617-494c-9168-1e3f4030297f_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross fixed assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b67aec90-7e15-4644-8848-7fb062bbc3e2_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Remaining Contractual Term, Outstanding</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_02750fb6-8829-47f5-b53a-86f41a5946cc_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for amended operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_7eecb115-1bee-413d-816a-d8376cf6253d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsTable_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable" xlink:to="lab_us-gaap_OperatingLossCarryforwardsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_30598534-b04f-473d-9fda-fba3c5736f2a_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_26afdec5-c1e8-453f-943b-0db1e40759f0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provisions for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JamesHamiltonTerminatedPlanMember_label_en-US" xlink:label="lab_arwr_JamesHamiltonTerminatedPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">James Hamilton Terminated Plan [Member]</link:label>
    <link:label id="lab_arwr_JamesHamiltonTerminatedPlanMember_documentation_en-US" xlink:label="lab_arwr_JamesHamiltonTerminatedPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">James Hamilton Terminated Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JamesHamiltonTerminatedPlanMember" xlink:href="arwr-20230930.xsd#arwr_JamesHamiltonTerminatedPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JamesHamiltonTerminatedPlanMember" xlink:to="lab_arwr_JamesHamiltonTerminatedPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_2f556ffd-72e1-4e97-95cd-1c618d45a813_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_a98f88a9-12d0-44e2-9c69-8fb26441348e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsLineItems_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="lab_us-gaap_OperatingLossCarryforwardsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_a2927b1f-5193-4f04-9197-61c0931b938e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2029 and thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_d474b447-c947-439c-b6d4-0e2e5ed05c13_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Share Activity Related to RSUs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_2fcc1aed-08dd-4ee5-9670-e4a465e56602_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_307ba030-7765-4694-bbd9-0f81c4315004_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_57d78692-0c11-44d7-b09d-c6e09a6d968f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross decrease for prior period tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_65cbe3da-8616-439d-ab60-70344510a40e_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_ba37d5e9-9f91-4608-a4e3-6ac756cdb38e_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_91a9a45d-8db0-4066-920f-84b2b076e13b_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ee8c151c-15a4-484b-99d0-7723775c3518_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_04791d2b-ae2e-4f5c-825f-37e80fc70f8f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_407ba76f-250d-4820-8f7c-59e9b7ccab13_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_e40304d2-5bd6-4d40-980e-a8303f205ccc_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_45aba18c-9bff-40a6-b115-266c809d4025_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfCurrentProductsTableTextBlock_02d9dd4a-8174-45c3-b7d3-7311a69cbc7f_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Company's Current Pipeline</link:label>
    <link:label id="lab_arwr_ScheduleOfCurrentProductsTableTextBlock_label_en-US" xlink:label="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Current Products [Table Text Block]</link:label>
    <link:label id="lab_arwr_ScheduleOfCurrentProductsTableTextBlock_documentation_en-US" xlink:label="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Current Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:href="arwr-20230930.xsd#arwr_ScheduleOfCurrentProductsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:to="lab_arwr_ScheduleOfCurrentProductsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_f4fa47cc-aec6-4ee4-bfdf-bc98ef0b0d70_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_43178e3e-6df4-438f-9ed2-6dea40f717f0_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross increase for current period tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JanssenPharmaceuticalsIncorporationMember_cd98b48f-f4d8-4f34-9fd2-ec1fb1c21c48_terseLabel_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen</link:label>
    <link:label id="lab_arwr_JanssenPharmaceuticalsIncorporationMember_label_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals Incorporation [Member]</link:label>
    <link:label id="lab_arwr_JanssenPharmaceuticalsIncorporationMember_documentation_en-US" xlink:label="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Janssen Pharmaceuticals, Incorporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:href="arwr-20230930.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:to="lab_arwr_JanssenPharmaceuticalsIncorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_246dd886-e986-49a0-86da-6fa8b505af2d_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_9acc3083-46a6-4ae8-b812-1c542a144f91_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_42ef97fe-e453-4981-bec4-c3b804701876_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Shares of Common Stock and Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTextBlock" xlink:to="lab_us-gaap_ScheduleOfStockByClassTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0466527c-07a9-4bc7-8a29-a41dc8e5def6_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_e7ffd4d2-7e01-48db-9e7e-5030d24d52f0_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BEGINNING OR PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ef58d8c1-2a6e-4961-a72a-833ab9d8f147_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">END OF PERIOD</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_c536c111-4ba0-4a61-905d-d13920d6de8e_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_InducementAwardsMember_c65866ce-bd62-4597-80da-7034410605f3_terseLabel_en-US" xlink:label="lab_arwr_InducementAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Awards</link:label>
    <link:label id="lab_arwr_InducementAwardsMember_label_en-US" xlink:label="lab_arwr_InducementAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Awards [Member]</link:label>
    <link:label id="lab_arwr_InducementAwardsMember_documentation_en-US" xlink:label="lab_arwr_InducementAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inducement Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementAwardsMember" xlink:href="arwr-20230930.xsd#arwr_InducementAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_InducementAwardsMember" xlink:to="lab_arwr_InducementAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_3f115d04-d69d-4e22-91b3-ddd4c1ed8895_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_459acc97-ffe4-46a8-af18-aa287eada2ea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Loss Before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_4abb6f3f-c797-47f4-bbcc-aa7fe4080afb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_d1622dd6-a7f1-4f08-8dfe-f8725371204b_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_InitialTransactionPrice_e3bc9ca8-3a45-430f-8f56-5c6c87f62e7f_terseLabel_en-US" xlink:label="lab_arwr_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial transaction price</link:label>
    <link:label id="lab_arwr_InitialTransactionPrice_label_en-US" xlink:label="lab_arwr_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial Transaction Price</link:label>
    <link:label id="lab_arwr_InitialTransactionPrice_documentation_en-US" xlink:label="lab_arwr_InitialTransactionPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Initial transaction price.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice" xlink:href="arwr-20230930.xsd#arwr_InitialTransactionPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_InitialTransactionPrice" xlink:to="lab_arwr_InitialTransactionPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_4b6d1ab5-3984-4a81-94da-1310b0da36fe_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_e17e2e91-a25d-4359-b79b-08dfd144cfb0_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in calculating</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_8a947e46-4b81-46e0-bfb9-76b6874c367a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_62ba7aad-ea30-4bf9-a2f4-9abfb6d50852_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_c95b7e45-5bcf-4e8a-a998-d5776f65e144_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_dd079c37-35f3-499a-8b98-909824f62ce0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sales and maturities of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_ad78fc35-d32c-450e-a0ec-fa6e7cd2f74f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_7d9f0881-8d67-47d6-a32c-d2798738f9c6_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_d7fa8d59-7f7d-4b00-a680-811a86bfa4ed_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumptions Used to Value Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_76e04af6-e883-4ca0-84ca-c3c44638bd79_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_c29e65ba-cef8-43be-95c2-07a6cd373a45_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_51523de5-ce0b-4e9b-9035-d10b7ede4b94_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e655dab2-0969-4615-aa18-6d210a6be684_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_c49f94e9-3fae-43cd-aae9-847783a9c00f_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AuditInformationAbstract_label_en-US" xlink:label="lab_arwr_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_arwr_AuditInformationAbstract_documentation_en-US" xlink:label="lab_arwr_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AuditInformationAbstract" xlink:href="arwr-20230930.xsd#arwr_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AuditInformationAbstract" xlink:to="lab_arwr_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_33919c83-c795-4933-bced-990693137297_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_1b574e5a-03ae-46a2-ade1-f339acc5d25b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_a2c5b4a2-7fb5-4cb5-b045-8329eb715cc9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discretionary match percentage</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Match</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_110745f0-a6eb-477b-89d0-3201ee47e6b5_terseLabel_en-US" xlink:label="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial milestone payments at first commercial sale</link:label>
    <link:label id="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_label_en-US" xlink:label="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Milestone Payments At First Commercial Sale</link:label>
    <link:label id="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_documentation_en-US" xlink:label="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial milestone payments at first commercial sale.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:href="arwr-20230930.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:to="lab_arwr_CommercialMilestonePaymentsAtFirstCommercialSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8eb8fa83-32dd-4ba8-919c-c6ccb5a05672_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period to recognize pre-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_4b72a681-bc07-4cde-89b2-fcb078a52e0f_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_45a95add-cccb-4e51-ba01-b652eecd811b_verboseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_c7e28042-461e-4477-8c90-690f4a765bb5_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_3a50f68d-2fbc-46ad-b1aa-fe3e584331e1_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_67e27781-ca44-4a69-a0c5-07c032af83c3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_5eb3efd2-04e7-45a2-aec4-af832a6b11ad_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_b550479b-2fb9-45fc-a4e7-166e2578b66e_terseLabel_en-US" xlink:label="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional remaining development regulatory and sales milestones payments</link:label>
    <link:label id="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_label_en-US" xlink:label="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Remaining Development Regulatory And Sales Milestones Payments</link:label>
    <link:label id="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_documentation_en-US" xlink:label="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional remaining development regulatory and sales milestones payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:href="arwr-20230930.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:to="lab_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_53be5eb9-dc3c-4025-9b83-61e84addd627_terseLabel_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer</link:label>
    <link:label id="lab_srt_ChiefExecutiveOfficerMember_label_en-US" xlink:label="lab_srt_ChiefExecutiveOfficerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chief Executive Officer [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ChiefExecutiveOfficerMember" xlink:to="lab_srt_ChiefExecutiveOfficerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandTwentyOneIncentivePlanMember_83c9d7a4-d53e-428a-9a0a-75271a3bf821_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2021 Plan</link:label>
    <link:label id="lab_arwr_TwoThousandTwentyOneIncentivePlanMember_label_en-US" xlink:label="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Twenty One Incentive Plan [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandTwentyOneIncentivePlanMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand twenty one incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:href="arwr-20230930.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:to="lab_arwr_TwoThousandTwentyOneIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4dc938c3-0c53-4b86-8ec5-e7734f2332d4_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_33ae6953-3427-409b-a037-281ec628c93f_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_87cf167d-f135-4cb3-921d-7b76be710a62_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromContributedCapital_82d5b4f2-be17-408f-9302-67757b51ea04_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromContributedCapital" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from investment in joint venture</link:label>
    <link:label id="lab_us-gaap_ProceedsFromContributedCapital_73e866c0-e6c2-47ca-bc1f-ca528e8364d7_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromContributedCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from upfront capital</link:label>
    <link:label id="lab_us-gaap_ProceedsFromContributedCapital_label_en-US" xlink:label="lab_us-gaap_ProceedsFromContributedCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Contributed Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromContributedCapital" xlink:to="lab_us-gaap_ProceedsFromContributedCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_992f08c3-259a-45bb-8468-cb06f71ee1a3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted- Average Exercise Price Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_231a08b4-fb6f-4a36-82d9-803e9ec42b9a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_0d708fbc-d827-4ad6-addb-f92e4c103f2f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_dbc5365e-aade-4854-825e-7602bdfc0423_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_0fd84a6c-5c81-430c-ada8-893d2ac48e03_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_a1da8647-e0ce-421f-8d5f-a8d0842db00d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_475f99c1-d86c-44b8-ba51-2b209f6edcb8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_7fd4d072-353f-4682-805b-f77b376aa2f6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_b77f7b2f-964c-4acf-afa4-32d2f21a1802_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsGross_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsGross" xlink:to="lab_us-gaap_LeaseholdImprovementsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_5e55bc57-e8af-425e-b862-90f5fd691e2e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security12b Title</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_457612f5-5860-44b8-813f-b2f5bc05b50b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market instruments</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_VisirnaTherapeuticsIncMember_e7834fc0-3f3c-47b8-b086-30825f572903_terseLabel_en-US" xlink:label="lab_arwr_VisirnaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visirna Therapeutics, Inc.</link:label>
    <link:label id="lab_arwr_VisirnaTherapeuticsIncMember_label_en-US" xlink:label="lab_arwr_VisirnaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visirna Therapeutics, Inc. [Member]</link:label>
    <link:label id="lab_arwr_VisirnaTherapeuticsIncMember_documentation_en-US" xlink:label="lab_arwr_VisirnaTherapeuticsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Visirna Therapeutics, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaTherapeuticsIncMember" xlink:href="arwr-20230930.xsd#arwr_VisirnaTherapeuticsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_VisirnaTherapeuticsIncMember" xlink:to="lab_arwr_VisirnaTherapeuticsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentEarned_50109631-81bb-4f86-b9dd-1b2a3ec23e48_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment</link:label>
    <link:label id="lab_arwr_MilestonePaymentEarned_label_en-US" xlink:label="lab_arwr_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Earned</link:label>
    <link:label id="lab_arwr_MilestonePaymentEarned_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentEarned" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment earned.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned" xlink:href="arwr-20230930.xsd#arwr_MilestonePaymentEarned"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentEarned" xlink:to="lab_arwr_MilestonePaymentEarned" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d88da177-3a69-4531-9337-f597ffe6a960_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a4f203b1-a92b-4aab-92f2-1c3bec3966e0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_325dceb9-bb3a-46d9-8f82-4af6e2ceb1c4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_a7055c08-a625-4b3a-baa9-97f2183f5de7_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class Of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_ccb1afba-3cfe-4d5a-a062-842e761451c4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a586dec9-4bdf-4404-b19e-6b127601f9df_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_88e16ee0-6128-462c-aba1-7574f1aa5c79_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_21d5347c-50ec-4019-91f0-dec2af62b093_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsDomain" xlink:to="lab_us-gaap_OtherCommitmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DeferredTaxLiabilitiesStateTaxes_93754e84-04f9-4271-8068-d7e5fdd44482_negatedLabel_en-US" xlink:label="lab_arwr_DeferredTaxLiabilitiesStateTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State taxes</link:label>
    <link:label id="lab_arwr_DeferredTaxLiabilitiesStateTaxes_label_en-US" xlink:label="lab_arwr_DeferredTaxLiabilitiesStateTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities State Taxes</link:label>
    <link:label id="lab_arwr_DeferredTaxLiabilitiesStateTaxes_documentation_en-US" xlink:label="lab_arwr_DeferredTaxLiabilitiesStateTaxes" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from state tax deductions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxLiabilitiesStateTaxes" xlink:href="arwr-20230930.xsd#arwr_DeferredTaxLiabilitiesStateTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DeferredTaxLiabilitiesStateTaxes" xlink:to="lab_arwr_DeferredTaxLiabilitiesStateTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_2fe4bb06-a4d7-4a91-9cb1-0439588a021c_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_f3f1d0fb-186f-4af5-ad6a-6a8432f2e72e_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Table]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_label_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Table]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_documentation_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of held to maturity securities and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:href="arwr-20230930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:to="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_4001c971-a65a-4f96-a7b6-c6b632d01b52_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_6a8804d7-47b5-4e40-8af3-3bdca575e396_terseLabel_en-US" xlink:label="lab_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capitalized research and development</link:label>
    <link:label id="lab_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_label_en-US" xlink:label="lab_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets In Process Research And Development Cost</link:label>
    <link:label id="lab_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_documentation_en-US" xlink:label="lab_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:href="arwr-20230930.xsd#arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:to="lab_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OperatingLossCarryforwardsNotSubjectToExpiration_30fa3116-2634-44a0-bd79-c3acf6272ae0_terseLabel_en-US" xlink:label="lab_arwr_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards not subject to expiration</link:label>
    <link:label id="lab_arwr_OperatingLossCarryforwardsNotSubjectToExpiration_label_en-US" xlink:label="lab_arwr_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Not Subject To Expiration</link:label>
    <link:label id="lab_arwr_OperatingLossCarryforwardsNotSubjectToExpiration_documentation_en-US" xlink:label="lab_arwr_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Not Subject To Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:href="arwr-20230930.xsd#arwr_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="lab_arwr_OperatingLossCarryforwardsNotSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_04f3521e-6e62-4b93-be27-22a7bc74aaa9_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_28517318-cf93-45ab-be69-17402b264199_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OlpasiranAgreementMember_188cdf8d-c1e9-4a8c-b747-9fa4a0e20bac_terseLabel_en-US" xlink:label="lab_arwr_OlpasiranAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran Agreement</link:label>
    <link:label id="lab_arwr_OlpasiranAgreementMember_label_en-US" xlink:label="lab_arwr_OlpasiranAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran Agreement [Member]</link:label>
    <link:label id="lab_arwr_OlpasiranAgreementMember_documentation_en-US" xlink:label="lab_arwr_OlpasiranAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Olpasiran agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAgreementMember" xlink:href="arwr-20230930.xsd#arwr_OlpasiranAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OlpasiranAgreementMember" xlink:to="lab_arwr_OlpasiranAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_ebb74d5a-c504-457a-89a0-0fab315cb1f1_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_84aa5918-4f73-4d0e-80ef-0b716604ad8c_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in unrecognized tax benefits expected</link:label>
    <link:label id="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_label_en-US" xlink:label="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:to="lab_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_9f4f462a-6f08-4d87-a1e8-9e177507305a_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_80b24e8b-6b77-49b5-bb4d-92fb17c19de1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets subject to amortization</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_57e19719-328b-47b5-a5e4-3b619a7c4e5c_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_6a4b4a7d-198b-4aa6-afdc-15c4f73ace8d_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_d950c8c3-5733-4692-bcbc-dea2c3937453_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2a43bdc0-9d72-4aff-a636-9ad77539c193_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_c4ff6182-be8c-411c-9458-6a3f22e9a1a5_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable Upon Achievement Of Phase Two And First Patient Dosed In Phase Three</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:href="arwr-20230930.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:to="lab_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFDICInsuredAmount_31ba4fb4-89f1-472b-a656-ab9e44a613c0_terseLabel_en-US" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount insured in FDIC per account</link:label>
    <link:label id="lab_us-gaap_CashFDICInsuredAmount_label_en-US" xlink:label="lab_us-gaap_CashFDICInsuredAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, FDIC Insured Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFDICInsuredAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFDICInsuredAmount" xlink:to="lab_us-gaap_CashFDICInsuredAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_c5c1e0d5-a103-4ea7-b02a-211c6a0056c1_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DrugManufacturingFacilityMember_04d79340-b5b3-4c2e-9ae0-dd719a35c68c_terseLabel_en-US" xlink:label="lab_arwr_DrugManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Manufacturing Facility</link:label>
    <link:label id="lab_arwr_DrugManufacturingFacilityMember_label_en-US" xlink:label="lab_arwr_DrugManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug Manufacturing Facility [Member]</link:label>
    <link:label id="lab_arwr_DrugManufacturingFacilityMember_documentation_en-US" xlink:label="lab_arwr_DrugManufacturingFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Drug manufacturing facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember" xlink:href="arwr-20230930.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DrugManufacturingFacilityMember" xlink:to="lab_arwr_DrugManufacturingFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_7cdb7cc0-0016-4235-b8b5-e8df7f7092ac_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_1686f13b-1c0e-46a9-8121-867fcf4e64c8_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock - restricted stock units vesting (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_080d63ff-4c94-460b-beaf-813c3d0c695a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_4edc9b5c-49aa-49ae-a5fd-982b41b798ba_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2004 Equity Incentive Plan, 2013 Equity Incentive Plan, 2021 Equity Incentive Plan and Inducement Grants</link:label>
    <link:label id="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_label_en-US" xlink:label="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousand Four Equity Incentive Plan Two Thousand Thirteen Equity Incentive Plan Two Thousand Twenty One Equity Incentive Plan And Inducement Grants [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousand four equity incentive plan two thousand thirteen equity incentive plan Two thousand twenty one equity incentive plan and inducement grants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:href="arwr-20230930.xsd#arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:to="lab_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_2f4ebc20-ea4e-4871-a529-0224efb8f9dd_terseLabel_en-US" xlink:label="lab_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease liabilities</link:label>
    <link:label id="lab_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_label_en-US" xlink:label="lab_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Right Of Use Assets Or Lease Liabilities</link:label>
    <link:label id="lab_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_documentation_en-US" xlink:label="lab_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets right of use assets/ lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:href="arwr-20230930.xsd#arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:to="lab_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementsAbstract_951e4644-fd61-409b-a231-798fe80b11a4_terseLabel_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreements [Abstract]</link:label>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration And License Agreements [Abstract]</link:label>
    <link:label id="lab_arwr_CollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:href="arwr-20230930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:to="lab_arwr_CollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_fd07ea30-3096-4e9d-869a-dcb9a08100ab_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation State Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_478f4221-2d42-485c-8f18-eccdd314b4e3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_e997e13b-198c-4ea0-91e1-36cf5cf337d6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_e459aa83-e0d5-401a-9ae7-8e60141830dc_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_7b68b0aa-9dfb-4452-a0ea-8d24407619c1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsLineItems_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsLineItems" xlink:to="lab_us-gaap_OtherCommitmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2c56cf19-0e9f-41b6-8bec-6f7a0ffa8e35_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of the Net Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7e05c407-f42b-4c29-9172-bd59b58e46d0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_ad30103f-b6ec-469d-aaf4-9111f80364b3_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_253e2695-34c1-4b72-9b30-4510715d18e5_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_WilliamWaddillMember_label_en-US" xlink:label="lab_arwr_WilliamWaddillMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">William Waddill [Member]</link:label>
    <link:label id="lab_arwr_WilliamWaddillMember_documentation_en-US" xlink:label="lab_arwr_WilliamWaddillMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">William Waddill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_WilliamWaddillMember" xlink:href="arwr-20230930.xsd#arwr_WilliamWaddillMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_WilliamWaddillMember" xlink:to="lab_arwr_WilliamWaddillMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_59a608e2-c2a8-4426-b1df-caf023f7485c_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_a6b93877-7445-4a9e-bcf4-6077e177f473_terseLabel_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_label_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</link:label>
    <link:label id="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_documentation_en-US" xlink:label="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of held to maturity securities and marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:href="arwr-20230930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:to="lab_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_2b5e6b57-8154-4966-a7c9-2d9fe5d3c022_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_f03bbdba-1cf1-4841-a731-3b03d6178802_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized losses on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_8371418a-da56-484c-848f-2765e5ed8155_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable_d2445f06-e369-4858-a761-957094bb6de9_terseLabel_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:href="arwr-20230930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:to="lab_arwr_OrganizationAndSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_73d45164-8e96-470d-92e9-928c9d438640_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_71b4c9de-e4c3-4593-91ec-e92ce9c3a5d7_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_38b1f133-7e1f-4f91-ae2e-a484b765f9cd_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_0351e7a0-dc58-4dc5-8e9f-2962ccfb9db7_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">California</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_62559a58-e3c8-4c73-9603-3bd8bf3b3d05_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_564f0e12-e968-4c28-b4b5-da6764144bd5_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_b110e2de-bec8-40df-a636-1d6aa92add4e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_f29820f3-9ba3-4773-969d-94538b81edfe_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_9ef87b62-7e13-442b-8732-6baf22137f83_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Permanent and other items</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_a3811810-34e6-4be4-ae9f-0104bc73fc4d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_7fc8ae36-efb7-401e-b327-e3d5159ce07c_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfOptionsToRenew_d26f96b2-0583-4d24-8d68-e8ef93e219b5_terseLabel_en-US" xlink:label="lab_arwr_NumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to renew</link:label>
    <link:label id="lab_arwr_NumberOfOptionsToRenew_label_en-US" xlink:label="lab_arwr_NumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Options To Renew</link:label>
    <link:label id="lab_arwr_NumberOfOptionsToRenew_documentation_en-US" xlink:label="lab_arwr_NumberOfOptionsToRenew" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of options to renew.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfOptionsToRenew" xlink:href="arwr-20230930.xsd#arwr_NumberOfOptionsToRenew"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfOptionsToRenew" xlink:to="lab_arwr_NumberOfOptionsToRenew" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_bad1587f-1be9-446c-981f-43980dbc8fce_terseLabel_en-US" xlink:label="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda</link:label>
    <link:label id="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_label_en-US" xlink:label="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceuticals United States Of America Incorporated [Member]</link:label>
    <link:label id="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_documentation_en-US" xlink:label="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceuticals United States of America Incorporated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:href="arwr-20230930.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:to="lab_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_faeb8042-447d-4610-8a81-14060382f502_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement_c1c02565-9305-44b3-9148-83d1292cba5f_terseLabel_en-US" xlink:label="lab_arwr_TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum state income tax credits under agreement</link:label>
    <link:label id="lab_arwr_TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement_label_en-US" xlink:label="lab_arwr_TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Increment Financing Award, Maximum State Income Tax Credits Under Agreement</link:label>
    <link:label id="lab_arwr_TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement_documentation_en-US" xlink:label="lab_arwr_TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Increment Financing Award, Maximum State Income Tax Credits Under Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement" xlink:href="arwr-20230930.xsd#arwr_TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement" xlink:to="lab_arwr_TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_1ead7c17-c74f-4dcf-be7e-fb7909fd6c37_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_61c42e43-1d75-4fc2-a12d-5ee0a9c257d4_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_5170fe43-56ae-4b86-8e64-0dc656f75a3c_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest in joint venture</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest, Increase from Subsidiary Equity Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:to="lab_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_768f5b41-09c0-42fa-84bf-ba7c5bddda5a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Awards Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_61143fe1-0ef8-440d-9956-dbae53ee150d_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current tax</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2ddd264e-9318-40a3-87a9-54109f925288_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_4087129f-b3b5-4d31-8009-ab373fe01156_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_HorizonTherapeuticsIrelandDACMember_05659e7a-a697-41fb-8f1e-461f16a2a8b0_terseLabel_en-US" xlink:label="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon</link:label>
    <link:label id="lab_arwr_HorizonTherapeuticsIrelandDACMember_label_en-US" xlink:label="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon Therapeutics Ireland D A C [Member]</link:label>
    <link:label id="lab_arwr_HorizonTherapeuticsIrelandDACMember_documentation_en-US" xlink:label="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon Therapeutics Ireland DAC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember" xlink:href="arwr-20230930.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_HorizonTherapeuticsIrelandDACMember" xlink:to="lab_arwr_HorizonTherapeuticsIrelandDACMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6def31bf-15cd-494d-ad23-fa35db823e3f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d7d3ef68-8611-4f2c-929d-8bc29df9204f_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_d3252c24-4035-4267-9bc1-7043e8d1e980_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits costs</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_175c1ded-67a4-4f1c-87c0-e56664e1f68e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_532024a2-4cda-461d-b479-a5984f6b9ef1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares reserve for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_183e01a5-9f80-4b08-bf13-0bcbafc4b3da_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_475acfb3-6dd6-463e-861c-4c47f655c760_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_54c966e0-f3d5-4c05-88f9-cfe1b3d071a5_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_eccd4c8f-905b-4bb6-ac6c-6ce243e8b527_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_844e24b5-6874-496a-9f8f-8dcbeca3b3b0_terseLabel_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related to the Sale of Future Royalties</link:label>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_label_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Text Block]</link:label>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_documentation_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:href="arwr-20230930.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:to="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_eaf4b142-0002-4ebc-91e3-2c8933586197_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JamesHamiltonMember_label_en-US" xlink:label="lab_arwr_JamesHamiltonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">James Hamilton [Member]</link:label>
    <link:label id="lab_arwr_JamesHamiltonMember_documentation_en-US" xlink:label="lab_arwr_JamesHamiltonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">James Hamilton</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JamesHamiltonMember" xlink:href="arwr-20230930.xsd#arwr_JamesHamiltonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JamesHamiltonMember" xlink:to="lab_arwr_JamesHamiltonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_0908f232-1d8b-4fc2-8173-633d74a032dc_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets and Liabilities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:to="lab_us-gaap_AssetsAndLiabilitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_UpfrontMilestonePaymentReceived_504fd9cb-226d-44fc-850e-c88d9963ddb1_terseLabel_en-US" xlink:label="lab_arwr_UpfrontMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront milestone payment received</link:label>
    <link:label id="lab_arwr_UpfrontMilestonePaymentReceived_label_en-US" xlink:label="lab_arwr_UpfrontMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront Milestone Payment Received</link:label>
    <link:label id="lab_arwr_UpfrontMilestonePaymentReceived_documentation_en-US" xlink:label="lab_arwr_UpfrontMilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront milestone payment received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontMilestonePaymentReceived" xlink:href="arwr-20230930.xsd#arwr_UpfrontMilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_UpfrontMilestonePaymentReceived" xlink:to="lab_arwr_UpfrontMilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_7cac57bf-88cf-4bcb-aee5-3b25cd3b8a4d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePayments_2e6e1512-18fa-4390-b2ae-b29c8467db16_verboseLabel_en-US" xlink:label="lab_arwr_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_arwr_MilestonePayments_label_en-US" xlink:label="lab_arwr_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payments</link:label>
    <link:label id="lab_arwr_MilestonePayments_documentation_en-US" xlink:label="lab_arwr_MilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePayments" xlink:href="arwr-20230930.xsd#arwr_MilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePayments" xlink:to="lab_arwr_MilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_90e11e7c-5d1b-4541-a00f-f249bf5eb8d3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 107,312 and 105,960 shares</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_4d4d6498-2040-47b0-affe-e5f776683abc_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. government bonds</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_9cfd9552-7323-469c-9039-2e4bfed5d814_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_056fe8a5-54a1-4ef0-95a6-744bc4491c93_terseLabel_en-US" xlink:label="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash received for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_documentation_en-US" xlink:label="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:href="arwr-20230930.xsd#arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="lab_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_0bee8448-540b-49f6-8eca-468bbe4bdcb4_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TracieOliverMember_label_en-US" xlink:label="lab_arwr_TracieOliverMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tracie Oliver [Member]</link:label>
    <link:label id="lab_arwr_TracieOliverMember_documentation_en-US" xlink:label="lab_arwr_TracieOliverMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tracie Oliver</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TracieOliverMember" xlink:href="arwr-20230930.xsd#arwr_TracieOliverMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TracieOliverMember" xlink:to="lab_arwr_TracieOliverMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_59de0d49-a9fe-48f2-a0b2-7514442af8d8_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_ee3938b9-a628-4de9-a10c-4531b3e0f435_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ebeb8884-2baa-4d07-bc07-023206edb4f8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNet_9a0808ea-cdc5-472b-92ab-964696372ac9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables included in accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet" xlink:to="lab_us-gaap_AccountsReceivableNet" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_d5b7f452-c3e4-44b3-8ff3-d874e79dc145_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplementary disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_b1d3aae2-17ee-46dd-abe6-812596b47297_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Operating Activities, Lessee [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:to="lab_us-gaap_CashFlowOperatingActivitiesLesseeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_906485fe-ac95-4529-836b-d3f2ceeeac07_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, penalties accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_2e32dcff-abd2-43e4-bbff-3886599c71f1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_70f47b4e-b311-4eea-8ed3-593ecb7481c1_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_5debc928-f0ed-458f-bfb5-4db3b785b23c_terseLabel_en-US" xlink:label="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers, software, office equipment and furniture</link:label>
    <link:label id="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_label_en-US" xlink:label="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers Software Office Equipment And Furniture Gross</link:label>
    <link:label id="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_documentation_en-US" xlink:label="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computers, software, office equipment and furniture gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" xlink:href="arwr-20230930.xsd#arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" xlink:to="lab_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_e6d61d7f-6288-4b26-8b29-03f7a917a30f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_b9d0566d-8ac7-449b-85b9-09ddb117d098_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_95cb9579-0e7a-411b-8c58-4fed501ba301_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_label_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties [Abstract]</link:label>
    <link:label id="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_documentation_en-US" xlink:label="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Related To The Sale Of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:href="arwr-20230930.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:to="lab_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_6f9771d4-b7d3-49e3-a367-0cbb1992a05b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_96ce4b60-76de-4d7f-9d1c-fb5dbeea9eef_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity debt securities</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_b873eff0-273c-4650-a9ac-519bda0bd034_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_25e03d9d-646d-4dfc-98a9-15f12b2c1295_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_3ec356ed-cdd2-49fb-9545-463fa89080f2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NovartisMember_c74c0cc4-681e-40b2-a4ab-712faeac319c_terseLabel_en-US" xlink:label="lab_arwr_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis</link:label>
    <link:label id="lab_arwr_NovartisMember_label_en-US" xlink:label="lab_arwr_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis [Member]</link:label>
    <link:label id="lab_arwr_NovartisMember_documentation_en-US" xlink:label="lab_arwr_NovartisMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Novartis.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember" xlink:href="arwr-20230930.xsd#arwr_NovartisMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NovartisMember" xlink:to="lab_arwr_NovartisMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_fb02c77b-4b07-487d-9ed6-907e69a71a11_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, minimum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_6d4df24d-e66b-4a8f-b138-9ff659feb814_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_85427418-795c-4c5f-b831-25852e789e6a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_9c1d648d-e8aa-4dc3-b01a-77a059533f14_negatedTerseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Held to maturity, Gross Unrealized Losses</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_label_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Current</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" xlink:href="arwr-20230930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" xlink:to="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_dc73e5ad-d9c2-4621-a0ff-89b13f93b949_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income taxes, net of federal tax benefit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60d5d60a-1bbc-456f-bff6-9e9882f64ce6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_d4187289-07da-494d-bb14-7ad69628b5f6_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_faf80180-6f18-4e05-91d8-2f2afb7ea1a9_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_f2b5d39f-6dd0-4664-afdd-8dfe10fab890_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_41ca170d-9f66-40e4-98a6-5cf18ebfd787_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OutsideOfEquityCompensationPlansMember_14561dfd-3aa4-4eaa-b8d1-a7a8fd0b3167_terseLabel_en-US" xlink:label="lab_arwr_OutsideOfEquityCompensationPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside Of Equity Compensation Plans</link:label>
    <link:label id="lab_arwr_OutsideOfEquityCompensationPlansMember_label_en-US" xlink:label="lab_arwr_OutsideOfEquityCompensationPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside Of Equity Compensation Plans [Member]</link:label>
    <link:label id="lab_arwr_OutsideOfEquityCompensationPlansMember_documentation_en-US" xlink:label="lab_arwr_OutsideOfEquityCompensationPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outside of equity compensation plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OutsideOfEquityCompensationPlansMember" xlink:href="arwr-20230930.xsd#arwr_OutsideOfEquityCompensationPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OutsideOfEquityCompensationPlansMember" xlink:to="lab_arwr_OutsideOfEquityCompensationPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_IncreaseDecreaseInCashAndInvestments_5ee15d62-e29d-47fd-b600-1bf944ccc2a5_terseLabel_en-US" xlink:label="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase (decrease) in cash and investments</link:label>
    <link:label id="lab_arwr_IncreaseDecreaseInCashAndInvestments_label_en-US" xlink:label="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) In Cash And Investments</link:label>
    <link:label id="lab_arwr_IncreaseDecreaseInCashAndInvestments_documentation_en-US" xlink:label="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase decrease in cash and investments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_IncreaseDecreaseInCashAndInvestments" xlink:href="arwr-20230930.xsd#arwr_IncreaseDecreaseInCashAndInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_IncreaseDecreaseInCashAndInvestments" xlink:to="lab_arwr_IncreaseDecreaseInCashAndInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_50ead3e7-c873-442a-b1bd-9ba3ab806f0b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LicenseAndCoFundingAgreementMember_0760ea2b-b524-41f8-aca3-ae8ec111fd02_terseLabel_en-US" xlink:label="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and Co-Funding Agreement</link:label>
    <link:label id="lab_arwr_LicenseAndCoFundingAgreementMember_label_en-US" xlink:label="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License And Co Funding Agreement [Member]</link:label>
    <link:label id="lab_arwr_LicenseAndCoFundingAgreementMember_documentation_en-US" xlink:label="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License and co-funding agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember" xlink:href="arwr-20230930.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LicenseAndCoFundingAgreementMember" xlink:to="lab_arwr_LicenseAndCoFundingAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_ebf69a88-6e4e-4dd9-b044-2247050c5c97_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_bd4ba22a-c150-4ea2-b3f6-b33c15d4fad5_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_0d977e75-b65b-4e66-b8df-603ad7ba1064_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets Future Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_f9a71c03-e970-4933-b3a2-d63685fca6a3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale securities, at fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_ca927fd9-d359-4c43-ae71-627c9ecf19ff_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Available-for-sale, Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AreaOfLand_10d1b49b-0c3c-4e97-a138-0e8b9cf3ea86_terseLabel_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Planned area of site (in sq ft)</link:label>
    <link:label id="lab_us-gaap_AreaOfLand_label_en-US" xlink:label="lab_us-gaap_AreaOfLand" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Area of Land</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AreaOfLand" xlink:to="lab_us-gaap_AreaOfLand" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_495b02f3-443c-4f66-b45b-487321c96e32_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Held to maturity, Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" xlink:to="lab_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_fc26a551-1477-4b03-a007-d92318019506_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization expense for property and equipment</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_d7f4b3d4-e977-4f97-82fd-3ffa69397f6e_terseLabel_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:href="arwr-20230930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:to="lab_arwr_OrganizationAndSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AtTheMarketAgreementMember_7922e858-6362-43c2-8b3e-03e80132ec69_terseLabel_en-US" xlink:label="lab_arwr_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ATM Agreement</link:label>
    <link:label id="lab_arwr_AtTheMarketAgreementMember_label_en-US" xlink:label="lab_arwr_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At The Market Agreement [Member]</link:label>
    <link:label id="lab_arwr_AtTheMarketAgreementMember_documentation_en-US" xlink:label="lab_arwr_AtTheMarketAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">At-the-market agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AtTheMarketAgreementMember" xlink:href="arwr-20230930.xsd#arwr_AtTheMarketAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AtTheMarketAgreementMember" xlink:to="lab_arwr_AtTheMarketAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CorporateHeadquartersInPasadenaMember_ad64b00e-0e60-43aa-9936-4c0d9d7c336d_terseLabel_en-US" xlink:label="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Headquarters In Pasadena</link:label>
    <link:label id="lab_arwr_CorporateHeadquartersInPasadenaMember_label_en-US" xlink:label="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Headquarters In Pasadena [Member]</link:label>
    <link:label id="lab_arwr_CorporateHeadquartersInPasadenaMember_documentation_en-US" xlink:label="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Headquarters in Pasadena</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CorporateHeadquartersInPasadenaMember" xlink:href="arwr-20230930.xsd#arwr_CorporateHeadquartersInPasadenaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CorporateHeadquartersInPasadenaMember" xlink:to="lab_arwr_CorporateHeadquartersInPasadenaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_e91e9150-dda9-4c0f-981d-f5e618020730_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_412ad254-537e-4ec7-968c-b0bbf33fe7a9_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Arrowhead Pharmaceuticals, Inc. stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_11f8bb6b-c89c-4d3c-bd14-e616f8c71568_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits that would impact effective tax rate</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_aab8bb2b-edb8-4162-ae9a-f619a643e861_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Finite Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_d163c1dd-f6a3-4642-91bf-103f03e60f54_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_b4df00a0-f193-433d-8d6e-0c7931b9a368_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfDistinctBundle_6eceb8a7-1c05-476d-ac36-29a99b1eadfa_terseLabel_en-US" xlink:label="lab_arwr_NumberOfDistinctBundle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct bundle</link:label>
    <link:label id="lab_arwr_NumberOfDistinctBundle_label_en-US" xlink:label="lab_arwr_NumberOfDistinctBundle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Distinct Bundle</link:label>
    <link:label id="lab_arwr_NumberOfDistinctBundle_documentation_en-US" xlink:label="lab_arwr_NumberOfDistinctBundle" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of distinct bundle.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle" xlink:href="arwr-20230930.xsd#arwr_NumberOfDistinctBundle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfDistinctBundle" xlink:to="lab_arwr_NumberOfDistinctBundle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_8fc9da62-66fc-4330-bfaa-ad2303d6e1ef_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RoyaltyPaymentThreshold_c261b0c7-51a4-440e-aa64-214619cb2df4_terseLabel_en-US" xlink:label="lab_arwr_RoyaltyPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty payment threshold</link:label>
    <link:label id="lab_arwr_RoyaltyPaymentThreshold_label_en-US" xlink:label="lab_arwr_RoyaltyPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Payment Threshold</link:label>
    <link:label id="lab_arwr_RoyaltyPaymentThreshold_documentation_en-US" xlink:label="lab_arwr_RoyaltyPaymentThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Payment Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPaymentThreshold" xlink:href="arwr-20230930.xsd#arwr_RoyaltyPaymentThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RoyaltyPaymentThreshold" xlink:to="lab_arwr_RoyaltyPaymentThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AmountIntendedToInvestForBuildoutOfFacilities_ed542a7e-f04c-490b-a618-ec5733cbd9c3_terseLabel_en-US" xlink:label="lab_arwr_AmountIntendedToInvestForBuildoutOfFacilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount intended to invest for buildout of facilities</link:label>
    <link:label id="lab_arwr_AmountIntendedToInvestForBuildoutOfFacilities_label_en-US" xlink:label="lab_arwr_AmountIntendedToInvestForBuildoutOfFacilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount Intended To Invest For Buildout Of Facilities</link:label>
    <link:label id="lab_arwr_AmountIntendedToInvestForBuildoutOfFacilities_documentation_en-US" xlink:label="lab_arwr_AmountIntendedToInvestForBuildoutOfFacilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount intends to invest for buildout of facilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmountIntendedToInvestForBuildoutOfFacilities" xlink:href="arwr-20230930.xsd#arwr_AmountIntendedToInvestForBuildoutOfFacilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AmountIntendedToInvestForBuildoutOfFacilities" xlink:to="lab_arwr_AmountIntendedToInvestForBuildoutOfFacilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d9915780-05db-499c-90a4-d95ba73d0840_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_6a3f730c-5084-4190-a7f4-ac6c1c4096e1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_3b1cda13-3577-40c2-af0a-a7fe6535a375_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FacilitiesMember_393d0c1b-65c6-4d79-963e-7439e20749ec_terseLabel_en-US" xlink:label="lab_arwr_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities</link:label>
    <link:label id="lab_arwr_FacilitiesMember_label_en-US" xlink:label="lab_arwr_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities [Member]</link:label>
    <link:label id="lab_arwr_FacilitiesMember_documentation_en-US" xlink:label="lab_arwr_FacilitiesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Facilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FacilitiesMember" xlink:href="arwr-20230930.xsd#arwr_FacilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FacilitiesMember" xlink:to="lab_arwr_FacilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_6bcbf8d6-1699-4ecc-937a-582d42486c88_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Stock By Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dcec6f19-dd91-438c-af8f-9f3522a19237_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_b246eb02-e680-4e74-816f-2492d73e3cf4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_ea73cbf6-0169-4239-8787-32a73472d80b_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss before income tax expense and noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_2f84b4ce-a32f-4db4-9170-fb62f828f191_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to Arrowhead Pharmaceuticals, Inc.:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f31932ca-03ac-4331-95a0-bc0d403b5310_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_11f76fbd-d4fe-4806-9baf-4eaddb254582_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_8bd9c7b2-b1fb-46a4-8fff-7feafc495dfa_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock_14ebf5c6-0659-41e6-b0ea-c9b79f8f4e8e_terseLabel_en-US" xlink:label="lab_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation and Use of Estimates</link:label>
    <link:label id="lab_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock_label_en-US" xlink:label="lab_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis Of Presentation And Use Of Estimates Policy [Policy Text Block]</link:label>
    <link:label id="lab_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation and use of estimates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" xlink:href="arwr-20230930.xsd#arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" xlink:to="lab_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_7849aa7c-0a85-46c0-b2d2-43b61b0d00c1_terseLabel_en-US" xlink:label="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash interest expense on liability related to the sale of future royalties</link:label>
    <link:label id="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_label_en-US" xlink:label="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Expense, Liability Related to Sale of Future Royalties</link:label>
    <link:label id="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_documentation_en-US" xlink:label="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Cash Interest Expense, Liability Related to Sale of Future Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:href="arwr-20230930.xsd#arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:to="lab_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_8728ab82-10a4-4ce3-9d5c-9336ca1cd79a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_730d5c78-c2b8-4fe6-99d8-e8611c4ec609_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_RoyaltyPharmaAgreementMember_e291a49f-1926-4f8a-9c64-b1b3dfee4d4d_terseLabel_en-US" xlink:label="lab_arwr_RoyaltyPharmaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma Agreement</link:label>
    <link:label id="lab_arwr_RoyaltyPharmaAgreementMember_label_en-US" xlink:label="lab_arwr_RoyaltyPharmaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma Agreement [Member]</link:label>
    <link:label id="lab_arwr_RoyaltyPharmaAgreementMember_documentation_en-US" xlink:label="lab_arwr_RoyaltyPharmaAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Pharma Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaAgreementMember" xlink:href="arwr-20230930.xsd#arwr_RoyaltyPharmaAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_RoyaltyPharmaAgreementMember" xlink:to="lab_arwr_RoyaltyPharmaAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_1642a96b-55bc-4814-87c3-c969cf5be7cc_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_8ab76577-a39a-4e7a-aabd-ffdbd68f133d_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_CommonStockPurchaseAgreementMember_866e959d-f9b1-4308-96c1-b15cc6459c77_terseLabel_en-US" xlink:label="lab_arwr_CommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchase Agreement</link:label>
    <link:label id="lab_arwr_CommonStockPurchaseAgreementMember_label_en-US" xlink:label="lab_arwr_CommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_arwr_CommonStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_arwr_CommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockPurchaseAgreementMember" xlink:href="arwr-20230930.xsd#arwr_CommonStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_CommonStockPurchaseAgreementMember" xlink:to="lab_arwr_CommonStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_da13bf54-2dbf-4f1a-a0dc-9732652fe267_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities_351ab666-63e5-4c12-9fd4-5e2822694f10_terseLabel_en-US" xlink:label="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities_label_en-US" xlink:label="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cash Received For Amounts Included In Measurement Of Lease Liabilities</link:label>
    <link:label id="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities_documentation_en-US" xlink:label="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cash Received For Amounts Included In Measurement Of Lease Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:href="arwr-20230930.xsd#arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:to="lab_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_a48bd434-5caa-46be-a4c2-91991b06e102_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7dee7a5d-e002-471f-a023-d900fb104feb_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Useful Lives</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_cd453009-7055-41b2-8a0f-68f8c651f893_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_c0db1cf2-2ce2-45c1-abaf-24de80ef3f20_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b4c486ca-3eaf-42e7-b05f-6d59bee8bc77_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_476da74c-3553-4ea1-b51a-9361f2973818_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_d2932df6-1492-4514-aab3-4e2887d080af_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_VeronaTechnologyParkMember_357bb792-67cd-4341-984a-c2a4ee66a19e_terseLabel_en-US" xlink:label="lab_arwr_VeronaTechnologyParkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verona Technology Park</link:label>
    <link:label id="lab_arwr_VeronaTechnologyParkMember_label_en-US" xlink:label="lab_arwr_VeronaTechnologyParkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verona Technology Park [Member]</link:label>
    <link:label id="lab_arwr_VeronaTechnologyParkMember_documentation_en-US" xlink:label="lab_arwr_VeronaTechnologyParkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verona technology park.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VeronaTechnologyParkMember" xlink:href="arwr-20230930.xsd#arwr_VeronaTechnologyParkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_VeronaTechnologyParkMember" xlink:to="lab_arwr_VeronaTechnologyParkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_69d391f2-4d3b-471e-9d63-c74eb84da849_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_c0ad7b4f-5961-4633-ad54-860dd97d202f_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_6705fa75-5785-4803-af30-526269801a2e_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_afd9d182-18d5-444f-bc19-541484ea5952_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AmgenIncorporatedMember_d63f0483-8aeb-4741-9867-1777bc148406_terseLabel_en-US" xlink:label="lab_arwr_AmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen</link:label>
    <link:label id="lab_arwr_AmgenIncorporatedMember_label_en-US" xlink:label="lab_arwr_AmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen Incorporated [Member]</link:label>
    <link:label id="lab_arwr_AmgenIncorporatedMember_documentation_en-US" xlink:label="lab_arwr_AmgenIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amgen Incorporated.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember" xlink:href="arwr-20230930.xsd#arwr_AmgenIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AmgenIncorporatedMember" xlink:to="lab_arwr_AmgenIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6553189d-c200-4754-b7f8-de97a6243ddb_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_c47cef9d-727d-4164-bb18-016da8d4c41e_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6b0a5b91-ce12-4629-831a-d351f9e90e8b_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total noncontrolling interest and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_63917e5b-435d-4ea8-b91c-2b2cbcbc77a3_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_821953fd-b020-4760-9ef8-e616b714ecfe_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_65827d70-54b7-488a-ad5b-a63fc1f48469_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_5f2c6f0d-ebab-4bbc-8f73-31bfecc8d2c4_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense related to uncertain tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_5765c2de-3db9-4ff7-adc4-49988d1c4217_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_76b3a65a-6faa-420e-a1f1-f12a15283c65_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_e5f8a966-4e30-403c-8e18-d5711046a14b_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_d75da1b0-b1ac-45bc-bfaf-b8161f59096b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summarized Information about Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_e8d2424f-8ef9-43df-a11d-af879f1e22e1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_e7a1cf22-5fe5-4960-9ec5-baf1ec472ff4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_192a1485-97d5-49b4-8ebe-9ed10c900c55_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_37fa2d0e-4c6c-4d19-a23c-c5d7d98932fd_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_c5650e5d-375f-471c-82d0-b71dfd3ce30f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_964283c3-33d2-4d01-8f7f-c5003f535364_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_25380215-34ba-4479-973b-25bc85770efe_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProfitLoss_ae28a41d-f245-498a-b452-014134cc49d3_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss including noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_f63ac759-161e-4110-bfcb-d49a76cd4d33_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_432418d5-5ff6-4c16-b9d5-c1bb34682bca_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss including noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_label_en-US" xlink:label="lab_us-gaap_ProfitLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss" xlink:to="lab_us-gaap_ProfitLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_181910c5-ea69-4d08-bc7a-c2bc04cb91f0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5fb8e66e-75e8-4437-8fb0-24bffd9c2a5a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_c36b705f-5018-434f-9e7e-0dfc49c296d3_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_57804ffb-613e-4377-84b9-8e2807188446_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee Lease Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_c6a5dfc1-7281-4824-8c27-e3bcd9d3611c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_OperatingLossCarryforwardsSubjectToExpiration_03d18a64-b516-416d-91db-cb3a34c70691_terseLabel_en-US" xlink:label="lab_arwr_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss carryforwards subject to expiration</link:label>
    <link:label id="lab_arwr_OperatingLossCarryforwardsSubjectToExpiration_label_en-US" xlink:label="lab_arwr_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Subject To Expiration</link:label>
    <link:label id="lab_arwr_OperatingLossCarryforwardsSubjectToExpiration_documentation_en-US" xlink:label="lab_arwr_OperatingLossCarryforwardsSubjectToExpiration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Subject To Expiration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OperatingLossCarryforwardsSubjectToExpiration" xlink:href="arwr-20230930.xsd#arwr_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_OperatingLossCarryforwardsSubjectToExpiration" xlink:to="lab_arwr_OperatingLossCarryforwardsSubjectToExpiration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_a48ac1e0-ecf2-4a5d-8031-1ea652b98bce_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_fc8846d3-7996-48cb-aef9-4e542fb1bbca_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Liabilities, Noncontrolling Interest and Stockholders' Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_b163f976-8176-426a-bba6-bf9461698e78_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable debt securities, Adjusted Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_432d83f0-ba6c-4174-a586-36f7efab9b34_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_b00c060d-6277-4b62-94fe-5987e62f4c06_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_08ca5502-b0e5-4c34-a35c-7ca0bbe77cd6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_0074c825-fa71-44a3-aa35-f96c7adcfaac_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_7f3fc107-6e5c-4031-9263-71dfe7fa082a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized pre-tax compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_b29e0b93-9a69-4957-b103-ce821e64dfd5_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponFDAApproval_8a3f737d-609d-492f-9a2a-f9f0ed86d518_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable upon FDA approval</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponFDAApproval_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable Upon FDA Approval</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponFDAApproval_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable Upon FDA Approval</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:href="arwr-20230930.xsd#arwr_MilestonePaymentReceivableUponFDAApproval"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:to="lab_arwr_MilestonePaymentReceivableUponFDAApproval" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_ce4b4bcd-5530-4808-8e2f-d94d3d6e19fe_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_585204b3-201a-4ac3-8c41-eebb57adc4c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_5c00fe28-c120-499e-a2ca-bf66a1ceb309_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0ac82ccf-84b2-4b95-8e4a-b4b6c9d46cd1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Volatility, maximum</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_429eb11a-e5d3-4161-a47a-cf27d5e18217_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred tax assets (liabilities)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_c2352d34-2c9f-490c-bd31-7a0d1e1404d7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_9400074c-a75d-47b0-b673-ce44192cb57f_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable Upon Achievement of Enrollment in Phase 3 Clinical Trial</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable Upon Achievement of Enrollment in Phase 3 Clinical Trial</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:href="arwr-20230930.xsd#arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:to="lab_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_c5cedcc4-c0b4-4ef3-bcd2-0c87675812ff_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetsImpairment_1bfe75fb-3cfb-4486-98d2-386a0336c726_terseLabel_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetsImpairment_label_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Impairment</link:label>
    <link:label id="lab_arwr_FiniteLivedIntangibleAssetsImpairment_documentation_en-US" xlink:label="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Impairment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:href="arwr-20230930.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:to="lab_arwr_FiniteLivedIntangibleAssetsImpairment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_e2bb702c-5291-4232-a17b-be87bad4eaf2_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity securities, at amortized cost</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_6337e4a4-e899-40d6-af5a-a385ac3c6642_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments, Held to maturity, Adjusted Basis</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_45386f06-df0c-403c-9419-56a0f0ebb61d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State income tax credits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_8eb0551a-a850-4e59-bbc5-0ff959511e6b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesNoncurrent" xlink:to="lab_us-gaap_LiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_2154ea5e-0b74-41b5-9b9d-1b6729d16e73_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceived_b6c25e0e-2b4f-4076-b2d6-4e2baece25cf_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payments</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceived_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Received</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceived_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment received.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceived" xlink:href="arwr-20230930.xsd#arwr_MilestonePaymentReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceived" xlink:to="lab_arwr_MilestonePaymentReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_TwoThousandsFourEquityIncentivePlanMember_d4a80bd1-c067-4b3e-b9cd-7a2f48c7f6a1_terseLabel_en-US" xlink:label="lab_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2004 Plan</link:label>
    <link:label id="lab_arwr_TwoThousandsFourEquityIncentivePlanMember_label_en-US" xlink:label="lab_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two Thousands Four Equity Incentive Plan [Member]</link:label>
    <link:label id="lab_arwr_TwoThousandsFourEquityIncentivePlanMember_documentation_en-US" xlink:label="lab_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Two thousands four equity incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:href="arwr-20230930.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:to="lab_arwr_TwoThousandsFourEquityIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchEquipmentGross_003ee8be-268c-49c2-9b4a-83dfa7dd5925_terseLabel_en-US" xlink:label="lab_arwr_ResearchEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research equipment</link:label>
    <link:label id="lab_arwr_ResearchEquipmentGross_label_en-US" xlink:label="lab_arwr_ResearchEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Equipment Gross</link:label>
    <link:label id="lab_arwr_ResearchEquipmentGross_documentation_en-US" xlink:label="lab_arwr_ResearchEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research equipment gross.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentGross" xlink:href="arwr-20230930.xsd#arwr_ResearchEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchEquipmentGross" xlink:to="lab_arwr_ResearchEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_c69a0c76-7df7-4890-a666-359c77b44210_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_87c0a1af-a465-4ddf-864a-4f94bca7a1a7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_02230a21-447e-4ba1-8271-f578ff580b59_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_ad8ee1e1-85c3-4bb8-a811-26bd43fc9eb8_terseLabel_en-US" xlink:label="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of eligible to receive tiered royalties on net sales</link:label>
    <link:label id="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_label_en-US" xlink:label="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Eligible To Receive Tiered Royalties On Net Sales</link:label>
    <link:label id="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_documentation_en-US" xlink:label="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of eligible to receive tiered royalties on net sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:href="arwr-20230930.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:to="lab_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_EmployeeContributionsUpToThreePercentMember_37285364-e993-4a4a-920a-c9ea38da206d_terseLabel_en-US" xlink:label="lab_arwr_EmployeeContributionsUpToThreePercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Contributions up to 3%</link:label>
    <link:label id="lab_arwr_EmployeeContributionsUpToThreePercentMember_label_en-US" xlink:label="lab_arwr_EmployeeContributionsUpToThreePercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Contributions Up To Three Percent [Member]</link:label>
    <link:label id="lab_arwr_EmployeeContributionsUpToThreePercentMember_documentation_en-US" xlink:label="lab_arwr_EmployeeContributionsUpToThreePercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee contributions up to three percent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EmployeeContributionsUpToThreePercentMember" xlink:href="arwr-20230930.xsd#arwr_EmployeeContributionsUpToThreePercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_EmployeeContributionsUpToThreePercentMember" xlink:to="lab_arwr_EmployeeContributionsUpToThreePercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfAcresOfLandPurchased_628c8c19-be33-463d-b9eb-20406443046c_terseLabel_en-US" xlink:label="lab_arwr_NumberOfAcresOfLandPurchased" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land purchased (in acres)</link:label>
    <link:label id="lab_arwr_NumberOfAcresOfLandPurchased_label_en-US" xlink:label="lab_arwr_NumberOfAcresOfLandPurchased" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Acres Of Land Purchased</link:label>
    <link:label id="lab_arwr_NumberOfAcresOfLandPurchased_documentation_en-US" xlink:label="lab_arwr_NumberOfAcresOfLandPurchased" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of acres of land purchased.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAcresOfLandPurchased" xlink:href="arwr-20230930.xsd#arwr_NumberOfAcresOfLandPurchased"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfAcresOfLandPurchased" xlink:to="lab_arwr_NumberOfAcresOfLandPurchased" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_4aff229f-7781-41d2-b050-b92d83eb5c11_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0fd4eaee-244a-4b67-89b1-6c47d4af50b1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_775f623d-ff9a-43e2-82a4-b0186148cb37_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_EmployeeContributionNextTwoPercentMember_699a44ac-c325-4b7f-887a-deebfe654b1a_terseLabel_en-US" xlink:label="lab_arwr_EmployeeContributionNextTwoPercentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Contributions Next 2%</link:label>
    <link:label id="lab_arwr_EmployeeContributionNextTwoPercentMember_label_en-US" xlink:label="lab_arwr_EmployeeContributionNextTwoPercentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Contribution Next Two Percent [Member]</link:label>
    <link:label id="lab_arwr_EmployeeContributionNextTwoPercentMember_documentation_en-US" xlink:label="lab_arwr_EmployeeContributionNextTwoPercentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee contribution next two percent.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EmployeeContributionNextTwoPercentMember" xlink:href="arwr-20230930.xsd#arwr_EmployeeContributionNextTwoPercentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_EmployeeContributionNextTwoPercentMember" xlink:to="lab_arwr_EmployeeContributionNextTwoPercentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_081d2288-9ef1-4f65-b973-33a5b09ec2f7_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash flow from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_fe397385-5d6b-4c17-a93c-7145ad193f94_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_2a3d89a4-6c19-44b4-b60b-87fa5d7392db_totalLabel_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total (in shares)</link:label>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_label_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding</link:label>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_documentation_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:href="arwr-20230930.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:to="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_184172e2-72f9-4627-b426-8bb0c41cc912_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnInvestments_e85322c1-ec21-4a0f-9c8c-55d314dd3a16_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss (gain) from investments</link:label>
    <link:label id="lab_us-gaap_GainLossOnInvestments_label_en-US" xlink:label="lab_us-gaap_GainLossOnInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnInvestments" xlink:to="lab_us-gaap_GainLossOnInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_a241e92a-5790-4145-8850-eb5ce31299eb_negatedTerseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments, Held to maturity, Gross Unrealized Losses</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_label_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Noncurrent</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" xlink:href="arwr-20230930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" xlink:to="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_c743d0d5-06c2-4cbf-9e5a-5a0cfd27d8e7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherCommitmentsAxis_label_en-US" xlink:label="lab_us-gaap_OtherCommitmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Commitments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCommitmentsAxis" xlink:to="lab_us-gaap_OtherCommitmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MauroFerrariMember_label_en-US" xlink:label="lab_arwr_MauroFerrariMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mauro Ferrari [Member]</link:label>
    <link:label id="lab_arwr_MauroFerrariMember_documentation_en-US" xlink:label="lab_arwr_MauroFerrariMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Mauro Ferrari</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MauroFerrariMember" xlink:href="arwr-20230930.xsd#arwr_MauroFerrariMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MauroFerrariMember" xlink:to="lab_arwr_MauroFerrariMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_490d5b4b-ebf4-48a6-85e9-5e845b66bbc1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_e08172af-6e28-413c-b1db-5a3829d9198c_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock - restricted stock units vesting</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Restricted Stock Award, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_d4fd02a5-20aa-4999-b62e-afd87b115f32_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Leasing Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_0e5da1de-464d-4aa8-9953-5aa43b07f3c4_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred tax</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_cf2b431f-c685-4cec-8094-484e7c1c4302_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercises of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_3c8d9180-c7e4-4cd6-8271-199e1f65f12e_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementAccountingPolicy_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Accounting Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:to="lab_us-gaap_CollaborativeArrangementAccountingPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_40c089cf-b308-4c84-9650-eff00c457d41_terseLabel_en-US" xlink:label="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK</link:label>
    <link:label id="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_label_en-US" xlink:label="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxosmithkline Intellectual Property Limited [Member]</link:label>
    <link:label id="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_documentation_en-US" xlink:label="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxosmithkline Intellectual Property Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:href="arwr-20230930.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:to="lab_arwr_GlaxosmithklineIntellectualPropertyLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_bb2eeefa-400b-42d6-82a6-6ebb854318df_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_4e4533ac-8208-40ea-be14-82d1851e6a9e_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_b8864d99-c021-41c8-92a5-3237cea3e1a1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_5c927486-ddd0-47ee-adcb-61812f98da2f_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ColoradoOwnerLLCMember_c48bc8cc-9476-445b-96b8-eb80db263ca8_terseLabel_en-US" xlink:label="lab_arwr_ColoradoOwnerLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Colorado Owner, LLC</link:label>
    <link:label id="lab_arwr_ColoradoOwnerLLCMember_label_en-US" xlink:label="lab_arwr_ColoradoOwnerLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Colorado Owner L L C [Member]</link:label>
    <link:label id="lab_arwr_ColoradoOwnerLLCMember_documentation_en-US" xlink:label="lab_arwr_ColoradoOwnerLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Colorado Owner, LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ColoradoOwnerLLCMember" xlink:href="arwr-20230930.xsd#arwr_ColoradoOwnerLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ColoradoOwnerLLCMember" xlink:to="lab_arwr_ColoradoOwnerLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_f4e42887-5bce-4fa4-a6ef-1a99b4c5b72c_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal securities</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_221a36b3-fa46-47da-9ee5-ab93a986cc4a_terseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Available-for-sale, Gross Unrealized Gains</link:label>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_label_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Current</link:label>
    <link:label id="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" xlink:href="arwr-20230930.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" xlink:to="lab_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_b14d1e62-74ba-4261-a7ce-db7776ae22e5_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of compensation</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="lab_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_476ae74c-1f32-4bb0-b3fa-af291ec70da2_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_IncomeLossAttributableToParent_label_en-US" xlink:label="lab_us-gaap_IncomeLossAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) Attributable to Parent, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossAttributableToParent" xlink:to="lab_us-gaap_IncomeLossAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_NumberOfAgreements_7cb343b6-dff0-4cff-92a2-bf170352d556_terseLabel_en-US" xlink:label="lab_arwr_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of agreements</link:label>
    <link:label id="lab_arwr_NumberOfAgreements_label_en-US" xlink:label="lab_arwr_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Agreements</link:label>
    <link:label id="lab_arwr_NumberOfAgreements_documentation_en-US" xlink:label="lab_arwr_NumberOfAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAgreements" xlink:href="arwr-20230930.xsd#arwr_NumberOfAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_NumberOfAgreements" xlink:to="lab_arwr_NumberOfAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_09ae624d-8e86-4158-84c1-a758c48a9eab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_661463c2-b417-472e-9dd0-a6c41d3bca21_terseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Held to maturity, Gross Unrealized Gains</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_label_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Current</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" xlink:href="arwr-20230930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" xlink:to="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JNJ3989AROHBVAgreementMember_5e8eb8e8-cb86-42af-a474-17f6c7318657_terseLabel_en-US" xlink:label="lab_arwr_JNJ3989AROHBVAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JNJ-3989 Agreement</link:label>
    <link:label id="lab_arwr_JNJ3989AROHBVAgreementMember_label_en-US" xlink:label="lab_arwr_JNJ3989AROHBVAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">J N J3989 A R O H B V Agreement [Member]</link:label>
    <link:label id="lab_arwr_JNJ3989AROHBVAgreementMember_documentation_en-US" xlink:label="lab_arwr_JNJ3989AROHBVAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JNJ-3989 (ARO-HBV) Agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ3989AROHBVAgreementMember" xlink:href="arwr-20230930.xsd#arwr_JNJ3989AROHBVAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JNJ3989AROHBVAgreementMember" xlink:to="lab_arwr_JNJ3989AROHBVAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_932edd71-0081-4ac6-9899-a2f62ae79d76_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_dba54d8a-2060-4ec0-9fa4-7e292af73c0f_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MaximumAdditionalTenantImprovementAllowance_e149457c-25f2-4604-b3ef-319609f4cbf9_terseLabel_en-US" xlink:label="lab_arwr_MaximumAdditionalTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum additional tenant improvement allowance</link:label>
    <link:label id="lab_arwr_MaximumAdditionalTenantImprovementAllowance_label_en-US" xlink:label="lab_arwr_MaximumAdditionalTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Additional Tenant Improvement Allowance</link:label>
    <link:label id="lab_arwr_MaximumAdditionalTenantImprovementAllowance_documentation_en-US" xlink:label="lab_arwr_MaximumAdditionalTenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Additional Tenant Improvement Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MaximumAdditionalTenantImprovementAllowance" xlink:href="arwr-20230930.xsd#arwr_MaximumAdditionalTenantImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MaximumAdditionalTenantImprovementAllowance" xlink:to="lab_arwr_MaximumAdditionalTenantImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_e4360c21-d986-49f5-8ecb-83dcd0d27454_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MinorityInterest_89f0897a-c2bc-4ffd-b043-993ed9a88aa8_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_label_en-US" xlink:label="lab_us-gaap_MinorityInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest" xlink:to="lab_us-gaap_MinorityInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_d0055d71-8713-4ecc-9bb7-34d1323dd311_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_a03bab52-0b2c-4b84-a026-bf44dc7a70fb_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_bcf56077-51e2-494f-8046-2a39ba37de55_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_cdaf6918-65f1-4ef6-a420-ad3cd5735528_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_c1b60bed-9af3-4728-b3db-6c3c70cd7b6a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c7c80aff-704e-4e5e-9242-fe0c9387abf4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_AROENacAndAROHIF2CandidatesMember_98172094-b1a8-4bd4-b3ac-6cdabc8fb694_terseLabel_en-US" xlink:label="lab_arwr_AROENacAndAROHIF2CandidatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARO-ENaC and ARO-HIF2 Candidates</link:label>
    <link:label id="lab_arwr_AROENacAndAROHIF2CandidatesMember_label_en-US" xlink:label="lab_arwr_AROENacAndAROHIF2CandidatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">A R O E Nac And A R O H I F2 Candidates [Member]</link:label>
    <link:label id="lab_arwr_AROENacAndAROHIF2CandidatesMember_documentation_en-US" xlink:label="lab_arwr_AROENacAndAROHIF2CandidatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ARO-ENac and ARO-HIF2 Candidates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROENacAndAROHIF2CandidatesMember" xlink:href="arwr-20230930.xsd#arwr_AROENacAndAROHIF2CandidatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_AROENacAndAROHIF2CandidatesMember" xlink:to="lab_arwr_AROENacAndAROHIF2CandidatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_3d635aa1-d462-45e7-b02f-caa1fca98c98_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_cb2d76a2-e4a6-4840-8918-99af43d683bd_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent liabilities</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_3f591228-fb2c-4847-8089-b1c6f5c7a1d8_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_2f33429a-e3dc-4daf-9c9c-3f1dd61884d2_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_4aca94d4-b8f1-415f-954b-0bd237646807_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Carrying Amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_8c5db371-3aaa-423d-9b07-2123f7d2f884_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_42a21d38-e0b9-4431-9af3-1c6d1af78e8c_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_572629d6-e733-49a5-8434-27bef7b62eec_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_adc098cd-cf9c-4bdc-b8c2-9e32983e80ae_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued payroll and benefits</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_69f5153f-d417-429e-8a85-603362e0d639_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_c362f055-c55a-4cc0-8e39-d469fb588cdd_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable upon receipt of royalty payments</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable, Upon Receipt Of Royalty Payments</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable, Upon Receipt Of Royalty Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:href="arwr-20230930.xsd#arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:to="lab_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_ff935099-dec1-41b4-8685-bddf98924ada_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_446f05ac-20f5-4bf4-92a2-6276188b4977_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_482f1dc6-f655-479f-8324-6c573c81867a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_60d20994-696b-422c-a25f-f190ca2c6f2c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ed4a5295-6f92-48c6-9ba6-1b658a6f6c8a_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_9dcec0bf-2ba0-4eb6-b988-23f531d1fa75_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_024ffb38-a59d-4f21-bbb8-28553de23796_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_9b2d8579-edda-4208-9f60-a58106691649_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market instruments</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_1c5e5867-89e7-4595-b7e8-5a4c3656626e_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_KenMyszkowskiMember_label_en-US" xlink:label="lab_arwr_KenMyszkowskiMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ken Myszkowski [Member]</link:label>
    <link:label id="lab_arwr_KenMyszkowskiMember_documentation_en-US" xlink:label="lab_arwr_KenMyszkowskiMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ken Myszkowski</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_KenMyszkowskiMember" xlink:href="arwr-20230930.xsd#arwr_KenMyszkowskiMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_KenMyszkowskiMember" xlink:to="lab_arwr_KenMyszkowskiMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_e1bae36a-43c2-4b9e-a295-02308a52aba6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_c4f18c44-c381-4f8c-90c9-98f87b699f52_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_666c8b6b-af20-4e5b-b204-8ec0d02961f3_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember" xlink:to="lab_us-gaap_LicensingAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_1b5b73bd-1259-471c-9d24-c7a55c33f0d5_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_5347f436-630b-403c-b7cf-5dcda1394c30_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JamesHamiltonAugust2023PlanMember_label_en-US" xlink:label="lab_arwr_JamesHamiltonAugust2023PlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">James Hamilton August 2023 Plan [Member]</link:label>
    <link:label id="lab_arwr_JamesHamiltonAugust2023PlanMember_documentation_en-US" xlink:label="lab_arwr_JamesHamiltonAugust2023PlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">James Hamilton August 2023 Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JamesHamiltonAugust2023PlanMember" xlink:href="arwr-20230930.xsd#arwr_JamesHamiltonAugust2023PlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JamesHamiltonAugust2023PlanMember" xlink:to="lab_arwr_JamesHamiltonAugust2023PlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_b3947fe0-c5a4-4cdf-b355-ecab8e6208c6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_c2cce7be-d8c9-4380-85db-8e87b1ebd3ec_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_05a8dd50-b74f-4b2b-ab98-1a975e8b82dc_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ffc4c049-6804-49c3-a18f-39df5654bcc1_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average diluted shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_21021369-f276-469d-a07f-ea14c86996b1_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Receivables and Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_596b0f37-9d14-4319-baa4-3ccbef060bf7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4e0a60e0-523d-40a6-8911-02eed9693aac_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_9e2f0ac9-00ca-46c5-9c1c-56ae1a287ddc_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_e956d14c-e4ad-4354-93ac-fd7315a0f5c3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_ed967efa-bf1b-460c-a7f1-e77a8ff770cf_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_MilestonePaymentReceivable_37aad6ca-ba6c-4b50-b6d3-3ad89d882809_terseLabel_en-US" xlink:label="lab_arwr_MilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone payment receivable</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivable_label_en-US" xlink:label="lab_arwr_MilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable</link:label>
    <link:label id="lab_arwr_MilestonePaymentReceivable_documentation_en-US" xlink:label="lab_arwr_MilestonePaymentReceivable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable" xlink:href="arwr-20230930.xsd#arwr_MilestonePaymentReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_MilestonePaymentReceivable" xlink:to="lab_arwr_MilestonePaymentReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_00e62bbd-ef64-4847-82e7-80e4443b0d22_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cancelled (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_21556577-ebbc-4d67-9084-945adf026734_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_72fbaf5f-4883-4f97-8e1d-ef0fc67b16fa_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_e8df707a-9b11-41eb-8c45-d8473c0a5b0f_terseLabel_en-US" xlink:label="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JJDC</link:label>
    <link:label id="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_label_en-US" xlink:label="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Johnson And Johnson Innovation J J D C Incorporation [Member]</link:label>
    <link:label id="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_documentation_en-US" xlink:label="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Johnson and Johnson Innovation-JJDC, Incorporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:href="arwr-20230930.xsd#arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:to="lab_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_996ee160-e083-49ac-bc90-b768a07a623c_terseLabel_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity award value</link:label>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_label_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Granted in Period, Fair Value</link:label>
    <link:label id="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_documentation_en-US" xlink:label="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Granted in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:href="arwr-20230930.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:to="lab_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_b7b24c40-0465-4760-b376-a6cabdcc35a1_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_7b1e30c4-21f7-48aa-a4a5-3b864ded28ce_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity securities, at amortized cost</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_874449ba-dc6f-4ede-9417-44bba36f556b_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments, Held to maturity, Adjusted Bases</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_0d928150-cf33-41e9-8184-ef528cff9560_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_60567a75-fc4f-4fbc-9cae-79083cee44e3_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_925809f8-01b6-4f28-8f5e-bd3ec62e5dde_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_f107d0c7-2d43-4d51-a62b-5da2ba797933_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_fbe46585-d140-4f95-9fe7-dcd48ddab74d_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_HorizonLicenseAgreementMember_e3fb40ed-b051-4708-a6cc-8b7fa5ca0e59_terseLabel_en-US" xlink:label="lab_arwr_HorizonLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon License Agreement</link:label>
    <link:label id="lab_arwr_HorizonLicenseAgreementMember_label_en-US" xlink:label="lab_arwr_HorizonLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon License Agreement [Member]</link:label>
    <link:label id="lab_arwr_HorizonLicenseAgreementMember_documentation_en-US" xlink:label="lab_arwr_HorizonLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Horizon License Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonLicenseAgreementMember" xlink:href="arwr-20230930.xsd#arwr_HorizonLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_HorizonLicenseAgreementMember" xlink:to="lab_arwr_HorizonLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeReclassificationAdjustmentForHeldToMaturityTransferredToAvailableForSaleSecuritiesBeforeTax_8221d9e1-0ac0-4bb9-aa46-7055737fe81f_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeReclassificationAdjustmentForHeldToMaturityTransferredToAvailableForSaleSecuritiesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gain (loss) on held-to-maturity securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeReclassificationAdjustmentForHeldToMaturityTransferredToAvailableForSaleSecuritiesBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeReclassificationAdjustmentForHeldToMaturityTransferredToAvailableForSaleSecuritiesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Transfer from Held-to-Maturity, Gain (Loss), before Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeReclassificationAdjustmentForHeldToMaturityTransferredToAvailableForSaleSecuritiesBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeReclassificationAdjustmentForHeldToMaturityTransferredToAvailableForSaleSecuritiesBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeReclassificationAdjustmentForHeldToMaturityTransferredToAvailableForSaleSecuritiesBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeReclassificationAdjustmentForHeldToMaturityTransferredToAvailableForSaleSecuritiesBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_9892a30a-2785-4131-b32a-a853cf7f9581_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation and Employee Benefit Plans [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:to="lab_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_9b6db9e9-1fe4-4705-815b-f7c74fbf48b4_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_6609d7c6-8669-4f56-a036-cee9584096e3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_fa163a59-3968-4c49-bb7f-5517e425e00b_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_15b90997-8909-46ea-bc86-13974911441a_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_8c2edda6-2c94-45c4-b07f-6bccc20be3ea_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_653fcd2e-5890-4116-bdd8-dece87964ed0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e123b440-d4e7-4c67-b1ec-3127a393eedd_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_bebbe15d-b286-4fea-877d-c26a208f31d8_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average basic shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_b24be9a4-d5e8-4c47-81d7-8aec6159121c_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_7220b219-cb22-4fde-b9a8-3fbb55c495be_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_ac1060f7-ac4b-4107-9a9d-1111482a61e7_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fixed assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_PatrickOBrienMember_label_en-US" xlink:label="lab_arwr_PatrickOBrienMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patrick O'Brien [Member]</link:label>
    <link:label id="lab_arwr_PatrickOBrienMember_documentation_en-US" xlink:label="lab_arwr_PatrickOBrienMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patrick O'Brien</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PatrickOBrienMember" xlink:href="arwr-20230930.xsd#arwr_PatrickOBrienMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_PatrickOBrienMember" xlink:to="lab_arwr_PatrickOBrienMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_LaboratoryAndOfficeFacilityMember_aa2867d4-3cd9-414d-948b-78844c0b925c_terseLabel_en-US" xlink:label="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory And Office Facility</link:label>
    <link:label id="lab_arwr_LaboratoryAndOfficeFacilityMember_label_en-US" xlink:label="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory And Office Facility [Member]</link:label>
    <link:label id="lab_arwr_LaboratoryAndOfficeFacilityMember_documentation_en-US" xlink:label="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory and office facility.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember" xlink:href="arwr-20230930.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_LaboratoryAndOfficeFacilityMember" xlink:to="lab_arwr_LaboratoryAndOfficeFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_65f77f27-33c0-4fe3-859f-d7eafed8b668_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total gross deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_9a21be89-22ad-4c96-9aa9-581a838ee0cf_terseLabel_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:label id="lab_srt_ConsolidatedEntitiesDomain_label_en-US" xlink:label="lab_srt_ConsolidatedEntitiesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidated Entities [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidatedEntitiesDomain" xlink:to="lab_srt_ConsolidatedEntitiesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_ResearchFacilityInMadisonMember_7616fd46-6e17-4b69-9491-eb6326bc5746_terseLabel_en-US" xlink:label="lab_arwr_ResearchFacilityInMadisonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Facility in Madison</link:label>
    <link:label id="lab_arwr_ResearchFacilityInMadisonMember_label_en-US" xlink:label="lab_arwr_ResearchFacilityInMadisonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research Facility In Madison [Member]</link:label>
    <link:label id="lab_arwr_ResearchFacilityInMadisonMember_documentation_en-US" xlink:label="lab_arwr_ResearchFacilityInMadisonMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research facility in Madison.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInMadisonMember" xlink:href="arwr-20230930.xsd#arwr_ResearchFacilityInMadisonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_ResearchFacilityInMadisonMember" xlink:to="lab_arwr_ResearchFacilityInMadisonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_17435dec-d3f8-4d76-9cb6-8a80e95aec8e_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss, net of tax:</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_bb420871-c094-4b94-9f15-86bafd33abca_terseLabel_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments, Held to maturity, Gross Unrealized Gains</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_label_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Noncurrent</link:label>
    <link:label id="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_documentation_en-US" xlink:label="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" xlink:href="arwr-20230930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" xlink:to="lab_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_94457237-6507-4850-ad01-8413a9137d60_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_de546dc4-0047-4e4a-b6cd-2c79aa97c6e4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_b90dd829-12bd-4345-aef6-264b30628c8a_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_05c94e56-e3fd-45f9-acde-60e4ddc20677_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_9cd3af47-6849-44cc-a798-bb7065c2654c_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling interest and stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_c451f8a3-635b-4a25-8f88-b5cf49a5dfc3_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non- controlling Interest</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember" xlink:to="lab_us-gaap_NoncontrollingInterestMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>16
<FILENAME>arwr-20230930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2023 Workiva-->
<!--r:d14395b2-bc79-4df5-8659-886540a562de,g:ab3d3e76-c740-4da0-ace7-13e457c841a4-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CoverPage" xlink:type="simple" xlink:href="arwr-20230930.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c9236988-ec69-47a8-8eb3-a73822041846" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_DocumentType_c9236988-ec69-47a8-8eb3-a73822041846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_3eeff7bf-b76d-4f17-88dc-2bc7fe2183f6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_DocumentAnnualReport_3eeff7bf-b76d-4f17-88dc-2bc7fe2183f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_15fe7fe4-3a18-4f63-b320-880802fb022c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_DocumentPeriodEndDate_15fe7fe4-3a18-4f63-b320-880802fb022c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_a26be392-a428-4ed0-b7bd-7d3f5e3978ce" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_CurrentFiscalYearEndDate_a26be392-a428-4ed0-b7bd-7d3f5e3978ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_855f0360-0338-4c8e-b61d-f555503dc44a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_DocumentTransitionReport_855f0360-0338-4c8e-b61d-f555503dc44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d9a2de3b-f5fe-4da4-8661-93a0afa84e5f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_EntityFileNumber_d9a2de3b-f5fe-4da4-8661-93a0afa84e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_9b0fb4c6-8858-4c60-925b-d22e6b91fd02" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_EntityRegistrantName_9b0fb4c6-8858-4c60-925b-d22e6b91fd02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_dea6203a-3113-48de-b414-576f8b3c592d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_EntityIncorporationStateCountryCode_dea6203a-3113-48de-b414-576f8b3c592d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_6babb800-6811-44fa-9c78-527aa2d8f1e4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_EntityTaxIdentificationNumber_6babb800-6811-44fa-9c78-527aa2d8f1e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_40ba8988-bda8-4f19-9943-821092fdfa88" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_CityAreaCode_40ba8988-bda8-4f19-9943-821092fdfa88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_5c6183a8-b4af-482e-ab84-30f286149d84" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_LocalPhoneNumber_5c6183a8-b4af-482e-ab84-30f286149d84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_8a9f29ab-042a-4876-b18d-ad6cdac77096" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_EntityAddressAddressLine1_8a9f29ab-042a-4876-b18d-ad6cdac77096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_52a51745-ed7f-4a5b-8d15-1d23c60d7103" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_EntityAddressAddressLine2_52a51745-ed7f-4a5b-8d15-1d23c60d7103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_717b981b-bd16-4b87-8019-d1613a265e98" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_EntityAddressCityOrTown_717b981b-bd16-4b87-8019-d1613a265e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_3082285a-3054-4610-a1f1-6105327e2f80" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_EntityAddressStateOrProvince_3082285a-3054-4610-a1f1-6105327e2f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bd1b83c3-e926-47a2-bd03-3d0d1fd9c02b" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_EntityAddressPostalZipCode_bd1b83c3-e926-47a2-bd03-3d0d1fd9c02b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_55b73a7c-83e9-4b0a-8d27-04a4a93ddff9" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_Security12bTitle_55b73a7c-83e9-4b0a-8d27-04a4a93ddff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_dd5eabba-818c-451f-8174-e79ac3041e55" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_TradingSymbol_dd5eabba-818c-451f-8174-e79ac3041e55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4264f63e-2bea-4870-a76b-60993be2ac9c" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_SecurityExchangeName_4264f63e-2bea-4870-a76b-60993be2ac9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_1b49efdd-eec1-4de4-b5ff-a91473986ddc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_1b49efdd-eec1-4de4-b5ff-a91473986ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_bb205047-d1c2-49cb-bfa2-cec1326bef5f" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_EntityVoluntaryFilers_bb205047-d1c2-49cb-bfa2-cec1326bef5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_a5ec3b3e-623c-4877-b79b-efb7c7afde09" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_EntityCurrentReportingStatus_a5ec3b3e-623c-4877-b79b-efb7c7afde09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a151a453-1536-4d69-a8e3-2d7bff79220a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_EntityInteractiveDataCurrent_a151a453-1536-4d69-a8e3-2d7bff79220a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_35a90882-1687-4b59-aaec-1a6ce88714b0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_EntityFilerCategory_35a90882-1687-4b59-aaec-1a6ce88714b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_ad832953-e8fa-4971-b213-5a303c18024a" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_EntitySmallBusiness_ad832953-e8fa-4971-b213-5a303c18024a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_fe82b06a-a2b8-45ed-8c0b-f790d01e32b0" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_EntityEmergingGrowthCompany_fe82b06a-a2b8-45ed-8c0b-f790d01e32b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_03def790-4e66-4e47-96a2-2bcca3c2c93d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_IcfrAuditorAttestationFlag_03def790-4e66-4e47-96a2-2bcca3c2c93d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_0165a47d-95cb-416b-81d6-d3adcb471cbc" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_EntityShellCompany_0165a47d-95cb-416b-81d6-d3adcb471cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_622ee445-4ea9-4daa-9e62-6a2db258ecd4" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_622ee445-4ea9-4daa-9e62-6a2db258ecd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_c28f7dfa-5f2a-41a3-ab9b-bd6a47e97586" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_EntityPublicFloat_c28f7dfa-5f2a-41a3-ab9b-bd6a47e97586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_a9c1c609-8d36-497f-9393-aa477e743027" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_a9c1c609-8d36-497f-9393-aa477e743027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_fcdd597e-33af-439f-bd10-db83825c480d" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_fcdd597e-33af-439f-bd10-db83825c480d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_15642e0e-9f5a-4af3-9b45-a714279af286" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_DocumentFiscalYearFocus_15642e0e-9f5a-4af3-9b45-a714279af286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_3653d1ae-b3bf-4b7e-8f3a-37f5cb5a1ed7" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_3653d1ae-b3bf-4b7e-8f3a-37f5cb5a1ed7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_66964669-d8f5-4222-8509-027fbcf56996" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_EntityCentralIndexKey_66964669-d8f5-4222-8509-027fbcf56996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_593e8f81-b563-4c9d-8284-1b113f736432" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_49f31b35-cf0a-4474-8f71-c548938126e0" xlink:to="loc_dei_AmendmentFlag_593e8f81-b563-4c9d-8284-1b113f736432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/AuditInformation" xlink:type="simple" xlink:href="arwr-20230930.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AuditInformationAbstract_450fb0ce-c8af-4cd4-9d23-98577c9fbac5" xlink:href="arwr-20230930.xsd#arwr_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_39a75595-4bea-4da1-a82f-f43e2eb2d7fa" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_AuditInformationAbstract_450fb0ce-c8af-4cd4-9d23-98577c9fbac5" xlink:to="loc_dei_AuditorName_39a75595-4bea-4da1-a82f-f43e2eb2d7fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_89dd18ed-c3f2-47d2-9d99-971c1ada5df6" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_AuditInformationAbstract_450fb0ce-c8af-4cd4-9d23-98577c9fbac5" xlink:to="loc_dei_AuditorLocation_89dd18ed-c3f2-47d2-9d99-971c1ada5df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_f9ebdae6-d948-4620-b968-96f8399e9fde" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_AuditInformationAbstract_450fb0ce-c8af-4cd4-9d23-98577c9fbac5" xlink:to="loc_dei_AuditorFirmId_f9ebdae6-d948-4620-b968-96f8399e9fde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="arwr-20230930.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_8b7cc6fc-8572-480b-8361-fdf520b52594" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_11847404-dba8-4e8d-a418-3ea67f8d80ca" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8b7cc6fc-8572-480b-8361-fdf520b52594" xlink:to="loc_us-gaap_AssetsAbstract_11847404-dba8-4e8d-a418-3ea67f8d80ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_2d6c381a-db32-433a-95c7-5234c46ad9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_11847404-dba8-4e8d-a418-3ea67f8d80ca" xlink:to="loc_us-gaap_AssetsCurrentAbstract_2d6c381a-db32-433a-95c7-5234c46ad9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_10e43195-d3b2-47a9-aa92-03b1d51ffe3b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2d6c381a-db32-433a-95c7-5234c46ad9b5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_10e43195-d3b2-47a9-aa92-03b1d51ffe3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_17bb98a1-be04-4413-9dfc-1fda0f78636f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2d6c381a-db32-433a-95c7-5234c46ad9b5" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_17bb98a1-be04-4413-9dfc-1fda0f78636f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_26b7b99c-80a5-413b-bbd2-8caa56125772" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2d6c381a-db32-433a-95c7-5234c46ad9b5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_26b7b99c-80a5-413b-bbd2-8caa56125772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_3f4f2b8a-2bb4-4ec4-a015-103dfcb08fce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2d6c381a-db32-433a-95c7-5234c46ad9b5" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_3f4f2b8a-2bb4-4ec4-a015-103dfcb08fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_8f92bd84-656c-43e2-a61a-954dc4d5328e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2d6c381a-db32-433a-95c7-5234c46ad9b5" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_8f92bd84-656c-43e2-a61a-954dc4d5328e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_951f4a43-8b99-4afd-92d9-854aba812181" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2d6c381a-db32-433a-95c7-5234c46ad9b5" xlink:to="loc_us-gaap_OtherAssetsCurrent_951f4a43-8b99-4afd-92d9-854aba812181" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f362aec8-040e-4c59-b525-7655b7507e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_2d6c381a-db32-433a-95c7-5234c46ad9b5" xlink:to="loc_us-gaap_AssetsCurrent_f362aec8-040e-4c59-b525-7655b7507e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9500a26b-200f-4c7c-bece-71c02f760544" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_11847404-dba8-4e8d-a418-3ea67f8d80ca" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9500a26b-200f-4c7c-bece-71c02f760544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9e93375e-5d05-4b4a-a7c1-15c6e5cb2171" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_11847404-dba8-4e8d-a418-3ea67f8d80ca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_9e93375e-5d05-4b4a-a7c1-15c6e5cb2171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_968fdefc-0609-4fe6-9539-1a87003269e8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_11847404-dba8-4e8d-a418-3ea67f8d80ca" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_968fdefc-0609-4fe6-9539-1a87003269e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_8d609342-3ac8-4b2e-938e-0a28f4994860" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_11847404-dba8-4e8d-a418-3ea67f8d80ca" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_8d609342-3ac8-4b2e-938e-0a28f4994860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_fcb1245e-6252-4d99-8e33-a3a6ffc84dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_11847404-dba8-4e8d-a418-3ea67f8d80ca" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_fcb1245e-6252-4d99-8e33-a3a6ffc84dd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_0a56d4e2-ddb7-45a4-bf04-3adcb3a659e0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_11847404-dba8-4e8d-a418-3ea67f8d80ca" xlink:to="loc_us-gaap_Assets_0a56d4e2-ddb7-45a4-bf04-3adcb3a659e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5736b5e4-89a0-483a-bd50-6a68ef581c7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_8b7cc6fc-8572-480b-8361-fdf520b52594" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5736b5e4-89a0-483a-bd50-6a68ef581c7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_8583399a-8f7f-4b5c-ad86-b07a017d0163" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5736b5e4-89a0-483a-bd50-6a68ef581c7b" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_8583399a-8f7f-4b5c-ad86-b07a017d0163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_144e1949-1042-4f3f-b4a1-bc1791cc275f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8583399a-8f7f-4b5c-ad86-b07a017d0163" xlink:to="loc_us-gaap_AccountsPayableCurrent_144e1949-1042-4f3f-b4a1-bc1791cc275f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_a25adf31-47e8-472f-8342-5f76b5346864" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8583399a-8f7f-4b5c-ad86-b07a017d0163" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_a25adf31-47e8-472f-8342-5f76b5346864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ee500f6e-b60b-4988-817d-37c0c7aeb20b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8583399a-8f7f-4b5c-ad86-b07a017d0163" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_ee500f6e-b60b-4988-817d-37c0c7aeb20b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_4f84fd89-d6c6-408d-bac2-1c1457364de2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8583399a-8f7f-4b5c-ad86-b07a017d0163" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_4f84fd89-d6c6-408d-bac2-1c1457364de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e8fea591-0e27-4d5f-a44d-f7ae1e6093ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8583399a-8f7f-4b5c-ad86-b07a017d0163" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e8fea591-0e27-4d5f-a44d-f7ae1e6093ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_3ffead0f-5341-41b6-a944-56714046da4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8583399a-8f7f-4b5c-ad86-b07a017d0163" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_3ffead0f-5341-41b6-a944-56714046da4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_45e62945-d7c7-4d74-9bfc-c19689376f92" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8583399a-8f7f-4b5c-ad86-b07a017d0163" xlink:to="loc_us-gaap_LiabilitiesCurrent_45e62945-d7c7-4d74-9bfc-c19689376f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrentAbstract_b84db157-66d1-44de-af9d-ccf2e5409f89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5736b5e4-89a0-483a-bd50-6a68ef581c7b" xlink:to="loc_us-gaap_LiabilitiesNoncurrentAbstract_b84db157-66d1-44de-af9d-ccf2e5409f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ebdb2580-cb1a-4754-9090-fdf4a1361275" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_b84db157-66d1-44de-af9d-ccf2e5409f89" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ebdb2580-cb1a-4754-9090-fdf4a1361275" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a5db78d8-cfbd-475a-b99c-93dec29c87bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_b84db157-66d1-44de-af9d-ccf2e5409f89" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a5db78d8-cfbd-475a-b99c-93dec29c87bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltiesLiabilityNoncurrent_ebf7da68-7390-4391-8869-10f4e6c32d3e" xlink:href="arwr-20230930.xsd#arwr_RoyaltiesLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_b84db157-66d1-44de-af9d-ccf2e5409f89" xlink:to="loc_arwr_RoyaltiesLiabilityNoncurrent_ebf7da68-7390-4391-8869-10f4e6c32d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesNoncurrent_a969d511-1586-43fa-ab3b-8edee20f4df2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesNoncurrentAbstract_b84db157-66d1-44de-af9d-ccf2e5409f89" xlink:to="loc_us-gaap_LiabilitiesNoncurrent_a969d511-1586-43fa-ab3b-8edee20f4df2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_88bc6297-0031-4b38-93b1-51f6ca7b222a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5736b5e4-89a0-483a-bd50-6a68ef581c7b" xlink:to="loc_us-gaap_CommitmentsAndContingencies_88bc6297-0031-4b38-93b1-51f6ca7b222a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_10ab7368-ec7c-4bbb-9de0-8e603c55560a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5736b5e4-89a0-483a-bd50-6a68ef581c7b" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_10ab7368-ec7c-4bbb-9de0-8e603c55560a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2854af38-0a22-440e-8032-ee5a243858e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_10ab7368-ec7c-4bbb-9de0-8e603c55560a" xlink:to="loc_us-gaap_CommonStockValue_2854af38-0a22-440e-8032-ee5a243858e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b8dfdd26-cb37-428e-b5f1-48b8354ce4a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_10ab7368-ec7c-4bbb-9de0-8e603c55560a" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_b8dfdd26-cb37-428e-b5f1-48b8354ce4a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_341ee937-47c5-47c8-8dcc-cf8aaecd8fad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_10ab7368-ec7c-4bbb-9de0-8e603c55560a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_341ee937-47c5-47c8-8dcc-cf8aaecd8fad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_517fe4a1-a1d3-4152-a1b2-e64cf2d9e95b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_10ab7368-ec7c-4bbb-9de0-8e603c55560a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_517fe4a1-a1d3-4152-a1b2-e64cf2d9e95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_db50efa0-805a-46af-951a-fa3048366477" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_10ab7368-ec7c-4bbb-9de0-8e603c55560a" xlink:to="loc_us-gaap_StockholdersEquity_db50efa0-805a-46af-951a-fa3048366477" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MinorityInterest_f0c32027-bcca-4d01-9a2b-4cda7618d386" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MinorityInterest"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_10ab7368-ec7c-4bbb-9de0-8e603c55560a" xlink:to="loc_us-gaap_MinorityInterest_f0c32027-bcca-4d01-9a2b-4cda7618d386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_503948c8-649b-421d-b803-deef960d7049" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_10ab7368-ec7c-4bbb-9de0-8e603c55560a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_503948c8-649b-421d-b803-deef960d7049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4c982188-a418-4289-90f3-5c11bc2b8646" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_5736b5e4-89a0-483a-bd50-6a68ef581c7b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_4c982188-a418-4289-90f3-5c11bc2b8646" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="arwr-20230930.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f2ba2164-5b47-401f-b139-ef5e7adb3d5f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ec7a4ac3-2fac-46f2-b3fd-b061b5ffe423" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f2ba2164-5b47-401f-b139-ef5e7adb3d5f" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ec7a4ac3-2fac-46f2-b3fd-b061b5ffe423" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_28f6b0e7-b932-45d0-a28a-6b74a06ba5b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f2ba2164-5b47-401f-b139-ef5e7adb3d5f" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_28f6b0e7-b932-45d0-a28a-6b74a06ba5b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_c5aaeb84-7708-49e3-9ebc-c32b16cb8bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f2ba2164-5b47-401f-b139-ef5e7adb3d5f" xlink:to="loc_us-gaap_CommonStockSharesIssued_c5aaeb84-7708-49e3-9ebc-c32b16cb8bcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_74c990a0-ce4d-4d3c-b4cc-127184dda44b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f2ba2164-5b47-401f-b139-ef5e7adb3d5f" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_74c990a0-ce4d-4d3c-b4cc-127184dda44b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="arwr-20230930.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_ff53e174-8f6e-40bf-98cb-693315b2c7b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8e5bc308-e104-45c8-8af4-c3fba0b43ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ff53e174-8f6e-40bf-98cb-693315b2c7b7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8e5bc308-e104-45c8-8af4-c3fba0b43ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_868444fd-4cf0-44eb-8db3-de761065d511" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ff53e174-8f6e-40bf-98cb-693315b2c7b7" xlink:to="loc_us-gaap_OperatingExpensesAbstract_868444fd-4cf0-44eb-8db3-de761065d511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ed169bad-78f1-4dcb-9ac1-40777ec5bd23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_868444fd-4cf0-44eb-8db3-de761065d511" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ed169bad-78f1-4dcb-9ac1-40777ec5bd23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_949db9b7-b73e-40c1-a7e4-a688497366ce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_868444fd-4cf0-44eb-8db3-de761065d511" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_949db9b7-b73e-40c1-a7e4-a688497366ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_0e3350e8-0beb-468b-922d-ffbb8862b877" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_868444fd-4cf0-44eb-8db3-de761065d511" xlink:to="loc_us-gaap_OperatingExpenses_0e3350e8-0beb-468b-922d-ffbb8862b877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_08072d1e-a45f-46a3-8f0d-eecd2e94df8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ff53e174-8f6e-40bf-98cb-693315b2c7b7" xlink:to="loc_us-gaap_OperatingIncomeLoss_08072d1e-a45f-46a3-8f0d-eecd2e94df8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ca0d9a19-0e72-4e5c-96e4-16173236cc6f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ff53e174-8f6e-40bf-98cb-693315b2c7b7" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ca0d9a19-0e72-4e5c-96e4-16173236cc6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterestAndDividend_bf737789-5444-4879-bc65-10b5f178c44f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeInterestAndDividend"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ca0d9a19-0e72-4e5c-96e4-16173236cc6f" xlink:to="loc_us-gaap_InvestmentIncomeInterestAndDividend_bf737789-5444-4879-bc65-10b5f178c44f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_04d1f5d7-79c1-4edb-96bf-995992870132" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ca0d9a19-0e72-4e5c-96e4-16173236cc6f" xlink:to="loc_us-gaap_InterestExpense_04d1f5d7-79c1-4edb-96bf-995992870132" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_b94950bb-4c9a-4c92-b19c-d6d90cb52693" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ca0d9a19-0e72-4e5c-96e4-16173236cc6f" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_b94950bb-4c9a-4c92-b19c-d6d90cb52693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_7d08fb1e-14b8-4ba8-a67f-fb133e32b0ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_ca0d9a19-0e72-4e5c-96e4-16173236cc6f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_7d08fb1e-14b8-4ba8-a67f-fb133e32b0ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4c2e345d-5fb3-4219-b95b-79aae158e3c8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ff53e174-8f6e-40bf-98cb-693315b2c7b7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4c2e345d-5fb3-4219-b95b-79aae158e3c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5a8aad37-723f-40b0-877c-741be4bb062e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ff53e174-8f6e-40bf-98cb-693315b2c7b7" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5a8aad37-723f-40b0-877c-741be4bb062e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_3f23a089-d748-4edc-871a-950fa5e47abb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ff53e174-8f6e-40bf-98cb-693315b2c7b7" xlink:to="loc_us-gaap_ProfitLoss_3f23a089-d748-4edc-871a-950fa5e47abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b3e5aa5f-74ba-4185-9858-7b1643e626c2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ff53e174-8f6e-40bf-98cb-693315b2c7b7" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_b3e5aa5f-74ba-4185-9858-7b1643e626c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_79cd16e9-1745-4add-bcc5-13461ff9cc5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ff53e174-8f6e-40bf-98cb-693315b2c7b7" xlink:to="loc_us-gaap_NetIncomeLoss_79cd16e9-1745-4add-bcc5-13461ff9cc5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_8bbf2888-7e1b-46e8-ab53-da73e05b327b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ff53e174-8f6e-40bf-98cb-693315b2c7b7" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_8bbf2888-7e1b-46e8-ab53-da73e05b327b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_decf6a82-5b4f-4eec-a2f2-bee6feb5a8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_8bbf2888-7e1b-46e8-ab53-da73e05b327b" xlink:to="loc_us-gaap_EarningsPerShareBasic_decf6a82-5b4f-4eec-a2f2-bee6feb5a8dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_76aabd46-ed71-4219-aae9-206fd3a2e03e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_8bbf2888-7e1b-46e8-ab53-da73e05b327b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_76aabd46-ed71-4219-aae9-206fd3a2e03e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0766631f-ae1f-4e49-bfc1-0b52a6213a01" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ff53e174-8f6e-40bf-98cb-693315b2c7b7" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0766631f-ae1f-4e49-bfc1-0b52a6213a01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5c812087-27b0-4c8c-8318-aad3ca8d2f52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0766631f-ae1f-4e49-bfc1-0b52a6213a01" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5c812087-27b0-4c8c-8318-aad3ca8d2f52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ced9e894-0f92-4bfa-a788-95f0974e11a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0766631f-ae1f-4e49-bfc1-0b52a6213a01" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ced9e894-0f92-4bfa-a788-95f0974e11a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_73769b76-a59c-46f3-af3f-a4802c68237c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_ff53e174-8f6e-40bf-98cb-693315b2c7b7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_73769b76-a59c-46f3-af3f-a4802c68237c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_fc773c5f-c42f-45a0-abb1-cdc1241352e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_73769b76-a59c-46f3-af3f-a4802c68237c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_fc773c5f-c42f-45a0-abb1-cdc1241352e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0e232b50-2ac6-4f32-b166-7addf33435b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_73769b76-a59c-46f3-af3f-a4802c68237c" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0e232b50-2ac6-4f32-b166-7addf33435b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a43ab160-e777-4393-b365-f9685da6c8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAbstract_73769b76-a59c-46f3-af3f-a4802c68237c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_a43ab160-e777-4393-b365-f9685da6c8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="arwr-20230930.xsd#ConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_5ea0ef3f-eff9-4b9e-8c73-cf202dbb5ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c2d23612-38cd-4695-bfbd-3fe64676fe43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_5ea0ef3f-eff9-4b9e-8c73-cf202dbb5ca4" xlink:to="loc_us-gaap_StatementTable_c2d23612-38cd-4695-bfbd-3fe64676fe43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_bc19caee-c203-4c94-aaf5-db58c84bbd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c2d23612-38cd-4695-bfbd-3fe64676fe43" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_bc19caee-c203-4c94-aaf5-db58c84bbd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_47acddab-92f1-4e20-a387-baf00a424d64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_bc19caee-c203-4c94-aaf5-db58c84bbd7e" xlink:to="loc_us-gaap_EquityComponentDomain_47acddab-92f1-4e20-a387-baf00a424d64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3855e176-71e1-4ade-ba78-bf9a2d998722" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_47acddab-92f1-4e20-a387-baf00a424d64" xlink:to="loc_us-gaap_CommonStockMember_3855e176-71e1-4ade-ba78-bf9a2d998722" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_7ceb2091-aa3c-476a-95a2-f92b99c1dc91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_47acddab-92f1-4e20-a387-baf00a424d64" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_7ceb2091-aa3c-476a-95a2-f92b99c1dc91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_062a9907-2c6e-46dd-a604-2809e2492325" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_47acddab-92f1-4e20-a387-baf00a424d64" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_062a9907-2c6e-46dd-a604-2809e2492325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_27ba09f8-d69d-43df-8ced-a5a26fd69547" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_47acddab-92f1-4e20-a387-baf00a424d64" xlink:to="loc_us-gaap_RetainedEarningsMember_27ba09f8-d69d-43df-8ced-a5a26fd69547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestMember_e9ff823d-442c-4402-9400-f0eb90683327" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_47acddab-92f1-4e20-a387-baf00a424d64" xlink:to="loc_us-gaap_NoncontrollingInterestMember_e9ff823d-442c-4402-9400-f0eb90683327" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_6f954bf4-1a35-4e20-b693-dba0166d691e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c2d23612-38cd-4695-bfbd-3fe64676fe43" xlink:to="loc_us-gaap_StatementLineItems_6f954bf4-1a35-4e20-b693-dba0166d691e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6f954bf4-1a35-4e20-b693-dba0166d691e" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_510b61c5-73aa-4fde-8b8b-e116b8a2f53e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_510b61c5-73aa-4fde-8b8b-e116b8a2f53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_a3db19e2-a8c3-4f48-9a37-9ab32ed431b9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:to="loc_us-gaap_SharesOutstanding_a3db19e2-a8c3-4f48-9a37-9ab32ed431b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_faec25d5-deef-46fb-b7f8-3d9ae62d42ab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_faec25d5-deef-46fb-b7f8-3d9ae62d42ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_72468b36-b7e2-4831-941b-fe937268c772" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_72468b36-b7e2-4831-941b-fe937268c772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7b3f5552-71b0-4242-9f7f-64741bd9bae2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7b3f5552-71b0-4242-9f7f-64741bd9bae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_16d70c18-9a00-411d-9db2-b7cef000e509" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_16d70c18-9a00-411d-9db2-b7cef000e509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_d5053adc-ebe0-47e9-bf32-1de353b564d5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_d5053adc-ebe0-47e9-bf32-1de353b564d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_abb94925-1522-4a2d-8fc0-44d0fa2c5398" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_abb94925-1522-4a2d-8fc0-44d0fa2c5398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ae139115-2765-4990-9c83-057751dcd9da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_ae139115-2765-4990-9c83-057751dcd9da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_81fe479f-712d-4812-ab1f-59e1ccf8df5e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:to="loc_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance_81fe479f-712d-4812-ab1f-59e1ccf8df5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_4b5c8c1e-0f5f-4d90-b4a0-de2e965c5f47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:to="loc_us-gaap_ProfitLoss_4b5c8c1e-0f5f-4d90-b4a0-de2e965c5f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c87ce50b-9f49-4645-b31a-ceae0b973fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_c87ce50b-9f49-4645-b31a-ceae0b973fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_65f89256-a369-47a8-81c9-555f947bcf65" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_60498b0f-bd45-419e-9d4e-52e93d844a23" xlink:to="loc_us-gaap_SharesOutstanding_65f89256-a369-47a8-81c9-555f947bcf65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="arwr-20230930.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_dfb225ea-3b3d-4dd7-924f-05dcb8fa4982" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_38d65fed-d0c6-44cc-9f95-e9d59fb742ac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dfb225ea-3b3d-4dd7-924f-05dcb8fa4982" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_38d65fed-d0c6-44cc-9f95-e9d59fb742ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProfitLoss_518e3347-4863-4f3b-9a49-cb5aa0e711a2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProfitLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_38d65fed-d0c6-44cc-9f95-e9d59fb742ac" xlink:to="loc_us-gaap_ProfitLoss_518e3347-4863-4f3b-9a49-cb5aa0e711a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_85dec623-7e84-49cb-aed2-9c47f5e28f82" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_38d65fed-d0c6-44cc-9f95-e9d59fb742ac" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_85dec623-7e84-49cb-aed2-9c47f5e28f82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_27862e3a-a54f-42d9-81d6-24cba15a7c08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_85dec623-7e84-49cb-aed2-9c47f5e28f82" xlink:to="loc_us-gaap_ShareBasedCompensation_27862e3a-a54f-42d9-81d6-24cba15a7c08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_4a8345d3-c4a8-4f6a-b391-3558bdc5f177" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_85dec623-7e84-49cb-aed2-9c47f5e28f82" xlink:to="loc_us-gaap_DepreciationAndAmortization_4a8345d3-c4a8-4f6a-b391-3558bdc5f177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_01a67977-0a75-423e-8cdb-fdfa55f3708f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_85dec623-7e84-49cb-aed2-9c47f5e28f82" xlink:to="loc_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_01a67977-0a75-423e-8cdb-fdfa55f3708f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_b482b37a-e227-4f27-886f-d170f12315ae" xlink:href="arwr-20230930.xsd#arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_85dec623-7e84-49cb-aed2-9c47f5e28f82" xlink:to="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_b482b37a-e227-4f27-886f-d170f12315ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnInvestments_3abaf707-08bf-4c07-8e46-df6685866379" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GainLossOnInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_85dec623-7e84-49cb-aed2-9c47f5e28f82" xlink:to="loc_us-gaap_GainLossOnInvestments_3abaf707-08bf-4c07-8e46-df6685866379" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4653a819-d6b7-4c56-887c-8ca6d6a6f6b7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_85dec623-7e84-49cb-aed2-9c47f5e28f82" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4653a819-d6b7-4c56-887c-8ca6d6a6f6b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_abf87d4d-642a-40b7-a809-6865a17d80e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4653a819-d6b7-4c56-887c-8ca6d6a6f6b7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_abf87d4d-642a-40b7-a809-6865a17d80e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e277cfe2-40f4-4f3f-ab09-efcd42ee0815" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4653a819-d6b7-4c56-887c-8ca6d6a6f6b7" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_e277cfe2-40f4-4f3f-ab09-efcd42ee0815" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_03edeb84-c135-4194-94f7-7e7f9f2c708d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4653a819-d6b7-4c56-887c-8ca6d6a6f6b7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_03edeb84-c135-4194-94f7-7e7f9f2c708d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_319a4e98-454f-448f-bef4-3e32843544aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4653a819-d6b7-4c56-887c-8ca6d6a6f6b7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_319a4e98-454f-448f-bef4-3e32843544aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f7ea75f4-be4f-4804-8fd6-5a25789b5f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4653a819-d6b7-4c56-887c-8ca6d6a6f6b7" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_f7ea75f4-be4f-4804-8fd6-5a25789b5f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_759ccb03-fdd9-4e25-91de-3b902e13e253" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4653a819-d6b7-4c56-887c-8ca6d6a6f6b7" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_759ccb03-fdd9-4e25-91de-3b902e13e253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0fadfbbc-d0bc-4bf2-8d78-2a39d314b5d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4653a819-d6b7-4c56-887c-8ca6d6a6f6b7" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_0fadfbbc-d0bc-4bf2-8d78-2a39d314b5d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_43901f7e-2695-4b87-aab3-05e4d4aede98" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_38d65fed-d0c6-44cc-9f95-e9d59fb742ac" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_43901f7e-2695-4b87-aab3-05e4d4aede98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a8e4e1c7-cd94-438c-958f-9608d3faaf43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dfb225ea-3b3d-4dd7-924f-05dcb8fa4982" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a8e4e1c7-cd94-438c-958f-9608d3faaf43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b68f7dba-e8b7-461d-ac19-2a7ef6f4119c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a8e4e1c7-cd94-438c-958f-9608d3faaf43" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b68f7dba-e8b7-461d-ac19-2a7ef6f4119c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_a067d65b-6a2b-4d1c-93ab-f74a7de5c227" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a8e4e1c7-cd94-438c-958f-9608d3faaf43" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_a067d65b-6a2b-4d1c-93ab-f74a7de5c227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_47acefe0-fa7b-4ee4-a7f3-6e38a2f60afe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a8e4e1c7-cd94-438c-958f-9608d3faaf43" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_47acefe0-fa7b-4ee4-a7f3-6e38a2f60afe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_de9f6fe0-1224-4499-8a28-215b403b755f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_a8e4e1c7-cd94-438c-958f-9608d3faaf43" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_de9f6fe0-1224-4499-8a28-215b403b755f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71923b03-f086-4902-a9b2-d0587b3da594" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dfb225ea-3b3d-4dd7-924f-05dcb8fa4982" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71923b03-f086-4902-a9b2-d0587b3da594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_07029a53-6578-429e-8d59-fdb8c0ebd54c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71923b03-f086-4902-a9b2-d0587b3da594" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_07029a53-6578-429e-8d59-fdb8c0ebd54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ProceedsFromSaleOfFutureRoyalties_1fc62355-0aaa-428f-8c72-5bac72064cc3" xlink:href="arwr-20230930.xsd#arwr_ProceedsFromSaleOfFutureRoyalties"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71923b03-f086-4902-a9b2-d0587b3da594" xlink:to="loc_arwr_ProceedsFromSaleOfFutureRoyalties_1fc62355-0aaa-428f-8c72-5bac72064cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital_af2ce429-ede2-401b-8661-07b5237a8f4c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71923b03-f086-4902-a9b2-d0587b3da594" xlink:to="loc_us-gaap_ProceedsFromContributedCapital_af2ce429-ede2-401b-8661-07b5237a8f4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_442493aa-b806-4920-b7c6-25e2b321ef47" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_71923b03-f086-4902-a9b2-d0587b3da594" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_442493aa-b806-4920-b7c6-25e2b321ef47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_e693dd6c-3f7d-4d72-9401-2748c3e5ad54" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dfb225ea-3b3d-4dd7-924f-05dcb8fa4982" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_e693dd6c-3f7d-4d72-9401-2748c3e5ad54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_add1430b-6b59-44aa-b507-e579608aabaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dfb225ea-3b3d-4dd7-924f-05dcb8fa4982" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_add1430b-6b59-44aa-b507-e579608aabaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9ea62d4d-171e-483d-99dd-be862f9aa05e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dfb225ea-3b3d-4dd7-924f-05dcb8fa4982" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9ea62d4d-171e-483d-99dd-be862f9aa05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_958795b2-f61f-444f-b93f-da1fea071e67" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dfb225ea-3b3d-4dd7-924f-05dcb8fa4982" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_958795b2-f61f-444f-b93f-da1fea071e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_a081bd59-4c4a-4440-b81c-92159a9b56a7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_dfb225ea-3b3d-4dd7-924f-05dcb8fa4982" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_a081bd59-4c4a-4440-b81c-92159a9b56a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_821c0a62-7f60-448e-93c0-9108f82a8560" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a081bd59-4c4a-4440-b81c-92159a9b56a7" xlink:to="loc_us-gaap_InterestPaidNet_821c0a62-7f60-448e-93c0-9108f82a8560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_64952378-8230-4af2-981f-2ec02660d393" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_a081bd59-4c4a-4440-b81c-92159a9b56a7" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_64952378-8230-4af2-981f-2ec02660d393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="simple" xlink:href="arwr-20230930.xsd#OrganizationandSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_3f4e4b21-b4fa-4459-a872-699cf46d37d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_fcf1af41-ece6-43bb-ad44-57d93d3764af" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_3f4e4b21-b4fa-4459-a872-699cf46d37d6" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_fcf1af41-ece6-43bb-ad44-57d93d3764af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements" xlink:type="simple" xlink:href="arwr-20230930.xsd#CollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_7c0390e9-7f66-4efa-8d76-fd13f7c46277" xlink:href="arwr-20230930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_530be849-c74f-45d3-89a3-4ce72e6f8d7f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_7c0390e9-7f66-4efa-8d76-fd13f7c46277" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_530be849-c74f-45d3-89a3-4ce72e6f8d7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipment" xlink:type="simple" xlink:href="arwr-20230930.xsd#PropertyandEquipment"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/PropertyandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9b7cb111-4e14-4701-a707-edf95148aa2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_47fb7dcf-2c5c-4e0e-9f45-75eaf2e7ef32" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9b7cb111-4e14-4701-a707-edf95148aa2a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_47fb7dcf-2c5c-4e0e-9f45-75eaf2e7ef32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/Investments" xlink:type="simple" xlink:href="arwr-20230930.xsd#Investments"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/Investments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_db8ae546-d075-4b87-b374-7d4a5e83003e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_178374c9-2eda-4a60-8564-3e243e494bc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_db8ae546-d075-4b87-b374-7d4a5e83003e" xlink:to="loc_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_178374c9-2eda-4a60-8564-3e243e494bc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssets" xlink:type="simple" xlink:href="arwr-20230930.xsd#IntangibleAssets"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b11df50f-14ef-4ac9-ad27-b3811ddaf88a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_5e41db9f-f647-4384-bac0-c39dba72d465" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b11df50f-14ef-4ac9-ad27-b3811ddaf88a" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_5e41db9f-f647-4384-bac0-c39dba72d465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquity" xlink:type="simple" xlink:href="arwr-20230930.xsd#StockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_67904643-075d-4757-9b9c-7ae6ef60966d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_677ba927-3b83-46b1-837b-d92168a73489" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_67904643-075d-4757-9b9c-7ae6ef60966d" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_677ba927-3b83-46b1-837b-d92168a73489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="arwr-20230930.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_38a7bd48-a780-45c5-9631-ef8d8585a47a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3af1eb09-72a3-437a-b17e-b5b80082c73f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_38a7bd48-a780-45c5-9631-ef8d8585a47a" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_3af1eb09-72a3-437a-b17e-b5b80082c73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/Leases" xlink:type="simple" xlink:href="arwr-20230930.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_b151d173-3cfd-432e-b95b-688e640e7941" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_d9f03fd6-60f1-41ee-bb14-75edf432ab3a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_b151d173-3cfd-432e-b95b-688e640e7941" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_d9f03fd6-60f1-41ee-bb14-75edf432ab3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="arwr-20230930.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc77965d-ade2-47ca-9da9-a754902c554c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6f5694fc-109e-477f-a2d8-20676c392094" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_cc77965d-ade2-47ca-9da9-a754902c554c" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_6f5694fc-109e-477f-a2d8-20676c392094" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="arwr-20230930.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_329595db-5459-4100-90da-2eea2c232563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_2a0b4b48-4e9e-4e51-b20f-4db787d2d1c1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_329595db-5459-4100-90da-2eea2c232563" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_2a0b4b48-4e9e-4e51-b20f-4db787d2d1c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxes" xlink:type="simple" xlink:href="arwr-20230930.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_9e62bfaf-6f23-4e83-ba4b-3b05ace1de10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_86a4e3da-c555-4bbe-bd0d-9d30f79af185" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_9e62bfaf-6f23-4e83-ba4b-3b05ace1de10" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_86a4e3da-c555-4bbe-bd0d-9d30f79af185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/EmployeeBenefitPlans" xlink:type="simple" xlink:href="arwr-20230930.xsd#EmployeeBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/EmployeeBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e2651078-9928-4716-b3fb-05ce9eeb9ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_c1d83ed6-d135-4b10-b958-5f3bfcb4e47b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndEmployeeBenefitPlansTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_e2651078-9928-4716-b3fb-05ce9eeb9ffb" xlink:to="loc_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock_c1d83ed6-d135-4b10-b958-5f3bfcb4e47b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties" xlink:type="simple" xlink:href="arwr-20230930.xsd#LiabilityRelatedtotheSaleofFutureRoyalties"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_d93a6788-8522-4a98-9025-fb37cdde2ada" xlink:href="arwr-20230930.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_dbf09dae-5cee-4870-89fa-9429d3891dc0" xlink:href="arwr-20230930.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_d93a6788-8522-4a98-9025-fb37cdde2ada" xlink:to="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_dbf09dae-5cee-4870-89fa-9429d3891dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/EarningsPerShare" xlink:type="simple" xlink:href="arwr-20230930.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e0d78f58-079e-4141-b06b-3c82048fb7a3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_955e24ed-a8b7-4e60-8a47-ee6fa8d0d131" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e0d78f58-079e-4141-b06b-3c82048fb7a3" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_955e24ed-a8b7-4e60-8a47-ee6fa8d0d131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/SubsequentEvents" xlink:type="simple" xlink:href="arwr-20230930.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_9c59a78d-4083-479c-9799-0932de4e0f61" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_b4c4af07-a0ac-4700-96d8-ef1866bb8457" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_9c59a78d-4083-479c-9799-0932de4e0f61" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_b4c4af07-a0ac-4700-96d8-ef1866bb8457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="arwr-20230930.xsd#OrganizationandSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_68ef7192-e0dd-447a-8a51-51d223d2b2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock_2d65867c-d71e-47dd-a71a-cac5f7c24eec" xlink:href="arwr-20230930.xsd#arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68ef7192-e0dd-447a-8a51-51d223d2b2f2" xlink:to="loc_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock_2d65867c-d71e-47dd-a71a-cac5f7c24eec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_fb3aa2c9-f5f0-45bf-9285-ab789dcc640e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConsolidationVariableInterestEntityPolicy"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68ef7192-e0dd-447a-8a51-51d223d2b2f2" xlink:to="loc_us-gaap_ConsolidationVariableInterestEntityPolicy_fb3aa2c9-f5f0-45bf-9285-ab789dcc640e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3831534e-9ba0-4ece-9048-9dd1942823e6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68ef7192-e0dd-447a-8a51-51d223d2b2f2" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_3831534e-9ba0-4ece-9048-9dd1942823e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_b43d4c8b-c236-4fa1-836e-e97fab4c77d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68ef7192-e0dd-447a-8a51-51d223d2b2f2" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_b43d4c8b-c236-4fa1-836e-e97fab4c77d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_f9588feb-0836-4d47-b5e3-7871b93cf616" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68ef7192-e0dd-447a-8a51-51d223d2b2f2" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_f9588feb-0836-4d47-b5e3-7871b93cf616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_bee6653a-dcc5-417f-9000-fcaa7d97744b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68ef7192-e0dd-447a-8a51-51d223d2b2f2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_bee6653a-dcc5-417f-9000-fcaa7d97744b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_e0c6ab6d-333c-4fd6-a44e-a3fce6010082" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68ef7192-e0dd-447a-8a51-51d223d2b2f2" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_e0c6ab6d-333c-4fd6-a44e-a3fce6010082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_d48797d9-17db-452d-81bf-60bf69f5bec3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68ef7192-e0dd-447a-8a51-51d223d2b2f2" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_d48797d9-17db-452d-81bf-60bf69f5bec3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_94f15fcb-89e3-4d67-847c-6a30e160d6bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68ef7192-e0dd-447a-8a51-51d223d2b2f2" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_94f15fcb-89e3-4d67-847c-6a30e160d6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementAccountingPolicy_2c71dfdb-6ce7-4516-aa14-40e5b4d29abf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementAccountingPolicy"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68ef7192-e0dd-447a-8a51-51d223d2b2f2" xlink:to="loc_us-gaap_CollaborativeArrangementAccountingPolicy_2c71dfdb-6ce7-4516-aa14-40e5b4d29abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_386d712d-74c5-4df1-a524-f753b9d9a1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68ef7192-e0dd-447a-8a51-51d223d2b2f2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_386d712d-74c5-4df1-a524-f753b9d9a1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_384e1eeb-25a1-4a06-bdb6-b75c45e58c02" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68ef7192-e0dd-447a-8a51-51d223d2b2f2" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_384e1eeb-25a1-4a06-bdb6-b75c45e58c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_fc151a2f-ce20-40cf-9dc0-3999021d945c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68ef7192-e0dd-447a-8a51-51d223d2b2f2" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_fc151a2f-ce20-40cf-9dc0-3999021d945c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_0c2ac46c-b59a-4d9b-bab1-8076e62f11a0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68ef7192-e0dd-447a-8a51-51d223d2b2f2" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_0c2ac46c-b59a-4d9b-bab1-8076e62f11a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_31f2a4e7-01b2-4104-a739-a6e70f3d4927" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68ef7192-e0dd-447a-8a51-51d223d2b2f2" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_31f2a4e7-01b2-4104-a739-a6e70f3d4927" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fa140f08-7097-4a39-bcd7-38bc94f9cdbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_68ef7192-e0dd-447a-8a51-51d223d2b2f2" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_fa140f08-7097-4a39-bcd7-38bc94f9cdbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="arwr-20230930.xsd#OrganizationandSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_1793cff0-ad9f-48dc-966b-9b87291ee999" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfCurrentProductsTableTextBlock_b1d6466d-0747-44c8-adde-70bd303ef3f5" xlink:href="arwr-20230930.xsd#arwr_ScheduleOfCurrentProductsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_1793cff0-ad9f-48dc-966b-9b87291ee999" xlink:to="loc_arwr_ScheduleOfCurrentProductsTableTextBlock_b1d6466d-0747-44c8-adde-70bd303ef3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="arwr-20230930.xsd#CollaborationandLicenseAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_b81f47cc-0367-4da4-a45d-c844a1a0d987" xlink:href="arwr-20230930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_5b83181e-fd05-4e0f-99a3-0e508b7a800c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_b81f47cc-0367-4da4-a45d-c844a1a0d987" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_5b83181e-fd05-4e0f-99a3-0e508b7a800c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_b1ea4689-9e6c-49d8-8670-816950042a50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_b81f47cc-0367-4da4-a45d-c844a1a0d987" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_b1ea4689-9e6c-49d8-8670-816950042a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentTables" xlink:type="simple" xlink:href="arwr-20230930.xsd#PropertyandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/PropertyandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6aeedd04-a050-4c3f-93a6-2c70a9d22774" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9b35acc4-5910-4d8e-9c1e-b52284675bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_6aeedd04-a050-4c3f-93a6-2c70a9d22774" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_9b35acc4-5910-4d8e-9c1e-b52284675bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsTables" xlink:type="simple" xlink:href="arwr-20230930.xsd#InvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d8d3cfd5-7a10-4086-b344-3be598cf004e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_683dd2e2-e2e1-4bcd-a55c-4dc744a3c66c" xlink:href="arwr-20230930.xsd#arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_d8d3cfd5-7a10-4086-b344-3be598cf004e" xlink:to="loc_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_683dd2e2-e2e1-4bcd-a55c-4dc744a3c66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsTables" xlink:type="simple" xlink:href="arwr-20230930.xsd#IntangibleAssetsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fa8748ff-ca2e-453a-90d6-94390862f0d1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_79b505e9-1405-4b11-bf08-750c4a7a9caa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fa8748ff-ca2e-453a-90d6-94390862f0d1" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_79b505e9-1405-4b11-bf08-750c4a7a9caa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_836e51c4-4f8b-4ac4-91ab-3c2bdbeeaa10" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fa8748ff-ca2e-453a-90d6-94390862f0d1" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_836e51c4-4f8b-4ac4-91ab-3c2bdbeeaa10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityTables" xlink:type="simple" xlink:href="arwr-20230930.xsd#StockholdersEquityTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_d05afa6d-0078-4600-b993-c0e023da79d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTextBlock_76d7775a-0c4f-4840-80f5-64d9f7be6479" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_d05afa6d-0078-4600-b993-c0e023da79d2" xlink:to="loc_us-gaap_ScheduleOfStockByClassTextBlock_76d7775a-0c4f-4840-80f5-64d9f7be6479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesTables" xlink:type="simple" xlink:href="arwr-20230930.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_262ddbaa-c80e-436a-bba3-dba48146a6f7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_5fd98ee6-143d-462d-94dc-568041db062a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_262ddbaa-c80e-436a-bba3-dba48146a6f7" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_5fd98ee6-143d-462d-94dc-568041db062a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e06a8ec7-9da9-43a2-8c0c-09982f914338" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_262ddbaa-c80e-436a-bba3-dba48146a6f7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_e06a8ec7-9da9-43a2-8c0c-09982f914338" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="arwr-20230930.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9731ef4a-5456-4f80-997e-0e4a664f0546" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_980b2024-3215-480b-9ccb-d03345adf21d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9731ef4a-5456-4f80-997e-0e4a664f0546" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_980b2024-3215-480b-9ccb-d03345adf21d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_904fe583-139f-4191-bbf5-01f449caf60a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9731ef4a-5456-4f80-997e-0e4a664f0546" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_904fe583-139f-4191-bbf5-01f449caf60a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3b4d1e69-306b-4b08-9bc7-96c1251b262a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9731ef4a-5456-4f80-997e-0e4a664f0546" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3b4d1e69-306b-4b08-9bc7-96c1251b262a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_f6d7a56c-75d7-48b4-a0de-411b2317ed59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9731ef4a-5456-4f80-997e-0e4a664f0546" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_f6d7a56c-75d7-48b4-a0de-411b2317ed59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="arwr-20230930.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4c4c6c8d-8673-484b-83d4-50cdac518e90" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_cf5e0fe7-e13f-40d2-92c7-805426dba640" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4c4c6c8d-8673-484b-83d4-50cdac518e90" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_cf5e0fe7-e13f-40d2-92c7-805426dba640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="arwr-20230930.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b5517329-1268-49ea-9808-83abc51c1da7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_49030e7d-ed85-465d-a378-b6ac9c31ee3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b5517329-1268-49ea-9808-83abc51c1da7" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_49030e7d-ed85-465d-a378-b6ac9c31ee3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_38c864e7-8a9d-4768-84d5-1d641c7c3148" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b5517329-1268-49ea-9808-83abc51c1da7" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_38c864e7-8a9d-4768-84d5-1d641c7c3148" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_cac1e14d-f44f-4cc9-bbd7-baacc84983ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b5517329-1268-49ea-9808-83abc51c1da7" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_cac1e14d-f44f-4cc9-bbd7-baacc84983ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_f30c64a8-5be5-4d55-b344-6cd10c554cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b5517329-1268-49ea-9808-83abc51c1da7" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_f30c64a8-5be5-4d55-b344-6cd10c554cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_ee95ff94-3bc5-4801-9948-56a3b2950172" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b5517329-1268-49ea-9808-83abc51c1da7" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_ee95ff94-3bc5-4801-9948-56a3b2950172" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="arwr-20230930.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_908d4bc0-97eb-41e2-b0da-b0d7f8d918fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ef275941-e6c5-45fc-8449-4f69773054cf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_908d4bc0-97eb-41e2-b0da-b0d7f8d918fe" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_ef275941-e6c5-45fc-8449-4f69773054cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#OrganizationandSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_f44af6d1-210c-475b-9b03-79bb76b2ff14" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_c9d63843-204b-42ec-9dc3-31ba7ba01209" xlink:href="arwr-20230930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_f44af6d1-210c-475b-9b03-79bb76b2ff14" xlink:to="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_c9d63843-204b-42ec-9dc3-31ba7ba01209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_607915de-bd56-4c6e-93a8-7d75f773bc64" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_c9d63843-204b-42ec-9dc3-31ba7ba01209" xlink:to="loc_us-gaap_TypeOfArrangementAxis_607915de-bd56-4c6e-93a8-7d75f773bc64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d648dca0-9fe7-40f5-aa97-3564ccec47eb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_607915de-bd56-4c6e-93a8-7d75f773bc64" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d648dca0-9fe7-40f5-aa97-3564ccec47eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaAgreementMember_0f43af0b-a5d0-4f3c-a90b-204006c3d78d" xlink:href="arwr-20230930.xsd#arwr_RoyaltyPharmaAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d648dca0-9fe7-40f5-aa97-3564ccec47eb" xlink:to="loc_arwr_RoyaltyPharmaAgreementMember_0f43af0b-a5d0-4f3c-a90b-204006c3d78d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsMember_2e56544c-721f-4b65-b0c6-9f395ce24496" xlink:href="arwr-20230930.xsd#arwr_CollaborationAndLicenseAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_d648dca0-9fe7-40f5-aa97-3564ccec47eb" xlink:to="loc_arwr_CollaborationAndLicenseAgreementsMember_2e56544c-721f-4b65-b0c6-9f395ce24496" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_f445efb7-bbcf-4842-a121-d2edad690923" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_c9d63843-204b-42ec-9dc3-31ba7ba01209" xlink:to="loc_srt_RangeAxis_f445efb7-bbcf-4842-a121-d2edad690923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_3bca016b-3992-4dbf-902e-1dc490ef0240" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_f445efb7-bbcf-4842-a121-d2edad690923" xlink:to="loc_srt_RangeMember_3bca016b-3992-4dbf-902e-1dc490ef0240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_bb740a07-201e-41d5-b595-4e0b7a1b6dc0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3bca016b-3992-4dbf-902e-1dc490ef0240" xlink:to="loc_srt_MinimumMember_bb740a07-201e-41d5-b595-4e0b7a1b6dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1094f974-e5a5-497b-bf1a-f2641da8f8bd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_3bca016b-3992-4dbf-902e-1dc490ef0240" xlink:to="loc_srt_MaximumMember_1094f974-e5a5-497b-bf1a-f2641da8f8bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:href="arwr-20230930.xsd#arwr_OrganizationAndSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesTable_c9d63843-204b-42ec-9dc3-31ba7ba01209" xlink:to="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9e1e84c2-fb9b-454c-b589-6ef3c90efcbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9e1e84c2-fb9b-454c-b589-6ef3c90efcbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_adade941-4715-40b2-b620-59197e976822" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_adade941-4715-40b2-b620-59197e976822" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_79284377-620a-4268-8a8f-6603233e04b1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_79284377-620a-4268-8a8f-6603233e04b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_IncreaseDecreaseInCashAndInvestments_f53f406a-dc82-436b-a297-38b349406a50" xlink:href="arwr-20230930.xsd#arwr_IncreaseDecreaseInCashAndInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:to="loc_arwr_IncreaseDecreaseInCashAndInvestments_f53f406a-dc82-436b-a297-38b349406a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_d0e6507c-254f-415f-90fa-75161a7afef7" xlink:href="arwr-20230930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_d0e6507c-254f-415f-90fa-75161a7afef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontMilestonePaymentReceived_59ae53ed-c123-48bd-bf57-2f87d5c82424" xlink:href="arwr-20230930.xsd#arwr_UpfrontMilestonePaymentReceived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:to="loc_arwr_UpfrontMilestonePaymentReceived_59ae53ed-c123-48bd-bf57-2f87d5c82424" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_4d0dab85-9ed9-4826-a474-665039209e6a" xlink:href="arwr-20230930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_4d0dab85-9ed9-4826-a474-665039209e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFDICInsuredAmount_f38b3349-f14e-4ca9-b393-6a3218ac9836" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFDICInsuredAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:to="loc_us-gaap_CashFDICInsuredAmount_f38b3349-f14e-4ca9-b393-6a3218ac9836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_b6821435-1d97-45a8-8e73-4a23721870e9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_b6821435-1d97-45a8-8e73-4a23721870e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_05830acc-a277-41bb-b68b-14eff470189a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_05830acc-a277-41bb-b68b-14eff470189a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9b2a1970-2fcd-40a4-9dbf-051399856c9a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ImpairmentOfIntangibleAssetsFinitelived"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_OrganizationAndSignificantAccountingPoliciesLineItems_fcdcac92-3bab-458b-af5b-b7f55d20c359" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsFinitelived_9b2a1970-2fcd-40a4-9dbf-051399856c9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#CollaborationandLicenseAgreementsRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_7d706bdd-49d7-4e0d-bbd7-9c8a9b6aec82" xlink:href="arwr-20230930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_dc7c30f0-edd9-42dd-9415-f6c16c3d5f41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_7d706bdd-49d7-4e0d-bbd7-9c8a9b6aec82" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_dc7c30f0-edd9-42dd-9415-f6c16c3d5f41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_c36d10cf-5442-4e11-9874-30a3ce654de9" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_dc7c30f0-edd9-42dd-9415-f6c16c3d5f41" xlink:to="loc_srt_MajorCustomersAxis_c36d10cf-5442-4e11-9874-30a3ce654de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4f5506d2-31c2-43fb-a9bc-525e7f4f31be" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_c36d10cf-5442-4e11-9874-30a3ce654de9" xlink:to="loc_srt_NameOfMajorCustomerDomain_4f5506d2-31c2-43fb-a9bc-525e7f4f31be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_7f00640a-56d7-45f7-a831-cec3c7be4f2c" xlink:href="arwr-20230930.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4f5506d2-31c2-43fb-a9bc-525e7f4f31be" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_7f00640a-56d7-45f7-a831-cec3c7be4f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember_dbd2afd9-0c91-4618-9b8b-e364e3153596" xlink:href="arwr-20230930.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4f5506d2-31c2-43fb-a9bc-525e7f4f31be" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACMember_dbd2afd9-0c91-4618-9b8b-e364e3153596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_311e0771-91e0-4807-b8d0-d3a3afd85ee2" xlink:href="arwr-20230930.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4f5506d2-31c2-43fb-a9bc-525e7f4f31be" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_311e0771-91e0-4807-b8d0-d3a3afd85ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember_33fa755e-8c76-4d96-a80b-a4ec66d98cfc" xlink:href="arwr-20230930.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4f5506d2-31c2-43fb-a9bc-525e7f4f31be" xlink:to="loc_arwr_JanssenPharmaceuticalsIncorporationMember_33fa755e-8c76-4d96-a80b-a4ec66d98cfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_c9932437-cfd6-4f91-96ef-cbea2e24240d" xlink:href="arwr-20230930.xsd#arwr_AmgenIncorporatedMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_4f5506d2-31c2-43fb-a9bc-525e7f4f31be" xlink:to="loc_arwr_AmgenIncorporatedMember_c9932437-cfd6-4f91-96ef-cbea2e24240d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_7a6fd717-7635-4a87-845f-20e78b9f1c91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_dc7c30f0-edd9-42dd-9415-f6c16c3d5f41" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_7a6fd717-7635-4a87-845f-20e78b9f1c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_623addfd-444b-4b98-911c-9da5642daac3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_7a6fd717-7635-4a87-845f-20e78b9f1c91" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_623addfd-444b-4b98-911c-9da5642daac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_14ff434a-2a9e-44bb-8073-bec728031f76" xlink:href="arwr-20230930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNet_607c5091-3494-441c-b2e8-e905b3dabd5c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccountsReceivableNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_14ff434a-2a9e-44bb-8073-bec728031f76" xlink:to="loc_us-gaap_AccountsReceivableNet_607c5091-3494-441c-b2e8-e905b3dabd5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_232186bd-a934-41c2-9d0a-f93d503b4286" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_14ff434a-2a9e-44bb-8073-bec728031f76" xlink:to="loc_us-gaap_ContractWithCustomerLiability_232186bd-a934-41c2-9d0a-f93d503b4286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_6f36daea-d1e7-47c5-bcf0-01d8e1410a87" xlink:href="arwr-20230930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4faa8f63-84af-4537-8074-efd8f6ab5a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_6f36daea-d1e7-47c5-bcf0-01d8e1410a87" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4faa8f63-84af-4537-8074-efd8f6ab5a2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_c30bc2a1-8641-4ce6-8016-64f8058b847d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4faa8f63-84af-4537-8074-efd8f6ab5a2d" xlink:to="loc_srt_CounterpartyNameAxis_c30bc2a1-8641-4ce6-8016-64f8058b847d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91fed46f-4231-4798-b6d5-604d18911c4c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_c30bc2a1-8641-4ce6-8016-64f8058b847d" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91fed46f-4231-4798-b6d5-604d18911c4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_15487269-434e-4141-8d69-478c2f61b9d9" xlink:href="arwr-20230930.xsd#arwr_GlaxosmithklineIntellectualPropertyLimitedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_91fed46f-4231-4798-b6d5-604d18911c4c" xlink:to="loc_arwr_GlaxosmithklineIntellectualPropertyLimitedMember_15487269-434e-4141-8d69-478c2f61b9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_9fde3b82-e183-4385-9d63-05a5542baf85" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4faa8f63-84af-4537-8074-efd8f6ab5a2d" xlink:to="loc_us-gaap_TypeOfArrangementAxis_9fde3b82-e183-4385-9d63-05a5542baf85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0341b19-968c-4c1c-9909-e0faee4076dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_9fde3b82-e183-4385-9d63-05a5542baf85" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0341b19-968c-4c1c-9909-e0faee4076dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsMember_c42389b0-1256-4891-9114-3035f6b5b4ca" xlink:href="arwr-20230930.xsd#arwr_CollaborationAndLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_c0341b19-968c-4c1c-9909-e0faee4076dd" xlink:to="loc_arwr_CollaborationAndLicenseAgreementsMember_c42389b0-1256-4891-9114-3035f6b5b4ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_aaeb0290-83df-4f9c-b18e-14100268b6ce" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4faa8f63-84af-4537-8074-efd8f6ab5a2d" xlink:to="loc_srt_RangeAxis_aaeb0290-83df-4f9c-b18e-14100268b6ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d10998ca-d3cc-4226-a206-afde40758d3c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_aaeb0290-83df-4f9c-b18e-14100268b6ce" xlink:to="loc_srt_RangeMember_d10998ca-d3cc-4226-a206-afde40758d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_341eb999-7790-4698-b2aa-ef1612d4a27b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_d10998ca-d3cc-4226-a206-afde40758d3c" xlink:to="loc_srt_MaximumMember_341eb999-7790-4698-b2aa-ef1612d4a27b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84a52fa6-9720-42b8-b90e-c3e94238c608" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_4faa8f63-84af-4537-8074-efd8f6ab5a2d" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84a52fa6-9720-42b8-b90e-c3e94238c608" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_9d179759-ff3d-464c-b5d1-b5240c961063" xlink:href="arwr-20230930.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84a52fa6-9720-42b8-b90e-c3e94238c608" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_9d179759-ff3d-464c-b5d1-b5240c961063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_2c7c1c7c-4339-4418-a462-f2a6f56d069c" xlink:href="arwr-20230930.xsd#arwr_NumberOfDistinctBundle"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84a52fa6-9720-42b8-b90e-c3e94238c608" xlink:to="loc_arwr_NumberOfDistinctBundle_2c7c1c7c-4339-4418-a462-f2a6f56d069c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_4dafed73-63c1-4ce0-a240-0be9d5edce28" xlink:href="arwr-20230930.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84a52fa6-9720-42b8-b90e-c3e94238c608" xlink:to="loc_arwr_InitialTransactionPrice_4dafed73-63c1-4ce0-a240-0be9d5edce28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_453b35f6-522f-4db5-a234-74d263e29693" xlink:href="arwr-20230930.xsd#arwr_MilestonePaymentReceivable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84a52fa6-9720-42b8-b90e-c3e94238c608" xlink:to="loc_arwr_MilestonePaymentReceivable_453b35f6-522f-4db5-a234-74d263e29693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_33d4a9d2-1859-4fb0-9e06-6054ad981324" xlink:href="arwr-20230930.xsd#arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84a52fa6-9720-42b8-b90e-c3e94238c608" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_33d4a9d2-1859-4fb0-9e06-6054ad981324" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_c6565903-fb5c-41a9-b4ba-c4053d9b0bee" xlink:href="arwr-20230930.xsd#arwr_CommercialMilestonePaymentsAtFirstCommercialSale"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84a52fa6-9720-42b8-b90e-c3e94238c608" xlink:to="loc_arwr_CommercialMilestonePaymentsAtFirstCommercialSale_c6565903-fb5c-41a9-b4ba-c4053d9b0bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SalesRelatedMilestonePayments_b00d7df7-fea6-4fe2-8917-6a11ccdf3991" xlink:href="arwr-20230930.xsd#arwr_SalesRelatedMilestonePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84a52fa6-9720-42b8-b90e-c3e94238c608" xlink:to="loc_arwr_SalesRelatedMilestonePayments_b00d7df7-fea6-4fe2-8917-6a11ccdf3991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7268fbf5-8830-48c0-be80-daff29d1ae73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_84a52fa6-9720-42b8-b90e-c3e94238c608" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7268fbf5-8830-48c0-be80-daff29d1ae73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_d119686c-e16d-4a5f-8cc2-5b6137de2d0b" xlink:href="arwr-20230930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_723a59bd-facb-48bb-b64c-a7b697a40354" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_d119686c-e16d-4a5f-8cc2-5b6137de2d0b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_723a59bd-facb-48bb-b64c-a7b697a40354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3f18059c-4598-48f8-b512-718a6de88d34" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_723a59bd-facb-48bb-b64c-a7b697a40354" xlink:to="loc_srt_CounterpartyNameAxis_3f18059c-4598-48f8-b512-718a6de88d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9162b83c-2626-4cfb-a2b8-5b33c083a866" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3f18059c-4598-48f8-b512-718a6de88d34" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9162b83c-2626-4cfb-a2b8-5b33c083a866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonTherapeuticsIrelandDACMember_60883199-17a8-4272-b967-cd739ef895a3" xlink:href="arwr-20230930.xsd#arwr_HorizonTherapeuticsIrelandDACMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9162b83c-2626-4cfb-a2b8-5b33c083a866" xlink:to="loc_arwr_HorizonTherapeuticsIrelandDACMember_60883199-17a8-4272-b967-cd739ef895a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_707bf7e5-8aa5-4b80-aaa2-e7ff65c4d87e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_723a59bd-facb-48bb-b64c-a7b697a40354" xlink:to="loc_us-gaap_TypeOfArrangementAxis_707bf7e5-8aa5-4b80-aaa2-e7ff65c4d87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b9735585-08b4-436e-87e1-5cd635e9991a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_707bf7e5-8aa5-4b80-aaa2-e7ff65c4d87e" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b9735585-08b4-436e-87e1-5cd635e9991a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_HorizonLicenseAgreementMember_0c175662-c5d9-4f80-8e6f-c33f6297a331" xlink:href="arwr-20230930.xsd#arwr_HorizonLicenseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_b9735585-08b4-436e-87e1-5cd635e9991a" xlink:to="loc_arwr_HorizonLicenseAgreementMember_0c175662-c5d9-4f80-8e6f-c33f6297a331" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6332d105-8c14-49a8-842d-c9e945093854" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_723a59bd-facb-48bb-b64c-a7b697a40354" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6332d105-8c14-49a8-842d-c9e945093854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_5431d5d3-3dd9-4127-933f-8144cf9306b2" xlink:href="arwr-20230930.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6332d105-8c14-49a8-842d-c9e945093854" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_5431d5d3-3dd9-4127-933f-8144cf9306b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_afdb6d34-0d95-4265-a229-7bd4a00ad986" xlink:href="arwr-20230930.xsd#arwr_NumberOfDistinctBundle"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6332d105-8c14-49a8-842d-c9e945093854" xlink:to="loc_arwr_NumberOfDistinctBundle_afdb6d34-0d95-4265-a229-7bd4a00ad986" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_8f2ac1a7-c30f-405a-b588-b4d14be93f1d" xlink:href="arwr-20230930.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6332d105-8c14-49a8-842d-c9e945093854" xlink:to="loc_arwr_InitialTransactionPrice_8f2ac1a7-c30f-405a-b588-b4d14be93f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_UpfrontMilestonePaymentReceived_f213688f-8072-48c9-9c0c-02685de25491" xlink:href="arwr-20230930.xsd#arwr_UpfrontMilestonePaymentReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6332d105-8c14-49a8-842d-c9e945093854" xlink:to="loc_arwr_UpfrontMilestonePaymentReceived_f213688f-8072-48c9-9c0c-02685de25491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c891b3c8-5e33-4dcc-97c7-024a45422342" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_6332d105-8c14-49a8-842d-c9e945093854" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c891b3c8-5e33-4dcc-97c7-024a45422342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_c128cc28-0ae8-44f9-9ade-70aae5fe6a17" xlink:href="arwr-20230930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_63b11947-ee69-4ce6-b8cc-66fea22c942a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_c128cc28-0ae8-44f9-9ade-70aae5fe6a17" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_63b11947-ee69-4ce6-b8cc-66fea22c942a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_98e1aade-bfb6-45ea-b6b9-365fc14ee502" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_63b11947-ee69-4ce6-b8cc-66fea22c942a" xlink:to="loc_srt_CounterpartyNameAxis_98e1aade-bfb6-45ea-b6b9-365fc14ee502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d25b2a8-8a9c-4da2-abd4-5f8c387e8699" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_98e1aade-bfb6-45ea-b6b9-365fc14ee502" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d25b2a8-8a9c-4da2-abd4-5f8c387e8699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_4b6f7277-ffd3-4cbd-848e-6f24525b3a14" xlink:href="arwr-20230930.xsd#arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_6d25b2a8-8a9c-4da2-abd4-5f8c387e8699" xlink:to="loc_arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember_4b6f7277-ffd3-4cbd-848e-6f24525b3a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d34b19a7-6507-4b58-b22e-4441f7605fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_63b11947-ee69-4ce6-b8cc-66fea22c942a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d34b19a7-6507-4b58-b22e-4441f7605fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9ce2d6cd-1d42-4a66-823a-57d807db62dc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d34b19a7-6507-4b58-b22e-4441f7605fa5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9ce2d6cd-1d42-4a66-823a-57d807db62dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LicenseAndCoFundingAgreementMember_e84b1796-c512-4948-8d24-c109e107d0e6" xlink:href="arwr-20230930.xsd#arwr_LicenseAndCoFundingAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9ce2d6cd-1d42-4a66-823a-57d807db62dc" xlink:to="loc_arwr_LicenseAndCoFundingAgreementMember_e84b1796-c512-4948-8d24-c109e107d0e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_03b3757c-7463-449e-ad2a-4dcd6f4190ae" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_63b11947-ee69-4ce6-b8cc-66fea22c942a" xlink:to="loc_srt_RangeAxis_03b3757c-7463-449e-ad2a-4dcd6f4190ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_04d7a724-f5e8-4478-87ac-c31e0d5a7fcc" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_03b3757c-7463-449e-ad2a-4dcd6f4190ae" xlink:to="loc_srt_RangeMember_04d7a724-f5e8-4478-87ac-c31e0d5a7fcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7030af54-b921-407a-958d-7ec97fb62ab6" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_04d7a724-f5e8-4478-87ac-c31e0d5a7fcc" xlink:to="loc_srt_MinimumMember_7030af54-b921-407a-958d-7ec97fb62ab6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4271e354-b7a1-45b9-98d5-1bdbd53a6f46" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_04d7a724-f5e8-4478-87ac-c31e0d5a7fcc" xlink:to="loc_srt_MaximumMember_4271e354-b7a1-45b9-98d5-1bdbd53a6f46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbd69c50-9589-4c01-8190-ec0d1851f949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_63b11947-ee69-4ce6-b8cc-66fea22c942a" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbd69c50-9589-4c01-8190-ec0d1851f949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_9f08be1d-a4a0-46c1-b189-c893032dc3c4" xlink:href="arwr-20230930.xsd#arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbd69c50-9589-4c01-8190-ec0d1851f949" xlink:to="loc_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales_9f08be1d-a4a0-46c1-b189-c893032dc3c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_1f9660d7-aebd-4e7e-8302-855b8e70de9b" xlink:href="arwr-20230930.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbd69c50-9589-4c01-8190-ec0d1851f949" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_1f9660d7-aebd-4e7e-8302-855b8e70de9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_b85e36ad-1323-4952-adaf-c782c56a7535" xlink:href="arwr-20230930.xsd#arwr_NumberOfDistinctBundle"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbd69c50-9589-4c01-8190-ec0d1851f949" xlink:to="loc_arwr_NumberOfDistinctBundle_b85e36ad-1323-4952-adaf-c782c56a7535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_fef0be86-0c4d-42b6-acc4-f034cd0571c0" xlink:href="arwr-20230930.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbd69c50-9589-4c01-8190-ec0d1851f949" xlink:to="loc_arwr_InitialTransactionPrice_fef0be86-0c4d-42b6-acc4-f034cd0571c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_f730ad11-4def-402b-af14-414819b58fa6" xlink:href="arwr-20230930.xsd#arwr_MilestonePaymentEarned"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbd69c50-9589-4c01-8190-ec0d1851f949" xlink:to="loc_arwr_MilestonePaymentEarned_f730ad11-4def-402b-af14-414819b58fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_4115d6c7-078c-4398-b0f6-008612a8b154" xlink:href="arwr-20230930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbd69c50-9589-4c01-8190-ec0d1851f949" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_4115d6c7-078c-4398-b0f6-008612a8b154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bb33f7d7-a3db-477b-89ac-e2c0d15e4fb5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbd69c50-9589-4c01-8190-ec0d1851f949" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bb33f7d7-a3db-477b-89ac-e2c0d15e4fb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_55186541-a303-45e7-84eb-e2ac01a02cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbd69c50-9589-4c01-8190-ec0d1851f949" xlink:to="loc_us-gaap_EarningsPerShareDiluted_55186541-a303-45e7-84eb-e2ac01a02cbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_75a40d71-3777-4cc4-a178-4f540d9e2866" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbd69c50-9589-4c01-8190-ec0d1851f949" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_75a40d71-3777-4cc4-a178-4f540d9e2866" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_93a517a2-5ad5-4b13-9709-0342e5c2eefd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_dbd69c50-9589-4c01-8190-ec0d1851f949" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_93a517a2-5ad5-4b13-9709-0342e5c2eefd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_e869080c-b307-406d-91ba-1d4abfdba64a" xlink:href="arwr-20230930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_520b73b0-67ef-4df2-8163-e2edc3f0d014" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_e869080c-b307-406d-91ba-1d4abfdba64a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_520b73b0-67ef-4df2-8163-e2edc3f0d014" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_514dd499-b6f4-42c4-ba07-0154899656fb" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_520b73b0-67ef-4df2-8163-e2edc3f0d014" xlink:to="loc_srt_CounterpartyNameAxis_514dd499-b6f4-42c4-ba07-0154899656fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a824876-4458-47ba-ad7b-25f96632a065" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_514dd499-b6f4-42c4-ba07-0154899656fb" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a824876-4458-47ba-ad7b-25f96632a065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_0dd812e5-b171-4577-86eb-54797ee01f83" xlink:href="arwr-20230930.xsd#arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a824876-4458-47ba-ad7b-25f96632a065" xlink:to="loc_arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember_0dd812e5-b171-4577-86eb-54797ee01f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JanssenPharmaceuticalsIncorporationMember_11314a4e-83b1-465f-b1a4-6c45804475de" xlink:href="arwr-20230930.xsd#arwr_JanssenPharmaceuticalsIncorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a824876-4458-47ba-ad7b-25f96632a065" xlink:to="loc_arwr_JanssenPharmaceuticalsIncorporationMember_11314a4e-83b1-465f-b1a4-6c45804475de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_e5191fa6-97c6-48af-a515-29cc9d973145" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_520b73b0-67ef-4df2-8163-e2edc3f0d014" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_e5191fa6-97c6-48af-a515-29cc9d973145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4e4f646e-29e0-40b6-b362-dcfceec37aaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_e5191fa6-97c6-48af-a515-29cc9d973145" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4e4f646e-29e0-40b6-b362-dcfceec37aaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockPurchaseAgreementMember_a914ef2f-ab3d-4117-ae0d-0bbbdb0fc6b5" xlink:href="arwr-20230930.xsd#arwr_CommonStockPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_4e4f646e-29e0-40b6-b362-dcfceec37aaf" xlink:to="loc_arwr_CommonStockPurchaseAgreementMember_a914ef2f-ab3d-4117-ae0d-0bbbdb0fc6b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_be2df002-4636-42f2-9c31-66c60a8d8db9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_520b73b0-67ef-4df2-8163-e2edc3f0d014" xlink:to="loc_us-gaap_TypeOfArrangementAxis_be2df002-4636-42f2-9c31-66c60a8d8db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fb6ca5f8-5a98-40dc-8119-84e96d6a4df1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_be2df002-4636-42f2-9c31-66c60a8d8db9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fb6ca5f8-5a98-40dc-8119-84e96d6a4df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsMember_485e010d-b213-4988-84a0-61e54c8f3465" xlink:href="arwr-20230930.xsd#arwr_CollaborationAndLicenseAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fb6ca5f8-5a98-40dc-8119-84e96d6a4df1" xlink:to="loc_arwr_CollaborationAndLicenseAgreementsMember_485e010d-b213-4988-84a0-61e54c8f3465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JNJ3989AROHBVAgreementMember_3fe33aa5-b4e7-4bdb-ae0d-8f08928862b8" xlink:href="arwr-20230930.xsd#arwr_JNJ3989AROHBVAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_fb6ca5f8-5a98-40dc-8119-84e96d6a4df1" xlink:to="loc_arwr_JNJ3989AROHBVAgreementMember_3fe33aa5-b4e7-4bdb-ae0d-8f08928862b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_82ef4dd7-6782-4e7f-a55a-22c8fce63700" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_520b73b0-67ef-4df2-8163-e2edc3f0d014" xlink:to="loc_srt_RangeAxis_82ef4dd7-6782-4e7f-a55a-22c8fce63700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1c9154f3-c39f-4dcd-8f97-45cea3288f87" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_82ef4dd7-6782-4e7f-a55a-22c8fce63700" xlink:to="loc_srt_RangeMember_1c9154f3-c39f-4dcd-8f97-45cea3288f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1b7e2e2c-d610-43e4-8fbf-2a0846cb3700" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1c9154f3-c39f-4dcd-8f97-45cea3288f87" xlink:to="loc_srt_MaximumMember_1b7e2e2c-d610-43e4-8fbf-2a0846cb3700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_217429f1-2204-4591-a613-f0847044abc7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_520b73b0-67ef-4df2-8163-e2edc3f0d014" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_217429f1-2204-4591-a613-f0847044abc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_fa4146ae-563e-4b32-8782-0a4a2effdc82" xlink:href="arwr-20230930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_217429f1-2204-4591-a613-f0847044abc7" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_fa4146ae-563e-4b32-8782-0a4a2effdc82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_94a18929-b155-4cee-b95f-0bfd519eb599" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_217429f1-2204-4591-a613-f0847044abc7" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_94a18929-b155-4cee-b95f-0bfd519eb599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentEarned_55e42e0f-7a49-4843-9b8d-33fa3b009b95" xlink:href="arwr-20230930.xsd#arwr_MilestonePaymentEarned"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_217429f1-2204-4591-a613-f0847044abc7" xlink:to="loc_arwr_MilestonePaymentEarned_55e42e0f-7a49-4843-9b8d-33fa3b009b95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_462e4278-6079-4552-8b1a-f9ec636be5f1" xlink:href="arwr-20230930.xsd#arwr_DevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_217429f1-2204-4591-a613-f0847044abc7" xlink:to="loc_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_462e4278-6079-4552-8b1a-f9ec636be5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctBundle_7742ed99-212f-4fe7-ac8f-b0d34ef346e9" xlink:href="arwr-20230930.xsd#arwr_NumberOfDistinctBundle"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_217429f1-2204-4591-a613-f0847044abc7" xlink:to="loc_arwr_NumberOfDistinctBundle_7742ed99-212f-4fe7-ac8f-b0d34ef346e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfDistinctPerformanceObligations_105dc928-fd7d-44be-858e-2396800a6681" xlink:href="arwr-20230930.xsd#arwr_NumberOfDistinctPerformanceObligations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_217429f1-2204-4591-a613-f0847044abc7" xlink:to="loc_arwr_NumberOfDistinctPerformanceObligations_105dc928-fd7d-44be-858e-2396800a6681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_c77b616e-896e-42d8-962f-6b8b35c4d154" xlink:href="arwr-20230930.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_217429f1-2204-4591-a613-f0847044abc7" xlink:to="loc_arwr_InitialTransactionPrice_c77b616e-896e-42d8-962f-6b8b35c4d154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5cec7912-1d29-4b66-b18c-75f094c265cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_217429f1-2204-4591-a613-f0847044abc7" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_5cec7912-1d29-4b66-b18c-75f094c265cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_813f4025-ad16-4a5d-9b9b-59fd27a7368b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_217429f1-2204-4591-a613-f0847044abc7" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_813f4025-ad16-4a5d-9b9b-59fd27a7368b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#CollaborationandLicenseAgreementsAmgenIncDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_0c93fabf-c487-46fc-9040-e07cc0f445b9" xlink:href="arwr-20230930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9d601756-e315-4c2d-ae3a-02f0dce59544" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_0c93fabf-c487-46fc-9040-e07cc0f445b9" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9d601756-e315-4c2d-ae3a-02f0dce59544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_a36cdbc2-5c13-41dc-a91d-ee44a144b035" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9d601756-e315-4c2d-ae3a-02f0dce59544" xlink:to="loc_srt_CounterpartyNameAxis_a36cdbc2-5c13-41dc-a91d-ee44a144b035" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1125e344-55e2-406a-b739-7a8573da79ff" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_a36cdbc2-5c13-41dc-a91d-ee44a144b035" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1125e344-55e2-406a-b739-7a8573da79ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmgenIncorporatedMember_c0a8fd7e-0706-4798-a35b-1fb5acc4ca49" xlink:href="arwr-20230930.xsd#arwr_AmgenIncorporatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1125e344-55e2-406a-b739-7a8573da79ff" xlink:to="loc_arwr_AmgenIncorporatedMember_c0a8fd7e-0706-4798-a35b-1fb5acc4ca49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6a72c49f-76bc-486e-920b-2ee2988ac110" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9d601756-e315-4c2d-ae3a-02f0dce59544" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6a72c49f-76bc-486e-920b-2ee2988ac110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e51870d-da5d-43c3-9cee-3c59b43a7c43" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6a72c49f-76bc-486e-920b-2ee2988ac110" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e51870d-da5d-43c3-9cee-3c59b43a7c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OlpasiranAgreementMember_6bea643a-de9e-44fa-94ca-2b26a16e1ca4" xlink:href="arwr-20230930.xsd#arwr_OlpasiranAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_9e51870d-da5d-43c3-9cee-3c59b43a7c43" xlink:to="loc_arwr_OlpasiranAgreementMember_6bea643a-de9e-44fa-94ca-2b26a16e1ca4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_5293ffd1-4728-49c7-b434-613a5b2a3569" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9d601756-e315-4c2d-ae3a-02f0dce59544" xlink:to="loc_srt_RangeAxis_5293ffd1-4728-49c7-b434-613a5b2a3569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4edacc92-7b9f-46b1-bbae-d92ffc45fb78" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_5293ffd1-4728-49c7-b434-613a5b2a3569" xlink:to="loc_srt_RangeMember_4edacc92-7b9f-46b1-bbae-d92ffc45fb78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_38f6e1bc-0fca-4a7c-93d8-937179dd19cd" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4edacc92-7b9f-46b1-bbae-d92ffc45fb78" xlink:to="loc_srt_MaximumMember_38f6e1bc-0fca-4a7c-93d8-937179dd19cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca8d059b-64e8-4949-830b-ea73855bf0c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_9d601756-e315-4c2d-ae3a-02f0dce59544" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca8d059b-64e8-4949-830b-ea73855bf0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAgreements_131db3a9-9013-41c8-8015-fa63879b2342" xlink:href="arwr-20230930.xsd#arwr_NumberOfAgreements"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca8d059b-64e8-4949-830b-ea73855bf0c4" xlink:to="loc_arwr_NumberOfAgreements_131db3a9-9013-41c8-8015-fa63879b2342" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_6f14df44-9ea1-488a-bf80-fe007b6a57c6" xlink:href="arwr-20230930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca8d059b-64e8-4949-830b-ea73855bf0c4" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_6f14df44-9ea1-488a-bf80-fe007b6a57c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bdb4a6f8-61d8-4efa-befa-18622084ec59" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca8d059b-64e8-4949-830b-ea73855bf0c4" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_bdb4a6f8-61d8-4efa-befa-18622084ec59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceived_c0dddcb5-99e4-4f80-966b-068b9250454e" xlink:href="arwr-20230930.xsd#arwr_MilestonePaymentReceived"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca8d059b-64e8-4949-830b-ea73855bf0c4" xlink:to="loc_arwr_MilestonePaymentReceived_c0dddcb5-99e4-4f80-966b-068b9250454e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_703f7ab4-c965-414b-915f-cd8239f90ede" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca8d059b-64e8-4949-830b-ea73855bf0c4" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_703f7ab4-c965-414b-915f-cd8239f90ede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_6e8bde3b-4a1f-493d-b1c3-e0f9c602b291" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca8d059b-64e8-4949-830b-ea73855bf0c4" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_6e8bde3b-4a1f-493d-b1c3-e0f9c602b291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_44cad62f-607d-4b97-844f-f206336317b7" xlink:href="arwr-20230930.xsd#arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_ca8d059b-64e8-4949-830b-ea73855bf0c4" xlink:to="loc_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments_44cad62f-607d-4b97-844f-f206336317b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CollaborationAndLicenseAgreementsAbstract_6b21e656-7fee-4a61-9184-d83020e2a493" xlink:href="arwr-20230930.xsd#arwr_CollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d56e9502-7334-488b-8d34-dc21b218001a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CollaborationAndLicenseAgreementsAbstract_6b21e656-7fee-4a61-9184-d83020e2a493" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d56e9502-7334-488b-8d34-dc21b218001a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_45cee61b-2327-4ff9-934a-673e01126503" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d56e9502-7334-488b-8d34-dc21b218001a" xlink:to="loc_us-gaap_TypeOfArrangementAxis_45cee61b-2327-4ff9-934a-673e01126503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_569db29b-2709-4879-abc2-b13fa7c77ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_45cee61b-2327-4ff9-934a-673e01126503" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_569db29b-2709-4879-abc2-b13fa7c77ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VisirnaTherapeuticsIncMember_9142bf54-cf09-4397-8478-d4919bf2970f" xlink:href="arwr-20230930.xsd#arwr_VisirnaTherapeuticsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_569db29b-2709-4879-abc2-b13fa7c77ca9" xlink:to="loc_arwr_VisirnaTherapeuticsIncMember_9142bf54-cf09-4397-8478-d4919bf2970f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesAxis_1b0eea0a-f68f-4fc5-971a-b12f6a668e7b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d56e9502-7334-488b-8d34-dc21b218001a" xlink:to="loc_srt_ConsolidatedEntitiesAxis_1b0eea0a-f68f-4fc5-971a-b12f6a668e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidatedEntitiesDomain_4957c87a-9dd2-44e4-a3d0-c65d071b69a4" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ConsolidatedEntitiesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesAxis_1b0eea0a-f68f-4fc5-971a-b12f6a668e7b" xlink:to="loc_srt_ConsolidatedEntitiesDomain_4957c87a-9dd2-44e4-a3d0-c65d071b69a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_0a59a058-bd5b-45bd-9ad7-45407c021224" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableInterestEntityPrimaryBeneficiaryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidatedEntitiesDomain_4957c87a-9dd2-44e4-a3d0-c65d071b69a4" xlink:to="loc_us-gaap_VariableInterestEntityPrimaryBeneficiaryMember_0a59a058-bd5b-45bd-9ad7-45407c021224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4d52fb55-3b2e-42d1-b1de-44c68bc9ddb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d56e9502-7334-488b-8d34-dc21b218001a" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4d52fb55-3b2e-42d1-b1de-44c68bc9ddb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromContributedCapital_bea060b9-d2e5-4e50-b576-6171f3e9daa2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ProceedsFromContributedCapital"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4d52fb55-3b2e-42d1-b1de-44c68bc9ddb7" xlink:to="loc_us-gaap_ProceedsFromContributedCapital_bea060b9-d2e5-4e50-b576-6171f3e9daa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#PropertyandEquipmentSummaryofPropertyandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_57993931-3db4-4224-b3a2-367a5375246d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_a5a5f6ea-ba84-4f9f-bc04-a92b14d4856d" xlink:href="arwr-20230930.xsd#arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_57993931-3db4-4224-b3a2-367a5375246d" xlink:to="loc_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross_a5a5f6ea-ba84-4f9f-bc04-a92b14d4856d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Land_98da90f5-e184-462c-af0d-f0b82068a55a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_Land"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_57993931-3db4-4224-b3a2-367a5375246d" xlink:to="loc_us-gaap_Land_98da90f5-e184-462c-af0d-f0b82068a55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchEquipmentGross_9fd32688-9fc0-4103-9681-264942a1eb99" xlink:href="arwr-20230930.xsd#arwr_ResearchEquipmentGross"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_57993931-3db4-4224-b3a2-367a5375246d" xlink:to="loc_arwr_ResearchEquipmentGross_9fd32688-9fc0-4103-9681-264942a1eb99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsGross_627370c7-f29d-4f51-9b53-2f64e74d31d2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseholdImprovementsGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_57993931-3db4-4224-b3a2-367a5375246d" xlink:to="loc_us-gaap_LeaseholdImprovementsGross_627370c7-f29d-4f51-9b53-2f64e74d31d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_cc6565b8-d686-43b5-9960-b846e995fd08" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_57993931-3db4-4224-b3a2-367a5375246d" xlink:to="loc_us-gaap_ConstructionInProgressGross_cc6565b8-d686-43b5-9960-b846e995fd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_4f3ef467-fcf3-45b2-82b2-7ceed08bf685" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_57993931-3db4-4224-b3a2-367a5375246d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_4f3ef467-fcf3-45b2-82b2-7ceed08bf685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a3ed7d67-544b-4bff-aaff-f13787dd0ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_57993931-3db4-4224-b3a2-367a5375246d" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_a3ed7d67-544b-4bff-aaff-f13787dd0ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_cb6aaaa3-a076-4b70-87f2-65ce42033278" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_57993931-3db4-4224-b3a2-367a5375246d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_cb6aaaa3-a076-4b70-87f2-65ce42033278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#PropertyandEquipmentAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_90c4a779-cdf9-46d8-bba2-b7d8d569df83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1e7467ff-a6d8-40c3-af34-7a630611f62e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_90c4a779-cdf9-46d8-bba2-b7d8d569df83" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1e7467ff-a6d8-40c3-af34-7a630611f62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_83f82b74-e2be-48f9-8899-9b35dfad1b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_c34b3571-506f-48c6-a9a6-48f22f50c6c4" xlink:href="arwr-20230930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_83f82b74-e2be-48f9-8899-9b35dfad1b7a" xlink:to="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_c34b3571-506f-48c6-a9a6-48f22f50c6c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_238d049a-ea0e-4df2-85f3-442b0ff9684c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_c34b3571-506f-48c6-a9a6-48f22f50c6c4" xlink:to="loc_us-gaap_FinancialInstrumentAxis_238d049a-ea0e-4df2-85f3-442b0ff9684c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_becc96d9-9fbf-4601-8e27-125fc07ec0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_238d049a-ea0e-4df2-85f3-442b0ff9684c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_becc96d9-9fbf-4601-8e27-125fc07ec0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_afdc70be-2f0f-403a-88a8-1be815ca0968" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_becc96d9-9fbf-4601-8e27-125fc07ec0b6" xlink:to="loc_us-gaap_DebtSecuritiesMember_afdc70be-2f0f-403a-88a8-1be815ca0968" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_a46a20d6-e743-4edf-9618-09123816787e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_becc96d9-9fbf-4601-8e27-125fc07ec0b6" xlink:to="loc_us-gaap_CertificatesOfDepositMember_a46a20d6-e743-4edf-9618-09123816787e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:href="arwr-20230930.xsd#arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable_c34b3571-506f-48c6-a9a6-48f22f50c6c4" xlink:to="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_13ab8789-71b9-40d4-b9be-864f9a24a855" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent_13ab8789-71b9-40d4-b9be-864f9a24a855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_d0bb415c-13c2-4bba-8e65-998cef4e30a3" xlink:href="arwr-20230930.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent_d0bb415c-13c2-4bba-8e65-998cef4e30a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_ab4f85f2-d47f-4358-bd05-1d3aafbc5f7a" xlink:href="arwr-20230930.xsd#arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent_ab4f85f2-d47f-4358-bd05-1d3aafbc5f7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_327911c2-6de4-4b46-8a73-e1d43bcb62ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_327911c2-6de4-4b46-8a73-e1d43bcb62ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e4d9ee85-b8c9-49ac-9599-1af1c2069563" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_e4d9ee85-b8c9-49ac-9599-1af1c2069563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeReclassificationAdjustmentForHeldToMaturityTransferredToAvailableForSaleSecuritiesBeforeTax_ceaf8047-0e05-4e6d-9b67-65ab66eec4e7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherComprehensiveIncomeReclassificationAdjustmentForHeldToMaturityTransferredToAvailableForSaleSecuritiesBeforeTax"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_us-gaap_OtherComprehensiveIncomeReclassificationAdjustmentForHeldToMaturityTransferredToAvailableForSaleSecuritiesBeforeTax_ceaf8047-0e05-4e6d-9b67-65ab66eec4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_2e172d53-30e5-4dc3-be87-77bdb0f794e5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_2e172d53-30e5-4dc3-be87-77bdb0f794e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_cd117dc2-42ba-4877-952a-4bfdd0efbff1" xlink:href="arwr-20230930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent_cd117dc2-42ba-4877-952a-4bfdd0efbff1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_8e8247b4-a74d-4e85-badb-b6175eacd6cb" xlink:href="arwr-20230930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent_8e8247b4-a74d-4e85-badb-b6175eacd6cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_b7836879-90ab-4988-84ba-177c5908cc8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent_b7836879-90ab-4988-84ba-177c5908cc8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_716c7c73-d947-489f-9f74-3669dbfb2cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_716c7c73-d947-489f-9f74-3669dbfb2cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_16477c5f-cf19-4cea-8c2d-cbaba3b10fe2" xlink:href="arwr-20230930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent_16477c5f-cf19-4cea-8c2d-cbaba3b10fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_3ca8fec2-0c44-451b-a411-622d4751530c" xlink:href="arwr-20230930.xsd#arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent_3ca8fec2-0c44-451b-a411-622d4751530c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_195b6b76-7dec-4728-a8b7-f2694f60beee" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems_3538cac6-1915-40e0-9515-2fd019322fa1" xlink:to="loc_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent_195b6b76-7dec-4728-a8b7-f2694f60beee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#IntangibleAssetsScheduleofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f9f9a29c-7b1a-4b8e-818d-fbb301e299d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8ccb6204-fc39-4b8c-a7f4-7b3527eff04f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f9f9a29c-7b1a-4b8e-818d-fbb301e299d8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8ccb6204-fc39-4b8c-a7f4-7b3527eff04f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_3af2c7cd-1e35-42be-a343-07ba266dafa6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8ccb6204-fc39-4b8c-a7f4-7b3527eff04f" xlink:to="loc_us-gaap_AssetAcquisitionAxis_3af2c7cd-1e35-42be-a343-07ba266dafa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_49ad35eb-71bd-48ec-b368-1fb93468663c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_3af2c7cd-1e35-42be-a343-07ba266dafa6" xlink:to="loc_us-gaap_AssetAcquisitionDomain_49ad35eb-71bd-48ec-b368-1fb93468663c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NovartisMember_48bf4020-43d5-4c58-bc9c-1d6e05d77f4a" xlink:href="arwr-20230930.xsd#arwr_NovartisMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_49ad35eb-71bd-48ec-b368-1fb93468663c" xlink:to="loc_arwr_NovartisMember_48bf4020-43d5-4c58-bc9c-1d6e05d77f4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_37f34994-2cc8-41d5-b543-54b647095c77" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8ccb6204-fc39-4b8c-a7f4-7b3527eff04f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_37f34994-2cc8-41d5-b543-54b647095c77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5c825666-31c3-42cd-8ada-191b55fb1c0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_37f34994-2cc8-41d5-b543-54b647095c77" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5c825666-31c3-42cd-8ada-191b55fb1c0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PatentsMember_5dbe86f0-86e5-4f36-8d5f-713f6750fc96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PatentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5c825666-31c3-42cd-8ada-191b55fb1c0c" xlink:to="loc_us-gaap_PatentsMember_5dbe86f0-86e5-4f36-8d5f-713f6750fc96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicensingAgreementsMember_e74c897e-ffb9-4b22-b25b-553607270939" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LicensingAgreementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_5c825666-31c3-42cd-8ada-191b55fb1c0c" xlink:to="loc_us-gaap_LicensingAgreementsMember_e74c897e-ffb9-4b22-b25b-553607270939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c00d6745-b7b0-42e1-882a-394d7cd26bf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_8ccb6204-fc39-4b8c-a7f4-7b3527eff04f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c00d6745-b7b0-42e1-882a-394d7cd26bf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_79269e7f-a58b-465d-a937-abf27d0d7534" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c00d6745-b7b0-42e1-882a-394d7cd26bf6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_79269e7f-a58b-465d-a937-abf27d0d7534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ca5be912-6efb-4e92-9f61-f31634a1699b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c00d6745-b7b0-42e1-882a-394d7cd26bf6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_ca5be912-6efb-4e92-9f61-f31634a1699b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FiniteLivedIntangibleAssetsImpairment_130ca673-618c-4e79-bd07-8ee198b49d11" xlink:href="arwr-20230930.xsd#arwr_FiniteLivedIntangibleAssetsImpairment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c00d6745-b7b0-42e1-882a-394d7cd26bf6" xlink:to="loc_arwr_FiniteLivedIntangibleAssetsImpairment_130ca673-618c-4e79-bd07-8ee198b49d11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c817c0e0-b899-4a22-9667-39f60d22b50d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c00d6745-b7b0-42e1-882a-394d7cd26bf6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c817c0e0-b899-4a22-9667-39f60d22b50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8bb12877-20b3-4886-8bf6-3d5e029bb9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_c00d6745-b7b0-42e1-882a-394d7cd26bf6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_8bb12877-20b3-4886-8bf6-3d5e029bb9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_2504deb5-b6a6-4f64-a06a-1ec8d4d0ae41" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f9f9a29c-7b1a-4b8e-818d-fbb301e299d8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_2504deb5-b6a6-4f64-a06a-1ec8d4d0ae41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#IntangibleAssetsExpectedFutureAmortizationDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a1e35b08-ee6f-4f61-8bb3-bc4e92c2ea62" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_186bcc00-f77f-4276-9ba2-f7236d1b0bff" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a1e35b08-ee6f-4f61-8bb3-bc4e92c2ea62" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_186bcc00-f77f-4276-9ba2-f7236d1b0bff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_33b2b467-8974-4dc2-92cd-54c2a8334102" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a1e35b08-ee6f-4f61-8bb3-bc4e92c2ea62" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_33b2b467-8974-4dc2-92cd-54c2a8334102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_335f6d71-30aa-4c2f-ae7b-66be08e62949" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a1e35b08-ee6f-4f61-8bb3-bc4e92c2ea62" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_335f6d71-30aa-4c2f-ae7b-66be08e62949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_aec71a88-a9f1-48c6-9138-bacc4803e8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a1e35b08-ee6f-4f61-8bb3-bc4e92c2ea62" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_aec71a88-a9f1-48c6-9138-bacc4803e8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2af4b470-0484-466f-af5b-e40e124df186" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a1e35b08-ee6f-4f61-8bb3-bc4e92c2ea62" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2af4b470-0484-466f-af5b-e40e124df186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_b9a550e0-c3e7-4246-8aa4-389deb92671a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a1e35b08-ee6f-4f61-8bb3-bc4e92c2ea62" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive_b9a550e0-c3e7-4246-8aa4-389deb92671a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_11f39131-ef01-4483-a13d-48421bf3801d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a1e35b08-ee6f-4f61-8bb3-bc4e92c2ea62" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_11f39131-ef01-4483-a13d-48421bf3801d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockholdersEquityDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#StockholdersEquityDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockholdersEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_70207901-50de-4f4f-a899-5748c3e441aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_43d4cbe1-3019-4e3d-b65b-c66346becf89" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_70207901-50de-4f4f-a899-5748c3e441aa" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_43d4cbe1-3019-4e3d-b65b-c66346becf89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_999fd6bc-da6c-46b0-93df-697c075c91b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_43d4cbe1-3019-4e3d-b65b-c66346becf89" xlink:to="loc_us-gaap_PlanNameAxis_999fd6bc-da6c-46b0-93df-697c075c91b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_cfc252d3-87d2-44f7-9526-149f07551aab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_999fd6bc-da6c-46b0-93df-697c075c91b6" xlink:to="loc_us-gaap_PlanNameDomain_cfc252d3-87d2-44f7-9526-149f07551aab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_53b88c6f-24c7-47a3-b790-4acf16fe6e35" xlink:href="arwr-20230930.xsd#arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_cfc252d3-87d2-44f7-9526-149f07551aab" xlink:to="loc_arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_53b88c6f-24c7-47a3-b790-4acf16fe6e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6bbd010c-17f4-4dad-882f-d6ddbb9cde91" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_43d4cbe1-3019-4e3d-b65b-c66346becf89" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6bbd010c-17f4-4dad-882f-d6ddbb9cde91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6d674baf-0cb3-4ed7-a36f-cdf58537382f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6bbd010c-17f4-4dad-882f-d6ddbb9cde91" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6d674baf-0cb3-4ed7-a36f-cdf58537382f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AtTheMarketAgreementMember_66576cf7-12e2-45e1-b51c-f5b51c4be971" xlink:href="arwr-20230930.xsd#arwr_AtTheMarketAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6d674baf-0cb3-4ed7-a36f-cdf58537382f" xlink:to="loc_arwr_AtTheMarketAgreementMember_66576cf7-12e2-45e1-b51c-f5b51c4be971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_041bc382-c7d0-41e0-b298-870422106674" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_43d4cbe1-3019-4e3d-b65b-c66346becf89" xlink:to="loc_srt_RangeAxis_041bc382-c7d0-41e0-b298-870422106674" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c7e50f05-a9ef-4958-ba82-b63e0eb6b865" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_041bc382-c7d0-41e0-b298-870422106674" xlink:to="loc_srt_RangeMember_c7e50f05-a9ef-4958-ba82-b63e0eb6b865" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f6cb86f5-88b1-4ebb-9d3a-031aec300bf3" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_c7e50f05-a9ef-4958-ba82-b63e0eb6b865" xlink:to="loc_srt_MaximumMember_f6cb86f5-88b1-4ebb-9d3a-031aec300bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_43d4cbe1-3019-4e3d-b65b-c66346becf89" xlink:to="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c9f904a6-54ac-42ce-a0dc-4ae23a4718d6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c9f904a6-54ac-42ce-a0dc-4ae23a4718d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_1eee02f9-8957-4b4e-99f2-8cfb8c5ea4ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_1eee02f9-8957-4b4e-99f2-8cfb8c5ea4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_8050c3b3-dc9e-4982-be93-c3559471c861" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:to="loc_us-gaap_CommonStockSharesIssued_8050c3b3-dc9e-4982-be93-c3559471c861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_60f6a94e-4105-4e08-b3d7-fbbf5bceb3bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_60f6a94e-4105-4e08-b3d7-fbbf5bceb3bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f5abc63c-848e-4cbf-b277-ef6fcaf9c3e4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f5abc63c-848e-4cbf-b277-ef6fcaf9c3e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_357817c6-dd9b-4887-a6d6-b2c81306f685" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_357817c6-dd9b-4887-a6d6-b2c81306f685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_1a9795a0-216f-4495-8b7b-09f2e4141db3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:to="loc_us-gaap_PreferredStockSharesIssued_1a9795a0-216f-4495-8b7b-09f2e4141db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_195b5e38-d941-447f-92ee-a58b4befa5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_195b5e38-d941-447f-92ee-a58b4befa5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ec158772-5333-4b2f-9192-6be97bfc3b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_ec158772-5333-4b2f-9192-6be97bfc3b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_4fabc078-129c-4e98-9fdb-e8c2aa7c0f14" xlink:href="arwr-20230930.xsd#arwr_CommonStockCapitalSharesValueReservedForFutureIssuance"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:to="loc_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance_4fabc078-129c-4e98-9fdb-e8c2aa7c0f14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_340fbe62-9702-48cc-ab8b-9580e02133a2" xlink:href="arwr-20230930.xsd#arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:to="loc_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock_340fbe62-9702-48cc-ab8b-9580e02133a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssued_452cc8e8-2fdb-44ec-9ac7-6c68e5a01321" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharesIssued"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0461c6c9-1003-404f-85b3-851f45f042b3" xlink:to="loc_us-gaap_SharesIssued_452cc8e8-2fdb-44ec-9ac7-6c68e5a01321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#CommitmentsandContingenciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_76311155-e771-4e5f-8c53-82abc1b0ac9d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsTable_43fc2e5c-cab9-48c9-bbe5-e7fc5d8a6970" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_76311155-e771-4e5f-8c53-82abc1b0ac9d" xlink:to="loc_us-gaap_OtherCommitmentsTable_43fc2e5c-cab9-48c9-bbe5-e7fc5d8a6970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e1e6a85e-2709-4c15-a9e1-8227c3743306" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_43fc2e5c-cab9-48c9-bbe5-e7fc5d8a6970" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e1e6a85e-2709-4c15-a9e1-8227c3743306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b3b4ea5-c745-4f26-8b01-233e1b490ee7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e1e6a85e-2709-4c15-a9e1-8227c3743306" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b3b4ea5-c745-4f26-8b01-233e1b490ee7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VeronaTechnologyParkMember_955cc602-0f24-43c3-97d1-17396f7678ea" xlink:href="arwr-20230930.xsd#arwr_VeronaTechnologyParkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6b3b4ea5-c745-4f26-8b01-233e1b490ee7" xlink:to="loc_arwr_VeronaTechnologyParkMember_955cc602-0f24-43c3-97d1-17396f7678ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DrugManufacturingFacilityMember_4890d56f-bd2e-48bc-a5c0-f5d1512aa11a" xlink:href="arwr-20230930.xsd#arwr_DrugManufacturingFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_VeronaTechnologyParkMember_955cc602-0f24-43c3-97d1-17396f7678ea" xlink:to="loc_arwr_DrugManufacturingFacilityMember_4890d56f-bd2e-48bc-a5c0-f5d1512aa11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LaboratoryAndOfficeFacilityMember_f5c9cc5c-9b2c-4f34-a5d6-c78a2e464d2c" xlink:href="arwr-20230930.xsd#arwr_LaboratoryAndOfficeFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_VeronaTechnologyParkMember_955cc602-0f24-43c3-97d1-17396f7678ea" xlink:to="loc_arwr_LaboratoryAndOfficeFacilityMember_f5c9cc5c-9b2c-4f34-a5d6-c78a2e464d2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_FacilitiesMember_67c2c420-ac33-4e0d-a313-c778b8ecfe4b" xlink:href="arwr-20230930.xsd#arwr_FacilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_VeronaTechnologyParkMember_955cc602-0f24-43c3-97d1-17396f7678ea" xlink:to="loc_arwr_FacilitiesMember_67c2c420-ac33-4e0d-a313-c778b8ecfe4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_82335894-a45f-484a-843d-76a681287332" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_43fc2e5c-cab9-48c9-bbe5-e7fc5d8a6970" xlink:to="loc_srt_RangeAxis_82335894-a45f-484a-843d-76a681287332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8a8cea1c-9e53-4b4b-bfda-d845b0048d15" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_82335894-a45f-484a-843d-76a681287332" xlink:to="loc_srt_RangeMember_8a8cea1c-9e53-4b4b-bfda-d845b0048d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1591c381-a2bc-4763-93bf-6d8d5921de85" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8a8cea1c-9e53-4b4b-bfda-d845b0048d15" xlink:to="loc_srt_MinimumMember_1591c381-a2bc-4763-93bf-6d8d5921de85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_4e4a13b5-e976-4de6-aedd-c777f0cdde59" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8a8cea1c-9e53-4b4b-bfda-d845b0048d15" xlink:to="loc_srt_MaximumMember_4e4a13b5-e976-4de6-aedd-c777f0cdde59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_4f6fbe3a-70e2-49d9-b7e9-1170de0544db" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_43fc2e5c-cab9-48c9-bbe5-e7fc5d8a6970" xlink:to="loc_srt_StatementGeographicalAxis_4f6fbe3a-70e2-49d9-b7e9-1170de0544db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_e7bf4742-c7f8-472d-88d1-55283ff1da32" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_4f6fbe3a-70e2-49d9-b7e9-1170de0544db" xlink:to="loc_srt_SegmentGeographicalDomain_e7bf4742-c7f8-472d-88d1-55283ff1da32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_9692f7f2-8757-401a-add5-67e99e3b1a44" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_WI"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_e7bf4742-c7f8-472d-88d1-55283ff1da32" xlink:to="loc_stpr_WI_9692f7f2-8757-401a-add5-67e99e3b1a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsAxis_e541eaa0-a6ff-4ee7-a161-b3e0c43c8aae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_43fc2e5c-cab9-48c9-bbe5-e7fc5d8a6970" xlink:to="loc_us-gaap_OtherCommitmentsAxis_e541eaa0-a6ff-4ee7-a161-b3e0c43c8aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsDomain_40e154c3-4fd0-4e57-8cd6-026b8b0ca773" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsAxis_e541eaa0-a6ff-4ee7-a161-b3e0c43c8aae" xlink:to="loc_us-gaap_OtherCommitmentsDomain_40e154c3-4fd0-4e57-8cd6-026b8b0ca773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TechnologyLicenseCommitmentsMember_814a5789-c3ea-4b14-acff-286653b52d32" xlink:href="arwr-20230930.xsd#arwr_TechnologyLicenseCommitmentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsDomain_40e154c3-4fd0-4e57-8cd6-026b8b0ca773" xlink:to="loc_arwr_TechnologyLicenseCommitmentsMember_814a5789-c3ea-4b14-acff-286653b52d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_d5061ae9-d1c5-46b5-b0e6-74cc7415ffc5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_43fc2e5c-cab9-48c9-bbe5-e7fc5d8a6970" xlink:to="loc_us-gaap_TypeOfArrangementAxis_d5061ae9-d1c5-46b5-b0e6-74cc7415ffc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1a169eed-1179-4d49-a569-bfc74b1373d8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_d5061ae9-d1c5-46b5-b0e6-74cc7415ffc5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1a169eed-1179-4d49-a569-bfc74b1373d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AROENacAndAROHIF2CandidatesMember_8d4a7e8f-3d9c-449c-80f4-78e33045f910" xlink:href="arwr-20230930.xsd#arwr_AROENacAndAROHIF2CandidatesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1a169eed-1179-4d49-a569-bfc74b1373d8" xlink:to="loc_arwr_AROENacAndAROHIF2CandidatesMember_8d4a7e8f-3d9c-449c-80f4-78e33045f910" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCommitmentsLineItems_f6907e63-269e-4e22-8cc7-a310b20b1626" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OtherCommitmentsLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsTable_43fc2e5c-cab9-48c9-bbe5-e7fc5d8a6970" xlink:to="loc_us-gaap_OtherCommitmentsLineItems_f6907e63-269e-4e22-8cc7-a310b20b1626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_501da8b5-9074-4f61-80d6-bcc3d8377f99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f6907e63-269e-4e22-8cc7-a310b20b1626" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_501da8b5-9074-4f61-80d6-bcc3d8377f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfAcresOfLandPurchased_e492bdbf-c810-45a7-bf3b-0631409d4fdd" xlink:href="arwr-20230930.xsd#arwr_NumberOfAcresOfLandPurchased"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f6907e63-269e-4e22-8cc7-a310b20b1626" xlink:to="loc_arwr_NumberOfAcresOfLandPurchased_e492bdbf-c810-45a7-bf3b-0631409d4fdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AreaOfLand_b92e335c-1c59-4ce5-9910-72ef7bd1170c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AreaOfLand"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f6907e63-269e-4e22-8cc7-a310b20b1626" xlink:to="loc_us-gaap_AreaOfLand_b92e335c-1c59-4ce5-9910-72ef7bd1170c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressGross_c619160e-4418-4af4-9205-609c4bbbfe84" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ConstructionInProgressGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f6907e63-269e-4e22-8cc7-a310b20b1626" xlink:to="loc_us-gaap_ConstructionInProgressGross_c619160e-4418-4af4-9205-609c4bbbfe84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AmountIntendedToInvestForBuildoutOfFacilities_a5b7bab1-00b2-4e6f-bfcb-3acc8b1a590f" xlink:href="arwr-20230930.xsd#arwr_AmountIntendedToInvestForBuildoutOfFacilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f6907e63-269e-4e22-8cc7-a310b20b1626" xlink:to="loc_arwr_AmountIntendedToInvestForBuildoutOfFacilities_a5b7bab1-00b2-4e6f-bfcb-3acc8b1a590f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TaxIncrementFinancingAward_4c38c8b8-9a15-4078-930f-b18db2f20f70" xlink:href="arwr-20230930.xsd#arwr_TaxIncrementFinancingAward"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f6907e63-269e-4e22-8cc7-a310b20b1626" xlink:to="loc_arwr_TaxIncrementFinancingAward_4c38c8b8-9a15-4078-930f-b18db2f20f70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement_0d829e05-4a9c-4536-b15f-20c3e76d950b" xlink:href="arwr-20230930.xsd#arwr_TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f6907e63-269e-4e22-8cc7-a310b20b1626" xlink:to="loc_arwr_TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement_0d829e05-4a9c-4536-b15f-20c3e76d950b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCredits_b3aa4b38-1474-408e-95a9-4ae96e5932f8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxReconciliationTaxCredits"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f6907e63-269e-4e22-8cc7-a310b20b1626" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCredits_b3aa4b38-1474-408e-95a9-4ae96e5932f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePayments_fe45a067-fd00-409c-aa33-05840dedcd9b" xlink:href="arwr-20230930.xsd#arwr_MilestonePayments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherCommitmentsLineItems_f6907e63-269e-4e22-8cc7-a310b20b1626" xlink:to="loc_arwr_MilestonePayments_fe45a067-fd00-409c-aa33-05840dedcd9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_2c156474-a90a-4ea6-98ed-5a011568cb2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_167c7c87-dc39-4245-9fd3-b58c37a052c9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_2c156474-a90a-4ea6-98ed-5a011568cb2c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_167c7c87-dc39-4245-9fd3-b58c37a052c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f37b3c7d-2458-4192-9bc8-4de2d7378568" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_167c7c87-dc39-4245-9fd3-b58c37a052c9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f37b3c7d-2458-4192-9bc8-4de2d7378568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a254951-57a6-466a-acb6-8cd08b4dcb8b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_f37b3c7d-2458-4192-9bc8-4de2d7378568" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a254951-57a6-466a-acb6-8cd08b4dcb8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInSanDiegoMember_9cba635e-f2aa-482c-a45c-31a7e59bdada" xlink:href="arwr-20230930.xsd#arwr_ResearchFacilityInSanDiegoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a254951-57a6-466a-acb6-8cd08b4dcb8b" xlink:to="loc_arwr_ResearchFacilityInSanDiegoMember_9cba635e-f2aa-482c-a45c-31a7e59bdada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CorporateHeadquartersInPasadenaMember_6e7b20d0-6e04-45e5-9c80-6f852689f530" xlink:href="arwr-20230930.xsd#arwr_CorporateHeadquartersInPasadenaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a254951-57a6-466a-acb6-8cd08b4dcb8b" xlink:to="loc_arwr_CorporateHeadquartersInPasadenaMember_6e7b20d0-6e04-45e5-9c80-6f852689f530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ResearchFacilityInMadisonMember_d6bf8d77-fc0a-4f1e-9447-db5a41fcc978" xlink:href="arwr-20230930.xsd#arwr_ResearchFacilityInMadisonMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5a254951-57a6-466a-acb6-8cd08b4dcb8b" xlink:to="loc_arwr_ResearchFacilityInMadisonMember_d6bf8d77-fc0a-4f1e-9447-db5a41fcc978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_099d4afd-3c40-4443-9f9b-1e24c332624a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_167c7c87-dc39-4245-9fd3-b58c37a052c9" xlink:to="loc_srt_StatementGeographicalAxis_099d4afd-3c40-4443-9f9b-1e24c332624a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_2efa7947-d0b2-4886-a3de-7381a8b2d688" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_099d4afd-3c40-4443-9f9b-1e24c332624a" xlink:to="loc_srt_SegmentGeographicalDomain_2efa7947-d0b2-4886-a3de-7381a8b2d688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_31fe4996-6a15-4bec-8c4c-5f0879fb00bd" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2efa7947-d0b2-4886-a3de-7381a8b2d688" xlink:to="loc_stpr_CA_31fe4996-6a15-4bec-8c4c-5f0879fb00bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_WI_1d8f66d5-e996-4a09-b8b1-6d64cd82597c" xlink:href="https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd#stpr_WI"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_2efa7947-d0b2-4886-a3de-7381a8b2d688" xlink:to="loc_stpr_WI_1d8f66d5-e996-4a09-b8b1-6d64cd82597c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d21b2bdd-b739-4897-8ff8-2de35698613b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_167c7c87-dc39-4245-9fd3-b58c37a052c9" xlink:to="loc_srt_RangeAxis_d21b2bdd-b739-4897-8ff8-2de35698613b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_74ba9c2f-2bb1-4f3e-8a0b-4707663d5aad" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d21b2bdd-b739-4897-8ff8-2de35698613b" xlink:to="loc_srt_RangeMember_74ba9c2f-2bb1-4f3e-8a0b-4707663d5aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_c4b88714-1089-410c-a358-54cddb7ac809" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_74ba9c2f-2bb1-4f3e-8a0b-4707663d5aad" xlink:to="loc_srt_MaximumMember_c4b88714-1089-410c-a358-54cddb7ac809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_220a3aac-b1cc-4c22-8cc3-fbef05699b0a" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_167c7c87-dc39-4245-9fd3-b58c37a052c9" xlink:to="loc_srt_CounterpartyNameAxis_220a3aac-b1cc-4c22-8cc3-fbef05699b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1c72044c-adda-491c-a1a6-dbc33793d869" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_220a3aac-b1cc-4c22-8cc3-fbef05699b0a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1c72044c-adda-491c-a1a6-dbc33793d869" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ColoradoOwnerLLCMember_4bf07c2f-0638-43b4-a0cf-33b8922ee084" xlink:href="arwr-20230930.xsd#arwr_ColoradoOwnerLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1c72044c-adda-491c-a1a6-dbc33793d869" xlink:to="loc_arwr_ColoradoOwnerLLCMember_4bf07c2f-0638-43b4-a0cf-33b8922ee084" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_SorrentoValleyOwnerDELLCMember_a4b6dbab-5717-4cec-bbc0-7d923fe6969b" xlink:href="arwr-20230930.xsd#arwr_SorrentoValleyOwnerDELLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_1c72044c-adda-491c-a1a6-dbc33793d869" xlink:to="loc_arwr_SorrentoValleyOwnerDELLCMember_a4b6dbab-5717-4cec-bbc0-7d923fe6969b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_bd2ddeb9-2f17-4027-81d4-763b367fff56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_167c7c87-dc39-4245-9fd3-b58c37a052c9" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_bd2ddeb9-2f17-4027-81d4-763b367fff56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0ccf403a-fe7e-4b38-88f2-1eb59c4f73cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bd2ddeb9-2f17-4027-81d4-763b367fff56" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_0ccf403a-fe7e-4b38-88f2-1eb59c4f73cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_c02b1dfc-4f35-4009-970e-08b8c9b7f960" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bd2ddeb9-2f17-4027-81d4-763b367fff56" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_c02b1dfc-4f35-4009-970e-08b8c9b7f960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NumberOfOptionsToRenew_35b66d07-601e-44bb-b711-4d3117bece42" xlink:href="arwr-20230930.xsd#arwr_NumberOfOptionsToRenew"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bd2ddeb9-2f17-4027-81d4-763b367fff56" xlink:to="loc_arwr_NumberOfOptionsToRenew_35b66d07-601e-44bb-b711-4d3117bece42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_f1937167-d497-4360-8820-e06372b5180f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bd2ddeb9-2f17-4027-81d4-763b367fff56" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_f1937167-d497-4360-8820-e06372b5180f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MaximumAdditionalTenantImprovementAllowance_c78698d3-7cfd-4a49-933c-65434deb2aa4" xlink:href="arwr-20230930.xsd#arwr_MaximumAdditionalTenantImprovementAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bd2ddeb9-2f17-4027-81d4-763b367fff56" xlink:to="loc_arwr_MaximumAdditionalTenantImprovementAllowance_c78698d3-7cfd-4a49-933c-65434deb2aa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum_e5a2169c-4d24-4fbd-8deb-a67da03a1c3d" xlink:href="arwr-20230930.xsd#arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bd2ddeb9-2f17-4027-81d4-763b367fff56" xlink:to="loc_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum_e5a2169c-4d24-4fbd-8deb-a67da03a1c3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_AdditionalTenantImprovementAllowanceLiability_589d662e-9ba7-4326-a284-22d861561f45" xlink:href="arwr-20230930.xsd#arwr_AdditionalTenantImprovementAllowanceLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bd2ddeb9-2f17-4027-81d4-763b367fff56" xlink:to="loc_arwr_AdditionalTenantImprovementAllowanceLiability_589d662e-9ba7-4326-a284-22d861561f45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_c67c612e-8dcd-40bd-9b0e-4c373c3220a8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_bd2ddeb9-2f17-4027-81d4-763b367fff56" xlink:to="loc_us-gaap_ShortTermLeaseCost_c67c612e-8dcd-40bd-9b0e-4c373c3220a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#LeasesComponentsofLeaseAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_01cc76a7-b9e2-43dd-9fe7-d357011b2fab" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f451496c-ea61-4409-88bb-a58503b0f26c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_01cc76a7-b9e2-43dd-9fe7-d357011b2fab" xlink:to="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f451496c-ea61-4409-88bb-a58503b0f26c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e8efa838-9ae8-4a12-a93c-b510f796f560" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f451496c-ea61-4409-88bb-a58503b0f26c" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e8efa838-9ae8-4a12-a93c-b510f796f560" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_41d0d4c6-9db9-425a-928f-f9bcefa3b295" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e8efa838-9ae8-4a12-a93c-b510f796f560" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_41d0d4c6-9db9-425a-928f-f9bcefa3b295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5ba042cc-b156-402a-a2fb-68bd7a9f086c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_41d0d4c6-9db9-425a-928f-f9bcefa3b295" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_5ba042cc-b156-402a-a2fb-68bd7a9f086c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5c2ea7ab-40dc-44cf-aefa-293a66d22efe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_41d0d4c6-9db9-425a-928f-f9bcefa3b295" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5c2ea7ab-40dc-44cf-aefa-293a66d22efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasedAssetsLineItems_f29b73df-5a51-494a-ad00-40e5065b6b26" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfOperatingLeasedAssetsTable_f451496c-ea61-4409-88bb-a58503b0f26c" xlink:to="loc_us-gaap_OperatingLeasedAssetsLineItems_f29b73df-5a51-494a-ad00-40e5065b6b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_76c21343-edd7-4260-823b-98517a4998a5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsAndLiabilitiesLesseeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_f29b73df-5a51-494a-ad00-40e5065b6b26" xlink:to="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_76c21343-edd7-4260-823b-98517a4998a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_4c75f67c-2d05-4f38-8fe0-2d3a87a7f226" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_76c21343-edd7-4260-823b-98517a4998a5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_4c75f67c-2d05-4f38-8fe0-2d3a87a7f226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_f4d30b94-648a-48de-b70e-08682255aad5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_76c21343-edd7-4260-823b-98517a4998a5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_f4d30b94-648a-48de-b70e-08682255aad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9688e73e-1ab9-4202-8eb2-8b3d7895d79a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAndLiabilitiesLesseeAbstract_76c21343-edd7-4260-823b-98517a4998a5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9688e73e-1ab9-4202-8eb2-8b3d7895d79a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_74c38583-a3dc-42a8-81ea-a682499f4368" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasedAssetsLineItems_f29b73df-5a51-494a-ad00-40e5065b6b26" xlink:to="loc_us-gaap_LeaseCostAbstract_74c38583-a3dc-42a8-81ea-a682499f4368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_b5a82fbf-c5b2-43b9-9cfa-4e6ede1a5b31" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_74c38583-a3dc-42a8-81ea-a682499f4368" xlink:to="loc_us-gaap_OperatingLeaseCost_b5a82fbf-c5b2-43b9-9cfa-4e6ede1a5b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_85354564-579d-4dcf-ba8b-7df4614a477d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_74c38583-a3dc-42a8-81ea-a682499f4368" xlink:to="loc_us-gaap_VariableLeaseCost_85354564-579d-4dcf-ba8b-7df4614a477d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_7b8c55b8-ca62-4dca-99c0-aa027f04a310" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_74c38583-a3dc-42a8-81ea-a682499f4368" xlink:to="loc_us-gaap_LeaseCost_7b8c55b8-ca62-4dca-99c0-aa027f04a310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_72a0ca52-a20e-43a1-ac8f-18336c273da2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_74534829-f2d5-43b2-8a8b-44c1100617f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_72a0ca52-a20e-43a1-ac8f-18336c273da2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_74534829-f2d5-43b2-8a8b-44c1100617f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7c14f3bd-d60b-4f5c-8f62-26c2a6599702" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_72a0ca52-a20e-43a1-ac8f-18336c273da2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_7c14f3bd-d60b-4f5c-8f62-26c2a6599702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3cabda56-f603-459d-94c2-63c3439a2a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_72a0ca52-a20e-43a1-ac8f-18336c273da2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_3cabda56-f603-459d-94c2-63c3439a2a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c8573bf0-8073-467a-808a-b2d958976b20" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_72a0ca52-a20e-43a1-ac8f-18336c273da2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c8573bf0-8073-467a-808a-b2d958976b20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_65150e7e-1356-4f15-9f51-6fa34fd44103" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_72a0ca52-a20e-43a1-ac8f-18336c273da2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_65150e7e-1356-4f15-9f51-6fa34fd44103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_eec4f0f2-40bf-4fa3-9fc9-e8171db6ad1a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_72a0ca52-a20e-43a1-ac8f-18336c273da2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_eec4f0f2-40bf-4fa3-9fc9-e8171db6ad1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f463cd49-5c63-4fca-97e4-2a30e635ebaf" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_72a0ca52-a20e-43a1-ac8f-18336c273da2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f463cd49-5c63-4fca-97e4-2a30e635ebaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d472d2a7-2e07-4b68-a652-3f21121d83f9" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_72a0ca52-a20e-43a1-ac8f-18336c273da2" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_d472d2a7-2e07-4b68-a652-3f21121d83f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_75f3e698-2e07-4bde-a575-a89a64f52607" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_72a0ca52-a20e-43a1-ac8f-18336c273da2" xlink:to="loc_us-gaap_OperatingLeaseLiability_75f3e698-2e07-4bde-a575-a89a64f52607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" xlink:type="simple" xlink:href="arwr-20230930.xsd#LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7a2a87fa-4e10-4921-afbb-f3d1ccd15951" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_92a27251-32c2-4861-8289-2a186a38b4b4" xlink:href="arwr-20230930.xsd#arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a2a87fa-4e10-4921-afbb-f3d1ccd15951" xlink:to="loc_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_92a27251-32c2-4861-8289-2a186a38b4b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities_bd04e663-59f1-4d3f-8da0-27e4612893a4" xlink:href="arwr-20230930.xsd#arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_92a27251-32c2-4861-8289-2a186a38b4b4" xlink:to="loc_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities_bd04e663-59f1-4d3f-8da0-27e4612893a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f391a3e5-6e05-4add-84c2-704196160959" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a2a87fa-4e10-4921-afbb-f3d1ccd15951" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_f391a3e5-6e05-4add-84c2-704196160959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_a66f7f72-9220-4c2e-a7a5-81730fd65953" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashFlowOperatingActivitiesLesseeAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a2a87fa-4e10-4921-afbb-f3d1ccd15951" xlink:to="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_a66f7f72-9220-4c2e-a7a5-81730fd65953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_d9d8168f-639e-4d65-ad6a-8cb838c12dce" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowOperatingActivitiesLesseeAbstract_a66f7f72-9220-4c2e-a7a5-81730fd65953" xlink:to="loc_us-gaap_OperatingLeasePayments_d9d8168f-639e-4d65-ad6a-8cb838c12dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_63cc240c-5b79-499b-b6d8-bae86f37df42" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a2a87fa-4e10-4921-afbb-f3d1ccd15951" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_63cc240c-5b79-499b-b6d8-bae86f37df42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fc469fe7-65ce-4b84-b0ff-287de2f5c939" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7a2a87fa-4e10-4921-afbb-f3d1ccd15951" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_fc469fe7-65ce-4b84-b0ff-287de2f5c939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9e7d5a97-e0e4-45b4-b9c4-707fa850f790" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32f00b9f-0328-49d9-a5fa-ba07d6ed6940" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9e7d5a97-e0e4-45b4-b9c4-707fa850f790" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32f00b9f-0328-49d9-a5fa-ba07d6ed6940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_16aff7d2-4695-419e-8e5a-9a904a52fa21" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32f00b9f-0328-49d9-a5fa-ba07d6ed6940" xlink:to="loc_us-gaap_PlanNameAxis_16aff7d2-4695-419e-8e5a-9a904a52fa21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_f1d1c123-92e1-4d28-9e93-d830a22cdb2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_16aff7d2-4695-419e-8e5a-9a904a52fa21" xlink:to="loc_us-gaap_PlanNameDomain_f1d1c123-92e1-4d28-9e93-d830a22cdb2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_a676aea6-d125-4c03-bbd0-f99ed85c973d" xlink:href="arwr-20230930.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f1d1c123-92e1-4d28-9e93-d830a22cdb2a" xlink:to="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_a676aea6-d125-4c03-bbd0-f99ed85c973d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_50af36d0-a7bb-44db-bc1a-f14685fb4573" xlink:href="arwr-20230930.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f1d1c123-92e1-4d28-9e93-d830a22cdb2a" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_50af36d0-a7bb-44db-bc1a-f14685fb4573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_04cc5ed4-4984-45e7-ac8b-6446f70879a6" xlink:href="arwr-20230930.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f1d1c123-92e1-4d28-9e93-d830a22cdb2a" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_04cc5ed4-4984-45e7-ac8b-6446f70879a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OutsideOfEquityCompensationPlansMember_05ec430a-e9e7-4802-b1ae-584cbc1b039d" xlink:href="arwr-20230930.xsd#arwr_OutsideOfEquityCompensationPlansMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_f1d1c123-92e1-4d28-9e93-d830a22cdb2a" xlink:to="loc_arwr_OutsideOfEquityCompensationPlansMember_05ec430a-e9e7-4802-b1ae-584cbc1b039d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_42a3898d-8e78-4bed-85d4-d6c29ec4283f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32f00b9f-0328-49d9-a5fa-ba07d6ed6940" xlink:to="loc_us-gaap_AwardTypeAxis_42a3898d-8e78-4bed-85d4-d6c29ec4283f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f81086d8-2a00-4c46-8731-6b45857009cd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_42a3898d-8e78-4bed-85d4-d6c29ec4283f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f81086d8-2a00-4c46-8731-6b45857009cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4aec6d9b-c867-46fd-a8b4-5aa95995985a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f81086d8-2a00-4c46-8731-6b45857009cd" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4aec6d9b-c867-46fd-a8b4-5aa95995985a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_4ba4a709-16e8-46d2-92b0-5e1eced6f58c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f81086d8-2a00-4c46-8731-6b45857009cd" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_4ba4a709-16e8-46d2-92b0-5e1eced6f58c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RestrictedStockUnitsMarketBasedMember_3d3f0be1-df2f-4843-bc32-372b80e53022" xlink:href="arwr-20230930.xsd#arwr_RestrictedStockUnitsMarketBasedMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f81086d8-2a00-4c46-8731-6b45857009cd" xlink:to="loc_arwr_RestrictedStockUnitsMarketBasedMember_3d3f0be1-df2f-4843-bc32-372b80e53022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RestrictedStockUnitsPerformanceBasedMember_0c80c9c9-886f-4202-91ec-4f11884483e5" xlink:href="arwr-20230930.xsd#arwr_RestrictedStockUnitsPerformanceBasedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f81086d8-2a00-4c46-8731-6b45857009cd" xlink:to="loc_arwr_RestrictedStockUnitsPerformanceBasedMember_0c80c9c9-886f-4202-91ec-4f11884483e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_7f083428-523d-459a-827d-41a3ca389810" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32f00b9f-0328-49d9-a5fa-ba07d6ed6940" xlink:to="loc_srt_TitleOfIndividualAxis_7f083428-523d-459a-827d-41a3ca389810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3a3fc7c8-b8a4-4bf2-8bd0-16060bd1e96d" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_7f083428-523d-459a-827d-41a3ca389810" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3a3fc7c8-b8a4-4bf2-8bd0-16060bd1e96d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ChiefExecutiveOfficerMember_14b820b7-78f5-475c-86a6-3d31fb72c1f0" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ChiefExecutiveOfficerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_3a3fc7c8-b8a4-4bf2-8bd0-16060bd1e96d" xlink:to="loc_srt_ChiefExecutiveOfficerMember_14b820b7-78f5-475c-86a6-3d31fb72c1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_32f00b9f-0328-49d9-a5fa-ba07d6ed6940" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_065e1f19-d04f-4fa9-849b-b47e314ceeda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_065e1f19-d04f-4fa9-849b-b47e314ceeda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_251c63af-0f97-4130-93f0-16fa1761c8b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_251c63af-0f97-4130-93f0-16fa1761c8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ed07769f-e56a-4fbb-8f64-6f364e4c6f0b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_ed07769f-e56a-4fbb-8f64-6f364e4c6f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_dc9c161a-61bc-4dd2-ba3c-620802fe8807" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_dc9c161a-61bc-4dd2-ba3c-620802fe8807" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_e5a9a007-ef2c-47fc-ac52-e9d746899bda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_e5a9a007-ef2c-47fc-ac52-e9d746899bda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3546b9b4-13cd-46cf-837d-d9d367d22670" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_3546b9b4-13cd-46cf-837d-d9d367d22670" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e89ca41d-8bf8-4d49-8c1e-b681cb9cddbc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_e89ca41d-8bf8-4d49-8c1e-b681cb9cddbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c02f34f2-4723-4921-a802-ff024e713a95" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c02f34f2-4723-4921-a802-ff024e713a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_68247de5-a6c1-4671-a985-e3e85a5b5154" xlink:href="arwr-20230930.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:to="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue_68247de5-a6c1-4671-a985-e3e85a5b5154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_68e25128-c338-4d65-9c09-b0b0e608fb88" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_68e25128-c338-4d65-9c09-b0b0e608fb88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1466518d-3fa4-445f-a934-8e0dc1ec7e86" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_8762e7e5-9021-4234-b502-60cd329c9c94" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_1466518d-3fa4-445f-a934-8e0dc1ec7e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6224af15-7cae-488b-904d-fa5ba0023437" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06187f63-5b9e-4fc0-ae3f-e964f17825c6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6224af15-7cae-488b-904d-fa5ba0023437" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06187f63-5b9e-4fc0-ae3f-e964f17825c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_abc04403-493b-439b-9e9b-75de8cd27151" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06187f63-5b9e-4fc0-ae3f-e964f17825c6" xlink:to="loc_us-gaap_AwardTypeAxis_abc04403-493b-439b-9e9b-75de8cd27151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca6d09c6-748a-4e35-89cc-21082394752d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_abc04403-493b-439b-9e9b-75de8cd27151" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca6d09c6-748a-4e35-89cc-21082394752d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ce8adfc2-f861-4db4-b058-b9517976292a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ca6d09c6-748a-4e35-89cc-21082394752d" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ce8adfc2-f861-4db4-b058-b9517976292a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_faadd36c-48a6-432f-9281-99465a672aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06187f63-5b9e-4fc0-ae3f-e964f17825c6" xlink:to="loc_us-gaap_PlanNameAxis_faadd36c-48a6-432f-9281-99465a672aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_e9573d81-3e4d-43f5-a5dc-60e13bd972b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_faadd36c-48a6-432f-9281-99465a672aa7" xlink:to="loc_us-gaap_PlanNameDomain_e9573d81-3e4d-43f5-a5dc-60e13bd972b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_cb9f6d76-5624-4a5f-8d81-946ab3f56699" xlink:href="arwr-20230930.xsd#arwr_TwoThousandsFourEquityIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e9573d81-3e4d-43f5-a5dc-60e13bd972b5" xlink:to="loc_arwr_TwoThousandsFourEquityIncentivePlanMember_cb9f6d76-5624-4a5f-8d81-946ab3f56699" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandsThirteenIncentivePlanMember_6f6785e0-f38e-467c-bff4-d417d28c3855" xlink:href="arwr-20230930.xsd#arwr_TwoThousandsThirteenIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e9573d81-3e4d-43f5-a5dc-60e13bd972b5" xlink:to="loc_arwr_TwoThousandsThirteenIncentivePlanMember_6f6785e0-f38e-467c-bff4-d417d28c3855" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_6ef512e8-557b-4f3e-b618-72a12b6e504f" xlink:href="arwr-20230930.xsd#arwr_TwoThousandTwentyOneIncentivePlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e9573d81-3e4d-43f5-a5dc-60e13bd972b5" xlink:to="loc_arwr_TwoThousandTwentyOneIncentivePlanMember_6ef512e8-557b-4f3e-b618-72a12b6e504f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InducementAwardsMember_7d755ba1-1558-47a3-9737-4de6080e09cd" xlink:href="arwr-20230930.xsd#arwr_InducementAwardsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_e9573d81-3e4d-43f5-a5dc-60e13bd972b5" xlink:to="loc_arwr_InducementAwardsMember_7d755ba1-1558-47a3-9737-4de6080e09cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb105c06-736f-4cea-ac18-87841cdab46a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_06187f63-5b9e-4fc0-ae3f-e964f17825c6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb105c06-736f-4cea-ac18-87841cdab46a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cc4ea8c9-5d96-40e9-aca7-a853b78d5c79" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb105c06-736f-4cea-ac18-87841cdab46a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_cc4ea8c9-5d96-40e9-aca7-a853b78d5c79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_eabec679-d78d-4c21-bf60-682bd820dc96" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb105c06-736f-4cea-ac18-87841cdab46a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_eabec679-d78d-4c21-bf60-682bd820dc96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_77a17245-7259-42a0-835d-13c2c0856157" xlink:href="arwr-20230930.xsd#arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_bb105c06-736f-4cea-ac18-87841cdab46a" xlink:to="loc_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding_77a17245-7259-42a0-835d-13c2c0856157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0105fc71-a030-4c79-853c-ac18ce350d73" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a8933325-024c-4d4e-b8d9-38ddb272d9d7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0105fc71-a030-4c79-853c-ac18ce350d73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a8933325-024c-4d4e-b8d9-38ddb272d9d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_830f1fd7-ea5e-4dec-abd9-8b5d90d4a221" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a8933325-024c-4d4e-b8d9-38ddb272d9d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_830f1fd7-ea5e-4dec-abd9-8b5d90d4a221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0e13c74b-0245-43d5-a804-ef8ca53bb486" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a8933325-024c-4d4e-b8d9-38ddb272d9d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0e13c74b-0245-43d5-a804-ef8ca53bb486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5d4e3612-6cfc-486f-8626-d1d0ab7d2a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a8933325-024c-4d4e-b8d9-38ddb272d9d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_5d4e3612-6cfc-486f-8626-d1d0ab7d2a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d780770c-aa69-4c5e-9868-26c3491b2121" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a8933325-024c-4d4e-b8d9-38ddb272d9d7" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_d780770c-aa69-4c5e-9868-26c3491b2121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d61b8b1d-c151-4f5b-aae4-45abc5f4c6a6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_a8933325-024c-4d4e-b8d9-38ddb272d9d7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_d61b8b1d-c151-4f5b-aae4-45abc5f4c6a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a61ac508-d191-4170-9d8f-4e8c36dce0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0105fc71-a030-4c79-853c-ac18ce350d73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_a61ac508-d191-4170-9d8f-4e8c36dce0b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d974cbd7-300f-478c-9c6c-148385d69e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0105fc71-a030-4c79-853c-ac18ce350d73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d974cbd7-300f-478c-9c6c-148385d69e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e6114aa9-df0c-49f1-8164-02dc8a7ca3ae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d974cbd7-300f-478c-9c6c-148385d69e9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_e6114aa9-df0c-49f1-8164-02dc8a7ca3ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_03fdce3b-b91f-436f-bef9-74be44b023ed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d974cbd7-300f-478c-9c6c-148385d69e9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_03fdce3b-b91f-436f-bef9-74be44b023ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_453e3fc1-7465-4bdc-914d-36574d7136e1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d974cbd7-300f-478c-9c6c-148385d69e9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_453e3fc1-7465-4bdc-914d-36574d7136e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_458b3164-ce5a-4518-b5b1-3fc3f8969957" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d974cbd7-300f-478c-9c6c-148385d69e9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_458b3164-ce5a-4518-b5b1-3fc3f8969957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_47874204-55bb-4b70-a297-062643fe51b0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d974cbd7-300f-478c-9c6c-148385d69e9f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_47874204-55bb-4b70-a297-062643fe51b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_56ce15db-f8b1-419d-9227-052213fa6de6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0105fc71-a030-4c79-853c-ac18ce350d73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_56ce15db-f8b1-419d-9227-052213fa6de6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_86a4f79b-fe7c-486c-a854-feee308b631e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0105fc71-a030-4c79-853c-ac18ce350d73" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_86a4f79b-fe7c-486c-a854-feee308b631e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_11d4b18c-a8fe-4ebd-9233-9e8ea025e447" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0105fc71-a030-4c79-853c-ac18ce350d73" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_11d4b18c-a8fe-4ebd-9233-9e8ea025e447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_07bb7b64-5f08-478f-b747-905b89c5ba6c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0105fc71-a030-4c79-853c-ac18ce350d73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_07bb7b64-5f08-478f-b747-905b89c5ba6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_94256275-ee3e-4d70-9e64-d15f5ac9ecac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0105fc71-a030-4c79-853c-ac18ce350d73" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_94256275-ee3e-4d70-9e64-d15f5ac9ecac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f32206c7-89ed-42ef-87ae-580a4267889f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_20834ff0-0ea7-4d0e-a64a-18eb43a57126" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f32206c7-89ed-42ef-87ae-580a4267889f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_20834ff0-0ea7-4d0e-a64a-18eb43a57126" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0015b4d0-827f-49c1-9983-b04a4861726d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f32206c7-89ed-42ef-87ae-580a4267889f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_0015b4d0-827f-49c1-9983-b04a4861726d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_6ca7d061-0b3b-4eed-ae46-54a7c8916707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f32206c7-89ed-42ef-87ae-580a4267889f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_6ca7d061-0b3b-4eed-ae46-54a7c8916707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2cdd7d5c-7407-48fb-9b85-c7a95a0acbed" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f32206c7-89ed-42ef-87ae-580a4267889f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2cdd7d5c-7407-48fb-9b85-c7a95a0acbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_f55a7d73-9cf6-4995-a080-5ea11c5cd45e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f32206c7-89ed-42ef-87ae-580a4267889f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_f55a7d73-9cf6-4995-a080-5ea11c5cd45e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0d9ceb36-9ea7-4606-94f6-90e14636b1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f32206c7-89ed-42ef-87ae-580a4267889f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_0d9ceb36-9ea7-4606-94f6-90e14636b1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_86259852-a2fe-4aac-bd0e-dd51d300282c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f32206c7-89ed-42ef-87ae-580a4267889f" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_86259852-a2fe-4aac-bd0e-dd51d300282c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7a0eb9da-feea-4c46-b6ad-e81386fc8bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f32206c7-89ed-42ef-87ae-580a4267889f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7a0eb9da-feea-4c46-b6ad-e81386fc8bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#StockBasedCompensationSummaryofRSUsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f018061b-fd58-4e39-86bb-06d81563a986" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c4a30665-6a91-4eaa-9dda-b819451a3340" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_f018061b-fd58-4e39-86bb-06d81563a986" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c4a30665-6a91-4eaa-9dda-b819451a3340" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_0a65b697-484d-4b4b-89ff-1571b43f3383" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c4a30665-6a91-4eaa-9dda-b819451a3340" xlink:to="loc_us-gaap_AwardTypeAxis_0a65b697-484d-4b4b-89ff-1571b43f3383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_143e46f2-cdf2-4aab-8f20-b8e4b68453fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_0a65b697-484d-4b4b-89ff-1571b43f3383" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_143e46f2-cdf2-4aab-8f20-b8e4b68453fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_ad0a2272-bf96-4d6d-894b-00825c118f5a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_143e46f2-cdf2-4aab-8f20-b8e4b68453fe" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_ad0a2272-bf96-4d6d-894b-00825c118f5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1102d450-e35b-4cc0-898a-86cce398c446" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c4a30665-6a91-4eaa-9dda-b819451a3340" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1102d450-e35b-4cc0-898a-86cce398c446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0adc21ff-f83e-41f9-8299-c6d921bb34be" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1102d450-e35b-4cc0-898a-86cce398c446" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0adc21ff-f83e-41f9-8299-c6d921bb34be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_42f0f725-e558-4f00-9019-a7e20b153e46" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0adc21ff-f83e-41f9-8299-c6d921bb34be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_42f0f725-e558-4f00-9019-a7e20b153e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2b502653-7014-491b-86ea-2f2f021e9cde" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0adc21ff-f83e-41f9-8299-c6d921bb34be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2b502653-7014-491b-86ea-2f2f021e9cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1522dfbd-c3af-40ca-a66d-07320886809e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0adc21ff-f83e-41f9-8299-c6d921bb34be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_1522dfbd-c3af-40ca-a66d-07320886809e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c77d414c-7d99-4d10-9fca-7646069ced0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0adc21ff-f83e-41f9-8299-c6d921bb34be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_c77d414c-7d99-4d10-9fca-7646069ced0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b45c2069-6a27-40fe-a64c-197eeb02f43f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0adc21ff-f83e-41f9-8299-c6d921bb34be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_b45c2069-6a27-40fe-a64c-197eeb02f43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0aa405e7-f087-483c-9302-aca2a13cc41e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1102d450-e35b-4cc0-898a-86cce398c446" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0aa405e7-f087-483c-9302-aca2a13cc41e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e50a03f4-446f-4c29-8741-3e09b9700ac6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0aa405e7-f087-483c-9302-aca2a13cc41e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_e50a03f4-446f-4c29-8741-3e09b9700ac6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f6e4b595-83d2-41e6-80ea-50156aa855ad" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0aa405e7-f087-483c-9302-aca2a13cc41e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_f6e4b595-83d2-41e6-80ea-50156aa855ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_018edd95-31e9-43b7-a930-2e1783e48297" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0aa405e7-f087-483c-9302-aca2a13cc41e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_018edd95-31e9-43b7-a930-2e1783e48297" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_765bc57c-0f16-491b-9c64-dac91ebad3da" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0aa405e7-f087-483c-9302-aca2a13cc41e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_765bc57c-0f16-491b-9c64-dac91ebad3da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d8f965b9-de1d-40f7-bea4-f50d85f5b707" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_0aa405e7-f087-483c-9302-aca2a13cc41e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_d8f965b9-de1d-40f7-bea4-f50d85f5b707" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_db3cb152-96ef-419a-aef8-1f029217abf6" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b3ff30b4-b417-4a7c-9be7-7450c7c75eae" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_db3cb152-96ef-419a-aef8-1f029217abf6" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b3ff30b4-b417-4a7c-9be7-7450c7c75eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_21d9725c-c11c-43ce-8e33-d68c2143cb6b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b3ff30b4-b417-4a7c-9be7-7450c7c75eae" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_21d9725c-c11c-43ce-8e33-d68c2143cb6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_d3c92bcb-93d2-48a8-8658-f26e2d6f0691" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_21d9725c-c11c-43ce-8e33-d68c2143cb6b" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_d3c92bcb-93d2-48a8-8658-f26e2d6f0691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_66974d19-f1b7-48bc-a8bd-ada74160d74d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_d3c92bcb-93d2-48a8-8658-f26e2d6f0691" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_66974d19-f1b7-48bc-a8bd-ada74160d74d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f541360a-ec88-455b-a0f5-e8a96a77f5bc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b3ff30b4-b417-4a7c-9be7-7450c7c75eae" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f541360a-ec88-455b-a0f5-e8a96a77f5bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84979e5b-7a79-493d-bf94-61926f5d09fa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_f541360a-ec88-455b-a0f5-e8a96a77f5bc" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84979e5b-7a79-493d-bf94-61926f5d09fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_9cb67c50-46af-4717-b44a-d90c3e05d318" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84979e5b-7a79-493d-bf94-61926f5d09fa" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_9cb67c50-46af-4717-b44a-d90c3e05d318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_c8f9ff5c-6dd5-48cd-9cb2-f514401acdbd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84979e5b-7a79-493d-bf94-61926f5d09fa" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_c8f9ff5c-6dd5-48cd-9cb2-f514401acdbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_40e4762c-1c16-4d60-a8af-b4fef542e6fe" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_84979e5b-7a79-493d-bf94-61926f5d09fa" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_40e4762c-1c16-4d60-a8af-b4fef542e6fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_fc0896a4-3430-421d-ab6a-0ff558924a56" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b3ff30b4-b417-4a7c-9be7-7450c7c75eae" xlink:to="loc_us-gaap_FinancialInstrumentAxis_fc0896a4-3430-421d-ab6a-0ff558924a56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f1421b7-ad2c-4fda-beca-0c52eb159b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_fc0896a4-3430-421d-ab6a-0ff558924a56" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f1421b7-ad2c-4fda-beca-0c52eb159b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_dc4436d8-91cc-4ef3-8b3c-75a8b0c47abb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f1421b7-ad2c-4fda-beca-0c52eb159b2c" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_dc4436d8-91cc-4ef3-8b3c-75a8b0c47abb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_188c4937-f91a-4b15-aac8-607fd2cd06ef" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f1421b7-ad2c-4fda-beca-0c52eb159b2c" xlink:to="loc_us-gaap_MunicipalBondsMember_188c4937-f91a-4b15-aac8-607fd2cd06ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CommercialNotesMember_e8a5bb9d-d1b5-4f88-ae25-9bf4f274797c" xlink:href="arwr-20230930.xsd#arwr_CommercialNotesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f1421b7-ad2c-4fda-beca-0c52eb159b2c" xlink:to="loc_arwr_CommercialNotesMember_e8a5bb9d-d1b5-4f88-ae25-9bf4f274797c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_c8b65631-c3fc-4916-a6a3-24fd56b3ea4d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f1421b7-ad2c-4fda-beca-0c52eb159b2c" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_c8b65631-c3fc-4916-a6a3-24fd56b3ea4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_bbbdc727-d647-47d1-9858-3b8e5737bc13" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1f1421b7-ad2c-4fda-beca-0c52eb159b2c" xlink:to="loc_us-gaap_CertificatesOfDepositMember_bbbdc727-d647-47d1-9858-3b8e5737bc13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_5cf3fe39-3649-4fd5-9582-e32948d15220" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b3ff30b4-b417-4a7c-9be7-7450c7c75eae" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_5cf3fe39-3649-4fd5-9582-e32948d15220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5be51a26-0040-4082-b036-266a6cab9d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_5cf3fe39-3649-4fd5-9582-e32948d15220" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5be51a26-0040-4082-b036-266a6cab9d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_57a057a9-041e-4a09-a2f8-e5813a72f923" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_5be51a26-0040-4082-b036-266a6cab9d6a" xlink:to="loc_us-gaap_MoneyMarketFundsMember_57a057a9-041e-4a09-a2f8-e5813a72f923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e42e59e-0851-441f-ba38-7130dabc181e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b3ff30b4-b417-4a7c-9be7-7450c7c75eae" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e42e59e-0851-441f-ba38-7130dabc181e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8129e8f2-97ff-46e8-9d62-5b6db6733854" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e42e59e-0851-441f-ba38-7130dabc181e" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_8129e8f2-97ff-46e8-9d62-5b6db6733854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_fb3ae3a5-b649-44a0-a2f0-ba8841ca4cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e42e59e-0851-441f-ba38-7130dabc181e" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_fb3ae3a5-b649-44a0-a2f0-ba8841ca4cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_866d6799-0342-4f58-966c-27ca1a792235" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e42e59e-0851-441f-ba38-7130dabc181e" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_866d6799-0342-4f58-966c-27ca1a792235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_47105dfb-4e1d-4134-bb34-f5eda62d2062" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_6e42e59e-0851-441f-ba38-7130dabc181e" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_47105dfb-4e1d-4134-bb34-f5eda62d2062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_15e0dffb-b2d8-41b1-9418-3fc80a60a501" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a53f2c8a-3642-4a92-8ba6-eddd99623224" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_15e0dffb-b2d8-41b1-9418-3fc80a60a501" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_a53f2c8a-3642-4a92-8ba6-eddd99623224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_99b275be-8fab-4408-a497-1705d1e7f358" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_15e0dffb-b2d8-41b1-9418-3fc80a60a501" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_99b275be-8fab-4408-a497-1705d1e7f358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossAttributableToParent_d83fb018-8bcf-411a-a4a6-220c7fecc213" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeLossAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_15e0dffb-b2d8-41b1-9418-3fc80a60a501" xlink:to="loc_us-gaap_IncomeLossAttributableToParent_d83fb018-8bcf-411a-a4a6-220c7fecc213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#IncomeTaxesProvisionsforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7eab2659-f08a-4960-94b0-52ff4beddcc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_d3ea5f53-75a1-4eed-8f12-664143c1a6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7eab2659-f08a-4960-94b0-52ff4beddcc0" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_d3ea5f53-75a1-4eed-8f12-664143c1a6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b5f5b82a-a9b7-4fe2-820a-6b37f21ec383" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_d3ea5f53-75a1-4eed-8f12-664143c1a6ec" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_b5f5b82a-a9b7-4fe2-820a-6b37f21ec383" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ed222163-62dc-46cc-9360-97fa5e74e0dd" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_d3ea5f53-75a1-4eed-8f12-664143c1a6ec" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ed222163-62dc-46cc-9360-97fa5e74e0dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_c83b9e2c-21f0-4ca1-a507-4bb9751cdff7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_d3ea5f53-75a1-4eed-8f12-664143c1a6ec" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_c83b9e2c-21f0-4ca1-a507-4bb9751cdff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_716509cc-da8f-4fb5-ae61-031ff8c5789f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_d3ea5f53-75a1-4eed-8f12-664143c1a6ec" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_716509cc-da8f-4fb5-ae61-031ff8c5789f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f9ffe45d-3644-467a-af5c-a5e4c14aa6aa" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7eab2659-f08a-4960-94b0-52ff4beddcc0" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f9ffe45d-3644-467a-af5c-a5e4c14aa6aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_90c7b5d0-927e-42d7-8d7f-194e3c99b179" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f9ffe45d-3644-467a-af5c-a5e4c14aa6aa" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_90c7b5d0-927e-42d7-8d7f-194e3c99b179" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7e4406cf-901a-4576-bb4c-b7f7902beeac" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f9ffe45d-3644-467a-af5c-a5e4c14aa6aa" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_7e4406cf-901a-4576-bb4c-b7f7902beeac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_ed3db670-850e-4f78-81a2-4da9f4c10592" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f9ffe45d-3644-467a-af5c-a5e4c14aa6aa" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_ed3db670-850e-4f78-81a2-4da9f4c10592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0254c10c-4a75-4685-9e14-df7ece54039e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_f9ffe45d-3644-467a-af5c-a5e4c14aa6aa" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_0254c10c-4a75-4685-9e14-df7ece54039e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bdd12cc2-7282-4c46-85fc-cf23ac7bbe7e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7eab2659-f08a-4960-94b0-52ff4beddcc0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bdd12cc2-7282-4c46-85fc-cf23ac7bbe7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_363696ae-aa66-4e8f-aea7-20b572a42f7b" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8d4f6647-ca24-493c-842c-5538057a3fb7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_363696ae-aa66-4e8f-aea7-20b572a42f7b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_8d4f6647-ca24-493c-842c-5538057a3fb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_bd36466b-3413-4ddc-a442-973bd49a9c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_363696ae-aa66-4e8f-aea7-20b572a42f7b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_bd36466b-3413-4ddc-a442-973bd49a9c1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1063cb6f-af3d-4155-be5f-aba8fa4ef0f2" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_363696ae-aa66-4e8f-aea7-20b572a42f7b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_1063cb6f-af3d-4155-be5f-aba8fa4ef0f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d15671cf-8722-448c-ab60-bd8a68351796" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_363696ae-aa66-4e8f-aea7-20b572a42f7b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_d15671cf-8722-448c-ab60-bd8a68351796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent_3ac7b9ba-e117-4984-ac0f-5142febdbbd8" xlink:href="arwr-20230930.xsd#arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_363696ae-aa66-4e8f-aea7-20b572a42f7b" xlink:to="loc_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent_3ac7b9ba-e117-4984-ac0f-5142febdbbd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_9cd29373-a8ef-4606-ba8a-81303c3de6b3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_363696ae-aa66-4e8f-aea7-20b572a42f7b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent_9cd29373-a8ef-4606-ba8a-81303c3de6b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_2e0b8225-06b5-43e4-9036-080fc2ad073d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_363696ae-aa66-4e8f-aea7-20b572a42f7b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_2e0b8225-06b5-43e4-9036-080fc2ad073d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_c631fb1b-8f72-4fb4-a596-0126d064f09d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_363696ae-aa66-4e8f-aea7-20b572a42f7b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_c631fb1b-8f72-4fb4-a596-0126d064f09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_510eca20-c70e-42aa-9cc7-14a97b38d452" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_363696ae-aa66-4e8f-aea7-20b572a42f7b" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_510eca20-c70e-42aa-9cc7-14a97b38d452" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_94689a07-7326-4c64-b983-c097a492ffcc" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_8719b566-7138-4e5b-a36e-8d7901c59051" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_94689a07-7326-4c64-b983-c097a492ffcc" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_8719b566-7138-4e5b-a36e-8d7901c59051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ba70ba74-0be4-44ec-9a55-3b8fe54370cb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8719b566-7138-4e5b-a36e-8d7901c59051" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_ba70ba74-0be4-44ec-9a55-3b8fe54370cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_9e051adb-7fde-4da3-857a-c728cf1e37e6" xlink:href="arwr-20230930.xsd#arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8719b566-7138-4e5b-a36e-8d7901c59051" xlink:to="loc_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost_9e051adb-7fde-4da3-857a-c728cf1e37e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_e555ca63-ee6b-4b86-a92e-b34f237c260d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8719b566-7138-4e5b-a36e-8d7901c59051" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_e555ca63-ee6b-4b86-a92e-b34f237c260d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_8abec5da-700a-409c-8d7d-4a55fa86e81d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8719b566-7138-4e5b-a36e-8d7901c59051" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_8abec5da-700a-409c-8d7d-4a55fa86e81d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_00d0e058-c44d-4ef7-a0c2-e5b12fd32429" xlink:href="arwr-20230930.xsd#arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8719b566-7138-4e5b-a36e-8d7901c59051" xlink:to="loc_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities_00d0e058-c44d-4ef7-a0c2-e5b12fd32429" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_68eece0f-e683-4962-9930-40647424c88e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8719b566-7138-4e5b-a36e-8d7901c59051" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_68eece0f-e683-4962-9930-40647424c88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_0dc71fb0-bc77-482f-b620-d89adf33ebdb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8719b566-7138-4e5b-a36e-8d7901c59051" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits_0dc71fb0-bc77-482f-b620-d89adf33ebdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_779e341b-6dcc-4fa4-b989-b13fb4848913" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8719b566-7138-4e5b-a36e-8d7901c59051" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_779e341b-6dcc-4fa4-b989-b13fb4848913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_42f51b3b-5765-4ba5-a388-f94589689056" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8719b566-7138-4e5b-a36e-8d7901c59051" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_42f51b3b-5765-4ba5-a388-f94589689056" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_40734f09-1ec5-4130-b9bc-d8a54a64b771" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_8719b566-7138-4e5b-a36e-8d7901c59051" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_40734f09-1ec5-4130-b9bc-d8a54a64b771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0a2ea25b-4405-4b0c-8588-e25a20c193b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_94689a07-7326-4c64-b983-c097a492ffcc" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_0a2ea25b-4405-4b0c-8588-e25a20c193b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_a2d9ef1b-a8c6-45c5-b518-833608d8dfc0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_94689a07-7326-4c64-b983-c097a492ffcc" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_a2d9ef1b-a8c6-45c5-b518-833608d8dfc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_3912836b-9221-41c7-9a70-0e30a228d95a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_a2d9ef1b-a8c6-45c5-b518-833608d8dfc0" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_3912836b-9221-41c7-9a70-0e30a228d95a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_a1e7028d-9811-4413-a0f3-1dbb7e072f2a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_a2d9ef1b-a8c6-45c5-b518-833608d8dfc0" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesLeasingArrangements_a1e7028d-9811-4413-a0f3-1dbb7e072f2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DeferredTaxLiabilitiesStateTaxes_7e429642-8458-41c5-ae8f-c012e1d75306" xlink:href="arwr-20230930.xsd#arwr_DeferredTaxLiabilitiesStateTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_a2d9ef1b-a8c6-45c5-b518-833608d8dfc0" xlink:to="loc_arwr_DeferredTaxLiabilitiesStateTaxes_7e429642-8458-41c5-ae8f-c012e1d75306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_3ee3bed7-e117-4017-9a98-605285819173" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_a2d9ef1b-a8c6-45c5-b518-833608d8dfc0" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_3ee3bed7-e117-4017-9a98-605285819173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_586f7114-40e7-40c7-8a17-dd5f98135c50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_94689a07-7326-4c64-b983-c097a492ffcc" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_586f7114-40e7-40c7-8a17-dd5f98135c50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c9a33fb9-c4c0-4a5d-bf53-a560276f2529" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsTable_46fb8e3a-14a9-47d4-9ba7-4785d0f17550" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c9a33fb9-c4c0-4a5d-bf53-a560276f2529" xlink:to="loc_us-gaap_OperatingLossCarryforwardsTable_46fb8e3a-14a9-47d4-9ba7-4785d0f17550" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f99f8a2a-6218-4e80-8b87-98b619ca5e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_46fb8e3a-14a9-47d4-9ba7-4785d0f17550" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f99f8a2a-6218-4e80-8b87-98b619ca5e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_557dc704-0c67-4a6d-a08b-045361e68ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f99f8a2a-6218-4e80-8b87-98b619ca5e2e" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_557dc704-0c67-4a6d-a08b-045361e68ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_44de37c3-2a41-4919-897c-19d3d258da48" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_557dc704-0c67-4a6d-a08b-045361e68ca5" xlink:to="loc_us-gaap_DomesticCountryMember_44de37c3-2a41-4919-897c-19d3d258da48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_21c4b17b-5383-4290-844e-62726b645016" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_557dc704-0c67-4a6d-a08b-045361e68ca5" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_21c4b17b-5383-4290-844e-62726b645016" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLineItems_2090ed98-a132-4d95-9ec5-8ce4b0912f50" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwardsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsTable_46fb8e3a-14a9-47d4-9ba7-4785d0f17550" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLineItems_2090ed98-a132-4d95-9ec5-8ce4b0912f50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_484cf8bc-1423-48c3-983d-1f9d491a56c4" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2090ed98-a132-4d95-9ec5-8ce4b0912f50" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_484cf8bc-1423-48c3-983d-1f9d491a56c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_c814c2c3-3220-474f-b3fc-562b0b968e8c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2090ed98-a132-4d95-9ec5-8ce4b0912f50" xlink:to="loc_us-gaap_OperatingLossCarryforwards_c814c2c3-3220-474f-b3fc-562b0b968e8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OperatingLossCarryforwardsSubjectToExpiration_c1d9e687-b44a-472b-af77-ad13040a8ea4" xlink:href="arwr-20230930.xsd#arwr_OperatingLossCarryforwardsSubjectToExpiration"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2090ed98-a132-4d95-9ec5-8ce4b0912f50" xlink:to="loc_arwr_OperatingLossCarryforwardsSubjectToExpiration_c1d9e687-b44a-472b-af77-ad13040a8ea4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_OperatingLossCarryforwardsNotSubjectToExpiration_b60f46aa-163a-419f-8976-ba4a5bdf1010" xlink:href="arwr-20230930.xsd#arwr_OperatingLossCarryforwardsNotSubjectToExpiration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2090ed98-a132-4d95-9ec5-8ce4b0912f50" xlink:to="loc_arwr_OperatingLossCarryforwardsNotSubjectToExpiration_b60f46aa-163a-419f-8976-ba4a5bdf1010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_1c9b4bc8-047b-48a0-98dc-5138cf48c1ea" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2090ed98-a132-4d95-9ec5-8ce4b0912f50" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_1c9b4bc8-047b-48a0-98dc-5138cf48c1ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_1686ed3c-1509-4ce1-8ca2-6c478e1ba9bb" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2090ed98-a132-4d95-9ec5-8ce4b0912f50" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_1686ed3c-1509-4ce1-8ca2-6c478e1ba9bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_a07b903a-71da-44d1-ae79-4bf28dd569b5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2090ed98-a132-4d95-9ec5-8ce4b0912f50" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued_a07b903a-71da-44d1-ae79-4bf28dd569b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_8d4b1c9b-fe85-4595-829d-547f584d1166" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2090ed98-a132-4d95-9ec5-8ce4b0912f50" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_8d4b1c9b-fe85-4595-829d-547f584d1166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_a799457f-83bd-4fa3-b991-a140963d7d22" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLossCarryforwardsLineItems_2090ed98-a132-4d95-9ec5-8ce4b0912f50" xlink:to="loc_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit_a799457f-83bd-4fa3-b991-a140963d7d22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_af28bcb5-4071-43d7-9cfc-a4fafefa042f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6f78a8ca-8460-4935-899e-714910305a99" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_af28bcb5-4071-43d7-9cfc-a4fafefa042f" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6f78a8ca-8460-4935-899e-714910305a99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_4651405e-05ca-420f-9382-1158fab06a0c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6f78a8ca-8460-4935-899e-714910305a99" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_4651405e-05ca-420f-9382-1158fab06a0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_011ff54a-b375-4c58-9a82-17ece774a51a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6f78a8ca-8460-4935-899e-714910305a99" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_011ff54a-b375-4c58-9a82-17ece774a51a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_c2f586fb-772b-4364-8519-2b3598381a27" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6f78a8ca-8460-4935-899e-714910305a99" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_c2f586fb-772b-4364-8519-2b3598381a27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ea89bc4f-4d94-4af1-942b-a1bad7a62ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6f78a8ca-8460-4935-899e-714910305a99" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_ea89bc4f-4d94-4af1-942b-a1bad7a62ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_396964f3-3988-4a11-acdb-ce5f9013af1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_6f78a8ca-8460-4935-899e-714910305a99" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_396964f3-3988-4a11-acdb-ce5f9013af1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#EmployeeBenefitPlansAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c4fee31b-811b-4138-9cd2-e7279d87dbe0" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c76515ad-705c-4c1d-9bee-b8568a41dc1c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c4fee31b-811b-4138-9cd2-e7279d87dbe0" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c76515ad-705c-4c1d-9bee-b8568a41dc1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_8dd25ff9-0fc3-40e3-8024-fa006e3e3a66" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c76515ad-705c-4c1d-9bee-b8568a41dc1c" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_8dd25ff9-0fc3-40e3-8024-fa006e3e3a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_50bf1640-b200-4420-92f3-b0c56c7d62b8" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8dd25ff9-0fc3-40e3-8024-fa006e3e3a66" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_50bf1640-b200-4420-92f3-b0c56c7d62b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EmployeeContributionsUpToThreePercentMember_212091da-a979-4b50-8a10-6e2dab622dda" xlink:href="arwr-20230930.xsd#arwr_EmployeeContributionsUpToThreePercentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_50bf1640-b200-4420-92f3-b0c56c7d62b8" xlink:to="loc_arwr_EmployeeContributionsUpToThreePercentMember_212091da-a979-4b50-8a10-6e2dab622dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_EmployeeContributionNextTwoPercentMember_a2ae8631-c040-4917-8e7b-01dc748c4e9f" xlink:href="arwr-20230930.xsd#arwr_EmployeeContributionNextTwoPercentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_50bf1640-b200-4420-92f3-b0c56c7d62b8" xlink:to="loc_arwr_EmployeeContributionNextTwoPercentMember_a2ae8631-c040-4917-8e7b-01dc748c4e9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ac80fb48-51fa-4c17-b0af-15d9e7b98b52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_c76515ad-705c-4c1d-9bee-b8568a41dc1c" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ac80fb48-51fa-4c17-b0af-15d9e7b98b52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_739e398b-d589-4149-b465-98f827f67e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ac80fb48-51fa-4c17-b0af-15d9e7b98b52" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_739e398b-d589-4149-b465-98f827f67e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_5631e43b-48e8-4a8f-b662-e5ee0902d1f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ac80fb48-51fa-4c17-b0af-15d9e7b98b52" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_5631e43b-48e8-4a8f-b662-e5ee0902d1f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_afb1d4ed-8474-4bd5-b45f-6ce613442485" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_ac80fb48-51fa-4c17-b0af-15d9e7b98b52" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_afb1d4ed-8474-4bd5-b45f-6ce613442485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_528c54b2-3a7e-4b78-a965-e3851876389c" xlink:href="arwr-20230930.xsd#arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1f9821ff-4f8d-41ae-a03f-ae6fc2bb0d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_528c54b2-3a7e-4b78-a965-e3851876389c" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1f9821ff-4f8d-41ae-a03f-ae6fc2bb0d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_031fe450-98a0-440e-9deb-d2358fb1cf8a" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1f9821ff-4f8d-41ae-a03f-ae6fc2bb0d8f" xlink:to="loc_us-gaap_TypeOfArrangementAxis_031fe450-98a0-440e-9deb-d2358fb1cf8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c533a23-98e5-4f65-8e21-853eab9cc762" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_031fe450-98a0-440e-9deb-d2358fb1cf8a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c533a23-98e5-4f65-8e21-853eab9cc762" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPharmaAgreementMember_af0a3a96-629e-427b-9ba7-d5d8a4bd4c7f" xlink:href="arwr-20230930.xsd#arwr_RoyaltyPharmaAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7c533a23-98e5-4f65-8e21-853eab9cc762" xlink:to="loc_arwr_RoyaltyPharmaAgreementMember_af0a3a96-629e-427b-9ba7-d5d8a4bd4c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_8736fb50-f7d0-4dee-9f1f-6fb38911db51" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1f9821ff-4f8d-41ae-a03f-ae6fc2bb0d8f" xlink:to="loc_srt_RangeAxis_8736fb50-f7d0-4dee-9f1f-6fb38911db51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_df9f53c7-2ec1-462e-ab1b-71788e3a141c" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8736fb50-f7d0-4dee-9f1f-6fb38911db51" xlink:to="loc_srt_RangeMember_df9f53c7-2ec1-462e-ab1b-71788e3a141c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_207f6fbe-a7ab-457f-aa91-ce66f6dca86b" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_df9f53c7-2ec1-462e-ab1b-71788e3a141c" xlink:to="loc_srt_MaximumMember_207f6fbe-a7ab-457f-aa91-ce66f6dca86b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0196c7d-0362-4abc-ac1e-694901f484f5" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1f9821ff-4f8d-41ae-a03f-ae6fc2bb0d8f" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0196c7d-0362-4abc-ac1e-694901f484f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_InitialTransactionPrice_49b91a82-69b4-4bd1-bb1c-0d61d0da78df" xlink:href="arwr-20230930.xsd#arwr_InitialTransactionPrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0196c7d-0362-4abc-ac1e-694901f484f5" xlink:to="loc_arwr_InitialTransactionPrice_49b91a82-69b4-4bd1-bb1c-0d61d0da78df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_0e9a855e-bf96-4022-83e3-e7e4c632e8ad" xlink:href="arwr-20230930.xsd#arwr_CashReceivedAsDueUnderCollaborationAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0196c7d-0362-4abc-ac1e-694901f484f5" xlink:to="loc_arwr_CashReceivedAsDueUnderCollaborationAgreement_0e9a855e-bf96-4022-83e3-e7e4c632e8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivable_76182be5-9ffc-4cd2-82b2-5021574fc516" xlink:href="arwr-20230930.xsd#arwr_MilestonePaymentReceivable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0196c7d-0362-4abc-ac1e-694901f484f5" xlink:to="loc_arwr_MilestonePaymentReceivable_76182be5-9ffc-4cd2-82b2-5021574fc516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_9895bc23-0ea2-4c8d-afa9-4da890851395" xlink:href="arwr-20230930.xsd#arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0196c7d-0362-4abc-ac1e-694901f484f5" xlink:to="loc_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_9895bc23-0ea2-4c8d-afa9-4da890851395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponFDAApproval_9dd9d07b-cf32-449e-a924-07e1b9a3608f" xlink:href="arwr-20230930.xsd#arwr_MilestonePaymentReceivableUponFDAApproval"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0196c7d-0362-4abc-ac1e-694901f484f5" xlink:to="loc_arwr_MilestonePaymentReceivableUponFDAApproval_9dd9d07b-cf32-449e-a924-07e1b9a3608f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_dd351f96-4cc1-4d4f-8fe0-2ef8b48c402a" xlink:href="arwr-20230930.xsd#arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0196c7d-0362-4abc-ac1e-694901f484f5" xlink:to="loc_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_dd351f96-4cc1-4d4f-8fe0-2ef8b48c402a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RoyaltyPaymentThreshold_1bbff291-ee01-41b1-894e-0d0c70b0033c" xlink:href="arwr-20230930.xsd#arwr_RoyaltyPaymentThreshold"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0196c7d-0362-4abc-ac1e-694901f484f5" xlink:to="loc_arwr_RoyaltyPaymentThreshold_1bbff291-ee01-41b1-894e-0d0c70b0033c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_e2416494-9007-4797-bc2e-77b31a99d3d0" xlink:href="arwr-20230930.xsd#arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_f0196c7d-0362-4abc-ac1e-694901f484f5" xlink:to="loc_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_e2416494-9007-4797-bc2e-77b31a99d3d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arrowheadresearch.com/role/EarningsPerShareDetails" xlink:type="simple" xlink:href="arwr-20230930.xsd#EarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.arrowheadresearch.com/role/EarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_dada3af8-c799-4433-820b-092936ebc444" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_d4d71033-c192-443e-b05d-f552eca25c83" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dada3af8-c799-4433-820b-092936ebc444" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_d4d71033-c192-443e-b05d-f552eca25c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_aee2939e-0eeb-4bba-aee3-fab41b48a43f" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract_d4d71033-c192-443e-b05d-f552eca25c83" xlink:to="loc_us-gaap_NetIncomeLoss_aee2939e-0eeb-4bba-aee3-fab41b48a43f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_f02c8a9f-2990-4fbd-bdfb-8ccfcc3a93a1" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dada3af8-c799-4433-820b-092936ebc444" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_f02c8a9f-2990-4fbd-bdfb-8ccfcc3a93a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7d0ed7be-102f-42d3-a8e0-b3edcc178a52" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_f02c8a9f-2990-4fbd-bdfb-8ccfcc3a93a1" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_7d0ed7be-102f-42d3-a8e0-b3edcc178a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_aa7d1e0e-a2c2-423a-941c-e88683c95bd7" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_f02c8a9f-2990-4fbd-bdfb-8ccfcc3a93a1" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_aa7d1e0e-a2c2-423a-941c-e88683c95bd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f4f949c1-8a89-403b-b586-b7679a59df29" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_f02c8a9f-2990-4fbd-bdfb-8ccfcc3a93a1" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f4f949c1-8a89-403b-b586-b7679a59df29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3d1e1622-1ed1-4909-a28f-3ebff6c2162d" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dada3af8-c799-4433-820b-092936ebc444" xlink:to="loc_us-gaap_EarningsPerShareBasic_3d1e1622-1ed1-4909-a28f-3ebff6c2162d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_18c26fba-aec1-4fbc-acd5-1573736d8eda" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dada3af8-c799-4433-820b-092936ebc444" xlink:to="loc_us-gaap_EarningsPerShareDiluted_18c26fba-aec1-4fbc-acd5-1573736d8eda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d63e265d-8f0b-47fa-bfe2-6471fbdcf656" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_dada3af8-c799-4433-820b-092936ebc444" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_d63e265d-8f0b-47fa-bfe2-6471fbdcf656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RestrictedStockUnitsMarketBasedMember" xlink:href="arwr-20230930.xsd#arwr_RestrictedStockUnitsMarketBasedMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_arwr_RestrictedStockUnitsMarketBasedMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_RestrictedStockUnitsPerformanceBasedMember" xlink:href="arwr-20230930.xsd#arwr_RestrictedStockUnitsPerformanceBasedMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_arwr_RestrictedStockUnitsPerformanceBasedMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllTradingArrangementsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JamesHamiltonTerminatedPlanMember" xlink:href="arwr-20230930.xsd#arwr_JamesHamiltonTerminatedPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_arwr_JamesHamiltonTerminatedPlanMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JamesHamiltonAugust2023PlanMember" xlink:href="arwr-20230930.xsd#arwr_JamesHamiltonAugust2023PlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="loc_arwr_JamesHamiltonAugust2023PlanMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_MauroFerrariMember" xlink:href="arwr-20230930.xsd#arwr_MauroFerrariMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_MauroFerrariMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_DouglassGivenMember" xlink:href="arwr-20230930.xsd#arwr_DouglassGivenMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_DouglassGivenMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_JamesHamiltonMember" xlink:href="arwr-20230930.xsd#arwr_JamesHamiltonMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_JamesHamiltonMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_KenMyszkowskiMember" xlink:href="arwr-20230930.xsd#arwr_KenMyszkowskiMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_KenMyszkowskiMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_PatrickOBrienMember" xlink:href="arwr-20230930.xsd#arwr_PatrickOBrienMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_PatrickOBrienMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_TracieOliverMember" xlink:href="arwr-20230930.xsd#arwr_TracieOliverMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_TracieOliverMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_VictoriaVakienerMember" xlink:href="arwr-20230930.xsd#arwr_VictoriaVakienerMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_VictoriaVakienerMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_arwr_WilliamWaddillMember" xlink:href="arwr-20230930.xsd#arwr_WilliamWaddillMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_arwr_WilliamWaddillMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>a1011-arrowhead_2021plan001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a1011-arrowhead_2021plan001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !63KKZW##;SZ+#;W+QRYGM9GV&:/!!"OT5@<
M'G@XQQ6M10!Q_AW1[[_A+;W7[G2(-&CFM%MC;1RJ[SN'+>9)L&W(!P.2>3[5
M9T;1;VR\?>)]6F11::A'9K;L&!),:.&R.W)%6=9\7Z9HEZ;.9+RXN%A\^6.S
MM7F,,62-[[0=HX/N<&DO?&.DVD-C)$US?-?0_:+>.QMWF=XL E\*.%^8<GUQ
MUH RY=,UWPYXGU/5-%L8M3L-5*2W%H;@0RPS*H7>A8;65@!D$@Y%-M?#>HZ_
MK5[K'B2WBM$FT]]-M["&;S3'%(<R.[X +-@# X '>M6Y\9Z-!IVGWD4L]X-1
M!-I#:0-++, ,MA ,C;WSC'0\TX>,M"_X1UM=>\,5DKM$PDC99!("08]A&[?D
M$;<9H PM*/C;P]H\.AKHEGJ;6D8@MM1^VB*-T480R(06! QG;G..M+J7A;5]
M2UOP3=:DUMJ!TMYY-0F**BEFCPI5/9L8^@-=CI]]!J>FVNH6K%K>ZA2:)B,$
MJP# X[<&J?\ PD6G?\)2/#GFO_:1M/MGE[#M\K=MSNZ9SVH PH_#VI>&?$OV
MSP[&DNC7\N;_ $UG""!SUFASP,_Q+W[>VGXOT";Q#HJ0V=PEO?VMQ%>6<KC*
MK-&V5W =CR#]:GT+Q/I/B0WRZ9<^:]C<-;W",I5D<''0]N#@]#@^E-;Q9HL>
MBW6KS7@AL;6>2WEDD4C$B.4*@=2=PP,=>U &!JC>,_$6CSZ(VAVNE?:XS!<W
M[7JS(B,,.8T W,2,XSMQFG'P'83^,(9[W2;*]TBUT:&QMQ=1I+L=)&/ 8<?*
M1S6C:>.](N;^VLYX=1L)+MMELU_8R0),W959AC)[ X)ILWCW2HM0O+**SU>Z
MELY3#.UIILTR*X .-RJ1G!'YT =#9V5KI]JEK96T-M;H,)%#&$1?H!P*Y_P;
MHM[HK>(3>HJ_;M:N+R#:P.8G"[2?0\'BGWGCG1M,TFTU/4OMEC;75T+5/M=J
M\3!R"<LK#(7 )R>*UM0U:TTQK);IRIO;E;6':I.Z1@2!QT&%/- '*:7X1NQX
MY\;7NH1+_9FMPV\,15P695B*/D=NM)I!\9^&]'@T,:';:J+.,06U^MZL*O&H
MPAD0C<I QG;NSBK=Y\1M(L)XH;JPUR)YI?)B#:5./-?GY5^7YC@$\5;N?'&D
MV.@MK-]%J%G:BX6WQ<V<D3EFQC"L <<]>G6@#%A\%ZC9Z9HJ&6*YOQKPU;4I
M5.U"S!]^P'G W* .N!3?$7@W4Y/&.FZEH_E_8)K^"[U*!FV[9(CQ*OJ2I*L.
M^%-=?!K=C<:]=Z*LC"^M8DF>-E(RCY 93W&00<=#27>N6-EK-CI,LC?;+U))
M(HU0GY4 +,Q[#D#GJ>* *GB[0)/$>@M:6]PMM>PS1W5I.PR(YHV#*2/3(P?8
MURGB'2=>\6Z:]AJ/@C2!?/ T"ZE<722I;[A@O&-A?W P.<<UL6GQ'TB_M8[J
MST[7KBWD&4EBTF=E8>H(7!KIQ?1?V9]O=98X?)\XK(A5U7&>5/(..W6@#DE\
M&"3QEIUS?6EK>Z;::&+'=.BMF42*00ASCY0>?>DM-#U?PI=:]!X?L;>73;R)
MKNRBWJGV>[(P4P?^69.&'IR*M6OQ&T*X2UE>/4[6UNB@AN[K3YHX&WXV_O"N
MT Y&"3CFMN#7;"YU^\T2*1C?6D233(4( 5\[>>AZ4 <EIGPJTJ/PS'INH7>J
M2RS1'[9Y>I3K'+*PS(VP-MP6)[<]Z=HV@>($E\'MJB1O+HWVJ"XF$@/F(8]D
M3COD@#/<'-=[6+HGBO1_$-YJ%IIMR99;"3RY@4*C.67*D_>&489''% ','P;
MJ=C\2=-U#3_+.@">>]EB+8:WG>%T;:.ZN2K8['=ZUM:YHM[?>./"FJ0(IM=.
M:[-PQ8 KYD6U<#OS5^W\3Z3=>)[SPY'<_P#$TM(UEDA92,J0#D'H?O+G'3-6
M[;5K2[U2^TZ%V-S8^7YZE2 -X++@]^!0!=HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *HZS*\&AZA+$Y21+:1E8=00I(-7JJZG;/>:
M3>6L94230/&I;IDJ0,_G0!P'@GQ#J@\.'2];NWFU%]+74K*\<_-<0O&&//\
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MUH[7BPCRU)\YE!4YW/T;_8% 'H/B+Q#:^&M-CO;F"YG62>.WCCME#.SN=J@
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MLDU"34$M(%O9$$;W C D91T4MU(]JEG@ANH'@N(HYH9!M>.10RL/0@]:DHH
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M_P"@-!_X&_\ V%'VW6_^@-!_X&__ &% &M163]MUO_H#0?\ @;_]A1]MUO\
MZ T'_@;_ /84 :U%9/VW6_\ H#0?^!O_ -A1]MUO_H#0?^!O_P!A0!K45D_;
M=;_Z T'_ (&__84?;=;_ .@-!_X&_P#V% &M163]MUO_ * T'_@;_P#84?;=
M;_Z T'_@;_\ 84 :U%9/VW6_^@-!_P"!O_V%'VW6_P#H#0?^!O\ ]A0!K5S_
M (YO[G3/ >NWMF2MS#8RM&R]5.T_,/IU_"K7VW6_^@-!_P"!O_V%7##_ &CI
MDEOJ%J@6>-HYH-^]2IR",X&<B@#+M?#NEW&GZ"[PDMI<:-:,DC)M^4#L1D'
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MN7:<?5210!Y/X>CUV'2=)\0VUM;PSSZ?-/<W+:FTLE^Q@9QF(J!N$@4X!.T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<"MNB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3A@4/1ACJ#SS[58H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M33;;$_EZ=J#:C!^\Y\XL['/'(S(W'TIFI^"=,U2\NYY)[Z!+X*+VWM[@I%=
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M)[2*6;<L)=64J./NX=N* .8&IWEK::MHTVL:K*\&MI9VK0(LEW/&8$F,08X
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MEL9V6ZW06T=Q( Q0R2I'O.>"1NSZ9J2^\&:7?VU]"[7,9O+Y-0:6*7:\<Z!
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MT2W05[A;.[N1=SV(8>2\N0Q;&-PRP!(! )'(Y.67G@S3[^/6XYKF\V:T5-V
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BH[@3-
M;2BV=$G*$1M(I90V."0",C/;(KC+;X@+;>&+VXU>V$>N:=*+2XTZ'.9;AO\
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M;RPH$ (9]V[)ZGH* .KHKD-4\7-I'CI]+G2YGMCIB7,=O:6S32E_-=6;"@G
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M*?%,&LW\^L136NNW$\5_#+;0VZL+3[*C1ONXXD?AOEY;.. !5V^TG4)_!'Q
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MUWK">9]JNX8X),M\NV,L5P/7YS5B^>Y2SD^QQB2Y(VQ!CA0QZ%CZ#J>_IDT
M87@#5;G6O VEWMXY>Y*-%+(>KM&[1EC]=N?QJWKVHW=E<:?#;2P1+<.ZR,Z-
M)*<*2!'&.6.>I[ 'ZBCIOA1]''AZWL;^[2VTN)TF02XCN=RG)=.[;_F![<^M
M:6K>'K;5M0T^_>XNK>YL2_E26\FTE7 #J<@Y!P/0C'!% '))X]O1X8T/5[Z-
M+*VO(I?M5ZML\T5O*K!4#J&RJ-\QSDXP!GG-=1J>O#1_!<^O3B.Y^SV7V@B!
MODD.W/RG^Z3W]*JV/@NSTVP@LK+4-1B@A2:,*9$<,DC!BI#J1P1QWZ^IK571
M-.7P^NA?9E;31;"T\AB2#%MV[<]>G>@#"UG4O$NBZ-J^I-)ID\%MI;W<3"-P
M?.0%BA7=RA &#D$>]#^(M3_MZ*PC%J(YM#?4%+1,2LJL@P?FY7YSQP?>K5AX
M+L++2KG39KS4;^VGMFM,7EQO,<+#!1< 8&,<\G@<\5':^";2UN8KHZGJDUS%
M9-8K++,I/E,0<8"@9&T<X[<Y- &!%XH\5GPQH&M/)I!&KS6,:PBWD!C\[AR6
MW\]01QQR.>M:$VM>*#-?:39QVMWJVGVR2R21PA8I9'+E%VO*"B[4 )RW)/3&
M#J'P=9?V#I6CB[O%MM+EBEMF#)O!B.4!.WD# [<]\TNJ^$+/5-9BU9;W4;&]
M6(022V-QY1GC!R%?@Y ).",$9ZT 8=YXC\3M?ZI:PKIUG)::/#J.R:)I2CMY
MFZ(E7 ;F/&X?D:?I^LZIJWC709%N8X;.[T!KUK7RRP#,\.>=PY^; /;GCFMQ
M_"=DUY>W*7%U$;NQ6P=$9=JPKNVA<J2"-S<\]?I26WA&QM+C2;B&YO%ETRT-
MG$PD \R'Y2%? YP44\8Z<YR: .0T?5[_ $#P1'J5M]G^P0ZY=KJ'F1EF2!KN
M12ZX88VY!.0>,GM7=Z7>W%_<ZA(6B-E'.8;8HA#-M #DG//S[EZ#[O?-8MQI
M3:#H3Z)INF7>K0ZB\X<RO'LA,N68R?=.PLQZ GKCL*Z#2-,@T;1[/3;8'R;6
M%8E)ZG QD^YZGZT <=K7BK5M,C\;RV\=AYFCPPS6[-"WSAHRQ#X;DCH",?2M
MC3-7U7_A,;C1=1:TEC:P2^A:")D,>7*%#ECNZ [N._%/O_!EAJ/]N">ZO-NM
M(D=TJL@&U1M 7Y>..*NPZ!!#KZZR;JYDNA:"S(8IM,8;=T"CG/.: ,W6=<U0
MZW<:-HL"M=P6*W99D5@2[.J+AI$XS&<D9ZCI63=2ZS=^-?!S78@LIY;&[>>U
M*>:(Y (@XW!\-U(![<]<UOZUX3L]9U2VU,7E_87\$9A%Q8S>6SQDYV-D$%<\
M].#TJ9_#5H=5TS4$GN8Y--B>&!%<%=K[=V[()8G:O).>/K0!Q%I<-H+^,[F>
M&RN+:SU&VC@MA;!%60Q0+$5RV%52PX]B<BMN[\1^(=&^U-J.GQ?9Y9+:&QN'
MV)^]ED$9#JLC?*NX-G(R..O-:K>#M-FBUJ&Z>XNH-9;?=Q2LNTMM"@K@ @@*
MN.>V>M0+X%TV31+G2M0O-2U.*X01^;>W)>2-5(*[& &T@@'/4D#).!0!E^,;
MOQ-IWAC5W:\LXT6:V6VN(8R)'C>14D5E)^4Y;@@\@]CS74ZM=7>G>'KNZC>T
M:[A@9P\[>5#N ZL<G:OX_C6<W@VRGT&ZTJ\OM2O!<A ]U<3[IAL;<F#@ 8(S
MTZYSFM#4]"M=8\/S:->R3R6\T81Y/,Q(2#D-N]<@'T]L<4 <=?\ C75[/3?%
MKP_9I)='M8;JWEFM7C$@=6)#(6!ZH<'CKT/4V[[QAJ'A[4-975Q;7%O:Z2-3
MB%M&T;+\S*8R2QW<A?FP.IXJ]<> =.NTU-;B_P!3E;4[9+:[=IQF14S@XVX!
MPQ'  ] *NW/A+3[Z_GN[V2XN?M%@=/FBD*['A))(("@YR2<@T 83+J/_  LK
MPS)J$]M*9-,O& AB*;6S!N&2QR.F._7UXW/$.IWUE=6D%G+;QB:*9B6C:65F
M4+M"QJ1E>3N;H,#IG-0Z?X,M;"_TV\.IZG=2Z=%)!;?:)E(6-]N5.%!;&P<G
MGU)XJ[J?ANUU/5K34WN+N"YMXG@S;R[!)$Y!9&XZ94'(P1CK0!R<OCZ]7P]H
M>J7"Q:=;ZEIXG-Z]N\MO'<$#:CD$%$.3R?S&.>K\2:G=:7X/U/5K(P-<6MG)
M<IYBET;:A;'!'!QZU1M? ]E9Z1'I<&H:BMFMI]B:-I$<21<X!W*>@)&1CBM:
M^T6TOO#TVAGS(;*6W-J1$0&$97:0"0>W% ',PZSXEG\06FE"YTQ!?Z6;Z*7[
M*Y^SE60%2-XWY\P<_+C'X4RP\6:KJ?A_1+P&SMY[V"<S!8VE<R1G:!'&#G:3
MDDD_*,#/.:WXO#-O%JEGJ*WEW]HM+-K*,DICRR5)R-O)RJG/M]:H6G@+3;(:
M=]GO-1C:PCEA1EF +Q2,&=&(7IN .1@CUH H6/C#4Y[3PAJMREI%IFLQK'<X
MC8M#<.F4PV[ 5B"O(.#CGFNGT.\N=0TT7EP8BD[N]OY:%?W))\LG).25P>W7
MI7-7OAN.+0;;P/;:9>W>E/$@:^GF0I"BN#CJ&W #Y<+C.,]S7:HBQHJ(H55&
M H& !0!Y7HFKZWX>\,)JD/V&72$UNX@N+8Q-YVV2]>/>K[L9#,/EV\C//IT<
M/B+Q!J<R7>DZ<DU@FI26DR/L4B*.1HWD#F0'<"I;&WD<>]:=MX0T^U/EB:ZD
MLENVO4LY&4Q+,7+[ON[C\Y+ %B <'' J.#P5I]MK=QJ5O=:A%'<3_:9K%+@B
MVDFZ[RF,Y) )YP2.10!=\0:A<Z?;6K6TEO&9;E(G>8%B%(.=B#EW.  H]2>V
M*Y6+QEK<VEZ;+&EFL\VO2:3,9(7 *JS@.!N^4X09!SU/2NLUO0;?7!9-+/<V
M\UE<"X@FMW"NC[2O<$$$,001WK,C\":;"L:QW>H!8]2.IJ#,&Q,<G^('C+-[
MG/)/& # OO%GB73],\1W+RZ9(V@7:I)BV<?:HV6-\ ;_ -V0'(S\V2!P.^MJ
M7B#7[B]UBW\/6"7$NES1P^7)L F8HDA!8R*4&UP <'D'KTJ[=^"K"]M=:MIK
MN]\O69%DN@&0<A54;?EXX51^%%WX*L;K6FU5;[4K:XFC2.[6VN/+2["C \P
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M*3Z60UI=HRB6,A=O7;M(*\$$8-1S^#["XBC5I[H2K?IJ+S*R[Y9UP%9OEQ@
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M>=)YI4X.T+@8 XPJC'M]:J:+X9L]#&HI!/<30W]P]Q-#.5*!W^\5 48!].E
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MI&O6:F]F4\PS0\*5]V!0?2,T :OC+Q')HWAV_N=,N+4W]K'',8I5+_NV<+G
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M'#*00?<&HM/TVUTN!XK96^=M\CR.7>1L ;F9B23@ <]@*MT4 %%%% !1110
M4444 5M0L8M2LI+2=IEC?!+03-$X(((PRD$<@=Z6RL;?3K86]K'LCW,YY)+,
MQ+,Q)Y)))))]:L44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %9NN:'9^(=/%G>^:$65)HY(9"CQR(=RLK#H016E10!C)X8TY+75
M8")G75(Q'=L\I9I (A%G/KM4<^O-5;WP3I%ZZL6O(0;=+69;>Z>-;B),[5D
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&1C ^7+ YZ*>*J6OB>[OKK3]/AMX$OKVUDO@79BD=NK*J,1P2S;EXXQSSQR
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MF>U:5DEMIQC$,JD9'?YL=C@=,]-9M</90->1QQW)C4S)&VY5?'(!P,C.><4
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MWCW0KM92C#&'!5B#G'0'C%=K10!2TJQFT^Q$-S?SWTY9G>>; +$G. !PJCH
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M@Y/'-=!:12P64$,]PUS-'&JR3LH4R,!@L0.!D\X%344 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M421@L0JA06.2<>I[FLWQ)HR^(O#>H:.TY@6\A:$RA=Q3/?&1F@#SK5;F;1?
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M\"F]O]1OX-3,%U<W]M?PLT =89(4" %<C>" >XZ^U0S> [NZ_M\W6NM*^N6
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;8RA+C9[YXS4@T+Q+INOS7^E/I4D%_#"MW#=L_[B6-=F^,JOS@KC*G;T'(H
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M=/@M6G>SOR$U,:4R+&K,)B0!T;E?F'(Y]JNW?B$6?A&\U^>PNK<6UM+.UK<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1^1#]H^T
M>4GG;=GF;1NV]<9ZX]JDHH **** "BBB@ J![*TDNENGM86N$X65HP77Z'K4
M]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1535+:>\TJ[MK6Z>UN)8F6*=.L;D<-^!Q7+Z)XS4
M?#B77=7^2[TR*2'4(^A%Q%\K+]6(!'^\* .SHKA=(UO7M-TG2M.NK5]6\17E
MN]_<QR3+ D"%A\N2#TW! ,<[2215A?'CWQMET;1I;Z22Q%]+$TZ12(A9DV*#
MG>X9&!&0.!SR* .RHKB;/Q1K=U\3;W0_[.0:=!9Q2DF8!EW,W[P\9.0 -O;'
M6J.B>.(+?PKHEQ9Z=J%T=3OY[.&*:[\V4.#(<EV_ARG_  $'VH ]$HKC#X]:
MSM]:75-(DM[_ $LP VT4ZRB<SG;%L; ZMP<CBKFG>*;RYU^;0[W1'M+^*R^V
M8%PLB.N[: K8'?(YQ@CTP2 =/1533+FZO--@N+VQ:QN77,ELTBR&,YZ;EX/X
M5Q?C;4]?O=971/"UVT%W86;ZE<LJ@[R.(8#G^^0Q/LM '?T5RS^-8)/#.BZO
M86WVE]8DCBMH6F$:B1E9BKN>F-C#H>1C'-;FEWES?6"S7=C)8W&YE>!V#;2"
M1D,."#C(/H>U %VBO,O"GBJZL= O6G%SJ=_<^(KJQLH'FY)W$A=S9VHJJQ]@
M.!6W<>/386=_]OT>:/4+"ZMK>:TBF63<)V"HZ-@;@<G@@'*D4 =E17'2^.VT
MY-876=(DL[G3K>*Y6&*=9O/21F1 IP,,77;@^HY-6]+\4WESXE30-2T5["\:
MR:\W"X66,H'5<!@!DY8YZ8QWR#0!TU%86OZYJ&ER*EAHLE^!"TTLC3B%$5?X
M0Q!RYYP..G45FGQO)=SQ+HVCRZA&;&#4)?WZQR"*7)78A^^V%.1D#H,YH Z^
MBLCQ'KR>'-,349K=I;83Q1SNK8\E'8*9#Z@$C(]*HZYXSL]"U*YMIX))([33
MFU"YE0_<7=M1 .[.=V.GW: .EHKDAXRN[.=[?6M#>PF>RFO;95N5E$HB +H2
M -K@,..1UYXJ_'XGCDD\-I]E<?VXA=/F_P!5B$R\^O Q0!O45SWB3Q/)H5_I
M=A;:9)?W>IM(D$:2!/F1=W)/ &,Y/8 ]>E4;OQO+:2W<AT=VL-.DCAU"Y%PO
M[F1E5F"KCYP@==QR.^ <4 =?17$:G\09=/\ [:G30II['1;D0WMP)U7"E4;<
MBX^8@/R..G4YJ_:>+;IM4N]/OM#N+:>.Q.H6\<<JS//&#@K@8VOD@;<D<]:
M.HHKB+WQ?*=(UVWU?29[">UTM[[R[>]!=XL," Z@%'!&/;(()J2V\77!_LK3
M-*T>>]N;C2(K]//NPH5#@8>0@DMTYP22?J: .SHK+\.ZU'XAT&UU6*%X!.IW
M1.02C*Q5E)'7!!&:R[/Q;=2:Q;65_HDMC%>B7[))),I=C&,D.F,IE02.3[XH
M ZBBN*TGQ]/J2:%=S:%+:Z;K+"*WN&N%9A(49P&0#[IV, V?3@9K=U[7&TC[
M%!;6AO+Z^F,-O!Y@C!(4NS,QSM4*IYP>PQS0!L45QK>/&VV$$>C3/J-U>S6#
MVHF7]U-&A<Y;H5( .?0YQGBJK?$2[BL;R\F\-S)!IEU]EU)OM2GR6W*,Q\?O
M  RL?N\'N: .\HKCM1\;WEMJ&N6UEX?FO(]$V-=RBX5,HT2R?("/F;!/R\=.
MO(K+E\3I%\3?MS7TXT1?"9U$Q[CLQYV=^SINV\9Z]J /1:*X^#QG?F6SCO?#
MTELVHP22Z>OVE7,KJF_RWP/D8KS_ !#@\U97QK:SZ'H&I6EN\S:U-%## &PR
M%@2^[_<"MG_=H Z>BN2L?&YN[JRDDTQX-)OYWM[.^,ZDNRAB"R8RJL$;!R>V
M0,T[2/&CZE=Z;YVE26UAJP<Z?=-,K&7"EQO0#Y-R*6')X'.#0!U=%8NO:^VD
M36%G:V37NHZA(T=O )!&N%4LS,Q!PH ]"<D#%8=S\0OL=E^^T:?^TDU--+EL
M4E5B)73>A5NC*P*X)QUYQB@#MJ*Y_7[N^'P_U:[EB:QOETV>0I'-N,+B-B,.
M,<CU%96B>,;A%T:VUC3);2"_LS);7DDX<R%(P[;UZH2N6ZGH<X- ':T5Q^G^
M-Y[I])N+O19;32]8D$=C=-.K,2RED\Q /DW '&">P.*LVWBNZ;7+2QOM%ELH
M+Z26*TFDF4NS(&;YX\90,JL1R>V<9H Z>BN$L?B+-?>&X];&@3I;W4D4%BAN
M%WW,[OLVXQ\J@_Q'L"<=,V/#^J:G>_$+6K?4+>6T\C3K4_9?/\V(,7FRZ'@'
M(V@G /RX[4 =G17*ZOXNN[+6K_2M/T1[^>RLX[R1OM"Q*48N,9(/S?)P.^>H
MQ4.F>.CJ%[H_FZ1+:Z=K$3R65U),I9MJ>8=Z#[H*@D')Z=J .PHKC['QT]T;
M.>?2)+>QU&*273YS.K&8*AD 9<?(60%AR>!S@U4M?B%>W2Z-(OAF<1ZW#NL#
M]J3+N$#D.,?(NW<=W/"],G% '=T5YOJ7C"_O)= E@L+F&\AUV6PNK".X!$CK
M!(0I?@%,E&R1QC..*V%\<ND%U;W&D21ZS!>QV(L%G5A(\B[T828 V;<DDC(V
MGB@#L**XN[\?FPL<W&CS?VBFI1Z;)913*Q\R1-Z%7P RL"O)QU.<8KIDU!X-
M$;4-4@%DT4+37$8D\P1!02?F &>!0!>HKD++QI>3S:9]LT&2S@U96.GR-<JQ
M=MAD5) !^[+*"1RW3!K'^&EWK&K:MXBU'5%NCMU&YMDW7[/%"$=0(EB^Z,?W
M^IY]: /1Z*\R\4^*-=\SQSIT5OY%KIVD++#<Q3[9(V9)2'&!G)V@8S\NW/>M
MZU\:26UTEOK6ER6$#Z?)?0W#3"0O'$%+[U ^5@&!QD_6@#KZ*YK1O%-QJ&HV
MUGJ&D/I[WELUU:$SK)YB*5W!L#Y7&]3CD<GGBJVOW>I:GXNLO#&GW\NG0FT>
M^O+F *92@<(J(6!"DDDDXZ#B@#KJ*Y,)>^#(=2U+4-<N=0T*"U,VR["O<1R+
MU"LH&Y2.,'G..:6'Q?>07B6NLZ(^GRW%I+=6N+E91((P"R-@#:X!!QR.O/%
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M ;( &X?,.G&>X-=O0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-;2W$A""2WD+D/@?*I)49]_:I='O=1U'XFW=U/#:))%H:J(+>X\Y8R925#N
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MUGI5E'9V%M%;6T>=L42A5&3D_F>:9'I6GQ7]U?)9P+=W:JEQ,$&Z55& &/<
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M;)H:A&U&&9;MT<DW40MR_F/S\Q#A#N//S>]>CQ00P6Z6\,21PHH1(T4!54#
M '88[5FZ;X8T+1KB2XTW2;2UFD4HSQ1 ';G.T>@SV'% 'FGA[2[73_#WPXUF
M!6&I75Q##/<ER7EC>"0E&/=1M7 [8%2>#['5;F30-=>#2K6ZN+N0W5ZVHN;B
M\R) \+1F, D$9"[CM\OCI7IZ:/IL=K96R64"P6+![6,(,0D J"H[8!(_&H8/
M#>B6NKOJT&EVL=^Y8M<+& V6^\?8GN>I[T 8GC;=I5UHWBB-B$TVY$5X >#;
M381R?7:VQO;::XRX2\U<V.IBWANX/$>LNPM[JX:&*6WBAD%NC,%;AMGF8P=Q
M(%>A^+=*U37=*?2+&6T@M+U&AO9I@6D2(X!\M<8+$;ADD8X/-7Y]"TNZT>+2
M;BQAFL(D1$@D7*J%QMQZ$8&#0!YRNGS+;6?AVZL-.OGFU*YEM=/34G:TMXTC
M!:.5O+RVUG)";>,CTK-TVW36H/!6G7;^99MJNJ0-'#,S(T2>=MC#<%DPH SU
M6O3Y?"7A^;3;?3I-'LVL[=R\4)B&U&.<D>YR<^N>:FM_#VCVMRES;Z;:Q3),
M\ZND8!61EVLP]"1P: ,[QEIEE)\/=7LWMHVMX-/E,49'"%(SMQ],"O/]/\/Z
M;-8_#*P^SB.UO[22:\CC)43M]D5CNQUR0,^O2O8+B"*ZMI;>>-9(94*2(PR&
M4C!!]B*K1Z1IT7V'R[*%?L"%+3"#]PI7;A?0;>/I0!YG>:7IMWI'CO4=04)?
MZ3++%92ERKV4<<"-#Y?/RY)SQ]XGO39=,AU^\\63ZU"99X=$LYE1B0(IC#*2
MX'9@1P>HY]:]%OO"^A:EJ*:A>Z3:7%VNW$LD0).WE<^N.V>E7#IMDTUW*;6(
MR7B+'<-MYE4 @!O4 ,?SH \ZT.PAL-;\!W\&\7FJ:?*;^=G)>Y/DH^7)ZX;D
M>G0<5I^,]*L+_P >^"OMEK%-OGN4.\9R%@9@/P89KL4TNP1K)EM(0;)"EJ0O
M^I4KM(7T& !4>J:)IFMQ11ZG8P7:0R"2,2IG8WJ/2@#RF;2+.+PGK>OK&?[4
MMO$LIM[G<=T(^W!2J^@(+9'?)S5A['5=3U?6-32#2HKNVUSRHM3NM1>.6!$=
M D03RR-K*0-N[YO,SU->GMHVFM9RV;6,!MIIC/)%L&UI"^\L1Z[N<^M0S>&]
M$N-835IM+M9-00@K<-&"V1T/U'8]10!@_$O$?ANSNIE+6-KJEI<7HQD>0LJE
MB1W X)]A6]J6L:/:V]E)>W$#QW<\<=J /,\V1B-NP#.?7(Z#FM*2-)8VCD17
M1@596&00>H(K&TSP=X;T:^-[INB6-K<\@2Q0@%0>H7^[^&* /.+JV@?P-JWB
MAP?^$GAU:54N=Y\V*1;K9'"/12FU=O0ANG-)XATRVN-)^(NJRAVO;"^WV<N\
MYMV6"%MR?W23U(ZX%>FOX7T*36!JSZ3:-?A@_GF(;MP& W^\!WZU8DT;39H+
MV"2Q@:*^;==(4&)C@+EO7A0/PH \R\3Z9:Z#>>((--1H$N?"-Y-/AR3+*A $
MC9ZOAF^;KS5J/PMI(\8>';5K<O!?Z1/+?1L[$7;H8=K2C/SD%V//]*]$NM(T
MZ^>1[JSAF:2W:U<N@.Z%OO(?]DX'%2?V?9BYM[G[-'Y]O&T4,FWE$;&5![ [
M5_(4 >/V$-W?6_AS1$LK74;%+C5E2TO[IXHG\FXVQJ2$?=M0MA2.V?X:T['1
MC=ZUX3TK6);>[MU@U0&&"Z:>(QK+%LB9B!OV#"\CJE>@W/AK1+RP%C<:7:R6
MHE:<1F,861B2S#T)+')'J:L6^CZ;:&T-O8V\1LXVBMMD87RD;&Y5QT!VKGZ4
M >7:;;PW%SI/AR[RVA_V]J<'V=W.QA'N,41]5'S$*>/E'I5C4]/MFUK1_#^C
M16VK:6CWS-8W]ZR0),AC_=@A&SL#OA"#C)Y^45Z'<^'=&O+&:RN=,MI;::8W
M#QM&"#*3DO\ [V>_6HY?"V@S:3#I4FDVAL8&W10"(!8VYY&.AY//?)]: //[
M31VNM8\(:5K$MO>6XAU0&*"Z:>)HUDCV1LQ W[!A3D=4K/M](M++PO'J<*O]
MML/$XM;29I&+0P"]\ORE)/";21CIS7K4&CZ;:FS-O8V\1LHVBMMD8'E(V-RK
MCH#M'Y4AT73#:M;?88/(:X^TF/8,&7?OWX]=WS9]: /,+:QU74=4O-66#2H;
MR'Q T0U.YU%TF1$G"" 1^61M:/"A=V#O!ZFH;K2[4>%-<U[:QU2U\1R_9KDN
M=T %Z%VIZ*06R.^37I[^&]$DUD:N^EVK:B"&%P8QNR!@'Z@<9ZU,VC::UG-9
MM8P&VFE,\L10;7D+;RQ'KNY^M '(^$-*L+?XB>-KF*UB2=;J!0X'(#P([?FW
M/UJR#CXU/_V+J_\ I0U=(FB:9'K,FL)8P+J,B"-[D)AV4= 3WZ"JNK^$_#^O
MW*7.K:/9WLZ)Y:R3Q!B%R3C)[9)_.@#B_$&JV2>/-4U.V>22WTKP[.FI2VCX
M8%F#1QAAT<;7(],UA7>F+81^)M)FTW3[*)_"\MT]I:W33@R(3LD<E5^?/<9S
MCK7K=IHFE6&F/IMIIMI!8NI5[>*%5C8$8.5 P<CK56U\(^'K(1BVT:SCV*Z+
MB(?=< .#Z@@ '/8"@#SE='-S>Z%I%KHVFWM@F@)=):W=V]O'YKMB20;4?<P^
M7GC&[CK7=:3<3:7\.H;G4[Q;M[73R\MS:2^;YBJA.Y7(&XD <]S5A_!?AJ33
MH-/?1+,VENS-%$8QA"WWL>F>X[UL+;0):BU6&-;<)Y8B"C:%QC;CIC'&* /&
MX8'TN>YABL;33DO/"MY</%;WCSR2X\O9),2J@O\ ,_S#.<MSQ6BUA'H#^%=0
MTJ-DU"\TNY^T2[BS7+"V#KOS]XA@"/3H.*[R#P9X;MHTCAT2R14WA<1#@.NU
MA]"N!CT K2_LVR#VC_98MUFI6V.W_5 KM(7TXXH \LT_2](LU^&M]9D?;;Z9
M9IY Y+7+&UD+R/S\S!FZGIN(KHOB/IECJ-[X0%[;1S ZTD1WC.4:*0E?H2J_
MD*Z&S\(^'=/NA=6>C64$ZR>:LD<0!5L$9'I]YNGJ:NZKH^G:Y9BTU2RANX X
M<)*N0&'0CT- 'E&KZ-8OX;^(.L-$3?V.HS/:3!B#;LD43 I_=.>I'7 !Z5/K
M%EJFLZSXIN4@TM+JRN(H[34;W47@>P AC=&11&P"EF8D[ANR0>E>G'1-+-E=
MV1L(/LUV2UQ%L&V4D!26'?@ ?A4-YX:T34=1BU"\TNUGNXMNR62,%AM.5^N#
MR,]* /.-:T>TOM/^).HW<;27=C*\EH^\_P"CNMI$X:/^Z<XY'7 KU2PD:;3[
M:5SEWB5F/J2!4;Z3I[Q7T3V<)CO\_:E*C$V5"'=Z_* /H*M(BQHJ(H55   Z
M 4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ KE_'VIV^D^'H;BYMIKB-KVWC"0W+0$%G !W+
MS@>G0]*ZBN8\=^'KSQ+H$5C8O"LJ7L$Y,K$#:CACT!YP* *6J^-M2M+KQ"EC
MH*74&A;7NI9+SR]Z&%93L&PY8 G@X' YYP.OM;A+NTAN8L^7-&LBYZX(R*Y>
MX\,WTL?C95>#.MIMM<L?E_T98OGXX^8'IGBMVT,>CZ':1WT\,(@@CB>1W"KN
M"@=3CO0!H45G?\)!HO\ T%[#_P "4_QH_P"$@T7_ *"]A_X$I_C0!HT5G?\
M"0:+_P!!>P_\"4_QH_X2#1?^@O8?^!*?XT 1>(M;70=,6Y$'VB>::.W@AWA
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MN@""!&-I)080;BY<Y/)&.!6-XW\57E_\-_$&%%AJ.GWEK#(UG=F1"&DB8%)
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M-I;:=K?-Z$<5/-X<UB^\56>HSZ9I%M-;W7FG5+69A/)!S^Y9-@W<$*26Q@9
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MR;2<JNWDKR0>E'_"':[<+<2W;V*SS^(K;5BL<C%5BC6,,@)498;"!P,\'C.
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MC&-N.^?PKJJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=7,J_P#+O]OVNC,.1'M'S <8+&NU\%Z>]CKFM'S]&1)$MR]EI0(CB<!_G(/
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M&-Y*XQG& .]7_#7C.;5=:ATV];2FDNK1KJ'^S[OSO*VE0T<G^U\XP1P<-Z4
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MN,X% %T:%I"O*ZZ58AII1-*1;IEY <AVXY89.">>:=_8VEG4_P"T_P"S;/\
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MW%I:Z1IMCYLVC6VIM+=2NJ*9=P*84$]5X/U]@0#L8-(TRUOYK^WTZTBO)O\
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MM/4K96=O;*0 1#$$! & .!V' KSGQ5;ZGJ?Q=T/3WCLYK&.TEN889I9 I(*
MNP48W YV]16I%XWU1]/M_$#:?:#P]<7BVRD3-]H5&E\I92,;<%B#MZX/7M0!
MU]QI&F75]#?7&G6DUY#_ *JXDA5I(_\ =8C(_"I!86:P3PK:0"*X+-,@C&V0
MM]XL.Y/?/6N>T#Q#J^N:]JD L;6'3-.O9;.29I6,DC* 1M7&.XSD]^.E&K:_
MK*^*VT#1[*SDE_L\7OGW4K*B_O&3;A02<X&/Q],$ VIM$TFXFMIIM+LI);4
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M;3+,W$Q4R3&!=[E2"N3C)P0"/3 KSO6-;U*R^'/BC1+Z\E77-'M3LNE<J]Q
M?]5.".<D##8Z,#ZUV2>(96U7Q#9_9TVZ5;Q2HVXYD+HS8/I]V@#::TMGEDE:
MWB:22/RG<H"63GY2>XY/'N:BT_2]/TF%H=.L+6SB9MS);PK&I/J0H'-<C;>,
M-<U:YTVSTK3K'[1>:)#JK/<S,$C+G!3@$GG&.G<]L&/2/'.K7\?AS4;G2[6W
MTO6Y?LR*L[--%)L=LGC:5)C8>N,'V !V\EK;RW,-S);Q//#N$4K("T>[@[3U
M&>^*KMHVEOJ8U-M-LVOU&!=&!3*.WW\9_6O.O#'B+6=%\)VM]-96KZ*NJ36T
MLC3-Y^)+MT$@&,;0S 8SD@$UJ_\ "Q<ZOUTO^S_[2_LWROM?^E[O,\KS?+_N
M[^W7;\WM0!U]QH>D7=XUY<Z7937+1F)II+=&<H1@J6(SC'&*M1VMO%/)/'!$
MDT@57D5 &8+G:">^,G'IFN;\,^(=7\0:EJ1>QM8--LKRXLO,\UC+*\;X!"XP
M%QUR<YSQ@<K?Z[K%QXBN]'T&SLI'L;>.:YEO)652TF[9&H4'G"$DGID<&@#:
M@T72K6X:XM],LXIVD,K21P*K%R""Q(&<X)&>O)JU';PPO*\4,:/*V^1E4 NV
M ,GU. !^%>1>)=3O_&>I^ S;V]K_ &=J?GRFSN9I &E2(EEDVCD*0<8ZFN^\
M9QZF?"LB:4MRTJR0^<EF^V9H0Z^:L1XPQ3=CG/IS0!IS:%I%Q<3W$^E6,L]P
MGES2/;HS2K_=8D9(X'!]*G_LVQ^S36WV*W\B8DRQ>4NUR<<L,8/0=?2O-1/H
M3:%XG_L/5-4AD31;C[1I&H/-O1MAQ*!,2P(Z$J<'([UMZ!X@UFVN- T[4K"U
M6VU&Q9[4PS%I4:-%;;)D 9(/8\$8YZT =B;.U)N";:$_:!B?Y!^]&,?-Z\<<
M]J1+&SBN$N([2!)TB\E)%C 98\YV ]0N>W2N'M/']Y]JN+:]CTA[@:=/>I!8
MWHF:W:+;F*;'&?F'(X^5OK2KXYU5-"TF_O+72K*36F3[$)[HJD49C,C/*Q Q
MP.%'=@,T =S#9VMM+-+!;0Q23MOE>- ID;U8CJ?K4%OH^EVEU/=6VFV<-Q<9
M\Z6.!5>7_>(&3^-<4/B'//:6D</]D17<E[-9RW4UV?L8>-0PVN!R7#*0#COU
MQSV*:E);>'CJ>J0"V>&W:>XBCD$@3:"6VMW''% $LVDZ;<:<-.GT^UEL0 HM
MGA4Q@#H-I&.*C?0M'D@M87TJQ:*T.ZV1K="L)]4&/E_"N;T_Q7K/G:%/JVG6
M<%AK;!+?R)F:2!VC,B+)D '*J1D=#Z]:M^"_$.K^)[,ZE=6-K:V#&2.+9*S2
M.Z2%"<8P%X/?.10!O0:7I]K,)K>PM8I07(>.%5;+D%CD#N0,^N*R;;0+N7Q8
MVNZK=P3M;QR0:?!#"4$".P+,Q))9R%49&!@'CFNAHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *PO$VB7.KPV$]A-%#?Z==K=VYF!*,0K*RMCG!5V&1TX-;M17%S!:0//<S
M1PPH,M)(P55^I/ H XN]\&:IJVD>*#?W5HFJ:W;);*(0QA@1 0HR1ECEF).!
MUZ<5V.GV[6>FVMLS!FAA2,D="0 *PO%7C33_  UX>355:&],[I';1I<*HF+,
M%R&Y&T9R3SBI]+\5Z??ZA%I<EQ:IJC6RW#P07*RH 21A7XW'Y2>G3F@#!T+P
M7JVG0:!:75U9/!HM_-/$\6_=+&Z2J-P(P&S(.G'!J74O!-U=7NI7T4UHUQ)J
MD.HVL<Z%H_D@6%DD'H1OY&<9![8KK8=3L+A9V@OK:5;?/G%)581XZ[L'CH>M
M26]Y:W9D%M<PS&,@.(W#;21D XZ<<T 9^@6-[96DOV];!)I92XCL8MD<:X "
MY."QX)R0.O3BL:3P_K^CZUJ%[X;NM/:UU*3SY[._5P(YL!2Z,G/S #*D=1P1
M4U[X[TN*QOI[%X[R2ROH;*6)90/FDDC3<.N0/-';D@BN@MM0LKU)'M;RWG6(
M[9#%*K!#Z'!XH Y67PKK9BT[46U>*[UVSO)+H-.C+;E9$*-"H&2B!2,'DY&3
MG-1'P7J-V[W][=VO]HW&KVFH3B(-Y:1P;0L:D\DX4\G&2>@KL+2^M-0B,ME=
M07,8;:7AD#@'TR.]8&I>++JU\13:+IWA^\U.>&WCN)6AFAC55<L!_K&7)^0]
M* "?PS<2WOBJ<3Q :S:1V\0(/[LK&Z$M[98=*9H_A:YTW4_M4EQ$Z_V+;:;A
M0<[XBY+?0[Q^5:VEZK/=P*VI:=)I-P\ICBM[B>)VDP <KL8@]^.O!JZ]]:1R
MM&]U LBE0RM( 06^Z"/?MZT <K8^#;FUTOP;:27,+G0O]>0#B7]P\7R_BV>>
MU1:%X1U/2([;3B=(_L^SB>**=+<_:9EVE4#DC"D C)!.[';)KH[G68#HUU?Z
M9-9WWDJ< 72K&6'9I.0M3?VI:111&[NK:WE=$8HTZ\;N!@\9!/ />@#GK7PC
M<P:+X.L3<PE]"DB>9@#B3; \1V_BX//I4.C>%]>TRWM-#_M&S'A^T:0 QQDW
M$\)W;8GS\J@;AEAR=HZ9-=4NI6#7<EHM[;&YB7=)")5WH/4KG(%8Z>+K/4-+
M:]T9[6\"7?V5UENEA Q(4+9YS]TE1_%VH S= \*ZKI4=O8S'2/L=G;-;QSPV
MY%Q/\NU"Y(PA ZX)R?2I=/\ "%U9V'@RW:YA9M!&)B <2_N&B^7\6SSVKI;C
M4K"TN8K>XO;:&>7_ %<4DJJS_0$Y-)=:II]EN^UWUK;[2H/FS*F"<XZGO@X^
ME '(W7@B[:6[O(9;*2[_ +:;4[>.X0M$RM (6C?TR-QR <'%7(O#.HRSZ)=7
M4FGQ2V.H27<D5I$4C"M"\81>,L1N!+'&>?:NL+ (6'(QGBN'T_XB7-]HT.M#
MPCK']E2IY@N(G@E(7^]Y8??C@]!GVH 76?!5_?1Z\]K=VRSWVI6E_;"4-M4P
MK$-KXYY,9Z>M;^N:7=ZYX-U#2I'@BO+VQ>!F7)C5V0@D=]N3]:L1Z]I,NDVV
MJC4;9;"Y56AGDD"*X/3DXY]NM1W7B/2K/6;'2I[R);N]1GA0N.0,>_?<,>O-
M '-2^'/%^J:(F@W^IZ59Z:T*V]Q)8Q2-/)&!@JI<X7(X)P>M&J>![R6]OX],
MDT^&QOM-CT_?-&S2VJ(KKB+L00W<C!&>>E=E%?V<]W+:17<$ES$,R0I("Z?5
M<Y%4O$.N1Z!I?VHPM<3R2)!;6R'#3S.<*@/;)ZGL 3VH Y;_ (0G5;B\?[5/
M8FUOM$72;]4+[DVA\/'Q@YW]#C&*T]%T77;$.;@:)%)%:&&!K6W(,LO&))"<
M%1Q]T9ZGG@5KQZK*NI7-O>1VD$$%NDK3"[#$$_>!4@%5'9CU]!5R"_L[J>:"
MWNX)IH3B6..0,T9]& /'XT -CMY+C2TMM2$4LLD CN1&"$<E<-@'G!YKDK+0
MO&6BZ8FB:9JNE/I\*^5;7=U%(;B&+HH*@[7*C@'(S@9%=?=W]GI\:R7MW!;(
MS;0TT@0$^F3WI+K4;&R,0N[RW@,QVQ^;*J[SZ#)YH Y63P(L%OX3M-/N MOH
M=W]HD,V2\V58,>/XBS$GZUM>)]$?7M%-K!.MO=1317-M*R[E26-PZY'<97!]
MC6A=:A96+1+=WEO;M*VV,2RJA<^@R>366OBFS37]4TR\>"S2Q6 B>:<*)3*&
M. #C!&WU.<T 9-[X=\2:S:O-J.I6,5[!=075A!!&S00O$23N)PS;\D'T&,=\
MU]0\%ZKKT&MW.J7=G#J5]:16ENML&:*!8W,@R6P6)<\\#  KNP<C(JM;ZA97
M<LT5M>6\TD)Q*D<JL8SZ, >/QH X^Y\*Z_J][J-]J=UI\<MWHL^F)#;!RD;.
M00Y+#)[YX';ZG4N]&U:/P]IFG6?]F72V]NL%U;7\9,4X" 9R 2,$9Z'.:V[;
M4["\BEEM;ZVGCB)$CQ2JP0CKD@\4D>J:?-9/>Q7UJ]HF=TZS*47'7+9P* .(
MM? >HZ.EG-8'2+JX6S-K-%>Q-Y2#S7D0QXR0$\QE"GJH'(Q7460U2SU:RL'\
MF2P33R9ID@\O_2 R 8Q\H!!<[1TQ6K;W,%W D]M-'-"XRLD;!E8>Q'!J/^T+
M(7WV'[9;_;"N[[/YJ^9CUVYSB@#B_B=)'<6.GZ?IUZD7B8W<<FFQH<R98E'8
MKU"!#)D].*T+GPG<:>= N/#SVR3Z/;O:)%=;A'-"RJ""RY(;**<X/?UKHX[V
MPFOI+:.ZMGO(E^>)9%,B#W'4"G7E_9Z?$);V[@MHR=H>:0("?3)[T <8?!>K
M16\%_#>63ZXNKMJLHD5E@8M&8C&,98 (1@\\CIS6SX:T34-+O]:OM2N;>:?4
M[A)\0*0L>V)$V\]<;>O?KQTK9N=0LK*..2ZO+>".0A4:655#$] "3S6'IWBF
M;4[.SN8;*!%GU">SD$MV%*B.1TW*"OSD[,[1CKUXH IR^'?$-EJ6J#0]2L[:
MQU2Y6ZEEEC+36S[55_+'*MD("-V,$GK6==>"-;9[I+6XTM8CJZZM%+(C>;,P
MF6012''"C& 1DX"\#FN\-Y;"%YC<0B)&V,^\85LXP3V.>,>M,;4K%+PV;7MN
MMR%WF$RJ'"]<[<YQ[T <K+X-NY?"6IZ/]JA$UYJCWRO@[55KD3;3[X&/K6UX
MIT:77M#-A#*D3FXMYMSYQB.9)"./4*13M,\3Z-JVG3W]K?P?9K>5XI9'D4!"
MKE,DYX!*G!/4<U=?4K&.Q%\][;+9D BX:51&0>AW9Q0!S?B+P;)K^IZC<-=1
MQ176F1V<>4W%)4F,JN1T*Y*\=\&K.F:%>RP:A#K5OI$<%U!]G^SZ?"0"I!#E
MF(!.<CC&!CJ<U=T;7H]9O]7MXHU":?<)"LJR;A,&B20,../OX[],UI&[ME29
MS<1!("1*Q<8CP,G=Z<$'F@#B-'^'MQ#X3UG2]7U%;F]U*)+<W<:'Y(HXQ'%P
M>I&"Q]2QIU]X1UK5_#FL:==_V):27=G]FB-E P!;.2[,0" <#Y1G'J:["XU7
M3K/_ (^;^U@P0O[V95Y/(')[]J?<W]G9M$MU=P0-,VV(2R!2Y]%R>3]* )D7
M:BJ>PQ7&Z!X4U30I;6TC71SIUDSF*80'[3*IW;$8XPN,C+#).WH,FM?1?%%G
MJ7AFRUJ\>#3X[K.%FG  .XC&XXR>*U)]1LK4@7%Y;PD@-^\E5>"< \GN>* .
M2L/!=_I^H6FNQZA&^O23LVIRMN$5S"^,Q =0$ 79Z;3G[QI^C>%-1T>^BMHA
MI!TN&YDG2<VY-TR,S,(SD8&"WW\YPHX'6NAUK7M.\/VL5QJ-PD*2SQP)D@$L
M[!1U[#.2>P!-4K7Q983:OJ=C<36ULEG+#%%-)<*!<&2)9!MSC^]C@G- &5%X
M)N5\#/HAO(DO$OGOK>X52RI)]H,Z9'&1T!_&H/$/A7Q-XJ\)ZWIFIZC8137R
MPI;PP*QA@".&9BQ&YBV/H,#W-=G<7]G:2PQ7-W!#),=L222!2Y]%!//X5%JV
MJV>B:3=:G?RB*VMHVDD8GL!G ]2>P[F@#F_$?AG5M>O?*9M+:Q$T4L-S+$WV
MJSVE2PC(&"25)!R,;CU ING>%-1TS4S%;C2#IAOI+L326Y:Y"NYD,8XQ]YCA
M\Y [9YKI%UO2S96]VVH6J07/$+O,H#GT!SR?:IY]0LK601W%W;PN=N%DD"D[
MCA>">YX'K0!C^+]#O-<T^R&GRP1W=E?P7L8N,[',;9VDCD9]:HOX4O9]*\70
M2W%N)]>5MA7=MB8VR1'/?&Y2?I71C5=.-PEN+^U,\F[9'YR[FVD@X&<G!!!^
MAHAU33[BUDNH;ZVDMXB1)*DRE$QUR0<"@#D9_!^J6VH7$^FG2)/ML$*3/?0&
M1H)(T$>^,8PP*A?E..1UYQ74ZQHUKKF@W>CW8/V:YA,+;."H(X(]"."/I5NV
MNK>]@6>UGBGA;[LD3AE/T(XJ)M2L$OEL7O;9;MAE8#*HD(]ESF@#DI]#\;7V
MDMH=YK&EBSDC\B;4(H7%U)&1@X0G8KD<;LD#.0*I"QU/3_B+=VWAP62+;:#9
MP+!=[@FT23!3E<G(QTQSGJ*V#XWBF\=GPS9P6\QAC5[FX>\5-A8D;$3!+L,<
MC(Q6O?:_I6F:S9:==7,45Y?!O*5F )"\\Y[=AZF@#FK+P3J.C3^%IM/N[69M
M*@G@NOM 9?-$S*SNFW.#N4X!XYZU#9^ M0L--)M[VV_M&#7)M6M696,9$FX&
M-^_*LPR.AP>:Z/0/%-EK=I$[R06MU+-/&EJTX+L(Y7CW <$YV9Z<5J_;[/[=
M]A^UP?:RN[R/,'F8]=N<XH XZ;P9J>HF^OK^ZM%U&]O;&9DA#&***VD#A 2,
ML3\YS@<MTXKH(=&EC\9W>MF5##/80VHCYW!D>1B?I\X_*E\1Z]_PC]E;SK8S
M7LMQ<QVL4$+*K,[YQRQ '3N:S!XU:*/4XK_1;S3]0LK"2_6VN'C(GB0<E71F
M'!P#GD9'% %J[\/3W'C[3O$*S1B"ULIK9HB#N8NRD$=L<5AP^"M773;;PX]W
M9'P];WBW"N%?[0\:R^:L1'W1A@!NST'3-='I?B6RO?#6E:S>306":A;QS*D\
MZ@ NH;:&.,GFM"ZU*QLE9KN]MK<*H8F654P"< \GIF@#-\.:'-HLFM-+*DGV
M_4Y;U-F?E5E0 'W^4TX:+*/&SZ[YJ>2VG+9^7SNW"0OGTQ@UL(Z2QK)&RNC
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M-UJ"K'-J&3;P,L;N&90R[C\N I(&2/2NMJ&YM;>]A,-U;Q3Q$@E)4#*<>QH
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MH[6!+B08>98P'8>YZFJ'B+0TU_2_LWGM;W$4J7%K<JNXP3(<J^._H1W!([T
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MZ<5SVN:G96/AWXH6=S=1174L\IC@9P'</:1!2%ZD$@\^Q]*]6AMX+<$00QQ
MXR$4+G P.GL /PJ*73K&>X-Q-9V\DQ0Q^8\2EMIZKDC./:@#SV+2K#4-?\92
M7EI#<,FE6B)YJ!MH,+YQGIG _(5G>&IM).H6,GB9[0Q/X3L#;->E=I7#^=C=
MWSLSCGI7K @A5G81("X <A1\P'0'UJ*33K*80"6SMW%O@PAHE/EXZ;>./PH
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M$0J,GOG.*[801+,TRQ()7 #.%&X@= 33;BTMKL(+FWBF$;!T\Q VUAW&>AH
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M.^ !751V-I#;+;16L"0(0RQ+& JD'(('3KS4HBC$IE$:^85"E\<D#H,^G)H
M\^\5S:GK_CO3='T:VM;J/1-NI7J74[11F5LB%2RJQR/F?&/2L*XEUW0?^$RT
M:[MK>UFUK3[G4].2SG:51,$VS*K%5.X_*^ .YKUY(8HY))$B19)""[*H!;'
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M<_Q%>F>X K)/AS7='U*_G\-:E81VE_,;F6TO[=W6*9OO/&R,#ACR5/?.",T
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MHDGG2-$J-N)(PX'(Z@]!3W\$:G>3ZC=W^IV[W-]=V%RPBA*I']FD#;5!)."
M!DGKD^PN>(?!3:]?:M.;T0"]T^"UC(3)BDBE>57Z\C++Q[4 8%_K&J:!XVEU
M/7H[.9K+PW=7 :R#(LF)8CLPQ)!R,9SSD=*?'\2+B.SU8&[T+4;JVTB;4H3I
MLY=$,>-T<GS$]67##&>>!BM*?P7JFMZA=7?B#4;5Q<Z3-IAALH614#LK;P68
MDGY3^GH2;$_AO7]3T'5M-U34]/Q=Z>]G$;6T*#<RD&5\DG/3Y00.O7C !L^'
MKK5K[2EO-5CM(I+@"6&*WW'RXV4$*Y/5NN<<?SKS1]2\17VA">^EM;N:+Q='
M#;(NY &2X*[223A.!C R!GK7K=E;FTL+>W+;C%$L98=\ #-<;!X(U&)I;=M0
MM6LAKJZQ#B%A(,RF1D8YP>N 0* (;SQQJ>AQZY;:PFFF\L6M!!-&S10,+ABB
ME]Q)4*58L<]!VK5\(>*_[?O-3L)+S3+V:Q\I_M6F2;H9$D#8XRVU@48$9/8]
MZCU?P9)J>HZQ>K>I%+>+9-;$Q[O)EMG=U9AGY@2P!''&:V-$M-6M_M$FK7-G
M))(P\N*S@,<<2@>I)9B3SST[#U ,709I7^)OC")I7:.."P*(6)"Y27.!VS2Z
M/-*WQ2\3PM*YB2RL2J%CM4GS<D#MG J;4O#NJP^))M?\/7]K!<W4"07=O>0M
M)%*$)V."K JPW$=P0:-+\-:G8)K6HRZG#+X@U15!N! 5AAV*1&JIDDJN23DY
M.: ,GQC;X\3Q76LZ7JFI:!]C"1K8%W%O/O8L[QH0QRNW# '&#ZUT7A!]/?PW
M;G2]3GU&RW/Y4T[EG4;C^[)(W?+]WYN>.:BO].\3)J(O=)U:T*R0)'-:WT+O
M$'7/[R,JP*DYY'(.!3=%\/ZCHUO"J:C#)+/?2WFHMY&T3%P<K&,G8 =O4G@'
MUH ROB]<36WPWOY;>62*036P#QL5(S,@/(JYJ.M^()O%5_HFC0Z<OV6RANO/
MNP[ EVD&S"D==@YSQSP:N>-_#<GBWPK<:/%<K;O+)$XD9=P&R17Z>^W%68-%
M>'Q7J.LF92EW9P6PBV\J8VD.<^_F?I0!QUEXJUK6O$WA2ZMY;:UTZ^TB2]GM
MW#-T:+?R" 2,G:<<9.<YI=#^)9U2^TT-=Z++%J@D\FTM9]US:D(TB^:-QSE5
M(. NUB!S5_3O ]_I+^%WMK^UD;2K)["Z6:%B)HG*%BF#PWR=\CFK>A^&=8TB
M&VTUM1LFTFSB:&$):XGE3&U!(Q) VC'*@%L#IR" 8]EXV\2S^$M*UZ73]-SJ
MMQ:P6ULK."/,)5F=NPS@C .!UR:OCQ1K=I_PD%E?+I'VW3%MI4N3(T%OY<Q8
M;GWDD;=C$X// &,U9MO!LL'A+PWHIO$+Z1<6TS2[#B01') &>,U'K?@NYU'5
M=1U*WO(%EG>QEACFB+)NMG=L. >0V_MTQF@#C?&?B=_$7PL\312W%A=/8WEI
M']JT]B89E:2)@0"201D@C)Z5Z)X[D>'X?^(I8G9)$TVX964X*D1M@@USFK_#
M_5]9TOQ!:W6KVIDUE[:9G6W8")XF3Y0-W*[4 '?.378>(M+;7/#6J:2DHB:]
MM);<2$9"EU*YQWZT >4SS>'O[+L(O"4VKCQ7*(FME1[O#,"N\OYGR&, G=GC
M!KH]=^)0TK5M45;S1H[;2YDBEM+F?;=7/RJSM&,C& V "#N*D<5T>L^&9-0T
MK2UM;I;?5-+>.6UNBF0&4;64C.2K+E2,]_:JTGAO5[?6+^;2]0LH+/4;A+F<
M36WF2Q.%57\LYVD,$'WAP23STH @F\;2V.C^*I[ZWB%[HL[1QPIG$RNH-N?^
M![@OU!K(UCXD76D7%]%<7.A03Z5!$UW:7%P4FNI#&)'6 ;N  P )#9/'%;FM
M>"?[6\86.L+=B*T0Q->VNS/VEH69H3G/&UFR>.<"GWOAO5X]:U&\T?4+*WBU
M,QO<&XMC+)"ZJ$WQ\X.55>&! (SSG% &;J/B[Q 9?$TNE6VFFTT-$FW7&\M<
M(8%F*C!^4\GDY'(XZFMG2_$TNI:QJ5L($2"VT^UO(CSN)F$A(/;C8/S--E\*
MR2)XM472#^W4VI\G^I_T=8>?7D9JE_PB6KV>HF?2]3M(H[K3H+&[\Z!F9?*#
M 21X8#.'/!R. >>E &.?B3<36>D 7>A:;=76DQ:E,VI3%(V,F0L<?S ]5;+$
MG QP<UUD?B9+GP"?%$$/RG3C>K"QS@B,MM)^HQ6+9>"]5T6VTMM)O[ W=OI<
M6FW!N[=GC<1Y*2* P((+-P>H/;%=?%9YTI+&\<7681%,[(%\WC#$J.!GG@>M
M '$Z1X&M=7\,VFI7^H:B^NWENEPVI1WDBO%(ZAOD4,%"KG 7&,#FM&75O$$^
MLW.B:,UA)-I=I"]U=7R-^_E<-A55"-N0N2><;A@56M?"_BS3-+&A:?XCM$TI
M%\J"XEM&:[@BZ!0P<(2!P&(_ U:D\,:OINIRWOA_4X%:ZM(;:X_M&-YF)B!"
M2A@P);#'(/7 Y% %+3_&FJ>)9M,@T*VLX))]-&H7)O=SA,N4$:[2.=RO\Q[#
MH<USWA[Q@^C^%=#T\76E:;<WCW]Q)/JDN(H@MRXV#!7<Q+\<CA2:Z6U\$7^@
M3:;-X>U"V62WTX:?/]MA9Q*H8N)!M88;<SG'0[NV*CT_P-J6BV.DM8:C:3:C
M8+=1.]W 3'/'-+YO(4@A@0O(]_7@ Z#PSXACU_PM;ZRPC16602>4^]-T;,C%
M6[KE20>XQ7/6/C#7'M-#UJ\M+!='UFXCABACW^? )<^4S,3M;/RY  QNZG%=
M?I]I/#I,5K?W"74^PK-(L0C5R>N%'0<X_J:Y2P\%ZI#!HVDWFIVTNBZ/<)/;
M!(&$\OEY\I78MMPO&2!SM'2@#&^']A?7/C[Q7JFHKITUS!>FW:=8F\U1Y:X6
M-BQVI[5M^.[6X74/#]^NHW21+JUG"+6-]L9+2_,S8Y;(P,'@8/'-:_A[P[)H
MFIZ_=O<+*-4O?M2J%QY8V*N#Z]*I^+-"\0:Y<62Z??:9;VMK<PW:K<6TCN98
MVW#)#@;3QQC/O0!D>*Y-*E\=0VGBB^-KHW]F&2U$ETT$3W'F$.=P(RX79@9[
MDBN<LM6.JZ=X6.L#4M5L=E] UI!O,\KQ2[(YI$4AF 12"3T9AGDUZ!J&G>*9
MULYK74]+$ZQ%+B&>S9H3)G(EC^;<".1@D@Y[5GP>"KW1'TNZT*_@-Y9VDEK/
M]NB+)<"1Q(S_ "D%6W@GN.<4 <E%J5S<:'X;TB0:A>6M_?WK?8X9B+@PQ%C'
M;2.6&TKE=V6'"8SZ]WX'ELO[+O+2T34+=K6[>.6ROY [VK8#;%8$Y3!#+R>&
MZ]A0C\$7UK9VMW:ZE!_;L%_/J!GD@/DNTP(DCV!LA,$ <YRH-6+71M:T:VGN
MX[J&YU;4M4@GO6C@(C$64C94!)("QKU)SP?7% &UXBU&?2M$GO+8V:2(5'F7
MLPBAC!8 N[>@!)P.3C'>N,7XB7)T:YE%QH\CP:G'8OJ<9<V2(\0D$K8.0,G8
M1NQN(YQ76>*-%GUO3[>.UFACN;6[BNXO/0O&[(<[6 (./Y'!K&M_#7B:SN]2
MO(=8T^2>_GCN)HY;0F-R(_+:,C=D)@*00<Y7G.30!T>AW=W>Z3%/>FS:9BW[
MRSDWQ2+D[74^A&#CG'J:Y33_ !Q=R^*[;2;JXT64W3SQBULY_,GM3&K,/,()
M!R%.< 8) YKH?"^A-H&D/:220F26>6X=;:/RXHR[$[47)PH_Q/>N<TSP1K5@
M/#\3:I8M;Z)(RPHELRF:-D9&9SN_UF&R,<9R3G/ !4L/&OBJ\T_PU?FPTH1:
M]^YBB#2!H9/+9P['."N$8[0 >@S4T_C^^T_3KB#4FTJVU*+6/[+^TRNT=J/W
M0F\UMQR!L.-N[EL#/-:FG^#)K+2/"-D;Q&.@R!W8(1YV(7CXYX^_G\*9<^"K
MEKB^O;:]@6]?5QJEJ98BR*?(6$HXR"05W<C&,CTH S8/B!?WEM:0Z>NE7U[)
MK']EO/!*6MW!@:594().,8RN3T89[U-)XSUFTBO].N+:PDUJ'5+?3H'CWK Y
MF175V!)8;5+9&>=O!YK5/AS4[QM(GU&_MFN++4C?,L%OLC">4\8C7G/&_.XY
M)YZ< 5=4\%7-[>:I?6U_'%=SZA:ZA:%XBRQO#&J;7&1D, 1QCK0!@3>(+_PU
MXE\5ZCJJ6+7<-CIT,;HYC@<O+,JLV[)107YY. I.:MQ_$>?[/?VD,^CZIJ4<
MMI#:S6$I-O(UPYC4-RQ4J5)(SR,=,U=E\#ZGJ,^LWFIZI;?;-0BM/*,%N0EM
M);R,Z$!F)9<E<Y(S\W3(Q:O?#&M:OI,\=_J5C%>K<07-E]EM2(H)(F#@G)W/
MN(P>1@=/4@%71#JG_"TM135A:FX31K<"2U#*DB^=*<[6)*G.1C)Z9[X'=5R-
MIX=U]-9U/6[G5++^T;O3EM(%BMV\J!E9V4X+$L,MD].]=7")%@C69@\H4!V4
M8!..2!0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI]HT[4$M[6R^U+OEL$S'+A,Y)<N[CC^!: /<Z*Y74]8U/4/$-IHV@7=I;[[
MZA)=S0&<%"P5%50R]3DDYZ#WJH=6\4ZAJL>B6[Z;I^H6VG)=WLC1-/&TCNRJ
MB#<N%.QB3R>0/>@#M:*\VUKQQJMG?S6+W>FZ9>V5A%/-!+ ]P+B=PQ,:LI&U
M!M'S<GYAZ<W+7Q%XA\1>(I]/TJ:ST^U&F6M\);BV:61&E#'85W*.W7M@\<\
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MT<CK^Z8'/ +#:?\ >% '045P%UXPUBXU.XM--%JD=QJZZ38S2QEMI2-GN)&
M8;L%2H&1R.:2Y\6:UI,U_IEV]I<WEG?:>BW*0E%E@N90ARFXX88<9SCH<4 >
M@45PGB_QCJ6@S^(5M$MV73M)@O81(A),CRR(0>>F$%=9HZ:HECG5[BWFNG8O
MBWB*+&IZ)R26QS\W&?04 7Z*\[L/&]X/$MK;7.I:=>V]T]RCPV5O)BV\M&=<
M3$[9.$(/ Y/'2DL_$_B@V?A?5;E].:SUZ[B0P) RO;1R(SJ VX[SM R<#!H
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MC2 $/QP?3[PZ^M/M/%6@WXO&M=7M)%LDWW#"48C3GYB?[O!YZ<4 8%CX$O\
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M1V\C\L<';GTR1@=,]JL6FNQ?\(C:Z[J#)!&]G'<S$9VIN0,<?G0!QNH:(OA
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M^!5BAV)'I]U'A5P%'E18'MT_2NZHH XKX474,OPZTJU1_P#2+.+R+B,@AHI
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M3[*$"IQSAPV?3.377Z9%(_PRLX51C*VCHH0#DGR0,8]:Z6B@#RKPG-:ZC/\
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M)IBI*0N\6$9L=!PPS_M5O:#H,.A6\ZK<3W5S=3&>YNK@@R3.0!DX
M %:M 'B[L9WO]6LY9;#3XO%GVJ2Y^S;MB-:!1,48<J78')'&[/:I-9MHY- L
MKRSU"XU-;OQ99SO<&V$2,0%4L@ P5^4?-T)S7LE(&5B0&!*G! /2@#S!=!_M
M_P 7_$[3) R+>06*Q2$8 <0DJP/^RP!_"L^)=5\<:!XCUIK6:.]AT7^RK>$H
M0S3E-]QM!]6*H#WVU[!10!X]?_9M5T#Q#?6VNSZK-#X<N+?RTL5A2)6 (1BH
M'S@J<+U&36QX@@?31X+NTOCI-A:6\D+W0MUD2!FB0)N!&%!"NN[U..]>DT4
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MA'( PX*<*>1S7?T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7O\ :#:!IR:B+ Q!T:;RVF9U5]J9&!A'4Y)Y)QQUJOJ?C.YTZV\62_V=$[:
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M2NUC.\*D+&P(:-U!&X$'DY!R 1B@!]OXV,L[:9)9+'K*ZC_9Q@\S,9;RS*)
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MXP94T&*U;EAYD;Q %&P<;>2>F<XY&.9=1MX_ ]CX<>R8^5'>Q:?,,G#PRL5
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MU?ZO!=16TOAN.TC<6[N4F63<R$*"02"N 1SMH ] \'ZW+XB\.1:G-Y.Z2>=
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MO9I-7GL[>_N-5TN&T3RKN[LS#- V[ A9MJ[^.>F1CGK0!T6I>*M$TB_2RO\
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M3SPGWAC>3OV]1BNN\7ZC+I^FVXAU)K"2XN5B#Q6QN)G&"2L485LN<=P0 ":
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MC)3J#N)/0YJ2.^U_0]8T.#4=8_M&/5HIED5K>.,02I$9 8RH!V_*PPV3TYH
M[FBO-=$USQ)]@\%ZQ?ZNMS'K<B07%F+9$1=T+NKJP&[=E!GG')P!4$/C+5M,
ML-4N]3U)_P"U+6QGGET:[LO*"NOW3"X \R,="<MD$'B@#U&BO*Y_%FO6&DZW
M)'>:C>"'1Y;Q+N]T=K407"$?(NZ-0RL&R <D;#DFM>>\\0V&N1:?<:V9EU+2
MKFY4K;1K]EEC,?\ J^.5Q(1AMQX'- '>T5R/PTBN1\-]%:>^DN'FLXW1G508
MP4&%&!SCU.3SS7)^']0UNRT%((M8>2ZU;Q'<62SS0H?LX$DS2.H  +$)P#D
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M:CI36ICEFF\IU*E$#A0588'?!S6KI-K?V?Q5FAOM1;4"-#4I/)$B/CSSD,$
M4\]" .OMD@':B[MC>FR$\?VH1B4P[AN"$D!L>F01GVJ:N"U.TU&]^*TL.GZF
MVG?\2.-GGCA21_\ 7R8 #@KCGGCMVSFH/#?B_5IK[0WU>:(V>HP7-HS*@55O
M+>1@6SV#HK'&>"O% 'HE0W-W;68B-S/'$)9%BCWL!N=NBCU)]*Q/!NHW^M:
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MHH **** "BBB@ HHHH ***Y_Q;K&H:/9V']F1VSW5Y?16B_:=VQ=^>3MY[4
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M7XOMJ-))-)N$C,I7;SO/&..*C?P K81-<OTMX;XZA:0*L>V"8R&1C]W+C+,
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MV(RA60JP(*D <>H!%4'\"0?V9%%%J=Y'J,>H'4O[0PC2/<%2I8KMVX*G;MP
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MTK5[+6K0W-C*SHKF-U>-HWC<=59& 92/0@=:O4 %%%% !1110 4444 %%%%
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M^Z. "IZ ],>U=[10!Y,D6K::_B^>.WO+>*X\0PL]Q':&21;?";I8E*G<1CJ
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M]MY=7G^V76]I]4B6-YBL:IO5 BD+A0.5!.W/3!/4444 %%%% !1110 4444
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MA_LZ,Q*19'' ))QQEFQ0 NMSWVH^-+#P];ZA<:?:FQEO9Y;;:))"KHBH&8'
M^8DXY/%<%XB?4-7L-!BO=6NVFL?&":9YT813(%9MLI&W'F $#/3.>*]1UGP[
M!K%U:W@N[NQOK4.L5U:.JN$;&Y3N#*5. <$'D#%4SX(TDZ=IMEFYV6&H+J22
M&3+RS@LQ:1B/FR6)/3\* *7Q&MY8OA7K<2WMSOBL'!FRN^4!<$-QCYN^ .O&
M*QX]&NKCQY;V*:YJ$(7P^ADN4,?GR?OVP-VW  SV&>!SUSWFKZ7;:WH]YI=X
M&-M=Q-#(%.#M88X/K5+2_#5OI=]%>_;+R[NDM!9^;<NK%HPY<9PHYR<9] *
M//[3Q3K.JVF@V<]SJY9[":>YFTF!#-*Z3>4I.1A5X).!R2.U6;S5?$RZ=IU[
MK4^LZ7;"Q/FW-C:(_E7"NP,D\>&;84"-@<<MG'%=4/ UA#9V,-C?:A8S62RI
M%=6\JB0I(V]T;*E2"<'IQ@8I;KP5:7$$4$6J:M:QBV%I*L-SG[1&,\.7#'/S
M-\PP>>O2@#D=2\1Z]>:EK,VE/K%Q+ITL<5E%8VR-:SD1)(WF$Y/S[R.#\HP1
MS78>-M3O--\-;["4V]U<W-O:)-M!,7FRJA;!XR QQGOBDG\$Z?)=O+;W>H64
M,HC%Q:VL^R.?RP%7=P6'RJJG:1D  YK6UK1[37](GTV]#^1-@[HVVLC*0RLI
M[$$ CZ4 >;:Y<W_@_P 2:Y=Q:A-?S6_AU7MY+S:SHQG*C<5 W 'GD>HK5U;4
M=5\#W\.[5KO5H;C3+VX>.\"96:",.&7:HP#D@KTZ8K;A\":9Y][/?7-]J4U]
M9FRN'O)0V^+.<84 #'MCUZ\U-8>#;*UNC<7=Y?:I(+9K2,W\BN(HFQN50%'7
M R3DG'6@# N(?$&E>"K[7AXDN+IVT2>XE2>-"$G\K>CQ;5&T Y^4Y!&*N:IK
M.H0:AX;CBNF5;K3KN:8 #YW2)"IZ=B2?QJW9^ -*ME,<]SJ%] MI)900W<^]
M;>%P R)@ \@ 9))P,9HL_ =A:W%K<3:CJ=Y+:026T#7,RMLB=0I4 *!T YZG
MN3@4 <IIT_B*XA\$S2>)KW?K]L1>#9%M0"#S08QM^5OEP2<_>)QTI&\1:Q!
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MZV2S,(\U4:*$QF.1\_+C .X\$$]^* .QTKQ/INLS6D5HTA>ZL$U",.F/W+G
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MWY&N@FTJ^:X^(#"TD(OX46V.W_7$6H7"^OS<?6@#2E\264/BH0/J[+;C1VU
MV_D Q^6'_P!=YG7IQM].:SM8^(UI8>&]1U.#3M1,]K"LR0W%J\>]7R%?G^'(
MY/4<9 R*Q[;1-2C\665U+H\MS;)X.^QR1O\ *LDV\$PDG@$C(YJA?Z7K%[X3
M\0Z7I-KKKZ8VGKY%KJJ_O$F#@^7$6^9EV#N2,XP>: .YD\;:;%J5KIK6NHF_
MN84G6V6T8R+&SLFYA_" 5.2>G'J*=;^--+N=2%E''>_O))8H)S;,(IY(PQ=(
MV_B(VM]=IQFJ&F17-]\1FUO[!=6]I+H<<*M<1%&5Q.Y*$'H<8./0BN8M+;6I
MM8T"^U"QUZ:]M-3=M0>5V,$89)47RH\[2HW+\RC@=3R: .ET?XAV=_X?;5;R
MRO+8&]>T@B$#,T[>8ZHJ#^)L)DCL<^E7G\=:+#I-YJ-TUQ:I93QP745Q"4DA
M9RH7<OH=P.1D8KC-+L-5L=+TDOHU^TN@ZY<W%Q"(O]=%,TX#Q<_/M$BG J36
MM(U37;?Q'JD.E7<<=_=Z8EO;S1[972"52\A3JH^8]><+G% 'I&EZ@FJZ?'>1
MV]U;I(3B.ZA,4F <9*GD9QD>U<WI?BQIM/U/Q'>RNND&Z^R:?;PQ;WD"OY>\
M8&YF>3( Z  >I-=A7ENB-J4'PIL+"R%X)["_-GJ2V0S<)&DS"39WR1M/'.&R
M* .O'C72S8/<&&^$ZW0LS9&V;[1YQ7>$V?[GS9Z8YS6MI6J6^L6"W=NLR*69
M&2:,QNC*2&5E/(((KS2WTQHSK*WV@^(GM)[^"[MYUFD>[A40!!*'W%BP92"F
M20K],9%=SX/.J'0O^)HUTSB>00/>*JSM#N^0R!> V/8'IGG- &'J_CZ&5M-3
M2/M2I<:O!9BZDM3Y,ZF79(J.1@]&YXZ$C.*VU\8Z4^K?8 +K!N#:"Z\AO(:<
M9S&'Z;L@CTR,9SQ7"V=IJ\7AGPQX:.A7_P!ITG5K9KJX:+]SY<<V?,1\_-D$
M'CH,YQCFQI/AU[?4H],OK'Q!/+%JSW2NMPRV6SSFF27KMXR,KUW9^M "Z?XW
MU+4]2\6W-S=7^G:=I:2I$HTT$0A8PQ=RW)<$Y"=#74KXST^UAT^V)OM0O;FP
MCO(UM[0M)-&>-^T<+ZD< 9 [BN:.AZI_8/Q-A^PS>9J,MP;-=O,X: *-OKD\
M5J>&-)OK3Q!HT]Q:2QQP^&8+5W9<!90X)0^_'2@#6;QMI+:?I]W:K=WIU!&D
MMX+6W9Y2JX#DK_"%) .>YQUHE\;:0%L?LPN[YKV W,:6ELTC+$" 78 94 G&
M#SGC&17"67AZ_P!.@T2]OK77$AC@O;>5-,9EFB9KDR(2JG)5ES]#MS6II5E<
M>%-<LM0CT'57L;G2OL_E)BXF@F\]Y=LAS_%YIYS@$8)H ZCP-K%QK_A&UU.Y
MF$TDTLX$BJ%!59G5>!_L@51L?&FFVNF3W=YJ=Q>(=6ET]&%IM99!G$05>6Q@
M@'J3BK'P\LKS3_!5G;:A:M:W0EN&>%OX-T\C#\,$5R.C>']6AL;9)M/G5E\9
M2WI#)T@._$G^[R.: /0-$\0V>NF[C@CN8+BTD$<]O=1&.2,D!E)![$'(-<QK
MGCNXAD\7Z?9V=S#<:/IIGBNFA)3S-DC9.>,?*N/7FMG1K*Y@\;>)[N6!TM[D
M6GDR$</MC(;'T-<QXAL-1_M;QY;QZ9>3#6-'1+.6*+=&SI%*I4MV;+  =\T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !39(UEB>-QE74J1[&G44 5=.T^VTG3+
M73K-"EM:Q+#$A8G:JC &3R>!5JBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ JE;:59V>I7E_;QF.>\VF?#':Y4
M8#;>F[&!GJ0!GH*NT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 4K/2K.PN[V[@C(N+V023RLQ9G(&%&3T '0#@<^IJ[110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ)I=MM#'S6497/H2,^W%7KWQ-HVG?;?ME\D(L6A2Y+*V(S*0(\G'<D<]N^*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>a1011-arrowhead_2021plan002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a1011-arrowhead_2021plan002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#G/'6OMX<\*75U
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M"!557C!SU8+C/H3Q6AK/P^\-ZIHEW80Z/IUG+-$4CN8+1%>%OX6! !R#@]:
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M-MWIT,7V6^1,&*:,?+(!GUZC/()'>JL?@&6W\.^';:SU7[-K&A1[+:^6'<C
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "CI137;9&S!2Q )VKU/L* .0L?&>I:A;VFIP>&;
MA]%NY%6*YBG#S;&;:LAA R%Y!."2!R1Q4>O>--;T": 3^%=\-U>I96TBZ@G[
MQW)"$C;\H.._2N5;4]$TZU@OO!GB"ZM=0EN$ \-23"0,[.-\9MVRT1Y;)4@#
M&>E=1\2_^/?PO_V,EC_Z&: +]UXLN=(T=KW6]%EM;B2=+>TL[>=9Y+F1ONJN
M, 'KU[ FJT_C+4](\FX\1>&Y-.TZ218VNXKQ)Q 6.%\T  J,D#(R!FF^/XYK
M67P_KRP2SVNDZAYUVD2%V6)HV0R!1R=NX'CMFLSQMXIT7Q/X2NM \/W]MJNI
MZJ@@@@M7$A3<1EWQ]Q5&22V.E '1:MXJFMM;&B:/I4FJZFL0GF03+%%;H3A2
M[G."<'  )X)J*#Q=<I::O_:FA75A>:;:M=M$7$D4R $C9*!@_=(P0"/2L2"_
MM?!?Q!UE]<G%K9:O!:M:W\WRQ%XHRC1L_16Z,,]<FKVJ^*]/\0^'/$]OI7F7
M=K;Z7,6OXP#;LY1OW:M_$0.3C(&>N: +LOCFRA\+:3JS6\LEWJT$<EGIT)WS
M3.ZAMH]AGEC@ <FNCM)+B6SBDNH%MYV4%XEDWA#Z;L#->1>&M#U/PUX<\/\
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M]K:P &2>0]%&2 !@$DG@ 5YUI>B^)/%VC:[JPATD6OBC)47AE$L=L 5A VC
MP/G'NV:6/5[R73_"VO:E%)--X9OI[#6EC4NT;>68C-@<D<JYP.C&@#LH?$VN
M07]I#J_A2XM;>ZD$2W%K<K="-CT\Q5 *C_:&0.YIMQXLU1_$NIZ-I7A[[<VG
M+"9I6O5B'[Q2PP"#Z&N?\1>,#=7=O)X3\807MS/+"D>E6<$5P64NHD9F +(
MI8Y.,8J2VTN_U+XG>,38Z]>:64CL=WV>*)Q(3$V,^8C=,=L=: -=O'RP:+X@
MN;W29[74-"C$EU9/(K95E+(5=<@@@'GV/%3V^O\ BB<1/_PB"K%)@[O[3C.
M>^-M<))&(/AKX]@U&267Q/'$Z:I+,P)F 4^4Z   1E/N@#CD5JZ7JG@^W6SE
M;XE7+-&$8PR:M&4)&#M(QT[8H Z*;Q;JLOB/5=(TKPY]N_LTQ++,UZD0)D0.
M, CT/Z4[6/%VH>'_  E<:UJ7A]HYXIXX4LX[I9#)O95!# 8'+=,=JXV>XT2'
MXF>+_P"UO%D^AL7M/+2*]6#S1Y"Y)!'./ZU>\47FE77PX=-*UYM9CBU.S#W#
MW*SL";B,[2P_E0!WFGZ_8:CX9@U])0EC);?:2['[B[<MGW'(/TKE++XGQWO@
M.^\3IHTZ?9;Q+06CS ,Y9HU!SC _U@X]JPKVSNX-<N_AS%&XT[5;U;^.11\L
M=DQ+W$8/;]XNT#TEK/U81Q_#7QTI?R8E\4X+*=NQ?M%OR/3% 'I-KK'B>6[A
MCN/"BP0,X627^THWV+GEL!><>E1:%XVM=:\3ZMH+6TEM<V,K)&SME;E5.&9?
MH2N1_M"L32]3\)1:I;-#\1;F\E\P*EO+JL;K(QX"E0.>3TJG9Z+<ZG:>(;[2
MRJ:UIOB*YN;%VX#-M0-$W^RZY4_4'M0!U*>)K^]34AI6B&\EL-1>QD1KI8LA
M45MX)'^V!BL_1/&FN:[<7:6_A3;'9WK65R[:BGR.N-V!MY ##ZU#\+=3CUFR
M\1:C%')$MQK4CF*08:,^3#E2/4'(_"I?AQ_K/&'_ &,EW_)* .WHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 8(HQ
M*91&@D(P7VC)'UIQ .,@''/-+10 4Q(8HV9HXT4L<L54#/UI]% #71)$*.JL
MIZAAD&A454"*H"@8"@<8IU%    , 8 I H484 #V%+10 R2&*7'F1H^TY&Y0
M<&G$ C! (]Z6B@ I" 2"0,CH?2EHH 0J&QD XY&12.BR(4=0RGJ&&0:=10 B
M(L:!$4*HZ # %   P  /2EHH 0* NT  >E   P  !V%+10 FT DX&3U]Z JA
M=H  ] *6B@!-BX VC Z#'2EHHH 0(J]% XQP*"JDY(&<8SBEHH :L:(<JB@^
MPQ3B 1@C(-%%    , 8%(  20 ,]:6B@!D<,418QQHA8Y8JH&?K3L $D 9/4
MTM% "%5.<J#G@\=:;Y,7_/)/^^13Z* &&*-CED4GU(I1&@& B@>F*=10 F!G
M.!GUI"BD$%1@\D8ZTZB@!@AB!R(TS_NBG  9P ,\TM% "!0N< #)R<4  9P
M,\G%+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD3AE;Z$<&I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXIY">04SSM'MQ][WI-7MS<:CXF@O]4T6PCFM+58WO[9I)Q#Y"A6A(=>DF_
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MXS[U[.UG:O+%*]M"TD(Q$Q0$H/\ 9/;\*1["SDM/LCVD#6W_ #Q,8*>OW>E
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MXI8'<Y8PRJ2%)[E65QGTVYYYJ5_$J-KUSI-K;K//:R0I<)YP615DVG>J8^9
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MC6OV.N/J.CZK9P+>PQ1WT-Q;M*H>-=HDCPRX.W P>.!0!/J7C6'3?W\EA/\
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MC5%BD9E+\M_#M)QU.#QZ\_K>N2ZQ<^#]0LX9H].N=8013B<CS4V28+1CC:V
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MC6K""U<01E?*>,'YUR3_ !$$#VH D/B'7](U2&PUR/3I6O+*>XMWLU=1')$
MS1L&8[AAN&&.AXK.L?&/B-M-\+ZU?6NF+I^M36\#6\0?S8S*ORN&)P1GG;C@
M'J:U4\,:QJ&HQWVNZE9S2VMG-:VJVMNT:[I0 \CY8\X4  <#)I?^$-D_X1?P
MOH_VU-VBSVDK2>6<2^2,$ 9XS^E '6T444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^/0^]-M;&ULK6WM;:!(X;9 D* ?<4#  _"K%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 9-#%<
M020S1I+%(I1T=0RLI&""#U!%8W_"%^%?^A9T;_P B_\ B:W** ,/_A"_"O\
MT+.C?^ $7_Q-'_"%^%?^A9T;_P  (O\ XFMRB@##_P"$+\*_]"SHW_@!%_\
M$T?\(7X5_P"A9T;_ , (O_B:W** ,/\ X0OPK_T+.C?^ $7_ ,31_P (7X5_
MZ%G1O_ "+_XFMRB@##_X0OPK_P!"SHW_ ( 1?_$T?\(7X5_Z%G1O_ "+_P")
MK<HH P_^$+\*_P#0LZ-_X 1?_$T?\(7X5_Z%G1O_   B_P#B:W** ,/_ (0O
MPK_T+.C?^ $7_P 31_PA?A7_ *%G1O\ P B_^)K<HH P_P#A"_"O_0LZ-_X
M1?\ Q-;@  P!@444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA+!0\F/E!)( &<5Q&E_"RU'A<:=J>K:PTUU&6OTBOF6*29^9#L'!RQ->AT4
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MU!&XG< ,] *M7ME%\/=)U"]T=YY([F2"&TTV>4M!%,[B,%2<LJDL"0#CCC%
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M *N5'"R >@8.IQZACWK-UB:ZM?BAI[V-JUU.^C7.(3/L0D2PX))R!WY )YH
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M"O4KA",DYR.F.:WD\;137UFL%D\]E=7;6BS0N6=&!90[(%XC)4C=NXR,@9H
MZNBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&,(2JJ1RQR/D'_UZR]6\%W>IGQ4!J,$::];1VXS;DF (I7/WOFR&/I732ZE
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MN+V**6WM[V]MF>1-X0;9A$AX/HNT?3':NU\>K)N\+N,^0FO6QG] "'5<_P#
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M0WV@B_NIWMQ(P<,J[E&0.<]^.:V9?!>KWEB=*O\ QA?7&DLOER1"WC2>6/\
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MXY9[=1(Q9V7=Y2E$8;L=S@<CW(CM/ \MIX=AT,ZI'=6*0RPO%=V:R(ZLVX'
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M(PP7#;N?O'/'Y5#XC\--XC@NK2>ZB^P75N(9();82;&RW[Q#N&U_FZX/0>E
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M>?F6/8KLCN " '"$@9R 0>><5+'QSJ-S%I5W<:/;PV5[J<FFLRW9=TD5Y$#
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M3@TBP:ZG#-EUCCC7[TDCL%1![EB!5VN0\=I)YWA:89^SPZ[;F;T 8.BD_P#
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M(L5VML8/M2#&)2AZ$\CT.W(X- ":?XGN7L+&[U?3EL%N;@VC;)Q*L<F\JAW
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M5UWA.&VL_&?BVVLXHX+4R6TD<<2!8R?* <J!QU !QWZT =0)KH:J\3+;BS$
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M8O)82I-WR9 F,]3\P[FMCX?Q6D<GB,PQ1(YUBX*%4"DQG;@CU7T(XH V+KQ
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M(DD"L1YJGC8<$=1@D'-<4-2N+5M$O-;LVL-*'VZWEET^#SH!.TH(F"LC$)(
M^TXXW'G!Y /2Y]8L+;4;33Y;F,75VK/#'N&65>I^G('XU!XAUR'P_I+7TP#$
MR1Q1H6V[G=U1>>PRPR>PS7$6NEZ=I/B#P5]GM;MM/2WOHH9+J LX+-&T8/RY
M7@,5! P/3%;?Q+CAD\+Q+)$LC_VA:%04W':+B,N0/3:"3[4 ;VGW]UY<@U86
M=NQF*6[Q3Y6X3 (8 \@\D;>>G7FK\D\,/^MEC3C/S,!QD#^9'YUP4XLH_%'B
M.VUR",Z;>6$"Z:3'N1X@C"2./'&[><[1R<J1G%9.B:$ESXD\.6GB>SAN[O\
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MZCM7/VOB.ZU35KB'2K>VGM;.^^R71>?;)C8K-(@P00"X&.^#R._)Z5%]ML?
MPT^%X=9L)E34E92LD48B83B7O\SA<9^\2",]:W/ <5I'?^*##%$CMK$IC*H%
M+1^7$ 5]5R#TXR* -B\\0,-?70M-MENK]81<3F23RX[>,G"EF )W,0<*!V))
M JS97U^^H7%K?V$<"1Q))'<13%TDR6##E001@'_@0YKEXTD\,_$[6=3OE8:5
MKEO;[+O:2D$L(*['/\ (.03@=LYK,U>1M3U+QFRW$]YHW]B 0CS6DMS<,)-P
M3DJ6X3@=#CUH ]':]M5B>5KF$1IC<QD&%SR,GMU%/,\056,J!7&5.X8;C/'X
M<UYND&DZ3IG@^6#3(X9+G:TMZL#.(Y1;E<R*OWY#EE&[H<]^#C>'[2TG_P"$
M'M[VT+&VO=2AF6YMRNU"9=BL" -IRH Z9X]J /5KW6M.L([62XNXE6[E6& [
MQ^\9NF/7C)^@J34M2MM)TR?4+M]MO F]B!DGT '<DX '<FO*H[>VCT:P)M0U
ME9>,)V"K 66*W9Y=I"@<(=RXQQR*[#XC*[^$[>5 ?L\.HV4TZXQ^Z6="V1Z#
M@GZ4 ;O]LP07-E97KQ0:C>(SQVWF D!>N3[9 SZGBJOACQ"==TTSW,<-M<?:
MKB 0++NSY4K(2"0"?NYZ=ZR?$<<$7Q$\+WEQ;;HO(NXC*(2X#GRB@) ..C$9
M]#7(6=M:1:7I%\L"+?+XLE8S;/WBPM/+DYZA"K ^F&SWH ]>-Q"+@0&:/SB-
MPCW#<1ZXZXJ2O+--2TO=8.F:T=437K369+N&..W 61?-8QR"4)_J_+(!!;H-
MOH*]3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MS@GN(;FX.X6Q,D:L1L5L$;_J 3UZ9J&TN=+EO)7M;RWFN9@-VR8.Q5<X &>
M,G@>I]:S7OKC5/AU)?W5L]K<W&EM)+ ZE3&YB)9<'D8.>M>;V6GV6L>!="L]
M$\(75OKGDV;1:K_9ZP+$R["TOG<$C 8\9+9Z<T >U57@O[.ZN;BV@NH99[9@
ML\:."T1(R P'3(YYKAGU/Q+J_P 2=<\/6.KQZ?8V5O;SK*+9)9%++RHW<<GG
M)SC&!UXJW'B[5+34?&D4/V?S;6_L;.R+0C"-.$7<^,%L%L\GMB@#TND9E7&X
M@9.!D]ZX37=1\1^%-+D^UZLEZEU=6]O:W8L]T\)<GS"8HUP^%&5P,Y."#3=+
MB;QG:WNFZL;F[M[&[AGM+Z[T][61^,\*53YU.X;@,8(XH [P2(6VAU+<C&>:
M=7)ZIX;M]-T?Q%?Z>!!>W&^^C>,8V3HI*OU/)/WO4'&,5MZ!J8UOP[INJA-G
MVVUBN-O]W>H;'ZT :!('4@4V2:**-I))$1%&69F  'N:Y/X@:)IMQX3\0ZG<
M64$UXFDS)'+)&&:,*CL-I(X.6)X]O2N;\2>'](M_@]-J$&FVL5R=)A#/'$JE
M_N-DX')!'!]SZT >IT5Q]SXRN=(O]9MM7LH%^Q6,=]#]FD9MZN[H$;(&&W*.
M1QS[5HZ1K&IW>M7%C>:<RVRP+-%>+#)&A8G#1$. =PX.1P0>V,4 ;S,J*69@
MJCDDG %"LKJ&5@RGD$'(-<.DAUSXL:AIU^HDLM*L(9+>V<91I)"=TI'0D ;1
MZ<XZU3U*_F\*?$&:#2K>,V=UHTU]+9!O+C$T3??& =I8':<#D@9H ]%ICRQQ
M;?,=4W,%7<<9)Z >]<5I_C'69;[08[[3+.&VUZU+V<L4[.8Y1%YFV0$#@C.,
M$XQBJ&F^(;^Y\'^&-1U>RL=0DO\ 5(DWOD>2S2, ZJ0>5Z#D8&* /1Z*XV_\
M:7$&E:QK5I:13:;I%T]O<(6(ED$9 E=3T&TYP#UV]1FJFJ>.=5M%\1SVNFV4
MEKHBQ3LSW#!IHFC$GRC;PV#WX'OG@ [QF5%+,0J@9))P *%97171@RL,@@Y!
M%8?B]8KGP)KF]%>-M.G;:PR/]62*Q?#NOZE;OI6D7-A R3:(+NT,,Q+L8Q&I
M1L@ $[U((.!R.>M ';T5Q-IXVO&N+NWEL(KF>+2#J2Q6;%OG4X: -R'8' W+
MWSQ6QX8\0)XA@EN;>ZLKNU 39+;$@ACG<CHQRC#C@^M &X)(VD:-74NF"R@\
MC/3(IU>;/=:MI/C#QK=Z'IUE<&)+2>>.:4Q&3$3$A<*<L>>3CMUSQJ/XYFU"
MS>;0;%KF1+&&]$+Q2,93*I=8@4!"' ^\>,D<=2 #M:*XV]\8W[+>#2](EFN;
M&.)IK.2*0R.[HLAB#*"J,%8<G.3Q@8S5?4_&>LVTGB,VNE6GEZ+:Q7C>?.P:
M1&1G*X"\-A2/0'U[ '=45GW>K1VGAV?6/*DDBBM&NO+4?,P";L#WK LO%.J7
M.KV5BMC93+>:5_:2RK.R",9 V'Y6W<LN&XR,\<8(!U]%<1I/BS7M1\-V6N2Z
M;IUO:7J0,CFZ/[@,3O=PP ('RX .23VIB^.K]],M9X=.@DF?6SI$FZ5HQD,0
M' *DC( X/(]Z .ZJ&.UBBGEG53YLN [DY) S@>P&3Q[GU-<%K/BW7%\.ZVJ1
MVEMJ.FZG;V4CQLSH\<K189<X(.)<>V#6IJ?BK48)M0MM-T\7MWIHC$T*12GS
MW90Y1& (3Y6!!;.2<8'6@#K7D2*-I)'5$499F. !ZDTX$$ @Y!KS;QMK,WB#
MP+XO2TM8/LNGP/!,+D'>9?*#MM'12@=>N<L".,9/9:I=S6'@^]O+=@L]O8/+
M&Q&<,L9(X^HH UZ*\^L=8\165UX8N-1U..[AUR)EEMQ;J@MY/(,JE&')'RD'
M=GKD8Z5-8^)]4G\+>!;Z29#<:O<P1W;>6,.K0R.<#MRHZ4 =W17FFFZUXNO?
M!]YKRWIG?[3);QVUO9*[QQK<E'E ZNX0-A>AP.">MS3O$UY+<:#%;ZY%J=O=
MZK+;2RFV$,H1;=WV2)@;7#*#P!QCB@#OZ*X/4/$M_'-XC@.IQV2VNIV]I;R?
M9C-($>&-V6-%!+R$LV 0?R%9L/BS7KC3K>VM[UOM/_"1+I9N;NQ\J1H6@\S<
MT1"X8;AV&=H[&@#TZBO)?%>H:ZOASQ1I4^LO+)IMY8[+H0(CR1S,F48 8X)S
MD 9QCUKN/%27MM\/M7V:A(+R'3Y7^U"-0S%4))QC SC''3/% '145YUH]SKE
MQ_8'AVWUIX#_ &,NH3WGV>-I&!*JD:@C: ,G)().!]:Z7P?JUWJVCS_V@T;W
MEE>3V4TD:[5E,3E0X';( ./7- '0'IUQ65H6AQ:#;W4,5S/.+BZENV,VW(>1
MBS8V@<9)JCXOU.;3[6RC@U,V#W%QL+0VC7,[J%8[8HPK9;(&200!FN7L?$^O
MZJGA^S@OA!-=WU]9W%S):;79(=VU_+8?(^%&0> 3R,<4 >EU#'=V\UQ-;Q3Q
MO-!M\V-6!:/<,C<.V1S7GB>(]?95T+^T4.H/K[Z8-1-NFX0K#YY;9]W?CY>F
M.^*T_!T5Y!XS\7PWUR+J9)+0>>$"%U\G@D#@'L<<<9P.E ';55$MOJEC*+6[
M1XVWQ&6%@VU@2K#N,@@C'J*XZZUW4X/&[V5WJITV$W44=E;S66;>\B*KNQ-C
MB7<7 7(Y"\'-8.D7FMZ-X:.KV^I(MFGB":!K'R%(ECDOFC8ES\P;+DC&!P.#
M0!Z1H.CQ:!H5EI,$TLT-I$L,;RXW%0,#. !^E+)KNDPP7D\NIV:0V3^7=.TR
MA8&XX<Y^4\C@^M<5J'BO4+3Q0@AU9[F#^UH;![2'3G-O&CLJ$-<;<>:"V<!L
M=L5Q_B'_ )$KXL?]A5/YQ4 >X7%S!:VLEU<31Q6\2&225V"JJ@9))/ &.]2*
MRNH92&5AD$="*YKQQ_R3/Q!_V"I__11KGY-=USPH^FRZC?IJ%K>:;<3&W$"Q
M^1)#")0$8<E2 P^;)Z'/:@#T:BO/O"/B;5;_ %FQ@N+J\OX;RT:6<R:3):QV
MLHVD!'9 &0@L.23\H.>:UM7O=6O?&5OH&FZ@-/CCL&O9IA LK.=X1$ ;@#AB
M>_3!% '5T5YKI'B7Q%K<6B:6U]%:7U[/J#7-W# K;([>8H%C5LC)+*,D'@'N
M:DB\5:W8W<27US'/;Z?KG]E7\HA"^;'+&IAE/]TAG13C@YH ]&HKS?5_&>J1
M3ZK-;SF*P_M2'2+22.U,[HX4M/($4%G(Y4#D97IUJM-XM\1"QAMK.ZF:236[
M>R@O[[36@,L,J$DM&RKDJP/*@9P.F: /4:*X4OXFN?%%UX?A\0^4EKID%PUW
M]CC,CRL\J_=(V@$*,C';C&36)%X\U+5+71(VOKC399](2_GELM+>\+RLQ0+M
M56VIE&)Z$Y !&* /5:AM;NWOK9+FTGCG@?.V2)@RM@XX(]Q7":5KOB+Q1J5M
M:Q7)T:2#2H+RZC:U#,\\C.NTJ_*H/+)P,-\W45J?#$L?ASHY< .4?<!TSYC4
M =/:W=O?6L=U:3QSV\HW)+$P96'J".M35Y'X1O==T3P5X/U ZDDEC=7$-D]A
MY"@+'(Q17#_>W X)[<D8K8'BS61X:ETTS1_\).FK#2!)Y8P6+;A-LZ8\GY_P
MH ]$J*ZNK>RM9;JZGC@MXE+R2R,%5%'4DGH*E'  SGWKQ_Q(FH,_Q1,VIRRV
M\-A&JP&-0,-"S 9QD;<D>_>@#V $$ @Y!HKSR_U_7/"=Z[:A?IJ,#Z+=Z@(1
M L8AD@"':I')4A\?-D\=:F\)>(M4O-<@M+FZO=0M[BS::66;29+1;:92ORJS
M(H96#-C.2-G7F@#M+C4+*T<)<W=O"Q&0LD@4D?B:+C4;&T2W>YO((4N)%AA9
MY HD=ONJN>I/8#K7 ^)6TQ?B='_:>A2ZO'_8PV11V(NBA\YN<$''IFL#4M.G
MT[0_#@>RDT^UG\:V\]G928#6\#$[5*@D+DAFVCINQ0![-17G6I>*]0M/$ZB#
M57N(!JL-B]I#ISFW1'94(>XVX$H+9P&QT&*KW/B#Q+'I&L:\NJQK!IFL26J6
M8MD*S0K<!,.W4'#8!&.G.<T >FT45YUXU\5ZAHU]J,UEJS_\2^&.7[#;Z<\Z
MG/+">7:1'D=,,N!R<T >BT5PDVNZG#XW>RO-5.G1M=QQV=K/99@O(2JYVSX_
MUN2P"Y'( P<YK8\4ZE?6]SHVE:;.MM<ZK=M#]I,8?RD2-Y&(4\%B$P,\<T =
M'17'?;?$.DZUX?TS4;ZWNEO+ZXB:9(@K2PK [IO&,*X8<[>" /4BLG6/%6NP
M_P!IQ6-Q"LT?B2UTRW,D0*K')'$2#Z_,Y.>M 'H]%<*\_B7_ (3:S\.1ZZOE
M)I@O+BZ:TCWR,)BN O1<@@>P'J<UEZ1XUU34=4LKJ.>]FBNM0:WDT]=)E$,,
M&]D5Q/LP6&%9CN(Y(P,4 >G5!>7MKIUI)=WMQ%;6T0S)+,X55'J2>!7G-EX@
M\2G1M(U^XU6-X;C5UL9+(6R!6B:X:'<6^]O'!XP.,8/6L#74U!O /Q+EN]3E
MN434'A$;QJ "!!AL@9Z8&.G'K0![6K*ZAE(*D9!'<4R>"*ZMY;>XC66&52DD
M;C(92,$$>E<;%XFFT/6;ZUU>5?[.&DIJ5DVT A8UQ,F>Y!VL/9JWO"TNJ7'A
MC3[C66!U">(33*JA0A;Y@F!_=!"_A0!:TB>SN=+@ET^^6]M,%8YUE$@8 D8W
M#K@C&>O'/-7J\H\+^)O$.MZ!X-CBO8+275?MXN9DMD^41.VTHN, X&/3G)!Z
M5VG@W4;^^L]2M]2N%N;C3]1FL_M C"&55VE6*C@'#8...* .CHHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBJ6J:M8Z+9_:[^;RHMP1<(SL[$X"JJ@LQ/H 30!
M0\3^'!XDL[.$7TUE+:7<=Y#-"JL5=,XX8$$<^E06>@Z];W<<L_C"^NHE.6AD
ML[=5?V)5 ?R-8_C#XBVVE>%(]2T5UGN+FY6VB,MK*5B;>%?S% #*PS]TX)/3
M-4)O'U\?%6BZ!;W<>9;<SW=W)H]R#(=R@*D>04!!Y8D@=_2@#H;?P-9VL.GR
M0W=PNHVEVUVU^<&6=W_UH?C!5A@8[!5QC J6Q\*2Z=?JUMK5ZFF)</<IIZA
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MH](T:QTR)V>.SMX[=7;JP10H)]^*=J.HVFDV$U]?3K!;0C+R-GCG X')))
M'))K,3QEH4FF37XO'6&&58)$>VE659&QM7RBN_)R,#;SVH =9>&K>R\6ZIXA
M2>5I]0ABA>(@;5$8P"._-4)_ FGW,GB)Y;FX_P")W)#,Y4@&!X@-C(<=05!Y
MSR*W=+U:RUJR%W83&6+<4.Y&1E8'!5E8!E(]" :QW\?^%XYA&^J!097@,C0R
M"-9%)!1GV[5;*G@D$]1G(H A;P6]U;W+:CKM]=W\KPO%=[43[.T3%D*(!MZD
MYR#NS@\5LZ/IMSI\<QO-4N=1N)GWM)*%55X "HBC"CC\22352W\8Z#<V%_>K
M?%(; @77GP21/%G[N4=0W.>,#GMFBV\8Z%=B'R[UE:6Z%FJ36\D3B8KN5&5E
M!4D<C(&>U %CQ'%<W6A7=A9*3<WD36\;D?+'N&"['T4'/OC Y-&FZ,VE-9PV
MU[*-/M+%+2.S*+MRN )-V-V<#&,XJU_:EG_;']DB<&^$'VDQ!3Q'NV[B<8'/
M&,YX/I7-77CBUTGQ9J^G:K-Y=K:V]O-#Y5O)*_S;_,9@@8[1M7G  SR>: .@
MUW2_[;T*^THSF!+R%X))%7)"L"#C/?!K/U#PN-1\%_\ "-2WKK$8$MVG6,;B
MBXQQTSP/\*DO_%^A:;%;27%]E+F'[1$8(GFS%Q^\.Q3M3D?,<#WK6-U;BS^U
M^=']F\OS?-W#;LQG=GTQSF@#G]0\&V^KZAJ%SJ-RTL=_IRZ?-$B;0$#,P93D
MD-N8G\O2K>@Z)>Z4O^GZ[=ZJZIY<37"(FQ/?:!N8X&6.3QVR<QVOC7P_>6E[
M=17S"*SM_M4QEMY8R(<$^8H9067@\J"*A'C_ ,,F5XEU!VE5/,5%M9BTRYQF
M(!,RCW3=0!<O_#\=QK4.M6DYM-3BA-N90N]98B<['7C(!Y&""#WP2*SM3T%;
M;3]<U6=Y;[5;FP>W#K$?E3:<1QHN2 6.>Y)ZG@8O/XPT)=)L]3%\9+6\)6W\
MF"2224C.0(U4OD8.>.,<XILWC3P_!#:2G4-XO(FFMEAADD:55(#;552206&5
MQGKQP< &=X3T*231O#5YJ4LCRZ=8HD$$D!B:)S&$8N#R6 RHX'!/!ZTL'@5;
M?1M-TN/5;AH-.OEO+??&A(VL65#C&1DG)ZGVK1?QEH*:1::H+XR6MY(8K?RH
M)'DD<9RHC52^1M.1CC!S69H_CBSN;/6;^^N8ULK;4S9VK11.7D'EQL%V %F?
M+,, 9XZ<&@"Q+X*@<:M:QWDB:7JTQGO+38#EVQOV-U4/CYA@]3@C--OO!27T
M?B.-K]XX]=C2*55B'[I538-G_ ?7//Y5>D\8:%'I,6IM>DVTLWV= L$C2M+S
MF/R@N_<,'*[<C%5_"_B0^(;_ %T1O&]I9W:0V[*A5MIAC=@P/(8,S#! (Q@C
M(H T[_2VU#P]<Z5)<%?M%LUN\RIR R[20/7!-8TG@I)WM#+J$NVWTN72\(@4
MM'(%!;.>&^1<$<=>*JVWC_3[74=;MM:NE@%GJ)MHFC@D94CV1E6D900F69AN
M; X]C6UJ'BS1-+U$6%Y>^7/\F_$3LD6\X7S' *ID]-Q&: ,FU\#2VTT4_P#P
MD%Z9XM+;3%=8HEVH<;6 "\%2 ?<^W%:^E>'X].U:_P!5>1'O;Y(DF:*(1*PC
MW8)7)RQW')SV XQ0WBK15UUM$^V9U%'V/"L3G8=@?+$# &U@<DXYQUXIFG>+
M]!U666.TOPQCB,^Z2)XU>,'!=&8 .H_O*2.1S0!#=>%C-JFJ7<&HRP)JL217
M<812<*I4&-OX3@D<[O;%5[CP4(M5AOM#U:ZT8BVCM)HK=$=)8H\A!AP0&4$@
M-Z58@\<:#=V=W<6MS-*+:$3LGV2979"<*R*4RZD_Q*"*X_P]\56DT+3-2UK]
MY)JETL4<%IIUPBVZG<3\Y#"4X ^[COZ' !U,_@UUUM]2TO6[[3?M$4<5Y%$$
MD$X0;5;+@E7V\;ASC%+=>#4N6\08OW1-:M$M)5$8/E(J,@VG/7#'KGG%77\6
MZ''JZZ6UZ1=&18O]3)L61AE4,FW8'((PI.>1Q3[3Q3HU]K$NDVMX9;V)G22-
M8GPA7J&;&![9/.#C.* &ZG'=Z=X.N8+1;BZNH;,Q1?9\+(Q"X!7/&>_X?A7+
M>$[&^M[F*+3K^YDM#&8[A;O0?L110AVD-M3<P;' R,$].M3>+_&]SI7BW1_#
M]A(D#70DDN;B6PFN-BJ%*A%3&[.>2"=O>M^'QGX?GNKNVCU%2]FLK7+&-PD(
MC8J^YR-HP0>"><9&10!13P0(O#6BZ/#JD\;:/.DUM<"-23L# !U/!X8^G8]J
MC3P&(U"C6+EP-7&K#S(D/[W.<< <$DY_#&.^G8^,M"U$7!@O'!MX#<R+-;2Q
M-Y0ZR*'4%E]UR*K)\0?#$D@1-29F:/S8@+:7]\N0/W?R_O#DC(3)'I0!%>>"
M8[ZWUV*34)5.K7,-T62-089(MFS;G.1^Z7(/7FEG\'3_ -MOJECX@O[*6ZC2
M._6-(V%SL& W*_(^.,KVQZ5NZ3J]CKFGI?Z=/YUNY90VUE(920058 @@@C!
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M>R&-EV$;0FPXV@#'7KG*1> K98G$NI7<\DFKPZM)+(%W-+&$&.  %.SH!QG
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MMY#-;/!YDKR1L(1O R<1MG' R/6O2-:TBVUW29]-NS(()MNXQG#?*P88.#W
MJQ'>VTM[/9QSHUS J-+$#\R!L[2?KM/Y4 >>:Q=?\)5JMI<Z597RQ6&E7PN&
MFM)(=K2QJJP@,HW-D$D#.-ON*>S7FE^!/!-OB[L+80P)>SVUGYL]MBW.,*48
MJ2^%+;<C..,UZ/10!XW#]HL[.PN+FUU4I9>*VNYVGM':40O%)MD8*O.=RYVC
M@G!Q5N#2]VIWFEZA?>)%DN-;-W%9VMHGD.C3"6.7S&BX5>-V7!&TC'05ZS10
M!X]?O-!X)U;PP^F7\VK?VP\V$M)&5XVO!*)M^-I&TCOG(QBNY^(=K+>^"KNW
MA@>=WFMOW:(6) GC)X'L":UH]?TF4V0CU"!C?,Z6N&_US)G<%]<8/Y58U#4K
M+2;-KR_N8[>W5E5I)#@ D@ ?B2!0!P'CK1]0U36]82RMIW,GAX(C1K]]EN-Y
M0$C&X@' /K61K=BFK>&/$]W8W7B35KLZ3]F#7UFL2G+[O+51$C,XQSP0-W7-
M>P44 <#XNLY+7Q!H.H_;-2T_3X+2XM7GTZW$K0LQB*@J8WPI"$9"\$ 9YK)A
MT=[?7OAX]G;ZK):QW6HSRR7T($D?FHS9D"@!-S,2 0.H& >*]4HH \OATV[7
MX;6$ LIQ<#Q$LS1^4=P7^T2VXC&<;><^G/2NA^(4<K:;H\L5G/=BWUBUGDB@
MC+ML5\DX'7 %=?6?IFNZ3K3W":9J-M>&V8)-Y$@<(>>"1]#^5 '$2:4GC?5?
M%<L$=Q#87>G6]G#<30/"7N$:1PZA@#\A9.<=1[5:^'<]YXBEO/%>IP&*YEBC
MT^)&_A6(?O2,=FF+_@@KJ?$"6TNDM%=ZG/IT4DB1^?;RB-]S,%50V#C)('KS
M4D$&F^&=!6*/R[33;"'JQ^6-%&223^))- &$EG+_ ,+>GO3;OY/]@QQ+.4.W
M=Y[DJ&Z9Q@X^E<IX7TDQW&D:3J-]XC>^T^^>4V8M46VB*ER)#*8AE&![.2=^
M/7'JEO/%=6T5Q!(LD,J!XW4Y#*1D$?A4E 'D2:/J4GA7Q6%M[Z)E\7/>@0Q?
MO7A6:)B\:L"&.%+#@@E>AI=5TN/4O#VKW5E-KVK/<WFG122W]HL8E6.=6.Q%
MC0D*&;<2N/?@UZ9!KVCW-^UC!JUC+>*2#;QW*-(,=?E!S6A0!Y[XK@FL_&\>
MJ3:CK%A92Z:+=9]-M5G)D61F*,#'(1D,,<#.T\]*?X5T?^S/%=D(;6^2UB\.
M0PQO>(/,0^<S;&*C:& QD#TKOZJZ?J5EJMM]IL+F.XAWLF^,Y&Y3@C\#0!YA
MX:$WAH^'-6U.RO%LETZ\LW*6LDC6\C7 ==R*"P#*I&<=AZU+>^8NO6FMR+K?
MAVPN],\J..PLED9769WVR)Y3[2X=6 P.<@\BO5** .>\,&WTO3M+T&&VU)!%
MIZRHUW&,HN0-CLORAQG[H["NAHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X/XS_\DFUO
M_MA_Z/CKO*R/$_AVT\5^';K1+V6:*VN=F]X" XVNKC&01U4=J ,/4)-9U/QW
M<Z)::U-IUE'I,-UFWAB:3S6EE7@NK#!"C(QV&,<YT?".I7GB'P)IU]=3F.]N
MK7]Y-$J@A^1O ((SD9QC'M6C'HUO'XBFUH/+]HEM([1D)&P(CNX(XSG+GOZ4
M:%H]OX?T2TTJU>5X+9-B-*06(R3S@ =_2@#R;0;749O#G@-EU><W%SJURRRR
M1QDP#R[C=M 49)Y/S;N3Z<5M7GB;6M*2^T:34;RZE37([".^BM$EN1"]N)SA
M$3:SC#*#M[YQQ72Z5X$M-*&G(FHWTT&FW<EU9PRF/;%O5U*9"@E?WC'DYZ<U
M8O/!MC=2ZA.MU=PW-W>17RSQLNZ":.-8U*94C&U<$,#G<: &>#-0U*]MK^+4
M%OW2WN=EK<WUI]GEGB**V67:HR&++D  X!KED\5ZY=:S<75JVL2B'5VLA8Q:
M86M6MTF\IV,NS._ 9\[L#&,5W^D:8^EVTD<NH7=_-+(99)[I@6)( P H"JH
M'  'XDFLU/"20ZK)=6^K:C;VDMU]LDL(G18GFR"3G;O"DC)4-@G/')% ',R^
M*=:@\-W^DF[#>)8]7&E03M&N6\Q@\<I7&W A);ICY#5:X\4ZY)J^H2V3ZQ,U
MCJ(M(K*#3/,MYHD*K(7E"9#G+D$, ,#CK792>$-.E\9Q>*&><7D<0C\H,/*+
M ,HD(QG>%=ESGH>E,D\))_:TUW;ZOJ-I;7%PMU<64#HL<LJXYW;=Z@[1N"L
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MWN("!)#(O1ER".Y&""""161)X%L[K2-9LK[4+V[GUA%CN[QRBR%5&%50JA5
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MDWFS[M'C:. 9&'#1^6=W'/'ICF@#-\8:A-;W&G65OJE]9O/YCM%IUH)[F55
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MG!2.25$=@>WRLW-277@E)[**Q@UO5+6S^Q)8SP1O&RS1*I7G<AVL02"4VY_
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MR$B0%,9&W!SGI^(KG/"/A_4],U?PVUY9O'Y6FWYFQRL+S7$<BQDCC(!(_P"
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MU%[:5;*328(DG*_(SAV)4'UQ0!KZMXKT[1]23394NY[Z2'SX[>UMVE=D!P2
MH[>_]152?Q_H,5IIMPDMS<?VE'(]I%;VSR22E" ZA ,[@6Y!Z8/H:RM6U+^R
MOBM#<M8W5U'_ &&RM]EA,KI^_!!VCDCC'&>W;FLWPWH.J6^N>%;RZT^:%0=6
MN959<_9O/E5XT8C@':>GKF@#KI/&6DQ:G]A?[5\LR6\EP+=S#%,^-L;/C 8[
ME'L6 .":E'BO2#X>O-<:=DLK)I5N"R$,C1L592O7.1T[Y'K7#MX>9=9U/3[^
MU\13B\U8W,2VLI6S:-W5P[-]U2ASD'D[1@'(JQJGAW4I/&<VBPV<K>']5OH-
M5NI@/W:&,'S(C[N\<)_%J .IG\:Z1;Z@+.078VO%%-,+9S%!)( 421\85CN7
MZ;AG&:P_$GBJXT_3?&\NGZJ9+W2(872![4!;5F3(^8_ZS=UYZ=*Q_%=MK6H3
MZU%+::[<SQ7L4EI%;[EM/LJ&-R<#B1\A_E.6SC@ 9J+6M$U6\7XH20Z;=,-3
MM[3[&/*(,Y$."%'<@\&@#U'3)WN=*LYY3F26!'8XQDE035JLC2;F6%;'3)+*
MZ4I81R-.4_=!AA3&3G._OC'2M>@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KGKW
MP3H>H:C->W$$Y,\BRW$"7,BPSNN-K/&&VL1@=1S@9S70T4 %%%% !1110 44
M44 %,2&*.621(T623!=@H!; P,GOQ3Z* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** *?]EVO]M#5]A^V"W^S;]QQY>[=C'3KWJY110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7)^
M,[B:YO-#\.02O"-7N6%Q)&Q5A;Q(7D4$<@MA5SZ,:ZRN/\9@Z=K'AOQ&_P#Q
MZZ==/%=M_P \XITV;S[*VS/MDT 9][K%C;ZQXZM_[*8G3M)CEF87<BBX3RG(
M0 <1X (W+SSGM3/M_P!AM/!'B2R1[>UU".UL+FT,K2+Y<R Q$D]61\#<>2&.
M:N7O@V_NM6\:7B3VPCUW3$L[8%FRCB)TR_' RPZ9JG?:;,EEX&\';DEO+-[6
MYNVC)*I%;*,MZX:0*HSUR?0T =GK&D1ZS:I!)>7UJ%??OLKEH'/!&"RD$CGI
M]*XGP#H\EXVH7MUK>N3R6.L75M$DNI2M&8XY"JAE)PW'KUKT:L#PGH=SH-MJ
M<5S)$YN]4N;Q/+).$D<LH.0.<=: .0\$^)M7LO"_A3[;I\3Z=?NMDMR;HM/Y
MAWD.R;<;25(^]GD'VJQ9^,8;"TUR6STV&"7_ (2233BUU?.(6DP"978@^6IQ
MC:!C. .M:-GX.O[?PKX5TIY[8S:1>0W$[!FVLJ;\A>,Y^8=<5%8^%-:TJSU]
M(5TF]_M+6IK\VMWN,4L#J!L8[3M;(!SM8<8[\ '6:1<WUWIZRZC9QVMSN962
M*82HP!X96P"5(P>0#[5Q?AW3+CQOI1\0ZEK6KP?:Y93:6]C>/;QVT2NRIPF-
MS87)+9ZXQ71^$-#GT#17M)UMXB]Q),EM;,6AMU8Y$:$@' ^@Y)X%9-EHGBGP
MRMQ8: =)N]*>9YK9;Z62*2UWL6*?*K!U#$D?=/.* ,W3_&6L:?9Q:7-;KJVI
M1ZW+HPF>00^8!$94D;"G'R[0V!ZD ]"W7_&OB"#1K^WALK.UUBPU&TMI\7!>
M,QS.A5D)3)W E2"!CDC) %1:KH%]H(\+16]U#<ZO<Z_)>7$\JE(YIFMYBPP,
ME5P HZX !YJY?^#-<U33=;NIY-/BUC4+VTN8X4D=H(UMV0JA?:&).ULG;WZ4
M 3S>)[;2?%VL/J.G^5<V&A)>W4\-T\BL 6S&J$ =0<-@$]\5<MO%>KV]_86^
MMZ1;6HU*"66U-O=&4JZ)O,<@*+@[<G(R.#5.\\$7VM:YK-[J4MM##JNAKISI
M [.8I<DDC*C*C/!X)QT%3Q>'_$.IZCIEQKC:=$NEP2K%]DE=S<2O'Y>]@RKL
M 4M\HW<GKQ0!'H_C;5+[_A'+N]T:"VT[70$@9+HO+'(8FD&Y=@&TA6Q@YZ$X
MS@:_B;Q#/HLVFVMK%:-<W\K1QO>W!@A7:N[!8*Q+'H!CGGTJA:^$[V#1?!=D
MTUN9-"DB:X()PX6W>([..>7!YQQ6GXFL-0U"VBAM+'2M0MR6%Q9ZED)("."&
M"M@@]MISGMB@#FIM3\02>/;,6VF1)?2Z&S2VMS=XAA(F&2656W=@,#.#SCD5
M?C\9:C>^'=,U*RTVRA:Z\U9VO[X10V[QL4*[@I+$L#C Z DXZ%?"_A"^T/4[
M&YN+B"2.WTM[,JC,=K--Y@5<C[BK\H).< <5F6W@?5[ :2Z1Z1?/:I>1M'>%
MC'$9I_,65!L.Y@ORD?+G^\* (9M?;7?&7PUU"#S((;Z*_>2 29&1".#CAL'.
M#^-:?PPGEGTWQ 9I7D*Z_>HI=B<*'& ,]JJZ1X&U:RU#P=+<3V1CT WJ2%';
M=,DJ[48#: #ZC.!V)K=\%^';KPY9ZK#=RPR-=ZI<7J&(D@)(P(!R!SZT <O;
M>)-:T4^,;^'38[W3M.U666X>6Z*2",1QEEB7:0=HRW) YP*T]5^(7V*YU"6V
MM[.73=,V?:WEN_+F?<BNWE1[3NVHRGDC)R!TJ"]\)^)FM?$VF6LVF&QUZZD=
MI9)'$EM&Z*C84*0Y*J<#*X/<YXDN/!-U;:O?/I^G:#=6M\\3F;48B\MJ518V
M"KM/F A 0-RX)- &K\0M7U'1/ FIZEI)B%S%%E9';&P'C<O!!(R, \5!)XGU
MT>*+;P['H]F]XUDE[<2_;&\J)#(R, ?+RQPHQP,DGH!DZ7C'0YO$7@_4]&M9
M(XIKJ I&TF=H;((SCMQ5;3=&U4^+QX@U$6<3/I2V<D-O*T@602L^02JY7!'H
M<YX[T 9VG^/VO=1LF:VLUTR_NWM+=TO-UP&&X*[Q;<!6*'&"2,KGKQ);>,=2
M?7H=+N=.L(9;SSUM8EO]\T;QJ6 F4+\@8 G*EL=.:KZ%X-O=&O+>V73]!^PV
MT\DB7_E%KMT)8HN-H"L"1\^XY"].>*>A^"=;TNZ\.R-#HJ#2)&65X6?S+Q71
MD:5FV</R#MY!).6'% #- \<ZT_A329[^'3Y-1U2YF2V>6[,<81&<LTAV?+MP
M%  ).1TYQI6_CJ\U)K"PTW3K635YYKB*9'NSY$0@(WL)%4E@=Z;?E'WN<8K-
ML_ FL6VBZ5:SVVBWLFCW,S6\<[LT5U#*7R'S&?+8;E(P&&5]ZT?^$8UNSN-(
MU?3[;1(]0M/M$<UG%N@MVBE*G =4)W+L3YBO// H M?#^ZNKNUUZ2\1HYAK5
MPK1&3>(\;?E![C.<<#Z"DNO&%[8^(X+*[L+**SGO191C[:#=$M]V7R@N-A/'
MWLX.<=JO>$-%U#1;34AJ<UO+<7NH2WA,&=H#[?EYYXP1],5S+>"-<CG!ABT8
MF#6#J:73LXGN@92^R0[#LPK8R"V=J\ 4 ;WAWQ1J&OWK.FG6@T[S98B\5YNG
MMV1BH\Z,J-N[!X!)'&?46_$>LZCI36ZV-K8LLBNTEQ?W@MXDQC" X8EFR<<8
M&#DUE67AK5G\7V>KWUMH\#VIE\R]LBPFO492JK(FT  9#?>;E1C%6/$/AW4+
M_P 2VFJ6D&F72):/:E+_ "1;EF#>:BA2&.!@CY<X'- &WH.KQZ]X?T_5HHVC
M2\@281L<E=PSC/?%<II?CO5+VUT/4[C1;>#2]5N1:*PNRTR.=P#%=@&PE<?>
MSR#CM70>#])N]!\*V&DWIA:6SC\D/"Q(=1PK<@8)'4=O4UC6G@Z_M_"GAG2F
MGMC/I5]%<S,&;:RJS$A>,Y^8=<4 ,?QU?K9R:XNDP'P['>&U,_VD^>5$OE&4
M1[,;=^>-V<#/M3-1\=:K:PZ]>V^B6\FGZ'=-#=22795Y%"HQ,:A",@-G!([8
M]HG\&ZX=(E\+K)I_]@R7IG^TF1_M"PF;SC%Y>W;G.5W;NG;-7+WPA?7/AKQC
MIJ3VXFUNYFEMV+-M0/$B#?QP<H>F>U '47.I6UO#,_F+))%&TGDHP+M@9P!U
MSBN$U'QIXAF^'^JZY9V.FHHT\W-M=6U_YRQDCE6!0?O%!!Q@J2""1W[!_#FE
MK=R:G;:;I\6LE"$OS:H9 Q7;DM@,>..O(XKCKCP)JNIP:X9[?1]+GU#3)+)A
MI[NR7,K$$2R HN,8('WCACR>* -35/%&NZ/I=M//INEAQ:-<3R3:CY<;D9Q'
M$2F6<@9Y  R!DU5'BW69O&96V@MFT;^PDU)4>8K(0Q.#C8?FR-N,XQSG/%1W
M?A+Q!J-V]S=VVB&6ZTU+"1WD>7[$5:3+P@QC=N#J2#MP5') J2P\):[;:EI\
M\W]G&(Z&FD7H29\IL9B)(_D^;(/0[<>IH UD\62RV/A6:.R3S-?0$*TI A)M
MVF SMY&5V].^?:L#P_XTUZ3PW:37EE:76I:EJ<]I8HMR57Y9)2WF'R_E5%C(
M! 8L .A-6=)\+^)8Y?"D6H/I:6OA\E,V\DC/<+Y#Q*V"H"GD?+D]3SP 8;'P
M9K]AIUI%&^FFXTC5);VP<ROBX25I=Z2C9^[.V7 (W<B@"U?>/KS2=.U7[?I$
M;:GIES:PRP6]P625)V54=&*@]VX('*]>]:FF^(M2_P"$B@T36].M[.YN+-KJ
M%[>X,J.5?:T>2J_,%*'\3Z5C7O@S6-6MM5NKR6QAU+4;RRE,44CM%##;R*P7
M>5!9C\YSM R0/>D^)X%S#I5KIE]'#XE-T$L44YDV2JT<C%>H0(68GIE!0!T_
MAG7&\1:4^I"V$-N]Q*EL=^XRQ(Q59.@QNP3CGC'-<7:ZZ]UJU]HVK:M?:/XG
M^U2&U660I;W$.\^6L0/R,"F 3C?G)S7H>FZ?;Z5I=IIUJNVWM85AC7T51@?R
MKD=?\,ZQXF\.2Z)J=OILC/(3%J'G,7@7?E75=GWPN!PV">^.* -%?%PB\0Z]
M9WMH]MI^D6\4TEVS(5 8.Q8@-G&%&  3P<XXJU'XJLEOTL[Z"YT^66V:ZB-V
M%"R1I@N058X*@@D'!P>E8VK^"[S5;_Q)"T\*Z?K=C# 9=S>=%)&' .W&""6!
MSN'0C'.0^\\*:AXD-D=>-M UK8W-L3:2,_F/-&(V?E5V@+D@<\M[<@%J]\21
MWVGW-M%;:C://ILMW:W+(%5U ZAE)*MRIPP!Y^M+X/UMKW0-$MV2YNK@Z7;2
MW-UD,JNT:G#L6R7/7&"<$$]:KZ9IGBP>'9-*U-]+;R;-K:*6"1\W)V[59\K^
M[XY(&[)[@#!K^#?"NL^$GM;:)[-],DM(EO(/.<F.Y50K21?)]UP 2IQSSZY
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M)R@WK@<X^; &>5\+Z1XJT*T%I)::&0X>2XNUNYI)IYRI^=\QC.6QGG@=.@%
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M44 (JJBA5 50,  8 I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?EC;OW;MV,8SNYSZ\U7ET'1YI;F672;&22Z %P[VZ$R@$$!CCYL$#KZ5H44
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M /&Q )7[JD'!P1TJI'I.OZ_KNFW^OP6-C9:9(9X+.VN&G:68J5#NY50 H9L
M#J>30!3LOB#>W-E8ZK-H @T:YO!9-<?:]TB.93$'V;!E-^!G<#STQUR+WQ=J
M;^%/&EYKFFK)8Z;>M B6M^T4GR^4-@=4! ^;=NSDY(QBHO#&DZYKO@S2=,,5
MDNDC43=277G-YI2.Z:3R_+VXR64#=NQCMFKNK^"]?O?#_C/0X4L?*UB[-Y:W
M+7# @L8\HZ[.,;#R">W% '077B;46U.?3=#T>._DLK:.>Z,UWY(7>"5C4[&W
M.0I/.!TYYJK#XZN-6N;"WT'2!=O>Z:NHHUQ<^2L:EMI5R%8@@\< \^PS3Y=(
MU_2->O\ 4=%M[&[74K:&.5+FX:+R98U*AQA&W*01D<'Y?>D\,>#KCP[JFG.)
MXY;:TT9;!GY#/+YF]FQV!Y[T ;OAO6U\1>'[355@:W,X8-"S;BC*Q5AGO@J>
M:Y#2/&4<.D#^SM-/VB[UJYL8TOM1;R]Z[F+&1E8J#M.$ /) %=1X0TBYT+PS
M;Z==M&TT<DS$QDE</*[CJ!V85S&G>$=8TOPW=:?-IVCZM'<:I<74UG=.0KQ2
M$E<,5(# X/*GZB@#M;&^GFTI;O4+0V$JAC-"T@?9M)!(8=0<9!XX(X'2N;TK
MQO=:E/8J^DPPQ:K"\NFM]M#,Y5=ZK*H7]V67)X+8P<\UI>&]"GT[PDND7[+E
MO.'EQR,ZPQN[%8U9ADA58*"1VKG_  SX2OM -JJ^'/#4<NGVS1I?Q+B>[<+M
M0Y" QY&=QRW4XH T]*\<QZS>V%A:6#_;G#MJ4,DFW^S@A*L'..27&%'&X9/
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M63V((=3Z$5O+HV@67B3PE;Z+9V@M]1L[B.]2)%*W5MY((:4?Q_/MY;/WCZT
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MA$T#HB1A8U$<R2$!5'<*1^-=!10!G6/A_1M,AN(;#2K*VCN?]>D,"H)>,?,
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MS\PY&1S716'C#1=0NI[:.YDCD@@-RQN()(5>$'!D1G #)_M#(KA?$MK>M/\
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MMLMXJQ>?/(\K*H)*;0J[3P ,Y&344NJ>(K3QUI&B2WT4\KZ)/+*%C"1S7"L
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MXJO\%[1X/AII<S7EQ,LR,5ADV[(<2/G9A0>>IR3^% 'H-%%% !1110 4444
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MBB[N[A;9+OR[.V:8F%]V'&T=/E/YCU%-N?'.BP06T\;7=U%<6JWH:UM7E\N
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MQ718H^[U5"KM[A?>@"S/X0AL-#UV6&:\U+5[VQD@-S>2!Y7&QML:X 55R>@
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MBMW>*W#G"F1@,+G]!R<"JD7CFT_X2/7=-N[:XMK;284EENY(F" %69B3C &
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MAME2"6X%NYAAE?&V-WQ@,=R_0L <9KH* "BBB@ HHHH **** "BBB@ HHHH
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MHEI96NHZ[.(;>QNDGA<EN)<%5P%Y8_,>,&M6TNHKVTBNH"QBE4.A9"AP?4,
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MI[.Z^T0%/+D$<"]^Q*M@]\&ND\&V5S90ZV+F!XC+K%U-'O&-R,^58>QKI:*
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M&E8JP]B.:YW0-4N_#5YXE@N/#NMW#7.LW%S UM:;DD1@H4AB0.=IKT:B@#S
MZ9X@L;"75+N&^MY=8U@7.I0:9^\GM[81%(T!7))RL>XKSR<5GKI^IVMAO.CZ
MNPM?%,.I%)%:>9[8Q@!LY)=A_$ 21TKU^B@#RHZ"SZIJ5G?6?B25;_4Q=0I;
M2%+5HG96W.>BE#G(/)VC&<UZK110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5S?C,:K_9UH
MVFK?/"MR#>II[JMPT.QO]66XSOV$@<D XKI*S=8T6'68H ]Q=6TL$GF13VLO
MENAP0>>0002,$$4 >>/KUU?W.F:9:7OB*^M%M)YY)+*-(KLNLWEJDN_;C9R#
MC[QP33].@U:_\=^$YM9N+^WOETJY>:'>J99)8ADJ,@;Q@L![=,5UK>!]-6WM
MEM[G4+6YMS*1>07!$\GFMNDWL<[MS 'D<$#&*F;P?IOVK1[F&6\MY=*0Q0M%
M.<O&2I9)"<[@2HSGGWH YKXMV7VK3_#[_:KF'_B=VD>V)]H^9_O=/O#'![4_
M[/J.JZMXBLUU_4K2/1(XH+4QR*"SF$2&67*_/RP&#QA3QS77ZUH5EKT-K%>B
M0K:W4=W'L;;^\C.5S[9[50U7P=I^K7UQ=M<WUJ]U$(;M;2X,:W*#( <?0D9&
M#@XS0!R>C:IJ_BSQ'HBRZI=65K/X>M]2GAM2%WS&0@\D'"GOCJ !GK6##ITZ
M:!>>7J=XTS^,U@229P^PK= !P",;NF<\' XKU>V\/Z=9ZM'J5M$8I8K);!$4
MX185;< ![&LY/ ^EQW-Q*LMYY<^H)J1@,V8TG5]^Y1CC+#)% %;PVUW8^,-=
MT674;N]M8+>UN83=N'=&D,H8;L#C]V#CMS67KFMZE;_$#6[&&\E2UA\*O>1Q
M \+,)&&\>^ *[2'2;6#6KO5D#_:KJ&*&0EN-L98K@?\  VJG=^%M-O=9N]5F
M$OVJZT\Z;(0^!Y)8MP/7)/- '*Z1-JMEJO@V>?6KV[.M6S_;(IF4Q[A!Y@**
M!\N",>X/.35GQM9-=^-/!:"]N[=7NYP1!)MP1;R'(XZ]1]":Z9?#UBLFCN!)
MG2$*6OS= 8_+.[U^6FZYX=M->:RDGFNK>>RF,UO/;2['1BI4\\\$$@T ><*N
MH:;X?\0:_::O>0R6GB*?RK:-@(64W05@ZX^;(8\YXXQCG-RXUGQ#>ZSJEUI\
M&N2SV>J?9K>* 1?8S$C*'5P6W$L-YW8R,KCI7;2>%-,ET>^TMEE^S7MTUW,
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MM<%9G$C;I ['.[<WS'/?D8H ETS4M5@\!IJ.K6[+J<%F\DT;@ LR \D+P"V
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%9>OZY%H.G+</$\\\TJ6]M;QD!II7.
M%49Z>I/8 GM0!J45EMJ5ZDVHI_9JD6L DB872?OW*DE.>4P1C<W'.:1-2OGD
MTU/[-4?:H&DF)ND_<.%!"\<ODG&5R.,T :M%9>@:Y%KVG-<)$\$\,KV]S;R$
M%H94.&4D=>Q![@@]ZI3>,=-@\;P^$Y4N%OIK?SXY"H\H_>^7.<[L(QQCH.M
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M/]3YUVX!Z>8(#M_'!>NQK&\2:&=<L8!!.+:^M)TNK.X*[A'*OJ.ZD$J1Z,:
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M()RQEB_LQ-LA;[Q89P<]\]:AE\)W,]U;W4UYITEQ; +!*^DQEX@.@4DY7\*
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MN;N^T^XGM_\ 4RRZ5&[1_P"Z2<C\* -ZUNHF?[&]U#)>PQ(T\:,-PW9PQ7J
M2#CZ&N7^*_\ R2_7?^N*_P#H:UU-K:+ ?.D$4EXZ*DUPL01I-N<9QVY.!GC)
MJ2YMH+RW>WNH(YX7&'CE0,K?4'@T <G\1+:*\TG1K:==T4NM62.N<94R $?E
M7'^+;&TTRR^)%G86T-K;'2;.7R84"('/F@D*. 2%7\J]=FMX+@()X8Y0CB1
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MAYJ3@&)Y@TAB# \'^,@'N!6K?VVES:]HMAH TN;2%?4"L.H!VM1<AH]RH.G
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0;V1$'S-N(!(''0&MG6_"4VM:U%>N+2*6WN89K2_CW)<P1KM+Q\##JV'')P
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MO2=6B\0WVOV\MG'*^DBTB1P\@6169PQ  +#+8P.>/PK<TYKRYT6V.HHD5Y)
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M'' 8OE)QP2P&.Q(Z5H>"KG3M5O='U.TU^.6]-HR7ME"I$CM@9-P"Y(96& Q
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MAB\HPD2*3M?<  IPP;UK3^U:+:W/Q!M_$,EJ-1FG)CCGQYDT!@01",'EOFW
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MY25&(8%D@0[6^A49!]*W?$\,=IXTU&*XU#0]+L)-'C2$:E9F1&CWR^:L>)$
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M-V#\IQ\N6X.>.=\'ZQKNC^%?#,S+8-I-W??83#L?SQOD<"3?NV_>_AV].^:
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M_9+F." SSA#-NB1R<'T+X_*M>_U[1]+NH+;4-4L[6>X_U,<TRHS\XX!///%
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M_P#2D_=@G'S<\<D#Z\4 5/\ A'=2NY]'NM3U6.>YL+Y[QO+M]B$-$\8C09)
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MSP<C&T->T@ZP=(&J69U(#/V3SE\WIG[N<].?I6=XQ\3GPEHT>H+I\M^SW$<
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MY'XZ?N6W?6*O4<5S:Z=9S^(H=?O-;6ZCC9H-/AW(L4+O\K8(Y=S@CD\#(Q0
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MDXKE[^WA7X>^.)A$@E;79G+XY)6=-IS[=J];ILDB0Q-)*ZI&@+,S' 4#J2:
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MN;Z#!BE(F7:@8'#,H//IN%:'B._L]*\37[VNH6-Q<7-Q:_:M"OH,R7+ ($>
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M\C:W:/.QN[F#S(Y%E(+Q^6&&$&U=H#<;>_-+:^"! =/FEU%IKN#57U6YF,0
MGE:-HR ,_(H##'7A1UZT <]=^*/%UCI7B2Z:ZTR3_A')]LA^R,/MJ[$DQC?^
M[(5\9&[)],<ZEYK/B>]USQ'::3<:?;0:3%#+$9[=I&F9XM^PX<;1D=>3R/3G
M0OO!BWNE^*;(WQ0:^Y<OY6?(S$D?3/S?<SVZUC#0M8OO&'BY;#5/[.BN$M87
M>2T\T.ODX+1_,N&&2,\CU'% %?6/'U\NC6FJV>H:;9K)I":BME+!)<33.REB
MC;2/+3@ /SDD^G.A+K_B+5=6U6VTF>QLX+.PMKQ'GMVE9FD5SL.&48^7KV]/
M26;X?,D=Q9:=JS6>FW>G0Z?<0^0'D*1(R+LDR-N5;!^4^V"<UHZ-X5ETV6^F
MN-06XFO+*WM'*P>6!Y2NNX#<>N_I[4 <_!XN:\\0^$KJ:QLPNH:)+?RR&+=+
M$0BL51^H7DY'? JIHWQ)N)GL[JZN[.[AO+2:YDM+:V='LBD1E"ER2'&U2I.!
M\V,<5T%CX"BL[WP[.]\95T;3&TXQF+ G#*JECS\OW>G/7K4VE^%+^RM8]+N]
M<-UHT%LUK#:BV".T97:!))N.[:O P%]3F@#FS<:_>ZKX!U#5KBREBO;MK@10
M0-&;=FM92$R6.\8/7 Y'OQL>,Q?-XN\'IISPQW3W%TJR3(75!Y#98J",\9P,
MCG%+I_@C4;>ZT!KWQ!]JM]#<_98EM!&73RFC D;<=S ,/F '0\<Y&MXA\.W&
ML:AI-_::E]BN=,DDDB)A\Q7+H4PPR.,$Y[^XZT <VOC#6M.G:+4S:31Z=K":
M?J$\410-#-&IBE W';AG0,.172:1K%WJOB?6X$$8TS3FCMD<*=TD^W?)SGHH
M9!C'7-<_K&D6VB>#]=@U:2YU;4-=>0O]EM&S+*4"HJ*N[8%"K@L>,9)KHO!V
MBS:#X7L[.[D\V_8&:\E)R9)W):0Y[_,2/H!0!SVH:[XIFU#Q6--GTZ&WT)E:
M))K=I&N/W"2E"0XV]3R >H].:?B+Q]>65B-4L]0TV")=-BU!+!X))YI]REBK
MLI B&  "0<G)Z#%2+X?U?5?$?C:&UU0Z?:WMQ%#+OM/,WH;6,%HCN&UN6&?F
M' XR*OW_ ,/GGBU.QLM7-GI>I6D=M/ +</(-D?EKMDW#"[0,@J<X.",T 3/X
MQDTN\\31:LL833K9=0M"@VF:W93QU.6#JR_BM4(-8\8WFJ1:/Y^FV=XNBPW]
MQ(]JS[9F=P8PN\<?*!G/&#USQ7UO1_\ A(_%WA_3\SS3:8O_ !-[I+9HH)(A
MLD6/YLAMTB(=H8X ;-=B-# \57.N?:#F:P2S\G9TVN[;LY_V\8QVH Y+1?%O
MB"Z7PGJE\U@+'7LQM:Q0L&@/DO(&#EOFSL.1@8!QSC)JZ#\1;K5+W3)OMEE/
M#J;2#[#%;.LEF-C/&S2$X?[H#<#EACI7267@M+/2_"UC]N+C07#AO*QY^(GC
MP1GY?OY[]*=H_A?4=($%DFNEM&M0ZV]H+4*^T@A5>3<=RJ#QA5/ R3B@#"T?
MQ/XFGL?">JW\VGFVUUE@>VBMV#0LT+NKAR_/*<K@8!QGC)T?AM/JUUH^H7&J
M:@EV3J5TD8$)0IMF<'DL?E/&!QM QS5RV\'+;Z+X8T[[<6&A2QR"3RL>=LB>
M/&,_+G?GOTJSX9\/7'AW^T(#J"W-G/=27,$7D;'A,CL[ MN.[EN.!T[T <_?
M^)O$+V?B/6].DL4T_0YY8A9RP,SW(A4&4F0,-F?F"X4].<YK*-K=ZO\ '&UN
M3<V<D*Z''=P+-9;S'&9_NKE^)/\ IH.G3%=%J'@BZN?[6L[36OLND:Q*TM[;
M?9M\F6 $@CDW#:& YRK8R<8K4B\,QP^-1XBCN-H72QIRVP3@ 2;PV[/X8Q^-
M &1XTFUA?$WA*VTW4H[2.XO9%<-"7#%8)#\V&7*XSQZX/;%<[IFIZ[H>B:GJ
MUO/9?V=#XBN(I+5X&:299+THS>9N&TC?P-I^[SUP.X\2>'KC6I]*N[+4%LKS
M3;DSQ.\'G(V49&4KN7LW7-5)/!:R>&;W1OMQ NM1:_,OE?=)N!/MQGGIMSGW
M]J .>N_B'<1:U>&*]LQ!::D+'^S?LSM-*@=4>02 X!!+$#&,+SUX[+Q3J4VE
M:(US;WEE9N9$3S[S)1 S $A1R[8Z+D9-4H_#.HVFJ7#Z?KGV;3;F\^V36PM@
MTF\D%U60MA58C)!4GDX(S5WQ'HDNM6UG]FO%M+NRNDNX)7A\U-Z@C#+D9!#'
MN.QH Y"U\;:M>V26%I/:2ZC+K7]F17S6KI'Y?DB8R&(L#N"Y7&<$X/2GW'B[
MQ%I\VLZ9<"PFO[>\L;&RF6)EC=K@X\QUW$\ YV@]0>>:;K/A>XT6UGU2;5KR
M>=M4AU!)[?3_ #6MYO+\IV9 V6A*\;1\RCN>M9<6F3ZAI_BK69Y-4G66[L[B
MUO(;$K*TD&T^9' V"8U/&.I"MC)Y(!JZMXJ\2: WB.UNI+"YDTW1EU"VG2W9
M!*Q9Q\R[CC&S& >V>^!)JGBG6-(72;34M5TZSN=4\VY-Q]C=TMHD5,1!0V7;
M<X^8D# /'2LZQT.Z\8:CXF>;4+B6VO\ 28M/^WR6+6Z>9ND)$<3\[5#+G)ZL
M>?3M-6\/W-U-IE[IVH)9ZCIZ/%'+)!YL;QN%#*R;E/)13PPP5H YK2O%^N>)
M;C3=-TZ6RM+EH+B>[NI+9Y$<13")?+0LI <_-R>!Q20^,-8G\/P3WE_I6E73
MZG=6DKM$\Q B=U"Q1@@N?E&3G@9.*DUZUN-"U#1M1EUB_%^L$]M/J(TS[3"Z
MLROL=$.4.1\A&1P02>];PMX3U-]&TW4H+Z73[Z&ZOY(S?6OF.\%Q+NRZ97:Y
M"HWMD@CM0!7B\0:]K^H^![BWU&"U6[GO8YU6V<I(T(D0MM+@X8+D*?ND@\XQ
M4^F?$2XOM8LW%[9R6]WJ#6?]G);.)H8]S(DADS@G(4D8QANO'.G;^ ;RQ32C
M::Z!-I=[<W%O)/:;]T<^XNCX<;FR[888[<5I:9X9U'2;M(;;7-NC1W$EPEF+
M8>9\Y9C&9=W*!F) V@]!F@#(^*D=O+IWAZ.ZL)+^!M;A$EK&H9I1Y<OR@$@'
M\Z?X;TK2(KNYDT7P;<:!?BW81WEU:(J9../E<D\X... >:W/%/A^X\06^GBU
MU 6-Q8WJ7D4K0>:"RJRX*[A_>]>U16^E>*HS)]H\46LP:)E0+I83:Y&%;_6'
M.#SCO0!CZ)XRU/6=1-H]K%;-H\3G725+ 2C(6.+GD-M+YYPN!U/&?X<^(%YJ
ME]IGF7ME<KJ<$DAM8+9T:Q81F10SDD., J3@?-C'%;^G^!+32;G3[BPN7CEB
MA>"_:1-YU!')9C)R/FWDL&[9(Z&I=%\,ZGI4<%E)KQGTJT@:"VMQ:A'VXPOF
M/N._:.!@+[YH Y[2_%?B:Y\'Z/JUQ+IPN]>FM[:SB6W;9;%@Q>1SOR^54L%&
MW' R>M3>*M2UW1?#T9U>#2M0<:M:PP3-;_+)&[#YC&2=CJ<@$$] :UE\$B/P
M7I&A1:BZ7.DF*2UO1$/EDCZ,4SR""01GH3S4&H>"+[6=+:WU77Y)[E[^"],B
MP;8D$1&(XX]QV@XY.22230!&GB74Y/&\VER:AIUGLN1'%IUU Z27,&T$RQRY
MPS9)PH4_=P<=:R]!^(=QJNJZ7)]MLYK?4KEX?L$5LXEM4PQC<R$X;[JAA@?>
MXZ<])?\ AC4=1U.-KG6EDTN.]CO4MFM 94=&#*JR[N$W#^[G!(S2Z-X9U'1I
M[>VBUS.C6KN\%F+8!\-G"/)N.Y5W<84'@9)QR 8WQ'72FU;PHNMVQN=.-Y/Y
ML(@>;=_H[[?D0$GG!X''6L1=1D\+Z3XGUKPQITUMHR+9BTM[N&2)'F,FV5DC
M?#*I5D&< $C/.*]&U'1AJ&LZ-J)G*'39I)0FW/F;XFCQG/&-V>_2F>)]"'B7
MP]<Z2UP;<3-&?,";L;75^F1UVX_&@#F[^_U33O%O@RPU0:9>W-]->;[A+3:8
M L6X"(EB5]">X["IM"UKQ)J]O:^(%>P.C7,LFZS\IEEB@4L%D\S<0S?*"5V@
M<\'CG8U?PVNJ^)M UDW1B.D/.XBV9\WS(]G7/&.O0UG:;X.OM-G@M8M>D&AV
MUP\\5BD&USN+'RWE#?-&"Q^7:.@!)Q0!B>%_B!=:QJNC^9>6=Q%JP<FS@MG5
M[+Y"Z;I"2'X7:>!\Q&.*Z/Q=K%SI?V&.WU6PTX7#.'EN(6GD; R!'$I!;KR<
M\#Z\+H/AO4M$:TM?[=,VD62&.VM1;!7VXPJR2;CN"C@8"]!G-3:UH%Y?ZS8Z
MKIVII8W5M#+;L9+83!HY"A.!N&U@4&#R/4&@#DG\>:G<:3HEV][I^CQ7EM(S
MWMU:O) \Z/L$>=P\L'!;+'..!T-=)XUNM1@^&NKWEM<Q6]['ISRF2++J"$RV
MPY!]<-VX..U4K7P7K&FZ0NEV'B2,6H66(QW5@)@T;N6&?G&7&YANZ$8^7CG:
MN?#5O/X)D\,+-(MLVG_8%E/+A?+V!O<XYH P+34O$=U>Z?X?MM2LX[F/3$OK
MJ^DLV?=O8K&BIYG'W6R2QSCH,\;WA+6I]>\/QW=W'''=QS2VUPL6=GF12-&Q
M7/."5R/K67'X2UBWELK^VUZW35H;/[#-.UANBGB#;D_=^8"&7GG=W/%;F@:'
M#H&AQ:;'+)-M+O),^ TLCL7=CCIEF)]J .3T?QE?7'BRPT^?4M-O8KZ2XC,-
MG!)MMC&K,N)B=LG"D'@<]*X>P_Y)SX0_['-/_1\M>A:9X%O]/DT'.O+)#H;E
M;2+[&%#0E&1E?Y_F?:1AQ@#'W3DU'!\-T@\.Z1I/]J,1IVLC51+Y'^L(D9]F
M-W'WL9YZ=* )_BL%/PXU(/&94,EL&C R7'VB/(_&J?A[2?#B:Y;R6?P_O=*N
M$W-'>36L2+&=I[AR>>G3O73>*M"/B7PY<Z4MU]E:9HV6;R]^TI(KCY<C/W<=
M>]5;32O%45W%)=>)[6X@5LO$NEA"X]-WF'% &/9>*M<NO$$?A5H;==8MIS)?
M7'EGR?L8P5D09^\^Y5QD[2&)X SGV?Q#N+K6H&6]LWMY]3-A_9JVS^<D?F&,
M2F3.,Y 8C&-IZY%;<'@1;9[6_CU%O[=BNVNI]1,7-QOP'C9<_P"K*A5"Y^7:
MI'(YM:?X9U'3+[R[77/+T<74ET+,6P\S+L7:/S2WW-S$XVY[9H YZW\8>(5\
M/ZUX@N/L+6]I=3V%K:K$P,DHN/*C=WW<#D J!S@G(Z59\47GB/0_!GB"XU;^
MR=5AAM%E@=K4JC/NPT;Q%FW*."#GO6K'X)M_^$3U+0)KN1X[VYGN?.10K1,\
MIE7')Y5L?7%5K_P9JFMZ)J]CK'B-KB2_MEMD,-MY44*@YW>7O.7/<Y'0 8H
MHWOBG4[?6;2Q2^TO2XWMK=[5+VW<1WKMG>BRA@$Q@ #!/.<$<54NOB'<1ZW=
MF.]L_(M=3%B=-^S.TTJ!Q&\@D!P""68#&,+ZGC>UCPCJ&J6<FF#7%32;B"."
MXMY+02, HP3$^X;"0.X;!Y%3Q>&=1L]4G>PUPVVF7%Y]LFM1;!I-Y(+JLA;
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M 2#\NP]*E\0QFZ\7W/B*WL99?#^FW,*:K$N?],ECW?O0N/F$.Y2?[VW'.P4
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M-<EU<SB"*2X%JL41*!L;2O#'#8)[8 KF=3?0H/B5XD;7-7U+30\5IY)M+J>
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M0K\-_$.V B5_$<DAPG+'[>N&_(#GT% 'H4OB318-872)=3MDU!B%$!<;LD9
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M!A54@<8X+, -O7Y36,]\MS(SKJAOXI?"U_;1&*S6&".7;$WD1A5'(53\I)(
M^M 'J4'C#P[<S7$,.L6DDEO$T\JK)G:B_>;W [XZ=ZORZMI\-G;7DEY"MO<M
M&D$F[B0OC8%]<Y&*XQ;)%U3X?0BW A2QGC9=G 4VZ_*?;BLKPS974WB>T\)W
M*2&S\)SRW =^1*KC%IS_ +*/)^,8H ](U/5;#1K3[7J-W%:P;@@>1L98] /4
MGT%<UXI^(>EZ'X*N/$%A<6U\0?+MXQ)@22;@"IQR",Y(Z\4>,9$L?$/A?5[S
M(TNSN9A<2E25A9XBL;MZ#.1GMN%<1XL!U+P+\0M3L(W?3KZ\M6M65"!,4\E9
M'4=P6!&>^TT >IZ%J;7WA^'4+J[L9<JS23VI80X!()!;G QSGT-16OB[P]>V
MLUS;:O:20PLB2,K_ '2YVIGV8G /0U:UV.WF\/:E%>132VLEK*DT< S(R%2&
M"@=3C.*\JU#4);O0-5@M[Z/7K*RCLIAJ45GLFC1+E6:*0J,,552W !'.1S0!
MZW)J-E%=R6LEU$D\</VAT9@"L>2-Y]!D'GVKG-5\>:8OAN^U/0[ZSOY;1H0Z
M!\@!Y%7)'!Q@D@]#BN0\3W(\4ZCXBDT(27D3>'4C1XD.V?$[,Z(?XOEXX[G%
M6_%VL:#XF\.ZFNDV;7<BV]LDMVEOA%0W"?N"3SNZG;CC'.* .^TKQ%H^MRSQ
M:9J-O=208\Q8GR5!Z'Z'!P>E<SXP\?#0?$6E:%:2Z>ES=^8T\UXS;($501D+
MR2V<#Z5>$17XKJZQD)_817(''$XP/U-4O$<;M\5_!#JC%%BU#<P' S&F,T =
M2=:TQ;&2]-["+:*8P/+N^59 _E[2?7?\OUKD-6\>7VGR^.TCM+=AX=@MY+?=
MN_>F2/>=_/8^F*YN]U*WA\(ZSX?;S#JO_"0M(;81L66-KY9!(>/N%2"&Z<@5
M'XC@F:Y^,&V)SYEI8A,*?FQ >GK0!ZII.L6VJ0A$FB-W'#%)<0H>8O,7<N1Z
M'G'TJU97]IJ5N;BRN(YX0[1[XSD;E)5AGV((_"O-?$4][X631O$.FP/)-J&F
M+I,D:CK.4W6S$>S[E)]&KM].T(Z+X,BT2Q?]Y!9F%),X+2;3ES[EB3^- #[;
MQ5H-[-=0VNJVLTEJC23*CY*JIPS>X!X)&<5:&LZ:5L&6]@8:A_QZ%7SY_P N
M[Y?7CFO-/!SVBMH#W>OSO+HMA(9K'[ L8LP(@CI*P&1@XP#]XKGFE\)6LVE^
M(X+^]LI+;3]7CE30T?)_L[<Q<QL.B&08<>FW9VH ]$L_$FBZAJ4NG6>IVTUY
M%NWQ(X)^4X;'K@\''3O4=KXKT"]N[BTMM7M)9[=6>1$D!(5?O'W [XZ5YIX6
MLY+JRT'2VUZX.KZ;!*/[/6R5#:R^2\;>8X&0I+<$_>.#S6MH&I:1?>%M&\/P
MZ?+-KEII<D#QB##6,@AV/O)QMW-\HZ[L^G- '?-K6FI!9S->PB*\4O;-NXE
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MI4EPEXWEK(P>54.S._:,%<8R<@T >D7%Q#:6TMQ<2I%!$A>221@JHH&223T
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M!;+Y2I^\&_@OO'&.<YSVJ_'KGB*?PCXMUZXU&$Q6 U&"UM?LR%28G;8[D]2
M-NWH1R<DT >DPS17,$<\$B20R*'1T.592,@@]P13ZX"QU77-?GTW3+#4TTUD
MT.VU">9+9',DDN0JA6X"C8Q.!GD $52UCQ5KL&I7.G/>O:7VGV$,C)8:7+>1
M7-RX8D%@A*1_* !\K?,>>* /3**JZ;=/?:59W<L#P23P)*T+@AHRR@E2#W&<
M5:H **** "LW4=&AU'4M*O9)'5]-G:>-5QABT;1X/MAR?PK2HH **** (;N&
M6>TEB@N7MI74A9D569#Z@,"#^(-4M"T.WT"P:VAEFGDEE:>>XG(,DTK?>=B
M!GH.    .U:=% !1110 4444 %%%% !5#6]*BUS0K_29Y'CBO+=X'=,;E# @
MD9[\U?HH 9%&(84C!)"*%!/M3Z** &2HTD+HDAC=E(5U )4^HSQQ[UEZ%H$6
MAI=/]JGO+R\E\ZZN[C;OE;  ^Z        *UZ* "BBB@ HHHH **** "BBB@
M HHHH Q;SPZFHZ]::E>7US+#9MYEO8G8(4EP1YAP-S, 3C)(&<@5M444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M<TZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ5RND2ZIXCM_#MG<V9U>--!6?RYM1:VS(9"AD) )=@%49/3<3U- 'M%<I/\
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MBNQA##Y@O3@G.'(Z8K>\#1"RN?$VF0L_V2RU4I;QNY;RD:&)RH)).-S,<>]
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@8K8:PM6U)-0,*F[2)H%E[A&()7Z94'\*YQ/'%O+X2T[6H;*1IKZYCM([(N
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M[3:.H6R3;LDPH4!GVC((XW-Z#GTBL'2_%$.L:_J.F6=A>-'I\A@GO6""(2@
ME!\VXG!Z[<>] %;PGX?N?"CW6C6^U]!3$M@6?,D)8G?$?49^8'_:(["L)IM;
MA\>^+QH]A;WADM[-,2S^5Y;^6^UNARO)R.O QG/'HE9,5_8)XLN=,BM E\]G
M'=S7"HH\Q-S(H)ZDC!Z] : .5TSPQKGA6^TQ],MK74$CT6'3)3)<>5LDC9F\
MS[IRIWG@<\4OAOPAJNEW/A%[KR2-*L;N"Y*OU>1D*[1W'RGZ5W]% 'E,-CKV
MLZ9XRT.PM+9[74=7N8&NY)]IMU;:')3'S<<C!ZGG&,G7NO#WB"P@\1Z3I-I:
MSV6M.TD=U+<;#:F2)8WW+M)8#;N&.N<''6NBN]8T[0O$.E:,MF4GUN6=U>%%
M"[T0.S/T))&.>:W: //-6\):C+<V=O9Z59>99K;QV6MQW!BG@C0+N#J!E^C8
M&=I#8..33-,\#G3M<"GPSHMPHU&2[75YB#*(VD,@&W;GS%)V@YQ@ ^U>C$@
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MS14F33+&"T2:0R2+"@4,Q[XJ ^&-";6/[6.DVAU#=O\ M'E#=NQC=_O8[]:
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M>VU-BX]C7FL.EVNEZ)X\N=,LX(+B+75LED#&+R[=W@5UW@$JNUFR0#CDU[D
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M-;FB%V]XSW=PG[U65EVA1'E1A=QVX7O7IVCZ5!HU@;2W_P!69IIN@&#)(TA
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M0S2VDGF6[R("8FZ94]C0!YQX?#W'B#2?#&]V3PW->RS!F)RH.RVSZ_NYL_\
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MJ:L\MQ=SH9VOY)?NR$;!$0%15Q@$=?05OVWBB^O?$-U8V>DQ365I="TN)1>
M3H=H._RBOW/F'.[)Z@4_P-H%WX;\/R6-Z\+2M>7$X,3$C:\A8=0.<&LW4_#>
MJZEXIMKUM/TF(VU['-'JT,K)<^0I!,+)M^;(RIRV,'. >* +D/C03>&M+UC[
M 1]NU%+'RO-^YNG,6[..>F<8]LT6_BS4;V_=[+0C<:/'?-8O=)<?O=RML:01
M;<&-6R"=V< G%8D'A/Q+'IVFZ(4TU;#3M82^6Z\]S)/$+@R[=FS"L 3_ !')
M '?(TM.T;Q/HUS+IFGMIZZ5)J+WGVQY&,J122&1XO+VX+9+ -NZ'.,B@#'T#
MQ7JNEZ0UQ<Z;]ITP:W<6DMW)=GS5WW;(I5-IW(I91]X'@X&!72?$'6=3T#PC
M/?Z2D37*S0QEI'QL5Y%7(&U@3D@8]R>V#0;PAJ)\%2Z/YEO]I;5S? [SM\O[
M;Y^,XSG9QTZ]^]:_C;1;OQ!X2O--L6B6Z=HI(_.)"$I(KX) .,[<9QWH S]>
M\7ZKH$#W-UHEL+:UMUGNY&OPI/7<L *?O"H&3G9G( J36/'$6A7U[9WUBXF$
M*RZ:L;[CJ!8A=B<<.'*@CGA@W3..?U_P7KFOR:VTVG:-Y^K6B1I<SS-*]B5C
M*F-,Q\@MSN!7!8G!P ='4_".L^([DZAJ%S#8WEC"G]D);2M(L$_#/(Y*C=D@
M)C&-F>[< %[7O%>K:';?:'T.W:*"S%U=M)?B,9P2T</R'S& !/.T<CUXQX_$
M.LQ>+O%$FDZ=_:4$4%I<;)[LPJB&(G:@VMEVYXX'')I-<\'ZWK=WJ$UQ8:-+
M-J6FQVWVB>1G-@X5@XB4I\P);(.5.>2#@"I+30O%^F7&J75K;:5(^HVEO;^6
M]VX\AXXBA?/E_,,GIP>!S0!#_P ))'>?$;0M2BN9DTNX\.2WQC+';C<K9*],
M@5MZ%XRGU/4+""]TV&TBU.!I[)H[L2OA0&VRKM&QMIS@%AP1GBLRW^'L]OJV
MCKY\3Z=9^'WTB5LD2,S8&X#&,8![U9\(^%KK1KJT%QH/AVU%G;F(WUI%F>Y?
M 4./D7R\C)89;)./>@#5UWQ'<Z?JMOI6FV5O=7LD#7+BYNOL\:1J0OWMK$L2
M< 8[')%0:!XTAUW5+>S%F\"76G+?6\CN"6PY22,C'#(V.A.<U7\4>%Y-0\06
MNLPZ/I.KE+5K62TU+ 4?,&5U8H^"#N!&.0>O%5/$/@_5KSP]I"Z,VF6&L6*2
M1$P1F*W5)HRDH10"1@E6'NHZ4 26_C^?4H;/^S-+@>:]>YDM_M-YY49MH7">
M:S;"06)&U0#USFGP^.[G4IM+MM)T83W5_:SS;9KKRT@>&18W5V"MQN)&0#D@
M<<Y#-9\$QI+HDVGZ1IFIPZ99M8_8=1P$,9V;75BC ,"GIR&-6])\,WEEKND7
M[P:9;16NFW%M+!8H8XUDDEC<;%QT^1LGC)YQSP 8]SXXUR\;PRVF:;;Q/>ZC
M<6EY!-=='A64-'N\L_+E-P8#/R@8Y->BUYZWA#7+.#2[BS6RN+JQUN\U#R9)
MVC5XIC+@;MAPP$@[=C7;V1U R7?VY+=4$Y%MY+$DQ8&"^?XL[NG&,4 ,U;3/
M[6L_LQO;VS^8-YEG-Y;\=L^E<-X*TBZO]0UJ6Z\1:[*-,UJ2VAC>])1HT6-@
M'&/FR6.?45Z/7/\ A;0[K19=>:Y:)A?ZM+>Q>6Q.$94 !R!@_*?6@#D_"OBO
M5;#P_I3WFFF?3KC4Y+$WLEV3-O>Y=581E3E 2%R6!]L#G:3QT[Z@C?V?#_9#
MZA_9RW7VL><9=_E[O*V_<,@VYW9[XQ4,/A#48_!VDZ29+?[1::O'>R$.=IC6
MZ,Q ..NT^G7\Z@TWP5/INLE5T'P]/;_VA)>#4YXPURJ,YDV;=GWP3@/OP  <
M<8H V?&NIW]E9:=8Z9.+>\U6_CLDN"H;R%(9G< \$A4;&>Y%-M?"NH:7J5G=
M6'B34YHE?%W!J,WVA)DP?NYQL;."",#VJWXKT&;7M,@6SN5MM0LKE+RSF==R
MK*F<!AW4@LI]C5.U7QGJ&H6?]H+INE6=N^^?['.UP]U@?=&Y%"(3R>IXXQUH
M I1>.[J2WM]7;1T7P]<W@M([S[5F;YI/+60Q;,!"V/XLX(.*AO?B%?6D&I7Z
M>'_-TS3-1-A<RB[ E8[U0-&FW#?>7(+#KQFH8/".NKHUGX5D6Q&BVMZDWVT3
ML99(4F\U8_+VX#9"J6W8P,^U6;KP?J,WA?7]-62V\_4-7-["2YVB/SHWPQQP
M<(?6@!U[X[O=(AUP:MHL<-UIEBE^D<-WYBS1,S+@ML&U@5((P1[U=MO%>HIK
M":?JFAFV>YM);NR$-R)6E$>W=&PVKMDPR\ D<]>*POB1HURMAXIUK?']FET%
M;10"=X=9'8G&,8PP[U:U/PUXD\1W$DM\]E8/;:7=6=I+;3NYDFF5093E1L4!
M1P,GD\\4 .D^(%U8VNJ-J>D6\5S9Z:VHI#;WPFW(IPR.=@V."1V(YZ\58E\9
M:O:W4MO<>'56673YK^QC2\W-,(]NZ-QL^1\.O3<.V:YZ[\!:U=6]XMKI6A:8
MEWHTVF&WMI3A&.TK(6$8W9(((QP,')Y%=I>:3-_PE6D:R\L"6EA8W,,Y=\$%
MS$01QC \MLDD=J (SXO@G3PV;"#[2==(:,;]OEPB/>[G@YV\#''+ 9J3Q#XA
MN=*U#3M.L;.WN;R_$K1BYNOL\>(]N1NVL2QW#  [$]JY?X=Z2AU[6-0@G2XT
MBRFELM'9/NB-Y/-FVGN Y" CM'72^+-,O-4@A@CT?2M7LB&$UK?N8R&XVNC[
M6QCYLC&>1@\8(!@OK.OMX^9;+22]Q+H,$SV5U>>5' WG2[LLH8%N@&!SCJ,5
MHKXROK[0=+U/2M&B=;RW:>0WEZ((X2,#R]VUMSDYQP!\I)(H\+^%M1T;5H+J
M]N8YUCT:"Q9@[,WF))(QZCE0' !)R<<BL.S\":O90Z-'+9Z1J/V:PDM&6[<L
MEM(TA;S44H=YP0"/E/R@9P30!-_;S:S\0/ ][:RSQ66HZ7<W!@+D Y1"-P'!
M(S5_X5W5Q=^$9Y+F>6:0:C=*&D<L<"4@#)["JF@^"]8L-4\'W%TUF(]$L)[*
M;RY68R9"JC+E1U"Y(/3/>MOP)X>O/#/A^6POGA:5KR><&%B1M=RPZ@<X- '-
M6'BO5=%M_$%[)IIO-+M=<GCGGDNRLB(9%7]VFT[@N1U*^@KH-9\77FC:F5FT
MJ(:8EQ# UQ)>!9G\PJN^.+:=RJ7 )+ \' XYIW?A#49_"/B/2EDM_M&I:C+=
M0DN=H1I%8;CC@X!]:S=9\$:Q>W>L&"RTB62YOH[V'4+ASY^U#&1!]P[!E"-P
M)&#TR30!O-XXB@\/>(-2NK,Q3Z+<2V\EL),F1ACR\''\89,<?Q=\54O_ ![<
MV+7LATF$VNEK'_:3->@21LR*[K$FW]YL5@225ST%-U;P9?:CXSMM122WCTFX
M>WN-3MRQ+/-;[C'MXP024SG'$8J+4O!=P?$6IW<&A>'M1CU*:.;[3J<>][5@
MBHPV[#O4A 0-R\D_6@#6^(&M:EH/@N\U+25B:X0H [MC8&8+N VD,<D<'USV
MP<4:OXCA\<ZM';:7%<W TJTE>V:_*P1'?-D*VPY9N /E&<<D8%='XTT2Y\0>
M#M0TFQ:)+B9%\KS20F5=6 .!P#MQ4.E:5J8\2ZCK-_%;0&]L+>#R89C)L>-I
M2W)5<C#KSCUH SU\>RZA!IS:+ID-Q-=:<FHR1W5X(!'&^0J [6W.2&'8?+R1
M71V&LPZGX;@UJSAEEBGM1<QP@#>V5W!<=-W;ZUP5M\/K[3K31Y'T?0]:N;?2
M8]/GAOS\D;H699$8QMD?.P(P">*[&_T2ZN? MSHEM);6=W+8-;J]K&8HHY"F
M,JHY5<_B!0!AOX_NK*TU9M2TBWCNK'3FU%(;>^$P= 2"CML&QP<9X(YZUM:K
MXCFLM3L]/MK))Y[NQN+I"\VQ08O+^4_*>OF=>V.AKD9/ >J7GVU4TW1=(M[[
M1IM-,%FY/DL<%)"1&-^3P1Q@ <DULVNB^(]0\1:;J>K0Z?:16EA<6ABMYVE8
MM)Y?SY*+P=AX[8ZG/ !SNF^)/$FH0^ [^:VCGOKV*Y81I<[(YQY*D/)A $QR
M< -C'&2:Z./QU<R64<(TA3K;ZF^F+9"Y_=^8BEV?S-N=@0;L[<]L54\->%=<
ML(_"D>H)91C0DG@9H9V?SD:,*K %!@YSD=O7M3Y/"&K6]Y)JMFUH]]!KDNI6
M\4DC*DL4D(B9&8*=K8R0<$<#UH EO/'\^F:=J+7VC8U'3KRVMI[6"XWJZS%0
MCHY49X8\$#D$>]+<:U<KXM\.6FH:1Y6K75M>.BQZBYABV 85@% ?<,<D?+SC
M-5+SP=K.K0ZE>W7V.#4-0U"QG,"2L\<4-NZD+OV@LQ <] ,D#WK:U3P]>7OQ
M \/Z[$\(M-/@N8YE9CO)D"A=HQ@].>10!A>%_'.KS:9HUQKEA"(-4U">S2[B
MN,^6P>3RU9-@XRFP'/. 3R:ZS3==_M+7]7TZ*VQ!IIBC:YWY#RLNYD Q_"I7
M)S_%[5P]]I,N@?"[5=(UV>RM1;/+<:;=13EGED\UIHR$*@A@Q08!;/-=AX+T
MRYTSPU ;]0-2O&:\O<#_ );2G<P_X#D*/910!@GQIJ>G:_XO?4[6$Z3HR1,@
MBFS)EDW* -@R7R.K?*>.>M;.G>(]2_MVVTC7-)AL)[RW>>U:"[\]6V%=Z-\B
MX8;U/&0>>>*Q]7\':IJ6J>*H5-JMAKD$!CN#*?,@EB0!04VX8%@#G<.*TK+2
M]=U+Q/8:QKEO8VBZ=;2Q0Q6MPTWFR2;=SDE%VJ F .3R<F@"UK'B"^MM:BT;
M1],BO[\VQNY1-<^0D<>[:/FVL2S'( QC@Y(JAJOC#5+'3H;Z+P_LB%G]JN%O
MKL6[(1G,2#:VZ08/H.G/-6-8TO6;?Q3'K^B0V=U(]E]BGM[J=H1@.71PP5NA
M9@1CH>M8.I^#->U&ZFDOH]'U*XO-,CM&O+E2/L4@W[VBCVD$'>,<J<J,T =1
MIOB:/4]7O+.&W(CM[&VO5E+<N)O,P,8XQL]3U]JP[;Q]>ZG#IG]EZ+#-<W>F
M)J3V\U\(FV,2-D7R'S&^4]=H'&3S4=AH'BC2[U;FVM],9[O2K>QN=]R^+>2'
M> Z_)^\!#YQ\O(QGO5.?P7K)\(:5H,NEZ)J'V;3DMTGFF>.2TN "#(C!"2/N
MD8VG*^_ !K:GX\DL;K4)(]-C?3=,D2.^FDNPDJL55FV1[3O"*X)RP[@9Q5WX
M@ZSJ6@>"K_4M*6,W,04!W;'E@L!N *D,02.#6"_@6[M]4NV&C^']76^EBE:_
MU.(-+"P1$D^78=X.S<!N7!8YKIO&FB7/B+P=J6DV;Q)<3Q@1&4D+N#!@#CH.
M,4 <[_:WB.+QYJ,5MI<-S<_V1:RO:M?E8(CYD^=K[#EFX ^49QR1BK:>/9=1
MMM-;1M,AGGN]/749([N\$ BC8X"AMK;G)# < ?*<D5I:3I>ICQ1>ZWJ$5M ;
MK3[>W,,,QDV.CRD\E5R,.O./7\>4M?A]?:=9Z+))I&AZU<VVE)I\\%\?D1D8
MLKHQC;CYV!& 3QZ4 =W9:Y!J/AB+7;9&,,MK]I1&X.-N=I]#VKFK/Q[?W7A_
M3]4;0XX&U9XH].ADO0/,+(SNTAV?(JA20?F)&. 3BNEATV2+PR--$=I%-]E,
M16VC\J$.5P=J\[5SVKF+CP5=2>"?#&G26^GWM[H@A9[:ZYM[C;$8W4DJ<<,2
M"5/('% $R^.[F806%MI4,FN27SV36OVO]RI2,2M)YH0DIL92/ESEL8I;;QW.
M\LD%UH_V>>/68M)=!<;AN>-7,@.T9'/ XR,'CH*H\+:M:G2M5T[2="L[ZQNY
MI?[.M28H7ADCV$&0)S(, [MH'&.V3DV.D:UJLWB&119G5;+Q);WWDF1A$VV"
M(^7OVY^ZV-VWDC.!F@#=\7>*H+;2O%EO<V$LL.DVT$CB*Z:%IA)DX#*,IC;U
M&<U:/BJ]/B:V\/Z=HXG8V,%[)/)=;%CB=V5OX268;1@?Q9/3%8NK>#O$.N:7
MXP^T_P!GP76MV]M';Q),S)"8]V0S;03U!R!W/'&3T6G:!=VGC)]7D>$V[:1!
M8@*QW>8CNQ.,=,,._P"% %'3O'C7MY8R2V$,6DZC.\%I<B[#2D@,59X]HVJP
M0X(8]L@9K&OO%6JZU#X7OTTTV>EW^L0?9YH[LM))'\V/,3:-H8#. 6]#5OP[
MX'ET>YM;-]!\/?9;5Y/^)H(PUU,AW; !L&UQD9;<>AP.>(K+PIXHCT[PYHLX
MTU;'0KV&47*SN9+F*/(7Y-F$.T\\G)'I0!M>.=;UC18M&_LB""1[O4X;:3S9
M=F0Q^[]QN&P06ZCMGLW4_%]_I.HJMWI$,=@+B"W>9KT"5FD*KOCCV_,BLX!)
M(/!XXJUXRT?4-7L=.?3%@>ZL-1@O5BGD,:R!"<KN .,@]<&N6U+P3KE[+J3K
MI^BM<W%_%J"7TLK--A&C86X/EY4 H1N!Z?P\G !NWWCDZ?>7FERZ8QUI;A(K
M&R$W_'XCYVR*V.% 5]W!V[#UXSL^(M;;P]I":C);"6)9X8Y\28\M'=4+].=N
M[...!VKF[_PEK>HZG-XC:Z@AUVUE4:7$LK&". 9W1N< GS,MN../EQ]WGJ=;
MTL:[X<OM+G"I]LMGA;G(0LN,@^QY_"@#*3QE;GQCJ&A2VYCBL[9IC>%_E9E6
M-G3&.JK+&>O<^E8FG>+&U3Q'82QZ-)'J-UX=;4(EDOW$80R#:C*%VY.0=^,C
MIS5.[\ >(+SPE;0M>6BZ[-=W$E_.';8T4Z-&ZJ=N20GEXR!R@KHF\+7"_$*#
M6H3 FG1:(VG",$[PQD## QC;@>M ')Z9XE\2:E;>!-0GMDFO;T7!$4=SLCG'
MDY#R80!,')P V,<9)Q5_5O%6HWUOHLB6#P:C:^)/L%Q:0W.4D<02$#?@90[D
M;E>/3BK/AGPGKFGQ>%(=02R1="$\+-#.S^<C1[58 H,'/4?KVJP/"&HC4A<>
M9;[!XE.JXWG/D_9_+QT^]N[=,=Z )#XZN+6VU&&_TA4U>TO8+*.T@N=Z3R3!
M3&1(57 PQSE>-IZU0\3^)=0;PKXLTR_M%TW5K32FNHVM;HRH\;!@&1]JD$,I
M!&!VZU:U;P=J5WJFL:C;2VRSO?V5_8B1FVEH$"E9,#@-\PR,]<^U0ZIX5USQ
M#;>([N^2RM+[4-*_LVTMXYVD2-<NQ9WV#DLW9> .] %G3O$NI>5I6DZ9IJ:A
M=1Z3;WEW)/=>5M5AA0#M;<[%6/.!QR>:P_"^NHUI\/8KN&ZN+K4/MOESM=NO
ME[0Q.].DF1P-W3J*VK?P_P"(-#U.UOM+BT^Y:72;>PNDN)VC$<D6[;(I"'<O
MSL".#P.:IZ5X%U:QE\#--/:O_81N_M;!CE_-4A2@QSR><X_&@"U;>/K^>WLM
M1?05CTFXU#^SFG-YF17,QB#A-F"FX 'Y@>3P0,E+SX@7MO8W>K0Z")M&AO?L
M*7 N\2.XE$1<ILX3=D [B>!P <A\?A#44\&6&D&2W^TV^KK?.=YVF,7AFP#C
MKM/IU[]ZY#6)+FT\/:CX:M+[2IK8:XHB"3M]J9GNED\GR2HY!8G?N(*CISD
M'L]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !2$A022 !U)I:X[Q^
ML<__  CMI>8.F7.KQQWBO]QUV2%%?L5,@3@\'@4 ;NMZY!HNF1W[(9XWN(8
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MIOQ/\53)96-L;6TLFB<1HGE*4DWD'L" ,_3F@#MKJ6#1]'GGC@58+2!I!%$
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MBS*JR2*>'<!V^9LGFN>\/6>G:E<^ +/5DCN+?[%J4<<%Q\R2;)4"*0>& "Y
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M=I9L6\^=KB8*D8;!)/J>@R3P* .[M/#^C6&H2ZA9Z38V]Y-GS+B*W57?/7+
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M0Q-(K,,8*G8>!R 1]*L1^.+B;PC9WZ6,8UBXOUTPV3.=J7 D*.">N %9_H*
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M"U\::;X=^R[S?6LMP+CS,;-A'&W'.<]<U:L-8$ND&_U+[)8JKLK$7:R1@!B
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M!Y%W.D$$B2*5=F;&0<XP.Y[5+K&MV&A:--JM_.J6D2;RP(.[T"^I/:@#DY?
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MG5_!5QJ6H:Q>I<6XEN9K.YM5E0NJO!GB0=U;)''8UTFLZQ9Z#I,^IW\A2WA
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M:K>:<OV/3[FR6.V5\,945=Y+?[HX[>ISQI0>%KB*/P<IN(C_ &$FV;@_O/\
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M[<MO\EHE*9]=N,9]Z /)9YM+FTA-7@AT%/*TMX[C1;\DQM"DLOS6TO;<P?!
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MIQM+9HY8VMXBDQ)E4H,.3P2P[]!UH DC),:D]2!3J** "BBB@ HHHH ****
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MC8Q/'<N6:-L$$$97D=UZ5!?> +S4M&N8[G48#J5[JL.I7,RQ$1CR]H$:C).
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M24V(9G4^80ZN9#(&##D$.<@]L"H?^$-LS9R1/J&J/<O,L_VUKH^<KJ"JX(&
M,$C&,')R#F@"3P?>1WFB$QW][=^5.\;?;HO+N(2#_JY!@99<]>XQUZUQ1N]1
M@MM6L]<O=7AU*6PO=T%RBO:76%8AH&7A=JX.W@X)R#C->B:/HUMHMH\%N\TK
M2RM---.^^25SU9CZX ''& *R(? NF1E@]SJ$\*PRPP037)=+=9%*ML&,_=)
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MWEY+J!C,]S<3DR_N^8]K#&W:>1COS6CH^B0Z.)V6ZO+N>=@9)[N;>YP, =@
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M:HR2PHI+1CYC\I X*]2*[*R\ Z3:36LLMQ?WK6D+V\ N[@N$B==I0# XQ^/
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MJHLA^;=AU7!7)Q@9'/'7^'H-0G\)VUOKP9[J2)DG$NW<RDD /MXW;<9QQG-
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MG/'0?%+2K[6OAWJ5AIML]S=RM 4B3JV)D8_H"?PH OZMXQT_1[^6VN+>^>.
M(;JYB@W16X<X4NV?Q. <#DXI+WQMI%AHNIZK/]H$.FW9LYT6/+^8&4 *N><[
ME(]C7'>-M)UO5YO$EI]@UB[>2-/[,$%VT5HL8C4MN57 9RX<88'.5Z#)%ZXT
M"_OO'\3?8)1H-^T.J7)D &V9(7B\MAGJ?W+?\ - '3:GXQTG2I8XIFFD:2U%
MT@ACW[D+I&@'NS.H [\^E7M(UB/6(9F6UN[66"3RY8+N+8ZG ([D$$$<@D5Y
MYH?AW4H]$U=M>T.>_P#(BM])@MA*%DEMH&SYJ'/4EBPY!)0<@UT/AF?5]/MK
M@26>L75A)?116:Z@RFYBB90'=R3DHK9QN^;'X4 =DS!%+,0% R23P!7G_A?Q
MMJ6J>)(EOXH8]'UA)GT9U0AR(7P0W/)9/G'L#6WX[AU2^\-/I6D12&?4I4M)
M)D_Y=X7/[R0_1<CUR17.:]\/K^ST"UET;7-5O+S16CN--L[@P^66C&-GRQJ>
M4RO7OS0!U<GBVRCUE].%K?R"*=+:6ZC@+012L%*HS=<_,O.,#<,D57A\<:;-
MYSBUU!;6..:2.Z:W(BG$6=^QL^QQG&<<9K NX=0E\21WVE:-K.FZE/<V[S.L
MH-G<0_)O,RDX#A-R\#=E1@D55CTC4YKRZL])TO5=+@NH+M+^UN9@]D&=&"M"
M23@F0J?E &"<@&@#NE\0V+2:/&/-W:NA>V^7L(_,.[T^6L*#XEZ+<16,Z6NJ
M?9K\E+6?[(=DTH!/E+@Y+\$=,9!&>*R])35[[4_!0DT*^LXM)ADBO)+D* '^
MSE!MP3N7(^]TY'OANE:!JD'A/P%:R6,BSZ??K+=(<9B41S#)_%E_.@#4U7QK
M92^%;_4%N=1TE[*[CM;@&V1IX7+)A2C94A@Z\\\'(YJ[JGCG3M+O=1M#9ZC=
M2Z<JR7?V6WWB)&7<')R.,?CP< X-<EXM\-ZQ?:/XSBM;"662]U:SFMU7'[Q$
M6 ,P]AL;\JZ%])OCJ/CJ06S[;^WB2V/'[TBW*D#\>* -&[\::7:W44$4=Y>;
MK9;R1[6 R+# V=KOZ X. ,G@\5HZ9K=EJV@0:U;NRV4T/GJT@P0F,Y(KA]$A
MU7PSJ#%M'GO&O=%L8@(V3$$L*.K++EAM7Y@=W(X;O6S\/5?_ (51H:B!9F.G
M+B)S@2?+P">P/]: )E\>Z9_9MQ?SV>I6UO#;K=*T]MM\Z(D ,G/N.#@\CBM>
M\U^PL-3-A=2&*1;*2^9V'R+%&5#$GVW"O-Y]#UB\T+6-,T;3=8M=.?3"%T_4
MI@RQW(="D<#%B=NT.#SM^[BM#6-/U7QEJU\\6DWFGVUQX=N[&.2\"H?.=XR
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M']*D75M2B$>H-*+6_%O--Y-SY,9>4NA(53R <DD$YQ0![!7*CXD>$R3MU1F
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MRCN'6(R-&Y.5!Y'R].ASSGC !Z#17E'A@>*;NVTK4;>+4X3?V$CWE]?:C'+
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M>0:1>,/ TAAN;F+S;2;4 ]T\:*<2*QD*JRLW #CC/(.!7HM% 'E"1ZYH^O\
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M:XG_ (1O6Q87#Z=I-];6-M>V-W9Z3>7J22%HI"TH1M[*BE=N 6QE3TS7J5%
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M))X H!# $$$'D$=Z\LU'5M8U74?%Q%[#_9 \.).EL8GW!9(YB"#OP'S]XXY
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M$D?R@!MIQA@1P/Q]#HH \VU.W%WK6J7=O<ZBEOJFE_8+J.70+IG!59 KJP4
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HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>a1011-arrowhead_2021plan003.jpg
<TEXT>
begin 644 a1011-arrowhead_2021plan003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MN)I%#+D' "HZ]NK?A2-K?C+^WM0T-5T3[5;V:7R7/E2^7L8NOEE-^=V4/S9
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MP'&_(<&,'(..HQ78:;;W5KIT$-[="ZN57]Y,(A&';.>%'0=AUX'))YH \?\
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MC"[V*X+;1P.><"@#R'0)-%DT/PM)X<FOG\3L;(W'ER7#*5.S[1YN[Y-NW?\
MCC%=:GB/6M4LO%<\UIIITK2FO;7RW5V>X,:DC/. N" ?7)Z8YZW0-,.B^'-,
MTII1*UE:16YD P'V(%SCMG%95KX4>WT3Q)IYNU8ZQ<W4ZOL_U7G+@ C/./PS
M0!B:-XBU34-,\.:9H-KIEE//HT>H2^=&YAA3Y56-$5@>23U/ 7O3-6\>:A87
M<.G7,^AZ-J,=@MW<IJ5QE7=F91'&0R_W"2W. 5XJ];>#-3T>WT271]2M5U#3
M],739FN;=GBGC&T@X5@5(9<CD]2*E/A76[.XAO=/UN"74'LEM+R:_MC()2K,
MRR*%88(+N,<C! [4 :B^(FN? @\265F\SOIWVV*U!RS-Y>X)QWSQQ7$:[KNH
M:SX&GN?M>C:G&M]I[02Z<[(-_P!ICS&ZL6*D87GWZ#%>CRVEVVBM:1:@\=YY
M'EK>>4I(?&-^S&WKSCI]*Y*?P-J&I2WEWJ%[81WER]GN^Q6K1HP@G\W<P+$L
MS<C.>!CK0!,/$>O6%_K6FZBFE2W5KIZ7]M+&S00[69U*R%V.,%,[L\CL*YC7
M_%4NN^ O&MA->:9?-9Z?'*MWIP81.LFX;2"S8(*'G/((Z5UOB/P9)KM_J-TE
MZD)NK""U17BW!7BG:8%N1E22 1Z9JAJ/@;6-7BU[[;J]IYFLZ<EI(([9@L+(
MS%"F6R5PYR#R3SP.* *-A_R57PU_V*Y_]#2M/Q8=1_X6!X432Q;BY>VOU$ER
M"R1C$)+%006Z8QD=>M:%OX2>#Q;I>MF\4K9:4=/,7E\N=P.[.>.G2I=?T#4-
M0U[2-8TV_@MKC38[A!'/"9$E\W8,-A@0!L/3OCTP0#FYOB'=VUI%97LVDZ?J
M@U*>PGN[EF%J@B4.7 + G<&0!=W5CSQ74>#_ !%_PDNBO=E[:26&XDMI)+5]
MT,A0\.A_ND8/MG'.*QX?!-_:Q07\.HVS:ZE_-?2RR6Y,$AE7:T>S=N"A0F#G
M.4![XKJ=)MKZUT]4U&[CNKHLS/)%"(T&22%5>> ,#DDG')H \W\/ZWKF@>%6
MU,16+:-#K%Q#-&P?SV1[QU,BMG:,%_ND'(4\C-;\OC:[L_#_ (BDN;6$ZQI5
MV;2*W3(69I"/LYQG.'#IGGLU01>!-6&F_P!BS:Q;2:/)J#7TZ?9F$Q!G,WE*
MV[&TG&21GKZ\5Y=/M?$GQ8AO-/ED>RT^,-J>$(BDN8F80+GNZ[W8XZ;5H [+
M5+V\T[PW/>?Z&;V*#<QFE\J /CDECT4<GZ"N*'Q#OET;6I89-*U6YTZ:R6.:
MSW)#,L\H3;@LQ##YN<D=#CM78^)]%?7] FT^*=(96DBEC>1-Z;HY%D 9<C*D
MJ 1Z&N<NO!&KZC/J4U[J]JSZB+-I5CMF58FMYO, 3+'Y2N0<Y.>>G% $6I^*
M_$VB2ZO;75MIMY<65C%J:?9HY%#0^8RRH06)W!5)!Z'TK>'B)[SQ7IVF::(9
MK26P:_N9SDE8V(6+;SU8[CSV4TFI6=GIFO7?B?4KR.*Q_LY+*5'0D#]X3DGO
MG>!C%9'PNT%]+T.XO9A/F\EQ:K<+MDCLX\K C#M\N6Q_M4 :NKZQJTGB>'P_
MHOV**<69O9[B\C:153?L55564DDAN<\ =ZX'QCJ>I^*M%\+QRQV$2R>(EL+V
MUEC>2-IXVE4Y^8;HCLSM(STYXKT'5]"U%_$$.NZ->6T%ZML;2:.[A:2.2/=N
M4_*P(93GZ@FLQO +?V7H-L-1#3Z?K U>YG:+_CXD)=G  /RY,G'7 '>@!_CN
M?4="^%NHR:9+;VES:607=!&46,!0I\H _)C^'DXXK*C_ .$F'Q U)+.32S?_
M -C6C332Q2>5D2SX54#;N<]2W&#P<UV'BG1/^$D\+ZEHWG^0;R!HA+MW;">A
MQWYJIH^A:A;:W<ZOJ5W;2W-S8PVKK;Q,B QO(VX98GD2 8]CZT <M)\2Y+FU
MT?RKS1=)GN],74)6U20["6)41IAE/56RV3@ <'-=GH^KR^(?"5IJU@(H)[RV
M66-9071'(Z'!!(!ST(S7/:?X)U30K32SI&I6?VRUT]=/G:ZMF>.5%8LK@!@0
MP);C)!#5V5E#+;V,$,]P;B:.-5DF*!3(P'+8' R><"@#Q[X?7FH:-X-LKVWM
M],FU37]2DM8YVA82%Q+,6>9]V7551L 8],\YK1\>ZSJ-QX#\::)JZVK7MA;6
M\JSVJLB2QR/P=K$E2"C \GM6]8> 9].\':5I4&I1C4-+OGOK:Z:$E"[/(VUD
MSDJ5D93@CUINI^ [[6]$\1QZAJ=O_:>M1Q0M+# 1%!'$<JJJ6)/)8DD]6]J
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M\ M?WGBJ>[U  Z]%: &&+!MY(%P&&2<_-AL>V* (=4\5:_X;^W0:LFFW$_\
M9%SJ%I);1R(F^$ M&ZLQ)'S*=P([\"KNF^(-=7Q%I-GJT-A]GU:TEN(5M@X>
M!D"$JY)(?(?J .14%[X.U;75OI=;U.S:ZDTN?3;7[+;,D<7G ;Y&#,22=J\
M@ #WK9D\/N^M:#J'V@ :7;S0LFS_ %GF*@SG/&-GZT 9/B:]UR'QYX6LM.N[
M>*TNOM#2QR(QWE$R<X89&#QZ$9YZ5SN@:SKFA^'A?)'8-I(UZ>VDC<.9W$MZ
MR;U8':,,_P!T@YP>1FNTU_0;W4=;T35M/N[>&XTQY<I<1%UD210K=&!!&.*I
M'P9)_P (F=%^VKN.I_;_ #?+XQ]K^T;<9]/ES^- &++\2Q'K<J"^T86L6J#3
MC8&4_;6'F"(RCYL8#$G;MY49S4X\;ZS%9>)=8N;:P72]&N;FT5,L)9W1@$.[
M.U5Y4$X/?ICG7M/#FKZ=J<R6.J6L6DSWS7KHUKNG!=M[QJQ;;M9LG.W(#$#L
M01^#%/A_Q!I-Q=DKJU[<72R(F#"9"&7@GDJ0#[T <_'\2WMK?5%DN]&UBXM[
M6.>!]+D(C+O((A&^68C#,GS9Y!Z#%:EQK/B:SOI=%OI-+-Y=:?+=6=U!#(J*
MT94.C*7)/#@A@1]*LW/AC6-;T;4+#7-5M<7$2)!]AM?+$3HV\2G<Q).X*=N0
M/E]\U):^'-4N=7;5=<O[2:YCLI+.V2T@:-$#D%W.YB2QVKQP !WS0!C?!K3G
MM/ %C=O%9*UY&)3)!"5ED.6R96).]O?BNI\3ZI<:1HYNK>:PMV\Q$:>_DV0Q
M*3RQY!8^B@C)-9FD:)JGA?POX=T6QN4G:UG2*ZD\KAX?F+=3\O;GGICO6AXE
MT6ZU>/3I;&X@ANM/O%NXA<1EXW(1TPP!!Z.2"#P0* .'O?&&N:MI&F/IM]IR
MS+XACTZ:X@1S%<#AU91OR%(.&7)SZUZE'O$:^85+X&XJ,#/?%<'+X%U=K>X(
MUFUDNCK$.L0R26K!1*JA71@'^X<#;@Y ZD]:[N(2"%!,5,NT;R@P">^!V% #
MZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *Q_$'B?2O#%O;3ZK=1P)<7$<$>]U7)9@N[YB/E7.
MYCV )K8KB_B7)#!I&C75RR);V^N6,DTK\+&@E&68GH/>@"Y;^.=)_M?4[._O
M]/LXK:>**VEENE47(>%),KD\_? XSV]:V;W6])TVZ@MK[4[.UN+@XABGG5&D
M[?*"<GFO/;F"QO+?XHWB)!.LMLNR50&#)]A1EP?3G(Q6/>8^T:Q#JFOV&F07
M^DVBHMY9>?)<1>3M(B.]22'W?*H)RP/<4 >SNZ11M)(RHB@LS,<  =237.:O
MXRT^V\'ZKKVD75GJBV$3.1!<*ZE@,[25SBJOCBUNC\,KZVBE>:5+:,2R&(DN
MBLID)3.3E0V5S[5Q6N""[\,>,M1@\26&K.=%2&4:=9^5$H!8H2P=E+ %AC.0
M"/:@#TP>)=*MK#3KC4]0LK"2^B1XHYYU3<2 <+N(SUJQJ&NZ1I,T,.HZI96<
MLYQ$EQ.L9D^@)YKRR\(M]1F_M#7-.TJUNO#UI'&;^S\X3QA7\Q(SO7Y@6!*C
M).Y:O6MQHGA_4M9MO%=U'-#-H]E%;R7D>Q[R%(F5U16YW%\DH.<L* .V/C#1
MWUV_T."_M?[2M+<3%))U522'.WKG*A,MQP&!J6+Q%86WA^SU/6-2TNU2=1^^
M2[4P,Q[(YQN%<2+FPM?%OBJV8I:RW6@6S6=O.0LKJL<^X $Y)4=<9QCFL[PC
M=6>F1>!+_69H;?3O[!EB@GN&"QQW!:,D;CPK% <9ZX(H ]2DUS2(;2*[EU2R
M2VF4O%,UP@1U R2IS@@#GBIK#4;+5;1+O3[R"[MGR%E@D#J<=>1Q7E6B6T%U
MKGAV00JVFS^(-3N;%2OR&+RG*LH_NE@6'X$5V/@I%CU'Q=&BA4&N.0H& ,P0
MD_J2: -RY\0:-9ZE'IMSJUC#?2XV6TEPBR-GIA2<\]JYR]\?0)\0+?PK9RZ6
MS>6LES-<7P0AB^SR44 [I>^TD=17*:I=:;;^&?'NDZ@\(UV\OK@VULY'GSEP
M/LQC7JP'R@$=-I]*WK")E^-3B<*TP\,PESCJ_GMDT =/K/BO1M U#3K'4KZ&
M":_D*1B255"@*S;FR1A<KMSZL!5/0_&FFZG^XN[RRM+][NXMX;1KA?,D$<KQ
M@A3@G.S/2LWQO<VEAXL\&7M_-#;VD=[<+)/.P5%+6[A06/ R>E<V;2WC^&U]
M<I"@G/B<R&0+\VX:D%!SZXXH ]-?6])CU9=*?4[-=1896T,ZB4C&?N9STYIF
MO:Y:>'=(EU&[$CHI5$BB7=)*[$*J*.[$D"O,4A\W5=2TR^\1V-C=/XB\^.R-
M@9+MSYRO"RL) 2I0*-P7 4$'@&NS^(-O<'1]/U""WDN%TO4[>^FAB7<[Q(Q#
M;1W(#;L?[- #'\8ZGICV\WB#PU)INGSRK%]J2[2<0LQPOFJ -H)(&06 )K<N
MO$FA6-R+>[UG3X)S)Y7ERW**V_ .W!.<X93C_:'K7&^,O$^B^+/"LV@:!J-O
MJ6HZKLAAAMFWM&"P+.X'W HR26QTK'U&^T"TG^)EOJ<ELMY<D1Q)-C?/_HD8
M54!Y9MQZ#D%AZB@#T%O%VCGQ)/X>2^MO[3BMQ-Y;S* 2=QV]<[@%W$8X4@]Z
M=:^([.'PY:ZKK&HZ5;1RCF:*\5K<MD\)(<;NG\ZXK394T_QG<6FIS11:A/X8
MM%1)6 >61?-W[<_>([XK'\&7%KIVE_#S4-6EB@TU--NXHYYV"QQ7#.I7+'@$
MH' S[B@#UEM<TA+*&\;5+);6<$Q3FX0)( "Q*MG!P 2<=@?2FQ:_HT^DOJL6
MJV+Z<F=UVMPIB7'7+9P*\QTZ"WO=7T>5(DDTNY\67=Q9?+\CQBU<[E[;3(KL
M#T/6FZW')!JVLO#<065G;^*;::XFFA\R&$&S7#NN5&/,*$G(P<'M0!ZC_;VC
M_P!D_P!K?VK9?V;_ ,_?GKY77'WLXZ\4]-8TR2TMKM-1M&MKIQ';RB92DSGH
MJG.&)P>!Z5Y1<Q&)[/58/$^GSV3Z\TMQ?C3R+.";[,45MOF88%@!O#8#MZBN
MK\,-HMEI33WFK66IQ7VLEK:=+/RX?M+8 $0)8'YE8AP<9)YH [FBBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;!;/ 4MG@<YQVKL*RM)T./2;_5[M)GD;4KH7+JPP$(C5,#_OC/XUJT %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%9>L^(-.T%(#>R2F2X<I!!!"\TLI R0J("QP.3QQ0!J
M451TC6+'7=/6^TZ;S8"S(<H4964X965@"I!Z@BI[V]M=-LIKV]GCM[:%2\DL
MC850.Y- $]%<WI_CO0-1OK>SCGN89;DXMC=6<T"7'&?D9U 8^P.:U=)U:VUF
MUEN+7?LBN);=MXP=\;E&_#*F@"_1110 45GZ1K-KK<%Q-:>9MM[J6U?>N/GC
M8JV/;(K0H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "L/Q%J=II'V2X^P"^U:1F@T^!
M%'FNS#+ ,?N+A06;H .>PK<K'UKPOHWB&6VEU2S,\EL&$+"5T*!L;OND==H_
M*@!GA?1I=$TR5;R:.2^O+F2[NFC&$\V0Y*H#SM P!W.,]ZQ_B4430],DN<?V
M='K%H]]N^Z(1(,EO]G=MS6U;>%-%M+6"VALSY5O="\B#S.^V8# ;+,3T[=*U
M+FV@O+:6VN88YH)5*21R*&5E/4$'J* *>K7&DQ16C:J;8H]S&MMYRALS$_)M
M'][/0CIUKRY-/6T\)WWB"&XNTU"#Q)((66X=41&U#8R; =I!#-G(.<^PQZ#I
M?@?PWH]['>66F(D\0(A9Y'D\H'KL#$A/^ XJ\?#VE-ILFGFS4VDMP;EX]S8,
MID\W=US]_F@#SI%U[4]7U+4[:TE^UVVMM#%>OJ?EQQPQRJOE>3T(9,^Y+Y]*
MU-$L[;5%N?$.I:O<V>HQ:W-")#=E$14G,:6^PG9AE &,9);/7%=7-X3T.XUC
M^U9;!6N_,64MO8(TB\*Y3.TL,##$9&!Z4U_".@R:U_:[:<AO/-$V[>VPR 8#
ME,[2X_O8S[T >9^'KZXN-=?1;_[18:'/KU^5N8WVB\N!,66 L#E%QD_[97;]
M?7+;3H;6_O;R-YC)=E#(KREE7:NT;5/"\=<=3S523PQHTNFW&G/8(;6XN&NI
M$W-S*7WEP<Y!W<\$8IUAHL5AK6JZFCYDU$Q%UP>/+3:,DDY/OQV^I .7FT^'
MQ)XS\2V^JW-TD.FP6Z6BQ7+PB$.C,THVD9;=QD]-E8'AYKKQ;K7A==8N[LQR
M^&Q=SQ1SO$)Y%E0*S;2/7=[\=J]"U;PIHNN7(N=0LO,F\ORF=)7C+IG.Q]I&
MY<D\-D<FKD>D:?#J$5_%:QI<Q6WV2-UX"PY!V =,9 [=J +M%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M(5LKSG%'BN7[!XZO)[[6[72;.ZTB.&*2ZM1,LV'D\R-<D?-\R':,ELCTKTH
M D@#GK00#U&: /(=?TJXO;+1](\/?:;K4--TE5U"?F"2:S* "V;@D22;<@'E
M<$]ZL7^IV/\ ;VEZO9ZS::+HEQH@@M);JT5XP5D.^'!("MC8-O4[2.U>KTA
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M2*:]\-J+5'.#,5$Y8+ZX')Q7HNGV%MI>G6UA9Q"*VMHUBB0?PJHP*LX&<XH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M!P-Q4JPY#*P(*D>H(-9D'@C08+6^@-K-.+Z V]S)<W4LTCQ'^#>[%@.>@(H
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M#\=1@D=: +6L>)VTS4_[/M=(O=2N$MOM4RVI0&.+<5! 9@6)*MA1D\?2G_\
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MD36D<DM^)6EE=>53YV 3('+$'IQ0!W.@ZQ)KEA]M.G7-G Y!@^T%=TT9 (<
M$[0<]#@^U2ZQJ;:38?:$L;J]D+K''!:IN=F8X'4@*/5B0 *I/>W&BV.@6GV0
M3/<2Q6<O[T+Y7[MB6'!W8V=!V.>U5?&^GZCJ.E6<=A#-<QQWL<EY:PSB%[B
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MSIZ-$ 0LHWA@<D< QL#C/-:]>)Z5HEC_ ,(CX?CC1XOM/BJ2.9HY&#,JR7(
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M6MY'%VLC6-Q<&%;U55LQ;AD_[70CY.>,T =!:VL%C9PVEK$L5O BQQ1J,!%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJLC+)#(7!?!8;8N?O?+GGWJ_I'C[P_K-U/;0WT:2QWALXPYQYKXR-OUPV/\
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M=)="::96(0[0=J#;[$[N#Q7:27TFI^ WOY8&MY+G3#,\+@@QEHLE2#SD$XH
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M\[2&/W&^9LD>O8@&KB>/O"[OM75XR3'YJ?NW_>+D#Y./G.2!A<G)QBISXRT
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M.V&QO!. %'0@C- %%O -HT.M+]MG634M074DE10&MIDVE2N<@X*CKUY%-N?
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M&\ORV1G$:DCGY?F.=H//6O4:* .+\5Z3/JWC?PTD=U?V<:6]Z7N+,A64GR<
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M8622"\GL#'<0D,1Y1.U?,P/FZ9'?K70_$"*2X^'?B&*&-Y)'L)@J(I+,2IX
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M&=J@X.TC)4D$8ZD$<UZ/10 4444 %%%% !1110 4444 %%%% !1110 4444
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M8R>QH YW2O$?B+Q#?Z/IR:C'9/+:WPO)H;=6)DMYUB#H&R!GK@Y&">.E5O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 44R:5(())I#A(U+,?8#)KE;;XB:5>P13VVFZ_
M-!,H:.5-(N&1E/0@A<$>] '6T45S.N>.=+\.SSIJ%KJJQPE ]Q'ITKPY;&,2
M!=IY8#KUXZT =-169HVN0:VDKPVFH6XB(!%[9R6Y.?0.!G\*TZ "BBB@ HHK
M*\1>(+/PSH[ZE?+,\2ND:QPIN>1V8*JJ..23ZT :M%5[2Z-S8QW4MO-:;EW-
M%<;0\?\ O8)'Y$US1^)'A_:9_P#B8'3@VTZD+&4VO7&?,VXVYXW=/>@#K:*1
M'61%=&#*PR&!R"/6H)KVVM[JVMI9E2:Y9EA0]7*J6./H 30!8HJI8WK7K70:
MRNK;R)VA!G4#S0,?.F"<J<\$X/'2K= !114-W<K9V<UR\<LBQ(7*0QEW8#LJ
MCDGV% $U%<>/B1H[7K68T_7C=)&)6A&D7&\(20&*[<X)!&?:MW3-<MM5O=0M
M8(YTDL7C27S4VY+QK(,#.>C#.0.<T :=%5/MK?VO]@^Q76WR/.^U;1Y.=V-F
M<YW]\8QCO5N@ HK%UGQ5INAW4-G/]IN+Z92\=I9V[SRE!P6VJ#A?<X%2:)XC
MTWQ D_V*2436S!+BWGB:*6%B,@,C $9['H: -:BBLU=:@G@TZXLH+B^MKYAL
MGME!1%(R';)!"_3/TH TJ*** "BBB@ HHHH ***S]$UBWU[2(-3M4E2";=M6
M4 ,-K%3G!/<'O0!H4444 %%%% !1110 4546]9M5>Q^Q70581+]J*CR6).-@
M.<[N_3&.]6Z "BBL^VUBWNM<O])1)1<64<,LK,!M(DW;<'.<_(<\#M0!H444
M4 %%9-_XAM-.\1:1HDT<QN=5$Y@9%!1?*4,VXYR.#Q@'\*UJ "BBB@ HK.?5
MXH)=2^UV]Q:VUA&)7NYE BD7:68H023M YR!^-(FMVLNO+I""0SM9B]#X&PQ
MEMO7.<Y]J -*BJEU>M;7EI;BRNIA<,RF6)04AP,Y<D@@'H, \U;H **KWE[;
M:?;_ &B[F6&+>B;FZ;F8*H_%B!^-5[/6+>]U?4M,C243Z>8A*S ;3O7<-O//
M'7.* -"BBF331V\$DTSA(HU+NQZ* ,DT /HJ.WGBNK:*X@</#*@=''1E(R#^
M524 %%%% !1110 457MKVVO'N$MYED:VE,,P7^!\!MI]\,/SJQ0 4457>]MH
M[^&Q>91=31O+'%W95*AC^!=?SH L454O;UK.2U5;*ZN?/F$1:!01$"#\[Y(P
MHQU&3STJW0 45!>WMMIUC/>WDRPVT"&261NBJ.2:K)K%M)X@FT55E^TQ6J7;
M-@;"CLR@ YSG*'MZ4 :%%%!.!F@ HK(\-^)M*\6:4-2T>Y\^WWF,DJ596'8@
M\C@@_0BK6D:K::YI5OJ5B[/:W"[HV92I(R1T/TH NT57N;VVLS +B98S/*(8
M@W\;D$A1[\'\J9;7K7%]>6QLKJ$6Q4":50(YLC.4()) Z'('- %NBBB@ HHK
M#OO%%K9>)K3P^EI>75_<1?:"+=%*PQ;]GF.688&?3)XZ4 ;E%4-8UK3] L#>
MZE<"&'<$7"EF=ST55 )9CZ 9K-TSQGI>I:G'IK17]C>S*7AAO[.2W,P')V;A
MAL=QU]J .AHHHH **9-+'!#)-*X2.-2SL>@ &2:2WN(KNVBN8'$D,R"2-QT9
M2,@_E0!)1110 445GZ9K%OJL^HQ0)*K:?=&TEW@ %PB/E<$\8<=<=Z -"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9&<8YVXK>7POHBZR=7738!?ES)YN/XR,%\=-V.-V,^]6]3TJQUFS-IJ-LEQ
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M5VL0JY&,< \YKU@Z#I3:==Z>UC";2\=Y+B$C*R,YRQ/N3S5-/!GAR-2JZ3
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MR;GSDDCD+ ')52""A!&/QJKXXU*[AM+#1=,G>'4]8N5MHI8S\T,8^:60?[J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MOM0L],M'N[^[@M;9/O2SR!$7ZD\4^VN8+RVBN;::.:"50\<L;!E=3R"".HH
MEHJ$7=N;PV8GC^U",2F'<-X0D@-CKC((S[4V:_L[:[MK2>ZACN+HL((G<!I2
MHRVT=3@<G% %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF;4V"3?Y@7?C<4#_ #;<_CCBK4_@VTGT'5M):YF$6I7CW<CC&Y&9PY XZ9%
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MMNXKNSP3QGV% &(_C359=:NIK::^D6WU8V0TV+29'B>%91&[F<(0'^\_WL#
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M0YPA".H8[CP, Y/ S5#5?B'HVGZ(-3A^T7 ^V1V;0_9Y4DC=F4$.I3<I"MN
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M(A*Q@PX&XC@9/ S5.V\,W&KV'BF+$EG?+KTEYIURZ$;)%CCV.,]5)!4^H)%
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M?.H7%L-V8Y?1Y S'_8ROO7H6CZFNL:1;7ZV]Q;><FYH+B,I)&W=6![@_GVH
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MQFNZN;.VO8A%=6\,\8.X)*@8 ^N#0!0@\3Z!<SI!!KFF2S2,%2..[C9F)Z
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MC%L 9R\JCR@>A;)^7/O7F%]:W=G\0/%'BC3(WDO-+DM?/MTZW-JT"F1,=V&
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MJ=I/A6+3]4_M6\U*_P!4U$1&%)[QUQ$A(+!$155<D#)QG@<UF7^K^*3XHL]
MT^31TG.F?;+B:XMY64N'"$( X(&3GG-2ZCKFOZ)86=I=1Z=?Z[J5W]GLH[='
MAA V[B[[F8X4*Q..O ]Z (S\/8(K>:PLM>UFQTB9F+:=;RQB-0Q)948H713D
M\!N_&*N:MX(L-1BT:.UN[S2_[&S]C:Q* H"FS'SJP/R\53EUOQ+X=O\ 3_\
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MR1^60Y)= Q0NJDDY ;N<8J[J?A"WO-0AU*PO[S2+^* 6PGLBGSQ Y",KJRL
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MN3G!KT>POOMR3M]EN;?R9WAQ<1["^TXWKZJ>H/<5;HH **** "BBB@ HHHH
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M3;,+&W%LY=C;NC122$$ JOE_.3C 9 ,FO5;*S@T^PM[*V0);V\2Q1J/X548
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MSDGGC\J65X%9I$_NL2,D>QI[68MK6X&F0VMM<2*2K&+Y"^W"E@N"0, =>@H
M\Y\+7-UXEUO1=,U'+2^%8Y#?Y'#W8+0Q'\4623_@0K5^(G_(<\#_ /8=C_\
M0'KH?#>@OHL-Y-=7*W>I7]P;F[N%CV!FP%"JN3A54  9/3/>M6:UM[EXGGMX
MI6A??$70,4;U&>A]Q0!Y%?:58?\ "&>+-5-K$VH1>()6BN64&2(K=+C:W51R
M>!ZGU-:JQ^&I;[Q9<>*3"M[#JR!)6!^T1QA8C!Y6WYP">FWJ2WO7HQL+-H)(
M&M(##*YDDC,8VNQ.2Q'<YYS4<VDZ;<WT5]/I]K+>0_ZJX>%6D3Z,1D4 >4ZK
M#I<GA3QU=WZ0'Q!%J5P()7 ^T(X(^RA#]X<>7MQZGWIVMZ3:7EE\3KV^M(9;
MV"%&CD=0QB<6<;90_P )W '(]!Z"O4Y='TR?4(]0FTZTDO8_N7#P*9%^C$9%
M3-8VCK<*]K PN>)P8P?-XV_-_>XXY[4 >6ZYIZZ-J"MH5NMO>3>%+YBT"X>6
M1?**L2.6?+$Y/.36CX*TY(-?TZYM;K0(HFTH@VVEJP:>/=&4D?/7:<@$\_.U
M>A_9H/.2;R(_-C0HC[!N53C(![#@<>PJ"RTG3M->5['3[6U:8[I6@A5"Y]6P
M.?QH XS68=-A^+VF7=W;6[.-&N'1G12S2++%MVD]6 SCOS7.>&GLU\2>%+A(
M=%M+?4+&YD:"U+/+Y3H'"W$K']X<CN.JMUP:]9N=.L;V:":ZL[>>6W;?"\L2
MLT3>JDC@\#D56'AW1%B:(:/IXC:0RLHMDP7((+$8ZX)&?>@#S;P<86\5V"79
MF.@+Y_\ PBQF^ZW)WY[Y"Y\O/_+/-='\0[*WU&]\(VEU&)()=:59(VZ.OD2Y
M4^H/0CN.*[%K*T>."-[6%HX&5H5,8(C*\*5'8CMCI3Y;>"=HFFACD:)M\9=0
M2C8(R,]#@D9]Z /'O'RV*0^*!9V.CV9TNT@@66=6:?(C\R,6Z@@1!=W! Z@D
MCBGZ[';1:K\1KFRCMDOFTRUDBE10)-K1R>:RD<\KDDCTKU:;2--N;O[7/I]I
M+<^68O.DA5GV'@KN(S@Y/'O2)H^F17$-Q'IUHD\,7DQ2+ H:./&-BG&0N.PX
MH \Q?1+5H]2CDU;PWIUK<:=!&T>G1MY1_?+Y+RKG!4_,AY&0QYQ5]&M/^$*\
M<6%QINFV<L%K(;IM-<FVE+0$AE4@;&P!D>P.3FN]M]$TFSMI[:VTNRA@N,^=
M%';HJR?[P P?QK,U?PG:WVCQ:)91VVGZ5).KWD%O"$\Z,')0;< ;B "?3([T
M 7_#;3/X6TA[G/GM90F3/7=L&?UK3H    & .@%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !7/^+/$?_"/6MD(S:+<7UR+:)[R7RX8_E9RSMZ!5/'<D#O705@^*-"FUF&P
MFM&MQ>:?<BYA6Y0M%)\C(R,!S@JYY[$ T <_;^/;S4(K:PL(=.N-8FU%[#?'
M.7M<)%YQE##DC81\O]XXSQ4D7C;5(KFZM;[3[9)[?6;73&\N1BI654)<$C_:
MR!^=37'AC6I(M-U"*?2XM8L+Q[B.*.%DMS&\9C:,D?,>#G?CKVQ6%8Z%JNKW
MOBF)KNU&K6VMV=\CE&\DND,3A"/O;<?+GKW]J .JO?$UY#J7B"RMK."1]-M;
M:>(RSB)6,ID!WL>%50F?IGVKB/&7BJ37?A?XQMGGT^:>P6 ?:=,G\R&17=2,
M'J",$$9_G6_>>"M;U.36;R]O-/:ZO_L+I J.8%-M(S^6V>61L@$^YXZ"J^K^
M M<UG2_$MM->Z=&^MV]NN(T8+;O$WW1ZKM[]<YX X !UGB*[O+#P9J-[8&,7
M5O9/+&9,X&U<D\=\ X]\5SVE>(_$-Q9Z#I4,5A-JUUIHOI[B9W\M(AM520!D
MNQ;V P:ZW5-..I:!>:9YFPW-J]OOQG;N4KG'XURMEX8\1Z?_ &1?P3Z6VIV-
MB=-EC;S/)FA&TJV<;E8%<]"/F(]Z -_PSK<FNZ5)-/;K;WEO<2VES$K[E66-
MBIVG RIP"..AKSF76/$=]H8N+X6T\L/BR.WMXXI&7)2X*["2.$X&#R<9R*]'
M\,:))H6ER0W$ZSWES<RW=S*B[5:61BQVCLHR /85SD'@K58S-;/=V1LQKZZQ
M"P#>9@RF1D8=,]@10 MSXXU#1H]:M]7M; 7UBUJ(6BG9(9/M#%$W,PRH4@[C
MZ#-:OA7Q.VMWFHZ?/+IT]S9"-S-IT_F0R)(&QCN""C CZ'O536O!<VJZCK-X
MMU"C7:636V]"X26VD=QO'=26 (],UL:!8:C:?:9=2738GE90D-A$51% [L0"
MQ))[#% ',ZY\1?[*U+5 C:4+/29$CN(KB[V7,^55G,2?[*N,9^\01Q5O4_&E
MYIFIW6BMIRR:O-*@TF-6/EW<;?QD_P .S#%_0 $?>%.N?"NIQ:WJ$^FMI7V7
M4ITN)7N[<R2P,%5'V#HP(0$ XP2>M,U/P5>:I?WFLR:@D>M12J=)E0'R[2-.
MB$=]^6W^H( Z"@":Z\1:_-JFIVVB:99WB:3Y:7*RS&-[B1D#E(N,#"LO+'J<
M<8S6=J?Q'^PZE?$'2TL=/N4MIX)[L+=R$[=[(G3"[^G\6UNG%7KGP]XCM]3U
M.YT74+"U75Q&]RTL;.]M*J!&>+LV548#8Y&>>E)_PBFIVFKWC6,FEO97UTMU
M++=V^^>(X42*O&U@VW()Q@L>#Q0 ^P\5ZCJ'B.\LX8-.:WM+J2WFMOM!%XBJ
M.)=A&"K'&!Z$'/:G^#O$^H^)42ZECTPV<L/F8M+DO+:OD?NIE('S8)Y'0J1C
MI45[X8UC4O$%K=74VF"*SNS<6][' 1=A/FQ%_=Q\V"<\@<C)S4,'A[7;74Y]
M>N3I2ZC!ITT"265NX:\D;:5>5>^"G"C/WC@T =I.0MO*Q&0$)QZ\5XGJ=[=Z
MW\// BZ?8V5GINHZI%$]EYTFTG=)A&(Y,9VY/?.*]DM?M-QH\/VM52[DMU\Y
M0.%<K\P_/-<59?#Z]M?"7A#1VO8&ET/48[R60 [9%4N<+[_..OI0!U5U+<Z+
MX6WVUI;-<6MNJK#YWE0J0 /OMT0=<GG ]:Y,?$2Y32=6E6/3-2NM/N;2(-IU
MSOAF6>14 !_A89;@^@]:ZGQ7HLVO^'Y;"WDB24RPS*)U+1N8Y%?8X'56VX/U
MKF9_!.M7L^HRW-WIZ_;WL962%&"PM;S!]J^H*]S@[NP'0 EO_&&OZ.=9@O=,
MLIKO3[*+446UD<J\!=ED'S '>H1B.QXZ5N-XC^T>)M*TO3TCGANK-[Z>?)_=
MP\",CU+,?R4U'?65MIWB.]\2ZG>6L&FMID=G+Y[!0N)';+$\8.\#ZU@?#'19
M;+0KW4O,D<7+&#36G0AELHBP@!'7G+-[AA0!WEU<QV=G-=3'$4,;2.1V4#)_
ME7&V7B[6S'H=]J&G64.G:XZQVPCE9I8&="\7F9&#D#!QC!/>NCTY+K5?"MM'
MK,02ZNK-5NXU4KAF3Y@ >1U/%<[I_A/6\:#8:I>V4FFZ'(LD#0(PFN"B%(]X
M/"X!R<9R1VH R/AI;:A=>)_%6JZE'9R7":G/:-.LCM(FWRR(TSP(Q^=+XJU3
M79-9\8Z<9+8:7;^'6E"!FWC<DV&'&-V5 /; '>NL\*^'IM DUUIIXY?[2U6:
M_38#\BN% 4Y[_+69KWA/5-0US5[JRN;-;75=(.G3+,&WQL!)M9<<$9D&<^E
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MW+:;)I]M%:!RB!R"SL6Y))5>,< =\UK^%-'E\/\ A32](FE266SMTA9T!PQ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M,5DPP_VB<<T >D6^J:?>7,MM;7UM//#_ *R**969/J <C\:1=7TUV(74;1B
M&($RG +;0>O=N![\5YOIK:)(_P /$\/&T-ZAS,+?;O6#[.XE\S'(^?9G=_%[
MUE6NE6*_ I9A;1B>[OX1/*%^>0?V@J@%NN   /3% 'K)U[1Q;O<'5K 0I)Y3
MR?:4VJ_]TG. ?:IKK4K"Q2-[N]MK=)3MC::54#GT&3S7"MH.D'XCZ[$=-M?*
M&A0'R_*7;DO,I.,8SA0,^@KE-*,LL.@F\O=%@MG\*6RQMK,!E1AEO-"?.N#C
MRL]>-OI0![-<:C8VD@CN;RWA<[<+)*JD[C@=3W/ ]36;XF\0_P#".VMG(EA-
M?37EVEI#!"ZJ2[!B.6( 'R^M<5X>T>UD\>:1%>/'J?V3PM;F&>6(@.1*P63:
MW(;'<\C)]:UOB@8Q8>'C-J#:?'_;D&Z[5U4PC9)\V7!48]QB@#=TS6]5N[HI
MJ'AJZTRW5"QN)[J!U&.V$<G\:OC6M*+2J-3LBT48ED G7*(>0QYX'(Y]ZY&"
MXTQ;+4T@\=R:Y+)8S*MK+=VTF/E)+ 1(K9 'TP36%I>AZ6?^%79L+<^;9N\N
M8Q^\/V8/EO[WS -SW - 'IRZGI[6L=TM];&WESY<HF78^ 2<'.#P"?P-8OB?
MQA:Z!X.N?$5FL.IP0O&H$,XVOND5/O@$<;L_A7GDT>F6\ME#?)#'IL7C:X!1
MP!&@\F0@$= NXY/;K5;QE]E/A?XAOI?DG3#?:=L-OCRC-NB\S;CC/W,X[T >
MS7>J:?82Q17E];6\DIQ&DTRH7/L">:G2>&662..6-Y(B!(JL"4)&0".W'-><
M7KZ'%XD\<_\ "2&S#-;P^1]KVY:V\CI'NZCS/,Z=_P *R/MNI^"M-T;6)(I7
MN]:T.*QEC8'<=02,&#=[L"RG_=% 'JLVL:9;PI--J-I'$[F-'>=0K,#@J"3R
M<]JDNM1L;$Q"[O+>W,S;8Q-*J;SZ#)Y/TKRNYT0>']=T_29+S1(;2#01&LFL
M0&2.5_,8W!7YU 8Y0MUX(JD+,P7/V6^UK0VM/^$=MHX;K5[1V$T'[S>8P9%*
MG[FX')^Y0![567<^(M+M->M=%GNXTOKJ-Y(XRP'"E1@\]26&!WP?2H] N((-
M.TW2)-06ZOXM/BD9B"KR)@+YA4\C)!ZUSNL"PA^+^@RW8MD:73+A(GE"C=()
M8MH!/5NN.] &YX;\5V7B'3+&<R6]O>749D%D9U:0 $C.."1QUQ6JNHV3WSV*
M7ENUXB[FMQ*ID4>I7.0*\HT;3K.V\">!;R&VB2Z?682TX4;SN>0'+=>G'T '
M:D\-VLD]SI0NM7T2WOXM:GD>%;5S?/*'D\Q&;S.C)GDKC;M]J /3=?UZT\.Z
M<+NZ6:5I)5A@@@7=)/*WW40=R?Z&LVR\5W9U6UT_6/#U]I3WA(MI7DCFC=@"
MQ1F1CM; )&>#@\U2\>O_ &?<^'-=G1FT_3-1\R[*J3Y2/$\8D('92P)],UI-
MXRT6XU"TTW3+Z+4;R[#%%LG641*%)\R0@X5<X&3U)& : -:/5-/EOGL8[ZV>
M\09>W693(OU7.12?VMIOVF.V_M"T^T2%@D7G+N8J2" ,Y.""#]*\GTQM,/@_
MP9#:&W_X2-=5M_/5<?:1*)#]I+_Q?=\S=GM^%-N=(T^;P3J-Q):1-/)XM(:4
MJ-^#?A" W4#:2/Q/K0!ZU#JVG7,#SP:A:RPHXC>1)E95;.-I(. <D#'O3K;4
MK"\25[6]MIUA.)3%*K!#Z-@\?C7DOCBUL[*?QK!' D%HUII#R1PIM!_TE@2
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MV.QO);?[--<V\8<PRW B'/3<Q!V@X/)':O)9Y]*BUC6KRP>!-,A\3Z9(\L9
MB4;4#MGH%W$Y/3.:L>+;^UU"W^)DMG/'/$NDV:>9&VY21YV<$<''3CN".U '
MJAU2SACB^UW=K;RR*AV-.O5N!@G&<G(![U(FHV4E\]E'>6[W<8W/ LJF11ZE
M<Y%<!I>G6E]\2M/>[MXYS!X8MGB$BA@K>:PW 'N!G![9/K6+X7M99Y=$^T:O
MHD&HPZI.[P):O]N>;,GFH[>8>""V25 QM]J /1-7\566FS6MO!);W=Q+?0V<
ML*3KOA\QMNY@,GCT.,U<UO7M.\/6D=SJ5PL,<DT<"9(!+.P4=>PSD^@!->26
M$FB'PGX&CS;'7%UNW^TJN//67S3YID_B'S=<]]OM7;_$]+;_ (1[3I;I8O)B
MU>R9WE VHOG*&))Z#'6@#J9=7TR&6"*74;2.2X ,*-.H,H/0J,\_A5VO)+N3
MP^+#X@#5FL3=2$FUWE2SVYMD\CRO4;MVW;_%[UZ9H0NE\/Z:+[=]K%K$)]W7
M?L&[/OG- %^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ J*XMK>[A,-S!%-$2"4E0,I_
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MX<RSHLBJ64@X4@-W!R0>E>AT 5FTZQ>2"1K.W9X !"QB4F,#IM../PJS110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %8WBG1)-?T&2RM[D6MTLD<]O<%=WE2QN'5L
M=^5_6MFJ][?6FFVCW=]=0VMM']^6>0(B_4GB@#CG^'BBY\+F*]"6^D0QQ7,9
M3)NO+*O&<YX(D4MWZFGW_@)[Z;QJS7ZHOB.&&),1Y,!CB*9//S9)SVKIQKFD
M&QAOAJEE]DFSY4_VA=CX!)VMG!P%8_0'TJNOBKPZ\=M(NO:84NG*6["[3$K
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M7J>%STK776M*?56TI-2LVU%1N:T$ZF4#KG9G/2@"KXJT/_A)/"VI:,)_(-Y
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M,F   2_7[G.-QQR#0!'X;T"YTJ\U/4+V2S^U:@\;/'90F.)=@(S@DDL<\GV
M[5B7G@C6)5OK>UU6SBM)=4758MULQD:42+)LD.[!0%<< '[OISU^FZQIFLP-
M/I>H6M[$K;6>VF60 ^A*D\UDS>,-/L?$6I:;JES:6$%I%;NEQ<7"QB1I?,^7
MYL#CR_UH IW'@R:?POKND&]C#ZI>R78D\LXCW.K8QGG[M=?5#4-<TG28(I]1
MU2RLX9O]6]Q.L:O]"3S2W6MZ58P)/=ZG9P0O&94DEG559!C+ D\CYEY]QZT
M7J*SY->TB+2EU635;)-.?[MVUPHB/T?.*<NM:4UC#?+J=F;.8[8IQ.OEN>>
MV<$\'\C0!>HJ&TN[:_M8[JSN(KBWE&Z.6)PRL/4$<&IJ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$&VO;J*&XN[2)K:%VP\X-ML^1>K?,".*[GQ'H,/B'0;_ $QW$+7<#0&<(&9
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M<$0D2+G#$G:H)RR^U>MA5&<*!DY.!UIA@B;9NB0[#E,J/E/MZ4 <!X;TV/\
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MMU\0_%KSV\<K#2K2,%U!PK>?N'XX'Y5VT<4<*;(HU1?[JC IVU<DX&3U..M
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MD\3OOP4W#!##(.?7@UN>%] 'AK1CIXNY+O\ TB:<S2* Q,DC/SCC/S=>_H*
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M-Q$0"M\BJ% )Y))XZ5K:?XEUW7_%5K9V36UE8-I=IJ<WG0%Y1YC-NB'S#!(
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M,"3R..,CO6MH]CJ-FD[:GJGV^>5PP*0"&., 8VJN6/N<L>30!PMQ?ZS;:O\
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M53Q7/KOGDM+8QV?D[> $=WW9SWWXQCM6%8> 8[&?PK*-1=_^$?2Y11Y6//\
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M9)'0M)(%^51L))P>2 ,YI(?%^J^1JEK+H/FZW87$,'V:TG+Q2>: 4?S"H*H
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M.\3S*CL ?+3&YO8#(R?>O.ET:#Q?:>(7M/$$VJW<MC#%'<BU6&))8V:2+#
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M\ZYN[@KYDK8 'W0        *UJ* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#-T+1H=!TI;""222-999=TF,YDD:0CCW8BM*BB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH AAM((+BXGC3$MPP:5LD[B%"CKTX'0>
M_J:FHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *QM?T.36#836U\UE>6%QY\$PC$@!*,C
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MJT$3E06).-S,<>] '74444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&XFPTIWR$ %N?8#\JS+GP?<W>J-J,^FZ*]PTBRN/-G$<CKC:S1@[&88')!/
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M$ $,0#G&,@YQ4\OBR[M+/-[H%U#?R7$=M;6PE1UN'<$C;(#C "L6STVGKQD
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M 'C$=N!S6YX9T_6(_$FOZOJEI%:IJ MO(A242%!&K*0Q'&>0>..<<XS7544
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MDET9'MDWDPQY(S(0IVEO]GO7344 %%%% !1110 4444 %%%% !1110 4444
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M-E)X8<\@]&7CCG9DO/%:^([/P]_:>G^?+82WDUX+(X0B55"HF_GA@.3VS[4
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MCK\N"WRLK Y(R",<#-;VI>([WP[>MX?@U32[)["S6XW#3'V7$CL^V-41L1J
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ML])N+JRDN;FX:U>=2R2>6%1 1@$AB23P !WS7;>&]7EU[PI::E/"(IIHCYB
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MO]&^S:T%N]1:^,O]G'*EK@3;<9YZ8S^-=OJFK6&BV1N]1N4@@W! S9)9CT4
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MNVNHM-=$2VMHW$J,R9"2$Y&3U!   ZT 8\>C6(U?Q%>266MR0ZS T/V<V!Q
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ML5Z!%+'/"DL3J\;J&1U.0P/((-/H \BTG=I*^!+N\@GBMH+S4XY&\ECY9=I
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M Q\UC. '# 8PN.23QM^E>S5GZ1H]OHT5U';O(PN;N6[?S"#AY&+,!@#C)XH
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M>>R(ZO#\T;88%N ,9W>W'K%GH]O9:QJ6IQO(9M0\KS58C:/+7:-O'IUZUH4
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MBR+XH$KJ(R"%^VR?,1Z;<<^E>JU6.H68U(:<;J$7K1&86^\;S'G&[;UQGC-
M'E,U_=7&HZ?-=3WR26OB R76GPV"I;VD?F.JR,PCW,S J<[CG>3C J*XD,7A
M36[1X+D7%EXI%Y/&(')6$W@<../F&WGC/%>O2W=M#<P6TL\:3W&X0QLP#2;1
MDX'? YJ:@#R+5(H[K4_$D%WJVL06FMO%+;6]G8))]LB>"-!M9XR58%2",KMX
M/&<UUOA:S:#QSXSG>)P99[15E9<>8%MUZ'OSG\:["B@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH *XWXA+</#X<2TE2*=M;@"2.NX(=LG..^.N*[*LW5]&AUAM/:65T
M^Q7B7:;,?,RA@ ?;YJ .%O\ Q3K6@_VUI<^HO>307MG!;WILP\B).,L?+C7#
ME0K8 ')(SFHKGQ;XAM]'NEM+BYEDCU.R@M;W4--:V,R3.%961D4'!R,J!P1W
MYKKK_P '6FH76J7+75Q%/?/;2K)'M!MY(.4=,@\YZ@Y!Z4R;PB][8"#4M9O;
MV;[=!>F5PJ@&)E945 -JK\O..3DG- '/:QKFL:=K(T%M=OQ+:V"W+WEMHYN6
MGDDDD"JZQQL$0!.P!.>O!JQINL>(?%FH"UBO)-!:UTRUN;E!:J\AN)@YVD2
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M1%*T,D'F9>(A<,">, 9 'K4]WXBU_2Y-7T0ZFMU>+J%C:6E]-;H&C%SC)95
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MJ1KY3,#\H0#:0<G/J?IC4T;1;S39WFO=<OM28QK$@G"(J*.^U  6/=CSQVH
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ML[U0(U:8/M(C(0?>W#E.5]0#=TOXB:-J-EJ=W+]HMH;&[-L3);2YD.[:NT;
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MA,DUN\:L3<<H=P&#CG!YQ0!V5SK6G6B6#37*@:A*L-KM4MYK,"P P#Q@$Y/
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M'+')''<\4 >HT5Y2_B;7=/BUGR[[5)8=+2RU!CJ5I'%,T+2NLZ851\NQ"0<
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MPY!! -4='\-VFCW5Q>"XO+R]N$6.2YO)O,?8N=J#H  23P.2><ULT4 %%%%
M!1110 4444 %%%% &3=^'K2_URUU2ZEN9FM#N@MVE_<I)@CS-G=L$\G..U:U
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !69KFAV^O6<4,TLT$L$RW%O<0,!)#(O1ER".A(P0002*T
MZ* .7;P/93Z/K-C>7U[=3:P@2\O)&02LH7:H4*H50!G "]SUS71VMNEI:0VT
M9)2&-8U+=2 ,<U+10!R%M\/K*PTZQMM/U/4;26QGFGAN4:-I/WQ)=2&0J0<^
MF1@<TVY^&^DW?AV?0I;S4#9RW;7:_O5WQLV=X#;<D-N?.<GYCS78T4 84GA/
M3I/%UMXD)F6[M[?[.D2L!%@;@&(QG< [@'/1C5O6-$MM:%A]I>5/L5Y'>1^6
M0,NF< Y!XYK2HH Y_4_"L6HZW_:L6I7]C-);BUN%M60+/$&+!6W*2""S?,I!
MY/-067@;3+"?PY+%/=$Z!#+#:AF7#K(H4[_EY.!QC%=/10!S6G^#8-.E1(]5
MU-M/A$@M[ S*L4(<$$ JH<@!CM#,=O;H,3:1X7&F:BE]<:MJ&I30P-;6YO&C
M/DQL5+ ;57<247+-D_*/>M^B@# U7PNFH:J=3M-4O],O'@%M-)9F/][&"2 P
M=6&02V&&",GFF+X+TJ)_#Q@\Z%-"+FU16!#;D*'?D$GJ3U'-=%10!E^(M"MO
M$V@76CW<LT4%R%#/"0'&&##&01U [5D#P+!<7,$NKZUJ^L1P2"6.VO)4$.\<
MABL:*&P>1NR*ZNB@#G;_ ,(Q7FJ7-[!JNI6*WFS[9!:2*JW!08!)*EE.T!24
M*D@"H[[P/IM_>ZY=RSW:RZQ%!'-L=1Y?E<HR<<$'!YR..E=-10!S%OX*MDN[
MZZNM3O[V74+,V=YYYCQ,GS8.%0!2 S !<#GD$\U6D^&^C3>&=.T&2>]:WL;D
MW*RF1?-E9BY<.=O(;>P/ XKL** .8U?P19ZQ>:A++J%_#;ZE"L5[:P.@2;:I
M5225+ @'L0#@9!YS=T?PU;Z1?W5\MU<W-Q=6\%O*\Y3YA$&"G"J!D[CGM]*V
MJ* .=T?PE'HMS 8=5U*2RM0RVMC)(ODPANWRJ&8 < ,6QVK7TRQ.FZ=#:&[N
M;LQ@CS[I]\C\D_,<#/6K=% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% #9)%BB>1L[44L<>@JAI6M6FL:#;ZS:[_L
MEQ#YZ;UPVW&>1ZU:OO\ CPN?^N3?R->8>"](\32_#+2IK;Q4EO;-8 I;G34?
M:NT_+N+9/UH ](T;5K;7=&M-5LM_V:ZC$L>]<-M/J*J:_P")+3PZMF+BWO+B
M2\F,,$5I#YCLP4L>,^BFLGX:SPI\./#,+RHLLEBFQ"P#-@<X'?%5O'POFUGP
M>-->W2\_M-_+:Y1FC!^SRYR%()XSWH Z'1M>&L22H-*U2R\L YO;8Q!L^G/-
M:X.>E>?>+&\26_A2==;O-/%M-=VD,LFGQR0E(7G59=Q9SP5..,<$UA^++"ST
M&;Q3IVBP1VEE)X7FN+BWMQMC64,51]HX#%=_/?;[4 >B>)?$EMX9T^&ZG@GN
M7N+F.T@@MPI>25SA5&X@#ZDUIVTTD]K#+- ]O*Z!FAD92R''*DJ2"1[$BO*/
M&'A31+7P_P"#]NGPO)<:[8BXED&YYO,P)"Q/7=M&?I4>J:-=7FJ>)UM;71;8
MZ9)#!8WMY>O VFQB&-HS&!&P5=Q8YW#<<@\"@#U"75A:R:B][:S6UE8Q"8WD
MA4QR+M+-M );Y<<Y ]LU>BE2>%)HVW1R*&4^H/(KQWQ%"EUJ?Q8CND60)H]K
M(%/(5UA=@1]" ?PKI?#UO::;XUTRVM8XK>V_X1L.L:85<F8%CCZMD_6@#T"C
M(KQ?2+*TU^/P%:W>9[&XEU9I(]QVS*)&8 XZC(!QWQZ58N-*U"_U/7KJ&#1H
M+BQU2.&VU&\OGBELT01^6B*(R C CC<-V\YH ]@KG=4\8VFF:V^D+IVJ7MVD
M"3N+*V\T*C%@,G/JIK3L[+3K?5-1N;4(+RY:,W9$A8DJ@"9&?E^7'0#-<9=1
MZX_Q8U3^Q+C3X7&D6OF?;8'D!'F38QM=<=_6@#K-#\16/B".X-J)XIK:3R[B
MVN86BEA8C(#*?4'(/0UK9R,BO&V:^N?"FJ:A=31/K>H:S:V6L6[$V\,*I(J"
M+(W$1L"/GY)63\*GN]-NM+BDTZZ72[+2;S6+&*XT_3;MG2!&#;PV438LA$7
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M- &_>^%]!U&XM[B\T>RGEMU"1-)"I*J.0O3H#T'04[_A&]$_MG^U_P"RK/\
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M(>%W'<>G'7CMQ?V;,RB[@+(GF,!(,JG]X^WO4L,T5Q$LL,B2QL,JZ,&!^A%
M'/>%/#]WH=YXBFNGA9=2U22\A\MB2$95 #9 P?E/3-8/BCP3J>M:CKQAMM*F
MCU6T6"*\NR3+9X0J51=AX).<AA@DG!P =[4O&NF65CJ<]LRW<FG7,5M/$C@'
M<[1C@]P/-'X@BM^&ZM[@N()XI?+;:^QPVT^AQT- '+6/AW4P?$4]U]ECEU6T
MAB1(Y6<(ZPE&R2HXR>#CIVKE_%FCNNF>$-!L[^%/$*0KIDJ0MN;[,\.R=L=0
MJA0P)'4#N:]1@N;>Z0O;SQ3*#M+1N& /IQ56[ET_3Y7NY%MDO'C.TG:LDH49
MV@]30!(]O%::0UM @CAA@,<:#HJA< ?E7G7@_2-<UGPIX)CNUL8]*L$@OA.D
MK&67;&?+39MPN"PR=QSM[9X[+2?$$NLV^C7":>JVNI6(NF9KA=T6Y00FSJW7
MJ..*U(+BPC@:.WFMEBMOD98V4+%CL0/N_2@#C/#'@RYT&[L;8Z+X>%M8L^-2
M6+==3)SL&-@V,,C+;FSCISPZ'P9J4?PSL_#9EMOML-S%*SAV\LA;H2G!QG.T
M>G7\Z[:*YMYWD2&>.1XCMD5'!*'T..E)#=VUQ))'#<12/&<.J."5/N!TH Q#
MH5U_PENJZKOB\B[TV&TC7)W!T:4DD8QCYQW]:P]'\%:EI^J>#+F6:U*:)I<E
MG<A78EG9%4%/EY&5/7%=A<:C&ME>36;0W4UNC'REF5<L 2%+=%SZGI5:+Q#9
M?;K#3KF6.#4;RV-P+<2!]H&P$;AP>7 'K@XH XN#P?XDM?#.F::D>FR3:/K
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MP@(&Y<$FNXCO+6;S?*N87\DXDVN#L/OZ4?;K01R2?:H-D0!D;S!A 1D9].*
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MD:&.;S)'5BK!6(P<$ @\5=NO NNWNBW$$\]A]KG\11ZLVQWV+&-F5!VYR-I
MXYX/&<#M;"ZVW&H1/9P6<,,X"2+,A\XMR6('W22>AY-7H;JWN=_D3Q2[&VOY
M;AMI]#CH: .;A\*S27WC'[7+&+77=BQ^6265?LZQ-D$=<@XZUB6?@6ZGTB[T
MJ\T?P[IZR:;)9&]L8MTTSLH42?<78,9)7+9)Z\<]7K?B.UTCPUJ6M0F.\CL8
MGD=(I1R5&=N1G!J]I]_'J%C;7"X1IX$G\K=DJ&&1_AGVH Y2QT7Q1=^(/#U_
MJZ:9!#I,4T3K;3O(TS/&%WC*+M&0/EYZGFNVJ![VTBB262YA2.0[4=I  Q]
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MH?'$D$M[H6GR6NGRR3W$DL4FI%C;Q%(SDE 0';#' /3D]JZT6\(N3<B&,3E
MAEVC<5!R!GKC)/'O45[I]EJ4*PW]G;W42L'"3Q*ZAAT.".M 'D7AVWL]5G\)
MV=RMK=6L>JZL!%&F(=H+L@"$G"="%.>,5:>P_L_2->U738 C^'/$<EY!#$N
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M[>OS[<$]R?>O2HK>&#S/)ACC\QR[[% W,>I..I]ZK6FCZ9I_G?8M.M+;SO\
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M %TD<*JTG^\0,G\: /)+;2H+/X8>"7M+;3XQ?7%HU_+=IF.;]TYC$Q'+*'V
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M)9VVFQ17CPRW;WL>8IYC;,R&8CEOFSC/\6WVKT^+0='@C2.'2;&-$9F14MT
M4L,,0 ."1P?458FL+.XL?L,UI!+:;0GD/&&CVCH-I&,#% '/> [0V6DWT8O+
M"XB-_*R)IX(A@SMW1KGT?<>./FKCH(+/3M16.&/2M42_EOQ:7]ME+V.1DE=U
MF7^,<,N>,$+QG%>JVUM;V=NEO:P1P01C"1Q(%51Z #@5!#I.FV]]+?0:?:Q7
MDO\ K+A(561_JP&30!YQI>HV5Q:_"JW@NHI9@@+(C@E=ME(ISCISQ^=8FBP:
M,G@;PO<V"VW]NG785$BX\\G[00ZD_>V^5GCIMQ7L%MHNE6<IEM=,LX)#)YI>
M*!5)?!&[('7!(S[FF?V+IT$OVJSTZPAODC*0S_9ERG!P,C!QST!% 'D4OG-!
MXK1#;BW?QC&MS]J!,/EX3 DQ_!NV9_6KUU9):82\N](DTF?Q#:B_MK!2MM#^
MZ/#@\89Q"2.F>O6NY\+^$WT:UU<:I<0:A/JUX]W<A8-D7S #8%);C [D]:VX
MM)TV#3VT^+3[6.R8$&V2%1&0>ORXQ0!YIXFL_"6=/738;-K>/Q/;+>#8#!&[
M)\RKD; " FX+QGKS7<>,(()_ 6MQ>5')#_9TQ1=H*\1DK@=." 1]!6C_ &+I
M7]F_V;_9EG]A_P"?;R%\KKG[N,=?:K@BC6(1*BB,+M" < >F/2@#RO1+?19=
M9\*0WD5@VF?\(^9+9'5/)-SF/S#CH7VGZX)]ZZ?X<;1X<NEM\?V>NIW:V&W[
MOV<2MMV_[/7'MBMYO#^BO8"P;2+ V:MO%N;9/+#>NW&,^]7XHHX8DBB18XT
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MV;48%COK5TW"1U&%<'L=N5(QR OIRFH^'+=](>TT>&STR?RVBAN(K9<VZO\
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M7&EV=^;&16F*W$A5@LCKGY0%)/!.3M/(R*S8OB.)-8C'F:3]@DU(Z<MN+O\
MTP'S#$)2G]TN.G7:=V>U:$?AOQ!I]_>P:5JEI;Z7>WYOI':(M<1%F#2(G\)#
M$'D]-QX/%&F^%=3TO4O)MY-+_LK[;)=B1[<M<A7<R&+)XQN8X;J!QC/- %;3
M?&VIWUOJ-^MGI]Q;6D=PSV=O<'[7 T6=J2(1U;;C@<$CJ.:;#XWU%/#LNJ/%
MI.H"9H(K)M.NBR/-*X01/D94J2I)],\ C%3'PKKUSK<.HW-[I<-W:13)!?V]
MJ?/F+H57S5/R[5R&*Y()4=*J3> ]1U*6_O;N73+#4)5MVA.GPMY9FAE\U99
M<;CGC'8$\GL 6-0\8ZQH,>LV^JV=B][9Z4^IVSVSOY<JJ2&1@W((.WGG(;M7
M2>'[O5+_ $Q;O5+>VMWG(DAB@=F*1E00')'W^N<<5S>H>#]8UZ+6KC5;JQCO
MKS2GTRV2V5S%$K$EF8MR23MXP,!>]=G9PFVLH(&()CC5"1WP,4 <&OCG7%TR
M77)=,L5TBVU%[*<"5O.9!.8?,7C''&0>N#R.*L/XVU&*Y\274MC:KH^@22I/
M)YC>;-B)74(,8!R<$D]QCO6+H&@ZQK_AJYT[[79IHT^M7,L^Y&\]52\=C&O\
M)#%.IZ9/!KJ5\&B;3_%EA>7 ,&O7$D@,8YB5HDC[]2"N: *K>)/$UE<VEIJ&
MG:<;G4[6:2Q2WE<[)XTWB*3(YR,_,,=#Q4T?C4WVG>%9M/MTDN-=D7,3D_N8
MU0M,?JN-OU(I]AH&N7&MZ5J&O7=C(-*BD6!;1'!FD=0AD?=]WY<_*,\L>:B\
M/>"9-%\57VIR722V8$HTZW"D?9A-)YDOMRV,8["@#"TWQBMAH=Q+96.G:=Y_
MB"YLGGN966WC8;F,LAZY8J!C@98<UIW>L2MXJ\$1:EI5FU]>/>A9XIBZP[(B
M=\9&,AUQU' /K3],\):SHFCWEK9W6G7#7.J7%Y)!=1$Q2Q2G.QCU!!P<@$<8
MQ4>G^ ;FRU'PM=_:K95TBXOIY8(8RJ#[0#A(AV5=V.>P_"@ B\;:L^G6WB)[
M"S'AZXO%ME D;[0L;2^4LIXVX+$';Z'KFH[KQMKD-IJNJ)IMC_9FE:D]G,'E
M;S9460(63 P,!@>>I!Z=Y(?!.K)IUMX=>]LSX>MKQ;E2$;[0\:R^:L1_AP&
M&[N!T!JW<^#;F?PMK^DBZB$FIW\EVCD'"!I%?!]^* '0,=$^);6,1(LM;LWN
MQ'V2YB90[#TW*ZD^ZY[FNOKCXP=;^)WVN'YK/0[.2V:4=#<S%2R ]]J(N?0L
M!72Z8E]'IL"ZG+!+>A/WSP*51F]@>0* +=%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;S@(\$IW9)ZA@-O4'!S5]O$L4OB8:'I]L]Y-$-U[,C 1VBGH&/=SV4<]S@4
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MWDTW4W W22L<M#.W>3^ZQ^\..HQ7?LB/MW*IVG(R.A]:'C21=LB*XSG##/-
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M.6('7ZT(BQH$10JCH , 4 .HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^'M+T3X3ZS?:;:_9[J?1&,DJR,2Q\O/<\<UT;>$8T^'UQX4@NW FLY;<W,B
MG=(#N<J,=V)Q^%6M5T ZEX*N?#PN1&9[$VGG[,XRFW=MS^.,T >?ZS9ZEJ4?
MP\33+QX-1CTR6YMW+':\J10L%?U5N5/LQK97Q!'K_B7P3?0B2$O]N2XMF/S1
M2I$ \;#U5@1^O>M^W\+&"\\,W'VP'^Q+22V*^7_KMR(F[K\OW,XYZU4;P-&G
MQ"@\46UZ88E#M/9>7E9)639Y@.?E)7:#QSM% ',Z-IGA_6?!4/B_Q>);NYU
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MWUA(07V;A- WWXF&1P< @]B :Q[?PQXETN^U232=?TZ*VO[V2\,=QIK2,C,
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MB2 RI=@7$GEN4=DAV'< 5; + G'2K?@/6+C5_"\2ZAQJ=B[6-\IZ^=&=I/\
MP(8;_@5<1K&I>'K9=4U'0]9U#0O$HDE8Z0),FYN03@-;'<&WD#YEZALYZT =
MC=>*M8?Q+J&CZ1X?BOOL,<,DLLM^(/\ 6!B %*'^Z:34_%.LZ5I^FM<>'HO[
M1U"_%G':K?@J,HSAC)L_V",8KCKN[TF+XA:X_B'Q#=:%-)9V)"6]Z8 [;'W
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M4@@KQQUS3_'EO<7>H^$X;6\DLYFU8[;B-%=D_P!&FZ!@0?3D=ZR/&OALZ9X
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M,-C/W>/IQ0!Z*Q55+,0 .23VID,\-PF^&5)4SC<C!A^E<;XGMHM>\=Z)X?U
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MF_=-6BAU VUZ3R98&54=O4-L&[U#&NFAUY?$/BKP3=M$;>ZC>_@N[9NL$ZQ
M.A^AZ>H(/>@#T7 J.&X@N WD31R;3@[&!P?PKDO'*G4-2\-^'Y9'2PU.]=;L
M(Q7S4CB:01DCLQ SZ@8K/\4Z!I7A4:1K>@:?;:;>1:C;6[K9QB(7$4L@1HW5
M<!N&R,\@K0!WC3VPDPTL0<<<L,BIJ\8BF\*V=YXOO/$'A.34_*U>=GO!IJSJ
MB;4X,AZ8Y/7C.:]!\ 6%[IWA"UM[Y6C/F2O# \OF-!"SLT<9;)SM0J.I].U
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MJ?(DW+G^$@<<Y4T:%#HVFZ[HT&H>$)/#>JQEH;>YME0V]RQ0YC,J?>R 6 <
MY&>M 'I/F1D,V]<+PQST^M+N79OW#;C.<\8KQ^T_Y$#XL_\ 83U/_P!%+5B6
M>7P_X'\1>$KQV: Z'<W6D2N<[X/);=#GNT9/_?)7TH ]6>6..,R.ZI&!DLQP
M /K1'+'-&)(G21#T92"#^->=65A:^)O%UKIVL0I=:?IFB6L\%G,-T3RR%@9&
M4\-@( ,YQDUH>%I/#%IXKO+/1;&_TRYN(#(]F]G);6[B-@ID164+N^< E>HQ
M0!VLLL4$9DFD2-!U9R !^)H$L917$B%&QM;/!STQ7'^--'N[O5M*U,:)%KUC
M:),DVFR.@.Y]FV55?Y&90K#!(^]Q7):W<:1%X-7^PM-O+5H?$5F\VDS((G@E
M,B'8J$[5#<$8.WYB<T >OLRJ 68 $XY/>LJ[T:!O$%KKJ7!M[B")K>;IMGB)
MR%;/HW(/;)]:X3QKKNIW]GH\%UX7U+3XCK5B3/<2P,H(F7C"2,>?I4GQ$U+1
M-6\2Z=X1UG5+6RTT0O?7[3SK%OX*11@D]=Q+X_V!0!Z8S*BEF8*HZDG %,CF
MAE)$<J.1SA6!KR.Y\0+KOP#UJ.2ZBN[K3D-C<2Q.'64QNH#@CJ&7:V?<T^^M
MM#N]9TG3O#7A&?1==^TQW,=TUBMGL@1U\TD@@N-IV[1G.X4 >L/<P(Q5YHU8
M=06 (I3-"(C,9$$8Y+[AC\Z\G2STZY\<>+FO/ S^('%_&!.L-L_EC[/%\N97
M4^_''-;VMZ!)<Z)H,FF^%H6L+&=YI_#TIBB#!E8#@$QEE8[L$X.>N: .\CEC
MFC$D3JZ'HRG(/XTH92Q4,-PZC/(KD?!,FA_:-6BTO2[K1[H/&]WID\0B$3%2
M%=$4E<-M/*G!VUC#5;W3/BOXE-GH=[JGF65EN%J\2^7CS<9\QUZY[9Z4 >C&
M1%W9=1M&6YZ#WJ-;BV+_ "S0EFXX89->/:K>W&H-\3Y[K3;C3I3H=N/(N&1F
M "3<Y1F'/UKH?#^F:-]ITYE^&#6<@*,M\UM9@1L,$/E9"W7G@9H ]!:Y@5BC
M31A@<8+#-.>6.( R.J ]V.*\;BF\*V=[XPO/$'A.34Q#J\[/>#35G5$"IP9#
MTQR?;.:6^TR>S\-^"[35M'?48VU>=XM+9HYF$#1S-%&2[;6VJ5ZG'''2@#V)
M;B"0G9-&V!DX8' IX92NX$%<9SGC%>>I8:9!H'B"6T\#'P_+_9DZ^>T%NAD!
M0Y4&)V/8'GCBM72/^2/V/_8!3_T0* .L$D9*@.I+#*\]1[4NY0P7(!/09ZUX
MJFE7>JP?#S^S9_(U.T\-M=63DX7S5%OA6_V6!93[,:ZBUUR'Q%XV\'ZA"C1.
MUCJ*30/]Z"53 'C;W!!'ZT =^D\$C;$EC8^@8&E:2*!1N=(U[9( KS#X>^"/
M#.M?#G3KB]T6S:[E\XM=I&$GR)7 (D&&!&!SGM6(UW)J]AX+35M.D\1>1J.H
M6IB98W:[6)9$5SYA"DX4$DGJI/6@#VA9K>0Y62)BHSD,#@4J7$,C;4FC9O16
M!-<$+'3;?POXDEL_!)\/2?V;,ID:&W0R@HW ,3,>,#KCM7&26^@7/@_2--TK
MP=/9^)+ZVB2PO_L2VO[\(&,@FR"<8+<9) Z&@#VZ&>VEDFB@EB=X6VRJC E&
M(SA@.AP0>?6IJXW4 VD_$GP_/&W.KV\UG> # D:)/-C?'J,2#Z-BNRH ****
M "BBB@ P/2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ K%U_P['XAETQ;FX9;6RNUNWMP
MH(G9 =@8^@/..^!6U6/XEU]/#NEK<_9GNKF>9+:UMHR TTSG"KD\ =23V )H
M 9XD\,VOB+19+ M]EEWI+#<Q(-\,B,&5E]P15&\\)78UF?5M%UR72[N[1%O%
M%NLT4[*,!]C?=;'&0>@&<U6G\2>(M!>UN/$FEZ<FF3S) ]Q87+NUJSD*I<,B
MY7<0"0>,]*#XB\47FIZU'I&DZ7/;:9=?9B)[QXY92(TD.,1E1]\ 9- &YH&A
MKH=I,C7=Q>W5S*9[FZN"-TLA &<# 4   *!@ 4GAG08_#6A0Z7'.TZ1R2N)&
M7!.^1GZ>V['X5S&K^-M;@\(#Q;I>FZ=-HYLDN]MQ<ND_(!*[0A7C..M7=2\1
M^(M!\):MKFK:=I?^B0"6"*UNI'WG/(8LBXZCIF@#6\0>'$UQK.YBO)K#4K%V
M>UO( "T>X892K AE88R#Z"JNG>%KA-:AUC6]8EU6\MD9+4>2L,4&X89@BYRQ
M'&23QTQ4>I>*;Q9=*TW2-/CN]7U"W^T[)93'%;Q #+NP!.,L  !DGTI=.\1:
MI!XA@T+Q%86UO<W<3RV=S9S-)#/LP73#*&5@"#W!&>>* -/PYHB>'=$BTR.9
MIECDEDWLN"?,D:3&/;=C\*3Q/H2>)O#5_HTD[0)=Q^6957)7D'./PK%\!^./
M^$OM9UNK,6-]%B00[]PDA8D+(I[C(8'T(JE'XXU6_P!.\./INFV9O-9GN8@E
MQ.RQQB'><[E4GD)Z=Z +L_@S4=5$$&N^)KB_L(I4F:TCM8X5E9&#*'8 DKD
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MY"!+YHCY8@<8\SMGI0!)+X#E70M,TRTUN:#^RK\W=C*T*R-$F'58B"?F"AR
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M[&_^UW=](JS6NI74C2--:YXBW'A2C9R!C.0<5;T&&5/B9XOE:)UCD@L CE2
MV$DS@]\5U@EC:5XA(AD0 L@894'H2/P/Y5!:ZE87LDD=I>VUP\?WUBE5ROU
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ME:66B6EW?>8V;F9H)(8[5 #RQ=1ELX 4<]>F*W'U;38XXY'U"T5) 2C-,H#
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M.+S6YIKM86C/F"/>$B4CKPB*<>]=KI7CG0+MK.QAN;DW$@6-5:QG4;NF"2@
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M=M(T:I<1,TJ[XPK@EU]1ZCWH Y#P&\IN]7CM+K4;K0$:+[!-J&\ONPWF*C.
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M#LA)65MXPA'9CV_&@":BHVGB2 SO*BPA=QD+ *!ZY]*DZC(H **** "BBB@
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M7+1H%(@E#*S,F1_$5!(.1G/K5BST#7;>\AFG\8ZA=1(X9X'M+95D'H2L8(_
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M&CXWX5% ).T DYX]*SD^'SPV3:3;^)=6AT%LK_9ZF,E4/6-92N\)VQG..,T
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M$!TR"K 9[,I((]ZZ%%"1J@Z* * '4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SOC/7;SP_H]
MO<6$,$MS/>P6B"?.P&1PN3CGC-=%7&_$M)3X>L98K>><0:K9SR+!$TC!%E#,
M=J@DX ["@ N?$?B#P[-;2^)+#3GTR>9(&O-/E?-NSG:I=''W22!D'C/2I9M?
MUW5M<U#3_#=MIX@TUQ#<WE^SE6F*AC&BIR=H*Y)/4XQ65XDU*3QU8Q>'M'TW
M4A!<W$+7E[=V<EM'!$DBN<>8%+.=H  '?G%2V5^?!.O:[!JEG?-I^HWIO[6]
MMK62=<NBAXW$8)5@5XR,$&@#=\->(+K5+C4=,U2TCM-6TUT6X2)R\;JXRDB$
M@':P!X/(((K+OO'$NF_$-=!NK1%TMHH0;T$YCGE+B-6'3:?+(SZD>M2^%(+J
M_P#$>N>)9[.>SM[Y8+:TAN$V2M'$&R[*>5W,YP#S@<]:@GT&/6O&GBBTU"UD
M;3[W2[.'S-I )#3$[6Z;ERIXZ'% %^_\71Z5KNLV]ZBI8:9I<>H/*N2YW-("
MN.G_ "S&/<UGOK?CB+23KDFC:5]E6/SVTU9I/M0CQG&_&POC^'&,\9KE8-"\
M0>(+KQ9HVJPRI>C18=/COG0B*[='E9) W3D,FX=B3742^.I9M#>T70=7_P"$
MA>$Q_8#8R!1*1C)EQY?EYYW;NGY4 )XD\5ZY9>%Y?%.BII5QHPLTNT6X\P3,
MI /;CO71:&_B"17?6QI@5E4Q?8O,S[[MWX=*Y?Q!X?N=+^!MSH,*/=75OI2P
M;85+&1P!G:!R><UWEN"+:($8(0<?A0!S%]K^M7WB.[T7PY;6.ZP1#>7=\S[$
M=QN6-57EFVX).0!D5%/XLU;1]#N)=9T4#4TNH[.UBMI<Q7TDF-A1CRHYYR.,
M'K53[8_@[QEKEQ?V5Y)I6KM%<PW=K;/.(I%C$;(X0%AG:I!QCDBH];GU?Q/H
MT>J66B7$:Z5JD%[907'[N:]CCX?Y& V9#-MSR<#@4 6KWQ!XI\-Q1:CX@M-)
METHR)'<M8/()+4,P4.=_#J"1G&#WQ2IXXEB^(UWX<O;1(K -'#;7@)YG:,2"
M-^PR-VWUVX[U0\3:TOC;09/#FCZ?JGVB_*17$ES8RP):1[@79V=0"0 0 "23
M4Y\-C7-=\;6=Y%-##=/:-;7(4@JZ0C;(A[E6 Z=QB@"]J/C.33)?%IDM%DBT
M.WAFC"M@RET+88] ,@<]AFI[*[\7_:85N[;1[FVN879;BS=PL#[<INW'YT)X
MRN#[8KEO#-SKR3^,;[5O#\US?+':P2VX3:EX8U9':,D88,OS >^*=HMOID?B
MO2F\&6>K65N9'.J026\\%JL7EM@%) %$F_9C9[YXH T&UWQNOBR/P]Y/A[SW
ML6O1+F;;M614QZYRV:TSXCU*+QK8>&YH+0RSZ2UY+*A; E5@N!G^')[\TR2U
MN#\7[>[\B7[,-!EC,VP[ YN(R%W=,X!./:JUW9W+?&K3KP6\QM5T26-I@AV!
MC*"%+=,X[4 03Z[XW@\46>A-#X>,UU;2W*R S;0$*@@]\_,*VK'7=0/C%?#U
M]#:[UTE+V26 MCS#*4*C/\/&>>:JW]K<-\5M%NE@E-NFEW2/*$.Q6+Q8!/0$
MX/'M5;6I)= ^(L/B*XM+J;2Y]+^PR2VL#3&"192X+*H+;2"1D X(YH TK[7=
M1_X3&3P]80VOF'2C>Q2SEL>9YH3:V/X<<\<UC6NN^-[KQ-J&AK#X>$UE!#.\
MA,VUA)NP!WXV'\ZL:&\VO?$*Z\1PV=U;Z9#IBV$,EU"T+3N9/,9E1@&V@ #)
M R3Q5C2K6X3XH^(KEX)5MY+"S5)2A"L09<@'H2,C/UH A76_%6H^(]:T[2X=
M&6'3)(HBUT9=SEXED)^7C'S8KJ=,_M'["G]J_9?MF3O^R[O+QGC&[GIBO,;R
MTT"/Q]XHF\0Z7J\IFGMS;26UK=NC(($!YA&#R"*]"\.3Z:^A1?V7#=0V46Y4
M2YAEC<8.3Q(-QZ]Z ,'QIXWNO#>H06UA8)>^3;F_U').8;4.JEEQU8Y8@>B&
MKGC/Q/>:#H%GJ&CVD6HS75U%#%$6($@<$C:1W../K7-Z#X?\0Z])K'B*341I
MG]MR&/['<Z>)'6V3*1JVY@5RN21C^*JEE9:O:Z%H_AR[M[J>;0O$5M"EQY+;
M9K4$M'(#TP%(4\\;>: .PO?&$1T#1-7TQ4GM]3OK:V&_(*+*X5N.S+R,>HJU
MXRUNZ\/>&+C4K**&6X26&)$FSLS)*D>3CGC=FN*\3Z-J.C^)M.M].LY[C1=2
MUJUO6$*%A9SK*ID)QT1Q\V>@8'UKH_BA;/=^ +V%+>:XS/:EHH$9W*"XC+8"
M\G@$\>E &AI__"8?;HO[2&A_8\GS/LQF\S&.,;N.N*S?^$ZCTB35[3Q,D=I>
M:>OG1"+)6\@)PC1 \EB2%*]FQZU1\/R>#+;6K=M+TW6H;QB41Y[.^"#(P<F0
M;1QW-5-0\/ZE\0;V37"9=,&F.1H*SQ;6,JL"9Y5(SM8J%"G^')QDB@#6NO$/
MB>'3M 5K#3[?5=7NFB,$[.4MT\MY &(Y+80 XXR:JZIXVUK0=.U^/4[&Q.IZ
M;91WT)MY',,T;NR<@@,I!4\?2H-2>]\81>$VN+/4]+N8M3D2^$(:-[=UMY02
MKX^X3@!NA# =:D\8>$H=/^'OB46"W]_J-[;JKRSRO//*%/RJ/89. !W- %[4
M->\4^'4M[W6;71Y].:XBMYC9R2++'YCA P###8+#(X-*FM^*M4\0:W9:3#HR
M6VFW"0;KLR[W)B1\_+Q_%C\*S=9\*1Z)KFB:NIU;5M.@N0ES:W5Y-=>2S$".
MX568\HW7@X#9ZBLF:T\/Q>-?%$OB+2M7E>:\C:WDMK6[9&C\B,<&(;3\P/O0
M!U^I:YKM@VBZ48]+_MG4GE!E9G%O&$&[@?>9B",#([G/%,OO$>N:#X<U&\UC
M3K/[3;SQ0V\L,Q6WG\QE17.<L@4O\V<].":H:C<^'9_#^FVESX;OKSPXQ=3)
M):3M):NOW28V7S0#EOG'3'H:I:.\EEI>O&VTC5=5\,&2!+:SOD=I3&<B<QI*
M-[( 5(4]<-B@#K=*N/$ZZH+?6+73Y;22$NEW8LRB-P1\C(Y).020P]#D#BHO
M$&OWMGJECHFC6D-SJUZCR@W#E8H(DP&D? )/+  #J3U%<WX8M[&'Q?:_\(E!
MJMOHWV>7^T(KB*>.V5OE\L1K,!A\YSMXQUK5\1+<Z+XST[Q.EE<WEC]CDL+Q
M;:,R20JSJZ2!!RPRI!QR,@T 3V6OZU8>(K/1?$=M9!K]'-G=V+-L=T&YHV5N
M5;;D@Y(.#65I/B/QIK'AP:];6>@FW82.MN\DJ.P1F4C=@@$[?I4YNV\8^+]#
MN+"SO(]+TEY;F:[NK9X!)(T9C1$#@,?O,2<8X SS7+:?X%N[CX81S0R:NNI(
MTDKZ;+?3QPW"B9B83%N 4.O' ')!H ]2T+5HM>T#3]6AC:..\MTG5'ZJ& .#
M7&-\0-2;X?:OX@AL;9KRSU%K*&%F8(_[]8@2<YS\V:[71IK>XT6REM+9[6W:
M!/+MWC,;1+CA"IZ8Z8]J\KMM*U$?"?7+4V%T+B37S*D1A;>R?:XVW 8R1@$Y
M]!0!WUMXPM)? (\52J4B6T,\L7=74$-']0X*_6N=L/'.OZCX8T:YCL+"#5;_
M %:73GBE+^5$4$I)XYS^ZQ^-03Z#J/\ PFTGAQ;60^';J^77))MI\L;>7@)Z
M<S!'QZ$U1M]"O;O1-$M)(M0M3_PE=W*\D :.2.,_:</G' .5YZ?,/6@#HKOQ
M?K.C6VOP:M96)U#3M+;4H'M9',4R#<,,& *D,OOD&NMTF\;4-&L;UU"O<6\<
MK*O0%E!P/SKD_$'A2WTWP/XI:S^W7^HWNFRQ--<2M/-( C;47/;). !U-/\
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M<ML+*25A<R^4Y1OF^ZC'!(!!X(R>:JW=C=M\1O UP+6<PP:?=+-((SMC)C0
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M]<6B"X,V\B*0IDXXYQ4-S?\ _"8^+O#K:79WPL=+N)+NZN[FTD@0'RV147S
M"S$MS@< 5S.DV?A>WFUA?$&CZV;Y]6O'W0V=Z49#,Q4@QC:01CI0!VFKZ[XB
MM==T30[*'2S>WMI-//),9/+5H]@(7'."7/7TJ?3?$>IP^(H= \16%M;W=S$\
MMG<VDI>&X"8WKA@&5@"#CD$=ZPM5U&VL?&7A76$L]2.EIIMS$&CL)Y'CR8MH
M90I8'"G[P[5=@>Z\6^.=)U6'3[RTTG1HYV6>\@:%[F65=F%1L-M"Y.2!DD4
M:?B?6]6T_5M$TS1XK)[C4I)EWWA?8@CC+_P\\X(IESJ7B?1]"UC4]6CTAQ9V
M4MQ"EH9?F=%+8;=VX[5D?$6UM)M;\+3:E97MSIL,UP;C[)#+(RYB(7/E#</F
MQ55AX?D\)^*++PYINK1W4^E3Y6XM+M?,PC !3*,%LMT')_"@#9TCQK)J7@?4
MM6EM4@U73;>1KJS).%D6/>N.Y1AA@?0^U$OBO5+V72=,T6RM9-4O-/34+A[E
MV$-M$V "<?,Q+9  QT))K!\6Z/J-AX8CUO2;.::XETC^S]2LXD)>:)H]J.%[
MO&S?7:6%6+5;OPOJNCZ]/I]Y/I]SH=O8W?V>!I)+62/+*S(!NVG>P. <$#-
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M;$0*PF"A7SC/F^8.0W?=G-<W(ER/B7XB6T\.6^M 6EB"9YT0Q<28Y<'.?Z4
M>B66H66I0>?87EO=0[BOF02AUSZ9!QFJK>(M#2]-FVLZ<+H/L,!NDWAO3;G.
M?:G:(LBZ8GG:3#I<A8EK:)U=1SURH .1BO,X1'>V?BW3$\'W.JW-QJE[''<B
M&'R@S' S(S K@\YQQVH ]-OM=TC2YEAU#5;&TE9=ZI<7"1L5Z9P2..#^56;2
M\M;^W%Q9W,-S"W22&0.I_$<5YE+'/IGQ M+6YT.;Q!<0^&K:*7RO*)#++("_
M[UEZD=N:RY9I6\&>+?$6GV_]C6&JSVUJMM&P62 +*(9Y'"\(Y#$$#D;030!Z
MM!XAT6ZOS86^L:?+> D&WCN4:0$=?E!S5R*[MIYIH8;B*26 A941P6C)&0&
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M7(!8JAQUSQ4OA15U;Q_?:K::,-$AL+5M/NK9_+66:5F1U+*A(VA>C9.=W'%
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M@AU#PY=3WD$2A4,D9"I(0.,D.RY[X]J .WM/$6AW\X@L]9T^XF;I'#=(['\
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M[J69)GUH1"ZBEP8\(FP #'0@\Y)K:HH XQ?AU:BT&F-KFLOH@X&EM.OE;/\
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MIU,I3! 5< *JC).  ,GG-=%10!Q<7PXMQID&DW7B'7;O2H8UA%C)/&D;QJ
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M/<1V]P%65H6"LZ@@E<X/!Q@X[$U;N;"VN]-FT^:%6M98C"\6, H1@C\JLT4
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+ 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>a1011-arrowhead_2021plan004.jpg
<TEXT>
begin 644 a1011-arrowhead_2021plan004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4EL')V$9(V\9Z9/K5&'P[<Z?XIFUC3;F*&"^0?VA9,A*R2C@2H0?E;'!X^;
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MCFKU_P"*KLZW<Z1H6BOJES9JK7<C7"P10EAE4W$$EB.< < C)K#\>6D%A<>
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M2R).(6MS+EU3<>!]X*1]:W=5OM!E\ >+;?2O%LNN3-I<SM'+?+.8U",,@ #
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M_P!T720JO&2K!AG';(%6J* "D"A1@  >U+10 @50NT*-OICBC  Q@8Z8I:*
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MZCJL[645^@LT3#02;L,"[J,_+TZG(QGG%1/'IO?$7AZTTS3;FZT_5K22Y^T
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MVJ(^I(R3TI-1AU32?'<NLVFD7&IVU[IT=J1;R1JT4L<CL-V]E^4B3J,XQTH
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MCNYANX;24&P59I4+A2T87A0"68YPHP<DC@T =2?"7AH#)\/:3C_KRC_PI?\
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M<L%QMW;BH9@I;& ?H30!;O\ P=HFHWLMW-;2)--;_9IC;W$D(FCP0%=48!@
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M=MVU1\RC&<Y.,5%_PGUJ]OIYATR^EN[VZFLA9@()(IX@2R-EMH^Z><XQSTH
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M:[S,Y#QC. RDX?&YL%@3R:I67@?0=/ELI;>WN%>Q5X[9FO)F,2, "JY;A<
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M%T58SOF#MER!DX08ZG'L: -YO"NDFXNK@17"SW4Z7$LBW<H)D0;58?-Q@ #
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M\.>(M--AK,FG1SWUKJM_<2V4,Z@O%<$G*,Q R#M.&QD9Z&I)/#6NRW,OB7[
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MW#*'!([C(KU*B@#-T2;5KBQ:;6+6&TN'E8I;Q-N,<>?E#MD@MCKCCFM*BB@
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MU+D,"D<IE"!,9W$X&>F.<]J=_9'VSXN3VMK-')I,9AUB\B0Y\N["M$@..!N
M5\=<QYH Z/QWKVH^'?"K:AI]JLMQY\,1#. $#R*N>>O7'XY[5B#Q+K=GXK\0
MA-)N;WR+*TG:T^U*J6WRR%P">"QQV'.WDCBM_P =:1>ZYX1NK+3T1[OS(98T
M=]H?RY4<C/;(4BJ]AI.IOJ_B'4;JV2W_ +3LK>..+S0Y5T60,"1[L.: &R>-
MS<1V[Z-I%QJ0?3X]2F D6,Q0R E!SU<[6PO^SUZ5K7?B"U@\(3>(XLRVB6)O
MD[%TV;Q^8K@D\!7=G#IDMQX=T_6IET6UL9(KB8+]GFA4C<"1RAW8..?E'!S7
MH#:+;W'A5M"GBBBMY;,VCQVXPB*4VD(#T [4 <Q9Z%XJU#0X=6/BRZ@UF>(3
MK;B*/['&2,B,IM+%1G!;=GO[5I7GBJ^@O[G3['17U*YL+>.:_,4ZQI&6!(1-
MW+,0"<<<$<\UG6G_  GMAHT>AQZ?ITMQ#&+>+6&NL1[0,"1H=N[?C'RYP3WQ
M4KZ;XBT/6]5O--M(=5_M2"#=)).(#%/&GEEF&.4(VGY>1@C% $Q\=?;+JSMM
M#TF;4I+S34U*$^:L2^6S8PQ/0]..>3[$B+2_B!_:9T6X_L6Z@TS5Y/(M[J21
M,B7:S;60<@?(P#=R.F"#2>%_"%UX>UC32726UM-"CT]I0>6E$FXD#TJOIWA/
M5+;PQX-L)$B\_2K]9[H!^ @64<'ORZT 36_Q#::WAU!]"N8](:]-C)>&9/DD
M\TQ!MG4INP">V>AQ6C<>*KFTUB."XT2YATZ6\%BEZ\B@M(?ND1]=A/ ;],<U
MQFA:?KFN^"X=%CLH!ITNKRS27QG *11WK2,NS&2Y*$#'&"#FI[GP;K#:E]L_
ML2QN+ZWUD7_]I2S@S7$/G;EB3(S'M0@8)Q\F!G.0 ;I^(#A);O\ L.Y_LRWU
M%M.N+LS(-CB;R@P3JRY*Y/&,]\&KW_":VD?A[7-5N+:2)]'FE@GMR069T^Z%
M_P!\%2/]X5E3>%-4?P3J6E!(OM5QK+WD8W\>6;P3#GUV=O6J.LZ1_:'Q6@L;
M2:-[*[CAO]7@!R5:V8B$GM\[%!CN(J .UU37(M%\-RZQJ$,B+%$KO F&?><
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M<%Z8'D$?F*A.0&/ //>LV;PWJESH'CBW,,:7&M&1K9/,!&6M8X\$]OF4C]:
M+NI^-?L4]\UKI<][8Z;$DM_<I(J^4K+O^53RY"$,1QP1U/%7_%>O'P_X2O\
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M(_A.[<,>U6Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** *DNEZ?/J,.H36-M)>P*5BN'B4R1@]0K8R!]*MT44
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 54L-+T_2HY(]/L;:T21S(ZP1*@9CU8X')]ZMT4 %%%%
M!1110 4444 %%%% $-K:6]E (+6"."(,S!(E"KEB6)P/4DD^YJ:BB@ JI9Z7
MI^G27$EE8VUM)<R&6=H8E0RN>K,0.3R>35NB@ HHHH **** "BBB@ HHHH *
MAAM+>VDGD@@CB>=_,E9% ,CX W-CJ< #/H!4U% !1110!4N]+T^_N+:XO+&V
MN)K5B]O)+$KM$QQDJ2/E/ Z>E6Z** "BBB@ J"\LK34;1[6^M8;FVD&'BFC#
MHWU!X-3T4 5K#3K'2K1;73[.WM+=22(K>,1H"?8#%6:** "BBB@ HHHH ;)&
MDL;1R(KHX*LK#((/4$5!8Z?9:7:)::?:06ELF=L,$81!GK@#BK-% !1110 4
M444 %%%% !2.JNC(ZAE88((R"*6B@".WMX;2VBMK:%(8(D"1QQJ%5% P  .@
M J2BB@ JII^EZ?I,#0:=8VUG"S%V2WB6-2QZD@#K[U;HH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
,H **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>a1011-arrowhead_2021plan005.jpg
<TEXT>
begin 644 a1011-arrowhead_2021plan005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6VACST_BQG [FL6'Q_'8:GXC75([Z2UL+M,-#:%A:P&"-LR$#@;F<]SP>PH
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M>'K_ %O58X+6)@DN@:A9^=T5))/*" GMG!_(UA2>&9M>T:^@@T[Q!'J*Z5)
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M+H^^:\>YC"*'\EHA&AS\^2Q.1QA>O-<Y;Z/K$O@KPCI1T>^CNM)\10270>+
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M:MQ&S'Z  G\*Q?%-GKJ>(M8U#2(+G>VBV\,<L(&XD7#F14SQO$9)'N17?44
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MGKGG'3/.,T:?X/TS3=1CN[>2\V0N\EO:O<,8(&?.XHG0?>;V&3C% &%\(?\
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M7:KE1_$ !@_[(/4"IE\(:6+B_N'-Q)-?V26-S))*27C52H_X%@G)H A^'O\
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MJ6ZVFL6^GO/:)'B69L$I\Q.4&X!N ?2LQO#&M6_A:+4H;-3K\&LR:Q'9K*O
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M[U)9C/E6!<M(V W(!!/(R0 :ZSQ7X:O]<U2!($"P/HE_8O,6&(Y)1$$R.O\
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MU*PLX#<PW$,0CG954ET9!\F1@8((SGD"F0>-4N]+@OK70M7F6ZE"6<8B0-<
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M/^,+W7=.TR35+'4X(DN[>"1%FBDCR%=0Y564J<$9!X!H J_\)5?^%+_5-/\
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M:I9SN-P&(TG1F//H 30! GCFR2+5#J&GZAI\^G)'));SHC22+(2L938S!MS
MKC/7@TRX\>V-AIFI7FIZ?J%A)IWDM<6TRQF0)*VU'&URI7.>AR-IXK(\6>%=
M2UG5M>E@MM\4UC8>1^^\OSI(+AY6CR#E21@;N,;NO%4-0\+3:AX8UI=,\,WU
ME<W!M(X_M^H>=-,J3!V!#2.JJO)'S9.3QTR =6_C':MM&F@:O)?7"22K8A(A
M*L2$ R-EPJ@Y&!G))QC@XR)/&LDOBVP.FP7VHV5[HQN8K.W1 Q?S0"S;RH7
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M(HW,5)!?.,#E>.*;XXD-WJEQ:VZ:I/-9::;EUM]0^R0VVXMME)!!=_W;8!R
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M;W,WG3+"!;PF0J6_B;'11W)X%>4^%I;W7-$^'MO>ZIJ!CO+:^:[*73J\X4C
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MF-5(*E@<'((S5J]^($=I)J[)HFH7%IH\YBO[F,Q[8@%5BP!8%L!LD 9 'TH
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M 51$5<9W.Y"@G(P.IY]#66/',%T-,72=,O=1GO[3[;Y,91&BA! RQ=@,[C@
M'D@^F: -/3_"VC:5'ID=E9")-,21+,>8Y\H/]\<DYS[YI)_"FB7";);$,O\
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M*PDB ("R MB3 9OO GFJ?B?Q+J.C>(/#VG66F/=IJ,\B2%70$A8G;:NYA@Y
M;)XP".IJ*?Q[! ]Q<C2KU]'M;K[)/J2E/+1PP1B%W;BBL<%@.QZ@4 :6E>$-
M%T6[6YLK:42QQF*(S7,DPA0XRL8=B$' X7'05H:7I=GHNEV^FZ?#Y-I;ILBC
MW%MH],DDG\:K^(M=M_#>B2ZI=12RPQ/&C+$N6^=U08'?E@:QSX[M[,ZFNL:9
M>:9)86JWGER%)#+$S%5V[&(W;AMVD]2* +VI>#-!U:_GO;VS=Y;B,1W"K<2(
MDR@87>BL%8C/!()'X"LA_ EK>>*;ZYNX9%T\Z=:VEL8+N2*0!#+O0E&#%2&3
M@D@X]JGE\:W$"7D%UH%Y::A'8O>V]O++$1/&F V&5B RY&0?7C-9VG^*Y;^'
MP1/JD.H6E[JJEDCMY4$,Q\@.6< D[#G*C.1WH Z*\\'Z'>Q6<;6CP"SA\B!K
M2XDMV2+CY-T;*2O X)Q5JV\/Z59RV$EM9)$VGP/;VNPD".-]NX8S@YV+R<GC
MW-><:7XSU6#7_$NM:S::L-.TZ[6V,"3PF&T0A 2R!LL1NW%AD8S7HT^N00^(
M['1$BDEN+J"2Y+)C;%&A4;F^I8 8]Z +-AIMIIB3I9P^4L\\EQ(-Q.Z1SN9N
M3W/;I6./ GAT3^<+.4.)_M$>+N4"&3=N)C&[$>6Y(7 /?-0ZGXEU&S\?:3H-
MOICS6MU;2S2S!T&-K(,C+ X7<<C&3D8S@UA^$/&UU_86A_VI87\L5[<-:#4W
M9"K3%W"@KNWXXV[L8R/3F@#L$\-Z1'IMIIRVF+2TN%N8(_,;Y) Y<-G.3\Q)
MP>*R+#0;R]\<R^)]5LK:V>VM3964<<GF.5+%FD8X&,] .< MZU)!XTAGU"%/
M[-NUTV>[:RAU$E/+>925QMW;@I964-C!(]P:D\7ZQ?Z?#IMAI)B34M5NUM(9
M95W+"-K.\A7^+"J<#UQ0!LZGIEGK.FSZ?J$"SVLZ[9(V)&><CD<@@@$$<@BN
M6MO EG;^)KYC;&;2+W2A:3_:+AYI)7\QB=S.2Q^4@ YXQQTJ[9Z1XFTS5+23
M_A(FU6Q<E;N&^ACC91@X>)HT'.<?*V1@]14%KX]@N7L[@Z5>QZ1?7(M;746*
M;)')*J2H;<%8C )'<=,T :%AX-T+3;AKB&TDDG:W>U:6YN))V:%BI*$NQROR
MCCMSCJ<QV_@;P];6]Q ME))'<0B!A/<RRE8@<A$+L2B@@$!<8('H*R[CXCV]
MNMQ<MHNHMIUKJ#Z=<7:A"$E$GEC"[MS G;R!_$.^0);CX@0:?:ZO)JFD7UE/
MIBP22P,8Y&>.9]BLI1B#R#D9[=Z -#_A"-!;3+O3Y;6::*[9'F>:[EDE8H<H
M?,9BXVD<8/'XFK4'AC1[>ZENEM#)/-:+92O-*\IDA7HK;B<]3DGD]R:S[?QC
M_I=[9W^BZC97=O9F^C@(25[B$'!V"-C\P.!MZ\BH)O'D=A8ZI-JND7MA/IUL
MEV]N[1NSPNQ4,I5B,@J00>E &CIO@[0]*E:6VMI2YA-NIGN99O+B/5$WL=B\
M#A<=!Z5:3P]I26VEVRV@\G2L?8U+L?*PAC'?YOE8CG/7UK#G\=FT:_2\T'48
M);>Q?48HV,;-/ I 8@!CAAD':>>:U;CQ+9QW&APP*]RVL$FW,>,",)O,AS_"
M!C\6% ":5X2T;1;L7-C;RK(D9BB$ES)*L*$@E8U=B$' X4#H*OG2[(ZRNKF'
M_3EMS;"7<>(RP8KC..H!SC-0W.LPVWB#3]':.0S7L,TR.,;5$10$'OSY@Q]#
M6)<>/;6(PI%IM[<33ZE/ID446S+2Q!LGD@!3M/)/'4T :*^$=$76/[4%H_VC
MSC<;?/D\KS2,&3RMVS?_ +6,]^M-D\&:#):W-O\ 8WC6XOCJ,C17$B.+@]9%
M<-N4]OE('7UJ@/'ELMA<-/IEY%J<-ZE@=-RAE:=P&0*P;:5*G=NSC /I23^/
M;:QT_4YM1TR\M;K39(%N+3Y9'VS.%1T*DA@23[_*1B@"T_@/PXUI<6WV&18K
MB6*=PEU*I\V,860$-E7X&6&"V.2:L2>$-"E&I>99%SJ<$=O>%IY"98XUVJ"=
MV1@'J.3W)IND>)&U'6+K2;S2KK3KV&%+E8YWC?S(F)4,"C$ @J01_.H]?\4R
M:'+.1HM_=VUK;_:;NYB"*D4?.<;B-[ *257.!CU% &E>Z/:7=R+TV\3WB6TM
MM$\N2@1\%E9<X()5<]^*XKPWX,O;7Q#I-[<:3:Z;%ID4BDQW\MUYSLNP+&'Y
MCB +$+GN..];5_XW%O?ZA9V.C7VHR6$$=S.T+1JHC=2P(+,,G /'4XJ[I'BN
MQUG4_L,$<J%["'4('D  FADSR.>H. 0?44 6]9\/Z;KZ6RZA#(YMI?-A>*=X
M7C;!&0R$$<$CK52;P9H,^IM?R6;F5YA</$+B00O*,8D:(-L+<#DKGC-6M UR
M#Q#I(U.WBDCMGDD6)I,?O%5BN\8['!(]JPH_&QU*U\R#2=0AL;R&8V.HD*4D
M*JQ!(!+("%)4L!GVR* .FU33+/6=,N--U" 3VEPFR6,DC</J.1]15?3M T[2
MK@W%K%+Y[0);M++/)*[1H6902[$G!=N>O/L*Y?PAXRN+G3/#%KJ6G7RG4[-%
MAU"9D*SS+#O?(#;AD*Q!(YQ6M9>+C<ZI!:7.C7]C'=B4V<UP$'G>7RP* [D)
M&2-P&0.W2@"27P1H$MC8V8M)88K&(P0&WNI8G6,XRA=6#,IP."36Q'86L.G+
MI\4"1VBQ>2L2<!4QC:,=!BN7TGX@1:I_8TYT:_MM/U@B.UNY3'M,FPOM*ABP
M^ZP!Q@D>A!II^(=OM@N1H^H'3;J^6PM;T>64ED,OEYV[MRKG)!(Y"^I&0#K+
M*SM].L+:QM(_+MK:)88DR3M10 !D\G@#K63-X.T*>&^C:R9?MUT+R=TGD5S,
M,8=6#90C ^Z152/QI#)J*)_9MV--DO38)J)*>6TX8KC;NW;=X*!L8S[<U+XT
MU6#2-*LYKB6_C62_@A!LG57+,V &)_A]1Z4 20>"O#]M,)8K)P_G13DFXE.Z
M6/E7(+<MSRQY/?-.UKPM8:O9:Q&$$5QJEND$\^YCPF=AQD?=W$\8SWS69J?C
MU+";65BT2_NH=%<?;IHC&%C3RUDW#<P+?*QX'/RGU&=CQ%K,FE>$M0UFR@-T
M]O:M<1H"!D!<YY(X Y/? XYH T+ZRMM2L+BQO(A-;7$;12QMT96&"/RJCI?A
MK2]'EAELX91+#;FV226XDE81;MVW+L<\_ETZ<5R%OXLUJ7Q!H;-I=Y))>:++
M,=/CEC :0218D)+;5&TMC)S\P&,UM0^.8KW3].DT_2KRYOKXS!;'<B/'Y+;)
M2[%MH"M@=3DD8H THO"FB0MIICL0ITR66:T_>O\ NGDSO/7G.X]<]>*9IWA#
M1=*U!;VTMI%E3=Y2O<2/'#N^]Y:,Q5,_[('I5W1=6@US2H=0MTDC20LK1RC#
MQNK%61@.X92#]*OT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:!;V_P#9\.GMEY&MHI3((RS%OO'J>>3ZYK7HHH **** "BBB@ HHHH ****
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ML*W(-$TRUDLI+>RBB:QA:"VV#:(HVV[E '&#M7\JFL]/M=/29;2%8EFF>>0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %;J7))."RD9X!KN** .$T^T\=:+HT>@6MOI=TEO&(+759;EE*Q@84O#L.6
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!S%SX\TFVU*]L1;:K<2V3B.X:UTZ:9(VVAL%D4CH0
M:V]*U6QUO3(-1TVX6XM)QF.1<C/.#P>00000>F*\_P!%L?$%WXL\:G1]:M=/
MC_M)0RS6'GDMY$?(.]<?3!K+TJ?^RO"VFZO:AE'AO6)[/4'27>ES$[[9I1P,
MC<ZOTXVD4 >P45P^@6-OXEM=;UG4I)#9ZG?*+4"9HP((&"Q$$$8W,K-[AA7<
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '.WW@3POJ5_/?7FC6
MTUS.=TLC9RYQCGGT J/7] NYO#1\/>'[;3;*QN(GMIRX*B")A@F.-5PS8+=2
M!G!YIVF>-+#4_%VI^'!%-#=V)PK28V3X52VP^J[TR/\ :%7;/Q#:75YK,#_Z
M.NE3+#-+*P"',:R9SV&' Y]* )?[ TPZ%;Z+):))I\"1HD+\@",@I^14'\*E
MU34?[+L_M/V.[N_F"^7:1>8_/?'I3XM3L)[6.ZBOK:2WD;:DJ2J48^@.<$U
M-?T8VZ7 U:P\AY/*63[2FUG_ +H.<$^U &1_PF@_Z%KQ'_X+S_C1_P )H/\
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MXC_\%Y_QH_X30?\ 0M>(_P#P7G_&NHHH Y?_ (30?]"UXC_\%Y_QH_X30?\
M0M>(_P#P7G_&NHHH Y?_ (30?]"UXC_\%Y_QH_X30?\ 0M>(_P#P7G_&NHHH
M Y?_ (30?]"UXC_\%Y_QH_X30?\ 0M>(_P#P7G_&NHHH Y?_ (30?]"UXC_\
M%Y_QH_X30?\ 0M>(_P#P7G_&NHHH Y?_ (30?]"UXC_\%Y_QH_X30?\ 0M>(
M_P#P7G_&NHHH Y?_ (30?]"UXC_\%Y_QH_X30?\ 0M>(_P#P7G_&NHHH Y?_
M (30?]"UXC_\%Y_QH_X30?\ 0M>(_P#P7G_&NHHH H:3JG]K6KS_ &&^L]K[
M/+O(?+<\ Y STYZ^QJ_110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M17&_$MY1X>L8HKB> 3ZK9P2-!*T;%'E"L-RD$9![&@#LJ*\]\2Z=)X%TZ/Q#
MH^IZF8;:XA6ZLKN\DN8IXGD5&QYA8JPW @@CIWJ[JWC2[TCQ%':7"Z4EJ][#
M:);M>C[9()"JB58QT4,W0\X4GB@#M:*\UM/&6M:=%XGO-3^P21V^L#3[1&F*
M*DC")5!8C C&XL3U^][5M:1XJU'6+?5[2R72;S5; Q%6MKHM;2I)T.X E2-K
M@CGD#UH ["BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N=\9Z%>>(-&@M[
M":"*Y@O8+M#< ["8W#8..><5T5% '&W'ASQ!XBN;1/$E]IRZ9;3I<&ST^)_]
M(=#E0[N?N@@':!SCK5"]\$:U(]_':W.F+#+JJ:I'+)&WFR,LJ2"*0]E&W (R
M< <"O0:* ."G\$:I*VN0_:;#[/>:BFJVK.C,R3KY?R.O0QGRR.#G#5L6>G>(
M+73+YX_[%MM1F9/(CA@;R(U&,[B,,Y/S>F,CWKI:* "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI")7C8@E@%+;& WA@#@XXXK-U*#1K_PEXEN+/R[N_OM5MKN2"*TD62$&6,8
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M9IC!(\@;+QLK,H=<XXR.AQR*=IT<'AOQ)HR2V=^F@?V2]O8M/$\IBE,I8JX
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MRSSRZ3Y$=G,$#J8G,8!4_,N&+$\'- '?:/HD6D>>XO+R]GF/S3WDOF/M!)5
M< !1N; QWK4KR#1=7U'3_"_@[2$U35A'=Z5]MDGLK!;F>-56)4B51&P"9<DL
MRD\ 9YKT3PIJ%_J'AFVNM6BDANQYB2>="868*[*'*'E=R@-CMF@#;J.:,S02
M1!VCWJ5WIC(SW&01^E>;:/XHU-];L%_M:\U"VU&WN7+RZ>(+<,B[D:W8J&9<
M9'S%LC!S3]$U?Q$MIX)U:_UIKI=<*0W-H;>-(UW6[R*ZD*&#909Y(.3@ 8H
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MRY<!7N+@KN(&<#"JJ@<GH!UJ]10 4444 %%%% !1110 4444 %%%% !1110
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MX$.K7+W,S KN5G*DA>,8^4=<UI:[H]MX@T*]TB[+K;W<31.T9PP![CWK0HH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*D_^+H_L7Q;_ -#?#_X*D_\ BZZBB@#E_P"Q?%O_ $-\/_@J3_XNC^Q?%O\
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M*D_^+H_L7Q;_ -#?#_X*D_\ BZZBB@#E_P"Q?%O_ $-\/_@J3_XNC^Q?%O\
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ML"4; .#Z'!!QZ$5)0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P#X*[K_ .-T =/17,?\+!\._P#/:_\ _!7=?_&Z/^%@^'?^>U__ ."NZ_\
MC= '3T5S'_"P?#O_ #VO_P#P5W7_ ,;H_P"%@^'?^>U__P""NZ_^-T =/17,
M?\+!\._\]K__ ,%=U_\ &Z/^%@^'?^>U_P#^"NZ_^-T =/17,?\ "P?#O_/:
M_P#_  5W7_QNC_A8/AW_ )[7_P#X*[K_ .-T =/17,?\+!\._P#/:_\ _!7=
M?_&ZEM/'&A7MW#:P2WIEF<(@;3KA!D\#+-& /J30!T5%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>a1011-arrowhead_2021plan006.jpg
<TEXT>
begin 644 a1011-arrowhead_2021plan006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH Y?Q)X4_X2C7M*.I>1-H=D))GM'R3-.1M0L,8VJ"QZ]35*Z^
M'NGV.K:3JWAFSLM-O+.Y#3;5*K/ P*R(< \X((]Q7:T4 <MHOA%+?P]K&CZL
M(;FWU&]NIV5,X\N5RP'(X(!_/I5)O"FMW.@Z#I]]J%O<3Z3JL-R+EBVZ:")C
MMW<?ZS:0#VR,YYKMJ* .=U?0+F7Q+IFOZ5+%#=P?Z/=K)D+<VQY*G /S*?F4
M_4=ZHMH&OZ'K>HWOAN;3I;34I?M$]E?ET$<V &='0-][ R".HX-=A10!S?A_
MP]>VNKWVO:U=07&K7D:0;;=2L5O"I)$:9Y.2223U/85F>#/ T_AG6=3N;FYA
MGM6#0:;$@.8+=I9)2C9'7<X''917;T4 <3X$\$7/A6\U&>\NHKD.%MK'9G,5
MJC.R(<CK\_...!6KX*T"X\,^&H],NI8I95GGE+19VX>5G'4#LPKH:* //+GP
M'JK>&M7L+>YL_M5WKYU:$R%@@7S5D"M@9S\N.*WK9_''VJ'[5!X>%OO'FF*:
M8OMSSMRN,XZ9I^L>)[FPU*6PT[0KW5)K> 7%P872-8U). "Y&YCM/RCTJN_C
M>*ZCTT:'IESJMQ?V?VY(D=(O+AX&YRY !). .>0?2@"AH_PVTHP7%WXFL+'4
M]9O+F2XN9RA91N;Y47/.U5V@?2J5S\/M2M]!U/1=)GLDL3JD.H:;%*7 A =9
M'C. <+N4XQG[QK=/C6.YT_2Y])TN\O[G4?,\NV&V,Q>6<2>8S':NUOEZG)Z9
MI5\<6A\-RZL]A?":&>2UDL5C#S+.F=R<';C"D[LXQSF@"G>>'O$GB9[>U\17
M.F0:3%,D\MM8"1VN2A#*K,^,)D D 9..HK8\8:)/XC\*7^DVTD<<URJA7DSM
M&&#<XSZ5H:1J,>L:+8:G$C1QWEO'<*C=5#J& /OS6:?%-L/'8\*?9Y?M)T_[
M?YV1LV[]FWUSF@#;2*.+/EQHF>NU0*P?"F@7&@#6A<2Q2?;]6N+Z/R\_*DA&
M <CKQ3/"_C2P\4W&I6UO%-;W%A.T3QS  NH9D\Q<=5+*P^HJ-_'6FPZ#/JTT
M-P%2^DT^*W10\L\RR&,*BCJ6*G'MUH R-0\#ZK=0^*+:"^MXH=?OH7D<%MZ6
MP15D4<?>(4@=L'K5G5_A;X7O-%NK73](L[&\:(BVNHDPT,@Y1@1SP0*MQ>,+
MVWO;2+6O#.H:;!>2K##<&2*9%=ONB3RV)3/3.",]Z8OC._N]3U.TTOPM?7Z:
M?<FUEF2Y@C4N%#<!W!Z,.U $^D:!J=OXJEUS49K9Y)]+M[2582W^M1G9F&0/
ME.[CO4-KX5O-.7Q#I]G/ -'U*.22VA8D-;3R AP.,>62=WL2>.:36_'/_"-:
M)9:EK6BWMK]HN_L[0*\<KQ+M9C(=C$%0J$\'-;&I^(+;3ETE]IGCU.[CM87B
M((RZLP;/<87MZT <AJ?PWNM0T#PW8QW\=O<6-FFG:C(F<7%J542HIQGDH,9]
M36GJ?A;5O[9UO4M'N;2WDO-)BL+7>6'DNK/\QP.@#<8[BF:IXZU/2+NSM[KP
M?J :]N?LUL1=VY$CX) ^_P <*3SBK&L>-I?#WADZSK.A7=H1=);BV,T4CG=@
M!LJQ&,D\9SQ0!!;_  I\'0Z-'I\FB6LK+ (6N"G[QCMP7S_>/7ZU7C\&Z]#I
M>@746IVH\1:+$]LLSJS0W4!XV2#A@<*AR,X8'KFNDA\0P2>++KP[)!)%<Q6J
M7<3MC;/&25)7_=; /U%)>>(H+7Q/8Z"D$DUU<V\ER[(1M@B3 W-]6.T8[T 4
M]/LO%5UK%O>:U>V-K:6P;%EIQ=Q.Q&,R.X!P.H4#KR3Q6-X=T3QOX:T6+2;4
M>'IX(9)722668,0\C/R F/XL59TGQQJ^N:5;ZGIW@O49K2X7?%)]LMEW#Z&0
M$?C75/>M#I#7UQ;O$R0&:2 L"R$+DKD'!(Z<'% '.:GH.NWEUH^O6TVGPZ]8
M)+%+$V]K::.3&5W8W#&U2#CKG@U)I>@ZQ<>*$\0^(9K(3V]LUM:6EB6:.,.0
M7=G8 LQV@=  !5*'XA3#2K36;_PSJ-GHURL;B^,T,BQI)C:S*K[@OS#/'%;M
MIXC@N_%NH^'E@D6>Q@BG>4XVL'S@#OVH @U'0+B\\<Z)KJ2Q+;V%O<12(V=S
M&3;@CC'&TYJKXO\ "UWXAU7PU=VT\,::5J*W<HDSEU'9<#K]:ZNN8\,>.-/\
M4ZA?6EK!/$;?YXGEQBYBWNGFI@\KN0C\O6@"&_\ #VM6'B>ZU[PW<66^_C1+
MZROMRQR,@PDBNH)5@.#P01574/#OB[5]%U:*[UFTAN]1C2V6&W#""UAS^\*D
MC<\C*2,G Z>E:=OXTL)O'%WX4>*:*[@C5XY7 \N8E%<JI_O!6!QZ9]*T;+6H
M;[7=5TI(G673O)WN<8?S%+#'TQ0!SM_\*O"-SHL]A;Z+:6\KP&.*X1/GC;&%
M<'U!P:JWGACQ7)K'AK6XKC2IM2TRQDMKH3O($E=PH+*0N>V>?6N_HH YD0>,
MKVRO+>ZN=)T^5HO]&N+(O*RR @C<KJ 5(!![\\57CT;Q%JVNZ3>Z[_9,$.ER
MO/&+%I'>5VC9.2ZC8N&)P,Y('-==10!FZ#<:A=:/%-JL4<5X7D#K&C*N [!2
M W(RH4\^M86C>$KS3?%GB_5I9X&AUKR/(12=R;$93NXQU/;-=?10!QA\%3M\
M/M(T47446KZ3#$UI>("5CGC7&?4J>5([@FJD'@34K'P]X9^PW]M#KV@PF))6
M1G@F5@ \;#@[3@'/4$5WU% ',V5EXLO-7M;K6;VPL[.VW-]DTUG?[0Q! \QW
M ^49SM ZXYXK;TT:@+,#4VMFNM[Y-L&";=QV?>YSMVY]\U;HH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** .)\6>)X#JW_"+PZQ9Z7))")+V]N)TC,,39 6,,>9&P>>BCD]A
M52RN=$\.^-K9TO+2WT:?08;>PG:91$WDRN64.3@G:ZGKS@^E=O/IMC<R>9/9
M6\LA&-TD2L?S(I9=/LIK9+:6SMY($(*Q/$I53[#&!0!YMIGBE=!\*VL<,UI;
M7FNZA>W-B]]((XH8&F=Q*^2,C:RD*.6+ >I&_#<>'M#\!W:PZ]97$4HG\R]>
MZC_TBY=2SY(.-Q)SM'08KJY[&TNMOVBU@FV#"^9&&Q],TW^S+ P"#[#;>2&W
M"/REV[O7&.M &'\/M0LK[P)H:6EY;W#P:=;1S+%*',;")<JV#P?8USQ_Y.,7
M_L6O_:]>@V]I;6BLMM;Q0ACDB- N?RIWD0_://\ *3SMNSS-HW;?3/7% 'E>
MD:?=0>%XO$^DQ-)J6EZCJ!>%.MU;&ZD\R+W/&Y?]I1ZUFV%Y$WAG1O%,2O/I
M-EXFO+N=D0G9#(\JB4CKA=X)[@5[1'%'$NV-%1<DX48&2<DTV*"&"/RX8DCC
MY.U% '/7@4 8$OCKP^)K*WLM0AU*YO95CA@L)%F?!ZN0#\JJ.23V'K7"Z6]@
MOB;Q<+KQO-H3_P!L/BW2YMXPX\J/Y\2(3[<<<5ZI;:=963N]K9V\#O\ ?:*)
M5+?7 YILNE:=-(TDMA:R2,<LS0J2?J<4 </J\EE<Q>#8[?6%UJ%=<\M[II8Y
M2Y,$Q(8H O (&,=,5B:@LWASQ'X<\)3!VLEUN*[TF4Y/[C9('A)]8V8 ?[++
MZ5ZO%96D**D5K#&JMO4+&  V,9'OCO3Y((I71Y(D=HSE"R@E3ZCTH XSQ_\
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MKU*'3K&W96AL[>-E.5*1*"#C&1@>E3R1QS1M'*BNC##*PR"/<4 ><3:$=?\
M$OC-+680:A;W-E<V%S_SRF6W&T_[IY4CN":E^'>LG7O%'BJ]DMVMKG_0XKFW
M;K%,B.KK[X8'![C!KT%(8HV9HXT5FQN*J 3@8&?PI$@BCDDDCB17D.795 +'
MW/>@"2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M889DU<3F?R0^%,2@3<^9DY..QYKJF\/ZA>:YX=U?4+RU:YTM+E9EMX61)3*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,'B>TTK3X);32[1DN9GN"DC.T.\B-0I!*JRGDC)...M:<4\T?PK2X25UF71
MZR!B&#>1G.?7/>@#J**\BTG4K",>%Y-"\5WNI:Q=36ZWEDVIM=J8V7]\70EM
MFT9.>,$8J]X?\2:QH^B&ZDL()M)&N3VLLSW+>=^\O&0,J[2-JEE&"<\'I@9
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MLH0,%YV2,1DGC/7!]#4FN^*O[&U:RTN#2+_4KN[BDF2.T,8VJA4,27=1_&*
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *@O+RULH#-=W$-O'G&^5P@SZ9-3U!=V5I
MJ$/DWMK#<Q9W;)HPZY]<&@#D_AGJ%FWPVT@)=0NUM9J9E1PQCZ_> Z=#5OP"
MC7'AE-:G'^EZRYU"4GKA_P#5K]%C"+^%;EII.FV"RK9Z?:6RRC$@AA5 XYZX
M'/4_G5F**."%(88UCB10J(@P% Z  =!0!R_@<_VE!J7B*3F74[R01D_PP1,8
MXE^F%+?5S6-XRS_PL;P_C73HO_$NO/\ 2AY7/SP_+^\!7GZ9XKT"""&VA6&"
M)(HE^ZD:A5'T J"]TK3M2*&^L+6Z*9V&>%7VYZXR.* .(UB[MH?"=U;W&O0^
M)OM-U;08N98DCBWRJH,AA"_)GD@]<8Z&N=M[:UNKCQ!ISZGH=NR:G9RP(EN1
M8RS",Y1H]QR#LP3G[R^HQ7J<>@:-#!-#%I-@D4Z[946V0+(/1ACD?6G-H>D/
M$8FTNQ:,Q"$H;="#&#D+C'W0><=* /+"-(N=1\+?:M)TNT2WURZM[D1,)+9G
M\AV)0L!A2Q!VX&&![BNQ^(X:+1=-U$QO):Z;JMM>72HNXB%&^9L#KMR&_P"
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M_(CTM[$PX.XL9 ^[TQ@8K&L_!6K166EZ%/?6;:#IEVEQ$RHWVB58WWQQMSM
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKXKTS3H[;4[FTCMY+!78)'(54DF09X'I7<Z;=S7MBEQ<6<MG(S.##*06 #$
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MTZLEHAC@1Q-F5U5/F)PI"@,1@@YQ6WJ/CG3-.NKV-[:_FMK!@E[>00;H;9B
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MPQQ@\4 >E=1FBFQ[_+7S,;\#=MZ9[XIU !1110 4444 %%%% !1110 4444
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M7&I![HQ.,R(D^XX)VY&6XR1D9H [G_A$/#7_ $ -,_\  5/\*/\ A$/#7_0
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M J?\(UX3SC^QM)!$?FD&V083^\>.!U_(^E4K:R\!7DRPV]EH4DCJ61!!'EU
MR67CE<=QQ3M1\&V<MC?"?5]35;C2CITSRW.Y67&!*P(YDYZ^YXYK)TK5-8TO
MQ%I&A>+["&6<LZ:9K%GQ',PC.5=.J,5!/H2..E &[IVA>#M6LEO+#2-)N+9V
M95D2U0@E6*G''8@BMVTL[:PMDMK.WBMX$SMCB0*HR<G 'N:\S\,:CJFD:/H$
ML5U$;&\UVZLI+4P\X::<[]^<Y!4>V/SK83Q+JB^(M*A^U17%M?:E<V;^3&#
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M67R9PASL? .T^^"*\LTOP_J/BKPAJ&DVXMH+<^([F9[QI3YD02Y+$HH7[W&
M=PX)JW>:CJFB7/CG5]/NHHUL]4MW>%X=WG P0 J3G@8/;G- 'J=%<)XD\2ZI
MI=W>36MS%+%:WMG!Y$489525XU<3,0,.=^5"$X&TD8-2IJ'B.]\1^(K>#5+2
M"VTF6/8AL]YD5X ^TG>,8)'/?':@#MJ*\XTO7_$EZG@^1]2ML:_9,TJ_9!^Y
M<1"3>O/)/(P>.1QQS;T[Q%JUSIL$%Q?0BY35[K3Y9(HOWUPL1D"F),%0QVJ6
M)^4#<>* .\HK@="\6ZCJ]OX?L9Y5M[S47OA+.J+NVVTA3"@Y4,WRD]1PV!TQ
M<?5];@OM.\/W,\<FHS07$\MS8J@)6-T5 !)A0Q$@+<'IP,'( .RHKBM/UCQ#
M'KOA_3-7>W2>\M+PW2P $!XFC",IYP2'R1R :QHM8UC68?!<\NI/#)<:M=P3
M>3&H#B-;@*2"#V0<=,G/I@ ]%M]0M;NYNK>"97FM'$<Z#JC%0P!_ @UFR^$]
M(EU&:_$=U#-.V^<6][-"DK8 RZ(X5C@ <CGO7/7'B[4;*[UZWFD@9H=7M-/M
M7\O:L2SK&=S<\XWGOS@=*TM0N=:TF*X6?5K-HI+N!+:5X\W'EL0'78JX:0D-
MLP,>O2@#=O=0T[1+2)KN>&TM]R0Q@\#<2%50!^ Q5VO+]7U>]U;P+JZ7V3)8
M^(+:T5G55=D6Y@(W!?EW8;!QQQ6[=>)+NT\8#3+^6:PBFNHX[&1H UM=H57<
MGF $K+NWX!(& , YS0!V=4K?5].NK^>PM[ZWENX,>= D@+QYZ;AU&?>KM>>0
MW%Q9^,?B-=6CHEQ#96<D;.FY05AD(R,C/3UH [Z*VAAFEEC0(\Q#28Z,0,9(
MZ9Q@9Z\#T%2UY[9^*=9L9='N=2N(KNVU#0YM0>&. 1F-XDB;Y3DYW!SU[CC'
M2M[0KC6;Y-)U26_M9;"_LQ+-#LVE)& 9!$0.5QN!W$G@$=Z .DJ-)XI)I(D<
M,\6-X'.TGD ^^.<>X]:9>W!M+"YN0NXPQ-)M]< G%>;33WP^#&D7\5])#=WL
MMG/<RH 3*T\Z%P<@\?.?R Z<4 >BP:I8W.HW.GPW,<EW:JK3Q*<F,-G;GZ[3
M^56Z\UU-M4L_%GBRYT_4$AN+30[68RR0!S(4^T$ C@ ''/'TQ6C_ ,))K&MO
M)::2I@NX]+M[U2HC*M+,'(#;SG8-F#MYYZC'(!V\DB0QM)(ZI&@+,S'  '4D
MTU+B%Y!&LBF38)-O<*>A([=_R-9SV<FN^&1::GF":ZME$_V27_5N0,[']CT/
MM7)>.M)N- \&:YK.EZCJDE]'I(M2)+@LK!2 9B,?ZP+GYOK0!ULGB71(O-,F
MJ6JI$2LDAD&Q6'4%NF?;.:U>M9.G:;IK^$[738H8GTQ[-8@F/E:,IC]16!/K
MNI7J^)SI=TD!T+"0QO&'%PPB$A,F>=IW!1M(/!.3T !VM016=O#;M;I"OE/G
M>K?-OSU+9ZY[YKAH?$>N:YJ/EV5Y%86\^@0:I$&M@[QNY;Y22<'H.W^-+HOB
M37+NX\(W-Q=6S0Z_9.[P+;X$+B$2!@<Y/<$$]^,4 =^  ,#@45YE8>)_% T?
MP]K]S>6D]K>ZBMA<V:6VP[7F:-9%;<3D$#CICWY.E!XEU7_A(](@-U%<6]_?
M7=K(8HQY""-9&38Q 9F&P!CRN2P!&* .[HKS>Q\3>(3:Z3J-S>VTD4^NRZ7+
M;I;;0R>;)&&SDD$;1_7-:,.NZM%J&JZ!=78.KB\B%@XB4![:3D/C')4)+N_W
M.,9% '0R>)]"B\[S-7LE\FY%I+NF4;)CT0^C>WL:?J.G:7XFT]K2\!N+828D
MC29X_F'!5MI!(YY4\'N*9/X=TZY%V)XA)]K9&G)5?G"] >.G)YZ\GFLDW,EG
M\5ELX_\ 4:AI+32J.GF12*H;ZE9,$_[*^E '4Q11P0I#$BQQQJ%1%& H'  '
M84^N=N-2O5\?6^CK/BTN-+FN2-@W)(DD:@@X]'/!S7-:3XF\0ZM'X107MM"V
MK07;7#BVW$-'T*\X[]/7UZ4 >CU4L-4L=46=K&YCN%MYF@E,9R%D !*_49%<
M7I'BW4M0BT'3)YXTO[Z[OH)KM(P,I;.RDJIR S87KD#YN.E9^B:K=Z.VI60D
M::YU#Q3/:^>JHK " /D!B%W$)CTR<X[4 >GT5P-]JWBW3HM/MYYK2*2YUI;-
M)'C5W>W=&96<*=H<%2#C@X'2NUT^*Z@L(8KZZ6ZNE7$DZQ>6'/KMR<?G0!9H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ K.UO0[+Q!IXLK]9#&LB3(T4C1O&Z'*LK*00016C7-
M>,_$MUX:L].EM-.EO7N[^"U(3;P'< CYF7YB,A>V<9P* %O? VBW\SR3_;?W
MT2172I>2JMVJC \T!OG.."3R1P<BK7BK39M1\%ZSIEC$IGN+":"",$*-S(54
M>@ZBN87QO=:;K7BDW>FZI=VEA)#*R0I&?L<)MHW;=EAN.2QPI8\'MBMO4O&U
ME82RB*QOKZ"VMTNKNXM44I;1,"0S;F!/ +84,0.<=* 'Z-X.TS3)(+LQSR7,
M=M]G1)[AY4@0@;EC5B0H.!T[ #IQ3=.\!Z'I=S8SP)=NVGN6LQ-=R2+;@JRE
M4#$@+ACQ[#T&-#Q!J=QI_A;4=3TV$7=Q!://!& 2)"%)'3DCZ=:Y[P]?:G>/
M;ZA8^*[/Q%8&-C=0)%%&Z':2OE[<8.[ VR'H>H(H WD\+:.GAQ] ^R[M-<N6
MB9V)RSER=V<@[CD$'CC'2JMMX)T:W!++=7$QN8;EKBYN7EE9XCF/+,2<+V'3
MD^M9&B?$)[WPU;ZE?:/>)<W=Y):VEM"(RURP>0 )\YQM5/F+%1D$CC%:(\<V
M"6%W+<65]!>VMS':2:<Z*9S+)CRU7:Q5MP(((;&,Y(P: +VH^%=)U26^EN89
M/-O4A661)61AY+%HV4@_*RLQ.15(^ -"W2R 7HGEV%YQ>R^89$)*R;MV=XW$
M;O0XZ<5EZQXMN9TTI;:"]TRZ77;6SO+>Y1=VQP3C*EE92,<J:Z?2=>M=;N+U
M;&.9[>UD\K[65'E2N/O!#G+;3P3C&> 3@T 43X*T<V,=N/MBRQSM<K=K=R"X
M\UAM9O,SN.5^4CI@ 8X%:VF:9:Z/I\=E9HRPH6/SN79F8EF9F)))))))[FN:
MNK_6]?\ %>HZ/I&HII=GI2Q"YN1 LTLLLB[PBAOE50I!)()R<563Q;>^%[G6
M;#Q-*+X:?9+J,-W;0A'G@+%6#)G:'5AV(!!'2@#=7PGIPC2-WN95BAD@@\R8
ML84? <*>O( &3G X&*:G@_24&FKMG9--MGM+9&E)"Q,H5E/][*JHYYXJF?',
M0DN(7T;4X;A;-[VUCF6-?M<2XW%/GX(W*2K;2 >E9FG>,'U.R\&W6HIJ.GW6
MJM\L,"Q>3.WE!R6RS,(^25Y#<<B@#9L_ NC6#VDD!OA):6[VL+->2,4B;'R<
MG&!M&!VQZU-)X,T6;PO!X=EAE;3[?;]G!F;S(2OW2K@[@1V.:IMX\LEF>3^S
M]0.EI=_8FU0*GD"7?LQ][?MW_+NVXSWJ.]^(5C9-J+_V7J<MKIEP;>^NHXT\
MN _+\QRX+#Y@?E!(') XR :D'A>SMK>WCAN;]98)#*+E[II)78KM)=FSOXXP
M<@8&!P*T-/TVTTO3TL;2();IN^4G.2Q+,3GJ222?K5NO.+'QKJLWBZ*\E:/_
M (16^OY=*M#L&1,@&V3=W5W65!]!0!T-GX4MAX8D\+WL;2:9&W^C.DA5A&'W
MH,@Y#(0!GN%![D"TWA/36GO9RUT9+VU6SG8SL2T0S@9/?YFYZ_,>:CU3Q9;Z
M=J[Z;'I]_?2PP"YNFM45EMHB2 S98$D[6^506P#Q6?'\1=/N?[*6RTW4[N?5
M+3[9;0Q1IN\L,%.XEP 1G/7'OG (!;N? FBW/]GL/ML$UA +6&>VNY(9#"/^
M6;,I!9?K710PQV\$<$*!(HU"(J]% & *YU?&EFVIBW%C??8FO#8KJ.U/(-P#
MMV?>W_>!7=MV[N,T6OC2SNM1A@6QODL[BX>UM]0=4\B:5=V5&&W#E6 )4 D<
M'ID W-0L;?4].N+"[0O;W$9BD4,5)4C!&1R/PJC%X<M$O+>ZEFN[F2U#"V^T
M3&3R<C:2,]6QD;FR<$\\FL$?$K3FAMKK^R=6^PW%RUG'="%"IG#,HC #[B25
MP"!C) R.<7(_'-G]DU![K3[^UO+&>*WDL9%1IGDEQY83:Q5MVX8^;USC% %B
M+P9I,-G96B&Y$-E>&]@7SR=LQ+$MGJ>68X/'S&HXO FAPS021I=K]GNWO($%
MW(%BD;=NVKNP =[9'OZ5%+X\L;6REEO=/U"VN8;N*SELVC1Y4>3&P_*Q#*<\
M%2?3J*S];^(<EAX<UZZAT6]AU/2HT9[6Z$9VB0'RY"4D(*9!S@YX(Q0!OP^$
M](CT:^TAX'GL;Z222XBFD+;F<[G.>HR3GCH>F*BL_!VG6-D+>*XU%F#HZSS7
MLDDJ;,[5#,3A1D_+T.3D'-:#:M%;Z%)JVH0S6,,,+331S[2\2J"3G86'0=B:
MY,>,+J\\6>'H38ZCIEK<V]U</%=(G[]%12K#8S8(R?E.&&1D4 =AIVF6VF12
MI;AMT\K3S2,<M)(W5C[\#IQP*I^(-);7K:+390!9/-'+<L3]]48.$ ]RHS[9
M[FLI?'2-;W+'0]4@G2Q>_MH;A8U:YB4@%EPYVD;ERK;2 >E0Z5XZFN] T6>7
M0[^;5=1M1<"SMA%DH%4M*"TF%CRX W-N.0,9H ZC4],L]8TV?3]0@6>UG79)
M&W<?4<@]P1R#5:UT&VM6DE$MS+<R0B W,LI:01C)"@]N23GJ3R2:RSXXLIAI
MRZ;87^I3WT#7*P6ZHKQ1J0K%][* 0QVXSG((IW@'5KC6_"J7]S,\KR7=TJM(
MNUMBSR*@([84 ?A0!KZ+H]KH&DP:98^8+2W79$CN6*+Z9/./K6;<^"M&NHK^
M)UN5BO[A;J>-+EPID!5MP&<+\RJ3CJ170T4 8=QX3TF\GU*6\B>Y_M.!+>[2
M5R5D1,[1CL1N;D8/-3:'X=LM A:.UDNYBP"^9=W+SN%'106)PHR>!6M10!@:
MAX.TC4=:.JRK<QW+H(I_(N7B2Y0=%E52 X'OVXZ<5+=>%=,N[V[NF2:-KZ-8
MKQ(I2J7*@8 <#VXR,''!.*VJ* ,>3PSI\E_=WH\Y)KJU6SDV2$+Y2YPH'08W
M-R.>:BA\)Z;;MI+1-<J=)A:"S_?$^6A4*1_M< #G/2MVB@#GX/!NDVUEIMI%
M]I$.FW!N;5?/)V2'=R3U/WFX.?O&E?P;H\L%]%+',XO;I;V1C,P99UQB1".4
M8;5Z>E;]% &%=^$M,OM.O;.[\^87Q0W4IE(DEV?=!88P!CH,#KZG-N#0[6#6
MY-8#3->2P+;NS29!122!CIU8G/N:TJ* ,B_\.6.I37#7+3M%<JBW$'F'RY0O
M(!7M[XQGH<BHI_".C74VJO<6SRKJJ@7<32OY;D*%W!<X#85?F'/ K<HH R(_
M#6G>5<)=))>FXM_LLCW;F1FAY^3Z<G/<]R<"J-OX&T>WT:ZTK=?2VMS";=A/
M>22,L)X\M"Q.U<=ACMZ"NEHH Q[/PUI]AJ[:I;F=;IX$MY#YIVRHGW=R]"1G
M[QY[9J74-"L]1O[:_<RPWMLK)%<0/M<*V-RGL5.!P0>1D<UIUCW&K&3Q-%HE
ML0)$M_MES)C.R/=M11[L0W/8*>Y!  R?PKI<]E86FR6*"QN!=0+'*01*"3O8
M]6.22<YR2<YJ]J>F0:OITEA=/-Y$@ ?RY"A8>A(['OZUQ^K>.C<:%)J&DO):
MK;:Q#93-<VS+N0SK&_W@ .K>XQSBNIM/$>D7UO=SP7J%+-]EQO5D,9P",A@#
MR",>N>,T &N>'['Q%I/]FZCYSVQ9'.R0HQ92"IW+@CD \4D&@6EOK$NJI+<F
M\EMUMGD:4G**25&.F06)SUY-3Z?K%CJDEQ':3%I;9@D\3QM')&2,C<K $9'(
M..>U8>H>(=7M3K'EZ%J,WV.:%8O)A5O.B;&YH\M\[#G(. ..N#D NQ>$='C\
M.2: T,DNG.S/Y<DK$JQ;?D-G(.[Y@0>#TJ]8:1;6$\ER&EGNI46-[B=]SE%S
MM7/8#)/'<DGFL73M:O/$NLZO;V$XL[#2Y_LCS",/)+.%#.!G(55R!T))SR,<
MPV'C6WM+K6M.\0W%O;7.D31(\Z@K',DHS$P')!/((YY'O0!JIX4T6.WM[=+&
M,16]\=0B7^[.69MWYL<>@P.U33:!9SZR^K%YUNWMC:%ED( B)S@#IUYSUK/E
M\=: NEZM?6]X;I=+C,ES%#&Q=1@D$#&2IQ][[O?.*EAUR"]U+1E34?LSW4$D
MOV"2W(>< #G+ %0O/;G- %:7P#H<ECIEJ@O+<Z8ACM)[>Z>*:-#U3>I!*G X
M-37?@C0[R4N\-PF^S-C(L5S(@EAY.'P?F.68Y//)SFK\?B+2I;R*T6\7S)G:
M.(E6"2LN=RHY&UB,'(!)X/H:JQ^,_#TUS%;QZI$\DEP;5<*Q'F@XV%L8!)X&
M3R>F: (CX*T@3VEQ%]LAGMK86@EBNY%>2$<A'.<L,\C/([5IZ1H]IH>C6^E6
M DCM;>/RX@TA=E'U;/\ A5^N3T3Q9+J/C'4]'N(!% (A<:=+_P ]XU8QRG\'
M''JK T ;.B:#9>'[>>"Q\X1S3/.XDD+_ +QCECD\\GFJ5SX-TF\@U6";[2T>
MJRK+=J)B-[* !C^[PJCC'2KNH>(=*TIIEO;Q8O(19)CM9A"K$A6<@$("0>3C
MH?2JMSXR\/6DZ0S:I$LKHDBH S$JS;5/ Z$T 5[SP+HE_)>O.MV?MKQ2SJEW
M(BM)'MVR;5( ;Y%Y'I5ZW\.6-K<ZE<0O<B34@HN"9B<[5V*1GH0HQD?SJ3_A
M(-+_ +1BL#=@3S.T<648)(ZYW(KXVEA@Y .>#Z&D7Q'I+7R6?VQ1-(',>Y&5
M9-GW]CD;6([@$XP: *UMX1TRT&CB$W"C1T*60\XGRU*[2#_>^7CG-0#P/HP,
M;+]K66*\DO4E2Z=7663/F$,"#ALG(Z?2I(O&_AN<V_EZM"5N0WDOM8*Y7.0&
MQC=P?ESDCM5RU\1Z3>Z<]_;W8>".4P-\C!Q)D#84(W;LD?+C)R/6@#+?X?Z"
MVG0V21W4*P7+W5O+%=R++!(Y);8^<J#N.0.#GUJ>_P#!>CZC965O(MU&]B[/
M;74-U(D\;-]X^8#N);ODG-2GQAX?2%)9-3BC5[@VH$@9&$P&2C*0"IQS@@56
MOO'&CVVB'5());J(7:616.%]R2LRKM8;<KC<#R.>,9)&0"S<>$]+G&G?\?43
MZ?O\B6*Y=9,/]\,^<MNP"23DGG.:AC\$:)#I]G8Q17"16=TUW 4N9%9)&W;L
M$'(!WL"!QS5:_E\4R?VQ)IMS;B(Q0R:=YMDVY7_C1@6&[([\;=W/0XT(M7FM
M?$<&CWY3?>6[7%LZC&2A421^^-RD'N"<],D 9<>#M&O(M7BNH))X]6=7NT>0
MX9E "LO]T@*N,8Z"HV\$Z3)IJ6<KWTS1SI<+=2WDC3K(F=I$A.1@$C'3D\<F
MNA;=L.W!;'&?6N(EU#Q+;>+='T*;5+-C>64UQ+*MGC:\9084;^GS'KZ4 :K>
M!]%-G>6NV[$-Y=)>3+]JD.Z52I#9))'*J3ZD<YJX_ANQENC-,]Q*IN$NC"\F
M8_.3&U\=L;0<# R,XS7/GQ/>:)XL:Q\0:A!]ECTE;EO)MSS)YI4L -S8VKG'
M;GTS72W&OZ9;6<-VUSO@FA\^-H8VE+1X!W@("=N".>G(]: (]"TAM'BO$-Q-
M*MQ=/<*LLS2^6& ^4,W.,@G'0;L>YA/A33C>:M=[KGSM6B6*\/G'#JJE0 /X
M< D<8ZUHC4[$Z6-3%U$;$Q><+@-E"F,[L^F*S;'QEX>U.\2TLM3CFN)(/M$<
M:JV9$QG*\?,0#R!DCN* '0^%=-@GTV51.QTVV:UM@\A(6)@ 5(_BR%4<Y/ J
M+1_!ND:$)%L?M:Q%62*)[N1TMU;J(E)PGX<U;A\2Z/<1:?+%>HT>H,RVK[6"
MRE020#C@X5C@^AJO;^,_#MW(Z0:K"YC1W8X8 !&V-SC&0Q QUY'K0!J6-C%8
M:;!8QM))##&(P9G,C, ,?,QY)^M85GX3MQX8?PQ>HTFFPL/LTB2%6"!]\8R#
MD,A &>^ >Y J>*?%JV_AV[N]'ODCN;*[MHKE)H2KQK)*BD,K@%<J^02*VH?%
M.B3V]]<)J$8CL"!<EPR>7D9'! )![$<'MF@"%_">FO-?REKHO?VJV=P3.Q+Q
M+D 9/?YFYZ_,>:KW/@71KE["3-[!/8P"UBGMKN2&1H1TC9E(++]:TH_$.ERQ
M7,BW)'V:18IHWB=9$=L;5*$!LMN7''.1C-.&NZ>UL9Q,^WS3#L\E_,,@&2H3
M&XG&3@#H": +T,,=O#'#"@2*-0B*HP% & !2R1I-$\<B*\;@JRL,A@>H(JMI
MVJ66JV*WEC<)-;DLN\9&"#@@@\@@@@@\BLJ+QQX:FO+>UCU>!I;B4P18SAI
M2-F[& <@@ GGMF@!]CX3T_3H1:VTMXM@/NV1N6:%1_= /.W_ &<[>V,4^[\+
M:9=WUW=LLT3WL0AO%AE*+<H!@!P/0$C(P<<9Q4;>,= :[ELDU6$7*/)$P"D[
M'1-[ G&.%Y]\''2GV&N6<6@Z;<7&I_;S<0!TGBMVW7  !+B-02!R#P,#(H D
M;PW8'4Y=07SHYY+061\N3:HA!)"A>@P23GKS5>#PGIEBFD&!;D_V,C+9()B=
MH*[2O/WLKQ\U6G\2Z0FGPWZW@EMIXC/&\"-+NC'5\("=HR,GH.]7HKVWN+%+
MV"436SQ^:DD7SAU(R"N,YR/2@#D?!'A:2S\.Z?'K%O<1W-I<2SI;2S*\:.SN
M0XVD@\-T)P#D@ \UH0>!-#MIK:2%;M/LMR]U;J+N3;"[[MP5=V IWMD=\^G%
M9V@>);C5X$UV;43;6 N)X)+*6S.&Q*T<7EM@,7.T9 W9)Q@'%;LGBO0X;&:\
MFU&.&&"802^:K(T<AQA64C<"<CJ.A!H KIX,TI+.WM%-T(;>]-_&//.1.6+;
ML]_F8G'3GI3=.L;K4?$7]MZII$=C/:0R6EJ/.65W5G!+DKP 0JX'49;/6M6R
MUBQU+3Y+ZSF,UO&SJS)&V<J2& 7&2<CL.>U<A<>.OM=IX9U:QE:UTZ_U$V\Z
MSP$%H_+E8$%A_P!,QTSUQF@#O:Q[726;Q+<ZY<@+,;=;.W3.=D08LQ/NS8_!
M5[YJ2U\1:3>Z:;^WNP]N)3"?D8.) <%-A&[=G^'&:L:;JMEJ]N\UC.)4CD:*
M0;2K1NO564@%2/0@&@"MJ7AZQU74;2_G-Q'<VJNB203M$61L%D;:1E254X]J
MIV'@O2-,.F&T%S'_ &8)%M09V8)YGW^#G.?3H.V*Q1XFU'5-7U_3+'4;6SUC
M3Y&2TTVXASYZ! 5D))!8,2<%2 HQD'O:O/%1T?QM<VFJ7B1Z8FE1W:HL)9E<
MR,K'Y06( 7/H.: +K>!M&-C!;*+E#;W3WD$R7#++%*Y)<J_7#%CD=#GI39/
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M5P S(KC![\,*NT >>^(].UWQIIUG#<Z1-8VBZQ;R"/SU6X6W4'S'8JQ"G).
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MP7;:6P/FY.%8_0&@#J**Y&T\)>%[R>[B&ASQ&VD\LM,)463C.4)/S+[BK?\
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M"1$V>ROT)'<#I5N@#S33=#UF#PYX-M9=)G6?3]7>YNDWQGRXR)ANSNP?]8O
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MJEM-)#YAD9"P#Y8XY!&%QZUZ!J'@?P_J=Y=W5U9RF6\*FZ,=U+&)P%"A7"L
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M <%HMUJ+:IHOA*34;J6XTO4KJ2\G:5O,E@B4-%O.<D-]HASGKMK,\.C6M;\
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MCI73>#-$O]'O_%$M[$(TO]7DNK<APVZ,JH!XZ=#P: ,J3Q??:1X@\7E].O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN "L .JGJ<=>-?4/ VI70U.VM];A@L;N^7450V9:03!D8!VWC<FY <  ]!G
MY *6H^+O$L%AXBU> :8MCHE\\!A>%VDN8UV$_,' 0@-UP<GL.^E-XSGTR+Q8
MNIQ1"XT?$]LL:D>?#(N8>I.6+AD..X[5-<>"WN?#7B+27U!0^LW$DYE$/$1<
M*,;=W/W?4=:R-;TVW\3_ !*TI;/SS'IR-_:S^61$ZHZR0Q$D89O,&[ [ ^M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&I6TMS%(1M,*OE\YZ\=N] &)=:EKFB:EJ>D7&MG4\Z)<7T<S01Q2VSH0HSL
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M+^["VTB'G//S,!QGK0!6U;QQ<7T.D3:;97]M8W6M6UM%?DILN$\X*XP&+!6
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M7$1MY=1-Y&UL@(VM(J@^8>,D*5'.,F@"RGCZ.ZFAM],T74-0N)=.@U()"8U
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M:X+MNDD7<"P*E>0&(VD8YH OR^-X9+NUM-*TN^U.>ZT^/485AV(#"Y(!+.P
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M+*,E\  GI7->-/"VL:[=^(8%TE[\W=LJ:;<R786&V CPRE-V=Y?)!VD'<,D
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M/_H[Q!HPK$[<GN ?F''!(;X/\(OI%UI-K<^&BLNFJ5;5'OMT;E5**\48<G+
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MUK4K.U65A>Z=>VD;2JOVCR.73.?E/4 G SB@#1T/7;_4OB!J-E=6UU91P:9
MYLYV5@LC2298%20<J%Y![8[5#>^(]1L/B#J5A;V%]J<:Z9;SQVMNR*$.^4.V
M78#)P@QG)QTX-6-#MM8N?'.H:Y?Z6UA:3Z=!;0I)-&\F4DD8[@A(!^;/!(QC
MG.0([V+7-+\=ZCK-GHDFHV=QIT%NHAGB1_-1Y6Z.P^7##)]Q@'G !HZ%XRTW
MQ!?16MHDZ&:Q2_A:10!)&S%6 Y^\K###W%7=%UV'7M+EU"SMYC LTL46[:/.
M\MBNY>>A(.,XKSG6]"U3PQX+\+O92PKXBMY&L44-PYN@P=1ZA&*O](R:].T?
M2X-%T:RTNU&(+2%84]PHQD^YZT >=1^.]8O['0=0DTV[MQ-KLUJ883&3<H%N
M L8 <\@H@);:,C.<<UT\?CF#[%=M/I=[#J-M>)8G3B8VD>9U#(%8-M(*MG.0
M  <]*Y_1?#NNVZZ+8W&EM$FEZ]<7;7'G1E)89!<$,H#;N#(@((!Y]CB37O!^
MHZAJ>M7AL?M,1U:TOH8!.(S<QI;")U# C:>6QDC) ['- &AK/C"U.A/-=QZK
MIMQ;:E!:7$$#1B9)&*E03DJ48,IR#R#ZUJQ>+$N?%EWX?M=,O)I;)T%U<#8(
MH5>,.K$ELG.<8 )X/:N2U7PA>7WA5X=,\.G3IY=6MK@P2W@DE:*-ER[L6*@\
M'Y0QX [\5U>AZ5>6?C#Q3J$\06VOY;9K=]P.\)"%;@'(P01S0!%XA\3:AI/B
MK0-*M-+DNHM0:7S'1D!PB$X7<PP1PQSVX&33K;QI;W.H0QC3KQ-/N+I[.WU%
MMGE2S*6!  ;< 2K ,1@D>XS'XHL-2;Q+X9U>PL'OH[":<3Q1R(CA9(]H8;R
M0#UYS6!H'@YM,U*TM+CPTTS6MZ\PU1[[]T4WL\;+&')\SE005 X)S0!JI\1[
M1]'U#6/[(U%=-L2R2W#!,-(LOEE%&[)Z[LXQCCKQ4W_"<S_VE/I:^&-6.I)
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MLK/'@R, PVN0Q!ZC(&*BT#PKJVGZIX>N[J&/=&=2N+W9("L,EQ(KJ@[MCD9
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M#US71T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44QY8X
MV17D56<X4$X+'T'K3Z "BFK(CE@CJQ4[6P<X/H:=0 4444 %%%% !137D2--
MTCJBCNQP*=0 4444 %%-,B"01EU#L"0N>2!UX_&G4 %%,DECA7=+(J+D#+'
MS3F940N[!549))P * %HI 0P!!!!Y!%+0!72QM8[^6^6!!=2QK%)*!\S(I)4
M'V!9OSJQ110 4444 %%,,T0E,9D3S NXKN&0/7'I2QR)+&)(W5T;D,IR#^-
M"LJNA1U#*PP01D$5E:5X8T/0YY)M+TJUM)9%VL\48!VYSM'H,]AQ6HTB)MWN
MJ[CM7)QD^@IU !113%EC:1XUD4NF-R@\KGID=J 'T444 %%%% !1110 444W
MS$\SR]Z^9C=MSSCUQ0 ZBBB@#(MO"V@V>K-JEMI%G%?,S,9TB 8,WWB/0GN1
MUK7HHH **8DL<C.J2*Q0X8*<[3Z'TI?,3S#'O7>!N*YYQZXH =1110 4444
M%%-\Q/,\O>N_&[;GG'KBCS$,ACWKO R5SR!ZXH =1110 51U#1=-U:2VDU"R
MANFM7\R'S5W!&XY Z9X'Y5<:1$V[W5=QVC)QD^E.H **** "BBB@ HHHH **
M*"0!D\"@ HIL<B31B2-U=&Z,IR#^-.H **** "BBB@"C)HNFRZQ'J\EE"^H1
M1^7'<,N71>> >W4]/6KU%% !1110 444UY$B0O(ZHBC)9C@"@!U%%% !131(
MAD,8=2X )7/(!Z''X4Z@ HHIKR(A4.ZJ6.U<G&3Z"@!U%%% !113#-$)A$9$
M$I&0FX9(]<4 /HHZ4U'21%=&5D89#*<@B@!U%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;> NX<<AL=14T6@ZO?\ B'QM::;J,5A:74T%M()K4R$)]EC&Z,[EPV"1SN'
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M(=&U.:YAL=5L[F2U_P!>L4RL8QZG!X'!YKRG6;T3>&_%6GZ5KMUKN@KIBO\
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M.-I(\MTHV^8WF X4_,VT8/W>>O&]H6JZ[K'BO6H7GM(M+TN]-N(Q 3)/F)&
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M4[2)V\LL2&F0#HPXSC([C(XS0!UT<L,CR11R1LT1"NBL"4)&0".W!!IX 48
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MW: I);EBDS8R?+!RQ&.: .>\,:5%J?Q U?Q3!#=1:<5"6JW$31"2=E433*C
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MP'#>S^+Y)+YP/$<$4+JL8_<>7&4!!S\V<Y[5HR^+]+A\81^&7EQ?/!YWL#D
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MZB@#+N_"FHW,6G71U]O[:L+B2:.\>U#1D2 JT?E!A\F,8^;(P#DU=\->'9-
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M?73[ZT@N-)<HTMYN\K@(2YV\[07V^N10 W3? $6D66@BRU!HK[22R?:A"/\
M2(78L\3KGD'.1SP1D5T&C1ZE''>_VE,9"UY*UOE5!6'=\@^7T'KSC&>:@O\
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MOS22F3&7+9X((X&,?E5>7P+<ZF93KNMF]?["]E!+#:B!T5F1M['<V]PT:$<
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M[G7=3O+421E=L31/L;!^[DY89_O"NB\.WL.D7WB9[I9(TN/$(BBVQL=S/%"
M>!T)[]*ZR;4;*WG>&:ZACE2$W#HS@%8P<%R/[H]:?:W5O?6L5U:S1SV\RAXY
M8V#*ZGH01U% $U<=\/XWC_X2C>C+N\07;+N&,CY>1[5V-% 'E6GV;1?#KPBB
MV[*ZZ]#(P"8(S<OEC^!ZU7T2T)OK31]0UR\2]M];DN?[-2Q4G<)GD$ADQG8R
MG.[/1L>U>NT4 <YXTETE=(BBUW39;S2YIE2>2-"WV;@E9#M^8 $ ;EZ9KSK5
M7$_ASQ38Z%J.I:KX?_LL$-=,\HBN-^/+CD8;F&SDC)QQZU[110!YYXP,]AXE
M>YLM.2Z,/AF^5+=HMT<F'APA4=1U^7N,UR.M7(N8==\K5+C58[CPS-#;S_9%
MAC=U8,8XPJC.T'.#G&<9X->XT4 ><^)H)--O?"5XFH-I.GVMI-;M=);K(L#L
MD>P,&!"@A'&?P[UF;-/T?3]/OK?Q#>V%W(MW)!>7FG P7*23;VC:/ QEL,H&
MTX/'I7J#:A9IJ*:>UU"+R2,RI 7&]D!P6 ZXSWJNFOZ/+:VMU'JEHUO=S?9[
M>43*5EDR1L4YY;*D8'H: ,BX\G4/AFIU>PGM(I]-0W-K9QG?!E!D(N,C;Z8[
M=.U<3<WUUJ$#3-<IKFFZ;J.GW,VIPV>QY8E=]R.%&',?RN=HX#=,UZQ<W=M9
MK&US/'"LDBQ(9& W.QPJCW). *FH XO0;J'6OB%JFL:8QETS^S;>U:X52$FF
M$DC?*3][:K $^^*YKX@7EQ/+XLTY)Y+69M/5;>UM;%7EU!?+8EF<J254EAQC
M;@\Y(KUFB@#S&'6])TW4/$QUBWDO8M76WFLH5MS)]OA,"((T&,$[@PP<8W9/
M!S6=K6H6>E:)\1-+U*"1+^^\V>UA,18RQ&V14*D @A"K9YPNTUZ_5/5M.CUC
M1K[3)G=(KRWDMW9,;E5U*DC/?F@#SRUU.WT36M86]\U7U'1;+[$BQLQN&5)5
M94P.6!9>/?/2JGAVWF7Q)\-F:*0"/PXZN2I^4^7'P?0UZ?%):Z<EEI[7"+(R
M>5 CL TFQ><#N0!DXJW0!Y!8Z?<0_!GP\\(EM1;:A'=73I!YC(HG8F0H0=VT
ME6Z'A?:EG%O'<VOB/^U;K5K&/7+>6^NFM!'& L#HLBA1\RJ7C!;'!'M7J6I:
MKIVC6OVK4[ZVLK?<%\VXE6-<GH,D]:M1R)-$DL;J\;@,K*<@@]"#0!Q7@ZZM
M]0\:^+K^SC?[+<&S,<QC*B;$; LN1R,C&>^*S=8O8M-\672Z;>/)=75_;&ZT
M2[L]ZW)_=KYT+XRNU0IW9*@QG(%>DT4 >4R6;+\--6VV["5_$K2\)\Q_XF*_
M-_WR!SZ"JFN:I))?7'G7;VQM/$4$LVG6]DH5($N(_P#297VECN4!MP(Z@<@&
MO8:AN+NVM/*^T3QQ>=((H][ ;W/11ZDX/% 'C&O6T[^%_BL%AD)EOHS& A^<
M8CZ>M>D>*T9_AGK:*I+G2)P% Y)\D\5N6FH6=\UPMI=0SFWE,,PC<-Y<@ZJV
M.A&1Q3[N[MK"TEN[N>."WB4M)+(P54 [DGH* /+KF6/Q#+X<T_04=;RPTN[2
M=/+*&UW6WEHC9 P2Y7 _V<U9\$)#>:GH9.MWEU<Z;8-&;,V"PK: JBM'(P4$
M'(& >NS->EQRQRPK-&ZO&ZAE=3D$'D$&F6MW;WUI%=6D\<]O*H>.6-@RNIZ$
M$=10!Q?BJ.1OBIX!D6-V2/\ M'<P&0N8!C)[5S=K-I[6LFB17-WJF@_V?<++
M;FQ*WNE)@?)N YZXVD;OE'+ 5Z]10!Y!>ZG<75C<3->IK-AIU_IERVK16?ER
M&-9R71]HPYC W94# <Y I?$,[>(;[Q3=Z3Y\EM]BTQUFC@+"5([F1Y"@(^?"
M@\<YP17K%M=VUXCO;3QS(DC1,T;!@'4X93CN"""*FH \?U**.^L[_6X-7N]<
MBAN=-:]=;(1QM#%.78*% WLH8EN#@8KI=#U"SUCXI7^H:<&DM&T:&/[2(RJ2
ML)7)VDCYL @9_#M7=T4 >?Z^YA^)FS>89+_P_+:6DA!PTYER%!]>0:RM-N[;
M4M*\!Z)I\4BZIIEQ ]Y!Y3*UHL4+++OR/ER3M_VMW&:]5J&UN[:^@\^UGCGB
MW,F^-@PRI*L,CN""#[B@#D?B),EHOAF^GW+;6NN0RSR!21&GER#<<=!D@9]Z
MY[4;;S? OQ,DC@+/<7<[(0ARX\B+;CUYSBO5:* /(=9M3_;'BC3=2UN\L5U6
M6(PVT-BLSW<9AC0>6Q!.596& ?EQGC.:[CQYI5YJW@J\M;%//O(S%<11DX\U
MHI%DV_CLQ^-=-5:TU"SOVN%M+J&<V\IAF$;AO+D'56QT(R.* .(UWQQIFN>%
M[[2](CNKG6;^V>VCT]K9UDC=U*_O,C"!<Y))QQ6;I]YI/A+Q=K=MJ[_+%HUA
M;"8QEA)M20%.!U; P.^/:O3+J[MK&W,]W/'!"&52\C!5!8A5&3ZD@?4U4M=&
MAM->U'5DDD,U]'#'(AQM41;\8^N\Y^E 'G'A5)= UWP5'JZR6[R>'6LT\Q3Q
M*98B(SZ,!V/I6=X81]-T/PSJE_%(FG66N7[7+&,D1;Q*L<C#' !.,]MU>TU1
MM=9TN^OKBQM-1M+B[MN)X8IE9XN<?, <CGUH \QN(EU?Q!)JMK"TNE7?B73V
M@<QD+*8X2'D (Y7=@;NAVT_Q3:71\2:_=0M-!#!?:5<33QP^9L10X+[2"&VG
M:QX. OM7K-% 'C]];&:!==L_$%Y=0+K4$MWJ/V! B!('C$BJ%PZ@O&"V,#;G
M^&NV\#PP&#5+ZWU.XU%;R\\QKB6W$*2,(T0L@  *_*!G')!KJJAEN[:&Y@MI
M9XTGN-WDQLP#2;1DX'? YH \CU75))-0W3W;VYM/$D<EQIUO9*J0PI<!1<2O
MMW$LNUMV[G=TP#6SH5[%:^*[+3=+O'O;-[NY:73[NSQ/IA(D9I%DP,*6.T!L
MY$@P37H%[J%GIT22WMU#;QO(L2-*X4,[' 49[GTJS0!P_C:>UL=6M+T:Q)I&
MHK:R1Q32VOGVUPA928G'][(4@ @]<9K(T?6;;1-6U"^\1V?]G?VGI=B]O!Y+
M%<+$P>W0 =58GY.OS#BO2;>[MKLS"WGCE,,ABEV,#L< $J?0\CCWJ:@#R;PH
MQ\'7NCW'B7?:1/X=AMHI94)$4BR.S1$@<-M:/COMQVJ7PGIT\.L^#GN+.2)1
M!J\\*21D&%))HVC!!^Z=C=/J*].^UVWVTV7GQ_:A'YOD[AOV9QNQUQGC-34
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M_LX[UZ[J.IV&D6AN]2O;>SMP0#+<2B-<GH,GO2S:E8V^FG4IKN!+$1B4W#2
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M)&YFA!R P92,@Y((Z9/7- &58:QXF\1ZQ9V(O'T7S-#AO;A1:J98YS(ZL )
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M\V*XVD!U&!D;B"5QP!TK663Q#<^)SX?B\0-&=/L$NI[K[)$6N9))'"AEQ@(
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MUS: (RR(HVG:64E"PX.WZ\'FI6\*22ZI%/<:U?3V,-W]LBLI A"29) WXW[
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M7LAW(\D3M;2JDZH,L8F*XDP 3\A-7G\1Z3'H]GJS7B_8;PQ+;RJK'S#(0$
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MJ.SMH+0J4O;9B8YU;L$.7# X&.<Y&,U'XREL19VUOK&@R:II$SD7#QPF8VQ
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MTO2+;2%NUMB^+JZDNI-YS\[G+8]JOT44 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M%BN,Y/)QZGDXKG_#?AW6[:3PBVHVMO!_8EA/8R^7<>9YF4A5''RCKY;<=N*
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ML+"6UGMKJPM?/,H:6*3>QD<*,*V H !QU]JI:WX7U[Q/#KM[=6MM975SI/\
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MQPS,\:*"![E3]*[J@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M$UJ*>POK(EH#.TQF?@^:N0 F.00/EY P#B@#L=B_W1^5&Q?[H_*N6O;V6_\
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M3:-A* L,%NF#S2V?CVX90]]IEO"+BPEOK18;T2L1&H8QRC:-CX(/&X<'GCD
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MSUQXMU71M/OKK7O#_D>3#') ;2Y\Y)G=PBQ%BJ[7W,HZ$8.<\4RX\9:CI/\
M:,&M:1;P7=OI<VIVZVUV98YDC^\A8HI5@2O8C!SVH VAX4T 1VL8T>RV6C,]
MNIA!$1;[VWTR>3[T^U\,Z'9/:/:Z5:P-:!A;F.,+Y6[[VW'3/?UK!B\::C'=
MVRZCHL=M!?6,UY9LEWO<^6JL4D78 I(8'@M2:7XVO[NXT&2_T:*ST_6XB]M*
M+O?(C"(RX=-@ !4-@ACT&0,X !OR^&M$GUN/69=*LWU.,#;=-$#(,=#GU'8]
MJFM]$TVUNC<P6<22EWDR!T=\[F Z!CDY(Y.>:YC2_B!]KFL)KRRM[;3=2222
MSF2[\R4!4,@\V/:-FY%9A@MC&#S4MCXKUZ^LH;Y?#<:6=[:O<V4GVPD@!=RB
M<!/W>X=-N_!X- '46&G6>EV$=C86T=M:Q A(HEVJN22<#ZDU'8:/IVEO.]C9
MQ6[7#F28QKCS'/5F]3[]:\^TSQ/>7>A>!+O7K(3WFIW2+%-;WC(!F(MYCJJJ
M"3S\G(''-;$_CN\BMKO6$TB)_#UI=M:RW1NB)CMD\MY%CV8*!L_Q D G% '0
MWWAK1-3NY+J^TNUN)Y(3 \DD8)9.?E/KU/YFIK?1-+M+T7EM86\-R(A")(T"
MD1CHG'\(].E<KJ7CK4K1=?N;;0HIK'0IREW*]YL9T$:.3&NPY8!CD$@<#!.>
M.C\0ZTVB>&;W68;4W8M8?/,0?:60<L<X/1<GIVH 6W\,Z'::G<ZE;Z5:0WUR
M")IXX@KOGKR/7OZTL7AO18([2.+3;9$LW,ELJI@0L>I4?PGD]/4UFMXQA_X3
M:U\/1VWF17%L)1>"3Y1(P=ECQCDE(W;.?3UK#@\71:QXB\+RKI3B74!J'V*3
M[:ZH$BX#,@&&W@ C(.W/&: .J@\)^'K:>.>#1;&.6.8SHZP*"KG.6''!Y-3V
M>A:58)LM;&&-/+\D*%R%C[H >B^PXKS6/Q-XDU'0/#^HW5M&T\GB1X8DM[G'
MFJ#<KL?Y%"JNU1GYLA=Q&>*[WP]KMWJEWJFGZC8Q6E_ITJ)*L$YFC=70.K*Q
M53T.,$=J 'VO@_PY8V-U8VNBV,-K=G_2(DA 67V8=QR>.E:\4$4%NEO$@2)%
MVJHZ >@KS/Q)X@\02CXA6+)!%8Z=I@,,D5P1)&6B=@PP@)+<9^;Y<#&<UM)X
MUN]*D1->TM+2U?3)K^"6*Y\URD(4NKKM 5\.#P6';- '30:'I5MI\UA#I]NE
MG.6,L'EC8^[[V5Z'/?UKG]<\#V<GA&70M T_3[.*:YAFD1AL1@DJ.<X4Y)";
M>:GT+Q5=:AJ\>FZE86UI/<6IN[?[/>>>-JE0R/\ *NUQO7@9!R<'BGZMXDU.
M#Q0OA_2=)AN[EK+[9YL]T88U7>4(.$8YZ8P._;&: -0Z#I<EE/:2V,+PW('V
MA'^?S<#&&)Y8 <<]J34/#VCZKIL>G:AIMM<V<1!CAE0,$(Z8ST].*Q]$\;+K
M5WHUNM@T+:A;W4D@:3)@D@D6-TZ?-\S'GCITYJG=>/KB-+=;71OM%Q<:Q<Z3
M'']HVC=%OPY.W@$ISZ GKC! .D?P[H[QP1_V= J01&")47:%C/5!C'RG RO0
MTR_\+Z#JMS:W-_I%E<S6H @>2%24 Z >WMTK%N/%>M_:[NVL- BO)M-AB?44
M6\*D2.F\QPC9^\(4@_-MSD5C-XCUG2]>\;7=GI@O;2Q>"XE6XNS"4C%I&Q6,
M;6RW#$@[1[\T =O+H&DSR7DDNGP.]Z@CNBR_ZY1T5_[PZC!]:'\/:/))!(^F
M6KO!";>)FC!*1G@H#Z>U8&O^-+O2;4ZC!I<$NF1V:WDDUQ>"%Y%()*Q)M.]@
MHR02HY %3_\ "5WMSXCN=.T[2X+F"SDA2X+7@2?$BJWF)$5PR*'&26&<,!G'
M(!O6.E6&FDFSMDB)4)D<D*,X49Z*,G ' R:9=:)I=[>_;+FPMY;KRC!YS1@O
MY9SE<]<<G\SZUS4'CMYM1A;[#;C2)[\Z?%<"[S.9 Y0.8MO"%QM!W9Y!Q@UL
M^(-=FTF33[.RLUO-1U&8PV\+R^6@VJ79G;!(4 =@2<@4 6(_#VCPM9M'IUNI
MLD*6V$_U*G@A?0$<8%1V?A70-.FMYK/1K&"2WW>2\<"@Q[OO8..,X%<]=^/[
MC3M/N_M>C9U.SU&WL9[2&XW*WG;2CHY49!#="!R"#CK73QZA<6F@2:CK-O%:
MRP0O-<10RF545<GAB%SP/04 3:=I=AI%L;;3K."T@+%S'"@1<GJ<"F6.CZ=I
MLUQ-96<4$MPV^9HQ@R-ZMZGW-</_ &_K6I^(_!,UYIJV%K?3S31B&[,A9#:R
M,%E&U0&Y4X&X<'GCDT?QDD.B0_V;IL<<UYJ]S9QK?:B_E!TW,6:1E8C.WA #
MR<"@#LK_ ,.:-JEV;N^TRUN+@PF R21@L8SG*Y].3^9J2WT+2K.\CN[;3[>&
MXCA$"21H%*QCH@QT7VZ5@3>*]:_M2PTB#P]&-3NK.6Y=)[W;'#LD"'+*C$J<
M@@@9Y&0.<0P>.KG4+?3;:PTE#K-Y-<PR6L]SLCMS;MME+2!22,E0,+SN'2@#
MH8?#6B6^KS:M#I5I'J$P(DN4B =L]3GU/<]Z1/#6B1P00IIELL4$QN(D"8$<
MIYWJ.S9)YZ\GUKG6\>7!@BMETVVBU=M1DTZ6&YO/+@CD2/S,^;L)(92I4;<G
M/;%.O-<D_P"$K\)V][HTD.IWL5Z44WS!(&C09!"C;(&XP2,@<XSD4 ;H\*>'
MQ<&X&BV/G&X^T[_(7/F\_/TZ\G\ZL6FB:982"2ULHHF 95P.%#'+!1T7) )Q
MUQS7G4?BW4+GP/%J?B'3TG636_L\ M;YXV'^DN@SM1>$P !SO R<5TFH^,=1
MBFUF73-&BO-/T4[;R5[KRY'8('=8DV$,55AU*Y/ H U[/PCX=T^*\BL]%LK>
M.]&+A8H0HE'H<=NO'3FM2UM8+&UBM;6)8H(E"QQH,!0.@ ["N2N/&NH7-[J$
M&AZ-#>I9V<-Z9I[LPJ\<BLP PC'=A>!T]2.^[#XALY/",?B1P\=DUB+Y@1EE
MC*;_ ,\4 *?#.B&!X3IEMY3S_:639P9<Y\PC^]GG/6F2^$_#TUQ+<2Z+8O--
M*LTCM I+..C'CKP/K6/:>+=7-SIL6H:';VHU>-VL"MZ7(D$9D$<W[L;"5!Y7
M=C!%8WPL;5+^?7-5U1-\KZA<0^<=0EEV[9,>6L94*JKCAAR?04 =U;Z)IMI=
M&Y@LXHY=[R @<!W^\P'0$Y.2.3GFDU?0]*UZV6WU:PM[R%&#JLR!MK>H]#7
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M#&3GI4U_XSU.RFFMAI-D]W8VBW5_&VH; N[=B.(E/WC84GD*.1SS0!O0>%=
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MSCIGVKO%N[9H4F6XB,4GW'#C:W&>#WX!_*A+RVDMC<I<0M;@$^:K@K@=>>E
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MH.K2^-)-5LEM)+2ZTDZ?,)9F1XB'9@R@*0P^;&,BNNHH XZ'PI?QZ9X*MC-
M)-#5!<LK'G%J\.4XY^9@><<?E6/H'@K6M*O?#L[6.BQ'2F:.XEAD;S;P.A5I
MF;R\[LD-M.<DGYAQ7I-% ',^!-'U3P]X:AT?4DM?]$9DAEMY6?S4+$AF!4;3
MSTR?K73444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<=\1$N9+/04L
MYHX;DZU;".26,NJM\V"5!&1[9%=C4<L$,^SS8DDV,'3>H.UAT(]#[T ><^+_
M  YJ4?A3Q-K.KZE%?WW]CS6T*VUKY$<4?WVX+,225'.>W2GZ[J-E?^+[!;2Z
MAGV^';]V\MPP ;R<=/7!KT9E5U*LH96&"",@BJ5KHNE62!+33+*W4!AB*!4&
M&QNZ#O@9]<"@#R^STO2['P+X ,UK;QZ?>SVCZF[J,3$V[F/S2?O+YA7&>!P*
MO:EI_AB[UG0K#28HI;(^(9/M4" F#S?LDC,JC[N/NY"\9)SSFO2'L;.2Q^PR
M6L#VFP)Y#1@Q[1T&WICVIL&FV%M#!#!96T45N2T*1Q*JQ$@@E0!QP3T]30!Y
M?=)96%]X@TB+3[$VUQXBM8X(+@E+6&0VT<I9U7&1E#\O0L1533;:WO[:]M5U
M#0EGM/$4DEK;2P$6,Y-JN5";CM'S.P.3R"0#7K5QI>GW<4\5S86LT<[!IDDA
M5A(0  6!')  Z^@J*70M'GCDCFTJQDCD""17MT(<(,*"".<#IZ4 >4P.NIZK
MI$4-AH5I9QV5ZD=MJ#--:"5;C;,83P". 1QPI(  S5W1-$L[SQ7X5L]0DM=6
MMX- GDB?:7BD GC"$!NH"L,9] :],N-&TNZLXK.XTVSFM8L>7!) K(F.F%(P
M*L+:VZS),L$0E1/+1P@W*G'R@]AP./:@#B/C)_R3+4/^N]M_Z/CK.UR*QT_Q
M7>ZHR:3JD3ZC:+<0RDQWUG-^Z1/*;^)?NOMXSEN3DBO2+FUM[R P74$4\3$$
MQRH&4X.1P?>H)-)TV;4$U"73[5[V,82Y:%3(H]FQD4 <U\0;6&]B\.6UP@DA
MDUNW5T/1EVOD'U!Z$=Q7(:_:VNGZCXGLX88[;1SJ.D-?11*$C$+,!*2!P 0%
MW>V<UZY+!#/L\V))/+<.F]0=K#H1Z'WIK6ELQF+6\1,ZA9B4'[P 8 ;U&">M
M 'DOB^STP3^,8-)M[3["/#)EN8[=%\M9PSF)B!P'VACGK@#VKT;3$LD\'PK8
M+ MM]DRH@ "9*Y.,<=<U>M-*TZPM7M;/3[6WMI,[X8851&SP<@#!J6UL;2QM
M5M;2U@M[9<XAAC"(,]>!Q0!X[::5!9_"OP9):6UA']MNK0W\MVF8YAY;E!,1
MRRA]@ )P.!THU^S:S\,R*+O398W\3V;>1IJD0V[_ ";E&>F3\Q [L:]A:PLV
ML?L+6D!L]NS[.8QY>WTV],>U1II.FQV<=G'I]JMK$P>.%85"(P.00N, YH \
MV\1O<Z%K6N>&[(LA\5[)+!@.(YG(BN3^"8D_.HM6LX-.\>ZW96R!+>W\$&*-
M1V57< ?D*[I= NKGQ9'K6IWD,T=FDB:?;10E!%OP&=V+'<^!MXP ,\<ULO96
MDD[SO:PM*\?DO(T8+,G]TGNOMTH \M?3(=*A\$W&CVL<-_/IER#+$@$DS&TW
MC<>K'> >>]5M,B\.I_PK)]+%J+Z213,8<;W_ -&DWF3');?_ 'N<EO>O7#:6
M_P"YQ!&# "(6"#,7&/EXXXXKD=,\%7L&L6-WJ.H6,\5C,]PGV;3Q;RW$I1D#
MS,&(8A7;HHR3GVH 7QJMO+K_ (3AU,1MI+WTOGK-CRFE$+&(-GC[V<9[@5QU
MY9V-QK-U8VD43:&WBFS5(HL>27-N?.4 <8)QN'3)/O7KUU:6U];/;7EO%<0/
MPT4R!U;Z@\&HXM-L(+>&WALK:."!@\4:1*%C;U4 8!Y/2@#F/"UI;Z?XY\6V
MEG!';VP^QR"&)0J!FC8$@#@$[1GZ5RVO6VGQ:]\2V:"U2Z.A1O"2BAR3#/O*
M]^<#./;->K)!#'-),D2++)C>X4!GQTR>^*@GTK3KJY^TW%A:S3^68O-DA5FV
M'(*Y(S@Y/'O0!YMJ6EQ:->>'7T*TCM[Z;0[]=\* /,XAC9=Q'+'?SDY.33_
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME3GG&?[HY/%97A[X@6EQ;QPZK+*MU)J,]F)4M7\E6$[I$C2 ;0Q4+P3W'J*
M.XHK#;Q?HZZQ_9AFF\T3BV,HMW\D3$9$9EQLW\CC/7CKQ5?QQKFH^'_#HO-)
MM[>XOI+J"WBCN,[&,D@3G!&.M '245R%YXU#^"K37]-B0O-=6]O)#.#F%GF6
M*1& (PRDL/J/2KVH^-=$TJ^GM;F:?-MM^U2Q6LDD5MN&1YCJI5."#R> <G H
M Z&BN6/C.VD\5:CH"PW,;6EFL_VO[-(R D.3GY<;0$!!SAB2!R*+/QAIUOX;
MTF\N+^74I+^,F!K2QD\RYQRS+"H+* .OI^- '4T5STWC?0H[.SNHKB>Z2\C:
M6);6VDF?8IPS%%4E0IX.0,'CK6U;7EM>6,5[;SI):RQB5)0?E9",@Y],4 3T
M5SEEXYT/4)XXK>2Z/G(\EL[6<JI=!!EO*8KB0XYPN21R,UC^ O%NH>*M3UB6
MY>2.U@NIH+>V_L^2,*B, "TK<%SW3@CT% '=T5R5WKFNZIXCOM'\.I80IIP0
M7=Y?(\B^8Z[A&B*5R0I!))[@8JS;:YJ.DZ1J-YXMM[:UCL6!^UVA+Q3QD#YE
M3EU()P0<^Q- '245SC^-]&6UAN%^W2BXD>.WCBL96DF"@%G1 N63!!W8QSUI
MTWC;0HH[%UN99S?P-<6D=O;R2O,BE0=JJI.1N&1U'/H< '0T5Q]_\1=+MXM#
MFM(;R\AU2Y> -%:REH]BONRH4G>&7&SKU/0&NBU;5K/1;$WE](RQ;UC4)&SN
M[L<*JJH)8DG& * +U%<\_C?08M(&ISW4D%N+G[(XFMY%>.;KL9"-RG'/([CU
MIMSXXT6TBADG^W(9(?M#)]AF+PQ9(WRJ%S&N0>6QT/H: .CHIL<B2QK)&P='
M 964Y!!Z$4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***J:A
MJ=GI5LMQ?3"&)I%C#$$_,QP!Q[T 6Z*** "BBB@"CK=@VJZ#J.G*P5KNUE@#
M'L64KG]:\[T"P$NI>$8+'P[=Z9?:4K#4[B2T,2;?)9&3S,8EWR%6!!/3)Q7J
M5% %33;[^TK%+K[+<VNYG7RKF/9(-K%<D>AQD>H(->4:?I>@6]]KG]O^$=9N
MKR75[N59HM-GD5XVE8H0RC!&*]A8!E*GH1@\UB_\(II/]V\_\#Y__BZ ,C2H
M/.\=6FH6VGW5O8#01!&9X&C*$3<(=PR#@ X/.*YK2K2^T@>"+NZTR_\ *M;G
M4DG$5J[M%YKOY995!(!]<8Y%=VOA;1W4,@NV4C((U"<@C_ONE_X1/2?[MY_X
M'S__ != 'G::'J;:1X@B?3+HF?QNETB&%OG@\V$F0#'*8!YZ<&MOQ/8RVOC2
MYU&=]?2SN].BAC;2(3*6DC>0F-P$;&1(""<#[V3706.A^']2@:>SDNIHED>(
MLM_<<.C%6'W^Q!'X4MCH?A_4K8W%G)=31"1XRRW]Q]Y&*L/O]F!'X4 21$^&
M? D7V.PO)FL+!5ALR/-F8J@"QG;U.< D<5QMG\-=:NO!,VEWWB66*340;J\A
M^R1$?:'(=COQNX;'.>PQ7;?\(GI/]V\_\#Y__BZ/^$3TG^[>?^!\_P#\70!Q
MVD:EJ\&LZ1K^M:-J?FR:0^G7(AM'D:.X24$DJ!D*^,ANG3FL_P (65U<W7@^
M[%A(L5OJ.LM-M7<MN6>0 %AP.<@>M=9KO@SPTEHVHWD^HV8M4):Z@U"<.J<$
MC.XG!P./85<T[P;X>M]/@CL8;I+;;NC"7TX!!YS]_J<Y/N: ..OM$;^V==T[
M4!XE=-2U 30Q:>F;>:-U099RA5"I4YW,.%&*%T1EU?4=+U >)7:YUEKJ*&T3
M_1'C:42+(9"FU=O<%@<KP.17=?\ "*:2!]V\_P# ^?\ ^+JO8:%X?U2P@OK*
M2ZFMIT#QR+?W&&4]^7H Y.^T>_D\$>++9=/N&FN=?,T<8B):5//B.X#'(P"<
M^@J;QKH6I:KKFNFSM;AA)H=LL;QC'F/'<O(8U8\;MHZ>XKKO^$3TG^[>?^!\
M_P#\71_PB>D_W;S_ ,#Y_P#XN@#@=3TH:KH6MW-C!XEO;EX+:W#ZG 4+@3AR
MB(45CMY).,<G!ZUO^)]+OKSQ+J;6]I+(DWAFYMD<*=K2LXVIGID^E;__  B>
MD_W;S_P/G_\ BZS=4M/">BS6L.HW=Q!-=,5@C-_<%I".N ')P,C)[9H D\*Z
MOCP_X=LFTW5(Y)+802&6S>,0/%&-WF;@"H)X!Q@GI2>,["^9]&UK3;5KNXTB
M\\][5" \L3(T;A,\;@&R!WQBK_\ PB>D_P!V\_\  ^?_ .+H_P"$3TG^[>?^
M!\__ ,70!R%_/<>(?$>FW6AP>*[>X%Y ]U]H\^UM(X48%P4<A6) QA0<YJG?
M6U]'X3\1>$!I=_)J6H7]P;>9;9S"Z32[UE,H&Q=H;D$@Y7ITKN_^$3TG^[>?
M^!\__P 71_PB>D_W;S_P/G_^+H XWQ9H>J'Q+=:9I]K<2:=XHC@CO;B-25MS
M$P$K,1PN^'"C/4BH]>T<VWB+7X[E/$1L]3AA6V@TB+=%,!%Y31,=A"'CJQ48
M;KUKMO\ A$])_NWG_@?/_P#%T?\ ")Z3_=O/_ ^?_P"+H Q/#^DSV/B;Q>QM
M9UAEBLXX)9%/[T);[3ANC8/!QWK.T_2KZ+PK\-X#8SK+9W$#7*&(@P@6TH)<
M?P_,0.>YKHM1T?PSI%K]JU*[DL[?<%\VXU2:-<GH,F3&:S8+GX?W5Q%;V_B*
MTEFE<)'&FN.S.Q.  !)R2: .<T31=3C%L)M-NEV^-;F[.Z%AB$I)MDZ?=R1A
MNG(JYKNEZB/$&M:E'IUU/!;ZSIM[LCB)::..(*YC'\97.<#^[756&A^']3M%
MNK*2ZF@9F4.M_<8)5BK#E^Q!'X56/AKPOKGVRP5KN5[614F OK@&*3AE();J
M.""* *7AJ^&H_$OQ#=+:3VT;:=9;/M$1C=QNF^8J?F7N,$ X%0:S<S:-\6XM
M7ETO4[FQ;0C:^;9V<DX$AGW;3M!QP,ULZ?\ #_0M.\QD_M"6>7'FW$VH3M(X
M'0%MW(&3@=LFJ%S<> ;.YEMKGQ!:PSQ,4DBDUMU9&'!!!DR#0 S7?$%SJEC8
MR65IKUE9+?!+Z1--D6X6/RW(**4+8+[ 64$@&N9CM-5T[1KO5+72M6EU'2]=
M-]##/$SS7$$T8C.#C#':Q) R05P:] M?#V@WUK'=6DMQ/;RKNCEBU*=E<>H(
M?!%2_P#")Z3_ ';S_P #Y_\ XN@#@(_"FI6&IZ'H:VD\MA?QV4^ISA"8UEMB
M\DF\] 7;RA[X->GVU]]IO;VV^RW,7V5U3S98]J2[E#9C/\0&<'W!%9__  B>
MD_W;S_P/G_\ BZV418XU1<[5  R23CZF@#E?B%9W5]H%G%:6\L\BZI9R,L2%
MB%692QP.P R34WB>SGN=>\)R16\DL=OJ;22LJ$B-?L\H#-Z#) SZD5MVFIV=
M]<7<%M,));23RIU (V-C..>O'I5N@#RK7-%U!_$.J:B(=3CM8-=@N6DLHR96
MB^Q"(O&,'=M9N< G ;N*Z_P99P06=_=0KJW^F71E:35%VRRD(J;]N 5!"@88
M \9[UTU5K34++4/.^QW<%QY$IAE\F0/Y<@ZJV.A'H: .&TCP3!JEWXBDU9M6
MCBN-5G(MEO)H89HB%Y**0&!Y&>])JVG:G:_$I[W2=.<QP>%IH+9A%^Y\X2@I
M'GIG@<>E=[;W=O=K(UM/%,(Y&B<QN&VNIPRG'0@\$5*S*B[F8*/4G% 'CIM[
M^YG\];?Q%=^?X>OK-I;VU=<7++&VQ4VC8/D(!QM)P 376)I]VNI^ 6%I,$M+
M:59SY9Q"3;A0&_N\\<UUBZG9MJKZ8LP-ZD(G:+!R$)P#GIUJW0!1T?5(M:TN
M*_AAGA20LOESKM=2K%2",G'(->;:?9WILK337TR_6>S\6-=2E[5PGE--*RR*
M^-K+@@D@\9&:]3@@BMH5A@B2*)?NH@P!^%2=* /,/$VB:E=ZWXANH;:^$27&
MEW*M;)^\D2(MYGE9&&90<XYY %='X-M+=;C5-0@_MN0W#11F?5D\MI0@."J%
M58 ;B,D#..*Z)M1LUOK>R-PGVFYC>6%!SO1=NX@],#<OYU:H X:.XN/!WBK6
MY;G3;^ZTK5IDNX;FRMFN#%)Y:HZ.J L/N @XQS7->++>]U71/%?B>XTZ>U@F
MM+6QLK:Z79+(B3;F=U/W=S/@ \X&2!FO7JYG4-8\(^)89=!EU[39GG<(8(KU
M/,+*P(  .<Y'2@#G]46Z\4:[>W5CIM_#%;Z!=V;&ZMGA,DTI7;&NX#=C8<D9
M'(YJE907E_JGPQN(]-U"./3H;B&[,]I)'Y#"V5?FW 8!8$ ]#VKT>#5K&YU2
M[TR&Y5[VT5&GA .8PX)4GZX-7* /*(+6_;P78>"O[+OUU2#48O,G-LX@6-+D
M2F82XV$%1T!W9.,5;N=)OS\/O$5LMA<&XFU^6=(A$=SH;U6#@8R1M&<^G->F
M44 <UX[EU/\ X1>:RT:":2_U!ULHY(T+" 2'#2L1]T*NXY]<5RNM>!=<TOPU
M8R:9K<U]+X?*7-A9?8XTW^6,%-RC<=R;ACN37HLFI6<5W:6KW"":[W>0O7S-
MHRV/H*M4 >6ZA>7%C:^-C-HVHR#6K875JQMFV;3:JC)*V,1E"IR&P<=,GBM'
MPE8W \5Z;?M;2"W_ .$4LX%G*';OWL2N[IG&#CZ5T&K>#-*UF]GN;EKQ#<QK
M%=1P73QQW*#H)%4X/!(^AQTJWJ/B'0/#YAMM1U;3]/)4".*>=(SMZ# )Z4 >
M?^&]":*32](O_P#A)FO;&[D<J4Q9Q%2^V4.5 96!X 8M\QR.#3_!>C&"3P]I
M]\GB1K[20=Z3)MLX'6-H]RN4 =6#$*%9C\W/0UZ?!/#<P)/;RI+#(-R21L&5
MAZ@CJ*>S*BEG8*H&22< 4 >9:-H]_%X0^'%O)I]PDMG>H]S&T1!A'D3#+C'R
M\D=>Y%0:QHFHOJ6K7H@U**W@\1PWA>SC/FM#]C6(O&,'=AFYP#]UN]>E'4[-
M=672S,/MK0F<18.3&#MW9Z=:MT >91:1YLVCWME;:W,LGB..XGFU*+$C*EM(
M@E*[047[J_, >!ZBH_%>E:C+#XWDAT^ZF$MYIDT0CB+&98S$7* ?>P%/3TKU
M&B@#G_$5[?3^";V\T:&X-V]ONA1K<B4 XS^[<9W 9(4CK@8KSC5K"\O(_$@M
M+/Q!>17VCPQ6TM_;R%Y629BXP5!3[XPI SR0,5Z[:ZE8WTUS#:7EO/+;/Y<Z
M12!FB;^ZP'0\'@U:H \Y\?Z#J6LZI>Q6%M(_F^'+N!'"X4R&6)ECW= 2%.!]
M:L07\NO^//#E];Z/J5M:VME=I-+=6;PA'<183Y@.FT\]#V)P:[ZB@#CO%0FM
MO&GA/4_L=W/:6[744SVT#2F,R1J%+!02 2#ST'>L0:3?CX<"U%A<"Y_X2#SS
M%Y1W[/[1W[\8SC9\V?3GI7IE% 'E5MHC)JMUI>H#Q+)))K;W<<5NG^B,C3^<
MDID*;0%XR-V[*X Y%==XZM+F\T>PCM8)9G75;*1EC4L0JSH68X[  DFNGHH
M\N\<:#JECJ0?1[*:ZT[6+^TEO(8$+?9[B.:-C-@=%9%(8^JJ>]27XN],L/&F
MAMI.H75WK$\\EB\%J\D4PFB5 &D VIM((.XC@9&:],9E3&Y@,G R>]+0!YQ;
MV-YI/BK4K2:TO)1=Z!;VT-Q%;N\321++N!<#"GD8SC.1ZUG>%[:^\-:?X.U3
M4-,U!H(-(FL;B.*U>26WD9T=2T:@M@[",@<<9KUBB@#R^_CNI-<LM>NK+7M(
MM+G3VA$.EQ>;+&XF9@)%5&(+JP/3@@@FNLL]$V_#K^Q;..XM3)I[PQ)=,#)$
M70X#%>,@GMZ5M_;[7^T_[.\Y?MGD^?Y7.?+SMW?GQ5@LH8*6&X@D#/) _P#U
MB@#S>R:ZUE?!>F1Z3J%I/H\T<U\]Q:O''"(X'C**Y&U]S,,;2>.:U_AS8W=A
MINMI>6TUNTNMWDJ"5"I9&?*L,]0>QKJ=/O[75-/@O[&99K6= \4BYPRGH>:L
MT <'(]QX5\3Z])<Z?J-QI.LLEQ'<Z?"\SP2B,1NK*F6&=JD,!CFN:O=(U:\\
M)>,OL=OXAET^ZLH8K&WU2626>20,QD98V)9004'(!..E>L7FH66GB$WMW!;"
M>40Q&:0)OD/11GJ3@\4^>[M[4PBXGBB,T@BB$CA=[D$A1GJ< \>U '(^*Y+V
M'5M)@']K1:4;>7>VDP%Y#,"@C1B%)12-_/ R!DBL3P1IU_#JOAO[5IUY";'3
M]0MYVGB8!)#/&0-Q&&R,D$<'!QWKT^J]W?6UC:7%U<S*D-NADE;KL4#)) YZ
M4 >8&SO]-CTB^FTR_>&T\4WUQ*L-L\CK$YG"N$4%BIW+R!WKLO&L]]%I-FUG
M]L2%KR,7DEE 99XX,'+(H4G.=H) ) )(KH;>>*ZMHKB%]\4J!T;&,J1D'\JD
MH \?ATR_E,D']G:NX/BNROU>\A=F:W\N,>8S8QQL.1U7@'%;'B73Y;;Q?JEW
M<GQ +2_L88X1I$1D$CIY@:)\(VW[P()POS-SQ7I%% %/2+1-/T6QLHTE2.WM
MXXE65@S@*H #$<$\<D5<K,TKQ#I.N27*:7?1W1MFV2F/)53DC&>AZ'IGI2ZK
MXBT70O+_ +6U:RL3)]P7,ZQEOH">: -*BH;2\MK^UCNK.XBN+>0926%PZL/8
MC@U-0 444A90RJ6 += 3UH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y#XD:
MM?Z+X9@NM.N&MYFO[:(NH!RK2 ,.?45U]97B#P_9^)=.2QOFE$23QS@Q, =R
M,&'4'C(H XO6+G7+FX\<W$&O7=G'HBK+910)'C<+5)"'W*2RY[<=3[8M6]SK
M/BW5=0BMM:N-*^PV5J\*VZ(5>:6,R%I RDLH^4;01T/X=/)X:L95UU6:;&MK
MMNL,./W0B^7CCY0.N>:S[_P)I]ZV8[W4;/?:I9W(M9@@N8D!"J^5/(!(RN#@
MGF@#(EDUO6]2\2*-=N-/;1DCA@6T1 CRF%96D<.K%E)8 +GH/4YJKI.L:SXJ
M\3:,G]J3V%E/X?M=4FAME7+2M(V5RP.%/?O@#IS717O@;3KJ:9[:\O\ 3H[B
M!+>YALI0B3QHNU0V5)!"_+E2#CO6C:^'=/LM934[9'CDCL4T](E/[M8D8LH
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MR6^H:G9W5E"T"W4,X,LD;$%E<N&W9(!Z9!Z8H I_#,2KX1=9I!+*-2O@\@&
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M/SH[;"F01;A@M@G&?PYQ4,WB2Y>'2M-L]5UR[CN+JX%P\=FJ7\*Q(A\E@R@
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M4<DG^A-:%<OXSM;MCH>IVMK+=C3-16YFMX1EVC,;QDJ.Y&\''L: )!XXT?\
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M;,R1NRPB-XI<'"] <MQACZ8H ]-U+5+32=,EU&[D(MXE!)12Y.2   .222
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MY6+[:S[S[;2#GTJC=6VM7.I6MU>6.O7%Y9ZYY]Q\S?94MQ*PC\J,':_R%#D
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M,@;TR",UYEX<T&1;;3K6YTWQ#_:&FV,D;M=SL;6*3RC%B,$X<-DXV]!UQTH
MZW3_ ![H^ISV4=O'?;+Z-I+29[5UCG*IO*HQZL #Q['&:QX?'T>J>&5U-WO-
M'7^U!:+(;3S!(/.9%4;O4* Q'W2:++2-0CT?X;Q-9RJ^G^7]K7;S#BSD0[O3
MYB!]37.S:1J\W@2/1%TB^%Y9>(1.^83M>-KIY-Z-T90I!)[9H ]"/C#2QX@N
M=%47+W5JP%RR0,8X 8Q(&=^BJ0>">^?0U6B\>:5/;3S16^H?):M>0K):NAN8
M5QEX\CYAROO@@XQ6?'H-[=:I\08C"T*ZJD<5M,PP'_T4)D'T#9%96A:*US'&
MK:=XA6^MM,EA+ZE<$PQ2,@4QQ@G# X^\O "CF@#I/"_C:U\06^EQS6\]I?WU
MB+Q8I8BJ.!MW;&/W@"X^H.:VM.UBTU6>_BM&=S8W!MIF*X7S  2 >^-PS[UY
MO<-=:7\,?#FO?V?=6VI^%Q DEO<Q^6\J[%BE1<]0P;@]RHKN_"&D2Z)X8M+6
MY(:]<&>[?^]/(2\A_P"^F(^@% &Y1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117-^,KLP:?9
MVT=SJ$4UW=+$D6G*IGGPK,45F("<*26)& #ZT :NJ:SI^BI;/J%QY*W5PEK"
M=C-NE<X5> <9]3Q1::SI]]JFH:9;7&^\T\QBZCV,/+WKN3DC!R.>":\GU6_O
M;WPWI$5\;HO9^,[>V07CH\RH&R [(2&(W8R">E=7X2_Y*K\0?][3_P#T0: .
M\HKAKFVO]<\?:UIG]N7]E96UA:RQQVD@0B1S*-V<9Q\O(Z'C/2L+0M4UKQ9J
M/AB"XUB[M8KG0Y+J[^R,$,TB3(H8''RYSDX[$CO0!Z7::E:WUQ=P6[NTEI)Y
M4P:)E ;&>"0 WU&15NO*9?$>L^?XIM(]0E1F\06NFV\IP3:QRE Q7(QG!.,]
MS4OB6^U/PNOB33K/5[Z:-=!;4();F7S);>57*'#XS@Y!P<X(.* /4:*R_#]C
M/9:6GVF_N;V><B:22=@<,P&50 #:GH.V:XN+7-3/P[T^^-]+]JDUY;=I=WS-
M'_:!CV_38-OTH ](JO?WUMIFGW-_>2>5:VT33328)VHHR3@<G@'I7F-[=ZPN
M@^(/$ UR_6?3=:EBMH%<"+REG5=CKCYL@D<]!C&.<GB3[=KGASX@:A+JUY N
MG_:+."UC<"'RT@4MN7'S%M[<GD9&,4 >J1R)-$DL9RCJ&4^H-.KR>^U/7KR_
MU2WTR/7&FTVVMX[ 6!B$'FF!9,S!V!<$L%(P0 ..:VM.34]>\=:_!=:MJ%G:
M6,=JT=I;2A0KR0G=DX/ (X [G/84 =W'+',@>)U=#D!E.1P<&JUSJEG9ZA96
M,\VRYOF=;=-I.\HI9N0,# !/.*\L\,-);_#SPY;IJ.MRW&H332?9;%U\Z4*7
MR%=BHC4':Q.>3QWJM<^)-0MHO".J7%G?:E>V=_JL"6X"O/)Y:RQH&*9!( &Y
MAD<$\T >NZAJ5KID44MV[JDLJPJ4B9\LQP!A0<#W/ JW7E^K:MJ5KX%T/5[?
M7GNKC5-7M&EG@.V,)(^#$B]D XP>>#GFHM8N=8;1_&VM)KM_#)HU[)]BAB<"
M-0D4;X88^8'<1@\#\: /5:*\XU*XU34[CQE?1:U=V)T6,)9PPL!&"+=969U(
M^;)?'/0#C!YJK<W^K0V^FZIJE_K-OIKZ;:21WUCM>*&7;F1KB/[S Y'.",9Z
M=: .QD\%:%+JC:@]K*7><73PBYD$#S#&)#%NV%N <XZC/6N@K!\87OV30#MN
M[JVDGFB@C-G&'FD+./DCR0 S#(W'[N<]JX3^U]<2UNM-CO-3LGB\065I&UY)
M'+<113(A9692RMRQ(R3P0#TQ0!ZS57^TK3^UO[+\[_3?(^T>5M/^KW;=V<8Z
M\8SFO-]4U+5=!E\2:1:ZO>2*'TU;>XN7$DEO]IE:.0AB.P7(ST-:VDZ<^E_%
M:2W-_=7D?]AAD-U)YDB?O\$;NI'&>??M@  [RBO._'>I7:7FHC3KO6VGT[3O
MM'E:<8HXK9SO*R3,[#?G;]P \*>.:2.[U3Q%J6LS?VQ=6']F6%M);QV[!8S+
M)$9&>0$'>,X&#Q@'OS0!Z+17EFB76K^(-1\*64VMWT$-QX:2_NC X5YI \8S
MG!QDMR1VX[TNE:MXBU/4H=3MK?7)&?5I(906B^PK:K,T1 7=NW*HW;L9+ ]J
M /4J*\M\*:MXBU2XT;5UM]<=;V9FOO/:+[&L#!MOEJ&W*5.S!QDX;/6J>GS:
M[-X=\):LWB34OM6J:A]BN!N4Q^2PE^ZI& XV ACDY]N* /7J*\IO=8U;2#J^
MAPWNIWB)K=M:12JZO=+#+ LKJK-@9R& )Z;O85+->>)(;6VLC-J^GP3Z[;P6
MT]ZT;7!@>-MZDJ6!PP."<]1G.* /3I98X8VDE=8XU&69C@#ZFGUX]XN2\AT#
MQGH[ZMJ$]M8RV,L#RS;I )2 R%L9*YY -;FN'4=$UH27^HZ[#I,20"UO[=EE
MBB(/S_:5^\<G'S$$8/48H [FQTNTTV2\>UC*->7!N9LL3ND*JI//3A1P*L3S
MQ6UO)<3R+'#$A=W8X"J!DDGTQ7.^-K^\M--T^VLKA[634=1M[)KA -T2.WS%
M<Y ; (![$UR?B.&ZM;?Q=X=;5=0N+-- .HQ/+-NDC;$JLA?&2C; <'WH ]!T
M77=.\0V'V[3)GFMBVT2-"\8;@'(W 9&".1Q4ESJ]A9_9_.N4'VFY%K%MRVZ4
MY^7C.#\IZ],5B> ;'[-\/]&3[5=2^?8029EDW&/,2_*GH!V':O/-.TZ8^%M'
MV:E>B6X\6R)YLD@<QXEN 67(P&/)).>><4 >UT5Y7J6K:MH<VMZ+;7^IW:#4
M+"&&3>LES&DXS(J,V!D[2%W="U=5X-?5A)J<%];ZI'8I(C63:FR--@K\ZEE9
ML@,,@DY^;':@#5UCQ-HGA_RQJVJ6MFTO^K260!FQU('4CWJWI^HV6K64=YI]
MW#=6TGW)87#J?Q%<KX4CBG\<>,;JY56U&*[BMT+<M';>2C(!Z DN?<U%KXM-
M-NK32]!G2PFUC6$CU&2T<;XR86D/'(1V6-1G'?/7F@#N:*\LUO4M8T6/Q%H]
MGJ]V_P!DFTR2UN9V$DL0GG".A8_>'RD\\X8BK;Z;J1\4:YHH\2ZP+.#3HKV,
M^>/-65C(OW\9V_)G;TR?3B@#TBBO,-%O-5\5:EH-O=:S>VL-SX:AOKA;1Q&T
MDQ<#=G''7)QCMVX,=GK.H:MI&DV,U]K5W?1O>I)'I7EQ2W"PS&)97D9E50,#
MC/S$^U 'J=4X-+M+?5+O4HHR+J[2-)GW$[@F[;QT&-QKSKP_?ZOXIO=!MKO6
M+VWBGT)KFY^S.(WED68(&R.AYR=O\JDT+7=6MH?"VIW^H37%E<W%UI%V9",;
MQ,ZP2G'\1\O:3_MB@#TVBN9\%7EYJVFWFM74\CPZA=R2V4;'B.V!V1X'^T%W
M_P# JY=]:OE\365]9W>M7%K<:T;)II?+2R:/+H8TCW;R5*_?V\E3S@T >G55
MU+4K32-/EO[Z;R;:+!=]I;&2 . ">I%>9V=WK"^'=*\12:Y?R7#ZXMH8"X\E
MH&O#"5*XY.WG<>1QV%5?$/V[6/ WB36Y]6NU9-2DMDM-X\A88[@1A2F/O'&[
M=UR?3B@#U>_O[32[&6]OKB.WM81F261L*HSCDU1TCQ5H&O3/#I6L65Y,B[FC
MAF#,!ZXZX]ZROB82OP\U8JI9@L9"@XS^\3BLK5(]=U74K?6)M$;1DTBUNI!-
M)<1R2RL\14*HC)P ?F.3U4<4 >@T5PMKJ]^\7PZ+7<A.H1YNN?\ 7?Z&S_-Z
M_, ?K6!I=_K?_" VNL2Z[?/?:K?IIRLS I;1M=&+>JX^_M!^8YY(["@#T^_U
M*TTR.&2\F\I9IX[>,[2=TCL%4<#N2!GI5JO-_%FC7NG:7;VJZ]=7,<NLZ<;?
M[3B2:V8S $[S]X$X(!'&#U' +F]NM!O?%&EOKNI&WCMK*6VF<"XN(Y)I'C*1
MYQDL54 '@$YZ4 >D5F:[H-CXCTXZ?J(G:U8Y>.&X>+S!@C:Q0@E3GH>*X&VN
MO$DT'B#2[)=:!M);.4075S"UYY+Y\U4D#,N2$R,G(R>G%1RZ]<RII6DV5SXC
MNHIKJY^U1!4COX?+1&$+,Q7C,@;<#DKC!(YH ]1MX(K6VBMX(UCAB0)&B]%4
M#  _"I*\M-QXENKGPOH]Y>ZGIOVN[OH9)'9!<26Z(7C+%<J'VX&1WR>M=7XS
MFO-(\(-?V-S.'TQX;F0[LM+#&P,@;URF[- '3U4_M*U_M;^R][_:_(^T;?*;
M;LW;<[\;<Y[9SWQBO/)_&5YIOB36=6GNVDT3R;N"TAS\OFVT<;$CW8F8?\ %
M,L9]<C\5VV@ZAJUX3_PB'VFX(DPWVGS@&<'L1D@>U 'HCZO8)=V5J;E#-?!V
MM@H+"0( 6((XX!'4U=KQKP[I4DVF_#:W34KV+[1:7$CR+)ET4PIE$)'RCCZC
M)QSS7>^"+B[>TU>SNKN:[^P:I-:Q33MND,8"LH8]R-V,^U '445Y:^J:Q;Z=
MXW\0'5;N1])O+JWLK7</*7Y$(9ACYL%N 3@8]S4T \7"+4K;3(=>5)+#<DFJ
MRP^9]H#KD1L&8*60MC/R@J.E 'IE%>5SZK=_8+6RL-8UNTN)-;M;:>'4E'VF
MV216R-QR'5L94_,,_E2:OJ^K^';[6-"M=0U*\C>73_(E++)<PB>1TD5&; )(
MC^7=T+4 >JTR26.)0TCJBE@H+' ))P!]22!7F3ZCXAM(#IK?VQ8V=_JEI:VU
MUJ#QM<QI(&,H5E+?W, GD>9["G>,M#NK/3=.M9/$&H7-N^OV(B#2?O8E:100
MS]7PPW*2,CWH ],DDCAB>65U2- 69V. H'4D]A3JXOXGV[+\*];C6XN%,5F?
MG#_,X P0Q[@]_6J\=I=ZEXJF\/G6M4@LM-TV&96BN-LLTDKR?,SXR0H0 #IS
MSF@#O*I2ZO80W-E;O<IYE[*\-N%!8.Z*S,,C@8"MU],=:Q_!>H7>N^"+6>_G
M9KIQ-!)/'A6<I(\>\8X!.W/'<UYQX=TR:;1_ RIJ=ZDEUJM\6E,FYHP$N0VS
M(^4D \^IS0![917E%SK.KZ<+O0H[S5;Q!X@6R26)T:[\@VHG**[$#.01N)S@
MGOBNR\&2:L;.^BU.#4(XHKHBR;4"AG:$HIPY0D'#%P#G) &: .EHKSVVNM2L
M?%K)K-YK%M-/=SK;,=KV%S$0YCC7'^K<* ><$E3R<TS3M;U*7PC\/;F2]E:?
M4+J!+IR>9@8)&(;UY /X4 =WINI6FKV$=[8S>=;2%@K[2N=K%3P0#U!JEHJZ
M5'<ZM'IHD$AO&DO-Z.!YQ5<D%A@C 'W>*\UT-;_1_ VC:_;ZO>%AJH@-F''D
M-#)=F)DV8^]\Q;=US[<58G\3:RA\46Z7-Y*?^$AAL(/(VF6*)PI98]V &(R!
MGH3F@#UFF22QQ &1U0%@H+'&23@#ZDUYDVH>(;:!=,<ZQ8V=_JMM:VUU?O&U
MS'&Z,TJAE+#K'@,>1O\ 84[QAH=U:6FD6DGB'4+F!O$%HL6Z3$L2L1D,_P#&
M0PW*2,C/>@#TZBN7\>7=YI/@&_GT^ZDBNH5B$<Y.6!\Q!D^N0>:Q1I6HMXYN
M= /B76/L,FF)>L?. E$WF,GRL!\JXYVC R!VR" >A4PRQB58BZB1E+*A/) Q
MD@>@R/S%>66FMZAKGASPZLE[K<]_)IC7$\.DF.)F.X*)I)'90!E6^7N2>.*;
MH@N?$?B[PK?WFHWL<]UX8:XD,$NP;R\(;  X!SDCU ]* /58Y8YDWQ.KKDC<
MIR,@X(_,$4^O%O#]S?6/@WPS9V\^LW"ZI>7;7 LY5\[;&TAVQEB N3AF(.>#
MCK6O)<^)96\.:5<WFIZ;]JU6YM_,F:/[1):B%G7<5RNX= ?50>M 'I&I:E::
M/IMQJ-_-Y-I;H9)9-I;:H[X )/X5:KC_ (B0_9OA5K< DDE\NP*>9*VYFP ,
ML>Y/<UBZYJ&J>#=4O7BU6\O]^@7=\4NF#*)X2FUE  VCYSE1QP* /2J*\K:]
M\1Z=H^LSHOB!+9=#N9GN=3>(E+I%!1X]C' (+Y' &U<5+=W&K6-CX;M&OM<U
M"36 UU>-9R()OEB4^7$6*A$RP/!SA>O)H ]/JCJ^L:?H6FR:AJ=RMM:QX#2,
M">2<  #)))/05P5I=>(+Z]T/P]J5QJ>GQSR7LK2NZ)=301%/*5F0D XD&2.3
ML]S7/^+A=WGAN]L+O4[V8:3XD@M(9C( TD;F)QO('S,N\@&@#V2RO(=0LXKN
MW+F*5=R[XVC;'NK $?B*RM5\8^'-#O#::IK5E:7 4.8YI0K8/0UJV=M]CM(K
M?SIIO+&/,F?<[>Y/>N:^)H'_  K/Q$<#/V&3^5 %RW\<^&+R)I+76K6X5)(H
MF,+%]K2.$0'&<98@5LWEW#864UW<,RPPH9'*H7(4#)P%!)^@%<?XZC=_ ^GI
M#)Y,K7^G!) H.T_:(\'!ZXK)UF[U/PZOC.QM]7OITM]"74+>2YEWR0RDS*=K
M8Z?(IQV/2@#MKK1M+\02Z?J5RDTZ0[9[>-I9%CS]Y6:+(!8=1N&16O7E^H7V
MKII^EZI?WNM0Z6VD6\@O=-VN+>?!:22>/[SK@H>A PV0,YKTZ-@\:NK!E8 A
MAT/O0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2_9K^Y:ZG ?DNSAS@]AD"J>J> M'U>XU"2>2]CBU%<7EM#<LD4S;=H<J/X@
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M_P $Z/IEU9SVJW"_8[B:YMXVF++&TJE7QGL<D_4TS4_&^GZ9=WL)L]0N8=/
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M22D:LD27)60@_N_N%?0CK56;P-IURQ\^]U26.14%S$UVVRZV]#(.YP #C&0
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M'"&>9XD<!5'^^H(.1QUP,UIIXZTZ2R\U++4#>?;#8G3_ "1]H$P0N5QNVXV
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MZ3M@",MG.<D+G& 3@G-/L/%EIJ&IBSALM0$3RRP17C0?N))(RP=0P.1@JW)
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M# 3),60'[ZD#[QX&*DA\87F@GQ2E[J2:[;:/91W4=TD:1MO;?^Y?9\N?E4Y
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MMHMK>7<<=ZPN(3BVZR%=A/)P%_X$: (?!_BG7+K7K4:ZX%EX@MI+S28S&JF
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M<QQ"0*^3PN2J]#U]JUM3\;65QXH\,Z?H6NV%TEW>2)=Q6TT<I,8A=AG&2OS
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M\GFA_/3:"6P/N\DC!],]Z +=%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 '
M?-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[@?.$*R\=QAN*Q?["\4?]#D__@MAH Z>BN8_L+Q1_P!#D_\ X+8:/["\4?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5[NPL]0C6.]
MM(+E%.X+-&' /K@U8HH 155%"J J@8  P *6BB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** (8
M;.VMY9I8+>&*29MTKH@4R'U8CJ?K4U%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1169K&D2ZL(1'J^HZ=Y><F
MR=%WYQ][<K=,<8QU- &G17+_ /"'W/\ T-_B/_O]#_\ &J/^$/N?^AO\1_\
M?Z'_ .-4 =117+_\(?<_]#?XC_[_ $/_ ,:H_P"$/N?^AO\ $?\ W^A_^-4
M=117+_\ "'W/_0W^(_\ O]#_ /&J/^$/N?\ H;_$?_?Z'_XU0!U%%<O_ ,(?
M<_\ 0W^(_P#O]#_\:H_X0^Y_Z&_Q'_W^A_\ C5 '445R_P#PA]S_ -#?XC_[
M_0__ !JC_A#[G_H;_$?_ '^A_P#C5 '445R__"'W/_0W^(_^_P!#_P#&J/\
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MU0!U%%<O_P (?<_]#?XC_P"_T/\ \:H_X0^Y_P"AO\1_]_H?_C5 '445R_\
MPA]S_P!#?XC_ ._T/_QJC_A#[G_H;_$?_?Z'_P"-4 =117+_ /"'W/\ T-_B
M/_O]#_\ &J/^$/N?^AO\1_\ ?Z'_ .-4 =117+_\(?<_]#?XC_[_ $/_ ,:H
M_P"$/N?^AO\ $?\ W^A_^-4 =117+_\ "'W/_0W^(_\ O]#_ /&J/^$/N?\
MH;_$?_?Z'_XU0!U%%<O_ ,(?<_\ 0W^(_P#O]#_\:H_X0^Y_Z&_Q'_W^A_\
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MR_\ PA]S_P!#?XC_ ._T/_QJC_A#[G_H;_$?_?Z'_P"-4 =117+_ /"'W/\
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M1;4-9@6TC2=RUNK(2KMP 7'.1R.>]=;XETJ36_"VJZ3"Z127EI+;H[?=4LI
M)QVYK*USPK<ZK#X72.XB0Z/?P74NX']XJ(5(7W.>] &5=^-]:@M-6U./2[(Z
M9I.H-:3[YF$LJJZJ60 8& P/)Y.1QU-_0M4UR[^(/B6QNFM3IUEY"QJK-N7<
MA8$<8R0?F]P,4VZ\&W5QX6\1:2MU")=4OI;J-R#A%9U8 ^_RU?L-#U&P\;ZO
MJJ2VKZ=J:0ET;<)8WC0J,=B#UH YGQA<ZW;?$*UNM(GN)!I^E->2Z>KG9=H)
M0KKMZ;]K$J?50*TX=<&H^/=/NM.N)+FPN/#LUU%$DF%D;SHMIP3@-@D9/3)K
M<.BRGQNFN^:GDKIK6?E\[MQD#Y],8%<N/AO/#X@UJ>TU%8=+O],N;2W@"G=:
MR3LK.5[;-RE@.Q8T +:_$&[ U.*Z32)[FVTF;4ECT^\\X1&/&8I2.ARR\CKS
MQQ4L7BSQ/+J.E6?]DZ:K:S:/<VC&X?\ <; A82_+SPX^[WXZ<U7;P1KMP"99
M=(MP^C7.DF"U1PB+(J[9 <9)W*,C  '3)Z]!'X<G36/#=X9X]FE64UM(N#ER
MZQ@$>W[L_G0!A_\ "P;AM-TZ.2/3;/5+FZNK:5KNY*6T1MV*NP;&6R=N!Q][
MVKIO"VO+XCT47NV)94FDMY1#)YD>]&*DHW=3C(/H17._\(-?6RP75N^GW%[;
MZA>W*Q72$PR17#EBI."0P^0Y /0^M=9HMG<V6EQPWK6IN<LS_98O+C&22 H]
M ,#)Y.,T :%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% %34].@U:PDL[EIUB?!)@G>%^#GAD(8=.QKSWPWX8M+KQAXHM9K[67
M@TVZMUMD.K7.%#0HY!^?YOF)ZYKTVL+1M"FTSQ'XAU*2:-X]4GAEC1<Y0)$J
M$'\5S0!PNK>)+VUT7QE<:':6UE=6>LQ6\LQD8F7<8U+]\-\P&.F,]ZMW6J2Z
M1\6+S4-3VXM/!YN;A(&)3*SL6VY^G&:N7?@"^GTGQ;:QWMNLNLZ@E[;LRL5C
MV,C!7^I3MZU:NO!=YK'B.[U35)[9([WP\VD3Q6^X[7:0L64D=,'OSF@!_AKQ
MI-JNM0Z;>MI3275HUU#_ &?=^=Y6TJ&CD_VOG&".#AN.*[.N9\.:-J]A<HVH
MC1UCA@\E38VY5YFX_>,2/EX'W1GJ>>!734 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-,_Z".O_ /@ZNO\ XY1_P@FF?]!'7_\ P=77_P <H Z>BN8_X033/^@CK_\
MX.KK_P".4?\ "":9_P!!'7__  =77_QR@#IZ*YC_ (033/\ H(Z__P"#JZ_^
M.4?\()IG_01U_P#\'5U_\<H Z>BN8_X033/^@CK_ /X.KK_XY1_P@FF?]!'7
M_P#P=77_ ,<H Z>BN8_X033/^@CK_P#X.KK_ ..4?\()IG_01U__ ,'5U_\
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MU_\ \'5U_P#'*CF\%:/;Q&6?5=<BC7J[ZY<J!VZF2@#JZ*Y?_A!-,_Z".O\
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M  =77_QR@#IZ*YC_ (033/\ H(Z__P"#JZ_^.4?\()IG_01U_P#\'5U_\<H
MZ>BN8_X033/^@CK_ /X.KK_XY1_P@FF?]!'7_P#P=77_ ,<H Z>BN8_X033/
M^@CK_P#X.KK_ ..4?\()IG_01U__ ,'5U_\ '* .GHKF/^$$TS_H(Z__ .#J
MZ_\ CE'_  @FF?\ 01U__P '5U_\<H Z>BN8_P"$$TS_ *".O_\ @ZNO_CE'
M_"":9_T$=?\ _!U=?_'* .GHKF/^$$TS_H(Z_P#^#JZ_^.4?\()IG_01U_\
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MA6$<DS.!$VW.=I1U8\]C6E>>$;S4SH$M_K)GNM+OS>O)]G"B4D,-B@'Y%&[
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\L0YRIXSWJ+2[5O#\>BS:5J*O>66G'3K@76FW1CD3?O5UVKD$'/'?/:O6**
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_+$T_P!GLD4LD0."[%F4 9X'.2>@KF?!-S?:/XMUCP_J=BM@M\S:K80K.)5
M8XF0, .CX;&. YK0UY)[+QK!J6FZCI<5]+IS0S6NHNR*T*/N$BLO=2QR.X/4
M=: +M_X\T33_  M#X@=[B6UFC:2.*&$M*VT$N-O;;@[LX P<FM'5O$-CHVC+
MJ=WYOE.!Y<<<9>21B,A54=3@'V&"2<#->?6K"V^ NL/=W,9>[M=2F@=@$\U7
M>5E*J3T8$-CW%=O<7UD?!LDGVJ#9]C*!O,&-WE],^M #Y_%=A!X7LM>,=PT%
M['"UM B S2M*!L0+G&XY'?'7G'-4F\=6,.DZE>76GZA;7&FM&MQ8R(GG#S"
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M-7:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
3 **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>a1039-firstamendmenttole001.jpg
<TEXT>
begin 644 a1039-firstamendmenttole001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB1;GQAXIM]<^(^JZ&EKJ<L5I!"693&';I@'&, 5K>-M;UG2? GA67PKXEO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5N9K@600A961AEU5R2,C. #C@5[;5<:A9$@"[MR3*8 /,',@SE.OWA@\=>*
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MXQ*,'C<&R.>?PH S?$?B31/B+X3UWP[X9U^'^TFM]QWJ\2A0ZY!9E P?N_\
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M\XH"X9)/E(/48QQ6AXYFN]&U>:*Q#B7Q98QZ?&RC.VY#A-Q]/W4K'/\ TSH
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MFZIXAT70_+_M;5K*Q,GW!<SK&6^F3S3KC7=(M+:&YN=5LH8)HS)%+)<(JR(
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M;W:&%;6X,<<[$.0),<]L YXR>M51=Z7)^SMXDL[6T>TU6UN(UU6&5RTAG\Y
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M[!]WFW2:E'*4PI(^4<G)P/QKSCXD>)#XM^&GAO6-0L9](MI]<CQF3+^2%?\
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M6^'D5J\!FAUMDN4C(W))Y4_#@=#C'7MB@#UIM<TE-3&F/JEDM^W2U-P@E/\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\'VJU0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3E@AC*E(HTV@A2% P#R<4 >,O%:V<T_VN../P_:>-)&NT*XBB4P+L+#H$$C
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MI/@\W[VO]F66K7JZDK;=D$Y:7R#,/X?8MTR*]RJ'[';;95^S0[9CF4;!\_\
MO>OXT <3X7DL;KXD>(+K06A?239VZ7$EM@PO=AGS@C@L$*@X]LT[QB]C;>/?
M!5U?FWBA\ZZC,L^ NXQ?(,GN6Z>]=M!!#;0K#!%'%$O1(U"@?@*)H(;A0LT2
M2*"& =00".AY[T >/S:3I[_#3XB7;V4#W+:CJ+F5HP7RCG;SU&,9%7=1U:!O
M%E_&9=!TR>'3K87%]K*M-)<(RLV(8RZC:"2#CJQY'2O4_(B\MX_*38Y)9=HP
MV>N1WIDEE:S2QRRVT+R1?ZMVC!*?0]J /%_"TMC!I?PSNK]H(X5N-0A,LZA
M#^]"*<]#G  ]:](^(L=Y-\/-<CL%D:X:U;Y8OO%>-X'OMW5T+VEL\8C>WB9
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M2$PB\A$AB)SL/<9[X.>:UJPO!NB3^&_"&F:/<RQRS6D6QWCSM)R3QGGO6[0
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M4KZULKN6T>>&X@&YHVPV%9P37;UP?P_OK.TLO$AN;J"$+K]\Q\R0+@>9UYH
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M\Q59%\MRD;'^ZSA01WZ5SGBBTT'08;W2M&NI;*VN+^P36+6W8I!:P2.5+*0
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M;NWCG$,JS1B10=CJ<JP]"#T->8:=XZL/#>E>,]6E75+H6FN26WE7-T) 9"V
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M9T^Z$EY,;SS[B?,;*2'Q]T$YP3DY' Q7JU% 'GMCX/U:VNM*E9(2+77[[4'
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MF);/7M-U)=)N+B*PU"\-[;W+Q#<7CE+,=PX!'&0>E=M:^!/#UK'?)]B><ZA
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M^H^ M U2^N+JXM[A3=D&[B@NY8HKDC@>8BL%;\1SWKH?(B%M]G6-5AV; BC
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ"&DSA3@]SUQZU1/Q%TN/QK8>%II+=;NXM5FDF^T+L21L;8AZLV<@>A&,YH
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M\4QGR6C93DX)+!F!&WO7M200QYV1(N3N.% R?7ZTODQ>=YWEIYN,;]HSCZT
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %( %    '84M% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\0AEW  ,X9SMYPH-)<>)=.L_$4\]S>WL5O%H@OWC=0(%BWGYMOWO,[8QT]Z
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M??F@"Q17C'AW5-+U#PX+[6OB;>Z?J)DG$D U2%#'ME<+^[92?N@''>NJ\/\
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M&H4D,3N7!!Q@Y]:1/',,2:BFJ:3?Z;>65D]^;:?RV::%1RR,C%21P""002*
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M*K6+R1'&]V-1M]R@8!? &<]\9KL]*U^]OO&&NZ+/8QQ6^GI \-PLH8RB0-U
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MHW=PMM!\I.^1@2%X''"GD\<5;H \NU/P_KTL7BG3(M)DD2]UFVU*WN1-&$=
M]ON7!;(8"-CR.W':M*&/Q#X7N?$%G9>'YM4CU*]EO;.YBFC5%:0#*2AV!4*P
MZ@'(KOZ* .!\+^$;_P /Z_H(D42VUCX>>REN%88\XRQM@#KCAL'':MKP?I=Y
MI:Z[]LA\K[5K%S<P_,#NC8C:W!XSCH>:Z2B@#AA'K?A?Q+KUQ::%<:O::M*E
MS"]M-&ICE$:H4DWL,+\H(89Z]*J:%X1U72+CP4LT:2?8!?R7TD;C;$\^6"C/
M)&YB.!VKKI/$VD1-<A[O!MKN.RF_=L=LS[=J].^]>>G/6I+K7]+LK6[N9KR/
MR;.58+ADR_ER,5 4A<G/SK^= &;X^TN]UKP/JEAI\0FNY$4QQE@N\JZMC)X&
M<=ZK:-9ZC-XYO=<NM.EL[>ZTJVB5971F617E+(=I/(#+STYKK:* /(/^$&U.
M+3M!O+S2+B]-A<:@MS86]YY,QCFG9T=&5U!( 4E2PR&]177^!M$;39=5O3HC
M:2MY)&(HY[M[BX=$4X:4EW4'+' 4\#KFNPHH Y:_T6[N_B!!?^418?V-<6CS
M!A\KO)&0,9ST!.<8XKE&T?Q+=> [?P#+H;QLBQVDNJ>=']G\A&'[Q1NWEBJ_
M=VCD]:]4HH X>'PK?7FE^.M/N%^S#6;J8VTI8$%&@C0-P<@;@>#SQ6!HWA2=
MKS0X)?!]U;3V4T<MW>7FJR2VZF,9#0J)B68L 1N4 #J*]7HH \5UJ;5=$^%.
MOZ';:?#>Z=&;E(M6CNXS$8WE8E67._S06*;<8R.M=?'!K7ACQ-JVH6VAW&K6
MFK1V[K]EEC5X9HXQ&5<.R_*0 =PSCGBM2'PIX1U'5)M3@T^TGN([IC*R,2@G
M4_,2F=N\'J<9S[UT-W=0V-E/>7+[(((VED;!.U5&2<#D\"@#SC2/!VM:?=:!
M+<0(TD<&IR7ABD&R*6X975!DY/<9''%6H_#6KK\/O!FF&S(O-.O-/ENHO,7]
MVL;@N<YP< 'H3GM7?6UQ%=VL-S VZ&9!(C8(RI&0<'VJ6@#R/4Y]5T'P?XST
MZRL(-0L'DOI5U&.\C"0"0,TD<JD[O,4L0  <\=*]*\.HT?AG24<$,MG""#V.
MP51N_ _AJ_U-]0NM(@DN)'$DA);9(PZ,R9VL>!R0:U)=3LX-5MM,DF"WES&\
ML46T_,J;0QSC QN7\Z .(\/_  ^@N?ATFCZU81VNHF2=Q<(%,T+F9VCD5U[@
M%3U]C6=J7A_Q'K-AX=U'7=(EO+[1I)[>\MK:\$+W<;A0)XG5UP?D4[25SEAQ
MQ7IUY=P6%C<7EU)Y=O;QM+*^"=JJ,DX'/04MM<Q7EI#=0/OAF19(VP1N4C(/
M/L: /+U\%WMWH^L7.GZ#_9=RUQ:3V<-Y>O--<>0^_$K%W503D* >,\UI^(G\
M5>*_#VM6,/A^2PMI--EB6*[DC,T]PV,!2KE0@&>6/)(KT*B@#@;G3?$-IXKU
M*XTVQ)^WZ)';6][YB;+>XC$I&]2<D$LO(!%<Y;^&-8NKOPS<GP_JXO;*_@FU
M&\U/4Q,6P"'\M?,8;<G.0%X  !KV&JEGJ5I?SWD-M+ODLY?)G&TC8^T-CD<\
M,.GK0!YQ+X7OUT'[-J7AE=5M3K5[<RP1SJES&CR,T<L+!U //(R#@UI:%-K7
MA/PSJ-Y?6M_/;&]C%A97MXLEQ#"Q1,-)D@_,20N2<8'6O0*:R*X =0P!! (S
MR.0: %95=&1@&5A@@]"*\=@\#^)K+1-0GBM5EU72;JWCT-6E7][;P2.5R<X7
M<DKJ02#Q7L=% '":5X4O-)U?P:$B\RWTS3;J&[FW#B:3RCG&<G<P<\51U#PO
MK,T>O".R+&Z\26E[#^\3YH4\C<W7C&QN#SQTKTFJD^J6=MJ=IILLVV[NTD>"
M/:3O"8W'.,#&Y>OK0!Q%K'XG\,)K6EZ;H37LEY?3W=A?>=&($\YMW[X%@XV$
MGH#N &*UM%TC4;7Q%XLN[J)=E^;?R)%( E*P!&(&20-P(YKJG=8XVD=@J*"6
M8G  '>LS0?$6F^);-[S2I99;=6VB1X'C#<9RNX#<.>HXH J>!M.N](\#:+IU
M_#Y-W;6B1RQ[@VU@.1D$@_A7G.O>%_$>LZ1KME?:-JFH:S-)/]FNI-2"6*Q$
MDQ[(Q( #MP "G7DD=:]FHH X_1-#OD\2^(;F[MVAMK^QLH8GWJ261) XX)Q@
ML/Z9KB-/\"W-OI-GH%QX2N+B[AD2*6_EU63[$\2L/W@19@V<#A-HP?:O9Z@G
MO;:UEMXIYXXY+A_+A1FP9&P6P!W. 3^% &7XPL;G5/!>N6%G%YMU<V,T44>0
M-SLA &3P.3WK+\.Z-J%CXNO[ZYM]EO+I5E;H^Y3F2/S-XP#GC</;FNDL-4L]
M3^T_8YO-^RW#VTWRD;9%^\O(YQGJ.*MT >7Z9X<UW1-+\+:D-,>YNM)FOUN+
M%)4$C13R,0R$G:2 $.,C@D=:NW\'BO4=2T[Q,VC*O]F7KM;Z494%P]N\1C=F
M;<4WY.X+D<<9S7H=% 'E?B'P]K_BJ'Q#JO\ 9$EG)<V$%A964TL?FR*LWF.[
MX8JO7 &[L:V/&EY>6'CSP?/9:>]^X6^W6\;JKLNQ,E2Q R.N"1GI7>55FTZT
MN+^UOIH%>YM X@D/5-X ;'U % 'G=WX7UW6%U?Q!]A6UU&;4;*]L].GE7+):
M]%D925#/ENY ^7)ZU:U.PUSQ;JJ7\FB7&F06&G7D44=U+&9;B>9 F $8@* .
MI(R2.*]$HH \_P!3TKQ!!X \,6%G#>!K5+:/5+:QN%BN&B6+#JC[@,AL9PPR
M <&L6W\'ZI+<>*FM=#N+"VU/06M+47=Z)I7F^?\ UA+L03N'<@ #G/%>GRZI
M9P:K;:9)-MO+F-Y88]I^94V[CG&!C<O7UJW0!Y1>>&[^[U#1]?U#PUJ-Q&NE
MC3[FPM[X17$#(Y*N"DBJZG)XW<<''6I;/PKJFF0:;KMCX?6"ZM-4FNVTQ;PR
MRR0R1>42TDCE3*!@X#!>,9S7J5% '&^&(-8N/&>O:UJ.D2:=:W=M:Q6J2RHT
MC!#+NW!&(!^8<9Z$<YSB[J.EWD_Q!T+4XX=UG:V=W%-+N'RLYBVC&<G.UN@[
M5TA(523T')JKIFI6FL:9;ZC83>=:7"!XI-I7<I[X(!H \ZUGP5JNHV6O$6>]
M_P#A(8]4MH#<>7]JB6*-2H=3E"<. 3C! ^M1)X4GO8=;FL?"MUIV[1[BUMVU
M#4&FN)9I%QM4&5T5.!R>2<=!7JM% 'GOB;PG>W_A[PM(MB]W-H^PW%A'<F%Y
M$,6QPCJPPP."/F .",\UBWG@^]O_  _XE;3?#$VGR75I';6B7E\TUS-APS;B
MTK(BCL,YZGOBO4-0U2STM;=KV;RA<7"6T7RD[I'.%7@=SWZ5<H YK1]+O+7Q
MQXGU":#;:WJ6@MY-P.\HC!N,Y&"1UI? &EWFB^!-)T[4(?)NX(2LD>X-M.XG
MJ"1WKI*J7.J6=G?V5C/-LN;YG6W3:3O*J6;D# P 3S0!YVMKXIL])\4:%'X;
MDE;5KZ\:TO!<1"%(YF(W2_-N& =V #D8'!I/'>B7FE:5X:71IP-0V?V#O/!>
M*:/:6^JE%?\  UZ)J>J6>C6#WM_-Y-LC(C/M+8+,%7@ GDL!^-0RZ!I<^O0Z
MW+91OJ4$9BBG8DE%YZ#. >3SC/- %K3[&#3-.MK"U39;VT2PQKZ*H 'Z"K%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %<+\4+-KO3M""W=S;_\3NS3,# ?>E4;N0>1U'OZUW59
M?B#0+7Q'I@L;N2>(+*D\<UN^R2.1&#*RG!P01Z4 <#!HE[?^-/''D:_J-BMN
M;78;9D#/(+5,,Y*G(X' P.3[8=I7B7Q#K']DM;7*?;+SPG+>*C@"-KH,@5SZ
M<D^W-=UI_AZTT^YU*Y26XDFU$1BX>5P2Q2,1@].I Y]ZSK?P%HD%O;V[)--!
M!I;:4(Y7R&@8@G. /F^4<C% '->#]6NHO$EE8ZGJ7B"UO9X'$MAK-NK)<R*
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MTFXEE*NH#,HA)S\O\6<-Z@#&*[?4O ^GZEJ]SJ/VW4K5KR-8[V&UN-D=TJC
MWC&>G&5(XH7P/IL47A]+>YOH&T)?+M9(I@&9#M#(_&&4[5SP.E '+S>(M67X
M.ZQJXOI!?PW5RD<_&Y0MT44?@N!2>)]4N)]9UF.UUCQ#-)9H%B@T6W"Q6K;-
MQ\Z1QM9B>2,\#C%;=Y\,M'ODO;>2^U5-/O)FN'L([K$"RL=Q8+C/WN<$D9YQ
M5NZ\":?<W^H3K?ZG;V^HOOO;*"XV0SMM"DGC<,@ ':PS0!SWA/4KC6/&7A_4
MKM@US=>$EEE8# +-+&2<=N:ZKQU?7.F>!-<OK*9H;F"RDDBD7JK!>"*71_".
MG:)<V-Q:O<,]EI_]G1>8X/[G<&&< 9.0.:3QS876J>!=;L+*$S75Q9R1Q1@@
M%F(X'/% & ?[6\-:SX:EFUV[U)=6G-K>0S[2F\Q,XDB  V %<8Y&#Z\US]AJ
M?B&#P"OB5_$%W-?ZC<#3X8Y50P6P:Z\H2;=N2P )R3CG&.*[;1/!5GIMU8WT
MUYJ-Y-9P[+6*\N/,2UW+A@@P.<<98DXXS5N+PAI">$V\-/%)-IK!LK(_S99R
M^0PQ@ACD$=,"@#F[UM4\(^(-.LDUR_U&UU2VNE=;UE=XI8HC()$8*, X((Z<
MBL*T?Q)_8?@K4SXKU$W.O216]TK+&8UC>%GRB[>' 0?,<\DD^E=S8^";*UO&
MO+K4-2U.Z%NUM%-?3AS#&WW@@"@ G RQ!)QUJS'X3TZ/3M"L5:?R=$>.2URX
MR2B,@W<<\,?2@#AM4U;6=!T'QY8Q:Q>7#:3]G>SNK@JTR"558@L ,@'...]/
M\5:AK>GZ]JL^H7VOZ?81E6T^^TV!+BT@0("QGC +$[MV<\8Z8KLM1\&Z7J::
MXMPUP!K2Q+=;7 P(P NWCC@>]5M1\!Z?J%Y?S)J&J6<.HG-]:VEP$BN#M"DL
M"I()4 $J1F@#F-6\17VK^+KK3X)]=;3K*SMY$?08DS,\JEM[,V<+@#"CKSGI
M4<^I>,;K0-%EOK;6Q!')<1Z@--2..]E"D"&38>Q&2P7O[<5V-_X*T^ZNX;NR
MN[_2;F*W6U\S3I1&7A7[J,&# XYP<9'K4+?#_2([/3H;">^TZ?3Q((;NUFQ,
M?,.9-Y8$/N/)R#STQ0!+X&U)=3\/%UU:?4C#<20M)=6_D3QX.1'*O'SJ" 3@
M9ZXJKXXU$VTFEV:ZK?6GVF1RUMIEN9;NY"KG"$ [%!(+-CI@9%;FA:#:>'[*
M2VM6FD::9IYYYWWR32-U9CZ\ <8' JOKOABVUR[LKTW=Y97UEO$%S9R!757
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MEC/:3W0L[2+9Y$:0,RA9%*DL6V$DD]^,8KHE^'NDI<*!=:A_9RW/VH:7Y_\
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M+W?AZZU'6!>S!;5[5S!=AYV=93+M*!<,"2>1MZ4 ==J?CCP_I%_+97=Y()8
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MEDE^Q+S?9TG-O(('ESC8LVW86SQ@&J/B33KBX\8>$_LL,BQQ17L;2HAVP[H
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M^&'W"&( P.U;.GPGP5K^F7M_9:A_9SZ#!IZ2+$UT]M)&Q8QOY:]PP^8#!*T
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M3;2%E=9Y&,>[IDCC'^T*LRZU%XC\<>#I;#2=21+.2Y-S+<6,D*VQ:W<",EE
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M<VLFR2)L$'!P1@@D$$$&FZ%X<M-!-U)%-=75W=N'N;N[DWRRD#"Y.   .
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:?3VN RR(<899 .G([=QUJ/3_BA?SZQX>AU'PO)8Z;KX'V*Z-VKL6V@C* <
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M[=*\4T/P'9:A\4_$WAV?5M;^PZ;# \&V_8/ET4G)[\DUZW_PF_A+_H:-$_\
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M'449(TSDLS,W)R3^=9_A;1_#>A?$B]UJ;QAX>?1XFFETNV748RT+S8W\9P
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MC&P3YLJ'YXST.,XSWH [S3O'6L0RW?\ PE/A.ZT>W@LFO1=1R_:(MB@DHS
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M(\0Z7:S_ !;\,W+QRM*+&[D&V9U!:-HBO ..K'([]\X%<OY3'X4'QZ=3O?\
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M8:GKEY:ZM/.DTUX;E]NYI=OD>63MV?P;<<?6@#J_^%<^"_\ H5M)_P# 5/\
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M SG.<J>U:->*>*(;[PEXMGM?#L5RME%H437ER)VEGM[<W4AD:/>26< G&3P
M?:O7=&BLH=&LTTZ4RV?DJ89#(9"ZD9#;CR<YSGWH C.N6H\3)H!67[8UF;T-
MM&SRPX3&<YSDCM6E7%R?\EL@_P"Q=D_]*$JM\2+O4/M7AW2+2*:6#4;QUN(X
M;K[,TP2,L(_,_A#$<XY.W'>@#L=5U2TT72KG4K^7RK6VC,DK[2V /8<FD_M:
MS_ME-)\T_;7MC="/:?\ 5A@N<].I'%>.>(+&]@\*>,M.NK<V>GQ6,5U!8/JO
MVF2WER03P=P1A@X/&0<5NWVDVFC?$)KNQ@G::R\,RW,"-<ROF1' 4'+'(]CQ
MWZT >IU']GA^T_:/)C\_9L\W:-VW.<9ZXSSBO%](CUN/2O#VOPVTL-[<S6\D
M^IW6N I>+(1OC,1.WY@2%4#((&.176>$=)CU'Q;XCUB\NKR6:QUB6"UC-RXB
MB7RD)^0':<[^X/08H ] KGO$?BU/#;,9M%UB\@2$SR7%E;J\<:C.=Q+#! &?
MI70UB^,/^1)U[_L'7'_HMJ *_ASQ:GB5E,.BZQ9P/")X[B]MU2.13C&TACDD
M'/TS715Y_J6J7NB_ J'4-.8I=Q:/;^6XZIE$4M^ )/X5F:/8ZIHWBG0F@L9-
M-@N6>*Z^UZX+G[<NPG<$8\N" V5[9[4 >IT5XGIU@]K\--"\6#4-1?6A>VX\
M][R0@QM<B,QE,[=NT],<GFK_ (FV:O=>)[NUL=6U$V!>(WSZE]D@L'CC!*Q*
MK98J?F)V\DXSB@#UVJ>H:K9Z6;07<NPW=PMK  I.^1@2!QTX!.3Z5YII5LWB
MWQ%H4.KWEY+;2^%+>[GACN7B6:4OC<VP@GJ?T]*S)+"/4]$\.VE_-=7*V?BV
M;3HG>YD#^2&E !8,"2 J@-U&.#R: /:JSM$UJUU[3S>VBRK$)I8,2  [HW*-
MT)XRIQ6@   !T%>'KI$=G\,=7\3P7=]'JMIJ-U+:R)=2*L.VZ8;0@.T@\YR#
MG<?:@#W&BO,?$4<.N>*-8ABT_5-7-E'''(?[1^QVMBQ3=\I# LQ!#$[6QP/:
ML:S_ +7\0^'?"=U(/[>QI1>YTK^U#:SNVX*+C((WXP5^8CD]<F@#V>BN:\!W
MMO>^%(!;RZB_V>26WD&HL&GC='(*,1P=O0'G@#)S7.>-9M0U'Q[IVA)8SWU@
M-/DNVM(K[[()I/,"Y9N"P4<[?5L]J .WUC6K71([-[I96%W=Q6<?E@'#R-M4
MG)'&>M:->/$ZC%I%G97S+Y=KXMLDMH3?+=26Z%U/E.X).5).-W."*HDZWKEA
MK^MM97/VZ"\N4@U(ZT+=+ 1,0J^62%"@ %MP^;)SUH ]OK$AB\/6?B@VMO8V
M<.L3V[73/';*KM&&"DEP/5AWKDK&T/C+Q9J%KX@GF,=CIUFT-M:W;QQEY49I
M)048;OF&T'D #WK/TJPL3\0;"]MK^XUF2#P]++%=M.^9WCF5!D X/'!XP2,G
M)YH ]8J"]NX["PN+R4,8X(FE<*,G"C)Q^5>):6VO3^%M-\41VTD>IS2Q3OJ]
MSK@6*3=( T;1$[0A!*!,<''>M^YTV'Q+9^.-3U6^NX[NPN+FVMBET\:VL4<0
M*D(" =V2QR#D'% 'I>F7\.JZ59ZC;AQ#=P)/&'&&"LH89]\&FQ:K9SZO<Z7'
M+NO+:*.:5-I^57+!>>G.UJS_  7_ ,B)X>_[!EM_Z*6N"UN/^QO%OCS6]/27
M^T+318;B%O-<A783 MM)P0, X(P,<8R: /6:*\RNM,@\+CPGJFDZA>RW=_?V
M]M<O+=R2B^CE4[V96)&1]\$ 8QZ5Z;0 45Y)%J5R/@?HEPU[-]IDO;9#*93O
M;_3 ",YR> 1],U'XE@NH-5U[6+N*]U.P@G++J>CZKMGTM412T9@)"Y7!)ZY#
M<B@#U^BO)=0FOO%/CC5K<:9=:M865M:FTBCU,V802Q[S*0""S$G /;;7:^ I
M]0N/!UD=3N8KJY1I(S-'<+/O578+EUX+   GU!H T?$'B'3?#&C3ZIJMPL-M
M$N>OS.>RJ.['L*CU+Q+8:5HUMJ4ZSNMV8TMX(H]\LSN,JBJ.IQGOC@\UE_$7
M2["[\&:U?7-I%+=6FEW?V>5UR8MT1W%?0G YK+U'Y-2^&\LO%N)60D]/,:T8
M)^.<XH W[3QII,^F:E>W/VC3_P"R^;V"\CV2PC&02!G((Z$$Y[4:/XPLM6OV
ML9+/4-.NO(^T1Q7\'E&6($ LO)'&1D'!&1D5Y]X^^?7O%4D?-M#9Z3]LQT&+
MHL<_\ Y^E=?XB59_B3X.B7#$17S2@?\ /(Q*.?8L5H T="\96&O7(ABMKNV$
MEM]KMI+E%5;B#=M\Q,,>,D<-@X8''-:FCZI#K6EPZC;QRI;SY,1D !=,D!Q@
MGA@ P]B.E>?W_A==(ELM&BU2YN7GLVL8LJJFSTU"K3<KRS$".,,>Y7T-;WA/
MQ5<:I/8VEQID%G!>Z:-0L!!,7Q!E5"N-HVL Z'C(Y([<@'845S'Q$U*[TGP)
MJ=Y8S-!<*(XQ,O6)7D5&<>ZJQ.?:L"^T2T\,^)O#EKI=S>F+5Y)K2]MY+R23
M[1'Y+,9/F8D,I ^9<?>H ZK0/$\'B.6[-G8WJ6MO*T2W<R*L4[*Q5O+^8DX*
MD<@5H7FJV=A=V-K<2[9KZ4PVZA2=[!2Y^G"GK7(?"73;6Q\&":!9 \UW=!]T
MKN"$N)57 8D#CTZ]3DTGCG2K34/&/@HW"RG=?2H=DSIP()&'W2.X'/7MTH Z
MO2-:M=:%Z;591]CNY+.3S !ET."1@GCFI+_1],U4QG4=.L[PQ\H;B!9-OTR#
MBO)7T*"7PQX^UTW5]'?V6IZA-:/#=21K R?,"%4@$DCDD'(XJU<S:IXG\87]
MM<:7<ZI;V5C:-#!%J9LU1I8][2X!!8DY /;;[T >N*JHH50 H&  . *6N9\
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M1S7%I($9Q"[;?-4JQ5D!SG!R,'B@#3T_P;H&FPW<4&GJZWD?E7!N9'G:2/\
MN%I"QV\GCI1H_@[0=!N_M>GV)2X\OREDEFDE9$_NH78[5]A@4_4O%&G:7JD=
MC<%\FSEOI9EP4@ACQEG.<\DX& >AK.T_QS'=W=A'=Z+J6G6VI';8W5TJ;)FP
M6"D*Q*$@$@,!G'KQ0!JKX:T=-$M]&6R4:?;NCQ0;VPK(V]3G.>& /6J]YX+\
M/7]YJ%U=::DDNHQ"*[S(X651MP2H.-PVKA@,C'6L*7XHV,,$U\VBZM_9=M=M
M9W-\(T*12"3R_N[MS#..5!^\.^0-33_&D%QJ%[9:EIM[I$UK:?;L7FS#V^2"
M^49L8(Y!Y% %BP\%Z!IM_#?V]DQO80RI<S7$DLFUA@J6=B2,=CP.U6K#PUI&
MF/8O9V2Q-8V[6UL0['RXV()7D\Y*CKSQ6/8>/(;NXT_[3HVI6%CJ3B.QO;E4
M"3,1E00&+)N ^7<!FJ<OQ-M([>ZO1H>K-IEE=/:WE\$CV0LK["<;]S+T)*@X
M!]<@ '0W'A71+JROK.?3XY+>^N#=7",6^:7 &\'.5/RKR,8Q2:5X5T71H[I+
M.R'^EC;<//(TSRC&,,SDDC!/&<<UD:?XCU.Y^)NJZ))97']GV]I \<G[K:A8
MR9<G=N(;  &.-IR!U/84 <YI_@/PUI=_;7MIINVXM23;NT\C^3E2I"!F(5<,
M?E''MP*WYX([JWEMYEWQ2H4=<]5(P17%^/[S6+F?3_#OAV\>UU.Z2:[::/&4
MCB0X!]FD:-?IFH=4\53:G\/]"US3YGMI+R^LDE"'!7=,J2QG\=RF@#K+/0-+
ML+BUN+6T6.6ULQ8PL&8[( 00G)_V1R>>.M3V&F6>F+<+9P"(7$[W,N"3ND<Y
M9N?4UQNE^+CIEGKUQJ3W5Y(/$$UA96\0W22'"[(T!(']X\D #-79/B#;6=KJ
M;:GI&HV-YIT"W4UG((V=H"VWS$96*LHYSSD8H W=8\/Z7KZ6RZE:^=]FE$T+
M"1D9'QC(92#T/3H:0^'=).F7^FFS7['J$DLEU%N;$C2'+G.<C)/:JI\6Z:/&
M,?AC]X;R2S^V+( /+VYQMSG.[ )Z=!6=%X]CO[>R?2-#U/4)KN)[A(HQ&@6)
M7*!V=W"C<1D#))'84 :6J^#M"UJ:&:]LF,T,7DI+#/)"_E_W"R,"5]CD5JV%
MA::780V-C;QV]K NR.*,8517,2?$338]!L=4^P:BQN[\Z<+18E,R7 WY1ANQ
MU0C@]QVSA]OX]L5M]8;5K&\TF?28DFN8+D(S&-\[&0HS!LD$8!Z\4 ;NJZ)I
MNMI:IJ5HEPMK<)<PAB?DE7.UN/J>.E&H:+IVJSV4]]:I/+8S"XMF8G]W(.C#
M']:Q;3QM$;AXM7TC4-&'V5[R.2]"%7B3!<DHS;6 ()4X-,T_QU%=W6GK=:-J
M6GVFI-LL;NY5 DS$$J"%8LA8 D!@,T ;.L^']+\0011:E:^<(7\R)U=HWC;I
ME74AE/T-5[?PCH-KIT5A#IZ+;QW2W@&]BS3*P82,Q.YFR!R2>E;=% %,Z59'
M57U,VZF\>W%LTA).8@Q8+CIC)/;O1I6E66B:=%I^G0>1:19\N(,6"Y.<#).!
MD].U7*XSQ!>:CJ_C.T\)V%_-IT'V)K^^NK?'FLF_8D:$@[23DDXS@<4 :NM^
M#- \17L5YJMAY]Q%'Y22":2,A,YQ\K#O3$\#^'$T5](&F@V+S"?8\TC%9
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MM?[/,<=BK);-!<21/$K')4.K!MI/;.*Z*O,-7\7:VW_"Q+9;>[M8]*M-UG<
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MJ "><8K6D7Q!XD\6^'KJZ\.7&F65BMRMU)-<1,V^2$J-@1CE<]^"<C@8K?\
M%7C30_!EO;3ZW<M"ES(8X]J%R2!DG [#CGW%6/$'B;2_#.DIJ>I3,MJ\B1J\
M:%\ENG3M0!P$NE>*D\#67@U/#SR/93VZ-?BXB$,L,4RL'0%MVXA1E2!CGD\
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M+'N#;3D]P2#72444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MN+G;)&\TARS[)&0$GN<*,FNHJCI&DV>AZ7%IU@C);1%BBLQ8C<Q8\GW)J]0
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M>W01'=.IAC"E1CY@2"!CT- '7:7XST;6-5.G6KW*SM$9X3-;21)<1@@%XV8
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ML<_=K/OFOM(\$>*O"LF@ZI>:C=27KVSP6C21W"3%G63S -H*AN5)SE0 #D4
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M-S VII(6@>'S0D8Q($?! 90#@],XIY\0>*8/!$/CR758FMV"73Z0+9/+%NS
M;1)]_>%.<DXSQB@#U&H+R\M]/M)+J[F6&WC&7D?@*/4^@KSGQ!XN\06%GXAT
MJRE1]=CU*.+3F,2D>1)'YJ\8YPJ3+G_9K:T776\8ZM/ NQ]$.CP-/$5!WRW
M+;<]>(P./]N@#LZ*Y7X<WL][X&L/M,ADFMC+:-(W5_*D:,$^Y"BNJH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,6)_?/W-8_QF\+VO_",:MXJCO=1AU"WBB5%BNF6+[ZK]T>S&I?AQXC\,>$O
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M8,K2[>!MZ<X]: -RV^+FH?8M'UG4?"DMGX?U*5(!>_:U=HW;(R4P#LR#R<9
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M/B#KNH>$](UC3O"322ZD9&VR7H2&WC4D!I)"HQNQD#'X^ODC>&M+;P+'9_\
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MS!YB 2#)Y(&=H(.>>W6GZW\4;NSUC6+;1_#XU*TT0 ZA<->+"0<$LL:D$L0
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M2W-W 8XS*2%!/J0#_*J_B_PN_B7PNFG(UN+F"6*XA%PF^%GC(.UQW4\@^QH
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MN>0B1F,[1U/8UD3-=VF@^-=*CSIB6^H:8(K:UO6F%J9)(]P1R 03U( P#D4
M>K_\(1X2_P"A7T3_ ,%\7_Q-'_"$>$O^A7T3_P %\7_Q-<=?V*>#?%\R^'DF
MC\_P_>7#0-,\BRS1%"CD,3EOF(SWS4FBZ/HFG:'X:\0IJ5TFK7:1M]H^T.[:
MC+)&28W!R""<GH-NW@B@#K?^$(\)?]"OHG_@OB_^)H_X0CPE_P!"OHG_ (+X
MO_B:\DTV/6;CPC8>*$M+:'5)9HYFURXUI@6<R &-H]N-IY3R\X'U%>\!E+%0
MP++U /(H XJ[TWP':/K,9\,:3)+I%JMW=(FFQ9"%78 $J 20A_2M#3_"G@_4
M=-M;Z+PKHZQW,*3(&T^'(# $9^7KS7':CI5E'XE^)5TL.)TT:-E;>W!>&;=Q
MG'.!266AVOAZ+X?ZGI[W"7M[-#;W<K3NWGH]L[$,"<8!48&.,<4 =U_PA'A+
M_H5]$_\ !?%_\367K.B>"M#.G?:?"6E,M]>1V2/'IT)".^=I;(Z9&.,\D5YO
M;)K.I>$[GQ.]G;PZK]HED_MJ?6FB-LZRE0ACVX5!@+LS@CZUZCX\LI]1^'^H
M-&H^V6\*WL.WG$L1$@Q^*X_&@#*OX/ .G>+].\-3>%-+-W?(721=-A\M.'*A
MCC(+>6^..U7;;1/!5WXBO]%B\)Z49K&&*6:3^SH=@\S=M7IG.%)Z="*Y&[D_
MMW0/$GCFT4NUM?V]S8GK^YL\%L?4M./QK3M-0M8_!/B_Q9<W5W!!J=W,8[FS
MQYWDH1;Q;"> 3MR#VW9H Z[_ (0CPE_T*^B?^"^+_P")H_X0CPE_T*^B?^"^
M+_XFN TNTGT3XC^%XHM%&B)?)=)-%_:9N)+E5BW R+]W(8 YR3DUDVVB0K\*
M[/6UN;U=6OKZ&WDNQ=2;EC^VA0JC.%P%'0>OJ: /5?\ A"/"7_0KZ)_X+XO_
M (FC_A"/"7_0KZ)_X+XO_B:XZ/P;HW_"R+O0_+N?[(?28[M[+[5+Y;S^:Z>8
M?FR3M'KUYZX-=#\-[F:7X=:;+<2RSO&)H]S$L[*DKJHSW.% H YE]1\&>1-J
M%M\-UNM%@9@^I0Z7;F,A20SJI(=D&#R!V-;UMIG@2\UR#2[?POI$C7&GC48I
MET^'RVB+!1SC.3D'ITK#TW3KJ'PN^L^"/%*)H;)).NEZK;K)!'R2T9?(>, Y
MXR<5#8VUAXX\9:%<W]D\-I/X8%P;))&1.95PIVXRHSD#IT/:@#NO^$(\)?\
M0KZ)_P""^+_XFLWQ!H?@KPYH5UJ]WX3TF2"V4,ZQ:?"6.2!QD =ZX.>ZU&'P
MW9Z#;--/9'Q1<Z;Y<EXT1>!"Y2 S<L 2 /4@8[U%K]K?:5HGBNP-K:Z;8OIT
M,W]F1ZB;HQR><!YB@J-BL.".F5S0!Z#8Z'X*O]:U72XO">DK-IK1+*S:=#M;
MS$WC;QZ'G.*H^*H/ 'A"&SEU'PKI;BZF\I1#IL+%% RTC9 ^51U/N*O>&O\
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M-(W&_G[HR>">E8FI>-&O;;0KN03:.UMXA^Q:E#).-J;()69693AD^ZWIT]*
M.G7P1X:35AJ:Z/;B[$OGAN=HD_O[,[=W^UC-7++18;+7]4U=&'FZ@L*NJKCB
M,, 2<\GYCSQP ,<9.0/&\9T&;6O[*O/LCS)!IRX EOF8[5*H<;5)/!8CCG %
M3Z-XGNKO5AI.LZ+-I%_)$T]NCSI,DR*0&VLO\0++D'USS0!>N_#&BW^IR:C<
MZ?%)>26[6KR\@O$P(*G!Y&">OK5A]'T^2*PC>U0II[J]J.?W3*I4$?121^-1
M:]JTVCZ<)[;3;K4;B2588K>W'+,QP"S'A5'=CP*YIO'UY9+JD6K^&[BRO;"R
M_M 0)<I,)H VUV5E[KZ$4 ;$W@CPU<:J=3ET>W:Z:43,QSM:0='*9VEO<C-;
M[*KH58 JPP0>A%85YXIMK;6=-TZ&&2Z-[:RWA>'YO+A0 [L#D[BP  ZFL:+Q
MUJD=SICZGX2O+#3]2N([>"XDN8V=6D^YOB'*Y[^E '3V6B:9IVBC1[.RBATX
M(T8MU'R[6R6'XY/YT+H6EIH0T06,/]F"+R?LI7*;/3!K@]6UEY;C3A93WT6W
MQDMI/YEP6W@(Q*CTCZ?+TK3U/Q_J6F6UWJ<GA&__ +$M)&62[DG2.0JK;2XA
M;YBN>F<9'- &WI_@OP[I=U!=6FEQ)<P-F*=F9Y%^4K@,Q)QAB,9QS5L>'M)7
M28M+%C$+&&02QP\[5</O!_[ZYKCI_$NMV7Q&U_3].TB\UD"UM)4A%RL44 P^
MXY<X#,2O '.#Z4DWBN+4_%'@O4X+F>VTZXM=1DN89&*A3&J!A(HX)0AA^!Q0
M!W@TZT&J-J0@7[:T(@,W<QABP7Z9)-&GZ?::59)9V,"P6Z%BL:] 6)8_J2?Q
MKE;7QW<RM9W=WX<O;/1+Z2..WU"2:,G,A C+Q@[D5B0 3ZC.*ZK49Y[;3;F>
MVMS<3QQ,T<*L%+L!P,G@9]Z ,&[^'7A&^U"2^N-!M7GD??)P0LC>K(#M8_45
MN+IEDFHK?I;1K=)!]F60#!$6<[1VQD"N!\-^.]4'@?P_)>Z1=7VMZF-EK"LT
M8-TJH&:8MTC7GH>1QQS75^'O$C:S->V5YITVFZI8E?M%I*ZOA7!*.KKPRG!Y
M]010!9F\-:+<:==:?-IT$EI=S-<31,N0\C')?V.><BJ]MX,\.VFG7=A#I<(M
M[P@W(8LS2XZ;F)+'';GBHO%.@)JMJ]T=3U:S>W@<J+&]>!6.,Y8+UKFO T$.
MF>![#QAJNN:S.W]G?:+D75])+%]W)(0G&>.* .^@TZTMKV[O(8%2XNRIGD'6
M0JNU<_0<4VPTRRTN.6.RMTA6:9YY O\ '(QRS'U)-<]8>,+Y]0LX=8\-W>DV
M]^_EVEQ+/')N<@L$=5.8V(!QG//&<UF+\2YS:G4O^$:O!HL5X;2XOC/'^[82
M^5N5/O,N<9/N>N* .JD\-:-)>RWCV$1N);B*Y=^?FEC&$?KU IMSX7T2[L+B
MQN--@DMKBX:ZE1@>9B<EP>H;/<8K,U7Q1K-MJ5Y;:5X3O-0ALPOFW#SI;HQ*
M[L1[_OX'4CC/%5)/B%]H.C)HVB76HSZO8M>P1B5(MB@KD.6.%QNZ\\C'.: .
MCTC0-*T&VDM],LH[=)6WRXRS2-ZLQR6/U-0)X4T&/2[+3$TNW%E93BYMH<?+
M'("6##WRQ/XUQNM^.]6N-#TF[TK2;F*[.N)87UJ9HPR.CX,.X\$/_>'&.M>D
M1.[PH\D9C<J"R$YVG'(R.M &1JGA+0=:OEO=0TZ.:Y5/+,FYE+)G.UL$;E]C
MD5+:^&M&LC:_9=.AA%I-)/;A!@1/("'*CH,ACQTYKFY?'VI6T46H7GA&^M=$
MDG2+[7-.BRH&<(KM"?F49(XZX/2NRO4GDL+A+5U2X:)A$S=%?'!/XXH KOHN
MF2R7[R64,AU!%2[WKN$RJ-H# \$ $BJFE>$= T47 L-,AC^T)Y4I;,A9/[F6
M)^7_ &>GM7.ZNOB_1O FOSVQ6?51#$UF(9'F9,11I)@,.2"LC#KG.3R<5Y[X
M,UE;[6M%DT;XB:C+J32J-2TO7I7VRC^)8AM*[NH R3T_$ ]ATGP9X=T.]^V:
M;I<,%P%*(^6;RU/4)DG:/9<59UCPYI&OF ZG9+.]N289 S(Z9ZX92" >XSS7
M*:O\5+33=3U*"UT34M1LM)8)J-[;*NRW;N,$Y;'?TQ5W7/B)9:;<:79Z787>
MM7^IV_VJWM[/ S#C(=BW0'M]* ->'PAX?M[2>T@TFWBMYWBDEC085VC(*,0.
MX*@Y[XYK1DTZSEU&/4'MT:[CB:%)3U",067Z$J/RKCY/BEI4'A2'69=/U%+B
M:Z^Q1Z:T.+AY_P"X!T(]_P"O%2Z+\1K;4;G4M/O])OM*U:PMC=O970&9(@/O
M(PX/I^/UH T[3P)X7L;V.\MM&MXYXI/-B89Q$W/W!G"CGH,"M'6="TOQ#9K:
M:M9QW4"2"55?(VN,X((Y!Y/YUPEM\9;*>WTJ_?P_JL.DZA.MLM_(J^6LI)&,
M9R0,')]CC.*T-<^)$5IK>I:-IVC:EJ3Z=#OO[FT52MME<CJ<L<<X'H<9P: .
MNCT?3XHK^)+5 E^[/=#G]ZS*%)/U4 ?A5'4/!^@:I;6<%WID3I9QB*W*LR-&
MF,;0RD'& .,U@_![4KW5OACI=[J-W-=W4C3;YIW+NV)7 R3ST %-^*VN7VF^
M';32]'G>'6-9NX[*U>-BK)E@68$=,# SVW4 =C9:99:=IL>G65M';V<:%$AB
M&U5!ZXQ]3S3M/T^TTJP@L+&!(+6!=D<2#A1Z5P/PW\72CP5JD?B2[<ZAX=FF
M@U"64EF*IDASW/ (]]M<SXI^)>HZQ9>&I=/TW6=&M[S68#%=.P5;J#Y@RG:>
M,Y4[3P1SSB@#U"X\&>';JS-I+I4)A-P]T I92LK?>92#E2>^"*DMO">@6FDW
M6E0:3:I871W3V^S*2' &2#WPJ\^V>M<OK_Q*CM]2UC2-,T?4]0.FP$WUY:*-
MMJ2I(ZG)(ZG'/!ZXKE/"WB6[ET'X;RZAJNL37E]->@B.;*W)60@";)RP P!0
M!Z;9>"?#>G"X^RZ5"AN('MIG+,S21MC<K,221P/RJS)X9T:2]L+QM/B^TZ?'
MY5K(,@QIC&W@\C'8YKRK1_B#K&M>&O'$VK0ZI:16<DQBN;8)&UJJE0(5/_/0
M9))/OS75O\0;;1M&\-V-K9:GK>KZCI\4\-LF#,T>P$R2,3@$\Y/J#0!T=SX-
M\/7>FV>GS:7";:R&+4*65H1W"L"& /?GFK,/AO1K>QLK*'3H([:RF$]O&BX$
M<@SAO<_,>3ZURC?%C24\':EKSV%['+IDZV][I\BA9H79@H!YQCGK[&K&C_$B
M#4O%=MH-SHFI:=)?0-/8RW2J!<( 23@'*\ G!_'% '3W6A:7?374MU8PS/=V
MXMIRZY\R($D*1Z98_G5"P\%>'-,NH+JTTN)+FW;=%,S,\B?*5P&8DXPQ&.G/
M2N:O/BLFGW:O>>&-8M](:\%F-1FC"#>3C.PG=M]_Z\5)H&IW\_QI\6Z=+>3O
M96]I;-#;M(2D9**257H,YH [?3]/M-*LDL[&!8+:,L5C7H,DL?U)-(--LQJI
MU3[.OVXP"W,W\7EABVWZ9)-8_BSPY<>(;:#[/K^JZ0;?>Q.GS>69,@<-ZXQ^
MIKS_ .$%GJ>J:!:>+M6\6ZU.(WF$EI/=%K<JN5RP/IU^HH ])UGPGH7B">.?
M4].CGFC0HLH9D?:>JEE()7V/%68=#TNWDL9(+&&)K"-HK78NT0HP 8*!Q@[1
M^5<9I_Q:L;Z[L7DT74[;1M0N?LMGJLRJ(I9,D $9RH)!P3Z=L'#=0^+,-K>:
MY;6GAS5+YM%E*WCP[=D:#.7))]CQUX/3% '77GA?1+^WO(+K3H98[V99YP<Y
M>10 'SG(("CD8Z5!;>"O#EH)O(TJ%6G@>VF<EB\L;XW*S$Y;.!U)Z5FWOCY%
MT?1K[1]$U/5WU>/S+>*WC V#&3YCGY5/;KS@UF'XN:7'X0N=?GTV]A^R7_\
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M&#HW?V '?W%0ZI\5[:SU#48+'P_JNIVVE';J-W:HIC@8?> R?F*X.>G0]N:
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ"5#8P?E]ZO>#?"XL]?_ +1'@NR\/Q10,@8W/GSNY(SC:2JIC/7D\=*]"HH
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M65U'/<ZQ'<(\LH3J$"_,,]<'N!TQ7L&I:E9Z/IT^H:A<);VL"[I)'Z ?U.>
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M&!;=H_-D7^#+ 'GID9JWXN\.ZIK&K^+8[.TD;[1I-F(&9=J3O'-([1ACQD@
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M=H!C'F,=V,*<8YS46G:)J$?PU\"6;Z;<K<6NJVLMQ"82&B42,69AC( SDDT
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MG9KNV_LR'[1<Q75I)%(L6"0X5@"0=IZ>E5E^)7AUIEB#W^^5/,M1]@F_TP9
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M3T(NH1-*Q1PF"2N!S@9PV178^ [ )J6MZHMOK0CNC#&ESJ[XEN0BM\PC**4
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MEM$,O+&A(8*.[#=N [[:S(Y+CQ-XVBUBTTV_MK"PTRXMVFN[9X&GDD*D(J.
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MAND 5-V+B0QG:2<YPRA1ZT >H^=$)Q!YB>:5+B/<-Q4'&<>F2*?7ED>H7?\
MPL%?$4M[(L(\*I?R6J1I@KDDQ@D9QNRV>O;I532_&^O2QZ1J?VW4;Z2\EB-S
MIBZ%*D$44A&3'-Y>24!SDL0V#ZB@#UUF5$+NP55&22< "JW]I61NK>U%U"9[
MF-I84#@F1!C++Z@;AS[BLCQY'++\/_$"PSM W]GSMO50V0$)*X/J 1[9XYKA
MH[#5Y-<\!VMKK)BN6T6X+WC6Z,ZQGR3A5QMR/E7)!XYY- 'K5(S*BEF8*H&2
M2< "O-E\3:Q;>'M5@OM>LK>YT_6?[/;4YX/F>+:KY2)00TN&P !CC..*RI=?
MU34],\8Z*=9O;NVCT0WD%W=Z:+:7!WATVE%#*0N-VT=3CD4 >NQR)+&LD;J\
M;@,K*<A@>A!J&UO[2]>X2VN(YFMI3#,$;/EN "5/H<$?G67X-AG@\&:.EQ=-
M<O\ 9(F\QD53@J"!@#' P/PK'\!_\A7QG_V'I/\ T5%0!VE%<)XLURYMO$(L
M$\2MID8M@\=OI]@;R[D<DY+KY;!4X '&2<\C%9%EXL\2:SH/@[[/>Q6M[JMY
M<VMU,UJ#E8A*-P0_=;]WG'3/7CB@#U*JL^HV5K=1VT]S%'/)&\J1LV"R)C<P
M'H,C/UKSRX\4^(-"A\2:7-?1ZC?6=S906-W- L?-R0H\Q4PIVG)X S4>IZ?K
M&G^.M,74]8.J1MH^H&*1[=(G5L1;@0@ *_=QQGKDF@#TNTNK>^M(;NUF2:WF
M021R(<JZD9!!]*FKRWPQ?ZOJ&F^%/#6EZC_9D<?AZ"_N;I(4ED8'"*BAP5'(
M8DD'M27GBGQ.L46B1:A;IJL/B&/2I;[[.I62&2!I%<IT# 8.!QE?0T >IU7L
MKZUU&T6ZLIXYX'+!9(SE202IY]B"/PKB;5_$^I^(+_0X?$I@_L:"$377V*)G
MNYI0S@LI&%0*%&%P3SR*N?"L2K\.M-6?;YPDN0^SIN^T29Q[9H VM1\5Z#I&
MH"PU#5K6WNS$TWE2/A@@!)8^@PI//H:UD=9$5T8,K $$=Q7DFI#4M+U_XE:G
M%J9D:VT^*58I+:)E;,4A13E>B]/?OFM[3K[Q)K7C2\LK?6$L]-TV"RG>%;5'
M:?S$)9-Q^ZIVGD<C(QTY ._ID<T4I<1R(YC;8X5@=K8!P?0X(_.O+_#WBO69
M->T^UUO7)+'4IYREQI%_IPAB(YP+>8+\QSC&6.ZM?X:VMW!-XI:XU&2Y7^V[
MA-K1(OS#;E_E Y.1QTXXH [RL]-<TN1XT2_MV:2Y>T0!Q\TR9W(/]H;3D>U<
M_JE[K.J^-F\/Z7JATN"TL4NYYT@2621G=E5 '! 4;"2<9Y XKE/#%[J.G?V7
M;3R0//<^*[^&Z=8AACB5B4SDK\P['..* /6ZKVM]:WWG_9;B.;R)6AEV'.R0
M=5/N,BO,]*\5ZU_PD-I;:UK<FFW\MZ8I-*OM.$=O)&6( @G"Y9L;<$L<GM3-
M,M_$<5OXTU32];CLX[35[N:*U-LDBSLH!82,?F . !M((Z\T >KT5QWA;Q/=
MZ_XCG5B$LGTBQOH8=HRC3;RW/4]%_*N;M/$GBC6[7PG:VFKQV=QJLFHK<W7V
M5'*K#(0A52,9P,>G.3F@#U6BO*M=\2>(-'UB\MM2U^?28X%C6QN9-+$EG=_(
MNYII I*$ON! *[1CK5K7/&-Y/XKN-)M]5N].M;.UAE:?3M+:^:>24%AR$<*@
M '8$Y.#Q0!Z717EEQXN\33^']&N[B/4=.MVEN(M1OK/2S)*NP@1.(9%)1'&6
M)VG'3BNR\%ZJ^L>'DN7U>UU4B5T%U;QF/<H/&]"!M?&,C% '0UF:W#I.HV@T
M75FC:/4MT*0.^TRD#<0N.<@#/'3&:YOQAK=Q9:Y;V*^(_P"RX6MS((K*R-W>
M2ONQG9L<+'COC).1QBN=TG7+W7[SP/=:B^^ZBU>_MGD,/E%_+BE4,R?PL0!D
M=CF@#LO#GA[1H[A=:M-0O-5F"/;Q75W=M/Y2AL.J9X'S+@GKQUKIZX_X8?\
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M3JWBG2- TCQ3?ZS%=P7DMM]KTX6J)'%'.RJ/*8?/N7>/O$YP>E 'I#,%4LQ
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MTG28KZ$N&^=V,@(;!Z?(.F.];>H^+=#T1+8:OJEK9S3QB18W?G'<XZA?<\4
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MS $G&<C%=I0!R \"):VVCG2M6NK"_P!+LA8I=HB/YT( ^61&&#R 1TP:?;^
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M_P!:=I;"^OR@G\*QK7Q;I]KHL%YK>KZ5$TKS!9()2(G".5PI;DD# (_O9Q0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:!?VBLN1Y<XMXEVG/0AJ>^IZ5JO@OPOX<T>,C7;6YLO]$6(K+9/$RF5W&/E
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M$_F,=I!]B*?XE5C\2? [!20K7V2!T_<5U[3PQRQQ/*BR29V(6 +XZX'?%24
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M+XA 8;BHY(5BK'Z9[5SVK7UGXC\1:SJNA.+FR@\-75O=7<2GRY)&P8XPW\3
M!CQTS[UZ@]Q!'*(GFC60J7"%@"5'4X]!D<TL,L4T*2PNDD3C<KH058'N".M
M&5X3!7P;H8(((T^W!!_ZYK6Q110 4444 %%%% !1110 4444 %%%% !1110
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M:/)+A]^%;/(&"..O.*ZC3=!\2+J-E-J_B5;FUL@=D-K:F W#$8#3'>V['7
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M-V;]NV17Z9'7;CKWI?$WA]?$6EI;"Z>TN;>>.ZM;E%#&&9#E6VG@CJ".X)H
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MLH25QM0D[5/!"\\'O6\_A_1SJ/Q.!TRT(CA3RU,2XCS:!B5&/E);DD=2!Z4
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M2T6XM5L]3DMH;I-P\GS4\G*MU^0KC/M0!ZU<:UI5I-!#<ZG9PRS@&%))U4R
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M_P"QV$,FK1-);_:-J8! 90'V9VDGUQS0![2NHV+VL5TMY;M;RD".42J4<GH
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MG]A+XPO?MAE_U0?RAY)DSQMW^O&<4 >NPZOIMS:+=P:A:2VS.$6:.960L3@
M,#C.3C%3BX@-R;831FX";S%N&X+G&<=<9[UY5?Z59^(->\7V7AHPFS?286=K
M3'E?V@CL\9&.-P"IG'MFN?F\279E/Q&M(Y<ZL)=(MXP#P?(4Q<?]=XY!_P "
MH ]KN-<TBSM8[JYU2R@MY"1'++<(J.1UP2<&I7U*Q2"*=[VW6&4%HY#*H5P
M6)!SSP"?H*\NN+>RT77[30;>'0K>XTO188WO];=F1HR6SY4>0#R"6;(Z@&L?
MPY:VFJ:)X(M+A(;FT_X2&^ C\K;&0!.R@(<X7H=I^E 'M-IJ5CJ%J;JRO;>Y
MMQD&6&5708Z\@XI+'5=.U19&T^_M;L1G:YMYEDVGT."<5Y)XFM(K*[\=VUK
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MI)G;VP0J].PH ]"1UD171@RL,A@<@CUI:Y#X6DGX:Z*"2=L3H,G. )& 'X
M5U] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !5:[TZQOVC-Y9V]P8SF,
MS1*^P^HR.*LUSWB#6-8LKR*VTO3[-D,1EEO=0N3#!'S@("%8ECR>P % &V+.
MV5@PMX0P<R A!G>1@M]<<9IWV>#,I\F/,W^L.T?/QCGUXXYK@8?B/=W>D:3/
M9Z/#/?7VI2Z8T*78\I9$#G>LFWYD^4'..A/7O)<>/M1TK2O$C:MI,"ZCH:PR
M/';7!>*=)?NE6*@@\,"".WO0!VMQI]E=VJVMS9V\UNN-L4D2L@QTP",5(+6W
M"1(((MD)!B78,(0,#;Z<>E<G;^*M:MM?MM-US1[6U%];37%HUO=&4J8P"T<F
M5&#AAR,BG)XUD?PAX=US["H;5[BT@:'S.(O.8+D''.,^V: .IEL[6XFCFFMH
M9)8\['= 2N>#@GIFH)-'TN8J9--LWVJ%7= IPHZ <=*Y;Q%XNUS1SJ5U#I6G
M1Z?8 G=J%\8);O"ACY2A2,=@2>33=&U$:I\2_MD1=8+GPW:W"(QZ;Y9#T]<$
M4 =:VE:<]F;-K"U:U)R83"I3/KMQBIX8(K:%(8(DBB085$4*JCV Z5S_ (ZN
M[>R\->=<VANH_MEJOEB9H^6G0 [EYX)!QWQ@]:Q[SQIX@:X\0_V7H-I-;:%,
MRSR3WAC,RB-7(0!#\V">I Z=<\ ';36EO<21236\4CPMNC9T!*'U!/0T?9+8
M6ZVXMXO)4@K'L&T$'(P.G7FN"3Q#JE]\1=&GMO)71KG07O2DMPRD(SQ$N5"D
M%QD #/0GD=#'!\3YGM+;6IK/3DT*XF6-0+\&\C1FVK*T6W&,D$J&R <]J .]
MNM-L+V6.2[LK:XDB.8VEB5RGT)'%6JXB+QMJ,FJ:V[Z5!%H>B331WMZUP=Y"
M1[\HFWD\C()'48JMI_Q#NWN=)EU*STV&QU:9((!;:@);B!G_ -6)4V@<\ [2
M<$T =K>:7IVHLC7MA:W+)]PSPJY7Z9'%3R6\,UN;>6&-X67:8V4%2/3'3%</
MIWCK4]6U69+#3+">T@OFM)K9;[%[&JN4,K1%<!>,XW9Q4W@^^UNZ\8^+H=0\
M@VEO>(D6VX=S'^ZC*JJE0 I!W'G[Q(P>M '7VMG:V, @M+:&WA'(CB0(OY#B
MFVFGV5AYGV.SM[?S#N?R8E3<?4X'-5->U&^TW3UDT[3OMUS)*L2HTGEQQ@]7
M=L'"@=< FN*OO&NL7&C^+--$6FIJVG:8;J.XL;YI(MC!@3NV[ED7:2 1R<<@
M<T >@6^G6-G-+-;65O!+*<R/%$JL_P!2!S3_ +);&W:W^SQ>2Q):/8-I).3D
M=.O-9GA*6^G\):5+J*Q"Y:VC+>7*T@(VC!+$ Y(P3QUSR>M4->U[6[*_E@T_
M3]/2V@B61[S5+PP1R,<_(F%;) '). ,B@#H)["SNIHIKBT@FEA.8WDC#,A]B
M1Q^%31Q1PQ+%$BQQJ,*JC  ] *R?"VO)XG\,6&LQP& 74>XQ%MVP@D$9[C(/
M-96H>)]9'C1O#NDZ1;W/E6T-W-<3W)C58V=E( "G+?*"/Q].0#JHH8H%988D
MC#,6(10,D]3QWICV=K(9B]M"QF4+*2@/F = WJ/K7"ZYX\UC0H9M3N](L(-,
MAG\OR)[[9>2)OV^8L>W;[A=V2*9!XCU/2_&WC2ZU0Q'1M-M()BJW#,T:A)&7
M8A4#<W.[D<@=>P!W=M86=DH6UM(( %V 11A<+DG'';))_&F0Z7I]O*TL%C:Q
M2,_F%TA526P1NR!UP3S[UQNG>/KQM0TI-5L],AMM6D$4'V34//E@D92RK*NT
M=<8RI(!X]Z[/4M0@TG2[O4;IBMO:PO-*0,D*H)./P% "OI]E+;K;R6=N\*MO
M6-HE*ALYR!C&<D\T]K2V:&6%K>(Q2DF1"@PY/4D=\UQT'C+6[<:3?:SH=M:Z
M5JLT<,3PW1DFMVD_U?FJ4 P3@':3@FL[X>6=[=>*?%&LZI96?VQ=0EM/M$=S
M)(Z +&?*4,H&P<$'@YSQ0!W\6G6,%F;.&SMX[4YS"D2A#G_9 Q4S0Q/)'(T:
M%X\[&*C*YX.#VKBOB-.B'0+;4+J2UT&YO_+U*9)#&-NQBB.PQM1G !.1]:J^
M#-1T^'QSK6@Z'=_:-&CM(;F)5F,L<,I9E=8V)/RG"G . <].: .VCTC383*8
MM.M$,K!I"L*C>0<@GCDYYJRD,43.T<:(9&W.54#<>F3ZG@5Q.KV4/B;XD?V)
MJ7F2:99:4MU]F61D62:21E#-M(SM5#CT+&N?MXKN]TJ.PO(+O5M(T3Q!<VES
M ,S2RVZQL8=PZR!6=,CG[H/.* /5Y(HYHFBE17C8896&01Z$4NU0FP*-N,8Q
MQBO,-,N_L]IHVG>(KM+.ST8"ZO#=S 8E9F-K S$\LJ8<C)Y5*],@GANK>.>W
ME26&10Z21L&5E/0@CJ* (;73;"Q61;.RMK=9#EQ#$J!OK@<U+]EM_*CB\B+R
MXB#&FP80CI@=L5S.K>)-93QA_P (YHVE6MQ+]@6]:YNKAHXT!=DVD*K$GY1C
M'J?3G.E^(Y_LJR5+"&+6KF]EL&M+FY"102Q9,C-+C[@&""!D[AQS0!V)TO3V
MNGNFL+4W$BE'E,*[V4C&"<9(Q4\=O!"Q:*&-&*A254 D#H/H.U<#/\2I;#1]
M;DNK"UFU+2?L[-%977FQ7$<L@0,CX!!!R"I'4#UKL-$GU>XL#)K5E;6=UO.(
MK><RKLXQEBHYZ@_2@"R^GV4MNMO)9V[P(VY8VB4J#G.0,8SS5AE5U*L 5(P0
M1P17.:_K6LV5^MMIFGV/DK#YLE]J5T8( <D"-<*Q+<9/0 8ZUA0?$6\U#3/#
M\NG:-%->ZO<7%KY1N\1QO#NRV\*=R?*3D#..U '>):V\31F.")#&FQ"J ;5]
M!Z#@<>U(;2V,+PFWB,3L6=-@PQ)SDCN<\UP]SX_U#2]$U^74M'B_M/19[>*6
M"VN"\<RS,FUD8J#T<\$=1[\7;;Q5K-KKK:7KNDVEM)-8RWMJ]K=&4$1D!HWR
MBX8;AR,B@#1B\*6A\2:MJUXL%VE^MN%@F@#"(Q!QN!.<D[_08Q6Z88C*DIC0
MR("JN5&5!Z@'MT%<J/&;GPMX9UG[$N[6I[2%HO,XB\[J0<<X_#-9%_\ $'6;
M>WUW4;?0;:32]#O'M[J1[LK+*JD9,:[",@,"<D>@H [NXTZQNYXI[FRMYIHO
M]7))$K,GT)&14TL,4RJLL:2!6# .H.".A^M<KI?B?5W\3VVDZSI-O9K?VLEU
M:/!<F5E"%0R2 J &PX/!([<UL^(M<@\-Z!>:O<H\D=L@/EI]YV)"JH]RQ _&
M@"]=6=M?0&"[MH;B$G)CF0.I_ T+9VJ0Q0K;0K%"08D" *A'0@=OPKE(O$^O
MV6JV%CKVCV5L=3#K9R6UVTJI,J%Q%+E!@D _,N1Q1;^.3=^'] O8+$&_U6[6
MS-HTG^I=2WG9..0@1STYP.F: .N$,0D>01('D #MM&6 Z GOU-12V%G/9BSF
MM()+4  0O&"F!T^7&*\^/Q1D^PMKJVFG'0%F*<WX^V&,/M,HBVXQWV[LXYK;
M7Q1K%YXVO=#TW2+>6TT]H#=7<MR4^25=WR*%.6'/&<<=>: .G2RM(X(H$M85
MAB(:.-8P%0CH0.U2>3%YQF\M/-*["^T;MO7&?2N>\?W=_8^ -=NM-94NHK*5
MUD,A0H IRRD G<!DCWQR.M<C'?\ B1?&VAK;65G/J,WAY]Z/=N((QYR8=FV;
MB<8& O5NN!F@#TVVM;>SB\JU@B@CR3LB0*,GJ<"G10Q0*5AB2,,Q8A% R3U/
M'>N&;XBO%X<2YGTZ*/5VU-])^RM<@1"=2=S&4CA  6SC/;%:7AOQ9-J>MW6A
MZC'8K?PP+=))877GPRQ%MI() *L#@$$=P: .C:SM6F,S6T)E+*Q<QC)*_=.?
M4=O2E:SMGAEA:VA:*8DR(4!5R>I([_C7&?%MU3X?SEQ(8S=VH=8L[F4SID#'
M/(R.*Y;3Y="LO'/AZ+PU9ZOHSS3N+HZ@L\,-Q%L/[L+*?F?=M(P.QH ]<M;2
MVL8!!:6\5O"O2.) BC\!2"RM1"D(MH1$C;T01C:K9SD#L<\YKB/$7CG6M!AO
M]2ETC3XM,LI&7R[J_P#+NKE%."\:;2N#S@$Y..U3:KXXOD\1SZ/I%IILDUO;
M1W'EW]Z;>2ZW@D+"NTYQC!).,G'O0!U]SIUC>R127=G;SO$<QM+$K%#[$CBG
MBTME8,MO$&#F0$(,ACU;ZGUKD=5\:W<.J6FD6-G90ZC)9K>W(U2\$,=NK' 0
ME0VY\AA@<#&<UL>%/$<?B?29+H0K!/;W#VMS$L@D5)4/.UQPRD$$'T(H V!!
M$)))!$@>0 .P498#ID]ZCM-/LM/1TLK2WME<[F$,80,?4X%<MX_\,:/JN@:I
MJMY:M)>VFG3&&59I$V;59APK '!YY%96@VGA_P #?#ZW\7"SD%P=*A>=A.[-
M*SJAP S$ LY'/O0!WEMIMA9S236ME;02R_ZQXHE5G^I YJQ)&DL;1R(KHX*L
MK#((/4$5Q>E>-KQ]>L-+UBWTN-M25_LSZ??_ &CRW5=QCD&T8.T'##()&*RK
M?XD:]+X9@\1/X:@%A=316]M&MYF:1VE$9XVX SG'/;G&> #T=+>&)R\<,:.5
M"EE4 D#H/H*6*&*",1PQI&@SA44 #//05PZ>*O%SZY=>'QH&F?VI%;I>+)]O
M?[/Y+$K@GR]V_<I&,8ZG(QSTGA?75\2^&;#6%@-O]JCW-$6W;&!(89[\@\T
M7;O3;&_,9O+*WN3&<IYT2OM/MD<5)<V=K>VY@N[:&>$XS'*@93^!XIFHSSVV
MF75Q:P">XBA=XH2V!(P!(7/;)XKD%^(UO)J?A.VBM-T.NVXFDEW_ /'L67]V
MI&.=S!E[=* -S1?#4.DG659HYX-2O&N3"8@%13&B;,9((^3VZ]*T[?3K*U0)
M;V=O"@4H%CB50%)SC@=,]J\UU/Q+J>J^*?#-WI>GI(?M^I6MJCW!2.9(TV>:
MYVG R'. #T&.M7M0\5276EWEIKFD1"_TW6+*VFBM[M_+8R/&T<BN #C# [2.
MV#UH [FWTK3K10MMI]K"H?S (X54!NF[@=>>M68H8H$V11I&N2<(H R3DG\Z
MXZ?Q;KMW<ZK+H.A07UAI4[6\QDNBDUQ(@!=8E"D<9Q\Q&3Q6-;:MXBC\;^,F
MT72X+E4^R3.+VY:';_HRGRU 5OF//7 'XT >DB"$/(XB3?* )&VC+@=,^M(+
M6W"1(((@L)!B78,)@8&WTXXXJEX?UB+Q!X>T_5X8VCCO($F",<E=PSC\.E<G
MJWBF#P[J/C34(M,,D^G6]E)*WGM^_#;@ %/"XYZ=<\T =J^G6,EZE[)96[72
M#"SM$I=?HV,BIEAB65Y5C02. &<*,L!TR>^,FN2MO$VOQ>(+;2=6T:RMI-1M
MII[%H;QI &C"DQR_(,'##E<CZUS?AOQKJNF>!--EU&.VNM1U&_GM[,RWI ;$
MLA9I79?E5=I QG("],X !Z6^GV4D,<+V=NT4;;T0Q*55NN0,<'WI_P!EM_)D
MA^SQ>5(2738-K$]21WS7 W/Q*FTW3-9^VV-G-J.F10SA+"[\V&XBDD"95MH(
M8'(*D>G8U:O?&>M:<;#3KW3-,M]:OVD>..2_(@A@0+\\C[<[LMMV@')YSB@#
MJ]2L[I[&Y&D36]EJ$H4+<R0>8!@]U!&[C('/&:B\.Z)%X=T*VTR*1IO*!,DS
M#!ED8EG<^Y8D_C7(R_$PV^C73S6EFNI6M_%82XO,VBF0;DE,VWB/'MD$8]Z9
MXC\0^(Y/AQXCN1:VEM<VUN3#>V5\7AEC*Y+Q,%W!EZ8('/>@#JM;\/)K6J:-
M=RRJ(].GDE:%H]XF#Q-'M//'WL]#TK3CL+.*R^QQVD"6I!7R%C 3!ZC;C%1:
M.]Y)H]H]_'"ET8P9%AD+J/3#$ GC':N1O?'.IMXBU33=)T[3KA]-D5'M;B_\
MFZN<JK$Q(5(QAN"3R0>E '8P:;96D:+:V=M (]WE^7$JA,]<8'&>,UE>&_#]
MSI,^H:AJ=\E]JFH.AGGCA\I B+M1%7)P!R>O5C7,S7VO)\4=9AT6PM[B1]+M
M';[;<M%'%AI>/E5B6.?IP<FM*W\9:GJOAS2M0TK1HA->F43M>7.R"S,;%6WN
M%).6!"X'/7B@#K1:6RQ1Q"WB$<;!D0(,(1T('8T\0QK*TJQH)' #.%&2!T!/
MXFO+]6\5S^(/#$T<T=O#>:?K]C:S-9W/G0R9FB8,CX!P0V"".,&NE\&N[Z[X
MR#,S!=8PH)S@>1%TH Z2VTVPLYI)K6RMH)9?]8\42JS_ %('-2?9+;[/]G^S
MQ>0#GR]@VYSGITZ\_6N*\:76I6WCGP>-*MDN;F07JB.68QQ_ZM/F<@'@<G@$
M]N].E^(+Z9I6KG5].2+5M,GBMVM89]T<[38\ID=@,*V><CC:?2@#LFL[5[G[
M2]M"T^SR_-* MM_NYZX]J;9Z=8Z>KK96=O;!SEA#$J;CZG YKC;;X@M8WLUK
MX@CTY,64M['-IMY]H0K$ 71@54A@#D=CSZ4B^,_$5N^ASZCX>M8;+6;J*"%H
MKPO);AP2/,4H!G [$C(Q0!W3HDL;1R(KHP*LK#((/4$4S[- &A;R(\PC$1V#
M]V,8^7TXXXKSV+Q<^EF>+2M$$UQ>>)+G3_+>[8!I A;S"2#M!*C( X&<9Z5T
M?AOQ!J&HZKJNCZO8V]KJ&G>4[&VF,D4J2!BI4E5(/RD$$4 ;SVEM(LRO;Q,L
M_P#K04!$G&/F]>/6B"UM[;_46\47RJO[M ORKP!QV':N2^)%]J]CI>DMI)C5
MY=6M(Y"\[1[@95PN54_*QX;V['I3YO$VOWFK7VG:%I%C<OIBQB]DN;MHT:5D
M#^5%A#D@$?,V!R* .MBAB@B6*&-(XUZ*B@ ?@*?67X<UR#Q)H%IJUO&\23J<
MQ2?>C=2593[A@1^%:E !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7#>)
M?">H:CXOAUF.PTC5[9;,6ZVFJ.RK;OO+>:@"."2" > >!S7<T4 >=Z+X#U;3
MAI/VBYL&-GKEQJ4A@#(K1R1N %7'!#/TSC ZU9\1>"=1U=_%I@GM5_MFVM(;
M?>S#88BQ;=@' .X8QG\*[NB@#G]8T"?4O%6B:FLD:VUC#=1S*2=[>:J@;>,?
MPG.2*Y.U\&^+1H^@:%<3:0NGZ+?6TZSH\ADN8XI 0"I7"';[G) Z#FO3** /
M,;_P!J]Q?>(=MGH5T^JRR/#JU[N>XM8W7:(U381\O8AP.^.U;_AOPM?Z3K5G
M?74MLR0Z#;:8ZQ,Q)EC9BQ&0/EY&._M77T4 8/B_1+CQ!H/V"UDB27[5;S9E
M) Q',CGH#SA3CWJG:^&;R"V\71M+ 3K-Q)+;X)^0- D8W<<'*GIGBNJHH X6
MW\(:M9W_ (<FC:QFAM-&_LC4$>1U.P^7EXR%Y.4/!QUK*TWX?:M86MGHZV'A
MG[+;2J/[6-JKW4D*MG:8VC*[R!@MN/KC->GT4 <I:>$7;3?%FGW\J&#7+N>5
M3$22D<D21\Y ^8;2>XZ5BZ/X+UBVN=)AN--\,6T.GR(TM_:VP:>Z"#Y1M:/$
M9)P2P8G/3%='JWC+3M)M==F9)YFT5(WND10#\XW*%)."<$'\:Z$'(!]: /-=
M7\#:YK5X$O(=$:1+Q9HM>0&.]CB$@8+M5 "P VYW8QSC-=-HVBZII?C#7[QS
M:/I>INEPC!V\Y)%C1-I7&W;A2<YSTXKI:* .6\<^';SQ'I]C%:+:SBUO$N)K
M*\9EANT (V.5![D$9!&1R*P[/P)J9O->FFBT?3X-4T<Z?':Z>K;;=OGP3\JA
M_ODDX'ICC-=YJ-ZFFZ9=WTBLT=M"\S*O4A5)('OQ2:9?QZII-GJ$2LD=U DZ
M*W4!E# 'WYH I^&;;4K+PY8V>K+:K=V\2PM]E=G0A1@$%@#R .,5RVK>#]3G
M\9W^KQZ?H>J1W<<26[ZH6+6!1<'8FQ@P)^;@J<]^]=AJ6L6FE26$=R7#WURM
MK %7.9"K-SZ#"MS[5?H Y_P1H5UX9\'V&CWLL4L]L'5I(<[6!=F!Y QP1QZ^
MM.MM$N(?'5_KC21&VN+""V1 3O#(\C$D8QC#COZUO5G2ZW9Q:T=()<W8LVO"
MH7CRPP7KZY/3VH \RNOACKD_A[4=(6U\/F[N)'D.N3%WNIP9-X##9E#T4D,0
M!T%=-J7@Z_U+7/$8DDM1I.O6$=O,P=O.@D174%5QM8?-GDCITKI]!UB'Q!H%
MCJ]O')'#>0K,B28W*#V..*T: //M&\(:Q!J&E_:],\,64-BP>:ZL;8--=E1A
M<!HQY7."2"3D<$5VFL:9#K6B7VESLRPWEN\#LO4!E(R/?FF_VO:?V_\ V*"Y
MO!:_:R-ORB/=L'/KG/'M5N>406\DS E8T+$#V&: .&3PWXIU.'1M*UJ72UT[
M3+B&=[BV=VENS#R@*%0(\D M\S=.*W_#6B7&C2ZXUQ)$XO\ 5);R+RR3M1E0
M '('/RGUJ[H&L0^(- L=7MXY(X;R%9D23&Y0>QQQ6C0!B^);+5KVPB&D26AD
MCF#2VUXN8;J/!!C8[25Z@@@'D>E9.C>'M7L)-7UB2/3(M7N;9;>SM(2QMK9$
M#%$+8!(+N2Q 'L*["B@#D=2T;7XM>L_$6E+ITVH&Q%E>VL\KQQ.-V\,CA6(V
ML6ZCD'L:O>%]$N= T6X%S)'<ZE=W$U[<F+Y4::0YVKGHH&%!/IFH+[QO8V#Z
MLLEM<,=-O+:SDV[?F:?9M(YZ#S!G/H:Z>@#A3X6U:TM-&U*)+:\U>WOI+^^A
MDE*)-)+&R,%;!QL#*%R/NIVKH/">CS:#X8LM-N7C>>)6+^7G8"S%BJY[#=@>
MPK:K-U_68?#V@7VKW$<DD-G$972/&Y@.PSQ0!Q^J/KD?Q>D?1([*9QH,7FP7
MDC1JP\^3!#*K8(/;'()Z5#/\.;QM/L;PMIM]K4&H3ZA<17<9-K.TXP\>,$J
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MS2ETD!V-EE!QRO<XKN_#>NP>)O#]IK%M%)%#=*65)<;AABO...U:M 'FEO\
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MC(^=K-]X@#ITR:T?&/A!]0\5VFOKHD&N0BS-G-923")UPY=9$)P#U8$$CJ*
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MP2X2.-59F4@NWH5XXYSVP:@C^(,-WI.DS6&E75QJ6IR2Q0Z>75&1HB1*7<G
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M1@N0  3ZG  ^@%</X=TV./XL^+KD7%V66&S;8UPQ0[UD)RN<$#''IDXZUWM
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MNRLM4@TZ9G^TSP2W$:JA.4CV[OQ^8<=ZR/'^I7FF^%6:QG:VGN;FWM/M*XS
MLLJHSC/< G'OBN7OM%_X1_Q_IWV?5-0N%;1K]E6[NFF>-AY66#,2PSQQG *\
M8H ](L;R/4+"WO85D6*>-9$$B%& (R,J>0?8U#<ZO:6FK6&F3.PNKX2M H4D
M$1@%LGMP17EJRZ[J&C>&+R4ZQJE@=$@DN(=+U+R;M9V&3,PW*T@(X'/4'BI6
M6+Q/J/P_6/7-1>-HK])+H_Z/<R; BLC$<JV1@D<\'GG- 'K=%>2W^I:EH_\
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M0HCY * * <]<C![UMV7C[2[Z[M8X[34EM+N<V]MJ#VV+>9\D !LYY(."0 :
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MCBO+JYCO&L8X+:'>\TJH'<(,\A0>2< 5C>)/'0D\"Z]?Z9]KT[4M+>))HKJ
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M+A=KQ%T*_, 3@C-<3(FLZ]X?T'PPWAV^L;BTGM#>W,P401) RL3&X)WEMH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M? V,.G7 !P1UO_"!6MO!IBZ;JVIZ=<:=9BQ2YMWC+20C&%<,A4\C.<#!-*?
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M&=%>6.$QK)N/ #.!N4$CN*ZS1? VE:"=(^QR76W2H[F*V5W!&V9P[ \9."H
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M?$Q!9T((() '8UCZ7X M=.O;&:76-7OX-.;=96EW.K10':5!&%!8A20-Q.*
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M1KA%P!\H[9R?<UYK'I5W;>!;\1ZQ>2S2^*TAB>X".(G6]QY@ 498D@MG@D<
M5[/IEA%I6E6>G0,[0VD"01ESEBJJ%&<=\"N>7P%8JUZGV_4#;7.HQZF+8NFR
M*99/,.SY<@,W4$GVQ0!S.J:SJW@*ZUZ :K=ZO%%HW]H0&_VLT<WF>7U4+\AR
M#CMBH]"U+Q#!X@TLHOB^\BN9?+U :M8QI JE3^\C*<QX;''(()]*[R^\,:;J
M6JW%]>(\QN+!M/EA8CRVB+;CQC.??-9FE^ [?3KZSN)M:UC4(K'_ (\[:[N
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MAX>M-S0%@26F<J02>,#(P.W.:I:=K6O^(M)\"P?VS=64NI->1WL\2()'6(,
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M %%%% !1110 4444 %%%% !1110 4444 %<_XQUNYT30P^GK&^I7=Q%9V22
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M%;".4022N&7RI"P4*ZD94Y(Z@8SGI3]&\6Z'X@NIK73+[S;B%!(\3Q/&VPG
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MDD4BAT=&!5E/(((ZBGUYII.M^(]7N]&T?29].TR"3PY::B\GV/>(W8LNQ$#
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MF5BH.1M.4'//TK?K#DUYT\=0>'O(4QRZ=)>F;=R"LBIMQZ?-G/M0!FIX&1/
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MZ5=6L%U;ZG9S6\\@BAECG5ED<]%4@X)X/ YH EU&R34M,N[&1F6.YA>%F7J
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MCSX0[;G2*;<-H))_A)&>#4VJ> +77+S4[K4[R6::>!(+%PN&L%4A@R'))?>
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MQ;IWB2\U6VLYH2^GW36Y"S*YD4*I\P =%RQ'_ 3]* *5GX3U.75].OM?U_\
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M_2B.NTIOEIYGF;%W@;=V.<>F: /*_$+3VWQ4O9KO5](TR.338ELI=6M?-C=
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MEM-"T,MO$\3G<R,@*L>N2*7[+;[=OD1;=H3&P8VCH/I[4 <GX?\ ^2E^,?\
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M"H 65Q*P4;MI4$=17J:(D:!$554= HP*C@M+:UW_ &>WBAWG+>6@7<?4XZT
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MC0$"!#;N &D+G.>@!"YP3VJQX>_Y"?A#_L/ZQ_*>O6(+.SBC M[:!$W;P(T
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M'I<,337R.+@%FDD9\JPY).WVSR*]4\-_\E$\;?[]E_Z(KJ18V@>5Q:P!Y?\
M6-Y8R_U]:E"(K,RJH9L;B!R?K0!QOQ1_Y%"+_L)67_I0E'Q0_P"13@_["=E_
MZ/2NR>-)%VNBL,YPPSS0\:2+M=%89SAAGF@#G_'_ /R3KQ+_ -@NY_\ 1;5Y
M]KGA*XL?!.FZPNI:WJVFP013:CI$]\YCFM]H+;0N/N]=IR"!BO8F570HZAE8
M8((R"*-JA=N!MQC&.,4 >2:S>1S?$'3]2@UC1[#2[C14_LRYU&U\V _.2ZH=
MZ!'V[,]R..U4=+TVSN5\*0M<1:EI\WB2ZFAVV9A@P(9&Q&A9LQ[P2#G'->QR
M65K-;BWEMH7A'(C:,%1^'2I/*CP@\M/W?W./N]N/2@#QWQ?:00Q?$^*&WC2,
M6EA-L1  &P^YL>N!R?:O4WO[)O#LM_8;+NS%N\D0M&!$J@$X0KZXP,5?,49+
MDQJ2XP_'WA[^M+'%'#&L<2*B*,!5& /PH \&&HV\^G^"6@O/#T,/]J64D.FZ
M;$SSVZEQGS92Y((SM;*C+'K7H7@.2QBU_P 862M EZNL22F$8$@B,<6&QUVD
MYYZ5V26-I'O\NU@7S&W/MC W'U/J:D$,2S-,(D$K##.%&XCT)H \U\1:K GC
M_48!+H.E306$(EO]85I7FC8N=L,9=5P#G.#R2.*YWP=:VVH6_P .(;F))XH[
MG5B(Y(L %7<KE#TQP0.V!Z5[3+:V\\L<DUO%))&<HSH"5/L3TIP@B5@RQ(""
M2"%'!/4_C0!YJOAZ/5[CXCZ):*L&^YMY;8(-HCG^SQNKCT.\ FKO@#4)?%^K
M7GBVXA:();1:= C#&U@ ]QQ_UT8+_P!LZ[/4[2[N-/N(],NX["]EQMN6@$NT
M@CDJ2-W (ZU%X?T6'P]H=MID$CRB$$O*_P!Z5V)9W/N6)/XT <MK$EC:?%W2
MWNV@B:XT>XBA:7 \R7S8\*I/5L9XZURW@>RM;V_^'XNH(YA%X>N)$$BA@&WQ
MC.#WP37L,D$4K(TD2.R'<A90=I]1Z4JPQ(5*1(NT;5PH&!Z"@#Q>?2M/MOA=
MXMGALX$ECU^?RW6,!DVW:A=I[8'3'O5S4G>U^(?BIM1UK0]-$T<!A_MBR\X2
MVPC (C)D08#;\J >:];,$11D,2;&.67:,$]<FFSVEM=;/M%O%-L.5\Q VT^H
MSTH Y_X>6_V7P#I$(N9KE%A/E2S0&%C&6)3Y"20 I '/0"NFHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *Y36?$&MQ^+X?#NC6%G+))8F\:YNI65(
M@'VX(4$G/&!QU]JZNO/M:_MH?%R!M$:R,RZ$QDBO"RI(OG@?>4$J0<'H>X[Y
MH 2;X@:JUG8V]KH]NVLRZI+I-Q \Y$4<J1E]X8#)3&UNF<$]Z9)XI.@:GXAO
M-1TF ZK;6-AYOV2=B+B61I$2-=W  8]<9^8YZ5;LO U];W&E7D]Y;RWD>KS:
MK?LJE59I(FCVQCG@ J!GL,U+K?@:;6M1\0SM>) NHV]FMLZJ6:&6!V<,1T(W
M%>,],T 21>)==TS6;+3O$6GV$?\ :,<IM9K&9W59(TWF-PRCJH)##T/%3>!]
M?USQ/I4.KZCIUE9V%U DELL4S/*3WW @  ]1@GCK5=?#WB+6-:L-0\0S:9&F
MFQR_9X;$NPDED0H7<N!@!2<*,]>M;7A/1YO#_A/2M(N)$DFL[9(7>/.UB!C(
MS0!R-WXAU+1/B#XFO;YHFT?3])AN&B65RP7,I&Q2-N]F&#[!>:TH?%'B&PN]
M(?Q!I5C;V.K3+;QFUN&>2VE<$HL@*@-G&,KT-&N^#+S6/$.J2&>V&E:OIBV-
MT&W>=$R>849/X3RXSG'2FIX=\3:K=:-%XAN],^Q:5<)=!K,.9+J5 0A8, $&
M3N(!;)':@"3XH76IV?@MY=+D2.0W=LCNTC(=K3(, KZD@'_9)^E8MG<^*$^(
M'BF/2[+39;K[-8O<-<3NL2N(F^1,+DY.>3C '/6NO\9:'<^(O"]SIMG-%%<L
M\4L3S E-T<BR -CG!VXX]:BT#1-0LO$&L:OJ$EJ9-2BM0T=N6(1XT*OC('!)
MX]NM &!)\2_M6F^'S816-M>ZO;-<L=1NO+AMD7 ;+8RQ+'  QGD\8K>\(>*?
M^$CBOX9EM1>Z?.(9S:3^="^5#*Z-W!!Z'D$$5S-M\.M0T[2_#LEN=+N]2TJV
MDM)H;U"UO<1NV[@X)5@0"#@]ZZOPMHU]I5O=OJ+6(N+F;S!!80".&!0  @.
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MDUD?>_U0*_)T^]\OT]Z *=UXY\1BQU_5;31M/;3=#NYX9_-N666=8C\Q0!2
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M>+B1XV\# $X-_<9_\!WK8\6>(XO"WA^;4Y8A,P9(HHBX0/([!5!8\*,G)/8
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-S#Y&;:P7G:V#@'TIFC^.$U>>P*Z'JD%AJ.?L=](B-')P6!8*Q9 0#C<!^%
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M&*:5"/O'<#M4'T_/ID]W_P *9^'W_0NQ_P#@3-_\71_PIGX??]"['_X$S?\
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M-3 # _, <@^U:MMHFJ>$]6TK5++1?ML"Z0FFW-G82C,#*Y=63S6&Y,LPY;/
M->@2RQP0O--(L<4:EG=S@*!R23V%);SQ75M%<02+)#*@>-UZ,I&01^% 'E4&
MDZYI[V6M75C;PZLOB"[NX=,>[C!N(IHBI5&)VEP,GG&=IJ"]TW5?&^L^-["6
MR73[J33;%(8))@Y4K))(JR,A(!8CL3@$5W=S>>%O%]EIUI<;+V#4/,FLPT3K
MN,1PS!L H1GKD'GBM31]!TO0+>2#2[-+=)'WR$$LSMZLQ)+'ZF@#@]&\.2S>
M(-/NHO"%SIALUDDEN-3U)[@+*4*J(E$S!ADG+,!QVS571/#FKVFN:5)IGA^]
M\/S1W ?53%>JVGS1X.X1Q;V.6.,?*NWO7IFI:E::1ITU_?2F*VA&Z1PA; SC
MH 2>M21WMK+>36<<\;W,"H\L2MED#9VDCMG:?RH +U;AK&X6S9$NC$PA9QE0
M^/E)]LXKR >%]=O8-!EGT#5Y-7LM0M;C4+W4-361&V2 OY*>85QU/W5P!CD\
M5[-6;)K^EQ11RF\1DDNQ8JT8+CSRVW8=H.#G@YX'>@#E%\/:H/!OCNQ-H?M.
MIW%^]HF]?WHDCVH<YP,GUQ[TRSL=;\+:Y)J,&BSZI!J.G6D,L=O+&LEO/"K+
M@[V *$-U!."#Q7H%% ',?#_3M1TKPA!:ZM;+;WOVBYEDB1PRKOG=Q@CMAA65
MXMT_5[OQ5 \UCJ^HZ#]CVK;:9>BW(N-YR9?WB%E*XQR0,'CFN\J"[O;:P@\^
M[GC@BW*F^1L#<Q"J/J20!]: /)M)\/:OX=32KQM/MX]0M=:O98-+-XF;B"9.
M1$['YF4<_-@G:<XIE];:UXIN_B';#2O(O9K&PBAM#,C,,&1L.P.T-@YQDX!'
M->D7T&@^*9;S1KV*.\DT^2-YHV5E,+LNY"K<8.T]5/>K>CZ%IF@6KV^EV<=M
M&[EWVY+.WJS')8^Y- '*>._#4VIZQHFL)IT^IP6*S0W%G;W1@E*2!<.C!ER0
M5Y4L,@USUQX#NM1T.^N+7P\;"3^T+:Z@LI]0D:XNHX<Y627S&",0[[=IXXR?
M3URN?UGQKH.A7PL;V[D-WL$C06]M).Z*?XF$:G:/K0!SOAGP^R^(WU*W\,3Z
M5%#:/%'+J=\\\SR,1D!1*ZB/CDGD\8K*T3PYJ]IKNE2:9X?O?#\T=P'U7RKU
M6T^:/!W".+>QRQQCY5V]Z]+TK5;#6].BU#3;J.YM)0=DB'@X."/4$'@@\BKE
M #77<C+ZC%>9>%- UZW_ .$(BOM(DM?[#%U;W+M+&P(,0"NNUB2"21Z\<BO3
MZ* /-]:T/Q,EUXLN=*BG07U]92*;>=8YI[=(T641L3\C<$ G'M572/"]\/&+
M:C;:%>V&GS:1<6ADU"^\^=I69""^9'(!P<8)Z'('%>I44 <WX"AO[3P5IFGZ
MGI\MC=6,"6KQR.C[]B@;P5)&#^==)5/2]4L]9TZ*_P!/F\ZUEW!)-I7.&*G@
M@'J#5R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KD_B=_R3+Q%_UY/7
M650UK2+;7M%O-)O#(+:[B,4GEG#8/H: .>\9ZY>^'_ "W>G;A>2?9[:)U0.4
M,C*NX*>"0"< \9Q7/Z?J&O6&J&*!/$LFG2V-PT\FLI'F&5$W(Z,O//(*].F*
M] U+1+#5]$ETB^A\VSDC$;*20>,8((Y!! (([BLBR\#V-O=M=W>H:GJ5S]G>
MVBEOIPY@C<88)A0 3@98@DXZT <AIUQKMEHG@KQ%/XBO[NXU6XM(+NVEV>0T
M<R=E"Y##@[LY)SZU0\3^(;^*RUW5M-UKQ!=W-C-*89+*V5-/@"'_ %;;QB3&
M"&())/3TKTG_ (133O['T;2\S_9](D@EMOG&XF(83<<<^_2LBX^&FD7-G>Z>
M]]JJZ7=O)(^GI<[85=R6)4 ;OO'=@DKGM0!1*:IXD\=:IIQUZ_T^P@T^TG6.
MR94;S'\SG<5) XY'?CTKG].DO_$5_P##F_O]4NQ=L]]%(\)5 YB#C=C'!8*
MWMZ5Z;8:!::?JMQJ433-<7%O#;R%V!!6+=M.,=?F.:RQX#TN.QTFVM[B^MSI
M4\D]M-#,%D!D+%U)Q@J=Q&,=* $\=MK2Z1:G1ENV'VI?MB6+(MRT&&W"(OQN
MSM]\9Q7":QJ3:C\.M<M(-8U&:X@U&Q"0:M:^7=66Z>+ DZ;QD$@^G&37IVO>
M'[3Q!;P1W$EQ!-;3">WN;:39+"X!&5//8D$$$$'I68O@+2SI][;7-S?74U[-
M#/<W<\P::0PL&C&0  H*] !U/K0!C^=?^%_%[V,OB*ZN;*XT>XO'EU(JX@EB
M9!O&T+A<.<J..*P;+7=2M=6\,7-OJ7B2[CU"]2VNI]1MUBM+A71CF-" R\@%
M<#&!R?7T;5/#&FZS?_:[Y'D8V4UBT>["M%+MW@]\_*.<UE0?#W3TETV2XU35
M[QM,E26S%S<@B+;T& H!&.,G)QWH XVR_P!9I'_8\WG\IZZ?XE03W7_"*P6U
MT]K+)KL*B=%!9/W4N2 01G&<9!YK8C\&Z7$;<J;C]QJ<FJIEQ_KGW;L\?=^<
M\?3FM'5-&M=7ET^2Y,@:PNENX=C8^<*RC/J,,: .'.HWWAN^\5Z9-XDF^RVN
MG07EM?:BHF:V:0R*>@!<94$#UXYJEI.J:A#XUT2PBO/$[66IQ7$<[:Q&J!V6
M/<KQ# 92#UX Y%=KJO@W2=9FU.6]69SJ5K':S 28 6-F9"N.0P9LY]A4%KX'
MLX-9L-7N=3U6_O[#>();NX#;592K+M"A<$'KC)(&3Q0!S>G>(M7O[70?#K7C
MC6DU*6VU*90 QAMCN=O;S 8AG_II6!;^)?$^KZ--XALD\2/J+32/:P101&PV
M+(5$; G)R!@MU!/'2O4;7POIEGXIOO$<,3C4+V)896+?+@8Y [$[5SZ[163<
M?#G2)WGB^UZE'IMQ,9Y]+CN,6TCD[CE<9 )Y*A@#Z4 6/'6IWFG?#O5]2LW>
MVNXK,R1L/O1MQ6([:KX8\6:&LNN7^I1:G!=&[AN-A3?'&) T8"C9SD8]#79:
MUHUKKVAW>D7>];6ZB,4GE':P4^A[4EWHEI>:KIFHRF3S].\SR &^4[UVMN'?
MB@#S=K_7;7X>6_C]O$%W)>LD=Y)8G9]E:)W \D)C(PK8#9SD5UWQ%O\ 4--\
M&37&EW1M;PW-M''* #MWSHIX/48)%,C^'.CQO'%]IU%M,BG^T1Z4UQFU5PVX
M87&=H;G:3MSVK>UK1K77M--A>&00F6.7]VV#NC=77]5% '%ZI>:CX.U?2[9=
M5O\ 4H5T[4KR47;*S3-&L;*"5 X&3CZUGRC7K#1?"FN_\)1?33ZIJ%B+V!]G
MDNDSJ2L:A?E SC@\C.:[_4=$M[W4[752N^\LX)X8$<_NV$H7<&&.1\@_6O,[
M/PG?7U[X?M4T/6]/73K^&[E2\OUDL[58SN*P ,2V2 !D< GI0 R.SU.#P_XZ
MUZSU^_LY-/U6_GM[>#8(BR'<=X*DOG&,$X KH+.WDO?C!;:@U[=(9/#\=P85
M<>7S)C9C&=O\6,]>_:NH_P"$4T[^QM9TK,_V?5Y9Y;GYQN!F&'VG''MUH;PK
M9?VYIVKQ7%Y#<V5O]E BEPLT74+(,<@'GMS0!S_B[3VNOB1X+<7UW!EKH;87
M  VQ;NX/7H?;TZUE)/KFL>$]8\81^(;RSN;:2ZDM+./9]GCC@9U"2(1EBVPY
M).>>,8KN=;\.6NN76G74MQ=VUSI\IE@FM9=C#(PRG@Y4C@BLJ[^'FDW<]V/M
M>I0V-[*9KO3H;G;;SN>6)&,C=W"D T 7+S6R? #:XUW%IC2:>MQY\J&18&9
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M$^+C=(<R%F((;<>3D$=/2M/0?#MGX>@N%MGGGGN93-<W-S)OEF? &6/L
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MKG+*3@A@3V(/05)_P@FC'P_=Z1(;J1;R87$]V\Y-P\P(*R;^S JN,<#'2@#
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M7ZDUI4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MDEDT^=41!EF)C8  #J: ,CPO<ZW%HD6O^(_$-G-836"W+1K8B 0;E#DE]YR
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MF_:W6X%O!;23.R'(W (IR,JV?3OU%5OB5;3WGPWUZWM8))YY+4A(XD+,QR.
M!R:@LK.<?%.2\:VD$/\ 8$,(F*';N\YR5W=,XP<?2@"S:_$/PO>W5G!;:B91
M>,L<$RV\GE-(PRL9DV[0Y_NDY[8S3KWX@>&["\N[6:\F,MD^R[\JTED%OP#F
M0JI"KR/F/'7T...LM*O8_A9X;M?L%PL\6N0RR1>2P9%^VLQ8C&0,<Y]*?8^(
M;72M5\=6<NEW]U/<:BPA%O9O*+AC!&/*W*"%(Z_-@8;ZT =GJ?CCP]I%[!97
M5\QN;B))HHX())B\;D@.-BG(^4\]OQ%1W7C[PW9:A+9SWS@PRB&:=;>1H(9#
M_"\H78IY[GCO7.^"] O]&\5:;%?0.7M?"UM:O-M)02"5BR!NA(XX] *RTGFT
MOP!K/@RXT?4)];G:\AA5+1VCNO.=RDOF@; N'!))!&TT >F6^M:?=3:A#%<C
MS-.<)=!E*^42H<9R.1M(.1Q67<>._#\%M8SBYGF^W0_:+>*WM)996B_YZ%%4
MLJ^Y KC?$WA_6K&>RLM.BFF&O:=#I&HSQ D0LA4&9C_UR:89]0M.US3&T/QW
M/>RWFN:;I5QIT%O;7&DVXF5#$6!B<>6Y7@@C@ \T =I<^-O#MIIMAJ$FI(;6
M_)6U>.-W\U@"2H"@G=P1CKGCKQ6>WQ-\*K;M,U]< 1,5G3[%-OML=3*NS,8]
MVQGM7,:-HDT-SX.F6PU18FU>]O)!?@-+&'BDP[A541[C@[2."V.M:,VG77V?
MXGXLYMUVK"#$1S-_H:CY>/F^;(X[T =9JWBK2-%^S+=7$DDMTI>"&U@>>211
MR6"H"=HR.>E5YO''ARWTJSU.34T%I>2&*!Q&[%Y "2FT#(;Y2-I .>.O%<'>
MZ==Z;KVC:M>W>N:?8R:!!9FXTVW\UH94.XI(OENP!R.<=5P:?I>BS+)X=N8K
M+5VBG\237KMJ*@RE3 ZB5E5%\L,0#@C.3[T =-J_Q%TV#P?K6L:69)KG3DVM
M;3VLJ.DA&5#H5#*IZYX'O74Z9?QZGIMO>PB0),@8>9$T;?BK $?B*\[\3Z5?
MW=Q\1UM[*>0W6DVJ0;8S^^94ER%_O$<<#U%=O;:U$WA/^UX;:Z=([9I! T#K
M*Q4'Y=A&[)(P!CF@#F+SQK?V_P 05M46+_A'8;F+3+B7;EA=RHSJ0WH/W:D>
MKU-XI\4ZGI.K:[;VK1".S\.2:E%N3)$P=P"?484<5SUM\.-=U/P%/%=>(KRW
MN]2!U":R^SQ!5NF(D +%=XPP4?>XQ4%Z^K>(;35=2FTJ]BN;KP6\$D;6[J?M
M >0,@&.N>0.I!![T =[<>,]+TNVL$U":5[ZYMEN/(M;:2>3;@9<K&I(7/<\5
M=L_$^C:A)I\=I?),=1BDFM"JMB54P'P<8!&1D'!]N#7'V%R?"7BFYU#5;*]:
MTU'3+-(+B"TDG\IXE8-$P0$J3N!&1@\^E9$NFZSI/@Y/$UKI5R-0MM:N-2M]
M/$9,JV\Y9#&4'0X<.1VQ0!Z%'XPT&;2[O4H]05[2TNOL<TBQN=LVX)L QDG<
MRC@$'-5+SX@>&[&\FMY[R8+!-Y$UPMK*T$4F<;6E"[ <G!R>.^*X;2/".HZ3
MXLTGP_\ 996TIUM=6N[@*=GVB&)D92>FYI!$_P"!K*\1/K&J^$M?L9O[;CU-
MI)PNB:?IGEVZKO)#M)Y?[P%?FR'RQ. #0!ZGJOCC0-'OYK"ZNIFO(4622""U
MEF=4()W813\O')Z#C/45+=>,-"M-*L=2:]\VWO\ 'V06\3RO/D9PB*"QXZ\<
M=\5F>'[68?$/Q)>O;2I%-96"Q2O&0&P)-P!/7&1D=N*Y#PY;7?AZS\&ZSJ&G
MWOV*TM;VUN%2V=WM6DE#*YC +8(4C('&1ZT =_\ \)OX>_L4:M]O/V8S_9MO
MDOYOG?\ /+RL;]_^SC/?I3H-=B\1Z-?_ /"/W9CU" % EQ R/#+C*B2-P& /
M';D=#7">(!=ZS=Z5XCM]+U/2],M-2F,D]E;C[7*CPA!<F)D)QD%>06V\UN^!
M[6)]=UG5XY=<N(98H81?:JJQ?: FX_+'Y:, N[&X]<\=* .H\.ZU%XA\/66J
MQ(8Q<1[FC/6-QPRGZ,"/PKAKGXF23>&=>U&V MWTW58[96FMI$7R#-&A9BX
MW8+Y'5>,CUWOADC?\(1!<$%8[JYN;F%3VCDF=D_,$'\:X_4+:YE\/^+M&.G7
MK7+>(H[M4^RN5DA>XB(96QAAA23CH!S0!Z#I'C'1-;O)K2TN95N(8O/,=Q;R
M0%HLX\Q=ZC<N>XJO9>/O#NH7]M:07<^;MREM-):2I#.WHDC*%;H<8//;-9OB
M2"_7QU;WMEI[731Z#>JBLA,;R[HRD;'I\Q'3ZUQ:-J&I?\(DYN-?O9[?4[22
M[MFTS[+:V('!4*(U^Z3@?,V "3B@#T/P?XO3Q3/K,8BDC-E?/!'FWDCS&,8)
M+@#<3G*]1QD>MB[\0VFF:WJ8O]6@BM+.RBGD@,+!HMS.-Y?HV[  4<Y'N*S?
M!#/;:KXIT^XMKF&8ZO-=HTD#*DD3A=K*Y&UNAX!S61XHTU[CQ)XGDGT>]U"S
MDTBS79;91W*S2,3&V.73AL#G@>M '8Z-XITK7;F:ULY)TNH4$CV]S;202!"<
M!@LB@E3CJ*76_%&D>'9+:+4[IHI;K?\ 9XTA>1I2N,A0H))^8<=3^!KD_!5S
MJ,GBJ:*"_P!2U71%LC_IFJV!@FAEWC$0D9%,@QN)XXP.>:V->M)IOB+X1N5M
MY'A@2^WRA"5C+1H!D]!GD"@"[!XU\/SZ%<ZR-0$=E:R&*<S1O&\4G'R%" V[
MD8&,G(Q58^.]'FTO4[FU>X-Q80&:2UFM)8Y<8^4^6RABI/< BN/U;2M1&M:W
MJ4>FW,\%GXDLM0:&.(EIX4MU5C&/XRI.<#NOK6C<O)XM\53:GI5E>+96VB7-
MHUQ/;/!Y\LI4K&H< G;M))Q@$T =;X2UW_A)/"VG:J4*2W$"-*OE/& Y4%@H
M89*Y/!Y!'0FJ!^(GA@7#Q?;Y"L4YMYIA:R^5#(&*[9)-NU#D=R.QZ$&I/A_<
M>?X$T:(P7,$MK:16TT=Q T3+(B*K## '&>_2O/K35H[CP)XG\-6^DWT^IWU_
MJ$%NL=H[1S-),X$AD V*%SSN((V_2@#T>\\9Z%8Z\FB37;G4F>-?(CMY'*[_
M +I)52 O(YS@9YJ&V\?>&[S4(K.&^<F:4P0SFWD6"60<;$E*[&/'8\]JQM(T
M2]7Q'XN@82+)-IEE;17;(0KL(I%)#=\$@G'M6 \TVI_#S2/!5OH^H0:Y";2W
MF1[1UCMC"Z%YC+C85PA(())W"@#MKSX@^&[&[N[6:]F,EF^R[,=I*ZVYXYD9
M5(5>>I..OH:NZMXLT?1FMDN+B26:Y0R0PVD#W$CH.KA8P3MYZ]*X.Q\06VFW
M7CNP?2[^YN;G4I5@%O9O*MPQAC'E[E!"D=]Q PV?6J":#J'AC5=)FU;4-;L[
M<:#;61N]*A$_ERQD[HW'EN0#D$$  X- 'HMUXW\.6>B6FL3:FGV"[D,4$JQN
MV]P&.W &0WR,,$9R,=>*R++Q[:OJ^N7-W<&+0[.SL[B.1[9U=/-:16++C=C*
MKU'')Z5SUEHDRV/AJ6.QU8I-XG:_D_M!0TH4QR?O75541@D X(X+=>:Z)-&_
MM/QMXPMKVVD^P7^FVEOYA0A7&)@P4]"1N'TR* .JGU6RMM2L]/EFQ=7H<P1A
M2=X0 L<@8 &1R<=16?KWB_1/#4T,&J7;Q3SHSPQ)"\C2!2 <!0<D;AQUQD]
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M/ODBMTO;>?;;.QA:0@)O &5!QU/% '<^-_%7_")Z/!>+$TCS7<, 'DO( K.
MQ^0'D*3CU.!R>*DU'QOH6ERQ0W$]PTTD N#%#9RRO'$>CNJJ2@_W@*I?$B*>
M3PFLD%O-<?9[ZTN'2",N^Q)T9B%')P 3Q65::O'X=\6Z]J=_8ZDUIK26US93
MPV,LI<+$%,3*JDHX(R P'WJ .[L[ZUU"PAOK.=)[69!)'+&<AE/<5YU)\3GN
M/#5]JD.+86>MQV<C36TB*+8S[-Q+@?-M#$@<J>H%=+\/--N]+\&6L%[;M;32
M2SS_ &9NL*R2LZH?0@,..QKB)+:YFT35=(;3KTW$7BQ+ID:U?:\+W8<.K8PR
M[02<=!UH ]"TGQAHFLSW,%K<R1S6T8FECNK>2W81GI(!(HRO'4<5%I?CC0-8
MOX;.SNY?,G#&W:6VDB2X Y)C=E"O@<\$\<]*YKQKH>HZSXGU*"QADW7/A:YM
MHY=I"&0RH0A;H"1G\,UDZ3;)JFH>&[7S_%US/97$<\MM>0)!#8F-2/F<P@-W
M4*K<@]: .X\;^*?^$2T..^6(R2274,"CR7D #. Q.P=E)QZG Y)Q4FH>-]"T
MR2**XGN6ED@%R8H;.:5XXCT>154E!_O =_2J?Q)AGE\'.T%O-<-!>6L[1P1E
MW*).C,0HY. ">/2N0NU>R\9:UJ]SJ'B6PLM7BMKBSETVS\P2@1!?+=3$[(X(
M. <?>]<T =WJ?CCP[I-M8W%SJ(,=_$9;3R(GE,ZC;G:$!S]]>/KZ'%6Y^)'A
M:T>5);^7,#*MQMM)B(,@$&0A?D&&')P.OH<<WX=T*;3]7\"J-.OX8;>SU%V%
MWB1X#(R, [*H4$@G P,=.U27&FW9\._%!193F6[DN/('E'=,/LJ ;>/FYR!C
MOF@#K=-\9Z%J^K?V99W;O<,C21;H'1)U4X+1NP"N!D<J345KX[\/7NHQ64-W
M*6GE,,$S6TJP32#.524KL8\'H><<5DRV-POB3P"Z6LOEVUI<I*1&=L68$ #'
M'RY(QSZ5RNE?;-/U#2[305UR!Q?J+K0=1LS-;VL>\[WCG* * ,E2&.<CB@#U
MC4]3LM&TZ;4-1N4M[6$9DD?H.P^I)X ')K&M_'.B7=O>O#+=":TA\^2VELYH
MYBG0,(V7<RD]P#5?X@65W=:+8W-K:R7?]GZE;7LUM$-SRQQOE@H[G'('?%93
M71\5>-['5-+L[U+'3M.NHY[FXM9(/->79MB4. 6QM)/&!0!H?#;6M1\1>&$U
M?4;XW$ER0WE"R:W6#(SL4G_6#D?-R#ZUV-<U\/;>:T^'F@6]S#)#-'8QJ\<B
ME64XZ$'D&NEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *HZIK.F:):B
MYU74+:R@)VA[B4("?09ZFKU<1XLTG4I/%6FZWI-KI^JW%C;21/IEW,(SM=E/
MFQD@A6^7;DC&* .KTW5=/UBT%WIE];WEN3CS;>4.N?3([U<KRL>*M/\ #L'B
MG6!X?NM(\01VL,MQITY4Q2_,8XY5*<,-S8)'/%6-%\9W\?B'3;2;5FUFWO0Z
MW.-)EM?LCA"P96*@,A(*X//(.: /3*KSW]G:IOGNH8E\Q8<O( -[$!5Y[DD8
M'N*XKP_?>,->TS3O$L%_9"VO95D.EO!M5+8MCB7)8R!?FZ8)XQ7-:5/J6D:)
MJTTUW!>[_%RVY66T7 8W*J[CK@G((_ND<4 >Q45P*ZEXI\02:[?:1J=K86VF
M7<MI;6LEJ)?M#Q#YC(Q((!;(&W&!SS56P\3Z_P"+M9L+;2;Z#2K2ZT*'4I':
MW$TB2-(ZE5R0,<#D_P!WISP >D5G7FOZ/IU[#97NJV-M=38\N&:X5'?/3"DY
M-9W@C6+W6_#:SZD8FO8;B>UF>)=JR-%(R;@.V=N<5YS;'4=1TKQGJ#^'-.U&
MR.HW:7[7<[)//%&2H2+"G;L11@DCYLXQUH ]BN+NWM3$)YDC,T@BC#'&]ST4
M>IX/Y5-7":9>P:YX]TO[.7;3[#0H[VU60DG?.=H8YY)$:$9/]\US4WQ'U.Y@
MU#5K/4Q&;>>5;72!I4LJW"1L5PTP7AVVG&#A<C.>: /6DN[>2ZEM4F1IX0K2
M1@_,H;.TD>AP?R-35Q>K7GD>+_"&KPHT8U,26,Z,,$HT1E0$>JLA^FYO6KWB
MW6-0L[C1](TEXH;_ %:Y:%;B9-ZP(B,[MMR-S87 !XR: .DEECAB>65UCC12
MSNQP% Y))["JNF:MIVM6?VO2[V"\MMQ3S8'#KD=1D5YGXPO]>M]$\5>&M0U2
M*Y9-%?4(;Q;8(TD7S(\3J#@'.,,.QZ5Z!X?L[BU\+6=LUTCS_9QB9(%0#(^7
MY!QP,#WQ0!H27]G"T*R74*&>4PQ!I -\@SE1ZGY3Q[&K%>&:;;:NOA3P@(-1
MA:XD\33K \MO\L)S<AF(!^;NV,CTKJ;WQCK7A2W\50:G<0ZI-I<%K/:3^1Y1
M<SLR!75>P8 \<D4 >E5 ][:QWD5F]Q$MS,K/'"S@.ZKC<0.I R,_6O/M \7Z
M@WB?3=.DU9]:M[Y769O[)EM?LLBKN!!( *'!7!Y!QS6QXU3['JWA;75X^QZD
M+:4]A%<*8CG_ ($8Z .G34;*349-/2\@:]C02/;B0&15/1BO4#WJCHUEI=I?
M:PVGW*RSW%WYUX@E#&.4HHP0/N_*JG!]:\ZTU_)\5V'CECB+5]7N=.=_6W*B
M.#/MOMP?^!U;TG5;[3/!-KJ-@L2ZGXKUIFADG4LD0F9BCD<9 BC&!GKB@#U&
MH9KNVMY8(I[B*.2X<I"CN 9& )PH[G )X]*X#5O$'B'PI)JEA?:A#J+MHMUJ
M%C=_9A$T<L*\HZ@[67YE(/'<'-8NO:KJVCP>$?$/B&\_M R7IN8[6RL]K1;K
M63$2X)+\D#)Q^5 'K]01WEK-=SVD=Q$]S %,T2N"\8;.TL.HS@XSUQ61X0O;
M_5?#\&JW]U;3-?#[1%';#]W#&W*H&ZL0.I/?/ K)\/\ _)5/&G_7OIW_ *!+
M0!VE-=TC +NJ@D*"QQR3@#\ZX7QGXNGTWQ+8Z#;ZA_9BR6K7<]XMD]TX4-M5
M$100"3DDD8 'J:Y;5=:U?Q)HFF(U]Y<MGXEM;=+O["T:W*EE,<NQ\%2,D%>A
M(]* /8PZ,[('4NN"R@\C/3-.KR0ZMJ7A'5OB)K<UZM[]E:V"PF ('D>.,1DD
M'("[@"!UZ]:T=!\8:@?$VF6$FK-K,%]O2<C29;7[*X4L&5B "A(*X//(.: /
M2JA2[MI+N6T2XB:YB57DA#@NBMG:2.H!P<?0UR'P\OO$>NZ1#KNL:E;O;W4;
MK'916H385<J'+YR20IXQCD>E9\UEK5[\5M=32=4BTY!IMF99FMQ,Q.Z7:H!(
M 'WB3UX&,4 >BU#=75O8VLMU=SQP6\2EI)96"J@'<D]*\NF^(^H36ND:?+<Q
M:;?3274=_>16;W(3[._EGRXP#]\X.3D*,]>*S_$6N:GXB^'VOV<M[YB6%Y:J
M+PV#0B]B>1, H^-K*V<XX.T>M 'KVGZC9ZK8Q7NGW45U:R@F.:)@RM@X."/<
M$59KA(9_$FJZ[J.B:?K-O81:-%#'+<BQ5VN9I$WYVDX5 ".!R23S66GB[Q+K
MO_"-V%A<6FG7U])?6U]-Y'G)&]N0"R*2,YP< G^+G.* /3Z*\HN_&^J2:IJE
MHNOI8OI3BU11I$EP+R94!=W*@A%+' 53D=?2O0= U>;6?"UCJTEH]O/<6XE>
MW8$%'QRO//7- ":GXJ\/Z+=+:ZGK>GV=PV"(I[A4;'K@G@>]:L<D<T22Q.KQ
MN RNIR&!Z$'O7"?#'3+&]\"VVK7=O!=7^K;[B^GE0,TKL[94D]A]T#H,5A6&
MK7GADZWX>T/REC;Q#%I^G-*"\=KYT8D<!<C(3#X7/4B@#UAW2-&=V54499F.
M !ZFJ^I6,>J:9<V,DLL<5Q&8W>%MK;2,'![<<9KSGQ[9^*+;X?\ B6#4-6M[
MRS%JLD5R+<1RDYP\;*/EQ]TAASU&#UK6CN_$FJ^(+G0++6H;0:5:PO=7ILU=
MYY9=Q4!"=JJ%7GN2>U '8+)8Z:EG8B2"W#XAMH2P7=M7.U1WPH/ ["K5>27V
MK:UXBF\*(CVMMK5IKMW8S3",M$'CBE5I%4GGY>0">O%7M6\;:SX2BUS3M0G@
MU"^M5M7L;HP% ZSN8_WB)GE&4GY?O#'0T >FT5YKHWC'4!KJ:>=4DUFWN+6:
M3[0VE26AMI47< <@ JPSCN".IS6W\/KKQ#JV@6FMZWJ4$ZW]K'+%:PVPC$/'
M7=DELC!Q@8/2@#?U#7M'TF:&'4=5LK.6;_5)<7"QL_T!/-7V=50NS *!DL3P
M!7'^*]":*SU?4-(T"'5M4U*$03+<S !45"!MW \?[(QDG.16=!I=IXD^$FEQ
MQ:K?MI\.G8D"GRFN=D94I)U(&Y3E0><8R1U .]M[B"\MHKFVF2:"5 \<D;!E
M=2,@@CJ"*EKG/ '_ "3KPU_V#+?_ -%K6SJ5C'JFF75A,\B17,30NT3;6"L,
M'!['!H KV/B'1=4NY+2PU>PNKF+[\,%PCNOU .:<==T@:L-*.J60U$C/V3SU
M\WIG[F<].:XG[)I^J>+M"T[PU:1):^')BUW?Q( J8C*"V5A]YCN!8=!CGGBL
M#[- WP"GUQHD_M0L^I?:MH\P7(N"P;=UR,!?IQ0!ZIJ6OZ-HTD4>IZM8V3R_
MZM;FX6,M] 2,U4M8]$\(:1+))?PVMC+<27!FNIU5=\K%SAC@8R3@5D>(?[!\
M/SWFK75D=0U?6$2WAL642/.57 CC4CY5YRQZ#))INB>#VTWPGH(O[5-1U?1K
M9_(A:;$8D<<KDY'RCY0Q!P!QUH Z^TN[:_M8[JSN(KBWD&4EA<.K#V(X-35P
MOPU9HT\0VES;_8M175'FN;!<%+;S%4H$8<,I4;L\9)/ KNJ ,_3-&M=)FU"6
MV\S=?W1NIM[9^<JJ\>@PHK0HHH *KW]I]NL)K47$]L95*^=;OMD3W4X.#5BB
M@#/T71[30=*ATZR$GE1[B7D;<[LQ+,S-W8DDD^]:%%% !1110!GZ1HUKHD%Q
M#:>9LN+J6Z?>V?GD8LV/;)K0HHH **** "BBB@ K/UK1K77M/^Q7GF>3YL4W
M[ML'=&X=?U45H44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %><>
M-)&7Q/'>Z9;>)K35[6'R/MVGZ8+F":)L-L8,<, ?H0<UZ/10!X]']GO(-4/B
M'1_&6K7FI6PM9+@Z1Y(BB!+*L:J<+ACNSSR!5K3=8U*'4[2[U:+QKJ,=FC+!
M -%\E6)&-TNUOWAQZX&><9KU>B@#QNU+VL=OIJV?C3_A'[:X$\6G#1L,,/O6
M,RYR8PW;&<#&:5BK-?1_V7XP-G<ZK'JJ0'1>8I5D$C -NR0Q Z]*]CHH \?O
M+FX-UJ?]DVOC/3;+59#+>6R:()#O8 .T;DY0L!SUYY&*T=+U.PT?6HK^S\+^
M+$BATR+38[?^RB0J1NS YSDGYL5Z?10!YUX>\1P^']/FM(_#?BV8274]R6;2
M2,&20N1U[;L5A7\LLTVJ1:?9^,[#3-6D:2]M$T4.2S#$AC<G*;@.>#SDC%>Q
M44 >4)XA32O&%AJ=EX3\31V']F_V9+$=-8%0C!H2O//5U_$52DDN8EO++38/
M&UAHUY.\TMI%HPWH7.YUBESE 22>AQDXQ7LE% 'F,_B%M9\:^'MOAKQ)%9:8
M9&9IM/;_ %SJ(TW$GA0K.22?2NT\1^'DU^"T9+N6ROK*<7%I=1*&,3X(.0>&
M4@D$'J#6U10!QS^!&O;36SJNKRWNI:K9&Q:Z\E8UAAP<*B \<L2<DY-=9;0B
MWM8H =PC0(">^!BI:* .,L/ )LFLHSJ\LMI8:H^HVL+0J#'N$FY"P^\,RDY/
MI5W4O!5CJ]YKDUY-*T6K6L-M)&GRF/RBQ5U;URV?^ BNFHH YG3/#6JPZK:W
MVK>);K41:(R00K"L"$L,%I I_>-CIG '7&:TO$6BQ^(M O-*EF>$7" +*@RT
M; AE8>X(!_"M2B@#EM0\$6=[X A\)I<R0100PQQ7**-ZM&5(?ZDKG\35K4_"
M=IJ'ARST>.:6U^P&%[*XAQO@DB ", >#Z$'J":WZ* .-?P+-?KJ<VM:U+?WU
MYITNFQS"W6)+>*0?-M0$Y8G!))[ <"M6X\,Q7#^'F-RX_L63>GRC][^Z:/GT
MX;-;M% &+X>\.Q^'/M\%K<.UA<7#7$%J5XMBW+JI_NELD#MDUE7W@[5'\3:A
MK6D>)IM,>_CA2:);.*8'RP0O+YQ]X]/6NOHH Y*?PAJ,LEAJ*>(YDUVTCD@:
M_-K'MGB=MVQXA@8&!C!!XSWIESX&FNM!-I+K]Y)J7V]-1%_(BMMF0@KMC/RA
M!C&T5V%% ''W/@-+Z]UI[W4Y9;/6;:..\MA$JYE15594;JI&T''(S5G3/#.J
MPZI:7FJ^)KK44LT98(5A6!6)&-TNT_O#CIG !YQFNGHH R?#6AIX;\/6FD1S
MM.EN& D9<%LL6Z?C65J/A&_F\2W6O:5X@ETZZN;>.V=/LR2QE4+'.&_B^;@]
MN>N:ZNB@#CO^%?P6EEI0TC4[BRU'3#*8[UD64S>:<R^:IP&#-SVP<8Q3YO!,
ME[X?U'3]1UN[N[K4)XIYKEU 5?+=&58XP<(OR >O)))KKJ* .8U'PK>/KESJ
M^B:W)I5S>1I'=K]G69)=@(5P&^ZX!QGIC&1Q2:=X'LM*N-!DMKF;&D+<8\S#
M-.TV-[N?7.3^-=110!R5YX.O5U+4;K1/$$^E1ZFP>[A6W24&3:%,D9/W&( R
M>>F<5TFGV2:;IUM91232)!&L8>9R[M@8RS'J3ZU9HH X[_A"M0TZXN?^$<\2
MW&DV5S(TSVAM8YTC=CEC%NY3)YQR,GI4I\ :<GAI-)M[JZCN([L7ZZ@6#SFZ
M!SYS$C#$]",8QQ7644 <=/X%EU2PU>/6];GO;K4K06?G)$L201@DC9&,C.XY
M)).>.E.;P=JD=XFI67B22WU5[9;:\N/L:,ETJDE&,><*R[B 0?PKKZ* .*E^
M'<2Z=I,%CJ]W;76G7<E]]L*J\DT[AMS/G@Y+'(QTXXJ0^ (+VQU5=8U*XO=0
MU(Q&2]1%B:'RCF+RE&0NT\]\DG.:[&B@#F++PQJ?VXW>L>([G4'2W>WAC2%8
M(U#?>=E4_.W Y/ YP!6KX?TA- \/:?I$<K3)90) )&&"P48SBM*B@#EM0\)W
M[:Q>ZCHWB"?2VU!4%W'Y"S!F4;0Z;ON-MXSR#@<5IZ?X>L]*\,1Z!9;TM8[=
MH%9CN;D'+'U)))/N:UJ* .:DT74=)\':7H^BWD@GLA;0";:F6C0JKE@W !4'
M..?2MC6+&;4M'N[&WO)+*6XB:-;B,9:/(QD>]7:* .,\.>#-9\.1V5I#XK=]
M-M<#[&-.@0.O<%@-V3U)ZDTQOAZ65M._MJ<>'7N_M3:7Y*]=_F&/S.OEE^=N
M,]LUVU% '$W_ ('U2X\77?B&R\4RV=Q/&L*(;&*;R8P/NH7S@$Y)QC)-7;SP
MKJ%U'I=V/$$R:WIXD47_ -F3;,C_ 'E>(84CA>F"",UU-% ',6/A*XT_3]0,
M.MW']L:C.D]SJ1A0LQ7: JI]T+M7:!VR3G-=/110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !169<:]I]K//%),2T&/.V1LPCSTW$#BM(,",YH 6B
MDR/6HS.HN!#SN*[L[3C'UZ?A0!+1587T!OFLP_[]8Q(5P?NDXSGZT37UO!:M
M<R3((5ZL#D>G;WH LT50L=8L]11VM9U?R_O#!!'YU73Q+IDA=5N#O1@I0QL&
M.02,#&2" 3D<<&@#7HK,CU[39I%2.Z1BV,,,[22NX#/3.WG'I5FPU"#483+;
MES&#C<T;+GW&0,CW% %JBJWVZV^W_8?.3[5Y?F^5GG9G&?SI;2]@O8W>!]RI
M(T3<$893@CGWH L44FX>M!(H 6BJL.H6]P+CRGW?9Y#'( IX8 ''OP14L<PE
MC5USAE##(P<?0T 2T5EQ>(-.FO?LBW&)O-,&&1@#(!DJ"1C..<5IE@.] "T5
M0?6;)+*[O&FQ!:,RS-M/R%>OY5)::C!>@^27X4-\Z%<@]",CGI0!;HJ-)D<$
MHZL 2,@]QU%+'*DJ!T=64]"#D&@!]%9IURR6]FM/,<S0E!(!$Q"[ONY.,<UH
M[AZB@!:*@-U$)3&6VD8Y8$ YS@ ]">*=!.D\2R+N ;D!E*G\CS0!+12$C&1S
M56QU&WU&%Y;=RR)(T9)4K\RG!'/H>* +=%&1ZU'-,D$+RRL$CC4LS'H .IH
MDHK/.LV0^Q8G#"^_X]BH)$G&[J/;FI$U&W?4Y-/60FYCC$C)M/"G@'/3L: +
ME%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 45'/,EO!)-(V$12S'T K-L]9%[H;ZBD15D5RT3'E67.0
M?RH UJ*SKO46M]"?41&&98?-V9]LXIMWJ,MIHS7YB#^6N]T&0=H/.,\YQT%
M&9X@M-3LOMFI:*BO<3VYCD3^(, =CJ.Y&>1W'TKQ_P 1Z?K'B?4;"]U/5M-C
MNK!%50T4D;9!!)8'OFO<6U8+H7]IF,,&C\R-%;.[/W1GU.13)M64Z#%JD%MY
MY=49(L@,=Q QD]^: .2T2Y\4>(%N[:^>%K2X" W$431I&F/F"!N6)]>@_2O0
MHD6*)(T4*B@*H'8"L_3=4BU,S-!@QH%P3U!(Y!'8@\8JO8:S/</9">W14O%8
MQM&Y.TKS@@CT[T ;=%8D&MO-X@ETSRDQ&6&X/R,*IY'ON_2KUO>M/?WEL4 %
MOLPV>NX9H NT5E:7K4.IR7:*-A@EV#<?OKV8>QY_*M6@#GKVZT&*YO$EM4ED
M5D>Z9+<OM8<J6('4<'VJ_P#V5IAA,?V.W\O>9,;!PQZGZ^]4+/2]0TW4]3:!
M8);:^G\\,[D-&2H# C'(XR.:Y[4_#U[;6]M),(YRDL<4BJ2?M&9PVYN.,+G/
M7J: .R33--0H\=I;@JA12$'"GDCZ&E73;"/[,JVD*BVSY "#]W_N^E<OI?A]
M[/7+6%7?9&C/=)L;R\>87B56/]TL1]!S5O5_#=[?W\\L<L0626.5)"Q#(%4J
MT?3[I_J: -2[.DZ,AU%X$C9G"&2./+%G;IQZDBH8&T.\=TCM(WE-QF5#!ADE
M()W,",C@=:I-X<N8O!]CI5NEN+B%X'D)<A69&5F.<9YV^G>H;GPU?W>LOJKF
MW$LDJ QJ[ +&B.O7'+$OZ"@#9&DZ&C" 6=F#M)$>Q?NY&<#TSBH9(="CN8+6
M2RB5S(R0EH< L5W-@_3J?;%<W/X*U.2&1,VLI:!H$=V(9%W(PR0O)X(SQ5ZZ
M\)22W+;+:T:T%P)$@+D +Y)C]..>: -]M)T>"*4FSM$C(!DRB@?+R"?I5T1P
MM(LH5"X3:& YVGM].!7$2>"]3-O-:>=;RQ-&X$LCG<2T"Q\C'3<N>O>M'2]!
MU&PU*6\>&V:0 B)A</PK;<H5QC QP?;H* -LZ#I(C93IUKL(.08QCGK^=5(;
MC0O[.MKF"*%K6ZG1(VCCR&?=A<_0COTK0U6"XN].DM[9PCRX1F)P54GYB.#S
MC.*YH^%M1@ANK*TFC^RM?1W<+.V&0@@N,!<=1D?4T =7<16]W T-Q''+$W#(
MX!!JM_9>F^6L7V2W*Q_, 5'&:Y4>#[YM%^SD6T5YYBRF03NX9T7&>1P&X!'I
MGK2ZAX8U>^N[N1ELECGC*;1*W&3&1_#VV$?CVH Z&^M=%M8&GN;2WV.VQCY0
M.XN0#^9QFGSZ?I4DXAEL87,AWDF(%05&.3V.#BN:;PIJ@#1*MFT)DWQH\C#R
M )S(-OR]P0/P%)+X.OTM;?[+'9+.JS^<6=L.78%>W8"@#J?[&TH;W^PVH$BA
M6/ECY@.@_04K:3I;C!LK8Y#<&,<Y.3^9YK%&A:FOAA-.W6[3K<F0[G)787+8
M!V]0#Z8XK'7P7K&W<)[:.X**@F65B0! 8SV_O$'\* .F@M]!EN+UDM;4/:R?
MOW:(#:W#Y)_$'-3(FC:M>32?9X)KBW81N[QC(XW#!/48;]:R+?PW>MHVO6L\
M=I"VHIB-(F+*I\H)SD#N,UES^#-4E:66%[2VG>0D.DC<)Y"Q[>@XW#/TH Z^
M32-)\AC)96OE* QS&, *,#\AQ]*KF\T5[+3+U5B>"1T2SD6/.TMP,>GI5:#1
M+F+0?[/C6.W\^;,X29GV(3EMI8<D\\8 YJDOAG48+)["&:+[-'J*W5N[-\R)
MG<P("XSN+$?6@#HY-/L)?-+6\+&5P\A*CYF'0GW%5(M TZ/4[B\,<;M+&D8C
M91B-5! Q^#&N;7P9?G1?LI^S)=[D<S>?(X9D4@-@CC=G!'H3R:34_"FMZA<W
M,G^A1I,A7:LK #/EX_A[;".O<=* .CU&UT.UL@][9VY@Q'" 8@PQNPHQZ G\
M*EFTS2))UCETZ!V9<[C""H"C R<<<' KEY/"&JD2Q*+-H'EWQH\C?N0)_,^7
MY>XX_ 5*GA&^@M(Q;1V:3^5.DI+MAR[@KV[ 8H VM5MM,T[34=C]FLC,AE2"
M($2DD  \'C..E;N\  GC/K7*MX>U)O"!TO? US]I\T$R';M\[S,9V]<<=*=J
MVCZMJ\KM*+6.,P2P)&)&.PL%Q+G ^8$'CT/6@#?NK*RO60W-O%,T62F]02N?
M3TIC:;IS)$6M(-L0PF4&%'H*X6UT2^N]0NU6-C,LI"S3%AN4.I*N-O1MO!!.
M :Z Z#?QZ%+:1- SR7OV@1NQV1QE]VP''8=.,4 = T-N9Q<,D?G;=N\@9V^G
MTJ)=)L-R.+. ,BA5(0<#L/U-<5!X*U-+,^:;62Y7R!N\Y_WBH,,I.,C. >_2
MNWTJS_L_2[:T "B) H4.6Q[9/)_&@">WMH;2!88(DBB7A408 _"I:** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
DB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>a1039-firstamendmenttole002.jpg
<TEXT>
begin 644 a1039-firstamendmenttole002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=%@U+4-/EO0MWIUK]KNH_+;]W%C.[.,'CL,FHH?&6@3G1Q%J 8ZR'-A^Z?\
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MDEIJ4D7^D0R1E"'!()VGIG&?QK<H *@O;R#3K&:\N6*00(7D94+$ => "3^
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MRI)/-,A8NS%3P,8 '&<YH ]%HKR>WUSQ!J\OA[2&UF6WF;5;_3KR\MT0-<)
MK$. 00K$*.<<')J::X\46L?B;0]-U"^U!M.O+0QRL\?VLV\J!I$1F 4N.=I(
M[^N* /4J*XCP'JJW5[J=DVIZO(\0CD&GZS;>7<VP.03OZ.K$<8SC'7FNWH *
MR=9\2Z5H,]G!J$[K/>,5@BBA>5WQC)VH"<#(R>@S7+6T6K>+M3\13IX@OM+3
M3;U[&SAM-@561%8R2 J=^2W0\8'OFL'2+BZ\4^*_ VMW-]=P3W6EW,LD<#*(
M]R-$& !4X5SR1GIC!% 'KM9NM:]IGAZR6[U2[6WB9Q&GREF=CT554$L?8"M*
MN1\8:<VHZKH;:=JMM9:_:/+/8QW4?F1SKLVR J"#T8<CD4 :FA^*]%\1231:
M;=EYX #+!+$\,B ]"4< X]\8K:KSC^W[_2?$$DOB?0+./6DTJYDL[ZPG9XKB
M.+#O%M8!EYVGG-8VCZWXGDMM%U>)?$MW=W<D+WD<]O$+%X9"-PC .5V@Y5NI
MQSUH ]@JC<ZSIUI'?O-=Q@:?%YUV%^9H4P6!(&3T!..M</8+K?B:RU;74\37
M.F2V]_/#:0C9]FACA<K^]4C+;MI))(QGC&*S)UNM,U;XGZK:ZK=_:+>P26+Y
MU*!C;EU(X_AQA?;KF@#U:&5)X8YHVW1R*&4XQD$9%/KSO37U3Q?K>H6DFN7^
MG6VF6UJJ+9,J/+++")&D<E3D<@ =.#699ZYK_B"7PIISZQ-:/<3:C:WUQ:(J
MF<6Y"AUR"%)QU XR<=J /5Z*Y'P7<WR:CXCT:\OY[]-,O4CMY[C!E*/$DFUB
M ,X+'FNNH HZIK.GZ+##+J-TEND\Z6\1;)+R.<*H YR?_KTNK:M8:'ID^I:G
M<I;6<"[I)7Z#\!R3[#DUXMXP\5:1KEVVHWMV\;V.IVT.GVC02?NXTG0RS'Y<
M;FVG ZA0.[$5V/Q3TO2];^'E_KCA[@PV!EL]SL(UW8(?8>-V#U(R/:@#N]0U
M*TTNPDOKR7R[=,9;:2220  !R220 !R2:M5QWB9S<>+O!>F/_P >TMS-=NO]
MYH8B4'X,P;_@(JDO]K>)=<\2R1:[=Z:FDSBULX8-H3>(E<R2@@[P2V,<# ]>
M: .TFU&UM]1MK"639<72NT*E3A]F"P!Z9P<XZX!/8U:KR^_U&[N/@UX?\1W$
MS2ZE:O8W@E;JSF14;_OI78?C7J% !4-U=065I-=W,JQ6\$;22R,>%4#))^@%
M<UXSO[]+G0M&L+M[)]6O3#+=Q@%XXUC9V"9! 8[< D'&:X_Q:NH6%IXI\,RZ
MU?W=F?#\FI0RS,IFC*ED:-FV_,C<'GGJ,T >E:+K=CX@TY;_ $YY7MF8A6E@
M>(MT.0' )'(YZ5>FFBMX))II%CBC4N[N<*J@9))["LSPS:FR\-:="US/<D0(
M?,G8%N1G' ' S@>PJKXY@-QX"U^,32PG[!,VZ(@'A"<<@\'&#[$T :*:UITE
M]:6272M/=V[7,"@$B2(;<L#C'\2_G5^O(K/1KFXU[P191:S?P!M F>2X1D\X
MH3"=BL5PHR0,XS@8SWI+GQ1KMAI,NBI?7]U./$<FE+>11H]U]G6(2\9PIDP=
MN2/?K0!Z]17"^#;W61XBO+">'6VT@VJS0S:PB"6.7=AD#+]Y2"",],&NZH I
MV^JV5UJ=[IL$X>[LA&;B/:1L#@E><8.0#TJY7%^'?^2H>-O^N>G_ /HMZJ>-
M]<U!/%&E:#:?VJEM-;2W=RVE1JUPX5E55!;[JY;)(YZ"@#OZ*\M37=:MO#M_
M;:E?ZKIT:ZA#!97=S9J]]<1. 3$J)D&7(8!L'CDBF:7JWB!=8U_2-,GU<O\
MV-]LL5UX1B1)]S("#_<.!P_<'M0!ZK17E6C^)+C2+JX-]?>((KR/3IYWTO6[
M=6%S)&NXM#,GRX&#D#.0>@Q531]:\3O!HFK1+XEN[N[EA>]CN+>(63Q28W>6
M <KM!RIZG'/6@#V"BBN5\<ZB;.TL(%U6ZL6NKG84L;<S75PH4DI$ #M/ );'
M ';- '545XU)XFUO3]!\<PPW>K1_V;;VMQ9-JBI]HC,A;=DKU4[>,\\UI:U/
MK.BZWIOAO^UO$.H+<PRW]W/:)$UP<%%$<? "1[B2<9/(&: /4Z*Y+P+>ZQ/%
MJ=KJD.H>3;7 %G/J$:I/)$R@X<+P2IR,]QBNMH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IKQI(
M'16 _O#-.HH YN+P/I$-UXAN(_/237HQ'=%7 V (R?N^/E.&/KSBM;1]+@T3
M1[73+9Y7@MHQ&C2MN<@>I[FKU% !1110 4444 %>9_$L-J\RZ3<>!]5U>&#;
M-!?V4RQM$YZ[3U!]>W3TKTRL6^U=;+Q%#;37\$5O]AFN9+=HF,C!&7+AAP%
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M#;QI.@C6+GC&.HSZUS,'A>*"VM[1?AYXP:QCD\V2S;45\FX<'(:1,8)'3C'
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MG&=JN5"EL?PYR.F,UE^,?B-I6AZ1K*6-\C:K91,%#0.T2S 9",X&S=_L[LT
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MG/4FO1J* .&L+G6=.U+4[^#P1J?G:C*DL^[4+4C<J!!CY^.%%:/_  D7B/\
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M=U9Z?&^I:K]MT\N;?4OM.;E0Y^8%B,,#P,$$8 ]*Z6B@#DV^'ND-IIMC/?\
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M9P^(Y-P![\XR/I6/8Z==1^!_AI"+.99+>_MGF3RB#$/)EW%ACCD\Y[FO4J*
M/#VL9].TW7]#U/4/$JW5S=W173K*QC>.^25B0R2&%L9# $EOEP>F!7<>&M,F
ML?'VH&2"8)'HMC;I-*-Q)4R;AO P3TSCVKN** /']'CGT?3_  )>7=E=I;VF
MI:BLVRV=C%YAF5"5 ) )(YQCFO5+'4HM0DO$BBG0VLY@<RQ% S  Y7/WEYZC
MWJY10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MA-Y,TRH N<9Y/3/&:R]<\7:5H=AI][+<0RP7UU%;Q2),NTAV +YS@JH.217
M>#K&SU;7O!S7\$5V(O"*.@F4. ^]%S@]\$C\35*>WL+7PPZSQ6\=A8^.-H\Q
M0(X(?M W#GA5YY[4 >U(ZNBNC!E89# Y!%4;?6])O+U[*VU2RGNDSN@BN$9U
MQURH.14&N7EM9^$]1O1"US:Q64DOEV[[3(@0G"LO3(Z$5Y'%<0#4? 9@F\-P
MJ;^$P6NE(7FBB:-@?,E+<CD @J-Q.<\4 >QRZYI$%PD$NJ64<TCF-(WN$#,P
M."H&<D@\8J2\U33].>)+V_M;9YCMB6>94+GT7)Y/TKRB71=,G\!?$F]FL;>2
MZ^WZBPF>,%U*<K@GD8/(QW)K0L)M$7Q=K4GBY[+]]IEF;1M0V[6M_+/F!"W_
M $TW9 YY% '<^%==/B7PW:ZLUN+<SF0>4'W8VNR=<#^[G\:M7FMZ3I]REM>Z
MI96T\GW(IKA$9OH"<FN;^% B'PST@0AA%^^V!NNWSGQFN&\1WUG>0>-FCC\/
MV"K--;SC4%:XO;F18PH**6&P'@(!D#KB@#T+Q#XQ;0]1U"T%D)A::)-JH8R[
M=QC;&SH<9]?TKHK&Y^V:?;7179YT2R;<YQD X_6O'=2D,NG-(S%B_P .Y&+$
MYSG;S7K>A_\ ( TW_KUB_P#010!E>%_&-AXBTNRFDGM;6^N@Y6R^T*TF%=ER
M!P3]W/2MB\U?3-.FBAO=1M+:6;B-)IU1G^@)YKQ&R;PZWP>2#3_L?_"3->_Z
M.B;?M7VO[1E"/XONXYZ;?:M*\##Q5XS&KW_ANV=I1E=9M6D=K7REV>6?,7Y/
MO<*,[L]R* /7;S5-/T\,;V_M;8*N\F:94PN<9Y/3/&:>+ZS:Q^W+=0&TV[_/
M$@\O;Z[NF/>O+O#&DVUWXM\-1:EC4A;^&"\4EU 5)_?*%8HV2#M..>>:Q;^%
M[?PW]FA-I;Z1;>,;A)A<Q%[:*,,VP2*"/W8<KQD#.* /6-1\5:38^&;[78;V
MUN[2UB=]T,ZE791G8&!QN/3'O5'PUXDU/6(].DN[;2TCO(9)LVE_YI0#9M7!
M4%C\S!L<*0/6O/[NUAGB\;2_VCHUYCP_)]HATJS9(!( YC=F+LOF ;NG.,>E
M:M_;S0:EX=BTF)8KH^&+XVZQ*%_>E(<$8[[J /2(-7TRYOI+&#4;26[B_P!9
M!'.K2)]5!R*J6>NPC0X]2U>:QL%9F5C]K1HAAB!B3@$D#IV.1VKA_#4_@@:-
MX-CMX8)=5#1B%+0@7$<WEGS6EP0VT?-OW<9Z@\5SVC7L TKPG9&VTH7>W4)H
M;S6)&%O$!<,&54! >0Y'4C !]: /4=9\4V^GZ9I]_9&&_@O+^WLU>*8%<2R!
M-P89!QGI6_7A6F2I)I%^L5Q:3QCQI9,KV<7E0MEH<E%R<*3G!R<]>]>G_$-;
MY_A[KJZ<)#<FT;:(OOE?XL>^W=0!L6NLZ7?2S16>I6=Q)#_K4AG5S'_O 'C\
M:F%_9F*"47<'EW!"P/Y@Q*2,@*<\DCTKS:[D\,SZQX)7P@;!KM;L'%CMW+9>
M4WF"3'1?N_>_B]ZY:]MKO;=Z+ L@/@9I]1AQGYOWR2P#_OSYBT >X2ZE802-
M'->VT;H0&5Y5!4D%AD$^@)^@)HLM2L=3@,]A>VUW""5,D$JR*#Z9!Q7DC6=M
MK\'A_6+R 31:]XI-T$E7.Z!894A5@>HV1J<?[1IWBVSDLI_B';:+ +?S-,L)
M9([=, KOD$IVKCGRPV<=<4 >KV6KZ;J3RI8:A:731'$BP3*Y0^^#Q4:Z[H[&
M4+JMB?*C\V3%PGR)_>// ]^E>;:+'!+XU\-26FL^'9'2*4I%H=BRE[?R^1*P
MD8*H.TC</O#CFLW2]#T*/X.:+=SO;Z;<37:.=0>U653)YQ*B?.,Q9"@Y.!A?
M2@#V*QU&RU.W^T6%Y;W<.<>9!*LBY],@XI;W4++3;<W%_=V]K #@R3R!%SZ9
M)Q7#> ;T/XDUVSDM='>Z6*"2;4-&=O(FSN"JRDD+( ,\$Y!'M3_$+:?%\4=(
MD\0&!=-_LV9;-KO'DBZWKN^]P'V=,^^* -KQ5XOL_#OA9]9A>VN]Y1+9/M"J
MLS.P48;G@9R2,\ UHV=WJ,_AU;LPV4NH-"SI';W!:!VP=H$A7.T\<X[]Z\EU
M""QN/#/BN33X89-"_M^R-@54&/<9(!,8^VTON'''6O:HHHX8EBB18XT&%11@
M*/0"@#@AXP\9'Q(V@CPMIGVU;,7A_P")JVWRRY0<^5UR#Q783:Q9Z=:VSZQ>
M6>GS3*,I+<*J[\#*J6QNP:YM/^2VS_\ 8N1_^E+US&L^<OQ0U\WU]X?M5:SM
M_LAURV,BM!M._P L[U &_=N'/:@#U*YU*QLD#W5[;P(4+AI954%1C)Y/09'/
MN*2+4K">P^WPWMM)9X+?:$E4QX'4[@<5Y+X?TNTN[_X>V]S(FI6:0ZG+;F6W
M9$*;D*81R3M4'Y<YX"GTIM_)8:2GB2P.G6DEI+XGMXX8;B0Q6L,C0QOOEV_P
M;ADKT)(H ]8M-:TJ_MI;FSU.SN((03++#.KJF!D[B#@?C2PZSI=S=R6D&I6<
MMS&NYX4G5G4>I .0*\=>8-K_ (Q07>D3N?"DWF_V3"8X0P+<$[FW, PR>."!
MBMUM'T[3;?X;365E!!,US'&\L<8#.KVLA<,>IR1DYZT =OX:\46'BBVNY[%T
M(MKF2W91(K'Y6*AN#P&P2/45H7^JZ=I4:R:C?VMFCG"M<3+&"?8L17(?##[!
M'8:W;6WV9;J'6+Q9XH]H=%\Y]@8#D#&<9_"L_P 47]LWQ EMUBT*UNK?349[
M[6V9D,3.WRQ1[@."/F;(Z@=J ._EU73H+:.YEO[6."12Z2O,H5E R2#G!&.:
MBN-=TBUAMYKC5;&&*X&8'DN$591_LDGG\*\;\,6EGJUGX(LKJ.&ZL_[;U/\
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MT$C@!G"C) Z G\37)KXQO-5T;2K_ ,/Z2MPM_$\KS7D_DPVNTX*NP5B6W9
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M@,I)52K#<.V"._%2>*/$^HZ/K&DZ1I6D)J%YJ:3M'YEQY21^6$)+':>,,?Q
M'?@ Z"WL+.SDDDM;2"!Y3F1HHPI<^I('-)#I]E;W,ES#9V\=Q+_K)4C 9_J0
M,FN+N/'VHM<WZ:?I5A*NF$1W@N-2$3/,%#/'"-AW;<XW-M!-6_\ A-[C5[C3
M[;POIT-]-=6"ZB[W=P8(X8F.%!(5B7)##&.,&@#K#:6QB>(V\1CD8LZ%!AB>
M22.YJ*_L([ZTN(B%626!X1+M!90PP?P[X]JY+2/B!/J5SIUO<:,;2:ZU2YTV
M2-KC<86AC9R>%P<E<?KFJ/C[Q%+<>'?&NEQ1- ^EV]LRSI(<OYO/3'&,8ZG.
M: .O\/\ A^TT#2;"TCCADN;6TBM7NA"$>4(@7)[]NF36B+2V#!A;Q!@YD!V#
M.\C!;ZX[US6N>(M<L;RZCT_1[,VMK&KO=:C>_9DF)&=L?R-G'<D@9.*P4\6:
MMK?BOP3=:;;HFF:G8S7$D,ET5/\ RS#[@$()0'Y>?F)/W<9(!WW]E:=YLTOV
M"U\R<8E?R5S(/]HXY_&K"PQ([ND:*[XWL% +8X&?6O/]*\6^1I=E9:+I!EU'
M4=0O8X+>>\;8HBE;S)7D()"]#M /W@!5B\^(5SI.D:V^I:,$U72&M_-M8;C>
MDT<SA5>-RH)ZMP0.1COF@#LY+"SFM/LDMI ]MC'DM&"G_?/2E:RM7L_LC6T+
M6VW;Y)C!3'IMZ8KEK;Q=JMKKATW7]%BM&ELI;VV:TNO/W+&1N1AM7#C<.F0?
M6H_"WC+5/$4EC<?V59-IMZA<366H"=[4[=P69=HP3TX)P>/>@#K[>V@M(%@M
MH(X8E^['&@51] *=)#%-L\V-'V,'7<H.UAT(]#6-XF\0-H4%G';69O=0O[@6
MUI;^9L#.06)9L':H522<'Z5S.M>+-<BT;Q%I5QIMO9ZY:Z6]Y"T-XS120X*M
M(C[ P9#_  D#)QS@Y !WP@B62201('D #L%&6QTR>]1M8VCQPQM:P,D)#1*8
MP1&1T*CM^%<Y\/\ 3GTSP-9!+&&WGFB6=D6Y>42NR##L[#(+8&1CCWK@5USQ
M%+X2TB\NX//N1XK\N%8[PLTV)9@8R2H"J" HZC S@=* /8_LEM]G-O\ 9XO)
M)R8]@VGG/3IUYJ:N(/CRXT@ZU%XFTV*SGTRS2]'V2X,Z31NS* I*J0VY=N".
M]/TSQM>MK6G:?K.GV-L-3W+;/9WXN#'(%+>7*-JX) /(R,C% '4Q:5IT&_RK
M"UC\Q@[[(5&Y@<@GCDY[U-]F@\J2+R(_+E),B[!AR>N1WS7+>/;Z\2'1M&L+
MJ2TEUB_6TDN8CAXHMK.Y0]F(7 /;.:Q/%/A.R\'^'+KQ%X:>YLM1TU/M#,;J
M21;I%.724,Q# C//4'&* /0;BPL[M8UN;2"81'=&)(PVP^HSTJ6.*.% D4:H
M@).U1@<G)_6O)-2GUG5/'^IZA'IMK,-/TB*XLO-U&2,0!_,(D"B,@N<<@]-H
MY/9_@@V^D6G@R2]TX176HVUQ=F[74))-P$",TDBL "S _=Z+C@G- 'J4VG6-
MQ<QW,]G;RW$?W)7B5F7Z$C(J98HUE>58T$C@!G Y;'3)[UQ^D^+M<U1-.U-?
M#?\ Q(]0D5898[DO<1QM]V5X]N AX)PQ(!S6=-\3)EM;K6(--M)-!M9GC>1K
MX+=2(C;7E2+;@J"#@%@2!F@#NIM,L+BV6VFL;:6!#N6)XE95/J 1BG_8K7G_
M $:'DJ3^[')7[OY=O2JNK:U9Z/H%UK5PY-I;P&=B@R64#(Q[GM]:YH>+M?LY
M=/\ [7\/6UI%JC>39LE\7,<Y4M''-\@V[L8W+NP: .S2*.-G9(T4N=SE5QN/
M3)]33Z\\^$UM<2Z->:Q?6L:WE[=3;[D7;RO-MFD&"& "A<8&.H&>.E>AT %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %<1XM\+7VK>)['5$T[3-9LH;5H
M/[/U*9DCCD+ B8?(X)Q\IR.G2NWKFO$?BN70]6TW3+31KK5+R_25XXX)(TP(
M]N[)<@?Q"@#EX/ 6O6?AZXAB;23?+X@36;>*,M' 578?*X4E<;2!P>,5V/B?
M2M0UWP=?:;:W*V5_<V^P2*QVJW&1D<X/(SUP:?H>KZGJ;SC4/#UWI(C *&>:
M*3S,YSC8QQCW]:V P;H0>W% 'G&E^"-1@\2Z!JD>B>']%M=->7SH+%V>2;?$
MR;B_EKG!(P#GJ3GM5OP]X*U+2CX0,\UJW]C17B7&QV.XRXV[<CGISG'XUWF0
M21D9%0W=PT%C<7$,+7+Q1LZPQD;I"!D*,\9/2@#!\9:-J>K6VE3:3]E:[T[4
M8[U8[IV1) JNI7<H)'W\].U8P\%:F9C(TMJ,^*%UD@.W^I$87;]W[V1TZ>]=
MS!,9+:&62,PM(JDQN1E21]T^XJ6@#G+;0+J'Q3XBU-GA\C4K6WAA4$[E,:R
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M \%^%-&\VV^TZ1<V4T[;FVL(2"VTXR3QQD#\*V?&6BW/B'PU+IMH\23//;R
MRDA<1S(YZ ]E./>D\/>*K?7KF[L9+*[T[4[/:;BRNU =5;[K*5)#*<'D'M6\
M&!) ()'4>E '+V?AR\MW\6L\D)&L3&2WPQ^4&!8_FXXY4],\5HZ#H[Z?X.TW
M1;PH[P6$=K,8R=I*H%;!.#CK6ON (&1D]!065<;B!GCDT <-HVB>,=,L-+\/
MK<Z?#INGNBG48Y&:>>W0_+'Y13:K$ *6W'C.*H_\(AXG@\+W'@NV?31HLIDB
M34&E?SX[9V)*>5MP7 8J&W =#BO1R0!DD >]4+/6;6^U;4M-AW^?IQC6<E<+
MEUW  ]^,?G0!B6?A>YL]3\3S(\(M]2MH(+9=QROEQ%#NXXY(Z9JM#X2OX]%\
M$69EM_,T*2%KHACA@D#1G9QSRPZXXKL]R\_,..O/2ER,9SQ0!Y)HECXGUGP]
MXCT6R_LY--O]5U"!KN61Q+;HTSB0",*0Y()P=PQGGI6QJ_@&^NK?Q/;V4MLD
M6HV=A;6@D=LKY!;=OPO'!&,9_"N_ABAB0^0D:*S%CL  ))R3QW)IX8$D @D=
M?:@#S?4? VJ7.OZW<-IVB:B=1?-MJ.H,SRV*; NQ8]A!P02,,N<\UI^&?".I
M:1J/AZXNI+8KIVA'391&[$M)OC(*Y ^7"'T//2NFT76;77]+34;+?]G>21%+
MK@DH[(3CTRIQ[5?+!1EB />@#@'\$ZM \VH6<]G_ &E!KTVJ6B2,WER1R)L:
M-R!E25)Y .#CK3M8\*^(O%>EW9UB;3X9A<07%AI_,]O$T1)/FL54OOR01C &
M.M=%XF\1'P_!9"&PEO[R^N1:VUO&ZIN<JS$EF.  %-7KR\N[;2&NX=-EN;H(
MK?8XY$#$G&5#,0O&3SGM0!S/AKPW?6FOG4KG1/#^CP1P&)(--B5Y)')&7:7R
MT*C P%'KR>*E^(/A.]\5:7:Q:;<Q6UY#*RF60D#R)(VCE48!Y*MD>X%4K?X@
M:O=ZG>Z;!X(U-KNR$9N(_M5N-@<$KSOP<@'I7=Y (&1D]* .+L/!$UE\1I]<
M66$:2(2]O:KG<EPR)$SXQC'EQ@=?XC5"U\&:[I>F>&&M&L)KW1[^[GDCDE=8
MWCG,O1@I.X"0<8Z@UZ&&!) (R.HH+*&"D@$]!F@#AI?!FHO\/O$>@B6V^UZE
M<7DL+;FV 2R%EW'&0<'G /XUV,]J9]+EM"P4R0F+=UQE<9JP6 (!(!/3)ZTM
M ' Z#X3UVU_X0[^T?L"?V DT#^1*[>:AA$:,,J.<CD=O4TS7?A_=ZS<^(9S+
M9[KN]L[VR6=3)&6@C"E95Q]UL,.,\'\*]!R!0"",@Y% '%^&O#=[::^=2N=$
M\/Z/!' 8D@TV)7DD<D9=I?+0J,# 4>O)XK6U+1;F\\9:%J\;Q"WL(;I)58G<
M3($"[1C'\)SR*WJ0LH8*2,GH,T >;W_@2^MM8UF;3]$\.:I%J<[7,<^J)^]M
M)& #?\LV\Q,C<!E>I%-NH7\*>)[#^S]3T9-2;2$M[FWOP;."9$<D21LBE5(9
MFR@'0CIUKTHL%&20![U6OM/L-0B5=0L[:YC0[@+B)7"GUY'% 'E?AG1];U70
M[?7K":RNK^V\0WE]&9"T4%W&X:-BA 8J#DE3@]*U;SP5XCU:P\8-?2Z;'>:[
M%;+#'%(Y2'R\@JS%<GC'..3G@5V>DZS;W^HZKIMO;M%_94R6[= K;HU<;0.@
M 8#\*U20H))  [F@#SS4_!FIS^+-5U$Z;HFJ)>B,6MUJ3LSZ>%0*0L>PAAG+
M#!7)/)[T:3X-UW1HO!;1-832Z-#-:7:M*ZAHY"OSH=O) 3H0.O6O1 01D'BD
M#!AD$$>U 'GEKX*UO28M,U"QDL9=4T^]OI1!+(RQ3P7$A8J7"DJP&PYP1D'J
M*34/!6N:W8:]>7TEC#JNJ-:)'!'(S16\,$H?!<J"S'YB3M SBO1:"<#)H YS
M5M!OKWQ=IVK6UQ%!':V-U;ER,NKR>7M8+C! V'.3Z5S6F^"=7;Q-I.J7FG:)
MIUS8N7NM0TV1A)J'R%=K1A%50203DMTXKM]:UJTT+2)=3NRYMXRBGRQN)+,$
M7'XL*T&95&68 >YH Y[Q7H=[J@TR^TJ6!-2TNZ^TP+<9$<@*LCHQ&2,JQY .
M"!6--X7UW6YM<U/518VM[=Z1)I=G:P3-(D2ODEG<J"26V]%X [UU>H:S:Z;>
MZ;:3[_-U"<P0!5R-P1G.?084UH4 4M'M)-/T2PLI2IDM[:.)RIX)50#CVXKB
M+3P9KL5M:V$K6'V:Q\0_VG#*LK[I(3)([!EVX##> .2#SR._:+K-JWB&31!O
M^V1VJW;?+\H1F*CGURI_*KX8$D @D=1Z4 <3XF\#3>)-6UF22XBBM+_2(K)&
MY9TE25I Q7&"N2O?GFH-#\*:E%KEA=76@^%]+BLPQEDTZ!7EN7VX!4F-3$O.
M>"3VS7?4A(49) 'J: ,+Q7X>?Q#IL"VUU]DU"RN$N[*X*[A'*N<;AW4@D$>A
MK!U+1O&'BRS&C:VFDZ?I<C+]MDLIY)9+A 02B!E78&Q@DDG%=Y10!R[^&[H^
M)-<OT:!;>^TN*RA3)RK)YF<C& /G'3WK/M?!=XL/@V&YDMVBT?3I;2\"N<N7
MA6/Y..1D'KBNW# D@$''7':C<-VW(SUQ0!P^C:+XQTVQTK0/M.GPZ;ISHIU"
M*1FFN($^['Y13"D@ %MQ[XK$C^'.HZ?;3Z39:/X8G@>=W@U:[MP]Q#&SEBK1
MF,B1AD@$L!@#(KU2LR37+9=;FT=$EDO8K/[844<%"Q4 'U)4T 1Z_H,.O>%;
MW0GD\J.YMS '51\AQP<# X.#BN>&B>*=<O=%CU]=,@M-*N4NWDM)GD>[E12$
M.UE41KDY(RQXQ786-Q)=V%O<36TEK++&KO!(06C)&2IQQD=.*G) !)( '>@#
M"\&Z+<^'_#46G7;Q/,D\\A,1)7#S.XZ@=F'XUO4 Y&1THH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *\]\:6=[?_$CPE!8:G)ILYMKXBXCB20@8BR,.
M".:]"JO)8VDU[!>R6\3W5NK+#,R@L@;&X ]LX&?I0!PGC"WU?1? EPE_XANK
MV.>]MX[F[,20-!;-*BR8,8&!@GGW-5[W2]+\->-]%M?#<,5HE]8W?VZWMC\C
MQ+&#'(R],[\ -U.2,FO1YX(KF"2">))89%*O&ZAE8'J"#U%9NE>%]"T,3?V7
MI-G:><-LAAB"EAZ$^GMTH \A71X=)^$/AV^T^%$N=7DLH-3N9KAXQ)"Q/RO(
M,E$SM3(' .*O76EW>B/XCMT@T/2H9?#=W)-IFF74LF\A2$FVF-54]5SG)SWQ
M7K0TG3QI0TK[#;G3Q'Y0M3&#'L_N[>F/:J>G^%- TJTNK6QT>SMX+M2EPB1
M"52,;6]1@D8]Z .!T?3]*U[Q'):^)XX9X;31+%]/AN6P@1D;S95!.-VX %NH
MP*Q- L++5],\#6,DLEUI\VK:H"6D),\8\YAN.<D' SZY.>M=[XD\*ZAJ%_ ]
MK8>'M0L(85CAM-5M^+5Q_%&RJ201C*G^Z,&M/PSX3M="T33;2X$5W=V3RS+<
MF(+MEE+%R@_A!WD?2@#(\%6-OH_B_P 7Z3I\0M].@EM98;9/N1,\67VCMD@'
M J+XDSW=^^C^&-.M4O+B_N1<W%N\WEJ]O 0[!FP=H9MBYP>]=M%96L%W<745
MO&EQ<[?.D5<-)M&%R>^!Q2?8+0ZB-1^S1?;1%Y GVC>(\YVY],\XH \RL[W4
MM'\4^(K+6X(]!@UZREO;>2"Y^T"&:*,+*ZD*IW;=KXQ_#[U5\*VD7AO7_#JW
M>CV$;7L,D5MJVCW1*W@\O?F:)AN8D+NW9.#7JMUIUE>SV\]U:PS2VS%H7= 3
M&2,$@]LCBJ&F>$_#VC7KWFFZ-8VERP(,L,(4@'J!Z#V% 'EN@V<.@W7A[4KF
MQL=1M[J_6*V\0Z;=,EQ<-(64"=&&7!S\P!.,=.*SUL-0U7PYK>O7<&A0ZA'>
M7'F:O=ZA-'=6,B2$(H58CM"@+A ?F&/6O8;;PCX=L]5.J6VBV,5\6+>>D*A@
MQZD>A/<BEN?"/AV\U8:I<Z+8RWP(;SW@4L2.A/J1V)H \]O--L/^$P\37=Y-
M!87S>'(96U&-#F&1Q*KRKP&Z >AP.U2^$;2/P[XMT>TN]#L+.XOK65+>^T:Z
M+07BJH<F6,@'.!D,<\G&>:]&N=#TJ\U.+4KG3K:6^BC:)+AXP75&!!7/H0QX
M]SZU7TKPIH&A7,ESI6CV5G.XVM)#"%;'7 /8>PXH POB<#%H>EZ@ZEK/3M8M
M+N[P,XA5\,2.X&0?PK7U[Q3I&D:1!>SNMXES+'';06Q61[AV8!1&,X;KGKVK
M<=$EC:.15=&!#*PR"#V(K$T[P7X9TC4/M^G:#I]M=\XEB@4,N>N/3\* .1M=
M'T3Q)X@\8S>*8XIKBQNA#$+A\?9+41(R.G/R9)8[AW'M6)X<LQXKU/P:GB%7
MO%;0+B5TG)Q.%FC"&0?Q94JW/?!KT_5/"N@:W=1W6J:/97D\8VK)-"&..N"3
MU'L>*O#3[,7D5X+:(7,41ACE"#<L9()4'L,@<>PH \:NM)TYO#\FGSV\;V-A
MXUCM;>.7YEA@:2/<@ST7YCQ[UM/H5G<^,O&M^EH+B\TFWM9-+CR2L,HMR5*K
MTSE4'X5Z%<>']'N[*[LKC3+66VNY3-<1/$"LLAQ\S#N>!S["I[/3+'3Y))+2
MTA@>141VC0 L$7:@/K@<"@#R9M-T?3O 7AGQ'H[*?$-Q<696\60F:\ED=1,C
MG.7!!?*GICMBNT\#?\A'QA_V'I/_ $3#6O:^$_#UEJK:I:Z+8PWS$MYZ0*&!
M/4@]B>Y'6M*VLK6S>=K:WCB:XE,TQ1<>8Y !8^IP ,^U '+*2_QDE$G2+0%,
M(/\ M3MO(_[Y3]*F\=Z.UWX UZVTRU07<MC(J+$@#..6*C'KSQZGWK0U/1I9
M_$&E:S9O&EQ:;X)@^0);=\;EX[AE1A]".,YK:H \K\*>/?"5I\'[,7&I6<;6
MFG?9Y[-Y )6D5-K*$ZG<<]N<UYU'I.IQ> _AE9FXDL+JYUAWMYBFYH0\@*.%
M/7KN ]Z]YG\#>%+K4CJ,_A[39+LMO,K6RDLWJ>,$^YK3O-(T[49;26\LH)Y+
M202V[2(&,3CHR^AX% '.Z;:ZIX+T?5]4\1^*9M:MX8?.7S+9(?*"!BP&TG);
M('X>]>#-#XFN/!TOB$>%KS[<^I?V\-9$J[54#.-G7:!D_P#UJ^G[_3[35+*6
MRO[:*YM90!)#*NY6 .>0?<"G+96J6(L5MXQ:"+R1"%&P)C&W'3&.,4 >.7'B
M.Q;XM>$?%]]*D&CZGHIB@N)3B.&;+%E+= 1NQGWKO=.\9^'M<\:7.AZ=&M]<
MQ6@DFOH%1X0N<>67!Y//3D<GT-:S>%M!?15T9]'LFTQ266U,*F-223D#L<DG
M(]:ET?P_I'A^W>#2--M;*-SEQ!&%W'U)'7\: 'ZQ!;R:'J,4RJ()+>02\<$%
M2#G\*R_ $L\_P\\/27))E;3X<D]3\@P?RQ5WQ+IMUK.@W.F6LRP?:P(9I23E
M86.)-O'WBN0/<Y[5I6\$5K;16\"".&) B(.BJ!@#\J /)4TO1=6\+^+M=UTK
M_;5K>7BFZ>0B6R,;'R5C.<H  A&.N>^:N>%M-M[SXBV&IZA80_VI)X9M+N9V
MCPPN&9E=O9L<?A7<WGA/P]J.J+J5YHMC/>K@^?) K,2.F?7';/2M(65J+]KX
M6\8NVB$)FVC>4!)"Y],DG'O0!QOQ7L;.\\)0&\@BE6/4K/!D&0H:=%;\U)'T
M-9%EX/T'6O'/C"&_T^*XM[>*RBMXF)V1+]GZJ.@.  #U&.*]'O\ 3[/5;&6R
MU"UBNK648DAF0,K<YY!]P#4=CI&G:;O^Q64%OO1(W\M -RHNU ?8+P/:@#QF
MQDU/Q#!X%T^Z@LM2MY-%>=;?5+EXXKB=65<G"-YC*G(!'<FN\^'$%S9PZU92
M3V!MH+XK#:V5Q),EF=BEH@SHO /.!TW8KH;GPOH5YI,&EW.DV<MA!CR8&B&V
M/']T=OPJYIVF6.D6266G6D-I;)]V*% JCUX% '(WT\5C\9M-FNI%ACN]$FMX
M&<X#R"9'*CWV\XH2>*\^-1-O(DJV>@M'.R'(C=YU*J?0D*3CTKJ=6T72]=M/
MLNK6%M>P [@D\8< ^HST/N*;I&@Z3H-JUKI.G6UE"YRR01A=Q]3CK^- '.^-
M)O#VHIHEKJ5Y<6PN[DFPU2SF5!;S*IQ^\S@%AN &"#R*I:=>:UH7CC3-!O-=
MBUZVOH9G5I($2YM B@AF*<,K=,D YQ77MH&COHPT=M,M&TU1M%HT*F,#.>%Z
M=>:BT;POH7AWS#H^DVEDTG#M#$%9AZ$]<>U &E#/#<1^9!*DJ9(W(P89!P>1
M[UQ<4\,'QFU$S2I&#H5O@NP&?WTGK7865A::;;"VL;:*W@#,PCB4*N6)).!Z
MDD_C6=JOA+P]KEVMUJNBV-[<*@023P*[!020,GMR?SH \^\4:I/<>*O$VK>'
M9A,^E^&)+>2X@.X+.TF]0".K*JLWMFJVCZ/<:9J7A.^LX?#VFFYF53<VNH32
MS:C$R$NK Q .2/FW,>".HKUBPTO3]*LQ::?96]I;#)\J"((OOP!BJ.G>$O#V
MD7[7VG:+8VMTP(,L4*JP!Z@>F?:@#RQ=*T!_ ?C'7)G3^V+/4=0:"Z\S][:R
MK*YB2,YRN6*G ZEC6AJ$,/B36=4-UH%EJ%S8VENE_<:S>>7!9L8MY$2*C,.N
M2W'/0\5U>@?#_2K"6:\U+3M/N]0-_<745R80S(KRLZC)'5<_@>E;5]X5T#4]
M274;[1[*XO%  FEA#,<=,^N.V>E 'E6AZ?!XJM_AM;:SOO+>32KTRQO(<2[3
M$%#<\@8!^H%1Z_HVEZ9!\3VL;2"VGABMEB:,89%>.-FQWY89/O7L-MHFEV;6
MK6UA;Q&T5UMRD8'E!SEPOH"0,U#=^&=#O[V:\N])LYKF>'R)97B!:2/(.UCW
M' _*@#@[GP5H%O\ $;1]-CL0+*ZTVXDNX"[%;IXWCVM*,_.1O8Y;/-<_<?:H
M?#=GH5J(CI?_  E=U8F&YN'BA,2LYCA9P&(0L ,8.< =Z]J:RM7OHKUK>,W4
M2-'',5^95;!(!]#@?E5:30M)FL+FQETZU>TNI&EGA:(%)'8Y9B.Y)YSZT >/
M:W8W>BZ-XTM%71].MSI"2OI>F7,DHBEWX$F&C54W+D$#KM!QWKJ9_#6DZ#X\
M\+Q:=:B)=1@O(+[YB3=J(@W[S)^8YYR>>:["U\*:!8Z9<:;;:/9165S_ *^%
M8AME_P![U_&M"6QM9KJWNI;>-Y[;=Y$C*"T>X8;:>V1Q0!QOPDL;&S\#1-:0
M1122W-SYQ08+%9Y%7/T4 ?2J\VF:;XD^)FMV7B."*[BL[*W:PM;@Y0(^_P R
M15/!.X ;NHP*[33]&TW2I;J33[&WM7NI/-G,,87S'_O''4U#K'AO1=?\K^UM
M+M;TQ9\LS1ABN>H!ZX/I0!Y);:;8:S;>%4O8$O[./Q'=6-G-/^\,MFJS;!N/
MWERHQ_NBO;P !@=*I_V5I_EV<8LK<)9,&M5$8 A(!4%1VX)''K5R@#B_#G_)
M4/&__7/3_P#T6]<Y_9$,FL?$'7H[8W&KZ;,S:<6)/DR"T0@JO3)..W.!7I\5
MC:07EQ>16\27-R%$TJJ TFT$+N/? )Q2P65K:S7$T%O'')<N))G1<&1@ N3Z
MG  _"@#QC1=*NK6T\):Q;1^'[&:YN;?.I1ZC-)<WX?\ UD;CROG9ANR"<*1U
M&*K>*HK;4?#GB?Q!::-:%(KB<+K.I7Q^U+*C;0L*JF4 8 *I8>XYKUZS\)>'
M=.U1M3L]%L8+TDGSHX%# GJ1Z$]\=:9+X,\,SWT][-H6GR7-QN\V1H%)?<,,
M3QU()!/4YH \\U_2FU76=1U'[)I?B%8["#[3:75PT%S8_NRVZ%R"HW9W9XY[
MUL>'=3MK_P =Z+>0O.EO=>%5>$739D8>:I^8]VQU/XUUNH>$/#FJR027^B6-
MR\"".-I802$'1?<>QXJ75/#6AZW#;Q:GI-G=QV_^I66($1CT'H.!QTXH \FB
MM[3Q!'I=O*YFL;OQC?[MCD"6,K*<9!Y4CCW!K>U^:'X9ZU)=:9;".QU/3#;6
M]N@ROVR'_4KS_>5R/^ 5Z!#H.DVXA$.FVL8@F-Q$$B "2$$%ACH2"1GWK)UO
M0-0UWQ%I;7360T33YUO50*QGDG4,%!S\H4%MV1R<8H T/#&C_P!@>&=/TLOO
MD@A E<G.^0\NWXL2?QKQGQ2EO?>$M?\ $MCH]HJ+=2M%K6H7Q^V>8LFT")53
MY &&%4L..U>^5A2>"_#$UY<7<F@Z>\]QN\UVMU._<,,3QU()R>IH Y4Z!IGB
M3XGZLFL6JWD$>DV;+#*28]S-+\Q7H2.Q[9.*Y[P[##K$?@O1M;)N-)*:B(X9
MV+)/+%-LC1\_>VQY(!]/:O7X=/L[>Z>ZAMHHYWC6)I%4!BBYVJ3Z#)Q]:IW'
MAK0[O2ETNXTJTDL5<R+ T0VJY))8#L<DG(]30!RWP[M+"PUWQE::8P-G%J4:
MH ^X(?(3* ^BG*@=L8[4>-EMM5\5:5HW]CKK%X+:6Z6TN[H0VBIN5=[C:Q=@
M3@#!QDFNPTS1M,T:-X],L+:S1R"ZP1A Q "C./8 5%J_AW1M>\G^UM-MKPPD
MF,S1ABF>N#[]QWH \;L8%NO#QTEVBCM4\;16PAL9V,42%%W1QMP0N2WIU/2N
MMA\+Z7!XWU_PS8VZV>EZCH,;RV\/""0R2)O Z!L =/2NWA\.:+;JJ0:59Q(L
MR7"JD*J!(@"JX '!   /M4]S9*);B_M+>V_M1K<PQS2KU R55B.=NXYX]30!
MYUX3U"Z\5:WHEG>Y\WPU;2'40>AO=S0)G_@*2/\ \"%=#\1K+^T=%L+,7EG#
M)+?Q>7!?;O(O& 8B&0KS@]?JHJ_X3T"XT:"_N=0>WDU34KIKJ[:V4B,$@*JK
MGD@*!R>IR>]:^HZ;8ZO9/9:C:0W=M)]Z*9 RG'3@T >+:S:Z?_PB/B?2+KP_
M%IEU8W=A<R6T5P)K5#)(J;XN!LRN[*X'7WKH]:T_3=3\5W&E6/AZRU-=+L(4
M9=3N_*L[.-MQ4QH$8DD#ENP &17<VWA;0;329]+M]'LH["X_UT A&V3W8=S]
M:AG\%^&;HVIGT*PD^RQB&'? IV(.B^ZCT/% 'E6B6=AJ_A[X<2ZE%!=#^T[N
MW$DAW@QKY^Q03R5&U,9]!6W+>0V_P[^)8FG1&6_U%,,V""Z (/QR,?6O0;CP
MOH-UIRZ?/I%E)9K,9U@:$;%D))+ =CDGGW-1WGA#PYJ&I2:C=Z)83WDB%'FD
M@4LP(V\\<\<9]* /-[NTBLO$VJ:I86D7]KP^#X[JVD"@OYV)4W#U.T*/H *K
M:-I-S9+X1U6UB\/6$ES<P9OX=1FEN-05Q^\1QY7SLPR?F.%(ZBO6WT+2I-0M
M-0?3K9KRS0QV\YC&^)<$;5/88)X]ZK6/A+P[IFI-J-CHMC;WAS^^C@56&>N/
M3/?% &K'/#,TBQ2H[1MM<*P)4^A]#7FWC:"]U;XC:5I#66G7]E_9TEQ#9ZE<
M/%#+,' 8X5&WLJXP". Q-=YINCP:9>:G<Q8WZA<?:),*% .Q5[=?NYR>Y-+J
MVAZ5KUNMOJNGV]Y$C;D6:,-M/J/0_2@#SS2[*R3P!XILM?OK)-)M;J3RQ87$
MDPL"%5MB.ZJ=RORH&>2![5A6VI:S_P (1XNU?49+B/QI#91Q.KIL:WM2JE7C
M )QD%W8CHP(XVBO7D\/:-'ID.FII=HMC ZR1VXB 16!R#MZ9SSGUJP^FV,E_
M]N>TA:[\DP><4&XQDY*9_NYYQ0!Y=I&C7&C>)_#4]E;^'=+6YWJ18ZA-,^HQ
M>62<@Q .0<-O8\8Z\T>&M-\-S^"M+\4:U/)#KDEXK3ZA&2;G[29MOD\ G;GY
M"F,;>W>O0]+\*>']$NWN]+T:RM+AP5,D,(4X/.!Z#V%*OA70%UG^V%T:R&H[
MM_VD0KOW?WL_WO?K0!YW<7D-O\,OB.);A$9=1U&/#-@AF/RC\<C'UJ8Z7IW_
M  L&ZNVM8?M?_"+1S+(0-V_YT+#WV +]*[N[\'^'+_49=0N]#L)[N5"DDTD"
MEG!&TYXYXXSZ59N- TB[O+:\N--M9;FV0QP2M&"T:$$%0?3!/'O0!YC8ZC'X
M/T#P;XMG+?8IM"2QO>>XB\V$_7<KI_P,55N](U2*3P?HUY;65VVHI=:A>VVH
M7#Q0W%XQ5RKE5;<5#G"D8./:O6Y=%TN;2XM+ET^V>PB"".V:,&-0F-N%Z<8&
M/I2ZIH^FZW9_9-4L8+RWW!A',@8 CH1GH?>@#DOAW:W.GWGB"P>338[6&YC\
MJPL+B29+-RF73<Z+@'AMHX!)Z5W54],TG3]%LEL],LH+2V4DB.% HR>IXZGW
MJY0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5S^M^)I-/U:VT?3=,DU/
M5)XFN/)658DCB4@%W=NF2<  $DUT%<EK6FZO9>,+?Q+I%E'J&ZQ-C<VC3")]
MN_>KHQX."6!!QU% %6X^(\4&E13_ -C7C:B=3&E2Z=N7S([@H64;L[2IP,-G
M&&SV-6&\8ZFUW%IMMX8GFU5+<7-[:B[C"VJLQ"CS.C,VTD =NI%8\?@_6[BZ
MMM6NXK=+VX\0PZG<P1R[E@@2%HU7=@;F QG'<^U:]]I^MZ-XPO=;T?3HM3@U
M*VBAG@:X$+Q21;MK D8*D/@CJ,=Z ,;PKXRG@\&Z<[V][J6K:GJ%Y%:VDDF)
M"%FD)WLQPJHH /7' %:EU\0X]-TC5KC4])N;:_TIX!<V2R+(625PJ.C#A@<G
MT.5(XKG&^'VK2Z!HDVHZ=8ZC?Z=?7L]QI[2[8IXYY&8['QPP^4C/N#4S>!K^
M?P_K*6OA_3=(DO)K3[/:PR!I-D4RNQDD^Z2<' '3U.: /0=%OK_4+#S]2TI]
M,GWD"W>9)3M['*\<^G:J_B+Q"F@06H6UEO;V]G%O:6D) :5\$]3PJ@ DD] *
MDU'5+BSUK1[&*U66*^DE263S,-"%C+AMN.02,$\8R/45G>+=(U"\N=&U?28X
MIK[2;EIEMY7V+,CHR.H;!VMAL@GC(H H7/Q!&F6.L-J^CSV6H:7;K=/:^:L@
MEA9MH=''!&<@Y (-=#H.I7^JV3W%_I$NEDOB**:5'9TP"&.W[O7&T\@BN&U[
MPKXB\4P:_J-S8PV5U=:8NG65E]H#G:)/,9W<?*"3@ #/ KTP< "@#A[3XCB>
MPU#5KC0[JWT:Q\U'O3*C&25)-@C1/O'<<8/ SQ5^S\87":G;6.O:++HYO(WD
MM9'N$E5]B[F5BOW6"\XY& >>*R/^$'OKWX6W_AJY:&&\GN9YXRQW)DW+31[L
M=C\H/U-4M-\%F;4HI;CP?I>AVL5O,MQ,DPGED9T*?NMOW0 6))Y/3% &E_PL
M:X6SL-2?PU>II&HW$4%I=F9,L)'"J[IU12#D=>W3(K>@\3Q3KXA86SC^Q96C
M?+#][B)9,CTX;%>:W=[K)\'>%-(VZ9/IZZA8007]O=;S>1I(NW9'MRIPH+9/
M&T^O'37NC^)[&_\ %-KIFFVUU:ZZWFQ7<ET(Q;L85C8.F,G&W(QU[XH DL/$
MLEYXQCU'-V+"7PM'J LT+/AFD)X0=7QQP,GI5^V\:7PU/2K;5?#EQIT&JL8[
M69[A'8/L+A9$'*$@'UP>#6-!X0\0P0Q_9)H[2[3PG%I<<XD_U=RI)[<X_P!H
M5GV'@G41K/AR_B\,VVG/I]TLE[<37_VBXF^1E)#<_+DY()R>..* )M+\4:G>
M64LFN07T&/%"VD#6]VJD'S=HB;:.47 !'\6:WKKQ[.G]HW=AX?N[[2-,E>*Z
MO8YD4Y3_ %ACC/+A><GC.#C-9 \*Z_OGLFLH1;IXGCU>*Y%P#YD)EWL-N,@J
M/S[5,-&\5:/I6L^'=,TVUNK6^GN'M;][H((%G)9A(F-Q*EFQMSGCI0!KWGC>
M0ZU%I6B:--JL\VGQZC'(DZQ1F)V8 EFZ=!C@YW>Q-;'AK7HO$FAQ:E%!+;EG
M>*2"7&Z*1&*,IQP<%3S6-H/A:YT3Q3!,I#V%MH-MIJ2$_,SQNW4?0BKO@S2+
MO1-%N+6]55E>_NIP%;(V23,Z_H10!D6GQ'$^GW^K7&AW5OHUEYJ/>&5&,DJ2
M;!&B#YCN.,'@9XK1T_Q7=OK-GIFM:'-I4U^CM9LTZ2K(5&YD;;]UPO..1P>>
M*QO^$'OKWX5WWAFY:&*\FN)YXRQW)DW+31AL=C\H/U-1^'?"DT/B6POCX.TK
M1(K1',LJS">620KM BV_=7DY+<D<8[T +X1\2ZJG@C04ATZ^UK4;Q9V:1Y=J
M(J2,,R2MG!Y  Y)Q[5#K_CK5)_"DESINFS6FH6NL0Z?>0F9"8V\R/*ANC!@X
M&1C&[VJA!X+UZUTKP]:WNF_VK86EO.EQIL5]Y($S2EDD)R XVDC!/&>E/MO
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M*B@8?.!@\D$=BI%<CKWAO7;G4?&<5I90RVNO::L4,YN ICE2)D"LI'<MU[4
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MN6\%:;JFC0ZK8:A:1QP_;Y[BVN$F#><DLCORN,J1D#GKFNIH **** "BBB@
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MNXY=PB\?5A5^O*O'&GIX?\)ZW:VNL7-^I>QGCTRYN#-+#_I*#(=V+;7(Q@\
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MWAEC#?> ="#@]QTK7KF-1U6]@^(^AZ7'/MLKFRNI9HMH^9D,>TYQD8W'H>]
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MM5E%I;VV9),(I>0#. F6&"2,Y% '47^D6&J:3)I=];)/92H(WB?."!TYZY&
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MDMMX/')/(YK&T[XA:1J5WI\4=MJ4,&HG;9W<]JR0S/MW;58]\ XXP<<$UUE
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MMQA6-L'8Z@\J2JY[XS5&_P#B'I-A)>,;34Y[*RE,-U?P6I>"%P<,"V<G:>I
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M)' ("EB#\HR>#@56O?'6[Q)X5MM,M[BYTW6(I)FFCMR<C:-N,D8P3EN,@8H
MOW?P_P##U[>3SRV]P([F7SKFTCNI$MYY.NYX@VUCD#/'/?-6=5\&:-K%^;VX
MBN(YWC$,QMKF2$3QCHD@0@.O)X/TK?K!UOQ;8:%J5KITT%[<WMW$\L$%I 9&
MD"D @>A^;/.!@'F@#1TK2;+1=)M]+L(O*L[=-D<>XM@>F3SWJ&T\/:79>'5T
M"*U!TQ83;^0[%@4.002>3U-<]'\3]"DMTN5MM4%J)1!<SM9L$LY2VW9*3]T@
MXSC.,CU%:.J^,K+3=2GT^*PU+4;FVC62Y2PMO-\A6R5W'(&2 2 ,G':@!C>
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M1N;"*3?<VRHTRA3A-^=H)Z9(&<=<8/<5-/*MO!),X8K&I<A%+' &> .2?84
M<[\.]/NM*^'VB6-[;M;W,-L%DB<8*MDY!KIJ@L[RWU"R@O+259;>=!)%(O1E
M(R#4] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7&ZU+?:QX\M_#D6IW
M6G6<6G&_E>S8++,QDV*NX@X48)..N1795Q/C33YYM7T^]CTG4YTABD07FCW*
MQ74))'R$,P#1L![X(% '-V>L^('9O#LFNS//<^))M/\ [1V)YD=O' LFU>-H
M<XQG'!).*T+[_A(=.U36?#.FZU>74K:1_:=A-<E6FBE23:8RP W*^!UY'-3^
M%_ ,;>%KNUU:WN;.2YU634[<+=%KBT; ",903F3"Y)R1\Q'-=1HGABTT2[N;
MT7-Y?7]RJI+=WLH>0HN=J#  51DG  Y- '(77CFYU R:SI3DZ?I>@/J=Q".D
MD\BDQQ/W^4(Y./450T;5?$J7.A7D8\37<MW-$NHB^@B6T,<@^9XPIRFTD$8Z
M@<UWFB^$-'T&TU*UL[?,&I3O-<)*=P.\8*#_ &0. *H6'P_TRQN;%VO=3NK;
M3W$EE975SOAMV PI48R=H.!N)QVH Y+[3KK^&/&?B1_$5^)-/FU*"SMD*")%
MC9@A(VY+ ]#GH!6M;_VQHOB7PH\VOWU^NL^;'>P7&SR@P@,@:,!1LP5QC)XZ
M^M=-_P (EIO]@ZKHV9_LNJ27$MQ\XW9F)+[3CCJ<59N-!L[F[TBYD,OF:4S-
M;X;C)C,9W<<\$T >76]WXF?P9HGB,>*+X7UYJ26?E,L;0+$\[1?<V\L.&R3U
MXZ5L7>M:GX,N_%EN-2N]4BLM'CU&V^W%79)&,BD94#*Y53CMSBNLC\&Z7%H%
MAHJFX^R6-TEW%EQNWK)Y@R<<C<?RJW-X<TZYU6^O[B-I7OK-;&>-SE&B!8XQ
M[[VS0!P6BZAXCM]5T26-?$]V+J58]2_M*");<JRG,D>TY3:V" .",YJB+WQ"
MGP_G\8MXDOS=VM[((K7Y/(:);HQ['7;ELC/.<CC'2NWT[P%IUA>V,\E_JE['
MIYS96UY<^9%;G& 5& 20"0"Q..U63X-TMO"<WALFX^P2R-(QWC?EI3*><?WC
MZ=* .0C5M)\8?$+4SKDUIY%O;L);@"2*,M$Q#% ,MMZ*,^W-1:/K&HVOC7PY
M;17GB6:TU(S1W+:Q"D<<I6%G5HUP&4Y7T P:Z_4_ NDZMJ&I7=S)=[=3MUM[
MNW2;$4H485B,<,O8@TRV\"V46JZ=JESJ>K7][I[,;:6[N VP,I5EVA0N"#R<
M9.!S0!!\+O\ DGUC_P!=[K_TIEKC_%&O7RP>(M1T[6O$-S<Z>\I@;3[94L;;
MRQG9(7&)",'<03UX':O4-$T:U\/Z3%IMD9#!&SLOF-ELN[.>?JQKG[GX<:3<
MQ:A:M?:HFFWTDDLVGQW.V'>_+,,#<.><9VY[4 +HFL7M]XYNK::8_9O[&M+E
M81]U9':3<1]<#\JXH->^(;;P/=W>K7JSOK=Y#OB=0<*;@*1E3R%4+]"?K7>W
MO@>QNKNUNXM0U.RN8+1;-IK.X\MIH5Y"OQZY.1@\GFH_^%?:.F@Z?I%M-?6D
M6G73W5K-!/MEB=BY.&(.1\[#GM0!Q4=CJ::1X^UJSU^_L7T_4[V>W@M]@C+H
MBL2X*DMG &,X 'O6_:W6I>,O$<]DVK7FEV=EIUI.R6#*CS2SJS;BQ!.U0N /
M4\UTR^%M/72]:TX&;R-8DFEN?G&<RKM;:<<<#CK56\\$V%Q-;7-K>ZCIUW!;
M+:?:+*<(\D2]%?((..H.,C)P: .)BUCQ#K5UHF@MKEQ;2?VIJ&G7=];*BO.D
M"Y#@$$*Q  R!P<FJWC/[=/I/B[2I]6O98-,DTH1,67<^XJ&+?+SDG=QCD#MQ
M7HEEX-TC3FTAK6.5/[*:9X,R%B[RJ0[.3RQ.2<YZTFH^#-*U1=;%P;C_ (G
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MA/=WDUML$DCJ8\$$J0#EO3ID=Z-?U'6]*U?4IM5U+7["VBF4V.H6<"7%C'"
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MYH YFYBU;PAJ_AV1O$%]JD>I7@L;R&[V%2S(S"2/"C9@KT'&#[9KG/MOB!?
M>J^*7\1Z@UPEY):P6XV"*.,7@3.-N2V PSGH<=J[O3/ ]AI^H6EY+?ZGJ#V2
ME;-+ZX\Q+?(P2HP,G'&6R<=ZE;P;I;>&)O#Y-Q]BFG:=CO&_<9O./..F[]*
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MF^6:0X!9F^@ XP!B@#F4CU/Q9XG\0P#7;_3+72IH[6VBLBBDN8U=I'RIW<L
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MN1K;VL@:T<0P^6ZEI_.QL*_*6!!))(XK2N=*O6\)?$R,6%P9KRZN3;J(6W3
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M55=B;1CD949YQG%;_C^TO6M]$U6RLYKUM)U..[FMX!ND>+:Z-L'\3#?G'?%
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M-M>PQ;"%N&A5<G)+*1MS@@D4 >CZ+K^G>(+>6;3Y7;R9#%-'+$T4D3X!VLC
M$'!'45.-5LCK3:0)O].6W%T8MI_U98J&SC'4$8SFN7\ 3ZM,=6^VS75W8+,@
ML;Z]L_LT]PNSYMZX4D X 8@$\U%K%VV@?$N/6+JQOYK"YT@6BRVEJ\^)5F+[
M2$!(R&X)XXH U[GQSX=M+:.XFORL<EU+9QX@D)::/(9  N2<J0/4\#.14EAX
MQT/4--O[]+QH(=/R+P743PO!QGYE< C(Z<<UP6@:;J4EQX9GN=)NX"OB+4;F
M6.6$YA5UF*ENP&2,'H3C!JUXDT'4]1OO'8M+&60S+IDT*E2JW/E$NZ*3P3A<
M?4B@#9A\>0:KXTT+2],>98+F&YDN([FTDA<JJJ8V7>H.T_-R.N*U+7QYX=O-
M0BM(;R4^=*8(;AK:1;>:0?P)*5V,>#T//;-<QJ-Z_B_QAHK:;INIP1165]%)
M>75E) (9)(U"H=P'((Y[=,$USFEZ3)+H6C>';K_A+Y-0@E@CGT\QK%;0&-@3
M*)O)*[ 5W##$G@=Z /3X?&>AW/B%M"@N99=021HI(TMY"L;!=V&;;M'&<$G!
MP:J^,/%Z^%[G1(C#)(+^]$,A2VEEVQ[6)(V _-D+@=2,D X.&>"[*:UU'Q9)
M/;20^?K4DD;.A7S$\J(!AGJ,@\_6HOB!YT*^'-02TNKF&QUB.>X%M"TKK'Y<
MB[MJ@DC+#IZT 4H/B-9:?K/B*TUJ:7987H2/[/9R2>3!Y2-OD**=HW%N3CI[
M5T6I^+M&TK[*LL\L\MW'YT$-G ]Q(\?'SA8P3MY'/2N>T[3[D1?$%FLYE-W<
MR&'=$09E^S(!MX^89R..^:Y6WTJ]TB\T34M1G\06%I-X=L[4S:9;F1X98P2T
M<J>6[+G<".!SD&@#UO2]4LM:TZ*_TZX6XM90=CKD=#@@@\@@@@@\BKE<I\/M
M/-CX?N)#;ZE!]LO9KK;J3J9VW'[[!54)NQNVXR,UU= !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !5>^O[/3+.2[O[J&UMHQEY9G"*OU)XJQ7"Z[!%JWQ
M5T+3-019;"WT^>^BAD&4DN Z("0>"55B1Z9S0!TNC^)M#\0^9_9&K6=Z8_OK
M!*&9?<CJ!56[\<>%+"[EM+OQ%ID%Q"Q22*2Z160CL03P:P_'MM!I^J>%]:M(
MDBU-=8M[,2(,-+#+E7C/J,<\],9K"\.W.K0ZOXM6P\)0:O%_;TY-Q)=QQ%3L
MC^7# GT.?>@#TR+5M/GTK^U8KVW?3_+,OVE9 8]@SEMW3 P>?:IK2[M[^TBN
M[2>.>WF4/'+&P974]"".M<%\1]6MK;P[I&B7@%BNL7$<=U'&"_E0+AY@-HY[
M)P/XZQ="\3Q6?A+QQI>BW#.=)CN+S37V,A$,BLZ@!@#\C[A^ H ] N?&?ABT
MU/\ LRYU_3HKW=L,+W*A@WH>>#[&KVB:/::!HMKI5CO^RVR;(][;CC.>3^-8
MGASPUHC?#VQTPV<$ME=62-,64'SBZ LY/=B23FMO18;.WT2R@T^Y^TV<4*QP
MS>;YN] , [OXNG6@#+?Q_P"$(IFAD\3Z2DBL596NT!!'4'FM^">&Z@CGMY4E
MAD4,DD;!E8'H01U%>,^'?$E]X?\  5Q=2>#3J&FPW=WOO/M$>W:9WR63!<*,
MX)P>!GI70>'5U#PGIO@K2([NVDBU*]N&F%O\T0C>.694C)_A!VX/>@#T.\O;
M73K.2[O;B.WMHAF265@JJ/4D]*GKRSQ[J]Y=Z-\0M,F=3:V-I:&!0H!4R9+9
M/?D"IM:\97L_BS5],@U>YTJWTSRXD-OI$EZ9Y60.2Y",%49 P,$\G/2@#TVB
MO++OQIX@GTK0KZ\%[H5C<VTC7EW;Z:UPT<ZOM"LC*2B$ L"5)Y S7<^$]1DU
M7PS9WDVH66H2.&!NK($1R88@'!Y4XQD=CF@#:HHHH **** "BBB@!KIOC9,L
MNX$94X(^AK+T'P_:>'K6:*VEN9Y)Y3-/<W4IDEF? &68]<  #T K6HH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH SSH]H?$(UO#_ &P6
MIM,[OE\LN'Z>N1UK0HHH **** "BBB@ HHHH *BN;=+NUFMI<^7*C1M@X.",
M&I:* *FF:=!I&E6>FVN[[/:0I!%N.3M4 #)]<"K=%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 <[JG@ZRU/4YM1COM2T
M^YN(UBN&L;DQ"=5SMW#!Y&2 1@\]:V--TVTTC3;?3K"%8;6W01Q1C^$#Z]?K
M5JB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *Q/$7AJW\0+:R_:;BRU"R<R6E[
M;$"2%B,$<@@J1P5(P:VZ* .6L/!TW]LVVK:[K=UK-U9Y^R+)$D,4)(P6"(.6
MQD9.<9XK3T/08M#DU5XIGE_M&_DOGW@#8S*H*CV^4?G6M10!D'0(G\6KXAEG
MD>:.S-I#"0-D8+;F8?[1P!]!4=[X:MKSQ1::Z9626*UELYHMH*7$3X.UL^A&
M1]36W10!PP^'MY!8MI%EXMU2UT)@4%DJ1L\<9ZQI,5W*O8=2!WKL-/L+72M.
MM["RB6&UMHUBBC7HJ@8 JS10!C>'_#MMH.@G2%=KF!I)G;S5'S>8[.01TQ\Q
M%8:?#N.VT6RT^RUF\MVTV]:[TV?:KM;!@1Y6",.F&8<\\]>*[6B@#B7^'4=Q
M8>(8+W6;RZN-=CA2ZN'1 5,><%5   P<8]OQJ]J'A&Y?6KS5-&UVYTF>^15O
M%CA2592HVJX##Y7 XR/0<<5U%% '*/X,FM4T\Z-K^H6,]G;FV,DN+@3H3N)=
M7X+;N=PQU(Z<59TOPK_8VFV=G9:I=(8[QKRZE*H6NV<L7##& "6S\H&,"NBH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O._C5KUWH7@'
M-E<2VTEY=QVC31??1&#,Q7WPN/QKT2N8\?>$1XT\+2Z4MQ]FN%D6>WF(R$D7
MID>F"1^- ''_  R32M.\6ZEIMFNO:7,UHDQTG52&#KD#SU.3SV(]_;CU>O.=
M)\'^+6U[4/%&MZCI9UW^S&T^P6T1_)C/+!WW#)^;D@#N?85W.CQZC%H]JFKS
M0S:@L8%Q) ,(S]RHP.* +M%%% !1110 5XI\9FLCX[\(Q:G!?W&GO'<>=;V.
MXRR# QM"D$\X/TS7M=>1?$Z6-/'&A:E9>)M!TW4M)CD/DZG(PSY@P#A0>,9H
M R_AG<V4?Q2O+/0I-3T_2#IVY]/U:0B667=]Y$8DX [_ %[&MS0/BOJNJ:-=
M>(KWP]%:^'[))1<7*W(9VD7[JHN 3G*C)XR3Z5B:+JVG7/CRS\5^+/'GAR:>
MPMWAM8-/8JOS @EBW/1CQ].F*=X>D\&VGPNOO!^K>,='9KMY6,UM/D+N(93R
M!D@@''M0!T%E\2]=MKC1;GQ'X9CT_1];E2*UN8KKS'B9QE/,7 ZCGMCGTQ7,
M:7XY;PUXY\8Z?:VS:CK&HZTD-C9M)L4_>W,6/W5&1_G.*MO>6VJ2:#IWB?Q[
MX8ET70YHYHA9NPFN6C&$\S=P..N/4_40W^E^#]0N_%.H-XPT*+5+Z]2\TJ[2
M<[[9D)(#''&<\XSZ]A0!Z!XA^(>IZ?XC7P[I>G:?<ZG!:+=7KW5Z((4)QA$+
M#+$YXZ=1[XJWOQ=/_"*>'M:TO1C=2ZO=FS-HTVUHY1D;0V,'G&#QP0:X[79M
M%O?$,?B.W\1>";W4;BQ2WO[;5 98!*H \V([<CH."!QZYJY/-X9?3/"%NOC'
MPWYVCZFE_>-$J6Z28.2$2-0,]N0,XR: -_5?B=K^DZE8Z)?:3I%AJ\ULUS,;
M[4/+MP-[*J*^,%B%SUQSBO0?#FIW>L:!:7]]8?8+F9<O )EE YX(=3@@CG\:
M\K\<:_HNOZG%/9^)O!^HV A,;6&L+Q&^?]8DB#>#VQG'7\-[X96RZ;X/M=+\
M.Z]I6K207HDU!E9VCBB<DLD6.0>.-W!Y)H ]*KC8';_A<]ZFX[?[ A.W/&?/
MDKLJXO5]#\3Q^.7\0:"VD,DNG)9O'?O(""LC/D; ?[PH V?$6J:GIR6R:98V
M\SS,PDN+N?RH+=0,[G(!)ST  _$5RP^)-S%X<UJ\DL+.ZOM*O8+1TL;KS(9_
M-9 "CD#G#]#T(QFI-:\,>)-=FT>_U.VT"]GL'F\S3I7D^RR!PH5\E2=ZX/52
M.>,557X?:P^GZ]#+/I<<FI7UE=QI;(R1Q"%D+)C'H@ /<\D"@#7A\7ZGIFL7
M-AXFT^SME33I=2CFLKAI0(XR Z-N5?F&X'(X-<_K&M>(]3'A"\O]*MK33[W6
M+66(PW3/+&I#%5E!4#D'L>",5UFM^%&UOQ(MW-(@L'TFYTZ9 3O/FE.1QC&%
M/Z5B#POXNN8O#^GWMWI/V'1KR"8S1&3S;I8N!E2,(<<D G)[@4 5-&\17.DQ
M:I:65J+W4]1\3WMM:0R2E$&/F9F;!(55!/ )Z"K^H^/M1T"RUN+6=+MQJ>FV
MB7L:VTY:*YA9]F5)4%2#D$$>GK2'P-JEN6O[*[M%U2WUNYU.T\S<8GCF!5HW
MP,@E3U&<$#K46K>"-<\1VNNW>IW&GPZG?V4=A;0P,[0P1+)YAW.5!8D_[(Q@
M4 7YO$_B6W.GZ=-HU@FMZG+(;:$7;&**!%5F>5MN=PW!<*.3WJ'P1<:C<>,?
M&)U2W2WNEFM5:.*4R1\0CYE) X/7H#S@UK^)-#U"\U/2=:T>6V74M-,BK%=%
MA%-'( '4E02I^52#@].G-1^%M$UG3]8US5-9GLWFU.2%UCM=VV((FW;E@,]N
M>_)P.E #?$&OZU8W\D%C::7!:PQ*[7FJWAACE8Y^1  >@').,9%9,'Q!U#5;
M7PP='T>"2YUV"X<+/<E8X&A*ALL%)9>6Z#)P/7A^J>#]3E\9W^LP6FAZ@EW%
M$D+ZHK,]B47!\M=I# GYL97GO1X:\#:CHK>%?M%U;2C1H;Z*5DW R><X*%1C
MT'(_+- #U\>WD&C:A]MTJ/\ MJTU)-+2U@GS'/-(%*%7(!"D/DY&1@U7TRYU
MR3XNP0ZU:VT$BZ%,4:TF:2*0&>+^\ 01T_$>M6+[P->W1UR:.\@BN[C5H-4T
M]R"RQO$B*!(.."58''8U;TK1?$<OC9/$.MR:;'$FG2626MF[OM+21ONW,HSG
M8>PQQUY- !X^\,:/JV@ZGJ=[9^;>6NGS>3+YCJ4VJS#@$#KS6/H%IX>\#?#N
MV\7"Q9;G^R87G=96+3,ZH<?,< L^.:[C6[&34] U&PB95DNK66%&?H"RD GV
MYK%N_"/]I?#6+PI=W"I(MC#;F9!N421A<, <9&Y0<<9% &?I/CFZDU[3M,U9
M-(_XF0<0-IM_YYBD5=VR08'4 X8<9&*H6GQ"UZ;0K'Q)/H5G%HDUREO)B[8S
MC=+Y7F!=NW;N/3.2.>*T=%\,ZS%K=E=W]GX=L(+16WC3+8,]RY& 260&,#KA
M23VSBF+X(OU^&5IX8^T6WVN&>.1I,MY9"W(E..,]!CIUH ?XD\6ZWH[ZC/%8
M:5!8V(RIU&^\F2\PNX^4 I '\()/)[42>,]5U#5-,T_0=*MI9-0TE-366\N#
M&D*,0,-M4DGD#CU]JS+WP#JTNH^(&CAT*X_M:5WCU.\1GNK5&0+Y:KMP0O\
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M=MOHU5RAE,9 &.-V,].^:[#6+VYT[2+B[L[&2^N8U_=VR,%,C$@=3P!SDGL
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M*98DE5P2JX91M+*?7' ZUIVWCO5-1UN\M]/L--GBL[YK26R:^V7Q56VM*(R
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MF#VV@V5S*T6EWNK107Y#E0T95R$8CHK.%!_+O0!LKX1\+L,KX>T<CU%E%_\
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M['AU94DVC=N83JS#W*@ _2J2Z+HFF>"?"UO%I4M[J&N_9FEA^U>4E[(L)?\
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M$\<3D*Q6)Q_!\PP.,<BNRH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MM\<BN NX!]K'R\CINXSP<&F_#O7-5U_0)[G5;:2.5;RX1)'9"&42N H"GC:
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MP_?WRZ+M:^FB>-51#&)-R[F!8X)^4?W?<9 .FCT;3(8K**+3[:..Q;=:HD0
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M7%E_QZRM&-T/^Z>U8-]XWDBO=1BTS0;_ %2WTQME[<0/&H1P S(@9@9& ()
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M_AOQ!%XCTV2Y2VFM9H)Y+:XMIL;HI4.&4D$@_4=C6Q0 4444 %%%% !1110
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M9^\O/7U!]* /(M:\$>(M8T+5[*\T)[_6YI)3'JESJ8,!0N2@CBW?(=N% *@
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M<;)XX-.&+-H9Y(Y(!C!"R*P<9'7GGO5S1/#VE>'+::WTFT%M%-+YTBAV;<Y
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MC(=RG(.5((P1ZT <#K4&OZ3XH\*W_B/5+/5K,ZB+:&"VMOLS1S2JRK)C<V\
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M6+F_EU"258,C+(;SS >N/N<T ;8^(MH;XZ>=!UY=0:,306C6BB2>/)!=?FP
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MFJ6GC;0-9L](N-1M+6UNXKD6Y7>F\Q;2H8C)^4\>@/T(!;C\=Z4^F"^DAO(
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MO(!7 Q@<GUN*=>O-!\5Z_P#\)->PSZ7?7WV*!-GDJD+,0LBE?F!QCD\#&/<
M]3JG<ZK96FHVFGSSA+J[61H(]I.\( 7Y P, CK7"V,VJ>+O%=S$VM7^FZ>-)
MLKL6UHRHXEE$ASN()P,<CN<>E9VD:M>ZKXC\(27\HFN[5M8M'N H43&(J@?
MX&0 3COF@#TW3=1M=7TZ#4+&7S;6=-\;[2NX>N" 1^-6J\H\,ZIK/BU?#VE7
M.LWEJC:(-1NI[8JLUQ(TA11N(. ,$G'7(K2U>[O=-LM,TF\\4WES,US.A&EV
MHDO;J-.54E00A7(WM@9XZ9Y .ZU/5+/1M/DOM0F$-M&55G*EL%F"KP 3R6 _
M&IYYH[>"2>5ML<:EW;&< #)->,:EJ6IWW@3QEI=Q<7_^A7]DEJVJ*AGC61X6
MP^W@X)R,\X//H.DU8:EX:UBWTU]:O=3M-7T^\$J7A5C'+%'N#H548!R05Z=*
M ._L;ZVU/3[:_LY/-MKF)98I,$;D89!P>1P>]6*\8L-;U"6U\+:!#_;:V4/A
MRUNY?[&1/.D=AM7+-T0!3TZD\UZ!X%O=8N]&N$UF*Z66WNY(8)+N-4EFA&"C
M.%XW<D''7;F@#IZ*Y_QO-J%IX/U"^TN5X[NS472[?XUC8.Z?\"4,/QKB;CX@
M75IXLU'53<^9X;^QS0VD>.&N(88YR1[L'=?^ 4 >D3:SI]O?3V4UTD4\%K]K
ME#@JJ0Y(WEC\N,JW?M2+K.GM?VEDMRIN+R!KB!0I.^-=N6!QC^)?SKS#5Y-;
M;2-:T;5-4NF>/P:MW/M(!-P6EW]NAV[3[>G6I8]'N;CQ!X'L8M9OX,Z)</)<
MHR^<4)A.P-MPO) SC.!CWH ]9HKD_ MW?2PZWI]]>RWITS5)+2&>?'F-&$1U
MW$ 9(WD9QSBL@3:K=>-?%5U+K-\FGZ$\,L%C 55)<VZNRN2I)4GL,<DT >AT
M5XWI.O>*+C3=*UV!?$MU?W4D,T\,D$0L'A=AN5!G*@*?E;J2.>M:=Q/K>L>'
MO%/B6'Q%>V$^GS7D5I;1;!#&D&X8=2I+,VTDG/&1CI0!ZC17E]WJ]QJ$VG6S
MZQKTTHTNWF>ST.W'FK(XSYDLI&T9[*2.A-4M/UKQ!X@T;P5:-K-W9S:C<WUO
M=W$2H)62'S,=BH?"#D=SF@#UTG R:J:9J=GK.F6^HZ?,)K2X7?%(%*[AZX(!
MKB+.TU;7=<UNP7Q)J5I'H@AM+8H4W2R&)7:6;*_/DL..!@'UK3^%X/\ PK#0
M!GG[*!D?4T =1;7MM>B4VL\<PAE:&0HV0KK]Y3[CN*GKQO2'U#1M&O;6PU:[
M6?5?%DVFFXF*.8%\QRTBC;C>P4C)XR1P*Z_3GO\ P_X\M]!?5;S4K"_L);E/
MMC*\L$D;(#A@!E6#]#T(XH ZZ6]MH+JWM99XTN+C=Y,1;YGVC+8'? Z_45'I
MVJ6>K023V,PFCCFD@=MI&'1BK#D#H017'>*+!KCXI^#I1?7<(\J[^2)U"_($
M;N#][.&]0!C%<C##JNF>!?$OB6RUZ^MY;#5+V:WM8]GD$+<-N#J5RV[GOQQC
MW /7X-2M+G4+NPAEW7-GL,Z;2-F\$KR1@Y /2K=><ZKJGB2YU#QC:://(TUL
M-/-O$K(K(CC,HC+<;R,XSWQ5OP-JHGUB_P!/?4M;\Q84E&FZW;[;B'D@NL@X
M=#P.^".O.* .@U[Q;HGAF:UBU:[:"2Z#F%$@DE+A<;N$4]-PZ^M5[;QYX<N[
M&\O(;V7[/9JK3N]I,FT,<#AD!//IFL#QJVJK\1_")T:.SDO/LU_M6\=DCQB+
M/*@G/X5/XGU/Q1IGP[UF^U V%GJ$.PP/ITCN I=02=ZCGDT =W52#3+.VU&[
MU"& +=7@03R9/SA 0O'08!/2N*LTUO5_''B9EUVZAM])N(A:6:%1$[-;HQ$G
M!)7)!P",9-97AG5-2M];TJUU[4_$-AJ-R&BN(=0@22TNY"A.+>1!M0@C(]0,
M8- 'IUK>VU\CO:SQS)'(T3-&V0'4X9?J#P:J:YK^E^&]/%]J]XEK;&01B1@3
M\QZ# !/8_E7+?"RQ:TT75&:]NKC=JUVF)V!"[9G&X8 Y;J??TK+\:ZA::KX[
MM]&O-/U*_P!-TZRDDN8[&T>?]].IC0,%'&(S(1_O"@#T\$$ @Y!HKR*S\3ZM
M+\*+2*WNI[+6K#4K;2IWEBPZ_O44%D;^\C*2#ZFM6/2M7;QU=^&CXLUG^S_[
M-CO_ #-\?GB1I'3 ?9PGRYP!UQVR" >D45X[%XNUS4='\):?)-J<DE[#<RWL
M^F1)]IE$,GEJ%SPN3@L1SZ=:LW>N>*++P;KZB34[9K:]LUTZ\U&)!.4DEC5E
M<+PV,D9ZD,* /6:J7NJ6>G2V<=W,(WO)Q;P#:3OD*EMO XX4]>.*\\UG4]6\
M"ZO>!-7O=5@?0[J^$=\5;;/$4P5*J,*=_*].*BU#1M0L[[P/?7?B&]U$W&J1
M-/'<%"AD,,AW1@*-H'S#'3!'I0!ZG17CM[?>(QX3USQ-'XDO4NM/UF:"UM\)
MY'E"Y\O;(NW+\$]^ !CWV[C4-3\'^)-3A?5KW5;=?#\^J&.\*DB:)@/EVJ-J
MD-TH [G5]'L==TV33]1B:6VD(+HLC1DX.>JD']:LVUM#9VL5M;1+%!"@CCC0
M8"J!@ #T KR?1M7\3?\ $BU*(>)KNXNYH3?K=P1"S:*3&XQ@'*;<Y4CJ!SUI
M]U-K]SX>\8Z^OB74()=&O[T64$6P1!8CN"N"I+@].3P,>] 'J8O;9KYK$3QF
MZ6,2M"&^8(20&([ D$?@:GKSO1K:2Y^+MUJ#7MT"^B6LY@#CRSN:4;<8SM'4
M<]2?I7HE !1110 4444 %%%% !1110 4444 %%%% %+5M(L-<L&L=2MEN+=B
M&VDD$,#D$$8((/<'-5M%\-:3X?,[:=;%);@@S32RO+))CH"[DL0.PS@5K44
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M(QR<J/PK3HH Y*R^'NE6=Q9$WFIW%G82"6SL+BYWP0,/NE1C)V]MQ..U:/\
MPB>F_P!BZSI69_LVKRSRW/SC=F;[^TXX]JW** ,-/"UE%XAM-:AN+N*YM[46
MA1)<1S1KNVB1<<X+$@\<UH:5IRZ5IT5DMS=7(CW?O;J4R2-EB>6/7&<#V JY
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKG/$WBM_#]Q
M9VEKHFI:M>7>XI'9QC:H7J6<X ]A0!T=%8'A#Q99^,=&?4+2"XMS#.]M/!<*
M \4BXRIP3ZBM^@ HHHH **** "BBO-/'&C7=A?:1<6GB;Q!#_:>M16TL27N$
M2.3<2$&.,8&.N* /2Z*\[\02WG@RZ\,06M[K6J+<:E(LD4DXDEGS VU,G:-N
MX \\#DYJQJ7C.&Z\/:TE]:ZMI%YIDULES##)'YRB21=C(X)4JW0^VX4 =Y17
M)7OCDP7^HPV6@ZCJ-MID@BO;BV,9*,5#$+&6#O@,,X'TS76*P90PS@C(R,4
M+17DNK:OIQ^(OB.SU[QIJ&BP6XM?LD,-]Y*D-%ES@@YYQ^==+8W6GVEYX6@M
M-<U;4H;Z2Y:WG:Y61)@(R2)#C+*,';CH: .UHK@[3XGP7>D?VLN@:HMA(R16
MLS>6/M$[2",1J"W'S'[QP.#SQS)K?C'58/"/B*XCT*_T_5=.M#*HE\MTP5)$
MBN&*,%P25Z\=#D4 =Q16=H%W<W^@6-U>6TEO<20JSQR,K-GU)4D<]>O>N?\
M'MUJ%P-+\.:->R6>HZK.W^D1'#0PQKO=@>W.Q?\ @5 '8T5Q5CX[AM_AM#XE
MU.&5I;<I;WT,2@NLXD$+C'^\<X]*!X^NSJCZ0?">K+JS0BY@M3)#^\AR07+[
M]J8(P03G)'6@#M:*Y-?'MC+X=T[5+>RO)KC49FMK;3U51,TRE@ZG)V@+L;+$
MX %1S_$&UL-+U:YU33;RQN]*6-[FS<H[E)&VJZ,I*LIYZ'/!&* .PHKE]/\
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M/VJR;8[A96"HZE2593D]#GY2,9JYI7BY[W7ET>_T2^TNYFMVN;;[2T;":-2
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MQ9.JLK33!50$^N,MQ]UO4T =C17E.M>+-??3OB)&8;JS73$ L[A9(QY)\M"
M-K;LMN+@]@<$@\5U>E>,VNM7L--OM%U#3SJ$3264UP8R)P@!8$*Q*-@YPP''
MOQ0!U=%07MTEC87%VZED@B:5@O4A03Q^5<C:_$:&XT1=6DT+4X;:Y:&/3E8(
M7OGDSA47=QT)RV!CF@#M:*Y$^/K6RM]3_MO3;S2[K3K7[7);2%)#)$3@-&R,
M5;YOEZC!(SZU9L?%=Q+)<1ZCX?U#3FCM6NT:0QRQR(O4!T8@-_LG]: .EHKB
M]-^(<5]'I5W-HFHV>EZHZ16M[/Y>TR./E#*&+*"> Q&"<=B#3[KX@10&^NH-
M%U"ZT?3Y6AN]2BV;$*'#E4+;W53U('8XSB@#L:*YK4?%XAU,:;I&E76LW8MU
MNI5MGC1(HFSM)9V RV#@#DXS6-!XTO\ 4O'&@V]CIU[_ &5>Z?+.ZR".-E8.
MBEF#-N&S)! Z[N,]0 =]1535;F:STF[N;>!IYHHF=(D*@L0.F6('YFN*\/\
MCN\;P?X=DO=,O+S7-4BS!;QF(-<!5#/-G<%1.>^#R!B@#T"BL7P_XCBUUKRW
M>TN+'4+&01W5G<;2\9894@J2&4CD$&LOQ]KVJ:%;:,VEVLL[7.J6\$OEM&"4
M+C,?SD8+] >W<B@#KJ*\UM/&>J6&N>+5;1M4U."QNDD<121[;6+R$8J-S#<<
M[CM7/ZC/1W?C2W_XED6D6%SJMYJ5J+R"" HFV# _>.SD!1\P'J3Q0!T]%96@
M:];^(+*6:*&:WFMYFM[FVG $D,JXRIP2#P0002""*U: "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "O-_B%H?B/5/$VE36NGSZOH"0NESIL.H?9-TI)P[
MG(W+TXYZ'UY](HH \I\#Z'XO\$^%;ZTM] M9+N?6VE$(NE\M;9E4%E;(/&W@
M'!]J]6HJCJ^KVFB6/VR^=DA\V.+*J6.YW"+P/=A0!>HJ*YG2UM9KB0,4B1G8
M*I8X R< =326ES'>V4%U$'$<T:R*'4JP!&1D'D'GI0!-1156_P!1M-+M?M-[
M.L,.](]S=V9@JCZDD"@"U7,^,M(O=6;P\;*$2?8]:M[N?+!=L2AMQY//4<#F
MNFHH YOQ%I5Y?^(O"]W;1!X;&]DEN&W ;%,+H#@]>6 XKG/$OA76=1N/&#VM
MJ'741IHM?WJC?Y,F9.IXP/7KVKT>FRR)#$\LC!(T4LS'H .IH \P\5^&-4U#
M6-3N+;PRW]J2\:=K>F7XM2@V@+YX+AF*GT5LC  %>E64<\5C;QW4HEN$B599
M ,!V Y./<U5AUW3+C^S?*NT;^TXS+9C!S,@4,2..FT@\^HK1H Y;1]#N;?QQ
MXIU*ZMD^RWWV3[,Y*MNV1%6XZC!]:EUK2+NZ\7>%KZVA!M;"6Y:X8,!L#PE5
MXZG)/:NDJC>ZO::??:?9W#LLU_*T-N I(9@A<Y/;A30!QECX<U:T^$UCHDVC
M65_=1'_2=/NG!66/S2S*K [0^"""> :SK'PCK+Z/XHLK.QN]*TN^TMK:STV^
MOA<$3E6!=2&81K@J,;O?BO4J* ,SPZUXWA^Q&H6+V-TD0CDMWD60J5X^\I(.
M<9_&N:N?!K>(_&^HZKKL5Q'9V\,=KIH@O'B9EY:5SY; \L0,'LO2NXHH \IU
M#P+JVGV_B'1=%M'FTB_FL[ZW,ET&9)EFC,RDNVXY5-^3Z8Z\5V1TJ\/Q*36/
M*'V$:.UJ9-P_UGG!L8Z]!UZ5TE8VF>)K'5]7OM.LH[MS9.T<UP8&$'F*0&0.
M>"PSR!0!P,W@/4W\-Z*T^FK=W.F:G>7$FG_:1&9X9I)/NN" & 96 ) Z@XI+
MCP7?WGA[Q$+'PS%I<EW%!#:P2W?FW$@60.Q=C(R*/0 YZ\\XKUBB@#D_$GA^
MZUCQ5H\ZI_H,=E?6]Q*& *&545<#.3T/3TKFSIGBZ;P]X>\-OH"*NE7EEY]\
M+J/RY88)%^:-<[LD*"00,8(&>*]0JB-7M#KK:,';[:ML+HKM./++%0<_4'B@
M#BKOPOJ\O@SQUIZ6H-UJM[<S6:>8O[Q71 ISG R5/7%:>N>&[S5O$.BN$VV<
M6FWMI<RAAF-I5C5<#.3]UNGI7844 >0:5X&O(+;2M)G\'0_:+62);C4YM09[
M9TC(^=(UD#;S@$*5 !]JZRST#48K+QO&\ #ZI<S26@WK^\5K=$!Z\?,I'.*[
M.B@#@-#T36]'\1^'KE]-\VW7P_#IMTZ3H#;2H=Q)!/S#M\N:ZKQ-9SZCX4UB
MQM4WW%S8S0Q+D#<S(0!D\#DUJT4 >7ZMX7O9AIRWOA,ZD;?3H(;>[TZ]6VNK
M:55PRNY==RYP01G'/!S7<^%K35+#POIUKK5S]IU**$+/+NW;F^O<C@9[XS6O
M10!R-]IVJQ?$>'5;>P-S87&E&QEF69%,#B0N"5)!(.<<9K)A\+:NGPR\,:,;
M4"_L;JRDN(_,7Y%CE5G.<X. #T-=UJ6H6^DZ7=ZC=L5MK6%YI6 R0J@D\=^!
M4UO.EU;17$1)CE0.I(QP1D4 >377@>[L;S6X5\)_VP]]=S7-I>_VCY42"4[M
MLR;U/RDG[H.X>AKU'2;(:;H]E8A(D%O D6V$$(NU0,+DDXXXR2:N44 >7ZQX
M/FMO%NLZBWAF77;?4F2:%H+\6[02! A1P74%3M!##)&2,5J:)X5U#3-9\*RF
MRM((+#3[N*Y6T<^7%+*\;!5#L6(R&Y_ED"N\K)U#Q)INF7L]I<R.LT%A)J#@
M(2!"APQSZY[4 <9J?A;6WTGQ(;>R66XG\00:E:P^<B^?$GD$X).%)\MNN.E,
MU7PSKNJ'Q'<#3O*?4KS2[B*)IHR0(O*,H)!QE=K#WQQFO1K.ZBOK*"[@),,\
M:RH2,$JPR./H:FH X'QIX5EOO%-AKRZ0^L6\=H]I/9Q77D2KE@ZR(2R@\Y!!
M(ZBM3P-HDND6-]+-I%OI37=R9%MHYFF<(  OF.68%^#]W@# YKI;FX2TM)KF
M0,4A1I&"*6. ,G '4^U):W*7EG!=1!Q'-&LBAU*M@C(R#R#STH Y/QSINKW]
MWI#6MM>WNDQO+]OLK*\%M++E1Y9W%ERH.[*[AU'7%<>?"-[8:3XGN)[2TT.&
M:[L;S3Q/=B2,/$PPDCY)RS  GD9?@G%>Q5#=V=MJ%I+:7D$=Q;2J5DBE4,K#
MT(- 'FUY>:WK/Q%T6"^TA-/9-+OBD'VI)G)81J6)7@+G '.3STJ>_P#!6HWO
MPN\-:4]K')J&D&UGDLWFV+,8U*O'YBG@D,V#TSBNRT;PQHGA]Y7TK38+624
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M#H<,/P((H P? VBRZ/IEVT^DV^EO=7+3"VBF:5E3 "^8Y8AGP.=O'2NHHHH
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MEGQ_KUGYZ'^(#=]#0!=M?B9HMVMG-%::I]BN9DMC>-:E889F.T1N2<@[B 2
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M#UXQ5K2M&U#P9J.E:DFA7$]JVD"QGM;&3SWM9!*THQO(+*=[ D'@@=J .@\
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MM&< 9QS6I110 5EZ?X>TS2]3OM2M;<K>7S;IY7D9R>2<#<3M7))P,#FM2B@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>* /$O!]KX:ET/.H?#Z_U:Z-W<A[V+3DE23]^^/F+ G P.G:NNUKQ!'X4O\
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M)PH"J!R>E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7<P.03@<D'G/K5O[!9^1/!]D@\FX+--'Y8VR%OO%AWSWSUJQ10!1O-&TO4!
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MO;:U+%( R2)I-PRL#T((3!%=1:ZC!>75Y;Q>9YEI((Y=T949*AN"?O#!'(H
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M:.#UK5T_4+35=/@O["X2XM9T#Q2H>&!H LT444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[RX1FFL)6FMR&("L4*'([\,:HW_A+2-2?4WN89&.I" 7.)"-WDMNCQZ8/YT
M<'XGGU>SUK6;Z_N-?6PCD!M-0T:X$D-DBHI836X(S@Y+%@<@]J]&OIX[KPS<
MW$4@ECELV=) ,!@4)!_&LK4? >C:E>W=Q(]_"E\0;RWM[R2*&Y.,9=%.#D
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M[MKWQ1IWC349];U"T:PGNK.UMX)]D,:11CETZ/NR2=V>",8KMO!G_(C>'_\
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M-K,J,"22H].E5?[!U>70O&B)I>KYO;RPEM1?,99YD5H]S$Y/(VDX_A&!@8H
M]$\-:K>:CK7B>WNI0\5CJ(@MUV@;$\F-L<#GECUK:U"_M=+T^XO[Z=8+6W0R
M2R/T51U-8'A6QNK37?%DMQ;R11W.IK)"S+@2+Y$8R/49!'X5)X]TB[USP5J-
MA8(LETPCDCC8X$A217V9_P!K;C\: #3O&^D7]RUO(MY82"W:Z3^T+9H!)"OW
MG4MU R">XSTIFF^/=&U*]M+=$OH%O2197%U:/%%='&?D8CG(Y&<9'2L?6;O4
M_&^F7VD6&@WEDDVG7$<MUJ4!A:.5E 2-,_>R<[B.,#J:JW$^H^)X?#6DQ^']
M2L)K"^MKJ]ENH/+B@$/)"/T<L1@;<\'G% &RWQ+\/J7?%^;6*X-M/=BS<P02
M!]F'?&!SC\QG&:M:KXZTC2+V[MIHK^8604WL]M:/)':@C<-[ <?*0>,X'6N4
MGT+4S\'/$.FKI\_VZ>ZNWC@"'>X:Y9E('?*X/TIGBFRNH=?U:ZL-/\2:?JLB
MJ;6ZT@F:WOB$ 7SD(V*01M.[' SF@#HI?&4A\?\ ]@Q0S&R;2_M2W*6S,-Y/
M#;NFP+QG^\<50T?QQ//KWAS2@USJ%M?Z6;E[X6)C,K[D"O@<(N"V[T)%!AUB
MW\9Z?=ZCIUQ-)=^'A9SS6L6^*.Y#;V#$?=7K@UG>&;#4]%O? LUUI5\4317L
M)S'"6^SRLT1'F#^$?*>: .U7Q=I+>&;?Q ))/[/GD2-&\L[B7D$8X_WC65IW
MCA9?$_BBRU"*6UL-'",+B2!D15" N68\<DY7U49%<:D6LI\/;'PB/#NJF_L[
M^'SY?(_<^6ET'WH^<.",<#D<YQBM#Q)H.JZI?>/=)@L+H/JT-K<6=QMQ#)Y2
M(&C+]%8E2,'ZT =EI/C33-6U"&R6&_M)KB,RVHO;5X1<(.24+#G (..N.<5T
M5>8:-IYU'Q1HTXT_Q8WV-GGEEUFX9([9MA7"@C]X3N(^7C'.:]/H Y2?XAZ%
M!<RJQO#:0S_9YM06U<VL<F<%6DQC@\$] >IJ;4_'&EZ9JMQI?D:A=WUO&LLD
M%G:/,P1@?FXXQQ^HKBDAU:Q^'5]X#_X1_4)]3=9[2*X6'-K(LCL1,9>BX#9(
M/S9'2NJ\-Z3=:?XWUV6:*0P-8V$,5PR\2E%D#8/MD9^M %Z?QOHL>EZ;?023
MW@U,%K*&U@:268 9;" 9&.^<8[UH:)KMCK]I)<632 Q2&&:&:,QR0R#JKJ>0
M>1^=>3V7AG5-/T_PKJ-W::W'#;6MU:W4>F%EN8"\Q=&VCYF4@8('L:[GP%IK
M6W]KWYL=3MA>W"E7U2<O/.J(%#LI&4] "<X SB@#I=5U2ST73)]1U"80VL"[
MI'()QS@  <DDD  =2:RM*\8Z?JFJ?V8;;4+*\,)GCBOK5H3+&" 67/!QD9'7
MGI2>.'U>/PG=MHD3R7NZ/B.-9'";QO**W#,%R0#W%<?HVGWDOQ#TC48H/$D]
MBEG<Q27>L9!WL$( C(&P?+UV@$^N* .BL?B7X?U!K%H1?BUO9%AAO7LW6 RM
MP$WD8W9X],\9J+Q5X_L=+T_6X;+[8]U8V\BM=0VC206\^PE%=\%<Y*YZ@9&<
M5B6^AZFGP?\ #>F_V?.+V"[LWE@V'>@6X5F)'; R33;D:GHFB>+_  ^= U&^
MN-2GO)[.:WAWPS+."1N?HI7)!!Y.!C.: /0]#N9;WP_IMU.VZ::UBDD; &6*
M DX'N:P]9\5SZ9X\T+04M)Y(+Z*9Y9$MV?D%0N&'  R2WH-O3-;7A^&2W\-Z
M7!,C)+'9Q(Z,,%6" $&L#Q)'=0>/?"NI1V%W<VD:75M,]O'O\EI?*VLP[+\I
MR>V* ,GP_P#$JV3396ULWKM%J$]M->I9-]G@'G,L:NZC:/EV<\]1GK73:MXQ
MTW2=1?3S#?7EU%&)9X[&U>8P(>C/M'&<' ZG'2N.FT+4S\&M>TU=/G^W3W5V
M\< 0[W#7+,I [Y7!^E,U72+K2_&VNW]U'XG:UU+R9K:30W8@LL80QR*O0Y7(
M)XP>HQ0!Z7I]_:ZII\%_8SK/:W""2*1.C*:I:WXBLM!^S)<)<SW%TY2WMK6$
MRRRD#+84=@.23Q5;P3ICZ/X/T^RDLY+)U5G:WDN/.:,L[,07P,GYO3CISC-9
M?CZRCNO[+DFTK4[B*&5R;W2966ZLF*X#(J\LK<@]<<<'L 7QXYT0Z(=4,ER%
M%S]C^S&W?S_M'_/+R\;M_MZ<]*2V\<:3/::K-+'>VDFE0?:+NWNK9HY4CP2&
M"G[P(4]/2N,\SQBGAV,2'69+#^UL"Y-HC:DMGL^]LV_>W\9V[L<XJJ-%U.>3
MQI)!I^NR0WWAXP6DNI$O+/(/,X /*<L,)@'OCF@#LE^)>@M-%%Y6IAKB,R66
M;"3_ $T#&?)X^?J#].>G-78O'.B2:!-K#RSPPP7!M9898&$ZSY \KR\9+G(P
M!ZUF2Z7>'Q#X#E6TD\JRM[A9V"<0DP*H!],G(KFM8\,:O<V^KW,=I?8M_%0U
M$1VS>7-- ($0M$3U89)'KM(H ]!T7Q/8ZW<SVD<5W:WL"J\EK>P-#($/1P#U
M4D$9&>:U+N3RK*>3S#'LC9MX7=MP.N._TKA?"&G"7Q=/JJ67B'R8K+[.MYK4
MS!V+.&*+$PSM&T'<<<\ 'K7;:DC2Z7=QHI9VA=54=22IH Y>U\=Z;::;H\,]
MQ?:I?WM@EU$;:Q;S+E>,OY:\+ZD=!5X>.=%?0H=6C>YD2>X-I';I;L9S."08
MO+QD,-ISGTSTKF_!>C:C9:UX9ENK&:)+?PJMK*SH0(Y?,C.P^C8!X]JJ3Z+.
MNB:HM_H.H74+>)KBZ5K.1H[F!"3MGA Y;KC [$]: -?Q!\1H;3PS<W^F6MW]
MMM[R"TGMKBT<20%W7.Y>V4;Y3T)('/2M9_'6E+K4.D"WU%[^00LT*6;L85D^
MZTF!\@&0#GH:X>XL_$EYX/UZ'R]:U"PBN[*;3EU&$+>R*DJ/,,8!8 +\NX G
M!KK_  W!<2^./$6K265S;V][:6!A:XB*,<+)N4@]",C([&@#2'B[23X83Q")
M)/[/>01JWEG=DR^4./\ >K/U#XC:%IUU?02K?R?V?+Y=[)#9NZ6W .YV P%Y
M_0\<5Q#1:S'\.T\'KX=U5K^VOE,LP@_<&,78DWJ^<-D8X'(YSP*W9]&U!O#?
MQ)A6QF,U_/<&U79S.#;(J[?7Y@1]: .ETSQKI.JZO'IL O(Y)XFFM99[9XX[
MI%QEHF(^8#(/T.1Q4$?Q T.2[6-?MGV1Y_LR:@;5_LK2YV[1+C'WN,],]ZHW
MFDWLVO\ @MDMY5BMK.ZCGD5>(2T**N?3D'\JX:P\,W<7AJU\+WFF>*KB^C=8
M)(5NFCT]E#Y\T28*A<#=C[V>,4 >C:C\0=&TV^O[-H=1N)M.(^V"ULWE$"E0
M^YB!@+@_H?0U ?&WF^.M*TBT@FGTZ^TYKM;B.W9@Q+)L8-T";6.3V)%,TW3+
MR/4O'<CVLBK>S*;=BO\ K@+9%^7U^8$?6L;P_8ZCH^J>!I[G2[UHUT#^SIS'
M"6^SS$PG]Y_='RGGVH ]-HJGIE^VI6AG:RNK,B1T\JZ0*_RL1NP">#C(]C5R
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MWB,AEDWYP64@*<<C'88QSF+3/$VOZ]IOA;2_[1%I>ZB]Z+N_AA3>4MG*'8K
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MVUP"1[CBM=F5%+,0J@9))P * .4OO XN-;U+5K+7M5TVXU(1I="V:/:RH@0
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M0M N4MM2U!(9V3S/+5&D94Z;F"@[5]S@4 9=QX"AEN=4$.M:G:Z?JLK37EC
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M;':2K<NP=,C&>#R*Z^@#FI_ ^DW1U071GFCU*S@M)HV8 !8MVQE(&0V6SGU
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MO4Y7GGL(7C">:_)8,4+ 9^;;G&>V.*[>O/=6\2^+M*T6\\3W-KIUOIEK,?\
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M@MP[*RF$D@ .I 9>HZBK6BZ_I?B*TDNM)NUNH(Y#$TBJP&X 'C(&>"#D<<T
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M%N7B:,E0^UADKD @YYKV"B@#QY;*TO-(\1ZI/)XBU*VN+NS)U&.W2&3=$?\
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M]37<56EDBNTN[."\"7"IL<Q,I>$L/E..<'N,B@#F/A\"]OXBNE_X][G7;N2
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M(/45+0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M^:)!M8@]1YA.<<XZ"@##T#Q)JVJ:;X>T?1UT_3;F]2\N9YEM<QPQ13E/DC!
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M<\5Q_B2*TT7QU87%KIRE5T#4-]O;+L:94\HJ@V_B!Z9KCDU&&X'@40ZCX?\
M+74[5HM/TJ E[5""/WDI<D=0I! W$^U 'KGAW7)-;;5Q) L7V#4I;)=K9WA
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M.X4 =]';00R/)%#&CN<NRH 6^I[U(J*F=JA<G)P,9->;/\39[?1-<?RM-O\
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M;MV5/.<8&?:IT\9:EJ/A;0]6T^SL;5=1B,EQ<ZA<[(+7 Z'&&8DY QCIDXH
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MH&3DX'4TM8VA7>N3/>6VN6%O#+ Z^5<VKDQ7"D9RH;YE(/!!_ FMF@ HHHH
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M:23!VR"%@2!]<<5V=% 'GLG@?6K&34[71Y]&%E?W$EPEQ=VI>XM#(<N$_A<
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M-$J[05)R5^7'7)'O4FK^%?%'B72=5M]6U2RA:YM!;06MH',"G>&,CEN2W&
M.!GKFN\HH P]2T.6^\5:#JZ3(L>FK<!T(.7\Q%48^F*S_$?A>[O?$%IK^EFP
M>\AMVM);?4(RT4L18,.1RK!NAP>I%=910!Q"^#=3FL+ 7E]9FZAUF+4I%@@\
MN)$3/[I .3]6Y/-4AX$UJPBO-,TFXT9-.N+B26*ZN+0O=6JR,695'W7P2=I.
M,9[XKT2B@#D+KP[K>FZ_<ZMX<N; M>VT4%U#?JVW=$"$D4IWPV"N #@<BHK7
MPGK5CKVCZFNK17TD-C)97\EVK;Y0\@D+)@\$$8 / %=I10!Q,7@:X7X>Z1H
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M61@K*7ZE=IQMZ 8IFI6WARZ\"^-;_7_LO_"1)<WBM+,P%Q$X+"!$)^8*5V
M<$$]>:]B&F:>+2WM18VWV:V96@A\E=D17E2HQA2.V.E<3KG@;6-9N=0AEN=%
MDM[TN@OYK &]MX'X:)&'!P"0&/.#SF@#I8+:&\\#PV]Q"DT,FGJKQR*&5AY8
MX(/6O+M$T;1]1T3X761M;9[6=II+J., +)(+5B=^.I)49SU'!KVF"!+:VB@C
M&(XD"*/0 8%4K30-'L#&;/2;&W,<K3(8K=%V.PVLPP."1P3W'% 'DOB*%M#M
M/'FG:,D=EIZW>G&2*(F.*&.4*)B-OW5('S8'3-;7A_3'TOX@:4(/^$<TX364
MOFV>CM(?M,0 VNPV!1M;&&)!.X@9KTG[!9^9<R?9(-]T MPWEC,P P Y_BP.
M.>U5=+\/Z-HC2MI6DV5BTO\ K#;0+&6^N!S0!ROQ"T]-2U7P_"EQI;WB/.\&
MG:M$S6UW\J@Y(& Z@Y7.?O'BN3AO=-N=(L?#Z>'(1<_VY-"NG/J&=/,R1^8Q
M+[3F,;LB,+][C'%>N:GI&FZS:_9M4L+:]@SN$=Q$LB@^N".M5Y?#6A3Z2FE2
MZ-8/I\9W):M;H8U/J%Q@'D\^] 'C<R_9=)^*-DD>F6ZQ6%L[6VE$_9XI"LF[
M&0/FP%S@#D5T]WX-\/V_C_PO9QZ7;BWN=/NFNHRN5NBGE%3*/^6A!8G+9YYK
MOX_#VB0V\EO%H^GI!)$('C6V0*\8)(0C'*Y)..G)JXUG;/<PW+6\+3PJR12E
M 616QD*>H!P,XZX% 'B-Y'+;Z*FCVRVJ:./%]S;/!=.R6PC +1Q/MSB,OVZ9
MP*[#P58RZ;XWU:W1]%M8C9Q//INDF0QQR;B%D.5"JS+D$#D[0<=Z[A])TV6U
MN+633[5K>Y<R3Q-"I25CU9AC#$XZFFZ7HVF:);M;Z5I]K90L=S);Q+&"?4X'
M)H \_P#'<]]:^+-0GTTN+V/PE>-$4^\")H^1[CJ*QM&TP65YX/O+)O#%@TTZ
M".>PDE>XOHRA,B/A/FR/F);@$#D5[";2V-X+PV\1NEC,0FV#>$)!*[NN,@''
MM5&Q\-Z%IE])?6&C6%K=R9WSPVR(YSUY SS0!XMJ=MX<E^#MYJ6I?91XI>X<
M7,SL!=?:?.PT9_BQMXV]-O..]=7X@CLM8\8>(%&C:-=-I\$,=W=Z[<$QP*4+
MCRHPI(&#DME<GZ5=O_A_JNK336VH7&BRVTTP,VHK8!;^2$.&$18?+T 7=Z#I
MFNRO/#FB:CJ$6H7ND6%S>18V3S6Z.ZXZ88C/% 'F?@&9[BZ^'TDDC2-_8EZN
MYCDX$D0 _  "MKXG"YGU7PK8[;)]/N+N7SHM0=EMI95CS$DA .<G<0#P2!7<
MP:5IUJT+6^GVL+0*ZQ&.%5,8<Y8+@< GDXZFI+ZPL]3M'M+^T@NK9_OQ3QAU
M;Z@\4 >):WI,</ACQU;3+HAB@BMYQI^G*[Q6=QR-Z[E"JS*>0O/'.,\]7-X=
MTFR^*<']GZ+I\<L.@2SP*EL@ F65 C# X(Z ^AKN;?P_HUII;Z9;Z38Q6#_?
MMDMU$;?5<8/0=:M_9+8W@O/L\7VH1F(3;!O"$Y*[NN,@''M0!X-I5C/)X-TC
M6/-\.6FHR743_P!J-),U^UR9!N1]J$LQ.5*<C!]!FNKBT_PWJEQXXN_%R6[W
M5K>R(99\>;;6JQJ8C%GE,Y)!7JWK7H">&M"CU8ZLFC6"ZB3N-T+9!+GUW8SG
MWIU]X=T34[V*]O\ 2+&ZNH<>7-/;H[KCD8)&: .*\)V>C_\ "S=9NH8(O/?3
M+&6WEGC G;>LF]CD [B N[]:L^-OL^H>*]&T@:3::G>^1-<QQ:E<>7:(H*J6
M9=K>8_/ QP,FNS?2]/DU./4GL;9K^)#''<F)3*JGJ V,@<GCWJ+5-"TG7(XT
MU;3+.^6([D%S"LFT^V1Q0!XUIMM;WOAK5=-_M#2+5(_%(%M;^6\FGS.(E/D$
M#I&6W'L,CIVKN/A[)#;:MK^DG1K33+VW>&6X33KCS+1RZD HN!Y9PO*XST-=
M8V@:,]I/:-I-B;:XV^=%]G39)M "[AC!P  ,],"I-,TC3=%M?LVEV%M90$[C
M';Q+&I/J0!UH XF6QTC6/B?KEOXE@M;E+>QMSIT%Z R")@_FNJMQG< "W48%
M<IIEA:Z[)X/TZ\#7>C?VOJ<=HLK%A+:HKF($_P 2_* ,]0!VKU[5-!T?7%C&
MJZ797PB.8_M,"R;?ID<5.-/L@ULPM+?=:@BW/EC,((VG9Q\O''':@#R#Q#!!
MI^J^)K*-!;:,MWHUO>K&=JQV>"K#(Z+C /L35ZZL_#EC\19(O#Z6<6?#EXT\
M-GM$:_-'M;:O 8@'/<@#VKT'6]&DO=/O!I<EM9:A<["]P]LL@F"_P2@_>4KE
M>N0#Q6)X=\%RV.MOJFHP:/ !:-:0V6EVOEP!78,[-G[S-M4= ,#O0!R7A31-
M-US7?#46J6<-Y!%X-LW6&=0\>[<1N*G@D G&>F34-L]HGA73M ?3Q?JWB*\M
MK&SN+GRK;;%)(564X;* =$P<D"O7;?3;"TDCDMK*VA>.$6Z-'$JE8AT0$#A1
MV'2H+GP_HU[8O8W.E6,UI)*9GA>W4HTA.2Y&,;B23GKS0!XGJ"?9+'XCV*1:
M7;*EG9/);:43Y$<A=@< @?-C;G ':O8O&"P-X-UA+F^DL(&M)%>[C1F,(*D%
ML+R<>U6(_#FAQ6[6\>C:>D+1"%HUM4"M&#N"D8Y ))QZG-:3HLB,CJ&5A@J1
MD$>E 'D&DPQ:'K,-E<:-HL5Q>:3<K;W^A3%8IHT0,3+%CZ8;)Y..]1^&+?2M
M0O/"]KXECM9;!/"UO)80WNTPM*>)2 W!<+L]P#7J&G^&M"TEIFT[1M/M&G&V
M4P6R)O'H<#D>U8WB'PQ>WDEFNF1:)+IUO#Y0TS4K(/ A!^5X]HRI XQTQZ4
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MYZ@9SQ7;PZ'I-OI3:7#I=G'I[ AK58%$39ZY7&#4=EX<T33K">QLM(L+>TN
M1-!%;HJ2@C!# ##<<<T :,<B2QK)&ZNC@,K*<@@]"#3J;'''#$D42*D:*%5%
M& H'0 =A3J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ***\S\;W>I:K\2?#OA&#5[S2K"ZMY;J>:RD\N64KNP@;MC;^OT
MH [?3/$>FZOJVJ:99S,]UI;HETI0@*6!(P3P>AZ5JUY-\*+>2R\<_$"WGOGO
M7ANK=#<RXWO@2 ;L<;L<$^H->LT %%%% !1110 5R^H^/]%TW6+O2I(]2GN[
M38)UM;"68)N4,N2BD<@BNHKS*S7Q,WQ+\:_V!+I*)YMGYOV^*1R3]G7&W8P]
M^M '=Z+K=MKUDUU:Q7<4:R&,K=6SP-D '[K@''/6M*N(\42:]I_@:;5;_5;2
MTU339/M2M:>8EO.%/$+JQ)8/G;]2,5S\?B#5[KP-)K8U.6#4-:U6&R:,$E=*
M1I1$4"L.'49R2!ECGH!0!ZO17FOBDWG@+0]6O=,\1W=S*UFHBLK^?[1*LAE1
M#.C.V0 'Y7&W..E-T-M>T[Q5I,<=IXC2RN?,COO[:OH90^$)5XP)&(8,.0HQ
M@].* /3*K6^H6EU=W5K!.DD]HRK.B]8RR[@#[X(/XUY)9R:M9?"VV\:GQ%JE
MSJD3K)Y<ER6@D3SMGE&/H<CC=][=W[5U'@S34M_'WC:<7-VY%Y$NR2=F3YH8
MVS@\9'0'L..E '>45P7B^[%QXGM]-2YU^Y9+3S6TW13Y+ EL"62;>N!P0%SV
M)YKF[*^\3:GX2LXTEU&Z^RZO=V]U;17Z17TT,98*HE! 8J<;MI^;'6@#V&BN
M2\ ZC'=Z=?6PO-5EEM;HJ]OJT>VYM05#"-CD[QSD-DY!Z\5S_B2YDU'Q%J\%
MK=>)KY[1$18M(E%K!9/LW'?(SJ)&.0W.<# Q0!Z;17D^EWVK>*9? \%SK-];
MQWVBS3WIM)?*:=E,0!R/NG)ZC!ZCO5";^V+7P5K^M'Q)K$EUH6J2VUF&N/E,
M4<P4"4?\M202"6SVH ]GHKRW5]0U76/'.NZ>+;Q'-9Z8L$4":-=16^UGC#EW
M+2*6/( '*X4\4R"Y\0ZU<>"=.U34KRPENH+\7_V2=5:<1% A+(2 Q&"2IXRP
M&* /5:H_VM9G73HWF'[:+8713:<>66VYSTZCI7F3ZEJUDMYX:CUB^,3>)(=-
M2^EDW7$4$D(E*ASSNSE0QR1N^E&J"X\%>+-?O;2^N[Y[;PPT]NM[*9GB(E/!
M8\E<\\D]^U 'K=4=7U:ST/2YM2OY#':PXWLJEB,D*.![D5YKH\WB*SU'0+J*
MW\1M]IG2/4)-4O8'MYT=3ED02G:P.&4(!P".:R]7MKS7OA)<^*[O6]0%W=2"
M1[;S_P#1E3[0%$0CZ#  Y^]N'7M0![9167XEODTWPSJ5X]^-/6*W=OM9B\SR
M3CAMG\1!Z#N:\ZTJ]U&P\:^&8XAXGBM=0::&Y.M7*LMQB%G#+%O8H05!Z*.<
M4 >LTR:5(())I#A(U+,<=@,FO')7U=?A[JGBW_A(M6_M"QOK@VT?VD^2$2Y*
M[&3HX(SUR0, <"MZ2VO/%5UXNN9M;U"Q_LRX>SLX+>?RXXPL*L7=>C[BY^]D
M8&!0!V0\2::VA6.L)([6E\81;D(=SF5E5..O5A].:UJ\R\-M]NT?X>:: 72V
MTU=3F4?[$2QQC\6ER/\ <K-^TZJ?AB?B!_PD&H#5O+^V^1YY^R[=_P#J/*^[
MC'RY^]GG- 'K]%<!I%M>ZU\1?$$USK&IQ6FF7%J;:RBG*19:!&8./XAGMTY/
MK5SQJ;V?Q!X5TRUU*[L8KZZG2X:V?:SHL+-C/_ >O4=1S0!V=%>0RV&I"P\;
MH/$VN!/#Y=]/Q=G<I\A9?WC=9!DXPQ(QFMJ*XO?%OB:STRZU.]L[2+1+>_=+
M&8P//+*2"2R\[5V] 1R>: /1*Q[KQ/IEG+JD4CRM)ID<4MRD<+.563.W  ^;
M[IZ5Y[:ZMJ]_J-IX1FUB\$"ZW=64FH1OLGEAAA$JH7'1B6VEA@D(?>J>J1W?
MAD_$@V>K7LDT-EI[P7$LQ::($R?*7ZG'/)YP10!Z/J'C'2]/U>;3'2]FN+>W
M-S<&WM7E6%-K,-[ 8!(4X'4_C6W!,EQ;QSQYV2('7<,'!&>1VKRF]LWT_P 0
M?$O4K;4-02XMM+2:(BY; 9H93TS_  D?+_=[4V75M7UKQ!_9S0^(;FUL=,M)
M-FD74<#/+*A8R2,SHS=, #(R#F@#URJ-GJUG?:AJ%C;R%I["18[A2I&UF0.,
M'OP1TKSC3K[Q!K5QX=\.ZQ>7MB)/MLEQ-#.B3W"0LJQJSQDA6P^6VG.5K:\!
MV3Z=XG\9VCWLUX8[V#$T[;G(^SH0&/<@8&>IQSS0!UL.K6<^LW.DQR$WEM%'
M-*FTX"N6"G/0_=-7J\ZGT/\ MOXKZVCZI?V<4>F6A*65P86D8M+@EEYPN#QT
M.1G.*I:7K^K06GA_5KW4)I[6VU2YT:^D+82=#(T<4[#ID,J G_:- 'J59%]X
MFTC3[+4+N:[!BT^18KK8I8QNVW ('?YU_.L[P1=W>KZ?>ZY<3RO#J-Y))9QL
MQVQVZ_)'@=MP7?[[J\XUK3/L_ASXE2Q7=VTG]IPQJ)9F=1G[.V[:>"03C/H
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MJ$X..H.,$=Q7)0Z!]K\;:!IZZIJ4,*>''>22*Y832 S(=ID^\!DCH0<*!TH
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MJV.>O##FKU<-\.+1[&Y\6VLEY+=M'K3+Y\I!=AY$.-Q'4@8!/?%=S0 4444
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MNHK#=KFTF-C)LN6Q]R,X^9NV!U/2@#<TCPUIVB21O9)(#'9PV,8=RVR*/<5
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M?)D^Q"Y^U;?,.?,\WSLYZ_?YQ^%5]5\$:3JVH7%Z[WUK-=(([O['=O"MRH&
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M(,\!OF^7IDY-6=/\::9?SW%L\-]974-N;DV][;-"[Q#JZ@_>'TY'>J5M\2=
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M"R%AR!D>AYZ5SNM_$BWEBTP:*;U%N]5MK:.\DLV$%RAE"R!'88/&>>.A(Z4
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MR+)&Z]&4C((_ T >5,^K3>$_#/AD^&=22]TR]L$NI3!^X1(9$!D1^C @9XZ
MG.,5W7C9]73PA?MH<)EU !=BJBNVW>-Y56X+!=Q /<"N@I&8*I9B H&23VH
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M@X(..G%<Y>Z-J^J:;K^K+I=S =4UFPF@LW3]Z(H7B4R,H^Z2%9L=0!S7JU%
M#9%+1LHZD$5Y5X1T[4\> (KC2+ZV;1EN[:[,\)4(WD@!@>A4DX![\UZE#<07
M'F>1-'+Y;F-]C [6'53CH1Z5+0!Y3XE\,:OJ5UXMEMK2Y/\ Q,]/O8%C;RVN
M4BB3>(V/&X8.#Z@5H>&M.%WXQMM0CLO$K16=M(OVO6YV38S[08TC89;(&2>
M,#K7H4\T=M!)/,X2*-2[L>BJ!DFFVEW!?V4%Y:RK+;SQK)%(O1E(R"/J* ./
M\>K=PZIX6U*WTV]OXK&_>6=+.+S'"F)USCZD51\4SWOCCPC?V-AHFM6=S;R0
M7*QWD(MS.$D#%$;)^;"G'OBO1*B:X@2Y2W::,3R*62,L-S*,9('4@9'YB@#S
M&QL+J\UN._TW3?$DUQ8V5RT,VOSLB),Z;5C5&'SY/4@@# Y-92V.L:C_ ,(O
M+);>*KJ]MM2M)M0%['Y-M;@-\^R-0 P!/! 8!0>:]?T_4+35+&.]L9TGMI<[
M)$Z-@D']0:LT >0ZI9:M::GJ,GA[3O$.EZY)?,Z0P$S:9=9<?O7+#8NY>6QM
M(/K3[S1[O1_$/B-KJW\4RK?W1N[1M&D;RI@R*-CX^XP*XRV!C'I7K=% &/X4
MTTZ/X4TS3S;&U:"W53 9O-,1Z[=^!NQG&<5YS:V6KV&IVZZ!IWB'2;\Z@#<Z
M>Y,VE^69,R.KL, %<D;2#DXQ7KU% 'G<>CZ@/ _Q"M?L4PN+ZZU%[:/9\TP>
M/"%1WR>!52^768M5L;:]3Q!!I::7 L/]BP O), 0Z2N 63'&.5'7FO3Z;)(D
M4;22.J1H"S,QP% ZDF@#R?PGH6KVLOA,76F7D!M-6U*2X$Q+F-72386?G=G<
M!NR<FNR^'5C=:;X$TVTO;>2WN(_-WQR+AES*Y&1]"#72Q2QS1)+$ZO&ZAE=3
MD,#R"#Z4^@#SN'PUJ-_X-\<Z6(6MKG4M1O6MS(-HD# ;3G^Z<8S67I&ER7^I
MZ!"^F>+&ELYTGN!J=RR6UHR*>5)!$AR< +U!.2*]$U?Q%I&@O:IJ=]';O=.4
M@0@LTA'7  )XR,GMFM2@#RV70=3/PJU#3QI\YNY-9:80^7\S)]N#[L>FSGZ5
MNZQ9:L/'=YJ.G6?FL/#DL-N\B_NVN/-W*A/3GC\*[6B@#QE+'5]0F\*S/;^*
MKJZMM2MIK\WT?DV]OC(;9$ H(!/! ("@\UJV.A:FFHZ6\FGSA(_%M_=N2APL
M+";9(?\ 9.5P?<5ZC10!R^D6-U#\1/$UY);R);7%M9+%*5^5RHDW 'OC(_.L
MCQ9I.H7?B759[>SFEBD\*W=JCHN0TK."J#_:/I7?T4 <)>:5?-IOP_CCLY2U
MC=P-<J$_U*BVD4EO0 D#\:T_B+8W6I> M4M+*WDN+B14"11KEFQ(I.!] :ZB
MLW6M?TKP[:)=:M>QVL+N(T+9)9CV  ))X/2@#F=3FN]!^(\NKMI&HWUE>:7'
M;(]C!YI65)7;:P!^4$.,$\>]8?A?1=8AN/!TMYID]N]OJ&JRW*LN1")/,V9/
M3!R,'OFO0(O$>CS+&T=_$1)=FR3KS. 3Y?UP#^5:E '+_#FQNM-\ :39WMO)
M;W,2.'BD7#+\['D?0UR]SX?U=]%UN6&PEDG@\5#5(K9OE-U$C1MA<\'(!QZD
M5Z7%<03M*L,T<C0OY<@1@2C8!P?0X(./<5'-J%I;WUK933HES=;_ "(SUDVC
M+8^@- '!W_V[Q;XCM-0M='U&SM--T^\5GO8#"\TDR*JQJIY.-I)/3I4?]D:E
M8^"_ =XFFSSRZ)Y$EW8HO[W!@,;$*>K*6SCKUKTFD9E12S$*H&22< "@#S3Q
M3'K'C+2+J:RT.\M;>SNK6XA$@^SW=WY;EI H/*X!&TGJ14_AG3A=>,;?48[+
MQ*T5I:R+]KUN=EVLY7,:1L,MTR6X P.M>A0S17,$<\$B2PR*'21&RK*1D$$=
M013Z .,\=2:LEYHPM1J2:69)?MT^EP"6Y3Y1Y8488A2<Y*C/ Z9KBI- U:XT
M+QW''I>L,+\V36@OR99YU4@,2<GG@G;V&!@=*]HHH XWQ5H]WJGC#0C!'((!
M8:C!+<*N5B:1(@N3VS@X^E<NSZM-X4\+^&CX9U)+W3+VP6[E,'[A$AD0&1'Z
M."!GCH"<XQ7K5% '-?$'1;OQ#X%U33+ ;KJ5$:--VW>4=7VY[9VXS[URVB:>
M=0\6:/<KI_BMA9>9-+-K-PR);,4*[44C]X3N(.#C'.>U>DRW$$,D4<LT:/,Q
M2)68 NV"< =S@$_0&H[/4+34!.;2=)A!,\$NW^&13AE/N#0!YQ8Z'JD?@/PE
M:/87"W%MKR3SQE#NCC%Q(Q8CL,$'/O5:^TB[T?Q1XAEN8?%,D>H7 NK1]%D;
MRY,HJE'"_=8%<9;C!'I7K-% 'F.EZ7>>#=1T+4VT2]>R71C82V]H3=RVDGF^
M: < %E.2,@<%1VYJ>]GU>?4O#'B"X\.W4,%OJ5TS6UM%OF2*2)DCDD0'AB3E
MO3//->CT4 9VF:O'J=SJ4"6]Q"]A<_9I/.4#>=BN&7!.5(<=<5S&JS7>A?$A
MM8;2=1O;&[TF.T5[&#S2DJ2NV& Z AQ@GBNTBMX8#(88DC,CF1]B@;F/4GU/
M YJ2@#RKPWHFL1S^$);S2YX'M]5U.>Y1ESY(D$NTDCC!W#![YJUK=IXAM-0\
M:WFE64Y>YFL/+DCA#NT:H!*T2MPSJ,X'K7H4VH6EO?6UE+.B7-T',$1ZN$ +
M8^F1^=6: /)[#3;Z;QK;7T%MXDN++^R[N W6K[MQD;80H0@;!QUVC<?7%3:+
MIVI:5-X!DN-+OBD>COI]P8HBQMI7\K!D'\(^5LGMBO2;#4+35+075E.D\#,R
MATZ$JQ5A^!!'X59H \.LO"]Y!X8A\+7FF^*KF^1Q;O"ETT>GNF_/F"3!4+CY
ML8W9XQ7:V_A^^O(_B%:&)[=M5E:.VFD! <-:H@8'N V?R-=Y10!X]I&C3W(\
M/:=/I?BMKJSN('N8[VZ9+.V,6#O1L%7 (^55Z@]JEOHM6TKP)XD\(CP]J5[>
MSO>&VG@@WPSQRNSAR_0, V-IYR!C.:]<HH HJMS%H06"-3=+;8C23@%PO /M
MFO(7LM<U/3]!>XM?%-SJ=OJ%I/?QW$?DVMN%D4OY:* K@=L;L#G(KUC2?$6D
M:[+=QZ7?1W36C[)C&#M5LD8SC!Z'IGI5Y[NWCG\AYXQ-Y9E\LL-VP'!;'7&2
M.: .,L=*O8XO'V^TE4WMS(UOE?\ 7*;9%&WU&X$?6LG0(=1\(WFFZC>:/J-U
M;W6@65HXM8#+);30J<HR#D [NO3(YQ7H]C?6VI6,%[93+-;3H'BD3HRGH126
M>H6FH?:/LDZ2_9YF@EV_P2+C*GW&10!S?P[MKVV\.7/V^PDL)YM2NY_L\@&4
M5YF8=.",'J.*ZVBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M!R#WKC[[X?P7SW\']M:G#I6H3&:[TY&C,<C,<L Q4NJL1R PZG&*Z]55$"*
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MW>4#<A2V.!1=?#RUG^V6L6KZG;:1?2M-=:9"Z"*1F.7 8KO56.<JK ')Z9H
MS(=1USQ5XKDL[/6Y]*TXZ/:7P6"&-I \A?C<ZGC@9X[#&.<X"SZOXED\ 7EW
MK,\%VU]>6[O;PQ %XEF7S &4X9@F".G)P >:].M- M++7[C5X2ZRSVL5H8AC
MRU2,L5P,9S\Y[]A6?8^"=/L%T=8[BZ8:5=7%U#N9?F:;?N#<=!YAQC'0=: .
M.T[4;K3Y]MM($%UXYGMYLHK;D*.2.1QRHY'-:>@R^*/$FCP^*+;Q +<SW+-%
MILD*?9A LI78S;2^\J"=P/4XQBMY?!.GK)&XN+K,>LMK(^9?]<RLI7I]SYC[
M^]4W^'EDQ>U&J:@NB27'VE])#)Y!??O(SMWA"W.T-C/Y4 4_AW97-OJOB^27
M4KBY0:U+'Y<B1@%O+B._Y5!S@@>F .,Y-+XUM+V]\=>#H+&^:QE;[;NN$16=
M5\M<[0P(W'ID@XSG%=%I7AR+2-;U34;>]NC'J,GG2VCE3$LN%!=>-V2%'<BH
MO$/A6'Q!?:;??VA>V-YIQD:VFM64%6< $D,I!&!C!X.30!Q6J>,-<\-VVN:,
MUV]_?6M[9VUI?-;!Y-ESG!:-  [KM;  &[Y>*C?4]=FBU/3!=>(KC3KC2YW:
M]U'2A;O;2H,X#>6JE7&X8()&.#77+X"TR31[^RO;F\N[B_F6XN+^20+.94QL
M92H 7;M&T 8'XFGV7@U$NYKO5-7U#5KB2U:T1KDHHBB;[P5451N/&6.3Q0!S
MFA7VH>'O#?P_FFU*272[N!+>Z$J(-AD@#0X(48"E=OONYR:S=)\;^(-0TJYL
MY;GR]4U'4K4Z:XC7,5I<?..,8.V..7DYZ5V$G@*SN? O_")W>I7]Q:*$6&X9
MD$T*H5*!2% XV@9QFK(\%:2OB?3->02K<Z=9_8X(P1LV8(!(QG(#,!S_ !&@
M#@Y_%_B#4WUF_L+G78I;2ZF@L+.ST<SVL@B8KB5]A)+$'.&&W-7=1\7ZKJGB
M$Z>&UW2H;:PM[B:/3--^TS>=,I;:Y*,$50,8P"3GGBNCO/ $$\VH+:ZUJEA8
M:E(TM[8VSH(Y&;[Y!*EDW=]I&?:K-_X-AFU"/4-*U.]T>[6W6U=[38PEB7[J
MLKJP)7)P>HS0!RL?B#Q7J4/A:Q>XGTJ\OKRZM;F:6R"/+'&C,L@C<?*6 !]
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M[#6M3TM=1Q]MAM&CVS$#;N&Y248@ $J1G'KS3M9\!:)K/AFQ\/R1RP6%DR&
M0-A@%!4KDYR&4L#Z@F@#G],UKQ%)=^$#>3*UQJUO?W;P/&@"C:KPQY R-H8
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M.DM/B/<-)%*?*\/V< FE&22'DW L."> 3BN6T<-H\/@N]O+>XBM;;5M421A
M[>7YC3+'D $@$D8/3F@#V(D 9)P*YVS\=^&;_48;"VU6.2>=RD)V.(Y6'9)"
M-K'CL36OJCRQZ1>R06HNIE@<I;GI*P4X3\3Q^->,B]NM2MO".-1O+EH-4LI)
M].MM*%O;:> P!5CLW#:3M W=,G&* /3+SX@>%=/NI;:ZUB&.6&4Q2C8Y$3 X
M^<@849[G JWJ_BW0M"N(H-1U&.&:5/,5 K.=G]\A0=J_[1P/>N,BL)/^$'^)
M:FU?S;B[U%D'EG=)^Y 4CU]J31[^+PIXBNKO6X;E8=2TNQ%I.ML\H)CC*O#\
MH)#9.<=\T ==X)UV?Q)X4M=5N?)\R:29<PC"%5E=%(Y/915.\\;06_C>;PT%
M7S$T\W(<JYS+G(3IC&T9SGOCK4?PNB>#X?6$;VLEH?-N2()%VM&#/(0"/H15
M/6)A9_%#?-',([W07MH)%B9E:42LQ7<!@''/.* )O"/Q&T?7-,T>.[U&W75[
MV!"\2(PC,I7)16/R[O\ 9W9K8U/QKX=T?4&L;_5(H;A ID7:S"(-T,C $)G_
M &B*XB#3Y8_A9X"A2TD66&_TV1T$9W(?,!8D=NIR?<UF7"3Z-?\ BRRU/6=8
MLGOKZ>>&TM=-CG6^BD VA',;9./D(SQCM0![.K!U#*05(R"#P17/ZAXY\-:5
M>SV=YJB1W%N<3QB-V,7 ;+;0=JX8?,>.>M7/#5DVG>%]*LF$ZF"TBCVW!!D7
M"@88CC(Z'%<+9^)-)T+QGXZBU"UN'EGN8=GE6KR_:?\ 1D'E#:#\W/0_WOK0
M!V.K>-/#FAM"NHZK#"T\:RQ !G\Q"<!EV@Y'T[<]*;?>./#6FZB]A=ZM#%<1
MLJR95BD1;H'<#:A/HQ%<=X&T.^TKQ+X>AU&W<3VOA?RF9AD1N9U.S/3(''X5
M7BU"WT3PMXG\-:E87<NL7=S>F*!+5W^W><S&-U8 @@AE!)/R[><8H ].M]4L
MKN\O+2"X5[BS*BXCY!CW+N7/L1SFLBV\3V=[JD,EOJMBVER:=)>8965R%<*9
M-QPHC R.>>AZ5PVO:5KOA^RTA;"*66^U?2(="O'C!813@*$F8C^Z&FY]A6EJ
M^B0VGB4Z?%IEQ=Z;#X2GM!!#PTBB1!Y:MTW%1Q0!U6F^,M!UN:2VTW44DN!$
M9E1XW3<@_B7<!N7IRN:KP>,=,L?#FE7VL:K:O+?1!HWM(I")SC),<>"Y'X<=
MZXSP[?73Z]I]GI^I76N:<MI.LIU'3O+N--&SY5\[:N2Q 4KC/&>U0>%)/^$9
MD\+:QK-O<16#^'$LA/Y#N+>82;R' !*[E(Y(_AQ0!Z*_C'P['H]OJ[ZO;+I]
MQ(8HYRWREP&)4^APK<''3%+IWB_0-5L[V[M-2B,-B,W1D#1&$8SE@X! P"<X
MQQ7G*V,]]?6NJ)83QZ??^,8KNWBDA*GRUMV4S%2,J&=<\@=CWK9U^P6X\4>,
M!<:9=WMI/H5NKQ6PP\Q#RY"'H6 P<?2@#KM'\6Z'K]R]MIM\)9T3S3$\;QL4
MSC< X!*Y[C(K3O;VUTVRFO+VXCM[:%2\DLC;54>I-><^$=0NYO%]K!::I/K^
MFBTD\R[O=.\F>QY7:AEVKN+'JN,_+FN@^(MG<W?AF%X+:2[2TO[:[N+6)=S3
M0QRJSJ%_B.!G'?% %NV\<^';VUO)K74!(;2+SI8S$Z.$[,$90Q7/< BJ7PY\
M0:AXH\-C5[^[MI6G8%88+9HA;\9V$L3OX(^88%94VH0>*_'.DW^B1SRVNG65
MV+NZ:W>-3YBJ$BRP&YLC=CMBMWX<Q20?#GP_%-&\<B6,89'&"#CH0: $NO&5
MM;>/H?## !I+)I_,VL3YFY0J<#&-I8YSZ#BLWP?\2=(UO2=(34-1MH]7O4"M
M%&CB/S3_  !CE0W^SNS4FJ3+8_%G3I[A)EANM'EM(I%B9E,OG(P4D @< GG
MKF[73YHO@MX4@6TD6:.]L9&C$9#*?M*EB1U'4DF@#N]1\:^'-)U%K"^U2**X
M3;YHVLRQ;NGF, 53/^T16\"& (((/((KQ6>.?2)O%>G:GK&LVDE[?7$T5C:Z
M;'.+^.7[NQS&V21A"-WRX[5ZSX>LVT_PUI=FPF#06D41$Y!D&U0,,1P3ZXH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MH-N!P,*.N>:S/'&M:AH6A1W6GIC=<QQ3W'V=I_LL1SNE\M2"V,#CWSVKF_\
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M4X)PFX@XSQDGO70V8\8Z=<[]1N=,U*U>VD=S'$;;R)@ 54$LVY#R,GD8S[4
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M4?%Z:FT+W@U?$CPJ51_W$6& ).,C!QDXSUKN: "BBB@ HHHH **** "BBB@
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M*&X&&^Z23G)SS6G!X6GL[[5KVRU1H+J^L8+2.3R WD-$' ?!.&^_G!]*O?\
M"5>'_P"V?['_ +:L/[1W;/LWGKOW?W<9Z^W6DMM;CC35Y]1O-.AM;&Y,?FI/
MQ&FU3^])X5\MT]"/6@#4@22.WC267S9%0!Y-H7><<G Z9]*DK+L/$NAZK83W
MUAJUG<VMN"9Y8YE*Q #)+>G SS3++Q5X?U'4FTVRUJPN+T#<8(IU9\=^ >WZ
M4 4_&OA*+QGH/]F27;VA$HD6:-=Q7@JPQD=59E_&H_%O@JT\5Z9I]B\QM8[.
MX613&F=T84HT?7@,K$5H1>*O#\^L'2(M:L'U$,5-LLZE]PZKC/4>G6M621(8
MGEE=4C0%F9C@*!U)/84 96KZ$NK:EHUX;@Q?V9=&Y"!,^9F-DQG/'W\]^E9>
MJ^!K75[O79KB[E4:K%;(OEJ%:W> LR.K=SN(/3M[UHV7B_PWJ,5U+9ZYI\\=
MHADN&CN%(C0=6//"^_2LKP!XLNO&.G7.I2R:;]G,A6&"T=GEA +#$I)QN("D
M8 ZT 6]+T'6XM6BO]9\2/?B")HXK>WM_LT1+8R\BAFWMQQT YP*S=&\ S:7'
MHD$NLFY@T:\EGM5-L$;RW1U\MB&Y(WD[L>V*KZI\3;."V\5C3S:SW>A!2L9G
M#>=PNXX'("LVT^XKJ=-\3:'K%Y-9Z=J]E=W4(S)%#,KLHS@G /3/% &1JG@6
MVU:ZUZ:>\E0ZJMKL,2@-;209*.I[G)!Z=O>G6_AG6IKB2;6?$SW@^RR6\4-O
M;?9XAO&"[J'.]O3H!S@5IQ^*= EU@Z1'K-BVH@E3;"=2^X=1C/7VZU%XPUR7
MPWX1U/68(DFEM(3(L;D[6.1UQ0!<T'2QH?A[3=)$QF%E;1VXD*[=^Q0N<=LX
MJOXD\/IXATZ*#[3):7-M<)=6MS& QAE3[K8/!')!!Z@FM:-M\2.>"R@UE1>*
M= GUAM(BUFQ?45)4VRSJ7R.HQGJ/3K0!CIX,N[NXO[W6M9%]J%S82:?"\5J(
M8K>-_O%4W,2Q."26[8XKH](L!I6BV.G"3S1:6\< <C&[:H7..V<52U+Q;X=T
M:]6RU+6["TN6 /E33JK 'H2">!]:DU7Q-H>AB$ZKJUG9^<,Q>=,J[QZC/;WH
M ;KVA+KG]F9N##]AOXKT83=O*9^7J,9SUJAJW@NSUO5=3NKV9V@U#3%TZ2%5
MP5 =GWAO7+>G:M6^U_1],TZ/4;[4[2WLI<>7/),H1\C(VG/.1SQ5BPU"SU2S
MCO+"ZANK:0926%PZM]"* .:M?"&IRZEIEQKWB ZG#I;^;:PK:"'=)M*B20[C
MO8 G& HR<XJ_X9\.S^'6U*+^T?M-G<W4ES!"8 C0&1V=P6!^<9;C@8Q5G5_$
M^A:!)''JVKV5E)(,HD\RJQ'K@\X]Z6]\3:%IMK#=7NL6,%O-&98I))U"R)P-
MRG/(^9>GJ/6@ U_2KO5;.%;'59]-NH)EFCFC&Y21D;73(#H03D9'8]JX3Q9X
M0O+/P9XLOYKHZCJ^J0P(YM+7R5"QN-H5 6)/S$DDD_3%=O>^+?#NFS6\-[KF
MGV\EPH>)9+A5+J>C#GH>QZ5L@@@$'(/>@#E+3PC>2ZQ;:AK^M?VK]BBDBM(A
M:B%5WC:SO@G>Y7C/ Y/'-5;'P1JMC;VFE1^*KA="M)5:*WC@V7'EJ<K$TX;E
M!P.%!(XS4OAGX@Z1K%C9I?ZCI]IJMS++&MGYX#';*Z+@$YR0H..^>*VM4\3Z
M%HEQ%;ZIK%E9S2C*1SSJA(Z9P3T]^E &%=^"=0\[5(=*\0R:?INJS--=6XM@
M\BNX D,4FX;-V.X;!)(Q2ZAX AO8->A34'C35A:#F/>8A!MQR3\V=OM^-;VI
M^)-$T8*=2U:RM R"1?.F5=RD@9&3R,D4R\\5>'].U"*PO-:L+>[EP4ADN%5C
MGIP3W[>M &=J_@FTUO4=7N+RXD,.I:?%9-$BX,>QW<.&]<L#T_AJK)X*U+5$
MEC\0>));Z+['-:1);6XM@!*NUI'PS;WQTZ <\5/?>.+#2/%MYI6KW=G8VD-G
M#/'//+L+N[2 KSUP$SQ[UOIJNG2/9HE];,UZI>U"R@^>H&24_O  @\4 <E%X
M$U20:$E_XC2:#1;B*:VA@L!"K[ 5^?YSEMI(!& ,G@U;M/ R6K::1J#-]BU:
MXU,?NL;S+YGR=>,>9U[XZ5T\=[:S7<]I%<1/<6X4S1*P+1ALE=P[9P<?2L[5
M?%?A_0[E+;5=9L;.=QN6.>=5;'K@G@>] '*:/IMMK?Q7U#Q':1W*V5I;K"3-
M"T:R7G*,ZA@"=L8"D]/FXKT.LN_\1Z)I422W^K65LCQ><C2SJH9,@;ASR,LO
M3U%0+XQ\---9Q+KVG&2] -LHN5)ER<#'/<@CZC% '.S_  \OFL-:TFW\1?9]
M(U6:::6-;)3.&ER67S2V"N3W7..,]ZW=-\,?V?KT.JF\,KQZ5%II3R]H.QBV
M_.3C.>GZU;U7Q/H6ASQ0:KJ]E92RC*)/.J$CIG!/3WZ5)J.OZ/I$:2:CJ=I:
MHZ&1&FF50RC )&3R/F7\QZT 847@9(O"6G:#_:#%;*_2]$WE<N5G,VW&>.N,
MY]Z9<>#=4ANM4_L/Q&VF6>IRM/<0FT$KQR, '>)]PV%L9Y#8/(K>C\1Z++HK
M:S'JUDVF*/FNQ,OECG'+9P#GC%96C^,;37?%5UIVG3VMU816$5TMS!)NRS2.
MI4XX&-@]^: +=IX:2T\26VKK>32^1I@TX),2[N X;>SDY)XYXYZUD-X!:(?:
M;'5FMM3BU.YU&VN3 '5///SQ,F?F4CCJ#P#Q6]IOBC0=8O9;/3=9L;NYB!+Q
M0SJ[ #J< \BL;Q-X_P!)T>UN8K'4-/NM5@FAC:S\\%AOE1&R <Y 8G';O0!!
M'\/C<V_B%-9UB6^FUL0^;+'"(?):+.PQC)Q@[2 <_=Y)S5RU\+ZM/=I)X@\1
MOJ5M'!) +6"V^S1RAQM9I0&.\XZ= #R!70ZA?6^F:?<7UU*D4$$9D=W8* !Z
MD]*P=(\=Z'J'A"T\176H6=E;SJHD$EPI$4A&3&3QEAGIU]J ,N/P!J?EZ/97
M'B>2;2]'NH;BTMS9J)&$1^5))-WS8' ( ]3FN[JKIVI6.KV27FG7<%W;/]V6
M!PZGUY%8%QXXT^+QA=^&EEMS>06/VD9F&YG^8^7MZY"KN/L10!4G\%ZNFIZU
M=:7XG:RBUB4/<1&S60Q@1JF8VW#:V%/)!'3CCG*\=:+9CPII'@S28[M+[S(4
MT]XHF80JI"O([XVC$9?.3DYK>\+>.]'\06&EI)J6GQZO>6J3/8I."ZLRABH&
M<\>G7%:EWXIT"PU1-,N]9L8+Y\!;>2=5?)Z<$\9[>M &A9VD.GV-O9VR!(+>
M-8HU'\*J, ?D*Q_$WAV?7'TRXL]1^P7FG77VB&4P"53E&1E*DCJ&/.:WZR+3
MQ3H%]JKZ7::S8SWZ$AK>.=6?(ZC /.._I0!GKX/1?#_B32OMIQK<UU*9/+_U
M/G+MQC/S8_#-0GP1^\U"2/5[JWDN].MK%9;<>6\1A+$.&SW+<CT&.<UNG7M(
M6QN+UM3M!:VTIAGF,R[8W! *L<\') P?6LO2?&NEZMXGUK1(;BW$NF;<D3@F
M3C+G'8(2%/OZ4 0Z7X4OH_$D6O:UJ\6H7EO;-;0>19"W 5B"Q;YF+'Y1W '.
M!S755E:7XGT+7+B6WTK6+*]FB&72"=7('3. >GOTJ%?&/AIK^"Q77M.-U.=L
M40N5W,<D8 SUR",4 .\,Z OAO2I+%;@W >YFN-Y3;CS)"^,9/3.*S/$'@A-=
MN=;F:_:'^U-,33R!%N\L*SMOZC/W^G'3K5G1O&6FZWXGUG0[>: SZ:RKA9@S
M2<#>0O8*Q"GWK1U/Q!H^B_\ (4U2TLSL\S$\RH2N0,@'KR0/QH J:SHFI7DE
MC<:5K4FGW-H&0J\7G03*P (>/<N2, @@@CGUK#/P[9=!DM8M7\O4Y-575S>+
M:KL$ZD8Q%G 7"@8SGOFNI37M(DT;^V$U.T.F[=WVOSE\H#./O9QUX^M&EZ[I
M.MVKW6EZE:WD$9P[PRA@A]#CI^- %V)76%%E</(% 9PNT,>YQVK'T?P\NEZK
MK.I2W'VFZU2X61F*;?+C50J1CDY &>>Y)XJ72_$^@ZW=2VVEZQ8WD\0R\<$Z
MN0,XS@'IGO267BG0-2U*33;+6;&XO8\[H(IU9^.O /.._I0!AW7@!)]8O+R'
M46AM[K4;34FMA#D++"1N(.?XP!GCMFMR#0EA\6WFO?:"6N;.*U\G9PNQG;=G
M/.=_3':@^*O#ZZS_ &0=:L!J.[9]F\]=^[^[C/7VZT77BKP_9:JNEW6M6$-^
MQ %O).H?)Z#&>">P[T 8$'P_>QT708-/UAK?4]%$BV]Z;<.KK)]]'CW<J>/X
M@00"#4TO@N]O]-GAU3Q!/=W<][;W;2>5MBC$+JP2.+<0@.WDY)).3FMK5_%&
M@Z#+'%JVKV5E)(-R)/,JL1ZX/./>EOO$VA:9;17-[K%C;P31^;%)).H61,@;
ME.>1\R\CU% %'6?!]IKNL2WE[*S03:7-ILEN%QE9&5BP;/!&WTK.M_!>KOJ>
MBW6J>)VO8M'E+P1"S6,R QLF9&W'<V&'( '7CGCJ+75M.O;::YM;ZWF@@8K+
M)'(&5"!D@D=, @_C4-_KEA8>'IM<:XB>QC@\]91( KKC*X;ISQCZB@##E\#)
M+X2U+0?[08+?7SWAF\KE"TXFVXSSTQG/O5[4_"EMJVO2ZA=REX)M+ETR6VV_
M>21@Q;=GCICIWJ/3O&^AW7A*Q\0W>I65I;7,:%B]PI5)"H+1Y[L#D8Z\=*V]
M/U&RU6R2\T^[ANK:3[LL+AU/XB@#F=-\)ZU:RZ=#>>*Y[C3=.8-#!%;B&24*
M,*LT@;YP!U 49QSFICX-0^&O$6C?;FQK4]U,9?*_U7G=L9YQ^&?:M;5?$>BZ
M$\*:MJMG9/,?W:W$RH6]QD]/>J\OB"W>\TUK2_TR2PN!<&21KCYV\L<^7CAM
MI!W>F* *EOX6N;'Q,-8M-4*1O81V=Q;-;AO,\L-L96S\N"W3!S6GX>74U\/V
M0UF4RZCY8,[E54EO<+\H.,9QQ4[:MIZV,%\U];BTN"@AF\P;)"^ FT]#G(QZ
MYJH_BG0(]9&D/K-BNHDA1;&==^X]!C/7VZT 4_$?AFXUC5-)U6PU%+*_TQI?
M*::W\^-ED4!@4W*<\#!!&.:R)/AW-<V?B**\UV2XGUQK=YIC; >6T1'W5!^Z
M0  .HQU-=U619^*O#^HZC)I]EK5A<7D>=T,4ZLPQUX!YQW]* #2="72]7UJ_
M%P9#JEPDY0ICR]L:IC.>?NY[=:=XBT*#Q'HLNG3RR0EF22*>+&^*1&#(XSW!
M KSR[^+ZQP:[?6]YH+VUI/\ 9+&W:Y/G3OO11*Q!QY>"[<#.%ZUVL7BW3-.T
M6PN?$&NZ/%-=)O22&;;%*,\,FXY(QCF@"+3O"^H?V_;:SKVM+J5S9Q/%:)%:
MBWCCWX#N1N8LQ  SD #/%:/A?0E\->&K'1EN#<"U0H)2FW=R3TR<=:GOM=TG
M3--34;[4K2WLGQLGDE4(^>1M.><^U8>M_$+0=(LM(O%U"RGMM2NUMTF%RH14
M_CDSW"\ ^A(SB@"]XJ\/3>(;.R6UU#[!=V5XEY!.81* ZAA@J2,C#'O26?AD
M6K^(':[+MK,GF-^[QY1\I8^.>?NY[=:D\5^);;PKX7O-;GV2)!'NCC,@3S6_
MA4'U-$_B_P /6FEVNHW>M6$-K=#,,K3KMD]=ISSCVH QHO MWIBZ5/HFMBSU
M"RTZ/3999;42QW,2?=+)N!# Y((;N1S70Z#I4^D:<8+K4KG4;EY&EEN)S]YF
M.2%7HBCH%' J]:W5O>VL=S:3QSV\J[HY8G#*P]01P:X75/B;9P6GBL:>;6>[
MT+;MC,X;SA\FYL#D!6?:?<4 ='XI\/OXBTR"W@O397-M=17<$_E"0+)&VX94
MD9'MD5DR>#M7MKJ_ET;Q+]@34B)+Q#9"3]]M"M+$=PV%@!P=PS6[IOB70]8O
M)K/3=7LKNY@&9(H)U=E&<$X!Z9XIL?BG0)M8;2(]9L7U%25-LLZE]PZC&>H]
M.M %:T\+I9Z]IVIB^N)C9::^G@3DN\NYD;>SDY)^3T[U2N/ Z7'AKQ'HWV]E
M&M74UR9?*_U/F;>,9YQM]JZ>[N[>QM);J[GC@MXE+R2R,%5 .I)/051T_P 2
M:)JU[-9:?JUE=74.3)%#,K,H!P3@'IGB@"O?>'$OO$%AJK74D?V2TGM=B#!8
M2[/F# Y4C9^M8]OX(U&2]TAM8\0G4;72)A-:@V82=F"E5\R7<=V ><!<GDUT
MW]LZ8=,74O[0MOL+,%%QYH\LDML W=/O<?7BH)O$^A6^HC3YM8LH[PN4\AIU
M#[@H8C&<YP0?QH U:\]G^&M])X?U+P[%XD,.C7DDL@C2R7SP78OAI2WS+N/]
MT$CC(KJK+Q9X>U&_2PLM;L+B[= Z0Q7"LS*1G( //!S]*6\\5>'].U---O=:
ML+>^? $$LZJ_/3@GC/;UH CTKP__ &;KNJ:H;KS7U"*WC9/+VA/*5ESG)SG=
MGV]ZP[7X?S:9INB+I6LFVU/28I($NWM@Z31.VYD>/<,C(!&&&"*Z+5O$^A:%
M-%#JVKV5E+*,HD\RH2.F<'M[]*=J?B+1M&M(KK4M4M+6";_522S*HDXS\OKQ
MSQ0!2\+>&IO#QU22YU-]0N-1N_M4LKQ"/#;%4@ $\?+QZ# YQFN@J&TN[:_M
M8[JTN(KBWE7='+$X96'J".#4U !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !7GGB;4M'TGXL:!=ZS)%#"NF7(BGFX2*0O& Q8\+QN&3W8#O7H=9,^@PW'
MBBVUQY6\R"TEM!#@%65V1B3_ -\#\Z /+'M[;4IK:ZB@5M$O_&D,UHK)A)5$
M#!W /56=6/H>?6NFEO=)\-?$W4[K7I+>RMKG3H$TZXG 2(*I<RQJQX#$E25Z
MFO0^@P*1D5QAU##K@C- 'D%G;2:?X,3Q3;6\L5KI>N7&HV<6PJ?[/D<K( O9
M2C,X'L*F6UF&@>%]6ND*7FL^)X-1F4]5#A_+7_@,80?@:]9+JK*I8 MT!/6A
MG5<;F R<#)ZF@#Q*?4;?2I9K;3-0M=03^V"Y\,ZI: 7B3&?):)E.3R=ZL01C
MO5G4%5+S5+R[C:32K/QDD]^-I8+&+9 '8=U5RA/Y]J]CV+OW[1OQC=CG%.H
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M+7QQX.BTZ**W<6M_#%L4*% A7:/H#@XKNB4#J"5#MP,]32LZH,LP49QDG'-
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M*[<#Y2.V*]WII12P8J"PZ$CD4 8D]I?_ /"!R6=M+,VH_P!F&*.20!9#+Y6
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M%P1S@X(/!P.E9=CX"O-&B\*_V9J4#2:+YZ2_:(3MF28@OM"M\I&/E'(''7%
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M\0&3C&<X[5ZO10!XK<^#_&UG8^-= L-(M+BRUR[FNX;][Q4VA^=FSJ6P ,G
M!YSBMW2?!VLVOC'P5J,UL@MM*T%;*Z;S5)28(5P!G)Y/4<5Z;10!XKXC^'>K
MP^,-?U&S\.P:[;:N%>%GU)[7[+)@@[U5EWKDYP.W<5:\1_#^^?2]"L?^$0TG
M5[&TM#')#:W<EM/!*26/ERNYS'D]&R>M>P44 <9\,= UKPWX2-EKD[/,UP\D
M,+3><;:(XVQ[^^,$\<<UQWB_P5XIUKQ1KYGTJ/6+&]@":9--J)BBL#L(),7\
M39Y''4#GDX]DHH \F\/>"->L]>\ 7EU9)'%HVGSV]X?.0['965<8/.<CIZU6
M\6^ -5_X3S5==LM CUZVU.! (CJ36C6TJJ%R<,-ZG&<=?IW]BHH P?!FB-X>
M\)6&F26UK;2Q*6DAM&=HD9F+$*79FZGN:\W3PIXY\/Z)K_A#2=*L;[3-5FF,
M.I278C,$<HVL'0\L0/3OZ]*]FHH \STOP%J.B^.?"=Q"JS:;I.CM9S7!< F0
M[NBYS@DUK> ?#FI:#JGBV?4(5CCU'5Y;JV(<-NC8G!..GT-=M10!Y[?Z'X@L
M_C-;>)+#38[S3+G3UL+B0W"QFW_>;B^T\M@ <#KFN>B\ >(E^"6N>&C9Q_VI
M=WIFBB\Y,,OG1MG=G X4U['10!XQXA^'FKQ>+&URWT"/78KO3XH)+;^TFM&M
MYD15#;@PW+A1QGUZ=_1? VA2>'/"5GI\UI:6DXW/+#9M(T2,QR0"[,Q]^>N<
M5T5% 'F-CX-UJ#3_ (DQ26R!]<EN&L1YJ_O R.%SS\O+#K7/WWPTUJ*W\):B
M='CU6;3],%A>Z:+\VS<9(9)5('!8YY[#KV]NHH \HMO"WB;2_AQJ&FZ3H.G6
M6K:Q<,)HXKII$MXG&TN[2.V]]N1\O'.<<<IX:\">(O#.D>)?"">7=Z)?6<IL
M;UG5629X]K*Z]<$]^<8]^/6** ./^&=GK>E^"K32M=TQ;&XL1Y$86X67S4 S
MO^7IR2,>U>?Z9=^*+3XB_$3_ (1O2+;4S+-#'(DMR(6C8H^QQGAE'S9&0>F.
M]>X53M=*L+&\N[RULX8;F\96N940!I2,X+'OC)_.@#Q]_AUXGT;PYX4TR& Z
MQI]GYS:GIL%^;42R2$LIWY&Y5S^G3FLF^\"ZAH?@37!JAT_17_MN+4M/S/NM
M\X($6[J  2 6 [5]!57OK"TU.REL[^VAN;:48>&9 RL/<&@#Q:UO=6\2_&;0
M6UB+3X6.E7"F&PN1/Y:,CC<SCC))X'88JII/PLUJRCM="N_"UA=PPW9:35YM
M3F\IX=Q/$".I#\\=N.?6O8]%\)^'_#LDDFCZ1:64D@P[PQ@,P],]<>U;- '+
M:AJ.JQ1>)5UBWL[/28X-MA<^<-TV4;=N!/!S@#IG-9_P<_Y)-H/_ %SD_P#1
MKUUNJ:3I^MV+66IV<-W:L0QBF7<I(Y!Q3]/TZSTFPBL=/MH[:UB!$<,2X5<G
M)P/J30!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR7 74%MY1]G ;882^!V)R,Y'8TV/6]8GTNXOA=B,)JALUC:!<A?/"<^^#^=
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MX9U:UD4/>W9F"LTQ((8MLY/3 /2J-]X>U:^2WF"103VEF+:-4F.78LA)+8X
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M=CIG'3/>N0_X1C5;4:BEO(LZZE8LD_F,%Q/SAA@<@[B"?84 =AY<$MH("BO
MR!=K#(*XZ'/M5)-#TQ(1 +8%!C:"['9CD;<GY<=L5SL'AW5GAOX[IF$LRF-)
MENC@*6R#M &"GUYQ[T-H_B!I+ F.'_1XT21EN2#)C<&/3N"#_/H* .@DT?2(
M5-P]K&HB ?<,\;<D'CTR3^-0_P!E:$]E;L+5'MY$6*+ 9AM+!ACT&<'/:N<@
M\-ZY;VR1&..:(Q(DL+7)^=_**L^<'^+!]ZE@\,:K%:A@B"Z6YMV4BY;:(D5
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M1HXI%NR%"MC V@<%<<'/;MFF/HGB,G3!LA/V4()9!<L#+ASN.,?Q*<_7(Z4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *QO$-GH\D-MJ>MNB6VE2F[5
MI7Q&K!2H9AT.-QQ[XQ6S7-^+_"0\6P6,3:G<V2VDXN (41P[C[NY7!!QR0,=
M: ,_P;!/J/B#6O%7V1[&RU-(8K6%UV/,D>[]\Z]BV[@'G:!FNTK&T/1]1TN2
M9K[Q#>ZJK@!5N(HD$>.XV*O7WK9H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>a1039-firstamendmenttole003.jpg
<TEXT>
begin 644 a1039-firstamendmenttole003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH *K2:A917\5A)>6Z7DREH[=I5$CJ.I"YR1P?RJS7F'B#_DX7PC_P!@ZX_]
M!DH ]$L]4T_4+9[FROK6Y@C8J\L,RNJD<D$@X!%26=[:ZA:I=65S#<V[YV2P
MR!T;!P<$<'D$5\T^ =5O?!=H^IW4A;P[KLMQ93-VMKA<[&/L0<?3/]T5Z_\
M!3_DD>A?2?\ ]'R4 =K#J-E<W<]I!>6\MS;X\Z%)59XL]-R@Y&?>HK76M*O;
M6>ZM-3LKBW@SYTT4ZND>!D[B#@8'/->/>.]8_P"$#^)FM:JK;%UGP^XC/3-R
MGRK^05?SKC/](^'7AWQ%X;E9_.US1K.X@0]?,<B.51[_ #/^"T ?1Z^(]#8
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M%% !1110 4444 %%%% !1110 4444 %%%4]3U6QT:Q>]U&ZCMK=2 7<]23@
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MD]CKEW8VFJL'O+:*.,DML"$HY!*94#UQVQ4VA>"K;0KG29H[N:4Z;ISZ=&'
M&]&=6W''<; *Z>B@#C]0\ QWY\0Q?VK<QV>ME7FMA&A$<HV#>K8SR(P,'CFI
M[[PA<-J]]J.CZ[=Z2^H!?MB111R+(RKM#KN!V/MP,CK@<5U-% '+2>#YK?[
M^CZ]?V$UI;?92TF+A9DSG+J_&_/.X8/..G%:GAW0;?PWHZ:?;R22C>\LDLN-
MTDCL69C@ #))X P*U:* ,NST.*S\1:GK*S.TNH1P1O&0-JB(-C'UWG\JP8OA
M_#9:=I$>FZK=6E_I0E6"]5$8LDC%G1T(PRYQ]" 0:[*B@#E!X(26SC2]U>]O
M+K^TH=2EN)<?,\1!5%4#:B?*!@5;UKPRVHZM;ZQI^ISZ9JD$+6_GQHLBR1$Y
MV.C#! /(Z$&N@HH Y&X\#"?08[)M;OVODOUU$:A)M=_/!R#L(VA>P4# HN/!
M-Q]IOI--\17NG1:EAKZ*&*-A))M"M(A8'RV8 9(^M==10!4TO3;71]*M=-LH
M_+M;6)8HESG"@8'/<UEP^%;>&P\0V@N)2NM32S2L0,QF2-8R%^@7/-;]% '(
M#P/):7UI>Z3K=S8W$6GQ:=*PACD\V./[IPP.UN3ST]J?;> [*W\(:CX<:]NI
MH+V:2?SY"#+&[MO#9QR0PW ^M=910!S,O@C3W\):?H,<]Q -/,<MK=QD>;',
MG(DY!!));.1@[C5C1O#]U8:G-J6HZU=ZG=R1"!=ZK%%&@.?EC7C)/5CD_05O
M44 8_B+P_#XAM((VN)K6YM9UN;6Z@QOAD7(! (((P2"",$&LS_A#[V6VU(W?
MB74)KZ_A6W-RJK&(8@>1&@&U6.3EN3^5=710!S-MX&TJQO\ SK%3;VDEC]@N
MK)0/*N(P,(6[[@"1NZD'!JM8>"+BS;3[>7Q)J5QI6G2*]M9D(A^7[BO(H#.J
M^AZX&<UU]% '&W/@'S3?6EOKE[:Z-?SM/=:?&J89F.7"28W(K'D@>IQC-.O_
M  (;B^U1[/7+VPLM6 %[:0I&0Y"!,JQ!*94 ''X8KL** .5B\$QVUUH-Q;:C
M/&VE6 TYU,:,MU!\F58$<9* Y%5[3P%+:16VG)XBU'^P[6598=/ 12 K;EC,
MH&\H#VSG QFNRHH X[4? 9NWU6&RUV]T_3]69GO;2%$8,[+AF5F&4W8&X#KS
MTS73Z;9)INEVE@CETMH4A5FZD*H&3^56J* ./O? ,=XNO0?VK<I9:S,EQ);B
M-"(Y5*$LK8SR(P,'BMC4O#T.I:Y8ZI)/(DEG;W$"HH&&$H4$GZ;!^=;%% '(
M0>"+C3;73(]'\0WMC+962V)8QI*DT:\@E&& V?XACTYK;\.Z%;>&]%ATRU>2
M1(V=VDE(W.[L69C@ <DG@#%:E% &3;Z##;^*;W7EF<S7=M%;-&0-JA"Q!'N=
MQIVLZ'%K,^E2RS/&=.O5O$"@?.P1UP?;YS^5:E% '.0>#[>#PK=:"E[=I'/-
M+.+B)]DL;O*9<J1Z,?Q YJ"U\&LVHS:AK.KW&IW;V;V*,88X1'$Y!; 4<L<#
MD_@*ZJB@#)\-Z-+X?T*VTJ34);Y+91%#)+&JLL:@!5^4 ' '7J:31] ATG4-
M7OQ/)/<ZG<B>5W ^50H5$&/X5 X^IK7HH Y*\\!6EU?ZE<+>3Q1W]Y:WLD"@
M;5E@8'</][:,_2ME=#B7Q7+K_G/YTEBED8L#:%5V?/KG+D?A6I10!QL7P_AL
MM/TE--U6ZL[_ $OS5@O%1&+)*Q9T=",,N<?3 (-3CP0DEG&E[J][>77]I0ZE
M+<2X^=XR"J!0-J)P!@5U=% &%?\ A6QU/6KG4+LM(ESIK:;+;G[K1LQ8G/7/
M.*RK?P'.MYH\MYXDO[V#2)A)9PR1QJ  C+AR "YP?O'T/J:[*B@#EG\$6C^%
M;C0#=S>3/>F\,N!N#&?S\>F,C'TJUJ?A*PUC5[F^O2\D=SIK:;+!T4QL^XG/
M4&M^B@#E=.\(WEM>6$E]XEU&_MM/YMK=U2,$XV@R,H!D(![_ %.:63P1:2>#
M=0\-F[F$%[+-*\N!N4R2&0@=N"<5U-% &''X=-OXOGU^WU":,74"0W-IL4I+
MLW;&R1N4C<>AYI?$GAQ?$$=BZ7DMG=V%R+JVGC57VN 5Y5N""&-;=% ''#P"
MLMYJ=Y?:YJ-Q=:C9K:S3*5B*;6+*T>T#;C/3G/?.35O3/"D\&NP:SJVLSZI>
M6T#P6Q>&.)8U<@L2$'S,=HY/'M7344 97B'0;?Q%IJVD\LT#QRI/!<0D!X94
M.5=<@C(]QR":R[7P<QO+J_U;5[C4K^:S>RCF>-(U@B;[P1%&,DX))ST'05U-
M% %+1M-CT;0]/TN*1I([*VCMU=NK!%"@GWXK!U;P0FIZCK5PNJ7$$.LV/V2[
MMU1&5L*RJX)&00&/'0UU=% &-=>'(+J[T*X:>0'1W9XP ,29B:/YOP;-8D7@
M![> :9;^(=1AT%9O-73XPBE1NW^6)0-X3/;.<<9KM**  @$8/2N%E^&P?3TT
MA/$%_'HD-PL]O8A(R(RL@<)OQN9 >@/3CDX%=U10!Q\W@5VN=76UUZ]M-/U>
M5IKNUBCC+%V4*VV0@LH( X[=B*Q/%7A<7NB^'/!%O;:A/]G,(.HK$5CBMU4Q
MR;G'&YH]R[>^X5Z710 U$6.-410J* %4#  ':G444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R'
MQ"NKNTTS39+:W4I]OC\Z\-G]J:R7#?OECP?F!P,XXW5U]% 'B-];W]_+XSFC
M?6-32Y\.>5!=7=EY)G8,^5C547@;A@$9/)Y&*[75]/F.N^!!;6[HMOYZ,Z1G
M$(-JRC/H,X'Y5W-% 'B\L_D_#'3O"3Z/J!UNRN;9)HELY"L92X4M-YFW:589
M.0>=WUKUG6]*@UW0[[2KH?N;N!H6/ID8R/<=?PJ_5;4+,ZA836HN;BU,JX\Z
MV?9(GNIP<'\* /*M$LM<\8>'O$EY=(4U2#2WT"VRV-TJ*?.?/^W)M&?]FF:3
M"VIW'A>Q-_XEN9[&XAF>RFTZ*WCL3&I!WR>2OR]5PK'<#7J>C:1::%I4&FV2
MN((0<%VW,Q))9F)ZDDDD^IJ]0!X9XBGU74O"OB2P8ZC:WKRW&-"T[2 L;#>2
M)'E,9WAA\Y8,,DX'-=_X:M)!\0/$5[);2*DMC8+%*Z$!L+)N )]#C(^E=I10
M!RGCNWGN(?#X@ADE,>NV<C[%+;5#\L<= /6N0U;2[JXU75E:QGDBE\6Z=)_J
MB0T02$,W3E1@Y/3@UZU10!YWXS$5KXMBOUO=9T6[-D(H]2M+4W4$P#L?)DC"
M-\P))'3.X\U0M)]1MV^'^J:OI<EH(GNXIUM;)E6+S%*Q%HU!,>X $CL2<XKU
M.B@#DOB%<W=KH=G):6J2 7\/FW#6GVDV:9),ZQ]V4@8],YKB4BO;[7O$=RL^
MKZG%-X7FABO+NQ\@2N&)V1JJ+Q\PQD9)SC(KV.B@#RNWN5US3?!.BZ?IE];W
MVF7-K<7:S6CQ+:)$A#@NP .[[HP3G.:I+*UG\,M2\$W&DWTWB"7[1 L*VCLL
M[R2,5G$F-FWY@Q8D8Q[5[#10!Y9XIT76;34TL=/CFE3Q+90Z=?W$2DB%XR T
MK'MF%I!GU5:-:L9M \?7%ZVHZII.F3Z=!;VMSI]BMRJ^66S"V8W*]0PP #SU
M(KU.B@#E?A[8&P\+\QW\8N+F:X5;]427#N3DHH 0'EMN.,UPNK^%-1U37M:\
M.+:S+IUM]KU>QGVG8;B:-1&H/3*R-,WXBO9** /(!8:AK?A*+6]0TR=;W6/$
M-G/-;/$=T<$<B1J&7' "H6_X$:ZG7;*YN/B%!)%;R/&= O(MX4[=[2187/3)
MP>/:NVHH \CTB\\C3OAO>2V=^D6F+)97F;*7=#*;8( 5VYQNXW8Q[UD+I]W9
M^'M5\-ZE?^(S>3W-PITRTTZ)TO!)(2'29H3P002S/E2#TP*]SHH XOP]ITMM
M\0]>FFAE*C3;"%)Y%SO($NX;L8)^[G'M4?@"X.B^!M!LKNTNXYIYIH500-^[
M_>2,"_'RK@=3ZBNXHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"+7SMOE@*3)\VTYVD8Z5NZOXZBT?X:0^+I[4%Y[2&>.U$GWI)0I"!L>K=<=
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'6NO1ZIK$D[V=G(;>:\+0 N4R F.@SP.V!7T5L0+M"C;Z8XI2BE=I4%?3'%
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MO/3(/':MKP->^ 7UZ2U\/>*]6U+4;JVDB2"]DF=,8W$C>@ (V]<^M>L,BO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME3\PSW!]0>?PH YR36/%>@6LNIZ_!IESIL=G+<W'V%6C>V9%W!/G<^8#@C(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH \T\?W6OV_CK0Y=!FD:6UL;F[>Q#$)=JC1AHR.FXJS;3C@XJ^GB&+6O&
MWA.]TZZE?3KS3+R;RU8X8@Q<,H_B4Y'L<UNW>B7,_CO3-;1XA:VME/;NI)WE
MG9""!C&/D/>N=3X>W=C\09=9TR^2WTN6VN,0<[K>YF"AG08QM)16QGKGUH L
MR>.]3LY]-EU+P[]BT_4+J.UB,EZ/M*%VVHSP[>!G&0&)&:AO_B)?VJ:Y=6_A
MQI].T2Y:"\N#>*A(4*28UV_,0&R02.W)[8-O\-]86QTJ#^RO#]O>6-Y;W%QJ
M0F>6XOO+D#,2QC!3=@DY+<\<#FNDN?!VHS>%O&>F++;>?K=U/-;$LVU5>-%&
M_C@Y4],T 6+7QK<QZQ#::UH_]FVUU9RWMK.;D2DI'M+B10!L8*P. 6'O52T^
M(DTB:=?WFC+;:/J,L<4%Q]M5YD\PXC:2(#Y0Q(Z,2,C-7]:\*3:QJ^D2R21B
MSM]/O+.Y 8[SYR1J"O&/X6ZX[5SFD?#Z_L_[+L9="\*Q1V,B&758[97GN$3I
MB-H\([8&6W'!R10!Z'9W%Y-<7B75A]FBBEVP2><'\], [L#[O.1@^E>>>+O&
MB^$/B+<RS"ZNE.@![>PAW-YLHF<DX' PJDEL< ?A7;SZP-&%U<^(;S3+"Q,X
MCM)7GV;E*YPY; W9#<#L*Y+^W_"K?$5_$#^*O#S6ITD6(4WT9</YI<\9QMP?
M7\* +>G7B^'/"MYXRUS5'U.XNXDF;[,Y,"JQ CB@0G &64;CR2<DU<T[QC=O
MK=II>LZ5#8RWT;O:-;WJW*LR+N9'PHVMMR>X.#S7"W$?AMM'U[PS!XS\.KX?
MNRMSIRR7R,UG,'#F,KT:(L,]> 2,=ZL:#J7AJ#7K6^GN?A]H\=K&X8Z=<0R2
M3R,NT$,44QJ 3P"2<X/% &_IWQ'O[S3='UF?PTUMHVI3Q6XN#>*TD;R-L#&/
M;RF[C.<XYQ4]WX]U1#KTEAX:-U::'.\=U,UZL98(@<^6NTY8*<X..W)SQS<-
MWH$?PZT#P^?%_AS[7I]Q:RRL-0381%*';:>N<#C@5=M]7\.1:/XQM&\7>'O,
MUJYN)K8C4$PHD@2,;_0Y4YQGB@#H;SQPTM_;6.AZ?%>W$MDE](;FZ%M'%$_W
M 6VL2QP> .W)K%U3QMJFI+X8GT6SV&;5WL[VVDN@A$L:29B)"D%<KNW#K@<<
M\<Y<KX7M[VPU!-3\%:TZZ9!8W-KJ-]& KQ# DC<JV,Y(((&<"K#WNCVNA:*;
M'Q+X,74K#5#J#VT-U';6Q#(Z;%* G@,/F(R<<T :FG^*]<TG_A,+J+1Y-3L-
M.U:XDFFDO0A2-40E(E(.[: 3CY1SQS7I=I<QWMG!=0DF*>-9$)'.&&1_.O,H
MM5\.)X=\8Z>?%WA[SM:N+N6W(U!-JB6((N[TY'.,UTFD>-?"-AHMA9R^*]#,
MEO;QQ.5OX\$JH!QSTXH Y3X/ZY=VVB75MK=_-.K6JZK!/<R%V$)+)(,GLK1Y
M_P"!BJWA3Q3JFD#Q;KNJBYNXS)97CV[S'_1()]S':#G&Q&7(XSM-9YL]"/A3
MPWIJ^-O#D5S9I)9ZBZ:@NV6SE;=(BGJ3\JXR .M=1::MX/&O>*9[SQ1X??3M
M8A@A2)+^/(1(BCAAG Z\8S0!T6O^-[?0KN\B^R274=EIC:C<21./D7=M10,<
MEB&.<C 4FC1_$NLZD)=^A6^&MFGM9[745G@E8=(VD"#8QR.<,,9]*\^\$ZWI
M5OX*U*2;QEHL.N7P\F&:[FC.V*%?*A#HQZ$*6(/_ #T/>F:??:78ZQ-K.F:K
MX(T.[6REA%O9ZL&ANYFQM>10JA54@D8!)SUH [NQ\7ZQ<>+8_#]SX>@CD$)F
MN9H-0\X6R8^7>/+'+'H,YZGI63\-_%LFH^']!TJV234KM+59-2NGF^6V!)V[
MF()9VQPOIR2*R_"'B>VT&-;:[UKP?)]HE,U_?C7=\\\AZO@Q@>@ R !Q5+PP
M/#OA2#P]<:=XK\,1WUO%]EU>-=001W<1);<#U,BDY!(&<D$@4 =<WQ"N_P"R
MY?$$?A]Y/#,4C WHNAYQC5MIE$.WE 03][.!G%3:I\0XM+T77;UM.>6YTN\2
MU2U27FXWA&C=3C@,KYZ'[IKB?M]I%X4F\$P>+?"8T9]\*ZBVIKYZ6S,24\K&
M"X!*@[@.^*TKV?PG/X]L-6B\7>'QI$<2&ZM6ODW231)(D3=<$!93GG^%: .G
MU;XAV>FQS3QV<ES;0Z5'J3RI(!@2.%B3I@;OF).> N>:K7_B/5K[PEXA^T:8
MEGLTB>XMKZQO1<0L=C<!PJD..#T_&N5\.3:/H/A?6+1/'/AI]3N66*UEDNXY
M(A;1 +%&X/8KN!ZXW'&:IVW_  C[RZU/#K'A#0EO=)GL?L=AJP>*>5Q@2.-J
MA0O084GD\]J .[\.>*QJ^F);64#WEK9Z>HOM0\[:HF\L'RE."7?G+'("YZD\
M5M^#[N._\&Z-=PK,D<UG$ZK/,97 *@_,YY8^_>O/-+N?#7AZY@_LCQ7X:AL[
MK3A:ZG:_;T53,B;4FCQW/(;.,C!ZBNC\)^*O"NA^$=(TJZ\6:"T]G:1PR-'?
MQE2RJ <$D<?A0!W=%<Y_PG_@[_H:M%_\#H_\:/\ A/\ P=_T-6B_^!T?^- '
M1T5SG_"?^#O^AJT7_P #H_\ &C_A/_!W_0U:+_X'1_XT ='17.?\)_X._P"A
MJT7_ ,#H_P#&C_A/_!W_ $-6B_\ @='_ (T ='17.?\ "?\ @[_H:M%_\#H_
M\:/^$_\ !W_0U:+_ .!T?^- '1T5SG_"?^#O^AJT7_P.C_QH_P"$_P#!W_0U
M:+_X'1_XT ='17.?\)_X._Z&K1?_  .C_P :Z"&:.XACFAD62*10Z.AR&4C(
M(/<4 /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH R;[7H;'Q'I.BO#(TNI).Z2 C:GE!2<_7=4NCZU::YIO\ :%H7
M%OYLL69!M.8W9&/TRI_"N:\2QI-\3O!\4J*\;VVHJRL,@@I'D&N$TS1M*E\"
MZ;:6DVDVMW)KER&M;R(FWO&228)%-MZ87!7/]T#!H ]P#!E# @@]"*221(HV
MDD941 69F.  .I->;>%H]"GTOQ'H>KZ59Z;;6MW"UW#'>[[+>P5E,;?+LY52
M4XY(]:[3Q78W&I^$-:L+3/VFYL9HHL=V9" /S- & /B!<W%D^K:?X5U2\T1
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MM% $7V:#_GA'_P!\"C[-!_SPC_[X%2T4 1?9H/\ GA'_ -\"C[-!_P \(_\
MO@5+10!%]F@_YX1_]\"C[-!_SPC_ .^!4M% $7V:#_GA'_WP*/LT'_/"/_O@
M5+10!%]F@_YX1_\ ? H^S0?\\(_^^!4M% $7V:#_ )X1_P#? H^S0?\ /"/_
M +X%2T4 1?9H/^>$?_? H^S0?\\(_P#O@5+10!%]F@_YX1_]\"C[-!_SPC_[
MX%2T4 1?9H/^>$?_ 'P*E    & *** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@"&2TMI;F&YDMXGN(0PBE9 6C
M#?>VGJ,X&<=<52D\.:'+%=Q2:-I[1WCB2Y5K9")F'1GX^8\GDUIT4 9\.@Z/
M;Z8=,ATJQCL"0QM5MT$1((.2N,9R ?PK.O-/\627DKV?B'38+9F)CBDTEI&0
M>A;SAGZX%=#10!P4_@35;G4AJ,]YX7EO0=WVA_#8,F?7<9\Y]ZT'T'Q9)=17
M3^(-$:XB5ECF;0B70-C(!\_(!P,_2NMHH YC^S/&O_0T:3_X)6_^2*R8O FJ
MP:D=2BO?#$=]G=]I7PV!)GUW>?G/O7>T4 <Q_9GC7_H:-)_\$K?_ "11_9GC
M7_H:-)_\$K?_ "173T4 <Q_9GC7_ *&C2?\ P2M_\D4?V9XU_P"AHTG_ ,$K
M?_)%=/10!S']F>-?^AHTG_P2M_\ )%']F>-?^AHTG_P2M_\ )%=/10!S']F>
M-?\ H:-)_P#!*W_R11_9GC7_ *&C2?\ P2M_\D5T]% ',?V9XU_Z&C2?_!*W
M_P D4?V9XU_Z&C2?_!*W_P D5T]% ',?V9XU_P"AHTG_ ,$K?_)%']F>-?\
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MF>-?^AHTG_P2M_\ )%=/10!S']F>-?\ H:-)_P#!*W_R1720K*L$:S2+)*%
M=U7:&;') R<#/;)I]% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%8PU\'QHWAS[,=PTX7WG[_60IMVX]
MLYS2:KXBATG7])TV>-0E^EPYN'D"K$(E5N<CG.[U&* -JBH8+NVNK87-O<12
MP$9$L;AE(^HXIEMJ-C>0O-:WEO/%'D.\4JLJ_4@\4 6:*K)J-C*)C'>V[B
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MU?Q#I]Y=:B&TRQD%Q'8+"/FG 8*[/G) W9"XZ@'- %KP]HD.A>&;'1AB1+>
M1R%AGS&Q\['_ 'B23]:\BM++1[OP5H^F"*T9O^$M$5[;H%#8^T3;5D YQMX
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M_>^M>A3V\-U"T-Q#'-$WWDD4,I^H-4[W1K&^TB327A6.RD 5HH@%&W()&,<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M"2>*OCEK=M<7.H648TB-HKFTD,9#Y0#GH1R>/:O:** / M!MSH?@KQ]X4O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<MK=Z?8?V<97MTE$L6[=]T_=;/<&@#+T+QSJUU!IT]T\$UJNN2:1=3"V:$R
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MN_F>:>UBB0LC.<OY4AY0,<GO@DXQ747-BD^E2Z>'98Y(##N)+$ KMSD]3]:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6.^TJZ1;N,9'R.K%5="!G/8CH,YK7^'>@7.@:%>+=P/;R7M_->""6;S9(U?
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M5.&QQE<&KUAX7TS3-3MKZSC>%K:P&GQ1*WR+$&##CKG(ZYH V:*** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MOIH[=5DOB#<MD_O2%"#/_ 0!6?=^#] O;"QLI]-C,%@FRUV.R-"N,85E(8#
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJT_^,T =/16/I.C7NG7+RW/B'4=21DVB*Z2 *IR/F'EQJ<]NN.:V* "BBB@
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M8Z8IUMX,TRUTW4;1)KYI=1(-U>M=,;B0CA?WG48'  P!SZT ;5V9X]/G-O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO$?_ ($1?_&Z/^$/N/\ H;O$?_@1%_\ &ZZ>B@#F/^$/N/\ H;O$?_@1%_\
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MD<M&R/=>4&7#X5MI!/7I@^M:DNK:G=>!'O4N(WO?G#M NP(P+84\G;R "<C
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
1BB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>a107-2021formofrsuoffice001.jpg
<TEXT>
begin 644 a107-2021formofrsuoffice001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** ,C5]2OK6_L++3[:VFFNA(<W$K(JA #V5O6H_.\4_\^.C_P#@
M9+_\:HU+_D;-#_ZYW/\ Z"M:\\0G@>)F=0X(W1N58?0CD&@#(\[Q3_SXZ/\
M^!DO_P :H\[Q3_SXZ/\ ^!DO_P :KS/PGXLUOP]K<'ASQK?S7-EK4*3Z9JC.
M5.64?NRPZ') ]CCLPQV<7BVWT/1M#LYUN[[4;S3C=@;LLX2,/(Q=B!GDX'\A
M0!L^=XI_Y\='_P# R7_XU1YWBG_GQT?_ ,#)?_C58LWQ.T>+0O#^KQVE_/;:
MY.+:V$4:[UD)V[6!8=P1QGI5*X^+>FVEAJEU/HNJH-)NQ:WZXB/D$MM5LA\,
M">RYZ<\8) .G\[Q3_P ^.C_^!DO_ ,:H\[Q3_P ^.C_^!DO_ ,:JCK/CS3-(
MN;J#RKBZ:SLQ?79@"XAA)P"<D9)Y.!S@'VS<A\46]QXEM]'@L[V1;BR%['?+
M%_HY0G &[U[].XH =YWBG_GQT?\ \#)?_C5'G>*?^?'1_P#P,E_^-5MT4 8G
MG>*?^?'1_P#P,E_^-4>=XI_Y\='_ / R7_XU6W10!B>=XI_Y\='_ / R7_XU
M1YWBG_GQT?\ \#)?_C5;=% &)YWBG_GQT?\ \#)?_C5'G>*?^?'1_P#P,E_^
M-5MT4 8GG>*?^?'1_P#P,E_^-4>=XI_Y\='_ / R7_XU6W10!B>=XI_Y\='_
M / R7_XU1YWBG_GQT?\ \#)?_C5;=% &)YWBG_GQT?\ \#)?_C5'G>*?^?'1
M_P#P,E_^-5MT4 8GG>*?^?'1_P#P,E_^-4>=XI_Y\='_ / R7_XU6W10!B>=
MXI_Y\='_ / R7_XU1YWBG_GQT?\ \#)?_C5;=% &)YWBG_GQT?\ \#)?_C5'
MG>*?^?'1_P#P,E_^-5MT4 8GG>*?^?'1_P#P,E_^-4>=XI_Y\='_ / R7_XU
M6W10!B>=XI_Y\='_ / R7_XU1YWBG_GQT?\ \#)?_C5;=% &)YWBG_GQT?\
M\#)?_C5'G>*?^?'1_P#P,E_^-5MT4 8GG>*?^?'1_P#P,E_^-4>=XI_Y\='_
M / R7_XU6W10!B>=XI_Y\='_ / R7_XU1YWBG_GQT?\ \#)?_C5;=% &)YWB
MG_GQT?\ \#)?_C5'G>*?^?'1_P#P,E_^-5MT4 8GG>*?^?'1_P#P,E_^-4>=
MXI_Y\='_ / R7_XU6W10!B>=XI_Y\='_ / R7_XU1YWBG_GQT?\ \#)?_C5;
M=% &)YWBG_GQT?\ \#)?_C5'G>*?^?'1_P#P,E_^-5MT4 8GG>*?^?'1_P#P
M,E_^-4>=XI_Y\='_ / R7_XU6W10!B>=XI_Y\='_ / R7_XU1YWBG_GQT?\
M\#)?_C5;=% &)YWBG_GQT?\ \#)?_C5'G>*?^?'1_P#P,E_^-5MT4 8GG>*?
M^?'1_P#P,E_^-4>=XI_Y\='_ / R7_XU6W10!B>=XI_Y\='_ / R7_XU1YWB
MG_GQT?\ \#)?_C5;=% &)YWBG_GQT?\ \#)?_C5'G>*?^?'1_P#P,E_^-5MT
M4 8GG>*?^?'1_P#P,E_^-4>=XI_Y\='_ / R7_XU6W10!B>=XI_Y\='_ / R
M7_XU1YWBG_GQT?\ \#)?_C5;=% &)YWBG_GQT?\ \#)?_C5'G>*?^?'1_P#P
M,E_^-5MT4 8GG>*?^?'1_P#P,E_^-4>=XI_Y\='_ / R7_XU6W10!B>=XI_Y
M\='_ / R7_XU1YWBG_GQT?\ \#)?_C5;=% &)YWBG_GQT?\ \#)?_C5'G>*?
M^?'1_P#P,E_^-5MT4 <S'JOB675[G3AI^DB6W@BG9C>2;2)&D4 ?N^O[L_F*
MM^=XI_Y\='_\#)?_ (U1:?\ (\ZM_P!@ZR_]&7-;= &)YWBG_GQT?_P,E_\
MC5'G>*?^?'1__ R7_P"-5MT4 8GG>*?^?'1__ R7_P"-4>=XI_Y\='_\#)?_
M (U6W10!B>=XI_Y\='_\#)?_ (U1YWBG_GQT?_P,E_\ C5;=% &)YWBG_GQT
M?_P,E_\ C5'G>*?^?'1__ R7_P"-5MT4 8GG>*?^?'1__ R7_P"-4>=XI_Y\
M='_\#)?_ (U6W10!B>=XI_Y\='_\#)?_ (U1YWBG_GQT?_P,E_\ C5;=% &)
MYWBG_GQT?_P,E_\ C5'G>*?^?'1__ R7_P"-5MT4 8GG>*?^?'1__ R7_P"-
M4>=XI_Y\='_\#)?_ (U6W10!B>=XI_Y\='_\#)?_ (U1YWBG_GQT?_P,E_\
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MZQ\(:;J^G:5=JT=[J1<6L?FS'S"@RW(.!P1UQ0!UU%8G_"(Z'_SZ/_X$2?\
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MFIV:E[2\ ,$C3RKOST&"P.?:@#JZ*Q/^$1T/_GT?_P ")/\ XJC_ (1'0_\
MGT?_ ,")/_BJ -NBL3_A$=#_ .?1_P#P(D_^*K+UFR\'^'EM&U19+=;N=;>%
MM\[!I&Z+E2<9YZXZ4 =?17.WGASPYI]C<7MU;M';V\;2ROY\IVJHR3@-GH*B
MTK1?"^MZ5;:GI\+S6ER@DBD\Z5=P/L3D4 =/16)_PB.A_P#/H_\ X$2?_%5'
M)X7\/Q-&LEOM:1MB!KF0;FP3@?-R< G\#0!OT5@R^%M @A>:6W,<:*6=VN9
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M)_PB.A_\^C_^!$G_ ,51_P (CH?_ #Z/_P"!$G_Q5 &W16)_PB.A_P#/H_\
MX$2?_%4?\(CH?_/H_P#X$2?_ !5 &W16)_PB.A_\^C_^!$G_ ,51_P (CH?_
M #Z/_P"!$G_Q5 &W16)_PB.A_P#/H_\ X$2?_%4?\(CH?_/H_P#X$2?_ !5
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M1)_\51_PB.A_\^C_ /@1)_\ %4 ;=%8G_"(Z'_SZ/_X$2?\ Q5'_  B.A_\
M/H__ ($2?_%4 ;=%8G_"(Z'_ ,^C_P#@1)_\51_PB.A_\^C_ /@1)_\ %4 ;
M=%8G_"(Z'_SZ/_X$2?\ Q5'_  B.A_\ /H__ ($2?_%4 ;=%8G_"(Z'_ ,^C
M_P#@1)_\51_PB.A_\^C_ /@1)_\ %4 ;=%8G_"(Z'_SZ/_X$2?\ Q5'_  B.
MA_\ /H__ ($2?_%4 ;=%8G_"(Z'_ ,^C_P#@1)_\51_PB.A_\^C_ /@1)_\
M%4 ;=%8G_"(Z'_SZ/_X$2?\ Q5'_  B.A_\ /H__ ($2?_%4 ;=%8G_"(Z'_
M ,^C_P#@1)_\51_PB.A_\^C_ /@1)_\ %4 ;=%8G_"(Z'_SZ/_X$2?\ Q5'_
M  B.A_\ /H__ ($2?_%4 ;=8GAS_ %NM?]A*3_T%*/\ A$=#_P"?1_\ P(D_
M^*J'PG;0V<>K6\"E8DU&0*I8G'RIW/- '0T444 %%%% !1110 4444 %%%%
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ML'+VJ,;<^23UV_ON ?3I0!B67B/6=/\ B@-)UV2\6TO+V3^S+J!P]O/&$91
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MB0=2I$P(Y^E &>^M^)8M<\*^$=<U-;:XO8+K[1>6CC,LBAA$-P P1\I(&,G
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M%%8G]OWO_0L:Q^=M_P#'J/[?O?\ H6-8_.V_^/4 ;=%8G]OWO_0L:Q^=M_\
M'J/[?O?^A8UC\[;_ ./4 ;=%8G]OWO\ T+&L?G;?_'J/[?O?^A8UC\[;_P"/
M4 ;=%8G]OWO_ $+&L?G;?_'J/[?O?^A8UC\[;_X]0!MT5B?V_>_]"QK'YVW_
M ,>H_M^]_P"A8UC\[;_X]0!MT5B?V_>_]"QK'YVW_P >H_M^]_Z%C6/SMO\
MX]0!MT5B?V_>_P#0L:Q^=M_\>H_M^]_Z%C6/SMO_ (]0!MT5B?V_>_\ 0L:Q
M^=M_\>H_M^]_Z%C6/SMO_CU &W16)_;][_T+&L?G;?\ QZC^W[W_ *%C6/SM
MO_CU &W16)_;][_T+&L?G;?_ !ZC^W[W_H6-8_.V_P#CU !:?\CSJW_8.LO_
M $9<UMUQ=MK=V/&6J2?\(YJQ9K"T4Q@V^Y<27')_>XP<\<]CTXSL_P!OWO\
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M$15YOX#O+CP;K?B3X>;R)UG\[1V;G,<F 3[A00Y'L_I76:SXB/AK6]%\':+
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M4 8G]@7?_0S:Q_Y+_P#QJC^P+O\ Z&;6/_)?_P"-5MT4 8G]@7?_ $,VL?\
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M'A__ *"<7Y-_A6W10!B?\)AX?_Z"<7Y-_A1_PF'A_P#Z"<7Y-_A6W10!B?\
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M!B?\)AX?_P"@G%^3?X4?\)AX?_Z"<7Y-_A6W10!B?\)AX?\ ^@G%^3?X4?\
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MZTZ&[^V7$,\]S<M.S0Q&-1D 8 +,>WK0!J4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[X>\2V/C.[T76-.O+A+>6UG:XM1,0J2H8AM=?4;S]00>>* .WHKRSP3KE_\
M$W5]8U2;4+NTT&RG^SV5G:2F$RG&2\CKAB<;> 0.?;GN])TW4-/U2_,^ISWE
MA(D7V5)R"T)&_>N0 6'*G)R>V>* -BBBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@&0.C>M<;X \):UX4\3>(]&ETN=_">HLSV\S2Q90D8(*ALX*G&<?PCBO6:*
M/+_ &AZY\-EU'0I],N-3TJ2Y-Q9WMFR$C( *NC,"#A1R,C.:W?&EMK7B#X>Z
MS8PZ2XN[R,QVUL)4W@<<N2VT'KP">,<UV=% 'F/ANQUWP[X,TZ&W\*79\0V]
MB;+S#-;B,9;(9F\S)"]0,=R.]/\ &/AK6(_B?X<\9Z=8OJ-O8PM;75O"ZB4*
M0XWJ&(#?ZP\9[5Z710!B:>MW?ZV=4GLI;*&.V\B&.<KYCEF#,Q"D@#Y5 YSU
MX'&>+\9^'M<U+XK>%M:LM*FGT_3/^/B821CJ3T!8$X^E>GT4 >?_ !AT+5O$
M_@<Z5HUA)=74EQ')@2(@4+G.2S#]*S/%_@;5]:T_PKKFE0+'KN@^4WV2X=5$
MP7:2FX$@'*\<XY/->IT4 8=KK6I7PA2/P_>6DC%?-:\>-4B'\7*LQ8XSC P>
MY%46TR[US7-1FOX;^QMXX_LMMM>(K-$0"YQ\Q&YN,''"+7544 >6?"[0_$7@
MNXUO1KS2KEM#-PT^G3F6)FQG&TJ'R"0%/ID'UJ'X4:1XB\%Z)JMMJGAN^:6X
MO&N(Q!-;ME2H&.9!@\5ZS10!Q23>(;J*T37/#OVNPNX9_MUIOBD,!,N8EP3A
M\)P<>@/M7-Z3X.UGPFWB_5O"&G?9A>1Q+INFW4@.77[[D;L*.6V@GZX&*]9J
M.>%;B!X79U5Q@F-RC8]B.1^% '-?#[6M7UWPI'<Z[;1P:E%/+;S"/&UFC<J2
M,$CJ".#C(.*X+Q;X6\2ZG\:=&\2V>A7$FF6/DK(_G0AFVLQ)"E\_Q>W2O8+6
MU@LK6.VM84A@B7:D:# 45-0!B1M=/XK:1M-N%M7LE3SV:/:'W$E2-V[H?3%<
MIX=^'7_"*?%"\U;2_ET._LI-UN#A8)R\9P!_=(#$>F"/2O1J* /+?!7AO6/A
MIJ^L6$>FSZEH-[,)[6>T9#)">FQT9@>F!D9Z>_'5Z[?^*6\*ZG=:)I21ZFJK
M]BM[AU9VY&XL =H.,X&X]!GK@=/10!D^&)M8G\-6$OB"".#5FBS<QQGY5;/L
M2,XQGWS6M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 >9?$2T\?S6FHZKHFMPZ78Z=&TL=JB@R7"H,L[/@@=#
MA>F ,X)XIZ3\3]13X'2^+=1BC?4H2UO&2NU9I-X17P.W.2!_=.,5L_$KQ+IT
M=N/"CZQ::=<:G&5N;B>0*+>V/#G!ZLPRJCW)Z"N6\?1:+J?P/O;+PC(MQINC
M2PJ7A^93MP6P?XB ^XGZT /D\:ZOX7;P!J-]J4U[;>(H1_:$<X7:C,(R'CP!
MMV^9T'! ]>:W?B%9>/KJVO\ 4="UJ'2K+3XS)%;(H,ER%7<S,_.WN OMSC/'
MGOCBSEU;P[\(K"V!:6X@C10.WR0 G\/Z5Z;\2?$]A;6@\+MJ]II]UJD92:XN
M) HMK<\.^.[$951ZY/0&@!_PN\4ZOXN^'L6I7JQ'45D>#S6&U)=N,.0/KSCN
M#TK#^'?B_P 1:[\2O$^E:U=PO%IH:*.*WCV1@K)M+#.6.<=R:[+P3=>'&T)-
M.\+SI/ING8MQ+&<J7QN/S=V^8$GU:O-OA9_R6OQ__P!=Y?\ T>: /:KB(SP/
M&)9(BP^_&0&7Z9!KQSX,>*O$7BG4M?.LZO<WB:=Y8AA"1H&+&3.<*,GY!W K
MV>O!?V=/^0KXO_WX/_0IJ /3O#GQ$T/Q+KU_H=M]IMM3LF99;>Z0*Q*DJVW!
M(.".?K6M;:_;RP:C<7,$UC!I[LDTMT45?E 8D$,>,$')Q7F?B_P->7]@/%WA
M@F#Q+IE]=NOECFY07$ORD=V SCU&5],8_B?6]0\7? ;5-:MK=X&N+]7O(4YP
MJ[%?\-R@_3K0!ZEIOC>#6+)M0T[1=7N=,&=MZL*!9 .K(A<2,/HO/;-5=5^)
M>C:18:-?36M_);ZQ@6C1QI\Q., @L"IY'6M/P/-;3^ ] DM"OD?V? %V]L(
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%X\0A>8=60'(!]<$G\ZM44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M-#)+ Z)(%@56*L0 <$$<5R<^@7^I3>*;N"SO)'BUD7B6%S')';ZE"L48*$,
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M(Y<J#[;L?A7+^(XM%\8^%3_;VAW\6N11,+<QV,HF$@SM,3JN"I.#C.!GG&*
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MKF&;="QC^9X2 7Q@'Y6(YSQ61X9L-:T+5=4LM5,MW96=G''87VTN\T6YR$8
M<NO0XZC![T 7=+\6:IK'AFPUNTT6W$-U;27+K+>E1&JXVKD1G+'YNP V]>:N
M>&=?U'7[+3[^72H;:ROK,7,<B71E92=N$8%%P2&)R"?NFLCP5'/9_"&QMKFT
MNH;F"P:*2![=Q(&P>-F,GKV%:GP_CE@^'^@V]Q!-!/!9112Q31-&R,J@$$,
M: -36]2.DZ/<7B1^9,H"PQ?\])6(5$_%BH_&N<^'.LZA>Z7?Z1K<WFZUHUV]
MK=.?^6JD[HY![,IX^E6=7!UOQ59:2PU""VLT:[:XC@=4>;[J*)"NTX!=CSUV
M]Q7/7EG<>$OBG8:G:1:K?V>K6S6VI.MO)/Y3)CRI&*KCU7V&: .N37YK_6+W
M3](M([@6#".ZN)IC'&LA&[RUPK%F ()Z 9').0*>M>*K_0_#E]JMSHR^99W*
M0-";G D#,BAU;9R,OZ#H>_%9_AR.;PIKGB&SU""?['J.HR:E:7B1,Z'S -T;
M%0=C*5XSC(/%<]JUKJMS\//%*2P:Q=/=:R#8Q2)/+(;=9HBNU3EE7 <]!T^E
M '=67B263Q3-X=OK%;>_6S%[$T4WFQ21[MA^8JI!#=B*J:=XHU;5;34Y[71;
M0FPO)K,QO?L&D>,X^7]UCD],U2TBVD\.>,KTW%K>7MKJJB6UU)HI)I80.MO(
MV"549W+G Y(/(K)\/V]I##KDVIVFNQR?V]/>PI%;7>)%$HD0A%&U@<=QS0!U
MDWB&_P#^$PD\/VVFV\CI9+>B:6[9 5+E,8$9YRM5-?\ &5QX:TO3]0U+2E$%
MQ>?9K@Q7._R$RW[T?(-R[5W'H1FLN[03_$]KV]L]5BMCH<<)DMXK@*)?.9BF
M^(<D COBKL\%E?Z=H>E&POVTU9I+4B>VEW-"+:6+<^5RH). 6QG(/>@#2\9^
M+(?!_AU]5:V:[?<JQP(^W>3R3NP<  $YQV]Z2[\1:A!XHL]"BTRVDFN;.2Z$
MC7C*JA&52O\ JR>KC!K@M6T;7_\ A6NJV>IVES=7=A%_9FGB&)I7N(Q*I\["
M@GYD6,>VQO6NBUI4N?B3I-W+;:H;*/2YT>:WM[A0KL\952T8SDA6X]J -37?
M%E_X=TC^TK[1EDACN1#.+6Y,C+&<?O$&P;L<Y'&,&M.76Q)_8\NGI!=VFI2;
M$G$Y4!?+>0, %.[A".HZUC&6WCTZRM[2SU,VT.IJ%:>VF9V!8NS'<N[:"V-S
M=<'KU-&V\.ZCX=\9:;;:='YGAF>[ENA&/^7";R905'I&Y?([ \=Q0!H-XHUN
M/6M-TF30K..YU"VEN$#:BV(Q'MRK8AZ_..F1P>:W)M6%AX<EU?4X3:BWMC<7
M$0;?Y>U<LH/&>AYXS6#JRRM\4O#TRVURT$5E=QR3+ YC1G,6T%P,#.T]^U7_
M !WIT^K^ ]=L+52UQ-92"-1U9L9"_CC'XT <]J_BR^\/?#4>)YD$NKZDL1M[
M=F/EQ/+_ *M,>BJ>>[$'UXW3X6N#I6#KFI_VQY>?MPNGV^;CKY.?+VY_AVXQ
M[\UA:WH,GCGX0:=#ILB+=_9;:[M"QPOF(H(4^F>1[9K=3Q>ITD2MI>I#5/+Y
MT[[*^_S,?=W8V[<_QYVXYS0!S^B_$B[OO!VC:G)IL,M[=:BNE7,?GF-8YRVW
M</E;Y>AQVSWK<U[Q/J?AW0M5U2[T>W>.PB24"*])$H)(89,8PP^4XQ@AAS7%
MMX1N_#W@;PWI=Q#<W-Z^O07U^;*.1_+RY+G<@RH48&>.F171>/-&%O\ #3Q!
M9Z;!?74UZNY(E\RXD9SM&.<MT7OTH Z*34=8@:7SM+M/+2V>8/'>LWS+C"L#
M&,9&[!&?N]*R[3QN+K0=!O!8?Z?K@!L[))L\;=Q9GVC"JO).#VQDFM#^SK2P
MTW4+VU%ZYN;8*5E>69SM#8 5\L#\QX_2N%TG3=0T_2?A_KIT^]=='LWM+^U^
MSN)HA)&J[Q&1N.UE&0 3@\9Q0!Z -0U:.]CMI]+@"R1.ZS1719 ZXPC90$9!
M)!P?NFLWP_XGU37]"TW6(M'MDMKTH=GVXF1%+8)QY8!P,G&>@K7BUB"[C9[>
M*Y>%4+/(UO(N/0 %<L?8 XQSCC/!^!K>WTWPAX=-U8ZXNJVG MFAN@@D;>F&
M##8HP^<\ =: -N[\;7UK+XD/]BQ20:!M:Y9;T[W0QB4E%,>,A3T+#D5HW7BN
M'?H<5C''+-K4;36OVB7R5V! YR<$[L,,*!Z^E<3J'AZ_UK6_&<MK!=A_MEK<
M06]PDD=MJ"1P(KQ-D!6!((SV(':NBU:31?%.D:;:ZMH.H)93QM("]G+')8RI
MLVCA<H?F;##CY>N* .GTJ]N[R.X%[9"TFAF,119/,5A@$,&P,@Y]*Y3XBZ\V
MB7'AQ;BYGM])N]0\F]>W9ED(V,44%?F +8SMYXQWK0\"1ZK;Z;>VVH75W>6L
M-VR:?<WJ%9Y8-JX+Y )PVX!B 2!GIBN*NH(]5U7QCH_C#2M3DN+V8QZ;<064
MDR_9A@QB)E!52&&XY(!)YZ4 =GX?U@:>\.CZK-=K?7<LTUE;S1R2RK;;_EWN
M 1D C.6R,@$U+X_\42>$O"DU_;1++>RR);6D;_=,KG S[#D_A7)^#-8UO2[T
MZ?XJT75)]?6)+6UN8[??#+ .1F1<JK9.7)/8>@%=-\2/#-UXI\(R6NGLHU"V
MFCN[4.<*TB'(4_4$CZD4 7;?PPZ6*BXUG59-2*?/>+=NHW^JQ9\L#/1=N/7-
M45UG5M$G\->'KBVAO[^\M'5[N6Z,>7A1=[$!&^]G-6M-\8VU[:H)M.U2VU#&
M)+*2QEWJ_<!MNTC/\6<>XK&\31RW'C7PE/=V=^(H(KPW+V<<S"$NB;07C'<@
MCWQ0!JZYXGU'0/#UYJESI-N[6UQ'$(X[PE9%=D4,&\OLSD$$?PFIK7Q/*?$E
MSX?O=/$.H167VZ+R9O-CFCW;3@E5(;=Q@BN9\6Q)-\/-4TS2K#5YE%W"R;[>
M=I9&:X65\;AO(4$_-T[9XK0T:UE\.^,[U;BUN[RVU4"6UU-HI)9(0.MO*V"5
M49W*3@<D'D4 6QXGUS_A(8M$;0[%;R2P:^YU)MH4.$*D^3URP]O>K^O>)E\.
M^%3K5[9RF18U=K2,[G!(RRCUV@,2?12:S95E_P"%O6]Q]FN3;C19(#.('\L2
M&9&"[\;<X!/6K=Y#/K?B.2!3)#;6$!7,]HS1S/("&P6P#M48R"?]8PH OZWK
M8TOPM>:[;1)>16]JUV%\S8)$"[N&P>HZ<5BW_CK^QWT275;!8+'4X]S74<Y<
M6I.W'F H,*2ZC=G@GD5SMJM_;?"WQ/X7FL]1FGT^WNK*RD^QR_Z5"4(B*?+S
MU"\?W?QKHH8(+\:#97MC<26TNDRP3I+:R;1N$(VOE?E)VMP<=* -]M0G&OQZ
M>+:,P/;M/Y_G'<,$#&W;_M#G-<YXEUV\F\:Z-X/T^=K5KR)[N]N8\;T@7("I
MGH68$9Z@=.:C\*Z1K.A^)I-+O&>ZTJTLV73KUSEC&SKB)S_>3;@'N"/0TGBC
M1[RS\=Z)XQLK>2ZBM87LKZ"%=TGDMDJZ*.6VL22!DD=!0 SQK)<^!M#_ .$E
MTNYO)(K*6/[9:7-U).D\+,%./,8E7&X$$$=#G-:&L^+=0TN&"[BTBWFLKF\@
MM;:5[THTGFE0'*^6<+EO4GC.*SO&_F>-O#[>&='BN&^WR1BYNI+=XX[:%7#,
M26 RWRX"CGGG YJSX\M6CT30[6SM;F98-5LGVP0/*4CCD4LQV@X  H MZGXG
MU32?L"W>BVXDO-333TV7I*_.NX2 ^6"1P01@<BK=UX@N+?QA9:"MC$XNK62Y
M$YN"-H0J"-NP]W'>LGX@0O>+X:CCM[V9%UJ":4VT4I,<85P6)097&1SQ4,UB
M++XIZ3/#!J4ELNFW$<D\GGSHCLT94;VR 2%/&>U %_3?%&K:M9:C<VNBVA^Q
M7<]H8VOV#2/$VT[?W6.3TR:ENO$FI)XJNM"L])MYY(+%;X.]X8]ZL[(% \LX
M;*'J<=.:Y?P[;VD%KK,VI6>NQRC7;B]ACBMKO$BB82(0@&U@<#J*=KNBWOB+
MQSJ4<)U#3GFT"&&*Z1)5B$PED<QLX 5AA@",\@G'- ';^&]>M?$_AVRUJS21
M(+I-RI(,,I!((/T((KBOM47_  M?6M,U+6KNWT^.P@GAB;4I(561B0V,./3I
M76>$;P7&@V]NVD2:3-:KY$MF8&2.-EX/EG&&3C((SP17*02I;_%[7-0N]-U%
MK*33X(8IQIL\B,ZDE@"$/KUH VO[2&B^&=3UK2)IM<MA*6AAEO&<Y4^6RI(=
MQ(W*<>Y/-:MMXFLKOPC%XCAW/:RVXG5!]XDC[G^]N^7'K6-<WL$NAZE;:;I-
M_#9Q2H4S8RHTLCR;WV1E0VT=2<8R3Z53TW1;[3=?U*P:!_\ A&DF_M:V*H2?
M,?.80H&<+(&DP.0=M %B+Q[=S^&?#VLQ:/#_ ,3JZCMHX6O"/*+[MI)\LY^Z
M<X'YTE_\0FT_2O$,TFD_Z?H,D2W=K]I^5EDP49'V\@@YY /%<S:V=W_PKGP#
M92Z?J:3VNIV[7,:VDRO"J[]S-A<J!D<^];_CKP_;6/P]U^+2;"ZGO=1*/)Y:
MR7$T[[EZGEN .!T ':@#N3/Y-FT]WY<(1"\I#Y5 !DG) X_"N>A\47MWH!U^
MTT@2Z88S/&K3[;B6$<[U3;C) R%+#((S@\4_5+Z#Q%IUUH=M#?JVH6LT+32V
M4T20JT9&XLZ@9R0,9SS[&L[1M2N-,\!VNE7.FW9UBSLA9_9$@9A+(B[ 5?&W
M8V =V< 'G&#0!:O/&JP7/A^:"UBFT7665(]1\\J(F9<H&38?O=!SUX.*U5U.
M]FUF\L[:R@DM[6-=UPUR5S*1GR]NP\@;23GHPKG%\++I?P</AR^B:\D@TYD9
M8D9R9L%AL &<A\8(]!6SX2+6W@?3)+F*Y2Y^R))="6)_-,Q4&0LI&XL6+=J
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M_P"-=!10!S__  B5O_T%M<_\&<O^-'_")6__ $%M<_\ !G+_ (UT%% '/_\
M")6__06US_P9R_XT?\(E;_\ 06US_P &<O\ C7044 <__P (E;_]!;7/_!G+
M_C1_PB5O_P!!;7/_  9R_P"-=!10!S__  B5O_T%M<_\&<O^-'_")6__ $%M
M<_\ !G+_ (UT%% '/_\ ")6__06US_P9R_XT?\(E;_\ 06US_P &<O\ C704
M4 <__P (E;_]!;7/_!G+_C1_PB5O_P!!;7/_  9R_P"-=!10!S__  B5O_T%
MM<_\&<O^-'_")6__ $%M<_\ !G+_ (UT%% '/_\ ")6__06US_P9R_XT?\(E
M;_\ 06US_P &<O\ C7044 <__P (E;_]!;7/_!G+_C1_PB5O_P!!;7/_  9R
M_P"-=!10!S__  B5O_T%M<_\&<O^-'_")6__ $%M<_\ !G+_ (UT%% '/_\
M")6__06US_P9R_XT?\(E;_\ 06US_P &<O\ C7044 <__P (E;_]!;7/_!G+
M_C1_PB5O_P!!;7/_  9R_P"-=!10!S__  B5O_T%M<_\&<O^-'_")6__ $%M
M<_\ !G+_ (UT%% '/_\ ")6__06US_P9R_XT?\(E;_\ 06US_P &<O\ C704
M4 <__P (E;_]!;7/_!G+_C1_PB5O_P!!;7/_  9R_P"-=!10!S__  B5O_T%
MM<_\&<O^-'_")6__ $%M<_\ !G+_ (UT%% '/_\ ")6__06US_P9R_XT?\(E
M;_\ 06US_P &<O\ C7044 <__P (E;_]!;7/_!G+_C1_PB5O_P!!;7/_  9R
M_P"-=!10!S__  B5O_T%M<_\&<O^-'_")6__ $%M<_\ !G+_ (UT%% '/_\
M")6__06US_P9R_XU7NO UE>[4N-5UN2!2&\IM1D*E@P92<GL0"*ZBB@"O8V:
MV%HELDT\RIGY[B4R.<G/+'DU8HHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDG(ZU =;\5:_HTVK^'4N//6\D2WMG%N+:2..4QD.6/F D*3D8P2 !CDZ>@^
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M#LH/EB3"E?3)S@]#%XF^R>()=.O[<^)-,UC3RQ@O;;1ICPP 961E(93CH?\
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M/O4'C&-Q].F/QWM-%O)XYFU>W;78'OXHHKF"32I(X7:,-M8NR?*/F/&>>.:
M.I71K-;>"WVL8H9O/VEL[Y-V_>WJ=WS?7GL*YB^NGT[XQZ5%$?W6JZ7+',HZ
M%H6W(Q]P&8?C7;UR]MIIU7QX?$3@BTLK,V=F3_RT=VW22#_9P%4'O\QZ8) )
M?%&MW&G7>C:;:+)]HU.Y:+?$$+HB1L[%=Y"[CM &>.2<'&*QS'XZ;3O$,,=Q
M+$\:B;2+F=+=II#M):*14!7&X8! !P:W?%?A:W\4Z?# ]U/9W5K,MQ:7=N<2
M02#H1ZC!(([U-H6CW>F1R2:EJ\^JWT@"M<2QI& HSA51  !R2>Y[G@8 ,?0=
M>F\2V7AR>QOI5$ML;J^^1"2 -GEM\ORDR9Z8XC:L1?&VJZ7X>\6WEY-'=W5C
MK1T^RW1A$7<(@FX#J 7)/.3ZUV'A_P +V/AR74Y+,M_I]TURP;I'GG8OHH8N
MV/5C60?A[:W.D^(--U"\>XM]:NC=R;(Q&T,IVX*')Z;%(SGIWH S=6LKRT^*
M/@<W.J3WJLE\,31QKM80C)&Q1P?0YQBF6^N^+-?T.TU_08KAFEN"XM)/LPMG
M@#E2I8GS VT9SG[V>,5KQ>"[^35]#U+4?$MS=W&D>:(R+:-/,#J%.[@\X')[
M]L=X;#X?/I=]<16/B&^@T&XF::320B%,L<LJR$;E0GJHQU/- %%[[Q-J'B+Q
MEIT&O?9(M+CMY+5H[2-F4O$SX^8$$9'.<G@8(YS+HWBZ_P!?C\)V/G"TN=4T
MQK^ZGB12WR!1M0," 2S9Y!P![Y&U#X5F@UCQ!J*:D/,UE(TD0P9$6Q"BE?FY
MX)SGOZ=*RG^&ZKHVA6]GK5Q::EH:E++4(HEW!",%70Y# @>W\\@#[W5/$/A^
MSM+#4+J.]N]0U8VMI<0(@D%N59P6#!4\W"%?[N2#@]#%+=^-].M-?=;2XO(4
MA273FF\C[3NR!(FV/Y6P,E>.V#FM'4O T.L>'OL%_JE[+?BX6[34UVI+'.HP
MKJ% 50!QM Z$]SFI+?PMJ0TR:.]\37EWJ3^7Y=\88T\D(X<!8U&WDKSG.>_
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M.T=C_HQ-S>R+V=XX\1_D6)^H%:6C^%9]-\2WVNW&L3W=S>P10RQ^2B(=F<$
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MB%!8Y4;-WK(#74UQTVH+:>,+C49EU><)";5(8]'F=$7=DE' .<D#)Y!"CTH
MQOAU>0Z1XFU_PC&D\5HLAU+3$GMWA/D2'YT"N <*_ X[FK%UK.M66K^*]'GU
M>5;B*S2]TB3R(B2K97;C;\Q$F%]2&'0\U'K3P:IXJTK7X!KUG<Z:KHBIH<["
M57QN5\KR.. ,8R35S4[C1M5\0:3K$^FZ^)]-W[%72;C$@;! ;Y>0&56'N!0
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M0A7S 5;:A!;D#KCM5/4FO;[Q/\/2OB*:9;E+EFGM!%Y<CK ?WJ@H1DAB.<@
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MV5K#4$*++;[5VA1A0"NT8.1D]S4U]X:U"'PO=V\6OZM-JTY0F_CV+,Q4Y5
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MN=1O)2/-NKC:&;'0!5 "J,G@#N3U-:E% ',7VEMIWCB#Q-$C-!/9FQO0HR4
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M>W$6@ZAJ""T$<86YCB!"J^%Z\#I@>W-2ZIK.L:-X%T;QDFI37,S_ &66^MF
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M-Q;1S-#+"74,8Y0 R^QP2,_C6!XQTV3Q'I?_  CT:L([QT^URXP(X%8,W/\
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MR1735C:#H!T6.1I]3OM3NI %:YO'!8*.B@*  .2>F3W)XK9H **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "J6K7L^GZ7/=6UA-?S1@%;: J'DY X
M+$#OG\*NUR'Q0O;[3?AYJE_IU]-9W4"HRR1;<G+J".0<<$],'WH Z\<@'&/:
MBN&U=]2N/B?8Z3%K-Y;6%SI4TSQ0[!AE=!E3MR"<]3G'.,5A6GBG5;/PXNFR
M:A-+<R^*'T**^EPTB1;S\Q.,%]H(!(ZD&@#O/^$CC'C-?#9LYUF:R:]6X8KY
M;*'5<#!SG+=P.G>KNEWMQ?VTDMQI\]BZS/&(YBI+*K8#C!/!'-<5%IWV+XTP
M1QW=TZ2>'Y2OG2F5HSYZ D,V3Z'!R*HV,GB+6?ACK$]GJ]XVLVE]=_9Y@P#2
M"*4@(0!CE1CH,$T >H52TR]N+Z"62XT^>R9)WC5)BI+JIP'&">#U%8.BZK'X
MJGTV_P!.NKB.Q2P6:0+*3F23[BMG(+(%<G/<K7*6GBK5K3PALEU"66]O?$[Z
M/'>2A2T*&8KNQC;D*IQQC)'':@#O)/$<<?C&#PXUG.)9K1[M;@E?+*JRJ0,'
M.<MW _&MJO.Y-+6T^,>FQB[O)(I=$N/EEG9V0^9'DJQ.X9XXSQCC%9,>O:PW
MP:TW66U.Y.HC41$T^[ET-Z8L,.A^3CI0!ZU6+J?B./3/$>C:-)9SN^JM(L<Z
ME?+0HA<@\[LX'ICGK7)^,M0OH!XIFM=4NY9["P$]M#9-Y:V++&SEIB2%<L0#
MM.X[1TYS3]3NI+WQ+\,[N8@RSF>1\# RUH2?YT >AT5SOCNXN[+P)K=Y8W<M
MI<VUG+-'+$%R"JDXY!]/K7-P7&JZ=XI\%N^LWEU'K,$J7<$Q4QY6 2*44#Y2
M".N23W)H ]&HKRO4-:U*T?3;ZVU2ZO'E\11VDUU$=MH87E*&%4)PQ48&Y1]X
M'YLUJP1:GK'C[Q7H\FOZC!9P6]I)"L#(C1%Q)D*0O R![G R<=0#OZ*\>M-9
MUU_A]X6\62ZY>/>R7EO!-"-JPRQM+Y;!E Y)'.<]>F*Z&YN=;\4:AXFM-,N?
MLTNG3BUM&6]:$Q/Y2N)&4(V\%F/#<87  .20#OR< G&?85C>'/$47B.+4'CM
M)[4V-])92),5+;TQD_*2,<^M<[8:EJFK>++;PUJEVJ26>D)=7K6$K(+B=GV?
M*PPP0;2<#'+<],4OPPA:WM?$\+S23-'XANU,DF-S8V<G'>@#NZQ;_P 1QZ?X
MHTC0Y+.=GU,2F*X!7RU\M-S \[L].V.>M<[XKN[K^T-82#4KN1[;2_-@M;!C
M&UJ_SGSI6R 0<#"G.0IPIY-8UQ/>>(-1^%US+>R6]W>V-Q++<0JH<,UJA8KD
M$ G)[<9H ]5HKR*^\3ZWX+B\6Z6^I3:B+$6CV-Y=@-)"+AMA$A  ;:<D9KI-
M9FOO#'BCPVMM?7=S8ZI<-8W<%Q*9#N*%EE4GE"-IR!@8["@#N:*\YLM3U#3;
M[Q1X;O+ZYN-1\V.32Y99#N:&;Y8\8[1ONW'K@<U<GN-0U'Q1?>&[>>8PZ=8P
M/N^W-!+(\F_,A95);&T<<#).0>, '=52?4HO[4738@9;D()90O2)"2 6/;)!
M '4X/8$U3\*Q:U;^';:W\0W5M=:I%N2::V)*O@G:3P.<8SQUKGOA]*^IW'C*
M\G=A/)KMQ:[@<,L<2HB >F!_.@#=\2^*+;PWX<O=:-O+>PV9VRI;LN5.<'.2
M.A(SC)]JW%.Y0?49KQ VOE? 3Q/*;BYE9KBZ4B64N.+H\\]SW/>NT,^H:)\1
M=)M6U6\O+74M/N9)H)BI1'BV$&, #;PQ&/SR>: .\JKJ%_!IED]U<$B-2J@#
MJS,P55'N6( ^M>>Z7-XJ\1Z!HWB73;VW@EFD6YG\Z^?R&@R=\1B\O:,#C.<Y
M')KT#5M*L=<TNXTS4K=;BSN%VRQ,2 PSGJ.1R <B@!$U.&3418*";@0+/(,C
M$:L2%SSSDJW3/W3[9SD\417E]=6NDV%UJ7V20Q7$T)18HY!U3<[#<P[A<X[D
M56U#PCI5K#'J>F::BZMIFG/:Z=*K-F-0A"KUYZ]\GD^M97P;D@D^%FD&$@N/
M-$V?O>9YC;MWO_\ 6H ZC2=;CU6XO;<6EU:SV;JDT5R@!!89&""01CN"16I7
MF\GB/6;Y/'L'FVUI-HEN5BNK2'$DA\II%)WE@ .F,'J<$46T>I6_@O3=9N?%
MMZDNHV]B)%E4./FVEEA51N\QP=N>3GGW !Z117F4&K:LK^/[)+N_M$TZSBN;
M(3R++- 6A=B-QWY!* X).,]J99WFKV0^'VIR:W>W+:NL4%W!*R^4P:W+Y QG
M<",[LY//TH ],2>*262))%:2(@.H/*Y&1G\*DKR6RO9?#-K\1];AGN9Y[*^?
MRUGF9U+&&/!8=\$C\!@5T<5IXDL-8L=42]B?2A!)]OAFOFG-P=N4>(&,!6R.
M0, @]* .WKDIO'L$-GK$YT+7&DTN=8I+=;3]Y*A8@2H,_,GRL<^@K#TI_%6O
M:+H/B2POK>)YFCN;L2WSF%X&^_'Y7E[5*] 0<Y')-=Z^EV<D5S&\.Y;IMT^7
M;,GL3G.,#&.F.,8H @M-;M;N[BML/')/ +BWWC FCXR5]QN&0>1D=CFM.N&^
M(\SZ?_PBE_;_ "S0Z[;Q#;W20,CK^(/Z5K^/;F[L? FM7MA=RVMU;6DDT<L8
M4D%5)Q\P/^- '145YC=R:[H-]X1U?^WKV^AU>YAL;VSFV^7^]0D/&  5VX/<
MD]SUS&^L:HOP_P#'ER-2NOM.EZE>1V<WF?-&L:J57/<#)ZYH ]2HKSG4'U?4
M?&FB:7'KU_:6M_HLLTH@V JXV#<IV\'YNISWQC-5]9UB[\/ZK/9Z_=ZM;V+>
M1'I^MQ.3"I"*&6=5X#,X8DD=&XVXH ].HKC-,NKJX^('BK2Y+RX:RBM+66&/
MS#^Z9Q)N*GJ,X%8GA_6=0U/P5X.GOM7G>:\,IN((<BYOL!\*K*1L ."QR!@<
MD=P#TZBO(+S7]=7X8>)+I-3N[>[TO6GM(9&*M)Y0FC4([8.2 Y&0<\=:Z6/^
MT-.^)<6DOK%]=6FI:5--(DS+^[D1U :/ &SACP* .VAGBN%9H9%=5=D)4YPR
MG!'U!!%#3Q+<) TBB5U9U3/)5< D?3<OYBN'^$=MY7@>*8W%Q*TEU= B64N!
MBXD&>>Y[GO3+JR\WXX6Q-U=J/[">4(LQ"@B>,8 Z8..1WH [^BO,;?5M3\0?
M#;4O&%MJ=S:ZC$;JXMHE?]U$D+L%B:/[K95.21G+<$<5WNA:DVK^'=-U22/R
M6O+2*X9/[A= Q'X9H T:*\LAUG4K>]\*7$6J75]]OU-[6[O =MK=*RR$".,G
M@+M&&4 ''5LTLS:S>R>/D;Q'J42Z2^^T\ID0J?LXD )"\KGL,9[Y[ 'J58NA
M>(X]=O-6MDLY[9]-NOLT@F*Y9MH;(VDC&".]<OIOB.\\0ZKX7T>>XD@%WH2Z
MM>/"QC:9CL4(&'*C+,QQ@\ =,YF^'MN;37?&D#3RS[-6&'E.6(\E, GO@<9Z
MG'- '>45PGC36;O1=92XOH-3/ATVF&NM-<[[2?<V9)%7DIMVX)R 0<@YI+/4
M[AO'/AVV@U66[L+W1))Y&#DI,ZF,+(/0D,>GK0!T7BCQ''X7TD:A-9SW,1FC
MA/E%1L+L%!.2.,D=,UM5XWKE]>WWPX\41W-W),UKXF6U@>4[BD:W,.U??&:Z
M5AJ_ASXBZ-8_VY?:C8:Y%<++'=[&,$D:;PZ84  ]-N,?I@ [+3+VXOH9WN-/
MGLFCG>)4F*DR*IP'&">#U%7:\LLO$^K6OA>Y$E\]Q=S>)Y-*CN9V"E(_-VCD
M+A3M! .W )SBKFKW?B;P9::_K+SP2Z6FGF2VM)KQ[F6.Y# ;@60'R\,"1DX(
MXQF@#T>HXIXIU9HI%<*Y0E3G# X(^H/%<[!HU]'J&GWD/B*X>TEMWCNXI7W_
M &EV7*21G.(R#DX48QVK)^$EMY7@WSC<7$K/>72D2REQQ<2<\]SW/>@#N&GB
M6=(&D42NK,J9Y(&,D?3</S%25P%[9>=\;K(FZNU']ARR!5F(4$3QC '3![^M
M4;;5=3\0_#O5/%MMJ=S::C"UU-:QH_[J)868+&T?W6W!.2P)^;@C H ]-K#\
M2^)[;PYX=OM9,$M[%9'$J6[+E3P#G<1T)&<9/M5G0M0?7?#&G:C(A@>^LXYF
M53@H70' ^F:\C^R^3\#/%LIN+F4FYO$Q+*7'%P>>>Y[GO0![:C;XU?&-P!IU
M<$)M0T7XA:':MJMY=VVJ6-RT\$Q4HCQ!"IC4 ;?O$8_/)YK/TNX\5>)?#VD^
M)M,O;>WFEE%Q+YU\_D&'<=T1B$948'&[.<C)- 'IO2HX)HKF".>%UDBD4.CJ
M<AE(R"/PK$\<QF3P'K^)98BNGSN&B<HV50D<CMQ7*6%[=V6E>!]!LYI&_M2Q
M,\AENFC8B.&,^6K@$J/FSQSA3R,T >E45Y9XD/B[P[X'UZ:?6A&T-U ]@T4_
MG2I%)*J,DC,@) R<$<^IXJ]XEM=8T"ZT$6_B?4Y1J.NQQ2B;RR%1D8E5PHP,
MID#IST- 'HM%>=V%GJ5QXV\0>&W\1ZM]@CMK>ZC<2+YR,^\$!]N0N5!P/Y9!
MH:=XB\077P[\-:Q+;WNJ1!Y5U1;%]ES(B,Z*ZX()P0"0I!/TS0!ZG16#X-U*
MTU7PW#=V6I2ZA TDNV:8$2+\[$(X/.5!"\^E8NFW-SXOU3Q1"VH7=D--N_L-
MHMM(4,95 3*P'WR68\-D84<=20#J=8U>VT33C>76XKYB1(B?>D=V"JHSW)(%
M0Z3JMU?W-];7>DW-C+:NJ[I,-',&&0T;C[WN."#7F.I:G>>*_AGX7U749)8K
MQM9MK>;R7*([+<;"X [G;D>A->NQVPBM!;B69@%*^8SY?ZY]: ,CQ+XHMO#?
MAR^UHV\M[#9G$J6[+E3G!SN(Z$C.,GVK<5MR!O49KQ VOE? CQ7*;BYE8W-V
MA$LI<<7)YY[GN>]=H9M0T3XB:-;-JMY=VNIV-R\\$Q4HCQ;"IC4 ;?O$8_/)
MYH [RBO,M+G\5>)/#VD>)=,O;>"::47$WG7S^0T.X[HC$(]HP.,YSD<FO3:
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M\*>*8?%FGRWUM8W5K#',\'^D%,ED.&P%8\9K>H PG\(Z5<:9J=E?1O>C5/\
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M&C\FSOH703+%@#8V4VLN ."O]:T=!\+6N@7NI7D%W>W$VH2B:<W$@8%PH&0
M !T_PP.*-)\1KJOB+6]'^Q2V\FE&$,\C*?,\Q2P( )P,#USST%6M:UF#1;6"
M292\ES<1VMO&#CS)7.%&>PZDGL >O2@"&_T#[;J,UY'J=]:M/;+:RQ1>6490
M6(.'0X;YVY%4+CP-ISG1FL;F]TV32(3;V[VDB@F(@ HVY6R#M'/7/.:T]&U*
M]O\ [7'?Z5+836TWE_,X>.88!#QM@9'/< @\5J4 <DGP\T==&U72FFOWMM2N
MS>R;KC+1R[@P*G'8JO7.<<YYJ>YMK/P]/!K6IS:GJERN+2.<VXE:!7.20D2
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MQ>1VF^)U"HS/LR23DC.>@/2@#1T?1K71+26"VWL9IY+B:1\;I)'.68X ')]
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ML3+&=^S+JKE@-PQG%;G_  DT9\8V_AY;20^?8M>I=[U*,H95P "3_%U./QH
MS;#X<Z7IFIR3VE_JD5A),9VTI;G%IO)SG9C.,\[<X]L<5TFJ6']J:9<6)NKB
MV6="C2VY4. 1@X)!QQWQFKE% %.VT\6NDQZ>D\I6.(1+*53< !@<;=O3VQ7+
MP_#338/![^%DU35?[+:02!#)&63#A\*WE\#< <5M:CXA&F^(=,TJ33KUX[_<
MJWD: PQN 2%8YR"0#_GI1L/&D5UI]U>W>EWVGQ65T;>[%T@5H1A660@'[A#
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M3+>SZM>:2DE_=RR7&CB=M.L9&@8.^W]^\BLN%'*A3U)) ..,?P]XHU'5=%\
MV%]>RA]92X-U<*VR27R5.$##!!8X)(P?E/K76+X%TU;^QO4N]1CGM;,6):.X
MV>= IRJ/M SCU&#[U5/PTT'_ (1JUT,/?+%9S>?:7"W)$]L^2<QM_#U/&,?C
MS0!1UN;4O"6GO;IK3W2ZCJUO!;_:)#OLX96P5,IW,0=K ,0<9[XIM_IWB#2H
MO$%R^I>3IKZ5++!;#49IYH;A 3O1W4,$QC*Y(SCUK??P5I%QX=NM%O\ [3?P
MW6#/-=SF2:1AC:V_L1@8Q@#'3K2Z/X.L-)M9X)+O4=2\^(P-)J-TTS"(]47H
M%![X'.!G.!0!S#ZIJ']G?#6Z^W7/FW[P)=GS3B<-;ESN'0G<,YI_A#3$'B+Q
MR8[J]CD74-BO]I=B,PH<X8D$\\$@XZ#I6K;_  XTF"'2XGOM6G32YA+9B6[/
M[H!2H08 ^4 _7@9) K3A\*V5MK&I:G;7%Y#/J&#,B3?NPX7;O"D8W;1CG(]J
M .'\.^)-0O/#/@"QO+^??K;3?:[LR$2.(U9@@?J"QVC(YP"!BM[5;2[T'1]8
M1O%<T4$]Q"UKYBM-/;HS!6B5BQ=RY#!>X)XZ5;D^'>B2^%+3P\[7?V6RD$MG
M,LVV:V8$D%' '(R>N>OTJ2?P)I=UH,FEW5SJ-PSRI.;V6Z+7/F(<HP?MCL ,
M<GCDT 9WA6^OAX\\0Z7*;Q+*.UM;B&WO+@S/$S;PWS%FQG:#C<0*YOPS/J]M
M\(/"=QIEI<7T,3N][:6DQBGEAS(/W9!!)#%3@$$XQWKN[/P;8V.LSZM#>:B;
MZ>W6"65[DOOVYPQ!&"PW'M@=@*98>"K+2]*TW3["_P!0MX].=FMG61"RALY4
MY4AAR>"#^@P .\$ZI8ZOH+7-A>W=S%]HD4K>;O.@;.3$^[G*YQSVQUZUT=<A
MJ_@Q)=(%IIMUJ%O=O?\ VY[N&X$;-,>KR8 #+T^4#!VJ.!S76R(SQLJR-&2,
M!UQD?3((_2@#QG2;B[L_@7XCN[&\GM+F"\O)$E@8*P(E/&<<?A@UTX:_TCQ]
MX70:M?W46KVES]JAGEW1[HT1U9%Z*>2..HZYZUJP?#[2[?PQ>^'4N[\Z=>NS
MS(TBEB6.6PVW(R:OR>%K:;5=(U&2\O&N-*1TMSN3&' 5MPV\Y  _#C% ',^'
MC?>+O".G>)H]>N+"]DN6N)2)&:!(ED8-"8MP3&T8W$9R,YKT.N3L_A[H]AJT
MU[:SZA%;S3_:'TY;IA:&7.=WE_7!QG' XXK<M-)CM-7U#45N;N1[WR]T4LQ:
M*/8,#8O\.>I]30!8O;NWT^VDN[@[54 <#+,<X"@#DDDX '4FO+O'>B7.G_"?
MQ3>RILOM4NH[R[C0Y\M/,C&S(Z[449/<[NU=WX@\*V_B.>UEGU+5+4VI)B%C
M=&'#$8+<<DX)'T)]31I?A&PTZUOK>6XO]22]3RYSJ5RUP63!&S+=%^8\>] &
M!X\W/XC\!I:\RG5]R[?^>8B;?^&VM;Q58IXCM/\ A%XE'E3F-KUATA@#!L?[
MS;=H'ID]N;MAX8L[&[MKEI[FZELX3!:&Y<-]GC.,A< 9)  W-EL#KUK&/PXL
MS+/(OB'Q,AN)#)*(]4= S'J<# __ %4 ,^+0 ^%NM =-D6/^_J5VU8VM^&;'
M7?#QT*X>>*P941D@8*2JD%1D@GJHZ5K0QM%"J-*\K*,%WQEOK@ ?I0!PGB+_
M )+)X+_Z];__ - 6LN6+4[^]^($,GB'5HTTPH]H(9_+,;?9Q)U4#@$]!@'OG
MC':W_A:UU#Q)8Z])=WB7EBKI;A&4(@<888*G.1Z_ABHT\(6:2ZW*MY>AM9&+
ML[DYPNP;?EX^7C_Z_- '.:/X@N_$&H>%M*O;J6)+S0%U.X:&0Q-<2G8NT,I!
M &68@$9X[#%/OY]4T#^QO#[:P;]M0U26+SYI3"\<(C:1(3(-S;ONC=]X@]LY
MK4N_AYI%WI>DV?VG4()=(798WMO/Y=Q"F -H8#D8 '(-6;_P/HVI^'5T:[6Y
MEC643K<M.QN!,.DOF'G?[^G&,<4 <GXCMO$WA_PCXNG?6FA@$"W.GI%>///;
MD##@R.H8J3@CN.F:O_Z=I?CSPQ#_ &O?W,.LV=R+N*>;*;HT1E9%'"'DCC\>
M>:V3X%T^3P]>:/<7VJ727JA+FYN;GS)Y$'1=Q'"C)X '4^IJW)X6MIM5TC4I
M+R\:XTI'2V)9,8<!6W#;SD #\.,4 <)X=M7L? 'C>[L[Z^@N;>]U/RI1<NY7
MRV8J?F)&>!EOO'UJ[JM[J%AX-\(>*C?WI@MH[1M5C$[8FAD10SL,\E68-[C.
M:Z=/!&FQ6^LV\-Q?1P:NTKW$0GRJF7_6; 00N[\QVQ6A%H%DGA@>'Y#)/8?9
M?LF)2"QBV[<9 ';C- '+^(M<N=,T+7/$=K<N(VGALK8O*3%&/-6)YL'(!W,W
M.",(#CDYO:;I6O6'BJ*Z:]C32)H#'+9S:A+=,THY5XS(HV\ Y .,<XK:;P[I
M<GAD>'9;59-,%N+;R6[H!@<^O&<]<\U1\.^#;+PVP:&^U.]*)Y</V^Z,P@3^
MZ@X ' ]^,9H P_C)G_A7<^W&?MEKC/\ UV6M&7PI>ZKXVTSQ%J]U;A-*CD6S
MM;9#R\@PSNQZ\= !^-:?B;PS9^*]-&GZA-<I:[UD9('"[F4Y7)P3P1GBM>*-
MHX51I7D8#!D;&X^_  _2@#R_2;AK;POXP9=4.FL_B>X03K&7<YE0%$ Y+L,J
M,<Y.:MV-]J0U[QAI@N-0M+>'38;JV2>X\Z6!V63)#,6QG:.,G';%;C_#W29=
M*O\ 3I+B^:.]O?[0:3S0KQW&X-YB,%&#D#CI[5+'X&TZ/4+N_6\U(W5W:BUG
MD:Y+%U&?F((QNPQ'3 [ 4 <7876JVN@_#W76UO49[G4;FVM;J*6;,4D<D;$Y
M3H6! .X\^_IU_P 3K^XTWX::_<VK%9A:E R]0&(4D?0,:E/@;3_[*T;31>7P
MM]'F2>S =,JR A,G;S@$C!]><UM:OI=OK6C7FEW8+6]W"T,F.N&&,CWH Y_6
M=FF^#M*M8-2;3X@]K;KY*%I)TX'DQX((9@, CIR>,9&%I][X@ENO'>E:?+/'
M<6J6[:=#>W/FO$\L1)7S"6ZD<<D FMX>&AKOAFQT;7/M,5YI<D3QW=LY0F2,
M82:-N1R,Y!Z9(]#3U\!:4MSJ5RMUJ0FU&.)+A_M;$DQ_=<?[7OV[8H H^"M<
MMM2U?4+5AJUAJ,4$?GZ3J4KR&(@M^\C9B=RMD#(/\(X&:O>))6?Q!I-F+ZZ(
M>.9VTVS9HY;C&T!S(&78BY.<D DCJ<"M2QT*"SU-]3EN+B[OW@6W\^XV;EC!
M+;0$51U.2<9/X5!JWA6QU?6++5GGO+:]M$:)9+6<QEXVP2C8ZC(SQ@^] 'G8
MUK6YOAEI5V=7O(KR/75LWE5P6DC^U&,!VQEL+QVSWS6Z+&]3XF7&@#7M7.G7
M6D"]D4W)+B03;/D;&8P0>0N.G&*U5^'.CQZ3_9D5SJ"6OVW[<$^T;ML@?>,;
M@< ,2??OFM3_ (1N ^)1K_VR[^W"T^QYRFWRMV[&-O7=SG^G% '!:9XEU6/P
MYIFFR7DD\L_B"XTK[5<3E':*,R%09 "0S;57<!GGL>:N:Y:>)="\.>+;EM9,
M%K]A:YL(DO7N)[=T7Y\22*&*$X[\=L9K??X>:)-H%WHMRUU/:W-TUYN>0!XI
MR=Q=&4 J<G/I^%2Q^!K :#>Z5/J&J7:WT?DW%S=77FS/'S\FXC 7D] .IH P
M()-0TSQ;X*?^V+^Y76+>9+R&>7=&Q6 2*57HI!'4<D=2>M8NK7,OBWX-^(?$
M=Q>W:32BY,<,<[+'#'&Y18R@.ULJN22"<MVP,>@OX2M)+S1;I[R],NCJRVIW
M)T9=AW?+SE>/_K\UFW'PVT>:/5;>.[U*VL-4+/<V4%QMA+M]Y@,$@GN <'TH
M H+>WVL>(6T"(E8;32;:<(E_):.[2;@7#1J20NU1C(&2<YXQ7M[W7K74O"WA
M#6M52:ZN/M,EW=VDA5YDB&4CW8!#?,"Q&#\ON:W=4^'^DZG)I\ZW.I65[81>
M1#>V=VR3F/\ N,QSN'UJ?4/ ^D:A8:?;;KNWFTZ0RVMY#.1<1N?O-O.=Q;G=
MNSGO0!C>#;06/Q'\<P+-/*@-B5,\AD8 Q,<;CR<=L]J3XEV4=Q/X3=Y+A2VO
MVL1$<[H,$/R " &_VNOO70Z/X4LM&UB_U6*YOI[R^6,7#W$Y8-L7 .!@9Z]N
M,\8'%2Z[X<MO$#V#75S=1_8;E+N$0LJ@2KG:QR#G&3QT]J .2O["^O\ XE3>
M'T\0ZO::>="6<"WN,.C^<5R&()S@#).2?7!(,VBO=>+U\3A]3OK6?3]0ETZS
M,-PT?D^6BXD95(#EF)8[@1CC%=*GANW7Q0/$)N[MK[[*+0@LNPQ!MV"H7^]S
MGK^'%0S>$;,ZI?:A:7=[8R:@H6\2UD4)/@8#$%25;'&Y2I]Z .%TWQ#K/B-/
MAU>2ZC=6;:J+J.\C@(59#'&^'QCN5R.PR,#BK-K9W]Q=^-M'?Q#K(MM)=)+-
MQ=GS4+P"3!D^\P!Z G')SGMV<WA'3I+O19X6GM1HRE;** J$0%=AR"#GY>.?
MY\TD7A.UAN]9NDO;T2ZP%%T=R=EVC;\O&%X_^OS0 [P5J-SJ_@C1-0O'\RYN
M+**25\8W,5&3^)KE/"&FJFJ>.VAN[V.5-2=$D^TNY&88SG#$@GT)!(' KN-$
MTB#0-&M=*M9)7MK9!'%YI!95'09 &<51B\)V-MJFJ:A;7%Y#+J7S3(DW[L/M
M"EU4@C<0 .<T <##JNL7'P_^'MZ-9O8[F^U*V@N9 X)E5]Y.XD<_='!X]0:U
M[+3[R7Q[KGAU]>U@Z;]B@NU'VL^:CLSJ0LGWE7Y0< CGVX.XG@+38]'TC2TN
M[Y;72+A;FT'F)E77.W)V\@9/!]><\5?C\-P1>(;K7$O+L7ES MNYRA4(N2H
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M&<FJ4?P^T&'P_;:+$MVEK:W0N[=ENG\R&0$D%&S\H&X\#CD]^:ZFB@#EM5\
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M6B1Z5JBRW$43*\<OF%98W7HZL,$,/6J;>!-)D\.W6BSS7]Q!=X^TS3W3233
M= SMDX'H,#\SGIZ* ,63PS:3:QIVJRW%V]WIT;1V[&08"L &!&,'( SGTJA9
M?#[0M.U>2_M1>1QR3?:#9+=.+7S<YW^5G;G//H#C X%=310!RM_\/M#O]>EU
M@_;;:XN !=):7;PQW0' $BJ1NXX]^];*Z+:IKJZNCSK,MK]D6(2D0A-V[.SI
MGW]*T:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6@#M=*U&+5]+MM0MTE2"X021B5=K%3R#CMD<UCW_ (WTC3K>]NYOM#6%A/\
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MKYL<]G,8+FWF3;)"XYP1[CD$$@^M.OM<M[.^%A'#/=WQB,YM[=066/.-QR0
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M?Q/HWA7PO<7<VMOK%G#=$?:()1<NBR/\JNP.!@MMR3T H U?^$-TS_GZUO\
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M9=W*D?-M((Y!#8X]:Y/X>VZ^*-&TGQ+?PWT.J))+,UVLH5;D,[CRR Q+(HP
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MPJ5*XC+L%#-DC/)' SSCH,D '245YWJ^HM:?%'0KM[?4 9M+NLV08R,6#(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.UO9[33K&Y@GN5MW95+)&$R0.<[#TZ=ZZ/Q9X?B\4^%=1T263RQ=Q;%?&=C
M@J<=\, :@_X0S2/^>FJ_^#B[_P#CM'_"&:1_STU7_P '%W_\=H S_#.M7VFZ
M#;:;XATR_AU&RB6!Y+>TDN(IPHP'1HU(Y !P<$'/%<7_ ,(_K%I\&[[37TFZ
M^W76J?:8K:./>_E_:4DR0N=ORJ3@X]*]$_X0S2/^>FJ_^#B[_P#CM'_"&:1_
MSTU7_P '%W_\=H S_%=YJ8U'0#:V-_-I$SR_;7LHB+A/E'ECLR*23N(P>!R.
M_$7&DZLOP^\6:2F@:C'/<:Z;BVB\K?OC,T;\$$YPJG)Z>Y->C_\ "&:1_P ]
M-5_\'%W_ /':/^$,TC_GIJO_ (.+O_X[0!E7*3S?%?2M0CL[LV:Z5- TYMW"
M*[NC*I)''"GZ=Z=\-(+W3?#)TF_TZZM9[2YN-SRJ DFZ9W!0Y^888<]*T_\
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MIMSD<@8'-4+FVU.X^$&A:7_8NI)>V<MC')"UN2W[ET+L ,_* IP3C/:O6:*
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MP_Q6=H_"-NZQM(RZI9D(N,L?.7@9XS0!?T_QU97VN7&C2Z;J=E?QP&YAANX
MIN8P<;H\$YY['!]N#B#2_B-I>J6"ZDMCJ=OI?V>6X>_G@"PH(VVE203\W&0
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M1E"C:Q)( Y) &>F:9X9U_7=62UMK_P .7FF30KB]EN=GELP&,1$,2V6P<X
MSSG%0?#JTU#2]&N=*O\ 3I[9X+VY<2R%=DH>5G4I@DD88=0* +%YXGO8/B):
M>'H],GDMGL9+EY4:/YCO100"P(5<MGN21@'%2WGC:QL[2\OQ9WMQIEE*T-S>
MPJK)&5.'.-VY@IX)53T/7!JEJEIJ%O\ %#2M7ATZ>ZLWTV:R:2$KB)S(C OD
MC"X!YY^E8FDZ;JVB^"M<\'SZ9<W-PYNH[&=$S%<1S%BK,_1""YW!L=.,T >E
M0S17$$<\,BR12*'1U.0RD9!!]*YNY\<Z=:"SN)K:[73+NX%M%J.$,)<DA21N
MW!200&VX[]"#6IH6D_V/X8T[2#*7-I:1VQD'\15 N1^5>>^$M/OM)LK?PQJ'
M@>.:^LV\J/5C!$UM)&#\LK,3NW8_A ))';/ !UE_X[TZP6_G:UO)+'3[M+.[
MNXU39%(VT="P8@%UR0#U[\UH:AXBALKNXL[>SNK^ZMH!<3Q6VS,:'.W)9E&3
MM; '/%>=^++'Q'KFC>*+*ZT*_NKU;U6T]HV46_V99$*E!NYD(#9X)YQD#BMI
MIM;\-^.M1U@>']0U#3=<@@)2UV--:S1J5VL"P&"#G.< T 5M9UNSU#Q;\/M?
ML1=36]T+QDC16W./LYP-F<9R2,_KCFNS\/>)+?Q%'>B.UNK2YLK@V]S;72J'
MC? (^Z2"""""":Y_5X-5NO&/@N_GTZ7%H]U)=F%=ZVXDB*HI/\1R0"1Z$]*L
M>$;6[M_%?BVXN+.XA@O;R.:WDD3 D41*A(_$'K0!E?$4V\/BOP<UQ<O;6UQ>
M21W3"X:)701Y 8@CC('6CPG=7$GQ(U6'1;RYO/"@LU)DDF::%+O=@K"[$Y&W
M.0"0#Z<5<\:VE[=>+O"%Q;:?=7%O87DDUU)''E8U9-H/OR>@STINEZ=J'@GQ
M1/:V%C/=>%]2+7") N3I\Y^\-O7RVZX'0YXH UM6\;6.D6MS?2VEY-IMI-Y%
MS>PJA2)MP5N"P9@I."5!P<^AQ/=^++:WDOUMK.ZOEL(TDN6MMAV!EWCAF!/R
MX/ /!_"N+TRPO=!U+4]&O?!/]K^?>S7%CJ*Q1-&R2N7Q,S<KM+'/!..@Z9F\
M4Z#<7.HWU]I-IJ.F^);5(X[&]L$(@O0$4A)!RNT,67Y\8 ')QB@#H1XJO6^(
M-WH/]E7!M;:Q2X,B-&2Y9B-V-V=HVD #DG/'2FZ7X^L]<56L]&UF2W<SH\WV
M8;(VB)!5B&X)QQ]>QSBLEMJEA\3Y-2FTZ:>VN](A@:XMP"D<B2.S@@G/1LC
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MH<!U;=N+%1PN.O7'. "+PUJ4&A:IXUD=+BXQK*1PP1MOED9HD^5-QY/)/7@
MGM7H43F>W5I(7B+#F.0J2/8[21^1KR-]#UZT\2Z[XITNQO!?P:EYUM:R*1'?
M6SI&DB8_A;*Y!.#QSQT]8LKHWEG%<&":W9U!,4Z[70^A'^'% '#> 8_^*O\
M&H9Y76WU%8H%DD9A$A3)503@#)[5L^3#;^.[^Y\N9S'ID4@C1B06,DH)"YQN
M(4#/M67IMO>^$_&OB.XN-/N[G3-7ECNH+BTA,QC<)M='5<L.0"#@C%;>F_:;
MC5M1UR>RN+:![:*W@AD7]ZZH9&+E1G&3(  >?EYQF@#,L_B5IEY::3?)IVJ)
MI^ISK;1WDD*B-)&8JJM\V>2.H! S@G.<6TU#2_\ A.]2B@TV\?7(=-1G?.U9
M8=YVJFY@N=V[D@?6N+M]&U>+X3>&M);2;S^T+/4H)9X!'RB).78YZ'Y<=#75
MVMM=GXM7FI&RN5L9-(BMDN&C(4R+(SD>HX8<]* +?@/Q)=^*O#$&J7=C);-,
MTC*2R%67S' "X)/R@ $D#-=/7&_#*TU#2_!MMI&HZ=/:3V+21LTI7;(3([93
M!.1@CDXZUV5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MW$MP"!G&>*TO"WBR.WLO"NC7.FWL"7UA&EK>2!!'*Z0AF7&[<. <$@9QQZT
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M;.>F.Y H W:*P_#_ (HM=?N=2LEAEMK[395CNK>0J2NX95@5)!5AT/MT%;E
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ML6<#EC@L3G 'H<D52E^(&FKI^@7T-G?SV^ML$MFCC4E6*EMK#=G/!Z9'OWH
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MG:1Z(E=/X@LM:TOP]H]KI,5Q>)'=)_:8M'$<\T1W&1D)(P6<Y."#R<$5V=%
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M203G;OX)P#CH,YKMK:22:WCDE@:!V&3$Y!9/8XR,_0D>YJ6B@#R2+PKXBE\
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M4A0<YXIVH6?B#0O%6F>)K311?0R:>;"^L+%E#0#S#(C)N(#8)VGIGK]/1**
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M)'MF#7)E#*=W3;UW8YXY[=/JEA?:A\0]'OET^Z6P33KFWFG^4>6TFS QG/\
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MZ2=-RG?LW^7G)3=QGKW (P:ED\;RGQ!J.CV?AW4KJXT]X!,4:(#9+GYP=W0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*V=-O=6TO3;:PA\*:F\-O&L49DO+8L% P 3YG.!Q0!E_$?\ Y#'@?_L/Q?\
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M+<6N;@L5D4$*22#G ) '3':@#/MVO9_B;XBTS^TKL6[Z3"\2^82('=G4L@Z
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M %%%% !1110 4444 %%%% !1110 4444 %9^MZ+8^(=)FTS48VDMI2I(1RC
MJP92&'(((!K0HH YG5_ 6AZR+%[A+N.YL@5@NX+J1)P#R09 =S9.3R3U/K4\
M_@[1YX]+C\N>-=,D\VU$<[KLDYRY.<LQR<ELYR<]:WZ* ,JX\/6-SX@M]<D,
M_P!NMXFAB992%5&QN&WH<X'Y527P5I"Z=JM@/M1MM5D>6\4W#?O6<88YSD9
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0<$9'0]J %HHHH **** "O.YC/X<^+]D+B]OI-)UNV>.VCENY&C@NDY("EL
M,O3WZ5Z)7*?$30)]>\(SBPR-4L76^L&4?,)HSN 'N1E?QH G>W_M/QR)4N+I
M(-+MP)4CN76.6:0@J&4'!VH,\C_EHOI1=>-=,LC;RSQ72Z?/<_94U#8I@\S)
M4 G.X#<"-VW;[XJWX9LKFVT-)+]0FHWA-U=A?X9'Y*CV480>RBO/_"UB^G6$
M7A75O ANM2M',4>HO91O:3(&)65I3T(&"1RW'J> #OI/$]JMS)'%:W<\,5XE
ME+<1*I2.5F5<$;MV 77) P/PK/TOQ=/?^+M>TJ32[J.WTP1+Y@56)+(SEB 2
M<,-NT $^N,X'-ZKI5XFO7&K^&X=5T[7#?JD]MY+FROXPX!D8D;!\G.[(.0>,
MD&MG2([O3/B3XKEGTZ\-K?BUFAN4BW1E8X=K#(_BW#&T9)STQ0 W2O%WAK1/
M!6G:A:+J(TNZNF@A,J/(X=IF4EBQ.!NSC)Z=NU;>E^*['5-7O-+\B\M+NUB6
M<I>0^5OB)($BY/W<@CG!'I7G-OIVI1_"G1-.;2=1%[!K23RP?97W+&+II"QX
MZ;2#^G6NK>&27XL3WLEC='3WT 6IF:!UC+^:SE"Q  ^4]^.W6@"])X_TB.VL
M+MH+\V6HRF&SN4M]ZSOS@*JDOS@D949Q74@Y ///K7B^B7]I!H>@6VLZ7XCA
MTO29Q>P$Z8S1Q8W%"\RDAT0-G<%7. 3Z5ZS:ZHUSK%]IYL+R)+58V6ZD0"&?
M>"<(V><8P: -"N \-^<WQ:\76SWE[);6D-FUO!)=2-'&9$);"EL<D5W]<&8+
MKPU\3-6UB>RN[C2]8M8%\^T@><PRQ KM9$!;!!SD B@#8O8@OCRPD,UV(SIU
MS*\*3R;&9'@"GRP<$@,W;O5'_A9FB&P^WBVU/["MT;6>Y-J0ENV_9ER3P-WU
M(R,@9%:%E+)JOB/^UQ:74%E:V<EO&UQ"T;S,[HS$1D;@ (U'(!))P.*\_N-.
MU*7X/^(=,72M0-_<:E-)#;_97#.K7(D!''3;S0!UEUOC^,^FJLTWERZ-.S1F
M5BF1)& 0I. <>@K2NO&NF69MI9XKI=/N+G[+'J&Q3 9"2H!.=P!((W;=OOBL
MVZ2>?XK:5?I9WGV,:3- T_V9PJ.[HR@DC@X4]>G>N<\*63Z=I\'A75O AN=3
MM'\J/47LHWM)4#?+,TI[@8)'+9'J> #OI/$]JMQ)'%:W<\,5VEE+<1*I1)69
M5P?FW8!=<G&!1)XGM4N)(XK6[GABNTLI;B)5*1RL5&"-V[ +KD@8'X5Q>J:5
M>)K\^K^&X=5T[6FU!4N+4PN;*_C#@&1B1L'R<[@0<@\9(-&K:5>)KUQJ_AN'
M5=.UPWZI/;>2YLK^,. 9')&P?)SNR#D'C)!H ])N[J"QLYKNZE6*WA0R22,<
M!5 R2:QX?%EDVMVVDW5M>6-S=Q--:?:D55G51EMI#'! ()5L'':D\;:/=:_X
M+U;2[)E%U<6Y$6XX!8<@'V.,?C7/>'KL:G)!+%X .EZK:QNTLUW9)$D;[2-L
M4@Y;<V!D<;<Y[ @&W8^.-+O[C3%CBNDM]59UL;IT7RYR@)(&&++D D;@,XJ*
M'QWIEYJDVF6UEJLTL5XME.T=F^(689#.>JKSU/\ +FN(@36;V3P=J5UH.M-?
MVE^3?AH=B1$QNN(TR%$8)'S 8QC))KK?!D=Q!XC\723V=W#'=:@)X'EMW19$
M$:+D$CU4\=: ,/1+RQL_ GC%M:DOYM.AUB^AD,;R22B(-@ -G<, =2?QKM_[
M9M;2VL;>TM[JZFFMA+#;1$&3R@!\S%V '4#);DGO7 QV-^WPX\=V7]F7XNKZ
M_OI+6$VKAI5E/R$#'0_IWQ4VJVUUIVM:'K\_ANYUG3'TE+"YMDM/,GMI%;<'
M$;#)!R0<>GTR =(WQ&T!=+L=0W79BN[S["%%NQ:*?."CC^$C!XZGMFMW1]67
M6-/^UI9WMI\[(8;R$Q2 J<9VGL>QKA->M'DTOP])I_AJ:PB'B"WOGM;:SPZ0
MK]Z258P0&[XZXQW!QZ4#N4$9P>>1B@#D?#_C;^TU\07&H64UA::9>2P>9+M(
M58U3(;:22Q)8X /! R36A'XNL_[872KJTOK.\D@:X@CFB!,Z+][9L+9([J<-
M[5Q$N@ZS>:!X[T*'3IX[NZU62_M994 @F7,3HH8G!+;"".W?%;GAN]M-0NH+
ML>!)M'N;5&-Q/<Z>J-&2I!6$J-SY/<#&,]R!0!/:_$S1;S33J4-EJ[6 MY;A
MKD6+F-1&Q#*2.C<9^G7!R*G7XA:1Y^FI);:E%%J46^TG>U.R5MF_RQC)+8Z<
M8/8FN?\ #UG?6_P,N]*GTZ]CU 6=Y"+9K=]Y>1I"@ QSG<O(X&>:6YM[PZ?\
M.E&G7Y:PEA>[ M9,PA8&0[N/[QQ^O2@#I[7Q;INJVFLQR6VH6TFFKB\MI82)
ME5ERK (22",X(/;M5&P\7>'M%\,^'/(74/L.HA(;'=$\K\@D!CSS@'C))["J
M-O'<Q>,_'-T]C>^1=V=LEO(+5R)62-U8+QSRP^O:L:WL=0B\(?#JU?3-0$^G
M7T$EXGV60F%4C=6)X]6% ':VGC?2;BWUF6X2ZL#HZA[R.[AV.B%2RL "<@@'
M&.>.E2V?BRUO-1_LXV5[!>-9_;H8953,T6<94AB,Y(&"0>17):@-;M?$?CR^
MTG2IYKBXL+9+(S6S>7,\:N' R,-C=P._O1I$-V?B-I&JII&M_99=)EMY;F]3
M#"0R(QW@GY!@'C ']T4 ;GA?QL-8\,-K.H64]FAN9(HP0K;SYS1HB[227X4'
MCJ>.*TK7Q;I\VI7VG7:3:=>64'VJ:*\"K^Y_YZ!E9E*\$'GCO7GD&B:X?AO'
MIL>B3R7^C:NUZUK<H%CO$%P[[$)^\"C9SC&>.M:E]IJ^,/"NM0Z-X2DT.ZGL
M'@$UY9I;32.2"(EQSL.#DG Y&,\X '^)];_M'7O!,UO;ZG;PW.J(8Y)"4BGB
M\MSR@;@_=(WJ#C\:]*KRZ_U'4M<A\&,GAO6(KBPU.)[V)[4J(ML3J2&. RY/
M##C'7!(%=QI/B%=4UC5=,;3[ZTET]U&^YCVK.C%@'C.>5RC4 8?Q UFZT]]
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MQODD(39F,AL,<+P?;WH Z'_A#-)_Y[:Q_P"#F[_^.T?\(9I/_/;6/_!S=_\
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MYM^W<"-VW'OCF@#IJ*I:MJ*Z1I-SJ,EO/<1VT9E>.  N5 R2 2,X'.,UC_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %<E\2[6ZU'X?:OI]C:S75W=0^7%%
M$A))W#J>@X]:ZVB@#SJ\TC4=)N=*\7>']/G>[$$5KJVF[=CW,0 &X X'F(>A
M[CC..L6N1W5GXT3Q&WA>XUO2;^QCMI85ME>XM9(W8@['Q\I#D''IGTSZ510!
MY_K&BV>JZ?IEOJ/ARZT^%FFGAETM")].D^783Y6?F8%LX!&0!SC-9\^G^)QH
M/A.YU&WNM3N=-UDRR%$43M;8D5'9<@;L,I(ZC//.:]0HH XO1X;P?$_6K^;3
M[J&VNK"VBCE>/Y"Z;RRY]MPYZ'L:P=0\-ZGKLGQ&LXK:>W.J_9VL9ID*I*8X
ME!&>WS+CGL<UZE10!R_ASQ#K.M?9XKSPY>Z7)$O^FR784(6QC;%AB6RW.< 8
M'J:XB'P]KY^',6F1Z*[:AHVK->BWN=@BO5$[OL4Y.04?J0!FO7Z* /-;[2YO
M&/A'6;73?"C:!-/9-"KW<$<,LDF0P0;23L^4@DXSD8'!J._O-9UP>#G_ .$8
MU6&XT_4HY+U'C55CQ$ZDJQ8!ER<@],>_%>G44 9VNSW]KHMQ/I=N;F]0*8H
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M%/F&4#& K0C XQN(H ](JKJ5Z--TRYOF@EG6WC:1HXMNY@!DXW$#I[U#K?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3NSP<#&*[S3FN6TRT:\>%[HPH9G@.8V?:-Q4G^'.<>U<Y??#[3+O7YM8@O\
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MUN^R2*1#E64X/(^E9B^ ]/6\U*[%_JAGU*U6VNG:XW;P 1NP1C=AF'H,\ 4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M2*8G8$'NNX#Y1D @'OU-;]% &')X7L#KUUK:-=I=W,"Q3)#<,B2;00I*YQN
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M)>RL8@05V#YN$P<;>_?-:VC^';'0Y[^6T:<M?S&XN!+*7#R' +8/0X '''%
M'%Z-:ZSK.E>&O$EMJT5N[F&>\F:]ED6Z1QAXC$0$4[C@8^Z1@5T'Q%URZ\/^
M"[J]LY#%,9(H?/ SY(>15+\]P"<>^*72OA[X?T74S>V,5S&GF&9+3[2YMHY#
M_$L6=H/IQQVQ70:CI]IJVGSV%_ EQ:W"%)8G'# T <;K N/#7C'PN=,N+I[;
M4IWL[NVFN'E5QL++(-Q.&7:<D=1UJ'P9ID$/Q \:.DEV3!=VX3?=RN#FW7.X
M%B'Z\;LX[=*ZC3O#-CI\]M-YMU=26D9BMFNIC(84. 0N>Y  W')QQFETSPW9
M:3JE_J-M)<_:+]U>Y,DI82,!@'!X&!QQB@"GXR\.Z?XHL;73KN[FL[P3>=8W
M,#;9(ID!.Y3],\>GYUSN@:KXDTSQ5#X2\7B"^:ZMI6L-7M@8WE1<;U<#!5L8
M.1CH.O6NTU?0K+6S:M>"8/:2^= \,S1,CX*Y!4@]"1CISS45EX=M+/4SJ4DM
MS>7WEF%)[J3<8T)R54  +D@9(&3@9/% 'ENC7K^'/A5#/8S7$#WNM/8R3>>[
M"")KIU9U#$A3MR,@9R<]:ZO5Y;KPMX[T"/39+J:RU.*YCNK22=Y1NBCWK(NX
MDJW8^N1WK;B\#:!%IVHZ<;1Y;'4'9YK>69V12S;CL!/R?-\WRXYQZ"KNG^'K
M2PNHKII;F[N88C##-=RF1HT.,A?K@9/4X&2: .3\-0R>)?"6@^)SKUU;7S2K
M=74J2L8Y!N(>W*$[0O\ ".,@@'KG. ^KFS\?^)M,N)+BRT_4]5MX)M3A<H86
M^SH50,""A<\;N@_'([G3_A_H&EZL]_:17,:M-]H%H+E_LRRYSO$6=N<\CCCM
MC I\_@71;J+68KA)Y4U@J;U7F)$A7&"/[I  '&* .@@MTM[=8$:0HHP#)(SM
M^+,23^)KRN_&HVS>+/",>IZH=4GFCNM%E^WRB39*.%#%L[(V1\CT]Z]0T^R3
M3K&*TCEFDCB4*K32%VP.F6/)_&H9=&L)M<M]9D@4W]O \$<O<(Q!(_\ '?U/
MK0!RWA+5%\7Q:7J$4UW%%:V&VXC6YD ^TN=K(W/S%-C?>R?G4UQ>J"6_^#.K
MO>W5W<RVVNF..26X<M@7BH 3GG"G ST[5Z[INC6.CP7,-A"(%N;B2YEV]Y'.
M6;_/I64O@;1!X=OM":.=]/O93-*CSL3YA8.6#=0=P!^HH P-<TN*7XG>&K 7
M%VD/]FWH9EN7\QANCR/,)+CZ@Y]"*T/AS/<&PUVQFN9[B/3M:N;2W:XD,CB)
M=I52QY.-Q&36LGA/3DU6QU(27AN[*)HH9'N6<[6.6SG.XD\DG)JQHWA^RT%K
MTV1F_P!-N&NI_,D+[I6QN;GIG X''% '(ZSI\VK_ !5;2'U;5+>QGT%YGBMK
MMH\/YZJ&7'W3TZ=<8/!(-:*'5?%@\265K>O!=:?>-96LYOY8Y+;8B['**,-N
M.6))^;)'05VS>';)_$J^("UP-06#[,&$IV^5G<5V],9Y]:S=3\ :%JNNMK$B
M7<%W*H2X-K=/"MRHZ"0*1N&./I0!S'B*^U;3=E]JJ7>J:,VFQ1SWNC7#(]E,
M Q>81J1E6#*V>P7TZRO$==^(MK8Q:YJ1TFZ\."ZVV]T\8ES*H##'*Y&#D8/;
M."<]?=>%[&YGN)%ENK=;F!;:>*"7;&\2@@+M_AX)&5P?>N9FT9C\5K-[:#4+
M.PM=#^QPW%M"RQHXE!$>2I4C9ZY' [@4 <_8Z[K&E6;^'Y]0FN88_$_]E1WM
MS.RNT!C,BHTH!.[.%W#G!XQQC2U^37/!&C^(=374XTM9XX?L]KY[W#6C&1(Y
M)5:09VX?=CH"!78W7@W0KWP]-H=S9>;93.99-SDNTI.XR%\YWYYSG].*;I_@
MS1K#2KO3GCN+V&[3RKAKZ=YWD3D!=S'( R< 8QG/6@")?#D,&KQW,6L7HLKF
MU:VDLWN7<7#'YA('+95@ >5ZCZ5D_!^UCA^&FDRHTI:5'+!YG91B1_NJ20OX
M 9K;\/>#=*\,G-DUY*53RHC=73S>3'Q\B!B0J\#IUP,]*M:!X;T[PU:O:Z8D
MR0,Q98Y)FD6,$D[5#$[1DDX'K0!RAL8!\;[R?_22PT&*?:EQ(-S"=QC ;!&
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M)P<[3[K@TMWX.T6[T6QTG[,\%I82I-:BWE:-HG7.&# YSRV3GG)[T 8>FO\
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M:/SG=R"Y*D$A0  .F23UQCI-.T>VTV>ZN4,DMU=LK7%Q*07DVC"@X   '0
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M>8;?5()S+:ZK\A)+<_*^/F (XQQ@'%>B:IJ$6E:7<W\P)C@C+E5ZL1T4>Y.
M/<T 9=MXMT^Z\:WOA9"?MEK:I<%L\-D_,H]P"A_X'[5OUX]XAM]6\.6>A^+)
M])DCN])NFFU.=9D?S8IVQ,, Y(!8;?0#VKL?&5W<Y\.S6SR2Z3-?H+U+;+/+
M&48I@+RR[L%@,Y Z8S0!V%%>82:9?P:7X]U 3ZK;:<MO(VDJUU-$8]L.YRJ%
MAM7S!\O XR!P:KR*V@>#O#NJ1ZC>>?K1T^TO9[B[<HB,F21S\F>%)&.#Z\T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI  S;#RJ@ 8W8)/;%<U-IFL)\._&6@G1KXW=Q>7;V[+&"LPEDW)M(/(P<DG
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MPFDN+[Q!'JJV28,BPK*G;.-Y52Q&>^.HKU*UF:XMHYG@D@+C/ER8W+]<$\T
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M\7_%-:U"EW=X./WZ@H4'^]^[<G_8([T =B=54:I::?\ 9;CS+B!I]XV%8U7
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MCW7$1)4,F'QU&,,0:++QI9:AX2@\16UE>M;SR+%'!B,3%C)Y8&-^ =QQC.:
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MDA67=N&6'&,<=3G@<'#Y/B)I)M]"GM;:^O(M;#?9&@B!RRJ24.2,-D8] >I
MR: .NHKC8=<TO4O%?A\WFAZE::Q/:W#VK72[/)08$BL V,G"]CUZBK=YXWLK
M2QN]26RO+C2K.9H;B]A52B%3M=@N[<RJ<@D ]#C.* .GHKE=3\=6=AJT>F0:
M;J.H7,UDU]!]CC5UG0$?=)8<\YYQT[D@'9O=3DM?#TNJ1V,\DB6_GBU8JC_=
MSM.3@$=_H>M &C17'Z#XR:X\':-J>IVDZ7FHK$D$*>63<R.N[Y &X7&3EMN
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M6C?.UU*,P(X/?(H WJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MC5FOHH[ED\J] G>0(O)X*MU8#G'OC?A>YU/0=5D@\&R:.S6$L CDBC$TTK#
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MNM6?PQOO <VF327H2:SMKH >1+$[$K*6S\NT-RI^;Y> <UZG2!@PRI!&<<4
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MDM9D M_-B*H%)8%BI(Y YQG'.*Z+P;/XA&GOI_B.RD%S:.T4=_N0K>1@X63
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M>'O#.I:PZ>8+.W>8)_>(' _$X%<[X1T*UU'PK8ZWX@@BU34M0MUNYI;B(2[
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M>->VMVLD2F%G W1R;N0H(SD9X]>@]!BMRVG);7*QL3$(Y0BX0\8.!V% '#>
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M2\">*K74-,C00:6\\4JR":*0E'(*' Y4IZ=Q]:7P]XK:W;PUHMWI5S;Q:A9
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M?_H(H NT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(;.^MK:..82QLNZ,/NX#;L'=P<=N<5UD,\-Q'YD$J2IDKN1@PR#@C(]#Q4E
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MPQ2_;+&WN$1(YF(,9?=CS$5<CIR<MMZ"NUDGAB>-))41I&VH&8 L>N!ZFI*
M/,-(\-:C#X-&@ZYX5BO;-M3G::!)XV(B=I'62/)7&"4 Y#8)X'>/_A"_$,&B
M6<EM)/<2:/K0OM-L[V<-*UJ%"F%GR0#RQ7).!@'';U.B@#CFTR]U3QA!XDFT
MVXMH[#3Y+>"WD>/S9I)"">C%0 !CD\DGL.>;M_#7B"'X:^%=&.CRF^TW4;>>
MXC$\. D<I<D'?@Y!X_I7JM% &/XHT4^)/"FI:/YA@:\MFC5S_ Q'&<=LXS7+
MSZ1K7B30-!T;5-+>RDLKJWFO;AI8VC<0\_N]K%CO(&,@8!.>1@]Y-/#;H&FE
M2-2P4%V !). .>Y-24 <?8V&IQ_%#5-5DTR9=.N+"&VCN/-C(+(S$G:&W ?-
MZ=JL?$+2+_6_!UQ::9")[L303)$7";_+E1R 3P#A3UKI(9X;A-\$J2IDKN1@
MPR#@CCT-24 <5+9ZQ=?$31]:?1YHK2'3YH)CY\3;'=E*C&[)P%YP",G@D<US
MY\*>)'T75);:Q6#4H/$LFM6,5Q+&4N$)QL8JQVDJ6'/?'/<>JT4 8/AZ]UK4
M6:XU/0UT:-4VB!ITFD=B1DY3@*,8'<YZ# SB>.ENY-<\/-I>FR7VH6CS7 ^S
M7,<4\4>T(2/,^0JQ8 @^V/4=S6+K/A72]<NX+VY6XAO8%*1W5I<R02JI.2NY
M""1['B@#AY[:\U#P=XGT"V\,ZC::UJ,3SN+J>!C<O)\I?>K!1C &.,#&!UK?
MU^#Q#+H&@K86$[K'-%_:5BEPD<LD04@J'W;<;L$@,,CCN:Z73-(M-)C9;<3.
M[XWS7$SS2/CIEW)8@9.!G R<5>H \IE\,:^ND^/+&#P_'"FL*ILDAN(@N3$J
M;<9 &"#GI[;NM;EUI>KS>(_!%XNDS^3ID4ZWA,L68R\(0<;^>1DXSQ7=44 >
M>V&C:[8Z/XUTQM):07]U>W%I,EQ'B83#Y0 2,8YSNQ[9J*/0]<2V^'B'2)MV
MBJHO<30_)B Q<?/\W)SQV]^*]'J.*>&??Y4J2;&*/L8':P['T/(XH \[OM/O
M;2X^(5]?Z2ALM3@B6U%S,FR=EA\O8=C%@68@#N<CH:BT5[_3=2T:;7O#&M#[
M&BV-M>3W=M.EOYA5,XC()R=JEB"<?C7H&JZ38ZYILVG:E;K<6DP&^-B1G!R"
M".000"".1BJ&F^%-.TR9)5FU"Z:,YB%[?S7"Q^ZJ[$ ^^,^] %7Q[X?N_$GA
M=[73Y$2_@GBNK;S#A&DC8,%;V."*J3Z=?^)?$?A[4KO3)M-ATDRSR)/)&S/*
MR; B[&/ R22<=!ZG'8T4 <AX1L-3LO$7B>XOM-EMH-0OEN+>1I(VRHC5.0K$
M@Y7]:?XVTS4KV;P]>Z;9F\;3=42YE@6149H]CJ2"Q R-PXS764UW6-&=V"HH
MRS,< #U- '':=8ZO;_$'6]7GTF46MU8V\4;)-$VYX]Y8#+ X^;@D#ISBN;M?
M#/B&#X;^%-(;1I3?:;JL-S<1B>' CCF+D@[\'(/ ]?2O4;6[MKZ 3VEQ%<1$
MX$D3AU)^HIQGA$IB,L8D W%-PR!ZXH \\\7>&;S7-0O;RST>YLM<@*#2]8M;
MB./*[5)$OS9*AMP(*GCIFO0)9)H+,N(FN9D3/EQ[5+M[;B /Q-3T4 <CHWA:
MUO-&:?7M&']IW;/+>)(ZL2['E058@J!A1[*,U6^'.F:QI/AV?P_K>FRQVMK+
M+'9RRRQR>;;%CM5@K$A@"1CIC'-=O4<L\,&SS94CWL$7>P&YCT ]3[4 >6CP
M!K</A-XD>.35=%N@V@%FZ0QR%D#'/!=6V$>BKZ5TGB'2];L_#>DV>C1R7GDW
M4;:C%%,(9;J+DR;6) !9SN/(SR,\UV5% 'EC>&]=C@\?06_AY((=:M$2RCAN
M(@ WV?R]I&0!@\GMUQNZUJ:]X?UN_P#!?AJ2QM NKZ)<6UW]BFE4"8QKM9-P
M)49!.#G\J[^HYYX;6%IKB6.*)?O/(P51]2: .*LH-<OOB5::]-H4]E8_V0]H
M_GSQ%T<RA^B,V1\O8_7%7/&NB:C?W&AZQI48GO-'O//^S%POGQLI5U!/ ;!X
MSQ76T4 <5/H]]J?BBY\2/IT\/DZ2]C;6KO'YLKNVYF.&*@#  RW<].,Z/@&P
MOM)\#:3INI6C6UW:0+#(C.K<CN"I(Q7244 <CKVFZK_PGV@ZU8V'VNW@MKBV
MGQ,J&(OL*L=W5?E.<9/L:R])T;7/#NE^(- CTQ[V"[GN)K"Z26,(%FR=LNY@
MP*L3D@'(Z<\5Z%10!E>&]''AWPOIVD(YF^Q6R1%QQO(')_$YKF/#WAS49O#?
MBW2-3LY;$:M?7LD4C21O^[GR ?E8X(SR#7<2SPPE!+*D>]@B;V W,>@'J:DH
M X?PI-XOC@LM(U?P_;VILPL<NIK<HZ3HG *(/FW, .N,9)]!5+PI9^+O#%HW
MA8:1'-9PS2?9-7^TH$6%G+9>/[Q==QXQ@\<@<UZ+10!Y]%:^)_#'BC6%L= C
MUG2M5N?MD4HNDB:VD955U?=R5^4$%0<>Y.*O7^EZQ+X[\*Z@;(S6]A;7,=W<
M1O&J!Y50#:I;=C*GMW'6NO\ /A^T?9_-3SMN_P O<-VW.,XZXSWJ2@#C-2\+
M7DOQ AU.T9%TN^MU754)Y=X6#0D>I.2I_P!D$=Z@URR\0Z-XX;Q!H^D+K-E?
M6D=M=V@G2*2-XV8HZE^",.017=44 4M+-ZU@DFH0Q07#DLT$3;EB!Z+N_B('
M4^N<<5R.C:;K7A6^\1VD6ER:C9ZC>RZA9S12Q@*\H&Z.0,P( (X(!R#Z\5W=
M% 'FFG^#]3\/W?@&UMK.2\MM$CN1>7$<D:@-+&1\H9@2-Q/;I^5>ET44 >7Z
M?X7UN7X9)X%NM->WE9FAFOC+&T(B,I<NF&W$[3@ J.>N!5]K+Q)X7\7:I/IF
MA)K6DZJT<P"W*1/:RJBQD-OZJ0H.1TKT&HYIX;:)I9Y4BC7J[L% _$T ,LEN
M%LHA=F/[1MS((ON!CU"^PZ9K@?"-GXN\,V(\*'2(Y;2WE=;76/M*;! S%@6C
M^\7&2,8P3CG'->BU'#/#<*S0RQRA6*,48-AAP0<=QZ4 <KH&GZE:^/\ Q3J%
MSITL5EJ'V7[/,9(R&\J,JV0&)&2>./RK&\-6?BWPY WAC^PX+FTBE<6FL&X0
M(L+,6!>,_,67/0<'@9 YKT9F5%+,P50,DDX %-BECGB26*19(W4,CH<A@>A!
M[B@#@;+3=?\ #FO^);>'2)-1T[69VO+>YBGC7R9&0*R2!V!QP,%0W':LVW\.
M^(8O!/@73GT>0W6D:C;W%TBSQ'9'&'!.2P!/S#@9Z&O4Z* .%E\/:G+XQ\4A
M[,G3->L(8!>+*H\DK&Z,"N=Q/S C Q[BD\)-XOMK6QT/5= MX/L(2)]56Y1X
MYHTP 50?-N8#'.,9)]J[NB@#R9= \3Z9X$\0^#(]%DO4E%S]@OH[B)8W24EL
M.&8,'!8]B#Z@<UZ7HR3Q:+8Q74/DSI B21[@VT@ =1P:O44 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !6%XL\1/X7TA=3-E]IMEF2.=O-V>2K,%#G@Y4$C/I6[5+6-
M+M]:T:]TNZ&8+N%X7]@PQD>XZT 9B>)F_P"$X;PS+9I&YL_ML<_GY$B;MN N
MWJ#UYZ<\UDZKXDMY;#P]=:EX?2XCOM6AAM6,JNL+%B(Y@2 >0"PP.A'(S6,?
M GB";1-"O);M%\2VTRQ7-RK=+9D\EU4]R$P_^_DCK70^,M%O;VW\.P:38^;'
MI^JVUTZJZ($BBSD#<1DX(P/U% $=CK.JZE\0]=T.ZL[5M,M;:WPIE)RK^82Q
M4K@DX VYP .IS7+>!/%$WAOX=^']^CR/I;WCVLEV)E7RFDN752$ZLH) )X]@
M:ZR#3=7T_P"(NK:M'8+<:?J%G;KY@F56C:+?E=IZD[ACG'J:YJ+PKX@C^%6F
M^'SIA.H6^H+.ZB>/;L%R9N&W>AQ]?SH ].N[E;.RGNG21UAC:0I&NYF &< =
MSQTKFK'QC--K.E:;?:4;635+-[NV"S[W 4*2DBE5V-AAW(R",\5MZQ'J%QH%
M]'I<@M]1DMG%L\F,)*5.TGJ.#CU_&N"T[P_XACU_PIJC:!#;FR@N(K\M>J\K
MNZ(#(S8._)4XY)YYQ0!=E^)<\>B7^L_\(Y<?8=-O9+6]=KE T81PC,HYW$$Y
M(Z>Y[= _B5XO&MOX>FL1&EU:O<V]V9OEE"X#(%Q]X9!QGISGM7'3^%M?F^'7
MBO11IC+>ZIJ%Q<6ZF>/;LED# D[N, <_IFMSQUI]S>>'-.O[(BSURQNX)+$R
M8;$K,(S&VTG*L&(.#COVH Z/2=3DU3[8YMEBA@N7MXY!)N\W8<,W08 8%?J#
M^-*\UMKO5;[1=.T^*_EM(5>\6>;RXUW@[8_NMN8@$XP !C)YK4TNPCTK2[:Q
MB8LD$83>W5R.K'W)R3[FN2BTS7O#_C[6=2L=.&I:9K0A=]LZ1O;2QILY#'E"
M.<C)'IZ@',^%M3LM+^#WAU[[1!?6\NI&)8GV!8':[<(QSW!/8'IVKOD\22#Q
MNWAN>Q$1:T-W#<F;(E0,%( Q]X$\C/3GFN)@\*>)(_AGI6AR:8AOK;5%NG5+
ME"!&+@RGDX&<'  S^%=5XS\/ZCK TC4=&D%MJUA<@I(^/EAD&R4'L<*=WU04
M 5?$'B2W'AZ&\U/P^E[:/J:6\2F577(EV)+\P'&[D8!X^M;%YK;7&KW>B:=8
MQ7T]O LEV)IO+C0/G8A.ULLP!.,8QU/(K-\:Z#=WGA6QTG1;+S?L]U;.J>8J
MA(XG5L98CG"X%5DTW7M"\?ZIK-CIG]H:=K<4'G()TCDM98EVC.XX92#S@DY[
M>H!D?#[7[30OAMI2RI'#-=W]W#;P2RK$JGSI6(9NBA0IR>>P )(%:4WQ/@@T
MCQ!<G3?/NM#*&>*UNEDBD1QE723 R/7C(/:L:Q\)>+-.\,:/<VMI:KK6C:C<
MW,=J]P"ES%,S[TW8PIP_!]NU;?B.T\4>*? 6LV<^CQV=W>0K#;V0NDD*'.6=
MY.!Z<#/3WX -6V\6SMXIL]&OM'ELTO[>2>SG:97\S9C<K*/N'# CD_@>*Y#X
MD:V?$/PMUB]M-+BN-*#[(;IY1O)64*943;]W<" =P..<8KH]0TK5+WQGX7U%
M=.D6TL;:YBN6,L>4,J*HP W.-ISC\,URK^%O%MM\,=1\"II,=SY>8[/4!=(J
M2Q&7>-RD[@P!QC&..OJ =Q?>*)(-3O=,T^RCO+RQM$NI('N/*>0-NP(QM.X_
M+SG !(Y].B$@$/F/A!MW')Z5P'BOPU=>)!/]IT!AJ$,"G3-3LKI$DMI=O1F)
M5MH;GH>">,XSV2V$T_AX:??W'FSR6OD3S(,;F*;68?4Y- 'G/Q UE_$/@&'4
MX-*C;39+ZV-M=O*/-"^>H$FS;PK8('S9PPR.3CJ]<\;0:7<ZA;6R6D\^GQA[
MB.>]6!B2NX)&"#N;;@\X'S#GKCD)?#WC!OAO'X0?1899[&6!8;U;M%BGBCF5
M@0#\P.T<@CL2"3Q6Y):>+/#WB_4M1TK2+?5M/UCRI9H/MBPM:SJ@0G+#YE(4
M=!GCIZ@&O9>,X-933DT6V^TW-]9_;1'/)Y2PQ9V_.0&(.[*@ 'H>PKF?&6H#
M7O!NC:C<Z5/8W4>N6L?DW4>'B83A6VG'*G'!'45?U72O%.F^*K#Q1IUI;ZK.
M]A]AU"R680\;S(K1LW'RDD<\D>YXG\5:9X@UOPW81FQC>]&I6]W)!%,NV".-
MPVW<V-QP.N.I/08H OZYXMN-).KM#I+S6^DVRW-Q--*85D!#';$=I#L ISR.
M2!4.H^.'M[_1+2PT6YO7UFUDN+4B5(P=J!]IR>.&&2< =L]*R/$.A>)-6U+Q
M)$^F0WMI?6'E:9+-<JJV;&(JXV<_.6.=P]AD"G6FBZ\NK>!;F?2MB:19307>
MRX1MI>)$&.1G!3)QZ\9H T;KQT;:*2)K&UAU*VMDGN[.ZU!(C&S+N$2L 0[8
M'L.1SSQ8L?'%KK-OH_\ 8]NUQ=:I;M<QPS/Y8AC0@.TA ;&&(7@')]LFLZ]L
MO%'A_P ;:CJVBZ7#K&G:ND1G@:Z6![>6-=@8%N"I4#/?C\TU'1_$EEXNTGQ5
M;6L6I3BR>QU"SBE6,JC/Y@,;/@':>.<$@#UX (_AJI75?&2M9I9L-8.Z",@J
MI\I,X( R#UZ#KT%='JVOW5EJ3V-GIAN'CLVO))II3#"%!P$#[6RYP3CC YS6
M;X-TS6+'6?$MUJ5C';0ZA?"Y@Q.)&QY:K@@#C[OK_C4>MZ;KMSXS64:?#J.C
M-9>7"DMP$2VN-Q)D9"#NR,8(!(QQC)- "/\ $*)M,\-7]KI-W<1:ZXCB =%,
M;%2VTY/)^4^@]Q5BR\<PJGB$:W9'3)=""27*^:)5,;J61E8 9)P1C'7BN8TO
MPQXCM?#O@>RN-* ET6]$MP([F-OD"NN1DCD[\X&>!USQ5G6O!>J>(+WQU;O
M;:WUJVM4M+AI%(WP@_> )(!;';IGZ4 -\13WEYXT\!W5YH\=H9+R0I*)@\B@
MPN?+?Y1M/(. 6&0>?7L_%?B >%_#5YK+6<MVEJF]HHV53CUR>WTR?:N4NK;Q
M=K=]X4NKOP_';3:9>&2[9KV,J^8V0LFW)QDYY&>V.]:GQ4_Y)?XA_P"O0_S%
M !%XXFC\2Z?I6IZ%<V%OJ@86%V\JN)& W;64<H2.F?TYP-XY>&33);C29(+'
M4=1.G0O)+MF#[F57:(J,(2IYW$X(..:;-I=_XCU'PU-=6#V5MI4GVR1I)$8R
MR",JJIM)^7+$DMCH..3CEV\,^+KFPTMKW1[>XU>QUN.\N;Y[Q=UU&LC$;./E
M4*1\IQC' .: .YTWQ+)>^*-6T*YL1:S6$:3*[3[A/&^<.HVC@8(/H>*A@\4W
MEW;Z28-'8S:FLDL1:8B&.) "&>0(=NX$;1CG/:LSQOH4^HZSH%S97(MK^=Y-
M/N=N3YEHZ%I1GU7;E3V)'K5OQ+IVL2Z[HILM/CO]$A21+FQ,RQ*'P/+=@>'5
M<'Y><9S@D"@#F?%FO6OB;P1H^LK8E9[?7[>(Q_*[(Z3[6"-W!QP>,Y%=3IWB
MV6]\2R>&];T*73;F:W:>V$DR31W,0.&&5X##/*\\=_7EX?!_B-?!L^G-86J7
M%OKPU*&-;D8GC$_F$*<87C@9Q[XKJETN\U7Q=9>(;RQELXM-M)8K>VD=&EDD
MDV[B=K%0 % 'S<DG.,<@'/>!-9LO#GPX@>7RT$FJ7-M;QEQ&I<SR8&3PH !)
M/8 \'I72>'O&,&MZYJ&C/%#'>6:)+NMK@3PRQMW5P!R#P00,>]<G;>$/$D7@
M>RBMK>*WUO2M7DU.VBFE4QSAGD.PLI.,K(1]?SKN-!O-?U#=<:SI46DJ%VK:
MK<K.[-W8LHP!V &>ISVH ?J6NBTU>TT>T@6YU*ZC>98VDV(D28!=VP2!E@!@
M')/L36#>?$2.QT'7KR;2ICJ&AN$O;)95^4,,JX<XRC#D'&?:I]<T74H/'.F>
M*M,M_M@CM7L+RU5U1VB9MZLA8A<AAR"1D5B:]X/U74M'\:7D-GC4?$*PPPVI
ME0>5'$H4%VSMR?F)P3V'/- '16OBV=_%%GHU]H\MFE_;R3V<[3*YDV;2RLH^
MZ<,".3^!XK6US56T>Q2>.SFO)99XX(XH@?O.P4%C@[5&<DXX%<_>Z9JEUXT\
M*:FFG2+:Z?;W$=R6ECRAE5 ,#=S@J<X]>,U>\;6FM7FC6Z:(GFNMY$]U;B;R
M6N+<'YXP_P#"3QW'&1WH K#QL4B\2I-IC&\T!%DGBMYU=9$9"X*LP7L#D$<$
M=ZBLO'4UQ>>'UN=$EM;+7(P;:Y:=6(D,?F;2@&0",X/MR!6+'X;UV&Z\:-#H
M=M!;:SI\4-K%!<( CK$Z;2, #E@2>G7&ZK3Z%K1L? 40TUR^BO&;S]]'QMA,
M9V_-SR<_3WXH W-*\6F^GU^WO+)+&?16Q,LD^X,I3>LF0O"$=#UX/'%;6E7<
M]_I5K=W-J;26>-9&@9]QCR,X)P.?7WKD/%'AYK[QUI$UG.L8OH'M]4AQGSK6
M-E<?^/$(3Z2FN[H YK2O%+ZXUO+9V$4VG3W,ML\JW&Z2$H'YDCV_*"4QC<3\
MPS7$^'_$,GA#1?%EW;Z(]QIUGX@NVN&BE6(11[E'R+_$0.<<#'>M6W\*WS^)
MM,URUTE]&U1;@G59H)T\B\BPV045CEF.TY*C'.2<"J\GAG7I? WC/2O[,87>
MKZA<W%J#-'C9*1C<=W!&.1^6: .LU7Q+<6EW-!8Z8;D06/VZ2>:4PQ%<D!%;
M:V7."<'  QSS6?/\0$%GX:N;/2+JY37@/(PZ*48H7"GGKQC/0=<U1O-)\1W6
MN S:7%=Z:^F)#;QSW*JEG<#.YF7G<3QA@"1C'&36?IWASQ';:1X#MY]) DT2
M;=<A+F-OD\MDR,D9.6S@9&.^>* .A;QK+$L5K<V%K8ZQ]G^T3V=[J*1K$I9E
M4>8 P8MM)&!P.I'&=;PKXDM?%?AZWU>TCDB27<K128W1NI(8''!Y'7N,5@:U
M8>)-'\;-XAT#3XM5MKVU2UO+)KA8'5D9BDBLW&,.01_D=9IAOVL4?4EB2Z<E
MFBB;<L6>BAL#=@=3W.>@XH Q;CQ7,Z:M-I.F?;[?29&AN6\_RW>15#.L2[3N
M*@@<E>>!7/>,/$,NK:/X1O-'2.?3=3U:T.7E*&099A&R[3@949]",8-7=(TG
M6_"UYXBM+;3CJ%EJ5Y+?VDRS(OE22CYDE#$$*&&05#<$\9XJE<^#=1TKPOX,
MT33;9KW^Q]1@N[F42(@(7>7VAB"22Y('IWH [;2])M-.%U/;64-G<WS^?=")
MBRM+@ GMZ=<#/6O(]/N=%ATV?P7X\TY-,UR<RA-6GCREV[$XF6;J&Y'4^W^S
M7M8):,$J5)&=IQD>W%<!JNGZ[XB\!MH&M>&EN-3EMA$;DW$30)+MP)<EMX(/
MS8"GG@$CF@#0U;7-9M?B!HFB6EO;O9SVLT[%IRK.4VCGY3@#=GOGVQS/<^,9
M!8ZIJ6G:6;[3M+E>*XD6?;(YC_UAB3:0VWD<LN2#CMG/G\.:QIVO^$;NRB74
M(],T^2PN)))A&V66,"0YSD90Y R>:ATO0]<\.Z=K^A6^G_;;6]GGFL+H3(JQ
MB;JDH8AAM8GE0V1[\4 ;Z>*X-0FLK?1(TOI[RS%^GF2F*-("0%9FVL023@#!
MZ'.,5R?BC4DUJR\%:M<Z7-IUTOB.&)X[I-LD>!(& )ZJ2H.>A&#3H_">N^#-
M3T74/#MI'J\5OI2:7>6KSK [!6++*C-Q]XMD'L?RN^+="UGQ+IFAP7NEQ7&S
M58[N]MDE39' %=3&&8J7;#=< $YZ#% '4Z3JL^JR3RI9JFGAL6]T9<FX']Y5
MV_=Z@$GG&1D$$T?$/BM]"UG2--32;F\DU-I$B:)T #(A;')[X')P #G/%5?!
MMEKNA?:=#OX9+C2K9\:;?/*A?R<<1R#.<KT![@<XJAXWEF@\<>!9(+=KB1;N
MZ_=*P4L/L[9P6(&<9/)% #H_B,\=AXA-_H-S:ZIH<7GW%D)T??$5+!U?@$8!
MSQD5!KOB]W\%ZCJ>L^#I)M'$$$J)-/$RW"N0?F4\KM;;U!/(.!V36/#&IZI'
MXNU-;%DO-6TT:;9VID3<JA6^=R&VC+/T!. H[G L>)]$U?5OA*VA6U@?[2DM
M88#$TJ *R%<DMG&/E.,<].* .@O-=:/7%T/3K:.YU 6WVJ19)?*CBCW;5RP5
MCDG. !V.<<9P;KXDV]MX9NM6_LJY::RO187MIO4-!*75>O\ $#N!!4'(/:I9
M]*U73_'J^*+*QDNK:]L%M+RT62-98F5MR.NY@K#D@C=[C-8FL>#=7F\-:X;>
MS$FI:SJT5\T(E0+#'&Z%5+$X+;4.<9Y;'09H [S1[[4+^*X;4-(DTUHYBD2/
M.DIE3 (?Y>F<D8[8KF]*\4ZBWB?Q8FJQ6T&F:.8PSK.3Y:>49-V-O)(//3&,
M<XR>TC8O&K,C(2,E&QE?8X)%<%/X4U.\UOQI9S0(NE^((8PEXLHS&1!Y9&SJ
M3N /ICOVH TI/&KV=OI.H:AI;6VE:I)''#<";<\32#,?FIM 4'ID,V">:V?$
MFH76D^&M2U&RABFN+6V>94E<JIVJ3R0#Z=._J.M<B^@:YKOA+2/#.K:>+8VD
MMO\ :[P3(T<L<)!S& =V6VC[RKC)]!GLM>L9-3\.ZGI\)42W5I+"A;H&9"HS
M^= 'F^LW5U>:!\.=7U"S22_;4[0AXF#R2AH&8\D+M+'MG ]:ZRS\<1JWB"/6
MK!M-ET2-)IP)A,'B=2RLI ')VD8]?6L-]$\17'A_P5:RZ/LFT:\MI;A5N8V^
M2*(H2#D#))R!Z#DYXJ35/"&I:WK7C-)(&M;76+&WM[:Y+H=LD0;EE!R!EA^
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M[[1/&R[9%!/ ;'0GBJMQHE_J7B*]\1R:?+!(ND-IUK:/)&9'9F+,S%6*@?=
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT=XK.!YF5.I"C.!7/ZEJ,^L^%]82YLK.2PDTN2:&ZMKC[1%*=K<<H.1@'\:
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M XW'L0!SP>WX:.I:+XCOM?NY7L;6YLKG3E@M?M%S@6$N&#G: =Q;(^8<\ 9
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M.4X&Q6 ..21P!6AX.\*GP[JFKW%K;_V?IEZ8VATT2[UB< [W '"[LC@?W?P
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MV,8V]NM4=)T&+_A96JZA:70?30L=TUNO*+?.C(7!]?*P2/\ IH#0!W"YVC<
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E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>a107-2021formofrsuoffice002.jpg
<TEXT>
begin 644 a107-2021formofrsuoffice002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%YO^ADUS_O\ Q_\ Q%'_  B\W_0R:Y_W_C_^(KH** .?_P"$7F_Z&37/^_\
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M7/\ O_'_ /$5C6?P]O+7Q+?ZNWBO4F%XB1LB*JR83.W+\@XR?X17<T4 <_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBH+N\@L;<SW$@1,A1P268G   Y))X ')
MH GHI%.Y0V",C.#U%5VOK=+]+)WV3R(7C5A@.!UVGH2.XZT 6:*** "BBB@
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M $$$'D$=Z6@ HHHH **0D*"20 .23VI: "BBB@ HHHH **** "BBB@ HHHH
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M!Z CL.M #+[6?&.E:7XGN)8 +6RL6N["]O(H]S,JDM&Z1O@].&P/<&G6NO\
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M!S>H^(=9U[X=Z#?O>_9KB378;2X\F(*)0MSL!(/3[H)'KQTXKU"YDN+/2)Y
MWVBXA@9@=N/,8 D<#U-<='\.9XO";:(NNNSQ:D-0M)VM5_=,)3* R@C?R3GD
M=L =^XMTECMXTGF\Z4#YY-H7<?H.@]OYT <-\&RD_P -[+4&?S;R_FGN+N8_
M>DE,K D^^ !^%.'B>YGU#QE'9:;;V>I:/;)YUS)(94E.QI(\* I/!.22,9'7
M%:.F^$;CPW>7C>'M0BM["[E,[V%S 9(XY#U,9#*4!_NG(],4RU\%SPCQ-<2:
MFCZAKZJLTBVQ$406,QC:F_)X/=NOY4 9FGZGXNF\&VOB"74]*VWEA:R[)8O*
M6VW;3)*7+8;Y23MP!G [<K:>*=5DNO%UC#=";^R[.*ZL[B[M"C'>CDAU&S(R
MG! '7O5^Y\$7%QX&TOP\-7$=QIC6[V]VMM\I,)&S?&6^8<#(R.::/!.H_P!J
M:UJ#Z^KRZM8I:S*;(!590RA@-V=N'/RYSG&6/2@#)L?$WB2.U\$:K>WMI-:Z
MXT-O/:I;[2K20EPX?/7*\C&.<=LU%I^LWNB:A\0=8OK^2\ATR8,("BKN @5E
M4$?=&3C]3DUMGP/=_P!C^%]/&KP@:!-%*CFS/[[RT**"/,XX)S[U.?!"R:GX
MB>>_,FEZZH^T6?D@,&\L1DB3/3 SC&00.>Q *]MJ/BN'7-->2UEN-*GC?[>T
ML<48MB%RK1[7+%2<C!W'OFL^U\1^*]6TW2==TBPFG@NY4>6S=(5C%LQZJ^_=
MO P>>"<\"M;PYX4UK2/(MM3\3RZGIUH,6T#6JQL0!A?,<$E\#Z<@$U5T3P)J
M6A2'3[7Q--_PC8E,D>G&V7S$4G)C$V<[,^V<<9'6@#>\6^((_"WA74-:DB\W
M[+'E8\XWN2%49[ L17):_;:I!XU\!O?Z@MSOO)O,00A DGD/]S'.WKPV3TYK
MM/$6A6GB;P_>Z-?;OL]W'L8H>5.<AA[@@'\*YM?!FNW%SH,^I>)HKA]&F,D;
MI8;&F!0I\Y+GYL'J ![4 0Q^(M:UOPSK'B+2+J*%;*:=;2T>(,DZ0D@^8?O
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MR2Q,,,DB;^01CD,,'D4 8VO^(]9CT?QQH4U[Y=]I5C]JMKZ&,*TL+H3@CHK
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MTZ]DL[6WF0%)WBQO,K=0"20-N,8!).>*JMJDGQCC@EU%DA30A/\ 9U0,B$S
M.H.,\[!\W7BK0\$ZE8>(-1O-$\1R:?8:G-Y]Y9_95D(E(PSQN3\A;OD'G\,:
M$OA61?%]GKUEJ)MEAL182VYA\SS(@^\88GY3G@G!R/0\T <]!XF\4ZQI-AKV
MAV,UQ%<3AC9,D*Q-;%B,ARX82 <YZ9XVU;N-6U#Q-9>*S87BVEKI<DUC&OE!
M_.E2,&0OGG;EMH"X/!.><!VD> ]2T2>2QL?$LR>&WE:1=--LI>,,<M&LN<A"
M2>V<'@@\U*?!-]9ZKK4VCZTEK8:R6DNK26U\W9*RX:2-MPVD]\AA0!<^'/\
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M,L<J0HSD]?;BK&K>#-2UKPQ+IE]KXDO)YHI9KLV@VXC<.JI&& 497N23D_@
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M_E@+YQV[=P8]"?N_6NH\)S>()=(=?$ENL5[%.\:.I3]]$/N2$(2%)!Y&>HH
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MA1FVC!/7D'MCCK6M0!APZ-J%Q?VUUK&IPW0M6,D,%M:F"/?@KO;+N6(!.!D
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MPHP  !V'<Y-7Z* .>D\.7#^.(_$BZ@@*69LOLQM\@QEPY.[=][('.,>U4(O
M\EG;ZOIVGZJ;?2-4DDDEMC!N>$R#$GE/N 4'G@JV">*VM,\16>K:QJNEVZ7"
MW&F-&L_FQ[ 2ZEEVYY/ ].XK6H YD>$1#XFTK5;.[CM[?3;,V4-H(,CRCMR-
MV[K\HQQ^=2S^'+B7QM!XC74$7R;1K,6YM\@HS!B=V[KD#MCVKH:* .)@\!7>
MGZK>MI?B6[LM'OIVGN=-6%&^=N7\N0\QAO8<9X(XQK)X;DC\;'Q&MZH7["+
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&0J2S@%<$%1C;C XZ<5FO\/K1=(TZSL[Z:TGL=1;4H[B.-#F5BQ8;"-H7YR
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MP#,A12JA^>F&/3%6YO!X;7M9U.#5;JW&K6ZQ7$"*N-RH45PV,C ;. >H'TH
MRO!?B<ZYJ:V\VJW:W\%J1?:3J%ND4T4N4PZX093[XZD<K2_$E+EG\*B#4+FV
M677;:)UAV8;.Y@3N4Y(*@@'CU!XQM6OAI_[=LM8U*\6[O+*W>W@D2 1$J^W<
M7P3N/R\8P!D\<U+XF\.KXCM+./[9+:3V5Y'>P31JK;9$SC(/!&": .4FLKZY
M^+E]:VNJRVDG_"/P![H1(\IQ-)R 1L!)Z_+CT [+HWB76-4\#>'[^YU."VFF
MO)+>]F6/,TP1Y$ AC"L"[%%) ' W8QVZ*W\,3VWBF77EU-I)Y+%;(I+""-JD
ML&."/FW$D]!VP*R+;X<&RT[1X+77+B*YTBZFN+:Y$*$_O=WF*RG@YW'![4 <
MQKVM:MJGPL\;I<W]U'+IE]):QR;$CEDAPA"2;1CHY!VX)Q]<^LV,,EO9QQRW
M4MRX',LH0,?^^54?I7)GX=6[Z7XCTZ?5KV:WUR0RR;@@,<A"@L"%&3E!QT[8
MKJM.M9[.QB@N;R2\F4?//(JJ6/T4 "@#SW5?$NMZ;-;W U07$AUZ.SF@MHE:
MU2!Y-@0N5!\T @G#$ANHQQ5YKCQ-JOCW7]%M?$ L;6SAM)X2MFDA7>7++SU!
M"\GKTQCG*GX9_P#$J.F1^(;Y+.+4!?VD8BC/D/YGF8)(R_).,^O(-;NG>&I-
M/\57^N'46F:]AB@DB:( ;8P=I!!Z\G/8YZ"@#F/[;\5^(-&EU?PZEQYZWDB6
M]N_V<6LD<<I0JY8^8"0I.1C!(QQR?0G5YK9E$CP2.F-Z;2R$CJ,@@D>X(KCX
MOA^]EJU[)IWB'4++2;^9I[K3(U0HSM][8Y&Z,-WV\^A'&.R96$16(JC 87*Y
M ]..* /(_#^L77A7X:ZGJT=Y+<3-JMQ;0Q3JGEK(]R4$AVJ&/7)&<=ABNJU3
M4M6\->*- MI-1EO[#5Y'M)!/%&&AFV[D=2BKD'!!!S[5+:?#^T7PGJ'AO4+M
M[VQO99)F;RPDB.[[\@@XX;D<?G5^V\-3M>:?=ZKJ1U";3586A, C =EVF1P"
M=SXR.-HY/&>0 8'A*7Q-X@FU">Y\2-%!8:M>61BBLXLRHA*J=Q'RD'!'!Z<Y
MSQB^&]3NO#7@37-56\GN9/[:N+:.*58]@D>Z$8D.%4Y^;)&X#Z=N[\.>')?#
ML&I1I?\ V@WMY+>DO#C9)(<MT/*Y[=?>LZU\ 6J^%]4\/:A>/>6.HS23N?+"
M.CNV\E2#CAN1Q^= #M/'BM/$NQS<OHTULP:2^^S^;!..A41?>4CJ#WKB]0U7
M5];^$VEZA>:K.MV^M)#*\"(@D47A0 C;T  X[XYS7>:#X8U'2L-J'B2\U>2%
M"EK]IB15AR,;B%P7;'&XG.,],FJ,?P]C7P3_ ,(T=4F*)=?:X+H1*'CD\WS>
M1T(W9[=* "ZU34[GQ%>>'K.XU(FPLXI9+FV6V\UWD+X+>9A< (/NKR3SC'-2
MTU[Q(UQX;\.:N8[+6;U)Y;VX@V-^[BZ;!RH9\KGKC#8'3%_5? \]YJMIK.G>
M(;W3M8B@^SS7:1QN+B/.</&1MX).../P%/U+P-'>+I5S;:K=VVKZ9(\D.HD+
M(\A?_6"12 &#>@QCC&!Q0!G^"X)[;XB>.HKBZ>Z<266)9%56(\DD [0!P.,X
M[5WM<I9^#;FSO=?OT\07GVW6(D1Y1#&!$R1[%=1CJ.PS]<GFNDLX9+:QMX)K
MA[B6.-4>=P TA P6('&3UXH GHHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHK"UG67BUK3-!LW"WM^'E>3 /D
MP(!N?!XR2549XR<\XP0#=HK@/^$KBT#QYK]OKNN>7I<%I:O;K<;1L9]^X#:,
MM]W/.3Q6_K.M&+PV?$FD7"7EK;1&Y9(R&2XA'+[3_> !(]Q@]: .@HJ&TNX+
M^R@O+:0203QK+&XZ,K#(/Y&IJ "BBB@ HHKSKQM=^)O#F@-JD?B&83RZBD20
MK;0&..*27"@90L2%(Y)ZT >BT5P/C,>(_#_A'7=0M_$ES((;/S('>" /'(#R
M,J@!!!';(QUYKI-*\3:1J%VNF0ZE!-J,<(DDA5OFQP"??!X..AZT ;5%94OB
M31X+^.REOXDFDE\A-V0K2?W ^-N__9SGVK5H **X;Q1XSNM#\7Z/;)&#H_GK
M;ZE.?^6;S B$9[8*Y/LR^M=K<7$-I;R7%S*D,$2EWDD8*JJ.I)/04 245PC^
M)S/\3].LK;59/[.?39YY[:6,1A"I3:_S*&P03R21P<5MCQQX7(MF&N696YD,
M43"3*LVXKUZ#D$ G@XXH Z"BLJR\3:)J.I3Z=9ZG;S7<";Y(E;D+G!(]0#P2
M.E9MAXAT;3]*U+4[KQ1#=V*WT@-Q*Z!("<'R5*CYMO;J>: .GHK*L_$NBZAJ
MD^FVFI6\UY F^2)7Y"@X)]P#P<=#UJIHVJZ>MEJEZ/$*ZE:K?.#*2I6W)VXA
M4J/FQD =22V.M '045S>M>-](T?P_J6JM*\HL%Q)"(V5PY&50J1E2>.O0'/2
MIW\8^'[>.W-UJUK \\;2(DC[6(4$L<'G P>: -VBL-O&/A\6D=V-3B>"2#[2
M'C#.%BSC>V =JY!Y.!P?2H-7\::7I.K:-8/+YC:F69)$!9%C$;-OR 0<D* /
M?/:@#HZ*S+_Q%I.ENZWEZD1C4/+P2(E/1G(&$!YY; X--OO$NB:9);QWNJVD
M#W"-)"KRC+H%+%A[8!.>E &K15.QU6PU+2X]3L[N*6QD0R+.&^4J.IR>G0UE
MCQQX886I77+-ENI#%"PDRKMN*XST'((!/!QQ0!T%%95AXDT75-2GTZQU*WGO
M(%WR1(V2%SC(]1GC(SS20>)M&NKV*TAOXFFF9UAX(65D^\$;&UB,'(!.,&@#
M6HK.L->TO5)+J.QNTG>T8I<*@),;#^$C'!]NM6;&_M=3LX[RRF6:WD&4D7HP
M]10!8HK*NO$FCV5V+:XOXHY/-6$DYV+(W1&;&U6.1@$@G(HO_$NC:9-)%>7\
M<30[3,2"5A#?=\Q@,)GMN(S0!JT5E7WB;1--O&M+S5+6&Y6(S&)I!N"9 R1]
M2 /7/%/M-?TF^T;^U[;4+>33\$FXWX48.#G/0YXP: -*BLZQUW3-1>Y2VNT,
MEK@SQN#&\0(R"RL 0".02,&H[3Q!I6I7CV%I?H;KRO-5,%69.F]-P^9?<9%
M&K17)?#W4;_4M$OWU&[>[FAU2ZMUE=5!*)(5484 =!V%=7)(D4;22.J1H"S,
MQP !U)- #J*P[+QCX<U*Z@M;+6;2>:='DB5),[U0D,1[ @_D:L6?B/2+^_\
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M#/@':N0>3@<&M&.1)HDEB=7C<!E93D,#T(/<4 .HHHH **** "BBB@ HHHH
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MZ0*JDD* 3R<#K0!Y-X:FO+&]T;3-%U>#6M"O+>4V7F@?:M+Q$2H8CJ@R$^8
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MA>PD5Y$AFB$01HALXR"#Q_M5ZI2%5;&Y0<'(R.E 'EU]86FG2:;_ ,(WK/\
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M!S7GOCCPQ-I'@BTU"QUJXFGT!XKNP298@'9,97*H&8LN>,G)ZYK6\5W">)?
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M/?*N^;[.LI1O*,N<;/,QLW9R,9SGCK55?%UF_C63PVL4_G16RS/(8'VY9L*
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M;G9>[IFD21-IV $D$DX ()->Q-&LD1C=0R,NUE/((]* ,D^*]%"::_VP[=3
M-D1"Y\_/(V_+Z<_3GI3-:UK3([#5;:XU5].:W@_?7*J5-N'!VLK$8)ZD=>E>
M:2:)KG_"-:AH]O'*C^#KQKK393S]I*D2PJ#WQ$S(1ZLOH:ZO5F:7X4>(M3NH
MS#<ZM87$_E/]Y=\16*/']X*$&!_%GUH T+GQC8:/=>'-+,EU>'4HBRW)@=BT
M:Q%MYVKRQ(7@#N20*R;#Q=#HOBSQA%KVLR&SM)K;[,)4W&-6A#MA47H"W)QQ
MQDU0N;N&UNOAAJ4I;['#!+%)*B%PKM;!54X!Y+ C'K3[6YM#XA^)LC21 2PP
MA2Q W@6VT@>N&X^O% 'I4$\5S;QSP2+)#*H='0Y#*1D$'TQ65+XJT2&\^S27
MP#_:!:%_+<QB8](S)C8&]LYJE\/'#_#KP\-V6CL(8W'=6" $'T(KS;7]7@O=
M U(".2QEM?$$;S:=!;$! +A<S2MMR6;[V<@<@ $C- '?K>WX^+LFF&_G:Q?0
M_M*P';MCD\X+N''/ [YZFG?#V_OK_3-7^WWDMW);ZQ=VR22XSL1]JC@ #@=A
M5!+RWD^-22B0*C>'0H+C;AC/NVG/1MO.#SBI/AC-')I^OA'4DZ[>R  ]5:3*
MM]".A[T =+J7B'2])F:&\N2LJPF=TCB>5DC!P78(#M7KR<#@^E177BS0++['
M]HU>UC%[&9K8E\^8@4L6&.VT$YKDO$FJ0_\ "8ZKIDD;V,SZ2/*GAMR\U_G?
M^[5MIPJYY &?FSD 5SFF7]DFF_"::Z<)!;^;'(\R%55Q;$9Y'0-CGH,=>* /
M2;;QQX9O-'NM5AUBV-E:MLGD<E#&WH5(!!]..:?9>,_#FHZR-(M-6@EORA=8
M1D%@.NTD8)'< Y&#GI7GOB2S2X'Q'URPVG3;C1T@,R?<N)U1BS*1PVT%1D=\
MCL:TKU++Q#_P@,6C/%+=6%U#<RF'&;:W6(^8'Q]S)VK@XR?H: -/0M5G6\\;
MQZMK,RVMC=B..YE*J;=#"K<8  P6XX_.M_3M4T^S\-:9<-JDM[!-#&L%S(I:
M6Z)7((4#+,0"< 9ZUQNEW=L+CXELTT85YBRDM]X?9U7(]1N&/KQ639ZG_8.D
M?#C7KM)'T>ST][2]DC0O]ED>- &91R.5*GTR?6@#TN/Q3HDNFR:@E^GV>*?[
M,^58.LV0/+*$;@^2!MQGD<5D^)O$,5WX(\1W.BZE+!>Z;;2L^V/9+"ZH6 9)
M%R,C';IT-8OB#7-'BT.'5M-TB#[#=:Q SZC):':CGK=;< MMP &/4GN!SB;C
M=S?%"UMFOKR:\TV)K=I+=M\X^S,N1A0.3P, 9[4 =SX<\::'?KIVDG5X9=7>
MT1FC).78("V&QAB.<@$D<U!X8U&[/BSQE;7^H236MA<0>29BH$2-"'(X  &2
M>?;FL"=;/Q+I?@2TT>2*>\T^[M;B9H<$VL4:?O ^/N9.%VG!)[<'%+4(;G5)
M/BE::5^^NYVMVAC1N9@L*!U7USAEX[G% 'I%GXDTF_U$:?!='[68_.2*2)XS
M)'_?3<!O7W7(J75-<TO1!;G4KZ&U^T2K##YC8+N3@ ?YXKC?#>I^$_%.M:9?
MZ=;ZC<:K9+)N^U2W!-AN0APV\[<DX7'.>HZ9J?XJ/#'HFBR7 !@77;)I-RY&
MWS.>._% &]IOC3PYJQO19:O;R&R&ZX!)78O][Y@,K[CBFV'C;PUJ<WDV>KV\
MC"V-V>J@0@X+DD  #C\#GI7.W"VFH?$V+7;">%K*ST>6*]O(W!C8LP,<98<$
MC#-CL,>HKG;.PN]0_9PM[328?-O8H%,EN@P[!9@\B8ZY(!X[Y]Z /3K3Q)I5
M[>BSAN6%RT7G1Q2PO&TB?WD# ;Q[KFBQ\2:3J5I>75G=&6&S=H[AA$X\MEY9
M2",Y'<=17):O=6GB_7O!MUH-PLTMI>&ZGDC/-O!Y9#K)_=+$JNT\YSZ&F7FF
M7EAX_OM)MH';2?$\0N)W7[L+QX6?/IYD949]30!TCZIIMYXET=8M<FCGD@ED
MBT]>%N4(!WNI7(V@9'3K5U?$6EO>Q6BW#&265H(V\E_+>102RA\;21M;(!_A
M/I7,^()H5^+/@\%U!2VO5;G[I98]H/IG!QZXK"TN:72]>TW_ (1_4UU'2KW4
M66?1;I0T^GLQ<O+&WW@@.3@\8/!^:@#N=&U#3IKS7)[?7GODBG'GI(X\NS(0
M953@#'&3R:L6GB72+V]BLX;O$\T9EA26)X_.0=6C+ !QWRN>*\QU.UN]9TOX
MH66CGS;R>ZB>*-#S,BQQ[POKD*R\=^*WM9O;3QC<^#9="E5[FVU..\G"?>M8
M%1O,60?P$G:F#C)^E '13>/_  K!%+*^M6_EPSFWD=0S!'&,Y(' ^8?-TYZU
MJ7NMZ?I[A+B9MWE^:1%$\I5/[S;0=J^YXX->7>=:MX(^**AXS)/?WAC'&9 8
ME"%?4%@0,=\U<U)HF.G:CI'B1-(UR#18"/M&&MKV++_NV!_B#!N1R-W2@#U&
MWN(KNVBN8'#PRH)$8?Q*1D'\JR[CQ3HMI.8I[Y4"S"!I2C>4DAXV-)C8&R0,
M$YJ3PY<7%YX8TRXN;(6%Q):QL]J!@0DJ/EQVQZ=J\QTZ5%^#VK^$-37/B.-+
MJV-DW^MN)G=FCD1>K EE;<.."<\4 =?XK\2BS\3Z#H7F7,4-Z\S74D$4F_8D
M1955E&>6(R5Y ';-:L,C>%/#%Q<:KJ5WJ45J'E\YX=TOEYRJD*/F('&?Q.*Y
M346_LWQE\.K6_ND:XM+:YCNI2W 8VZKECVW,#C/6NV\2123^%]7AB1GDDLIE
M15&2Q*$ "@#BM9\6SWFB^"];M+V>PAO=2M$O(2NQ"CQEV!9E!(&!R#@C/6NO
MLO%.B:K;W\EIJ4>VR^6Y9@4,.1D$A@.".0>AKS>;4K*[\#?#:-9 ?LVHZ>LX
M="NPQPE7)R.BG )Z UT-A>6L7Q1\6R//$L;:;:Y8L "5\S=SZC(SZ9H Z#1=
M6TZU\,:;*-8N-3AG&R"Z=#)+<GDY"JN3P#T'09]ZUM/U&UU2T%U9RF2$NR9*
ME2&5BK @@$$$$?A7DVA06-U\,_!L,NL3:+J,"R&UOTQB"89!20-QAE;H<9X'
M?GO/ E_J5_X?D?58K?[1'=S1"XMEVQ7:AO\ 7*/1CGV/)'6@#IZ*** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BN!L_%]\?B;_ &?<@+H>HPR0:;)_
M?GMV/F_GE@/4(,=:[/4-3L],CB>[FV>=((HE"EFD<]%50"2>">.P)[4 6Z*Y
M\>-O#ICOG;40GV ,UTLD3JT.WKN4C(ZC\.>E+9>-?#VH?:#;:B'%O'%+(?*<
M?+)PFW(^8D\8&3GC&>* -^BLFR\2Z3?R7L4=T8Y;%0]U'<QM \2D9#%7 .W
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN$<[>H^;)Z<U)JOB_5QI7C#4K2:&UE\/W)AAM)8@PF545MS]&^?<0NTCH.M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%95WX@L++7].T68S"\U 2& ")MA"+N;+8QT[9SR*U: "BBB@
M KE-:TUK'QMI7BE 3"EM)I]\0,[(F(='_P!T.,'T#9Z UU=4O[3B_MO^RO)N
M?.^S_:/-\D^5MW;=N_INSSMZXYH YJ^\'ZBOBJYU_P /:^--;4(T6^ADM1.D
MI085URPVL!QW%+XNT<ZMX<@\(V\DDKWCQ"YF<Y9(%</)(Q]6VD#U+<< X[$
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M,'=';[_E2$_)N^AQVKMJ* .,U#P9J4?B:;6_#>O?V4]Y&D=[!):B>.78-JN
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M +'&.O?)S6'X7U/6]#\$^ ;N.^A:PO;BWT^2R\@?=DW /OSG<",\8';'&3W
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M*7#ELAN#N QQP/7K59O!=U:Z[JM_H^M&RM=6^:\M'MA*/,V[3)&Q8;&(ZY#
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M>I7/C;Q5H\E_)]FL[>UEMB(TW1&0.6P=O/W1US0!T6I:DNF);LUK=W'GW"0
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M5MS>0S[NV.1T&/RXI9/&>J^&K#QG'J%T-3FT:>W2TFEC6,N9U78'" #"LW4
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M\V\MDMS"T&514R5.=V2<L<^OM6_10!Q ^'F/ \7A4:L_V:.X$XF\@>82)?-
MZX^][=./>NTV%H=DI#$KABHP#Z\=J?10!PT?PZ:+PI9^'AKMPUK9W,<\#/ A
M*B-]Z+QC//4GK@=*UI?"@NO%,VMW=TLJSZ<=-EM?)PC1%BQYW9SDG\./>M8Z
MB1K:Z;]BNR#;F?[7Y?[@?-MV;L_?[XQTJ[0!QWA[P-=:"T-JWB6_O-&M6#6N
MGS(@\O!RH:0#<P7L.!P/2MGQ/X<M/%6A3:7>/)&KE7CFB.'BD4Y5U/J#5O3=
M1.HK=$V5W:^1</!BYCV>9M_C3DY0]CWJ[0!R4'@^_;7]*UK4?$<]W=:=#+"N
MVUCC60/MSN'/]WG'X8I;'P=<Z=9ZC%;:TZ37FIG4_.$ ^21F!9<9Y0XQCK@G
MFNLJHNHP'4VTY]T=R$\Q%<8\U. 64]\$@$=1D9&""0#SCXCZ);Z1X#\7:G<7
M,3:AJR0+(8X_*5O+8!0JDDDX)))))^@KL;71/M^H:;J]]J,>H?8HV^QF*((F
M7&TR-@G<VW(R,#D\<\=#2,<*2 20.@[T <=!X!2UTF\T"#4G3P]=2,[67E#?
M&K'<\:29X0G/!4G!."*OZGX7FU"+4K-=12/3=0A$$EJ]L'$8"[28SD;3C'4$
M @<>MC2?%>F:QJ]_I$+2PZE88\^UN$V. >C#^\O(Y&1R/45:_MB+^W?[(^S7
M/G^5Y^_:-FS.,YSZ\8Z^U &8OA)(?$6DZI;WACCTRS-E#;F/<#&=N<MG.?E'
M/\ZK0^"#;:?X@L(=7G%KK$EQ(8FB4B S?ZP@\$GKC/3/0UUM1R3I'N!.YPA?
MRUY8@>@H Y=_!"BUT!X-0:'4]"C$-K>"($/'M"%)$S\P( S@CGD8IU[X+2_T
MS7(9[X_;=;017=TL0&(PNT(BY^4 $XR3R23FM7PYX@M?$^BQZI91SQP2221A
M9U"N"CE#D GNIJP=1(UM=-^Q7>#;F?[7Y?[@?-MV;L_?[XQTH QI?"<LVI>'
M;YM2&_1$=8U$'$N]/+.[YN/E]._/M6AXFT&#Q/X<OM&N)7BBNX]ADCQN4@@@
MC/N!6M10!S+^%;J;7-$U:XUAY[C2DE4%[=0)?- #YP1C@#&.G?-4I?A[:WEA
MK]E?WTDL6LW0NV:-/+>"4!=K(<GIM7KG]:[.J2:B6UJ33?L5V D"S?:C'^Y;
M)(V!L_>&,D8Z$4 8>G^%=3@L;B+4_$MSJEP\#6\,TUNB"%&X)VKC<QP/F8GI
M[G*#P-:3> 8_"-]<R3VL42Q13H/+D38048=1N! Y_2NJHH Y;3?"-PMG/;>(
M=<N=>22!K95GB2)5C88;(7EF(XW$D^F,G+++P4T6GZ;I=]JCWNEZ;*DMM"\(
M60^7_JQ(^<,%XQA5SM&<]]+6_$UCH<>GR3I/-'?7D=G$]NH90[MM&XY  S_*
MMJ@# B\.2Q>-)_$?V\%YK5;0VYA^41JQ88.<[LD\].>E'A6TU:T@OUU/49[]
M&NF>UEN(A&XC('&T= &W 9YQ[8K?HH Y2_\ !9N]?U/4H-8NK6+5+5;:\MTC
M1MX4,JE68$KPQ!QZ]JKVG@.6T7PP%UJ20^'U98#);K^\!C\O!P1QMX'?/))K
MLZ* .3USP9-?^(8]?T?7+G1M3\D6\\D422I/&#D!D;C(R<&NBTZQ73K&.V$T
MLQ7)>64Y>1B<LQQQDDD\ #T %6J* .7N?"$FH>5;ZCJ0NK*'4?[0B1K<"5&$
MAD5!)G[H)Q]W..,U5O? <ES<^(/L^MW%K9:Y&WVFV6%6Q(8_+W!CS@@ E>^.
MHKLJ;(_EQL^UFV@G:HR3]* .5_X0IX#H$]IJ\JWNBV[6T,L\*R)+&RJI#J-O
M9!@@C\:QO%,6F:5X?\2:/]L-QXCURQEEVLA#W3%/+14&,8& H0$G')SR:Z.P
M\86VJ>&;?7;'3M1N()[@P+#'"#*N)3&6*YX4$$GG@5T5 '&ZCX'DU"#1+RTU
M6?2=;TRV6!+N!5D#)M 9&1N&7(S4FJ>!$U71K:"?5[P:M;7(O(M5 42K.!C=
MM "[< #;C& /K7744 <M/X.;4O#.I:5K&L7-_<:C#Y,UX8TC*@9VA$4;0 23
MW)).3Z;VF6D]EI\5O<WKWDR##3NBH6_!> *MT4 <FO@2T9_$$-Q>3SZ9K<C3
M36150%D955F#8W?P@CT/K4MIX3E"Z5%JFJ-J%OI+B2T5H0C%U4JC2-D[RH)Q
M@+SR0373T4 9^MZ4-:TB;3S<S6OFE")X<;T*L&!7/ /'6LJ[\,7>KR64>LZJ
MMW9V=PERD,=J(FED3E3(VX@@'G"A<D>G%=&DB2 F-U8 E25.<$'!'X&G4 <=
M<^!KA/$=WJVB^(KW2$U AKZVABCD25@,;EW@[&(ZD T[4_ IDUFUU?0M9N=&
MOHK9;.1HXUF6:%?NAE?@L.S=:Z^B@#F-1\'+>1Z,T&J75O=Z7<-<1W159'D9
MPPDW C&6W$],#L,<5(GA1?\ A)K[5[B[^T1WMDMC+;/%P8USCG/4[CGUST%=
M'10!R%IX%$&CV^@W&IR76A6TR216LD0\PJC;TC>3/S("!QM!X )Q5V#PS-;>
M(=:UB+41YFJQ1Q-&T&5C$8(4CYN3ACG/7VKHB<#-9&@>(K7Q$FH-:PW$7V&\
M>RE6= I\Q I.!D\?,* $\+:"/#'ARST9+DW,5HNR.1DVL5SGG!Z\UL45D:YX
MBM?#[Z<MU#</_:%Y'9Q-$@(61S@;B2,#_"@#7HK(A\16DWBJ?PZ(;A;N&U%V
M79 (V0MM&#G)YSV[5KT %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %<)\5YKIO#6GZ3;2^4-9
MU6VTZ:3GY8Y"=W0C@[<'V)%=W6;KNAVGB'2GL+S>JEEDCEC.'BD4Y5U/8@@&
M@#D[KQ%JWA7Q!_8UXMI<V,VESW5B]O 83$T"Y:,KN(*XQ@]>U)X7FO+7X+VM
M[:WMK;W\UDUV;R];$:RR$NSN?JQ-=+%X>CDU'^T-3G^W70MFM4)C"(D;$%\*
M.[8&3GL,8KG]/\)I<>!;GP)J<DZ1P@QPW$9P9(0^^)U/3*_*&'J/0@D -!UN
M_;XA-H[75[<:=+HXO4:]B5',@E"%EP P4@]& Y''%<UXIUZ[\-ZK\1(K)V4/
MIEO>QE>/*E<>2S#W(VG_ (#7:VWA$V?B&W\17>O7UQ=P636LS2+&J2Q[@_(5
M1M (SQC/<]<TT\(IKQ\4WFI(\0UV);6)&7YXH$0JC$'HQ8L^.WR@\@T 9GCM
M)M-^&&D:'ITGD)?36>E&1?X(WPI/'J!@_4UJ6VJ:IX>\:Z3X:N_LD^F:C:R?
M8WMX#";=H5!*$;F!7:1CO5VWTA/$'@U-!UV)TNH(XXIV0X*R)C;-&WH2H8'\
M#R"*O0:(L6I1:OJ=X;NZM;=H89&01K$C8+M@?Q-M7)]!P!SD PM'N7M/B[XB
MTQ"?L]U8V]^5[+(,QD_4A5S_ +HJ]K.LW#^-=)\,VT[VRW-M-=SS(!O*I@*B
MY! R223C.!QC.:DT#29#XDUGQ)<QM')?^7!;1N,,D$8X)'8LQ9L=0-N<'(JS
MKGAJ'6+_ $[4XKF2SU/3G9K>YC ;Y6&&1E/#*1VX/H10!SMKJ6J3:AXM\+WF
MH3.=/@CN+6^1$$K12*3L;Y=N05(SCD>_-7?A;;R0_#G0W>[FF62RB*I($Q&,
M=%VJ#CZDFM2'PVL,6JR?:W;4-4 %Q=E!G 7:H5>@"C.!SR23FI_#>B#PYH-I
MI$=T]Q!:1B*)Y% ;:.@..#^5 ',6D%R_QHU0'4[SRDTJWE$64*8,C@I@KPO&
M>,'WKDM-O-8T/X:2:_8:M)"MGK$H^QK$ACF1KPHP<D%L_,<%2,?K7ID_AA7\
M6_\ "0V^H7-O.UJMM+"@4I*JL64G(R,%CT(ST]<Y#?#N%O!T_ADZM=?9)KDW
M+2^6GF!C+YI .,8W>U #;_5=6UG7M>TG3)+R!M,2*.-[4PC]Z\>\,_F=1R
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MW8)&=N<?7I5RZ\$[M9L]9L-9O+/4X+86DTX2-_M,0.0'4KMR#T( H X2VO\
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M*2XN/B_JTHU*]\D:7:S+"VS: S/\F"O XSQ@YZDUHVW@&VMM(.@_VA/)X?\
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MMIUV+RV62)0ZN,[07'55W<# / R3WK?\(&G]B>(-+.JW!AURXDN+EO+3<C2
M!@G' PHZYH AU74]0N+VW$6I/!%-I?GQ6EB@:Y,Q/WVW*56,# !) ))!SQ7/
M7VKW6O> ?A]JE\5:ZN=:T]Y65< MN()QVSBNJ'@<)J\.HPZS>PR?84L+E8U3
M%Q&A)7.5.T\GE<>V*K0_#N*#PYHNBKK%XT.DWD=W!(Z(6+1G**>,;1GZGUH
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M1&M]^UBI(."3@Y)P>30!WVE:A'JVCV6I1(R1W=O'.BOU4.H8 ^_-7*P_!?\
MR(GA[_L&6W_HI:XOQ)K^K:;;:AJ-MJLUS/:ZQ%$/LRC[+#"TB)Y,F[&Y\,<E
M<D$CE: /4**\_N!K>K?$/6M#C\1WEE8QV$%Q'Y$46^-F9QA6*]/E&<Y/;(K
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M9(06;ZX %2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:9B,$ #;(6B&Q?4[LXZ$G&?6Z* .0N?A_;/X@NM6L-9U73!?$->VUG,%CN&
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MF5%\L-C<P"@ L=H!/MQC)RW0?#,>@WNIW,6H7=P=1N3=3),$P)" ,KM4$#
MQ[5NT4 8OB#PW#K[Z=*UY=6=SI]Q]H@GMBNX':5((96!!!/:H+;PG'::UJNJ
MQ:G>^?J4,<,H;RV"",$*5RN<@$\DG.>:Z&B@#CT^'MG%H&B:,FJZ@+?1[I+J
MV;]UN+(25#'9@@9/85<U'PA'JD6HVMUJ5W)I^HR*]Q:,$*\!00C;<J#M&>3W
M(P:Z2B@"&Z@>>TD@BN)+9G7:LL07<GN-P(S]0:JZ/I2Z-HEMI<-S-*EO$(DE
ME"[\ 8!.  3[XYK0HH \[U'PHGA+P)K-C83ZS?VM](3)%$$9[<2L!(\8102
M"6VC.<>Y-1Z$;N;4;5M$\6ZYJ40D7SX;[3PD0C_BW.8D(8#H <DXXQG'I%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@#S*P\7:IX<\<7NE^(+F2YT&YO?LMAJ$H4&";8C^5(5 &#OX)]/KCKK<W/\
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MWW( -ZLIVKOSQP77IBN?LV_X0SXM3P2WLUU8Z_;+)/+(BCR;E. 6V*%4,O?
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M[(I%<69@=G+"Y5MXP.0V<[NA)KW 7,1M1<LQ2';O+2 I@>X."/QH Y^W\?\
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MKZZGB1U)-]%,/E\L?QG^':,D8 H ] O-8L;)8#+,7:X!,*0(TKR #)*J@)(
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M(7;8LR%B .3@ G\*[*B@#@9;N.[^+6B7J0W MSI,\8DD@=0KM(A4'(^4D D
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MK#;6Z".&%%CC0=%4# 'Y5CZ=X?NK?6I]1U#6;G4?GD-G#+&B):JYY VC+'
MR>@SZG.X<X..#VS0!Y5HM_8IIGQ#T^>-I9[C5[Q$MEC+-<;HU4*HQ\QSV'3.
M3@54AM)_ VHZ"_B"WU&;36T."PEN+$RM]FN(V9BK"(Y*D/@'GI7H7AGP[-X?
MEU9Y+Y+D:C?27S 0>7L=P 0/F.1\H]ZWZ /+=9M["WM?")TW2)[*S_X2%+PQ
M-"Y<1['!FD4@E,L0>>>03@Y V]<;/Q7\*R!',<5I>+)($)1"XCV MC )P<5V
M]% 'E4!_XIWXG)Y4NZ[N+IK=?*;,P:W55*#'S98$<5*'/V_X7MY<V+:%Q<'R
MF_<YM=@W\?+\W'..:]0HH \WT^.=-4^(6F&TNOM-[*\UO^X;9(C6ZJ"'QM^\
M,8SG/XUB_:+B'P?X$U8:;JD]EHT0M]2@ABEBF3,(C+J/E9@C#DCCD^^/8J*
M/)O$%K;ZIX7O=9\+:+>R)]ML[JY:5)!-J"0OEE"R?,P48P3UY Z5I2ZU:ZW\
M2_"FH:?#>RVHL[M'E^QRJJ,WEX#$KQTY["O1Z* .-^*%O//X(E>""68V]U;7
M#I$A9MB3(S$ <G !/X5FVVK07OQ;@U2&"\_L]M >);I[614+>>&YRN0, \G
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*MU]*RO"&JZI<:OXBT;5;I+R72KJ-([E8A&722,. 5'&1DC(K>U.-%TR_D"
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M$1"4C<*?;[Q  Q[Y/-)X/T0ZWX)\)M>ZE'=6-E!;7$<$<04F5$&T2-N.0A[
M#E1G..0":TU?6/$]EXAO=+U$V3:=>36=G"(D=)&B R9-P).YL_=*X&.]9EMX
MQUOQ!=^");"ZBL;?7;:Y:XB, <H\:#)!)YY)QTZ#.>E=&G@^6QOM7DTC5&LK
M75G,UU 8!)LE88:2)LC:Q&,Y##(SBC_A"X(-3\.7-A<BVMM!BDAM[;RMP974
M(VYLYS@#!]<DYH 9X)U34[N77M.U2[^V3:7J+6\=R8UC:2,HKC<% &1N(R *
MS]7CO)/C!HL2:I=Q0-IEQ((D"%5(>,' *GKW)YXX(K>T'P[)HNI:Q>->B?\
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M#OI[:?\ ;]/;RD&$4D3*2%^9E.TCV/>NITO3SIMDL,EU+=SDEYKB;&Z5SU)
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M7[I*AE(8= 0>G&* . \3ZWJ'B'X->)3?3&&^TJ[DT^[,"*([AHY$&[!!(!#
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MZ6ZL+@ ';,JM@%?X@5+9'X\XQ6#X?\4:L?%%OX<\8Z4EEKK02BQU"U;=!=*
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M9+';M.<JQ Y[UF>'9O$NLZWK?F^(F2WTK66A6(6L>)HA&IV,<9 ^;J.>O7C
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M),OYG)4%@, =FZY&.CTRVOM1T'3O^$AAC74(]DEQ%"^8S*IX/'49 ;'KCTH
MV**\\\5>)[O2-?O+/4;^[T:TFB1=+U%8%>U,A!W"5BK;3NXYP,<\=:[VXWR6
MDGD3>6Y0[)  V/?'0T 345XV/$7C"W^&6F>/'UT3F+9)=:?]EC"3Q&78WS 9
M#<YR,# QCN>D6;Q'J_CSQ!I%OXB>RM+..SGAVVD;LN_>63D<@A>>_3'?(!Z!
M17G<&N:SX@\':QXFT[4WM);:6Y-G:^6C1%(20%D!7<2^TY((QN&.G+(/$>L:
M]XA\,+::B]A9:SH\EY)"L*,T3@)RK,#S\QQG(]C0!Z/17E U3Q0_@_Q;=?\
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MY8ZEHL(M[74(%7>8L ;'4_*PP!^-=K10!0TC3#I=D8I+N>\N';S)KF?&^5\
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M$IGO;"#9LD<_>*L06C+=RO/H1QCLZ8\L<90.ZJ7;:H)QN.,X'OP?RH Y/4_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MQ!<+J=YOUQ0+C*QXCPFP;/EX^7CG- %[PIJ4^L>$-&U*YQ]HN[*&:4J,#<R
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MC >-@HVL @'&T<CD]R:C?X=VDGA34?#KZK?FTU"Y:YF?$>\,S[V .S !;VH
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MFT>SCO+*ZF2)I4+PNY4_(%(RGIT-1SZAXET6/PAKTFNS7UOJD]K9WMC)"@C
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M)SOP5^]QG^[G'!QB@#UBBO+UU#7-!U/Q7X?F\1EH8-/COK'4]14.UMO)4AR
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M8>.%<KP<@'/?!Q6:]M>O<_$J\L]6N["2SG\^/[-M&YUME8;B0<KP.!COG/&
M#UJJ8U*&356T^$-+-$@><K]V$'.T$^IQP/3DXXS!X=OI=4\,:3J$^/.NK.&>
M3 P-S(&/ZFN.\":LT?@KQ'XCN$:6=K^]NY5[GR^%3\%10* /1**\NU'6M7T_
MX8Z=XZAU*>:^\NWN[JW+9AFCE90T03HNW?@$<_+R3DU>6+6-9^(/B+2AXDU&
MTL[6&SN(5A6,%"Q<E?N_=.WG/)XYXP0#JO%7B*+PKX>NM9GM)[F&W +I!MW
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+ZPMM3TZXL+V(3VUQ&8I4;^)2,'I5FB@#EM"\"VFB1B%]4U74;:*-HK>"]N
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MZJB@"O864.G645I!O\N,=78LS$G)9B>22222>I-6*** "BBB@ HHHH ****
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M1Y?FONV[?,P-V?7IC/X8]J /&;V:[U?X06-SJ%_>7%PNNK&93,REP+TH-V,
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MG^T-IBW1%IYN<[O+QZ\XSC@<<5IZ;X<M],UW4]7BNKJ2XU(H;A9&4H2B[5P
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M!F8>7Q@#+MU!Z^PQ8C\"V$-UJEU#J.JQW&IPI%<R"ZR3M&W<,@X;!(SV[8H
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MPEX69MISD9(!_P#K5B>)/!L'AO3-$M],FUJ]@BUJTECM69[A+6)9-S;55>%
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MI93R*T<+#[N#M#,%SP&8@<>@QN7]E;ZEIUS87:>9;7,30RIDC<C @C(Y'!-
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M[JVFU"2Y:23&4>/>@VG@Y (&.W%7O^$-TQ[[6[FY>>Z76HUCO89BOELJKM7
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MSL;:?4%^[9*YE'F'!!ZX /0$@GI@^IV%I'8V<<$4T\RJ!^\GF:5V]RS$G^E
M%FBO-=2GN=)\3^(M'N-1U$QZI8+<Z2PNY T<N?+:.,D\'>T9 ]&YX%3^#=2N
M?$&GZ)8W%Q=)?Z491JV+E]QFC)C"N<\AVR^#QA,=.* .GN]<O;#2]:O[K1I5
MCT_>T*K.A-S&J;MX_N]Q@\\50F\:B'3O"UZ=-D9-?D@B4B48@,J;QGNV #V'
M3M6!8W-W+X?^),%U>W%TMM<744)G?<43[.IVCT&2>!5:\_Y$WX6?]?\ IW_I
M.U 'HNM:B=(T6]U$6SW/V6%YC$C!2P4$GD\=!1HNI#6=!T[5!$8A>6T=P(RV
M[9O4-C/?&:K>*_\ D3M<_P"P?/\ ^BVKS=+;4?#_ (1\$^(=/UG4GED_L^VG
MLI)MT$L4JJNQ8^@(R,$<\<Y- 'K]%>:)_;WC*TUR73;T6=]:ZG-:VTXU"6,6
MWE/A0T*H5;(&3NSG=Z  >@Q1F\TJ-+F17,T($CV\C*&)')1@00/0@YH EMKF
M"[A\VWE62/>R;EZ;E8JP_ @C\*EKQ'3UN=.^ 6G:AIVHWUI=-<1*72Y<C!N]
MA&"< 88Y"XSWS7:ZCIO]D:CIMD->UF[^V74UP;!IRTMS^[ VK("OEQH?F(SC
M)QW H [FBO&[K5=9'PMUJ;^U;V&ZT[7VLXI%N"SB,7*)L9S\S@!B,GK73PB\
MTCXGMIT.JWDUO>:++=.MY.9$29)54. >$&&.0N![4 =[7,S^*KF2YNAI.CR:
ME;V-ZME=M',%D5R%+%$(PP4.N?F'?KBN;\*ZI-_;UEHOB%-6T_7?LTBNLMT\
MEMJ/ W2Q-NP&&"V  5#8[<9>F7!\,>%OB#K5D]P;JSUBZ2(R7,DBKD1 ,RLQ
M#$9SD@GCK0!Z]17%6NCZU'K^G7T.IK!ILT+Q743:E+=&Y)7*/'O4!6!!/'!'
M;BN;\.6>HWWPYN?$%QXDULWMO#J"H!=?(0LD@4L,<D;>#U'3H!0!ZS17E,<]
M_HW@?P]K1UK4;B[UJ/3[2<W5V1%$'P6=>#L8CY2_)YSUYJ_K$NO^"K;7M=%U
M$UB--9X-/EO9;IEN%8#S%:0 A,,-R^OUH ZK7O$?]AZCHUJUC),NIW@M!,'"
MK&Q4MR.IX4]OQK=KS#7],6"Y\ 7OV^\NI9=5A\UY;AG65FA=M^TG:IZXV@#!
MQTQ75?$*>YM?A_KEU9W<]K<06DDL<L#;6! R.>WX4 =+17E][#JN@:EX/UB#
M7-3NQJMU#8WUK<3EHG62,G>B]$*[2<CGU)YS7EU'4%^''CZ<:E?>?IVJ7B6D
MWVE]\2IMVJ&SG ST- 'K%%>;ZC#?:IX[T;3#K>IVUI>Z'+),EM<%#N!C 93V
M;G.>OX&JVMZA=>'-2N8==EU?^QV:".RUNVNG9;;:B*5N$4CJX8EB#G?VP, '
MJ-%<3I4T\_Q!\7Z=)>736:6MI)%']H?$1=9-Q0YRN<#ICI6'X=U2ZU+P7X)>
M]U>^FN;M97DM(7/GWY4-UDW*55,AB2<'@=P" >I45XW=ZKK(^%OB*7^U+V"Z
MTW77M(9%N"SK']HC4(7/S, '(R3DUU$<-QIWQ0CTK^T]1N+/4=(FFGCGN6;$
MBR* Z8QY9PQ&$P/:@#M[>Y@NXVDMY5D17>,E>@96*L/P((_"AKF!;N.U:11/
M(C2)'W*J5#'\"R_G7$?"&SB@\!V\J-,6>>Y!#SNZC%Q(!A6) ]R!SWS3)]/A
ME^.4+L]R"=!:7Y;F11N%P@ P&QM]5Z'J0: ._HKRRUU"_P#$'PMU+Q>FI7EK
MJ\?VJYA$<[".#R7?;$8\["-J '<"3N)]*]!T6\?6?#.GWMQ&T,E[9QRR(K%2
MA= 2 1R,9^M &?XH\60^'?"]]KD-LVH1V;E)$BD"X8-M()/H3@X!KH@<@&O#
M3916_P"S_P"(I4><LUQ<(1).[K@79 P&) /J>I[YKM)#=Z%\2]-@CU&_NH-0
MTZYDN()YRZ%XRA5D7HA^8C"@#VH [ZBO,-'_ .$A\2^'-$\36>I0VL[NMU<S
M/J,K1/'D^9$8=NQ0.GJ-N<YR:] UG3Y-4T>ZLX;N>TFEC98KB"1D>-\<,"#V
M...] %^BO/O"6JS^(])T*QFGNH[_ $]I!JP%P^\20YC*.<Y.]R& /&%(JA;-
MXA\7^'KC5M-U".QOX[Z;RYWU"54@6*8KY;P!=A&Q><DDYSGL #U"HA<P&[:T
M$JFX6,2&/N%)(!_,'\C7F_B76+O2-:OI==_M&+1YVB^QZOIUPYBLSM4%)HU(
MP"^3N(.0X'88N:3I\#_&#Q+(LMT&%C:2*5NI,9;S.V[!'H""!V% '::9=7EW
M!*]]I[6,BS.B(TJR;T!PKY7IN'..HJ[7CEWJ6K)\)-?O$UF_%Y::U)#'<><=
M^P72QA2>N-I(P,5U-NMUI'Q6MK!-3O[FUO\ 2Y9YHKJ<R*)4D0!E'1.&(PH
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M>QF,F=I7!7H.G7OF@#T*BO)(;_6KOX2^'O%GV^^FNM-(GOHXIW7[7;I(5D#
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MRSFM;A/,AFC:.12<;E(P1Q[&L73O"%AIZV,9GN[JWT_!LH+F4.EO@;1MX!)
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M[T/3=6>^M&OHH7F^T&P6Z<6OFYSO\K.,YY] <<<"NLILDB11M)(ZHB LS,<
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M,MS-;F+S-^#&Y7.<#KBMV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMV*-MV@DD\_+Q@\ <8H XJYUB]\)Q?$*WL[RZ>WTXV;VIN9WF:#SU <AG+'
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MBBO+KRYN/"'B;Q=%I,ER\47AX:E'#/.\P$X:0;AO)/.T9]<5?TO1;JYD\/\
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M/7Z4 >Y4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M <9*MV/2LWP7X@E\4^$[/69[9+:2X,@,2-N"[9&3KQG[M $W_",:4]MJ$%Q
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MF.&[9S)E7?8K'JRH3M4^X ITW@7PU/K[:W)I<9OW8.[AW"2,.C,@.UB/4@T
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M7$)NI2))"<EC\V>3R?4BK=WX:TB^O;&\NK0RW-BI6"5I7W!3C(8Y^<<#ALT
M>86CQ^&_!_Q U338A;W-OK=Q DL8.Z*(F$,1] 2WX5TDNDRZ'>1^)M.U2T$/
MV";_ $&U@8)J!$9=&),C98;<[L9(R,\UU47A;1(+S4+M-/C\W4<_:@Q+)+D
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M66^UZA"SHDD(F;>?/4@&/R\*%!R"  ,BO1[CP]9'44U>&!GU6W@:&WEEN9<
M8^Z?FQ@D#/!SUKSK3/!D3VJ03>#-7L=9P3)>0:MY5J)3R9%V39"Y.0!'D=,4
M >IW-G!+IDEG*GF0&(QLLC%MRXQ@D\G\>M>,VUG!%\!/#KPKY4EQ>61D=.I/
MV@ 'ZU[7;1O%:Q12RF:1$"M(PP7(')/UK 7P%X:331IR:<4LQ,)Q$EQ* '!W
M#&&X )) Z DD"@#$TZQATKXM7NF6;W"6=YH8N9HS<.VZ43%-^220VTXR#6)H
M,&K7OPPLETV2*ZNX]7N&-K?3'%\B32YB+'/) SSD?+SQ7HO_  CFF?VS_:_E
M3?;_ +/]F\_[3+GRLYV_>QC//UYZU6A\&:%;:?#806LT5O#<&ZB"7<H*2G=E
ME;=D$[FSSSDT 4? 6I6=_8ZDMOI]SIES#>%;O3[CG[-)L7Y5(X*$8(QQSP!4
MWBF2XO;K3]%L[=;AI9!=74;2;!Y,; @$X/WG*#&.0'K:T_3+33$E6UB*F:0R
MRN[L[R/@#+,Q))P .3P !T%1Q:+8PZS+JR)*+V5!&\AGD(*C.!M+;<#)(X[F
M@#AO"LMSX;^)6KZ'>VR6MKK@.J64:R[U$HXF4' Y/#8QP!575;:+2O$_B+0)
M%<Q^(;1)],^<@I/GRW1#U7#,DG'0;CVKN]3\+Z1K&IV>I7UO))>61)MI5N)$
M,1/7:%8 9P,^M7I]-L[J_M+Z>W1[FSW_ &>0]8]XPV/J.* ."\#W(UZTTBRN
MXE2Z\.K)'?CIBY4F-<GN&"O(??8:Q3,%C\(ZOIDDLL5UX@$1U6>3%Q>1R&7<
M&4#_ %?& ">BCY17J]IIMG8S7DUM;I%)>2^?.R_QOM"Y/X*/\FL%/AUX32%(
M5TA1%'<"YC3SI,129)R@W?(,DY5< ]Q0!SNE:#:ZM\1?%\=Y-?2Q6-U8SVT?
MVR0!'\D/G[W(SG@\#)P!7-ZEY'B;X#:MXCOAYFK3^;))*6.^$K,5$0_NJ% &
MWH>IY.:]:L/#VF:9JEYJ5I \=W>;?M#F>1A)M&%RI8C@<#C@<5F7/P]\+W;W
MQETT[+]M]U"EQ*D4K==QC#!=W'7&: .A6-)K(12+N1X]K#U!'->)+8VMM^SK
MJLD$*QR//*C,OHMZ0!^ KVZWMXK6WCMX$"11J%51V%8+^ _#4EC>6+:;_HMY
M+YT\2SR!6;=NZ!N!NYP,#/.* .?FMAH'Q2LQIYN&^W:1<R7$;S._GR1LA5B"
M3\W)&1V.*S= TZ?Q)X7T#Q0FO6MK>I)'<7-Y' QED;.)('/F8*ECM"XP., 5
MZ WAW3&U>VU5HIFOK6,Q0S-<R$JIZC!;!S@9SUJA:> O#%CKKZS;:3''>O(9
M25=]F_\ OB/.P-[@9H Z2BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ K-U[7;'PWHMQJNHNRV\ &0HRSL3@*H[DD@ 5I5YU\9(IU\,Z5J*1O):Z9J
M]O>7B*,_N5)!..X!(_R* .FBO?$\MD+PZ58QL5WBR>Z;S,>A?;M#>V",_P 7
M>M+2+U]2T:QOI8&MY+B!)7A;K&S*"5/T/'X52U^]D_X0_4-2TR]\MTLI+FWN
M(@K@X0LI^8$$'BO/+EKG7='^&U]J=[<3W.H72&X=6\L,'A=BNU, #MG&?>@#
MUVBO-[O0M$MM<.@:=:_:!9Z2Y^QW<I:VM8WD8^8-VYC(3D#!X5>J\9P+7?J?
MA'X7S75S<O+->)#(XG<%E\N3@X/7Y1SU]Z /8YIHK:"2>>18XHU+N[G 51R2
M3Z5'8WD.HZ?;7UN28+B)9HR1@E6 (_0UY9/IEG9GXHZ-#;H--AT^&YBMF^9(
MY&@D)90>A)53]14L<D%EI_P^TE/L5I8:G:EYQ+!NBFG$$>Q7 9=Q.6(R>2!U
MP* /5J*\IUFU?P5IEQ;1ZU%]@O-8M?M$*P,D-A#(3N4#>2$8J,KN& 3ZUU&A
M>'4T7Q7<W<.IVRQ7UH"=-M+8Q0[E8?O@-[ '#8.,9_"@#KJYS7/$%YI7BCP[
MID=M ]MJDTD4DK.=Z%8V?A<8[#G/X5G>-K759-2TZ\TVRLM86UBE,^CW3!3,
MK%/WD9(*[UQCGLY]:YEY=-UP_#DV,=U#8RWEVGE2L4ECVQ2!D)!SP05Z]* /
M6J:Y<1L8PK/@[0QP"?<X./RKR7_B7Z';_$72VN;O3](@N+81+9-\\;31)E8\
M\#<Q [#D]*V= BDT_P"+5Y9K:VUA!-H<4[6=JV8PXF90QX +8XR!Z=>M !)\
M0-43X6W/BM=.LS=03R1/ 96V +.8L@XRQZ'M^%>@R%Q&QC56?!VAC@$^YP<?
ME7BTW_)NNK_]?D__ *6FO:Z .>\%Z_<^)O#::E=P103-//$8XF)4;)&0<GK]
MVNAKPR#P]83?!_4=?WSPZM83WL]G=).X:)UN'VJHS@;CP1CG/TKI81-XK\4Z
MOHNLO8K<16%J8K:[MC(0'CS(\8WK@AR06'(PO- 'IU8_BO5KG0?"VI:M:013
MRV=N\_ERN54A02>0#Z=/U%'A6T>P\,V5F^J/JC6ZM$;QUP9=K$<\GIC&<G.,
M]Z\TE%KXG^%?C+6-3B2;54>^5F?[]KY>0D:GJH"A>!UW'.<F@#UG3+IKW2;.
M[D55>>!)6"] 64'C\ZM5YA!+_:OB;2_#]Y)9?9CX?MY[:WO;<S1S.21(0N]0
M6 "^I SC&34#PR:#<>%_"T^N0WVGRW-W&TUW 6B,BA3' PW_ # ;F !8\J!C
M*T >K45Y!XP\/#0/A_XH@CU8RJ;FWN8K6W1H8[,O*H*J-Y^5AD[>@STYK6U'
MP_IUO\5=*M8HY$@U+3KDWT8F?%R49"IDY^;[QZ]>AXXH ])HKQF/4'T#POK5
ME!/]ETN#Q;]A9G+,EM:L8RR]00F3@\CAC6MK]C<^"['Q!KVD:E;)--I+,FG6
M5KY<0964?:0-[#(#?0_A0!UOB3Q!=Z+JV@6T-M!)!J5\+221W.Y,JS<*!C^'
MKG\*W;NZ@L;2:[NI5BMX4,DDCG 50,DFO,]9TK2;:?X>7^GQQEY=2B!N5.6G
M5H7;<[=7)(SDY/)]374_$FWAN?AMXA6>)) EA-(H=0<,J$@CW!Y!H Z2UN([
MNTAN8L^7-&LBY&#@C(J6O,LV\&M^!=!-O#%I%[:2SRPJH$=Q.L2E5<=#P2V#
MU.#V%:GAF.73/B+XDT:SR-&6WM[J.$?<MI7W!E0?PAMN[ X_.@#6U3Q!>:?X
MUT#15MH&M=36X+3%SO4Q)NP%QCG(YR>_%='7!^,;2*^^(_@FVGW&)UU .JL5
MW#REX)'.#W]:YZV-AI>@^,M(EGN[;38M<CM[6&T?Y_W@B/DH6X568D'H &-
M'KM%>;Z#8(WQ \3:-=6=K!97&G6TCV-LV8E8EP2.!\V .0!T'IFJWA)!<6:>
M!;Z-9+G1K]S=,Z\R6Z$/%(?=]\8/J ] 'J-%>61:?_PF\GBNUN]0L[:]L]1D
MA222W+7%G&N/*>-O,78,#=D#!.[.:[]9[BW\+"XAF-]<QV6])2FWSW"9#;>V
MX\X]Z -2BO.?"UAHVN>$O"_B22^DCU)'BFFO87 EN)V^5XI#@EE+DC;V &,
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M)-*!RX3.T'Z;C^=6"RCJPZXZ]Z"P&,D#)P,]Z ,#4_ _AG6=735=0T>VGOD
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M8DD$="&SN!]\YK3#*2 &&2,CFJ=IJMG?7][96THDFLF5)]O(1F&0OUQ@_B*
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MGOM J:QT/3=-O+F[L[58;BZ.Z>12<RGU;)Y/O0!S'Q74/X(VDD W]F,@X/\
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M5[%[+4+=;BUD^_$^=K>Q'<56;P[I+W-E<O9JT]B"MK(78M"#P0ISQD<'U'%
M'F:C2M'TSQ[I4IN+724U2".&WL6"$-*D1V)GA59C@]L$U/+=7OA[Q7XQDL8+
M2WN(_#J726EF/W:S+YFTD8&YL <X&1CBN_D\):#-%?Q2Z9!(FH8-VKY83$="
MV3R1@8/44^S\+:#I][%>6FDVD-S%#Y"2K&-P3).,_B>>O)H \WU*QTF3P?\
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MV'R+F5HP6E3&W#>O''TXH Y+P?--8^+#H^M:#:Z=K*V!,=UI^/LUY"KJ"V,
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MXBNCC2[6:>VGE/W87E3:C,>P)[]L5Z%<74%K;F>:0+&,8/7<3P !W).  .M
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M3M&NK"VO+E(Y[Z;RH$+ $G!)/T '7W'K5R>^M+7R_M%U!#YAPGF2!=Q]L]:
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MT<N>F6/4G ')]*<+^S*!Q=P%2<!O,&"< X_(@_C4@GA:8PB5#*HR4##<!]*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "N:\:V5S?Z?816&H06>HK?)+:?:4W132JK,(W [
M$!CQR" 1S72U6OM.L=3A6&_M(+J-7#JDT8<*PZ,,]#R>: /(]=U WG@?5A?Z
M/%I>I6.O6AOUC8-#YA>']XC=@RE2>_//6NH%Q:O\<@(Y82__  CK*VUAG=]H
M4@'WQS78?V/IG]G2Z<=/MC939\R Q H^>NX=#GWJ*S\/Z-I\D$EGI-E;O!'Y
M4310*IC3).%(' R2>/6@#QBVT#3I?@)I>J6=I$OB!6C-C=Q >>9_/VJJMU/I
MMZ>W%=/XI:^T6\U[5Q#9ZWH+RQ'5+,_)<V;I''AHF/! &U]I[GCJ37H-MX?T
M:SO#>6VE64-R6+&6.!5;<>IR!U/<]Z)-!TB:]>]DTRS>Z=E9Y3"NYROW23CD
MC QGIB@#C+D&U^+NJ7&GVZ?:W\+^:JA,&203-MSZGA17+7DVEW_P+T:_+PRW
M8O;62:9R/,^TF=?-+'KNY;/M[5["-)TX:D=2%A:B^*[3<^2OFX]-V,XJD_A+
MPY)<3W#Z#IC37#!IG:U0F0@@Y;CGD _44 <S)]DL_C1=78145O#)EE:->7Q/
MUXZG _05RUG=64<WPYN[.6VMK!KF8VZ/*'G$312;FEDR!DG[PQP>YKUM='TM
M+\7ZZ=:+>!/+%P(%$@7^[NQG'M5:'PMX?MU58=#TV-5F%PH2U0 2CHXX^]R>
M>M '%^#_  YHEWXI\7//IEI*UIK2O;[HP1"WE(<J/X3D\XZX&>E<\EPND> M
M::+]QIL7B^1+SRD!$=MYZ[OEQC;T!&,$<=#7KUIH^EV$T\UGIUI;RS_ZYX85
M1I/]X@<_C26VBZ59P7$%MIEG##<9,\<<"JLN>NX 8/XT <+=:/H%S<:SJ$'B
MAO,U#1GM[B2U,7E)%T69@@'S#=@$GD CL<7/"MWJ=MXODT?Q#IMFNJ+IX>'4
MK#B*Z@5PN&7JC MTZ<G%=39>&]#TZQGL;+2+&WM+C/G016ZJDF>/F &#^-3V
M.DZ=IA8V-C;VQ8!28HPN0.@X[#)P.U '(>/(;9O%/@E[B.(J=3=&:11@CR7P
M#GWJ'PT;76/%GC6RU>*&9_,B2*.0 J;(Q_)M_P!DG<3CN:[>_P!,L-5@6'4;
M*VNXE<2*EQ$LBAAT(!'7WJ&^T/2=2G2>^TVTN98U**\L*L0IZKDCI[=* .>^
M%C7I^'FFB]DDEVF18))#EF@$C",G_@.,>V*Y_6K"/2_&.LZ&MHCVOB^T!A7R
M\JMROR2DX[!&$A_W3WKU!55%"J J@8  P *8]O#)-%,\2-+%GRW*@E,C!P>V
M: //? +3:K#9:9J, ,WA;S+28LGRM.,QQLO_ &R!)_ZZ"N=N;2VC^&_Q0AB@
MB6.+5KLHBH,(?+CZ#MWKV2.WAA>9XHD1IGWRE5 +M@+D^IPH'T JI!H>DVT=
MS'!I=E$EUG[0J0*HFSUW@#YL^] '":W;:=>>*?AY:K';R6K/=!XTQL;_ $4G
M! X.>,CN#SUK%U""&Q\.?%FQM8T@M8G#QPQ@*B%K="V .!DUZBGAS0X_LNS1
MM/7[(,6V+9!Y(SGY./E_"D;PWH3BX#:+IS"Y(,^;5#YI_P!KCYOQH XA]/LM
M,\>> );&VB@ENK6[2=XUPTP$*,-YZMSSDYYK*L!!JWP2\07&J #6H'O);N0\
M2Q7B.S1\]01^["X[8 KU#^P='\VVE_LJQ\RU&+=_LZ9A'HAQ\OX4/H.D2Z@=
M0?3+-KPE6,YA4N2OW23CDCL>U '$HUXWCOP"VI9%^=&N3<@\'S-D.[]<US#W
M%IJ_P+\47&I"%]8$URU^)<;X[@2G8#GD84(%'H,"O89M)TVXOXK^;3[62\B&
M([AX5,B?1B,BJESX5\/WE[->7.B:=-=3+LEFDMD9G'3!)'/'% %JPFC&BVT^
MX-&+=6W+SP%]J\BAO+#[-\/[VQEM[:P?5G:W667?<F-EEWO+)GN>JX."1EC7
ML\,,5O"D,$:11(,*B*%51Z #I69'X6\/1*5CT/344SBXPMJ@'FC.'Z?>&3SU
MYH \X70M(N9OBAYNGVLBQ$M$&C!$9-J&+*.BG/.1S5F^M9(? /@[QM!#Y^HZ
M)96]Q,<9>:V:("9<^H4EAZ$'UKT,>']%'VG&D6 ^U<7'^C)^^_W^/F_&LC5=
M*U9C'HFC6FF6?A^: Q7$BDI+$"<,(T4;>5X!SP3GM@@%CPLB7D5UX@V /JL@
MEB8K@_9U&V+WY4;\'H7-<WXAT?3-2^+VB17ME!/'/I5T)4D0$2X:/ 8?Q8R<
M9Z=>U>A1QI%$D<:A$0!54#  '054ETC3)]0CU"73K22]CX2Y>%3(OT;&10!Y
MM'#I-WXA\6>&M6U"#38U2*"WMY$B"_8O)4+Y9<=%;>>.A.:LZ/<V-KX\TK2;
MV^>XL(-!1M*EOB/WS;R'?)P"^P)[[<^IKN]2\/:+K$\,^IZ397DT'^J>X@5R
MGT)%.U/0]*UE(EU/3+2^6%M\2W$*R;#[9'% 'CEY':#X9>.'MEA^S1^*"\9C
M V*OG0<C' &,].U=M=36<OQKT]5D@=FT.=' (.<RQD _AVJ[X3\/7-G!XCM=
M8L(#:ZEJ<UVD199$:*0* K#U^7D<BMRU\-Z'8F VFCV$!@0I"8[=5,:DY(7C
MC/?UH \@U"SM!\&?&,8@B$=OK]QY("@>5BZ0#;Z<<<=JZKQ9;:5X7USPX(D@
MTK2KR]D-Y<)$NPSB+$+2;@0?XN3WYZC-=I_PC.@?99+7^Q--^SROYDD/V5-C
MM_>(Q@GWJU<Z5I]YIQTZYL;::R*A3;R1*T>!T&TC% 'E7B:"P\/:)JUQINJR
MW=C?ZI9MK'EE/)@B9L2;=@ !8!=P]&'K6_?+IT7QC\-2VHME:72KE=T6T;E!
M39TZCEL5V=MHVEV>F'3+;3K6&P*E3;)"HC(/4%<8.>]5[+POH&FR0R6.B:?;
MO#GRFBMD4IG&<$#C.!^5 '.?%B.%O!L<DJ(0FH6AW.!\H,Z9^E4]9N-(G\5:
ME:V?V1+B#12EQ+<L# D)=OECC! +$@[CD 84<]*[Z\LK74;22TO;:&YMI1AX
M9D#HP]P>#55O#^C/<VMPVDV+3VB".WD-NFZ%1T"''RCV% 'FMGIUMXB^#?AF
M&.56UR**$Z9*I!>*Y0;ER>R@#+?[/;.*ZWX>7UM?:%,QA\C6$N'35XWQY@NL
M_,3CJ#QM[;< =*W;;0-'LC;&UTJQ@-L&$!CMT7RMWWMN!QGOCK4MMI&FV5Y-
M>6NGVD%U/_KIHH55Y/\ >8#)_&@#D_B##'I5QHOC%8UW:/=!;IMN3]EE_=R?
M7;D-[8-<WIJ7%GXBU3P^]H(;;Q<!J%NJQ[?*1CMG5O1O*VGV9J]8N+>&ZMY+
M>XB26&12KQNH*L#U!!ZT-;PO<1W#1(9HU9$D*_,H;&0#V!VC\A0!PUY9VL'Q
MET7RK>&/?HMRC!4 W*'C !]@.*Y15LXOA-X^1%@2X%[J2[5 #;1)T]<#(_,5
MZY)I.G2ZBFHR6%J]\@PERT*F11Z!L9%0R>'=$E-T9-'T]S=L'N=ULA\YAT+\
M?,?K0!P\FGV6F?$#P%)8VT5O)=6EXD[QJ TP$2,-YZMSSDYYKF-0TVQE^&7C
M_4)+6)[R#6KUH9V4%XBLRD;3U7GTQ7L!T#1S+;RG2;$R6PVP.;=,Q#T4X^4?
M2F#PUH0M9K4:+IPMYGWRQ?94V.WJPQ@GW- '+65R;GXMWMIJ:JZ_V/"^G+(,
MJRECYQ7/&2=H/? ':N/U**6T^$WC:T4G^S+?6C%IX)X2(7$657_9#[@/H:]=
MN="TF]AMX;G3;26.V_U"O"I$7;Y>/EX]*=<:-I=W8)87&FV<UDF-EO) K1KC
MIA2,"@#DDO4F^,UU8:F4Q'I2-IL<OW6W,?.9<]6X4'OA?3-<)=V^GGX*>,HH
M8[<Q6VMW!@"@$1@7"A=OIQ^E>R7_ (>T75(K>*_TFRNH[<YA6:!7$?\ NY'%
M-/AO0C:RVIT;3S;S2&62(VR%7?.=Q&,$Y/6@#D=5TK3KWXT:<+FS@F$FB3-(
MKH")"LL>W</XL=LYZ#TKFEA$7PU\26MO<0VUO9^)YHXK>1]D<D:W*D09Z*&S
MCTYYP,FO6/[#TG[7'=_V79?:8T\M)O(7>J_W0<9 ]JP?$?A8OI"VV@:7HZHU
MVD]Y9S0B.*\5<G:Q53@YVG)!Z8/!- &7;:5::EXWU+Q4\=O;6Z:4+==KQ23K
M("Q:4%"VW"$*#G)^@%5?"S:AHGB/0]&UBTLKU'LI8M)UFR^7S(55&*RIV)"J
M<@X)QZFM/1/!MNFJ6^HR>%M&T-H-X*6+B1IPR%2KX1!L^;..<D#ICGJ;'1-*
MTR3?8Z=:VS;=@,,2KA<YP,#@9YP* ,'QM<V,=SX=MKF,R74VI*;-7E\N(2*C
M',AP<@#D+U+;>G6O/;P6T_@KXH6TLMG<F.\DG01* @;RH\NBY./F[YZU[)J.
ME:=K%L+;4[&VO8 P<1W$2R*&'0X(ZU7?P[HD@N ^CZ>PN=OGAK9")=HPN[CG
M X&>E '!ZIH>E)XS\ JMA;@7<5TESA!_I"B -B3^^-PS\V:P]9>;1M(^)4&D
M1&"UAO[5GBMAM\N)XXO.*@=,KNSCMFO6SH.CM);2-I5B9+48MV-NF81Z*<?+
M^%/M]&TNTFN)K;3K2&6Y&)WC@56E_P!X@<_C0!QOB*VAC\7>"+W0EB6269X6
M^S@!9++RBS9QP5&%([ D8ZUR&H26D/PA\?V\C0HRZU>JD9(!!\T%0!].17K^
MGZ'I6DL6T_3;2U)&TF&%4XSG' Z9[5#-X8T&XNKFZFT;3Y+BZ79<2O;H6E7C
MACCD<#KZ"@#C9M,TS4/C'9&:TMKA)?#KNX9 RR$3Q@%AT;';.>@]!7+306\?
MPQO(?+C%O9^*VBA4@;8H_MB_*/0<U[ -"TA;M+I=+LA<HGEK*+=-ZI_=!QD#
MVIJ^'M$2QN+)='L%M+D[IX!;($E/7++C!/UH NP" P!;<1^2,J!'C;P<$<<=
M<UYKHFG:?+!\1T>SMG5;Z90#$IP/LZ''3@9KTN&"*W@2"&)(X8U")&B@*JC@
M  =!5&/P[HD2W"QZ/IZ"YSYX6V0>;_O<?-^- 'E$^GVFD_!31M9L[*-)I[6R
MBU*ZC7]ZUJ60R MU(['T''05UFO6<<?Q$\(7&DQQ W,=Q#=K$!LEM!&"-P'!
M4,5Q[M[UV=MIEA9V)L;6RMH+0@@P1Q*L>#U&T#'-16&AZ5I:NMAIMK;!UV,(
M857*_P!W@=/;I0!XS<:1IJ_!GQ9=+90">VU*[^SRA!NAVW'RA#U4#T&*[.]T
MZRTKXI>#FL+:&V>ZM+];AHE :8!8V&\]6.23DYY-=</#6A"SDLQHNG"UE??)
M#]E38[>I7&"?>I?[#TDW-O<G2[+S[88@E\A=T0]%.,C\* ,/Q_=:?;Z/81W\
M3R_:-3MHH(_-\M&FW[D\QL'Y/ER>#T]:XIA!->?%2UNIK&X)L8I-D2 )Y@MI
M,D*2?F&T9/7(SQ7J]_IUEJMF]IJ%G!=VSX+0SQAT..G!XJK_ ,(YH?[S_B3Z
M?^]B6"3_ $9/GC'1#QRH].E 'F\&G6-A'\+;ZUMHH;N9HTEG10'D5K0Y#-U(
MX'6KM^LW@[QCJ.G:=;A8/%2;[,I'E8;T823./X=I$AS_ '&KO#X>T0K;*='L
M"MK_ ,>X^S)B'_<X^7\*S=-LM=OM9%]K\-A#%9/*+**U=GW;N!(Q8#!"94 ?
MWV]J -O3["WTO3K:PM(Q';V\:Q1H.R@8%>.W%]83Z1X6O]-D@@L9/%2/$)Y-
M]TY,SB1W;(V@Y(VX/RE<GM7M=9/_  BWA\^?G0]-_?RB:;_14_>.#D,W')!Y
MS0!Q>E:+H^H?$7QVEQ86EQ T%D^UHPR$M%)EL=,GUZ\GUKF;*QM(_A5X$U58
M(QJ U.Q'VLC,N/-V[=W7&WC'3'%>PC0](%Q<7 TNR$UR,3R?9UW2CT8XRWXU
M$?#6A&TBM#HNG&VB??'#]E38C>H7& ?>@#E/#P@U;Q9XXL-<ACEG$\<8CF (
M^QF,; ,_PD[R<=R:Y70VN5TKX97&I2%BFI7$4,\Q^9H2DHBR3ZJ%QZC%>LWF
M@Z1J,T<U[IEG<2QIY:/+"K$+_=R1T]NE/U#2--U:R%EJ-A;7=J""(9X@Z CH
M<'CB@#RW4?L%Y-\75'V>9!9Q. ,,-ZVK<CW##KZBK4>FV.GZK\,KJTMHH;BX
M5TFF10'E!M"2&;JW('6O0O\ A'-$(G!T>P(G14E!MDPZJ %4\<@   =L4X^'
M]%/V;.D6!^RC%O\ Z.G[G_<X^7\* /.=)L=.N-)\?V$EW!ILD^LSP).$7,:L
ML0'']S)Y'3&:W_"5]J,?BO4-+U_2[2#65LHI#?6)_<W<"NZJ<'E6!9N#_(5U
M$F@Z/+-=32:58O+>*$N7:W0F91T#G'S#@=?2I;+2[#30_P!BLX+??@-Y2!<@
M= <=AV]* .2UZZ9?BKX9M+T#^SI+6X:W#?<:Z&,9[;@F['U.*Y+Q#9&WL_BE
M:V\:_P!DI;131QA?DBN6B)DVCL2-K'ZCUKUN_P!-L=4MQ;W]I!=0A@X2:,.
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M6"=(TM_"'Q2<V-J6AO;SRCY8_=X@1AM_N_-SQW'M0![!=7EK91"6[N8;>,G
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M"[B 2%!/<XP*YGPSK-]JEGI_B&7Q#82:9-9+)?VI" 6LK*& 5QRH&<$.2>*
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M:-)U+ #J2,]!WKB8_&#Z]<ZM)IOB?3-.73=0$$<4[QM'<0JJ%W8GYL$N0"I
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MD@D&F66^W&(6\A<QC_9XX_"FC0='$<T8TFQ"3',JBV3#G_:&.?QJ^2%4LQ
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MB_U"TM"PROGS*F1[9-8OC7Q9!X7T#[6MQ;"YGDCBMUED !WNJE\9Y"AMQ^E
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M42( %?R5RH'  .* /._"TNH:-J_AK2IY;36M$N8)!I&I1#9/ BQYVR <,NT
M;AWQGG%;'Q398O"MI<2$+%!JME)(YZ(HF7))["NLM=+T^QE>6TL;6WD<89XH
M50L/<@<U//!#<P/!<1)+"XVO'(H96'H0>M 'G\>H:7?_ !JE5;JUGBD\.B/[
MZLKD7#$@=C@5R&FVUG!\&?!-XD4*3_VQ:-YP #;OM!!.[KTX^E>T)I>GQKM2
MQM57RO)PL*@>7DG9T^[DGCIS3#HVEF(1'3;,QJ2P7R%P">IQCV% '#:-JEFG
MB[QU9:]-!%=M(GEK<L%#V?E80+GJN2V<=V.>M<IX>UJ#3O#OPYN;O4FM-)6W
MN;>6ZCV,L%R<;-Y96"_+O&2.-QZ#->T3:9I]Q-#-/8VTLL'$3O$K-'_NDCC\
M*5M.L7L?L+65NUGC;]G,2F/'IMQB@#R7Q9IWAZ+P)KEUI=\U_%<ZK:S373.C
M1><TT8?RR@ !QC=C\\@X]:LM.L=.21;&SM[99&WN((U0,V ,G Y. !GVIK:7
MISVT=LUA:FWB_P!7$85VI]!C JS'&D4:QQHJ(HPJJ, #T H \\TJ[MH/&OQ#
MMI9XTGD:!DC9@&91: D@>G!YKF[*WM+?X=?#*YBBACG;5[(&50 QW!PV3UYZ
M?A7L,MA9S2222VD$DDB>6[-&"67K@G'(]JB.C:68UC.FV9122J^0N 3UP,4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU]X@FOA:[-1U%KR+R)6<J"JKM;*CGY<\>M:4/B70[B1(XM6LV>0@1J)ERY)
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MA5 R2?PH X"?P)J4.E:5!9O9R74>O#6[YY)&17<NS,J84^H )Q]WWK1ET'Q
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MV6H:?:ZI926=[")K:4;9(F)PX]#CJ/:G6=I!86D5K:Q^7!$H5$!)"@= ,]J
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MT/3;U+?5-.DM1I6&#2QRJ0D9V]2",@]L;CVKNZQ--M_#FL7P\2Z?!97-V0T
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M.W*_?(R >E7KOPYXJT_Q1-KOA^]TMWU&&)-1M;Y9%C,D8VK)&5R1QQ@^G7T
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M* "BBB@ HHHH ***Y_Q?XB'AC28+U]J0R7,<$MP\;.ENK9S(RJ02. .HY84
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MQFN!-*R;PF8\!!@KR2>6Z<<[^A:A<ZKH5G?7EA+87,T0:6UF&&B;N/S_ $H
M??ZSINF2QQ7EY%%-*"8XLYD<#J0HY(^@HL=9TW4Y9(K*]@GEC ,D:."T?^\O
M5?QKB?A/<'6[37/$EW\^HWNI2Q.S=8HH\!(AZ  YQ[UKQZU9S^/[[3;72KF/
M6X;$%[B7RQ"\1;Y"2&+'G..,C)H ZVBO/?#_ (J\8ZWX4B\11:5I<T,EK,T=
MG%(ZS/,KE5P6.T)@'.3GC/? OZ5XKOKOQ=<: 9M.O2--%[%<VRM&@</L9#\S
MY&2#D'U&* .SHKS&R\>^(Y?"NB>);BSTM;&[O5M;F!/,,F&F,0=#G QQP0<]
M<CH-*TU/58_B7XE%WJ$']FV%C;R^5]G;*QGS&.#O^]QRQ!SQP,4 =Y17"6_C
M#7+EM#OK?3'NK#4I(Q-!'83K):QR#*R&4_(X'&[ '7@GK4=YXVU>?3[C5-"T
M\WL,%T\*V0L9VDN420QNRS#Y%.0Q P>!R<G  ._HJEJ.IP:9HMUJMR'6"VMV
MN)!CY@JJ6(QZX%<O:^*->DU31\Z:;FPU#BX$-A/&UD2,JQD?Y9%[$@+Z^U '
M3:9K6FZS]J_LZ\CN1:S&"8QG(60 $KGOP1TJ_7FFBZW'X=A\>:B\9D*:^8XX
MQGYW=(44< G[S#. 3CL:UAXMU33=4N?[4LWGT>*QDNVOX;":W$+1@ED82$YR
M!D$$>F* .UHKEK+4_$]TVBW@LK*73]03?<)'E9+)63<A+%L2>A 4>U<WHGB/
M7-.\/^,-9OIXK_[#JMQ"$CMF!&PHFX8<_(JC.T#/!^:@#TVBL'PUK$NM">YC
MO].U#3BD9M[FR4KECNWJREFP1A?3K6-XGN]9C^(GA2QLK^"&UN5NY#');E\O
M'&.6PXR,.<#C!Y.>, ';T5QZ^(]7U>WUR[T%+(Q:5<R6J17$;,UU)& 7 8,
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M[7W;AG) P.*SVU35O#/@WPQJ\@TN:S5+:"YG-HZO:V\BH-P/F'.#C/3L<<4
M>DT5DP7]W<^)KNSB,!L+6",R-L._SGR=H.<<*%8\?QK4.OZGJ%A=6,=L+6"S
ME\PW-_=$%(, ;%V[E+%B<#!XP?6@"[J^M:;H-@U[JEY':VRD#?(>I/0 #DGZ
M42ZUIL.L0:1)>1C4)T9X[?.6*J,D^P^M>;^)O$,WB;X'ZQ?744<=Q'<?9Y/+
M!"L8[E5W -R <9P>E=#KW_)6?!W_ %ZW_P#Z#'0!VU%9NOWFH6.CS3Z9:)=7
M89%5)'"JH+ ,[$D<*"6(SSBN7M?&E_+<^)K2,Z??/I5G'=V]Q"'CCF5E8D'E
MNA0\@X.>U '=45YJ/'7B:TTKPWXAU&PTS^Q-4^SQSI S^? TH&),D[=N3]WD
M@8Y]+1\3>,M1O/$=KI%AHXET>X"*)VD;S@8PX48Q\QSU. ..#U !V-YK6FZ?
M?V=C=7D<5U>OLMX2?FD.,\ ?0\T^'5K&XU6ZTR*X5KVT1'GB .45\[3Z<X->
M>WFOQ>*4^&^MQ1&);O4BYC)SL80R!AGO@@UN'QA-8Z_XLAU*"!+'1+*&[5X<
MF2165V(.>,_+P/?K0!V58UQX1\-W>H_VA<:#IDMX6W&=[5"Y/J21R?>J5EJ'
MB>6[T>>2RLIM.OHR]R(LJ]EE=R?,S?O!GY3A1ZUCS^--7L+_ $A+^&QC:_U3
M[#+IRY:>V1BPCD:0.5R0H.-HR&XZ4 =?8:UINJ7-Y;6-Y%/+9.([A8SGRV(R
M 3T_*B^UK3=-N[.UO+R.&XO)!%;QD_-(WH /YUY_:/XC7QOX\_X1R+36G6YM
M6/VXOAS]F7"@+C!/J3QZ'LW4?$*>*M'^'NM+ 8&N-=CWQ$YV.J3*PS_O*: /
M4:*X?4_%^J2C6&T&V6=],F:!8'L9YC=2*H+*)$PJ==HSGD9.!76V=S-?:3!<
MB%K2>>!9/*G0DQ,5SM89'()P1QTH MUC2>$?#<NI?VC)H&F/>EMYG:U0N6]<
MXZ^]<AX1UCQ*W@.XU/=;:E>/?SHH9/*"?Z0RL[$O@HJY.T8X&,]ZU]$\3ZAK
M&LZ_H\,^GS36,4$MK>QQ.(I!(&X9=YS@J1E6P<^U '8T5Q'A3Q7K?B&Z%E<6
MUK:7NGR21ZQ$8GQ&V[]VL9W<[E!;=R,?45TGB&XU*ST"]NM(CAEOH(FDBBF4
ME9"HSMX(.3T% &G535-4LM%TV?4=1N%M[2!=TDK D*,X[<]37&?\)W<FZ\&2
M++8G3_$"8D?RGWQR;00!\^ "QV\]#ZU/XE\4ZQI/A'Q#KEM#87$5E,R6JRHX
MW(I".6^8Y._<!C'W<]^ #M@P90P.5(R#5'3-:TW61<G3;R.Y6UF,$S1G(60
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MI-M^C11L5DG1&:%".H:4#8,=\GB@#(\-Z-XPT^.WL=7UC3[JPLE"PO!$Z3W
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M" 3N(.#QSQES> /$3Z/<::NJ:<R#5AJ4,\D+F64B428E.>PXXSD #C%>E44
M<M!X>U2T\;W.NPWEH\%Y9PPW,;QL'WQ[L%.2 #N[YQ[U4T7PUKVBZ//;13Z>
M\TNJ2WK*Q?RY(Y2Q:)OER/O<'GIG'8]I10!PL7@6:TT'Q396"V=F=>#*MK$S
M>1:[HO+9E^49)Y8X"CH.V3>NCI.D^"H="\57MA$CV)M2OG &=4C"L4#8)/L,
MD9%=95:YTZQO9[>>ZLK>>:V;?!)+$K-$WJI(^4\#I0!C>!]&GT+PE8VMY))+
M?-&LES)+]]G( PWNJA5^BBHM?T'5KWQ/HVLZ;=VBBQ26-[>[1F3YP!YB[2/G
M&,?0D9%=/10!YQ)\/]:?P'K/ALZC8NU]?/<1S>6R[%:;S3N'.22,8& /4UT&
MH:%J5]XRT'7,VB1:=#/')%YC%G,H4$@[>VWOU]JZ>H;N[M[&UDN;J58H8QEG
M;H.WYYXQWH Q?&>A7GB+P^;*QNHH)UGBG F4M%+L<-L<#DJ<<US]YX=UFSN_
M$FO7M[8O%>Z/Y,L,,3 JT:28"DGI\W4\GT%==I6OZ;K,UW!93LT]FX2XADB>
M*2(D9&5< X(Y!Q@U;O+>UNK26&]ABFMF4^9',@9"/<'@T <!X9T.^\1?#[PC
M:7YM4TVW@M+IC$S&2<(JLB%2 %YVY.3G;T&>#P]_:S>+_'B:;]CP]]&H>=V!
MB;R$^; !WCVRO3KSQV'AR]T2]TK=X?$"V$4CPA8(?*164X8!<#O5FTTC3-/N
M)KBRTZTMIIN99(8%1I/]X@9/XT <H_@::RM?"5EI4L'V;09O.8SL0TQVLIZ
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MXF+,#'N#*%P IQG)WCTYBU?QA<:7K-EI-]>66DRW-@DT5S=Q,T$UP20T6X,
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M@/V+S]"=OL[B%ML@$(D^<;^O.."*8?!>I_V!X3TP7EIG0+B&<R%&_?\ E(R
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MDP(XE67=P<DD;2,\=1QR:L:5I7BL6T@US6+&[F2)HH%M[=HE8D8\R7DY..P
M')]L7/!NAW/AKPI8:-<SQ3O9Q^4LL:E0ZYX)!Z&@"&^UVYE\7Q>&M.>&*X%D
M;Z>>5"X1-^Q5501DDY.2> .ASQSM]XCU/5?"'C739S;6VK:+#-'/)'$QCFC:
M%F1T&[*%E]2V".];^K>&[E_%EGXGTFXBCOX;9K.>&<'R[B MN R.5(;D'!],
M5!)X0N&T7Q)&MQ =4U\.+B<H=D8,?EJ%'4A5]3R<GC.* +?@F"=?!VB27;V\
MKBQA\EHX"A1#&ORG+-D\<D8SZ5DS>,+B3Q5?:%'=V5E?P7$2V]G>1,&NX2%+
M.C[@">7  SC;R.>.F\/V%QI>@6&G73Q226D$<'F19 <*H7.#TSCIS7/>(?!]
MYXE@N+#4);*2V:Z6>UNMC"XLU# D(>YX(!R, ]#B@#(0ZPOQ$\<MHTME#.MM
M8N9+J-I!Q')A=JE>OKGCT/;5L_%FI:KX;\-ZM$EG96VHPF2]NIF!6!MORHB%
M@6+-P.N .AS5NV\.:E:^)O$>K+<6K+JT,,21$,#%Y:LH)/?.XGM6/I_@/6=*
MMO"PM=5LC/H<4MN1- SQ2HX WA0P(<8QU[GD4 5I?'VMCP!+K<-O9->6VJ'3
MY0\;HL@\\1;E4G*$@@X).*V9]>US3-0MM)U*2R:]OI)YH9;.TFE6*WC"?>0'
M)?<X&<@8Y]CER?#S5V\,ZEHHU>T=;O53J"2M;L"G[T2X(#<DD <8P/6MSQ3X
M8U'69M*U;2M1CT_6],+F*1D,D4BN 'C<<$J<#GJ,4 9$WC36]*T&[NM9T\VZ
MV^H);G4!:2",VS?\MS$3N&.A&>"0?:NI\.:A-JEC-=/>V-];M-_HMS9\+)%M
M7J-S88-N!Y[=!5--,\2"RAEFU6TFU'SQ).@A9+9H@K+Y2KDD?>SN))SVP *=
MX6\,1^''U66-88?[1NOM!M;8$0P':%PO3DXR3@<GIQ0!T5%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML,\'/7KQTH Z>BO/3XOUJ\\!S^-M.-L;2+S9X["2(_O+>-RIR^<ARJEA@8'
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M-D)&<<JP!%0PZ]IUQKT^B1S,=0@A$\D1C8 (3@'<1@\^A/2O.;SQ#KFN^"/
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M%'(3+(&*@AV V +GCDYZC'-C4_#&I:I9W]C<ZK;7%G?6XBEBN++=L?;@NF'
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MS 94JJ/ED/3;R1Q\U<O'XO\ %@^'=CXM>\L6*7GDSV@ML+.IN3#][)*X!&,
M].<YKKM \.:_IOEKJOBAM42V4K:JUH(\'!4-*0V9" 2.H]3DX(S1\/+H?#]/
M"G]M1;%N//\ M/V(Y_UWG8V^9_>XSGI^= %NTU37;/X@C0K^]MKN"\TY[R)D
MMO+\AT=5V_>)92&[G/%<GKVOZYJGPE\07<]^D-S;:I)9.UO$%$D0G6+;@DD
M@G/.>V:[J;PY>3>,[3Q$=1@!M[)[3R/LIPP8ABV[?QRHP,=/SK)_X5[))X-U
MKP]/JZM_:5V]XMQ':[3$[2"3&TN=P# =QQ0!V=O'/%:K'-<>=, <RE N?3@5
MY=I'B/4/#GA;Q?K=Y>M?R6^M7%K%'*@7?)YB1(21T'W>!T XKT^RBN8;.-+N
MY%S< ?/*L?EAC[+DX'MD_4UR1^'D4^G>(M*O=1>;2]8NI;L0K"$>"61@Y;?D
M[L,H(X'OF@!^I:QJWAGQ#H,%[=K?V&K3_8Y"80C03E24*8ZH<$8.2.N33?BQ
M+=V_PTUB:SNWMG6-0S( 2R,P4KD],@]15^#PU>W-UI,^NZE%?G2F,D'E6QB\
MR7:4$CY=LD G@8&3GT N^*M 3Q1X8O\ 19)VMUNX]GFJNXH000<=^0.* .4\
M20:@OQ \$0QWD;79BU "XEBX'[M.=@(S@=LBFVGC35;+1]7@OFBO-2L];32;
M>9(@@E\PIL9ER!D!SP",[1R,YK<E\+ZE<^(-!UBZUF&6;2DF5E%GM$QE 5NC
M_*  ,=?<FJ$WP[%[8>(;2^U/<NKW@ODD@@,3VTRA=I4[CG&Q?3OZT 7]'NO$
MR^)YK6]M9IM%>V$D=W.L221S!L&,A&^92.0<<=.:M>([Z]L[G34ANHK2RFD=
M;F?AIONY1(D(.YF;V)P#QZ)X?T76K%Q+KOB ZM+&GEQ;+5;=5!QEF )W,<#G
MMS@<FF:_X:N]4UW1]8L-4%E=:=YJ[9+?SDD20 ,,;EPWRC!S^!H Y&7QQX@'
M@.XU.%[4WEIK1TUVFMROFH)Q&#C/R-@C/![\"M5=7\3Z1X[LM#U2]L;RWUBW
MFDLYH[0Q_9Y8@&92N_YEP?4'Z5S_ (Q\.2^%_ >IPR:R9Q?:Y#=QM)"J&-GN
M$9LX/S$=>PXZ"N]BT2277K?7=6O()Y;.W>*U6&(QQQA\;W.68DD*!UP!GKG-
M ' KXQ\9I\.K+QR]UITEM$2UWIZVQ!EC\TH6#[OE([#'09)/2N@DU3Q3JGC7
M5]%TW4["U@M[6VNH))+,N0'9LJ1NY)"_>XQZ<Y&+\/=#F\2?";2].NM0@;29
M79IH8X3YC*L[-Y9?=@ D<G;G!Q[UVUEX<N;3QKJ'B W\3QWEO';FV%N055,E
M2'W]?F.>/RH Q8_$.LZYX?UK7=(NHH%L)YX[2U>(,DZP\'S#]X%B#C:1@$=:
MJ1^+]<U_6/#L.CSVEG::SI4EYF:W,CP,NS/\0#XW$ ?+ZG/2M:'P7=:>-9M-
M+U5+?3-6E>:2![;>\#R#$AB;<  >H!! /KTK%U"R32_B;X2TO2)[>U6TTBXB
MCCE7>"@,8"D!@<D#.<]N] %&]\;>*=,\*^*H;B:R;6O#]S#&;@6YV7$4I78V
MW=A6PWN/:MWQ%J7BKPY86]U-J=A.+G5[: *EF5,<,C*I4'?U!SR0>/2IM5\
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MO/E^4^_/Y5QBWD-_KFJ:E%XRT.PNC?.%LM7TZ-[F'8=J@%G5@/ERH _B]2:
M/6--:Z?3;=[UD:Y9 TA2(QC)YQM+,1CIU-<'<^+-9T^^T@W%U!)-=ZT-/NK.
M"/?!#&[,$Q*!_K  I()[GY17;Z)/>W6BVLVHQI'=NF9 BE03V(5N5R,'!Y&<
M'I7%P_#74(-&T[2U\2G[/I>I+?V9-D"W#LVV0[OG/S'D;?<'L 7[77=5FU;Q
MKI[728TE87M)/*&X;X3(0W8\\=N/SKGY=6UG7#\-;UM2-NVH[I9DBB&PR?9W
M;=@]>I '3G/I72W/@Z^_M_5[^QUL6]OJ\$<=Y$]J'?<B% R/N 7(/(VGVQVK
MQ> ;FWT?PQ:P:V%N] ?,-PUH&61"A0J4W#'!ZY/XT 9,<>KMX^\=_P!E7\-I
M-';6+F:2#S22(7P N0 #W//]:OZ9XUO-<MO"-G%Y=M>ZW9O=W$RKN\I44;M@
M/&68C&<X /!K5M?"M[:ZYK^IKJL+MJ\,411[0_NO+0JIR'&[(8YX'/I6?:_#
MV2QTOPXEMJJKJF@!DMKLVWR21L,,DB;^01W##!Y% %._\6ZYI:>+]+>:WDO]
M&L/[0M+MX,B:$HQPZ@@!@5(R.#UQVJ/6M;\7Z/\ #R^\3-J>GN[6=O/!#]C/
M[HM@.-V[YB=P.2,<'BMV]\&27]EKYGOXAJ.M6WV2:Y6W.R*$*5"HF_/\3');
MDGTP*=K'A&YUCX??\(L^IQQLT$<#W0MB<JF.0F_@G:.YH SM3.I2?%[2+>/4
MWCMCI<\HA$:E00\8/U)]>W;OF(^-=1TV+QI/?^1<?V/<Q0VJQQ^6#YB+M#9)
M/WG&3G\JW+[PS=W?B72M<BU1;>YM+>2VG"VVY9D<J3MRWR'*]3N^E4CX"2Z'
MBB'4[Y;BUU]E:2.. QM"54*I5BQSC:#TZC\* %MKWQ;;^(88VLIKS2YK>0RR
M3K#$T$RC*A=KDE&Z8()''-5?!GBR3Q%>PQMJH%Y' W]I:5<0"&:WF^7[@P"4
M!W#G=U7FKNC>&->M(/)U?Q5)J20Q-';$6HA925*AW8,2[ $^GJ<G!$MMX4G?
M7M*UG5;VWN;W389(HYH+7R7FWJ%)D.YLC&>!QDY]J $\>:KJ>@Z)%J]A,J6]
MK<1F^4Q!R;<L [+Z,H.?3&:H#Q9+:?$._P!)OM03^RQ8&[MI!$!M90&D0M_$
M51D<8[-SFNPO[*#4M/N;&Z3?;W,312+ZJPP1^1KDU^'-B=$\/:?+=2R2Z1.L
MS7!'SW'RE75N?NL" 1SP * (M0UKQ#I2>$1<7$!?4[]+>\1H,.H9&?:"#@8V
MX/')YXZ5%H!U&7XD>,UGU)Y8+9;55B:-<;&B=@H] "Q^O>M[Q)X=N->O-&GB
MOX[8:9>K>!6MS)YC!67&=PP,,:A3PO=VOBK5]:L]56)-3BB$MO);;\/&A16W
M;A\N#R,9R.O:@#@O"6K:WH7P_P# ][%=VQT^ZNH+"2S\C+%979=_F9SN!YP!
MCZ]:UT35G\?^/CI-]!92I;V+F62#S22(7( !( ![GG^M:,7P]NH?"&A: FLQ
M;=(O(KI)C9G,GEON52/,XY/)S^5:=OX6O;;7?$.J+JD!;6(HHS&;0XA\M2JG
M/F<\,<]/PH R-/\ &M]K.F^&(H872]U;3WO;AK=%8QA-@(0.<<L_?. #P>HR
M/&-SX@G^$GBB+Q!9^5)#*J6T_P @-Q#YJ;6958A6[$5KGX<7,&A:!!8:^UIJ
M^A*T=K?I; J\; !D>,L0P.!WJ_J_@V_USP=>Z+?:[YEY?%//O#:C "D$*D88
M!1QW)ZD]Z +5SK-UJ'C27PY8W'V5;2S6ZNKA45G)=B$10P('0DD@]@,=:R_A
M<LZ:9XA6YD22<>(+T2.B[59MXR0.PSVJ]J'A._?Q/;^)-+U:&SU+[,+6[62U
M,D-S&#D?)O!4@]#N]JM^$_#4_AJ+4TFU'[;]NOYKW/DB/8TAR1P3GMZ4 8N=
M1D^-$EO_ &DXM8]&2=(/+4JH:;#*/KL'/6JC^+-9LM0T(75U!+-?:L;"\M((
M]\$"MOV!90/]8 JY!)ZG@5TEWX9FE\:Q>(K;4C;_ .A"RN(/)#>8@<N"K9^4
MY)!X/'H>:YZW^&VHV^CZ/I@\39AT>_6\M#]A7=@%_E<[OF;YS\PP/4&@!VM>
M(/$.B^+QHLES"T.L1[-'N#&JB*<$;UE_O84Y&,9Z=3FM?5=9O8-=L?#UJT\E
MR]F]W/<0QQF3:K*@VJQ"C+,<GG &,<Y#-:\%/K^G:K!?ZA&]U=,AM+I;<JUF
M$(*;?GZALMD$9+'/&!46K^#-4U$Z3J5OXA^R^(=.1HA?I: I/&V-RO$6P<X!
MZ\'IVP 9UQXH\2Z-X<2Y\0V,UJD>I-;W%];PK(XM-K%9_+4L%).U6'..3CI7
M5>&=0.J:2;M=3M]2@DE8P7,  #1\8! Z,.0>G(Z#I59-#UF*VM677A)?I.9K
MF6:VS'."A78$5AL4<$8)Y&3G)S-X9\-P^&[>^2)HR][>/>2K%'Y<:LP PBY.
M!A1WY.3[4 9\6KW^O^)-=TK3KT6,>D"*/S1$LC23.N_D-_ !@8&"3GD5S@\>
M:]?:'X?N;=;*VO)];_LB_B:)F7>-^60YX7Y0<8SSC(QFNI?PO<V?BF]UW1K^
M*VDU")$O8+BW,L<C(,)(,,I5@.#U!'H>:I3^ 0-.T2SLM16$:;J0U.226W\Q
MKF;+%B<,N 2[?IZ4 3>&]6U<^+M>T#5;J&\^QQV]Q!/'!Y1VR!LJ5R>A7@^_
M-9_CE;I_&W@A;*2**Y:XNPDDJ%U3_1VY*@C./3(SZBMVP\.W%GXRU/7WOXY%
MOX8H3;BW*E!'NVG=O.?O'/%+XA\.S:OJ&D:E:7JVM[I<SRP^9#YD;AT*,&4%
M3T/!!X]Z .4/C76_#<OB+3-<:WU"[T^*WFL[F*+RA,LS^6H=<X!#D=#R*WM.
MNO%,?BF&"XM9KC1IX&,L\Z0QO;S#H $8[D;I@@D''-+=^!K35K+6TU><W%UJ
M\:1331)Y8B1.8Q&"3C:WS<DY)], /T+P]X@L%7^UO%!U1H$*VNZS$0!QC?)A
MLR'''4#DGDX( .!\)ZMK>@?#;PEJ,%W;?V?)>I:2V9@RSI).REM^>&!.0 ,>
MN:Z7QCXFUG0X=?NXKR"(Z?%'-96L47G>:F 7:? R@)RH.5Z=ZEB^'EU%X)TK
MPVNM1;=/NTN5G-D<OLD\P*1YGJ>3GI2ZC\/KV^'B6!-?\FRUX;Y8_L@9XY-@
M3(<M]SY1\N,^C#K0 NMS?:/B1X"FQCS(+Y\>F84-0>&K>^_X6KXP+Z@76-+'
M>ODK\ZF.0@>V/;K6N_A.]DUKPYJ4FKQN^C12QE3:?Z_S%"L<AQMP ,<'W)JQ
MI?AR[T[Q;K.N/J,,J:H(5>W%L5,8B4JN&WG^\<\?E0!T5%%% !1110 4444
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M".I8N""H";E^7(X'XBLK3_$_B8:#X+U^ZU.&:+5KNWM+FT%LJ@B7<-^[KN!
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M6*,E6)Z*0,<<\]:V-4EN]4^(GA.>TF2TFN='N9/,*;_+#>43@'@GGC/'L>E
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M10 4444 %%%% !6+XG\-V_B?2TM9II+>:"=+FUN8L;X)D.5<9X/<8]":VJ*
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MU6T$@M[N%9HQ(,-M89&0">: .>B\&WR:_=ZR^OR27-W8"SF5K5 A(+88 '(
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MM9S;-?I//+<*JEU2(+\J!@1DEAR0< 'N<BC>-XETC1;A;W6[$?\ $R18KQU
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MGS:1)=& HORR+*B@A@-W0G@DTM]X,&J^%KW2-2U:ZNKJ[*/)?LJ*X=&#)M4
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M<TT1%5D_MFRVEAD ^:,9'<5<M?!][_PD6FZWJ/B&XN[JQ@D@ 6WCC617(SD
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M%J.L7 FFFDD$96$1AD5V57&.H8 -^/'%9MI#=O\ &?4U.J7GDQZ5!*L/[LH
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M+Z_N]&T^:V06&I);I);^>=VX3,5;;_!@<#&>?2W=:UJ6J^(-1T?3I;R,6%K
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M1#J>JIJ.E:NLZM$+98S:R1H7&PCEE(!&&)/O523Q-KT_PT_X3JUO\2*K7?\
M9S1H83 '(,9.W?NVC.[=][MCBNLMM#%[JECK%_?QZ@UI$ZV9BB"(-X 9S@G<
MQ QD8&"<#FLVW\ 16VCW'A^/49/^$=FE+_8C&-Z*6W-$LF>(R<\8)P2-U %$
M:IKFL^.Y-*M-9:RT^?18M0CV6T;21%Y"O!8$9P!U!'7CN-CX?ZQ?:[X-M+S4
MI%EO!)-!+*J!1(8Y63=@<#(4'BIU\-/'XOE\0Q7JK(]B+%;<P_(J*Q93P0<[
MB?PX]ZE\*^'O^$7T;^S5NVNHQ-)*KN@5@7<NPX]V- '.Z-#=O\7?$V_5+QHH
M;6S986\LIM;S3L^[D*#DC!!YY)KD_#M_K6A?##P_K%IJFRV34C!)8^0A26.2
M[=&W,06#?-D$$#V/6O23X8:/Q;=:_::E- ]U;QPSV_EJR.8]VQB>HQN.0",^
MM9"_#S9X,M?#(U>3[-;70N5F, \PD2^: ><8W'TZ4 ,OM8US6M0\0V>BO>02
MZ9(+>!K=;<JTOEJ^9/-.=N6 PH' )SD\=9H\NH2:+:2:M#'!J!A4W,<3;E5\
M?-@^F:YV_P# ]Q)XCEUS2/$-YI%U=HB7ZV\221W&T8#;7!"MCC//\\]5:6L=
ME:16T6XI&H4%VW,WN3W)ZD]S0!Q>C7_B+Q3X=T[Q'I>J10&YN?,-E-&I@^S!
MRI0D*7W[1G.<;O055DU--$^(/C;59$+I9:+;7#(.K!!*V/TK0TOX?G1[J:"S
MUZ^CT"69ISI(1-@).2HDQN"$_P (QGUY.=)?"<;>)-6U6XN1/%J=JMI/:M%\
MOEJ&  .<Y^8Y]<]J .;U/Q!KFB^#='\7OJ)NHYC;27UD8D$7ES%1B,A=P*EQ
MC+'/>GZAXJNK3Q;<:3J>I7.C2O>1#37D@0VEW#\FY?,*DAS\XZC&5Q[ZMGX'
M$&EV6BW6IR7>C6,R2P6\D0#D(VZ-'?/S*I P-H/RC)(X,VI^$'UBVN]/OM2\
M[2[JY%PT#P O'A@VU'SP"1W!/)P1V *]MJ>KS?$36]&-^HM8M.AN+8>2O[IG
M9P3ZM]T=3BN4TWQ-XH;P;X3\3W.M"4WU_!;7-H+:-4D224H23C<&'!&"!QT/
M4]VGAN:+Q7?:_%J&)KNU6U\IH<JBJ25(YR3ECGUK)C^'HB\(Z3X=35G%OIET
MES%*8 78H^]0W.,9)S@<C'X@$.J>(-1;7?%5D=2.E)I5A'<61V(1/N1F:1MX
M.Y0P"8&._<C'0^$+G4[[PIIU[JY/VZY@2:5#$(_++*#MQ[?G7 ZQ=Q3^--4>
MX\5S:!=1O'#%;W>GQS+*J+Q)$9%. 69N%)/&3UP/0?#,FI2:,AU2?[1-O8).
M;?R&ECS\K-'_  DCM^@Z4 <?#/XQUW4/%=G8^(X[-],NPEJ5LHVW9B5PC;LX
M7)Z\GGJ,8-.R\7>(?$0\"R6E_'IXUR"Z%TJVZOM>*,_,N[/<$@=.F<\@V/#"
M3ZEXM\<Q:?K,4"S7J A8Q(VWR54O&<C!SD9(89 X]>B/@FW@O_#DVGW1M8-!
MC>.V@$>X.'38VXDY/'ICG)YH I6]_KFF^/=)T2_U<7UL^D2SS-]F2,R2HR#?
MQTZG@<4S1;[Q%XG\/:7XCTS5(H#<W E>RFC7R1;;R"F0I??M .=V-V>@XK=N
M/#C3^,K3Q#]M*M;6SVJV_E JR,06).<YR!_A61I/P_.BW,EO9Z]?)H#S&<:3
ML38I)W%1)C<(\_PC&>^<G(!2N=9\1Z]'KC^'S=17%A>R6EJJ+;F!WCQGS=YW
M_,<_=Q@$8YY/9B]EMM#%]J$(BFCMO.N(HSN",%RR@]\'(KFY_ DT?B&\U/1O
M$5_I,.H.)+ZU@1'65\8+*6!V,1U(YKK8[:&*T2U6,>0D8C"'D;0,8YZ\4 ><
M7?B;7H?AM;^.XK[>VU+N733&GDF%F ,8;;O#!3][=U!XP<"^+[7M7\=ZKH]M
MKC65BNG074+1VL;21EV8<;@0?NC.0?;'6KEMX!BM]%/AXZC))X>\WS%LGC!<
M)OW^5YF>8\]L9QQNK2B\.2P>++[Q!'?CS;JV2V\EH<JBH25(YSG+'/K[4 0_
M#_6KSQ#X&TS4]096O)5=971=H9D=DW8'3.W/XUC>'X;MOBAXR,FJ7DD<"6>V
M)_+*E6CD8+]W("DDC!'7G-='X3\/#PKX>@T=+MKF*!G*2.@5L,Q8YQP>6-0#
MPL\'BC4=<L]3F@;4(HTGMS&K(SQJ51L]> >@(R?RH \Z\+7^M:'\.O!.I6^J
M8M)KV&SEL?(38\<DK*26(W;@3D$$#MCN>JN]8\0:[)X@CT)KR&;3;EK2U\E;
M<QO*J*Q\WS#NP6;'RXP.>3TGC^'OE>$](\/IJS^1I=U'=0RF ;V*/O4-SC&2
M<X'(Q^,MWX&N/^$CN=8T?Q%>Z0]\%^WPP11NDY48W*'!V-CN,T =/IDEY+I=
MI)J,*0WK0J;B*-MRI)CY@#W&<U:J*VMX[2UBMH01'$@1<DDX QR3U/O4M !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%87BNZN;33+=[;48; /=Q)-*ZEG:,
MM\R1* V9&Z 8/6@#=HKRZ7Q)KD.D?$".*^N8I-%19[*2YBC:5 T'F;6X((ST
MSS@\\U+<ZCXFT*[\)ZM-K;WUGK%Q!975D\"*L;2IE70@;N"#G).?;H #TRL>
M]\16MCXDTO0Y8+@W&I+*T,BH/+'EKN;)SG.,=N]<%%<>+]5T3Q5>6WBB6"?1
MM2NH[51:Q8E6)5(63Y>F..,<DDYX M+JSZ]XG^&.K21B.2\M+R9T'16:W0D#
MVS0!WUIJ#7=_?6ILKN 6CJHFFC"QSY7.8SGD#H>G-7:\UNO&&J:$GQ N;FY^
MV+H\D"V:2HJJGF1J0#M R S\]\#K74P:=KEGK%K<+K@NM/:W=;J*Z106EQE7
MCVJ-HZY'3'YT =#61H/B*U\0_P!H_9H+B$V%X]G*LZA274*21@GCYA7$V'B'
M6(=;\)(^J27Z:E--!?2I&HM96$;./))4-A2N PX([DU3TO3]<NH_'%QH^O2:
M;+;:W<R1(D".LKB.,XD+ G;T&!C')YZ  ]!O_$5KIWB+2=%F@N#/JAD$,BH/
M+'EH7;<<^@[ ]:V*\P369/$.M?"W5YHQ'+=K=2R(O0,;5LX]L]*LMJGBCQ)I
MFH7_ (?DGANX+^6"U0M"+?;%(4*R _.=P4D],9&.G(!Z-15<K-<V&TR-;321
MC+Q$,8V([9!!Q[BN$\/:WK%_H)T>\U.7_A(X-5:QN9UCC!"J=Y<+MP%,(X..
MI% 'H=%>?W&I:_X@D\0PZ+-=03Z;<M9VC1-"$\Q8U;=*'R2"S8.!C;TYJ#7O
M$VK:-/:-XB>[TRQFT^,'4-.C6:&WO"6#^9E6.W[FW(QUSGL >BF1%D6-G4.^
M2JD\G'7%5+/4&O+R^MS97< M9!&)9HPJ3Y4'=&<\@9QVY%<,T=S=?%30&&LW
M#H^A23!H&0QM\\62N5(PW4GKTP0*;)K>N)8?$3&K2>=HY+V4GDQYC MQ)MQM
MP1D]QF@#TBBO.+34]=LM5\$7%QK4UW#K<1CNK9XHUC4^1YBLF%W Y'.2<Y[=
M*JZQXGUG^R_%MQ'J+V6L:9?^3I]BJ(?,C^3RSL()?S,MS^6,&@#U&LGQ+XAM
MO"V@W.L7D-Q-;VX!=;= S8)QW('ZU<L%GBTZ 7<KRSA 9'<*"3U/"@#VXKR?
MQ+J%[XK^"6J^)6U&:%+I7>*T14\M85FV!#QDDA<DYSGIQQ0!["K;E##H1FD>
M1(R@=U4NVU03C<<$X'J< _E7$>)-0U*&[OH[?59(Q#I?G6UK8HK3)*-Q,LI9
M=H3@  D9PW!(K#N+N_UZ_P#AA?S:E<V\M_%)+*MOL""3[*S%PI4C/)'.< \8
MH ]5HKSZ?4_$/B%=?71)KJ"XT^[>SM"C0B/S(U4DRALD[F)S@8"XQSS7<:<]
MU)IMJ]\D<=XT*&=(FRBO@;@I[C.<4 6:PV\6:;#XHB\.W7G6VH3QM);B9,).
M!UV,"03WQUK<K@_&'A6V\6>(5LY)&M[J+3S-9W<?#V\RRC:X/\QW% '5ZAK$
M>G7ME:O:W,KWLABA,2J5+A6<@DD8^5&//'%:->9Z+XJN=6UC0M$UR-;?Q)IF
MI.EW$.!,OV2XVS)ZJW'T)]Q5B75/$OB.SU>YT"6>"ZM+^6UM%#0^1^Z?:1(&
MRQW8)/3 (QTR0#T(R()5B+J)&4L%SR0,9./3D?F*=7GEG%?3?&-S/?W,9_L&
M&X>!'1HU8S,&097[ORCD<GUKHO&5]JFG:(MUIEK<W.RXC-TEHH:?R,_.8P>K
M=..N,XYYH Z&BO.8_&:/H,$^DZO+J(U'6([&%Y$1)K0,@+1L&"C>"CXW#^)2
M=W<UB'Q1;Z-XK%S>746E?V7)/:2O+%]IBE5"67*#E#Z]1V(H ]!%Q 88YA-&
M8I-NQ]PVMN^[@]\Y&/K69'XBM9/%DOASR+A;N.T^V&1D C:/?LX.<DYSV[5Y
MY>V=TGA[X:A=8OPLUW:J0#& H-N2,#9SC;QNSU/6MV><:?\ %ZXN)"\HM_"V
M]B<;FVSL3TXR<4 =]17GFFWOBW5K#P]KM@\A6Z,4][#/)"+<V[KEA&!\X9<C
M!)R<'-4GO?$=Y8>.7'B2Y@;1;F4VC1P0Y(6%9 K94@KGT /O0!ZA17FZ:SKD
M$_@G6)=6DECUQXXKFQ\E%A420%P4XW@@CJ6.?8<4YM4\3^)-.U&^T"2>&[M[
M^6"U0M#]GQ%)L(D!^<[@"3TQD8Z<@'HU-DD2)0TCJBE@H+''). /Q) _&N#\
M_7M3^(%_HAUR>RM/[*AN@MO'$S1.SLI",RG(^7J0?;%<W<:GJGB#P/X%OKS4
M[A+J77XK:=X JB4K+(H<KM(S^[!QTSVZ8 /8J*A,,GV/R5N9!)LV^>0I?./O
M8QMSWZ8]J\LTCQ#XBM_AI#XUO]<>YD-N\1M&MXUB,C3^6DA( /&>1D#''&,D
M ]9HKCK>+Q;;>((Y(FEFTR2VD6:/4)(=RS@91D\L=">".@ZBLWPEXBFUC5(]
M-OM4U&PUJ*T<7VF7D*(QDRO[V$[<%1AL8)&"#B@#T.L>+Q%:R^*YO#H@N%NX
MK079=D C9"VT8.<DYSV[5P=OXIUV7X5>'-<;4W_M"?4(H9Y!%'B5&N3&01MP
M/E],5MM&9?C1=QK(\1;PV@#IC<O^D-R,@C/U% '5ZCJ2V.E7-_#;3WWD!OW%
MFHDD<@X*J,\D'/'L:N(V^-6VLN0#M;J/K7C^D7FK:3\ [S6;+6;M;V/[3*CR
M+')M(N9 >JY);.223STQ74:K>ZU)XZT#2[;6);6TO]/GEE5(8V960)\RDJ>?
MF/7(]J .ZHKS"/Q/K]AX!\4S+</?7VCZK)8QW3Q*7\D-'F1E4 %E5V/3'R\C
MK6O87VHS?$5=/L=:EO-$735NY6 CD"RE]JJ7"Y 9<MC/;C@T =7JVH-I6F2W
MBV5W>F/;_H]I&'E;+ < D9QG)]@:NUR7Q*U+4=&\#7VI:7>-:W,#18945LAI
M%0CY@>S'I574[G6;CXG1:';ZU-::?/I$ERRQPQED<2HN49E/.#_%N')XZ$ '
M;T5RGP_U2_U+0;I-2N3=7-CJ%S9?:&4*TJQR%58@ #.,=*S+N37]3^(>JZ#;
M^()K&R33H;F,Q6\;/&S.X(4E3Q\HSG)],=: .^HKS+1?$FN7WAZ&#4M4A@N[
M'6YM,O9XHOWUX(P<"% I^9CMS@< ,>*J7?BCQ!'\/O&ES'J%Q!>:-?R16TLL
M<1D$>(V"O@%21O(R.>E 'JTDB1*&D=44D+EC@9)P!^)('XU4DU!DUF'3OL5V
MRRPM+]J6,>2F"!M9L\,<Y QV->>>,],UBWM]#ENO$M[.MWX@L (DCCC2++#(
M&%RP# $!LXP,Y/-= ]]J=I\3M,T@ZC+-82Z5+,T4B("9$=%W$JH.<$\=/:@#
ML*Q[#Q%:ZAXBU/1(X+A+G3DB>5I$ 1A)NV[><G[I["N)?Q%K-G=>'IO[5:]>
M\UHV-XT$:_8BC&3"1DJ&+*%7YESR&!)Z5LZ'_P E;\6_]>5A_*6@#M:Q]:\1
M6NAWFEVUS!<.VI72VD+QH"JNP)&XDC' /3/2LSQMJ]_HJ:?=1V]])I0D?^T)
M+! \T2[?E;&"=N>6QSP/<'E]>O1JVA>![JRUI-1$WB-#%?&,<J1/MW* HW*N
M 1@<B@#U.BO/K+4]:L=5\9Z0VMI.=/M(;FSO-25%6%I$<GS"BJ-@*@].!1HV
MLZDWCBTTG[?>SV5YH[W'FW,2*3,KHOF1C:"%.X\, .F!B@#T&BO*=*U[Q#;^
M!+KQC?ZY)=?8/MJ?8C;QK'.5D9(RQ !&"!TP, >Y/26D?BJ+Q!IL\<TTVER1
MNM^M[)#][&4>+RQD<\$=,'UYH [*BO._"GB:YO\ 7+/2]7OKVPUZ-7-YIEW$
MJQW'!^>!@O*@],'IG.<9K;^(%QJ]AX4N-4T:[EAGL"+B6.-$;SH5(,B_,IP=
MNX@CN* .IJEJ.H-IXM=ME=W7VBX2 _9HPWE!OXWY&$&.37%'Q<UK\0X%DU6:
M3P[>Z>TD3%(Q''<*@E*[@N[F$A\$]^_9VL7^OZ5I7A2=]4N%GO\ 6;>&ZCDB
MCSY4K$^4<*,;0 N1R>: .GC\26LGB>ZT 6]T+NWM!=LQ0;'0MM&WG).0>W:G
M^'?$-KXETU[ZTBGBC2>2 K.H5MR,5/ )[BL"#_DMMY_V+\/_ */>CX7_ /(L
MWW_87O?_ $<U &[#XBM9_%=QX=$%PMW!:B[+N@$;(6VC!SD\@]NU;%>=:E8W
MFH_&&[M[/5)=.9O#\6Z>&-6DQY[\#<"!^1_#K5+2_&.N?9(-#O93/J:ZY/I+
MWL*(C2I%&9-X#?*'8;5].3WH ]2HKFO#<?B*WU74XM5=I-,8H]@T[H9TX^=6
MV<$9Z'KZUF>)KG6G\>Z+HUAK4MC:ZA9W32;(8V*,@3#*6'7YN^1[4 =Q17#Z
M3=ZEK>N:UH;ZS<Q?V)%;VYN(8XUDGF>/<TK J0!TPHXZYSQC$M/&.N7>F>&Y
MI;KRKO\ X2$Z/J CC7R[@+ORP!!*YVKT([T >IT5P5QJ^KKXB\:V,>IR+%8:
M=#=6>8HSY+LLA./EY'RC[V:S++6/$%M8^ M8N-;FN1K+P6UW:M#&L1$D+-O&
M%W!@5R3G!] .* /1-6U*+1])NM1GCEDBMHFE=85W,549.!QVI=*U&+5]'LM3
M@5TAO+>.X17 W!74, <=\&N"N]1O?%?A7QE?)J,UI!9-=V5O!$J;2(D(9GR"
M26.>.,#&,'FFZ%K%Y+8>%?#MI]I4?\(Y!>RM;-&LC?*B* 7X ')..>5Z#.0#
MTJL>V\16MUXHO- 6"X2ZM8$N'=T 1E8D#:<Y/(/:N376?$^G1Z+H&K7"1ZEJ
M>IRP1WJ[&<6J*9-S #8)2,+TQWYJ71+66T^,>MQR7DUR#I%NR--C<J^8_P N
M0!GG)R>>: ._HKD_%>IW^F^(O"L=I=O'!?7YM[B':I61/+=NI&0<J.A%8FHZ
M[K=O<?$:*'5)%&CV4-S8EHHR8F,#R,/N\@E1US0!Z/17E\VI^)]%7PAKLVMO
M?6NJSVMG>6+0(J+YRC:Z$#=D'KDG.>PXKU"@ KDI/B%ID4>G22:?JR+J+B.T
M+6A'G,1D  GN.>:ZVN ^(2JFN^!%50JC6T  & !L:@#K=*UF'5GN42VN[>6V
M<+)'<PF-N1D$>H]Q[UI5@>*[B>TL[62VOX;'S;N*.>0H6EDBR<QQ *Q:0] ,
M'@FL+P[?:SK3^*](.I7=K+8W2I9W,L<331!XE<!A@JP!/?G!Y.: .\HKS_X?
MZYJWB*:1-2U$K=:.OV2]MT\LBYFR?WV0N0A &W;C)SZ<^@4 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %8GB;PW'XDMK-3>7%G<65TEW;7$&TE)%!'(8
M$$88\&MNB@#S?Q7X7AT/PSXSU3^U;RXGU73RCQ3E,/*L112,*#N/3:./0=,;
M.@Z)'?Z3X?OK[46O8-/A26V0JJJLGE[=SD?>906 Z8R<C/(Z^J6HW\M@+7RK
M"YN_/N$@;R #Y2MUD;)'RCOCF@#SWP=IS:TGC*T75I(;2\UNZ\R*-5+-$VT;
MD8\@,,C/(XXP>:ZZY\)6\NLZ%J%O<R6J:+&\5K;1HNS:ZA"#D9^Z !@C%;<E
MRB&1%'FS(F_R4(WD<XZD=2".:SO#/B"W\4^'[;6;6&:&"X+A4F #C:[)S@D=
M5]: ,Y?!%E)/XB:]N);N#7@HNH'555=J!!M(&1@ >O(S3-&\$G3K;[+?:[J6
MJVT<+06T5TR 0H5*GE0"S;21N). 3C&:TK'Q'!?>)]2T);6XBN+"*.5Y) NQ
MU<M@K@D_PGKBMF@#B+7X<);0:)$WB#5)!HLNZS)\H;(]I39PG/RG&X\\<8J^
M/!@BFU=;75KN"RU>9I[NW54)WL K;'QE<@ =\=L&NAO;G['937/DR3")"YCB
MQN;'89(&?QJIX?UJ#Q%H%EK%M')'#=Q"5$DQN /KCC- &?=^$;:?5-!O+:XD
MM$T,,MK;Q(NS#)Y9!R,XV\#&*SS\/HX=<O;W3M=U/3[/4)3->V%NZ^7*Y^\0
M2"R%NY4@^A%:]GXDAO?$6JZ*EG<I<:;%'*[.%VRA]VW9@_[/?%7]+O9-1TRW
MO);*XLI)5W-;W  DC]FP2* +2(L:*B*%10 J@8 %9%OX:L+;Q9>^(XU87MW;
MQV\@S\N%)^;ZD;1]%%;-% '(7W@02^([C6M+UW4M(EO0HOHK0H4GVC ;#*=K
M8XW"KUSX89S/':ZC+;VD]FME);-&LB;%##<N[D-AB,G(.!D&NAK&U+Q'!IGB
M#1](EM;AI-4>1(IE"^6I1"Y#<YS@>G>@"C_PA-G#?Z+=6-Y=V1TJT-BB1%2)
M8/E^1BP)_A'(P>M1MX(1H_$B'5+G&O@BY^1/W>4V?)QQ\O'.:ZNB@#EW\&JY
M\.DZG<9T+_CWQ&G[SY-GS\?W>.,5Q,%SYVL:C,/%.N:'J,]Y*YTU]-$[+SM7
M86B)8%54C:2 #CMFO7J* *&BF_.C6G]J$->^6/-8(%R?4J"0#C&0#@'.*Y*7
MX8P'1M2T*VUR_MM#OG9_L*+&1"6;<P1BI8+GG&>OXY[RL:Q\1P7_ (FU/0EM
M;B*XT^.*1WD"[7$F[!7!)_A[XH RY? L<FK7=\FM:E&+ZT2TO8U\O_2 @(5B
M=GRG#$?+BF1^ (8=+\/VL6LZ@D^AMFVN@(R^TIY90@J5QMXZ9[\FNPIB2QRM
M(J.K-&VQP#G:< X/O@@_C0!R5UX!7_A(+C5M+U[4]*-[M^W06S*4G(&-WS [
M6QU8<_C6Y%H[6^K6UU!?W,=G;VGV9; $>4>1ASGG< ,=?_KZE8WB'Q'!X=6P
M:XM;B9;V\BLU:(+A'D8*"V2#CZ T ;-99TB0^(QJ_P!NDX@^S_9]B[-N[=G/
M7.??\*U*9#-'/"DT+K)&X#*ZG(8>H- &5?>&=.OO$FF:^\>W4=/$BQRKU='1
ME*MZCYLCT/U-8TO@!$U^\U'3==U/38-0D\V^L[9U\N9^[ D$H3W*\^XKL:HZ
MOJUKHNG/?7;,(U94"J,L[LP55'N6('XT 9TGA2#_ (2FVUVVO+FUDBM%LGMX
MMOERQ*Y=5.02,$GH1D<5?U;39=12V,%]-9S6TXF22-0V2%9=K CE2&.?YBHM
M)UB74;N^M;C2KVQFM&4$SJ"DH89#(ZDANG/<'K6K0!R5[\/M+U/3M4@O99C<
MZE<I=RW4&(GCE10J-'C[N /<G)R3FK%CX1*:9>VFK:S?ZO)=V[VK37!52D3#
M!50H !/<G).!Z5<TSQ'!JGB#6-'2UN(9]+\GS6E"[7\P,5*X)XPO?'6MF@#D
M7\"))H&D::VM:@9M)N(Y[6[Q'O38I15V[=I&TD<C.>3FKR>%D7Q7_;[WT\DG
MV :>T$BJ4:(-NY.,EL]\_A704C':I(!8@9P.IH X[1/A]'H5PL5MKFIOHT<O
MG0Z4[J8HVSN W8W%0>0N<>N:LQ>"UBM_$,(U2X(UUF>X)C3,99 AV<?W1CG-
M:/ASQ#!XEL)[NWMY[=8;J6U9)PH8-&=K="1U]ZV* .5D\$I)9>';7^U+@+H3
MH]N1&F7*(47?QS\I(XQ5=OA_'%KE[?:=KNIZ?::A*9KVPMW41RN?O,"02A;N
M5(/N*[*B@#GX?"ZV_BBXUV"^D26:T6S$'EKY:1J25QQG()/>LR/X=VT/A>QT
M--5O%%A?"_M;D+'YD<H=GY&W:1EVX([UM:AXC@T[Q)I&BRVMPTNJ&40S*%\M
M?+0NP/.<X'IWK9H A$+I9B%)W,@3:)G 9B<?>/;/Z5SVF^!]/LO!#^$KF::^
MTUD>/]\%#[68MU4#D$Y![<5TDLL<$+S2NJ1QJ6=V. H'))-/ZT <GH_@F33K
M9K>\\0ZIJ<20M#;+=%/W"LI7/ !9L$C+9X)QC-7+7PQMU33=0U"_EOKC38GB
MM9'C56^< ,SD?>; QQ@<GC-;LLL<"!Y75%+*N6.!DD #\20/QI] '"#X90_V
M.NCC7M2738+M;JT@41C[.1)YF =N6Y)QNR!Z5O1^&A'XP/B,W\[SFS%D861=
MAC#;L\#.[<2<]/:MVJ5G?RW5]?6SV%S;I:NJI-*!LG!4'*8.<#H<XYH YE?A
MY;IX1O\ PRNKWW]G7;/M4B,F!'<NRJ=O.68\MD^F*T7\+&3Q!I6L/J4YGTZW
M>W1/+3:ZOC<6XSD[1TQ7144 >=>(M!'AWPOJ\:W>J30ZSJ:W%W/;0AGM=[*7
MD"JI)0! "N#UYX)IWAB6^DU>U.F>++S6;$NWVJ*?34BC1=IY\Q47YMVWCDG)
MXQR/0Z* ,7Q5X=C\5:!/H\]U-;03LA=X0I;Y6# #(('*BHF\-,_BN'Q"=1E^
MTQ69LQ'Y:["A8,2>,YW 'K6_10!B>&O#B>&[>\ACO)KE;J[DNV,JJ"KR'+8P
M!QFN57S+CXSZF;/45MW_ +)AB^X'5V$CEEP?XE!!X/&>0:]%IAEC69(6=1(X
M+*A/) QD@>V1^= '*3^ +,V^E_8M0O+.\TZZDNTO$V-)))+GS2X92IW;CVX[
M<<57G^&]M-IFO:>=9U$P:U+YMP&\LE6PH8@[>IVCV'0 5VU% &#K?AA==T6T
ML;B_N(Y[2>*YANXE4.LL9RK8(*GZ8Q33X6#>)[+7'U*Y>:UM6M CJI$B,06+
M$#.20#Q@#TKH** .$@^&4%OI>G:<FOZH+;3+U;NQ7]U^YP6.W.SYOO'ELX[5
MO6'AM;#Q3J.NK?3227T4<4D+*NQ5CSMP<9S\QSDG.:W:* ,W4=,N+N^M+RUU
M"2TEME==H0.DJOMR'!YXV@C!!K"?X?VGV;3H8;Z>'[%J3:KE$3][<,6))&,!
M?G(VC'&*Z^L\:C,=2O+3^S;O9;Q)(D^%V3EL_*A)ZC'.<=: ,'4? -IJMUK\
MUW?W+)K=LEM/&H50BIG85.,Y&3USFG6_@F2+6K#6)O$&HW%_:6SVI>18PLB$
M@@%0HQ@J#QR>YQ49^(=@/ T7BP:??&RDE,7E@)YB'S3$"PW8QNQT)ZUUTCF.
M)G6-I"H)"+C+>PR0* .=T?P;9Z9X9N_#\]Q+?V%R92ZSA0<2$EQE0.[''I4'
MA[P2^A-%'-X@U/4;2U!6SMKIDVP#! Y !<@$@9.!Z5J>&?$%OXHT"WUBUAFA
MAG:15CF #C8[(<X)'53WK7H YJS\(B*XT>6^U&:_.CAA9M+&JODILR[#[WR\
M=!ZG)KHY(TFB>*10\;J592,@@]13J* .23X=Z*OAG2]!(E>VTZY2YC9CEF92
M<ACW!4E<>G':M+Q'X<7Q%_9P>]FMA87D=['Y2J=TB9VYR#QR>*VZ* ,)?#>S
MQ?-XC%_+]HELQ9F$HNP(&+ ],YW$GK3O#'AQ/#-A/9Q7DUS'+<27&954$,[%
MF^Z!QDUK7$Q@MY)A%)*44MY<>-S>PR0,_C5#PWKMOXF\/6>LVL4L4%VA=$EQ
MN R1S@D=J *E]X:,WB5=?LM1FM+W[*+.0>6LD;Q!BPX(R""3R#]0:IZA\/\
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M#^V8$@O4N"@5PBE00%48(R>F*=H'@I=!V@Z[J]\D"%+1+R97%L",94;1D@<
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M<$9/IG'?O7?V-E%I]E%:P;S'&,;G8LS$\EF)Y))))/<FL ^";9F\1$ZG?_\
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MB$BUNED3S-I3RRARNW&WC@ ]\YR:Z'4].34](NM.>:6&.XA:%I(R"X5A@X+
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M(=_R<G: .,5B>)/#BZ-X?\13V[ZO?'6IT-VL 4O"IVHTB*BACM0?=YSCW)H
M+*^N[SQSI<&BZ]=7FBR6!N;PJT<JAPPV;F925W@GY5(^[D8P:[^O.= -W+JE
MJ^C^*M>U.$2#[1#J-B$B$?\ %ES$A#>@!)SC(QDUZ-0 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *Y_7O"%IX@OX+RXU#5;>2W0I&+.\: +GJ?E[GU]JZ"B@#)T+P]:^'X9
MTM[B]N7F<.\U[<M/(<# &YN<#GCW/K6M110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
K %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>a107-2021formofrsuoffice003.jpg
<TEXT>
begin 644 a107-2021formofrsuoffice003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.M0>'/!VJC4;:^1]/O[I[A%M7) >=BNWCYLA@>,\<FO14<.BN,X8 C(P?RH
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MG 4#DDD]!63:^*=(N[ZVLTN)$FND+VPF@DB$Z@9)C9E ;CGCMSTJE\0=+O\
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MR^R"WC:61O15&2?R%<SX3ET'4]0NM8T2RNSYL2QRW]T)E:4CH@\WE@O<]!D
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MNNU?Q!I^A/9)?R2QF]G6V@*0NX:1ONJ2H(!/;.* *7_"+S?]#)KG_?\ C_\
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M@DQC)(('8XX-4/&'B*T@T#7;>"XO%N;2U<R36<;G[,Y0LNYU'!Z'V!!. <T
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M;& 3@\'TKO** /(O"?V,Z1I_A;6O#.HR:YI[)%Y<L<K6Q*'"SB0G8%QSGKV
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MT@L6MWA8>6T<B_O=V,;-J[MP.#T'/%=)H^Y/BUK[M%/Y<EA:Q1SM"P1V0ON
M;&"1D=Z[FB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1QW:VS^2CN<*COC"MGC'8]<4_4/'NBZ??W]@RW\]Y8JCS06]E([[6R<@ <J
M,ENG(YYK@8K._3X(:5IITO4OMT6H1L]O]BE\Q5%WYA)7;G&WG-=%I^J6UC\6
M?%#SK<;)+"R962W=\8$G!"@D$YX!ZX- '21>,]%NM-TN^LKAKM-48I91PKEY
MF )88.,;0ISG&,5#/X\T*V\/7&MS2W"6MM<-:W ^SN7AE#!2C #Y>2!D\<CF
MN*TZSU3PSIFA0S:9>165]J5Y=7+VEJ9I[)),F*,!02FX'#%1D<C(ZUFW5EJ
M^'?C;3$T75Q<7&MM/;QO;22/(C21,"",EN%8DY/3DY(H ].M/%^F7NL3Z7$E
MXMW' ;E$EMG3SXP<%HRP&X9('X^E)9^,-*O_  U<>(+<W!L("X<M"RO\APWR
M'G((/&,\5CWOFS?%C1+R.TO#:KIEQ$\_V60(K.R%0S;< X4]:I+HEY:?$.ZT
MFW53H.I.FLSKG_5RH<,F/1W$3^^UQ0!Z"D@>%92&0%=Q#C!7Z^E8*^,](+6;
MLT\=G?2B&UO7B(@F<] &[9P<$@!NQ-:.NV,NI^'M2T^"7RIKJUEACD_NLR$
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M";R,;L \>H(Z\5RUDLL/B_Q+<QZ;K;VE[HT0AGN+>5C(R^9GKR#D@!, \_=
MJNMO>+X$^'5L=-U'[18ZC9O=1BRE+0JB,&+#;P 2* /0],\26.K:CJ5A:K<?
M:=.8)<I)$4VDC*@9ZY'((XJWI6IP:QIL-_:B003#=&9$*EAV.#V/:N+\7Z7J
M-MXMT_4-%(1M;C.DWV&VE5VLZ3#U9%$GY@5WD$$5K;Q6\"".&) B(O15 P /
MPH Q;[Q?I>GK=RR?:)+6RD\N[N882\=NW&0Q')QD9P#M[XK&\:>(FM[OPY8V
MHN9+74KU/.DME)$L.QVVJR^I"DX[>QK(T9+O0_#GB?PUJ6GWD]W+<7;VK1V[
MR)>I-DJ0X&T'+$,"1COQ276DWFBV?PYTR2WN[J33)T-U);V\DJ1@0LA)900
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M8K$T=[CPQXS\3KJ=M=O:ZG.E[9W4-N\RO\@5HSL!PPVC /4=*YVTT&_T+2/
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M:<BR^=;(CR,4^0!L[<-T)X/'_P!:F7^LVVGW,%H5EGO)U9XK:!=SLJXW-V
MR.20,D#J:I^%(K@Z,-1O8O*OM2?[9/'G)C+ !4_X"@1?J#6'JL=WH_Q2M/$$
ML%Q-I-SI9T]Y(8FD-M()/,!95!(5AQG'4<XH T+_ ,8VC>#M6UG2_-FDLHYE
M:(Q'?#,BDE9%/*X(&<]JJ^"[!;VSTOQ ;K54NI+!$NHYY6\JY=E5C(5;(R#G
M!7'!QTK&?2KJ/2/B)JJVET(];1TLK58',C[;?R]VP#<-[D]0. ":['P@6'@_
M1HY(9H98K*&.2.:)HV5E1000P!ZT 4X]3TI?%^K"&34IM3MK*,SVNV3R]FYM
MIC4X4L3GD<>_6J_AOQQ#K/A>SU>XM9X7O)3'!"(^9&+/M53T)"KR>!P3Q4%E
M'/\ \+<UBX-I=+;R:7!"D[6[B)G5W+ /C!X8=ZYG0["&?X7:)H.N:1K4$EK=
M>5)/!;R)+:2@RLLJ$ D@8 W %?GZ]< 'IVFZG%J:3F.*>)K>4PRQS)M96 !_
M$88<C@]JNURG@4:U'8ZA;ZM<R7L4-V4L[Z:'RI;B':N&=<#)!RN['.W/O75T
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP569<_>ST;ID=* /0Z*Y'1->T&WTW6+^R:^\H:L\$RW&_>UTS(NQ%<Y4%F4
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MV\$K1&><?ZQY&4@D X 7..YK4BBT[2_%41M]>V@6\D4FERWIE)8E2KHC$L"
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M#Y65&)(8$=!P03WIMI\0='OKMX((-298KF6UGF-FXC@>-=S>83]T<'KSQT%
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M&W-I('<22EE(&.F.<]N]=%J%WJ,OBBQMI=+U-](ETP&-[2%D9[C=S'*_!10
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M[KU'XUY3K2ZYJNDSF\T+5VU&UUR.8Q00$0+ LX(:, @2$KR6PS9)R0*]CHH
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M*@1[W"[CDC/7@#OC.!S72UR7Q(T^]U'P;+'86LEU/%<VT_DQ#+NJ3(S;1W.
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MW'/4%AP,Y^G-0^$!.T6G:7?^ A9ZK8[%GOY;6+[/\F 9(Y <LQQP .">3@4
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MM@*D.!WW*WE'V85Z#0!P-EXP36_"'B*]US2;V'3H)+J"58BK-Y291ERC;MV
MQ)X ['I6HOBW2-)A\.V$5K?E=3M@;)5B,A"K%O"L<G+;0!U/)YXYKF[*QU2U
M\#>--%ETB]%Q--J#6[! 5G\XMY>S!R<[N3T'>I_L=]_:'PXD_L^\V:;#(+P^
M0W[@FV\L!N/[W'&?7I0!KK\0[)[;4631M9:ZTURMY9BW4RPKMW;C\^W!!R,,
M2>P-:Z^)K*>STZXL4FO6U&'[1:PPA0[QX!+'<0% W+G)') ZFN8LK>[BU_Q_
M<O87@BOUA-HWD-^^VVXC.WC^]QS]>E<];Z1JFD:5X-U6?PU/JL-CIAT[4=.,
M ::(G81(B-PQ!7''8_D >E^'_$5EXCM)Y[02QO;3O;7,$RA9(95^\K $C/3D
M$CGK6M7*V-^VF:,;^T\)7%JES=(J65O!&DX5L RRJIP.YQDD #/?'54 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8_B;P[;^*M"GTB[N
M;F"VGV^8;<J&(#!@,LIQR!6K$C1Q*C2M*RC!=P,M[G  _(4^B@ I&7<I7)&1
MC(.#2T4 8OA_PU;^'HI E[J%_/+@/=:A<&:4J"2J[CT4;CQ[FMJBB@ HHHH
M**** "BBB@ HHHH **** ,30_#-OH<]Q<"^U&_N)B1YU_<F9HT)SL3/W5S^>
M!G.!6W110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSZ#XFMEM;J.Z0VXM,F1#E<[I&X![4FL"35[O3K__ (1WQ);:EI[,;>\A%KN
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ML'E,MN&E4-:-O+@Q$*,$,Q.3D]NG%:N@>'#H@9[C5M0U6Y*[!/?2!F1/[J@
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M6;;+*K;H#''DD8/.0Q';'O67H":WJ_B?7TG\2WJ6VDZL@CB6.("2/RU8QO\
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M57\B-L@8QD[R/I78>._^2?>)/^P7<_\ HIJK/X&M##X?5-2U".70XVAMIT=
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MJ%G<:G>R:?J#*UQ:N48'"J,*Q7< =@SSUR1@FND    & .@H 6BBB@ HHHH
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MT;HCJS0%LY"CC/. !GOFD.OZO=>&OAUJ9U&:.74;VUBO$C"A9PT;$D\9Y*]
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MBO*?#LFL7'PQ@\47?C&[MKN;3W0O<!7@C)DX?8!DO@8')R6  Z"M;2+V_/Q
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M=5C2SGM7TZ\:SD68J2S!5;(VDC'S>M<WKED)_C#X>)N;I ^G73;4G90-K1]
M.!G//KQZ5SSP7JZ5\2=2L]6O+&6PU&XN81;,%#.D",-_!W#@#'3KUXP >P45
MP']MZCKVN6.D)\JMHD.HR+'=O;,[R,5R&12V%V]!@?-SFNB\)6^MV>B"U\07
MD%W?0RLHFB<L6CZIO.U?FP1GCG@]Z -'5M3MM%TB\U.\;;;6D+32$=<*,X'O
MV%.TW4+?5=,M=0M'WV]U$LT;>JL,C^=<_P")[C[9JVGZ.+&>]MT(O+V*%5/R
M*?W2L&(&"XW?]LB*Q/A?<OIW]L^#;J.>!]*G,EFDQ <VDI+)R"<D'()!XR*
M/1:*\GOK[6[?3/%?A^+4[]]?M;Q)-+D67YY89!N1>>" %D#<?PD]:Z71=:3Q
M)%::O87LEO90:6))#)*6C$SC($F3R8PK9S_?'I0!V=%>8:7JNHP^)?!D2:A?
MW,&J0W"W=S,Q\J\98=XDBC8Y0;AQ@*"#T(I=$GU1X_$VLWWB#4YHM!U>[\NV
M5D"S1QQ*=CX7D<\ 8QUZF@#L_$OB./PU9VMS+9SW"3W45MF(J A=@H+9.<9/
M8&MNO(=?2XU/X=>&M?NM1N9;N\OK"YF42GR3YDBG8$^ZH7( (&?EY)R:]>H
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MN>I/.<\]:VZ* .,O/AKI5[;:M9OJ&J)8:G,UQ+9QSJ(TD9@S,ORYY(Z$D<Y
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MU];6]E;7:-<01EQ&7";0[LK*2V&^]R3SUYKI)_!NEW>B:KIET9YQJQ+7EP[
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M/N(! ..OI7<44 <]XD\'6'B864MQ<WMK?6+%K:^LY1'-'D88 XQ@XY&*AOO
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MXCSG;(I0J>>X /Z5TM9FLZS#HZ6BLGF7%[<+:VT6<;Y&!/)[ !22>>!T)XH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&:S$S2J!92G*2,C<(2/F!![?C7G5S9"+X??#1(9YT:;4M.;>TAD*$P-]W?D
M#L,8'I7K5S;Q7EK-;3KOAF1HW7U4C!'Y5S2> =,CTW2[ 7NI&'2YTN+7?.&*
M.@PG4'A02 O3GD&@#E[K6]1\(WGCN*"]N[V*PTZ"]M5O)3,8I'#@\GG;E0<=
M.#C%;MCIFNQ:[I.IP:G$NFO&RWD<VHRW(N@RY1D#(%1L\_+@$'&*V!X4T]M8
MU+4IGGG?4K<6UU%*5,;Q@$!=N/1C^?-5/#W@33/#4Z/:7>ISQ0Y%M;W5VTL5
ML#P?+4\#@D9.3@GU- %3XM?\DK\0?]>X_P#0UJ(^%+WQ#?\ AK4-4N[=+/2
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M=FW-@[<@$X/'IQCF@"M'?R>(/B!JFBS7%Q!9Z9902"*"=HFEDEW$N60AL*
M!G&22>V(?A3$8/"U[$TCRE-6O%,CG+-B5AD^YK6O?!EC>:M:ZLMY?VNI00_9
MVNK:4(\T><[9!MPPS[ U;\/>&K'PQ:3VU@]RT<\[SOY\S2'<Q).,].OX]\T
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MF!C KT+0/ NG>'&!M+[5)EC0I;)=79E2U!&/W:G@<<9()QQT)J/_ (5_I?\
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M<M!*'56E5I!G;AP2N",X]:U;31-6B\0V%_%J:V^FSPO#<0?VC+<FY)4E'0N
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSTG@O29H]'5S=;M(0QVDBW#(XC*A2C%<;E(4#GTK1US1;'Q%H]QI6I1&2TG
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MVUM% A8I$@12[%B0!CDGDGWJ2B@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*.[,&;21-Y*R^;TX!SC[V1Z] "WI&IIH_C+Q]-=3W,MK:R61CC:1I6&Z')5
MQSDLW"CJ3@#H*Z"^\8Z=IEYIMI>P7T-SJ._R(OLS,3M4L0=N1G ^Z,G)'%>?
M:GIFM+XZ\2^)M+M+XSV5Q:W%K;RVT@BOT6#RY47Y?OCD*W4'/8DUT6KW<VK>
M+/ ^IPZ7J:0P2W$ER)+*0&WWP% '^7CYCCT[].: -^P\9:1?:9J5](\UDFF.
M8[R.\C,;PD 'D<]001C.<U)#XILVU6#3+BVN[.[NHVEM8[F,+]H"C+!2"1N
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MPVV8E(YT\AB#L#$ @D<, PSTKHM0\;Z1IUO?W<HN7L=/G^SWEW%%OCADXRI
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MZXU_P3IVJW6LZP;];UV:5M1G99$CG(V,A?:057;TKTN:58(6E<.549(1"Y_
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MF.20NOF2'A""W.>F.]3^)])N5U74M1\/QZIIOB*W6*.,6]L[V>IJ(TPKC!3
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MP4LO.>"1PP!YZ4 ;]%<U)XVTV&73FF@NX['4IA;VE^R+Y,KMG:.&W -@X)4
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M &7<+;WL)C4R0LQ 4G#88'<.5)ZUJW'B&VM_$4>AM;W)NY;9[F+:J[9%0@$
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M%1022>@%8ECXAM]8-I$EE?1VVH0--;W)VJDB8!R"K;E)# C(!_(T ;M%>6>
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M[6XETVX3:9A&FR2/#<9PQQVXXS7::9HRZ>QEEO;N_NBNPW%VRE@O7 "A549
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M[$CZ]LUV5% '&^+[>]3Q=X1U:WT^YO+>RGN5G6V4,R^9"54X)'&>IZ"H-?\
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M.2-4#C(]0>.M=[10!YCX/CE2VTW1-1\!>1JVGF..74)+2,VQ$>!YJR]2Q R
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M,.6R?XL 8'J:N>-+C58)=&%E9W<^GO=D:@UBFZ=$V';M[@%N"5Y Z$9KJJ*
M/&KK2-6'@[X@:7%H&HQR:A>&6S0H'\P,D8 R"<GY6)/('KFNMU&.YN?B#X0O
MHK*\-K;6MTD\IMW B:14"!LCC)4_3O7<44 <C\0])U'4M(TZZTN(W%SI6IP:
MB+8$ SK&3E!GC.#D?2H)[9]?\<:%K\5K>6]GI%K<F1I[9XWD>5541A" QP Q
M) QG&,UVM% '!^!;>[T_X8M97EC=P7<7VK,#P-O.^1V7 QSD,.E<^UK<Z?\
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MB30;!"6A9>K$ C)ZC@CWXKTFBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMPW)8'!]\UIZ[8WUWI_AR2U\//9K'KT%]):01+NA@0$%I-IV[^<X&3R!S@T
M;<?C:.:/7(ET?4(M0TF$3O97'EHTB,"596#E<':<\Y&.F>*N>#-9N]?\)Z;J
M5[:R037%O'*Q;9M<LH.Y=K' Y[X/M6"VFW]SXZ\3S+93K;7VD1VMO.Z81Y%\
MS(]OO#D\5'H>MZCX6^'NA1WOAO4BUJD-G<J"FZ(*N&EP&.5R..YS],@':ZGJ
M$.DZ3>:C<DB"T@>>3'7:JDG^5>9^+TFO_@9J&MWY;^T+ZUCNV*N1Y8=E*QC'
M\*JV,=SDGDFN_P#%>F2ZUX0UC3(/]==6<L4?/\14@?KBN1OK*\\4? :.QTV
MR7TVF0Q"$D*?,3:'7G !!5ASW% &];>-K&X\21:#=Z=J-C+=H[6<EY $CN@H
MRP7DD''.& ..U-TC4FL/&VH>%9&9HA:)J%CN.2D18H\>?16 (] V.@%5[RUG
M\5>(_#MXEC=6EII4LEU,]U'Y;ERA18U!Y/4DGIP,$YXCAM'O?C/<ZA&/]'T[
M14M)&_Z:R2F0+^" '_@0]: +OB_Q+>Z#=Z';6FGRW(U&_2W>1&08&"Q4!F'S
M$*>3@ 9YSBN>AU%]*^*7B*:+3=0O)9-,M9?LL&'<'=)NY9@HQQQN^F:V_'EE
M?3OX<O;*QFO1I^KQW$\4&W?Y>QU) ) ."P[U!IL=[#\2M9U6XTZ[CM)].MXD
MD\O<#(A<LHQUQN'/0]J #5?$WAW5_#?A_5+JSO+JQU"^M_LNP%3%.7PA?##&
M&SD9(X[UL7WBF"TN-1BAL;N\_LT*;LV^S]V64,!AF!/RD$X'0]SD#S^TT76(
M?A=X6TM])O/MUEJT,]Q (\E(TG9RV<X/RD=#_(UI^+=$N+_5M0U/1K/5--\1
MP^6MA>VH(BO5V*0LW\. Q93OQP!UZ4 >CW$\=K;2W$S;8HD+NV,X4#)-<]IW
MC6SU"^TFV-E>6PU>W>XL)9@FV95 8_=8E3M8'! X]^*U]0.HKH5TUDL3ZF+9
MS K?<:;:=H.>V[%>;V%EK4_B'P7J\WA_5//MDN(]1GNG3?YCQ!<XW<1AMV,
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M9Q/&[31L.&C;=AO3!(.>*DT#QI9^)5L'TZTN9([JW,\CDIBV 8J%D^;(8D,
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M6MU=W-^([=2K6L5RR03@D'$B#AAQT/7H<BMJB@ HHHH **** "BBB@ HHHH
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MM=732[@Z9'I+637 *;1(9=PXW;L8'7%=FQ@LK:21MD4*;I7;H!U9B?U-3$@
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M(U4<;\GE3G&: .GUG6+70[#[7=$X:1(HT! +NQPJ@D@#D]2< 9)X%<_#\0;
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M+*6/ '/3('-4O%>A>)M;A\6V$^C&_-PF-)N6N8Q#%'L'RA"<K)NW?-CG/W@
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M/DQ:R)H_+:$'ABGW]X7C&,9ZD"@#9@\;S7FNWFE6GAW49GL;R*VNI-\8$2N
M1)][D8(.!DXZX[]=7(^%]/U*S\7>*[N\TZ6WM=0N8I;:5I(V#A8E0\*Q(Y&>
M1TKKJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(3QD9Z'M4H96 *L#D9&#VKSKP,8O&U_KGB+5HDNEBU&2RT^"90R6\48'*J>
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MIT.KZ9<Z?<-(L%S&T4OEMM)1A@C/;(-&EZ=#I&F6VGV[2-!;1K%%YC;B$48
MSWP!6'?^+9[;Q6/#UKHMQ=7+V+7D4GG(B. X7&2>!SR3Z< YK.E^(GE^#QXA
M_L>41PW;6E]"TX!M763RRQ."&4'J1V.<=< '<45F2:I(NNVFF1VRR":W>XEE
M$O$2@@#C'.XMQ_NMZ4FLZO)ICV,,%E)=7%[/Y$8&51/E+%G8 [5 4]CSB@!D
M'AVTM_$EQKR2W!O9XA#)F3*% 257;CC!)]ZUZXFY^(D=KX4UO67TJ6271KM[
M2ZMXIE(W+M^97.,KAE[9]JT+;Q9,WBNWT2]TB:S%Y;O/9SO*K>:$(W!E'W#A
M@>I_ \4 ='--%;Q-+-(D<:C+.[  #W)I]>4?$G6_^$A^%VIWUKI<<^E>:JPW
M;RC?E9@OFJFW[N00#N!P<XQ7J<S2);NT,8DE"DJC-M#'TS@XH DI"0 23@#J
M37#GXB@>$['Q =+V07%[]CFC>X"M:OYACR_R] PYQTR.M;U]J\B76HVATW[5
M#:V8GEV2+ERVX>7AL#.%)Y/0CUH U1=VQ@CG%Q"89" DF\;6)X&#T.>U/\Z+
MSQ!YB>:5WB/<-VW.,X].:\MUR73=4\!^!]1L=-BLH&U>P:VA"@^0K2#Y0<?G
M6Y'!%%\<Y'CB1'E\.[I&50"Q^T8R?4X 'X4 =S16;K.LPZ/%;;HVFN+N=;:V
MA4X,DAR<9/0  DGL >O2L2]\9W6EV&OSW^@72R:/&LS>4X:&="I;='(P7.,$
M,,9!]: .MHKD4\;R16@NM1T>2P@N&A2PDGN8P+EI%+<\_NPH4D[N<=L\5!!\
M1;5AKD,MD\MYI,2S&*PE%RMPC?=,; #)SP00,4 =K17-6WB>ZEU^\T&;38H]
M3ALEO8E2ZWQR*6*X+;05(8?W3P<\UC>&/'%Q+X#T_7-;CA26_F,=OB< 2.TC
MX4Y "*H7J2>%/4\$ [ZBN9\/>,;?6];U#1GBBCO;)$ES;W GAEC;HRN .AX(
M(&/>KVIZS<6NJVVF66GM<W$\,DYDD<Q0QJF!\SA6^8EA@8]>E &Q161X7\00
M>*/#MKK%O"\*3[@8W()5E8HPR.#RIYK7H **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MN9\;6NMW6FV2Z+$;@)>QO>VR3"%Y[<9W(KD@#)VY&1D CO735%<W5O9V[W%U
M/%!"@RTDKA57ZD\"@#S0^&=>2/QY##H5O!!K=FD=G'!<( K?9_*VD< 8)R3T
M]-U:4VC:P]UX$D72Y=ND _;/WL7R9@,7'S?-R<\=O?BN^HH \J7P[XHTOP;X
MD\'PZ0+V"Y%T;"^6YC12LN6VNK'<&!8]L'/4=:]&T2*YM]"L(+N)8KB*W1)$
M5]P!"@=>_2K]% 'G/A+PXTGPSU?P1<.89K9[NQ+D<A9&9XY,=P5=3^8K4\*3
M>,1:V6EZSI%O9K9(L<U^ETL@N0HP-B 97=@$EL8YQR>.B,^DY?5OM-LHB4Q2
M7(F 4 'E7.<<$GKTR>F:O\,O!X(Z@T <;#9/J'Q?N-40?Z-IFE+9,W8S2/YA
M7\$"D_[XJ]XNTI-:CMK&]T%=7TR3?YZJZ+)"_&QT+,O/WAP0>?P._;6L%G#Y
M5O&$3)8]R23DDD\DD\DGDTOVJW-T;43Q?: F_P K>-^W.,XZXSWH \WD\*^(
M[7PMH:JLNHW.DZU]MAMI[A?.-J"ZK&9"=I<*P[XXP#P*6\\):YXAU'Q@+VSB
ML;;6]/MX8)#<!S')&&P& Z\L,]NN">M>CW-U;V<#3W4\4$*XW22N%49.!DGC
MJ0*EH Y/PY?>+[B*W@UO18;$VJ8GF2Z27[6P7 \M1]T$\Y8C'3OD<J_A;Q"_
MPHO?#XTEQJ$VH-.B&>+;L-R)L[MW]WCZ_G7JU1?:K?[5]E\^+[1L\SR=XW[<
MXW8ZXR1S[T 1W37+:9.]M%BZ,+&..3'W\< \XZ^]<1H'A:?2_%<.K:7I-QHE
MG+;R'4M/$\;0S3'&SRE5B 0=WS?+QCCDUW=O=6]Y%YMM/%/'N*[XG##(.",C
MN""*EH \I?1M1L?AC<:+?Z4C:A=ZJS6UN]RJM(7G,@,;J3M=5R<G@%<G(!SL
M:'=ZA:>)!<ZSX6U&&_OHOLL5[+>6\^X(K2"(!"H4'#G..3U/2NMUK0=,\0V:
MVNJ6PGC202QD,R-&XZ,K*05/)Y!J+2O#FGZ1)YL'VJ:;&T2W=W+<.H]%,C,5
M'3@8Z4 <!%X7\01_"K2M .E.=0MK])Y$$\6W8MP9<AMWH<?7\ZL>)- \3:TW
MBJVETF*\2]MMNE3S7*!;8&/!0)SM<MGYAP<\L !7IM% '!'2-?3Q!X4U==,B
M<VMA+9W4/VE1Y);9M8G'S#Y>=N?;-9U[X?\ $D.G^.M&M-(6XBUJ2>YMKO[2
MBK^\A5=A4G<&ROICGJ*].HH X*#1];7Q1X1O9=+(AT[3I;6Z=)XR$=U0#&2"
M0-G/'?C-$UIXI\.>,]5OM(TB+6-+UAHYGC^UK ]M,J!"3N^\I"CID_U[VB@"
M"R6Y6SB%XT;7.W,GECY0QZA?8=!GGBN"L]#U^ST'Q+X?&FY?5+R[D@OO.0P+
M'.3RPSORH)X"G)QSW'HE% '"^+O#ILO!.DQ:3,(]2T.2V73)9!]YQMB"-CLX
M.TCW]JZ[2=/32M*MK%'+^3&%:0]9&ZLQ]R<D^YJFWA;1W\2#Q ]IOU,($$K2
M,0H (!"YV@X)&<9YK8H Y"?3-6M?B<VM6]BMS87&EI:/()E4Q.DK.?E/)R&X
MQWZX'-<S-X6\02_"O6-!&E.-0NM0>>)#/%MV-<"7);=QP,?7\Z]5HH X*ZM?
M%&A>,[[6=(T9-5L-8BA-Q:O=)#+;2QKM!R<J5*XSC/(_/M+ 78L8C?F/[406
MD$7*J2<[0>,@=,X&<9P*LU%%=6\TLL44\4DD) D1'!*$],CM^- '$:/HVK^"
M-:U5-/TU]4T+4KIKU([>6-)K65L;UQ(RJR' Q@Y'H:TO$FB7_C/PGJNE7"?V
M<EW!LACD96<."&#.5) &0!A2>,\]AU5% '#W.EZSXI@\.VVK:8U@VFWL-]=R
MM-&ZR/$#@1[6)(9B#E@N!GO52#0]:32_'D+:7*)-8FF>S'G1?,'A$8S\W'(S
M]/RKT.B@#SR?1-:?3O <2Z5*7T>6)[P>=%\H6$QG'S<\G/T]^*K>&Y]0%WX]
MM;+2Y+IY=7F6.3S45 YBC&'W," .#D \9X]?1Q<V[W+VJSQFX10S1!QO4'H2
M.H%95AH^C^&9;NYBF:W.H7 DF:XN6(DF; &-QQN. ,"@#D[3PMK6A76@:9'9
M1ZOH=GI@MVC>=8T2ZW9,KJ?O+CIPQ7GC-9NG^%O$MKX-\):5-I ,^DZREW-Y
M=S&08E>0DC)')WC ]CG%>L44 <EINFZE%\2=8U:6Q>.PNK.""*4R(<M&7)R
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M-M!)P -QX&3UP.MHH \MM?#.OP>"?!.EMI3FZT?4H;BZ43Q8"1[\E3NY)W#
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M9\6P_"Z]\##1DN7AQ':WZW4:QS1>:'!*D[E8#C&,<=?7UJ%I&@1IHQ'(5!9
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M&Q5;^_N[B6$>>FS;++O!)SQ@<'W_ $W/'-@]_P"!Q(O^BZK9/#<V.2"R7*L
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MD<DUWY+6DCXWAAM)9<C("\T :5UXYM2PBTTV4DWV..\*WUX+4;9 2BC*L2Q
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M&IZW/89MKC3X;=?*F0DR(68\$C@[L GTY KG;?PEK\/PWT#0C8*;ZPU..ZF
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R=:\-:/XA\A
MM3LQ-);DF&57:.2//7:Z$,,^QK6HH H:7HNGZ-&R6,!0OC>[R-([XZ9=B6.,
MGJ>]7Z** "LB?PQHMSXBBU^>PCDU2&,11SL2=JC)&%SC/)YQGFM>B@ HHHH
M**** "BBB@ IDT,=Q#)#-&LD4BE'1QE64C!!'<4^B@#G;'P+X<TV57M;!E5#
MN2%KF5X5/48C9B@QVP.*Z*BB@ (!!!&0:YNW\ ^&;68R6^F^6A8L;=;B40$G
M_ICNV?AMKI**    8' HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *JZCIMEJ^GS6&H6T5S:S#$D4JY5N_P#/FK5% &)I?A'1='F6
M:SM9/,3_ %9GN99O+[?*)&;;QQQBMNBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]W;JK30JX+QAL[21U&<&K- !1110 4444 %%%% !1156'4["XOI[&"\@ENX
M&FA20,\8/3<!R.AZT 6J**8DL<C2*DB,T;;7"G)4X!P?0X(/XB@!]%%% !11
M10 4444 %%%% !1110 445'-/%;0O-/*D42#+.[!54>Y/2@"2BLO_A)=!_Z#
M>F_^!2?XU*FMZ5+<VUM'J5H\]R"T$:3*S2 9R5 /(&#S[4 7Z*** "B@D $D
MX ZDUG0^(-%N9'C@U>PE= 6=4N48J!U) /&* -&BBB@ HHHH **** "BBB@
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M[B3Q&FFVPC3:(K%V?S6X^<E@-H]%YZ\GB@#GOB'=R7GB;PCX5+,MCJUU(]X
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MD%N&D7RE3<SR87((Z8&<DCG'S5SGB/QQK;>!_$TEO9I:7VFND7VKY_*FBD(
MDB) .[G!'\)[FNB\6:%K6J'1]8T:6UM];TJ1I$AG8M#*CKMDC+ 9Y &#CMVZ
MBOKF@^(_%/@;5M/U%["VU"\C18((79H8MC!OF<C)+$<D# &.O)(!;U/6[NQ\
M2>&+"]TNRD?4)ID%PLI8V[+&S?*"@Z@ 9R.XQ39/%6H7EKK-[HMC;W5MI,\D
M#++*5>Y>, R!, A<<@$YR0>@YJ/5-&U_5-<\+:G);Z>ATV:6:ZC6Y<XWQE J
M'9\V,YR=M0Z=X=UOP[+K]GIB6ES8:G<R7=N\TQ1K:20?.K#:=RYY&#GL?6@
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MJW\6:Q_;>F6LFE&>UU!&W/#;3I]C<+E1([+AE/3< .>U '3_ -C:7_T#;/\
M[\+_ (4?V-I?_0-L_P#OPO\ A7,>%?$WB+Q',)WTO3[?3X;RYM+EA<,T@,9*
MJ4&W!&1@DX/7@8YV]<U*^L9K&*T@B$,[/]HOIS^ZM$52=S#()R<*.1UZT 7/
M[&TO_H&V?_?A?\*/[&TO_H&V?_?A?\*XB;XBWR>!;[78=/M)YK#4C83!9B$?
M$JQATXY!W X)'UK7MO$6M#QC+X?O[.QB>>P:]LY(9'<+M<(4DR!D_,#D4 =!
M_8VE_P#0-L_^_"_X4?V-I?\ T#;/_OPO^%<OIGC*_OO"=Y>RVMM%K5M?&P:Q
MW,56?S BJ6ZD'<K;L< Y[5U=Y>Q:9I<]]?2*L5M"TT[J. %7+$#\#0!GWR^&
M],>V2^BTRW>YE6&!)(T#2N3@*HQDG)'2KO\ 8VE_] VS_P"_"_X5YUXLU#5=
M6TGP=J<\%K%9WFN6$R0C=YL(9\IN;.&)!Y  P3U/6NJ'B#4M6NM:BT&&T<:3
M+]G;[26_TB<*&9%(/R ;E&X[N2>.,D V_P"QM+_Z!MG_ -^%_P */[&TO_H&
MV?\ WX7_  KFM+\>1^([70UT>%4NM5@EG(N,D6R1$*^X#!8[R% R,\G(Q4>H
M>+->TC1EN]1TF"&9=633R-YVSQNZJLR8)*@Y^Z>>.M '4_V-I?\ T#;/_OPO
M^%']C:7_ - VS_[\+_A60WB"^7QS<>'4MK>0#3/M\,A=D)/F;-C<'CC.0/PK
MF(/B'KK^$='\4/I%E]@N[E8)X5G;S1OE,8*9&W@XZGGVH [[^QM+_P"@;9_]
M^%_PH_L;2_\ H&V?_?A?\*YVW\5:A9^*KS2->MK.&./36U.*:UD9PL:MM96W
M 9(X.0!]*J0>-M4FN-$N(])DN+#5)$1TAM9O,LPXRCNY78R]-Q&,9X+#F@#K
M?[&TO_H&V?\ WX7_  H_L;2_^@;9_P#?A?\ "N&G\=>(_P"QO$FI0Z1IH30;
MV:&97N7/FQQJK':0OWL,3D@#H,'FK=YK6L7/Q$\/VUG-;IIUUILMV(I%;)/R
M<L0>H#<#Z]>P!UW]C:7_ - VS_[\+_A1_8VE_P#0-L_^_"_X5SFE>+I]:U.>
MWLGL2UK?O:W5BY*W,,:L5\WKR#@'&,8;J2*U/&&MW/ASPIJ.L6EM%<R6D1E\
MN60H"!UY .?IQ]10!):^$_#UE<W-Q;:+81S7+;YG$"Y<_E3[VTT'3K22[O;;
M3K:WC&7EFC154>Y(K!?Q5K%C% VIV%G$=2FCCTY8'DE;F-G<RJ%S\H4G"YR3
MC/\ %5.\\0:AJGA[QCINHZ=)&+33I6AO5MY(H;E&B;H'&0RG@C)H ZVVT_1;
MRTANK:QLI()D62-U@7#*1D$<=P:E_L;2_P#H&V?_ 'X7_"N6TC5+ZQ\(>$H+
M:*&*WETN)[C4+D_N;8+$F 1N7)8G Y'0UBZKXTU?5?A_9:I8?9[2>35H[&YV
MEF# 7 C.P\8#8[]B1[T >A_V-I?_ $#;/_OPO^%']C:7_P! VS_[\+_A6#?^
M)KR+4IM(M1!]OMK9)YY3;S2Q[G+;$ 3D9V$DD\<8!YQ6T_QM=ZG:Z%;#2I+#
M6=4$K/;7BL!;)%]]R, L"=NT<9W=1@T ;5FOAO4+JZMK.+3+B:T8+<)%&C&(
MG. V!P>#Q5W^QM+_ .@;9_\ ?A?\*X[P5]K_ .%@^.A>K"+@3608PYVL/(X(
M!Y&1@XR<>IZU9\3:CK4'Q \+:=93VR6ETMU(R.K99HX_XB#TP_ ]1GTH ZC^
MQM+_ .@;9_\ ?A?\*/[&TO\ Z!MG_P!^%_PKGSXFU/4H=;NM"MK66'29Y+8Q
MSEMUU)& 752.$P3M!(;)!X K:\/:Y;>)/#UCK-D&$%W$)%5NJGNI]P01^% #
M;VUT#3;22[OK;3K:VC&7EFC154>Y(J*30O#VMZ6N=.LY[.YC#@I&%$B$9'(P
M<$&N(BU'6=3\*_$C^TYK:6*W>]MU5%8;=MNH 7)^[CGUR2:O>'O$6JZ9#X+T
M^[LK0:;JEFD$+I*QF1U@#@L,;<$*>!T]: .PM/#FBV5K';6^EVJQ1C:BF,-@
M>F3DU-_8VE_] VS_ ._"_P"%<?J'CR_%C<:II&FO?VMO=-!]ECMIFFN%23RW
M='4; 00Q"\Y Z@G [M'$D:N 0& .&&"/J* *$FG:-"\2265@C3-LC5HD!=L%
ML#CDX!/T!J3^QM+_ .@;9_\ ?A?\*\U^)%V][/<ZI8ZA%'<^%9([BWMS,%\^
M;AY5(SD@1%0/=F%=KJ7B*=O S^(]!@BO#]D%Y%#(2/,3;N(R.C8_48H U?[&
MTO\ Z!MG_P!^%_PH_L;2_P#H&V?_ 'X7_"N8;QK(NM^%;=39M8:_ 9(Y_F#*
MP0.%QG^+. ?48YJ[+KNK_9)9[6QAG1]1^R12@D+%$I*O-)D]%*L,#K@'(SP
M=#;VMO:*5MH(H5)R1&@4$_A4U<"/'UY_87BNZBM[&\N- )/F12E8;B/RQ(&'
MWB#C(QDC(ZU8_P"$NUJTL+:ZU#3;%3JDEM!I445PQ9Y)02WF\84*!NXSP,<T
M =4FK:=)JSZ4E[ VH)%YSVRN"ZID#<1V&2.M7*\^LQ?K\;BM^;9V'AUMDD"E
M0R_:%ZJ2<$'/<Y]NE=7KNHWU@EH+&U23SY]DUQ*?W=K'M+&1QD9'&,9')ZT
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M92KQDC.U@>A'0U:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRH.00!D''2NZH) &2< 4 06<,L%G%%/.9YE7]Y*1C>W<X[#/;M7!/\/M0O-
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M):SB.5P6+A1E04YQL'4C.>U7_P"P=4M_B#<:]:R6;65W916\R2EA(C1LQ&T
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M=%VIDG.%!Z*.@SS@<\U;HH Y'2?#^KV?Q"UK7YQ8_8]1@AA5(YG,B>6",D%
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M-H,BONCP/FZ8P2/7VKG]0\#^))=!\5:!:S:6+'5[N:[AN)'D\Q3*P8HRA<
MY^8$\=N>/3** .1BT'61X[L-=E^P&WATMK&55E<.69U<LHV8P-N,$\]>.E5#
MX>\5Z)XGU.[\.76E2:9JLPN)X-0\P-;S;0K.FS[P( ."1^'6NLTS5].UFW>X
MTR^M[N%)#$SP2!PKCJ#CO5V@"*VB>"UBBDF::1$"M*PP7(')/UJ6BB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=&NK:$Q-<2P-&&<E5R1C)QD@<YKCCX-UG_A%?">D+)8&70[NWN))#*^)1""
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M;5(_!<?@R]GLVTI7(DNXF?SIH?,+E/+(PI/0G<>.U6;GPSXETOQ7?:KX7O\
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M,\DT =51110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116+XCUQM&BL(H$1[
MS4;Q+.W$F=BLP)+-CD@*K' Z\#(SF@#:HKC]3\2ZSX6T_7M0UVTMI]/LHHY+
M.YMOW9N&;Y?+9"S%2'(&[I@].*74/$.L>'=6T.+5_L5Q9:K<"R+V\31M;W#
ME!RS;U.".@(Z^U '7T5YI/XS\5G0O%.IPPZ.BZ!?31,CI(WGQQJC$#YAM;!/
MS<]A@8R=75?&XM=8L+!KNSTM+ZP6YMKB_B9HII&)_=;@RA2!@GG)W#'3D [:
MBN1NO$U\-1AT9-D&H)I\=W=2"RENE1G)4*%C/JK')/0#&<Y&3)XS\3Q:;X<D
MGT:VM+S4-2_L^XAN1(@SAB'3N%(7/()&<<XH ]$HKS^3Q)XB%OXTTRXGL(]1
MT:T2YM[NWMVV,CQNP!1G/S#81G..0<=CT'@9KQ_!&BR7MQ'.\EC ZLD94A3&
MO#98[F]3QGT% '045Y[8:SJ-CXV\;W6I:A"^FZ3!;R-&MN05B\J23"G?@$9.
M20=WMQB:]\8:QI/AO2O%-[%9-I5VT+7-M'&PEMHYL;6#[B'*EER-HSVQ0!WE
M%9VOWMSIOA_4+^T2)Y[:W>95E)VG:I.#CGM7#?\ ":^*++3_  SKVI6FEMHN
MK&VBGC@#^= TRC$F2<%<G[N,C@9/6@#TJBN \1^,]8T".]NYH["-+>^CACL6
M!DFGMF=$\XNK_)DL<;E[8Y)JQJ>O>*9/&M[X=T>/2%,>G)>PS78D(YD*8;:?
M]D].F>_0@';D@ D]!5+2]4L==TN'4-/F%Q9S@^7)M(# $@\$ ]0:Y#PO=:_<
M^+O%\<]_:3?9;B*&-#;LH ,(90#O. "QSP2>>F>$T3QS>ZKX7\,3&"U35M>E
MDC10K>5$J;V9L9R<*G3(R2.10!U:PZ1X7T>XEAMK;3]/MT>>400A%4 99MJC
MG@>F:NVUS#>6D-U;OOAF19(VP1N4C(//L:Y74=8\4:1H'B6[O+.P<Z;$T]E<
M#*I<H(RS!HPQ92",=>>M4[OQ7KXO_"5G8VVG,VN6<DKO-O C=8E<G /W<MTY
M)QC(SD '=T5P&G^+O$S)XDTFZTVQN/$&D&)H_(<QP3QR_=?YVR-HR2,]L"I[
M#Q5J%_K>M:+%>6,S6]@EW:W\-NP0[BRD%2Y#@%>"&QV[4 =Q63_PB_A_^TO[
M1_L/3?MV[=]I^RIYF[UW8SGWKB_"_B?4++P#X9DO+A+J^UA@D+BUD<H=KR.[
MJK$R'"G[H7DCH,D=+X;UC6;[5=3LM3L6%O;E&M;];62W2=6'*E)"2&4\=<'V
MH V+K5K&QU"QL+F<)<WS.MM'M)\PJNYN0,# YYQ5VN:UO7;_ $WQEX:TN**V
M:SU-YTE=PQD4I$7&WG S@>M<]/XM\5R6GBV:UBT>/^P)GQYB2/YR+$)-O##!
M()^;I[=Z /1JJ:GJEEHVGS7^HW"6]K"NYY'Z ?A2:5??VIHMEJ")Y?VJWCG"
MGG;N4-CWZUYBMUJ][X ^),FI7T-RL4VHVX"P%#E(E48.\@+@?=QGODT >K6]
MQ%=VT5S V^*5!(C8(RI&0>?:I*X#1]>UO3=1\(:;>)8-IVKVACB6)7\V%HX0
MX+,3A@0#P%&/4]2VX\;:S=:9_:^AV#7L"W31K8+83F2:)9"C,LWW W!8#!&.
M.M '?32I!$TLAPBC)."<?E6+:^-/#-Z\26VO:?(9FV18G4>8W]U<]3["MP'(
M!Y&?6O"]$T^_\1? I?#VG:/+<W-U<RK'.[(L,.+EF+EBV1C!Z#- 'LIUO31K
MBZ+]K3^TFA,XMP"3L! )/8=1UK0K@1;R6GQ5\.6\TQFEBT">-Y3U<AX@3^/6
MDE\9ZQ8ZAHT=_'8(]_J?V&?3XP7EM5;?Y;-*KE<D*#@@9#<=#0!W]'2N F\3
M>*KC4_%EE8II$1T01O&\R2/Y@:+S-I 8<GINR,8Z'/'6>'-6_M[PUIFK&+RC
M>VL<YC!SM+*"1^M $FEZWINMK=-IMVERMK.;>8H#A9  2N2.>".E7Z\HTFX\
M3VA\;W/AZ/3'%OKEQ*\=X'+38CC)1=I 4X'4YR3T'6MN'QQ?7-SX3OUCM8M"
MUY0C,\;&6"<KE8RVX##$$ XZCWH [RBLG2+^\U"]U-G,!L(+DV]L4C(9RH <
MDEB#A]R\ <J:R]5\27/]O7>C::RQ36EM'-+,]A-=#=(6V+MC(QPA))/<8[X
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MA%;31L7N4A)#G>& 0G:VT;3VSUX .YJIJFIV>C:9<:CJ$PAM+==\LA4MM'T
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M' ],8_&J7AKPOXHT)+?1YM>M9]!M&'D,(&%V8U.5B9L[0HX!."2!CC/';T4
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M5(X22D,2DM@,0"Q+,23@= ,<9,.O:#?:GXE\/ZI;2VZ1Z5++(R2;LR[T*$#
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MO/$&C^,-9UCPWIEU<?9-/E6]FLM5FR"8WCW "%#G<S,% '.,G@T >A$@ DG
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M!DQ6\2QJ6.2<#&2>Y/4F@# FUBZU3QK=>'+.Z:SCLK)+B>>-%:1GD8A57<"
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M+AR<AL\@=.W.,GJ[7PQ=VFO^(-634HB^KI$IC:U.(?+4JISOYX)STY]*S%\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M$_=^7=(P'&. :Y_4?%>M_9/'5[:ZH\=CI4GV>TE-O&S"94&47Y<,3(P4[LX
M QEL@ ]2K(B\00R^*YO#XM;@3PVBW;3';Y>UFVJ.&SDD-P0.E946KZG=ZM9>
M'4F6.]@L8[K5KQ44^63P$0$%0S,&/(("CIR,<MI/B$Z7I^N>*?-^WW.L:LNF
M:8\@ 65(R8XR=H^[D2L<#D ^M 'JM%<:E_K%O<WM_<WUV-#L].D>>:>V2%GF
M'S;HD*[@H4-]_(.1C.":3P<WBK5-*T#5=3U1%A>W:2ZMC;*'G+C*$D ;0N>
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MVEOGNELAR!_O2LX_"H8(]4\'^%/!J1WC(9;ZW@U&%HU(D:X8F0Y(W ^8_8T
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MBXA241R8W)N .#CC(SS7F4VK:CXE^'NFZ7?S">YUG5CIWVA4"&>VCE8O)M'
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "LG4="^WZC#?)JFIVDD2&/R[:XVQN"<_,A!4GWQ
MGWK6HH K6%A;:9:+;6D>R,$L<L6+,3EF8GDDDDDGDU9HHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
'"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>a107-2021formofrsuoffice004.jpg
<TEXT>
begin 644 a107-2021formofrsuoffice004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 6 !)7(^9>>HXJZ"" 0<@T %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKR??D;!7+'UZ#TH A\,7&LSZ5X>M;O2;5--:RC+3)<&4Y6-2F5*#;R,YR<$
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MV:9=QW*3FS.7V2;U4CS..3R?3TH A\9>)]:T.#7[R*\@C;3TCEL[2*+SO-3
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M51\1P:@OQ$\%PQ7D;79M]0'VB6+@?+'SL!&2![BNJ\5Z GBCPQ?:*]PUN+I
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MZ=;I?3)->",>=(B[5+XYP.PSTKB\:#XW\;Z7JFEW!N1I"RBZFBR$)W+Y<39
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M"D;L'!#$= &VCOP3BN[TJ"^M=+MX-2O5OKQ%Q+<K"(A(<]=H) XQ0!<HHHH
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MM:MK5KI'V9)5EFN;J3RK>V@7=)*P!)P"0   222 .YKDOA)_R+6J?]AF\_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0!3O%'A]/%.@7.C3W4MM;W*[96A"EB,@X!(('3TK9HH K:?:M96$%JT[3F%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BN9?Q@1XLN/#D6C7LU[#;"Z+(\01HRVT$%G'?MBK>B>)[/6[V^T]8;BTU&P
M91<V=RH#H&&58%2592.A!- &W1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M10 4453U*[NK.W62TTZ6_D+8,<4B(0,'G+D#_P#70!<HKG_[<UO_ *%*]_\
M NW_ /BZ/[<UO_H4KW_P+M__ (N@#H**Y_\ MS6_^A2O?_ NW_\ BZ/[<UO_
M *%*]_\  NW_ /BZ .@HKG_[<UO_ *%*]_\  NW_ /BZ/[<UO_H4KW_P+M__
M (N@#H**Y_\ MS6_^A2O?_ NW_\ BZ/[<UO_ *%*]_\  NW_ /BZ .@HKG_[
M<UO_ *%*]_\  NW_ /BZ/[<UO_H4KW_P+M__ (N@#H**Y_\ MS6_^A2O?_ N
MW_\ BZ/[<UO_ *%*]_\  NW_ /BZ .@HKG_[<UO_ *%*]_\  NW_ /BZ/[<U
MO_H4KW_P+M__ (N@#H**Y_\ MS6_^A2O?_ NW_\ BZ/[<UO_ *%*]_\  NW_
M /BZ .@HKG_[<UO_ *%*]_\  NW_ /BZ/[<UO_H4KW_P+M__ (N@#H**Y_\
MMS6_^A2O?_ NW_\ BZ/[<UO_ *%*]_\  NW_ /BZ .@HKG_[<UO_ *%*]_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** ,ZWT:&WUFYU1;BY:>Y18Y%9P4*KNV@#'&-S=/7G-/?1[&37
M(=9,"_;XH&MUF'!,;$$J?494$>G/K7,Z_P".+[P_I5YJMQX?9K"WN?LZN;M0
M\G[SRPP7;P"?4]*UXM6UEI[FVFT(13+;--;D789)G'&PMM&TY*\D=_:@#-'P
MT\/+:K:J+];>*[%Y!$M[(%MY V[,8!^7DGISSUK4M_"UE::IJ.HV\]W'<Z@B
M1SL)<@J@(3 (XP"0,>O>KD6HF*TT\ZFB6EY=[4^SB3?B4J6*!A][&&Y]JS[/
MQ%+<^-M0\/260C6UM([E9Q+N\P.Q7&W''W3W- %<> ]'7P_8Z&KWBV%C,L]O
M&)^493N7YL9.#R ?7Z4FJ> -%U76O[7D:^M[YD$<\EG=O!]I4=!)L(W?I744
M4 9CZ#9-J>G7Z>=$^GQ/%!%%(5B"L ,%!P< #'I6G110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% ' _&7_DFE[_U\6W_H]*Z7Q:&_X0_66CFFAD2RF=)(9&C=
M65"00RD$<BG^(/#FF^*-/^P:K'++:[@QC29XPQ!R,[2,X(S5J[TRWOM)FTRX
M,SVTT9BD_>L&92,$;@<\CWH \PFM(]17X43W;322S0A7D\]PQ_T0L3D'J3U/
M4UK7=W)I?Q%\4WENGF2VOAN*6-#D[BK2D#WZ5TTW@S19],TS3WAN!!I;*UFR
M74BR187: '#!L;3C&>E68/#>F6^NRZS%%*+R6$6[DS,4,8Z+LSMP,GM0!Q^C
M:;J.HV?AGQ);:U%#N\J2ZE\^23[:L@ :-E)VABQXX^4\ "NVT_28M.N]0N([
MBZE:]F\YUGF+K&< 80'[HXZ5D:/\/_#NA:D;[3[26(AS)' ;AVAB8]62,G:I
MY/...V*U]/T:STN[U"YMED$E_-Y\^^5F!; ' )X&!T% &A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5GZUHFG^(=-DT[4X7FM).)(EE>,.,YP=I&1Q6A10!@
M_P#"&Z&RP)/;37<4!!BBO+N:XC4CH0DC%<CMQ5C5_#6DZ[<6=Q?VSO/9,S6\
ML4SQ.FX88;D(." ,CH:UJ* .=7P+X:33-1TU=+1;/49?-N8A(X#/D-E>?DY
M/RXP:35? OAW6K:SAOK!G-EG[/*L\B2IGK^\#!CGJ<DY//6NCHH QYO"VC3:
M?IU@UD!;:=<)<VT:.R[)$)(8D'+<DDYSDGG-;%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !17+V?C.WNOB#>^%O**F&V66*<])7!_>*.QVADZ=]WI73LP52S$!1R23TH
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MKL ,# Z54U/2['6=/DL-2M8KJTDQOAE7*M@@C(^H!JV!@8'2@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/$'GD+9*J<9&T # Y.<5U]I<Z=<_&NYG26VD_P"*?B9'R/\ GLY)'_ 2/P-
M'72>)=#BM[.XDU>Q2&]Q]E=IU GSV0Y^8_2K;:A9I?I8-=0B\=#(D!<;V4=6
M ZX]Z\O\+Z*GB;X,"RL)HUO;6[N)[&1"/W,Z7#O&1Z=A]&KK/!-]/XDMV\3W
M=J]M)<1);10.,&-4_P!9],REQ[A%H W[[6=,TN6**_U"UM9)L^6DTJJ7P,G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "FO&D@PZ*P']X9IU8?BKQ/9>%-(%]>;F+R)#$B@G<[$
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M)H TGBCD.7C1B/[PS2300W$?ESQ1RIG.UU##/T-<-IVIZO--X\MY-4F9M.F
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MM-L7N+_SO/1%AD*Y>X.W.551DD@%L >M &A)&DJ%)$5T/56&0:!&BL65%#$
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M_7=>BUW2+NXOKR"T:.6ZDFDVV\1.=C[N 2><'G@GM7>4U41 0JJH)R0!C)H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMMH&FD1.F\A5; ST)&#BN9^'WB,-\-M-U36-2>=YIYHQ/*2[S,9W5%  RQ(
M  'X4 =U1619^*-&O[ZXL8+T"[MP3-!*C1O& ,Y8,!@8YSW'-):^*-'O-2AT
M^*Z87,\9E@66&2,3H.IC9E < <_*3QSTH V**\\^)?BN*U\&:DVE:I=V]Y!,
MD0GMHFV;_,4,AEVE0<$C 8'(QUXKT(D*"20 .230 M%8MGXMT2_O+6UM[PM)
M=J[VI:%T2X"_>,;E0KX'/!/'/2J4WQ"\*V\5Q*^K*8[:<V\[)#(XB<8SNPIP
MOS#YCQ[T =/15"^UBQL# DTS&2X!,,<,;2NX R2JJ"2!D9.,#(]:YGX;:K<:
MM9^()9K^XO8XM;N(8))^&6(*FU<8&W&3Q@<YH [6BJ6L:BFDZ1<WS(9#$F4C
M'61SPJ#W9B /<USGP\U[4-7TB\L=;*_VWI5W):W@7@,<Y1Q_LE2,'O@T =A1
M63J'B72=,DN([JZ8-:QB6X\N)Y! ASAG*@[1P3SC@$]!567QOX:A2S9]6AVW
MF[[.5#'S-H).,#T'X]J .@HK#C\8:)/IEOJ%O=2SV]Q$TT?D6TLCE%."Q15+
M  C&2!S5A?$6DRZ9:ZC!>+/;7?\ Q[M K2M+P3\JJ"Q(P<\<8.>E &I161;>
M*-%NM(FU2*_3[) YBF9U9&CD!P49" P;) VD9Y''-<W8:[+??%][&&^O39#1
M6F:TGB:())YR@,%95)^7N<]^: .[HJAI&M:?KUA]MTRX%Q;>8\>\*5^92588
M(!ZBK] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %8GBK6?[&T21XY%2[G(@MB1D+(
MY"AR/[JYW$^@K;HH \O\<>%9=,\#VM[IVM7D]QH3Q7>GQRK#AV3'RY2,,Q9<
M\9Y/7-2Z[XC1=6\(^,_(N)-$2*>&\V1,SV;RJF&= ,\%2IXXS[\^ET4 >7^.
M;W3]2^'>I7.E61@BO+VVD25;<QR7;":,O($*AB !]XCG:>V"=+P=JYT;4-0\
M-ZS.CW$;FZ@U0X"7T3\AG;H) ."/0#'%=]10!XC R)\#=)M]I6Y354=HMI#K
MB\+DE>H^3GZ5UVD7Z:!\0/$YUF98;?5#!=6%W(?W<R+'M*!NFY3_  ]3G(KT
M"B@#RBU\*ZC#\(I/*A>'4+.]EU?3('4AH=LID1,=B5R,=M^*=-::VWB.RUF"
M">-?%MN;2\BS@V:@;HG/HPA$F?\ :KU6B@#A/%)AMO'_ ($50J16\MUNP/EC
M4P%%SZ G &:YNRN-(M9];\+>++#5IKR?4+B6"",W#17\4DA="H0[.^#G &.3
MP<>OT4 >;:5J">%OB-KT.M12VT.I0VC:=*$>1&6./:T08 _,&)P.ISGO7-6$
ML%K\*/#5W.+NUFT[7#/&S6DC(I\Z4_.H&2A1CRN<$BO;JPO$.A7>K3Z?=Z?J
MTFG7EC([QMY(FB?<NT[T)&>,X(((R?6@#@A+IWBJS\;OHFKQ7&O:Q8!%LXT>
M/8D:%% \Q5+$EB"V !N XZG0\/ZEX?\ %%QIKVVGZI_;UDK$I>M<XTYRN&)+
MDK[ #)/''!QV6G:3>QW*7FK:BE]=QHR1&*W$,<8;&XA<L<G Y+'IQCG.Q0!X
M5/J:)\#+SPO=P7,>OV16*XM# [.S?: V\$#D-G.[H2:]IN[G.CSW4-L]R?(9
MT@9"K2?*2%P1D$].1WJY10!XQI^IQ76I_#[4%2Z"PRS1S6T%B\<%DS6[*(44
M+V/&22>,Y -6?,A;P;\4(Q@R7-[=F%<<RAH552O]X%@0,5Z]10!Y79:HNA>-
M-%U;4S(ND7GA^*S@NPA9(9U;<R-C[I/'7N,=JV?AK.LK^*\13H)-?N9D,D#H
M&1@F"-P'<'CK7=T4 <GK<T>M>)[#08K^2V^S WTSQ!22ZD"-!O5E)Y+D8R-B
MGO7.W0;P7\5[*^DOKB[M==MC;W[R(F89(\>5(WEJH ()7)'KSQ7IU% 'DNN:
MOINB^+O%UI+?_94UBV@21[FTFD57,13?&44AEVD?*2/F!YQ4]S-HR3_#:/2[
MU;S3;.9HUN.N%6!HPS_W?F '.,'Z5U*^&M<LM4OKC3/$HBM;VX-Q)!=6(G9&
M( (1PZD#   (.,5OZ=8)IUKY*.\C,[222OC=(['+,< #DGL,4 >?Z_J%OX<^
M(]S>Z^NHQZ1J-E!';WEH\X2*2-GS&XB.>=^1D'^=4-2CL?#-QX:U>'2=2M/"
M\:74$B6[3"2V\UD99653O 8H<@],\C/%>M44 >2:Y%91Z38>(?#VEWK:5%KL
M%_?N5E:2Z100TP1_F(4E3[XST -:]EJ]EJOQBMKZP,L]K)H#1+<) ^PMYX;&
M[&.@/MGCK7HE% &=HNKV>N:=]ML!((/,>/\ >1-&=RL0>" >H-:-%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %87B/PY)X@
M^S>7K&HZ=Y.[/V.X>+?G'WMK#.,<9]36XRAE*G.",'!Q7C5K)'_9/Q N[SQ#
MJ=K/IFI7*64IU.8>2%4%%"%]K#<<8(.<XH ZO_A7-Q_T.'B'_P #YO\ XNC_
M (5S<?\ 0X>(?_ ^;_XNI_#?B^ZD\.^'XM6L[B?7[^R-RUM BJQ1< N=Q55S
ME>,]6X'%6I?B#H<6A:7K)^UM::E<+;0E;=B5D+%</Z8((_ XS0!G?\*YN/\
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M7V.]O6L+>]V+Y4DP++M^]N&2K $KCCKTH RO^%<W'_0X>(?_  /F_P#BZ/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:3\D_P#B:/\ A4?A7_GVD_)/_B:[JB@#A?\ A4?A7_GVD_)/_B:/^%1^%?\
MGVD_)/\ XFNZHH X7_A4?A7_ )]I/R3_ .)H_P"%1^%?^?:3\D_^)KNJ* .%
M_P"%1^%?^?:3\D_^)H_X5'X5_P"?:3\D_P#B:[JB@#A?^%1^%?\ GVD_)/\
MXFC_ (5'X5_Y]I/R3_XFNZHH X7_ (5'X5_Y]I/R3_XFC_A4?A7_ )]I/R3_
M .)KNJ* .%_X5'X5_P"?:3\D_P#B:/\ A4?A7_GVD_)/_B:[JB@#A?\ A4?A
M7_GVD_)/_B:/^%1^%?\ GVD_)/\ XFNZHH X7_A4?A7_ )]I/R3_ .)H_P"%
M1^%?^?:3\D_^)KNJ* .%_P"%1^%?^?:3\D_^)H_X5'X5_P"?:3\D_P#B:[JB
M@#A?^%1^%?\ GVD_)/\ XFC_ (5'X5_Y]I/R3_XFNZHH X7_ (5'X5_Y]I/R
M3_XFC_A4?A7_ )]I/R3_ .)KNJ* .-L/AAX;TW4+>]MH)%GMY%E0_)PP.1_#
M79444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4*7E
MK)<M;I<PM.OWH@X+#ZCK4U</HU@U_9^-[>"86MS/J-S#'= ?-$6@C ;/L3F@
M#LX[JWF=DBGB=E;:P5P2#Z'WI8IX9]_DRI)L<H^Q@=K#J#CH?:O-O#][!9Z]
MHFB^)= CTC7+,,EC=VZ VUX!&RD(XZ9!W;&[@=ZT[;Q6]GI6H7 TRTMYO[?_
M +-/D_ZO<TBIYTAP,_>R>F>!D=: .ZHK@M1\:ZSIUCXDE_L^RF.C7,4 D$CJ
MLWF;#G;@X($@!&[J*O'Q-K-O?Z]I\]A92W=C9Q7EL(I]B,KEQM=GP!M*$EN
M1V% '7T5YOKOC+5#X;\7I9S6ZW6E01/%>1PNJR)*I.54G@C!PV2#P:Z0:WJ,
M?B>;1)1:LRZ9]M6948#=O*;2NX\<9ZT =)17 VWC/7=4A\-KIVGZ>L^M:9)>
M W$KA(W0(<' SM^<>]71XKU6YE$NG:;]K@BOS93Q)$^[".4DD60X7Y6!^4CD
M#J"<4 =>\D<0!D=4!Z;CBA'61=R,&'J#FN+^+D:2?#+5M\:OM,! (!Y\Y*JQ
MZ7J>F>,-4\0:5HHLM/CTDQFR:6*(7MR&W*V%8JN!\N]L'GTH ] HKAU\=36T
M7B)IX(KP:3I\=^CVJLBS!@_RC=G(!C/S@D$'VI]QXSO-+O[U+V"UN+*TT@:J
M]Q;%E.T[@$ .022O!R,CMQ0!VM%<]I6KZQ<:X;2[T_-D]MYJW<<3QB.3.#$0
M_+<'(88Z'@53O]7U&V^(D=HUU#'I46D2WDD9C))Q(@))W=0.G'&3US0!UM,>
M6.+'F2*F>FXXS7(0^,+Q;3P[JMS;0_V9KLL<,:)GS;<RJ6B+'.&S@ X P3WJ
M'XK11R>$(#) LVW4K/"D DYG0$#/'(X_&@#MU=77<C!AZ@YI:\]\(Q)>^/\
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M/ R.N* .OFGAMH_,GE2),@;G8*,GIR:DKSWQX^I'PAJJZO:VWE6UY8O:W47
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MJ.YN(K.UFN;APD,*&21ST50,D_E7F_AG6'L?'^VYO#+'XFMS<^6QS]FN8_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
F444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>a109-2021formrsuawardemp001.jpg
<TEXT>
begin 644 a109-2021formrsuawardemp001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** ,C5]2OK6_L++3[:VFFNA(<W$K(JA #V5O6H_.\4_\^.C_P#@
M9+_\:HU+_D;-#_ZYW/\ Z"M:\\0G@>)F=0X(W1N58?0CD&@#(\[Q3_SXZ/\
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M6W10!B>=XI_Y\='_ / R7_XU1YWBG_GQT?\ \#)?_C5;=% &)YWBG_GQT?\
M\#)?_C5'G>*?^?'1_P#P,E_^-5MT4 8GG>*?^?'1_P#P,E_^-4>=XI_Y\='_
M / R7_XU6W10!B>=XI_Y\='_ / R7_XU1YWBG_GQT?\ \#)?_C5;=% &)YWB
MG_GQT?\ \#)?_C5'G>*?^?'1_P#P,E_^-5MT4 8GG>*?^?'1_P#P,E_^-4>=
MXI_Y\='_ / R7_XU6W10!B>=XI_Y\='_ / R7_XU1YWBG_GQT?\ \#)?_C5;
M=% &)YWBG_GQT?\ \#)?_C5'G>*?^?'1_P#P,E_^-5MT4 8GG>*?^?'1_P#P
M,E_^-4>=XI_Y\='_ / R7_XU6W10!B>=XI_Y\='_ / R7_XU1YWBG_GQT?\
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MM^=XI_Y\='_\#)?_ (U1:?\ (\ZM_P!@ZR_]&7-;= &)YWBG_GQT?_P,E_\
MC5'G>*?^?'1__ R7_P"-5MT4 8GG>*?^?'1__ R7_P"-4>=XI_Y\='_\#)?_
M (U6W10!B>=XI_Y\='_\#)?_ (U1YWBG_GQT?_P,E_\ C5;=% &)YWBG_GQT
M?_P,E_\ C5'G>*?^?'1__ R7_P"-5MT4 8GG>*?^?'1__ R7_P"-4>=XI_Y\
M='_\#)?_ (U6W10!B>=XI_Y\='_\#)?_ (U1YWBG_GQT?_P,E_\ C5;=% &)
MYWBG_GQT?_P,E_\ C5'G>*?^?'1__ R7_P"-5MT4 8GG>*?^?'1__ R7_P"-
M4>=XI_Y\='_\#)?_ (U6W10!B>=XI_Y\='_\#)?_ (U1YWBG_GQT?_P,E_\
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MZQ\(:;J^G:5=JT=[J1<6L?FS'S"@RW(.!P1UQ0!UU%8G_"(Z'_SZ/_X$2?\
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MFIV:E[2\ ,$C3RKOST&"P.?:@#JZ*Q/^$1T/_GT?_P ")/\ XJC_ (1'0_\
MGT?_ ,")/_BJ -NBL3_A$=#_ .?1_P#P(D_^*K+UFR\'^'EM&U19+=;N=;>%
MM\[!I&Z+E2<9YZXZ4 =?17.WGASPYI]C<7MU;M';V\;2ROY\IVJHR3@-GH*B
MTK1?"^MZ5;:GI\+S6ER@DBD\Z5=P/L3D4 =/16)_PB.A_P#/H_\ X$2?_%5'
M)X7\/Q-&LEOM:1MB!KF0;FP3@?-R< G\#0!OT5@R^%M @A>:6W,<:*6=VN9
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M)_PB.A_\^C_^!$G_ ,51_P (CH?_ #Z/_P"!$G_Q5 &W16)_PB.A_P#/H_\
MX$2?_%4?\(CH?_/H_P#X$2?_ !5 &W16)_PB.A_\^C_^!$G_ ,51_P (CH?_
M #Z/_P"!$G_Q5 &W16)_PB.A_P#/H_\ X$2?_%4?\(CH?_/H_P#X$2?_ !5
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M1)_\51_PB.A_\^C_ /@1)_\ %4 ;=%8G_"(Z'_SZ/_X$2?\ Q5'_  B.A_\
M/H__ ($2?_%4 ;=%8G_"(Z'_ ,^C_P#@1)_\51_PB.A_\^C_ /@1)_\ %4 ;
M=%8G_"(Z'_SZ/_X$2?\ Q5'_  B.A_\ /H__ ($2?_%4 ;=%8G_"(Z'_ ,^C
M_P#@1)_\51_PB.A_\^C_ /@1)_\ %4 ;=%8G_"(Z'_SZ/_X$2?\ Q5'_  B.
MA_\ /H__ ($2?_%4 ;=%8G_"(Z'_ ,^C_P#@1)_\51_PB.A_\^C_ /@1)_\
M%4 ;=%8G_"(Z'_SZ/_X$2?\ Q5'_  B.A_\ /H__ ($2?_%4 ;=%8G_"(Z'_
M ,^C_P#@1)_\51_PB.A_\^C_ /@1)_\ %4 ;=%8G_"(Z'_SZ/_X$2?\ Q5'_
M  B.A_\ /H__ ($2?_%4 ;=8GAS_ %NM?]A*3_T%*/\ A$=#_P"?1_\ P(D_
M^*J'PG;0V<>K6\"E8DU&0*I8G'RIW/- '0T444 %%%% !1110 4444 %%%%
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ML'+VJ,;<^23UV_ON ?3I0!B67B/6=/\ B@-)UV2\6TO+V3^S+J!P]O/&$91
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MB0=2I$P(Y^E &>^M^)8M<\*^$=<U-;:XO8+K[1>6CC,LBAA$-P P1\I(&,G
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M%%8G]OWO_0L:Q^=M_P#'J/[?O?\ H6-8_.V_^/4 ;=%8G]OWO_0L:Q^=M_\
M'J/[?O?^A8UC\[;_ ./4 ;=%8G]OWO\ T+&L?G;?_'J/[?O?^A8UC\[;_P"/
M4 ;=%8G]OWO_ $+&L?G;?_'J/[?O?^A8UC\[;_X]0!MT5B?V_>_]"QK'YVW_
M ,>H_M^]_P"A8UC\[;_X]0!MT5B?V_>_]"QK'YVW_P >H_M^]_Z%C6/SMO\
MX]0!MT5B?V_>_P#0L:Q^=M_\>H_M^]_Z%C6/SMO_ (]0!MT5B?V_>_\ 0L:Q
M^=M_\>H_M^]_Z%C6/SMO_CU &W16)_;][_T+&L?G;?\ QZC^W[W_ *%C6/SM
MO_CU &W16)_;][_T+&L?G;?_ !ZC^W[W_H6-8_.V_P#CU !:?\CSJW_8.LO_
M $9<UMUQ=MK=V/&6J2?\(YJQ9K"T4Q@V^Y<27')_>XP<\<]CTXSL_P!OWO\
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M$15YOX#O+CP;K?B3X>;R)UG\[1V;G,<F 3[A00Y'L_I76:SXB/AK6]%\':+
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M4 8G]@7?_0S:Q_Y+_P#QJC^P+O\ Z&;6/_)?_P"-5MT4 8G]@7?_ $,VL?\
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M'A__ *"<7Y-_A6W10!B?\)AX?_Z"<7Y-_A1_PF'A_P#Z"<7Y-_A6W10!B?\
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M!B?\)AX?_P"@G%^3?X4?\)AX?_Z"<7Y-_A6W10!B?\)AX?\ ^@G%^3?X4?\
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MZTZ&[^V7$,\]S<M.S0Q&-1D 8 +,>WK0!J4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110!4GU.RMM1M-/FN$2[O Y@B)YDV %L?0$5;K
MY[^*MYK%IK^B_$.SD+6%G>M:VT8X&Q#]X^TA$HS_ '0OK7MDFH0:SX1;4K*>
M00W-GY\,D;E6&5W Y'0B@#8HKY]TKQ=JC_!>Z\13^*KN/7XKDI;AIU;S?F4!
M/*((/!/0>_:NC^(OB/Q#9?!_2-?6>XTO6I6@$XB8IC<I+ J>!T!P>1TH ]?H
MKR/5O$>IZ1XZ\'V&@:O/J2ZC@:C8O()Q''E/WF>63@N>N/E^M:%QXHU#Q)\8
M'\'6=U+9Z7IMN;B]> [9+AL+A0_55!=>F#P>>E 'IE%>8ZQXEOO!7Q0T31WN
MIKK1-<41K%<.9'MYMVT%7/S%22O!)ZG%4]#U35-+^,FK^$M;U2]GL[VW,VEL
M\S JOWMH([@!AD\_)[T >M45XW\-?&-VNI^*])\0:G=WTM@IN;6:1R&EMNS*
M!CJ"C CD[Z7XJ7^N>$? ^@3VVLWL.H2720W4PG+;MR,S#GC (X/H* /8Z*\:
M^(_BQ;?6/"=MX:\3%DNKT6]XMI?>:60L@&[DX/+<U9^(.M7FB_$SPII\>LW5
MCI5Z"+P&Z*J0#C)8GY>.^: /7**YCPM&;F635[/5[N]TF[BVP1W$WF!61V&]
M#C.&&#R>U<YXU\?W7AKQ[X>M]A70VF:VU"?^$2NJE5)[;0RO[AO:@#TJBN!^
M,6I7^B_#VZU/3+V>TO()8@DD+D<,X!!'0\'O7.>)O$6O>"O"'AGQ;:ZG<7L%
MPL"ZA97;!UEWQ[BRL1N0Y!Z''(XXY /7Y'$4;2,&(49(52Q_ #DUR4?Q0\(S
M7%W;Q:C<236>[[2B:?<DPA3AB^(_E /!S74VMS'>6<%U"28IHUD0GN",C^=?
M/_@#5$TGXQ^/9VL[R\8RW06&TMVE9C]HZ<# ^IP* /=M'US2_$%@+[2+Z"\M
MB=OF1-G!]".H/L:T*\*\ ^#_ !!X/\ >,=6U$2Z9<7%J\]I;QRX>$QI(P8X.
M!R0,'TY%/TOQJ9?@7<:C<^*/^*E\N5UW7P$P99"% 3/]W'&.>M 'N5%<E\-[
MVXO?AWI.I:A=RSW$\!EGFGD)R<GGG@# [5A^!_'MYK/C[Q#H6J1M ?DN]-C<
M8/V<JOZD%'QZLWI0!Z317E'CC5[^P^+?A?2XM6N[73=0C8W423E%.-V#G^'H
M.F*L>#_$.JW?Q2\0:!#J$NJ^';:!7CNG(8P2D)E!(H&[DL,')^7V- 'I]%>,
MVGB;6_#/Q8L[35-3N+GP_K,MS;6RSMN$$B3LB@$\G[J#D])*=XX\2:VGQ+\+
M6MEJ=Q;:3?7YLGAA;:)@DB*[$]1\S.G_  #(ZT >R45S7CG5KS1/!]]+I<;R
MZDT+QVB*<MO"%BW/7:JLWOMQWJ'P-XOA\2^ +/7II '2$B\Q_#(@^?CWQN'L
M10!U=%>7?#[4]2^)*ZCXBU&_O+734NFM['3[2=H0JJ 2SLF&9OF'?'!XJ_XP
MAUKP_P""/%%Z-;O)6A19M/F+A9(0  5.T -SGD@D@C.2,T >A45Y3X,OI/$_
MA[1UM_$U\^NBW2]N]MWO7 D *2)R!N&X<8/%+XBU74X/CUX>T*'4KR/2[VS:
M:>V29@K.!,<^H^XO QTH ]5HKFM3MKJ?Q,8;6^N86FTR=D7SF\M90R*K[?;<
M?;VS7!^)Y]5T3XE^#_#]OKVJO9WZD79>X.Z4@XSD=/PQ0![#17E'Q0DUGP?\
M/KJ\LM=OS<KJ"FWG:8EUB<#*-V."#@XSC'/6G>+?&.IZ/IWA+P[HUP5UC7O*
M1KV?]Z85;:"^&ZDEOH,'CI0!ZK17+W/AB^M]-5=*U_5%O59"\ES<&43J"-RD
M-D+D9Y0+@U6^)NOZAH'@N]FT=&;4WC8Q%1DQ(HS))]%7]2* .QHK#\+ZY;^+
M_"%AJT1*K>0@N(W*E''#J".1A@17$?!'6=4U_1]7N]7U&ZO9H;YK>,S2$A4"
MJ<8Z9R>M 'J=%><_$[Q;-X6U3P\UX+R/P]/+*M_-9DJX8*/+7<,$#)).""=O
MM@]!X1N[?4OM6H:9KQU71YEC%L'DWM PW;T)(W=U/S?-^0H Z:N8OOB%X9TW
M78]$O+Z:+4I"JQVQLIRSEC@;<)SD]Q73UX)X\_Y.4\+?[EM_Z,DH ]Y1@Z*X
M! 89&X$'\0>13J\K^)T_BW1]4CUKPQ?3M#80+<WNGLQ9)4W$$A?8#D#MR.16
M[X>\2V/C.[T76-.O+A+>6UG:XM1,0J2H8AM=?4;S]00>>* .WHKRSP3KE_\
M$W5]8U2;4+NTT&RG^SV5G:2F$RG&2\CKAB<;> 0.?;GN])TW4-/U2_,^ISWE
MA(D7V5)R"T)&_>N0 6'*G)R>V>* -BBBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@&0.C>M<;X \):UX4\3>(]&ETN=_">HLSV\S2Q90D8(*ALX*G&<?PCBO6:*
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M>C:18:-?36M_);ZQ@6C1QI\Q., @L"IY'6M/P/-;3^ ] DM"OD?V? %V]L(
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%X\0A>8=60'(!]<$G\ZM44 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*J; 0^-NPD9W9P >>>* -1_%EM=7FG66C(E_<W]K]MCS)Y<:6_ $CM@D9)
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MDMTT(_Y<)O(E!V^D;ENG0-]:N^#5E3Q#XN>6VNH4GU(2PM-;O&LB>3&N5+
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^@MKG_@SE_QKH** .?\ ^$2M_P#H+:Y_X,Y?\:/^$2M_^@MKG_@SE_QKH**
M.?\ ^$2M_P#H+:Y_X,Y?\:/^$2M_^@MKG_@SE_QKH** .?\ ^$2M_P#H+:Y_
MX,Y?\:/^$2M_^@MKG_@SE_QKH** .?\ ^$2M_P#H+:Y_X,Y?\:/^$2M_^@MK
MG_@SE_QKH** .?\ ^$2M_P#H+:Y_X,Y?\:/^$2M_^@MKG_@SE_QKH** .?\
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M >X[?2JNF:Q8:P+LV-PLWV2Y>UFQ_#(F-R_J* +U%%% !1110 4444 %%%%
M!114%U>0VEO/-*QVP1&614&Y@H!.=HY/0_7% $]%<O#\0= GMM&N%EN!%J\S
M06[-;N-L@8*5?CY#N('/4GTK>LM0@OQ*(BRRP/Y<T3C#QMC."/H00>A!!&10
M!:HHHH ***I:?J2ZA)>(MK=P?99S 3<1%!*0 =R?WEYZ^QH NT5DWGB*RL?$
M6FZ'*D_VO4!(86$9\O"+N;+=.G89ZBM:@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **R;'Q%9:AX@U+184N!=:>D;S&2,JI#[MNTGK]T\XQ5^\O+>P
MM7N;J01Q)C)QG))P  .222  .22 * )Z*B2=61"ZF-W7<(VQNP.O STR.E9V
M@^(;/Q%%>R623J+.[>SE$T>P^8F-W!YQSWQ0!K4444 %%4&UBS6WFN-[&**7
MR-P4G?)NV[5_O'=\O'?CL:NLZI&7<A% R2QZ#WH =15+2-6LM=TFVU/3IA-:
M7";XW QD=/SR"*NT %%%% !1167XBU^S\,:'<:O?I.UM;C+B",NWY=OJ<"@#
M4HK!E\7Z3#K4^DR-<+=PV9O2OD,0T8&3M(&&8#L*=I/BS2M9L[&[M9)5@OBR
M0O+&4S(I(,9ST;Y3P>N.,T ;E%%% !1110 4457O[L6&GW%XT,\X@C:0Q0)O
MD? SA5[D]A0!8HJ*VG%S:PSB.2,2HK[)5VLN1G##L?44]G52H9@"QPH)ZG&<
M#\ ?RH =15*'4EGU>ZT\6MVC6\:.9WB(BDW9X1NY&.1VR*NT %%%% !115+4
M]4MM*@CEN"Q,TJP0QIRTLC'"JN>Y]\  $G % %VBLS1=;BUJ*Y*6MW:RVT[0
M30W46QE< 'L2&&""""1S4VJ:DNEVJW#6MW<AI4BV6L1D8;F W$#^$9R3V% %
MVBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L_6D1=#
MU-PJAFM9-Q Y.$.*T*J:G:27^F7-I%,(3/&T9D*;MH(P2!D<\T <S\+T1_A?
MX<WJK8M589&<')YKA](O]:T'X:)KMCJ?E06NKRJ]EY",LZ/>%&#,06!^;C:1
MT[UZ?X9T%_#7AJVT6*\^T):Q^7#*\6#CG&X \]>V*P3\/"?!4OA@ZN_V:2Z^
MTF;[.-X/F^;CKC&[VZ<4 7#JNII\54T<W2MIKZ.]VL'E@$2"54R6ZG@G\ZR?
M"?BJYU76;73M2U*YLM;B#F_T>\@2,-P<- P7+*#T^8Y')]^B/AN5O&,7B-[\
M&5+$V)@6'"E"P<G.[(.X?EQ[U7M/",@NM%GU/4?MSZ,&^RR& )(Q*;,R-D[N
M#T &3@G.* +OBF[O+/2X9+2^M[(-=1)--+RPB+?,(Q@[I#T48.2:Y>P\5:S%
M;^-T"3W\NC*LMBMQ"$E</#O"LJ 9YZ<!L'!YKIO%'AO_ (2.VL52^ELKFQNT
MO+>>-0^UU!'*G@C#&N<UCP_-X:T[Q3KB:GJMY-J=NB2I!&N]'"B/S5V+GY0=
MV . #P3B@".WUK6I]<\(P6.M_;+;5K1[B\)@C;R@B*P8;0-JLS;.<]N^:;H^
MJ>([N7Q!?W>N@66AZK<(]NEFF;B%(U;83U7KD$<]<YXQ1\.37$=W:KX?\:P:
MPOFQK-9KI,29CR Q=T"E"%R06[C&"3BNST'PQ_8SZSYUX+N+5;I[J:-H0H5W
M 5@.3\N .#^= &#I^H^+]1B\/:Q9)/+;WABDOK>?[,L"P2+DM$5/F97(QDG(
MZU =;\5:_HTVK^'4N//6\D2WMG%N+:2..4QD.6/F D*3D8P2 !CDZ>@^ Y]!
MDCM8_$>H3Z'!)YEOIDB)B,@Y53)C>5!Y"Y'09SW;%X ELM6O9=-\17]EI-_,
MT]UIL:(59V^]L<C=&&[[>>>"., $*7?B'5/'6N:(FM&QMH;*WGA,5M&SQ,Y?
M(!8$'[HSD'VQUK A\4>*&^'VC>+9=73S!=Q6]Q:);(([A3/Y+%B06#'K\I '
M3%=S;>&I;3Q3J&NPWRA[RWCM_(,'R1JF=F,-G/S'/K[5DCX>%? \'A8:N_V:
M&X$ZS>0/,)$OF@'G'WO;I^= #;_6-;UC4_$%AHSWD$FF,L$+6ZVY5I3&),R>
M:<[<L!A0. >>>*TNJ>+'\2^&-*N;R'3I=0L)WO(HH4E$<L83)5CG^\2.P[@U
MI:AX(N9?$<FNZ1XANM(O+J-([\00I)'<;1@-M<$*P'&>>/QS<?PD!XATC58;
M]U&F020QQ.F\R"3&]G;.2QV@Y]<]: .!\0ZKK-[\+/%T-YJT[W.E:HUC]IC1
M(VN(M\?#@+CI(0=N,X],@^N6L,EO;K%+<RW+KG,LH4,W/?:H'MP*Y*3X?1W&
MA>(M*N=2D:+6[IKR1TB"M%*=I^7DY4;%X/OS75V,$UM9QQ7%V]W,!\\SJJES
M]%  'M0!Q?PZFFUKPKJNJO<2PW6IZC=2--'@O&%;RT W CY510,@UQJ"ZD^
MFDW4U]/<RW%Y:N!/M(1OM8R<@!CD\G))KT7PKIA\-76IZ,ZD6L]Y)>6+X^4I
M)\S1^S*V[CNI!'0XSD^'!C\(Q>&UURX-E!<)-"7A0M&J2>8J\8S\W4GJ .E
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M+?:QBAF\_:6SODW;][>IW?-]>>PKF+ZZ?3OC'I441_=:KI<L<RCH6A;<C'W
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MT#4=2;4(([.&\@D>%(VCWLZLGR  C*Y&>?<U6@^''V70M,TF+6[@P:=J0U&
MR0J2&$C2*IQC(RQSW/J.E;EMX=D@\8W/B%K[>]Q:I:M (<*%4E@0<YSEC0 S
MQ+>7EK=:4D.H)9VLTSK<>6F^YEPA*I"FUMQSRW' %<@OB+Q/=?#O6]2MKR4:
MCHNHW$1)@BWSP1/\P8;2H?9GE0.178:]X8?6-8TG5K;4YK"\TTRA'CC5PZ2
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M2>%/#W_"+Z*-,6[:ZC66257:,*P+N78'!YY8T ;E%%% !1110 4444 %%%%
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M9^(-#,PEEN#(()7A%JT <J4/\8.T?>Z[L]!P.S\5"4^$M7,-S-;2+9RLLL)
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M20*+F.,[D#E?F /<9S6!'\.?#D6EV&G);W @L;K[7;_Z3)N1\YQNSG;TX]J
M)W\:6*ZW>:.MCJ4M[9HLD\<5OOVHWW2"#SGVYK3T/7=-\1Z:NH:5<BXMRQ0G
M:596'564@%2/0BO.;[4]4T?XF^,K_2M+34IH-*M7,!F*,0-WW0%.X]3CCIQS
M5_PN]IX2^%NJ^)K.\75'NQ/J\DBIL1Y6&=@7)*@$ $9SP?I0!Z117%6/_"5G
M6=(NXI9IM-F0C4%NW@VG*@H\6SD<]B2"/?FL[P[XFN[[7K;2=7U&^TS75:4W
M&GW,*"*Y7:V&MVVX(4[2.>@.<XS0!Z(DB2%PCJQ0[6 .=IQG!_ C\ZJ:KJ)T
MO3VNQ97=Z59%\FTCWR'<P&0,C@9R?8&O*K"ZU?2/A?XMU:SUN\%W:W]Z4:58
MY.5E(R<IG)'OCT K<\3S>)/#_@VZUE?$DTLTLUH5C^S1!8@[HCJIQG!W9&>1
MCKUH ]&IKR(A0.ZJ7.U03C<<$X'KP#^5<HVH7FN^+M:T.WOY;"/3+: [H0I>
M264,0Q+ _*H4<#J2<U@:Q:ZW_P )+\/[?4]:?[<TMREP]D%$32+ _P X5E(W
M8..1@9. * /3*1FVJ6P3@9P!DUY]<:IXB\0C7QH<MU#<:?=O9VAC, B\R-5)
M,H?YCN).<#A<8YYJ[8ZOJ>N^*)=#GN&T]M/TZ">\%H5)>XE!.%9@?D7:>G4D
M9X&" ;_A[Q#:^)+":\M(IXDBN)+9EG4*V]#M;@$]Z2^\0V]IJ?\ 9L%M=7UZ
ML0FDAM54F)"2 S%B ,D' SDX.!7._"I)(O#>I1S2F:5=9O5>0J!O(E.3@<#/
M7BHO$V@>(+?Q++XH\&WMN]_Y*07VF71_=W*KDKS_  N W'3KU'.0#J]*U^QU
M>RN;N!I8XK:5HIOM$9B*,H!8$-@C&>OMZ<UIUY!XD\2IXE^$GBBYAM[O1M4M
MI1'J5IN&X2?(I!..5*XZ8SCZYZZ?4KQO&EAX234;E1_9TFH7%T5C$L@\P(J#
M"A0.220,\#WH [&J]]=I86$]W)')(D*%V6)=S$#T%><S>-=6T>77]#N9UN+R
MRU&SM+6_EC _=W6-K.  "R#=V .!QUKIY]/UBRGU-Y=6^UZ1)I[!8KA5\Y)Q
MG)!50-A7MZ],"@#7T/5[?7]#LM6M4D2WNXEFC60 , >F<$C/XUH5Y;\,=6EU
MO0]'TJTU&:P72;"$W,(C3S+K>@*L-ZG$8Y&X<DYZ #/J5 !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !6)XF\-Q^)+:R7[;/97%C=I=VUQ %)2101R&!!&&/!K;K'\2^(K7PK
MHLVKW\-Q)9P8\UH%5B@) !()!/)'3- ',ZSX;;P]IGBC6;>]UB_N-4MTCFBA
MVEPP41^:NU0<JIW8' P<#IC-\/R70N[-- \97NJ1K+&LMI-I2(GE9 ;>XC4H
M0N<9.<@#!Z5Z*M\SZ8+T65QDIO$'R>9C_OK&?QIFCZI'K6DVVI0P3107,:RQ
M"8 ,48 @X!.,@_6@#RZVN?.U;4)U\5ZUHFI3WDKG39=,6=TYVKM+1DL"JJ1M
M) !QVKM+'PY?7>J:-XAU._D74K2T:!X4B14</@MN'.&. >#@'IFNHFD,4$DB
MQO(44L$3&YL#H,]S56RU 7.F6MY<P2V+7"H?(N<*Z,W13@]<G% '/:EX%^T>
M))M<TK7-0T>YND5+U;78RW 48!(=2 P'&ZL#Q:MK9^(M.LI-6U/0K:TL2L%X
MMO\ :(9V=AN5BR,-X" DGD[OKGTVN;N/&=G;ZAK%BVG:JT^F0>>52U)^TK@9
M\G^_@D ].M &%:^'[_Q1I36]]X@O;F"VNH+S3=2-FEO*LJ;L_)M =!\N"5YR
M>N!6O;>!X(M3U>]GU6_N3JUJMO=I(4 ?:K+N^51@X8X P/8\8W=(U2WUK2;7
M4K42+#<('594VNOJ&'8@Y!J[0!Q<_P .K>X\.:;ICZSJ(NM+96L-00HLMOM7
M:%&% *[1@Y&3W-37WAK4(?"]W;Q:_JTVK3E";^/8LS%3E4  "HG7T^\22<UU
MU07MY!I]G+=7+[8HAECC)]@!W)/ % "VB3QV4"74BR7"QJ)748#-CD@?6N/E
M^'%O)X9U/P^-8OUTZ^F:41XC_<AI/,95.WG+=VSQP,<UU7]HI]J2T$,IN6A\
MYHAMS&O0;CG&200,$]#V!-<[%\0K":'4YTTK5C!I<[P7LBP(PB=.6X#DD <Y
M /% %^?PT;GQ-IVNS:A*9[&!X%C$:A'5\;BW?)VCH:RM)^'D6BW316FN:DNB
M>:9ET@LIA5B<[0V-VS/.W.#WSSG>?Q+I"^&O^$A%XCZ68A*LZ G<#P !UR3Q
MCKGCK5=/%"K?V-G>:1J=C)?2&.W:>-&5F"EL$H[;3A3PV#^M %[7=*77-"O=
M*>=X([R%H))(P"P5A@XSQG!K(?P<))O#LAU.?=H0(@Q&O[S*>7\_']WTQZU9
ML/%5MJ'B:^T".RO4O+%$>X+J@15<94Y#'.?:K<VLK!KUOI!LKIIKB)YDE4)Y
M>Q"H8D[LC!=>,9YXS0!SU[\/([M->MH]:OH-/UIGEGM(U3:)74*S!L;L' .W
M.,CTXJ_%X0$6MZ3JG]J74DFFVK6D:R(F'1L9+84<_*.F.E=*3@$^GI7'CXC:
M9_8B:J^FZS'#]L^QSQO9$26S;0V^1<_*FTJ<^A% #T\#(NC^(=-.J7!BUV:6
M:Y;RTW(9%"N$XX& !SFI6\';+G2+VUU2>&_TRU-FDK1HRRQ'&0ZXZ_*O((K<
MM=2@N;VXLL-%=6^&>)^I0YVN/53@\^H(."*N4 <O>^ ]*U'0+[2[M[AY+V?[
M5->!@LWGC&V12!A2N   , #'K3;7P?<+I-Y::AXAU#4;BYMVM1<SJ@,43##!
M5  R>,L<DX'I7544 9^A:4-#T.RTI;AYX[.%8(Y)  Q10 N<<9P*H:AX82?Q
M'%X@L+R2QU)8#;2LJ!TGBSD*ZGN#R""#]16_10!S%YX)M+KPKJ&@K=SQIJ4C
MRWER IEE=SECTP,\#@<  "M^QMWM+*&WDF,QB0)YA4 L ,<@<9J4RQB80EU\
MTJ6"9Y(& 3CTY'YT^@#"T;PV-'U?5]0%]+.VJ2K--&Z*%5@H4;<#., #G-9&
MD_#R+1;MHK37-271/-,RZ064PJQ.[:&QNV9YVYP>^><]1JVHII&DW>HR0S31
MVT32ND(!<JHR<9('0>M)I.I1ZOHEEJD,;K'=VZ7"(V-P#J& /;/- &-=>$!?
MHUK?:C+<:>;[[<('C7<CB3S @?J$W>V<<9QQ2GP>B:SK.H6^J7<(U9%$\ "%
M X3R]XR,YV]LXSSBKOA[Q%!XCAOI(+:XM_L5[)92).%#;TQN^Z2,9/K6Q0!S
M4/A".'P&WA,:A.;4VK6@G*+Y@B*[<=,9P<9Q574? 45[;:,]OJUY9:IH\7DV
MVH0*N\QX *NI&U@0!QCK^5=?37=8T9W8*BC+,3@ >M '-:AX,AU'0(].FU.]
M-U'=1WHOR5,IG0@JY&-N. -N,8 %5]4\"?;-8@UG3]>U'3=42 6\]S#L;[2@
M.?G5EVYSG! X].!C=T'7+'Q)HMMJVFR&2TN 2C$8/!(((]<@UI4 <IJ/@:WN
MFTJZL]1O++4],+^3?*5D>0/S() PPX8Y)Z<GC%6]!\+#0]7U74CJEW=S:FZ/
M,LRQA0RH%!&U0<X'KCV[UT%% &/?Z/<W.HR7=OJ3P++;"VE@>%9(V +'=@\A
MOF(ZX]0:S/\ A K& >'OL%[>61T2)X(6C*L9(W #AMRGD[0<C&.<>W5TA. 3
MC/L* .8'@Q+:[U9M-U.XLK75G,EW;HBL/,889XR1\C,.O4=\"HM5\ V=T^DW
M&D7MSHM[I4/V>UN+0*V(<8\ME8$,.,\]ZU/#WB*#Q'%?R06UQ;FRO9+*1)PH
M;>F-WW21CGUK9H Y>_\ !<=_9:;;OJEYOLKY-0,[A6DGF3H7XQCM@ <  8 J
M?1O"L>A:UJ5]97TRV^H2^=+8[5\E9,8+IQE2>IYP:Z&B@##\2>&U\0)82)>S
M6-Y87(N;:YB56*M@J058$$$,>*R_^$!C+>(7;6K]WUV!(+HN(SP(]FX?+P2"
MW3 &>G K7_X2*#_A,!X;-M<+<FR:]$Q"^6R!U3 YSG+=P.E'B?Q+:>$]'DU6
M_@N7LXBHD>!58IN8*,@D'DD#C- %!_!JN?#I.ISYT+_CW_=I^\^39\_']WCC
M%/A\'0)<>(Y)[V>9->7;<QE54(/+\OY"!Q\OKFI;?QA82:S%H]U;WEAJ,\;2
MV\%U&%,ZCD[&!*DCTSFK'ASQ%!XELKFZM[>>W%O=2VCI.%#!XSANA(Z^] %&
MP\*7>F6FEQ6VOW;2:?$T"-/&C+)&0@"LH X 08((.<Y)S6EH.A6WA_3FM+8L
MWF327$KD ;I'8LQP. ,G@#H *U** .9O_" U."YL;W499],N;H73VSQKE"'#
M[4?J%W#G@GDX(JK=^ PWB.ZU?2M>U+23?;3?06I0I.0,;AN4[&QQN'-=A10!
MST_A*W;Q!IVKVEY<V<EE:FR,46TK+#N#!"6!(Y4<@@^]:6M:;_;.BWFFFX>!
M+N%H7D106"L"#C/&<&K]% '+3^";>YT#2=.>^N%N-':-K"^15$L110HSQA@0
M,$8P:LGPN)6U"ZN;UY=1OK46;70C5?*B&?E1>@Y8GG.2?0 #H** .9/@NUE\
M GPA<7=Q+9_9A;+-A5D5!C;T&,C [4-X2>75]$U.XUF[GN=)64(TB1XE,BA6
MW  8X QC&/>NFJ"2Z18;EX@9WMP=T41!;=M#!?J01U]10!E:'X<71-0U:\6]
MEG;4[C[3*KJH"OM"_+CM@#KFC4O#BZEXETC6S>RQ2:6)1%$JJ5;S%"MNSST
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M0!5 "J,G@#N3U-:E% ',7VEMIWCB#Q-$C-!/9FQO0HR4 ;?')CN =RGT# ]
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MZV[!/*1<Y./EW9) ).><#T% '%>!;I=#\<:]X8\B>VLKP_VKIL<\9CP&XE0
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MC2X7@A9Q&WF1MM^5QM .-@P1@^] %KPEJ%OJGANVO+753JD,C2%+IAAF7>V
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MCM&^[<>N!S5R>XU#4?%%]X;MYYC#IUC ^[[<T$LCR;\R%E4EL;1QP,DY!XP
M=U5)]2B_M1=-B!EN0@EE"](D)(!8]LD$ =3@]@35/PK%K5OX=MK?Q#=6UUJD
M6Y)IK8DJ^"=I/ YQC/'6N>^'TKZG<>,KR=V$\FNW%KN!PRQQ*B(!Z8'\Z -W
MQ+XHMO#?AR]UHV\M[#9G;*ENRY4YP<Y(Z$C.,GVK<4[E!]1FO$#:^5\!/$\I
MN+F5FN+I2)92XXNCSSW/<]Z[0SZAHGQ%TFU;5;R\M=2T^YDF@F*E$>+808P
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M.:=[@_:"I(=SN;&U1P2<UL44 96A>'=/\.6$]GID9ABFN);ANA(9V)...@X
M]@*Q_P#A7FD/X=OM$N)[VXMKNZ:\+R2*)(IF;<71E48.[GO^7%=;10!S%GX+
MAM]<LM9N=8U6^OK2!K='N)4 9&(.&"(H/0?7OFJ,GPRTN339],.I:JNG/<_:
MHK59U"6[^9YAV?+G!;^\3C)Q@\UVM% ')WGP_P!-O+O5IFOM3CCU> 0WMO%<
M )*0FP.>,[MOO@]P:F'@FS6309!J.H[]$!%L6D1MV5V$OE#GY>., =L5TU%
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M'_%830V5K3$^G9RJ[!N_><_*<?\ UZ[R>^ L[V2RC^V3VP8>1&X!:0+N"9/
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M!;WE[;Z=J4C27=A$Z")V;[^"5+*&[A6'MBNGHH ;'&D,211(J1HH5548  Z
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MI8:E,\LD*S+B/>V]E3*G +<\Y/H1DYTI?"\,^NZ7K$NH7SW.FQ/%$"8PK*X
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M6*NEN$90B!QAA@J<Y'K^&*C3PA9I+K<JWEZ&UD8NSN3G"[!M^7CY>/\ Z_-
M'.:/X@N_$&H>%M*O;J6)+S0%U.X:&0Q-<2G8NT,I! &68@$9X[#%/OY]4T#^
MQO#[:P;]M0U26+SYI3"\<(C:1(3(-S;ONC=]X@]LYK4N_AYI%WI>DV?VG4()
M=(798WMO/Y=Q"F -H8#D8 '(-6;_ ,#Z-J?AU=&NUN98UE$ZW+3L;@3#I+YA
MYW^_IQC'% ')^([;Q-X?\(^+IWUIH8! MSIZ17CSSVY PX,CJ&*DX([CIFK_
M /IVE^//#$/]KW]S#K-G<B[BGFRFZ-$9611PAY(X_'GFMD^!=/D\/7FCW%]J
METEZH2YN;FY\R>1!T7<1PHR> !U/J:MR>%K:;5=(U*2\O&N-*1TMB63&' 5M
MPV\Y  _#C% '">';5['P!XWN[.^OH+FWO=3\J47+N5\MF*GYB1G@9;[Q]:NZ
MK>ZA8>#?"'BHW]Z8+:.T;58Q.V)H9$4,[#/)5F#>XSFNG3P1IL5OK-O#<7T<
M&KM*]Q$)\JIE_P!9L!!"[OS';%:$6@62>&!X?D,D]A]E^R8E(+&+;MQD =N,
MT <OXBURYTS0M<\1VMRXC:>&RMB\I,48\U8GFP<@'<S<X(P@..3F]INE:]8>
M*HKIKV--(F@,<MG-J$MTS2CE7C,BC;P#D XQSBMIO#NER>&1X=EM5DTP6XMO
M);N@&!SZ\9SUSS5'P[X-LO#;!H;[4[THGEP_;[HS"!/[J#@ <#WXQF@##^,F
M?^%=S[<9^V6N,_\ 79:T9?"E[JOC;3/$6KW5N$TJ.1;.UMD/+R##.['KQT '
MXUI^)O#-GXKTT:?J$UREKO61D@<+N93E<G!/!&>*UXHVCA5&E>1@,&1L;C[\
M #]* /+])N&MO"_C!EU0Z:S^)[A!.L9=SF5 40#DNPRHQSDYJW8WVI#7O&&F
M"XU"TMX=-ANK9)[CSI8'99,D,Q;&=HXR<=L5N/\ #W29=*O].DN+YH[V]_M!
MI/-"O'<;@WF(P48.0..GM4L?@;3H]0N[];S4C=7=J+6>1KDL749^8@C&[#$=
M,#L!0!Q=A=:K:Z#\/==;6]1GN=1N;:UNHI9LQ21R1L3E.A8$ [CS[^G7_$Z_
MN--^&FOW-JQ686I0,O4!B%)'T#&I3X&T_P#LK1M-%Y?"WT>9)[,!TRK("$R=
MO. 2,'UYS6UJ^EV^M:->:7=@M;W<+0R8ZX88R/>@#G]9V:;X.TJU@U)M/B#V
MMNODH6DG3@>3'@@AF P".G)XQD86GWOB"6Z\=Z5I\L\=Q:I;MIT-[<^:\3RQ
M$E?,);J1QR0":WAX:&N^&;'1M<^TQ7FER1/'=VSE"9(QA)HVY'(SD'IDCT-/
M7P%I2W.I7*W6I";48XDN'^UL23']UQ_M>_;MB@"CX*URVU+5]0M6&K6&HQ01
M^?I.I2O(8B"W[R-F)W*V0,@_PC@9J]XDE9_$&DV8OKHAXYG;3;-FCEN,;0',
M@9=B+DYR0"2.IP*U+'0H+/4WU.6XN+N_>!;?S[C9N6,$MM 15'4Y)QD_A4&K
M>%;'5]8LM6>>\MKVT1HEDM9S&7C;!*-CJ,C/&#[T >=C6M;F^&6E79U>\BO(
M]=6S>57!:2/[48P';&6PO';/?-;HL;U/B9<: ->U<Z==:0+V13<DN)!-L^1L
M9C!!Y"XZ<8K57X<Z/'I/]F17.H):_;?MP3[1NVR!]XQN!P Q)]^^:U/^$;@/
MB4:_]LN_MPM/L><IM\K=NQC;UW<Y_IQ0!P6F>)=5C\.:9ILEY)/+/X@N-*^U
M7$Y1VBC,A4&0 D,VU5W 9Y['FKFN6GB70O#GBVY;63!:_86N;")+U[B>W=%^
M?$DBABA.._';&:WW^'FB3:!=Z+<M=3VMS=->;GD >*<G<71E *G)SZ?A4L?@
M:P&@WNE3ZAJEVM]'Y-Q<W5UYLSQ\_)N(P%Y/0#J: ,""34-,\6^"G_MB_N5U
MBWF2\AGEW1L5@$BE5Z*01U')'4GK6+JUS+XM^#?B'Q'<7MVDTHN3'#'.RQPQ
MQN46,H#M;*KDD@G+=L#'H+^$K22\T6Z>\O3+HZLMJ=R=&78=WR\Y7C_Z_-9M
MQ\-M'FCU6WCN]2MK#5"SW-E!<;82[?>8#!()[@'!]* *"WM]K'B%M B)6&TT
MFVG")?R6CNTFX%PT:DD+M48R!DG.>,5[>]UZUU+PMX0UK54FNKC[3)=W=I(5
M>9(AE(]V 0WS L1@_+[FMW5/A_I.IR:?.MSJ5E>V$7D0WMG=LDYC_N,QSN'U
MJ?4/ ^D:A8:?;;KNWFTZ0RVMY#.1<1N?O-O.=Q;G=NSGO0!C>#;06/Q'\<P+
M-/*@-B5,\AD8 Q,<;CR<=L]J3XEV4=Q/X3=Y+A2VOVL1$<[H,$/R " &_P!K
MK[UT.C^%++1M8O\ 58KF^GO+Y8Q</<3E@VQ< X&!GKVXSQ@<5+KOARV\0/8-
M=7-U']AN4NX1"RJ!*N=K'(.<9/'3VH Y*_L+Z_\ B5-X?3Q#J]IIYT)9P+>X
MPZ/YQ7(8@G. ,DY)]<$@S:*]UXO7Q.'U.^M9]/U"73K,PW#1^3Y:+B1E4@.6
M8ECN!&.,5TJ>&[=?% \0F[NVOOLHM""R[#$&W8*A?[W.>OX<5#-X1LSJE]J%
MI=WMC)J"A;Q+610D^!@,05)5L<;E*GWH X73?$.L^(T^'5Y+J-U9MJHNH[R.
M A5D,<;X?&.Y7([#(P.*LVMG?W%WXVT=_$.LBVTETDLW%V?-0O ),&3[S 'H
M"<<G.>W9S>$=.DN]%GA:>U&C*5LHH"H1 5V'((.?EXY_GS21>$[6&[UFZ2]O
M1+K 471W)V7:-OR\87C_ .OS0 [P5J-SJ_@C1-0O'\RYN+**25\8W,5&3^)K
ME/"&FJFJ>.VAN[V.5-2=$D^TNY&88SG#$@GT)!(' KN-$TB#0-&M=*M9)7MK
M9!'%YI!95'09 &<51B\)V-MJFJ:A;7%Y#+J7S3(DW[L/M"EU4@C<0 .<T <#
M#JNL7'P_^'MZ-9O8[F^U*V@N9 X)E5]Y.XD<_='!X]0:U[+3[R7Q[KGAU]>U
M@Z;]B@NU'VL^:CLSJ0LGWE7Y0< CGVX.XG@+38]'TC2TN[Y;72+A;FT'F)E7
M7.W)V\@9/!]><\5?C\-P1>(;K7$O+L7ES MNYRA4(N2H V]B2?YYH X+0O$^
MKWOAGP;8S7)FN-3N+N&:>2<PM*L!D"KYBJ2&;:N2!DX//-=EX6T_6],O=5AU
M.^BGLWD26RA-T]Q+ I!#*SNH++D?+G/<56?X<:')X7AT"1[QK6WG-S;2^=MF
MMY"Q8LC@ @Y9CSGK6UH>@P:%;/''<WEY-(09+F]G,TLF.@+'L.P&!R?4T <I
MJ-A%-\;--9I;H9T:9\)<R* 5EC P V /4=#WS5&TO[_Q+X!UKQ-'J=Y::E#+
M=/:K%,RQP"%F"1M'G:V0OS;@2=Q]L=IJ/AJQU+7++6))+F*[M$:)6@F*"2-B
M"4?'49 /:JC>"=-\S45AN+RWL]3<R7ME#(HAF9AACRI9=PZ[6&: +WAW49-=
M\*:9J5Q&89;VSCFD121M+H"<'J.O%><Z!;R:?\+?%][97U]!=6]QJ31RBY=R
M#&[E3\Q(SP,MU/K7K4<:0Q)'&BI&@"JJC  '0 5S:>!M,BL=8LHKB^2VU5I6
MGB$^53S>9 @((7=^8[8H YRYNM3GU/X=1)K%]#'J-M(+I8W'[PBUW;CD<G/<
MYYYZU6MK._GN/&^D/XAUD6VD.LEFZW9\U2\ DP9/O, >@)QR<Y[=A_PA]GY^
MAS?;+W?HJ%+,[TX!78=WR_-\O'_U^:?%X2M8;K6KA+V]$NL "Z.Y.<+L&WY>
M,+Q_]?F@#DM,\1ZIKJ>$M-DD#27VB?;[@_:GM3/(/+7 =%+#[S,0,9XYP,'J
M_"-EK6FV5W9ZU?Q7C)<NUL5F:62. \JDC,H+,.>2.1BJ5W\.M&N]%TO33/?Q
M-I/%C>03^7<0#&,*X'3  Y!Z4:QX-$OAE-+TZ^U2.Y%P)Q>K>$2M* 0'E<\N
MHX^4?W5 P!P =-?P+<Z?<0NTBJ\; F.1D8<=F4@CZ@UXS!:B/X$^&I(Y9O,G
MO;$DO*SA3]H'*JQ('T&*]M(!4@\@C!KDD^'6D1:##HL=WJ*V,$ZSQ(;C=L*-
MN11D'"@G.._?- &-/J-]X5\9Z];I?WM_:Q^'FU40W<IDQ,CL/E_N@@#Y1@5-
MI=IXCO%\.Z[;:G"D,HCDOC+J,DL=U'(!]V(H$1LD;=N/3FNG_P"$8M&\1G7)
M;BYENFM/L3HY0QM#G=M*[?7G/].*SM#^'VD>'[Q9;.YU-K6-S)!837;/;0,>
MZ)^)QG..O6@#<UG1--\0Z:^GZM9QW=HY#&.3.,@Y!R.0:CA\.Z1;ZXVM0V$*
M:BT MC<*,,8QC"^G8>_ K3JGJLEQ%ITK6MO<SS<!4MFC63D]09"%X]Z /)?!
M?AS4O%GP7L]$6\MK33;F:83RA"\Q07#,54<*"2.O/':NK:WBL_B]HMM"-L4/
MA^:- 3T42Q@?H*=X9@O/">D+I>G^%==>T1F:-)[NS8H6)8X/F@\DD\YI9XKZ
MX\30Z\_A?71=16[6RH+JS\ORV(+*1YG<@'.<\4 8(U74+>;PM>VVJWM\+S6C
M:W%\9"MM=(_F?+'"6( 7: & 'W<@G.:FEBU+4-5\?V\GB#5HXM-\M[40S^68
MV-OYG50. 3T& >^>,,A\(I#8V5DGAKQ3]GL;H75HG]JVP$!&?E7$W"_,??WK
M2CT^\BGUJ9/#GB(/K"A;H_:[(YPNP;?WG'R\?_7YH Z+PG,VM>%/#^KWP$M[
M)8Q2F0]G>,;F Z G)Y]"1WK0N]-M6TB^M/+417,<@ESSOW*022>O%5?"MH=/
M\/6MA]CO+2.U40Q17<D;N$4 +S&2",<=<\<U+K_VN72+BST]";RZC:&*0CY(
MBPQO8^BYSCJ<8% &)\+;^XU+X8Z!<W3%I?LWEEFZD(Q0'\E%:_BK3[W4_#-_
M;:9=SVFH&)FMIH9"A$@&5!([$\'/K62_@Y;4>&+;3+F^MXM&VJ#'/MB>,;=P
MD3^-F ('8;F/H#UU 'DZ^+FGO_!NN0W-X-,FC2WU6(W#^7#+)E(RP)ZB1'#9
M]03U%6/&"S7'@6*_-Q.?M^M6L\ D<N(HC.OE[03QE<,1ZL1V%=<_@C0I-!U/
M13:8LM2N'N;A0<$R,P8D>F"!CTP*M:]X<M/$-A!8W,L\,$,J3*MN57YD(*]0
M> 0#B@#GM-%YIWQ/O=$&JW]Q9W.CK>_Z3+YABE\TH2F1A01S@#&>U8.C>)-2
M7P7X=@N=1N'FU379;":\D?,@C$LO ;L2$"#'0'C! KO?^$:@_P"$D.O?;+O[
M<;3['G*;?+SNQMVXSNYS_3BL[_A7NB-X6D\.S&ZFL6F-PA>0>9%(6+;T8 $'
M<2?Q(Z<4 9OBK2;C2O"7C0G6)[FRN=*E>WLKAVD>W*Q,'(=F+,I)!P> >G6J
M%C]MT?7_  $8]5OI8M5MI(;JWEES#A;?>I5.BD$=1R1U)KIX_!5BNA7VES7^
MIW0OHO)N+JYN?,F>/!&S<1@#!/0#J3UYJ1O"%F\^B3->7I?1@1:'<G&5V'=\
MO/R\?_7YH /'<US;> ]<NK.[FM;BWLI9HY82 P94)')'M7-ZOJFJV6GZ!J,U
MIJ6HZ/\ V<IOAIUPRW$<C!")2%8,ZX#\9[DGH*[?6=*AUS1[K2[F25+>ZC,4
MOE$!BA&",D'&15!/#*0-:/;:IJ-O):VPM%9&C.^,= P9""1ZXS^9R 3^&+NW
MOO#&FW-IJ#ZA ]NNV[?.Z7 QN;/.<CGWS6M5/2=+M-$TNWTVQC\NV@7:BYR>
MN22>Y)))^M7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "J6K7-[9Z7/<:=IYU"[0#R[43+%
MYG(!^9N!QD_A5VN-^*L]U:?#C5KNRO+BTN(51DDMY"C<NH(R.<8)H [(=!D8
M-%<'K$5S=_%6PTXZIJ$-C<:1/)+!!<-&I*R( 1CE3SU&#Z$5@6/B"_L/#\>F
M2ZC<M&WBR31?M<LI:5+<.Q WGG<<;=W49XY H ];HKS_ ,627O@7P_XDUK3]
M5N)P]JC6MC<,9?L[A@C2*SL21\ZDKTR/>C7_ +3X9O\ PK?Z7?WEQ'>ZA%I]
MW'-</*MQ'*I_>88D!E*[LKCC(Z<4 >@45YOX6TJYUK5_$+W>OZUMT[79$MTC
MO"!M\I/E;U7YNG;''4YY=/[:7X.6OC./Q)JS:O8EYE$ER3%*HG92CIT;([G)
MZ#H * /<**X73+J3Q9XK\36%]->6\6FBWA@@@N'A9-\>]I"4()8DX&>@7CJ<
M\LFL:YJ7AWPM]IU6\BNE\2'2I[B!]GVF)3(-Q X)^0>V0>* /8ZAN+J"T1'N
M)5C5Y%B4GNS$*H'U)%<1-I:V.M6FAQ:QJ^H[;*:06+W;K(-\@Q-).&!VKRBC
MD]P#@UR?F3Z]X$^&]_J=S<S7<FM10R2BX=&89E&25(^;"#YNO7GDT >TT5Y[
M*;[Q#X@\2:';S/&-,2""W/\ :4T$D>^(.)3M!+G<>K$_<]SEMC>ZE=^+=(\)
MZQJ?GFVT=[RZGM)&C%W,)?* )7!PH#$@8R3STH Z?PYXC.OS:Q$UB]HVFWS6
M;!I Y<A5;=QP/O=.:'\1F/QQ#X;:Q<"6R>[6Z,@P0K*NT+U_BZG'2L#X;VPL
M[WQC;K)+(J:[( TKEVQY4>,L>3Z9/-,UNR&H?%_3+9Y[B&-M$N-YMY#&[#S8
M^-PY7Z@@^] '?T5Y+8^(=2L?#<6FM>S3 ^*IM&6YN+AA)Y*LY4&7!8$[0F[K
MSQ@X-:>KZ9KFBZ1XJN?[7>WM'TR6XM+:.]DFE@FC0DLDC@,%/&1V./6@#T>F
M3,Z02/%'YDBJ2J;L;CC@9[9KS*5[O0O#?A^_75]0GN->EL;2X-U>,(XPT;,2
MAP?++8"DCGG/7FMA-(UG3)==>353#87-BTEO:)>R3RP2H/F='< A3D9'8X]:
M .NTV>ZNM-MI[VS^Q74D8:6V\P2>4W==PX./45:KR5;O4[GPG\-9AJ]_%-?7
M$$-RZ3',H:%V);.=QRHZYKI/")GL?&_BS1?MMW<65J+2:!;J=IFC,B-O 9B3
M@E0<9XH V=2\1G3_ !9HNAFQ=UU03;;GS  AC3>1MZGMZ=:W:X+QK:&^^(/@
MFV%Q/;B0WX,D#;7 \D9P>V>F1SZ8/-9MCI6K2ZCXO\'P:[J9A@@@N=.O'NG,
MUM)(K?(T@.67*@X/;\Z /3Z*\_\ #&LOXKAT& 2W4%SIR/)JL:W#AEF3,0BD
MYRP9PS\YXC]ZO?%2>ZM/AUJEW97EQ:7$(C*202%&YD52,CG&": .RJ*YN(K.
MUFN9W"0PHTDC'^%0,D_E7":O'<:%KNCZ3!J5]<KKEW+),;R^9!F.+(C1U4F,
M,><+Z8& <5'>Z)J5EX5\86VI:DTUHUK)<V=LE[*\EL/*?*M(<,R%AP#QU'-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %9GB#0;/Q+H\VE:@9?LDV/-6)]I8
MY SUZ@=/2M.B@#%;PS:OKMMK37-VU];VYMHW,@QY9()!&,') .:I'P#H4NC:
MEI-Q'-<6FH7#7<RRRDD3,<EU(P5.0#QQ^M=/10!@Z;X1TO3M.NK*0W6H)=Q^
M5/)J%PT[R1X("$L>%&3P,=32Z=X3L-.-EB:[N8[ $64=S+O6WXV_+QDD*2 6
M)(!(!YK=HH Q=+T&R\.R:C=V\EVYO9C<W(8F3=(0 6"@9S@ 8'ITKDOAUX6$
MG@/3K/6(]1C\F9Y9=.NE*1[Q*SJ2"H)'W6QG;GMFO1Z* ,6[\,65SK3:O#+<
MV5^\0AFFM9-OG(.@<$$''8XR.QJ&Z\&Z3<VFEVBB>WM]+F6XM4ADV[91G#D\
MEC\S9SG.3G-=!10!AZAX3TW4M=@UF5KJ.]B@^SL\%PT7FQ9W;'VD9&<FJ4?P
M^T&'P_;:+$MVEK:W0N[=ENG\R&0$D%&S\H&X\#CD]^:ZFB@#EM5\ :+JNI6^
MHEK^SO88A 9[*\>%Y8QT5V!RP]^OO5C4O!>D:BVFR*L]E<::NRTN+.4QR1H1
M@KGNI[@YKH:* ,;0_#&G>'Y[Z:R-R9+Z7SIVFN'DW/@#."<9X'/7WIT_AVTG
M\1Q:\9KE;Z* VZ%7&T1D@D;<8Y(!SUK7HH Y@^ ="DT74=(N(IKFSU"X:[F6
M60DB9CDNI&"ISSQ_C2VO@;3+;1;W3#<ZC<)>Q>1//<W;2RM%@C8&;.U<$\#'
M6NFHH P[KPGI-_X67PY?1/=:<L:QJLKDNH7[N&&#D8&#UJ+3/!VGZ7IUU9QW
M6H3M<Q^5)<75TTTHC_NJS9VCD\#'7UKH:* .:7P/I:6.CV:S7@AT>0260$W^
MK8 @9./FP"1SGK5^R\/6EAKU_K,4MP;N_5%N-[Y5@@(3C'& 3T]><UK44 96
ML>'K/6;BRNIGGAO+%V>VN;>38\188;U!!'!!!%5KE8/">E7=_::;?ZG<2RJ\
MXMU$MQ.QPNXY(S@8X&  . *WJ* ,#POI0LUU#4Y;(6=WJUR;J:'C<@P%16QD
M;MJ@G!(W,W6K?B#0;/Q+H\NE:@9OLDQ'F+$^PM@@@9Z]0#QZ5J44 8FN^%=,
M\2:/%INJK+.D3K)%,)"LL;KT=6&,-4<'A#3[?0KO2?/OI8[Q2ES<3W+23RJ1
MM(+MDXQQQC':M^B@#F[WP/HVH^&;;0+Q)YK.TV?96,I$L!084HXP00.],?P)
MI,OAVYT2>:_N(+L@W,T]TTDTP'0-(<G [ 8'YG/3T4 8FM>%=,\1:)'I6J++
M<11,KQR^85EC=>CJPP0P]:IMX$TF3P[=:+/-?W$%WC[3-/=-)-,!T#.V3@>@
MP/S.>GHH Q9/#-I-K&G:K+<7;W>G1M';L9!@*P 8$8P<@#.?2J%E\/M"T[5Y
M+^U%Y'')-]H-DMTXM?-SG?Y6=N<\^@.,#@5U-% '*W_P^T._UZ76#]MMKBX
M%TEI=O#'= < 2*I&[CCW[ULKHMJFNKJZ/.LRVOV18A*1"$W;L[.F??TK1HH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M -N*&RTSQ1"UOKS>6()(I=-FO3*2Y*E656);.%(P/7@=<QV?Q#T.^E*PK?\
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MSO;9=.N6O+I[JV>$Q#RROE?,!N8L0#MR, GTR ;/CCQ))X4\)WFK16LEQ+&
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M@)Y(Z4 7J*QE\26PM)YI[:ZMY(;D6GV>5!YCRD*550I(.=PYSCJ3@ FLJ_\
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MC66*1>C*PR"/J#6!<>.-+MK0:A)%=?V1Y_D'4PBF!6W;,GYMVW=QNV[??'-
M$O\ PANF?\_6M_\ @\O/_CM'_"&Z9_S]:W_X/+S_ ..UA^*]5GD\<Z!H;Z=<
MW6G3Q7,LT*>7MN2J+MZN,A=Y)#8YP1G%:6J7-K\.?A_>W4+7%Q!I\3O"MQ*7
M8EF^1-QYVY8*/04 6O\ A#=,_P"?K6__  >7G_QVC_A#=,_Y^M;_ /!Y>?\
MQVJ.A:&DWAZVU/Q#>3W.H7$*W%Q.UR\:0EAG;&%8!%7.,C!XR3FH+?Q/HWA7
MPO<7<VMOK%G#=$?:()1<NBR/\JNP.!@MMR3T H U?^$-TS_GZUO_ ,'EY_\
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M;6^W<(P0"Q+,J@9(')Y/3.#6?:>--(O]&L=1M3/+]NF:WM[81XF>5<[DVD@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQG%=O_PAFD?\]-5_\'%W_P#':/\ A#-(_P">FJ_^#B[_ /CM &'?V<]IX_\
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M0Q[/^^G/K7J5% '&>()-1@\5:5:+IE]+H)M'4G3EPWG;EVH[ @I'M'J 3C/
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M%%% !1110 4444 %%%% !1110 4444 %%%% !6-XD\2V7A:QBO+^*X>&6=(
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MN9" V>"><9 XK::;6_#?CK4=8'A_4-0TW7(("4M=C36LT:E=K L!@@YSG -
M%;6=;L]0\6_#[7[$74UO="\9(T5MSC[.<#9G&<DC/ZXYKL_#WB2W\11WHCM;
MJTN;*X-O<VUTJAXWP"/ND@@@@@@FN?U>#5;KQCX+OY].EQ:/=279A7>MN)(B
MJ*3_ !') )'H3TJQX1M;NW\5^+;BXL[B&"]O(YK>21,"11$J$C\0>M &5\13
M;P^*_!S7%R]M;7%Y)'=,+AHE=!'D!B".,@=:/"=U<2?$C58=%O+F\\*"S4F2
M29IH4N]V"L+L3D;<Y ) /IQ5SQK:7MUXN\(7%MI]U<6]A>2374D<>5C5DV@^
M_)Z#/2FZ7IVH>"?%$]K86,]UX7U(M<(D"Y.GSG[PV]?+;K@=#GB@#6U;QM8Z
M1:W-]+:7DVFVDWD7-["J%(FW!6X+!F"DX)4'!SZ'$]WXLMK>2_6VL[J^6PC2
M2Y:VV'8&7>.&8$_+@\ \'\*XO3+"]T'4M3T:]\$_VOY][-<6.HK%$T;)*Y?$
MS-RNTL<\$XZ#IF;Q3H-Q<ZC?7VDVFHZ;XEM4CCL;VP0B"] 12$D'*[0Q9?GQ
M@ <G&* .A'BJ];X@W>@_V5<&UMK%+@R(T9+EF(W8W9VC:0 .2<\=*;I?CZSU
MQ5:ST;69+=S.CS?9ALC:(D%6(;@G''U['.*R6VJ6'Q/DU*;3II[:[TB&!KBW
M *1R)([.""<]&R, YZ4[X?07FE^$+F"_L+JWG2[N9?*>/YF5Y6=2N.N010!-
MX=U_0;3P9HDNCVMREG>DQ:?9D[IG.6)'S,>RLQ);  ZU3\0_$(V/A3Q%>V.F
MW2ZEI!$4T$^P>4S#*R$AB&7D'Y22?05S>FZ)XAT?P;X(U&WTFXFO_#\DJW>G
M'"R/'(&5BF>&(!!'/.:Z/Q6FL^,/ASKT-OHUS:/<6X6UM;G:L[D'+$@,0N<
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MBJ3_ !!L$\'S>)3I]_\ 9(+AK>:+$?F(PD\LG&_!&[T- '79&<9Y]*0D 9)
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:Q;^#W@8!!%IP>*.>3GYG<@E5 !X&2?E/K73V%VNH:=;7J(Z)<1)*JN,,H8
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M/B7QAX=UAK"YL;?2$N)'^T@*[22($"  G@#))Z=,9YQV+,%4LQ  &23VH!#
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MF^*1)%SC*,",T >=1:7K5GIWC_3?['N)/[3N+JXM)T>/9*)8515'S9W9!SD
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MTE5<#);=N!!&,?B!S7K%% 'GT\/B"?5[*UO=#NKC26TM(XX%FB$<=UDAO/\
MG^9<8Q]X>@)Z8VE:+KT'ACP#9SZ'=)-I%^)+I=\9V($==W#>K#@<X'2O6J*
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M '.W(R,CC/6L3P]I&KZ5J/C!SX?^SVM^4EM(X)HL,?)5-@&0 <YSG ST+=:
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M:; M^\6_2A<_9GNDG3<IW[-_EYR4W<9Z]P",&I9/&\I\0:CH]GX=U*ZN-/>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH ***P]=U^YTN5;;3M%O-7NRGFO%;LB"-,D LS
MD#)(. ,DX/I0!N45C>&/$MGXJT9=1LTFB D:&:"==LD,BG#(P]16S0 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *IZC?Q:=;&9D:25R$BB3[\S]E7WZ^P&2< $U<KGM=\'V7B#4(;VYO\
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MGAC='\F2Y^5]I! ; &X9 R#UH XWQ?<7GAWQ:A76;Q-(UB);>Z+7,K?V6S.
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M.ZUZ?5E:^MY+H@W<%M=O%#=$?\]$!PWOZ]\Y-=2T<;Q&)D5HV7:4(X(],>E
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MKDC.1UH ]C)"J68@ #))[5SFL>+4T\>'IK6U%W::S=Q6T=P)=H02*65L8R>
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M'=:@)X'EMW19$$:+D$CU4\=: ,/1+RQL_ GC%M:DOYM.AUB^AD,;R22B(-@
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M-]3FN2P4XCRI4$G V = ,Y[T =917.Q^+H&U:WTR73-0M[J[MWN+1940>>$
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M!%CX;_$I!+/_ */J.HF-O.?<NR-2OS9R<8'6@#URBLSPZ3_PB^DGJ?L4/_H
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M1F5XX "Y4#)(!(S@<XS6/_PFMCG0"+.],>N@&TE CV E=^&._@[>>^>@R>*
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MF);IYH52[,P) X^[N('6O0-0UU+.YEM;:QN]0NH81/+#:[-R(20I.]E&3M;
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M.,Y&!P:CO[S6=<'@Y_\ A&-5AN-/U*.2]1XU58\1.I*L6 9<G(/3'OQ7IU%
M&=KL]_:Z+<3Z7;FYO4"F* $#S#N'RY/ R,C/;K7"^*]%A\4ZEH][I>BWUEXA
MM[R&1KZ2W,/D1*<N'?[LG&0 I;D^F:]+HH \_ET;49?&OC"V:RN5M=>T^"&&
M^3;Y<16.1&W'.007&  <_K6;)I.JZW\+;3P1=:9<VVI1K;V<TK1GR4CB=<RK
M)]U@53( .[)Q@=:]2HH \\M)M:\(^+]>B.@7^J:?J]RMY:7%D$;9(45623<P
MVCY1@],?I3\7^&M1\3>+-*29+JV,>F2(][:HQC@N2\;I_O+E.<\>N#T]/HH
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M.>O;ME-+7Q!9V/A#3KW1-3_LR+2A!<Q6I02?:5" "0AQB/ /<9/WNF*]/HH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_ETRVEQY@P<R2?*>/N^U='XOT"U\3:$VEW-W):222HUM<1'#Q3*=RLON,=*
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M_B=KNS%];:%JTMBR[TF$<8+I_>$9</C'0;<GL*Y?XU2R1>"K3=G["VJ6PO\
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M-:I-%:*D;D;2^$9<M@D9/ R< 5#'IUJL^M^9X<\336>L,TEU92?9_)WLH5F
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M6US'<H> =R'O[$9!'H34/BCPK8^*K*"&[EN;>>VE$]M=VLFR:"0=U;^E;E%
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MU=>>*.:*)Y%624D1J3RV!DX_"F7DTMM8W$\-N]S+'&SI A :1@,A03P">G-
M'.6_@6WBU>RU2;6-6NKRUMGM?,FF7][&Q!PP50."HZ8SWS5FR\)06UQI<USJ
M%Y?G2E9;,W.S*;EV$DJH+';D<^O.3S6U9S27%C;SS6[VTLD:N\#D%HV(R5)'
M!(Z<5/0 445B>)O$:>&K6TN)+.:X2YNXK7,;*!&9&"@MDYQSV!H VZ*Q!XC3
M_A-?^$:-G,LIL&OA<,R[&4.J8 !SG+=\=.];= !1110 4444 %%1S3Q6X0S2
M*@=PB[CU8G  ]ZDH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML_,N-@*PL<LHV*HY(&3UXH \\A^WZ;\-OA^^FZM>VK7EWI\,N)-X*NHR,-G
MX^Z"!Z@UO:I!J/AW7_"%E%KVIW4%UJ,R3+<R*QD4QNX!(4$@$# K27X>Z<FC
MZ9I8U+5/L^FW$=Q;%IE9D:/_ %8Y7&%[#OWS6KJWANWUC4-+O9[NZ2739#+
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M9D:3R]JE68@-@X+;-N<9^;CGFKQ\-P'Q3%XA-Y=F\CM?L@7*;#&6#$$;>I8
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MUO%C^SQJO[R5Y" L8&?O$G'7'OCFK?B*SU34-#NK72+Z&RNY4*K-+"9 N1V
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M>SV;PL[WGFJ!&X( 3;U.02<].*NUP4*7FC?$G1M)&K:E>68T6=F2YGWF1T=
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M:T[6/(\C[9 LWE;MVS(SC.!G\J -6BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[B\TF>29Q*REB(8F[$8Y8]/6O5* "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M>HQ2V-NMPT11':52'P(]C$,?D(QGKCUKB(K:ZN=7\<7-]X7O[G3=3-D$AEC
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MW8YZU6\10ZEH]OX=L=.M;VYTJ.4QW[V0S<;0A"D'((!;[S#!]^:XV\T75_\
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ML\HGE,0RL0>#QD=L=2#D"+PS>"_N()Y/ DFC7-JK-=3S6D:A3M(*P%<L^3W
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MQ/-+"R)%'$BL65SPQ;  "DGYN<8- '97WBZTLUU"2*SO;RWTUMMY/:HC+"0
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MK(NUXW4X96'8@BM.LOP_%Y>EAAI46E)*YD6T1%5D!Z;POR[CU..F<<XS6I0
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MYU^;17TK4+>[%JUW;"=447,8.T[?F^4Y(X?:>><4 /\ ^$+T;_J)?^#6Z_\
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MJQM+N318YC#)J$84QKAMA?;NW% V1N ]^1S0!9_X0O1O^HE_X-;K_P".4?\
M"%Z-_P!1+_P:W7_QRGKXIMW\32Z"EC>-=+9_;8Y!Y?ESQYV_(=_)R<<@?EBJ
MVG^-;34_#::W;Z=J!C>Z^RK;,(A-YGF>7@C?@?-ZG..>E $W_"%Z-_U$O_!K
M=?\ QRC_ (0O1O\ J)?^#6Z_^.51N?'T$5WK-I!HFK75QI 1KE(HXQ\K*7W
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MW;=R;6/?C#8(R* .DHKA(_BKI3V&G:F^EZM%I-\XC&H20*(HF+$ /\V<9'4
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MKH/$GA^V\4:++I5[/<16TQ4R>0RJS;6# 9(..0#Q6I&A2)4:1I"!@NV,M[G
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MW#$%>QZ'ZX]>HH \W\1V6H:EX4MOL7AF2S=]4MKE;*)$$BQ1NK,TFT[0QP<
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M '$S:?<:IXR_X2465U#;6>E26L221[99Y';) 3KA0,<XR6XX&:N_#BSN]-\
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M?;%F9D\MX]VWY><YSP1BN/\ %6I1W^H^"=9&GSH_]KO'&N%9Y$$<F"N#C#$
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MQW,Q@9HRDS?(H<AC_"&8<\\G%7_'MG>ZQHVE+I-F]\5U*UNV\IT $2.&)RS
M'CIBFZC9ZE+\3M'U2+2[A["WL)X)9P\>%>0H0,%MQ^Z<\4 :K_V5X#\(R&&"
M==.L$9EAC+2O@MD*N3GJV!S@>P%1VWB@R:S>:/<:9<1:A;VBWJQ(Z.)8F)7Y
M6R!N!!!!Q]34GC(:VWA.^'AT9U3:OE ,%8C<-X4G@-MW8)[XKEM*TS4K3X@-
MK,/AJYMK"?1A;G?/$TOFB0L?,^<DL1CG)[9(YP 7K/XE6UY8Z-J7]C:C%IFJ
M7"VR7<FP+'([%4!7=NP2.2!@9ZFMO3_$T=]XHU+0&L;BWN;&-)B\I3;,CDA6
M3!)(X.>!@\5PEOX>U^'X7>&-';1;@W]AJ,$UQ")8OE2.8N3G?@\=,'-;WCK1
M[RXU70M3TB<6NI2R-ILI/5K>527Z?Q)M\P=LJ: )M<U:6Z\$S^*]/MI+:ZT]
M'NH/,8?OHHSEP=I.4=5./^ MP0*ZO3[Z'4],M;^W),-U"DT9/]U@"/T-8/C5
M8]/^'&KVEK#PU@UE;0H.K.OE1H!]645+H<=_H=MH7A_^SGFM8-.6.:_65=L;
MQJJA=O4YY.?\@ Z*N#^(/AW3X_"?BG6FBWW[VCRI,S',16(*-G/'W<\=S7>5
MSOCNTO-1\#ZQI^GVDEU=W=K)!%&C*OS," 26( % &1I/A32)/"6F:BML$N&T
ML><5)Q,'A&=PS@G.#GKQ[UD^ _%BZ3X+\'6=UIEXMI>I'9QWWR>7YS E5VYW
MX."-V,9KL-)BN[?P+:6TUC,EY#8)"UN60L7$84@$-MZ]\UQ46@:['X!\$::=
M&N#>:5J5K/=QB2+Y$C)W$'?@]> * .KUKQQ::1%J%PEK)=V^FMMO'CE0%" "
MP56(+E003^0R00-Y-2M9=(758I-]FT'VA74?>3;N!_*N!M[/7?#GB36+=?"J
MZU8:E>->VMVLD2F%G W1R;N0H(SD9X]>@]!BMRVG);7*QL3$(Y0BX0\8.!V%
M '#> K:+QGH"^*M?@CO9]0ED:"WG4216L*N55$4\ _+DMC)SS5RPU'0=$N_$
M,^EW$]W]GA26XTV'):VV!B0H<@("#D+QR#CK5?P=IVJ^ [.7P]/8W%_I$4SO
MI]Y;;698V);RY$)#!@2>0"#GM5>RT35_MGC_ %5M,F1=:BB2RMV=/-?9"T9)
M&["Y)XR>G7% &E;_ !!2?24U1]!U2.RF@@EMI2J$3O*P54'S9!!8<G QSTQF
M]'XPC$FN6]QIMREYHT23SP1LC^9&ZE@R$D \*V0<=*Q#:^)K+X5:+8Z?8W$>
MHVD=K!>6R2HLS1)M$HC<-M#$ X.<_0U2M-&U:VUWQ5<6_AN:WM-4TN*.W431
M;O,59 5?YOODL"3DCJ2V>* -RR^($-V^@R2:/?V]EK05;:[EV;?,9"X0J&W=
M 1G&"1QQS3=(\874^M^*%U.T-IIVD2!3*9$(C01[RS8.22#GC..!6*=%UL>%
MOA_9_P!CW)N-(N[:2]021?NUCB9&.=^#RPQC/%3W'AC5KZ^\=Z4]FT5KKBA[
M:_\ ,7RQ^X"8(SNSN'IC&>>F0#=A\<6IUW3=+N[26V.IJQLY&D1PS*,E'"DE
M&QR.W;.>*@N?B'IMJ+*ZD@D.EW=R+:.\61" Q)"L4SN"$C[WT.,56\,RZ]>+
M;V6J^$HM,G@7;=7V^)DDP,9B"_-ECSS@ 9Y)Q69X2L?$.B6<'AB[\+02M:-Y
M46L[XS"T(/RN5^_O XVXY(Y('- '?ZQ/%;:->S3VTEU"D+F2&/&YUQR!D@=,
M]ZY_1O$6F0>'_#5OI-@8EU.VWV%FT@79&J!B"Q)Y (Z9)SZ9(W]:2630[^."
M%YIGMW1(T(!8E2 .2!W[FN"A\-M=>!_#&AZ_X;N9DM;39-)#(OG6<R! CH5?
M.#\WW<]!D8H [_2[YM1L%N7M9K5R[HT,V-RE7*G."1VSP>AKFKGQ[Y=WKEK;
M>']3N9]&VFY53$HVE-^X$O@_+C ^\<]*T?!=GJ]AX:AMM:N)KBYCDD$;SL&E
M\G>?+\PC@OMQFL*VTW5HM=\>73:3<>5J<<0LR'C_ 'I6#RR/O<<^N.* -X>+
M;*XM]':QCDNI]7A^T6D PI\O:&+.3PH&X ]3D@ &L?5_'QM_#'B.ZL]/D75]
M%0BXLYV4>42NY9,@X9".1CDXQQVQ=)\/:YHH\&:Q_9LTDNFZ:=,U&R5T,BJ0
M,2)\VUL,O(SG'2K6J^$]1UBV\<:C';-#<ZS8I:6=M*RAB(T(RV#@%F. "> !
MG&<  [C1;JXO-'M9[J!X97C4L'923P.?E)'-8.L>/[#2+:[O3;23Z?93^1=3
MQR)E&#!6*H3N8*3@_0XSBMOP_)=2:':?;+&2RF6)4,,KJS#  YVDCKGN>,=.
M@X;2['7_  YJFIZ2?"L6JVMS>S7-CJ/F1JB+*Q<K-N^8;23R <]A0!T,WC93
MKMSH]AHM_?7<5JEVGEF-4EC<D ABP '!ZX/H#67J7C^:?P]X:U71;"5X=8U&
M&U;S&57B^<ATP3C<=C+GH.N>E6[.PU.V^)=]J<FG3-8MI,-JEPAC"O(CLQ 7
M=D [AC(KF;/PYX@MOAYX:MFT:<WVDZZ+Z:U$L6]XO.E?Y3OVDXD'!([T =?_
M &EI[_$&&UDT6X36AI#S)<,R8\G>N8P0W7<>X'3K@UR]WKEYXK^$WBRZU/3_
M "?+BO1'\ZLJF/<% P<DC;U(Y-= ;+5)?BE8ZN^ES)9+H[VLDOF1D)*TBOMQ
MNR<!2,@8S6':Z+KT'P[\5>'FT:8W,[WPMG$T>V?SF8H5^;@8;G=C'OV .FLM
M>AT[1=#L4C$][-IZ2I%YBQ@(JJ"S,QP!E@!U))Z8!(CL?'^EZAHR7L,,_P!I
M:^.G"Q^7S?M(ZIG.W 'S;LXV\^U8%]I>NZ;>^'M?M= .IK#I@TZ_TUWC$L8!
M#!T))4D$$=>GZ3:[I6OW46A>(;+18XKK3+]K@Z2DB!V@=-C L/E,G4]<<XR<
M<@#M!9W^,NN&6P:SE.DP%U+!A(?,?YP1U&,#G!R#7H=</I$.K7/Q,N]:FT2[
MM-/N-*BMU>=XMRNLCMAE5R>A[9[9Q7<4 %%%% !1110 4444 %%%% !1110
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MU/WR%()Z#L"3D!C>(-'U#Q7X::/2VGGO[*:YT_4&V@)'L4L!SN!(*YR!U^M
M'845S&F^,%OK77Y9K%K27197BGAEE!)VKOW# ^Z01@]^>*?>>+!:RQV?V:%=
M2-LMU+;7%VD0B5B0JESU8D,  ,?*<D<9 .DHK'\+^)++Q9H%OJ]B'6*7<ICD
M W(RDAE..."*IW7BQMNJRZ;ILFH0:4YCNV24*Q=5#,D8/WV4$9R5YX!)H Z2
MBN/N?B!:B704TW3;O44UN*26SDA9%#%$W;3DY!Z YP!SSQBNBLI&U71HGU#3
MFMFN(OWUG/M<IGJK8R#0!<21)4WQNKKDC*G(XX-.KQ_P/XR;PM\--"EN]#O6
MT9"T4^I(R;(2TS '9G<5!(!;'TS7;ZUXVMM+DU".WBBNGTZ,27*-=)$W*[]J
M _>;;@XX'(YSQ0!U-%4='U:UUW1K/5;%BUM=Q++&6&#@CH1ZCI6')XTS;0ZC
M:Z5<W>DRW?V07,!W.3O*>8(P,F/<,9SGO@C% '545R)\;7$OB'4=&LO#E_<S
MZ?- D["2)0$E&=X^;D 8..O7IBJ^H_$O3-.A6_9(Y-*^T_9GN$N4\Q3NV;_*
MZE-W?.<<XQ0!VU1_:("B/YT>V0[4;<,,?0>M<UK.MKJ$.MZ;9Z8-2CLH2E[N
M<*NXIN\M00=[A2"0< 9'.>G*^'-0T^R^'GP]BU'26O1<3V\5M+\NVWG(;:_)
MSD -C _*@#U.BN.T_P 3ZC-X[\1:==VL<.FZ9#;MYGG#Y%99&,AX[@ 8[;::
MGQ%L/[0TB*6%5M-7D$-K,EPCNKL,H)(QRF[MR<=#B@#LF940N[!549))P *%
M8,H92"",@CO7F_Q UM=;^'GB8V>F"\T^VCE@-RS@'S$X+QJ1RJ-P6R#P< ]^
M\T;_ ) >G_\ 7M'_ .@B@"[1110 4444 %%%% !1110 4444 %%%% !1110
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MQ\5YM8.F3#36TE+$7'F1\R"9GSMW;MN&],\=*W/$#ZK'I?F:- L]XL\1\II
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M=C@\?06_AY((=:M$2RCAN(@ WV?R]I&0!@\GMUQNZUJ:]X?UN_\ !?AJ2QM
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M<&KU% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)'2YW26^T/CS8]N!DJ!C/&X=: .BM[NVO%=K:XBG5'*,8G#!6'4''0^U9O\
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M3N .>I&=I[8S:U7QS#;2WL6G+97$ME"DLJ75Z+=G+)O"(-K$MM(/.!\P&>N
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M[M8I0%12C*$0G!8@,.3C..V<#M4=)$5T8,C#*LIR"/44Z@#B=<TSQ)I?C/\
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MV]W!--;D":..0,T9.<!@.G0]:+F^M+-X$N;F&%KB010B1PID<@D*N>IX/ H
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MDL%E,N7CE9PX?;C! (]: $L_&UVVM:#I^H:9':OK4<CQP&<^?;%4+@2H5'4
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MQZQH\XG6WFD/ERJ5VNF\#C(Z'% %#0_M8^,NM?;+>WAE_L>#!@8LL@\U_FY
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MCL-+LXK2UCR5BB7 R>I]S[FKM% #51$+%552QRQ QD^IIU%% !1110 4444
M%%%% !1110 4444 %%%% !1110!GZSHFF>(+ V.K6<5W:EP_ER#C<.AJY!!%
M;6\<$$210QJ$2-%"JJC@  =!4E% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
%44 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>a109-2021formrsuawardemp002.jpg
<TEXT>
begin 644 a109-2021formrsuawardemp002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%YO^ADUS_O\ Q_\ Q%'_  B\W_0R:Y_W_C_^(KH** .?_P"$7F_Z&37/^_\
M'_\ $4?\(O-_T,FN?]_X_P#XBN@HH Y__A%YO^ADUS_O_'_\16;J7@>^U"5(
MCXPUI=.=&CNK4F-C,",8#[1M&.#P?PKLJ* .>'A:50 /$>N #@ 3Q_\ Q%+_
M ,(O-_T,FN?]_P"/_P"(KH** .?_ .$7F_Z&37/^_P#'_P#$4?\ "+S?]#)K
MG_?^/_XBN@HH Y__ (1>;_H9-<_[_P ?_P 11_PB\W_0R:Y_W_C_ /B*Z"B@
M#G_^$7F_Z&37/^_\?_Q%'_"+S?\ 0R:Y_P!_X_\ XBN@HH Y_P#X1>;_ *&3
M7/\ O_'_ /$5C6?P]O+7Q+?ZNWBO4F%XB1LB*JR83.W+\@XR?X17<T4 <_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBH+N\@L;<SW$@1,A1P268G   Y))X ')
MH GHI%.Y0V",C.#U%5VOK=+]+)WV3R(7C5A@.!UVGH2.XZT 6:*** "BBB@
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M $$$'D$=Z6@ HHHH **0D*"20 .23VI: "BBB@ HHHH **** "BBB@ HHHH
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M!Z CL.M #+[6?&.E:7XGN)8 +6RL6N["]O(H]S,JDM&Z1O@].&P/<&G6NO\
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M!S>H^(=9U[X=Z#?O>_9KB378;2X\F(*)0MSL!(/3[H)'KQTXKU"YDN+/2)Y
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MI8;&F!0I\Y+GYL'J ![4 0Q^(M:UOPSK'B+2+J*%;*:=;2T>(,DZ0D@^8?O
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MR2Q,,,DB;^01CD,,'D4 8VO^(]9CT?QQH4U[Y=]I5C]JMKZ&,*TL+H3@CHK
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MTZ]DL[6WF0%)WBQO,K=0"20-N,8!).>*JMJDGQCC@EU%DA30A/\ 9U0,B$S
M.H.,\[!\W7BK0\$ZE8>(-1O-$\1R:?8:G-Y]Y9_95D(E(PSQN3\A;OD'G\,:
M$OA61?%]GKUEJ)MEAL182VYA\SS(@^\88GY3G@G!R/0\T <]!XF\4ZQI-AKV
MAV,UQ%<3AC9,D*Q-;%B,ARX82 <YZ9XVU;N-6U#Q-9>*S87BVEKI<DUC&OE!
M_.E2,&0OGG;EMH"X/!.><!VD> ]2T2>2QL?$LR>&WE:1=--LI>,,<M&LN<A"
M2>V<'@@\U*?!-]9ZKK4VCZTEK8:R6DNK26U\W9*RX:2-MPVD]\AA0!<^'/\
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M,L<J0HSD]?;BK&K>#-2UKPQ+IE]KXDO)YHI9KLV@VXC<.JI&& 497N23D_@
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M_E@+YQV[=P8]"?N_6NH\)S>()=(=?$ENL5[%.\:.I3]]$/N2$(2%)!Y&>HH
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MA1FVC!/7D'MCCK6M0!APZ-J%Q?VUUK&IPW0M6,D,%M:F"/?@KO;+N6(!.!D
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MPHP  !V'<Y-7Z* .>D\.7#^.(_$BZ@@*69LOLQM\@QEPY.[=][('.,>U4(O
M\EG;ZOIVGZJ;?2-4DDDEMC!N>$R#$GE/N 4'G@JV">*VM,\16>K:QJNEVZ7"
MW&F-&L_FQ[ 2ZEEVYY/ ].XK6H YD>$1#XFTK5;.[CM[?3;,V4-H(,CRCMR-
MV[K\HQQ^=2S^'+B7QM!XC74$7R;1K,6YM\@HS!B=V[KD#MCVKH:* .)@\!7>
MGZK>MI?B6[LM'OIVGN=-6%&^=N7\N0\QAO8<9X(XQK)X;DC\;'Q&MZH7["+
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&0J2S@%<$%1C;C XZ<5FO\/K1=(TZSL[Z:TGL=1;4H[B.-#F5BQ8;"-H7YR
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MP#,A12JA^>F&/3%6YO!X;7M9U.#5;JW&K6ZQ7$"*N-RH45PV,C ;. >H'TH
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MEK@SQN#&\0(R"RL 0".02,&H[3Q!I6I7CV%I?H;KRO-5,%69.F]-P^9?<9%
M&K17)?#W4;_4M$OWU&[>[FAU2ZMUE=5!*)(5484 =!V%=7)(D4;22.J1H"S,
MQP !U)- #J*P[+QCX<U*Z@M;+6;2>:='DB5),[U0D,1[ @_D:L6?B/2+^_\
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M#/@':N0>3@<&M&.1)HDEB=7C<!E93D,#T(/<4 .HHHH **** "BBB@ HHHH
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MZ0*JDD* 3R<#K0!Y-X:FO+&]T;3-%U>#6M"O+>4V7F@?:M+Q$2H8CJ@R$^8
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MA>PD5Y$AFB$01HALXR"#Q_M5ZI2%5;&Y0<'(R.E 'EU]86FG2:;_ ,(WK/\
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M!S7GOCCPQ-I'@BTU"QUJXFGT!XKNP298@'9,97*H&8LN>,G)ZYK6\5W">)?
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M/?*N^;[.LI1O*,N<;/,QLW9R,9SGCK55?%UF_C63PVL4_G16RS/(8'VY9L*
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M;G9>[IFD21-IV $D$DX ()->Q-&LD1C=0R,NUE/((]* ,D^*]%"::_VP[=3
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M?+)PFW(^8D\8&3GC&>* -^BLFR\2Z3?R7L4=T8Y;%0]U'<QM \2D9#%7 .W
MSGI3+?Q5H]Q?FQ%S)%<^2;A8[BWDB,D8ZLF]1N ]LT ;-%<PGQ#\+206EPNJ
M V]U*88Y_(D\L/N*X9MN$R0<;B,]1Q5_3O%.C:MJLVF6=V7O(H_-,;1.F^/.
M-Z%@ ZYXRN10!L45BGQ9HHOK:T:[97NI3#;R-"XBED&?E60C8QX/ /.#BJ5Q
M\0O"]JEV\FIY6SE\JX,<$C^4< DMM4X49'S=/>@#IZ*YG4_&=II_B31](6&Y
MF.H1R3":*WDD38JY^4J#N))7IG ZXR*WK^_M=,L)[Z^G2"U@0O)*YP% H R'
MT+4;KQ&UY>ZR9M*C=);;35ME41R*N,M)U<9^8#L<>E;]9%MXFTFZN+FW6XDC
MGMHA/+%/!)$XC.<,%=02.",COQUJC;>/_#%X]@MOJ8=;]_+MY!#)L9R2 I;;
MM5CC@$@GCU% '2T5BZUKMA9QW5H]W/'<) 9)#:PM*T"'.';:K!1P<$^A]#6?
M\-KZZU+X=Z)>WMQ)<7,T&Z261MS,=QY)H ZJBN/'BZ/6;SQ'I%JM]:2Z='Y:
MW'V9U._87)RR[5&,8SC/49R*I^!O&NGS^&O#=EJ.IR2ZK>VJ#?*CL))-N2ID
MQMWXYVYS[4 =Y16-J?BG1]',OVVY=$@*K/*L$CQPEL8\QU4JG4'DC@@]#6M\
MLT/ROE'7AD/8]P: 'T5Y'9:GK\GA/QGK'_"3WD5SHFI7D5L)4B:)HX0"J."F
M3G.,@@\BM2'Q#JFJ:O\ #F_>:>T35HIWNK)&Q&Q%N6!QU(SR,GTH ](HK$F\
M7:';W+027A&VY%FTHA<Q+,<8C,@&T-R!R>IQUIE[XST"PO[FQGOB;NV022P1
M0R2. <XP%4ENAZ9Q@YH WJ*J:9J=GK&FV^HZ?<+<6EPF^*5>C#\>1]#5N@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *P_%^A3>
M)O"U]HL-TEJ;R/RVE>,OM7O@ CG\:W** (+.*6&SABG='E1 K,BE02.X!)Q^
M=3T44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7.ZYX=N]5\2:%JL-
M[#"FE222>4\)<RET*$9##'!]#S7144 8_BG1IO$/AG4-'AN4MC>0M"TKQE]J
ML,$@ CG\:O:9;2V>EVMK/(DDD,2QLZ*5#8&,X)./SJU10 4444 %%%% !111
M0 5SWBWP]=>([?3HK>\AM?L=]#>DR0F3>8VW!>&& :Z&B@!%SM&[&['..F:6
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "L3Q7K']CZ)(\4@2[G(@MCM+;7<A0Y _A7.XGT
M%;=% 'F'CCPK+IO@>VO-.UF\GN-">*ZTZ.582&9,?+E(PS%ESWY/7-3>+-=L
M+O3_  EXF1[B!X;T2+NMY)%BW1-YB2JH+ XR 0#@\XQFO2:P=>T"]U+4+'4=
M-UF33KRS61%W0K-$ZOC.Y"1S\HP00>OK0!PL>I:%?^'?'MY8ZLEUJ>J6<DDM
MLL,D>P"$Q1JJN S$\9..2>@JUK*W)^%WA6]L+6XNH],>SN+NVM2RRF)(]KA0
M,$,I.<<?=KN=-TJY@N!>:G?_ &Z]$9B1UA$21H2"P502>2JYR3]T8Q6K0!Y7
MJ<&F>+/#6NWOA&QO;B_EL/*:\N3.K2;75_(7S>6R V<<#(&>:T_#NK>&O$6J
M6&HVVGZF=1L4D:634&N!_9X9"'!:0[23P, GCGM7H-% 'B1VGX /9^6WVDZA
MGR-A\S_C^WYVXS]SYOI76:PXNOBGIOV6<#S-$N85G7E5=V0H-PXR<$@5Z#10
M!Y%X3N-&OM)T?PYJVCZJ_B#3'B1K*<W!BCDBX$X;/EJH'S ^^ #D9GCEB.D_
M%)?XKF2?R1MYF!M@@V_WLMD<9YKU:B@#RR.X%IJ?PTU"2*=K>+3)[>1XX6?9
M*T,0"$ $@DJPP>X-=?X^NY++P1J=Q'ID>I%47-M)%YJD%@"Q0?>"CYL?[/:N
MDHH \QTC4+=?BK_:!N;^YM;C0 HO;BV=$=A,6./E"JH&.P'U)YP+,B+X,>$+
M=D9;B#5;9I(MAWQA;@LQ*]1A3DGT(]:]MHH \VTG5DT'QCXLL]9697U.=;JP
MG$+2+<Q>6%"*5!R5QC'O6M\*"P^&6AQO%+$\<&QEEC9#G<>F0,CW'%=G10!Y
MS97*Z?XO\?074<T;70BFA8Q-L=!;!20V,?>&WKUXK"B=(_AW\-XB"LMMJEFT
MZ;3NB"APY8=5 R,D^M>QT4 >2Q7>F:;K7B/0/%=EJTAO[^6XM! +AX;V&7&$
M C.W</NG.!TYKT^QCCLM)MH_)6UB@@5?*+Y$051\N[N!C&?:K=% 'EWP]T?1
M]7_X2A=2L(;AW\075Q$ES%D/$2I1PK<,N<X-;'BMXXOB'X'/1(9;HN0/EC#0
ME5SV )X&>M=S10!XGXCU$ZAH&M1M9W5I<VVN([V%M9LJ!!<(?/=@OSLX^;.<
M=,#C-=?I]Y;M\7=4NV8QPMHT"B252@R'=F7GH0""1U'>N]HH \Y^'>LVNB?#
MG1(;Q+A9)KZ6T6-8&9D>2>1DW #*C&#D\8(KT:BB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN$<[>H^;)Z<U)JOB_5QI7C#4K2:&UE\/W)AAM)8@PF545MS]&^?<0NTCH.M
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%95WX@L++7].T68S"\U 2& ")MA"+N;+8QT[9SR*U: "BBB@
M KE-:TUK'QMI7BE 3"EM)I]\0,[(F(='_P!T.,'T#9Z UU=4O[3B_MO^RO)N
M?.^S_:/-\D^5MW;=N_INSSMZXYH YJ^\'ZBOBJYU_P /:^--;4(T6^ADM1.D
MI085URPVL!QW%+XNT<ZMX<@\(V\DDKWCQ"YF<Y9(%</)(Q]6VD#U+<< X[$
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M,'=';[_E2$_)N^AQVKMJ* .,U#P9J4?B:;6_#>O?V4]Y&D=[!):B>.78-JN
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M +'&.O?)S6'X7U/6]#\$^ ;N.^A:PO;BWT^2R\@?=DW /OSG<",\8';'&3W
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M*7#ELAN#N QQP/7K59O!=U:Z[JM_H^M&RM=6^:\M'MA*/,V[3)&Q8;&(ZY#
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M>I7/C;Q5H\E_)]FL[>UEMB(TW1&0.6P=O/W1US0!T6I:DNF);LUK=W'GW"0
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M5MS>0S[NV.1T&/RXI9/&>J^&K#QG'J%T-3FT:>W2TFEC6,N9U78'" #"LW4
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M\V\MDMS"T&514R5.=V2<L<^OM6_10!Q ^'F/ \7A4:L_V:.X$XF\@>82)?-
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M+2^6GF!C+YI .,8W>U #;_5=6UG7M>TG3)+R!M,2*.-[4PC]Z\>\,_F=1R
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MW8)&=N<?7I5RZ\$[M9L]9L-9O+/4X+86DTX2-_M,0.0'4KMR#T( H X2VO\
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M*2XN/B_JTHU*]\D:7:S+"VS: S/\F"O XSQ@YZDUHVW@&VMM(.@_VA/)X?\
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MMIUV+RV62)0ZN,[07'55W<# / R3WK?\(&G]B>(-+.JW!AURXDN+EO+3<C2
M!@G' PHZYH AU74]0N+VW$6I/!%-I?GQ6EB@:Y,Q/WVW*56,# !) ))!SQ7/
M7VKW6O> ?A]JE\5:ZN=:T]Y65< MN()QVSBNJ'@<)J\.HPZS>PR?84L+E8U3
M%Q&A)7.5.T\GE<>V*K0_#N*#PYHNBKK%XT.DWD=W!(Z(6+1G**>,;1GZGUH
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M1&M]^UBI(."3@Y)P>30!WVE:A'JVCV6I1(R1W=O'.BOU4.H8 ^_-7*P_!?\
MR(GA[_L&6W_HI:XOQ)K^K:;;:AJ-MJLUS/:ZQ%$/LRC[+#"TB)Y,F[&Y\,<E
M<D$CE: /4**\_N!K>K?$/6M#C\1WEE8QV$%Q'Y$46^-F9QA6*]/E&<Y/;(K
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M9(06;ZX %2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:9B,$ #;(6B&Q?4[LXZ$G&?6Z* .0N?A_;/X@NM6L-9U73!?$->VUG,%CN&
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MF5%\L-C<P"@ L=H!/MQC)RW0?#,>@WNIW,6H7=P=1N3=3),$P)" ,KM4$#
MQ[5NT4 8OB#PW#K[Z=*UY=6=SI]Q]H@GMBNX':5((96!!!/:H+;PG'::UJNJ
MQ:G>^?J4,<,H;RV"",$*5RN<@$\DG.>:Z&B@#CT^'MG%H&B:,FJZ@+?1[I+J
MV;]UN+(25#'9@@9/85<U'PA'JD6HVMUJ5W)I^HR*]Q:,$*\!00C;<J#M&>3W
M(P:Z2B@"&Z@>>TD@BN)+9G7:LL07<GN-P(S]0:JZ/I2Z-HEMI<-S-*EO$(DE
ME"[\ 8!.  3[XYK0HH \[U'PHGA+P)K-C83ZS?VM](3)%$$9[<2L!(\8102
M"6VC.<>Y-1Z$;N;4;5M$\6ZYJ40D7SX;[3PD0C_BW.8D(8#H <DXXQG'I%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@#S*P\7:IX<\<7NE^(+F2YT&YO?LMAJ$H4&";8C^5(5 &#OX)]/KCKK<W/\
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MWW( -ZLIVKOSQP77IBN?LV_X0SXM3P2WLUU8Z_;+)/+(BCR;E. 6V*%4,O?
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M[(I%<69@=G+"Y5MXP.0V<[NA)KW 7,1M1<LQ2';O+2 I@>X."/QH Y^W\?\
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MKZZGB1U)-]%,/E\L?QG^':,D8 H ] O-8L;)8#+,7:X!,*0(TKR #)*J@)(
M(YQCD>M<AXH\1+>V7A;4M"U:7[+<Z[;6THA.T2(6(9'!&X'*X(X[Y%<WI1O?
MA[J7A>[\1QSG3SH(TZ6XCC:46LXDW[6V@D C:N?]D>E7_&CVEYH/A_\ LVW;
M2X9_$,$\;QP"-PF6W7!0K\O)SEAZ$]<4 >B6VKV5WJ-S8022/<6K!9AY+A4)
M (&[&W."#C/>N6^(^H:EID?AZ33=1GLS=ZS;6,WEA2&BD+;OO X/ YI? .KO
M#%/X8U-$CU737*-,@/EWJGYA,I[LP.6&20<YH^)UA=W.A:9>VEM)<G2M6MM0
MEBB7<[1QL=VT#J0#G'M0!L>+GN;3P=J5Q9WDUO<VUL\D<R;2VY5)&<@@_E3K
MKQ-HFBWB:5>ZF?MHA,HC96>1U! S\HY/(P!R>PK+UOQ!I?B'0;C2M'O$OKN_
MC\A8X,L8P_!:3^X%!).['3'7 JMJDL2_&/0W=E"QZ7<HS'HK,R%03V) .!0!
M?U7Q-H&I>"+K4QK\UCIS@QM?6X9)86!P0 5W!LC&",U)?>+[73O%.F: 8;N6
M2Z@>9IA;2.-JX P57DDMR1P.^,BO/+R1)/AC\184RTD^L7;01@'=('9"I4=P
M<$@CK@^E=1JEW';_ !#\):DRRO:2:?<P)+%$T@,C>657Y0<$X/7TH ZP^(]+
M^UI;>?(6><VRN()#&902"@?;MR""#SU!'8U8U75K#0]-FU#4KE;>UA&7D8$X
M_ <FO-H6GTWQ%#-X<U%KFTO-89+[0+M-S0,93YD\1^\B@@O_ '3G.>U=;\2"
M/^%<Z_'U>2RDCC4#)9BN  .YH L#QSX;-ZMH=359GB,T>^-U611UV,1AR,CA
M23[5-:>+M"O=*O=3BU!5M+%BETTR-$86 R0RN P/([<YXKD=1N+9_$?PWD5T
M,<2S%V'2,&WVC=_=RW'/<8K+U'4%L[KXDW,>G1:DK36;)!)$9$D41HCOM'WP
MAR2!_=[4 >BP^*-)GDNXEFF6:TB$\T,EM*DBQG.&"%0Q'!Y /2B'Q1H]QH"Z
MY#=,^FN0%G6&0[LMM&!MR>>.E<9H-W%+\6S<QW%]>0W6A(L=W-;,JR,)F)Q\
MH55 QZ#ZDT_1=(O=/\877A00G^P;>X76;=\_*J,6*P8[8F!<>R4 =EXEDF7P
MIJD]K<2VTR6<DD<L8 92$)'4'T]*YWP?XZT:YT?P[IEWJXDUBZL("?-#?O9/
M+4L/,(VE\]1G.:Z;Q%#)<>&=5AA1I)9+.9$11DL2A  'K7G"Q0^(?A_X-T/3
M\2:I:26+3*%(>R,(7S6<=4(PP&<9)XS0!Z!J7BK1M(:07UVT:1,J32B%VCA9
ML8$CJ"J=1]XCJ/45L A@"""#R"*\D@NM)L=3\0^&_%MGJKSWFH3SVL<7VAXK
MZ&5MRA0AVY&=I!P!@<\''JEC"+?3[:%81"L<2H(@V[9@ ;<]\=,T 6**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHKG_&/B=/"FB"^:WFG>2:.",1QLP#.P4%L
M=!S]3T% '045SE_XZ\/Z9<"WO+F>*X-NUR(3:2[S&I )"[<YYZ=<9/04MQXX
MT"VAEG>[D,$$<4MQ*EO(RP+( 4+D+\N00<'D Y.* .BHK#O_ !=HFFZFFFW-
MT_VQX3.D,<#R,Z#'W=H.X\C@9/M3K/Q9HU_HR:K;7+/;O-]G"^4XD\W=M\O8
M1NW9[8]^G- &U17,:YXOM[+PGK>J627#3Z?'*GEO:R I,L6\!AMR%P5.[[O/
M6L_0)H(+?3M>FU;66>ZM4@ELIUE=;B<J'+QQL,@XW?< 7&>PH [>BN<D\=^'
M8=(N=3FOFCM[6?[/<!X) \,N0-KIMRIR1U&.1S43?$+PRC;7OY$S=?9%+VTJ
MAI,;L E<$$<@]".E '445A6WB_2+RPAN[5[F83^9Y<*6LAE(1MKGR]NX 'C)
M'4CU%20^*M%N-%@U:"]$EI<2"*(HC%WDSC8$QNW9!^7&1@^E &S17">&-7EU
M#XF>)[<7=Z]K#;6I6VN0R"%VW[@$(&,\<]QCDUU]_J=MIPB\]G,DI*Q111L[
MN0,G"J"3@=3T% %RBN;E\>>'8-#EUF6]D2Q@F,$[_9I2T$@."LBA=R')'4#J
M/6M6VUBRN]0FL87D:>"-)),PN%4,,K\Q&W)';.: +]8!\-7!)/\ PDVN#V$D
M/_QNGQ>+]%EO;.U6Z<&]9DM)6A=8IV7J$<C:WMSSVS1>^+M&TZ7;=7,B1>>+
M=KGR',*2DXVM(!M!SQR< \'!H C_ .$9N/\ H9]<_P"_D/\ \;H_X1FX_P"A
MGUS_ +^0_P#QNH=0\?\ AO3+B^MKB]D-Q8[?M$45M+(R!@2#A5.1@9)' XR>
M14&J>/=.M(] EL1+>V^LSJD4\$+R($P23\HR6^4C;UZY'% %W_A&;C_H9]<_
M[^0__&Z/^$9N/^AGUS_OY#_\;K;>YABM&NI7$4"(9'>3Y=J@9).>F!ZUE:?X
MKTC4[VWL[>:4374!N;82P/&)XAC+(6 !ZCWP0>E $/\ PC-Q_P!#/KG_ '\A
M_P#C='_",W'_ $,^N?\ ?R'_ .-U9M_$NFW5W;6\+S-]J=XX)?L[^7*RABVU
M\;>BMWYQQFM"\O+?3[5[FZE$<2X!)!.23@  <DDD  <DD 4 8W_",W'_ $,^
MN?\ ?R'_ .-T?\(S<?\ 0SZY_P!_(?\ XW4D7BW2)7OXO,N$N+!!+<6[VLHE
M5#T8)MW,ON :73_%NC:HFG/8W,DZ:BCO:LEO)AU0@,3\OR@$@9;'6@"+_A&;
MC_H9]<_[^0__ !NC_A&;C_H9]<_[^0__ !NJ=W\2?"MDERTNHR%;68P7!2UE
M?RF !);"\+R/F/%7-0\:^'],EM8KB_R]W ;BW$43R>;&!G*E00>".!R<B@ _
MX1FX_P"AGUS_ +^0_P#QNC_A&;C_ *&?7/\ OY#_ /&Z=)XPT9-/2^66XE@:
MV6[/DVLCM'"PR'=0N5'!Z\\'T-6#XETLQ6TD$[W2W,'VB+[+$TQ:+CY\*#QR
M/KVH J_\(S<?]#/KG_?R'_XW1_PC-Q_T,^N?]_(?_C=6O^$DTUH+.6)YIA=V
M_P!JA2&!W<Q<?.5 R!\PZ\\XKF_$&K27&O\ @:\TZ_N5L=0NFW1JQ1)HS"SK
MN7@^G!_*@#:_X1FX_P"AGUS_ +^0_P#QNC_A&;C_ *&?7/\ OY#_ /&ZMZ;X
MCTS5KR_M+*65[C3V"7*-;R(8V/('S*,Y'/&:M:;J=KJVGQ7]F[O;2C<CO&R;
MAZX8 XH PK[PKJ<UE+'9>+]9MKEA^[ED$,BJ?==@S^8IFG>#+BRB<OXIUJ2Y
MF827$H:)?-?:%W8\LXX4#&> !3;KXE^%+2.>2747V6]P;>=EM96$+C&=^%^4
M9(&3P3G'0UMW6NV%JD+>9)<-/&9HDM8FF9T&/F 0'Y>1STY'K0!I45SC^._#
M:6&GWQU)3;:A)Y=LZQ.0S\Y4\?*1@\'!X-1P?$'PW<-;)'>3>;=)(\,36DH=
MQ&<, I7.<\;>I["@#IZ*Y4_$;PR--DO_ +7<&&&1H[@+9S%[<J<-YJA<Q@>K
M 59U'4=*?Q'X?A?5KN*ZG,DEI;V[,(KL>62=^!M8!1N&2.<4 =#17'VOQ M)
MYO$1>QU 0Z.Y0A;.0M)M0,QZ8'7@'''/2KVB>+;74O"VFZO<I+ ]Y'&1#Y$F
M6D9 VV,$9<8SRN1@$] : .BHK&M/%>C7=C?W:W@BCT]BEXLZ-$\! SAE8 CC
MIZ]LUS,VNO=?%?0;2VN=1BMY;&YDFM)XWA1L!=C;6 SU;UQ[4 =_16?J^MZ?
MH5O%/J,S0PR2K"KB)W&]B H.T'&20.:8_B#38]9ETAYG%]%;&[:+R7YB!"[@
M<8;D@8!)H TZ*Y>V^(?AF[6P>"_D>&^E\B";[-*(S)N*A6?;A6)' 8@G@]ZT
M-6URPM6GLI)[GSUA\V46D+R/"AR QV@[>AQW.#CH: -BBN'^'VOD_#30K[5;
MR>YNKI74,VZ669][G  R3P"?8#L!6K)X[\.PZ1<:G-?-';VT_P!FG#P2!X9<
M@;73;E3DCJ,<B@#HZ*S=(U[3]=%T=/E>06TODR%XG3YL \;@,C!!!'!KC)?$
M-O<?$75- UW5KO2G01?V5&DQ@2=2N6<-T=MV1M;(XP 3F@#T6BL/39;C0] 7
M^WK][FX6>1!.R O,&E;RP%0<L5*C"C\*?:>*='O$U BZ\AM-YO([E&A: $9!
M8,!P1R#T- &S16''XMTF6[ELPUTMW';?:A;O:R+))%G&Y%*@MSQ@<USI\9Z3
MK_PY?6-1N]2T:TG(S/;1RQR1CS#L"N%.20 "1D<D<9H [ZBL^^UFSTZ>.VE:
M62YD0R)!!$TLA48RVU02!R!D]SCK6?-XV\/0:)%K+ZBOV"640K*(W.)-VW:P
MQE3G@[L8[T =!16-IGBG2=7U2XTVTGD^UP1B5HY8'B+1DX#IN W+GC<,BJWC
M3Q2GA/0A=A(Y+NXF2UM(I'VJ\KG W'LHY)/H* .BHKF="U331I]Y>2^(DU.X
MM(RU]*DN$BP-QQ$.%& <<9('4TW1M>0^%!XKUFX-M;W48N%1B=L$+']VH ZL
M05SU)9L#C H ZBBLBTUK3M:N+S3(I;B*[@13-"Z/#(BMG:PR <'!Y'I6%'XV
M32M"\1R:L?,N_#TACFV@*9P5#0MCH"X91Z;L]J .THK#CTW4[K0XHKC4YK:]
MN,/=S08W)D<I%G(0 X&<$X!_B.:Q_!2W\K^(;&XUB;5-*@NQ#8WCR@S?<!D4
MNN,[6. >N0: .THKGO#6M2WMUJVCWKA]0TBX$,KX \V-U#QR8' )4X..,J<8
M'%:=_J]GILL,,[NT\^[RH(HVDD<+U(503@9&3T&1ZB@"]17.7OB^P'A/4=;T
MYWN1:)*"BP.625%)*2)C<F".<@8K/\%P2:G9Z5X@.J:L9I;!!>6]P9!#-(RJ
MQ=5<8&"3@QX4@^U '9T5R]KXJAU;Q9K/AQ(;V$V44(\\0.,NX<D[L85<*N"<
M9).,\5S_ ,/O&]DO@[P_!K&HW,VH7KM#]HECD=6E,C[4:7!4,1C"DYQCVH ]
M(HK'U7Q/I>C"<W<DQ6V4/<-#;O*(%/=RH.WCGGMSTK3AFAO+6.>"59()D#I)
M&W#*1D$$>W>@"6BO*K&XU:ZC\=3'Q+?VIT>\E2S=G1DB54W@,&4[AG@YYQWI
MT'B35]9TOX=:Q/-/:3:C>^7=6\3%(Y5V2')'<':& Z<T >IT5@WOC'1-/EN4
MN+IPEK*D%S,L+M%!(V-JNX& ?F7OQD9QFEOO&&BZ=JTFE3W$IOT@^T?9XK>2
M1V3./E"J=QSV&3P?0T ;M%4='UBPU_2H=2TV?SK6;.U]I4Y!(((."""",&KU
M !1110 4444 %%%% !1110 4444 %%%% $%[%//8W$-M<FVN)(V6.<(',3$<
M-M/!P><&L_0-&N-*@D>_U%]2U&?;Y]V\2Q[@HPJA%X51R<>K$]ZUZ* "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ KC?BA#--X(E:&"68PW=K,ZQ
M(7;8LR%B .3@ G\*[*B@#@9;N.[^+6B7J0W MSI,\8DD@=0KM(A4'(^4D D
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MK#;6Z".&%%CC0=%4# 'Y5CZ=X?NK?6I]1U#6;G4?GD-G#+&B):JYY VC+'
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M,8SG/XUB_:+B'P?X$U8:;JD]EHT0M]2@ABEBF3,(C+J/E9@C#DCCD^^/8J*
M/)O$%K;ZIX7O=9\+:+>R)]ML[JY:5)!-J"0OEE"R?,P48P3UY Z5I2ZU:ZW\
M2_"FH:?#>RVHL[M'E^QRJJ,WEX#$KQTY["O1Z* .-^*%O//X(E>""68V]U;7
M#I$A9MB3(S$ <G !/X5FVVK07OQ;@U2&"\_L]M >);I[614+>>&YRN0, \G
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*MU]*RO"&JZI<:OXBT;5;I+R72KJ-([E8A&722,. 5'&1DC(K>U.-%TR_D"
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M$1"4C<*?;[Q  Q[Y/-)X/T0ZWX)\)M>ZE'=6-E!;7$<$<04F5$&T2-N.0A[
M#E1G..0":TU?6/$]EXAO=+U$V3:=>36=G"(D=)&B R9-P).YL_=*X&.]9EMX
MQUOQ!=^");"ZBL;?7;:Y:XB, <H\:#)!)YY)QTZ#.>E=&G@^6QOM7DTC5&LK
M75G,UU 8!)LE88:2)LC:Q&,Y##(SBC_A"X(-3\.7-A<BVMM!BDAM[;RMP974
M(VYLYS@#!]<DYH 9X)U34[N77M.U2[^V3:7J+6\=R8UC:2,HKC<% &1N(R *
MS]7CO)/C!HL2:I=Q0-IEQ((D"%5(>,' *GKW)YXX(K>T'P[)HNI:Q>->B?\
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M#OI[:?\ ;]/;RD&$4D3*2%^9E.TCV/>NITO3SIMDL,EU+=SDEYKB;&Z5SU)
M  [  #   JAKWA>R\07^CWER6673+GSXRO\ &"I!0_[).TGUVXH Q)-8UF"^
MT?0)9+J34+FRDO;J6W6 2(%9%"+OPG!?DX)^7ISD4[C6_%^B^'&GUBSNF6'4
M_+DN;6.*2X^PX)$IC7<N\':&P.F2!6]XI\(_\)!<V&H6>ISZ5JVGLWV>\A0/
MA6P&1D/#*<#@T]/#NHQ6EJ5UZ:348[G[1-=30*5G^1DV&-2H5,$8 (Y&<Y)-
M '%^)M4DUCP);7^G>)I+VUEUFV2.>!41FC:2,;)!L&&4Y.,#/&1CBNGO=2U;
M3_'_ (>T<:AYME>6MT\HDA7>SQA<$D ?WN@ Z4RY^'UM<Z)J-F+PP75]J":B
M]Q!"%5)E*E2L9)&/D&022<DYJ_/X8N)_$>CZS)JA>;38I8@KP#][YF-Y.",?
M=&,#CWH XJX\0>+/^$4\6:PFN1))H>I7$<4:V:8F2+;\K9S@$$].<GKV'4W>
MNWMSXPTG1EG;3[2\TV2\%PBJ6EE!4>4I<$<*2QXR>.V<QGP&[>'O$.CMJV8]
M;NI;F:06_P T9DQN"_-TX&,YQ[USWBIX8O$5EIU_XE_L7[%8*D<]W8I);73,
MW.T2 J&4(N3G/S<8YR =1\/M4U?6= DOM6N$G8W$L4+I"(PZ([*)!@\AL _R
MH75KS7?&6M:%:7TFGQ:1! 7DA1&>268,P^^K#:J@<8R2>O%3^#IM2EM+A;S4
MH]3M5*_9;U+3[-Y@QR H."!QAA@')]*?=>%W7Q0_B'2KX6=[/ +>Z22'S8IU
M7[I*AE(8= 0>G&* . \3ZWJ'B'X->)3?3&&^TJ[DT^[,"*([AHY$&[!!(!#
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MZ6ZL+@ ';,JM@%?X@5+9'X\XQ6#X?\4:L?%%OX<\8Z4EEKK02BQU"U;=!=*
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M9+';M.<JQ Y[UF>'9O$NLZWK?F^(F2WTK66A6(6L>)HA&IV,<9 ^;J.>O7C
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M),OYG)4%@, =FZY&.CTRVOM1T'3O^$AAC74(]DEQ%"^8S*IX/'49 ;'KCTH
MV**\\\5>)[O2-?O+/4;^[T:TFB1=+U%8%>U,A!W"5BK;3NXYP,<\=:[VXWR6
MDGD3>6Y0[)  V/?'0T 345XV/$7C"W^&6F>/'UT3F+9)=:?]EC"3Q&78WS 9
M#<YR,# QCN>D6;Q'J_CSQ!I%OXB>RM+..SGAVVD;LN_>63D<@A>>_3'?(!Z!
M17G<&N:SX@\':QXFT[4WM);:6Y-G:^6C1%(20%D!7<2^TY((QN&.G+(/$>L:
M]XA\,+::B]A9:SH\EY)"L*,T3@)RK,#S\QQG(]C0!Z/17E U3Q0_@_Q;=?\
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MY8ZEHL(M[74(%7>8L ;'4_*PP!^-=K10!0TC3#I=D8I+N>\N';S)KF?&^5\
M9PH  P      *SM5\*6]_K=OKMI<S:?J\$9B^TP@$2QDYV2*1AESSV([$5T%
M% '.'PL]WXETW7M4U W%UIBRK:QP0B*-?,7:Y8$L2<>^/:ETGPHFFOK?F7TE
MQ'K$SSSH4"[&90IVD<@8 ZY^M=%10!PUK\./L]OH<+>(M1D&BR[K/Y(AMCVE
M-APO/RG&X\\<8JZO@G%AXCM#JDI37GD>X/E+F,N@1MG_  $#KFNBNKZ*UM;J
M8*TYME+210X+],XP2.<<\U!H&LP>(=!LM7M8Y(X+N(2HLH 8 ^N"1F@#&?P4
MK2^'YTU6ZAN-&A>V26)$S-$RJI# @@'"+R,=_P *W_" &WUR]O-,\0:EI]CJ
M$IGO;"#9LD<_>*L06C+=RO/H1QCLZ8\L<90.ZJ7;:H)QN.,X'OP?RH Y/4_
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ KF/&FNW&CP:1:VLGE3ZKJ<-@)]H/E*^2S 'C=A2!GC)'
M!QBNGK)\1>'K+Q-I?V&],B!9%FAFA;;)#*IRKH>Q% '/RWNI:/\ $"RT#^T+
MB?3]7LYI(7D"M+:S18)(8CE2&'# X/MQ4'PV;7-:T#2_$&J:_<7!EBF22U\J
M-8V(E8!\@9R,?3&.!CGHK;P\4U#^TKN_FNM16W-M%<-&BB%"06VJ!C)(&2<]
M!T'%.\+>'8O"N@PZ1;7=Q<V\!8QM<;=P#,6(RH&>2: ,KQ9J&H6'B;PG':WL
MD5M>7[07$ 52LB^6[#DC<.1V-8,L^OWVI>.K9?$EY;QZ3Y;VABBB#*3!YFTD
MIRN3TP"?6NQUOPW'K>I:5>R7MQ ^F3_:(4B";6?!7YMRDXP2.,=:JQ^#HX[K
MQ!<+J=YOUQ0+C*QXCPFP;/EX^7CG- %[PIJ4^L>$-&U*YQ]HN[*&:4J,#<R
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MC >-@HVL @'&T<CD]R:C?X=VDGA34?#KZK?FTU"Y:YF?$>\,S[V .S !;VH
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MFT>SCO+*ZF2)I4+PNY4_(%(RGIT-1SZAXET6/PAKTFNS7UOJD]K9WMC)"@C
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M)SOP5^]QG^[G'!QB@#UBBO+UU#7-!U/Q7X?F\1EH8-/COK'4]14.UMO)4AR
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M8>.%<KP<@'/?!Q6:]M>O<_$J\L]6N["2SG\^/[-M&YUME8;B0<KP.!COG/&
M#UJJ8U*&356T^$-+-$@><K]V$'.T$^IQP/3DXXS!X=OI=4\,:3J$^/.NK.&>
M3 P-S(&/ZFN.\":LT?@KQ'XCN$:6=K^]NY5[GR^%3\%10* /1**\NU'6M7T_
MX8Z=XZAU*>:^\NWN[JW+9AFCE90T03HNW?@$<_+R3DU>6+6-9^(/B+2AXDU&
MTL[6&SN(5A6,%"Q<E?N_=.WG/)XYXP0#JO%7B*+PKX>NM9GM)[F&W +I!MW
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+ZPMM3TZXL+V(3VUQ&8I4;^)2,'I5FB@#EM"\"VFB1B%]4U74;:*-HK>"]N
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MZJB@"O864.G645I!O\N,=78LS$G)9B>22222>I-6*** "BBB@ HHHH ****
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M1Y?FONV[?,P-V?7IC/X8]J /&;V:[U?X06-SJ%_>7%PNNK&93,REP+TH-V,
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MG^T-IBW1%IYN<[O+QZ\XSC@<<5IZ;X<M],UW4]7BNKJ2XU(H;A9&4H2B[5P
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M!F8>7Q@#+MU!Z^PQ8C\"V$-UJEU#J.JQW&IPI%<R"ZR3M&W<,@X;!(SV[8H
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MPEX69MISD9(!_P#K5B>)/!L'AO3-$M],FUJ]@BUJTECM69[A+6)9-S;55>%
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MI93R*T<+#[N#M#,%SP&8@<>@QN7]E;ZEIUS87:>9;7,30RIDC<C @C(Y'!-
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M[JVFU"2Y:23&4>/>@VG@Y (&.W%7O^$-TQ[[6[FY>>Z76HUCO89BOELJKM7
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MSL;:?4%^[9*YE'F'!!ZX /0$@GI@^IV%I'8V<<$4T\RJ!^\GF:5V]RS$G^E
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M^P72QA2>N-I(P,5U-NMUI'Q6MK!-3O[FUO\ 2Y9YHKJ<R*)4D0!E'1.&(PH
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M>QF,F=I7!7H.G7OF@#T*BO)(;_6KOX2^'O%GV^^FNM-(GOHXIW7[7;I(5D#
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MRSFM;A/,AFC:.12<;E(P1Q[&L73O"%AIZV,9GN[JWT_!LH+F4.EO@;1MX!)
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M[T/3=6>^M&OHH7F^T&P6Z<6OFYSO\K.,YY] <<<"NLILDB11M)(ZHB LS,<
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M,MS-;F+S-^#&Y7.<#KBMV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMV*-MV@DD\_+Q@\ <8H XJYUB]\)Q?$*WL[RZ>WTXV;VIN9WF:#SU <AG+'
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MBBO+KRYN/"'B;Q=%I,ER\47AX:E'#/.\P$X:0;AO)/.T9]<5?TO1;JYD\/\
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M/7Z4 >Y4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M <9*MV/2LWP7X@E\4^$[/69[9+:2X,@,2-N"[9&3KQG[M $W_",:4]MJ$%Q
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MF.&[9S)E7?8K'JRH3M4^X ITW@7PU/K[:W)I<9OW8.[AW"2,.C,@.UB/4@T
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M7$)NI2))"<EC\V>3R?4BK=WX:TB^O;&\NK0RW-BI6"5I7W!3C(8Y^<<#ALT
M>86CQ^&_!_Q U338A;W-OK=Q DL8.Z*(F$,1] 2WX5TDNDRZ'>1^)M.U2T$/
MV";_ $&U@8)J!$9=&),C98;<[L9(R,\UU47A;1(+S4+M-/C\W4<_:@Q+)+D
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M66^UZA"SHDD(F;>?/4@&/R\*%!R"  ,BO1[CP]9'44U>&!GU6W@:&WEEN9<
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MW#REX)'.#W]:YZV-AI>@^,M(EGN[;38M<CM[6&T?Y_W@B/DH6X568D'H &-
M'KM%>;Z#8(WQ \3:-=6=K!97&G6TCV-LV8E8EP2.!\V .0!T'IFJWA)!<6:>
M!;Z-9+G1K]S=,Z\R6Z$/%(?=]\8/J ] 'J-%>61:?_PF\GBNUN]0L[:]L]1D
MA222W+7%G&N/*>-O,78,#=D#!.[.:[]9[BW\+"XAF-]<QV6])2FWSW"9#;>V
MX\X]Z -2BO.?"UAHVN>$O"_B22^DCU)'BFFO87 EN)V^5XI#@EE+DC;V &,
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M)-*!RX3.T'Z;C^=6"RCJPZXZ]Z"P&,D#)P,]Z ,#4_ _AG6=735=0T>VGOD
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M8DD$="&SN!]\YK3#*2 &&2,CFJ=IJMG?7][96THDFLF5)]O(1F&0OUQ@_B*
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MGOM J:QT/3=-O+F[L[58;BZ.Z>12<RGU;)Y/O0!S'Q74/X(VDD W]F,@X/\
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M5[%[+4+=;BUD^_$^=K>Q'<56;P[I+W-E<O9JT]B"MK(78M"#P0ISQD<'U'%
M'F:C2M'TSQ[I4IN+724U2".&WL6"$-*D1V)GA59C@]L$U/+=7OA[Q7XQDL8+
M2WN(_#J726EF/W:S+YFTD8&YL <X&1CBN_D\):#-%?Q2Z9!(FH8-VKY83$="
MV3R1@8/44^S\+:#I][%>6FDVD-S%#Y"2K&-P3).,_B>>O)H \WU*QTF3P?\
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MV'R+F5HP6E3&W#>O''TXH Y+P?--8^+#H^M:#:Z=K*V!,=UI^/LUY"KJ"V,
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MXBNCC2[6:>VGE/W87E3:C,>P)[]L5Z%<74%K;F>:0+&,8/7<3P !W).  .M
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M3M&NK"VO+E(Y[Z;RH$+ $G!)/T '7W'K5R>^M+7R_M%U!#YAPGF2!=Q]L]:
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MT<N>F6/4G ')]*<+^S*!Q=P%2<!O,&"< X_(@_C4@GA:8PB5#*HR4##<!]*
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:V\:_P!DI;131QA?DBN6B)DVCL2-K'ZCUKUN_P!-L=4MQ;W]I!=0A@X2:,.
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M6"=(TM_"'Q2<V-J6AO;SRCY8_=X@1AM_N_-SQW'M0![!=7EK91"6[N8;>,G
M>5P@SZ9-+!<07,8D@FCE0@$-&P8$'H<BO.+G48]/\0^"M4N;V&0'2)%:VFG2
M-AN6,F52Y"DYPI&0<'C.#6Y\.]#M]'TF^GB-DSW]_-<G[(RN(D9R4B+K][:#
M] 2<4 ;UP]T-?LU34;6.V,4GF6;H#+*W&&4YX YSQWJ5]8TR-D5]1M%9Y3"H
M:=06D'\ YY;D<=>:Y'5X(!\9/#K^5&))=-O%D.T9< QX!]>]<1<Z7IH^%GQ!
MG6SMQ+!K%Z(9 @S&%E!4*?X0.P% 'N#NL:,[L%102S,< #U-<%XD\?++\/=5
MU[PQ?6CRV;E0742;E$OEE@ 1@'D@G(([5W5N?-M(BV&W1@G/.<BO$Y9;4? #
MQ! LD0N$N;CS$!&]1]L.,CJ.HH ]HAO[.XN9;6&[@DN(<>;$D@+QY_O '(_&
MJ>FW$L4&H2W^JV=S''=2%7B 1;>/@B-SD_,HZDXZ]*Y6ZL;+3_BWX>2SMH8!
M/I=VDHC0#S &C(W>O.3S6)HVGP7/A;Q186]_'I;?\)9,+28(#&DJRQM&I7H5
M+!1CWH ]2M+ZSOT+V=W!<(IP6AD#@'\*2[U&QL"@O+RWMS)]SSI53=],GFN7
M\%ZCJ%QJNNV.M:;;6NL6KPFYGLV)AN@R'8ZYY!PN"#[52\6PZK#XAN]3T*>Q
MO)X=-1-0T>]&%FM]TA#(W\+'YQSP<#- ':7.I6%E:K=7=[;06[8VRRRJJ'/(
MP2<4]KVT5(7:ZA"SD"(F08D)Y&WU_"O,+77[&3Q;I37U[-HVGWWA^!M-\_R]
MHR29(RTBD;L>7Z9"CVJM?:#H%E;>"+/3I&O]/&O-'%-<%'WHR2%E4J #'NR,
M=#[B@#TV;Q!H\.E7.IMJ=H;&VSYTZ2JRH1U!(/7VZTW3=?T[4M!@UB.ZA2UD
MB21F>5<1;E!VL<X!&17GMQ:V]MJOQ4M+:"..'^RH)!#&H"AC;RY( [G J%]9
ML[+3?AS++J*VND_9Q'<746PI#<FW3RMY8%0<%QDCC.>* /45U33WL?MR7UJU
MF?\ EX$RF/T^]G%/AO[.YN9K:"[@EG@.)8DD#-&?]H Y'XUY)XQTC0+?P#XK
MN=,U!]1\^\M;B:5FC:*.8RH&\LHH"L5QNQZCUK>U"RBTSXJ62Z/;06\\N@70
M58D"AV#H4SCKSZT =V-3L#?_ & 7UL;S&?L_FKYF.OW<YI)]4T^VNXK2>^MH
MKF7_ %<,DRJ[_12<FO.O!U[X6UOP7X9COIDDU6RN8W^S^:5N1? D.64$,<DL
MQSQC)/ K/MGT/7=-\3Z+XHU^6PNUU2=KFV+0I(RB3,+QED+GY @7!/0 =J /
M8*HKJ=I?>=;Z=J5E)=JIP XEV$<9958' )'<5'>B)?#5PMS-<1PBS82RM_K5
M79RQQ_%CGZUQ?A>;5-'\3:5HNLQ66H(VG2KI>L68VEX%\LLLB=!TC.0<=/4T
M ;/@3Q5_;OA+1KO5;RT75+^-W\D,J%\.P^5,Y( %=%<:IIUI<1V]S?VL,\F-
MD4LRJS9X& 3DUXMIEE9P?!_P3J$=O"MV-8M6^T!1O_X^"#\W7IQCTK0\;W^G
MW.B_$)+1[>V="D=W]I??+<2K&NWRU)&Q0 ,'G)#8 QF@#O-6UG4K+X@>'-*C
MDA_L_48KII4\KY]T2*1\V>GS>@Z=:/"^LZEJ/B#Q/8W\D+IIUY'# 8HM@V-&
MK\Y))//K^58VH7,5U\0?A_-%,DJO:W^'5@P)\J///U!JWX-(/C7QU@C_ )"$
M'_HA* +>M:[?:9X[\/Z<;BV32[Z&Z>?>F&4Q(&!+DXQ\WH.G6NDM;VUOK87-
MI<PW%NV<2Q2!U./<<5Q/B^UM+SXE^";>^ABF@=+_ #'* 58B.,@$'@\C/X5R
M.L6QT(>.I=(B>'P^EYI[3QVJ HN&!N@BX(^Z5W#&.H/0B@#V&SU.PU'S/L-]
M;77EG#^1*K[3Z'!XJ:>XAM8'GN)8X8D&6DD8*JCW)KCM%@\/7WB^#7--\02Z
ME?R6)A989(3'Y.009 B#!!( SSU]#B+QMJD6E>,/!\VI2"+1C/<+-+(<1I.8
MP(2QZ#J^">AY[4 =G;WMI>6HNK:ZAGMSG][%(&3CKR.*99ZE8ZBKM97MM<JA
MPYAE5PI]#@\5YKXP?2+'0[F\T,B33I]=M9]<EAD,D31EAY@ZD=DW <8;GO6S
MK5H)/BKX9FL%1UN+&[34@H!62V"KY>_L1O;C\: .N&KZ89(8QJ-H7G8I"OGK
MF1@<$*,\D'@XIUUJFGV4JQ7=]:P2,,JDLRJ2/4 FO%(]/L(/@:NH16T"74.K
M QSA1O3%_@8;J  3P/4UU'BXW^EWOB36+%K/5M)V1KK.E7!V2Q!8E.Z)_P#<
M(.#WSCF@#M1XHTEO$SZ MY";Z.$2NGF#Y23A5_WCR<=<8]:M/KFDQE0^J62E
MMV ;A!G:<-W['@^E<;;2V3_&&^-RL48NM"MBD<X +EI7&,'J>0*R/!NA:7+\
M-]6NTTZV>]CDU..*41 N@+2+M4]0,<8''/O0!Z?_ &A9;X$^V6^Z< PCS5S(
M/5>>?PIMQJFGVEU%;7-];0W$O$<4DRJ[_0$Y->4?VGI[>%/A2HO+<O'=6>\>
M8,IBW=3GT^;CZU+#)HFM1>+M#\4:\^GSG4IC/;NT*,\.0870NA8_(% P3C ]
M10!ZE?W]K80;KF]MK0OE8WN'"KNQ[D9^F:P_ &MWWB#PI'J&HO$]RUQ<1LT*
M;5(25E&!D]@.YK!T"^AC^)NMV.K2L'33+-=-^VD!WM]A,IYXR7^]]/:K/PA>
MV_X0*.&U>(I%>72A8V!"CSWV]/;&* .QN=4T^RGC@NK^U@FDQLCEF56;/ P"
M>:==ZC96&S[9>6]OYAPGG2JF[Z9/->4>-;_3[C3_ (AQ6KV]M*D*1WAN7W27
M$BQ H(U) 10,8/.3G &,UJZB=2FGM]9\.7VGZA<QZ-$M[I=V<I<0;G^9''W6
MW!U.>#@9Z4 >DHZ2QK)&RNC ,K*<@@]"#59-4T^2X2W2^M6F=F1(Q,I9F7E@
M!G)([^E4_#-W;:GX2TJZM[9X+6>SC:."7DHA484^O'?O7G?AS1K;_A#O&%]I
MFGV[:O::EJ@L)4C!DA<;@HC/5>O 'K0!ZA#J>GW%Y)9P7UM+=1?ZR%)59T^J
M@Y%<UX=UK5M5A\60W=Y:13Z??RVMM.(=L<:B-"K,I8YP6R>?RK \/?\ "+Z_
M!X3U"W\03RWMEM%K9PM LB,5Q(CJJ!MH&=V3T&<]*CM8H+CP[\4DF2.1!?7;
M8< @$6R8/X$?I0!Z';WL=IH=M=:CJ-JX$*&6\#".*0D#YADX )Y'/>GMK&F)
M;17+:C:"";_52F==K_[IS@_A7F,.J1Z<WP[.I:@^GZ9+HFR*Y&S8ER8XL;BZ
ME02FX ^YYY-:C^#=(U3P9XAT[0=0EO&GNVO8+AFC:.*\&''EE%  W  XX&2/
M44 >@&\M5GC@:YA$TJ[HXS(-SCU ZD50TJ[>#2!+JFKV-TWG.OVF+$<?WR%7
MJ1D<+UZBL7P?J(\96L?B"ZM=B?91:+#*G1S@W'!Z@L%3_MF?6O/!:VC_  2L
M@T46(M>VQD  H#?$':>W'IVH ]KM[^SNY9HK:[@FD@;;*D<@8QGT8#H?K3!J
MFGFZ:U%]:_:%SNB\Y=XQUR,YKC(+*UL/C.UO8PPVB2^'"S+ @0$BX #8'&0"
M:Y71;.R\1>%?"VAR7FESG3]4%S)=/<Q.+F-7<G"$E]TFX9# =3G/&0#V*ZN[
M:QM);N[GC@MXE+R2R,%55'<FN*U?QO)<:)X=U;0+JV-M?ZG:VTZ.F]Q'*V,=
M?D;'J#U[5UNKQ*=!OHP@V_9G 4#C[IQQ7DQ>RNOA-X"@1X9/^)CIB3*C#();
M!!QWX- 'K]K?V=\91:7<%P8FV2>5('V-Z'!X/M3(-4T^YNY+2"^MI;F+_60Q
MS*SI]5!R*\VU:"73?&/C&'0(%M[E_#"2Q1VR!<RAI0I '\6, ?A5C0/^$6U[
M_A%=3M/$$\UY9J!:6D+0*Z93#HZJ@;: #G/I[C(!VOB;Q%9^%?#]SJ]Z&:.$
M +&GWI7)PJ+[DD"JUM%XJGLEN9[O3;:Z==PM!;,Z1_[#/O!8]MP 'M6%\7=*
MO]2\%I/IT#7$^G7L-\8$&6E5"=P [\'./:MZYU:QUWP3<ZIIUZQMY+1Y8YH)
M2C(0I/4'((/4>W- %S3-0F_L:QFUGR;.^F4)+$7VCS>A5<]>>GJ*D?6])CM(
M[M]4LEMI"0DS7"!&(Z@-G!QBO)?+35? WPVO-4=[RZNM8@\Z:Y<N[AEDRN3S
MM.!\O3VKJ;P:'I'CJWTNPM['3+F/2I96FFPL"0O+\P2($ N67).1@#OTH [E
MKRU1(7>YA5)B%B8N )">@7US[56;7-)2PN;\ZE:&TM<^?,LRE8R.H8@\'VKQ
MK3([&_\ AM\-UE$$\B:Y% ^<%E4M-\A[@$ <?2NF:TMK7Q?X_M+6"**%]%MY
M##&@"EMDHS@=^E '=:3XBTW6-!@UF"ZA6UDA65F>11Y090<.<\$9&<U=MKZT
MO;7[5:W4$]OS^]BD#)QUY'%>2Q:Q:6/A3X;2RWXMM*2.)+VXAV,(9C;8B,FX
M$#YMW4<'GC%3>(8M*TC1]9U32-6NK^UN=1LI]8DA,4D21AP'*A$V[BH4N"#D
M$9X- 'J5EJ5CJ2NUC>VUTJ':Y@E5PI]#@\5-<7$%I T]S-'#$G+22,%4?4FN
M0T*VT"Z\8MK>FZ_+J=]/8>5*(9(6B\H,"K.(U'S9. 3SC(['$7BNZ>W^(G@Q
M;OC2Y)+E=S?<^TF/]UN[9QN"^Y- '7+J=@]B;Y+VV:T'_+=95,?7'WLXZUR?
MA37M6\5P:;KEGJ-C]AG,AO-/907A0EA&58<A_E&=W!YQC%1:1:F#XF^*Q;JH
MTN2TMY+E/X!=$')QTW; I/U4FI?A&L8^%N@LBJ"UN=Q ZX=NM ';4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %,FABN(7AFC22)P5='4%6!Z@@]13ZBN;JWL[=[BZGB@
MA3[TDKA57ZD\4 0V.F:?I<31:?8VUI&QR5MXEC!_ "K"PQ+,\RQH)7 5G"C+
M 9P">^,G\S56+6-,GLI;V'4;22UB)62=9U*(1U!;.!CWI(-;TJYO/L<&IV<M
MUY8E\E)U9]A&0VT'.,$<^] %N*&*"!((8TCB10J1HH"J!T  Z"JMAHVEZ4\K
MZ=IMG:-,<RM;P+&7/J< 9HMM8TR\AFFM=1M)XH?]:\4ZLL?^\0>/QJQ;W,%Y
M;I<6L\<T+C*21L&5AZ@C@T 46\-Z$UQ-<-HVG&>=@TLAM4W2$'(+'&2<@'GO
M6F  ,#@5Q7A[6M4U+2_%@O\ 5+:WFL=2N+.WNS"JQP*J)M8J3S@MGD\^M=&F
MIVEAI-G-J.K6A\R)!]J9UC2=MN2R\XP>3@$\4 31Z3IT-G+9Q:?:I:S$F6%8
M5".3U++C!S[TZQTVQTR$PV%E;VL1.2D$2H"?H!7->+O$%W96GA^\T>^MVM;W
M5K6VE=5$@DBD?!VMG X[X/X5T5CK&F:FLS6&HVEV(#ME,$ZOY9]&P>/QH FN
M[*TU"W-O>VL-S"2"8YHPZDCH<'BH?['TS[2]S_9MGY[J5>7R%W,",8)QDC%<
M?XDUO6-%^&<NK66O6>H7<,ZJ;V*W4I(K7 CV@!BH*AL9YY6NHNII%\0V2#6+
M:"'R9#)8.JF2?IAP2<@+@YP.] $ZZ+I2V$E@NF68LY?]9;B!1&_U7&#4UE8V
MFFVJ6MC:P6MNGW8H(PB+] .*Q-,\=>'-4%^\6KV216EP8"\EPBA\!<L,G[NY
MMH/0XXK8;5-/2&"5[ZV6*X(6%S,H$I/0*<\GZ4 3SV\-U \%Q#'-"XPT<BAE
M8>X/6J5IX?T;3YUGL])L;>91A9(;=$8#T! X%.UG5[70](N=1O)8XXH(V?YW
M"[B 2%!/<XP*YGPSK-]JEGI_B&7Q#82:9-9+)?VI" 6LK*& 5QRH&<$.2>*
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M:-)U+ #J2,]!WKB8_&#Z]<ZM)IOB?3-.73=0$$<4[QM'<0JJ%W8GYL$N0"I
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MD@D&F66^W&(6\A<QC_9XX_"FC0='$<T8TFQ"3',JBV3#G_:&.?QJ^2%4LQ
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MB_U"TM"PROGS*F1[9-8OC7Q9!X7T#[6MQ;"YGDCBMUED !WNJE\9Y"AMQ^E
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M42( %?R5RH'  .* /._"TNH:-J_AK2IY;36M$N8)!I&I1#9/ BQYVR <,NT
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M?A7L,MA9S2222VD$DDB>6[-&"67K@G'(]JB.C:68UC.FV9122J^0N 3UP,4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MU]X@FOA:[-1U%KR+R)6<J"JKM;*CGY<\>M:4/B70[B1(XM6LV>0@1J)ERY)
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MA5 R2?PH X"?P)J4.E:5!9O9R74>O#6[YY)&17<NS,J84^H )Q]WWK1ET'Q
MGBW7-:LS81F\TU+6U+S,2DJ;BK,-F-I+<X)Z5U=G>6^H64%Y:2K-;3QK)%(O
M1E(R"/PJ&TUC3K^_N[&TO8)[JSV_:(XW#&(MG ;'0_*>/:@#BA\.TO=2U:X>
MTMM(M]3TR2RN[>QE+K+*Q!$N-J@%><'&3N.<=]+PW9^-[:.WL=<N-*>ULU"B
MYMF?S;H*,*&!&$[%B,YQC'-='=ZQIUC?6MC=7L$5W=MMMX6<;Y#C/ Z]NM7:
M /-)O ^OS?#K7/#I_LT76HWTMQ')]H<HJO+YF#^[SD8QTYKH)=#UC_A/[3Q%
M!]A$+Z:+&ZC>1BT>)?,W)A?F[CG;Z^U=75*QUC3M3GNH;&]AN9+5Q'.(G#>6
MQ&<$CO0!D^-/#<OB;1H8;2X2WO[*ZBOK.5P2BS1G*[@.<')'XU$NBZAJOB;2
M]<U:"VMGTN"9;>"&8R[I90%9BQ5< *N ,<[B3C&*V[K6-.LK^TL+F]ABN[LE
M;>!G&^3 ).!UQP>:=;:I8WE[>6=M<QRW-DRK<1J>8BPW*#]10!@^#]$U71;G
M76U!+/R]1U.6^C,$S.5#A0%(*#GY>OO3O%.AZEJ.K^']4TLVK3:7<R2-%<NR
M*Z/&4."JGD9SC'/K73T4 <;:>']:MO$7BO472P=-7A@C@ G<%3'&4^8;#@'.
M>"<>]8T'@GQ-I.C>&+G2KC3EUO1+=[22*5W-O=0MC(+;0RG*@CCK7I=% &;H
MR:L+5I=:>V^UR'/DVI)BB7'"@M@L>I)('7IQ6%JOAC4;;Q@OBOP\]L;R2 6U
M]9W3%([F,'*D. 2KC&,X((XXKHDUC3I-8?24O87U!(O.>V5P75,@9([<D=:-
M5UC3M$LFO-4O8;2W4@>9,X4$GH!ZGV% %>W75;YE_M""WLX #NAAF,S2Y&,,
MQ50 ,]!DGCD<@\C9^"]:M/!5UX)\VT?2WWPPWYE;S4MW8DJ8]N"X!(!W8Z'M
M@]Q/JEC;:E:Z=-<QI>7:NT$)/S2! "V/H"*MT <E;^'-0LO'RZQ;Q6@TV+1U
MTV*,SMY@*N7!QLQCMU]_:L&;P/K\WPUUKPT?[.6[O[N6=)/M#E%5Y?,Y_=YR
M.G3FO2Z* //6EU%/C/*\%I;RRGP[%YL1G*A?W[_=;;SSZ@?T+;CP/K,%C;RV
M<MC/=R:R^JZC9SR,EO.7! 3<%)PGR8RO)7)':NI2WT >+Y&3R?[?^RB1_G/F
M^06P,\_=W=NF:VZ /-KKP5XDN-,\9V9DTH_V\P>)A)(NPF-5.?E/ V^^>OR]
M*V;K0-9N/$GA/4O+L5BTB*9+A?M#%F,D83Y/DYQC/.,UV%!&1@T <)<Z39:S
M\2[+4M.ODDA6T\S4HH6#1RF-P;<L1_$'WD?]<Z[>='D@D2.0QNRD*X&=IQP:
MJ:3H>EZ%;/;Z3I]M90NY=D@C"!F/<XZU?H \QL_!?BN*R\-Q2G1A/I%^;B:8
M2R,UWE74RL=H._YLD<Y/\0Z5IIX6UQ;;QK&5L,ZZSFWQ</\ )NB$?S_N_;/&
M?3WKNZ* //(?"/B'2;[P[K6G?V?+J%AI2:3?6LL[K'-$N"&1]A((89Y7I6SX
M0T/5](U'7[G4OL>S4KXW<:V\C,4RBK@Y4?W>O?T'2NJHH X_5-!UV;QH^IVK
MV$]C+8?94%T[AK-\G<Z* 0VX$ \J>!S@5R4FD:SX<MOAQI5RME-?6=])&JQR
M,(V40OU8KG)&>WI]:]0@UC3KG5)],@O8);VW0/- C@M&"<#=CI3+[1--U.[M
MKJ\M5FGM3N@<L08CZK@\'WH XOQ5H=PNA^-/$>H"*.YN-$DM(88G+B.)$=N6
MP,L68GI@ #K5FPT74?$.B^$EU"*V@L].-O?%HY2[3.D?[L %1M&3N/)Z8YZU
MV6H:?:ZI926=[")K:4;9(F)PX]#CJ/:G6=I!86D5K:Q^7!$H5$!)"@= ,]J
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MT/3;U+?5-.DM1I6&#2QRJ0D9V]2",@]L;CVKNZQ--M_#FL7P\2Z?!97-V0T
MOD0%\*2I7=UX((_^M0!HZ;81:7IEM8P9,=O&L:ENK8'4^I/4^YKG[C0]6C^(
M@\061LWM)M.6RF29V5T*R,X*@*0<[L<D8Z\]#U51M/$DR0M(@ED!*(3RP'4@
M>V1^= 'G$O@?Q!+\-]6\-_\ $M%W>WSW*2?:'V*K3B7!_=YR,8Z5I7VA>*M.
M\6W&O>'FTR1-3AB2_LKV1PJR1C:KHZKGIP00.GY=K%/%.I:&1)%#%24.0"#@
MCZ@U)0!6L(KF&QB2\G6>YP3+(J[5+$Y(4=E&<#.3@#K5FBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *:[K'&TCL%102S$X  [TZL7Q/8ZCJFCM8:>+;;<,J7)GE9
M,PY&]1M4\LN5SVSGF@#S:+78-/\ 'FB^+O[3AD@\0.UA=6XG5C!&QS:G;GY>
M -V>A8^M>C:WKKV.JZ5HUFD;:AJ32>69<E(HXUW.[ <GJ !D9)ZC%5_&7AC_
M (27P?>Z1!!:QW%P@$;N2JQ.""&!"D\$#L,^U9.H>&/$MV?#NM)<Z>/$6CAX
MY SN8+N-U"OD[=RDXR.#@^M &18:CJFC>)OB7J4D%I<7EG;6D^U6:..14AD8
M'^(@X'3)Y[]ZTSXR\0PMX9GETW3WM==18XT29U>.5HO,!8D$;3@Y !('KTH;
MPEXBGN?&%S-)I:MK]E';I&CR$0LL31Y+;>1\Y/3G';-3S^%M:DL_!T*_8-VA
M21O,3.^)=L1CPOR=\YY^GO0!/IOB?6);KQ-IE]9V+ZAH\<<J&&1UBF21&90<
M@D$;2#6>OC?4U\->#K^UTNR/]MS10-'YK((BR,P"C!X^7KV]#6C%X=U>'Q+X
MIU,"Q:/5[:&&%#,X*&-&4%OD[[\\=,=ZS8O!>MQ>'?!VFAM/,F@W4<\K^<X$
MH164!?DX)#9YZ8H TM+\2ZS-J'B32KZSL6O])CBFB,,CK%*DBL0"2"01M(/'
M/M5"W\?+%X3\+ZA="STQ-8&UKB5";>V.TD*>1UQ@9('4^U:,/A_5X/%7B35@
M+%HM4MH884,SAE,:L 6^3H=_;ICO5;2/#&LZ9X2T;0IX-)O[>U@>WO+>=V\N
M=>-K E#@C!X(QS^( *GBC5_$<5CX8*3V,#WNMQVTWE*S+*F]VC8'=PK*BDCK
MSC.,YM7?B3Q2WBJ]\/:;I^E/<6]C%=K-/-(J-N<J00!D'Y3@<^Y[&F/A]?V?
MAG2['3KBU6?3M:_M2"WE=S#&FY\0JV-V 'ZXY/89K:L="U>'Q]<:]<-9-;3Z
M?'9L(W</N1F;<%*XP2Q&,\>IH S=>\;:GH23W=U:V<$,6H);)92,3/<0EU0S
MJP; &6. 5Z#D@FI5U+6#\6;RQDN[8:;;Z7'<",HWRJTA#'.?O?)UZ8[=2<K4
M? GB6[TG7M-6]TMUOM26_AN9A(97 D5UCDP, *%P",\ # KH'\.:J?' UOSK
M%[:YTU+&]C97# J[,2@]#N(Y/'7GI0!GS^.-17P</&<%G;R:,&\QK7#"X^S[
M]OF!L[=V/FV;>G&[-27OBKQ#<^*I]$T*PTR7_B6QZA;SW,[A75G*_-A<@G!P
M!]<]JK6O@C6+;P;<>"FN;1]'<M%%>F1O/2W9MQ0Q[=I8 E0V['0XXP=>U\.W
M]I\0&UJ-;1=-_LQ-/2(2MYBA'+!L;<=\8S[Y[4 =2N[:-P ;'(!R,UQ7BF_U
MJ'Q]X3T^QN;>.UNC=.R21L=S)$?O$$9&&X'KSZ5KZ/>ZU-XCUFUO_L,FGPLA
MLY+7=N4'.4DSP7& >.F1ZBH/$F@:EJ'B'P_K&F36JRZ7).'2YW;625-A(V]Q
MC..,^HH Y2*]UG3O%OQ$NM'M[)WMWMIW-TS!2%M5.T!><G!Y)P/?MT"^-OMU
MOHB641BN=3TX:B2UO)<"",A>"D?+$L^.H'!.>@,</AG68[_QA<G[ 1KB((!Y
MSCRRL7E?-\G<<\?3WK.7P5XCTVQ\-7FC7NGQZUH]B-/FCG+M;W4.%X) #*<J
M"..M '3^$];U#6]-N'U/3)K"ZM[E[<AXG1)@O26,. =K ]^G-9%SXE\377BG
M6M!TC3=,\VPAAFBFNIWVL'W?>"KG)V@8' Y.>@/3:/#J<5F7U>X@EO96W.MN
M"(H^  J9Y(XSD]23TX XZR?44^+OB@V$%K-_H%D'6>9H\']Y@@A6]\\4 6=)
M\;ZAKGA[3KZ#3XK.62XEM]2EN'S%8-$&W%N5+ D #D?>Y/'-8>.=8N/!.M:S
M865G=76CWDUO,BEMD\<>"9$YR/E.<'/0\T?\(+JNGQZ#)IMW9W$UG>W%[>PW
M89(;B6;)+C:#@H2=N1^.:T/#FES^$UUM]>U+3!:ZEJ4EU&^3&"T@&5.\X'W3
M@ GZT :0UNXO+S28M+>UN8KNT:[DD8,!Y8"[2""<;BP SG@$\XQ7)-\0?$*>
M"V\4MI>G"UM;QX;J 2N9'43^5^[., CCD]>>!WU_AWH2:/HMW/:S-<03S2"P
M\TX"6BNYB0'GY?F9@?1Q]*S'\"ZX_P ,[_PN9-.%S<W3S";SGV*K3^;TV9R.
MGZ^U &W%XDU:T\:0:-K%M91VUY:2W5O);R,S1^65W*^0 >&SD8Z=*SD\=:I<
MP:5JECI,UWIU],BM;Q6,_FQ0O]V;S,;&XP2H'&>&.,UIW^@:GJ'C72=9=+);
M6UM)K>:+SF+-YNW./DQQM]LY[5G>&O#7B[P_%%H7]J:=+X?MWQ!<;'^V+#G(
MCQ]WVW9X';I@ CN/&'B60^*EL].TM3H+Y)EF=A*@B$F!@#YB#UX ]^S+_P 0
MZQJ7B3P*^G36]O9:M;379AE1F.X0!@&((R ).!ZC/IBY'X7UE&\9$_8#_;N?
M(_?O^[_="+YOD]!GCZ>]1)X0UN"+P7-;SZ>+O0('MI1(SM'(K1+&67 !R-H.
MTXZXSWH ZCQ)KMMX9\.WVLW:LT-I'O*+U<YPJCZD@?C6->^)-4T'5-$BUJ&T
M:TU:<6@>V#!K:=AE$.2=ZG!&X;>1TK5\4^'X/%/AB_T2YD:..[CV^8HR48$,
MK8[X8 X]JR#X>UC6?["C\0&Q":3<I=L]M(SFYF12J$AE&P9;<1EN0![T 9FA
MQW]Y\3O&-O>-93VWD6,4T3Q,0T924A0"<=SG.0<U>^(5YJ6E:7HL>D2P6T<V
MJVEM(#&?N&1<*,$8'&#[<<5<T?0]5L?&^O:S.+,VFJ+;JJQRL9(_*5ER04 .
M=WKQ[U-XST&\\0:3:Q:?+!'=VE]!>Q?:,A',;AMK$ D ^H% '.7AU5?C!&+-
M+-[]O#6&>4LL2G[1UP,L1[9[]:MZ?X^ENO#6G7,]HD>J7E]+IYBB5Y462,OO
M<!1N*A8R<=>0,CK5Z+0M9'CY/$4OV!XAI7V%D65U8OYGF;@-IXSQU]_:L%/A
M_K:>&XH8;ZSM=9L=6EU.QG0M)&2[,3&X*@[2'(.,_P!* .E\-Z]JFHZKJ>GZ
MEITL:VI1K>^6UE@BN48<@+)R&4\$9-8'B"X.L?&+0O#EWSIUK8OJ9A;[LTVX
MHFX=]N-P]ZZO08?$&Q[CQ#-8_:" J06 ?RD'<Y?EF/T  'U-4/$_A.35M5TS
M7=,NDL];TQF\F61-T<L;<-%(!SM//(Y&<T )XXU32M,TZR.L6%U<0R7L(@>W
M1&,<X8-']Y@0<CKT['K5&^\3>)I?%M]H&DZ9IOFPV,5Y&]W.P!#.5*MM'!^4
M\#([Y[&3Q'H&N^++;3;.[BTZPBMKZ&\DEBN7G9O+.=JJ8UZ^I/'H:N6^AZE%
M\1;O7V^R?89[!+,()6\P;'9@V-N.=V,9_&@#*U[QMJ>A)/=W5K9P0Q7Z6R64
MC$SW$)=4,Z,&P!EC@%>@Y(S5RZ\1:_)XUO?#FGV6G Q6"7<5Q<2N1AG*_, ,
M_P )X'USVK#U'P)XEN])U_34O=+=;[4EOH;F82&5P)%=8WP, *%P",\ # KH
M;;0]9B\=W'B"7[ \4NF)9;%E=6WJ[/NQM. 2V,9..O/2@#FM0\7ZUK'A#PGJ
M=F;>QDO]:AM+N/#/\RS,I .1\I:/GN0<9ZUT&H^*-06^OM-T](GO=/@C:9C9
MSS))*Z[A&!']P8P<DG[PX.#61!X$UN#P5I6E"?3_ +?IFKC4HF+N8I?WKR;6
M.W*_?(R >E7KOPYXJT_Q1-KOA^]TMWU&&)-1M;Y9%C,D8VK)&5R1QQ@^G7T
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M* "BBB@ HHHH ***Y_Q?XB'AC28+U]J0R7,<$MP\;.ENK9S(RJ02. .HY84
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MQFN!-*R;PF8\!!@KR2>6Z<<[^A:A<ZKH5G?7EA+87,T0:6UF&&B;N/S_ $H
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M'&.6PXR,.<#C!Y.>, ';T5QZ^(]7U>WUR[T%+(Q:5<R6J17$;,UU)& 7 8,
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M[7W;AG) P.*SVU35O#/@WPQJ\@TN:S5+:"YG-HZO:V\BH-P/F'.#C/3L<<4
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MW(I".6^8Y._<!C'W<]^ #M@P90P.5(R#5'3-:TW61<G3;R.Y6UF,$S1G(60
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MI-M^C11L5DG1&:%".H:4#8,=\GB@#(\-Z-XPT^.WL=7UC3[JPLE"PO!$Z3W
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M" 3N(.#QSQES> /$3Z/<::NJ:<R#5AJ4,\D+F64B428E.>PXXSD #C%>E44
M<M!X>U2T\;W.NPWEH\%Y9PPW,;QL'WQ[L%.2 #N[YQ[U4T7PUKVBZ//;13Z>
M\TNJ2WK*Q?RY(Y2Q:)OER/O<'GIG'8]I10!PL7@6:TT'Q396"V=F=>#*MK$S
M>1:[HO+9E^49)Y8X"CH.V3>NCI.D^"H="\57MA$CV)M2OG &=4C"L4#8)/L,
MD9%=95:YTZQO9[>>ZLK>>:V;?!)+$K-$WJI(^4\#I0!C>!]&GT+PE8VMY))+
M?-&LES)+]]G( PWNJA5^BBHM?T'5KWQ/HVLZ;=VBBQ26-[>[1F3YP!YB[2/G
M&,?0D9%=/10!YQ)\/]:?P'K/ALZC8NU]?/<1S>6R[%:;S3N'.22,8& /4UT&
MH:%J5]XRT'7,VB1:=#/')%YC%G,H4$@[>VWOU]JZ>H;N[M[&UDN;J58H8QEG
M;H.WYYXQWH Q?&>A7GB+P^;*QNHH)UGBG F4M%+L<-L<#DJ<<US]YX=UFSN_
M$FO7M[8O%>Z/Y,L,,3 JT:28"DGI\W4\GT%==I6OZ;K,UW!93LT]FX2XADB>
M*2(D9&5< X(Y!Q@U;O+>UNK26&]ABFMF4^9',@9"/<'@T <!X9T.^\1?#[PC
M:7YM4TVW@M+IC$S&2<(JLB%2 %YVY.3G;T&>#P]_:S>+_'B:;]CP]]&H>=V!
MB;R$^; !WCVRO3KSQV'AR]T2]TK=X?$"V$4CPA8(?*164X8!<#O5FTTC3-/N
M)KBRTZTMIIN99(8%1I/]X@9/XT <H_@::RM?"5EI4L'V;09O.8SL0TQVLIZ
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MXF+,#'N#*%P IQG)WCTYBU?QA<:7K-EI-]>66DRW-@DT5S=Q,T$UP20T6X,
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M@/V+S]"=OL[B%ML@$(D^<;^O.."*8?!>I_V!X3TP7EIG0+B&<R%&_?\ E(R
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MDP(XE67=P<DD;2,\=1QR:L:5I7BL6T@US6+&[F2)HH%M[=HE8D8\R7DY..P
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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ML,\'/7KQTH Z>BO/3XOUJ\\!S^-M.-L;2+S9X["2(_O+>-RIR^<ARJEA@8'
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M-D)&<<JP!%0PZ]IUQKT^B1S,=0@A$\D1C8 (3@'<1@\^A/2O.;SQ#KFN^"/
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M%'(3+(&*@AV V +GCDYZC'-C4_#&I:I9W]C<ZK;7%G?6XBEBN++=L?;@NF'
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MS 94JJ/ED/3;R1Q\U<O'XO\ %@^'=CXM>\L6*7GDSV@ML+.IN3#][)*X!&,
M].<YKKM \.:_IOEKJOBAM42V4K:JUH(\'!4-*0V9" 2.H]3DX(S1\/+H?#]/
M"G]M1;%N//\ M/V(Y_UWG8V^9_>XSGI^= %NTU37;/X@C0K^]MKN"\TY[R)D
MMO+\AT=5V_>)92&[G/%<GKVOZYJGPE\07<]^D-S;:I)9.UO$%$D0G6+;@DD
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MW=A6PWN/:MWQ%J7BKPY86]U-J=A.+G5[: *EF5,<,C*I4'?U!SR0>/2IM5\
M-JGA[6K!M32.]UFX2>\O/LVX?(5V*B;Q@ (HY)[^M:?B?PY=^)-+L;0ZC#;R
M6]U#=/(+8L':-@P 7>, D>IH Q_%VOZQI/\ ;DT5[#;K96(N;&"*(3O.55F<
MS+@E$R H/R]SGM5+4+[4]3\:>!)8M0:VAO[&XN3 L895<1(<\]3B0CGI^)K2
MU#P+>WFH>(I8M=\BUUZU6&ZA^RAV1A&8P4<MPN#RI![X(ZU(?!-X#X8GCUS;
M>:'#)!YQM 1-&Z*A 7=\I 08/S>X- %"Z\1>)M6L]3O?#EM))+9WLEM;VYCB
M,4_E/L?>S.&!)#8QC QUKN/](N=.!^:TN)(AU <Q,1^1(/X5R*>"-4T_7;^Y
MT3Q-+I^F:C.;BZLC:K(5D;[[1.3\A;Z'!KLXHUAA2)!A$4*H)SP* /,O!NH:
MW%\*]+U+^TX&>YN,W%Q>;5\B-IW\QP3]]SG@'N>_2MG0=:U?6KSQ1I$5Z5FT
MZ2(6=W<6NQR)(@X$D9 S@\<!<BJT/PXO;;PUIVD0>(=ITJ_6\L)&LP53:SG;
M(N[Y_OGG*]!@#G.A;>#]6LM3U[4;?Q&%N=7CB#,UDI$3HFS< &&1CH.W&2W<
M J>"?$6L^))FAO94M[C22]MJL(529+C<<;,<A-HSGOD =":B;Q-KRP>/?](L
MS-H8W6A^SG;M\CS<$;LD]LY_#M6JO@QK/Q-8:SI-]%8^3:_9;N 6Y=;M <@L
M=XP0<D-R>3DGI4+>"KMAXL_XFT/_ !4*[6_T,_N/W?E\?O/F^7Z<_E0!G6?B
M'Q%!?^#;B^O+6>TUV,1RV\=OM,3&#S X?/)R#D8 YX%1:KXPU@:-XOU2TGBM
MIM!O#;PV<L099E54.Y^C?/N.W:1VZ\UL/X-O'3PLO]K0C^P""I^R']_B,Q\_
MO/E^4^_/Y5QBWD-_KFJ:E%XRT.PNC?.%LM7TZ-[F'8=J@%G5@/ERH _B]2:
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MI?AR[T[Q;K.N/J,,J:H(5>W%L5,8B4JN&WG^\<\?E0!T5%%% !1110 4444
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M".I8N""H";E^7(X'XBLK3_$_B8:#X+U^ZU.&:+5KNWM+FT%LJ@B7<-^[KN!
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M6*,E6)Z*0,<<\]:V-4EN]4^(GA.>TF2TFN='N9/,*;_+#>43@'@GGC/'L>E
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M10 4444 %%%% !6+XG\-V_B?2TM9II+>:"=+FUN8L;X)D.5<9X/<8]":VJ*
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MU6T$@M[N%9HQ(,-M89&0">: .>B\&WR:_=ZR^OR27-W8"SF5K5 A(+88 '(
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MM9S;-?I//+<*JEU2(+\J!@1DEAR0< 'N<BC>-XETC1;A;W6[$?\ $R18KQU
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MGS:1)=& HORR+*B@A@-W0G@DTM]X,&J^%KW2-2U:ZNKJ[*/)?LJ*X=&#)M4
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M<TT1%5D_MFRVEAD ^:,9'<5<M?!][_PD6FZWJ/B&XN[JQ@D@ 6WCC617(SD
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M%J.L7 FFFDD$96$1AD5V57&.H8 -^/'%9MI#=O\ &?4U.J7GDQZ5!*L/[LH
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M+Z_N]&T^:V06&I);I);^>=VX3,5;;_!@<#&>?2W=:UJ6J^(-1T?3I;R,6%K
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M1#J>JIJ.E:NLZM$+98S:R1H7&PCEE(!&&)/O523Q-KT_PT_X3JUO\2*K7?\
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MN R1S@D=J *E]X:,WB5=?LM1FM+W[*+.0>6LD;Q!BPX(R""3R#]0:IZA\/\
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M#^V8$@O4N"@5PBE00%48(R>F*=H'@I=!V@Z[J]\D"%+1+R97%L",94;1D@<
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M<$9/IG'?O7?V-E%I]E%:P;S'&,;G8LS$\EF)Y))))/<FL ^";9F\1$ZG?_\
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MB$BUNED3S-I3RRARNW&WC@ ]\YR:Z'4].34](NM.>:6&.XA:%I(R"X5A@X+
MC./44 >;_;M?@TOP'JB^(;MIM8:WM;J)XT:+$D!;<%QG>"N<DGD],<5LZ-<:
MI!XG\5Z!)K-Y<16UM;W-K<3B-I8FD5]PSMVD94$ CBM*3P/;2:=H%C_:=^(M
M#DCDM2/*R2BE5W?)SA21QBK2>%8HM>U36$U*]6XU&!()5_=[45<[=HV9R-QZ
MD]: .&AU[7[GP)X!U!-9FCNM2U""WNW\M&$JOO))XS_".A K>T6;5(?%WB?P
M_+K-Y<PPVMO<VT\PC,L+2!PP'R[2,J" 1@5;C^'UE%HFAZ2FJ:B+?1KE;FU.
M8MQ9<[0QV<@;CZ=:T(_"T<7B#4=:CU*]6YOX$@D7$>U57.W:-F<C<>I/6@#A
M8/$&O7'P]\":DNL3)=ZAJ=O;W3[$(F5W;.>,]AT(XK7MH-7?QYJWAIO$NI&Q
M-A#>K+B+SXV9W0JK;,!3M!QCZ8YSIQ_#VRA\/Z+HR:GJ(MM(NDNK9LQ;BZ$E
M0QV8(!)[5I1^&8X_%%QX@74+S[5/:K:LF(]@122,#9G())ZT <-9>)=;F\'>
M#KZ3493=SZ\NG73A5 N(A+(AW#&,D(.1CO6[)J.I_P#":^)]-CU*>.WATJ*Y
MMP%1O)D8R9*Y4_W1P<U97X=V,?A>'0X]2U +;WGVZVN28_-@FWE]PP@!Y9N"
M#UJ>#P1##JM[J9UC4Y+R]LUM)Y':,[@,_-C9@'YCP  /2@#C8=4\0IX2\$:\
M/$%TUUJ5W:VEQ$\:&%EFR"2N,E@<'.?R'%=/H5QJ%A\1=5T&XU2ZU"T_L^&]
MC-UL+QNSNC %5 VG:#C'':I_^$!L_P"P-%T<:GJ"V^CW$5Q;,/*WEHSE QV8
M('TYK2@\-Q0^+)O$7VZZ>YEMEM6B;9Y>Q26' 7.<DG.>] &7X\O;_18-,URW
MO9HK"TO8EU&%,;7MW;:6.1GY25/&.,UC0^)[JP\8^)+&YN[JYM9+;S-(#E0'
M=6\N2)"!DGS2JC//7ZUWNJZ;;ZQI-WIMVNZWNH6AD'?:PP<>_-91\&Z03H!,
M3$Z&2;4DYSE-IW>O.&_WE!H QK^?5M(\7>"--;6+BXBNA<QWBNJ8G=(2P8X4
M$?-VSCIQ6)I-K(EK\2I'OKN;R[BX3;+(&#?Z,O)X[=!C@ =*[K5/#<.J:]I.
MKR7EU%-I;2-!'%LV,77:V[*DGCCJ*I-X*M?M.N2Q:EJ$,>L@FX@1DV*Y0(SK
ME2<E1W)'?&<8 .0T:?5-%TSX<7,>K7,EOJ,5O9S63*@A"&V+*5&-P8%1SDYY
M[<5$T-_N^)5]8ZO=6$EE=-<1_9PGSNELK#>6!RO &!COUXQV1\#VQL?#]I_:
M=^(]"='M3^ZR2B[%W_)S\I(XQ2KX)MEA\01?VG?E==+&ZSY65W)L.SY./EXY
MS0!E6/B.[\0>(-"T5YWMDN-!75KEH#M:5F*J$!ZJ 2Q..>G.,YQ]5U;4)/"W
MQ)\/:A.UT=(M6\BZ< ,\4L)=5;  ++TSWXKK3X(M$319+:^NX+[1X?L]M>+L
M+M%@*4D&W:RX [9R,@BIKCP=97.AZMILEU=;]7)-[=@IYLN5"X^[M "@* !P
M!Z\T 8UKJL]YK^@>%HKB2V@_L4:A</$=KR@%8U0-U49))(YX'/6N?LFOM(\/
M_$Z>TU.X6\L[R::*Y*HSDK;HP!RI!X &<9[]:[*^\#VUT^D7,&IWUIJ6E1^3
M!?0^7YC1XP4=2NUA^'6HD\ 6JV&OVC:MJ3KKA)NV9H\\J$8K\F 2!Z?3% &3
M>7^LS:WX$M8-9N+>+5+.8W05$;<RP*P8$K][+'KD9QQ5:+7/$6F^%_'$-I<3
M:G?Z-=-'92SJ'DV%$;D  ,5W,1QSC%=3_P (=!]NT"[.I7QDT2)XK8?N\.&4
M(=_R<G: .,5B>)/#BZ-X?\13V[ZO?'6IT-VL 4O"IVHTB*BACM0?=YSCW)H
M+*^N[SQSI<&BZ]=7FBR6!N;PJT<JAPPV;F925W@GY5(^[D8P:[^O.= -W+JE
MJ^C^*M>U.$2#[1#J-B$B$?\ %ES$A#>@!)SC(QDUZ-0 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *Y_7O"%IX@OX+RXU#5;>2W0I&+.\: +GJ?E[GU]JZ"B@#)T+P]:^'X9
MTM[B]N7F<.\U[<M/(<# &YN<#GCW/K6M110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
K %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>a109-2021formrsuawardemp003.jpg
<TEXT>
begin 644 a109-2021formrsuawardemp003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M.M0>'/!VJC4;:^1]/O[I[A%M7) >=BNWCYLA@>,\<FO14<.BN,X8 C(P?RH
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MG 4#DDD]!63:^*=(N[ZVLTN)$FND+VPF@DB$Z@9)C9E ;CGCMSTJE\0=+O\
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MR^R"WC:61O15&2?R%<SX3ET'4]0NM8T2RNSYL2QRW]T)E:4CH@\WE@O<]!D
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MNNU?Q!I^A/9)?R2QF]G6V@*0NX:1ONJ2H(!/;.* *7_"+S?]#)KG_?\ C_\
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M@DQC)(('8XX-4/&'B*T@T#7;>"XO%N;2U<R36<;G[,Y0LNYU'!Z'V!!. <T
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M;& 3@\'TKO** /(O"?V,Z1I_A;6O#.HR:YI[)%Y<L<K6Q*'"SB0G8%QSGKV
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MT@L6MWA8>6T<B_O=V,;-J[MP.#T'/%=)H^Y/BUK[M%/Y<EA:Q1SM"P1V0ON
M;&"1D=Z[FB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1QW:VS^2CN<*COC"MGC'8]<4_4/'NBZ??W]@RW\]Y8JCS06]E([[6R<@ <J
M,ENG(YYK@8K._3X(:5IITO4OMT6H1L]O]BE\Q5%WYA)7;G&WG-=%I^J6UC\6
M?%#SK<;)+"R962W=\8$G!"@D$YX!ZX- '21>,]%NM-TN^LKAKM-48I91PKEY
MF )88.,;0ISG&,5#/X\T*V\/7&MS2W"6MM<-:W ^SN7AE#!2C #Y>2!D\<CF
MN*TZSU3PSIFA0S:9>165]J5Y=7+VEJ9I[)),F*,!02FX'#%1D<C(ZUFW5EJ
M^'?C;3$T75Q<7&MM/;QO;22/(C21,"",EN%8DY/3DY(H ].M/%^F7NL3Z7$E
MXMW' ;E$EMG3SXP<%HRP&X9('X^E)9^,-*O_  U<>(+<W!L("X<M"RO\APWR
M'G((/&,\5CWOFS?%C1+R.TO#:KIEQ$\_V60(K.R%0S;< X4]:I+HEY:?$.ZT
MFW53H.I.FLSKG_5RH<,F/1W$3^^UQ0!Z"D@>%92&0%=Q#C!7Z^E8*^,](+6;
MLT\=G?2B&UO7B(@F<] &[9P<$@!NQ-:.NV,NI^'M2T^"7RIKJUEACD_NLR$
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M";R,;L \>H(Z\5RUDLL/B_Q+<QZ;K;VE[HT0AGN+>5C(R^9GKR#D@!, \_=
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MR)>I-DJ0X&T'+$,"1COQ276DWFBV?PYTR2WN[J33)T-U);V\DJ1@0LA)900
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M8K$T=[CPQXS\3KJ=M=O:ZG.E[9W4-N\RO\@5HSL!PPVC /4=*YVTT&_T+2/
MUK/8WC/!K,E[/'#;O*+6-_-(#%00,;U!]\T >HZ1JL&M:7#J%O%<112[L)<0
MM%("&*G*MR.0:RX/&VCW$]DJ-/\ 9[ZX>UM;LQ_N9I5+ J#UZJV"0 <<$UT)
M)VD@9..!7C+S:GJ.G^&+RZT364O[/7HY;VUBLG2"U3,G$: !6'(.\;CR<L,@
M4 =]=?$#1+6;4X=NH33:81]JCALI&:,%=VXC'W0.<]/3-7'\7Z2M[H]JKS2-
MK">98R)$3'*NW=][H/EYP>:Y:T6X77?B+,]A?K'=QP_9R;23]]MM]A"?+\WS
M<<9_*HO[%N;SX+Z.$22SUC1K2&ZMS<1F-HIX5!(8-C@@,I[8- '?0ZI!<:M=
M:<BR^=;(CR,4^0!L[<-T)X/'_P!:F7^LVVGW,%H5EGO)U9XK:!=SLJXW-V
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP569<_>ST;ID=* /0Z*Y'1->T&WTW6+^R:^\H:L\$RW&_>UTS(NQ%<Y4%F4
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MV\$K1&><?ZQY&4@D X 7..YK4BBT[2_%41M]>V@6\D4FERWIE)8E2KHC$L"
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M#Y65&)(8$=!P03WIMI\0='OKMX((-298KF6UGF-FXC@>-=S>83]T<'KSQT%
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M&W-I('<22EE(&.F.<]N]=%J%WJ,OBBQMI=+U-](ETP&-[2%D9[C=S'*_!10
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M[KU'XUY3K2ZYJNDSF\T+5VU&UUR.8Q00$0+ LX(:, @2$KR6PS9)R0*]CHH
MX?2S/%\3->U&:POHK6;3[9$D:V<@NF\LH(!!(W#IG/;-9GASPQ/JOP4M]!O8
M9[#4(HW:,SQM&T$RR,\;\CL=IR.V17I=8NO>'%U^6U,NJ:E:P0[Q+;VD_EI<
MJP *R<9(X[$'DT 4O IOKW0(]<U6-8]1U14FE13D(@4*BCVP-WU<U2\6QSMX
MT\'7$5G=S0VEU/)<20V[NL:M"R*20/[Q'\Z[-$6-%1%"JHP% P *6@#C-9AN
M'^*?ANZ2TNGMK>TNHY9T@<QHS[-H+ 8YVGZ=ZXR9K<P>(="N=*\0_P!AWFK2
MS2+::8UPK 2 OLF0X"LR$D;25R1G/3V:N4T_P2^E*+:Q\2:U#IH)*V6^)@H)
MR5$C1F0#GLV?>@#.CN!?_%#3-:M+>[ETR30WC6Z6VDV;GD1U7..#M!^G3KQ7
M-2:7JDOP_P!<BCTJ_,Z^)&OT@-NZR20_:5<,BD#=\H)P.:]=MX(K6VBMX$"1
M1*$11T  P!4E %:*0WVG[_+FMS,APLB[77/0D=CWQU]:\OLM.U-/A-=>!;G2
M[K^V$CDLHV\AS!*&<E9A+C8% .3DYX(QG /K-% ' W]G/9^/?!P2VO;BVTZR
MN8)[I+9V12R1A,L!CG:?IWKJ/$\<,WAN]AN=.DU&WD0)+:QJ2\B$@-M YR 2
M1]*UJ* /+[/0M933/$^AV%UJ-]HEQH[QV)U.)DFBG=77RE9P&9<8// R!ZU%
M#-J%\_P^:/0-71=,?R[OSK4Q^6WV<QGAL<9_BZ>A/;U6B@#S7PU>:OX9_M'P
MQ=^'=0O)3>SS65W'%NMIHY7+@R2$X0@L<@\^F3Q6G8+/!\4];OIK2\%J^FV\
M2SBUDV.Z,Y8*<'/WA]>V:[>B@#COA;:W-C\/-,LKVUN+6Y@\U9(IXF1ES(S#
M@CG@CI6?9Z;?>"_'NM:BEG<7FA:XRSN]M&99+6X&<[D7+%6R3E0<<<=Z]!HH
M X&X@FUCXK:'K%I8W9L;"RN$GN)K9X0K/C:!O +=_N@TGA%=2L](\8F+3;@7
MDNJ7MW9Q74#1K.& ,?+ <$C'K]*[^B@#R2P74KC7_ VK2Z+KC2VZW$=^\\!0
M12/#MPL>0$0'@$ +C').:5[*_?P!\0;,:9J'VG4-2NY+2(VD@:99 H1@,=#@
M_3OBO6J* //S'>V_CKPUJ@TR^EM6T>2S9D@.8I2T9 <'&P?*>3@5C:):-I<=
MWX8UCP-)J5V+F4VU\;))+:XC>0NK22'A<;N0<GCC)XKUFB@#R^2%O#_B_7(-
M6\(7.M6&J3K<VEU:62W&TF-4:)\_< V<9.,&O1=+@^S:7;0_9(+/9&!]F@ "
M1?[(QQ@=.*MT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %<UXY\1W/ACP^+VULGN99)XH 5
M*@1[W"[CDC/7@#OC.!S72UR7Q(T^]U'P;+'86LEU/%<VT_DQ#+NJ3(S;1W.
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MW'/4%AP,Y^G-0^$!.T6G:7?^ A9ZK8[%GOY;6+[/\F 9(Y <LQQP .">3@4
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MM@*D.!WW*WE'V85Z#0!P-EXP36_"'B*]US2;V'3H)+J"58BK-Y291ERC;MV
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8_B;P[;^*M"GTB[N
M;F"VGV^8;<J&(#!@,LIQR!6K$C1Q*C2M*RC!=P,M[G  _(4^B@ I&7<I7)&1
MC(.#2T4 8OA_PU;^'HI E[J%_/+@/=:A<&:4J"2J[CT4;CQ[FMJBB@ HHHH
M**** "BBB@ HHHH **** ,30_#-OH<]Q<"^U&_N)B1YU_<F9HT)SL3/W5S^>
M!G.!6W110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSZ#XFMEM;J.Z0VXM,F1#E<[I&X![4FL"35[O3K__ (1WQ);:EI[,;>\A%KN
M8896!D*LK#J,?3% %6&X\07EYXP\*V^J3B\TZ.*XTR_(7?B1"RQR<8(#*1DC
M)!]15_PUKDOBC3_#LEO=7$;K 9]0&X9W+F,QOQWD#'MQ&?6I-*NY=+FO+D>&
M?$$]Y>N)+FXE%MND*J%48$H   P !Z]223'HK1Z#<:G/8^$==5]1NC=39%OP
MQ R!^]X&<G'JQH S['5/$LVC^-4L[F;4-0L=5,%HK[$?R@L1*+@!0VTMCCKB
MEL?$<>I^'?$]SI.KZE;7=G9[C97T8^T6,JH[<AP<AL#KGH<$=F0Z=+;P:LD6
ME^+D?4[Q+Z24?8@T<JLC I\V,?(HP01BII+:2X&JRW&@^)7O-3M1:3W*I:*R
MQ , JCS,#[S<D$\^P  $T_Q%?7Y\#:-)=RH^J:2+V\N5($DNV)#M![$LQ)(Y
MP.,9JCJNNZWI2>.-'34[@MI>G#4;"\*HTB*R,3&Y*D-AEX.,X[U9?2P=-T2W
MCT'Q1'=:(H6POE^R>:BA0A4_O-K*5 !!'.*EN;(WFFZQ:W&@>)FGUA!%>78%
MH)&0+M"#]YM50"<<=R>IS0 VWO-8T_Q+X+>76;J[BUJ"5+JWE5!&"L'F*R #
M(.1SDG.:;IOB*Y3Q7;Z5KUSJ&F:JU[*8A(,VFH0_-L6)AP" 4..&R.<YI[V<
MLEUH-PVC^*]^B*1;\66'RFP[_GY^7CC%+':3'[#'=Z+XHO+:QNA=V\,RVGR2
M#.WYA("57<<#Z9)'% &[X[U^?P[X:-S:E4N9[B&UCD9<B(R.%WD=\ D_7%9^
MHWFH>&O&OAZTCO;F[T[6&EMIXKA@[1R*F]9$.,C."".GH!4VN72^(M&N=*U+
MP?KLEK<+A@/LX((.00?.X((!!]JIV7VJ&^L[V^T7Q-J5S91M';/<+:#R]P 9
MOED&6(&,GMG&,G(!%X%L&B\8>,7-]=R>5J**5=P1)F!.6XY/Y=*E^(=O)-K/
M@[;>7,(?6%C*Q/@?ZN0[L8Y/'&>G-&BK/HFJ:G?Q:)XHG?4IA/.DPL]NX+M&
MW:X(X '7M3_$+2^(HK$2^'O$UI-8W2W=O/;?90R.H(_BD8$$,>"* **Z9<7_
M ,4O$5I#JEW9#^RK,--;[?-8YDQ\S @>IP.?4<YK:'XOU?5O#W@NUED+WNKQ
M7#7$R.(FD$'! ."%+9!) S@'&.HT;:&XM/$%[K,6C^*_M-W;I;NK?8V553.T
MC+YR,GDDYSS62WA>V_X1?3]$70_%R'393-8WJ/:K<6[$DG#+( 1R>"/Y"@#L
MO"MOX@LY-2M]:N$GMA,'L"TOF3+&1RLA"C.".#R2.IXKG_&#7"_%GP(;6**6
M;RM0VI+(44_NEZD*V/RJ_HEW=Z-;.KZ%XGO[F0@RW5VULTCXZ#B4  <X  ')
M/4DU3U.";5/$^F:\^B^*8KG31(+>.,6?E@2+M?(+DG('K]* (Y?"MWIUKXY\
M2:I/ U_JUBZ^1;9,<,<<+*HW$ L2,9.!]*73+B=/"W@6V2_>*";3(_,L[8'[
M1=$0)MV,/NJI)+$D#[N3SSKZKJMUJVDW>GR>&O$,,=U$T+O$+7<%88.,RD=#
MZ5SXT=H_[#>VTOQ?;W&CVYM8)XS9[GA( V."Y4\*.0 ?QH SY/$GB!_AJM\N
MJ3PWUMKGV$R,D9:2/[2(P'P.H!P2I&<=:Z?3)]2T[XGW&B3:K=7]G<:2+X"Y
M"9CE$NP[=JC"D'I[5@?\(U&-'GTM-)\8K:S7_P!OQYEHQ5]^\ %G/&[GG)/<
MFM^RMI;KQM#K<NF^(K>X-I]B+3BU$ CSOR0K%L[AU'\J .UHJAHNF/H^DPV+
MW]Y?M%NS<WDF^5\L3\QP,XS@>P%6+R![JSE@CN9;9Y%*B:';O3W&X$9^HH \
ML\96\WB:SUC4K.ROGO[&9#HUQ% 613;L26!_VGWK[A5->B^&M<@\2^&M/UFV
MP([N%9"H/W6Z,OX$$?A4VDZ6NCZ+;:7#<321VT0ACED"[\ 8&<  G\*SO"GA
M*W\(VD]I9W][<6TLS3"*X*$1LQRVW:HP">W2@"I<ZC-JGCV;PX+J:UMK;3EN
MW\AMDDK.Y4?-U"J%[=2PSP,',EU#6M-U#PKX4U#5A<7FH27/VF_A0([1Q)O5
M!V#$,F2.P.,$@UL^(?!EMKNJVFKPZA?:7JELAB6[LG4,T9.2C!@0PSSTZTZ]
M\&:?>6%A#]HNXKO3YOM%M?K(&G64_>8E@0V[)R",$<8&!@ Y;5=:UG1M1\6:
M''J5PRVVBMJ^GW3!7DAQN!C8L"&&Y<@D9QGFJ\U[XCT:S\'>(FUZYO8]2FM+
M6]L98T$1690 R8&0P/.23D^@XKHO$NC0:?X3\47TD\MWJ5]ILL#32*-S 1L$
MC15  &6/ &23WIOA70([WPYX:GOKZXNTL+>&6&WE55$<PCVY;"@DID@ ].^2
M,T 48M<O?#OB#Q)I6K7MS>%K=;S2-[ &1&^3REP!\PD*@'J0P-=MI5M<V>DV
MMO>73W=U'&HFG?&9'QR> ,<YXKE1]A\:>*M.NAIEXB:#/,S3W=NT69?NJBY^
M\,_/D="B^M=M0!YG!K6K:]\-]0\96>IS6U[%]IN+:W&#$D<+L!$Z8^;<J<D\
MY;@@ 4S5I'U_Q-\.-3^T75J=0CFF\N-P/*)M2WRY'7G!S72KX$LHH=2LK>^O
M(-*U*1I+FP0IY9+_ 'PI*[E5NX![G&*MZEX5M]1UC2-16]NK5])W_98H!&(Q
MN78<@J2?EXZ\4 6O$43MX6U)$N)XG%I(1+$VUP0I.0>QXZUYC);2Q_#'X=;+
MJ4R2ZEIC*TN&$9*] ..!Z5Z]<01W5K+;S#='*A1QTR",&N33X>VJ:-I.EG6=
M5:#2KF*YMBS1$J8_]6I^3&T?3)[D\4 8T_B#4_"FJ^,8);^XU2"PTJ/4;87>
MTLLAW@KE0ORDJ#C'':M6QMO%"ZQI%_#>"33I$(U!;FY5Q*&4;'B 4;3GL" 0
M:U&\(64NNZCJES<W-P=0M!97%M)L\IHAGC 4'^(]^]5?#O@6#P]+$$UG5KVT
MML_9+.[G#16_&!C !. 2!DG'UYH 9\4O^28>(?\ KS;^8K,/A?4_$Y\(W-^U
MG:Z=I!AO%2&1I)9Y%4; 254(OKUS75^)-!A\3:%<Z1<W5Q;VURNR4V^T,5],
MLIQ5S3;+^SM.M[,7$LZP1K&LDNW<0!@9V@#MZ4 <#:7$]KK?Q,GMKZVL9XY(
M&2ZN?]7"?LRX9O8?YS4^C:GJ!\?)HZW>I?8+G16N@UV%WF59%7S$#9*@AC\K
M =/NUJW7@#3KU/$4=U>WTL>O;#=*60;"@ 4IA000%'7/3FGVW@F.#6[369-<
MU:XU"WM6M#+))'^\0D,-P" <$ \8SCG/.0#A;;6/$2?#?3?%4OB&[ENXM2$3
MPE(Q%-&;LQ$. N2<'L0!@8 ZGUN^D>+3[F2.:*%TB9EEF^XA .&;V'4URP^'
M=B/"*>&AJNI?84N/M ;,7F;O,\W&=F,;^>GMTKIK_3H=3TBYTR\+207,#03'
M.&967:>G0X- ' :3K6I0^*_"5M]OO+NVU2SN/M4\X BN9(T1A)$IPR#)/8 @
MC&>M/T;Q%<_\)3::5KUSJ&F:P;J8B.49M-0BP^P0L.!@%#C@_+SDUKVGP_M[
M:YT2YDUO5[B;1P\=LTDJ#,;*%V$*@XP!S]X]STQ<A\'PK_9L=WJ-W>V^FS_:
M+6.<)E' (7+!02%#' ^F<XH 7Q]=WNG^!-9OM/O)+2ZMK5YHY8U4G*C./F!'
M]:P=1O=8E\4>#;*#6;FWM]3L;AKE42,G<D2$,"5Z_,>N1[5U^OZ-%XAT.[TF
MXGFA@NXS%*T.W=M/4#<"/TK//A"%M4T34&U*^,VCPO# /W>UU=0K;_DY)"CI
MCI0!2\!WM_,?$&G7U[->_P!F:H]M!//CS#'L1@&( !(W'G%,U+4K[4_&-YH%
MJTT<5I8Q3GR+@0N[R,XW9()PH0<#C+<YXK8T/PW#H5YJES%>W4[:E<&YF6;9
M@.0!\NU1@8 '?I5+Q#X*MM=U:UUB#4;_ $O5+>,PB[L9 K/$3G8P8$,,\].M
M '(>++/73\/M)C\0WX;4X=5M8I7M'&V0&==K,-H^8#'3C-:/C#3''B_P/'_:
M5\=UY,F_>NX8@<[A\O7M]*Z#4_!=IJ>AVNDOJ%_%%!.MR94=&DEE5MP9V=3D
M[N>,>G3BI]5\+IJ^IZ3J$VIWL<VER-)"(A& S,I4E@4.>"1QCK0!SL]WKGB&
M[\166EW,\$NF2BTM72X6/;((E?S)!M.\%FQ@\87@9R:GL-3U75O$D7AW5+L6
MT]KI,=U=FQDV^=,SE#M;&0J[<X&.6P>G-S4O 5M>>(9-;LM7U32KNX18[O[#
M*JK<A1@%@5/S <9%/U?P'8ZA>:??65]?:3?V,/V>*YLI!O:'^X^X,&&>>>_-
M ',^)-.U:%?!%KJNN375XNM"&6>WQ&'!21E9EQC> %Y^O'-=YKNI_P#"/^%]
M1U/:TYL;228*QY<HI//UQ5#4/!EE?Z9IUH+V^@EL+I;R&[216F,HW99BZD-G
M<V<C'TQ6X]I#-8M9SKYT#QF)UE.[>I&"&SUR.M 'GNJZMJ^B>#M"\6QZG/=2
MRM:M?6[X,4\<Q4$(N/D(+#:1Z<YH=M;U+Q#XXL/^$CO[>#34@DM?)6-60M"7
MQG;]W/MD\9-=#8^"+2SL[+3I+^\NM+L9EFM;.<H50J<H"P7<RJ>0">PSG J:
M/PC#%J6NWR:E?"7641+@?N\)M78NSY.,+QSF@";P;J=QK7@K1=2O&#7-S9Q2
M2L!@%BHR<=LFN)T>UD0_$F1[Z[F\N>9-LL@8-_HRG)X[=!C@"O0/#^BQ>'="
MM-(MYYIH+6,1Q-/MW;1T!V@#]*RV\%VOVS6[B'4M0@36!_I$$;)L5R@0NN5)
MR5&,$D=\9Q@ XW19]4T71?AO=Q:M<R0:@MO9363*@A$;6Y8$#&[<"HYSSSVX
MK1-YXF\4V.K7>AW+6UY:ZA-;6F;A5B3RGVXD3:=VX DYY^88Q6Z? MJ=.T"R
M_M34!%H<B26I_=9)12J[ODYPI([5#-\/;/\ MZ[U*RU;5=/BOG\R]L[2<)#<
M/W8\94GN5()]J .KMGD>UA>8()612XC.5W8YP>XKAOA-_P @/7/^P[>_^ABN
MZ\H+!Y41\H!=JE /E'; /%<OI'@;^Q+2ZM;'Q%K$<-S.]Q(/]'SO<Y8@^5D9
M]NG;% '&6L\]CX^^)<ND7]MI]NEM;NUU.,PPW)3EB/7[V>O/8UT&D:C?2>/I
MM#%SJ:Z=<:)]J4W9 E$@E">8F<L@(/W6 P1T%;,O@+0G\)7GAR.&6&TO#OGE
M20F9Y-P;S"[9);(!R<]/2BR\&16OB*VUV76-3NK^&U-H[32(%F3<&&X*H P0
M/NXSWSSD X?PGJEYHWPN\.M!=W$EQJ^I?8@\L@/E[IIB2I(/S-M(R<\D&NVT
M"T\167B&]6^G#Z--"KV\<UQYLT4H.& .T90@YY)P?K59/AOI'_"+S^'I;J_F
ML'E,MN&E4-:-O+@Q$*,$,Q.3D]NG%:N@>'#H@9[C5M0U6Y*[!/?2!F1/[J@
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M6;;+*K;H#''DD8/.0Q';'O67H":WJ_B?7TG\2WJ6VDZL@CB6.("2/RU8QO\
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M57\B-L@8QD[R/I78>._^2?>)/^P7<_\ HIJK/X&M##X?5-2U".70XVAMIT=
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MJ%G<:G>R:?J#*UQ:N48'"J,*Q7< =@SSUR1@FND    & .@H 6BBB@ HHHH
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MT;HCJS0%LY"CC/. !GOFD.OZO=>&OAUJ9U&:.74;VUBO$C"A9PT;$D\9Y*]
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MBO*?#LFL7'PQ@\47?C&[MKN;3W0O<!7@C)DX?8!DO@8')R6  Z"M;2+V_/Q
MOM%2?4[:QET9+N-;N422I)YI3>NXL5R/X3W'04 >@5&)XFN'MQ(IF1 [)GD*
M20#]"5/Y&O(--U/7%\!^$?$TNOW\UW/J,$$T3,OE21R3%&#+CDX[YX[8K9M#
M_9GQ#\>:GYMU*;*QM;A8C.Q5OW<K;<>G' [9H ]*HKSS2XO%&HP>'->M=0@6
M.?RI;_S;YWBN(9 ,A(MFU&!(VX(]"3UJK!/XH\6>'Y-:T:]AM+Y;V7R6EOG6
M&...8KY<D(0J<JO)/.3G(&  #TVBD0ED4G&2,\'(I: .:/C&,^)KKP_#HVIS
MWUM MP^SR AC8X!!:4=ZNZ)XEL-=GO;6!9X+ZQ<)=6EPFR2(D97(!(((Y!!(
M/K7'JFH/\<-7_L^:VB?^Q8-QN(6D!'F'IAEQ53PK'/\ \+$\6Z3K<CIXBO;:
M.X%Y9/MB^SKA4\L'E&4L,ABV2/3J >IT5YMH.K:A?Z+#X9N[ZY'B&VU,VM[.
MLI#^6A\PRCT5X]JCMEQ7;Z_.]IX<U":*_AL)([9REW.-R0G:<.P/7'6@#2HK
MS?3M9O=.\:6]L)-2DT^70I;MTO7+--)&R_O%5B6CR&/RG'^Z,5=T!-3\0>'?
M#_B6+7I+>YG=+J\5B6@DB;.Z )D*N,@!L9RO.<T =W17 :>^I^,])UB]L]:G
MT[4(-2FMK0HQ,=NL3@8>/(#E@"3NS][C&*6YO-5\2Z_X@TJQN/+&FI#'"\-\
M]N5>2+S!+A5;>,G !)7Y>G- '?5'//%;6\D\\BQQ1*7=V. J@9)/X5YO.WB=
MO$GA+1]0\0/%-=V5VM^UAMV,\6T;D)0$,<G.0<'. .M<YXEEU2+P;\0_#FH:
MI>7L>C_9Y;6[DDQ*\<PW>7(1C=CWZY],"@#V*\O;BVN[&*'3YKF.XE*2RQLH
M6!=I.YLG)&1CCUJ[7$>()+W2?$?@VVM=2O!;7-[)%/$\@82CRG8;B1N.".F<
M>U8LO]L7][X^A;Q'J<2:65>T\EU0H?LXD )"_=!/08SWS0!ZC17G9\1:C<V/
M@*XOIV@TW5+82:C<QMY?[XP!XU+#!16;<>,= ,XZZG@1M5G;6IKZ_N[FQ2_D
MATXS[2&MQC# [=S<[AN).0,^] '6//%'+'$\BB27(12>6P,G%9'A_P 1Q^()
M=5C2SGM7TZ\:SD68J2S!5;(VDC'S>M<WKED)_C#X>)N;I ^G73;4G90-K1]
M.!G//KQZ5SSP7JZ5\2=2L]6O+&6PU&XN81;,%#.D",-_!W#@#'3KUXP >P45
MP']MZCKVN6.D)\JMHD.HR+'=O;,[R,5R&12V%V]!@?-SFNB\)6^MV>B"U\07
MD%W?0RLHFB<L6CZIO.U?FP1GCG@]Z -'5M3MM%TB\U.\;;;6D+32$=<*,X'O
MV%.TW4+?5=,M=0M'WV]U$LT;>JL,C^=<_P")[C[9JVGZ.+&>]MT(O+V*%5/R
M*?W2L&(&"XW?]LB*Q/A?<OIW]L^#;J.>!]*G,EFDQ <VDI+)R"<D'()!XR*
M/1:*\GOK[6[?3/%?A^+4[]]?M;Q)-+D67YY89!N1>>" %D#<?PD]:Z71=:3Q
M)%::O87LEO90:6))#)*6C$SC($F3R8PK9S_?'I0!V=%>8:7JNHP^)?!D2:A?
MW,&J0W"W=S,Q\J\98=XDBC8Y0;AQ@*"#T(I=$GU1X_$VLWWB#4YHM!U>[\NV
M5D"S1QQ*=CX7D<\ 8QUZF@#L_$OB./PU9VMS+9SW"3W45MF(J A=@H+9.<9/
M8&MNO(=?2XU/X=>&M?NM1N9;N\OK"YF42GR3YDBG8$^ZH7( (&?EY)R:]>H
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MN>I/.<\]:VZ* .,O/AKI5[;:M9OJ&J)8:G,UQ+9QSJ(TD9@S,ORYY(Z$D<Y
M!QC6B\+6\7B6'71?7S745I]C"NZ%&BW;B#E<D[AG.<_AQ6[65JVM)IMU86,<
M8FO]0D>.VA9]BG:A=BS8.  /0\D<4 5(_"=O%J6M7Z7]\)M81$N>8\ *NU=H
MV<84X[_G54> [!=*T33EO]0$&BS)/:?-'D,H(7<=G( )'XULZ+J-SJ>G>?>Z
M;/IUPKM&\$S!L%3C(8=5/4'O6?K'BR#2_P"PY(K9[NWU>[BM8KB-U"+Y@)5C
MW/ )X'XB@!+SPA:WZ7EO<W]]+87DXGFLF9#&Q!!P#LW!25!(#?S.9(O"MO#J
M^KZG'?WJW&JQI'<<QE0$!"[1LXP"?7KSFMZB@#CI_AMH\WA[3-(%UJ,1TIBU
MA>Q3!+BWSU"L%QCZ@U:N? FE7WAU](O9[ZZ+2K.;V6<FY$J_=D#XX(Q@8&,=
MJO>*/$,7A;0+G6+BUGN+:V :58"NX#(&0&(SUJA#XWM5U73=.U+3K[3)M37-
MF]QY;1S' .T,CMAL$<'&>U #[#P;!9^((-<FU75+V_AM3:>9<2IAHRV[!5%4
M=0/RYS5_Q#X?M/$FGQ6EU+<0^3/'<PS6[A7CD0Y5@2"/S!J'0O$8UO4M9LOL
M4ML^EW*V[^8ZDN2H;/&0!@CO6Y0!S\WA*U;5H=6M;Z^L]02W^S27$+JS3QYR
M!('5@Q!Y!QGWQQ6GI6E6NC6(M+16";VD=G.6D=B69V/<DDDU=HH PY?"]J_B
M:37HKN]M[N6!8)4AD CD"DE2P(.2,GV]0:S1\/=.'A6/PX-0U'[!'<?:%^>/
M?N\SS.NSIOY_^MQ7744 <IJO@*QU+7!K4.I:KIVH-$L5Q-87 B-RJ]/,&T@G
MW&#^E=+:VL-E:16MNFR&)0B+DG 'N>3]34K$JC,%+$#(48R?;FL7POXB7Q-I
M<UZMI):^5=2VQBD8,P,;%23CCJ/>@".7PG9KK<^L:==76F7UR +EK4KMN,="
MZ.K*2/[P /O2V/A6VLM2O]4^VWDVIWT2PRW<A3<$7[H50H08_P!TUKR7<23-
M;J=]P(S*(5(W%0<=^.O'-9GA7Q"OBC0UU-+5[4--+%Y4C!F!1RAR1Q_#0!03
MP%I2^!SX1>>]DTW $;-(HECP^\%6"CHPR,@T^W\$VMOK::S_ &KJTFH"T^R-
M-)< [UW;@2-N,@]@ /4$ULF[NQK:68T]S9FW,IO?,7:)-P CV]<XYSTJ[0!R
M2?#[3H_#6GZ E_J*V5A<+<0?/'O#*V]<G9R W-:(\*V0\23ZV)[KS[F%(;F'
MS!Y4X0$*67') 8]\>U;E8UOXFTZY\6WGAN.3-_:6R7,B]MK$C'U'RD_[XH R
MM$^'FF:!=J]IJ&JM8QR&6#39;HM;0MG(*KC/!Y )(!YZ\T@^'6E1ZU=7]O?:
MI;6]Y*9KK3H+K;:SN>I9,9Y[@$ ].G%=?10!GP:4(-;NM3%[>.;B)(_LSRYA
MCVYY1,<$YY-:%%% '-MX.B_X26YU^'6-3@O[B%8',?DE?+!R% :,]^_6EMM!
MT[PM_:NO+%?:AJ$T>^XG;]]<2J@R$11@#IPJ@#I71T4 <IX;LX-2U^^\7?V9
M/8RWEO%:Q+=1>7,T:9)9E_AR2!@]HP>];FMZ/:>(-%N])OU9K6ZC,<@5L'![
M@^HZU?HH Y>T\#65MJ^GZK)J>JW5Y90-;B2>Y!\V,D'#@*!P5'3&>^:BTCX>
MZ7HE[YEG>ZF+!9O/BTQKG-K$^<Y5,9X/(!) /..E=;44ES##-#%)(JR3,5C4
MGEB 6./P!- '+R?#W2VUR[U*"]U.TCOG\R]L;:YV6]RW<NN,Y/?!&>]2:SX$
MT_5M<368+_4]*O\ RQ#++IMQY7GQCHK@@@X['@_D*ZFB@#SK7=,$?Q$\'V]D
MU];6]E;7:-<01EQ&7";0[LK*2V&^]R3SUYKI)_!NEW>B:KIET9YQJQ+7EP[
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M/N(! ..OI7<44 <]XD\'6'B864MQ<WMK?6+%K:^LY1'-'D88 XQ@XY&*AOO
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MXCSG;(I0J>>X /Z5TM9FLZS#HZ6BLGF7%[<+:VT6<;Y&!/)[ !22>>!T)XH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&:S$S2J!92G*2,C<(2/F!![?C7G5S9"+X??#1(9YT:;4M.;>TAD*$P-]W?D
M#L,8'I7K5S;Q7EK-;3KOAF1HW7U4C!'Y5S2> =,CTW2[ 7NI&'2YTN+7?.&*
M.@PG4'A02 O3GD&@#E[K6]1\(WGCN*"]N[V*PTZ"]M5O)3,8I'#@\GG;E0<=
M.#C%;MCIFNQ:[I.IP:G$NFO&RWD<VHRW(N@RY1D#(%1L\_+@$'&*V!X4T]M8
MU+4IGGG?4K<6UU%*5,;Q@$!=N/1C^?-5/#W@33/#4Z/:7>ISQ0Y%M;W5VTL5
ML#P?+4\#@D9.3@GU- %3XM?\DK\0?]>X_P#0UJ(^%+WQ#?\ AK4-4N[=+/2
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M=FW-@[<@$X/'IQCF@"M'?R>(/B!JFBS7%Q!9Z9902"*"=HFEDEW$N60AL*
M!G&22>V(?A3$8/"U[$TCRE-6O%,CG+-B5AD^YK6O?!EC>:M:ZLMY?VNI00_9
MVNK:4(\T><[9!MPPS[ U;\/>&K'PQ:3VU@]RT<\[SOY\S2'<Q).,].OX]\T
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MF!C KT+0/ NG>'&!M+[5)EC0I;)=79E2U!&/W:G@<<9()QQT)J/_ (5_I?\
MPBK>&_M5]_9K3><4\Q=V[?YGWMN<;_F_^MQ0!ER37GAWXC1VZ:C?WMK=Z1<7
M4T%S,7'FQLN&0=$R&(PH ]JJ:0GB/7=$\/>);/4X()93%<WCR:A*T,T3#]Y%
MY.S8A&< CD%>I.3782>&[>7Q#::Y)=W;WEM UNF60*4;!8$!>Y /\L5F:7\.
M]%T?4C<V4VHI:^=YZZ=]K;[(DF<[A'TR#R <@''' H Y.=-3N].^(,K^(=75
MM)N)7L_*N-FPK KC.T#*Y_AZ=>,\U8GC_MCQI\/;ZZFN1->Z5<2R^5<21C=Y
M43<!2-O+'..O?.!77+X,L5@UN$7=[LUHLUYET^8LNTX^7Y?EXX_G1)X*TV5-
M%#3WH?1T:*UE2?8_EE0I1BH&00H'KQUH Z.BL^PTF+3[_4+M+BZE:^D61TFF
M+I&0N,(#]T<=*T* //O#,9E^*?Q%C$CQEAIPWIC<O[AN1FN9TZ]UA/AUX6\3
M2:]J<M^VI10R*\Y\N2-[@HRLO1N.YR1VP.*](L?"=MIVM:GJ]O?7PO-3""Z9
MF0AMBE4(&W V@\8_'-4U\ :6GANST!+J^%A9SBXA7S%W!PV\?-MR0&R: -O7
MH5N/#^H1.TBJUN^3'(R,/E/1E((_"O*!:"+X1^!#%-,KSZEIC;GD:382PY4,
M2 /8<>U>R-$LD#0R_O%9=K;OX@1@YQ7*I\/=*CT:QTI+O4A:V-PES;AKC<49
M#E ,@_*O8?GF@# N=5O_  EXB\60PWMY?V]MH0U2*.\F,NR4&0$ GHIV@D#C
MTQ6CIUAK\EWH.M6^J1+9NBF]$VHR3I=I(HVE4*!4;<01MP.<=*Z#_A%[)M?N
M-9FEGFN+FU^QS1R%3&\62=I7;ZDG\?2J&@> -)\.7226=SJ4D$3%K:SN+MI(
M+<G/*(>AY/)SC)H ?XXUBXTC3-/2V=8WO]1@LC(S[-BN3GYL';D#;G'&[-4;
M;P]KHU/4[>;5FMM,O;3]Q"FH2SSV\X('F([@-MP1E<D9QV-=)KNA:?XDT>?2
MM4@$UK,!N7)!!!R"".A!YS53P_X7M?#RL8[W4;Z9E""?4+EIG5!_"I/ 'T'/
M&<X% '+^$]3NM=T71])N;FZ35;&XECU5EN'#[H#ALMG)WLT9QTVEL=*KQ-XA
M\8Z7JE[I=\ME?P:C-!;RF_D1;<12;0KPJA1LJ,G=DG=VX [JQT+3].U;4M4M
MH0EUJ3(UR_\ >*+M7Z<?J:Q;CX=Z--KMSJL<VHVIO&WWEK;7;1P73>LB#KGO
MR,\YZF@#'CAO]7^(NI:7<:Y?I9-I%O<>79W&Q0[.X)1@,@< Y')[G'%<VTUQ
MKO@3X?WFI7=U-='7X[9Y1.Z%U625 3M(RV$7YNO7GDUZ<GAJVB\17.N175TE
MY<6XMFP4V"-22H"E>Q)/\\UGI\/](3PY:Z&L]\+:SNA>6T@F DAE#%LJP'JS
M=<]: -G5;O\ L3PY>WL:/-]AM))51F+,^Q"0"3R2<=3S7GNIZEJ6G?##2O&U
MKJ5W-J82UNKF-IF:&X$K*'B\O.U0-^!M (VCGK7IT<$<=LMO@O&J;,2$L6&,
M<D]?QKG[+P1IEC;PV4<UV^EP3BX@T^20-#&X;<,<;B W(4L0#CC@4 84^F0R
M_&^$M+=C.A/-\MU(OS"X08X;[O\ L]/:ND\8W!MO#-PRZH=,9GC07"1EWY=0
M411R68948Y!.:D?PW;/XI7Q#]JNQ>K;_ &4 ,NSRMVXKMV^HSGK[U-X@T"R\
M2Z2VG7_FB(NLBO"^QXW4Y5E/8@B@#C+"\U$>)/%>EB?4+2VCTR&ZMXY[GSI8
M'(<$AB6QG:.,G\*R;"ZU6V\._#[7FUO4I[K4+RVM;F.6<F*2.1&SE.A;(!W'
MG/?ICMX_ VG1:C<Z@MYJ1N[FU%K-*UT6+J,_,0>,X8CI@=@*3_A!M._LG1],
M%W?"VTB=)[,!URCIG9D[>0,G@^O.: ,2;59?"'C35K?4KN\N;'4;(W>F+).S
M8D3B2!,G[QRI7OSBNQT*QN-.T2TMKNYEN+I8P9I9)&<LYY;!)SC.<>U<_,%\
M7>([.&XT*^MX-#OFG^U7L(199%4JGE'.64EMV>GR#UKL: //=+^W>-/#VH:I
M#KMSIFHQZC-'"\;L8[5(I<!&BW!7RJY.[^_Z "K=A=OXJ\7>)].N+R[@MM+\
MB"W2UN'A(+Q[S*2I!))( SD87IR:N-\/=&.MW6I12ZA MY)YMW90W3);7#]V
M=!USW&<'N#DU?NO"]I/KCZS;7-U87\L0AGEM64><@Z!U96!([' (]: /.X]>
MU_4?#WA=I]6NH+M?$ATFXG@VJ+E%\P;R,8)^0>V0>*Z;P]'<1>-?%/AZ;4M0
MN;"."UN(O/NG:2)I ^\*^=P!V@X!X[5L7/@S2Y[/2;2-KBV@TNX%U;)"XXE&
M?G8L"6/S-G/7)SFK$/AJWM]=O]9BO+M;R^B2*4[D*A5SMP-O&,G\^<T >9Z3
M9QP_LYZK.KSEY+.]#!YW91B:4<*3@>^!SWKJ-1NKRVU_X?1P7MQ';W)>.>W1
ML)(!;LPW#OS^%:\'@;3;?PC-X72YO?[+F#*R-(I8*S%F ;;GDD_TQ5B?PG:7
M-QHT\EY>&32,FU(=1R5VDM\O/R\?_7YH Y[3A?>-=-UVYAUJZTV_MM4FM;9X
M9&V6HA< !HPP5]P!)W9^]Z 4VTLH9?C5=3?:+A\Z'!.&2YD",WG..@;&T@#Y
M>G?'-:]Q\/M'FUVYU5)M0MC>$->6MM=-'!=$=Y$'7/?D9YSG)K2G\,V$_B6#
M7MUQ'>10"W(BF*I)&&W*&4=<,2?YY% &#\559O"5LJ.48ZI9 ,!G:?.7FLR_
MGU/P3XTMUAU34-4L-0TZ\N)+:]E\PQ2P*'#(<#:&SMP..?ICN-<T.R\0Z8UA
M?K(8BZR*T;E&1U(96!'<$ TRRT"WM;QKVXGGOKUH?(^T714L(\Y*@*JJ 3R<
M#)P,YP* ./TFW\1:I9>&_$%KJD,0E\J:^:34)9([F*0#<@B*!$;)&W&,'CFJ
MGA306O+7QU!9W]_;79UBYA@G6]ERC>7&58_-R0<<G)QQTKI-&^'FC:%?">RG
MU$6J2&6+3WNV:UA<G.Y8^F0>1G.#R.<5J:;X:L=*UC4-2M7N5>^E,TL)F)B$
MA !<+TR0!S^6* /-AXKN38>$-:-Q?+'9LL&OP_:7V1DOY :09ZB4,WN <YXK
MH-7U>[L=-CU"WN90NN:S%:0F6X8)% 25!0\A-^PD$#CS!Z"NC?P;HKZ=K=C]
MFQ#K4CRWF#RS,H!(/;ID>Y)JQJWAO2M:\/-H5[:J^GE%18U.W8%QM*D=",#%
M '&ZQ-XB\&6/B#6/ML)L/L.^VLY;R2Z>&<,%,@:10=F&!(YY ]:U+72-=B\0
M:?>PZHL.F30O%=1/J,ER9R5RCQ;T"JP()XX([<5I:7X,TW3K"YL[B>^U1;F(
MP2/J5RT[>4?X!G@+].O&>@J'0/ FG>'&!M+[5)EC4I:QW5V94M01C]VIX''&
M2"<<="<@'GT%YK$7PPLO$[:_JDE_;:IY:AISY<B&\,95UZ."I[],#&*]BO8$
MN;&>!S(J2(5)CD9& QV92"/J#7-_\*_TO_A&/^$=^U7_ /9WG^?L\Q=V[?YG
MWMN<;_F_^M74JI$81F+D#!9L9;W..* /$K>U$?P$\/21RS>9/>61)>5G"G[2
M.55B0/H,5U,VH7OA;QMK<$=]>WUJOAY]4\F[F,F)D=A\O]T$=A@5L)\.M'CT
M&/18[G45L8IUGCC^T;MA5MZ*,@X4,<X_/-:G_",VC>(_[=EN+F6[-I]B97*^
M6T.=Q4KM_O<Y_IQ0!R^E6OB&^B\.:_;:I%'%*(I+XRZA)+'=QR 9"Q% B-DC
M;MQ@\<U:^+\*R_"W6RS2*8XE<;)&7)W 8.#R.>AXJ[HGP]T?P_>B6RN-2-M&
MYD@L);MFMH&/=(^F>3C.<=>M;FM:/9Z_HUWI5^C/:W49CD"M@X]CZT <K?SW
M'_"767A:U>5K<::]Z1+J,T4DK&0+CS0&<[1DXR/O#TK%UB+Q/HVA:-:W?B&0
MW)\1P6RR6TV]OL\C JDK,H+,!Z]1C.<UU6J> =*U>UT])[K4DO+ DV^HQ73+
M<KG[WS]P?3&/3%27/@G3KK3;&R>YOPMG=+>++Y^Z62=3D2.[ EB/RZ#& , '
M.ZEIU]H_C+PEI,'B/6I+6^DOC/Y]P'8@1%@,XZ#)QG..W(!JE;VE_.GCC3&\
M0:R(-'DWV3B[82H6@$F&D^\P!Z G'7.>W>7_ (<MM1UK3-6FN;H7.F[_ +/L
M90H+KM<D;><CCV[8JO'X1LXI=:D6\O=^L#_2SN3GY=N5^7Y?EX_^OS0!R4VN
MZV_AOPMKEQ9W^I:;+I:R:C'ILQCN$E=4(EVJ077A^ >^>PKM?"UY;7_A?3KJ
MSU"34+=X1LNI,[Y,<9;/.[(P?<&JMGX0M].AL(['4M1M_L-M]DB*NAS%QA6#
M(0<8&#C/OR:UM*TNTT73(-.L8_+MX00H)R<DDDD]R223]: .#L+N]\5>%?$6
MLKJ5Y9W]M=74=H(9V1+80\(K(#M;.,MN!SN/;&,_4YV\3VGPVUB\^T0W%]=Q
MF5(KB2-03!(25 (P2>XYP<9KM9/!>G&YU&2"XO+6#4V+7UK!(%BG8C#,<@E2
M1P2A7-3ZGX5L=3FTJ1I;BW72W$EI';E51& V@XVG/!QCICM0!HW=K')I4MJS
MS",PE-RS,'QC^^#NS[YS7CD%J(_@1X<DCEF$D][9$EY6<*?M Y56) ^@Q7MN
MWY-K'=Q@D]ZY)/AUH\>@Q:+'<ZBMC#.L\4?VC=L*MN11D'"ACG'YYH IZ:+O
M3OB?>Z(NJW]Q9W.CK>XN9O,,<OFE"4R,*".P&,]JQM'O_$=U\,K.[M7NM4NH
M]4G%S&;GRY[B!)I041^,, %.!CA2*[G_ (1JW_X2,Z]]LN_MYM/L>[*;?+SN
MQMVXSNYS_3BJEGX)L=.TJVT^TOM0A2UNVO(9%E7>DC;]W)7!!WMD$$<T ,\#
MZO8ZQIMY-97-^X6[99+;4-WGVC;5S$VXD\')')^]745GZ7H]MI)NI(FDDN+N
M7SKB>4C?*^T*"<  850   .*T* "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M*JZG?PZ5IES?SY,5O&TC!>2V!T'J3T ]30!G6WBG3KKQA?>&8W/VZTMH[A_0
MACR![@%"?]\5MUX[KJ:CX;70?%T^C7MO=:=<L^KSL\+))%<-B4?+(6(5B-N1
MP!VQ7:>,KZ[AE\//#+*-(GOE6^>W8[RA1MG*\[-V"<=ASQF@#KJ*\ODM]5AT
M;Q[?IJ.JQZ?!!*VDN]PX(VP[V*[N=H<84^F0.*;(]WH7A?P]J*ZMJ$]QKKV%
MI<-=7C".,,A8E#@^66P%+#GG/7F@#U*BO-=;;7O!>G>(=72_C6T>S#6]DUU)
M<M!*'56E5I!G;AP2N",X]:U;31-6B\0V%_%J:V^FSPO#<0?VC+<FY)4E'0N
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MSTG@O29H]'5S=;M(0QVDBW#(XC*A2C%<;E(4#GTK1US1;'Q%H]QI6I1&2TG
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MVUM% A8I$@12[%B0!CDGDGWJ2B@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*.[,&;21-Y*R^;TX!SC[V1Z] "WI&IIH_C+Q]-=3W,MK:R61CC:1I6&Z')5
MQSDLW"CJ3@#H*Z"^\8Z=IEYIMI>P7T-SJ._R(OLS,3M4L0=N1G ^Z,G)'%>?
M:GIFM+XZ\2^)M+M+XSV5Q:W%K;RVT@BOT6#RY47Y?OCD*W4'/8DUT6KW<VK>
M+/ ^IPZ7J:0P2W$ER)+*0&WWP% '^7CYCCT[].: -^P\9:1?:9J5](\UDFF.
M8[R.\C,;PD 'D<]001C.<U)#XILVU6#3+BVN[.[NHVEM8[F,+]H"C+!2"1N
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MPVV8E(YT\AB#L#$ @D<, PSTKHM0\;Z1IUO?W<HN7L=/G^SWEW%%OCADXRI
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MZXU_P3IVJW6LZP;];UV:5M1G99$CG(V,A?:057;TKTN:58(6E<.549(1"Y_
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MF.20NOF2'A""W.>F.]3^)])N5U74M1\/QZIIOB*W6*.,6]L[V>IJ(TPKC!3
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MP4LO.>"1PP!YZ4 ;]%<U)XVTV&73FF@NX['4IA;VE^R+Y,KMG:.&W -@X)4
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M &7<+;WL)C4R0LQ 4G#88'<.5)ZUJW'B&VM_$4>AM;W)NY;9[F+:J[9%0@$
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M%1022>@%8ECXAM]8-I$EE?1VVH0--;W)VJDB8!R"K;E)# C(!_(T ;M%>6>
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M[6XETVX3:9A&FR2/#<9PQQVXXS7::9HRZ>QEEO;N_NBNPW%VRE@O7 "A549
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M[$CZ]LUV5% '&^+[>]3Q=X1U:WT^YO+>RGN5G6V4,R^9"54X)'&>IZ"H-?\
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M.2-4#C(]0>.M=[10!YCX/CE2VTW1-1\!>1JVGF..74)+2,VQ$>!YJR]2Q R
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M,.6R?XL 8'J:N>-+C58)=&%E9W<^GO=D:@UBFZ=$V';M[@%N"5Y Z$9KJJ*
M/&KK2-6'@[X@:7%H&HQR:A>&6S0H'\P,D8 R"<GY6)/('KFNMU&.YN?B#X0O
MHK*\-K;6MTD\IMW B:14"!LCC)4_3O7<44 <C\0])U'4M(TZZTN(W%SI6IP:
MB+8$ SK&3E!GC.#D?2H)[9]?\<:%K\5K>6]GI%K<F1I[9XWD>5541A" QP Q
M) QG&,UVM% '!^!;>[T_X8M97EC=P7<7VK,#P-O.^1V7 QSD,.E<^UK<Z?\
M#CP3%+I>H_VKI]S%MC@B!FA9$<L?+8CS%(&" >C9SQ7KE8NN^&K?7;BSNC>W
MUC>V>_R+FSE"LH?&X$$%6!VC@@]* .9\.ZC927^O3R:?K5OK.I0^?*+W3VA\
MU(U$:K$HW A=PXR3\V?IB6NFZE%X$^'UD^EWPN=-U.WEO(_L[$PH@D#,>.GS
M#IG->D:9HJZ?(9IKZ\U"ZVE/M%VRE@I() "JJ@$@9P.<#.<"M.@#S?4$URW\
M4^,[_2=,FEGGTN".R:: ^7+*@?<.>#]X8SP:ATN"^/CW0=7&BZUY#:;-!<7%
MX!O$A9"2P+?*.#@  ?W17IU% '&_#VVNK6'Q MU:7%L9];NKJ(31,F^)VRK#
M/KZ=15?Q VK7'BRYL9M+O[C2I-/ M6L\*CS$MN$SY& !C"D[3D\$XKNJ* /)
M-)L=4CT/X<PSZ-J$4FEW&;L- 28U$3)N.,\;FZ=>^,4_Q!X<U;7I_B+:V=K<
M1/J4=DUE)+&42<PJ-ZACQR1MYQG/I7K%% 'FU]J.I>(->\&W\?AO5X#9W4KW
MB30;!"6A9>K$ C)ZC@CWXKTFBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-UK6[;0K6":
MX261KBXCM8(H@"TDKG"J,D ?4D#BM*N9\;2ZS%IMDVD6UQ/&;V,7R6A G^S\
M[O+R1SG:,@YP3C'4 $-YKEMK^A>)]/,%S:W>G0O'<PR,%928]Z,&1B"",'K]
M17'S(#\/?A?-N?>+_3%R'(!!7)R.AZ"M#2]-U&SU'QTPT"\M[;4;>)K3)5RY
M$&PJ<,27+=>HZDGUCFTS5/\ A!/ 5D-+NS=:9?6,EY$(^8EB7#D]C[8SGM0!
MZ9<3Q6MM+<3R+'#$A>1V. J@9)/MBN>'C6R1M,DNK*]M;+5'6.SO)E01NS#*
M @,60L.FX#WP>*O>)])?Q!X4U32HI?*DO;62%'.<*64@9]O6N.N-/U3Q/X/T
M/P]=:7=6=[;3VQO9)%Q'$L)!9D?HV[;A0N3\W.,&@!^I3'Q!\3+KP_JFC7%U
MIB:4N(G:(JI>5E,_W\CA0 1\XP< 9YZ35M6L_ OABWEF@OKFQM1';F1&61T&
M0JLY=AD9(R?>LVW@NU^+=[J+6-R+"32HK1+DQ_(95E9B/7&&ZXQQUKI=9TNW
MUO1;W2[H9@NX7A?V##&1[CK0!2'B6#_A+$\./97:73VINTE8)Y31@A3@[LD@
MD#&/?IS7(>,]4BOO^$3U1;:\A6+Q&EOM;DR*HD!*JC$,"R<=SBJ/_",>+'T;
M0]=8*/%-A,EIR<C[-@PL3ZY)\X__ %JZ#Q=I,T<7A"TTVRN)X--U6WFD,:[O
M+AC1U+$]S\PX')YH U+#Q;:ZH=9M)=-U"VNM-53<6DR+YC(ZDJR[&(((![\8
MJMX?U[0[3P?H3:1:7*6MZOEZ=99W3,.6(^9L< $DEL =^E4[2WO(/'WBK4'L
M+O[)=6-O'!*(B1*\8?<!W_B'7K7-V&C>(='\*^!M4M])N)[W0!+%>Z=PLCQR
M+M8IDX8C@CGG/UH O?$37;;7OAGXHC6"[M+S3)(XIH9?E*L70@@J2K*5/J?I
M77V7BRWNO$O]ARV%_:7#P-<V\ES&JI<1J0"5PQ((R.& /M7.^-&UGQ1\.-8A
M@T.\@ENQ'':6<H7SVPX9F<!BJC X!.>/<"K]_!=W/Q-T#4HK&Z-E#8W$4LQB
M($;R%"H.>?X3]* +OCKQ'=^&= 6\L[-[B66XBM]P90(][A<X8C)YP!Z]<"KD
MWB)8[R&PCT^[EU*2 W#6:F/?%&#MW.V_:,G@88YY]#C-^(VG7NI^$'CT^U>Z
MN(KJWN/)C(W.J2JS 9(&< U0\C4M-^(0\2OIMV^FZEIRVTT:*));61&+*612
M25()^[G!ZT :\?CG1Y/#TVL$SHD%Q]DEMG0"9+C<%\HKG&[)'?'.<XYI\'BV
MVD\1OH,]C>VUZD N6\Q4,8B.?GW!CQD$?7\ZXO5O#T]OX6\1WMQI\[W6L:Q%
M<VMI%(JS18=%1ER<&3"E]N?8]ZN6$T.L:W>#4M+\06.K:I8-IL-W?V:1Q*@5
MWV+L9@"?F8Y/.WC'2@#HF\<6,5QI0GL[R&SU640V5ZX3RY78908#;EW#IE1[
MXKG;KQ'>>)/"WCN"[TVYM8K#[5!$XE0;#' I 8J^2Q8EN 1@@9.*;X.AU"WM
M]/T34/ \=OJ-ALCEU,Q1&W9$P/,5P=Q<@< #J<G%*FGZM::=\0=-;2+MVU*>
MYGM)DVE)1+"J(HYSNW#G( '<T :'A3Q;;P:;X4T:XL+^'[;I\26UW)&HAE=(
M0S*/FW X!P2H!QP36GJOCBPTFTGOY;2\ETNVG^SW%]$$,<3!MC'!8,0K<$A3
M@YZX-<[)8:B;?X=*--NRVEE#>CRO]3B QG/K\Q[9XYJKI&GZAH-Y?Z%>>"AJ
MIDO)IK'4Q'$T3)(Y<><S'<NTL<\$\<#ID Z>^\>VEKK%YI4&D:M?7=K%',R6
MD"OOC<D!E^89 Q_AFM_5]5MM%TR74+LL(8RHPN,LS,%4#) R6(') YY(KF-+
MM+R#XH:K>264ZV<VG6]O'<"/;&SQERP'<#YACM[UN>*88[GPY=03:4=4AE*)
M+9J.9(RZAB.1R%RPY'(H YWQUJ!U#P'XJMIK&\LYK33S,#(Z@-E6VE2C'(!4
MY!_*KFA>+;?[1HNASV%_;O=V8:TN9HU$5P8T4N%^;<" <_,HR.GORTOA_6+3
MPKXMTC3CJE]H]S8B+2X+U6,R2LK!D7=AO+'R\M^'<G8N;2^E\1> ;I-/NS#I
M\4XNV\HCR2\'E@'U^;TSZ]* -9?'FGL]K(+2\^PW6H'38KS:FPSABN,;MP4L
MI7..H].:SK"!!\8M=CR^R71[=F!D;J9'!QSQP!TKF;VS\2ZG8:=/J/A_49]8
ML=>BN;APZ>5Y*RD@0 OC&W;DX&<$L:ZRR@O(_BEJ>IRV%REG+I4,"S;,J9$=
MV91CGHW7H>U #?A2-O@=5RQVWUX 6))P)W[FMO4?$D-E<W5M;V5U?W%G +BY
MCMMF8E.=N2S %B%;"C)X[9%9?PVL[S3O"K6E_9S6MPMY<2;)5QE7E9U(/3H1
M6=,VM>%?B#K&HQZ'>ZMI>M) RM8["]O-&FS:P9E^4@ YS@4 =#%XOT^[MM+D
ML([B[FU.$SVUNBA7\L ;F;<0% R!R>IXS5*X^(.EVN@:KJLMK?!M)D\J]L_+
M4S0MVR-VT@@@A@2".]4+^RUFR\;Z-XKDLGGB:PDL+ZWM?WC6P9Q(K*.KX("M
MCGC(%8WB+PUJ5]H_CS4K:PN#<:\EO!:6FW]XRQ(%WL/X<DL>>0 ,\G% '96?
MC"VN?$4&C2Z??VDMU T]I-<1JJ7"KC=MPQ8$;@<,!3['Q5#J)LI+73[R2TO6
MD6WNE\LHY56//SY7.PXR/KBL?4(+RZ\>>#[^*PNS:VEM=)<2F(@1-(B!0>_5
M3G'2LG0]#O++Q%I>HZ'::CI"W,K-K6F3 _9 "A)=,Y&XOMQL/0\@8(H O6'B
M_P#MKPGXEO-<T6\73[:6Z@FCB9&/E1_*R95\[L!B3P/0]*EG\5OILW@O3]'T
M>Y>PU.'<@#Q[A$L!98QO<?,/E))/0<$DUFV.G:O:>#O&NC2Z/=^=<SZ@]LZ[
M2L_G;O+VX.>=W.0 *DFT_58(?AY?QZ3=SG2D,5Y;QA1)&6M_+Z,0,!NISCO0
M!U$/BVVFFUV!;&]$^BA#<Q$1Y8,F\;#OP?EYY(K'O?'<SW/A%M+TNZGM-<+2
M[B8U?8(F<( S@!NA))Q@<$DU2EM]6T[Q7XPVZ+=W*:U;PO:S0[3$I2 QLKL2
M""#[$D=!5&STK6[+1?AU</HEX\FCDQ7=LAC,B[H#&&^]C&2.I!'>@#L=5\7V
MVEV]_<BPO;NWTX9O9+<1D0?*&88+ L54@G;G /KQ6W9W<%_8P7MK();>XC66
M*0=&5AD'\C7F\=G?Z!XHUF*]\&/KEIJ=T;RTNX(XG,;.JAHI"Y&U01P?0_EZ
M'#:LVCI:2K%"Y@$;+;C"(=N#L]AVH PI_'>G6^GKJKVMW_8K3>2=2"H8A\VS
M>1NW[-W&[;COTYJ2[\9V]OK]SHD&EZE>7\-LMT$@C7$B%BHVLS =0>3@<<9/
M%<A:Z-K)^%DW@.XTR8:DJ-91W 3-N\9?B;?T "G.T_-D=*W+#3[G3_B7-=?9
M+HZ?'H<-DER8R0\D<C,1QST(YQ@GB@#7L/&.G:EH.G:K:1W$G]H.8K>VV@2M
M(N[<I!. 5V-DDX^7KTJ?0_$UKKEYJ-BL$]K?Z=(L=U;3A=R;AE&!4D%6'((/
MY5YM:^'M=M/!_A^[707N[O1]1NYKC2[A5!GAF>3E<Y4L RD#UKT/PNWVE)[M
M/#G]B02!52*:*..=R,Y+!"0!R  3GKTXH DU/Q-#I^J-ID-E=7MZEH;UXH-@
MVQ!MN<NR@DD$ #T[51F\?Z3'8Z%>1P7T\&M$+:M%#NP2I;##.<\'@9JGKPUF
M?Q>UI+I=W>Z+)88MQ;NJQFXW'=Y^6!(QC .1UX)Z<SI6E:S#X9^'UK/HM[%+
MI-Z'NU*AMB!'7=P3QEAQUXSB@#N=.\9Z?>)K)O(+G2Y-'PU['>A08T*[E?*,
MP((!Z'M7,>(=2;4/&G@68Z;?VBRWDC1O.RA73R7."JL=K<@X(!Q]"!5U_P ,
M:KK][\0;6WMIH!JEM9K93R+M25H02RY[9.!SUS5N^N]:U_4O!]V?#&IV\EA>
ME[U)!&HC)B93M);YER>O<>_% '5^,]=N/#7A'4M7M;0W,UM"SJFX *<?>;)Z
M#T&37):_?2-XK\ :G<6=Y'.TER&@R&:3_1FQA48KR3UXQGG KJO'6FW6L>!-
M;T^QC\VZN+1TBCR!N;' Y]:YZ[34K_7? U]_8U_#%8O,UR'0%H@T!C4MM)ZL
M>@R0.3B@#>T_QII]Y8:I<W%O=6$FF3>1=6URB^8C$ J!L+!MVX8P3DFIK3Q5
M;S^(QH-U975A?O;FYA2?85FC!P=I1F&0>H.#]:XC4_#>L:P?'<=K9/'+>7=I
M=V!N4Q'<&%8R5.>F2F.<=<]*Z3PM<2:C=1S'P6=!>%")Y;B&)6+$8VQ%3DCN
M6..F,'/ !T&IZS#IMQ96QBDGNKUV2"&,J"Q52S'+$#  JA)XMMXK:Q9["]6Z
MOKN2T@LV5!(9$+;LG=M  1CG=R,8SFJOC32[+68[&SU+2[NZM"[/]JL]WG6<
M@ V.NWYNY' /;C&:YR)/&-AI.C6]XFI:E8+J$Z7#Q%5O7M<$0%SD$$GEB"&Q
MC..10!T%S\0=-M/#.J:Y-9WXCTNY>UN[<1J9(Y%(!'#;2/F7D'O4DOCBW@UQ
M-)FTC54GN(7ELB85Q=A<;@GS94C(/SA<#DXKA;K0=:_X07QWH\/AZZBEU#46
MFLXUV$.K"/ !#=@C9/3MDFNNU6&[N_B#X3U&&PNS:6L%TMQ*8B!$9%0*#WZJ
M<XZ4 :6G>--/OM)O;Z6"ZLY+*Z^QW%K.B^:LV5"H I(8L77&#@YJ:P\4V]WX
MBET&XM+FQU%+<7213[")8B=NY61F'!X(.#7!WGAS6M1L?%OV73G%R^M0ZG8Q
M72;8[I8Q'\ISTSL(P<=JZSPM.VH7(N5\'MH(CC*RO<PQI([G'RIL.2O7+'&>
M,#K@ L>+KW2+9]#CU>RN;@3:K EHT.0L=P3\C,0PX'/'/TJ.Y\;P0ZQJFDV^
MCZK>7NG1I+)'!$GSJV<%2S ?P]\9[9J#Q_:7EZGAT6=G/<FVUNVNYO*3.R)"
M2S'\QQU-1:=#=VWQ&\2ZE+878L[FSMHX)1$2)&C#[@!U_B'7K0!IVWC+3K^P
MT>ZL(YKEM7C:2UA&U7*J,OG<0!CH>3S^=9FM^-;RTCT!K/1KS_B9:E]CD60Q
M*\95G#)@OC<?+.#G&.<YQ7-Z1X;6;P!X:T3Q#H6I(]JDVZYM0PGL9@P*,I3G
M#!CTSR!D=<69]+\3CP[X7GOX+O5+C3-<\]^%^T/:CS%1G!(&_#*2,YYYYS0!
MT=YX]M[75KO2X]#UFZOK2**:2"W@5VV.2,CYL'&.?TS4X\;61T?7-2^PWP31
M)I(;N+;'O!10[%?GP1@COGVJCI,%\/B?JVH3:=<PVMSI]O"DK+E?,0N67(]-
MW7H<<&N?O;#6;2Q^(.CQ:'>W+ZL\]S:7$87RG62!5QG.=P*D;<9)([<T ==<
M>-K*#4-*LEL=0FGU2U:YMA%$I# *&*Y+<'YA[#/)%4?^%D6ATJ_OET/66;39
M7CU" 11[[78,L6)?:PP<_*6..U9]O9:G_P )-X&N)=*NXH[#3IH+MF4,(7=(
MU4$J2#RAZ9QQG%0P:?J(T?XAQ'3+P2:I-.]DIB/[X/ L:X]/F'?% '92^(K8
MBT6QAFOY[JW^U110%03%QAR7*@ [@!SD^G!QC?\ "R=&.EZ??K;W[)>7_P#9
MQC6 %X)\D%' /48/W<Y[9S7,/I>IZ3<>&]:D\,RZQ:IHL6F7UB(D:>WD3D.J
MMPW)8'!]\UIZ[8WUWI_AR2U\//9K'KT%]):01+NA@0$%I-IV[^<X&3R!S@T
M;<?C:.:/7(ET?4(M0TF$3O97'EHTB,"596#E<':<\Y&.F>*N>#-9N]?\)Z;J
M5[:R037%O'*Q;9M<LH.Y=K' Y[X/M6"VFW]SXZ\3S+93K;7VD1VMO.Z81Y%\
MS(]OO#D\5'H>MZCX6^'NA1WOAO4BUJD-G<J"FZ(*N&EP&.5R..YS],@':ZGJ
M$.DZ3>:C<DB"T@>>3'7:JDG^5>9^+TFO_@9J&MWY;^T+ZUCNV*N1Y8=E*QC'
M\*JV,=SDGDFN_P#%>F2ZUX0UC3(/]==6<L4?/\14@?KBN1OK*\\4? :.QTV
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MS K?<:;:=H.>V[%>;V%EK4_B'P7J\WA_5//MDN(]1GNG3?YCQ!<XW<1AMV,
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M9Q/&[31L.&C;=AO3!(.>*DT#QI9^)5L'TZTN9([JW,\CDIBV 8J%D^;(8D,
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M6MU=W-^([=2K6L5RR03@D'$B#AAQT/7H<BMJB@ HHHH **** "BBB@ HHHH
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MM=732[@Z9'I+637 *;1(9=PXW;L8'7%=FQ@LK:21MD4*;I7;H!U9B?U-3$@
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M(U4<;\GE3G&: .GUG6+70[#[7=$X:1(HT! +NQPJ@D@#D]2< 9)X%<_#\0;
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M+*6/ '/3('-4O%>A>)M;A\6V$^C&_-PF-)N6N8Q#%'L'RA"<K)NW?-CG/W@
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M/DQ:R)H_+:$'ABGW]X7C&,9ZD"@#9@\;S7FNWFE6GAW49GL;R*VNI-\8$2N
M1)][D8(.!DXZX[]=7(^%]/U*S\7>*[N\TZ6WM=0N8I;:5I(V#A8E0\*Q(Y&>
M1TKKJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(3QD9Z'M4H96 *L#D9&#VKSKP,8O&U_KGB+5HDNEBU&2RT^"90R6\48'*J>
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MIT.KZ9<Z?<-(L%S&T4OEMM)1A@C/;(-&EZ=#I&F6VGV[2-!;1K%%YC;B$48
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M=S&08E>0DC)')WC ]CG%>L44 <EINFZE%\2=8U:6Q>.PNK.""*4R(<M&7)R
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M-M!)P -QX&3UP.MHH \MM?#.OP>"?!.EMI3FZT?4H;BZ43Q8"1[\E3NY)W#
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M9\6P_"Z]\##1DN7AQ':WZW4:QS1>:'!*D[E8#C&,<=?7UJ%I&@1IHQ'(5!9
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M&Q5;^_N[B6$>>FS;++O!)SQ@<'W_ $W/'-@]_P"!Q(O^BZK9/#<V.2"R7*L
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MD<DUWY+6DCXWAAM)9<C("\T :5UXYM2PBTTV4DWV..\*WUX+4;9 2BC*L2Q
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M&IZW/89MKC3X;=?*F0DR(68\$C@[L GTY KG;?PEK\/PWT#0C8*;ZPU..ZF
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *R=:\-:/XA\A
MM3LQ-);DF&57:.2//7:Z$,,^QK6HH H:7HNGZ-&R6,!0OC>[R-([XZ9=B6.,
MGJ>]7Z** "LB?PQHMSXBBU^>PCDU2&,11SL2=JC)&%SC/)YQGFM>B@ HHHH
M**** "BBB@ IDT,=Q#)#-&LD4BE'1QE64C!!'<4^B@#G;'P+X<TV57M;!E5#
MN2%KF5X5/48C9B@QVP.*Z*BB@ (!!!&0:YNW\ ^&;68R6^F^6A8L;=;B40$G
M_ICNV?AMKI**    8' HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *JZCIMEJ^GS6&H6T5S:S#$D4JY5N_P#/FK5% &)I?A'1='F6
M:SM9/,3_ %9GN99O+[?*)&;;QQQBMNBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ J.XMX;NVEMKB))H)5*21R*&5U(P00>HJ2B@#GM
M/\$>'M+F22TL741D-'%)<RR1H1T*QLQ5<=L#BNAHHH **** "BBB@"KJ6G6F
MKZ;<:??PB:TN$,<L9)&Y3U&1R/PIFE:38:'IT6GZ;:I;6L0^2-/U))Y)]SS5
MVB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]W;JK30JX+QAL[21U&<&K- !1110 4444 %%%% !1156'4["XOI[&"\@ENX
M&FA20,\8/3<!R.AZT 6J**8DL<C2*DB,T;;7"G)4X!P?0X(/XB@!]%%% !11
M10 4444 %%%% !1110 445'-/%;0O-/*D42#+.[!54>Y/2@"2BLO_A)=!_Z#
M>F_^!2?XU*FMZ5+<VUM'J5H\]R"T$:3*S2 9R5 /(&#S[4 7Z*** "B@D $D
MX ZDUG0^(-%N9'C@U>PE= 6=4N48J!U) /&* -&BBB@ HHHH **** "BBB@
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M[B3Q&FFVPC3:(K%V?S6X^<E@-H]%YZ\GB@#GOB'=R7GB;PCX5+,MCJUU(]X
M<>;'"H;RS_LL3R/:NNUGP_I^MZ))I5S;Q_9RN(P$'[IA]UE]"#@BLWQCX6D\
M0QZ?>6%REKK&EW N;*>12R9_B1P.=K#@XY_E5FWG\27<0ANK"ST]R,23Q79F
MQZE%*#)]-V,>AQ@@$+Z_>W^L:KINB6]M+)I:H)WN9"JO*Z[A&N <<8RQZ9'!
MYQB_\+&DN='\/ZC8:2'&J:@-.FAEGVO;3?-N7&,'[AYR.QQ5ZWT'5=!\7ZQJ
MNEQ6]Y9:N(Y)8)9C$T,Z+MW [3E6'7N".,UE/X%U*STKP[:V1M)I;+6?[6O9
M))&C#N=Y94 4_P!_ SCA1ZT 7[;Q1XEN=;U;05T?3AJ=G'%.DAO'\AHWSC)V
M;MV5QTQWR.]5?B+=S^'O#&JVNBK*=:N?LC1&YVM%(-X('RX(S&W.1]*U+/1M
M6M?'NL:X8;1K2[M(8(E%PV_=&6.2-F #N]3C%<5<Z+J_AGPSX"TJYCM)+ZV\
M0 J(YF,;AA,_WBH(X;'0T =38^-=5CU76=&UC0PNK6-D;^VAL9C*MW%R,(2H
M.[=A>G4U8T_Q=>2^*8M N[:S^U3:>UX!!.2874J#%(,$@_,/F]CQ5;5O"NL:
MS=ZUJ\=Q'INIW&E_V;8;)"QB7<79F8#@EL#Y<X SR3Q7T[PUXB@\2Z'JQLM'
MM8;+3Y;.6U@G<[=Q5MRG8,Y*].,9SEJ *Z_$76?^$77Q))H=K'IT-Z;6[7[6
M3(!Y_E;HQLPV"0><9YX[UTB^([N+QZ/#MW9P16\UHUS:7(E),^T@,FW& PR"
M>3Q7+/X)\0O\,;WPULT\7D]\;A9/M+^6%-P)N3LSGC'3WK6\>6*ZS:Z7':7R
M6?B""^B^S-"X9XRXQ*/7;Y1=CQ_"* .CT+4KC5K*2[FABCB,\B6YC<MYD:L5
M#\@8W8R.O!%8;>)]=NO$VN:%IVDV33Z?##+'+/=L$D$@8\X3(/R@8Y'7GIGJ
MK2UALK."TMT"001K'&@Z*H& /R%<U8:-J]GXZU[6S#:/:WUO!% HG8/F(-]X
M;, '=V)QB@#'@^(FI3^'M$\1_P!BP1Z3?3Q6\X:Z)FC9W\LLJA<%0WJ03Z"M
M#Q/XQO\ P_#K%X=/@2STU4*&ZE,9OB5W,(CC'RCCODY&!BL:+P3X@B^&6D^&
MMFGF\LKR.9W^TOY;*DWF\'9G)Z=*EUOPCXFU)_%<(_LV6/6+?9:W4\S^9;+L
M ,(4+C;NR<@CKD@GB@#?N?%-S:^*M%TZ2SA73M7B9H+MI3N$BKN\LKC&2.0<
M\X-:FDZE<:C=:ENAB6TMKDV\$JN292H&\D8XPV5ZGE37,>++%KGP%!I]U<VT
M&OVOD2V0@?<4NE8"+;G!()^4G'0FM355U/PQX)5=#%G/=VB+N:^9E67G+L=O
M)=B2<=R?PH Z9MP4E0"V. 3@$UYV?'=S8>!-6U^#0;2-[+4I+66VCGP"PE$9
M?.SYB6;)R!GUKT"&222UCD>+9*R!C&3]TXZ9KS>?P3XAF\ :[H.S3A=ZAJ;W
MD;_:7V*C3++@G9G(VXZ=Z .EL_$FI#QHN@:IIUO;K<V;W=K)#<&0X5@K*X*@
M!OF!XR.V3UI_CS66\/\ A*ZU+^S;?4(HGC$D$[X7#.J@XVG."0<<=.M17&C:
MM<?$'3-=\FU6SMK&6VE7SR7W.RMD#9@@;<=1G-2>/]#U#Q)X.N](TT6_VBX:
M/#7$A15"R*YZ*3_#C\: *-WJVMCXL6FDP_9O[/\ [*DN-C.P+?O8U+'CJ.0!
M[GGFI]#\6S^(+I38QV<D"W<MM=0>:1<6@3> SKC^(J..,;NIIU[HNL-X\TWQ
M#:)9F(:>]C=1RRL#'ND5]R87Y_ND8.WZUF'P??WWB#2-8N;.RL=6LKG?<ZC:
M3'-U" 1L90HR6^7.>!@X)Z4 =+XHU^+PUH;ZE,J^6LL419R0D>]PF]B <*-V
M3]*SKKQ9+I6BW6I7L-M<1"2**QDLY=R7C2$*N"?N_,<'DX SSTK8UR&^GT[R
M]/AM9W,B^9!='$<L6?G4G:W49QQUKA'^&+RZ1KMK8M'I,=U<P7FGVB.9([6>
M+DMCH YX('0 ?0 '3-XDO--\4:=HNLVL"KJB2?9+FW<E?,0;FC8$<<<AN_H*
MYSPQK-OX=TKQC>RIN_XJ>>**,'&^1S$JC/8989.#@9/-;YT;4M;UW1-3UBVM
MK4:2))%BAF,OFS.NS.=HPH&2.Y)'3'.)_P (+K%WX?\ $=C-/;6=W>ZPVK6%
MQ#(TGE/N1D# J.Z<XSU]J -S2/%-W=^*)-&NK)6B:V^T0WULKF+.<&-MRC##
MJ.>1Z5H:WKITV_TS3+:))M1U*1T@1VVJJHNYW8^@&.!U) XZB#P]_P )7.XD
M\1IIML(DVB.Q=G\Y_P"^2P&T=<+SUY/%4_%WA_5+W6-#\0:(UNVHZ3)*/L]R
MY2.>*10KKN .T\#!P: ,/0I[^V\>>/YY[.UDNHK6R81I(5CF CD(.2I*Y';!
MY]>M7K/QQ;Q>&?"UP8;+3%UE,1F5MMO;X7<$R,<G@ <=_3!?8:%XB3Q#XFU:
MXMM.0:M:0Q10I=.Q1XT9>3L&1\W7';H>M,TWPQJMIX-T30-1TW2]2M+:V:WO
MK9Y25?&W8Z%DZC#<''7KP* -:3Q'>P#2[&>RA36-2FGCBB$I,2I&6)E+8R5V
MA2!C)+@<<D9FM>,M<T#PQK.IWF@1^;IMPL2GSRL=S&Q4"1/E)_B&5/H>:RE^
M'^MZ5I6B7&C7=O\ VGHUY<2VMM<RL\(MIC@V^_&[A0N&QU%:GB70O$_B;P/J
M.GW TZ+4;TQ!(5F?R8%1PWW]N68X.> .@[9(!<N/%.IZ=-':ZII]I:W-[<,E
MD%N&D7RE3<SR87((Z8&<DCG'S5SGB/QQK;>!_$TEO9I:7VFND7VKY_*FBD(
MDB) .[G!'\)[FNB\6:%K6J'1]8T:6UM];TJ1I$AG8M#*CKMDC+ 9Y &#CMVZ
MBOKF@^(_%/@;5M/U%["VU"\C18((79H8MC!OF<C)+$<D# &.O)(!;U/6[NQ\
M2>&+"]TNRD?4)ID%PLI8V[+&S?*"@Z@ 9R.XQ39/%6H7EKK-[HMC;W5MI,\D
M#++*5>Y>, R!, A<<@$YR0>@YJ/5-&U_5-<\+:G);Z>ATV:6:ZC6Y<XWQE J
M'9\V,YR=M0Z=X=UOP[+K]GIB6ES8:G<R7=N\TQ1K:20?.K#:=RYY&#GL?6@
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MJW\6:Q_;>F6LFE&>UU!&W/#;3I]C<+E1([+AE/3< .>U '3_ -C:7_T#;/\
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MP0.%QG^+. ?48YJ[+KNK_9)9[6QAG1]1^R12@D+%$I*O-)D]%*L,#K@'(SP
M=#;VMO:*5MH(H5)R1&@4$_A4U<"/'UY_87BNZBM[&\N- )/F12E8;B/RQ(&'
MWB#C(QDC(ZU8_P"$NUJTL+:ZU#3;%3JDEM!I445PQ9Y)02WF\84*!NXSP,<T
M =4FK:=)JSZ4E[ VH)%YSVRN"ZID#<1V&2.M7*\^LQ?K\;BM^;9V'AUMDD"E
M0R_:%ZJ2<$'/<Y]NE=7KNHWU@EH+&U23SY]DUQ*?W=K'M+&1QD9'&,9')ZT
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M92KQDC.U@>A'0U:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MRH.00!D''2NZH) &2< 4 06<,L%G%%/.9YE7]Y*1C>W<X[#/;M7!/\/M0O-
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M):SB.5P6+A1E04YQL'4C.>U7_P"P=4M_B#<:]:R6;65W916\R2EA(C1LQ&T
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M=%VIDG.%!Z*.@SS@<\U;HH Y'2?#^KV?Q"UK7YQ8_8]1@AA5(YG,B>6",D%
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M-H,BONCP/FZ8P2/7VKG]0\#^))=!\5:!:S:6+'5[N:[AN)'D\Q3*P8HRA<
MY^8$\=N>/3** .1BT'61X[L-=E^P&WATMK&55E<.69U<LHV8P-N,$\]>.E5#
MX>\5Z)XGU.[\.76E2:9JLPN)X-0\P-;S;0K.FS[P( ."1^'6NLTS5].UFW>X
MTR^M[N%)#$SP2!PKCJ#CO5V@"*VB>"UBBDF::1$"M*PP7(')/UJ6BB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=&NK:$Q-<2P-&&<E5R1C)QD@<YKCCX-UG_A%?">D+)8&70[NWN))#*^)1""
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M;5(_!<?@R]GLVTI7(DNXF?SIH?,+E/+(PI/0G<>.U6;GPSXETOQ7?:KX7O\
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M,\DT =51110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116+XCUQM&BL(H$1[
MS4;Q+.W$F=BLP)+-CD@*K' Z\#(SF@#:HKC]3\2ZSX6T_7M0UVTMI]/LHHY+
M.YMOW9N&;Y?+9"S%2'(&[I@].*74/$.L>'=6T.+5_L5Q9:K<"R+V\31M;W#
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MDEB#A]R\ <J:R]5\27/]O7>C::RQ36EM'-+,]A-=#=(6V+MC(QPA))/<8[X
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MA%;31L7N4A)#G>& 0G:VT;3VSUX .YJIJFIV>C:9<:CJ$PAM+==\LA4MM'T
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M' ],8_&J7AKPOXHT)+?1YM>M9]!M&'D,(&%V8U.5B9L[0HX!."2!CC/';T4
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M5(X22D,2DM@,0"Q+,23@= ,<9,.O:#?:GXE\/ZI;2VZ1Z5++(R2;LR[T*$#
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MO/$&C^,-9UCPWIEU<?9-/E6]FLM5FR"8WCW "%#G<S,% '.,G@T >A$@ DG
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M!DQ6\2QJ6.2<#&2>Y/4F@# FUBZU3QK=>'+.Z:SCLK)+B>>-%:1GD8A57<"
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M+AR<AL\@=.W.,GJ[7PQ=VFO^(-634HB^KI$IC:U.(?+4JISOYX)STY]*S%\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "D)"@DD #DDTM<SX_OIK+P9?I:G%Y>A;&V]?-F81KCZ;L_A0 6OC2VN]#CU
MB/2M3^Q3[?L[".-FN-S;1L17+<]>0. 34!^(%D'U-/[)U<MI:AKP+ A\H%=X
MSA^?EYP,UOVMG9Z/H]K; *MMI\"JC,/N*B;<^WRYKE?AE;F\\*W6M7<0,FO7
MD]\Z.,_NV.U%/ML5?SH W]/\1PZCX@O='2SNHIK."*:624)MQ)G:.&)S\I."
M!TK9KQJ#6=7ET75_$6CW7V6XUG7DM[.0Q*YN%$BPQK\P("!$9B1R23@C'/:7
M?BF6[\2ZCI5D;I8=,1!.UI;^;+-,XW"-<@JH"XRS=V R,$T =C167X=75D\/
MV8UV1'U/9F<IC&220. !D# ) P2#BN4TR]\2^([OQ$FFZR+:TMM2%M;W$ULC
MD+'M$BK@ '+;QDYQA<=20 =_17G@\3ZSXGTJ]N_#KW$;R3/!IJQVZF,A6VF:
M:1U*A<@D*,':.Y/#=5\1ZQ%XD\2PP:D8=-T?2TEN9/)0B.9E9SLR.3M"X#$C
MYB3G@4 >BT5YMHVN^)[J_P#!$-W?*'O[62XOH1 @WQK$,NQQE29'3 7 QU]!
M8U7Q;?R^$-:\46=Y]EL[<R1:9&L:M]J=6V!GW G#2<*%QQSGG@ [34]5LM'M
M4N;^8Q1/*D*L$9LN[!5& #U)'-7:XV>^UF#Q+X3T7^T6>XDMI+C5,11X=8T4
M$_=^7=(P'&. :Y_4?%>M_9/'5[:ZH\=CI4GV>TE-O&S"94&47Y<,3(P4[LX
M QEL@ ]2K(B\00R^*YO#XM;@3PVBW;3';Y>UFVJ.&SDD-P0.E946KZG=ZM9>
M'4F6.]@L8[K5KQ44^63P$0$%0S,&/(("CIR,<MI/B$Z7I^N>*?-^WW.L:LNF
M:8\@ 65(R8XR=H^[D2L<#D ^M 'JM%<:E_K%O<WM_<WUV-#L].D>>:>V2%GF
M'S;HD*[@H4-]_(.1C.":3P<WBK5-*T#5=3U1%A>W:2ZMC;*'G+C*$D ;0N>
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MVEOGNELAR!_O2LX_"H8(]4\'^%/!J1WC(9;ZW@U&%HU(D:X8F0Y(W ^8_8T
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MBXA241R8W)N .#CC(SS7F4VK:CXE^'NFZ7?S">YUG5CIWVA4"&>VCE8O)M'
MS'&V<<<^]=:^MR7^JZM#;WGV#2=%7;=72*I9Y=F]E&X$!44@GC))QQ@Y .IH
MKR\^)O$:^!?"MW+>O_;6MWT8"101_P"I<E\!2IQB, 9[$Y)K5M/$>I6.K>,;
MG4KY;C3='MHGV+$JJDWEM(Z*0,D!2@^8DY/;I0!TF@^((=?&H&"UN(!97CV;
M^=M^9TQN*[6.1DX^H-:DKM'"[K$\K*I(C0C<Q]!D@9/N0*\Z^&OVF\T>WMHM
M0N;1['Y]1A,"AY[B8"<L=ZDA?WF 1UQV R>]U74(=(TB]U*X.(;2!YW^BJ2?
MY4 5-"U^'7UOC#:7-N;*Z:TE6?9_K% +8*,P(&<=>N:UJYOP%ITVG>"].6Z'
M^F7*&[N2>IEE8R-GZ%L?A724 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "LG4="^WZC#?)JFIVDD2&/R[:XVQN"<_,A!4GWQ
MGWK6HH K6%A;:9:+;6D>R,$L<L6+,3EF8GDDDDDGDU9HHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
'"BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>a109-2021formrsuawardemp004.jpg
<TEXT>
begin 644 a109-2021formrsuawardemp004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 6 !)7(^9>>HXJZ"" 0<@T %%%% !1110 4444 %%%% !1110 4444 %%%%
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MKR??D;!7+'UZ#TH A\,7&LSZ5X>M;O2;5--:RC+3)<&4Y6-2F5*#;R,YR<$
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MV:9=QW*3FS.7V2;U4CS..3R?3TH A\9>)]:T.#7[R*\@C;3TCEL[2*+SO-3
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M51\1P:@OQ$\%PQ7D;79M]0'VB6+@?+'SL!&2![BNJ\5Z GBCPQ?:*]PUN+I
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MZ=;I?3)->",>=(B[5+XYP.PSTKB\:#XW\;Z7JFEW!N1I"RBZFBR$)W+Y<39
MR0X\P#MLSW%=[0!Y5K.OZY?_  Z\>O-?I#<Z9?7%I'+;0[,Q*B<<DD$[CSG/
M/%;&L>(Y_#$6B1:I?SV^EW$#>;JD=L&$4OR>6C\$*I!;G'.!R.:M)X#=]"\4
M:5=:HLD>O7$MPSQVVPPLZJ.,N=P&T>G>K\>A:TD5LLFLVUR%MC;W,,]CF*;.
M,$*'&W !ZDYR?; !JZ)--<:+:37%U;W4KQAFN+?'ER?[2XSP:OUD^&=!@\,>
M'K31[9R\5N&PQ&,EF+' [#+' [#%:U !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<[XNUZ;1;;3
M;>TV"\U2_BL89'&5B+Y+.1WPJG [G% %U?$-BWB@^'AYWV\6INSF(A/+#!>&
M/!Y/;/>M6O.X[.\A^,_E2ZG-/N\.N8YGCC$D?[]<CA0IYYZ=ZJP>+]<F^&OA
MG7S=J+V\OX(+G$2[)$><H>,<''I0!W,/B&QG\2SZ GG?;H+<7+AHBJ["VT$$
M]><],CBM6N&*/)\9K](Y6A=O#D0610"5/GOS@\?G5;2/$>LW/AR[TV[O<>*(
M-3_L]V6)  2VY75,?<\K+\\G:W- 'H5%5KIKB'39VMRDERD+&,SG:K.!QN(Z
M#/7%<+I7B35#XI\/Z;+J;7L.J6,[W$H@58DFC5"3 X4;T^8C)W#&.>M 'H=-
M9U4X)YP3@<D@=<#\17F5SXMUV+X8^(M:6^'V_3-0N((I/)3#I'*$ 9<8Z'MC
MFM*5;Z7XT6\0U2Y2 :&TZPA4*C,Z!E&5Z-M&3UXX(H ZG0_$%CXBM[J>P\[9
M;7+VLGFQF,B1,;A@\]^^*U*\:@O];T7PIXTUS2]0BMUT_P 07LQMVMPXGQ*-
MRLQZ#'3;@^_:NY_MNZUKQC=:#9W;V,5E8Q7,TT:(TC/(3M4;PP"@#)XR21TQ
MR =95+4=3CTTV@D@N9?M5PMNOD0E]A;/S/C[JC')/2O.+SQMXB3PO?%)K:/5
M=*UN/3)Y?)REPC2(%<#/R95^>#[8K9UJ]\3>''T)9];@O!?Z]%;2$62QD0."
M=@^8CC:>>O/M0!W=%<+XPU36=(*P:?JDDFL:G.8M,L(XHM@  R[EE+;5&68Y
M[@>]2R:KK,VLR>'8KBZDN;&PAFN;RSB@#22R%P,+*=H4;"< $\CD8Y .UK*T
M[Q#8ZIK&IZ7;>=]ITTQBX$D10 N"5QGKP.O3I7+6GB'Q(TGASP_J\4>GZWJ'
MGO=31;'VQ1#[R#+*&?*]<@?-QTH\&PW%O\2/',=S=-=./L.)6158KY38R% &
M1TX Z4 =]02 "2< =37,:KK5Q)XTL/#%G.;5IK.2^GN%56<(K!%5-P(R6)))
M!X7WR,5=8U2\B\9>&[V\;[5I,(DBOHHU#30R1LRAAC:&&"I( SU % &Y_P )
MUHRRQ><UQ#:36\ES!>R1'R)8T&6(89Q@<\@9'3.10GC6Q;6X=(?3]5CNYBA0
M-:,5V,"1(6&0%XP<X(/45P.J6ETG[-T4G]IW!0Z5;MY>R,#:0GR9VYQSZY]Z
M[#7=1UC0[_PK;1:EYT-]J(MKDRP)O=2C-P0  /EQP,^] '9T5Q2:EKOB6+Q!
M)H=_'93:;>O8VL3QJR2R1A2QE)4G!)(&W& ,\YIUSK6L:CKE]HMI]H@FL+2!
MYI;%8'_?2ACC]\1\@V]ADY/(QR =G17G$^M^-8Y?!UE?-::;?ZE)/!?1")90
M"D;L'!#$= &VCOP3BN[TJ"^M=+MX-2O5OKQ%Q+<K"(A(<]=H) XQ0!<HHHH
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MM:MK5KI'V9)5EFN;J3RK>V@7=)*P!)P"0   222 .YKDOA)_R+6J?]AF\_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0!3O%'A]/%.@7.C3W4MM;W*[96A"EB,@X!(('3TK9HH K:?:M96$%JT[3F%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BN9?Q@1XLN/#D6C7LU[#;"Z+(\01HRVT$%G'?MBK>B>)[/6[V^T]8;BTU&P
M91<V=RH#H&&58%2592.A!- &W1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M10 4453U*[NK.W62TTZ6_D+8,<4B(0,'G+D#_P#70!<HKG_[<UO_ *%*]_\
M NW_ /BZ/[<UO_H4KW_P+M__ (N@#H**Y_\ MS6_^A2O?_ NW_\ BZ/[<UO_
M *%*]_\  NW_ /BZ .@HKG_[<UO_ *%*]_\  NW_ /BZ/[<UO_H4KW_P+M__
M (N@#H**Y_\ MS6_^A2O?_ NW_\ BZ/[<UO_ *%*]_\  NW_ /BZ .@HKG_[
M<UO_ *%*]_\  NW_ /BZ/[<UO_H4KW_P+M__ (N@#H**Y_\ MS6_^A2O?_ N
MW_\ BZ/[<UO_ *%*]_\  NW_ /BZ .@HKG_[<UO_ *%*]_\  NW_ /BZ/[<U
MO_H4KW_P+M__ (N@#H**Y_\ MS6_^A2O?_ NW_\ BZ/[<UO_ *%*]_\  NW_
M /BZ .@HKG_[<UO_ *%*]_\  NW_ /BZ/[<UO_H4KW_P+M__ (N@#H**Y_\
MMS6_^A2O?_ NW_\ BZ/[<UO_ *%*]_\  NW_ /BZ .@HKG_[<UO_ *%*]_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** ,ZWT:&WUFYU1;BY:>Y18Y%9P4*KNV@#'&-S=/7G-/?1[&37
M(=9,"_;XH&MUF'!,;$$J?494$>G/K7,Z_P".+[P_I5YJMQX?9K"WN?LZN;M0
M\G[SRPP7;P"?4]*UXM6UEI[FVFT(13+;--;D789)G'&PMM&TY*\D=_:@#-'P
MT\/+:K:J+];>*[%Y!$M[(%MY V[,8!^7DGISSUK4M_"UE::IJ.HV\]W'<Z@B
M1SL)<@J@(3 (XP"0,>O>KD6HF*TT\ZFB6EY=[4^SB3?B4J6*!A][&&Y]JS[/
MQ%+<^-M0\/260C6UM([E9Q+N\P.Q7&W''W3W- %<> ]'7P_8Z&KWBV%C,L]O
M&)^493N7YL9.#R ?7Z4FJ> -%U76O[7D:^M[YD$<\EG=O!]I4=!)L(W?I744
M4 9CZ#9-J>G7Z>=$^GQ/%!%%(5B"L ,%!P< #'I6G110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% ' _&7_DFE[_U\6W_H]*Z7Q:&_X0_66CFFAD2RF=)(9&C=
M65"00RD$<BG^(/#FF^*-/^P:K'++:[@QC29XPQ!R,[2,X(S5J[TRWOM)FTRX
M,SVTT9BD_>L&92,$;@<\CWH \PFM(]17X43W;322S0A7D\]PQ_T0L3D'J3U/
M4UK7=W)I?Q%\4WENGF2VOAN*6-#D[BK2D#WZ5TTW@S19],TS3WAN!!I;*UFR
M74BR187: '#!L;3C&>E68/#>F6^NRZS%%*+R6$6[DS,4,8Z+LSMP,GM0!Q^C
M:;J.HV?AGQ);:U%#N\J2ZE\^23[:L@ :-E)VABQXX^4\ "NVT_28M.N]0N([
MBZE:]F\YUGF+K&< 80'[HXZ5D:/\/_#NA:D;[3[26(AS)' ;AVAB8]62,G:I
MY/...V*U]/T:STN[U"YMED$E_-Y\^^5F!; ' )X&!T% &A1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5GZUHFG^(=-DT[4X7FM).)(EE>,.,YP=I&1Q6A10!@
M_P#"&Z&RP)/;37<4!!BBO+N:XC4CH0DC%<CMQ5C5_#6DZ[<6=Q?VSO/9,S6\
ML4SQ.FX88;D(." ,CH:UJ* .=7P+X:33-1TU=+1;/49?-N8A(X#/D-E>?DY
M/RXP:35? OAW6K:SAOK!G-EG[/*L\B2IGK^\#!CGJ<DY//6NCHH QYO"VC3:
M?IU@UD!;:=<)<VT:.R[)$)(8D'+<DDYSDGG-;%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !17+V?C.WNOB#>^%O**F&V66*<])7!_>*.QVADZ=]WI73LP52S$!1R23TH
M6BD5U=0R,&4\@@Y!I$D25=T;JZYQE3D4 .HIJR1NS!'5BIPP!S@^]'FQ[@N]
M=S9P,\G'6@!U%48]8LI=:GTB.8->00K-*@/W%8D+GW."<>E7/,C,AC#KY@&2
MN><?2@!U%8_BG59]%\-:EJ%I]G:ZMK62XCCG)P^Q2Q&!R>E6-%O9M2\/:??2
M*@GN;2.9@N0H9D!..O&30!H45S7@[Q#=Z[87TFHK;13V^I7%DJPY"L(VV@\D
MDD\FNDW#.,C/I0 M%-+HH)9E '4D]*=0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4-:U)=(T>YO2GF/&N
M(H\X,DA.U$'NS$#\:OU3U'2;#5HXX]0M(KE(G$B+(,A6'1A[CUH \P\5:5KG
MAW0M&\1&TLFN?#MP;JXF@N7:2X20_P"D?*8P/FW%NO&*WO$>LV<_B_P;%=2Q
MOH6H)/*C/_JI9MBF+=G@\,Q /?'<"NSO=.L]1L7LKVW2>U<;7BD&58>A'>J,
MWA30+C11HTVDVCZ:IW+;-&-B'U4=OPH X?Q.ND^%].C@L+AUTFZ\10G5EWYB
M@20$LG'"H2$++Z-SP:M>+K?3_#NB^)]5\/RO%J%Q8QO/#:M\D<:L%,@5?NML
M+8.>=O'0UVD7A_1X=$.BQZ9:KIA4H;41#RR#R<KWYYI-(\.Z/H-B]EI6FVUI
M;2$EXXHP Y/'S>O''- ')Z=H.C7.NZ1K-IJUBT<]M) MOI]N(TO(BN<2 ,<A
M<9!XP>.]<%!X>L&^ ]GX@MHV77K1B]G>(Y,JR"Y*JBG/0YQMZ9.>M>PZ9X7T
M+PVUS=:+HEM;SRCY_LT:JS]]H)( 'MD"L'X>^$%T?PMI]OJ^EI%J-K([MF0.
MA<NQ5P 2-P! W8!XH SK:UAA^*'B:Y6QM3?QZ3:S19C7/G'S.0?4G SU/%9_
MARQT[Q#X9\,ZXVN6T-[;3PR2306X%R]P?EDBD;<2VYB01CG@]*],DT73)M7B
MU:6PMWU&)/+CN6C!D5?0'\3^9]:J6WA+P]9ZV^LVVC646I.26N4B ;)ZGV)[
MGJ: /.HS:>(? 'Q O-5ABFU2&:^CD\T O (U/DJN>5  !&.IR>I->C>$R#X-
MT,@Y']GP?^BUIE[X/\.ZC?3WUWH]I-<SQ^7+(T8S(N,?-ZG'<\BM2SLK73K2
M.TLK>*WMXAM2*) JJ/8"@#QV+PWHNI>!?&NI7\"_:[34]2DM[HN0\#HY92AS
M\OS <#K6OJ4,GAX>$_'NHVZK<QVL5GKCF/Y@DBJ/-/NDF,]\$BN\_P"$8T3[
M=)>#3+<3R2"60A<!Y!R'9>A;/\1&:S]9MM:UC4WT=]/M%T"01M->-/F1P#EH
MO+V_Q8 SG@$GKQ0!5M-!T>_\)WLNOVD$<.L3"\O$E;RL98&)68$8*@(.O4'U
MKL ,# Z54U/2['6=/DL-2M8KJTDQOAE7*M@@C(^H!JV!@8'2@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/$'GD+9*J<9&T # Y.<5U]I<Z=<_&NYG26VD_P"*?B9'R/\ GLY)'_ 2/P-
M'72>)=#BM[.XDU>Q2&]Q]E=IU GSV0Y^8_2K;:A9I?I8-=0B\=#(D!<;V4=6
M ZX]Z\O\+Z*GB;X,"RL)HUO;6[N)[&1"/W,Z7#O&1Z=A]&KK/!-]/XDMV\3W
M=J]M)<1);10.,&-4_P!9],REQ[A%H W[[6=,TN6**_U"UM9)L^6DTJJ7P,G
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "FO&D@PZ*P']X9IU8?BKQ/9>%-(%]>;F+R)#$B@G<[$
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M)H TGBCD.7C1B/[PS2300W$?ESQ1RIG.UU##/T-<-IVIZO--X\MY-4F9M.F
MLY3''F(>0'P!MP>3W!J_X6\56I\)>&7UG4D&I:E9Q.GF<-.Y49P .3D]!0!U
M<D,4T1BEC22,\%&4$'\*YS2=!O[#QKKFLR&U^RZC'!&D:.V^/R@P&?EP<[OP
MQWK<&HVAU)M.$Z_;%C$IBYR$)P&^F>*M=* (H[6WBQY<$28)8;4 P3U/U-*U
MO"\ZSM#&TJ#"R%064>QK!N?'GA2T7=/X@T]%\\V^[S@1Y@ )&1Z;ER>@S5+7
MM3OK;QYX0MK6^<6&H-<B>!54K)LA+*<XSU]\=* .J>UMY)EF>")I4.5<H"P^
MAIY1"X<HI8 @,1R!6;>^(]'TZY%O>:A#"^]8R7)VJ[?=5FZ*3D8!(SFC4/$>
MD:5+)'>WT4+1('ESDB)2<!G(&$!(."V!P: +\5K;PR/)%!%&[_>94 +?4]ZD
M=%D0HZAE(P01D&J5YK&GV'E_:+E5,B&10H+G8,9;"@X49&6Z<BFRZYIL-C;W
MC7:&"Y020% 7,JD;LJ "2,<\#I0!=,,1;<8D+>NT4TVT!1D,,91OO*5&#]:C
MT_4+/5;&*]L+F*YMI1E)8FW*>W7ZU6U'Q!I.D,RW]]'"44.^<GRU)P&?'W5S
MGDX'% &@(T5BP10S  D#DXZ4(BQH$10JCH%& *IW>L:?8I$T]RH\X%HE0%VD
M &255<D@ C) XS4$GB;0X=+@U.35K-;*=@L4WFC;(Q.,+ZG/&.M &DT4;,6:
M-22,$D=1Z4GV>#&/)CP.VT5CKXQ\.-+=QC6K,O:*&F7S!\H)P#[\\<9YXJ1?
M%>@/I4&IC5[/[%._EQ3&4 .^<;1W+9XQUH U'MX))(Y'AC:2/[C,H)7Z'M4E
M8^F^)]#UVZNK+2]7M;FZMQ^]2&0,R=L^XSWY%8W@76KFX\-ZA>:UJ'FFVU*Z
MA-Q-M3")(57.  .!Z4 =7<6EM=H$N;>*90<@2(& _.G+!$L0B6)!&. @48'X
M5CR^+]#BT_4;W[<&33EW7481O,C&,C*$;N>W'-&D^*-/U+PW9ZR\RPQW$<9*
M')*NRAM@XRQY[=: -DPQ&(Q&)#&W5-HP?PH,,1SF).0%/RCH.@JKIFK6&L6[
MSZ?=1W$:.8WV'E''56!Y4CT/-1:CKVEZ2YCO;Q(G$9F90"Q6,<%V !VK_M'B
M@"]]GAP!Y,>!T^44X(@<N%7>1@MCDBLVY\2:)9O:+<:M9QF[0RVX:9?WB!2Q
M8<_=P"<]*?I>OZ3K5G+=Z=?P7$$+E)71N$8<D-GIQSS0!=CMX87D>.&-'D.7
M95 +'W]:!;PB<SB&,3$;3)M&XCTSUKA]2\4_:/'_ (3LM+U9FL[UKC[1;B,!
M956%F1PQ7)7/<'!P*[:ZNX+&V:XN95BB7&68]R< >Y)( '<F@":HH[6WAE:6
M*"))&&&=4 )^IK&U'7=+N-"U)TUM-.$*&*6Z<!&M7*Y!(<##<@@$>E7$U.SL
MM-L7N+_SO/1%AD*Y>X.W.551DD@%L >M &A)&DJ%)$5T/56&0:!&BL65%#$
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M_7=>BUW2+NXOKR"T:.6ZDFDVV\1.=C[N 2><'G@GM7>4U41 0JJH)R0!C)H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMMH&FD1.F\A5; ST)&#BN9^'WB,-\-M-U36-2>=YIYHQ/*2[S,9W5%  RQ(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M];RU:Y-LMS"9UZQ!QN'X=:FKDM3BV?$+PNS+'YS6U[YCHN-QVQ5UM !1110
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M@E'4]1D \$$$=:#H!EL]12YOY9KJ_A\B6X**-B88!44#  WL><G)Y)X%;5%
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%** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>a97-arwrxclawbackpolicyf001.jpg
<TEXT>
begin 644 a97-arwrxclawbackpolicyf001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH Q;S2+Z[\266H&
M^M_L-JC@6;VQ8EVP"^_?P0,@?+T9NN:YKQ;\.)_$/B_2?$>GZQ#I=WIN-A%F
M9#( V0&.]>.6&,=&-=_10!P6O_#Z^UWQSHWB<ZU;PR:6JA(!8E@^"2<GS!US
M^'O27OPW=?B#%XPT/5UTR[9=MY!]E\R.Z]<C>N,C'KR >M=]10!P<'P^O8?B
M?-XU.M0-)+$(6M!9$#9M"\-YG7Y<YQ^%)HGPW?PQXYOM=T/5UM=.OSFXTMK;
M<A/7*L'&WG)'!QDCI7>T4 <5IO@67PQX@U+4_#5[#;V^I$/<V%S"7C$@S\\;
M*P*]3Q@CGM@8L>'O T6E^)=0\3ZE=_VAKE]\K3"/RXX8\ !(UR2!@ 9))./K
MGK:* .:\5>"]/\67NB7-[C=I=X+E1MSYBXY0^Q8(3_N^].UWP=8:]XET#6[C
M'G:1*\BKC_697@'Z,%8?0^M='10!S?CKPO-XR\+7.A1W\=E'<E/,E: RG"NK
M# W+CE?>LB\^'][>?#"/P4=9@5%B2$W8LCDHC*P^7S.OR]<_A7=T4 <%=?#R
M]N?A>G@DZU L:QI$;L61R55PP^7S.O&,Y_"I++P=XETSPA;^'K'Q-8P"" VZ
M7BZ4QF53Z$S8!]\=J[FB@# BT"[CU^UO#?6[Z?:6AM8;0VIW+G;EM^_&3L ^
M[P/J:Y[7?AQ<ZE\0K#Q?IVLPZ=<V:*GE"R+B4#.0Y\P=0Q7@=*] HH \_P!2
M^'FHWWQ)M/&D6NVL5Q:1>3';M8,Z%=K+R?-!)^<^G:M+2/ EO9^+;GQ7JEXV
MHZW,OEI)Y?EQ0)C&V-,G''&22>3ZG/744 9?B/2YM;\.W^E07,=L;R![=I7B
M,FU74J2 &7GGUK,\!>$Y_!7AB+0Y-0COHH7=HY%MS$?F8L01N;/)]JZ>B@#@
M_%GP]N_$_C#1-?768;7^R)%DA@-F9-Y#AOF;S!Z8X%)XN^'MYXJ\4:%K?]M0
M6K:/(LL47V(N'8.K'<?,'&5%=[10!B)H^H/XG_M2ZO[6:V6V\B.V%H08\D%F
M#ESRQ"YXZ*/J>:U/X<75Q\2;;QGIVLP6$\*+&]N+(NLR@$'<?,'52!T["O0*
M* .#E^'U[)\3XO&O]M0!XXO)%I]B.-FTK][S.O.<X_"FV'PW?0OB!=>)=!U=
M;*VO1_I>FM:[XY">200XV\\C@X)/8XKOJ* .8D\)S:AHFNZ3J][;W-OJKR,/
M*MC&8MP '5VR00"#QR*R/%?PT7Q!X'T[PI9:C'I]E9>60YMC*S;%(_OJ!G.3
MUYKOJ* .8'AS5=F@POJMHUMI8'F1&Q;_ $A@A13GS/EP#G'/.#V%97C[X</X
MSOM)O;358]*NM-D,D4R6OF.3D$<[U& 5!Z5WE% '&>*_ $?BEM,U%[\V7B#3
M2KP:A;P\9!S@QDG*YYQGN>>3G5M[#Q%/Y2:GJUFL2,&?[!;-&\N.<%F=MH/<
M 9]Q6]10!P&M_#S4-5^(UAXQAURV@FL8Q%#;O8,ZE?G^\?-!)^<],=JWK+1-
M97Q$FI:EK-M/;10/'#96UD8$5W929"3(Q8X!'_ C[YZ&B@#@=/\  &H>&O%N
MKZUX;U6UB@U=_,NK.\MFD"ODG<C*ZGJS<>_TQUVDZ8VFPSM-<&XNKJ8SW$VW
M:'?:%X7)VJ%50!D\#DDY-:%% '!7/P]O9_BA;^-AK4"R01F);4V1(*;&7EO,
MZ_,3G'X5I?$'P=-XY\.'1DU*.QB:59'D-N96.WD ?.N/UKJZ* ..U'X?66O>
M K3POK4XG%I%&D-U!'Y;(R+M5@"6YQG/.#FK&F:/XKLM.BTV?Q!9311((UN_
ML+"X*C@9S(4W8_B((]0:ZFB@#"FT.^DUS3;K^T8GL+&)D%M-;F1W<@*9#)O'
MS;00/E_B;KFN=\7?#B?Q%XNTGQ'I^L0Z7=Z;C819F0R8;(#'>O'WAC'1C7?T
M4 >?^)OAYJ'B'QGH_B1=<MK:;2POE0FP9U<AMQW'S0<'/:MPZ'KEUK^G7^H:
MW:O:61D=;2VL6B\QV1D#,S2MT#' QWKI** .+M_"6NP>#O\ A&)=;M;JU:U^
MRFYFLR95C*[2 -^&P. 3TXSN[Y^H>$M1TK5_",'AS6[RWLM.,<,NG*"8YH0V
M9))&! R5R.0<DC&*]$HH SM>TZ;5]!OM-@N([=KN!X#*\1D"AE*DX##GGUKD
M_#GP^O\ PYX O?"L&MV\JW E5;EK$@H)!@_+YG)].1^-=[10!FWNCPZSH$NE
M:VL-Y'/%Y<^R,HK>X!)*GH1SP16$/AYI<_P\A\':@SW-I"FU)AA74AB58>C#
M/TZ]CBNOHH Y'0_#_BC0]*@TA-?L;BTMT$4-Q-8L9UC' !Q)M) X!QVY!KJ+
M2 VMK% 9I9RBX,LIR[GN3VS],"IJ* "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M-C'J5W#?6265CI_G(7M"S3S .S?Q@*N OKU/I7.>!?%'C'QAX2MM=6XTX/\
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MPR>9OAC;S%V/N4'>O/!]1R>/<U7&D::M]]N73[07?7SQ"OF?]]8S5RB@"O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#(&7+<#:>=V#GL>W57]EJ-W\1]!U1-,N!8P6-Q#/*7C'EM)L(!&[)^Z<X!H
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M:"V\R/ECG!W;MN.?6M&^T_59_$?@>\CTJY,.FK-]L;?'^Z+P^6!C?SSZ9XH
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M?1V^ T1#^8LBJQY7)((SD=>:P?$/A+5[WPUXSN;;3I7U#Q!<P&&S$B I'%L
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MZ#KCK0!/X \0WWB?PK;ZI?6A@>9I&4AE*D>8X"C!S\H &2!FHY?$>H-\2O\
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MF>98;'[3-&HN<H7+9S\@ !)W<]!@DXH ZFJ.L:5#K>D7.F7,DJ6]U&T4OE$
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ML]W D\>X8.UE!&??!H MT5R.H>.5T]+F[DTR?^S;74%T^6=FVOO+*N]4(^9
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M?8DAN(@H/DJFW&0!@@Y_3=UK=NM+U>;Q'X(O%TJ?R-,BG6\)EBS&7A"#C?\
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M\\,ZWJ$'Q#@&GM#_ &TBFQ>26/$A6$)@X8E<D=^QJYJ>CR^(=(TFRU[PI-)
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M0.@[T <#+\2KB/P_?:X/#EP;+3KN2VO";E T81]C,H_B(ZD<#T)[;$/BR?\
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M@U:6UEM+=59Y[@NJ%VVC RS#)YP!GFIDT>_MOB7;ZG%8N=+AT;[ )?,3._S
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M(4TO]SJUU%;-$;CYH3))L!SM^;U[4 =K4,-W;7$LT4-Q%)) VR5$<$QMC.&
MZ'!!YKE)O&.K2>)M5T33O#;7<VG_ &=V=KQ(P\<A.6Y'! &0._/3'-*7Q/+!
MI?CB\TO1+2SU'268RM(X_P!(98@^]MJ\D+C )YQC(H [BXN[:T$9N;B*$22"
M)#(X7<YZ*,]2>PJ:N!FUZ:W\+^$I]:T:WOWOKNSA61I@_E2.!MF.Y =X.XX
MX]>:T-;\;QZ=/J<%E'97$VFJ#/%<7H@=V*A]D8VMN;:1UP,D#UP ==17(V_C
MF+4KFQM=,MHC=7FGK?QPWL_D,RDD;%^5LL"ISZ<=<\=/93R75A;7$T#02RQ*
M[PL>8R0"5/TZ4 *+NV-V;07$1N0GF&'>-X7.-VWKC)ZU-7#1QQ0_'"X=(U4O
MX<5G*KRQ^T-R?4\5/:^.+AM1T&"^T@V::TTBP)),?/B*J6'F1E1C('8G!]:
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M S&1D[L<!3P2.9HO%-Q%XC?0-0TY(=0>U-U9F&XWQW*@X90Q52K XR".G.:
M.EHK@-.^(6JZCX8;Q''X6<:8ME/<F0WR;MT;'Y-N,X(!.[U!XZ$VX/'5TNEP
M:GJ.BK8V=[';_89)+U/WTDHR5;CY HYR<_+VS\M ':45Q,7Q&M(9]8BU*"-/
M[-MUNA-93_:(IT)V@*VU</N(7:?4<UJ)K6N#5H]/GT )Y]JTT-Q'<,\*.O\
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M?NI;C$XAV1X3.Q<'<0.<':/>@#T?5/#VGZS>6-U>I,TUC)YMN4G= CXQG"D
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M)Z#IZFII=.\5^'_%VIW^AV%IJ>F:PR3203W7D/:S*@0MG#;E(49QD\?GWE%
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M;:\"IC>!TRR#IG@^M=-H5WXKNPLFN:7:V @C(:.VN1,US)CJ,@!%Z\$DY(Y
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MC"L/!OB2R\)>$;7R=/>_T&]$K1?:6"2Q[77._9P?GSC!Z5I'2/%V@^*=1O\
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M"%;;5;PW$1CFW$*45-K# P?ESQGK6;X6TCQIH%M!X<E.G2Z3:ML@U,2MYWD
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M#+]DC5@AW+P6)<X XR 3QT-'X:FX-YXQ^U11Q3_V[)O6)MRY\J/D' X/7\:
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M+%F.#A0JD]/0=ZPM8\5:]H6C>(+R\T>%O[)5)89A(5BO$89.WJ593P<Y'YT
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M)&DA>)E)62,D D\'@]\9[B@#TRBLWP^]W)H-D][Y?G-"AS&Q;(VCDDCK6E0
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M]% 'GY\+^));[QA=2C2]VNV,5O$BSN!$ZQLG)V'(^?K@$XZ#/#W\*ZZ;#P3
M$T[=H+QM<DW+X?;$8_D_=]\YYQZ>]=[10!P.E>'?%GAW4-1T_2I],?1+VZDN
MHIYV?S[/S#EU" 8?!)(R1[^E7K?P_JN@^+]5U;2EM[RSU9(C/!/.8WBFC7:&
M!VME6'7OGIGI7844 >=R^!-3M=+T&VL&LIIK36O[7O9)I6C$CDN65 $;^_@9
MQPH]:V]4T35;OQ[H>M0)9_8K"">&4/.PD/F[>5 0CC;W(SGM74UF:GXATC1F
M"ZCJ$%MG;DR-@*&.%+'HH)R 3@'% '-WVA>*-*\8WVM>&GTZXM=42,7EK?N\
M?ER(NU9$90>-H&1[?DS5?#?B6V\0:=XET:ZLKK4X[1K*^@NBT44\9<N"A )7
M:Q.,YX[^O= Y&1THH XS7_#VOZMI6D3>=8R:K8ZK%J+1,[I 0H(\M6VE@,'[
MQ')R<#.!7N="\6Z3XKN]:T%]+N8M4CB%_:W;O&L<R+M$D;*"<8&"#Z?EW=%
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MUC;3PS+]H8N3)MY4;,$#;W(SGM3_ !?HVKZG<Z+<:9]DGBLKHRW%C=R-'%<
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MZA;Z):P:FELEU'&J,ML[.@P /O$ G.,]!C..<9.E110 4444 %%%% !1110
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M*$#LBL@PG#  G//8#DL'C#6[SQ%IVE6>CP0&^THWZ_;9'1X6#*"LB[<C&XC
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MD5YU+X'UR;P-XET(OIPGU>^GN8Y!,Y6-97#$'Y,DC&/?VKT"W$ZV<8E2,3A
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M&? WB '_ *!MS_Z*:N6\,ZG*_P -_#6GS^'[V6TNK.TM))G,1BV.JJ6.V0N
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M'&5=W(V.O0,1C&>"171^)=>A\-Z%/J4T9E*%4BB4X,DCL%1<]LL1SV&37/\
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MS;11+-;:@EG+;QR9.&C*R9(8>Q.1Z5A>-[@VGQ1\ SB":<H-1/EPJ"[?N5Z
MD9H [G3]4T_58#-IU];7D2MM+V\JR 'T)!ZU;KSCX?Q'7/%FN^-[4+;:9J2)
M;Q6NX>8SQ\-)*HX5LC '7!Y]Y[GQQJ\VFG6-%TU[^U6Z,0LDL)VEFB60HSK*
M/D!X+;<'CC.: /0**Y*;Q!K.J'7/^$<@M';29/LXCN5)-U.$#L@.Y0@^8+DY
MYSP .94\0ZAJ.NC0[.*"SOH;".\O#<*9A"SG"Q *R[CPQ+9Q@#KG@ ZBBO.[
MGQYK \(ZQJ5O8VHU+0KMK?4K=E9U95(S)&00<;3NP?0CW/2W&O-'=QRQ3V[Z
M;#I[7UW*(R3L_@*G=C# .>A^Y[T ;]%<+;>+M<GN-#N8M+>YL-2=%FBBL9T>
MS5QE7,K?(ZCC=@#U&11I/B#Q=KNHZI;VEMHT$6FZH]G*\K2N6C"*P*@8RP+=
M\ @XXQF@#NJANKNWL;9[FZF2&",9>21L*H]2>U<;I7C#5+[PG=7$T5G%K\%^
M=/>T",42;S J@_-D@J0^[T.<<5U.K!O^$?OA(59OLLFX@8!.PYXYQ0!7L?%?
MA[4IXX+'7-.N)I?]7'%<HS/] #D_A6O7AUMI>H>*O@WX5T72=.N/MRO#*E^X
M"1VH5B3(&)R3CC"Y/-=]JGBO47GUF#1(5DFTLB+8]C//]HEV!R@:/ 3AE&3G
MDGC Y .SJFNJV+:P^D+<H;](!<-!SD1EBH;TZC%<;/XN\2W.LZ3IMAI-G:SZ
MCI<EV$U!G#02KM!5P . 6QQR>#Q5ZU\3:A;^+KK2M9@L88[71DU"6:W+-SN*
ML,G'R@JQ QGI0!V%,FFBMX7FFD6.)!N9W. H]2:X2[\;:K9>#[3QE+;6K:/*
M8Y9K14;SXK>1@%</NPS %25VCJ1GC)UUUZ^UC6]5T_1&LT33%C66:YC9Q+*Z
M[PBA6&T!<9;GENG'(!N:9J=EK.G1:AIUPEQ:39\N5,X;!(./Q!IVH:A9Z58R
MWM_<QVUM$NYY9&P%%<E\(\_\*LT3@ [)./3]Z]8-O>:S?^$/B2^I7MO<1PRW
M]N%2 H1LMU V_,0%QVP3G)S0!Z;!/;ZA8Q3Q%9K:XB#H2.'1AD<'U!J+3=*T
M_1K06FF6-O9VX);RK>,(N3U.!WKA]!\0:SI:^"K&Z@L3IFJVB01^66,T3K '
M4L3\I!"G@#CU-3ZOXTU;1YTDNH+&)&U5+,6#9:=K=GV+/N5L#)Y *].,YH [
MVBN(TN\UF?XJZ_:2WMNUC:VMJ4A\ALA7,AX._P"]D<D@YXX&*V/$'B Z7?Z=
MIL"_Z7?^8RN8'F$:1@%FV)\S<LHQD=<YXP0#?HKAXO$/B^YT/67M]'A_M+3I
M3]G\^VEBBOX\9!0,0RMU&#GG'/.1<\.>*Y=>TZ77088]$CM@VYH664RJN9>"
MQPJD;>F20>P!(!UE%<E8:WXDU&UT/5[73[2;3=297EMP=LUM ZY60N6PQ QE
M0N><#.,UFWGC?5YM.GU70].:^@ANFA6R6QG:2X1)#&[+*/D4Y#$#!X')R<
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MJ_APW$,_A>^61;>%F836B2*=R*<$,N2<9P1[U)X:T3Q?IT=MINL:QI]SI=F
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M6[6)1-)&NU6?'S$#L"<\4 3T444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%<]XWUF^\/>$-1UC3Q;M-9Q&79
M<1LRN!VX8$?6@#H:*\=F^+&N:/X3\.^*=5L].N--U60QS0VR/'+ 03R"SL'X
M4GH/3WKU6\U?3-/,0OM0M;4R_P"K$\RQE_IDC- %VBN%^(WC/4O!_P#8<FGQ
M6<T5_>K:R"=&) /\2D,/U!K2@UG6)OB%<:8/[+;1([3<&2X!N1-D9!3=D#G^
M[Z<]J .HHJF-7TPZA_9XU&T^V_\ /MYZ^9TS]W.>E-AUK2KGS/(U.SE\I2\F
MR=6V*.I.#P/>@"]14=O<074"SV\T<T+\K)&P96^A%<O\0_&L/@3PV-3>(33/
M/'%%#G[V3EOR4-^./6@#K**AL[N"_LH+RVD$EO/&LL;CHRL,@_D:X+XE?$1_
M">A_;-#NM*O+J*Z6"YM9&\QDW!CDA7!7E>X[T >AT53?5;"&9+>>^M8KAEW"
M)Y55B,9S@G..#4'_  D6A_8?MW]LZ?\ 8]_E_:/M2>7N_N[LXS[4 :=%<MXO
MUS5M-CTK^P6TF22XND$PO;E8\P'JR989/3IGZ&MR76=+@FEBFU*SCDA4M(CS
MJ"@'<@G@4 7:*YKQ3K]S;>$)=2\-W&E7-T^T6K7-RJP2?-\V&W $XW=QTK23
M6;6UT^PDU:^L+6YN8E.TW"A'? )"$GYAD\?A0!IT5S>O>.-$T"[TJTN+R!I]
M3E185$H $9ZRD] H'?N?QQK#6=+,AC&I69<)YA43KD)C.[&>F.<^E %ZBJ,F
MMZ3%81W\FIV26<GW+AKA1&WT;.#5?5?$VCZ/X?DUR[OX/[/1-PF1PPD] F/O
M$] !0!K45PFJ>-+^[\-Z)J7AE]&>XO9(6N(;R\5?*C90S*#N&6&0#W]C787V
MJZ=IFS[??VMIYAPGVB98]WTR>: +=%5;K4["R2-[N^MK=)/N-+*J!OID\T6V
MIV%Y<SVUK?6T\]N<3112JS1GT8 Y'XT 6J*9++'!$TLLBQQH,L[G 4>I-5;/
M6-,U"*66RU&TN8X?]:\,ZN$_WB#Q^- %VBLT^(=$"QL=8T_;+)Y49^TIAWX^
M4<\GD<>]6+_4;'3(!-?WMM:1$[1)<2JBY[#)(H M45PG@+QIJ/B?Q#XJTR^C
ML_+T>Z6"&6V1E\T%I!N.6;^X.GK3/BMXTU;P)X?MM6TV*RG$ERMNT5S&YZJS
M9!5A_=Z8[T =]17G/B#Q]J_@E=)O]>MK.\T;4&6-[FRC>*2V<KN&49FW#&>A
M'0^V>ZN-5TZSM8[JZO[:"WE *2RRJBMD9&"3SQS0!<HKB?B-X]3P9H=I<6GV
M:>[O;A(81(^556R3(0""5 '8CDCFJFE:_P",G\8VFG7Q\-S:5*96,UK<_OVC
MP3$P0MG)&#P",9Z4 >@T5FOXBT2**2636-/2.-@CNUT@"L<X!.>"<'\JR/%N
MMZOIS:0NAG2I&N;I!<"]N%C/DGJR989/TS]#0!U-%<W<^.-%MO&$/AIKR#[8
MT+2REI0JQ8("J<_Q-G@=<#W%1^&=9UC5-<UZ*^_LLZ?;S*M@]G<"1V0[N9 &
M.#P.H'.>N,T =115.TU?3+^>2"SU&TN)H_OQPS*[+SCD Y'-12>(-%A25Y=7
ML$2$[96:Y0!#G&&YX_&@#1HJK<ZG86=FMY=7UM!;/C;-+*JH<],,3CFI;>Y@
MO(%GMIXYXFSB2)PRG!P>10!+1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %<A\4CCX7^(<_\^C?S%=?7+>-;#Q%J-M:P:%9>';N/
M+&XCUN-W7MMV!?\ @6<^U ''_#?P5I'B#X?^%[_5S<7PM4>2WMI9?W$;>8W.
MP 9Z?Q9K-;SG^)'Q+.KC.S1&%N).@M]G\/MZ^^:WK'3_ (IZ9"8;"P\ VD1.
M2D$5Q&N?H*BO]%^)>JR))J.E?#V[=!M5IX+AR!Z#/;VH \[U![]OA)\.CJ)?
M?_:P\HR?>\H,VS\,8Q[8KM',R_M&ZN;0 W/]A$Q#U?:F/UQ6C>Z-\3-2$0OM
M)^'MT(1B,3P3OL'MGI2)HOQ+BO\ [?'I'P\2\_Y^%MYQ)TQ][&>E '/?"Y/#
M?B+PII::W=^5KNCZO)<;7GV323N^06!Y;<<#ZKBK=_9WO@SXR7%OI<#?8_%]
MNR)L'$-P/O/_ ,!R7/LYK4CT+XDPZJ^J1:/\.TU!\[KI;><2G/7+=:4:;\79
M;ZVN[C_A#IIK1I#"THG^7?@$C:!T&0/8G.>#0!Z;:6L-C9P6EM&(X((UCC0=
M%4# 'Y"N"\1:5=>.H];@M[6QN; PMIUO+-=M&8Y58-(X C;.)%0=1S$?6D;_
M (7 ZE6C\$%2,$'[5@BJEGI?Q0TZ*2*QTWX?VL<GWT@AN$#?4#K0!A?##Q'J
M4GPT\1^&<NNOZ#!<1P1Y^?[K; /4JX*^WRUPVKMI;?LX:"4-N=0&IOYAX\W=
MNDW9[_=V?AM]J]1M=!^)%C=_:[/1OAU;W//[Z&VG1^>OS 9YJ ^%?'YDE<^'
MOAL7FD$LC&TFR[C.&/')Y//O0!7\>P6U[\9? $4\<<T,D;Y5@&5AR1GU%<C:
MZ?8MI_QCW6L!^RW#BW!08BS)+]W^[]U>GH/2N^ET/XE37,-S+H_P[DGA $4K
M6\Y:,#H%.,C'M40\-_$)5F4:#\-PL_\ K@+2;]YSGYN.>>>: .0\4.7^$OPT
M9VW,+R 9/H 1_05T>I65I??M*1PWEO#/%_8Y8I*H92<-S@U=D\.?$.6WAMY-
M"^'#PPY\J-K68JF>NT8P,^U/;0OB0]V;M]&^'37)7:9C;3ER,8QNQG&./I0!
MYOICE_V7=;#-D)JBA0>WSPGC\S^==5XFL]9M(-$\3^'+NWN+K3O#D"W^EW !
M66T()+ '[P)4Y P?E&/2MH>&OB$MJUJ-!^&XMV8.T(M)MA8< D8QGWI9_#?Q
M$N4C2?0_AQ(D2".-7MIR$4$D*..!R>/>@#G?$$]E?>)/A+?BQ2TM)XA^ZEY"
MJ!'A2QZ@#H36AK6FZ=K/[1.EVEQ%%/82:+DQ#F.1<28! ZCH<>PK:O-+^*&H
MQ117VF_#^ZCA8-&D\-PX0CH0#T--;1OB8^HC4&TKX>M?#!%R8)S(,<#YNM %
M7Q&/#GA7QYX6TO3W^P74-G,D"7$^VR@@??N9P>78D-@!AD@9/2N"T1DN/V8O
M$<1*R26]^I5>IC!DAY [?Q?K7I=QIOQ2N[N"[N=/\ 37-O\ ZF:2*X9X_P#=
M8\C\*9!I'Q-MK:XMH-+^'L4%R29XD@G592>I8#@Y]Z .1\?FS/PF\!?93!D7
M5EYOE8X?[/DYQWZ?I6[^^?XW^,!JHS GA\BT$GW?)(3=MSVW;\_C5I_#GQ#D
MM8;5]"^'#V\&?*B:UF*1YZ[1C _"I;W1/B7J2Q+?:3\/;H1*5C$T$[[ >H&>
M@]J /,=7:^?]FO0SJ&\@:N!;&3KY6V3'X9W8]L5Z!I%M;:=^TE>VUE#';P'1
ME!CB4*I^YV'T%7[S1_B;J$$4%[I7P]N88?\ 51S03NJ<8^4'@<>E)'HGQ*AO
MEO8M(^'D=VHP)UMYQ(!C&-V,].* -3XPW>DVG@*1]7>^$1N8A$ME*(W>4$LH
M+$$!>"22.WKBN3\"ZC]I^/OB.1[VRF-SID;;K-\Q.X$/"G)W$#<,]\$X'0;]
M[8_%74K9K:_LO 5U;L03%/'<.I(Z<'BH5T?XFI<_:5TKX>BX\KR?-$$^[R^F
MS/7;[=* /((K*T/P+U^\^SPFZ77PBS;1O"[4X!Z@<G\Z]*UFX=_C9X#&IL#I
MQTPM 93\AG*29//&[_5_^.U='ACX@"W:W'A_X;"!F#F/[)-M+#@'&,9Y/-2W
MFA?$G4+.&SO='^'=Q;08,4,UO.R1XZ;0>!^% %'X.-:#QU\15LS%]G_M!#$(
ML;=F^;&W';ITI_[1I_XM[8_]A./_ -%R5?M-)^)^GSRS66F?#ZVEE),DD,-P
MC.2<G)'6DO\ 1_B;JI4ZCI7P]O"GW3<03R;?INS0!D?&>7^TO _AWPY8+]JU
M6^N(7AMHOF<JL9!;'898<_7TJM=-<Z#\6O#ND:I?VT%M%X?2SM9KR,R0E]NU
MR/F7#-M(SGT'<5T-CI'Q-TQF;3]+^'MH6&&-O!/'D?ABDU/1OB9K4<<>JZ5\
M/KY(SN1;F&XD"GU&[.* ./\ B#H=MH/PO\*Z=#J0U6*VUE8H[MHP,I^\)4')
MRH/'!QQ[5TOB1(XOVCO!J(JHJZ=* %& !MGP*M7>B?$J_BABO-(^'EQ'"-L2
M36\[B,>B@CC\*1M#^)3WD=X^C_#MKJ( 1S&WG+H!TPV,C':@#@)+*SG'QFGF
MMX9)89QY3NH)0F63./3D#\JO>*'+_#7X6N[;F%U;C)/8*!_05U@\-_$,"<#0
M?AOB?_7#[+-^\YS\W'///-+)X<^(DL$,$FA?#AX8,^5&UK,5CSR=HQQ^% %/
MR[.']I:[-TD"1-I(9?-  +97D9[YS7.VCW\<GQH;2]XNA,,>7]X+YDN\C'?;
MNKMI=+^*$]Y!>2Z;\/Y+JW&(9GAN"\0]%;J/PIMIHWQ,T^XDN++2?A[;32Y$
MDD,$Z,_?DCDT <F/.BD^"_\ 9 Q<M&1+Y74Q'RO-SCM@OG\:JW-E9W/B;XOR
MSV\,KPV3M$SJ"4;:>1GH<@<UVEEH?Q*TVX:XL=(^'EM.P(:2&"=&()R1D=L\
MTP^'?B(7G<Z'\."UP,3'[+-F3G/S<<\@'F@#G[;2=5UKX6^!)M"U1+?7K%9;
MBRAE(VW&TD%03QN"XP#QC=VY'H?PMUDZYX*CNWTU-/F^TS+/#&"$,N\EV4=@
M6)..QR*YQO#WQ&>TCM&T3X=&VC),<7V:?8A/4@8P"<"NT\'VOB&RTQ[;7[?0
M[?RV"VT6CHZQ*F.A#=#GTH Z*BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)%<>:616"LKC:-K<@X!8>YH ZBBN7\.>*Y_$EO8WUK:VLFG7<;,TD-R7DMV
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M!8W)N,QM*T>[RX6PAPA"J,@]#D@=,5AVM]J&C>-?B%/I&DP730FTF=))_(3
MM@2 0K$L><< >I'< ]0HKD_^$YM)['19+801SZK9_;8UNYO+2*/"YW$ Y.7
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M2TGU"SM;>\LK>Y,$D27/^E.%?RW=(PIR P) )&0,\5J2>#=*NK_5]0-E:/\
MVK;K%+&R';-WW2>ISCIC&/4\ '1Q7$$Y(BFCD( 8A&!P#R#]#VJ2N \3PQ^
M_"6CZG9,=NBRP02GIYML["-T(]/F# =BHKOZ "F2RQPQ/+*ZQQH"S.YP% [D
M]JYR3Q->WDNKKH>G0WJZ5(89O-N#&990H9HTPIY 8#)QSQ[US/BOQ-)K_A/P
MMJ>C1QO8:CJ]D&$TQ1B?.'[M@%(QN7!.>,=#0!Z%8:G8:I$TNGWMM=QHQ1G@
ME5PK#J"0>#[5:Z51T_3X+62>\%E;6U[>%7NC =V]@,#+8!; [D"N:EUC67^*
MW]B"&U;35TK[1L,S D-*%+$;""PVD!>F"?FYX .LM+ZTOXVDL[J&X1'*,T,@
M<!AU!([CTJ>O(="\1WOA+PSXBU&#2(KC3+/7[PW+&X\ME0S;?W:!3NQG/)7V
MSV[C5_%JVFIW&F67V%KNW@2:3[9=>2OSYVJ"%)).TD]AD=<T =-161X8UU/$
MOAVSU=+6:U^T*2T$PP\; D$'\0<'N,&M>@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK/77
M='>\-FNJV+70;:8!<(7!]-N<YJ]'(DL:R1NKHX#*RG((/0@T .HHHH ****
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M&VC(E!<,A8DE?0[O7M7-0>"_$:?"J'PR\5B+S3YH7MR+ABMP(YO,R3M^3(&
M.>>M>GT4 <)J6E>++'Q1%XFT:UL+F6ZM%M=0TV6Y*+\K,R.DFWDC<0<C\.>%
MUS0_%4ESHWB+3Y+&76['S5GLG<K!+#+MS&KXSE=JX8CDY/'2NZHH S-%.KRV
MS7&LQV]O<2$;;6WD,BPJ.Q<@;F/.3@#H!TR<'X@Z?))!HFLQ*6_L;4XKN8 9
M/D<K(0/8-N^BFNGN=3L;*XM[>ZO((9[EMD$4D@#2-Z*.I_"K5 '*>)M(U.^\
M1>&=;TE+6X_LV2<R1S3&,,DL>S<&"GIUQCFJ=OH6LPZUXTO'M8BFL1Q+:A9A
MG*0^6=WID\\9XKLK>WAM(%A@C6.)?NHO1?8#L/:I: /,H/"GBC1=.\+ZCI,=
MG)JND6)TZ[LYIB([F([?NN!P05!&1_+GO-&_M5[1IM86"*YE;<+>!RZ0K@87
M<0-QZDG ZX'3)T:* "L#QGHNF^(O"UYH^J726T-TH5)F8#8X.Y6&>N" <=^:
MWZKW=C9W\:QWEK!<HIW!9HPX!]<&@#DM)\1ZQ;645EJ2:3<W42A/MT6IHL4V
M/XV4C<I/< 'GO5;5K<Q^)]&\36.JZ?>7EI#):WD#7"1>=$YS\AR0"K<@'J.I
MSR>K_P"$<T+_ * NG?\ @*G^%'_".:%_T!=._P# 5/\ "@#@]7TA=2T[Q?=K
M>::NI:_;I:Q0->)MAC1"H+-W))8G&>PYZU=O%>XU[P;?+/IPCTA9?M0-\F<O
M#Y?R>N#SSCBNEM].\*7=W<VEM8Z/-<6VWSXHX8F:+.<;@!QG!Z^E6O\ A'-"
M_P"@+IW_ ("I_A0!Y_?6%Q<Q^/42XTP?V_&J6A-\GRXA$1W^G3/&:O74<D^H
M>"[A9].VZ-N-T#?)DDPF+">O7/..*[+_ (1S0O\ H"Z=_P" J?X4?\(YH7_0
M%T[_ ,!4_P * .+2&1=6\;W7VC3MFM11I:#[<F04A\KY_3)YXSQ59M/N(O#7
M@J."[TE[_0)8O.A>_54D58C&2K@'U!Z5WO\ PCFA?] 73O\ P%3_  H_X1S0
MO^@+IW_@*G^% '(_9?\ BM=6O)+[29--U?3X;:XD%Z%>)D#A@JX^;._@Y&/T
M,'A2Z\1:1:VGA^^O]";3[';&FJ)>CS)(%^ZOE8X8@!22<#W/7M&\.Z"JEFT;
M30 ,DFU3C]*HV%MX.U2::&PMM%N98,>:D443%,]"0!T/8]Z .3T=M>\-7-YH
MVGWVA7.BSW,D]K>S7H62T61BS*8\'>02<<C/<CMZ9&RM$C*^]2H(<'.X>M9D
MF@>'X8VDDTC3$C499FMHP /4G%6].N[&^T^*?39X)K,@K$]NP:/"DKA2., @
MCCTH YCXDV+ZYX>M_#D(S-JEY#&<?P1(ZR2.?8*GYD#N*[&HA;PK<M<",><R
MA2YY.WT]A[5+0!Q>F:+K/AC7-?;3[6&^L-6N3?1;IO+:"=@ X?(Y0D Y7)'3
M!K.N? ^H:=X.\+Z#I:Q7+:7J,%]/+))Y8?9(9'VC!Y+,<>W>NTD\0:+#*T4N
MKV"2*<,K7* @_3-7HIHIXEEAD22-AE71@0?H10 J$LBLRE"1DJ3T_*N6O-&U
M:+XD0:_9PVTUG)IGV&822E'C(E\S<!@[L@XQD<]ZZNB@#S&?P?K\_P /?%&A
M?9K=;S5=0GN83Y_R*DD@?YCC.1C' /:M*]TKQ3I7BM_$&@VEG=QZC;10W]A<
MW'E%)(\A71P",8)!&/\ ZW>5%<7,%I;O<7,T<,,8R\DC!54>I)X% $6G)>)8
MQC4)(WNSEI/*'R*2<[5SR0.F3R<9JU4-K=6]]:175K,DUO,@>.6-LJZGH0>X
MJ:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "N#^*^JW=CX<T_3[*=[>36-2@TYYXSAHXW)W$'L2!C
M\37>5@>,?"\/B[P^^FO.UO.LBSVURHR89E.5;'?N#[$T 7_["TK^P_[%^P0?
MV;Y7E?9M@V;<=,?UK(BU%]/U"R\(Z4L<UU:Z<DTDUPQ"QQKB-,@<EF(/'& "
M?0&:PN?%IMUM[[3M,6Y4;6NX[IFB;_:$>P-[[<C_ 'N]4;OP[J=CXTMO$NF-
M'=L]B+&^@GD\MI%#;ED4@$;@<Y' P>* ,Z]^(US:^%]5U :3&=1TB]6ROK1K
M@@*6=55T;;\RG<",[>_I5Z7Q1KT'BQ=!DT:R\V[M7N;*1;P[5", PE^3CA@?
ME#>GN,S6? NJ7WAG7X;?['_:NN7T5U-OF810K&R%4#!26^5.N!RQK:N]&U:X
M\?Z5KJPV@M+6REMY5,[;]TA4Y V8(&WU&<T 9,WQ#O[7P;J6KRZ1 UYI>I'3
MKN!+D[-V]$W(2N6'SJ<''>M"W\7:K:^,[30==T>&TCU**233Y[>Y\W<8QN:-
MP5&&V\\9'8$]:Y'Q7HFJZ+\.O%QO4M =0UJ.^@\J9GP'GA 5LJ,$;>V>M=K=
M:'J.M^(M-U6\2&Q&EPSBW6.3S6::50A?H!M49QW)/(&.0"E!XWO4U70;;4=.
MAM3K$CQBT:4BYM<*S(74CD$+STP3WJM/XYU[['XEN+;0K(C0)W6;S+UL2(D8
M<[,)]X@GJ !QR>V?9^#O%<=IX:6:/2!<Z3?F>XF^T2,UWE&4RL=@.[YLX.<^
MHK23PMKHTWQO;&.PWZ[)*UL1<-A-\0C^?Y.,8SQGTH T9_&%Q%K/AN+[%$NE
M:Y'F*[>4AHY"F]8RN,98=.>Q_'029_$']MZ?<6=I)I\3FU1I<R+,VP%MRX P
M"VW@]0>F*Y[Q%I:_\*PAT:]N((=8LK6 VGD2[F%S'@1%,@$Y< =/XB*Z_1=.
M.E:/;6;2>9*BYFEQ_K)&)9W_ .!,6/XT 8%WJ%EX#TS0M&CDM[>*XD-M'<7)
MV0QD*7YQTR> N0.>O&#T.E7%Y=6 DO[>."X\R12D3EU*AR%8$@<,H#?C5#Q%
M87.HK!;_ -G66HZ:X=;RUNB!N'&TIE2-P(/7'7KG%0^"O#TOAC06TZ23,?VB
M62"'S#(+>)FRL08\D ?S- '-^-Y4M_BGX F:WDGP-0!2)-S']TG;VSFJEC=P
MWGQO22TMY-(VZ<RW,5S'Y+ZB2<J53^,+UW=>,=*W_$FA:Y?^./#FMZ?!8O;Z
M0+G<D]TT;2F5 O&(V QC/O[4V?POJNN>.M'\0:M]BM+?1TE^S6]K*TKRO( "
M7<JN  !@ 'Z\T +-XSO9= U#Q%IFGPW6E6,DJE3*5EGCB)$CIQ@8*M@'KCJ,
MU8O/%EQ)#%=:9;0C3I-.6_74+QRD+EON1 ]F(Y.>G'!S678>%-<T;P_K/ABS
M%I+IMX\_V.ZDE(:W2;.Y73;\Q4LQ&#SWVT\>$=7TW7+,:;]BN=)M]*33X!=R
M,&LV7(,BJ%(8L,9Y4G&,@4 *_P 0+R?3?"E[8:/'*NOD(%DN=IA?8S8/R\K\
MOWNN/X3TK0M/$6KW=_#HDEA9PZRMJ;J]'G&2&!"Y5 " "Q;&<<8&>O&>>TWP
M;XEL]'\&6DL>F,^@W!DFVW+C>FQD&WY.3\V>P[>];6HZ#K=AX\_X2;1$M+J.
M[M%M+VTN9C$?E)*2(P5NF<$$?_6 *WPL,ITG7C/$D,QUZ]WQHVY4;>,@' R
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M&"3CDDXZ 8,7A33/&6F6EEHNJ2Z:=/L L:WL#N9KB-/N*4(PIP &.3QD#KD
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MP ,Y;&>> .3KS>+=<O?$UQHNB:;I\G_$NBO[>YN;EPA1V(&X!<@\=!GUR.E
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M)I=A;Z=YUQ!<,+AFD#1N54H-N",C!S@]>!QD [.BBB@ HHHH **** "BBB@
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MZ;(BR1LC_=8$'G'% 'E/A'2]5U_X:7NBQK:Q65[>7D+W1E8R)&9W#X3;@MU
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M&ZA7C;;R 0%P1TQ^(V-$CUD0//KDEI]JDP!!9[C%$H]"W+$Y.3@=ACC)U**
M.9UWPS-<^(]/\3:3+%%JMG&T#I-D1W,#<F-B 2I!Y# '!Z@U#JWA_4?%<]C#
MK4=K:Z5:W"W+VT,S2O<R+]U6)50J \D<D\=*ZRB@#EI]$U9_B/;^((ULC8Q:
M>]D4:9Q(=TBONQLQQMQC/XTFFZ)J]GX[UO6Y$L3::A#!%&JSOYB^4&P2-F.=
MWKQCO74LP52S'  R2>U5=,U.RUG3H=0TZX2XM)QNCE3HPSC^8- '!#X?ZO/X
M3OM/DN[2UU(:P^KV%Q"[2+'*9"ZA@5'3)'&>N?:M>?0-?\3^'=0T[Q1/8VQN
MK8P)'II=E5C@^82^"2"!A>W/)SQV-% ')^'K;QM'Y47B"ZTF2.U4A9+0R;[M
ML$ R;AA!W. <G'0<&/PSHVM^&?!VH6<C::+X27-Q;2&9VAW.S./,RJD $X..
MU=A2$ C!&10!E^'+S4+_ ,/VESJL4,=ZZGS1!N\ML,0&7=SM8 ,,\X-:M%%
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M8QQP2?YU=JEI$5_#ID$>I-;M=*H#_9P=@P,<9Y/Z5=H **** "BBB@ HHHH
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MZYO[I;6']VT@4[68L57YFPJMP.IP,CJ #5M;6WL;6.VM((H+>(;4BB0*JCT
M' J:N-L=8\57D^L6*6<'F01K+I]]/92PPW&1S&R,VY6!XR"1@YQQBD\&^*=5
M\5".5X;>V6T0P:G$\+!TNP2&C3Y^ !@Y(.<C'?: =G17&6WB'Q#K>CQ:[H-K
M9W%G)=F-+.3*R20+(8VD\PL%5N"P&T\<<FHM3\6ZK/\ VU_8,"RR:9,T"0/8
MS3?:I%4,RAT(5/O;1G/(R>* .XHK@V\4^)[[Q1!HMC86%F]QHRZB/MH<O;N7
M"E7 (SCD8&.N<\8.!JWB_7]4\&3I(UMIVJV&N0Z9J"Q1LZ2YD3!0E@0I##(.
M21D9&: /3I]6L;75;/3)IPEY>+(\$6TG>$ +<XP,9'6KM<K=ZYJMAXV\/Z).
M+.6#4(+AY)DC96W1*I^4%B #N'<]*H-XMUC4/#&I^)M'CLGL;*2;RK65&+W,
M<)(<[PP"$[6VC:>V>O !W-%<)_PF.JZIX@T:ST:*Q%EJVE-?PRW(<O&?D^\
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MY8I9L<O%$8U/IP68_K7$^,QJ3>/_  6EM=VT<;W-R8UDMV?:PMWR6PXW<$@
M8QGJ>E '4VEYHOB[1W:$PW]B[-%)')&<;APRNC#(([@BK]I96MA:I:V=O%!;
MQC:D42A54>@ Z5R]KJ^I:M>ZY;:!_9T']F3>0[30,PN;G8&?[K#:O(&?F.<^
MG.0GQ"U/5+#PI=Z396D8UFXDM9X[DL6AE17W $8R 4/N1Z9H [BQT?2]+DGF
ML;"VM7F.Z9X8@A<^K$=3[FDTK6M.UN.YDTVZ2Y2VG:WE9 <+(H!*\]<;ATKB
M;>Y\6'XE:38:GJ&FAQI,\\D5M;.8B?.121EP=Q7&">!SP<YK'LM6US0='\=Z
MOI2V!AL=>NIYDN5=FF 6/<J[2-O'<[N>PZT >NU2.K6*ZTNCFX']H-;FY$.T
MY,8;:6SC'4XZYJQ:SK=6D-PH(66-7 /8$9KG7U[45^(W_"/B*U^R-I3WL<GS
M>9O$BI@GICD]!0!T]%>7_P#">>)T\'2^)I+?21;6=^UO<P*LA>5!/Y64.["D
M9SR&S[=*]0H CGGCMH'FE;;&@RQP3@?A5/2M<TS7+<W&EWL-Y #CS83N7/IG
MI6A7 _!<8^%.D8_OW'_H^2@#L;S5K&PO;&SN9Q'<7SM';(5)\QE4L1P,#@=Z
MNUS6O:]?:9XK\-:=#%;-::G/+%*[@F12L3.-O.!T'7-9UKXPN=0\27FDP75A
M;WMI?"%M.N8F6:2W##,J,6 ;*Y88!XX]Z .VJEI.K6.N:9#J.FSB>TFSY<@4
MC=@E3P0#U!KD?#5UKMSXS\81S7]K,EI/%%%&UNR@ Q!E (<X +'/!).>G:C%
MX]UN7P!X=U^*SL#<ZEJ$=I-$=X10TS1C;R<' ZG/KCM0!Z317'Z?XCU:V\5:
MMHNLQVDWV;3TU&"2RC924+,I0AF.6!7@C&?05E?\)MKLFC>%]6@BTYXM?N%@
M$!1\VY<,RG<&^; 4AN!SSQTH ]%K)O/$VBV%U);76HPQ21 &7).(L\C>W1,C
M^\16MVYKRVYO]<^&VKZO/?:4^K^%M1O)+U[JU&Z:T+XW"1/XD&.O8=^U 'IM
MK=07MK%=6LJ302J'CD0Y5E/0@]Q4M>::U?E-$\#+X4U.!='N]2@MX\P%@Z!6
M90?F4X!3!7@Y'48P=/Q1XGUS0H-6G/\ 9T*6-FL]L)8R[7[!2TFU5?=&HP!D
M@XSDG H [BBN)NO%6M2^(/#VGZ=;V"0ZQ8270>XWLT3*J'G&,CY^G?'456M?
M'E]!X?U!]1M[635[76?[&A6#<D4\S%0C8))48?)&3]TT =@^MZ:FMQZ,UVG]
MHR1&9;<9+;!C)/8=1UJ_7GLR:E'\8]"%_/:SC^RKHQM!"T7.Z/<""S>V#GO[
M9+XO&>L6^KZ#;:C'8+)J5T]M<V,0+269VLR9D#%2<*,C SGCI0!W]4-7UO3=
M!M!=:G=I;0EP@9LG+$X  ')Y-<GIWB3Q/J.M:Q"$T>"QTC45BN7D\PL\&P.V
MW!^^ >I&/:L#QGJVJ^(OA8-;'V2+3KNYMI$MC$QE6+[0FQB^[&XX4D;< '&>
M,D ]:K+UCQ'HOA\0G6-4M;$39$?VB4)OQC.,]<9'YUJ5Y]XPTWQ-8ZQ<^);"
M+2]7L8H%5]+NK?$@C3);RWR1N))/09P!S@4 =W;W=O=64=Y!,DEM+&)$E4_*
MR$9# ^F.:BLM3LM1B::SG6:%?^6R@^6WNK=&'T)KSWQ/K#^)[WP?HFE1*VFZ
MO"=0N(I'\I9($166)B <*21N ';'>J'CCQC>3^!O%FBRV8TW5=/-O;RB"7?&
MT$[JH=&PIP5+ C'% 'IEAKFF:I*8[*]BF<)Y@"G[R9QN7^\N?XAD>]-FU_2K
M>Y>"6]C5XW$<AYV1N<85F^ZK'(P"0>1ZURGC(C2O%'@.2S7RV%^UD%7@>2\>
M&7Z?*I_ 5R>KWTVBMKOAR]E63PKJFHR)+K2(6^PO,VZ2%^Q.3@/T4MSDC: #
MVFBFQA5C55.5  !SGBN*\6>*=9T)-9N(UL+>"QMA/:).IE>^PI:3 5P4"\+D
M@\\]* .W) &3P*H:5K6G:W'<R:;=)<I;3M;RL@.%D4 E>>N-PZ5B#Q-<:GK=
MCH^F"&&>73EU*XEG0R"*-B%1 H*Y8G/.> O0YKDO#6OW'AW2/$DEPD$VI7?B
MV2QA5,K&\TGE*#W(7JV,DX&,]Z /5Z*Y*7Q!JNE>+[#0=1^R7"ZK!*UC<PQM
M%MEC&YD=2S<8.00?;'>N7'CWQ?\ \(-%XQ-AI+V$$CB\M4\SS7C69D+(<X7
M X.<X)XZ4 >JT5P5IJ>IW'Q2OE.HP'2X=)AN8XVMV^6-W;.#O^\=HRQ![#'%
M-A\9ZY>VND:MIVG-=V-],GF6BV$RR10/TD$Q.QB!@D8QS@'C) .OUQ]*CT>Y
MDUH6YTY4)G%PH9-O?(/6GZ.-/_L>T?28XH]/DB62W6)-B[& *X7 P,$<5Q>M
MZYJ/B+PCXNGTQK2*PLH[JS FB9WG,:$2,&# *,Y"\'ID]<5TW@S_ )$;P_\
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M;7/">DZK<(B37EI'.ZQ@A064$@9[<UKT %%%% !1110 4444 %%%% !1110
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MAJ$-]$9D+(QC)^5L'.#D]*Z&LZ+7=.GUV;1([C=J$,(GDAV,-J$X!SC!Y]Z
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M741=VNH(&%S#&)=XB QCI\N=V,?PDBNHU'5;+284EO9Q$)'$<:A2S2,?X54
MECP> #TJ'3M>TO5KB:WLKM9+B !IH2K))$#TW*P!7.#U H RM/\ #VI:7XLU
MW5+>ZM7L]3:.;R'1@ZR)&$QNSC;P#TSVK"@\!:M;^"-#\/B[LFDTS4$O#.0P
M$@24R!=N.,DXSD]/?CT2B@#CM0L;G2/$^I^,KN:".RBTC[.\<89W01LTF\<#
M=R2,<?6N0T1=9T72['4;>Y\'ZDL:>9$L9D6>5WY81X9D$CDD?*H!)]*]@(!&
M#R*S[30='L+IKJSTFQMKAL[I8;=$<_4@9H T*YFVL/$VG)>P0SZ9>0SW,\T)
MN \9@61V8*< ^8!N_P!GT]ZV;C5K.TU2RTV:1EN[T2&!!&Q#! "V2!@8!'4C
M-6I94AA>60X1%+,0,X &>@H X9OA[+8^%/#NDZ3?1+/HM^M\LEQ$=DK?/O!5
M3\H)D8@ \8 ]Z34/!6N7=WXEV:O9FWUVS6"1Y;=C)$PB*83#8"$DMCG&3]:[
M/3=1M=7TVWU"RD,EM<()(G*%25/3@@$?C5J@#BK/PIK$&L^&;^>ZLI?['LI+
M2145D\S>JC(ZXQL'7KST[4;CX=WU]I6MVTU_!!<W>K_VQ97$(+?9YAMV@@XW
M ;>O'7I7H=9>I^(M*T:X@@U"[\B2X.V%6C8^8?1<#D^PH YX>&O$E]XGTS6]
M2U#387M;.:UD2TBD.?,V_,I9A@_+GV]ZS+/P#XAM]-\.VCZOIN=$O?.C=;5\
MS*0X+/\ -RYW9^N22:[6T\0Z7>WJV4%R3<LA=8WC="RC&2-P&<9'YUIT <OH
M7AJ[L-1\1RW[VTMMK$_G>7&6RGR!"IR.<@=>*YM_A_XC'@J3PA'J^GOIT4L;
M6EQ+"YF$:RK($< @<8QD=<8XZCTRLZ?7=-M]<M=&EN-NH72.\,6QCN51ECG&
M!CZ]Z +\8<1J)65I !N95V@GV&3C\S6!/9^)[B\OK=K[3DTV<XAE2%_M$2$8
M(P3M)ZX;]#TKH:* .9U#PFBW&@WNCF.WN=$4PV\<F?+D@9 C1L1R. "&YP1T
M-07'@>VU>#Q"VKLIGUR-(I?)Z0)&,1A2>I!);) R>W%=;10!S$/AV^OM8TC4
M-;GMY6TB-Q L .)964*96S]WY<X49P6)R>*J'P?=IH.L>'HY;633-2EG<32@
MF6 3,6<;<8<@L2K$C'&0<<]E10!%;6Z6EK#;19\N%%C7)R< 8%<1JW@G6;Z]
M\5"WU2T6SUZV$1,T#/+"1&4V*00-G.?;)XR<UWE5[*^M=2M5NK*=)X&+*LB'
M()4E3^1!'X4 <6G@W7+#5M)US3M1L3J5OIZZ=>Q31.L,\0.5*X)*L#WYS[=*
MK_\ "N;ZYT?6+6\U6W6ZNM7.L6<\%NP^SSC;M)!8Y'R]/<\FO1** .;BT*]U
M#Q!INM:T;59M-AE2WBM2S*7D #R$L >@P%QQD\GMQG@G1K_Q'\*(=&DEMH],
MNY[A99E9O-$7VARR!<8R<$;L\ ]#BO59(TFC:.1%=&&&5AD$>XJO8Z;8:9"8
M=/LK:TB)R4MXEC4GUP * ,%_#%U'XW;6;6YMEL9[".RN+:2(EMJ,S#800!D-
M@YZ5F^'?"?B;P^J:*FNVLGAR!\PY@;[6L><B+?G:!VW8)QTQQCI-8\2:7H2N
MU_.Z^7%YT@BA>4QQYQO8(#M7KR?0^AK0BNK>>S2[CF1K9XQ*LH;Y2A&0V?3'
M- '#?\(3K=A#XCTS2=0L?[(UDSS!+F-S);22J0X4@X*D^O3T/?K/#NFW&C^'
M-.TRYGCGEM+>. R1H4#!5"@X)/I_^JIM,U?3]:MWN-,O(KN!)&B,D+;EW#J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<YXWT&\\1>'3:Z;=I;:A#/%=6SR#*&2-@RAAZ$BNCK*
MU[3;W4K:V73[Y;*Y@N$G65HO,'&<J5R,@@X/(X)H Y#0O&/]I>)M/T7Q;HTF
MC^);?>]JWWH+GY"&\M_0CG;GL.21BJFC^)=0T'3?'>NZO>1WD&G:I,@B6$HS
M,L<*HJG<0J\@8P3WR:Z>?P[?ZQKNDZAK,UF(]*D::"*U1LR2%=NYF8\  YVC
MOC)XJE_P@33Q^)]/O+Y)-'UR=[DQ+#B6.1E4$[\D$ H"!MZ_D0!VI>(-9\.7
M>@RZH]I<V6J74=E,(8BC6\T@^0J2QW)D$'//0^U-37O$6N:3>:MX=CLI%@O'
MM[>SG4@W"1R;'9I-PVDX8KQQ@9SGBQ#X7U*]AT6VUV^MKJ'2)TN$:&(J]S(B
MD1L^20N,Y(&<D#D#@T['P9KFC:GJ$.D:]%;Z%?W#W,EN]L6G@9SEQ$^X  GI
MD''IW(!EWFN1Z/\ %G6HU:/^T+[3[.WLHY#A7F)E(R>, 8R>_&!DD ^B6"7J
M6:+J$\$USCYW@B,:9]@68_K7':O\/FUK6-:NKNX@-O?V<5O"BHPDMWB+&.4/
MG[P+9Z"NHT*VU2STF"VU>]AO;N)0K7,<9C\S'<KDX/KC]* //_B/IMU)KKZ]
MIBYU30;."_@ _P"6B+)+YL?T9,_D*N>,M4MO%W@V6*P??8R:1+JEP1_<$;&%
M#Z$R#/\ VR85URZ9>_\ "43:D\MLUI+:K;&'8=_RLS;LYQ_%C&/QK"L/A_%H
MG@_6=!TJX53J1G42SJ6$,<FX*@&>BAN!D<DGO0!7T*_O[#X;>#C:&UAMY+.V
M6[N[AP!;Q^2#D*2-S%MJ@<]>AK.NO'NMQ> ?$VKP+:->:+J#VBM+;NBS("F&
M*%@5;$GTXZ<UJ#P3JT.E>%(;;5;1;OP\0J&2W9H9U\OR\LFX$,!D@@]<U4N_
MAWJMSH/B;23K=L4UN\^U&0VI!C8[-W ;G_5@ <8R<DT 5O',^J:?!H5YXAN;
M$6T7B2UFB-M&X\F((Y8/DG<1SR,9]!T'0GQ/=6OAC4?%=TUN^D);FYL[>)/W
MK1[<KO?<5RQ[ < C/.:F\2^'=0\01:(/M5K$^GW\5])F)F65D!&T#/ .X^M4
M+'P'):V6MZ&]Y&WAO4M_E62H0]GO'S!'SC;N^8#''\P!\&L>*/[>L+?[*+BQ
MNXW6XF^PO"+.0+E&^9OG0GC'![Y[5'\+[C5+SPQ+=:C?)=-)>W0SY.U]PG<$
MD[B,<<  8'%6O#>@>)M.-O;ZSXBAO[*S&(!%;&.67 POFMN.<#L!R0"2>]KP
MCX<O/#-K=64M_%<V9N99K=5A*.HD<N0YW'<03@8 _'L 9/BF?5U^(OA&TL]0
MBAMIQ=N8G@+C>D7WFPP)X<@#C'7FK$.O:QKZ:]/H4EI$NE74EG#'/"7^T2QJ
M"^XAAM4D[1CGC//2KWB'P[>:IKNAZO87T5K<:8TPQ-"9%=)4"MP&&", CM52
MU\+:EHNIZS)HM_;QVFKRFYDBN(BQMYV&'D3!&X-@':<<CK0!K>%/$$7BGPMI
M^MPQ&);N+>8R<[&!(89[X((S6;;ZYJT_CS6-!)M!!;V$5S;/Y;9#.S#Y_FYQ
MM[8K9T'1;7P[H5EI%D&^SVD0C4MU;U)]R<D_6LN+P]?P>-M0\0I=6Q2ZLTM4
M@,;97868,6SSRQR,4 <C;^-_%+^!]$\5N-+,5S=)!<68B<%P\QCW*^X[<<<;
M6]<GI716FLZ_#XWN?#U]-I\YETTW]M+%;N@B(DV%&!<[AR#G([UGI\/]1C^'
MVG>%AJ=J6L[E)_M)@;YPLOF@;=W'/'6MQO#]Z?'<7B1[JW$2:<;%K<(V2"X<
MMNSZC&,=* .+7QWXOC\!6'C>:'2GTX$&\LXXW$K1F0H71BV 1Q\N#TR3V&[)
M=16WQBOKN0XAB\,)*Q _A$\A/Z5B> ]"N_$GPBT?2KJXMAI,Q+3%%/FO&LQ;
MR^N!DC!;TXQGFNQ?PQ/-XXN=<FGMWLY]-&G-:^6=VS>6W;L_[1&,=* ,>U\4
M^([U-"U*ST]KFSU!XS<VHM'0V\,@R)%E)PQ7(SQSVQ563Q1XLFTCQ=>03:3$
MV@74RJ&MG83I'$K[<;QM)!/.3UZ#&3H^'/"/B'05@TI_$:3^'[5P;>,VV+G8
M#E8FDSC:.F<9(XX%.B\&ZDFE>++,W]J3K\LT@<0M^X\R,1D8S\V ,]N: (4\
M4:[%JGA:YN?L)TS7_D^S1QMYEN3$9%/F%L-TP1M&/?K45WXNUZ^T^\U'P]9F
MY^SW;P169M'87*QR>6Y\W("DX8CCC SG/%Z;PAJ,L/A-!?6H.@LK,?*;]_MC
M,?'/R\'/?FH+7P;K^D:M?IHOB&*VT2_N'N9+>6VWRV[N<OY39P,GD9! ]#W
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M/+#[2=PVI\RKGKG)[<Y=Q=^()_B5X>MYKF"T$FDRSRV?E&18Y,QAQN##<>2
M>@'8Y-7)_"6N67BF^U?P]K5M9Q:H$-];7-L9E$BC;YD>&&#CL>/7/:Y>>%;Q
MO$>BZO8ZFJ/8VTEI/]IB\UID<J2P((P^5ZD$<].U &GXFUV'PQX:U#6KA#)'
M:0F38#@N>BKGMDD#\:P=2\0ZSX<N=!GU-[2YLM4NH[*=88BC6\L@^0J2QW)D
M8.>>A]JZ/7M%M?$6@WND7H;[/=Q&-RO5<]"/<'!_"L.'PMJ5Y!HMKKM];74&
MD3I<(\,15[F2,$1L^20N,Y(&<D#H." 9>BQ:E)\6_$ZRWEL\:VEF'4VS?-&?
M-(4?/P>N3SG/05Z %55"@ *!@ #C%<WIWAZ_LO&VK:\]U;/!J$4,7D+&P:,1
MAL'=GG.XYX%=(V[8VS&['&>F: .'^'2.=%\1QPL(W.NZ@J-C[I\PX-</JE_+
MI_P*ET#4+"_MM<LV2!5:VDPTXG!21)<;3G@@@Y/->G^$O#]YX=M]1AN;J"X^
MUW\UZ#'&4VF1MQ7DG('K3Y] DU?5K2^UB6-X;&3SK6RB!,:R]!(['EV'.W@
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MZV<"0B5^K;1C/M].U<9J7P\U>]TOQ%I<>N6RV>JWQOD9[4M*CEU;8S;L%!L
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3'UX!K'\,S7VC:EX9L3-:ZYX>O#)_9-\HVW-K^[9ML@'#+MRI/KUYP* .O\
M'>K7^@>#-2U?3I(EN;.+S566/>K8(X(R#^M85SXLUS0-0\+_ -IO9WUCKLL=
ML3# T4L$K@%3]]@R\\\ C%:'Q595^%WB$LP -J1R>Y(J;1/"^E7$&B:Q/YUY
M<VUJAM6GG:1(=R#)12<9]\9H W+G6=+LKI;:ZU*T@N'("Q2SJK$GIP3GGM6'
MKNKZE8^.O"NGP7$:V&HO<K<1>4"S%(BR_,>@SCH!TZURNC36USX(\<Z?KY07
MT=W>&^27[Q##,3C/;;M"G_9&.E+;+?6^I_"B+5W8:@(+@3"0_-N^R]#[] ?>
M@#OM/FDDUK50=9M[N)3%LLXT4/9_*<AB#D[B"1D#&*EBU[1YWF2'5;&1H$,D
MH6X0E%'5CSP/>O+M:2Y2X^+,>CKBY\FS.R#AB/)^?&.Y7=78:1JG@[Q'J.BW
M^EO;75]%;.MNMO)\UK"RC<)$!PHX"X8=3Q0!T::SI4NGO?QZE9O9(<-<+.IC
M4^[9Q4L>HV4MV+2.\MWN3$)Q"L@+F,G ?'7;GOTKSC3;&XTW7[SX?"W;^RI;
MD:E;N%^1+,L7DB_[^@)C^[(?2N\6713XG>)?L?\ ;HM S84>?]GW<<]=N[MZ
MT :E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNK&Y-W&RJXZJPW<JPX/X?2I[;QI]JA$%YJ_A>R<C$ES;ZPLWU*(57GTR>/\
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MZ_MX(YY;:!Y1%)(4#;03C(!QT]*OU0URUN+[0=0L[01&>XMWB3S7*J"RD9)
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M[<Y*KM4#..I)(Z8YQ#X+UY_!/BG16_LT7&L7MQ<1.+ARD:RG.&_=YR/8<^U
M&LOBG58?%>DZ=>:?:I9ZQ%,]FT<[-)&T:!\2<8Y4_P .<'UZUBR>/?$\FAZM
MK%KX>L7MM'O)X+N,WC;W2(X8Q_)S@ G+8]@:V;SP_K-UXB\)ZD$L%CTA)A<+
M]H?+&2,)\G[OG&,\XS7.^%[35]4T#QCI=G':)#>:WJ,'VF25LQ!W*L=FWYB
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M<GBTFVM1I7V"2UM6<^5B3>-F5 8?@N/0XYRAX&\1?\*FN?!IDTLRX\F"?S9
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MJ&Z.6[+J3L7I@C !ZG)(P,9H?4];;XMC2EDMAI\>D?:1&=P.&F"L3ZM\O'8
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M26(Z\=L\$'CR=1XK1HK;46T.VCN8I;'(6X5T8XQEL$%""03_ $H [+[#9_\
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MG)7.<8"[3T_C%9N@>(=7TQ/!=A=VEG_9NJV:01-&[&:-T@#@M_"00IX'3U-
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M$]/RH Y>3PMK+_\ "&X-A_Q(L&;]\_[W]T8OE^3T.>?I[UV<_P#J)/\ =/\
M*I*CG@BN8'AGC62)QAD89!'H: /+/!FAZAXG^#^A:-="TCTN94::59&,KQ++
MOV!-N 25 )W'C)QV&EK/@CQ!J \6VL5]IS6VMJ#%/.KF:(! !%QP$!&003C)
MX.:[O3],L=)M%M-.M(;2W4Y6*% BCZ <"K5 '')X=UL^+-"UB=]/9+"QDM9E
M1W4L7VDE05/3:.IY]NE6O[ U*#X@S:];3VOV*ZLH[:=) WF*49F!7'!R&QR>
M/>NGHH R?$V@V_BCPU?Z+=.R17<13>HR4/56]\$ _A6+_P ([K.KQ:%;^('L
M3'I-S'=-+;2.S74L:D(2K* @R=Q&6Y&*["B@#@U\(ZU_8OC.Q+6&_7YII(F$
MSXB$D8CPWR<X SQUZ<=:ZW1+2>PT*PL[KR_/M[=(7,3%E)50,@D \X]*OT4
M<M'H.JV7CK4]<M);-[34+:%)(I2PD5XMP ! (P=W)[>AK C\"ZY'\.;#PSYN
MG&XM;U;DS>:^Q@)S-C&S.><?K[5Z110!P\_ASQ3I?BF^U7PY>:7]EU78]Y::
M@)"(I54+OC*=<@#(.,X_+L;.&2WM(HIIVGE50'E88+MW..W/;M2O=0QW,=NT
M@\Z4$H@Y) ZGV'3GIR!W%4[/Q!I5_:K=6UXCP-.UL),$+YJL5*Y(X.1@>IZ9
MS0!A77A?4M-\77/B3PY+:^9?QI'J%C=LR1SE.%D5U#%& X^Z0<UK_8;_ %:V
MGAUE;>&WFA>%K6UE:0,&&"6<JI/!.!M&.O/&-BB@#@(?!6KS>#8?!NHW%G+I
M,31QF\1V\Z2W1PRH8]NU6PH4MN/'.*UK/0]4L_&^LZX%LWM[VVA@BC\Y@RF/
M=@GY,<[NV<8[UU-% 'FZ>!=<3X:Z?X7$NGFXM;M)S-YK[&59O-QC9G)Z?K[5
M+I[ZFOQ:\3M96]I*QT^R\Q)IV0 XDQA@C9'7L.U>AU1AT73+;4I=1AL+>.^F
M&)+A8P'<>A;J: .,_P"$$U33X]!DTV\LYYK*\N+R]BNPRQ7$LV27 7."A)VY
M_.JMUX"\0S^&?$FC_;-,<ZMJGV])<2)LR\;D$8/>/ '/7.>U>ET4 <M<Z-J+
M^.K#Q'*;**SM;"2VE4SMN&]E8L#L P-O?&?:LVQTO3M6^)<VNZ7?)<6:6L;W
M*P.'BDN0'6-MPR"PC9LCW0^E=S(B21.DJJT;*0RL,@CN#[5@Z%JGAB&=-#T0
MVUL?*^T16T,!B22,G[\? 5US_$N10!T%<-J7@Z_UO4[*ZOXM.CNK'4OM,&IP
M.PN! )"RQ%=@ZKA#\Q'4XKN:* (;R&2XLIX(IF@DDC9%E7JA(P&'TZUY[8>"
M?$UO%X5$EUHZMH4SEC&LC>>K1LAD).,N<Y([G)W=J](K/O=<TS3IUM[J\C2=
MEWB%<M)M_O;5R<>^,4 <W:^$-2A'BVQ:[M/[.UR2>:-PK&5'EB"$$=,#&>,Y
M]JIKX4\3I9>%/]*TJ2;1/D>V?S/(E41B-7SC.]<%AQ@;O;)[BQO[34K5;FQN
M8KF!B0)(G##(ZCCN/2K% 'G,G@77W\*^+-&:\TV1M:O);B*0!T">9MW;ASTV
M\ 9Z]:V;OP_JUUXG\,:KBR6/289HYD\YR7,B*IV_)VVYYZY[5UM!( R>!0!Y
MS?\ @?7+W0_&&GB33D;7KKSXW\YR(1M52#\G)PGZUMWV@ZM>^*_#6K[;)(]*
MCG2:/SG)<RHJG;\G;;GGKGM6YI>M:=K4=Q)IMW'<I;SM;RM'G"R  E<]\9'2
MK] 'GMQX!U'4;;Q1#<W5O:OJE['?6<]N[.UO+&$V9!49Y0'\3]:UK"Q\97&G
MW":[=:0TPMVBACLO,5)&88WR,PR,#^$#')]L=910!Y\/!FM)X4\):0'T\RZ'
M>07$CF9]LJQ C ^3@G=^&.];6EZ!J6F^-];U59[1M.U4PR,A#>:CQQ>7M';!
MP#G\,=ZNWOB[P[IVKII5[K5C!?O@""28!N>F?3/;/6MJ@#!\8^&QXJ\.RZ:+
M@VUP'2>WG"Y\J5&#*<=QD8/L:JC0]3U;6]'U/7$LHFTH2/'%:2O()9G7;O)9
M5V@#.%YY/7CGIV940N[!549))P *Q](\6>']>NIK;2=8LKR>$9>.&4,0.F<=
MQ[CB@"AX9T/5-)UO7[R\^QF'5+L7*"&5F:/"!-IRHS]T'-3>--#O]?T..UTV
MX@BGCNHK@QW&?)G5&R8Y,<[3WX/2M*ZUS2[&[%K<WT,4YVDHS?=W'"[O[N3P
M,XR>E,UGQ#H_AVW2?6-2MK*.1MJ&9PNX^@'4T 8NA^']:L?&>JZW>W&GF#4;
M>W1XH%?<C1!@ ">,?-U[XZ"M?Q/IUUJ_A?4],L_)$UY;26X:9BJKO4KNX!)Q
MGI5J/5M.FTK^U([ZV;3_ "S)]J$H\O:.IW=,5!HWB+1_$,4LFD:E;7JQ-MD\
MEP2A]QU% '-ZIX7UF_\ "OA[2T-@MQI=S:32,9GVN(,<#Y,_,1^'O5ZWT358
M/'>HZ_MLF@N;&.U2+SF# H68$_)C!+8]L=ZZFB@#S73_  -XBTW1?#-M%<Z9
M++HUW/-)!*\A@N!(6(;[N0Z;SC@\\Y%)=^ ?$-QX:\4:1]MTQSK.H_;4DQ(F
MS)C+9'/_ #SP!SUSGM7I=17-S!9VTES<RI%!$I9Y'. H]30!S-_X>U'4/&FG
M:Q,EF+."QFM)HO.8LWF[22/DQQMQVSGM5#POX:\5^'[>'0I-4T^70;5_W$ZJ
M_P!K,0.1&?X1Z;ADXZ 'D=AIVHVFK:=!?V$PFM9UWQ2*" P]>:M4 <+<^$-:
MN;SQI+'>V]I_;T,4=O+#(Y> QQ[!GY1U]CQ[TFG^%?$,/B+0=5FDT>%+"QDL
MI;:V63:%)0@H3CKM[@;<_P 5=I>7MO86YGN91''N"C@DLQ. H Y))X ')JOI
M.M:=KEO+/IUR)DBE:&4;2K1R#JK*P!4CT(H R?!VA:AH,.K1WYMF^VZE/?(8
M)&;:)6SM.5'3U[^U)XPT+4=<.B_8#:K_ &?J<-^_GR,N\1Y^484]=W7MCH:Z
M:B@#C_$?AW79/$EEXD\-7=E%J,5L;2XM[X,89X2VX#*C((;)!QW_ #QO&<.K
MP1^#FNI[:XU-_$,4A"ADA4^5)\B]2%P.O)R2<=J])K"UD^&I]8TRQU=+.;49
MG+644R;WW*"Q9>/EP >>* ,VZ\&G7M1U:^UORD:]TTZ7'%;.7$41)9FW%1EB
MQ!Z8&T=:K1^$]8O]!TG0=;EL9++3YH7>XA=S)=+"<H"A4!"2%W'<W0XZ\=QT
M%% ',:#H>I:=XL\1:I<_9#;:K)#)&L4C%X_+C"8.5 .<9Z\>]95MX0UNT\,>
M)]#6XT]X=3DNVM7)=643D\OP?N[CP,Y]17>44 <1_P (MK'VKP9-FPQH,;).
M/.?]Z3#Y7R_)QQSS]/>L_6+"]\/67C35+VYTZ"/6VC2V9B9%CD*+"H<,H4@G
M!)/ YSD"O1ZBN+:"[MWM[F&.:"0;7CD4,K#T(/!H \]T:WUWP]J6FM=:?X=F
M@DV64;V=[/).D1(_U8E!^0?>(!'"Y[5W]_'--I]Q%;A#,\;*@D8JN2,<D _R
MJGI?AO0]$D>32M'L+%W&&:VMUC)'H2!TK4H \]'@K6D\%^&-$5]/,VCWEO<2
M2&9PLBQ-D ?)D$_I[UH7WA*[U7Q;JE]>_9AINH:/_9<B1RL90-S,6&5Q_&1C
M/;/M7944 <9X9T?QEIT=KIFKZIILVF68"QW%NCBYG5?NA\_*O;)&<XQW)K$A
M\!^*(]&TJP>_TEWTS6%U$7#+(7NL,Q+2'LV&Z<YP.1BN_BUK39]9FTB*[C>_
M@B$LL"Y)12< GMU[5?H X77/!VH>(G1;^/31/;WJSVFJQ.RW,$8D#[0NWDXR
MOWL<@X)'+[KPOKL?B+Q'<Z=<:?\ 8M=@C$AGW^;"Z1&/Y0!A@1CDD8]#T/;T
M4 >?V?@W7;2+P4AFTZ4^'E992'=?,!B,6%^4] <Y.,^@JYJ_ASQ%:^+I/$/A
M>\T\->0)!?6FH!_+?9G8ZE,D, 2,=*[2B@"KIT%S;V,:7MP+BYY:615VJ6)R
M0HR<*,X R> .35JBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB-?N
M]97XF^'+"UOH(K.:VNIO*> M\R!1DD.,\.<=,<]>W;US6N^'K^^\4Z)K>GW=
MO"]@D\,J3QE@R2A>5P1R-O?CF@#CK?4-;TJ\^(FHZ.MA_H=\;F078=O,"6Z,
M44*1@D#[Q)^E=7/XCU&XATJYMEM+&PO;$7+7EW^\ D8*4A5 RL6(8G(_NXQD
MU33PEJHM?&$)ELLZ^7,9#-^YW1"/GY?FP!GMZ>],M/".O6.J:%>V]_8'[!I0
MTR6.:-W5<$?O8P",,0H!![#&30!C7OBO6M>\)^"M5M9K>Q;4M7AM[F+RF<%E
M=^AW [<Q9V]3D#/7/IZB86X#NAFVX+A"%+8Z[<YQGMG\:\]M?A_K%IX.T;25
MU*R>[T?5%O[=VA8(ZAW;:_.<GS#T]!]:]#A$BPH)G5Y0HWLJ[03W(&3@?C0!
MYS>>.]<LO!^O:C+%IPU31;\VT]MY+[73*[67Y\\JVX?E[UU/]LWMS=J=-%O>
MVR::+MPJE6E=\^4J,6P VUCR#C ]>('\'02>-[C7GEW6UQ:K'-:$?+),H9!(
M?I&[+CW]A5;1?!,FC>!K_P /1:G*)[E)HH[P9W1*04BQ_NH$'U!]: *VF>+]
M2;Q1HNCWYL)6U&UEDF2U5@;.:,*S1EMS*^-Q'&#D9[U)X9\87'B.^B2&YL \
M<\L=_IK1LES:*H;:3EOF^8*"=N/FXJM8>#?$$.H^%;R>^TI!HD$MLT4%NX5H
MW15R,G[QV^P&>]64\'WU[K.AZGJGV!=0TMRSZA:[A-=+L90C @8!R">3TX S
M0!U&L?\ (#O_ /KVD_\ 037B$$S>)/A;X6\"P6CV^H:C"DMO?76U8D6*3<S1
MD$EGP"-N <$]*]PU6"XNM*NK>U\KSIHFC4RDA1D$9. ?RKC8/A[-)\.K#PW=
MW44>H:9A['4;?.Z*522K@$<=<$9.1F@#<US7GTB\TO282S7=XLC"5K=Y]J1A
M=S%$Y8DLHZ@<DYXP<:'QIJUMI\Z:GI92^;4HM/L96AD@ANO,/RR;7^90!N+#
MG[O!YJ76?#'B/58='U.+4;&U\2:2S^7,J,UO<*Z@.KKU4' Z$XQQ[.U?PCK'
MB/PVT.J:M#%K27$5W:SVD3"&VEC.4VJQ)/4Y)Y.?8"@"Q?:_K7AR+6+O6K2W
MN-,M+59[>ZMAY9ED)P8BA9B#G'S=.:CM/$&O_P#"2V=C+8?:[&[BD+W,=A/;
M"TE49 <R9W*W0$ '/:ED\-:SXB\/W^G^*[^T8W5N;=4TV-E1,X/F'>26;(!'
M0#!]34OA[3/%]L88]?U>PNX;12(C:Q/')<G! ,Q)('7.%'7!SQ@@&.GC#Q%/
MX UC7+2ST]K_ $V\N8VMPCE)(XG(8CY@=V 3[XQ@5T2:\]U-ILMG<6TEC+9&
M^N9C$W$>!L*_-\N[+8SGA6]*C\'^'[O0=-O[2_>WF^TWL]T#%DC$K%BI!';.
M,]_:F>$O!\7AG1[K3I)S=12R2+'N_P"6=ON;RXL^BAC^+&@#(@\9ZW=Q:+J=
MEICW5AJ$L?FVR6$ZR6\,@RLGG'Y&P,$@#'/!XR8/$.N:CXB\#^+KK33:1Z=:
MQ7=H!-&S/.(T(D8,& 7G<%X/3)Z\6_#?A;Q3H,<.BMKEG-X>MF_</Y+"\\H'
M(B+9V@=MV"<=,<8K?\(/KMAI_B/1=+O[ Z/J_P!HDC%RC^;;/*I#*,<,N3P>
MH]#0!UGA3_D3]$_Z\(/_ $6M<1:-XC7QQX\_X1R/33.MQ:L?MQ<AS]F7"@+C
M&?[Q/'H>W>Z#87&EZ!I^GW4T<TUK;I"TD:%5;:H&<$GTK$CT#6=,\3:[J>FS
MV+Q:P8G/VC>K6SI&(P0 ")!QG&5^M &1#\0-0N](\+:\EO;6^DZG<?9+[S49
MGM9=S(,$,!M+KMR1QD'G.*ZVPO[N\UW4X08#I]H4B5@AWF8J&<9S@@!E[=21
MVYYK5],\-:#\/G\'WE[&?,LW6&%Y%%Q<2$YW(O4N9"",=R*Z;PUI4FC>'K.R
MN)C/=*F^YF8Y,LS'<[?BQ- $.OZEJ%A+8K:K:PVLKL+J^NF&RV4+E?EW*6+-
MA1@\56\%>(I_$FDW4]U'$L]I?3V;M$K*LGEM@,%;)7(QP2<4WQ)H.J:CKNAZ
MKIEW:HVG/+OM[M&:-]ZA=XVG[RX./]X\BCP?X=U#PZNK1WM[;W*7FH37D9BB
M*$>8<G=DG\A^9[ $'B+Q#K=AXNT?1-,MK%UU*&X=9;AG^1HPIR0.WS=!DG&.
M.HRK/X@:A96NOVFOV5N-8TBXMX,6F_RKC[00(64'+#D\CD\?A4OBPW0^*/@L
MV8A:80:@=DS%58;8\C(!(^N#TJ>^\ _VQI_B WUV(-2UF2&3SK?)%L8<>2%S
M@M@C)/&=QZ4 .A\1>(EUFXLVL%NK4V;3PWOV&>U2.5?^6;A\Y!'((^F.]9=E
MXU\3'P3%XMO;335TV2SCD,<"RO+$[2JK2%<X,:H68@'/R]>>-[3-.\7M:2KK
MNI:9/*D+1PI:1O&LC$8WRDYYQ_"H Y/MANB^']:T/P%8Z);W5G]OLO+1)B&,
M<B*X)##&1N7*]^N?:@"M-XU-AX:O]=-UI^JV0\I+&6R)032.VW8V6;:0Q7/H
M#T[58O/$.JZ%XCT?3]5%G<6NK,T$4]O&T1AG"[@K LVY6Y (P01TK+G^&5MJ
M%IXBCD$&F?VN(66&Q):."6(EA*,A<L6(R !P/?-; T'5-5U#1[S7FLBVDLTT
M:VS,1/,5VAVR!L !)VC=R1SQR <U/XZ\41^%];UT6FDB'1M0FMYHCYA:=(W"
MG:<_*<$G)SGT&.?3$8.BN.C $5Y_)X&U:7P7XDT%KFR$FL7LURLP+XB$K!B"
M,<D8QVSGMCGO+594M(DG""54 ;825S[9 H Y'P%?2ZVGB#77PTUQJ4MO!N/"
MPP_)&OL,[F/NYJQX7U"3QIX0O!JUM;IYL]S:21P [=JNR9&><\9SZU'X.L'\
M.W>N:&Z@;KZ6_LMQPLD,N#@'U5]RGTRI[BG>'K"X\$^%KU=1>&<BXFN4%ON)
M<R.6$8!&2V3M&.N10 _X;ZU<Z]X$TZ[O7+WD8>WG<]7>-RFX^YV@_C4S:Y>Z
MGXFU31-(>UA?3(8FN)KF)I09)02J!59> HR3GN!BG> ] F\->#-/TVZ(-VJM
M+<;3D>8[%V'X%L?A4$GAR_T[QG>>(=&DMG&HP1Q7MI<LR!FCX2164-@@$@@C
MGU% &$_Q$U270=.N[;3K1;TZXNBW\$LC8CEW[6V$=CP03TST.*W=#UW5Y/&&
MI^'M82R9X+:*[@FM%904=F4JP8GD%>HQGT%9MUX"NAI-C;6ES;-<KK8UN\FD
M#*)9=Y<JH&< Y !SP%'6M>UT*_B\?7?B"1[;[-<6,=IY2LQ==C,V[.,')8C%
M %GQ-KYT2+3X8422]U*\CL[97SM#-DEFQSA5!.!UX'&<UG#Q%JEEXN/AR_2S
MEFNK-KJPN8D:)&*G#QNI+$$9!R#R/2KGB[PT_B.QLS;7(M=0T^[CO;.9EW*)
M$[,.ZD$@U&FA7]UX@CU_4%M!>VUH]M:V\4C-&I<@NY<J#DX  V\#/7/ !1\"
MZ_XD\4:9I^M7L&EP:;=6[DQQ&3SA('(!&<KMP#QUZ'O@;7B#4;_3_L7V1+:.
M"64K=7MRP\NUC"D[BNY2Q) 4<]ZK^"-!N_#'A*RT6\EAF>T#*)8<@."Q;H>A
MYQWZ5'XGT'4]4U30]1TRZMD?3)WD:WNU9HI=R;=WR\[EY(^IH YZ?Q+J7B#X
M:^+YE>VAN=.-[:-,D+A942(D,JELH2&'4G!'>LZ];6K3P]\/3%>V"FXNK2V!
M6R;<(S%O"D^9DC,8R!C/'3'.Y;^#-:M]"\6Z:U_8S?VY-<2H_E,GEF9 K$\G
MIC@?F:GU#PGJMWX;\-VD5S9QW^AW-O.K,&:*;RXRAST(R&)[]* 'ZCXGU ZC
MJ.F::8_M>G0Q^:[:?/.DLSKN"@1GY!C'))/S=..<^3QCXFFO/#%G#H]K8W.L
MV]PTD-]OW6\L2@G(&/ER<CN1Z9R+5]X8\267BB77?#NJ:>LM_#''J-O?0.8I
M'0861-IR#CC&?QJU=>&M5E\2^&]4-Y!.-*6X$S2[E:=I@ Q  (4#' YXX[9H
M Z/3S?#3+<ZF+?[<(QYXMMWE[\<[=W.,],UPOP<F?5/"=UK]V=^HZI?32W,C
M=?E;:J>RJ!P.V:]$KE-+\-W_ (6O-0_L(VLVG7L[7/V*YD:+[/*WWBCJK94X
MSM(X[&@#G)]43PO\9M64$KIEUH)U2]C0<"2)BID ]2JX/KQ726.J>)[P:+?I
M964NGZBN^XB3*R6:,FY&+%\2=@0%'7BEM?!L<]SK&H:U*MU?ZM;FSE,2E4AM
M\$>4F>>Y))ZGG Z55\+^'O%.CP6FE:AK-E<:1886!X876YF1?N)(2=H XS@$
MD#'KD Q-%\5:CHOA_P 7Z[K-U%>I9:M<6Z11PF-G=2D<8!+$*IX&,$C.<FN@
MOO$.K>'];T2WU@6<]GJTWV02VT;1M!.1E0<LV]6P1G@C%4&^'L]WI7BC1;Z^
MA.F:Q>2WD+11GSHI'96!))QA67H.OJ*TAX>U75I]$;Q!+9N-)F%R#;%B;F8*
M55V! V ;B=H+<XYP.0#D='O/$]A!XUO- M]-E2VUZ[FDCNR^^;"(2B;<!3@<
M$YR3T'6NB@\=_P!M"PCTI3!)=:;'J#N]G+=>6')54VQXYRK9)(^Z,9SP^W\+
MZUIY\0VEG=V7V36;N6Z^T.&$ML9%"L G(? '!W+SU!J"]\#ZCI5_I6H^#KZV
MM9[*Q73I+>^1GBG@4Y7<5P0P.3D=<_F 5I/&WB:/3?#[RZ)!:WFH:E_9\\5R
M)$&<,1(@."%(7/.2,XP<5VVC_P!J_P!F1C6C9F_RWF&RW>41N.W&[GIC/OFN
M;U7PSK>I#099;ZTFNK#45U"=V#(CL%9?+C7G:N&X))/&3DDUV7;F@#C?'&AZ
M?/X,U+2H;&*6\U1F2W0J"SW+DD/GK\O+$]E4]A756%LUGIUK:O*TK0Q)&9&Z
MN0 ,GZXKDKC2?'1URYU"VU#P]M;*6ZW%M,[01_W00X&3@$G')QV  O7$OB2T
MU?P_;I>65S$ZE=10Q$2.<9,BXX1 0>OJ!R30!T%Y:07]I):W*"2"4;9$/1E[
M@^H/0CN*Y+4M&@U#XDZ!=6,*1/I$,SW<T:A?D=-D<1(ZY)+8[!>VX9ZK4EOG
MTV==,>".]9,0O."45O4@<G'I7+:)H_C2QFMX;S4]$-F)?,N7M[67SYCU.69R
M,L< G' Z8P, &%X94:QX*\>75\ \EY?WZ2ENH1$V*OT50,5O>")+>_\  FC:
M_JPC:Y_LM$FN)\'"*#N.3TSU)[X&>@I9O"-[!%K]AI=S!#8:Y(\TK/GS+9Y%
M"RE !AMP&1DC!)//2C5O#NO)#I>G^'KC2;?2;")$6WO8I)/,9<!2VUER%P"!
MZ\GH, "> _#R:=X;N4FM/+MKS49K^VLW7'D1L^8UVGH0 K8[$^U4?#MY;2?%
M;7UN]+NM,U2>SB,,<H39<0(2#+N0D%MS 8[ #WQN0V_C*/29VEO]&FU1I5,2
MBWD2W6,8R/O%MQYYR1TXJQ9:/<2:ZNN:H;?[8EL;6&*WR4C1F#.=QP6)*KV&
M /<F@"YKEW?V.B7=SIED+V]C3,,#.$#MG')/0#K^%<WIOBR_NO$^HZ&DVG7Q
MBTY;VWNH$:.,DN4*'YFR,C.0?;K6OXQT.Y\2>%;W2;2[%K/.%VR,"5.U@Q5@
M.JL!M/L361;^&O$">+3K\UYIA9]+%B]O%$ZJI#EAM.3QSU(]L=Z ,C3_ !WX
MBFT#POK]U:Z8MAJUW%:301A_-4R,5#JQ.  0/EP<CN.@W)]<U'6Y/$-OHYM(
MX-++6SO<1LYGFV;F488;  P&>>2>..<R+P+JT/@GP[H"W-D9=(O8;DS$OB41
MOO QC@G..^,=\\7(O"FMZ5KVM7&CWEC_ &=K+>?/!=*Y:"<KM9D*_>!]#B@"
MS\+_ /DF/AW_ *\TJ#Q7XGUC0UUBXC2PMK>QM!/:BY!D>^8*S2*H5P4"@ 9(
M/7/05K>#-$N_#?A'3M'O+B&XEM(A'YD*%5('3J3GZ\?2L/5O!NM7NI^*&M]2
MLQ9Z[9"W)GA9I;?$13:N"!L));V)/!H I>+[R_U*;P'>6LT$$-YJ,,JQ20LY
M5S#(P)(<9 !Z8'/.>U3Z?<:I!\4M7@GO;(6D&FP7$BQVA0'<S!C]_P"\=@^8
MYX &.*LW'A/6I['PG"US8-)H<T<TK8=1*40IM4<XX/4]^PJ^_AJ^/CB?6X[B
MU^QWEC':7<#HS/\ (S'Y#D#!#$'- &1#XTUJ\@T?5+'3'N["_E3S;5+"<200
M/TD\X_(V!@D 8YX/&38T_P 0>*M5\3ZOIMM;Z1';Z7?0Q3/*9"SPN@=MN/X\
M'J0!_.F>&_"OBG0$BT7^W+.7P[;O^X<PL+P19R(MV=H';=@G'3'&-7P_H-_I
M?B3Q!J5S);-#JLT<R)&S;HRB!,'(P<@9[8]Z &?$6\O].^'^M7FFW*V]S#;.
MPD*;B!CG;R,'T/./2N<UT:BFM_#PE[:>\\^?8=C1IS;-C(RQX^O/M7:^*-&/
MB+POJ>CK,(6O+=X5D(R%)'!(K"F\-:[=7_A>\N;C3VDT=W>58PZB3=&8\+G.
M, YR>I["@"M!XXOM/LO$J:U!;2WNC74-NIM%=4G\X)Y7RDLP.7 .,^U:&F:[
MK<GBE-.NK)KC3IK<R+?1V$UL(9 ?N.)"<@CD$$>F*S[SP%<ZJ_BU+VZBBAUU
MX)87@+%[:2%5"'D#/**W;T]ZV/#UCXKC=#XDU2PN%@7;&+&%D,QQC?(2<9Q_
M" !DY[#  GCKQ!?>&/#$FJV%O!.\<L2,DQ/1Y%3C'4_-ZBLS_A*M=T;QE::3
MXCMM/6QU*":6TGLRY,31+O='W?>^7G< /IZ'Q<W?\*XO@C!7-Q:[21D _:(Z
MTY?#USK&OV6IZTMLJ6$$T4%O;NSAFE 5W9B!CY00% [DY- &-!XSUN[CT74K
M/3'NK#4)8_-MDL)UDMX7&1)YI^1L#!( [\'C)ETGQ%XKU?6-5@AM=)6VTO4_
MLT^3(7DBV*QV=M_/?@Y]LT>&_"WBK08X=%;7+.;P_;,/(?R6%YY0.1$6SM [
M;L$XZ8XQH^'_  _J6DWOB*>>:VQJMTUU%Y3-F)B@3!R.?N@YX^E %#POXTD\
M0017PO=.:W2%WU"T6-DN+%P,[6#,20#N!.T9QD=>*]SXVU:#P5#XU6VM7TEB
MLTED$;SUMV;:'$F[:6 (8KMQU&>,FU%X,GO?$&FZQJT6GI>6MO+!<SV>X-?A
MTV8D! PHY.,MSCD56MO VI1^$'\&3WEO+HF[8MSEA<?9]^[RRN-N<?+OST_A
MH LOXB\07WC"_P!"TM-+2*.PBO(+F<2/P[,/F4$9^[T&,9SD]*U_!>OS>)_"
M-AJ]Q D,\X=98T)*AT=D;&>V5)%5;;P_?VGCB]UV/[(;::PCLXX-[*R["S D
M[<<[L8[>]3>"-!N_#'A:WT>\EAF>!Y6$L.<,'D9^AZ8W8_"@#G-2_M<_&&\7
M119+=-X>A_>7FXHH^T2?PKR3^(]?8RZ=\0KJ?1(TO;)(-;&JOI$T42/+&LJ*
M79U5?F9=@R!USQD=:V;W0=3B\;_\))IKVDOF:>MC+;7+-'@+(SAU=0W][&".
MW6LR^^'LLN@!+/4_L^NKJ;:NM]Y?R&Y.004S]S:=N,G@#KW $?QIJ^DV7B.Y
MU32I)[;3+<7-K=1VLMLER,<H5DR5*GJ<D8YQQ4Y\1Z[;^)_#^E2+IUQ#J]N\
MYEC1T,7EA2X^\V00XP>.?K4&M3:YI?@K5KSQ)JVGQ74L'V6'[+ WV>)I#L#,
M')W99ADGA0.G7.?H::SH6HZ=E/"MW!(8[1!8RS?:%A)'^KWLPV+]XJ,#"DT
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M P<@X!QG'&:U*XK1KZX\<?"C[9J"11W-]:S9\@%5C<,P4KDD@@JI!SU&:U/
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M5U6OM0MM-MQ-=2;%9UC4 %F=V. J@<DD]A0!P^G> ]6L=.\*6KZG9R_V!,9
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M]D2SO8;B!I+>X122K8!#!AD]_;/7/5:3JMKK>F0ZC9-(UO-G89(VC;@D'*L
M1R#3M4U.TT;39]1OI&CM;="\KJC/M4=3A030 :;:SVEBD5W=M=7)):68KM#,
M3DX7^%1T [ #DGFK=0V=U%?V5O>6[%H9XUEC)&,JPR./H:FH **** "BBB@
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M,\MWH ]>KB_BO<7MK\-]6GL;LVSJBJ[!<ED9@I4'MD-UKM*Q?%F@#Q1X6O\
M13<&W^U1A1,%W;"&# XR,\@4 <MXEBU)?B#X'C2YMWO3%J(\]X2$'[M.=@;G
M [;AGU%+:>-M3L]'U>+41!=:E9:RFDPRQ1%%E,A38Y3/8.20#SMQGG-;$_AG
M5;OQ%X?UFZU:U>72DG5T2S*B4RJ%;'S_ "@!1CK6=-\.WO;#Q%:WNJ#_ (FU
MZM_#+;P&-[690NT@ECNQL'IWH T=&U#Q$?$\UE>VDDVD/;"6*]D@$+1RAL&,
MJ&.X$<@XXZ'-=57/^'])U^T<2^(-<CU*6-/+B$%L($[9=AD[F./8#GCFN@H
MX[7]9U^'QOIFA:9-81PW]I/+YL\#.T3)MYX8;A\W3Y?K6/9^/-8L8=6TG6(;
M>;6[#4K>PCE@C(CF$_,;[,YR%W$J#S@#(SFK7B3[2?BWX7%G- DPL+P[9E)#
M#,?'!!'U]NE6[_X?1:KI6K)=WSIJFI74=X;Z!-I@DB $6P$]%"@<G)R>F> !
ML>K^*H+W587M@]C'8&YM;^YMMFR9>L3HK@L".01CTYK-MK[Q7K?P[GUN[U#3
MXK>[T1IA#%:MO1]A).[=C!'MQD=<9._8Z#XC;3KJ/6?$$%Y=R6[6\+1V?EQH
M&ZNRAOF8X'< <XZFG6/A>]LOAZOA<:C \J69LUNOLQ V%=H)3?UQ[T <]H.L
MWFE>$O NEI-;R7NKVT$5L[08%O$MN'<D;OF;  '3D@]L5H2^)-8T[Q%JOAVX
MDMIKF/3#J=A=M"<,JG:R2*&&2#W!'!Z<5))X%GD\.>'[,:G&FIZ 8C97J6Y"
MG8@0JZ;N0RC!P15U_#%S=7M_JMW=6_\ :ES8?8(F2$^5!$26/!;+$DY)R.@'
M8D@'*3^*/&<'PT?QB;O2=C:9'<);?9')60D9.[>.H.>G' YQD[-[K'BBR\8:
M3I1NM->'6;>=HLVS#[(\85LYW?O!AO\ 9R?3I4D_@>\G^%Z^#3JL(86ZVOVL
M6I^XN,?)OZ\>OX5?O/#5_>>)M UEM0ME_LJ.9&B%LW[WS%"L<[_EQM&.#0!D
MZ?XD\12:+XEMV-A<ZKH][]F2X<>1"\9"-YC@MQM5F)&>=M%CXJU*;6/$&F07
M4%RMGI\=[:74UJR[MVX$, 5WKE>&7'7J:9>_#V^O+3Q!$=:BCDU2^BOXV6U.
M(GC*85@7.]3L&>G]*N+X/U@Z_?ZQ+KELTU]IRV<L:V1"!@6P5^?(7YNA))/?
M'% &/8^+?$O]E^#=;O)K![36KB"UGM8[=@RF56(D#[O5?N[>AQD]:VFUG7==
M37W\/R6L3Z7=-9P13Q[A<3(JL^\Y&U26VC'/&<\X%<>!+]?#?AC2%U>V_P")
M%=0W"RFT;]]Y0(52/,^7()R<FI#X-UC3_$>H:AH'B!+&SU2037EM+:"7;+C!
MDB)88) [@C/KTH ?=>(=4O-6N](LT:UNK*TAEN'B@^T8FD#$+R1\HV]>ISQC
M'.WX8OM5U'P[9W.MZ?\ V?J3*1<6X.0K D9')X( /7C-86I^#-2BU^+6O#6M
MC3KHVR6EU'<P?:([A$^XQ&X'>,GG//MSGJM.M)+*QC@FN7NIAEI)G !=B<DX
M' &3P.PP* ++;BIVD!L<$C(S7EO_  E'C>Y\+:QKUK+I&-'O+E)+8VS_ .DQ
MPL0V#O\ D^4$C[V3W%>IUY;X/TR_USPUXFTV*_MXK"\UF_AE98BTJ(TA#A3G
M&2#P2.,YP: -I/%]UK]P;?1Q+;A=/M[QI%MO/8-.K,BD9   7GN<\8QS1?Q/
MXQ+^$K:XL[+3;[5GG@NX9HB_ENB,P=2'Y4X#;>O;<.M:.H^";ZWUNWU?PKJ\
M>E3I:)93P36_G0S1)]S(R"&7H#GI^.;%YX2U"YU/P]?#6$>32999Y&GMBQN'
MD4JW1@$&&.!@XX]* (;?5_$-CXRT+0M4N;"X6ZL9YIY(+=D)DC*@8RQXPP[5
M2_X2S6M1\$7OC+2WMOLMN9Y8;&2(GSH(G96W/G(<A&(QP. 0>M;]]X=NKOQM
MIGB!;Z%(K*WE@^SF EG$FW)W[N/NC'%95MX%N[#1M4\/66IQQZ%?O*1&T!,U
MLDN?,C1MV"#EL$C(S_%0!+8^*I?$^LQ6&CS"U@&FPZA-.\8=_P!]S&@!X' )
M)Y[ >M5OA8)AH>LBY9&G&N7HD:-2%+>9R0"3@9]ZLS^"[FP\26VM>&[^"P=;
M-+&XMKB RQ2Q)]PC#*0R].O(_6_X0\.77AJUU"&YU!+S[7?37@*P>7L,C%B/
MO'/Z4 =%7GWE:B?C?(!?1!!H:OM,&?W?V@Y7[W7C[WZ5Z#7-CPY>CQ\_B7[?
M!Y36(L?LOV<YV"3?NW[^N21TH P1XLUB]\!W/C/2C:BS@\Z:&P>+B2WB=E;+
MYR'(1F&!@<#!ZT^Z\3:_JGB33-/T*XL(+35-&;4()+FW9GB.4QNPV&^]TXQG
M/.,&Q;>!+JPT/4O#=GJ<::#>O)MC:$F:WCD),D:-NP0<M@D9&>]:'_"*31>,
M--UFTNX(;.QL38)9_9R3Y9*G[^_@C:,<4 =%:B=;2$73QO<!%$K1J0I?') /
M09S7/?$.XO;3X?:Y<V%T;6XAM)'$BKD@!3D#T)]>U=-6;XATA-?\.ZCI#RF%
M;VW>#S ,E-P(SCOCTH X/68[]+GX=*)X);HW+>6[1%44&V;&0"2<?49]NM78
M_&FIZ/;^+(-7-O>W6BSV\<,L,1B6;SU7RPRY.,,V"0>E7Y/"&K7$GAJ:XUFU
M>719#(=MD0LO[LQX'[SY>#GOSZ#BF77@#^T[CQ7_ &C?I);:^(<I#"4>W:)0
MJ,&+')X!Z#D4 6-.U'Q*/%,-K<6DESI$\#,]R]N(&MY1T&-QW*PZ=P>YKK:Y
MGP[HGB*R>,Z]XB34TMUVP"*U$)8XQOD.X[CC/' YSR<8Z:@#@?C!_P B1'_V
M$;3_ -&K5W4]8U__ (6%#X>L+BQAM;C3)+I99;=G>-ED5<D;@&Z\#Y>O.<8-
MOQOX8NO%NC1Z=!?Q62K<1SL[VYE)*-N  #+CD4K^'+^3QK;>(FU"V_<V#V1M
MQ;-\VY@Q;=OXY4<8H PM-\;ZD^A6\-T+9]8EUR311,J$1%D9LR[<Y^ZI.W/)
MQR,UIZCK6N>%['7;_55M[S3[:.-[&9?DDD=OE*.!P &*\CL>]9S_  WGFT&\
MLI-9"7K:N^L6=Y!;;3;3LQ;E2QW#DCJ.#6J_A2]UG0+_ $_Q1JJWSWD'D9M8
M?)2$==RKDY;(!R3V& .<@$-MJ/BH>([>U-N9].N8'\VZEM/*%I,!E>-^71NF
M.H]:YRS\:>*7\&Z'XIN9M.\B>^6VN;2.W;+HTYBW!RWRD<8&#TR2<X'5:#H/
MB:P$:ZQXECU%;5"MMMM/*+'!4-*0Q+D G@8]3DXQE)\/+^/P'8>&!K-N?LEV
MMR+DV;?-ME\T+M\SCDXSGI0!)IDFK3?%CQ#"VI(;>"RM3'$T&0JL9#@88<YY
M)[^V!56+Q/XIO/A_K>KV9LGU73;VYC$?V=O+ECA<@@+NR#@$CD\\5T,?AN]M
M_&ESK]OJ421WEK%!<V[6^XEH]VTJV[Y0=W((/U'4/\)>'+CPY8WUM<WL5W]I
MO9KO<D!CVF1BQ7!9LC)H 9!K[7[Z9<V-U&^GM8?;[IS%DF,@;,<_*6.\]_N$
M5AVGB?Q/J%MHFL:?I[W%I?R1M<6AMPHBMW&0ZR%N64$9XP>< 5N^%?"%KX7T
MN[L(Y&GAGGD90_\ RSB9B5B'^RH)_,^M97A_P7K>@>7I:>)3+X=@?=!;-;#S
MU3.1$9<_=_#)''% &Y:>,O#=_K']D6FM6<VH[F3[,D@+[ER6&/;!_*N(\#7^
MJV:^-SIVBG4&'B2]95%RD6YOE^7YOPY]Z].,"+N>*.)9<'#%.]<AH'A/7O#W
M]K_9=;TYSJ6H37[&33G/EO)C(&)AD# H YSP!>3Z?\,;QM)GMFU&/4)/MD5U
M^YCT]FD'F+AB.$4D]1D_E6Q:>,-5-QXMM+>/^TY-*LXKJQ/V=HWG+HYVE>-P
MRG!4#(/XT'X9B'PS/8VFKR?VG<:FNJSWLT(99IPX;#1@@;,C[N?>K<?@_6DU
MK5]67Q#$EUJ5I%"QCLL".2/=M91O^Z-WW223_>Q0!5LO'ENV@:KK\&K0:I86
M5F97@$7DW$4PS\CK_"#P!QQ@\FK46L^);;6[%KBU:XTF:*0WTIMO)^R,J[E9
M3N)93R,')'7/:GS> X-4U+4K_5OLWFZAIQTZ=;.(QB12<F1B2<MP,>F.I[.T
M#POK]C'%9ZWXC74].MD*0Q+:B)Y!C:/-;<=V >@QDX))H Y+QCJ>J>(_A(^O
M&>&&SO)[>1;/RLE8?M"!/GSG?]TGMR1CO7KE>;O\-]8'@^X\)0^(8!HXE1K5
MI;,M/$@E$@0MO 8#'' /T%>C1AUB42LKR #<RKM!/L,G'YT <Y\0M2N](^'V
MN7UBS+<Q6C>6Z]4)XW#W&<_A4O@:RM[#P)H4%JH$?V&)\C^)F4,S?4DD_C6U
M=VD%_9SVEU$LMO/&T<L;=&4C!!_ US&A^'->\-6::5I^L6EQI</RVPO;9FF@
M3LFY7 <#MD ]J 'ZMJ">']0TK1-*CCBNM<O96#.N4B 4R2O@8R3V'JV?:J,O
MB76-.\0:QX>GDMIKJ'3#J=A=M"<.@.UDD4,.0W<$9!Z<<Z.N>$7U6'3;B+47
MBU?3;G[5;WDB;P6(PR,@(^1AQ@$8P.?4?PQ<W5YJ.J75U;_VI=6'V")DA/EP
M19)/!;+$L<DY'0#MR <S'XL\4IH?@_6WFTV2+6I;>UEM/(9=K2H2'\S=V(^[
MMZ'&3UK2B\0>(+/6/$FD7=U8W-Q8Z>FH6MPMJR+AM^49-Y)&4X.[/-/;P+?_
M /"-^&-(75K8?V%<P7 E-HQ\[R@0HQYGRYSR<FI=5\/75MJOB'Q'+?P-%<:2
MUJ;<0%2H0.P;?N]6/:@# _X3#Q98^'?#GBN]?39M*OOLR7EI% RR1B7 \Q7+
M<G)'RXXSC)ZUJW_B?7]0BUB;P[;M)+I]V]M! ;;>EP\9 <.^X;<G(&.F 3G.
M!5\(Z#=:_P##OPI;ZA=V[Z;!#;7)CBB(>78 R(Q)( # 9P.=O;FM'_A#=:T[
MQ#J%YH'B);'3]3F^T75I+:"8I*1AGB8D8+8[@C/8]* (SKGB:^\:?V% ]E8)
M+HT=^#-;F22W=I-I4@. Y&".H'/?%48?'U^G@;3-8U)1"&OY;/4KRV@,BVZH
MTB^:$YP"R*.<@;CUXKH8?"]U;^,_[>BU"(Q+IBZ<EO)"S-M5RX8OOY.3SQ53
M1/"6L:#I-O9VVL6LACO)KF0/:,$F24L3&1O.,%LAN>G0T /;6]3;PU#?V>HZ
M7=0RWJJVHAU6*.U)Y?&[!<=,9^\>G:N=U+Q3K%YX2\=P17OE3Z.I\B[%L8Y'
MC:$/@JV-K<D;L=.0.]:;?#F2#38DTS4(+.ZCUG^UU06Q:V#[=OEB/<#MQSU'
M.2,=IO\ A KN8^*UO-:66/Q# $<):A3$XB$>X?,<J,<+U]2>M $=WK&LZ#I'
M@Y4N;6:/4+ZVLI]UN0PC="?E.[ (VXY!Z]JOPZSJ?B'5=>M-(NH+1-)E%LCR
MP^9YL^P,V[D809 P.3R<U%>^$-6O]+\/6T^LVIFTB]ANS(+(A9#&I55 \S@$
M$Y.3SZ#BK,?AB^TOQ)J>JZ+?6\*:H$:ZM[F$NJRJ,"1,,.HZJ>N.HH YV'Q]
MK.JZ;X3N["&SMWU2]DL;N"=&;RY$#Y*L&^[E,XQD\<BN@\+:QJMQXA\1:'JT
MUO<RZ7) T=S!"8@Z2H6 *[FP001UYJJ? )MK?PW;Z=?QQ1:+<M=,9H"[7$C!
MMQ)##&2['H:N0>&=3M-=\2ZM;:K;I/J\,:0C[*3]F>-"J-RY#]<D8'2@#J:*
MKV,=S#I]M%>3K<721*LTRIL$C@<L%[9.3BIGWF-O+*A\':6&0#[B@#S;XB1V
M/B>2]T*>_6V-A:^="=Q'^F-S%R/[JCG_ *ZCTKJ? WB,>*O!VG:JW%P\>RY3
M&-LR_*XQVY!/T(JWX>TJ[TFRGCOKN&[N9[B2XDGCA,6XLV<$%FZ#"CGHHK+\
M,>%+[PYK6M70U*"6PU.Z-W]D2V*>3(?O%6WGKQGCMVH ZNN!^(L=ZVK^#Q;W
M<<4;:U&%5H=V'\N7YB=PR,=OUKOJYSQ-X=O->OM%GM[^"V33+U;S;);F0R,%
M9<9#C PQ]: *L>KZM'\1?^$?DEM&MGT8WHD6W*MYPD6/+?-R.IP,=<9XS7+C
MQGXK7P0?%,L^F^7::@UO/:I;-F=/M'E'#%_DP#P,-TY/.!V+>'+T^.E\2"_M
MP%TXV'V<VY[N'W;M_J.F.E8C?#R_?P#=>%SK-O\ Z1=FY^T_8V^7,WG$;?,_
MO#&<]* +/BSQ!K&DMK$D5Q:VT=G8_:;*,1^?)=.H8OO4'<L8PHSQUSGM4-QX
MHUVYUCPE;6+6,,.NV,MP_FPLYA98T?J&&X?/TXZ=:FO_  3J=WJGB">/6XHK
M?7;-+>YC-IO>-EC*#RV+X"G))!!ZG!!.:=9>"]2MK_PM=2ZQ;R_V%:R6VT6A
M7S@Z*AYW_+@(/7G/T !1M?&^I6.@:W_:0MKK4M/U<:7!(B&..9G*"-F7)VX\
MSD ]%KH[=/$T.M302SV=QIKVF^.Y:+:\=QNQM*!OF3'/4'C&36)+\.VOM,\2
M6-_J:LFLW@O4DMX#&]M* NT@ECG&Q?3O6QHFD^(;93)K6NPW]Q'&8X/*M/*C
M!_ON-Q+-QV( R?6@##T;Q5K>J_#[1=:D>Q@FN[DI>W#D)'!$)'4LBL>6^55
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MM(RXP6PQ^7KP/;O6=9^.-4F\!^'=0F6%+S4=373;FY5/DA_>NAD / )V #/
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M3M4TZT.ER0BWD:S+[]\6\(06XZX+<^P%4;/QQX@URS\%3V;6=FVM27%O=))
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M,]Z .RHKFBWB'2[Z"\N[VVN])%K))?YC"-"ZC(,0 Y4\C#$GWKG;OQ9KEO\
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M2) D:*BCHJC %.H YU?#EVOC:3Q)_:,.7T\6/V?[,< !RX;=OZY/IT_.L/\
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M8:MIFH6GB!DDM=,73)M]HK>;&K9#)\V$;WPPZ<54LOAS=V6A:!I2Z\KQZ+J
MO8F>R^_@OA3AQ_ST;)^G2N_HH Y27P4MYK7B"\O[Q)[36K1+2:V6 H410P!#
M[CS\Q[>G2F^'/"FKZ0EO:ZGXDDU.PLUV6L!M5C; &%\Q@27P.G3GDY(&.MHH
M X?0_ FI:#)_9]MXFG/AQ9"\>G-;+YB*3GR_.SG9GMC..,UW%%94'B&QN/$E
MSH,?G?;;>!;B0-$5786VC!/7D'IQQ0!BM\/M->'Q/"\CM'KQ8E",BW+*-Q7W
M+@N>G./2KUWX7\[P++X9@O#&);,VKW,D?F,VY2'<C<,L22<YZFNAHH Y.[\'
M74__  C4\.KK!>Z&K1K,+7<LJ-'Y;?*6X. ,')P>QI8?"-W#J'B:[&JPLVN(
MBD&T/[G;'Y8/W_F^7Z<_E75T4 97AO2'T#PYI^D/<K<_8H%@641[-RJ,#(R>
M<#UK5HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X/Q"E[)\5O#,,6
MJ7,$$EI=OY2*A564(,X*G)(8CG..V.<]Y7/ZUX9?5-?TG6+?49+.XT]98_DC
M5Q)'(%W#GH?E&#S]* .&5]9M9OB/J&DZDED]E>-<C-NLAE9+=&VG=P%.,<#/
M/48YZ%?%-_J]YI6GV<=S%)<Z/'J<[V8A,B[R JKYIVX!W9X)Z=*M+X+G6W\3
MPG54(U\L93]E_P!3N3RSM^?GY1W[_E5:[^']PT.B7&FZ]+IVL:3:BR2]CMU=
M9H0 -DD;'!Z ]>N3Z8 -KPG+K\NC%?$END5]',Z*ZE/WT8/R.0I(4D=1GJ*I
M^(+[48M;CM8M2%I:O9N\:6L:RW4L^X ?(RL/+ ZGCDC)%;>DZ?)IUEY<]Y+>
MW+L7FN90%,CD 9VCA1@  #L._6LB_P#"L]QXN&OVFKS6;268L[B%85?>@8L"
MI;[AR3V/TH P=#\9ZCKNE^#K9I$MK[6[>:>XN(T!V+$!G8K9&YB1U! &>.E7
MK_5O$'AS3A!J-S:W-Q?:O%8:==;>5CE/#2J JEE ;I@' JI'\,3;^'=%L;77
M[F'4M%D=[#4%@3,:MPR%.C*1UR>?IQ6IJ'@A=:\-S:=J^JW-S?2R),-055C>
M*1.4,:CA0.>/<\Y.: (-;U76_!FGZ[K%]=1ZEI-M:++:B4*LXGSMV-L55V$E
M>>HYJ'5]8UGPQ+X>O;F_^WVFHW<5C=PF%%$;RCY7B*@$ ,,88MD'KGFM"#PA
M->:3>67B;6)=:-U;FV+&!(%2,]=JK_$2 =Q)^Z,8HM/"-P8=)MM6U4:A:Z3*
MLULOV?RW=T4JC2MN.XJ#G@+DX)H Q5\1ZS_PC7CNX-^3<:)<W"VDOE)G;'"L
M@##&#R3G@4^;7?$-QKWA&RM]0@@BU?399YR;8,5=8T.X<^KG X [YZ5;O? 4
M]Q)XCBMM=EMM/UU7:>V%NK%)6CV%@Y.=I !*X[=15F#P;-!JOAZ]_M8R?V+:
MO:HLEN,RJZJK$D$8.%&,#ZYH XOQ%K&M7GPL\8P7>J2&ZTG47LC<PQI&;B+,
M?# # R)"#MQT^M=AK6HZOH_B;PGI\>H>=:W]S-%<F6%/,DQ&SCD  #@= .G6
MHI?A\+K0_$NEW.J%H]<N6NG>.#:89#MZ98Y'R+P??FKU[X6O;^^T&]N-8\R?
M297FW-;#]\[*5.0&&T8)P!^9H YR?5_%5U-XVC@UJ"V&BL'MREFK%OW(DVG<
M3QS@GD^F.^B/%=_>GP1$&%G'KUL9[BX10=CB%7$:[@0"Q)Z@\*<<\B]'X/N(
MY?$T@U1"=>'[S_1O]3^[\OY?GY^7U[\^U<IXDMH=&7PUX<O/$8TN"PLVV7UU
M9(]M.5"QJC*^5\P*"<Y&,\#G@ ZGP1J>L:I+K8U*ZCN+>RU"6RMI%@"&54Q\
MY8'!/)4X &5/TI/'.KZQI,OA]=)N+>+[?JD=E*)H=^0RN<YST^7IU/J*/!4^
MH.+B&35[36-,1$-O>6UD+=0V3N1=I*N  #D=,XY[9OQ0F1'\(QK>16T__"06
M[J[X.T!)/F()&1D@'IUZB@"%=;\3Z/XCUGP]?ZG!?/\ V2^J6%Z;0(4VMM:-
MD4@'G&#^>:@35_%R?#*7Q:^N6S2-HJW26_V%<)(%W%MV1G([$8!Z"NI?PO)<
MW&HZA<WT<FI7EG]A29+<K'!#DDA4W$DDDDDMV'88J+_A#Y/^%>?\(B=2!C^R
M?8OM/D?-Y6W;]W=C=CO^E &9J&M:^?$'@^QM+^"&+5[29YRUL&(9(E;=U]6Z
M<=.XXJE!XRU?3-)UNVO;B*\U"SUJ/2[6Z>((&$NS:SJN!\H<DXQG Z=:Z%O"
M=P^K>'-0;4TW:)#)$B"VXF#H$8GY^.%&,=_7I5*?X=P7]EXAM-0OVECUFY6[
M+0Q>6]O*H4*R'<>FU>OOZT :T%GXCMM7N5;5(;G2WM 8I+B)?.BN,\\(JJ4V
M\\G.?:N+@\8>);CP#X.U:*[M?MNJ:G%:W)DMQA@\CCC!X&% X&?<'FNQT;0-
M7L8VDU/Q%)JMXL1B@DDM5C2,'&244_,QP,DGMQC)SP_B;15\)>$?!N@C5HRU
MOK]MY-Q)&%(7<[;F7=@@$\].* .BT?5/$&F?$*3PUK5_%J5M=6)O;2Y6W6%H
MRKA6C(7@CD$'K6!X,UNXTSX;>$+"S1VN=3NIX%:,(615>9V*[R%W87 SQSG!
MQ@]W:Z#*-9FURYO(KC4GM1:P.D!2*&/.XX7<226P2=W8 8[X"?#:,>"K#P^=
M7F2?3;@W-CJ$,822&3<S9(R0P^8C'&1^= #)]3\:Z5IVO22Z?<W<$!A>PF*P
MM<M&6 F&R,[695W%>!GN#6OX.UVWU^.[NK+7/[3LP455DC6.:!^=R2*%7';&
M1_B2#PUJXTR1;OQ--<ZJSQ,MZ;5$5%1PVT1*0,-@AN<G/7@8MZ1X=73=:U+6
M)I8I+[4%B28PP^4F(P<?+N8EOF.23Z=,4 4O&VK7^C1:+/8W'E_:-6MK29"B
ML'CD?#=1D'T(-5I];UB'QSK6E6S"ZCAT9;ZUMW51^^+NH7< #@[1U]:U_%7A
MT>)=(2T6[:SN(;B*ZM[A4#^7+&P925/4>U92^"KQM;O=7G\0W#W=WIG]GN4@
M5 IRQ#KW&"W SVY)S0!E:)XYCGLK_4'U6>:73=-EGU#2;R!8;B&5 &X 4';@
M,._4<U<L;[Q?->:'?1033V-T =0CF^SI'$C+D/"5;?P>S;LCWK2/@]+[54U'
M6KB"]G2QEL?W5MY/F1R8W;_F.XX'&, 9;CGBKX=\%:AH1@M)O$]Y?:-:$&UL
M9844H!]T/(/F<+V''0=AB@#D_%&J:AXK^#.M^(H[]H+6X67R;-8D*>2LI0;B
M1NWG:6R" ,@8X.?6+;_CUA_W%_E7!R?#.9=!U7P[9>()+?0KYG9+4VJNUON;
M<RJY/W,YXQGWKN[2![:SA@>9IFC0*9& !;'? XH Y&WUG6I?%WB[3#>0>586
MEO-9_P"C\1EUD)W<Y;[H[_A6!I_B;Q,- \%Z_=:I#-'JUW;VES:"V55(EW#?
MNZ[@0#Q@=L=SUR>%KB+Q#KFKQZD@?5;>. QFVR(@@8*0=W)^8Y]?:L]? ,R>
M&O#^BKJZB/1;J*YBE-KS(8R2H8;^G)SCK[4 =FX8HP1@KX.TD9 /T[UY,/$/
MC>;P#=^*H=7LR^FSW!DL_L8VW,<4K!LMG*_*.,>G).>/6681QEY&4!1EF/ '
MO7E?@+2G\2>!+[3FU6(Z9<ZA="XABBS+L,S$J'#8 8?[).&.#TP :EQK/B/6
M?&,&E:3JL.GVE[H(U&)FM!(\+F10.I^;K[#!/&<&B;6O$^L6NL'0S.;O3;EK
M. )';^3/+&%W>;O;< S$_=Q@8Y-="/#+IXTB\0Q7B(D5A]@6T$''E[@_WMW7
M(';&.W>LV;P/>P>(KW4]#\2W6E0:BXDOK1($E5WQ@NA;[C$#DX- %%]3\6:C
MXT_L)+^VTKS-%COG MEF:WE,A5E!)PV",9Z8SQT-0:1XI\07GA^:&_O+.VOM
M-UHZ;?WFT#S8UYW1)@@R-E0%P>IX[4A4Q_&E;33-0MK=X?#L<(29?.!Q,WRD
M;E.X#!Z_SK6N? "M9V1L]4EMM2MM2?4VNS$'$TS@A]R9 P0<  \ "@#'_P"$
MLUP>&/&\L5WFYT-W-K/<VH61D\H2 .@VC/.,X'N*=KVJ>+=$^']YXC.N6TLL
MD-I)%#]A4>1N95<!L_-G>#DCMT&>--_A_,]OXFA.O3.FO+MF\RW0["8PC,,8
MR<#CH!Z'K5[6O"4VM>!U\-2ZD(QY<4;W*V_+",J1A=V 3M&>O>@"GJFHZ])\
M1X-!L]2AMK*?2I+G/V8.Z,LB+D$GD\\=N>0:R(_&FM6O@&^O+F2.:^LM8?2Y
MKWR@JJ@G$9G91P,*<XZ9]JZI_#ES)XPMO$3:A'YL-DUGY(MCM968,6SOR#E1
M^'YUR?B#23X4\*7=I/K,T4.K:Q]IEOH[3*6N]_,?S!E@8SMVX/'S8)P30!N6
M&HZU_P +'NM$.H"ZTN"QCNVD>!=ZN[,HC+)M ^[N'&<9JS\1WN8OAWKTUK=R
MVLL5G(XDBQNX4Y&2#C/3(Y]"*Q/"$]VFJP0Z=XGTS7=-<M]I6STY(1 -I(;?
M&VW=N"KM(R02>U=GKNDQ:]H-_I,[M'%>0/ SIU4,,9'TH X'6K>\CNOAU''>
MF2X:Y?9-/&IV9MF[*%SC_)J<>,-6T&V\86^H7":C/H]Q;1VT[1+&7^T!-@8+
M@?*S^V1Z5LMX-O99/#TL^M^;+HTAD5FM0!*2GEX(## V_4YYSVIL_@*#4+CQ
M,=2O//MM?6(31)%L,1C4*A5MQY& >1U'X4 2:=)XJB\4PQSPW,^B30-YTEY]
MG5X)1TV^4>5/3!!(/>JOQ=O;NP^%FNSV3,LIB2,LO4([JK?^.DUH>'?#6JZ6
M\9U?Q-<ZPMNNVV62!(MG&-S%>7;'&2>YXR<UO7UC;:E87%C>0K-;7$9CEC;H
MRD8(H KZ%;6]GX?TZVM HMHK:-(@O3:%&*P]4U$Z9XAT3POIA%H=2:YN99E4
M,8T7YVVA@1N9W[@@#/'2GZ/X:UG0K2/3;+Q"LFF1#9 EW9^9/$G91('4$ <#
M<I_&I=6\(17\FE7EK>RVVJ:7*TMO=NOF;MXQ(LBY&Y6[@$8[8H YZ^\3ZYI<
MOB[1WNXY;O2]-.IV-[) "7CVL2KJN%W!EQD  CM4;ZUXHMY/!US_ &M;RIKB
MK#- ]HNR-FA+B0$$,2"#D9 /H*Z&Y\'F\M-<-Q?*VHZS;?9)[E8,+'%M*A43
M<<?>8\L>3Z8 CF\'7$L/AJ/^U$']A,K1G[+_ *XJAC&[Y^/E/;O^5 &(_B'Q
M#IT'CNRDU**ZN=#M8[NUNI;902'B9]C*N!P4P#[\YJ*37O%>D#PIK5[J5O>:
M=J\UM:7-DMJ$,+3+\LBN.2<]<\>@':WXKT(Z3I'CK79M1C8:KIC1M"T6P(8X
MG5 K;N2=QSQR>F*M>&]#;6?#GA:XO]2BN[.PA@N8(H8=NZ58\*7;<=VW)X 7
MG!/3% &;KOBC6M):6Z_M".22+68[8VEO")(%MGD5 ))-N5E(;=C=P2.,5?:]
M\2:EX[UW0K;6(;.VM[.">"1+17>,N7X^8D'[HR3^ &<U%/\ #6:32KS2X_$5
MQ'92ZA_:$"?9D8Q2>:)"&8\N,YQTZ\YK;L_#-U9^)[_7%U19);RUCMBDEMT$
M>=K9##)RQ)X ],4 <H/%VOS?#GP_XO-T(X5D0:O'%"IW0^84>1<@D$8SCI@G
MTKM+&\N-0\27QANRVF6L4<6P*I#SL-Y(;&<!&C[]6/I7/1#1/ /A*S\*:O>M
M?"ZCGAMH5M6WW0.2T>%R,G?@=.OUKH/!^@CPUX3T[2LEI(8AYK,VXESRW/?G
M@>P% %3Q'-<^&/#4ESI=O=7#?:4DNWA02S[&<>;(JD89@.@Q@>F!BI?!^LPZ
MYI]S>6NMIJMHT^()-BI)$NQ<I(H5<,&W'D#@BM/5K&ZOH8!97QLYX9EE$GE^
M8& !!5ER,@@\\U3T/P['H]_JFH&2-[S4Y4EG,47E1Y5=HPN3SU)))))H Y[X
ML0S2>%;9H[N6%1J-HK(BJ0V9TP3D$\=1^N:N:AJ6K:9XY\+:0+\3V=^EWY^^
M%1([1H&4DC '+= !T[UI>+?#DGB?2XK!;X6B)<1SE_)\PDHP91U&!D<TS4/#
MEQJ'B71-:?4(T?2A,!$MN<2>:H5LG=D< 8_K0!QT^O>+)="\9W\>M6\+Z#>S
MB$+9*1*D<2/L;). <GGKD]>,5T%[K&I74VFLE^+&VN]-\]([2,37+SG:0 C*
MP\M0>6XY(R12CP/.-)\3:>=50IK\LLLS_9>8C(@1@OS_ -T#&>_K2P^";JWU
MBQU*WUV6&6'3DTVX"6ZD2QH<J5W$[&YY/(/I0!@0^,?$5_X8\#:C!<VL$VL7
M:VUT#;[@3M?YASP/DS@8Z]15H>+M3\.-XUBU6Y&IKHD$-U;R>4L3/YJ,=C;>
M,!E'/7!JU9?#J:QTCP_IR:XTD>B7?VJ$R6H^8_, IPPXPY]\]^U:+^"HKK5O
M$-U?W2W%KKEO';3VPAV[%165=K;CSACSCKC&* )[6V\31ZEITYU2WNK"6!_M
MT<L:KY<A4%##M4$KG((9CQCG-8.F>(=>N_">O7,E_8I>66L36:W,ZB*.*%)%
M4MCGY@N2 <Y..O2M;PYX3U+1A;PWWB6YU.ULUVV<,L"1[!C:"[#F0@' S@=\
M9P11?X=R/H=]IYUITFN-6_M>*X2W \J?>'P5+$,N1T/YF@"3P[KU[>^)_$6C
MSW$]S:6EO!/;2W-N(9<2!]P("KQE>,J#SWI_PH_Y);X>_P"O;_V8U/9>$;RS
M\0W^M'79)KF^M(X)4>V0)N3=AL#!P-Q^7.?4FM'PGH!\+^&K/1?M7VJ.T4I'
M*8]A*YSR,GGF@#$\7^*'T#7+6&_NKK3-'FMSMU*&W65%N-V DI*MM&,$<#.3
MSQ6;?'4KGQYX*5M<D83Z=<2NUL(S$\BI'EURI!#;CSV'3&3GK=3T>^O+V>6#
M4(4MKBU%O+:7-KYT;8+'</F7G#8/4$"LE? 45J?#9TW4[BU.AP26R,460RQN
MJALYX#?*"#CCTH QO$GBC6M&BO[T:A&\MKJD4*V=O")(%MF=$ E?;E92&)P&
MXR.,5:B:[3XOZNTNJ77V6WTF&<0[4*A2[Y4?+G'RYSU]^F%N_AK-<:7JVF)X
MAN([&^OOM\<?V=&,4AD$A!8\LNX<#CZFMH>%9%\6+KJ:K-N>S2TNH6B0^>$8
ML#G'R\L<@#IZ4 8%CK?B[5].T37=+M9Y8KR2.6XM)/LRP"V?KL;=YF]1CD]3
MGY1T"-J?B>_U+QG9PZU%:C2&C:V>.S5C\T/F;3NSQDX/4GMCO>T3P#=Z%+]B
MMO$MX?#JRF2/2VA0E 3NV>;][9G^'CCC/)S>@\)W$%_XDNUU.,OK87>#;<0E
M4\L8^?GY?7OS[4 <Y%XG\1#3?!?B":_A,&M7-M:W%@EN @$J$[PY^;<",]<<
MXQQDW+O7/$FM1:W+X=2X6?3[R2TMHU6W,,KQXW"4NP?DY'R[<#'6KC>!9CX?
M\.Z0NK*$T.YAN(I/LN3(8@0H8;^F"<XZ^U$O@:]M_$-[J6B>);K2K?47$M]:
M);I*KR8P70MGRV(')P?Y4 53JGB>^\=)H9OH=-CET-+YT6W61X)3)M90Q)#$
M8QGI['@USNH:SK&M^ -!N+G4I(KM?$,5E<O;HJK/LN=@8@@X^Z#@<9ZC'%=W
M%X6>V\6KKMO?*JIIPTZ.V:$L!&&W EMV2<_I[\UEK\/&'A;^QO[7821ZB-2@
MN5MP#'+YOF<J6(89)]* *_B7Q/=:#K)T[4=5N=+MI+1!8ZF]LCP2W!+;A,VP
MA>B8 VC&>>E=Y Q:WC9F5F*@EEZ'CJ*YW4/#-_J%O?6DNL)+9WUN(9XKBS$F
M#@@NF& !.>X(&!QUSNZ?90Z9IMK86^[R;:%(8]QR=J@ 9/K@4 >?^+?%&M:'
M::U?QZA&9K&[B$-G;Q"6+R"8Q^_8KE';<QP&'\. >:T[R_\ $%U\1[GP_:ZK
M%:69TE;Q'6U5WC8RE.-Q()X[\<GCN(-0^&TM[8:_IR>(+B'3]7NS>F$6Z,8I
M2RL?F/++E1@<8]:V8/#%W#XM/B!M5$LQT\6)22V&" Q?<2&'.X]@!CCWH YK
M2O&VJ7?AOP_;32Q?VQJFHS:>UT(P%58G??(%Z;BJ# Z9;.,#%6M(M[FV^,^J
M)<WKW>=#@,;R(JL%\Y^#M !YSS@<$?6GCX:@>'K;3UUB2.\LK]]0LKZ. !H9
M68LP*DD,I+$8XXK4TSPK>VOBU_$5[K375S)9+9R1);+%&0K,P(Y)'WNF>N><
M<  TO$UU>V?AV\N-.GM(+E%!6:\;;%&-P#,3[+DCWQ7+6'B+59/$'B#2HKZ6
M:*WTV.]M+B]M CJQ+@@J F5^7(R!^(KI?%7AY?$^@R::;N2T<R1RQSQJ&*.C
MAE)4\$9 XK*3P9>C7;O6)/$$DES=Z>+*96M4"'!8A@!R -QXSG/4GI0!SMAX
ME\3+HG@G7;K5(9HM7NH+2YM!;*JD2JWS[NNX$9P,#MCN=N'Q!>Z-XPUO3=>U
M!FLULOM^GOY2+F)<^:#@<NIQ]0>E.'@.9?#OAW1UU90FB745S%(;7F0QYVAA
MOZ<G./TJMJC:'XY\4:99VKO<7.A7SR7DBQNBPA5(,1)&#N?9P,Y"GTH ZS0E
MU!=$M#JLIDOGC#S951L8\[?E ''3/?%:-%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !117&^(-0UF/Q_H6D6>IBVL]0MKII%$"LRF,)A@3W^8^WJ#T
MH [*BO+%U/Q3)X=\7M_PD;K/X>N)Q!.+2+?<!(Q(HERNW'./E"GWK97Q/J&K
MWVE:=;)=127&C1ZG.UEY._+D* /-. H.[/!/W>G.0#NJ*X.*^\5VND:=%KM[
M!93&_>&:5%5[BY@VDQ^6BJR^83C< . "1BJ-CXH\12>%-=G2*[O+C3-::T)C
MAC-S]E4HS$(!M:0*Q'3MTH ]*HKR_4_%\[?#O6M?T#Q*]V;:XB\DR01B2$%H
MU:*5"@YR6.< \CDUTE_JFHP?$G3=)BO"+*[TZXF:)HT(61"@5@<;OXCQF@#K
M**\KTSQ%XDA\'7WBV_UH7$6FO>HUB+1%6XV.RQEF'*X('3L/7FNBLV\6)XAT
MR4?:9]*E1EOQ>?9E"'&4>+RSGKP02>,=^: .RK)UWQ%9^'DLGO([AA=W4=I&
M8H]P#NP4;CT R?\ ]=6M7U&/2-&OM3F4M%9V\D[J.I"*6(_2O,_$C:GJ/A'P
MCK5YJ;NU[JNGW$EJL:")!(ZLJK\N[Y<@9+'/.>V #UBBN$O=8UW6[[Q#::(U
MY!+IDHMK=H!;E&E\M7S)YISMRP&% X!.<GBK<ZAXONO$^BZ-)J<6E37ND2S7
M*PP)*(9T* LI.<\MT/&#Z\T =PNI!M:?3/LEV"EN)_M)B_<'+$; _P#?XSCT
MJX0&&" 1Z&N+L+W6E^(-SX>N]6:>!-$BN!(ENB,)3(49^AY.W.#D#/2J6AZ[
MK-UHM]H][J3GQ);:H;!IA%&/E)WK(J;<;?)!;D<[3S0!Z%3652,LH./;-<+>
M:MKFL7VOV.C27T4NELMM!) +8AYO*5]TOF<X)8#"@< ]SQ+8ZWK6J^(K/P[>
M2#3;R#2UO=1:UV.6E9M@1"P8!>&8\$\J,]<@'0Z#XAL_$,5\]FDZ"RNWLY1-
M'L/F(!G ZX^;OBM:N$^&$<L-OXICGG,\J^(KL-*5"ESA.2!P"?;BM+Q_>:MI
M7AB75M)NI(FL76>XC2-'\V ,/,'S*<$+D@CTH ZFLG4O$5GI6L:7IEQ'<&?4
MI&C@9(\H"%+'<W0< ^IKECXM>T^(HMI]5DDT&ZT]IX&\N,(DRJ)&3<%W']TR
MN.>_?M1UZ/57O? )NKQO[0FU"60O-$N8=T#D+M4*"5!Q[D4 >FTA56^\H/U%
M>97'C/5?"UAXW2^N_P"U)-$DMQ:33QJC-YZ+M#A  0K-V XK8UC4M7\*ZUX=
M:;4I=1L=3O%T^YCFBC4I(ZDI(A11@94Y!SQ[\T :]MXNTZY36FCAO -'?9<@
MP'<3MW?*O4\'T%:.C:K;ZYHMEJMJ)%M[N%9HQ( &"L,C(!/-<3H__(2^)7_7
MP/\ TE6LZVU#5=#^%7@_6[*]EBT^TM[7^TH4B1BUN0 S@E205R#QVS0!ZK16
M)I]W<:AXCU"6&\9M,MDC@2,*A5YB-[,&QD@*T8ZXR6]*A\;^(9/#'A6YU&!$
M:XWQPP[QE0[N$!;V&<^^* .AHKBM4U+5O#/B?0+>349;^PU:5K.03Q1AH9=I
M9'4HJ\'!!!S[56\'7'B36[R]NKS7Q]FT[6+NS:V6TC_TB-#M7+=5P<'CWSG/
M !WDC^7&S[6;:"=JC)/T%5M,OQJFF6]\+:YM1.@?R;J/RY4]F7L:74C,NF73
M6THBF6)BDA7=M('7!ZUYPOB?Q%-X*\":E%J2)=:M>P6]VSVZL) X<DX&,?='
M Q]: /4:*X_PUJ&JQ^-/$&@ZCJ+ZA#:PV]S;S21(CJ) ^Y3L !&5XXSSWJ]X
M[U"_TGP/J^I:;<+!=VMLTR.8P_(&>AXH Z*BO.+G5?$^@ZSX7OKS5TO]-UFX
MCLY[/[,B"!W0LC(P^8]#G)_+/$6H^)=;T^YL)O[4%S)+KZ6-Q%;Q*UHD#R%
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MK'MMV2,.&CP,YZCYBPSSCM6GX,U+4IM3\1Z1J5\U^VEWJQQ7+QHCNCQJX#!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!6%J'AUK[Q7I>N_;3&VG1RQQP>4"K"0 -DYSGY1C'3WK=HH Y*/P6Z6/B2U_
MM0E=>>1YV\@9C+H$;9S_ '0,9SS5>\^'YE@T6:QUNZT_5M)MQ:0W\$:GS(0
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MSJ%;S$QNQ@GCF@#%\/\ @6?07AMO^$CU&[T:V;?:Z=,J8CP<J"X&Y@IZ#('
M]*TO#-GJMG)JG]H:C<WMO)=%[5KF,(Z*>J@#^$'@9YX)Z$5OT4 8?BCPX/$E
MG9QK>S65Q97<=Y;SQ*&VR)G&5/!&">*R)/ #22>(9&UV[=M=MEM[K?%&>B&,
ML, 8.TD =!Z&NSK'U/Q%:Z5K>DZ5/!<-+J<C1PR(H**54L=Q)]!V!H SG\'R
M._AMSJ9!T$?N<0#][\GE_/S_ '?3'//M6?+\.2MIKFG6&NW-II.K^:\MF(4<
M1/(,,48\A3_=_(BNYHH J:78_P!F:7:V/VB2X%O$L0EE"AF &!G: /TK!NM,
M;2O':^(T4FUO+,65YM'^K96W1R'_ &>64GME3TR1HZ+XBM=<O-4M8(+B*33;
M@6\WG*%RQ4-D8)XP1UQ1J7B*UTO7-)TF:"X:;4W>.&1%'EJ54L=QSZ#L#0!!
M:>');/Q1JNNQWX,NHQ1Q-$T/RH(P=A'.3]XY]?:J%CH\W@[P2=#T^=[ZZQ*M
MEN0*Q>1F;+8XVAF))[#U/7KJ* ,KPSH</AKPUIVC0-O2S@6/?C&]OXF_$Y/X
MU2U+PL]YXIMM?M-5N;&YCM39RK&B.)8BV_'S [3GO7144 <-;?#@6FBZ3I<6
MM7#0:7J(U"#S(5)W!F8*<8RN7;/<^HZ5H7&GP>'=;U;QC?:@WDO:)'/$EN6"
M1QDD$;<L3\QSU_"NH9E1&=V"JHR23@ 4*P=0RD%2,@CN* .1\*:?I][X@U?Q
M=902)'J0CC@:1&3S%51ND"L 5W$*.1SY8/>NOHHH Y!/!#KH_B/33JC&/79I
M9IW\@9C,BA6"<], 8SG'O4TOA"2:3PY(=3(;0N8<0#]Z=GE_-S_=],<\^U=3
M10!Q@\ R6VMWUWI?B+4-.T_4)C/>:?"J%7<_>*,03'N[E>?0CC!>_#Z.YNM>
M,&KW=K9:U;B*YM8T0@$1^6"K$$@;<<>W7'%=G10!S%OX6OK.WB@AUMI8Q8I9
M2I=VRR)(J[L-M!7!PV.XP!D&J\G@*&WC\/\ ]D:G<:?-HD+V\,NQ93)$X 8,
M&&,G:#GL>U=?10!PT_PV2;0==TC^V[LPZS>&[G9XT9D8E3\IQU.Q<YR/0"M;
MQ)X27Q+860EU">TU.QE$UM?VH"O&^,$[3D$$=1WKHZ* ,K0](N-+AD:^U2?4
M[Z7'FW,R*F0,[55% "@9/XD\TWQ+X?A\2Z0;":XEMRLL<\<L6"4=&#*<$$$9
M XK7HH YYO"R7UQ-=:Q=F\NI+-[)&CC\I8HW^_L7)PS8&22>@QCODV?P\EMO
M^$?,GB.^E;0R5M3Y42_NBGE[#\O7;QN.3QQ@\UV]% '+GP@]PVG1ZCJ)O+;3
MKP7EL&@"RJX)*J7S]T9Z  G R3SFE#\/FLM5O'T[Q!J%GI%],T]UI<:H49V^
M]M<C<@;N%P?0CMVM% '*MX,:W\2WNL:1J]QIPU!5%[;)$CI(RC ==P^1L<9Y
M!]*T/"?AU?"GAJTT6.\FNX[92JR2JH."<X  Z<]\GWK:HH PM>\.MK>I:1>"
M],!TRX^TQH(@P=]I7YN>F">GYU5C\)2Q7_B*[74OGUQ564& 8BVIY8V\_P!W
MUSSS[5T]% &9X>TC^P/#]CI N#/'9Q+#'(R[2548&??%:=%% !1110 4444
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M1Q^&O*\57GB"/4)Q<7-LML8BBE%122N.,YR3U- '':)XSU74]"\$V4]SLO\
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M ;IT1I "B= %"YQP,J1Z@U3MO%>K:7HVM6=Q>27MU:Z_'I5M=2J@?9(8\,V
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MSG QM#/U(QSBNRN_!MGJT>J/JES)=7&I6?V)YD 3RH>3MC'..3N).<G'8 4
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MHMY9(P@4E?EX) ^@SP!@5?U7PDNKZ'IVES:E<HMC-#,LJ(F]VB(*;LC'4#.
M,T 9^CW>J6/Q(OM!N]5GU"TDTR._C,Z(K1.9&1E78H^4X!P<XKLZP5\- >+'
M\0G4)_M+V0L3&%0($#%@1QG=N)/7\*T-&T^;2])M[*>_N+^6($-<W)!DDY)Y
MQ]<?A0!>HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*J:=J=CJ]H+O3KN&ZMR<"6%PRD_4?6K= !1110 4444 %%%% !1110 4444
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MQ$;'LH[<(V1\Q8'ZC'O71T4 >'^";/P3-\)+:W\06MF;[$YE18O]+SYKE2H
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MG,=W9W'Q9T*0LN#H,B+YB[2':1"%P>02H;CJ15FUN[6'XQ:T[SQ(@T>!2S,
M 5=RPSZ@$$UWM% 'A]G-;Q?!3PI$61)8]6MW=.C)MN2S$CJ,+R?8UM:YKFF>
M'_''B02:E!;C5["W60WD4NP,%=5>-D5@R[3R#CGH>M>K5RQ\/:_9ZQ?W>E>(
M8$M[Z83207MB9S&VT+\C+(AQA1@'.* +?@I=,B\':7;Z/J"ZA8V\"PI<J<[]
MHP<^AR.G:MZJ>F:<FG6SH)#+++(99I6 !D<]3@<#H!CT ^M7* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MMVE<9!#<'(&.]>?:%JGV'1/ =I<V\MLGV"2*34$M#+-!( H\A?E)0MWXR0H
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MUD-S0VSYW*I8D$AN03G.#R,X-;% !1110 4444 %%%% !1110 4444 %%%%
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M$W]I00I<6ZNL4I\Y5=/, P1C=WP<$<T >CT444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% %:\LHK^-8IRQA#!FC!P'P<@-WQD
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M%E10HR,GG K1H X#30+3XJW3M;-!;QZ!!;AE1C$KI(Y**^,' (KG-#T^SNO
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MUF;2T@NUEB@2<R20,L95LX 8_P 7'(_^O6C110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:]@ED'H6PP&>^U0?3%=]10!YU+<V5MXHN=>T9]9LY[R%(;R&;PW>RQ3;.$<
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MN_.DADG6W!@CWX=FVC)Z#DXY-;% 'C;Z+ /"USX7AUGQ FB-*LEM$WAB[>6
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
*%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>a97-arwrxclawbackpolicyf002.jpg
<TEXT>
begin 644 a97-arwrxclawbackpolicyf002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%YIUHML=I"S-&K[T5NA/(4\]ZV/#6IZ%XDU33KJ#1-475;,.93?K./L!92&
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MTD/D%N^"1ST-=;X2?1;^ZO=6T;3[F-+A8UDO;I95>X*YP,2?,0HXSTYP.AH
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MC^T+) ZF("V*$L".!N.,G@U=MI$76OB6[*X2X2+R6,9Q+BVV';Q\WS<<9YH
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MEN5MH&E\E#D@M@>@)P,G'.* ->BL;_A*M',VDHET9%U;_CREC1F27Y2V-P&
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MYKJ6C:1<6>D1PV.I>&VW7%Q8WMI&RO:L=@/F@ A?,!R5;^[@X-9[77B33_\
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M38',JN%)V]=H/'X=:Y*>RU!_@SKFG+I6I&]FU.22.W^Q2[V5KH2 @;>FWG-
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MK(8XR'QM0]"?Q[4 6-/U?4_#OQ)B\*:A?2ZAIVI6SW&GSSX,T3IDO&S #<,
MD$\]!S7?5P%MHNH^)_B"GB:]MI]-T_3[.2UT]),+/([Y#RE>=@P< 'GH2!TK
MHM#\.SZ-<R32^(=8U(.FT1WTJ,J\YR-J+S0!D^$;B];QCXQL[J_N;N*UN;=8
M/.8'RU:$,0   !D]A79UQ7A-9E\=>,9Y+2\BAN[BW>WEFMI$20+"JL06 '!!
M%;NC^(H=8U/5+!;*^M9M.E"/]JA\L2J2P62,Y^9"4;!]J *^J>,M+TJ;4$E6
MXE73422_>"/<+97&5+<Y/'.%!(')HOO&6D6&J6VFN;J6ZN;<W$"0VSOYJ#'W
M2!ACR.!G'? KB_%[:IJ3>--,ETC4V+6>-.6RMV$5R/*Y=Y%QO8'C8QZ  *35
MRQ^U2^,O!]VVF:C%#!H\L,SR6D@$;MY>T,<8!.T]>G?% '567C'1[W0)]9$T
ML-M;RM!.DT3+)'*K;3&4Z[LD  9SD8KG$U.6Y^,EA!LU&V4Z1-));7#G83O0
M*ZJ&*YQD<<^M<W<:9K,FBZQ=6>EWSRV?B_\ M@6KV[QM=6ZE?N;@-V<9 _V?
MI71Q:@^K_%#1=4M=,U1;'^RYX7FGLI(@CLZ$!MX!'0\]/3- '7ZEKMKIM[:V
M+)+/?78=H;:%0794 +-R0 !D=2.O%9DGC[0(M$L-7:>?[)>W M8V^SO\LF_8
M5?CY<$'KZ'&:J>)[R]A\6:1 UA?/I4D$HDN;"!GE\W*[8RZC=&A')((R0,D
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M-+GNWAC,J/(X<S,IW%B=HW9QD]/RH [BBL+2_%5EJNMW.D"WO;6]@A6X$=W
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M)N,OVI]F]@1QG&=QY]Z /6**Y[5?&-AI<^HQ&WN[DZ9 MQ?&W12+>-@2"=S
MGA6.%R<#Z52O/&3IXMT72K/3Y[FUO[5[L7$>S#H N-H+ X^8$YQVQGG !UU%
M<YJGC33=(AGNYX;M]/MIO(N;Z)%:*%\A2&YW$ D E5(!X/(.,@2M#\9)S$]Q
M-$WAT3B$2EE+>?C*!CM!( Z8% '=45SMEXST[4/"]QXA@@N_L<#.K(T8$N4;
M:PVYZYR,'!/8<C.Z9F%J9O(DW!-_DC&_.,[>N,]NN/>@"6BO+=$O+37;?5=>
MU_[?8MI>K3RI?"4((HXG"B'Y6)(P,%<8))[FNVA\4VC:O:Z7=VMW87-XC/:"
MZ10)PHRP4JQPP'.UL'VH W**\STM'-A\2(3<W9$-W+Y3_:9-Z8MU88?.X<^]
M;GA;6X;#P#X36X,L]Y>V$"00Q_-),WE!FQD@< $DD@#UH ["BN;;QMIJ6&K7
M$EO>)-I'-]:&,>="N-P; .&4CG*D@@'TJ0^+[$7NB6OV:[W:S'YEHX5-C +O
M.3NX(7G'?MF@#H**Y'Q7K^C#PWKJZQ;:B-/LV6"Y>W!#,2%;Y&1LC@KDG YP
M>XJ[?^+M-TK5[;1G@OI;R>W::%(K=GWJN. >YY'T[D4 =#17.6OC;1[CPW=:
MX[3VUO:3-;W$4\6)8Y@P7RRHS\Q)  &>HJ6#Q79R>(5T&:TOK?4FB$XBDAW#
MRR<;]R%E SQR>M &]4$%G#;RS2HI\V9MTCL22<=!D] .PZ#GUJ#4]5@TM;?S
M5>26YF$$$,>-TCD%L#) ^ZK'DCI67<^,;*RM4N+NSOH%:^6P8/&N8Y6*A<X;
MH=PY&10!T5%9*^(;/_A(Y]#D66*ZAM/MA9P ABW;=P;/J#UQTJE'XSTR6ZTV
M!X;N*#524L;MT CN"!GC!W+D<@L!GM0!T=%>6>&?%EKX8L/$TFH)J=S;6_B"
MZ22=4:86\>Y54N['.![9..U>H-)B$R*ID 7< F,M]* 'T5Y+XB\3W7B?X0>)
M-0>TO-/>!Y5B99=F DNP*2C9)P.0>/K7<6/B^PN-931VM[Z&X:V-Q \UN52X
M1<!C'W.,CC //&: -G4+5KW3KBU2YFM7FC9!/ 0'C)&-RD]Q530]%31+)HOM
M=S>W$C;Y[JZ8-)*V  3@ #    ';UR:R-.^(.D:G,!;VVHB 23QS74EJRPP&
M($MYC'[G .,_CC(JW%XOL6U>PTZXMKRT?449[*2XC"I<;1D@8)*G'.&"F@#H
M**YNX\;:9:O:231726%W<"V@U#8OD-(20!G=N )! 8KM/KCFM^YF:WMWE6"2
M=E&1'%C<WTR0/UH EHKQFTFTG6OAQ#XK\4Q:U&Z>;)<7-G(RFY5Y''E_(V=B
MX4 ':!@8/7/I]QKMO:7*6,%K=7=P+87#10;2R19P&.YAG)!&!DG!H UZ*QF\
M2VK)8BV@N;JYO;?[5%:Q*HD\K ^9MS!5'S <GJ<#-4[;QSH][I^G7-G]HGDU
M&9X+>V5 LID0$NI#$ ;0IR2<>F<B@#I:*\\\;:[;:]\*?$=Y8R7=O+9B2&1-
MYBDBFC8!E;:<'KZD'-=Y:L180M@L?*4X'4\4 3T5S^G>,+#4](U34HH+J.'3
M))(KE)D5'5XQEQC=V'KBIIO$<:(BPZ??7-T;<7+VD2)YL49S@L&8 $X( SDX
M.!P: -2ZB>>UEBCE\IW4J'V[MN>^*SO"^@KX8\/6FC1W+W$-JNR)Y% ;;G.#
MC@U2M_&^D7UKI4VFF:^?55D>UAA4!V$?^LSO*A=IX.3U]:BF^(&B0>&H=>D^
MU"SDG^S$>0=T<F_85?LN&XY./3- '4T5SMMXPMKJ5;>+3-46[>65([:: 0R2
M+&%+2+O91L^=><YYZ=:U]-U"/5+".[BCEB5RPV3+M=2K%2".QR#0!;HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB_$D%[!\0
MO#&JPZ?=7=K%!=V\K6Z;O+9PFW=SP#M/)X'>NTHH \R2UO/L'Q(3^SKX-J+2
MFS!M9/W^;<1C;Q_>&/UZ4^SEU:&3PQ876D:H=+718XY/LL)23[4NT&.5L@H@
M ]0I/4D"O2J* /'-.TO6+7X<^$H9-#U!9M'UY9[F 19D\L22DLJ@Y8#>M>O)
M,6MEF>*2,E-QC(RR\9Q@9R?IFI:* /*M'TF.;X>1:5KFAZF\;ZM.[B."19K<
M-)))',F!NX^7IG[W3M75>!;?6;2TU&UU*[NKRTBN=NGW5[&4N)(MJYW@@$X;
M(!(!.,],5U=% '&^--*U4ZOHFN:#$'U"WE>SER./(F&"S>H1PCX]C5'PUX5O
M=#\7WNGJCGP["ZZE:N[$DW#H8V4D]<$.Y]V4UZ!10!P^GVMTWQ&\63&TN4@N
M[*VA@G>%ECD9%D# ,1CC</KVKEX[35#\*?#FDOHFII>6%]:>=&;9B<1R[G88
MS\H SGOGC->P44 <2JSCXN3:D;.\^PG0EM_/^S/M,@F9RO3KM.?TZ\5R<6FZ
MFOPDT_33I6H"^CU@3O!]E?<$^UF7=TZ;#G].M>Q44 <6L<[_ !@2_%G=_8CH
M?V;[0;=PGF^=OVDD<';S^G7BG>.-/U ZKX:UZQMY;M-(O&>YMH1N=HI$*,RK
M_$5SG Y.37944 <!>V$VI^+-2\2PVMVEI'H3:?&KVSI)/(SE^(R V!P.1U;V
M-;7P_AGM? .B6EU;S6]Q;6D<,L4T91E90 >#_.NEHH XSQ!#<2?$OPC=1VEU
M);6D=XL\R0LR1F1$"9(&.2I^G?%84-I>_P#"+_$:W.G7XFU&ZNWM$-K)F97A
M5%*\=V!^G>O4** /-[JWNW_X5T5T^^/V!U:[Q:R?N1Y!C^;CCYCC]>E1V]M>
M#1_B-&=.O@^H3W#6BFUDS,&@5%V\=V!_GTKTRB@#S.XMKPZ;\.4&GWQ;3Y86
MNP+63,(6 QG=Q_>./UZ55TVUDT74-5T+5O \VKM/?37%E?):1RPS)*Y<"61O
MN$%B#GL.!TSZM10!YYI@U#PIX]UPW>DWES8ZNMO):W%A;F1(WCC"&)@/N#@8
M)P,=ZY^UT[5H_A-X>TZ71M12\M]7CGDA-N2PC6Y:0L0,X&TCKCVKV.B@#S/Q
M3_;&IWGBO39=(U*:WETW;I1M8]L4K-$VXRMD98,<!&[#A23264.IVVL>!=1?
M1=1,4&DRV4R"(;XI"L>-XS\H.T\G\<5Z;10!Y3I=K)HUYJ>@:MX'EU:26]FF
MLK];2.2">.1RX\V1ON$%L'.>!QGC/006US%\7%NC93K9KH*VGGI;L(1*)MVT
M'&!\OX=LYKMJ9-'YT$D6]X]ZE=Z'#+D=0>QH X"/0KNV^(]UI]OL.A7S1ZS<
M1YYCG0[=N/1W$<F?6-A7H+,$1F.< 9. 2?R'6LCP_P"'HM MG07M]?W$F!)=
MW\WFRN%SM!.!P,G  [D]2:V* /(U\/ZMK'PV\4:5;V=S;:A-JT]];1W,+1B9
M?/$JC+ #Y@,=>#UKHM1CG\8ZIX5FAL+ZS_L^\^W7;75N\1BVH1Y8+ ;R6('R
MY& 3GIGNJ* /.=-M[N.#XA;]/OE^VW$LEJ#;/F93"J#;QS\P_KTJC9Z;JNG6
MOP]UK^S[R2/2+(V6H6BPMYT6^)5+JF,MM9>< DCIFO5** ..TK1VU#QSK7B"
M6WECL+JQBL8XYXC&T^"Q=BC $#D*,@9P>V,\B?"7B&+PI*OE2/>>%KDG0ADE
MKA$DWY([[H]L8'^R?6O7Z* ."\9:3?'X2:GIT5M+=:I>1%GCMT+EYG?>^,=@
M2<9Z  5)=K/-\2?#E^EE>FTBTZXCEF-LX5'<H5#<<'Y3].]=S10!Y%<V$I\$
M^-H;S2]1W76O/<VB+$8Y'#/$(Y(]P 8AAG;U.,=ZVO#^K6MYXTBU#4[+6[?5
M9K7[!;R7FEO;0;03(R@Y8;V(SR?X< >O7:_H%MXALHK>XGNK=X9EN(9[679)
M%(N<,#R#U/!!'-1Z=H#VDT<]]K&H:I+$28C=F,",D$9"QHH)P2,G)Y..M %+
MQMI]CJFFV=GJ.GWMS;/= F:R5S+:,$8K*NS+#! ' /WJXZ^TSQ+)X$GCN1?:
MM_9^M07%FTD.V[N+6-T8EDX)8?,!D D+TZ5ZO10!YG>V>H^)/&^I2PZ7J%I9
MZAX8>PBNKB'RPDC2/C<#RIYZ=>G'(K1\&ZWJ[Z7INAWWAG4+2_L(T@N;B>("
MV"H-I>-\_.6 X"YY// KNZ* /))=/U"3X>>/;)=,O_M6H:G=RVL1M7#2I(5V
M,..AP?IWQ7J.FL7TNU)1T/E+E9$*L#CH0>15JB@#QZ?3M67X3>)_#QT743?-
M=7(B"P$K-OG+J4(ZC:<YZ#UKI]2$\_Q#\)W\=E>M:6]G=+/+]EDQ&9%3:#QP
M3M/T[UW5% 'FFAZ'?ZG\./%.B-;W%G=WMS?&'[3$T882LQ0\CH<C/I5CPS*N
MJFSMKGP))I>J6RXN;R>RC2*)@,%H9!RQ)Z;>F<D\<^AT4 >4>$K22QTZT\+Z
MKX$:75+)A"NH/91M:2(I^68RGOCG'WL_7CU.:58(7E9795&2$0NQ^@')J2B@
M#R*'3=2_X9ZFT,Z7?C5/L[P_93;/OW-*Q';D8YSTK:\3Z7;ZO>6UPL6MZ;J5
MO8*UGJMA;RE@Q+;H9%"G(X4[6'\1Y'?T.B@#R])?$V@>(-&\2:KH]UJ N]&C
ML=0BTZ(226\ZN7#;!U4[B#C@'\,ZVN:CK;RZ#+_8U_#IEQ<2F[2TCW74*[?W
M8;:24W$DL5.0,#/7/=44 >.MI>J+\._'FE+H6I1SWFHW$EI&T>\R+)LVX()S
MT.3T]Z]9T]_,TZV;:Z9C7Y9$*L..X/(JS10!Y[JFA7<?Q%%O9[/[*U^$3ZG'
MGE6MV7Y@/20,B-^)J+7H9]$^(%SJUWX9N-=TG4K6&+=:VPN);66,MQL/.U@V
M<^M=9H'AJ+0?-D.HZCJ5S+\IN-0G\V14!)" X  R3VY[]!C;H \]NFU"SOM!
MMX?#ES9:),D[30:7"HEB<D&-'*$; 1RQ4@;N"< YYH:;JL7PTN]*.A:DERFO
M>>D0@+%HQ="0D8SD!1UZ'L37L]% '&>,]-L=;N-*2ZMM6B94EEMM4TZ.7SK.
M3Y, A02-P)X(Q\G-2^'=3URPT#18-<L;R]OKJX>![B& #RTRQ2689^3*A<^Y
M]>*ZZB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX@HRI!/ Z$=<GF@#NJ*\U\-'Q)K-AJ6H3^*;M#I^H7ULL:6\.)%0E4+97J"
M>...G.:SH-9\2#P?X,\0_P#"03/=:C=VUK<0O!&8764E2Q4 -N!P<[@..@H
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M57/&6(&>*;;>(H)M8BTF>SO+.^EB>9(YXQ@HI4$AU+(?O#@$GU KD? [M/\
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M<Z?;:7]LFC63/F.PRB-ZE0CY[Y*UT.D:/;:/#.D!>26XF:XN)I2"\LC=6;
MZ #     %0:#X;T[PWI\]EI\6V">XEN'5N>7;)'T P /0"@#D=+?Q7J^G>'?
M$%E>Q+]H,4]\LUWF&2!QED6/9\K+D;3G/')-1:/-K-S=>)K^Z\0Z@\&AZM+Y
M=NJQ@31I$K>6^%Z<\8QW/)/&UHWP[L-#O ;35-5.FI+YT6EO<9MHGSN&!C.
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MTZP33=+M["*::1((Q$DDI!<@# R<8S^%85AX*73-1U.^L]?U:*;4IA-<<6[
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MOC=N 3.3M'0CIQ0!R6F7/BOQ%H.C>)-,NXHI9Y%N)UFN_P#1V@).Z+8$X('
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M;3L"VT# &0 /TK2H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKW33X5;PX;_4?[/:?[01OCW[O,\S[VSIOY_^MQ3[SP#IE[?:I=2WFI+_ &K
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M2T4 <[<^%H)$O[F6\U*XO[FR^Q?:D>..=(LDXC*JJ@Y.<D=<=A6AX?L;G3-
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MR ,#)P!T Z 5>HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M<Y0;0HP2Q).,GUX%95M\.]'MQI8:ZU2<Z7)OM#+>,3$-NT(,8PH'''7C).*
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M=9O!J:%>R6]Y BO>>2HM8HRV&PV?OJ!D*!UV]N:ZR&*."&.&) D<:A451@*
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MHEM<WTNJ7T$^GB&SA\O[-<^<&^T9&6^0<KM/'/6KM<'H\,^H>-O'>E3:A?\
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MO.V[R'1W5)"?OL/EY8=,5;M8M3M-<\<:#I.J7"E;*WFL6O;EY?(FD5P<.Y)
M)53['I0!Z517F.G>((!#KMO?2ZEX7U>WTLM-%>2-<Q1 9'VB$EB'Y(!Q@D@=
MZDTE[N#Q]I>G[M0BL;[196DCN;MV>5E9 )2-Q\MR&/(;//."* .ZN-1=]*N[
MK28%U"XA\Q(X!*(Q)*A(*;CP/F!&:NPM(\$;RQ^5(R@O'NW;3CD9[X]:\>T:
MU-A\"M<O+*ZO;:XB^W,CQ7<@VE)I-N!NP.G.,9[UTJ:G-J/C#0/#MS-,EDVA
M_;WV2LAN)=RH%+ @D ;FQGG(STH [^BO&_$.H:K8>'OB)I$>I7PBT8V\UA="
MX;S4650QB+YW,%[9)."/:NF,4^C?$W0(H=1OYH]4LKHW<=Q<-(CM&$*L%)VH
M?F(^4 8[4 =!XG\1OX=&EL+$W*7U_#9%O-">49&P&Z'/?BMZN'^)Z-+I>@QK
M(T3-K]D Z8W+F3J,@C/U%9KQW/A/QW+8P:Y??V5?:1<7<S7T[7'V.2,C]\"Y
M) ^;D=#^6 #TJBO+])N;RT\7>"TAN+]K74;*Y$\MU.Q:]*1HPE:(E@F2<CG.
M&P0,8I^CZI=6'B?3=/\ $D=_;WLMU*UKJ,-PTMGJ2LK[4(SA#A@0I'&SC&:
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MZ*6Z3_EH0Q S[@8!]P:V: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+SRM(=7LAYY_=%5VK_O8''.>M6(_"VF)J>J7[)+++JD:Q7B2ON25%!55*G@
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MP'DGG>5R!T7<Q) &3@#CFK>L:/8:_I-QI>IP">SN%VR1DD9P01R.000#D>E
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M2%22Z*2$SMY#'C&.!Q7<6G@30;/1;O2DAN7MKQ/*N&DNY6DD3!&PN6W!<$\
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MGF@%P#AL[1U[BO2;SPSIMYJW]J;9[>^:+R9)[:=XFDCZ[6VD9QV/4=B*9?\
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M$%TOVF0).H7:"ZAL,P'0D9'7K3V\$Z"T.E1FUEQI89;5A<R!E5@ RLP;+*0
M"&R"!CI0!P5QI<=]_P +-N7N+N.2UF::#R+AXMDBVJL'^4C)! ZY'MUK2MM6
MO==U7P[I-U+$RW/AZ._9)G9%N)6VAONXW%1SCI\Q..!CK5\':,J:L@BN=NK9
M^V_Z7+^]R-I_BXXXXQQ5?4/ /A[4]+T_3[BTE\O30%LY4N)%E@  &%DSNQ@
M8SV'I0!QVKZ9J>B:5X>L9_$-S<2KXF@@#PSN"D#_ #")\D[R.,%L\8J_::'
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M%$Y!!()"C&>=H!R,@]WX7T*?0=6U:-M4BFMKDQSQ:?%$RI:9!!*Y9L*Q!..
M"#B@#H+][N/3[A["&.:\6-C#'*^U7?' )[#-/MFF:UA:Y1(YRBF1$;<JMCD
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M6\9DD<]@/Z^U %8>']-77AK8AD_M'R?L_G&>0_N\YV[=VW&>>G7FM.@<C-%
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M.FPPWZMB.\M@L98S1AACY@V\C@Y^E>FV.H6E[!;M;S*?.@6=$)P_EL.&*]:
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M(F2<=,]FQ[YJ]=-J/]I:?]DELQ8EG%V)0WF-\OR>7CC.>N>U86F>(-5O=?\
M%FF/'9@Z281;,%;#>9&7^?GGL.,4 :]WX<TF]NI[FXM TMP@CG(D91,HX"N
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MXZCVZ')'>LG4)9/#>D?$R#1(S:V]K=6KI#:C:(4DCC\XH!]T[2QXZ8S7J/\
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M&NY+TK+LXW-Y>S&1SQFK=QX4\/W>MQZS<:-92:E&05N6A!?(Z'/<CL>HK8H
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MX46><*)9 ,,X7.W)[XR?SK-OO"GA_4]5BU2^T:RN+Z+&R>2$%ACISWQVSTH
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MZ;H6DZ.\SZ;IMK:/,<R-#$%+_4BIM1TVQU>QDLM1M(;JUDQOBF0,IP<C@^]
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M)GC!(/4'!(XJAXCMM*\,>*_#EM$EMI&DWLMS)+(L2B(W>Q!&7S\H)4. 3WH
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M;7?&GVF'=(Q5!Y@RQ'4#U(HN[J&U@+2W,%N6^5'F8!=W;N,_3->'Q:5IUO\
M!--4BM(5OK;5LP7(4;XL7^T!6ZJ,$\#CD^M=WI]U#>_%OQ)8:LL;-!8VPTZ*
M8 @P,K&8J#UR^ Q_V0.U &OX$UR^\1>%TU#41"+DW$\3>0I5,)*R# ))Z*.]
M=#)<0PLJRS1HS= S 9KB?A$($\ Q16Y3RX[R[50IR //?'Z8JU\2-+>[\,?V
MI:P+)J.BS)J-MD9),9W,OT*[ACUQ0!U:W5NSLBSQ%ER64.,C'7-4KN:[DNM.
M>PO;);4S$7 D&YI5VG"QD' ;//?@5YH-7DL?& \2:;:I]B\66YM+,^5@FXC
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MI5DUQ)$87E-NI=HR,%2<9*X[=*@UCQ/I.B6UE/=WD(6]N(H+?$@_>%V R/8
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M;[.GEM]5Q@T^/2--ATPZ9%I]HE@5*FU6%1%@]1LQC'X4 3VSV\D"M:M&T.2
M8B"O!P>GOFN!T.]M;GQMXXM-;:$7*F-(X[@@ V7E\;<_PY+$^YYKOX((K:!(
M((DBAC4*D<:A54#H !T%5;S1=*U"[AN[W3+.YN8/]5-- KO'_NDC(_"@#Q_P
ME?B/2?A:D[J=*+7*2DG*+=;6\D-[\MCWK2\31ZG8:UX_D\/^8D3Z-%-,(>-M
MT=P)7'1_*&3CG[I]*]._L72O[,_LS^S+/[!C'V7R%\K_ +XQC]*GM+&TT^#R
M+.UAMH<D^7#&$7)[X% ')Z/<>#]9NO#FHZ9+!)=PVSQV4=M+S%$R#<'0'H,
M?,.&([FO/S=V</P(M[22>!)XM7VF(L R$7Y)X[84Y^AKV6PT72M*EFET_3+.
MTDG.96MX%C,A_P!H@#/XU$?#NAM+<R-HVGF2Z8/.QMDS*P.06./F((!Y[T <
M?;Z;IEY\9M4WVEK,DFBP2D,BLK,97&XCH3C SZ5QO]GV,/P&EOH[:$75OJ/[
MF?:-\86_VJ%;J !D8'J?6O:/[&TO[4]U_9MG]H=2C3>0N]E(P03C)&.U1?\
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M+'EW+P*TJ8Z88C(H X>S,5K\4=: *+=MHEJ;?[1M#O)ND )]6)QG'>L;PT-
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M#[T'1-)-Q-<'3++SIP1+)]G7=(#U#'&3^- '._"J1I?A=X>9V+$6H7).> 2
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MV+?*^W!&T-L/0CB@#UVX\4:%;Z/=ZJVK6;V5H#YTL4RN%(_AX/WO0=33]/\
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M;'PSI]K8R7,EG%"$@>Y.9&C'W2>!VQC@<8KF?&\-K<>._ L=['$]NUS=!EF
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MDJHR2 3T !)JJ?$FA+8QWQUK3A:2/Y:3FZ3RV;^Z&S@GVKS/3+&5M9^%J:W
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M+B*Y"[9&9 0Q&=S,3P1R<TV_@N_#GB_4="L(G6S\6#SK=XUXMKCA;@^W[O\
M>#/=<4 >DV]Q#=P)/;S1S0N,K)&P96'L1UJ*\U"RT]%>]O+>V5CA6FD" GVR
M:E@@BM;>*W@18X8D"(B]%4#  _"N0\5VFI2^(K"Z\/:G:P:W;6DNVRO5S#=0
M,R;AD<J0RIR/49XH DUOQ%=6OBSPI#9WUL=)U)[@3D*&W!(6<$/G&,@=!VZU
MTEKJNG7UDU[:7]K<6BYW3Q3*Z#'7+ XXKS!;NSUV[^&4SZ:EI!+->#[$Y#*A
M6)Q@>JY&1[$5!?7.E:7%\2H[VT$VG"_M-UM'(8EW.D8R67[J[L%CZ ]>E 'J
MEMJ=EJD4PTO4;2X=!@M%()0A(XW!3_45YXWC'Q!_PI9/$RW5N-36=DD<VX*E
M?M1BPHS@87'7/3\:GT/4(7^,EX)-4LKF6?1(1FVPJ,XE?Y5&220/<GZ#BN;,
MB?\ #-#MO7'VD\Y_ZB% 'MM<EK6O7NE>/M#L9+NWBTF[MKJ6<.@4J8E4Y+D\
M#YO;I76UP7BNWL[GXH^"XKZ*&6%H+_"3 %6;;$1P>">,CZ4 =I::C97]F+RS
MO+>XM2"1-#*'3CK\P.*98ZKIVI^9]@O[6[\H@2>1,K[">F<'BO(-6MFT9/&U
MWI43Q^'5U33WF2U0%<(5-UL7!!'W0PP1PP/ (KM="3P[J7BY-<TS7Y=6U!['
MR9&BDB*+#N!'F"-1ALGC//7T. #M'=(XVDD95102S,<  =R:\_@\2W_BB35G
MT+Q%IUA)I]^]ND,RI*DL"!=\K<[NK$@@@< 'KFO0J\U\,+;7'AKQ^LBQ21_V
MSJ.X, 1]T'F@#M=.OXH-(T[[?K%G=3SQJJW2E8UN7QU09QSUP,U:LM5T[48)
M)[&_M;J&-BKR03*ZJ1U!(/!KR9;:SN?!WPH\^*&3?=6T9WJ#N7R'RI]1G&15
MG4Y]+TC5_B<;JS:73Q8V336MLWEE]T;J>1]W/&3Z4 >G6FK:?J?FIIVHV=S(
MBY;R95DV9Z$@'I6)X#UC4-;T2[GU.6.6XAU&YM@T<>Q=L<A4<?AZFN7TG4+<
M_%W3F?4]/F,GA]XD%HP\M3YT96,')+'&3SVYP*V?A>RMX?U0J01_;5]T/_38
MT =K)(D4;22.J1H"S,QP !U)-5;35]-OTE>SU"TN%A_UIAF5PG&><'CBL/XB
M7>GV7@74I=4M6NK,A$>)9#&&+.H&6'*KDC)],]>E<M9WEI<?%?48[O4=/O/M
M/AY PA"B)F$KG:!D[L#GDD_0<4 >@QZ[I$UQ;V\6JV+SW"EX(UN$+2J,Y*C.
M2.#T]*BUS5[;3+&96U*RL[MHF:#[2XY(Z?*6!//%>2Z=:V<'PJ^'EY'#"EP=
M9L29@H#$F4@Y;KTX^@KH](U.S.L_$"RUV:".^,[82Y8+OL_* CQGJOWLX[M[
MT =;X'U6[USP1H^J7SJ]U=6RR2LJA06/L.E;]<?\+)HIOACH'E2(^RT5&VMG
M:PZ@^]=A0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !4<\$-U \%Q$DL3C#1R*&5AZ$'K4E<IX^U;4
MM&TBQNM-NE@9M1MH)<QARR/(JD#/3@GG% '0'2M.,R3&PM?-0!5?R5W* ,
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M%))"K,@]%)&1^%7** (X((;6!(+>*.*)!A8XU"JH] !TJ2BB@ HHHH ****
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MX@6UM-;64_V%1/N??-?GR"4**3A4"G&5!)Y.5QDZ;WUM=>)_A?+%<QR*\%T
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M12W<:L/J"<UIQEFB0N-K$ D>AKSF[NH;/X[S230S2JWAA05A@:4G_23V4$T
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MSNTG:;SGV,JS>;Q\F<GI^OM4NK^#O$>H7'BM([G3&@UNU$44TYD:6WQ'M\H
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M!+MN+5V;!:1I%;!"\JQ''?':KVB:=XON(1:>*;O2Y+6.-HRUB)-]UE2N9-P
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M(R>7*@VB1&"MD$=5('(SF@#''Q$O[S1O#M_8Z;;K)J.I_P!F7<$\K9AE&_<
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M_5KN6[BE=7,JF1@S(PZ  YY&21V'4 &IJWB/Q&/&*^'](M-,+3:4][#-=.^
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M I>/:1NR ,@D=* -!?$.H:CKHT.SB@L[V&PCO+PW"F80LYPL0"LNX\,2V<8
MZYXP;KXB:G#X7O;Q-.M1J>FZHFFWL+.VS)=5#Q]R"'!&2,>];$GA>_T_Q7#X
M@TBXBGF>R6RO8+R0IYX4Y60.JG#CG/RX(/:L_4_ =[<^'+^TMY[7^T-2U--2
MNIGW!%*NK!% !) "*N3CN>^* +#>(/$\?C)_#KP:29+BQ-Y:SJ9-L(5PK*XS
ME_O#!&W/M6=+\0-9@\&SZFVGV4E_9:N=+ND5V$;,)1'N0'GG<.">*Z"70]3D
M\?6OB'_1!!%ISV;0^:VXEG5RP.W'!7'Z\=*XKQ3H.HZ#X"U=+B2U,E]XABOH
MFC+,$,MPAVL"!G'J.OM0!T:^+M9T;Q='I/B:UL([2\M9KFSN+)G.WRAN='W=
M2%YR /ISPVW\8ZW<-HE[;Z6]U8:E(BRP1V,ZR6D<@RLAE/R.!QNP!UX)'-:D
M_AN?7-=M]2UM+9([2UFMH+>WD9P3, LCLQ5?X1M QW)SZ9WAGPYXNT2*VT:Y
MUFPGT.S($$JQ.+MXU/RQL<[0. "1DD<<9R #.G\;>*#HOB?4H++2570;V:*1
M':1O.CC56(&,8;!/S'CH,=ZUM2\;+!K%AIRW5EIIOK!;JVFU!&,<[L<>4&#*
M%(X)ZD[A@55'@W6#X>\7Z:9;'?KUS/-&XD?$(E0)@_+S@+GMG/:K=[X:U._T
MI-*OK32-0T\Z?';M!<.X\N9=P,BG8>H*^A!'!H LZAK.MVSVD;QV-@CV/FS7
M=S^\0W/ $"('5B>ISD\# KF-1\5ZQKGA7P1JUC+!8C5M3MXKB(QE^<L<9W#Y
M<Q\CJ>.1SG5LO!FM:1J^DW%GJMM<PVFDIILAO8V9D(.3+& >K< @D< <G%5+
M7P#K5KX)\/Z0+^P>]T34([N%C&XCD5"WRMWR0YY [8]Z -T:_?0_$"/0;N*S
M^S_V0UZ;E-P<LLBJ1@_=7DG&3VYK*F\;:I_PA?\ PFEM;6LFD@F4V95A.;</
MMWA]VW=@;MNWIQGO6HWA[49?'=OKL\EG);+I;:?*@+*SEG#EP,$ 9&-N?QK*
MM/ ^J6OA"Y\&"[MGT21GCBNBS?:([=FW&,IMVEL$J&W#J#MXQ0!:D\3ZW?>,
M)-$TF'31"^EQZA;W4Y=N&<J-RC&>G08Z]>,'6\%Z_/XF\+6VI74$<%RSR13)
M&24#QNR$KGG!*Y_&JD'AR^M/'3ZW;BT%D-+33HH/,8, CEP<[2,<XQ^/M6/:
MZ9XG\'^#[>RT^?2Y+Q=0DE*.';[0DCNYC08!#98#/0 $G&* /0JXL^*=6U+2
M=9UC1(K-[739YHD@G5B]UY7WR'# )DA@ORMT!/7CM*XFR\)ZOHD>N:=I5Q9M
MIFJ32SQM.6$EF\H^<!0")%SR!E?3GK0!6E\<:KJ5_P"'8= M+%H-<L)KF&2[
M=\QLBJ<.%[ MCC.<=NM=O8&\.GVYU 0"]\M?/$!)C#X^;;GG&>F:Y.+P9<:=
MKOA>;36MQIVAVDMILE=O,D#JH+<+@$;,^^3TKM* /+-,G\2VVK>.)?#MMITS
M1:J9'2\9\RXAC^1 O0GU)QDCCO6M!X\N[L>$M3CAMHM#UTB&1Y%8R6\Y!VID
M$ AF!4''4>]7;;P[KFEZGX@DTZXL6@UB?[0)IBZR6KE A^0 B0?*"/F6J/B/
M2O#^E_#T^#1>1I<)9JMC!YJBX>4']VZKG))D Y'&<T =1IE_=WVJ:HK>3]AM
MIA!"RH0SN%!?)S@@$[>!U!]*I^+_ !*OABSL9Y7C@@N;M;>6[FC9X[8%6(9@
M"#@E0O4 %LGI6GHFF_V3HUK9-(99(TS+*>LLA.YW/NS%C^-1:U:ZA=);+9+9
MRQ"0_:K>[R$GB*D;<@'!R0>AZ>] '/:GXHU;3-*TV^SIMU'=ZM#9B2 ,4EAE
M8*LB$.<'D\<C^MB[\6RZ7XLU;3[Y8?[/L=(_M3S8U(D"AF!4Y.#PI/;K60WP
MYN(/"MQ8:;-:VMS_ &NFK6EO\S6]NRLI$0X!V_*3P!RQP*N-X.U74_$M]J.L
MW5B;74-'_LVXM[='RN6<G:Q]FZD<\\"@#0L=4\37,NBW9L+.73M03?<)$2LE
MD"NY"6+8D]#A1S7#Z=KNL^&O#7BW6;"WL9+.R\0WLEQ'.6WRKYH#!,8"D ]3
MG/H._7>&-"\6Z5;VNEZGJVGW&F6 "0201NMQ.J\(LA)PH'&<9)QCUSG2^!M8
MF\%^)M"::Q$NLWT]TLH=]L0E<,01MY(QCWSVQR >A(P=%8=&&17+KKVIZSJ6
MM6FA?8D&E.(&>ZC9Q/-M#%1M9=@&5&[GDGCCGH[594M(EG""54 8(Q*Y]B0*
MYBW\.ZIH?B;5]2T9[.6UU8K--;W3LAAG VEU*JVX,,94XY'!H YN3Q?J?B6Y
M\#7FES16,.H74Z7%M-$9"LT<<@*L0RY4$' X['VJ:&76H?B%XZ?1UL3<K;6#
ML]V&*9$4G&U2#SZYX]ZOGP#<Z=8^&4T>\MS<Z-=2W$CW2';.9582'"G(.7)
MS[9J_9^'M6M/$OB352UE(NK0011KYC*4,2,H+?*>NXGCIC'/6@"K:>.VU+2O
M#KV\/DWFL6C73?N)+A8%0*&^1/F;YG '(XR<\8-"]\<^(]/\.7-Y/HD:W-MJ
M4=F'FCDACN8G=562-6Y&=W()XQU--A\ Z[I^@^&FTO4K*#7-!C>!'D5FM[F)
M\;E<8##H#QG&/RTM<\->(]>\-+:7=[I[:@]W#<.4#I!$L3A@B#DG)'+'!Y]
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MEO9E@MT(),CGH!@?SXK0KS#Q1/K-Y'X%OK][,0W.N6DIMXHF#0LRN5&\L=V
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M,(W:17*[B K8(&0V!TS0!Z!17GFG:SJ5CXS\<7>I7\,NG:3% YB6W(81"%Y
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M "/N"-L +X^4,< GW->>MX!U5OAQ=>%#>V?F3W+3_:=K8 ,_G8V_7CK7H=%
M'+WGAZ_OO&>F:Y(]H(+6TEM9(,L2_F;=Q!QVV],<^U9OAWPCXE\/JFC1Z_;R
M>'(7S"# WVM8\Y$6_=M [;L$XZ8XQW5% 'G%]\/M<N=(UO2X]9LOL][J0U"*
M22V9I=WF*^QSNP0-N!@9QCH!BMZTT#5;;QI=Z_)/9S">PCM/+ 9#E"S;N^ 2
MQXYP.YKJ:* .)T'PKK6@^'-/TE;C3KN*W:<7$4JL([E)7+XZ':02><-D=N:U
M_"/AN/PMI$UE&4"2W4MR(HLB.#>V?+3/\(_#/)P,XK?HH YC6/#^JW/B_3M=
MTV_MH_L]M):R074+2* [ ETPPP_R@>XXK/T'PGKOA_18-.34+"\@CNIWDAFA
M95GBD9FVL><-ELYQCC&#G-=O10!S_A'PU'X7TZ[MHO+1;F\DNA!#GRH-^/W:
M9_A&/0<D\#I3/$OAZ]U;4]#U+3KN"WNM+N'D N(BZ.KH488!!S@Y'-='10!R
M5KX;U2U\0>)=3\^TD&L0PQHAW QF-"@)..<[B<#&.GO6.GP_UBRT/PX=,U:V
MMM;T&-H(IFB+0W,38W(Z]1G Z$XQ^7=WVH6VFPK+=2;0[B-%52S.QZ*JC))Z
M\#T-5=+\0:;K-A->V,LDL<$K0S+Y+B2.1?O(R$;@1D<8[T .T6UU.WM6?5[R
M*YOI3E_(C,<,8[*BDDX[Y)))/I@"AXL\*Q^);>S>.Z:RU+3YQ<V5XBAC$X]5
M/WE/0CO5_1]?TOQ! \^E77VF%&*-(J,%W#J,D 9'I6E0!AV\'B2YB$&I3Z?
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MX<:\LQ)J=W+<"<!L1B1]Y&WN0>!SW]N>LM_$>E7%[#9+<M'>39\JWN(7AE<
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MW#EX 5*B9BQ'/=2>#^E-A\)ZG=Z7H^D:U>6MQ9:7-%*)8E8277E?ZL.IX7D
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MRNIXTD(8)(! W4=5R,COCKSTKUBJ=UI.G7UQ%<7>GVMQ-%_JY)85=D^A(R*
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M_EQF,#&[Y<@D]^:?<^!SJ6L^)+C4;J*6QUNTCM7@2(J\80,%8-D@GYL].PH
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MF"VPCM)I?-8C(4;%//MUI;?Q7HMQJ4>F_:G@O903%!=V\EN\F.NT2*N[\,T
M8NJ^#-6UWPCJ&DZIX@26\OU1)+E;/"1HK;@J1AA@YSDDG.?8 :FOZWHVD:9'
M8^)+R M?Q/"(A&P^T\8957DY.X#&>X%;[,%4LQ 4#))[52TZ^T_7=.M-3LGC
MN;:5?,@EV_AD9Z'J* ,SP1H)\-^$;#3Y#(9UC#3&1MS;R.A/?:,*/912^*O#
ML_B.+38X;Z.T^Q7\5]EX#)O:,Y"_>7 ]:NZAK^GZ=>1V4LDDM[(A=+:WB:60
MJ.-Q50<+GC)P,]Z73-=T_5Y9X;69A<6Y GMYHVBECSTRC '!['H>QH Q=?\
M"-WXBM=4TZ]U"VETV_=&5)+4M):X15/EMNQDE2P.."QZ]*ZE4V0A$.-JX4MS
M^?K574]6LM'MTFO92HDD$4:(C.\CGHJJH)8\'@#L3VJM8>(].U'4FTZ(SQWR
M1&9K>>W>)@F0-WS 9&3U&>_H: .7D^'EY+X*U/PXVM0XO[UKMK@61RFZ42E0
MOF<\C&<]*V[GPY>W7B_2]?;48!]AMY(# +4_O/,V[CNW\?=&.#^-=$&#9VD'
M!P<'O2T >3>.?#\_AWX;^+7GU*&;^U-2BO1M@\ORW::$$#+G( 0?K7<#0;J]
MUJQU?4;RWFFL(I%LUA@*(KR !I&RQ).!@ $8!/)SQN3VT%RH6>".4#D"1 V/
MSK.T;7=.U6XO[*P$BMILH@F5X3&%8KG ! .,'TH P;/P'+#X$U3PO<ZL)$OC
M.RW$-N8VC\UBQXWG(R?4<<4ZT\&ZHOB#2=8O==BGELK1[.6**Q$:2QL5/ W'
M:?EYZY[!:[!W$<;.P8A1D[5+'\ .367H7B72/$L5S)I-WYXM9C!.K1O&T<@Z
MJ5< C\OY4 <]H'@;4] /]FV_B-V\.)*9(;$VP\U%+;O*\W/W,^V<'&16G8^&
MKS3?$NM:I:ZH@@U-DE:V>VW%)5C"9W;AE< '& <]_6]J_B;2-"N["TU&[,5S
MJ$ACM8DB>1I6&,@!0?4<GUK5!W $9P>>1B@#@$^&LL7@O2-&CULQ:CHTYN+#
M48K?:4;+'#(6(8'<01D9XJ]J7@W5-:\.S6FI>(#)J<DL,J7,=J%AC,3[U7RM
MW()ZY.3QV %=E67:>(+"^UZ^T6$S?;+%$DG#Q,B@/G;@D?-T/(X]Z ,.'P9?
M/K]_JM]K8F_M#3A97,45J(QQNP4)8D#YSP<G/?'%%CX+N5TC2-&U/48;K3-*
M:)HHXK8QO-Y7^K\PER, @$@ 9('09!["D9@JEF("@9))X H Y8>#C-KWB*]O
M;R.>SUNV2UFM1 5*(JLHP^XY)#G/'I4/AOPGKFC?9[._\42:AI5G@6T!M5CD
M('W!)("2P7CH!G SQQ772.(HVD8,0H)(52Q_ #D_05A6_C#3+OPJWB.UCO)[
M$,RA8K9FE8K(8SA/O=0?PH /"JZVEO?+K-^+\"Z;[+<?9A 6BP#C:.P.X ]\
M9Z8)CUSP]?:Q_:-LU[:/IU];B%K6YM3)Y38(+J=XYY'&.J@YKHZ0L 0"0">@
MSUH Y"3P7<V>J:+?Z)JJVTFG:=_9C_:;?S_-@^4@\,N'!4'/(]JIQ_#J9?#=
M[I3ZTSO+JIU2"<VP_=R>;Y@# $;AD#.-OX5U]GJ<5[?7UI'%<(]FZH[2PE4<
ME0V4)X8<]JNT <M-;VNF:U9Z[XFU:S6Z"FQL@%\F)&?YFQN8DNVP<YZ#'J3S
MF@^$#X@^' M)KB:QN#JD^H6-U$,M$WGNT<@'<$'/N&KTF6&*=-DT22)G.UU!
M&?QI] ')KX1OM4T.^T_Q5K)U0W=N;?,%N+=8U/.X*"<OD Y/' P!SF3PYX=U
MS3/LZ:QXC.IPVB[;9%M1"3QM#2-DER 2.PYR<G&.HHH YWPAX;N/"VF/IK:B
M+NT261[9?("-&KNSD,<G<<L>>..U&I>&[B[\7:?X@M-1%K);V\EK-&T D\R-
MF5OE.1M;*]<'Z5>TCQ!8:Y/J$-D9B]A/]GG$L31X? . & /0CG%:E '&0>"+
MK3[/5]*T[54AT?4Y))#"]N6EM_,'[P1MN P<DC*G:3WKJ[&R@TW3[:QM8Q';
MVT2Q1(/X548 _(58HH \[_X5OJ2Z/%I:>)%%M:ZH-1M"UD&<,)3)B1M_S\D\
MC;[YZ5N6GA:^L]?UW51JL,C:K##%L>T/[ORU*@DAQNSN)/ ]L5U%% 'G\/PX
MNK+2?#BV.M)%JV@!TMKLVN8Y8GX9)(]_(([AACM6UH/AF^TKQ+K.M7FJ173Z
MH(?,BCMO+5#&FT$$L3CD\?3FNFK+L/$%AJ6MZEI-N9OM>G",W >)D WY*X)
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M:ZKQ#X@L/#&BSZMJ1F%K"!O,432$9.!P!QSW.!6BD<:,SHBJSG+$#!8^_K0
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M3R?FVG&[IQ]W/-7H_!MU;?VW;6FL^5IVL7,ES<(;;,R-( '$<FX  @<94D4
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M< N PPOSMZGIS5ZZ\"QZCJ?B*?4+Q9K77+:.VFMTAV&,1A@I5MQY^8GIU H
MPO$=OJB:[X#GO]2^TF74P98A$JHDAA<_NR!G;U&&+'ISUS8G\0>*=:T^^U'P
MW;3O+;WLD%M;D6_D3+%(4;S&9@X)VL<C&..#U-I? NKS)H27WBAKA=&N5F@9
M;%5=U"%0')8Y.#][ [Y!/(?'X$O[#6KZ?1_$UU8:5J$[7%U8+;HY\QOOF.0\
MQ[O8'';M@ K2ZCXLU/QKJ>AV>J6FG)#86]W&6M!*T;,S H?FPWW<%L_0=ZL_
M%W_DE.O_ /7!?_0UK4LO#,MEXRNM>6^C,4]K':?91 1M1"2N&W=?F.>*D\8>
M'9/%?AJ[T07HM(KH!9)/)\QL!@>/F&.GO0!Q-T9_%WCGP_HM]"NE#1/*U6/>
M^^2]P!@1D# 4$?-SGVXS75RZM?Q_$V'1!<9L)])DNMA1=R2+(B @XZ88\'/-
M+K7@]M9T_2RVH?9M8TQUDM=1@AP4(X8%"3E6'!&<&C4?"VH7FN:;K=OK,=KJ
M5K;O:SNMIN2:)V#$!2_RD%00<GZ4 <7XDUB^UCX-^-#?RK+):7UQ9HX0+E(Y
ME5<@<9KK]4UJ_N/$\N@Z<+M#;V27,LUJL+2;G9E4?O3MP-A)X).1R.]&3X<R
M/X1USP^=<D:/5KR2Z>62W4M&'?>0 ",G@<GWX%7-;\&WVH:Q9Z[IFO-I>M06
M_P!FFGCMA)%<19SM:-F[')!SQGZ4 :OA2XUVXT"%O$EHEMJ:LR2!&4JX!^5_
ME) R,9&>N:VJIZ78OI]BL,UU+=SDEYKB4 -(YZG X [ #H !5R@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "F2RI#$TDAPBC)-/HH S-&UG3?$VEKJ&GOY]HTCHK/&5R58J>&&>H-
M5H/%.CR3QP1NP@EG:UBN/*(@DF&045NA.01Z$@@$GBN4\%RSV_PFU6:UR+B.
M34FBV]=PEE(_6L'5P+;]F;3Y;8XGCMK*:%EZB7SHSD>^2: /0[CQ9H^G^(#H
M9@O/[1,/G^5!92/F+.W?E01C/%6]+\3:1J][/8VMT1?0#=+:SQ/#,H]=C@''
MOC%<P^?^%^09Z_\ ",MG_P ":I_$5?LWCOP#>V8VZB^I&W)7[SV[ >8#Z@ _
MADT >E5EV_B'3;KQ!<:'#.7O[>$32IL8!5)VCYB,'GTST-4]/\:Z!JNL?V59
MWDLE[EAL:UF097.?F90O8]ZRH/\ DMEY_P!B_#_Z/>@#M:I:AJ2Z?)9HUK=S
M_:K@0 V\1<1D@G<^/NKQR?<5=KE/&.K:EI6I>&197*QP7NK1VEQ&8@Q=&5FZ
MGI]WMZ]: .KHKSYKWQ+J7BGQ?I<&NK9PZ=%;26SQVB,R%XW;'S9!&0,YR>!C
M'-&B^+]0U^V\(V?G"UNM6L'O+JXC120(PH(0," 69L\@X /KD '5^(_$-EX7
MT:75=06<VT14-Y,1<Y) 'L.2.216M7FGCV#6K;X4>)(=:NX+MEN$^RS1KM=H
M/.CV^8  -XY!VC'2N@EU74(_BA#HHNV-A/I$EUY11<I(LJJ"#C/0G@YH ZNL
MD>(;(^*O^$=VS_;OLAO,F(B/RPP7ACU.6'3/>N*M?&FJIH;0RW*RZA=>)9-%
MMKAXU'EH)"-Y4  D*I^IQVJS#:7=M\:HTDU&6ZW>'93&\\:;D/GIG[@4$9YZ
M9Z\T =KI>I+JMJ\Z6MW;!97BV741C8[6(W '^$XR#W%6FBC=MS1JQ]2,UY;-
MXL\2)\+;W6DU&/\ M&VU5K;S#;KAD^TB( #H.#UP37166H:U8?$D:)?:F+ZS
MN],>\13 L?D2)(JD+CDJ0W\1)XZT =G2,VU2V"<#. ,FO+!XK\0WGA?2-7MK
M_P K4KW5_L,^FF!&$*F1E* 8W;D50Q)/J3QC'IDZW T]UCG5;@1X$I3(W8Z[
M<_I0!2B\069\-_V[=I<6%H(C+(MY$8Y(U']Y>N?;OD4FFZ_%J.IW6G-97UI=
M6R+(RW,0 =&SAE925/0C&<CTKS;7]1U'Q#^SW%J][?2?:IHXGG\M$592;A1R
M-O 'MCWS7J]O;RPVGDR7DT\F#^_D5 _/LJA>/I0!3U[7['P[HMWJMYYKV]J,
MRB",R,/P'3J.N!6C#*L\$<JYVNH89ZX(S7C82Z;X.^-YKG4KJZ/VF^CQ-L.2
MLA&[(4'.!ZX] *ZNVU#6M*\8^&K"XU,75CJ]G/FW\A4%NT2(P*,/F.02#N)_
MP .\I"0 22 !U)KSBUU[Q9K^BV&OZ%!<OY\^_P"R2?9A;/;[R"NXMY@?:,Y_
MO9XQQ6C\7[N[LOA7KLUD664Q)&S+U"-(JO\ ^.DT ;4'BS3[Q&GL8;V\M$)!
MNK>V9XCC@[2.7'N@85HZ7JEGK6G1:A82^;:R[MCX(W88J3@\]0:9HD%O:Z#I
M]O:!1;1VT:Q!>FT*,?I6%K.I'2]>T#PSII%HVK37,SS*H8QJ@,C[0P(W,S#J
M" ,\=* .LHKSR\\1:WI>I^)]!>]$T]II1U6PO9(5W!/F!1PH"DAEX.!QUS53
M^VO%$%EX)U+^VHY?[;\FWN+=[1/+5I("XD!&&W C)&0#GH* /3J*\^@UC7[.
M]\9Z3+JPNI=,LXKNSNI;= R[T<E650%(!3CCOSFJ UWQ1#H_@C5SK4<AUI[>
MVN+9[1/+!EA+>9QAMP(S@$ ],"@#T]CM4G!.!GBJ6F:I'J>E6^H>1<6B3#B*
M\C\J13G #*>A)_F*YC1+_6U\5^(O#UUJOVO[/;07-K<RVZ*T?F;P5(0 , 5R
M._KFN5N=6U;7_AYX$U.ZU2XCN;W6+5;@P*BK)F5L$C:1\I4$#IZ@T >O%U#A
M"PWD$A<\D#&3^H_.EK@(X+U?C,8'UF^DBBT))MK"+!S/M88"8 ;8"2,'/<#
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M!)&T @$#/< <NOB'QJ_PW/C%-;MWDL99VELC9H$N8XYV4AFZJ=HXV^G.2<T
M>OT5P<OB'5O$&H:M9Z-]NMS8PP^6ULMN<RRQ"4&3S3]W#*,*!T;GIBO)JWC
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M>2/7]13J\_B-Q%\7M9DEU2\^S6^DPS^3B,J%WOE0-N<?+G@Y]^E5)O$^NO\
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MP/)!&2<?UJC!X'MXK2TTMKMGT2SNOM4%D8^0P8NJ,^?F16.0, \ $D"NK!R
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MJ\*2KC 8#@'TJR_A'_B>Z)J<>H./[*CF1$DCWF8RX\QG;(^8XSQCG/TKIJ*
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M\VI@I'N C&QXV!7"DRD#@#A6Q7<5RW@[1[6VGUC7+>UDMCK-W]H6.12K",#
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M>([>R47L]E<V-VEW;SPA25D4$<A@01ACQ5.Q\''3]2UJ_BUF]DGU5$$WFJA
M=4V;P HYQVZ#TZ4 ><I:W<?P.\-2IJ]\BR7%D/*7RPJ@S 8X3)'.<$GD#K7=
M76I:C<^);KP[:W&HL+&RBF>>W-NLLCR,X!.\!< (/NCDGGWE'@&#_A!8/"QU
M*Y\BU:-K:Y"*)(RCAU)XVGD>G3\Z-6\#-?ZE9ZO9:]J&GZS;P_9Y+V((QN(\
M[MKH5VGDDCC ].!@ Q+[4?&=E9>$;?4+^&TU&\U$V5X88T=9$VNROTX;"@X'
M&?;BN\T>SO+#3(K:_P!1?4;E"VZZDC6-G!8D95>. 0/?%8M[X,2[71L:I=*^
MEW7VQ9'57>>;!!9R1T.X\#&.V !CJ* ..\4W^KV_C/PKI]AJ1MK;49+F.=/)
M1\[(68$$C.0?PR!D'H<6VF\27$_C#23XGNE_L5UDMKH6\/G/OA$@5_DVE0?1
M03ZCI77ZOX<_M77]'U;[;)"^E/(\4:H"KEUV-NSS]T\8Q5:'PD8+[Q!=KJ4I
MDUL*)@8EQ'M38"G_  'USSS0!CVFOZEJNA^$KV74%MEU"S,MU!:INN;B78I
MC7:0%!+%CQCY><9KFM2UR^U;X7Z?>:FSS7-OXAB@9O+&]Q'=;1E4XW8 Z=37
M7VWP^6Q_L)[/6[VWGTBV:S25$C)E@;'RL&4C/RCD"HE^&T*:,=+36;W[,-2_
MM%-ZHQ5Q)Y@7..1N.23DGVH T/"^H3^)K.378=5D%I=96WLU1,6V/E.\E=WF
M9Y(S@'CGJ>/7Q/XC?X5:9K"ZKC49-5^S2RF!")$-VT>",8 VXZ8/O7:Z=X4_
MLG7]2U2QU"2%=1P\]H(U\DR@8,@'4,>IYY[^M9J_#N)/"=OX=&K7/V:"\%XL
MOEIO+"3S<'C&-QSTH -.OM8T_P"(MYH=SJ4NI6TNDC4(UECC0QR"4H54JH^4
M\=<D8ZUST'B77]0T+PS>VNK2)JVI:E]EOK)8HV\A-S>9A"N5\L*.3VZYR*["
M]T22SU^X\6B>XNKJ'3&M19PQK^]4'S,+WWEAQSCM7 Z%)=1Z?"FA^-=0DU(1
MY_LZ?24=_,ZE)&,:N!N)!8L/7- 'L:@A0"<D#D^M<#XPU;5K)O$4EMJSHUEI
MPN;.VL8U=HF579GN-ZD!20 !GD!L FN^7=M&[&['..F:Y+4/ D5]J>N7*:O?
M6UOK=N(;VVB"%7(C\L,&*DK\O8'F@#?T2\DU'0-.OI@HEN;6*9PO0%E!./SK
MF_%]]K%OXK\+V&FZF;2#49IX9P(4?A868,"P/(QQVR!D$<'I-$TS^QM%L]-^
MU2W0MHEB$LH 9@HP.  .@'_U^M4=9\.?VOK>CZG]ND@?2Y'EA1$4AV92K;L]
MMI(XQ0!ST-YK<^JWOAL:CJ%S/I=I"9+VU2WCDEDEWD,P?C "J  .3G/:GQWO
MB9+30+?7;Z&TO)(YEO(+ ![BYD7 0QC:0%Q\S'@ D<@5HZ[X*_M/7XM=TS6;
MW1]36+R)9K8(RS1YR Z,""1V/_UJ)O!$?]IZ9J-EJ]_:7=E#) \PV2-<)(P9
M]V]2-Q89R!^'3 !S=CXL\02_#_3]5FBO;LQ:C-;ZC)9Q(;@0(TBAPH&W.0F[
M:.F<>HLCQCYNEZ,FE:Y_: UK5?LL5\T:AX(L;F4KM $@ VC([@D&M?2_ [Z)
M9Q0:?KEZGDWLEW'YJHZX?=F-A@%ERY.<YR!R,43_  _TVXTR>!YY8[R74?[4
M%Y" C177&'0<@#  P<Y&<Y)S0!5DU/5M+\<-X<?4);BUO].DNK2XDC0R6\B'
M#+P &4@@C(R#QTKG=.\0>)?^$4\&>)+C7))GU&_M[6ZM?L\:Q2)*Y4GA=V\<
M'((''3U[V'PZ_P!NFU.ZOC<:F]K]DCG\H*L,><G:GJ3@DDGH.@XK)3X?1Q^&
M-&T)-5N!;Z3=1W,$GEKO9HVW(&[$9)Z 9XH Q_&GB'6M(LO$E]::J6GT]HWM
MK>TC5XX8\+D7!9?O,2WRALX*D 5+J=K>ZC\7Q%9:B^G._AL%IXHU=P/M'1=V
M0#G')!X_,7[_ .'$-]!K]K_;5_%8ZU(9Y[:-4VK,0 7!*[L?*ORYQQ6E)X3D
M76;36+75[A-1AL_L4DDT22+-'NW_ #* ,-NYRN!VQ0!P.NZOJM_\)_%NGZS.
MES>Z3J,=D;I$">>HEB96*C@-AN0*[/4=7O\ 4/%E_H5DU[$EE9Q3,]F81(SR
ME\$^;QA0@Z#DGGWFU'P+9W_A2[T!;RXB2]G^T7=R K2S2;PY8Y& 25'08 &!
MBFZWX*;5-7M=;LM:N]*UB&'[/)=6J*1/'G.UT8$'!R1Z?E@ T_"S:X?#ULOB
M-81JJ;EF:$C:^"=K<< D8R!WS6S533;!--L8[9999BN2\TS;GD8G)9CZD^F
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MMNEWZ ":3*_O8F P5&&X4XP>G&: /0JK:A>QZ;IMU?3*[16T33.L:[F(4$D
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M$$9Y(R<\$XQFI]-O;[Q9?^)88=4N; :9=FPM?)VY5U0$RN"#NRS=#Q@=,\T
M=M17-^ ?$%UXG\%Z?JM[&L=W('CF"#"ET=D)'L2N?QKI* "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M *Q?$OAN'Q);6:/=W-G/9727=M<6Y7='(H(!PP((P2,$5M52U:]GT[2Y[NVL
M)[^:, K;0$!Y.0.,D#OG\* ,&/P%8B;7GGU'4;A=<MQ!>))(N#B/R]XPHPV.
MWW1V XPLW@>*?2M(M'UG4OM&E3K-;7F8_,!"%-N-FS&TX^[[\G.>J'(!QCVH
MH Y"_P# ,$^OOK.G:UJNE7-Q&D=Y]DE7%R%&%+;@?FQQNZU>_P"$2MD\0Z?J
M\-Y=1-86K6D, VE/+;&<DJ6))4<YKH:R/$^OQ^&/#UWK,UK/<PVJ;W2#;NQZ
M_,1Q^OM0!E+X$MQHVO:6=5OC#K<TL]RQ$6Y6D #[?DX! '7-8%W8M:_$_P .
M65OJ<R&STB6#[0R*VYMR;4?C&2!G P> :](AD$T,<@& ZAL?44^@#F;OP/IU
M]X<U/2)Y[ECJ<WVBZNPRB5Y05*MTP,;% &,8%;]E;O:6D<$ES-=.H^::;&]S
MW)V@ ?0 "IZ* ,W7]$M?$>@WNCWID6WNXS&[1G##W'N#BLRY\'17#Z7=G5+W
M^UM-W"+4#L+NK##(Z[0I4C'  QC(YR3TM% &;I6BP:5+>7 DDGO+V02W-Q)C
M=(0H51@  *   !^I))T3R" <'UID4T4X8Q2*X5BC%3G# X(^H-#SQ),D+.HE
M<%D3/+ 8SCZ9'YT 8FB>%+;18-5MS=7%Y!J=S+<SQW(3&^3[X&U1P?0UGZ!X
M!@\/S1I%K6JW.FV[;[73KB8-%">H[;F [ G X/4 UJ^'?$<7B(:F8[2>V;3[
MY[*1)]NXN@4D_*2,?-ZU=N;V>#5+&TCL)YH;CS/,N4*[+?: 1NR<_-T& : .
M<L?A[::;J-P]GJNI0Z7<3FXDTE9%^SER<GMN"D]5!P>AXXJ\WA*.'6;_ %/3
M-1NM/?40OVR.$(RR,!@2*&4[7QQD<'N,UT54]6U%=)TNYU"2":>.WC:61(=N
M[:H))&X@'@>M %4^&]+'A9O#:6X333;&U\L'.$(QU/?G.?7FHW\+:7-X1'AF
M>$RZ=]G%NRL?F8 ?>S_>R-V?7FLJV^(NER6VE7=W9:AI]EJI5;.[NHT\IV89
M4$H[;">V[%=?0!S&A>#WT5?WOB#5=1:.,QVK7DBM]G'3( 4!FQQN;/''&3F]
MX7\.P^%=!@T>VN[BYMX"WEM<;=P#,6(RH&>2:37O$<6@7.DPS6D\HU*]2R22
M,KMC=LXW9.>@/0'I5U+Z=M:DL3I\ZP) LHO"5\MF)(*#G.1C/3O0!=KFV\'Q
M3^1%>:C=75G!??;XH)53Y) Y=1N"@[0QX'7@#)'%=)10!R%[X M[N?7?+U?4
M+>SUI6-U:1% AD*;"X)7<. #C."1SD<4E]\/K6Y32);75]2LM1TJ#[-!?PLG
MFM%C&QQMVL/PZUV%% ',7O@JWO;?2HFU*_5M.O%OEE+(SS3@$;I"RG/#$8&!
MC & !BY9>&X[+Q1J&O+>W,D]]''%+"X3RPJ9VXPN>-Q[]ZVZSM.U1KK28+V^
MLY=,>1]AM[EEWHQ?8H."1\QQCGN* -&N*O\ X;6-_!KMJ=6U.*QUB4W$]K&Z
M!%F.,NIV[OX1P3CVZ8VXO$<4GC&;PV;2>.>.R%[YS%=CH7V#;@D]<]0.E;5
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M5X(S$MW:[<O&3G8ZL"KKGGD9'8BN@HH S;32I(Y!-?WTU_,H(0RHBHF>#A5
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M+C1KFYGM[>XVB1H-NX@$'&6! Y [5%=^'9KFYFF76+M!<6BVD\9CC9'4%OG
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MY-7*S]"U:/7=!L-6AC:*.\@2=4?JH89 ./K6A0 4444 %%%% !1110 4444
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M)[LEHMVYP VT[. 0 /PJRWA&V?4M#OFU"^,VC1O';#,>&#*%;?\ )SD #C%
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M(6.'9&7RPV[NF2=W.<_IQ4_ASP[;^&=->PM;FYGA:9YLW!4D,[%FQM4<9)-
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M94$;-"JX(*Y SQNQMYZ\'%'2+J"?P5XYTA;::XO+K5-2AAMUA8^:SL57!QC
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MXR% )' /4XYJ[H.AB_\ $WC'5)X'&E:PL%ND<J%/.5(BKOM/.#NP#WQGH0:
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M+0O&5KJ/A*PUN]22V-TL86,POEY'^ZD8QE_PS6[J<3SZ3>0QKNDD@=5'J2I
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M01"0L5"LY7"DD< \\C.,US>E3X^)MCJJ0:W/9S:')";NZM)%S)YJ,1M*@1@
M'@!0>V2><>&WNT^"FCV)TZ_%Y%J:.]O]CE\Q5%V9"2NW.-O.: /3]4URP@EG
ML&-U),D/FSK9QLSPQG(#$KT)P< ?,<' .*Q_A9>7%_\ #71KJ[N9;F>5'+S3
M.69SYC<DGDUF:5?S>'?'_B1=3L[YX-7DAN;"ZAM9)5D C"F,[0=K#'0XJ_\
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M0Z-8R0V\][)#+*TZ1W<I<P!L?NU)Y"CL"3C)YHU+7;73;ZUL"DUQ?72N\-M
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MSKBW:&.9=^T+E"RY7A0,9(XZ5NV%C'I]N8D>25W8O+-*07D<]6;  STZ
M  "L#0O%VG7$^F:,PNTNKBS$D$LT#+'<;5&_8Y^]C.?IR,U8O?&>E:>5DN/M
M"V)N/LIOA'F!9=VW:6ZXW?+NQMSQF@#H:*YB[\>Z/::K>:9Y>H37=FT2S1PV
M4CE1(2 W3E1CENG(ZYK1\0>(].\,6"7NIO*D#2+$&2)F 9B ,D#"C)ZDB@#6
MHK MO%MC=Q$Q6NH"<SO;QVTMJT<LI4!BRJ^/EP1\QP.<=>*JO\0M BTE]0EE
MN(XX[O[#-&UNV^&;(&UQC"]1R3@]B: .IHKF1XZTK^TKC33;ZDM]%$)H[=K*
M027"$XW1KC)&>N<8[U:L/%FDZAH(UB*65;?S3 8Y(B)5E#;/+*==^[C% &Y1
M6':>+-,N+O4+.=I;&ZL(A/<0W:A"L1_Y: @E2O!Y!X[XKE-?UW[=XP\$M;+J
M=M%<WCD>9NCBN(O*8@E<XSG!PP#<]* /1Z*YG2M5T0:QXFN(;J[22U>-M0^U
MEUCAQ'D; _W1M&20,'KS5JW\5V$NLV^E3175I=74336HN8M@N%7EMON 02IP
MP':@#;;<5.T@-C@D9 -8?ACPZ_AR"_B-[]J%W>2WA)BV%7D.6 Y/&>G\S4EC
MXFL]0FLU@@NO)O0S6MR8QY<R@9R"#D9 R,@$]JN:EJMKI,,4ER[;II5AAC1=
MSRR'HJCN>"?8 DX )H NT5A1>+=,?^TDF%S;W.FH)+JUDA)E1",A@JYWJ?5<
MBFZ!XPTWQ)*BZ?%>F.2V6Z2>2V9(F4G& Y&"P/4#W]#0!OT5S.J^.]'TG5+G
M398]0FO;> 7#PV]G([%"VW<N!R.N2...N>*72-2T:;Q+XB:VN+T7=NMN;Y;K
M>D40V-M**^ OR@DD#!X- '2T5S)\=Z.G]G/(E\L.I@FQE6T>07/&?E" L..1
MN R.:YK3O$D/ASQ5XX-XVIW=O;7,#JD:R7)AC\@,QYSM4$D]?ITH ]+HKDM4
M\;1VNM^&[.RM+B[M]86299XDR&C6(N-O()))0^PS6G+XFLX[AXUANI8H[I+.
M2>*,,B3,5 4\YX+KDXP,]: -JBJ]_?VNF6$]]>S+#;0(7DD;HH%9MOXGLIM7
M@TN>*YLKRYC:6VCNH]GGJOWMI!(R,@E3A@.U &U17FT$Q\:>*O$FEWO]KVL=
MK);Q6<MNS0M:GR]Y;(. Q8]P<C KK-8\5:9X?OK#3[TW37-X'$ CMWD\PHI8
MC(&"QQT'.2.* -VBL&/Q99SV4$]M9ZA/++!]H-JMN1-''DC+*V,<@@#J<' .
M#2V_B[2+W3-/OK"9KQ=1W?9(H5_>2[?O<'&-N.2V #P>HH W:*P+;QEHUUI<
MU^LTBB&[-C)"T9\U;@$+Y6T=6R1TSUSTJ2W\464]W>6+0W,.H6D0GDLY4 D,
M9Z.N"589XR"<'@\T ;=86@>'9=(DEN+W5[S5KQQY:SW04&./.=JA0!UZGJ<#
ML !&OC32&TG2-55IVLM6F2"VE$1^^YPH8=1DYYJK?_$+1+&ZU*T\O4;BYT[;
M]IAM[&1V0,"V[&/N@#.[IR,$T =76!H/AR71=4UB]:^%Q_:DXN)$\G9L<*%X
M.X\8 Z_G44GCO0$M](N$N99H=7_X\Y(H'97(!)&0.&X(V_>SQBH$^(.DR)?J
MEIJC7=BP%Q9"R<SH"-P<K_=(Y!S^M '5T5D1^)=-N-+L+^TD>Z34%#6D<*Y>
M7C=P#C&!U)P!WK,E^(6@0:3/J$\ES$EM="SN(FMVWP2D@!7 X4<CDG![&@#J
MJ*P+/Q?IU]JEWIL4%\EY;V_VD0S6S1M/%G&Z,-C(SQVY-1>"/$[^+/#T>IO9
MS6WF/)M#K@;1(ZJ <\D!1GWH Z2BN67Q2UUXZO/#7V"Z6*"T21IU7&XNQ&00
M<A0%//7/T!/,^"/&5GH_A:)-5FU"8-J=Q;O>/&\J1$SLJ"20YQG@=3U&<9%
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M#'?:$EG#=-;N(O,_>9P^,<;@>M5/"4D%W!I6E:AX&N+?6M/:,33W%D!!&T>
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M^\C"+& P!)SDD '&WW%=S10!XW/8ZA)\%-=TU=+U+[=/?S-%;_8I=[AKG>I
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M$R2\C;G=B269CW8DDD^IK.\2>'!XB73E:]DMA8WD=ZGEH&W21G*@Y[<\C]:
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M341YHH+4DE6!.5SC( 7KP#D8S3V\<:5Y.ASQ1W4MOK95;.9(QL+$9"L21M.
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M]ASDBJ1^)>C#1Y-4%GJIM[>5HKW%H<V;*VUA+SQCN!DXYQ52&SN+7XDZ-/\
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M:"WF .Y]IPI&<'GMFO/]/COW\8^%-7.C:XR+97$5Y/=189)&$?5,_(HPV
M?X0: .B_X69HAL!J MM3^PK=&UFN3:D);MOV9<D\#=]2,C(&16S'XDM9/%4G
MATP7*7J6_P!IW.@$;19V[E.>>3CIFO-KC3=2D^#_ (ATQ=*U W]QJ4LD-O\
M97W.K7(D!''3;S75>/;:\$&D>)]$C!U73[A$BBF!3SXIB(VB8'D<LIYZ%: .
MJTW5(]4%RT4,R+;SO;EI  &93AMN"<@'(^H/I5&^\46MG-?1Q6MY>FP4->&U
M16\C(W8.6!8[>=JY."..1F_I&GKI6DVUBKF0Q( \AZR.>6<^Y8DGW-<?H0O/
M"GB+Q/;WUA>W%KJ-Z=0L[BVMWF$F]0&B.T'805 &[ ([T 7-5\<I%?>&4TJT
MEU"TUF1F6XA*X*"-FPH8@[L@=<8 /?BL:RUM="^(/C:22#4[U%AL95MX0T[(
M/+D+D G"CVR/:J-EX9U3POH_@!9+"XNCIEW/)=QVJ^8T/G))@8[A2X!/3BMO
M35N8?&_C6\FT^^2"[M;18'^S.1(T<;API YP6 ]^V: .DC\3:?<Z=IUY9>;=
M_P!I1^9:0PJ-\BXW$_,0% !&22 "0.I K+E^(VA0:1+J$XO(Q;W@L;B%H#YD
M$V0,/@X Y'.<'L37#66E:II7AWP3JEQX;N=3BTRTFLM1TYK;=-&'*D.B,/F(
M*#IV/UQK^)+4WW@QGTKPI/I_VC4;69;:*R"3R+'(K-)(J?=X!P#SQ[X !WVC
MZPFLP3RI97UJ(9FA*WEN8F; !W*#U4YX-:--1Q)&KJ& 89&Y2I_$'D4Z@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBN(^+J9^&&LR!Y$>-$92CE>?,4<X/(P3P: .WHK+O]:2SN
MOL=O9W-]>"'SV@MM@94S@$EV4#)! &<G!]#C.M?'.CW^E:9?69FG.IS&"VME
M0"4R+G>I!("[0K$DG''?(R =+17+)X^TH1ZR]S!>VO\ 8RDWOFQ ^60 0 5)
M!)!!&.HJY8^)+?4=9ET.>SO+*]-H+L1S;?GA)VY5D8X(/!&0: -VBN)^%>1X
M/E4L[;=1O%!=BQP)G Y/)K9U_P 567AVZTZWN[>\E>_F\F'R(MXWX) //4X.
M * -VBN>M_%BW=M$8-&U4WKQ-,UA)&D<\2!BH+AG"C<5.WGGJ. <4D^(VB36
M>CW4$=]-'JLK00[+<DI(N=R.,\,-I&!G\N: .NHKD8_'UO,^I6T>A:TVHZ<5
M\^Q$*&0(R[E<'?L((Z?-D^E:-OXKT^^TG3+^Q6:Z_M--]K!&H$C@#+9W$ ;>
MY)QGCJ1D W:*YFV\<Z3-I]]<RK<6\UC<BSGLY4!F$S$!$ 4D,6)&""0?7@U@
MPWLDOQJB,ME?6C#097:*=PX;]\F"H5F7MC P<CZ$@'HE%<CX<US0(/#=Q>Z;
M;W<%LVH2Q>3-EI9+AI-I"@L>KG@9 '? S4Y\<Z9;W&J6VHPW6GW6FVXNI8;@
M(2\)X#H49@1GCKP: .GHK-L-6:\OI[.73[NTEBB27,^PJZL6 VE&89&TY'T]
M:76M:M=!L%N[L2,'FC@CCB&6DD=@JJ,D#))[D#WH T:Q-<\-1:]<VKW&I:C!
M;PAEEM+:?9%<JV,K(,9(X[$=3ZU77QC;&/6@VG7ZW6C!6N[4*C2;&7>K+A]K
M J">#GC&,U8M_$]M=Z/I.IV]K=2Q:H4%NB[-_P RE@2-V.%!)P20 : -H
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MM;VD\ CEN-JAF=,MC9@YW$CTZX%,_P"$UL?L6KRM97PNM(&Z]L=B>=&NW<&
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M5+CS"<[L'Y?>M.\L]2T3QQJM^?"KZ]IFL>5+&\2QF6VE6,(582$?*0H.<\4
M=/#XQT_4(=,.E)+?RZE;FY@BCPI6(8!=RQ&T D+ZY. .#CA="O=-M/!_C^XU
M;2KR335UBX%S9 @R*GEQ[@3N[>H;Z5LSV&M:'XXT[Q&FCFZLY],.GW5KI^TM
M:-YAD4J"1N7G:2,=,X[5F-I&NS>#_']HVAW<<^K7D\MFC-&3('1%'1N,;3G/
M'H30!W3ZY;6D5C9V=K)/<36HFBMD=5*1  99F( Y( YR3]"11T_QYINJV=G)
M9PSM=75S+:+:2%4>.6,$NK$G' '8G.1BN>U;3M5L-;T7Q#%X=;6+7^S%L+VQ
MVH9H"&W*ZAC@\D@X-7]5TF+6=(L[;5_"CQ64\SS".SP)[!@JA)"4/WC\V=N<
M9 Y - '7Z7J!U*Q^TFTGM6$DD;0S[=X*.5/0D8.W((/0BN7T#QM+=IXFO-8L
MWL;'2KV6(S.Z,L:1QQDJ=IR6)+-P".< FM+P1::Q8^'S;:Q<W%RZ7$HMI+H@
MS&WW?N_,(_BQ^/3/-<A<>$]8U/1/'?AQ[.2W.IZA+>VEXSKY3AA&47@[LY0@
M\8 _*@#L%\70Q:CIMIJ&GW=@-3^6SEGV%7?&?+;:QVN1R >O3.>*A\<^(KWP
MWI-I/8V;7$EQ>P6Q8,H$8=P#PQ&202!VSR2*R[^TU+QA'X9ANM+N;";3]0AO
M[YI@ J-$K?(A!._<Q&".,9S@X%:'Q#TV^U+PY!_9]J]U/;7]M=&",@,ZQR*S
M!<D#. >] &)>W;V?Q?M+Q-,O);F;P_+_ *)&5+EO/3@DML7@==P'OG%='I_C
M73]0T"'5%@N8WEN6LQ9N%$OVA6*F/KMR-I.<XP,YK-\G49?BA9:Q)I5U%9#1
MI+9W.UMDC2JX4X)YPO.,C/&37+_\(UKY\-RW$&CF2]L?$D^JQV-T5 NX'+C:
M#D@$JYZ]"* /0=&\4VVK:OJ&D/;S6FHV(1Y8)2K;D;[KJRD@CMZ@]12ZIXEC
ML)KJ"VLI[^>TB$UPD#(NQ3D@?,PRQ ) 'XXR,P>&)IKPR79\-?V'#L"".9(Q
M-(V>3A"<*.V>3GH,<\YJEEJ6A^/-2U/_ (1@Z_I>K)"081&TMM+&FS!#D?*P
M .<\4 ;)^(6E>1H-W';W<FGZTZQ6]Z @BC<]%DRP*G((Z'D&H/$GC6YL?A_J
M?B'3M+N,PJRP-,T85AG:)AACE,\CNPQQ@YIVKZ--XCTBW\,W^F"TL;J)I;N2
MW52D.&W)$A_OYP2V,?*<8+#&+=V7B?7/A-K'A^_TV7^UH83;P2MM5;U$8;''
M/RD@<@XYH [&3Q"81:V[6%P=1N(VE6T+QA@BD NS;MH&64=<\].#C'_X65I1
MTRUO197Y\W4AI4L2QJSV]QNP5<!CGU^7=G\:RM=M]8&NZ1XJC\,2ZA;?8VLK
MS3)?+,\2E@RR*"2I.000#T(]\/UZQU/4-)T.2V\.M:E-=MKUK2$1AX8(R-S2
M8.W=WP">"!V- &Y!XS$\NLVAT:^@U'38%N/LD[1@S1MG:RL&*X^4YR<CT[58
M\$:W>>(?">GZG>VKPS7$*R$DKM?<,Y7:20.W.#60=.U"X^(NM7@L9TL[K1DM
M(KAP ID#.2.N1PPYQ5_X=P:A9>"=,T[4=.FLKBR@6W=960[V7@D;2?E]"?R]
M0"G'KNFV=_XSO--T6Y_M2P6)[X.ZK]H(B)0@EB  @]C[$UL>#M6N]<\):7J-
M];/#/<6D,KEMF)"R*Q90I. 23P<'VKGK72=2F\0>/RUC-%%JL,26<LF LA6
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M?1]7UCQQ8W=FC11:B8(",@P*8QPA'W>3GBK-E<R:%\2/&+6&DSZA,;.QD:*
MHF<+)N8LQ R?3J3VZD 'IM%<U#XUTZ[T?2+^U!=M6C,EM#(ZQG &6+$G "Y
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M*H>+X]-B^+?AO[=;H]M/971F3R3()",;2R@')&>N.* /3:*Y31/[%^U:I?\
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M+@, W[L'[^%()Y'MDU>N?$<*ZM::391&ZOKJV:\5-VQ5A! W,3TR6   /X4
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MNQ9WJQV:7V4V"9L[5VYW8."-V,4 >HT5RFM>.K/2(]1F2V:Z@TQL7C),BLI
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M#4KFYBOC( ^\3.H7*G=M"@+M/RX KJM6\3&PU"ZLK;3I[N:TL_MLY#!%$>2
M%)ZN=K<=..2* -^BN3F\>V:CPZUOIU_<QZ]&9+5HU3C$9?:06R&Q@?W1U)P*
M8GCL?V1KEW)HE\EWHDFV\L0T;2!=H<.I#;6&TYZYX- '7T5B+XCCEM-$N(+5
MYAJQ7RE1U^12ADW$YZ!1SCN0.]5/B'%')\//$#.@9HK">2,D<HZH2&'H0>]
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M$Z+##/\ -O,JL<D_=P<-C' Y)KNZ* /+=)T7Q!#;_#M9]#GC.C!UO,31'8#
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M_=Z GCJ1TK$MO#_BJ4^%KV[\/JVJ:??&34+F:]C9Y\HZ[PPS^[RP.WJ.@7%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@:7RD(&<#.22> ._MT!JK9^)X_[&TJ>[M[A;Z_55AM0B^9,^S<Q49P%QDY)
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M,P#@@5TEXL&I>"?$L^E>$I],:\TZ2WC5K 17-S(48 %%YVC( +>IZ 9/H=%
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MQNUO.V\EO-;E K,,$;1P>H/>L:;PKK>E6UMXAMK":XE3Q)/K$NFH09!!*"F
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %8FNZ]<Z9(EOIVBW>K7C)YC0P.B"-.F6=R ,G.!R3@^E;=5-0OH=.MC/(K.
M[$)'$@R\KGHBCU/Y#DG !- %#POXFM/%>D&_M8IX&CE>WN+>X7;)!*OWD8>H
MX_.MJL/POHC:)ITXG*&]O;J2^N]A^7S9#D@>P "@]]N:W* "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ KG]=\(6/B&^@N[N\U.&6!"D?V2]> *#
MU/RD<GU]JZ"B@#)T+P]9^'X9H[66[F:9P[RW=P\\AP, ;F).!Z>Y]:UJ** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
0H **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>a97-arwrxclawbackpolicyf003.jpg
<TEXT>
begin 644 a97-arwrxclawbackpolicyf003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ME8RSZ-<6?V=K@Q-Y8?RL##XP&!Z'UJY\/=4U?P!XGO?!.KQ7=WHD<I^Q:C'
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MF,OITCOM.S[W&T#+%"#GML-,^&/BS4Y?B!XC\-:]K$]_):EC92RD*K1HQ#'
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MX9OKZVA:>\6,K:PJ,F24CY1COZGV!J*#QAI=^L8TOS[Z>0@"**%P5SW<L $
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"TOE%]F[:,D9P<=/2@"[16;X?U0ZYX<TS5C"(3>VL=P8PV[9O4-C/&<9K2H
M**Y4>++Z7Q=>^'+?2(Y+BT@2Y:1KO:C(QP,?(3GVK9TN^O+M[J*]T\V<L#@#
M$HD612 =RG [Y'3M0!HT444 %%%% !14%W>6]C"LMS*L:-(D0+=V=@JC\20/
MQJ&6XOUUBW@CL4>P>)VENC, T;@C:H3&3GGG/&* +M%%% !16)JNO7.F:]I5
M@-)GGM+YS&]ZDB[87P2H*]3G!Y[5GV?C&X>QU&[U'1+C3X]-N3%=J\BN4CVA
MA*-O!&U@2.H'/- '5T4B.LB*Z,&5AD,#D$>M+0 4444 %%%% !1110 4444
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MF:1K,3R;)!O.3@#+#/3K79:9H5_IWBJ#4$U**&PN+<Q26(GDF$SCYED4N>&
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MK>33O^/.6V<QO ,8(4CL1P0<@^E7=.TNTTJ*5+5&#32&6:1V+/*YP"S,>2<
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M,,4CR^>8%UG]P)>N_P K&W=GD<<=L5)>>'+J\U.]OSX3E@EOH_+NUMM;,27
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M=L*PR5"KCKC)(K+C%[I.K>%/!NHZTVHVMQ<79FF^93((T#1P,Q8E@-_.3R%
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M>.!Q: YCLU+B-Y(P/NY!+?5<T >A52TJ;49[+?JEK#;7/F./+AE\Q=@8[3G
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M9=OG/OR 1C;CGJ*ZWQGXANO#.AKJ-M:PW'^D0PN))"NT2.J9  .?O=,BNBH
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M3'+$C++(5P'=4R, YY8<9'UK5F?4AJ]JD,-LVG-&YN)&D(D5^-@5<8(/.>:
M,D^!/#K:)<:,;.8Z?<RF:: WDQ#N6W$D[\\GGKUIVM^"/#_B&6TFU*S>2XM%
MV0W"7$B2A?0NK!B/J3U-=#10!#9VEO86<5I:0I#;PJ$CC08"@5-110 4444
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M6./J>30!YWXFS8_&KPCJ%V=MC-:SV<4C?=2<@D#/8L" /6O1)YHH(B\S*J9
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M$<KQRA#U7>I#$'T)Q3;SPUHU]86UC<6$;6EJP>"%241&'0@*1R.Q[5J$A>I
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M>CQ?;3'I\2F^_P"/K&?W_P#O^OXTR?PMH5SHR:/-I5L^G1D-';LGRQD="O\
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M%V"^@9B2![=*CG\-:+=7TE[-IT#W$NWS6V\2[?N[QT?';(.* /.K*T.L>*_
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M#!%Y,OAK#(JC8R^> ..F,8'T%9&DV$&F:EK?PZ-K&(+N[%W;_(,&RDRT@/\
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M#&GW*6-S>$;9KA9 %)/W3B/(4^AXZT>)=-T/3-)T@:0P:UB\6VLSN7W)$[2
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MQN[8/$AN(0\HS&N\9<>H]: ,G2_"NE:?!8-)96T][91"*.[>(&10.RL<L!V
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M9D%M<PS&)ML@CD#;&]#CH:J:/)=#3"^HW]I=RK))NFMEV(%#' ZGD#@\]10
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MQQPQ)%$BI&BA511@*!T '84ZBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/C;&L]_->*WAYRC3(@9?](3(^15!'?IW- 'H-%<SX]N=7T_PG=ZEHMR\5S9
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M %%%% !1110 5S7BS1Y;NZT;6K2,R7FCW1F$:_>DA=2DJK[[3D#N5 [UTM%
M'+W'AE=1\2#Q'8ZQ<VHN+,6L\<:*PEC#%A@L"4()(/\ 0UF2^&)]'^'A\&:?
M>S7D]U$UI%+*BCR8GX9CM' 52>O).!W%=W10!7L+*'3=.M;"W7;!;1)#&/15
M  _05DZSX9&JZ[I6KQ:A/9W.GB6,&)5;S(Y -RG<#@_*,$5O44 <FO@MU@\2
MQ?VF2-?+&<^0/W6Y/+.SG^Z.^>>:K7GP^:6#19K#7+G3]6TFV%I#?0Q*?,A
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MJ,R:[---,_D &,RJ%<+STP.,YQ[UUM% %+2+!M+T>ST\S><+6%85DV[2P4
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MU-PD9:/R#F8XV[<-E ,#CS%K:^(W_)-O$G_8.F_] -0^%=.LKK7-7\66UI+
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M0Z?)H7VL0[$^27S0FX';GIV)(KEY?$WB,^ 8]0CU=A>IX@-B97@C/F1?:?+
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M$RPQP<(,[2.IKMM3\*B_\36NO6^J7EC=Q6S6DGD!")82V[:=RG!SW'-9-O\
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MYIE&)&D)&23UXQR: ,9+S6KK5;_PY'J%_--I5I )+NW$$<DLL@8^8P?C  &
M!C.[.>*2QUGQ%<:KH'AC6)H[35)+*:\U&:T*G>J.$14)& 6SN; XQ@8K5USP
M2NIZ_'KNG:Q?:/J8B$$TMKM83Q@Y 96!!(['_P"M2:AX&MKF32KNRU&\LM3T
MS>(KU2LCR!SF02!AAPQ)/;!/&* ,[P#!+;>*O&\,US)<NNHQ?O9  Q'D+C.
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MN@1W4[<Y*CH20/3I0!S&C7>KZ-;_  \D&K2S6>IV\5I-9-$@B1?LVY2IQNW
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXA\/6&L0Q/%%>0K*L;D$J#V.* -*BBHGN(TF$&X&9D:18P1N95P"1^+*/Q%
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M;&_@A:%)8@H)C8@E&212.H'8'CK3Q8KX>TBXCTJ"2XOKB1Y-TARTT[?QR-C
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MVA=UCD8LZC<HW;AG.#@=#6UJ\=_X3BU378-5FN+"#2Y7^P73&0O<("X=7)R
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M"N>^(5Q?:7HUMKEG=7$<6G744U[#$Y FMMP$@(]0#NS[&NOJ&\M(;^RGL[E
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M 2;"YW9&?<D9ZUU]WX#TNZTVWM5N+V">"^.H+>PR 3FX.=SDE2#G)&,8Q@
M 5#)\/-,D&M@ZAJF-:C6.\S<!MV%"DC*G!('X=L"@#(BFU33_%G@W?K-[=1:
MU;3)=PS,/+RL D5D 'RD'ODD]R:9;ZOJ&B7GB?P[?7MS=:BQ2;2))I3F2*8B
M.-1C^Y(<,?0YKIY/"-M)>Z'=OJ%\9=&5EMN8\'<NP[ODYRO';\^:S+#[-XO\
M4V&NMHU[:+I$<T<<E_;F%WD<A<*IZJ%#'/JPQT- '6V=NUI90V[3R3M&@5I9
M3EG/<GW-<7X]BDF\3^"8XIV@=M2E D0 LO[A^1GC/U!^AKNZQM7\.6^LZGIE
M_-=W4,NFRF:!82@7<05).5.>"10!P[^(]2\+VOCV W\]ZNCM;M9RWC;VC\Z-
M2=QQRJL<_2MZVTKQ-!XBL[A-16+2IH7CNXY+YKAV?;E)(@T856R#D#Y<=N*T
ME\&Z:;W7+BYDN+I=;14O()BNQ@J[%QA01A>.OOUJOH'@>V\/[1%K&L7:Q(4M
M4O+D2+:@C'[M=N,XX!.<#CH3D XG2=6UJR^%R^-+K7[ZYNXHIX1!*5\DEK@Q
MK(PVY)7K].,8%==9Z;XDM/$UI=?;8O[(EA>.[@GOWN&>3&4>/,8"G@Y (&.@
MXK0TOP;IFF>%9?#3-/>:9(LBF.Z92=KDLPRH'=B?4=JB\.^";7PZZ%=4U:_2
M%2EM%?7/F);J1C"  =N,G) X&,F@#S/2UUC0_@OI/BO3==O$FL$#_8#M^S2Q
M^<59"N,DG).[.<],<8[F^U.?PU\08)M2U"X_L/5;5Q")9/W=M<H-[#Z,@)&>
MZD"M"P\":?86$&F"\O9](MY1+#I\S(8E(;<H)"AV4-R S$9QG.*J>(/LWB_4
MU\,S:->M%:7D-Q/=7%N5@VI\_P CG[Q;[F!V9O2@#<\,QW0T2.XO9)VGNF:X
M*3.6,*N2RQ\_W5(7Z@U#XON9+;02T6IC3F>>&,RA"[NI< QQ@<EV&5&!G)_&
MMZLCQ'X=M/$VG1V=W+<0&&=+F&>V<+)%*ARK*2",_4&@#BK?5=56Y\>V"76H
M6D=A8PW5D)Y%EE@9HI"?F)?()0'!)QD]*J_:=;@TCP!JJ>(+\W&K-;6MTCE6
MC*R0%BP4C[X*YW'/)YR.*ZP> K$7>J77]I:J9]3M5MKIVG!W@ KNP5QG#,/0
M9X I[^"+-].T.Q_M#4!%HDD<EIAH\[D4JN[Y.<*2* .7GU_4O"=UXYA%]<ZA
M%IMA!>6GVQM[1NX<$9 &5RH..W.*V;73?$R:WIM[#J<:Z;+$Z7PEOFG,Q9?D
MDB!C"JP/.!A2#TK7_P"$0L)-8U74;B:XN#JEN+:ZMY2AB:, @+@*".&/?O53
M0/ EGX>=/(U;5[F&!2MI!=W/F1VN01\BXZ@$@;LX!H X--2UZ+X9KXH?Q#J$
ME[9ZF8U0LHCE3[9Y15P!\V5/L!@8 []I;7TOB3QMXATJ2[N;:UT=+>)$MI3&
MSR2H7,C$<G P #QP<@]I#\/=./A23PV=0U'[!)/]H;YX]^[S/,Z[.F_G_P"M
M5JZ\&6TWB :Y;:EJ%CJ#PK!<R6KH!=(O3S%*D9'J ".U '!^%[G5M.^%?A^>
MSM;S4;6*]NSJ,-D^RYDB\Z8;DP03AMI(4@GITS7H'@S4[/5_#RW5CJ4U_ TT
MH#W (EC^8GRW!YRH(7GT!YSFJVE^!;31=/LK33M4U. 6<LLD;^:KD^8265@R
MD%223C'7GK6QH^C6NBV\\5L79KB=[F>63&Z65SEF. !Z= !Q0!4\7W,EKX<G
M>+5%TUS)&GV@H7;!=0511R78948!.2*Y*UU/5%U?QEIL=SJ%I!;:;#=VBW$B
MRRP.RR9(9B_!V X)./:NS\1^'K3Q-I7V"\DGB594FCFMWVR12(<JRG!&0?:L
MM? EDM_?7QU/56N;ZT%I<.TZG>!N&[&W&<,1C&T=@#S0!R=C?:S::5\/=:DU
MR^N)=5EM[6[@E8>4Z20LV=N/O J#NSG)/;BM>369O"GC75K;5[RZN-/O;(WF
MF!Y"=ICSYL"^K<J1WP<5KGP-9'3-#T\:AJ AT65);3#1Y#(I5=QV<X!(_&J=
MW]F\8^)+*VDT:]CCT*_:X>YN[<QHSHI5!$3]\$D-D<83GJ* .CT*TN[+1+2&
M_N)+B\$8,\CONRYY(!] >!["M&BB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M+'GDJ" 3],L/SKQM[S68?AG?>)#X@U1[_3M4D6$&?Y&0703:ZC[X*G&#P.,
M=^J2PB;XXW+F6ZR-#BFP+F0+N\]AC&[&W 'R].^,F@#OZ**Y7QAJUU9WV@:9
M;,$&J7C0R.9C%\JQL^P. 2I8A1D#/4#&<@ ZJBO--5NO$7@ZQU-Y=2B-M?75
MK#8(]R]S+9>8X21B\B@LO.5SG!XZ5H7\,VE?$;PS86VHZB;2^@O#<PRWDD@=
MD1=K?,3@_.>F!TXXH [NJ4MW=IK%O:)I\CVDD3O)>"10L; C"E>ISD\CTKRZ
MZU?5$^#WB+4%U.]%[8ZE/';W'GMO55N @!.>1MXYS76:A<WD?Q7T>S%]<_8K
MG3+EWM@^$W*R -@=^3R<T =;%<0SO,L4BNT+^7( ?NM@'!]\$?G4M>6^$?#\
ME]X9\66^GZEJ%I>G6+Z*WN%O)3L97^4D%B#R!DGDCO6GX:UJ3Q3:^'[=9KJ"
MZLE>354$[ADDCS'Y3G.3NDRPSV0^M '?T4A(52Q(  R2>U>56VJ:A;WOA"Y@
MU2^ODOM0>WN;YY&6"\5ED;]W"6(505&" O3C(.: /5J*\OOIM0L=1\6>'&U/
M4/MES%%=Z)+]J?>/,_=A 2?NK+C/^RV3TK4\(ZNWB6ST.;[1<Q-8VC/J*&X?
M/GY,>Q\GYAN25N?[J]C0!WE%>4VVJ:A;WWA"Y@U2^ODOM0>WN;UY&6"\5ED;
M]W"6(505&" O3C(.:N:1%?WFO^*;B[U_5V@T74UEA@BF"AU$2N8V&,%#G&T8
M_.@#KO%GB,>%=#?5'LI;J-)(XV6-E7;O<("<]LL.@-;E>->(&FUWX+1>)+N_
MNGN[N:VN)$6=O) :Y0",1YVX7CG&<KDGDU[+0 45YAXUU"]AMO%MW8ZK?37%
MA"CPBUE:&+3RJ!BK_-B5F.3C:V 0#@8K6U'5;IO$^@PZE<2VVBW>G22-+%*T
M0:Z^4@.ZD%1M+$<@$GN0* .YHKR"^F\2V7PKO=2GUG5(KO\ M%$M7E8*S6YN
M B$C 8;D;)YR>#70:@E[H_B32O#\.J7UXNK/<W;M>WQC;,:IB*-T7*K\Q; Q
MTZXR* ._HKS:\N?$7A73397NI0S+?ZQ!;VC-=N\MM!*3E7E9-W52H8@D9]JG
MU#3O$>D6WB.Y_M8V]@^E2S6T OI+F>&=!DLCR+D(1C(R<'&,9H ]"HKREFU6
MWL?A_J,>OZI]HU8P6MV'FW(RO;EB0A!7<"N0Q!.>N:?<:YJ/A*;Q]##?75Y%
MIMG;75I]ME,S1/(KAOF/)7(!Q]: /4Z*XJVTC7H]=TV^@U58M-EB>.[CDU&2
MY-P67*/$'0*C \_+@$=JXR"\UF+X867B=O$&J27]MJGE@-/^[D0WAC*NO1P5
M/?I@8Q0![']HA^U"V\Q?/V>9Y>>=N<9^F:EK@+&PB/QJUB0RW65TNVE ^TR;
M<EY!C&[&WC[O3VYKM-4O3IVD7M\(S(;:!YM@ZMM4G'Z4 6Z*\JU#5-3M/A38
M^.;;4[J355C@O)XS,Q@F#LH>+RL[0 &P" "-HYSG.A]CU#6_B+X@TR3Q!J]I
M9PVMG<11VTP0QLQ<D#C@?+@COW/% 'HM%%>::!K5U#XET[2O$;:G8:PTLK)*
M9VDLM24JV/+YVJ0"K!<#&,=Z .^T^[N[J2\6ZT^2T6&X:.%GD5O/0 8D&.@.
M3P>>*NUY1+J6K)X&^(DPUF^^T:=J-RMM/Y@WHJQH0H..!DGIBKEW%J5KXI\'
M1Q:]J@76H9HKQ6FW*0L'F HI&$;(QD#//KS0!Z+=2RPV<TL,#7$J1LR0JP4R
M,!D*">!GIDU@ZEXJETF'0&O-)G275KJ&U9/-0BVD<$X8@\XP>@P<=17,V=QJ
M-I:?$'2DU:_=-* DL[B6;S)H]UN)-N]LD@-TS4.IW$UWX.^&5S<2O+/+J>FO
M)([99V,+$DD]230!ZA17EWC;4;V"R\6WMAJM]/<Z>D;PFUE:*&P*H&*/\V)6
M8DDC:V 0#CBKFJ+J.K_$'3],&N:E9V=[H<L\B6DHCVN'0!E..#SUY/4=Z /1
M:*BMH3;6L,!EDF,:*ADE.7? QECW)ZFO+?%.K7]GINLZK8:K>W5Q9ZO$BW$4
MC1VUNGF1H;<Q[MLA 8[CM/+<D$8H ]7HKA]7OY?^$ZN;#5KRYLM).EB2S>"9
MH@TNXB0[E()<#9A3^ -<Y+)XHMO!/@V;4=8U*VU6^UBVBN@Q4'8[$;2-H[!3
MM/<D'TH ];HKSYH[RT\50>$HM0O;V'[#)?E[O47AFD+2[0HE1=Q"#.!Q]X9S
M@56%UXBT=]$\-:EJ,%W/>W]PHF6[=',*1[TB>4)N#_,.0 2 .>: /2J*\J\5
M0^)_#O@?Q5,^N/$D9BGT]8;MYI[=68*ZM(ZABI.=IZ]1GBM/4[6_L_B-HVGQ
M:[JGV;5[2Z-TAGR 8]A!C&,1D[B/E X]^: /0J*\IA\1ZEH7AGQ-!_:$\YL=
M>33[>ZNY=[PQ2&($LY!SMWM@D'MUQBMYM(\0V&IW=P-4^S:9/8NAMSJ$ES*L
MZ@D21M*GR\ @CIWQ0!W%1+<0O<R6RR*9HU5W0'E0V<$_7:?RKR;3[O5K?PQX
M U]]<U*:ZO[VUM;F.6<F*2.4,&!3H3P#N.3GOTQO^$K"*/XF>-I!+=$Q3VI4
M-<R,OS09.06P>2<9Z=L4 =_TKGM8\5P:7_8;Q6SW=OK%W%:Q7$;J$7S 2K'N
M1@$\#\14WC*%9_!6MHS2*!8S-F.1D.0A(Y4@]OQKSZ\LA%X ^&J03SHTVI:<
M_F-(9"A,#?=WD@ =AT'I0!ZY17G%O=W>CZYXUTLZ_<16MMI\-W;W=_(9_LCN
ML@9N>2N5!V]/2C1[R]B\>:7IPGU,6%[HTLD@O+AF:5T9 )54L3&2&/&0>>0"
M* /0H;B&X\SR9%?RW,;[3G##J/K1<W$-I;27%Q(L<,:EG=CP *X;X4V4=OH%
M_*LEPS'4[R/$EP[C F;!PQ(SZGJ>YJ3XNVZS> )W9Y5,=U;$>7*R YG13G!&
M>">O?GJ* -ZY\1BV\8V/AYK*7==V\LZ7)9=F$QD =<_,.N/QK<KSS7--#_$W
MPQ8Q7=W#'_9UZ#(LS-*1F/(WMDCZ]1VQ679^(]3TWP]>6!OYIV3Q2=&BNKJ8
M^8L)((W28)S@E=V"1D'M0!ZO45Q<0VEM+<W$J101(7DD<X55 R23Z8KF]#TO
M7--\373W-[&=)N+<&*SDO9+J6.96 +*TB@["#R,G!QZUE?&@71^%.L_9-V<1
M^9MZ^7YB[OPQU]LT ;MCXFN-4LUU#3]#O9]/<;HI6:.-YE[,B,P.#VW;2?2M
M+1M5BUO28-1@BEBCFW829=KKAB,,.QXZ5-ISV\FF6CVA4VS0H82O39@;<>V,
M5RVLZF6\;Z%X:@E:WLKN.ZNIVMW*-*R'[@9<$?,69L$'CZY .RHKSNW35;K7
M/%GA"/5+U8X;:*ZTZ\,[&6V:16^1GSE@&7(W9.,@YJ?PIJ\OB;2_#\)FNHKN
MS5VU11.^X21YC,;\Y.Y\L,]D/K0!WM%>86<GB3Q9X:&NZ7J$5E?"[D=)9=0E
M$,:1RE3%) $V$;%P2><\YJU:6>H:U\0O%-A+XAU:"TLOL$\,=O.$VEE=BO3[
MIQ@C'.>>@H ]%JO?7)L[&>Y6!YS$A?RHR S8'09('ZUYO92^)/%?AF+Q!IFH
M0V5[]J>02RZA*(41)6!B> )LQM&"3SGG-:-K<R^+)_%YGO;NW33;A["VBMYV
MCV;(P3(0I&\LS'[V1A0,=<@'5^&]:3Q'X<L-8CA:!+R$2K&S9*@]B:U*Y/X8
M_P#),O#O_7DE=90 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SWB/P;I
MOB6YM+R>:\L[^SR(+VQG,,R*>J[NX/H1_,UT-<[XB\5'P_J>E61TZ2Z;4YC!
M T<BKAP,X;/08[\T )<>"].N+73(#<7JC3KD7D3^<&=YQG]X[,"6/)Z\<].E
M68O#4$'B"]UN.\NUO+R%89#E"H5<[<#;QC)_/G-26VJWSZG%:7>CS6R2HS+/
MYR.F5Q\IP<@D$D?0UK4 >8>)?"\>BZ;X2T72UU:6UM=;2Y,D432M;IB0LVY4
M( W/GYL]?2NYMM @@FO+LW-S+?7<:Q27DFWS BYVJH"A5 R3@+U.3FM:B@#F
M(_ >CQ^&;/0=UT;:QE$UG+Y@$MLX.0R,!U!)ZYZXZ5::R@\/PW^MNE_JM_Y
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M2X78&('\07CT]0:ZBB@#S'Q!HT6GZMI-F\?BF+3K&P,5OJ6DR2S2EF8;DD"
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M8C&U,?+@Y/H!7IU% '"67A-]<T.[TW4]2UV;29I(I(!?NHN<J=Q).W<%W!"
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M7,UY;7UD2;>]LIO*F3/4;@.A],5%J'@31=3T"+2;G[4PBE%Q'=_:&^TK,/\
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MH/[JLRF11[*PQVJUJ?A;3=3CL.);6?3G\RSN;9@LD)(P<$@@@C@A@0>];5%
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M$N=,DBM/L=NEZBK.06W.2 3@<*%SS][L10!M1Z.D6MIJ:WU^=EH+46K7!:'
M;=O*GDOVW$]*TJP)- 9_&\6NQS7,82U,$JF<F.4?P@1]!@DDGV&.IK?H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHJCJVJP:19"XG#,7D6&*)/O2R,<*B^Y
M)^@Y)X% %ZBF0F4PH9U192/F5&) /H"0,_7 JAJVK+HRPW-T@%@SK'+.#_J2
MQ 5F']W) )[9!Z9( -*BBJ\U];6]Y;6DDJK<7.[RH^[;1EC]!_4>M %BBN?\
M.>(;C6]1UVTN+..V;2[P6P\N4R!QL5MV2!C[W3%=!0 445SLGB9[K7[K1=%L
MTO;FR53>2RS>5# 6Y5-P5BSD<X P!U(H Z*BL6RUB^DUPZ5?Z7]F<6YN%GCF
M\R*0!@I"G .1D9R!C(ZYK:H **** "BBB@ HHKG[+Q#<7/C?4O#\MG''':6L
M5RDRREC('9AR,#;C;[T =!17->*?%%SX<N](@BTZ*Z&IWBV4;-<F/9(P)!/R
M-\O'4<^U7H+_ %E=1MX+W2;:.WFW#S[:\:78P&0&!C7@X//^- &O1110 444
M4 %%!( ))P!65/J=Q=Z''J&@0P7[3%&B$DOEHZ%@"V[!_AR1ZT :M%%% !11
M10 45SZ^(KC_ (6!_P (T]G&L)TUK]+D2DLV)%3:5P,=2>I[5T% !15'6;V;
M3=%O;Z"!)Y+:%Y1$\FP/M&2-V#CIZ5S4OC6ZC\/^$=4&G1,NNSVD,@\X@P&9
M=V0-OS8Y'4=J .SHHJ.X>5+>1X(TDE"DHCOM#'T)P<?D: )**P_!^OOXH\)Z
M?K4EN+=KM"YB#;@F&(QG STJ^LVH_P!MO";2$::+<,MQYOSF7<05V8Z8P<YH
M NT5S_C#Q#<>&='CU""SCN5:YA@</*4VB1P@8<'/)Z<5T% !13)C*L+F%$>4
M#Y5=MH)]"<''Y&L7P;X@?Q3X3L=:DMEMGN@Y,*ON"8=EQG ST]* -VBBB@ H
MK(U/74M=,UBXL5CN[C2T9I83)L&X('VEL'!VD'IW%3>']3;6O#>F:J\0B:]M
M(K@Q@Y"EU#8S[9H T:**1F5$9W8*JC)). !0 M%065Y!J-A;WMJXDM[B-98G
M'\2L,@_D:GH **** "BBB@ HHK)U_7$T.WM"8_,GO;N*SMT+;09'/&3S@  D
M\=J -:BLO1[O5IDNUUBPAM'@F*Q2Q3!XYX\ AQW7K@@^E9>L>+OL4/AZZL+>
M*[LM8OH;59S*5*"3)#A=OS# /<=J .HHHHH **YSQIXGE\(Z*-46P6\C\Y(F
M3S_+8%V"@CY3GDBHH?%[V_BNT\.:SIWV&\O8FDLY8IO.AFVC+*&PI# <X(_&
M@#J***Y^3Q#<1^/8/#C6<8@FL'O%N1*2Q*NJ[2N./O=<F@#H**I:?-J,K7@O
M[6&W5+AEMC'+O\R+ VNW VD\\>U7: "BBB@ HJE=3:BFI6,=M:0RV<A?[7,\
MNUH@%^3:N/FR>#R,5=H ***Y_P 6>(;CPY;Z=-#9QW"75_!9N6E*&/S'"[@,
M'=],B@#H**** "BN>L?$5S=>,]6T"2RBC6RMHKB.99BQE#E@,C:-OW?>M72I
M=0GTN"75+6*UO67][#%+YBH<]FP,\8H N4444 %%%% !115(3:C_ &V83:0_
MV9]G#"Y\WYS+NQLV8Z;><YH NT5RWB7Q@-(\*/KVFP0W\"7"P,3*4 S,(21A
M3NPWT^M=30 4444 %%5[N^MK$P"XE5#/*L,0/5W/0#\ 3] :;J=S+9:7=74$
M*32PQ-(L;R; V!G&[!Q^5 %JBN<TK7M3UKPGHNL6.GP-+?"&2:%YRHBC;[Y!
MQ\Q Z#C-='0 4452,VH_VVL(M(3IIMRS7'F_.)=P 39CIC)SF@"[15>ROK;4
M8&GM)5EB61XBR]-R,58?@P(_"IV940N[!549))P * %HK+FU*ZNM(L[_ $."
M&]6Y:)U\V4QCR6()<'!Y"G(%:E !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !7"^+Y';XD> ;1L_97N+R9AV,B0?)^/S-7=5B^(]$;5HK*XMRB:AIURMU
M:L_"E@"&1B.0K*64^F0><4 8ES=1:K\3IO#^HG=:0Z4ES!;,Q"S.TC*[D?Q;
M0% ],DTFJZ5#8?"77=*?4I]12VT^[0W%RVY^%8A2>^W@?A6MK/A31O%8L[G5
MM/D6YM\F)UF:*6+/5=\; X_$BFZSX?2[\.CPS80"UT^=/)G=3@1PY^=1W+,,
MC/N23G@@$_@ZYGO/!.@W-T2;B;3X'D)ZEC&I)-<UXBTVTN?B]X7>6+<TEC>;
MCO(SM\O;T/;)_.N]BBC@A2&) D<:A451PH'  K.U3P[I6LWEE=W]L9)[(L8'
M61T*A@ P.TC<IP,J<@^E 'FESI4%]!\3KF66Y62TN))K?RIWC$<BVRL'^4C)
M! ZYZ>YSJ6^J76O:UX?TB\G@9+GP]'?>7<ABMQ,Q ?@$;BH&0.VXG'&1UR^#
M]$6/5(Q;S[-5R;T?;)OWV1@Y^?CCCC''%0:CX#\.:KI=AI]W8LT.G@"T<7$@
MDA  &%DW;L8 XSV'I0!)X/TNZT729M-N]6_M)H+EPCD',*'#+$222=H/4GH1
MZ5S'PLW6NJ>-M/O#C4DUV6XD#?>:*0 QM]#@XKO--TRSTBPBL;" 0V\>=J@D
MG).223R23R2>35'4_"VDZKJ$>HS0RQ:A&NQ;NUG>"7;_ '2R$%E]CD4 0>,]
M8ET3PIJU]9!6U"WL99H5(R1@#+8] 2"?I7(ZRC:1X>\*>(-%GF:^ENK..9_-
M9C?1S8#"3)^8G.03TQQBO0;32;.SAEC2-Y/.&V5[B1IGD'HS.22.3QTY-4-/
M\(Z-I;6_V:WE$5JY>VADN)'C@8Y&41B0O4XP.,G&,T <G<71\'^/-4MW#S6^
MN68ETV.5RR_:5.QH%R> Q=&XXZ^E2W,+VWBK1?"#7$36HTJ28"ZW,MW,'4,3
MAAN(&YL'(Y)QP,=O>:797]U97-U;I+-8RF:W<]4<J5)_)C^A["J7B'PIHWBJ
M""+5[/SC;OOAD5VCDB;U5E(([=^PH \^UO1[[1=&T?3Y/$%S<LOBBWB1H99$
M,$,C!A"V6._:"""V< BM.:QAL/&EEX2MYL:?+8S7L<-]-),LTID 89+9;:N2
M%)(Y)QD9'42^"] FTVRT]K.06UE,+B!4N94(E!R'+!@6;/.22:D\0>$M%\46
M]O%JUH9C;-O@E61DDC/JKJ0PZ#//.* .'D2^T"Y\/^%+S6WO+._U>9)95+*T
M40C\R.U+%BQ!+*,YR5XZ5J:#I]MIWQ@U^*U3RXGTJU<1@G:AWR#"CL.,X'&2
M?6NAN?!F@7>@1:)-IZFQB<2QJ)&#I(#G>'SNWY)^;.>33]-\):/I6JMJEM#.
MU^\(A>XFNI97=1G&XNQSUZF@#F?B@CRWG@M(Y6A=O$$ $B@$J=K\@$$?F*Z2
MWT^[L=6>?4-8DO+6>%;>.*=$4JY8DXV*,Y'Y;:EUKPQI/B":UEU*&:5[202P
M%+J6+RW'1AL8<^_6B+PQID5]#>'[;+/ &\II[^>4(6!4D!W(!P2,XSS0!Y_%
M!'I7CYM!NKRXD\.W]Z)K>9W<[+M5R;0R$_=Y# ?5>?FK8N_,\2^-_$&@SS0"
M.SM8/L\$N_(5U):5-K#Y@Q W=1@8QDYZ.Z\':%>Z)%H]Q:RR6,4WGHANI=PD
MW%MV_=N)R2>O6HM:\#>'_$%Q:W.HV<CW-JGEQW"7$D<NS^Z75@S#ZD]3ZT <
MOIKW"^)]"\):WJ_]J01Z7/*9B"@O9TFV;7&3N*(&X).3DGD"F:]IP\/VOARU
MM-5N[DQ^*+>(M)*=T4<A+>02.J %>#GM77:MX+\/ZW865E>:>HBL<?9#"[1/
M!QCY64@CH._:I+GPCH=UH":))98L8W$B*DC*ZN#N#AP=V[/.[.3SF@#E;J))
M_'7C"PD9VM'T2&1H/,.S<3)DXSQG SZUS\MLME\ M%N[22XMYBMBS-%.Z[BT
ML:D$ X(()X/%>DV/A#1-.U*34+>T;[7+ +>2629Y#(@S][<3N/)Y.3[U7'@+
MPV-"&BBQE_L\.L@A^US<%3E1G?G /(7. >@H QO%#IX8\<Z)XEFF=-,NMVGW
MH>0^7$[#,4NW. <@J3Z$55U>YGTRQT%7D^R+K^K9NFE9@$5D=XX3@@KR$4@$
M9(;U-=UJ.D6.K::=/OX!<6I*$QR$MDJP9<GJ>0*9K6B:;XBTN73=6M$NK27&
MZ-\CD="".0?<4 8WAO0KG0M=U/=JD3VEVJ2Q:=&C!;8CAF7<QP&/;@9''>L#
MQP]]8ZI?ZA=:;)JV@&T6*5K.;%SIC ,6D1<C.0P)((/RC/ KLM!\-Z7X;M7M
M],@:,.07>25I7?'3+,2<#L,X%-O?#.F7]U<W,RW >[C$5P([F1%E0 @*RA@.
MA/;/)H XZ6VLO$'Q5L 999+&X\+F0&.1H_-0SH1DC!P<@XR/?TJAH]XO_"!V
MUC>:C?$1^()+&WBC?=)=JDS;8"S$?*5&"2?NK^%>@CPQI*ZRFK);R1WL=M]D
M1X[B156'KL"AMH&0#TZBJ+^ O#CZ6VG&RE^S&Z^V@?:YMR3Y)\Q7W;E;)/((
MZT <OI3W,,GQ'TZ15AM[:)'AM8Y3)'#OMMS!"0, GG  &<U4N/\ DG/PO_["
M&E?^BZ[B+P3X?@EU"6*Q9)-0B$-TRW$@,B@8Y.[J1U8<GG).:=)X-T*33=-T
M]K:?[+ILB2V<8NYAY3)]T@[\G';.<4 .\8W4-GX/U2:XU*;38A 5-W N9(R>
M 5']XD@#W-<MHHN+'XH&Q6V-A:3Z#YYM!-ORZS!0[@?*'P2#@G/J:[G5-*L=
M:TJ?3-1MUN+.X39)&Q/S#ZCG/?/6LRS\%:!8:E;:C#9N;RWA,*3RW$DC%"<X
M8LQW8(&-V<8&,8H \GL])-C\$=*\5:?>WT.M6*(]NRW+[&S/M\KR\[2K9QC&
M23SFNVN;R?3?BEJ\T;3RK'X:%V+9IF9?,$K_ '03A<[0.,5T=CX-T33O*2VM
MI!;PR^=#;-<2/#$^<[EC+%1@G(XX/(Q5M?#^FKX@?71#)_:3P_9VE,\A!CSG
M;LW;<9)/3K0!Y9JUO;ZI\(=%\0S2O<:E<W5G<3W.\Y=WG7<AY^ZI. O0;1CI
M7030S^+_ !)XKTB6ZABDLFCAMT??O@1HE82IM88)<M\W7@#.*VF^&WA9H)K;
M[!,+2683FU6[F6%9 P;<L8;:IR.P'ITJQJ_@/PYKFH07]]8,;N&,1":*>2)F
M0?PL58;A]<T :6@1SP:!90W6H#49XHA')=A=OG%>-V,GKCUKQJRTC[)\#[+Q
M18WU]!K-@&EMG2Y?9_Q\,/+\O.TALXQC))ZGI7ND,,5O!'!#&L<4:A$1!@*H
M&  .PK$L_!NAV'EK;VLBV\<OGQ6K7$C01R9SN6,MM'/(XP#R,&@#F=7NT\%^
M.;?7;YI5TG5K5H9@SLRVUT@+C:"<#>H9<#J0/6NM\,Z=)IVB1+< K=3EKBX4
ML6V.Y+%!G^%<[1[**R]0CO\ Q%K0TF[T)H=*L[J*Y-[-(C+/LPZA%'(._&<]
M@1WKJZ /*M$TVTMK+XE211;7CN[I%.XG -NI/?GDGFJ^G6@TK3_ACJ=K<70N
M;S[/:SEIW*O$UL3LV9V@ J,8';/7FO0)/!^ARW>I7+6CB74EVW6RXD42?+M)
MP& 4D<$C!([\TA\&Z&;;2[<VT_E:6RM9+]LF_<D# Q\_.!QSGCB@#B[>SO?&
M^G:[,-6AL=1M=3GA6Y^?S;$1280##@ % "1C!R2<UV7B:%+WX?ZHERRSAM-D
M9F4%0Y$9.<=AGG%17O@#PSJ&NMK-QIH-Y)CS2LKJDV.GF("%?\0<]ZZ*:&.X
M@D@F0/%(I1T8<,I&"#0!Y98S"P\.?#O287CM[75K=&N&E9BDL@MU*H<$'#$]
M <$J!T)!A\8:+>^'O OBP+KDA0M;W-K:VSR1_8PSA6 .\DHV#\IX&#Q7<2>
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ME 3.5.T$_+D #C%=@=+LFU==5,"_;E@-L)N_EE@Q7\P#5<>']-7Q"=>$,O\
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M+O9PBLY8(&;DA0=H)["M>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ\ ^&?$^BNQU<RV3&=6)>]\TJKI(?X\[B<'H1QC% 'JDDB0Q/+*ZI&@+,S'
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MR@B) RS'<3\V2!G_ !-9FG?Z-J_@&]L1(MO>S3(UY-)_I-_&T+-NF &,$@,
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M&>[C)5<':MR0!]!772V4>A_%'P^; S!M1T^[^UAIF;SS&(V4MDXR"3S[XZ4
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M0_\ B1SVHADU"6[#"*,G#QA&RY;9PIZ D>E=/9S-<V-O.P :2-7('0$C-3T
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MKH]O% 4AU+3[K[<@D;%UL*%?,Y^;DGKUZ'BNRE\+Z-/H2:)+8J^F)@+:L[%
M!R!C/08&!T&*D?P_IDFI6VHO;LUY;)LAF:9RR*>H!ST/?U[T >7FUB@^&7Q'
MT^'?'::?J%VMI$CD"%1&C!5P?N@L3CIS6MJ>FZ?<^-_AZUU9VTOFV%T)#+$K
M;@L,97.1S@DD>F379_\ "):']EOK7["#!?N9+M#*Y$['J6YY)[^M27/AC1;V
M&QBNM/BG2P.;7S,L8^,8!)SC'&#QP* /.XHXM'O/B?J6EV5O'J%H0]JZ1+N1
MC:AB5X]<L?7FM/2M%M)G\/>)]/U>RCQ'A19VI5]0#IS'*QD8N003D@D$$GO7
M;)H&E1ZS/JZ6$(U"= DL^WYG &!GWQQGKCBJ6D>"O#6@ZE+J&E:-:VMU+D-)
M&O0'J%'10?;% 'E>I)9:_P# &[\0WD<4^L2MYL]TP_>)+]H *9ZA0,*%Z8Q7
ML^I?\@F\_P"N#_\ H)K'N/ /A:ZENY)M&MV^V-ON%RP21LYW%0=N[CKC)Y]:
MWX[>&&W6WCB1(57:(U4!0/3'I0!XBF@6UG\)O#'B;3%EC\1P_8Q;3+*Q:4O(
MJ&+&<%2K'Y<8X^M=1JTL/@+QW<:DEJ'LO$%L8T15Z7L8)6,>@E!QCNPKLK#P
MMHNF2QO9V"Q")B\,>]C'"QZF-"=J'D_= ZFJ!AUC7/$"1ZIH\%GI>FW9GMYC
M<K*UVP4B-@H'R ;BQR<Y '3- &CH6G6_A_1[+33)")MOS$87S93R[ ?7)QV'
MTKG_ (N6\,_PNUTS0QR&.#>F]0=K!A@CT/)YK:UWPU::[J&DW4\$9ETZX$\4
MY8[XR&5MJ@<?-M )/;MSD:M[96VI64UE>0)/;3H4EB<95E/4&@#@/$6EV!\9
M^ K"*WCBM&:]W10?NU.;?)'RXZ]_7/O7/S7;>%]$\;VFG,;33K36K9,)DK;0
MR^5YNT @@8+< C&3C%>FQ^$]#ADL'BL%1]/!%H5=AY.?O8YZGN>_>I(?#>D0
M-?E+%#_:'_'V)&+B?C'S!B0>./I0!@Z/X=M].\60:M:ZI91I>6AC-CI]KY45
MP 01*0'89&0-WH0,\U2^*ZLUMX25'*,?$UD X .T_/SS73:#X2T#PQYW]BZ7
M!9F;_6,F26'IDDG'MTJ?5?#^EZXT!U*U%Q]G<20AG8!''1@ >&&>O6@#!O\
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M:6WE0J5('F@;FP3G';/X5JQ^%=#CT^]L!IT36E\YDN89"765SU8@D_,>.>O
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %->1(UW2.J#IECBG5Q.NKI]_X\BL3&ES?1Z5)(\=Z0;6"!I #
M)LQEI"5QP0-H.2.,@':D@=2!VYH5E<$JP;!P<'/->(:?%%J'@#X9/<.TDO\
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M@<\8RQ=![A'H ]1:1%959U!;A03U^E.KRB.TM?%\WB_3M6U"RM;JWOY(RTT
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M)+=/4DG\:DAN8+E6:":.4*=I,;!L'TXH2YMY)9(DGB:2/[Z*X)7ZCM0!E_\
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MOH=DCVS%H6,88QD^F>GMZ=JW#+&&*F10P&2">0*5'26-9(V5T895E.01Z@T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>U7[+4[#4E<V-];70C.',$JOM/H<'B@"U161XB\2:;X8TX7FI7"1*\BQ1*S
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MX8/*BV (T:OSR23SZT =317*>(-<O]+\:^&+%+B"/3;\W(N0\?S#RX2X.\G
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M[3*)#WX7.: +=%8MAXKT?4M?OM&M;V"2ZL]@D42#ER&)4#N5"\XZ9]C3M?\
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MX![BF_V%HYMQ;G2K'R0VX1_9TV@^N,8S0!Q%_:C3OBJ\>C6\-O<OX7G\J.)
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M_P"')XJQ)&DT;1RHKQL,,K#((]"*HV&A:/I4CR:=I5C9R.,,UO;I&6^I4#-
M''^&I(;KQ+X[L-=6,SM<@LD^,-8F,!,9_@^_GL"3W-<]::9JG_"F-"UDH\NJ
MZ"YU"T\S[[VZNWR'OAH>WLM>JWFD:;J$T<U[IUI<RQ?ZMYH5<I]"1Q5LJ&4J
M0"I&"".,4 ><>)+J>^^&^N^);*.8F_2)XPJXD^Q(XR,'U0ROS_ST-6M-A\*:
M]XBT[5[37FU:Z^QO"(4:$I]G(R1,B("%!Q@-T8CWKO(XHXHEBC14C50JHHP
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MZ=37HDD:31/%*BO&X*LK#(8'J".XJG!HNE6T<L=OIEG$DPVR+' JAQZ$ <T
M>/:;9V=O\+OAU>QP0I<G6K'=.% <YD96RW7IQ]![5;\;:CIUSI/Q"BM9+>TD
M4)'="X??-<RK&NW8I.$4 #!P<D,>,9KU0Z%HYA2$Z58^4C%D3[.FU2>I QP:
M?)I&F2SRSR:=:/-+'Y,DC0*6=.FTG'*^W2@#BKRZAN_B#\/IHITF5[*_PZL&
M#'RXL\_4'\JN>#&!\:>.@"#_ ,3"'_T0E=4=)TTRPRG3[0R0 +$YA7,8'0*<
M<8]J=;Z;8VD\D]M96T,LGWY(XE5F^I YH XSQM;VMUX^\"PWL<4EN]Q=ADE
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MJU7)>%(-!DUS5]4T;5)-3FO!%]LN4D1X2R@A0-@"[]O7'.",]176T <[XO\
M$,.C:!J30ZK96NI16KS0),RDE@I*_*2,Y(P/ZU!IFI75]I?A*YFURWMKBZMH
MYKBV>--]Z6AR0O(*X/S?*.WI7%VFK69\*?$:PUF>"/5_M-Z98KA@'="F(2H/
M5=H4+CTJ2&:TF_X5+/')"[;/+WJ03Q:$%<^QXQZT >ER:SI<-X+.74;1+HN$
M$+3*'+'HN,YR<CBB\UK2]/G2"]U*TMYGQM2:948Y.!P3W/%>=7<][HFI3WUC
M/;:UX>N=<5;FQE&VYL[HS!<QD?> <!MIYQCMDT:7JWA]SXR\/>,)H([F;5)7
MD@N7*/<P-M\GR\$,WRA0 O/ ]: /0[W7=(TYY$OM4LK9XH_-D6:=4*)D#<03
MP,D#/J11=:[I%C)%'=ZI90/+M,:RSJI?/3&3SGMZUQ#:?I=Y\9(+>ZL;=D;P
MSS;W"*W_ "W PP.<G;D=^]9,5WH<MWXO\.>*=;?3#+?2$VKF*-9[9E41&,LA
M)PH  4Y&!B@#T"3Q?H\?BQ?#C7L OC 965I0-I+*JISU9MQ..N![BI]'G:5]
M3=]:M]1C6Z8((E1?LJ[5/E,5)R1UR<'YJX^REM--^*^GPRRO"C^&(H(!=L!(
M["? 4^K],@5S5\)T\#_$A-+CW;-?9IHH!R8 (?-  _V0V?;- 'KMGK.EZC,\
M-EJ-I<R(NYDAF5RJ^I /3WJ%_$V@QF,/K6G+YDI@3-T@W2#&4'/+<CCW%<GX
MB-OJWBCP->Z)+%+*9Y'+PD$&R,9WYQ_#G8.>Y'>N1N+33_\ A5OQ(E6"WWKK
M%Z%<*,C$BE0#VP>GUH ]NI&8*I9B H&22> *ALG\RQMY-V[=$IW9SGCK7)_%
M0W:_#Z^>UC>1$>)KE(QEF@$BF0?3;G/MF@#IK+6=,U*5XK'4;2YDC 9UAF5R
MH/0D ]/>N-_X2>Y\3ZYK.F:!XBLK*XL'B2S'[N9;LE-[E@<L5&=OR$$8)R>E
M.U[RM2\;>"+[19HY)=TSR20D$&S,?.['\.[8!GN14O@V6-_'7CL(ZL1?6^0#
MG'[A1_,'\J .W&=HW8SWQ6"_B[23XH?PXE];KJ"P>8P9Q\K$@*F,\L>3@<X
M]:WZX3[7;VGQMN5N)XXFGT*!(0[ &1O/?A?4\T 2^#/%ZW6E;=?U>R74)-1N
M;6!79(3*$D*J%7//0>M=5J&K:=I,8DU&_MK1&SAIY50''7J:\8NHK,?!/Q/>
M*D'G#69F$P W B[&TY^AX^M=3J.L6FG?$W4[?7=9;2[:]T^#[#,_E"&5%W^8
MFZ12 =S9QD9S]* /1XI8YHDEB=9(W 970Y# ]"#W%/K!\&V&FZ9X4LK/1Y+B
M33H]_P!G>=MS,A8D$'NISD>V*WJ "BBB@ HHHH **** "BBB@ HHHH ****
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M%:&TCLK=+8G)A6)0F?IC%9U@FMVVN307MS'=::;<-!-Y020.&^82$?*>"N"
M._'&:LVNO:1?78M+74K6:X*EUC24$LHZE?4#U% %R&V@MX?*A@CCC/\  B #
M\A3+2QL["-H[.U@MD8[BL,80$^N!WK-N/%_ANTCDDN-=TZ-(Y?)=FN4PKXSM
M//7!'':K">(=&DU9=)35;-M09=ZVRS*9",9SC.>G/TYH MBQM%M6M1:P"W;.
MZ(1C8<]<CIS2P6EM:VPMK>WABMP"!%&@50#UX'%9ESXN\.6:3/<Z[IT2PR"*
M0M<KA'/.T\]<=JF7Q%HKZK'I::K9-?R)O2V$ZEV7&<@9].?IS0!8MM+T^S*&
MUL;: INV^5"J[=V,XP.,X&?I5NL!-6M+75=:N;CQ%;S6MK%&TEF G^A8#9+%
M?F);'0^G%9G_  LO0!X;T_6#=1!;Z>*&.'S1N4NP'S?W<*=QST_*@#K+JSM;
MZ PW=M#<1$Y*3('7/T-->QM)+9+9[6!H$QMB,8*KCI@=!5:[U[2+&UCN;G4K
M6."12Z2&0891U8>H&1STJ2;5]-M[**\EOK=;:8 Q2^8"LF1D;<?>XYX[4 6H
MHHX(ECBC6.-> J# 'X4YT61&1U#*PP5(R"*@LKZTU*SCN[&YAN;:0926%PRM
M]"*COM5L-,"F^NX8-X)4.V"P'4@=3COZ4 ']DZ=Y?E_V?:[,YV^2N,^N,4\:
M;8K*DHLK<2)C:XB7*XZ8..*Q/%/BZST'P7>:];W-K.!;L]I^]!2=\?* 0?F'
MT[9IWAX7UQ<F_7Q&FJ:9-;J/*\N,F.<8R5= /EQ_"02#WH V?[.L?MOVW[';
M_:\8\_RE\S'^]C-+<6-G>/$]S:03O$VZ-I8PQ0^HST-8T/BW3+_Q+J'AVVO8
MDO;6),L6&2[;_E4'[Q4+D]>OUK'\!^,X+_PQHXUW6K0ZU?-,%C=TC>7$SJN$
M&.R@#CG% '7MIM@T*0M96QB0DJAB7:I/7 Q0^F6$CAWL;9G4 !FB4D =.U1:
MCK>EZ0 =1U"WM<C=^]D"X7ID^@]^E74=)8UDC971@&5E.00>A!H BCL;2*X:
MXCM8$F;.Z18P&.>N3UI(+"SMKB6XM[2"*:8YDDCC"L_U(&3^-<O;Z]?>)O%6
MJ:5I5P++3])98;J[5%>66<C)2/<"JA1U)!YX [UJVD>N6OB!(+B[6\TIK5V$
MK0A95E#)@.5PI!!;&%'0YSQ0!H2:5ITL\D\EA:O-( 'D:%2S@8(!.,GH/RJW
MTK.AU_2+B^6RAU*UDN6W!(UE!+[?O;?7'?'3O4%UXK\/6(N#=:WI\0MF5)MU
MPH\MCG"GG@\'CVH U)H(;F(QSQ)+&>JNH8'\#5<Z3II0(=/M"H)(7R5P#^7M
M5<>)-#.HV^GC5[$WER@DA@$ZEY%(R"HSSD<CU%17GBWP[IXF-YKFG0>0ZQR[
M[E1L<YPIYX/!X]J -*XL[6[MOLUS;0S0<?NI(PR\=.#Q2&PLVM4M6M(#;I]V
M(QC8OT'05%<:OIUK;P7$U[ L5QCR6W@^;QGY<?>XYX[5$?$.C"QM[TZK9"UN
M6"02^>NV5B<;5.>3GC H L?V98;D;[#;;H^$/E+E?IQQ3X+&TMI&DM[6")VX
M9HXPI/U(JC;>)="O!>&VUBQE6R_X^BDZD0^['/ X//L:E77M'?2_[435;)M/
MSC[4)U,77'W\XZ\=: -"H7L[62221[:%GD78[% 2R^A/<>U8LDFM_P#":VOD
M7<,NB26I,L'D?-&W.'$G?)P-OID]JT!KFE-?+9#4+<W+NT:Q>8,LZ@EE'J1@
MY Z8YH D_LG33&(SI]KL!)"^2N 3WQCV%._LVP\TR_8K;S",%O*7.,8QG'IQ
M3[Q96LYA#,T,FTE9%4':?H017GOA_7O$VJ_"Z+Q8=7M5O/L\MPT,UJOD$1LP
MVD@AAD+USQGI0!Z!'I]E%#)#'9VZ12##HL0"L/<8YI]K:6UE L%I;Q00KTCB
M0*H_ 5D:#XFM]6\'Z?X@NPEA%=0)*RS. $)XQD]<GIZY%:-EJNGZE%++97D$
MZ1,5E*.#Y;#J&]#[&@"Y48MX5N&N!#&)F4*T@4;B!T!/7%4;/Q!H^H3-#::G
M:S2"/SMJ2@DQ_P!\>J^XXJ.V\3Z#>7D%I:ZS8S7$Y<0Q1SJS2;/O;0#SC!_(
M^E %V+3K&"[DNXK.WCN9/OS)$H=OJV,FK-<+XO\ %HM;O08-'UFW$L^LV]K<
M0IL<R1L^' )STZ''(SVKNJ (YX(;F%H9XDEB;JDBA@?P-1O864DXG>T@:4?\
MM#&"WYXJLNOZ0]^MBNI6INF8HL0E&68=5'J1W Y%<YK?BF&3QG;^&(=:BT[=
M92SRW*/&9%D#HB1@." ?F9L8R<#WH Z@:3IPC:,:?:A&()7R5P2.AQCW-._L
MRP#1L+&VW1XV'RERN/3CBJ]I;:G%H$=O?:BLVHI'A[N&$(&8?Q;#D#MD?7&*
MY#P7J'BOQ3X#L==76K6.^N5D81260,.5=E ."&YV]0>] '<FPLS>B]-I!]K
MVB?RQYF/3=C.*L5PNE>,_P"W_"6KF^OH?#FK:?*]E=S.RLEO,.CKOX93U&?<
M>]=+-X@TC3(X8]0UFSCE,'FYEE5"Z 9+XSP._I0!?N+2VNU5;FWBF"G($B!L
M?G4?]F6'F>9]AMM^-N[RESC&,9QZ<55G\2:);64-[-JMHEM/'YL<IE&UD_O
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M\E<$^N,4Z?3;"Z@CAN+*VFBB(,:21*RH1Z CBH=0US2M*?9?ZA;VS;/,(DD
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M'A0$NT)BCV#JH'/7CI[T <'X:N8= TGP18:IY5A=-%>R6NH7[$"WA9\B, D
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M1%[*&"..3#%H5 #\  \=> !]!4A@A:-8VB0HOW5*C ^@IZJJ*%50JCH , 4
M>9^*-6T__A)/$^G^9#IUX-(19)9#NFOE*R%4B4\87)!(!)W8XQFL_26;4/#O
M@^Y\/^(K:RUZUT542.Y >WNHPL?F1MSD%65<E>1_+UHPQ-*)6C0R %0Y49 ]
M,U%)8VDT2Q2VL#QKC:C1@@8]!0!D^"M1;5O!VF7K6"V+2Q'-NARJX8C*G^Z<
M9'L16]0  , 8%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !65J7B;0]
M'G,&HZK:6TPC,ICDE 8(.K$=<?SK5K@/$<]A_P +?\(Q7$MOY@M+T!'89#,$
MV\'N?FQZ\T =1<>*=#MK.*[EU. 6\L2SK(#E?+;HY(Z*?4X%6KK5]/LX(9Y[
MN,1S_P"IVG<9>,_(!DMQSQGBO-KK4M&T7QMXDTKQ1=SZ=:Z@L3V3!F2&>#R5
MC:,;1C((;C_:I;34-+\'^.=*%\)--T*30Q;:9)>,VV-A*69&9ONL5V'![ #M
M0!WB^+?#[V#WZZO:FT280/,'^19, [">S?,.#W..M7&U;3UU,Z:UW$MZ(C-Y
M#-AO+'5L>G(YKQ^]877PS^(4\".T?_"2-/PA!V+);LS8QG@ FNG.OZ5J/Q?T
M:YLKZ&XMWT>X1)XVW1LWF1G ;H3@'..E '0:?X@TC3]'O=1O/%-M>60O) +J
M1T5(\GB%2O#;>G<FM"'Q-H=Q'=/!JEM*MI-Y$VQPVV3LO'4GL!UKR'4+^Q?X
M/>/56ZMV#:Y<[0) <YN%*X^H&1]*Z_QQ>6>DWGA?7 630(IY!=W-CTCWQ;(I
M"5_A'*Y]#CVH [6TUW2KZPGOK>_MWMK<LL\A?:(BOW@^?ND=\XKEAXE>[^*.
MF:=9:H\EA-I\\TMH8PNUE*;6Y4-@@G'.#VKE_$?]CGP_>Z]X;%U?6,FJ65SJ
M]RKO(MQ%$WSA0>NT!=Q QZ]#C9DU[1M4^+GARYT_4+:ZCDTRYC$L+A@26C(4
MD=^O'49]Z .V\0R7$'AS4IK2X:WN(K:22.555BK*I(X8$'IZ5@>#O&FE:AHV
M@V-YK=K+KMSI\$LL+2*)'=HPQX'?G./TKH/$"/)X;U1$4L[6<H55&224/ KR
M]8;#6OAIX(TS2FMY=8AELG18""]LR;3,[8Y7 #;L]R!U(H ]1LM=TO4I[J&R
MO8KB6T.VX2,Y,1]&'8^U6+&_M=2M$NK*=)[=\[9$.0<'!Q7!^)H=2\.^-$O]
M'B9D\21#3YMHXANE!\J<^P3?GV05WEC9PZ=86]E;+M@MXUBC7T51@?RH JZC
MX@TK29&COKZ.%TC\UP<GRX\XWMC[JYSR<#BF7GB70]/DC2[U>RA>2(S(KSJ"
M8P,E^OW<=^E<'XJU>Q.O^+=,+QZ==_V2HW!-T^H@QR$*@((V+D@X!/)Y %9V
MGW^FR7OPEGGF@,*:;/'YDN HD6"$8R>,AACZ\=: /1XO&/AN;1&UE-;L3IRL
M4:X,P"AO[ISW]NM2V7B?0M2U:?2K+5K2>_@!\R".4%UQP>.^#U].]>4>*;&-
M=$^*6I6(7^RKM;58VC_U<DR >:R]CR0"1U(/I74ZM!8:MXQ\$S:$UN\MFTDL
MDEL01%:^61AL= 6*@ ]\X[T 6- UFZETKQC_ &OKWV=;+5+BTAOIA&GV=!&F
MT] N06SR.3746^I6=EH=A/<ZD+A)88Q'<L/FN25R&"J.2PRV *\YL-0L6\(?
M%+_2[<@WU^?]8.08% _,C ]338-<M]"G^'^MZA*/[".BFS-T/FCM[ADC(+$=
M,A2N?K[T >DIXAT>72_[234;=K/?Y?FA^-^=NS'7=GC;USQBL+Q=XB#^ =>U
M+0-4\J[L(7)>-5+1NHSM97!VG'J :Q==UCP[9:+9ZCI]A:K8WFNQRC49480)
M,1DW1Y&X C:"2 3WQUYVYN([JV^*MK;74M]-/:PRQ-Y?S2K]F W *H&,]"!R
M,=>M 'INB>+-%U*:+2XM8M)]42!6E@64%\X&[CN1WQTK/\):I?3ZSXLM]1OV
MGAT^_$<+2JB^7'Y2MCY0!QD\FL*^CT_79_ 8T%[:>[LKF.X>6U*D06JQ$2!B
MOW0QVK@]3]#6/=RRW^F_$^#276ZN_MT<@AA<%I(U2+> !UR%=?KQ0!ZE8^(-
M)U*\>SM+Z*6Y1!*8@<,4/ < _>7_ &AD4>(9;B#PYJ4]I<-;W$5M))'*JJQ5
ME4D<,"#T]*Y+P]J/A'Q1X@TW5M*N[O4-2MH7&7DDS:HRX82 \#)P #DYY' )
MKJ?%$L<'A/6))9%C064V68X ^0T 4/#FOQCP-X?U#5[P&YO;. EF&7FE:,,=
MJ@9)/)P!ZU>?Q3H4>EKJ;ZK;+8M)Y7GL^%#YQM/HV>,'G->>66NZ;9>&/AN)
MI+2$R6FQ-4F.4LV6 !E'.W>V2HW<#!X/2I?"6G6GB?PMXX\/O</(]QJ]W\\J
M;74MM,<A&!@[ANZ#ITH ]%&N:8VK+I0O(O[0:/S1;9^?9_>QZ>]3V>H6FH+*
MUI.LHBD,4FW^%QU4^XKR0ZIKLEIH/CR2QG-SI[KI5W:!0&G#'RY6_P"_VS _
MV2>]>K:/8MIVDV]M(P>8 O,X_CE8EG;\6+'\: )+W4K/3E0W<ZQF0[8UY+.<
M9PJCDG'/ JG)XGT*'1_[6DU:S33\E?M#2@+N'!7_ 'L\8ZUS.KW9TGXO:9?:
MDXBTJYTF2SMYY#B..Y\P.02>%+*HQGKC%<;XIC2'PK\3+^.6-=(U"ZM_L7S
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M8$+'L_\ =/'0XJXVKZ>FH6]@UY$MW<H7@B+8:50,DKZX'I7E%\RZKHWQ8DL
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M=L=;?3#:VL7V>:!%9GN'+YR&!R%VJ-O&<GGIBAK%Y9>*;#P0V@31/>1:E;W
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M".PEO(4NY8S+'$S8+H!DL/4#O7GWB^?1=>\ >,=0\.P)<O<VB&XO8$.)V3H
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MBEH[BV\QM8F8%77+'[4"I]S@9'L*[>\O[.3XSZ0(KNW+OHDX0B0'):1"OUR
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ML'=F(R% 'KUZ#)XKA]#O[72K/QGHGB.1(KR:_NIUCEZWD$J_(8Q_'Q\N!DC
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M0>017&^.-6MM+U?PV+F.*!)KF4#5)8]XLSY9^[V#/G:"<@<\&NS  & , 44
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M8YSWHQGK0!A^$;+3+#P[!#HUG+::<6=X(Y2Y8JS$[L/\P#$D@'L>W2MRBB@
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M)*,P@'OL1Y%/U7TK"L[G1K:?7/"WBVRU66]GU"XE@MXS<-'?Q22%T*A#LSR
M<X QR>#@ [[4_'7AG1[FYM[[5HHIK95:9 C,4#' ^Z#_ /6[U9O_ !5HNERL
MEY>&)4D6*2;RG,4;MC"O(!M0\C[Q'4>M<QHWD1_%W4(]B)C1;:!!G< RNY9
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MT:B4.X!"[""RG:^[@$$C- 'J4OC+P]#=BU;4HVN#;?:EB1&=FCR!D  Y)+#
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M(!QW[Y'%6:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M""&0'LRH 1^8K \3>=:?$?PMJ1M+N:U2WO(&>W@:3:[B/:&VCY<X/)P..2*
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M[2 1^-<)XAT>^M_'*QZ<H^P^)X?LVH@-@Q&+!,@]VBW)]=IKT-55%"J % P
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M#5=-M[^VW^1<1B1/,0HV#Z@\BH]0U:UTZ2"&4N]Q<;O)@B0N\F!DD =AQDG
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M9WT/3+B&WGG6TU>SN9E@C:1Q&D@+,%4$G ]*I6]Q-H_Q*O\ 5[ZWNETK6;"
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M%KY2UF\\#1I<8&?E)'7'.#@D<@5+IOB73=6N-1M[1IVFTY_+N4>!T*-C./F
MSQSQ7':FS^,M+\*6MI:75O?6NHVUW=)+ \9LQ$"7#$@ '/R@=\Y'&35GQ!HV
MHV_CN.?3(7-EXAMOL.I,G'E&/D2Y]3&9$'OMH Z=?$VGR65I<P"YF-Y$9K>&
M.W?S7C&,MM(R!R.3CJ/451;Q_P"&UTZQOS?/]GO;C[-$WD2<2Y(*-\ORL,'@
MX/%<_P"+,Z%XYL=9O-+O;S0I=/\ L+FQ1W:UD60LK%4YVD'''H*IZW;VR:?X
M:DTS0;JSMF\20WS1+:N9/+"L&FD4 E<G'7G&,\Y  .TMO%VF7EE%<6R7LCR^
M9LMOLKB8A&VL2A ( .!DXY('4XI\'B[1;K1H-5@NS);W$OD1*L;>8\N2/+V8
MW;@0<C'&"3QS7*^+)&T;Q[::Y?Z;?7NB7.GBS>2S1W:VE60N&94YVL&Q]15#
M4K?^RK[POXETWP_=6VB6E]<R75M' QF FB""X>,9;(.XD<G!&0"2  ;'A;4Y
M;[XF>*H//OO(AM[0K;718>2Y\PMM4\ '@\<'BN[8!E*G.",<'%<'X;NOM?Q/
M\0WL5K>K:75C:"&>6TDC1RF_/+*,?>'7&:[QB%4L>@&30!YIX7NH[S6?%<&K
MZ_>1QV.J/#;*^HM'LB"@X^\,@9/)KHQXATSPMX8L[[4M2N[BQN'W0WCQ/*=D
MC;HP[*#CAE4$^@KE_",EC;:WXPDU73+K9=ZL\L#2Z9,XDC*@9!V'C(-;MU=6
MFI>$QHD&D7 L[UCIMHEQ:R!1$JA3+(" 448.,X)PN",Y !TMMK%G=7M[:Q-)
MOLB!.S1LJ*2H;&XC!.""<'C/-48?%VDS:C961DFC>_!-G)+ R1W&!D[&(P>.
M1ZCD9KD-$M=13PMXC\ RQ7 N[>">"RU%H'6.[21"58OC&\%L-S[\\T>%+O3M
M7&E6=SX5U&'6[ IYWVR"016KJ,-(LC?*<X.W')R.V30!UMSXRT6TEC$T\@@>
MY^QBZ\IC#YV<;-^,=01GH",$YJ5/%.ER#5@LDY?22/MB?9WW1Y7<,#'S?+SQ
MGBN)\%:G<:5H,'@W5=!O9M8L9FC0O:LUO,/,++/YI&T+R"3G.1P">*?/-+I?
MBCQ[;36-\\FJ012V1AMG=)0+?8WS@;5PPYW$4 ;U_P"/;."^\,Q6=O=7-OK8
M:5)X[=V'E")G& !DL3MXQP,DXXJU;ZII7_"5ZN8KO4I;ZVM(C<VA20QQIEMK
M(F.6/.2N<XKB[-;FSTSX7WTVG:@(M.C:"Z5;.1I(F:VV#*!=V"W&<8KHM*\P
M_%O7)VMKE(9=-MHTE>%@C.K.64-C:2-PZ&@#<M/%ND7WAV/7K:6:73I7"1R+
M;ON8E]@PN-WWN.E.U3Q1IVD+<-<?:76UC$MR8(&D\A",Y? XXYQUQSC%<QH&
MAW^G>,-2T0P,/#\-T-7MI/X=TF?W..F%D#O[87UK-N9(="\9^(+7Q!HFIWME
MJTRW%G<VD$DR2 Q+&T3!.A&WC/4>U 'IMK=07MI#=6TJ2V\R"2.1#D,I&01[
M8K \5>*U\-W&D0?9+B9]1O$MPT<3.J#DGIU; . .>_:M;1[9+31[2WBLDL8T
MC 6U0@B$=EXXXZ<<5S/Q#296\,7J6UQ/#9:W#-<?9X6E9$V2+NVJ"2,L.@[T
M 9Z^(!I7Q,UG[3/J4]JVEV\\5FB23,K,S[ML0!*\ 9X&.]=#+XZ\/0Z7I>I-
M>L;35'5+2587(=CG@D#Y3P>#@\&L?3IR/BMJ]]):W<5O)I-NBR/;.%+*SLRY
MQ@D!AP#7(:;%<P^ / =M+I]^L]GKZS7$1LY=T48DF.YAMX&&4Y]Z /3+;Q?I
M=Y:VTMN+MY;DR"*V-LZS-Y9PY*$ @ XY.!R!U.*9)XWT&+0I=9>ZD%E!-]GG
M/D.7@DW!=KIC<IR0.1W%8^JBYT?XI66OW$4TFD76E-8-+'&SBVE$GF N "0K
M#C/J!FN:U[P_J%YX:^(.I6=G<-%JES;2VEMY9#R+#Y>]PAY^8JV.,G /<4 >
MFOKEA'K\>AO)(M_+"T\:&)MK(I )#8QP2.,YK.N?&^AVD7VB6>;[&;DV@ND@
M=XVF!(V J"2<@C(&,C&<USPU-=7^*.@ZE:6.HFP.FW$7VB2SD10S,A .0"HX
MZD >A-<K:WFCQ:(WA[4I=4M-'M]5DN%C;29W8(DY<)YR@J5+#.X#@''O0!U3
MZ^NF?%*],MSJ,]G+H<-S%9HDLK;VE8$I$!D'"C/ QWKM='U>RU[2;?5-.F\Z
MTN%W1O@CO@@@\@@@@CVKDK6Y23XN76HQQSM8R:#$B7*P.8G82N^ ^,$[6!X-
M3_"N.6#P+;V]Q;SV\T=S<EHYX6C8!IW93A@."&!_&@#J-4U2ST739M0U"<0V
ML(!=R">I   ')))  '4FJ$7BO3))-0AD-Q!/I\2S7$$EN^]8VSA@ #N'!Z9Q
MCFJOCR[N[+PC=366GB^D#Q!H_(\\HF]=SB/^(J/F ]0#VKD;.0Q^.=:NTM=9
MFM;O0D$=U<VLN9&#29X*C;U&%P.O"X.: .LL_'_A^_FTQ()[@QZF0MK.UK(L
M3N02$WD;=V >,YXQUK1TWQ)IVK:CJ.GVC3FZTY@MS&\#IL)&1]X#.1R,9R*\
MVCBN$^'GP[MVL;WS[/4[-[F+[))NA5 P<L-N0!D<GUK?\7Z?J5EXLT_5-#^6
M36HSI%Y@X*Y5GCG [L@$GX4 =II>IVVL:?'?69D-O+DHTD;(6&<9PP!Q[]ZN
M5%:VT-G:0VMN@C@A18XT'15 P!^0J6@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *K:
MA86VIV3VEU'OB?!X."K Y5@1R"" 01T(JS10 R%'CA1))3*ZC!=@ 6]SCC/T
MJM?:;%J+P"Y)>"%Q*(?X6=3E2WK@@$#ID ]ABY10 445B:GXKTS2=9MM)N?M
M)O;F-Y88X[9WWA1R%(&">1P,GUQ0!MT5R!^)&A_V7<WPAU)ELY'CO(ELG,EJ
M5^\9!CY0!S[C.,X.-RXUVTB6V\@2WDMS$9X8K9=S/&,9?D@ ?,.21U ZT :=
M%<3J7Q%LET[1[O2K>XNTU'44L6(B(,+;OG1E."'PK #\>G6B^M?V7\5+]I/[
M3GADT2&=+*,23,',K [8\D+P!GH/SH ]$HK#M_%ND76@V6LP3M);7S".V4(?
M,DD)(V!>N[(.?3!)X&:ET_Q)I]_=7MF6DM;RQ4/<V]RH1HT(R'SD@KP>02*
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M+\@5LXY[GY3QUX]QFG'XNTXZF^FW$5Y:W@MS<QPS6[;IHAP60+G)'=?O#TH
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M;M%OX!#+N RI!'- &E17/:S>Z5'XJ\/VEY->I?R22M9I%O6*0B,[MY'RG '
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M WJ*9%+'/"DT3J\<BAD=3D,#R"*YWQ'K]HECJUE$+V66UMBUR]EN!MLJ2I+
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MCFN]HH \C:TOG^&WCVT&F:C]IO=2O7MH392AY5D8%"HV\@^O;O6YJ*SS>+?
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MC:))@B2>8H=@ .& R3CGVK%T'48%'A@:]8>(H4T=%2VDGTEXXD=D$8,L@)!
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M,<D(7/)8X/.",\9R#75:MXNL=(BO9Y+>[N+:P(%[/;QAEM^ ?FR03@$$[0V
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@'(+!CM) .T''/H<7)_$< NVM+"UN-2N$A6>1+0IB-&SL)9V49;!P,YXSTH
M3PWX<B\-V]Y##>7%RMU=27;>>$R'<Y;&U1QFMJN5MO'VEW>F:-J,=M>BUU>\
M-E;NT:@K+O=<.-V0#L8]_P"E:,7B:Q?6=5TR59K>73(4N)Y)@HC\MMV&!!/'
MRGKB@!NN>&HM>NK62XU+48;:)626SMY]D-RK8RL@QDCC'!'!/K6V  ,#@5SJ
M>,;,:KIMC<V=[:?VF&-C/.BA)B!NV\,64D<@,!^?%267BJ#4#9O;6%Y):WK.
MMO= 1F.3:K-_?R,A#C('X4 ;U%<MX+\3WGB:+4I;G39K18+Z:W3<T951&P7:
M=K$EL@D\8YX)K3O=>BMM2.FV]K<7U\L/GO!;[ 4CS@%B[*!D@@#.3@]A0!K4
M5R<_Q#T2#0;;6-MW);3W0LV5(#O@EW;2L@_A(/7],UMZ-JQUBUEG.GWUB8YF
MB\N]A\MVQ_$!DY4YX- &C17F7Q.\00ZC\.->:RMK^6VAS#]N@8+&)%<*W1@S
M*&RI.TC/T)':W.MI9NMG;V=S?WBVXG>"VV;E0Y )+LHY(( SDX/H: -BBN2C
M^(VB3VNBW%NE[/'J[O' 8[<DJZ@[D8=F&TC S^7-)'X_MI?[2A30]9:_TYA]
MIL1 AE52NX/G?LP1T^;)["@#KJ*YY?&6F3VFBSV23W;ZRI>SAC50S*J[F)W$
M!<#KD]>F:J3?$+2+?PZ=:DM[X0I=FRFB$(+PS!]A5L''#$<@GVS0!UE%8&F^
M++34->N-&>SOK*[BMQ=(+N,()H=VW>N"2 #P0V",]*X[Q]K\6K^'-+NK*UO_
M +))JUJ(+U6"Q2CSE!.T-N*D X++@_B,@'J%%17$KP6[R)!).RC(BC*AF^FX
M@?F17E_A.[L+_P +Z=XPUZWO(-0AN976]1U#73/,Z+" K%F7E5"D <#'&: /
M5:*P[?Q1;/K1T>[M+NQOS ;B*&=5/GH/O%"C,"1W7.?;'-4M#\<V?B"[@AL=
M+U8Q22S0M<O;8BA>,G*NV>"<<?4=#0!U-%<]KGC"RT+5[/2YK._N+N\CD>!+
M:#?YFP9*CD9/(_/G IK^,(18M<PZ3J<SQ6RW-S;+&BRVRL"0KJ[#Y\ G:,GC
MW&0#HZ*Y)_B+HIDTV.TAO[UM3MFN;3[-;EO-5<949(^;D9';G)&*6T^(>BW7
MA_4-6>.\MO[/F%O=6D\6V>.4D*JE<XR2P .<<]>#0!UE%<]'XM@>XU2T;3=0
M2^TZ%+B2TVQL\D;9PR8<JWW3QG.1]*6W\765WX9L=>MK6[EMKUXT@B4)YC%V
MVKQNQU///'.>AH Z"BN3G\?6<4^L6\&DZM=3Z05^U1PP+D*5W[AN8 C'..IS
MP#S2Q>/]+FETADM-0^PZLZ1VM^T(6%I'7*H<G<"<8SMQGO0!U=%<]J_B^TTF
M"^N39WEU:Z><7L]LJ%8. QR"P+8!!.T'&?7BH)?'6G#5UTNTL]0OKF2Q%_"+
M:$%9HB0 58D#OU.!QUS@$ ZBBN%U7XA#_A%--UG1]/N9A>W\=FRR!$:!C*$=
M64M][A@,<9Y) KJM0'VS0+H3130>9;L60OM=.#QE#U^AH T**\N\$>.K+2?!
MGA:UU&TU..&XAB@&I/!_H_FMT4N3GD\9QCWZUV^F^)K?4M?U/1DM+N&[TX(T
MOG*@5@^=I3#$D'!YQ]<'B@#4EM(9YX9I4WO"2T>2<*>F<=,^_;)J:J.CZI'K
M.FQWT,$T,4A.P3!<L <;AM)&#V]15Z@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KC=>DU9O&EK;2:9>W>A/9';]C( :XW\B4[@0FW& 3M))R#QCLJ*
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MZU[/!;C=(8UN)PVT<;B-PXK9FTC5?$/B'Q@#I=W96VL:+':V]Q/M 5PL@^8
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M^2.SB\/BS:6W@;R5F$H?8F!G&!QQCMUXKNJ* /(5T;5_^%?F(:3>&YMO$8U
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M+:J0&DBD38Y7) + <@9&>:J7>E76I^)]1\2I97,<2:(VG6\+IMEG=W+D[<\
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MX=H_<Y@,8SSS\WIGCFL?Q%9WL%G\4KVXLIX;6^LHVMI7 Q(([?8W?(Y]<9H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%,:6-8FE:1!&N26+<#'7FB&:*XB66"5)8V
M^ZZ,&!^A% #Z*** "BFK)&[NBNK,APP!R5/OZ4Z@ HHHH **:KHXRK*PZ9!S
M3J "BBB@ HHHH **** "BBB@ HI@EC:5HED4R( 60'E0>F1^!I] !1110 44
M44 %%%% !1110 4444 %%%% !13)98X8VDE=8XU&69C@ >YH,L8D6,NH=@2J
MYY('7 H ?137=(T9W9511DLQP *4$, 000>010 M%%,EECAC:25UCC499G.
M![F@!]%-CDCFC62)U>-AE64Y!'L:=0 4444 %%%% !131)&9&C#J9% +*#R
M>A(_ _E3J "BFR21Q)OD=44<;F.!3J "BBF"6-F=5D4E.' /W>_/I0 ^BFQR
M)+&LD;JZ,,JRG((]0:=0 4444 %%%% !1110 44UY(X@ID=4#,%&XXR3T'UI
MU !1110 44UY(XV17=5+G:H)QN/7 ]:=0 4444 %%-WKOV;ANQG&>:=G(R*
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M>6[1O&J2*"HQDGY?O<EL=.,D@5!I_P 08+_19KH:5>1ZC;WZZ=/I[ %XYV8
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MK!9L0'\Y68.I/0!=C$MZ#U(%*?%\B7FJ:5+IWE:U96GVR.W,^8[B+IN23&<
MC!RH(]#7(:?X0\0VGA[0+I=/*:IHFJW%W]D>:/%Q#,[EE5@Q ;:XQD@9!KIS
MH5WK/BVXU^>U>Q5=*;3[>*=E+LSMN9VV%@ /E YSUZ<9 +O@35]0UWP?INI:
MC"J37$"R[E<$/N&<X[?2G:OXJ;2_$MAH::5=7,]]#++"Z.@5O+ R.3Q]X<G
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M"6)!:/[Q< XQT) Y[TEKI/B+0)_%>EP:0^HV.L7$][:7<<\:^6\JX9) S @
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MO"G Z'//( QWJY+XFN9[C4X='TQ;]M+(2YS<>7NDVAC''\IW, 1UVC) SUP
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MX(8+G?OVC&TKC/.<5Z510!R%SI>HCXEZ?JT.GNVFV^FR6;2"5 =S.K A2V<
M+]>>E7/&UIK5YH*1Z&-\RW,3SP";RFG@#9>,/_"6'&?3-='10!YK%X<UV#4?
M%DL.AVMO:ZOI<4%O%!<H/+=4D7:1@#.7!)Z#G!:IFT#6O[(\!6PTUC)HDD+7
MG[Z/ "0F,[?FYY.1[5Z)10!POBOP\U_XVT::TG$37L,EKJ<6,^?9H0_/_ L)
MGTEKN)$62-HV^ZP*GZ&LG1_"^C:!<WESIEBL$]Y(9)Y-[,6)))Y8G R2<# K
M8H \^\(6'C'P]80^%I=/M7L;1RD.L?:1S!NR!Y6,[P#CGCZXYGTC2-;\+W?B
M*TM=/_M"RU*[EOK299D7RI)1\R2AB"%##(*AN">,\5W5% 'G5CX,O]"O? EM
M:0&ZM-#BN%NIPZKEI8]N54G)&XD_3UJU;:-J\5YXXF;37VZO@V@\V/+8A$>#
M\W'(S]/?BN[HH \G^SZCHFJ_"ZRGL'>\LK6ZMY8$D3+;;=5)4YVGID9(_"M/
M5O!&I:ZOB34U9;#4[]K4V*2,&\K[,0Z&0KD99L],X&.IR*["^\/:=J.L6.JW
M*3->6.[[,ZSNHCW##?*" <C@Y%:M ')Z=>^+=2LIO[7T*#3C' RF**[29KF0
MC V] B=3R<]/0YYV/PQKL?@7P;I/]FDW>D:A;7%R!-'C9$23M.[DG/ _/%>G
M44 ><Z_X4OM9U0ZA;:2^G:]!=J;;6+>=%5H XR)5#;F^3*[=IS@<@$XK>)O#
M7B?6%\66DFG6][]MCQIEY+<@""/8!Y2H1\K9!R> <\G@5Z3+=VT-Q!;RW$4<
M\^[R8V<!I-HR=HZG Y.*FH X?^R=>C\8:#K:Z? RIICV-U']I'[@ET8-G'S#
M"XP!U]N:SKKP5J6N6GCJPNH39QZW-'-:3&16 *(@&X*21\R _0UZ310!Q-SI
M6L>*%\.Q:OIQL3I=[%?W4AF1UEDB4A1'M)."QSE@N ,8.:SAX>UL^&O'=B=-
M83ZW<W$MH/.CQMDB5!N.[C!7)_K7H]0VUY;7BNUK<13JCF-S$X8*PZ@XZ'VH
M JZ%#-;Z!I]O<Q&*>&WCCD0L#AE4 \@D'I7F7A:QU+Q!\(9/#]O8LB7L]S#]
MM:1/+2,W#[F(SNW ;@!C!..1V];D021LA+ ,,95B#^!'2L_0]!T_PYIXL-,C
MDBM@S.(WF>3!8DG!8DC))/XT <VVCZOH_C[^TM,TY+RPN=,BL2S7"QF!HW8@
ML#R5(;^$$\=*Y^R\*>)+7P5X7TN73$:YTS6EOIA'<)@Q"61SU(^;YQ@9(XZB
MO56944LS!549))P *CMKF"\MH[FUGCG@D7<DL3AE8>H(X(H Y3Q=H4?B*=+7
M4?#[ZA8B -#<02QQW%M/DYVEF7 QMY!ZCH>V4WA_Q/I[>"M2DC&LWVDPSP7J
M_:%1W\U% 8,^ VW: <\GK7HM% 'F!\/^,H=,\4?9;:"&XU#5DO$2*\VM-#A
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M\Y'>6:50IP0<!0 <$D$D]!CD ;X4\7ZKXH6VNE\/?9M.D>>.6X:\5C&\;E0
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M?+=+H]K%I4T&K:E"\YLKQC$;=$P&+G!/4@#CG/;G%&Z^(#V>D^(Y)])/]J:
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M/^TU<6D]O,63S4&XQOE1C(Z-W]!57PWXLUOQ%=DKH,$-C!?7%G=3&\W,C1Y
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M]1B::TF&)(Q(R;QZ$J0<>U7:* (;6VBLK6*V@#"*)0J!W9R /=B2?QJ:BB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBH;NY2SM9+ATE=8QDK#&TCGZ*H))^E $U%<]_P )C8_]
M [7?_!/<_P#Q%'_"8V/_ $#M=_\ !/<__$4 =#17/?\ "8V/_0.UW_P3W/\
M\11_PF-C_P! [7?_  3W/_Q% '0T5SW_  F-C_T#M=_\$]S_ /$4?\)C8_\
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M_P $]S_\10!T-%<]_P )C8_] [7?_!/<_P#Q%'_"8V/_ $#M=_\ !/<__$4
M=#17/?\ "8V/_0.UW_P3W/\ \11_PF-C_P! [7?_  3W/_Q% '0T5SW_  F-
MC_T#M=_\$]S_ /$4?\)C8_\ 0.UW_P $]S_\10!T-%<]_P )C8_] [7?_!/<
M_P#Q%'_"8V/_ $#M=_\ !/<__$4 =#17/?\ "8V/_0.UW_P3W/\ \11_PF-C
M_P! [7?_  3W/_Q% '0T5SW_  F-C_T#M=_\$]S_ /$4?\)C8_\ 0.UW_P $
M]S_\10!T-%<]_P )C8_] [7?_!/<_P#Q%'_"8V/_ $#M=_\ !/<__$4 =#17
M/?\ "8V/_0.UW_P3W/\ \11_PF-C_P! [7?_  3W/_Q% '0T5SW_  F-C_T#
MM=_\$]S_ /$4?\)C8_\ 0.UW_P $]S_\10!T-%<]_P )C8_] [7?_!/<_P#Q
M%'_"8V/_ $#M=_\ !/<__$4 =#17/?\ "8V/_0.UW_P3W/\ \11_PF-C_P!
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MLM)X@C^(;^'?^$BG:TO-+:]\PVT7F6[+*$(B^7 !##[X;&.YYH [ZBO,]/\
M&&KQ>'8[6YG>ZU!O$,NB+=*D:NZHS'?M.$WE4P.V2#@]#TOA\>)(M>OXM2\V
M31WC5[22Z:'ST?HR'RN"O<$\CI0!T]%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MOEK-<(B!$]%5 !SQDG).!Z"MNB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_A$?#7_0O:3_ . 4?_Q- &C]OL_^?N#_ +^"C[?9_P#/W!_W\%9W_"(^&O\
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MO:3_ . 4?_Q- &C]OL_^?N#_ +^"C[?9_P#/W!_W\%9W_"(^&O\ H7M)_P#
M*/\ ^)H_X1'PU_T+VD_^ 4?_ ,30!K1313 F*1) ."58&GU5L=,T_2XVCT^Q
MMK1'.YEMXEC#'U( %6J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO5']CZ;8&Y@M"/W<DN.'*]#C/'IMX[T >K)+')'YD<BNG]Y3D?G1YT6"?-3
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MC1E(*MZ@$Y'ISZFL7P?IM[:^*?&%[<VLL-O?7L<EL\@QYBB,*2!U'([UV5%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
2%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>arwr-20230930_g1.gif
<TEXT>
begin 644 arwr-20230930_g1.gif
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MI.+TXJ?=J7+(=YO8GV#!9D.T2@
M
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M!^B!!'B!(*A_L39YE^=Q(Q> 'F5JNS9D4J: Y85K+CAK=9>"-EB# +B!'"B
M 'AWIO>#&MAY5Q:#0^AP%LB#)=A820A3%-B#3<9KHB=[_U0X$3F%)9^" SS
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M*J+7[,<K7=RT<\VD@0W7=>+7B038/R78=(:C4%K0ZD*U<\MG=6M4(UG77DQ
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MO7\''U[\>/+ES9]'7]["0O8#2HB 'U_^?/KU[=_'GU__?OT@*!8]:("=UAN
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MF$:(@8B(33=U-8>'B;AT_N=[51>(47>'XL>(,*>)DBB&Z:1_ @B*)O*"$'B
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M1R9XP>0<':LM@+=0&"N.)R8U+\3"3<%WGB2Q)O$U/?.Q4K)Y['%A--,C<^*
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M#6-8PQG:,(<XW.%DJ@*>ZC60>.V3FOKJM\"BG8I[V;/:\":(/ZXM47#V4Z#
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M=%(BFZ]VLG-QBX7KL//&8K!Z7+96_!\YJ\6%ER]7:.=!:X7ZFGC<MD<=[ 6
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M/LH1><6?QBZZQZ9%LD657-DZXY.'HRFO4HY5HK&TKM29];92(03#874W*7Z
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M0!QR*Q+R)PA!% 4$(O,H$O-1'NV,'.GL1%9%5=JQ*/\P'1,*'Q_QM@+1#>9
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MDZF5@1E'F<F9>;F9?>9-8A66IED<+* ZH0B3)1F3K/@3J/>*+NF:K5F;<EE
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MW.,?!WG(13YRDI?<Y"='><I5OG*6_[<<X%" .4.Z, 4HR)SF-J]Y0F:><X1
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M(TI2A,6F9,JG?$6H+$E=M$6J+,E")$"LC$&M]#FN[ *M[,9I/,:P9,9N$,N
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M6@NC)T0&?1:D2/!1#OS4FET2ODNEK&3B.B[$5NS#;6':32T(%ZVITDT4;(N
MHF$^U?4JI2D4^JW7=+N6<5@LY^=FF8OO#":]D9YTI2^=Z4W_[Q5%?AAPJ8L
M&U?AY-2'5NH60["-V9/AX+!VZF.T[:^F89KD8#N@;\NGV6_4Z8JER), 'Y".
MT EKA=F#M;2[1-"W/(JU)S1S:H@$V$WCR1;QQA23(Q#=Y%X*3:(XU2_;EV0B
M7HC3,9]YS6^>\YVOS!Q/C75+5W+?ULBQZ%_C!Q&MV*Q[A!/_&&1>X?1PCFQ*
M*8)1-HUE./07Z?/7,UVQ^V_VGGN4@G+ZKKT,;#PTM"!*^T64- QP_@*D0>)?
M\_I7SHP)/YS<'HM!9EXU)YH+MIU#DL1^/.MT&[]M%U1?]E^.7Z*ZV//UM__]
M\9]_I]<OZJC'MS42BVF(H1?\CSET_TAEC.W"8FV""(P@;$TUCD%$"@(\! \B
M&$LU+"FRN"2K_J,9K,$U1F 9F&'FN"0A+A"W.(&76H-+&L*GS(T:U"LU1H"]
M+"?#5H.BI$LA/K UCN%K9@X;KFVBOJ>IFFV'&H7Q\(N"]@9=+,7G0J?,4N7#
MK$0B]*\*K? *L3 +L8M18K  P<L7>L]!7.'JO/ UQ@[E<K!4IB+QMN,49@EY
M1D#GQ$+P,$1X5&,6NE $? ')S.8V[FTU;B'74H,%%>($L2P/>Z%:\@PCEN$/
M6>,8HF'@;+#.^D,A?L$14R,06<-Z?HLUQ$]A*"9$Q,>LYLOKCDC$@HF;4B+C
M'NP]IFC^M.DP%F5Q%FFQ%D,(;C:M#*7N&-B+M&:ATG21-;ZF-F9H MM+< IE
MA\0.<LZG E7"$#$Q-7J!JA "VL1F$U'"$)>C%W+".U"C2#;P.+!*IZP1-E0(
M  ="\#RG\KP#3)"QMS"&4U*GMD3%[@@' ?_GOM:0_FRQ'_WQ'P$R('%E.[XQ
M&/'-R(((9$;)(#.Q?<[D]1@D94)18H)A-9)AIF(*(Z>1(.BP);1Q.4@O)&8.
M'*WE(XWD8(@,2NQ,(BIP(T:22#AQ$E-C:: L^[:C[]AE7WX/S_R#/^ OQ;+I
MK%2'9401(@3R*)$R*95R*?\_(TB8X?08$KQNX6N4@B,*$KS\( ];HS@PQ]D&
MSDS(J $YH2*98WF>9AP)PB1] 1A&+0[%I0L7ZO0V$"S4DBU!,$B:81G,,"Y=
MPP^0["QO\(AB<.$@"S;"41W+2%(6PG"ZR";AC#TH*]82YW*^[D.JPX#J*"<O
M[[IJ)BTZLQMFY2\^$S3]PG9&<S1I!C7G(C29DC1!HS21#F;J0C5G!C9[Q38]
MDR]$HS%:$S&NI?^B<A>IH<<N8A;L<(6&@Q-ZATAP<'\\3&T&S)UB#RI7 \E:
M<B ^DB8Y0LDB$*GT4EFDY]IBD!.QLS7\0#N;@3LW)6Q:H^KF!!A3 PCM)?RR
MXSO_A2,\F68:QA-3Z)-!],4_W 3MNH[,]FQ_!HB)A-+!6B_G0@0I>(0U<Y,V
M925&*%1"9_,S(?1U7"5#%\-"\X)#'U0W.ZA54H0P<%,S3I0S4M202-1#2;0M
M5M1#;V1%8;1%>9-&<)-&"\-&170M=+0W)ZTD3#(X7P,8',H9< ,WM$$;DH,Y
M,HI1:H@ZBPP;PI,AI#0U]*TK08:,I(LEBE$KJY,CA; BM+'F*H(]5Z/'F.:V
M-I)MKC(^I4(;BP8ET/0.]V8'(9 /KV(:C@$8;@HC*K D;HO'AL@5WI3J+")0
MMZX;+TZG&&78:&(\I@MQ_&@)=<IPCG ?0VX=0Y0V2Q1'_TKT4T%T-3OS4V?'
M5$>55'\41AKC1F%E56&'1UT5,&!5,FJ5,FYU1&4U16V457LT0F>U1VIU5VLD
M1X,5,8C51X\52/%"EHAT.8ZA&%0-L,R$6K<!&ZB3!3+-5)IA2('C%K03(@X5
M-D"**5Z/7+ZGM,+$2JLL'<=Q(0S1%_S&%0PQ$C6"-?1J_4(O)NE56=ZQ7I."
ME0C+B)HFEF22YNID*_\*M?95'&_PS=0G'VTR_8I.7?LP%>7%(=EFB40N4U[K
M((**'W/$5)551EE$5$O59.-B0U5V9U@V5S\T5V'61EK6=61U1Y?U1'(V,V;V
M=D@66(,5-F?%6'O6188U62?T5_^+EBYVM4>7EEG3(B;L\UEY<&FPCV/OB(9^
M 4RGQ8R(X4ICX\@V1""F85Q?(],0T"MW1XFT:=I4J.$:KA=N2O"&PA"'P7'@
M,S54C2"FENH*9C[Z=BXYP6X9AA/R5@1BB",$402@ZL_ZD"3HD"$"UU$A(G"#
M,##? ^[TIMSV3*7RYWPXU]QJ@MIFK8A>36[*J%-5\V=QM$)+,U57%D-K-F=>
M=F>9=G:?]F5F-U9M%R]R%V=_M3-^EW=U=&B#UE5M<W=;-WC[8EF'MS*(-C)X
M-7E[%VKC8N"\-2JGQ4&BZ\=0PA6^-CC D%%&*1J]INPX9 "C1%XMK#J8</$J
M).%F[W&:$]43D\(0]]8VJDDU6J@@#G=O_Q9L-O'L^G4U^E<[]C<U^M<5$E@$
M@ ?=0HZX %7#FN%_U6PBZE0$K ?\QI2YB*IMHLF,E MU>LOZ^&Y$_//XK"+/
MJ$KQ6F9'7K1DGY=G7U8M8!<NC)=Y8X=Z<_>&(]166)>#9I@T=5AGBYB&C_B#
M6I:'\\)7;7B(2>-H=5AY-R-Z(2-&D;=ZK?_W+;9"]JAV-93A3]MD&J1/(QT+
M&_ZKN,QV-;9U.YP!&\1N&-0T0,H6;%O#4=[.V"+UZ[@P:4S'5!2U@%4#I.9C
M.54#@/$T-?:**"T">>:2&0R1#X?"D!4X(=XTB)IJA\XB4%TAD44 O8YJ(!RY
M(JXS\K@5\D#EP#0YK"[.&*_/B-(,\1PUE7MKAE07-8,8:&.7-WUXEWG9=7]9
M:$]4=F%&12040GM9+G+95V_T-(5Y>OVB16OTF47TAF.XF8\51+$9FI/X=F5T
MF[-Y58W7EW,VBZ&8B%7UF4LV9IMWB6NXG=4Y,8KWG7-3AH_XF']TF<U9BR^T
MFWW4B5456*^8GEW_\XEA%56UF$85&I^3V'GIF9IK)I_]&8NWV:"K%Z&K.:-U
M$YR9UV0Q.C6)>9K]F7;HXR6)U'HZY%JI,UKWMDTHV0P'%H6BP:_:KQE@T'>$
MZRNE(H\.M)8'#'GT398>Q1G+LSH]C($'JR(\N;B*RY%=X28B6=T:F+"ZE35\
M$IJB OHZ>*DE1BF<6DR#JZ9=\==<L:K<9)A$;H\(%*LAI9D 1=H"!@T'[C.H
M6)HM.IQCV)Z).)F9N5?W>J-3=I@#.U0CVE-Q.:]!&K'[VJZ-63;UVJ[OFK%5
M5K+Y(H<=>YWS6K%]MU5W-IH=6[.!-K!C]K(-^J^A>)YEDXGU>K%=5)JY_]EU
M%8.B4=9I.3N(29NT(]NP*QNW$]M$>]>S^?DN*!NS>3NW@;N?<1BO;[NSCS>U
M*SJTEQF= WJT2QNTC1NP-?JOT3FSBWNX-]NY:9NO70<G&OA9K?8A9H$7HJ07
M#C@_I10;Q)B\N ,Y"NJ@5$;]'G6!O-11.&$9B4JW*E D(IEO7AJ #W>!R^8F
ML)%,64-/6Z+ 6\*3$3QMN5?FA% @#KR(1&7! ;/.[NX>U8@8+81Q^HP^)H=Y
MD.HY].:^T49<R@=^1!:)D]FO39NU?[9I1]K&KWFPL;NY@YFP@=O'PYO&OYO(
MH9NRD5:[(1O'>WRD=YQD;U;'"]NZIQNU>]7(3?\;LJ];L'E4GLNY:=?YKD7:
MNG%\S+'<MSL:S+><:,%[N;$\R07C=[\YNN-<S8\\0\O<F^'9S&_\RY76SB%Z
MRI-[HAUZR+7<GFG\R:_\T+.<RN&YR^\\QU^'/@ N&(\AIKMI:)0AM$@Y]+9D
M&_X((F;AIO%J[*P&M@0(UA9Q0<@R-4S]YQJ"@X,K&UF#P@1BJHGBI5?R^6YC
M@"?"$)$O!0>K>0YW3E=/KK<B<I53P[J'(,K1>LC6?O\,YDYB.E!X3P)FVDU9
MEDYK?-1(STZ]J[!I.H2WN ?]LT/3SAO=W,\]68&YR<?\SK5[WL5\S6<VSR.]
MS:-<EY'<W7%W5EES==G_W- !/KC#7+I'F^#_?.&#M\]]O*^9&5D+O>%SV**I
M.^(Q'M$S/K)C^^$7>[4MOK2?6.3K689%&N)-?C"H^.3;7=([5,@-?>,%^N/U
MG.53_N81'J!#7N-_^.![?IJ1V^;I?>9Q/K3K_>BS7.>)GN-?GN)#>N1!*"=<
M(1IU\1,Y@@"1YAC,DB/!-EH7>"(6R](24G%0QR<"AW,.HM5C RS5+\#3LM9Y
MKL 39.;&1HB(XC@UF$,,L1A+0>X%(H/'A@A)UUT?-MJ3IOGPTA7P_C GBK+6
M%;^#Z>P?R/LDKXGF->V>#!<#)=WX2$49G9QGFX?W?=W9/>&C_-UU&>5=F\=1
M_[[&C5ZX\9WT]7W?&WOV(;V7V5SH?7ZOXQWHOWOWBW[H29ZA][F=9?[G@??B
M>[_G=7N*"W[BA_S1.Y[AI7_G?7ZA[YFBCS_G:=7@?;G='X/XH]_WK1_DE1G.
M&5KI29[W$W[]N?_]X=_T$5NWMY_>!5[(V7GIS?_\H=_] :*;P($$"QH\B#"A
MPH4,&SI\R(F3JV;,?HFXB#&CQHT<.WK\:,V5JXC;CGT4(5+DR64C(SH[R=&/
MKUXP:YXD5HH3Q9$CFTUD-G&B3F81?5+,"70G)Y,8?15MR5,BIVD:J464"$QC
MRZL3J6G\%76$QF$CDUY=MC'DU:P9>3;CE).3UXQ@(_^Z8HI1;<^>S)HI^W55
M:C.J&:WR%)N1K$ZHG-!J5#M5([&K2GU&C+LU<-RG;X4:%2PTM-W%HRT7)?HV
M,%S5ELOF?&LTJ&6?S![:;@@@M^[=MG<#Z.;[=_"!PPD6!^[;>/*'QP4&_XU<
MMW/>T7,;7#Y=>G;KVZ%7]]Z\.W/LQ+F7IWZ>^O."Q;&[)_^=._R%VL\?K'_?
M?'2$Z)5['__??OD%F-Z ]B74'W[7Z:>@?[<AJ-^!_.$G77\.0OA?@_YE&"%[
M&CYXH80#<DB@A!\*.&&)(IYX(FX=@IA>B?/!Z*&*VX6X((D*68CA<PVV2&&'
M"@)9WY!"'FECCCY&R"*#+Q82F)V!(TJ)XI0.$6E>BS1NR667_UZN%A$Q-HU)
MID?*0$78266Y M-D/,U59IQR C.:1)T1M5E4.;E"U%-U^I+1,5+!U9=GKJ1Y
MD55QL871979*)&9&SFQ6RT;8-(-9,W!F9,UJKC!Z$5>!18J1,U*Y\I)&P,RR
MDV4E773I9X=6%5BE&EW:DT3#<!223XB*8!5M/P6EVFHY;58H47RV)E&R@ZXF
M:Z%*>=HLL9D2^U-JU7)"%%#.<N(EB$LFJ21TR1TWXWL6SMBCC,N]JQZ/Y*F;
M)7KTJLACNP"^V%ZZ\19I;[[]:EECP09CB&/"(KI(X(<./ZD=P0"3&Z2-!%^)
M)$,5YULEE1+72V['75:LL9,6@XSOP_\4FXPPC5J.Z^Z/[+K\)(Y-@E?SPNV&
M%^6.+!\L<HX+R]QPSC7Z2*70/?N,<\PI/ATTT$R7W'3(X5Z-==8"<=5,,7)^
M;=,QG373#%X?15438'8!"G;;)_724FR%7A67::1ME:?9(Q2[9D2_3F87J"A1
MUM*F(JC=DMD7'8,-,<M8PW9:?7(B.%_$&@Y6:JY$CI$?P%CS"S7%T)21+],
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M4X>>#WL2356&*W%R&P6UX^>7%].C/_WJ7S_[(3O/CLPB]:N??R6C<=C%:]6
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M8"PC@=828@LK]<)EN2=9>QN7VW:%G\]-\'*NBE#G:EBVLV&(;LPY%FL:],/
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" #L!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>arwr-20230930_g2.jpg
<TEXT>
begin 644 arwr-20230930_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'E M4# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M=HQDX)Z<CKZU63QM:"^:RNK"^MK@$@*T8()'7D''<?G6D8NDW-:&%J*5N_\
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M0 4444 %%%% !129 (!(R>@]:6@ HHHH **** "BBB@ HHHH **** "BBB@
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MWX9R*W],UBTU5&\ARLJ??A<8=?J/ZBNRUCG::+]%%% @HHHH **** "BBB@
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MT=%5+:^CN.#\K^GK5NL&FMSI335T%%%%(84444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8GB74H;+3FB+L
M+B4?NE1L'(/4^U8VE:/>ZT\VH:B=B72J'&!\X7H0.@^O6NKN=/L[Q@US:PS,
M!@%T!(%60 !@# %82H\]3F;T[$M-O79'&ZS\.K#4V:6VU'4;&X.#OBF+*2.F
M5/!_2N7O=(\:Z#%+%.BZYI\LT<L\EN2L[A"" W?'R@<9KUJBK=*/30ATDFI0
M=FNQYI9>,K#49BCDV]Y-=JK07*[1!%_%SQS_ %-:USK5O8P?:3Y"P)J0M7+/
MG,7 +CWR1^%=%JF@Z=JPS=6L+R#H[1@FN=F\*-9MOM])LK@+]TJ<$?\  6./
MUJ7&:5E9A!5%*\K-?<4[B_DUB=8++?(+:Z,L5R01E#P5SQA<$C\JU5>*VB,:
MN&=FW.PZ$^WH*R[B34XTV26%U"@_A2 D?^.\53\^7./*GSZ>2V?Y5C"$HZRU
M86?,Y-:FK=7C,C*2&0@@J>00>HI]CK'F'<\:">%?*W;>=G4#Z=./:LZ&QU*]
M($-C.0?XI5\M1^+5H#PGJD"F6.XM9)'P70[E ]@><_D*Z*7-?78N"UU+3ZD=
MFU2%4# 51@"LZYNQM+,V .22:F7P_K;G!CM4']XS$_R%:EAX4BBD6;4)OM3J
M<K&%VQ@_3O\ C^5;\R6QOS)$?A6PD!EU.92IF79"I'(3J3^)_D*Z:BBH,V[A
M115>ZNTMD]6/04TK[$MI*['7%S';IESSV%8D]U+=/CMG@"FDRW<W=F)K7M+%
M( &8 R?RK6R@M=S&\JCLMBK::9G#S<#^[6JJ*B[5  ]J6BLY2;-8Q4=@HHHJ
M2@HHHH **** "D"J#D*!^%+10 4444 %%%% !1110 4444 5I;..699,8(//
MO3KBTCN!\PPWJ*GHI\S)Y4<_<6LMJ^>W8BK=GJ/2.8^P:M-T5U*L,@UC7E@T
M)+Q\I_*M5)2T9DXN#O$VP01D=**QK&_,1$<ARI_2M@$, 0<@]#6<HN+-8S4D
M+1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2YGH<[KTY2Y8.[\CJJ*9#*L\$<R?=D4,/H:?6)84444 %%%% !1110 4444
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M%6JKEY="XRTT,2W\*:9"X>59;IAT\]\C\A@?I6T %4*H  & !VI:* N%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !114<[R1P2/%$99%4E8PP&X^F3TH DJK?Q&2V)'5>:RM.UF;4M7C
M15EAC5)5EMY(\%2I7!)[]3T.*WB 1@]#33:?H$HWCZF'ITWE7(!Z-P:W:YZY
MB-O<D>_'O6U:3">W5LY(X-:5%U,:3M[K)Z***R-@HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@!,4M%% !1110 4444 %%%% !4-S<+;Q%C
MU["EGG2WCW.?H/6L&XN'N)"S'CL*N$+F<Y\NB-33F:4R3,<D\?Y_2H=7/,8]
M!_G^56M-7;: XQDU0U5LW.,]!C_/YU2UF3+2F6M)'[AC[XK0JIIR[;1>,9/_
M -:K=1/XC2'PH****DH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[0@'.Q<"L.!/.NE7KD]_2IANV74V43>MUV6\:]]O-2445B;K0**** "BBB@
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M-!@-OH5FK??:,2/_ +S?,?U-.O;V2WDV*H^M.G25MM2ZV(DKQ3T\B\ %
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MH+J_><[4RJ^@[TZST]IB'DX3^=:J*CK(PE-RTB16EF]R^3PO<FMV.-8D"(,
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MBBB@!&564JP!!Z@BJ$VA:5<-NDT^V+>HC /Z5H44 9/_  C&C9S]A3_OIO\
M&K=KIEC9<VMI#$?5$ /YU;HH **** "BBB@ HHHH ***1F"J68@ =2: %K/O
M;\1 QQ'+=SZ5#>:CG,</3N:K6MF]R^3PO<FM8PMK(QE-O2(VWMY+J7V[FMZ*
M)88PB#@?K1%$D*!$&!3ZF4[EPARA1114%A1110 4444 %%%% !1110 4444
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M[N$O:1[KC<A<QR8&-ORD#: >>IQ7H]SI]G>6RVUQ;120(R.L;+\H*D%2![$
MCZ5%-H^G7 OA-90O]O01W6Y<^<H! #>HP2* /*?$S3SW'C=_[-M);&5;/[7=
M2'=+:HT*YD1,?,5!W#YAR*OS1SZ3XVUWQ%8&2?\ LTVD=X@.3/:-"-Y]V7 <
M?1AWKT@Z1IQ2\4V4)6]0)<@H,2J%V@-ZC;Q]*=;:996;S/;VL4;3*BR%5^^%
M7:H/K@<4 >3P7,=[X"\,:%':S:A;ZC>7%Q<0VH5C);1S.YX) P6,8Z]Z[?X<
MW\UUX2BL[I9$O-,E>QF24 ./+/R[L9Y*%#^-;ECH6E:8T+6.GV]N88C!%Y:
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MIII?#S<+V%:RJJ*%48 [4M%3*39T1BH[!1114E!1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5A:$
MM[,;S^TP9MLQ,+R1@87H5''8C]:W ZL6"L"5." >AJEK%]!IVE7%S<22)&J[
M=T6-X)X&W/&>:F26[Z&D&[."6KL+J&JV>EVTDMQ)@1J"8T&YL$X' ]ZKQZA>
MWLUN]C;1&P<*YN99.64C)"J.<_7%8UCX6CFO)-0&I7%[;7EIY9DG<%SG&",*
M!Q@'\*W-'ETY8I+&PG64VQQ+@YPQR3[=<]*F\F]=C2I3IJ/NMMK?M_5RCK?B
M*RT[4;6SNBAMY2RW&^)F"_+E?;'K5@7^BZ07M3+%:QL@F!<X1P<#*D\'MP/4
M55EN] U/5'B-N+N\CD$3*8R1QU//! YY]J3Q%;Z--<:=!J=RL2!_W<&.#V_X
M".V>G:AU.;X;::"]FTU'775^ENGXNY-%X:L%U6WU*UV1K'\R+&."-I'!SC'.
M>E;;AFC8*VUB" ?0URNJ7VHWLUK+X>S):VK_ #%!B.4]-H]1U'H#]*ZM22BE
MEVDC)'I3@DFXI6%4<I1C-RO<P=%T*^TZ_FN[C43*)1AH0"5)]<GOUZ#O6_63
M9^(+._UJ?3[>6-_*B63<'Y8DD$8]L#\ZUJJ,%!61$ZDJCO+_ "VT*ER\TH,=
MN.O#/Z54CT9<YEDR>X%:U%5<Q<$W=E:.PMHQQ&#]:G6-$^ZBCZ"G4479226P
M4444AA1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5F:KK$6ERV\4R3!;C<HF1-PC(Z9'?Z#TK3J.:
M"*XB:*:-9(VZJPR#2=[:%0<5+WE=%;2K:"VL$\B0S"7]ZTQZRD\[C]:K:YI6
MG7UL\^HEO*AC)R7.Q>^[;T)%:B(L:*B*%51@ =A7,SZSJ\'B-=(:RM[N&:3<
M)E8KLB/56'/S#UZ$8Z&A/V:TT*C3]M)]>NI/HLFG7VGK8V#W#VJ+O,NXH58G
M.W'!'?CI5'3+G3--UFZBL&DEE=RLT94KL5"2S9/WNN..N*AUF.]\-"4:);*L
M%PIWR,/]6><!3VQR1NS][VI]S>I;>(+81:4UQ<26Z?9[AI-OFDC&9.W3C/)_
M,5S\MDI-KF6FW0Z&TN9J[BU?_A_/T&:7J.F7?B'4;S!CO(MQA5HM@D7:/FY_
MBZCZ$<4R#3;_ ,2Z? -7@5Y$E/\ I!4*NP@'&W@GV([_ (T[4]+M=;@@MM,G
MTJUC9B7DB.96E0\HHXX![GD>E7;B_P!8L]1L=/D1;A9;4J^TA6:3D9W'T&.W
M4U4[WN]/0M)<EHN[\]TE?^K?>1^(UDOY;/2]%>6.[@(EWPDK'$A! RPXSQP.
M];NCSR2V(BN;F*>\A.R?RR,JW8,!T.,9K&\+Z$MA+_:-K=HT%Q'B2)!E21P.
M<XXP>@'4U;M?#446JWEW+(Q2:7S%C1V49SG)P:UDW=-1]3F7+RN+E==++\/U
M$LM'T,ZQ)/:L6O+5AO E8["0< _AGBM^LNRTV.TUJ^N4G4M<89HAU'N?QSCZ
MFI[>RN(KDS2ZA/,.<1LJA1GZ#M2CIT"HU)_%?3K_ %W+M%<M\0[JZL_!\TMG
M=2VLYN;9%FB.&4-.BG'X$UR6JVU]9R^,88?$&L+'H]E%>V8-T24E9'8[B>67
M*#Y3D<GBK,3N=0\8^']+U"6QO=12&>'9YH9'*Q[ON[F VKGW(J_;ZSIUWJEU
MID%W')>VBH\\(/S(KC*GW!'I7E6K3:O=/XVNK5[;[*]A9OJ$1C)E>(P$R>6<
MX4[-V,@\U;CM6B\2:WKVA*99=)>S9(U.3<VC6R;X_<[0&7_:4>M 'HA\1:0N
M@/KK7T8TM%9FN"#M !*GMGJ,5?M[B&ZM8KF"19()4$B.O1E(R"/PKR+3;J74
MO!7@_1M.MUOOM=Q+?RPM)Y8>WBE9OF)!P"[1]O45V'P\N)XM!N]$O(_)O-'N
M7MFBW[RL9^>+GN-C*,_[- '4V%_;:G8Q7MG*);>4;D< C(Z=#S5FO';?6+Z'
MPOX9UK4-5N+FS2T!N;:&_,-R7,N!,!UE&/EV$_3)KV+M0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>arwr-20230930_g3.jpg
<TEXT>
begin 644 arwr-20230930_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" '0!"0# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[%/Q"\9>!?#-GXN\6>'=&EO(=-GO1:0,B@&XE:0XP(HO,DQU.P#O0!W/A?\
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M#_P_T7XT_$?]DNWT']G?6[J C4;;7/,UJSLYV AN'C+9^8,-N^*-6.!N&02
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M=U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6Q%*C'GK7MY6O\KG'CL2J%%U'OT.:\+?\%1_#?C+PY;:O9>'=;?3WN+BWNI
M,FU\H[1)@#YHV8$*PZX.,XK-U/\ X*T>#M7\/0/X:M)]1U:=)7:U/S/#&@!,
MRJ"#(GWAQ@\=*_.WXN_#_P 1Z3;>%_#_ (=\37OA[2)V_LV*[M[GS%,2SRR
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M[1?B&Y\)_L^^.=4L[>XNKS3O#]_<V\$$;22S2);2,J(J@LS$@  #))K\U?\
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M]4^.GA3QM\?OV@OBE^T3'X%G6YT/1?$<K+IT,J$%&D5I)"X!4$J"H; W9'%
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M/'/A6V:TM;SP_J4C63QDG)-MYB!9#N(+HPW# 8' P ?FI^U'^W%X]_X*H?\
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M7-97O:S/2:***Z3Z@**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7 *[5KRO_@D3\1?@QX$_X*D_MG:Y^TCJ_@C1_C5;^-KF/2;GQE/##]GT@23
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'0ANYVY(!K[F^*GQ#G\9_&*S\,2Z1X9T_4-1TV:XU'4YX_MT<#[3-)M<<N>
M@ (Z\' -?/\ \=+#Q%\&- \/>#?#K0Z-J%_?MXITG44?;;:EN99!',>/GB5?
M]7UVD8[U\9]:A0;A4H?O+O2?\KM9I;W['X?/$47*2C35FW:3Z?UW9Y%XI\6:
MO^Q-\4KW0)M6FDG=9=8U.Y%F+#4[B(QX,"W#Y8PA@N 1U)JSKG_!3.W_ &K/
M@3IGPVTRWU/3+BTNM@N+QE#%!)^Z?STQ\P4<D\G:2,UP.O? OXF?MV?M":CX
MPO\ 3M*UOPSX#FBD\13/JQLK>[1R7:U64_,7=5) 7[JGD\UU'[9^G1>)_P!E
M_0O'.E:=H'A_4M2,FFQ:5:?)>65I'.8XRZ)A5*A?=B.<Y:O5JX_GI4</)^_>
M[DNG8]&=.DJ-.$Y/VD[:IKW>U_U/H#XC^)X_VN/ASXLT?2O"F@O'X76VL;*:
M2Z>WNU;RV'[E$&)"Q7<S'J?J:^1?B#\7]"UY-,\*WHN++6[&5K:^6WC,,T8(
M&U<'J^X9Y%?=7[,/P)A_80_9I2Y\/7,_B_XC^,[&WEO-1=)'EU*&3YT2%&SY
M:Q*WS #DJ<D=*^,/^"D7C\Z[\4M \4IH=Q/?Z59RZ?JF^V6*Y2<3$QLP'.6^
M;!(X7'/-<_UR-9TL%"&E.ZO?N<]*A2EB_J[DVTG9[+FZ7N<5X \'ZAX9\7>,
MQ-\1=<\/.-.$UO9R6?F#4W<L423G:BY ^89R3C%=QHO[ 4WAV&T\0>.;K4[_
M %C5%@E:PV@&[N7&Y5 ;Y2B 99@"%&/6O#?A9XCU?XO>+9[F]"65P6MA 99C
M%&ELCDD,N#NY_BS7U'^TQ\5/%NM_ ?06T4WM_IUE+=0:V8[P?:[Q J"1$D3A
M;=5)_P!XMR:VQ5.M0J4W0=I?:=OAMM]YTX^IB:5:%#G2E*UWM;RNMRIIW[1?
M@CX=?$'_ (1:V6YT.WTR]BC06%UNM=1*DB>3S OSD'Y0J$KD?C7[4_\ !,']
MO7X8ZWH>D_#72H8-*U-(_M!D4A5O99"I!9>JR,",]N*_GQC^&6N:+:C^S_"T
MG_"/:M=#[#J$B&5[%,[_ "D&-IY'WE'7BOI7X*?%3Q+^SA^TIX<\6RZAJBZ_
M8P62R6ZV,3H\<?2&4#A&\L#!QGGUKUXYA059.I6LI1;EI]I>2_,*68QRW%0Q
M.'G=27O=>OX'])/Q$\53>$?#/V^WM/MCQW,$31DD8229(V88!/RAB?PK?3C
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M9+;EOMJM1Y+3JU<7&O"^F_DOU/?%/RTM%%?0'Z&%%%% !1110 4444 %%%%
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MT.B@#Y@^!7_!&;]E[]FWXFQ>,/!GP0\#Z-XCMY/-M[TVS7+6;]FA65G6(^Z
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M#7A;QWNU1[(O+=?OHXV,;("-Q+QXRI/09.!BO0O!_P"SO;^*_BGK/PQT3Q#
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MG2NIK[25252TI.[/U; 8=4:$:=K.VHJMS3@<TRE5L"I.L?1110 4A.*6D/-
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MW%[YVCWXCDMXIG.^TF^XZ+VV-A6 [,6]:Z.LWQ=X7M/&GAVZTR_C\VTO$V2
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M1\$_B!I=YX/\.^&-2\#^'A-ID^GVFFQ6J7\$WR/</LQN8*0!(0!D '.*\/\
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M[3_[-=QX;T+Q!XOO]8UW7-.B\/Z7="W&JS/I$OE^>[D1I!&P\QY7!$84D G
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M6MTNM-JDVJ0;>+B9V12DC'.4RV,?>- 'U-1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 (5W5C^/!<?\
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ML:^5_A1I'[4G[._P8TOX7Z;X-^''C2?PS9+HNA>.;OQ')I]J;*)1';37NGK
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M  Z\)_":XN-6TK0=/UPZU?:SJ\UN]JD\TZQ1QQVT,4TVU "[NX+;0N#]6T4
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MOMSQ(+EX%(1W YP3R5!SC/:KM%<_-I8WZZCD/RBG5&.*>K9- "T444 %%%%
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M;X _MN>!OB[\.OAY<ZEXH\(:#XR\=^'=-UQ/#,VNVYOX&N[:.<1+&6$CX\S
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M$._X0:R\&^.=,TFR DNXYK99])N51!S(NH-Y!/)VZ@Q)XKZA_P"">_[.^H?
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M0 /<FN8TW]H?P!K/Q&E\'VGCCPA=>+8,^9HL.L6[ZA'@9.8 _F#CG[M>/_\
M!8*,R?\ !+7X]J/.^;P3J(_<_P"L_P!2WW?]KT]\5\M_M(K^R[9?\$IH+?X?
MOX;/B=-.@/@!='V#QE_PE94&S9 /]+%^;K;YIDPV#)YOR;J /T1\0?&/PCX2
MUN#3=5\4^'=-U&ZNH;&&TNM2AAGFN)@3%"J,P8R. 2J@98 X!K/UK]I#X>>&
M_B+;^#]1\>>#;#Q9=E5@T6XUJVBU"4MC:%@9Q(2<C'R\U\C?LO\ P7C\5_\
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M=G#M8HVZ4L$&&!4Y/!!'6OSP_8DU;]G?PY^R_P"-=(_:$N/A]#\8-3UK4O\
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MZ HKRG]GS]MWX7?M3>&==U?P-XMM-6LO#$GEZQ]H@FTZ73/D\P/-%<I'(B%
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MZT#QSX+\(:K\.;;2VT+5]>T/49[-)&)&H?:@JJ"$?9&FUADR C< :^Q_A_\
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M'!P.IP>.*\A\8_!F#P;_ ,&W>A>&]'\.RV]S9> ]#NX]/ALF%PEZ)K2=I?+
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MI'_!$C]IGQGX?TZ?6/%FC6DEM8EUL[_6)I9TG;L'56",>-W;C%=-\'_^"/\
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M\4/"U[XRO/@YX4\-^&Y#=W\/@O2II+WQ/,$*I'))=1@6EN&/F,L?F2,55?,
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M%%W(;+4HYXXXX_M;:=+B=#N;8AVY.TDY&!RU:R_$O2R/^8A_X 3_ /Q%<O\
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M^\(^-M/UG0Y4USSIKR:[;4I'8(D:I"3',&5Y" @^4QC=GFOV;_9J\'7G@3X
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=$(SC]G4QDXR?Q'S5^P7^PUXP^%OQ&/CGXESV,FN6VG/86-I:7+S0V@>1BQ
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MIWA'Q;I7F6GEO%I$<-L3N>*:Q6W.^(8.'4KR0<9(/<5FZ#IW@&_U"*>"0O\
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M6Y5 6*DKOXQR<#@5L6?_  ;C:A9V$J_\+)MO,NIK>2Y5+"79.4.2Q)<L"&Y
M'7 R17E5ZV#DTZN-E?KRZ+Y:'7"%5*T*2MY[F=^UTO[$?[05F][;:E=>!]<T
M^X\G[9H^D;3*KL?G>%N&C5CST(K\]_$!M?@1?WEUX2\1V&L1'S$L;F"V,?VO
MYSL('59'^N4R*_630O\ @@!X"MI+CSO&NMWD1LWAM#%%&&2Z;F25VYWC<!\G
M'N:G\*?\&^?PSTKP->Z;K/B7Q-J>I7$ADBOX=MN+8D8RL?*EN6Y)_BKMP7$F
M P<'3C5E):6OK^B?XG/4R^O5DI.*7<\%_P""3_\ P6%L? 5M/X/^(MW<7%M<
MRJFEBS9KQ[)\?,IYSL(QSG[P/'-?KGIU]'J6GPW,+;X;A%E1A_$K#(/Y&OP&
M_:0_9HO/V./CMJWA+0+_ $NPAT=O)FUNZL8XIUM/E,9/'S!BQ)QDYX%?I;_P
M2*_:UO?C+X;\0>"=9U4ZW>^%EAN-/ORX(NK*15"[<#.U20!NYYY)KBXKR:E*
MBLRPNSU:6UM-?\S;+<8XU?J\_D?::C)IX&* *6OSX^A"BBB@#!;_ )*7%_V#
M'_\ 1RUO5@O_ ,E+A_[!C_\ HY:WJ;Z>A,=@HH S2[#2*$HI0O-.Q0 @6G44
M4 %%%% !1110 4444 %%%% !1110 4444 %(WW32T4 ?%OQ?^#'A;XQ_\%OO
M!1\4:/IVNQ^'/@UJ5_9VU] L\"3-K5I%YAC8%6*JQVD@[2<C!KB/V6?#_P %
MKW5OCM)^T!;?#R;XIR^-=6C\2CQN+0RPZ()6&E"V^T=+#^S_ ""ACPN\RY^?
M=7WXWAO3G\0#5C861U5;8V8O3 OV@0%@YB\S&[86 ;;G&0#BN=^(?[/W@+XN
MZS8ZCXK\$>$?$^H:9Q9W6K:/;WLUISG]V\B,4YYX(YH _-[X5:Q'\,?!?[(W
MC37+W4;#X4^'/BAXFT_P[K&ORNK6.@WEMJ,&B/<RS?,D3IY:1O*1\KP@D9%?
M1'A[5_#'[1'_  5PUF71KG1/&?ASP]\(/[$UZ2W:*_L89[O5A-%:3,-T9=XH
M6?RSSMP2,$5]:>+/!FD^.O#5WHVM:5INL:/?Q&"YL+ZV2XM;E./D>-P59>!P
M1CBJ/PT^$'A/X+^'SI/@_P +^'O"FEM(9FL]&TV&QMV<]7*1*J[C@<XS0!^/
M_@_X<Q6W[!W['<4#> /"GP_U3Q9KLWB6Z\1:(USX=O-32:\32EU..*2$.F\2
M+&9G\L2+"&!^45[3X#^$6DM^UYX@&H?%WX.:5:W/PWUFT\=VOPP\-RZ3:?V;
M,BI#>ZA=BZEM[>X@9G>!F D9?-_A%?H^_P -_#S^"Y/#9T'13X=FC:&32C8Q
M?8G1B693#MV$$DDC'))JA\/_ ('>"OA-X=NM(\*^#_"_AK2KYBUS9:5I4%E;
MW!(VDO'&BJQ(XY'2@#Y._P""4WB;1_ _COQC\);?2_AAJNI^"-"T:>+QSX"M
M88+'Q/I<@GBLUO4CR(;]!%(SQ[W5EE5U(#;1I_\ !0RT\*:G^UO\ H?BV+=O
M@\)-6D=-3"G0G\1A(/[-&H[_ -WL\HWAA\WY#-M_BVU]2?#7X0^$_@WI$VG^
M$?"WAWPI87,QN);;1]-AL8993P9&2)5!8X')&>*TO%/A+2O''AZZTG6M,T_6
M-*OD\JYLKZV2XM[A.NUXW!5A[$4 ?%?@OP_X!?\ X*GV%O\ !JV\/S^'[_P)
MJ47Q3M/#\<#Z%*?-@&E"X2(>3]M;-V /OF'=N^7;71?\$)O!VC>&O^"9'@"X
MTK2],T^2_EU5[J2SMDB-TR:K>(K.5 W%54*"<X  KZC^'/PG\+?!_0/[*\)>
M&M \+Z7YAE^QZ1I\-E;ER "WEQ*JY.!SCM6EX>\-:=X1T:+3M*T^RTS3X-WE
M6MI L,,>YBS;44!1EB2<#DDGO0!\2Z39?#V]_P""H'QE7XZ+X9GUP:;I7_"N
MH_%8A.G#P_\ 9E^UFP$_[KSOM_G_ &@K^\QY&?DVU\[VT/A^P^&/[?2?LXR7
MH\/)JGAWSAX=+D16?V6'^V1I17D*+7[7Y?D_*'W>5_#7ZD_%#X*>#OC=I,-A
MXS\)>&?%UC;2>;#;:UI<%_%$_3<JRJP!]P*T_#?@K1_!\;C2=(TS2O,CBA86
M=JD&Y(EV1*=H'RHORJ/X1P,4 ?F3_P %.](_9'B_X)R:==> Q\,XKR.YT5O
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M)-9?"_PA/:76K:*+23SH;Z6&[DABLU;RG22=>)401G+&LOX!>&OAOX!@\;?
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M$#><_/@9SBOU?QBLC5/A[H&MG4S>Z'H]V=:CCAU SV4<GV](\^6LN1^\"Y.
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M#;Q6SX<\,Z;X.T&TTK2-/LM+TNPB6"UL[.!8(+:->%1$4!54=@!@4 7J***
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MXK\,:H]_I>FFUET1X[G3K79;H2^(XBF8LEB%4;R22:^A_B1^R3\;OVEM(L?
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M8Y;CV?8!V'ITH Q0 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MVNDZD;J,W4D[1^5OFN9)=JYS@;B<<BM0#%#Z#0M%%%(84444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7P/\ M9?"KP)\?_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MLKXY_:]^%/PQU"_M/$GQ,^'WA^YTN>.VO8=3\1V=I):32+N2.19) 4=EY"L
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M@;\+G.T8 /L:QU>WUO3HKFTEANK6YC6:":)P\<R,,JZL."",$$=B*\#\,?\
M!0WP#JO[5WQ%^&=_XK\#:<? 6F:;>&[F\06ZR7$MP;D3PLC,-A@,$889)'FK
MN R,XG_!'V-++]AC1]-@^6PT'Q!K^E6$6XD6MK!K%Y'#"N>BH@55'95 Z"OD
MG_@JC\/O#]SI_P"W1_Q)]*CEF^'_ (.5YX[2-)AY]Y?+*1(!N!<8W'.3@9/
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M=U;'C+]I_P"&_P ./'-KX7\0^/\ P3H/B2^VBUTK4==M;6]N=W"[(7<.=W;
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MC)XL\8> -9\-^.?@/;P77BCP?)?13F2*?#07%G=HNR>WE0L5?8K;HV1E5@:
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M)^(?B6TUG7O!WA37-8T\@VE]J.D6]U<VN#D;)'4LN#TP176T4 8_B_P)I'Q
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1M'TS55U:XT>UA>XN#>W$ZJD;S-<3J5C0%56$ DECC[16W51T_,T[R@?7\Z
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
D* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>arwr-20230930_g4.gif
<TEXT>
begin 644 arwr-20230930_g4.gif
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MF%UL9BFKV<YR%FM,[&MDUWI9SY;VLZ=-+6)7:UG6;I9K(U0@+YR(_U$!@@>
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M"?FIZZJJ[1JO[SI!?,F'2I>%XA9EP4JMA/\"7N+E 5WZG90SKN[PI?N7-2(
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MLE7"([S##DS &&S%6HS 65QXL)J1X>=HF"3##7LB-<P= 1J^!K .)(+&!1C
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MZJ7K_Y('(2UI][C=59:V-#6T^:JIOKRZ[_>\6RD)'_9F%4&=.Q!, .'ZA'Q
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M8G\[W:N^=JHSQ^T*@7O;J9]UZ&-?^M;_$F<DVA.@WOTM%)&?P5K,>W>F32W
M7XOP<6/YXV,D!<.[:KV>>>D1,>[)* :0FE ]0U.>[>LZLYL[MJL[,L&[HV(=
M_)"]#Z&]%K,]3\*]FM$]W6 _WWL_SLN1X:-[O\5##!IB"Y.B*0FD+H;(OJ4S
MP+!#P+%3P.E+P.KS)P8</\.()M]!CF12.I#PC">3C#&Y)S5I/>/QD!@"BO9+
MBJ92B?2[K02SK?ASN2A,DT%I%,A#J:03H8)0BT-:$CO / ]\I"RQ0EVRE#(
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M"V%8EF$8YF4<MB(==E8>MJDO9MR,>]\A1@[.Q8X#Q R[.PX\HYR\9(X(K.#
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MAN_W_JW@\K C/S(D1W*V&D $B*O[RB^0MD$D>  SM('F$%YR"K1 "(2N_*9
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MH .ZG1?ZE?]YH@<ZEALZGR.ZFP\ZF??YHA]ZHU?ZHU\Z#W\!_A*MYBZ D1J
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MUFM!"GM]\W?_(Z)BFM$Z;$&I*9[&EVF\XXUN\^?OG__]]___ 3  !?!1IJ\
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M<LNZ/?5M,TQG[,#YS;2>M:UK[=Q8ZWK7D"&?HAK;0P2I>)OHBP1.)Y<"=BQ
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MT\JK1>DY^][*JD%/N,UKG_/;[S[W*8+]\!>\ZE4/@>E3\-T,9* -*8A$H@P
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M-J7U(:YS=_W[>@D'Q0%,F%U;F+#KX+O--^VX\XXU"8(K@9H$:VMNM1"(*0^
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M+@3E4-P UN$JZ. & I,*F@141RDZK' YPK@-!V]C@ M::#D90Y#MW!&"AI4
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M>M,KPI T[%)B_[&D"6U3$375V-B^W_3)M#2O+N7-0(M//)3+:#*#?1@ Y1B
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M,I^MW*<^^\G/?_HSH  =J$ +2M"#&C2A" 6E/1OJT(>.)GL7,4 Y7+8;+FK
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M0><:G"TC06OS0T-T1#>R'+M#"Y2!![1! C3 1J> !]!#"SR SCS -XM "[1
M28M 2^RRU]C4Z\FPD3HB !]6U-Y%.P(T!@YRJ,;T3SH88#&%RTGI"=H*0:^@
ML/ :L#CCW_E*W?@C&6*B0TMT5$OU5#\P'#] "T1" V3 1C=  FCT5C> ,T0"
M2%\ ,VSU66= &X2  ?^LM"&E:!\]JG\"%Y;MX2%)64[_41*"L-/P*#P'*-K=
M7).*S;H)-.!E(K @-$,G-$ >]D(W]=M4"%5+]F13-HV^<0C0PU9KM$:G0%BG
MP&=S=0,L #4PPT9[M5>K-5LW673!4Q*2&EN&:(G6LXBR="T.I4O7M*3Y,$^/
MH @.YC(W8+>EU% [=60O].XEA''/C6/[BAGN'E1#=65+]W13]W*Z<02< 3N<
M=F=S=UAS=%<W #.X@P=T]6DW0"2L=5NKLV]6%U'UXGV@F>I-YE@(I6T"Z6T2
MC6"/\G/]%$F^$=->63+VVW$S=V,C-T(H-U,W=X$W(X$_=75#>(1+.&JZ5@C_
M9'4&H'98.X.&<[@S;#@SD'8&='<"I  UJ':.Z30?OC6I3@JHQN73G-[21C-P
MRG-V4G"*,Z@B4J5D)G(CSC:/TSAQ$SCO$8L_TLU23\B1&SC]&;:13_B30WF4
M>Z+.4 -YD_AF-T!GMT%8BWB6>S<(A("5;WAG@_B)KYBF/  Z;UM@!N43#U5=
M5IG8_90=&:,\N?G9L8=>]F%=O)377!/3FF8#^1PF(K4*-G1R+W>N';1"-SFA
M!YV40WJD2WH &H [B "&:[0SH/:&:[27;[F'9T!*I\!F;WD#>(!*KS96@'*+
M.^5\WY6L><<>S@HM[O1(/J )"[.EKN->[3%O8FIO7JO?6RA(41?WO\6-<Q_X
M<C_VSQDU@A]U6<9#F9 )F$R[F5"[M&/[M6N[M7-[M7M[MG<[N'_[MI/EI)N[
MXQE !&AVEG?Y1K=!)'@ ,[3!AK-["K1 "(AXEZ= !M"#.YC_N8JYZ';ZL3P?
M\V#F.0"+&8$,YX)J+5=$Z2'1^!??N5227Z0N_"<'M$,8=7.WS:$_N(,O=E('
MWI!OO%*//+1_3,=4#,: 3,9X#,NKO,NOO,;$?,O;?,WC?,KK/,SO/,WW_,O[
M?,*0R+D3_>"M SULM#-T=QMD #-\P04D13?+.WB'\Y:/NE=GP *4<XXI%HU[
MK9;17A$;L'5NVA)V:IE)@*#\IQZSY"**V@UO4U)6XF:.YX GNX5,ALB?/++3
MW[&#/,DSN[([.4\"C^TXS_ T3_'04.'CSN&W$.-#_O,8ON(+S^-+?N-3_O(@
M?O!HON5O_N0C3^4OON! 3]&;/L11_T.'TWL;I#0<2T +;+A:?\%6.T.79T +
M;/V*W1%]S*;9J'F!_@?WT?9TFG'50JU@^W;Q/TUQ:5_2*FEAQ9[=][UQ/[53
M-_CUP\VR)SERKZ!A0A*Z.,_W9TOX4Q#X=X[XHW_YC__YJW_ZHY#Y?X[[\X[\
M+P_]D__[KW_\M__^E\OI \0_@0,)%C1X$&%"A0L9-G3X$&)$B1,I5K1X$6-&
MC1LY=DSXQ5F#% U"AESPP( !"=2H24AIH$6&-B%:-$B08&2"!E]2>O3Y$VA"
M=Q+<O2,JX>A1=^60NJ-65&G3ED.I/HT*E>K5J5>;$IUJM"K5=U:SEHW*-6E9
ML&>OAF!:E?^K6:5DNPY],!>MV;)6\Z:5\!! 8  &!?\K;/BP0,&)$S(>Z/BP
M8\6+*1,.C'AQ4,V;.7=6V X?:-&A28\V71KU:=6I6:]VW1KV:]FQ:<^V71OW
M;=VY>>_VW1OX;^'!B=OV?!QY<N7+F3=W_AQZ=.G3J5>G1Q)[B@S,7!J(X,6'
M#R\04DKPX($:LP850H[T$*)G=?D9C]*5RU;OT7=9)>SG:W^E_(:*JR[\^G-J
MP+W".C"J_=+B2ZX$D7*0/_[*"2%" BED4$"OS+I0P:OF&Y'$$DV<J+@4AUM1
MQ199?-'%&&&<4<8::;P1N!-UW)'''GW\$<@@A1Q2HDBR$RF#%E*-ZL '/OBP
MP09\R(-I@1",+"D%=LZ SP B=ZQP+JKT0M!#O/A3JL*UQ )0K#"ORNJ!K=J4
M$*X%RR0PP[NP(C NM\R4LZZQ$O0SOT#==,?+1!5=="$<';41TD<EC93222VM
M%-,;&=V4TTX]_1344$5]:"1GVFO@/0/6\0+*5FWP(J40(H# IE,S6."=!]89
M_Q6Z LD$$TP.\3P36+]"#/ L$)&*BZ\&Z>PKQ*&4=<<L-KG",*DR,R2SP+OJ
MH[,J/:G9D-=RS67NTG0S75?==ME]U]UX*SV7WGKMO1???.UMPU22VJ/&@')\
M<!5*'P!>IQP1;&J@#21;B"""+O7EK%"HE J!SV=_E?/7!RNTKU@)]%QP3VK/
MTHO0N-9*REN2Z\(8K;?PG-GDDC.&=N*<=69(WI[A_=GGH($>6N@9=SX:Z:25
M7IIIB!;6SID,T#/@ 8(+IF8=E4;:FJ04:.*IZ8V<U=8JIK2*=L)"*;0V*P>'
M_?9DC[5E6:JA-F3;V&2+U3CML[FB1D^M-GPVJK -/_^7Z,2+5ISQQ1UO?-W#
M)9^<\LHMW[%A4Q-H#[YUA+':!Y0,^()?D41BA[LSE+Q<HKWR1EEF!(W2ZN*C
MXE2K+KX"WWC JV9'.T*V 3T4VFP[+%3;WZ6*>ULUN6(=>B(?GQYRZJVO'GOK
MH]^>^^Z]_SXA#W0ZM0TE#9ABX%9]F*(\#QHP?:0&6K!R=? 1ZHIF _E[8%J]
M":1K<%;9T('LMK<"":N T++/N-I6E0"*Z2C8VLO::H:_X]UI<,@:"IOLU\'J
M9 ^$UQ-A"$DX0AQY$(4I5.$*S74=KB4 =0 S  3 (Q[V94T$.BE5UT+PA21)
M;(47= KQ^-:RXA'%>4[9G9E=;#<50'6L9'*"T,P4>+*GJ(DL9KO/WLAR1:4D
M461/G-L0AP*1RUCF(&<L2&8F@T864LZ$)91C'.DX1SN*YHUYU.,>^5BB+[RO
M83EI@ A>$B<(=&=TXQ-)2-K G3+\__"->&(@\VXF1*\LD3\#M&0#(02@F$DP
M?Y3L7;#N!,$)(B\K>(.B?LIB1C4^9C!K?&4;(Q-+@LRRCTFKXR[OV$M>_A)>
MN13F,(E9S(Y<(!(Z[%H";B6ZEZ2D!4;:6@9"DH$0A" DA'RCG2RF)S"&15!M
M\947]0*HVR4Q9<?"9/X&U#(UA5.291%0AXB23E\1I4YIP1CN).25P@$&,K:$
MY2S/6%"!MM&81_/E0H'94(8^E$4)E>A$*4I1 RP@ SHL"<.8\07 /> "$5#/
M^TKB#)UP!P09D!\05<C*2UHQ@0E<IP3*P4T-CC$J@#O+.OE&%[](D$U6:5:T
MK"543;*2+O_KN&DJ'82WFL(4@4IQ)4$/6IE;'A0Q;JQHOAS:58A^U:MA#<U6
MR5I6LZ)P'2$(I+],U[7S&*D!&2B5(!O0@1#$3YLL;*??MCA%<!K+>7[Y8E"W
MM4\DCM%:ARU>!67WQ::$$TX+]"<7%\13_?E5C$1Q959A*4O,7+6J6,7E67DE
M5M."%;6G%2%I6=M:UQHN)2G%3GOD&M<$:$,G-RF57$,"@@=<)ZYY7>%<,L@M
M!'VLGS/-3P:IR-S8W7-#H.1;?CQ9G\#=<T#]:R 5S;(A_Y@2NP3:+&?)^]GR
MFG<RE)',:S^56O>J]KWQ%1I[Z5M?^YZK/.H921NXE@*<V.0FI_)GK]3<\<>,
M-F #+$UAAKBK,ISFLTZ0]5 2Q9@@^ZR,*EH\VS<O]I9Y4I%9>:'P9$F<( ZO
M2:H [6QYU2B9%HL6J_=E%'QI+%\;U]A1,M;QCGDLI)=0PWTA8:N L].O!D2"
M&G?E;0,6L/\KO?K-;>6D[I3YFC>X,>N"8=QBQN@RR5&&M\O%%:4$0(DL,5.2
M+MI=5E;&2TM;JG>]!M5JCQ5U8SOC^,YV#@Z=^=QG/T?GF2'P0&TSMT-G[!<[
M1[[F&=X7/V8H&(62'*Q:I!@\O9R8G8I=9<?>Q,0(&<6(4@9+8B^=V-A%=I-H
M:1E96JGB@;Y8EC >#"Y'^V<?X1G7><YU6']C:U__&M@>>:8!0L ,E2KS5/V*
MVG9"D)Y&P^\+V[QRQ2SHT@X=U<(N<R"GNTNFXOK5I0!B]<P ]$#]93JF.)5N
MN8O5YO3&TL6S?C.\81QL(.D:W[O.=R_W;&]__QO@"7EFUB003>W_ )*M<17)
M NS:!G:\[WTJ56DDA:C*EL!TU%5.DR>SO5/\.;BQ=K$XEIF767EVV(IX<2?*
MEW+ ;?W3(;26LV78./.K!GQ'[5C-OO7=<YXSCC<X%_K0@3WLEX1 !!Y(0=3B
M*I,V>( >(5C'%\[@ 68PPP-GN+K6/4!Q:X=WTWPS%KB9.]V2G[QC72Z4=+\^
M2733%*C]?#"?Z$8G+_.5+.[N['JS:M7S_IWHU;&!:GQ>^)\;OEVV:4?@&=_X
M';\D:\^L*01:( (0@& #+?B"2R)/-=&5(R6@A[0'7?>K=&)Q[#8SX!#?OLFO
MT(R<1-$PL6SGN[$;"/9M.MO+D9L\OS@>$?C!%_[PB5_\'QD=^:)'_O*?_^EU
MNL/E=3F]8)0U+EA0@E+-A",EL%C-[J2H$I]?S] "@3=FZOO*^.E7__K9WW[W
M2X3Y\9?_L*5]Z;BDNN.EMSTXGZCAMPPU]=[&_@*0C,*/*F#&9CP-L,($PQYK
MS/(/G^CB_2:0 BO0 B_0W^9/ ^//ZWCO^[9+6:AHW>ZFGZC-@"@H*M0,IZ#+
M[IY%9N"&NLKN 36HBUP&+2@$ W-0!W>0!WLPH380"(VN_J[(Y S0GXS'35*P
M6\#O )^K0V['L9#0T@S0I^()[.9N!4N-]Y1'RG[/![\0#,-0#,>0#*L#?S!)
M[3@$[;I"S$S0R^AB=_ F;D &*=@.!4FFVZQP0$RPS=H(:\VXHJD"Q[NFJPP+
MT1 /$1$341$-0D NC(G&C.4R+2W&PLH::_^@9?;^T+$@K"7.Z0J_+#^@4-N,
MD'9<IY308A%34157D15;_U'X;@8&<^>4/$FY[HXK+ M.DK#Z9)':&LP&?X5D
MP&ULHN]X+BCO7!$9DU$9EY$97>L 6X^=."[V(##+BJ+2T(0829%.*+'42$[U
M,D[WF@<I1''"2DP!^<\LFE$=UY$=V]$=OX<8!F  ]D$>Z]$>[Q$?\U$?]Y$?
MY7$"^A$@_3$@^]$,!M(@!Z @#[(>$U(A&S(?]\$,Z'$ XA$B)9(B(U(>+](B
MYQ$C)Y(C-[(B,_(C13(D/;(D-9(D.Q(E35(E1Y(E0;(E3](E5Y(F9](F91(G
M8U(G89(G4[(G7](G@Q(HA[(F<_(GBW(GA1(IC_(FDY(HFY(IC5(IH7(JI?(I
MK?]R*:O2*;/R*K>2*KLR*KT2*[^2*\N2+,]R+--2+-<R+-M2*]T2+-]2+N.2
M+LU2+>'2+MER+O,2+]%2+^O2+_OR+O<R, ES, 'S,/G2,/]2,1&3,0O3,07S
M,1,3,AO3,BL3,RE3,R>3,YF2(.+1(4,3'QER'SN2'TTS'U%3-/51-5-S($ES
M-453-2ER'CU2'NFQ)'&S(W53(GGS-EW2-VLS-X&3.(?3.'>S.)'S.'LS.9ES
M.7_S.853.:?3.:D3.JU3.JM3.Z]S.[.3.[_3.\,S.,>S.<&3/*/S/+$S/;MS
M/<VS/,7S/=L3/M$S/NN3/N]3/>TS/_&3/?6S/_G3/0'G=#[WDT#_LT #]$ '
MU$ 7%$$95$$;%$(?5$+EDT+],T(K5$ Q-$$UU$$Y]$(M=$)!U$-#-$-%U$1+
M%$4W]$15-$4[=$5=M$4_-$9)E$5K%$8[DB"80B7<84>IQ4=_%$AKAEI&AG_P
MJ4>!M$A]] &0M*:"%)^"%$K=@7^B]$='ADJ5%$B?E$J35$B/=$B;]$J'E$F)
M8DF5U,.D%$SQ24^X%$W_XAW?%$[C5$[GM%QF:EGN%$]=CF4(YT[M0A,/J$^S
M)4_SM'<&%5 -]4_9PE!#IE %%5$_#AL#U60^KAI%ADXO%5,S55,W_Y4Z!-"4
MP O_&,L()_53.TU(0=5)1?54GW14Q\0 Z:E48]5'6S4MP,M4LY$J.%57=Y57
M>]57(P)6?5%8*XE8Q8Y/_[ 7@\6 T$U9GZ\2!<L$,^U7IY5:J]5:Y=0O[F[U
MDL)ML 4:RTD&/7 -LXOMMM5<[TE;B0?=_+#B2E"SKA5>XU5>Y]5$@M!>XR.(
M\F(:Z^G_4(VFH,6PW"%@$?!!D(@L((O"T/%.=H=0GJ)D O:=.@G"D#4**6U-
M3(S\Q"G"P(T_Z-5C/Q9D0W8S[M5>ZX]/?.JZOHM V.X%6Y9_RE4681" @D4&
M#RC-+(ACA85"M@W<O'59MRN!:"K=V%#;1#_6:(\6:9-V(4@V"#O0GE153V&5
M&T%,J825TK(1&JO/3N)F!I]+:Z7(>#BFB51/:<O6;,^67N4OR;Y \R( 8YK_
MEH7JSJ>V;5B#U9+>3N.\[USI:6<EL6/0< ]?[BH =P[9;"+BS>]>K=9 BXUB
MK3'4BW'Y#FTGEW(K=ZN6SQU:H P\H UTHM&@K@5$YP'85@1:H/(JSR5,EDY2
MA@ /:]/"BV8:MB^PL L+T&)I=VZ=*!BC,12)*)1&L=4B(G$QP^_@3'*)MW'?
M+<:,=]Z&UW*?%WJCEX^,[@&B2>'>YR:NUQDB(70OP-@4+@-D CXZT.-J5_IP
ME7A(37" 5VO!3J?FL UG)GX/),Q")%W3+EG%2R*&MY::E]X6U[P""G']-[VD
MUX /&(%5:-A"@!Z.[6FZ)@7BYWT6P-D ["9F8O0Z_PC_)K%N-+:#7S?;<N6>
MRI'[7+?:4&9=79=-N%!. M8<14[U7L8)/2:)$'8J]A=R!ZJ T4N'$:)_(_>5
MDI>\CC>!B]B(CWAIGBD"SH =;N*_N$;(!(D9W,%]G%@G(F%\G^SN-&F!<%%H
M9W<0SXVYQ.7,P%4N7I!NJ2P68?>IF"N#Y+!J)21<D5!DC@*'Y4V@?IB'=SB-
M#"J/+X,QB)B(D9B0"]F0S>7HC"2C$B!S2FK(0H(9TJ.V<B(% ,;KQ$5CN'!V
M0?&=)DMB_0860ZYVB&5?^VJ3!&5B1TF,R-%=C^>3T5% [IB'C9>/>[B/<[B
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MUT:$7G"A%F06&S<X3O8D\Z(8S>A%*\K1CGKTHW8*I&="( (/+,A#BFQ#&SQ
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MC/_X 1/Y! /YDR_YCF_YE'_YE;_YFM_YF?_YF/\O>=3SI#])(4.Q"4#O7&L
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M/NG>#@85E/\MS%2OFK5L^;=VI7MN@A6\8 8WV,$/AC#WJ@)8_* ( BT0 0A
ML($6?($J%#; HYY2CA$_);("--+M1EO4^!J):Y3MEB9=%TD6GX6#H;JQ B=[
M)&FAUIXO3LL'Q>EB2P(YPD=&<I*5O&0F-]G)*XENE$D<92J75+V?/:KN1BFM
MI@;/J5I=2U+YJ=]LB5DU_N5J!0.ZU!K;D[,;=)*96[S4]])%:'29[^KF?)8G
M]]G/?P9TH 4]Z#=6V="'MK)>4X-/45)-@*2KK ;%&;0ACWEK,6[DDG(UPLO"
MF#;O%&U\-WMIU\YXT?0=#:@39>9:0K?:U:^&=:QE/>NR(-K6AO^^<IW5W%78
MA+-W(&Q=GO\[[%*Y]LQ8)FK1P&Q 8:].P&&>JK;$W*)S\H;6U\9VMK6];6[W
M^=;?CNZ)4;VU!@[/6@@R]KC+G6=V%X]TS7:=.8O:3A_WQK-><_'+NKUO?O?;
MW_\&>, /1T_:T0;3:=[SG'/Z+(0_.[9&-1WP#BQ"K&&UX /D*L6]NMYK@6N^
MH6*D0 4^<I*7W.0G1WG*;X)BM(#Z-AE$M]1:#&045[JHO/$QI[V<2DF^F]Q-
M8J"RIY5BV02YY_!E)W!4OG2F-]WI3X=ZJ[\J+=; ]DD]Z[B-6[QL1NY7A TL
M-^U^W2V<X1=U#H^O([>\<6N]]Y1Q?C;_PK\6=;K7W>YWQWO>/PJS:?&FG00T
MIXQ97.J?*\;-(;RWT7D,8-4B*>Q+0CI/LU7VT*HE!/L8P#[,@'EB#"#SFQ]
MYS_/><]KGO2C#WWI02]ZTZ<>]:Q?O>I/WWK8SS[VKY>]ZVF?^]KK_O:[QWWP
M@3_\WQ??]L?W/?)[OWS>-U_XQD]^])G_?.4[G_C5I[[TK0_]Z5]?^]GO/O>W
MCWWOAY_\X@?_^+]??O6;?_WH9W_ZY1]_^L/?_N?'__OS[W[^M]__\[\__1/
M_@/ _?N_^C/  AS  PQ  D3 !51 !VQ !DS !Y3 "IS "*1 "+3 #;Q #LS
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MSL$RB($M:( MB,$P[,(<= .8$L$[I 9SE,/5O$,'A.F7[@*4#L.^VL(R!_R
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M7]LJJ4Y6)0NP>'C"YR+-V4CO8%'-V_S5']O.97W6:?W%\_S6T^T!5*&Y1R#
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M0?S#09R@0M0L0&22N5@OR0N7-A27,IQ$2JQ$%32 !<B K^N=-C 4IWF "XB
M*0*4E'&&YS@B$&B.@/];+2O,PNW3F@09E:CJ.*FQ.'6:F@41/^W:,8)PE3W:
MFHC;-:B2*EUL->[!&B\D0V5LD3 40TL$&0P<I7JH#'>9N4W**P*$-L\11 02
ML\% .<0@+,$)QW 91\80QP.8QG,LQW0DQW<Q1[U@1W6,QW=LQW6LQWE$)3"S
M1WK<QWQ$QW^41W?41LACBV<\2(1,2'9;AQ#@K5+LMT"!(EUJ /$(E$9I@ X(
M@>EH !\T+_"J-;@;O.BB.,&S(_/Q+I%HB%IYGU@;+X=;0NC:E.'R&F$TKG)*
MQOY9QJAH1IU4R#UQH;EXN0M20Q5ZMLG#O8),H;_IEPG;K\[8"Z=LC*C,C*G_
MM(RJ7(VKA$J[>,JYR,JNW$JI!$NJ%$NK)$NLW$HB>1C=HRB?;$NW?,O5NI14
MW*7=V9D$T(;GF!3>D8[M ($'^!.*[$A6Y!4QV@FJ*3\Y,BN,2S7";#LC_ \&
M63^T2KM:VS'W4[OL"IOO0I^2%#+X"XL/49L7 9%LF3^XS!-JB[8\#"P1S"MS
M&Y<5FB^*\JO^^PS&H0O1J!@G69C=O)@=\<TCF9C?%,[@W)?A-,[B))CC5,[D
M/)CC-#.X:!W"N:_*P!%'<KDA.4WMW$[NO*7@F:)!@;$44)[DL;10BT$/<(?A
MT\0&V("R0ZTC/!9<2;N-Z[M;G F#2*=3\0A/F2=M_Y(U4?D>G "\54E"D^ F
M 5TU)>,C+APOG'1&GMQ)T^S)[H23F0L<= &PN$#+ULF1:AR,:5N7OS@=*JFO
M$0TP.X0@@"DH"&+#%L6G%X7#&&51RH/1&I71&Z71^++1'<71'OTHR/N1$$J=
M'ZE0(SU2),4=F*$&#]BEA[0BL$L!EFF 2%"4[MB.!5 JCQ0).O+/\U$G#*%%
M;\*^E\@/]H@XQEP)YTH[DM@)L\$5]2D:-9HX6*R^+GV(!X70^HM0"4W2-QFE
MUF03<%'# PI4;#S#0<--OQ@DQ2(Y%37 OOJRU/&\?B@,2K742*K4Q[C43<U4
M3&4+3<4,3A553^U44/U4?WL20<W"-I=C'%7%+#^-55F=U8^)F1#P /&@-+"S
M2$JCCDC8P3/@MP9@AO<\+6##Q>&",GC*D.)"FEXC/)B@-8:PKI><G@C!.V)$
M4(W['@Y9+EQ#R>W)4_M9D3V=4&:D571-5W5=5W8E-AI<E.9X02MB&9TIE!"0
M(GX3E"__F+Y?1+BH:162^%<IDS(NE0A;;"NI^<5;D2X>.S_&5".3( F(@TR\
M8U;^.$)=0\;X6T8P5,9R;5>0#5F1'5F2G::8<;&9B83H(+XI;8X46(",; -V
MH [J:([F^,'Y8*<FG,^0;!"W^]F=S<\"?;\@R\P%[<4JC"/^Q)YJO<SX2=/.
MA(\\G0H^-4T4 :"2S5JMW5JN[5J1H4&8"0$1\  IM5GC:0,/H(<06(<O. /L
M8 8/. -F8 :Y]8#I>SBQP;LO?<QV,EAU*C_P.Q^_=4FR*HC"_2I=*PBPX2,=
M$Y\Y35-ZVMAQC1OY4[S%\UK,S5S-W5S.+0Z8<;&8N0\(: $1U@ !$-@ &GL9
MT$VQ3BN'2W'=8C6M(#S:ZGG6;O7/BTM6=XH?B5C3CH@UBC,_X2W"C.BNHLW;
MN/N:A','E<1,6:&N \6)SIU>ZJU>Z[U>/ %;[85=[>W>F+G;(03:[MNCB74C
M5_M7S\0CQ13)BG5%R#6RAL-""CE,Q83%@E@_RNPFB\->_NU?__U? *X-[QU@
M J9!G#5:^70'"!B*+B 08A@*![@N^N1/_LB5^IR>9\W@=FI>;0K>_QP;[@F!
M$QB*#JA6^[Q"HN59!@E@%FYA%W[A_BU@&1[_8'X]FJ*!@!(8B@D($ <8"F)X
MJO< O_O4B?PH,HDP./6Q/E"QS*(5R:X:80#@X*N1*Q#>GL$MPOF 82W>8B[N
M8I"=83 &VQ_LUJ558'@@BB](B0<&@ BVS+QER136"&G%IE9,20J!P@NNOK@C
M4 F 8NYK0BGNGNI96OW,&B\^9$1.9$5>Y!]B/XDHAPC(8:+H@(7H80!0!Y-<
M,H7E70P)JYT]QO>P.&I=W_33D%PT1@>!XA)>T.]+(_9ET/I@9%F>95JN95O6
MDP0>%APNBA,HB#46!@>! $H@"DK !8U8XS9V!PX8B@$0B&&>  >@ P"@!I>
M@%(@BA-0OH6X9@# _P5AZ(*A"(>!@ !P!H NT&8)0.8'((AE!H!F)@@SD&8
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M@1?XU_Z)9-TNG(#K7I: 0;=DU);D#X&'@U!L=NYJF2:)'-:'*Q0(26Z)PAX
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MPQRSS#/3_%BAU(3P10M??,%BN0G6O%9055FWWHR.>@6<,%9U<)-!'IY\HM,
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M&_E\FK;P^^___PN?_@G@ .H?8/U02GD ZQA X$E?]/F  DK  @C18&U3"T1
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M5F90?<WAK:JCKL5A5\17)U75%068'OWJ[5DJL?[KS.HBP=KLS=*'@JR#Q(B
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M^= R)>X0%_$P%W<19FS1%W_Q,IH)(GYKZ!"P^(S1 05G"'7+;11.FQ3-Z!C
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M9V<"A"("T+5-'  J_C93:;9*2S(VX,QEL2W]I!4J(I<]SS"4R/8N'N0!IFL
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MC03%U6.KUAT@X&IQ6"C8M;\%HEV% @(\VV+3=64E0!C"H62;N%<[#!VI5'1
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M( 8WJ,$.<G!F" RA"$=(PA+JC!J0.98SI <"=ZQC+S"40 M&E($0?$%YN,I
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MV&\Q-L(13LR>'),HP98*K_\#MSA6 1IDS\YXLS>N\6=3^^,@#WEV9HA(PB2
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MY%N^6<,CZ6AKHDJQ7;.Z[K.^0HJ^3+64H#5*/RB4V>*U24<;'%9%0&*^ !S
M CS !*P=PD ,#N  ".P ZI# "OS #HS Q* ."US!"=S "2S!&8S!$QS!#OS
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M^&>^.TTL;;C[&^+T)$(V6@2#:KQ5B\X#0SK6T8YWQ&,>::>X'=Y0=#N:W[E
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H<8I5O&(6M]C%+X9QC&4\8QK7V,8WQG&.=;QC'O?8QS\&<I!+'!  .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>arwr-20230930_g5.jpg
<TEXT>
begin 644 arwr-20230930_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY-)T7P#KFF^$3,I'E^=I\\$&W/1DLH2' QS<Y[UZ+_P1$_Y1G?&+_L8-9_\
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M1!)&P96&5(/!%?E?_P &_P!^]_:5^.$\?S(8H,..1S>7&* /(/C)_P %3/\
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MZT+#Q3J][!I'AFY\M',5Q*2\D@5P02D$<S#((W!<U%_P1X_Y1N?##_KPO_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+X<_#+QYI@LM:T'P9IUCJMFLZ2B"XBMT5TWQDJV&!&5)!QP2*])HH *^&_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1/ =]<7.DZCYGV2:ZT^:UD;RY7B;,4Z)(OSHP^91D $9!!/S?^S_ /" 1?\
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MXN)$,48$8&W@D T ?45%?-O[#'A+QW\4/AAX%_:S\:_M'^,M4UCQ5I9U36M
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M0:;=0V^J:K$FKVJA'N(XQY3%S&[/$J,QCQD!FR ?7E%?#4GQ4^/VI?L^^$?
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M\*ZAK7QCL[>7RR^I6\CZ1'8RA>BO>)>7&P\%;9#SQ7US0 4444 %%%% !02
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MBOQUX0\#^"-0^)/BKQ!;VFA:5IDFH7^ILVZ**UCC,C2Y7.X! 3QDGMFOG_\
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M-/O_ ![J?B'Q=H3^&[O2+N,O.UK817K36WE>8C0[(4EQ'MD!+,!]RT %%%%
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M)XA^)^@ZE/J'AR.Z31;_ $CQ/J.ESVR7/E>>HDL9X68/Y,>0Q(^7C&3GOZ*
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M1G2/3XQY=JKEE'[ULS328XWW# $XS7M-%% !1110 4444 %! (P1110!E_\
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M'RQ(41[03D 5ZM110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\
M0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\
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M#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\
M0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'P
MQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\
MOJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T
M&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_
MT&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\
M,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%
M%/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\^,/_
M 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I_P#S
MXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']G:?_
M ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%'
M]G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#
M_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\
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M^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\ WZ%']G:?_P ^,/\
MWZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I__/C#_P!^A1_9VG_\
M^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G:?\ \^,/_?H4?V=I
M_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY_9VG_P#/C#_WZ%']
MG:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\ OJKG]G:?_P ^,/\
MWZ%']G:?_P ^,/\ WZ% %/\ X3'PQ_T&H/\ OJC_ (3'PQ_T&H/^^JN?V=I_
M_/C#_P!^A1_9VG_\^,/_ 'Z% %/_ (3'PQ_T&H/^^J/^$Q\,?]!J#_OJKG]G
M:?\ \^,/_?H4?V=I_P#SXP_]^A0!3_X3'PQ_T&H/^^J/^$Q\,?\ 0:@_[ZJY
M_9VG_P#/C#_WZ%']G:?_ ,^,/_?H4 4_^$Q\,?\ 0:@_[ZH_X3'PQ_T&H/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %>4?MS_ /)H_CW_ + +_P#H:UZO7E'[<_\ R:/X]_[ +_\ H:T
M=U\+O^29^'?^P%:?^B4K=K"^%W_),_#O_8"M/_1*5NT %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %>4?MS_\FC^/?^P"_P#Z&M>KUY1^W/\ \FC^
M/?\ L O_ .AK0!W7PN_Y)GX=_P"P%:?^B4K=K"^%W_),_#O_ & K3_T2E;M
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E'[<__ ":/X]_[ +_^
MAK7J]>4?MS_\FC^/?^P"_P#Z&M '=?"[_DF?AW_L!6G_ *)2MVL+X7?\DS\.
M_P#8"M/_ $2E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7E'[
M<_\ R:/X]_[ +_\ H:UZO7E'[<__ ":/X]_[ +_^AK0!W7PN_P"29^'?^P%:
M?^B4K=K"^%W_ "3/P[_V K3_ -$I6[0 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 5Y1^W/\ \FC^/?\ L O_ .AK7J]>4?MS_P#)H_CW_L O_P"A
MK0!W7PN_Y)GX=_[ 5I_Z)2MVL+X7?\DS\._]@*T_]$I6[0 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*/VY_
M^31_'O\ V 7_ /0UKU>O*/VY_P#DT?Q[_P!@%_\ T-: .Z^%W_),_#O_ & K
M3_T2E;M87PN_Y)GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBLGQWXX\*_#/P5JWQ%\<ZNFGZ-H6
MG37^JWSQLX@MXD+R/M0%FPJDX4$GH 30!K44V*5)XEFC)*NH9201P?8TZ@ H
MHHH **** "O*/VY_^31_'O\ V 7_ /0UKU>O*/VY_P#DT?Q[_P!@%_\ T-:
M.Z^%W_),_#O_ & K3_T2E;M87PN_Y)GX=_[ 5I_Z)2MV@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\
M?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q
M10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2
MT?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+
M6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\
M?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q
M10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2
MT?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+
M6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\
M?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q
M10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2
MT?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+
M6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\
M?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q
M10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2
MT?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+
M6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\
M?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q
M10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+6Q10!C_\)+J__0H7O_?2
MT?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+
M6Q10!C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+6Q10!C_P#"2ZO_ -"A>_\
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M]B_X275_^A0O?^^EK8HK\KQV/QN9XJ>)Q=252I)W<I-MOU;.N,8P5HJR,?\
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M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL
M44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WT
MM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\ WTM'_"2ZO_T*%[_WTM;%
M% &/_P )+J__ $*%[_WTM'_"2ZO_ -"A>_\ ?2UL44 8_P#PDNK_ /0H7O\
MWTM'_"2ZO_T*%[_WTM;%% &/_P )+J__ $*%[_WTM6M*U6]U"1TNM$GM0JY#
M2D8;VXJ]10 4444 %%%% !1110 4444 %%%% !1110 4444 %>4?MS_\FC^/
M?^P"_P#Z&M>KUY1^W/\ \FC^/?\ L O_ .AK0!W7PN_Y)GX=_P"P%:?^B4K=
MK"^%W_),_#O_ & K3_T2E;M !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM2PT/@HTURTXKIHOB?F_.UD[&U+#TZ6N[[O<****^--PHHHH **** "BBB@
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MN?\ Y-'\>_\ 8!?_ -#6O5Z\H_;G_P"31_'O_8!?_P!#6@#NOA=_R3/P[_V
MK3_T2E;M87PN_P"29^'?^P%:?^B4K=H **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ J*^OK+3+*;4M2O(K>WMXFDGGGD")&BC+,S'@
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M?/!VDOZLSJ/AK\2_ 7QB\!Z7\3OAAXJL];T#6K1;G3-3L9-T<\9[CN""""I
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*/VY_\
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MBBBOFS4**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>^*WPH^'?QQ^'FJ_"GXK^$[37/#^MVIM]2TV]3*2H>001RK*0&5U(964,I!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_P""<OQ='_!1#_@G!<75AHVG3-=>)/#%C&9!I$;',I$7_+;3W'WXC_J>H^0
MQ?<O_!-S_@I5\)/^"AGPO_M;0FAT?QII$"#Q5X1DGS);,<#[1"3S+;L>C=5)
MVM@X+>YQ7PC@%EZX@X>DZF F_>B]9T)O[%1;VU]V771-NZE+.C6ES>SJ:2_,
M^E****_-CJ"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKQ#]JO
MX_\ Q/\ #VK_ /#.'[-'@U]7^)WB+PCJ&J:1=7%W;V]GHEO$R0+>S-.")2)Y
MHPL*HVX@[MJ\D ]OHKS34/BM\=K3X1Z1XGTO]F/4;SQ=?WQM+OPI<^)[&%+#
M:90;F:\5GC\DB)64QH[GSHP8P=P7A_"_[?NA0_"3XD>//C)\+M2\*ZY\*]57
M3O%'A>WOH]0:6YE6(VBVLZ!%F$YFB5,A#N;Y@!R0#Z#HKPWP9^UUXRT[XIV/
MPH_:6^!H^'EWKGAZ]UCP[?Q^*(M4MKJ*S"/=P2ND49AGBCD60J Z%=Q#G'.!
MX6_;Y\4:FG@OXA^+_P!G&_T/X;?$/6[73/"OC";Q%#+=;[LD6,UU8K&#;PSG
M;M<2N5\Q-P7- 'TC1110 5Y1^W/_ ,FC^/?^P"__ *&M=C\3/C+\+O@W8VNI
M_%#QK9:);WLQBM9;UR!(X&2HP#SCFO!OVN_VN_V:?'/[-/C'PEX2^,>CW^I7
M^CM%9V<$K%Y7W*=HRO7B@#Z"^%W_ "3/P[_V K3_ -$I6[7'_"SQGX6?X8^'
M'76X"#H-F0<G_GBE;W_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8
M_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H
M-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5
M%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/
M^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#
M4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I
M45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8
M_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H
M-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5
M%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#4'_?5'_"8^&/
M^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I45F_\)CX8_Z#
M4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8_P"@U!_WU0!I
M45F_\)CX8_Z#4'_?5'_"8^&/^@U!_P!]4 :5%9O_  F/AC_H-0?]]4?\)CX8
M_P"@U!_WU0!I45F_\)CX8_Z#4'_?5>+?M6?\%,/V-_V.-*DF^+_Q:MFU81;[
M;POHJ_:M3N,C(Q"I'E@]GE*(?[U=N7Y=C\UQ4<-@J4JE26T8IR?W+IW>R)E*
M,%>3LCWNO%OVL_\ @H-^R;^Q5I#7GQW^*UG9ZDT/F6GAK3_])U.Z&.-ENAW*
MIZ!Y-D?JPK\VOB'_ ,%9O^"DO_!1_P 2W7PJ_P""?7PCO?!?AUI/)N_$$$JF
M\1#_ !3ZA)MAL\CY@L7[T<A7>O2OV3?^"!'P8TC5U^*?[=_QGE^(7B.ZF^TW
MFAZ??SI8M,3DF>Y?%Q=G/.?W0/((<5^F0X!R7AF"K<78Q4I;K#T;3KORD]84
M[]VVGW3.7ZQ4JZ48W\WM_P $X+Q__P %<?\ @HY_P4:\5W7P>_X)K_ K4_#>
MCE_*NO$,4:2W\<;<!YKR3%MIX(YP"7!'RR$\5Z-^RK_P;M>'9=='Q<_X*"?%
MJ^\>>(KR87-]H.FZC/\ 9I)3R?M-ZY%Q<GUV^5R/O.*_1#P!I?P:^%7A2U\"
M_#+1=$\/Z-8IMM-+T>R2V@B'^RD:@ GN>I/)K9_X3'PQ_P!!J#_OJN?&^)=;
M!8:6!X9PT<#1>CE'WJTU_>JOWO.T;-;*5AQPJD^:J^9_A]Q3^&OPM^&WP;\(
MVW@'X3^!-)\.:+9KBVTS1K%+>%#W;:@ +''+'))Y))K>K-_X3'PQ_P!!J#_O
MJC_A,?#'_0:@_P"^J_,:M6I6J.I4DY2>K;=VWW;>YUI)*R-*BLW_ (3'PQ_T
M&H/^^J/^$Q\,?]!J#_OJH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*B
MLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_
M $&H/^^J -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,?]!J
M#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZH TJ
M*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\ A,?#
M'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'_0:@
M_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*B
MLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_
M $&H/^^J -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,?]!J
M#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZH TJ
M*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'_0:@_P"^J/\ A,?#
M'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*BLW_A,?#'_0:@
M_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_ $&H/^^J -*B
MLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZH TJ*S?^$Q\,?]!J#_OJC_A,?#'_
M $&H/^^J -*BLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[ZH T)H8KB)H)XE='4
MJZ.N0P/!!!ZBOR5_X*1?\$Q_BQ^Q!\4A_P %%/\ @FS+=:1#H]PU]XC\+:1'
MN.E \RS01 8ELF&?-MR"(P20#'D1?JU_PF/AC_H-0?\ ?5(WB_PLRE6UF @C
M!!/6OJ>%.+,QX2Q[KX=*=.:Y:E.6L*D'O&2]+V=KKS3:>5:C&M&SWZ/L?-__
M  3)_P""GWPL_P""A?PWVH+?0_B!HULI\3^%#-VX7[7;;CF2W9B/5HV(5LY1
MW^HZ_)+_ (*8?\$W/%'[,_Q-7_@H5_P35UJ31=1T>Z;4/$'A70QAK)N3)=6D
M6-KV[ L);4@J%9MJE"43ZR_X)D?\%9/A-^WE\/%TKQ/<V?AWXCZ1; ^(/#AD
M(CN5& ;RT+9+PL<94DM$QVMD%7?Z3BGA/+L3EO\ K%PVW/!R?[RF]9X>3^S/
MJX?RR[63;T;QHUI*?LJOQ='W/KNBLW_A,?#'_0:@_P"^J/\ A,?#'_0:@_[Z
MK\R.LTJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J
M/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/^^J -*BLW_A,
M?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[ZH_X3'PQ_T&H/
M^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\ A,?#'_0:@_[Z
MH_X3'PQ_T&H/^^J -*BLW_A,?#'_ $&H/^^J/^$Q\,?]!J#_ +ZH TJ*S?\
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M_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\
M\^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%3
M44 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?
M_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^
M,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U
M% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I
M_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\
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M:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\
MWZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%'
M]G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?
M_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]
M^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4
M?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G
M:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\
MWZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%'
M]G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?
M_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4?V=I_P#SXP_]
M^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G:?\ \^,/_?H4
M?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\ WZ%344 0_P!G
M:?\ \^,/_?H4?V=I_P#SXP_]^A4U% $/]G:?_P ^,/\ WZ%']G:?_P ^,/\
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MKEF9Y9+B/AI-X;_E[1WGAY/H^KIO[,NBWZVQI5IPG[*KOT??_@GV?_9VG_\
M/C#_ -^A1_9VG_\ /C#_ -^A4U%?EQUD/]G:?_SXP_\ ?H4?V=I__/C#_P!^
MA4U% $/]G:?_ ,^,/_?H4?V=I_\ SXP_]^A4U% $/]G:?_SXP_\ ?H4?V=I_
M_/C#_P!^A4U% $/]G:?_ ,^,/_?H4?V=I_\ SXP_]^A4U% $/]G:?_SXP_\
M?H4?V=I__/C#_P!^A4U% $/]G:?_ ,^,/_?H4?V=I_\ SXP_]^A4U% $/]G:
M?_SXP_\ ?H4?V=I__/C#_P!^A4U% $/]G:?_ ,^,/_?H4?V=I_\ SXP_]^A4
MU% $/]G:?_SXP_\ ?H4?V=I__/C#_P!^A4U% $/]G:?_ ,^,/_?H4?V=I_\
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MY.8\^9='.?FE8(W>*OT'T?1M'\.Z5;Z%X?TJVL;&TA6*TL[.!8HH8U& B(H
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0P6(HXCGA6DXMW<79_<^AS4\NQ=#%>TAB).#=W&5G\D^AYUX#_;6_9+^)GQ
MU7X4>"OVAO"MWXGT75I],U'P^^K)#>)=0R-%*BPRE7E"NI7<@93V)R*]0K\Z
M?VF_^#;O]E3XQ:QJ/C+X/_$_Q3X'UK4;F6YF2ZE_M>R:5V+LQ29EGR6)))G/
M7I7H7_!+?]A;]KG]@^7QW;_M#_M%WGCWPV-/MD\$:-IVKWEU'"J>:\["VN !
M!*<0JJ1E@<MS11Q&8*NJ=:DK/[2>GS6X8?%YJL2J6(H+E=_>C*Z^:>I]J45^
M2_AC_@XR^//P4\9R>!OVYOV']0T27SW*MIB7&FWL,(;C-K? B9L8RPDC4GD
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M>QKV,DSG$Y)BW5I-VDN623:YHNS:=M]D[/30X,SP/]H825'FLWL_\_(_/?\
M:#_X*/>//^"?G@:RUG0_@]J_C*VU.ZWFS-I<16-O$IQ(YO5C=(7)P N&)ZE1
M]ZLGX4_\',W[)OB;RK;XM_!CQIX5G?&^:P-OJ=M&>^7#12$?2(_2OT>TW3-/
MT?3XM*TNTC@MX(PD,,:X55':O-/BM^Q#^Q]\</,D^*W[,_@G6KB7.^_N?#L"
MW7/7$Z*)1^#"OM,/Q)P#C(.&;97-S;=ZM.LU)KI[C2AHN[;\S# X#$X'#1I1
MJWMW7Y>1P7PI_P""N?\ P3C^,7E1^%_VKO#5C/+@"V\2R2:2X8_PYO$B4G/'
MRD@]LU] >&_%7ACQEI2:[X0\1V&JV4O^KO--O$GB?Z.A(/YU\2_%;_@W@_X)
MU?$'S9O"&@^*O!4SY*GP[XC>6,-[I>K/Q[ K[8KP#Q)_P;<_&/X9ZK)XG_9-
M_;BN-,O1_J$U*QN--E3!R,W5G*Y/U$0Q71_87A7FG^YYK5PS>T:]+G^7-2=E
MZLZ_:8N'Q03]'_F?K117Y#_\*H_X.3_V5.?"OQ&G^(>F6W^L(UJQUKS5';&H
M*MV<_P"P-U.B_P""\'_!1?\ 9RE6S_;&_8)5(HFVO=-I6HZ"\HS][S)UGB;Z
MJH4\8I?\0GS;&ZY1C<-B^RIUHJ?SC/EL_*X?7(1^.+CZH_7:BOSJ^%/_  <K
M?L6^+?+M/BA\.O&_A&X;'F3"RAU"U3_@<4@E/_?JOI?X4_\ !4S_ ()Z?&?R
MX_!'[6?A!9IL".UUR_.E3,?[HCO5B9C[ &OF<SX#XSR>[Q> JQ2ZJ#E'_P "
MC>/XFL,10GM)'OU%5])U?2=>T^/5M#U2WO;69=T-S:3K)&X]0RD@_A5BODVG
M%V>YL%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **YOQO\ %OX<
M_#[5M-\+^*/&VDV>MZX)AX?T2ZU&..[U-HDWR"")COEV+\SE0=J\G KF?^%G
M^*OM?VCSH?+W9\CR1MQZ9Z_K7GXO,L+@YJ,W=OMT]3S<9FN$P,U"HVV^VMO4
M]*HJKHFJQ:WI4&J0J569,E2?NGH1^8-6J[H2C.*E'9GH0G&I!2CL]0HHHJB@
MHHHH **** "BBB@ HHHH **** "O*/VY_P#DT?Q[_P!@%_\ T-:]7KRC]N?_
M )-'\>_]@%__ $-: .Z^%W_),_#O_8"M/_1*5NUA?"[_ ))GX=_[ 5I_Z)2M
MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **;++'#&TTTBHB*6=V. H'4D]J^*OVSO^"[/[&O[+'VOPMX$
MUD_$KQ9!N3^RO"]TILH)!VGO<-&O.01$)7!&"HZU[&2\/YUQ%BUALMH2JS_N
MK1><GM%><FD14J4Z4;S=C[69E52S$  9)/:OC?\ ;._X+A_L8?LF?:_"_AWQ
M'_PL3Q=!N3^P?"ERCV\$@_AN+SF*/D$%4\R12.4%?%XL_P#@L]_P6?;?=NWP
MP^$U^>%(ETW3KFW/HO-SJ65]<P%A_P L\U]D_L8_\$,?V,OV4OLGBGQ=H/\
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M^"/P7LSJ'Q?^,/A?PM#LW"3Q#KUO9@CV\UUS^'6OF;]I+]F/]N3]M+_@GGX
M^'%U\59_AK\6HFTVZ\<WL>N/:QW+QVTL-W'(=,+1R+([K,(E_=AE4?+MP/F[
MX9_\&OW@"6[&L_M#?M:>(M=N)V#W</AO1XK-BW<>?<M<%_\ >**?:E7Q6.YD
MJ%&Z:3NVE:_2V]Q8C&YESJ.&P_,FD[RDHVOT:WNNI]S?M<_\%!_V<?V+?A+H
M?QK^+.KZG>:%XEF2+09_#FG_ &S[:SPF9-K;E0!HP64LP! X-?"OQ'_X.?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]O::?-:3W4MK9K=M%$ERD;'>C*%8@ MD=C7Y]ZS_ ,'&O[4OQIU*7P]^QO\
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M> H49595$U&R=M;-[+2^Y]N5!J>J:9HMA+JNLZC!:6L"%Y[FYF6..-1W9F(
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MY-_:8_X+I_\ !2C_ ()O?&[6_ J?L#Q>,O@AIGV:3PSXNFT#5;'[4LEM%-=
M:FGF6KA+EYTXBRFW:V<5?#>7YEQ+CI87#*/.HN5FU&]FE9-NS>NWJ*K.%*-V
M?ME17Y!? ?\ X/(/V$O&_DV/Q\_9_P#B%X#NI<>9<:=]FUJQB/?=(K0S$?2
MY]J^^OV-/^"J7[ G_!0+5KGPW^R9^T7IOBG6++3&U"^T(V%U9WUO;*\<;2M!
M=11OL5Y8T+ %<NO/(S[&9<*\191%SQ>%G&*WE:\5ZR5U^)$*U*?PL^@Z***\
M U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JEXA\-^'?%VCS^'?%>@V
M6IZ?=)LN;'4;5)X95]&1P58>Q%7:*&DU9B:35F?.]A_P2E_8(T#XZ:!^T9X+
M_9\TOP[XG\.:E]NL)/#\DEI:&8*P4M:(WD?*6W JBD,H.>,5\[_\%'O^":7_
M  4,^,'[3M[^UM^QS^ULNA7ATFTL;/PTFJ7>DRP00(<Q+/$SQW >5Y9,2+&O
M[TJ<XR?T0HKBK9?A:U)T^7E3=_=TU[Z'GU\JP5>BZ7+RIN_N^Z[]]#\V_P!@
M+X^?\%O/#W[4WAW]FW]M7X/B^\*WB73:IXVU+08V^RQ0V[N@COM/<6SN[JB
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MANXL'K\LJL/TK;HJZ=2I2FIP;36S6C!I,^:O%'_!(7_@G?XA\3VOCC3OV9M
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MD5A86.E646FZ990VUO @2&W@C")&HZ*JC@ >@J6BBOAVVW=G0%%%%( HHHH
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M\'=8^/\ ^T+XYA\->#] 6$ZOK5Q:S3);":>."/*0H[G=++&@PIY85\'?$O\
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MRR=F?L]17QC\!_\ @X._X)!?M!>3;>'/VT/#V@7LN ]CXY@GT,Q,?X3+>)'
M?JLC#WKZV\#_ !#\ ?$[0H_%/PV\<Z/XATR7_5:CH>IQ7<#]^)(F93^=>%C,
MLS++I<N*HSIO^]%Q_-&D9PG\+N;%%%%<)04444 %%%% !1110 4444 %%%%
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MT.6;4+IP>2/MU_RI'IY+#/?U^P_@#_P1O_X)X?L\^1>^'_V?=/\ $&IPX/\
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M3X:?\&UW_!&7X9^7<0_L@PZY=)C-UXF\5:I>[_K$USY/Y1BOH/X:_P#!./\
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M>1 DDXC&]E&2%)ZD#)X]S4M%?+FP4444 %%%% !1110 4444 %%%% !1110
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M>R2?9-"\-)'<B,L=H>\NYYS(^W&6,0Y]:_:'[%XW_P"@W9?^ Q_QH^Q>-_\
MH-V7_@,?\:\S)^(\YR"-18"KR>TMS:)O2]M6G;=[6+J4J=6W,KV/S^^#/_!J
MW_P1\^%'E3>)/A+XH\>W$."MQXS\97/+>K1V/V:)OH4(]J^L_@S_ ,$Z_P!@
MK]GGRI?@I^QQ\-?#ES#C9J&G^#;,79QT+7!C,K'W+&O3OL7C?_H-V7_@,?\
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M8HK'^Q>-_P#H-V7_ (#'_&C[%XW_ .@W9?\ @,?\: -BBL?[%XW_ .@W9?\
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M/^"/'A#_ (*U^"?"OA+XN_&_Q!X9;P;=WEUH[^'8H#!+-<)$C-<12QL9-HB
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M4]UI>K:5?VR:AJFF:G>6D]]I,<CR2Z>SVL\1V.SG!.[9N8K@G->PT4 <!/\
MLP?!(_"6S^!FD>$[G1?"]A,);73O#.N7NE.CAF8L9K.:*9BS,S-N<[V.6R>:
MR?AO^Q1^S7\*/AYK7PE\'^ KL^&/$%B+/5- UCQ+J.I6CP?O/DCBO+B58 3*
MY)B"$D@G)52/5:* /-_@Y^R7\"_@1KUQXJ^'_AJ_.JSZ<NG#4]<\0WVJ7$%D
MK!EM8I+R:5H80P!\M"JD@$@X&,SP%^PS^S%\-/&MEXZ\'_#V>"YTJ[FNM#L)
M]>OKC3M)GFW>9+:64LS6]J[;VYBC4C<0N :];HH **** "O*/VY_^31_'O\
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MI;Q1^0'C_P#X,T?V!=8WR_#;]I+XLZ%(^2$U.YTW4(D/L%M(6Q]7)]Z^EO\
M@C'_ ,$2/#7_  1\U#XEWNA_M!7/CW_A87]DK&;SPRNGOIL=E]L.W<MQ*)O,
M-T"3A,>4.#GC[IHKKQO&/$N8X">#Q.)<Z<K734=;--:VONEU)CAZ,)<R6I#?
MR7D5A/+I]NLMPL+&")VVAWP=JD]@3@9K\(IO"?\ P>>_ F9I=(\3'QC8QL2X
M2]\)ZB''H!<A;DC_ '>:_>.BN?),^>2^T7U:E64[756'/:U_AU5M]?EV'4I>
MTMJUZ'X-'_@K[_P=-? 8;/BM_P $TCXG@B_X^+MO@_JMP !U/FZ7<B)?J013
MH?\ @[S_ &N?A%,MM^TY_P $MQ9NK!9MFNW^B$'IPMW9S_D3^-?O'39H8KB)
MH)XE='4JZ.N0P/4$'J*]W_6GAVO_ +SE%-_X)SI_E<S]C56U1_F?CE\)_P#@
M\J_9-\8ZQ8Z#X\_8Z^)6EW5]<QV\<>@:AI^I9D=@J@>;);9Y(]*_8^O.?%7[
M'O[)'CO4HM9\;_LM_#G6;R"=9H+O5?!%A<2QRJ0RNK20DA@0""#D$9KT:O!S
MO%Y#BW!Y;AI4;7YDYN:>UK-ZZ:FM.-2-^=W/*?VB?VY?V0/V1]<T/PY^TY^T
M5X5\"7?B2*>31$\3ZHMHMVD)02LKOA0%,B9R1]ZI_ '[;G[&/Q7,8^%_[7'P
MQ\1F7_5KH7CW3KLM[8BF8Y]J\=_X*1_\$9?V._\ @J=K/A[Q'^TS/XN@U#PO
MI\]GHUWX8UU;4Q1RNKOE)(I$8DJO)7L*^&_'W_!F!^QOJ6\_"_\ :Z^)FC9S
MY8UZRT_4@OU\J*VS^E>CEV!X-Q."A];Q=2E6UYOW?-'=VM9WVM\R)RKJ7NQ3
M7J?LE!<074*W-K,DD;J&22-@58>H(ZT^OP=G_P"#07]JSX2S/=_LS_\ !4;[
M'(&+0^9X>OM%8'W>TO9OS _"F'_@CS_P=)? ?YOA-_P4S/B:VA_X]K1?C!J\
MP '0>3J=L(E^@)%=O^JW#E?_ ';-Z;_QPG3_ #N3[:JMZ;_,_>6BOB[_ ((M
M>$?^"MG@_P"%'C/3O^"M7B\ZKX@7Q#"G@TFXTF;%@L ,DGF:<H+;I6(Q-\X\
MO@ 'GZK^-/CK4?A?\'/%OQ,TC1)-3N_#OAF_U.UTV*)G>[DM[>258E5/F8L4
M"@+R<\<U\GC<!]4S"6%A4C4LTE*#O%WML].]O4WC+FCS6L=-17X1Z5_P>1_%
M?P!?IHG[0W_!,R:PN<XE:U\:SV$BXZX@N;!B?IO%>M> /^#S#]@O5PD?Q*_9
MH^+&AR-PS:7!INH1(?<M=0-CZ*3[5]-6\/.,:*YOJKDN\90E^4FS%8J@_M'[
M!45^=7@#_@ZA_P""-GC,HNN_'+Q)X69_X=?\!ZBVT^A-G%.!]<X]Z]X^$W_!
M:'_@E7\;]:L/#?PY_;J^']QJ.J74=MIUAJ.K'3Y[F>1@D<2)=K$S.S$*% R2
M0 *\7$\-\0X1-UL)4BEU<)6^^UC15J4MI(^G:*Y_XI>.O^%:^!+[QM_9?VW[
M%Y7^C>?Y>_?*D?WMK8QNST/2O'_^&Z/^J7?^5O\ ^T5\]4Q%&E*TW9FMFSZ
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M7PWID.B>'='M;"RMUVP6EE;K%%&OHJ*  /H*M45\]B<=C<;+FQ%64WWE)O\
M-LV48QV04445RC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *X_Q3\!/A-XUUZ?Q-XF\*?:;ZYV^?/]NG3=M4(.$D 'RJ!P.U=A14RA
M&:M)7 X_PM\!/A-X*UZ#Q-X9\*?9KZVW>1/]NG?;N4H>'D(/RL1R.]=A111&
M$8*T58 HHHJ@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KRC]N?
M_DT?Q[_V 7_]#6O5Z\H_;G_Y-'\>_P#8!?\ ]#6@#NOA=_R3/P[_ -@*T_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *\H_;G_ .31_'O_ & 7_P#0UKU>O*/VY_\
MDT?Q[_V 7_\ 0UH [KX7?\DS\._]@*T_]$I6[6%\+O\ DF?AW_L!6G_HE*W:
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O*/VY_^31_'O\ V 7_
M /0UKU>O*/VY_P#DT?Q[_P!@%_\ T-: .Z^%W_),_#O_ & K3_T2E;M87PN_
MY)GX=_[ 5I_Z)2MV@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KR
MC]N?_DT?Q[_V 7_]#6O5Z\H_;G_Y-'\>_P#8!?\ ]#6@#NOA=_R3/P[_ -@*
MT_\ 1*5NUA?"[_DF?AW_ + 5I_Z)2MV@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ KRC]N?_ )-'\>_]@%__ $-:]7KRC]N?_DT?Q[_V 7_]#6@#
MNOA=_P DS\._]@*T_P#1*5NUA?"[_DF?AW_L!6G_ *)2MV@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ KRC]N?\ Y-'\>_\ 8!?_ -#6O5Z\H_;G
M_P"31_'O_8!?_P!#6@#NOA=_R3/P[_V K3_T2E;M87PN_P"29^'?^P%:?^B4
MK=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-O[7/@+X5?"_]K_XA_%ZQU30O'>NZ&GB3X?Q>&[:&UT?3]7D1(6MKE1]H:6
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MKGXX?]&,^.__  )@KUWX7?\ ),_#O_8"M/\ T2E;M '@O_#7/QP_Z,9\=_\
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M\-<_'#_HQGQW_P"!,%'_  US\</^C&?'?_@3!7O5% '@O_#7/QP_Z,9\=_\
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M_AKGXX?]&,^._P#P)@KWJB@#P7_AKGXX?]&,^.__  )@H_X:Y^.'_1C/CO\
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M5*N>=^*'[<7C7PMJWQ&O/AM^ST?$WAOX3$KXXUJY\60Z?,K):)>3+:6SQ/\
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MXU\/?$GP/HWQ$\(WGVG2M>TJWU'3+@KCS+>:-9(VQVRK XH UJ*** "BBB@
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MC<C $'!]C4U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M?P]/&QNO$=KJ<$;V?V*,#-T6D)@*Q[MC)AMM?2?['_P^\0_"?]E/X<?#7Q=
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
C%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>arwr-20230930xex311001.jpg
<TEXT>
begin 644 arwr-20230930xex311001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% %9?^/QO]P?S-6:K+_Q^'_<'\S5F@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** *R<WK>R#^=6:K1_\?TG^X*LT %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110!6C_ ./Z7V459JM'_P ?TW^Z*LT
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@"K;_P#'S/\ 4?RJU56W_P"/FX_WA_*K5 !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 $X&368GB+0Y'9$UG3F=<[E6Z0D8ZYYKB_C7JE[IO@399
MLR+=W"P3.IP0A#$C/OM ^F1WKJ)_".A7_AF/138PK8B,"+RU&4/]]3C[W?/?
MOF@"Y-XDT*VN'@GUK3HID)#QO=(K*1U!!.12GQ#H@LQ>'6-/%J7V";[2FPMU
MQNSC/M7DWB.]O]/^,>MW.FV O+A-&8A2ZKY8V+\_S<''IWS72>-K+3--^%6O
MI"L:>>L5S+"@ "2.T8!"CH"5!^N: .ZLM8TS4B18ZC:71'403J^/R/N*C?Q!
MHL=S);R:O8+/%GS(FN4#)CKD9R*\;TTG6/%G@C35LTT.ZL;*.Y^T;@'OHRB\
M*5'.0K<$]V'6NA^+>D:9IGA&)[:UACFN=725W(R[NY9FY//X4 >A1>(=$G3?
M#K&GR)NV;DN4(W8)QP>N 3CVIYUW2%QNU6Q&02,W"=!P3U[5QWQ'T32M.\!^
M)+VWM(+>6YAA$I"?*Q1\(<#@-\Q&?IGI7*>-VV?#WX>HEO'*2]HP7 !;]T/E
M!/0'//T% 'K2>(-%E@::/5]/>)>KK<H5'..N?4@?C5FVO[.\:1;6[@G,>-XB
MD#;<],X/%<196J:C8>(M2O='CTZ\M8[FQ6W54XB,44GS%1AOF&0>VXUYVNK7
MND?L^6AL'>)KN^>"66,X(0ER1GKSM ^E 'NT>KZ9-/)!%J-H\T7$D:SJ63ZC
M.15QG5!EV"C(&2<<DX%<Z? _AYM#M]+33H8X8-K12*@WJZG(;=U)SU]<FN7^
M+6MLNE2Z39:I;VEW#$M]('=0\@1QLC7)ZD@MQD_(!CYJ /1Y[B&VC\R>:.*/
M.-TC!1^9JL-8TQB -1M"3P )U_QK%T>33?'OA/1]1O8$G3*SM"V"OG*"I!'<
M D\>PKA/ _A_3/$>H^/+'4+2%HCJ11"D:AHOFD *''RF@#UA=3L'F\E;VV:7
M.W8)5+9],9ZU)+=VT$B1S7$4;N<(KN 6^@/6O*M.CAMOCKXKF2TCD:WTQ9HX
MP@^^$A/'H3SS[U;^&%C:>*?"=_JVMV\5]?7US)'--.H=M@ PJY^Z!G@"@#TU
MYHHV59)$1G.%#,!GZ4I=% )90#TR:\.\-F;QC\,;C2M7D>]2WU:WM+>Z49=4
M:2-259AG@,>O.#BI=-NY=,N;?P#XNMDNIK:^MGTJYFBW++%YR J,CIMW=>V5
M/04 >W5&)XC*8A*AD R4W#('T_"N5^)FM7GA_P !7][IY9+CY(ED3_ED&8 M
M[<'CW(KG;_PUI=I\(EU." 1ZI#8)?)J XN/.V[RQD^\<DD=>AH ]-,T0<H9$
M#  E2PR*575_NL#]#7B7B6]76M*^'6L7UA%>7]S<H)D5$WW #*"O. 03V/'S
M5Z+X.LK%UN-8MM'329YW>VDM4B6/ CD8*6"\;L=2#B@#J20HR2 /4TF]=N[<
M-OKGBO-KZ7_A*?C!-X;U+,FD:?8"X^R;CLFD.P[G ZXWC@Y'R^]=+<>#]'MY
M;FZM[.&.![*6WEM G[I\E6!V?=!!4]!SGVH Z7<H."PS]:3S$SC>N?K7@_AF
M2.?X,ZQ/<:9<7-T/-=;[:K%&1?D.XMN&W)Z=,GU-6O%%C:1? K1[^.VB6];R
M9&N H\PLXPY+=<D8!]<#TH ]N\Q/[Z^O6CS$*EMZX'4YKR?XAV6F:5XQ\$K%
MI436\DDL,MM!"O[Y 8]B$<!@"<@&NCTK0='N/">H7L>DP6L&JV8>:P\H!$9-
MY!V] W(SCNH- ':^8F[&]<^F:4D#&2!GI7BGP_T[3-;T'0;2]T1FNY?M$_\
M:S1C<&CD^4+(#DD<#![+7;?%B*,_#K4KC8OGV_EO#)CYHV\Q1E3U!P2./6@#
MM!(A;:'4GT!I=R\?,.>1S7E_@73--UA]+N?[(%C>Z5964ZW9A"/=-)&^]B0?
MG4\<GG.ZL?Q9!_PKKQI;ZE8-!_9FI0O T$_SK9EB SJO4)DJ<#@\KQD4 >SA
MT;[K*?H:4,"2 02.M>7^-O#FD^&OA!=C2(8EDA$,B7D8 D=FD0%]P[L">G&#
M@<5=\(6-AJ&J+=P:9)IEQI?E,[;=C7?F0$,7 .&&2"#R>/<T >AD@=2!2Y&<
M9YKRCX?/%\0]0UC7]<5[I8KD16=I*Q\JW0#((7.-W3GU%/\ B9HBZ%X"U2YM
M[JX8F\BEMB\C,UJ#M5D1B20IP3CISB@#U2BN7U#2++^S_#]N\*NL=Q$@)X+#
M8<YQUR0"?6N,\;>'K;1&\)6D$T[M=:PD=S,96#S*[Y(//3G&* /6Z*\?^+&B
MP^'?!TMSI\]Q&T^I(R 2-^Y!C(95.<A25!QZU<\>Z<-!MO#_ (JLXV^S:?)$
ME[;JQVR1$C!(Z$@G&3_>'I0!ZI17)VMK9>)?$\NKIMFL+>U%M&1G;,[@,S'U
MVJ5 /^TWI7FWP_@M=<TR[TF^CNI+FYO[B*&\+2?N%6'(PX/)!YVD^IH ]UHK
M-UW4CH?AN_U()YC6=L\H7^\54D5P7AVPEUKX83^(-4O+N36+F&>Y2Y%PRF J
M6V>6 <*,*. .>] 'I]%>%:_XEU#5_@SINOM<30:M%="U:Z@E,;.HW9SMQUP,
MCU%=M86&GZK;ZE?6G]HVR60EMY89YI@)V,2/O*.>"&;AAUQGTH [^BO%/ =W
M_;WAO3].O+K6#J=]-<*M\;F<+&$4L"&W;6(('R^A.:V;.5K?XY:G9M<W0T^"
MP^U"W$[F-7^0E@F<=R<8[T >I45YMX#D;QY!J6OZM=7$J->-#:6L5Q)$EO&H
M!'RJ1\QR.3D\=LUF_$;3K_POX%NYX=;U&6=]3$D$QN9 \43J!Y9.[Y@"OZ_6
M@#UNBN*\,P6NK:@U]:3:C"MA)]FFBGFGQ/NA5B2DAX(+Y!QR/J*\\@UV*SN_
M'L6HZOJD4L%V\&E%+B<B.3=+M4$':,[5X;L#Z&@#WBBL3PA_:_\ PB>G?V]G
M^T_*_?YQGJ<9QWQC/O6W0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 5;?\ X^KC_>'\JM54MN;FY]G'_H(JW0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MIY8BX^?.[/\ $.,9J2\\6PV-MK%Q-I>H"+2CBX8>4<_*'RO[SGY64\XZ^O%
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M,&\3)K%W;75OKLGG.L4)4PR;F8%22>A<_D*]"JEI^J6^HFXCBW)/;/Y<\$F
M\3=1D G@CD$<$4 9_A+1]2T'0H=,U'48[_[/\D,PC*-Y?8-DG..@]@*W:**
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MV\294]"-RD<=P:[N[T^RU"-8[VTM[E%.56:,. ?4 BIEAB6)8EC01J %0*,
M#T% 'GO@SQ3I6B?"[29)KN!YTA"+;+*OF.Y<@*!GWKFKBVDU#XT^*X;?48[4
M&SA\PL5VRHH@WQDGID C(Y%>NR:/IDURMS+IMF\ZD%96@4L,=,'&>*9/H.CW
M,SS3Z38RRN<L\ELC,Q]R1S0 [3-5L]6CGDL9%EBAF:$R*059AC.".HR<?4&N
M&O)(V_: T\!U)712I /0[Y#CZX->@VUK;V4"P6L$4$*YQ'$@51GV%0?V/I@O
M/M@TZS^U;M_G^0N_=Z[L9S0!Y?XFTT6%[JOB#PCXLG.KPW6;G3C*LBO(6"[
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M?Q5FJEERUQ_UU-6Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZS>\M+ZWFMHRP>9) 44KUR>@Q0!<HJM8:C9ZI:BYL+J*Y@)*^9$P89'459H
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MM( )/T&<9]01VH U:*:CB10R\@\@^M.H **** "BBB@ HHHH **** "BBB@
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M6A!!9%VJ?O 8/L36[10!Q5]X-;3=?TK5?"FG:;:R6Y=+I6<Q":)@/EPJ'D$
M@]O?-4M4\(Z]?Z1XGLU73U?5K^.YA8W+X5%*?>_=]<1CI_>]N?0J* .'O]+\
M2OXFN-8:PL;[R8VBTN(W>U;;(YD8%.6) Z'@9'O5:_\ "_B2\\037NS39/)U
M&.ZMIKB9RWE+C$2@*1'CDDC[QQGUKT&B@#A-1\+ZU?3^('B^SP22W]M?Z?(T
MI(+Q(BX<8X!V>AZ]\4[6?#NK:R-9U(VL<-[=:0=+@M?/!'S,2SLV.Q;@>WO7
M<T4 <#<>%=4U/5<SQ"VMI/#[Z6TJRAF61BIS@=1P15G1=.U#1;*2[N="T*RN
M+.S=6FMRJ_:7 X._:/+3Y<G.>OM7:TC*KJ590RGJ",B@#-TRY_M[PY;W%W:&
M#[9;@RV[\X##D>XK#\/V^O\ AK2+?1&TQ-0CMMT<%U'<JB^7D[=X;D$#CY01
MQ77T4 <B=+UG_A,=*U:YACG6WL)H)WA8*/,<A@%!.<#;MR?4'UK&TSPWKNG:
M3X/LS8AY-,OY)KITE0JL;>8,C)!/$G8=C[5Z/10!Y]H_A?4],U&>TDT/2)XA
M>M<P:O*%:54:3>05*[BXR0#D#IZ5L>'[#4;3QCXFN[JQ>*UOY(9+>;S$8,$C
M"$$ Y!/7I_\ 7ZFB@#D?$5KJ\_C3P_>VVER76G:>)WG9)(@S,\910H9QTSSG
M%27']MW%KJ$-KH45K#=.D2I*\3,=Y(EF<!BI 7&%R23G/%=510!YQ%X4UA/"
MFM^$([1%T]#OTNZED0^8 X?9(%YZC&['3K[SW'A_5]2T*Z-KX?TK0K]##)"D
M91C-)'(LGS,@ "';@ Y.>3C'/H%% '%ZS9^(O$?A;4(I]-ALKDB%[>U^T!F=
MT<.VYQQM.  /Q/6LZ_T'Q!K4OBMY]/6V75-+BAM5:Y5RKIO^0XZ9+=>E>BT4
M <BUKJ]UXJ\.:A+I,D,-I:W"7!$\;"-I @ ^\"<;.< ]1C-&E>&;VS\87]S,
MZ-HZS->6,6<E)Y1B0^P'S8_ZZ&NNHH X'P_X<OK"YM[6ZT"P+VERTB:JSJ^Z
M,L3E4^\KX(7GCJ>> =WQ1HMQJ,FEZC8"-[[2[GSXXI&VK*I!5TSV)!X/J!VK
MH:* .1O[;4O%.H:7%/I<^G:=8W:W<S7,D9>5TSL5 C-\NX@DDCIQ44<.K177
MC-ETNY1KPA[-PT9$A$"1C'S<<KGGM[\5V=% ' V]IK*:#X)M!I$X-A-"MZK%
M,QA(BFX?-@C+?7 Z5<T2WUS3;B[TJ328FA_M*2ZAOW=3%Y4DA<_+G<)!N*CC
M'?/'/944 ><Z!H6I:;);V5WX8M9);.Y>8:HTBL'3<S HN=PD(..<#OGM70>
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MI"#P!P%3!X.<\UN64T%K?^+X-0TV[>![K[3@VK,D\1AC7 .,,<J>!SQ7<4A
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MR*MT"7CD'RR#*@#MQU^]Z<@'9T5S-]XPBTU[Z6[MT6PL[>*1KI)P0TLA^6(
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M(,R).N?W;#/!.#CK^7-2:5XEN=2\2W6FMI-S;P0VL$XDEV!E,@<X<;LC[NW
M!Y!SQB@#HZ*S-0UN&QO%LH[:YO+MHC/Y%LJEA&#C<2Q Z\8SD]A6;+XXTM3I
M8MXKR\.J)(]L+>'<6V#+*<D8(Z<].^!S0!TM%4=(U:VUO3(K^TWB)RRE9%VL
MC*2K*P[$$$?A7 P:W =2UNSU'Q5?VES'JAM+.&-U)"L$V8!4Y^9FZGH/:@#T
MRBL*Z\2VFDI-#=-/=2V,"R7TT$.1$",[F Z9 +8&>/PJ&]\;:19W\-DJWMW-
M/;BZC%G:/-OB) ##:#D<T ='17+IX^T1H4G87T=NUPUJTTEG(JQR@D;6R,@D
MC&,?7%:FDZ_::Q/>6\"7$5Q:,HFAN(3&RAAE3@]B ?RH U**Y;Q7?W]AK'AD
M6MVT4%UJ(MYX@@/F*48\D\C[O:G:A<7FK>*)]$M;^:PCM;);AYH I=I'9E0?
M,"-H"DD=R10!T]%8GA+6I-?\-6E_.JI<MNCG5.@D1BK8]L@USC^*;K3_ !]K
M&ES7TMV1%#_9NF[8E,LCAB1NV@X7;U)X!.<G% '?45FZ)9ZC9Z<BZKJ;W]VP
M#2.8T15/<*%4<?7)J#5/%&FZ3<2PSF>1H(Q+<F"%I!;H<X:3'W1@$_09H V:
M*XSQ-XAE.IZ+IM@U^+>_#2M=6$0<N@0E0C'(ZX)]@/6NHLXY-/TJ)+V]-P\$
M7[VYD4)OP.6(' H MT5R'A#Q->:QJFJ6FH0M QV7EBC8R;5QA>W7*DG/.6JY
M+XXT:*[O;8_;7>Q<I=&.RE<0X7=EL*<*1T/0]N.: .CHKF[3QQHU[9-=0F[,
M?[H1!K9PTYE!*",$?,>"..F#V&:D;QKH<=BUW+<2QHET+.56@??%,>BNN,CZ
M]/>@#H**Q1XITW;J9?[3&=,_X^E>W<%,\@CCYLCGC/%8%KXH32?%'B2/5]3N
M9+.%K9H5>V)%LKKD[BB_*N6 RW/R\D\F@#N:*R-4\3:7H\DJ7<LH,,0FF,4#
MR")"2 SE0=HX/7T-177B_1K._P#LDEPQ*M&DDJ1EHXVDQL5F' +9&/\ ZXH
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M8+]FNQ!A'VJ4VNA8\,IP>>O/M76T4 8<V@SZEX;O=,U:_,\UZA$DL2;%B)
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M7 !(R?FS^%/U*QU6Q\3-K6E6<-Z+FT6UF@>41%65F9'W$'(^8@CKT(S72T4
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M&R2ZDEG8:?)=L88)V02JDH27HRH>6"CD^E '5T57O[EK+3[BZ6!YVAC9Q$A
M+8&< D@5S^F>,UO[O3X[C3+BQM]0M&N;:>=U ?:JLR[<Y& V<GJ!F@#J**YB
MW\9P23:8\UG+#8:K)Y=C=,X(D8C*[EZKN )'7WQ5KPOJNH:M:WDM_:I!Y5Y/
M A20-D)*Z8Z#IM SWH W:*Q=6U][&\-E9:?-J%VD!N98HF"[(^0#D]68@@*.
MN#TQ5>;Q5N>"#3],N;N\>T6\DM25B>*)NF[=_$3D;?8YQ0!T5%<J?'-I.^DK
MIMC=7W]JP2RVQ0!1F/ 96R?E.3@D\#U-4;OQU<S0>'9M+TN67^T[F6%XGD16
M5HPP9.>/O*?FST7OF@#N**YK_A+U36X[&;3+N&WEO#8PW<FT+)*%+'"YW;?E
M(#8P351?%EEIMKJM[_9^JL(M66TN$<^8RNPC 906.$.Y< >O YH ["BL;1_$
M*:KJ-_I\EE<V5Y9>6TD4Y0DJX)5@58@C@_C2>(-?DT1(1#IEQ?22+(Y$9")&
MB %BSMPO7@'J: -JBN4_X3FWFFT2.STV\NO[8M6N;<IM&-H!*G)X(R.3Q[FG
M0>-[:X31Y8]/NO(U.9K=92R!895+91_FZ_*V,9!Q0!U-%9^EZLNJ2WRQP.B6
MEPUOYC,I61E^]MP3T/!SCD&J4_B40:AJEB=.N6FL+5;K"LF)HV+#Y26Z_*W7
M'2@#=HKE_P#A-8'FTZ"#2[^:;4;(7MLJ*F'7"DKDM@$!N<X''7I4$GC*:XO/
M#BZ=IDTT&K))*=SHCJ$7E=K$<@D$GVP,YH Z^BN)N?B/!;65W>G0=6:SLY)(
M[F?9&%C9)-A&2W)SZ9_G6W=>)K6PU6^L[R*6".SL_MK7#%2C1YP<8.<@@C!%
M &W17.^'_&-AX@OY["*.2&[AC68QL\;AD/&0R,PX/!&>*N:SKBZ3+:V\=G/>
M75SO,4$+(K,$ +8+L!W''7\C0!K45S$?BN>3Q#;61TR>*SDTS[?++)M#1 GH
M1G/'(( )S[4RW\<VUS;7;#3;Z&YAL&U&*WG55:: 9 8') R1T.#STH ZJBN4
MLO&?F>&]*OKC3YWO;VU%Q]FAV#*@*7<%FP%&\8R<\]*EB\<Z5=/IJ6<-[=/J
M,#7%L(H/O*IPP)) !'O_ %% '345SMIXTTN\.G&..[6'4'\J"9X"$\S#$H3Z
M_*W3(XZTP>-]+.L0V.)?*GF:VAN_E\J2=208QSNSD8SC!/ - '2T5R^F^.],
MU-;22.WOHX;NY:UCFE@VIYH+ *3GOM/MV)!XJ3PQXDN=>U+7()["2UCL+OR(
M]^,X"J3NPQYR2>.,$4 =)16=J&LV^GW=O9F.:>\N59HH(5!9E7&X\D  9'4C
MK7.>(O&"GPY:7.DBY8WE]%9.\:JKP,9 KH0Q^5\;@/0_@: .THK.T6QDL+)D
M>[O9UD<RHMXX>2$-SY>[J0.>I)]S5/3O%NFZE=VT$(G07@D-I+)'M2X$9^;;
MSGWY R.10!NT50UK5[;0=)GU.\64V\ W/Y49=@/7 K+/C33_ +1-;"SU,W4<
M0G6 VC!Y(B<;U!QP#USB@#HZ*P)/&&E^7:-;>?=FZM3>1K!'DB$8RYR1@<@8
MZ^U1/XL237M'L;*UDN;;4K9[E;E-N HVX."0?XLG\,9[ '245@)XQTJ2]@M@
MTP^T[Q:R^7E+@J,D(1R>G&0,]LUD:AXSTK5?#%Y=I_;EI9JBM]LM[5T8_/C"
M-C!.1@^QH [:BL+4/%>GZ9>26]Q'<[86B6:9(LI$9#A ><\GT!QGFJ%A<W0^
M)NK6;7<\EJ-/AF2%WRD;%V!VCMTH ZRBN9\<ZS<:1HD*VJ3^?>74-JDL(7,>
M^10>I')7<![XSBJNG:]8Z$\VFW5YJET8YXQ++=@.;0S8\N)G!R>W/S8W<F@#
ML**P]1\5Z;I<TBW'GF&&1(I[B./='"[8VJQ'.>1T!QN&<9IVC:])JNIZM:/I
M\\"V%T;<2OMVOA$;/7.3NR..F._% &U15'4-5@T]X8F26:XGW>5!"NYW"C+'
M'H,CD^H'4BLN?QMHT%K97 :ZE6\E>&)8K9V;S%!RA7&0V5(QUS0!T5%0VMPM
MW9P7*)(BS1K(%D4JP!&<$'H?:LJU\4Z==W=M GGHEV#]DG>(B.XP,G8W?@$C
M.,CD9H VZ*Y:/X@:'*D4@%\()9VMEE-G)M\T$C9TSN)!P,5)J/B73KC1+V1+
MN^M#!.EM*T5N1-#(2I&593@$,.2,<T =+16(GB!G\73Z%]@N<16\<WV@(-GS
M;^ISP/DP..N:=XBUY- @LW:"69KJ[BME$:%L%FYZ<_=#8]\4 ;-%85WXMTNR
MFD2;[3M@V_:95MV9+8L 1YC ?+P03Z=\5N%@JEB0% R30 M%<T?&MA)IUU=V
M]O>.L5F]Y#N@*BXC4#YD)ZCYAZ'FF?\ "<:=;Z=9SWL5U'-/:?:Y(DMV8QQ
M#>Y]%!/6@#J**P#XHB_X2B+2%MY3"UC]L-UM.P L ,GL,9))]JLV'B33M1OD
MLX6G662$SQ>; Z++&" 60D ,.1^!!H UJ*HZGJUII$4+W329GF6")(XR[.Y!
M(  'H"?PIVF:I::O:?:;.0O&':-MRE2KJ2K*0>00010!<HHHH **** "BBB@
M HHHH **** "F/\ ?7\:?3'^^OXT 4='/_$NA]R<5HUF:'QI,&>O/\ZTZ "B
MBB@ HHHH **** "BBB@ HHHH ***K+J%D\OE+>6YDWF/8)5)W#JN,]1D<>]
M%FBH4O+:2)Y4N(6CC)#NK@A<=<GM5&^\1:3I^B2:Q+?0-8H,^;'(K!SV"G."
M30!J457-_9A(G-W $F_U3>8,/].>?PIS7=LDOE/<1+)D#:7 .3T&/?!_*@!U
MQ%Y]M+#YDD7F(5\R,X9<C&0>Q%<WI'@BWT>ZMI(=8UB6WMR62UFNLQ%CG+$
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MG^+VK:T?3AI&BV6FB9IEM($A61@ 6"C R![ 5<9U4@,P&?4T;UW;=PW>F>:
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M,P#94?=8]15*\\*>(?$%]J4^K2Z?:Q7NF"R5+65Y&B<-O#<J 03G(],5W]%
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M]N\DS&-U1K>92PQ+;N "4Y P<]16[!X3T*VU:35(=-B6\DD,K29.-Y&"X7.
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M&]E)$N[=NSNY^;+<]R34I\':$=7DU/[%B>202R*)&$4D@Z.T>=I8=<D=>>M
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MFNI91=7+3K$\ID$((&55CSC()QP!G'N0#5HHHH **** "BBB@ HHHH ****
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MQ=$1++EMTCR;3M!*^G4BGZC<W-[XE\$7=W;_ &*X>ZNT>V$_F# B?!!  8$
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M&%P-ASM921A@<'!&<XKE;O0=9\WQ;8QZ<LD6NO\ N;HRIY<2F((2XSNR.2,
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M9Z!I<D$=S?\ SW$(GA$43R^9&?X@5!!%067C;3;F+6KB1+B&UTN<PR2O;O\
M-A5R<8SG+8QUQ@]ZP?#_ (;U71M>\,1R63O;V&E26UQ=+(FP2,0V -VX@$$9
MQW%7-/\ [3\*+XJNY]*>>&6_>^A=+B-1(C*@Q\S#!&&)SCIQG- ';T4R*3S8
M4DV,F]0VUQ@C/8^]/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVT4BW5X<SNT[L'/;Y2Q QT&!P.!Q6C110 4R2*.9-DL:NN0=K#(R#D?K3Z*
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M6Y91;21QE 5.P[E.<XP.:Z;PMIUUI'A73-.O/*^T6MND+^4Q925&,@D#T]*
M*<OC*RAN)2]M=#3X;@VLVHLJB%)=P3:<G=C<=N[&,]ZYWQ%XHO[_ $?Q=!!;
MW5@-((6*\AG"L7&UL<'/(/IC'?-32^%=:DTN_P###Q6TFCW=ZTXO?.Q(D+2B
M1T*%3EOO '.._M3-6\+:\+7Q9:V,-G/!K#"6)FG*.K;47:1M(P K'.>>.E '
M2P>*K)[F_AN8;FS-G;BZ+7$>W? 0?W@QDXR",'!XZ56/CG2HX+YYX;V"2RMA
M=RP20_.82<;P 2,9ZC.1@Y%9NJZ#K&N:MJ;2V<5M!=Z,MHDAG#A9@Q?!&,E<
MMCWQ[U7N-&\17GAK5[630M'M+BYM&M8X[%P/,9NKLQ VJ.,+R>3F@#K]'UF'
M6H))[>WO(H5;"/<P-$)01D,F[DJ?6N6UV;5-6\:-HD8U2UL([#S?M%E.L;B5
MI,*_WLE0%88(ZGIT-=CIRR)IMLDMN+=UB53"&W!,#& >]8IM=9C\:S:DMG:M
MI[6:VP(N#YI*LS [=N.2V,9]\]J *6B^*M/AT'261M7O5OI)H[>6:/S)9&5G
M)#$<#.TXZ #&<8.-%?%UB^GP726]XSS79LEMO*Q+YPW94@G P%)SG&.]<YX?
MT'7M+TWPK:2Z?'G3;N>2X87"D!'$@!'K_K/_ !VB71_%$MHZK81(C:Q)=RVI
MNPOGP,#A2R@_Q'YEQ@@8YYH Z"3QII45GIURRW974)GMX52W9F$J$@HP&<'*
MD>^/3FI[?Q5IUSIOVR(3LWVEK3[-LQ+YX.#'MSC(P2><8&<XKDM-\*ZW8PZ'
M;S:;:F.RUB>]<6UP B(V_:%! Z%\X]%]\4Y/#WB:-Y-2AM;=+VVUN:_@@>4;
M9X9%V%2PSM8*3ZB@#?F\1:;JD=@([S4+.0ZD+<JD)#"9.3%(<%0#]>>QJTGB
M_1Y-2^PB:7S#=-9+(87$;3J,F,-C&1S^1JAJ5OX@O;73)7TZ SIJ27,D$4X
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M#ZB@#=P,8P,>E!53C*CCIQ7)WWCRVL9;[.E:B]OIUQY-]<!5V0K@$/PQ+##
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MHHH **** "BBB@ HHHH *AE.+B'_ (%_*IJBD'[Z+\: *NCL&T>Q(/!A0_\
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MH **** "BBB@ HHHH **** "HY& DC!/)SBI*8Z@RH3U&<4 5-+_ .058?\
M7NG_ *"*O52TP8TRS'I"@'_?(J[0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !29!)&1D=15'6=5AT72Y;V92Y4A(XP<&61B%1![EB!GMFN0\$
M_:U\<^+!J%XEQ=/%92/L/R(2DF50?W5X'OU/6@#OJ**XCXCZ1:?\(OKFL,A:
M\2R$<3D_ZK:Q.5]#\W7VH [>BO+O%N@6VD?#M]2MXY(KSR;)9$CDPK.)8P6
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M=4T^"^MQ((9T#Q^8A4E3T.#ZCFJFJ:[%IUREG%:W%[>M&9A;6P!81@@%CN(
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MB6;Q''>HHC7)B$T;E^OHC>_/3FF:YI6IW*^.%BTRYE_M$6RVN O[W:@5CR>
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M#!!)4YXSR"?6NN\+V2V=A<LFF-IR7%R\PADE,DIR "\A+-\Q()X)XQWS6X2
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MIMG-<V^/)FD@5GCP<C:2,C!YXI++1-)TR>2>PTNRM)9!AY(+=(V89SR0.>:
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M+801RR&60;V8LYZL2Q)SQ27.@Z=>:HNI30N;Q86@619G7$;9RN 0._YX/84
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MMUK/F#R$_=94)\OK\@QS]>M-@\(75O=6LZ:W*3;:<=/13 N-AQ\WURJ_]\T
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M@K?Q#<G.,C</6M?1[S3)=<\*:A<A)Y;K1A'%<>296:8-&#\P!P1\V2>G.>]
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M+/#'=RI%,Y.26C#;3GOQS70@!5"J  !@ =J6B@ HHHH **** "BBB@ HHHH
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M=QQQEAW^M)9VNL75I?6>EK<R1S:5/Y+7=LT=Q82L5)MQ(P4.C$8&.FT'@#D
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M6GSW][,L-M A>1V.  /ZUY3J-A;Z3:VT.FQW$-S!I[1QZ?J4;3QW]N\CD19
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M4ERX;8SRE V<= 3N_/M6F[^,+./4HGO['=-%&]I:F_$D^=X#A',: ;@2%R"
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MOJ6EW::=/I4":DR//Y:RRS((0VU3F.-FRQR.0 ,'GM0!VY90P4D GH,]:6N
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M\*VT;B!G:P/6@#&;PK=-J6C7;ZP\O]G)*K&:(L\S2C#MNW#;[ # ^G%9FB^
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M[@#G!QV/<=QQ5B@#RZX:R75_'T<D[6T4EQ9$2PQA]C!4!<K_ !*)/O?C72>
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M]FO'C!($Q5LJPW8^7&<CGWJ33IX_$5U8PZ_</'#)H%K=0'[0T697!\R0'/+
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MHC;/7*@8.: .#O[Y9/$7C2V@O6DM5T02F(3ET20J^XA<X4D;<X]JY_5KP?\
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M.]=#IUA;Z7IUM86J;(+>-8HQUX QS[T^ZM+:^MVM[NWBN(6^]'*@=3WY!XH
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M"-P3/)'KB@!]%%% !1110 4444 %%%% !1110 4444 %%%'6@ HHHH ****
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M5[?QV]S/]IFL%F @>4\EL8W<G!(#8/<4 4='\2WVH>*;S3KB>TMVBDD4:=-
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M);GRR(F#*B(&&T9 R<DG\L=8,XYZT >:W=BNN^)?%0US2;6]@T^&$Q*+EE=
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M5Q+XUM->6YB$,%H]J8#&=S!F#$[L^H';UK/T[PGJ.E:C,EMKK)H;W+77V(0
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M5]F-WJBC/UXKF-1O;:7Q?J<J3:4+MKR,+I^H0SB:4Q(!&RJC8;YMQ4[#P>O
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M.X0JJQIC<[LP55&>,EF YXYK+'BAX8KH7VE75M=0SQV\<.0PN&D^YL?H??\
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M+FXU_3=;L)(A<V<<L+139"21OCN 2""H/3UH JCQO:-!ITRV=SLNK\Z?+N*
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M29T98D"X; /REF+9'&1BK6J36NK:SK>G:Q>/"MMI<3V<8N6BW!E8O+@$98,
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M/-,4LOS*NV)-S?,P&<>@SD^@!->:07-UK&A>%X[C4)Q<QZ_/;-<!@TBA5N%
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M3@/N9MISV4'/7TI$^(-M=BP73='U*^DO[,W=NL:HH(#!6#$L-I!/)/'IG(H
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M@8]S5V#1M.3339-IEBD$F&F@C@7RF;CG;C!Y ZCL*RK?QSI$\[Q,E[ 3 ]S
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M %*/ I6/_=!''X5;DBCFB>*5%>-P59&&0P/4$=Q6+HOBO3_$#J-/CO7C(?\
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MOM>9H'C5H>/G4L &7D<BF0>(;/6[:Z@T^XN8+@6HG1WMRC!&!VNN]<$<>AH
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M0<>8N0-RY[C-.TWQ7HFL3P0V%\)FN$9X2(W"R!<;L,0 2,C(SD=Q0!S'A_P
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MY^SV=XLLA5F7Y& D56VL4)&' /!*DBDLO$FD:C<&"UO5=_+,JDJRJZ X+(Q
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M;P?IM_>W"W%S-&2\JJ%#_,1D  8&!Z4 ;]%%% !1110 4444 %%%% !1110
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MTMX96FE\QY3UPAW'"#GKU)'H:]3JCJ^DVFN:9-IU\)&MIAB14D9"P],@@XH
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M J1P<YH Z"BL_2M0N;Y)1=Z;/83Q, R2,KALC.59201V[<@UH4 %%9NOZO\
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MCDA44L< G@>PH =15/2M5LM;TV+4=.G\ZUEW;)-K+G:Q4\, >H(JY0 4444
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ML$>@(PO8"NA.@:2VJ_VFVG6YOLAO/*#=D# /UQQFB#0M+MM5EU2&QACOIO\
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MQ4(T1@VN[2*(SU0!B0%/<#K4=IX/T"QTZZT^UTV.*UNUVS(K-\Z_W<YR!R>
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MF*WECNY4D1#_  [PVXK[$\4 4OA6&7X<Z8';<X>X#-CJ?/DYJEJE_P"(_/\
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M, 8PAXG+99C\QW\ ^F!UYS6UOPSK6O0ZQ>36]E!?W.F_V;;0K.6559MSNS[
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M)UBXM+K0+>V,EK'-N210V^*15Y^;(Y..@^M>@V=J+7PQ%:F PB.TV>2TADV
M+]TL>3CI0!-;ZSI=W=BTMM2M)K@IY@BCG5F*_P![ .<>])_;FDFZDMO[3L_/
MB#%X_/7<H7[Q(SQCOZ5Y?X2T^WOM \$G2K!X[^WN!/=70M60"(!PX,A #;LJ
M, GVZ5I>&K:W!TR/4=%UDZIILDQFDG\XPQC#;I%/W7WYP%7))/3O0!V%WXBL
M+FRE_LG7-)^T(8V+2W"E%4L,YP>XW >^*OWFM:7ITRPWNHVEM*^"J33*A.3@
M<$^O%>8SZ25^!=O;C2)O[3*11^6MFWG!A,&.1MW#@$YZ?G6U?R%M0\86-SI=
MU.=1B064JVKR))F!5$9(!"[7.[G ^8GL< '5^(]=M="TF:XFOK*VG*,;<7<@
M59& SC&03^%/\-ZG+K7AK3=3F1(Y;NW29D3. 6&<#-<*8K[1IKVVUZSO+\R:
M)!;6MS#;27(\Q8R)5.T-AF<@Y.,@#)KL/!*O'X(T6.2WEMY([..-XI49&5E&
M""&YZB@#>HHHH **** "BBB@ HHHH ****  ]*A;_CX7Z&ICTJ)O^/A?]TT
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MH2KOQCC;ZT =RSJI4,P!8X4$]3C.!^1JAH^N6&NQ7,EA)(ZVTYMY1)$T95P
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M[@".#QU/% '>4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M8[B4R+#&>"J@^HXYR<<=*@T[P1H>FVD]I'!-+;31-!Y-Q.\B1QMC<B!C\H)
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M9<-L W%W*Y &W&0/<U*OB'7WTB4I/"EW!KJ:>#<PKF2-F0#=M. </R5].,4
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M110 5&W^M_"I*B;_ %P^E $M%%% !1110 4444 %%%% !1110 4444 %%%%
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M\F(6.Z(8R1@<GYAQUK)G\8:/K&ARSVNHZA9P;H,7D=HP^^X"A2RD')^4^F:
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MLYKNZE2*"%"\DCG 4#O7/+XP@F\1:=90&V?3[VSDN1="<$J5*@J1T'WAWZT
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M "BBB@ HHHH **** $/2HV_UP^E2'I4;?Z\?2@"6@T44 ( !TI:** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@#@_&^KZC:7UU'IVI7$;6FE2WOV>UC
M3*NN<22LXQLX(VCD\^E1RZOK5[XE-K#JLEI;/X?34=D<,;%92Q'!93QQWS^%
M=/JGA30M:O!=ZCIT5Q.(_*+,6 9,DX(!P<$DC/2DA\)Z+;R^;#:R(_V7[&"M
MS+Q#_<^]T[^N>>M '*66O:UK)\&P)JDEH^J:?+-=O'#&Q9D5?F7<I .3Z8]J
MGT#7]5O1X5>YOV;[;)>PW*^6@$OE%PK<+P?E'3 ]JW[?P7H=I/82VT$\)L$>
M.V5+J4"-7Y88W=_\/2GCPAH8L+>R%DPAMI6FA_?R;HV;.XJ^[<,Y.1G!S0!R
MNG>(=7NM$T\2ZC=27<VK7-L?L\$1FFC0N !E=B@84LQ X![FDBO;O7/#?@>Z
MU5UDNVUD>:R@ ,R+. >./X1TXKIQX'\."TBM1IB""*=KB-!(X"NPPQ'/0CMT
M]J>O@[18[:RMX+>6W@LIS<P1P3NBI(<\X!YZD8Z8)'>@"'QMJ%_IF@QW6G77
MV>;[7!$6\M7RKR!#P?\ >S^%8]]<>)WU>?0=-U3?<VUF+D7$@BC:1G=PH9?+
M(**% .T \]:ZK6M#LM?M$M;\3&))%E BF>/YE.025(S@X/U JKK/A+1M>N+>
MXU"V>2:W78DB3/&VWJ5)4C(]C0!S<&H>*-8U>_TZVUFSM_(TZVN/-@@64><X
M;(4G@H2IY/.,8[TW1/$VJ^,9-/MH;B32?,TM;Z66&)&9W,A3"[PPV?*3TSR.
M?6:/PJ;CQMJ+3Z9>V^E/8PV<$EO=+%&53=N4JD@;!!4#(['IWZ*Z\+Z9</:2
M1K-:2VD/V>&6UF:)EBX^3(/(X'6@#CH/%.OZL/#$4-Y#937UQ=VMRRP!U9H5
M?# -T&5SC_\ 55_PM!J#>-_$]OJ>JR7WV>*TB<-$BI(&B9B-N/E&6;@'OSFM
MX>$=)6?2I(HYHAI8;[)'',P5"W4D9Y)&0<]<G-.NM(CL;Z]UO3+-YM6N41&0
MW31QR$#:I<9V_*.^"< XYH S_ %V\VC7UBVW;IFHW%C$5.1Y:-E!^"L%_"N)
MU1[V?P!XOEN+^6Y9=>\A!*%P-ES$JG@ ] !CIQP*],\.Z,-"T:.T+B2=F::X
ME QYDKG<[8[9)./;%4+WP-H][;WT!-W#%?7 N;A(KE@K2!MV0IRHRP!. ,X%
M &6WB#6+"7Q-I]S>V,ES8017-O<S1&-%60'(8#.=I4XQR<BL6_\ $NIZCX:\
M7VAN+J/[%Y$<4SVPBG*3*-VY<?+]XX( (&#UKKKWP3I>H7.H3W4EW))?1QQR
MGS<;?+.4*X'!!Y_&G#P5I!AU.*0W<O\ :<2Q7;2W+,TF!@-DGKCCV P,"@#5
M\EK71VAEF>Y,<)#2/@%\#O@ 5Q'@R_U>QTOP=;R26LNG:A:M&$6,J\)6+>GS
M;CNR%;/ KN(M.C@TK^STFG\ORS'YCR%Y,'ON;///X5E6O@[3[1]':.>[/]D(
MZ6H:0$!6&"#QSQQ0!@Z!XIUFZUZTL[B6"]BNXKAR]O;LL,;QD86.0XWK@@$X
M/)Z^EKP7XCU'6KZ6#4;E([F&#==:?+:F&:WE)&-N3AX\9P>O3/6KFG^ -&TR
M2R>"2_S9*Z0!KMRJ(W5<=,=ZNZ5X7M=+OQ?&[N[RX2#[-$]TRL8HLYV@JHR,
M@<MD\=>M %'6]5UF'QII.CV$UG%;7MO-([RPL[J4(SC# <AAC\>O2L>P\4^(
M9=,T+5;IK%;>[U :?- D#;G)D:/S Q;Y>5^[@_7G ZR\T""]UZSUAKJYCN;2
M.2.((5V@.,-D%3GH#^%9T7@BUCL+2R?5-2EBM;PWL?F/'GS2V_)(09 8L?\
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MVN=R[U9LXV\D]^1C:,9Y-12>$M2M]8N)])UU[.QO=AO('B\QRRJ$+H^059E
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M4EGD8*?+1<=2#G(X%/?P??12"6TUH[SI*:;+]H@\PR[-V)"VX$$ESG^=0_\
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ME8B43*N!O*F,G /)&3P><34K;4AX+\=1RV>JD7ES%+;&YM_GEW",$X4?[/3
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 (>E1M_KQ]*D/2HV_P!>/I0!+1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!DZAH,>HZUIVJ->74,NGES$D6S8VX8;=N4GD<<$>W-:U%%
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M*2,9 /2B21(D+R.J(.K,< 5Y=!!X:;QSHT"/8O97&BO+,#*"L[*RD-)D_.0
MYRV?ND]JH^']0LY?#?@QM;N()=%VW4%Q]JP\(F#?NA)G(&%W8W4 >O/-''$9
M7D18P,[V8 8^M5)]9TZWNK2VEO(1-=D^0N\?. "21[<=?7 KRYR@M&!U:VM-
M.75I9-%^WHK6<R*G*-DC$>2VT]L<=JL1R:9-K'@&]NM.M+2U,=Y$J8#Q+("N
MS8Q'()!9/8\4 >KU&T\*([M*BJAP[%@ I]_3J*Y[X@M GP_UPW#HJ_9'VEVQ
M\^/DQ[[L8]\5Q_B*TTFTTOPY<)=)9:-<LSW5W%"EQ$T[(H1I P8'.'&X@X-
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M.1CK[4 =S17%Z9XOOO$":5;Z=%:VU[=6;W5PUP#(L.Q_+P%#*6RP89SP!WJ
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MJ\ C.]"^795.SI@9'.1TYQT^EW5Q>Z;#<75J+6=\[H1)O"X)'#8&00,YP.M
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MPPX)1<#L!CGK4]]X+O=2N]>>ZU:$PZO9K;,L=J5:(IG802YS]YLCOQTKLJ*
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M." 5!QCGUIUSX5U+5XIY=6O+1[X:?+8V\D,3;%\P8>0@G[QP.!TP>3FNOHH
MYI= U)/#>EZ4;JRE6UB$%PDMN6BN(PA4 C=D'H>O:K_A[1!H/AVVTE;AY!"K
M*),GC+$X7)) &<#). !6M10!PFC>!M5T>;2I1JUE*=-CN(XE^QE3(),$EV#\
MME1SC\*-.\)Z_9Z;X:LY;NPE_LF[:XFD)D+2Y##@XZXD<\]P/>N[HH X>'PA
MKEM8QZ7#JMG_ &=;Z@MY;L]NQE51)YGEGY@.O?GCL*Z#Q/I$^N:%)96MPEO<
M>;%-'(Z[E#1R*XR/?;BMBB@#B9_">LW.I>()Y+RQV:MIZV>\(VY"%(W;>F/G
M;C/8>]-3PEX@TZYL;G1]8M(95L8K&\6:W+HZQY"2*,Y# $\$XYKN** ,C5-'
MN-0\*7&CIJ,L<\MKY'VS'SDXP6/U[_4US:> ;R6WU:"[U.T$>HZ?'9LEK9F-
M8S'N"%<N< !N1W]17=T4 <-+X%U#4;JXFU;5+603Z0^ELMO:LFT%MRL,N>1Q
M]:NV.B^)%UC2[_4+[3I#96LULXBB<&8/L()R>#F,$XZ>^>.LHH XNW\':E:Z
M)I=I#J5LMUIVH27L<I@)1]_F94KNR/\ 6GG/:MCQ/HUYK6BI!97JVFHP2QW%
MO<;,JLBGN/0C([]>];E% '+7?A[6-3M+:XO-0MEU2UNX[J#RHV\E-HVE<9W$
M,"V3[CTYJ:CX3U2]AU2Z2>S74M1EM]^2WEQ0Q$$(#C+$D')P/O>U=I10!Q]Y
MX:U6YUO7+\-9!=1TU;*-#(V4(S\Q.WD?,?R'KPNC>']:TJYTYR;!X[/24T__
M %CY=E PWW> 2HX]#^%=?10!P]CX4UJUM/"L#S6#?V+*S2,&8>:I0H,?+P<,
M>O<#UH;P?JLNDF*2XLENXM<_M>#:6*?ZPN4;C/=AD>U=Q10!QE_X/O[S4/$L
MJWL$<6L6\"HP0[XI8AA3CH5SSZTLV@>)]7T*:WU74K&&]1(C:M:(Q031N'$K
M9 ZE5X P.>N:[*B@#&T.WUQ3)/KDMGYQ18TALMQC&,DN2P!R<CCH,=\UG7'A
M[58-6URXTZXM#;ZO&N];C<&AD";-PP#N& .#CD=:ZJB@#CXO#6HZ?XAT"6PB
MLCIFEV369\R=EE8-LRP4(1D;,XSSGM6GXHT2?6[6P^RRQQW%C?0WL8ESL<H3
M\IQR,@FMVB@#A[SPIK5[!XI62>QWZW#%&A4L!&538S'Y<\CG&>.F>].'AWQ+
MINKR7>D3:5Y=Y:0Q72W.\F.6-=H=,#YACL<=*[:B@#&U_3+S4/"%_I5K)'+=
M7%HUL)+ABBDLNTL2JGU)P![<5D:AH.OS:=H-S8RV-OJ^EG:T;R,\$L97:REM
MH/("G.W@_G7844 >9^+DU1)/#]K>7>F?VA<7<MSNGD,$,.Q%Q''*!O7D@YZM
MSGCBI["QO-:\+WVC65IIMJ\-]%+)/%=O/%.PD$CG>5SN)49SG&?PKOKJSM;Z
M$PWEM#<1'G9,@=?R-20PQ6\2Q01)%&O"HB@ ?0"@#D=1\,ZEJ'BBTU/98Q-;
M74<J7D<KK.( !O@("@,I.[DMT8\50U3P?KDUCJMG:-I[QW>KIJ,;2S.A !1B
MIPAQRF.^<YXQ@^@44 <AXG\+ZEX@NXI1)8F'[%) 8+E6D6"5_P#EJF,98#@$
MX_6H-,\+:UIFHZ5>"2PF.G:-_9RJ7=?,<;2&)VG RH'?J3[5VU% '%:1X5U7
M24\+!#9.=*AFM[D&5_F639\R';URG0XZ]:Z76[2XOM(FMK5+:220J&CNES'(
MFX;T;@\,NX9P<9K0HH P?">A/X>TR>T.U(GN6EAMTF:5;=" -BLP!(R"W08W
M8]ZQ9?"&J/::_I(DM/[/UF_:ZDN/,82QQN$WJ$VX)^4@'=WSCM7<44 </>^$
M]76T\0:78263:=K#;@\TCK);%E"2 *%(<87(Y'/6J&O^ M:U&:YBMKC3I;8K
M;BUEN]YE@$6TF-<# 5BF2PY.>G KT>B@#D8/#-_+K'BN2]:V2SUN%(D:&5C(
MFV+R^5*@#.2>IQ[]:JZ5H/BB&]\.#4!I)M]'CDB:6&>0O,I38#L,8"G &>37
M<44 <YXAT>_FUO2-<TQ8I;G3_-1[>60QB:.10" V#@@@'I6)?>"]2F\/WT-O
M]C%_J.JKJ,X>5ECC =6" A#N.% S@9))KOJ* ,GQ#I<VN>&;[34E6"XN8"JO
MG(1^H_#-9,&G^)Y_$%MJ6H0:2J0:=+;;8+F0EY7*,3S&,+F,#N1D]:ZRB@#S
MW2O!^NV-OX/MY1IQ31))&G=;A\N&#+\H\OL&SR1Z>]7F\.:_9:MK']F2Z8;#
M5)UN#)<!C+;284,57:5?[H(R1@_3GM** .2T[0-<TC4;ZWL;JS&E7EZ;TS/N
M,\19@SQA<;6!Q@-D$;CP<"JE[X6UR6&\C@FLE,6JC5+%M[ NV[<4D^7Y1]X9
M&>HZ8Y[BB@#S_7?"NKZS8^(;OR((K_4[2&TBMO/RJ*C$EF?:.3GH!V]^+OB7
MP[=:]:64,VFPR,EL0DJW/ER6D_RX99 ,XZYP/X1P:[.B@#GO$&AW.L>!+K2)
MIO.O7M OF@8WS* 0?Q915*5+G78M \2:2L4MU9B026URYC)#J%D0D [75E'4
M=01Q774Q(HXBYCC5"[;G*C&XXQD^IP!^5 '!W'A+6II+>_C6S2^GUF+4[R-I
MV$:I&FQ8@0IW''.< 9!]J[^BB@ HHHH **** "BBB@ HHHH **** $/2HV'[
M[/H*E/2HF_UX^E $M%%% !1110 4444 %%%% !1110 4444 <3XT&EQ>*/"U
MQJL,3P+)<(S21;P 8NXP>,@')X'6N86RGT^PCO4M]1306UNYG1+6W!DAB==J
M.L;*3MW%CC&0&S7I%_H4=_K>G:HU[=Q26&[RXHRGEMN&&W J2<CC@C';%:M
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M O4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 &HF_UP/;%2U&?OXH DHHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **P
M=/UUKL7NIW,D%IH\,C0PO*<&4JVTR%CP%+ @#OU[@5-=:N;C2&U+1)K>_C@9
MFDCC8-YJJ#N12.C^F>XP<9R #8HJO8WMOJ5A!>VD@DMYXQ)&X[J1D5A^,/%:
M>%;.VF^SM</)*/,5<DQP CS)#CLH(_$B@#I**Q/%&L7&D>%KK5M/$$KPHLBB
M7)5ER,]".QXIBZW<_P#">/H+10_9AIHO%D&=^?,V8/;'6@#>HJM?:C9:9;_:
M+^[@M8=P7S)I BY/09/>JSZFDMSIWV2^T]K>Y+9W2Y:4 ''E8."<]?:@#2HJ
MG)JVFQ3F"34+1)@<&-IE# XSC&<]"*<^IZ?'(D;WULKN_EHK2J"S_P!T#/)]
MJ +5%9[7TD.HW1N)[&/3H(%8N9<2(Y)SOSP%QC!^M<SI?BW4]:MXM0LFT,:?
M+*(]LUVRRQ?O,#. 06902%^4@D=: .VHJM-J-E;7,5M/>6\5Q-_JXGE57?Z
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M'>P?<JB4?)SR?3W]=:RM6B2)K:$QI]Q#&,+]!VI\MO#/M\V&.3:<KO4''TH
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MK9;Q8X;@A)X&;;D$KE2""",'MSSPEUXB\2_VSX?MQIEE:I?SRYC>[+ET6$N
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M=-/F0.;>\M)+WSB5VPQ(JDL_/^V!QGFLVT\?Z;=&;_1;I EDU_%S&QF@7&2
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MS:ZLC,=4LK"T>-?+W6S;C.<YWYP-HY/R\]: .AGG2WMY9W#E(E+,$4L< 9X
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M;A-1\X )$9O-((^\)!R!@$=#D4 >A5BS^*M,M]=.C,;E[X&(%([9V $A.&+
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ML"06\,<,*#"1QJ%51Z #I4E% !C--V#)/<TZB@!-HV[><?6D"   9P/>G44
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MK3[*]K]EA^SN"&B\L;&!Z@CI7.>*/#%QJL&CVFFQZ=#8V5XMQ-;SQ?(ZKD!
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M4 16MK!96L5K;1+%!$H2.-!@*!T J6BB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8-%,/](,?G9183P=GE  8P.N>M>M6>KV%_?7=E:W*R7-GL\^, Y3>NY<_44
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MW =KTQ"&1R3^[4<R,V1DG@  =ZZC2DB?XJ7MQ)(V^32;:2+]Z0),EP2!G##
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MXJ>H&YNA]* )Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]I?07%O<);&U>(&221P"@3:2K9SUSQ@YQ0!JQ:5IT.WRK"UCV+M79"HVKDG
MXZ9)/XFF1Z+I42*D>F62(DGFJJP* K_WAQU]ZQKGQUIEE8ZK<75O>Q2Z64^U
M6IC4RH&^ZPPQ4J?7-$_C:SCLM8E6ROEGTRV^U-!/%Y;21G.'7)Z?*>N#QTH
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MSQ66IB_B\Y75L"1WV$Y;/W\9XZ=\\$_@S59VUR2._M[:>[OH[^SEC#,8I(P
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MNLZC9W1:-;1H3(((#O4,TNP%2O))W]N ,]>VB</$CJX=64$,O1O<4 /HHHH
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M0(N?0# J6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *SM:U>#
M0]+N-0NF"P0)N8GN>P'N36@>O6N#\1X\5>+;+PVA+V-G_IE^>QQ]Q/Q//X4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 '..*H[L:H%]4)-7JI,%&J*<<E#S0!=HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "JQ\O[:/D.[!YQ5FJY'^FC_=- %BBBB@ HHHH
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M#_GTA_J*ZJB@#%L-*UBTE9KC7?M:'^%[-$Y]<J16I DJ+B61'/JJ;?ZFIJ*
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M (F-U'<73L68Q1[(U_V5!).!CN22<_0 %VBBB@ HHS1D4 %%&1ZTFY?4?G0
MM%)D>HHR/44 +12%E'5A^=&X>H_.@!:*3>O]X?G1D4 +11FC- !12;@.I%&0
M>] "T444 %%%% !1110 4444 %%%% "'I4;?ZW\*D-1,?]( ]J )J*** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA_PH'@OQ@/\ FH5[_P" ,/\ \36K9^.],N8;N26"ZMOL]@=2594&Z:UY_>*
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M<O\ C7>T4 <&/#7CW&/^$XA_\%R_XTG_  C?Q _Z'>V_\%J__%5WM% '!?\
M"->/\?\ (\6^?^P<O_Q5)_PC/Q _Z'BW_P#!<O\ \57?44 <#_PC'C_OXYA_
M#3E_QKL=+M[RVTV"&_NQ=W2*!),$V!SW..U7:* "BBB@ HHHH **** "BBB@
M HHHH *KD_Z6![58JL<_;0<<8H LT444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M!YJ D_:L>U3'I43?\? ^E $U%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5&1\^:DIN!F@!U%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4T9W&G4FX9QGF@!:***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IFSYLYI]% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %-!.XTX]*BP?,!VX'J* )
M:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ INX XIU1XR_TH
M DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FC[QIU&!0 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !24M)N&<4 +1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %-*9.<TZB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***@O(YY;9DMI5
MBE)&'9=P'//% $]%-0$#D_3C%.H **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ I*6DH 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
DB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>arwr-20230930xex312001.jpg
<TEXT>
begin 644 arwr-20230930xex312001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ SBBBHR^) GMF@
M!D/^ME_WJGJO#_KIA_MX_2K% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 5 W_'TO\ NU/5=O\ C\0?[)H (?\ 73?[_P#[+5BH(/\ 6R_[U3T
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'H:B;_ (^5/^S4IZ&H
M6_X^D_W30 D'^MF_WJL56M^9)O\ >JS0 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 (>AJ)O^/A?]VI3T-1,?])0?[)H ;:]93W+FK%5[7_EK_UT
M-6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/0U$?^/E?]TT -M?^6O_ %T-6*K6?(E_ZZ&K- !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 AZ&HF_X^%_W:E/0U$W_'PO\ NT -MONOC_GH:L55
MLC\DG_71JM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "$A022
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MLF@".R/RO_UU:K=4[#F-S_TU:KE !1110 4444 %%%% !1110 4444 %%%%
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M_G6S!"MO;QPH6*QJ%!8Y.!ZFN.MO%FJS?$ZY\*O%9BWA@^T^<%;>R_+\N-V
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M%K1)H?L=RZ3(EQ UQMDC5C@-M )Q]<4 ;'B#0K?Q)H\VEW<T\5M-CS/)*AF
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"WUC0/ ]]X4FT2^.JMYR1.(LVS[^ WFYV@#.3G!P. 37I?\ :FG?\_\ :_\
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MU&">U>V:\-W9O"L2PXS\S !B648"DG!SQS7<-/$F_=*B[,;LL!MSTS4F1ZT
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M1X-!^S6<1ENM8+SS/&I>7>Q8AFQR.< >@%=M>>";F_\ $NCZ[<:SONM,C$:
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ME[%:1O,.['!Q@=!Z"@#SG7;0> _&DMK"UL-'UZW%HKW*"46&6P1@_P '4A>
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M)&VJH]2:E!# $$$'D$4 +156/4K*74)=/CNX7O(D#R0*X+HIZ$CM4ES=VUE
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M))4:1,;T# E<],CM0!)112,RH,LP4>I.* %HI 0PRI!![BEH **** "BBB@
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M:K:;97#+Y:G([9)SDYSW/:I=6T.#5FAF\Z>UO+?/D7=LP62//4<@@@\9!!'
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M:Z,?VF(1R3*@SVR0,\9H Q--\2:G%JCZ1=6%OO72%U"W$<QS@';L<D8R3W'
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M$GAVSUPZ@L=D=<@2&R"+]Q9P@W$C=O)&[&0 .,<9KIOB<I?X<:R@ZM$H&?\
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MRN.1GN.E7X/#MI:FS-O/>1_9I7F.+AC]H9@03+D_/Z\],#''% %ZTCNX_/\
MM<\<NZ9FBV)MVQG[JGDY(]>]6:Q]!TR\T]]2>ZNIYDN;MIH8YIC*84( V@GH
M,@D =,XYK8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** $/0U"W_ !]Q_P"Z:F/0U __
M !]Q_P"Z: (-';=I4!/=:OUGZ+_R"+;_ ':T* "BBB@ HHHH **** "BBB@
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MPA"DKN(4$Y(XR0./6M6@ HHHH **** "BBFQRQS('C=70Y 93D<<4 .HHHH
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M-Q+9-(5M[A[:3S(RA$BXW#!YXS0!H45GZKK%II$<)N?,:2=RD,42%WD8*6(
M'H%)_"IM-U"WU738+^U+F"=-Z;T*M^(/(- %JBBFI(D@)1U8 E25.<$'!'YT
M .HHHH **** "BBJMU?1VEQ:PR1S,US(8T:.,LJG!/S$?=''4]Z +5%(&5BP
M# E3@@'H>O\ 44%E#!2P#'H,\F@!:*** "BD9U09=@HR!DG'). /SI: "BD#
M D@$$CJ,]*6@ HHHH **** "BBB@ HHHH **** "BBB@!#T-0L/])0_[)J<]
M*A/-TH_V: *NB_\ ((MO]VM"L_1?^01;?[M:% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 0W=U!8VDUU<R"."%"[N>@ Y-<=X=\1:1K7B"35#
M>HUS<6^RUM0"6MH%^9BY'"LQP2.V%'8UV]% %;3]0M-5L(;ZQG6>UF&Z.1<X
M8=.]<%?:AI!^*E^ESKZ6!32H8B4NDCR_F.2IS_$ 0<=>:]%5550J@ #H *8;
M>$R>88H]^<[MHSGZT >/6=W!9>$KR.^MWN=*;Q$%M[NY)1;A6.?-F_YZ(#@G
MH&P*99?9&\-36/\ :=C&UEKDTMJ-1M_+LY 4)"%6/RH=S;3V/3UKV=E5AAE!
M'H12.B2+M=593V(R* /(I9M.FB\/IJ:)I6A26=S'&'C6:%+CS<'#$%=I4$HW
MH>.M7[5M(M-1TK2M?>231!IK+82ZJ %E<2,&+9& VS9MSS@]B:]/**R[64$>
MA%!56QN4'!R,CH: .4^&;(?A[I*H5.Q'4@'H=[<5S&J_8KA_%EUJ12/Q)8W#
M'2V63$JKY:FW$2YR=S=0!@DD<UZG3#%&SAVC0N.C%>10!X_JD<,UWX^N+Z;;
M>V^EVLB*)R DWE/D@9ZAN!Z;O>O5=%N6O-#L+EY!(\MO&[.,?,2HR>/>K36\
M+$EH8R6ZDJ.:>JJJA5  '0 =* /%I$TRS\+7FH6&HD74'B%HX)DNR2(S, 0.
M<8*,?J,&NC@T2PU;5O&'AN";RX%CMGME2=LPRF-@7'.>NW/Z]:]"^RV^,>1%
MCKC8*J:G8W4]FZ:5=Q:?=LP/V@VZR\9Y!4D9S]: .:\&R3Z_=_V]=V[VSVMN
M-.6$YQYB$^:PYP1N^4<?PFH_B1/=P#P^=.-O_:']H-]F6X/RF3R)0OZD8]R*
MZ[2].BTK3HK*%G98\DNYRSL22S$^I))_&II[6WNE5;B"*958,HD0, 0<@C/?
M(% 'E=Y<:/=^#+2[L[R>&_EU:V74&:Y*3+,90) X! &,L0 ,#J!1J]]+H=IX
MQL-)ED6VM[BS8E9V9H4D"B9@221T[=,DUZ6=%TH^?G3+(_:#F;]PO[T]<MQS
MU/6GP:5IUK/+/;V%K#--GS9(X55GR<G) YY]: .%N-)M]1\1ZIX>TZ8C2KS2
M!<GRI2RPW._:CJ0>"1SC.#C/K7/VVO7<5QI^M#2YO*\@Z-/$7?#7VW PI. N
M5";^O)]*]>M+*TL(?)L[6&VBSG9#&$7/K@4HM+8*%%O$ )#*!L'WR<[OKDDY
MH XR*PAT#7O!6EM<*TD-K=1EW<YD?8FX\G/)R<5R_A-[J]U33];_ .$BMI=4
M=9_M.EQHXFEDV-\DJF0A0I4 ':HZ#N*]7FTVQN+N*[GLK:6YBQY<SQ*SIWX8
MC(I8=/LK>ZENH;2WCN)O]9*D85W^I R?QH \KM+C2+E_!.LF^635;J^!O6DN
M26$C1/N4H3A0'PH&..!WJ4QW6H>()8/MTR:K'K162]2[\M3:#&8@NX'.,+@+
MUR<]Z](70M(2[^UII5BMSN+^<+= ^X]3NQG/O7&GX<SW226VI2Z1=H\KN;]K
M#_3"&;<1NW8#=@W;CB@#)G>:^U[4;F;Q%!97VGZF$CB=93,(@PV1J@D"NKC'
M\)SFO4;>]M;MYDMKF&9H'\N58Y QC;^ZV.A]C3'TVPDODOGLK9KM!A9VB4R*
M/9L9'4U6TK1(-*NM1N8]IEOK@SR%8U0>PP.I]6/))^@ !RWB.WL6^*7AR2\?
MRPUG<*&,QCRP9-HR",\D\=\]ZYZS1=/TO1=5M+V=;B;Q.]O(BW#"/RWN)%92
M@.T\8.2,\CM7JUQ96MX8S<VT,YB;=&98PVP^HST-5!X>T41)&-'T\1HY=5%L
MF%;CD#'!X'/M0!P5U+<W-_XQLHM6$?\ Q,;5(4N9W\MR4#&'<#E QR..G2NI
M\"W4%SH,HBANK=X;J2*:WN9C,89 >45S]Y1Q@UJ2>'M%EBGCDTBP9+@YF4VZ
M?O#ZMQR>3^=6K*QM--M$M;&VBMK=/NQ0H%4?0"@#CY[$ZG\3KNVDU/4(H(+&
MWN5@@NF1?,\QQR/3"CCH>]8WAB:?5KO3M2F\2Q+>2SRQ7-HC2><YPP,90N53
M;@$$(,!1Z\^AKHVF)JAU-=/M5OR"#<B)1(0>OS8S31I%A;7=QJ-GIMFNI2(0
M9O+",YZX9@"<$]>M 'G.DQ7L.F^&=7AUG4+G4)]3:UECFN"Z20^9(&!3IE0-
MV[&?7C&+%OJ%PVAZ9KL=]<G79=56VGMVE8*VZ8HT)B)PH5.1P"-N<]:Z3P7X
M37P_ID?VZTTYM55GWW=LN6D#-NR25!!YQCT K;31-*CU1M333;1;]@0;D0J)
M#GK\V,T ><WNDIJ&@^,[Z\U'4[K[#/>)!;K=OL5?*& 5!^8 \\^GUKO/"R6<
M?ARR6QE$L?E(6(F,N&*@D9)./I5JQT32]-^T?8=.M;;[2<S^5$%\P\_>QUZG
M\ZM6]M!9P+!;01P0I]V.) JK] .* /)?%MY;ZOX7\47-Y=-]OL-46VC@\]D6
M.)9D"_N]V&R,MN(ZD^@K>U.X-VGBZYNM1FM[[26+621W)011B%'C?:,!MSE@
M=P(.,=J["YT#1[V\:[NM*LI[AD"-++ K,5'0$D>U.N=#TJ]O8KRZTVUFN8@!
M'+)$K,H!R "1V/- 'G%W?ZEKMY)#J&N0:'<PZ?:W$0E+QE&9 TDB@.H;#Y4J
MP;&WW-7WFOHO%EI?7LTUY8S7%M"D]M.\1M92B_NY("<%7+;LXR-PST%=U>:1
MINH7-O<WEA;7$]LVZ"26(,T9R#E2>G('Y4QM#TE]3&I-IUJ;X$-]H,0WY P#
MGKG'% %+QI-+;^"=:G@FDAFBLY9(Y(W*LK!2001[BN._M'4O#^JW*VUY=WK-
MX9?4"EQ)YFZX5E 8#H.#T&.GK7HU]86FIV;VE];17-M)C?%*H96P<C(/N!5:
M#0-(M;N&[@TRUCN88_*CE6(!D3&-H/88[4 <=:R2?;O#7V2_NKVSUVUE6_#S
M,=W[H-YJX/[L@\$*0.0.H%;7P]@A@\%Z<(9'?,?(:5GVD$C R3CIT%;%CH6D
MZ7.\]AIMI;2R AGAA5203DC('KS4UCIEAIB2)86<%JDKF1UAC"!F/4G'>@#C
M+^5]9UO7HKG6[C1YM*,9M3'+A50J&,K)P'#?,N#D #UJ.^O9]0'BNY;4KBSN
M]&/^AXF,:H/)5U9TX#!F+?>!XX%=C=Z#I%_?Q7]WIEI/=PX\N>6%6=,'(P2,
M\'FF7OA[1]1OXKZ\TVVGNHL;)7C!/!R,^N#R,]* .$N;_5[W4-?:?4+VT-MH
M45ZMM#+M6*8HY/.,X!'3OW]*FTRY6Y\7:'JVH74JR-X76YE<2LJEMZ$G:#@C
MDDC'.!Z5V\^@Z3<W%Q<3Z=;237*>7.[1@F1?[K>HX'%*-!T@&S/]F6F;(%;8
MF%3Y(]%XX_"@#A?#.L:A)XETJT:_N9;/4=+>X,D\P9Y6!7;*$Y$6=QPH)XZC
M(J/0KS5M6T#P?))K=[%+>7=U%<2*5)D51,1G(Z_( #V^N*[:W\*>'[3R_L^C
MV49C+M&RQ ,A888@]1D #CT%,B\(:! EDD>FQJEC(9;9=S8B8G.0,^M %3P5
M<W4MGJMI=W4MTUAJ<UJDTIR[(-K+D]\;L?A7/^.->NK2]U?[!?W FTW3UN!&
MCB*.W<L2"YS^\+8 "%2.O(S7<:;H^GZ.LZV%LL GD,LH!)W.>K')ZU#?>&]$
MU.]^V7VEVMS<>68O,EC#$H>QSUH YN\^W:AKFH1IK5Y;6_\ 8\-R$@91MD+2
M#*G' ^0$CO\ 3BJMSJ]UI$7AWQ9?W]R^G75HB7\(=MB2O$"DBH..6!4CIE@:
MZ8^#O#V^=UTN%#/"()0A90T8& N <8P.E03^'YWDM-+A2RA\.6_EN81O,K,C
M;E7G@)D*?7C'0T 7/#-M>6V@V_\ :$T\MY*#-+YSEC&6YV#/91@?A7'ZKJ-Q
M:V'CI%U.\B&G^6]J[SD-&[1!L*Q.2"QZ'Z5Z/61>^%]#U&]FO+O3+>:YFB\F
M21EY9,8P?P.,]<<4 <_KG]I2:]KL<&M7EO;P:/'=QQQ%!MD)F (.W./W8)'?
MUQQ56TC&I^,?#M]=W<XG?0#,&28H#(7BR0HXYW<C&#@9'%=._A+0GFEE.G1A
MY8!;.59ES$  $P#]W '%2Q^&M%BAM(DTVWVV:,EN2N6B4]0K'D?G0!Y[ILVJ
MS^!=-\2SZ_J4EU)=0P-'YH6+;]K$9)4 9)7@YK4UK7[S2+_Q2+>\=DB>Q1?,
ME)6U\TD.PR#MP"#TP...U=='X:T:/1&T5=/B_LUN3;-DKUSQGISS]>:9:^%-
M LH[A+?2;5%N8O)G&S/F)Z-GKUH H^%X-0M+W4;>]U:.]CVQ20P^<9GA!W Y
M<@$ABN1Z8-9?CR_O;*X65)+W^S8K4FY;3KC;/:EF^68I_&@VL/P-=5I&AZ7H
M-JUMI5C#:0LVYEC7&3ZGUI+_ $+3=3G$U[:K,X3RSEB R9SM8 X89['(H XR
MZ-O:ZOXLUB'5)K65;&V=+@LTBJ"CX/EDX/L#P#^-4+RYO;G0_&>GW4]VMO!H
M\=U!'+=>9+&620D,P]2@)7)'/7!Q7?7OAK1=1N9+F\TRVFFDA\AG=,DISQ^I
M_.FVOA70+*%HK?2+.-7A:W?$0):-CDJ2>2#D\&@#C]5FUFY\1#P]I>H_9(K;
M3XYXYKB]:-W=V;+YVMYH7 ^4D#K[8$GU74-8EMI/$LR1C0(KSS[;:D1EW.ID
M'RY"G8&Q]>W%=9>^$/#NH0VL-WHUG+%:<0(8P!&,Y( ';VZ5/+X=TF:ZFN7L
MQYTT'V>1@[#,6,;, X ]AZF@#D=*UG5%F\)7$VJ2SMJVG2SW$$B+M++$C@K@
M#&"?QS5/0K_Q'>6MKK4NM6@MK^UE9HX[OSF,GE,X$:&("-D(.1N/ (.3S7<0
M>&=(MIK&6&S"O8(4M3YC'RE/4+D]/;Z4RV\)Z#97-U<VNEV\,UVK+,\8*E@W
MWAQTS[8H Y7PO>ZO):^$KBZUBXN1JMM*+B.0*!D1[E*D#((QUR<YK0^%R2?\
M(+9RRW,TTDDDS,)6W8/G2#Z\]3GO6W!X6T6VDLI(;((UB"MJ1(_[H$\@<]#Z
M5<L-)L-+:X:QM(H&N)#+,4&"[$Y)/XD_G0!SEU->ZQXJUC31J5SIL6G6L,D!
MA*KO=PY,A)!W*, 8/'!K 2\O/$.M_#^_N;B>VEO+6ZDD2%MJAA&/F4$'KD^O
M!KNM2\.:3J]RES>V@DG1#%YBNR$H3DHVTC<O^R<BI)]$TZXOK6]DMO\ 2+12
MENZNR^4#P0H!P,C@T ,\17PTWPWJ5X;G[*8;9V$_E[_+.#AMO?!QQWKG/!^J
M:C)XEU72KI[MK:*VM[F!;QE:9-X;.XKZXSC)Q787=I;W]I+:7<*36\RE)(W&
M0P/4&L[3/"^AZ-<_:=.TRWMY_+\OS$7YMN<XS0!G^+I]0BO?#T-CJ,ED+K4/
M(F**AW)Y;MCY@>?DX^O>N8EU378=&\27"ZY<L^B7XAM]\<9,JYC8B3"C=PQ
MQC'OV] U#1['59+62\A,CVDHF@(D9=CCHW!'/]"1WJG)X3T66UOK9[1S%?R>
M;<K]HD_>/ZD[L^G3T'I0!R?B'Q)J-GJUY-9WLTT-MJ%K;D0J@BC#,@>(@Y,D
MAW,2!C:,?2DO+B31M0\=ZK:7LOVV)[= DK@I&K1)M<C!.%+N?H.E=5<^"_#E
M[<RW-UI%O//+MWR2 LS%< $DGKP.>M6CX=T<WMS>'3K<W%S#Y$SE<^9'@#:1
MTQ@ 4 <3K<_B/0O#^O71UI5Q:"XM46Y%Q(C!@&.3$OR'(&.?;%:5W/JVD:GX
M8A.M75TFH7K"<2QQ@%3"6VC"@@!AD<]^_%;,/@KPY;:?<6$&DPQVMQCSHU+#
MS .@)SD@9/'2KTNAZ=.]B\MN7:Q(-L6D8^6<8R.>3CCF@#A]/UW46\5:7)#J
M-S=V-]J%W;2-(%6%E16*"-?O?+MP6R,D'K6S\/\ _4^(_P#L/WO_ *&*T(O!
M/AJ&[-TFC6OGF?[1O*D[7YY&>G7H.,\XK1T[2+'21.+&$Q"XE,THWLVYSU;D
MGD]SWH Y;Q5:M-\0?!V+JXC#R70Q&P 7$#'(XZGH?:LZWUO5(_&>FJM_=W%G
M>ZE=6KM*J)"5C#X2-!S\I&"YQD@]J[B\T33[_4+:_N;??=VN?(EWL#'GKC!X
MSW]:J+X0\.I>M>C1[3[2T_VCS"F3YF2=PST.23Q0!CZ'=76K0:?KC:^8?.N)
M(9[-MIC/S,%B4<$.O'/).#GBI?AQ D/A0,MS+,\ES<,_F2;B&\YQ^9QD^]:]
MMX6T.TU=]5M]-@COG=I#, <[F^\?0$Y//N:L:;HNFZ.;@Z?9Q6QN)#)*8QC>
MWJ?S/'N: ,"[O;[4?%FKZ7%J$]E%86$4L7E*F7D??ECN!R!M48Z=<UEZ3J.M
M^)I=%8ZO<:>M[H_VJ9(8HR?,61!N7<IP&![YX/%=AJ&@Z9JES'<7=MOF1=@D
M5V1BN<[6*D;ES_"<CVIR:)IT>HPWZ6JI<PQ>3$RL0$3^Z%S@#@<8["@"IXMU
M>XT#PCJ6J6R"6XMH"R!AD9Z9('89R?I6!=W6IZ/J:V<&LS74%YI5Q="1]CO%
M+'M(=?EQM;?C'(XXKMYH8KB"2&:-)(I%*NCC(8'J".XK+M/#&CV,4\5O9[5F
MB\ERTCL?+_N DDJO/W1@4 <KH\FL7DGAKS?$%\5U;23=7 V195U6$_(=GRY\
MPYSG^M,L]>U=[/P8\FH2,UW?S6UU\B#SE7S ">.#\@Z8KKX_#FDQ-9-':[38
MQ&*V(E?]TA&"%YX&./P'H*2/PSH\4=DB68"V4C2VPWM^[<G)(Y[\_F?6@#,\
M&6YC.M3&\N)V;5+A621PP7#8';(. *JZP\I^)^CKYTRQQ:;<2B.,_?8.G&.^
M>*Z6ST?3K"]N[RTM(H;F[;?/(HYD/J:+[1M.U*ZM;F\LXIYK4EH'<9*$D$X_
M%1^0H XNVUW5!I'AKQ"-0DN!J=W'!=6>$V*),C"8&04('?L<UU_B%KU=!N_[
M-ECCO2H6$R.$!8D#:&/ 8YP#ZD4RS\-:187YO;:S$<Q9G \QBB,V=S*A.U2<
MG) !Y/K5Z]LK?4;1[6[C\R%\;ER1T((Y'(Y - 'F%U?75_ING1C4-6C*^([:
MVGM[K FMA@':S 8<;@K!CZBKU_K^HV>OM'::E=74$.K6=D[;$$**X56C)ZO)
MR6)&,<?2NR/AC1VL)[*2R$L,\HFE\V1G9W&,,6)+$C:.<]JK3>!_#%Q-)-+H
MEHTDFTL=G4KC!]CP.10!QJZA>:1_PFE];WLPF_M>.VC:5MT<0?REWG(.-H8X
MX(''!KL/#W]KP:E?VNJW]K.FR.6VA6?S9HU.X,6.Q,J2../7FK<WA?0YY;N6
M33+=GO(_*N#MQYB\<$?\!7GKP/2I-$\/:5X=M6MM*M%MXG;<WS,Q8^[,23^=
M &)XMU"^M[^.WLKRY1A8SS^3;(N0RXVR2,W 0<C'4D]\5L>&-1EU?PMI6HS_
M .NN;6.23'=BHR?SI=3\-Z1K-W!=:A9+/-"I1"68 J2"58 X89 X.15O3].M
M-)L(K&P@2"UB!$<2=%R<G]2: +5%%% !1110 4444 %%%% !1110 'I4#?\
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M!Z5-J_B"TT6YL;>YBN7DO7:.$00E\LJEL''J <5D6FA:K=ZKH-WJ@MXCHR2
M-#(6^T.R>7G&T;5V\]<Y..@R;7B'3;Z^UKP_<6L"R0V-VTTQ:0*0IC9.!W^]
MG\* (8O'FE20^<UO?QQQW/V2X=[<[;:7=MVN0<=2!\I.-PSBK%SXQTVUUA]/
MEBNP([B.U>Y\K]RLT@!5"V>N&7M@9'-<M>>%M>G\)^(M+2RA\_4M7:\C)N %
M6,R*_/'7Y,8]Z77/"GB35M8GN3%:2JNH6]U;27%XP\J)-I,:H%(4Y!);O[T
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MAOX999KR66<S1'/E^:^]5P>I/(/0=,4 =O1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>%-&>&YLI#*S,<)O>W9LY?CUZ;UYXJFNO7MWK=TEK<7GV3Q#$BZ/)YKD1,I
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M5ZE]'*Z13QB.5XB)HRA)4X)&>JGL>]<CX=N+O5UL=;EUV6WE>\FAN+!V5HR
MSJL07C:PPISU.#FL^RU>\DTLVUQJ=W<3R>()[2,0L%DF1-Q";_EV ;021V!
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M6C8SZU=Z]I-Y=>&;VT6UTZ>"?,L)7>YB("8?)'[LCD#J*[:B@#S;0M%US2]
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MN(UD3>NUL$9Y'8U/-#'<020RKNCD4HR^H(P12QQQPQ)%$BI&@"JJC 4#H *
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M?S<EO7Y3Q[4 ;M%<E)\0]*BL9;N2SU2..-8I,26I0LDC;%9=Q (R0.O>NMH
M**** "BBB@ HJK<WRVUY:6QM[B0W+,HDCCW)'@9RY_A!Z#WJU0 44V.1)8UD
MC=71AE64Y!'L:=0 445%+<PPB4LXS$GF.J\L%YYP.>Q_*@"6BJ.D:O9ZYID6
MH6+L\$F0-RE6!!(((/((((J]0 444R26.+;YDBIO8*NXXR3T ]Z 'T5G:7KM
MAK$U[%92.TEE,8)U>)D*OZ?,!GZBM&@ HHHH **** "BD9U1=SL%&0,DXZ\5
M674(7U633@LOG1PK,6,9V;6) PW3/!XH M45C6/BG2=1U0:?;3R-.R.Z$PNJ
M2*C;6*.1M;!XX)K0OKZ#3K4W%P7$894^1"YRS!1P 3U(^E %FBBB@ HHHH *
M*JW^H6VF6AN;IRL895 52S,Q. JJ,DDD]!6,_CG0DM5G\^X<$.6C2TE:2,(V
MUBZ!=R@-QR!0!T=%5=.U"WU73X;ZU+F"8;D+H4.,XY! (_&K5 !1155]1MDU
M*/3][-<NADV*A;:H[L0,*#T&<9P<=* +5%5;W4;33A"UY,(4FD$2NP.W<>@)
MZ#/09ZG ZFK5 !1110 44R65(87ED.$12S'&< <FJ^F:G::SIL.H6$OFVLX+
M1OM(W#..AY[4 6Z*I7^KZ=I;PI?WL%LT[;8A*X7>WH/4^U7: "BBB@ HHHH
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M\-Z/<Z-%I$VGPOI\6-EN0=JXZ4Z/P[H\5Y/=IIT GN(?(F?;GS4_NM_>Z=Z
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MU&/6[[_B5WL?D0DILVE8F*GY>GS$?CW/-;6C0%_BEXI<S3X6VL\)YAV\J_\
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MN;F>"XW7,JSR(EU(J&5<8?:&P&XQFK]IX>L+.YU&=5ED;43FY$LA=7^7;T/
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M2YGO$NK $0W<$YBF&0 V67'7'-:UG:0V%I';6ZE8HQ@ DDGN22>22<DD]2:
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M=+B\TYL3 1;6PCE3U'7_ !JSXQ34+?P3%!=32W]X+JW:26UM'&Y5F5V.Q=V
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M&'.."9%/7G/UJC81WFG>!O"Z7.GZO%#IMS(M^+>%DDB)WA7"D98 L#D ]>M
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MEO:QM]U9'3<\GU((4>@!]37/:!I#>)-+UN]O8(8]3@U.Z-I>P2$2Q2J=H^;
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M!R06X/X^U8T]UJ&D^,==O+/2[6:Z_LFWN;A//,:,5:;.&VDEB  ,@#CDC R
M>@45Q]YXW<11G3M.:YF-C'>O$WF9 D!*(/+C?YCM/7 Z=><;5UK,D'A.37!9
M.K)9?:S:SGRW4!-Y1N#A@,CIUH UJ*XN/QM>BQTZ6[TF."?5 'LHEG:7='LW
MLS!$)&!@< ]1G'-6(?%]W<0:1'_9#V]]J-S+;B*Z9HT3RU9BV2NX@A?E^49S
MSB@#JF=4QN8+DX&3C)]*=7!/XC&O:1H]_>:#:R1/K$=O$KW18Q2*[)Y@&P9P
M0<#W%:=EXLN-0\27>DP6MJ&MIWAD22Y*S*H0E9"A7E&( RI/4'UP =55:_L+
M;4[*6SNXP\,@P1T(/8@]B#R".01FN*T?Q=KO_"-:3>W&G07LNH7TML"EQL*_
M/)MR"N,#9CKG !Y-6M9\;7VA;?MNE01E1 '0W?SR-(V&\H;?F"=R<4 =E$AC
MB1"[.54 N_5O<X[UG)H=K'/J-S&\R7=^-LMR'_>* ,*%.,*%[<=>>36!JWC6
M]TV]UV*/11+!HT<4TTS7&T21NI)VC:?F&.!TX/(XS=@U?4KCQW)IZK;_ -G)
M81S\NPD!9B,XVX)XQC/3\J -S3]/MM+L(;*T39!$N%!))/<DD\DDY))ZDU9K
MFO%?BB;PVBR)8Q2Q"&2:26>Y\E?EQ^[3@[I&SP..G6H6\67UQJ.GV>FZ0LWV
M_3?M\,DUSY8493Y7 4D??'(W<D<8R0 =717+VOBQM8L=+73[ ->:C \Y@N)=
MBPHI"L6903]XX&!S[<U4^%H8>!85= A%U<@H#D+^^?@'O0!V=%>8^&M7?P[)
MKZQZ>ATT>)&@DE,NWRQ(8D78N#NP2"<XX(QGG'0WOC.6P\0P6%QI\<=O/>I9
M1L]SB>1F'$BQ8YCSQNW9]J .MHKE'\7W$#:Y!<:?&EWIS1)!"LY;[2TG^KQ\
MO 8E1T.#GTYIZI\0#IVHS6J:>MQ]ED2&X2-Y#*7(4GRU$9# ;N[*3@\=,@';
MT53M[B\EU"[BFLQ%:1B,V\_F F;();Y>JX.!SUS5R@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH #43']Z!ZBI343#]\#Z"@"'3?^0;:_P#7)/\ T&K=5K+BRM\?W%_]
M!JS0 4444 %%%% !1110 4444 %%%% #9$\R-DW,NX$;EZCW%8*>"]&7PV=
M:*62P$AD17E.Z-BV[*MU!W$G\37044 <'XG\+,EGI,&FVNH7CIJL-S<7'VK=
M,B(&&=[MDX#< >I_'>7PAIC:9=V5TUS>-=LKSW,\I\YV7&P[EQC;@8P!C\ZW
MJ* .=?P9ID^FWME>2WEV;X*MS/--F61%/RKD 849/  ZGN:N7GARPOWTZ2X-
MP9M/)\B5)V1QE=K E2"<CK6M10!R][X#TN\T^>R^TWT$<]__ &C(T4PW--US
MR",9P<8["JWB;PS(NGZS=:3#=7%_JGE1W:K<A&:)3SY>[Y0P4L!VYYS78T4
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M)&SDEQC&TJ=S9!'>NMHH Y>Z\(W%QIXM?[;N'\R.5+IKF))5N/,QDLO !7:
MN. .QK>TRPBTK2[33X&=HK:%84+MEB%&!D^O%6J* ,/2O#SZ7+J\D>I3LVI3
M-<,2BYAD("Y3@\  <'/3ZTFG^'IH=1CU#5-5FU*[AB:&%GC6)8U8_,0JC!8X
M7)/IQBMVB@#B]'^'<.DW>GS?VS?3IIYE6VA98P@BDZH1MYSGENI]JZQ;.&""
M2.TBBMBX^]'&!SZX[U8HH YW3_#$^D>$(]!TW5Y[=H.(+SRD9T&[=@@C:>XZ
M=#3)_"/VS0]7L[[4);N\U.#R9;IT"[0 =@5!P I8G'J3S72T4 <C+I>I^)M
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M'R;\J022"&[\YJM:>#Y;"_T::VOXO*L&FDF#VV7N))<^8VX, N<\#!Q75T4
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MM#_N+_Z#5B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY&.<DT >FU5?4K&/4H].>[A6]D0R) 7&]E'4@>E5?$>K_P!@^'-0U7RO--K
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M3%-9Q6$NK:A)8)%#$]O(482",Y!+%=P/3)!'2NIS37D2/;O=5W':NXXR?04
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MC (7&T+MXVXQ@^O-=+10!RMYX)74-*N+:[U6ZDNKF>*>:["(&8QXV*%Q@*"
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MAQ% RKY^U "",CYEZ8W?2NP\#1:2KZG/HMY/=6<[QON$*Q6X?!!$0  SC!;
MQDCOFNN$<:LS!%!;J0.M*JA5"J  .@% '%_%-H%\&C[1(L8-]; ,7VG_ %@S
M@^NW<?H#6%XCMM"TG7[;3[Z46&@3:>QMG\@30F=I"7P6#8<J5(/Z\\^H/&D@
MPZ*PZX89H**5"E00.@QTH \GUJ[T[31HMO?3K-;RZ-/# NL-LD5V*A9&R" 2
M.#QD#/T.G8P:?IM[X!BBO;2[=!/$US;N&65C"02".N7&,^M=1?>&Y;C6I-4M
M=4FMY985A>-HDECPN<%0PRIRQ/!P>XK0T;28=%T\6D+O(2[2R2O@-([$LS'
M &2>@ % 'G&G10MKETEO9V.I)<V-W+;74,865-Q!,5RO0\D $^A]\0V%MX;U
M1? ]A(MOL:V>*Y@ *"63R%.&'&[YB>>?F!'7(KUL*H)(4 GJ0.M!5202 2.1
MD=* /'=;OK:W\4;[6)+26TUVV67,#M<&$!%9MXX2'& %YSG/?%)?1Z?;6WBS
M4MEL+VUUZ%K21B-RG=%NV_4!\X[ ^E>R44 >>:5J.DZ#XN\87VJM';R"6.99
MFB+-Y'EH,@@$[2Q' ZFO08Y$EB22-@R. RD=P:AOK./4+&:TE:18IEV.8VVM
MM/4 ]LCC(YJ:.-(HDCC4*B *H'8"@#SCQ.MO_P )SK7F"/#^%I V['S,)"0/
MKC%9VAQVFG1:$-(,46K7OA>93M?+27 6(Q[O<$2 9Z8('3%>M44 >>>#]1\,
M,ML^FV\L6H1V#1:@3&4$&W!8SDX^?<#@G)Y)Z9-97AZ6QL=-\ :C>>5%&MM/
M;2W#KPI*?*C-VR<X![YKU<*JDD* 3R<#K00#U .#GF@#R;1;K3+;2-)BO/DT
M%=7OHIEN$VQJV]C")0P&!SG!& <9Z57@FTJST-V@\J*T'C*(VY7"(B;XVSSC
M"[0:]@*(5*E5*GJ".*'1)  Z*P!S@C- 'D.K'3$O/'E]))%OL;RUFMW63F&3
M:FYDP>&)!!QR>AJSXTO]-O-?U#39[W3XSJ&GVPM;J\FV"U)=R63CTPV01R #
MZCU,P1'=F)#N^]\HYK ?PK(FKWU_::M/ +YE:6-H8Y-I50OR%@=O Z'(ZT ;
MMHMNEG"MIL^SA!Y7EG*[<<8]L5R%\]LWQ>L+>1XB9=&F5HF(^?,B\$=^ WX
MUUUE9PZ?8P6=NI6&!!&@/H!@5*40N'**7' ;'(H \>LX],G\ >'T@;3$NH%F
M+VNHQ;(+B0*!(K$XQ)M8$-ST/;->F>%3$?">DF"UDM(C:1E+>5BS1C:,*2>3
MCUK5=$D&'16'7##-.H **** "BBB@ HHHH **** "BBB@ J,_>J2HV_UGX4
M$8^1?H!4E,CYC7Z4^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M ,K7]9_L:S@=8A)/=7,=I K-M7S'. 6/8#VY["LJ]\0:QIOEVEY8VR7=U?):
M6<XD_=2AE+%RN2PVX(VGJ<8.#D:VOZ';^(-+:RG>2)E=989XSAX95.5<>X-9
M$W@G[;IRKJ&L7=UJB7$=U%J#*H,4B?<VQ@; !DY&.<G//0 S=3\;:KHFG^((
MKJTM+C4-'B@F\Q"T<4Z2<9"_,5(.>,\XZU=N/%6JV4VM6L^F0S7EG9)>V\=J
M[/O5F9=K<9W KV'(]*=JO@?^U],U:"?4B+S5?+2XNE@'$:'*HBYX'N23R?;$
MUSX3NKK5[O4'UF2&2XM8K8&VBV-'Y;;PRG<?XB<@@\'% %.V\8RS:3#)#=:=
M>W%Y?+96<T0:.,L5W$R(264KAOESDX'3-9WB#4Y]1\.>*]"UJWMI+W3;-9UF
MB0^7*&4E756R5(*XZGZUKGP';SV5PMU?2O?S7J7XO8HDB,<R !650-O;G.2<
MGVQ)=^#I;S2-3MY-7D:_U-5CNKUK=,F-1@(J#  P3ZGD^V !^H:_%IOBVYCN
M[. 06VCR7INUYEV*XW)TX'&<9Y(%<]>7=]J/C?P-J5Q:VT<-P+J2!$.955K<
MD*Q/!.,=. ?7K727/A5]0U=[V_O4FCFTU].GA6#9O1N6(.XX.?T_.LZR\!W5
MO>Z1)<^(KFZM])61+:)K=%8*R%,%QR<*<9H -&\8W^J:W_9AMK02R6,ERI1F
M*PRJRJ8F89#D;QDJ>/2JEEXOU2S\)Z%)=Q1W&HZE;^=$\4,TJA BDEU16;<2
MP' QSUXP=#0_ TFC:CI]XVMW%Q]AM&LTB\B-%,1((!P,YR,DYR>.G.61>!)[
M?2]+MX/$-XEWI3D6ET8D.R(@*8BO1A@#D\\=NE $FG>*[[6(]+M%TPV&I7D$
MT\T-ZCXB2-@AXP"=Q88SCC.>V9?AY UMX26!H8X&BO;M#%%]Q"+B0;5]AT%.
ME\)7 N=/OK76IX]2M5D26YEB63[0KD%@R\ #(!&W&,8K3\/:/+H>F-:37K7D
MC3RSM,T80EI'+MP..K&@#)\4>*;G1-0ALX%M(FF@:2*6]9DBED!XB#CY5;C/
MS'N*CN_%E_:Q^)\V5NTNBP17*CS"!*C*7*G@X8!2,\C)%7O$?ARXU^.YMOML
M*6=U;B"6":W,H4@DB1#N&UOFZX/0>E4=4\$S7C7Z6>L/:0:A8+972&!9&?8"
M%<,3P<,0>N0>,'! !DM=W@^(\UYI&EP37EQH$,\BR3^4K?O#P2%)+8  X[#)
M&*NMX[N+B#29;.RMH?[0M7F1+Z<QB24''DJP!&[/KVQQUQH#PK>V^J6^I6.J
MQQW2Z<FGRM-:[PRJ<AU ==K9)ZY'2H;KP4TFEII-O>P_V9]D6V>&ZMC,=P)/
MFJ=ZA7^8\XZX]* )[G7+33=>U&;4+".&2TTI;IKE&WNT6YLIT&,,#WYR*R!+
M?7?Q#\.W]YI4%HTVGW.QEG+R8^4A'&T8(W9XSRQ].=.X\&R7=]=?:-39]/N-
M+73'@,7[W:,_/YF[ELL?X>],L_"NM1:MI-Y>>(8;B/3(Y(HD6PV-(K@#YVWD
M9^4= .E %;3]?:Q\+6MSIVB65H)KVXBE1KD16\&R20,[/M[E./EZD"GIXZN+
MO1] OM/T<SOJ\LL"Q-<!?+= _?&"N4.3V'.">*2V\$:A;V.F1?VU!)/87DUT
MK/99C<REF.Y-_P!Y2Q*L",>E%EX)U*QAT.%-=B==+O);K<]E\THDW94D/@<2
M/SCJ1Z4 2'7H+#Q%>W&K:6EK=VNBK=7%Q'/YF8P[?NU&!G#!L'J:@M?B$\OV
MP2Z2[&*P:^A-L[2*X SY3$HNV3V&1[UIZCX3_M77-1O+RZ1K2]TW^SC;I"0R
MKN+;M^[DY8]O2H+;PSX@CTPVL_BEGEB@\FVEBM/+"G(^>0!_G.  ,%1C/!)S
M0!>\-:]/KT4\YBM#:@(8;BUN?-60D'<IX!5E.,@^M;U<-<Z#K6BZ7JUYI%Q:
MP:I>RQ,L=G9$Q%E)R2I)P7S\S=!@?6NY&<#/6@#C'\266EW_ (LN5TM8;BQF
MMEN9C*2)]ZJ%=L [0JD9P#P#70Z)J,VJ6!N98K=5+XCDMI_.CE3 (=6P..2,
M$=0:PU\+ZLNLZ]?1:G;P?VE/;RIB%GVB(!=CC<-P91@\CK6CX6\/'P]:WD9D
MA)NKEKDQ6\92*(D %44DX'&>O4GI0 [6]?ETC4M+LTTZ2Y.H2M$KK*JA&"%L
M'/KM/^>#B1?$"7[*;FYT22&&'4#IUVPN5;RY=X0;1CYQD@D\=>,UKZYHU_J6
MNZ)>6\]LEMIT[3.DBL7<E2G!' &&/XUSTW@?6)='U*R6^L0]WJ_]IHYC<A#O
M#[2,\\J/UH TK[QG/8>(HK";3HDMIKR.SC9[D+/(6 _>+%MYC!.,YZ]JS_%^
MK2ZSHNHV]MIQ>QM;V&VENFN/+8N)$#[% R0,[2<COC.*DN? ^J7%[>SKJ]K!
MY^H0ZBC_ &0R2!T"C86+C*#;P!SS^!6_\$ZM)8ZQIEAK$$-CJ,_VH&2!FE@E
M+AFVD,!@D9&>F<>] %W5_'-OIEY=Q1VK7263I'<B-CYN6P3Y:;2'P&!/(_&N
MK5@ZAAT(R*Y-O#.MV^L7T^FZY%;66I$274?V;<\<NT*SQ$G +8'WLX]ZZQ5V
MH%R3@8R>IH X?PYJ"V%QJ&C:1:Q7%R-3N'>$S%%MXL\,QPV,G@#'//8&IYO'
MCPSZH6T:46FF7R6ES.9U& Q4!PO?[P./3OG@5X_!NL6^H_VO:7MA!JIO7F=U
MB;9+;ORT3]SR 0>W/K3+GP7K%UIVOVS7EBK:O>1W)8*^(]I7Y??[@Y]S0!J:
MCXNFM7U6:UTT7-CH[!;V3SMLF=H=O+7:0VU6!.2OH*CN?&I@GU%$LX7CM].7
M4K:1KHK]JA/4CY#@C'YE?7(9<>$;\OK<-K?PPV>MKFY1HR6AD*;':,Y&00!P
M>A_*M"Z\)65Q=Z++&QBCTQ##Y8&1-#@8C;V#*C=_N^] %$>-VDM1<V^FBYB7
M2?[3F\FXW% <XC'R\L<'T^Z>.!FWHOBE]5U*&SGTN:R-Q9"]MS+(I+IN"D%1
MRI&5/T/8\5!8^#QHWAW5],TV=2]\\IC,P.V%'X"  YVJ"<>_UI;+P]J=OX@T
MK49;BS:.STW[#(BJP+$E26'_ 'P./<T :'BW5+G1?"6J:E:*AN+>W9X]YX!Q
MUZ'..N.^,<51L_$6HS?9+&/38I=3^Q+=W"/=;4122J_,$)+-@G& !@Y/3.KX
MATG^W?#NH:5YOE&[@:(28SM)'!QWK&3P[K%I>6VIV=_9#4!9+9W*20,89%5B
MR,N&W C)'7!ST% &[HVK6NNZ1;:G9EC!.N0'&&4@D%2/4$$?A69=^)GMM<U+
M2Q9*TEIIXOT?SL"1<D;3\ORG*GUK0T+24T31H-/25IO+W,TC#!=V8LQQVRS$
MX[5CZSX8O[SQ!<:G87UO#]JTXV$Z30ERJ[F8,I!'/S$<YH A7QP;B#36M-/C
M>>^L5O4@ENA&[ _P1C:=[#DD<<8]:Z^O/Y_ FIOHUII#7EC<V\%I'!#/)$R2
MVDB CSHL$G<?EXR/N_A7?1J4B1"Q8J "QZGWH \\TOQ<^@IJ:7MGJ=QIUOJ\
MMN]_++YBP*7 09=M[*,C)' S70#Q;Y;Z['=V)AFTF,2^4)@S3J02I7@##8 '
M/WLCMSFW7@[5+R#4=(ENK,:/J%^UY,X5O/VEPYC Z=5 W9Z'I3;RVTSQ-X^L
MY+*=Y3IH==2$>1&61PT4;GNPD!8#_9.>M ':P-*]O&TT8CE*@NBMN"G'(S@9
M^N*YR^\91V2W-XUC(VDV=Q]FNKWS%_=L"%)"=64%L$\'@X!KIZXR?P7=366L
MZ.+V$:1JETURV8R9HMY#2*N?E.2#@GIN[XH I>)M9U>XLO&-F8$BL[.PWPW,
M%T5<$QLP/ !YXR,X&.^:T= \61>5!I]_9W-FT6F+>)/.5(FB4 ,^ 21SS@@'
M'I2:UX7U2[_M^*QFLEM=4L5MUCE#*T;A2F<C(VX.>G48XZU7?P?J-YJ5J]V]
MK':KHCZ5-Y,SEP6Q\Z_*,CY1W'4^G(!)!\1["9+TBTD+6]BU^BQSQ2>9&O+#
M*L0K 8)4_AFD_P"%@'[)83/HEQ;?VA(B6ANYDB20,A?<6YV], 'DDBGIH'BB
M;PS=Z3?ZC82_Z%)9P&)&3S=R[ \I(."!V4<GO4ESX=U*X\*:9I,]OI=TMO;B
M"YMKAF,4NT!597"[E(QGIWQ[T =+87,EY8PW$MM);22+EH9,;D/H<5A7WBR6
MRU;4M.&D32265H+Q2)D'G1YP2H)SQALY]/<5JZ%ITFDZ):6$MPUP\";3(Q)S
M[9/.!T&>< 5F>)/"HU_4-.N5N# (6:*Z ZSV[<M']"RI^&: '1^)DO+:U*6,
MLB7>G/?$12J2B # Z@9;=QSC@^E9.C>()?(\)6NDZ?<-IU];NQ>>=2Z*@& Q
M/)/.>/85=T+PE)X?T_58;>6.>29I$LQ(=HAA)9DC) S@,[GH>M5M)\+:SI=A
MX7B2:Q\W2DEAN,EV5T8 97@<\#@_G0!7T;Q ^D3W-M-::E=6LNMR6AO))C(L
M#,X2-?G8MMY4<< GUS5N?Q+8Z/-XFU Z7J7FV4D*W(+[A(",*Z*6P%P>W)],
MBHI/#_B%M/EMU32PSZPNH@FXDQL$HEV?ZOKE0,^AZ4NK>&M;U*/Q-&K:>HU/
MR5MB97^14X._Y>I'/'T]Z -O2_$2ZCJ]SILNG7EE<0PI<*+@)^\B8D!AM8XY
M4\'!'?T">*]5O-&T"2\L;?SYA)&G+A=@9@N[GKC/2JUMH^IGQVVO7(M$@;35
ML_+CE9F#!]Y/* 8R2/P![X%_Q'IL^KZ#<V5J\:3OL:-I<[<JX89QSCC% ')R
MZ]=Z'XL\17+:;J-XBV%K<RP1SJZVX'F[\;F &0,@*.2#Q713>)U>=(--L9K^
M0V:WK"-U3;&V=@^8_>;!P/;DBL^[T'79]0UZX7^SBFIZ=':*#*X*NH<$GY#Q
M^\;W^4=,G$6F>&-9T1;"XL)K!KI-,@T^Y28N8SY60LBD#/<_*0/K0!8?QW:2
MI9'3K.:\:[LC>Q1[UC9E!P54$_,XYRH]*9KWQ$TCP_JKV5R&?R6C6X=)8PT6
M_&W"%@[8!!.T' /?G%&]\#7SZ9#ID3V=S#!:JMM=3,8I[6XW,S3(44GG*_+N
M ^7'<U8F\)ZO#K=]<6%UIYMM0"-++<P%I[>4($+Q^N0H.">#S[$ [4$$ CH:
MXZ'XCZ3/XBCTA(W8S2O#!*DT3;Y%SD% ^Y02, L #78@8 &<UQFC^&-:TB\>
M!9=+DT^.>2>";R2+HAF+"-FQ@#)(+#)QV] "?2O'EOJK::R:5J$%K?S20)<3
MJBJLJ[L(?FR<A#R,C/&2<XR?^$GDU/PWK<^MZ7<-90:DUIMM+@*R;751\P*G
M&X DC)^;IBK&G>&-?L=$T/3V&FN=/OWNI6$\@WJ2Q 'R<']XW7^Z/7ADW@_7
M$T;6],MKC3GAO]1:\B,A=656D$C!B ><J ,#OG/:@#1;Q/>?\)AK&E'3+B:S
ML;..4M"R;B6#L2 6!R<!0/4$G'%1V_BK3-(\,:,UG:W,JW5J)K>U:=/,6( $
MEGD< XW 8R23P.^)SH6K1>)=3U>W>RVW]C'$T4C,2DJ!@ "!]W+#G&>.G/&7
M'X/UJUL?#SV[Z7)>:9:&RGAN0SPS1_+A@=N5;*@]._Y@&@_CRTFMK:73;*XO
MGGLC>B!&592@)!"J3\S AL@9Z>XSUH.1FN(USPAJ6KV<5O(VGO*D(\F[7=!)
M93;F):+:I)7!4;21]P9/)-;UCJ5]<>)=0L6A@?3K>*,QW,;'<)#G=&V>">,\
M= 1GK0!)KVO6WAZT@N;J"YECEN$M_P#1X]Y5G. 2,Y(SZ9/M6=;^-+6XM=1;
M^SM1AO;%XTDL9H@)29" A&TD%23USQ@YIGCR1X],TLQ>69CJ]GY:R/M5F\U2
M 3@X''H:S-2\+:WJ*ZKJ:20VVH7IMT%HLI*M!$Q)C:0 $%\G) X''/- %V;X
M@6=KI&J:A<:;>D:7<BWNHX3&Y4G&&!W %?F'OD]*6'Q3JESXBTFQ.A7-E%=)
M.\@NG0. A09P">/G'OGCMDY*>"-9MM+UNTM%T:-=1NH+B.)=ZQ1;-A9<!>1E
M,#UR3QTKI-2TK5+KQ!HNJVLEG&;6&:*Y23<W$GEGY, 9P4[XZT 4=%\1Z?'I
M=W/;VFH&1]4GMUM9'$DTD^XEE7+;0.">H  -3#QF%73OM&DWEL]WJ']G/'-M
M#12XR#P2&4@9W UCIX/U^ULI)[2YLX]1@UB;5+<!V:.19-P:)R5!'RL1D9_"
MM+4-#U[5K"PN+J6R_M&UU*.^C@W,(8U52OEAPNXD@D[B.IZ8% %+Q?K4U]X.
M\4);B\L+W2I BR03E6+85U(*'."''!K3O_&$&C$K=V=WY%N+=9[DKA0TI"KM
MSR^,Y;'0>IXK/?POK\FF^(XI)M/>YU:YCF0[W"Q@*@()VDG&P >O7CI46O\
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M%%% !1110 4444 %%%% !1110 5$Q_>@>HJ4]*B;_7K]* '1_P"K3Z4^DI:
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MRR0QO)$28V902A/!P>U244 %%%% !1110 4444 5X["SBN7N8[2!+A_O2K&
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M2/3!XJ6B@#.ET#1YGMGDTNR9K8Y@)@7]WU/R\<=36@RJZ,CJ&5A@J1D$4M%
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M3=(TZUDN86B9OLH*D$$88#&1SR,C-:.E:=#I&DVNG0%C%;1B-2W4@#VJY10
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M),NHF8O(NWA43/&6'()4GVZ9/15\7V!O(XFANDM9;@VL5\R 0/*"1M!SGJ"
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M%Y+>0V5O'=2_ZR9(E#O]6 R:2#3-/M6#6]C;0LK,X,<*J0S?>/ ZGN>]9/\
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M]ZV\;?==\<X(!/&>!GI45UXXT6T7>[W+1K"EQ,ZV[8@C<X5G! (R>V">^,4
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M\+"TABD1]@D*Y;)0X'\.>]6KOPQK C\0Z7:M;/I^N.TOG2.=]JSJ%D&W'SC
MRO(].E=Q2;@6*@C(ZCTH X3_ (1S6K2Z\2PVMK;RVE_I\5K;.]SAMR1^6-PV
M\ AB?P]ZVM&U#4X]1L]&O;*WCV::)9'BG,A216";2-HX8<@^S#M70LP52S$
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MT,4[Z=)/OBEE\L,)(RF<X/0X[5J:;H.D:/DZ=IMK:L1M+11!6(ZXSUQ[5HT
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M5#1CHH ;"CD],=3ZFDA\,:3!=:?<QP2^;IT)@M2US*PC0C!&"V#QCKGH/04
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%%  >E0L?])4?[-35789O$]E-
M%BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ (!!!&0>HK'LO"N@Z==K=6FE6L,RDE&5/N$]2HZ+U/3UK8HH R
M]8\.Z9KSVC:C#+*;23S8=D\D85^,-A6&2,<9Z<^IK4HHH **** "LS5] T[7
M?LPU".606THFB"7$D85QT;Y&&2,<9Z<XZUIT4 %%%% !4<4$4)D,42(9&+OM
M4#<Q[GU/ J2B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7VK3R2WU];+)L@@:225L L5CC4G SS@8%:<_B?2(+"VO?M1EAN2?)\B-I6?
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M010&Y)DC= T0ZNI8#>O3E<CD>HK'M]%U":]\7VS126T>HQ1QVUZ2IW$0",G
M;<,$9YQ698Z-=2Z7(+[P6K7,%DUNXFOP_P!H)P"L1R=H.,Y;;CCZ@ [!/$&F
M/:377GND<,@B<2PNCAR 0H5@&).X8 '.>*A/BS0EMHKA]1B2.68VZ%PRGS1U
M0@C(;V.#7%_V#X@ET>2-([J]M;+48;JTAOY1'=31JI#QEP>V?E)/8]L5;N]$
MU">#1WL] >S1-=BOIH/.1I%14*M)(V\@DDC !/ ]>  ;^H>-=*L]#_M6!I;N
M'[2EJ5BB?<LC,!AAC*]0>1SD8SD9OW?B/2K%PMU=&+Y59BT3[8PWW=YQA,^C
M8KC]1T36;NW\3F+2Y%,VJVMW:Q>8@\](_*#$?-@$^63SCJ*=?Z/?2:UJ N?#
MDFI6VK>7*C27>V.W?RU5HY5#<J-F<@'.<4 :?CWQ4=!\.7\VG7.-0MPC#$#2
MJN6 PY VKD'C)%=<S!%+,<*!DD]J\RU_0->70O%FC6VES7W]J7:W=M<QRQJH
M!\L&-@S C;Y?'4$$=*],#$Q!RC!MN2G&1[4 <]8^)M+LM'TY[_7X;MKLR"&Z
M,7E^>5)SA5&!@<>^/>MG3]1L]5M!=6,ZS0DE=PR""#@@@\@CT/-<3I^FZM%9
M^$S=Z1)&]C?W$EQ'&4801N)50#!Y WITZ 9/2MCP9%?1-K[7EI-;+-JLLUNL
MJ@%HV5<'CW!H EU7Q&B7&K:5:--%?VEF)UF^S.Z LKD9.-N/DZD\YQU!I?#7
MB>SU73["&:]B?5'L([F=$'!)52Y4C@@$]B<54U.TU0>(M8>#37GM;_2HX%G6
M5!MD0S?*5)SSY@YK/TFVU"VNO!4;Z=>I]@TN2WNVV#8C;(UVGGGYHNWMZT ;
MFG>(+"+1H+BXUC^T?-EE6.:*V.Z3:S9 1 20H&"<8XSWK;L[N"_LX;NUD$MO
M,@>-QT93R#7FFG:)>_\ "(:?;W.FZI:7L-U=30W=KCSK5FD++\N?F5U;!'(X
MY]1WWAT:B/#NGC5XHXM0$*B=(\;0V/;C\N* -.BBB@ HHHH **** "BBB@ H
MHHH #TJ!O^/I/]TU.:A8?Z0#[8H FHHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HKFO&-U>VL.D"RU![(W&IPV\CJJG<CY!'S \^GOZUS]
M\WB"ZU?4]$T[6=D^FPQ20375V(G8N"QDD58B)%'W<<#CUYH ]%HKSJVO=>UG
M6-3M%\2_9X[?3+:ZCDMXXO),KH26W,A/EY7/K@U-I.IZAXIGL;.YU2>P<Z-;
M7Y^R!4:25V8%B2#\J[1\O0[N<B@#OZ0,"2 02IP<'H:\UTO6==\07'A:.;5+
MBQ%_9W9N1 D:ES$X577<IP6!!XXP>,=:Z'PI;&'6?$S-?7,[?VCMV2R @?N8
M3G&..N/3 % '545S-Y?7-]XT;0H[N>RABT_[5OB50TCE]O!8'A0.1CJPK!T;
MQ!K5_K7AA+JY8+=)?PW(C4!)FA;:D@XX)Y/''M0!Z$\:2KMD177(.&&1D'(_
M6G$ C!&0:\PTW6==O=+\.I_;,Z2W>JW=I--Y<;%D42[3RO4;![>H-=UJ=S/H
MGA2]NQ(UU<6-E)*'E !E9$)RV !R1VH U$18T5$4*JC 4#  I:X>_P!2U#0/
M#MWKL>N'4D;2S/#!/&GS2C!\Q=H'R8897MQ2:KJ6J:%J4%G#JDU[%J%A<S+-
M(L9:"2*,,'7"@;6ST((SC% '<TC,%4L>@&3QFO/M%UC6D_X12]N=0DO(]5L)
M'N+<QHHWK$)%*8 P3R#DXYZ"M+P_=ZAJ$&AZY)K\9M]0C)GLG1-A=D+*D1 !
M#(00<DDX- '1:1J]EKFG)?Z?,9;9V90Q1D.58J>& /4&KU>6>%M0O[#2/#"6
ML[);7FL7=O<)L4JPWRL.2,@Y7L:UKG5];72]1V7-S<M;:R\#&T2+SQ;! V$!
M7#,N1G@D@&@#M+F_M[2XM8)F8274ACB 1FRP4MR0.. >3BK-<$GB.\DC\)36
M>K_:[?4+^6&>0P*ID3#E0PVC:R[0#C'(-59?$VK'PS>>++:]=UM;YX?[-,:%
M&B67RPO W"0@AL[OPQ0!Z/17GFLZUX@M&\6W46I^7;Z,\4D"?9D/F QJ[1L2
M.GS 9&#[U8U?7]1M_%<=I)?S:=:3R6PLI#;H]O,21YD4C[25D(^Z,CM0!W=4
MM6U>PT.P>^U*X6WM4(#2,"0"3@= :K>)KV?3_#5_=VMS!:SQQ$I-.I9$/3.
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M8V=&P@(Y!.>N.W/>INV+N(+8Y(Z9H 6BN;\5:W>Z2;=;22TCWQR/F96E>1E
MVHD:D,<DY+=% YZUC:GXRU./2=$NHOLE@-2L$G%U=0O);K.P4K$S*1Y8.3\Q
MS^AH [VBJ=Q>_P!GZ-+?WN/]'MS--Y?(^5<MC\C7.P>(=6@NM";419FSUE-B
M&&-@UO,4+JIR3O4@$9P.?04 =$^K:<FIIIKWUNM\ZEEMS(/,('^SU[U<KB_!
M$$]W)K5S?M:3F/6;D)BWPP="$W@ECCY1C'8=ZM3W.HO\3(+%+M%LAI;SF$QD
MYS*BGG=UXX...>.: .F@GAN84F@E26)QE7C8,K#U!'6I*\\\)ZCJFF6WA2P\
MJV.E7R2P*$1B\3(KNI+$XY"GC';J:T="\0^(=7O+&[_LU/['O"Q+;%5H4P2A
MW>8=V2 "-HZT =E6=IVAV6E7NH75HLJR7\HFG#2LREP,9 )X_#T'I57Q'J]S
MIB6,%C")KR]N/*13@[5"EF;!9<X"],CDBN=G\3^*;9=(M[G3K2WNKO4'LF:8
M?*Z["R2*JNVWIRI)Z8SSF@#NWC1]N]%;:=RY&<'U%,ANK>Y:58)XI6B<I($<
M-L8=0<=#[5Q]KXKU'[/%8W/V0ZK+JLFFI*D;"(A!N+[=V?NYXSUQSBE\"+.F
MK>+5N9$DF&JG<Z)L!_=IVR<?G0!VE5-1U2PTBV^TZC>06L.<;YG"@GTY[UBW
M^LZHVH:O%IRVZQZ7 DC++&7:X<J7*C##:, #.#R3QQSEO=W>N^+?"U]:S)'8
MW6F37?DRPY(1O)R#\V"2' ]N>M ';12QSQ)+%(LD;@,KH<A@>A![TU+FWDN)
M8(YXGFBP9(U<%DSTR.HS7/\ C%IM.\)[-,=+3;/;Q*$BRJHTJ*0 ,8&#6-?7
M&JV/B?7YK V1NX-*M9Y9IX6*N$,V5 #9&[ZG&.] '?45Q>H>)==N;B2'0-.2
M9X;.*X(D0,'>0$JF?,7:,+UP>3TXYZAY[DZ.UPL2179M]XCD.Y4?;G!P>0#Z
M&@"Y17 Z?XRUJ--!U#6+>Q&G:S%\BVH?S('\OS!DD_,& ;@ 8XY-6-!\0>*=
M7EM[DZ9"NFW\#2P2L@3[.=NZ/=^\)D![X"F@#L+J[M[*'SKJ>.&,LJ;Y&P-S
M$ #\20*FKSZ7Q#KTG@BVUV\M=+FCNC9/'!Y+-L#N S-DXR"5*^GOUK4O]?U9
MY->FTS[%]FT8!729&9IW""1UW!ALPK  X/.?2@#JY)$AB>65U2-%+,[' 4#J
M2>PHCD2:))(W5XW 964Y# ]"#Z5P][XCN?$^FZG;Z-Y$,,.EI<3F\B+E_.B+
MH@ 88^7J>>O2NC\*?\B?HG_7A!_Z+6@#7HHHH **** "BBB@ HHHH **** $
M/2HV_P!>/I4AZ5&W^O'TH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M&>5SGI0!7M_#VGP&9G22YDFA\AWN9#*QB_N9/1?;OWJ#2O"UAI$L,D4EU/\
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M2V]A),#!"[9R5&,G[S8!)'/K7344 9>NZ%;:]:PQ3RSP2V\RSV]Q VV2*09
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M% !1110 4444 (>E1,?]( ]JF/2H&'^EH>VTT 3T444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MH-2M9[6S7=,UO*LFWT'!ZGC ]ZOZ??V^IV$%[:R+)!,H965@P^F1QD'@^XH
MLT444 %%%% !1110 4444 %%%% !5=I5%VB8Y*DU8/2JSQAKQ'/\*F@"S111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M!;CR]K&/+%6#$# 7@#GC S6\(21_:_#9U47<+V=FUM:(^F2HK;]N"TA!&<*
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ML#53Q1;6MWXE\-QW>GO=0K/*78VK2QKF-@NX@$#YB.OUKJZ0LH8*2 3T&>M
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M:<*&W*3G'&00<=Z2Y\%6[ZS+?V>HWM@EU&L=Y;VS*$N HPN<@E3CC*X..XH
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M$&8# _=YQMV\8S]2: ()O&6IV]KJ$ATJ"=[/6(].989SRKF/:PR,;OW@&"0
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MZ*** "BBB@ HHHH **** "BBB@!#TJ-O]>/I4AZ5$W_'POTH FHHHH ****
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M'BO[6SA$+H>.9"!_K 2V&.3C<>10![!17C=E=Z4+;Q!91:S#9V5WI]F\<EC
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M5LVW:608^\1GG_:/K6S110 4444 %%%% !1110!#=6XN[26W9Y$652A:,X8
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MM5HK>]TM=.55C/F1A22&WEOF^\V<CG/6J4/@&ZAL]10:VK3W^F+I\N+-$C4
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MRYMIU>ZR$*IC?P1DKQT 7IS4UEX;N-=\-WFEZK=ZREA.R&(7AA%RNT[CG8I
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M7.7PHZ8 Y]:CL? VI6+++'XA5+A--&G(\5B$554Y1@-_4$Y///M7;44 <,/
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MSVENDBF=U38[JR/DE5<9QGGKUJA<66@Z=JG@>.[4KI*K?(DFI[09(\!DW @
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MI;1B.""-8XT'1548 _(5*RJZE74,IZ@C(H Y;P3'-"NL)&Q.DK?N-. (*"+
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M2* )Z*** "BBB@ HHHH **** "BBB@ HHHH R?$FMCP[H<VJ&TDNEA9 T41
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M>;:S;-I5WH6BW%]I,$FFZ486GO;B6TCF#$+A)$().U,E<X^;OV]%\+3--H$
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 &H
MF'[W/M4M,QEC0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "FR1QRKMD177T89%.HH 155%"HH51P !@"EHHH **** "BBB@ HI&95QN8
M#)P,GJ:4G R: (Y8(I@!+$D@'3<H.*DHHZ4 %%'2DR..1STH 6BB@D#K0!#<
MVEM>P^3=6\4\6<[)4#+GZ&I(XTBC6.-%1$ 5548"@= !3J* "BDR-P&1D\@4
M$@'!(H 6BBB@ HHHH **** "BBC(]: "BBB@ HHHH :Z))&R.H9&!#*PR"#V
M-*JJBA54*H&  , "EZ44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1-_K1]*EJ-
MOOY]J )**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP&%R1@G.,Y&,YKS6YU35(-"\=P?;IK633C;3VRVVH22FW+CYD$AP2/4=,DT
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M348X8VFLKT!MIR098I%P&C8]L<$5UM_.+73KFX::.%8HG<RR#*I@$[C[#K0
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M1-_KU^E2U$W^N'TH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBG2$OC:M<,,3?9S-Y;>2)?\ GGYF-N[MC/7CK4$WC70H+F6W>ZD\R&X6VFQ
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M"4&<#*D8X)''8D=.*UZ* ,2?PAH5UIUC87-@)[>Q;=;++*[F/VW$Y*]MI)&
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MZM@;R1R"1T(KHJ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<PPW=S]MM&O8XH8P7$*@%F() XW 8!)] :C;Q6TWB#0[*PLI;BSU*T:\-P
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M !1110 4444 %%%% !11547<AU5[(VDPC6!91<X'EDEB"G^\, _0T 6J***
M"BLN?7(++2M0U+4()[.VLFD#M,!EU7^)<$Y#=NY]*BTS7;C4-2ELYM"U.Q$:
M;_/N%C\IN1P&5VR><_@: -FBBB@#DK:UBTSQ=K%E<!Q;ZZJSPR[3M\P)LDCW
M?WL ,!Z9]*ATKPGJ$$&BVNL7EI-8Z'M>V\A&5I752J,Y)X"J3P.IY)[5V=16
M]Q#=PK-;RI+$V<.C @X.#S]0: .=\+P+=ZMK?B- ZPZF\26X92"\42E0^#R
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M+$X%6[OPWK0U^]U"W@T>XBU&*/S4NLEK655";D.P[UP!P<<CM79I(D@)1U8
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MS IDD:13D8Y4D?E763S1VT$D\K;8XU+NV.@ R345A?VNJ6$-]93":VG7?'(
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ML#;MSMY/./3MZ** //KWPE<1^*-4F3P[I6J6VIN)DNKLJ6M'"A2&5E)921N
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%10W,%P9!#-'*8G*2!&#;&
M'4''0^U $M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 'I4+
M$?:%&>=IJ:J<@S?PMDCY6XH N4444 %%%% !1110 4444 %%%% !1110 445
M@S>*4CUFYTF+2M0N+NWC65UB$6#&QP'!+C(R#QUXZ4 ;U%9VCZW9:[://9.W
M[MS%+%(A22)QU5E/(-7;BXAM+=YYY%CB099F/ % $E%%% !165<^(+.RUVUT
MBZ$L,]X&^S2.H\N4J 2H(/7GN!4S:K$NN)I/D3><\!G#X79L! /.<]2!T[T
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M,@^SPO*SIC)8*H)P 1DXX[UH:?J%KJNGP7]E,)K:= \;CN#0!9HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK \3^)X]!BAM[>!K
MS5KPE+*R0_-*WJ3_  J.I)H OZOK5EHENDMV[%Y&V0PQ*7DE;T11RQ^G2L)=
M,\1>)8$EU:_FT2V;YA8Z<^)L9!'F3=0?4(!]35KP_P"&Y;2X.L:U,M[KLRX>
M8#Y(%/\ RSB'\*^_4]ZF\3Q:K>VL.EZ8/*%ZYCN;O=@V\./F*_[9' ]"<]J
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M+'&."[MV&>!U)/0=:U*Y#P49=8N=3\57",@U!Q%9HP^Y;1Y"'_@1+-^(KKZ
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JGIVHQ:G%-+"&
M\N.>2 ,1]XHQ5B/;<"/PJ/7-1_LG1+R] !>*,^6I_BD/"+^+$#\:XCQ+IUQH
MVEZ?#;/)=PZ=8LUW:P736\X'\5S&P(!8')P<]?>@#O;B^2WOK.TV.\ERS8VX
M^157)8^V=H^K"J.H^(H-.U_3='DL[N2?4=WDR1JA0;>6W$L",#GIT/&3Q5;1
M[A-8UR[U*,EK:VA2T@)ZEF DD/ZQCZJ:Y[X@V=[J/BGPQ9:;?&QO98[Y8YP.
M4/E+^(STR.1U% '5:5XBM]8U34+*UM+O98R&*2Z=5$+.,953NR3SZ<8Y[5L5
MQ_AS78#H-]I=M91V6KZ3$RS:>ISAPN0RGJRL<'/7GGFN>T2XEN;2QO8_%?GF
M[TZ;SK9)9FDD?9N+\N?**MW 4<X':@#U&BO,/"LMY$_@V675-0N#J]A.+L7%
MT[@E45E8 G"D=,CG'7)YJIX;O;^'2O!FIOJFH7$U]J,UK.L]T[H\>90 5)P2
M"H()Y[9QQ0!ZU6-JGB:QTR"TF(DN([F^6P#088)(6*_-DC@$$&N&\/W<^I7U
MGJDGB&."]>_EAN]/661Y'R[#RBA?:NT<AE48 )]:SM/L;7_A -(MY;B: OXC
M$;GS&9D87$F  3\IZ=,>IH ]CJEJ^K6FAZ5<:E?2>7;6Z[G;\<#\<D5A^%&D
MM]9\2:2;BYGM[*[B\AKF=I757A1BNYB20"3C)[U6\2)+XAUQ-(M[*&^M+%#+
M>Q2W!B0NZE8U)"MG"EFQV^0T =A'(DL:R1L&1@&5@<@@]#3;B5H;>2589)F1
M2PCCQN?V&2!GZD5R7@346M/#]SI&JRK%=Z$QM[AI).!$!NC<L<?+LQSQ]T]*
MZ]71XQ(C*R,-P8'((]<T 9^A:]I_B/3%U#3)C+;LS)EE*D,#@@@]*;IOB'3M
M6U/4-/LI3+-I[A+@A3M5CG ST)X/3TKSZUNM0\+VU@NF0&2/Q!IUN+8 96.^
M$:+N..@*?.3_ -,SS6AX5T:&#7_&6CVEU+$L<=E"MQ$Y#AQ!@OD?Q9Y/O0!Z
M+17G.F:U=ZM:R"^O+G3YO#UG+'J$P+[3<8*ABHXD 53)CGEUJ+3KZ*QM=1L_
M$=[J-C-:6D%Q+<1:C++'<PJ_$L9)+(7(VLHP3G H [?Q#KMOX;T6?5;J&:6&
M$J&6$ M\Q"CJ1QDBM2O'M?M;N'P!K]YJ5S=I>7Z136^F374LJVT FC !WD_.
M21N/O@8YK5DU^]3POXEU8R7,?B2V!CN;'SF*6*9 5TC)VD!/WF_'S'/;@ 'I
ME%<0UO/;^(K/3-/U2^DL=4TR9VD:Y>4Q.FS9*KDDC._H#@USMMXLO;$:7?7T
M]X\6CL]AK@WNP:4EDC8 <,<J">O$B_@ >LUEV^N6]SXBO-%6*87%I#',[L $
M(?.,<Y/2N-UV35;>VM/-EN[@1V#SZC9VUZ\-Q!YC9\U""-X3#+MSCCI6-K&I
MM:>-KD_:KB+2;FQL8[S4DD*2PQDMM;(P1N. 6[9/X 'JSW3KJ,5J+69DDC9S
M. -B$$#:><Y.>/H:LUR+NUO\0=$MK:^N7M)=,G8PM<-(C;63:YR3DX8_,<UU
MU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%%  >E1-Q.I]JEJ)O]>OTH EHHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "HW;##K_G_]=244 <-<_%CPA9W<UK/J,JRPNT;K]FE.
M"#@\A<5&/C!X+)_Y"DH]_LLW_P 37>T4 <'_ ,+=\%?]!E__  #G_P#B:7_A
M;W@K_H,O_P" <W_Q-=U00#U&: .$_P"%N^">^LO_ . D_P#\31_PM[P1_P!!
MI_\ P$G_ /B:[L #H*:44G)44 </_P +<\$_]!P_^ D__P 32K\7/! /_(:;
M\;6?_P"(KMS&I'W%I/*4?PK_ -\T <9_PMWP1_T&C_X"3_\ Q%'_  MWP1_T
M&C_X"3__ !%=GY:_W%_+%'EK_=7\J .,_P"%N^"/^@U_Y*3_ /Q%(?B[X(Q_
MR&\?]ND__P 179^3$>L:_P#?-'DQC@1J/^ T <3_ ,+<\$?]!W_R4G_^)H_X
M6[X('_,=/_@)/_\ $UVWDQ]T4_\  :41(.D8'X4 <)-\5_ EPH2;51*@8, U
MC,P# Y!Y7J" :JWWQ&^&VIR1R7]S;W3Q?<:?397*_0E*]&\M?[@KGM<\6:3X
M>U.ST^^BN?/O6"V_EVQ<2,2!M!]<D<>XH QHOBUX$CR(]95026(6SF&2>I^Y
M4,_Q(^&]U=)=7%U:S7$>"DLFG2LZXZ8)CR*Z:X\0Z?;^(H=":&=[Z9!(!';E
ME5,XW,1T&>YK9\E",;$Q_NT >?-\1OAH]]]N:YM#>9#?:#ITIDR.AW>7FA/B
M+\,XQ<!+FT07((GVZ=*/-!Z[L1\Y]Z[W[) O2!.?]D4OV:+_ )XI_P!\B@#S
MU_'_ ,+G6!7EL2MOGR1_9LG[O/7;^[XZGI26_CSX6VD4,4$MC'' YDB5=-EQ
M&WJO[O@\#D5Z$UI Q!:W1B.F5'%1R)9QR112)"LDI(C5@H+D#)P._ )H XF/
MXE?#B*]>^CO+9+M\[IUT^42-]6\O)J&;Q_\ #"<,)I;)]SF1MVF2'+GJW^KZ
M^_6NOT?6M'UUKQ-.?S&LYC!.K0-&8W'52& K3^SPG_EDGXK0!P%E\1?AIIMQ
M<7%E>6]O-<G=-)%83*TAR3EB(^>2?SI+7XB_#>QO+B\M;^W@N;DYGECLI5:0
MYSECY?/-=H)M-?59--'E&\CA6=HM@R$)(!Z>H/\ DU9-C;L/FMXC[&-?\* /
M.U\<_"T7-U<+/8B>[1DN)/L$@,JM]X,=G(/>KS_%#P ]G]C?5[<VQ3R_*-K+
MMV],8V]*V-?U_P ,^%FA_ME([19O]7(+1G5CW&54X/L:M:O>Z!HNDG5M16UC
MLEV_O3%N^\0!@*"3G/:@#FK3XD_#NQMH;>UU*UAAA),2):2 (2",J-O'!/YF
ML^3Q]X L$N[K0K_3K759DP)WT^8ACG^+:@)'XUW>E3:7K6GQWMG;9MI.8WDM
MC'O&,A@& .#G@XYJ]]BMQP+:/'^X* /.M%^(?@;3M.FBN]<BN+J[D>:\<6$X
M25VZC!0_*!A0#V%21^._A9%#+!&]@(I2&D0:9)M8CID>7SCMZ5Z%]CMQR((_
M^^%K-N]8T?3]:LM)N2(KV^!^SIY#$28Z_,!@8]SZ>M ''#QU\*@C(#IP1\;E
M&E/@X]?W=.3Q_P##&.]:^CN[)+EX_*:7[#('9  NTG9DC  QZ"O0S;1$8,*$
M?[HJ(Z?:$8-G P]T'^% '"Z?\1/AMI*LNGW]E:AP-WDV<BY Z=$J4_$WX>LL
MJ'5+7;-()9 ;23#N,88_+R?E7GV%=G_9MEN!-C;9 P/W8X'Y4O\ 9UF>/L-M
M_P!^Q_A0!PM]\0?AIJ<J2WU]8W,B*55I;21R%/4<IT]J8_CSX8RW%Q.]W8M+
M<1>1,YLI,R1\#:?DY' XKJM)O= UF>^AT^&"62QF,%PIMRA1QG(^91GH>E2I
M=Z&VO-H:K;C45@^TM (?^6><9SC'7MG- '&VWCGX7V5U#<VUQ90SP)Y<4D5A
M("B\\ B/@<G\ZU/^%N^!_P#H-_\ DI/_ /$5UXL[<# MX\>R+3OLT(_Y8)_W
MR* ./_X6[X(_Z#1_\!)__B*/^%N>"!_S&C_X"3__ !%=C]GB_P">2?\ ?-!M
MXO\ GDG_ 'R* .._X6YX'/\ S&S_ . D_P#\11_PMSP1_P!!H_\ @)/_ /$5
MV'V:+_G@A_X"M'V6'_GC&/\ @(H XX_%SP.!_P ALC_MTG_^(I!\7/!&?^0Z
M/QMI?_B*[![*WD&'MXV'N@IIT^T8DM:Q$GJ?+7F@#DO^%M>"O^@ZG_@/+_\
M$TO_  MKP5_T'4_\!Y?_ (FNN%E;@8%O'CV1:46L(Z6Z?]\B@#CC\7/!.?\
MD._E;2__ !%._P"%M>"3Q_;T?_@/*/\ V6NO^R0'_EVC_P"^!3#I]JW+6L+'
MWC7_  H Y/\ X6QX(_Z#\7XQ2_\ Q-'_  MCP1_T,$7X0R__ !-=7_9UF?\
MEQMO^_8_PH_LVS'_ "XVW_?L?X4 <I_PMCP1_P!!^+_OU+_\371Z)K^F^(K'
M[;I5VMS;;RF]01@CZ\U8.FV;+M-E;D'J/+&/Y5+#;QV\>R")(E!SM1<"@">B
MBB@ HHHH **** "BBB@ HHHH #TJ)O\ 7K]*EJ)O]>OTH EHHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MLQT'L,^]/FUCQ#<Z;XULM+U*=9-#N/,M+H[9&90"7A)(^8C!'//(S7<Q>$-
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MD;!E8>H(ZU+69X>T6'P]H5MI=NVZ. -SC&2S%C@=ADG ]*TZ "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****  ]*A8XN
MD'JIJ8]*@<?Z2A] : )Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MG%X2T:V\PK+?:O+;-+;PPQL$ W;5!VH&8G&3ZGOB@#US4M4L='M#=:A=1V\
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M /2HF_UZGT%2U$Q_>@>HH EHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "HRN9 WH*DI,<T +1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %1MGS!UQBI*:6 ;;WH =1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %,*YD#9Z4^DH 6BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *;D[C3JC/WJ )**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ J)C^] ]14IZ5$W^O7Z4 2T444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !43?ZP&I:;@9SB@!U%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4@I33=P#;>] #J*** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ J,KF3/I4E)CG- "T444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !24M-'WC0 ZBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *04M% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
(4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>arwr-20230930xex321001.jpg
<TEXT>
begin 644 arwr-20230930xex321001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M[8S4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 0)_Q\O[
M*!4]0I_Q\O\ 05-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% $"?\ 'S)]!4]5X_\ C]E_W15B@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** *\?_ !^R_P"Z*L57C_X_9?\ =%6* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH KQ_\?LO^Z*L57C_X^YO^ U8H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK.U[4Y-%T&^U..W6?[)
M"T[1M)LW*HR<'!YP#CC\JP-,\8ZCJ-EI-\-$B^RZ@T>?*O=\L".VT.R>6/ES
MW!H ["BHOM$'/[Z/CK\PXK!M?%L4_C.^\-RVQAEM;<7/G^8"CH2H'I@_-^E
M'1T5EWFJW-OKECIT6FR3Q7*.SW0D4+#@9 (ZG/\ G-9OA#QC;^*M.>X:%+.9
M;F2W$#3!BY0#)7@$CGTH Z:BL1?$(CU'5H[VV%II^GHC_;GF4I)D$MQVVD8J
MYHVLV6O:7#J-A*)()5!'(RO?!'8^U %^BN3D\:26_BS3]%N]#O+>+40_V6Y=
ME.]DZY09*C'.2<\C(':OJ?Q .D^(;6PO- U&*PN;K[)%?L %:7..%Z[<]#QD
M#(!% ':45#=W!M;62<0RSE!GRX@"S?3) _6LGPEXF@\6Z$NK6UO)!"\CHB2$
M%L*<9..!]* -RBBB@ HHHH **** "BBB@ HHHH **** ($YN)<>HJ>J\/,TG
MU'\JL4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD4&81+'S]X^8IP/P!/X4S7M%_P"$I^$<%M9D2W LH9[5HSDF1%! !]3@K^-
M'37FMBSUVQTHV5S*]['(\<D6TJH3&[?D@@?,N#SDFL2Q^($6I'419>'M:G.G
M2M#<JJP!D<9R #+ECP>@-+X#EO-:TJW\1ZI$4N[BUCAB#=HU&6;VWMEOH%]*
M\]\,/!<^*-?O1K]O:VD/B(W302RHB31AG.[)YXR#UQ0![-IFH1:KI-IJ,"ND
M-U"DR+( &"L 0" 3SS6#_P )Q;7#WKZ7IE_JEG8N4N;NT\LHK 9(4,X+D=]H
M/MFM.&ZCUOPL\^D/Y:7%LXM7  QP0I ].AKB?A5?VNB?#RZAU646<NFW$HO(
MY_D:+/S#(//(/'KVH Z/5/'VDZ;X8@\11QW-]I<IP9K4(=A)P P9E.<\<9QC
MG%21^+GDDM(_^$>U>,WD;/;.X@*.1&7"Y60[20IQG%>0R6=S8_L_7KW4?D1W
MFH+/:Q,>1&67&/R)^G->K>"]/O+&S:[OM0^W6\]K;207$@52BA#E,* ,#.<]
M]Q]Z (=/^(MOJFD7.JV7A[6YK.V=DE94@W*R@%AL\W<< CH*F@^(&GW'B6ST
M*+3]1-U>0)<Q/MB"&-EW;B=^1@9R,9XZ5P7PML+O5K1+VSU8FSMM;DGFL"J
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MY3X<7>BW/@C3X]#)%M"FQXF?<\4AY8-[Y)/0#GCBNKH **** "BBB@ HHHH
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MEV-ZP6&YN=FU2>5$@5B4R/4?7% $$?@$/XRU'Q!?W\=VNH6S6DUH;;:OED*
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M-3T7P]:6UD-0C>.0L6P-R[=W<DCTJP?&6ECQ/'X=9;I=2DSLC>$J&4 DL&.
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MU$@R3& <M[XST]\]JA^*U]:ZO\/[.TTUUN)]4GA^Q0Q$%I!G.0/0#CVS7IA
M(P1D52MM'TRRG:>TTZT@F;.9(H%5C^(% 'DVO6EQ#\2O FGRW[6]Y%IPBDN(
M]K,KA&!/S @Y/J.]>F^%M,N=(\/6UG?2":[CWB6;O)EV()^N<_C6E)96LLOF
MR6T+R?WVC!/YU/0!Y=\:BJ:7X?Y _P")JA_0Y-:WQA"CX8ZJ> 6: ?7]ZE=K
M-:6UR09[>*4CH70-C\Z)+2VEC2.2WB=$^ZK("%^@[4 >)^,8KBR\(>"I+K79
M[F"2XM)$MI88E6,+'RP95!P-P&"3U[XK?\;QS3_%[PM!:ZC_ &?</:3K'<!%
M<HQ5P/E;@YZ?CQ7H4N@:-,D:2Z382)&"(U:V0A 3DXXXY)-+<:#H]W+YMSI-
MC-)@+ODMT8X' &2* ,3P--%;:3;Z'(4?4["TB^VM&RN QW *6!Y;"D_0BN8\
M4:&^H>)M:UGPKK4NG^(=,1!>6Y(V3KY892<\?=..<C*]NM>DV>G6.G*RV-E;
MVJN<L((E0,?? JM>>'M%U"X-Q>Z187$Q8,9);=&8D# R2,]* /*?$>K2ZQX4
M^'E[,D5E<W.IQ/M5-JC#8+A?0\-^-=3-;75MX;U3PV+U;CQ)<PWL\3Q@;S&T
MA()_NYWJ /4^W'976CZ9?>7]KTVSN/+7:GFP*^T>@R.!19Z/IFGRM+9:=:6T
MC#:7A@5"1Z9 Z4 <;\'[JV7X:VD1E1);.29;I6^4Q-YC-\V>GRD&LKX@36RZ
M[\/M0MGBBTC[?YGF ;$&XQLI[8XW&N_N?#&@WM[]LNM%T^:ZSGS9+9&8GZD5
M=O;"SU&U:UO;6&YMVZQ3('4_@: ,J6=9/'EI C[C#IL[2*,?)ODAVY[C.QL?
M[IKP[3GU5?ASXH%DT,EC_:A%_$$_?"$XRRMG Z8Y4]SGBOH"RT;2]-M'M++3
MK6WMI,[XHH556SUR .:6UT?3+ R&STZTM_,&U_)@5-P]#@<B@#R[QY)I(^%_
MAB/1[@2V OK9+=BP+,%5@<_[7K[YKH_B_*]O\-=4,6%,K1*YP.074']!74GP
M[HAB6(Z-IYC4E@AM4P">IQCVJQ<Z;8WENEO=65O/ F-D<L2LJXX& 1@4 <I>
MJ/\ A2TK8&X>'B,XYQY%<#JO_)M6G?[Z_P#HYJ]I_LVQ^P_8?L5O]CQC[/Y2
M^7C.?NXQUJ$Z#H[6RVQTFQ,"L66(VZ;03U(&,9H YCPUYND",ZY=QW,M[)#_
M &<1$%.!!R%&>-J[LM[GUQ7$3VM]X8TD>)/#&H+JWA.^E5KC2[H!P@D< @<]
M=QV\<@XSG&:]>M]!T>TG6>VTFQ@F7.V2*W16&>#@@5!%X5T""XBGBT:QC>(@
MQ[85 4CH0.F??K0 WQ7(J>#=:=SM7[!/G/;]V:X?X?-<Z=X.TS5=3GBDT>/3
MB(XEC^99?/R!@D[V)QC '('?KZ5>65KJ-J]K>V\=Q;O]^*50RM]0>M9,7@OP
MO!,DT7A[3$DC8,CK:H"I'((XH Y3XG:5)KSV\.A0RMXCTY?M27$+;##'S\I;
MU8@[5]B>!G.;/K/_  D_P+OUT*$P7EO"L5U:Q,=R88&3KR0R[CSDG)')S7IM
MII&G6,UU-:6-O!)='=</'&%,IYY8]^IZ^II;/2=-T^1I++3[2V=QAFAA5"P]
MR!0!S_@2^TQ?AMI=S%+''9P68\YG880J/GW>G.:XWQI#&WCWP#%H[Q6L11OL
MK"+*(OR[?DR.,=N*])?PSH,MP9WT:P:5G$A8VZY+#HQXZ^]/O/#VC:C>I>WN
ME6=Q=)C;-+"K.N.F"1GB@#S'0H9H?VA-134+F*YN5L 1*L7E@G9'T7)YVY[^
MM0?$%M0\0QWNM:?87Y_L2X5K&Z0+Y06(GSFY;));'13Q$/>O5?\ A'M&_M-M
M2_LNS^W,23<^2OF'(Q][&>E/CT32H=,?3(]/MDL7^];+$!&?^ ]* .1U?4K'
MQ?X6\,W059+/4=1A6:$GCE7#(?H01^%<OI]AJG@CQGIOA5@]QH5Y?BYT^=SS
M&0&W(??D9Z>O<UZ=%X6T""&.*+1K&..*3S8T2!0%?CY@,<'@<^U:4UK!<-$T
MT,<C0OYD9=02C8(R/0X)_.@#S'X?"6#XH^.(M0.+UYE>+>,,T6YR,9[;2GZ5
M>LO%!\17/BV Z)#:W.FVDEK=7(N=Y;'F;54;!D9#G/%=M?Z+INIRQ37EE%+-
M%_JYB,2)_NL.1^!J*V\-Z+9VEQ:V^F6J0W/-PHC!\[_?/5NIZT >7?#%;N#P
MC97VI3P'PU%:7GG1E<;7\U3E\GYN V, 8Y]:]>GO(;6PDO9F,<$<9E=F!!"@
M9.1UK+7P=X:6'R5T'3A$3G8+9=N?IC%:.H:=::K9265]")K:3&^-B0&[\XH
M\AGO+[POX\T?Q3?PWELFL,;74UN%&R,L<H%()X4;?^^">];,\LA_:#M5OT4P
M_P!FD:><]\$L?K_K!QVQ7H%_HFEZK;Q6^H:?;7<,/,:3QAPO&,@'VIMWH.DW
MUI!:W.GV\D-N (%,8_=8&!L/5<#TH DF@TZ?5(C,D+WJ0,$#8+",LI/'IN5/
MQ%<-IFUOCUKBG!']D1@C\8Z[BPT?3],DEDM+98Y9?]9(26=O0%CDX]J;'H6E
M1:NVK1V$":@X(>Y5,.P..I[]!UH RO'D5P/A]K46GJ5D%FP58^,*!\P'_ <U
MR\$UB?V>"P9?)_LETRO'[WD8_P"^^M>FUA_\(=X?,S2?V9%M9_,:#)\DOG.X
MQYV9]\4 >-:_'?Q^!/APESE+O[0=GG G"[QY>1D<;=O'I7L'AFSU-&OKC7/+
MEU 74J13(A5?)(0@("3A>!QD\@]3S5S5O#>CZZT#:G8QW)@_U6\GY/<8/M6H
MBA$5%Z*,#)S0!YU\3U4:OX*;:-QUR$$XY^\*@^(6F:AI6JWGBRW\F>T?29=/
MN(99=C1[ONLG!R22./\ '([?5O#.C:[-'+J=BET\7^KWLV%]P < ^]33:'IM
MSJ$=]<6RSSQ8\LRL76,CH54G ;GJ!F@#BM T'58_A';Z)!-;6^LS63_)=IN*
MH[,=A';AL<@@'L:P=,\17C?#WP_9/X>U4Z?)!(MQ_9D+R&18SM521@JKG))S
MT! X.:]/U'PYH^JWL5[>V$4MU$AC28Y#!3GY<@].3Q[FM"*"*&W2"*-(X44(
MJ(,*JC@ #L* //O@E+YGPZA38Z^7<RKEEP&YSD>HYQ]0:]%JGI>E6&BV*66F
MVL=M;(25CC' ).35R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** *ECTG_ZZFK=5+'I/_UU-6Z "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#D?B+XFN?#?A>:73CG4
MI!F ;=VU5(+N0>P7^8I^K>(#=_#:7Q#IUU+;LUG]IC>$(Q5L?=(8$8#<'CM2
M3^&[C6_$E]=ZMYT-HL0MK5;>YVB2(\R!P/[Q]^@%<OHW@_Q/IO@/7/#,EM;O
M'<.YLF%SGRU8\JW';&?J30 S3?%^NC3];\-Z]>R6?B;3H)+F&ZBCCQ<HH+#
M*[>GMT]P:LZYJFNP?%G1O#%MK]Y#87EEYLC+% 7W 2\@F,CGRQGCN<8[:WCS
MP*OC#3[6[A2.VUFV*LC,W!7JT;,!R.N/?ZFJ^M^&M:N?BOI?BBUM8I+*QM3
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M[5P&G@CD6.6&0<[AN(5@26[@\_F :K6'BK[?/;QZPGV(K$8KEX(_,7YF\P$
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MA^XNYI+G>NV<2,#'LYSVYR!BO6: "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"E8=)C_ --FJ[5+3_\
M5R^\S5=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"EI_^
MK?\ ZZM5VJ6GG]V__75JNT %%%% !1110 4444 %%%% !1110 4444 %%%%
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M% %#2^8')_YZO_.K]9^E?\>K?]=7_G6A0 4444 %%%% !1110 4444 %%%%
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MTY+9E;/R,W)"\_ASCH]4L5U32+W3V<HMU \!8=5#*5S^M226=O+=0W4D0::
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MH45P1U'SX!Z'-8UGH5I<Z=XZET:P@6^CFD&GR10@.BF( B(XXW88<=:]<HH
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MNBY8]=HJU:Z7!:ZG>Z@K.]Q=[ Y;& J#"J, <<DY.3SUP   7J*** "BBB@
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M"3]Q&" 5C:39#"I/0="3ZDDU!IMA)J7Q%U^VUFUM09],MBR6[LP^\V#N(!W
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M3M2N&:4-@ ,4;H<_W<#GI6MXJU2\BU#1=#T^0P3ZK.ZO<*,M%%&NYRN>-Q&
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MF?:0,9W-PRD[0< _6LZ^\3R&V\51:CIU]!9:>#$9K5T,FQHU.Y?FR&P^X<<
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M$;[D 4J I. "<G@GUJ;5K#7-9DNM+GCL(M'G(#7"2N9RG&5V;=H).><X'H:
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M<.A(^Z1ZBL*+QG:NUI*UG<II]Y<&VM[T[/+9P2HR,[E#$$*<<^V: .BDBCE
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MTU;L^>\C0HQB81O(OWD5\;2P] :VZ ,VW\/Z1::BM_;:=;PW2QB(21H%(0#
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M-(!%J/// QC#?WAM^7GM6AJNDP:Q;Q0W#S((IDG1HGVD.ARI_ \X]J .'O\
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M;RF4A2<J0V?P[5VEI'/HT.D:7;VCW,.PQSW6\+Y>U<[V!Y)9O3N: ->BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"XU35&$VM7Y$EQ(HX0=D7V% &GX<\.VOAO2HK.VR[\M-,_+RN>22?K6S110
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M%% !2$XI:0C- &;H "Z#8 ?\\5_EFM.L_1AC1K(#IY2_RK0H **** "BBB@
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M(M4]./F<^P%=0Y.,+UZCFN)\/*OB+Q7J'B2X0^1:,UCIX8Y&T?ZQ_J2,?04
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M3_T&K]9^C*JZ/9!5"CR4X_X#6A0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% $,MK!/-#++$KO Q:(L
M,["1C(]\$C/O4U%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDE3_ ,!&!7=T4 8EEX5T+3P!;:-8QE>A$(R/QQ6Q&BQH%50H'84^B@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MULZ3J43@'ELX'!!_&O)U\-ZS'X)\::)%I5R+^?4);B&41866'?&<*W\6X*V
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MI8 ?+PV,^_;KQ52YO;QOAIX<T.*QN;:\O8#:W5V;61OLMN'P^<#.6VCCO^5
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M%%% !1110 4444 %%%% !1110!6LN;.W.,?(O'_ :LU6LQBSMQ_L+_Z#5F@
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M^O&?KBFZ)KDFIV%U=WEG_9\<-P\:F296#HN,29' !S0!L45@>*?%MAX7\/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 >::C'+X8^,)\1:@DA
MTC4;'[+]J524MG&WA_[H^3KP/F]C6YX@U_3]:\&^(8],D>[C_LR?%Q"A:)F*
M,H56Z,V>PSCO77D @@C(-(JJB[5  '8"@#P[PA;OI_BWP)]GL! DFES?:Y5B
M(+,?,R'/J"@ZU6C2\@^'K36-M*+:+Q.9KM%MRVZ(8*ML_B7[G'3@5[W10!XG
MXPTJUMOAHD-G<3:B)=9\^)VM2FT-DN$7'"9S[=:]=U)H;;0;HC;'!';, %&
M!MX  J_10!X;\,I;;P]H*ZQJ%U-'+:"Z4Z>0Q>3=Y14HF.IV$9^GI6C\0X8%
M\2Z=K4&GR2F)(X=<AA0,&BD(PC$<LWRMT'0#)'&?8:* /(O%,9U#QK]FO)GM
MO#U]HP@LIDLFFC&XAB ,?(_ (.,\+2W-M#_PF%U8^*X=0FTN_P!(@@M+F6)F
M8,NTL/D!"R%QN/N!ZC/KE% 'DGC""WL?%>L,MI,([_PI);PL+=W,T^X[02 3
MNVA>3R,#-4UM$_X1WX;3WMFTEI;R.ESO@+A,C&&&#U(Z>U>ST4 >5:5H=EJ_
MQ#\=:;<6H%C=V\*+B+"Y"@$KQC(;GZT[PEIFOCPA=/=V8BU/1K&YT_3CM&]Y
M.3O![#A%'T;UKU.B@#ROX6VMOOT^Z6\NC>)IQMY[4V9C6/$F[+O_ !-DMCN0
M3Z&M#Q=9W&G?$SPWXIE#G2K>*2VN9!]VW+*X#MZ*=_)Z#;S7HE! (((R#U%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN?TOQIH.K6UW<P:E;+#;3&%WDE5>^ >>Q/ ]:75/&6AZ58V-Y)?V\D%[<+!
M\<JE6RP5FSG&U>23VQ0!OT51EUK2H;^&QEU*T2[F ,4#3*'?/3"YR<XJ,^(=
M%$B1G5[#>\OD*OVA,M)Q\HYZ\CCW% &E15*TUC3+])WM-0M;A+<E9FBF5A&1
MUW$'C\:CA\0:-<V1O8-5L9+57\LS)<*4#_W<YQGGI0!HT5E7'B71;:PO;Y]3
MM6M['BY:.4/Y9]"!DY/8=344/BS0WTRROYM4L[>*[0/&)IT4YP"5Z]1D ^E
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M;*C!.,[O3FO7:* *=_*(]'N99H@V(&9XRI;/R\C Y->96^FO:_#KPK>V^F3
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ME^G1:ZZN-TW3[?6/'DOB2.RN8(H+;[.'N(VB\V;)&\(V#\J$KN(Y#X'0UV5
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MJ#_VZL2WT,$<B_8@Q5HL%=I+9"DC)7WZT :C>)=1E\0W^D66C)</9>2TDAO
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M3Y1S,K*5 '/RX!]^E6?#OAS6-#2UL9-:2?2K(L((Q!B5TP0J.^<$+GL!G H
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M9LK*7.W/) '/IB@#O:*C@GBN;>.>"19(95#HZ'(92,@@^E24 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ IC<NGXT^F.?WJ?C0 ^BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *BD_UT?XU+44G^NB_&@"6BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BD_UT7XU+44G^NB_
M&@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BD_UT7XU+
M44G^NB_&@"6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *BD
M_P!=%^-2U&XS+&?3- $E%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4QSB1/QI]12?ZV/\: ):*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ J*3_ %T7XU+44G^NC_&@"6BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH *C?_ %L?XU)3''SH?K0 ^BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *C=PLL:D<MG%25%(@:6-C_#F@"6BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *8_WU_&GTQOOK^- #Z**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IA_UB_C3ZC;_ %J?
MC0!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,;[Z_C3ZC
M;[Z_C0!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %,8?O$
M_&GU&Q/FK^- $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5$W^N3\:EIC??7\: 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !4;']Z@^M25$<>>GXT 2T444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 (20.!F@$GJ,4M% !1110 4444 %
M%%% !1110 4444 %%%% !43 ><I],U+4#D"= 3@G/% $]%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5 ZJ;J,GJ <5/4+C-RA]C0!-1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %,/#J:?3&^\OXT /HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "F-U6GTU^U #J***
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IC]5I]-?M0 ZBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *8WWE_&GTQ^JT /HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FL,D>U.II;D#UH =11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %1L,R)^-25$Q_?K]
M* ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ /2J\A'VV)>
M^TFISTJNZ'[?$_8(P_E0!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "H6'[]&] 14U1-_KE^E $M%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5"W_ !\I]#4U1,#YRGM@T 2T444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !4;']ZJ^Q-/-5Y&/VN'W5J +-%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 &JCR*+Z",KEBC'/ITJV>E0/C
M[7&>,[30!/1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5&)
M^V0X_NM5LU58?Z7"?]EJ +5%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 53=S_:4$?&#&Q_E5RJ;@?;X&[[&&: +E%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 'I4#[?M4>1D[3BISTJ%Q_I*'_ &30!-11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !Z5&R_O%?/08Q4E1
ML?G [4 24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 AZ&F!\R[=K?=SGM4E% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4W SG'-.J(_ZU: ):*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ /2H6/^D(/8U,:A<'[2A [&@":BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *B8XG'N*EJ(_ZT4 2T444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4E+10 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %1D$N#BI*;NP<4 .HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "FE<G-.HH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HQ110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1149!WC@T 24444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !111B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH ***0G'6@!:*** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ I" >HI:* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
0B@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>arwr-20230930xex322001.jpg
<TEXT>
begin 644 arwr-20230930xex322001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445'OQ*5/I
MF@".$YEE'HP_E5BJ\/\ KIO]\?\ H-6* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ J G_2 /5:G[5 ?^/D?[M "0_ZZ;_KI_[+5BJ\/^NF_P"N
MG_LM6* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J$_Z_\ X#4U
M0M_K_P#@- #8?]=-_P!=/_9:L56A_P!?-_UT_P#9:LT %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !4#?\?(_P!VIZ@;_CY'^[0 VWYFF_ZZ#_T&
MK-5;?_6S?]=!_P"@U:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M21S$2(2VXC=Z$_CZ$5M:QI']K:<MHNH7UB5=76>SFV2 KV).<@]P0<T >>^
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "H#_P ?2_[M3U W_'TO^[0
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MSXGZC>^$K[Q-)HEL+"RN/(FC2[;S?X/F4%,'[XXR*Z'4?&L$-MX?:S6'S-<
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M:V33!J$Y-RPZAF$:?)R=H&<XP30!>LO!6GV'BVZ\2075ZMY=$^='YBB)P1@
MJ%[<$<YR/K3I/!UE-XQB\42W=XU_"GEQ+N3RT3!&W&W./F;OGFJGAOQ+KNN#
M3KR;1;:'2[^)I$FBNC(\6!E0ZE .>G!-2^*/$>K: +N[M])@N--L[07$TTER
M8V8EF!1 %.2  <GU% $FN>#H->UW3]6FU*]AET_YK:.(IL1\Y+8*G). /PJ7
M4O"T-UJXUFPNY=-U7RS$]S JMYJ<?*ZL"&Q@8Z$53TCQ3J-U:1:IJFF6]GI$
M]@;Y+F*X:4QJ K8D&Q<':Q/&?NFJUMXUU"_T&;Q'9Z&&T6/<X,ESMN)8ESN=
M4V[>,' +<X[4 :6E^$+323J-S!=W3:IJ'^OU&4JTOM@;=H [#&.!Z58/AFRG
M\*+X=OV>]M%A$.Z8+O('W3P ,CC!QVJYHVKVFNZ/:ZI8N7MKE-Z%A@CU!'J#
MD'Z5Q]E\0M0OKO7X8?#\;C0I-EUMOOF<98$Q@Q@'A&."10!W%G;)964%K&69
M(8UC4MU( QS^5<S%X'33XKZUT75;O3;&^<O+;Q*K!"0 QC+#*$@>X] *JZO\
M18+'P):>+;&P:[LYV"F.27RG4DE?[K X8$?XUK7.NZE!;:/,FEV\AU"58W7[
M81Y18%@<^7\W .>G..O6@"E?_#[2;OP=%X7MY;BSTY"&;R=I>0@YRQ8'G//'
M\N*Z/3K)=.T^VM%D:7R(EB$C@!F"C S@ 5SFE>+[[4O&FH^'7TB&$Z>%:><7
MA8%6 *[5\L9)R."1CFG^._&,O@K2H=2_LU;VW>7RG_TCRV5B,C VG(X/IVH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *@;_CZ7_=J>H&_P"/I?\
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MP<D;:-X!\/6FJ"YN5352EF70F%H=YV/,F,LFWY@O7ITKV1D5\;E#8Y&1FG4
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M>S2-+*%RJLP+$@$EA].<8J]K7@&Y\1^']0@U2ZMI-6N;A98;Q5($"J?E11U
M +#&>=Q.:FU?P1>^(/#^FQ:EJ4(UO3)%DM]0AA."5Q]Y2<\XR<$<X/M0!?E\
M)26ZZ>VFZOJ:RVUQ&\WVF_ED6XC#?,K D\D$XQCG':N+\.WWE?$SQ587U[K$
MUE;@);PI-<S"/=UX4DCKP3T[5WEE'XIGN8AJ<NF6UO&0SFR+R/,1V.]0$'KC
M)[9'6LS0_"6H:1XRUS7S<6LBZF.(!N!C(Z?-CGWXH Q?@S=76I:+JMY>WM[=
M3+?O"AN+B23:@52  QP.2>V:FT?QI?3_ !1ETZ\C,>EZE:!],).=XC+?./\
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M<%692#TZ^U=[>W<-A8SWEPVV&"-I'/H ,FL"PT/5;6:Q!FL888BAN6@5_,N
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MT+*,$^PR>#QQ65$NHV6G:A;7LT<WB*Z-X+&2--N5*!@0N257*H._.*I_!F:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %0'_CZ'^[4]0-_P ?0_W: *^E<V0_WS5^J&DC;9+GNQJ_0 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6R!@*5W'DXR!CKZ&@#H**C@F2XMXYHPX210ZAT*-@C/*D @^Q&14E !1110
M44A(&,D#/ ]ZHZ3K6GZY!--IUQY\<,S02-L9<.N,CD#U'/2@"_114/VNW^VB
MS\U?M)C\WR\\[,XS],F@":BBJFH:I8:3 L^HW<-K"S!/,F<*H/N3P/QH MT4
MTNBQF0LH0#<6)XQZYJ&RO[/4K5;FQNH+JW8D++!('4D<'!'% %BBBB@ HJJ=
M2LEU-=--U%]N:,RB#=\Y0'&['IFK5 !1110 44UW2*-I)&5$4%F9C@ #J2:K
MZ?J-EJUFEYI]S'<VSDA98FRIP<'!^H- %JBH+>]MKJ2>."=)'MY/+E53DHV
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M+J*UN;ZVAN)CB**255=_H"<GH:MT %%-21)5W1NKKDC*G(R#@_K3J "BBB@
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M&._.*PM5\*2MIU[#I6H7]O=7UTMP]PMT4\IQU; '(P "G0\=.M=2H*HH9MQ
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MM^YU8<@%D"X]=I'>N8>V@LM#\'6NI+E5U9Y8X[N/YHK3$NP/GH,&/[WJ!VH
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M "BBB@ HHHH **** "JS#_34_P!TU9J C-XO^X: *VB?\@BW_P!VM"L_1/\
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M[MW8%F=@/O'@ 9Z8]30!VIZ=<50TO2H-*AE6-Y)99Y#+//*07E<\9.,#H
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M57SV0R%W ^_CY1M.1C/K4>J?:=8\)#Q*?$-[IZ#3DN(8K0^6BR[<G=D9?+$
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M))QC/!ZXJ";QK:VEKJS7>GWD-UI<*SSVAV,YC/1U(;:1P<\\8^E '2B-!(9
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M"L<].,YZ4 =*(8EF:81()6&"X4;B/K5:QTVWT][MX0V^[G,\S''S,0%Z# &
MJC\,G)))P+W7Y1XD7019W(LVTUKB6Z28!T4D*'!W;OEPV<9.2..,FGX,\7)=
M:?H6G7<=\T]Y:LT5Y< ;;AD +@$G<2 >I&#@XS0!V<EO#*'$D,;AP VY0=P'
M0&HUL;1'#I:P*ZC 81@$#IBJVOZD^C>'[_4H[=KAK6!I?*4@$@#)Y/8#G\*X
MP^)=3C\8:1)-9Z@QNM'>1M.MW5P\@=<.,-L QGDGIQUXH ] C@BA4+%$B #
M"J!@>E25RQ\>Z2VA:=JD8D8:@&:"!WCB<A3AB2[!1@\=>XQ6QH>MV7B'28M2
ML'+02%EPV,JRD@@X)&010!HT444 %%%% !1110 4444 %%%% !4!_P"/L?[M
M3U ?^/K\* *NAD'1[8CIMK1K,T#_ ) EK_NUIT %%%% !1110 4444 %%%%
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M0Q+"KHR9+9.>I!.1]/K6?:> GL[;08(]9E/]BR.]NQ@7+!A@JW/3!(_&NSI
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MY-*T2RTZ2=9S:PI")%CV;@H !QD\X [U'X@UVV\-Z+/JMY%/)!  76!-S?S
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M1DO*PQN8G)('89/ [# [5C7.@7L'B&;6='OHK>2ZC2.[M[B$R1R[?NN,,"K
M9&>01CCBNAK+O==MK34TTU(9[J^:$SF"!02L8.W<22 !G@<Y.#Z&@#,U7PS?
MZUII6[U15OX[J*[M7BA(B@>,Y4;"Q)!YSD\Y[8JGJW@J[U>TUMI[^W6^U6&*
MV+I"VR*-"3P-V222><^G'KTVDZI;ZSID5_:B012%@%D7:RE6*D$=B"",5=H
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M?(OK#QC=^(M32RM=+_LR.W>0W))0JQ<D@J!C+D=>P/? ZHR(KA"Z[R"P7/)
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MTELMM]C-N?E4$G(??UW$G[O3CWH XO1-2TR]\7>'FBNH)8_^$>=;MU;Y=PV
MAVZ9 #9!Y'M6-I::-?Z?\/+34)%:*4WD3_Z044\'"-@\DL5[^W.:]I"J.BC\
MJ3RTX^1>.G% 'CNIV&G3>*-3T[4]7FTZ6SF@_LR!+<-,T*HNT0.?FY8,"%/N
M:9XA6P*_$.Y6X GLIX9+1UN"##*44L4YX;<IZ>F/:O9MH+!L#([XI#&ASE%Y
MZ\=: /*]5F32==UVS\,3_P"D3>'EGBCAG,CR2AV^<$DEGV$'/4YSWS66T.AK
MX2UZ_L-;DN89M(/F1Q1K#'%,"#'Y@4Y\XMD>I ;=U&?:!&@.0J@^N*-B8(VK
M@]1B@#RJYM;!=>GT[3IHYX[OPU*\\#3>;YTF<HYR26<Y)SUQ[5GW4ND2^%O#
MQTY](E^S::SS6-TOEQW#[(Q(8WZ"=2.O4;C[U[*$0$$*H([XILEO#*JK)#&X
M4[E#*#@^HH H1W4TWA=+NQ@D6=[(2012CY@Q3*JWOG -<%HDEK,?"%U9W:G6
MIV*:K$&S),#&QE\Y<\;7'&X<< >E>H5&D$,<LDJ11K))C>ZJ 6^I[T <?X A
MTE9=>:PCLUE75;A"854$)E<#C^'T[4[Q1::9J_B""R.H-I6N6MN+FROHY55R
M&9@4P?OK\HRI]?K75P65K:EC;VT,);[QCC"Y^N*2XL+.Z</<6D$S 8!DC#$#
M\: /+;S7-3O= TEM8NK.*P.KRVM]>Q1,8)U4$)(<$#8SCDY R!VR*<SZ;:2:
M#I=YJSWGAB>ZN5^T2%DA9]JF.,/N^:,%FP<XRO7Y:]4:"%X/(>)&A(QY94%<
M>F*22V@E@\B2"-X>/W;("O'3B@#RZ]L=!A\0>"(VFEGTV(WL<=Q>2-E\;6C
M8XW#)POJ ,9IC:J\>B7\,%S*-/3Q5]DOY)+ABT-KO ;+DY"D\9R.#[UZL88F
M\O,:'RSE,J/E.,<>G%1QV5K$)1';0H)?]8%C W_7UZT >4>)#%8Z1XOT_3KR
M0:3;P6LD CN&VPSLQ#(K9R<J%)7)'/3FNIT+%E\1M6TZ"ZFEMFTZ"X(EG:7,
MA=P6Y)QD$=,#I751Z7I\-DEE'8VR6J?=@6)0@^BXQ4D=G:PS>;%;0I+M"[U0
M X' &?3@?E0!S7Q-('PWUS)_Y8#_ -"%;ES<0BQCM_[12SGGC_=2;DW<#JH;
M@X^E6KJTMKVW:"[MXIX6X:.5 RG\#5:XT/2;RU@M;G3+.:WM\>3%) K+'@8&
MT$8'X4 ><6_VM?"_A*QN#&\</B);<R0+MCN$C:3;)[Y90V>YYJ;XA:N;:[U>
M2SOIUO-.LX9%#77DQP.SD@HHYD=@.0> !UYQ7?:QHMMK&E_8G+0A&22"2+@P
MR(<HR_0@<4?V/;7<:2:K9V-W>& P2S?9QAD/WE ;)"G^[DT 8'BN0_\ "1^#
M;FT=6E>_9 0,AH6B8O\ -Z8 /OQZ5>\:7L]EI-KY<K003WT$%U,K%#'"SX<[
MQ]SCC=QC/8U=31RVNIJ$[Q&*UB\JQ@2/:(00-[$YY)P .!@#W-:<T,=Q"\,T
M:21.I5T<9# ]01W% 'E/BV>]T2Q\5Z;IUY=+IT%A#=1.MU(7MIGDVE Y.[#
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MDR[AABS$Y8D=R<T <W,VHZ?\1XYKF.VNXKC39ULU@5DDA$;*S*<DAMV4&?\
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MNB:C>7-W=6"O<74/D32!V4NF,8X([$CZ$CI3X_#>E17D5T+>1IHK<VJ%YY'
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MGB:?1GN)4CV[&;Y"QP00,YYQSCH17:R>&]*DOUOC;,EREL;1'CF=-L7]P!2
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MU--?P7H+Z?:V8LC&EK*9H98I725)#U;S =V3W.>: ,SX;HT>E:PCR-*RZU>
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M_6M*B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:?3[2748;]X%:[A1HXY3U56QD?C@59HH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@!#UZ].M+110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[+SKF=MD:;U&2V"5R %W8XR*ZK2['45L=1L-0\1[6$T4D;07'F26H)!\LR.
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M,*PQ/'S)'$#MD<'N2QP#T 7O5;0WO+?Q]K%OJ5G;"ZN[:.YCN;9V*F%#L$;
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M9/AW2FL;:Q:TS9VPPEN9&,9_WESA_7YL\\UJ44 8NK:$NIZSH]YA$&G2/()
MS!^0!L '&#CDG.-H '.18UC0--U^*&+4[=IDA?S(P)73:W8_*1S6E10!D0^%
M]'AT^YL1:%[>Y8/*)97D9F  !W,2P(P,8/&.*CF\(Z'<:;<Z?-9L]O=2"6X#
M3R%IF'0N^[<WT)/05MT4 84?A#1X;6YMX8KF(7$8B:07<I=5!SA6+$KSZ8SW
MJ[I>BV>D^8UN)GFE"B6>XF:61PHX!9B3@9/'3D^M:%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !116/XKOCIOA+5KQ6VO':R%#G&&*D#]2* .<\)L/
M$?C'6O$LGSPVK_V=8'L%7EV'U)'/N:[NN<\!:>NF>!M(@"[6>W69_4L_S'/Y
MUT= !7'ZO?W_ (AUV7PWHUR;:V@0'4[Z/!9-W2*/T<CDGM]:W/$FKC0O#M]J
M6 SPQ$QJ?XG/"C\6(%0>%-%.AZ!!;RL9+N7,]W*W629N6)_'C\* +FCZ+I^@
MV"66G6R0Q*.2!\SGU8]S[FK]%% '*Z4Z:;X_U;28@J07=LFI*@XPY8QN0/?"
MD^_UKJJY&)S<_%NX*_<L]'6-^/XGEW=?HM==0 445#=W<%C9S7=S*L4$*%Y'
M8X"@=: /+OC3KVRQL_#UN_[ZY833@'H@.%!^K<_\!KT[3K5;#3+6S3[L$*1#
MZ* /Z5XQ?VMSJ>F1^+K^'][JNLVZ0*YYBME)VC'O@?7 ->X4 %<EX@D;4?&V
M@Z*-_D1!]0N0!\K!.(P?7YN?P%=;7%VKO'\8;Y;@@>9I*?9><90/\P]SNR?I
M0!U5EIEEIQF^Q6T=N)FWR+&-H+8QG'3-6J*X_5/%T][>R:-X4A2^U#;\]V3_
M *-;<=689RW^R/\ ZU $OBOQ@NCM_9FF1K>:Y,N8K<'Y8AC[\AZ*H'/)'Y<U
MS?PDTJYNDO\ Q9JCF>]OW,<<K\G8#\Q';!( X[+2^(-&C\(>#+B*&4W6NZU*
MMG+?2_?D:0_-]%QG ^E>A:5IT.D:3::=;C]U;1+&N>^!U_'K0!<HHK)\1>(+
M3PWI3WMR"[$A(8$^_,YZ*H]: ,?QYXEDT?38].TX[]:U(^1:1KU&3@OGMC/'
MO]#6GX3\/1^&?#MMIRD/,!OGE[R2'EC_ $'L!7!> ;#4=?\ 'FK^(]=5!<V1
M^SQQ*P98G(Y48)^ZO'U8]Z]8H **9++'!$\LKK'&@+,[' 4#J2:@T[4+75;"
M*^LI1-;2@E' (! .._N* +5%%% !1110 444C.J*6=@J@9))P!0 M%9L_B'1
M;7(N-7L(B!G#W* X_.LZ]\>^%K!6,VN6;%>JPOYC?DN: .CHKD(OB!;WP)TK
M0];U!/X98K3;&?\ @3$=N:T8+[Q+>/C^Q;6P3^_<W?FM^"(,'_OH?C0!O444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "'I4+
M.HNE7(W$=*G/2JYCC^TJY0;]N,T 0Z5QI-B/6!#_ ..C_&KU4M+_ .098C_I
MW3_T$5=H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%Y+JUX2I3(.W!;&,JI_ 5<3Q'\.DO4O!JNC_ &A(?LXE:X!/E\_(<GD<]#0
MD5WJ-OJWAN"+5;JXAUNSE\YVV-Y;K$'$R?+@<G&,;>1QQSA1>+M5T^YTLZA?
M2R)I=S+:Z^Q"A!ND*0R<#@'.[ [8]*W],\0_#G1Y/,T_5=)@;9Y:E;@':F<[
M5R?E7/.!@9YIT_B3X>745_%-JVD2)?LKW2M.,2LH4 GGL%7\J ,_5YM<CTO3
MIS<W\L;)/>WEK:3A+R%&(,113]]8\[2IZD]^E8>J^()++Q397L%[)+#=^';6
M*;5@@!A1YV!G*YX.>W0$\YQ@]9J'B'X?:I=0W5WK>G-<0HT:2)>F-@K=5RK#
M(/<'BHI=8^&\UR]Q)J6D-(]L;1O]) 4P_P#//;G&WCICB@"_<S75AXL\+V4&
MI7$UG<PW/FK(ROYI5 RN6QG/S>N.G%=97G]OJ'PSM+NSNH-3TV.6R!%L5OCB
M(')(5=V #D\8K=_X3_PC_P!#%IO_ ($+_C0!T=%<W_PG_A/=@>(=-/\ V\+_
M (TO_">^%._B#3A_V\+_ (T ='17.?\ ">^%#T\0:<?^WA?\:7_A._"W_0>T
M_P#\"$_QH Z*BN?_ .$X\+XS_;^G?^!"TW_A._"W_0>T\?6X3_&@#HJ*YS_A
M//"N?^0_IW_@0G^-/7QSX789&OZ=_P"!"_XT =!17/'QSX7!_P"0]I__ ($+
M_C2_\)QX7_Z#^G?^!"T =!17/'QUX6 _Y#^G?^!"_P"-)_PGGA7_ *&#3O\
MP(7_ !H Z*BN=_X3SPM_T'M//_;PG^-:>G:Q8:Q T^FW<%U$K%2T3AAG'3(X
MH OT444 %%%% !1110 4444 %%%% "'I4;?Z\#VJ0]*C;_7@^U $&F?\@VU_
MZY)_Z#5RJFF\:=:_]<D_]!JW0 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'HHJ:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0]*C;_7#Z5*>
ME1-_KA]* "#_ %2?[HJ6HH/]4G^Z*EH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHJG!JEG<:G=:=%.K7=HJ/-&.JA\[?Y&@"Y114=Q,+>VE
MG,<D@C0MLC7<S8&< =S[4 245%;3?:;6*<1R1^8@?9*NUUR,X8=CZBI: "BB
MB@ HJCI6K6NLVC7-H9#&LKPMYD90AT.UA@\\$$?A5Z@ HHJO:7D=X)C&DB^3
M,T+;UQDKU(]1[T 6**K:A?1:;837DZR-%"NYA&A=B/8#DU8!R 1GGU&* %HH
MJG_:EK_;(TG>_P!L,!N-IC;!0,%SNQ@\D<9H N445'//%;6\D\[K'%$I=W8X
M"J!DD_A0!)16;IFO6&KSSP6K3": *SQS0O&VUL[6 8#(.#S[5+J6K6>D0Q2W
MLIC269($(1FR['"C@''/<\4 7:*** "BBB@ HHHH **JWNH6VG+"URY19IE@
M0A2<NW ''\ZM9'K0 4444 %%%% !10"",@YHH **** "BBB@ HHHH **** "
MBBB@ HJO>WMMIUJUS=RB*%2H9VZ DA1^I JQ0 4454FU2QM]2M].ENHDO;E6
M:& GYG"C)('X&@"W15:[O[2P\C[5<1P^?*L$6\XWR-T4>I-6: "BBJ][?V>F
MVQN;ZZAMH%ZR32!%'XF@"Q15:\U&ST^S-W=W,<-OP/,8\$G@ >I.>!WIUG>V
MNHVJ75E<17$#_=DB8,I_$4 3T52_MC3/[5_LO^T+7^T,9^R^:OF8QG.W.>G-
M/&IV#:DVFB\MS?*GF&V$@\P+Z[>N/>@"U156^U*QTN 37]Y!:Q%MH>:0("?3
M)HT_4[#5K<W&G7MO=PABAD@D#J&'49'?D4 6J*IZAJVG:4J-J%_;6BN<(9Y5
M3<?;)YJ6UO;6^B\VTN8;B/\ O1.&'YB@">BBLNV\2:'>WRV5KK%A-=.2%ACN
M%9S@$G !SP ?RH U**** "BJ]U>VMEY'VF>.+SY1#%O.-[G.%'N<&K% !111
M0 45#'=6\T\L$4\;S0@&2-7!9,YQD=LX/Y5%%JFGS:A+817UL]Y$,R6ZRJ9$
M'NN<B@"W14$M]:03I!-=01S/C;&\@#-G@8!ZTR34["&_BL);VW2\F!:.!I '
M<#J0O4]#0!:HIDTT5O!)--(L<4:EW=SA54<DD]A3;6YAO;2&ZMI%E@F021R+
MT92,@C\* ):*** "BJTFH6<-_!8R7,2W<ZLT4)8;W ZD#T%6: "BBB@ HHHH
M **** "BBH(KRVFNI[6*='GM]OG1@\IN&5R.V10!/159-1LY-0DT]+J)KR)!
M)) K NBGH2.V:LT %%5EU"S?4'T]+F)KR-!(\ 8%U4]"1V%6: "BBB@ HI-R
M[MN1NQG&><4M !1110 445"+JW-V;03QFY5/,,6X;PN<9QUQGO0!-1110 44
MR::.WA>::18XD4L[N<!0.I)[4VWN(+NVCN+:9)H)5#))&P96!Z$$=10!+111
M0 4444 %%%% !1110 4444 (>E1M_KP/:I#TJ)O^/@?2@!T0_=I]*DID8PB@
M^E/H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"KJ5_!I>F75_<
MDB&VB:5\=< 9X]Z\YMSJ/AS7M&U[4K)[=K]C9ZI,\B%2TK%XR,,<!&^7)_AQ
M7HNHZ99:O9M9ZA;1W%NQ!,<@R"1R*CU+1=.U>Q6RU&SCN;96#".49&1P#0!:
MNI!#:32F18@B,QD9<A<#J1WQ7F^D:E?QVFJ66HZEJ-IJL>E&Y$K3++#*@/\
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MN!K.27SFB.<;_P"\#G(/N*EN?#&B76F6VG2Z=";6UP8$7*F/']T@@CWYY[T
M8OPYMA:Z'J,0N7G(U:\#-(<MD2D?,?4XS^-5[V]O=1O/$[IJ=U8R:,!]FBCV
MA?\ 5"3S'!'SACD8/&!Q@\UU&E:)IFAQS1Z9916JS2&601C[S'N:AU#PSHVJ
M7HO+VQ26?8(V;<R[U!R%< @,,\X;(H Y/3=4UCQ#XDM+634[NQM[K0[?4S!
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MPOHXT:XTIK0R6ET<W DE=GE/'+.3N)X'?M0!:T:%H-'M%>9YG\E<R2!0QXR
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MZ99[:^ME=(;FW8!U5A@CD$$=#@@\BBRT"WLX[L_:+J>YNT"37<LO[U@ 0,$
M!<9) 4 9)- &1XMTW5YM2TW5M FMY-2T]9#]AN&PL\;X#8/\+<  ^]3^#-0L
M=2M-1FM;";3[G[:WVZTE !CGVJ&QC@@@ Y[Y)[U/-X5BD6P9-5U2&YL;<V\=
MRDRF1U.,[]RD,3M'44^/PQ:Q6$MLMW?"2:Y6ZGN1-B65U*_>(&,$*%P !CCB
M@#'\(_Z=XK\5W]V=UY#>BSC5EYB@5 5QZ!BQ/N>:ZFUL+6TN;N:WC5)+EQ)-
MM &6"A<_7 'Y5GWWAJVNM2?4K>ZN]/OI$$<D]HX!D4=-RL&4X['&:<OAVV2
M(EU>K(;E+F6<3?O)F4Y"N<<K@ ;>!CB@"YJT44^C7T,\XMX9('1YF( C4J06
MY].M<)I%U=Z)JVA:'XJL(O-MY#%I.JVJCRI?W938_=6(;IP"<>E=[J5A!JNF
M76GW(8P7430R;3@[6&#@_0UEVOA6W@FLGGO]0O4L<&UBN9598V (#<*"Q )
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MBBB@!#TJ)O\ CX'TJ:JAD(U!8\<!,T 6J6C%% !1110 4444 %%%% !1110
M4444 (P)4@$@D=1VKS&P\5^(+;2[+4[K4;>\\W5FTY[-H%C,B^84W(5YR,9(
MY&,UZ;(Q2-F5&<@$A%QEO89(%<=X"\.MIVG27.JZ-#:ZJUW/('81O($=RPPZ
MD\8..O:@!NA^,((;[5K#6]4#3Q:LUI;9AQA"J; 2HP,L6P6ZUO2>)](BU7^S
M7NB+GSE@.(F*"5EW*A?&T,1SC-<9J7A_6Y]!\0VL6E3--=Z\EY OFQ#?$&B)
M;._C_5G@X/(_!FN:)XDO]<-P-(DECM=9M[V QW,4<3PIMS\N03(><E_3@]B
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M?C% &UX6\3?VU:2_;C:V]XMW/;K"DN=XC;:2,\GIZ5M_VA9?;?L?VNW^U?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 !YJ!C_I0'L:GJN?\
MC['TH L4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5<_P#'
MW^%6*KL/],'T- %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *KL?\ 3 /458JLP_TU?H: +-%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 56;_ (_5^AJS59O^/U/]TT 6:*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ JN?\ C[ ]JL&H&7_2@WM0!/1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 (>E1-_Q\#Z5*>E1-_P ? ^E $U%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 57/_ !^K]#5BJS?\
M?J_0T 6:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JLPS>K
M]#5DU P_TD'OB@">BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH #58S*+P1$?,03FK)JH\.=127_8(H MT444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% "'I43?\? ^E2GI43?\? ^E $U%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 AZ5"V?M2XZ8.:GJ G_2OPH GHHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "H"0+P?[IJ>JS#_35^AH
MLT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%  >*@9?]*#>U3'
MI43?\? ^E $U%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 AZ
M5$W_ !\#Z5*>E1-_Q\ >U $U%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 AZ5$W_ !\J?8U,>E5V;_2E'JI- %BBBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *KD?Z6/858JJW_'\OT- %JBBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *K$$WR_[IJP1D8JNV[[8N"-H4Y%
M %FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***0GD#UH 6BFHZNNY3
MD4Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH #4+#_2 ?:ICTJ)O]</I0!+1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%%   !THHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** $/2HV_UX^E2'I4;?ZX?2@"6BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH 0]*C;_ %X^E2'I43?\? ^E $U%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 AZ5$W_'P/I4IZ5$W_'P/I0!-111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 (>E1M_KQ]*E-0,W^E
M!<=J )Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@!#43 ?:0
M>^*FJN3_ *8HSV- %BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *I,P.J(N?FV'BKAZ<53*?\35)/\ IF1_*@"[1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 !Z568?Z:G^Z:L]JK/_ ,?L?^Z: +-%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 'I59CB]0>J&K)Z<558*
M;Y/4*: +5%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 'VJ [
M?M@R?FVDU/5&1,ZLC;CQ&>* +U%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 53>5%U.-"/F*'FKE57 ^W(<#.TT 6J*** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ JHQ/]HJ.VPU;/2JK ?V@O/\  : +5%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 &LYW)UI$RN/+)X;G\
MJT#TJJR+_:*-M&[8>: +=%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 57/\ Q^#_ '35BJY.+P?[M %BBBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *@9?\ 2@V>U3'I43?\? ^E $U%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 AZ5$W_'P/I4IJ)C_I 'M0!-1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %5V/\ I:#U4U8JNPS>*?12
M* +%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 R0N /+ )SSDTX9
MH(!Z@'ZTM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %0'_C['^[4_:J[#-XG/\)H L4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !4# _:E;' 4U.:B8_O@/44 2T444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !3,9DSZ"GU&3AJ )**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ -1-_KAZ8J6HR?GQWH DHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH ****  U$P_>AO05+3=HSF@!U%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 'I49)#X[8J0]*B;_6_
MA0!+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !J%F'V@+GG
M'2I3TJ%A_I0/'3TH GHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** $/2HV_UX^E2TS +Y[T /HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "FC[QIQII8!MO>@!U%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 5&5S+N]!4E,)PU #Z*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ J,_>J2DH 6BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH *;CG-.HQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !24M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074432065952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Nov. 20, 2023</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--09-30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38042<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARROWHEAD PHARMACEUTICALS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-0408024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">304-3400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">177 E. Colorado Blvd<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Pasadena<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">91105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security12b Title</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARWR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction [Flag]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,432,210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:30.6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%">Portions of the Definitive Proxy Statement to be filed for Arrowhead Pharmaceuticals Inc.&#8217;s 2024 Annual Meeting of Stockholders are incorporated by reference into Part III hereof.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000879407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074432059216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Rose, Snyder & Jacobs LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Encino, California<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">468<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074429618400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 110,891,000<span></span>
</td>
<td class="nump">$ 108,005,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,410,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available-for-sale securities, at fair value</a></td>
<td class="nump">292,735,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Held-to-maturity securities, at amortized cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">268,391,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses</a></td>
<td class="nump">8,813,000<span></span>
</td>
<td class="nump">7,289,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">7,082,000<span></span>
</td>
<td class="nump">20,204,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">419,521,000<span></span>
</td>
<td class="nump">405,299,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">290,262,000<span></span>
</td>
<td class="nump">110,297,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Intangible assets, net</a></td>
<td class="nump">10,262,000<span></span>
</td>
<td class="nump">11,962,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Held-to-maturity securities, at amortized cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">105,872,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">45,297,000<span></span>
</td>
<td class="nump">58,291,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">210,000<span></span>
</td>
<td class="nump">218,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">765,552,000<span></span>
</td>
<td class="nump">691,939,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">35,866,000<span></span>
</td>
<td class="nump">2,868,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">39,763,000<span></span>
</td>
<td class="nump">46,856,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and benefits</a></td>
<td class="nump">17,963,000<span></span>
</td>
<td class="nump">12,251,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">10,563,000<span></span>
</td>
<td class="nump">2,776,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">866,000<span></span>
</td>
<td class="nump">74,099,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other liabilities</a></td>
<td class="nump">435,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">105,456,000<span></span>
</td>
<td class="nump">138,850,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrentAbstract', window );"><strong>Long-term liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">104,608,000<span></span>
</td>
<td class="nump">78,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">55,950,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_RoyaltiesLiabilityNoncurrent', window );">Liability related to the sale of future royalties</a></td>
<td class="nump">268,326,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesNoncurrent', window );">Total long-term liabilities</a></td>
<td class="nump">372,934,000<span></span>
</td>
<td class="nump">134,750,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 7)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Noncontrolling interest and stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 107,312 and 105,960 shares</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">198,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">1,300,395,000<span></span>
</td>
<td class="nump">1,219,213,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(3,222,000)<span></span>
</td>
<td class="num">(136,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,026,030,000)<span></span>
</td>
<td class="num">(820,755,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Arrowhead Pharmaceuticals, Inc. stockholders' equity</a></td>
<td class="nump">271,343,000<span></span>
</td>
<td class="nump">398,520,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Noncontrolling interest</a></td>
<td class="nump">15,819,000<span></span>
</td>
<td class="nump">19,819,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total noncontrolling interest and stockholders' equity</a></td>
<td class="nump">287,162,000<span></span>
</td>
<td class="nump">418,339,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities, Noncontrolling Interest and Stockholders' Equity</a></td>
<td class="nump">$ 765,552,000<span></span>
</td>
<td class="nump">$ 691,939,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_RoyaltiesLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalties, Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_RoyaltiesLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 26: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-5<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481404/852-10-50-7<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 23: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 201.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074433051904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Mar. 16, 2023</div></th>
<th class="th"><div>Mar. 15, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">290,000,000<span></span>
</td>
<td class="nump">290,000,000<span></span>
</td>
<td class="nump">145,000,000<span></span>
</td>
<td class="nump">145,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">107,312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,960,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">107,312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,960,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074434077728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 240,735,000<span></span>
</td>
<td class="nump">$ 243,231,000<span></span>
</td>
<td class="nump">$ 138,287,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development</a></td>
<td class="nump">353,188,000<span></span>
</td>
<td class="nump">297,307,000<span></span>
</td>
<td class="nump">206,342,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">92,549,000<span></span>
</td>
<td class="nump">124,431,000<span></span>
</td>
<td class="nump">80,981,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">445,737,000<span></span>
</td>
<td class="nump">421,738,000<span></span>
</td>
<td class="nump">287,323,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(205,002,000)<span></span>
</td>
<td class="num">(178,507,000)<span></span>
</td>
<td class="num">(149,036,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterestAndDividend', window );">Interest income</a></td>
<td class="nump">15,299,000<span></span>
</td>
<td class="nump">5,033,000<span></span>
</td>
<td class="nump">6,120,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(18,326,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="nump">1,538,000<span></span>
</td>
<td class="nump">765,000<span></span>
</td>
<td class="nump">2,070,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other (expense) income</a></td>
<td class="num">(1,489,000)<span></span>
</td>
<td class="nump">5,798,000<span></span>
</td>
<td class="nump">8,190,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax expense and noncontrolling interest</a></td>
<td class="num">(206,491,000)<span></span>
</td>
<td class="num">(172,709,000)<span></span>
</td>
<td class="num">(140,846,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">2,784,000<span></span>
</td>
<td class="nump">3,785,000<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss including noncontrolling interest</a></td>
<td class="num">(209,275,000)<span></span>
</td>
<td class="num">(176,494,000)<span></span>
</td>
<td class="num">(140,848,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Net loss attributable to noncontrolling interest, net of tax</a></td>
<td class="num">(4,000,000)<span></span>
</td>
<td class="num">(431,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</a></td>
<td class="num">$ (205,275,000)<span></span>
</td>
<td class="num">$ (176,063,000)<span></span>
</td>
<td class="num">$ (140,848,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Net loss per share attributable to Arrowhead Pharmaceuticals, Inc.:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (1.92)<span></span>
</td>
<td class="num">$ (1.67)<span></span>
</td>
<td class="num">$ (1.36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (1.92)<span></span>
</td>
<td class="num">$ (1.67)<span></span>
</td>
<td class="num">$ (1.36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average shares used in calculating</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">106,750<span></span>
</td>
<td class="nump">105,426<span></span>
</td>
<td class="nump">103,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">106,750<span></span>
</td>
<td class="nump">105,426<span></span>
</td>
<td class="nump">103,745<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Other comprehensive loss, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized losses on available-for-sale securities</a></td>
<td class="num">$ (2,964,000)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(122,000)<span></span>
</td>
<td class="num">(67,000)<span></span>
</td>
<td class="num">(87,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive loss</a></td>
<td class="num">$ (212,361,000)<span></span>
</td>
<td class="num">$ (176,561,000)<span></span>
</td>
<td class="num">$ (140,935,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -SubTopic 20<br> -Topic 940<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481913/940-20-25-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482925/835-30-45-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483013/835-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterestAndDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterestAndDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074425731040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Non- controlling Interest</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Sep. 30, 2020</a></td>
<td class="nump">$ 461,779<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
<td class="nump">$ 965,410<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="num">$ (503,844)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Sep. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">102,376,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">76,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">11,305<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">11,304<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,052,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">899,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized losses on available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(87)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(87)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(140,848)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(140,848)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2021</a></td>
<td class="nump">408,822<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">1,053,386<span></span>
</td>
<td class="num">(69)<span></span>
</td>
<td class="num">(644,692)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104,327,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">120,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,893<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">5,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">606,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,027,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized losses on available-for-sale securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(67)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance', window );">Interest in joint venture</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(176,494)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(176,063)<span></span>
</td>
<td class="num">(431)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2022</a></td>
<td class="nump">418,339<span></span>
</td>
<td class="nump">$ 198<span></span>
</td>
<td class="nump">1,219,213<span></span>
</td>
<td class="num">(136)<span></span>
</td>
<td class="num">(820,755)<span></span>
</td>
<td class="nump">19,819<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">78,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78,130<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 3,054<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">3,053<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">439,350<span></span>
</td>
<td class="nump">439,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Common stock - restricted stock units vesting (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">913,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized losses on available-for-sale securities</a></td>
<td class="num">(2,964)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,964)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation adjustments</a></td>
<td class="num">(122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">(209,275)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(205,275)<span></span>
</td>
<td class="num">(4,000)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Sep. 30, 2023</a></td>
<td class="nump">$ 287,162<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="nump">$ 1,300,395<span></span>
</td>
<td class="num">$ (3,222)<span></span>
</td>
<td class="num">$ (1,026,030)<span></span>
</td>
<td class="nump">$ 15,819<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-23<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(2)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-24<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483421/250-10-45-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 5<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-5<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (h)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480528/815-20-65-6<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483550/848-10-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479343/105-10-65-6<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482615/740-10-65-8<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479654/326-10-65-4<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480336/718-10-65-15<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-5<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481674/830-30-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-17<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481694/830-30-45-20<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-3<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-15<br><br>Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-16<br><br>Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074434110880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss including noncontrolling interest</a></td>
<td class="num">$ (209,275,000)<span></span>
</td>
<td class="num">$ (176,494,000)<span></span>
</td>
<td class="num">$ (140,848,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash flow from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">78,130,000<span></span>
</td>
<td class="nump">120,893,000<span></span>
</td>
<td class="nump">76,673,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">12,493,000<span></span>
</td>
<td class="nump">10,421,000<span></span>
</td>
<td class="nump">8,267,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">(Accretion) amortization of note premiums/discounts</a></td>
<td class="num">(2,017,000)<span></span>
</td>
<td class="nump">2,910,000<span></span>
</td>
<td class="nump">266,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties', window );">Non-cash interest expense on liability related to the sale of future royalties</a></td>
<td class="nump">18,326,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnInvestments', window );">Net loss (gain) from investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,432,000<span></span>
</td>
<td class="num">(1,708,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">1,410,000<span></span>
</td>
<td class="nump">8,845,000<span></span>
</td>
<td class="num">(9,409,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">11,603,000<span></span>
</td>
<td class="num">(19,291,000)<span></span>
</td>
<td class="num">(360,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">32,998,000<span></span>
</td>
<td class="num">(6,589,000)<span></span>
</td>
<td class="nump">2,628,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(14,965,000)<span></span>
</td>
<td class="nump">17,750,000<span></span>
</td>
<td class="nump">9,522,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(129,183,000)<span></span>
</td>
<td class="num">(112,501,000)<span></span>
</td>
<td class="nump">223,258,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease, net</a></td>
<td class="nump">46,590,000<span></span>
</td>
<td class="nump">13,428,000<span></span>
</td>
<td class="nump">3,192,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">65,000<span></span>
</td>
<td class="num">(169,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="num">(153,890,000)<span></span>
</td>
<td class="num">(136,131,000)<span></span>
</td>
<td class="nump">171,312,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(176,737,000)<span></span>
</td>
<td class="num">(52,777,000)<span></span>
</td>
<td class="num">(23,567,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(246,141,000)<span></span>
</td>
<td class="num">(223,391,000)<span></span>
</td>
<td class="num">(240,703,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from sales and maturities of investments</a></td>
<td class="nump">326,723,000<span></span>
</td>
<td class="nump">270,751,000<span></span>
</td>
<td class="nump">122,592,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(96,155,000)<span></span>
</td>
<td class="num">(5,417,000)<span></span>
</td>
<td class="num">(141,678,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercises of stock options</a></td>
<td class="nump">3,053,000<span></span>
</td>
<td class="nump">5,186,000<span></span>
</td>
<td class="nump">11,305,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ProceedsFromSaleOfFutureRoyalties', window );">Proceeds from the sale of future royalties</a></td>
<td class="nump">250,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Proceeds from investment in joint venture</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">253,053,000<span></span>
</td>
<td class="nump">65,186,000<span></span>
</td>
<td class="nump">11,305,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">3,008,000<span></span>
</td>
<td class="num">(76,362,000)<span></span>
</td>
<td class="nump">40,939,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate on cash, cash equivalents and restricted cash</a></td>
<td class="num">(122,000)<span></span>
</td>
<td class="num">(67,000)<span></span>
</td>
<td class="num">(88,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">BEGINNING OR PERIOD</a></td>
<td class="nump">108,005,000<span></span>
</td>
<td class="nump">184,434,000<span></span>
</td>
<td class="nump">143,583,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">END OF PERIOD</a></td>
<td class="nump">110,891,000<span></span>
</td>
<td class="nump">108,005,000<span></span>
</td>
<td class="nump">184,434,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplementary disclosures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income Taxes Paid</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (2,000)<span></span>
</td>
<td class="num">$ (2,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Expense, Liability Related to Sale of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ProceedsFromSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from Sale of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ProceedsFromSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481877/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) on investment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(c),9(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482312/912-310-45-11<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received by a corporation from a shareholder during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480767/946-205-45-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481231/810-10-45-19<br><br>Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 33: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4J<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4J<br><br>Reference 34: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4K<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481175/810-10-55-4K<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-2<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074436944336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Significant Accounting Policies</a></td>
<td class="text">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the &#8220;Company&#8221;) are primarily engaged in developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#8217;s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#8220;RNAi&#8221;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. The Company&#8217;s RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s current pipeline:</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.962%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Therapeutic Area</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stage</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product Rights</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cardiometabolic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plozasiran (ARO-APOC3)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Two Phase 2b and one Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zodasiran (ARO-ANG3)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Two Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Olpasiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amgen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pulmonary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-RAGE</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-MUC5AC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-MMP7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liver</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GSK-4532990</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GSK</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fazirsiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Takeda and Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNJ-3989</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HZN-457</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Horizon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-C3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-PNPLA3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Muscle</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-DUX4</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-Clinical</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Central Nervous System (CNS)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-SOD1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-Clinical</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr></table></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(1) On October 30, 2023, the Company entered into an Assignment and Consent Agreement with Janssen. See Note 15.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(2) On October 6, 2023, Amgen announced that it has completed its acquisition of Horizon.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates lab facilities in San Diego, California and Madison, Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company&#8217;s principal executive offices are located in Pasadena, California.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidation and Basis of Presentation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements include the accounts of Arrowhead Pharmaceuticals, Inc. and its subsidiaries (wholly-owned subsidiaries and a variable interest entity for which the Company is the primary beneficiary). Subsidiaries refer to Arrowhead Madison, Inc., Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;), and Arrowhead Australia Pty Ltd. For subsidiaries in which the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interests retained in such entity by the respective noncontrolling party.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;). All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform with the current period presentation. </span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s primary sources of financing have been through the sale of its securities, revenue from its licensing and collaboration agreements and the sale of certain future royalties. Research and development activities have required significant capital investment since the Company&#8217;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#8217;s pipeline of drug candidates and its headcount have both expanded </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">significantly. Additionally, significant capital investment will be required as the Company&#8217;s pipeline matures into later stage clinical trials and as the Company plans to increase its internal manufacturing capabilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At September&#160;30, 2023, the Company had $110.9 million in cash, cash equivalents and restricted cash ($7.9 million in restricted cash) and $292.7 million in available-for-sale debt securities to fund operations. During the year ended September&#160;30, 2023, the Company&#8217;s cash, cash equivalents and restricted cash and investments balance decreased by $78.6 million which was primarily due to cash used to fund its operations, offset by the $250.0 million upfront payment received from Royalty Pharma (Note 13) and $110.0&#160;million in milestone payments from the Company&#8217;s collaboration and license agreements (Note 2). </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In total, the Company is eligible to receive up to $2.8 billion in developmental, regulatory and sales milestones, and may receive various royalties on net sales from its licensing and collaboration agreements, subject to the terms and conditions of those agreements. The revenue recognition for these collaboration agreements is discussed further in Note 2.</span></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Summary of Significant Accounting Policies </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, judgments and assumptions. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results could materially differ from those estimates. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Variable Interest Entity (&#8220;VIE&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A VIE is an entity that, by design, either (i) lacks sufficient equity to permit the entity to finance its activities without additional subordinated financial support from other parties; or (ii) has equity investors that do not have the ability to make significant decisions relating to the entity&#8217;s operations through voting rights, or do not have the obligation to absorb the expected losses, or do not have the right to receive the residual returns of the entity. The primary beneficiary of a VIE is required to consolidate the assets and liabilities of the VIE. The primary beneficiary is the party that has both (i) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance, and (ii) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE through its interest in the VIE.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2022, the Company entered into a license agreement with Visirna (Note 2) and consolidated Visirna&#8217;s financial statements in which the Company has a direct controlling financial interest based on the VIE model. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all the facts and circumstances, including its role in establishing Visirna and its ongoing rights and responsibilities to assess whether the Company has the power to direct the activities of Visirna. In general, the parties that make the most significant decisions affecting a VIE and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also considers all of its economic interests to assess whether the Company has the obligation to absorb losses of Visirna or the right to receive benefits from it that could potentially be significant to Visirna. This assessment requires the Company to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to Visirna. Factors considered in assessing the significance include: the design of the Visirna, including its capitalization structure, subordination of interests, payment priority, and the reasons why the interests are held by the Company. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Visirna&#8217;s inception, the Company determined whether it was the primary beneficiary and if Visirna should be consolidated based on the facts and circumstances. The Company performs ongoing reassessments of the VIE based on reconsideration events and reevaluates whether a change to the consolidation is required. As of September&#160;30, 2023, there were no events to be reconsidered in the consolidation. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly liquid interest-bearing investments are classified as cash equivalents. These investments mainly include commercial paper with maturities of three months or less when purchased. The carrying value of these cash equivalents approximate fair value. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $7.9 million and $7.3 million restricted cash at September&#160;30, 2023 and 2022, respectively, that is primarily held as collateral associated with letters of credit for the Company&#8217;s facility leases. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Concentration of Credit Risk</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially expose the Company to concentration of credit risk primarily consist of cash, cash equivalents and restricted cash and investments. As of September&#160;30, 2023 and 2022, the Company&#8217;s investments were primarily invested in money market funds, certificates of deposit, commercial paper, and corporate debt securities through highly rated financial institutions. The Company also maintains several bank accounts primarily at three financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities are mainly held-to-maturity investments, available-for-sale, and marketable securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These held-to-maturity investments may consist of investment-grade interest bearing instruments, primarily money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper, which are stated at amortized cost. The Company does not intend to sell these investment securities and the contractual maturities are not greater than 36 months. Those with maturities less than twelve months are included in short-term investments on the Company&#8217;s consolidated balance sheets, while those with remaining maturities in excess of twelve months are included in long-term investments on its consolidated balance sheets. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security, and no gains or losses on held-to-maturity investment are realized until they are sold. The Company reassesses the classification of held-to-maturity at each reporting period.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The available-for-sale investments may consist of investment-grade interest bearing instruments, primarily money market</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">accounts,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">government-sponsored</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">enterprise</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">corporate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">bonds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">and/or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">commercial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">paper, which are accounted for at fair value.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Changes in fair values are reported as unrealized gains or losses and are recorded in the Company&#8217;s consolidated statement of operations and comprehensive loss.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">On September 30, 2023, the Company changed the classification of debt securities to available-for-sale from held-to-maturity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">As a result, these debt securities are carried at fair value.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketable debt securities consisted of mutual funds that primarily invest in U.S. government bonds, U.S. government agency bonds, and corporate bonds. Dividends from these funds were automatically re-invested. These securities were recorded at fair value, and all unrealized gains/losses were recorded in the Company&#8217;s consolidated statement of operations and comprehensive loss. In April 2022, the Company sold all of its investments in mutual funds for $122.3 million. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors its investments closely. If an unrealized loss is determined to be other-than-temporary, it is written off as a realized loss through the consolidated statements of operations and comprehensive loss. The Company&#8217;s methodology of assessing other-than-temporary impairments is based on security-specific analysis as of the balance sheet date and considers various factors, including the length of time to maturity and the extent to which the fair value has been less than the cost, recoverability of future cash flows as compared to carrying value of the security, the financial condition and the near-term prospects of the issuer, and the Company&#8217;s ability and intent to hold the security. If a decline in fair value of investments is determined to be other-than-temporary, the securities are written down to fair value as the new cost basis and the amount of the write down is accounted for as realized losses. The Company did not recognize any other-than-temporary impairments of its investment for the years ended September&#160;30, 2023, 2022, and 2021. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property and Equipment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from <span style="-sec-ix-hidden:f-426">three</span> to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically assesses long-lived assets or asset groups, including property and equipment, for recoverability when events or changes in circumstances indicate that their carrying amounts may not be recoverable. If the Company identifies an indicator of impairment, the Company assesses recoverability by comparing the carrying amount of the asset to the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An impairment loss is recognized when the carrying amount is not recoverable and is measured as the excess of carrying value over fair value. There were no impairment charges during the years ended September&#160;30, 2023, 2022, and 2021. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intangible Assets Subject to Amortization</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization include certain patents and license agreements. The Company qualitatively evaluates intangible assets for impairment annually or whenever events or changes in circumstances indicate that it is more likely than not that the carrying amount of intangible assets may exceed their implied fair values. As of September&#160;30, 2023 and 2022, intangible impairment assessments indicated that there was no impairment.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether a contract is, or contains, a lease at inception. All of the Company&#8217;s leases are classified as operating leases. Leases with terms greater than one-year are recognized on the Company&#8217;s consolidated balance sheets as right-of-use assets that represent the Company&#8217;s right to use an underlying asset for the lease term, and lease liabilities that represent its obligation to make lease payments arising from the lease. Lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the expected lease term.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize  lease payments on a straight-line basis over the expected lease term. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that it determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing. If the license is not considered to be distinct from other performance obligations, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time. If the performance obligation is satisfied over time, the Company then determines the appropriate method of measuring progress for purposes of recognizing revenue from license payments. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, the Company&#8217;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a Clinical Trial Application (&#8220;CTA&#8221;) or a New Drug Application (&#8220;NDA&#8221;) in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas. The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in the Company&#8217;s consolidated statements of operation and comprehensive loss. Typically, milestone payments and royalties are achieved after the Company&#8217;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or preclinical program. Milestones or royalties achieved after the Company&#8217;s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its licensing or collaboration agreements. Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment. Additionally, future royalty payments are not substantially within the control of the Company or the customer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using the input method; Labor hours, costs incurred or patient visits in clinical trials are typically used as the measure of performance. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations.  If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain judgments affect the application of the Company&#8217;s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company&#8217;s current operating plan and, the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope of Financial Accounting Standards Board (&#8220;FASB&#8221;) Topic 808 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For collaborative arrangements that contain multiple elements, the Company determines which units of account are deemed to be within the scope of Topic 808 and which units of account are more reflective of a vendor-customer relationship, and therefore are within the scope of Topic 606. For units of account that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of Topic 808, the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative arrangement based on the nature </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of each activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to research and development expense or general and administrative expense, as appropriate. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#8217;s research and development operations, and costs to acquire technology licenses.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock-Based Compensation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation expenses for all stock grants are based on their estimated grant-date fair value. The fair value of stock option awards is estimated using the Black-Scholes option valuation model which requires the input of subjective assumptions to calculate the value of stock options. For restricted stock units, the value of the award is based on the Company&#8217;s stock price at the grant date. For performance-based restricted stock unit awards, the value of the award is based on the Company&#8217;s stock price at the grant date, with consideration given to the probability of the performance condition being achieved. The Company uses historical data and other information to estimate the expected price volatility and the expected forfeiture rate for stock option awards. Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#8217;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting basis and the respective tax basis of the Company&#8217;s assets and liabilities, and expected benefits of utilizing net operating loss, capital loss, and tax-credit carryforwards. The Company assesses the likelihood that its deferred tax assets will be realized and, to the extent management does not believe these assets are more likely than not to be realized, a valuation allowance is established. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates or laws is recognized in earnings in the period that includes the enactment date.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Earnings per Share</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units outstanding. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended September&#160;30, 2023, 2022 and 2021, the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units outstanding during the period due to their anti-dilutive effect. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign currency translation adjustments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the Company&#8217;s wholly-owned subsidiaries&#8217; functional currencies are not the United States dollar, which is the Company&#8217;s reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Translation adjustments arising from the use of different exchange rates from period to period are included in the accumulated other comprehensive loss. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no recent accounting pronouncements that have significantly impacted this Annual Report on Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//235/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 275<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//275/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//810/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074436622848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text">COLLABORATION AND LICENSE AGREEMENTS<div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of revenue recognized:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GSK</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Horizon</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amgen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240,735&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243,231&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,287&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance of receivables and contract liabilities related to the Company&#8217;s collaboration and license agreements:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables included in accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liabilities included in deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Glaxosmithkline Intellectual Property (No. 3) Limited (&#8220;GSK&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;22, 2021, GSK and the Company entered into an Exclusive License Agreement (the &#8220;GSK License Agreement&#8221;). Under the GSK License Agreement, GSK has received an exclusive license for GSK-4532990 (formerly ARO-HSD). The exclusive license is worldwide with the exception of greater China. GSK is wholly responsible for all clinical development and commercialization of GSK-4532990 in its territory.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the GSK License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibility to complete the Phase 1/2 study (the &#8220;GSK R&amp;D Services&#8221;). Due to the specialized and unique nature of the GSK R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the initial transaction price totaled $120.0 million, including the upfront payment, which was collected in January 2022. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company has allocated the total $120.0 million initial transaction price to its one distinct performance obligation for the GSK-4532990 license and the associated GSK R&amp;D Services. As the Company has completed its performance obligation related to this agreement, the upfront payment of $120.0 million was fully recognized in the year ended September&#160;30, 2022. Further, GSK dosed the first patient in a Phase 2b trial in March 2023, triggering a $30.0&#160;million milestone payment to the Company which was paid in the third quarter of fiscal 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also eligible for an additional payment of $100.0 million upon achieving the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $190.0 million at first commercial sale, and up to $590.0 million in sales-related milestone payments. The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has also performed certain development and manufacturing activities, including the manufacture of drug substance and drug product under GMP conditions, for GSK pursuant to the GSK License Agreement, for which the Company has been reimbursed for its costs. The Company recognized $0.3&#160;million and $4.8&#160;million in connection with these efforts for the years ended September&#160;30, 2023 and 2022, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Horizon Therapeutics Ireland DAC (&#8220;Horizon&#8221;) </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June&#160;18, 2021, Horizon and the Company entered into a collaboration and license agreement (the &#8220;Horizon License Agreement&#8221;). Under the terms of the Horizon License Agreement, Horizon received a worldwide exclusive license for HZN-457, a clinical-stage medicine being developed by Horizon as a potential treatment for people with uncontrolled </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">gout. Horizon is wholly responsible for clinical development and commercialization of HZN-457. On October 6, 2023, Amgen completed its acquisition of Horizon. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services, including the Company&#8217;s responsibilities to conduct all activities through the preclinical stages of development of HZN-457 (the &#8220;Horizon R&amp;D Services&#8221;). Due to the specialized and unique nature of these Horizon R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the Horizon R&amp;D Services, which are the responsibility of the Company, Horizon will be responsible for managing future clinical development and commercialization of HZN-457. The Company conducted all activities through the preclinical stages of development of HZN-457. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the agreement, the Company received an upfront payment of $40.0&#160;million in July 2021. The Company determined the initial transaction price totaled $40.0&#160;million and has excluded any future estimated milestones or royalties from this transaction price to date. The Company allocated the total $40.0&#160;million initial transaction price to its one distinct performance obligation for the HZN-457 license and the associated Horizon R&amp;D Services. Revenue was recognized on a straight-line basis over the timeframe for completing the Horizon R&amp;D Services. The Company determined that the straight-line basis was appropriate as its efforts were expended evenly over the course of completing its performance obligation. Further, Horizon enrolled the first subject in December 2022 in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HZN-457, triggering a $15.0&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 21, 2023, the Company received notice from Horizon that it has elected to terminate the Horizon License Agreement. Horizon exercised its right to terminate the Horizon License Agreement for convenience. The termination will take effect on December 21, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has performed certain development and manufacturing activities, including drug substance and drug product manufacture under GMP conditions, for Horizon pursuant to the Horizon License Agreement. The Company recognized $1.5&#160;million and $2.5&#160;million in connection with these efforts for the years ended September&#160;30, 2023 and 2022, respectively. </span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Pharmaceutical Company Limited (&#8220;Takeda&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October&#160;7, 2020, Takeda and the Company entered into an Exclusive License and Co-Funding Agreement (the &#8220;Takeda License Agreement&#8221;). Under the Takeda License Agreement, Takeda and the Company will co-develop the Company&#8217;s Fazirsiran program (formerly TAK-999 and ARO-AAT), the Company&#8217;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, fazirsiran, if approved, will be co-commercialized under a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50/50 profit sharing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> structure. Outside the United States, Takeda received an exclusive license to commercialize fazirsiran and will lead the global commercialization strategy, while the Company will be eligible to receive tiered royalties of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on net sales. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Takeda License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of fazirsiran drug product is completed and delivered to Takeda (the &#8220;Takeda R&amp;D Services&#8221;). Due to the specialized and unique nature of these Takeda R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. Beyond the Takeda R&amp;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States. Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Takeda License Agreement, the Company received $300.0&#160;million as an upfront payment in January 2021 and an additional $40.0 million upon Takeda&#8217;s initiation of a Phase 3 REDWOOD clinical study of fazirsiran in March 2023, and is eligible to receive up to $527.5 million in additional potential development, regulatory and commercial milestones. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has allocated the total $300.0 million initial transaction price to its one distinct performance obligation for the fazirsiran license and the associated Takeda R&amp;D Services. Revenue is recognized using the input method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). The Company previously expected these clinical trials to extend to September 2025 in order to demonstrate long term safety and efficacy in the open label extension (OLE) part of the studies; however, in August 2023, Takeda initiated a Phase 3 OLE study available to patients participating in these Phase 2 studies. Based on this new information, patients enrolled in the SEQUOIA and AROAAT2002 studies are expected to complete their Phase 2 study visits between June 2023 and December 2023, shortening the Company&#8217;s performance obligation. As a result, effective the second quarter of fiscal 2023, the Company changed its estimates of the revenue recognition to better reflect this newly estimated performance period. The effect of these changes in estimates resulted in accelerated revenue by $70.5&#160;million, or $0.66 per share (diluted) for the year ended September&#160;30, 2023. There were $0.9&#160;million of contract liabilities recorded as current deferred revenue as of September&#160;30, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also recorded $4.5&#160;million as accrued expenses as of September&#160;30, 2023 that was primarily driven by co-development and co-commercialization activities.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 3, 2018, Janssen, part of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson, and the Company entered into a License Agreement (the &#8220;Janssen License Agreement&#8221;). The Company also entered into a stock purchase agreement with JJDC, Inc. (&#8220;JJDC&#8221;), Johnson &amp; Johnson&#8217;s venture capital arm (the &#8220;JJDC Stock Purchase Agreement&#8221;). Under the Janssen License Agreement, Janssen received a worldwide, exclusive license to the Company&#8217;s JNJ-3989 (formerly ARO-HBV) program, the Company&#8217;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#8217;s Phase 1/2 study of JNJ-3989, which the Company was responsible for completing, Janssen is wholly responsible for clinical development and commercialization of JNJ-3989. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Janssen License Agreement, the Company received $175.0 million as an upfront payment, $75.0 million in the form of an equity investment by JJDC in the Company&#8217;s common stock under the JJDC Stock Purchase Agreement, and milestone and option payments totaling $73.0&#160;million, and the Company may receive up to $825.0 million in development and sales milestone payments for the Janssen License Agreement. The Company is further eligible to receive tiered royalties on product sales up to mid-teens under the Janssen License Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the inception of the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&amp;D services including the Company&#8217;s responsibility to complete the Phase 1/2 study of JNJ-3989 and the Company&#8217;s responsibility to ensure certain manufacturing of JNJ-3989 drug product is completed and delivered to Janssen (the &#8220;Janssen R&amp;D Services&#8221;). Due to the specialized and unique nature of these Janssen R&amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined the transaction price totaled approximately $252.7 million, which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, two $25.0 million milestone payments related to JNJ-3989, and estimated payments for reimbursable Janssen R&amp;D Services to be performed. The Company has allocated the total $252.7 million initial transaction price to its one distinct performance obligation for the JNJ-3989 license and the associated Janssen R&amp;D Services. The Company recognized this transaction price in its entirety as of September&#160;30, 2021, as its performance obligations were substantially completed. There were no contract assets and liabilities recorded as of September&#160;30, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 7, 2023, Janssen voluntarily terminated its collaboration agreement with the Company, dated October 3, 2018. Upon termination of the collaboration agreement, the Company regained full rights to ARO-PNPLA3, formerly called JNJ-75220795. ARO-PNPLA3 is in Phase 1 clinical trials that are now being developed by the Company.</span></div><div style="margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Amgen Inc. (&#8220;Amgen&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 28, 2016, Amgen and the Company entered into two collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the &#8220;Olpasiran Agreement&#8221;), Amgen received a worldwide, exclusive license to the Company&#8217;s novel RNAi olpasiran (previously referred to as AMG- 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the Olpasiran Agreement, Amgen is wholly responsible for clinical development and commercialization. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Olpasiran Agreement, the Company has received $35.0&#160;million in upfront payments and $21.5&#160;million in the form of an equity investment by Amgen in the Company&#8217;s common stock. Further, the Company received additional an </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$55.0 million in milestone payments; $10.0 million upon Amgen&#8217;s initiation of a Phase 1 study in September 2018, $20.0 million upon its initiation of a Phase 2 clinical study in July 2020, and $25.0 million upon its first subject enrollment in a Phase 3 trial in December 2022. The Company has substantially completed its performance obligations under the Olpasiran Agreement. There were no contract assets and liabilities recorded as of September&#160;30, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, Royalty Pharma Investments 2019 ICAV (&#8220;Royalty Pharma&#8221;) and the Company entered into a Royalty Purchase Agreement (the &#8220;Royalty Pharma Agreement&#8221;). In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive up to an additional $535.0 million in remaining development, regulatory and sales milestone payments payable from Amgen and Royalty Pharma. See Note 13.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Joint Venture and License Agreement with Visirna Therapeutics, Inc. (&#8220;Visirna&#8221;)</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2022, the Company entered into a License Agreement with Visirna (the &#8220;Visirna License Agreement&#8221;), pursuant to which Visirna received an exclusive license to develop, manufacture and commercialize four of the Company&#8217;s RNAi-based investigational cardiometabolic medicines in Greater China (including the People&#8217;s Republic of China, Hong Kong, Macau and Taiwan). Pursuant to a Share Purchase Agreement entered into simultaneously with the Visirna License Agreement (the &#8220;Visirna SPA&#8221;), the Company acquired a majority stake in Visirna (after accounting for shares reserved for Visirna&#8217;s employee stock ownership plan) as partial consideration for the Visirna License Agreement. Under the Visirna SPA, entities affiliated with Vivo Capital also acquired a minority stake in Visirna in exchange for $60.0&#160;million in upfront capital to support the operations of Visirna. As further consideration under the Visirna License Agreement, the Company is also eligible to receive potential royalties on commercial sales.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074527340816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text">PROPERTY AND EQUIPMENT<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s major classes of property and equipment: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computers, software, office equipment and furniture </span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,240&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,182&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,509&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,283&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,655&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,373&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">332,213&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,851&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41,951)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,554)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,262&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense for property and equipment for the years ended September&#160;30, 2023, 2022, and 2021 was $10.7 million, $8.7 million and $6.6 million respectively. </span></div>The increase in the construction in progress during 2023 was mainly due to the continuing developments of manufacturing, laboratory and office facilities in Verona, Wisconsin. In May 2023, the Company completed the development of the San Diego facility, which resulted in the reclassification of related construction in progress to leasehold improvements as of September&#160;30, 2023.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074434142176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Investments</a></td>
<td class="text">INVESTMENTS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following:</span></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">295,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">295,699&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,964)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292,735&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 30, 2023, the Company changed the classification of its investment securities from held-to-maturity to available-for-sale. This change enables the Company&#8217;s need to be able to respond to market and liquidity risks in managing its portfolio. Such investments are carried at fair value with any unrealized gains and losses reported as a component of other accumulated comprehensive loss. At the date of the transfer, the carrying value of the Company&#8217;s held-to-maturity securities was $295.7&#160;million, and net unrealized losses of $3.0&#160;million were recognized in accumulated other comprehensive loss. The Company does not believe that the available-for-sale debt securities that were in an unrealized loss position have any credit loss impairment as of September 30, 2023.</span></div><div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term investments (due within one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,391&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,661)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,730&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held-to-maturity certificate of deposit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,391&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,661)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264,730&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term investments (Due within one through three years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,569)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,303&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total long-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,569)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//320/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-6B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br> -Publisher SEC<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//946-320/tableOfContent<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 940<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//940-320/tableOfContent<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//942-320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074435771424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">INTANGIBLE ASSETS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The following table presents the components of intangible assets: </span></div><div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"></td><td style="width:24.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful Lives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,407&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,857&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,595&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,262&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,958&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total intangible assets, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,857&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,895&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,962&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during 2023 and 2022.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Intangible assets amortization expense in each of 2023, 2022, and 2021 was $1.7 million. None of the intangible assets with definite useful lives are anticipated to have a residual value.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the estimated future amortization expense related to intangible assets as of September&#160;30, 2023:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.272%"><tr><td style="width:1.0%"></td><td style="width:60.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization Expense</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending September 30, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,762&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//350-30/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074436899456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text">STOCKHOLDERS&#8217; EQUITY<div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s shares of common stock and preferred stock:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.818%"><tr><td style="width:1.0%"></td><td style="width:31.294%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;16, 2023, the Company&#8217;s stockholders approved an increase in authorized common shares, par value $0.001 per share, from 145,000,000 to 290,000,000. The amendment to the Amended and Restated Certificate of Incorporation was filed on April&#160;27, 2023.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023 and 2022, respectively, 12,709,837 and 14,000,392 shares of common stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Company&#8217;s 2004 Equity Incentive Plan, 2013 Incentive Plan, and 2021 Incentive Plan, as well as for inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules.  </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 2, 2022, the Company entered into an open market sale agreement (the &#8220;Open Market Sale Agreement&#8221;), pursuant to which the Company may, from time to time, sell up to $250,000,000 in shares of the Company&#8217;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#8220;ATM Offering&#8221;). The Company is not required to sell shares under the Open Market Sale Agreement. The Company will pay Jefferies LLC a commission of up to 3.0% of the aggregate gross proceeds received from all sales of the common stock under the Open Market Sale Agreement. Unless otherwise terminated, the ATM Offering shall terminate upon the earlier of (i) the sale of all shares of common stock subject to the Sales Agreement and (ii) the termination of the Sales Agreement as permitted therein. The Company and Jefferies may each terminate the Open Market Sale Agreement at any time upon prior notice. As of September&#160;30, 2023, no shares have been issued under the Open Market Sale Agreement.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481062/946-235-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481004/946-505-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480237/815-40-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//505/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-16<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074439166304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIES<div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were no contingent liabilities recorded as of September&#160;30, 2023 and 2022. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 20, 2021, the Company completed a purchase of 13 acres of land in the Verona Technology Park in Verona, Wisconsin, which is being developed into an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility which will support the Company&#8217;s process development and analytical activities. As of September&#160;30, 2023, the Company has incurred $166.2 million and intends to spend an additional $120.0 million to $130.0 million to complete the build out of the facilities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of this land acquisition, the Company entered into a development agreement with the City of Verona to construct certain infrastructure improvements within the tax increment district and will be reimbursed up to $16.0&#160;million by the City of Verona by future tax increment revenue generated from the developed property. The total amount of funding that City of Verona will pay under the Tax Increment Financing program is not guaranteed and will depend on future tax revenues generated from the developed property</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also became eligible to receive up to $2.5&#160;million in refundable Wisconsin state income tax credits from the Wisconsin Economic Development Corporation (WEDC) as incentives for investing in the local community and creating new job opportunities. As of September&#160;30, 2023, the Company has collected $1.5 million of these credits. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Technology License Commitments</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has licensed from third parties the rights to use certain technologies for its research and development activities, as well as in any products it may develop using these licensed technologies. These agreements and other similar agreements often require the Company to make milestone and royalty payments. Milestone payments, for example, may be </span></div>required as the research and development process progresses through various stages of development, such as when clinical candidates enter or progress through clinical trials, upon NDA and/or certain sales level milestones. The Company did not reach any milestones during the years of 2023 and 2022. During 2021, the Company triggered the milestone related to the progression of the ARO-ENaC and ARO-HIF2 candidates and made milestone payments of $2.4 million.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//450/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480327/954-440-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482648/440-10-50-4<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074429601296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">LEASES<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November&#160;19, 2021, the Company entered into a 15-year lease for approximately 144,000 square feet of office and research and development laboratory space in San Diego, California, for which the rent commencement date began on April&#160;19, 2023. This new facility accommodates increased personnel for its expanding pipeline of current and future drug candidates. Pursuant to the lease, within twelve months of the expiration of the initial 15-year term, the Company has the option to extend the lease for up to one additional ten-year term, with certain annual increases in base rent. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lease agreement grants the Company the right to receive an Additional Tenant Improvement Allowance (&#8220;ATIA&#8221;) funded by the lessor, with a maximum amount of $7.2 million, subject to a 7% interest per annum over the base term. Further, on September&#160;25, 2023, the Company executed the first amendment to the lease, which grants a second ATIA with a maximum amount of $23.6 million, bearing interest at a rate of 9% per annum over the base term. The Company has received $27.8 million ATIA from the lessor as of September&#160;30, 2023. As a result, the Company remeasured its lease liability and right-of-use assets to reflect these additional allowances and the related increase lease payments. The Company has further concluded that these ATIAs have no effects on the classification of the lease.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Significant Leases</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pasadena, California</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases 49,000 square feet of office space located at 177 East Colorado Blvd. for its corporate headquarters from 177 Colorado Owner, LLC, which lease expires on April&#160;30, 2027. The lease contains an option to renew for one term of <span style="-sec-ix-hidden:f-669">five</span> years. </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">San Diego, California</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company subleased space from Halozyme, Inc. for additional research and development space in San Diego, California. The term of this sublease commenced on April&#160;1, 2020 and ended on January&#160;14, 2023. On December&#160;23, 2022, the Company entered into a new six-month lease agreement with 11404 &amp; 11408 Sorrento Valley Owner (DE) LLC, effective January&#160;15, 2023. The lease ended on July&#160;15, 2023.</span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Madison, Wisconsin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company leases space for office and laboratory facilities, which expires on September&#160;30, 2031. The lease contains options to renew for two terms of five years. After accounting for additional rental square feet added pursuant to amendments to the lease agreement in 2019 and 2020, the Company currently leases a total of 115,000 square feet.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease assets and liabilities along with their classification on the Company&#8217;s consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"></td><td style="width:33.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.080%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,563&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost along with its classification on the Company&#8217;s consolidated statements of operations were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.388%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,730&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,757&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,498&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,259&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,763&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,962&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Variable lease cost is primarily related to operating expenses associated with the Company&#8217;s operating leases.</span></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There was $1.4 million, $0.3 million and $0 short-term lease cost during the years ended September&#160;30, 2023, 2022, and 2021, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents maturities of operating lease liabilities on an undiscounted basis as of September&#160;30, 2023:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"></td><td style="width:82.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,735&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,341&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,156&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,697&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78,526)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,171&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"><tr><td style="width:1.0%"></td><td style="width:65.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash received for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for amended operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074433256368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has three plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan (the &#8220;2004 Plan&#8221;) and the 2013 Incentive Plan (the &#8220;2013 Plan&#8221;), 0 and 3,408,707 shares, respectively, of the Company&#8217;s common stock are reserved for the grant of stock options and restricted stock awards to employees and directors of the Company as of September&#160;30, 2023. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March&#160;18, 2021, the Company&#8217;s Board of Directors approved the Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan (the &#8220;2021 Plan&#8221;), which authorized 8,000,000 shares (subject to certain adjustments) available for grants of stock options, stock appreciation rights, restricted and unrestricted stock, performance awards, cash awards and other awards convertible into or otherwise based on shares of the Company&#8217;s common stock. The maximum number of shares authorized under the 2021 Plan will be (i) reduced by any shares subject to awards made under the 2013 Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. As of September&#160;30, 2023, the total number of shares reserved for issuance was 6,204,720 shares, which includes 217,922 shares that were forfeited under the 2013 Plan, and 1,979,364 shares have been granted under the 2021 Plan. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there were 707,432 shares reserved for options and 683,825 shares reserved for restricted stock units issued as inducement grants to new employees granted outside of the Company&#8217;s equity-based compensation plans under Rule 5635(c)(4) of the Nasdaq Listing Rules.   </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of awards outstanding:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2004 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2013 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inducement Awards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Granted and outstanding awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,522,207&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,838&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">707,432&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,263,477&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,886,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,671,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">683,825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,241,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,408,707&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,705,153&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,391,257&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,505,117&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Option Awards</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the stock option activity for the year ended September&#160;30, 2023:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,721,384&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.73&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancelled or expired</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50,708)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.72&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(439,350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at September 30, 2023</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,263,477&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.68&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,795,879&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at September 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,141,592&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.45&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,786,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic values represent the amount by which the market price of the underlying stock exceeds the exercise price of the option. The total intrinsic value of the options exercised during the years ended September&#160;30, 2023, 2022, and 2021 was $12.2 million, $27.6 million and $66.9 million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation expense related to stock options outstanding for the years ended September&#160;30, 2023, 2022, and 2021 was $8.4 million, $10.8 million and $12.4 million, respectively. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of September&#160;30, 2023, the pre-tax compensation expense for all outstanding unvested stock options in the amount of $2.9 million will be recognized in the Company&#8217;s results of operations over a weighted average period of 0.4 years.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#8217;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and </span></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subjective variables. Because the Company&#8217;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the assumptions used in the calculation of grant-date fair values of these stock options based on the Black-Scholes option pricing model: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.69 &#8211; 4.57%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.40 &#8211; 1.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.4</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.2 &#8211; 90.4%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.61</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.64</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) The dividend yield is zero as the Company currently does not pay a dividend. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(2) The risk-free interest rate is based on that of the U.S. Treasury yields with equivalent terms in effect at the time of the grant.. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(3) Volatility is estimated based on volatility average of the Company&#8217;s common stock price. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(4) The expected term represents the period of time that stock options granted are expected to be outstanding, by using historical exercise patterns and post-vesting termination behavior.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(5) No options were granted during the year ended September&#160;30, 2022.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted stock units (&#8220;RSUs&#8221;), including market-based, time-based and performance-based awards, have been granted under the Company&#8217;s 2013 and 2021 Plans and as inducements grants granted outside of the Company&#8217;s equity-based compensation plans. At vesting, each outstanding RSU will be exchanged for one share of the Company&#8217;s common stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of the Company&#8217;s RSUs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2022</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,069,931&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.39&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,243,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(913,146)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.99&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2023</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,241,640&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.43&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of RSUs was determined based on the closing price of the Company&#8217;s common stock on the grant date, with consideration given to the probability of achieving service and/or performance conditions for awards.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 8, 2022, the Company revised the equity award made to its Chief Executive Officer on January 1, 2022 consisting of 800,000 shares, equal in value to $38.4&#160;million, that was a 100% market-based award. The revised awards consist of 99,521 RSUs and 149,282 performance-based RSUs. No incremental expense resulted from the modification. The fair values of these awards were estimated on the date of grant using a closed-form valuation model (Monte-Carlo).</span></div>For the years ended September&#160;30, 2023, 2022 and 2021, the Company recorded stock-based compensation expense of $69.7 million, $113.6 million and $64.2 million, respectively, related to shares of RSUs. As of September&#160;30, 2023, there was $94.4 million of total unrecognized compensation cost related to RSUs that is expected to be recognized over a weighted-average period of 1.6 years.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074435357872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date using the exit price. Accordingly, when market observable data are not readily available, the Company&#8217;s own assumptions are used to reflect those that market participants would be presumed to use in pricing the asset or liability at the measurement date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Assets and liabilities recorded at fair value on the consolidated balance sheets are categorized based on the level of judgment associated with inputs used to measure their fair values and the level of market price observability, as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#160;&#160;&#160;&#160;Unadjusted quoted prices are available in active markets for identical assets or liabilities as of the  reporting date.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#160;&#160;&#160;&#160;Pricing inputs are other than quoted prices in active markets, which are based on the following: </span></div><div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Quoted prices for similar assets or liabilities in active markets;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Quoted prices for identical or similar assets or liabilities in non-active markets; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;     Either directly or indirectly observable inputs as of the reporting date.</span></div><div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#160;&#160;&#160;&#160;Pricing inputs are unobservable and significant to the overall fair value measurement, and the determination of fair value requires significant management judgment or estimation.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. Thus, a Level 3 fair value measurement may include inputs that are observable (Level 1 or Level 2) and unobservable (Level 3). The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and consideration of factors specific to the asset or liability.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses prices and inputs that are current as of the measurement date, including during periods of market disruption. In periods of market disruption, the ability to observe prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2, or from Level 2 to Level 3. The Company recognizes transfers between levels at either the actual date of the event or a change in circumstances that caused the transfer. At September&#160;30, 2023 and 2022, the Company did not have any financial assets or financial liabilities based on Level 3 measurements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis, and indicate the fair value hierarchy of the valuation techniques utilized by the Company: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:33.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available-for-sale debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,553&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261,182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292,735&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261,182&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293,082&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:33.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Held-to-maturity debt securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total held-to-maturity debt securities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,973&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">313,060&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">365,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial assets</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,235&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">313,060&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404,295&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">    </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt securities were reclassified from held-to-maturity to available-for-sale recorded at fair value on a recurring basis. The fair value of debt securities are priced using model pricing based on the securities&#8217; relationship to other benchmark quoted prices as provided by an independent third party, and under GAAP are considered a Level 2 input.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no transfers between Levels 1, 2, and 3 of the fair value hierarchy during the years ended September&#160;30, 2023 and 2022.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses of the Company approximate fair value based on the short maturities of these instruments. At September&#160;30, 2023, the Company did not have any nonrecurring fair value measurements of nonfinancial assets or nonfinancial liabilities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074435360352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">INCOME TAXES<div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Provision</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the loss before income taxes are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(194,639)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(170,570)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(140,846)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,708)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(202,491)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(172,278)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(140,846)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes consisted of the following components:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:69.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.170%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.170%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.174%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,710&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current tax</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,785&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,785&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the tax expense based on the statutory rate to the Company&#8217;s actual tax expense in the consolidated statements of operations. A notional 21% tax rate was applied as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. federal statutory income tax</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Permanent and other items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-deductible compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-4.6&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign-derived intangible income deduction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-1.1&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-1.7&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-20.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-28.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-1.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-2.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the significant components of the Company&#8217;s net deferred tax assets and liabilities: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.404%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,208&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,441&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,810&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,296&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,479&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,973&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304,470&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262,872&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Valuation allowance</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(284,626)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(242,394)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,878)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,088)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,966)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,390)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax liability</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,844)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,478)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is recorded to reduce deferred tax assets to the amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended September&#160;30, 2023. Such objective evidence limits the ability to consider other subjective evidence such as its projections for future growth. On the basis of this evaluation at September&#160;30, 2023 and 2022, a valuation allowance of $284.6 million and $242.4 million, respectively, has been recorded. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of September&#160;30, 2023, the Company had accumulated federal and state net operating loss (&#8220;NOL&#8221;) carry forwards of $134.3 million and $491.5 million, respectively. Of the $134.3 million of federal NOL carryforwards, $34.0 million was generated before January 1, 2018 and is subject to the 20-year carryforward period (&#8220;pre-Tax Act losses&#8221;). The remaining $100.3 million (&#8220;post-Tax Act losses&#8221;) can be carried forward indefinitely but is subject to the 80% taxable income limitation. Of the $491.5 million of state NOL carryforwards $2.9 million can be carried forward indefinitely. The pre-Tax Act U.S. federal and state net operating loss carryforwards will expire at various dates through 2041.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) Sections 382 and 383, annual use of an entity&#8217;s NOL and research and development credit carryforwards may be limited if there is a cumulative change in ownership of greater than 50% within a three-year period. The amount of the annual limitation is determined based on the value of the entity immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. If limited, the related tax asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. To date, the Company has not completed an analysis pursuant to Sections 382 and 383. Future changes in ownership may occur which could limit the Company&#8217;s ability to utilize attributes.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Uncertainty in Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has adopted guidance issued by the FASB that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#8217;s financial statements and prescribes a recognition threshold of more-likely-than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more-likely-than not that a tax position will be sustained upon examination, based solely on the technical merits of the position and must assume that the tax position will be examined by taxing authorities. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s gross unrecognized tax benefits:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance of unrecognized tax benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross increase for prior period tax positions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,495&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,481&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross decrease for prior period tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,489)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross increase for current period tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance of unrecognized tax benefits</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,536&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended September&#160;30, 2023, 2022 and 2021, the Company has recorded income tax expense of $0, $3.5 million and $0 respectively, related to uncertain tax positions. The Company&#8217;s policy is to recognize potential interest and penalties related to unrecognized tax benefits associated with uncertain tax positions, if any, in the income tax provision. As of September&#160;30, 2023, the Company has accrued interest and penalties of $0.6&#160;million and $0.9&#160;million, respectively.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the unrecognized tax benefit at September&#160;30, 2023 are ultimately recognized, excluding the impact of U.S. Tax benefits netted against deferred taxes that are subject to a valuation allowance, approximately $3.5 million would result in a reduction in the Company&#8217;s income tax expense and effective tax rate. The Company expects that $3.5 million of its unrecognized tax benefits to change over the next 12 months.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to taxation in the U.S. and various states along with other foreign countries. Due to the presence of NOL carryforwards, all of the income tax years remain open for examination domestically. The Company has not been notified that it is under audit by the Internal Revenue Service or foreign taxing authorities; however, the Company has been notified of an income tax examination by the state of California. There are no other audits in any other jurisdictions.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480990/946-20-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//740/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-21<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482526/740-270-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074437852384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text">EMPLOYEE BENEFIT PLANS<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors a defined contribution retirement plan which is under Section 401(k) of the Internal Revenue Code and is designed to adhere to ERISA Fiduciary standards. Substantially all of the Company&#8217;s employees are eligible to participate this plan. Under the terms of the plan, an eligible employee may elect to contribute a portion of their salary on a pre-tax basis, subject to federal statutory limitations. The plan allows for a discretionary match in an amount up to 100% of each participant&#8217;s first 3% of compensation contributed plus 50% of each participant&#8217;s next 2% of compensation contributed. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended September&#160;30, 2023, 2022, and 2021, the Company recorded expenses for the matching contributions under this plan of $2.2 million, $1.7 million and $1.3 million, respectively. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also provides certain employee benefit plans, including those which provide health and life insurance benefits to employees.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndEmployeeBenefitPlansTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 710<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//710/tableOfContent<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 712<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//712/tableOfContent<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 715<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//715/tableOfContent<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndEmployeeBenefitPlansTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074435358688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Sale of Future Royalties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract', window );"><strong>Liability Related To The Sale Of Future Royalties [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock', window );">Liability Related to the Sale of Future Royalties</a></td>
<td class="text">LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 9, 2022, the Company and Royalty Pharma entered into the Royalty Pharma Agreement, pursuant to which Royalty Pharma agreed to pay up to $410.0 million in cash to the Company in consideration for the Company&#8217;s future royalty interest in olpasiran, a small interfering RNA (siRNA) originally developed by the Company and licensed to Amgen in 2016 under the Olpasiran Agreement. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid $250.0 million upfront and agreed to pay up to an additional $160.0 million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) $50.0 million on completion of enrollment in the OCEAN Phase 3 clinical trial for olpasiran, (ii) $50.0 million upon receipt of FDA approval of olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a)), and (iii) $60.0 million upon Royalty Pharma&#8217;s receipt of at least $70.0 million of royalty payments under the Royalty Pharma Agreement in any single calendar year. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has evaluated the terms of the Royalty Pharma Agreement and concluded in accordance with the relevant accounting guidance that the Company accounted for the transaction as debt and the funding of $250.0 million from Royalty Pharma was recorded as a liability related to the sale of future royalties on its consolidated balance sheets. The Company is not obligated to repay this upfront funding received under the  Royalty Pharma Agreement. This liability is amortized over the expected repayment term using an effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate may vary during the term of the agreement depending on a number of factors, including the amount and timing of forecasted net revenues which affects the repayment timing and ultimate amount of repayment. The Company will evaluate the effective interest rate periodically based on its current revenue forecasts utilizing the prospective method. For 2023, the Company recognized non-cash interest expense of $18.3 million, on the consolidated statements of operations and comprehensive loss.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related To The Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liability Related To The Sale Of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074439103296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">EARNINGS PER SHARE<div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the computation of basic and diluted earnings per share for the years ended September&#160;30, 2023, 2022 and 2021. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(205,275)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(176,063)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(140,848)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average basic shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average diluted shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basic earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.92)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.67)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.36)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Potentially dilutive securities representing approximately 4,053,000, 3,885,000 and 2,063,000 shares of common stock were excluded from the computation of diluted earnings per share for the years ended September&#160;30, 2023, 2022 and 2021, respectively, because their effect would have been anti-dilutive.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074437894016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">SUBSEQUENT EVENTSOn October 30, 2023, the Company entered into an Assignment and Consent Agreement with Janssen, whereby, the Company consented to the assignment of the Janssen License Agreement to GSK, which assignment shall be effective upon the receipt of certain anti-trust approvals.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//855/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 855<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483399/855-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074433054016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</a></td>
<td class="num">$ (205,275)<span></span>
</td>
<td class="num">$ (176,063)<span></span>
</td>
<td class="num">$ (140,848)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074429799440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MtrlTermsOfTrdArrTextBlock', window );">Material Terms of Trading Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the quarter ended September&#160;30, 2023, the following directors and officers (as defined in Exchange Act Rule 16a-1(f)) adopted certain trading plans intended to satisfy Rule 10b5-1(c):</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"><tr><td style="width:1.0%"></td><td style="width:14.014%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.335%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.823%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.365%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.410%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.373%"></td><td style="width:0.1%"></td></tr><tr style="height:28pt"><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Adoption or Termination Date</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Plan Start Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Plan End Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares Vesting and Subject to Sell-To-Cover </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:114%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Other Shares Being Sold (Subject to Certain Conditions)</span></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Mauro Ferrari</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Board Member</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">09/28/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/11/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/31/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">3,147</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Douglass Given</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Board Member</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">09/26/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/11/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/31/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">2,911</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">James Hamilton </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:114%;position:relative;top:-2.97pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Chief Discovery and Translational Medicine</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">08/15/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/03/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/31/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">52,500</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">James Hamilton</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Chief Discovery and Translational Medicine</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">08/22/2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">12/01/2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">11/29/2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">35,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Ken Myszkowski</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Chief Financial Officer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">09/07/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/05/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/31/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">30,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Patrick O</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8217;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Brien</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Chief Operating Officer and General Counsel</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">09/03/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/03/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/05/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">4,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Tracie Oliver</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Chief Commercial Officer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">08/28/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/05/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">07/31/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">17,625</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">Victoria Vakiener</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Board Member</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">09/28/2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/11/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">05/31/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">6,519</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%">William Waddill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">Board Member</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">08/29/2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/11/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">01/31/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">n/a</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%">3,934</span></td></tr></table></div><div style="margin-top:3pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) This column indicates the total number of shares vesting, but the 10b5-1 Plan provides for the sale of only those shares necessary to satisfy payment of applicable withholding taxes.</span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(2) Termination of a trading plan that was intended to satisfy Rule 10b5-1(c).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=arwr_MauroFerrariMember', window );">Mauro Ferrari [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Mauro Ferrari<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Board Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">09/28/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">3,147<span></span>
</td>
<td class="nump">3,147<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=arwr_DouglassGivenMember', window );">Douglass Given [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Douglass Given<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Board Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">09/26/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">2,911<span></span>
</td>
<td class="nump">2,911<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=arwr_KenMyszkowskiMember', window );">Ken Myszkowski [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Ken Myszkowski<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Financial Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">09/07/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">26 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=arwr_PatrickOBrienMember', window );">Patrick O'Brien [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Patrick O&#8217;Brien<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Operating Officer and General Counsel<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">09/03/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=arwr_TracieOliverMember', window );">Tracie Oliver [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Tracie Oliver<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Commercial Officer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">08/28/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">208 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">17,625<span></span>
</td>
<td class="nump">17,625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=arwr_VictoriaVakienerMember', window );">Victoria Vakiener [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">Victoria Vakiener<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Board Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">09/28/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">141 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">6,519<span></span>
</td>
<td class="nump">6,519<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_IndividualAxis=arwr_WilliamWaddillMember', window );">William Waddill [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">William Waddill<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Board Member<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">08/29/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">3,934<span></span>
</td>
<td class="nump">3,934<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=arwr_JamesHamiltonTerminatedPlanMember', window );">James Hamilton Terminated Plan [Member] | James Hamilton [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">James Hamilton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Discovery and Translational Medicine<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrTerminationDate', window );">Termination Date</a></td>
<td class="text">08/15/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">52,500<span></span>
</td>
<td class="nump">52,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrAxis=arwr_JamesHamiltonAugust2023PlanMember', window );">James Hamilton August 2023 Plan [Member] | James Hamilton [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndName', window );">Name</a></td>
<td class="text">James Hamilton<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrIndTitle', window );">Title</a></td>
<td class="text">Chief Discovery and Translational Medicine<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrAdoptionDate', window );">Adoption Date</a></td>
<td class="text">08/22/2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrDuration', window );">Arrangement Duration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">364 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TrdArrSecuritiesAggAvailAmt', window );">Aggregate Available</a></td>
<td class="nump">35,000<span></span>
</td>
<td class="nump">35,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MtrlTermsOfTrdArrTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MtrlTermsOfTrdArrTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrAdoptionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrAdoptionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrDuration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph C<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrDuration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrIndTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrIndTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrSecuritiesAggAvailAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrSecuritiesAggAvailAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TrdArrTerminationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TrdArrTerminationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arwr_MauroFerrariMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arwr_MauroFerrariMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arwr_DouglassGivenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arwr_DouglassGivenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arwr_KenMyszkowskiMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arwr_KenMyszkowskiMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arwr_PatrickOBrienMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arwr_PatrickOBrienMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arwr_TracieOliverMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arwr_TracieOliverMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arwr_VictoriaVakienerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arwr_VictoriaVakienerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arwr_WilliamWaddillMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arwr_WilliamWaddillMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=arwr_JamesHamiltonTerminatedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=arwr_JamesHamiltonTerminatedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_IndividualAxis=arwr_JamesHamiltonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_IndividualAxis=arwr_JamesHamiltonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrAxis=arwr_JamesHamiltonAugust2023PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrAxis=arwr_JamesHamiltonAugust2023PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074433875408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock', window );">Basis of Presentation and Use of Estimates</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Use of Estimates</span></div>The preparation of financial statements in conformity with U.S. generally accepted accounting principles (&#8220;GAAP&#8221;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, judgments and assumptions. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results could materially differ from those estimates.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationVariableInterestEntityPolicy', window );">Variable Interest Entity</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Variable Interest Entity (&#8220;VIE&#8221;)</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A VIE is an entity that, by design, either (i) lacks sufficient equity to permit the entity to finance its activities without additional subordinated financial support from other parties; or (ii) has equity investors that do not have the ability to make significant decisions relating to the entity&#8217;s operations through voting rights, or do not have the obligation to absorb the expected losses, or do not have the right to receive the residual returns of the entity. The primary beneficiary of a VIE is required to consolidate the assets and liabilities of the VIE. The primary beneficiary is the party that has both (i) the power to direct the activities of the VIE that most significantly impact the VIE&#8217;s economic performance, and (ii) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE through its interest in the VIE.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 25, 2022, the Company entered into a license agreement with Visirna (Note 2) and consolidated Visirna&#8217;s financial statements in which the Company has a direct controlling financial interest based on the VIE model. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all the facts and circumstances, including its role in establishing Visirna and its ongoing rights and responsibilities to assess whether the Company has the power to direct the activities of Visirna. In general, the parties that make the most significant decisions affecting a VIE and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also considers all of its economic interests to assess whether the Company has the obligation to absorb losses of Visirna or the right to receive benefits from it that could potentially be significant to Visirna. This assessment requires the Company to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to Visirna. Factors considered in assessing the significance include: the design of the Visirna, including its capitalization structure, subordination of interests, payment priority, and the reasons why the interests are held by the Company. </span></div>At Visirna&#8217;s inception, the Company determined whether it was the primary beneficiary and if Visirna should be consolidated based on the facts and circumstances. The Company performs ongoing reassessments of the VIE based on reconsideration events and reevaluates whether a change to the consolidation is required. As of September&#160;30, 2023, there were no events to be reconsidered in the consolidation.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Cash, Cash Equivalents and Restricted Cash</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All highly liquid interest-bearing investments are classified as cash equivalents. These investments mainly include commercial paper with maturities of three months or less when purchased. The carrying value of these cash equivalents approximate fair value. </span></div>There was $7.9 million and $7.3 million restricted cash at September&#160;30, 2023 and 2022, respectively, that is primarily held as collateral associated with letters of credit for the Company&#8217;s facility leases.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Concentration of Credit Risk</span></div>Financial instruments that potentially expose the Company to concentration of credit risk primarily consist of cash, cash equivalents and restricted cash and investments. As of September&#160;30, 2023 and 2022, the Company&#8217;s investments were primarily invested in money market funds, certificates of deposit, commercial paper, and corporate debt securities through highly rated financial institutions. The Company also maintains several bank accounts primarily at three financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Investments</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment securities are mainly held-to-maturity investments, available-for-sale, and marketable securities.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These held-to-maturity investments may consist of investment-grade interest bearing instruments, primarily money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper, which are stated at amortized cost. The Company does not intend to sell these investment securities and the contractual maturities are not greater than 36 months. Those with maturities less than twelve months are included in short-term investments on the Company&#8217;s consolidated balance sheets, while those with remaining maturities in excess of twelve months are included in long-term investments on its consolidated balance sheets. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security, and no gains or losses on held-to-maturity investment are realized until they are sold. The Company reassesses the classification of held-to-maturity at each reporting period.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">The available-for-sale investments may consist of investment-grade interest bearing instruments, primarily money market</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">accounts,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">government-sponsored</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">enterprise</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">securities,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">corporate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">bonds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">and/or</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">commercial</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">paper, which are accounted for at fair value.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">Changes in fair values are reported as unrealized gains or losses and are recorded in the Company&#8217;s consolidated statement of operations and comprehensive loss.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">On September 30, 2023, the Company changed the classification of debt securities to available-for-sale from held-to-maturity.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%">As a result, these debt securities are carried at fair value.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketable debt securities consisted of mutual funds that primarily invest in U.S. government bonds, U.S. government agency bonds, and corporate bonds. Dividends from these funds were automatically re-invested. These securities were recorded at fair value, and all unrealized gains/losses were recorded in the Company&#8217;s consolidated statement of operations and comprehensive loss. In April 2022, the Company sold all of its investments in mutual funds for $122.3 million. </span></div>The Company monitors its investments closely. If an unrealized loss is determined to be other-than-temporary, it is written off as a realized loss through the consolidated statements of operations and comprehensive loss. The Company&#8217;s methodology of assessing other-than-temporary impairments is based on security-specific analysis as of the balance sheet date and considers various factors, including the length of time to maturity and the extent to which the fair value has been less than the cost, recoverability of future cash flows as compared to carrying value of the security, the financial condition and the near-term prospects of the issuer, and the Company&#8217;s ability and intent to hold the security. If a decline in fair value of investments is determined to be other-than-temporary, the securities are written down to fair value as the new cost basis and the amount of the write down is accounted for as realized losses. The Company did not recognize any other-than-temporary impairments of its investment for the years ended September&#160;30, 2023, 2022, and 2021.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Property and Equipment</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from <span style="-sec-ix-hidden:f-426">three</span> to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company periodically assesses long-lived assets or asset groups, including property and equipment, for recoverability when events or changes in circumstances indicate that their carrying amounts may not be recoverable. If the Company identifies an indicator of impairment, the Company assesses recoverability by comparing the carrying amount of the asset to the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset. </span></div>An impairment loss is recognized when the carrying amount is not recoverable and is measured as the excess of carrying value over fair value. There were no impairment charges during the years ended September&#160;30, 2023, 2022, and 2021.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets subject to amortization</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Intangible Assets Subject to Amortization</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets subject to amortization include certain patents and license agreements. The Company qualitatively evaluates intangible assets for impairment annually or whenever events or changes in circumstances indicate that it is more likely than not that the carrying amount of intangible assets may exceed their implied fair values. As of September&#160;30, 2023 and 2022, intangible impairment assessments indicated that there was no impairment.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Leases</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether a contract is, or contains, a lease at inception. All of the Company&#8217;s leases are classified as operating leases. Leases with terms greater than one-year are recognized on the Company&#8217;s consolidated balance sheets as right-of-use assets that represent the Company&#8217;s right to use an underlying asset for the lease term, and lease liabilities that represent its obligation to make lease payments arising from the lease. Lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the expected lease term.</span></div>The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize  lease payments on a straight-line basis over the expected lease term. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenue Recognition</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that it determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing. If the license is not considered to be distinct from other performance obligations, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time. If the performance obligation is satisfied over time, the Company then determines the appropriate method of measuring progress for purposes of recognizing revenue from license payments. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Typically, the Company&#8217;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a Clinical Trial Application (&#8220;CTA&#8221;) or a New Drug Application (&#8220;NDA&#8221;) in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas. The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in the Company&#8217;s consolidated statements of operation and comprehensive loss. Typically, milestone payments and royalties are achieved after the Company&#8217;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or preclinical program. Milestones or royalties achieved after the Company&#8217;s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its licensing or collaboration agreements. Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment. Additionally, future royalty payments are not substantially within the control of the Company or the customer. </span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using the input method; Labor hours, costs incurred or patient visits in clinical trials are typically used as the measure of performance. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations.  If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its consolidated balance sheets.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain judgments affect the application of the Company&#8217;s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company&#8217;s current operating plan and, the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementAccountingPolicy', window );">Collaborative Arrangement</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Collaborative Arrangements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope of Financial Accounting Standards Board (&#8220;FASB&#8221;) Topic 808 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. For collaborative arrangements that contain multiple elements, the Company determines which units of account are deemed to be within the scope of Topic 808 and which units of account are more reflective of a vendor-customer relationship, and therefore are within the scope of Topic 606. For units of account that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of Topic 808, the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative arrangement based on the nature </span></div>of each activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to research and development expense or general and administrative expense, as appropriate.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Research and Development</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#8217;s research and development operations, and costs to acquire technology licenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Stock-Based Compensation</span></div>Share-based compensation expenses for all stock grants are based on their estimated grant-date fair value. The fair value of stock option awards is estimated using the Black-Scholes option valuation model which requires the input of subjective assumptions to calculate the value of stock options. For restricted stock units, the value of the award is based on the Company&#8217;s stock price at the grant date. For performance-based restricted stock unit awards, the value of the award is based on the Company&#8217;s stock price at the grant date, with consideration given to the probability of the performance condition being achieved. The Company uses historical data and other information to estimate the expected price volatility and the expected forfeiture rate for stock option awards. Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#8217;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Income Taxes</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting basis and the respective tax basis of the Company&#8217;s assets and liabilities, and expected benefits of utilizing net operating loss, capital loss, and tax-credit carryforwards. The Company assesses the likelihood that its deferred tax assets will be realized and, to the extent management does not believe these assets are more likely than not to be realized, a valuation allowance is established. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates or laws is recognized in earnings in the period that includes the enactment date.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings per Share</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Earnings per Share</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units outstanding. </span></div>During the years ended September&#160;30, 2023, 2022 and 2021, the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units outstanding during the period due to their anti-dilutive effect.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation Adjustments</a></td>
<td class="text"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Foreign currency translation adjustments</span></div>One of the Company&#8217;s wholly-owned subsidiaries&#8217; functional currencies are not the United States dollar, which is the Company&#8217;s reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Translation adjustments arising from the use of different exchange rates from period to period are included in the accumulated other comprehensive loss.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Pronouncements</span></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no recent accounting pronouncements that have significantly impacted this Annual Report on Form 10-K.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Basis of presentation and use of estimates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementAccountingPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for collaborative arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementAccountingPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480981/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationVariableInterestEntityPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-5A<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2AA<br> -Subparagraph a<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481203/810-10-50-2AA<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationVariableInterestEntityPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//830/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482573/350-20-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 30<br> -Topic 350<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-17<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-25<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-28<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-19<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(f)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 12<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 19<br> -Subparagraph (2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480032/946-320-S99-19<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480321/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org//606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org//718/tableOfContent<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074437939248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfCurrentProductsTableTextBlock', window );">Schedule of Company's Current Pipeline</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the Company&#8217;s current pipeline:</span><span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.021%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:27.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.962%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Therapeutic Area</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stage</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Product Rights</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cardiometabolic</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Plozasiran (ARO-APOC3)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Two Phase 2b and one Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zodasiran (ARO-ANG3)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Two Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Olpasiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amgen</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pulmonary</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-RAGE</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-MUC5AC</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-MMP7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liver</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GSK-4532990</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2b</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GSK</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fazirsiran</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 3</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Takeda and Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNJ-3989</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 2</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">HZN-457</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</span></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Horizon</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-C3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1/2a</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-PNPLA3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Phase 1</span></div></td><td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Muscle</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-DUX4</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-Clinical</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Central Nervous System (CNS)</span></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ARO-SOD1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pre-Clinical</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arrowhead</span></td></tr></table></div><div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(1) On October 30, 2023, the Company entered into an Assignment and Consent Agreement with Janssen. See Note 15.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(2) On October 6, 2023, Amgen announced that it has completed its acquisition of Horizon.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ScheduleOfCurrentProductsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Current Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ScheduleOfCurrentProductsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074437936592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Revenue</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a summary of revenue recognized:</span></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GSK</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,657&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,764&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Horizon</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23,206&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,816&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Takeda</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">162,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">85,834&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">90,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">356&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,452&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amgen</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">240,735&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">243,231&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">138,287&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Receivables and Contract Liabilities</a></td>
<td class="text"><div style="margin-top:9pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the balance of receivables and contract liabilities related to the Company&#8217;s collaboration and license agreements:</span></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:60.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.386%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables included in accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,410&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract liabilities included in deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">866&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">130,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074437985152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s major classes of property and equipment: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Computers, software, office equipment and furniture </span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,240&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,182&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Land</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research equipment</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,509&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,283&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,813&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">42,017&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">166,655&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,373&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">332,213&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,851&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: Accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(41,951)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(31,554)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,262&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">110,297&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074437958624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock', window );">Summary of Short-term, Long-term Investments and Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s investments consisted of the following:</span></div><div style="margin-top:7pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Available-for-sale debt securities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">295,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,964)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">295,699&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,964)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292,735&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>The Company does not believe that the available-for-sale debt securities that were in an unrealized loss position have any credit loss impairment as of September 30, 2023.<div style="margin-top:7pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:42.851%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">As of September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Adjusted Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Gains</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross<br/>Unrealized Losses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Short-term investments (due within one year)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">218,391&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,661)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">214,730&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held-to-maturity certificate of deposit</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total current investments</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,391&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,661)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">264,730&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-term investments (Due within one through three years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Held-to-maturity debt securities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,872&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,569)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,303&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total long-term investments</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,872&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,569)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,303&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Held to maturity securities and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074437869920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text">The following table presents the components of intangible assets: <div style="margin-top:12pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"></td><td style="width:24.967%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.425%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross Carrying Amount</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated Amortization</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Impairment</span></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Net Carrying Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Useful Lives</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in years)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,321&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,407&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,274&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,855&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total intangible assets, net</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,857&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,595&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,262&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patents</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21,728&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,770&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,958&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">License</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total intangible assets, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,857&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,895&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,962&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Intangible Assets Future Amortization Expense</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents the estimated future amortization expense related to intangible assets as of September&#160;30, 2023:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.272%"><tr><td style="width:1.0%"></td><td style="width:60.954%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.106%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.107%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortization Expense</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ending September 30, </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,762&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,262&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074437929056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfStockByClassTextBlock', window );">Schedule of Shares of Common Stock and Preferred Stock</a></td>
<td class="text"><div style="margin-top:6pt;padding-left:27pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s shares of common stock and preferred stock:</span></div><div style="margin-top:6pt;text-align:center;text-indent:27pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.818%"><tr><td style="width:1.0%"></td><td style="width:31.294%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.644%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.644%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.649%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Par Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Authorized</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Issued</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Outstanding</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">290,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">107,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of September 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,960&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.001&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-4<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-5<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481142/505-10-45-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-10<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480244/480-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-6<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074437936592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Lease Assets and Liabilities and Lease Cost</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease assets and liabilities along with their classification on the Company&#8217;s consolidated balance sheets were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"><tr><td style="width:1.0%"></td><td style="width:33.503%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.656%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.476%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.409%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.080%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Assets and Liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease assets</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,563&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,776&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-current operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities, net of current portion</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104,608&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">78,800&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease cost along with its classification on the Company&#8217;s consolidated statements of operations were as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.388%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Lease Cost</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,278&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,730&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,757&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,498&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Variable lease cost</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">728&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">814&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,259&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,763&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,962&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) Variable lease cost is primarily related to operating expenses associated with the Company&#8217;s operating leases.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents maturities of operating lease liabilities on an undiscounted basis as of September&#160;30, 2023:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"><tr><td style="width:1.0%"></td><td style="width:82.696%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amounts</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,735&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,341&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,514&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,156&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2029 and thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">124,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">193,697&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(78,526)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total operating lease liabilities</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">115,171&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow and other information related to leases was as follows:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"><tr><td style="width:1.0%"></td><td style="width:65.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.271%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.274%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash received for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for amended operating lease liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid for amounts included in the measurement of lease liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating cash flows from operating leases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,204&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074439111024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of Awards Outstanding</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of awards outstanding:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.429%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.043%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2004 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2013 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021 Plan</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Inducement Awards</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Granted and outstanding awards:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Options</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,522,207&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,838&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">707,432&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,263,477&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,886,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,671,315&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">683,825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,241,640&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,408,707&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,705,153&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,391,257&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,505,117&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summarized Information about Stock Options</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a summary of the stock option activity for the year ended September&#160;30, 2023:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.328%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.849%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Exercise<br/>Price<br/>Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Remaining<br/>Contractual<br/>Term (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at September 30, 2022</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,721,384&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20.73&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33.03&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cancelled or expired</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50,708)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60.72&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(439,350)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding at September 30, 2023</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,263,477&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22.68&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,795,879&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercisable at September 30, 2023</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,141,592&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.45&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,786,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used to Value Stock Options</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides the assumptions used in the calculation of grant-date fair values of these stock options based on the Black-Scholes option pricing model: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.69 &#8211; 4.57%</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.40 &#8211; 1.1%</span></div></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.4</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86.2 &#8211; 90.4%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (in years)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.25</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average grant date fair value per share</span></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25.61</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">N/A</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48.64</span></td></tr></table></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(1) The dividend yield is zero as the Company currently does not pay a dividend. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(2) The risk-free interest rate is based on that of the U.S. Treasury yields with equivalent terms in effect at the time of the grant.. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(3) Volatility is estimated based on volatility average of the Company&#8217;s common stock price. </span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(4) The expected term represents the period of time that stock options granted are expected to be outstanding, by using historical exercise patterns and post-vesting termination behavior.</span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%">(5) No options were granted during the year ended September&#160;30, 2022.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Share Activity Related to RSUs</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity of the Company&#8217;s RSUs:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"><tr><td style="width:1.0%"></td><td style="width:71.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.083%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of<br/>RSUs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-<br/>Average<br/>Grant<br/>Date<br/>Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2022</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,069,931&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">64.39&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,243,644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34.32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(913,146)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52.99&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(158,789)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">53.80&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Outstanding as of September 30, 2023</span></td><td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,241,640&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58.43&#160;</span></td><td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074437852384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information about the Company&#8217;s assets and liabilities measured at fair value on a recurring basis, and indicate the fair value hierarchy of the valuation techniques utilized by the Company: </span></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:33.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Available-for-sale debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,553&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,093&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">231,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total available-for-sale debt securities</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,553&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261,182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">292,735&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial assets</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,900&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">261,182&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">293,082&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">     </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:33.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.074%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Held-to-maturity debt securities</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. government bonds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,973&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Municipal securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commercial notes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">271,333&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Certificate of deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total held-to-maturity debt securities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,973&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">313,060&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">365,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Money market instruments </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39,262&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total financial assets</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91,235&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">313,060&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404,295&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074439128272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Components of Loss Before Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of the loss before income taxes are as follows:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:63.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.415%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.416%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Domestic</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(194,639)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(170,570)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(140,846)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,852)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,708)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(202,491)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(172,278)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(140,846)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Provisions for Income Taxes</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes consisted of the following components:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"><tr><td style="width:1.0%"></td><td style="width:69.872%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.170%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.170%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.174%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,074&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,710&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current tax</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,785&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></div></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Federal</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State</span></div></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred tax</span></div></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax provision</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,784&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,785&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents a reconciliation of the tax expense based on the statutory rate to the Company&#8217;s actual tax expense in the consolidated statements of operations. A notional 21% tax rate was applied as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. federal statutory income tax</span></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State income taxes, net of federal tax benefit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Permanent and other items</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-deductible compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-4.6&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign-derived intangible income deduction</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-1.1&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-1.7&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-20.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-28.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-29.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effective income tax rate</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-1.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">-2.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of the Net Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the significant components of the Company&#8217;s net deferred tax assets and liabilities: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.402%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.002%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.404%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">September 30,</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands) </span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">171,319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">75,208&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">66,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,441&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">38,810&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,296&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41,479&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,082&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,961&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Intangible assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,523&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,973&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,636&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,162&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax assets</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">304,470&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262,872&#160;</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Valuation allowance</span></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(284,626)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(242,394)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fixed assets</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,878)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,088)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right-of-use assets</span></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,966)</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,390)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total gross deferred tax liability</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(19,844)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,478)</span></td><td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net deferred tax assets (liabilities)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Gross Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s gross unrecognized tax benefits:</span></div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.718%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance of unrecognized tax benefits</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross increase for prior period tax positions</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,495&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,481&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross decrease for prior period tax positions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,489)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross increase for current period tax positions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,049&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ending balance of unrecognized tax benefits</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,536&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,481&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 9<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Paragraph 12<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074437956192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="margin-top:6pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the computation of basic and diluted earnings per share for the years ended September&#160;30, 2023, 2022 and 2021. </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended September 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in thousands, except per share amounts)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(205,275)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(176,063)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(140,848)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Denominator:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average basic shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average diluted shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">106,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">105,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,745&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Basic earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.92)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.67)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.36)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Diluted earnings per share</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.92)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.67)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1.36)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074427417504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Significant Accounting Policies (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 09, 2022</div></th>
<th class="th"><div>Apr. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,891,000<span></span>
</td>
<td class="nump">$ 108,005,000<span></span>
</td>
<td class="nump">$ 184,434,000<span></span>
</td>
<td class="nump">$ 143,583,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,900,000<span></span>
</td>
<td class="nump">7,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available-for-sale securities, at fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">292,735,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_IncreaseDecreaseInCashAndInvestments', window );">Net increase (decrease) in cash and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(78,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sale of marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived', window );">Intangible assets subject to amortization, impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Amount insured in FDIC per account</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember', window );">Royalty Pharma Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderCollaborationAgreement', window );">Upfront payment</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementsMember', window );">Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems', window );"><strong>Organization And Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_UpfrontMilestonePaymentReceived', window );">Upfront milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivedAsDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received as due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivedAsDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_IncreaseDecreaseInCashAndInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in cash and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_IncreaseDecreaseInCashAndInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_OrganizationAndSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Organization and significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_OrganizationAndSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_UpfrontMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_UpfrontMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsFinitelived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsFinitelived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482913/230-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074432712224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 240,735<span></span>
</td>
<td class="nump">$ 243,231<span></span>
</td>
<td class="nump">$ 138,287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">29,657<span></span>
</td>
<td class="nump">124,764<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">23,206<span></span>
</td>
<td class="nump">29,181<span></span>
</td>
<td class="nump">6,816<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">162,516<span></span>
</td>
<td class="nump">85,834<span></span>
</td>
<td class="nump">90,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">356<span></span>
</td>
<td class="nump">3,452<span></span>
</td>
<td class="nump">40,687<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=arwr_AmgenIncorporatedMember', window );">Amgen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 91<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479777/606-10-55-91<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arwr_HorizonTherapeuticsIrelandDACMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arwr_HorizonTherapeuticsIrelandDACMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arwr_JanssenPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arwr_JanssenPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=arwr_AmgenIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=arwr_AmgenIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074439138592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and License Agreements - Receivables and Contract Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CollaborationAndLicenseAgreementsAbstract', window );"><strong>Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Receivables included in accounts receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,410<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract liabilities included in deferred revenue</a></td>
<td class="nump">$ 866<span></span>
</td>
<td class="nump">$ 130,049<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480833/946-310-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(5)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481058/954-310-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074432720704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 22, 2021 </div>
<div>USD ($) </div>
<div>bundle </div>
<div>obligation</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,735<span></span>
</td>
<td class="nump">$ 243,231<span></span>
</td>
<td class="nump">$ 138,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctBundle', window );">Number of distinct bundle | bundle</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 120,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree', window );">Milestone payment receivable upon achievement of phase two and first patient dosed in phase three</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember', window );">GSK | Collaboration and License agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommercialMilestonePaymentsAtFirstCommercialSale', window );">Commercial milestone payments at first commercial sale</a></td>
<td class="nump">190,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_SalesRelatedMilestonePayments', window );">Sales-related milestone payments</a></td>
<td class="nump">$ 590,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CommercialMilestonePaymentsAtFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial milestone payments at first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CommercialMilestonePaymentsAtFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment receivable upon achievement of phase two and first patient dosed in phase three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctBundle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct bundle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctBundle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_SalesRelatedMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales-related milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_SalesRelatedMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074429194736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 18, 2021 </div>
<div>obligation </div>
<div>bundle</div>
</th>
<th class="th">
<div>Jul. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,735<span></span>
</td>
<td class="nump">$ 243,231<span></span>
</td>
<td class="nump">$ 138,287<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_HorizonTherapeuticsIrelandDACMember', window );">Horizon | Horizon License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctBundle', window );">Number of distinct bundle | bundle</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_UpfrontMilestonePaymentReceived', window );">Upfront milestone payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctBundle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct bundle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctBundle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_UpfrontMilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Upfront milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_UpfrontMilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_HorizonTherapeuticsIrelandDACMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_HorizonTherapeuticsIrelandDACMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_HorizonLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_HorizonLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074432748224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 07, 2020 </div>
<div>USD ($) </div>
<div>bundle </div>
<div>obligation</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 240,735<span></span>
</td>
<td class="nump">$ 243,231<span></span>
</td>
<td class="nump">$ 138,287<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.92)<span></span>
</td>
<td class="num">$ (1.67)<span></span>
</td>
<td class="num">$ (1.36)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 866<span></span>
</td>
<td class="nump">$ 74,099<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,763<span></span>
</td>
<td class="nump">$ 46,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda | License and Co-Funding Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctBundle', window );">Number of distinct bundle | bundle</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda | License and Co-Funding Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales', window );">Percentage of eligible to receive tiered royalties on net sales</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember', window );">Takeda | License and Co-Funding Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales', window );">Percentage of eligible to receive tiered royalties on net sales</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 527,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctBundle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct bundle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctBundle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of eligible to receive tiered royalties on net sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-40<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-41<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074429579600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)<br></strong></div></th>
<th class="th">
<div>Oct. 03, 2018 </div>
<div>USD ($) </div>
<div>bundle </div>
<div>obligation</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development, regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">866,000<span></span>
</td>
<td class="nump">$ 74,099,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember', window );">JJDC | Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderCollaborationAgreement', window );">Upfront payment</a></td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember', window );">JJDC | Common Stock Purchase Agreement | Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of future royalties</a></td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | Collaboration and License agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="nump">$ 73,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctBundle', window );">Number of distinct bundle | bundle</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfDistinctPerformanceObligations', window );">Number of distinct performance obligations | obligation</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 252,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | Collaboration and License agreements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments', window );">Development, regulatory and sales milestones payments</a></td>
<td class="nump">825,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_JanssenPharmaceuticalsIncorporationMember', window );">Janssen | JNJ-3989 Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentEarned', window );">Milestone payment</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivedAsDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received as due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivedAsDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment earned.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctBundle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct bundle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctBundle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfDistinctPerformanceObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of distinct performance obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfDistinctPerformanceObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_CollaborationAndLicenseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_CommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arwr_CommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_JanssenPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_JanssenPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_JNJ3989AROHBVAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_JNJ3989AROHBVAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074432606960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration and License Agreements - Amgen, Inc. (Details)<br></strong></div></th>
<th class="th">
<div>Sep. 28, 2016 </div>
<div>USD ($) </div>
<div>agreement</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 866,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,099,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember', window );">Amgen | Olpasiran Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfAgreements', window );">Number of agreements | agreement</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderCollaborationAgreement', window );">Upfront payment</a></td>
<td class="nump">$ 35,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of future royalties</a></td>
<td class="nump">$ 21,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceived', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000<span></span>
</td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Contract assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember', window );">Amgen | Olpasiran Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments', window );">Additional remaining development regulatory and sales milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 535,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional remaining development regulatory and sales milestones payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivedAsDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received as due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivedAsDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payment received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074429084656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 25, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Proceeds from upfront capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_VisirnaTherapeuticsIncMember', window );">Visirna Therapeutics, Inc. | Variable Interest Entity, Primary Beneficiary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Proceeds from upfront capital</a></td>
<td class="nump">$ 60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received by a corporation from a shareholder during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_VisirnaTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_VisirnaTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidatedEntitiesAxis=us-gaap_VariableInterestEntityPrimaryBeneficiaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074432711136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Summary of Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross', window );">Computers, software, office equipment and furniture</a></td>
<td class="nump">$ 2,240,000<span></span>
</td>
<td class="nump">$ 2,182,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Land', window );">Land</a></td>
<td class="nump">2,996,000<span></span>
</td>
<td class="nump">2,996,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ResearchEquipmentGross', window );">Research equipment</a></td>
<td class="nump">56,509,000<span></span>
</td>
<td class="nump">38,283,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">103,813,000<span></span>
</td>
<td class="nump">42,017,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="nump">166,655,000<span></span>
</td>
<td class="nump">56,373,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total gross fixed assets</a></td>
<td class="nump">332,213,000<span></span>
</td>
<td class="nump">141,851,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(41,951,000)<span></span>
</td>
<td class="num">(31,554,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 290,262,000<span></span>
</td>
<td class="nump">$ 110,297,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Computers, software, office equipment and furniture gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ResearchEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research equipment gross.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ResearchEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Land">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depletion of real estate held for productive use, excluding land held for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Land</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480842/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074433050336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense for property and equipment</a></td>
<td class="nump">$ 10.7<span></span>
</td>
<td class="nump">$ 8.7<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074429725952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Short-term investments, Available-for-sale, Adjusted Basis</a></td>
<td class="nump">$ 295,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent', window );">Short-term investments, Available-for-sale, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent', window );">Short-term investments, Available-for-sale, Gross Unrealized Losses</a></td>
<td class="num">(2,964)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, Available-for-sale, Fair Value</a></td>
<td class="nump">292,735<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Marketable debt securities, Adjusted Basis</a></td>
<td class="nump">295,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeReclassificationAdjustmentForHeldToMaturityTransferredToAvailableForSaleSecuritiesBeforeTax', window );">Net unrealized gain (loss) on held-to-maturity securities</a></td>
<td class="num">(3,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short-term investments, Held to maturity, Adjusted Bases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">268,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent', window );">Short-term investments, Held to maturity, Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent', window );">Short-term investments, Held to maturity, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,661)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent', window );">Short-term investments, Held to maturity, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,730<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Long-term investments, Held to maturity, Adjusted Basis</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">105,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent', window );">Long-term investments, Held to maturity, Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent', window );">Long-term investments, Held to maturity, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,569)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent', window );">Long-term investments, Held to maturity, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent', window );">Short-term investments, Available-for-sale, Adjusted Basis</a></td>
<td class="nump">295,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent', window );">Short-term investments, Available-for-sale, Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent', window );">Short-term investments, Available-for-sale, Gross Unrealized Losses</a></td>
<td class="num">(2,964)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term investments, Available-for-sale, Fair Value</a></td>
<td class="nump">$ 292,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short-term investments, Held to maturity, Adjusted Bases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">218,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent', window );">Short-term investments, Held to maturity, Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent', window );">Short-term investments, Held to maturity, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,661)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent', window );">Short-term investments, Held to maturity, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">214,730<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Long-term investments, Held to maturity, Adjusted Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,872<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent', window );">Long-term investments, Held to maturity, Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent', window );">Long-term investments, Held to maturity, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,569)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent', window );">Long-term investments, Held to maturity, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,303<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems', window );"><strong>Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Short-term investments, Held to maturity, Adjusted Bases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent', window );">Short-term investments, Held to maturity, Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent', window );">Short-term investments, Held to maturity, Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent', window );">Short-term investments, Held to maturity, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of held to maturity securities and marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 326<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479344/326-20-45-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeReclassificationAdjustmentForHeldToMaturityTransferredToAvailableForSaleSecuritiesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustment, of unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeReclassificationAdjustmentForHeldToMaturityTransferredToAvailableForSaleSecuritiesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074427414384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets - Schedule of Intangible Assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 10,262,000<span></span>
</td>
<td class="nump">$ 11,962,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="nump">1,700,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">24,857,000<span></span>
</td>
<td class="nump">24,857,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">14,595,000<span></span>
</td>
<td class="nump">12,895,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">10,262,000<span></span>
</td>
<td class="nump">11,962,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis | Patents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">21,728,000<span></span>
</td>
<td class="nump">21,728,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">13,321,000<span></span>
</td>
<td class="nump">11,770,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 8,407,000<span></span>
</td>
<td class="nump">$ 9,958,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Lives</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember', window );">Novartis | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Gross Carrying Amount</a></td>
<td class="nump">$ 3,129,000<span></span>
</td>
<td class="nump">$ 3,129,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">1,274,000<span></span>
</td>
<td class="nump">1,125,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_FiniteLivedIntangibleAssetsImpairment', window );">Impairment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 1,855,000<span></span>
</td>
<td class="nump">$ 2,004,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Useful Lives</a></td>
<td class="text">21 years<span></span>
</td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_FiniteLivedIntangibleAssetsImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Finite-Lived Intangible Assets, Impairment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_FiniteLivedIntangibleAssetsImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 928<br> -SubTopic 340<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483147/928-340-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=arwr_NovartisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=arwr_NovartisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074426677600">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets - Expected Future Amortization (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2025</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2026</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2027</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2028</a></td>
<td class="nump">1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive', window );">Thereafter</a></td>
<td class="nump">1,762,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net Carrying Amount</a></td>
<td class="nump">$ 10,262,000<span></span>
</td>
<td class="nump">$ 11,962,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483154/926-20-50-5<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074433140608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 02, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Mar. 16, 2023</div></th>
<th class="th"><div>Mar. 15, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">290,000,000<span></span>
</td>
<td class="nump">290,000,000<span></span>
</td>
<td class="nump">145,000,000<span></span>
</td>
<td class="nump">145,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,960,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,312,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,960,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember', window );">ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember', window );">ATM Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance', window );">Common stock shares value reserved for future issuance</a></td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock', window );">Percentage of commission to sales agent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember', window );">2004 Equity Incentive Plan, 2013 Equity Incentive Plan, 2021 Equity Incentive Plan and Inducement Grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock reserved for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,709,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,392<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CommonStockCapitalSharesValueReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock, capital shares value reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CommonStockCapitalSharesValueReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission on aggregate gross proceeds from sale of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-13<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074425800336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br> ft&#178; in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 20, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>a</div>
</th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Contingent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,655,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,373,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_TaxIncrementFinancingAward', window );">Tax increment financing award</a></td>
<td class="nump">$ 16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement', window );">Maximum state income tax credits under agreement</a></td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCredits', window );">State income tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsAxis=arwr_TechnologyLicenseCommitmentsMember', window );">Technology License Commitments | ARO-ENaC and ARO-HIF2 Candidates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePayments', window );">Milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_VeronaTechnologyParkMember', window );">Verona Technology Park | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfAcresOfLandPurchased', window );">Land purchased (in acres) | a</a></td>
<td class="nump">13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember', window );">Drug Manufacturing Facility | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Planned area of site (in sq ft) | ft&#178;</a></td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember', window );">Laboratory And Office Facility | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Planned area of site (in sq ft) | ft&#178;</a></td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember', window );">Facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConstructionInProgressGross', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">166,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember', window );">Facilities | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AmountIntendedToInvestForBuildoutOfFacilities', window );">Amount intended to invest for buildout of facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">120,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember', window );">Facilities | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherCommitmentsLineItems', window );"><strong>Other Commitments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AmountIntendedToInvestForBuildoutOfFacilities', window );">Amount intended to invest for buildout of facilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 130,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AmountIntendedToInvestForBuildoutOfFacilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount intends to invest for buildout of facilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AmountIntendedToInvestForBuildoutOfFacilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone payments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfAcresOfLandPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of acres of land purchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfAcresOfLandPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_TaxIncrementFinancingAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Increment Financing Award</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_TaxIncrementFinancingAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Increment Financing Award, Maximum State Income Tax Credits Under Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConstructionInProgressGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConstructionInProgressGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=arwr_TechnologyLicenseCommitmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=arwr_TechnologyLicenseCommitmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_AROENacAndAROHIF2CandidatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_AROENacAndAROHIF2CandidatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_VeronaTechnologyParkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_VeronaTechnologyParkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074432638128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>option</div>
</th>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 25, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 23, 2022</div></th>
<th class="th">
<div>Nov. 19, 2021 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>option</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost | $</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember', window );">Research Facility in San Diego | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MaximumAdditionalTenantImprovementAllowance', window );">Maximum additional tenant improvement allowance | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum', window );">Interest per annum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_AdditionalTenantImprovementAllowanceLiability', window );">Additional tenant improvement allowance liability | $</a></td>
<td class="nump">$ 27.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember', window );">Research Facility in San Diego | California | Sorrento Valley Owner (DE) LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember', window );">Research Facility in San Diego | California | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember', window );">Corporate Headquarters In Pasadena | California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="nump">49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember', window );">Corporate Headquarters In Pasadena | California | Colorado Owner, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | option</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember', window );">Research Facility in Madison | Wisconsin</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Office space leases (in sq ft) | ft&#178;</a></td>
<td class="nump">115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NumberOfOptionsToRenew', window );">Number of options to renew | option</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Operating lease renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Tenant Improvement Allowance, Interest Per Annum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_AdditionalTenantImprovementAllowanceLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Additional Tenant Improvement Allowance Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_AdditionalTenantImprovementAllowanceLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MaximumAdditionalTenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Additional Tenant Improvement Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MaximumAdditionalTenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NumberOfOptionsToRenew">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options to renew.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NumberOfOptionsToRenew</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_SorrentoValleyOwnerDELLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_SorrentoValleyOwnerDELLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arwr_ColoradoOwnerLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arwr_ColoradoOwnerLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_WI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_WI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074429026272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract', window );"><strong>Lease Assets and Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right-of-use assets</a></td>
<td class="nump">$ 45,297<span></span>
</td>
<td class="nump">$ 58,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities</a></td>
<td class="nump">10,563<span></span>
</td>
<td class="nump">2,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, net of current portion</a></td>
<td class="nump">104,608<span></span>
</td>
<td class="nump">78,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total</a></td>
<td class="nump">13,259<span></span>
</td>
<td class="nump">9,763<span></span>
</td>
<td class="nump">$ 5,962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">10,350<span></span>
</td>
<td class="nump">7,278<span></span>
</td>
<td class="nump">3,649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">1,179<span></span>
</td>
<td class="nump">728<span></span>
</td>
<td class="nump">814<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">1,730<span></span>
</td>
<td class="nump">1,757<span></span>
</td>
<td class="nump">1,498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAndLiabilitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAndLiabilitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074432608400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">$ 10,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">15,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">15,341<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">14,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2028</a></td>
<td class="nump">13,156<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">2029 and thereafter</a></td>
<td class="nump">124,951<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total</a></td>
<td class="nump">193,697<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(78,526)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 115,171<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074435692368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Supplemental Cash Flow and Other Information Related to Leases (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash received for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 48,391<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for amended operating lease liabilities</a></td>
<td class="nump">17,071<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 5,204<span></span>
</td>
<td class="nump">$ 4,500<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term (in years)</a></td>
<td class="text">13 years 6 months<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">8 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">8.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Cash Received For Amounts Included In Measurement Of Lease Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowOperatingActivitiesLesseeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowOperatingActivitiesLesseeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074427276848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 08, 2022</div></th>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Mar. 18, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,204,720<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.2<span></span>
</td>
<td class="nump">$ 27.6<span></span>
</td>
<td class="nump">$ 66.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.4<span></span>
</td>
<td class="nump">10.8<span></span>
</td>
<td class="nump">12.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized pre-tax compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize pre-tax compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 69.7<span></span>
</td>
<td class="nump">$ 113.6<span></span>
</td>
<td class="nump">$ 64.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period to recognize pre-tax compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,243,644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,241,640<span></span>
</td>
<td class="nump">4,069,931<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized pre-tax compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">99,521<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=arwr_RestrictedStockUnitsMarketBasedMember', window );">Restricted Stock Units, Market-Based | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue', window );">Equity award value</a></td>
<td class="nump">$ 38.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=arwr_RestrictedStockUnitsPerformanceBasedMember', window );">Performance-Based Restricted Stock Units | Chief Executive Officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">149,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember', window );">2004 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember', window );">2004 Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,408,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">217,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,886,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,979,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Plan | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,671,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_OutsideOfEquityCompensationPlansMember', window );">Outside Of Equity Compensation Plans | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">707,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_OutsideOfEquityCompensationPlansMember', window );">Outside Of Equity Compensation Plans | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserve for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">683,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Granted in Period, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=arwr_RestrictedStockUnitsMarketBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=arwr_RestrictedStockUnitsMarketBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=arwr_RestrictedStockUnitsPerformanceBasedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=arwr_RestrictedStockUnitsPerformanceBasedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_OutsideOfEquityCompensationPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_OutsideOfEquityCompensationPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074433978016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details) - shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options (in shares)</a></td>
<td class="nump">2,263,477<span></span>
</td>
<td class="nump">2,721,384<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">6,505,117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember', window );">2004 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember', window );">2013 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options (in shares)</a></td>
<td class="nump">1,522,207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">3,408,707<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember', window );">2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options (in shares)</a></td>
<td class="nump">33,838<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">1,705,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arwr_InducementAwardsMember', window );">Inducement Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options (in shares)</a></td>
<td class="nump">707,432<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding', window );">Total (in shares)</a></td>
<td class="nump">1,391,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">4,241,640<span></span>
</td>
<td class="nump">4,069,931<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | 2004 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | 2013 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">1,886,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | 2021 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">1,671,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) | Inducement Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Share-based payment award (in shares)</a></td>
<td class="nump">683,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsFourEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arwr_InducementAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arwr_InducementAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074432711088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summarize Information about Stock Options (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">2,721,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">32,151<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Cancelled (in shares) | shares</a></td>
<td class="num">(50,708)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(439,350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">2,263,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Options Outstanding, Exercisable (in shares) | shares</a></td>
<td class="nump">2,141,592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted- Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 20.73<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">33.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled (in dollars per share) | $ / shares</a></td>
<td class="nump">60.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">6.94<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">22.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 21.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contractual Term, Outstanding</a></td>
<td class="text">4 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contractual Term, Exercisable</a></td>
<td class="text">4 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding | $</a></td>
<td class="nump">$ 26,795,879<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Exercisable | $</a></td>
<td class="nump">$ 26,786,757<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481112/505-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074434131536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions Used to Value Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">3.69%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">4.57%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
<td class="nump">86.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Volatility, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Volatility, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value per share</a></td>
<td class="nump">$ 25.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 48.64<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074433108176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of RSUs Activity (Details) - Restricted Stock Units (RSUs)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of RSUs</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning of period (in shares) | shares</a></td>
<td class="nump">4,069,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares) | shares</a></td>
<td class="nump">1,243,644<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares) | shares</a></td>
<td class="num">(913,146)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(158,789)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">End of period (in shares) | shares</a></td>
<td class="nump">4,241,640<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted- Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 64.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">34.32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share) | $ / shares</a></td>
<td class="nump">52.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">53.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 58.43<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074428870416">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - Fair Value, Measurements, Recurring - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">$ 292,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 365,033<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">293,082<span></span>
</td>
<td class="nump">404,295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market instruments</a></td>
<td class="nump">347<span></span>
</td>
<td class="nump">39,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">31,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">7,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">22,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">231,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">31,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,973<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">31,900<span></span>
</td>
<td class="nump">91,235<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market instruments</a></td>
<td class="nump">347<span></span>
</td>
<td class="nump">39,262<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">31,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1 | Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">261,182<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,060<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">261,182<span></span>
</td>
<td class="nump">313,060<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">7,093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">22,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,727<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">231,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,333<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2 | Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Money market instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market instruments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | U.S. government bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Municipal securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Commercial notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale debt securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3 | Certificate of deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481830/320-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479440/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481800/320-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074434143600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Components of Loss Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (194,639)<span></span>
</td>
<td class="num">$ (170,570)<span></span>
</td>
<td class="num">$ (140,846)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(7,852)<span></span>
</td>
<td class="num">(1,708)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossAttributableToParent', window );">Total</a></td>
<td class="num">$ (202,491)<span></span>
</td>
<td class="num">$ (172,278)<span></span>
</td>
<td class="num">$ (140,846)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.20)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074429184592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provisions for Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 1,074<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">1,710<span></span>
</td>
<td class="nump">304<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,481<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current tax</a></td>
<td class="nump">2,784<span></span>
</td>
<td class="nump">3,785<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision</a></td>
<td class="nump">$ 2,784<span></span>
</td>
<td class="nump">$ 3,785<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-9<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482659/740-20-45-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074434029696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal statutory income tax</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes, net of federal tax benefit</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">8.60%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">6.80%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Permanent and other items</a></td>
<td class="num">(4.60%)<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent', window );">Non-deductible compensation</a></td>
<td class="num">(4.60%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent', window );">Foreign-derived intangible income deduction</a></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(1.70%)<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(20.50%)<span></span>
</td>
<td class="num">(28.40%)<span></span>
</td>
<td class="num">(29.30%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="num">(1.40%)<span></span>
</td>
<td class="num">(2.20%)<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Compensation, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax benefit from difference to income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074438813712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 60,495,000<span></span>
</td>
<td class="nump">$ 171,319,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost', window );">Capitalized research and development</a></td>
<td class="nump">75,208,000<span></span>
</td>
<td class="nump">324,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">66,407,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">59,441,000<span></span>
</td>
<td class="nump">38,810,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">25,382,000<span></span>
</td>
<td class="nump">2,844,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">10,296,000<span></span>
</td>
<td class="nump">41,479,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits', window );">Accrued compensation</a></td>
<td class="nump">3,082,000<span></span>
</td>
<td class="nump">2,961,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">1,523,000<span></span>
</td>
<td class="nump">2,973,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">2,636,000<span></span>
</td>
<td class="nump">2,162,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total gross deferred tax assets</a></td>
<td class="nump">304,470,000<span></span>
</td>
<td class="nump">262,872,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(284,626,000)<span></span>
</td>
<td class="num">(242,394,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="num">(9,878,000)<span></span>
</td>
<td class="num">(1,088,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Right-of-use assets</a></td>
<td class="num">(9,966,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_DeferredTaxLiabilitiesStateTaxes', window );">State taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(19,390,000)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total gross deferred tax liability</a></td>
<td class="num">(19,844,000)<span></span>
</td>
<td class="num">(20,478,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets (liabilities)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets right of use assets/ lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_DeferredTaxLiabilitiesStateTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from state tax deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_DeferredTaxLiabilitiesStateTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479853/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-6<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074432167584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 284,626<span></span>
</td>
<td class="nump">$ 242,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Income tax expense related to uncertain tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 3,500<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Unrecognized tax benefits, interest accrued</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued', window );">Unrecognized tax benefits, penalties accrued</a></td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits that would impact effective tax rate</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit', window );">Change in unrecognized tax benefits expected</a></td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">134,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OperatingLossCarryforwardsSubjectToExpiration', window );">Operating loss carryforwards subject to expiration</a></td>
<td class="nump">34,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carryforwards not subject to expiration</a></td>
<td class="nump">100,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Operating Loss Carryforwards [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">491,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_OperatingLossCarryforwardsNotSubjectToExpiration', window );">Operating loss carryforwards not subject to expiration</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_OperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Not Subject To Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_OperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_OperatingLossCarryforwardsSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Loss Carryforwards, Subject To Expiration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_OperatingLossCarryforwardsSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of statutory penalties accrued for a tax position claimed or expected to be claimed by the entity, in its tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074433596768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Gross Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance of unrecognized tax benefits</a></td>
<td class="nump">$ 3,481<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Gross increase for prior period tax positions</a></td>
<td class="nump">9,495<span></span>
</td>
<td class="nump">3,481<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Gross decrease for prior period tax positions</a></td>
<td class="num">(1,489)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Gross increase for current period tax positions</a></td>
<td class="nump">3,049<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance of unrecognized tax benefits</a></td>
<td class="nump">$ 14,536<span></span>
</td>
<td class="nump">$ 3,481<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074429567120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Employee benefits costs</a></td>
<td class="nump">$ 2.2<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionsUpToThreePercentMember', window );">Employee Contributions up to 3%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Discretionary match percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of compensation</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionNextTwoPercentMember', window );">Employee Contributions Next 2%</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Discretionary match percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Percentage of compensation</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionsUpToThreePercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionsUpToThreePercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionNextTwoPercentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=arwr_EmployeeContributionNextTwoPercentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074426713584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liability Related to the Sale of Future Royalties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 09, 2022</div></th>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties', window );">Non-cash interest expense on liability related to the sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,326<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember', window );">Royalty Pharma Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_CashReceivedAsDueUnderCollaborationAgreement', window );">Upfront payment</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivable', window );">Milestone payment receivable</a></td>
<td class="nump">160,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial', window );">Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponFDAApproval', window );">Milestone payment receivable upon FDA approval</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments', window );">Milestone payment receivable upon receipt of royalty payments</a></td>
<td class="nump">60,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_RoyaltyPaymentThreshold', window );">Royalty payment threshold</a></td>
<td class="nump">70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties', window );">Non-cash interest expense on liability related to the sale of future royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember', window );">Royalty Pharma Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arwr_InitialTransactionPrice', window );">Initial transaction price</a></td>
<td class="nump">$ 410,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_CashReceivedAsDueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received as due under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_CashReceivedAsDueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_InitialTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Initial transaction price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_InitialTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable Upon Achievement of Enrollment in Phase 3 Clinical Trial</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponFDAApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable Upon FDA Approval</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponFDAApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Milestone Payment Receivable, Upon Receipt Of Royalty Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Non-Cash Interest Expense, Liability Related to Sale of Future Royalties</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arwr_RoyaltyPaymentThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Payment Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arwr_RoyaltyPaymentThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arwr_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140074438796880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2023</div></th>
<th class="th"><div>Sep. 30, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss attributable to Arrowhead Pharmaceuticals, Inc.</a></td>
<td class="num">$ (205,275)<span></span>
</td>
<td class="num">$ (176,063)<span></span>
</td>
<td class="num">$ (140,848)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average basic shares outstanding (in shares)</a></td>
<td class="nump">106,750<span></span>
</td>
<td class="nump">105,426<span></span>
</td>
<td class="nump">103,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average diluted shares outstanding (in shares)</a></td>
<td class="nump">106,750<span></span>
</td>
<td class="nump">105,426<span></span>
</td>
<td class="nump">103,745<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (1.92)<span></span>
</td>
<td class="num">$ (1.67)<span></span>
</td>
<td class="num">$ (1.36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (1.92)<span></span>
</td>
<td class="num">$ (1.67)<span></span>
</td>
<td class="num">$ (1.36)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potentially dilutive securities excluded from computation of diluted earnings per share (in shares)</a></td>
<td class="nump">4,053<span></span>
</td>
<td class="nump">3,885<span></span>
</td>
<td class="nump">2,063<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-15<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-7<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482635/260-10-55-52<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482765/220-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-8<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-11<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483443/250-10-50-4<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480167/946-830-55-10<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483581/946-220-45-7<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-22<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-30<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-31<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482810/280-10-50-32<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483499/205-20-50-7<br><br>Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B<br><br>Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2<br><br>Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org//1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>arwr-20230930_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:arwr="http://www.arrowheadresearch.com/20230930"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2023"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2023"
  xmlns:us-gaap="http://fasb.org/us-gaap/2023"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="arwr-20230930.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2023-11-20</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:MauroFerrariMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:MauroFerrariMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:DouglassGivenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:DouglassGivenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:JamesHamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:JamesHamiltonTerminatedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:JamesHamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:JamesHamiltonTerminatedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:JamesHamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:JamesHamiltonAugust2023PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:JamesHamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:JamesHamiltonAugust2023PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:PatrickOBrienMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:PatrickOBrienMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:TracieOliverMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:TracieOliverMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:VictoriaVakienerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:VictoriaVakienerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:WilliamWaddillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:WilliamWaddillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:MauroFerrariMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:DouglassGivenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:JamesHamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:JamesHamiltonTerminatedPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:JamesHamiltonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:TradingArrAxis">arwr:JamesHamiltonAugust2023PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:KenMyszkowskiMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:PatrickOBrienMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:TracieOliverMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:VictoriaVakienerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:IndividualAxis">arwr:WilliamWaddillMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2020-09-30</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-09</startDate>
            <endDate>2022-11-09</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-22</startDate>
            <endDate>2021-11-22</endDate>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-22</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-22</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:GlaxosmithklineIntellectualPropertyLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:HorizonLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-18</startDate>
            <endDate>2021-06-18</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:HorizonLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:HorizonLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:HorizonLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:HorizonTherapeuticsIrelandDACMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:HorizonLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-07</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-07</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-07</startDate>
            <endDate>2020-10-07</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:LicenseAndCoFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:JohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:JohnsonAndJohnsonInnovationJJDCIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-03</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-03</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:CollaborationAndLicenseAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-03</startDate>
            <endDate>2018-10-03</endDate>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-03</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:JanssenPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:JNJ3989AROHBVAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-28</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-28</startDate>
            <endDate>2016-09-28</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-31</instant>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:AmgenIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:OlpasiranAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidatedEntitiesAxis">us-gaap:VariableInterestEntityPrimaryBeneficiaryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:VisirnaTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-25</startDate>
            <endDate>2022-04-25</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:PatentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">arwr:NovartisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2023-03-16</instant>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2023-03-15</instant>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-02</instant>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-02</startDate>
            <endDate>2022-12-02</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arwr:AtTheMarketAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:VeronaTechnologyParkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-20</startDate>
            <endDate>2021-12-20</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:DrugManufacturingFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:LaboratoryAndOfficeFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:FacilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <instant>2021-12-20</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
        </entity>
        <period>
            <startDate>2021-12-20</startDate>
            <endDate>2021-12-20</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">arwr:TechnologyLicenseCommitmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:AROENacAndAROHIF2CandidatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-19</instant>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-25</instant>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:ColoradoOwnerLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:CorporateHeadquartersInPasadenaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arwr:SorrentoValleyOwnerDELLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CA</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInSanDiegoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-23</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:WI</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arwr:ResearchFacilityInMadisonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-18</instant>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:OutsideOfEquityCompensationPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:OutsideOfEquityCompensationPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsFourEquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandsThirteenIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:TwoThousandTwentyOneIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arwr:InducementAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arwr:RestrictedStockUnitsMarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arwr:RestrictedStockUnitsMarketBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-08</startDate>
            <endDate>2022-07-08</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-08</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">arwr:RestrictedStockUnitsPerformanceBasedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-07-08</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">arwr:CommercialNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-235">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-236">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-237">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-238">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-239">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-240">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-30</instant>
        </period>
    </context>
    <context id="c-241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-09-30</instant>
        </period>
    </context>
    <context id="c-243">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">arwr:EmployeeContributionsUpToThreePercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-244">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">arwr:EmployeeContributionNextTwoPercentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <context id="c-245">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-11-09</startDate>
            <endDate>2022-11-09</endDate>
        </period>
    </context>
    <context id="c-246">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-11-09</instant>
        </period>
    </context>
    <context id="c-247">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000879407</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arwr:RoyaltyPharmaAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-01</startDate>
            <endDate>2023-09-30</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="obligation">
        <measure>arwr:obligation</measure>
    </unit>
    <unit id="bundle">
        <measure>arwr:bundle</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="agreement">
        <measure>arwr:agreement</measure>
    </unit>
    <unit id="acre">
        <measure>utr:acre</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="option">
        <measure>arwr:option</measure>
    </unit>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-33">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-34">FY</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-35">0000879407</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-36">false</dei:AmendmentFlag>
    <ecd:TrdArrDuration contextRef="c-22" id="f-85">P20D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-23" id="f-86">P20D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-24" id="f-87">P28D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-25" id="f-88">P364D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-26" id="f-89">P26D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-27" id="f-90">P2D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-28" id="f-91">P208D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-29" id="f-92">P141D</ecd:TrdArrDuration>
    <ecd:TrdArrDuration contextRef="c-30" id="f-93">P20D</ecd:TrdArrDuration>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-75" id="f-426">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-154" id="f-669">P5Y0M0D</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2023-09-30</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--09-30</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-38042</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">ARROWHEAD PHARMACEUTICALS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">46-0408024</dei:EntityTaxIdentificationNumber>
    <dei:CityAreaCode contextRef="c-1" id="f-10">626</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-11">304-3400</dei:LocalPhoneNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-12">177 E. Colorado Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-13">Suite 700</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-14">Pasadena</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-15">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-16">91105</dei:EntityAddressPostalZipCode>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">ARWR</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-20">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-24">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-25">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-26">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-27">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-28">false</dei:EntityShellCompany>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-29">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-8" id="f-30" unitRef="usd">2300000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-31" unitRef="shares">107432210</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-32">&lt;div style="margin-top:6pt;text-indent:30.6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:7pt;font-weight:400;line-height:120%"&gt;Portions of the Definitive Proxy Statement to be filed for Arrowhead Pharmaceuticals Inc.&#x2019;s 2024 Annual Meeting of Stockholders are incorporated by reference into Part III hereof.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-1" id="f-37">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-1" id="f-38">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:MtrlTermsOfTrdArrTextBlock contextRef="c-1" id="f-39">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the quarter ended September&#160;30, 2023, the following directors and officers (as defined in Exchange Act Rule 16a-1(f)) adopted certain trading plans intended to satisfy Rule 10b5-1(c):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.242%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.014%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.410%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.335%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.410%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.823%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.410%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.365%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.410%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.365%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.410%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.365%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.410%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.373%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:28pt"&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Title&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Adoption or Termination Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Plan Start Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Plan End Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Shares Vesting and Subject to Sell-To-Cover &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:114%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Other Shares Being Sold (Subject to Certain Conditions)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:30pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%"&gt;Mauro Ferrari&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Board Member&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;09/28/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;01/11/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;01/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;3,147&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%"&gt;Douglass Given&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Board Member&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;09/26/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;01/11/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;01/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;2,911&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%"&gt;James Hamilton &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.52pt;font-weight:400;line-height:114%;position:relative;top:-2.97pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Chief Discovery and Translational Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;08/15/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;01/03/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;01/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;52,500&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%"&gt;James Hamilton&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Chief Discovery and Translational Medicine&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;08/22/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;12/01/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;11/29/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;35,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%"&gt;Ken Myszkowski&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Chief Financial Officer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;09/07/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;01/05/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;01/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;30,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%"&gt;Patrick O&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2019;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%"&gt;Brien&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Chief Operating Officer and General Counsel&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;09/03/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;01/03/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;01/05/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;4,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%"&gt;Tracie Oliver&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Chief Commercial Officer&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;08/28/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;01/05/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;07/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;17,625&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%"&gt;Victoria Vakiener&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Board Member&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;09/28/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;01/11/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;05/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;6,519&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:114%"&gt;William Waddill&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;Board Member&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;08/29/2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;01/11/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;01/31/2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;n/a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8.5pt;font-weight:400;line-height:120%"&gt;3,934&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) This column indicates the total number of shares vesting, but the 10b5-1 Plan provides for the sale of only those shares necessary to satisfy payment of applicable withholding taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(2) Termination of a trading plan that was intended to satisfy Rule 10b5-1(c).&lt;/span&gt;&lt;/div&gt;</ecd:MtrlTermsOfTrdArrTextBlock>
    <ecd:TrdArrIndName contextRef="c-4" id="f-40">Mauro Ferrari</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-4" id="f-41">Board Member</ecd:TrdArrIndTitle>
    <ecd:TrdArrAdoptionDate contextRef="c-4" id="f-42">09/28/2023</ecd:TrdArrAdoptionDate>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-4" id="f-43">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-5" decimals="INF" id="f-44" unitRef="shares">3147</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-6" id="f-45">Douglass Given</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-6" id="f-46">Board Member</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-6" id="f-47">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-6" id="f-48">09/26/2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-7" decimals="INF" id="f-49" unitRef="shares">2911</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndTitle contextRef="c-8" id="f-50">Chief Discovery and Translational Medicine</ecd:TrdArrIndTitle>
    <ecd:TrdArrTerminationDate contextRef="c-8" id="f-51">08/15/2023</ecd:TrdArrTerminationDate>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-9" decimals="INF" id="f-52" unitRef="shares">52500</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-10" id="f-53">James Hamilton</ecd:TrdArrIndName>
    <ecd:TrdArrIndName contextRef="c-8" id="f-54">James Hamilton</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-10" id="f-55">Chief Discovery and Translational Medicine</ecd:TrdArrIndTitle>
    <ecd:TrdArrAdoptionDate contextRef="c-10" id="f-56">08/22/2023</ecd:TrdArrAdoptionDate>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-10" id="f-57">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-11" decimals="INF" id="f-58" unitRef="shares">35000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-12" id="f-59">Ken Myszkowski</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-12" id="f-60">Chief Financial Officer</ecd:TrdArrIndTitle>
    <ecd:TrdArrAdoptionDate contextRef="c-12" id="f-61">09/07/2023</ecd:TrdArrAdoptionDate>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-12" id="f-62">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-13" decimals="INF" id="f-63" unitRef="shares">30000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-14" id="f-64">Patrick O&#x2019;Brien</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-14" id="f-65">Chief Operating Officer and General Counsel</ecd:TrdArrIndTitle>
    <ecd:TrdArrAdoptionDate contextRef="c-14" id="f-66">09/03/2023</ecd:TrdArrAdoptionDate>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-14" id="f-67">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-15" decimals="INF" id="f-68" unitRef="shares">4000</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-16" id="f-69">Tracie Oliver</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-16" id="f-70">Chief Commercial Officer</ecd:TrdArrIndTitle>
    <ecd:TrdArrAdoptionDate contextRef="c-16" id="f-71">08/28/2023</ecd:TrdArrAdoptionDate>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-16" id="f-72">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-17" decimals="INF" id="f-73" unitRef="shares">17625</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-18" id="f-74">Victoria Vakiener</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-18" id="f-75">Board Member</ecd:TrdArrIndTitle>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-18" id="f-76">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrAdoptionDate contextRef="c-18" id="f-77">09/28/2023</ecd:TrdArrAdoptionDate>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-19" decimals="INF" id="f-78" unitRef="shares">6519</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:TrdArrIndName contextRef="c-20" id="f-79">William Waddill</ecd:TrdArrIndName>
    <ecd:TrdArrIndTitle contextRef="c-20" id="f-80">Board Member</ecd:TrdArrIndTitle>
    <ecd:TrdArrAdoptionDate contextRef="c-20" id="f-81">08/29/2023</ecd:TrdArrAdoptionDate>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-20" id="f-82">true</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:TrdArrSecuritiesAggAvailAmt contextRef="c-21" decimals="INF" id="f-83" unitRef="shares">3934</ecd:TrdArrSecuritiesAggAvailAmt>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-8" id="f-84">true</ecd:Rule10b51ArrTrmntdFlag>
    <dei:AuditorFirmId contextRef="c-1" id="f-94">468</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-95">Rose, Snyder &amp; Jacobs LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-96">Encino, California</dei:AuditorLocation>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-31" decimals="-3" id="f-97" unitRef="usd">110891000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-32" decimals="-3" id="f-98" unitRef="usd">108005000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-31" decimals="-3" id="f-99" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-32" decimals="-3" id="f-100" unitRef="usd">1410000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-31" decimals="-3" id="f-101" unitRef="usd">292735000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-32" decimals="-3" id="f-102" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent contextRef="c-31" decimals="-3" id="f-103" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent contextRef="c-32" decimals="-3" id="f-104" unitRef="usd">268391000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-31" decimals="-3" id="f-105" unitRef="usd">8813000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-32" decimals="-3" id="f-106" unitRef="usd">7289000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-31" decimals="-3" id="f-107" unitRef="usd">7082000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-32" decimals="-3" id="f-108" unitRef="usd">20204000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-31" decimals="-3" id="f-109" unitRef="usd">419521000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-32" decimals="-3" id="f-110" unitRef="usd">405299000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-31" decimals="-3" id="f-111" unitRef="usd">290262000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-32" decimals="-3" id="f-112" unitRef="usd">110297000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-31" decimals="-3" id="f-113" unitRef="usd">10262000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-32" decimals="-3" id="f-114" unitRef="usd">11962000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent contextRef="c-31" decimals="-3" id="f-115" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent contextRef="c-32" decimals="-3" id="f-116" unitRef="usd">105872000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-31" decimals="-3" id="f-117" unitRef="usd">45297000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-32" decimals="-3" id="f-118" unitRef="usd">58291000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-31" decimals="-3" id="f-119" unitRef="usd">210000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-32" decimals="-3" id="f-120" unitRef="usd">218000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-31" decimals="-3" id="f-121" unitRef="usd">765552000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-32" decimals="-3" id="f-122" unitRef="usd">691939000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="c-31" decimals="-3" id="f-123" unitRef="usd">35866000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-32" decimals="-3" id="f-124" unitRef="usd">2868000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-31" decimals="-3" id="f-125" unitRef="usd">39763000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-32" decimals="-3" id="f-126" unitRef="usd">46856000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-31" decimals="-3" id="f-127" unitRef="usd">17963000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-32" decimals="-3" id="f-128" unitRef="usd">12251000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-31" decimals="-3" id="f-129" unitRef="usd">10563000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-32" decimals="-3" id="f-130" unitRef="usd">2776000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-31" decimals="-3" id="f-131" unitRef="usd">866000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-32" decimals="-3" id="f-132" unitRef="usd">74099000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-31" decimals="-3" id="f-133" unitRef="usd">435000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-32" decimals="-3" id="f-134" unitRef="usd">0</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-31" decimals="-3" id="f-135" unitRef="usd">105456000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-32" decimals="-3" id="f-136" unitRef="usd">138850000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-31" decimals="-3" id="f-137" unitRef="usd">104608000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-32" decimals="-3" id="f-138" unitRef="usd">78800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-31" decimals="-3" id="f-139" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-32" decimals="-3" id="f-140" unitRef="usd">55950000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <arwr:RoyaltiesLiabilityNoncurrent contextRef="c-31" decimals="-3" id="f-141" unitRef="usd">268326000</arwr:RoyaltiesLiabilityNoncurrent>
    <arwr:RoyaltiesLiabilityNoncurrent contextRef="c-32" decimals="-3" id="f-142" unitRef="usd">0</arwr:RoyaltiesLiabilityNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-31" decimals="-3" id="f-143" unitRef="usd">372934000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="c-32" decimals="-3" id="f-144" unitRef="usd">134750000</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingencies contextRef="c-31" id="f-145" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-32" id="f-146" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-31"
      decimals="INF"
      id="f-147"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-32"
      decimals="INF"
      id="f-148"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-31"
      decimals="INF"
      id="f-149"
      unitRef="shares">290000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-31" decimals="-3" id="f-150" unitRef="shares">107312000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-31" decimals="-3" id="f-151" unitRef="shares">107312000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-32" decimals="-3" id="f-152" unitRef="shares">105960000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-32" decimals="-3" id="f-153" unitRef="shares">105960000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="c-31" decimals="-3" id="f-154" unitRef="usd">200000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-32" decimals="-3" id="f-155" unitRef="usd">198000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-31" decimals="-3" id="f-156" unitRef="usd">1300395000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-32" decimals="-3" id="f-157" unitRef="usd">1219213000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-31" decimals="-3" id="f-158" unitRef="usd">-3222000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-32" decimals="-3" id="f-159" unitRef="usd">-136000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-31" decimals="-3" id="f-160" unitRef="usd">-1026030000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-32" decimals="-3" id="f-161" unitRef="usd">-820755000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-3" id="f-162" unitRef="usd">271343000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-32" decimals="-3" id="f-163" unitRef="usd">398520000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest contextRef="c-31" decimals="-3" id="f-164" unitRef="usd">15819000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest contextRef="c-32" decimals="-3" id="f-165" unitRef="usd">19819000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-3" id="f-166" unitRef="usd">287162000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-3" id="f-167" unitRef="usd">418339000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-31" decimals="-3" id="f-168" unitRef="usd">765552000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-32" decimals="-3" id="f-169" unitRef="usd">691939000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-170" unitRef="usd">240735000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-33" decimals="-3" id="f-171" unitRef="usd">243231000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-34" decimals="-3" id="f-172" unitRef="usd">138287000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-1" decimals="-3" id="f-173" unitRef="usd">353188000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-33" decimals="-3" id="f-174" unitRef="usd">297307000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost contextRef="c-34" decimals="-3" id="f-175" unitRef="usd">206342000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-176" unitRef="usd">92549000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-33" decimals="-3" id="f-177" unitRef="usd">124431000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-34" decimals="-3" id="f-178" unitRef="usd">80981000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-179" unitRef="usd">445737000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-33" decimals="-3" id="f-180" unitRef="usd">421738000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-34" decimals="-3" id="f-181" unitRef="usd">287323000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-182" unitRef="usd">-205002000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-33" decimals="-3" id="f-183" unitRef="usd">-178507000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-34" decimals="-3" id="f-184" unitRef="usd">-149036000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-1" decimals="-3" id="f-185" unitRef="usd">15299000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-33" decimals="-3" id="f-186" unitRef="usd">5033000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InvestmentIncomeInterestAndDividend contextRef="c-34" decimals="-3" id="f-187" unitRef="usd">6120000</us-gaap:InvestmentIncomeInterestAndDividend>
    <us-gaap:InterestExpense contextRef="c-1" decimals="-3" id="f-188" unitRef="usd">18326000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-33" decimals="-3" id="f-189" unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="c-34" decimals="-3" id="f-190" unitRef="usd">0</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-191" unitRef="usd">1538000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-33" decimals="-3" id="f-192" unitRef="usd">765000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-34" decimals="-3" id="f-193" unitRef="usd">2070000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-3" id="f-194" unitRef="usd">-1489000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-33" decimals="-3" id="f-195" unitRef="usd">5798000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-34" decimals="-3" id="f-196" unitRef="usd">8190000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-197" unitRef="usd">-206491000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-33" decimals="-3" id="f-198" unitRef="usd">-172709000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-34" decimals="-3" id="f-199" unitRef="usd">-140846000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-200" unitRef="usd">2784000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-33" decimals="-3" id="f-201" unitRef="usd">3785000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-34" decimals="-3" id="f-202" unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-203" unitRef="usd">-209275000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-33" decimals="-3" id="f-204" unitRef="usd">-176494000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-34" decimals="-3" id="f-205" unitRef="usd">-140848000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-1" decimals="INF" id="f-206" unitRef="usd">-4000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-33" decimals="INF" id="f-207" unitRef="usd">-431000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest contextRef="c-34" decimals="INF" id="f-208" unitRef="usd">0</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-209" unitRef="usd">-205275000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-33" decimals="-3" id="f-210" unitRef="usd">-176063000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-34" decimals="-3" id="f-211" unitRef="usd">-140848000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-212"
      unitRef="usdPerShare">-1.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-33"
      decimals="2"
      id="f-213"
      unitRef="usdPerShare">-1.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-34"
      decimals="2"
      id="f-214"
      unitRef="usdPerShare">-1.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-215"
      unitRef="usdPerShare">-1.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-33"
      decimals="2"
      id="f-216"
      unitRef="usdPerShare">-1.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-34"
      decimals="2"
      id="f-217"
      unitRef="usdPerShare">-1.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-218" unitRef="shares">106750000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-33" decimals="-3" id="f-219" unitRef="shares">105426000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-34" decimals="-3" id="f-220" unitRef="shares">103745000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-221" unitRef="shares">106750000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-33" decimals="-3" id="f-222" unitRef="shares">105426000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-34" decimals="-3" id="f-223" unitRef="shares">103745000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-224" unitRef="usd">-2964000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-33" decimals="-3" id="f-225" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-34" decimals="-3" id="f-226" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-227" unitRef="usd">-122000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-33" decimals="-3" id="f-228" unitRef="usd">-67000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-34" decimals="-3" id="f-229" unitRef="usd">-87000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-230" unitRef="usd">-212361000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-33" decimals="-3" id="f-231" unitRef="usd">-176561000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest contextRef="c-34" decimals="-3" id="f-232" unitRef="usd">-140935000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding contextRef="c-35" decimals="-3" id="f-233" unitRef="shares">102376000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-35" decimals="-3" id="f-234" unitRef="usd">195000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-36" decimals="-3" id="f-235" unitRef="usd">965410000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-37" decimals="-3" id="f-236" unitRef="usd">18000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-38" decimals="-3" id="f-237" unitRef="usd">-503844000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-39" decimals="-3" id="f-238" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-40" decimals="-3" id="f-239" unitRef="usd">461779000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-41" decimals="-3" id="f-240" unitRef="usd">76673000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-34" decimals="-3" id="f-241" unitRef="usd">76673000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-42" decimals="-3" id="f-242" unitRef="shares">1052000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-42" decimals="-3" id="f-243" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-41" decimals="-3" id="f-244" unitRef="usd">11304000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-34" decimals="-3" id="f-245" unitRef="usd">11305000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-42" decimals="-3" id="f-246" unitRef="shares">899000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-42" decimals="-3" id="f-247" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-41" decimals="-3" id="f-248" unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-34" decimals="-3" id="f-249" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-43" decimals="-3" id="f-250" unitRef="usd">-87000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-34" decimals="-3" id="f-251" unitRef="usd">-87000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-44" decimals="-3" id="f-252" unitRef="usd">-140848000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-34" decimals="-3" id="f-253" unitRef="usd">-140848000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding contextRef="c-45" decimals="-3" id="f-254" unitRef="shares">104327000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-3" id="f-255" unitRef="usd">197000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-3" id="f-256" unitRef="usd">1053386000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-3" id="f-257" unitRef="usd">-69000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-48" decimals="-3" id="f-258" unitRef="usd">-644692000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-49" decimals="-3" id="f-259" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-50" decimals="-3" id="f-260" unitRef="usd">408822000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding contextRef="c-45" decimals="-3" id="f-261" unitRef="shares">104327000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-45" decimals="-3" id="f-262" unitRef="usd">197000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-46" decimals="-3" id="f-263" unitRef="usd">1053386000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-47" decimals="-3" id="f-264" unitRef="usd">-69000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-48" decimals="-3" id="f-265" unitRef="usd">-644692000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-49" decimals="-3" id="f-266" unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-50" decimals="-3" id="f-267" unitRef="usd">408822000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-51" decimals="-3" id="f-268" unitRef="usd">120893000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-33" decimals="-3" id="f-269" unitRef="usd">120893000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-52" decimals="-3" id="f-270" unitRef="shares">606000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-51" decimals="-3" id="f-271" unitRef="usd">5185000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-33" decimals="-3" id="f-272" unitRef="usd">5185000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-52" decimals="-3" id="f-273" unitRef="shares">1027000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-52" decimals="-3" id="f-274" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-51" decimals="-3" id="f-275" unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-33" decimals="-3" id="f-276" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-53" decimals="-3" id="f-277" unitRef="usd">-67000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-33" decimals="-3" id="f-278" unitRef="usd">-67000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="c-51" decimals="-3" id="f-279" unitRef="usd">39750000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="c-54" decimals="-3" id="f-280" unitRef="usd">20250000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance contextRef="c-33" decimals="-3" id="f-281" unitRef="usd">60000000</us-gaap:NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance>
    <us-gaap:ProfitLoss contextRef="c-55" decimals="-3" id="f-282" unitRef="usd">-176063000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-54" decimals="-3" id="f-283" unitRef="usd">-431000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-33" decimals="-3" id="f-284" unitRef="usd">-176494000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding contextRef="c-56" decimals="-3" id="f-285" unitRef="shares">105960000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-56" decimals="-3" id="f-286" unitRef="usd">198000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-57" decimals="-3" id="f-287" unitRef="usd">1219213000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-58" decimals="-3" id="f-288" unitRef="usd">-136000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-59" decimals="-3" id="f-289" unitRef="usd">-820755000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-60" decimals="-3" id="f-290" unitRef="usd">19819000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-3" id="f-291" unitRef="usd">418339000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesOutstanding contextRef="c-56" decimals="-3" id="f-292" unitRef="shares">105960000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-56" decimals="-3" id="f-293" unitRef="usd">198000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-57" decimals="-3" id="f-294" unitRef="usd">1219213000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-58" decimals="-3" id="f-295" unitRef="usd">-136000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-59" decimals="-3" id="f-296" unitRef="usd">-820755000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-60" decimals="-3" id="f-297" unitRef="usd">19819000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-32" decimals="-3" id="f-298" unitRef="usd">418339000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-61" decimals="-3" id="f-299" unitRef="usd">78130000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-300" unitRef="usd">78130000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-62" decimals="-3" id="f-301" unitRef="shares">439000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-62" decimals="-3" id="f-302" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-61" decimals="-3" id="f-303" unitRef="usd">3053000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-304" unitRef="usd">3054000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="c-62" decimals="-3" id="f-305" unitRef="shares">913000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-62" decimals="-3" id="f-306" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-61" decimals="-3" id="f-307" unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="c-1" decimals="-3" id="f-308" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-63" decimals="-3" id="f-309" unitRef="usd">-2964000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-310" unitRef="usd">-2964000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-63" decimals="-3" id="f-311" unitRef="usd">-122000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="c-1" decimals="-3" id="f-312" unitRef="usd">-122000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:ProfitLoss contextRef="c-64" decimals="-3" id="f-313" unitRef="usd">-205275000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-65" decimals="-3" id="f-314" unitRef="usd">-4000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-315" unitRef="usd">-209275000</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding contextRef="c-66" decimals="-3" id="f-316" unitRef="shares">107312000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-66" decimals="-3" id="f-317" unitRef="usd">200000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-67" decimals="-3" id="f-318" unitRef="usd">1300395000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-68" decimals="-3" id="f-319" unitRef="usd">-3222000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-69" decimals="-3" id="f-320" unitRef="usd">-1026030000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-70" decimals="-3" id="f-321" unitRef="usd">15819000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest contextRef="c-31" decimals="-3" id="f-322" unitRef="usd">287162000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss contextRef="c-1" decimals="-3" id="f-323" unitRef="usd">-209275000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-33" decimals="-3" id="f-324" unitRef="usd">-176494000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss contextRef="c-34" decimals="-3" id="f-325" unitRef="usd">-140848000</us-gaap:ProfitLoss>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-326" unitRef="usd">78130000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-33" decimals="-3" id="f-327" unitRef="usd">120893000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-34" decimals="-3" id="f-328" unitRef="usd">76673000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-329" unitRef="usd">12493000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-33" decimals="-3" id="f-330" unitRef="usd">10421000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-34" decimals="-3" id="f-331" unitRef="usd">8267000</us-gaap:DepreciationAndAmortization>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-1" decimals="-3" id="f-332" unitRef="usd">2017000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-33" decimals="-3" id="f-333" unitRef="usd">-2910000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium contextRef="c-34" decimals="-3" id="f-334" unitRef="usd">-266000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-1" decimals="-3" id="f-335" unitRef="usd">18326000</arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-33" decimals="-3" id="f-336" unitRef="usd">0</arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties>
    <arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-34" decimals="-3" id="f-337" unitRef="usd">0</arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties>
    <us-gaap:GainLossOnInvestments contextRef="c-1" decimals="-3" id="f-338" unitRef="usd">0</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-33" decimals="-3" id="f-339" unitRef="usd">-4432000</us-gaap:GainLossOnInvestments>
    <us-gaap:GainLossOnInvestments contextRef="c-34" decimals="-3" id="f-340" unitRef="usd">1708000</us-gaap:GainLossOnInvestments>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-341" unitRef="usd">-1410000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-33" decimals="-3" id="f-342" unitRef="usd">-8845000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-34" decimals="-3" id="f-343" unitRef="usd">9409000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-344" unitRef="usd">-11603000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-33" decimals="-3" id="f-345" unitRef="usd">19291000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-34" decimals="-3" id="f-346" unitRef="usd">360000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-347" unitRef="usd">32998000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-33" decimals="-3" id="f-348" unitRef="usd">-6589000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-34" decimals="-3" id="f-349" unitRef="usd">2628000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-350" unitRef="usd">-14965000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-33" decimals="-3" id="f-351" unitRef="usd">17750000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-34" decimals="-3" id="f-352" unitRef="usd">9522000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-3" id="f-353" unitRef="usd">-129183000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-33" decimals="-3" id="f-354" unitRef="usd">-112501000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-34" decimals="-3" id="f-355" unitRef="usd">223258000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-356" unitRef="usd">46590000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-33" decimals="-3" id="f-357" unitRef="usd">13428000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-34" decimals="-3" id="f-358" unitRef="usd">3192000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-1" decimals="-3" id="f-359" unitRef="usd">0</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-33" decimals="-3" id="f-360" unitRef="usd">65000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities contextRef="c-34" decimals="-3" id="f-361" unitRef="usd">-169000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-362" unitRef="usd">-153890000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-33" decimals="-3" id="f-363" unitRef="usd">-136131000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-34" decimals="-3" id="f-364" unitRef="usd">171312000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-365" unitRef="usd">176737000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-33" decimals="-3" id="f-366" unitRef="usd">52777000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-34" decimals="-3" id="f-367" unitRef="usd">23567000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-1" decimals="-3" id="f-368" unitRef="usd">246141000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-33" decimals="-3" id="f-369" unitRef="usd">223391000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments contextRef="c-34" decimals="-3" id="f-370" unitRef="usd">240703000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-1" decimals="-3" id="f-371" unitRef="usd">326723000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-33" decimals="-3" id="f-372" unitRef="usd">270751000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments contextRef="c-34" decimals="-3" id="f-373" unitRef="usd">122592000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-374" unitRef="usd">-96155000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-33" decimals="-3" id="f-375" unitRef="usd">-5417000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-34" decimals="-3" id="f-376" unitRef="usd">-141678000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-1" decimals="-3" id="f-377" unitRef="usd">3053000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-33" decimals="-3" id="f-378" unitRef="usd">5186000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="c-34" decimals="-3" id="f-379" unitRef="usd">11305000</us-gaap:ProceedsFromStockOptionsExercised>
    <arwr:ProceedsFromSaleOfFutureRoyalties contextRef="c-1" decimals="-3" id="f-380" unitRef="usd">250000000</arwr:ProceedsFromSaleOfFutureRoyalties>
    <arwr:ProceedsFromSaleOfFutureRoyalties contextRef="c-33" decimals="-3" id="f-381" unitRef="usd">0</arwr:ProceedsFromSaleOfFutureRoyalties>
    <arwr:ProceedsFromSaleOfFutureRoyalties contextRef="c-34" decimals="-3" id="f-382" unitRef="usd">0</arwr:ProceedsFromSaleOfFutureRoyalties>
    <us-gaap:ProceedsFromContributedCapital contextRef="c-1" decimals="-3" id="f-383" unitRef="usd">0</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:ProceedsFromContributedCapital contextRef="c-33" decimals="-3" id="f-384" unitRef="usd">60000000</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:ProceedsFromContributedCapital contextRef="c-34" decimals="-3" id="f-385" unitRef="usd">0</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-386" unitRef="usd">253053000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-33" decimals="-3" id="f-387" unitRef="usd">65186000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-34" decimals="-3" id="f-388" unitRef="usd">11305000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-389" unitRef="usd">3008000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-33" decimals="-3" id="f-390" unitRef="usd">-76362000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="c-34" decimals="-3" id="f-391" unitRef="usd">40939000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="INF" id="f-392" unitRef="usd">-122000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-33" decimals="INF" id="f-393" unitRef="usd">-67000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-34" decimals="INF" id="f-394" unitRef="usd">-88000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-32" decimals="-3" id="f-395" unitRef="usd">108005000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-50" decimals="-3" id="f-396" unitRef="usd">184434000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-40" decimals="-3" id="f-397" unitRef="usd">143583000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-31" decimals="-3" id="f-398" unitRef="usd">110891000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-32" decimals="-3" id="f-399" unitRef="usd">108005000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-50" decimals="-3" id="f-400" unitRef="usd">184434000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-401" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-33" decimals="-3" id="f-402" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-34" decimals="-3" id="f-403" unitRef="usd">0</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-404" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-33" decimals="-3" id="f-405" unitRef="usd">-2000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-34" decimals="-3" id="f-406" unitRef="usd">-2000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-407">ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;General&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the &#x201c;Company&#x201d;) are primarily engaged in developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company&#x2019;s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (&#x201c;RNAi&#x201d;) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. The Company&#x2019;s RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s current pipeline:&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.962%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Therapeutic Area&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Stage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Product Rights&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cardiometabolic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Plozasiran (ARO-APOC3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Two Phase 2b and one Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Zodasiran (ARO-ANG3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Two Phase 2b&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Olpasiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pulmonary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-RAGE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-MUC5AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-MMP7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liver&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;GSK-4532990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 2b&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fazirsiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Takeda and Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;JNJ-3989&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;HZN-457&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Horizon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-C3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-PNPLA3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Muscle&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-DUX4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pre-Clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Central Nervous System (CNS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-SOD1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pre-Clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) On October 30, 2023, the Company entered into an Assignment and Consent Agreement with Janssen. See Note 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(2) On October 6, 2023, Amgen announced that it has completed its acquisition of Horizon.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates lab facilities in San Diego, California and Madison, Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company&#x2019;s principal executive offices are located in Pasadena, California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Consolidation and Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements include the accounts of Arrowhead Pharmaceuticals, Inc. and its subsidiaries (wholly-owned subsidiaries and a variable interest entity for which the Company is the primary beneficiary). Subsidiaries refer to Arrowhead Madison, Inc., Visirna Therapeutics, Inc. (&#x201c;Visirna&#x201d;), and Arrowhead Australia Pty Ltd. For subsidiaries in which the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interests retained in such entity by the respective noncontrolling party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;). All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform with the current period presentation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company&#x2019;s primary sources of financing have been through the sale of its securities, revenue from its licensing and collaboration agreements and the sale of certain future royalties. Research and development activities have required significant capital investment since the Company&#x2019;s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company&#x2019;s pipeline of drug candidates and its headcount have both expanded &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;significantly. Additionally, significant capital investment will be required as the Company&#x2019;s pipeline matures into later stage clinical trials and as the Company plans to increase its internal manufacturing capabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At September&#160;30, 2023, the Company had $110.9 million in cash, cash equivalents and restricted cash ($7.9 million in restricted cash) and $292.7 million in available-for-sale debt securities to fund operations. During the year ended September&#160;30, 2023, the Company&#x2019;s cash, cash equivalents and restricted cash and investments balance decreased by $78.6 million which was primarily due to cash used to fund its operations, offset by the $250.0 million upfront payment received from Royalty Pharma (Note 13) and $110.0&#160;million in milestone payments from the Company&#x2019;s collaboration and license agreements (Note 2). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In total, the Company is eligible to receive up to $2.8 billion in developmental, regulatory and sales milestones, and may receive various royalties on net sales from its licensing and collaboration agreements, subject to the terms and conditions of those agreements. The revenue recognition for these collaboration agreements is discussed further in Note 2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of financial statements in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, judgments and assumptions. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results could materially differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Variable Interest Entity (&#x201c;VIE&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A VIE is an entity that, by design, either (i) lacks sufficient equity to permit the entity to finance its activities without additional subordinated financial support from other parties; or (ii) has equity investors that do not have the ability to make significant decisions relating to the entity&#x2019;s operations through voting rights, or do not have the obligation to absorb the expected losses, or do not have the right to receive the residual returns of the entity. The primary beneficiary of a VIE is required to consolidate the assets and liabilities of the VIE. The primary beneficiary is the party that has both (i) the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance, and (ii) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE through its interest in the VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 25, 2022, the Company entered into a license agreement with Visirna (Note 2) and consolidated Visirna&#x2019;s financial statements in which the Company has a direct controlling financial interest based on the VIE model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all the facts and circumstances, including its role in establishing Visirna and its ongoing rights and responsibilities to assess whether the Company has the power to direct the activities of Visirna. In general, the parties that make the most significant decisions affecting a VIE and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also considers all of its economic interests to assess whether the Company has the obligation to absorb losses of Visirna or the right to receive benefits from it that could potentially be significant to Visirna. This assessment requires the Company to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to Visirna. Factors considered in assessing the significance include: the design of the Visirna, including its capitalization structure, subordination of interests, payment priority, and the reasons why the interests are held by the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At Visirna&#x2019;s inception, the Company determined whether it was the primary beneficiary and if Visirna should be consolidated based on the facts and circumstances. The Company performs ongoing reassessments of the VIE based on reconsideration events and reevaluates whether a change to the consolidation is required. As of September&#160;30, 2023, there were no events to be reconsidered in the consolidation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All highly liquid interest-bearing investments are classified as cash equivalents. These investments mainly include commercial paper with maturities of three months or less when purchased. The carrying value of these cash equivalents approximate fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was $7.9 million and $7.3 million restricted cash at September&#160;30, 2023 and 2022, respectively, that is primarily held as collateral associated with letters of credit for the Company&#x2019;s facility leases. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Financial instruments that potentially expose the Company to concentration of credit risk primarily consist of cash, cash equivalents and restricted cash and investments. As of September&#160;30, 2023 and 2022, the Company&#x2019;s investments were primarily invested in money market funds, certificates of deposit, commercial paper, and corporate debt securities through highly rated financial institutions. The Company also maintains several bank accounts primarily at three financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investment securities are mainly held-to-maturity investments, available-for-sale, and marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These held-to-maturity investments may consist of investment-grade interest bearing instruments, primarily money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper, which are stated at amortized cost. The Company does not intend to sell these investment securities and the contractual maturities are not greater than 36 months. Those with maturities less than twelve months are included in short-term investments on the Company&#x2019;s consolidated balance sheets, while those with remaining maturities in excess of twelve months are included in long-term investments on its consolidated balance sheets. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security, and no gains or losses on held-to-maturity investment are realized until they are sold. The Company reassesses the classification of held-to-maturity at each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The available-for-sale investments may consist of investment-grade interest bearing instruments, primarily money market&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;accounts,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;government-sponsored&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;enterprise&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;securities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;corporate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;bonds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;and/or&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;commercial&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;paper, which are accounted for at fair value.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;Changes in fair values are reported as unrealized gains or losses and are recorded in the Company&#x2019;s consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;On September 30, 2023, the Company changed the classification of debt securities to available-for-sale from held-to-maturity.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;As a result, these debt securities are carried at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s marketable debt securities consisted of mutual funds that primarily invest in U.S. government bonds, U.S. government agency bonds, and corporate bonds. Dividends from these funds were automatically re-invested. These securities were recorded at fair value, and all unrealized gains/losses were recorded in the Company&#x2019;s consolidated statement of operations and comprehensive loss. In April 2022, the Company sold all of its investments in mutual funds for $122.3 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company monitors its investments closely. If an unrealized loss is determined to be other-than-temporary, it is written off as a realized loss through the consolidated statements of operations and comprehensive loss. The Company&#x2019;s methodology of assessing other-than-temporary impairments is based on security-specific analysis as of the balance sheet date and considers various factors, including the length of time to maturity and the extent to which the fair value has been less than the cost, recoverability of future cash flows as compared to carrying value of the security, the financial condition and the near-term prospects of the issuer, and the Company&#x2019;s ability and intent to hold the security. If a decline in fair value of investments is determined to be other-than-temporary, the securities are written down to fair value as the new cost basis and the amount of the write down is accounted for as realized losses. The Company did not recognize any other-than-temporary impairments of its investment for the years ended September&#160;30, 2023, 2022, and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from &lt;span style="-sec-ix-hidden:f-426"&gt;three&lt;/span&gt; to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically assesses long-lived assets or asset groups, including property and equipment, for recoverability when events or changes in circumstances indicate that their carrying amounts may not be recoverable. If the Company identifies an indicator of impairment, the Company assesses recoverability by comparing the carrying amount of the asset to the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;An impairment loss is recognized when the carrying amount is not recoverable and is measured as the excess of carrying value over fair value. There were no impairment charges during the years ended September&#160;30, 2023, 2022, and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Intangible Assets Subject to Amortization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets subject to amortization include certain patents and license agreements. The Company qualitatively evaluates intangible assets for impairment annually or whenever events or changes in circumstances indicate that it is more likely than not that the carrying amount of intangible assets may exceed their implied fair values. As of September&#160;30, 2023 and 2022, intangible impairment assessments indicated that there was no impairment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether a contract is, or contains, a lease at inception. All of the Company&#x2019;s leases are classified as operating leases. Leases with terms greater than one-year are recognized on the Company&#x2019;s consolidated balance sheets as right-of-use assets that represent the Company&#x2019;s right to use an underlying asset for the lease term, and lease liabilities that represent its obligation to make lease payments arising from the lease. Lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the expected lease term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize  lease payments on a straight-line basis over the expected lease term. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that it determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing. If the license is not considered to be distinct from other performance obligations, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time. If the performance obligation is satisfied over time, the Company then determines the appropriate method of measuring progress for purposes of recognizing revenue from license payments. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Typically, the Company&#x2019;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a Clinical Trial Application (&#x201c;CTA&#x201d;) or a New Drug Application (&#x201c;NDA&#x201d;) in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas. The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in the Company&#x2019;s consolidated statements of operation and comprehensive loss. Typically, milestone payments and royalties are achieved after the Company&#x2019;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or preclinical program. Milestones or royalties achieved after the Company&#x2019;s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its licensing or collaboration agreements. Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment. Additionally, future royalty payments are not substantially within the control of the Company or the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Further, the revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using the input method; Labor hours, costs incurred or patient visits in clinical trials are typically used as the measure of performance. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations.  If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain judgments affect the application of the Company&#x2019;s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company&#x2019;s current operating plan and, the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope of Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Topic 808 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For collaborative arrangements that contain multiple elements, the Company determines which units of account are deemed to be within the scope of Topic 808 and which units of account are more reflective of a vendor-customer relationship, and therefore are within the scope of Topic 606. For units of account that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of Topic 808, the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative arrangement based on the nature &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of each activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to research and development expense or general and administrative expense, as appropriate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#x2019;s research and development operations, and costs to acquire technology licenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation expenses for all stock grants are based on their estimated grant-date fair value. The fair value of stock option awards is estimated using the Black-Scholes option valuation model which requires the input of subjective assumptions to calculate the value of stock options. For restricted stock units, the value of the award is based on the Company&#x2019;s stock price at the grant date. For performance-based restricted stock unit awards, the value of the award is based on the Company&#x2019;s stock price at the grant date, with consideration given to the probability of the performance condition being achieved. The Company uses historical data and other information to estimate the expected price volatility and the expected forfeiture rate for stock option awards. Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#x2019;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting basis and the respective tax basis of the Company&#x2019;s assets and liabilities, and expected benefits of utilizing net operating loss, capital loss, and tax-credit carryforwards. The Company assesses the likelihood that its deferred tax assets will be realized and, to the extent management does not believe these assets are more likely than not to be realized, a valuation allowance is established. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates or laws is recognized in earnings in the period that includes the enactment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Earnings per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended September&#160;30, 2023, 2022 and 2021, the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units outstanding during the period due to their anti-dilutive effect. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;One of the Company&#x2019;s wholly-owned subsidiaries&#x2019; functional currencies are not the United States dollar, which is the Company&#x2019;s reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Translation adjustments arising from the use of different exchange rates from period to period are included in the accumulated other comprehensive loss. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no recent accounting pronouncements that have significantly impacted this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <arwr:ScheduleOfCurrentProductsTableTextBlock contextRef="c-1" id="f-408">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the Company&#x2019;s current pipeline:&lt;/span&gt;&lt;span style="color:#ee2724;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:22.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:27.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:19.962%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Therapeutic Area&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Name&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Stage&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Product Rights&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cardiometabolic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Plozasiran (ARO-APOC3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Two Phase 2b and one Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Zodasiran (ARO-ANG3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Two Phase 2b&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Olpasiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pulmonary&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-RAGE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-MUC5AC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-MMP7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liver&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;GSK-4532990&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 2b&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fazirsiran&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Takeda and Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;JNJ-3989&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;HZN-457&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Horizon&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-C3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1/2a&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-PNPLA3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Phase 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Muscle&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-DUX4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pre-Clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Central Nervous System (CNS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;ARO-SOD1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Pre-Clinical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Arrowhead&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) On October 30, 2023, the Company entered into an Assignment and Consent Agreement with Janssen. See Note 15.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%"&gt;(2) On October 6, 2023, Amgen announced that it has completed its acquisition of Horizon.&lt;/span&gt;&lt;/div&gt;</arwr:ScheduleOfCurrentProductsTableTextBlock>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-31" decimals="-5" id="f-409" unitRef="usd">110900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-31" decimals="-5" id="f-410" unitRef="usd">7900000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-31" decimals="-5" id="f-411" unitRef="usd">292700000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <arwr:IncreaseDecreaseInCashAndInvestments contextRef="c-1" decimals="-5" id="f-412" unitRef="usd">-78600000</arwr:IncreaseDecreaseInCashAndInvestments>
    <arwr:CashReceivedAsDueUnderCollaborationAgreement contextRef="c-71" decimals="-5" id="f-413" unitRef="usd">250000000</arwr:CashReceivedAsDueUnderCollaborationAgreement>
    <arwr:UpfrontMilestonePaymentReceived contextRef="c-72" decimals="-5" id="f-414" unitRef="usd">110000000</arwr:UpfrontMilestonePaymentReceived>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments contextRef="c-31" decimals="-8" id="f-415" unitRef="usd">2800000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock contextRef="c-1" id="f-416">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;The preparation of financial statements in conformity with U.S. generally accepted accounting principles (&#x201c;GAAP&#x201d;) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. On an ongoing basis, the Company evaluates its estimates, judgments and assumptions. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenue and expense. Actual results could materially differ from those estimates.</arwr:BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock>
    <us-gaap:ConsolidationVariableInterestEntityPolicy contextRef="c-1" id="f-417">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Variable Interest Entity (&#x201c;VIE&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A VIE is an entity that, by design, either (i) lacks sufficient equity to permit the entity to finance its activities without additional subordinated financial support from other parties; or (ii) has equity investors that do not have the ability to make significant decisions relating to the entity&#x2019;s operations through voting rights, or do not have the obligation to absorb the expected losses, or do not have the right to receive the residual returns of the entity. The primary beneficiary of a VIE is required to consolidate the assets and liabilities of the VIE. The primary beneficiary is the party that has both (i) the power to direct the activities of the VIE that most significantly impact the VIE&#x2019;s economic performance, and (ii) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE through its interest in the VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 25, 2022, the Company entered into a license agreement with Visirna (Note 2) and consolidated Visirna&#x2019;s financial statements in which the Company has a direct controlling financial interest based on the VIE model. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers all the facts and circumstances, including its role in establishing Visirna and its ongoing rights and responsibilities to assess whether the Company has the power to direct the activities of Visirna. In general, the parties that make the most significant decisions affecting a VIE and have the right to unilaterally remove those decision-makers are deemed to have the power to direct the activities of a VIE.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also considers all of its economic interests to assess whether the Company has the obligation to absorb losses of Visirna or the right to receive benefits from it that could potentially be significant to Visirna. This assessment requires the Company to apply judgment in determining whether these interests, in the aggregate, are considered potentially significant to Visirna. Factors considered in assessing the significance include: the design of the Visirna, including its capitalization structure, subordination of interests, payment priority, and the reasons why the interests are held by the Company. &lt;/span&gt;&lt;/div&gt;At Visirna&#x2019;s inception, the Company determined whether it was the primary beneficiary and if Visirna should be consolidated based on the facts and circumstances. The Company performs ongoing reassessments of the VIE based on reconsideration events and reevaluates whether a change to the consolidation is required. As of September&#160;30, 2023, there were no events to be reconsidered in the consolidation.</us-gaap:ConsolidationVariableInterestEntityPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-418">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Cash, Cash Equivalents and Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All highly liquid interest-bearing investments are classified as cash equivalents. These investments mainly include commercial paper with maturities of three months or less when purchased. The carrying value of these cash equivalents approximate fair value. &lt;/span&gt;&lt;/div&gt;There was $7.9 million and $7.3 million restricted cash at September&#160;30, 2023 and 2022, respectively, that is primarily held as collateral associated with letters of credit for the Company&#x2019;s facility leases.</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-31" decimals="-5" id="f-419" unitRef="usd">7900000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="c-32" decimals="-5" id="f-420" unitRef="usd">7300000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-421">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/div&gt;Financial instruments that potentially expose the Company to concentration of credit risk primarily consist of cash, cash equivalents and restricted cash and investments. As of September&#160;30, 2023 and 2022, the Company&#x2019;s investments were primarily invested in money market funds, certificates of deposit, commercial paper, and corporate debt securities through highly rated financial institutions. The Company also maintains several bank accounts primarily at three financial institutions for its operations. These accounts are insured by the Federal Deposit Insurance Corporation (FDIC) for up to $250,000 per institution. Management believes the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which these deposits are held.</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashFDICInsuredAmount contextRef="c-73" decimals="INF" id="f-422" unitRef="usd">250000</us-gaap:CashFDICInsuredAmount>
    <us-gaap:InvestmentPolicyTextBlock contextRef="c-1" id="f-423">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investment securities are mainly held-to-maturity investments, available-for-sale, and marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;These held-to-maturity investments may consist of investment-grade interest bearing instruments, primarily money market accounts, government-sponsored enterprise securities, corporate bonds and/or commercial paper, which are stated at amortized cost. The Company does not intend to sell these investment securities and the contractual maturities are not greater than 36 months. Those with maturities less than twelve months are included in short-term investments on the Company&#x2019;s consolidated balance sheets, while those with remaining maturities in excess of twelve months are included in long-term investments on its consolidated balance sheets. Discounts and premiums to par value of the debt securities are amortized to interest income/expense over the term of the security, and no gains or losses on held-to-maturity investment are realized until they are sold. The Company reassesses the classification of held-to-maturity at each reporting period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;The available-for-sale investments may consist of investment-grade interest bearing instruments, primarily money market&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;accounts,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;government-sponsored&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;enterprise&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;securities,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;corporate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;bonds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;and/or&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;commercial&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;paper, which are accounted for at fair value.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;Changes in fair values are reported as unrealized gains or losses and are recorded in the Company&#x2019;s consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;On September 30, 2023, the Company changed the classification of debt securities to available-for-sale from held-to-maturity.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:103%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:103%"&gt;As a result, these debt securities are carried at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s marketable debt securities consisted of mutual funds that primarily invest in U.S. government bonds, U.S. government agency bonds, and corporate bonds. Dividends from these funds were automatically re-invested. These securities were recorded at fair value, and all unrealized gains/losses were recorded in the Company&#x2019;s consolidated statement of operations and comprehensive loss. In April 2022, the Company sold all of its investments in mutual funds for $122.3 million. &lt;/span&gt;&lt;/div&gt;The Company monitors its investments closely. If an unrealized loss is determined to be other-than-temporary, it is written off as a realized loss through the consolidated statements of operations and comprehensive loss. The Company&#x2019;s methodology of assessing other-than-temporary impairments is based on security-specific analysis as of the balance sheet date and considers various factors, including the length of time to maturity and the extent to which the fair value has been less than the cost, recoverability of future cash flows as compared to carrying value of the security, the financial condition and the near-term prospects of the issuer, and the Company&#x2019;s ability and intent to hold the security. If a decline in fair value of investments is determined to be other-than-temporary, the securities are written down to fair value as the new cost basis and the amount of the write down is accounted for as realized losses. The Company did not recognize any other-than-temporary impairments of its investment for the years ended September&#160;30, 2023, 2022, and 2021.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-74" decimals="-5" id="f-424" unitRef="usd">122300000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-425">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Property and Equipment&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Depreciation of property and equipment is recorded using the straight-line method over the respective useful lives of the assets ranging from &lt;span style="-sec-ix-hidden:f-426"&gt;three&lt;/span&gt; to seven years. Leasehold improvements are amortized over the lesser of the expected useful life or the remaining lease term. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company periodically assesses long-lived assets or asset groups, including property and equipment, for recoverability when events or changes in circumstances indicate that their carrying amounts may not be recoverable. If the Company identifies an indicator of impairment, the Company assesses recoverability by comparing the carrying amount of the asset to the sum of the undiscounted cash flows expected to result from the use and the eventual disposal of the asset. &lt;/span&gt;&lt;/div&gt;An impairment loss is recognized when the carrying amount is not recoverable and is measured as the excess of carrying value over fair value. There were no impairment charges during the years ended September&#160;30, 2023, 2022, and 2021.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-73" id="f-427">P7Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c-1" id="f-428">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Intangible Assets Subject to Amortization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets subject to amortization include certain patents and license agreements. The Company qualitatively evaluates intangible assets for impairment annually or whenever events or changes in circumstances indicate that it is more likely than not that the carrying amount of intangible assets may exceed their implied fair values. As of September&#160;30, 2023 and 2022, intangible impairment assessments indicated that there was no impairment.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-33" decimals="INF" id="f-429" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:ImpairmentOfIntangibleAssetsFinitelived contextRef="c-1" decimals="INF" id="f-430" unitRef="usd">0</us-gaap:ImpairmentOfIntangibleAssetsFinitelived>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-431">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether a contract is, or contains, a lease at inception. All of the Company&#x2019;s leases are classified as operating leases. Leases with terms greater than one-year are recognized on the Company&#x2019;s consolidated balance sheets as right-of-use assets that represent the Company&#x2019;s right to use an underlying asset for the lease term, and lease liabilities that represent its obligation to make lease payments arising from the lease. Lease assets and liabilities are recognized at the lease commencement date based on the estimated present value of lease payments over the expected lease term.&lt;/span&gt;&lt;/div&gt;The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes the appropriate incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis an amount equal to the lease payments over a similar term and in a similar economic environment. The Company records expense to recognize  lease payments on a straight-line basis over the expected lease term. Costs determined to be variable and not based on an index or rate are not included in the measurement of the lease liability and are expensed as incurred.</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-432">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The revenue standard provides a five-step framework for recognizing revenue as control of promised goods or services is transferred to a customer at an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. To determine revenue recognition for arrangements that it determines are within the scope of the revenue standard, the Company performs the following five steps: (i) identify the contract; (ii) identify the performance obligations; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the Company satisfies a performance obligation. At contract inception, the Company assesses whether the goods or services promised within each contract are distinct and, therefore, represent a separate performance obligation, or whether they are not distinct and are combined with other goods and services until a distinct bundle is identified. The Company then determines the transaction price, which typically includes upfront payments and any variable consideration that it determines is probable to not cause a significant reversal in the amount of cumulative revenue recognized when the uncertainty associated with the variable consideration is resolved. The Company then allocates the transaction price to each performance obligation and recognizes the associated revenue when (or as) each performance obligation is satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes the transaction price allocated to upfront license payments as revenue upon delivery of the license to the customer and resulting ability of the customer to use and benefit from the license, if the license is determined to be distinct from the other performance obligations identified in the contract. These other performance obligations are typically to perform research and development services for the customer, often times relating to the candidate that the customer is licensing. If the license is not considered to be distinct from other performance obligations, the Company assesses the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied at a point in time or over time. If the performance obligation is satisfied over time, the Company then determines the appropriate method of measuring progress for purposes of recognizing revenue from license payments. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the related revenue recognition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Typically, the Company&#x2019;s collaboration agreements entitle it to additional payments upon the achievement of milestones or royalties on sales. The milestones are generally categorized into three types: development milestones, generally based on the initiation of toxicity studies or clinical trials; regulatory milestones, generally based on the submission, filing or approval of regulatory applications such as a Clinical Trial Application (&#x201c;CTA&#x201d;) or a New Drug Application (&#x201c;NDA&#x201d;) in the United States; and sales-based milestones, generally based on meeting specific thresholds of sales in certain geographic areas. The Company evaluates whether it is probable that the consideration associated with each milestone or royalty will not be subject to a significant reversal in the cumulative amount of revenue recognized. Amounts that meet this threshold are included in the transaction price using the most likely amount method, whereas amounts that do not meet this threshold are excluded from the transaction price until they meet this threshold. At the end of each subsequent reporting period, the Company re-evaluates the probability of a significant reversal of the cumulative revenue recognized for its milestones and royalties, and, if necessary, adjusts its estimate of the overall transaction price. Any such adjustments are recorded on a cumulative catch-up basis, which would affect revenues and net income in the Company&#x2019;s consolidated statements of operation and comprehensive loss. Typically, milestone payments and royalties are achieved after the Company&#x2019;s performance obligations associated with the collaboration agreements have been completed and after the customer has assumed responsibility for the respective clinical or preclinical program. Milestones or royalties achieved after the Company&#x2019;s performance obligations have been completed are recognized as revenue in the period the milestone or royalty was achieved. If a milestone payment is achieved during the performance period, the milestone payment would be recognized as revenue to the extent performance had been completed at that point, and the remaining balance would be recorded as deferred revenue. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The revenue standard requires the Company to assess whether a significant financing component exists in determining the transaction price. The Company performs this assessment at the onset of its licensing or collaboration agreements. Typically, a significant financing component does not exist because the customer is paying for a license or services in advance with an upfront payment. Additionally, future royalty payments are not substantially within the control of the Company or the customer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Further, the revenue standard requires the Company to allocate the arrangement consideration on a relative standalone selling price basis for each performance obligation after determining the transaction price of the contract and identifying the performance obligations to which that amount should be allocated. The relative standalone selling price is defined in the revenue standard as the price at which an entity would sell a promised good or service separately to a customer. If other observable transactions in which the Company has sold the same performance obligation separately are not available, the Company estimates the standalone selling price of each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, discount rates and probabilities of technical and regulatory success.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Whenever the Company determines that goods or services promised in a contract should be accounted for as a combined performance obligation over time, the Company determines the period over which the performance obligations will be performed and revenue will be recognized. Revenue is recognized using the input method; Labor hours, costs incurred or patient visits in clinical trials are typically used as the measure of performance. Significant management judgment is required in determining the level of effort required under an arrangement and the period over which the Company is expected to complete its performance obligations.  If the Company determines that the performance obligation is satisfied over time, any upfront payment received is initially recorded as deferred revenue on its consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain judgments affect the application of the Company&#x2019;s revenue recognition policy. For example, the Company records short-term (less than one year) and long-term (over one year) deferred revenue based on its best estimate of when such revenue will be recognized. This estimate is based on the Company&#x2019;s current operating plan and, the Company may recognize a different amount of deferred revenue over the next 12-month period if its plan changes in the future.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:CollaborativeArrangementAccountingPolicy contextRef="c-1" id="f-433">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company analyzes its collaborative arrangements to assess whether such arrangements involve joint operating activities performed by parties that are both active participants in the activities and exposed to significant risks and rewards, and therefore are within the scope of Financial Accounting Standards Board (&#x201c;FASB&#x201d;) Topic 808 - &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. For collaborative arrangements that contain multiple elements, the Company determines which units of account are deemed to be within the scope of Topic 808 and which units of account are more reflective of a vendor-customer relationship, and therefore are within the scope of Topic 606. For units of account that are accounted for pursuant to Topic 808, an appropriate recognition method is determined and applied consistently, either by analogy to appropriate accounting literature or by applying a reasonable accounting policy election. For collaborative arrangements that are within the scope of Topic 808, the Company evaluates the income statement classification for presentation of amounts due to or owed from other participants associated with multiple units of account in a collaborative arrangement based on the nature &lt;/span&gt;&lt;/div&gt;of each activity. Payments or reimbursements that are the result of a collaborative relationship instead of a customer relationship, such as co-development and co-commercialization activities, are recorded as increases or decreases to research and development expense or general and administrative expense, as appropriate.</us-gaap:CollaborativeArrangementAccountingPolicy>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-434">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs and expenses that can be clearly identified as research and development are charged to expense as incurred. Included in research and development costs are operating costs, facilities, supplies, external services, clinical trial and manufacturing costs, overhead directly related to the Company&#x2019;s research and development operations, and costs to acquire technology licenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-435">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/div&gt;Share-based compensation expenses for all stock grants are based on their estimated grant-date fair value. The fair value of stock option awards is estimated using the Black-Scholes option valuation model which requires the input of subjective assumptions to calculate the value of stock options. For restricted stock units, the value of the award is based on the Company&#x2019;s stock price at the grant date. For performance-based restricted stock unit awards, the value of the award is based on the Company&#x2019;s stock price at the grant date, with consideration given to the probability of the performance condition being achieved. The Company uses historical data and other information to estimate the expected price volatility and the expected forfeiture rate for stock option awards. Expense is recognized over the vesting period for all awards and commences at the grant date for time-based awards and upon the Company&#x2019;s determination that the achievement of such performance conditions is probable for performance-based awards. This determination requires significant judgment by management.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-436">&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial reporting basis and the respective tax basis of the Company&#x2019;s assets and liabilities, and expected benefits of utilizing net operating loss, capital loss, and tax-credit carryforwards. The Company assesses the likelihood that its deferred tax assets will be realized and, to the extent management does not believe these assets are more likely than not to be realized, a valuation allowance is established. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates or laws is recognized in earnings in the period that includes the enactment date.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-437">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Earnings per Share&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed using the weighted-average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted-average number of common shares and dilutive potential common shares outstanding during the period. Dilutive potential common shares primarily consist of stock options and restricted stock units outstanding. &lt;/span&gt;&lt;/div&gt;During the years ended September&#160;30, 2023, 2022 and 2021, the calculation of the effect of dilutive stock options and restricted stock units excluded all stock options and restricted stock units outstanding during the period due to their anti-dilutive effect.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="c-1" id="f-438">&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Foreign currency translation adjustments&lt;/span&gt;&lt;/div&gt;One of the Company&#x2019;s wholly-owned subsidiaries&#x2019; functional currencies are not the United States dollar, which is the Company&#x2019;s reporting currency. Assets and liabilities are translated at the exchange rate in effect at the balance sheet date. Revenues and expenses are translated at the average rate of exchange prevailing during the reporting period. Translation adjustments arising from the use of different exchange rates from period to period are included in the accumulated other comprehensive loss.</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-439">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There have been no recent accounting pronouncements that have significantly impacted this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-440">COLLABORATION AND LICENSE AGREEMENTS&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of revenue recognized:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Horizon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Takeda&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;243,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;138,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balance of receivables and contract liabilities related to the Company&#x2019;s collaboration and license agreements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Receivables included in accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contract liabilities included in deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Glaxosmithkline Intellectual Property (No. 3) Limited (&#x201c;GSK&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;22, 2021, GSK and the Company entered into an Exclusive License Agreement (the &#x201c;GSK License Agreement&#x201d;). Under the GSK License Agreement, GSK has received an exclusive license for GSK-4532990 (formerly ARO-HSD). The exclusive license is worldwide with the exception of greater China. GSK is wholly responsible for all clinical development and commercialization of GSK-4532990 in its territory.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of the GSK License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;amp;D services, including the Company&#x2019;s responsibility to complete the Phase 1/2 study (the &#x201c;GSK R&amp;amp;D Services&#x201d;). Due to the specialized and unique nature of the GSK R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the initial transaction price totaled $120.0 million, including the upfront payment, which was collected in January 2022. The Company has excluded any future estimated milestones or royalties from this transaction price to date. The Company has allocated the total $120.0 million initial transaction price to its one distinct performance obligation for the GSK-4532990 license and the associated GSK R&amp;amp;D Services. As the Company has completed its performance obligation related to this agreement, the upfront payment of $120.0 million was fully recognized in the year ended September&#160;30, 2022. Further, GSK dosed the first patient in a Phase 2b trial in March 2023, triggering a $30.0&#160;million milestone payment to the Company which was paid in the third quarter of fiscal 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also eligible for an additional payment of $100.0 million upon achieving the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to $190.0 million at first commercial sale, and up to $590.0 million in sales-related milestone payments. The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has also performed certain development and manufacturing activities, including the manufacture of drug substance and drug product under GMP conditions, for GSK pursuant to the GSK License Agreement, for which the Company has been reimbursed for its costs. The Company recognized $0.3&#160;million and $4.8&#160;million in connection with these efforts for the years ended September&#160;30, 2023 and 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Horizon Therapeutics Ireland DAC (&#x201c;Horizon&#x201d;) &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June&#160;18, 2021, Horizon and the Company entered into a collaboration and license agreement (the &#x201c;Horizon License Agreement&#x201d;). Under the terms of the Horizon License Agreement, Horizon received a worldwide exclusive license for HZN-457, a clinical-stage medicine being developed by Horizon as a potential treatment for people with uncontrolled &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;gout. Horizon is wholly responsible for clinical development and commercialization of HZN-457. On October 6, 2023, Amgen completed its acquisition of Horizon. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;amp;D services, including the Company&#x2019;s responsibilities to conduct all activities through the preclinical stages of development of HZN-457 (the &#x201c;Horizon R&amp;amp;D Services&#x201d;). Due to the specialized and unique nature of these Horizon R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represented one distinct bundle and, thus, one performance obligation. Beyond the Horizon R&amp;amp;D Services, which are the responsibility of the Company, Horizon will be responsible for managing future clinical development and commercialization of HZN-457. The Company conducted all activities through the preclinical stages of development of HZN-457. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the agreement, the Company received an upfront payment of $40.0&#160;million in July 2021. The Company determined the initial transaction price totaled $40.0&#160;million and has excluded any future estimated milestones or royalties from this transaction price to date. The Company allocated the total $40.0&#160;million initial transaction price to its one distinct performance obligation for the HZN-457 license and the associated Horizon R&amp;amp;D Services. Revenue was recognized on a straight-line basis over the timeframe for completing the Horizon R&amp;amp;D Services. The Company determined that the straight-line basis was appropriate as its efforts were expended evenly over the course of completing its performance obligation. Further, Horizon enrolled the first subject in December 2022 in a Phase 1 randomized, placebo-controlled trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of HZN-457, triggering a $15.0&#160;million milestone payment to the Company which was paid in the second quarter of fiscal 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 21, 2023, the Company received notice from Horizon that it has elected to terminate the Horizon License Agreement. Horizon exercised its right to terminate the Horizon License Agreement for convenience. The termination will take effect on December 21, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company has performed certain development and manufacturing activities, including drug substance and drug product manufacture under GMP conditions, for Horizon pursuant to the Horizon License Agreement. The Company recognized $1.5&#160;million and $2.5&#160;million in connection with these efforts for the years ended September&#160;30, 2023 and 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Pharmaceutical Company Limited (&#x201c;Takeda&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October&#160;7, 2020, Takeda and the Company entered into an Exclusive License and Co-Funding Agreement (the &#x201c;Takeda License Agreement&#x201d;). Under the Takeda License Agreement, Takeda and the Company will co-develop the Company&#x2019;s Fazirsiran program (formerly TAK-999 and ARO-AAT), the Company&#x2019;s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, fazirsiran, if approved, will be co-commercialized under a &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;50/50 profit sharing&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; structure. Outside the United States, Takeda received an exclusive license to commercialize fazirsiran and will lead the global commercialization strategy, while the Company will be eligible to receive tiered royalties of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;20%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; to &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;25%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; on net sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of the Takeda License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&amp;amp;D services including the Company&#x2019;s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of fazirsiran drug product is completed and delivered to Takeda (the &#x201c;Takeda R&amp;amp;D Services&#x201d;). Due to the specialized and unique nature of these Takeda R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. Beyond the Takeda R&amp;amp;D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States. Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Takeda License Agreement, the Company received $300.0&#160;million as an upfront payment in January 2021 and an additional $40.0 million upon Takeda&#x2019;s initiation of a Phase 3 REDWOOD clinical study of fazirsiran in March 2023, and is eligible to receive up to $527.5 million in additional potential development, regulatory and commercial milestones. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has allocated the total $300.0 million initial transaction price to its one distinct performance obligation for the fazirsiran license and the associated Takeda R&amp;amp;D Services. Revenue is recognized using the input method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). The Company previously expected these clinical trials to extend to September 2025 in order to demonstrate long term safety and efficacy in the open label extension (OLE) part of the studies; however, in August 2023, Takeda initiated a Phase 3 OLE study available to patients participating in these Phase 2 studies. Based on this new information, patients enrolled in the SEQUOIA and AROAAT2002 studies are expected to complete their Phase 2 study visits between June 2023 and December 2023, shortening the Company&#x2019;s performance obligation. As a result, effective the second quarter of fiscal 2023, the Company changed its estimates of the revenue recognition to better reflect this newly estimated performance period. The effect of these changes in estimates resulted in accelerated revenue by $70.5&#160;million, or $0.66 per share (diluted) for the year ended September&#160;30, 2023. There were $0.9&#160;million of contract liabilities recorded as current deferred revenue as of September&#160;30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also recorded $4.5&#160;million as accrued expenses as of September&#160;30, 2023 that was primarily driven by co-development and co-commercialization activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Janssen Pharmaceuticals, Inc. (&#x201c;Janssen&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 3, 2018, Janssen, part of the Janssen Pharmaceutical Companies of Johnson &amp;amp; Johnson, and the Company entered into a License Agreement (the &#x201c;Janssen License Agreement&#x201d;). The Company also entered into a stock purchase agreement with JJDC, Inc. (&#x201c;JJDC&#x201d;), Johnson &amp;amp; Johnson&#x2019;s venture capital arm (the &#x201c;JJDC Stock Purchase Agreement&#x201d;). Under the Janssen License Agreement, Janssen received a worldwide, exclusive license to the Company&#x2019;s JNJ-3989 (formerly ARO-HBV) program, the Company&#x2019;s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. Beyond the Company&#x2019;s Phase 1/2 study of JNJ-3989, which the Company was responsible for completing, Janssen is wholly responsible for clinical development and commercialization of JNJ-3989. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Janssen License Agreement, the Company received $175.0 million as an upfront payment, $75.0 million in the form of an equity investment by JJDC in the Company&#x2019;s common stock under the JJDC Stock Purchase Agreement, and milestone and option payments totaling $73.0&#160;million, and the Company may receive up to $825.0 million in development and sales milestone payments for the Janssen License Agreement. The Company is further eligible to receive tiered royalties on product sales up to mid-teens under the Janssen License Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the inception of the Janssen License Agreement, the Company determined that the key deliverables included the license and certain R&amp;amp;D services including the Company&#x2019;s responsibility to complete the Phase 1/2 study of JNJ-3989 and the Company&#x2019;s responsibility to ensure certain manufacturing of JNJ-3989 drug product is completed and delivered to Janssen (the &#x201c;Janssen R&amp;amp;D Services&#x201d;). Due to the specialized and unique nature of these Janssen R&amp;amp;D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined the transaction price totaled approximately $252.7 million, which includes the upfront payment, the premium paid by JJDC for its equity investment in the Company, two $25.0 million milestone payments related to JNJ-3989, and estimated payments for reimbursable Janssen R&amp;amp;D Services to be performed. The Company has allocated the total $252.7 million initial transaction price to its one distinct performance obligation for the JNJ-3989 license and the associated Janssen R&amp;amp;D Services. The Company recognized this transaction price in its entirety as of September&#160;30, 2021, as its performance obligations were substantially completed. There were no contract assets and liabilities recorded as of September&#160;30, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 7, 2023, Janssen voluntarily terminated its collaboration agreement with the Company, dated October 3, 2018. Upon termination of the collaboration agreement, the Company regained full rights to ARO-PNPLA3, formerly called JNJ-75220795. ARO-PNPLA3 is in Phase 1 clinical trials that are now being developed by the Company.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Amgen Inc. (&#x201c;Amgen&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 28, 2016, Amgen and the Company entered into two collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the &#x201c;Olpasiran Agreement&#x201d;), Amgen received a worldwide, exclusive license to the Company&#x2019;s novel RNAi olpasiran (previously referred to as AMG- 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the Olpasiran Agreement, Amgen is wholly responsible for clinical development and commercialization. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the Olpasiran Agreement, the Company has received $35.0&#160;million in upfront payments and $21.5&#160;million in the form of an equity investment by Amgen in the Company&#x2019;s common stock. Further, the Company received additional an &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$55.0 million in milestone payments; $10.0 million upon Amgen&#x2019;s initiation of a Phase 1 study in September 2018, $20.0 million upon its initiation of a Phase 2 clinical study in July 2020, and $25.0 million upon its first subject enrollment in a Phase 3 trial in December 2022. The Company has substantially completed its performance obligations under the Olpasiran Agreement. There were no contract assets and liabilities recorded as of September&#160;30, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, Royalty Pharma Investments 2019 ICAV (&#x201c;Royalty Pharma&#x201d;) and the Company entered into a Royalty Purchase Agreement (the &#x201c;Royalty Pharma Agreement&#x201d;). In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive up to an additional $535.0 million in remaining development, regulatory and sales milestone payments payable from Amgen and Royalty Pharma. See Note 13.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Joint Venture and License Agreement with Visirna Therapeutics, Inc. (&#x201c;Visirna&#x201d;)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 25, 2022, the Company entered into a License Agreement with Visirna (the &#x201c;Visirna License Agreement&#x201d;), pursuant to which Visirna received an exclusive license to develop, manufacture and commercialize four of the Company&#x2019;s RNAi-based investigational cardiometabolic medicines in Greater China (including the People&#x2019;s Republic of China, Hong Kong, Macau and Taiwan). Pursuant to a Share Purchase Agreement entered into simultaneously with the Visirna License Agreement (the &#x201c;Visirna SPA&#x201d;), the Company acquired a majority stake in Visirna (after accounting for shares reserved for Visirna&#x2019;s employee stock ownership plan) as partial consideration for the Visirna License Agreement. Under the Visirna SPA, entities affiliated with Vivo Capital also acquired a minority stake in Visirna in exchange for $60.0&#160;million in upfront capital to support the operations of Visirna. As further consideration under the Visirna License Agreement, the Company is also eligible to receive potential royalties on commercial sales.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="c-1" id="f-441">&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a summary of revenue recognized:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:37.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;GSK&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124,764&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Horizon&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23,206&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Takeda&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;162,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;85,834&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;90,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Janssen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amgen&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;240,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;243,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;138,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-76" decimals="-3" id="f-442" unitRef="usd">29657000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-77" decimals="-3" id="f-443" unitRef="usd">124764000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-78" decimals="-3" id="f-444" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-79" decimals="-3" id="f-445" unitRef="usd">23206000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-80" decimals="-3" id="f-446" unitRef="usd">29181000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-81" decimals="-3" id="f-447" unitRef="usd">6816000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-82" decimals="-3" id="f-448" unitRef="usd">162516000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-83" decimals="-3" id="f-449" unitRef="usd">85834000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-84" decimals="-3" id="f-450" unitRef="usd">90784000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-85" decimals="-3" id="f-451" unitRef="usd">356000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-86" decimals="-3" id="f-452" unitRef="usd">3452000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-87" decimals="-3" id="f-453" unitRef="usd">40687000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-88" decimals="-3" id="f-454" unitRef="usd">25000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-89" decimals="-3" id="f-455" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-90" decimals="-3" id="f-456" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-457" unitRef="usd">240735000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-33" decimals="-3" id="f-458" unitRef="usd">243231000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-34" decimals="-3" id="f-459" unitRef="usd">138287000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c-1" id="f-460">&lt;div style="margin-top:9pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the balance of receivables and contract liabilities related to the Company&#x2019;s collaboration and license agreements:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:17.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Receivables included in accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Contract liabilities included in deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;130,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsReceivableNet contextRef="c-31" decimals="-3" id="f-461" unitRef="usd">0</us-gaap:AccountsReceivableNet>
    <us-gaap:AccountsReceivableNet contextRef="c-32" decimals="-3" id="f-462" unitRef="usd">1410000</us-gaap:AccountsReceivableNet>
    <us-gaap:ContractWithCustomerLiability contextRef="c-31" decimals="-3" id="f-463" unitRef="usd">866000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-32" decimals="-3" id="f-464" unitRef="usd">130049000</us-gaap:ContractWithCustomerLiability>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="c-91"
      decimals="INF"
      id="f-465"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:NumberOfDistinctBundle
      contextRef="c-91"
      decimals="INF"
      id="f-466"
      unitRef="bundle">1</arwr:NumberOfDistinctBundle>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="c-91"
      decimals="INF"
      id="f-467"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:InitialTransactionPrice contextRef="c-91" decimals="-5" id="f-468" unitRef="usd">120000000</arwr:InitialTransactionPrice>
    <arwr:InitialTransactionPrice contextRef="c-91" decimals="-5" id="f-469" unitRef="usd">120000000</arwr:InitialTransactionPrice>
    <arwr:InitialTransactionPrice contextRef="c-91" decimals="-5" id="f-470" unitRef="usd">120000000</arwr:InitialTransactionPrice>
    <arwr:MilestonePaymentReceivable contextRef="c-92" decimals="-5" id="f-471" unitRef="usd">30000000</arwr:MilestonePaymentReceivable>
    <arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree contextRef="c-93" decimals="-5" id="f-472" unitRef="usd">100000000</arwr:MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree>
    <arwr:CommercialMilestonePaymentsAtFirstCommercialSale contextRef="c-94" decimals="-5" id="f-473" unitRef="usd">190000000</arwr:CommercialMilestonePaymentsAtFirstCommercialSale>
    <arwr:SalesRelatedMilestonePayments contextRef="c-94" decimals="-5" id="f-474" unitRef="usd">590000000</arwr:SalesRelatedMilestonePayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-95" decimals="-5" id="f-475" unitRef="usd">300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-96" decimals="-5" id="f-476" unitRef="usd">4800000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="c-97"
      decimals="INF"
      id="f-477"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:NumberOfDistinctBundle
      contextRef="c-97"
      decimals="INF"
      id="f-478"
      unitRef="bundle">1</arwr:NumberOfDistinctBundle>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="c-97"
      decimals="INF"
      id="f-479"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:InitialTransactionPrice contextRef="c-98" decimals="-5" id="f-480" unitRef="usd">40000000</arwr:InitialTransactionPrice>
    <arwr:InitialTransactionPrice contextRef="c-98" decimals="-5" id="f-481" unitRef="usd">40000000</arwr:InitialTransactionPrice>
    <arwr:InitialTransactionPrice contextRef="c-98" decimals="-5" id="f-482" unitRef="usd">40000000</arwr:InitialTransactionPrice>
    <arwr:UpfrontMilestonePaymentReceived contextRef="c-99" decimals="-5" id="f-483" unitRef="usd">15000000</arwr:UpfrontMilestonePaymentReceived>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-100" decimals="-5" id="f-484" unitRef="usd">1500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-101" decimals="-5" id="f-485" unitRef="usd">2500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales contextRef="c-102" decimals="2" id="f-486" unitRef="number">0.20</arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales>
    <arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales contextRef="c-103" decimals="2" id="f-487" unitRef="number">0.25</arwr:PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="c-104"
      decimals="INF"
      id="f-488"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:NumberOfDistinctBundle
      contextRef="c-104"
      decimals="INF"
      id="f-489"
      unitRef="bundle">1</arwr:NumberOfDistinctBundle>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="c-104"
      decimals="INF"
      id="f-490"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:InitialTransactionPrice contextRef="c-104" decimals="-5" id="f-491" unitRef="usd">300000000</arwr:InitialTransactionPrice>
    <arwr:MilestonePaymentEarned contextRef="c-105" decimals="-5" id="f-492" unitRef="usd">40000000</arwr:MilestonePaymentEarned>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments contextRef="c-106" decimals="-5" id="f-493" unitRef="usd">527500000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:InitialTransactionPrice contextRef="c-104" decimals="-5" id="f-494" unitRef="usd">300000000</arwr:InitialTransactionPrice>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="c-104"
      decimals="INF"
      id="f-495"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-107" decimals="-5" id="f-496" unitRef="usd">70500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-107"
      decimals="2"
      id="f-497"
      unitRef="usdPerShare">0.66</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-108" decimals="-5" id="f-498" unitRef="usd">900000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-108" decimals="-5" id="f-499" unitRef="usd">4500000</us-gaap:AccruedLiabilitiesCurrent>
    <arwr:CashReceivedAsDueUnderCollaborationAgreement contextRef="c-109" decimals="-5" id="f-500" unitRef="usd">175000000</arwr:CashReceivedAsDueUnderCollaborationAgreement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-110" decimals="-5" id="f-501" unitRef="usd">75000000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <arwr:MilestonePaymentEarned contextRef="c-111" decimals="-5" id="f-502" unitRef="usd">73000000</arwr:MilestonePaymentEarned>
    <arwr:DevelopmentRegulatoryAndSalesMilestonesPayments contextRef="c-112" decimals="-5" id="f-503" unitRef="usd">825000000</arwr:DevelopmentRegulatoryAndSalesMilestonesPayments>
    <arwr:NumberOfDistinctBundle
      contextRef="c-113"
      decimals="INF"
      id="f-504"
      unitRef="bundle">1</arwr:NumberOfDistinctBundle>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="c-113"
      decimals="INF"
      id="f-505"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <arwr:InitialTransactionPrice contextRef="c-113" decimals="-5" id="f-506" unitRef="usd">252700000</arwr:InitialTransactionPrice>
    <arwr:MilestonePaymentEarned contextRef="c-114" decimals="-5" id="f-507" unitRef="usd">25000000</arwr:MilestonePaymentEarned>
    <arwr:InitialTransactionPrice contextRef="c-113" decimals="-5" id="f-508" unitRef="usd">252700000</arwr:InitialTransactionPrice>
    <arwr:NumberOfDistinctPerformanceObligations
      contextRef="c-113"
      decimals="INF"
      id="f-509"
      unitRef="obligation">1</arwr:NumberOfDistinctPerformanceObligations>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-115" decimals="INF" id="f-510" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-115" decimals="INF" id="f-511" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:NumberOfAgreements
      contextRef="c-116"
      decimals="INF"
      id="f-512"
      unitRef="agreement">2</arwr:NumberOfAgreements>
    <arwr:CashReceivedAsDueUnderCollaborationAgreement contextRef="c-117" decimals="-5" id="f-513" unitRef="usd">35000000</arwr:CashReceivedAsDueUnderCollaborationAgreement>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-117" decimals="-5" id="f-514" unitRef="usd">21500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <arwr:MilestonePaymentReceived contextRef="c-118" decimals="-5" id="f-515" unitRef="usd">55000000</arwr:MilestonePaymentReceived>
    <arwr:MilestonePaymentReceived contextRef="c-119" decimals="-5" id="f-516" unitRef="usd">10000000</arwr:MilestonePaymentReceived>
    <arwr:MilestonePaymentReceived contextRef="c-120" decimals="-5" id="f-517" unitRef="usd">20000000</arwr:MilestonePaymentReceived>
    <arwr:MilestonePaymentReceived contextRef="c-121" decimals="-5" id="f-518" unitRef="usd">25000000</arwr:MilestonePaymentReceived>
    <us-gaap:ContractWithCustomerAssetNetCurrent contextRef="c-118" decimals="INF" id="f-519" unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-118" decimals="INF" id="f-520" unitRef="usd">0</us-gaap:ContractWithCustomerLiabilityCurrent>
    <arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments contextRef="c-122" decimals="-5" id="f-521" unitRef="usd">535000000</arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments>
    <us-gaap:ProceedsFromContributedCapital contextRef="c-123" decimals="-5" id="f-522" unitRef="usd">60000000</us-gaap:ProceedsFromContributedCapital>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-523">PROPERTY AND EQUIPMENT&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s major classes of property and equipment: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computers, software, office equipment and furniture &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;332,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(41,951)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense for property and equipment for the years ended September&#160;30, 2023, 2022, and 2021 was $10.7 million, $8.7 million and $6.6 million respectively. &lt;/span&gt;&lt;/div&gt;The increase in the construction in progress during 2023 was mainly due to the continuing developments of manufacturing, laboratory and office facilities in Verona, Wisconsin. In May 2023, the Company completed the development of the San Diego facility, which resulted in the reclassification of related construction in progress to leasehold improvements as of September&#160;30, 2023.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-524">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s major classes of property and equipment: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Computers, software, office equipment and furniture &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Land&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103,813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;42,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;166,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;332,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;141,851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(41,951)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(31,554)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;110,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross contextRef="c-31" decimals="INF" id="f-525" unitRef="usd">2240000</arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross>
    <arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross contextRef="c-32" decimals="INF" id="f-526" unitRef="usd">2182000</arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross>
    <us-gaap:Land contextRef="c-31" decimals="-3" id="f-527" unitRef="usd">2996000</us-gaap:Land>
    <us-gaap:Land contextRef="c-32" decimals="-3" id="f-528" unitRef="usd">2996000</us-gaap:Land>
    <arwr:ResearchEquipmentGross contextRef="c-31" decimals="-3" id="f-529" unitRef="usd">56509000</arwr:ResearchEquipmentGross>
    <arwr:ResearchEquipmentGross contextRef="c-32" decimals="-3" id="f-530" unitRef="usd">38283000</arwr:ResearchEquipmentGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="c-31" decimals="-3" id="f-531" unitRef="usd">103813000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:LeaseholdImprovementsGross contextRef="c-32" decimals="-3" id="f-532" unitRef="usd">42017000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:ConstructionInProgressGross contextRef="c-31" decimals="-3" id="f-533" unitRef="usd">166655000</us-gaap:ConstructionInProgressGross>
    <us-gaap:ConstructionInProgressGross contextRef="c-32" decimals="-3" id="f-534" unitRef="usd">56373000</us-gaap:ConstructionInProgressGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-31" decimals="-3" id="f-535" unitRef="usd">332213000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-32" decimals="-3" id="f-536" unitRef="usd">141851000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-31" decimals="-3" id="f-537" unitRef="usd">41951000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-32" decimals="-3" id="f-538" unitRef="usd">31554000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-31" decimals="-3" id="f-539" unitRef="usd">290262000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-32" decimals="-3" id="f-540" unitRef="usd">110297000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-1" decimals="-5" id="f-541" unitRef="usd">10700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-33" decimals="-5" id="f-542" unitRef="usd">8700000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization contextRef="c-34" decimals="-5" id="f-543" unitRef="usd">6600000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="c-1" id="f-544">INVESTMENTS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.851%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;295,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;292,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total current investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;295,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;292,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 30, 2023, the Company changed the classification of its investment securities from held-to-maturity to available-for-sale. This change enables the Company&#x2019;s need to be able to respond to market and liquidity risks in managing its portfolio. Such investments are carried at fair value with any unrealized gains and losses reported as a component of other accumulated comprehensive loss. At the date of the transfer, the carrying value of the Company&#x2019;s held-to-maturity securities was $295.7&#160;million, and net unrealized losses of $3.0&#160;million were recognized in accumulated other comprehensive loss. The Company does not believe that the available-for-sale debt securities that were in an unrealized loss position have any credit loss impairment as of September 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.851%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term investments (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Held-to-maturity certificate of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total current investments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;264,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term investments (Due within one through three years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock contextRef="c-1" id="f-545">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s investments consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.851%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;295,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;292,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total current investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;295,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,964)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;292,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The Company does not believe that the available-for-sale debt securities that were in an unrealized loss position have any credit loss impairment as of September 30, 2023.&lt;div style="margin-top:7pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.851%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.803%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.278%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.806%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Adjusted Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Gross&lt;br/&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Short-term investments (due within one year)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;218,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;214,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Held-to-maturity certificate of deposit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total current investments&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;268,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,661)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;264,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-term investments (Due within one through three years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total long-term investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,569)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100,303&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent contextRef="c-124" decimals="-3" id="f-546" unitRef="usd">295699000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent contextRef="c-124" decimals="-3" id="f-547" unitRef="usd">0</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent contextRef="c-124" decimals="-3" id="f-548" unitRef="usd">2964000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-124" decimals="-3" id="f-549" unitRef="usd">292735000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent contextRef="c-31" decimals="-3" id="f-550" unitRef="usd">295699000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent contextRef="c-31" decimals="-3" id="f-551" unitRef="usd">0</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent>
    <arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent contextRef="c-31" decimals="-3" id="f-552" unitRef="usd">2964000</arwr:DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="c-31" decimals="-3" id="f-553" unitRef="usd">292735000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-31" decimals="-5" id="f-554" unitRef="usd">295700000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:OtherComprehensiveIncomeReclassificationAdjustmentForHeldToMaturityTransferredToAvailableForSaleSecuritiesBeforeTax contextRef="c-1" decimals="-5" id="f-555" unitRef="usd">-3000000</us-gaap:OtherComprehensiveIncomeReclassificationAdjustmentForHeldToMaturityTransferredToAvailableForSaleSecuritiesBeforeTax>
    <us-gaap:HeldToMaturitySecuritiesCurrent contextRef="c-125" decimals="-3" id="f-556" unitRef="usd">218391000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent contextRef="c-125" decimals="-3" id="f-557" unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent contextRef="c-125" decimals="-3" id="f-558" unitRef="usd">3661000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent contextRef="c-125" decimals="-3" id="f-559" unitRef="usd">214730000</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent contextRef="c-126" decimals="-3" id="f-560" unitRef="usd">50000000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent contextRef="c-126" decimals="-3" id="f-561" unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent contextRef="c-126" decimals="-3" id="f-562" unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent contextRef="c-126" decimals="-3" id="f-563" unitRef="usd">50000000</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent contextRef="c-32" decimals="-3" id="f-564" unitRef="usd">268391000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent contextRef="c-32" decimals="-3" id="f-565" unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent contextRef="c-32" decimals="-3" id="f-566" unitRef="usd">3661000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent contextRef="c-32" decimals="-3" id="f-567" unitRef="usd">264730000</us-gaap:DebtSecuritiesHeldToMaturityFairValueCurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent contextRef="c-125" decimals="-3" id="f-568" unitRef="usd">105872000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent contextRef="c-125" decimals="-3" id="f-569" unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent contextRef="c-125" decimals="-3" id="f-570" unitRef="usd">5569000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent contextRef="c-125" decimals="-3" id="f-571" unitRef="usd">100303000</us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent contextRef="c-32" decimals="-3" id="f-572" unitRef="usd">105872000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent contextRef="c-32" decimals="-3" id="f-573" unitRef="usd">0</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent>
    <arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent contextRef="c-32" decimals="-3" id="f-574" unitRef="usd">5569000</arwr:DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent>
    <us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent contextRef="c-32" decimals="-3" id="f-575" unitRef="usd">100303000</us-gaap:DebtSecuritiesHeldToMaturityFairValueNoncurrent>
    <us-gaap:IntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-576">INTANGIBLE ASSETS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The following table presents the components of intangible assets: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.967%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Intangible assets amortization expense in each of 2023, 2022, and 2021 was $1.7 million. None of the intangible assets with definite useful lives are anticipated to have a residual value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the estimated future amortization expense related to intangible assets as of September&#160;30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.272%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.106%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.107%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending September 30, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="c-1" id="f-577">The following table presents the components of intangible assets: &lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:24.967%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gross Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Impairment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Net Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Useful Lives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in years)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,274&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Patents&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21,728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;License&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total intangible assets, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,895&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-127" decimals="INF" id="f-578" unitRef="usd">21728000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-127" decimals="INF" id="f-579" unitRef="usd">13321000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment contextRef="c-127" decimals="INF" id="f-580" unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-127" decimals="INF" id="f-581" unitRef="usd">8407000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-127" id="f-582">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-128" decimals="INF" id="f-583" unitRef="usd">3129000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-128" decimals="INF" id="f-584" unitRef="usd">1274000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment contextRef="c-128" decimals="INF" id="f-585" unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-128" decimals="INF" id="f-586" unitRef="usd">1855000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-128" id="f-587">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-129" decimals="INF" id="f-588" unitRef="usd">24857000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-129" decimals="INF" id="f-589" unitRef="usd">14595000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment contextRef="c-129" decimals="INF" id="f-590" unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-129" decimals="INF" id="f-591" unitRef="usd">10262000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-130" decimals="INF" id="f-592" unitRef="usd">21728000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-130" decimals="INF" id="f-593" unitRef="usd">11770000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment contextRef="c-130" decimals="INF" id="f-594" unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-130" decimals="INF" id="f-595" unitRef="usd">9958000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-130" id="f-596">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-131" decimals="INF" id="f-597" unitRef="usd">3129000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-131" decimals="INF" id="f-598" unitRef="usd">1125000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment contextRef="c-131" decimals="INF" id="f-599" unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-131" decimals="INF" id="f-600" unitRef="usd">2004000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife contextRef="c-131" id="f-601">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="c-132" decimals="INF" id="f-602" unitRef="usd">24857000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="c-132" decimals="INF" id="f-603" unitRef="usd">12895000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <arwr:FiniteLivedIntangibleAssetsImpairment contextRef="c-132" decimals="INF" id="f-604" unitRef="usd">0</arwr:FiniteLivedIntangibleAssetsImpairment>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-132" decimals="INF" id="f-605" unitRef="usd">11962000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-34" decimals="-5" id="f-606" unitRef="usd">1700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-1" decimals="-5" id="f-607" unitRef="usd">1700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets contextRef="c-33" decimals="-5" id="f-608" unitRef="usd">1700000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock contextRef="c-1" id="f-609">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents the estimated future amortization expense related to intangible assets as of September&#160;30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.272%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:60.954%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.106%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.107%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ending September 30, &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths contextRef="c-31" decimals="INF" id="f-610" unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo contextRef="c-31" decimals="INF" id="f-611" unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree contextRef="c-31" decimals="INF" id="f-612" unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour contextRef="c-31" decimals="INF" id="f-613" unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive contextRef="c-31" decimals="INF" id="f-614" unitRef="usd">1700000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive contextRef="c-31" decimals="INF" id="f-615" unitRef="usd">1762000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="c-31" decimals="INF" id="f-616" unitRef="usd">10262000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="c-1" id="f-617">STOCKHOLDERS&#x2019; EQUITY&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s shares of common stock and preferred stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.818%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.294%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Par Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;16, 2023, the Company&#x2019;s stockholders approved an increase in authorized common shares, par value $0.001 per share, from 145,000,000 to 290,000,000. The amendment to the Amended and Restated Certificate of Incorporation was filed on April&#160;27, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2023 and 2022, respectively, 12,709,837 and 14,000,392 shares of common stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Company&#x2019;s 2004 Equity Incentive Plan, 2013 Incentive Plan, and 2021 Incentive Plan, as well as for inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 2, 2022, the Company entered into an open market sale agreement (the &#x201c;Open Market Sale Agreement&#x201d;), pursuant to which the Company may, from time to time, sell up to $250,000,000 in shares of the Company&#x2019;s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (&#x201c;ATM Offering&#x201d;). The Company is not required to sell shares under the Open Market Sale Agreement. The Company will pay Jefferies LLC a commission of up to 3.0% of the aggregate gross proceeds received from all sales of the common stock under the Open Market Sale Agreement. Unless otherwise terminated, the ATM Offering shall terminate upon the earlier of (i) the sale of all shares of common stock subject to the Sales Agreement and (ii) the termination of the Sales Agreement as permitted therein. The Company and Jefferies may each terminate the Open Market Sale Agreement at any time upon prior notice. As of September&#160;30, 2023, no shares have been issued under the Open Market Sale Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ScheduleOfStockByClassTextBlock contextRef="c-1" id="f-618">&lt;div style="margin-top:6pt;padding-left:27pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s shares of common stock and preferred stock:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.818%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.294%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.425%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.644%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Par Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Authorized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;290,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;107,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Common stock&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;145,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,960&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.001&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockByClassTextBlock>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-31"
      decimals="INF"
      id="f-619"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-31"
      decimals="INF"
      id="f-620"
      unitRef="shares">290000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-31" decimals="-3" id="f-621" unitRef="shares">107312000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-31" decimals="-3" id="f-622" unitRef="shares">107312000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-31"
      decimals="INF"
      id="f-623"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-31"
      decimals="INF"
      id="f-624"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-31" decimals="-3" id="f-625" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-31" decimals="-3" id="f-626" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-32"
      decimals="INF"
      id="f-627"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-32"
      decimals="INF"
      id="f-628"
      unitRef="shares">145000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-32" decimals="-3" id="f-629" unitRef="shares">105960000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-32" decimals="-3" id="f-630" unitRef="shares">105960000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-32"
      decimals="INF"
      id="f-631"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="c-32"
      decimals="INF"
      id="f-632"
      unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-32" decimals="-3" id="f-633" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-32" decimals="-3" id="f-634" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-133"
      decimals="INF"
      id="f-635"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-134"
      decimals="INF"
      id="f-636"
      unitRef="shares">145000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="c-133"
      decimals="INF"
      id="f-637"
      unitRef="shares">290000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-135"
      decimals="INF"
      id="f-638"
      unitRef="shares">12709837</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-136"
      decimals="INF"
      id="f-639"
      unitRef="shares">14000392</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <arwr:CommonStockCapitalSharesValueReservedForFutureIssuance contextRef="c-137" decimals="INF" id="f-640" unitRef="usd">250000000</arwr:CommonStockCapitalSharesValueReservedForFutureIssuance>
    <arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock contextRef="c-138" decimals="3" id="f-641" unitRef="number">0.030</arwr:PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock>
    <us-gaap:SharesIssued
      contextRef="c-139"
      decimals="INF"
      id="f-642"
      unitRef="shares">0</us-gaap:SharesIssued>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-643">COMMITMENTS AND CONTINGENCIES&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were no contingent liabilities recorded as of September&#160;30, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 20, 2021, the Company completed a purchase of 13 acres of land in the Verona Technology Park in Verona, Wisconsin, which is being developed into an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility which will support the Company&#x2019;s process development and analytical activities. As of September&#160;30, 2023, the Company has incurred $166.2 million and intends to spend an additional $120.0 million to $130.0 million to complete the build out of the facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of this land acquisition, the Company entered into a development agreement with the City of Verona to construct certain infrastructure improvements within the tax increment district and will be reimbursed up to $16.0&#160;million by the City of Verona by future tax increment revenue generated from the developed property. The total amount of funding that City of Verona will pay under the Tax Increment Financing program is not guaranteed and will depend on future tax revenues generated from the developed property&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also became eligible to receive up to $2.5&#160;million in refundable Wisconsin state income tax credits from the Wisconsin Economic Development Corporation (WEDC) as incentives for investing in the local community and creating new job opportunities. As of September&#160;30, 2023, the Company has collected $1.5 million of these credits. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Technology License Commitments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has licensed from third parties the rights to use certain technologies for its research and development activities, as well as in any products it may develop using these licensed technologies. These agreements and other similar agreements often require the Company to make milestone and royalty payments. Milestone payments, for example, may be &lt;/span&gt;&lt;/div&gt;required as the research and development process progresses through various stages of development, such as when clinical candidates enter or progress through clinical trials, upon NDA and/or certain sales level milestones. The Company did not reach any milestones during the years of 2023 and 2022. During 2021, the Company triggered the milestone related to the progression of the ARO-ENaC and ARO-HIF2 candidates and made milestone payments of $2.4 million.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-31" decimals="INF" id="f-644" unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-32" decimals="INF" id="f-645" unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <arwr:NumberOfAcresOfLandPurchased contextRef="c-140" decimals="INF" id="f-646" unitRef="acre">13</arwr:NumberOfAcresOfLandPurchased>
    <us-gaap:AreaOfLand contextRef="c-141" decimals="-3" id="f-647" unitRef="sqft">160000</us-gaap:AreaOfLand>
    <us-gaap:AreaOfLand contextRef="c-142" decimals="-3" id="f-648" unitRef="sqft">140000</us-gaap:AreaOfLand>
    <us-gaap:ConstructionInProgressGross contextRef="c-143" decimals="-5" id="f-649" unitRef="usd">166200000</us-gaap:ConstructionInProgressGross>
    <arwr:AmountIntendedToInvestForBuildoutOfFacilities contextRef="c-144" decimals="-5" id="f-650" unitRef="usd">120000000</arwr:AmountIntendedToInvestForBuildoutOfFacilities>
    <arwr:AmountIntendedToInvestForBuildoutOfFacilities contextRef="c-145" decimals="-5" id="f-651" unitRef="usd">130000000</arwr:AmountIntendedToInvestForBuildoutOfFacilities>
    <arwr:TaxIncrementFinancingAward contextRef="c-146" decimals="-5" id="f-652" unitRef="usd">16000000</arwr:TaxIncrementFinancingAward>
    <arwr:TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement contextRef="c-147" decimals="-5" id="f-653" unitRef="usd">2500000</arwr:TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement>
    <us-gaap:IncomeTaxReconciliationTaxCredits contextRef="c-1" decimals="-5" id="f-654" unitRef="usd">1500000</us-gaap:IncomeTaxReconciliationTaxCredits>
    <arwr:MilestonePayments contextRef="c-148" decimals="-5" id="f-655" unitRef="usd">2400000</arwr:MilestonePayments>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-656">LEASES&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November&#160;19, 2021, the Company entered into a 15-year lease for approximately 144,000 square feet of office and research and development laboratory space in San Diego, California, for which the rent commencement date began on April&#160;19, 2023. This new facility accommodates increased personnel for its expanding pipeline of current and future drug candidates. Pursuant to the lease, within twelve months of the expiration of the initial 15-year term, the Company has the option to extend the lease for up to one additional ten-year term, with certain annual increases in base rent. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The lease agreement grants the Company the right to receive an Additional Tenant Improvement Allowance (&#x201c;ATIA&#x201d;) funded by the lessor, with a maximum amount of $7.2 million, subject to a 7% interest per annum over the base term. Further, on September&#160;25, 2023, the Company executed the first amendment to the lease, which grants a second ATIA with a maximum amount of $23.6 million, bearing interest at a rate of 9% per annum over the base term. The Company has received $27.8 million ATIA from the lessor as of September&#160;30, 2023. As a result, the Company remeasured its lease liability and right-of-use assets to reflect these additional allowances and the related increase lease payments. The Company has further concluded that these ATIAs have no effects on the classification of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Other Significant Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Pasadena, California&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company leases 49,000 square feet of office space located at 177 East Colorado Blvd. for its corporate headquarters from 177 Colorado Owner, LLC, which lease expires on April&#160;30, 2027. The lease contains an option to renew for one term of &lt;span style="-sec-ix-hidden:f-669"&gt;five&lt;/span&gt; years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;San Diego, California&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company subleased space from Halozyme, Inc. for additional research and development space in San Diego, California. The term of this sublease commenced on April&#160;1, 2020 and ended on January&#160;14, 2023. On December&#160;23, 2022, the Company entered into a new six-month lease agreement with 11404 &amp;amp; 11408 Sorrento Valley Owner (DE) LLC, effective January&#160;15, 2023. The lease ended on July&#160;15, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Madison, Wisconsin&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company leases space for office and laboratory facilities, which expires on September&#160;30, 2031. The lease contains options to renew for two terms of five years. After accounting for additional rental square feet added pursuant to amendments to the lease agreement in 2019 and 2020, the Company currently leases a total of 115,000 square feet.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease assets and liabilities along with their classification on the Company&#x2019;s consolidated balance sheets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.409%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.080%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Assets and Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease cost along with its classification on the Company&#x2019;s consolidated statements of operations were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.388%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) Variable lease cost is primarily related to operating expenses associated with the Company&#x2019;s operating leases.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There was $1.4 million, $0.3 million and $0 short-term lease cost during the years ended September&#160;30, 2023, 2022, and 2021, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents maturities of operating lease liabilities on an undiscounted basis as of September&#160;30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.696%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2029 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(78,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.271%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.271%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash received for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for amended operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-149" id="f-657">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LandSubjectToGroundLeases contextRef="c-149" decimals="0" id="f-658" unitRef="sqft">144000</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-149" id="f-659">P15Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <arwr:NumberOfOptionsToRenew
      contextRef="c-150"
      decimals="INF"
      id="f-660"
      unitRef="option">1</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-149" id="f-661">P10Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <arwr:MaximumAdditionalTenantImprovementAllowance contextRef="c-149" decimals="-5" id="f-662" unitRef="usd">7200000</arwr:MaximumAdditionalTenantImprovementAllowance>
    <arwr:AdditionalTenantImprovementAllowanceInterestPerAnnum contextRef="c-149" decimals="2" id="f-663" unitRef="number">0.07</arwr:AdditionalTenantImprovementAllowanceInterestPerAnnum>
    <arwr:MaximumAdditionalTenantImprovementAllowance contextRef="c-151" decimals="-5" id="f-664" unitRef="usd">23600000</arwr:MaximumAdditionalTenantImprovementAllowance>
    <arwr:AdditionalTenantImprovementAllowanceInterestPerAnnum contextRef="c-151" decimals="2" id="f-665" unitRef="number">0.09</arwr:AdditionalTenantImprovementAllowanceInterestPerAnnum>
    <arwr:AdditionalTenantImprovementAllowanceLiability contextRef="c-152" decimals="-5" id="f-666" unitRef="usd">27800000</arwr:AdditionalTenantImprovementAllowanceLiability>
    <us-gaap:LandSubjectToGroundLeases contextRef="c-153" decimals="-3" id="f-667" unitRef="sqft">49000</us-gaap:LandSubjectToGroundLeases>
    <arwr:NumberOfOptionsToRenew
      contextRef="c-154"
      decimals="INF"
      id="f-668"
      unitRef="option">1</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-155" id="f-670">P6M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <arwr:NumberOfOptionsToRenew
      contextRef="c-156"
      decimals="INF"
      id="f-671"
      unitRef="option">2</arwr:NumberOfOptionsToRenew>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="c-156" id="f-672">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LandSubjectToGroundLeases contextRef="c-156" decimals="-3" id="f-673" unitRef="sqft">115000</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-674">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease assets and liabilities along with their classification on the Company&#x2019;s consolidated balance sheets were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.393%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.503%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.656%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.476%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.409%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.080%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Assets and Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;45,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-current operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities, net of current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;78,800&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease cost along with its classification on the Company&#x2019;s consolidated statements of operations were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.293%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:32.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.388%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Lease Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Classification&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,278&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;728&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;814&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,259&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1) Variable lease cost is primarily related to operating expenses associated with the Company&#x2019;s operating leases.&lt;/span&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-31" decimals="-3" id="f-675" unitRef="usd">45297000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-32" decimals="-3" id="f-676" unitRef="usd">58291000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-31" decimals="-3" id="f-677" unitRef="usd">10563000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-32" decimals="-3" id="f-678" unitRef="usd">2776000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-31" decimals="-3" id="f-679" unitRef="usd">104608000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-32" decimals="-3" id="f-680" unitRef="usd">78800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseCost contextRef="c-157" decimals="-3" id="f-681" unitRef="usd">10350000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-158" decimals="-3" id="f-682" unitRef="usd">7278000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-159" decimals="-3" id="f-683" unitRef="usd">3649000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-160" decimals="-3" id="f-684" unitRef="usd">1730000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-161" decimals="-3" id="f-685" unitRef="usd">1757000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-162" decimals="-3" id="f-686" unitRef="usd">1498000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-157" decimals="-3" id="f-687" unitRef="usd">1179000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-158" decimals="-3" id="f-688" unitRef="usd">728000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-159" decimals="-3" id="f-689" unitRef="usd">814000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-160" decimals="-3" id="f-690" unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-161" decimals="-3" id="f-691" unitRef="usd">0</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost contextRef="c-162" decimals="-3" id="f-692" unitRef="usd">1000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-693" unitRef="usd">13259000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-33" decimals="-3" id="f-694" unitRef="usd">9763000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-34" decimals="-3" id="f-695" unitRef="usd">5962000</us-gaap:LeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-1" decimals="-5" id="f-696" unitRef="usd">1400000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-33" decimals="-5" id="f-697" unitRef="usd">300000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost contextRef="c-34" decimals="-5" id="f-698" unitRef="usd">0</us-gaap:ShortTermLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-699">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents maturities of operating lease liabilities on an undiscounted basis as of September&#160;30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.181%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:82.696%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.104%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amounts&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2029 and thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;124,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;193,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(78,526)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;115,171&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow and other information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.878%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.927%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.271%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.271%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.419%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.274%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash received for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,391&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets obtained in exchange for amended operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-31" decimals="-3" id="f-700" unitRef="usd">10735000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-31" decimals="-3" id="f-701" unitRef="usd">15000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-31" decimals="-3" id="f-702" unitRef="usd">15341000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-31" decimals="-3" id="f-703" unitRef="usd">14514000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="c-31" decimals="-3" id="f-704" unitRef="usd">13156000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="c-31" decimals="-3" id="f-705" unitRef="usd">124951000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-31" decimals="-3" id="f-706" unitRef="usd">193697000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-31" decimals="-3" id="f-707" unitRef="usd">78526000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-31" decimals="-3" id="f-708" unitRef="usd">115171000</us-gaap:OperatingLeaseLiability>
    <arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities contextRef="c-1" decimals="-3" id="f-709" unitRef="usd">48391000</arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities contextRef="c-33" decimals="-3" id="f-710" unitRef="usd">0</arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities contextRef="c-34" decimals="-3" id="f-711" unitRef="usd">0</arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-3" id="f-712" unitRef="usd">17071000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-33" decimals="-3" id="f-713" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-34" decimals="-3" id="f-714" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-715" unitRef="usd">5204000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-33" decimals="-3" id="f-716" unitRef="usd">4500000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-34" decimals="-3" id="f-717" unitRef="usd">3100000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-31" id="f-718">P13Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-32" id="f-719">P7Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-50" id="f-720">P8Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-31" decimals="3" id="f-721" unitRef="number">0.080</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-32" decimals="3" id="f-722" unitRef="number">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-50" decimals="3" id="f-723" unitRef="number">0.085</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-724">STOCK-BASED COMPENSATION&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has three plans that provide for equity-based compensation. Under the 2004 Equity Incentive Plan (the &#x201c;2004 Plan&#x201d;) and the 2013 Incentive Plan (the &#x201c;2013 Plan&#x201d;), 0 and 3,408,707 shares, respectively, of the Company&#x2019;s common stock are reserved for the grant of stock options and restricted stock awards to employees and directors of the Company as of September&#160;30, 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March&#160;18, 2021, the Company&#x2019;s Board of Directors approved the Arrowhead Pharmaceuticals, Inc. 2021 Incentive Plan (the &#x201c;2021 Plan&#x201d;), which authorized 8,000,000 shares (subject to certain adjustments) available for grants of stock options, stock appreciation rights, restricted and unrestricted stock, performance awards, cash awards and other awards convertible into or otherwise based on shares of the Company&#x2019;s common stock. The maximum number of shares authorized under the 2021 Plan will be (i) reduced by any shares subject to awards made under the 2013 Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. As of September&#160;30, 2023, the total number of shares reserved for issuance was 6,204,720 shares, which includes 217,922 shares that were forfeited under the 2013 Plan, and 1,979,364 shares have been granted under the 2021 Plan. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, there were 707,432 shares reserved for options and 683,825 shares reserved for restricted stock units issued as inducement grants to new employees granted outside of the Company&#x2019;s equity-based compensation plans under Rule 5635(c)(4) of the Nasdaq Listing Rules.   &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of awards outstanding:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2004 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2013 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inducement Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Granted and outstanding awards:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,522,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;707,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,263,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,886,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,671,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;683,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,241,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,408,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,705,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,391,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,505,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Option Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the stock option activity for the year ended September&#160;30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.849%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,721,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cancelled or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(439,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,263,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,795,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,141,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,786,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic values represent the amount by which the market price of the underlying stock exceeds the exercise price of the option. The total intrinsic value of the options exercised during the years ended September&#160;30, 2023, 2022, and 2021 was $12.2 million, $27.6 million and $66.9 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation expense related to stock options outstanding for the years ended September&#160;30, 2023, 2022, and 2021 was $8.4 million, $10.8 million and $12.4 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of September&#160;30, 2023, the pre-tax compensation expense for all outstanding unvested stock options in the amount of $2.9 million will be recognized in the Company&#x2019;s results of operations over a weighted average period of 0.4 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option valuation model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company&#x2019;s stock price on the date of grant, as well as assumptions regarding a number of highly complex and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;subjective variables. Because the Company&#x2019;s employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the assumptions used in the calculation of grant-date fair values of these stock options based on the Black-Scholes option pricing model: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.69 &#x2013; 4.57%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.40 &#x2013; 1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86.4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86.2 &#x2013; 90.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.64&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) The dividend yield is zero as the Company currently does not pay a dividend. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(2) The risk-free interest rate is based on that of the U.S. Treasury yields with equivalent terms in effect at the time of the grant.. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(3) Volatility is estimated based on volatility average of the Company&#x2019;s common stock price. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(4) The expected term represents the period of time that stock options granted are expected to be outstanding, by using historical exercise patterns and post-vesting termination behavior.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(5) No options were granted during the year ended September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted stock units (&#x201c;RSUs&#x201d;), including market-based, time-based and performance-based awards, have been granted under the Company&#x2019;s 2013 and 2021 Plans and as inducements grants granted outside of the Company&#x2019;s equity-based compensation plans. At vesting, each outstanding RSU will be exchanged for one share of the Company&#x2019;s common stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity of the Company&#x2019;s RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,069,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,243,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(913,146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,241,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of RSUs was determined based on the closing price of the Company&#x2019;s common stock on the grant date, with consideration given to the probability of achieving service and/or performance conditions for awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 8, 2022, the Company revised the equity award made to its Chief Executive Officer on January 1, 2022 consisting of 800,000 shares, equal in value to $38.4&#160;million, that was a 100% market-based award. The revised awards consist of 99,521 RSUs and 149,282 performance-based RSUs. No incremental expense resulted from the modification. The fair values of these awards were estimated on the date of grant using a closed-form valuation model (Monte-Carlo).&lt;/span&gt;&lt;/div&gt;For the years ended September&#160;30, 2023, 2022 and 2021, the Company recorded stock-based compensation expense of $69.7 million, $113.6 million and $64.2 million, respectively, related to shares of RSUs. As of September&#160;30, 2023, there was $94.4 million of total unrecognized compensation cost related to RSUs that is expected to be recognized over a weighted-average period of 1.6 years.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-163"
      decimals="INF"
      id="f-725"
      unitRef="shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-164"
      decimals="INF"
      id="f-726"
      unitRef="shares">3408707</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-165"
      decimals="INF"
      id="f-727"
      unitRef="shares">8000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-31"
      decimals="INF"
      id="f-728"
      unitRef="shares">6204720</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-166"
      decimals="INF"
      id="f-729"
      unitRef="shares">217922</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-167"
      decimals="INF"
      id="f-730"
      unitRef="shares">1979364</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-168"
      decimals="INF"
      id="f-731"
      unitRef="shares">707432</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-169"
      decimals="INF"
      id="f-732"
      unitRef="shares">683825</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock contextRef="c-1" id="f-733">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of awards outstanding:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.429%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.436%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.043%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;As of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2004 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2013 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021 Plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Inducement Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Granted and outstanding awards:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,522,207&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,838&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;707,432&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,263,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,886,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,671,315&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;683,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,241,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,408,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,705,153&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,391,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,505,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-163"
      decimals="INF"
      id="f-734"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-164"
      decimals="INF"
      id="f-735"
      unitRef="shares">1522207</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-170"
      decimals="INF"
      id="f-736"
      unitRef="shares">33838</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-171"
      decimals="INF"
      id="f-737"
      unitRef="shares">707432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-31"
      decimals="INF"
      id="f-738"
      unitRef="shares">2263477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-172"
      decimals="INF"
      id="f-739"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-173"
      decimals="INF"
      id="f-740"
      unitRef="shares">1886500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-174"
      decimals="INF"
      id="f-741"
      unitRef="shares">1671315</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-175"
      decimals="INF"
      id="f-742"
      unitRef="shares">683825</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-176"
      decimals="INF"
      id="f-743"
      unitRef="shares">4241640</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="c-163"
      decimals="INF"
      id="f-744"
      unitRef="shares">0</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="c-164"
      decimals="INF"
      id="f-745"
      unitRef="shares">3408707</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="c-170"
      decimals="INF"
      id="f-746"
      unitRef="shares">1705153</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="c-171"
      decimals="INF"
      id="f-747"
      unitRef="shares">1391257</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="c-31"
      decimals="INF"
      id="f-748"
      unitRef="shares">6505117</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-749">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a summary of the stock option activity for the year ended September&#160;30, 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:45.328%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.846%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.395%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.849%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;br/&gt;Per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,721,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33.03&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cancelled or expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(50,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60.72&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(439,350)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding at September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,263,477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,795,879&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercisable at September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,141,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.45&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,786,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-32"
      decimals="INF"
      id="f-750"
      unitRef="shares">2721384</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-32"
      decimals="2"
      id="f-751"
      unitRef="usdPerShare">20.73</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="INF" id="f-752" unitRef="shares">32151</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-753"
      unitRef="usdPerShare">33.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-1" decimals="INF" id="f-754" unitRef="shares">50708</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-755"
      unitRef="usdPerShare">60.72</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="INF" id="f-756" unitRef="shares">439350</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-757"
      unitRef="usdPerShare">6.94</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-31"
      decimals="INF"
      id="f-758"
      unitRef="shares">2263477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-31"
      decimals="2"
      id="f-759"
      unitRef="usdPerShare">22.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-1" id="f-760">P4Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-31" decimals="0" id="f-761" unitRef="usd">26795879</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-31"
      decimals="INF"
      id="f-762"
      unitRef="shares">2141592</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-31"
      decimals="2"
      id="f-763"
      unitRef="usdPerShare">21.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-764">P4Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-31" decimals="0" id="f-765" unitRef="usd">26786757</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-177" decimals="-5" id="f-766" unitRef="usd">12200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-178" decimals="-5" id="f-767" unitRef="usd">27600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-179" decimals="-5" id="f-768" unitRef="usd">66900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-177" decimals="-5" id="f-769" unitRef="usd">8400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-178" decimals="-5" id="f-770" unitRef="usd">10800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-179" decimals="-5" id="f-771" unitRef="usd">12400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="c-180" decimals="-5" id="f-772" unitRef="usd">2900000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-177" id="f-773">P0Y4M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-774">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides the assumptions used in the calculation of grant-date fair values of these stock options based on the Black-Scholes option pricing model: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.69 &#x2013; 4.57%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.40 &#x2013; 1.1%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86.4&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;86.2 &#x2013; 90.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.25&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 19pt;text-align:left;text-indent:-18pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average grant date fair value per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25.61&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;N/A&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48.64&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(1) The dividend yield is zero as the Company currently does not pay a dividend. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(2) The risk-free interest rate is based on that of the U.S. Treasury yields with equivalent terms in effect at the time of the grant.. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(3) Volatility is estimated based on volatility average of the Company&#x2019;s common stock price. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(4) The expected term represents the period of time that stock options granted are expected to be outstanding, by using historical exercise patterns and post-vesting termination behavior.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-align:justify;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:120%"&gt;(5) No options were granted during the year ended September&#160;30, 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="3" id="f-775" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-33" decimals="3" id="f-776" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-34" decimals="3" id="f-777" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-1" decimals="4" id="f-778" unitRef="number">0.0369</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-1" decimals="4" id="f-779" unitRef="number">0.0457</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="c-34"
      decimals="INF"
      id="f-780"
      unitRef="number">0.0040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="c-34"
      decimals="INF"
      id="f-781"
      unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-1" decimals="3" id="f-782" unitRef="number">0.864</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-34" decimals="3" id="f-783" unitRef="number">0.862</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-34" decimals="3" id="f-784" unitRef="number">0.904</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-1" id="f-785">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-34" id="f-786">P6Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-787"
      unitRef="usdPerShare">25.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-34"
      decimals="2"
      id="f-788"
      unitRef="usdPerShare">48.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-1" decimals="2" id="f-789" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="c-1" id="f-790">&lt;div style="margin-top:6pt;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity of the Company&#x2019;s RSUs:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.214%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.930%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.083%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of&lt;br/&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant&lt;br/&gt;Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,069,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;64.39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,243,644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34.32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(913,146)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(158,789)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;53.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Outstanding as of September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,241,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;58.43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-181"
      decimals="INF"
      id="f-791"
      unitRef="shares">4069931</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-181"
      decimals="2"
      id="f-792"
      unitRef="usdPerShare">64.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-182"
      decimals="INF"
      id="f-793"
      unitRef="shares">1243644</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-182"
      decimals="2"
      id="f-794"
      unitRef="usdPerShare">34.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-182"
      decimals="INF"
      id="f-795"
      unitRef="shares">913146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-182"
      decimals="2"
      id="f-796"
      unitRef="usdPerShare">52.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-182"
      decimals="INF"
      id="f-797"
      unitRef="shares">158789</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-182"
      decimals="2"
      id="f-798"
      unitRef="usdPerShare">53.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-176"
      decimals="INF"
      id="f-799"
      unitRef="shares">4241640</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-176"
      decimals="2"
      id="f-800"
      unitRef="usdPerShare">58.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-183"
      decimals="INF"
      id="f-801"
      unitRef="shares">800000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue contextRef="c-184" decimals="-5" id="f-802" unitRef="usd">38400000</arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-185"
      decimals="INF"
      id="f-803"
      unitRef="shares">99521</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-186"
      decimals="INF"
      id="f-804"
      unitRef="shares">149282</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-182" decimals="-5" id="f-805" unitRef="usd">69700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-187" decimals="-5" id="f-806" unitRef="usd">113600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-188" decimals="-5" id="f-807" unitRef="usd">64200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions contextRef="c-176" decimals="-5" id="f-808" unitRef="usd">94400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-182" id="f-809">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-810">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The fair value of a financial instrument is the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date using the exit price. Accordingly, when market observable data are not readily available, the Company&#x2019;s own assumptions are used to reflect those that market participants would be presumed to use in pricing the asset or liability at the measurement date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Assets and liabilities recorded at fair value on the consolidated balance sheets are categorized based on the level of judgment associated with inputs used to measure their fair values and the level of market price observability, as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1&#160;&#160;&#160;&#160;Unadjusted quoted prices are available in active markets for identical assets or liabilities as of the  reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2&#160;&#160;&#160;&#160;Pricing inputs are other than quoted prices in active markets, which are based on the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;     Quoted prices for similar assets or liabilities in active markets;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;     Quoted prices for identical or similar assets or liabilities in non-active markets; or&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;     Either directly or indirectly observable inputs as of the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:72pt;text-align:justify;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3&#160;&#160;&#160;&#160;Pricing inputs are unobservable and significant to the overall fair value measurement, and the determination of fair value requires significant management judgment or estimation.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In certain cases, inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, the level in the fair value hierarchy within which the fair value measurement in its entirety falls has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. Thus, a Level 3 fair value measurement may include inputs that are observable (Level 1 or Level 2) and unobservable (Level 3). The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and consideration of factors specific to the asset or liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses prices and inputs that are current as of the measurement date, including during periods of market disruption. In periods of market disruption, the ability to observe prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2, or from Level 2 to Level 3. The Company recognizes transfers between levels at either the actual date of the event or a change in circumstances that caused the transfer. At September&#160;30, 2023 and 2022, the Company did not have any financial assets or financial liabilities based on Level 3 measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis, and indicate the fair value hierarchy of the valuation techniques utilized by the Company: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.194%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total available-for-sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;261,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;292,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market instruments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;261,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;293,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;     &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.194%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;313,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;365,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market instruments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;313,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;404,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;    &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt securities were reclassified from held-to-maturity to available-for-sale recorded at fair value on a recurring basis. The fair value of debt securities are priced using model pricing based on the securities&#x2019; relationship to other benchmark quoted prices as provided by an independent third party, and under GAAP are considered a Level 2 input.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no transfers between Levels 1, 2, and 3 of the fair value hierarchy during the years ended September&#160;30, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses of the Company approximate fair value based on the short maturities of these instruments. At September&#160;30, 2023, the Company did not have any nonrecurring fair value measurements of nonfinancial assets or nonfinancial liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-811">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents information about the Company&#x2019;s assets and liabilities measured at fair value on a recurring basis, and indicate the fair value hierarchy of the valuation techniques utilized by the Company: &lt;/span&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.194%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;231,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total available-for-sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;261,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;292,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market instruments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;31,900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;261,182&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;293,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;     &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.194%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.074%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.469%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.077%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. government bonds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Municipal securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Commercial notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;271,333&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Certificate of deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;50,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;51,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;313,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;365,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Money market instruments &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39,262&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total financial assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;91,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;313,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;404,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-189" decimals="-3" id="f-812" unitRef="usd">31553000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-190" decimals="-3" id="f-813" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-191" decimals="-3" id="f-814" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-192" decimals="-3" id="f-815" unitRef="usd">31553000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-193" decimals="-3" id="f-816" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-194" decimals="-3" id="f-817" unitRef="usd">7093000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-195" decimals="-3" id="f-818" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-196" decimals="-3" id="f-819" unitRef="usd">7093000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-197" decimals="-3" id="f-820" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-198" decimals="-3" id="f-821" unitRef="usd">22205000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-199" decimals="-3" id="f-822" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-200" decimals="-3" id="f-823" unitRef="usd">22205000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-201" decimals="-3" id="f-824" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-202" decimals="-3" id="f-825" unitRef="usd">231884000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-203" decimals="-3" id="f-826" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-204" decimals="-3" id="f-827" unitRef="usd">231884000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-205" decimals="-3" id="f-828" unitRef="usd">31553000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-206" decimals="-3" id="f-829" unitRef="usd">261182000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-207" decimals="-3" id="f-830" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-208" decimals="-3" id="f-831" unitRef="usd">292735000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-209" decimals="-3" id="f-832" unitRef="usd">347000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-210" decimals="-3" id="f-833" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-211" decimals="-3" id="f-834" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-212" decimals="-3" id="f-835" unitRef="usd">347000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-205" decimals="-3" id="f-836" unitRef="usd">31900000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-206" decimals="-3" id="f-837" unitRef="usd">261182000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-207" decimals="-3" id="f-838" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-208" decimals="-3" id="f-839" unitRef="usd">293082000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-213" decimals="-3" id="f-840" unitRef="usd">1973000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-214" decimals="-3" id="f-841" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-215" decimals="-3" id="f-842" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-216" decimals="-3" id="f-843" unitRef="usd">1973000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-217" decimals="-3" id="f-844" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-218" decimals="-3" id="f-845" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-219" decimals="-3" id="f-846" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-220" decimals="-3" id="f-847" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-221" decimals="-3" id="f-848" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-222" decimals="-3" id="f-849" unitRef="usd">41727000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-223" decimals="-3" id="f-850" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-224" decimals="-3" id="f-851" unitRef="usd">41727000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-225" decimals="-3" id="f-852" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-226" decimals="-3" id="f-853" unitRef="usd">271333000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-227" decimals="-3" id="f-854" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-228" decimals="-3" id="f-855" unitRef="usd">271333000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-229" decimals="-3" id="f-856" unitRef="usd">50000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-230" decimals="-3" id="f-857" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-231" decimals="-3" id="f-858" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-232" decimals="-3" id="f-859" unitRef="usd">50000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-233" decimals="-3" id="f-860" unitRef="usd">51973000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-234" decimals="-3" id="f-861" unitRef="usd">313060000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-235" decimals="-3" id="f-862" unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesFairValue contextRef="c-236" decimals="-3" id="f-863" unitRef="usd">365033000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-237" decimals="-3" id="f-864" unitRef="usd">39262000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-238" decimals="-3" id="f-865" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-239" decimals="-3" id="f-866" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="c-240" decimals="-3" id="f-867" unitRef="usd">39262000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-233" decimals="-3" id="f-868" unitRef="usd">91235000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-234" decimals="-3" id="f-869" unitRef="usd">313060000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-235" decimals="-3" id="f-870" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-236" decimals="-3" id="f-871" unitRef="usd">404295000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-872">INCOME TAXES&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Tax Provision&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the loss before income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(194,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(170,570)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(140,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(202,491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(172,278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(140,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes consisted of the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.170%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.170%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.174%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of the tax expense based on the statutory rate to the Company&#x2019;s actual tax expense in the consolidated statements of operations. A notional 21% tax rate was applied as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. federal statutory income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Permanent and other items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-deductible compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income deduction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the significant components of the Company&#x2019;s net deferred tax assets and liabilities: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.404%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;304,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(284,626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(242,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19,390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19,844)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,478)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is recorded to reduce deferred tax assets to the amount that is more likely than not to be realized based on an assessment of positive and negative evidence, including estimates of future taxable income necessary to realize future deductible amounts. A significant piece of objective negative evidence evaluated was the cumulative loss incurred over the three-year period ended September&#160;30, 2023. Such objective evidence limits the ability to consider other subjective evidence such as its projections for future growth. On the basis of this evaluation at September&#160;30, 2023 and 2022, a valuation allowance of $284.6 million and $242.4 million, respectively, has been recorded. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of September&#160;30, 2023, the Company had accumulated federal and state net operating loss (&#x201c;NOL&#x201d;) carry forwards of $134.3 million and $491.5 million, respectively. Of the $134.3 million of federal NOL carryforwards, $34.0 million was generated before January 1, 2018 and is subject to the 20-year carryforward period (&#x201c;pre-Tax Act losses&#x201d;). The remaining $100.3 million (&#x201c;post-Tax Act losses&#x201d;) can be carried forward indefinitely but is subject to the 80% taxable income limitation. Of the $491.5 million of state NOL carryforwards $2.9 million can be carried forward indefinitely. The pre-Tax Act U.S. federal and state net operating loss carryforwards will expire at various dates through 2041.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;) Sections 382 and 383, annual use of an entity&#x2019;s NOL and research and development credit carryforwards may be limited if there is a cumulative change in ownership of greater than 50% within a three-year period. The amount of the annual limitation is determined based on the value of the entity immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. If limited, the related tax asset would be removed from the deferred tax asset schedule with a corresponding reduction in the valuation allowance. To date, the Company has not completed an analysis pursuant to Sections 382 and 383. Future changes in ownership may occur which could limit the Company&#x2019;s ability to utilize attributes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Uncertainty in Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has adopted guidance issued by the FASB that clarifies the accounting for uncertainty in income taxes recognized in an enterprise&#x2019;s financial statements and prescribes a recognition threshold of more-likely-than not and a measurement process for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. In making this assessment, a company must determine whether it is more-likely-than not that a tax position will be sustained upon examination, based solely on the technical merits of the position and must assume that the tax position will be examined by taxing authorities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s gross unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.719%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Beginning balance of unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross increase for prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross decrease for prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross increase for current period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ending balance of unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended September&#160;30, 2023, 2022 and 2021, the Company has recorded income tax expense of $0, $3.5 million and $0 respectively, related to uncertain tax positions. The Company&#x2019;s policy is to recognize potential interest and penalties related to unrecognized tax benefits associated with uncertain tax positions, if any, in the income tax provision. As of September&#160;30, 2023, the Company has accrued interest and penalties of $0.6&#160;million and $0.9&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If the unrecognized tax benefit at September&#160;30, 2023 are ultimately recognized, excluding the impact of U.S. Tax benefits netted against deferred taxes that are subject to a valuation allowance, approximately $3.5 million would result in a reduction in the Company&#x2019;s income tax expense and effective tax rate. The Company expects that $3.5 million of its unrecognized tax benefits to change over the next 12 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to taxation in the U.S. and various states along with other foreign countries. Due to the presence of NOL carryforwards, all of the income tax years remain open for examination domestically. The Company has not been notified that it is under audit by the Internal Revenue Service or foreign taxing authorities; however, the Company has been notified of an income tax examination by the state of California. There are no other audits in any other jurisdictions.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="c-1" id="f-873">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of the loss before income taxes are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:63.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.416%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Domestic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(194,639)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(170,570)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(140,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(202,491)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(172,278)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(140,846)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-1" decimals="-3" id="f-874" unitRef="usd">-194639000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-33" decimals="-3" id="f-875" unitRef="usd">-170570000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="c-34" decimals="-3" id="f-876" unitRef="usd">-140846000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-1" decimals="-3" id="f-877" unitRef="usd">-7852000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-33" decimals="-3" id="f-878" unitRef="usd">-1708000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="c-34" decimals="-3" id="f-879" unitRef="usd">0</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossAttributableToParent contextRef="c-1" decimals="-3" id="f-880" unitRef="usd">-202491000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent contextRef="c-33" decimals="-3" id="f-881" unitRef="usd">-172278000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:IncomeLossAttributableToParent contextRef="c-34" decimals="-3" id="f-882" unitRef="usd">-140846000</us-gaap:IncomeLossAttributableToParent>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-883">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for income taxes consisted of the following components:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.696%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.872%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.170%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.170%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.407%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.174%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,710&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax provision&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-884" unitRef="usd">1074000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-33" decimals="-3" id="f-885" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-34" decimals="-3" id="f-886" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-887" unitRef="usd">1710000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-33" decimals="-3" id="f-888" unitRef="usd">304000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-34" decimals="-3" id="f-889" unitRef="usd">2000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-890" unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-33" decimals="-3" id="f-891" unitRef="usd">3481000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit contextRef="c-34" decimals="-3" id="f-892" unitRef="usd">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-893" unitRef="usd">2784000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-33" decimals="-3" id="f-894" unitRef="usd">3785000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-34" decimals="-3" id="f-895" unitRef="usd">2000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-896" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-33" decimals="-3" id="f-897" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-34" decimals="-3" id="f-898" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-899" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-33" decimals="-3" id="f-900" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-34" decimals="-3" id="f-901" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-902" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-33" decimals="-3" id="f-903" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit contextRef="c-34" decimals="-3" id="f-904" unitRef="usd">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-905" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-33" decimals="-3" id="f-906" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-34" decimals="-3" id="f-907" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-908" unitRef="usd">2784000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-33" decimals="-3" id="f-909" unitRef="usd">3785000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-34" decimals="-3" id="f-910" unitRef="usd">2000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-911">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents a reconciliation of the tax expense based on the statutory rate to the Company&#x2019;s actual tax expense in the consolidated statements of operations. A notional 21% tax rate was applied as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. federal statutory income tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State income taxes, net of federal tax benefit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Permanent and other items&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-deductible compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign-derived intangible income deduction&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-20.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-28.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-29.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;-2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="INF" id="f-912" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-33"
      decimals="INF"
      id="f-913"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="c-34"
      decimals="INF"
      id="f-914"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-915" unitRef="number">0.004</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-33" decimals="3" id="f-916" unitRef="number">0.086</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-34" decimals="3" id="f-917" unitRef="number">0.070</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-1" decimals="3" id="f-918" unitRef="number">-0.068</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-33" decimals="3" id="f-919" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="c-34" decimals="3" id="f-920" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-1" decimals="3" id="f-921" unitRef="number">-0.046</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-33" decimals="3" id="f-922" unitRef="number">-0.017</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="c-34" decimals="3" id="f-923" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <arwr:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent contextRef="c-1" decimals="3" id="f-924" unitRef="number">-0.046</arwr:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent>
    <arwr:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent contextRef="c-33" decimals="3" id="f-925" unitRef="number">0</arwr:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent>
    <arwr:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent contextRef="c-34" decimals="3" id="f-926" unitRef="number">0</arwr:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent contextRef="c-1" decimals="3" id="f-927" unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent contextRef="c-33" decimals="3" id="f-928" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent contextRef="c-34" decimals="3" id="f-929" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationFdiiPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="3" id="f-930" unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-33" decimals="3" id="f-931" unitRef="number">-0.017</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-34" decimals="3" id="f-932" unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-933" unitRef="number">-0.205</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-33" decimals="3" id="f-934" unitRef="number">-0.284</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-34" decimals="3" id="f-935" unitRef="number">-0.293</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-936" unitRef="number">-0.014</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-33" decimals="3" id="f-937" unitRef="number">-0.022</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-34" decimals="3" id="f-938" unitRef="number">0</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-939">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the significant components of the Company&#x2019;s net deferred tax assets and liabilities: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:71.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.402%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.002%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.404%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;September 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands) &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;171,319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;75,208&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;324&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;66,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;59,441&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;38,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,082&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,636&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,162&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;304,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;262,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(284,626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(242,394)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Fixed assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,878)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,966)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19,390)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total gross deferred tax liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(19,844)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cff0fc;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,478)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cff0fc;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net deferred tax assets (liabilities)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-31" decimals="-3" id="f-940" unitRef="usd">60495000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-32" decimals="-3" id="f-941" unitRef="usd">171319000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost contextRef="c-31" decimals="-3" id="f-942" unitRef="usd">75208000</arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost>
    <arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost contextRef="c-32" decimals="-3" id="f-943" unitRef="usd">324000</arwr:DeferredTaxAssetsInProcessResearchAndDevelopmentCost>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-31" decimals="-3" id="f-944" unitRef="usd">66407000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-32" decimals="-3" id="f-945" unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-31" decimals="-3" id="f-946" unitRef="usd">59441000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-32" decimals="-3" id="f-947" unitRef="usd">38810000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities contextRef="c-31" decimals="-3" id="f-948" unitRef="usd">25382000</arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities>
    <arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities contextRef="c-32" decimals="-3" id="f-949" unitRef="usd">2844000</arwr:DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-31" decimals="-3" id="f-950" unitRef="usd">10296000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-32" decimals="-3" id="f-951" unitRef="usd">41479000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c-31" decimals="-3" id="f-952" unitRef="usd">3082000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits contextRef="c-32" decimals="-3" id="f-953" unitRef="usd">2961000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-31" decimals="-3" id="f-954" unitRef="usd">1523000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets contextRef="c-32" decimals="-3" id="f-955" unitRef="usd">2973000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-31" decimals="-3" id="f-956" unitRef="usd">2636000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-32" decimals="-3" id="f-957" unitRef="usd">2162000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-31" decimals="-3" id="f-958" unitRef="usd">304470000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-32" decimals="-3" id="f-959" unitRef="usd">262872000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-31" decimals="-3" id="f-960" unitRef="usd">284626000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-32" decimals="-3" id="f-961" unitRef="usd">242394000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-31" decimals="-3" id="f-962" unitRef="usd">9878000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-32" decimals="-3" id="f-963" unitRef="usd">1088000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-31" decimals="-3" id="f-964" unitRef="usd">9966000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements contextRef="c-32" decimals="-3" id="f-965" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <arwr:DeferredTaxLiabilitiesStateTaxes contextRef="c-31" decimals="-3" id="f-966" unitRef="usd">0</arwr:DeferredTaxLiabilitiesStateTaxes>
    <arwr:DeferredTaxLiabilitiesStateTaxes contextRef="c-32" decimals="-3" id="f-967" unitRef="usd">19390000</arwr:DeferredTaxLiabilitiesStateTaxes>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-31" decimals="-3" id="f-968" unitRef="usd">19844000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-32" decimals="-3" id="f-969" unitRef="usd">20478000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-31" decimals="INF" id="f-970" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-32" decimals="INF" id="f-971" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-31" decimals="-5" id="f-972" unitRef="usd">284600000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-32" decimals="-5" id="f-973" unitRef="usd">242400000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:OperatingLossCarryforwards contextRef="c-241" decimals="-5" id="f-974" unitRef="usd">134300000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-242" decimals="-5" id="f-975" unitRef="usd">491500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-241" decimals="-5" id="f-976" unitRef="usd">134300000</us-gaap:OperatingLossCarryforwards>
    <arwr:OperatingLossCarryforwardsSubjectToExpiration contextRef="c-241" decimals="-5" id="f-977" unitRef="usd">34000000</arwr:OperatingLossCarryforwardsSubjectToExpiration>
    <arwr:OperatingLossCarryforwardsNotSubjectToExpiration contextRef="c-241" decimals="-5" id="f-978" unitRef="usd">100300000</arwr:OperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:OperatingLossCarryforwards contextRef="c-242" decimals="-5" id="f-979" unitRef="usd">491500000</us-gaap:OperatingLossCarryforwards>
    <arwr:OperatingLossCarryforwardsNotSubjectToExpiration contextRef="c-242" decimals="-5" id="f-980" unitRef="usd">2900000</arwr:OperatingLossCarryforwardsNotSubjectToExpiration>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-981">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s gross unrecognized tax benefits:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:47.233%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.718%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:15.719%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Beginning balance of unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross increase for prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross decrease for prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,489)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross increase for current period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,049&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ending balance of unrecognized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-32" decimals="-3" id="f-982" unitRef="usd">3481000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-50" decimals="-3" id="f-983" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-40" decimals="-3" id="f-984" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-985" unitRef="usd">9495000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-33" decimals="-3" id="f-986" unitRef="usd">3481000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions contextRef="c-34" decimals="-3" id="f-987" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-988" unitRef="usd">1489000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-33" decimals="-3" id="f-989" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions contextRef="c-34" decimals="-3" id="f-990" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-3" id="f-991" unitRef="usd">3049000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-33" decimals="-3" id="f-992" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-34" decimals="-3" id="f-993" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-31" decimals="-3" id="f-994" unitRef="usd">14536000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-32" decimals="-3" id="f-995" unitRef="usd">3481000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-50" decimals="-3" id="f-996" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-1" decimals="-5" id="f-997" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-33" decimals="-5" id="f-998" unitRef="usd">3500000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-34" decimals="-5" id="f-999" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued contextRef="c-31" decimals="-5" id="f-1000" unitRef="usd">600000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued contextRef="c-31" decimals="-5" id="f-1001" unitRef="usd">900000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-31" decimals="-5" id="f-1002" unitRef="usd">3500000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit contextRef="c-31" decimals="-5" id="f-1003" unitRef="usd">3500000</us-gaap:SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit>
    <us-gaap:CompensationAndEmployeeBenefitPlansTextBlock contextRef="c-1" id="f-1004">EMPLOYEE BENEFIT PLANS&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors a defined contribution retirement plan which is under Section 401(k) of the Internal Revenue Code and is designed to adhere to ERISA Fiduciary standards. Substantially all of the Company&#x2019;s employees are eligible to participate this plan. Under the terms of the plan, an eligible employee may elect to contribute a portion of their salary on a pre-tax basis, subject to federal statutory limitations. The plan allows for a discretionary match in an amount up to 100% of each participant&#x2019;s first 3% of compensation contributed plus 50% of each participant&#x2019;s next 2% of compensation contributed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended September&#160;30, 2023, 2022, and 2021, the Company recorded expenses for the matching contributions under this plan of $2.2 million, $1.7 million and $1.3 million, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also provides certain employee benefit plans, including those which provide health and life insurance benefits to employees.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationAndEmployeeBenefitPlansTextBlock>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="c-243"
      decimals="INF"
      id="f-1005"
      unitRef="number">1</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="c-243"
      decimals="2"
      id="f-1006"
      unitRef="number">0.03</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
      contextRef="c-244"
      decimals="INF"
      id="f-1007"
      unitRef="number">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="c-244"
      decimals="2"
      id="f-1008"
      unitRef="number">0.02</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-1" decimals="-5" id="f-1009" unitRef="usd">2200000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-33" decimals="-5" id="f-1010" unitRef="usd">1700000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-34" decimals="-5" id="f-1011" unitRef="usd">1300000</us-gaap:DefinedContributionPlanCostRecognized>
    <arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock contextRef="c-1" id="f-1012">LIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 9, 2022, the Company and Royalty Pharma entered into the Royalty Pharma Agreement, pursuant to which Royalty Pharma agreed to pay up to $410.0 million in cash to the Company in consideration for the Company&#x2019;s future royalty interest in olpasiran, a small interfering RNA (siRNA) originally developed by the Company and licensed to Amgen in 2016 under the Olpasiran Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid $250.0 million upfront and agreed to pay up to an additional $160.0 million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) $50.0 million on completion of enrollment in the OCEAN Phase 3 clinical trial for olpasiran, (ii) $50.0 million upon receipt of FDA approval of olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a)), and (iii) $60.0 million upon Royalty Pharma&#x2019;s receipt of at least $70.0 million of royalty payments under the Royalty Pharma Agreement in any single calendar year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has evaluated the terms of the Royalty Pharma Agreement and concluded in accordance with the relevant accounting guidance that the Company accounted for the transaction as debt and the funding of $250.0 million from Royalty Pharma was recorded as a liability related to the sale of future royalties on its consolidated balance sheets. The Company is not obligated to repay this upfront funding received under the  Royalty Pharma Agreement. This liability is amortized over the expected repayment term using an effective interest rate method. The effective interest rate is calculated based on the rate that would enable the debt to be repaid in full over the anticipated life of the arrangement. The interest rate may vary during the term of the agreement depending on a number of factors, including the amount and timing of forecasted net revenues which affects the repayment timing and ultimate amount of repayment. The Company will evaluate the effective interest rate periodically based on its current revenue forecasts utilizing the prospective method. For 2023, the Company recognized non-cash interest expense of $18.3 million, on the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;</arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock>
    <arwr:InitialTransactionPrice contextRef="c-245" decimals="-5" id="f-1013" unitRef="usd">410000000</arwr:InitialTransactionPrice>
    <arwr:CashReceivedAsDueUnderCollaborationAgreement contextRef="c-71" decimals="-5" id="f-1014" unitRef="usd">250000000</arwr:CashReceivedAsDueUnderCollaborationAgreement>
    <arwr:MilestonePaymentReceivable contextRef="c-246" decimals="-5" id="f-1015" unitRef="usd">160000000</arwr:MilestonePaymentReceivable>
    <arwr:MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial contextRef="c-246" decimals="-5" id="f-1016" unitRef="usd">50000000</arwr:MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial>
    <arwr:MilestonePaymentReceivableUponFDAApproval contextRef="c-246" decimals="-5" id="f-1017" unitRef="usd">50000000</arwr:MilestonePaymentReceivableUponFDAApproval>
    <arwr:MilestonePaymentReceivableUponReceiptOfRoyaltyPayments contextRef="c-246" decimals="-5" id="f-1018" unitRef="usd">60000000</arwr:MilestonePaymentReceivableUponReceiptOfRoyaltyPayments>
    <arwr:RoyaltyPaymentThreshold contextRef="c-246" decimals="-5" id="f-1019" unitRef="usd">70000000</arwr:RoyaltyPaymentThreshold>
    <arwr:CashReceivedAsDueUnderCollaborationAgreement contextRef="c-71" decimals="-5" id="f-1020" unitRef="usd">250000000</arwr:CashReceivedAsDueUnderCollaborationAgreement>
    <arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties contextRef="c-247" decimals="-5" id="f-1021" unitRef="usd">18300000</arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-1022">EARNINGS PER SHARE&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the computation of basic and diluted earnings per share for the years ended September&#160;30, 2023, 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Arrowhead Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(205,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(176,063)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(140,848)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average basic shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average diluted shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.67)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.36)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Potentially dilutive securities representing approximately 4,053,000, 3,885,000 and 2,063,000 shares of common stock were excluded from the computation of diluted earnings per share for the years ended September&#160;30, 2023, 2022 and 2021, respectively, because their effect would have been anti-dilutive.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-1023">&lt;div style="margin-top:6pt;text-align:justify;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the computation of basic and diluted earnings per share for the years ended September&#160;30, 2023, 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:52.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:13.901%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year Ended September 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:6pt;text-align:center;text-indent:27pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(in thousands, except per share amounts)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss attributable to Arrowhead Pharmaceuticals, Inc.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(205,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(176,063)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(140,848)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average basic shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted-average diluted shares outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;106,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;105,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;103,745&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Basic earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.67)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.36)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Diluted earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.92)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.67)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1.36)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-1024" unitRef="usd">-205275000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-33" decimals="-3" id="f-1025" unitRef="usd">-176063000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-34" decimals="-3" id="f-1026" unitRef="usd">-140848000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-1027" unitRef="shares">106750000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-33"
      decimals="-3"
      id="f-1028"
      unitRef="shares">105426000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="c-34"
      decimals="-3"
      id="f-1029"
      unitRef="shares">103745000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-1" decimals="-3" id="f-1030" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c-33"
      decimals="-3"
      id="f-1031"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="c-34"
      decimals="-3"
      id="f-1032"
      unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-1033" unitRef="shares">106750000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-33"
      decimals="-3"
      id="f-1034"
      unitRef="shares">105426000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="c-34"
      decimals="-3"
      id="f-1035"
      unitRef="shares">103745000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-1036"
      unitRef="usdPerShare">-1.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-33"
      decimals="2"
      id="f-1037"
      unitRef="usdPerShare">-1.67</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-34"
      decimals="2"
      id="f-1038"
      unitRef="usdPerShare">-1.36</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-1039"
      unitRef="usdPerShare">-1.92</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-33"
      decimals="2"
      id="f-1040"
      unitRef="usdPerShare">-1.67</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-34"
      decimals="2"
      id="f-1041"
      unitRef="usdPerShare">-1.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-3" id="f-1042" unitRef="shares">4053000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-33"
      decimals="-3"
      id="f-1043"
      unitRef="shares">3885000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-34"
      decimals="-3"
      id="f-1044"
      unitRef="shares">2063000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock contextRef="c-1" id="f-1045">SUBSEQUENT EVENTSOn October 30, 2023, the Company entered into an Assignment and Consent Agreement with Janssen, whereby, the Company consented to the assignment of the Janssen License Agreement to GSK, which assignment shall be effective upon the receipt of certain anti-trust approvals.</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>118
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MTM;V.U0Q<+'HC(\3 O23)0",(UMI9 ".---YC,B@@[!;"'4=M9FJ_1QUU5H
M=8P$JC4;&<8IT%0!8()3![E!'&&G?%@TVY,[IO?%[*D/*?KX5'G-\EAQ_;Y2
M@I>EZ;Y%5YT@]1!JP5&0V@O@$L+BF,2>':@,Q 9>$CB:\"!QL%OC7%NT06J
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MUFU)M+>@[8/BN^9>\(XKQ;?-5Z,HF3  _?][SM73@_F!_BYZ\1]02P,$%
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MR) I)"P#@DFI#8ZI#:RI33[1MJC$54+LV+H^S0[;]JDU[L@"_?J.B*NLJ\M
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M-S_VHN!W5C5<K!,-W[74F%_=:O6[-VWF0]YOMC($)7'H:[<T@MXQ!TK+#*>
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M'JYI7M*V;R#>OV>,?WG2_S;.\?><;OX"4$L#!!0    ( !R!?5=\KE,C$ @
M #,E   8    >&PO=V]R:W-H965T<R]S:&5E=#<N>&ULK5IM<Z,X$OXK*M_5
M5:9J/$82K]G$58E)=EUUDZ3BV=G/!.28'4!>P$ZRO_Y:8!L[:N3,K;\D@!\U
M>EJMUJ-&%R^R_%$MA*C):YX5U>5@4=?+\]&HBA<BCZHO<BD*^&4NRSRJX;9\
M'E7+4D1)TRC/1LRRW%$>I<5@?-$\>RC'%W)59VDA'DI2K?(\*M^N129?+@=T
ML'WPF#XO:O5@-+Y81L]B)NK?EP\EW(UV5I(T%T65RH*48GXYN*+G(7=5@P;Q
M/14OU=XU452>I/RA;J;)Y<!2/1*9B&ME(H)_:S$16:8L03_^VA@=[-ZI&NY?
M;ZW?-N2!S%-4B8G,_DB3>G$Y\ <D$?-HE=6/\N4WL2'D*'NQS*KF+WEIL5XP
M(/&JJF6^:0P]R-.B_1^];ARQUX"Z/0W8I@%[W\#N:< W#?A'&]B;!G;CF99*
MXX<PJJ/Q12E?2*G08$U=-,YL6@/]M%#C/JM+^#6%=O5X(HM*9FD2U2(ALQK^
MP:#6%9%S,HFJ!;F%P*C(D/P^"\G9OS]=C&IXJ6HZBC<ON&Y?P'I>0!GY*HMZ
M49&;(A')H8$1]';79;;M\C4S6IR)Y1?"K<^$68PC'9I\O#E#FH<?;TX-;/AN
M 'ACC_<-P-7L-W+[W_L_9N3V\?XKN7^X>;SZ-KW[E5Q-ODV_3[]-;V;GF-M;
MLS9N5J6+\VH9Q>)R /F@$N5:#,;_^1=UK5\PEYW26'@B8P?NM'?NM$W6QW>0
M*C-9520MXFR5I,4S*6010P26,LO4;5K4 MY;8SYM;7N-;94QU^,ALP+F.99E
M78S6^QY#H-1S[<#6H"$&M2W?]O>A!VR='5O'&#Q7R9^0(MH96TO(PT T3C-!
MBJT;X*FZCM5<GL-<)O-2Y@26C3*JE3>:O)O6J:C0('-.&62G-!:>R-B!V]V=
MVUUCD,UJ&?\8JN4F(;',80VN(K6*81YL+;E[@^_YE%MZ0.E RBP_X'H\(29=
MU^.]T>3M:'E&6J$ 7\5IU"[(14*B7)9U^G<O-P_ILHWT>(( +9M1G9H.])GK
M]3+S=\Q\([.SJS@NA:+QZ8"46N8*60L"Q/-TE5>C)*UBN8+YA/'UM=Y!>J">
MSE<'LH#J8QXB.-?M91OLV ;F'"B+83/AMZF.B%<5HX( XRR-GM(LK=\@6V3-
MJ@\IHEX(4D60-\ ?\U6]*@4IY5N4J;R .2+0Q]/GS-4=H0/?N\"$.&!/K4[2
M6!]; \Z>0?A^:E->6JS%)E6B(L8ZUM,) K%MSO1118"P-EC]Z9[NJ35J5@N+
MJ'@6:G7;S^%5)6 !4#-V.[I]^7QC_D0)_:36PE-9.W0MZUS+C%$#*:*9^&H5
M%>DZ>LH$ZD&FQ[Z-S.T) O1]6U<2(0(<@HP(^L.ETY;4J+7&#Z581FFRG?]M
MC$B8[27L+<H2)L,F>%"F7&<*WD;2.X(<TJ!->>_)(E#N6OU<.^%'S<IO-W[+
MZ*UW\&SM[9P%@8]0TI%#U_$#A)&.9"XS3/9.W%&CB%&,RI7H1@]EY""NMP,7
M4:P(E'J-M-4HZ<C 8:R?4B><J%DYA6(N(.X2F&1K4:SP0=+US9!",/E8Y&%8
MRAP+"ST=RQAGCF&H.N5$S=+I?I>,,P&R\+,2W2@W7>#8KA-@Z0/13-QF>JB&
M")+#[.MGU:DF:I9-]RI3H#1TX:+U7X<@01DBL"%U#;FO$T'TB K:;GN6I5RG
M"<3<TQLY6RG-KD0!M@5"J>H"94@=[J-CAF&Y2SD6C8B&\@#9/VZL$T#,^JF:
MPO3N^\WL(S4%9A16/RL/3FHM/)6U0Y]VRHL9Y<?X857&BTBMH:"1(:0@?$!#
MJ_54_+5*ETI8HAZEF!:$W1JR:\"P#O,\'1IB4,8=PU:)=4*(F870 =,CLIDA
MVH79;JN(WM/#L(QS3";@=BW/ZM_ELDX5L6.J2,9")%6[,5#[GE88Y1'L?)I$
M\!'FNI"!'9#'D$4*@3+/\AR,-Z*Y&',,V9QU HD=+XTU"7&3 S<,CZ= AFBA
MP*4.HC$PJ&,C6^000T+8N%[_<LPZY<3,=;'W"?!V>G=U-_E( CQIP>NDUL)3
M63OT:2?=F%FZ'<X:53$0KZ*,TTVBJ%1-#%9555;!HTB77]QRL.FB QWJZ\6%
M$ %2"C;[ ZC3<\RLYW2R/U,>8;HB8XW.1LCJ4(VF"7+(KU-VS*SL#OEUJ4ZE
MA3]E"A<@SQ51E-YQ]8= 7-0!H='8(;M.^K'_0_K-TR(JX@]D.UV8,:<G4G6H
MVQ.JB-HSABKOQ!X_7NU*B[A4^PYREHCVZI,:2>6#SZTGE$A90P@7FT*1*@N6
M::SJ?^IW] .37L8"'R![900X]%SN(J4Q!&I; >_7^[P3:-PLT&[F<Q'7:HJ*
MU[@IDQ$0^$W-\Q_Z 9-P3"<WP8 NLO1A.+]_V>.=<N-FY79]\^OT[DXM<_>/
MY.'F<7H?HH20$I8:5V0]QZ"^;7/D*Q<&M;GC]RLVOO>-U*S8;NY"<G]KHH35
MJBP?D983#(JS#S&HQOZ04J?&N&V4*+/5<IDU']NC\HVHSPZ9K"#AXG5;;I1V
M/_VU]Y36PE-9.W1DI_6XN4HVW7[D4)5.U'=Z-4N+B:.0T @Y['HGJ;A94DV+
M6.:"?(M>04,]]'7?U3X?:]W7(4,L^1Z#M31&>Z=)<E$^-Z=R*M)45]M3&KNG
MNY,_5\UYEW?/K^EYV)[?Z<RTQXF^1N5S6E0D$W,P:7WQP+EE>T*GO:GELCFS
M\B3K6N;-Y4)$B2@5 'Z?2UEO;]0+=N>DQO\#4$L#!!0    ( !R!?5<JSK'3
M.R0  /5S   8    >&PO=V]R:W-H965T<R]S:&5E=#@N>&ULW3W;<MM&EK_2
MY<U.V54D+<EQXL1)JFCY,IJ)997ES&S-UCXT@2;9,0APT(!DYNOWW/H&@)*2
MG7G9%ULDT-VGS_W6S1]NF_:SVQK3J2^[JG8_/MIVW?[[IT]=L34[[1;-WM3P
M9-VT.]W!QW;SU.U;HTL:M*N>GIV<?/-TIVW]Z*<?Z+NK]J<?FKZK;&VN6N7Z
MW4ZWAU>F:FY_?'3ZR'_QT6ZV'7[Q]*<?]GICKDWWR_ZJA4]/PRREW9G:V:96
MK5G_^&AY^OVKK_%]>N%OUMRZY&^%.UDUS6?\<%'^^.@$ 3*5*3J<0<-_-^;<
M5!5.!&#\4^9\%);$@>G??O:WM'?8RTH[<]Y4?[=EM_WQT8M'JC1KW5?=Q^;V
MST;V\QSG*YK*T;_JEM_]^KM'JNA=U^QD,$"PLS7_K[\('I(!+TZ.##B3 6<$
M-R]$4+[6G?[IA[:Y52V^#;/A'[15&@W V1J)<MVU\-3"N.ZG#^U&U_8WS2BJ
M2W5M-[5=VT+7G5H61=/7G:TWZJJI;&&-^^%I!ZOBV*>%K/"*5S@[LL+IF7K?
MU-W6J3=U:<I\@J< ;H#YS,/\ZNS.&:_-?J&>G<S4V<G9LSOF>Q9P\(SF>W9D
MOHEMJO]>KES7 L_\S]2.>;ZOI^=#.?K>[75A?GP$@N),>V,>_?2G_SC]YN3E
M'=!^':#]^J[9_R44NV>%C^^6EQ?_6'ZZ^'"IEI>OU?7%N\N+MQ?GR\M/:GE^
M_N&7RT\7E^_4U8>?+\XOWERK=Z8VK:[4LH6];$$UJ*NM!I$I3-\!7)6;J8NZ
M6!"TMG.@ 5;.EE:WB.G'((:F;4VIND9M36MLK8"K26QO3'50VJEN:]2?_N/%
MV=G)R_-FM]?U@3Z=OGRB=&O4OK6@42R\:^H-J!)8I0;1A-'-'E&Q,R6@HC8X
MD>Y4!]JK@U>(OGI5&55:9T"TG5H=E+.5J0L<AJMN3!A6Z-X9_'*W4+\X?$&K
M5=O ;O=-VZT!W8UJUNKCY5*AZK3 /[@_W+19KY$60*!=4\)W\%II*MA>>YC1
M,LFN3K]]21MN]1Z'PR2;C6GI+9P:P#8M( Q@-+"Q8@O,X':(.UN7/7R'X\H9
MS&_VM';9M[3'SW53?"Z;VQI7[W2[ 8U/NUN,YWTLR(8'-F#:PEZ2%8FU:\2C
M@IT@.@K0K8(K6V_M"DF-8)LO^"ZI<5A:*[<W!3(L+4_[;PT@7J_72'-!_+YM
M8#O=>! \Z(!'%NK3!-X0X#EJZ5)02!SH0&,>5 4,T0)WP!/82JV['GEVK[OM
M+3R%11"<E/R-1Q.BT6W[3A'Z B3"-7-D#!P@V$2X@!O W-$LA'Q!EILD=M$#
M^P,F]W9O4!:_QRD\["!41JM+O3/JND/HKQ@QBNRG4^>Z+6VS,[ ."KRZJIK?
MM+.MKM7CY<</\^75A_-G3]2GVP:%$ACX;$7[:6"O_,6S1&[_T939X,MWP['Q
MW0_57MX-\^P !>JJKW9-#19>X10?E^_>R NG3\]T,AZ?OO_E_/GR_([G[Z^^
MG7[Z,TJ/>G?]U_G7SY^=???=2001OE1O]6^VS:'[I#^;4M/FXS1_N?S+_-EW
M+[[SH]5?=.V 5.KQZ1/UYW]<PNP! /7GIK6_ 4,^/GM"T)T_.P[YU>75S\OP
M/'GXOG<%< 2^\_J7__H:Z&GFYT!V5)3):^<&]5.E+L%\-+U3UP?7F9UZ?'YY
MS8M??WA]>FPP O^A5A^*KED!EKRMS'0-Z$J0>-*5P.F IR6(Z*;>(2<BCLZ;
MFN1[N6F-H6]O;;?U^%FH:V/4)8BB.GV^((PD"W[CUV..T'4-5JD@H43ET"G
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MMCN SFR!,!9HD7*I=6(.T,0?U IT+-I2^/L)\& Z/?D1J+436?.T1WAGZF_
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M-";>>9M"T2S8YBEXA/22QD)CAVFR,JHO'D1((\=D@7$@.+1-O6GPVQ4&)H/
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M-C,-483)[X-(*8V/';>AL,*YD @PR&&QG?=[?\1/S@U3K[2<<LQ.#^+I5>[
M^7UE\+R>>[R<&W7_Q-'@#&_234**'&'MS'1CZU&O:<('/VI;XOT*\<(;"C7"
MLL$1HB,S>#31#$Z?'(*WE52M@C)'>]V:\)'LJ]XMU/LCMNG_L//)S0Q2C='1
M%C*+8>]20Y@I,!UAD@KMB()<_Q2XD\I'"F@JGN,);GT3_S2L_@@?E\S3:?%N
M@>&6)<-#7EQZC,&WR_GD<[8HES;1ZY<$DJR]F,YF'3U;DA^4R15,O-<#H87]
M8X+RBY5;8-)#*).J\LAYA6YP[$4L%MX0U?F*<3R)3M6#:6G(Q/1^R$,S)FT!
M\!CNX,NB!R QI9K(6?!>:9:X QC*&Z8("JP>W44PO#HCNY?DD";C.=&!]@$(
M)<WJ2<8LR22F=!L$2POUEL_#^^/%#Z5]FL]*<GD#YX%4-8=@-W[6"H4!6UGE
M@'N1GEV^,](G+7$OZ\0@RF>;,,\M&;TI<4WU2I(/Y?Y<= OBN9L0XGM1N6]G
M%%NO_3U$DRB.YW\*JFU)GV$XW<RB2[V_.D\*)ZP5,F4</>N$P*#'."IM5O@R
M^WKIW4%'3TVZT+:"M_X=H4JRL.?)T <X. H:#LG3G,=0YCV?8TG*OYI#?FZ^
M&>1@C\Z,55%?'<9<8Z%=$L&Y61;G8#"+10NZ:\CN5GWKF,/YYK<UWZ'DFKHV
M%36)X'AI"Y!WN&/8>V'^3(\IMFP?.:,3XA1P>M!W6JB_^_IQBKPLB 8NN2/E
M:NNTC)HP[[!M1]^;+S@2U@\B>K&K]'+DI&,BYF_[D>?BA81$7;@+*+K^ONZ2
M-T%$3][6^]X[[R_5SZCO%>RZI>Y>MCA24$.B 1A42[3.RKT<PTN#LEQ4[V+3
M1)H\B+M;9+>&)#=QQ&.7R<'U">N'%X*2HC;K-5X=$-ZE"B]5<Q(-ZXW\--;3
M2V*R.Z3892 +>80RHY:;(<_]@600546/W;:#275*%7#KZW''Y$&=^OY^L^3>
MBWC%29($.-8M,%6IVN.]+P>^6\]\T8C#Z;OPDL,/CV,7(ZH@;!O@\^SQ$,)C
MPE!\.MIOR '@KE=T-V$205$RFV*DNZ2&C@B'86E;Z&3(([>ZQ=8(O"@K%&=B
M]ZU.,N%4*%G39;U=$KZ/R>>U60UNK3H]F],Q#<_!EOTV6B]IE*'R'7D_6!0.
M;AQ8VV5:.TS]1.IN_4WN9"FR,7F]<>2\<L29OF/K&ZQ8J%\I01K1DIPWCQIL
M=<C/S*,*H=LC^+)WN8+- I!=V%LRD5RE,G7D"\]Z^5."M^ NQ&MRN%YVM% :
MCS<F]QA=B]/AU*L&?0^?NWJ[O'X5DE>?&M!]ZL7)"S6_"_$L%7=AF4^U4_N.
MVF'A L1'F<I?]W-$U; NZVLK%Q$Q](,K 5;3FXZ@(Y+NF(EZK*0NSK>>XHV@
MIBZ;=AX\>G;O0.=L[?ZA:&<(OCGYAM$S6CRP1VZ-]V"M>CE 'S8Q(]6?I,M3
MU22I\[QX0_'\GEN]_+$'O'LD7(FS8B'!MG*^'2#,G=PZ!<X*<CM9.AZ"MPCP
M[0[Q0J+LGBK2D\K_QL'#6.-N%-+^,_<QRVY) B>>41B<4%ES,B)>08LTD'2>
M')VDBT-]PBZYJ<?+Z3"[$EAX1%0;NG.FMILKWECI(2]7M #8F*O0.-/F'F>"
M+LF\8&<I<6R^9LJO=&(*;XKE]Z99VF?#BV:>77!)F:UY/ (5;OE/[B+.^Z2=
M\M<I$OS^5C\GK;#3);QP_JWUZ6]FX!)](]?)KN2M&7FLD6$'%W2^3N;E%J+L
MHC"Y.+^FRQ,J0U=A)C5+?=<%S-@]0*VNI'D\T%EGT$62=SXZ$?NB.%VT)A(X
MQ#ND9W2!5$5_80Z(+J7T/OYLX*O*,=KLQDJ>$"TN713,-Z60?U7YVO2T]W,$
MZO12168,?T]*P5>14D##)U4DY0'.V'77%)_GKXCQ<2GXFEGH&C!II/Y1I \"
MJ2@XJ?!>'YA";5KMTQVI&-DV:0^D=^;EQ)T&@V,5/&4C5ZV2.56)DY3&%*_P
MXK#Y=;%ML,HB0U@#D?;%>X'$P&0Y$HY%<"VN@) NR*-5(!_>QBK)DTG@'&O0
MY&( ?DJ:9Y:/(U\"]W*OC\=SA$0#OD*HH]Y+7C%Q[X5(DS (\OX]D,Q8W>:9
MI T@L@Y]4GEI8QB7Q!,]*\,NF\_IILYBC\R6W-4'2_,U3&P*;,V_-"3U]N!(
M<W)6(BO> 3B*NHL-A-D;,,G:\+6\U,B$W#W!A@OU1O1*'N0&SQE/P23%:2\D
MPL12BZ!N6C?&*&?M(2 3FB:C0CUY2*+0[AJ;CB;*SF1!)G&?=R6M)WG+[YU"
ME7S!(%2I,QP"ZM4AB;-)_:(S\$E_@0&OP\^XZ"\/[$KV18VH""3MBE,@'U(%
MCE&;7W7NPQ]\MC+=K9%.J7B\+%;M\@-620$%5UGY>_.G:#&]BUDP<<1IX58I
MF(0;D7%1+'8E[>Z-0R,B5S#S)P)(?YG+Y1)TO@ 0$DASI&.%*J=VVS3AQQ22
MN#U!?0Q-I6V90\JLRI'D3$*F7:['P->2[G+ONH^.1S3I&C.ZWM_K:DS:WO(%
M4RY>OH;JX*&L$@[/L'TPM>:\"HSB3%^::N$KM^A'6[[([PNDM48^(I/D7.EV
MF7 $+F6HX47@\824D=QOAYVY3"3#R0[J*+M_5^P5<C,O A9V@L?0]>WPP!%U
M<+:8L'*C8IH.G=9RL@BQ$UKZ0;'Y@7@9"IE_^I&((LZ(#QP]L'R0L\]M\2W]
MI)DIYUI^.*?NZ;P*W3Z[VV$2&D<#\'U'R5\<F-?FZ&*"U[:BF?_U"_.UN!7_
M@D:X/>@/0'?7^,EKA3*O87B;4.(TI*N/KOV^[\A6.+'%!M\[,$DRS7/?.J+A
MP9"%SHGH]?V^_8RQF=R.8S&!VMEY@(M!)7?'X USG/DJY <59%MI\\&'VAQ3
MS$=_8T3>P"/MA;1PR3KI12S=L$<(U!\$=.W@4,C85_<FQ<.^\,?GIK27WU<\
M?A/Z^.6XB2>?/!Z?" \Y^$%8-3V]EY96\I5A.0C(L30T(-G$#2)'*#$Z@=3S
M==PQ"9GM3.Y<\)JJ"9U]$YU"$,IS1XGQ#N!4;\='@[=^93>#MPW_IE#(1N(5
M2J$[H>9;'^LNRY;D8^2^V1LS>5\LZG%TCY9TPA @H-N% 3'X8Y#J]&3^U\74
MC_D]37Z*$:+X#?W@)%W,7'?\JXSA6^5_TW+)/^487^<?Q'P/L2_>4%*9-0P]
M67S[_!&?1?,?NF9//^RX:KJNV=&?&'N:%E^ Y^L&-)I\P 7"+WW^]+]02P,$
M%     @ '(%]5USZIY(\%   >D@  !@   !X;"]W;W)K<VAE971S+W-H965T
M.2YX;6S=7.MSVSB2_U=07N]47$7+>EA^Y%6EV)Z,,XGMLS.9NKNZ#Q )25A3
M!$.05C1__78W !*D2-F9<?9N[TLB2V"CG[]^ -+KE<KN]4*(G'U;QHE^L[/(
M\_3EP8$.%V+)=4^E(H%/9BI;\AS^S.8'.LT$C^BA97PP[/>/#I9<)CMO7]-[
M-]G;UZK(8YF(FXSI8KGDV?J=B-7JS<Y@Q[UQ*^>+'-\X>/LZY7-Q)_+?TIL,
M_CHHJ41R*1(M5<(R,7NS,QF\?'>(ZVG!%RE6VGO-4)*I4O?XQV7T9J>/#(E8
MA#E2X/#?@S@3<8R$@(VOEN9.N24^Z+]VU'\FV4&6*=?B3,6_RRA?O-DYV6&1
MF/$BSF_5ZA=AY1DCO5#%FOYE*[/V$!:'A<[5TCX,'"QE8O[GWZP>O =.^AT/
M#.T#0^+;;$1<GO.<OWV=J17+<#50PQ<D*CT-S,D$C7*79_"IA.?RMR!-S*<J
MXT9'2<0^RA!T+MADG@D!ZL_UZX,<=L+U!Z&E^LY0'790'0S9)Y7D"\TNDDA$
M=0('P&+)Y]#Q^6ZXE>*=2'MLU _8L#\<;:$W*N4>$;W1D^2>M,K-_GLRU7D&
MCO,_;2HP&QRV;X#!]%*G/!1O=B!:M,@>Q,[;G_XV..J_VL+^8<G^X3;J?]IL
MCU"]_OAQ\N[Z=O+Y\OJ*3:[.V<?+LXNKNPLV>7][<?'IXNKS'?N\$&P&VZN5
M3.8LY]-8L#13#S(2FG$7W4S-(&8?1%((^#]4\T3^(:*7[#\%SXQ3,#!I+I93
MD95VQ7^&^,^ O9 )RQ>JT"";WF/O[WYENVQX&AR-C^'%8'@8'!\=PJN?_G8R
M' Q?L5]4)O\ 50Q'P;!_A"L')P-V%)P,CMAG?B\BS@9'PV ,?YZ,@Y/1(3OM
M!\<GA^P#3[06"1N-C]@H.!P/V6$_.#HY9I/E'-X>CH-^OU]NX_[_K'(>(T>P
M^'@TIE>P\VB S(U.@B$0:%.4T0ZH0H-T O DYDDHC+)"(1]PD29[AA _Z'HL
MEGPJ8YE+^" 3,<]!=;FBQ\_4,N7)FI@Z?J7AF:97Q-8K>.D5+SOUWE#YK<>0
M3,*X0)M)Q-%0%1@=%<>>'4#\X'#0!]9:V/?) '**+(/7SDMVV<G1$:FO'_0/
M3]G[F']3>BGSQ3WZ*;M,<L!N /,"-'^305K*\C5[<:4 %_; _6$E4'N!C S[
MK\!AZ-7@U1Z[3MB5>C B#X<D\B @ET(5>8IDH""1$7^@89ZPBV_ L(:TL1E>
M[ 4^6.VVN<+MWV._@;]GM%'K0L/+@CN5 @.PMRCW=D:$%(PK]P_'H^'I:9^]
MP)PLLGC-)K?7^[_<G<-6Z'2;3TJ-R3&.(+<(2##Y@IB!=> *Z"K@?\ ,N%;&
MSA8RX3WB")]:@$NM@2^=*DC$:&OD@L<Q"\$J,@1;1&# 6*6D%..Y2^ JE#R6
M?W!'WN<;K"_!?V"W3.8J6_?8)">&P#\JAK:HRS<92)3D<B9!:0J\))(Z!S(Y
M _>@DH7":QK+.;%B%.2>C03P $D5(VK!#0_W M^/07M9P_?QTS*>4$YP0*AZ
MV.U/?)F^.F>(\?"Q#NPC%/4M45HJ$\-BC;$,&DMCX(66WX C"#8X&#*=%]%Z
MP\_<=G=VN\K-SB&*+#+H5!@#D"]%K$CD5_@TX7F1"5^[36HN)&0&J@1WS WF
M@.KT0J:5[UA%U&W1HD\0I:;-3% V3/*FO:9%$L6D6*19@!;QX^^V(CH1@ VX
M)<!/HKFI_=(,V 7= &C#JMW!L-_K0S45Q_!ATUQ%.LL O%C*U\;;5@L9+MB*
M&WP%E1@ @\118*)#[*PSA)%,,1B1]M=L5I#:!8BZ)/R&K>$/$% SB*9,K7E,
M  D[+X$)"+PV[ED$#V]N!<&H0I,6%E;(AHA;=4*Q^(30H<"W;E.&LA\/^!G7
M6H'C(3-MW@61KFL>LR"M&N^/B)..S6N9#_3#ZVC0,!IZ>$,%:+]98<#,E2.,
M,IY@:RQ*1'M1 K;]N<A@569@.E+::GHF,XT[@N5@1\R,-G:'4U TJAO>^\0S
M<!Y,L@&^.9^+#!V-L]V1SUWI$*4$]13O.6'*9<DXJ"*+V%?P0X1N$'HF-4(R
M[E=W%%19K!6#6)Q7, X\1Y%$!<-#-=WU?>Z*E/JGA10/+DKJPANE>"H8&0V4
MNENJ#+!"0W411Q[*V64,VTD&+2-+E9;8IL7KH/2I5.4(\; L@29O*2(98CU@
M<R5"RKP YX!$PGB*E:C1_)+_ T2$:NM>Y-IX22103%>KH@:J7+5I MVT 2BF
M2/'-W<&IKQY .J,.CYH&I#$BV$?&I_6 I!5ZW_GUYNX;]IL9558F!+)6"0S,
M0+54B22P1P(M/0@;%1#2M)DQ$$# G%+ 4D;[N8#P)3E7L.<:HP\".F\#&7 >
M&YNBRGW-W ]Q6\P 8 KCY=AR4^G7!-EJ';$29<4<:F/HMBCND1*]Y=@OJ(!Z
M_^D&RV+CL$#2UD,L+3)=\"IF.JH&7&["J(E 4] "J%(NIT )I,.5B$6ATDT[
M>."QV^^-*A\ EG</>R>^A8'7Q X?7-X$CL0,R.>ZA%,$']V%/B,BC# 44-T@
M0A,=O;+A >8RGHHBEZ%FE^A.\,#YY*RLA.U"OQK^4("?#4Y<)>Q(;:^&G])=
MU(H51_9)A3&F<.T*D\XG*UZK2MFK;-M+YE_^ZPKRU7& (MB:=1\<#8*@Q)*I
M0,>TS@Q$I^M**=C45A"48YE,HB+I5"A(7<:Z14(M&Y8($9L#F%4VZBZDOZ^(
MMI+TT(;78:[048X"FUU,OUI/ICS\6D@MR^<-/]WU]A;%_S^JN1$?J>I."%RP
MF:F0"A[/5#$W( &U:FDA<AER4=]6E55:??_9BG5=&>??M&1_)];* DR7)*[6
MYIEIA1J=DG52RWJ%!2N 7 CAC> "'O@</<+6WW\RV'SOM3Z#AGH>K^G$0-X>
M>OZ$H*WH/6Q4&1^*F%J4P5_MF6J$46G_PBZGM<,Y_&$-C@OH+<U-EP?WV*T=
M9ZW,.,<5"Z@TAL-D/"78IX'6E&M0@7IPUI=+,<OX4KC"%''<X5GW?H]A:]N>
MR!N5RJ B$ =S'.K(528K@6;\EIJ:!.4!'RKY#!462>AL'H_=G9O7/CDA1&*S
M9-5(0.WW#T0N\-AS\' SJL.AI-=3#+!TC=02]1FP-.:AF*I]+^F:7@)K%:V%
M-HVFYC.1 U;D*D8\(R"!AQ<<& W5/>B$"B<TL7LS6B=\B6]64=KLW0;CO]Z[
M:8%@TMF\U8:6 Y?D6Z$@43EZ.H65TS'97^8F2NW0 MDB_^!VU-29[JO217Q#
M8-2VGLC0D[Z#CG7E!%P(^L30AK5[6#KLSOD]U<7H <KW "MWCUU6G6I="2C?
M\[0EC_4@?LO2W8\X531[DBVJ[FHO!KUQO;T8>F_\Z/;"GIG<F)B@]@)<T['9
MG+:;U7Z+X<K38]H'=K,$OW_BCD^<J?V?0>=HIO8!O*7^I%:C:VTGC^2CH=JW
M7M5:8/[,_P @DX!0Z#!SP'%O//]Y\NO^Z>DI$<91_63R>2]H)6- 81\J>6'[
M+/#(L "7%*K00(I'$#J0QTAIMU<3B61< \A"V$%B_MSH:*B-J3<O5.)A4A2(
MKEYR(V_B,>#A_@!XSF6>K5-MSFR@7X) !@?Y'199)/LM(6>XR^%I#(-2%1!>
M,SN30<AV=5J(J%U57"*R\<39N'\P[J,"9P!=&GP/A8 ,5E#8 2@6N<9&KV57
M:[OM)RAFUE[M[/%*QB$.8QQ&X0[S6$UYW%(=8D[-Q7Q-]6HL-IT%A'S:E&8&
MT?%W7#(<_]W-;&A6T]VC=;OO_^T6[4]U:-ZYB"OQ4H W3QUW%__QV_7EQ!R6
M!!M/J62N<$L[F<7P@^@;]OON>(6"70$.:6H1+//UA(&YN7*46E:0_OR:<H91
MDDFWUE8M2/6<C6$'R7]97_A,76&'&-_9%%HJ/Z(G[ *?;6"X 0UFD HU'R!I
MBDA-F7Q_<_O]30Y<;B^A"E;-"J,^+_6395TNT[294]-V@*4GV^38:()1$9FV
M_4 Y%@2(ZQ[Y/E%("F$P''1+ CA'#8';DP#VYH'C\K-*(>6=]$_,G!TDU46X
M"*PRK&JHWEN:"POH05A@99%)B.B]=#QCXK;BC7H?;=I6DXICLX5-OE96MRQ@
M]7ZJLZ=_&G27*6QW5#N%P4TVF_[Z2>3 \%D[UZEWRG264]5KA+T&6AVJ5F<X
MMQ?GOU]?GS-OFH&068?#QB$7[B]U:_IS)R'#XWHAZY]!E8-6SQY![8BG%IO>
MC.&)!Z-UG3[KW,!3RI;100?,59,#61L<0 %C T@F:0%MB,@7"BIOO(IHQ@KF
M1HP[BGO >:^?E "O=:&M^-5P9F.=D\)E3)=8;='JLF;-%R#,]^IZAY3P($VI
MBN$16NUK#VFI3:?\+KZ!M2E15IT)>-$8G0*C-*-QD%@"WE#%Q6*%NH"0LGT]
M,0>P!W3#M6NL\<(J T@2L=F [H^^N/YXL5>#0LO_*[90*]!\AGC%)L6\T+EU
M96LI&QUTUN B ZBY^N&!RYA;3[=&T![ TW0DL3IP58C=&]*?LR*-P_!\4R;F
MIBU!84FO')E8&3N,8^D2TE7JKY=$4 [X;*R=)TQ%OL)S,#H<*GM#?QHSHA/<
M#%3:5<1U9?D)=A\ MT4,P6P:?:J''QN#U($Q7.#1I9E$.$<NL;5QV9 "DS))
MCF0S,<,A2*EF=,\R%'RNX;54D;U'92<2KLXR^],Q:K6]D:J\&B=PS)1[U]JF
M:[9[W*\ +\"DLMOO'1WA7I2#!7L1R;B I_9J;7MGUT[L8;K&?X#6:8EG-)5K
MO3A8I;VPR#(ZM&_>P..DS([MO&&L5A6]W4-_2H$G3F%6X-30I= NHJ:LI*%8
M)O%.))@DRL K$E394RNBJMSHE3<YZS,+R,Z72=@K1Q5V5=NL8H2<X;&H71/4
M\**=O%6+;>8^J$6B@2W"=O=7\,C0XY&[A6[?+;.-#?,T-H $&=[C2"JDP*^.
M:ZE2_/#A_*RI)'C+D0_:I2IC'BQF*FF>2DPQH)TZ_T +RDCDX,9QL'4^TREP
M:9C6T]^@O=]O@ZD/5Q_V1Z<GI\T;E.^^[+GI3?MXAN[;_*CIC'?(3 ^MS1&S
M2P%DJW !Q1^06@A\/P<P>P?XG14(2C,S#*SU5$T!FI<+T6>M,H*6RQ'F$*-Q
M9%U._2M[/-<!M^.ELX+>XAOM)?3@>/Q8"1T 0(_KIV94S8%K4#D,:/^UP%93
M)@^ ^R0!0!3YM5V[>1%[N:0Y$7I]47GVME P,%$=)N!?RDQ^O M)$&'H.KO'
M(_\&8Q-@EGS=K+I/A@T9FP8Q5X1:;D&YE-2I^[]\4ZE^2\DP7-U.*AY'ANYI
MV1,=YG]_Y/7X16 O/IH&WT+RL<%62?([QEI.J6UIZCD'6UTT_RTF6YT35;'E
MF)VF"-^HM 0PW1V.A[WC*LP-0%LW--.7#2S+S06$I2R6YKC1096[U+8)9G40
M Q(KA5MO.^*L?16ERB#4CE5UM8\@[GH=M4J=AC6SG_) [XD]?4U-S]O3E^&Q
MI:/ODJ;S:*_C[H/]7@06 1DUM^VE\R!P!_;MO-L#?'N4B:J(UU4TUWJ'1%7M
M AZ:V]EB5^?0T1U "3T!"6)[V#>JZH('%1=);HK[\L@XLG<K:[<)ZR5IS1TC
M>J91I$.%@(,L_RC9(GX'X6:!,.<4CG@EW!QKD_-A&7AS=?-Q,J+C7%,;0OF"
ML8FN<#P&K#L^'?>\E0B6,BDO*6S,.1!D."E[U7;1T&.K9R_QU6IQ>LMO5[Q9
M"5WA'!RYRW];^PR,ZJ=\0<Q,$.LES&;KX%=H=Z:%?\)W$FL9XSI.N9F6;;0#
M3J"_6.<G"O1LZG!5;O;"&U%EK@6F2R-L\NG]/CLY[6.+CO;]>#,I&P**&]B*
MJ"U5+,(BMI,6P&(Y3PP5(%:$>/HG'LAM8YDJH)"#W5_PO1+"L=['-H)Z2&#D
M 9(A^3E.H2)!5V] 79G4]PS3-3!$%_:QK%(ZC.%?TU%DD50/7 ,SO#S+]6W3
MHF2GW.<HVA_=*F_@MS?<;M2CC4RF[9V'07U6_)3*W(KW>&GNW4UJ[1Z\P33L
MM3MN<+R9%5_A-R>:P_8R@+?,V@>VQI.U\*9AQ.YP@R+B9SN=87-6[UT![ =6
MI>,V>O5[6&;>Z*J#QK<Z-FYI;:;ICN2S-6L5VSSI!Z2M2_^&%5V!N:6F9&U'
M/+# >95&6YRRR[/)EQ*7ZXM+@'YDUE,^M='_U;"QP4G+O.0R*<_AZA5+&3^5
M/KNH;4@L3?61QP[,3,^&=UV]A@TC9@50@UM1.5?&7./BV^,6]6(.?T%BV[E1
MXU!KW,0/0\%+KZU'1YU=KI.%;M%5Z;2NH!XXD@"O@0YM ![T08%5V1<[ &O/
M>%3/?)$@?,)K7]9HC-SL$C_1FZ)J. ZL>W[7"+&VK^]:[KW.>6)0N[QF$I9[
MZ-'K-5;W0>VZ7#-U((076>/HOD1(S+#[YGC+X+I%"+R*0_EN*7*H,V#3\@L<
M5("]][_!C-]F]WOO&_JF1K6'2(LI4@ >:#W>3H6EORH<:WWB(2^(Z\]<KG@"
MX7;CJ82S.YK:M\1PS2Q:+HNX&@Z6E6VG!5KM='<SJ2SCNP!]N2.CXHB^ZX:)
M4--52E!&:7D^0YW8HW.Z^*#LJ8,Y ,\>[-F?YX"D(@&8K=9"V!)0K1*147N=
MQJ 1=[% T@6I-ASJE-*O&3PA P,]='PUFP&.5W?1OL@'Q<[<?!D'W+[L,NF0
M79*/TJ$-<;5[U&\O.=SH&FU6I'C!R!TD9C8W@9M8JG28Y09<=<F+#;$>NZ35
M_%*F!WK5-+@V*FM\Q5#WVGY,Y,#[/1A8/:=?O<'2!US _#1,^6[YPSH3\WLR
MU7+SJSR?>#9'7([%#![M]X['.Z9=<G_D*J5?EYFJ/%=+>KD0'!2!"^#SF0)!
M[!^X0?ES0V__"5!+ P04    "  <@7U7J!^\WF8#  !/!P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970Q,"YX;6R556UOVS80_BL'-2@20+ DRI)?:AMP$@\M
MT'2>DVX8AGV@I9.M51)5DHKC_OH=*5MQ <?#OE \\N[A<SS=P\E.R&]JBZCA
MI2PJ-76V6M=CSU/)%DNN>J+&BG8R(4NNR90;3]42>6J#RL)COA][)<\K9S:Q
M:TLYFXA&%WF%2PFJ*4LN][=8B-W4"9SCPBK?;+59\&:3FF_P$?77>BG)\CJ4
M-"^Q4KFH0&(V=>;!^+9O_*W#[SGNU,D<3"9K(;X9XU,Z=7Q#" M,M$'@]'G&
M.RP* T0TOA\PG>Y($W@Z/Z+_8G.G7-9<X9TH_LA3O9TZ0P=2S'A3Z)78?<1#
M/I'!2T2A[ B[UK=/)R:-TJ(\!)-=YE7[Y2^'>S@)&/IO!+!# +.\VX,LRWNN
M^6PBQ0ZD\28T,[&IVF@BEU>F*(]:TFY.<7JVE%1?J?? JQ06WYN\IAO7$T\3
MMO'PD@/.;8O#WL )&#R(2F\5+*H4TY\!/"+5,6-'9K?L(N(CUCT(?1>8S\(+
M>&&7:6CQPO_(U(5EP2O]<\+PUWRMM*1_Y.]SN;?(_?/(IF_&JN8)3AUJ#(7R
M&9W9^W=!['^XP+O?\>Y?0O\?%;J(<Y[E<O7K<K%Z^A/F7^YA\=O73\N'Q9<G
M>-HB9**@CLVK#6B^+O#0MOD/5*!I^TZ4-:_V[]\-63#XH.B?_$=(2 JN%'F(
M#.I3WGCD/0:JJ\9RC;(KKAD87.<5 8M&D;^ZL?B-1JE<4"+3.R[1)=@L3_ 5
MS6)GC:QRW4B$*V NZ_OV&PP9?#;;S!V-XL.XHKRY3+8G"%'L1OX(PJ'+AB%\
M1NKPK2A2R$M*X!F-CX+ #]UA$$*?N7XP(&X5_2Q-JRM$FSPW=*7D%\=N'$4&
M-!R$$(;$A\*"?N .HX#0E1K#/$F:LBFXQI3T@VJ1Y+Q5*&++2R%U_J-=N*:X
M413<P'48N%'4OX'EV4MUH2+YIJQ'OLMB1K,@H-EH /<7\?&%M%V94LLWRF6W
M3+GW=&\*T/3VF0K:D;DVEF8![+B"J\#O#4BSBH+.<N%J^&I9QZNX%W<+='TU
M6H4N]CTXUS;>B<B5*#=6RA4DHJETJW?=:O=:S%N1?'5OGYH'+C=YI:# C$*)
M9>2 ;.6[-;2HK62NA28!MM,MO7@HC0/M9T+HHV$.Z-[0V;]02P,$%     @
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MC7KC40"Z&6^:A565'RF6RM* XL6")D+43H&^YXJ:J%TX!]V,.?L74$L#!!0
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M0<,"=#[3VC4+=M#^U+GX!U!+ P04    "  <@7U7 ^."4_<%  "P#0  &0
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M9X%?'%_<Q/BJ&>=W X,T7V#3-L?1)FE^ @$93UMD??O$KDXR?:F4*^-X\H'
M,3B^=T9F:-A+.T.A<Z(Z- *?'YXDR#UFOC6H/6'Q@8ECB ^O> IS%&B($K.(
M=8CG>:LI^"1>M-GU46XZC@V$S9X'TG%OH8+O @6(I-O<M'.P'*($TSC: AC9
M5?*.&%74U)IT*#N[EAJ%Q-1$ R-QT>]W[X8Q>WJ0S'[#[C[RW"ULO'&+KL@M
MXK<"UQ7#FR[4_=O^<^0XW<(?Q=.WS(5T"V50.YI#=3)ZNS=(=>H6P=;Q3I[;
M@!M^?%SBDXH<"V"?SZMNP0[ZC[2C?P%02P,$%     @ '(%]5^WY=G_I"
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M/;,H2QOP_]*8LKT@!=T;Z=O_ %!+ P04    "  <@7U7[N]HPP<,  "T'P
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M^@7)_Z>J*R'US@U+TM24()0L%>)"6*113W;;??8.":P/>"_;B;0T+3R_^/=
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MY>14-\@8\A:T UZ)=%C%K@G'G/HN"G5OYH$J/]UD  T8DD2M\K;A8+TF2D"
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M:05VBD:S)$A*HW0R[4LB8S>MZ;"N;UQF@"VN@BW!#=Y,7:XZ+OK;-M_6UD+
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MUL=13*!9C0* GA)2.=NC  G.Y%3R 1DJE:U+]((Y++=Z-RJV@MDII"*TKRG
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M0X?OX=K-JB(,6KX_<JDBMNF2U7_MKZB3=#.[W9[NMY^DFW,OUE1 =+3[ZN4
MDSW>&=-+L'6\I\ULP*TO/F)6HV1Y ]8+B];<OK"!_N)^\B]02P,$%     @
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M68ISC_I H]J@%[U^-3X*WN_Q.AV\3O?17_9!_H.X6L:KGU>K'[]@=4W/^%S
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M^6FJAQF-X0R$#QG80\YPYFC.8RQS?Z 8!# C#^=OBQ1<5.=2@8QTS0<FCYI
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M    >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;'U6;6_B.!#^*Z.LM$>E+8$
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MD\A12.\850?XVQZ>O0"?,/B@E=M8^%'56'\-$!'7@3 [$KYE%Q$7V%Y!&H?
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MZPW:.I!]K10>%C9!^W]@]@]02P,$%     @ '8%]5TYK4J]] P  R0@  !D
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MW.!_#=#. <\KI>SCPB7H_[TL?@!02P,$%     @ '8%]5]_'0@>\ @  308
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MRJ!M3LG$LV!!6"@6H-NJV#Q.3?R%T"ZE$8DO:8=22B)ZWNEA76[6V6=1K?_
M>_NTXJMVW<,9[^:,^H.&<]"Y//M8_X]S5Q&%6RU>@%[Y06;PR2MIZVYO3]M9
M.:E'Q(=[/6COF5YQ:8B )8;2[CF.)ET/K]JPJO0#8Z$LCA^_S7'>@W8.>+]4
MRFX,1]#^@R3_ %!+ P04    "  =@7U7IP60>AL%  !8#0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970S,BYX;6R]5VEOVS@0_2N$VRT:0(EU6):<)@:2;/<
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M:O^IK(NRK6XS] [8;&Y]<H@.1['_+QTT[JP]*JKGDLOU#N6E7=TQ*H&9JG"
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M,$UJF*L*QCT"X[CDD\CU6I&W><K2?8 IZ-0JYC:*7;F#B'>LF!#/MHAKN]X
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MA_W[.=:9\5!-4M#9C! )E?()>MB6RE1!60QL:-!8'YW0L3PG)M>TX%"!^7?
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M.&_Q1+D6.[J"N:4>&0+X :S%]]^1 /\TIIE)LL@064=/K]'3T[$O:O7&!*N
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MDF7EY19H#+P(4/?7C,GG1?$%S91[\3]02P,$%     @ '8%]5YZ;9@QN @
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M>4H$S$?6C7L=N>T\H&CQ9PP;>7!,\D>9</XM/[F?C2PG[Q$PF*H<0?7'&NZ
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MXT="=YD:@'=G %M.#O1:.V #QC=C?-#/U7(+C&? !.?WQH0)S9C?5JSJC6/
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M&8B\@;X_YUSM3O+=X.H_&,;_ U!+ P04    "  =@7U7GYY4>T$#   <#0
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M0'X_8TSL#I( ^=M9X_\ 4$L#!!0    ( !V!?5=@+C1+LP0  /X<   9
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M9-WZL*EJUNUAVH,#-\&JL9EM0KM?/QLH2E671-'R$&SP.?[.38P=55S<RPQ
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M5^EO3)ITC/:JV V5/TS9^LY59"X_>=ZIO!?:6WE(6@A*(U TUYXVS ;0:38
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MV KH]W<$T#* /@F@=$= OPSHOS1@4 8,7AHP+ .&3P+<P8Z 41DP>NE)C\N
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M?=[_]9-@R=[N%@='V[](E=* ^KI0&H/2?"@M0-'JTJAL86JWA5L.4-F.C$S
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MV=?#^\ETP3I0P0[4T\YC,M_,J*K+]J^:AE"FR+@+,(**C&!P[=8UA$V%7%U
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M632GFT4[C7:\WZEV >8Y]!DT7%)U8IUN!FT@VAT , <'L%:TCZ\7X9K*9NE
M-0=0S>%SBG6'E/*HU&3? 1 Z].537%+9 =WR*5(O<EJ["?!LVR$N6*\!I&Q&
MI2;;"6SFS*I:ZI F^JC49-\!_SDX_TU\TG69C;F6U=U_HB,3YP &.C@&3@IM
M4@9T^K)ZW'2'8AOHSL$3<0I;A7H^L=8[5]WKL*&Z %/NF-0:4ZP9X:+*.X=T
M<)<+W.7.*KWFDB(;E9KL.Z [%Z<[I45S/JF&7B(/$?#+'5,592K5(EQ1>8IT
M()0+".7.JB3JDM(7E9KL.X T5\<F [=;]^PL=!U0YK;VB-+O,, EE2=V] X#
M%W#)Q7&I]2P;62;"!95MT@%4+@"5.ZO]!BXIBU&IR;X#8G-U[#=PNU36LYL(
M[WKJSF@@/(]^NP$NJ;S#&4N]R58!M'EXL@QB?4RE"!=3MD<'<WG 7-ZL]AIX
MI+DX*C79=P"#GHZ]!E[/7H.>?45XWU-M ]#SZ'-EN*3RY'9S9<B^(@\PS!N5
M*U.M&.&JRL;I0#8/D,V;51[-(Z4]*C79=ZW3073DT;R>/%K?#B.\\ZG& ?9Y
M]'DT7%)Y=KMY-&R'D0=4YN%4UHK[\;4C7%/9-AWPY@.\^;,Z!\0GY3XJ-=EW
M@(@^?3T5EU1VP.AZJ@_TYX^II_:=^_86;ZD\>!VDY@.I^;.JFOJD*3\J-=EW
M0((^3H+3GG=^E]Y.TU9XOU/M @[T<0Z<%-&D$.ACJ3W9*B ['T_&C:\6^><_
ML89>(@\0\,D?DU?CBC4B7%39\5J.26N=DS:KW)I/RF=4:K+O@.)\G.*4%DTW
MH]99X=@E\@%S@%G!F"HH5ZD1X8K*I\WI0*4 4"F850DT(*4L*C79=P!D@8X=
M!L'Y8BC>[U2[ , "^AT&N*3RQ([>81  &@5C=AAPA1H1+JALDPZ""H"@@EGM
M,@A(X8M*3?8=<%J@8Y=!<)[9\'ZGV@5X%]#O,L EE2=V]"Z# (@M&+/+@(\L
M$.%BRO;H *Z@=5[NK#87!+3G[NHY>+=]\JZ.[04OJEB<G^EYLFVMDW%-^I38
M&4WE@P7-T4DQRV0MRT:EQ51+1&=DU8W3P6R6V3I&UYQ5VNQE.&3^TW(@K]DZ
MD=?4D3I[4?70Z->!?I;9.C'7I$^?G=%4G^#1"33+;!V8:XXY$82K%8K.B*J;
MI@/C++-UP*XYJW-!7H9#YC\MQ_6:K?-Z3?I*ZAE-=2?XR(WD8-FR]5U)U3=5
M?0BSARC)C5C<EVW,R^J#"MGANY\.;XIT5W]]TEU:%.FV?ODHPHW(J@O*W]^G
M)18W;ZIO9#I^!=?J?U!+ P04    "  =@7U7X?$U6<@"   ?"   &0   'AL
M+W=O<FMS:&5E=',O<VAE970V,RYX;6RM5EUOVC 4_2M65DV=M#:?!-I!I$(V
MK=(J5:7='J8]F.1"K"9V9CO0_?O93LB NJP/?0';N>?XG&-RS7C#^*,H "1Z
MJDHJ)DXA97WINB(KH,+BG-5 U9,EXQ66:LI7KJ@YX-R JM(-/"]V*TRHDXS-
MVBU/QJR1):%PRY%HJ@KS/U,HV6;B^,YVX8ZL"JD7W&1<XQ7,03[4MUS-W)XE
M)Q5001A%')83Y\J_3&-=;PJ^$]B(G3'23A:,/>K)=3YQ/"T(2LBD9L#J:PTS
M*$M-I&3\[CB=?DL-W!UOV;\8[\K+ @N8L?('R64Q<48.RF&)FU+>L<U7Z/P,
M-%_&2F$^T::K]1R4-4*RJ@,K!16A[3=^ZG+8 ?CQ"X"@ P2'@.@%0-@!PM<"
MH@X0F61:*R:'%$N<C#G;(*ZK%9L>F# -6MDG5!_[7'+UE"B<3*YIQBI ]_@)
M!#I#,U;5C *5 K$E^L:$0%-0/RY >X6G*4A,2O%!01[F*3H]^8!.$*'HOF"-
MP#078U<J=7H/-^N43%LEP0M*_ #=,"H+@3[3'/)] E?9ZKT%6V_3X"CC'.IS
M%'H?4> %H470[/7PP )/7P_WC[@)^Y,*#5_XWY-"*1%9R42CCN7GU4)(KMZ>
M7[;$6\;(SJ@[RJ6H<0831[4, 7P-3O+^G1][GVQIO259^D9D>TE&?9+1,?8D
M53D*23);8BUR:)"Z9:Z3,_\BBL.+L;O>#<-6-_0&0V^_+K751=XHBONZ/0N#
MWL+@J 75\U1'HS8'+3#>W7$X&@0'^BU52O_H0/WS*L^N.^YUQT=UWS.)2YOJ
M^'E.ZKV)+OP#W98Z?Q@$PT/EMCI;[NY.ZZR K\P5)%#&&BK;3M.O]K?<E6GN
M!^M3=?NUE]4_FO;JO,%\1:A )2P5I7<^5*GR]CIJ)Y+5ID$OF%3MW@P+=8,#
MUP7J^9(QN9WH#?K_!,E?4$L#!!0    ( !V!?5<'PH&83P,  &X-   9
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M Q%0"1#W9X3P[4 N4!^QPO]02P,$%     @ '8%]5TK1AL?) P  !PX  !D
M  !X;"]W;W)K<VAE971S+W-H965T-C4N>&ULK5?;CMLV$/T50D6*+9#HYOO6
M-K!K)V@>4BS62?I0](&61K:P$NF2U'K[]QU2LFPYE.2'Z,$6J3F'<V9X&<Z/
M7+S(/8 B;WG&Y,+9*W6X]SP9[2&GTN4'8/@EX2*G"IMBY\F# !H;4)YYH>^/
MO9RFS%G.3=^36,YYH;*4P9,@LLAS*OY[A(P?%T[@G#J>T]U>Z0YO.3_0'6Q
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M#,&K1,Y+$94J[Y?>- B]<&[?'V(9Z!9X_BSH=HNT+CTSX$D3\$0;<#VA!7Y
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M@"%19-^#.^^C</6>"M?_O1S^!5!+ P04    "  =@7U7EXJ[',     3 @
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MCA^?96>;_BV?C?^:/'\!4$L! A0#%     @ '(%]5P=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  <
M@7U7)'18Y.\    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    "  <@7U7F5R<(Q &  "<)P  $P
M@ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( !R!?5?MGSP6
MZ@<  (PQ   8              " @0X(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    "  <@7U770<T#T "  ##!0  &
M@($N$   >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ '(%]
M5U/V"VD"!P  'A\  !@              ("!I!(  'AL+W=O<FMS:&5E=',O
M<VAE970S+GAM;%!+ 0(4 Q0    ( !R!?5<6I K@Y@(  .$*   8
M      " @=P9  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M"  <@7U70Y]@0WH&  "7'@  &               @('X'   >&PO=V]R:W-H
M965T<R]S:&5E=#4N>&UL4$L! A0#%     @ '(%]5WZ*\"NS"   VTD  !@
M             ("!J",  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4
M Q0    ( !R!?5=\KE,C$ @  #,E   8              " @9$L  !X;"]W
M;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  <@7U7*LZQTSLD  #U
M<P  &               @('7-   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL
M4$L! A0#%     @ '(%]5USZIY(\%   >D@  !@              ("!2%D
M 'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( !R!?5>H'[S>
M9@,  $\'   9              " @;IM  !X;"]W;W)K<VAE971S+W-H965T
M,3 N>&UL4$L! A0#%     @ '(%]5VV99D%W!   _@H  !D
M ("!5W$  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  <
M@7U7?3AINW $  !O"@  &0              @($%=@  >&PO=V]R:W-H965T
M<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( !R!?5</UPQ-?P4  /8,   9
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M970Q-RYX;6Q02P$"% ,4    "  <@7U7IKJ.\QP,  !F(   &0
M    @(&RI   >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    (
M !R!?5?K'ZZ)Y ,  ',(   9              " @06Q  !X;"]W;W)K<VAE
M971S+W-H965T,3DN>&UL4$L! A0#%     @ '(%]5]R_%;R(!@  Q \  !D
M             ("!(+4  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"
M% ,4    "  <@7U7=:0% 24#   :!P  &0              @('?NP  >&PO
M=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( !R!?5<3Q6E/C (
M *T%   9              " @3N_  !X;"]W;W)K<VAE971S+W-H965T,C(N
M>&UL4$L! A0#%     @ '(%]5Y1V$O)^ @  L@8  !D              ("!
M_L$  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  <@7U7
M9J.)[X *  #:3   &0              @(&SQ   >&PO=V]R:W-H965T<R]S
M:&5E=#(T+GAM;%!+ 0(4 Q0    ( !R!?5> WN6H3!@  &%1   9
M      " @6K/  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%
M  @ '8%]5T* (+#" P  &0@  !D              ("![><  'AL+W=O<FMS
M:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    "  =@7U72+__FV<#  #U!P
M&0              @('FZP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+
M 0(4 Q0    ( !V!?5<Z6VA0&P,  )4&   9              " @83O  !X
M;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ '8%]5_ )5;M)
M P  &P@  !D              ("!UO(  'AL+W=O<FMS:&5E=',O<VAE970R
M.2YX;6Q02P$"% ,4    "  =@7U73FM2KWT#  #)"   &0
M@(%6]@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( !V!
M?5??QT('O (  $T&   9              " @0KZ  !X;"]W;W)K<VAE971S
M+W-H965T,S$N>&UL4$L! A0#%     @ '8%]5Z<%D'H;!0  6 T  !D
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M=#,V+GAM;%!+ 0(4 Q0    ( !V!?5>:#F-57@8  +<R   9
M  " @=(6 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @
M'8%]5T&!NJ3\ P  \18  !D              ("!9QT! 'AL+W=O<FMS:&5E
M=',O<VAE970S."YX;6Q02P$"% ,4    "  =@7U7GIMF#&X"   ;!@  &0
M            @(&:(0$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4
M Q0    ( !V!?5==#/6F @4  ),?   9              " @3\D 0!X;"]W
M;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ '8%]5V:3UB5+!
M81D  !D              ("!>"D! 'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6Q02P$"% ,4    "  =@7U7-]NL)U &  "4+P  &0              @('Z
M+0$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( !V!?5<'
M\A,+"P4  )@A   9              " @8$T 0!X;"]W;W)K<VAE971S+W-H
M965T-#,N>&UL4$L! A0#%     @ '8%]5_L@YBR=!   S2   !D
M     ("!PSD! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !V!?5=@+C1+LP0  /X<   9              "
M@3A. 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ '8%]
M5T?JQERV @  F D  !D              ("!(E,! 'AL+W=O<FMS:&5E=',O
M<VAE970U,"YX;6Q02P$"% ,4    "  =@7U7%HD,*! %  #E)0  &0
M        @($/5@$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0
M   ( !V!?5?W0 V&(@8  ) N   9              " @59; 0!X;"]W;W)K
M<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ '8%]5XJK-<WY!@  *4(
M !D              ("!KV$! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q0
M2P$"% ,4    "  =@7U7C>"\2 4$  #1$@  &0              @('?: $
M>&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( !V!?5=J(/;%
MSP(  /,'   9              " @1MM 0!X;"]W;W)K<VAE971S+W-H965T
M-34N>&UL4$L! A0#%     @ '8%]5[-V[2F7 P  6PP  !D
M ("!(7 ! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    "  =
M@7U7AT>: _4)   '=@  &0              @('O<P$ >&PO=V]R:W-H965T
M<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    ( !V!?5>]S*-![@0  "HD   9
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M970V,BYX;6Q02P$"% ,4    "  =@7U7X?$U6<@"   ?"   &0
M    @($8F0$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    (
M !V!?5<'PH&83P,  &X-   9              " @1>< 0!X;"]W;W)K<VAE
M971S+W-H965T-C0N>&UL4$L! A0#%     @ '8%]5TK1AL?) P  !PX  !D
M             ("!G9\! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q02P$"
M% ,4    "  =@7U7+=XZ8T0$   5$   &0              @(&=HP$ >&PO
M=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( !V!?5<(/BIS9P0
M (07   9              " @1BH 0!X;"]W;W)K<VAE971S+W-H965T-C<N
M>&UL4$L! A0#%     @ '8%]5R_>+&E  P  <PH  !D              ("!
MMJP! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    "  =@7U7
MZUKEQ'4#  !T$   &0              @($ML $ >&PO=V]R:W-H965T<R]S
M:&5E=#8Y+GAM;%!+ 0(4 Q0    ( !V!?5=<5@17G00  /,:   9
M      " @=FS 0!X;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%
M  @ '8%]5UF15B?- P  < T  !D              ("!K;@! 'AL+W=O<FMS
M:&5E=',O<VAE970W,2YX;6Q02P$"% ,4    "  =@7U7N*UE#D@#  #*%
M#0              @ &QO $ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( !V!
M?5>7BKL<P    !,"   +              "  23  0!?<F5L<R\N<F5L<U!+
M 0(4 Q0    ( !V!?5=(@5#UB@4  -PN   /              "  0W! 0!X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  =@7U7L 4 O38"   <*@  &@
M            @ '$Q@$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    "  =@7U7X<M&R/T!   ]*0  $P              @ $RR0$ 6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     3P!/ * 5  !@RP$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>247</ContextCount>
  <ElementCount>388</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>82</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Organization and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/PropertyandEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/Investments</Role>
      <ShortName>Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Intangible Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssets</Role>
      <ShortName>Intangible Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/EmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Liability Related to the Sale of Future Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties</Role>
      <ShortName>Liability Related to the Sale of Future Royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9954471 - Disclosure - Organization and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9954472 - Disclosure - Organization and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables</Role>
      <ShortName>Organization and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9954473 - Disclosure - Collaboration and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables</Role>
      <ShortName>Collaboration and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9954474 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/PropertyandEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/PropertyandEquipment</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9954475 - Disclosure - Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/InvestmentsTables</Role>
      <ShortName>Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/Investments</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9954476 - Disclosure - Intangible Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssetsTables</Role>
      <ShortName>Intangible Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/IntangibleAssets</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9954477 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/StockholdersEquity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9954478 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/Leases</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9954479 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/StockBasedCompensation</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9954480 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/FairValueMeasurements</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9954481 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/IncomeTaxes</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9954482 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/EarningsPerShare</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9954483 - Disclosure - Organization and Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9954484 - Disclosure - Collaboration and License Agreements - Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails</Role>
      <ShortName>Collaboration and License Agreements - Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9954485 - Disclosure - Collaboration and License Agreements - Receivables and Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails</Role>
      <ShortName>Collaboration and License Agreements - Receivables and Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9954486 - Disclosure - Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails</Role>
      <ShortName>Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9954487 - Disclosure - Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails</Role>
      <ShortName>Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9954488 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails</Role>
      <ShortName>Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9954489 - Disclosure - Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails</Role>
      <ShortName>Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9954490 - Disclosure - Collaboration and License Agreements - Amgen, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails</Role>
      <ShortName>Collaboration and License Agreements - Amgen, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9954491 - Disclosure - Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails</Role>
      <ShortName>Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9954492 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails</Role>
      <ShortName>Property and Equipment - Summary of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9954493 - Disclosure - Property and Equipment - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9954494 - Disclosure - Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails</Role>
      <ShortName>Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9954495 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets - Schedule of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9954496 - Disclosure - Intangible Assets - Expected Future Amortization (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails</Role>
      <ShortName>Intangible Assets - Expected Future Amortization (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9954497 - Disclosure - Stockholders' Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockholdersEquityDetails</Role>
      <ShortName>Stockholders' Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/StockholdersEquityTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9954498 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9954499 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9954500 - Disclosure - Leases - Components of Lease Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails</Role>
      <ShortName>Leases - Components of Lease Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9954501 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails</Role>
      <ShortName>Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9954502 - Disclosure - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails</Role>
      <ShortName>Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9954503 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9954504 - Disclosure - Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9954505 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Summarize Information about Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9954506 - Disclosure - Stock-Based Compensation - Assumptions Used to Value Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Assumptions Used to Value Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9954507 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of RSUs Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9954508 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9954509 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Components of Loss Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9954510 - Disclosure - Income Taxes - Provisions for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Provisions for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9954511 - Disclosure - Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9954512 - Disclosure - Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails</Role>
      <ShortName>Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9954513 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9954514 - Disclosure - Income Taxes - Gross Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Gross Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9954515 - Disclosure - Employee Benefit Plans - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails</Role>
      <ShortName>Employee Benefit Plans - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9954516 - Disclosure - Liability Related to the Sale of Future Royalties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails</Role>
      <ShortName>Liability Related to the Sale of Future Royalties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="arwr-20230930.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9954517 - Disclosure - Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arrowheadresearch.com/role/EarningsPerShareDetails</Role>
      <ShortName>Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arrowheadresearch.com/role/EarningsPerShareTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="arwr-20230930.htm">arwr-20230930.htm</File>
    <File>arwr-20230930.xsd</File>
    <File>arwr-20230930_cal.xml</File>
    <File>arwr-20230930_def.xml</File>
    <File>arwr-20230930_lab.xml</File>
    <File>arwr-20230930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>arwr-20230930_g1.gif</File>
    <File>arwr-20230930_g2.jpg</File>
    <File>arwr-20230930_g3.jpg</File>
    <File>arwr-20230930_g4.gif</File>
    <File>arwr-20230930_g5.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="820">http://fasb.org/us-gaap/2023</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="57">http://xbrl.sec.gov/ecd/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>124
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "arwr-20230930.htm": {
   "nsprefix": "arwr",
   "nsuri": "http://www.arrowheadresearch.com/20230930",
   "dts": {
    "inline": {
     "local": [
      "arwr-20230930.htm"
     ]
    },
    "schema": {
     "local": [
      "arwr-20230930.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd",
      "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "arwr-20230930_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "arwr-20230930_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "arwr-20230930_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "arwr-20230930_pre.xml"
     ]
    }
   },
   "keyStandard": 332,
   "keyCustom": 56,
   "axisStandard": 24,
   "axisCustom": 0,
   "memberStandard": 29,
   "memberCustom": 48,
   "hidden": {
    "total": 15,
    "http://xbrl.sec.gov/ecd/2023": 9,
    "http://xbrl.sec.gov/dei/2023": 4,
    "http://fasb.org/us-gaap/2023": 2
   },
   "contextCount": 247,
   "entityCount": 1,
   "segmentCount": 82,
   "elementCount": 668,
   "unitCount": 10,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2023": 820,
    "http://xbrl.sec.gov/dei/2023": 39,
    "http://xbrl.sec.gov/ecd/2023": 57
   },
   "report": {
    "R1": {
     "role": "http://www.arrowheadresearch.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.arrowheadresearch.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R5": {
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "longName": "0000005 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity",
     "longName": "0000006 - Statement - Consolidated Statements of Stockholders' Equity",
     "shortName": "Consolidated Statements of Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-40",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-40",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "0000007 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProfitLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies",
     "longName": "0000008 - Disclosure - Organization and Significant Accounting Policies",
     "shortName": "Organization and Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements",
     "longName": "0000009 - Disclosure - Collaboration and License Agreements",
     "shortName": "Collaboration and License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.arrowheadresearch.com/role/PropertyandEquipment",
     "longName": "0000010 - Disclosure - Property and Equipment",
     "shortName": "Property and Equipment",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.arrowheadresearch.com/role/Investments",
     "longName": "0000011 - Disclosure - Investments",
     "shortName": "Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssets",
     "longName": "0000012 - Disclosure - Intangible Assets",
     "shortName": "Intangible Assets",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.arrowheadresearch.com/role/StockholdersEquity",
     "longName": "0000013 - Disclosure - Stockholders' Equity",
     "shortName": "Stockholders' Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.arrowheadresearch.com/role/CommitmentsandContingencies",
     "longName": "0000014 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.arrowheadresearch.com/role/Leases",
     "longName": "0000015 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensation",
     "longName": "0000016 - Disclosure - Stock-Based Compensation",
     "shortName": "Stock-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.arrowheadresearch.com/role/FairValueMeasurements",
     "longName": "0000017 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.arrowheadresearch.com/role/IncomeTaxes",
     "longName": "0000018 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.arrowheadresearch.com/role/EmployeeBenefitPlans",
     "longName": "0000019 - Disclosure - Employee Benefit Plans",
     "shortName": "Employee Benefit Plans",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CompensationAndEmployeeBenefitPlansTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties",
     "longName": "0000020 - Disclosure - Liability Related to the Sale of Future Royalties",
     "shortName": "Liability Related to the Sale of Future Royalties",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.arrowheadresearch.com/role/EarningsPerShare",
     "longName": "0000021 - Disclosure - Earnings Per Share",
     "shortName": "Earnings Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.arrowheadresearch.com/role/SubsequentEvents",
     "longName": "0000022 - Disclosure - Subsequent Events",
     "shortName": "Subsequent Events",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:MtrlTermsOfTrdArrTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies",
     "longName": "9954471 - Disclosure - Organization and Significant Accounting Policies (Policies)",
     "shortName": "Organization and Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "arwr:BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "arwr:BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables",
     "longName": "9954472 - Disclosure - Organization and Significant Accounting Policies (Tables)",
     "shortName": "Organization and Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "arwr:ScheduleOfCurrentProductsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "arwr:ScheduleOfCurrentProductsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables",
     "longName": "9954473 - Disclosure - Collaboration and License Agreements (Tables)",
     "shortName": "Collaboration and License Agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.arrowheadresearch.com/role/PropertyandEquipmentTables",
     "longName": "9954474 - Disclosure - Property and Equipment (Tables)",
     "shortName": "Property and Equipment (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.arrowheadresearch.com/role/InvestmentsTables",
     "longName": "9954475 - Disclosure - Investments (Tables)",
     "shortName": "Investments (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsTables",
     "longName": "9954476 - Disclosure - Intangible Assets (Tables)",
     "shortName": "Intangible Assets (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.arrowheadresearch.com/role/StockholdersEquityTables",
     "longName": "9954477 - Disclosure - Stockholders' Equity (Tables)",
     "shortName": "Stockholders' Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfStockByClassTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.arrowheadresearch.com/role/LeasesTables",
     "longName": "9954478 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationTables",
     "longName": "9954479 - Disclosure - Stock-Based Compensation (Tables)",
     "shortName": "Stock-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.arrowheadresearch.com/role/FairValueMeasurementsTables",
     "longName": "9954480 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.arrowheadresearch.com/role/IncomeTaxesTables",
     "longName": "9954481 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.arrowheadresearch.com/role/EarningsPerShareTables",
     "longName": "9954482 - Disclosure - Earnings Per Share (Tables)",
     "shortName": "Earnings Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails",
     "longName": "9954483 - Disclosure - Organization and Significant Accounting Policies (Details)",
     "shortName": "Organization and Significant Accounting Policies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails",
     "longName": "9954484 - Disclosure - Collaboration and License Agreements - Revenue (Details)",
     "shortName": "Collaboration and License Agreements - Revenue (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-76",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails",
     "longName": "9954485 - Disclosure - Collaboration and License Agreements - Receivables and Contract Liabilities (Details)",
     "shortName": "Collaboration and License Agreements - Receivables and Contract Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:AccountsReceivableNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:AccountsReceivableNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
     "longName": "9954486 - Disclosure - Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)",
     "shortName": "Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-91",
      "name": "arwr:NumberOfDistinctPerformanceObligations",
      "unitRef": "obligation",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
     "longName": "9954487 - Disclosure - Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)",
     "shortName": "Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-97",
      "name": "arwr:NumberOfDistinctPerformanceObligations",
      "unitRef": "obligation",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
     "longName": "9954488 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)",
     "shortName": "Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-31",
      "name": "arwr:DevelopmentRegulatoryAndSalesMilestonesPayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-104",
      "name": "arwr:NumberOfDistinctPerformanceObligations",
      "unitRef": "obligation",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
     "longName": "9954489 - Disclosure - Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)",
     "shortName": "Collaboration and License Agreements - Janssen Pharmaceuticals, Inc. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-31",
      "name": "arwr:DevelopmentRegulatoryAndSalesMilestonesPayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-8",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-109",
      "name": "arwr:CashReceivedAsDueUnderCollaborationAgreement",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
     "longName": "9954490 - Disclosure - Collaboration and License Agreements - Amgen, Inc. (Details)",
     "shortName": "Collaboration and License Agreements - Amgen, Inc. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:ContractWithCustomerLiabilityCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-116",
      "name": "arwr:NumberOfAgreements",
      "unitRef": "agreement",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
     "longName": "9954491 - Disclosure - Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. (Details)",
     "shortName": "Collaboration and License Agreements - Joint Venture and License Agreement with Visirna Therapeutics, Inc. (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromContributedCapital",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-123",
      "name": "us-gaap:ProceedsFromContributedCapital",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails",
     "longName": "9954492 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)",
     "shortName": "Property and Equipment - Summary of Property and Equipment (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-31",
      "name": "arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-31",
      "name": "arwr:ComputersSoftwareOfficeEquipmentAndFurnitureGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetails",
     "longName": "9954493 - Disclosure - Property and Equipment - Additional Information (Details)",
     "shortName": "Property and Equipment - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails",
     "longName": "9954494 - Disclosure - Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)",
     "shortName": "Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails",
     "longName": "9954495 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)",
     "shortName": "Intangible Assets - Schedule of Intangible Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:AmortizationOfIntangibleAssets",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails",
     "longName": "9954496 - Disclosure - Intangible Assets - Expected Future Amortization (Details)",
     "shortName": "Intangible Assets - Expected Future Amortization (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.arrowheadresearch.com/role/StockholdersEquityDetails",
     "longName": "9954497 - Disclosure - Stockholders' Equity (Details)",
     "shortName": "Stockholders' Equity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
     "longName": "9954498 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
     "longName": "9954499 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShortTermLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShortTermLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails",
     "longName": "9954500 - Disclosure - Leases - Components of Lease Assets and Liabilities (Details)",
     "shortName": "Leases - Components of Lease Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails",
     "longName": "9954501 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)",
     "shortName": "Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails",
     "longName": "9954502 - Disclosure - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)",
     "shortName": "Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "arwr:OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
     "longName": "9954503 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
     "longName": "9954504 - Disclosure - Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details)",
     "shortName": "Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-31",
      "name": "arwr:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails",
     "longName": "9954505 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Details)",
     "shortName": "Stock-Based Compensation - Summarize Information about Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-32",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails",
     "longName": "9954506 - Disclosure - Stock-Based Compensation - Assumptions Used to Value Stock Options (Details)",
     "shortName": "Stock-Based Compensation - Assumptions Used to Value Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails",
     "longName": "9954507 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity (Details)",
     "shortName": "Stock-Based Compensation - Summary of RSUs Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-181",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-182",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
     "longName": "9954508 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "shortName": "Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-208",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-208",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails",
     "longName": "9954509 - Disclosure - Income Taxes - Components of Loss Before Income Taxes (Details)",
     "shortName": "Income Taxes - Components of Loss Before Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails",
     "longName": "9954510 - Disclosure - Income Taxes - Provisions for Income Taxes (Details)",
     "shortName": "Income Taxes - Provisions for Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails",
     "longName": "9954511 - Disclosure - Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Details)",
     "shortName": "Income Taxes - Summary of Effective Income Tax Rate Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails",
     "longName": "9954512 - Disclosure - Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Details)",
     "shortName": "Income Taxes - Components of the Net Deferred Tax (Liability) and Asset (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails",
     "longName": "9954513 - Disclosure - Income Taxes - Narrative (Details)",
     "shortName": "Income Taxes - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-31",
      "name": "us-gaap:DeferredTaxAssetsValuationAllowance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails",
     "longName": "9954514 - Disclosure - Income Taxes - Gross Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Gross Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-32",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-40",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails",
     "longName": "9954515 - Disclosure - Employee Benefit Plans - Additional Information (Details)",
     "shortName": "Employee Benefit Plans - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails",
     "longName": "9954516 - Disclosure - Liability Related to the Sale of Future Royalties (Details)",
     "shortName": "Liability Related to the Sale of Future Royalties (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "arwr:NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-246",
      "name": "arwr:MilestonePaymentReceivable",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.arrowheadresearch.com/role/EarningsPerShareDetails",
     "longName": "9954517 - Disclosure - Earnings Per Share (Details)",
     "shortName": "Earnings Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arwr-20230930.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r549"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r430",
      "r461",
      "r462",
      "r464",
      "r763"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r568",
      "r569",
      "r570",
      "r742",
      "r743",
      "r752",
      "r753",
      "r754"
     ]
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r526"
     ]
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Lease Assets and Liabilities and Lease Cost",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r954"
     ]
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discretionary match percentage",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match",
        "documentation": "Percentage employer matches of the employee's percentage contribution matched."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r103"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, net",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r866",
      "r881"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: Accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r43",
      "r169",
      "r614"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Amortization",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r170",
      "r308"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units (RSUs)",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r93",
      "r176",
      "r609",
      "r630",
      "r631"
     ]
    },
    "us-gaap_AssetAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition",
        "label": "Asset Acquisition [Axis]",
        "documentation": "Information by asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market instruments",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharesIssued",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shares issued",
        "label": "Shares, Issued",
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r528",
      "r531"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events [Abstract]",
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Axis]",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r890",
      "r956"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "arwr_DeferredTaxAssetsInProcessResearchAndDevelopmentCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopmentCost",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development",
        "label": "Deferred Tax Assets In Process Research And Development Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareReconciliationAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share attributable to Arrowhead Pharmaceuticals, Inc.:",
        "label": "Earnings Per Share Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee Lease Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r797",
      "r809",
      "r819",
      "r845"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Potentially dilutive securities excluded from computation of diluted earnings per share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r229"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r446"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "calculation": {
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails": {
       "parentTag": "arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based payment award (in shares)",
        "periodStartLabel": "Beginning of period (in shares)",
        "periodEndLabel": "End of period (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r444"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r444"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee Lease Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r550"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable debt securities, Adjusted Basis",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r261",
      "r299",
      "r605"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r447"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtSecuritiesHeldToMaturityFairValueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesHeldToMaturityFairValueCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_HeldToMaturitySecuritiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments, Held to maturity, Fair Value",
        "label": "Debt Securities, Held-to-Maturity, Fair Value, Current",
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), classified as current."
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings per Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r35"
     ]
    },
    "us-gaap_DebtSecuritiesHeldToMaturityFairValueNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesHeldToMaturityFairValueNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_HeldToMaturitySecuritiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term investments, Held to maturity, Fair Value",
        "label": "Debt Securities, Held-to-Maturity, Fair Value, Noncurrent",
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r876"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AreaOfLand": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AreaOfLand",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Planned area of site (in sq ft)",
        "label": "Area of Land",
        "documentation": "Area of land held."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent liabilities",
        "label": "Loss Contingency Accrual",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r314",
      "r865"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r764"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock reserved for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r450"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Cancelled (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average grant date fair value per share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r449"
     ]
    },
    "us-gaap_InterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "label": "Interest Expense",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense."
       }
      }
     },
     "auth_ref": [
      "r76",
      "r145",
      "r191",
      "r238",
      "r544",
      "r684",
      "r779",
      "r971"
     ]
    },
    "us-gaap_ConsolidationVariableInterestEntityPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConsolidationVariableInterestEntityPolicy",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity",
        "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined)."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r70",
      "r71"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r545"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r242",
      "r246",
      "r248",
      "r739"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total operating lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_ConstructionInProgressGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConstructionInProgressGross",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Construction in progress",
        "label": "Construction in Progress, Gross",
        "documentation": "Amount of structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Receivables and Contract Liabilities",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r909"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax expense related to uncertain tax positions",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r482"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arrowheadresearch.com/role/EarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r224",
      "r226",
      "r227",
      "r228",
      "r232",
      "r524",
      "r525",
      "r602",
      "r622",
      "r738"
     ]
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r475",
      "r481",
      "r487",
      "r493",
      "r498",
      "r504",
      "r505",
      "r506",
      "r642"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r946",
      "r947"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r477",
      "r478",
      "r487",
      "r488",
      "r492",
      "r494",
      "r636"
     ]
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r885",
      "r946"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities, net of current portion",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits, penalties accrued",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties Accrued",
        "documentation": "Amount of statutory penalties accrued for a tax position claimed or expected to be claimed by the entity, in its tax return."
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "us-gaap_ProceedsFromContributedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromContributedCapital",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from investment in joint venture",
        "terseLabel": "Proceeds from upfront capital",
        "label": "Proceeds from Contributed Capital",
        "documentation": "The cash inflow associated with the amount received by a corporation from a shareholder during the period."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized losses on available-for-sale securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r180",
      "r181",
      "r182"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_CompensationAndEmployeeBenefitPlansTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndEmployeeBenefitPlansTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlans"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Benefit Plans",
        "label": "Compensation and Employee Benefit Plans [Text Block]",
        "documentation": "The entire disclosure for an entity's employee compensation and benefit plans, including, but not limited to, postemployment and postretirement benefit plans, defined benefit pension plans, defined contribution plans, non-qualified and supplemental benefit plans, deferred compensation, share-based compensation, life insurance, severance, health care, unemployment and other benefit plans."
       }
      }
     },
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r124"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance of unrecognized tax benefits",
        "periodEndLabel": "Ending balance of unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r476",
      "r483"
     ]
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanTypeDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Type [Domain]",
        "label": "Retirement Plan Type [Domain]",
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_JamesHamiltonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "JamesHamiltonMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "James Hamilton [Member]",
        "documentation": "James Hamilton"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937"
     ]
    },
    "us-gaap_MoneyMarketFundsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MoneyMarketFundsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Money market instruments",
        "label": "Money Market Funds [Member]",
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities."
       }
      }
     },
     "auth_ref": [
      "r911"
     ]
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentPolicyTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment in financial asset."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r632",
      "r633",
      "r634",
      "r635",
      "r706",
      "r707"
     ]
    },
    "arwr_OlpasiranAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "OlpasiranAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Olpasiran Agreement",
        "label": "Olpasiran Agreement [Member]",
        "documentation": "Olpasiran agreement."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_MilestonePaymentReceivableUponFDAApproval": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "MilestonePaymentReceivableUponFDAApproval",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment receivable upon FDA approval",
        "label": "Milestone Payment Receivable Upon FDA Approval",
        "documentation": "Milestone Payment Receivable Upon FDA Approval"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Gross Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r765",
      "r943"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross decrease for prior period tax positions",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "arwr_WilliamWaddillMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "WilliamWaddillMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "William Waddill [Member]",
        "documentation": "William Waddill"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross increase for prior period tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns."
       }
      }
     },
     "auth_ref": [
      "r484"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "verboseLabel": "Contract liabilities",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349",
      "r361"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue, net of current portion",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349",
      "r361"
     ]
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept."
       }
      }
     },
     "auth_ref": [
      "r939"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities included in deferred revenue",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r349",
      "r361"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesGrossUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross increase for current period tax positions",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r485"
     ]
    },
    "arwr_NumberOfAgreements": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "NumberOfAgreements",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of agreements",
        "label": "Number Of Agreements",
        "documentation": "Number of agreements."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r796",
      "r808",
      "r818",
      "r844"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits that would impact effective tax rate",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r486"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r926",
      "r927",
      "r928",
      "r929",
      "r930",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937"
     ]
    },
    "arwr_MilestonePaymentReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "MilestonePaymentReceivable",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment receivable",
        "label": "Milestone Payment Receivable",
        "documentation": "Milestone Payment Receivable"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/Investments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "documentation": "The entire disclosure for investments in certain debt and equity securities."
       }
      }
     },
     "auth_ref": [
      "r137",
      "r146",
      "r147",
      "r161",
      "r255",
      "r259",
      "r533",
      "r534"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r432",
      "r433",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459"
     ]
    },
    "arwr_VictoriaVakienerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "VictoriaVakienerMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Victoria Vakiener [Member]",
        "documentation": "Victoria Vakiener"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability Related to the Sale of Future Royalties",
        "label": "Liability Related To The Sale Of Future Royalties [Text Block]",
        "documentation": "Liability Related To The Sale Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_FiniteLivedIntangibleAssetsImpairment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "FiniteLivedIntangibleAssetsImpairment",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment",
        "label": "Finite-Lived Intangible Assets, Impairment",
        "documentation": "Finite-Lived Intangible Assets, Impairment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total gross fixed assets",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r115",
      "r168",
      "r615"
     ]
    },
    "arwr_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 6.0
      },
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r604",
      "r615",
      "r769"
     ]
    },
    "arwr_DevelopmentRegulatoryAndSalesMilestonesPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "DevelopmentRegulatoryAndSalesMilestonesPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development regulatory and sales milestones payments",
        "verboseLabel": "Development, regulatory and sales milestones payments",
        "label": "Development Regulatory And Sales Milestones Payments",
        "documentation": "Development regulatory and sales milestones payments."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CommercialMilestonePaymentsAtFirstCommercialSale": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "CommercialMilestonePaymentsAtFirstCommercialSale",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial milestone payments at first commercial sale",
        "label": "Commercial Milestone Payments At First Commercial Sale",
        "documentation": "Commercial milestone payments at first commercial sale."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation State Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_LicenseAndCoFundingAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "LicenseAndCoFundingAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License and Co-Funding Agreement",
        "label": "License And Co Funding Agreement [Member]",
        "documentation": "License and co-funding agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Axis]",
        "label": "Cash and Cash Equivalents [Axis]",
        "documentation": "Information by type of cash and cash equivalent balance."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Share Activity Related to RSUs",
        "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year."
       }
      }
     },
     "auth_ref": [
      "r58"
     ]
    },
    "arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments, Available-for-sale, Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Current",
        "documentation": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Current"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ResearchFacilityInMadisonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "ResearchFacilityInMadisonMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Facility in Madison",
        "label": "Research Facility In Madison [Member]",
        "documentation": "Research facility in Madison."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted cash",
        "label": "Restricted Cash and Cash Equivalents, Current",
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r167",
      "r200"
     ]
    },
    "arwr_RoyaltyPharmaAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "RoyaltyPharmaAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Pharma Agreement",
        "label": "Royalty Pharma Agreement [Member]",
        "documentation": "Royalty Pharma Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Axis]",
        "label": "Income Statement Location [Axis]",
        "documentation": "Information by location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r310",
      "r311",
      "r683"
     ]
    },
    "arwr_JamesHamiltonTerminatedPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "JamesHamiltonTerminatedPlanMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "James Hamilton Terminated Plan [Member]",
        "documentation": "James Hamilton Terminated Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r154",
      "r155",
      "r613"
     ]
    },
    "us-gaap_CertificatesOfDepositMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CertificatesOfDepositMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Certificate of deposits",
        "label": "Certificates of Deposit [Member]",
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r775",
      "r776",
      "r777",
      "r778"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_HorizonLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "HorizonLicenseAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Horizon License Agreement",
        "label": "Horizon License Agreement [Member]",
        "documentation": "Horizon License Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement Location [Domain]",
        "label": "Income Statement Location [Domain]",
        "documentation": "Location in the income statement."
       }
      }
     },
     "auth_ref": [
      "r311",
      "r683"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "arwr_AdditionalTenantImprovementAllowanceLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "AdditionalTenantImprovementAllowanceLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional tenant improvement allowance liability",
        "label": "Additional Tenant Improvement Allowance Liability",
        "documentation": "Additional Tenant Improvement Allowance Liability"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r862"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assumptions Used to Value Stock Options",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "arwr_TwoThousandTwentyOneIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "TwoThousandTwentyOneIncentivePlanMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2021 Plan",
        "label": "Two Thousand Twenty One Incentive Plan [Member]",
        "documentation": "Two thousand twenty one incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summarized Information about Stock Options",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r58"
     ]
    },
    "arwr_CorporateHeadquartersInPasadenaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "CorporateHeadquartersInPasadenaMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate Headquarters In Pasadena",
        "label": "Corporate Headquarters In Pasadena [Member]",
        "documentation": "Corporate Headquarters in Pasadena"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "TaxIncrementFinancingAwardMaximumStateIncomeTaxCreditsUnderAgreement",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum state income tax credits under agreement",
        "label": "Tax Increment Financing Award, Maximum State Income Tax Credits Under Agreement",
        "documentation": "Tax Increment Financing Award, Maximum State Income Tax Credits Under Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_MaximumAdditionalTenantImprovementAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "MaximumAdditionalTenantImprovementAllowance",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum additional tenant improvement allowance",
        "label": "Maximum Additional Tenant Improvement Allowance",
        "documentation": "Maximum Additional Tenant Improvement Allowance"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r796",
      "r808",
      "r818",
      "r844"
     ]
    },
    "arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of commission to sales agent",
        "label": "Percentage Of Commission On Aggregate Gross Proceeds From Sale Of Common Stock",
        "documentation": "Percentage of commission on aggregate gross proceeds from sale of common stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r546"
     ]
    },
    "arwr_LaboratoryAndOfficeFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "LaboratoryAndOfficeFacilityMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory And Office Facility",
        "label": "Laboratory And Office Facility [Member]",
        "documentation": "Laboratory and office facility."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DeferredTaxLiabilitiesStateTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "DeferredTaxLiabilitiesStateTaxes",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "State taxes",
        "label": "Deferred Tax Liabilities State Taxes",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from state tax deductions."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_HeldToMaturitySecuritiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Short-term investments, Held to maturity, Gross Unrealized Losses",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Current",
        "documentation": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits, interest accrued",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued",
        "documentation": "Amount of interest expense accrued for an underpayment of income taxes."
       }
      }
     },
     "auth_ref": [
      "r942"
     ]
    },
    "arwr_ProceedsFromSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "ProceedsFromSaleOfFutureRoyalties",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the sale of future royalties",
        "label": "Proceeds from Sale of Future Royalties",
        "documentation": "Proceeds from Sale of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_JNJ3989AROHBVAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "JNJ3989AROHBVAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "JNJ-3989 Agreement",
        "label": "J N J3989 A R O H B V Agreement [Member]",
        "documentation": "JNJ-3989 (ARO-HBV) Agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationFdiiPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationFdiiPercent",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign-derived intangible income deduction",
        "label": "Effective Income Tax Rate Reconciliation, FDII, Percent",
        "documentation": "Percentage of reported income tax benefit from difference to income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to foreign-derived intangible income (FDII)."
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]",
        "label": "Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]",
        "documentation": "Schedule of held to maturity securities and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional remaining development regulatory and sales milestones payments",
        "label": "Additional Remaining Development Regulatory And Sales Milestones Payments",
        "documentation": "Additional remaining development regulatory and sales milestones payments."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_HeldToMaturitySecuritiesCurrent",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term investments, Held to maturity, Gross Unrealized Gains",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Current",
        "documentation": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity",
        "label": "Equity [Text Block]",
        "documentation": "The entire disclosure for equity."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r201",
      "r331",
      "r333",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r345",
      "r347",
      "r522",
      "r702",
      "r703",
      "r716"
     ]
    },
    "arwr_CollaborationAndLicenseAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "CollaborationAndLicenseAgreementsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration and License agreements",
        "label": "Collaboration and License Agreements [Member]",
        "documentation": "Collaboration and license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ResearchEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "ResearchEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research equipment",
        "label": "Research Equipment Gross",
        "documentation": "Research equipment gross."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents and Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r138"
     ]
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arrowheadresearch.com/role/EarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r193",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r222",
      "r224",
      "r226",
      "r227",
      "r228",
      "r232",
      "r524",
      "r525",
      "r602",
      "r622",
      "r738"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued payroll and benefits",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFlowOperatingActivitiesLesseeAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:",
        "label": "Cash Flow, Operating Activities, Lessee [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CommercialNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "CommercialNotesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial notes",
        "label": "Commercial Notes [Member]",
        "documentation": "Commercial Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "verboseLabel": "Revenues",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r236",
      "r237",
      "r241",
      "r244",
      "r245",
      "r249",
      "r250",
      "r252",
      "r359",
      "r360",
      "r597"
     ]
    },
    "us-gaap_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss including noncontrolling interest",
        "verboseLabel": "Net loss",
        "terseLabel": "Net loss including noncontrolling interest",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r164",
      "r183",
      "r185",
      "r196",
      "r202",
      "r211",
      "r219",
      "r220",
      "r235",
      "r242",
      "r246",
      "r248",
      "r291",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r508",
      "r511",
      "r512",
      "r525",
      "r535",
      "r603",
      "r617",
      "r644",
      "r680",
      "r697",
      "r698",
      "r739",
      "r766",
      "r767",
      "r780",
      "r880",
      "r904"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EarningsPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Earnings Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r221",
      "r229",
      "r230",
      "r231"
     ]
    },
    "arwr_SalesRelatedMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "SalesRelatedMilestonePayments",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales-related milestone payments",
        "label": "Sales Related Milestone Payments",
        "documentation": "Sales-related milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_OperatingLossCarryforwardsSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "OperatingLossCarryforwardsSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards subject to expiration",
        "label": "Operating Loss Carryforwards, Subject To Expiration",
        "documentation": "Operating Loss Carryforwards, Subject To Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_FacilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "FacilitiesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Facilities",
        "label": "Facilities [Member]",
        "documentation": "Facilities."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_TwoThousandsFourEquityIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "TwoThousandsFourEquityIncentivePlanMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2004 Plan",
        "label": "Two Thousands Four Equity Incentive Plan [Member]",
        "documentation": "Two thousands four equity incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Defined Benefit Plans Disclosures [Table]",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r53",
      "r54",
      "r55",
      "r56"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r794",
      "r806",
      "r816",
      "r842"
     ]
    },
    "arwr_RoyaltiesLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "RoyaltiesLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liability related to the sale of future royalties",
        "label": "Royalties, Liability, Noncurrent",
        "documentation": "Royalties, Liability, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CollaborationAndLicenseAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "CollaborationAndLicenseAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration And License Agreements [Abstract]",
        "label": "Collaboration And License Agreements [Abstract]",
        "documentation": "Collaboration and license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Takeda",
        "label": "Takeda Pharmaceuticals United States Of America Incorporated [Member]",
        "documentation": "Takeda Pharmaceuticals United States of America Incorporated."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-sale securities, at fair value",
        "verboseLabel": "Short-term investments, Available-for-sale, Fair Value",
        "label": "Debt Securities, Available-for-Sale, Current",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r299"
     ]
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss attributable to noncontrolling interest, net of tax",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r136",
      "r183",
      "r185",
      "r219",
      "r220",
      "r618",
      "r880"
     ]
    },
    "arwr_PatrickOBrienMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "PatrickOBrienMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Patrick O'Brien [Member]",
        "documentation": "Patrick O'Brien"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableInterestEntityPrimaryBeneficiaryMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable Interest Entity, Primary Beneficiary",
        "label": "Variable Interest Entity, Primary Beneficiary [Member]",
        "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r509",
      "r510",
      "r513",
      "r514"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r793",
      "r805",
      "r815",
      "r841"
     ]
    },
    "arwr_TechnologyLicenseCommitmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "TechnologyLicenseCommitmentsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Technology License Commitments",
        "label": "Technology License Commitments [Member]",
        "documentation": "Technology license commitments."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CashReceivedAsDueUnderCollaborationAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "CashReceivedAsDueUnderCollaborationAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront payment",
        "label": "Cash Received As Due Under Collaboration Agreement",
        "documentation": "Cash received as due under collaboration agreement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r795",
      "r807",
      "r817",
      "r843"
     ]
    },
    "arwr_ResearchFacilityInSanDiegoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "ResearchFacilityInSanDiegoMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Facility in San Diego",
        "label": "Research Facility In San Diego [Member]",
        "documentation": "Research Facility in San Diego."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_NumberOfOptionsToRenew": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "NumberOfOptionsToRenew",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of options to renew",
        "label": "Number Of Options To Renew",
        "documentation": "Number of options to renew."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetirementPlanTypeAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Plan Type [Axis]",
        "label": "Retirement Plan Type [Axis]",
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement."
       }
      }
     },
     "auth_ref": [
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r425",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761"
     ]
    },
    "arwr_NumberOfDistinctBundle": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "NumberOfDistinctBundle",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of distinct bundle",
        "label": "Number Of Distinct Bundle",
        "documentation": "Number of distinct bundle."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsAndLiabilitiesLesseeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAndLiabilitiesLesseeAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Assets and Liabilities",
        "label": "Assets and Liabilities, Lessee [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class Of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r174",
      "r175",
      "r234",
      "r332",
      "r333",
      "r334",
      "r336",
      "r339",
      "r344",
      "r346",
      "r637",
      "r638",
      "r639",
      "r640",
      "r744",
      "r864",
      "r883"
     ]
    },
    "arwr_VeronaTechnologyParkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "VeronaTechnologyParkMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Verona Technology Park",
        "label": "Verona Technology Park [Member]",
        "documentation": "Verona technology park."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Stock By Class [Table]",
        "label": "Schedule of Stock by Class [Table]",
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r118",
      "r119",
      "r120",
      "r173",
      "r174",
      "r175",
      "r234",
      "r332",
      "r333",
      "r334",
      "r336",
      "r339",
      "r344",
      "r346",
      "r637",
      "r638",
      "r639",
      "r640",
      "r744",
      "r864",
      "r883"
     ]
    },
    "us-gaap_ScheduleOfStockByClassTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfStockByClassTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Shares of Common Stock and Preferred Stock",
        "label": "Schedule of Stock by Class [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r44",
      "r46",
      "r47",
      "r48",
      "r49",
      "r50",
      "r51",
      "r86",
      "r87",
      "r118",
      "r119",
      "r120"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustments",
        "verboseLabel": "Foreign currency translation adjustments",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recent Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r797",
      "r809",
      "r819",
      "r845"
     ]
    },
    "us-gaap_OperatingLeasedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasedAssetsLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Leased Assets [Line Items]",
        "label": "Operating Leased Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r885",
      "r946",
      "r947"
     ]
    },
    "us-gaap_ScheduleOfOperatingLeasedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfOperatingLeasedAssetsTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Operating Leased Assets [Table]",
        "label": "Schedule of Operating Leased Assets [Table]",
        "documentation": "Schedule of long-lived, depreciable assets that are subject to a operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r771",
      "r772",
      "r773",
      "r775",
      "r776",
      "r777",
      "r778",
      "r886",
      "r887",
      "r950",
      "r970",
      "r972"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r945"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r490"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r153"
     ]
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 7)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r77",
      "r607",
      "r658"
     ]
    },
    "stpr_WI": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "WI",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Wisconsin",
        "label": "WISCONSIN"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ImpairmentOfIntangibleAssetsFinitelived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ImpairmentOfIntangibleAssetsFinitelived",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets subject to amortization, impairment",
        "label": "Impairment of Intangible Assets, Finite-Lived",
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of a finite-lived intangible asset to fair value."
       }
      }
     },
     "auth_ref": [
      "r882",
      "r900"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipment"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r114",
      "r154",
      "r155",
      "r156"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r159",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r732"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r885",
      "r947"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r300",
      "r301",
      "r302",
      "r330",
      "r344",
      "r521",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r620",
      "r741",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r894",
      "r895",
      "r896",
      "r897"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_LiabilitiesNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrentAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term liabilities:",
        "label": "Liabilities, Noncurrent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of Individual [Domain]",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r849"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Assets",
        "label": "Assets",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r172",
      "r202",
      "r235",
      "r243",
      "r247",
      "r291",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r509",
      "r513",
      "r535",
      "r606",
      "r672",
      "r769",
      "r781",
      "r904",
      "r905",
      "r957"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r851"
     ]
    },
    "us-gaap_LiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total long-term liabilities",
        "label": "Liabilities, Noncurrent",
        "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r80",
      "r81",
      "r82",
      "r83",
      "r202",
      "r291",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r510",
      "r513",
      "r514",
      "r535",
      "r904",
      "r957",
      "r958"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sale of marketable debt securities",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r194",
      "r256",
      "r290"
     ]
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CorporateDebtSecuritiesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate debt securities",
        "label": "Corporate Debt Securities [Member]",
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment."
       }
      }
     },
     "auth_ref": [
      "r752",
      "r754",
      "r969"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Short-term investments, Available-for-sale, Adjusted Basis",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Current",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current."
       }
      }
     },
     "auth_ref": [
      "r299",
      "r892"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]"
       }
      }
     },
     "auth_ref": [
      "r252",
      "r747",
      "r910",
      "r967",
      "r968"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets subject to amortization",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r37"
     ]
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplementary disclosures:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r834"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r852"
     ]
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromStockOptionsExercised",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the exercises of stock options",
        "label": "Proceeds from Stock Options Exercised",
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r17"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_DebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DebtSecuritiesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities",
        "label": "Debt Securities [Member]",
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions."
       }
      }
     },
     "auth_ref": [
      "r36",
      "r773",
      "r974"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r848"
     ]
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LandSubjectToGroundLeases",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office space leases (in sq ft)",
        "label": "Land Subject to Ground Leases",
        "documentation": "Area of land subject to a ground lease."
       }
      }
     },
     "auth_ref": [
      "r952"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r850"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r328",
      "r334",
      "r561",
      "r735",
      "r737"
     ]
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible Assets",
        "label": "Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for all or part of the information related to intangible assets."
       }
      }
     },
     "auth_ref": [
      "r305"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r448"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "us-gaap_OtherCommitmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Line Items]",
        "label": "Other Commitments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r853"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average discount rate",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r558",
      "r768"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r796",
      "r808",
      "r818",
      "r844"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Table]",
        "label": "Operating Loss Carryforwards [Table]",
        "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization."
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r386",
      "r391",
      "r528",
      "r569",
      "r742",
      "r743",
      "r752",
      "r753",
      "r754"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029 and thereafter",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r386",
      "r391",
      "r528",
      "r568",
      "r752",
      "r753",
      "r754"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r854"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity [Abstract]",
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r792",
      "r804",
      "r814",
      "r840"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r796",
      "r808",
      "r818",
      "r844"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLossCarryforwardsLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating Loss Carryforwards [Line Items]",
        "label": "Operating Loss Carryforwards [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r528",
      "r570",
      "r742",
      "r743",
      "r752",
      "r753",
      "r754"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares reserve for issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r787",
      "r800"
     ]
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Intangible Assets Future Amortization Expense",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r40"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r98",
      "r682"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r559"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r955"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r855"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r821"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r528",
      "r531"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ContractWithCustomerAssetNetCurrent",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract assets",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current."
       }
      }
     },
     "auth_ref": [
      "r348",
      "r350",
      "r361"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r179",
      "r202",
      "r291",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r509",
      "r513",
      "r535",
      "r769",
      "r904",
      "r905",
      "r957"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r790",
      "r802",
      "r812",
      "r838"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized pre-tax compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Retirement Benefits [Abstract]",
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r786",
      "r787",
      "r800"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r791",
      "r803",
      "r813",
      "r839"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction [Flag]",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r786",
      "r787",
      "r800",
      "r836"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized pre-tax compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r938"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r792",
      "r804",
      "r814",
      "r840"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r856"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r61",
      "r428"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expense",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r96"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationDepletionAndAmortization",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization expense for property and equipment",
        "label": "Depreciation, Depletion and Amortization",
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r239"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of Options Outstanding, Exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r437"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "calculation": {
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails": {
       "parentTag": "arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r436"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-In Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r465",
      "r466",
      "r467",
      "r645",
      "r886",
      "r887",
      "r888",
      "r950",
      "r972"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r435",
      "r436"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective income tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Available-for-sale debt securities",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r262",
      "r299",
      "r600",
      "r891"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r457"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, minimum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r941",
      "r948"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk-free interest rate, maximum",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Stock Option",
        "label": "Employee Stock Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents [Domain]",
        "label": "Cash and Cash Equivalents [Domain]",
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r167"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r431",
      "r432",
      "r433",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r429",
      "r431",
      "r432",
      "r433",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r427",
      "r429",
      "r431",
      "r432",
      "r433",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r783"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r25",
      "r162",
      "r188",
      "r189",
      "r190",
      "r208",
      "r209",
      "r210",
      "r212",
      "r218",
      "r220",
      "r233",
      "r292",
      "r293",
      "r347",
      "r465",
      "r466",
      "r467",
      "r496",
      "r497",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r523",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r560",
      "r626",
      "r627",
      "r628",
      "r645",
      "r699"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. federal statutory income tax",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r204",
      "r480",
      "r503"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r162",
      "r208",
      "r209",
      "r210",
      "r212",
      "r218",
      "r220",
      "r292",
      "r293",
      "r465",
      "r466",
      "r467",
      "r496",
      "r497",
      "r515",
      "r517",
      "r518",
      "r520",
      "r523",
      "r626",
      "r628",
      "r645",
      "r972"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EarningsPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_MinorityInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MinorityInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest",
        "label": "Equity, Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r141",
      "r202",
      "r291",
      "r319",
      "r321",
      "r322",
      "r323",
      "r326",
      "r327",
      "r535",
      "r611",
      "r661"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r798",
      "r810",
      "r820",
      "r846"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign Currency Translation Adjustments",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy."
       }
      }
     },
     "auth_ref": [
      "r536"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HeldToMaturitySecuritiesFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Held-to-maturity debt securities",
        "label": "Debt Securities, Held-to-Maturity, Fair Value",
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity)."
       }
      }
     },
     "auth_ref": [
      "r148",
      "r282",
      "r600",
      "r605"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Fixed assets",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r945"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r162",
      "r188",
      "r189",
      "r190",
      "r208",
      "r209",
      "r210",
      "r212",
      "r218",
      "r220",
      "r233",
      "r292",
      "r293",
      "r347",
      "r465",
      "r466",
      "r467",
      "r496",
      "r497",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r523",
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r560",
      "r626",
      "r627",
      "r628",
      "r645",
      "r699"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r13",
      "r28",
      "r516",
      "r519",
      "r560",
      "r626",
      "r627",
      "r878",
      "r879",
      "r880",
      "r886",
      "r887",
      "r888"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HeldToMaturitySecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Held-to-maturity securities, at amortized cost",
        "totalLabel": "Short-term investments, Held to maturity, Adjusted Bases",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Current",
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as current."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r893",
      "r899"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": -1.0,
       "order": 1.0
      },
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income tax expense",
        "totalLabel": "Income tax provision",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r158",
      "r219",
      "r220",
      "r240",
      "r479",
      "r499",
      "r624"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r941",
      "r948"
     ]
    },
    "us-gaap_HeldToMaturitySecuritiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "HeldToMaturitySecuritiesNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Held-to-maturity securities, at amortized cost",
        "totalLabel": "Long-term investments, Held to maturity, Adjusted Basis",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss, Noncurrent",
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r257",
      "r893",
      "r899"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Permanent and other items",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments."
       }
      }
     },
     "auth_ref": [
      "r941",
      "r948"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income taxes, net of federal tax benefit",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r941",
      "r948"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of RSUs",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.arrowheadresearch.com/role/EarningsPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arrowheadresearch.com/role/EarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average basic shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r222",
      "r228"
     ]
    },
    "arwr_AtTheMarketAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "AtTheMarketAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ATM Agreement",
        "label": "At The Market Agreement [Member]",
        "documentation": "At-the-market agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Awards Outstanding",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r15",
      "r16",
      "r59"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r25",
      "r120"
     ]
    },
    "arwr_SorrentoValleyOwnerDELLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "SorrentoValleyOwnerDELLCMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sorrento Valley Owner (DE) LLC",
        "label": "Sorrento Valley Owner (DE) LLC [Member]",
        "documentation": "Sorrento Valley Owner (DE) LLC"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Land": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "Land",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land",
        "label": "Land",
        "documentation": "Amount before accumulated depletion of real estate held for productive use, excluding land held for sale."
       }
      }
     },
     "auth_ref": [
      "r875"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security12b Title",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r782"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock - restricted stock units vesting",
        "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross",
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r86",
      "r87",
      "r120"
     ]
    },
    "arwr_RoyaltyPaymentThreshold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "RoyaltyPaymentThreshold",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty payment threshold",
        "label": "Royalty Payment Threshold",
        "documentation": "Royalty Payment Threshold"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ColoradoOwnerLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "ColoradoOwnerLLCMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Colorado Owner, LLC",
        "label": "Colorado Owner L L C [Member]",
        "documentation": "Colorado Owner, LLC."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_TracieOliverMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "TracieOliverMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tracie Oliver [Member]",
        "documentation": "Tracie Oliver"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_OutsideOfEquityCompensationPlansMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "OutsideOfEquityCompensationPlansMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outside Of Equity Compensation Plans",
        "label": "Outside Of Equity Compensation Plans [Member]",
        "documentation": "Outside of equity compensation plans."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_MauroFerrariMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "MauroFerrariMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Mauro Ferrari [Member]",
        "documentation": "Mauro Ferrari"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r329",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r528",
      "r568",
      "r569",
      "r570",
      "r742",
      "r743",
      "r752",
      "r753",
      "r754"
     ]
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails",
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r330",
      "r344",
      "r521",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r620",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r894",
      "r895",
      "r896",
      "r897"
     ]
    },
    "arwr_NovartisMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "NovartisMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novartis",
        "label": "Novartis [Member]",
        "documentation": "Novartis."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss, net of tax:",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "BasisOfPresentationAndUseOfEstimatesPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation and Use of Estimates",
        "label": "Basis Of Presentation And Use Of Estimates Policy [Policy Text Block]",
        "documentation": "Basis of presentation and use of estimates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest in joint venture",
        "label": "Noncontrolling Interest, Increase from Subsidiary Equity Issuance",
        "documentation": "Amount of increase in noncontrolling interest from subsidiary issuance of equity interests to noncontrolling interest holders."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r52",
      "r135"
     ]
    },
    "arwr_MilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "MilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Milestone payments",
        "label": "Milestone Payments",
        "documentation": "Milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_OperatingLossCarryforwardsNotSubjectToExpiration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "OperatingLossCarryforwardsNotSubjectToExpiration",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards not subject to expiration",
        "label": "Operating Loss Carryforwards, Not Subject To Expiration",
        "documentation": "Operating Loss Carryforwards, Not Subject To Expiration"
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Liability Related To The Sale Of Future Royalties [Abstract]",
        "documentation": "Liability Related To The Sale Of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "USGovernmentDebtSecuritiesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. government bonds",
        "label": "US Government Debt Securities [Member]",
        "documentation": "Debt securities issued by the United States government."
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r785"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsNet",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails",
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Net Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Net",
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r598"
     ]
    },
    "arwr_TwoThousandsThirteenIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "TwoThousandsThirteenIncentivePlanMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2013 Plan",
        "label": "Two Thousands Thirteen Incentive Plan [Member]",
        "documentation": "Two thousands thirteen incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedLossNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_HeldToMaturitySecuritiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Long-term investments, Held to maturity, Gross Unrealized Losses",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Noncurrent",
        "documentation": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Carrying Amount",
        "label": "Finite-Lived Intangible Assets, Gross",
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r112",
      "r599"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r528",
      "r529",
      "r530",
      "r532"
     ]
    },
    "arwr_DrugManufacturingFacilityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "DrugManufacturingFacilityMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Drug Manufacturing Facility",
        "label": "Drug Manufacturing Facility [Member]",
        "documentation": "Drug manufacturing facility."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_RestrictedStockUnitsPerformanceBasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "RestrictedStockUnitsPerformanceBasedMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance-Based Restricted Stock Units",
        "label": "Restricted Stock Units, Performance-Based [Member]",
        "documentation": "Restricted Stock Units, Performance-Based"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_KenMyszkowskiMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "KenMyszkowskiMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ken Myszkowski [Member]",
        "documentation": "Ken Myszkowski"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock - restricted stock units vesting (in shares)",
        "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross",
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r120"
     ]
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_OrganizationAndSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "OrganizationAndSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization And Significant Accounting Policies [Line Items]",
        "label": "Organization And Significant Accounting Policies [Line Items]",
        "documentation": "Organization and significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total financial assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment receivable upon achievement of phase two and first patient dosed in phase three",
        "label": "Milestone Payment Receivable Upon Achievement Of Phase Two And First Patient Dosed In Phase Three",
        "documentation": "Milestone payment receivable upon achievement of phase two and first patient dosed in phase three."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_InducementAwardsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "InducementAwardsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inducement Awards",
        "label": "Inducement Awards [Member]",
        "documentation": "Inducement Awards"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_RestrictedStockUnitsMarketBasedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "RestrictedStockUnitsMarketBasedMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Stock Units, Market-Based",
        "label": "Restricted Stock Units, Market-Based [Member]",
        "documentation": "Restricted Stock Units, Market-Based"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Held To Maturity Securities And Marketable Securities [Table]",
        "label": "Schedule Of Held To Maturity Securities And Marketable Securities [Table]",
        "documentation": "Schedule of held to maturity securities and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other assets",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r171"
     ]
    },
    "arwr_EmployeeContributionsUpToThreePercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "EmployeeContributionsUpToThreePercentMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Contributions up to 3%",
        "label": "Employee Contributions Up To Three Percent [Member]",
        "documentation": "Employee contributions up to three percent."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DouglassGivenMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "DouglassGivenMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Douglass Given [Member]",
        "documentation": "Douglass Given"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Components of the Net Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "arwr_CommonStockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "CommonStockPurchaseAgreementMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common Stock Purchase Agreement",
        "label": "Common Stock Purchase Agreement [Member]",
        "documentation": "Common stock purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Provisions for Income Taxes",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r129"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity",
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options (in shares)",
        "negatedLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r86",
      "r87",
      "r120",
      "r440"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding",
     "calculation": {
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total (in shares)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_JohnsonAndJohnsonInnovationJJDCIncorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "JohnsonAndJohnsonInnovationJJDCIncorporationMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "JJDC",
        "label": "Johnson And Johnson Innovation J J D C Incorporation [Member]",
        "documentation": "Johnson and Johnson Innovation-JJDC, Incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsequentEventsTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/SubsequentEvents"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Subsequent Events",
        "label": "Subsequent Events [Text Block]",
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business."
       }
      }
     },
     "auth_ref": [
      "r563",
      "r564"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "arwr_JamesHamiltonAugust2023PlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "JamesHamiltonAugust2023PlanMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "James Hamilton August 2023 Plan [Member]",
        "documentation": "James Hamilton August 2023 Plan"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Loss Before Income Taxes",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions."
       }
      }
     },
     "auth_ref": [
      "r885"
     ]
    },
    "arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantedInPeriodFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity award value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Granted in Period, Fair Value",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Granted in Period, Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_NumberOfDistinctPerformanceObligations": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "NumberOfDistinctPerformanceObligations",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of distinct performance obligations",
        "label": "Number Of Distinct Performance Obligations",
        "documentation": "Number of distinct performance obligations."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_MilestonePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "MilestonePaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payments",
        "label": "Milestone Payment Received",
        "documentation": "Milestone payment received."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "AdditionalTenantImprovementAllowanceInterestPerAnnum",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest per annum",
        "label": "Additional Tenant Improvement Allowance, Interest Per Annum",
        "documentation": "Additional Tenant Improvement Allowance, Interest Per Annum"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseholdImprovementsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements, Gross",
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-cash interest expense on liability related to the sale of future royalties",
        "label": "Non-Cash Interest Expense, Liability Related to Sale of Future Royalties",
        "documentation": "Non-Cash Interest Expense, Liability Related to Sale of Future Royalties"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_ScheduleOfCurrentProductsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "ScheduleOfCurrentProductsTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Company's Current Pipeline",
        "label": "Schedule of Current Products [Table Text Block]",
        "documentation": "Schedule of Current Products"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CommonStockCapitalSharesValueReservedForFutureIssuance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "CommonStockCapitalSharesValueReservedForFutureIssuance",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock shares value reserved for future issuance",
        "label": "Common Stock Capital Shares Value Reserved For Future Issuance",
        "documentation": "Common stock, capital shares value reserved for future issuance."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_IncreaseDecreaseInCashAndInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "IncreaseDecreaseInCashAndInvestments",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net increase (decrease) in cash and investments",
        "label": "Increase (Decrease) In Cash And Investments",
        "documentation": "Increase decrease in cash and investments."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_VisirnaTherapeuticsIncMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "VisirnaTherapeuticsIncMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Visirna Therapeutics, Inc.",
        "label": "Visirna Therapeutics, Inc. [Member]",
        "documentation": "Visirna Therapeutics, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r527",
      "r528"
     ]
    },
    "arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Short-term, Long-term Investments and Marketable Securities",
        "label": "Held To Maturity Securities And Marketable Securities Table [Table Text Block]",
        "documentation": "Held to maturity securities and marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_AmgenIncorporatedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "AmgenIncorporatedMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amgen",
        "label": "Amgen Incorporated [Member]",
        "documentation": "Amgen Incorporated."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash received for amounts included in the measurement of lease liabilities:",
        "label": "Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities [Abstract]",
        "documentation": "Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_JanssenPharmaceuticalsIncorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "JanssenPharmaceuticalsIncorporationMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Janssen",
        "label": "Janssen Pharmaceuticals Incorporation [Member]",
        "documentation": "Janssen Pharmaceuticals, Incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_OrganizationAndSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "OrganizationAndSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization And Significant Accounting Policies [Table]",
        "label": "Organization And Significant Accounting Policies [Table]",
        "documentation": "Organization and significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_AmountIntendedToInvestForBuildoutOfFacilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "AmountIntendedToInvestForBuildoutOfFacilities",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount intended to invest for buildout of facilities",
        "label": "Amount Intended To Invest For Buildout Of Facilities",
        "documentation": "Amount intends to invest for buildout of facilities."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "TwoThousandFourEquityIncentivePlanTwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2004 Equity Incentive Plan, 2013 Equity Incentive Plan, 2021 Equity Incentive Plan and Inducement Grants",
        "label": "Two Thousand Four Equity Incentive Plan Two Thousand Thirteen Equity Incentive Plan Two Thousand Twenty One Equity Incentive Plan And Inducement Grants [Member]",
        "documentation": "Two thousand four equity incentive plan two thousand thirteen equity incentive plan Two thousand twenty one equity incentive plan and inducement grants."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "MilestonePaymentReceivableUponReceiptOfRoyaltyPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment receivable upon receipt of royalty payments",
        "label": "Milestone Payment Receivable, Upon Receipt Of Royalty Payments",
        "documentation": "Milestone Payment Receivable, Upon Receipt Of Royalty Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r177",
      "r303",
      "r304",
      "r734"
     ]
    },
    "arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Short-term investments, Available-for-sale, Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Current",
        "documentation": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Current"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_UpfrontMilestonePaymentReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "UpfrontMilestonePaymentReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront milestone payment received",
        "label": "Upfront Milestone Payment Received",
        "documentation": "Upfront milestone payment received."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNet",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Receivables included in accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business."
       }
      }
     },
     "auth_ref": [
      "r667",
      "r718",
      "r774",
      "r966"
     ]
    },
    "arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows from operating leases",
        "label": "Operating Lease, Cash Received For Amounts Included In Measurement Of Lease Liabilities",
        "documentation": "Operating Lease, Cash Received For Amounts Included In Measurement Of Lease Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "DebtSecuritiesHeldToMaturityAccumulatedUnrecognizedGainNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": {
       "parentTag": "us-gaap_HeldToMaturitySecuritiesNoncurrent",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term investments, Held to maturity, Gross Unrealized Gains",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Noncurrent",
        "documentation": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Gain, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_TaxIncrementFinancingAward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "TaxIncrementFinancingAward",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax increment financing award",
        "label": "Tax Increment Financing Award",
        "documentation": "Tax Increment Financing Award"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseCompensationPercent",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-deductible compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Compensation, Percent",
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Compensation, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "arwr_DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "DeferredTaxAssetsRightOfUseAssetsOrLeaseLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease liabilities",
        "label": "Deferred Tax Assets Right Of Use Assets Or Lease Liabilities",
        "documentation": "Deferred tax assets right of use assets/ lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_AROENacAndAROHIF2CandidatesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "AROENacAndAROHIF2CandidatesMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARO-ENaC and ARO-HIF2 Candidates",
        "label": "A R O E Nac And A R O H I F2 Candidates [Member]",
        "documentation": "ARO-ENac and ARO-HIF2 Candidates."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r253",
      "r254"
     ]
    },
    "arwr_InitialTransactionPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "InitialTransactionPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Initial transaction price",
        "label": "Initial Transaction Price",
        "documentation": "Initial transaction price."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r829"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r233",
      "r597",
      "r632",
      "r646",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r659",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r668",
      "r669",
      "r670",
      "r671",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r679",
      "r681",
      "r682",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r699",
      "r774"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r74",
      "r134",
      "r184",
      "r186",
      "r192",
      "r601",
      "r621"
     ]
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arrowheadresearch.com/role/EarningsPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss attributable to Arrowhead Pharmaceuticals, Inc.",
        "terseLabel": "Net loss attributable to Arrowhead Pharmaceuticals, Inc.",
        "label": "Net Income (Loss)",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r95",
      "r108",
      "r144",
      "r164",
      "r183",
      "r185",
      "r190",
      "r202",
      "r211",
      "r213",
      "r214",
      "r215",
      "r216",
      "r219",
      "r220",
      "r225",
      "r235",
      "r242",
      "r246",
      "r248",
      "r291",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r525",
      "r535",
      "r619",
      "r680",
      "r697",
      "r698",
      "r739",
      "r779",
      "r904"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r830"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Noncontrolling interest and stockholders' equity:",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r831"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_GainLossOnInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "GainLossOnInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net loss (gain) from investments",
        "label": "Gain (Loss) on Investments",
        "documentation": "Amount of realized and unrealized gain (loss) on investment."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r863"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r833"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r769"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from the sale of future royalties",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "us-gaap_NoncontrollingInterestMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NoncontrollingInterestMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non- controlling Interest",
        "label": "Noncontrolling Interest [Member]",
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r347",
      "r886",
      "r887",
      "r888",
      "r972"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r832"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total noncontrolling interest and stockholders' equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Including Portion Attributable to Noncontrolling Interest",
        "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r67",
      "r72",
      "r162",
      "r163",
      "r189",
      "r208",
      "r209",
      "r210",
      "r212",
      "r218",
      "r292",
      "r293",
      "r347",
      "r465",
      "r466",
      "r467",
      "r496",
      "r497",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r523",
      "r538",
      "r539",
      "r543",
      "r560",
      "r627",
      "r628",
      "r643",
      "r661",
      "r678",
      "r700",
      "r701",
      "r715",
      "r780",
      "r884",
      "r898",
      "r951",
      "r972"
     ]
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r823"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash flow from operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r824"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r789",
      "r801",
      "r811",
      "r837"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r532"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Axis]"
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r647",
      "r648",
      "r649",
      "r705",
      "r709",
      "r712",
      "r714",
      "r717",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r733",
      "r746",
      "r773",
      "r910",
      "r967"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r312",
      "r313",
      "r719",
      "r902"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesSummaryofEffectiveIncomeTaxRateReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r941",
      "r948"
     ]
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquireInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of investments",
        "label": "Payments to Acquire Investments",
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period."
       }
      }
     },
     "auth_ref": [
      "r104"
     ]
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AmortizationOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization expense",
        "label": "Amortization of Intangible Assets",
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r38",
      "r41"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arrowheadresearch.com/role/EarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average shares used in calculating",
        "verboseLabel": "Denominator:",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r598"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease term",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Finite-Lived Intangible Assets",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40"
     ]
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease renewal term",
        "label": "Lessee, Operating Lease, Renewal Term",
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r953"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r796",
      "r808",
      "r818",
      "r844"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average remaining lease term (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r557",
      "r768"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical",
        "label": "Geographical [Domain]"
       }
      }
     },
     "auth_ref": [
      "r250",
      "r251",
      "r647",
      "r648",
      "r649",
      "r705",
      "r709",
      "r712",
      "r714",
      "r720",
      "r721",
      "r722",
      "r723",
      "r724",
      "r725",
      "r726",
      "r727",
      "r728",
      "r733",
      "r746",
      "r773",
      "r910",
      "r967"
     ]
    },
    "srt_ConsolidatedEntitiesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Domain]",
        "label": "Consolidated Entities [Domain]"
       }
      }
     },
     "auth_ref": [
      "r207",
      "r509",
      "r510",
      "r513",
      "r514",
      "r562",
      "r729",
      "r903",
      "r906",
      "r907"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ConsolidatedEntitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ConsolidatedEntitiesAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Entities [Axis]",
        "label": "Consolidated Entities [Axis]"
       }
      }
     },
     "auth_ref": [
      "r207",
      "r509",
      "r510",
      "r513",
      "r514",
      "r562",
      "r729",
      "r903",
      "r906",
      "r907"
     ]
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r789",
      "r801",
      "r811",
      "r837"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r822"
     ]
    },
    "us-gaap_IncomeLossAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Income (Loss) Attributable to Parent, before Tax",
        "documentation": "Amount, before tax, of income (loss) attributable to parent. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments."
       }
      }
     },
     "auth_ref": [
      "r97",
      "r190"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 107,312 and 105,960 shares",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r608",
      "r769"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeReclassificationAdjustmentForHeldToMaturityTransferredToAvailableForSaleSecuritiesBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherComprehensiveIncomeReclassificationAdjustmentForHeldToMaturityTransferredToAvailableForSaleSecuritiesBeforeTax",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net unrealized gain (loss) on held-to-maturity securities",
        "label": "OCI, Debt Securities, Available-for-Sale, Transfer from Held-to-Maturity, Gain (Loss), before Adjustment and Tax",
        "documentation": "Amount, before tax and adjustment, of unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r258",
      "r877"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r472"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r659"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r87",
      "r659",
      "r678",
      "r972",
      "r973"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-Based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r426",
      "r434",
      "r453",
      "r454",
      "r455",
      "r456",
      "r459",
      "r468",
      "r469",
      "r470",
      "r471"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of eligible to receive tiered royalties on net sales",
        "label": "Percentage Of Eligible To Receive Tiered Royalties On Net Sales",
        "documentation": "Percentage of eligible to receive tiered royalties on net sales."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r89",
      "r120",
      "r610",
      "r629",
      "r631",
      "r641",
      "r660",
      "r769"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Grant Date Fair Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r105"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]"
       }
      }
     },
     "auth_ref": [
      "r252",
      "r747",
      "r910",
      "r967",
      "r968"
     ]
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of compensation",
        "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay",
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2024",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total gross deferred tax liability",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r84",
      "r85",
      "r140",
      "r489"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Numerator:",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCostAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCostAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Cost",
        "label": "Lease, Cost [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred tax",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r131",
      "r157",
      "r500",
      "r501",
      "r885"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r113"
     ]
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from sales and maturities of investments",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r768"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": {
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Five",
        "documentation": "Amount of amortization for asset, excluding financial asset and goodwill, lacking physical substance with finite life expected to be recognized after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShortTermLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShortTermLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Short-term lease cost",
        "label": "Short-Term Lease, Cost",
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r768"
     ]
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration and License Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r151",
      "r160"
     ]
    },
    "us-gaap_CollaborativeArrangementAccountingPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CollaborativeArrangementAccountingPolicy",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement",
        "label": "Collaborative Arrangement, Accounting Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for collaborative arrangements."
       }
      }
     },
     "auth_ref": [
      "r152"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r552",
      "r768"
     ]
    },
    "us-gaap_VariableLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "VariableLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Variable lease cost",
        "label": "Variable Lease, Cost",
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases."
       }
      }
     },
     "auth_ref": [
      "r554",
      "r768"
     ]
    },
    "srt_ChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "ChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Chief Executive Officer",
        "label": "Chief Executive Officer [Member]"
       }
      }
     },
     "auth_ref": [
      "r890"
     ]
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenue",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r910"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Useful Lives",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r847"
     ]
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Line Items]",
        "label": "Disaggregation of Revenue [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751"
     ]
    },
    "us-gaap_MunicipalBondsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "MunicipalBondsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Municipal securities",
        "label": "Municipal Bonds [Member]",
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DisaggregationOfRevenueTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disaggregation of Revenue [Table]",
        "label": "Disaggregation of Revenue [Table]",
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor."
       }
      }
     },
     "auth_ref": [
      "r360",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r751"
     ]
    },
    "us-gaap_LicensingAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LicensingAgreementsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "Licensing Agreements [Member]",
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory)."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r474",
      "r940"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Remaining Contractual Term, Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Remaining Contractual Term, Exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r455"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r796",
      "r808",
      "r818",
      "r835",
      "r844"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r858"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r857"
     ]
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleAmountOfUnrecordedBenefit",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in unrecognized tax benefits expected",
        "label": "Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit",
        "documentation": "The amount of the unrecognized tax benefit of a position taken for which it is reasonably possible that the total amount thereof will significantly increase or decrease within twelve months of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r106"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentForeignTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Current Foreign Tax Expense (Benefit)",
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r885"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Axis]",
        "label": "Income Tax Authority [Axis]",
        "documentation": "Information by tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r859"
     ]
    },
    "arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial",
        "label": "Milestone Payment Receivable Upon Achievement of Enrollment in Phase 3 Clinical Trial",
        "documentation": "Milestone Payment Receivable Upon Achievement of Enrollment in Phase 3 Clinical Trial"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r788",
      "r860"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of exchange rate on cash, cash equivalents and restricted cash",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r537"
     ]
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r867",
      "r885",
      "r947"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r788",
      "r860"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets",
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents and restricted cash",
        "periodStartLabel": "BEGINNING OR PERIOD",
        "periodEndLabel": "END OF PERIOD",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r106",
      "r200"
     ]
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r166",
      "r202",
      "r291",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r510",
      "r513",
      "r514",
      "r535",
      "r769",
      "r904",
      "r957",
      "r958"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r788",
      "r860"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for amended operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r768"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesProvisionsforIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current tax",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r131",
      "r495",
      "r501",
      "r885"
     ]
    },
    "us-gaap_OtherCommitmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Table]",
        "label": "Other Commitments [Table]",
        "documentation": "Disclosure of information about obligations resulting from other commitments."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "(Accretion) amortization of note premiums/discounts",
        "label": "Investment Income, Net, Amortization of Discount and Premium",
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "arwr_HorizonTherapeuticsIrelandDACMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "HorizonTherapeuticsIrelandDACMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Horizon",
        "label": "Horizon Therapeutics Ireland D A C [Member]",
        "documentation": "Horizon Therapeutics Ireland DAC."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Arrowhead Pharmaceuticals, Inc. stockholders' equity",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r90",
      "r91",
      "r111",
      "r661",
      "r678",
      "r700",
      "r701",
      "r769",
      "r781",
      "r884",
      "r898",
      "r951",
      "r972"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current assets",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r769"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Domestic",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r502"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCredits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxReconciliationTaxCredits",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State income tax credits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits."
       }
      }
     },
     "auth_ref": [
      "r941"
     ]
    },
    "us-gaap_OtherCommitmentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Domain]",
        "label": "Other Commitments [Domain]",
        "documentation": "Other future obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherCommitmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OtherCommitmentsAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Commitments [Axis]",
        "label": "Other Commitments [Axis]",
        "documentation": "Information by type of other commitment."
       }
      }
     },
     "auth_ref": []
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2023",
     "localname": "CA",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California",
        "label": "CALIFORNIA"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails": {
       "parentTag": "us-gaap_IncomeLossAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsofLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile."
       }
      }
     },
     "auth_ref": [
      "r203",
      "r502"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r555"
     ]
    },
    "arwr_NumberOfAcresOfLandPurchased": {
     "xbrltype": "areaItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "NumberOfAcresOfLandPurchased",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Land purchased (in acres)",
        "label": "Number Of Acres Of Land Purchased",
        "documentation": "Number of acres of land purchased."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": [
      "r205",
      "r206",
      "r328",
      "r334",
      "r561",
      "r736",
      "r737"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Domestic Tax Authority [Member]",
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetAcquisitionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetAcquisitionDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Acquisition",
        "label": "Asset Acquisition [Domain]",
        "documentation": "Asset acquisition."
       }
      }
     },
     "auth_ref": [
      "r949"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r825"
     ]
    },
    "arwr_MilestonePaymentEarned": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "MilestonePaymentEarned",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment",
        "label": "Milestone Payment Earned",
        "documentation": "Milestone payment earned."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "arwr_ComputersSoftwareOfficeEquipmentAndFurnitureGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "ComputersSoftwareOfficeEquipmentAndFurnitureGross",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/PropertyandEquipmentSummaryofPropertyandEquipmentDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Computers, software, office equipment and furniture",
        "label": "Computers Software Office Equipment And Furniture Gross",
        "documentation": "Computers, software, office equipment and furniture gross."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes Paid",
        "label": "Income Taxes Paid, Net",
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes."
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets (liabilities)",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r944"
     ]
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r945"
     ]
    },
    "arwr_EmployeeContributionNextTwoPercentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "EmployeeContributionNextTwoPercentMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Contributions Next 2%",
        "label": "Employee Contribution Next Two Percent [Member]",
        "documentation": "Employee contribution next two percent."
       }
      }
     },
     "auth_ref": []
    },
    "arwr_GlaxosmithklineIntellectualPropertyLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arrowheadresearch.com/20230930",
     "localname": "GlaxosmithklineIntellectualPropertyLimitedMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "GSK",
        "label": "Glaxosmithkline Intellectual Property Limited [Member]",
        "documentation": "Glaxosmithkline Intellectual Property Limited."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r784"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period to recognize pre-tax compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r197"
     ]
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "StatementTable",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed."
       }
      }
     },
     "auth_ref": [
      "r208",
      "r209",
      "r210",
      "r233",
      "r597",
      "r632",
      "r646",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r659",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r668",
      "r669",
      "r670",
      "r671",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r679",
      "r681",
      "r682",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r699",
      "r774"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r108"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r945"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r63",
      "r64",
      "r945"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r596",
      "r881"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r826"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r332"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r42"
     ]
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/EmployeeBenefitPlansAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee benefits costs",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r421"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r659"
     ]
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization and Significant Accounting Policies",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r109",
      "r110",
      "r133"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r659",
      "r678",
      "r972",
      "r973"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income tax expense and noncontrolling interest",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r94",
      "r143",
      "r235",
      "r242",
      "r246",
      "r248",
      "r603",
      "r616",
      "r739"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r598"
     ]
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from compensation and benefits costs."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r945"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets by Major Class",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "documentation": "Information by major type or class of finite-lived intangible assets."
       }
      }
     },
     "auth_ref": [
      "r306",
      "r307",
      "r308",
      "r309",
      "r598",
      "r599"
     ]
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense):",
        "label": "Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r86",
      "r332"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Authority [Domain]",
        "label": "Income Tax Authority [Domain]",
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJointVentureandLicenseAgreementwithVisirnaTherapeuticsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r507"
     ]
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r945"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r198",
      "r199"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other (expense) income",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r101"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r827"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r828"
     ]
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r799",
      "r808",
      "r818",
      "r835",
      "r844",
      "r848",
      "r856"
     ]
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r861"
     ]
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r769"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "us-gaap_InvestmentIncomeInterestAndDividend": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "InvestmentIncomeInterestAndDividend",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income",
        "label": "Investment Income, Interest and Dividend",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r99"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.arrowheadresearch.com/role/EarningsPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arrowheadresearch.com/role/EarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average diluted shares outstanding (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r223",
      "r228"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails",
      "http://www.arrowheadresearch.com/role/IncomeTaxesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Valuation allowance",
        "terseLabel": "Valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r491"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.arrowheadresearch.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r786",
      "r787",
      "r800"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorName",
     "presentation": [
      "http://www.arrowheadresearch.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r786",
      "r787",
      "r800"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r439"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r799",
      "r808",
      "r818",
      "r835",
      "r844",
      "r848",
      "r856"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r440"
     ]
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.arrowheadresearch.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r786",
      "r787",
      "r800"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cancelled (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r442"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted- Average Exercise Price Per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PatentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "PatentsMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Patents",
        "label": "Patents [Member]",
        "documentation": "Exclusive legal right granted by the government to the owner of the patent to exploit an invention or a process for a period of time specified by law."
       }
      }
     },
     "auth_ref": [
      "r132"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued expenses",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "us-gaap_CashFDICInsuredAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "CashFDICInsuredAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount insured in FDIC per account",
        "label": "Cash, FDIC Insured Amount",
        "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation."
       }
      }
     },
     "auth_ref": []
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r384",
      "r424",
      "r456",
      "r457",
      "r458",
      "r571",
      "r595",
      "r625",
      "r650",
      "r651",
      "r704",
      "r708",
      "r710",
      "r711",
      "r713",
      "r730",
      "r731",
      "r740",
      "r744",
      "r762",
      "r770",
      "r773",
      "r901",
      "r908",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Right-of-use assets",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements."
       }
      }
     },
     "auth_ref": [
      "r64",
      "r945"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]"
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r424",
      "r595",
      "r625",
      "r650",
      "r651",
      "r704",
      "r708",
      "r710",
      "r711",
      "r713",
      "r730",
      "r731",
      "r740",
      "r744",
      "r762",
      "r770",
      "r908",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RangeMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsJanssenPharmaceuticalsIncDetails",
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails",
      "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails",
      "http://www.arrowheadresearch.com/role/StockholdersEquityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r384",
      "r424",
      "r456",
      "r457",
      "r458",
      "r571",
      "r595",
      "r625",
      "r650",
      "r651",
      "r704",
      "r708",
      "r710",
      "r711",
      "r713",
      "r730",
      "r731",
      "r740",
      "r744",
      "r762",
      "r770",
      "r773",
      "r901",
      "r908",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
      "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesAdditionalInformationDetails",
      "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]"
       }
      }
     },
     "auth_ref": [
      "r315",
      "r316",
      "r317",
      "r318",
      "r424",
      "r595",
      "r625",
      "r650",
      "r651",
      "r704",
      "r708",
      "r710",
      "r711",
      "r713",
      "r730",
      "r731",
      "r740",
      "r744",
      "r762",
      "r770",
      "r908",
      "r959",
      "r960",
      "r961",
      "r962",
      "r963",
      "r964"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2023",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r835"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/IncomeTaxesComponentsoftheNetDeferredTaxLiabilityandAssetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total Liabilities, Noncontrolling Interest and Stockholders' Equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r142",
      "r612",
      "r769",
      "r884",
      "r898",
      "r951"
     ]
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "calculation": {
      "http://www.arrowheadresearch.com/role/EarningsPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arrowheadresearch.com/role/EarningsPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of dilutive securities (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r889"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2023",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "940",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "715",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "30",
   "Topic": "350",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "405",
   "Topic": "942",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(2)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c),(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.21)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.25)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02.31)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "320",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-2"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "350",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(CFRR 211.02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480244/480-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-10"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-4"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-5"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "S99",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-3"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-4"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "715",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "740",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2AA",
   "Subparagraph": "a",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-2AA"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "820",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "835",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "210",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03.17)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//205/tableOfContent"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 201.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.20)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7(c),9(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//235/tableOfContent"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//275/tableOfContent"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//360/tableOfContent"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//440/tableOfContent"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//505/tableOfContent"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "710",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//710/tableOfContent"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "712",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//712/tableOfContent"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "715",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//715/tableOfContent"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "38",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-38"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//810/tableOfContent"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-23"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "940",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//940-320/tableOfContent"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04.9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//942-320/tableOfContent"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//946-320/tableOfContent"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//606/tableOfContent"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//808/tableOfContent"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1403",
   "Paragraph": "(b)",
   "Publisher": "SEC"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(210.5-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//260/tableOfContent"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//320/tableOfContent"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482955/340-10-05-5"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483032/340-10-45-1"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//350-30/tableOfContent"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-1"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-3"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480535/715-20-45-2"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(10)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(9)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(k)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-2"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-6"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-8"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480606/715-80-35-1"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-9"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//718/tableOfContent"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "15",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//740/tableOfContent"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-10B"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//830/tableOfContent"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//842-20/tableOfContent"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-1"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//855/tableOfContent"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "855",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "928",
   "SubTopic": "340",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(f)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(5)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "12",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-12"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "19",
   "Subparagraph": "(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-19"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481058/954-310-45-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-18"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii",
   "Section": "6"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-10"
  },
  "r866": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r867": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r868": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(a)",
   "Publisher": "SEC"
  },
  "r869": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r870": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r871": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(b)",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r872": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r873": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r874": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "(c)",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r875": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11"
  },
  "r878": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4"
  },
  "r879": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5"
  },
  "r880": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6"
  },
  "r881": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r882": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28"
  },
  "r883": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1"
  },
  "r886": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23"
  },
  "r887": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24"
  },
  "r888": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5"
  },
  "r889": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1"
  },
  "r890": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13"
  },
  "r891": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1"
  },
  "r892": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2"
  },
  "r893": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5"
  },
  "r894": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9"
  },
  "r895": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r896": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r897": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3"
  },
  "r898": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3"
  },
  "r899": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3"
  },
  "r901": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10"
  },
  "r902": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//450/tableOfContent"
  },
  "r903": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r904": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r905": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r906": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A"
  },
  "r907": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B"
  },
  "r908": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B"
  },
  "r909": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10"
  },
  "r910": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5"
  },
  "r911": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1"
  },
  "r912": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r913": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r914": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r915": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r916": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r917": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r918": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r919": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r920": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r924": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r925": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r926": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r927": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r928": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r929": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r930": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r931": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r932": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r933": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r934": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r935": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r936": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r938": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2"
  },
  "r939": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1"
  },
  "r940": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1"
  },
  "r941": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12"
  },
  "r942": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15"
  },
  "r943": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A"
  },
  "r944": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2"
  },
  "r945": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6"
  },
  "r946": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9"
  },
  "r947": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r948": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1"
  },
  "r949": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "15",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3"
  },
  "r950": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1"
  },
  "r951": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28"
  },
  "r952": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r953": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3"
  },
  "r954": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4"
  },
  "r955": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6"
  },
  "r956": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r958": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7"
  },
  "r959": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r960": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r961": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3"
  },
  "r962": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r963": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r964": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4"
  },
  "r965": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2"
  },
  "r966": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1"
  },
  "r967": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B"
  },
  "r968": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H"
  },
  "r969": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1"
  },
  "r970": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4"
  },
  "r971": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3"
  },
  "r972": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r973": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3"
  },
  "r974": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>125
<FILENAME>0001628280-23-040219-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-23-040219-xbrl.zip
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M&;F-Y#FDB>;6SJ,; PRWG<YBH9 [?VU5/_B+_P^)_)<2_C\K_P-02P,$%
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MRRW;Z4+E;\4*;T5KL,W.'7O/)D-'?(I4KEBQ5/7%:_A#<YU*[:FX(23$'26
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MLY8UN#\;COP#H1TYR!Q)Q:58&59'>H_%:YWLJ[W,<FQ"I(17UV5-;*+P42!
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MLSO<Y??,Z7%_I*8[.@+BO#G\LW19.IN;\GU:XOA\P'T.JD*P0%"BH#\-2*6
M11DD^$]#$(^_[ 7V:.R@PD"_#7U<<THF'CP$%@SQ/CV&F'\ZJ5Q#X$4^_47:
MZ*D$!&T'F;KZG9/84'_9%OX]L+EOT/A\H>+6;/^6%B>S'W]4/Z5''Y/44W^!
M.N6'9V QH&0%]1F4Z++Z;OHL7J:E7JT62R=%5!#23]3?:I+WJ7TO!D,E V 0
M>F4H=U8%G3<>2#Y9;6>1:XMM140DXL<1D'/D\X]2XSW]VCU3GZM'ZF_\?C&4
MJEF#4KE<K)1>"*5@R.",S %*DA\]7!]2M6U#2BZ/WR)3%']:,-G#V+%-.[SD
MHSY,8=GP5-CJR,=!%[3O;"MB3N/!AATC2SF]9)'OG7/?9[XM/OOY_<+1XEW'
MDZY[M(&JZZ]_M \U*A:PER1TUSLX:>@>Y0:Z9UYTZ[ @^&S?<?=-4GI=XV*;
MI'Z<&_#^"HIM\(6-;"?TG@+O2K/T?&:!3@Q6P+)94$6V7?3ZHLK^)H_7B<;_
M[O"_G2-=+FF<+L=I([J-@A A_F;/='GK]J\F@%<_U%LWYC>&T]] ^YD$_WSW
M[H/O;]/Z*F_=9Y 79&R)V//C:;AAH6^;WZ\_^?8;-<#*^?$U;!D96R+V_'@;
M0+B:-K]VP,#UWR:MY\?;L%U<;(G4\^-M^&:;H>?;[!O[#KSDK9)[?JS_[>-C
M.R1?R8\Q_KOM.#8;_<XL"_[U)@F^DA_+>-O8V!*YY\=,?<48X8["__FQ4E\S
MC+4C9.3'I'V#CO8L$$!^S.@WZ)3- @'DQ\Y_30_NCI"1'T/_-3V,.T)&?MP"
MK^@!VQ$NM$L@4_BH:O]!EK"1A<SR[5CNU8QEBU=>LK5DMO@-][N8\!QOCTB7
M)U^E4@<&S$3]N&9B^=SW^.,9=STR:N:'E33[9!IV:HCWZ=4G7EN"T"PDMJ?.
M;'GU,UO9X)G=NN6]+AQ*J\.AO$$X9,X 545*W1#VA-]@050X:7JCL>?"GX$0
M+NHU^'WDN=W0,[]OU1U:VB!3S9S-MR;,&R#+L3Z..3?,MMINDXWMD&W7';U)
M^&?.S%L7_J89C2('/6/7X9#[^)[/ASC:'6^[IC?BN<%%YJR\-7'1X2&S76ZU
MF._:[FV0&\!GSJ1;$_!7GHL[\CVP+]S;-NP-]*8P+^"O;=V"V]W6,A=.S:IX
MRX#^5\M<:#9+^E\6$)2Y>&T>E)4L("YSL=W,:399P)*V?U=3$,H;5!"T_;M;
M^&O[-SNXT/;OC@"O[=]=@O\P8_;O)K>F[=_GZ'^[B0,=:OLWXPC2]F].$9=W
M^_>U!&P6<)5W*_B5?14[PE+>[>;7\E6\*$MH!N:YMY5WX*O8)/SS;A_OVE>Q
M25SDW61^55_%!@%_E+ETWXRJ4EL"OS;H\Y.,?:0-^HPC2!OT.45<W@WZ5S82
M=X2EO)OR.W&[[ A7VJ!?39G;9!=W;=#O%O[:H,\.+K1!OQO U[5!OU/P9]:@
MQSLCKP<-WV?N+:$A44G=\2;,"2<W0^:/6./6Y_3"]A4C3(U8+=*1>O5%UWMD
MUHA_#$%-. VL[XF[XQJN=6&;\#F/4?4V#8YZYNSYP ]/.X@?@1O\\Y(]V*-H
ME!L&E;GJY$JQ5%L]XEG;%&UESIA=1%NVFRO:RIS1*0[H7Y[?C((0U&<_2##5
MSPY[\(*1'0Z_X\W9J&HX#C?#".P?>7/FA0V/N?4VN6OFS-5\8&LW&1KUS!FW
M^<#6;FI_ZIDS?Q_%UA?/M__QW-Z0^VS,H] V@[;/'080:#3?)/,[SIR9G%D$
M[8;?'6?.D,XL@G;#XHXS9T@_BJ >^\XM)CP<)B&(.<%7%R40.:8",+WI_G&&
MCE9_C+;V&U7\CC-I5N<+<SMBBIF+D^</<SOBEIET-RS%W*_,#0+NSJ!NBB7[
MR3[=.66-^?)@[!Y-.^*#^7)=[!Y-.V)Z^?)9-$:WW'W[VE^^7!.OC93=,+23
M?+DC7ALINV%?)YET032]"',BQ@""R14;\6TX79]<2!YBUF5,&JA45B.:U*OK
M$4W<^]OK._8M[3:F&]5DFP R?:Y&6M2#>V[8?N1:#E\\I'BVRG SI)U)YXTF
M[54CMD<;BMB>9-(5I.E@Q<8R*:[U(CK(I&/I69DVFL*R26&9=(!I.LBTK7J2
M27><)IILV]*9= X^0C0OB1UOA$[D F;)8^O4 6IL^7A%HS[YZHNH(Y,^24T=
M"ZACU?O:Z=5J>2/4D4GGJ*:.6>H ':.\NCI2W1!UE$N9=--J\LB&MEHNY<UA
M_(.2QV[TTG(IDT[79Y6<; 3Y"NNNU?3.(Y=N;%^1 EY*^!G.3*JO0I8SKSXS
M8.%&N/"YR((< _ZY?F"A7,JD1WD[GD1-Y-DE\EFRS)R#6Q-/?H@G<[YK33S/
M")HFS<"7A#+*I4RZI;6,RPRE;:J@NES*G"];TT-^W!&9<W5KXMDI,\F;<_M7
M;^@&%+F4_VJ[KG='T<Q??SUKKI- OQ'2W'$\M7Q,?*2Z A^9??5%?*2<.:]W
MW%(LZ@>V93-_TF4.H(W:1:80%C>1O(E\<\A6]S%JVGT;M)LWE_S+:X7R2BY3
MJ3=+ 2^2>N5<>-U?);51T]:F:2N3SFY- 5D51IES0N>#7'Z]^K5Z<GS2Z%Q_
M^?1MBT'B;7&)S+F/-=I?P=PN9\Y+O K0KYTQ"VQX\EJ&TBO4DB;.]1$BN'+\
M/ 3'@7.F8+.X*B]^_(SX>3F7'M^W2#4IC6&&;A[3&&9>?9G&D$L7[ENDAFT)
MB<SY9#6"0?G;'((KF76>_K@(KI32%0,O0W#F/(P:P1AQK6P,P3^0 U&3SD:E
M>R5S_L%5$/S-!O2Z+%45X)J;0;(;>(YM(1);"!";S]S^\XWY-NL[7-W[0V]-
M;GQ[Q/S))^[R 8P._]QZQD:I5JP<KJ#NS[[Z(G6_DCD'H<++N>TR%R#OM.$\
M^-&48M0+9[P?=KD9^834_)S0S/GFL@CQ#=YX7:YDUBWV),2;W,<Y3)$*=,;'
M7F _)?PR!/C,>I8 \';(+^P[;@'?!XED@P1H! $/@T\3T83.8<&,I+@!+#P=
M*5IY#31=P_P[ N%'4:FI/+SR[H#]VSEB:IGU&CT+TR(ZF,P#U%A?A/7,NI+>
M$I2KF?7G:"ZZ67E9S:QC1W/1+6(]<]Z>-PGEK3M&UI80U6+Y:#-[R\(-FW-[
M.]S,WC)K+M\XS)TMY[CW>D,O"IAKG7N1+ZZ=;KLF3G;'\8/$&[VA[8><NT^\
M=0\_3ZY=ON"UA@O<V(I,XJV???8*;6 W=QXS:Y3_>'C=*)_-G,V__=C%4T4A
MC; WY)?,_P[2]%62RB@85=I(%]5R-7.F_8^"T-F*SB1*'X\/I%Y]47R@FED3
M/QLXVI)TK&7.YL=31B6I)).X=^NS\1"S=.4A#,?^Z>_MEQ\]U;06Y6 (@A#%
MXQCG_#3!"&(R:,A]SV4];@Y=S_%N)S> ZRT?PC*>K$IIE4,X\^HS^R4QTY^_
MAR$*_5-\H#Y>(]>SECD/0_;HZLR/;B^9&PV8&4:^[=Z>,]-V %9;Y1XS]/+,
M-.'@[\%\AC#2"SYX#KUDSC>1/7JY$'5%GC^!UZX' ]ODV:>863QG-FUD=3Q(
MH.<I%Z"6V>R++8#]67K]2KTA,X30['JK,H+0E0RU#"%TZVZJ'3+]K;MJLJI?
MSP(B<RX.=6JOPR'WL:>('5+\+.F3C T?6<N<>.TUDG(;G>O6%3.!E6"Y9/N\
MTF2N18F6V[[D8S=W,Y9KF76%K,[;.SS@S#>'2D%MNUWFGMG\UML$KW]*+V\V
MMJ<*P_]_LA&N>)@YUTO6T+R]3B+Y)*#I=9SC1Z[B'*]Z#><L/6;.99,U>MP9
MU9"B6=E,G/LP<YX6C>8MV!.';\#1TE1E45\XL_Z.0/OB?M!V;UC 8!U,XUKA
M.G/>G2?*WII@3OC,\J[O7>Y?7&SL/A9-6ALGK3?@9]JNM'B$S+N>[\."O&_,
M<?B$B/VLM0%RWREU4="_LIGV48?9S<UZ 75=,LL.7MY'ZH4!J SQD,QE:BDL
M8^7UB,= OO!,-DT_5B\I! ,5G/$[[GA$!ZV',?K"MI^,LXOVZH>9]5-F'F,[
MNH#M,+,^P\QC;$=>WJ/,NO]6PMAG#MH,R"+7:E@CV[6#$+LGWO$WS1>/,NLB
MRP'.=L09CS+K[\H!SG;%&[/KO'JT9B-84K21FRR$H\QYDE8$O*J%R2G8L^ME
M>13L<6W1ZX&]3"5_S^QR.POV[+H?,D'MF5"Y,NL\R,;1R 2.,NLN:-PSWYHZ
M[-3/K='8\2:<4RG/]7B37=\74,5U% :PF>N!T R:W@A5-]+U\.W\9!$?9=;)
ML 3/'0[JLFW2)7> :;SO+NATOVI</XWK>F;=$]G@N]L">V8]# O /JT=I_.7
M(^+.K$]@*_;E;MAHAM"=5W?"<_3\'Q[9F75A9$9)>4/B,K..D\P@.[]".K/>
MF;?*.3/K:MF8&9]3!TO][3M87HJ9'447ZWESB;P^9G840SS.K -CEYC9DN@X
MSJS;(D.R>I/=[XXSZ\'8-<"S(*^/,^=PP&3BGAUB_S(P".P[VXKB1&),8A_:
M?-!ZX&:$)J#H+>-OR=&@LJ;GR$'T4/O$@FU?>8DGL;RZLI!\]65DD3G7A":+
M&;*H%TNKW(0Z^^K+R$([,;9%C"\6V$DDOTQ@9\Z;D8>S?\/]@>>/F&OR+3&
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MVOMX5#F:/1OOUM"?*=7N9NBY,_HS7HI8+=6*59#?>=.9UN5##<OR>1#(_US
M>.48#)6]C^5ZW6@=&$U</+,\XY-S9\W[F%X^:26>M+KWL1O9P CJ/PSPD;RO
M_9YW'PM.O%?LA@4,CCW;&+B)OU[[-R"F@9>N+L7Q&JDF !=>=^VYY3QW-3<>
M3.?\QQZG#C68KB?E<NDP.YA_DF,+9B9W93#7,D+N\#&R%672@_0:^P!S;.QN
M\ =N1J%]AS8-<'0>/&*QI#7N5TE;R(,-LX.C/6T!)NU0[H/I.8[\($*#-/0,
M>(.$<[FRWW^'*$>G5^L!S%+WEAL-,SQ=SS+-C>>]?E Y66Z,/==0JU0.RN6C
MC0]+JZWNP*,?&R>OR;QF<RWF#G,942X<J(HX7UG?Q07T[- A%P]GYM P'18$
M,UETF;<25U/L>Z!$P6*-[F34]YS]8"MFRRXW>"5]=81(KI@?<,7[H0V_3%GG
M.C:L9'XH$4H'=6!G1N YMF6HW63!L-NTET#*FTFYTJ?3$6M(=1$X )!V0\_\
M7C!^*AV42F5CS'SC#LOUGN%I^1$!+(^B.(DQ=(_1B?Y[1\-P+2)56HX(1\R:
M%<@&9BR*$V"%H!U=L<!B?QN?':\/BG$7U&8S-$2AY],^K\RX.U:S$-92(&^7
M*)!7:%2LI3G;+KJ.DEGJ6]OW8DNA[5K4;,WH3PQFF$-N?C=&F )HBPTFHCHV
MF$_&/7><XG<7C&$CX"R #5OP((BX7\"PC\4'MBN"/IT(E(9:Z5"!*@%A -;!
MVH;I[S#S;SAQ5\[;IFGCE++2WL<_>3!O_ZZG-SV5K+$:5!]>15M;/#=0X6XV
M[;UERG>]T,!"?!O9 G #2@GP*:TF6,PFJN@$%[DD\@00V0.-[A@]NZ#)=0_[
M-\^)W)#YE#[A!_$A+X,..Y>BM.,SGC]R3Q#[_9!3.&>&XO?+[XPA\',D<\M@
MCA/3>O(0]+E\ <9\A.X3G#\I+_$QY5!9$;:LH%?'/C<YV6#EBD%)E8&Q#^.!
MTF($$9@HP=##- *5HQ0.63B[]GL6S!]5^ECNX5V!_(#[%;''/J@^\+S_%ZHW
M\#Z]"A_A*N0XU%R#%D&+9$%HG)0,BTV"]>68S"H5*7FHXH8LC*847M%B3(NQ
MK9UKI'<@]9$=AG X2*/W/1?-&F=B<#!Q)D8;E7!FD@O\C(7,.!>B+G7LIV,D
M95]2Y>OPV\@1\=!NL6?LHQ>K_L&H5"L'L5)H4UK0F-*"MLP$Q(+CL\V#=^N?
MW 1D$##R(,<GMZI/KCZY6SNY9'TYL ]N,-.$DXNWGUA$RVAZN0M_!;75+2Y\
M$(S@R,,LOA)#0/XC@,&D@.(;A@.9AS"[-6Y][SX<JL<'(,TYK8U,/4H8#O T
M__M?QY4*;'/)"NEQ^8-Z[<D7EJY/O8<27+Z[9*GJ366+EBO]8F61X7ZPJLV>
MH_R\\N'!X='SXC.//:L<E.J5C4=]RI6#DY,ME(<<'!W6<P*"HX.3ZN8A ( M
M'3]OFSN@@M)!C>)-&QYV>R?A).NE1QL25P(KSRA\\)O X6\]?[+ [4PO$>\W
MY4M3#S1>@'NQ6))L-E/5QPUNM;KK:>#64LZ$I[>1:JJ1;YIJS&/W+6#3^S&Q
M>;5(V=08S3%&U^7Y7=3:/T4!#!0$3Y:;XAW7W65Z_IOC\Z72'!W]H)I!2]IK
MG\E<:PI\/TTM1WL?6XLMO:4^E]P2RS:9CG[UN:^NG]BP>R?3X!%G3L&P%_N@
MYD.@Z#@F=S'(=8R%AIX1!<(1!/L4O3P6E)![/LWE3'#R>QNFAFD-%[;F(<^_
MLP/2$^2E<*CM8QT;OHQ](2WF6X&!*>^VM2P;H[K/%F9C'&@?Y%:B!S(B* 4V
MY@ZB)XZ%(<?Z!$0)8 <+?F%I3#2_1$=<N?XA,%@0@%Z /RF,\<& DT,=%08J
M(X,O;?2SNT .*$E\SS$\X,4)*IGJ"A' SX]IH5:J)7*[N\SO,QBV>/W@\ D%
M'/?+A\;7@^Y!\\"H5XXP$?P=;GRZ2YGTTW= C"5H<6#[(Q%E&,/<#%\"\J6T
M%XM6S"++#N6Z=D1XJPOAMCGP&[A@SV],T7;NL-LGVS;5'^O;] 8)GISNP9 [
MCF*9QOZ"+*>49QD([=T.TSS65MEQ=ROK8,>/=(CYD4)->4O^&!C!- D#&-A:
M53) T4LUA>3!F7)H*E4321/>?#:5:SJ1)8Z/^$RF6@PHP11_,CW?YW%I,2HP
MOH_)%QXRX#O;BP)GHOCOHEG7YL$-'P9XI7.GVC.=VVXW'(4MW%HSWO R/IP^
MAR=8%G)2K]4^K%>*-T^)B[HB/_W5*UJ8E:>Y-O)EHC,/5%)!*E,*4O2>H$D2
MY7%V .HRID>Y#Z"R.)/ #F1!._JH[WBQSU!+10' W4#H.)BA (\H\RF>/4GE
ML<XS6T_H!\E4!Q]TZCL\%/$2I.:</)0B=:)2*QV42V?%,IS,UZ5O0D%,;GGB
M>YC%SFYO 2U(/"-*71=E&(1A2B".,77GD;*'ZBR&S>6?7A22*2)=4UC9$6!E
MAP%RD]!/(?8!,C&\LYH23]@8;)8'&TXP!S[UDV0-YY0[ M]'KBT80Q18>S.<
MHK('VH4)GSK!+WO%XWEY?4/:Z;GCL1",59,A-$_B]H:EO8^5@[BAH)KQH]&W
M'0>G%J0<C3W!>DW'"X2QA3L: _]8!)C4MN$?EW@QF%$MB^Z%!T9W"">,SLQ"
M %&QD21^@JYEX]'TQ!_J!:#[@ J1/-2Z1(8YT#[^IUSZ;]2W1Y[/U4%;CA4&
M)XTR^OA#4LPPF?LCID'K9()Y3!9VWU=)30DLRFF:*NFAA[E*%@>!.0)Q$PLF
M]0&)GBA0B<(N<(<@8#[0,Z86>RCP F0!Z1$&<3,-..UCX%W!RID(&3E?#8+4
M%7 N+*06A8J5DJ"+N!!^GNX#(IA9TJ\F2;]]=;X@=9(P3855@N:NIV20EIEN
M-"I:7EB4 \8GI12?%&H_72_4JI5"I5R:/S%!3-1("#,G(EGB9=R#%J64$:3H
M!&VNVLES0;E1&L$']>-5)?8+1G[EFINSZ^;7R]95KXOMSZX[-]>=!O;:__2G
MT6F=MSJMJV8KO<NU5:Q@VBB)6Y\F\"K@"N1Z#[[[Y #R8G( OLN!1L:H\J#%
MN^K9JY8.MM"K>[73=X->$)E^A41Z)C.R@-'<@/R9&%VE\J22M9'M-$!)NL?[
M.0QQ#XG)(W)V!P9 [""F<SC'-4,T=C8N.1<"<2#H?N@Y%FHSJ%W9"3 C1_<5
MH-&7XQDWS ^-=KL-(L'GWF#F5,PJL$NTSQC2>4G!RM?]&^F[54 :D2/W%!14
MAA2U]+85N8+2]!/6#SPG"N<_>>H:EG7OB<'K?\0WPQAT8W8+"KO/V7=0RH#;
MG3+GGDV"O??++I.IO<95,GBKPJM3+FSGH"2VM';V(#RL;+YIQ''IH%X^WGS3
MP(.3H]46NXV :TS8&^/^3W<S%EAEKSNC  =H5++)&S)MOF<,?13 _UKA6J<J
MB*Q&IV>T?W[/9@_/EH-V<[Q5G<A,A!2S3Y%/=BK9.$6N,N.+*?)H[V.*&+=[
MC+</M%5FW 30>JU+HWSPK&.\,4H>#%Z/KBC.B&\M0==NUK(>SCZM0.C/W,>S
MR&Y+,'WA6M:#Z==N^ZK5[6[S(#S1F(IRE39M?KYASE5>@BLMAW<IAT^T''X6
MT$@.-[0@SH\@!J1UM"#>.$S;W=^,[8'UAR75<TVJ&X=IH]F[[FB5,3]"MEK5
M.F/V=$9LE*-UQF< C73&3UIGS(T@1J1]U8)XXS"]ZK2ZUQ??6F=:<]P\<+N:
M8#<.TU[C_%S3ZN;AVM2TNG&87E]29I<V<W*C%QX>:3,G@V;.H39SG@4T-',J
MVLK)CR &G-UH0;QQF':N;UH=O+]>B^+<\"XMBC,IBH^U*'X6T% 45[4HSH\H
M!IQ=:%&\<9BV/C<NM/]F\W#5:N/F8=JY;K9:9^VKSUIOS(^@U7IC%O5&+#76
M>N,S@(9Z8TWKC;F1Q8BS2RV+-P[3]E5+JXV;!ZL.46\>IHWS5N]/3:R;!^R9
M)M;-\]5N\^*Z^[6C?>,Y4@J?LG%TG;?N/#!'-S75>4"W'L@=2;Y1IT!=.P6>
M!31T"AQJIT!^E->Z=@IL Z:-SF^MGG%^W3%Z7[1[8 L UF6ZFX=IZW.[V^LT
MKGJRPV!7$^[F@:S3V3</T^O+R^LK3:Q;X B:6#<.T__[M=W[LZ"I5>L$>:#6
MU@5U?=;4NG'(Z@#7YF':NV[^]N7ZXJS5T12K'05YH-A&K]?J=(W&E>:Q6X#N
M*CY<3;%KRJWN5\U>MP%8G2B]>9A^[32_-+JMKG&M>S-H_T N2);\ YI8M<&5
M!V)M-;]VVKI^.5<Q^L.ZKD/)7LI)K:133IX%-$PY.=(I)[D1Q8@S[:G?/$PY
M3'_'+2V(<\.Y#H^U(,Z@(*YJ0?PLH*$@KFM!G!]!7-4AG6W M''5^-S"_IHZ
MC6Y[0-85=YN':;O;_-KMMJ^O=#AR2YQ!$^W&87K5N/BSV]8!GNU 5U\QM 4V
M>]6X:K9UL[%MP%9GUV\>IM=79^V>U@JV!E_M#-T\3%O=KQ<]K11LB2%H@MTX
M3&]:G08R61U(SX_#4_OOL^B_/ZII__VS@$;^>WU=]:[7LA[2_J^6Q1N'Z=?&
M5:_= W'\K:5M'DVV^2';"T6UFF(W#ET=<-H\3*<M'C7%;AZZ.MJT>9A^NO[:
MT[2Z>;CJ/)0MG'_J0::)=>. U0[[;:@"OVG/9VY<14<GVO.90<^G[EK[/*"A
MY_-8.S[S(X3K.C-I&S#5F4G;@ZVN/M\\3'N-'B7:Z_Y)FFAS0[1?;VXNB&H;
M'=WF8POPU8[ZS<.TT6MHZSPWYHRVSK-HG==U@X_G 0VM\Q-MG>=&""/.=!W&
MYF'ZI7'UN=4UVKH08TL UIKCYF':[C8^=UK22O^]W?NB"7?S0-:9'EN08,WK
MKV"C(]GJNV4TT>:):-M7G[6*L!T ZZC3%E0$'772*FV>Z%5E+6N7:&Y\2-HE
MFDF7J&ZU^#R@D4M4EVKN>BWK(4W[1#</T^NK7N?Z0N=_; F\^DJBS<.T<]UL
MG6'-FU8?<R-OZR6M/F90?3S2ZN.S@$;JXR>M/N9'%A_IKEO;@&GOB[[*<AMP
MU?>N;AZF5^?7G4OJ$:<5Q]Q(VGI9*XX95!Q/M.+X+*"1XMA\JXIC/4/"^-&U
MK(>TG<8 7P^F+US+FMQ#Q0!WJCV^48+=:7^--TJPK<^-SADF!FEZW3AL=YH4
M]$;I];K3:G_>;=[E&Z767S6U;ARF7SOM[EF[20W<-<UN'KX]3;,;A^F7QFZ;
MP[U14MUIR/R-DFJG]:UUI:EU&W:LIM:-P_2J>]-JZKM<\N79?,I1KW:DIH53
MNO<4)DN(Q[V5D/[<5W,21IC%8OW5Z6;1C"^EF^,*B/M&IV>TV^UG'?478EW3
MI YMS='DH0YM/0MH&-HJE]YJ:.L-YID@TG1YV^9AVNZ ]GK=Z19T8M3F@=O2
M!+MQF/[1:G[5MQYM![8ZZ73S,#T_;S=;R%]UT=)6X*OK[+; !SHWUYU&3_/8
M+<#VLZ;7S=/KMU8'VXKH'@WYL<!UKG0F'4K'VJ'T+*"10ZFL'4KYD<7'VC[?
M!DRU?;X]V&I;9_,PO;Z\:5UU=:5=OL2MUAZSJ#V>E+7V^"R@D?98R:?V^$-*
M#D1:%S2=3KOWIW']^U6KT_W2OC&NSXUFJ]-KM*^,3ZVKUGF;.IV*Y^0 OFQ<
M-3Y3?W3ZL].Z:/1:9T:W=]W\[<OUQ5FK Z_T>O"Z%D:Y.;U:&&52&-6T,'H6
MT$@85?,IC'Y(TQ"1IDW#S<-42G+MR-@X9'=:\_U6J?6"G!BHA^IL+DVT^2':
MELZ+V0)D=UI$^T:IM=.XZC9DW;=.Y]H*B'6.]^9AJG*\-;UN ;::7C<.TZNS
MUDT+_D<G=.7);:2]H)GT@M:U%_190",O:$U[0?,CC>OZ!I-MP+33OFJV;_2%
MC=N K;X5=_,PC:]RU@2[>>#J&W$W#]-62WN3M@3:KB;7S9-KYUN[J>\SRY$I
M4Z_H;E>ZV]5Z= -CJ'97WW2WJ[S1Y-OT995+^@;I9T*-O%F'VIN5&^V5L*;K
M$[< U#^^M#^U>]KDVA9\M8M@"T!M8WN+MG;";@6XVDNP!:#V&CU1YZ0I5E-L
M+BBV^:5U]O5">[;R9-<\Y=K2AOIN#/45;X76!#T+-3+4C]ZJH?X&[U4AK.D[
M ;< U.L.]F@O_J9O MH"<'>J0;Y5BOUZ>=GH_*GUQ_R(V_KAVPF-'F5.(?A!
M;<D38*_MSU>-WM?.\PH8\AX0U928#4HL5]!S?-;ZP^A=&^>Q#[FK?',B"-+]
MP1T?Y\7<B2Y$[*/E-N]#UG>X^CT!<[F*VB$L<^P%-DWO<P?6<<<_W-M6.%3R
M//&5P-YI:?H)ZP>>$X7SGP@<?ORY[[^?75WB?W%LV_IE;Q5VNJ<^&OI3XKOE
MQ;[/V?<B&X3</V7./9L$>^]3JQ[9;C&YWV6[DZ1<1+H]K=3'BA"7;R(Y"?-O
M81[@7*?EX_0Y,+D+:]LZ5<^E_U2(JJ\[OS<Z9\6+Z^O?VE>?$X<^O:'%6SE)
M[^2O* CMP43\9 ,K<E. VL+>:,13.X3YS<?/$^VV-[0#H^&Z$7.,#A][?FAX
MKG'N^2-A0IHP K/=P#"!+<$_C('GWS/?*CJ>]QUP#SM@(1_!O@+CW@Z'\$8X
MY,:(,Q>?>@.CRTTD?*-2;^"?^!1^BGPX#K"QAAGBK^63:K5@L,!@,)3%+?BW
M:TT_+;<6?-IZ,(?,O>6),6KS8]QSPP9J@G^%0Q8:060.']M#G\,K_;]@8B/T
M:,: #;@Q9'[?\P$*<'1"CF-QG_<G!P@I^ -@.(Y\..,<)YTD!Y0 A&\(-(]#
MFS^8?!SB^@QX,_1\% 3P(?PP(H9GC-@$UVAQ&-[")<(?R[=S8/P../&BT'#L
M$4 -'N*6;KG+?2"0<*+ "D/P6P^>%XQ[S[<" 2> Y;__=5RIE#[ M 7Z9_F#
M^NG>=IS9W_C#&" W^VN?.S:_X[,_,Q?DG#V&M<9/U*-;C\V/#3AE=YX_^WL0
M^O;\X +GL[^.'>;._>9[?RU8M.E%SMSW'$[S*+E@^7L(#(#/#8% -5DP_1W0
M&H\.FW<CGGB":'#Y+<D3B9: 2VS 8P])SKACODV$$ @2A/?@F>F-QLQ'P64
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MV!YS9/8&GJ0/]*8XFQ*N<-H!'(H?C+T0*0-6T0?.,+#%LND)\T/@%<'0'A<
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M7!!.]C+.":M$+@XO*&5@AEDDN?(,XR]([0U^I'7!K'0\DY](F.*A[',IG6$
MM"SAKS'*9%=(":,_,2)22HD-"W4!T.*Y"6M3\1TTF'! 9@[1')+VJ2\1B6P
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M[-!GMXKAKC,5P(*9$?KV#:'Y2]=,!,S-#25@/'60#3*"2>T>R/ Q!0-BYD_
MH) :'CY0.B6;E$]H@MB, 4+UH]M;.JXH-488G!AY#C<CAY.CI&_CDD%UA45[
M8@B,L*?X Q_U00AQH??W0;^C^*-P$E&8GJ!(:Z)S !1M6^AGPLG!.."VC+A1
MU%&$#>Y!3P2( *='.PO.SDS(E )U,NN$^=\Y>04KI<KA"[F'/;HU M_\98_Y
M]WX1!JR63JJE_[DM']S:@SV#.>$O>S>^A[Y1\4O:RU$I'XT?/LB)I \#'0&S
MB9LXM7@L?01'1Y7Q WH3=J=<+;6)%ZM;*,?;23E.(27 QZ=$-)DH/VD!Y9^W
MS>DORIS#O<:V')[JA&8CW<=(I, PD$V8W''DF;3=H=VW0^&FYP_XKO)2@T$\
MYB9ZQNDX%U0*DL$& \S"4*%\WT.S>OXC>!!RVST@1!1%*#-,&J3HAI7,BPL?
ML,M"4+8<.([A\)Y-E!A/JI2>4KV$'S@"K0!5LGA6R8R*J&SB!T)#>\'!S KN
MNRD&2=M''W#?LR:"F0DN!U"_XRXJS(@C%%TQD@7J1;052< ((G_ ,$]&J/+P
M4^0POR#3&A(_*3Y^8'SQ[A%C!16T@8EC)I^<?QI8)L6:YI=^?)_%P2#\7%(&
MSJD8?HI,#I2>@LN?;DML6<HA-"OD(NXI,D!+22>:P#I Q:1L&0??%1D3)%\M
MR<>G<HTL'%*,@ 130DZ9+A36Z@LQBW):TA_I ()<.<40Q-$14GB6^#$T(Z/M
M:FECC#1X40"C*&?95$XJ#4[NM0!;<, F4<N1PFBZ915JBK&W.T?Y@D3R5W(8
MSYVF\N%_4TKV,F]]YAWOE26.]V7Z0^7@K_&MU!\>%9#BO31)5&NEYVD5M</:
MTUI%MEDNI2H/[-N($B'&MBGEY%2V@C04MN>,F*)H';(N+\(#CDY:RHD4?$!X
M) *5+DD"5.6?,<&:B;W#8\=CEGHD/1A%X:>P$M-A.J;#'PI3?:#=342\4>47
M2Q!SPD  2XX9G!1*<,#>$$EVF+F"W!6_?Y]<K)H"![,#]1=9.S3:F-F^X.\B
M;^S6QQ@PKEB\BKP4'>N '5!&<$ 8/8C7.X*_8OU%*.]@;\RK%\2;A?R7ZD4@
M] NA])@,-,A)*)0/DU(] T]8]^G-,#=>(TYM#)'+HG6%<R )%21>52@=(]F&
M8HC G!T/X(6>(;4R(9E(@,PQ^Y4=1,M8Q&L3_F]\,J]*DR<FP2Z,2\^BE.YG
M[0ZXPXSW>X?[)=([VG;RT&-NG#3FJP>'"(NNT",6*>=2'0&D!)YI4Q8 :;H?
MELOX3(*_7-DY^&$)B\%_LTAW1)U.<B"9"T0YQ:9OCT'VR40?2JU=1Y7[D"^L
M9?G0=-!]CR+-4N4'F ,*QT;#>&,P_@+/8Y,'),#:H%VN[FEHST'[>HSQL<B5
MIB8&T>*(!BHO(LU-I/D:GBML8Z4XD4823%P.HCA J9U04@="HT&_C&1#J'MI
M7&Z3.\TY E A!]P""M%S$%%&-N),9'4"</]!_X2,KL6I*PDGF'#EQ/XO&1:E
M1V25Q''+E=303/EY>[1+93==*M_7?J]C7VX%LT>(I6<L=8'3!(%9)*S/%=B#
MXB8B=+WM[.+9\'YGW,#J,:DW__[212'MQ^BI=_D.LY]I]T:$ ;1_,+AFW\)!
M*N+Y(T:9.EXV);+#WD68C+O"FV<'0<2+\8D41Q49+IB4&.SB(FW8!^Z,WFYR
M&**-?"#7AX\Q[MWG8%B;6(4AC?_9[:0*]6!L+_#&PTD<#!&[FFZJ']D.FKBR
MM",<HKT/@YAH!F-%C^=_IV(C4QJYH0(7"91XZW<<3&.'!ZE88KRH@/(T0-9(
MA[ *VL,PZ#R3=9Q4MBAFD<HQKC;."D3G/WF@70X:M#'@&!A0!8PSN2$^)X^V
M-\;J-@< 0>F-TI-,>P'!^49R-&91*ETQODUU8AA^&<(7 %3A!";U0#D]E#:,
MJ?*Q"WLNZ</W8#1.OAKU(7 K61;O4VB6?%/.K>?;X7 43+/S!Y[C>/?*'P6*
M""6\(UI0AE%1"$:4\9\HX,@M0Y059V*<R@U@B,D6^DY\(L1)_$ %R4@3 *#O
MW)^EB _QP5+Q:.X.J8A!T<5WFT+3LBYR#EP)]QQM3"E74PD;A.3W%P7#R;G?
M0I0IE3$J^0N>7(7CUY"\CRI5V92SC\)T>EP]JN@+*.;I&,RZ8RZFDP2G0@*(
MPPGS10.L(/1EX3-P..'P-;T =?18^0=5,!3)<,P:P7FAPF>T=$4U;NR^&(CB
M3HS,6=1=(L384YR.AQ4ZZ&I&]\8(CG[?<VP<E[*U*"\#RQ!59L8T#DS+4HP$
M*Z=P):E0HA YT3B==<*<P)M)S9FZ3;'J!1D#Q:3]*!'!*V!ZS@CSP*3RZ_G
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M\OG%&4519=&43$:@'@ZV^U>D*LO=@<-&\G8PI/=I*2;%9/O,_([S4JHQ'I;
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M5E(4L]4DO0G"@_7EX23,7HAR*:,!K) PN=)=(UEJ%_/980]>, )Z_$X]L=M
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M7UV*$G5#. .!2DC%_ Q*!X!17</%_2DN<$N.6A4<)?:!;M<'&^Q>S&[U )H
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M0"ER1SP$D2@41W6K-F!X[!#;H%U1OD<(JJZ%GXP\OV];JC_?"+5%$7=(=05
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MH/S,;25BK-( SASZGINJ</UDW-F^N/]45- >&)_XQ$M37+R!N($0T(2L]U/
M4/&(5-X"9:[/E".(Z@'8P!0?FRI>4&O)5;KW6GD.CQ#WXKR'<OWPJ;R'@O%3
MZB6I^<>ISJ[!_XY$DUML\$<HZ$_HW*MW9^E$NB(%XXBF1_.QLRSXW+0C ^6Z
MBIXJB=80*(Z ]G^J5Z<K3G,P[)$VDV5Q7)G9WRPUB48-"WI1J*+ I7!_<;^(
M=*\(L>!ICXCH:;;V!H@=A&AC[-N.3.JK3CG#':6ABF!07#(B2DEF:L720BE!
ME 5#I('/B&D0&=A?)5E*(L_8DH%G3Q@V&H!A!Y'CB+(6ZNB!@D#<PEXP8NF
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ME!21"K@E.DT*39$P&E+BC,DMD8(;62@#[[DH!)J.E&1HS^]8JD,$K^SYF_8
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MOO@64(?\ZQ(;T/KD5EF!C(S]]E6W_?E++]^JY%+N 6P7/5!.$6\''R_A)EL
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M7:LTP&)C+R&RC0:V9O[.)XF[X*GWSB*A'C<(2@IV6,]W5:L^WPEAL?P.TDH
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M! ]/G]R\@P=_X1;2*CTS;I6O/X0>'P:1"OS7__ZQJ0O4O>"3P'5!KX0JUL-
MPWP,>]/9OC0<MU9W,E$>B+0HNO9OZ*/4%9HK>?;AM],\ U%5+W;H.;'GN8#[
MVZ PQZ+^#NM[F]T<I7;[ WX^>1KNM__?W_Y3\&E!,X": >4(%["=ETBRT,(F
MAT]P$N!?<R[H-\^XAO6MB0.@IN"\JJK/TRW?MIQ-'8RR]=(L%W%HIHX<?I5K
MZ([CVC4AM>35-#/;SHR-O]'OU=O"M3W#&O99+6P(T?^:A>X*>35D!)796=F"
MW(V_[T /4B'(T7=C5G_?V/^!WIPH4M6>0^=O^/(W+][B12:UP0-X%6;-#D7
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MA4^)!>KE+?.3!<4C3'%OW<.IC=#=XJ6 ___V?Q6;[0\OU$HH;2H4IZ-GX.[
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M,"Z6O$G]/GGCPL6*/C\B,[5W7S=MS)N\P$P@+<;?*%#"C;?.713AG4R9JFC
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M\,AP*PBU&"14%*F QE_+R\FF%+Q/[>/1M6%6!@YR75)E$.,3L<71^..7RON
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MKJ<O-S=<TT[F1E8LWYZ\S2Y)AZVS\VNM-Q9 R"'@?L7(,&TV9V:]?U>SXQA
M:NU5U. I<LZ-0C1DY/'J#(RI20W2:T8OB-<I3?! )LW=ZAZFPA:W'@RG->@[
M?(^;OH-_:GU>4H)WIUEAHI!T7/.W7PP9#TSNT!#BRD9"@XF4$6HW026+C *I
MO9?DD/-\YA?E&C17%9L'48B)HA?&DP(*)C.&&=%4BC:G"VR=PB*X,X83B1.3
M2GFT/D)T"S[6*IOPS$LQJEJ-SO^+6QP]05-_+\Y^C_KO+ )'<#;*1Q?5UPA7
M?U\/Z^#Z#-$P(JMYQNE@(0@\Z,&WU=06DQ%_*4J4 3:A(L8&7PI S6HVR&U!
ME.V4K= 6[A4M*L9\N)P8MV5!QILO)7R(,O"J*-'7O%_V=-EG85[LI$V-<9D+
MX4CF(T?,QMQ*:;>N\\-!E,\=>[[-F&,V[.6XW$G*@'HF.#$+3-Y#L!:(_I)Q
M8-RBP'[F3Q$L:#3:U53V5]>N+=QA=U_EV'#&3._N,+)I+/YS[?DS/6;1[=&H
M)W@#8[T6Q'U[?AW-"PII7>MI Z)OB5\_I(2/=TRP^=49AA<+,F8)BN_;FAL,
M4#T'-AF+SW,M'B J _P0[D$D".A>=$OC57C#C<1I+J"%&ZF.S&L<#GK2]M2:
M95O*)EPA01^'H=6<,K_1KH\D8R27L.MJ/)><I8HES^2"*HKYID,JB%5-_Y 4
MC"'_TRK]<B1GD9HPH;ZXAUL8W.+Q78-;_$4FZ V8[RO*$Z-'LU@,T)8#BBM&
M7#194^\86>S[/$<&**V25)8X+4MP$2L.I%@(&2-3I!)V+!1 DZ"WA_.XZYX/
M\C"=:J0_^NRWW_EY)QZR]DA.BW6(,-M@S]+YU*A@ \<.)^GNTB+PM..B"V37
M!+DA'B)G_@NZ"-[X2"RA"##]LBBXZ)_X&FVA2;.S#/)"D*:6 DDY;\$XA:&'
MUH4I!O<56R*85=8J12ZA:'N:"<:X0AKP]!U;80)O.4HRH-U-WI6/5.!R<(5+
M_!V+-W=&HT=@*Y.N5'!"O:E9A&!S/6&E0$%1SG;\=R1);A8?0]C2+[CZUQI,
M?-)_39^".Q"F?"6=X.%T[@BE/-MK]]=Z1SPCS>)@2^S0^+\5\2I&6A"RW$KZ
M8WIUDM7&Y'N/H5^[F6L21UD;$G9Z;C, RUHN4"H/,D!QZS5F.=Y*;W#61-CE
M@C^]CM,RWH9:Z6_,8KSACN%-3U\\_:Z<D09T[8U%K-TU7%$P0^QPPU%$9+<Z
M@(/;[+::?4K \&@X)J !=U>X#(8JWLEEBZKS$MXRAX7FNH0&!"<%% /\;U<*
MKJL-\0\"1U8G;0';M^>6J6&Y0Y D*O2IOF2#IM<DHGG=<-$BM+N[6#3%E8*&
MX<*"A1S)3+,VE/]"=@9D!P0;FTSVW/T,GXSL1@DZA@0P5\\T3-"&>&7[O:.V
MH:>E,J.WGX/BA3Q#RZ&0/H7XR[D(M++ZYZ[2?Z2O4_&;8WQ=0=/#/;C]T@;]
M_UBBP2PO5F9T73" ?)6>_!AJ" >U9?>J:TVPN#X71OC/;1SRV @3A"'N<._6
M]"@P1VK=18D[0AH2'76%E;8.R"MAJ3NM44103*CON=!LM-1I04TO$I:"MC$6
M#%89+#0P'C)#(&'565=KLM;E!I&3G/(/"BL+MJ!A/(W+!8=IKF+I41:J%2.T
MK$]-W%Q7W#-\2;]-B16"NR.5S"PFK0?%$RB?AB2I<HCT2[' ?+EKNG[K0[P)
MY@Y9))P?D8O@%8X;3C@FH5289Y_)10EQ]-9(](HB,-1T:^,L*-DK=K5(7VRV
M!>J 7<-,+%U!B-S]H3?$Z<9;<C.2PDH1_>!D";F, ):(6U.R@6(X<"UUR=4W
MK7B)P^=<7=1C[+?1MJ9M+Y3-YC#[!9O2.=86U88X\X4PIS@K,O;AFVZ^9V$;
MZ[-T3@G0<IZ]XWW_0$1!X*?ADR.2X/S=A[>M%93WZ@:G#GO"Z[RG#<"+&-,N
M# MK,WKZM11\SK/^#)[EUY:=H>"I4*.U,8V=$)\8:8]'W.'O4+=+,S;"@RQJ
MQO)H$@A[D@B<0A/J"N;Q# #R1(+@MM0==1&MB$J-"$/.<E,:?B$\/\2GQR+:
MF4@R[4TE":3A;3Z_P/#DD]ZMCBMTQHFQUK6NX\GU9QTS8S#8O1%"Q/D>9L[8
M3T>+91Z[]9(:[R4RN'=$QLCY8P6UOM^P<O-"8KP;CL6@S#]@:4I4-<*NR&,Y
MS.Y 9?P;= 68C)XR^A5,N.\>CW!+N?7&-5-6*UP8,U]3H[%)K-SEM9#H&[(M
MJ%8W&I]ELB,%>41SW[R,4%%!4*(+_O-6R\GCX^7)?]HR[<<KF+[Z.J&7M&B_
M@,=1@R,R-(,VA+3.5,0&=;'KL@765:8O@_]"/5B&* )1K8)KC1T-:H&01_/7
M6;.'R)#G'B5V!B$ IR,LL6G9-5]2\2!)\/AZ98Q-FR2&3FO6NUA@,&/6U$&S
MN:3KEC>:>BWDOW],+>23OSY^]/P)_74(,,J^.\&.]]).84)D93_%'FZXO=2T
M+EW%8:.[-PX?QS9N,GO5_2/!,/BI:W]'B9;>4;O&%A5X9N\K\*L&3 Q\<]_@
M='$84I@W_1[W#(N;78315 V9VVI$<'R,]_;&AQH%T<L/=T Z2" 9)3H5:;B0
MP'7Q(UH$PK\F3>G2W.!$7N^S[HXZL.D)Z'D:9-51R&N+JJ17D-1*+SPWHU[F
M?IPW^IIX='(&&]4O3:>2A(GVAE;YA/W-2>"]F7%46#4K.OA?QT)L.7CW[M'T
M]4_8JD""=HAP*"+>5A[%_OYF$QI2@LG:N&(X;HNRXTK(?EOEOE1V KZ7.MBJ
M?5]6W)\(]^3:I9?Q):<&9G5/7!]SMT]N=^[VVZ^B/HVY%I)&YYINN?TV//EX
MO>E9-DD3(U'&"Y#"W6C-;<0FE.GOK^GZ!:=0(P'B*^S;$J00QHS!>$''0(?$
M5&/,CM0?[JY:%F4BQ"S[UBM/%JXER[JX".H-R1?BL:5>]:+IKUVSZU,L>Q"R
M2R31H9(W9,>9USNB(" %2H-4JXN65E0<*P1[$54S*NLW&4]N2)\9$NFWD>ZS
MEF'%!M77]&"=-R5P63'2KTN.="K-M$V"G>8>UC&> '^>-)BL#5/$-MZUD6UM
M@D_E->FW3<LA,M!5H&GGTGNL"RMJS%0TW4T^I:_MN^YUY_X03'>HP!5PM;+I
M%NBBI2P\KKU9O5P>4*N!>!0.,R06GSR22!5IO:4&@2 MR*87MK2I0\@5'P1V
M,@3K3#7AP[%<:R*V1HOI2^T/Q>$!<7G 455,\+G9D.5#I$*4!3P@&.87O^3_
ME+6:E$HX3%'Z-+'Z>1,QPVBNU 04/:#('R:5DV2C"R/'E!=8B42=:&V']+:C
M@-#@-I41<J*1LVLWRYY$7HNPDAB-\OVK&/+$W/0F71TNLITX/W0X.&L[+[C?
MY3*0IXDM&6Z31OQB[%!3SG7-WX9R,]LU+3L>+ZO+LN&]O$T+,&X21%:PJ1B:
M$I=.\Q+$0@P2&%HJ5]686>)$/\O!)EE'ZICG8 ?&=]:&.;DXE.&AIG![A?<V
M!"'& J;WHX6S#38."X'[T+A;U"@OWF?E"TIG-_0A"]HXUYK9))/*-<NF("*6
M,@0.XJ"97P%J!WDM& N'=4%]T4$!$M9UT&&%C15J'5*X_JOX3EPO>@>ENP:+
M/ZW=*'\&\P9124(-L;L2BY>4%!&F-$&"K)7\MW47KY4=SF7"5! K35O?&TYX
MAR<.HZ<A]L$!;*"Y 9>'RF6*AK9[PS&D>;'5M==^.ENYV];+Y':)LO&;_'8P
MO5W+"FJR"Q;W+I)JOQ0-@OO?@%9M,%<\"]T5!B#6]=4!'2R. &-86/^=/)B:
MV)I>D\Y^? O(2&_KC=K!U #S*L2JT=C((V;(D_3Q/D;L+5',36'1:U!$3ML=
M#!*^3EOB !?E0KC-"7Y/O/Z"-S*<>J?DQI0O;R2C)%EIJKZ7[&UZNXB%5O2'
M(+)(8ETG'(FY4'T#_ /&??@:QVO5]"6(T^37A?-)M,(^UU?9LK@$=<=Y>_\H
M-BYDT.X&20WJOF]O'&8_PXD!-3#GA-#4JYE6.&%;DK#_LJ8!\1SA\.THM&4&
M6P)JC>S'5$D0FWQ())FQS21GB=U &L%$@B5L^E%?H;-U3H:1>8)P[FG9)33E
M48%[0G T28B*EHE-*RKXE_2')K;TT*,)2] #DX0TMN$&L@IP850] [6V$(ZH
M'^70E(MS!X06:O$6' $400O5M=;I>^]Q1YJN^/F]];R_P?V@KD'""P>JHN&
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MRU[*LO<3R0L-\7,B601"@OHOM*E23#IGS/=O\$:,=F*+8'PEE:?W!'@/_,8
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M]F_77?;QD[,O_C3_U>LN>_W?OOKB#[?SL%_>Z+*?8WQYC,,TTGKX7Y]\^<D
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MF3\>DT,Z@JF+S08E'TD"Q@.3JC6Q*GVV^*%.Y2+#$UPT^=X%:>:]H7#CR*1
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M@7CMNNN9D)1SAF"$CL9UMGJK -Y_A1"AI08YQG<FQ#8 J%FS*QV,CZP5=O+
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MV%LA;%1$[5GP"-?B)OS,8_(=+8_SE;Q'>E7F\)H:/KU;.[$0U:D*5P$K8FO
M9.Y>Q/-I0"_DOM0#(NR^0M H]A[-(?X%%+*W);6$C@\X>DGV-\19F[DRT[8P
MXU9Q-%Y_QC=28+_L.UR8#R9@2=81D#?L&*76@++3+(XVH[K[4GRG]Z87>OGW
M\U*C\6<3[$*J=F"?BV;O>D6)W#J*A("M&!@!6\-E.U[""C'W!WKXG$L=,D=?
MD5=.[$N6XV"'T4-[H\0. +T$?!7S,;@M=[FK5V\4S&@+U],BN.4HTI?M[+V(
M3ZHFD..A;-ACN$KX^'#DL>>1R4"E;]SVN$0S9(GCK[WE31/$FES?_]ULN,(_
MT6_&10<?4& L"*Y4= Q95Q60V">0K/71RL"6,<2[M$)($T;Z^&Z2,5$735YQ
M9F[R%8UJ%[>.Y%D[RW#&^X\W<<3@"U,K+E1K<&/T6MR=H\]'N-DP#2"$B>+7
M &B^H6 D_/=?C%MU)'-65$UCQ6QV[F0H=Q0YN:>31]&M[1X2+&*"F?5F\2IO
M$P^E<$]<&A7LCG-[9>O27- ,+R9SOZY@]>^>7"INY=A8.@;%,,"OMP7:5]JD
MX= :N]5("-"WM&;5R/^-R]%;Z%L]<.?J9T#T6-.),_&MI>"[KF%".8F#8+J$
MY;&H2BS"*H1)EC%K,4E(TLI9(5S]X+H+?WC0-+$_1U]^.**TOI.TME2<9*0U
M 14S^'I\@7UJ?]C51PB:Q?P$,L8\"3+JX<K!0%$+G/7$\?0POJAH6N+58S(H
M:?VU C+=AC^QV)6;PM5)!O(. J"_E#S(U?A2_+2\)(A681^W(%HHY:'MI<Z
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M*30YA1M?(4U)^;Y_2K<EP0DA&=XZ>(R)<+B*_;*L$D;% 7+)6LE4>-&)D,6
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MLVRJ:R:[":1:K_UQ-:B]GL4SM,>VDV[VH4"%A)=K$.V7.R3UP<#LNI/O,?=
M$MJO^ZBP/?&,68(><F AJ8A[J-#T.#K_6:5SM%,BCJ@A(;7"CNNRI(4\H;J
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MA#74^HLV<\7S:MDL_'5;(D/?JDA!V4C-O?0\0_Q8(DZ 1F6I<:*%V$,WY.%
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M8ATCV#!R%U@<.K;YV.\DX%!I&* [0B:)$K9/Q#PO;&#$N8I/UWX.R_AOZ5_
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M!M9&PIL9/(80$O I#BZ"PH??:%1ID, @PMM7N,\VAJ-8@OC,G$"/3F FOAK
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M#]/*?H?&DB?X:,8V>LZM_&L!_KX%>.OM6H#7 OQ\!;C;W6KM=-<"O!;@9RK
MF]WMUL[;M0"O!?B9"G#G;;>U]8Q,B+6<?J=RNM5N=592T7XC_*7G$,[Z>'!^
M=/!?3<57*PS:LGKQJO_X?WM;^Q]_.7G4F-6RX%>K)G/+:[NF+UQMG7:?^-/J
MH7JM1>[YB-QNI[6]O9:XM<0]GI+KM%M[NVN16XO<XXG<9K>UO1:YM<@]WJ?M
M[;:ZFZLF<;<(UHN1G^<C)IWV9JM]LV9ZDI#$#=B0SR,D46L7>^K"FN<7CCCY
M[Y/#IZBA>3%*:+DO7''M=/]ZF.=@-ZU%;N5$;F^OM77/_/]:XM82=R_G<+?U
M=F\M<FN1>\0<^UYK^YZYR[7(K47N7EJNT]JZ:T#BP45N+5DO0+)VMEK=)SP_
M_Q:6_5;[A_^\%?GK6\_K73!==UJ!___.CL^/SWX_/KHOTNW6YO)?? N@_/<'
M@[/KS\5S@L%Y#@#&;U<1P/CCP:_''XX=U&+$;O]\?GYR^I%0B>&"]_]S?D)H
MQ.]./AY\/#PY>!\<GGX\.KG0:V#3?GY_09><?CH^.\ ?&H#?E]S!.[?MX$7(
M/$^QL*>_@[HZ.?[C9> /*CS;(+Z*TWQ2!N-XD/3A4H%!F\*V)URF(NHSU- @
M*6/"T.S-@C))D1<BNR0$ILO8W,:(<O#'<2OX7.(%4= K\F@0($'%,$^3''&;
MSCX>!'VX*"FG!4("(A94C&Q""2)/C/,!0W4.XA04<#$+&X&>X&]%-,';X2&7
MEP)!"(]."$^J4 C <8R0<4DY1G0I!*N#O^&- X26BR>,@%L5])%?LKS_99!?
M,R@=+&@\Y<]KR8-AK,X#)XB$RU@9,%+\W'Z<IC(7229$%XQ?B->6"</=10;
MD)Y.WU?$,+'1<!CWISJQDR*'T4[G;X(?IG&2\: V&&*+IX/:<&$UHUF0(@0P
MJ'!F"LFB*7QC&DRBZ0BT.#X07^TN9:Y?C#-2CJII0#-AWBH2L(&+3"!?/#$O
M:T,@>/(P[U<XI;AXL&IY5?1CA7RT<TR+''_MIS ;L(EF ?PYA;?2;2-X/*U
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MPFX">&T:+RH'OE>H:BT+]Y0%5,A8M ]Z>VNWNX_&_A3#[FCOZ+IS.7F:HK2
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MCD'<SWF1?X9C-"ZX[/Q,=M(9_'J9D5/TE'7H$IWQ33]8FD$^\1?7D158J6Q
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M4> :Q@D:W)@.I0!CFLYN-&4U6GACM$"-XW(4Q],EBT)7R#NZJ8+'*6: ,_+
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MQ1_A[-IJI6D>?N=UM_#_/X%S),G,9^<;W<LU<L+S:M 1LZ&=CO/C__I\>G+
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MA9*^8_R 2G*??Z3,6@ZGZ23B8V"!G3 B(\S8"MNM]ER8J68LE!*0FHM3B3Y
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MW;D 'T'H_XG5/%]44$<530NQ+(_KN6<6"0;Q-7E.Z+@R0$VMH;::93M2(G-
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MK+;B!--DRUEDB8J=4,P/P6,-=@H/B;YE#3,3=8N?0XK \%"E'  'I?X 2V)
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MU)M;2'N;;FDQTC+K6NR[HJ5IN]SOOR(AG7#URDWW\G$M.@888??#<6I*.JY
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M%]OW7!P'?(SU(/-8RAEFG]DA'Q_\657LK#6CPGR C/^)T,YY%*/2ZZ?DD_)
MX3,A# OT,)"J;\>4S*,*^F=*VW4C5DZ&LC,6,+G'T+-^HK%$<7ZO ]L:H%4&
M5 MBJB5KP3_@>HI#0D9%F/AO!-X(1IE15_DG3O'C^%5#^S)[)=@-^I=)0V$)
M8&H> C#IY0.F%(TN[[[?7]\^ME'92^#) 9ZE@$:Y?@.'D]V<A8^5!:"E'X(
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M&7H1CB"(\,2\C7^%08K7P5^[0SL(Q X*R^P0HU#Q=5UJD2B@[$+VP^EH,,O
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M1PYQ5?B3RY(.%&!QXOO$?6:U,"I[28'9JQOYKAT,]GN%$:F,:L[L^+^8G48
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MWR4X2W ^=G#>BDA(?);X7 "?_[ =QR9#Y0\<N>-(>);P?.3PO!6)D.@LT;D
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M+!"PL/FP"VG,MRB^DL#F4"=LB[VS'YX&H$X*J!WL1BUT /*+W;4=A.-Q99(
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MA%.'LIG&6F$LO%P<^SFCX(M8WMC8-@ERWE3$>HDW)PEH=IJFD9S>^9[.BIN
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M\X^3T(_HM'>7C+[M]BZS8T^9KH;+.54"J"3E0984T?6I49])C2/8,$/HPH"
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M;YS, PP:(&PXFJ_LU:^S1^9N_D0>"P"=TE7;2-IJ&[*O]IM[Q5+DX'JBQ@T
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M($%,3.9VI4XF1E))K<^/*^(+ZA M6]2K,>E+*9R"MTDF!,BKI'(%ON?/18=
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M)=*TR+D7._6*>$3[Z'30V\,D=$T >TH 2R3G$@*H*$$[&$AH-IJ=88TH9(6
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MTVHV/SP$,L#BBI.R#HMO#NZTFB7)0^]Y-!P0NO1H=8KNO*M[LV+ AT_)0U4
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M>1V=]5:7BT^)*IB4JH(?CO]#K(#6=6=%OJ.U.M8\G!!A"98KK:GN3 13F-O
MN#[\^,4CA!9=!O+:@<GJ!IH^/.X%<3WS!_<G_,OVA1\/(YN]3S"M/T,[JN=L
M.\(WT[-F@B+)M>'Q9,W())R3Q^D7&ZP%\A5DU605,\\H%4O@TB^!2[\(%RQQ
M/77G<_<5.%!@A9V7'O$I06@=][@V/"W6:J\2]X.P&[[Z&_"%%]_;4'C:,+JJ
MH>Y2=UK1NH;>;[[@L-J5^M4*#M=[I;;CJ'RR?+);)FMT-:5WE!K9YU>(54K*
MTPJW<;N,T0+\IZ!*XF:5.N#5C?'SKB=.*9F)0PFCC*+GQ-R!F/=)TPE.OAW(
M]P"&8'V>OE09][M/IN%<0 ,V?PA_ZNK^50LS'=RMKT;'-:7_R^LO-5R7^OR[
M)R0D++D<<0772-:TVU#Y)1$^!K^LLM_ISG<60N)W4MJR@GJIH?WL>=O]PY?5
M2-R&^!MUWVJ?L VPOJ785P8\;9\C^,0(SKC-6:^Y-J:-SE!6157A]>(YI@^*
M:9J0M '0:>BB1@;@0.)7J3A^VR*3'TCMK)V!W!D.1$U:UWVX-?!M;S"K%@C6
M'.+BKE?=9A86^VI/26ZS85[6ATGH89@BW5Z\+:"M/6QM_)9/RQVNK^R4?FWL
M@I=2509'=FH&*E;%DI5BQBZOT,MAU:"G,=! %(I*7^- NT:@'<;\W[GZ)4?5
M1:#J0$:YCJ)JT.M=,*CV.R4[._M^<"#['NLGROO8]^=[6;^052H*#BGD2]0Z
MAS[K@,BUW7<"G^'8O@H>P&@@F&M&2W@=7\X/+>>'IIPL/,[1Q)Y1UW3A',(Y
MY(0<<A#OT-CU<(AS ^>&ENN+';Q:@]8R$Q6];N&B%G%#U4?YY7+^PMUA<X7Y
MQ K/)^9C\'QBGD]\O9D_JG3D<):A\'QBCN"6(+BA )2A@I,!F.[7["?%,<TQ
M70_3APD9:3R?F..W+3)YER!/KS,T1*/7>I/BLO.)<=</D6]@Z#R?F.<3UQ$_
M\K&=FC[/)^:P.H:G@0WB &B7G*3'@;86:(<Q_W?MS,91=1FH.HA1KDM29ZB(
MDG3)5Q^N*Y]8+91];<2^UR69YQ/7R2>.:LZM'AE?3[;,?@2X((FN'-?/T25E
MKUSDO?;M%)EGG-,XI^W-:<VX?KJ$ATR*.-@QRYGS'N>]UJR\&=X[A#>L2[L>
MAG$^XWQVF7QVH/A CR9-&#MF9I\!G]5*P-W6,^HR^MN8'A$\\M,FK]B@QH'5
MS>=O"!S!3H0U;6X#AA(1IA[Y,X1/X!%[*BQ=3#2TT6E.GX5%PFX%KN<+Y)?M
M!UWAP5WS_2N!(6VDB3VUX?63T(.MH'6%Z2LQ(;B;+U1]&41_M8,9</:4LJ\0
ML@+G<RQP3O<C:C0$% $)8<)T/1.'N\&AA;'IV[[@ E=@BQW;R_V\*Y3L<+9M
M$?FUI V*;/C3M&:8A(WD9LG78DQU67@U?>%_:K4=U')M!WNKHBIK:#].5Z55
M-5&EIZ)*KRE*CSJY?KW)J>I19X<'5MUBN&#[!P+PQAS^0(X&($9=K KQLJWH
M!G:W["7MM!&XPLS\"9^!#/+M"0@?X2?VGUSA^ITZ7[F;.E]]"8/0(UG*WC'.
M*&^)I4O&:O.K<Q-%M+/?UHY=!*:[H%LSI10JEQZT^2';ON+VF_FK'<QTB.O%
M?Z@BSE=[>"5=$X[;PJNO=)6^LDL++UWJ&CVM\29+2E>6FF^RI,(R5?4@DZW6
MQ:SYWDWGD^55L3E1E@DC0;5K1YAZ!S>G\2*K4>5?Q/2$.P>GNW*3K-EN.1?4
MO*2D_\LUWTTL]]%!3VF'N(>X=[9#VPA5NQ?[9<9I]LI"*UJ@#S#R\RN9_R3?
MX#6SVD>"LH09:2 #6I_F<;;ZJ;(<Z36AB932Q5]>/E3#?(3FP?.K6YM]Y)W8
MIUU<<B%J6#]H.8"K3T \!,/-/$)JLYS"-58KP ,LU^<:ZZ0,],4-O=K\HW*5
MU0KL /\,N,HZ-XZ#9VMSG,8U5BNP\SPC'C&G ?&XWCH9%XV0_CNS4H^R4MVD
MDW9QS)E>9]YP#^(4 =!KR'#;<^U<!.V6VR;K.U8=W6^_CB>9XF<:KC':CMJ9
M:_+Q<G?32O/S</=MQ;24<6]LC&5#UPQI;"AZKT\&FJY8$TV1]'_+/:VS)2-A
M<(24C8(TIMEC#X_/=X+>%6HFP02N]<?,G<..^'=_AG;P]N &Y+/M6W/7#[V2
M#!>YSU@4"$@FHR#Z#$?.Y[T\/3_>_I^_/W[]?/?CB:9E]S\*=__W]_OG?ZV]
M+[A[#L_CE"[DT]OMW/3]DDD/2B8]*$[ZKROH2!>-SY8L6]F8X!.!] :U#DWG
M*4GY.5&R85F&CQ\N8 $P",OQN747,+&W:/-\P9^9'J%).Y:[6+@X9: QS05<
M>F1*/(],V&<KV3M%GEM%0(:$T2PU3+U9NKZ-/_A $XE Q$<9-Y$:R?PJRM>1
MTI^88Y"U8;#^)V6)0Z?(M?IRHT@K],K\[\Q+)=X+N1F#%_/'#75D/ICS5_/-
M[_R61R# +TO"=:LO0#-:_?"O8^^W8=E\UK.&LH%QD,DJYL!%J1 E*7#'S><R
M].Y 'NR2SZ7*7<78+9]KT[!RKZMKS:>)25U-Z;5ILJ<:UFA_^MG:1XWSS%1[
MHKIDETH!EY:S]]WTA']B+C-/1BO+: R#F8LFR:1*H"%WP6AEV1="D'O?#SDQ
M(F(\AH$/+C].^$"B9#NAFA7B%[(Q&W)(S_%,H59O"K590=[.1R\SSET>KKS-
M>+M[9;)>9$#Z,L+.WXE'3=+:X6<&#AI] DONT7L*\,83->C2,:,PLY3&HXS.
M4.I*DMSZ<V&>@U -0RPXM@]\F$N4&KQUCRX4+-MG2*+4VFP#CHA51-RH6P'!
M#/[:8*#=\_JB*C=UD,7!T (P9!R>VHA0VHB(2VRKE3\+X>VUVK*"@]A_R6[7
M-0$5=2<3\(3%<"XRZVU'NRV_[7N;;EIGV*MON!U.)5_9!A<U;]G^EEEB&RO2
M*;V6M&?B&[MQ8]=:59MW5S_A[I9G<^E'3^9JYZ,7'V.NTO_XL*?,/!K,H\'7
M%PW>5FASMVBPTN?1X*L(]]2 S]XN!9;OTW9P*G@ \&2(.%PTV,#87T\T= Z&
M"P+#'M%@56HC(G@T^-P-PRNW_W:.!JLRCP:W8.]WM-N:C0;#ZW@TN%6:MY%H
ML*KR:/ Y;.QNT6!UU^XSC=E-E]B'XM$1OIF>-6,4E'4QZD)0>CTQ<Y55,)=+
MS_U)6U4(MF-YQ&3-#,Q$*B>7&.FFB\+2]%A-^<W]#-:9!G*^.G]CL2&UM\XP
M$);$8[,7A:GG+H2:O"'G6S$<(AR168:>A"-*-1N6B*\]_QH4WWO^_22YKG3^
M70$OU,+;G0GM7@++08R.\ .*PHGP@_ATQX5;9.4I-C>AS1'N'<OUEJ['[DUB
M0XVI/6<]/49+SYXS["M]AOT+Z',RVE3X/VGH(F*KAR6Q\-KO_$VLCX[>%G10
M2'P"N3!!24(<GV[ R/-,YX7@)GYZ2Q_Y;K[A1Z-7TYL\A#CMQVF$J9^F/4?)
M^\7U_@:_K5AR(@.M 6T/V)<,<: 6^VU0@M1>O'XNB\?(E$;92C6*B6GK[IS3
MCD#8C\)#&4^[$($Y9CH6$<(E;4!!/,OV*7^Y2QS*IW3\B7TKG!?\&'X=>+85
MQ)XYI:DOO. JD/L\P8P71U] OX"')JRA3D']*)*D":R$ K(T-BOZ283O<]-!
M8,MJX<.DAT[A"^QX-)_C?^G*G$EHT3UA<_"%A3DA*&$<X$>R6,[=-P(T8E/[
M$<)\>Z VWEGOWVGOX^XK#Z8_,?\4OMIL_?B4WQ6$;<(DNCV&\N1LQ O8#)^)
MQ8Y+E;AA46;'!'I;"K;8=H"&,#\7\ \T]?X@@>";V*#DQ2.,X._P=[C%BO3Q
M$1_[QAY[PL=&\6/T ?GC>S B0@]A2.7_Z\RV9KD7+\RW2%4'L&"J(^"_HN#C
M;H=+_*!6+R49M-*&!HL9]7=K+NW G#.FI2;'CXAY@'%9CYO[B('J<K"&:>>]
M]9H1K:Z4B\LX)\?9P<QSPY>9\ \R!<O<AE]]_7H+/&%1W)JL,@7N$C#T2]1S
M[#?@$M"4#G8+FHO4S(/_%]S HS?1OKIT-!CA7;2;H^=OPF/T8;Q_3(G'NV7[
M@N,& G8RLSW6Q(9N5+285!*L!T9^P%<;?KTTW_)K$TQ* )!?N-U (@:$M3AP
MJ  N0F&0A8*: P*8ERAA@%Z/T]OD78_.Z 4F^@)F"&TI_=US+4(F_A< *"Z#
M/1L!*-GX&R7=>;DS5+O%'?]+O-%F/#X(+G@![!%[ ]#4(C:5W,@,)A*5[FCT
MNQP@JM'Y=P=^#P/ <]XK"GY@\87MH+W%F#^[W[B%\,[D$:8S:%LCTYO;\#J8
MR#O[?8(U_+>9;OVJ-O+#\7_ 4(F-OB>ZEF1R5-"_LZ/AXI=&FUWZO(^F_<(.
M:.LD+%QH.WDDX8@IB$"LL"9MZ8(VDPMX0\!AJ!2B:P?N 1X"N-L6Z0H;#;0=
M+#&CBC%2-:"2D3Q*9^BX:VT&VC!L3( (-AVY&I*V5:ZI4RVJW_)J4?VZU:*H
M\ B03O[( <L1"0-"V (4;BH9I:G%VDF:6JR^=/OX[=O]\[>[A^<G8?3P6;A]
M?'B^?_C;W</M_=W3UJI19>5GV%M*WKVQ;M/A]H2.^ %5L6U5V*6O=F"_T 6=
MO]?WI6CWK-A&P*Q94?K3!*$4@GDP-^T%,]_GH$WFL1H!Z/F"S>2VZ\$_3>\-
MMAHL,"JOQZ$/<_"QU243LVD7TCDJ(Z9ZX,UT?)%VI?,BRS]TXG^)^,_5UZ)I
M )CR[0FU(^&+,743<(I4[RW<$#N8HJ(S?=>!+]^BCGGP6'[=U"@P+0L8 "R!
MN6V.[3FZ$&CYYQOMX:RI&@#7A_H_C991_ JCIPS]-L(9F?-1<&MZWAM\2(W&
M.L)9VWS$5ON,I?$)]DJU1U&=6/%+@V1[4.N"#8.U&B:;^QBF_6FW^EIM$SX9
M87_^TB?G%+*]D?.,"!;=<DZ0T4QTXZR9R>3(6A";5DD4&+RA#1Y9'#P967C.
M,/T*X/@>O6I2!E$,FJHE$2$KLD+GB*Y(!/X38.Z8PC.Q9@X0]>5-^ X&#G[+
MOA&%_P45C5++$2/?% 34F* \FY"?9 YN<.H3T_CY+RIY0':MM_C^G 9%&FQ)
MP1^!5&2+K^UK@D4%W%7N9_I_AM@V=NJ"TS;QPA=0*4XXA6]9MVCXBTE6I-F^
M*]QRK+3'"FG:7H45SLTQAHQ=CRT(_%LPW=-%L@VFRL4/ETO7"TI=;ZK30!E&
M $C<%=,QYV_TO(EZWC^IR-OJ&&39"3"-!R\A37VI%]70MO0Y!BW@@\%(1[IW
MP&T%X]WWJ0];M\FQAN%'7>^61!ZC)L8"8S$P'<!OQ1  N X,/Y,)+30))*JY
MO#4=L*F$&%'3X9Z^CTR>W7L'0Y9?7.]3:,\G;A@\3K^P/;9)[=7V,.E+D4I<
M]F2UM4-06N]DJ\$K[NJVU<1BG8)SC*\5X+VQZSU-WGX9YRI+TXO6!K*=:@?3
M^C.T64G435'0O 1( @6T13?]%0H5&#C2,I2P$1<*%EC*IHWGK%//9)]A1VA[
M08]@J0%!!XH456#^8D>R] T3FX7A*9]1>37&R+Z]&*,A/]DI+*KI&S#Y;/ZZ
MC]_^!9P&\%Z=%WJT41N >*->+\$?DXLQ",=O912$3Z/.V7EZ>+ /X*H*8&\2
MCS78IHX3C)!J:2#L$HC^QJ)" =;ACYT.>,,T9+UN@YD9K+XVB4&FP1 @B)!0
M1$A(@B]Y\<Q%' =] =V#1R/1:28=:$*H-(1%9M82K<"OMH28[2HRS,@#!VX=
MFRB5V"2UQ$_!I+DPWMQW >X6@%,@(%%H=W1 >Q0>W0W[_9VP_\T$4RA<T)P$
M/)!>$'CV%N2#'?B_(U22"%EM+E$[0Z7;V\(D(!L\@L"ECG1BJ0KTR!S9PUTP
M=%EL3BFDTF?OX+_NPK; TD]EV6WF;/W=_]Y]OGTO,,N$';G%1VSQP6 DH^8N
MFCX8Y$5B,Q,+DTCH,WCL]A]W++C4KL('=C&.L&PQH<>/]39XLVV4[-T/<$\=
M5&YTZ>EFUMX^[&!4LGV)CF6:%'RE:&?.RM&E!;@S+M-7,*(=GVY45=_W'(](
MGU>P.&?+3@2U[4VH*6%'E>!I"AHU?T/<Z$C?!S'=[)B- I\>RF/&%F69G%&1
M^!&Y$VYZ6/>&ZF "=@/\.Z"AP.B7 @;Q7B* );/,OIBJ0#]S9LLBA?0@2/!M
M()[I9;]TIV",QH=Z.::$U2W,/P@"&X2!Z[!XGN>^F7.0 $N6 P'O^Y9\'W\F
MTM637R::FF(<RJQRDI"_OGU5->_E<ZAYOQ^[GXB[-QR&@,6:G&='9^EK&3:.
M#2PC!YO* G8X'X?F?3Q3IFHO\T-1\$,<#GA\!JQFP01I(,'"G-H)J'.?^1X"
M/;5G8R<C)T\':.@!9]'CR8?/H_B</Q8^[,!XCJ]-.=;/'Y/"ZZ(C?).N[RWS
MI#!A82$DP1L0@*YB)6+[F3U2C!7"Y%Y>J/>$GZ8"@[(L2Q6@)P[1ZC)GO:,?
MCS=W#^8M?0O^X^_W7Y0L:?!SFM^S*(@9'*.F,3C88 PF<BQ*[ZIO&O30LM/6
MF@;=HM KL0TJ'J;J4LL/4P=U#U._(D^1QR7Z2 "SKYBB7-*ZIJ<7#S![>O'P
M].O=Z&G'4U(V7,E+-G>W::]]\P@B T,/B1DN&V4A_Y40R.;MTXPJ&_A,O 4F
MSC@!<D..HV QU@>0.BAMTMW%B'9O===N\!D0;G@$@:;%7K'J7/:%5%@$")PG
M=NCZ[/Z-7NQD2*P;N>[1R+6V.7)-:"I6'*VF]M4Z]9,)< .$+)J]_P10^FR3
M%U<4;@%X,$''-IGUE6;;>?AK=-V($Z5-HF0%B^P%<_UR2=41+%14&QCF /2E
MQP06S?%A4CF^0C#!S!S?=1S0.K'%2WXMV6T186DO"8*1)@AAY#N*ID?!$7HH
MD8KZKO ]DRU(O4Y\A9C$RL!$_@EZ +9SEJ1&P<ML+Y<]A.WO\%#[).@UUJ,7
MDY&*7B\]K*<)N;AHF"")SLQ3L&_)?V._+L"\5^G@[9'E C^[/PAL=G&! /-7
MUYOXQ"E!.*H@4)<EYW'I44 3NT#G9LYQ,TJW()EA/"^Y,P0Z4K*O[D6T#32.
M&YM.I@/R?YY@FOI@8Z2^1U/ISC\0_IS@*8UD1ZG3.2LN]FRS,3>8[2C=SF?B
M('_>IZ%L880]TVBF>9I*>C^*4TAI\!7$1!3TQ:1$UXOH;X)A1Z-LF5AM37O.
MV&3/L<'3V;/)9^:>3+VNI:>#(=#?<$@F9O-VS-JYJ_EE*?DCI K+N:=ZW ^^
M$V\$V%Z4):OJ*BRA)%75CGY+;U,A9RP$&)Y%QBE3( -UA2^AAQ$%$17(2HA/
MZ96%^,@O8H51 J<PM3UX0^%V4"SOJ>J* &H*/D;NP#D 5#6%F]Z:J.'!<:.!
MAZ!V]0W &8/08H'7:!\P-U7PHKM1=9&47^B!D 1NCU&"I,T 6@VY)2G0-7=2
MV73<6F&%7^,,L]I[J<->]KN#]9%@BM@D+L]$W^;L*!HT-]$&#.=!GG_PD,+$
M=-()-;*8.$_3XZCIB++[QIW>8%#2I!U_F22?SJDH8G'!5)B;,0W\)%,O=MB3
M*Z+L/6FP;W7;IDP.X+98\W!"^=N,WX4$B/*.'3!NIE."$<THM=S"SJ3LVE_&
M>J/OV^/LN0U!=.9R4;(\P=3H&D%*,3>BC4O;8#RP>4PPMX_NTP=Z3HI/8:<V
MWP33QLPZ'Z<\2OR00^><V7+UG,.>NCF1J3'O4 <_5S/J.(?,Z<.#.)J3%PAR
MOR_<F3X>Z0%]S8DK?)K_G'03/RR^14N$&3$G.&: -\&I0,+?)C][?'50D]-[
M14SW,JZGOA7Q5WS$2%;UF2Q@3R(5P9+VV>VQV)OQ"'4@83JUG9=U-[$;=%X&
M:YP75$]4U68AC./=V+]N9O8$$/\!?P^NWA045@1X%C/=QUEH'7N7!A?:P]\^
MMDFG(0C&&137?S?G[G_?,)?^WK$8*V04WMK8RN: 2I15$N&"IA+%+T_B*JO7
MTV7*)!)]$[OR#M__PP1'TWN+GM!BG9_)Q8TL:'7[-4T:G-GL7?<*I^$[QCA6
M'>P^./X^< ,-Q10\[%5/D]KLLJQ)FO#_F8OE1_KW0'AR:4#(Q6:?<_+&I)#P
M[O/=>R:)F+F +FB>;+TT1!6+GY3 X7SUL0MBR&_FQ/;11TA2/-K#C9&VC5C1
M];(AS4SD,LTOC%5-1LF4&L6J7*IHXDOL^ZF9=54!FE,S?8Q%O99<RD-QXF=<
MNG4\K!\B0M97F/)B6FN5@\$+P;-E&O$-Z5V/HB!U,,4N:ZC MQ@-SD1P$_?>
MS_GW&<D  E>19",^8916+B"PB/$\ 9<99?9M\H/+K3K]2%9=7^T,9;F\5EF6
M6MW",52=8S*8V:WK!\^8&E8\'^MKQ:.KOE8\'SO;2"9F,(/E%AT 1YABWBZ5
M-ID[26 - 'CCI%W;*SB=SIH+^ YM-$LM[;$YI]%-?T;P%?2F&:U$@=ZS_V$O
M_4(K5*7I*[35+>;!F4N??(C_^ A2?SDWWS[8#B4(_=''?/H%9GFL5,2B+V1?
M1PD@AM%5#143(J*2HM&+MW>%5]5N3U(;;S8/P^H]?:=A-[]2Z^\VZJ;)RFI7
MVG'8S=]IDG&0R0[6?YT=MODV\X=IL' 6?9YSC2D::O/<OE52%22,4IG[-96Y
M-1IQG,5:;W,:H]DV(Q?2W+QBC^]&6L='@T1J;V6<RZ&G4D=V-$G8DPUB7!I7
MO*-7)]P0AICX[\OV<R7;N<>;5379/*G-U>(3[SWGOE21H1>P^!_%8\HF5KX*
MMSH4.^L6 Q?>>ZIN0\.5R!B^Y7'ZNT^HN5JW]'R_UQEJ/5$QBJDR[>@3PQF$
M,TC-&N_-,HC>&?8&P"!MZM7&[:L][*LSLB1NHYQR=\6<FC<5CFC;@K_NL;SK
M:ERSM^&0Y 5&(*LM&/$BBR3V]&*]*M[!Z)P4Y-Y &'2&BMCO%Y-^C]44^Y*=
MR0?7N;$:40.70(V"?A %AR41QC3""AW5XMB\M>VQ-0U@V=I1QM!^IIJH2\5T
M]+/W4SFN]E1<N^-J('6&_8$X:%7/Y)+F7N5I%\99IK)8+E[Z21-7:"IW_;05
M6B@J*9,0J4;,F-N<P%*X+L_+M.3+M"@K]&IEF9;U=0V4]>50:))8RU.8@#A=
MB1&H;@Z3HG85XP Y3$I747<;=EM:T %RF)2N.M#X9 \TV<$9)US)O?/,S_D7
MUE:XHQ< KBGY"A. >:H53[7BJ5;-IEIQ>NY+3_GJ4M<RJO-"MI'GKK7JT2N(
MXZ]FQ%G5[)M+6/J/-;>2>5(<S_FI7@>G7R<TC-Y#[5BP3 ^TU5Z;8L&<+3A;
M;&2+P<'9 DO!B4K_ @_>.%=<*E<8!^<*M3-415TKUH4[>59H@T;Z&4#^;[3G
MT)PUL9LL; ?;2]'S.:R\@>TC> IA#<[1I8-S#O:7$?MJ32N+IPT>8?-KI?7L
MM/D]NOF]FK=-^.8?8?-KY=[LM/G8W5;4C)J6)+\P<9Z/'CNH1Q-#3L!E_S0]
MF^:(% -[C<ZFUQWT*DRH)%$)H_4W:E<NR4#!@L6L^-H[^?U*I@V/2O(,SZ/'
M\6)NVEW+X+T44>ZWR3/C,#IVW*L$1D6D##K#OG*!<2V.D\J1H$HX,3K#@5QL
M>\8C/3S2TRH*-1KIV:*(I_8O,KGY+_'<$HXQI,Z09NTK'[FCW[J-WQ+EV6OC
M9;[Q[=WX+1&>*KK04,"ZYA=]#["5S[3T\T&]SP,>E>9S/U78YHF++03J)']>
MYA%K(Y2Y'"&TI5#YKEZ_@87)55'I->7V-[%M+4]OX#S+>;;2K6SU4$RK=8:&
MV*];08;S+.=9SK-;>%8[%,_V.L.>:.C%WK#GQ[.5"RVHIRFTL!46M,["._F]
M4'(&*=B^L/1@%SUX8]+W,G S582BL)F/16I=RZ8/Q+U$"L475HH/^2LM7C;6
M43BGFA4>$5Y-OV:7UO(>K3&S/<U<+\#>136Y+NW%:F#J1+<8@D[;ZM::[XI&
M/\2$^YVAU"TJ]J1W+$9QZ\U9JS_GXK0&,*V2SD7XVQO: "_#0).0-BI&9J!M
MI*(V;&M:V\8=[:)>3[*(W?B6K,/;_&VU<6+-CDC%CEA)\9MO9@#S#-[6=$LR
MC(OIB\0*NM MH;)NB>T.L?[+@I$ &R*EI6#*JJ0)%'@ LPDVF L=UO[(M_W-
M78LK]4"2E;)+CYA?=-P>2(.N/)!WJ1\R4+H@9YHO'-'KRE*U*A?G4+BU>M&&
M2ZM>,**]Z/.5!MMQ^_DLR+?]RG$-)W(ZE:;6.46W08QJU5V#XO(NS6<M6>'E
M^)Y;@[P;S)GOYALMZO8Y) \PY/,KF?\DWV#\F5_3504VI!<Z^VIO;U^UE-^.
M<Y(UI?]W9KS>6ZO\-J4DE2SU\HYAF^(.-#&>7]W:3(&WG,L;N-9DBG)@'NEX
M]QP5H+X34U15AIPI8J:8>8349@N%LH6J[=_F@^N*>FS1Y[KB&&SQQ0V]VER!
MI^J:V-L_^94KBYI<,>#*XBA<8?^LKRLTFFLB]VIVO."Z8F^N,&AX/<!3&EIW
MFJN.0S/)",F\,Z?@=6]%$XW>WF855R"UDTGKBJ'KS!ZIM78N'E;$0VV)@ ?9
MABKJ#30<K;-S7*VNA0UNM6 OEB&>AMIX;$(VE*:LH%CWD".MXZEW1V.JWS.'
MTG>_+'B4';C5YK ^;6G34XK6Z?NZVK9EO-5F/5Q^Z,<N==3HVU91VO'\S\-0
MIM6RZ @=VFH+FP&H<[DGROVFXJ9GD0_:[ERIIW"YG-/66"![+-.?"=.Y^TH]
M9Q==9U#R;)<11)G$4);72;,?U[;/JD2/4Z4^];N#_F"7U">]US64_B$Z\<A&
MXPE51E?I[SH?/M?-<VTT3XUW+6JF:U&SM<HN))V,-\KAC7):3L]:C7(.)#0O
MA)J-)H^>76F$6[1A/6(1^R?H$[!=!9/E(H,E:\W#"8U;T7L:"S!A0X_:OFG#
MV8R[_:$*BY^BO@(?8Y_*H1L.AV2UW=A.^P(EGAKX7IZ[*%RXVPFZ*Y2I?-VX
MZAEIV\A9/6Q4ML*+"?^LB?Z8WJNW6L@94/<C$JU?7"^ZY'$?R=5[YULJ41^G
MN6 1B-/:X2*C,]0&HFJTZ3B8LQ)GI1VJ7QR6ES956>O+NY;7XWS$^:AM%2E.
MR4>[5BML67K2V3ET/_#O&W=Z$X)[9OH^ 5?.'0<F/$A=.?++FIG."XE\/7;O
MOL8I:A->3!UR7Y@<NNSF8)L/1BDT'Z>_^V2$N'R,4'GOW$68!('4T.&IC'=.
M^J+4P-EIZTJ0<^ZY3.[95@NN,?;9K+C5QA0W9QW..NTHR78DUM':R#I7D&9+
M#S&6IGV* XPM+C<?H^$Q&G+A^ $&5Y97JBQKI:_&]U%J.V"TEJDBM:FU#^<+
MSA=[^%\-,8;>&6IB;_\:,9PQ.&.TP[MJB#'ZG:$JRJUBC/J]C<_3J.9CG+:_
M\@D$P/_2?Y#)C0F3,E^( )ZQ:3OI&1 MV8S)D;1 <^%^XZFRV<[A9NO&$M1J
MH09U7G[&&S-B^_(CWA;Z)1;AEG.2%:9H?9B$'NY2*DOQ[IC:38HS1C,9\DUL
M:A.5(VRBT1GV^0X>: =[TN%W4)$ZP\'&';R"X&Q!T<1W\06@=I6^LKNK_^NJ
M5 0F]IAXFV\K;['=5T#_.=JI'[!1WXF'=S<2P_U&26$N \R[+2EZ>H(=^0L'
M\:%!K!P>Q J">.]RUAS$',1K0-R3#@]BE8-XQ;C*UYPHV&*;6FM%0VM8(6'I
M^C8^\($6=;!_DJ@P0H2$S*^BJZ=2^A-S[+OS,%C_D[+Z#HU2;WMU"[D'<_IR
MD[GXS.B5^5^<,.+,5DQ+&??&QE@V=,V0QH:B]_IDH.F*-=$42?^WK*N=^%>S
M)'JV!!S?C#UB_G%#"TQ^,.>OYIO?^2U?^L)V;K*$7T>S")PW:.YF*X(,_SKV
M?AN6K6)-;Z'!$8J)%&Z>TF(B#X_/=X+1%>IUK$)1,'<QD^%QBHWDB.-3Z/Y@
MU4:P.Y?_-#,]\@G$R"2.QA:Z5_45C0DH@#Z(F2#Z#-^7[VGU]/QX^W]N/HV>
M[CX+MX_?OM\]/(V>[Q\?UOHU<1.N+%^E+\47E+Q6Z9QG09CGM)V?,#-](< *
MZ<)R#D/"WV8@+#WWISUAZ=;DS] .WF[&N#% A'3ONL+OL!*/IJDHDJ0)=_1)
MX=Y!>0#21O@.(PKO\'O,,%*DC_0Q_)3^6_[X/B[?"@/(ZN9?PO?97XK"6DWF
M(Y#\8KO[W%'9_<.759 "21:N\Q0 X&[-I1V8<PI)_P<!.K.K!U_" #!\[_NA
M"7--M)F4 K17VE .EUE[OEKS\ZURNI%9C(ZG&YHT$/M2L3RCP.:=[VLG8I92
M6;M(BTX6D ZS%>!W^"LZ2PHR_,6+9[(D)_:,N\2W^)1T6($0V!7K$D4#O)K>
MQ,<B162QG+MOA+ ')[8',W$]?V4:F_NYK3;C.T>>?G2$;Z9GS=C*Y($8-1TL
MVXM/+E /Z?$Y(9>Y1)XGC!E'GN>^SH@Y$;[#%B],BX346(*]!A;MTI$W,RM\
MGV?6UYEMS00S#&:N!ZO:@1MZ6[@A51]9!0-+P51)5">?W@H:9H0P>J"&[^.4
M,<\HF6)M;NF#'8N-5$J;J43<(KSSP_%_@.B(70N,4--V!'."8*(J#R3B3].>
MTSI9R!B4*?P"5X@Q'\"V$>S42DMW(1P8/\;<@CP1.JOL(PI@MM/%P1Y&O"2R
M=*V(L=+:8-$'L!O49,9YV0YVC?78 Z^V3P2F')"]V2(KR("N@%IH8?ZR%^%"
M8,X'728;(8.4,*-E(EP)K_9\+HR)\,Y^#\N=A!8V;@0N!TZ/!LB0.5K"P@2-
MEATLTB@"->R$?YB@]KTW08XY!VGPSH87V([E$;K"M:]PP\ /X =X$A6]KO1-
ME#0K;Z(J5UP["Q"5%N[3G$Q$[- ++ M_P.Y-B8T[FML(Q\4^OWZ8D,T/K613
MW[$=A=?1F9@(E'!.1>Z8X,P#O%CEL3&Q[^^,S&DAN*7Y1A="?H$7AZ]9 II(
M\I0[I^L.S%\$$U@1*PYA7$V[!U.2I?-XCS_T21#,69HKXJXKC#8):";& EH\
MLP"5G"*Q(U5'J];5E#'YJ&,K1<R@,]0Q04WL*VM%3"QLHU3BVF20=?U0='AD
MTNL+ R]8)OZ]\QWTG5N?$D9G"$)%-)1BX_$8&-24?<4&SBFWE'"EN)MUUF\_
MD51L>"<:?4-4]9)>T1&99B;H\#$A#E,VY1+W$DRD>]2T$QK>$%G/"(:.VEL_
M.+5A#I)J"":YJ*GKT9\3BUECNO9RC9,O%QQM?:"* Z48)2Q=;L%?P#7ZL68T
M44NAS4!O5406%J@Y!V"6NA,Q,Z!J1U]XC4VSUCV._&G&2S]"L)MZNMI[9[U_
MI[V/!WLP_8GYI_#5]FE:/#[E=P5AG][@3]8,[*$YB91-40"AH[:V/7@?\TDO
MO3VX"=;(8H%6%FQ#9!ME#+A=*MQ&R^\<N\2M+$E=B849Z]:X5?2NIC1?-566
MNP-MMZ[AFU^IJ0?H1<XGRR<+WZE=25./4NI7Z9]G_=X5]TR(/;,#E?2\D#*=
M2;S[R)5DSY]ND6_&Z5:[R"ZG6WVZW:?N '7!*UU-Y?3;T%[NHBXCE"_Z;Y&#
M2&/EA?CO7I6%F\$6'YV/?I&C5[0SLRE@_;;(DG5%$VA\KD*7O0O*.-PU3V/?
MR/IC*JP?HJ3'+>5R,J'(7<OE'.[*<XT\UBL S[:DF0.#IT(P&WL@BSU%$962
MI!J.H=-CJ"^U'D.8F*6* W7  =1& !TLD: Q /77'R!R!)T<08?+1&D,0(/.
M$#28KHI:_P1:K,F":BUW#7Z4GF7OU(^[:DF;<V<?N:\<BG]8CON] WL2TH3-
M1TPD>9Z93L19#Y@HZ<-NU7<MC#96XFSZNC[')^+S8"[N?OC<+O<UFE(V&.B7
M60V,PS0'TX,YTP>'J8PPU?NRJ,I[WRSE,&TY3 ]V->3@,-V0V,A!>ED@/5A2
M_<%!JF+Q3T4#>:JU2>7O< K4GMK95<_1U_!1KF$T+$J8N"'FG=;H&'V9;+;V
M\(BV%=LW;#)RMG-;)K12P_G3=F[#T  4&E84>\ZHBA[A^*][_G5Z_%?0-+U-
M]\TY&W VV/L([RS80$?GM2_U1+FG<C;@;-#\0>19L$$?V4 U9%'I<6W V:#Y
MT]2SX )ZY;^'RD ^(RZH4,9N36DS9=W-R@/=(Z4C?L!;R[95H?X9O>8LL'U=
MO2S0_&U=^K88:)MO[FK&E=W<Q0O4V:(X@AD1**DHA76M!=8L>DUAD4IW?1&2
MYW2S5^MU565P+E<ZI:YJ]/ADSVNRU>Z--W<?]*QN0['J%Q7N_UPJ 9+J^;2L
M:50-F/Y]%U60HO_XCE6DV%_$$RC5.-%*B):T<:#_NH61T/P+S3G]]S-M>?.O
MJOUN+I5\HY<7C[Q@<P8DRCW0R'9\VZ+_^J<Y#\F>UQ.G4VEJM?-ZXIHK1=DK
MB4'QZKZR6PHAH\,U>Y,'RRUL*C>W)V%N;E^1176P?RO3.AM^\(R#/!=6[^6X
M-VK;QMTUNCS66OMY<FKH3\"$H%RUF5T+'; :9-:5[@>QJ4.MG#(NE;%>0[=?
M-\)_UAQ:9XQ#73D^V0P;ZIO5LDR6<E:-BB/L9&-<7F^5-<<S!S8DZ!XDQ4/_
MYKE^Q?ZV&2&E=(:J(LH]N1WM66IQ*>_S4U-7RONI2K\6'NNJ2Q6OO':EO=5E
MBX%X[F,TY%6?A8*[I379YZQ8>E26?1^/^OPDS+N6J;L[W 3ZFYT+9O>TSK G
MB7VI>*^^$%O;!=2GMKHO$H<MU'0E4*RK[GJ=H0[>8<WK^6>%QG,?XYK\N1BO
M5^;1-:[C,%_AGI:A_QQZ0 LF'-B)83;9(Z%W;16F=X:::HAJKWA7I[H.:[&1
M?)$X:Z4.8PC<68/U08-UC;T/(%H,Q7,?@Y^"KA0PYZ>@EU.AJ+=[A:+S/F/A
MIZ#\%'0SN[;I%!3[N"E=O68AP_/FT(9T;5N1637W'1$UW@ZZ<6W0)0ESF5PY
M3)-3<CH$%FE]F(0>9HDG>-0E<)^Z:N&RPD[%W/>3TY<OC2]#YFZ6M=(!96V2
MY4@3'.L:2#HFH.ABW^B)@[[1HCAC0W&U-K-*I!;IC9+FW)*(#OPBX*F<ELRV
M[N:TZ HZ+;(FBSUC[]!_@W X<<3E9(AOF]RHKF*;I,QYRH#3N4,9,5#3'=)5
M;&O=U?8N!W<YO-^0!=!6W![)65H/R77.DES!6=+065(:<9;VU "7+\DO0R+O
MXBPU _N\LR37MLQZS%L:P/^O78[DD(=:35=::%,A #.^U"?8\>X)/W'[L-][
M5!6 WO0W%T#=0!B_":\SVYK1SV"I?Y! 6**JC>L%T&[L\S<\#6*E \@OBY")
M3[\DD7+._X05%^@*.)\ ZS.NSB7_H)\,,Q$F](@_*47@;ZY%P&[EB;2?(&WD
M^6KZPO_482:YW\]RTTWO0(9->B9,"U;N$H;04\;":E=*M^CM" "J.?PAUB7"
MX R)T ?ITN_J:XE 45&3#L89T@&KW>C=8C0J!0-P_9)@I0\R?^L*5>IWM+O@
M"<WZN:$*#'8PW0A,*H:_"2QX;F+WC\ 5LN5._%S3T6S)D]/+F=%\[EHXZ7*,
MW;&5U0:'T1D.NL6$DD,)BL.LHH\=%*1N\<#K@*Q^H)7(5')OVI!+8]:1C]I^
M+6,A!X)9<A.8O\IY&=G4G,]SK!M&U;E7N-MVLI8-O+4>) ;29DC<+99S]XV0
M)^+]!&NG'!A)Y7!6Z(H*^.SWMZX?/+C!OPB\UG)?'*#D))O%6!M1&/[<(/V%
M5_BO,$:9&+\NIA-.RW3>: WE_D>T#_UP'M#M<I<D2L867#"E!5-XC5Q@P60^
ML+"D"@P?WNR6H^ [$AV93OWB>M%'^%P%G[RO=H92RI.Q#\ 40_?\.9#6!S-M
M+[6]B0D&?[X0&%)9L$$/PM075'FZ#"43]"7@-R]X%4T(_=@\_S0'%^WFR9JY
M<YAJ- RZ ?C PIV0.7, 2I_#F3 VIT]2?3HA(/( >!/*\J&/'DP\G?BE^64$
MGHE*.V)_,7)D)J[@N($P Z *""'\K1=U!*.(1F4!D!.FX7S^AH,X_A0P#=X@
MF_&$!,1;V Z;8.2J;",@D,Z<3@EM.@8^51E_L><C3ZF$N&!?^,!GP*[P7]/W
MPT4DU]"A\U@^GN#00Q+\S0RV&.:/0G-.?M%5Y;&*>$9FM!U&ZQQZ(X1H6%EM
MZ?J45SY0NPDT3UI0[2_YFGA15%1*?V*.?7<>!NM_4BB!<WPND+&DUY<;15NA
M3^9_9UY:PN>%W(P]8OYQ8TYANA_,^:OYYG=^RS,_<'Z6A.M6'X4K;C"6EI4!
M0UIEIVP^*YL6"RE%NU&8QH)O0"H&\:=JS:J%)Q)"?CC^#S-K@(L\&[G-[PJ?
MB&4BIY>Q"XG4Q(J2IWQM@<X 10=3@359P%JP0'MJ6\!%P!(3&SC1PT#'U',7
M,+CKE\H+9)EQ- ,8$7RXQ(;(3-=VEF&0XT=XC8 R$I:!$H3Q_:J4B 6I& 5*
M;":)J+SS8R'E$(OX/M #AEEZ[D][ N8+NB\VJYP(OX#_+(CIAQXI%T5VL(Y4
MJ];CWF4VLQYMUF;Y9RS-1RF1UI3<Q/Y8%UMRD^X?"XQEX1+ZJ<T%YIL5SA/-
M0N7^#=4"Z:[ZT4;[J]!G'F^D.K;KWP^5O(>3E.HT!EU%UG:IU-D;=&5-:;Y$
MH]*5!KO6C-STG2;M5J7RLB:K':7XI=P[ST)\6(E0N,L'H#"MJ4[]O3IGP57/
ML-M-M8TY7W56>RB2;3P_/::%7)F>28'#1E_?ZRH5)E#BA2"Y;Y3NH*A14!/B
M )WAN][[%2NZC5!H)??()ZWO23?K)'FD2^:EPP3 7 ,7X,TF\\F!D#_H59C4
M.NBK7;G$FLI@7]Z&?7XCCSDX3I1:NN$ZL-K88=\7L.3I45[&'8I1]SD"W0\P
M^;?VND.//_:;>LUU.C_':S\<R)N K*IGA&2=(YDC>2V2M3-"<O^\D'SL2T*G
MLO!^V/X?-U./T!0X@D<_@H=5[L_1PE-J>#<'V+\2%Y4"[2QD2<Z\TPXJ2A!R
M7P!Q]Q'@4)1\LQU[$2Y*)<>@,U2[>LFI/94G\D?AS)9J_EJ[5 ,3WDO2?__2
M'+ /=/_AF$[[]G,'R@$/OXT.<56 2Y.ZEDF3-R$;$"@#B::P%.N7[2I06K#:
M]3)E@%ETW6)][3*1<G5AK9\N&AAS.W@[2X-'W<?@V7_OSEI$G2">]<\$;<Q[
M*F%6I3,<Z"4IK\WM\X&*Q5R0_C\.P2Z:N4X1F<ASUR;]KU(F*[D1U(C^/\EJ
M-^A_K3,TI!*1TH@!<*91C\0 "&AW0]MA^<OOS](*T X;]FAKE/30-]LW<5_%
M"^P#K++>57K'N,%^AGY\M>UNMQM_7MRAEH>[3L4>>@7V:+3IBU&BF[)9LC=R
M6?[,"7<SZ=H;WR1B-TM6DF#Q?I'@5VQP?$FE((]9T'R?[E/TR\^P:0G7E)2
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M,(9!_T#W6*#^\4GO&)X@]I3KGI<O?19WJE#6HHC?#=G8*79PL&84=]1,NW?
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M.?V#I#%<(+!EL<> H0A\# R8^7!IOD6?P(_A4R\$TI)?@&.?^/&VW+H+6"N
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MR(>NQ&1$W8XYO4%7UIKOF",K76FP:ZN9S6UH=#[9 6^:LZEW!.^4T^9..1=
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MI)84G>2)OZVPK:N JR0M(X.KYDIH<9/ZT%!*HI8>*%TGW#$;]RKLFKI2.OZ
M99[4ELYZ9]@S1$UKR35T;BRW0CKO":H^V,T#<2 WU7>S[9+YC$WGK\3T23;/
MB1O0S40V?N!;'J>_^R0*)GJ4U)G<O=IL->@,E9ZH#EI2H(U;TJ</;!P 90:@
M3!QH+;DCRJWJ];"Z]NI/AXY^Q)^5E+X=.9-/K%&TOZDX2#W6ZV%!*$E4C)94
M0^?&>"N,\5,@$3L?R:+6W_NXDEOPA\;>R+*\D$SVUP/785X=3 _4YC$%O&11
MXM;\1</M8,*^-MRPTI%HZ'L'^KA=?VB W:?U\5F&+S?K&Q/G?W/=R:L]GP,G
MI61F7]7F* W,=;&GM*32'[?66R' FP18CXKL?OL!=O5&.&U9R*WNYC+5D9ZU
M^45'?M'5EG3LY19U*P3R;E#"TCFBK+??.3NXM:STVBUZG]W G NP'-\OJ^-0
M5TGN45VG;92I?N^CWMHO1Y;4]AX09;5ER: S5"5-U/I-Y4,<K$)0DSX$9S3.
M:+M[43LQ&AY=ZXHXZ.]?\^YTC+9)H<?/1!NALJ(R#9N8%<9HIDI$ZV=XK44&
M*C0TV#LJ=/8R_'PD];N#VD1EI;CKR6U=PJKTFJ@K1<_]?7N"7(U;0)Q'VK.T
M>CQ2UYQI@$=DX!%-$56CF)C7(AXY!^/E#,>X5D,D5^TH6XR3ESRZKO.5+W@5
ML&Y$KVH\O&V+O>!Z+8<R13,)[]\]K(T5O'V?FTXP<B9W?X8VO>5?6^4JG:$A
M#OK%.A+5%6[[3I(XMUPJMU0W2@_"+2IFPTB#5G/+U:>6T?M"-^[T)O2O,[GL
M" H(;V !44:>A\W+D)=J1[)U#56/H5]6/.2RD75X6;T56!L+9NC-%<S@^62'
M!M-38 :T>1V_D+W_A>P,"U&ZTNXL=3A'/Y]2,SRSK'D+>@<\55#Q?;"7#5$U
MBDDAUV0PGVUV61R-?.,)9M>5]W(0#R)I6+='Y09]0"5*6>F&VEX#SS#CG';R
M11\D_-4(IV&BF21J>X6&6YIBMJ][U0XN*C].?%C3ZN]=YFBQMO%UL&:MYRN#
MFJ1,JR74[J; _<.7K5DC&0D%R*WAL/:EIAW6$W6L/>;!%^=CSL?U#8W#\K%\
M^7R\WA8I-HI>VU_W;'H7CX2?Q=QJP?8%CUA(?#!+7/A[$L*G998*?(L]C,T%
M[&T ?YH!_GCA>EC#\P\R?\//',%Q WQT3& LDW4R&6-=* %?Z]#!?!\/$+ I
M,NLN_)/0'B<.>:%-B07RTP9B6404;,>:A[A' @%: G()[:4\#8/0HS%JVM36
M9IVO'8)M%DSOC2V$OCQ^=(+K"EA="[H ORN,<MV:ES;\' =WQ_]AG=R+$X(_
M* EA-:\F:_ALA8N0]5)FW=!@+B&EG N I$\$,X^0FS=B>L(2=LZ=",1!:B>]
M1AD[J9(H8*/,KO 46K/,+)*7S^V%';69CN(_N%  I@\/>(*+ETT%/RS^T,<!
M8;[XZZ7GTN_A5R@,8OH Q[X&LZ[PZ-#Q8<?LJ&LU_)=D@!.LFS?=0NQ,*0IF
M*=)@M/_9(W[1.UBFJYX*/85F@W>+9Y\",.2<K@=666\9RO&7H=*$W6XQ&!,O
M0\3N0DN&D_F;*,P '6-"G$06=%=:CI^CP!-&%,)K\"IF.[(# 2:":47,#,PY
M)<!2YIQNMT\/Q)QBY\-WJ" 5Z>/#XU?ZE_SQ/>N&*,1-!6J#7M&VH'[?QF 9
ME& -&57K%DM\[ YV0-W1IM_K##5#[A:[ ):#'&3;E&YY:_=#W[H?J/HB8 +F
M\ITWQ8861D^<UJ_JB>F79_?NU]+VJ)RJO5"LT:YUBX=/R3I1N;X0!^> Y@.9
MHI'Q#Q/,+^ M&?E7'E!P@G**%%YLGB@24[59VL1Z-^;7I4=NL&_/"'Z&C$S\
MF'V[PO,,#9>%:3O(YD<AZ8,;-$%5#,%+TB;X).MW_6 - 8!N#MIN2#X;Y6!$
M093F4Z!)@';>. Q**#^0_K)JD5&+A:YF5^X[GC@QMHD3Y#ZF"@J\U]"JCH*3
M =YXZQ:+JR;+K(  QB99-OJ]^]2MIC3SA,-R50+!Q1"T+7^:P*BA+TRHI0^6
MLQN^S("G-;E[_O;(]]#S0W0U(H:YQU;H#M#K!^M, \;(A)K)LC'01338 174
M57B'CT?,BP\EW/H4F_+J0*%D5P=@V)@.2,JY@'F6,!HL%!8.W@)UY_L??8I?
M?'A=A\FHH=G*5BW,-\0%Y6F8DTWYV:,>I)EU@ZP9IH@!7@3W%42X/[.7.(T7
M\,@"ZA+!A'H@*UYM<"[ QB@Z2 Q>D:/I,KD1K2F5*/C>"8$1%T#HC(^)#Z/[
M0>)?LL4+]F(!BS*I %O"6[QX&])9LIFC S;VR9\A]5%7OF1DF(8>=;;,Z90*
MP!G)3<R)O2I<$SB:]].8:LSH] @S,A/G6GAUP_F$^<P+<!R!ZSQW09\M>N+
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M!!L,:!'GHE-W$C:XH!RKM1?&^46#2\N ;=ARBZ!3RJU&3=N-9VESC![$KMH
M4DVJ:5EQD'*0'L3JV012N:;=<[06WZO%@LZQT,ZFFD)*9_@]4[BS)'L(*Y2Q
MJCPV5C'+-4)M]GQN!*^()_"4O/_N%ZN4^.7_E7=V*PC"4 !^%1]@19&"5UT4
M$E04876O-@C21OX4O7WG;-.Y'&10%'4S0=C8&3N;./9]*4O&B@C49"X)?6>[
M/]SUN0=#8).>,R ]@X.+/!OCHZ.A#P6)0E+BNHXQ2,Y >O'!Q(?BQ/N>>'/.
M'&=Y)L\U5@G#3&31P;J@@X_*K@F2I($_]1;J%+F3G(<T"HJ,2H6>8/Y)GN(^
M.%.A[D168J<<W&YSU3*0K-HJ-;]3-U-3:CK/TN30GDA/!:Q?'B?U&S!LZ QI
MD-5LITF3\S<CWUMMO,7:\K90/O#&_-1FP<<#!3'+*&>2>&1 1&HV&*0\9_AY
M4(%OQ^R(6TD-A\N1MU/H,;PGJ%I(:7C5VXQ$)45K#52CDO,I&[#F0F12:Q^J
M3/P9*1&=JB:D;APCDE21-3G87= [*XI[J8[B20?3(,LKDG_6+O?T4\J_(E?W
M]='0RI#MKO#8YTD\O %02P,$%     @ '8%]5RYUVA5S%@  -_H  !$   !A
M<G=R+3(P,C,P.3,P+GAS9.U=6W?;MK)^[Z_@T<MIUZKB>Q-G-=E+OJ7.MBTM
M6T[W6Q=$0A*.*4 %0-OJKS\#D)1(\0*2DAITTWUH9!(S ^ ; (.9 ?CKOUYG
MOO.,N2",?NH<O-OO.)BZS"-T\JGS.+SJ?NC\Z_,//_SZ/]WN?\[N;YP+Y@8S
M3*5SSC&2V'->B)PZ<HJ=WQE_(L_(&?A(CAF?=;N?-=DYFR\XF4RE<[A_>!07
MB]_RC][!\='IR>BP.W+?GW:/O?%)]\,O)Z?=#_#_XWUT\LNAAW^>?$2C(^\(
MO_^EZ[X_WH=B:+^+7/R^>W"$CT_>NQ^.#]"Q9OHJ/@IWBF?(@:91\?%5?.I,
MI9Q_W-M[>7EY]W+TCO')WN'^_L'>?VYO'G313E36)_0I5?IUQ/VX_-&>>CU"
M L?%$7_AJ>*(<_8RQ<CC6&#$W>D[E\WV5+OW3X_V8S+%E)2((51(1-VE&$_R
MKES,L3C()X+W>^J]$K3?W3_H'AYD2,V4A]W]H^[10;*2GER2)6MXLA>^[#A(
M2DY&@<17 /@%'J/ !Y* _AD@GXP)]D";?*ST)54@\5HB/L'R#LVPF .>=7KS
M\P^.H] FLSGCTJ$9'F,D1KK.@DM-UG%"S;AA+I):X55)$3<O4WX/^U*HO[KJ
MKW>OPNOL59<:B.X$H7DMR4F:4'KTI$X-$FI^<'IZNO>J]#:_!KGZI\MWU<_N
MP2&H1 VQ18I<73;\U8WIME&'U9BM5X>8;L,ZY([-(ETP4>J_Q:;56 [TVM6(
M*&M5(W_BJ(A%3*! .*DC4&#WW80][WF85!E_Z\75CSHC+L4$NUX=F7%Q]:.Q
M3"'GO([097G]*T<LHI1)S4$]B9[-YX2.6?@ 'JDA\C$>)_=X'*\<F54T9S+2
M_\ "ZG+F&V:NO3EG<\PEP2*Y FL&4X['GSIJ'>[&Z\(?/AJ]@YK$13("TH-=
MO=X#$NS?K%H2TRI%_]01@(&/P[ZQN>%SCNLV?*Z65AH"_8]OOXO\NNT'$C?P
M_SN:[^%QW>8#":&D0>L5]1#>.\3[U#EGL($8H G43CU_O+^N8,9I^2O*F'TL
M8%6SS_OZOP.GN]I\=!U-Z2C27_?6"=98!0)[??I9_U[7]X@X*E)"N*8HE>G2
M/9Q+%CV,N[2DHWN!1^0U5;LK79/:_9UA8.SVPW2W:P9.@D.+>O^<4<%\XJEM
M[QGRE8'Z,,58B@9J7\3)B,<1@/  /8B7XV#%RHEX.2&S-VBD&" .K9IB2:">
MV\,IS=8(VG%UT)P?4[Q_:BF(R]X2;-R'15!732#JG;,9M'**J2#/^(:)S09?
M#3%&D$_*0%X)<MC868ER0):3$N8H:6^HCQ\D<Y^FS/<P%Y=_!D0NMH9T#FLC
MNK]41S?)_G^=4, ;H.-S)*97/GO9WHA=<33"][XZ?(JKH]FV"+0^GR!*_M*U
M@"GI@4PH&<,"1&7/=5E ):&3 728"YN1VOC58FZ$\H.R2(EP?28"CN&/)'L]
MGR8$."L)3BRB1;">,]]'(\;CKK\A+JPRN#?A.%3X!F/1Q-$(X.DZ@"F>&L&(
MJ[-BVR+0!N&V?P$=H1:/N6I_;9QRF9B@.=A?AR9FHU%9,FH1&-?T&0O9;*PD
M:8U=?[#>]0GJ5O6W1'1"1C[N"=%D;YUA8.SYPVS/QRR<D$>+^G\+9G<#\_K@
M:!V#UAO1LQD)![_>C6H+!M-&YE<9+R,PQ]G%>LDMVKPF^+4(H1N,1 ,P(C)C
MOY^L]WM(V*(.UC/ &31:.V/ '&SF\BY@8P3@E]P9J:LY.4E6+8+D"A'^#?D!
MO@5EA%YI9A;E<S$"\GX=$,7'T8R<)*<6X7%-H5/Q$+TVF(B2M,:^S^RY0VI'
MD[>HPR]G<Y\M,#[#%-C*@8]H_9[/96*$(+-KCMDX$1]',VH1&#<$C8@/=N$]
M]I4?3S(YQ0_(QVQ\%4CHI'NV0+YL8C+58&T"[C"SIUXR=R+NCF0Z@U8)4![(
M4(2SE-$B3"\1IV!-B@'F#U/$ZV<49!@8\<ELO&,6#O!P-),6 ? 0C 3^,X &
M7#XW6MTS#(P 9/;?*Q9.R*-%_5_'5_ZW..2K..9/3T^.C]]G!E)=Q[SS8_RK
M36'O.F ,T<C?,=Z1""/:F5%;'^U05)NP-D9/&@)<E:\1U8P?KDILIHU(YL57
M&H)7PLJ(5\8]EQ^P:2-"B?A)0V"R'(QX9-QV"1[M!"$=C6F,1"X;(QP9)UXF
MM--&4+(!FH:P%#(R I-QYN7%>]J(3>CF;XA'BMB(0<:I%Y*WL=?S@P2;C(HB
M9D94,GZ^HKA#&W'*#1TTA*F,EPFE#QFG7D$PHHT@)2(+C9?[=0Y&0'+29U81
MBC:BL.X(;0A% 1LC'AGW0-:KVD94ZGAB+K!$Q-^MMR>68<0SXQBH[^Z)9+4)
M;J-?YAX_8QK@IE#7Y6^$.2?=IX+_I^M$<MY S@?!Q>19SW51 A9'KHS#@!N,
M].U)-BI&QK%163&6-5BFBZDZ.(E*O&E-'G9??/3*Q(S(Z1-0XVLJL>]C5P;(
MCYU\=^SHAD )[.U,@QK5PJA-&;],16U:JXV3K,[*]?GC'7OG'/WD1+5Z4Z\\
M8']CG/P%V](IYFB. TE<<<VQ#T4O>N<[4Z=*4HWJD_$>552?2+J3%.]$\AVH
MP)NFY,>.GK"'!F"RSY"K.PWYRA&!Z&+7LT]UT4:=R7B[*NI,6 4G70<GJL3;
M%%.&WE=$!;0OW74"-N8[TQ>C1*.:-#J<!L4BR6MZ(GY6?HAW;^J1!U9O-L%T
ME]JP+L $_FG&JU<1?"WH#>J2<<D(E=_@%W1KSGMUA^@W(@BG*&49['*FV+1&
M1F7*>"2KSB2J9DY4M?QBX:6K4?U2UDR+E3 OC>(AF,T07[!QWLNFNM58D%%E
M,D[3@FP.E2*IY:ELX:*,CS<5T!W1\SS-'OF)6ZNV"7VI "/D&;]J(>0K.<G[
MMUJ)<R*I9CGP'J:,2XGY[(;1B?HW40BZ\A;Q)^BHD8\?L!OPC=QN6Q9OU)&,
M4S:95)2:"W0MNDK\SXZJB/Z9*JZT:E499U6;EBI2.J](W0;N!>J8Q_J;YKI2
M5X)1'7)RS-:3FD I(CE**W*2GMZP%I>O<^S"WCT\;=.;P<B)PEG;PMHLP8AU
MA02VKA/+B0\.)26U$NIL7EI32(LY&:&KF.+60GA*+B38JK765(X1VAQ?8LFE
M"&^V6S;!\0Y@@XH\-XY\%[ Q0I?Q[T5)CUUGR:O%L"BW-J-8WZZGGX1KC':0
M;!RM;B#" .?)?O9P;0SG2HXR@?3C>,4,?2KM#C^'_;3<OMPB&>T#EA>ATHDN
MD^@HY4E[I!YTMTKN45?B"K*A-FRQ D9=R3CDEKJ2V$&MZI&XJ)5.(@5*:HWV
MX3G)ZCBZ/F_JM 4T_SCX[@H%57A3*0M4:CX/OR"%_/B^5YB_^W**><*46M[3
M$%)M.BEM(M.H-!DO;T)I5H)7]]#J]4H+3QF/B<LCXH,;+=22_,,6&YN7%=D:
ML<Z_UR[O-$?;#=#\'E].YU\X4O.A&H:!5%\'4U\HU&GDC0?[YA*-\&<\MR7P
M)U:,2'0X\%?"P[3YMW&^#A;Y"R<F1C1B@=3%^W/U]T[THZ)(HX)D?+E&!0')
MJ65 RP[)G$CZFX(LNPUV?,$L[)5'H=9J?41K=]I179Y1-2I?0*C\2RNQCI*K
MC(+P,-J;8ABF^?N'1]%S8=G=U$M<3X01_GSWL7'I4+*<6%@K\<X]UYG[$";1
M/.=35,1#<DFEC'TWX!P6X8V<'G]GW8P:EO%B%YUA+7X#M2QRJL4U=9!,DNN-
M2U3=%F]N$R=<4PY1)L09AE[%B0+-PY'U91B5)N,_3YVSS;A=0983"EL[D-MN
MS ></1/UR74USK<+M8FU">'L-R#6$%X)T,/_#=95'R]7_,OQ&*LU>#7$[I'$
M,/$QZL($N6&6P6;RC I0?I0^96TLY2;*.$JTDY;==L5(SK]RBN^PO,!CS&%Y
MA-?+^V!A"=6+Z98G_.H"C:J1\ZF,DME?W6D+DIU8M-:.'Y?2?](V@ZY V_5C
M8W]E&2\CJADGY1JJ[79,)KKV"P=[YI%RF-LFE/RE!U-T^_8VENXJ[(U@YB2+
MIL#40IRD%#TL8SFMA#CO1O:M9B+5%F"$.>,XS+\._BWW*!52K'RM>^, 8FT)
M1J0S?L#:]\>W$NOUBXL:#]T"/D;<,@Z\O!N0_KN!^77O57Q$\SF!>4<]"?^F
ME(5UUX_@"0YCWAHVQ%_X'Z6W!-SBV0CSCH-&0M\D\JDC>8 [#D4S_*E3B902
M=1+/QS'IZXC[Y.,<<\(\5?M/'2\(C^EU'!& '"(#]1>LG<'\4R<L3B2>=1P9
M%I>\JWZ)@X\>FR%"K^&EXM39*VSD7: JTQ_W7("S/[Z!*@X"4#WEX$VV;HQ\
ML6Q>.=$NVP7JBBJTZH%Q]?ER%??P\:+_0C&_N+RY,:!FHK("L'/F,XX\IJMG
M;%)1:2N:HH+*Q,/]<9B%G@PG:+.AO&E5J:UHZA#J3W#?A^T++V]67LG=-:%Z
M"]9MBB$;AC9%?]VFZ$7M*FIA$TY;[X'P";"'M;!"ZV^)CX5D% _0(OK>6,'<
MF%.R3N7#=R,$&NS""YA@P6ZNU:89R):(+RJTZH('DUM$@S$T(U ]<85<C4RY
MBAK)K!ARZT"L[@![G#/:<Z<$/VN2_GB@5J[A"^M1[XIP(0=0-W5BFL%Z=DW#
MMU..<670MR++W(N$JJ0<F=$:#X]VIS3)*Q=[AHL=;]1E7<!2%$[BS9A][^G@
M'JNBZK2;CH<_@EDJPO.L.C)>/GPJ$ELQB.+]O+XPCXR",*=DKJ9LT%'80KA0
MO+RYM5A8T>@+%DQ\),076(.I82K,*VK#<OT5JB=^0S/BP[34"R:!D(?[AT?*
M,BIO405"&]JG=Z[9Q"?.$9WHHF>+59%H5NZ](.Y%24B]\.X$N;B&.90'>J76
MV<W#*:)1F4328^',_[?7H\:J4&?FTSF=C5?5DKUB,4'S]6VW5M$U!?X UP4.
M_[VF*@D>@$K<8%#8W&K$UEJ$\8']_O@\T)OA 6=>X$97T@_QJSSS8<TJ'@Y5
MZ7<YT<M83(4&Q[=S,3Y7=R*9UN["XE8L7+V9,IG4=:344_NJ4.>N&#\+B.^Q
M ,S/R%37W^LKP+ F%TO-U,)+^"+H0)AI(:S,P KP+_!(KBY2Z3TCHNL$N*F]
M-9C3P2S0^^UE@ _Y*O"FLJ.BP5JH$EOA;:FBI(_EJ=DZ7J*@>>%84*C[@:<V
M:(G$P_YX_2!?8?]M5<8&B\=..S*M)+]A'^:.Z-3A(J$BR:#O%U#M.T;=6NK7
MB+.MQD8B(29,8;TGDRG _A@?2>_SREK6B)>EH[)WW[^\0RX83O#KM^NKPW-E
M 'L L\$M7('0BNGZ6H6RD#^$C8* 1BBO-2=NL8NIL+RUMF1J)UECTVG3-K/<
ML7=UT>O-YYP]([^A:S#%P=*AV/?G2!#0N^7-GX; 3&%Y*P;>[U )@F:_(\^#
M7^5-R2]K@V(N0[#+2UO-T=I$T=UX$0CL&2:8;S2N&@PD:T?.-^)*Q@GZAIX(
MIJ;(7U%I&]3M2F5>@.'PK.S3]/URU[,Y(GQ69K]5I+;51JL>L#0[2!KQLL99
M$D O)]+W3)'>XO+?.X 3W[2M+F2["K1KM>+J5H72BG7N C]CG\W#J7*B=DB,
M+U2,#91-+"=380QHU^9CZS!NZL106\E=.4A2O&WMN/LH'3$.\U_36^0183+J
MC616#)/4UF.(^8Q0A5/-0%D^H0TK=[B>+$(W9L4YKIS&"MBB#,OU+R942LLL
M(K*B8<,7L A8H$Y<#U_@S:*OOG>F8N1@/IFULC*Y%8U=G0H88@H3&UB#L!?6
MA7J^ON_*77JK%L4!BWI<;)UFA^A51P_54["80:2R+52L^!:]DEDP>Y PP2Q/
MZISKRL!:XF&^5.7"/MH.<VM]3>=Q0.XWC+P_ \0EYN*:#I! 'NB$*4FV$K$=
M(T;"?B',%JHXZ9516-&D>+4)#4B5%234_=2%JEQ8WM:!?8L"SJXPYXB3<JSR
M2MI@1.@K,OKC0>+(!^P 'H7*O@:!,^5=UVEZB_#_YGWP!AQMV0W?L6>8*H@A
M'K%>RHHAMXI'J@ MXGP!>W2U&(@[)A^"T?]A5P[9Y>N<Q%4Q!C:K,K+459>P
MF\1P2F )T'D>#<RN<G(KX&\03U7X[B92N\[94@7)R]H=8*Y]6R"]8=YO$0<K
MU.3?F-XNQ%]/[$4\&1:NW*(VK%RKA+2T,B:<-?G?11JN!R-2)\4VY+J%GO'D
MQRF4Y&XPTEGQ#1VAU]0+7+S,2C4L9D6EK5#7KVQ*A38CHE_7E,+BJ^1\_7IQ
M7B?UJP$G*[I ?0&$43V]Q <R*^X2JE!:T<3&"=?&-.OHOEO8^.D6+:^VVW[N
M]P95L37Y*PXR7Q!@3EV96-CZ(Y],=)7,,6H3^8[B1M4#UU5\32IU%O8UJA$]
M2H/91HZK++-MQ^Y7J^H\/(Q3:>^C\]KCRJEO?]%58MDJN)D;V2S6@LVXVCHV
M$G/K.9H3B?SP"FT]I%64A(>)H&&#KH4(5*4*>ZDI.UO=(_E?.#;E2I316+%0
MQ=]L6&Z1H_MPU4E&+ 3>+ W8%'K_NZ1_[T!^$_N[XEF6;;"VQ5=5YYQMZ<ZG
M 2-[-CL)+\T5"WALAB7<-,GP6>3&,92*@VPYQ?2IKWC#I$TZP_;*GOI9,8.6
MI\[JO^8P.:7C =5O9JC*SE*'U.-\S!ELSNH>R#3261ODJW*_+)B0L'P%4 Q:
M$!F0J:MA0A.WL'>V*F.'#K#JIGIQY+=!L-C:T1#U.9JHHZ?J.ZA"70[=I[W)
MA&/8/F*=>#7@S,78$U><S<)-1,*8+NR.K?#>Y8Q:71FB8'^5C6?Q/%J'AZ7J
M<H-&RG\79C+VQV#!X&IWWU0@M&+MS+EH&2PRG>2A[V"M<HBL@-#6?63#V%.]
MU,[Z;"T= =GIJJJ7I@*EK9Z8KW=?CTX_G*J3@6??*GK&RVFL&.RKJ?@>*Q)8
MK;>5_;T-UK9.&(VC>,9KK;;!^7M[5AH>NM[!=/J/2)(_9ZI>45"PISZ7E$XR
M-FS]*Y-;,>'$J?W*J3 /O0>PY!5G[!44MW1I5'8[6-0$^7?,>-Z\H+ 5,!5G
M9VTGQ^N?E."UPBES0V=/ZIL85R742E8:?JG'R-(>J7%IY27E,#^IW]$5E4?G
M/M@"KKJ/@#0^_%Y/A*6]F+ET ZJO#&0AXED/9O.$R73.1-GBV(29I3WS#7.P
M&X?8G5+FL\EB /:.(:I70F'%A)KT!%WZ1)]C'K+(=3HD&*!;[H+Z] Y+;1-7
M<BS586>'+TE7)HK)5[\?V4!EJ2XG\WL+0C/5$X0-#*S0]-4-;^7MRI:SHOK+
M8;-,'JF0O%Q.9.O&8XB>L(?6KJE3R<4JSU@=H^B/>V".P./JUQQNQM,*#3!N
MJ(P9%-49?.^M^@"IQ/*G_ADGI@N+<XO:D*B=S$?IB8L Z[.':1",IQSK,;'5
M2[DR@"*=TT$G6<&+4(72BM&9O1O@ =$+@B>L[IT"ZW16-"].9XW2>95-1_&+
M,?MUO?CWOJ5I/2OW+*!>R<ZXJ/AW3]I5P?E '>I]8&/Y@C@. W=+=Y3Z%D/
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M7O *O<DU_OG+Z<)I84?^K[2BF4H4DW0%/.5F\[&N#]83%&K;NC>!7.]S.SO
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MHW*&:), KX-CWU.EJ(>GVA50#V%5^'UM6GT%-2!_-I3^%LKXUG5TPOLGXN;
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M"]GN%X7> VDOY_4YI?6W3[S\I O+]+<YK]+%^_GTOZFT8W5GL^&U)6.]X@V
M;3!CC .>D68:IQ;_C458<1]A.^ 853*Q)X,N.;8'E%6?R,@.@%L5RQG@S%N[
MHQPA%(9IM$GM8@8)(J5<@E#,(3,4N2[@&%-0;4S<VE54'8M=;\?\ J?+?^#L
MF,X08J@:@]?@#$^*\:Y"D$Y#SH5GR)9JL'=1R#;XQA28&X)D@\NL&ZMN&WWK
MUWZ**Q:4-2B"%%MQAD&> ,H&-++IFTD8D0]E WQ#]1AFP(4Y25BKR")#"NWN
MU<!S$K0+_*5JKY11(C^LDF]O*-^%,; CFWK8 SL*[5%-@@N8>8N1)3L+GH)I
MNX^%&*QC/]2K0"[D@/?Z2'V@? ^&P2/Q; ^9'=8\N "RF%R%]A&(>0^&'5@(
MJB2@BM8HIU+5CV(A;$>XQS82]B3<(80W$,.N7LUU&L)JAZ97ZW,G+(:J7&Q=
MOPR!R4% S#J!,%YX+8OQJ7>KQ^U1[AW)O?62LLM8SB9%*L73D@-HT^XI2_Q3
MXD_E[4$7$ZTVSO6>E"TACBDI,##KK@5K!Q3F$#;%M0GYIJ$VR8VFIG!VU8&5
M*:D:<^O.6-G5B*4UYU,:;(P!BZXI%;>#5;$3F#'9%0<BVZ/(\7'9=S$T)ZQ'
MGAL"'RK;1UD@)"$L)%6B",%:G79QGG8"LZ61,:S[]#W0;U=!'BHAM<;Y^RD/
MY*1KQMO\@<KQC!;UZE_VRCEM^Y#.::6]QM@I<_1B.F<ROYQ^:K7YEQ_;$J95
ML0-4 JO$39%9Y9_0M/)\*P5JK8PTO>^%NQO1OE;>'9]^8;%<.N0NJ@H!?09E
M6Q]Z7IP\?"J\6G)4N9@:N]^2L3W*4<6/.I+JJF$WL/RZ>5EWX#RI5N$]G90S
M'ER1K8]+N]B@. 2> AD\YJ2[7VYQ'Z8QF7"/0Z'M1=/''+L#TB]''W&ZW!2.
M%*'1),7V@:KM4C=B)X6\@>"$+EF&&DQ^D,'UH,>-RJ0:@ X#3?SC&$CM,'R[
MV^7DU/O%[:^C@73_0P8UD+8<XV$,)+19"E<M!%^8>;DH2(D4Q*"\C1:+ZW[#
MV^,92!>F_+3[PO]GF;U8'"\G)D>9J@\0M8N\#+4$;'W,)?NPR*Y-RK)W=G$W
MI&,*BG7DUC9V4B<Q'L)6N@TKOW>2R&@CFEW7VGF:(A(D:06@%-JA*+&HWC<=
M[(;T.[*K#DRY;<7X2)3[E77)N\\T^T1_7\S7']A"E&@#NQ4@O9",N?4N4M)"
M+5F(Q%:'MP=TBQ^ >$Q)N-%0<"^Q/N+N]XXI11.7:\W9$(-EG":T33M4#Y09
M?6VGOVKO_-..4,=T&&\TY-M-D(_)NL^+B68WV!2MP1J>&5/9/<;0/&-7V-^*
M!J7JW8US)Z!C.@LX+L9M*<1'XMNSNJ;EN84@*I+WKMT<X31/D?<0LTK@2!7I
ME>2=^7$-O4MPQ]1J?S3<VUV@AXFG; Y2K]HA_,6\G>%9U,TK)^/!^<56I7L$
M5'9X2M>(RKZC[!12V3RT93\GN52A B&XJ#V8Y&6+M!I@)\ 6*;--HK<=??[P
M?7>T?^!RVE*MWT8C-$5#O+%2VUU-XHTUU':?ME)(Q<9,W7M57P,QIO#&;G*^
MNM'L-\_=%-CE:_LV.(K(DC1OGZI8W1)+#H*U$J0)5E7A,5WM [NWO*^C&%-P
MH8_ ]YSI0RJ,\_.@IU6>O'$NZLT7/+8_S7'^V[R<7EE$Y4=<3?=7)QTQ#*!L
MAIJA;JJ(=1_=<B7G6>?*Y\<T\4&7ZH1@+B<'1ED'Z%K?CEA+<D'DZ'KWMW@H
MMKX[V[>; %/)WB :D*1XT2E1(!!;AXXBMB5L<^V=VO@.[HT=A#%W;X&[B:1C
MSZ<[1GQQM?[\)?-;V?H_;D5EAJ1A0Q]BQ::DL=4TA@I*U4)9ZZ2[WUVU$]!Q
MZ<\#<&MX<7Z?&G@BQZ"#&<6HM?#563JT'L[9*:W1@4<;P BT;/MG#SXDE;R(
MU9?>-RH>2@\_]#G7TQ:8B_9L&,N3@VIL&">?B4<2@RLNZ8C].^_MAO6[U.3;
M<&ZKW;:74 ^CZB^@/0LEUV))"-)@0\Q@M&-/O&0!B"JB(F>-?RRK>(M,P.C4
M^R$(MXL('X=GFR19)B,#F@#%RP(&>4V$R!:/BI0$"AEH@$CAEB#'E&0?']>V
M%N.CL&U3!951U(JEMB"3Y;V7M]W@D,"5HDIPTK$A_(AD>V@9VZ%RZJ/CVM9"
M?!RJM528+EH'3Q%05EX04CM(AO%JK#(4C"4\+M4>F- \5#)]?%3;5H@'I]KE
MU&N.T=;6 5-)7A#&E0C)V012U&*B#L[KWKGTG8".*8L^*M+M+L[#A&7>KA?Y
M7S\R^-+RS#1?;3[Z/ #QMR6VD +.RZOC]6K-WWFP;S_@<J_$^OX/[1ITZ3P'
M>\98-@==-A]_#=*S)4-YOVD;_^/7;V\YI=NSS[@LKSYN+E Z[6"[_OK+YA:+
M#1LWUTB_^X#ST_=<&,TDVB!*"TTK(=FM4-)#D.2!"+5S1GICY7U2?0S@^^[*
M^\*] .77XZ-$RXD7V4KI"5!X Z9:";&=;:HR.HI!&"UZ^]C=!S&&L,_HE\%5
MC?"X5.IFI^P\C'LG^M?%INDRE=/AV:AXJA."++IU]V8++&5V+K63/O&OIG]5
M_L$&-X8XUO^>%30H]0YCAYWW&_L[6Y+'RY.K86Y\L2Z6-U4 GKZEX/K\7RWF
M;UJKD27+9=_:E4/"ZVK;/=J\=LJTG4 Z?_3SZ2K/%@W0A*J/B72[!K.D%IOS
MS.&P41'1J1Q-4-T;FMT&YE#-W"8R*R6CRB!LNX!6:5:.4A<0F94AL@=75._<
MV4.QC<%HZLN:7;NT;26E?C<HXNI#NT66OS5]\(D!SF^> X/)*9\"6(R:YX G
M(AB7(;=+Y7.1[(GW)M&#P8W!<!B61</(:?#6W.< )T+)37-P(.-\.X;A()&Q
MK:LQR5CY?]G;;KT7U)AR6</0IJ]<#M7V@W^D=_CERBF.Q6KU([&]01?>L%?C
MC^T?T[GUQY[C[&0LG3RF/?;9>KV<IN/-G3[O%J_QI!.Y=J864Z#='@#&N +)
M4 6;E4&MHK8H.B_<NQ'MNU=]^_1VG?I/B_EZ.C]FJ_0T+,V.S[7I9]7->\!\
MDK-41>O8;F:QK8X (89"X(O7JL9H8NP=IMH=[9A,JXX<N[K%'4B<W53E#GB?
M\P^K]31/=$K!,#;PH37M(F. E7T!ET40&(SQN7<C]#W@CLDJ&Q<!=Q+HP;7O
MZ^7BTW35!L#PNRO=^SY]*%V[U:@ZJ=C3)K3G3SL],/PCS:E.UY,H2A(U%=#!
ML@UF0F&3G=DG*4>!+DH9>Y^QNQO1WE[ER:>?[K/7!XRZ5? SSZ6*$8RP%5"Y
M -CN;8Z%G+[:Y*_7@&^#-"9EV9$MU]S(CH+I%X,X!44\RSB[#DHZFTIPO$GJ
M=B"HR I)Y03LG?@BG%*2>KN.]T :DV8[ %MZ"*8W6]ZN<4W/YN4E_X,;H%7G
ML+A6GI2QW0R/'F(R&3953$:$2+%WR=F#@(TIY# \<SH*J>/5,)487+EMV%(9
MW@$=08DGU48("2D#><K6"*-JZ+W;W .IUX@O2>.VX6=$F]LE(1@*6Z06%<1B
M$V2?I%<!G<N]#\1N@V],>KHGDZ[?LC20S+JOHU/M<!LV)X*,.DE@=[J58V"!
MB"D!F4K!1NG#U=L'N_'I;F1CTN&'8%)'.?7GT(D]>ALV--5C9B5462FTSM>>
MO7,A0+ ]*BB1$*+__6\/038F;7X0#O634^=XV@WF2T@^%Y?!)=DZ#O*FF-B]
M 1ZM0IE4%:[WC18#Z^_;1FJL:)70#AP&RTY;NUE)4JO+L6R?*^M+TH]IL8PA
M]+P?/VY;#STDTMLQNM5(T)4-;!<AR!9J%-Y#P*1!,C#G6A/BT+MY^39!IC&$
MA_N2I*,\#A[Z/2_C_[E6RNOIIV_1ZS=LD+ZAO)CGZ6RZ>7B?>/!.CQPJ2+S_
M^#M%CF]^_DU)AHG/0I;J JC*7#*M=5ATBD![J9V7P7CJK? >CF[?S>TA<MC4
MKSXK_WF\6F]J$]NE2**XZ$ XV6Z=$[S$#!LEI"D74:.0LG>Z=A><8]*6 _'M
MZMXXN#B[:=6'(/WI0ZNU_F5^9A;PFT[*>5J)S8DD9[/%9YQGFJ#6/E$SPY.)
M8'1%"-YH4+[=[8,^A>YG$SL/84QZ>T1T'8H$!V4RO_@38Y_R:E/*:*FR@5A;
M#R[KVLE?8<%F=AN5I8JA=^!F.X2CNKMK1$3<488'Y=F+,IV^IF7>7 S,OI+2
MKAG50H-Q+0N *H/DM9%RS2:5QR#:!8ACZD,Q(J+M*L2#,NW71;/"C_EM:4:G
M+MC-1Z9.>OJ&:(M$!R6*UE"CG36W@:!6SRRJ4?5O5=%_%&-J9C$BO@Y(A3XW
M9.XZB(O0SQ:D\3XZRJUY93+MRL@"(3@/SJO$1H95.ETYKG'+V?2.H,;4[V)@
M7CZJ/ ^ZP=Z<H:35)*22R18->7,0)4D)(84,)- +;9+/IO>!H7WP/H2<_O=!
MSH.+]Z"$?'96L-2@'_/G?;WTYDD,A-D8#[78W(SB!.ADA"R,K=))_M[["&@'
MV ^A9_C?1\^>PG[4XTWK#_0KK2\$#\[[(N&\; ()_<\Z/?R9ASCXM.,,= JT
M7PO;G%R3KHU32F$"EVT$TSK28Q *8DI:FN9>AZ'*H2XCV<NPO/:1O\Q?+Q>M
M\_F;4^GP#O^</M%L\;'%6C?V;Y+9.R,%.W*MT9?2%6+,[-(Y,E)G44QYF 6Y
MR]/'%!/O0(U+9N'@TNA>GW..]#RV]!.O[Z]UL6R-1%:3A-8;$J*5;R8P(@FV
M!2(;IS5JZT3U.@U5,WD/M#$%JSOR:$@!]?%EKR%[TV;X5?WM["JV5\NK+?DG
M[,)H*WV BEHR2H<05+N^D5314GG%W-]MQ[G_X6,LY1ILP^DLB^'VFV^M(GD"
M+E.:'5YV,40%ZQHL5T([JB* 78^"B*((/;AFOAW>F$+&A]AW.@EJ."9=+MF:
M.,%DMCQXN3GPV<)\P5<"P>ZK(J^S+H-KK,N0QA2T/01C]A#(H/;-V6LWQ.+8
M+#NMWEI-"GFCJM--HQ;>'UFWIM85-\2"-B87L'MT:W>T8PJ\'L@*&D",(Z#=
M'>D**ZG4K%R[7#TW$R\"(O&&FZLJ(7J73.]BIR'&,:8P[*BHVDGTPY'X;XM%
M^3R=S1CSU<NR)TF+8DL[4IS;Z1(1)* E!HR5/=>@90V]TZK;X!M3</40I.LE
MJ@$-_U;\QVZKM%XF#]FSU6@RL@-;R$!4O@B*2D4QU,F&RT@>0I#X.R+(]M,_
MW/G<BUYI%#(FS6#:Y6",*%2(Y"PH&VVH"046,_11EUN#!GO1_L*GOEXNV)M:
M?WT]P_GZM)7P)A XH9I*$.A!2&2!>!4@2NF I%,Q80WJ:H"DYWIX",0QQFWW
M9M(=RZ6[V+I'WRX@W.1R3[*W0BE;0VN+WNI.C:P" D8#KFA3,QIG]96%='^H
M[<8GC3$ VXT0_>=Z"(UZ 54+\TWG[R]T!U]-E*NE(&_KE@4+K$5: X\H@+UO
MU8+#*70_)?%@<&.,RAYH.]E75,/99A= _DKK"4J=)8\>L'AVH=DN@&1\N^Y.
MNA0M6:%Z-XB\!U+W$=]0PA]KE5XGP<-DL\B@(DB9326G@U39HO=F\%'O=C9#
M'JHFOB=Q[K58]Q31@&[QQCI/[*$'(RT$*NQ+>>\A!IV!JG72%S8/RN">S UU
M!./0QP<AR/9R.(Q+XZK45K))*!RU<\"6 +6/X$,U.66&-!@S[G=I'OE4S2$(
MLK=0#E,V]C,NYVP.K%[3<A,)W*,:[+:/ZEKD]2"\G6JW_KDA(Y5GGVB)[^GD
MNII7]?ET=LROGEPZ=_&Z'1V$E*84("_:M>.5_3%L?>M,LB;HJ"SVCB)L"7'?
M'>?&Q]WVL&]G;"=.:I>LD&!KY.U1V@Q)*\&N"A;RQ5J>G$/,S/U0QQ1H&))_
M5[>M0TBVF^*[96*NX6P7 N6)IR*<TP9\HLVIV 1M/L#*BAH#65-[5W1L!7!,
MIM.C4ZZ+%!^H.D]?;U\2KNBO?_@?4$L#!!0    ( !V!?5=TC2,XHET  -,J
M!  5    87)W<BTR,#(S,#DS,%]D968N>&UL[+U;<ULYDB[ZOG]%G3JO)[MP
MOTQ,SPZ77>YVAZOLL%T]^SPI<$G8G):X/"3E*L^OWXFEJR516B2Q2(IR3(_+
MEFGB0^8'(!/(R[__[S]/CG_X@K/YI)O^]4?^%_;C#SA-79Y,/_[UQ]\_O 3W
MX__^C__UO_[]_P'X/S^_>_W#BRZ=GN!T\</S&88%YA_^F"P^_;#XA#_\9S?[
MU^1+^.'M<5B4;G8"\!_]/WO>??XZFWS\M/A!,"$O/G;QM[-_RUQ)KZ. F*P'
ME8L&9[0'1[\J%K01&?^_C_\6HLP2K8%D%:./!08AH04N46F;G.)!]5]Z/)G^
MZ]_J+S',\0>:WG3>__&O/WY:+#[_VT\__?'''W_Y,\Z._]+-/OXD&),_77SZ
MQ_./_WGK\W_(_M/<>_]3_[>7'YU/[OH@?2W_Z?_\^OI]^H0G 2;3^2),T]4
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MGE)QN>C6U]?KHSUL;FY)BW=<4V_\EO)VUI7)HBZB(Q5U<HDCL*(+J$Q+(:K
M(".)P.BDB[*-"74U^F$39$TIWZ'PS1\FVCRO)$<ND6:1''+E01D2290\0,*
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M6$OJ8LK+Y'QQE@CD5F0M0;(:6Y>3A(C.@K5]CS3K%;9VNQ^ ]+0HV5(_#:M
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M'U1!H0UQEJ!\6E1JH:K6N3/WP'UU\CE,9B=GB64L!6,ET-F<"*'U-<7"D@V
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M/5QHQ3$$!L$4,O(1+01N.$2)+"F97 @X9&5N$(5P& =S,RF/T*S@)J8++@]
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M<)#1EW\W$Z3/>'R7YUTUGY1 <>HH)(>^.Q.<R-)JUD%4Q$:0@3K&LZIMI;:
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M[Y(+V\BZ=A[^?8CEJ34U^7QST5R@5F%A@S^$PCAU)7?)NUG:DJ+$>D9)N6[
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M(R,#"\0P8TM'$";;E47L6X$;-NSZ^MM&8)7U]M[_/KB^O;Y/8Z0F(W <WOA
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M$D'_B1F)P%G)X'F)D'G)D/\JYS3C5]R+MU-:CTL&SJ>W'Q?WG^K'KTS3U^.
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M!O/J5V:6+/.!^;R[)8V,R-,59Q,.":[G1:Y,G^>E;U>=E\6I];Q7Y><^7=>
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M^<8PL.I","NDMU3BX<[!T54 5=9W[A+YC.[HQZ]T^\#<$@V/Z[(-61W__LM
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M25)T901HEE+DM7"P>KAE2I(%6L,OI%92:%.Z*/91R72?\O[$)O!K%B?D$%"
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MRODEP:FHO\T^QEMD%'EZ,ZTN.SXN0)":?C.KA$P01*CQ![S5N;\,PGY7P]9
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M.#GMEE)*.'4V"OP^)FF2$&69E7'B>(DN "&^;RZKT 0]PQL$1KWH1.]&MMZ
M6]J@X>9X\5@%>7S0[YA-+1>@XY1K']M,Q^6N%+.IDTG<*HME;BOEZ&,!Z&>L
M5-.KE8MD/!.45;<P^:Y6.'S:NY"P8@FC8W=2/.S+;1GJ9>T_V?(]?G%W/1-5
MJ3[&&C#=<91/RM^[AM*OUBO@5($S->P2RNAS8[L/,(57YQ/RJU4?L991_#P*
M+HTU8(%H'P8Y>Q\0'M'C8<LAF 9AL<:L3X4\JS.,^AJ#]X?A =U44/.15#0>
MB[R/>@8VM(\8@GL)73<?)QUY(G<14&LQZF-VEYA$S\#'#JIQG)&NC2=]FNSD
M<5B5I>72JY21^[$UA&U+S@5!5UGZ_UK-"4@6IGY55 K4_55@ ='/W*0!^^_H
MMG&]O$JPMJQQ5G,[#IJX>@E.J]0I^/<D\Z'48.XH0NM\V6Z($[IGOQT]-%M6
MD>:!BYZF;L@_Y:SC,D8K(?P;BC)Q#5O\E?ND3I@C)=\M<]#Q8VL4W*57M_>0
M<KJZX2/JPY#P]6 M?;HR_P%$9VV-X"ARPR6P.#4ZNV_D"#B&X?Z!.*2_:F\5
M/E:]F?9B3:^/@AU3?=TDBF)-QSYOT7,]VB%YC0)_F ;W%<3R/",7MHLK:;U6
M2>A4;.)8/D%DS8X4,7,WDO24;6ZJX_7L=J 5PC9A]-S#56E5R*/TPEH4+=?:
M".THGSH0< N/0E?Q ^V?+%7I"L"VS@,>1;F^F>8&_MEUN[H@N*&&7]MD1"DM
M]15LE:+(-Q4QO\1+$K;!2.<W*9T#NH_T'Q;Y\@<!PM]Q,-_9_KZ]!FKW/N<_
MS5L"6/7;JM:WREK.K /V93VTWGHJZQQ>5VTQG^G/^)<F.3]#,P-6*E6? =PW
MW<7&O,/] L];2Q$<F\T&3Z/MY>IQ/SU909$T,A.J!LQMT@M0I IWKN?ITT=T
M1<,1IP6QG6R^1)7@(PA\H=C7VTP7?;,GDBP_[<:"(/WH&,>H&R9^6/O]0=M/
MN ,_9NT.T_(&@[0LP-!MA,GAT>ZA$;C R@"R5WKSV/[3Y!;M5^#.?!K+ :?)
M!5',K"[^:NFQ_+O0RG?0:;X>IY/8A8 #XV:!(/@=V]9"#*?X)LZPNS'_CZY$
M:\K#62SX>W,7' U$A1P^LN\NKZ,"3',ATBSJC%_/CJ_3E\X;T=F:Q!<V)]U(
MW_47+BKA)]UY3$Z<T9>8T8& (#ZY(*H &%;=R@.)"OYFHWY[CX@/%B&_&E9^
M$'H]BH$C__A$(@/I525T=6[ 3D@,J!.?$NG97*B< H@=@Q4_C?0"%Q ,WX,I
M>%*&+L-A6!3[TG_[=6P?/V:A>:$@N1FS%BO@G8D[>D$C6QF,'"HBMI A+(#U
MC!0;FDE.!J\%'V3P)TNXU.J9+)(9X&6;],KVCTCF9A-. ?1>O?7\U8P=> C]
M=K"H?6"ZT(HK:TG71Y2A^I"@(LA7.V<*\T9WY'>EC9+V#DD@;!9CJT@9_Q2%
MP!7-^>-XL1*1J*]N19,S?RXP7BEIW)HP4VO].));CRYA(,YLN=4)]-YMI2KX
M),NOH=IBS3GZ05U*MZ2$NH9*?T14!31!T-#Y>7:$T$9^Q+J.1+[+L&0"HM,Y
M2)PP+/TN8FLZX.-4X'8I$509R4B6/5T$&T?$PT@A^&\T!!G;K3.2!KW+]V(F
MC(<*PN0SB=Y[#T3:AL_@U^ICKGGCB.\&KQM[9@]!R=YEL-SHYE&4;]:;+E9Y
M.=IZ$V6*?-$8?\,*Z78C?!O+9)>T_F2GO$>G FLQLE>S]>UAO& Q&'8I+6Y,
M(:'58+^7F<G7EWKQU2RVB_V/OT<I8-!7#^VWU/ *6.:.>>\R-31.R_^:R'E3
M36>5'WCC:^>4TJ>0L@]1L/Z)VN+8];K<YT2>]:,[ABW0T?.A '86P=:1;"-E
MZNV5K-B'>R&9(IMH::%KH3JHZVX1<=6?0H10O)OVE9K#*_.QG96ZGX;1G0I^
M*D &F9W6:5F,_)9 +HOUCS#-.K,>TNUW,IP21TUXC"%7'S<Z'>W+SS"U [MC
MD37F'[.Y@_^XT7 N@/_5.SU^F,@UF.AZAN5PJ3@VFN@N>-2I1G8_LDV1H#?X
M+B.^I&'U$Q92>HTR9Q\QZJS6G$H!6+B/%[98JV]EDJY<1+I61+5HCV,%74!T
M>NZGHZEP6%I)MT<,-Q> ?6$VIA/]@Q3-_\# A3H!E5C71!]Z=1>7+LU/9U="
M^-AO:A<E7G__P=#B<Y-$V]P(8DF-]TP]X/2GSO9Q$2U\AI5VPE:4AD5@3KEE
MO6F("8%)-:@R,G\S09TX31S/-H. W1@:"1, :U7X H[P:FXY9B1[F0V/X/6[
MBV,@D6?_W1@1,V<*6@ZAS\D,X<=E5-TTG3Y8]B?42/')L_8.7^M)=U8J$,R$
M2V!\\#UBN'9S:&!S,EPU_?'DC[U<6@3QL!N"H+>![)7ZV'O5YJ#\YJ]%@Z;2
M7PHZ\=2T?E<7J_84T=7)9CHV G<8)76TL3[E0<A6C<;P.A6G!_8546RT,2I7
MNAI4?HNG>'1;<[=)X3X7FW54;3Q&PN)8#0 ;& T;S@BKNKT)-9GJZ*6KF@HK
MC?*C0(DS, 4+^$=5@#!2R!)I30J%_Q@:[U15A3)5:0E)P#.!+3*(T"(H**4"
M%^$ 0"A2@"&31.^_(]=&:/$@@T([<'E3T:>N./J,CM)38T"IW?EGVUXOJ&M*
M'4^&<)R4T3QMH"-XF_1SBEP>U=M/,I1420;]Z'Y@?$0XR?[5VC^JMH>3G.I5
M]A=1K#WKT6"8>JK_6,>9C@Q_M:_X50,^PT+259F?39Q--0HO+I(P+=8@/4"]
MYE>;(9P*+<L>XZG;U(J^SJ(+Z0HT\3+T5-P<(^QK4C6K;<).K9__0EC]XB2C
MYNQG/D;XS[4MS W\ZU\)1PU;88?%=9MD=0)G:$&[1J[EQ^TJI7"?M<CV^LA#
M/RU\E+@<K$SIK6:N4H_IK.THHV!.MKNJ0>H62& Z6)=X6ZJ]/'*Y)G$-'9$4
MK= 7(4PP:4%H1;;Z[B?G+F#L]JI=43%(M18D#V!& QB?1C.(1F!.?T:A2<>A
MPNY@\PBN.1#N7D?O\)>P>5/0S+*;5\KHL,KSOJV+B*>SP&7M[$DR6U44+0HS
M?]$54B<5L9V\!F>?\]"-CI8U4#)]5C"CF=@R5UM65S/_'7-<Z&OXN];PS62P
MJ_3SGXCRUUX#B!=_#RKEZ)L9',<ILE@RA?X2)T'VI![K>6<<G8TL39T0# V5
MO&_/8-/!BQ %1JC2RJWQ_2PR>38(Y@ ,!1<<>:;>T%VO]]<TU$$06AH33.S4
MXTS%+3XZXO0#HB?(::IXV5L"M:!M7C_[YD_X'DHH2F#6S?/5R>A/$N^2C"M,
MUF"62L^_"5;EE>"60&R0SO:@(\B!%==W-6[)$3<3B(=2-QMCP7%UCU?XB!OX
MJ-4&))QWUNM91A,ACML4/_OEI$.T8^E&9SLGW&Z5.H&]Z;@BRSR[W+="8&(D
M:WFP9B%%#MLP]7R'<!\N.=4U%<J_3+7L1-&<2A]]7P11S0DN=Z8B5V!^E[T:
M.]ZA_2KCG =.GYIPWKB!-V$^PXI$_XK-2O3&5KI'0]#MR/+%QCI?UX'-SF;Y
M6%9QST;#SIJ9,YL,9%=L_A[:001S.>69Q]L:)7IZ--,:,R>DQ!!!*:!W 0Z.
MS0OP1(6JW?3#1]B".X]30\LQF;ETG)$CQ)*5*/)(LGD'00NH,\L6($S_42#3
M?K13<<D@2P7[. 0++Q!F=T8)9;3<F>?Q9>3U-(">/S%78I>$7 ?SY)!:9N6(
MY) >KZV783_.YR#,Y/A,>#[SXY =!W%\'F)+J^S%.,OE^#R9)>&VG7!@S"T9
M36A38#LSO*'WL+B<162[8+HW_DX=])NG[Y<Y*Y$<QVL='$#O8IG(XW$69HX;
M4T:\EKC/N#TI,C&DK<28=+C/#4\M^">KH,)\*V%-S[=/QAPGM__RCXS)X/X%
M9,%@"'II^VB5)F$WVFXPZN>0P6DS\45.7>4X);J\O>)H0(RT@J6TW9+@N<\8
M)VJA\."<I(M22Y54OA^_QSRU+)Y6HV$5 #XHOR52*[AU'<"C;ZM3S57\VJ;V
M[]A&_;H<[7FRR)7T 7L37;?5\;6<M.  4T_$HC_J:=HA9>)T\]5T4VS'F?[I
M;MC^/?C\.0:B]VAO<:=XE?%L]S+]P30/9D=_">46:RK;!FO$:07+>-KYF_CX
M3X9#/5VLS'"2]GBY@L4TKOZQK,KZ'?NBUDB8MJL0&ZF)X\TS^VO)+[0:&$5>
M[C=E.5EL&[WN%W];1\;E=HQS=69IDN>U)CU')H;I/UZ%W#&5'3$-W+'M';']
MW''SX<SYGLDIS:9Z8- 'OQ/N.Q+>N!-!'8DP/$DHG4DX/%TZ8)PXUMUK:QCC
M32*)-X[CG&-[L;J;ZA.;&>0JK*/53P\3B8Z?:^R+,&,?3@'<.PZ!A ,;D9&B
MSJ*F+9GM-_T\1WX3.V3H2L[S&9C7S>\_.9SX+#5L[2;'.HI0>(MQ;KN*27A+
M:+I*8%+RZ_\'"D#UOYXWXV'K[K"D3SJE5SJEWU+!Z73U@9YLD!.5%PLK%:I_
MC_AO:RF7,2\AM_*GUR0B?Z>4;O:>FA)=T_<[88O'2#A7AS7*1E^3?B_M\E)J
M_7>,O;*\;OCU<>]2FU.<F[J6%C6<FOBB1[NT3SNU5[NU7SNVGW$US88W7YY?
M,0:XA_MB>$;N>K,WT;E^#&5UBO9K77F\8'2!M,I/\CG\(!-I/@P!:1Q"NU7!
M"+&9?:>[ 4@AVS9YXA63_; %7P9+*GR[V>N5^^EP/Z+$X_:8-Q!5+_>6G_M\
M9#O'=[S'?SS(A[S(C_]\-Q12<K+F!,^3N*\\RQ>2.*/W:(]X.['RF<$DF87P
M@[0I.+7R_W0+67]Z*\D30B-+4^=\G@YXQI9W>$JX:@=E; ][]$:O4)(9]CDR
ML=SYSX,RYF:?\G$,;QU]HOK&O;0Q+Y*\V9\]VJ>]VJ_]V6\P9L W$_)T:N@X
M!M  !M3]W=L]WN^]WO=]WO\]WP.^W^^],:W*R1?I!6 PDT%G: 4[1E-R$!LQ
M%?8.19.3-WE<!N_5.><6>/!/J5_&=Y#F734(0T=TR*4<Y%\TO VU0;,Y\D5T
MR'8GGLLK=\)'0"L?QF?3R@:&&RL;V_\^\ >_\ \_\?]UH_MTD5*98T@9>XO_
M0/*F1N7J-*)J1HG36=@#Y24J/.8S2-$/3(PE5CJ1GOE^NOD)"WX;ZO=]]5:+
MGK PL5+#D[HG/:%NC"HGM'K4V=7+?M9O+/3&)$ TB#%C ,$9,084'!A#X,$&
M!1,>M-!PH,*"!"UTT[B18T>/'T&&%#F2Y$8 )U%J1'FR9$N7+V'&E#F39DV;
M-W'FU+F39T^?/X$&%3J4:%&C1Y$F5;J4:5.G3Z%&E3I5HP6# SB(T+J5:U>O
M7\&&%8&#8,*L8M&F52NBSPR",2ZP6#N7KM:W5ZT.8,@0X]L&&"OJ+0OQ8.&%
M%!L.^*O0X<+""1'G94@8HM[%#O,2GAQQ;P,+?$%?_ZT86F'BQ@(]^]6,VD+I
MP*TG;Y;]T.#>OJ[+JJZ]>/)MU*LKZL8]W.'NX+T9#Q\ >W%F"Y]-0_S=F"#5
MG2M9=L-NG7MW[]_!AQ<_GGQY\^?1IU>_GGU[]S^M(IQQMF[]L!L$%KQ@GW]8
M' D+ZJ&_ ;EB03/!HCLH.05GR*_!&":R33$ KRJ((@1YR/""B"AZL+8/;4-N
M( <AS$^A"*]ZL*#6RAI1/@M'Y,$&'C8,3C,0;XS.0=.>@]$X@Q +#K7C%+3(
M+80..\Y!XB0DR#03J9-.R8J6C/*N(2D+\D.(,GK/(^P 4&DE+\DLT\PST4Q3
MS379;-/--^&,L[WB!BB!P),[:3!H!AON'+"$NW#HDT 6[E+L,<'XLHQ.(@O"
M  <:'GV4!!IBZ*PUZ>+K8RL_,!",LQ9Y6VRYLIY+--'2Z/3+L;LZVX\K(T;3
M5"M.52U2T80V.]2QY"R#;3?@<B/.,@ ]4S31RSSE$CF'@&7RLB:7310ZX$)U
MR[+#1'OHVNK0!-.D[.0,5]QQR2W7W'/135?===G_I<I(.P7ECP4D"Y(KWKHN
M>!'>>^MRH8_*"LMO(LY6Y)!*A!1"JX\>_J,.(0$+E-)'BW#;Z\ C&6116  O
M-<B"'+HRHC"(MYK70X,_O%!@;15#>+F"G9P2R"2O$HA%%&]&>:&!&VO6RI9G
MYDQ'F8T4]K&,(^*,Q>BZ? ]<;TE*J22I70(W:JM%HGHDK=OMVNNOP0Y;[+')
M+MOLDC0>@$]^Z^.A-AK87LOMM^".NZX-"DTHK_AH"RVP@?R:8:T2+JAP!GNY
MRH$AR4 -'."73=6VN":W7;SR&5S="E:"$-\J7VLEO-4Y$%-;#C1<=7TV,9\]
M]=LS&Y,.#+!@HS4-6M65_SQ0V-![\_M6HMT#4_@PM1OSV^U &I[XD)1'7DSG
MOQR>>:C/KM[ZZ['/7OOMN>_^)?D&XL%N?.6;883QPS(Y(EG15XL#8!>Z".$B
M5?2PH;GZ0'A$]K?"H:'5ER8SB\V@-0$DV(\ IC%2@>Q5%N*?5G(0,[<(#"(N
MNA",&+.CP "-8BJ*D,$0))]+)8U5$>I8Z*Q$N2?-3X53FMB#5BB_3Y$P,4QC
M3_.@YCSE?02'R^-(#XU7/.'Q$(?1&Z+WD)A$)2Z1B4UTXA.A<J2_&*%]:YF#
MM680J"IV)4\ $M\6TV(#OV2F;V5D$JD(0I<_\64&^])*6T#W%\O]#5E<:MVO
M?O]FJ?A9S@*9TPH0#.)&$1#J.!>Y5K4@XZO @0Y4DBDC7C B&"=997(.$]7D
M:.,:U?GL=@ADUFYJ5<$:1JY6?VM186X(Q.P@KX@_!*(17RE$Z;FRA[2<)11Q
MF4M=[I*7O?0EV%*D13"*Y3\7(=D61X!%/PX3+$"(R D_6+^A0<8Q=6E81.C#
M@DXQR$$:LUV0[&BD*C4I;1Y;#@,U5[X-;*IA&DP0X!CC3:+9+H"U090&#4,P
MRKB&A/ST9 N#)JQO,@J&0B*H"%%&P0>M1Y528^4.;=G*XZGR>4><J$1E2;U?
M;I2C'?7H1T$:TJ7X*@;,%,L(*+3,]GG@+H(T:5<PP*J"W)!&5X\I'8"ZT@<<
M8, (/)B#5WHPF()DB$;68@RK)'FK8$''II_!8\4N-Y!E&B$S,R!JX924K;_]
M[FBU$T[NG(27I'',6*Q1E,-(V)FGIO";_\SD)RG'.T0NSD:.K(AZ-)K151KO
MH;#TH5XO^M<C]K4CT -L18F'-9$NEK&-=>QC(?^;RZIV[J6O8A 5MQC4B BS
MLE[Y'(RZB<&546AG]^,*!]R26LQN!:7Q2VUJ$6*BES4(@XRQ6"&+-E#"O)5"
M'^N*,QGTVLH038*Z4Y%ME;:B42K7,25*4C1S1L"+5*F,+V*KC6(H4!>>K* S
MLZ=T%9@?%^$%KT&,:&+Y:MB+$I%JZCUL7M?KU\!&EK[UM>]]\9M?<OEJ .?K
M;%?\4)$^4C9N+"@<@![XWT$R<C4,0M5RIC73OW0%;X0Q'U?@B*L9V8##9($(
M#7H@(Q[TH%@TX $'_##(.1BA<+0EY3US<.(4#Y(#/,!!DEY'$'1JA:KZV7"'
M%05B$?/ J4;H05;Z4&/_FI5&:#B0\:QJ[&&G5H9+P<(D215T,,/@;I-NS:JS
M;K2[U9D*,[O*FV/*RS7$HM>A%@VL1-V;0S>O&<YSUN^=\9QG/>^9ST4!V-H4
MO)4>1&0&&*CBW 9BZ$!CF$+BM9]KB[;EX'0EF?-K8U<X,]43"1)SZ_P*"YQY
MT ?E@#Y?X0 )S(F1J19&T]+E- T(+ (_>+BXA?' 3\/" 1I4\#0X1F@&*>0C
MV?;,RS4SJ-"P.T^#QA"\M$D;T!0JD#0K%K'5IK-@&[H\]V;TS=ANZ'FIW6=Q
MCYO<Y39W?FWUQ45KY0(LF@_Z,JR7=7/E3YZ:9..V1;&TRILK%?94YY(9D1V+
M_V!S!1'D:L-2 B0AT@((%TL@3CF0@1=\XDZ-@2"/^97-T7$&#@\+#TYE.%19
MSK9#@N2PC--E9WV9K0W.=R@-$W-+H3'?T_YK?*%W2[W6DMOLM9K.L_US.Y^;
MZ$4W^M&1GD2E<7;1'.A87,87TXBH>]X\@%]PI_F@#UJH*Z@-#M5%@+>%K+HA
M+G5?WSX%!#7N%BZ_5<BJ+61VM&RH?C'PN%A*4#&3_V\@6T^1HW5;;"D%]&<#
MW5)W)38A)U$FYC9,S[8?JF:+!IW-X5;OY(/NUW GG?.=]_SG0?^FP)5TWEK)
MDWSD?B<0M$BEB_8P[#Y%Q[UEE2]=88&(>Y!@D0D\9%V!23U:  F:AS!]*QO@
M0*S=YJFILFBJCOD]6$@\*KT07RL<./Y7>%!'D4L?GB&B#,<UN=;;L?QVJQ&S
MDJ!C\63Q:G$SL+G/]ZKFP_9\:N:=K^;C&Q/XAI[__??__P'_T#K@:08\;=[F
MA=!B[4[( O5*;RLZ:"_\CN_$":$,@BX.<.Q"IH L0.YZP APP,E*S7.@) 8H
MJP]HX"\:Y )<JIC.J?<.8ODBPNS\P @<!>S8HME(D-)BZB\:0 6]XL;0JKFX
MZ=<\1#X";^6,C?  RI]6:&B\RT)@9.MLQ^9N3L[:RX<BC]IN;O[NKW@BRMH*
M*WFPT/X"L S-\ S1, UC F/4I@%%(/D2XNX(1(P,HFX:L-X<YS82A4Y>AG&0
M1'#F0F1R8^*<SRM8  >>@Y*L"JCB".S^)+4NHN,H3(XP)P-?, ,KPJ6<+B\6
M$=,\!>Q63T]4JRNN*$N$BE3L2(68_R-5U(K)!(\5ORG,\LAVDDH(72XP&$J'
M!BN]GD9K-(H,J6>6@LB\?I%KAE'^U# 9E7$9F?'SZ(?Z%,P/L,HM_$M0#"PW
M$FS1W 8A6 0"^8Y^7(L;:8,VYF(;$04&#>X'G^-((L+A_,!!9H!_\N<4Y2/C
M1(@0"6B9 *GL/,NU&J :M>*:XC%B *0@ Z0K-H2:&B-"2.2=+D2Z_ D)!Z^V
M"D_9  8Y7#&$RN*" D8B<O';>@ZC0++;($HD*8HD-Z\957(E6;(E[8O72*\!
M;8 P<& #;/(F<3(G=7(G!3$A;'#=#NR3JDSZ7H98-&;)U*(/8  2':+Y'$*0
M$&VLJ+$KR/^"()9)ZE G:9:)4G3,$MON531&D![1P@ M("_E*H6J("N1*Z1.
M=H;R: XI2TB*R\3/\!ZLY4#)=!*C5-H*5^1(5(HE-@PBE4YR.W@.)8'QVP[S
MVH(1HUSR,2$S,B73EQ2H $MO 2/QM31S,SES,_4C 17,9,KG#V,K29;#9KJQ
M8PA#+#8 !)82BT0('2^-*]J-8!S##GFL(>1P+8(*0IRRCUQP( 1IU_)I !PN
MI@9B-]6B!USD-$-DE!2(9EXD(J\K"2ER"5,H2ZSK&Z>S-GKD9!2B/4!2%X=N
M,<'MEB"JL!QSYU)R,MWS/>$S/L<&(CNQ 3E 5 PR/_5S/_,SX^9RK01$Y5AN
M@S(X47:><P HK#/S4^*"<S9GA0VI; "8#@Y_<B[PHRO!\A(S5"\$R<-BYS@-
MHD+78O4,B1/32JNL3#'2CUKJDKCVL/SLJ6+LZ34F"5%B)W48PFFR,/]V+FN&
M3CUYT=O(\#RG9]OD\TB1-$F5_Q1./J3U%HTXA3!*96Y*A= #W' KNFBV]D@B
M'"U^-L8MNBY%\I-!OE)S',2- LXBA+ KQ"A\!@2UEN,W5VU$!&D:'>,X!4-$
MW0>Y$.6#_G+9O$^ZB$TB:VT$G9 )86\Z6@9U1N295D=O+J)IEG12*;52+?52
M?T)V0G#=1&:#!N-3@VVLJ&PP%,T-">4Q3N623D5HJ,6IPG0_#;0'O;(!W(A0
M[&VL)M0@RK(^X+1,>2P^G'(YZG2$%,+A$)$@=K4NX%1H) PN*:=9K:L5A;(Z
M[Q)&'\Q2]F;*^'#)RDR.! -3P35<Q75<QU5;DO-*824A+L#Z1L#Z.*!=V=5=
MX?5=Y?^571>PT*Y4!)CSA2#D@PP*18RF(+J.M(QD@("3*X# W03I14QN('#S
M#2V$ZCAEIS# 42IVIS#68C^0]UZE[\A..+LB@FQ&-[EHZKAB8BLV95,V8S&V
MG5@HM! OXB2PH#CI4(^K(O\IU2!-@U3SE&114LDU:(5V:(E6)0GH+9Q4P:A*
M0Q6P(DJU :NRK/+RGEJ465[U148#!2N"Z3J5((936P$FX^[U:<?BM2AI'141
M56>@XIB6QX*#TZ0/(XR51<BV*CDS;1EL6D]'JU25$F]U=82#6F$1K%S1^Q*)
MH"HG5&9C((JV<1WW<2'7&0&'5MVPQPX63R*";-<-CG[-2!38I&.RS),(;6 /
M*%HCHM5 %L/&RV*(SV4 <2M*H!L+MC@+XW+=-A_=KC X37\DPN%.3V#IS5;(
M*I]P*Y_H\S" HV#2BCOMLE!?-MF, X-R0P-%ZV<R4E 7*G*U=WNYMWOOJZH>
M=M&HRBH&KC\0,='<T 4 "28717&3!G K)R'"U"TI)L>6CR]<2K.$Y@(>Z!$K
M M?2R6<KA6%&@_6\$@:]MBOR4A*Y @@3PC()+CYB[@((.$:9)9'N"=EHYT]1
M8TO,[Q5?-!8/KS/FJ*M:549[P_V\=X59N(5=_SB7/!<T*VOCDK8NB%-"KY3N
MNE.A9BL*3R@Z+F)@)<A@NU$?"</L1L!_Y /6?E MK;0K>F :"X*)V8(K]69M
M7=!V"8Y+!6D$#P)$Y>.)N2**H82*37 (F4M0'35::3%%_M YFY>#;A8[):1*
M8(98C#!:N4LMD>2%_?B/ 3F0RX9Q]/2EEG8 RI<_SG<&PC?02%24W U18.Z0
M4@XZYE?DIHPO*DXP?L_ZH ]"'713."#$1H# YA$#,]17(Q@C.,UQ[ ZF4L2E
M_&"4GRRGS(Q(0B3E\.@YBZM WVK\%MA:Z00ZFHLU9J=E>*.1+&<P!;F9G?F9
MH=E-CN9P2B]AXU10;O\8&O_+0VO7M@:CG" D>5/D=:M/PFS#=H(UE.=B!)P*
M2F8@!.I"C)Y)3ANTBXFDX6#J(3<5+>29FEBU0A8U>NL'@^H)F"=RCFT66O8)
MA(;PNV!6YJ(YHB5ZHBF:/ HE6?^K:VN8+A:YD?^KWI)E@UXG,(42H%QF?GF+
M=JS2*^LDI](BF6BN(BX @L6BGRN";56YQQ*8*^+H+>86%==U+FRZDC1)6RG'
MJ E-DI>W9LE/A LW,FK1;[D*:# R1ROZJK$ZJ[6:*!3H EQ@W@"I;0<DFZ$V
M6*#3W1HUC:6D1WQ$B)%KR;2XQ]*1IT& -:64T/8D+;3I<>+:8W,W=;?"B_&N
MF2MV39+=HI '"2L[1IY238X?$IF50TNT2PD3&I\N\KM&R':*B[E69*L]^[-!
M.[1;8H3RFE-935 ZNO3J[99%8U%BSB]]V4:LSR9'67@OR;8N8 2,S_I.;Z>W
MPBUH@*8W(*9 =?W<0@5C;02(#*FD:EYU3=6<.TNMB@-H&[5<F0;<U?JBEM<P
MIP22F\@ 1#I#6J:R\G ]>(RLK'9<%'?$KY*?.N9<.8ZR2K3IN[[M_SNKXT,_
MOGK1@$N5^X.LYVWW9LI04&B\\%B@<<,SM<Z$\H,V-G.\!"D2&P 'C, #6XQ1
M'<RU)FBG>LI1+MQ6<H,SRV<S4>1H8>N[.C.7\9K#><##3]PM:>O10 B:#,B?
M+H5;L=-0H7<XWDF?Z">@E\N"8^"^B;S(C1R04P2C#?FT^P0Y&7G>1B"9R0R2
M.0:]DP4P>(LT;Q63#L4@ P=N,W,=R]M8@B4S.3,K#1=7]")"U9Q1-JAWWJ(@
MK0O#S1P2QXJNM@R40OA4")?+8^>7FW?/ZS*4(.<OK7S*[*UW:./(&;W1'=UQ
M\\D"9!B,@$N+^P,KM=FDJM) 00N7N2N/N?^TY&"'MFRTL249TM19WV8WH$E;
MR[T<?.JG8WA8YGI80?@.'O-8%B%05"D&?(RDG!X;P5^[FT)+U$4WNW#VC"3F
MT^M.>KV8(AX]VJ5]VBG5RI03C+HVD>W#R3W:I.A0SI-9E(9KKI8J50[)XD3%
MXK(,/U$1L.W"F\N[^T9ZG[ LO%%PC&S$2Z42>6^#D@K=A(4/13W50$D'(RU)
ME_WRF(EZJ4&8O:]7T;],=$9O2XKEBA."VC$^XS4>,HV7IDTJK/V;/SHE(3(=
MC [P@ HHN0C(9O@5(X*=G"YR2: P>LTLPHU;R^3XK0_%>$,7<,/91Y8,N<BT
MV"'[>%E>I5G(II:&Y42 >%"S\TKRF"&)R[&?USJ)+:$+!KKP^%.B"4(V_NO!
M/NS/\$-*OHHT&K6=JMN'*4_B7*9$9.+?F\\[N%#F" 6CZJS&O:5YFKP377%!
MU6=)B[?LZD]/L31:O5KP_4>67L5Y)>'U$M7/G47?V^)MI&J=Q:UTG19'3L]+
MAZFB6H7%/O1%?_3_C<[!2KNSC.#ML!DBRKY]K%N$ +=#[!@<Z^=S#0F-U1AI
ME.OVS]G=14 BWA?GX7)DWYA+D_X/34-,B9^>-/O7A\MPN)5@M:Z-1Q7F?P8<
M8P\\<=QF==SJZ_C89!SJFYWB 0=H2?_\T3_]\>M0H [UF4]0N#TT62J\=^/9
M(D?1J_QW$*-0)*W^ 2)&@QDQ" X0.&, P1D)2XAX^# AP08%%5:<:)&BQ $6
M$E)LH)!C0H0#!@RL>'!BP8LB,X;L>'!@S)$-+) 4*-!"R9 J:][<:##C2HTA
M<4Z4:+2D3H0D4Y9L2I-G4I5(95)U694F2I0P;UKURC1ARFYDRYH]BS:M_]JU
M;-NZ?0LWKMRY=.O:O8LWK]Z]?/OZ_0LXL.#!A L;/HPXL>+%C!L[?@PYLN3)
ME"M;!FQ1X0P,$#M[_@PZM&B(1E9>&(W:,P:Q.%*[?@W:!E*%%!7J)&A!XPRB
MLV=8R!V#(VV6PST&YVF2Y<*252OJ9L@P^<;:R8L/3[D2J<';&@O6SHU<>O"@
M!E<R/V[0MU2@,8#7!JI3I]#K8B5^)'[5N/6KX!=.G2K==4)-=]%_]GD7''"]
M^;>??!I1=%F$$DY(88467HAAAAINR&&''GX(8H@BCDABB6[!I)D-L*WHFA$P
MY<"B:*L51$.,-H:V@5A%R9332R.)-=2/+245D_]-V@U8X$=/^032D30)F1])
M1CXU77T"[702419I9Q147GF4T%)9_AC<3R01&%1%5SJ)4W<;=?D5;TV=&=9.
M54DE9Y[-W<GG?S)UQ2-(6R+Y9@,F'HIHHHHNRFBCCCX*::223DIII96:IQ '
M-V[Z$!"XG<8I1!CLU%JH-[)P@97<%8C=;@D*FEY*O+UW6W4!ZOC>?EL&EV6!
M0**9F7&_#C6>@BP!5Y*2&\VGWJHJV08M=]'"6B9N\JGGZIZWAC0@M_E1MUUQ
M[U'D7I(LS8H>@'F.A^YZQ0KG&U&Y9CO>#(L"@"\ '^)K(K^/^4L6P(<*W!;!
M?.4+&,*6TI4OP K?];"L8@WKNW#%W4Q<<<,6;\QQQQ;K6- %+I@:HQ'1P4@R
M#D;62'*,./P:;$PAR=121VO^1&5&Y46WE4_:7G5>?4[-%%.2&0$J]$OG9E=S
MF'#B.=&44!^74Y#9D10G4SM"771/S=6$9Y):B=454%AU&V76? X*])I*.:7F
M2;,Q]W8, T^,L88:C[@W8P_W72+@%QL<L5YX&US7X1ZSE7?>B0M^F..+0RKY
MI'A/CGGFFO^'&.MF+:]H<GN@FDI#2*5^_AH/T=%';G$K&:M9NJRG>R!]M>8:
M\[.]#N?LS+ZRW=Y]6@(MZWCC>5LMK;X_^"ZV0=--[[SLFNLD]%/=IB[MOF=+
MI9]+UX[VK4GQQE&3Q&:K?+(W/VLOB8>_GR'D'LH?N<.%\UWX_??;]?[^<?6/
MN,4UCGYOJ5S]_+>Y?A'049=+H ,?"$'*J*<B*D)=:ER4$)29:D8S8)D%49.C
M[L&,/'9JB<PPLIRC".=*4AJ2S[K%$;<MYR5#^MF59';"EORL2$*:29MNUY'E
M,.U)1<(.V(I$)!L"*4Y">>&.@H2VF\EIB4*3H?>R$L4FZ:QK(CG_D\X8PI2:
MA$D^ZW%? P=W1@HAD$-K+,S? A@B_1$.CG(!8!O78D>*;6Z =\3C @5CP CB
MKX^*2J,@#XG(1/H%)0QQR =%4QJ.C"Y4JRG)Z1X)FA&DBF[J$Y90D(7">DWO
M/,J;#2AOM[2PF<]-\KH(N-H#+3"Z"2=AZ\VX?#5+ZPPH3+%D3BE?<A\"=3(S
MQ.1>^,)W2ZD,TS_K I:K2.E*VJ6K5KFC95&>QZ!RN6J0= RD(O5&1P;.48]X
MR2,YZYC'!/(QG(S[8V"\^<T-P5.<[HRG/>_YS1[&0%.8_(SJ$C))3G'0@_WL
M3!]2128Q$DV&+E0ASE1XE#+]B9=#O*+2_ZR2LZ$9[4D,U6)^3MA"(C(R9U[+
M#*:JEI5J*<=/40EEUM1&IRDV49\T:VD6Q99%4A8EE)WS4T;#!-28B&B> 2,D
M/BMCU$3)\9R/ZYLA"[A.=F;,J5)M)U,/6-6C7H:HC'JJ5K\*U@<N: 0%[4P/
M%C(#'JAUK6QMJUO;:CPCE+4S+/! ?62:PO,U+S[6>25]=FH406T+73U-YC/1
M-Q3@S9)\K>/>=F2JS>IP28N]?&:P!/LMV8$Q=D$[WD>1Z9R5ALE\:?N>@#Y*
M*SGUIYC!]%U?3YJ>]H&HGH,KV%6+BM2L)M4MNU7+;@G86Z/2-C%+-<MO!<=5
MM$@NN;Z];5IZ._\8;S+7N,Z%JG"KB\:L/A>[U/4C=ZG[W>XVEW^W;2-TQ]M<
M!&I7O/\++QKG8K_A*M>][VWO >%+W]J&=;\+@]L,+L""N8J  [_RS6\.C. $
M*_@WFYV!(^?*@I?!3*.!2AK8KN;$@HB49\/;E4(M&K[X;%@I9,,(?N@&(%;Y
M"*1R*S .FVBD:F$E)U(;FTFPMTJ70/.EM4J;C7VHH[65%HM1XBB/@O)");*-
MQ)V5#'3E.U]]50Y^9U&O5>M;%H11.;T-[*/"M@S>*OL+S-M57)2S3# MFYG+
MT[6R=[&<73[&^;KY@[)5V8FQ-9?YJ5->JGL!&.4Q[RW/?(8<H+UKQZ([>EEC
M9#XTFO6\9T9+NM'F5#2_M@QI2R>5T(7V\Z$Y;>A)+[!_MDUGJ2^=:?!V.M6/
M#F"?6=UJ0#N:O[3_CM2\ "Q@#'A6.<@Q&U#($]""5M(I"_G.[*A"S5ZV\DBZ
M^0ZXF.?,\D6S>/!:]GUBV9UR::8[L\,.9P?%/'B!TK%->D]Z>HP3:A9[E(?]
MC?1X@V/3IC#<KHHL:J<-6E\BJ-J# FV.J1(\]$#&JZ7."YA-K>CT*AS.<V9U
MHA>-\$>+.>(3)W68$ZYJBP>:S L_<YDQKNE!4QS1&S\85\U9WD3'NN(5#V^E
M5Q[GD%.ZSBK/N,J3BW)RSKKF+7^XQG-.,93+/,T<1S3/8Q[KF[\\Z45O>""!
MSENA1UK/LRZYU9G^])P[?;VU[CJ(P"@1' 2XK"R Y59VIE)OFT=-^Q2P_PA,
MQDF<_HZ4S)P2TU*RX1\%=2D<WMF2;'82Y%"/2D\B$]W&A,)DB=@I-!.30Z,#
MJ(UVS2LZDVBAS@Z\(P&JEC'=*$MYG?@A;W'(&^X92PRD%"]67K9^@_6>#1[J
MB"TWY;0'><A5??6&6Y?FY^0]T1&'7,"]L?>S'R?Q%]WQB=M^^7/&?3GMW'.I
M:CWZ:WZUP' N=:1'=>?"S_[0J8S][&M\Z_*#^OBA3G[TIQ\NZD?Z]\T\_?<;
MT/OR/WG\L7[&\;,Y]_1//ZBGZW4!"")DI! >,'8%Y0<\< '!\CMYU1L*<0%&
MX =NMQI6<EJLXBKI SU:$B"WI!_B@3L:MEJZ\?\NT.1)CB5*Y6,;W+99N^(?
MZ=$='EA,M(1NG;4L>85-:&-8R40ES80\C#4]X*,C1C1X)_A*0*A,D'=XT40^
MC.<KM.0;V]0857=EL&=\R>=I'L=PY?=[M"=]7'A]77A5P>=J8:A'O/=QSJ>%
M59AQ6EA<++>&# -]T<=^]'=_CI-&]:1^455_LD=5W@=T0:>'Z/=S=FA^F$:(
M@8B(33=U-8>'B;AT_N=[51>(47>'XL>(,*>)DBB&Z:1_ @B*)O*"$'B ;F>*
MH1)A$U8K9"1%A1(U4$1C1"0U<U<57:$44_)X;8)%1/(E1F1"Z8)9W')C)L1+
M5$0T/^9X?R<SO9AB,J7_41Y1-DNR)YW')G)B1%7D418%4=[#(T2X0RSU8A&%
M=XY!A6]FA4RU1L.7>R"'AFG(?&IX9R2W?,#EA]6ECO/H/_7(AN;8ALK'?'Z6
M?.@TAS;G<OE7?)VHB08)<>VH:0VI>[?GD,T'CX8$?X-XD()&AMWWAQHI:@A)
MD#+'=/VH??1%=8_X9=9WDB8Y?!MIAAXID2%Y:O4HD\>7DG0FAB()D2\)D@07
MBCTY(DDX V1UBD-I(Q'&@+LB;=_&(-CB'>>!;1BX@^<#//KV3->B3,%2E?O!
M2,93;L52+K/4$\93;4786N&"+;?!5X>E@T%H;$B)@DUX;R>X+1Y6A+=RA*FT
M_Q'JYEH_\TIH26_F0XZ?R(]&]X>!MH^3>''XZ%SW*(\%QX8TYYC9]9CQY8_N
M.&I?2)-FF)@25YEQV%XU.7).MWLW&9$X*7)=YDY>A8ZGB9&^!W.JN8X0&7Z>
M)F4H&6F;F'0ZZ7XVEY.]J9)<IYL2R8<;)X@9>8:V69H)"89WM&JM.8:LJ5V_
MB9/*N3^7PY,^B9T?XCP6L0%$Z9VO<5"K,T/8)$58PG?=LTJQLCY;!!4ZMCY<
M,3:6MU"79XRM6%%!93;0PYXS1(U;$Y_2B%)GTS:[2%F.UWE@8T.!8BY'A">U
ME$4)BF%=\C7:@J!P@U%!$IB9V)F->)J>.5^;J68ZIVN9FUF9S(F9D0F9DQE_
MC/F.[-A^@QFB(#I.'MJB,5F<_2>:-MIR^'=P'1FBF*E;T-F;[C><HSEUR;E_
MMSE_RWF<U?E_L2F<R$F= +B;_5BDO*F;OYF9/%I]3,I=T@6=ID:ETLFE"@E\
M3YJ=:?]:(FXY SWPG6\:&B.@ !9X'@HB6:E5$*MR+>2A/<N!5P%7I[K$;>I&
M6HH530LB.Q>(GND6@T&X3-FCISQ!;ZC$E^PV15!X+=<#6M5#/KA1EMDCA* J
MC/DI66LYBC@('A;Q+QI*HL19F!OJCE@6HYRIF/QHHM]EHK1:HVA6IJC9I+!*
MJXIH71*GC[KZCW 47%IZ=#T7DU=7B2N'HU":I%<:D=1Z9UYXH[A*/V@ZG:^Y
MK1TIK=8JI3E:A_DHI%7JK5F(I,KJ:&!ZJV4(FF)J9]S:ARRY?U2JIODJ(4FC
M$$90BG#ZG:JS$YUUH6S"47YJ$_]6GL1V,W2#- RK4$_4-H+_8D5:PHP5MD)C
MTFM>-(N!XJ!0PD5!M7;&6&3]UIY\1XW]Z5*#MT7'J(TJ"R=M$HLQE(U-J"SH
MT45-LJK7&:O#>JQ?.J+WF*+&FIBW"E4^6V=(^ZPLRG!%^ZR.*;2_YYGJM5YY
M^*+2BIM$^K2<.)M_=JY+NI+9^IGPZIQ&JJ2Q1[9B>[;J:G5@2YI8-[;8ZI#N
M6K8[NJXL^7)T"[3F&J^>.*_@2I!*Q[>H=E[Z:K@29!X,<0'=";#>R0*5Q"56
M H-L68)V@H&QI5E^]4P(<B0,"QQZ66]:23[]T8#F$DO#XH''0[I<HF^R\EGF
M895OF4JVLBZX\UGWIBOO5KI &*I(_R@T\.&4.T0NUD@O]!(9^'I<OPJLG9F2
MG#FT-<JT/1N0VV6LN;JKEBFU'5>X:1BUQS>UR!J=*.FWQH==;MNDEZ@XK(JD
M1C>W:'N^:FNV;6N1:8NN>KN^,6>^T^J^=DN'\6NWUMJ^;)N_]7JN6)NU :QU
MR/N)PHJN#8FOAPO!DS&$*=*X0[D!"#6P2T1&#M5X"96P,Z:PZ9FQVUB?1R9X
MP>0<':LM@+=0&"N.)R8U+\3"3<%WGB2Q)O$U/?.Q4K)Y['%A--,C<^* (B2@
MP+C#>G)3C3J*-/NQ#34T3#8 <;1IE+F\[)6;6$JB5*N\^SB8V.N]*HI?6PR]
M5-P7% FVW_^[F$$ZD'=K7OM[OX3IG(349E_KQB-ID\]9P->*QX1+OK>YOM99
MQU@ZP <<G&RVQVJ;=7E<K74\QTZ:FHE<MY8(G L\7)#,Q_D5P9D<&6!7+QCP
MKQ6,2?\T+.L6+],$6,)16:5[;)>U:]6Q*KKT.KVF$;W#/JQ<.R@8-(*"PJYC
M@<Y3RQR1J80%("<X%7>)@NQS&V:9S G2NLZ&):8KN\YDS'OI+:-:JIF5'HX*
M.[\Q5'(\HO"(QHBYH5K<JN \O26:O3#:363\O,R[SEYKG*LISS3:M(:\%^/J
MQR+Y='J<K6I<G?(+FLX:IL]%G 7=P ;-F^:;F>^[T+5)FP8]R*7YV9+:ZKZ(
MK-!L'%]]_,='RJPZVM'[S+\"V9P$C="Y^<":C-*,$1WUD1!N"LJ8M %V%60[
M@1!EDW@H<<.)U<)0TC-Z=XT/A5,XG': 1;*\R#,15<)DLM+#"!,36V,TB[)J
M8SUN4L1(S)\U%4,W'8,WO'=18U,<?,0X-61P$F.S(<26:\+$%C3<),GE_*UG
M"M=X7,4RF:2GILXTV<5:O,7M+*-I'+YQ+;UO*+T<RK,<7<C=>I$BFK:*/<4<
MR=@6+<!X.YUFJLB&G-&1C,4EF<!>"K?U:YRM!MJC&;;O>\4Y.L@1;;7DR]!X
MUJ6.S=C=6JYO3=<=+9HGG=*W_XT8AJ<9.""4+]TR+& RJ],]L3.Y*QA:=FI9
MS;+*U.&,KXS+R=TEM,$<=JH4JV1:'FALSTTH4HE85@)O/WBH /*H[8*4*AB6
MNR$5H M+JL)*QJ-D<7F!O%O-O:0^V3@<F@MMF,I-?IW.<&C.EO9Z<4C.YES8
M#:R1(1W:;EVL6PB^7^S?L1W@L"K8]-RK7!>MB.W:@IG:C;UTPWG:>,M]T]>U
M\NK((W>()9ZW@:RU@DG8BWC9)*[1GCV3E'BUKAKB"'?2#F>(F[V]N.WCA#%A
M#,$#G^S;,=(#+3#!6XE94M* -80D279V(KM*CD=3/(U1/N,G98UB2$Q-9=/3
M.80K]/]9>35++&3^NS_TY5?!H%C^N]Z()%NNY"7F0PT:>B\KU3V1L'&#BT2R
M>#Q%TQ,E5/O=MS0*R)>9<@$YX('K>G!KQ@WMT"C^Z.G,U]7[?YA<S_J%QO3<
MQA?.SX4=T9Q8UP?=Z1L.V3&>V!P'B4"*X[*MX5*GMX(;XPBLOES[V(I>D9'-
MMO5JXZQZM9A8N//4?R<.G#].[$ ^-XK[8$7.(B,@8;V<E 9&O,G$N:6J;,>Q
M;"F8>15!NHJ:'1Y5/.AM@MO#@*>:W9>Z6--VYK;;Q-H&%.N"/,6K;]GF[7")
MW*WE@K<D@_ -W;[+$^U&S9XJEEO"@J-5+ H4FNG(XKR*7@+_WN"$?;T)1X60
M68X\ZH;]#:P3'W5^-+T37L4$;.GK)\GRK-H\B;;DI7\>SL@5_>H6-^+G1X\)
M+XEO+.(J?NK^?'3BR_(IG^OU9]F\'JT19]M$%9I<*^K%;O0JK282,0,XD.S*
M#D(5.+"_$XT/BWER0WA<=)]"DB7L*5AL_C8/>V1$4D.ZJ-322#1+XJ!G#R9P
M/BPNRVTCE11-'=U57?4?);G<N.?D(_::H=8J?%-$=D7H\<(<MF)A)(M.43:(
M@O&;;G\:W[/OS+Y$R[T$EZ*+/G1>+&9<W-F/X_@>.D>:3WVSSJ%Q&ZZ6#Y F
M;\FR+M"0SMJL2<C_"\DV6I"1_$>^_TK:""Z9'TGZA6S)-YJU9 K;Y$J8 ![R
M0SKZAME45>7SKD_\1^_\D(&#FN$!+NWTH0$"%2BY3OGLW,;*KC-,A/7,'XBY
M@0KO>\G,]!*[*.Q8XJ\\J^B#H]5$97[=S>$MU"+,</G^J5L[Q**?WPT0,P8T
MB"%0(,$!,V8@M("P8,(8"!<^G!&1XD"*""$2-(@Q84*.,09 -"BQXH""!3E"
M3%AQ)<J*"KO-I%G3YDV<.77NY-G3YT^@084.Q0G *$^C 'XF)7J3:5.H4:5.
MI5K5ZE6L6;5NY=K59]*C7G6"5>H4K%BT2\^F9=NV)UFW0^'&I5O7[EV\>?7N
MM0F39,L+);1$#"9<V/!AQ(D5+S[<PX/"D7YA1A1(D?)(EQL%6AA@X: %SR@;
M5'X9,?1E"Y=5C_9KT&),S:]'CGY],?+IF)0MTSZY^Z/+AYXI=_PM>G=J@1]3
MAW3I^J7SE)@C_I8-&R/LA=29;XS^<++KEIT[3G=.6OONW=#5?VS >3IJT<DQ
MCUQ=?G9$OOGU1UV;\^G;L*3Z;S\""S3P0 03%&HNNL@*T,&R%)R*00DKG(G"
M_3"T<$,.._3_\,.A%!))/H4:N,"($1A3<446"W.A#QXN4 @\Z9([:2+I3!()
MHH9$8FXE[*[[JZ*&AAR1,\ZX(XXCB=A+B3@>">H1QX0XH_+&!IR$[B.6/DHI
M)"!A>JXZS+($KJ0O;9MHO8-VE+),D=*$,DR01$H2QS5'K&Y/-H6\DDPZHUN3
MN_!Z[+'*SNK,<<090'0TK?YL&A"I /FK]%%,,]5T4[LT; M"4#FE=%)1\?*4
MKU-+57555EOEJ3(29YSA AOZ<*%%7'-EP08<9HQL/N],,]+,C8K=[%CZDE/-
MNOK$>X\U8<GCKCT;8?U2V?:D#2VYTVA3+KXO<9MO.<OBXQ(Z:&DC__9,V;Q\
M;EKDZ&/M3,V4',A&X[+%UKUTT\O1.>IR/(_-R^BEES4KY5UOVT0?\LVU1EV5
M>%2F( 2*5*(PGGACCCN6,%6T0+5X8Y ]SJKDNU V>6666[:KI1U_G1&##OK(
M]6;%2C B/!OU)*G</T_J,C>68F*HSN2 W)'H&:Q$$M$^@1,S9CP39KHV,T>4
MB$G+[B336.EZ;/+&^:3&M\TPQ1[Q-Z6!U,A@,,G$T>F6W%[:HD6W'-1@/]\&
M=&V6Y"2TY\%+4R]BER4666/_+FV*\<0CEWSRQR-M</$(2;:<<JI4KLMSSD,7
M??2^1)2OI1E/!($%G',M@0<<1H/LUQJY'/]H.5B+-7:Z?^/K-MAT=8\M2].Z
MF[==XAHRV'ALDV_.LN;7EI9=A.6>UEIS@=MN8?7N7G?/X]_M'K+:)(-ON.G3
M!YC@MMGWCC5W!U:XWM6T([W44!=T/./][_?_?Y.!KBLB"^#F '@Q ^Y%@ =D
M8 -9-:.8R4Q6..!!"3;0.L2,8 .PD]7L9!8=)67D(1(Y5-7\!C,_=29K5B(A
MUZ"6,/E9BR 2N<C6M/.SK6E-A^%!FKU(M+8V\<TZ48L,W 1GH[:),&_*B1N4
M$E62'IHM=\M;21([8K<E!E%+1_P;C; #O1$Y4(QC)&,9S7A&-*91C6MD(U9,
M1SO,='!6%+3!!C9\D*+%V'$#-H"=C#H(QR?-IS,%"YRRR >QO^@F7<AZDG?(
M%J_F3"99%OG>#,^6J.V9)E[.FE=KS >>=A6,DI",4R1) [SE#*QXXQ%?^<!V
M,*O))C3N"I<D YF]4(9/.^9QGWVH6,,;LD]WO./=[1#71F0F4YG+9&8SG?E,
M:/]&$RI"@Z,$Y=@ ;#;  QBX0#;E^$?:D:V08)RAEH14Q:4I#6)VRA*<<FC.
M(=XIAB$T5#NGAB9QBNE@(YQ>$HLSMW:RB83S9%MUXG8NOPEM35;"&WBT=ZXA
M<LF*400?]'S8-^_5T#:-G&B;%-4T%H+QF-(D:4E->E*4IE2E*V5I7IK6R-,5
M$77?E!4@?W7+W 1)-#*EXA11<Y%FX? BD<3=3EVR''*1C5[G$D]GD$0:A<JK
MJ$!%)+N:%T+J+/640213^8:*O! "3'>Y4PYY1#G#C,[PJ;@LC2[7E[Z.GA4]
M!SD;7"WZ/&;-JZ5[Y6M?_?I7P 96L ULVCJIR5-?.?'_+Y*Y&NW>!%*T7M&B
MAO,A>HI3V:P.B4X3L9OV&JE"1F&FA+$,6];::1L5#LZ=0!S<0LN&$1AFYZ)J
MF].1U)E1%*H63;^)R:%F:UK+[JV+BKIHD\;9T7<NUD\%&6QSG?M<Z$97NM.E
MKE=J:IUJ5E-0?O%.[SAJG6V!CW[!>VLEOQ0P)1$/6N/A&UBAA"SW" TW<5JD
M9*::+=Z,2VY86Y^\ND,^YM@56=H#S69\,YNB9D;!6#7PZ0H"57L)!WZB[.\O
M?5G1I.%+P,D:)K5VVH#JAEC$(R9QB4U\8F=";)9P[&UB&P5*A:ID:><ZX@EY
M1-$<]NEG'YU;#^]9IS UD9*"G@L8"Q$54BT:K5P79?+04F(U8@4YADU$5-&6
M^T5UJI9+P?4GX0QIKXYB-(LI##!R=[@F&BK$ BAF<YO=_&8XQUG.B?-,>7CW
MNP73TC[+>N7#X!69]C25JL"#*FN_=DD-1S:$O)%>\$;2+0A3#UWW[5F9MPK"
M]:B26WY><&:,NFA>+G;#DZEO)#?<T\I*N<)\XG D83+2.<=:UK.F=:UM_WUK
MJQQR;.>MJQ%[/*C6R*:%0)1Q3N=ZFZSQT(=QFQ+6AIK"H2G-:2&I'=^D R=\
M-KFJ95IVFIC:I+CFF,G"1:= 8U D)V>9;U@L[D9S8^:/[OHCN*9WO>U];WSG
M.\2S.R1JDLJ[3.-Y?F=M\%AM0]Z-(,<[\1UU1V99UTRJU5[F<I@NV5J\]19R
M?@1^C7H5GFA'AC7AH>XTI\M'\OH1S-1N/37X>GFOLHW:HO:%M;YM?G.<YUSG
M.W>@A!W94!JON]A,3#?0/-(TC4264:5\CJ+GJ?3KG!NM""7VWE+[Q1+=36^_
M>1K8E(;MK+Y+T9L9>V1D/*QCAQG'=^UBUO069O]V"YW&I#XVGMXY$<_P7.][
MYWO?_?[W1X4WT)/.GG$0^9V%FRO8>*U7H5GCX?V6W7I-5<[X,))QT0@'6U;F
MERE=B?&"*UBNE1:B+"?-K4('<[SGT=?&S6K>=9;:Y.%^.<SCI_)6JP3PN^=]
M[WW_>^!79: &"])C6<(0>W(6B.@4[;4+&>B?$8G&85(^<>1T?3H9*8A86OJB
MJFRVYC<M8$&C-I!G/'T1EOY'.HSKUK-MMBX+K.A)'NZ?@JS1=]?][AI9<_#]
M_W\ #$ !W+EWR[1 TA[X4C]_P9W$X[-BHBNPJ@U6&J$K>BU:PB\(>S!PV;/P
M*3DP8;AJ*Z99BJ_N^30IK9JXTSFDV]L=V/.>S/+ A7N]73)!#&N\&CP(U5NJ
MR:JY >Q!'_Q!( S_0NFJ--M MQ0Z"6HC0NN#F!PRB=0*J4-)/VDQ/WRJ#;4I
M.R_2(2HYNJ]#.^(0/R3BIRJAH?C+#G,3.B)Q"/=9NR^<*+A+O\KJD[BKOTFR
M,'-Z&R',0SW<0S[L0VDJ#JP!C6.C/'T9/2$!1(<K)8=Q.*XB0NISKW_I"'81
M&.SJM_RBN(R[M$DR')]RJ[":L1-<-U<[JQ<4,!?DP!C*I?)*Q?9)-0J,.=C3
MC-'P0UJL15N\15PDG>NZ/\GBD=@BDY!2P\*)-T5\"="Z+*$[*!E2D[;9L3M)
MDJL#FK+[/F(D+CM$HM\".JEA.S>L.[!;'CF$0_CSQCF\O[GCHKC+175<;D=V
M;$=WU)28,)VZNXS,4[QHD<3+TP[-FR)8)"4PF2=\V:02W)T4E V8DI<A@9?K
MJRI_@<'> +D!LQX97#6$F\0^,RU6)+1AR<@+FRC;0SEU>4>1'$F2+$F3/$F4
M3$F57$F6;$F7?$F8C$F9G$F:_ZQ)F[Q)G,Q)G=Q)GNQ)G_Q)H Q*H1Q*HBQ*
MHSQ*I$Q*I5Q*IFQ*IWQ*J(Q*J9Q*JJQ*JR3)+H "*+")K-S*FNA*KM3*L/1*
MFLC**0C+L_Q**$C+LEQ+M'Q+M63+F9B"K+0)NB3+N:S+FKA+N]1+FN#+O?3+
MO,3+;@#,OQ3,PD1,PQS,OB3,Q4Q,QU1,R8Q,RFQ,RPS,RL3,RSS,S.3,S<S+
M+NC+T S,T3S,T@1-T4Q-TE1-S]1,UVQ-V&3,UYP)K23,VK2)VZR)W*2)W:1-
ML=3-W^3-X/1-VQS.;NC-XS1.Y%Q.XWQ,YYS,SX3,Z'S.SD3-U;Q.TV1-Z^1-
MQ(2"[G/\SN(\S>,$3]PD3]TT3^ZT3?2DS?4<3_5\S_*$S_.4S_2,S_*4R_'$
M3^_4SR[@3_^\S^F$SMF4S@&ES@"M3@*-S0253>$L3@?%3>6,T <%S@D53OUT
M2^"\4 V%4/PTT (54 7UT! %408MT04]4>:L4.*$_U#"O$I<:P*PI(DF\$Z\
MG%'!M-$:I=&:L-'3Y-$=]<X>!=(?[8(@)=(A/4T@Q<LD/4_!7-+T1-*LA%+O
MG$\IK5(JO=(GQ5+VG-(L[=(MM5(O=4\P_5(M%=,RI=$Q-=,P1=.O)%*\)%+!
MA-,W==,VA8(FJ-,[+<NLS-.9<%,^[08_;=,N^%,X)50B-=1!%51$752U3-2V
M=-0^]4Y"E=1&G51(!51*?51+M50NQ=0H?=1.C=)09=-(_=0^==/2E--4154]
M-55 =5.RE--8A=56#4Y9K=59W4U8S55;[4I>_=6VU-7:C-5A#59;+5;B#,YA
M)<ME;5!E1=;DW,UF359FA?_6:8W69Y56:]U6;>W6;/W6:M56.O7-<4W.<M7*
M<W52<_5+=/5+):#5F7C7&.T&>0W.>B7+>\55?3W5>;W54]71?_5+5,U5@155
M/0784GU3A/54A8W3A3584&W4AIU3(VW5TX33BX530<W8BIT)'!W2'+W1A851
MD2W9D#W9'9W7;H#1X639&E59ETW9X?15M9S9WJ198W51>ZM-)$57"NW93HU6
MH%72WH16;*50HAU.HUW:HFU:I5U8="7:)H5:JIU:JY5:K 7.J0U:GOU9KQ7.
MK05:L?U:<LU:L#7;LM5:M#U:9T5:MSW;THS:N"55<^U4N6W0CN79N152XLS;
M=L7_V[WU6[X5VL M7+SE4YY%7'15W$P56L:% B]PULA-ULG%ULH=ULNMS<SU
MV63=6[OMVF1]7-%UUM$-W?2TT]-%W*Y47:UD7=3=TM<54V:%6-E]TMGEW-K]
MTMME5]I%T]W]7=L-7MT5WMPM7M\EWN,=7N4UWMX%76SU7.AUUNCM7+P-5W:-
MVNH%7.WM6\/E7E!-5;H55?!U5?']7IIX5]Q%WTY5W])DW_/%67J%7_7%5_FM
MW]V<W_>]7_NU5_B-VFJ=5_\]VW"=696%UW^=4YM-8(55X)I=8 1^X#J%X(,5
M3YVM-;IE6(G-X(CE31O5S0[F8*[]8-H4X>,D83OE6MP5_UJR5>%@O=@4[DH7
M#EH8UN"$I6$,WN :QN$;SF$>'L]W95(E+=?Q;%(A]LX?YLXC9L\D]F$H76(C
M;N*>A5'@E&+AI&+?M&) 1=^OU.*RY.(^]>(L=E@&SEDRCM0Q-F,5C5867>.:
M9>,&=>,5G4_[E&,ZKL\ZWM(YMF,]QN,[=L\\YN,]]N,^7EA!#F1"5EE,)4Q$
M1N1#-LY%=F1(5N1('DM*;F-+#M9*QN1+-N-,YN1-3F2N1$PA?E5%%F53+F7"
MG-%4-DY5MHE65LL_Q=18WM.PG.78O6((C>76S65>GN+RU.5+'4]@'N9?+N;S
M).8S=54U)=,U5>8+?F9G5N9#E3[+:6[3)J#F0<7F:[9F;>YF;OYF/=UF#NY/
M#R;G<99+.S7G$5;G"FYG=WYG>(YG>9YG>JYG>[YG?,YG?=YG?M/N9W_^9X .
M:($>:((N:(,^:(1.:(5>:(9N:(<F'3>(Z#:(:(JN:(N^:(S.:(W>:([N:(_^
M:) .:9$>:9(N:9,^:91.:9.>:(EV@X=^:9B.Z39S Y:N:9J^Z8G.:9S>:9WN
M:9[^:9\.:J >:J$N:J(^:J-.:J1>:J5N:J9^:J>.:JB>:JFNZJ?>Z8IN YG>
M:J[NZK^R:)N^:;$.:[)NZ;$VZ[(^:[5.:[9&:[=>Z[=N:[B>:[FNZ[B^:[K&
M:[O.:[[>:[_6:\#NZ\"V:9:F::\^;,1._^QF(NS!;FS!?NR_AFS'CFS*GFS+
MEFS,KNS,OFS-[NR69NR(5FS1'FW29B"*UNG-3FW/5FW.;FW6?NW5CFW7EFW8
MGNV[KNG2SFW=WFV3 >VV%@.;!NZ6%NZ;)NZ)-FXW0&[E#F[F'N[F+N[G/N[H
M3N[I7F[GOF[HQF[IUF[JYF[KSF[PWN[P[N[Q_F[Q/F_R1F_S3F_V7F_WGF[!
M#NO0YFWZKF_[=A3.%@.:UN\VX&__WF\ [^\ _V\!+W "/_ !3W #5W $7W '
M;W (9W )?_ )CW *OW +S_ *WW ,YW -[W 0M_#&)NO[+G$3/_']V&SA7O'M
M9O'N=G$8;W$9?TOQ&8]Q&K]Q&\_Q&M]Q'.=Q'>]Q(/]Q(?=Q(@_R(A]R(T]R
M)$?R^'YKET9Q*(]R*?<*VJYRVZYM++?R++]R+>]R+O_ROB;PSYYR,B_I<S,?
MBKM>\B-?<R5G<S5O<SA_<SEW<SJ/\SJ?<SO/<SR?<^%&;[&>[S,/=$$/=-0F
MZP\_= ]/]!!7=$1?=$=O=$AG=$E_]$F/=$J_=$N'\/XN<+0>=$__=!1O[#V_
M<U+7\U(?=5-/=51?]5-O=55W=3S_Z2<'=5JO]8,N;%PWZ[/6ZF[0ZTRO=&#'
M]&#_=6$O=F(_]F%/=F-7=F0O:UZW=6B/]GL^ !% [K]ML+YM74]S6,_V5]]V
M5N=V;>]V</]V<??V5-]UBI9V=$]WG:UV66]KWX[K9H]W9I_W9:]W>;=W>K]W
M?<_W"0=L=?]W@/]G2M3&ZK]^=[@.=W)'>(4?]X5/>(9_>(>/^!^'ZX"O>(O_
MR5RO;8,W]/W&=X_?]X_G]Y ?>9 O>9$W>4Y?ZXM?>9:G2<PFA$2( T68!$6@
M YN_^9O'A)E7A$1@A(.7[H8/>H@7>HD?>J,O>J0G>A>7]99O>J<_R3]O:T:0
M>3K0 PP:##V@ T6(@SVHZ0,7<+1&>;$_>;(G^;(?>[-/^V:7:/XV[*=_>[C/
M179O<4( !$SP@ZM7$4U0!#L ^NT^>J4'?,%/^L$/?,(_?!L7Z[C72<R)D 1:
M?(>F=I^F:;NWF;S/%3_ !$ @A(YO>[4_>]#_?-%'>](/_=*_<(D>K,<ZOXK5
M]Y#65Z#7UXL%@OW,$9#:IXG9-Q 'X8K8KQS'_X^SV'VM@)S.Z1]'(?Z:R'VO
MZ'T&8GZ*R0_04?]^J*?VL]Z#N[_\R]>$2*!NP^_^PO]^Q =_[P__;?_S#VG\
MV^<0Z5>+WL><HD@@X6^<U8_^QX]_2T%^V7=^5#%^_4E_@  @<&"W@@8/(DRH
M<"'#A@X7#B38+2+%B 4K4DR8\>!&A14]"C28<>/'AR812CRIDF/*E2Y?PD09
MTF3)F#8;UKRI<R?/GCEC_NP)U.+)CD*/(DVJ="G3ICK=0&WC1NI4J(PF]1&A
M=2O7KEZ_@@T+U@\F1E/%M!%S=FU:MFK;PGTKURW=N'7GVLV+=^_=OGK]\OTK
M.#!AP(8''RZ,>+'BQHD?,X;\-JH;ITTQ!K6<U*C2S" QSV1)5.;HSRW_-99V
MR%GTZ:&M-;]<#5OG:YBO/<\6VA$T4=ZA+Z:6#3SU<)$6=PN_65OW\MQ(F[/^
M[1QB\NG6GU<OFCWW=N/0KX,/+WZ\T#92SU-VDTB/V/;NW[_O$\<-6OI2T>*_
MK]\^__K^]__7'X #"EA@@ <2B*"!"3*XH(,*0MA@A ]*6"&%%TZ8H84:8KBA
MA56!2)YKO(FH'''8G6@::*3=5AU&#'4W7&VXK12C>#:6.)%T-K4(0(X[U>3;
M3$+ZZ)UTGF66DF]&[@ADD]C]Z-.3J!49)8U18AE=E3SBZ)2-7689IIACQ@25
MF51)%0E[\+'9IIM] ,*79'-&5J=C=M)YIYYY__*)IY][_MDGH(-"U@:9U"UY
M*$XI,L<HBRMJN:6,4V(&HZ.1JCAEC9>*""9YWVDG:7&*TE0:D9-6RB2F5)ZH
MY$<M>:J:IJ1>!ZJ.HG8:*ZVS75DJI[S^.NFNPQ)+[)D@2K6>F\LR^YX?B@3H
M88?3<EBMM-92>ZVVV7*+K;?;?MLMN-N&2*R0Q3[J98Q$;IDJD[BB.BN\B+;:
MJZ^SYFKKC_K*BBN_8^9T;KPO<L1JC_5629#"1P:KTK_H=H;OJ%;J"O%2]O;[
M,%-?-FRQQQ\SA1ZRB635K,DG?^7'?'$%VC*A+@L:,\PSOURSS#;3?/-A'KLX
MFL]#MH8<I2E"FNZ]17!B;)32!+]K*=-&/^3NN_,*2R^\'#-*G*E$<]KE;\DM
M%V1HJ4H=G:7> :<JJ[9EK?76KL+Z=+R?H;VPI+&*/>^5;B\:MTQF1[VNT($C
MV3;:#O<F'-::_JRQVK>V*]%V)'F=>..BOBVCP48^+IOB'8,<_[KH"Z5Q+%6$
M:(*RZJMOU<<>:8TKKNSATAY[[;/;GCONN]_>^[:&A@<ZX)E62N+4(:U6]/%W
MEVVP\GU__7; GS=?->&</;^\BLY#E^CCG;LMM_:A0NYYDY#"S2[FV:]HM]"5
MAQU^].E'_A/[8R./-,.@DWAPDM-?C6SS*U]SC&>UD<BK>08<W_46.#"J$=!_
M$82@TQ*%0-RP:U,"2Y[EY);!\DUP<X\2WNA*^+&JH DJBF ="UF'"4+H+&<R
MQ!D-8UC#&=HPASC<X62J I[J-9!X[9.:^NJWP**=BGO9L]KP)H@_KBU1</93
MH,"^ET0E+BUHES/B_8"(Q2FN[XI#!/_C\P1H/ =";VA:C!O](L4\\=&F8^K[
MXOX(YK\C5G&$A;MB!8/CO8$=[8]\7)X?/QBJ),Y1CTL4HAEW1+FG%?&!D)3>
M(DUH2=&9AS]2V4/)6NC)DZGL/_7AG>Y\1\I3FC*5I5PE*EFIROI0Y8=P#*(B
MQY@W0SKQ?;HL8R0#240DFN\X").8$]T81D%2LHM5Y& ;"9E,*9XFBRQR'FGH
MMK8F8N^9U3PDU9CIO2P"$&.(TY?\ZGC-B>GH<*RAYO<@=T[.37.$Y'LG"-N9
MQCSB4I+/K"0=2Y)(9]JKB/I;(]"8)E!]@I.+_+PD0XG5%F01 A.?G*CJ]& 6
MED7EAAK5X4;_><C1CWHTI!T%U%1JM=#MU;)XKP+H+IOV0%2YE*7!&J0%@UG0
M\_W*@ [\9ST)&%.$;E&$/;WE_&9I&GJ)9ITH56=2XTDEI4+5GK?B9AK[R45"
M8O4HT&0B/)_*U&UV%6KN]&I8FUI6J5HSJF8=*S>7V5(M_?2@OCPC3^6:,426
M<VX)ZZ5=W^K3A@+68E#)SU0X2='#@C).L&LE8U796%="]K&2=2QEQS5*DWJQ
MC_+$%!GK*#EO7A6F4.LL,6DJS--*T'IH36E611O31Q)TK^$3J_5@Z\B@IG.<
M>H/;6NG9([*F];='!6Y5-9M2-C[1H"=UB12AUUNPQN^-SOWJ6@LXQ, *SO.Y
M9N47:0<:VY_6EK0-?&,'BYI<S^*KNZJMFGA7Y4';NG:U@9UOF-+3EC@@-K\G
MPX1<1 K2D?XWP/X=,( )#)F26@>-M)3JJ[)YQ_6&59=(A?!?QQL4^%Z8DD*M
MJFT3NE3X#K>G"P;?9V=$/PJF%5'J_$XT<2K=OE%WJBG6[E)KC-#1HM:[XJ3J
M]?H5X^V:N'Z$H[&,BZQBS<'85V ]LI%'[%+JR?9)6_17UX9Y4\\R>')6UK$(
M.YNI^*H-Q/2D+YG_LX0LJ*!.OVIN5A_LL!\WE*ZRDXVLG.M,YSO/.<_?NFR"
METM;F^;ONRBUZU![*6+P]A'*.A9?0LF+X@L&^LI9;F9?&P;:,!LZ@LQ-H&Q_
MW%OA>OIPH%XRD6EK:@5+&-)<;I3$6'Q>?([:U4)F<J4I:*L6V[J@&G1QB0U9
M:RE7^<$5#J^PB[O92Q\ZV7]5-'LS7>9GYX@R;=F#']9L[67Y(1)LR:B "^SM
M;H/;P.+^M@P1W.<=MY/9R.[RKZ/\06;/-;6Y=/0?E;TY51,;V+U>] 8MG==F
M&]K/3;8F;WVL75P/>> *7_BM'07:#+<1W_8>47HK[FX^.KC4Z(RN3"V7__"/
MH_/(W(7BE?'*5Y+G.LB2QK'*4Z[OE0-NW4:#=X?S".V;AR>3^HG$M7N^+&CA
MV<YZ#CK1AVYTH=N9S^?VE(-?[B.9Q[S='=\W5X,(:&/2>Z<Y/7%YT0IB@:[Z
M:$*M.3*-^K>$%SS),4:XP4=-XX9;][OKGG+766WQCQ-:M6P$.<>!VCB0JSWD
M!"<FA>L)=K_7?<-5G_F_[:WEED-8S%Y//./W/4B<8SXWQYH*?GWN>39A(MSD
M'KWH2S]NTY-^,3=RW*'5W?C*XW*7WT0Y52%NWJ9C/-BO;J;C*1UP?PO:\,Z>
MFY)EM>*['WQ_:'<QDTEMW,4+R\N%5B[K;=Q\6O\3/L1[-[C@CX]BC2^<N++N
M_O-A+\;?0_ZN7)T[[=4_Z']#'=/I)[O ,V__GHA,*BO\//_?\PBD%QT 'ET
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M]!@001'B<$.S!G]RD,$')8PP0LV"J@H30O1:C#,1"IS0C?V,PH2TRMI0!"E
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M4TB(9/#J(!$2871<:^U6\LS4<1KQD+TH5# WE#FATR_I5$-MHW]8JB:,*<9
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M4#1Z2*P/-*W4T-N_%)2LXY5\YS6W%?NDUQINWUK"K]BX?UNX)YS"C_BX,?R
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MG^Q#I<X:KEST+KC*F.3IGV*T1G5TEXS_BDP<"5<>R:D$IP?S5:9N>J;4>(C
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MW"N\V2NVS0N[K=NC>DLO>YN]'16$I^2X.2<H)4=X(INQ,IBF'5MX:]J6&KO
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M"+W!1JW=3IRE4>_41 _T&W_27J[X6WZ\BRW@:_[4_;WZ?I[XG#_?,\_M  %
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MK$5O;,=J?,<FB$=R1,9$M$$=U#DYS,?9F\9][+I^?,9_U,> ],>")$@!]#:
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M&VHXX84B,DCBAR9V:&&**([HX8LLQICAB3#6*..--,XED(%1^9A71&JY^*.
M/JY&T'H;,?<=>4F6U&1.4#HYGFZ]23G2E5."M*26U7%IG'D<+5DE2U]>%V:7
M'HV9)ILPF:G2EV_B9*:<;=IY)YY*[2<D)\OX8A^@@=HW C5&TF;D6Z8E6A&
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M(B/ BF=[ZBG!6N7"-F7#/D=5 J-[ZBNAVJFA7JXT8NC@[2R(;NJH8F.$4NQ
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MUV,W_EUW;_C9OV<G+_Y^_.GMVU<GWMVW]]+3KK[8=J.M->CJZXTXZQ $SC\
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MK> JRYNR3>V*"*_L:O) :.9TSH%&Z-?PRE+>*6]4Z%?.Y?$.[V^V[]KNBNQ
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M6]B%7QB&8UB&9YB&:Q@S P( .U!+ P04    "  =@7U7(&0MXE!R  #2@
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MHI-<-*R]&(9&<*\W1BBA.U 3CG!2#4 56R#.ZKP/3!IJ5<"4SB= WV9AV!-
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M5<(LO1+YLZZ9'Y+6GKLE.V N]Q"D>TQN:MFM7R:PZ2#U)LF^(+I>!(!;Z$D
M.9?D1+/0\9?^?%(RF3,GC^T9$'!DV]JAS%5E+O(,VNZKMV;IY7_^6XI32ZYN
M>AT6R#N^E)[!K^Q][.8K5I6:3^ZP\H@](  56QQ,\3U^ HR>/^]Q'V;IAW^0
MR?S\!2/^*OQ:]I:^LVA!QP08H7G/\@QQ@A_4F15HHN]@T&CCP&)#IJ7P H-,
M6Z"<9X>1R ]@%.90FL<@X;XG/A\P7ZH!I,>Z*L]ZK^YQCQHP9E=V::-=,<V2
M?JG"$/&H5UY!=D7092-4YERL1(^?*^"GM_V^$!= 'YPK_@&'(PM2&0$F45[#
M8=6:KOUD;,F,?+\J#\F8^V:-EAA>)?T=ZT]56.2(&7)GV-#@?(C7DJ\TD=+&
MY!-D4H2\0 C$0FFS.5UM;T8:":(&2VN!F6@;K&R$9337[V4XNG.5YZ!$)UQ6
M+C*Q:.V?30-5N\N@(F_=&FM+TT+$EN7*,C96;8*.F0P)VCL]?!^?=]-TC.-4
M65<9\5X&*S\!#HL<?_S4)E#D=WFE'8 RIBD@FY4Z $&D9OO%,Y^^$>9YG)),
M8EP]'(83%;M(!^>%OYE>Y>.2IQSYC5/(($#$3/S]-$=@3,D95&I/$.6@\D%F
MX$ +:R,08OJ/4,BPSO0;F3YGXE)A$FCXL/=C*TBOS,FX(5XQF44'KLYYD_:N
MR>MT68%,=4K]=>:H-8U6&%]<'YHA#)87EK"$UO$N@Z>1;W"1A.L)0%:/3S0J
M5%_L\Y'3,'4'J>4N?A;B1$Q42C?14M%J3/=<.:E7_%.JD;^Z>$K.=ON SISB
MZ\*S1\\&7?[XKF=^(6H*<IFSXRT-B7P[QK646Z5"ZIXTW\>IOB&%VG2='=&[
MVBT))?SF$Q+]E$=<' Q2G@.3/?5D0DT:.OQ+!KH !P[$R15@)G3=F@GNBFTW
MJ0X')0PP?J%62=G4E!YW=6'SVGWU_B'P$#-C>5]=R.,?)A3ZO^2(^?\:E#DL
ML_EU,QDOCWA8&%IU'6E#9N^ PBF%JX>:POFEV=\\RFG-/ZW[/1,GJC8Z./:X
MDQ@@<'? _XF)XH$>!)0%F..C&*C&26G87!RIJ7=X*=%4WHO7S"Y"FF8]:6A"
M0CK9H]B9BG7_!*INGWC$4>_QJ9'MM>[D<DV-2J9N51X_"T;S'AS!HJHV*H!.
MQZEC>R3:O_=RJ-U)->.OF;5AVUI:5?<JGS2IFD+_T#]!^P30,5H0G^N(9@!)
MRW=EQ#>Z363U=_%(G2FMFU*4Y>W#:\;F*GD9]Q"4KUH6V]GFP9V_5>J:\:Y4
MLXB? "B6<?.0 9"AX5=R!<Z1L8!^B:@;H6_S>-QG> Z%7/K,Q,F2Y!.4)B0R
M''/ZD7 FZF9;F^4C<5+$'B?/AKJ&X")+Z"R;3"@C<^!FNYZ,M,GF2*YTCIKM
M#?#UU\+*1@O;GUOSQ="Y37[^1"ILQK*M9WZ1 ;&U.W03U#CK'SB]5KT\T?9G
MXNS'PP:U.QC?6(IA74,^<"MMS.5)LI;+%AL<<ULE_#$EW$;[1>]^@[L'&0OP
MXL$S5=,LH\O4#7W_FEP14'F86=M0+PS82K2W_O/8M(LIH<NP*D!Z'VIOX*/-
M5F38B-,Y>^!6&[I$*:/Q!(C;-CYGJ?W!__8S>4T\E:=8<EFZEWR1&VF9S+='
M^59[ME(!IW4%<K,#!'?27)R<.N>1&HBS=N$YWU*QR?DO(/.5]HJTA.T7]J)1
M;Q&OCPYFT_V,*-_16,^@CGF-RP-GI4=-''!0>N]8UR/"OIR#9PY 9&_$*:92
M;]"O9%X0R:'Z+S>@9,L)Y8.NM:?^G=610^IC#5/?F8=,=(AO3$L$G>.+E);M
ME?P<WE:2<77@KMB%?>18R2F<%HNKL9_QT->NY">P-#,09&[_5'(&U4UNL-'@
M(3P5[D:W\BBHK73^^5;IQ4CN=!,*/@H6XX505L'&F*40,S>9EO;[_Y/#WO\E
M &I^NRQ</R'X8-^S/ XN7&4:1]G"3_J%OY7313U?WAJ=Q@<ZEX)DK+[#&G6:
M1B?QB^E[)CIA!-CA_63LN_Z;(/N#$87^-ZXI)2>/?*8*+$82%:QBE8E/EF50
MYVLU#TU8K[DS[JHZR<\:00T&"_0P)BHT7+]-AH@JL?87%<.%APC;8N/]"F^A
M2F2KZC)JT(;+\2(#Q_,N2MI/>3F-S7!IV*OJJD.*,H+L;602/D6Q(J%%]J>>
M-Y;1J*-#0X(HQ3E\DV;39UN_?5T7"T9ELDD'AL(+$>8X.@>8'&J\%'9&7]J$
M;Z-]&N+&LH;P_2UW=V^^C/SY;#%(WC6V5OW,GN*V?MC^5,V[$!I_9U/@1+=#
MXL2<$UED"_@L#VO76\=[\'[?X> 5QK8[I9XHD2,YQ=&,C_4GR_Q!'6 \<P]R
MKO097U";L5%QW)K9;HEOT(BE%$=G<F%@QU_>S/*L:FU&" ^:=IY"BUO*0"Z@
M/W(E:G:6QD&<:;:*$V@TGW5B'YNK!O[)P#A65J/,A$F4-Z=S0:[([]Y76)AY
M<R]_.S'0EI7#WS4G%$H-WCPVEG"XM*0)Z-0+[15$_IS]FPUP19%9+^7E81]7
M >&2N>U^N+T/B.6'45(UP6IOZ0!-U"8N*$:#K\RG2R2T(?A<[++T/MP(SE+G
M,4I?7*FE8+7DGUF46/?W^_$]D?]>+/IWB/\BAVY%7Y :"1CX47LVG,B7(J4$
MX<D-V,[E>7.6$S[=.(1?1!SO%]G;V2!\YF1RQ!IBK&@R\K-'R_73E(A=)4+X
MQ.^&Y[/%E8-B76)];:55455P)%O1?Y5EHX00?=ML.:7;27*V%8!\P_-V,R7_
M^#%S<$1CX[42HR7KH6'3$^#9Q5TP%*DRC;.6ZL^NEG^G.@#)W,8WQ-%*:,:/
MS'@"]"0=?.9LFN-AJ8NEL?D(Q6@Q_O8^7X>T\XAL*\NR9M\0F(.3*S_%RVT1
MKMH228.3WY3*+<FRN8W]?IP09Q ]: S@ /HL$OZ^=<8R3;6S/EPWZF=-CDN;
MS0OOE"[FLJ5$$4M&ZIAV7V?G5Q""XVQ7L*NE-<M5LG7,SP36U;MHKYK-D$-#
M.._7RR@$JQSU>#%3G&8MZBH;^*<[,Y0HK57>(&:(,NB+V-:L<"Z!$U-C(E7U
MD>5X@G0R 31U;-7F]V\Q+C69T8GY+\)5DK8LG>'T-7#R [AX0_A8*N4O1<PW
M%EENBLIF[5[E-=<]MU?]TP;&!@(@ HA2 !V\]1CEZMDUJ^@:OJ48>@Z[YP]T
M$WMOKWH%7WN@E.@O_A7X38_DWW#28& -#;DKB:*]Z"-]J#'+91/\^"I2ZJ44
MQ[;5UV//:+JJK_2$!ENTI[+/]CL%^4%&CEY>XJGUOJ]RZ8[N@,R>,:T46SS(
M[IYJ$^KL=E^PJU"1N$:Z?]FPMP7R^BN*_I5_4_Q21"_:@)1/^;PT_IP'&\+X
M[1QB,]MCSY%'?:S6,Y"-+I$-_W6OZUHB$7U*X)L_CN*$A=:NSAXGY%7I2(*J
M'P))K-^M6&>S3F,O4.H+#^9;=^(<R@W3A*_XOI'ZK8?7TD5(,D#,*G,)[ 9[
M5^GJIZ,? Q=GJ]-A3D>U4C+4\WG8NYK\6!^T^BV,?J3XE#0=[#EDI[_S=L1B
M$,8Z@X(./2SU%=.GM-3?M HYOR<0KQ/&[9]U:E^4;)3A>&S\_+@Y].7+9YLU
MH&E*2W.6[7&L"M0<>B) G=BVK; B/&-_,RXFX]50!@  , '[:H;#*\O3?-O
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M9?]8JVGXM;CG083E);?R^IQ[,<,T@+X!\BA8:3ML,>-(4ZM']4Z5K'@E"5G
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MN([90;;9_O"GJ@M!U@NP4^159#QGC>T5G\E[,\6+.AS@#FG;E]M) K!M"NX
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MTV;>#"[4+,+Y"J/I7P/TLJ\P&G\'CWKC3XO%?.$+;^;M:1[[2J7[22,Z7 N
M_BQ5NG0K)]&A9-$RN?K+0)8JNEUA3CPH8RME;E,-"3-_W5YC8ZTHJ4*?2\]D
MN3Y+07F_W3P"TK6/8A;9#[L2Q[,I7:]JI^+">$5XO,9N0WX0TV_81X_$]UB
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MY)E"FDL7^CU%2WQ-[;*92QG\57>?$??!Q>C%,/+>')A;B;NP%C1S$ZU8\//
M8:#*E4^D7[6GQ^(H]T]]FT,N0C-H,%78*SGB,"WUSE?9,OC2_^K&$J:(X4\Y
MNG/ZNLVZ'B59$DP:"0;)MY$,C2Z&(.Q%7QBX_7__=/_3H'B9_R]02P,$%
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MBO-H.$!0T!GI8^)5T'])7K_DCC[TH)HRTP%Q__]=W!)72;Z$PKMXVAC!\HQ
MQ'X93V;MGXROH_GOV4#?P=_ZJ%*-#$-<C#\]JE9Q_C@;W*S(JAS1EL-[U?='
M6YT0"*1T%-J3!ESGBT:((GZH5T?MLV <-@K:9C9<17E7V"N>2;'?%FGAB3T'
MT0D +73GH.>Z47\7.X53F6]'?N9UT3$%#@N/%%(&-[XO$O[,]B&X300!8]^
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M[IX0Y4E"YZ"X>4)H;U99,&ZKN%T9(Q<_9"G#99BYV-4:8_B>=D\P[U(H%&\
M!J1%.HC>I$>$Y>[J)#2KGS8[/ @(Y/RY_8S_W:AWA->WSU>BTS3][R=_N;X]
MO.8.@H2:Z7"#_CO$XLJ31(6=1"LGUD 1*2"^%?Q2NKZ;!IK'DMV4L581HES6
M_3KOHG@C]]6UPV=, 49MHJX2/"'ZD95ZJ_9&=KW_3'>.1KCL>"M-F3'JE+_C
M-4.]:88X?$I.G?[SFD*_5::"#N*TE0BRL> ^"'O%WS5F15/[A;R\KYMF\9Q"
M*815R2@&&4SGV%F9MI9*-S)V%H)_OM!]^I9C,W%IFB;R@S#S@;FJN6W=$;N)
M*2O"'"YX]D$SF*A/"FM/L)@(5AZGD!WEB7.06<,_J=Z,=])?*E:4#.MJ'64D
M6P\'7+DB:\B2W5M.1M\]2E48]1S5H]>S7?J]&_0,]8(R#G -WR#X;H=-WIJH
M+HR(O&O=B!KS%A.HHQ(X,.7.;Q'/$@I(7"?9$BWA_Q!*>A8@[/;GH![E)<%9
MIE&VC(O:K@UUZ R!A[IWXBXZ#,<6AV_90QOEHMK#_?'VII.5?KY[+N-\HZT-
M9$RJR4TAVI3X&S98O>%V%B>T EF /-[)BZ_7%IU 7/9 2!!<B8OW3G5E[,Q8
MW[G>4'GQE;8P?:5FM<3'+*YW]O.OR3(1FQ[K),_M@K\(E45@^^)]W>OO"HVW
MRB5_HKP 8A>*A\SUT&X^3*,_%_FRGE5IO;7@HM!976^EF%\ZQ[2+J7W\]W#M
MS!THF!2Q:@1=C<\H=QR,\#NM]/>!E^O[B;=\GW?R>!77%U4GY9)?GI',= 2+
M7:Z'ONSD1 PN43?AEY_[5?LUL(H8[I15R"-+MUD[>D:DKCQ,5\Z4&?<>.EG&
MI*TVQ<,??UP""AV:?PCLT[<UVN=E9G%2[RX:"$EE.A7=HPW>5.K6K2@R?^(E
ME=D4E%7W:_?TC\>3!X7/?C]O2,UOT-MI&I##] Y .$G0S_:VWE:\5J9[C:W1
MKMYW)FZH/7A5)JW'ORIR\@M5,[;WVFU&G:]WU!&'9 <2M7">*Z[YOH^2W8.2
M0?2/Z?1IFIZ1FO&5G>7%7G9Z"7)P:]_*[>+#!?M9N4H;15Y#,6F/R]+$?!ZF
M[(OKM<\"8?_,P1_BST'12OE^F]A734VSE3E%S>TQHT[-^6;WGV=]#X&6_@E,
M_COSAA",SXPL%I4U#JG/FNEL"^J8.-+Z!N%P*DRT>?F@239%RZ\];>KG%1S1
M@2#<65VT?8I)B#_ BKBPW'S\2-OV\B-U",[J;XRZM=Z_73_?!6(6=0)9<A;$
M?5OL:6-C3V@1]!.=ERBQS06.G-5TQKT($K8?>$:W>X5___VDST>WUR--;T/O
MA?T4V>4J,+ZU!7-P+([#VPT3K5P*OH^8=>C+QOB%R:R]>GYS;TL@_?93U:&A
M?>\=_%QKV-N622-[G< 3S6Q%&Y)T@)E5Y^:C"]<\7WUUN4\8NV^QXXQANOHQ
MZC]D@(!,DM&$E.0EE3G?^6/C',+D_J2H4:X%-%.30=^$A4$1LVCNH)VV$0C#
M;>^S#V5C>2U77KXY![D/0$-&DS>18_W.]AP&R>$[CDM6Z.%-$0W.4K-@D3,V
M[YYE_ ,D*S#2FX7IR$X(;II<PN&6MF_=](47UNM':7O,1S/U5K$I)(Y.48)\
MI0C;-$F+!O":B-2SRI<(:8 J] J [@^_CQ6-Q Z A:6.FG 'E 3)L:6\Q$=Q
M70+<* *[)QI"'DW<7]K\9L$Y)AWUM>*&&,8AU/U:1O>5-@K=K>?-PR_W\&6/
MJ,0C&^'&285;SWR;4QHXA&K%[VVID Y]7))/_ (<U;]=?_ TB^.HO[S\%Z[:
MUW&P1^]%P+1LV= S>XOCIA7DWDOL06*G4"[YK!!_G#7"ERLG^2#USLX[,2%W
M^NMZ3@P;'8DS6+=H!V/+@74Q('K-&EO]0@G"[8424811+=MZV;G%?01\G6<*
M:V2"+Q2 3-V:GH0,77Y3VT*S-O2X0.I8D,PH3PST@C2XQP0[2-FWU#9/M:N\
M$ T3E<^.8[P%$U\?CG/>:NWH9QCT>HT"''X_'/-;@*=]'*YKL7SC,=NP- IQ
M&;]O+?TS3KOTK^E_>2_R?Y#J83E 3K('QD.Z38%D :)'O3@:F\;NG>L6O6JA
M719:LC6QV%T\>#K"U1FJ(\6Y(C_R2MMB"U9>/R95\"FPX"K-82"9+0F0Q(%3
M,(.[>9Z% -2.$)_O2;BD7,>:FJUT;(JILY?*Z?,*&;!^(O%%OL!;C,QHBZ\>
M@.#OH0 ID_ZT^4$R!XK'$4X/E"F$E7=AUM1])K<P6B-B*O-NS997<U($N-IC
M[);$2.'5L]52-&40 U[6\N1<$-E#$1:#Y($KG8,NG)(\\3)-O6A(R0OR)7A0
MXHR6&AP:>EKF<]JOUGQ(ZE@R_@5:3FD1RSVEL"Y_,N,\ ;JR"K] *.FJ9.ZS
M;JTJQQ,0X+#<A5N3ZRT9N^5>K_4V7DQEZJ7J.TO/,:]+*A$!I[$0TB^;D"#G
M@X-;D)?HQJ9=?AQD#HQ;)G&9F./]XY66.0?QB7_E6(!T7T&3K-U;=?I^OQ6&
MG2UJE=.]&Q?GA K"JS&&!ZR>F(%R5V1PR=SBTE;RGFN --,A)EOPX<":JPH;
MV^37'6M2.QLC]^<V.I#+8AB73EOS5%&VWD11MDW*8W1H?4KN'^['5A;)S:!7
M-"XL4^-A%D:Q]N0I(_5N)6A=DDE#92LCZ=53T>64!87OBZM*A3H@> /Q&;);
MD$R#[#8@>7\(B\5MQ@<+AUK@?R9MS=RT]YKEO7/5[NYEVG^ZY!=-KK1/KDB2
M!(.)DN11"#])B5(L,80)VM80H,^#&1J,9#=,V)?NOQKC'Z[1C:Q0F$L.@(69
MW1)RW^/#":(8R6.=:M/2>_NRU8H'X.7%A6Y:7_&Z>UD3-S]>C_G6%P6B$<\E
M35,P!B+W.UYKH=PPA(UT(2Y/!OM? ,IQ[63Q([X']5G?-Z;W/Q+%S5MOL%T0
ML]IZ)R)UXCL9=KS/>O4B-Q5@36'+G92A^203RMF9/"1V^F@6Z@I-%KD,H/&G
MJZ9-$]DZ$_H3P4CE<'?]]69-Z8AW&SJ+PK<NK:W "9#= X(ILKL1H5&7C=U,
MX</1#X)3O$NW!>X_H_O1EOKS_M/P4;8Q>=&C2RNO4Y\=P2;&,@>MA)PK)5_'
MYH_F@DCME&]N([L529&$.C)C#C[4 ##\.(@#<\!!Z(G@,+AT3;S %&_C1_J7
M7&(1U:QUY;)X;2<J8)7,3)DW70W00+1$=BLKP>@@\]DXE1X':']K2D$<3L:_
M_TMD[MSW6NEEEQI]'D=K]R2)FD/1 C5:1#^R^QYR!25@3>+V7@&3+JMGI\ #
M5O0K_;E,:Z;;E<J4*GY\1X6.WKHS"HFL_!%UFY8&)D:2/ ?%^NV>F*06<!.:
M!@\PS+CL/2Y(M+M]/EB'(%31&G3S YV CJ>X+)6I0<R'+RHN ;<@"A0J^P2Z
M\K;U#!U[#G*!OE!>9H-3*G_L;/<!TSP &T#PXMMK>S\7U?8*1GZ$7/4WMU&5
MCHU_\)U*/ #V!;QK1KQ)_KG<()+R$4">ZIR5',,8MWQ:GY-O$-P392MWZ]M*
M.Y]4LB1;=KLR'ZH]-5FDN8)^[R]W54U,Y$V!;D"6\XF6!\UAVZD"GB]1T_D<
M1'\=,0WE/EEF!F)Z>RF?3BE).';0W33*U?"]ZV4G=5:@:UJ++,W>YYI=ZA0'
M-/"QN- $Z$H,M'$P499$MQJX6IT*X>05C+Q6;XC:TVBS;FUT>W.[[MLU(C$V
MO[DGEYS$PB^VX<?V;.+MT_D11! 5,$EQ4-)9@:8E%@FHV*] NY&,889]SSKK
M2H>PD;*G@_<GK[3D#CDW*GP__'CM*N^C%IEDKE''?\LB\G<8+_(1&KAZ#NJ"
M8IHH16&OC/.J7"R):J64Q%,-A.I%ETP%/4]E_'B$U6'I?6K\!'N/E9\UJFMV
M5RTVE3]!356)D$WB+B0SLD+W9@EW>[6A>/0@)!%Y03,0:^]6W]".)Q>)V6JZ
MO,OPW;ADRX9C+F3MI8KNZJ+?*-G3(P:$_28S?:#,_ME94CL7SB2F\QJ@MS(J
MUS>"RV.%]C.457CU2'(::KY^=/$]]8)7C+;_V\WHM.DT0,:JKNH7#&^ 3#T'
MX9,][:J:JK<1/,T3/KOU.[:R5<7>M8TE+A[,\LS7_.AUE#:@>.,#X+)>'-1I
M&2-E!HRN0E\@E(!50NK?Q?E>G#_W2$O]7$X(.CWN;?RUS,7O]\SOQ V-+7'J
MM:?>&_SP'MP+7G!> :<A!"DX*X5>T.;V<&0BZ!;A#GA'"W5*MT+4+?MFLT1M
M-Z9</#_JR(G,V(PW4<7,*6U#\$_ NP>X4>=3B;/7VM1A&CU_]ZL?D67'I8.=
MB[8F'72*;[O[9"ULR)=QO/<<6EP#O_EKO8-/H'WWKJ#XM6]/D'A ZE4:?"B9
MN85(KQ)%X1SE=OZ#4!'X)2"-$+&B\@(NX_O143):3C+! K^WWAIN8#]T.<;7
MM(N3HPG]C6GE%(G70<T5KJCLL1)M;A/ /<NU8Y0:.#X+QKKN8-+K>(/0]+)*
MA'DA4_4PKF(T'1'R^,M7U+7%!Z_ >V&QGM_MCXH2Y>2 G,[B*.T("EA*$"/J
MZ+UN2A#[#=3@2VYUI)D0P$GUN@DFX1 ?WP"AEYH!=2'Z I>2(^BOH*]U<B*[
M'<E:B#X(_KX&*I;O'%0KV5?)-8ADA$.4,P)P&CLF=6%. TOB+GR'P\,\J3.L
M-0]?0@KA<]68:@QDQ3&/>(_$1U")/HF\ZS!1?\!MHQ77OY2$.%4YW5X>Y!XZ
M$F.)9%B)89,ZHD"WN]J:?',\Z( N[/=I$["Y"HO]:_GMJ61L2<L\=TWA!9O\
M;ZEO+UX4U58OI;\(^A/8!<7?'Q,F3Z#PGLCH('^JK9L[!5)Y_4_ANN2!V/4\
MNV@_V4H,MUG*V%IM:S52FFJ(9WV97IN!LE8@FJY8$ZI?YZ OO_?"RX!LTW0I
M* =F"<C]^WU0[Y?(K</\Y,3>2X;KK.6SHNA"]',T4Q X!L:J*,<09G\_5@>_
M&5_Q<;)^X>(%L888":9$C6-A$_&3JI>%2\TC"'I*AC@'$=T0 W+8,4!JC,3U
M&^L>38+@]!'<</[)*J4+[=Z>!]+UTRE)=S)^LINJ*K],&<WHB-0)6>;NY ]#
MK=*3A*WQOQU0O>H$/*P7&I]1;S>R-<FJL9=>-+@_\[33%GF<N:(<IIWY]]4C
M.OGO6E=ME$L%\Q)!Y,?M1D0&P)#,>$0TAS_";^Y)$C5)D4"F9W588J1U=X$4
M$(D,%2XN\Y5J^V3^8OY!BZR:DX-]F%0RU]_+%#1\PP]VFP!78+L6!+W3FC:
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M\8-26(C8N_7RZ?*TS2(]L.3!TKYAB?-XOKI!BJJQ"<884]RQ-'MF\EY;#"B
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M[DD3F9RT>D-1Q6D;F0BG+E:R+C$5(7;P ?P*B.N"46PG*7(=6]S.7CA.Y=]
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M1&98]=WM[&2T')EU]'"Q]$OB_9JS?->3\;BW5<MM=_/ <X=(3K>.\L$K0*B
M)K[ZXHE[Q]"UB'3"6N*=-]N7K+)&W[HVJ9,=9+_F:UE/E1Q[I?$Z1]P*<*&P
M14=@Y.V] C JNR7%(6_('T4*]VR]"$G^T4W<:/4)H4DO"H[1=0H$>XV,?TQ1
MRROQ13ABZ09[:*%FV'FKJ<C32Y;!+,4^(::SC&"FGTT1G'?X$F)3Z.S )ZWH
M@(,C[ ;:>]A[U505QUR_91CECXJJWOQ5@+L]D5MEO;(FE<-R5[A?OY+/U&:$
M-5W&F3Z*)^<C>,\0_P QI& 88T>)^_D)QHZE#:_%ZPV]<T/]O*8T)MHPM%YS
M:^O']=6&T #&9/JG;R<XDSN8/=NOS[/;_W8,47(B&8"MC"&+<O3_[%3[?STE
M C="F5/]'X+&W.4D 3O0/^A4GY*BT!LK",[+RBN FYYAU)D1WFOX7!)GUGBS
MU>Q-X.^[QP6H$^>.RH<?VV[NSG9K#2'YDOK66>?]+!VR(']^6XIFR4;9J<1:
M1'*7 VMA&L19>^Y-_!4 [8!C:LIVJ$79C)V__?JSSK>BI5"#A(0LA]E\%"A(
M/2+UQT;FTV7 W6]$5F)(DI#T</"MM^K^)DA\"-I[-0G=$E.*?V> LS_3.KM0
M1V=7![>T)#+E$I;27Y;?Z]_VNF6V+-2(O[B@)-A>9C<;TJ+P&G[Z;U%"9=&&
M"W\N1F$SMUZQUL32?;:HV!;PTI0WKX'UVV--O$/AU%TB91"U68XC6KOUY03-
M*X!QL(:XW52'2L#7^.];!M_/>,QK?^5C+8$K%R^6FG*EO=ET2J=JU.;N(1M3
M;H9S>B;7']=CEBI.$<5#+BL)G.JE6G07;;\66D]!*%80:,_.]&_F\48?$"_T
M=Q 8+K,H#Q_,E;<%:^2=C 7'#7 &?3+Z$?5H/.)M=%6>P=R45/;%.^+T.MEE
MHQA!"+U!;6>GPX_,%PY8-+4AX2.Q23/[\%:6H_5'XO-7R&K\:05L_ K0(GR&
M9%^$ZF_6VMO>#[95K!5+XVOY-.S$U["E^;AS9YMWL>?1$8QR'<^+3F]V+E^W
MV^M AQ0I!*8-3:1*:S^A9'3<Z>/A5J!-6TN=[7\E%.*1)J-;$F M\JQ^!D$%
MZW]GDF2P>QA]<.U95\ ;-PA OW)5Q;I\T:37G@792DZ"O #2O& _T-)+0RG\
MU 7K-:NH$@6(W[(TYOEK"?9;0M2?FMV\#A<")OM (VJ4;KA6JFZE5]H[R!^7
M^<J;7WIHD$*9M2 C9[Q?I?539]^%'=/78Q*]GWTZ2?GNR"\-[W0IQPXLYGP*
M3/NKU1CQS=W@D9AFB+O*ZQ<BP,$@^(=:GKS^\]DSZD_T WP,0C55FF]+N"$[
M=>5'E*2Y7>*<:4IH9&!9;AXQNMQW842<1A:SNIA%^Q"VNQMK(G/QTBCWC$YU
M_Y^B^U95FZS4?9TA@&%6$"=5C-*I4BCS*QJMG.!S\QSEH5]-5P"Z?1A/TL!;
MKAOKE%[FQI8.ZKZ\DQ;EZU3+"A:I.3]";P<]G)3]O2HUI-R[:OFG&B-Q86_.
MSG]@,G294\L:17*/OR6W$TO)K_J*'&SE18V6R)< ?RI';R2B7!(DDY?[W*MT
M&%M:+A;/! O)'7AOSW)&4O\$?GN5"QRZY._2#W2MV*MV]2MS-]Y/L7%X$'](
MEB?[_>UDL;NBQ Z-672,$N4>\EYG<$2*'G5&^KHG5OVNRG3,#6A\37D,AQQ%
MLY+A^R!]0OT$S$OLT+$[BJ![P*OTVOC#4@3 \U&Q4#S[1C:=IUCK=F%T(P(6
MQ0";3N_!QJ/LRU(#:);\%^?X6$RU *'?9BMTG.0LSCY_IH>,DG;;(/%3%<O[
MZ3,R4>7,K?*O.S)S-H;:>3\\]/GB*B *Z.O[/60'?]_R45VV<=Z/@\VU]X37
MV;- 3SA;MR'-^=O$P U9[C3I?.R[9W.2<0J"6=NC#7.NL]/I;(^?/>_D5CI[
M[LA**A"KO[7X%=K</+_[QQLES?%'U:]TPELAXB.?C+%-V4B4^_,,.Y)!8:KD
MY.1Y4Y$>MT;EJ*8)E5^XJ$6^%6]VCR^2\/W!"%#7?9WPT(@?.8LMN1>*OZPT
M*EN;&:RM,H>FHT0JWMLW-G>*LQ+Y7B=?;M+5:GEBV42@0-K8#F*52.W2V#,-
MK\*B90;'@B0PEN2[YF;@Q OLQ*^8%M[V-8OO(55C#]^,.:D,65?MUH\P"<I6
MH433N".+42OJG:--,0Y)/J.H I+4C3 S< +JG,OC;#ZHE;&955;R]'66.O/_
M6P3*QX2!+"M!DAN1H(#2:\9^%,_-.N?IMYIKHJ@TIFAP)KC5UFG!: AR;RM2
MV'[W*/WUC3<RG'[5\T;DWA] '"60>I&E%[-_+G4\^4\V6?SWQ-_KUV3/O5&P
M!C_Y\2Z*M[W.D<@6M]5*$/#G%KR6^/#-?+R.;T7Q^W$SXD#+A6>69J>CQ<Y*
M]XT*$A5>P$OS=QH Y_V\6S/-X^-Q<6L"^EUYAQ-->S_R5O@",9]3IA_SI'](
MT5$_SOE31D?B!O:L>"KI*32V4&0A5GS!%^SM^/QX@9]UH,+P$_E7ZA'=I:)0
M4.I9XN7GN;.PU*V=7.F2#M<(*!"MX DWGBEJHLG:6&'*FES.">,T_GZKE)<B
M(*6Z%V&9\.8S86_>B$P!06=A[['8>F)II1_B5)>^1$?5U+*_27%KT%D=(!$^
M20[.Q,D<8*XU\3!2L>&Z1&UZW_(@"LRIQ>F_^JO5VM;3LOK7W^"7DXW_@(]M
M&B-@X^$;R/Y;< *NYV#C6C>YQK\&J:.5;T 4!MF)&4GU^U;I"=Y^ >[A:<<_
M?47;!'@IPFU+&4DT#6^[SX%G/! .+N<Y=YJ[S!.H,K=C/HBP(V7(^)^G4=P,
MVWN!Z"(I] A@2?G^J^/%8$=TBFB>M?9:75?Z!MUG[?% S[%=!4->)H0&P.<*
M0']MPWM(H*[(+^VXZ/=0?G1GKO!A8X;%K,A1WO058$[BT6.[[GI;_HWH ^\_
MHZ_+&UNRQB#Z72W'FNQLO+SN:M$_A1(?Q[^J^Z])=/\58&7NO[1Z2K'\OCQR
M+#S"_KE<ER>+9NL7&?CI]&!<)Z[6>BIRG7T>I.A<,K5UR>PII)\N5RN<-R;A
M#>;S[)!)!'EJFOW4!H3/ME;\U[BDEDB2A$HZ<\*-#!17(F.13V8%9O7/!W:E
MRK,Z R+XO'CGI,#7HS:ZAA*DMGUQKY6HL?$PR6-FMBYUY@1O[G*?8S+^NAO_
MHGD1$W.QA[\*J*3SV.9JI!3&EX4][W7/@^H#?#@?-:P%.E)VAXY[W@Q+>4/'
M- 'N:<P?.&*$:K;@HDHW[2GVN44:'GF>=N:RK]MJWFBC,O-7YQ$*BY?AJFXL
M"A7:V)/NJ*V/VE_G^&Q1S;JCLJ_[Q5D6Y"1^,SC40\1T( C6[N,J@DDH_=X!
MW7!O#BPT!UOZIYWP\CE;@\6_B[\9#*AN,J+@V,Y?6;U>N2$ZAF4PC!\K$P'2
MJ-FSN& BEA=;KZU9O4P!M?.IC;_78069[<9W411!-;%KBPEH+J#>4E/<SY5W
MCA6HTH7FWM_1B2HOHD(TP-?;@8A DD.$>KD!J?U9P C0XV*\G;-?AE;#[.;[
M?B."TB\F-:ZU8[DCO2U@V#HUEB)2Q)>+NE^);<97@:,PQ+/<POV--6KU._GW
M!]K):C5A[=_)WTV"*Z\/4,8 L%$XR!P3C$;$R:=72]=6[*.X,J+^6$M'.UF1
M11C,V3SBS#WR48CV[T4+9N#?V36,<6!_F,RH<-IE7LA"%6>4'DQM6U_C7'YN
M6,:Z"^//Q;ZNJ&L[<+MC4^#S6WG"]R5]AZU:!;T%,>_:&D^1([_["0$^C(]2
MUA@YC+[V.I\EDNOT;K[8%R2]1R MU"FT=_<L=M<O\_ 4LK/,UI[H7OFTH\X'
M0?T<Y8\CS3FQZ*&]!G@2 ,I3'[O:#Z/ )D6);+:#OV[/^@8'2R7ZJW/HWG1K
M>QL_9EVWR"LK6S<<"YB<[>(M=9-GG1/V7:56E!2J:'R_YMA*,BH*^G*#,/0Y
M3VYTRFH7Q@:;) +P_#X5^IM3I'BM?E./">29/H=6:SVX,6='G?ZA5^"N(O@:
M($H:.(&#N[@G2T.--K^4&4$/X:_%'K3-G,)9(>S .Y#L?I\QC$":*VSN7K*C
MBY)Y7KRQ6N4ZH]EA_;4Y/>_ CO3:D^ EMC:2_."T^20#BIUUK4Y9BVGHKX=/
MEH2J5MHU<DL^9:I7\VK^;,'JYI>[%=!E7@%<II;-3?'V.-C<B)W84I="Q7X6
M>;)/$>2=.A81S:)RS5#1!>TI<J*EB21\"?R#PZSAVM\ S_LK1@56Q."NRM&H
M\L'/!%>_:^Q_A_1++G?\R)+J]-"FPO#8,)Y0<(8<YIB[:P#>!>7W3=WZ'21I
MY;<;"94+*.]S.G<R:]S[.$KCG]2DV%%H4O0 U:XBG5O,&^L]T/-^G1:OOA4P
M Q+8,J2%.&JFQ2E&I98-N'K>X[W9Y%-5R?=&ATNHK"A4SIL9>AMKG@2EIHL\
MG;H%<;3$+GQY$:V#G-ULJX\0[(^,G"_:?",NB['*H\6*QF"/!EHZE*/_)$BH
MS0J;>S8GYGJDMRQNS_"J,&E-F]4RDFB981=S$=]7]$,<7 -%LY51GMP0,\WF
M#'?[)T^TQE8MHS1I*4_K M#*!Z>;P'@K9&X%I+./^RY.G_CQG>.[ZE]G?QLM
M<W;_>M]_;!#X3[NN/Q8P%+TU$EV[&V7Q1X1;SO/(:;[(KS%>TMR@E-M/]FM:
MVF<6X&,:5=!2-'$NOX$B#B9$4&E;@LIM ^E&R^VM!LAV([H\MTIQ M$HM];
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MK@#&>D<4UM>SIY2,J?4_<CS^\CR0Q"C1VGTOU%"Y] I 2Z! '\4J<<^^;%S
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MM7-JCP46T!7_$F#ZN='4@RG'5I_)XM]=.Q\!_.^!=6KLY>J'6J]FZ@(EU,\
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MS/@2<.,\-=^=N-IT\4S\LHQ._J=ED:%4@#9+I7'.QR<2B9D%=)-3L7 JORL
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MYTT_$YIHP>VIW-="BEOM\VYF&2^TB!\,G_I@W9O"S4#F34=%$)W07_::5&]
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M2R<3VG<J]=?=.]OG(!KT(0=^FA&D25N&%-QLHAI(SIH_O+I8'_;-.L'Q^:K
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MN?H1S]9LN(<.QZ(D:I93FP7K1U4W_[6^R;TQ],VV7Q0.&_I]O3GV[4R@<':
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MNE"+%E&9!Q?5[69&[C)AGZ:5-:FGQ][>XLU</G/>J'A "UYG31_-K<WM'F0
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M&"=0V<4W%5(9]WV_R;*B_E14P>RD/<Q--OFL9*1_#/+,!\_NN](,XZJ#7-:
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M7"V>OW&02?DCN+ON9:$5M-WK#27>.+X H=_0DCSH[X&:.VJOO$(+_;.]^%)
MO0W1S^&V\EU;S &,S'X:;0X-INH"+7BSM-#\(,"R?U&$I,K+56A?I5ID(/BS
M]55(QO<GO38QP7_L1*1)'CG+19S;EE,A@JSB)HUFRFO[Y)"VMC;HGD[FK0_K
M5:IT1,-^)"#Z/HVDL;PT"&."4DVFIFE\L 'FF.=: ^OD._HE'/<:%8JKUUS*
MOF4M<B')OJ]./VZ"]BULB6@)F[-?9MO!^RT//P3$]2<A>%52?EKQR)VF\>8-
M\U)'O<4509.!SW(7$G(9U/]A-Z")T2IP;0(XP8/$$$= LVY'B[1<])Q4/385
M+)0YH["^H*RD?Z'[;3&C5+<UC:F7XK<%;4/V15EBE>W@6IB;A9;%2P:MXVI-
M55!]&$__C[7CT*L8V?-Y^H_D+GRYZ$6_H<@$F)D2I9.:CP4-FQ),QX,+O79V
M:D5OO+3#")R].V:H_^@!B%R/I.G%].K^/0%E6H,OT<8(D0N:"/?&'S5U.M5W
M7FRF57P9J7D#>_NU.^&MW^=MITF2[(IU HK%6PD*8 >B!8FYZ?OAYJ>R^U:=
MX]YQ:/6W;TQDAN:_BI<V%F47CM]\].[,FR&\00T]S7&1="0IS9E=1"LC"4+I
MJ:!EM-?H[+<E<E(7$"8_4J7W.EH$Z!L:&#M?8JN'DVP.$HUK-)B$:5(Q$GX\
M]N3AXS>UZ"?UL]NV0&18]6B)O2\?KV7/#KO<^!V_^LN=H,NBPH/LE=(9DZ.T
M"7#;:#R*A2I">M^!'P[KBU8G\<5;,?80CY,Z8)*_+O\N;8.I<;Q9F7,?_5Z6
M.Q 1EJ5W'1#'Z^?VTV1(R8G=&C!WB0?SQA^WILC>]-^8,AR^;/&\O7*533XA
M_53_L"M+.[!J>-L*'U5N- FE6XA']LMF*.MR679'B>FZFDS+N;[\E:I=: @_
M,.+2?KUJQ/%3NTJNDF=@Z51.E&MUC(FC Z$H"=): P$L C]P_/%OE -HC.0O
M]:W?*?SB[U>SW&(AWM9JSG$CU2;K^GR>:\'!"8@#$4[42&K993/ZV>V)-X$\
M(LD8C.W4A43"_=6<EX)Q@R,"#N29BY%6C/%ZBKYA2US1HMZ+,LW$XF3\Z,4M
M7BL[8:H6-8Q/*[:86WKWP0NT>_YP0,JS;'R<L->9MI08#PJ,,WI&A!_H#(E,
M\:>JX:-N8ZZ\#[_ZN-VX*\T[?>#/BX<X$,/UB^%5-);HT6M4$:"#='O@I4\.
MU)BD;=,RN=X*OR6?<-.=]5V&#:<-Q_DG+ZX_EBTCU@^>@!@0!M-J4>(8)SEB
M?4I([?E7/Y^H'ELQ%Z8QGOU@FZWND;5V%O$YJ& %Q1,]$4I&GM'1($#3M/(Q
M>\E'K3V!\A^2%+EQ"]Z-]Z1>BF<RM^U/>;KI2SYT4W*9B]7QU3^-/*<MZ 4J
M!W&5)H!X]%/G\@HZ62NZI!13-[\1L*4>,55X:J'5YJY&SQO?&I]YS4H86#S[
ME22Z@:9RR<$3\'JU%0"2(%)-@ C"*P<[-3)U] EA$X\3*+=6[K>WYBU."3[T
M>V%?$]K07]WQ^LQWV^?#81">&)@B$U7R^%.T,%4*_;-;*U]/:T)-_I9QU;_7
MHE&:N+2@LQY2UZ5B='8VD7(K:EO%P@ &S\;GJV$7FD/(NN@3D9A;8SVMWAKQ
M2F48!A-=$!I)[:_QOVXE?C98E0XO(GZ<T@U;1CZ/EI[6XT"X=0%^9<"V192G
MTYAB]W6&'I_\?6>S$&?W;!5?B786?/?,T"KYC+VF"/^I*2PV];B/4Z/%J7Q0
M$7C:@V8@BU!=SSWO6Y!^1:^$99KOA6,C^K*[=DDO+/_R$0L=]!9PFYP!A)-D
M'!63$>'+P_!9!ZQG@.J"_]Q&KT[RDT!UK+9CUH7*[(@+)+.4TWQ?[0X@20F?
M]9A/T8W9CE2)R6# 6$[4JIGQXC:)/M,:#+^,8;+403I0VSF<-_9U!_/+&\)L
MZ2<@9Q@+PH2D,=B%9%_:TI@""Y2,BW6WM W4S&EO?MJ)CPR/DU][?N9^C>$7
M4CU#QQ#;C"4V6I=T,=&/!%MQ/^C/.@>'FK=-U@3S4Y5\RXKNK<WVYXU6F0FV
MS3U[>O5K R>WI[Y<.6O+GH@R\!6/?+;(T31)A1$@+,"MQ64QU:/WU:P5;6\?
M<CZ7J_DXORZ"RGU?#/GA1NP6V)AJSBE=D/-C*%58H<@-73ZCW+CNRB!W9GG_
M[IE8361\3-,NNA>6$L.%T&>HTJ4B.;MOB_2H<O9S/'&4J]W5*7=^^CDMX+32
M?JPTGD^^>UQT6JVYQR2DX9D=K:)\)"9#Y"UW56Y<1BPN#H=:>DFXW!^X.7HY
MR!'\[%1LI EL:6JZC#=.U>;?<)"^9(BPMMFD<T?7)]%=O>"[JROK6:\O^E;1
M<]/]B=EEI C IP>0S2E !;&-\"J&%6$6\VX G^&G2%7C[?'\,(O1R?E,&MSO
M'S,1'):9YR]CQ%P1%5@] ;G5 Y*FN11P]/A<_0 K(U: UD2 ",T9@;/<IY[L
M5NC)="BX96Z)"[QKD-GY/'!^?R'TM\4W$509*3^SV2Q9#]PQ2;U9O1EQ,<>#
MW@'JHV$^A[O%!FK.O)75/Q7S+%H%@!!$WOA%OCM-_1&[13L6HS ]9-7M$)[^
MP!>-6LI*+!]L;W/T_;XTZ$6?!?RA:-A30X$X(MH)^:C0-";)22R_G_TVMYC^
MSTL["C7=E1+Q"7YC3]+?OA/YM]^&79IMA<SLX9&?/Z@&D=0%]Y(*0A83_$B*
M?5IR$;6+6=PE3 GFX[?N3JNKO!)L95 RXE2W#-VB*"^14X#(D!5A%<P8?+VW
M$9Y@%^??O*ND5N@:'L/,.B1ASK@DQL[$\B[^G!.01<KJ S,T:_Z#\ %EF&*N
M";><K\:UGN9)?8S17;>_?:OH:;H!9H[^@F14,YLS(\_W !D$>4,"6S\;Z^8B
M"$WTKZ@'VC#KF B/]NFV:]IVWIWV8LHW7GZF!7]G>EFAO]AKH'OQ#XWIS4HK
M<#.&F+E$CB/IHGM]BZY&<2X9F%R@)S!K,XE[C7_QH1R\%K<ZSY0\K/0!J@)4
MS^J=ITVIGX"$8KS-4E'G&YM:_+3Q_0(\P^_K8:'26399ELW9OY27G:\^ ['?
M=9ZM-R;M]==?1,@1YSM'4]5V!3$1.G)5DN3:2.&B1J4-EFR>!V;^7O1?HMFB
M!_*@%Z)EJ-JD.W;'JSMHMFBA2DR[7_'L(]ACZ]:8%J611R>@L5A<.@);?#6K
MGPV0;DNDR0'U*XY[*2&.5FM#*_IU&; @F$??U,J=?..,J<6UJ1#)9T/B<A_[
M$;7\6[)S.N(DR[X3$/N[EOR;)-Z$.L-(+\7=0C-TZH:#?9Z,U*WT, ,;GGG-
M+^+7:S"4.U3=_V90)\?T!2V/$?9OG8!<BGQF?&S%1:.0,6_>QIQ:_QH">BIJ
M7@BCX_?=YQB?T21H8W:#:/RPK.5$B(F6(-L%N\U\/BY;1_U 01_.\EIRS:'-
M95[N^5YR-@CL?.H<*Q%5XC MZ^,<)N:]3^NX[:+=]ZZRCJ0[5R2>:%?+LAN6
MU*"?0_@1EXF>AB:&@R(RQ/5G.U+YWTY7@452WR4)VD:X[4W8D[5F59C@!DJ"
M6&.WAJSVSC\2(@J^_B<869XW?C?VZXM[Y24/Z Z;,F7H?U6/ E*>65( Y -"
M+(&<0-(!GZM3??-7.TK4*T CI59.1#U#;K#.;?%'Z;4;"*3JX)EPY(!C5@K:
M6;!( X-F56.C@],HGY<X4/QP)T7&.2#%.Q!J[RO@(W%OZJ#5]%NC@5NBI&.C
MN,'A'" !?@)XD[8_+PF(=\<P $-]* 5'W?XPSSN3[W[J?<.^R_GJ,6>J37A/
MQ YF,0 XFZG@7;Z!:(')/:JVN'ZUW<Q6@(/)>\T1JV #*;%K3X4N)L7J1/:B
M&PW[%=F VX,:<_E8,TZ?&*YN:YYN<WBZ-[O^>R]S7 ><T#1NK"HKR!MSK:FY
MT?_Z"Y?0?=J%4Q_YHMX$^M4!2&P3D#:8#^&HT1/?CJBH2[M8Y/MA?G:V4-.O
MM-G0A27:=+XA7,+#HO\MZ6\8!IU6S WTE'W] !CW+X))^L]4U+KS[0Q*6/]>
MN7K\2Y'K&HMV^EIWVPIR%XV'Q/YW9/'IXDHZ:BW#4WSK4S(^,'ET3^);<N[S
MD@DVQG=^\7+IN3J]<1DTXZ;;C\E$F%71AM&"*+'-.?4>$F8Y$UGC.RTP,)A<
M#J=#>)8#)>L8W=\9(4(7Y:7:I8-??'V1G>?W-D]W?>>_?V9(7<2V/K9G$=@4
M*1(XJ<6,$5CJ=])K&VL)MSJP<)LTF3,\1\6A5W[I/Q6YU=&?F-\2%42 916?
M(_*E[2"TZ^"C?7;2*6K*Y_+RHZIQN$7']=^' 5W)" J]H^N]ZF/X.S;%28@G
MLR\:QW4?Z#FNU>R>Z 8'X2^_/T^7>J=@7[8,\N9M$@-[5V"Z>M"C&!_%65/P
MW&4=I9I-FOBD#M\*^HR3T0>X9W\$PDBUX$EV_^."ZY=CL@F+-B.S8D_\Y\IY
MW,^&H#2/W^F<(PXPP_,'41S$#8K%3,Y''S(Y9I,E;@J\J'F,O\6O:'%><\#D
M(R*8:/I\95>[+Q]UC=A3F:H&IVZS"D19G?_'_.M74NJ91==,MJN5)>_89(#+
M%,'M.<;!:K/G$&[4Y2$29/!( :F74Z*JI1HAE?_.?IY;@X'Y3K:%9_Y0NDZ]
MN'!U2VAZPO=--/'^KK;I<68P.F%E8"YMUMM)!<K__L,3RY%L_6E!Z_T+_KBV
M\/TV3\WU2P14P3A5OW+[Z0+6/=([3 JIU-IY5])68.X!/?_\F=#62Z83"4DB
M+:LB.L=U?V&,B! B8Q*GG]3Z#5)Q3MU6D^^*>;K=9M7[J,)H^]\\4J$LQJR%
M%R-_,# .UL_\Z8\8':S>>PZ^$"W^E8@>C* A&=[4'QX)14SEUF/\[7?V39[L
MW^DCB/Y.4[Y;Z>KG_%E!:?ET;2,<?.R@\9XDC?XE;J!K0$0 B/,CG2YZZY^/
M33IS?ZI/V,N7JW^Y8Q5:(GEH<2VP.=OV=4,"V>>_UCG'Z*DY:8RP;^]<6+Q_
M,XS;)Z(GZ[EYMRWSTH:QUX1\1_S9L_/-@Z*KT18OV_WU(ZV:*/>HFL2IRO*9
M+2<(T0 95<^RV7J@M5ICL26J9#9?K:F,6*[_QB::61JK@R27'Z=V6U,LX0,U
M(6RI;>K@"R&"17I[CX@IQ-WFB2')MYM::;[[?<:!XMA+B/(,S!.W$<,.ZCUB
M/-4 \*[?8-.VD^IZ/^^]JU6W<KY *OV3\)>%MY'67"0S<A(L^7^B;2^YNB*M
M LAB:))U.L29Q'V*OW)C-JLPYK6A>4;+C\I=YF4P8+/2ZXD583L%0FPEF8T\
MT$8N#NRBZ;8=]ERG],C0#^M$4CAFX7MD:R"0V&G&OH";HVIW$G=_:J7BQ(VB
M@Y^+OJ27VE$L_ 4*,%W 7AKP1H0>9_Z%S7&MH!.H+K5.WZ>B^7ZT++'->]'N
M*OGD'=4HW58_^"+;\G@%M!Z^F4IVT?'7ZVF RL.W:1=T6;$#L P1$%%'CWZJ
M&T8<NC<!"QYRM!X@'R$$?A[H>1=? K,X4S13]C2?\#T(_?6 @2\1O?PF6D%=
MCX68G!&MOK6H!MPFGH >-/QLCF%!)\OO*OX^ 34M2$S@T3]Y;TTKW2 -SMB4
M*?/GAVM>WZ6ZGRK%\035<1GZ7$ 07DP^3Q.'[P]A<^ZWI@R[RC?G<3*["Z)"
M8)]DY@,,7\\C6G:,20D8 >FTYE%6'Y0X<;&0L. TZR_?;!MBH[_[I7?^\;-/
MV7?.<G18,_)XF@*]>%8H-G^1IX5DF*R ,']_1T$Q&-XBXT0;5Z9CDZ#K[G?@
M&)(12@4!7;0+\I3SQA\1_$!'2(4#/ W: 4R3V'J/*O[EY7.DKM]-FEHW:7ZY
MG*ULOYHZ_]U-],GUE=2_"[?)9TEM S$<WNIH7CTU'PB['ACP?)A@W4B<UQ-N
M&Q=\6#QW4[*>7/3]J5*73?G#J)079=T^WR\J08TJ,YNO(V1"5J=4W_^@(IN%
M[S@:DLUDJW*&1X:1NYX\123!%<.$:#8@0MA^8%&6.)K87#5OR/.[H:K7%2;+
M\:):HN:CD3#HM-1QDC\-$G\OFE(.]B"#4.MK,HVP7HF,2=&2:G!E,0K"RULL
M?A.\NRB,RW:[PL5HRW<Q1XLCGM4?(73\6D]L$\FSHV-/TEXQJ%PY[(9P_]@4
M,,@O-<0/BZF_4=<=^,XQ).MHTG:9&=4_/V I+3Z]%RT'6!H#T0C;0 *4#0<\
MO*$PTB15<L&;P#4.U6G+__0+@6O8L]/C)YGFKT2=F;8:"Q%DA1JCTHW]PMT#
M\GD/SD<HWWU6S1;@17_K_V;SM,!U6"L5E-Z;<Y A8C;\D\8CR4W'-]NFP,RU
M9\I^E&-6FO@^Y7QB*^.B;I )1V"\T0E(H#B'FX[+$$F C;S5Y%YS*#!)BN5,
M/3_P?X8YS((?K[4ST53F3U6&&_*I&^+]?HMLYT5OUTD)L)IX@R+X@7Z[IJ]D
M7J^!X<"$Q"4,.M',KWP!9^<[MX-T;?*>EA5 _FL$'SRDN5GW0YDA?AS+K/3]
MGC=3)VM@&:_,4R:SM[0;.CPYO\PW4>/B8*_H,X.<:-;95@,NJTX<:/_D-VG?
MQ0U*WX_^@'+"/\]M\WJOG4OF- D8_IS!JXPAZ9R*B*!-X_1?88N!@?XC3[*O
MXY>I!-$770U=E($(Q1B?P]L$:RJW=+]A7P%OAB]QNW\.G=ER-IM\Q2]_9&*-
M/>?3X%9%>=^NQ:U89:S$]/=B1<"0\H@:0')?3XH>^C"S&2U98 *U:&GP>J+:
MA<R]?7^O?6>NQ-HEVN:ILFP9\XM':+7PC]YA/P?K7$R-\Y ]097'Y2>@Y6P(
M.\17V&ETT*IIM+2NB:X%>2?'TC[PO;XX:U62<ZGA?=:/FK@EM7&JPG^B#\<8
MYF'Z4,) ,A%I//DWJ7W<_V]"J$?[PUQQEL:KL<(SHG(?-<7K[4@QR1"B*7KN
M@!"U5N;B%U2]<60V-\4$"^FQN259(.EN>Z;:7_S<K<;X:P8JC@S_;1GZ'9<C
MM G"NJI@7D#=SQ?3]F#Q>4W(0KZ=PTX8[> J_\KUTQ+UWPG([B%A\]B?KPTV
MVK8</L0R9W(3=S1S,%0/2,,^P^)1UWVA&5#NTLF0#(M-@6DC8V0#QKLK=E5Y
M@/V7Y^\/7^KO_Z )T0:@K'^E4@67SCIA*QU29BM^.OUVD7/32K_R"U%BR.^R
M_^>M]0A-]/1[!1$/ 'R-[@FH_P24-G>N+>5WG9-]9*)\8.!3^]P;-E6RZ/2G
M 9H\#9XG((85']Y0SGJJ7"%,><LW7.&1G.3L]=O9_?ERY_UO" <HZX<_VG;^
M-5&=D7NTOX&R$PY(?%A[X=YBY)NEEG%:?TPS3^$BSL?:B7%:E9(EO5N@][+Y
M6QUV'6Z?E&'SYT<J]8!$UP)PQ(2'X!4Y9GPYP$IR_LZM2L?UZ]KGA:T,CU:5
M9?_EG!8+\2#XA3GC+.W!SH5?!L/X9B5]?K=.?[=<7-%* %A:9*V26$D57">.
MWB.J_2ZL^:]UN[@B\'*V+!"*2WMLH-RP7]'A;T2[NML;*$7/R&BJYBY945^_
M@20$_1S:GLS.274</07!>+,34*_+$\0Y/T@"36QAWL'>X5M519JZ+[81@?@6
M/M*G-!)-U F"UD6$_(W(0[)^ET<)/K,U3R;)LB0<"E 9CLLA'FFC,RLKK;5X
M^3,G(.-/R88P*3__K4'-2GNS5X-FX&N/^]^ZK<=!*]#$N_5S4P<KBDG4F\M%
MGH^T%O82\P0S]*CM8EO?]!]T!:BT&('\UXN-ZA1DOU;=2_W^J4O7SM[>).8[
M3GY0<_*HFV8XYZ/LO?PX]HKOGY6-_R2*A?<$E)W/=YP /@$9RL.LF$] 7XV3
M:;U9)Z"RO+8J5/$SK'-IK(KQIW&9>U=N_3$= (G:A?R_#%VYNQ0\/O;?H$(H
MH(2'I<<0[??.@;F]CD*[P,EZK#[6Y-#I'W)$B>%:._TU_AF>QQ^QWJ*[TN(,
M[5FSGI@3T+GZ$%CF>/0/WB4V*:!2,2/$BWI/QU^>Y=-&O)7 @U:*H3';S@E(
MM"2+N7L(B0R) A8%)Y#]]%;JO(:/[%T]%.\SD^/HG-<4501;>>E:UR^!"!U+
M*3%-![$HA6UUK:Q4*@<>S+4EX,D;9M>:!8M4J[Q^C/N2;ED,%R\ 41>!1S6&
M1&QO3*-&AMK0@@$&;Y:L)P,O-"/^;JC_MC6EQ;K:6L:0<J \_$?"M-C.8/_E
M?K?HRY?0._!(:R)VE^/T]0.FW,?J@LTN 4&8I?.0!K5-^3E9"K]GU^2S,;O[
MF&#W11E;:M/(/.<U_2AOPBB#MYX6<7(QH];;SK^A;*G?N>,3JM4XS?[5RB_X
M/(_[<H"!YD<(JQX[W&P9G3R2<PJ:S$!D7X']70]?74&3I,&%M_^>OKQ:MQ(W
MHG(#G$5C X)XVG:$*<(#]'#Z/B3;/S->WR9XWG:_G;@#$/K'TJB>ZYZCJ6;Y
M,RT8IYR'YWY_VGGG:'.GB67(,SOCZ.EB48'D@:6$@D>UHY@HCPEL*)I%1T,A
MQ_NX4/GJ[<@/CFE5?KN_13W"XEXS74(LX7F.]$Y K%0=&G,.QO/FF%FR1T9)
MSCUUI:CG8\\]+"\N/.,T$A?*]DD^]6K<X@7 !(^K%>]#L1'12<W5:_)![A7>
M#VSMYSG5LTF#J35W5UZ.Q^J9GD:3);S0D C)I+H2\Y:, 9>/6]'G?S1[$TBC
ML;4N\=C^(X=X>,W4/_$O2<=G+52P/9-YCT)$U<<J3VW/TDQ\7TFQIYY))LRT
MP1+Z3.P,3>Y?^8'L=Q&E#0MDGH 6=O8S\,G#ARRXF#2_*"/B-)[M&8UUD\N;
MQD%L2T9<<0E2:L_#&4ZX-"39FC$8W,V]Z1KW]1*AN=L2+R^+%1'I' ^I53&;
M4JW^M5_WI+[VM)K":^V>.LIE1Q^$L%Y&L_TW2V&YBGP:4@RUW1!(\AZ5J4J?
M9#J!(7T^XJX<CO6^A1<3,</9:SBSH5P6NE9QCGQ4]L+>.8VD4\04 ;6/-_>H
MF&73'!_]+F]JO9LQ(54-3QUYR#KPZ%9\4"RH_@--B"I-;.L]IJ?(]CD)_-!1
MK#A,@C9L"B#4K5:_@-KR.3_^6@[*G*S [[%Z+W*,E4XTU^H-W9]87EBUF[OQ
M"2.R)H<SOV&>)_'VHI%T#PAA7#Z+T.TYM?D[A#LT,PW_YE_O^TTHL:Z,9/-L
M$W/J-P]H2R$=Y'?W7MOA"<A+EO(]_-*A^O0(^0<0C<%G[?Y%-J7GEV&^?H2'
MC8@(*]RQBG%/IKAYZX=?D(^>7CV$R$0M6A.GM\P&V.*++P(+Y1B7%0@3W'-@
M2GT\_!/.U\Z!CW3G6./JMQJZ@S/-5(WE6G OJ7T\.$/EWA_Q5%[>T"J&7\]#
M[U1Z@:\J?BL##.FYZ0YS3OVL/0YQ@Z.7WQ:$3,=B,9KUXAUC]I__P*V_T'Z^
MI"WX,+! 4%[I]MU[&NF>,<.I!]!D:)-U7+1R3*\=VBLC;  E,-9M&5X!P/HZ
M_=YJM92'Y9%?#IU;N6=UA5XFK"\>&)D<##")4BNE#2VQ(G1K?3ISLS#H,S-;
M=ANX*D?<AGK#\(>,7I+*,U;I[_2(_GVZ;<>HRN0=.;7(GEO,LG=A_^@$%ARP
M%VJFQ:[=8@Q0QMW4_+HB+>Q%OY^U#-VI(-*F:>>+2.O]?$X"XVKRKO<+!^O+
MMS0^R0^LI?$61L$+@JV:/BG?%/[8"W[5\((]/=VC :7L]9R4@P?O0BJWVE36
M!Q8U '.1,AW.UPK@774MQH(AL>7J%[M)_*+%UWS_U2U]CA!&)OT.]FKVNRHO
M=C!,T4^U,VB=."QO[EJA]X7)#33J/<9>'[Y] KHPBO&0??7?T+$[LY$27 Z*
M,X_[]T WZ35Q?_C[O=B+K1^O\'/3[4]CD7%ZYX^1)R!?Y*S_0:\3]VGQ\VQ/
MBB15B=]T'Z]Q;8ZL9AQ3=/<-OP=R,U->O'3M\+",=5IMGZ\/S0H/^R^D?:AG
M@6=SHWWV>^RGNH22> M($^@QQX6$*"F3F\,SL1W?^8Q_E99O94+@YM.^OZ([
MM@3.9=:&>P:&N'L'!5;>\VC.LWFT.'6K@GGP[K<&*_<OO1B.'].*!+/94?Q>
M>G.1&,::"$X(L1<^8ZF7[Q=>BC/C+;RLW?:YYIG![/I5NF$0XCK)]S[1>I!M
M[@1$=B1EU,>K]EQ5Y$!(DZ1J_3QC*FXIRG$\"=Z4+T74W<8ESZ'G#QO2IPL!
MV'),8C1;3"\'Q#,R)3CF-/'0 4DQ+%"JW4_5&>ANVQS+8<'&_!#_GV+<*/SL
M?%$KS9G>60QM6=\M6[%54-MR/%+H$ACER?W"?M[8/TN.XVN<F#A'KM5<5ZRF
MYJ5-LPG$]<J-.1:M1Q6)175O8*#6U!%^'M%44?642= <]T7UN/0'C.N*NW\J
MHD=X8_YKM[9%7-!A8DP?'8!=E,I&,5,T.6?"3T"0N8'Z;WZ@N0=#G_.'9K^J
M)9Z&R 7 &Y^A[7C<U2*CH_L.MV5.E?\A17&P,C<,J-<@(PL6G1U[R^<TA%9;
MT__R'%U:SII%XK$8JW8]82!J.8OMN&Y-]NMI41LL:P_5@V=NK,+D&=8-)*I%
M'KY-<+Q8NRS,["20CVMVE#J@>)QM_:E#T?Q%"3;J<GOZ"ZQD'>1B+^JOUTQ'
M4GA91M6<A"Q7Z%V/R=C$'\)$B9DI:-8RDEU?<$/%:T&*?LTI2'92S'#*4MB]
MLX_9\&I_T+OB>/!%WZ4&]&Y("4+[S3M N J8[FM%">>8OLA0$#:PQ_%,,;S>
M"A#E?'V8LF.;CM.RWJKOAR5$LP,#I;?? UU]*$&2:9$_P:8V)$I9<$,LX-HE
MBT?NC,*?JXV)*YBORX".CJHPMQ=OM<#M]\PR-.SYC 11F]8=.MN;_$+LYS=O
M@*5H$U!Z!!]%DS8&;3Q5QSBJ_#NXQ0F(QO6F6\M?=4AF=ZW]$_(NRMLY]R=#
MKFW)\Y']V6#6Z8*CIL]H;E7P<PV[7UHBM:X?C? ]!B;BEKSC, K/+Y\:(J0\
M5?BIMC]/934\ FM?,.+;):C=T;R)FO#Z<ZM1K;GKWE[ZB]#6*9=V9WS*G@V:
M*9K3"WH.(2^5A5_0\29S.<UO652]K,B.+'Q3'+[Z<B;/,USX=7;DRKO3&,W?
M+4=Q=_S/+Z5BR2O@F4*\/=S77$_ Q%F1S S4F/'J3:,/G."-2^08[8S%T"4D
MSZJQ+S'([+_SDGS!Q(_HAJE_-*;M88),,QV8+#:BL$,M15G_UI^]?UBBYQ?/
M>5S]UWB0=N8'31+P6#<@B:25 PEWNT$.-CY6@0OVIG1?EH1BJX.V9+5[D6>[
M+Q&W[[<T_B<2"*42V]F;\BTM*&3%35_A;HM/WJ[Z^G2/9A]^$E("O27$0A2#
MV68C/T-/H7-YKE9P( *:K!I,BBY:-H$,Y-'$*5K"5O)&$JD$[<1.\6&+=)##
M-3J&L7T2],9&%G'"X?3M\Q"F.2MA5/$@>!Q5M\QX^3S5=C4J@<(^EQ Q)0OY
MC=AK"U\,AR[ZL:\SI5*,J'0E1LMX_-18< [^7YR?P>LG*Q3^YX$IU)HG,]>N
MM6-YBD@:R\B$:-6-3]Z+UXCY20C;RKFO:QC?FLT Z&WF%<%<22O02GK<#3#G
M*?)+R:$$9FB+D%8Y"%,!EL8^\P_&\MK:[/I$6;M65.];.]=?^SI],_NT^_FX
M@1!T\]EH^J[3-Z[T4D+X"%C"8VCLSDL7<_JU39_-O>XLI%B*0><%\6PS9-AA
M=RT%DHE"$;&QP8KG8#3L6'"1]/=4?O".56 O2O-AS=U0NEQ]"9F-=\N/2X!$
M(A83P]NM>J21BM M 0KOODSHR:QUX5EM>OGC]2\KATSL:=9\Z>N+]].@75"A
MF-7O?.GT 9 T[JO-5_#'2.<L>XK?XFC#L^/1@IA0!T-LX?3:@E,MT=?L^+GD
M<1SBNEXIFI6O;[327NW?8)VK&:?P#9X_K)BLOWN['(%=H6P%$B/:UC@4ZRG>
MP9*OX:23N]7>>5WQ])*3GS:=*&GA)?<.I5@^SFC8DVS-5#8:-'%#[TP2MZ#/
M(<0WD%@=SD7%/SIC=<(7?F[9'_E3#$95PE!;H$.-FUGXW ,J]P2A$>&>A;'P
M]2[?&"8NZ-@T%"KN@!NK.GS9FFE[HQJ+8<BV@W8.S]6!\#8J-[TQ$!).D<#9
M49EZB'KYQ Z4PN8028_P;<H>S8J[_>E28O\U+7';X[*=6WCGD"SOJ'41Y_H?
M]<^7SE$ODYKNI9F1\I]1U0@+>HMFZK)^OL;Q-/XERK?&:M#BLE7F\V5A-HP(
M>Q;FR".M?/.(Y9J@U]\A>TU\T]T4T4&Q!^R7SU+;L:ITAQ/+BDFM<X:[T\3H
MWSA"V,ZA)T'V9J3$%)29>EFW8JJV-,U(9P-6D?3[[N,FJ_TBB2)X+KO!T\%&
M&AW<%X^.=2:U??8=9:?*3^I<KJ>J3=;]K4]SXLJ>6K*:"+8J$LN3]_Z1RYG4
M;F <C_=4,NYXA/'\:X;/_ZQXALJK4=F[>(&8_RRS_+;C"<C5FY<,]A$OR?FF
MO_3SW[!THAX(SO79NZ8N>1EY?@/3[U;D8+-!)J\\' E:W[FYMBZ]MU[U[QW;
M&\AR'DIWXC')L[\^V?64 $\CLXUZMN NB@3##-G4_C7CP8V>1;J'9>JD^*_<
M_9(M/,)]-[VV)98/\@2=N,A',J-R)Y-M.B81VN^VK'-&"0\FG+Q)9A+QPM=T
M;C1=D1 O&CJ>^N4\/;%T,9H;;K]\D)QY2C:L7B*\X^FUUQO'53>>^'W/.$ .
M/7\4)L3RUFVJ8B^Y1DW>8N2(,#A".#!5\%.02+2S=USQ/7QB8!VPO)R>V4QW
M.$H1!(+(B)\G(+=1H6'*'4/BOEFJAL!@8_05(\(*:$JLD\_R'&B(LAIK'P[V
MV(^&*@[M']9_B%G.+^OW)#, CU$R?G[_P#OOV=6;NDZSTIWQJ&?S_H?=*]Z_
M_!?^>%Y?5]N*5CPNIM*3Z =#G<2GN]F6CV']6OY+C3[Y1VHMPZMU$[G[:\$*
M[3KI'*G;Y/2_[]B2(9[UL[?Q>X-@7#ZY9[H;BC=A&PAKLZ/EEYV;W%GIR9SZ
MZ:7^9)/S[J4'7QSVKM+Y?6 ZU$>,+J-C]=B)GE3!W%/3TZGZ,M>+>$>X3.]0
MS<+8D39-G:V3H7/=8; W.5\R959N")V[@_OQ(L9!3D?7I<)I<7YN9A;GX&/!
M!)-,Y3'L#"BAOWMCZ,7'ZIQBD/"YTP26&((_ 0&WS9)C/C7# ,/O'N(5QZF0
MAE?2@5!I_^^>;UUK08@$BC B@.BYLTW:(W\8HP82ZMG@AN:G6G[<;7=Y<J^L
MR;NYJU:A?R ,_!KS/>5UA<706]4GE6<?=\-H3"<@/(<6;3!/8.I-H6/8?WN\
M>ZB!J"=*09[A4;XZ3FZFUVTOYPJ>?<IOO6'8CYQ=^@SF;S%FWN,%^'H7K_:,
M&^ $,USU6U%YWSU#Q;S-4Y_2'09^J2N 7O3^LQ4:5N_J<=")@/'48FZ\MW>+
MZIH4O/0 9RTJ$OJ?M8<@,PF]!=*).C<I;$;EFP*F^9(GH.>HRRT8VSDL4_L5
MGJ,K3]_Q.G_DYGH+8JQP.I5A6Z^EQK=(HEG/8U@*,W'?Y/[2=N4@C$ "H3,@
MS0J?V$<I ZT<?OOWI6&.E=&^?U$3^,6$"J/W:G4)9;W'Z?L]R;GNG(*\A7J^
M^G&41DIAH(/_?% !:7060V,B+<<\BV&@"N.7N(&P/CV=*>HE\DOWNJT(UN:V
M!\]A4AUGI$(\TJ\4"FD\.B538V)J3$HEOG+G_9.1[D754TL;$@RIEV-P%>CF
MN1D[MAW+IY*'Z6A/BD+8GW3_=;75Z(N =:D/A&@BK. 81+#>&2H/G[OO03N"
MG5LT6J& V84N.70N,4]-<1+;%A[LBBTK8%*/2[J(QXFT6N\8W=SRZ3EXH&^0
MQ-5Q'"-(#RLNVPZZR*9YJ<X%[0E-WB/)P;\ 7+V5 UNXP<Y@>]BNZ,Q@]%C3
M]Q'-D2U0#[$1\Z %",0#:FF'(;I.K ISVKA->=K(0=/Y5SJU8#U;CW.IOW8E
M,B</GY\R*!W@A\\0'XAIJRN#O?-2[\QHBT=(7UW NG":"9I.2WE<Y M09M=X
M2P4NC<C^B^&OR;#$_XZK+;J_N!&A.SM5EBE\8]1=" F[^V>UI@/<S9P3.TLO
MS4U'--ME_@B_30XY[MCMCC##@)\CB87P0DP$0P^^NC\>Q@_<?J@T ',->X]\
M,\=CG>DM_ZWJT1]WPU[W]U2>G#[HF1B8!+$N30/#ELH+YFW9XUK:H(E-=+]!
M0)<7S,OR(BF^AUR!>:-B=ZT<R@;O!RI_FIL\,!GMA3(L(@P2!KG@QAAEH'-*
M48S5[V^[H'F2#L],VSG$YW8)9_5KWB@10'IYCQ%8LB"IO\2#6;R+):?R/<JJ
M;3<#;D9%=S!R?O\H<O.%'DE7AOZ/ S60Z'0:Y0S$+0@;LK]3@RI%+F9M)W(!
M3QP-0EQKGSO]L$ES.'SO44AG[7_W<J?0%'+@!)2,NOPS9KEB;C@_%:%/A-W.
M,24R),.6AZ#/(\X65*3G]4H*%&[^FM<_,Z*@7C.OBK)-+GHVO6%[7*0'_DK2
MH'%9$:43S-+C6-162NUCO!/2/7>U=1;?1OW.C2% >_>8$)YCKA,(%SSL(KS)
M--7LNGQ(D;K@AOF1/]/5QH2]]!^,:\D8R.P?#$T)X"*IW <+H+AP7C'$IN!A
MR[X&>R!D!T'G1V"VN9/C3=(/#" MVLVW+UR]*6JSQLE].,U#SJ)R&:[PYI/*
MR+:M/X/K&>&1O;+OM[6*L\)=\&N&8]+=K5W9LFG53!R/W%L*'NR+[UYB"?HB
MU0.S JXL+\3@?T6SHTZA3!$AS2EG5#I:T2OU-J7R:NE\53HH@K7;:C191^4]
MH'VS>;PY0V_(>'Q'S$;^R<ZRC6AK!OSAG0<\#T-!S@_.;?T_I_?^_[PX\@/+
M]S=_/J"_%#K^\/6PE S=*\LW&I$63\3^VVU%'><U[\UA\)'PZ*,CBDFVM#(F
MT%LZ7R'PF_\6O;-;)KQ^>.]\]!<(5S3//+"_WO^<?%=5&]((=XP>+_:;G*-?
M-6GK>'#C[,NB[R;1W?Q_YAIT HD4(R#Y?>W[!E?A'8[VES<?5]@$B\9?C!$X
M4.X^0ETL+&U)H[)I7,JSK)<T_QVC<P+BT3$DF"6B.:1:TP8BEI*ZK4M>PJI/
M0)4Q0][3WYD%SUQ[XY\V\<(G'X,& =4$6,;*& %(=B]ESM IS^?T'9P:>\OR
M ABYR<\8SZ13<"QY7 U97H)<H#[Z-/4/? [>9#?6;5@U7[BS9:K@DF?Q^8^4
M3N\@?F2O9QAQ2  #EST'8LYMY7A-Y16$I:@>GL^3]_CV6^+%#NC32_=>DQEZ
MG]^,/ZTWX$\HBO7<QQ][.C?@+0%JFWY<6+T+T8-+S5G]A;[&)Z"+/K 0%YTL
M7S<%'3/6)NT[-@H#?VYG\YV#K\<K.58^@RP7GX!:PC['\&XZJ1$7WQ!DA]H]
M6>'R_YYU%>,S5=9D@K[TLG2L@,[(?D&XXG%FL_4$.^^C[D49(.HC[BJJPD]+
M)T<.;^UV[S:GIN@J_*IO"R!+T8=G?19(>A-.1!.2RN0BHKY/S^6^"C/3OCON
M*?/B>G^1GBNN-G@ZZ:J%3[)L#VK(>ZGB]W>7JX%=!3Z+GH]($V3SXYH3T),3
M4.I<5I;E'9*66LNO/#)Q]-K$<+9!Q!T-AB]7,;^$([C>3JL1(+.^9"S1++9%
MV&!?,47)UB'-9LVEZEO,V.?]29UWJU\I/1%N!4<U,;V&>HHX.&IAI,U-X>P5
MG[DG4U\^J=]^O?8X>OMKYL"GARQ!3EE$#.W"7FU,G[AK9!T\%&N5J;@P/S^K
M,A 8>G_XPJNL<X_:KLSW@ 3;A:R1=N&UDB+WN.>M[Y"U+MLS3_F%(YD7HH=B
M6C3BH\& P98DZ6BS;5M^I-#;71+SM:(K;V$M.-AC3E"^EU%W&])G3+D/WSOE
MT.U=2X*]A%9[TJ5RXT23Y>H:(1&V;\/ME.FMK+C3.JX2Q=^5J@C<;9[]VU&P
MLYDSY"G3F:APL,N>@.%45EY0]G5=D=Z=P#MJ8/(CO)(M*"8+:4:!^9D,#4EW
MM#TDD%TY"9F^(YE^69;DD&L?:5T"W_BC3>&3$,D8;]Q>BA,K"9U.(,FWI>DX
MJ/HF:>2,5C2W/;\89N#8*R8)"0_L6N4Y@% Y^/ Z!XW;2"[11 )QK:U2W]M9
M1"+]#1/;U5BMC['M+KV+< )*$F@@;0\<M?5GA$Z?@NX3<YT?BZ,Z#6^>P.2Y
M/]YYP1ZF?@FI4!'+/Z*4>ASPWX1*A'H7X$*1]LJSSDOJ7S"6W[G6[?0PC?L9
MCT(W""O8#GJJ6;<H/? MT^K#9IA[:5OA]?V/ 57/UZ=-S"*%94I3J35'/TIS
MK0M"9>B+74Y ?%<5*0P06J;=TJ,%F]O(YZ>,-?/?3+RG4T=_2_[^E=(^S\50
MI,_-S6VN#_K_OISH3A/NU>/N9B0@A=UY3H"D18PFMXQRSWHIXS#'A>_9&[_]
MN==0%>9\QSS^Z<A-;(E4K"XM=5]QQI#<,H'V1\]J]T)YFXO #W^H[@G:,&\$
M[]Y@:[;#SYZ7",#(W/N$?Q6O-5WW@^ZA&I33UBNS.CS<W0OZFVG=YB!*61]:
M/Y(%R- *\;NNM O/B30V+@3K- WB_96(>92MRWBOL:G;3P^Z:WQ-859A/>G:
MM?N1";S'Z_<]8B&W_RZ8"MO-F,#D5/H7))YCRJ+.+T^F MC[QR7_]LYO@EEI
MK%0FP.P]58D4\SRX<(]]J!3H/-O62%1X>6XT5_([><I"HTANFO-#)G^%8)N*
MR@?+(G 2LB5LT"QIJ:4'?4J@Z7.><:;IQ><F$1X(3WQOT+F*H]D%NSN/U9NT
M>[H&<[JT\E^H/ZAF4?[!.-V2&[;B>'7H05=SCN6$:\>G#*F.Q-\OG6:%7F1N
MO_W8</8,7). ,@("25ARU7$%2G#S/Z5EJJ *_NCF(3";?SQEO>C+QH=J&:YF
M@2@F!<72%[>]5<=VG>.9K'2W^+,OZB20J:15= KAN$H5ET4/A]TD*2")?WJG
MVXXF/_U1LV\*C-$X$IK(RKO[SBNS[UT46>\5W=$5V(J)\JJBK9KP]>G[+S 1
M5JMLLQ(@X>R@?77^@/E]75\+=878 FK/,4K'N 9 TY@H%%>-N&"V9!I+H2&0
MJ(<D"+YJ0(Z06(PNOEWR"37B.U8JN&.Q+MMX37V]X$CQ$?"/] <+YN3#&\:5
M >YLZ=W");,^>M=)F96>X5+)WH%A:X*^VH+GWGCF&69*O2PPRG5U1,/;0?3;
MX6[[IR)YT3324JY>_*>\A9=;IE>YX,L5YV\K/SEZZU,1YR@6B B@; 69M<2D
M8UR*T"(NI=.$@-O&Z/%_D2&=G>-J6!1?L?N/],YO+W;:+HB-_'JA9SM]B7@J
MUN03$"E_IXA"3QM&G4&1V/K2% 41!D0\:BRD*,!QSBM::,S/.3EXNGKMDD)=
M>G:-MY"?0,?CIR5&HN"//ZW7#_JR@*M[J=2LE$7>GGS\]""; .#:&U:L0ERK
M())^,R#KY;O.1FJG67N[MW98P6>N?A7-4W_\VET,E7P<AU*&CZZ@^QA(X%2$
M/;$2RVN74%Y@U;*L%/*_J'OOH";;Z$TX"((TZ;V$CDJ)=*0D\B)-1,!"AZA(
M$P(B"$%"0I'>! 04E(B@@)1(1UJ T!&1+B"$! &1EBC"HX2P>??[S;<[L_O'
M[LYOOIWOCWLF>>8\)7?.N<YU/7/N<W.7#MX0DRT06S)/<<*NRJ/)T)\E7K[,
M2^6XY_A V+P/.;P'EPYCI4O3U"90RI'5-)>VZ:UOG50!FWUWH8"MS@GURY>Z
M2YE91+M/#MF)F=O<(M*B&--?1L8F&_%1ZNE"37E0L50;O3[T>:KNRX@0KW>;
MFJYFP8IOXI]JE90&E];FYUEE3)XKY[J9#HH*,D,_ IKI'/G41%)95^:\GBL5
M0ACC7@!FE^%)#<:LLY;O/Q1$ND=N5_JTWLU*>5EW5-K@/&\G=)J=!6L*)!Y:
MH,<Q=4V)X%YXBH%CSZ(G";MPRR;2DC+8GNE*B7KQL]0Z9#^Y5 .>Y#PU+'S&
MBBF%.<V.;>9O4'+5P_2K.Y]F?GXBK]MZ6;?(/?=P-??B>FW&=L;R F@YZ_J]
M@H[.3+;G(4;"XX$WB-HQ@EJ\[S0CLR]*EY([S[<<U300YWZ1,=MFE7X8[@9#
MG*"?ASIE/3% ;D+#KQRY<AT_N34S&J0<\"XW,M=62]3R238[&Y1!"$YJ36'\
MHCCW[W^>)5\!L_\^!G'Y=QI3TL)]>H+A3DM(!]OM31%S[Y9LL_;'=4DC)^-C
M'B)*[X)X)F60[^:;<$&O773ZIO;W9S;2)T;/I(LH,RM0+LB@=;K1,]B&F[BM
M"@HSG-K1_SR\9N1-DMI6:)OCC<*;'2U%AOZN7MY_;@P9U19[]B2H(H4HX30A
M6^>CLCW;+Z:]LW#>K4Z^36F164B#4Z,$#V?J9I1%CUFCOZZST9_%DLYD)Q:4
M!=.?9M!%N6B8S<!E%Z#G<'\8F"1G9F+!6Z'&D"YQ'P(Q^EI>2QO>NC#=MM>L
MX6ZG,/6<959WG87[1--6Y<D;@Q!W?!_/@F&O-!LC!_EL@,6K]T;5@WB) .;2
M]+?W^<AZ9TAIH]6-6SOSG9$K101MIKT^H9^9Z3#?W30L&.,+EP#DEQ_0H)^U
MX?'-Y_V*Y*BPU&WU1J'.:<7FC/4MW::FGSW_#'!]?JX< =V+N2GA+_X=<^L8
M-)](!@]@)6FW* .].$Y?J-!LI\CF?H%,IF5[]@[1SBH44$=/9>NSC3P9>7JM
M^ FJ.N^:)=MX6EB%CH>4QU*4U=8,^>NBF?@PA=TDBR^9*>4WZ,E%Z,!$9PCP
MY]"4=H4*WP8'4^*6^["/$;^W)<SCX%1(,NJF5-_,R]>F(0JU\ZYF?LP#BGV]
M2Y=&/V:5^DE;W>GV7\<F8!H@:3"?8]!"\WX:%3O K?=/71L01/$QFZK!M6NI
M5M\F<UH&Z43$][5?YZ<,?M%X]K+0'T?TDOG,]GU1Z,\3S'+=DC:%)[&J4PZ)
M[<?69S22K-I37]IVH:7P[3F]?\U>5+UZ%C@W+[%0GMN-O,2G$G __87/#VO(
M0AU/(E0/F'U+LT) +"8[)?SLD;/F4VK.TP^QW*-,<H@:*ZV!8,'/+1[LOO>9
M@B^"K::C;.U3K6JSUR+D8D_=:,\>)O'K,"O42X,.<(EH74RWM1&"XK^\WIVN
MW NC5+=S4B-7A%^&5UM#DM4#92@'CZN*G58Q^JR_?%INMC0]OE15^$U3=_62
MSC>P!(-B%3\JZ\?-B>P_ :Z3QP10YZF?6K'L#W%\?AZ*%*Y\OB\>K@.<ICH=
MHPUC\BY?2RS37EW>E-.0/REJQ_9#6T"M]]P/4Y7HX>$'HM*/Q:-0B&(&#HU0
M0WHW*.O++YNC&U1@B=+@\=G>(B5J?,?TG@TFQ%.HUT&X*>_G):<J;HDAE>$3
M?\J+G=9%CT%\^.6W>%ZT,/ICIU''%(JMQ /E [B3CR1Z"L8252$O&[9]#O\A
M3R-VJMY&566-<?>O\G/U_B =G!P"'2:D +O]F(;,;?9#A9KG*_ T82Q'(R[A
M44:%W]M-.^0UE84HZ^[8G;O-"<NCP?(641S6<JJE"JK%S>^>O+DGY;^???2:
MKDV?P(JAV"BX*P"\V(_(KL-Y2L"->L4QW],E,EU7 E];=?YR@BZW\NB%.T+N
MH/3!>Z##<RDTZF?&'+[!2K5['<K[P1JFT() %&GWL:ZU8,%L/.[NAU:JU'2K
M6ZKU2&%DP\/FS)$GEN.7J!>RY"6>BU'4:>&,.'RWZ;*^+;"".XF" ?$4%5)?
M(D'-)!3QSR&9O;6U=?8W6%$I6\(_,N+.3\0*_SFQN1?U.YS2(@K,>ZP%VPV.
MZ[\PW6Y&""H;R;'[$'L",.QI'4A#A5"%?Y&:< 'S5=G?/R^YSGUUD]AT;;";
MF,O-N! 7H.KI?25(#.< ^%,)*T6)U#$WP&2EC1A_0->;HLE#4HUD<=_GO;9K
M\BXYLB-T&E=+<X9D-=H_GP]]%N08*%@-BK+UC!(N"52,M5Q+3N:@OO<*N'_?
M0@I).W</6*"?<D6L/,,L%W6*!8D0@7MT,<A#^3<OE>:1'OK'H(; WM@0U<P/
M[8NKEY=9YD\I\$<Q,R:_N%,6/Y N0N+I/H(1V/KUYK6 0N=9U!7OG"N4G>?K
M$LAGKCTCBA]_7:ZI$ V]R6>H%<K"_+U A3S&AIX'2W2"T9/2:H K%4:@GR@(
MXJ*IXJF_\Y.-H(&>];.E"=NW;AP:U8P%-?!+:^X\N%&YO!SB(77T >\[ I_#
M=,,:+))1QI2!RX!?M?/W@[_-<2O6S=23';F;W7SM&0<??S+'Z3]S?9;TDWY=
M_2_HD%SI>F_F(#RG6_#SD%H]RW.^;E\KINC;TU8L?$6OXN#JR)']+(! /5B9
MS6CGH1A F+Z[^/0LE&N/8OJD-1I:\2D'U_.6#',\_?V#5"WX"*IJ"F-*3$_/
ME=S*BC\&L7RDPM*,G _-T%,"R(.+=92Q5#64:^D\W.7+U\+"L_/&_.,.:W-?
M6,\/M[G?3%@=<A@2>\53YXO+AIZAS\+X2?]VV7.E*5-^CQ%L.;_///)**&.1
MAK@VX*ED6X78C= /*[?%=5[WZYVU<B\PR;WTIY*3@&\4V18[M$)_AHL9B5%6
MK@)PDAHG"9*28RHM3U6KWGGU\/Z,PZS<J>U;!7)25P90_1=!=SG23,5!A]=2
M@)(!,.7FR%@TL>X@0X>85"0T&8I)D091C<MB=K6==*X?99;?"^^\[O2U+W2S
MU?#LG9?>W@^)_*4IIIHA@[1_._J6 F4FP.9R)@^P,' , G4J?3\&\38B&UB.
M0?%A!V%_\Q-P95RR$*Z?P^K;>C$2ESNORX;>*0R)YOGL\@\2-[H=1.?8).-3
MBC2H-@?1=%GTIR)6RFQ\8]NB@.V$441(V#P^17K"(<%YWO+NI?<)5O8SJ@-:
M"(DO#X0[KA.(E&M8?OH4AKN3OYL")X@_0*Z3/^5BJCZB;+6Q<T4\]>]?J@4I
MO[RSH#C[]TJJX%DQ6SW9$;FXB^#;5M6N?5'<E;8<BU_EK02YEJW.U>AIUCRX
M.#@DI<>1O6*?TO]Y-%C5[A(V8K'GW?X/Y __93 GD7;KWZT)!E"BXW1U%T!W
M?XU VDU5GD29D>ZV--9.9^UHOZ(:E^[*=VN[FF,BY>H&3\DD"'W'4]Q2,>*C
M#-_X276F1!V#$@.$#:OU?_C<:"P*0Z*) 8*FJP8(C-9MQ3K='=$AUF@HWF&H
MS''0D1%K>@-CR0QMJ .)A_/@23?G@4K23+YG\,JN\+U]D;H-/N*2;!ZG%'1(
MR=GMSSF%\.Q;O 8@T6RV4OH MB$S!:WZ8TF/$M1KPW:%<M ;E!"^O^\RO*$'
M"7YS[XD;8=T%[J(5(]=W+I#U O0N<M%*GR4Z\HV@_<63_UE#N\;&( 64/LE\
M#*JV.9MUW5/[<?!%::U#>WKW,8B;H;&YE42-/$LB\L.J/(AV]4%R.W+F4 !\
M?L";[0W*Z_ JIKO=@"V5(=0JQQ*D%:"\D]J;]D%1/JB[+PS-R^[6/B4$WD'?
M?F*8T8*;9.Z[PW! <1AAD=7&UK4CH:=;5-[ZC#X+A>WR[_/._7H\OG:%>\>@
MZ) ;W1,5I7GK+]!CF#J/0LK(LOES$EQ()S-=YT;,]6O3$-4G5JB1GKLK87QA
MK[/#3]J/.DP?@^X$/5Z2GIS';+DB..;G=2_EJ33%&MIUG1BVONUZ5-->T$/-
MIPEZ=CU2?TX>O-51M.!,Z75=3?EQ0EXBB6,U<20#4)!T[/8P.NI\")DW=&^?
M@M#@Q0M(MFUFRZG?KG8?8_UR-$SY'_#V7U?_,[#+\R;\]OT/\8]JKN>D+QZA
MS52E(&$O2LJ*MZ0-*18]H] H'\+?0-Q#<L5>4X9_I%7NR9HG6;3^];CG$N&C
M V(#DK/#8#$\(A412.9A7S [JBZW?O37?:V1]864^,-SXPU9[_OMKW)%# Q_
MD9P5>T<?6](&)H4ZB#U![/<*S)ZZY'R]5["?JY 1@*9Q2K[(?_KUMO7]$]$:
M(]YX4_SR"SSE\@S@\QJ.Q)(;:UY6^7O(RZTVB%5E;>\]C_YRESO[XU9<Q06)
MC A<745&SZT*/8_ :^[2V[16:26M,^C%_KQ^BRT-1B"TS&B+&:E5(E><)W4P
M/ !Z%;=7"*Y/]"M&UO)38_ACO]6%M'$6Y?YE8X%>B8R$@)@^A[W]\H7P=M[L
M9+L5"Z],AOYG4&VY*.ATSUO<F);JIR8#7&/U3_=,'\['9?](/OD3?ZZ&]$^&
MWY'*)X-_:UI/H\# !WO,?[Q/ 3:<Y.F7K\#WN3!'XHWM_^[SQ,YI)FAW_G]E
M-YUWCS[%^)"--<DC=HU-G75MII+[!WRJM5?*WM4UF4CWWAP^<Z(IMW3A>Y[]
M@@N!NZ/]3(6D7;^\Y137R9N2()#HB:IQ,Y#0RE_LUNK#=^A% XL^W+9U:-U$
MNT $26GRBL5HUGI'\P>!Q$\G8MC=6X:4+^!NE7L5G-+3:K=Z+W*GE_M5N#83
M"=-P#-IJ)L/%:'!*9A\DH5-NHEV'*M'C$"YN6(.[>_"((?DJ$ZP4:EN=YNY>
ML99\,*#J\T"S2,PI9:6=Z5 *94%UW$8$41W) VDTC6I73(]8!: *F)I.KB5>
MKDO9(<]XYRKD%CC??=CLE85E/GGBW7+.;VV1^TNN5;56DK7Z7VO2Q)P>Q9Y-
MCPIH+C(IX($%'H-46XC-LU+!NQ?!BC2CHSR\+VYN@?003X E,D@A76)H.5U.
MZS9IT;_70&KZ$YZT;13,_2'C@L/2=O4DNV1FO:S HZ;3MP%&I+$LSZ+5[V%%
M Q6HC57-<$$C,&F,F[.PDLN:ZZ_;KQ&UJ4HQ]L-=O?B+)YY$!GL<4J_OIXW3
MA5%.0 A)93#0IP/(P3R\[6ED9E3IT]R0O5UPY<6V5U)Y/_K.N=UN6++X0._8
M"8P_,J[[+RYZMV][^L/$;\-G2L\L!#\E0P'GG+OEK\W$!AW$0&O11FQD&$V@
M\@9U?6OQT P0A@GZ[1^ )=JOPY(0ZO/C<]I/LU2?FLGMC&3M7Q^4W\V\O$$_
MA_Y(Y*5I'5Y:1%T#S,A!W'[SS4D-J5'RO70IJD[5I)_![%SJ41[5*^;Q>[=+
M=9;/F;+&H[V&*\"F\TNN'@O)Q7EBK\=X)%@]C <$$^T:M:KD?(TV!#Y:$K@_
MX9>8*Z3WF'[Q;)$.A8'#+G@#3]\Q*%G:B+J318[R),\F[G7(;SU"/]L/0X/]
M==K@YQ:=YPJXW&(YLU?;>VP_@KK',<N%:!F&.,I<OD'GHSK$L_7QQ/QE*9),
M.;@VZ;%B3I5*V^!?=''[1_1RTAB7ID+20E;)]^XD''KR&.3[4GAW_\T45# U
M$K<]PL.U +S<L;*M;Q!P&PFLS0B/B'GMF>;)XOC*=6EAC,^W-/FS9* YR]W@
MM S&$X]%H]EI(4VMU/"DQF-0DC3[>ZIZ\1MN/<(C]>17@TN2GTL=E@+7^?5;
M6@O^$;(=$W_-=>Y;CO6A('V0K@#P4;7(^1DT>!1)D,K69[T@T=8AWQ-V;=ZW
M">+/;+K^;KCOVP=LF->3F)=9&6'?CH0%F3^C;R"DGS)]PXK ?/QQR41&J#!R
M#9A0L3"_0-- W*Y17>(?B]H_U&EVKWZAU*,GF6%2(]!'K!?I9? 5? ,X%?60
M$M)+Y\T8(2O/[:!,2)G"+FY6MZ5+N*Q!4PCOYMMREI12/X4 #KVG51Q--E%J
M&;Y?V+_#SH%HA*-&_.UCD#A*_"@)[^?NV5<$R^_K5 !&R'BN>YF8-QMO9]SY
M5CY,5H>Y%D.2R&>?U3G%V[=G6^&*Z0KH(9@$W@\A-]"%%4!%+7L#?B>/.OH;
ME1,;4E.C_/L=9GZJ)ON%K!F:^DM6)7F?O_N>J_*]!J[JXYF1V'<6Q8++,9&1
MG]F&.R\PV$DHK!=AO?)QUD.MT*H%J"9S2_06L!:_76".(%D?:4[,&/JG0:\Y
M.&]?LRD]Z:5HZ[(*\\W\0MA/.L*UGRP&'/N)_%"Q[P6P1)IIB?^OYD1MZUI8
M<D$/G?-E/C2TU+6_AW]!;O%P% _M,CETO#5VV3S=Z0';ZD7IJ,-K]+&"\&U;
M"D\O]-14T&[HL]_E)9&(RX-G/TSL%.<J-[6FG3_G<78EX^*I[KFX;MQSF!_N
M2\E^QE$ME'F(LM(/%V3<=_[R5R=WMWN/3L>%YG?*ZS;?_R2\JO!T "'QQ_7E
M[<6\+J[*)^BE <%X9NFXC!=V;$DTU:.GLSW2^L!F5.4]WGLN\'[$'<.UQA0M
M@;GNH_R@6U0M@03OG\XQX"4ALCAXBXE:>0U0)L%CI<\ J<ONUY?7XVL"9//M
MF\=KY*GFS6^<;"5G9@2\31$2>CF"#ZY&YYGIWU2UB6I[+_ Y>#)%E^<RB/:+
M(73TG>G]L"9\KT0',UDY$<K[%?G3T/BZPWL@ZY6;+0G/_W4@\,E+6^OVIN<<
MGVHM) 6Z94^FV;^W?SGZ;RL7,$VK^@>$6D]6+R-+!?4+@P50MT^7O/'_F_<T
MM+C:A+70/V!RP86O506FJ6<9?K?NDFC>8LM19M3;A1]Y])L?>;^:/0F['#,K
M7]Q=43L*0OVFCNW?H4[G;TOBA>E\0 ZAP"+Y(;>T,7/O(^6D;<5"*RIW@Z:5
M8M5;2R=K%HKVY,F'7%5U=764TOM%_R[!?HBL'( )T\\CRU:4TT,SA?JHA5U-
M11SMXWONQEL(;5'9;$J=2WU]FY)Z<U".^MTATOV2K1/%B?+: =*QT5!KRL$6
M_O 2-.85H'4#**3L\'#Y";CV19!?*A.R3<G5=R:$V8;/[<R\MSY7;J5H%BB6
M(I>M,45?@%&N8KCH\QC>3C$@SAG?/CD6HV.O6XP(#.LCNY]OO3+O-2BZR/0A
M=L)-6HM5XY?X7X@OVQL6[V@CY?V*HV<Z8RE+!A3'7O )_U9H#)6MZ\[/F:E-
M\8B.B=^%G+7@^8":$@=G(>?B!+-L33%IV>Z33RG2!D?I4#7Z9]A)^GG?(F/J
M^F-5=;H<TGRWIU4WD]2A9-E@PS9FX="1^\;3>)0@;'?5_N9UI@>]LS-M%F].
M,H<),OW<P];Y]([%8OEQ*$=*:B_]-#\2>WFR"F53#-0,KUES5K9)>#4FVC7E
ML?&;R<;+IZ_(YO;ZHAU8L+Q'+1C/T9 N<"U/JL],NV?$.Y0]4$T%]_S-:"9'
MR=L*'X/F?JE7>IY\Y]S5M]_MQW_&1/;.E["07P5'O!QLMTUE;@^RO?AYAOG;
MK@2=0>PP?FTOV0@P890_A0Y/F%>J1KS[D=<I/A%8_9M'3*>T4J==S]Q/W-#W
MROB 0O)I\JINPDT%L#-PEG)ZG>38#TF3/H.]T=R>2O9N]G_7'9B5BS"^-8FH
MVM=0YG+J@LM+GI>JG)[1L>]B_L)A5/LOK/U19+"^OZ58BE4A=@Y/Y_<_.1VH
M'=& W\;7P>8(0V&S$K3JA:0_M6F_UW!$^B",G\Z!<J.6):%Y-F&G[TY Y9>4
M&JM\BS0F=KPS;:=1STAY/V?\PWF:O%)TD7=%EQY7JI-5?@3SQS%PNPWYBN?9
M-H-L@X7OY<-8'O((H"X=@Q[CX( 7>8$H].-@<J/"7[K\0-<Q[!CDW9B@U;0D
MVCGQ^GS?H&7"FJI5S3'(^:AHIQ&R$$(X!@FSO@EL>@2+@]!4_X8_O5)GW+=:
MW?4,>E_([,,UC6PGZ>G-!$58C[&!_?M'/,/11B7[4D<O=_!>/'.IA$ZFCJGM
MWX4O.:QG(P?E-!1>1\[MF MFF[-TH]_Y%QZ]AGG#13>Q4@T\*43.=NO7OM*Z
M$Z$?4+"*+_YYMB&E0/Z5"*-OL9X2JN^'N/I*,YR&#G>JJB0R43<Y]$5+?,<N
M@X!C$('X'L=(.,+H"0]U $OE(?,DX!HA@C2M=@##FEBRD4UX^QWZ</AC7>_$
MA>R Y7Q([( OT\6^<#P_WI/S&"3!P)$+H6.Q&ILS>?,96-*BQ"6#>M?:^*+>
M!>$G2N&@)9.N,8E$-\?/'DY[X%Q#23NVCT7GCG+IBJBS1Z_:O59VXZ3E*0\[
M<+TE)V>3C73("X;) ?GV"8HQ#SF=J[]89AMI]&9?ZJK\<[FKXM-#_!WBG&$?
MMAZ71E<!,ON++J0.&.SV&8?-NA4@J[A?/(K(Z)?P1 A&%O(JYR;U6R,.^Y[E
MP$V2NK:,'UW;$MM@4$)U]!RF#M*+F2?T"?\5V#P&\<@ @05O\ZM<O]J^_D17
MIJSVO=C0ZDC;5'ZJ\+1?T/+F%7_Y-'U]G/A1OA$WM6!@O^FHLG$W@2Y+2:J;
M@BI6-WZ*)Q]!O\V5*&65;;<U%BSF7?PHX5_":OYS*C8Q&%8L<7';\OV[['_*
MAX:Z-B^"%7@ )85.M:.7J.NER.8!1P-<'UP8>$T<" $FN(WE;?1<&GS38YH:
M[MQP65#0^*?6D)^:^#7\@GP%@*&XKG3BJ3""06(&S8>R>8DRF^#M7[&WR^*;
MTQU,3FX2-&O-6_W:?2*GO8]7]>,[KD)SGO%#!F0P7>@#H5)?T?N/0:(PGQBR
M[6F:(M66($+1[7BW=._O70_USSOJN'9YQ6_5VE379W=O?'ALHY!MGKVM@O?S
MME-Y125NN:[8&(R1PI-18M1SSNBS*.W)]8F:AYD"3M5]N+2M'5136W-'"G>"
MS"\SP7+*+[XTD)@5VT9UW$1ZB=09YE4P@W?7B?2E8_;)E,3^L62H/B5W!.E*
M,&A.E*$T)X;.D=_7BV3/6RI;K84HU.G-O5^-36/A*%E3GL8C8'-_-_>KCIX;
M62RK&%\F6GR8I0\U_?1-JR5\6R3<?_ J]H&<RFS:6L<M&:G$54MY4*@@TR]L
M;^8<9H#.<51B9$J%+>^TD52D; <<'/+0YSZW7_<+UGU9/NJ;8.C__6Y,[Y.O
MJA;#MQ,LS*XRV?F_/<IF!#/"9WEZ-ZW]Y@J,OYL\E@3G:SP5]'MDT]#4KVS!
M@L7#ICJW5/%YWJGK,B+>X3YAGGDK<_M,7QZ%ON*R.S'^/]^V_O]PA. %C")Y
M"'!V]Q^_"#J]894YDO"(MF-0NG[?\&65,.V:K:#A0XU=)[0RD%^,/"?SMZGV
MK5_Y(O?H\ #VK6TU*GR%N/#W&$2>C7Y-#8__S39.TY'&&LT6>/6:;NNY2CTA
MF_PR#S\[<.>#E/]*2Z>><B\DS4.G0^]L]7<#W<P3]YJL9+)[')]HSB\YGSW<
MEI8JY3+_FO'-L2-^T.>Z2\V2^?LW46.=##X.!L[LQ)<BB?842,)ZSN$]HF7+
MU XNF2]5?X59@IE+B]]<*R/-/!C^ M^D1Q/2ZL6*H=D[4VNL:[[S#2F^7"H,
M?A C1^5-IJIRR$DT?6+CZCK!R33Z"-L-^Z*U$C00E) 1RVUP"F43*5W:J3P3
M*$P*#/!,(G"Q:LN9_J010,SMWPZJB0P/HY@%I>!YZ=H E$B>3=8>V04A#18.
M$&6G9G9^EPP3)-/3ZMX%,L>D=_TT]U^R&SFO_37PC<[!UP\/^@T"(WSZP'/-
M_=BFLC@U&B>%NHQP#ZVO]!BN5BM7.;L4LQJ$_TG?"KR@:"&ZACV4QG2S=JJ"
M$^>G"M8:?4A,E><=*4=?+S1&"*'>8D>N1/=H7GZ_$R&*^X)C0QF.HYC?+,Q]
M_^N5^UBW:>->T8US59XF\=>Z[I)+J8[QLM2K+YKJQC (\5%!TM:.Q]*5$E;F
M!T_"LL];W+?$B;O9NOM9G<'U]DV_:"Q:%S@\2Q]9$CW*HI_>*.*A5*>%.30%
M%[=D67FW%?IRJVCQ6^GO/'(L?8<0>H+B#+"EH7X0 8W"8U#*&T;B$O^*&9FI
M/@;%B1V#@'=__N9*67WXY!@P-$3T=#?QG!1LTS@&_:B*6RZ7H'L\#**)CAZ#
M^NR/0:=L6HY!^2]=CT&L6ACJ3?%PSL[^3[ZCGI@>D:!C$,REF<[EP_"P<L8=
MSO'\^3.-IWCJ'8.$S%_V[-;6%V@Y$2GQ)@P[ X:=]W]OQ_B[_IOA*3#UP>O_
MMPDP=:)N#\\^OV&0U9JV:&5HL1I4L&855A,2T_+B@8H=E]U?;DXSP6NB_SNA
MY-AU#&K,[\&=0&$8-',04&%\YWOH]^:SCFV\8[@N73#OJ'K+R/FA<-5CQ=[;
MB46RU^[RA0;<C>5-.21W(H'10W8_< -X&Z&<9N3S]KN'+.5NT2DX-P,JW.4+
MG^$<[47\0B32(B(=HP>[NS<88'L,\BS%;3D?WJ)=IXAL'8."FLWC2%(':1"4
MB.]HR%L@J)=OJ-G&5TXA-:S=5NMAZ[)^C!LD9& 34SN[]?L=(Y^>^PU/'R5?
M4#>Z';X<B>5U0\$1'K: )?A:I+F?V]>\83JMP7Q,@NUO=73*X<&R[=;D,FP.
M:](^B>(D(2"$L/GT@?E=FSH!G;TO"VLV*@(*N#30I]Z8KAJE7W3V-LJYPP$1
MJ&P.*3P>;-]>Y%HQM0"NLS9Z594C$?"'U8$K1#F_3?G"F#83M8%8[QC=J<L0
M]RR;T^WN)&/Y7O'JG;@@A'$?63O;2A(JX?\L-^-!M_<)DZ*5HM]KK=R[R9WR
M]&%,/98PG6^-IX1GHA6 ^06/][-&)B$E7S9_N=YS_.GDE[/8DVU59W&:#-*
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M.A"EI<7%O1#.I3IKWN9[:Q![I1#O0A"E0A#O$!"E$!#O<YRMI=XQ:XR4E!
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MEKM3EDGYBA)HELR#EDJHE&N9EED)ED;YE6P)ET0IEW;)<#XC=3WC?Z.%(C5
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M;;$(#V5IHO#FL/##C.*67.]KC<-#35M/%0K5DPP41W(49"5";KX$EW(HS^\
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MU)&+_W==SGGF#5%NI6::3QWZX_Z)J#C?,+_G+W^DV^=YR$X!7+?#!MAVF:O
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M,E'^.(@MWOQ0@ *;6/O:QQX>EN]+MYJ,?+I8O@QE[8';08EQHD>? )5-)Q6
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M>C +SS#CAN_W_JW@\K C/S(D1W*V&D $B*O[RB^0MD$D>  SM('F$%YR"K1
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MT?P4*6]ZRISV=*=!_6F\9%JTZON0!-B7@B,V.+='3,$"4MD&=@"1E+4F=64
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MT<KIYEIX>G&.^,3)W+Q-?W\XC_5XCQD7]%"M#,2E KXJ!<Z 'K[ '03E ;Y
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MS#I">'P-0@A?I%-6N+'G2Y]K^:>C>\)A&:'_^=L<O*F[C;F+.MHA7,FT A_
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M3>DYL*6)NB*-FH61<(AI$#.1!DAM RE =[A$)1("^S  ^V &9DD, W"6:3D
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MVNKXD$?W=V>]DQ?[4U_QDD?]&S_YC'1[VJ]]VP?JN(_Y.J![$]B%;NB=<N@
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M$LP)%3[C*G?>2$"QW6]4<%34J&+JS:BP4U5H,94V :M7_1$MC^5\3]4":Q1
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M72!1RH.M4U&@8+$$7.!1"-^AX1R>#!R^82B"XBB*8K!YXBD&6AW>TO(9H 9
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M)B*U"C9T<B]WKAVT0C<YH0>=E$-ZI$MZ !J .X@ AFNT,Z#VAFNTEV^YAV=
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MFQ*=:K0JU7=6LY:-RC5I6;!GKX9@6I7_JUFE9+L.?3 7K=FR5O.FE? 00&
M!@7_*VSXL$#!B1,R'NCXL&/%BRD3#HQX<5#-FSEW5M@.'VC1H4F/-ET:]6G5
MJ5FO=MT:]FO9L6G/MET;]VW=N7GO]MT;^&_AP8G;]GP<>7+ERYDW=_X<>G3I
MTZE7IT<2>XH,S%P:B.#%AP\O$%)*\."!&K,&%4*.]!"B9W7Y&8_2E<M6[]%W
M627LYVM_I?R&BJLN_/IS:L"]PCHPJOW2XDNN!)%RD#_^R@DA0@(I9%! K\RZ
M4,&KYAN1Q!)-G*BX%(=;4<4667S1Q1AAG%'&&FF\$;@3==R1QQY]_!'(((4<
M4J)(LA,I@Q92C>K !S[XL,$&?,B#:8$0C"PI!7;.@,\ (G>L<"ZJ]$+00[SX
M4ZK"M<0"4*PPK\KJ@:W:E!"N!<LD,,.[L"(P+K?,E+.NL1+T,[] W73'RT05
M770A'!VU$=)')8V4TDDMK133&QG=E--./?T4U%!%?6@D9]IKX#T#UO$"RE9M
M\"*E$"* P*93,UC@G0?6&?\5N@+)!!-,#O$\$UB_0@SP+!"1BHNO!NGL*\2A
ME'7'+#:YPC"I,C,DL\"[ZJ.S*CVIV9#7<LUE[M)T,UU7W7;9?=?=>"L]E]YZ
M[;T7WWSM;<-4DMJCQH!R?' 52A\ 7J<<$6QJH TD6X@@@B[UY:Q0J)0*@<]G
M?Y7SUP<KM*]8"?1<<$]JS]*+T+C62LI;DNO"&*VW\)S9Y)(SAG;BG'5F2-Z>
MX?W9YZ"!'EKH&7<^&NFDE5Z::8@6ULZ9#- SX &""Z9F'95&VIJD%&CBJ>F-
MG-76*J:TBG;"0BFT-BL'A_WV9(^U95FJH39DV]ADB]4X[;.YHD9/K39\-JJP
M#3__E^C$BU:<\<4=;WS=PR6?G/+*+=^Q85,3: ^^=82QV@>4#/B"7Y%$8H>[
M,Y2\7**]\D999@2-TNKBH^)4JRZ^ M]XP*MF1SM"M@$]%-IL.RQ4V]^EBGM;
M-;EB'7HB'Y\><NJMKQY[ZZ/?GOONO?\^(0]T.K4-)0V88N!6?9BB/ \:,'VD
M!EJP<G7P$>J*9@/Y>V!:O0FD:W!6V="![+:W @FK@-"RS[C:5I4 BNDHV-K+
MVFJ&O^/=:7#(&@J;[-?!ZF0/A-<380A).$(<>1"%*53A"LUU':XE '4 ,P $
MP",>]F5-!#HI5=="\(4D26R%%W0*\?C6LN(1Q7E.V9V976PW%4!UK&1R@M#,
M%'BRIZB)+&:[S][(<D6E)%%D3YS;$(<"D<M8YB!G+$AF)H-&%E+.A"648QSI
M.$<[BN:->=3C'OE8HB^\KV$Y:8 (7A(G"'1G=.,324C:P)TR_/_PC7AB(/-N
M)D2O+)$_ [1D R$$H)A),'^4[%VP[@3!"2(O*WB#HG[*8D8U/F8P:WQE&R,3
M2X+,LH])J^,N[]A+7OX27KD4YC")6<R.7" 2.NQ: FXENI>DI 5&VEH&0I*!
M$(0@)(1\HYTLIB<PAD50;?&5%_4"J-LE,67'PF3^!M0R-853DF414(>(DDY?
M$:5.:<$8[B3DE<(!!C*VA.4LSUA0@;;1F$?SY4*!V5"&/I1%"97H1"E*40,L
M( ,Z+ G#F/$%P#W@ A%0S_M*X@R=< <$&9 ?$%7(RDM:,8$)7*<$RL%-#8XQ
M*H [RSKY1A>_2)!-5FE6M*PE5$VRDB[_Z[AI*AV$MYK"%(%*<25!#UJ96QX4
M,6ZL:+X<VE6(?M6K80W-5LE:5K.B<!TA"*2_3->U\QBI 1DHE2 ;T($0Q$^;
M+&RGW[8X17 :RWE^^6)0M[5/)([16H<M7@5E]\6FA!-."_0G%Q?$4_WY58Q$
M<65682E+S%RUJEC%Y5EY)5;3@A6UIQ4A:5G;6M<:+B4IQ4Y[Y!K7!&A#)S<I
ME5Q# H('7">N>5WA7#+(+01]K)\SS4\&J<C<V-US0Z#D6WX\69_ W7- _6L@
M%<VR(?^8$KL$VBQGR?O9\IIW,I21S&L_E5KWJO:]\14:>^E;7_N>JSSJ&4D;
MN)8"G-CD)J?R9Z_4W/''C#9@ RQ-88:XJS*<YK-.D/50$L68(/NLC"I:/-LW
M+_:6>5*167FA\&1)G" .KTFJ .UL>=4HF1:+%JOW911\:2Q?&]?843+6\8YY
M+*274,-](6&K@+/3KP9$@AIWY6T#%K#_*[WZS6WEI.Z4^9HWN#'K@F'<8L;H
M,LE1AK?+Q16E!$")+#%3DB[:7596QDM+6ZIWO0;5:H\5=6,[X_C.=@X.G?G<
M9S]'YYDA\$!M,[=#9^P7.T>^YAG>%S]F*!B%DARL6J08/+V<F)V*767'WL3$
M"!G%B%(&2V(OG=C817:3:&D965JIXH&^6)8P'@PN1_MG'^$9UWG.=5A_8VM?
M_QK8'GFF 4+ #)4J\U3]BMIV0I">1L/O"]N\<L4LZ-(.'=7"+G,@I[M+IN+Z
MU:4 8O7, /1 _64ZICB5;KF+U>;TQM+%LWXSO&$<;"#I&M^[SG<O]VQO?_\;
MX EY9M8D$$WM_P"2K7$5R0+LV@9VO.]]*E5I)(6HRI; =-153I,GL[U3_#FX
ML7:Q.):9EUEY=MB*>'$GRI=RP&W]TR&TEK-EV#CSJP9\1^U8S;[UW7.>,XXW
M.!?ZT($][)>$0 0>2$'4XBJ3-GB 'B%8QQ?.X %F,,,#9[BZUCU <6N'=]-\
M,Q:XF3O=DI^\8UTNE'2_/DETTQ2H_7PPG^A&)R_SE2SN[NQZLVK5\_Z=Z-6Q
M@6I\7OB?&[Y=MFE'X!G?^!V_)&O/K"D$6B "$(!@ RWX@DLB3S71E2,EH(>T
M!UWWJW1B<>PV,^ 0W[[)K]",G$31,+%LY[NQ&PCV;3K;RY&;/+\X'A'XP1?^
M\(E?_!\9'?FB1_[RG__I=;K#Y74YO6"4-2Y84()2S80C);!8S>ZDJ!*?7\_0
M H$W9NK[ROCI5__ZV=]^]TN$^?&7_["E?>FXI+KCI;<].)^HX;<,-?7>QOX"
MD(S"CRI@QF8\#;#"!,,>:\SR#Y_HXOTFD (KT (OT-_F3P/CS^MX[_NV2UFH
M:-WNII^HS8 H*"K4#*>@R^Z>16;@AKK*[@$UJ(M<!BTH! -S4 =WD =[,*$V
M$ B-KOZNR.0,T)^,QTU2L%O [P"?JT-NQ[&0T-(,T*?B">SF;@5+C?>41\I^
MSP>_$ S#4 S'D RK W\P2>TX!.VZ0LQ,T,OH8G?P)FY !BG8#@5)IMNL<$!,
ML,W:"&O-N**I L>[IJL,"]$0#Q$1$U$1#4) +HR)QHSE,BTMQL+*&FO_H&7V
M_M"Q(*PESND*ORP_H%#;C)!V7*>4T&(14U$55Y$56_]1^&X&!G/GE#Q)N>Z.
M*RP+3I*P^F21VAK,!G^%9,!M;*+O>"XH[UP1&9-1&9>1&5WK %N/G3@N]B P
MRXJBTM"$&$F13BBQU$A.]3).]YH'*41QPDI, ?G/+)I1'=>1'=O1';^'& 9@
M /9!'NO1'N\1'_-1'_>1'^5Q OH1(/TQ(/O1# ;2( >@( ^R'A-2(1LR'_?!
M#.AQ .(1(B62(B-2'B_2(N<1(R>2(S>R(C/R(T4R)#VR)#62)#L2)4U2)4>2
M)4&R)4_2)5>2)F?2)F42)V-2)V&2)U.R)U_2)X,2*(>R)G/R)XMR)X42*8_R
M)I.2*)N2*8U2*:%R*J7R*:W_<BFKTBFS\BJWDBJ[,BJ]$BN_DBO+DBS/<BS3
M4BS7,BS;4BO=$BS?4B[CDB[-4BWATB[9<B[S$B_14B_KTB_[\B[W,C )<S !
M\S#YTC#_4C$1DS$+TS$%\S$3$S(;TS(K$S,I4S,GDS.9DB#BT2%#$Q\9<A\[
MDA]-,Q]14S3U4353<R!)<S5%4S4I<AX]4A[IL21QLR-U4R)Y\S9=TC=K,S>!
MDSB'TSAWLSB1\SA[,SF9<SE_\SF%4SFGTSFI$SJM4SJK4SNO<SNSDSN_TSO#
M,SC'LSG!DSRC\SRQ,SV[<SW-LSS%\SW;$S[1,S[KDS[O4SWM,S_QDSWULS_Y
MTST!YW0^]Y- _[-  _1 !]1 %Q1!&51!&Q1"'U1"Y9-"_3-"*U1 ,31!-=1!
M.?1"+71"0=1#0S1#1=1$2Q1%-_1$531%.W1%7;1%/S1&291%:Q1&.Y(@F$(E
MW&%'J<5'?Q1(:X9:1H9_\*E'@;1(??0!D+2F@A2?@A1*W8%_HO1'1X9*E11(
MGY1*DU1(CW1(F_1*AY1)B6))E=3#I!1,\4E/N!1-_^(=WQ1.XU1.Y[1<9FI9
M[A1/78YE".=.[4(3#ZA/LR5/\[1W!A50#?5/V<)00Z90!151/PX; ]5D/JX:
M189.+Q53,U53-_^5.@30E, +_QC+""?U4SM-2$'5247U5)]T5,?$ .FI5&/5
M1ULU+<#+5+.1*CA55W>55WO55R,"5GU16"N)6,6.3_^P%X/%@-!-69^O$@7+
M!#/M5Z>56JO56N74+^YN]9+";; %&LM)!CUP#;.+[;;57.])6XD'W?RPXDI0
MLZX57N-57N?51(+07N,CB/)B&NOI_U"-IJ#%L-PA8!'P09"(+""+PM#Q3G:'
M4)ZB9 +VG3H)PI U"BEM34R,_,0IPL"-/^C58S\69$-V,^[57NN/3WSJNKZ+
M0-CN!5N6?\I5%F$0@()%!@\HS2R(8X6%0K8-W+QU6;<K@6@JW=A0VT0_UFB/
M%FF3=B%(-@@[T)Y454]AE1M!3*F$E=*R$1JKST[B9@:?2VNER'@XIHE43VG+
MUFS/EE[E+\F^0/,B &.:_Y:%ZLZGMFU8@]62WD[CO.]<Z6EG);%CT' /7^XJ
M '<.V6PBXLWO7JW60(N-8JTQU(MQ^0YM)Y=R*W>KEL\=6J ,/* -=*+1H*X%
M1.<!V%8$6J#R*L\E3)9.4H8 #VO3PHMF&K8OL+ +"]!B:7=NG2@8HS$4B2B4
M1K'5(B)Q,</OX$QRB;=QWRW&C'?>AM=RGQ=ZHY>/C.X!HDGAWN<FKM<9(B%T
M+\#8%"X#9 (^.M#C:E?Z<)5X2$UP@%=KP4ZGYK -9R9^#R3,0B1=TRY9Q4LB
MAK>6FI?>%M>\ @IQ_3>]I-> #QB!56C80H >CNUINB8%XN=]%L#9 .PF9F+T
M.O\(_R:Q;C2V@U\WVW+EGLJ1^URWVE!F75V73;A03@+6'$5.]5[&"3TFB1!V
M*O87<@>J@-%+AQ&B?R/WE9*7O(XW@8O8B(]X:9XI LZ '6[BO[A&R 2)&=S!
M?9Q8)R)A?)_L[C1I@7!1:&=W$,^-N<3ES,!5+EZ0;JDL%F'WJ9@K@^2P:B4D
M7)%09(X"A^5-H'Z8AW<XC0PJCR^#,8B8B)&8D O9D,WEZ(PDHQ(@<TIJR$*"
M&=*CMG(B!0#&Z\1%8[AP=D'QG29+8OT&%D.N=HAE7_MJDP1E8D=)C,C178_G
MD]%10.Z8AXV7CWNXCW.X@ ,9@)%WEP_9EW\9F(,D)8 2S";\ZX$S9Y*Q P0$
MK59,)Y(S_]A^>&^H[@Z4!B>5PH62XA>$H4I:;E5OPX_Z8%65-IC*\A!HH?5Y
MI@J/_3<Q$/=Q$S<S&K>=(1?.VJ\ [AF?\UF?]YF?^]F?_QF@ UJ@!YJ@"]J@
M#QJA$UJA%YJA&]JA'QJB SJ8)SIL#, =1&"12>*"0\)S$<U4,D $),"8&?E]
M/"!UX[81L1$4-4P4B[ 1,5G$V!6=R^\4"Q#E-O%UIE9?TZ0M8@>R,,OLBE:=
MBQ>>9>Y__5B <7F>*V.0A2^BGQJJHUJJIYJJJ]JJKQJKGYJBMSIIO,.!M4."
MVR 2K*YTD"0%YD>N)CD#Z(%'.Y"!9I8.6[ /R3EMA&K\SKD1 _]7#V^Q0.30
M?+F/3YN5?1.+7 "*>7/YQ61->1&;G7-8B/78GK-:LB>;LBO;LB\;LS-[G[F:
MLW-F'8#KT$RG#;;C"R[@*9*,&1I&)[X@ @+)B6\%7U5H?TPXU%ZX%#7M4 B6
M]L1U')\(0@)K%-N7VR+1TCI9KBLUJ&L06:?*<3]+GOLWQG2XYJB*@-^MEM=/
ML[-;N[>;N[O;NZ^ZL\,;7ZCAD0$II(VNX!BIAU0J:D;BAZ 9?%0-&L,Y;WP6
M*;P65*,JW4XI_&"746>P4 (G^VZ*"==7D@;(FNW8L)L;LIDWNG<8LFOYL)6W
MEQGONR\<PS-<PS<\N\7;P^D%)$QGHTYQHCQ8 I%B8B9J0K<6AB?@^WORFIM)
M;(0_!$\D3-.NT78-MF!K1KF_L:?/D0CYVH3;%9U<CIR&9[?EQ+ 5&[J!F"&@
M6XAG&9=Y^<&!C\.O',NS7,NW7* _W,MYY3HV2CNX(R6^(SS&HWW00SW8PW12
MQ<7_O:?ZJEFOC^O!F#"HUBF<YS:4N?FT23G=-D2Y8A'&W?6+48D8.\2(N5S1
M%YW1&[W#OQS2/^5*X.>]F<1)H$1*H*E*)OW0M(1+I&W(?Z=?NX(<<?J_*8N(
M*DS"_EJ3P]&$2XX8U=<<A_Q.!!"++,S4W32!'9W7>]W7?[VA(UW8.:543B55
M5L5J8(789J69W1M7=(5\K6NFQX;V8%9:V(Y;HY6W]7NII/V:K3;3U S0'PQM
M7OE_@A>!@5W=UYW=V7W8WUU1^,61*SE@TL=5#$95$F9A BE)(.;-NX=]S;>.
M@?$H8F=X:EO_:MS.)\UWM_7!!O8*O4D*'3'"/G'48IA,L1*]W3>>XSL>R^$=
MY(?D::A):@"F:D ':[0&?GA(\_Z=>[Y50_YV);2YX:OLA 4]&P=\@UN6N#9H
MRZAEBCXP?>]0$X,;48K8XY->Z9=>LT/>Z7^DD3=')#KG<P@F=%*"= 0,=21
M=5Q^>Z;K&@W6IBK)A:W1U<U^R!WV3P9=3VO^5WXG9W\V OFITT2IPO3O632>
MZ?>>[_L>JI\>\'=$?(ZD?%("?>Z=?53"?59>?NC'Z_^C1RZP_:@4J%">BO8&
M/F_X@KY)E7Y;^8A0D$-T:K^;J]PUIL"G\)MSU2><=SHJ?/C\'O9C7_8+.O!K
MOT1<R'1@Z)EGJ(:\X(8,((=$G(=\J'Z&B\;_FM;GI)+4/ACEWA)WNT]F6 IK
M3Q=3311;W?<N$5@P396Q0N]\F-Y(Q/6=>O;+W_S-W_;37S[^B&%R?Y *B1H.
MZ26^0)&6CJ,DX)&*OZ6<@D*\!2#>N:/F3D)!@P@/#BRX4 )"@@8A,G0HT.'$
MBPDS8CRH\2+$BAPW)CP(4F)'DQ EA&!H4B"U!QICQDQ9T&3-B0@KCD2(\)_/
MGT"#_@, 0*A1HCZ1&EW*M*G_TZ=*GTJ=2K6JU:M8LVK=NK6 UZ]@PXH=2[:L
MV;-HTZI=R[:MV[=PX\J=2[>NW;MLN>K=R[>OW[^  PL>3+BPX<.($RM>S+BQ
M8Z,7(B5HD**!LQ0),BQX8*"S9P,M(E&FG,%9@PPA0I@68>"Q:\<X%2K42$VF
MR(OO;-9FF!NW1=HL&7I,^"[A;N &>T=D2=QV\HSED,=TEYMGPX7%-V:?SM/X
M0(U5HS95*O[UT:+FTZM?_Q2O^_?PX\N?3[^^_?OPV>O?S[^___\ !BC@@ 3N
M9\ "&4R6@FFFM<',%R\]<$$$S#1@(8/.3,:,!"!DT$ +K14H8E >Q68=<A.Y
M)-*)_R7^=I-W+DJ@4T,@24 3=[-EQ!U*&,5HHHX3O82C0S %]]!&U*AX'7?A
MH3<445"B%R640$U)Y9-1)G4EEE=F6:6515GYY99<BE?>B&B^AM^:;+;IYIMP
MQBGG6&G6:>>=>.:IYYY\]HG5.B&T,9HSIE5F60H>>"#::95=UL!D#700@J&L
M^>G?=#89%$)TO-'F8G6W 0DC0YMZ6J2HH0ZYXJK$$<3J;9EVVJ*L"97Z8Z?3
M-?F3E^1)Z627P/K:JY;"^KIKKV8ZB>6RQ#[YI:70\C66.5]1ZY6U!6"K;;7<
M7MMMMM]NZ^VXX)(K;KGHGJMNN.R:VVZZ[Z[K[KSPTBMOO3CXWJMOO/S:VV^^
M_^[K[\  EQ7MP0@GK/#"##><9F<=6B9Q"AE4EJ VDR600*,5FP;" _18F$&E
M#O\_AE.-2[HHY'(&F;AD0]S-B- Z/CJ7ZD0KV5B0BBR'NK.))J'(LHPM]GRB
M!*<>!!.+&67:$U51):OEU,Z.236S54>M]=7-'NOULU5GK6S)9/\SY]EHIZWV
MVFS;5_;;<,<M]]QT6]J9!!56UD9E?&_\J,:%4I:9!^Y\<=ID&X18-V$9/7 <
M=3M-5]R0.-H:4=(^AJ"1YD:^G"FGW>$F$><P&MWY<\%M-QOD+JMNNJJ22Z0K
MU\.*+53M5^,>MNZT_SHV[KPO'FW;Q!=O_/'(GRW\\LPW[_SST%?E&34>2&P9
M@Z,U2AFA%D9"S:0=-[# .M'W=;/.,:)J4:8S)EG0TJO_<R=!.3G23[2.,I>3
M\T:W(A3=_; KR8MT@CF<2.=UL'.?S20PN[#9[H%@DQK5) C!K^7N=\;:%=?*
MEZ?D>?"#( RA"-/"P1*:\(0H3&&=/A,"#U2L 8)R%(/T9KU(I.8,%C(4,Q2G
MPJJ,RG6^.9W/'N<0'(%*4Z"K641DLD"%Q.HW#WC?$YN($,?-2C?\0]VHEJ,<
M)PJ1@5#S700S>";=;<V!9RRCLL[XM62=J8<%&J$<YTC'.K()6V"!HQ[WR,<^
M^E$KGS% ")CA(05-['J6R4 &F!$":E0H>Y3YPA^=(I)8T>1S^YM?SJ83*J<E
MS6<L2IG+5(8D6&$D:"C;8JH$PH@^EE5$@4B37RK=T4 )UJX\P );!=.(P36*
M<8QC&MLD_6/'8AKSF,BDRS"7R<QF.K-YGUF' 200&HI9*(:F.0UE%B"I-K##
M0B+3YC.!PC3M2 Z*ORGBJUXWQ"^ZPU82 6*M0 <Y=B9G-Y/##J98E$^+Y%,W
MY=1B%6$7OX+4TI<3]%VQ>M=&A%YPH19D%ALW.$[V)/.B&,WH12O*T8YZ]*-V
M"J1G0B "#RS(0XIL0QL\0(\0K.,+9_  ,YCA@3/,U*8>_^@H*&^TI"<*)R.9
MA%DJ[[<BF86N:1/1WRBG^")TCO)EZ@L)08U30!PI,$@*.2@PT0@FAB94EVZ<
MDBZ)14&*@O2L:$VK6M?*UK:ZE3&>D>9GZ >!%H@ !"#80 N^( $#R-4 #^",
M <K1&<+R\)FMFNHZ"_JIJ"+M.$M\:LL<"S]5J4YUH&PGCO1YSAP55'/6@2Q4
M#:K"-[[UM*A-K6I7R]K6JE"DL#4L;&?[F8X>"7]& J 06\)8'TG$IY@RX/DR
MN[[592JH-^+)*UG",Z8-;;1#LQ]Q+])#T[KVNMC-KG:WR]WNKH>VX UO('5J
MU9A8L9RJ>XDEW?&R?O(FGO9D+YL759D^+RJ1.07Y'V//9U5:7<1R/2(5/1L[
MD>H*T[L(3K""%\S@!FM7O! &KVUCPU2?)E<D0Q6N^KBCU!CQ5"9!#6Y ,5*1
M_7W8E#F18O^@*U69T,3!,(ZQC&=,XQK;^#\1SK%(R1M$RKUSP+?Y9SE=1=_8
M')' &CEB4N=+4" &S1U ON=& $PDT1JQN#M)W1-OS.4N>_G+8 ZSF/\1;%[T
M=?AG1S5ND*K*7.-F^+=L]NULSHQ4VM3()7'6,*J"-F*@_DA^ <[5F =-Z$(;
M^M"(3G3=%-)%GL"O-EDFI3S-V=LB][=F$\GS<[%<NGJ.UFF:%4F4V4L0]RH6
MC(I.M:I7S>I6N_K5A-&PSR3;OA:Y3TB!EB])4C3=/CLVP^H#+BO1'!.4795%
MR7T G<_,(XO ^MG0CK:TITUM+T>ZU]CYL!9=]EOA_C;-CP-P/(GHSBIC6\28
MQC2D PQ<C%16G3[*#C4&,(!]F&$? R &O>V-;WW7^][YWC? _<WO@/^[WP)'
M^,$-7G""#SSA#'_XPAVN\(9#G.(1K[C$+3[_\8M[O.,@Y[C(-TYRC9L\XRC'
MN,H_/O*3KSSD)4\YRV/^\I;+'.8NGWG.<7YSF]><YCKO.=!Y_O.=^SSH11>Z
MT8=^=*(C_>E.CWK3I\[TJB_]ZDK/>M*W#G6J8YWK4K>ZUKLN=K![?>QA_SK9
MU9YVM)_=[&5?N]OCWG:XL_WM<K?[W.].=[S7/>^ _[O@_4[XH0-%LL:IT;&'
M=.)T_DPBLSZV9RDR$,SI]G[M[IGD;_O3V6#11<1>JK'WR^L3O:/@^%YXZE$/
M\=4#W/7XAGV]6T][U=>>];;//>YW__K;]U[WO^=]['T_?. 77_BS-W[RD2_[
MYA-_^<&/_O&E#_WI_UN_^MAWOO*US_SG<Y_ZW[]^^+/O_?)OW_S=/[_ZT\]^
M\*/?_>N'?_O%_W[ZQ]_^\R?__?6?__'[O_[\)W\"B'\#&( $>( &F(#_MW\+
MV'\ V( %"($(*($*^( 6R( 7Z( 8N($:V($1F($?R($AZ($3"((E*((G6&_D
M-!P_=C2B=&J@5"OJYGB.A1SGY4Y*9FI8YAOQ56JV06[[1%S&X2FSYV^SQWH*
M=X2]EX2QMX0&IX3#QX2V)X5(^(1-&(56.(596(5&>(5'N(5.V(5:*(9<2&]0
M^(5D&(9FZ(7#EX98Z(9HN(9C*(=EN&]S:(=U>(9M2(=JB(=]J(=%R(=O*)N(
M<>B'@VB(A0B(5/B';!B(B+B'C^B(B@B&ASB)< B)EDB(F-B(BUB)G$B)B?B)
MERB)HJB)I'B'F1B)G1B*J%B*J@B*F]B*LIB'KIB*MEB+N#B+C*B+GLB+K$B+
MOAB+P#B,NTB,O6B,OUB,RGB,RYB,S/B,SAB-PMB,TPB-U2B-IXB,U[B-V4B-
MW6B-WXB-J\B-XQB.Y B+YAB._O^V@DX#:")6$[.T@QR&6Y-U,N?&*LU59Q?1
M(W@F*L#&8B9!9Z$7$3R#8N[P -66D JYD S9D XY3OY5CQ6&>*FS.?(8A#5S
M@_:49$8#>I6C7_*V7TMT90 I5?BE(T+3(P^YDBS9DB[YDC"),)Q'C\,E-!TY
M8.^8DP09)#RC> 7%;3UR*NDV$"@#*Y5EC_>E2DCI@@81DT[YE% 9E5(YE;%&
M6?AD$Y<%A*P#@\^1DSW2."JC*@#E:<#!*O4%6C!32O&59*+E4ZY#E7 9EW(Y
MEW3YDC'28<ZQ7#-Y2KEF9VGIE\JUCUQI5*E4)$_4;)T'':57>HXE$I@S;'M9
MEY(YF91!69F6214ZEIF=P6.-Z6CMAI9111/*,8.C9$5*-I88>9);^5Z9=4G4
MH6W#<65<I)61Y2*D0UV7F9NZN9N\^92:F9G_G%E0F2=J([9Y'KF1IY,1)6%L
M>AF#2W*4#W%G[A::B7E*E@<3,I,JTI41O=F=WOF=X/EJOZEC$]:1GC:1Z11%
MHV)EB=E9I_9N*U9D3[8Y.!D2/HABR/::K6EIM[(;64$F9 6@97)@MX-+6B,L
M0=%5QR)6"6I="AJ>$!JA$CJAC1%>W_,%>Q4!FD.>'$61NL4^,5B8D+DB.UFB
M7CE5M::3>99IK81ACDEY_'EY1 E*6,&@"VJC8"*@#>I+!]HU ^HE/[JC:I2C
M%%JD1GJD2(H5L^4.+5 &'M &D$(9+-4"@O4 &"H"+6!7=M57Y<F:8(DKWJ9E
M3[5N<J9D2C.?W[%?_SX%FHW%3TEY';1Y'?W$9)GF@]LVA*(27S4*I%VS);RB
MH\%THPOJHT#ZIP1:)@5ZH(>:I(S:J([ZG2+U *&A31:B,93J#)% I1= 2-J4
M4B%P6,Z4:]UF.D2&9B(Y*TR)59W):[P578+926T60#M52>MDF%ET,\=V%0\J
M4<B2J./AI\"*H%S2H(-Z'C8ZK&/UJ,JZK,Q:F8$4 O102(\R*"E0K> D/HY4
MJ1J3 &WPJ5WJ8V%I7/W5:%ZZF@1UGT-S-.V(7X^#KG7*@EU$;J;F3NM5FZ)T
MF^Y(2U9!)602+#Y:K$MAJ#W*JXLZH#N*-0C;K J[L P;EY\1 6? #MO*-P^#
MDD/3R@SN4#W;.ADV!*K_S91?F>1KO3:?"X28B<>7H=01*3NK5E4CSO4B+,:5
M2)E?'A&/I-4D81)6ANJK 2M68D*P_YJHQ\JO;C1H&G6T2)NTR-.P3*MJ(R4:
M"<*MB,0]5&L:S.!(+U09&T,-'LM, S4=5"8K%]9D0]DJ[#9$G>8Z/;,=^9I.
M,OM/8-J5?]D<)PEOH1,K^TJTBAJL/&NL>NNO0,L4?RNHA6I=-J:TB)NXBALG
M3=NXA]89U/,HF#&M-.0,62LQ(-!"CQ(X5]NURR02(>L_H0M*V?D0MHJ<3).=
M'T%BG<-48EF4L!-BF8)K,QF//J5K.]&<J#85.:I0_3JD =HL/MNK@2L5P?JS
M_PG;98N[O,S;O/'AN- [9@;@#B(0M9:A,6U@&I!2N98K A(PN5+; ![ I1R5
MKSCQ26:K*328IFT;.WTYA(%V3J-B.8V#II\'9>L[9$@R3Z%)2OE[L\;;NPC*
MMP>+J,LRO,(:++_3L\6BH'PZ%#?FO!(\P12<%]%[P5YF !$@K11C*# 4"3*5
MO3E4,2T0 A63M1E #^[@N<,D6;,1 700)5TP :/)$](E$91 %! 0*LOY@E]D
MNT4%LV5&7T35-$9%NC5IDILE>:VJK[QKH -\O&3UJ\$+N%(LO(.;L%><O#!6
MP5[\Q6",P6)\8^L0,H<R&FVP2%]P 03Q/<P@*)/Q!7 1("B8H3&:L9GEVV,8
M 0$E8"5=L!M]^4XG0!2J T_QHTKMJIIWZFZH*;^,'+>:EIR<A6VB:;>P\C1/
MW$M]NK?'6L!8\[>%2Z1!&K3'B[PS!L:HG,K,.\:L/&/4,+79U ;>*U+4U" A
M\ 4>8KD6 R(L_SQ)'O%H-=(!?6PEX4!<Y3#( - !;GO(@4Q%0@RG0JBJ,:L;
MLY02I:O$?ZFJ)5$D[XN; 0R\"AQ,AOO) VO* :JS$&4U-PJH#J;*[OS.1]O*
M\NQ@7Q XV+,9=T,-M>$9+9 !W=H"?Z.U#? %>%Q1=(LJ$$ 4)S!-BD 47>"_
M)C+(^M!NH(9>;<MH]^6N/H:OW.$XUI%>2EEJPPEOJIEY\ZP5\)S2*EU,)]W2
M"!8RV$,Q&](9$> %/N #7@ !=Y,HV5H!@>,!G]K+?R3-I2/, ' "\W/,1-$!
M[D ,1.$ "($+1#$!#H',FC,!1($+'- %4UT<$)## % "N' 1$% *4/]R F.-
M$$X- ,3  6!] B$; 6!= FT]U54- /D6P\C, 1,! 3%,"?;#E<(6GS,:*S/:
MLJ+DTE>QTHS=V""DV)"=7:(1.!3#RQW@ WS !S9@ _B@TZ"Q "$PV8?"#F<0
MU-^JR 61T$<-$\) %)3@$&NM#A'! 40Q %&4P_! #>6 U0  UF?=VE%"!V.]
M*<(0PU/B  RQUEP=)?"@S 5!VU.RW -0$#G\UE)]U!/!VQ"0-.(V9?1D28#&
MMHPVMG&K9DT9V5/AV.J]WFV#WNZ]6HWRTY^Z#EZPV?9M U[0&2$0 1"PN:.A
M&>_P .33H358$$9M)0-@$ [PU QQW1-0$,CCW $/P-L"'"5(+0$';B6*4! +
MGJ,/+@$PW+L)[@[(S.#(' $&KM=%=+>[!J.Q!)26YKJH.D4U\M[MP=XXGN-P
M8N,\[E;9BR&4P;7EX /WO=D^P+7K4 XB,*UTG $M$ $1(-1^I%A? "8/71!K
M[0!% MW3+0'(7!L4+@P&D.$CSMLG4!"\30D04 X=\-;1L=8 X #3A,QG+@&\
MW04Z[0[",,Q=CLP#,+T2L-8C;M8   'UZ(Y5U9@A>6F+Q31)T^-,H>.2/NEN
M ^F6?E:46QH9X %<^P!%;N34($W?"TF7$0)[)>7_?028AXWAP^S0^Y 0'2[;
M ^'@$+[4[L#; Q =#]#AUY S1GWEPZS,,&$ P>X.'5[G[G#==1[A1%(.M.[E
M2]WL??S'Y3#M<9J2,3-YC.>R2V*SKW/I0D'IXC[N> 'NYLY1V)0 A3+?PO#I
M/B!87R#"?,,.&W(&(,)C:/H;JKW0Y; .2;/6PH 07%[K=+ IO*WE!='0 & &
MTV0C?0 =0.*_7 T.?]0-C^8 0 >UD>5%LN\.T<>OW=<QW.4Y;/'9_=0=+@S;
MV<P45J[ M6&BZAWDZB(+,\[G\1=(P<[81>XXG_-O<>X\[TP>,!F!TP:\/ 5$
M;M\^, 4[;;&&4L*9BNI\Y.)J:=3_2!T_SV[L# [MR3SA66T1U]WE!<'5U+[<
MSFT0Q1[K""'U[,7L#5[;!G$")=#K$R'U#U]$>'G81E*0&\:<Y>8Y[T-G99NW
M@ENP@[&K#O3$-)^S@M]:9B$P!=/XC/_X 1/Y! /YDR_YCF_YE'_YE;_YFM_Y
MF?_YF/\O>=3SI#])(4.Q"4#O7&L $&#3.(WTTB0"AC1#M^SD3K]'ZNDI9*W0
MW,P3T%WH$L#'1*$.,)'#^N 0O#W6U*'P(RXC?6P-% \ > [B= X3 (\0&G_K
M#FWH>@XE("_]-,,3)0X P@ 3,$$S*<^V12+>X.W#+U^N/!'^/Z6^WIS)QMH8
M!&Q63B'S_X#?8 !10.! @@4-'D284.%"A@T=/H084>)$BA4M7L284>-&B/\\
M?@094N1(DB5-GD294N5*EBU=OH094^9,FC5MWL294^=.GCU]_@0:5*C'+PT:
MM&F0HD&"!B(,/'U #8*$IP:^,'66-&L;9A+*9&AA8.A8LBO=23B;%NW:M-0Z
ME !P8JT$MN[@ L";%T 'M"?P=G W 2^NLQ)PX1VP]D$7 %WHOM6K%Q=:!W@=
MK(4LMUR$NY'Q3NC;F&Y:=X?S\E6;>NX#MM0*NV8[5W5AU:UK%WXW&RWLP@]R
MKVV9=Z1PLGB' _AH/#ARG,K+/H<^E.-TZM6M7\>>7?MV[M6C?^D''U[\>/+E
MS9]'GU[]>ID7(C%5ZBQ%@@P+'E3%WR)2TJ09LF8((82LG&*O0)9L>X<:M-Z1
M#0*\3B M-ESH\$R8PORB0T'! " ,+0X0*TP"N"A9:\(*RSF+&+S48<V=+QYD
MS3#/\AK@++](;$N"$.XRHYP69>-MM]E28U"WV8*4+<'80B1RM-CH8FLYYSS2
M*SGFJ+SR'\]"BLRD*;ED;L8LQ21S2C.[)%/+X[ DSD W9^HN3CGGI+-..^_$
M\Z W]^2S3S__!#1000?]TX %,H OJZV8^8*:!QZX( )FC&I 46>8Z@J$#!H(
MB_]0-V^3#3.XY"JLG!!HZ\ OO"B9*BU5 =MPLK-,FT MQJX) ;,-XVJ5,KR(
M*2PSMCK8U0'3:I3 +UQC6^?5U&#[S<A07VN+MB6O50M;M-SAS=&UHMU6K>74
M!*E++<>\DK@VA6M3I"_+#5-=YXR;-]YXX;727BNQ/-==-L_-TE- #S(G3X,/
M1CAAA1>>3F"''X8X8HDGIKABGM8) :GXLE*JTA0\\&"_!C*(3RFF&N@@A(X)
MM'B\:9<,\@%W;N-6,2-_G%G:M![%60*9G[JVY[,,R'9HFGF.[4, !L"YR-W8
M8A#J(",\<D$%K=4927>B?O;)*%FB=TQ^^]V7[+*_?'?_[#4!!E/ML]-%UVVS
ME:.[;;0#;CD]AO?FNV^__S8X;\$')[QPPP]'_*:G-*VT\11('CD!;9A*(('X
M2,X*A ?H,2H#EA,?RLBIM=69]+DD,+5TW9Q4W710SXI655G7TOIT;K'6L>C1
MJ $WMFAYO_W)UZ\54MR5Z(9[[#/EQK=Y=_%^^_E_FZ^7>NBC-YO<NT$G#W#O
MOP<_?/$;XKY\\\]'/WWUQP-Z4J7:4"I^RY>JG..DZ// Q<@;V$"L]7?2%M18
MMSO=%9!T!L1=Z0*80-?%)BH24!J$7O:LF06P'$MRV@#;$I4"NL9IP:N6!A?$
M.K"E*SG84][ULM>O+:4MA=)C_U/RYA:W%;9MABF<T?_*PI""":2'!?AA$ <B
M1!\.T8A%1"(0CZC$)!*1B4]T8A27*,4F3M&*5<0B%*^HQ2Q2D8M?]&(8MRC&
M+H[1C&5$(QC/J,8T&D2';X1C'.4X1_-5A1H>:%RE%,6?^&@E*PV(!#54AKD&
M+& ==*3);GXS.M9!JW5J@8WP!DB\W$126J8CWB5)$RO=!.DWDMP9 27 F]9)
MTI.BHV!L2KBOZF4/>279WMK6]JY8DJV5+X3EO?AU2T0*97R_!&8PA1FX7A;3
MF,=$9C+%@Y\0> !R2)%/XZ()3:-$(D!G,$K'F.$_9:H$@:2<VM58EZ#7%6ET
MLR$G*&K#2<%T@C $%\36.D>3RJK%LY0@M.0(L^8S(>ES-$H*H3M6><)6+F^%
MKW0>#&W(MH3BDI<(+9LMT<7+&G8S)L/$:$8UNE&+6-2C'P5I2$7Z$?P8( 3,
MV!1\'*?'2F4@ \P( 34FQ<>D?&&D_R31UN\0V,^Y_.XW/ZJD6E)GNW["3BW@
M&BJ3OI7 ?"I26CXMFFI.U=/@@4LUP(N-M]IBU4Q"R8"J/-Y$K:?+Z:T+HB0Q
MZT3U)5$4R@M>:V5KOFS8KIO6U:YWQ6M>];I7OAX./^LP@ 3T\SBC0/./FTK!
M E+6!G90:F2/W:OHDH2M#[9&>)&,D5HRNRUU6C9;=0G5!"NKU-7M%(3P[*#I
M6C1:S$Y0GZX!(>D&.KT3QO!N57JK"\%DKGSQ%F %5>MMVW76&OJVK\=%;G*5
MNUSF-M>Y*"EI54(@ @^DP!F;<FD;VN !>H1@'5\X@P>8P0P/G&&\YO7 7H'$
MP$F>)9^/M/_-M<[9U=*>\S98C9 $/NG>#@85E/\MS%2OFK5L^;=VI7MN@A6\
M8 8WV,$/AC#WJ@)8_* ( BT0 0A L($6?($J%#; HYY2CA$_);("--+M1EO4
M^!J):Y3MEB9=%TD6GX6#H;JQ B=[)&FAUIXO3LL'Q>EB2P(YPD=&<I*5O&0F
M-]G)*XENE$D<92J75+V?/:KN1BFMI@;/J5I=2U+YJ=]LB5DU_N5J!0.ZU!K;
MD[,;=)*96[S4]])%:'29[^KF?)8G]]G/?P9TH 4]Z#=6V="'MK)>4X-/45)-
M@*2KK ;%&;0ACWEK,6[DDG(UPLO"F#;O%&U\-WMIU\YXT?0=#:@39>9:0K?:
MU:^&=:QE/>NR(-K6AO^^<IW5W%78A+-W(&Q=GO\[[%*Y]LQ8)FK1P&Q 8:].
MP&&>JK;$W*)S\H;6U\9VMK6];6[W^=;?CNZ)4;VU!@[/6@@R]KC+G6=V%X]T
MS7:=.8O:3A_WQK-><_'+NKUO?O?;W_\&>, /1T_:T0;3:=[SG'/Z+(0_.[9&
M-1WP#BQ"K&&UX /D*L6]NMYK@6N^H6*D0 4^<I*7W.0G1WG*;X)BM(#Z-AE$
MM]1:#&045[JHO/$QI[V<2DF^F]Q-8J"RIY5BV02YY_!E)W!4OG2F-]WI3X=Z
MJ[\J+=; ]DD]Z[B-6[QL1NY7A TL-^U^W2V<X1=U#H^O([>\<6N]]Y1Q?C;_
MPK\6=;K7W>YWQWO>/PJS:?&FG00TIXQ97.J?*\;-(;RWT7D,8-4B*>Q+0CI/
MLU7VT*HE!/L8P#[,@'EB#"#SFQ] YS_/><]KGO2C#WWI02]ZTZ<>]:Q?O>I/
MWWK8SS[VKY>]ZVF?^]KK_O:[QWWP@3_\WQ??]L?W/?)[OWS>-U_XQD]^])G_
M?.4[G_C5I[[TK0_]Z5]?^]GO/O>WCWWOAY_\X@?_^+]??O6;?_WH9W_ZY1]_
M^L/?_N?'__OS[W[^M]__\[\__1/ _@/ _?N_^C/  AS  PQ  D3 !51 !VQ
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M(?90^I&41GPB#*:1B 0D PWD C6D3=XD3N:DEG"0.[1 &7A &U1&FZ0 X[3
M^(1/1(I "US/]7C/.9Y0"U+1*U65V923$<Y&/PFA+#&5$A*01^K)V&BE12P5
MV)S&&5(-0LAD=N@D6[:E6[XE?@C. ]@,S[1)8M2E,T2"45Y N/!,NK1!",1)
M,WUA, *BCFQ3;* AC)!BZ<2.P@1C- *089K$&A[2-^T.1,60(38C5N&/+&IF
M&'*$6G:,Q]!D3)@F:I[F0%H'39)F:[(F0<*E;,XF;2KBMX0 /8A+99"+F*2
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M&:_Q%[>Q%+-N!.AF8(!)SD2"Y+0!@#!("K1 "#1(D&8 /5QL3P2O7Q"!DVK
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MCQ^ZH2<ZHB^ZHC<ZHS^ZHT<ZI$]Z"L<3CL(K@U1V?_L '_"!#=@ /C2Y ;3
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M"$PQD!TS"6=:&/BWD6/'C@X-2/AAZX,&4Q].?MA#I&%# ^[<N30P)XBI($1
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ME4;-L7MIQ*/WV.C'-?[Q?X7LBOX0N;]$+E*1C63D(QT924A.4I*U,N0E,6F
M!60@6M,*$#.^L*8'7" "S'#0?_[C#/__6 0$&8B0W\+"(<%Y*'3B$E%+(&>5
M!Y0.7^4(W0>:,0=?CB2#1/!EY7ZB(@W99 XXF=P<]A"$#CFN [\TD2^7*0:V
M/.R:+Z(;$6L'&)X9JHM>)-Y9C >H+=V,=W.!$Y@"4RBTM%-D;UI3EQ"C.T']
M#DWTE,#R\KDG+_&EC) JC=#V>"F$QF:AK>FC'NF(-#[*\8X'K:/1QN=0B^81
MD'[<%" URE&/$A*3AJPD)5%Z4I6FE*4K=6E+8?I2F6*GI#7MWSI"T#9I 8B
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M#!"<T/^6/+Q/&E'6<WFJ]*VW6\O!VXRMO-U(.ZO#LYIQ\%!86BY $:R#IOV
MN[=3//\:"M8E6YO;8=YY8]Y#KM[Q_=[UG=[WW=[Y_=_]/>#S'> '7N#[O> 1
M_N 5GN 7WN 9_N$=/N(3'N(G7N(;ON(Q_N(UGN(WWN(Y_N,]/N0S'N1'7N0[
MON11_N15GN17WN19_N5=/N93'N;Q7=EJ?3%Q/>=S_0)"0!760!S$801&0!MJ
MH ;L !P8 .F1?@D:W2R77!1OE2KU9+9;+$354;.NYZWADZN368QP,.HV !M
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M(HLPN<@3C !F2&.(-:9X(T;][<ACCS[^"&200@KY5Y%&'HEDDGJM 4Z3X+@
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M?Z-*%H))*>NFFPVSW%77*8J(F\6'VM5MW=>=JGCA#BU0!A[0!@G0 .&= AY
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M8<J<+G-BW(FQ'$'W-=V;E)!_?ON''I@(OO[>>RB_ 1',J3Z("BI0 @8/C(G
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MR'(+]I$WEWG.>:YSFOM<Z/[L.=&!;G.8IS>6(6=ZTYW^])_]"<8)8 <S8&L
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MG;W.K *52CC1'MDCMB89>T[[)I.AMY9%M;46UZ4>8JLYS6<>,S&#*<QA G/
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MK1;;;K5%MAU5Q1V7W')M9( !E=#%9: 6=-ME-UV(7) HWHK J;$X(:?Z#5%
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MX]96<5JPO"@SIYVSE>/(QT9"<Z#SA.<[UWO>^;YWM=X=\($O5X /N&SE$MG
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MVUJHD"@0S+(LU5JP(@HJ,<X$#GMP)FZ0#G/0#NN0HN10#_=P-(1,T@!.II;
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M>(,O6(,[.(0]6(0_&'97%X57^(1;V(1?N(1CV'0;XB/!@F(I(>Z>XF+AP8.
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M2Y.-4^#,_-C'9C+SF<Z,)C2G*<UJ2@Z9V,RF-K<Y2'JD2%<9\,!D'M !+_C
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M"!9M.)+16)+2:)*&9HTJN9*+!D,[!3R'X5S-)Q@J$@G%LU(+M@")N$TSF'Y
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M4AI=ZE;7NM?%;G:UNUWN=M>[WP5O>,4[7O*6U[SG16]ZU;M>]K;7O>^%;WQ
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MUSTA4UWZ7>EK[MD]4I._PB?";ESFV^5P[E::02&_@,#CQV+WN)!P; J&YEX
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M+ _ ".W=1[ IU#]Z(2C;IW.V0F4_^O9=R[)8:7STW81G\?6APX^%\6V#O6*
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M.>.SNG@F5,417K<+OH5NE0=7O?- 1;@>7G+BO?OWSB[(58>9R;,"WW\5+6T
MA_1L ;CL.CF(9N42E.&J$([/74P\T)4/Z?)Z]989=,?S  PY_N#0Q_UO<$]A
MI'LPFJN!,T,,<*\;H?-ZMN#IV)R7JN67$?Q&NQ\>S-@,OSNSZYN\9B *XDRZ
MINK_)Q9$:QQ+$LXP9E>C(9P%F +G(.H2$,<N)H])+<"Q8JLP0EMS3K=A==!Q
M"9U+G^5HQ",O35-'[9!:5#$0%7" 2B$"VOV_WI%=,^CM/1A)9)>R]X5IC:\-
M_C(E$T=&$O?='MJ_1^E3K;2@6I%2$+0!))U>/,UK8V:-LD%UIS6_MY%G/[11
M,GQCD=IP^>CWAUYY#8_;T\@GC]N,:X9ZZ.7J'/K=G]!.[6?N;:>6,Y5F64+8
MBZFGZ#(%TH]^I29%EZ0K JK&4G>>.>6-?SON<6A>CI_ LV,"4DPKX)8(!NT&
M^SY:GL 9\14%1"O7$M"E/$TT#CYV_Z/)DJB]&N(NC):"JP6OM7*+(3IR/ YO
M04AH@83_$"H!"U#V[N-"6K2H4)PW$762_C!<ND_FKPUFYG'A%>O%L-ZL R7N
M]N%OSGW/-8TXQ+P(3MD$+#,5,=UGNI0PW:=0<*8?9PC+U[+@JS>\ K6;C/RS
M8'9"W\U+TR0B'5%;S8?JO7-87EY.JYE. 6>-LC'EC& ET-(L7W9%B_9+ZQ.5
M<RL[A\;-\PQULH>C*C?V1_J<*H]6WQ>%00J."N+&7VCS4EQGXCA"1DQKE@W[
M?J?I$_0$M'DL_4^!LA-?NXWZZ\G'^3\< PHO!J1^LM<]&7W/]5[Q?B>^'YT(
M!L@S*4&L$,"4>9-UE WB!HOGH4*/@;3_^NOO)#VWEJ;\Q27YV4"7YD]8S:EU
MJ>(QJZW<;/;!RF1K2XZP*^W&DM$@%S)3,(@5[))$HD*[U*8,#&1=)D;FS\:/
M*%,[ZRV'AG(V[0=_7'GH_^X*Z)TVAY?ESB['7RW8B](!QLF8]<A]7O!5R860
M@4WY3TX&DX4.I6D+0KKO2<8#45'7]7ZN:O-N<2$4HW4GI@L2QQ$Q)V,(5;9
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M%[ +HA'M'TVV^[:;U&GWNT>CA* W0-\D,=W7\*2'BT;LID[I)R@G0/;)G _
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M,@4F(DMW%MR(9'GX8_"$;[^/QQOIN"(KY?$Q@V/-ZBWQ5T\&0)3>O76M1RZ
M'T&$$7Z<C\#,/Q!<,!>\:NQ6BQN.8[$[3[$65_&Q+FJS^,/HF$; C1?1 ^=P
MZPG'3(XR?'K%6>>-&NS#LVQS8U!3ACWY=?!"D@UTTG(2SD\V^S"DH6.LXI;Z
MF0:PJ)VT^I1)E4J)KG&XY36K^#)%9NC8+6K76Z@7EJ5O?L8.B^J,UB>DX%'Q
MNA<P^<>)P;OF([JR9<HOXU<V=-I'64UJWY6DL3Z^6_FU^/"(Y26@I26$ R9(
MIPFUA!>XR7:+AZZJQ.:RM6IBHR'>8#=)UP+SR?8K"2)\<:VVT<C3!G0IV^C#
MDUZF,P#YZV8!TH/;=II9?193L0N[W=LAW8UM1R9U+X 3-/TM[.(OWG(!$>1V
M NMZVNY]4V$V/MVC^ZJ&\EI+B^$^RSA(EYB!X8Q_XF,G?J;M_0/-BK!)P]''
M;?D7>TG-"5,\9^)$^JTB/Q(-J#)\A26_.5E;V5MO;5NT1VATT2?1R(J,UA'=
MAD"I6U<<KO.X*Z54,C%DW#1DT=Q3'NSCK(7)X5QS<<U]".ZM4';(M&37'! ?
M]G21HE<T7H?1J!:J^^G1'S&D&Y J\B7#WN3NDIL-G TJO(HIV78AF<%N5!,?
M+(K9(E@A]JY=!;.;<=L'Y]*[JJ^5:C-_><%^)_EIM26+CC?3EJ\BO:H*(90Z
M<D0)69:X6$ ,QZ:^!B>B-$@T@/@&_!0^["%5I'E$95%5Q_&;0>2H4X3K+0V=
M4\9!XE,,2NW1_7]+M/\!QAN*.K$&.DT"$W;2CTQ.>9UT^ODI-U6;FQID][:@
M]*NY@O):@_15!;/B,C:Y@J+"O!$0'Y1=GYA>3G8=O2>6)SFYI:P4:F:V4_RT
MJ+%!7?#6#4]YGM+,RY<5=I0SOU^2S,.CMRIP MAS95C_P%YQ)@$[D%KUZ+;N
MM?72V<NJV.KG SZMMS)N: 0$BUVZ!;(RP;O&&0!N0ILQ"0]:PK&J'%!43R1P
M^H"3=2/85QSXGG2ME."4%6,:%OVV Z)F>AK3Q?GB_$?FD'Q!A >:SD%$#RC@
M'JK.4.BQ@U:5"5,GY9!+^!,[&9&97\-UCT;)%SS%RN8K)SJG76)._UW072U$
MS6&[Z>#]4?B78/*Y6@CC=X<7/G7'9#(U[ZE'%*<\PD+.?")UR5"6]WIJ0BQ-
M27+PP1!H>CM()1U3T4A(Z*1<+(>QGV]^>4+]>V?53[<K+SP9N"]GZV=(!F,2
M-=?N76<!%\"4<;()NN%88&+DN;BE3;A"S%<Q^.&V>N-TVKB4T='>6XGU'D%[
M1V3#!UX>#YHNV?(@7=C(/P%3Q?W>$3=H@C/J>^@YJKDYX[0MN:P 2_[VQNG9
M]Y(3I,'G[F%W%<>\7W&JCB'<4?=ST%WV<#[?.>#X3MVF?Y!FF=,,BG_#:N.Z
MKU&S[8X.X;V6L9PKDU(L(&/-J!BWNN5#.D>$=+HJX@R071X?1EM">&13),?K
M39O7-6\]LKR=XY3H,GU-#>2YL(1IO,UX$90$V)N/!U<G;&WCDGLSP3PPX,+,
M!%X\U^-B[IO6,F(:#7"]V<GGBMLK]5D+2=U+5U]SUU23>QBS@F>SDJC\4,Y>
MJA)N,E77\G5TV0U<W(_#/+&FWY5I_*8Q*@+H>\;A+&_J^[OM7A*,#&)'>!D>
MX+7H+:!-C7@.D4 #</\ ;RN?7MF8P/I9U/5SK/M72GZ(:[SRN>O.4.\W%I8
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M-!MQ>M]6_%1.H-SE4:E,G#Z/?G6VX-&GR0O;8O!\>IE.!$M*3B"(G;B)1?=
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MDOT=D-1O'/Q=+0RQA.*:J<;Y"8BM(_0<4F#5Z,>."2>G@SEH@&]LHS3 E>*
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M;B=%Q28/G9)=SB\(#OUT#V W*>'[]8;E?LU6+.OQON1-;2Y?7%?OUU8+&QI
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M\/OI0:YUTMBN;1A0H"-2D^^(4V%A09(BUJPS2>X5XW^D_1/H.8C<0\[D4\V
M?6@" X)RPINIZ>_7HM3'_=T2(>__<!3]F_TT)5#I3*.%^@5<%9<[&*\I=@W:
MV!>C^B/PJ'>68MM1286 E65_N]<=)TXQ\UV^()YGF>[Y@:!]7K<MY=U8YF=%
M?.#M+-MIT[+3H:?,=4?"#$==S^)1#T%B4-?#7BH(;Q"?7+A>)51_POI&LY'R
M]J*8P^Q'&Z U)(NNY__UDU^3V41]PCUZN-GTNT-T[;SP^H0D_+5Y3BI7<7N^
M<1T_BJ^P[]NWJ<P3]Y9$H]^Y-V9.]XF[P//A=%5;E;4U3N(@*E*Y@??GF)+^
M'W5_BX[ DBVC"SQG/SZ^W%NB<^/VY/K\%$P,L]J:<WZQ>M-7#?&^B 98WVK[
MGF6OK&7F+YF>UR:[<.@^7_8#)$5)1"\\&-W(DP/60<B\9;U:XAIXS]?G6_([
M ]]=_'+:/;:)NAGD5R+*) Q4\N_PN8%%7[LGQG(9UY#LAT$?]V[("<MU9^SP
M<',+J.H*Y$E1."W!EL0"  #*[MEU!*GRK[8X)-G4LC5:CIQQO,Q>=[K.9!H2
M/E[[)D/XGDU!3)(<ZH7FOV9F\SQD6H<02-0GV<&DQJAL9']<N6-E8FF)_MZ
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MKT]*,!(FN6-@'P0D4_49A4P5%<7>=\6ZI5N5Y'B$7FR#.!%#M>F$:K I>6O
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MIP7+"_+\H'BX4CB/[">/8X/\N/OM/&=9!5%C^?$(]C8QF!#.!MF%C .QC<+
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ML4$Y1/]#*,GU:6C*<T]+8D;07M.>SH/9'K)80G_5T-=@W]0&B VIAG1CF08
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M$<A__WGROZ&[5^X-I:5/3PY7USE8_@+_4Y=-737-_]T#^+]:_5>K_W0K*)4
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M)RZAV??T@Y=D^@4.]I32+?W>9QH;WI[QYAC7@UDF[X+53T!S,,=9Y]T34)G
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MP'T /IQE]SHO!^4. &W^LSG%CV=L@-E?).P]]P2\T2D81XGQ6,(BN0*#S4"
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M:@"KN<+>*A^%U-72(XTB^XE6LW7(H:O"\;%_Z,]80#:4 ,<MXC<P%<EM.\S
MR!&J^T?I -]SR?ZI].^O!9[E\&Z)M$$L&!.W3T#Y<,XXYPP'YH2D?5RIM]W:
MUK5,CO_&WGM'-16M^Z)15$0ITD00B J*B(!*4X1$5$!$1$1ZB8AT >DM)"K2
MFZ"  A*E"$B)2(= Z"@M]!*$A$1 >B(2%J1PP][OC;?W/N^=<^Z]Y[YS[GO[
MCSE&UIAK9,TUYU=^OS7G]WT_!U#5:&/@Z5;#8; DECB+GLAH$=#/8>' !^%Z
MY(Q^_QLA!5\73.\:@DIGI-=8"]%<"TF3['6>*6";%:+GY/PF;!_K"(XRUAJ
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M!@)(QVO7YURK)46J8^A9-771IGX,<3,IN@"R&0RUXP-D/-O1 O!'S.3&8P3
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M(!_M@"8FNUX3#9<_4M9:C&_$IZ7SA16OE'))X!_'W>J<>IM.@Y3/3',"@<%
M)'-+)Q.6?Z9J0RI-6!X/B]Z:8ON"*O;P5]BK?!U+_(BMRH] B <6L;A6U%Y"
MCBRIIH>Y0BZ64U@E@>=/)PQ:E/34A1U<29*\-:I@OS]=&Q3#=,B.V<J<EWC>
M<_'V)T'N BWIV@>9=0U6P00K>'QAAU%\[BKB!N('E.*6&+4#\@1/LCE0!;H-
M//EI!W23@HJJ3&D88"AR1CH,>YP?^1AE(-:M,JB[]]W-XH]&S^[G2+Y'-J,
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M='>@LF\E2RFKU7*K:)#0__A._+18%? 1XY?%S0O+A62GCY^94%MZ612L+ 0
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MG8K>R8IR07QNXR@BD,=V#%$0.##V+081\HD=$T11B'240QO!W!1%& "6 CO
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MLL'7F[S/./^#U6,0%:!!L;9!;\S7;AZU(7],TL>6J2V^[QN^)4BPP7P!UO9
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M1)Q^8;Q=K,OR$Q,EXJ6,9K,2[?BV]?#"#WW'LW$(:1A8$%$[A!$)$+1MAJV
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M.8 =0SN9.C5/NJ\Y@)+=7<XA10P._BAFO6M?%1E:LJI47G*@!(>>ZV'(D!M
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M25'% F 4_(2+1#,\RI 65-N[&KE=1AYQ:O07NRVP%66JS$#,Q'B3T(NVW=[
MU\HD,$J\D3,H-;1C-03!I#M59U"TNT-U3E'#Y/1WECP^B8Y\*::P^+%)T?DA
M6:ZD_]D3%M_WS:HL2C'TRJTQ^E^KHI0JON!AP"/FA) B2T:DLFP8^0&#L4^)
M'1+B,=_3D=2!..8FJQ\Y9Z2LTX@)[/+$K6"DE=?ODQ04E3&:]UF'MI*:;$[
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MJ$I1&88ID2=7YF5I@$0<4&YD8;*@86X*=,="$^.REDPT15B>&U;RIII4OF/
M['RR626]HV9D[$<^-?9A5_3?@(Z#&O\=#TUH^&7\C:7^%0@Z$N V%$PJBZ^
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MOQ>S@.?3$\U-'+31NSUB544>?+'<@QFZPS+!)68C"P5;N"QBG8>QN"+4^<S
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M"S6,@E4%J#-#3E;L:9BE?EVG"T_:6MM55G*QJLM;UH.O[S?5NL)U,X)%)I!
M<8!A+#RI[+$T@=CG*<RXGR21EX1>A,UL[D/3S6W;MZ;DAN2V\&I#-.A1;6J
M'P1<UPSO"L9IC/%]!&],(+0PRNL@<X5I?G#XB0WT.JP>F^FUWK*[;OY6%.S/
M?+F\7;&[E1SRL58ZZIBTNCWYZZX56.J1 /&4P)@D"409B2 AB*GV,L1/J)\Q
M;F2]TI]Z;E)F1VX7>=N+ ,//15GE_S$(2;)8"[U+WC@(CRR .J+K$-8CI&]
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M;P3$D=?>[&W+S(BNB^"OK]M__CWGI4KJ>_VD4OKJ@'Z611Y-:0BC) PABK,
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M$C"AE4JVKY.Y$74G)GCNYFF]$=3 SKN$IX8=[ "ED1EP ]"&R!X< F1@"3L
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M2BN&2UN&[P4I[2)]:8PC:6KX, E2'Z(T0#"E00)Y2"C+6!C[/C5A'+/NYT9
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MJ2KKQ4->+_F=^"C;^9&S-5[^(Z^_?^7+1N#J>_[\4+27!MX53SA?+?P4^4G
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M@5.E@\TKXTL^EP#5XV,',(U,PWMYO#H9P2^=E)<#$HW9=P '1Z1[J9=)N79
MU6.*'7K\2F:]7=??FY2$[XHGG*\641+$0<9BR),PA"C#$4Q1B&"0$"X2$@><
M4Q-3[5)'<S/1]C[SK:3@]U96S7B>06P-*>$*Q*;C! .P[$GA A*N6>&XF]>A
MA0O*7N2%2\];IA1]>EX6+YQ_Y<U5N;WK#5T!\05FU,M2RB 5F<K#QZC<UM$
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MJ)!RJP=82T7:?S_7*G=!V>JR>=3D/I;EB/7SQD3C,#+#[(9@$]2W4^$&*"5
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M71RC.U%P3R>TBHSNQ 9' 3\WAQ$_#H-\C %S%>NCW_&T(3_&@)Q$_IBW8!,
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MZ(]M(3\OHAGB40QYF N)&.49Q)1Q&'L<,48#+TX2'8FH.O'8Q.":;L4,PLM
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M%Q@'D#NL?6L$F%L6[CC:&P%0_XISDN",.'V63Z;S:97>FGR9<V8G7OD<?:0
MV\JZFXF38%%!,,XI;Z4QS:>Y/$+2L%:O'\"UU,((0'5+2!.&4FJ&#E@DN2CC
M:%<(D:&4&)TS(KKF^2*WB!CV:J,?X!PFZ1$\3EXR<)6Y-V&.69$Y0E"ZU-P5
M2;X$RX"8LD"O<G&M'R_N(&-8N/3J7>TIZQ' Y;?%?'&3BW/@7PHH!99]X!X8
MUB:IJ!-X0Z:2&VZED*9V4&T,GD>)&O8*K \HM=7#"(ZLU_.ON-H4MYVQ<YEW
M0B[@].LTXSQ/8K'26N=!D[T&Y:R'F$R=JU93X:U+9,6;7[<\2M:P#GAC("SZ
MU<HH@';&PH5KQU3F16<+UM<H 3.=UZ9N1:^]%\XR+EO706^1,*Q#W3> ]I?V
M[F#Q9V"9XZ=Z:?RQ;?.S>P4UB10>:!9K_J4/]8N R'V";+)G*6I!%KVUO_0@
M1<.Z3OTBJJ$N1F"-[F?$9N9*),>0JUBGE00'=7P!T/>D1"DB:UX1=1B>>O.?
M^L53&PV,P#6_"BHN7@:F\U-BZNJ][!<LB^5YB=;'\ U7+[^1_$A]TWE8?G]-
M[NGJGHQ;E01*I3/H0H&Q$B3JZ'4D*QX"<NU0IM;SKWID9]CDUC["@;'H?C3;
M@%@\W\:_X!Q+K?D*+H0LR?,0LE3Q,G#6)K"*1U0Q,B-:7Z3>0\JP=2W]P>\P
MF>\-G:^XC(MFH[ 71/?F8D86(0.K3:"MJE.$<B+:-Q.960D:E0VQ=1;/U>K#
M5HST 9$])3L"@_(;KJ_,:Z?ZE"A1AZ +X3R2#\J=)CEI!S9RHR0:85+KD')G
M(CLAS#TEA/6KIS'$"M<9G%  G;E!#R0N#2KD7*L!-7"I#"_%TY];]SRZ04 G
M /DG"Z"=Y#L"*W51[7Z1[?\>"?%I.IN&K1%FL0CG"./(Z^L44DP3M80<K$2F
MHQ3-!\!UHZS;+2I[2GCJ024CL$+;7/T25M,TR9B*"4[4#%[R]! 3!%$+3!!-
MP4B.8&Y]6W$G(<->QO>A\4= M;OX1XBA%]/9Z1KSQ)H08E8&,%M^%FI2C.E)
M]Z9D&02R[7ZUS5%T3LJP=_(#X&@?%8P 27_'.N09\S.* L,G_.WT).+R;;E5
M"7#.WHOI*LT6J],E;FX\+B7)K#%&\@(!>=T_RD,LB4,=ZAF,X!2OM,XJ;4-Y
M-WOWI-*;!U#I$P+RF;W7R7'!G 7:X0Q4<A1"2T[;/V29R-B+HEM'F#L1..PQ
M/ 2"]@3Q[NH<+U;/Q7F["BMA]NB\ E:\ !5KTVM+QY;7A7FKD//0^GUT1Q*'
M/>['B]<F*AT!8N_H47C1G_!2?%9:XZ,U$+3?E,=+"'7:;5".B62<D+;U)+,.
M9'6SI$^JR*2U,D: KX<:83[[&J:S>@_Y:K'\$&;X =/I\JSM3/Z_IV?959?-
M,DNR5B9=("E!>U@'1BY]Y)!RXD)QJ04VS]-N1/NP9WYS4-V5=G)L#8\<V<0N
M'1OSLR%SZ?O'99BO2,Y5X_.\^=OL3/^WI<!02!$U Q'JB-4B:YJ.,6!#SD5*
M)75LW<NM'TZ&]1R&1/V1M#^"/?" E/?J7Q>4#,0O [36UOE!$J(T&HHW3N=@
MDFO>C+TQ"\,F&/:-^B'U_:0:R5UORW!'#\$;+!W6>>*^#H6]=YMXC*WV3>4>
M:G>(@6%%,9;B*>KR""Y9":F0$'.,.@75V'!T(NSP!K'GBWRL^VB21!9UK"-(
MES+M7:\ID(T99$&CC#4%5>O[@IL4C*997",LW.[#NK>\1W <7U)_)I%JK1?S
MNEN??9NN)C%QGP(B),%D30!7$$+1D*-VR:D8LVW]AO0@02/!TAZ:O@\T!XM]
M!!C:XN'%XB1,YQ-E0\HYU(K=VCL !<5FTEF(H3 6E%#9M+:O=Q(R$LP<KNCM
M1\>#I3X"Z%QK./8KUFO2B71:(R=?TW+D-54(B7;K:&OY(++WSHK6KS&WB!@X
M\>%PQ=[?UFT/*8\ )O?,=#IGQB:,@GE.>T=2>&)-37\-@D("44<-\YQ\ZP?G
M!PD:.-^A.7S:27\,4'I\XM(Y8\R(X#VS0"$NTOF>,P3#% C'/ KEA12MIPIV
M)F[8.X,>(-:+5D8 M^T!2N=<"!M#G7@,V7CR'64N%' @L4([QQ3ZIE:M;ZWN
MIF38:L3V0&H@[Q&@YNZ[KW->T)?BA"0VE$AUH*8 KQB#PC!Z9IR4HC5V'J)G
MV + ]@AJ)OL1X.@R^GA#>V*3X# QA; >BP(>I#X3331>4L@1&#>&M@+O+:2_
MI&(D3=X;QO'["7@$$*'#=8EAA2_P[+^OY[?OR=[37GBU6/X1EGE"9ZUWD16(
MN99R<(_@LT+0 KW,3JG0O*'CCB2.).#?$Q&WJT%[4\\(T-=JB!5GT?"DP<H0
M0!4*9UUT$9!S$UT0-<&FN5$[VC2S/C..^P-73^/*=M#TWOC^@LOIHKY<+==M
M4'XKY2_('$E\ H)+DMA0#GR0EKY$*3 KR9NG;(PL3_.HV#M(_J.!T57RQ^KC
MXIY+F0VKD>2YZ>9/\?-&H>^1Y+F:KO$#+K].4QUC1)352IA/\\VG;(8;34K
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M:I1@G>71RT1A5VN;=B\QPTYNZ E%;40_ @S=V_MFFZ^(:(R6 >CXUZ"X)9>
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MM!?3V>D:;VV!(JSVB@.:N@5T2>3W*@^J&&^M9&2K6_>4WY/4D0Y8WP5##_B
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M\3W,UM_?D==Y$BZ;T)TSPHJ2H; (06=&[J5,$#S]E;8J8R;);%WN="8^M,K
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M/%%A;4&2XYDSX IS7CA7AY1UNY9X8)5AH\6C@:>9H(>^E;_L!> $%I6S)6?
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M=3(?3LLS*F_9^PP_LD9//[W[_\VGL]7?Z:N+1;[GYW_23O_[=#E=S/#CY[S
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M_^@R_3'D&+U)M(=+J.T7&0>7A04N=(G,YLB":8S)EO2/:SJ; .IN^==8VNT
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M8,&ZHD'9VBK/H 'R#7@)5D1>6EBP1TCH"$ M53YO+_\.XL\GC?U#MO[-]0P
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M@8FB9#=#4P:)%/MKNOF<]N(A<#OUEIO;"^?)O+7O%8V*Z6RA,%=?&V4$+YD
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M9;V]<R+_F'+S\*\?UP\<'3N-Y-Z!@7HY7WR9+W"5[[6VT06CC>0098DUN]4
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MN1ZN>;.HI@R,ZU_V<<J/AX@.ML.+KS@]JR)\-5]\(%-Q$]I]'^A-'!<^NR+
MVU) F>R C(4 '4P*QDKIM&J,]&UIZR1AYOCPN3N';0A==H#1O^6S]''^&ZXJ
M_=]N^+C5&R5(S!(UA+5G18=0/8,8B<XYQ2.J6%I'3D\2U4FFS>BH;*N]#N!X
MOX-U3P79Q!F3C/7D&DDER.'7M,^,B2!L1([6"R%U8UAN3=SIIU6T@><PVNP
MIAO)WL>(LISI5 *H=1DYE^0V!5G+R'-"(Y)@1K0^RA\BYO2OF1J=W4VTM3_L
MYBL\.T+!_^L9?9D_XE]Y6?LH4$1)FVU>WLR7RY]RF2_RK0\<4+B_SS)M"_ /
M9K11(?WU,C>(NJYKYCJS5 A9021'R H<O.(.9(F.H6&H6>MJQT?(.=3>;7YU
M%? KVN<OY[/5='91WRN^Y,5:D_<(GKY8KJ9Q@EH6$1W6F[DZF],+< $-Y)22
M]T9((5H'-P>0.VZ\TPI1=RW@L?37P=&\!ZL4TN7II]G$^R"L#AE<03H2%'.
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MI*;\LT<#I%3 -J2$M500L6YD^\$L="G*H8]/-.<?&\64C$W]!U!+ 0(4 Q0
M   ( !V!?5<P>&UF@14  .1$   <              "  0    !A,3 Q,2UA
M<G)O=VAE861?,C R,7!L86XN:'1M4$L! A0#%     @ '8%]5PK!"PO2#
MNB(  !P              ( !NQ4  &$Q,#,Y+69I<G-T86UE;F1M96YT=&]L
M92YH=&U02P$"% ,4    "  =@7U7UF8Z]@D.   '*   '
M@ ''(@  83$P-RTR,#(Q9F]R;6]F<G-U;V9F:6-E+FAT;5!+ 0(4 Q0    (
M !V!?5=4>NDE\ T  .DG   <              "  0HQ  !A,3 Y+3(P,C%F
M;W)M<G-U87=A<F1E;7 N:'1M4$L! A0#%     @ '8%]5^*-$(0B#0  PR<
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M,#(S,#DS,%]C86PN>&UL4$L! A0#%     @ '8%]5W2-(SBB70  TRH$ !4
M             ( !LZD# &%R=W(M,C R,S Y,S!?9&5F+GAM;%!+ 0(4 Q0
M   ( !V!?5<+Y211H5 ! ,Y0 0 4              "  8@'! !A<G=R+3(P
M,C,P.3,P7V<Q+F=I9E!+ 0(4 Q0    ( !V!?5<@9"WB4'(  -*    4
M          "  5M8!0!A<G=R+3(P,C,P.3,P7V<R+FIP9U!+ 0(4 Q0    (
M !V!?5=RR7K6 9(! #2C 0 4              "  =W*!0!A<G=R+3(P,C,P
M.3,P7V<S+FIP9U!+ 0(4 Q0    ( !V!?5?U^2A0I7(! (=R 0 4
M      "  1!=!P!A<G=R+3(P,C,P.3,P7V<T+F=I9E!+ 0(4 Q0    ( !V!
M?5>0!'AONAD! $Q[ 0 4              "  >?/" !A<G=R+3(P,C,P.3,P
M7V<U+FIP9U!+ 0(4 Q0    ( !V!?5=M7C:'X2X! "[%#  5
M  "  =/I"0!A<G=R+3(P,C,P.3,P7VQA8BYX;6Q02P$"% ,4    "  =@7U7
MKTJV63>R  !Y;@@ %0              @ 'G& L 87)W<BTR,#(S,#DS,%]P
M<F4N>&UL4$L! A0#%     @ '8%]5\FCE_#O P  $0P  !<
M ( !4<L+ &%R=W(M,C R,S Y,S!X97@R,S$N:'1M4$L! A0#%     @ '8%]
M5^3[:!P[ 0  _ $  !<              ( !=<\+ &%R=W(M,C R,S Y,S!X
M97@S,3$N:'1M4$L! A0#%     @ '8%]5X04N#8[ 0  _ $  !<
M     ( !Y= + &%R=W(M,C R,S Y,S!X97@S,3(N:'1M4$L! A0#%     @
M'8%]5U-*\%$[ 0  _ $  !<              ( !5=(+ &%R=W(M,C R,S Y
M,S!X97@S,C$N:'1M4$L! A0#%     @ '8%]5S.E('L[ 0  _ $  !<
M         ( !Q=,+ &%R=W(M,C R,S Y,S!X97@S,C(N:'1M4$L%!@     5
- !4 GP4  #75"P    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
